PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Farina, A; Gaetano, C; Crescenzi, M; Puccini, F; Manni, I; Sacchi, A; Piaggio, G				Farina, A; Gaetano, C; Crescenzi, M; Puccini, F; Manni, I; Sacchi, A; Piaggio, G			The inhibition of cyclin B1 gene transcription in quiescent NIH3T3 cells is mediated by an E-box	ONCOGENE			English	Article						Max; cyclin B1 promoter; cell cycle	DNA-BINDING; BREAST-CANCER; MESSENGER-RNA; MYC; MAX; EXPRESSION; PROTEIN; DIFFERENTIATION; AMPLIFICATION; DIMERIZATION	Cyclin B1 plays an important role in cell proliferation. Its expression is tightly regulated at the mRNA and protein levels during the cell cycle and is found to be deregulated in various malignancies. To enlighten the signalling pathways which lead to the cell cycle dependent expression of the cyclin B1 gene, we studied its transcriptional regulation in quiescent and proliferating NIH3T3 cells. We previously showed that the transcriptional activity of the cyclin B1 promoter decreases in quiescent cells. Here, we map a quiescence-responsive element of the human cyclin B1 promoter to an E-box sequence, CACGTG, which spans positions -124/-119. Nuclear proteins protect this sequence in a DNase I digestion assay and bind, in electromobility shift assays, an oligonucleotide spanning positions -133/-110. Max-specific antibodies block the DNA-binding activity of protein complexes to this probe. A mutation in the E-box core sequence abolishes the decrease in transcription that occurs during quiescence. Finally, we find that over-expression of Max protein in proliferating cells specifically inhibits cyclin B1 promoter activity through this E-box. Moreover, Max overexpression in proliferating NIH3T3 cells leads to down-regulation of the endogenous cyclin B1 protein. In conclusion, these data support a model whereby E-box-binding proteins mediate the decrease in the transcriptional activity of the cyclin B1 promoter observed in quiescent cells and suggest that Max contributes to this response.	IST REGINA ELENA,CTR RICERCA SPERIMENTALE,LAB ONCOGENESI MOL,I-00158 ROME,ITALY	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena			Piaggio, Giulia/AAD-7336-2022; Piaggio, Giulia/J-7214-2018; Crescenzi, Marco/J-3603-2018; Manni, Isabella/ABH-6460-2020; Gaetano, Carlo/P-9997-2019	Piaggio, Giulia/0000-0003-2114-1892; Crescenzi, Marco/0000-0003-0156-1494; Manni, Isabella/0000-0003-4823-0596; Gaetano, Carlo/0000-0002-5238-1832				AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; BERBERICH S, 1992, ONCOGENE, V7, P775; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DESIMONE V, 1987, EMBO J, V6, P2759, DOI 10.1002/j.1460-2075.1987.tb02570.x; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P3467; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; GALLANT P, 1994, EMBO J, V13, P595, DOI 10.1002/j.1460-2075.1994.tb06297.x; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GONG JP, 1994, CANCER RES, V54, P4285; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HOPEWELL R, 1995, MOL CELL BIOL, V15, P3470; Hurlin P. J., 1994, V59, P109; Hurlin PJ, 1995, ONCOGENE, V11, P2487; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LAROCCA SA, 1994, ONCOGENE, V9, P3499; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAHER M, 1995, MOL CELL BIOL, V15, P3129; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; PIAGGIO G, 1995, EXP CELL RES, V216, P396, DOI 10.1006/excr.1995.1050; PINES J, 1990, New Biologist, V2, P389; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	36	25	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1287	1296						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808703				2022-12-17	WOS:A1996VJ20200020
J	Shivakumar, CV; Das, GC				Shivakumar, CV; Das, GC			Interaction of human polyomavirus BK with the tumor-suppressor protein p53	ONCOGENE			English	Article						BK virus; p53; p53 binding; p53 transactivation	WILD-TYPE P53; TATA-BINDING PROTEIN; TRANSCRIPTIONAL CONTROL REGION; NUCLEAR FACTOR-I; DNA-BINDING; P53-MEDIATED TRANSACTIVATION; SV40-TRANSFORMED CELLS; ACTIVATION DOMAIN; TRANSFORMING GENE; TRANSGENIC MICE	We have been studying the interaction of the oncogenic human polyomavirus BK (BKV) with the tumor-suppressor protein p53 to understand the biology of this virus as well as to understand the basic mechanisms of p53 transactivation. We here demonstrate that p53 binds specifically to the viral promoter at two different sites, S-I (np 361-383) and S-II (np 314-336) in the late region. Site S-I is a 23 bp domain comprising an unique combination of a 10 bp consensus monomer binding site (Pu Pu Pu C (A/T) (T/A) G Py Py Py) which is contiguous with a GC-rich Sp-1 motif that binds p53 in the SV40 promoter. Site S-II also spans a 23 bp sequence containing two tandem consensus binding sites with three base pair mismatches in each and a one base pair deletion. A dimer of a 100 bp region spanning both the binding sites or the site S-I alone induced p53 responsiveness to a basal promoter when cloned upstream from the TATA box, but a similar construct using S-II did not. One tumor-derived mutant protein, p53-175 H, which is defective in DNA binding, also failed to transactivate the reporter gene. We further show that p53 binding-dependent transactivation is abrogated by BKV large T antigen, thereby suggesting an interaction between these two proteins in vivo. In contrast to the isolated p53 binding site, viral early promoter is repressed by p53 in H 1299 cells and the mutants are defective in this function to varying extent. This is suggestive of an involvement of cellular factors in modulating p53's function in the context of the whole promoter. p53 binding sites in BKV are flanked by the binding sites for transcription factors Sp-1 and NF-1 and we show that these transcription factors are present in the immunocomplex with purified p53, implicating modification of p53's transactivation function by protein-protein interaction. Thus, oncoprotein synthesis in this virus might be modulated by p53 in vivo by a complex mechanism other than simple DIVA binding and sequestration of the TATA binding protein. Together with SV40 and polyomavirus, which also harbor p53 binding sites, this viral system will serve as a model to understand the role of p53 in viral infection.	UNIV TEXAS,CTR HLTH,DEPT MOL BIOL,TYLER,TX 75710	University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)					NATIONAL CANCER INSTITUTE [R29CA047611] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47611] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; ARTHUR RR, 1986, NEW ENGL J MED, V315, P230, DOI 10.1056/NEJM198607243150405; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; CHAKRABORTY T, 1989, MOL CELL BIOL, V9, P3821, DOI 10.1128/MCB.9.9.3821; CHAKRABORTY T, 1991, J GEN VIROL, V72, P1935, DOI 10.1099/0022-1317-72-8-1935; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CORALLINI A, 1987, INT J CANCER, V39, P60, DOI 10.1002/ijc.2910390111; DALRYMPLE SA, 1990, J VIROL, V64, P1182, DOI 10.1128/JVI.64.3.1182-1191.1990; DAS GC, 1995, ONCOGENE, V10, P449; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEB SP, 1994, ONCOGENE, V9, P1341; DEYERLE KL, 1987, J VIROL, V62, P3378; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P185; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; ELDIERY WS, 1992, NAT GENET, V1, P45; ELDIERY WS, 1993, CELL, V75, P817; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1049; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FORRESTER K, 1995, ONCOGENE, V10, P2103; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GARDNER SD, 1971, LANCET, V1, P1253; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; JACKSON P, 1993, ONCOGENE, V8, P589; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUNZ C, 1995, NUCLEIC ACIDS RES, V23, P3710, DOI 10.1093/nar/23.18.3710; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MAXWELL SA, 1993, ONCOGENE, V8, P3421; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MILLER SD, 1995, MOL CELL BIOL, V15, P6554; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OROURKE RW, 1990, ONCOGENE, V5, P1829; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; PAVELETICH NP, 1993, GENE DEV, V7, P2556; PERREM K, 1995, ONCOGENE, V11, P1299; PIPAS J, 1992, J VIROL, V66, P1289; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P8974, DOI 10.1073/pnas.91.19.8974; SAMBROOK J, 1993, MOL CLONING LAB MANU; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P10277; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SAUER F, 1995, SCIENCE, V270, P1825, DOI 10.1126/science.270.5243.1825; SEGHAL PB, 1993, ONCOGENE, V8, P3417; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1993, ONCOGENE, V8, P2059; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SHIVAKUMAR CV, 1994, J GEN VIROL, V75, P1281, DOI 10.1099/0022-1317-75-6-1281; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; SPANDIDOS DA, 1995, INT J ONCOL, V7, P1029; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WATANABE S, 1984, J VIROL, V51, P1; WATANABE S, 1989, VIROLOGY, V169, P204, DOI 10.1016/0042-6822(89)90056-1; WATANABE S, 1985, J VIROL, V55, P823, DOI 10.1128/JVI.55.3.823-825.1985; WATANABE S, 1986, J VIROL, V59, P260, DOI 10.1128/JVI.59.2.260-266.1986; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; ZAMBETTI ZP, 1992, GENE DEV, V6, P1131; ZOUMPOURLIS V, 1995, INT J ONCOL, V7, P1035	93	25	25	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					323	332						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710371				2022-12-17	WOS:A1996VA25200011
J	Matoskova, B; Wong, WT; Seki, N; Nagase, T; Nomura, N; Robbins, KC; DiFiore, PP				Matoskova, B; Wong, WT; Seki, N; Nagase, T; Nomura, N; Robbins, KC; DiFiore, PP			RN-tre identifies a family of tre-related proteins displaying a novel potential protein binding domain	ONCOGENE			English	Article						eps8; SH3; tre; signal transduction	INSITU HYBRIDIZATION; CYTOGENETIC FINDINGS; GENE; ONCOGENE; CLONING; KINASE; GTPASE	Eps8 is a recently identified SH3-containing substrate for tyrosine kinase receptors, To understand the role of eps8 in receptor-mediated signaling, we cloned cDNAs encoding proteins that bind to its SH3 domain. One of these cDNAs predicts the synthesis of an 828 amino acid protein with homology to the N-terminal region of the tre oncogene. We designated this protein RN-tre for Related to the N-terminus of tre. RN-tre is ubiquitously expressed and maps to 10p13, a region known to be involved in translocations in various leukemias. Tn addition, a 10p13 monosomy syndrome, characterized by developmental alterations, has been reported, The regional homology between RN-tre and tre, which is limited to their N-terminal portion, prompted us to investigate the origin of the tre oncogene transcriptional unit. We were able to show that tre is the fusion product of a 5' genetic element, homologous to RN-tre and a 3' element, encoding a de-ubiquinating enzyme. Moreover, we identified, within the N-terminus of RN-tre and tre, a domain (named TrH, for Tre Homology), which is conserved within several proteins from yeast to mammals and has protein-binding properties in vitro.	EUROPEAN INST ONCOL, DEPT EXPTL ONCOL, IEO, I-20141 MILAN, ITALY; NIDR, NIH, CELLULAR DEV & ONCOL LAB, BETHESDA, MD 20892 USA; NCI, NIH, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; KAZASA DNA RES INST, CHIBA 292, JAPAN; IST MICROBIOL, FAC MED & CHIRURG, BARI, ITALY	IRCCS European Institute of Oncology (IEO); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950				ABE R, 1983, CANCER GENET CYTOGEN, V9, P139, DOI 10.1016/0165-4608(83)90034-1; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3583; BERGER R, 1988, CANCER GENET CYTOGEN, V36, P123, DOI 10.1016/0165-4608(88)90082-9; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DALESSANDRO E, 1990, CANCER GENET CYTOGEN, V45, P231, DOI 10.1016/0165-4608(90)90087-Q; DAVIDOW LS, 1987, J BACTERIOL, V169, P4621, DOI 10.1128/jb.169.10.4621-4629.1987; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GREENBERG F, 1988, AM J HUM GENET, V43, P605; GUPTA K, 1993, ONCOGENE, V8, P2307; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HUEBNER K, 1988, ONCOGENE, V3, P449; KARLSSON T, 1995, ONCOGENE, V10, P1475; KRAUS MH, 1991, METHOD ENZYMOL, V200, P546; Matoskova B, 1996, ONCOGENE, V12, P2679; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; NAKAMURA T, 1992, ONCOGENE, V7, P733; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PUI CH, 1987, BLOOD, V69, P1289; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICHARDSON PM, 1995, ONCOGENE, V11, P1139; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SHAPIRA M, 1994, AM J MED GENET, V52, P34, DOI 10.1002/ajmg.1320520107; SOLER C, 1994, J BIOL CHEM, V269, P12320; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TAKAHASHI E, 1991, CYTOGENET CELL GENET, V57, P109, DOI 10.1159/000133124; TAKAHASHI E, 1990, HUM GENET, V86, P14; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WONG WT, 1994, ONCOGENE, V9, P3057; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2563	2571						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700515				2022-12-17	WOS:A1996UW48700010
J	Howard, JC; Berger, L; Bani, MR; Hawley, RG; BenDavid, Y				Howard, JC; Berger, L; Bani, MR; Hawley, RG; BenDavid, Y			Activation of the erythropoietin gene in the majority of F-MuLV-induced erythroleukemias results in growth factor independence and enhanced tumorigenicity	ONCOGENE			English	Article						friend erythroleukemia; Epo rearrangement; advanced tumorigenicity	MURINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; WILD-TYPE P53; TRANSGENIC MICE; INSERTIONAL ACTIVATION; RECEPTOR GENE; CELL-GROWTH; EXPRESSION; ONCOGENE; FLI-1	Retroviral insertional activation of I;li-l is the first detectable genetic alteration associated with F-MuLV-induced primary erythroleukemias, while mutations within p53 are only observed in Epo-dependent (ED) cell lines derived from syngeneic mice serially transplanted with F-MuLV-induced primary erythroleukemias. In this study we have determined the mechanism of growth factor independence in several Epo-independent (EI) cell lines established from adult mice previously injected with ED-erythroleukemia cell lines or serially transplanted primary tumor cells. Here we have shown constitutive expression of the Epa gene in 12 of 15 (80%) EI-erythroleukemia cell Lines. Among these 12 cell lines, eight were shown to possess clonal rearrangement of the Epo gene which could be detected in the tumors used to establish the majority of these EI-cell lines. Analysis of the pattern of proviral integration revealed that the activation of the Epo gene in these cell lines is independent of retroviral insertional mutagenesis, but apparently the result of genomic rearrangements. Furthermore, the acquisition of growth factor independence by these leukemic cells confers a selective growth advantage in vivo and is associated with enhanced tumorigenicity. Together these observations suggest that the activation of the Epo gene in the large majority of these F-MuLV-induced erythroleukemic cell lines establishes an autocrine loop resulting in the constitutive of the Epo receptor transduction pathway, thereby conferring advantage in vivo and in vitro.	SUNNYBROOK HLTH SCI CTR, DIV CANC BIOL RES, TORONTO, ON M4N 3M5, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO, ON M5S 1A1, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto			Bani, Maria Rosa/AAB-3397-2020	Bani, Maria Rosa/0000-0001-8178-1432; Hawley, Robert/0000-0003-3512-5818				BEN-DAVID Y, 1990, New Biologist, V2, P1015; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BENDAVID Y, 1992, MOL CELL BIOL, V12, P4449, DOI 10.1128/MCB.12.10.4449; BERGER LC, 1994, BIOCHEM BIOPH RES CO, V202, P596, DOI 10.1006/bbrc.1994.1970; BERU N, 1989, ANN NY ACAD SCI, V554, P29, DOI 10.1111/j.1749-6632.1989.tb22406.x; BONDURANT M, 1993, ERYTHROPOIETIN, P241; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HANKINS WD, 1989, ANN NY ACAD SCI, V554, P21, DOI 10.1111/j.1749-6632.1989.tb22405.x; HINO M, 1991, MOL CELL BIOL, V11, P5527, DOI 10.1128/MCB.11.11.5527; HOWARD JC, 1993, ONCOGENE, V8, P2721; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KRYSTAL G, 1983, EXP HEMATOL, V11, P649; LACOMBE C, 1991, J BIOL CHEM, V266, P6952; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANG RA, 1990, IMMUNOL TODAY, V11, P244, DOI 10.1016/0167-5699(90)90098-T; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; MCDONALD J, 1987, MOL CELL BIOL, V7, P365, DOI 10.1128/MCB.7.1.365; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1990, LEUKEMIA, V4, P20; OLIFF A, 1981, BLOOD, V58, P244; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RENCRICCA N J, 1970, Blood, V36, P764; SCHUSTER SJ, 1987, BLOOD, V70, P316; SEMENZA GL, 1990, MOL CELL BIOL, V10, P930, DOI 10.1128/MCB.10.3.930; SEMENZA GL, 1989, P NATL ACAD SCI USA, V86, P2301, DOI 10.1073/pnas.86.7.2301; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P8725, DOI 10.1073/pnas.88.19.8725; SHIBUYA T, 1983, P NATL ACAD SCI-BIOL, V80, P3721, DOI 10.1073/pnas.80.12.3721; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YANG XM, 1994, P NATL ACAD SCI USA, V91, P6924, DOI 10.1073/pnas.91.15.6924; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	42	25	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	1996	12	7					1405	1415						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622856				2022-12-17	WOS:A1996UF07600004
J	Kiefer, P; Mathieu, M; Mason, I; Dickson, C				Kiefer, P; Mathieu, M; Mason, I; Dickson, C			Secretion and mitogenic activity of zebrafish FGF3 reveal intermediate properties relative to mouse and Xenopus homologues	ONCOGENE			English	Article						zebrafish FGF3; fibroblast growth factor; mitogenesis; protein chimeras	FIBROBLAST GROWTH-FACTOR; LIGAND-BINDING SPECIFICITY; PROTO-ONCOGENE INT-2; FACTOR RECEPTORS; FACTOR FAMILY; DEVELOPMENTAL EXPRESSION; CLONING; CELLS; PRODUCT; LAEVIS	Zebrafish (Brachyodanio rerio) Fgf-3 cDNAs expressed in COS-1 cells give rise to a heterogeneous set of secreted proteins with relative molecular masses in the range of 29-30.5 kDa. These proteins associate strongly with the extracellular matrix but are quantitatively released into the culture medium in the presence of heparin (5 mu g/ml). Extracellular zebrafish FGF3 (ZFGF3) also contains a smaller sized component that appears to result from an amino-terminal proteolytic cleavage. These properties are similar to those described for Xenopus FGF3 (XFGF3). Receptor binding experiments indicate that ZFGF3 has a higher affinity for the IIIb rather than the IIIc isoform of FGFR2; properties that are more reminiscent of the mouse than the Xenopus homologue. Consistent with the FGF receptor binding properties, ZFGF3 shows a restricted mitogenic potential and a reduced transforming activity on NIH3T3 cells compared to XFGF3. Hybrid proteins made between Xenopus and zebrafish FGF3 implicate the C-terminal region in determining the differences in receptor binding affinities, mitogenic potency and transforming activity. Thus, ZFGF3 shows the structural and secretory properties of XFGF3, but has biological properties more akin to those of the mouse homologue.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; UNITED MED & DENT SCH,GUYS & ST THOMAS HOSP,DEPT DEV NEUROBIOL,LONDON SE1 9RT,ENGLAND	Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London			Mason, Ivor/B-1859-2008	Mason, Ivor/0000-0001-8390-3050				BAIRD A, 1991, CANCER CELL-MON REV, V3, P239; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BATES B, 1991, MOL CELL BIOL, V11, P1840, DOI 10.1128/MCB.11.4.1840; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; DELL KR, 1992, J BIOL CHEM, V267, P21225; Dickson C, 1989, Prog Growth Factor Res, V1, P123, DOI 10.1016/0955-2235(89)90006-9; DIXON M, 1989, MOL CELL BIOL, V9, P4896, DOI 10.1128/MCB.9.11.4896; EMORI Y, 1992, FEBS LETT, V314, P176, DOI 10.1016/0014-5793(92)80968-M; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KIEFER P, 1993, EMBO J, V12, P4159, DOI 10.1002/j.1460-2075.1993.tb06100.x; KIEFER P, 1991, MOL CELL BIOL, V11, P5929, DOI 10.1128/MCB.11.12.5929; KIEFER P, 1993, MOL CELL BIOL, V13, P5781, DOI 10.1128/MCB.13.9.5781; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; KIEFER P, 1996, CURR TOP DEV BIOL, V25, P77; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; MAHMOOD R, 1995, DEVELOPMENT, V121, P1399; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MATHIEU M, 1995, J BIOL CHEM, V270, P6779, DOI 10.1074/jbc.270.12.6779; MATHIEU M, 1995, IN PRESS J BIOL CHEM; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; PETERS G, 1991, SEMIN VIROL, V2, P319; POULIN ML, 1994, BBA-MOL CELL RES, V1220, P209, DOI 10.1016/0167-4889(94)90137-6; SEDDON AP, 1995, BIOCHEMISTRY-US, V34, P731, DOI 10.1021/bi00003a004; SHI DL, 1992, DEVELOPMENT, V116, P261; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; STRAHLE U, 1992, Current Biology, V2, P135, DOI 10.1016/0960-9822(92)90256-A; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; TANNAHILL D, 1992, DEVELOPMENT, V115, P695; WILKIE AOM, 1995, CURR BIOL, V5, P500; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZIMMER Y, 1993, J BIOL CHEM, V268, P7899	42	25	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1503	1511						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622866				2022-12-17	WOS:A1996UF07600014
J	Mautner, J; Behrends, U; Hortnagel, K; Brielmeier, M; Hammerschmidt, W; Strobl, L; Bornkamm, GW; Polack, A				Mautner, J; Behrends, U; Hortnagel, K; Brielmeier, M; Hammerschmidt, W; Strobl, L; Bornkamm, GW; Polack, A			c-myc expression is activated by the immunoglobulin kappa-enhancers from a distance of at least 30 kb but not by elements located within 50 kb of the unaltered c-myc locus in vivo	ONCOGENE			English	Article						chromatin analysis; c-myc; gene expression; immunoglobulin enhancer; locus control	BURKITTS-LYMPHOMA CELLS; REGULATORY ELEMENTS; GENE-EXPRESSION; PROMOTER SHIFT; 1ST EXON; T-CELL; TRANSLOCATIONS; REGION; PROTOONCOGENE; TRANSCRIPTION	50 kb of contiguous DNA sequences covering the human c-myc coding region and approximately 20 kb of flanking upstream and downstream sequences were cloned onto a prokaryotic F-factor derived plasmid, which also contains a selectable marker and the plasmid origin of DNA replication oriP of Epstein Barr virus (EBV). Since these plasmids replicate extrachromosomally after stable transfection into EBV-positive B-cell lines, the gene regulation of c-myc can be analysed independent from chromosomal integration positions, Despite the presence of all known c-myc regulatory elements on these constructs, expression from the stably transfected c-myc gene was barely detectable in either cell line, Hypermethylation of these plasmids could be excluded as a mechanism for the lack of gene expression, Insertion of the immunoglobulin kappa-intron and 3' enhancers, however, activated c-myc transcription, when placed adjacent to pr separated from the c-myc promoters by as far as 30 kh, These results indicate that transcription of c-myc in vivo requires additional and still unidentified control elements located outside this 50 kb fragment, and experimentally demonstrate long range enhancer function in vivo.	GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT GMBH, INST KLIN MOL BIOL & TUMORGENET, D-81377 MUNICH, GERMANY; GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT GMBH, INST STRAHLENBIOL, D-85764 OBERSCHLEISSHEIM, GERMANY; UNIV MUNICH, ABT PADIATR GENET, D-80336 MUNICH, GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich			Hammerschmidt, Wolfgang/ABG-3921-2021; Brielmeier, Markus/M-7352-2014; Strobl, Lothar J/M-7357-2014	Hammerschmidt, Wolfgang/0000-0002-4659-0427; Brielmeier, Markus/0000-0002-8715-869X; Strobl, Lothar J/0000-0001-8389-1862				BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; CANN AJ, 1988, ONCOGENE, V3, P123; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; FEO S, 1994, ONCOGENE, V9, P955; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; HALUSKA FG, 1988, NUCLEIC ACIDS RES, V16, P2077, DOI 10.1093/nar/16.5.2077; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HENGLEIN B, 1989, MOL CELL BIOL, V9, P2105, DOI 10.1128/MCB.9.5.2105; HORTNAGEL K, 1995, ONCOGENE, V10, P1393; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; JOOS S, 1992, CANCER RES, V52, P6547; JUCKER M, 1992, ONCOGENE, V7, P943; KAVATHAS P, 1980, P NATL ACAD SCI-BIOL, V77, P4251, DOI 10.1073/pnas.77.7.4251; KEMPKES B, 1995, J VIROL, V69, P231, DOI 10.1128/JVI.69.1.231-238.1995; LAVENU A, 1994, ONCOGENE, V9, P527; LAZO PA, 1990, P NATL ACAD SCI USA, V87, P170, DOI 10.1073/pnas.87.1.170; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; MAGRATH I, 1990, ADV CANCER RES, V55, P134; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MAUTNER J, 1995, NUCLEIC ACIDS RES, V23, P72, DOI 10.1093/nar/23.1.72; MENGLEGAW L, 1987, EMBO J, V6, P1959, DOI 10.1002/j.1460-2075.1987.tb02458.x; NISHIKURA K, 1986, MOL CELL BIOL, V6, P4093, DOI 10.1128/MCB.6.11.4093; OCONNOR M, 1989, SCIENCE, V244, P1307, DOI 10.1126/science.2660262; POLACK A, 1991, ONCOGENE, V6, P2033; POLACK A, 1993, EMBO J, V12, P3913, DOI 10.1002/j.1460-2075.1993.tb06069.x; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; PULVERTA.RJ, 1965, J CLIN PATHOL, V18, P261, DOI 10.1136/jcp.18.3.261; Sambrook J., 1989, MOL CLONING LAB MANU; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STROBL LJ, 1993, ONCOGENE, V8, P1437; SUN LK, 1986, NUCLEIC ACIDS RES, V14, P4037, DOI 10.1093/nar/14.10.4037; TRAVERS AA, 1992, CELL, V69, P573, DOI 10.1016/0092-8674(92)90218-2; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; ZEIDLER R, 1994, GENE CHROMOSOME CANC, V9, P282, DOI 10.1002/gcc.2870090408	40	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	1996	12	6					1299	1307						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649832				2022-12-17	WOS:A1996UC06700015
J	Hagmeyer, BM; Duyndam, MCA; Angel, P; deGroot, RP; Verlaan, M; Elfferich, P; vanderEb, AJ; Zantema, A				Hagmeyer, BM; Duyndam, MCA; Angel, P; deGroot, RP; Verlaan, M; Elfferich, P; vanderEb, AJ; Zantema, A			Altered AP-1/ATF complexes in adenovirus-E1-transformed cells due to E1A-dependent induction of ATF3	ONCOGENE			English	Article						LRF1; ATF; cJun; E1A	TRANSCRIPTION FACTOR E2F; JUN PROTO-ONCOGENE; C-JUN; DNA-BINDING; HETERODIMER FORMATION; RESPONSE ELEMENT; UP-REGULATION; E1A; PROTEINS; CREB	The adenovirus (Ad) E1A proteins alter the expression level and activity of AP-1/ATF transcription factors. Previously we have shown that in AdE1-transformed cells cJun is hyperphosphorylated in its N-terminal transactivation domain, which parallels enhanced transactivation function. To find out whether the interaction between cJun and other cellular proteins is altered, we have searched for proteins which would physically associate with cJun. In this report we show that in AdE1-transformed cells cJun specifically associates with two proteins of 21 and 23 kD. These proteins are not expressed at detectable levels in the parental cells or in cells transformed by oncogenes other than AdE1. The cJun-associated proteins represent different forms of the bZIP transcription factor ATF3, the human homolog of rat LRF1. The expression of ATF3 is induced in AdE1-transformed cells and is a direct effect of the expression of E1A. Through induction of ATF3 expression and the subsequent formation of cJun/ATF3 heterodimers, E1A alters the repertoire of AP-1/ATF factors and may thereby redirect the corresponding gene-expression program. Since the induction of ATF3 is a function of sequences within the transforming 12S-E1A protein, cJun/ATF3 complexes might be involved in establishing cellular transformation by AdE1A.	FORSCHUNGSZENTRUM KARLSRUHE, INST GENET, D-76021 KARLSRUHE, GERMANY; LEIDEN UNIV, MOLEC CARCINOGENESIS LAB, 2300 RA LEIDEN, NETHERLANDS	Helmholtz Association; Karlsruhe Institute of Technology; Leiden University; Leiden University - Excl LUMC			Piris, Miguel A/AAP-1445-2020	Piris, Miguel A/0000-0001-5839-3634				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BENBROOK DM, 1990, ONCOGENE, V5, P295; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CARTER R, 1991, ONCOGENE, V6, P229; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHU HM, 1994, MOL ENDOCRINOL, V8, P59, DOI 10.1210/me.8.1.59; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DYSON N, 1992, CANCER SURV, V12, P161; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAGMEYER BM, 1995, BIOESSAYS, V17, P621, DOI 10.1002/bies.950170708; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HERR I, 1994, CARCINOGENESIS, V15, P1105, DOI 10.1093/carcin/15.6.1105; HOEFFLER JP, 1992, J INVEST DERMATOL, V98, pS21, DOI 10.1111/1523-1747.ep12462126; HSU JC, 1993, CANCER RES, V53, P3789; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KITABAYASHI I, 1991, NUCLEIC ACIDS RES, V19, P649, DOI 10.1093/nar/19.3.649; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; SCHOLER H, 1986, SCIENCE, V232, P76, DOI 10.1126/science.3006253; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDEREB AJ, 1992, MALIGNANT TRANSFORMA, P115	39	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					1025	1032						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649793				2022-12-17	WOS:A1996UA88400010
J	VEYRUNE, JL; CARILLO, S; VIE, A; BLANCHARD, JM				VEYRUNE, JL; CARILLO, S; VIE, A; BLANCHARD, JM			C-FOS MESSENGER-RNA INSTABILITY DETERMINANTS PRESENT WITHIN BOTH THE CODING AND THE 3'-NON-CODING REGION LINK THE DEGRADATION OF THIS MESSENGER-RNA TO ITS TRANSLATION	ONCOGENE			English	Article						MESSENGER-RNA STABILITY; TRANSLATION; AU-RICH SEQUENCES; C-FOS	MESSENGER-RNA DEGRADATION; IRON-RESPONSIVE ELEMENTS; PROTEIN-SYNTHESIS INHIBITORS; UNTRANSLATED REGION; RICH SEQUENCES; TRANSFERRIN RECEPTOR; STABILITY INVITRO; GENE-EXPRESSION; BINDING-PROTEIN; GROWTH-FACTORS	The instability of oncogenic mRNA such as c-fos mRNA is controlled in cis by sequences present in both the coding and the 3' untranslated regions (3'UTR). The latter contains AU-rich elements (ARE) which, depending on the cellular context, mediate either their rapid degradation or inhibit their translation. These observations, along with the known increase of the Life spans of many unstable mRNA promoted by inhibitors of protein synthesis, raise the possibility that both processes are linked. To investigate further the putative involvement of translation in both coding region and ARE-mediated rapid decay of c-fos mRNA, we designed an expression vector based on the use of the ferritin mRNA iron regulatory element (IRE). The latter structure links translation to intracellular iron concentration when inserted at the proper location within the 5'UTR. Rapid degradation of a beta-globin/c-fos 3'UTR construct was prevented by Desferrioxamine, an iron chelator, and facilitated by ferric ammonium citrate or hemin, while stability of other mRNAs not containing the IRE or the ARE were unchanged. The same conclusion was reached when tbe stability of a c-fos mRNA devoid of ARE was assessed in function of iron availability.	INST GENET MOLEC MONTPELLIER,CNRS,UMR 9942,F-34033 MONTPELLIER 1,FRANCE	Centre National de la Recherche Scientifique (CNRS)								AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; BELASCO J, CONTROL MESSENGER RN; BICKEL M, 1992, P NATL ACAD SCI USA, V89, P10001, DOI 10.1073/pnas.89.21.10001; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BONNIEU A, 1990, ONCOGENE, V5, P1585; BONNIEU A, 1989, ONCOGENE, V4, P881; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; CHEN CYA, 1992, MOL CELL BIOL, V12, P5748, DOI 10.1128/MCB.12.12.5748; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; GOOSSEN B, 1992, MOL CELL BIOL, V12, P1959, DOI 10.1128/MCB.12.5.1959; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Greenberg ME, 1993, CONTROL MESSENGER RN, P199, DOI 10.1016/B978-0-08-091652-1.50013-X; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HENTZE MW, 1988, GENE, V72, P201, DOI 10.1016/0378-1119(88)90145-X; HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; KRUYS VI, 1988, GENE, V72, P191, DOI 10.1016/0378-1119(88)90144-8; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MATTIA E, 1989, P NATL ACAD SCI USA, V86, P1801, DOI 10.1073/pnas.86.6.1801; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MYER VE, 1992, P NATL ACAD SCI USA, V89, P1296, DOI 10.1073/pnas.89.4.1296; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SCHIAVI SC, 1994, J BIOL CHEM, V269, P3441; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; STEARNE PA, 1985, J IMMUNOL, V134, P3474; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WINSTALL E, 1995, MOL CELL BIOL, V15, P3796; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	53	25	28	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2127	2134						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478533				2022-12-17	WOS:A1995TF29700024
J	SHINTO, Y; MORIMOTO, M; KATSUMATA, M; UCHIDA, A; AOZASA, K; OKAMOTO, M; KUROSAWA, T; OCHI, T; GREENE, MI; TSUJIMOTO, Y				SHINTO, Y; MORIMOTO, M; KATSUMATA, M; UCHIDA, A; AOZASA, K; OKAMOTO, M; KUROSAWA, T; OCHI, T; GREENE, MI; TSUJIMOTO, Y			MOLONEY MURINE LEUKEMIA-VIRUS INFECTION ACCELERATES LYMPHOMAGENESIS IN E-MU-BCL-2 TRANSGENIC MICE	ONCOGENE			English	Article							C-MYC; PRE-B; CHROMOSOMAL BREAKPOINT; FOLLICULAR LYMPHOMA; CELL LYMPHOMAS; T-CELLS; N-MYC; BCL-2; GENE; ACTIVATION	E mu-bcl-2 transgenic mice bearing the bcl-2 proto-oncogene linked to the immunoglobulin enhancer (E mu) sporadically develop B or T cell lymphomas after a long latent period. To identify genes that play important roles in development of lymphoid malignancies, proviral insertional mutagenesis with Moloney murine leukemia virus (MMuLV) was carried out in two lines of transgenic mice expressing the bcl-2 gene primarily in B or T cells. MMuLV infection of non-transgenic mice induced primarily mature T cell lymphomas. By contrast, infection of newborn E mu-blc-2 mice with the virus accelerated lymphomagenesis, and nearly all of the mice eventually succumbed to clonal pre-B, B, or mainly immature T cell lymphoma, indicating the active contribution of the bcl-2 gene in lymphomagenesis. Southern blot analysis of tumor DNA from MMuLV-infected transgenic mice revealed a proviral insertion at the c-myc gene in 26% (9/35) of tumors, at the pim-l gene in 6% (2/35) and at the pim-2 (recently renamed tic-1) gene in 23% (8/35). Some tumors carried two activated oncogenes. No insertion was detected at the bmi-l gene. These data suggest the usefulness of this transgenic system for analysis of lymphomagenesis involving the activated bcl-2 gene.	OSAKA UNIV, SCH MED, BIOMED RES CTR, DEPT MED GENET, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT ORTHOPAED SURG, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT MOLEC PATHOL, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, INST EXPTL ANIM SCI, SUITA, OSAKA 565, JAPAN; UNIV PENN, SCH MED, DEPT PATHOL, PHILADELPHIA, PA 19104 USA	Osaka University; Osaka University; Osaka University; Osaka University; University of Pennsylvania								Acton D, 1992, Curr Top Microbiol Immunol, V182, P293; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; ARMITAGE JO, 1988, J NATL CANCER I, V80, P576, DOI 10.1093/jnci/80.8.576; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BERNS A, 1991, J CELL BIOCHEM, V47, P130, DOI 10.1002/jcb.240470206; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BREUER ML, 1989, EMBO J, V8, P743, DOI 10.1002/j.1460-2075.1989.tb03434.x; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COMPERE SJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P129, DOI 10.1016/0304-419X(88)90008-X; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; CUYPERS HT, 1984, CELL, V37, P141; DAVIS B, 1985, NATURE, V314, P550, DOI 10.1038/314550a0; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GAUWERKY CE, 1988, P NATL ACAD SCI USA, V85, P8548, DOI 10.1073/pnas.85.22.8548; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HARRIS AW, 1988, CURR TOP MICROBIOL, V141, P82; HAUPT Y, 1992, ONCOGENE, V7, P981; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HEDRICK SM, 1984, NATURE, V308, P153, DOI 10.1038/308153a0; ISHIMOTO A, 1987, J VIROL, V61, P1861, DOI 10.1128/JVI.61.6.1861-1866.1987; KATSUMATA M, 1992, P NATL ACAD SCI USA, V89, P11376, DOI 10.1073/pnas.89.23.11376; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MOLONEY JB, 1960, J NATL CANCER I, V24, P933; NUNEZ G, 1990, J IMMUNOL, V144, P3602; REDDY E P, 1980, Cell, V19, P663, DOI 10.1016/S0092-8674(80)80043-2; ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4; SAWAI S, 1991, NEW BIOL, V3, P861; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; SHIMIZU A, 1982, CELL, V28, P499, DOI 10.1016/0092-8674(82)90204-5; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; STRASSER A, 1993, ONCOGENE, V8, P1; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WEINBERG RA, 1989, CANCER RES, V49, P3713; WU L, 1991, NATURE, V349, P71, DOI 10.1038/349071a0; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	53	25	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	1995	11	9					1729	1736						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478600				2022-12-17	WOS:A1995TD09400007
J	SAITO, Y; OGAWA, K				SAITO, Y; OGAWA, K			WILD-TYPE P53 AND C-MYC COOPERATION IN GENERATING APOPTOSIS OF A RAT HEPATOCELLULAR-CARCINOMA CELL-LINE (FAA-HTC1)	ONCOGENE			English	Article						P53; C-MYC; APOPTOSIS; CELL GROWTH	MYELOID LEUKEMIC-CELLS; CANCER-CHEMOTHERAPY; MESSENGER-RNA; CYCLE; DEATH; INDUCTION; BCL-2; MUTATIONS; RADIATION; PROTEIN	p53 and c-myc are both known to be involved in apoptotic cell death as well as positive or negative regulation of cell proliferation, but it is not well established whether their functions are mechanistically correlated. We found that FAA-HTC1 cells, a rat hepatocellular carcinoma cell line, expressed c-myc independently of cell cycle and no detectable p53. To investigate possible co-operation between p53 and c-myc, the dexamethasone (Dex)-inducible wild type rat p53 was stably transfected into this cell line and c-myc expression was suppressed by treatment with c-myc antisense oligonucleotide (AS). p53 expression in the p53-introduced derivative resulted in apoptotic cell death, but it did not inhibit proliferative growth of the viable cells. On the other hand, when c-myc was suppressed in the p53-expressing cells, both apoptosis and cell growth were inhibited. These results indicate that p53 can act in the same cells either as a growth-inhibitor or apoptosis-inducer depending on the status of c-myc expression.	ASAHIKAWA MED COLL,DEPT PATHOL,ASAHIKAWA 078,HOKKAIDO,JAPAN	Asahikawa Medical College								ASKEW DS, 1991, ONCOGENE, V6, P1915; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLOMBEL M, 1992, CANCER RES, V52, P4313; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FUJIWARA T, 1994, CANCER RES, V54, P2287; FUKUDA I, 1992, CELL STRUCT FUNCT, V17, P427, DOI 10.1247/csf.17.427; FURUKAWA K, 1987, Tumor Research, V22, P71; HALDAR S, 1994, CANCER RES, V54, P2095; HARPER JW, 1993, CELL, V75, P805; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KADOHAMA T, 1994, ONCOGENE, V9, P2845; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERRITT AJ, 1994, CANCER RES, V54, P614; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; RADINSKY R, 1994, ONCOGENE, V9, P1877; RAMQVIST T, 1993, ONCOGENE, V8, P1495; ROBINSON WS, 1994, ANNU REV MED, V45, P297; ROBINSON WS, 1994, ANNU REV MED, V13, P711; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SAETER G, 1990, Critical Reviews in Oncogenesis, V1, P437; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SOURCCI T, 1988, NUCLEIC ACIDS RES, V16, P11384; STRANGE R, 1992, DEVELOPMENT, V115, P49; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TSUJI K, 1994, MOL CARCINOGEN, V9, P167, DOI 10.1002/mc.2940090308; WANG YS, 1993, ONCOGENE, V8, P3427; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	53	25	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1013	1018						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566958				2022-12-17	WOS:A1995RX18000001
J	LALLE, P; MOYRETLALLE, C; WANG, Q; VIALLE, JM; NAVARRO, C; BRESSACDEPAILLERETS, B; MAGAUD, JP; OZTURK, M				LALLE, P; MOYRETLALLE, C; WANG, Q; VIALLE, JM; NAVARRO, C; BRESSACDEPAILLERETS, B; MAGAUD, JP; OZTURK, M			GENOMIC STABILITY AND WILD-TYPE P53 FUNCTION OF LYMPHOBLASTOID-CELLS WITH GERM-LINE P53 MUTATION	ONCOGENE			English	Article						P53; LI-FRAUMENI SYNDROME; EPSTEIN-BARR VIRUS; LYMPHOBLASTOID CELLS; GENOMIC STABILITY	DINUCLEOTIDE REPEAT POLYMORPHISM; TUMOR-SUPPRESSOR GENE; CANCER-PRONE FAMILY; FRAUMENI SYNDROME; BREAST-CANCER; CHROMOSOMAL-ABNORMALITIES; CYCLE ARREST; FIBROBLASTS; APOPTOSIS; PROTEIN	Increased cancer risk associated with germ-line p53 mutation was linked to a deficit in the ability to maintain genomic stability. Accordingly, normal fibroblasts from cancer-prone individuals accumulate genomic aberrations with concomitant loss of mild-type p53 allele during in vitro culture. We tested whether such changes also occur in EBV-immortalized lymphoblastoid cells. Both normal and p53 germ-line mutant lymphoblastoid cells maintained functional p53 and genomic stability during long term in vitro culture. These unexpected differences between fibroblastic and lymphoblastic cells suggest that phenotypic expression of p53 deficiency is cell type specific. This could contribute to selective tissular localization of tumours observed in patients with Li-Fraumeni syndrome despite the presence of a mutant p53 allele in all cells.	CTR LEON BERARD, INSERM, CJF 9302, ONCOL MOLEC LAB, F-69373 LYON 08, FRANCE; HOP EDOUARD HERRIOT, INSERM, CJF 9307, CENT HEMATOL & CYTOGENET LAB, F-69437 LYON, FRANCE; INST GUSTAVE ROUSSY, DIAGNOST MOLEC LAB, F-94805 VILLEJUIF, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy			OZTURK, MEHMET/AAS-7241-2021; Moyret-Lalle, Caroline/G-2742-2013; LALLE, Philippe/G-7734-2018; ozturk, mehmet/G-3330-2014; Paillerets, Brigitte Bressac-de/D-8954-2018	OZTURK, MEHMET/0000-0002-6092-9706; Moyret-Lalle, Caroline/0000-0002-8359-2018; Paillerets, Brigitte Bressac-de/0000-0003-0245-8608				ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BIRCH JM, 1994, CANCER RES, V54, P1298; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; BOND JA, 1994, ONCOGENE, V9, P1885; BROWN AG, 1993, NAT GENET, V3, P67, DOI 10.1038/ng0193-67; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DEINARD AS, 1992, NUCLEIC ACIDS RES, V20, P1171, DOI 10.1093/nar/20.5.1171-a; DELDEIRY WS, 1994, CANCER RES, V54, P1169; DUTHU A, 1992, ONCOGENE, V7, P2161; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FREBOURG T, 1992, CANCER RES, V52, P6976; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HARDNEN DG, 1985, ISCN INT SYSTEM HUMA; HARVEY M, 1993, ONCOGENE, V8, P2457; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; IAVARONE A, 1992, P NATL ACAD SCI USA, V89, P4207, DOI 10.1073/pnas.89.9.4207; JIANG HP, 1994, ONCOGENE, V9, P3397; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; Jones Michael H., 1992, Human Molecular Genetics, V1, P131, DOI 10.1093/hmg/1.2.131; JULIUSSON G, 1990, NEW ENGL J MED, V323, P720, DOI 10.1056/NEJM199009133231105; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KLINEDINST DK, 1991, MUTAT RES, V250, P365, DOI 10.1016/0027-5107(91)90193-R; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAW JC, 1991, CANCER RES, V51, P6385; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; LI FP, 1969, J NATL CANCER I, V43, P1365; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LYNCH HT, 1978, CANCER, V41, P2055, DOI 10.1002/1097-0142(197805)41:5<2055::AID-CNCR2820410554>3.0.CO;2-X; MAGAUD JP, 1985, HUM GENET, V69, P238, DOI 10.1007/BF00293032; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; MAZOYER S, 1994, ONCOGENE, V9, P1237; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OCONNOR PM, 1993, CANCER RES, V53, P4776; OFFIT K, 1991, GENE CHROMOSOME CANC, V3, P189, DOI 10.1002/gcc.2870030304; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLSON DC, 1993, ONCOGENE, V8, P2353; Sambrook J., 1989, MOL CLONING LAB MANU; SAMESHIMA Y, 1992, J NATL CANCER I, V84, P703, DOI 10.1093/jnci/84.9.703; SANTIBANEZKOREF MF, 1991, LANCET, V338, P1490, DOI 10.1016/0140-6736(91)92303-J; SHAY JW, 1993, BREAST CANCER RES TR, V25, P83, DOI 10.1007/BF00662404; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEEL CM, 1977, NATURE, V270, P349, DOI 10.1038/270349a0; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; TOGUCHIDA J, 1993, GENOMICS, V17, P535, DOI 10.1006/geno.1993.1368; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WILLIAMS WR, 1985, FAM CANCER, P151; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZECH L, 1976, INT J CANCER, V17, P47, DOI 10.1002/ijc.2910170108; ZHANG Q, 1994, MOL CELL BIOL, V14, P1929, DOI 10.1128/MCB.14.3.1929	66	25	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2447	2454						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784096				2022-12-17	WOS:A1995RE54300023
J	ODA, S; NISHIDA, J; NAKABEPPU, Y; SEKIGUCHI, M				ODA, S; NISHIDA, J; NAKABEPPU, Y; SEKIGUCHI, M			STABILIZATION OF CYCLIN-E AND CDK2 MESSENGER-RNAS AT G1/S TRANSITION IN RAT-1A CELLS EMERGING FROM THE G0 STATE	ONCOGENE			English	Article						IMMEDIATE-EARLY GENES; DELAYED-EARLY GENES; DELTA-FOSB; FOSB CELL CYCLE; CELL PROLIFERATION	IMMEDIATE-EARLY GENES; CULTURED MOUSE CELLS; 3T3 CELLS; MESSENGER-RNA; C-FOS; SHORT FORM; EXPRESSION; PROTEIN; JUN; FIBROBLASTS	mRNAs for cyclin E and Cdk2 have a role in the commitment to DNA replication in the cell cycle, and are induced in Rat-1A cells by serum stimulation. Cyclin E and cdk2 genes are transcribed in quiescent cells, but their transcripts rapidly turn over and levels are kept low. The rate of transcription of the cdk2 gene is slightly increased after serum stimulation, while that of cyclin E is fairly constant. At the G1/S transition of serum-stimulated cells, transient stabilization of the two types of mRNAs occurs, an event which may lead to induction of each mRNA. Artificial expression of an immediate-early protein Delta FosB results in proliferation of quiescent Rat-1A cells, and this is accompanied by an efficient induction of cyclin E and cdk2 mRNAs. In Delta FosB-expressing cells, two types of mRNAs are stabilized to the same extent seen in serum-stimulated cells. The expression of cyclin E and cdk2 genes is upregulated by stabilization of their transcripts, at least in part. We propose that Delta FosB may have a role in regulation of progression of the cell cycle in serum-stimulated Rat-1A cells by triggering stabilization of mRNAs for cyclin E and Cdk2.	KYUSHU UNIV 69, MED INST BIOREGULAT, DEPT BIOCHEM, FUKUOKA 812, JAPAN	Kyushu University			Nakabeppu, Yusaku/A-8902-2011	Nakabeppu, Yusaku/0000-0002-6739-242X				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; DULBECCO R, 1973, NATURE, V246, P197, DOI 10.1038/246197a0; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; FINANCSEK I, 1982, GENE, V18, P115; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOVARY K, 1991, NEW BIOL, V3, P870; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LU XP, 1992, J BIOL CHEM, V267, P2841; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; METZ R, 1994, EMBO J, V13, P3832, DOI 10.1002/j.1460-2075.1994.tb06694.x; MILLER AD, 1984, CELL, V36, P51; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; NAKABEPPU Y, 1985, J BIOL CHEM, V260, P7281; NATHANS D, 1991, ORIGINS OF HUMAN CANCER, P353; NIKAIDO T, 1991, EXP CELL RES, V192, P102, DOI 10.1016/0014-4827(91)90163-O; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NOGUCHI E, 1993, BIOCHEM BIOPH RES CO, V197, P1524, DOI 10.1006/bbrc.1993.2650; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Sambrook J., 1989, MOL CLONING LAB MANU; SCHIAVI SC, 1992, BIOCHIM BIOPHYS ACTA, V1114, P95, DOI 10.1016/0304-419X(92)90009-N; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TAMURA K, 1993, ONCOGENE, V8, P2113; TODARO GJ, 1965, J CELL COMPAR PHYSL, V66, P325, DOI 10.1002/jcp.1030660310; TREMBLEY JH, 1994, CELL GROWTH DIFFER, V5, P99; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WIMMEL A, 1994, ONCOGENE, V9, P995; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	56	25	25	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1343	1351						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731685				2022-12-17	WOS:A1995QR65100011
J	AVILA, MA; VELASCO, JA; CHO, C; LUPU, R; WEN, DZ; NOTARIO, V				AVILA, MA; VELASCO, JA; CHO, C; LUPU, R; WEN, DZ; NOTARIO, V			HYPERACTIVE AUTOCRINE LOOP MEDIATED BY A NDF-RELATED FACTOR IN NEOPLASTIC HAMSTER-EMBRYO FIBROBLASTS EXPRESSING AN ACTIVATED CPH ONCOGENE	ONCOGENE			English	Article						MITOGENIC FACTORS; ERBB-2 TYROSINE KINASE; NEOPLASTIC CONVERSION; CELL PROLIFERATION; CPH TRANSFORMATION	NEU DIFFERENTIATION FACTOR; HUMAN-BREAST-CANCER; GROWTH-FACTOR; PROTO-ONCOGENE; EGF RECEPTOR; SIGNAL TRANSDUCTION; TYROSINE KINASE; POINT MUTATION; LIGAND; CELLS	We described previously the characterization of a novel oncogene, cph, activated in primary Syrian hamster embryo fibroblasts by exposure to 3-methylcholanthrene (Velasco et al., Oncogene 9: 2065-2069, 1994). The present report describes the participation in the neoplastic conversion of cph-expressing (81C=39) hamster fibroblasts of a hyperactive autocrine loop involving a nea differentiation factor [NDF]-like protein, The tyrosine phosphorylation of the p185(erbB-2) receptor in the human breast carcinoma MDA-MB-453 cells was stimulated by conditioned medium from neoplastic 81C39 cells. The extent of this stimulatory effect was much greater than that induced by conditioned medium from normal 84-3 hamster cells. The p185(erbB-2) tyrosine phosphorylation-stimulating activity was partially blocked by the heparin analogue pentosan polysulfate [PPS], a known antagonist of p185(erbB-2) ligands, and was partially purified from 81C39 conditioned medium by heparin-Sepharose chromatography. The level of p185(erbB-2) tyrosine phosphorylation-stimulating activity in the heparin-Sepharose fractions correlated directly with their content in NDF-like protein as immunodetected with an anti-rat NDF antibody, Consistently, the steady-state level of NDF-related mRNA was found to be four times greater in neoplastic 81C39 cells than in normal 84-3 cells. However, the levels of erbB-2 mRNA were similar in both cell types, while the expression of erbB-4 mRNA was upregulated in the neoplastic fibroblasts. The ability of 81C39 conditioned medium to stimulate protein tyrosine phosphorylation and to induce other PPS-sensitive growth responses on 81C39 cells themselves suggested the involvement of an autocrine loop in their neoplastic conversion, The participation of a NDF-related factor in this autocrine loop was confirmed by the ability of an anti-NDF antibody to block the mitogenic activity present in their own conditioned medium. The involvement of the cpk oncogene in the upregulation of NDF-related expression was evidenced when cph-transformed NIH3T3 fibroblasts showed elevated levels of NDF-related mRNA, and their conditioned medium induced tyrosine phosphorylation on MDA-MB-453 cells, reproducing the effect of the medium from 81C39 hamster cells.	GEORGETOWN UNIV, MED CTR, DEPT RADIAT MED, DIV EXPTL CARCINOGENESIS, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, VINCENT T LOMBARDI CANC RES CTR, WASHINGTON, DC 20007 USA; AMGEN INC, THOUSAND OAKS, CA 91320 USA	Georgetown University; Georgetown University; Amgen			Avila, Matias A/Y-6342-2019; /AAB-6461-2022; /AFP-0764-2022	Avila, Matias A/0000-0001-6570-3557; 	NCI NIH HHS [CA49858] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA049858] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BACUS SS, 1993, CANCER RES, V53, P5251; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BARRETT JC, 1978, P NATL ACAD SCI USA, V75, P3761, DOI 10.1073/pnas.75.8.3761; BERWALD Y, 1965, J NATL CANCER I, V35, P641; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIPAOLO JA, 1969, J NATL CANCER I, V42, P867; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HIRAKAWA T, 1991, ONCOGENE, V6, P289; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG SS, 1992, J BIOL CHEM, V267, P11508; KRAUS MH, 1988, ANN NY ACAD SCI, V551, P320, DOI 10.1111/j.1749-6632.1988.tb22358.x; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; NOTARIO V, 1990, ONCOGENE, V5, P1425; ORRURTREGER A, 1993, P NATL ACAD SCI USA, V90, P1867, DOI 10.1073/pnas.90.5.1867; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; TARAKHOVSKY A, 1991, ONCOGENE, V6, P2187; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELASCO JA, 1994, ONCOGENE, V9, P2065; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WESTERMARK B, 1991, CANCER RES, V51, P5087; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569	51	25	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	1995	10	5					963	971						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7534900				2022-12-17	WOS:A1995QL03800018
J	WANG, Y; FARMER, G; SOUSSI, T; PRIVES, C				WANG, Y; FARMER, G; SOUSSI, T; PRIVES, C			XENOPUS-LAEVIS P53 PROTEIN - SEQUENCE-SPECIFIC DNA-BINDING, TRANSCRIPTIONAL REGULATION AND OLIGOMERIZATION ARE EVOLUTIONARILY CONSERVED	ONCOGENE			English	Note						P53; XENOPUS; DNA BINDING; OLIGOMERIZATION	MUTANT P53; WILD-TYPE; GENE; MUTATIONS; SITE; TRANSFORMATION; COMPLEXES	The well conserved human and murine p53 proteins are tetramers that can activate transcription from templates bearing p53 binding sites. Since the normal function of mammalian p53 is necessary for preserving the stability of genome, we examined the properties of purified Xenopus p53 (Xp53) to determine whether it shares similar biochemical activities. Xp53 was shown to bind specifically to sites containing the p53 consensus sequence derived for human p53. Moreover, Xp53 transactivates reporter genes containing a human p53 response element in vivo. Finally, Xp53 can be crosslinked into tetramers in a manner similar to human p53. However, Xp53 forms hetero-oligomers with human or murine p53 only very ineffectively, in contrast to the efficient hetero-oligomer formation that occurs between human and murine p53 polypeptides. Taken together, our data indicate that sequence specific DNA binding, transcriptional regulation and oligomerization of p53 are common properties of vertebrate p53 proteins, and thus they are likely to be required for the biological activity of the protein.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027; INST GENET MOLEC,INSERM,U301,F-75010 PARIS,FRANCE	Columbia University; Institut National de la Sante et de la Recherche Medicale (Inserm)				soussi, thierry/0000-0001-8184-3293	NCI NIH HHS [CA 58316] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA058316, R01CA058316] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALL PA, 1993, ONCOGENE, V8, P203; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOEVER M, 1993, ONCOGENE, V9, P109; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kay BK, 1991, METHODS CELL BIOL, V36; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; Reed Michael, 1993, Gene Expression, V3, P95; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TACHANG F, 1993, DEV BIOL, V159, P163	30	25	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					779	784						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862457				2022-12-17	WOS:A1995QH61200020
J	LEIBOVITCH, MP; SOLHONNE, B; GUILLIER, M; VERELLE, P; LEIBOVITCH, SA				LEIBOVITCH, MP; SOLHONNE, B; GUILLIER, M; VERELLE, P; LEIBOVITCH, SA			DIRECT RELATIONSHIP BETWEEN THE EXPRESSION OF TUMOR-SUPPRESSOR H19 MESSENGER-RNA AND C-MOS PROTOONCOGENE DURING MYOGENESIS	ONCOGENE			English	Article						H19; C-MOS; MYOGENESIS; GENE; EXPRESSION	SOMATIC-CELL EXPRESSION; MYOSIN LIGHT CHAIN-1; MURINE SARCOMA-VIRUS; SKELETAL-MUSCLE; MESSENGER-RNA; ALPHA-ACTIN; MOUSE; GENE; CDNA; DIFFERENTIATION	We have cloned and sequenced an almost complete c-DNA and the entire genomic sequence of rat the H19 gene, which is developmentally regulated in skeletal muscle, The data base comparison revealed a 92% homology with mouse gene H19. However the rat H19 ORFs do not display significant homology with the H19 ORFs from other species, In contrast to the mouse, the rat H19 mRNA is not easily detectable in fetal rat skeletal fibers. Its level increases after birth (up to 12 to 18 days) and remains stable thereafter. The pattern of H19 mRNA expression in rat muscle in vivo is very similar to the c-mos gene expression in this tissue, suggesting an interrelationship between H19 and c-mos products during muscle differentiation. Indeed, our results indicate that overexpression of c-mos protein in the muscle cell line C2C12 induces a concomitant increase of H19 mRNA expression. Furthermore, repression of c-mos protein expression by anti-sense RNAs extinguishes H19 mRNA expression and inhibits the differentiation process. These data suggest a relationship between c-mos and H19 expression and, in addition, the involvement of both gene products in the process of myogenesis.	INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,URA 126,F-94805 VILLEJUIF,FRANCE; CTR PERRIN,RADIOTHERAPIE SERV,F-53011 CLERMONT FERRAND,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	LEIBOVITCH, MP (corresponding author), INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,UA 1158,39 RUE CAMILLE DESMOULINS,F-94805 VILLEJUIF,FRANCE.							BAI W, 1992, ONCOGENE, V7, P493; BAI WL, 1992, ONCOGENE, V7, P1757; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; GARFINKEL LI, 1982, J BIOL CHEM, V257, P1078; GLASER T, 1989, SOMAT CELL MOLEC GEN, V15, P447; GOAD WB, 1982, NUCLEIC ACIDS RES, V10, P247, DOI 10.1093/nar/10.1.247; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; GUILLIER M, 1991, NUCLEIC ACIDS RES, V19, P1339, DOI 10.1093/nar/19.6.1339; HAN DKM, 1992, CIRC RES, V71, P711, DOI 10.1161/01.RES.71.3.711; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HERZOG NK, 1989, ONCOGENE, V4, P1307; KURATA N, 1989, EMBO J, V8, P457, DOI 10.1002/j.1460-2075.1989.tb03398.x; LEIBOVITCH MP, 1991, BIOCHEM BIOPH RES CO, V180, P1241, DOI 10.1016/S0006-291X(05)81329-4; LEIBOVITCH SA, 1989, ONCOGENE RES, V4, P157; LEIBOVITCH SA, 1990, ONCOGENE, V5, P1149; LEIBOVITCH SA, 1991, ONCOGENE, V6, P1617; LEIBOVITCH SA, 1993, ONCOGENE, V8, P2361; LENORMAND JL, 1993, NUCLEIC ACIDS RES, V21, P695, DOI 10.1093/nar/21.3.695; LI CCH, 1993, ONCOGENE, V8, P1685; LI H, 1994, J CELL BIOL, V124, P827, DOI 10.1083/jcb.124.5.827; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; OKAZAKI K, 1992, EMBO J, V11, P2443; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; POIRIER F, 1991, DEVELOPMENT, V113, P1105; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; ROBERT B, 1984, CELL, V39, P129, DOI 10.1016/0092-8674(84)90198-3; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SETH A, 1987, P NATL ACAD SCI USA, V84, P3560, DOI 10.1073/pnas.84.11.3560; SHIBUYA EK, 1988, DEV BIOL, V129, P253, DOI 10.1016/0012-1606(88)90179-0; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; TSUI LV, 1993, INT J ONCOL, V2, P493; VOGEL M, 1987, DEV BIOL, V119, P481, DOI 10.1016/0012-1606(87)90051-0; WILES MV, 1988, DEVELOPMENT, V104, P403; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	46	25	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					251	260						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838525				2022-12-17	WOS:A1995QC62400004
J	ASAI, A; MIYAGI, Y; SUGIYAMA, A; NAGASHIMA, Y; KANEMITSU, H; OBINATA, M; MISHIMA, K; KUCHINO, Y				ASAI, A; MIYAGI, Y; SUGIYAMA, A; NAGASHIMA, Y; KANEMITSU, H; OBINATA, M; MISHIMA, K; KUCHINO, Y			THE S-MYC PROTEIN HAVING THE ABILITY TO INDUCE APOPTOSIS IS SELECTIVELY EXPRESSED IN RAT EMBRYO CHONDROCYTES	ONCOGENE			English	Article							C-MYC; CELL-DEATH; MAMMALIAN-CELLS; DIFFERENTIATION; BCL-2; PHOSPHORYLATION; IDENTIFICATION; PROTOONCOGENE; MECHANISMS; DOMAIN	Gene transfection experiments demonstrated that overexpression of the s-myc gene under the control of a human metallothionein promoter induced apoptosis in cells such as rat and human glioma cells. In contrast to c-Myc-mediated apoptosis requiring withdrawal of serum growth factors, s-myc expression induced apoptosis in glioma cells in the presence of 10% fetal calf serum. Whereas, s-Myc-mediated apoptosis was suppressed in proportion to the increase of bcl-2 expression as seen in c-Myc mediated apoptosis. The s-myc gene was expressed in rat embryo cells being committed to differentiate to hypertrophic chondrocytes which undergo programmed cell death. CAT assay demonstrated that in the NH,terminal region, the s-Myc protein contains a domain structure required for expression of transactivation activity that is approximately six times higher than that of c-Myc. Therefore, these findings strongly suggest that s-Myc may play an important role in transcription regulation of a set of genes whose expression induces programmed cell death in vitro and in vivo.	NATL CANC CTR, RES INST, DIV BIOPHYS, CHUO KU, TOKYO 104, JAPAN; YOKOHAMA CITY UNIV, SCH MED, DEPT PATHOL 2, KANAZAWA KU, YOKOHAMA, KANAGAWA 236, JAPAN; TEIKYO UNIV, SCH MED, DEPT NEUROSURG, ITABASHI KU, TOKYO 173, JAPAN; TOHOKU UNIV, INST DEV AGING & CANC, DEPT CELL BIOL, AOBA KU, SENDAI, MIYAGI 980, JAPAN	National Cancer Center - Japan; Yokohama City University; Teikyo University; Tohoku University								AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; ASAI A, IN PRESS J NEUROONCO; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FARQUHARSON C, 1992, J CELL PHYSIOL, V152, P135, DOI 10.1002/jcp.1041520118; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KUCHINO Y, 1990, GENETIC BASIS CARCIN, P239; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MEEK DW, 1992, BIOCHEM J, V287, P1; NAGANE M, 1992, JPN J CLIN ONCOL, V22, P143; NEMOTO Y, 1990, GENE, V91, P261, DOI 10.1016/0378-1119(90)90097-B; PENN LJZ, 1990, CANCER BIOL, V1, P69; SETH A, 1991, J BIOL CHEM, V266, P23521; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SMEYNE RJ, 1993, SCIENCE, V363, P166; SUGIYAMA A, 1989, P NATL ACAD SCI USA, V86, P9144, DOI 10.1073/pnas.86.23.9144; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WURM FM, 1986, P NATL ACAD SCI USA, V83, P5414, DOI 10.1073/pnas.83.15.5414; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	30	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1994	9	8					2345	2352						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036017				2022-12-17	WOS:A1994NX62900028
J	JALAVA, A; MAI, S				JALAVA, A; MAI, S			FOS AND JUN FORM CELL-SPECIFIC PROTEIN COMPLEXES AT THE NEUROPEPTIDE TYROSINE PROMOTER	ONCOGENE			English	Note							NEURO-BLASTOMA CELLS; HUMAN NEUROBLASTOMA-CELLS; TRANSCRIPTION FACTOR AP-1; DNA-BINDING; C-JUN; Y GENE; KINASE; EXPRESSION; TPA; DIFFERENTIATION	In this study we have investigated DNA-protein interactions at an AP1-like motif of the neuropeptide tyrosine (NPY) promoter during in vitro differentiation of human neuroblastoma cells SH-SY5Y to mature liferative sympathetic neuron-like cells. neuroblast-like cells originate from the parental cell line SK-N-SH from which two phenotypically distinct major cell types have been subcloned: the neuroblast-like SH-SY5Y cells and the epithelial-like SH-EP cells. SH-SY5Y cells can be induced to differentiate towards mature noradrenergic ganglion-like cells by the protein kinase C activator TPA (12-O-tetradecanoyl phorbol 13-acetate). Interestingly, the effects of TPA are mimicked by the protein kinase inhibitor, staurosporine, which induces the expression of TPA target genes such as the neuronal differentiation-associated gene NPY in SH-SY5Y cells. Following activation of PKC, the effects of TPA are known to act through the transcription factor AP-1. To study transcriptional regulation during sympathetic differentiation of human neuroblastoma cells by TPA as well as by staurosporine, we focussed on protein complexes at an evolutionarily conserved AP-1 like motif located at nucleotide positions -70 to -65 within the 5'-flanking region of the NPY gene. We show that both c-Jun and c-Fos are part of the protein complexes that bind to this sequence in SH-SY5Y cells. Both staurosporine and TPA enhanced and modulated the binding of these DNA-protein complexes concomitant with the NPY mRNA expression. On the other hand, the absence of these complexes in the SH-EP subclone was associated with the absence of NPY mRNA expression and a lack of differentiation-associated morphological changes. The data suggest that Fos and Jun heterodimers are part of the protein complexes that bind to the AP-1 regulatory element of the NPY promoter in the neuroblast-like SH-SY5Y cells. These protein complexes appear to contribute to the cell specific expression of the NPY gene and seem to be required during differentiation of SH-SY5Y human neuroblastoma cells further along the sympathetic neuronal lineage induced by either TPA or staurosporine.	ABO AKAD UNIV,DEPT BIOCHEM & PHARM,SF-20521 TURKU,FINLAND; BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND	Abo Akademi University			Mai, Sabine/E-5667-2017	Mai, Sabine/0000-0002-5797-2201				ANDERSSON G, 1994, CELL GROWTH DIFFER, V57, P27; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEDLER JL, 1978, CANCER RES, V38, P3751; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GIARDINA SL, 1987, ANAL BIOCHEM, V161, P109, DOI 10.1016/0003-2697(87)90659-2; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAMMERLING U, 1987, ONCOGENE, V2, P73; HEIKKILA JE, 1989, J CELL PHYSIOL, V140, P593, DOI 10.1002/jcp.1041400326; JALAVA A, 1993, J CELL PHYSIOL, V155, P301, DOI 10.1002/jcp.1041550211; JALAVA A, 1992, FEBS LETT, V300, P114, DOI 10.1016/0014-5793(92)80176-H; JALAVA AM, 1988, EXP CELL RES, V179, P10, DOI 10.1016/0014-4827(88)90343-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Maniatis T., 1982, MOL CLONING; MINTH CD, 1990, J BIOL CHEM, V265, P12933; MINTH CD, 1986, J BIOL CHEM, V261, P1974; PAHLMAN S, 1981, INT J CANCER, V28, P583, DOI 10.1002/ijc.2910280509; PARROW V, 1992, J CELL PHYSIOL, V152, P536, DOI 10.1002/jcp.1041520313; ROSS RA, 1983, J NATL CANCER I, V71, P741	27	25	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2369	2375						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036020				2022-12-17	WOS:A1994NX62900031
J	TASHIRO, S; KOTOMURA, N; TANAKA, K; SUZUKI, K; KYO, T; DOHY, H; NIWA, O; KAMADA, N				TASHIRO, S; KOTOMURA, N; TANAKA, K; SUZUKI, K; KYO, T; DOHY, H; NIWA, O; KAMADA, N			IDENTIFICATION OF ILLEGITIMATE RECOMBINATION HOT-SPOT OF THE RETINOIC ACID RECEPTOR-ALPHA GENE INVOLVED IN 15,17-CHROMOSOMAL TRANSLOCATION OF ACUTE PROMYELOCYTIC LEUKEMIA	ONCOGENE			English	Article							MOLECULAR ANALYSIS; MAMMALIAN-CELLS; T(15-17) TRANSLOCATION; DNA FRAGMENTS; RAR-ALPHA; PML; SEQUENCES; ONCOGENE; REARRANGEMENTS; AMPLIFICATION	Acute promyelocytic leukemia (APL) has been characterized by 15;17 chromosomal translocation, which involves the retinoic acid receptor alpha (RARA) gene on chromosome 17 and the PML gene on chromosome 15. The breakpoints have been mapped to three cluster regions in the PML gene, and to RARA gene intron 2. We have examined the distribution of breakpoints within RARA gene intron 2. An extremely restricted region (ERR) of 50 bp within RARA gene intron 2 was identified as the duster region of breakpoints by polymerase chain reaction and sequence analysis of DNA from APL patients. To study experimentally the mechanism involved in the translocation, ERR was tested in NIH3T3 cells by in vitro transfection-recombination assay, in which target sequences were placed either downstream of the SV40 promoter or upstream of the neo gene. Cells were conferred resistance to G418 only when the promoter was fused to the neo gene by recombination of two target sequences during transfection. The molecular junctions were analysed in five clones, and all of them were shown to be confined within a 20 bp region in a 148 bp DNA fragment containing ERR. This suggests that ERR might be the illegitimate recombination hot spot in mammalian cells.	HIROSHIMA UNIV,NUCL MED & BIOL RES INST,DEPT HEMATOL,HIROSHIMA 734,JAPAN; HIROSHIMA UNIV,NUCL MED & BIOL RES INST,DEPT PATHOL,HIROSHIMA 734,JAPAN; HIROSHIMA UNIV,NUCL MED & BIOL RES INST,DEPT BIOPHYS & BIOCHEM,HIROSHIMA 734,JAPAN; HIROSHIMA RED CROSS HOSP,DEPT INTERNAL MED 4,HIROSHIMA 734,JAPAN; HIROSHIMA UNIV,SCH MED,DEPT PEDIAT,HIROSHIMA 734,JAPAN	Hiroshima University; Hiroshima University; Hiroshima University; Hiroshima University								BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CHAKRABARTI S, 1986, MOL CELL BIOL, V6, P2520, DOI 10.1128/MCB.6.7.2520; CHAMPOUX JJ, 1988, GENETIC RECOMBINATIO, P655; CHEN SJ, 1989, NUCLEIC ACIDS RES, V17, P7631, DOI 10.1093/nar/17.19.7631; DARBY MK, 1986, EMBO J, V5, P2257, DOI 10.1002/j.1460-2075.1986.tb04493.x; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DONG S, 1993, GENE CHROMOSOME CANC, V6, P133, DOI 10.1002/gcc.2870060302; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.ge.21.120187.001541; JAEGER U, 1993, BLOOD, V81, P1833; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAMADA N, 1981, BLOOD, V58, P1213; KARIYA Y, 1987, GENE, V53, P1, DOI 10.1016/0378-1119(87)90087-4; KROWCZYNSKA AM, 1990, NUCLEIC ACIDS RES, V18, P1121, DOI 10.1093/nar/18.5.1121; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MORRIS T, 1993, P NATL ACAD SCI USA, V90, P1392, DOI 10.1073/pnas.90.4.1392; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; PONCE MR, 1992, NUCLEIC ACIDS RES, V20, P623, DOI 10.1093/nar/20.3.623; ROWLEY JD, 1977, LANCET, V1, P549; RUBNITZ J, 1986, MOL CELL BIOL, V6, P1608, DOI 10.1128/MCB.6.5.1608; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; STARY A, 1992, NUCLEIC ACIDS RES, V20, P4269, DOI 10.1093/nar/20.16.4269; TASHIRO S, 1992, ONCOGENE, V7, P573; TASHIRO S, 1992, CANCER-AM CANCER SOC, V70, P2809, DOI 10.1002/1097-0142(19921215)70:12<2809::AID-CNCR2820701214>3.0.CO;2-#; TASHIRO S, 1993, JPN J CANCER RES, V84, P110, DOI 10.1111/j.1349-7006.1993.tb02841.x; TSUKIYAMA T, 1989, MOL CELL BIOL, V9, P4670, DOI 10.1128/MCB.9.11.4670; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; Yunis J J, 1986, Important Adv Oncol, P93	33	25	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1939	1945						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208541				2022-12-17	WOS:A1994NR68500018
J	FIJNEMAN, RJA; OPHOFF, RA; HART, AAM; DEMANT, P				FIJNEMAN, RJA; OPHOFF, RA; HART, AAM; DEMANT, P			KRAS-2 ALLELES, MUTATIONS, AND LUNG TURNER SUSCEPTIBILITY IN THE MOUSE - AN EVALUATION	ONCOGENE			English	Article							RECOMBINANT CONGENIC STRAINS; ETHYL-N-NITROSOUREA; TUMOR SUSCEPTIBILITY; MICE; TRAITS; GENES; TOOL	Lung Tumor Susceptibility (LTS) in the mouse has been shown to be influenced by loci within the Major Histocompatibility Complex (MHC) and the Kras-2 regions. In crosses between susceptible and resistant strains, one allele of Kras-2 has been linked with a high LTS, whereas the other allele has been linked with a low LTS. Furthermore, these Kras-2 alleles affect differently the occurrence of Kras-2 mutations in lung tumors. In this study we evaluated the relationship between LTS, Kras-2 alleles and Kras-2 mutations, using Recombinant Congenic Strains with identical MHC haplotypes. The Kras-2 region indeed influences the frequency of Kras-2 mutations in N-ethyl-N-nitrosourea-induced lung tumors. These mutations are associated with larger tumors. However, Kras-2 affects LTS only marginally. Several strains with identical Kras-2 alleles and mutation frequency differ widely in LTS, while some strains with different alleles and mutation frequency do not. We conclude that a considerable part of the genetic variability in LTS is caused by LTS-loci other than Kras-2 and MHC.	NETHERLANDS CANC INST,DIV MOLEC GENET,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute			Fijneman, Remond/X-4199-2019	Fijneman, Remond/0000-0003-2076-5521				Cochran W.G., 1977, SAMPLING TECHNIQUES, V3rd ed.; CRAXTON M, 1991, Methods (Orlando), V3, P20, DOI 10.1016/S1046-2023(05)80159-8; DEMANT P, 1986, IMMUNOGENETICS, V24, P416, DOI 10.1007/BF00377961; DIETRICH W, 1992, GENETICS, V131, P423; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; GROOT PC, 1992, FASEB J, V6, P2826, DOI 10.1096/fasebj.6.10.1634045; MALKINSON AM, 1991, ENVIRON HEALTH PERSP, V93, P149, DOI 10.2307/3431183; MALKINSON AM, 1992, CANCER RES, V52, pS2670; MOEN CJA, 1992, ONCOGENE, V7, P563; MOEN CJA, 1991, MAMM GENOME, V1, P217, DOI 10.1007/BF00352328; NUZUM EO, 1990, MOL CARCINOGEN, V3, P287, DOI 10.1002/mc.2940030509; OOMEN LCJM, 1983, INT J CANCER, V31, P447, DOI 10.1002/ijc.2910310409; OOMEN LCJM, 1991, EXP LUNG RES, V17, P283, DOI 10.3109/01902149109064419; RYAN J, 1987, J NATL CANCER I, V79, P1351; SKOPEK TR, 1992, P NATL ACAD SCI USA, V89, P7866, DOI 10.1073/pnas.89.17.7866; Slebos R J, 1992, Diagn Mol Pathol, V1, P136, DOI 10.1097/00019606-199206000-00007; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; WRIGHT SP, 1992, BIOMETRICS, V48, P1005, DOI 10.2307/2532694; YOU M, 1992, CARCINOGENESIS, V13, P1583, DOI 10.1093/carcin/13.9.1583; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804	21	25	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1417	1421						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152802				2022-12-17	WOS:A1994NH40100013
J	MAZOYER, S; LALLE, P; MOYRETLALLE, C; MARCAIS, C; SCHRAUB, S; FRAPPAZ, D; SOBOL, H; OZTURK, M				MAZOYER, S; LALLE, P; MOYRETLALLE, C; MARCAIS, C; SCHRAUB, S; FRAPPAZ, D; SOBOL, H; OZTURK, M			2 GERM-LINE MUTATIONS AFFECTING THE SAME NUCLEOTIDE AT CODON-257 OF P53 GENE, A RARE SITE FOR MUTATIONS	ONCOGENE			English	Note							TUMOR-SUPPRESSOR GENE; BREAST-CANCER; FAMILY; NEOPLASMS; PROTEIN; PATIENT	Codon 257 of the p53 gene is an extremely rare target for somatic mutations (accounting for only two of 1600 published mutations). We report here two constitutional mutations both affecting the second nucleotide of codon 257. A thymine to adenine transversion resulting in an amino acid change from leucine to glutamine was found in one proband who developed multiple independent malignant tumors (osteosarcoma, phyllodes tumor, soft-tissue sarcoma). Her mother died of early-onset breast cancer. In the other case, a deletion resulting in a frameshift in the C-terminal coding region of p53 was found in a woman who was diagnosed with breast cancer at age 34. This woman belongs to a family with features of Li-Fraumeni syndrome. In both cases, the p53 mutations identified in the proband was found in other members of the family. Codon 257, even if rarely mutated in somatic cells, may thus be an important target for germ-line mutations.	CTR LEON BERARD,ONCOL MOLEC LAB,INSERM,CJF 9302,28 PROMENADE BULLUKIAN,F-69008 LYON,FRANCE; CTR HOSP REG BESANCON,REGISTRE TUMEURS DOUBS,F-25000 BESANCON,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Universite de Franche-Comte; CHU Besancon			Mazoyer, Sylvie/N-7559-2017; Moyret-Lalle, Caroline/G-2742-2013; ozturk, mehmet/G-3330-2014; LALLE, Philippe/G-7734-2018; OZTURK, MEHMET/AAS-7241-2021	Moyret-Lalle, Caroline/0000-0002-8359-2018; OZTURK, MEHMET/0000-0002-6092-9706; Mazoyer, Sylvie/0000-0002-2135-0160				BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BRUGIERES L, 1993, CANCER RES, V53, P452; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; EELES RA, 1993, ONCOGENE, V8, P1269; FELIX CA, 1993, ONCOGENE, V8, P1203; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ICHIKAWA A, 1992, BLOOD, V79, P2701; KRESS S, 1992, CANCER RES, V52, P3220; LI FP, 1988, CANCER RES, V48, P5358; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; METZGER AK, 1991, P NATL ACAD SCI USA, V88, P7825, DOI 10.1073/pnas.88.17.7825; SOBOL H, 1992, HUM GENET, V89, P381; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001	16	25	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1237	1239						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134127				2022-12-17	WOS:A1994NC04800028
J	PRASAD, DDK; RAO, VN; LEE, L; REDDY, ESP				PRASAD, DDK; RAO, VN; LEE, L; REDDY, ESP			DIFFERENTIALLY SPLICED ERG-3 PRODUCT FUNCTIONS AS A TRANSCRIPTIONAL ACTIVATOR	ONCOGENE			English	Note							ETS-RELATED PROTEIN; PUTATIVE ONCOGENE SPI-1; MURINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; DNA-BINDING DOMAIN; C-ETS-1 PROTOONCOGENE; C-FOS; GENE FAMILY; FLI-1 GENE; V-ETS	ets oncogene superfamily consists of a family of transcriptional factors that functions as activators and/or repressors. Previously, we have identified a member of this ets superfamily namely erg, ets related gene. erg gene was shown to code for at least two proteins erg-1 and erg-2 because of alternative splicing and alternative usage of initiation codon. In this report we show that erg gene codes for an additional erg variant protein, erg-3 as a result of differential splicing which results in the insertion of 24 amino acids in the coding region of erg-2 protein. RNAase protection analysis revealed that erg-3 transcripts are expressed in a variety of cells. Erg-3 was also found to activate the transcription of the reporter TK-CAT gene linked to er g target sequences suggesting that erg3 codes for a sequence specific transcriptional activator.	JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; NCI,FCRDC,PROGRAM RESOURCES INC,FREDERICK,MD 21702	Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NCI NIH HHS [CA 51083, CA 57157] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051083, R01CA057157] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; COQUILLAND M, 1988, ONCOGENE RES, V2, P335; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P85; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; OHNO T, 1993, IN PRESS CANCER RES; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; PRASAD DDK, 1992, CANCER RES, V52, P5833; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; REDDY ESP, 1990, CANCER RES, V50, P5013; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SETH A, 1990, ONCOGENE, V5, P1761; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; [No title captured]	53	25	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					669	673						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290279				2022-12-17	WOS:A1994MW24800037
J	QUINLAN, MP				QUINLAN, MP			E1A 12S IN THE ABSENCE OF E1B OR OTHER COOPERATING ONCOGENES ENABLES CELLS TO OVERCOME APOPTOSIS	ONCOGENE			English	Article							RAT VENTRAL PROSTATE; PRIMARY EPITHELIAL-CELLS; TUMOR-NECROSIS-FACTOR; GROWTH FACTOR-BETA; ADENOVIRUS TYPE-5; C-MYC; E1A-12S PROTEIN; TERMINAL REGION; GENE-PRODUCTS; DNA FRAGMENTS	Neonatal rat kidneys are still undergoing growth and differentiation. Within 24 h after placing these cells in culture, programmed cell death has been activated. This is evidence by intranucleosomal DNA digestion. Cellular DNA synthesis and proliferation cease between 48 and 72 h after plating and the epithelial cells begin to die. The adenovirus E1A 12S gene, in the presence or absence of the E1B gene products, restarts the proliferation program of these cells, retaining their differentiated states. 12S can accomplish this in the presence and absence of serum. Expression of the E1A 13S gene results in cellular DNA degradation due to necrosis, but not apoptosis, brought on by the expression of the 13S-dependent viral genes. Those cells that retain the 12S sequences escape apoptosis and proceed to become immortal. In addition, 12S enables Madin Darby canine kidney (MDCK) epithelial cells to overcome TGF-beta 1 induced inhibition of proliferation and apoptosis. Thus, E1A 12S may be an anti-apoptotic gene.			QUINLAN, MP (corresponding author), UNIV TENNESSEE, DEPT MICROBIOL & IMMUNOL, 858 MADISON AVE, MEMPHIS, TN 38163 USA.				NCI NIH HHS [CA50540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI GR, 1990, J VIROL, V64, P3427, DOI 10.1128/JVI.64.7.3427-3436.1990; BELLETT AJD, 1985, MOL CELL BIOL, V5, P1933, DOI 10.1128/MCB.5.8.1933; BERK AJ, 1986, CANCER SURV, V5, P367; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BRENNER BM, 1990, J AM SOC NEPHROL, V1, P127; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; COLOMBEL M, 1992, CANCER RES, V52, P4313; Cope FO., 1991, APOPTOSIS MOL BASIS, P47; GALLIMORE PH, 1974, J MOL BIOL, V89, P49, DOI 10.1016/0022-2836(74)90162-4; GAYNOR RB, 1983, CELL, V33, P683, DOI 10.1016/0092-8674(83)90011-9; GERSCHENSON LE, 1992, FASEB J, V6, P2450, DOI 10.1096/fasebj.6.7.1563596; GRAHAM FL, 1974, COLD SPRING HARB SYM, V39, P637, DOI 10.1101/SQB.1974.039.01.077; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; Kerr J. F., 1991, APOPTOSIS MOL BASIS, V3, P5; KERR JFR, 1965, J PATHOL BACTERIOL, V90, P419, DOI 10.1002/path.1700900210; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; KYPRIANOU N, 1988, ENDOCRINOLOGY, V122, P552, DOI 10.1210/endo-122-2-552; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; LASTER SM, 1988, J IMMUNOL, V141, P2629; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; NEVINS JR, 1981, CELL, V26, P213, DOI 10.1016/0092-8674(81)90304-4; QUARMBY VE, 1987, MOL ENDOCRINOL, V1, P865, DOI 10.1210/mend-1-12-865; QUINLAN MP, 1989, ONCOGENE, V4, P1051; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; QUINLAN MP, 1992, J VIROL, V66, P2020, DOI 10.1128/JVI.66.4.2020-2030.1992; QUINLAN MP, 1987, P NATL ACAD SCI USA, V84, P3283, DOI 10.1073/pnas.84.10.3283; QUINLAN MP, 1993, ONCOGENE, V8, P257; QUINLAN MP, 1986, CANCER CELL, V4, P327; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROTELLO R J, 1990, Journal of Cell Biology, V111, p477A; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SEARLE J, 1982, PATHOL ANNU, V17, P229; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; SHENK T, 1991, ADV CANCER RES, V57, P47; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPINDLER KR, 1985, J VIROL, V53, P742, DOI 10.1128/JVI.53.3.742-750.1985; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; SUBRAMANIAN T, 1991, ONCOGENE, V6, P1171; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; TAUB M, 1984, METHODS SERUM FREE C, P3; TELLING GC, 1993, J VIROL, V67, P1600, DOI 10.1128/JVI.67.3.1600-1611.1993; TOMEI LD, 1988, BIOCHEM BIOPH RES CO, V155, P324, DOI 10.1016/S0006-291X(88)81088-X; Tomei LD, 1991, APOPTOSIS MOL BASIS, P279; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VANDENELSEN P, 1983, VIROLOGY, V131, P242, DOI 10.1016/0042-6822(83)90549-4; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WILLIAMS G T, 1992, Trends in Cell Biology, V2, P263, DOI 10.1016/0962-8924(92)90198-V; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Wyllie A.H., 1981, CELL DEATH BIOL PATH, P9; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	59	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3289	3296						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247531				2022-12-17	WOS:A1993MG78200012
J	MULLER, E; BOLDYREFF, B; SCHEIDTMANN, KH				MULLER, E; BOLDYREFF, B; SCHEIDTMANN, KH			CHARACTERIZATION OF PROTEIN-KINASE ACTIVITIES ASSOCIATED WITH P53-LARGE-T IMMUNE-COMPLEXES FROM SV40-TRANSFORMED RAT-CELLS	ONCOGENE			English	Article							LARGE T-ANTIGEN; SV40 LARGE-T; TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING DOMAIN; WILD-TYPE; CYCLE CONTROL; P53 PROTEIN; 3T3 CELLS; MONOCLONAL-ANTIBODIES; PHOSPHORYLATION SITES	Interaction of viral oncoproteins, such as SV40 large T, with cellular growth suppressor proteins Rb and p53 is presumed to inactive or modulate their growth suppression functions, thereby leading to transformation. An additional transformation-related activity of LT leads to hyperphosphorylation of p53. To search for kinases that might be responsible for this effect, p53-LT complexes were immunopurified from different SV40-transformed rat cell lines and assayed for associated kinase activities, in vitro. Protein kinase activity was readily observed in p53-LT immunecomplexes from wild-type transformed cells but was low or undetectable in p53 from mutant-transformed or normal cells. Optimal activity required the presence of Mn++. p53 was phosphorylated at all sites found in vivo. In contrast, LT was phosphorylated only at a subset of formerly identified sites and at additional sites not seen in vivo. The p53-LT-kinase complex was assayed for the presence of casein kinases, cdk like kinases, or DNA-activated kinase, using specific effectors, antibodies, or purified enzymes as tools. DNA-activated kinase or cdc2/cdk2 were not detectable, although the purified enzymes phosphorylated p53 in vitro. Casein kinase 2 represented the major activity, which on p53 phosphorylated not only the C-terminal Ser390 but also several sites in the N-terminal region. One additional activity, not identified so far, may represent an LT-induced or activated kinase. This kinase seems to enhance overall phosphorylation of p53 and, perhaps other substrates, and may thereby contribute to transformation.	UNIV BONN,INST GENET,ABT MOLEK GENET,ROMERSTR 164,W-5300 BONN 1,GERMANY; UNIV SAARLAND,INST HUMAN GENET,W-6600 SAARBRUCKEN,GERMANY	University of Bonn; Saarland University								BALL RK, 1984, EMBO J, V3, P1488; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BAUER M, 1987, J VIROL, V61, P1821, DOI 10.1128/JVI.61.6.1821-1827.1987; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHEN JD, 1992, ONCOGENE, V7, P1167; DEPPERT W, 1990, ONCOGENE, V5, P1701; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1988, ONCOGENE, V3, P313; ELLEDGE SJ, 1991, EMBO J, V10, P1653; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; GADBOIS DM, 1992, BIOCHEM BIOPH RES CO, V184, P80, DOI 10.1016/0006-291X(92)91160-R; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HEBEL M, 1986, Z NATURFORSCH C, V41, P94; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAY G, 1981, P NATL ACAD SCI-BIOL, V78, P2932, DOI 10.1073/pnas.78.5.2932; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25; KERN SE, 1991, ONCOGENE, V6, P131; KRAISS S, 1990, ONCOGENE, V5, P845; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1991, CANCER CELL-MON REV, V3, P341; LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1989, COMMON MECHANISMS TR; LUO K, 1990, ONCOGENE, V5, P921; MANFREDI JJ, 1990, J VIROL, V64, P5250, DOI 10.1128/JVI.64.11.5250-5259.1990; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEEK DW, 1990, J VIROL, V64, P1734, DOI 10.1128/JVI.64.4.1734-1744.1990; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1990, ONCOGENE, V5, P973; MEYERSON M, 1991, COLD SPRING HARB SYM, V56, P177; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PATSCHINSKY T, 1992, J VIROL, V66, P3846, DOI 10.1128/JVI.66.6.3846-3859.1992; PERICH JW, 1992, BIOCHEMISTRY-US, V31, P5893, DOI 10.1021/bi00140a027; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SCHEIDTMANN KH, 1991, J VIROL, V65, P1479, DOI 10.1128/JVI.65.3.1479-1490.1991; SCHEIDTMANN KH, 1989, CURR TOP MICROBIOL, V144, P85; SCHNEIDER HR, 1986, EUR J BIOCHEM, V161, P733, DOI 10.1111/j.1432-1033.1986.tb10501.x; SCHNEIDER HR, 1989, BIOTEC EUROPE, V6, P82; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHOHAT O, 1987, ONCOGENE, V1, P277; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOUSSI T, 1990, ONCOGENE, V5, P949; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TUZAON PT, 1991, 2ND MESSENGER PHOSPH, V23, P123; VANROY F, 1984, MOL CELL BIOL, V4, P232, DOI 10.1128/MCB.4.2.232; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WALTER G, 1980, P NATL ACAD SCI-BIOL, V77, P5197, DOI 10.1073/pnas.77.9.5197; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WEISSKER SN, 1992, ONCOGENE, V7, P1921; ZHU J, 1992, J VIROL, V66, P6872	89	25	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2193	2205						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393163				2022-12-17	WOS:A1993LP17100020
J	LAUDET, V; VANACKER, JM; ADELMANT, G; BEGUE, A; STEHELIN, D				LAUDET, V; VANACKER, JM; ADELMANT, G; BEGUE, A; STEHELIN, D			CHARACTERIZATION OF A FUNCTIONAL PROMOTER FOR THE HUMAN THYROID-HORMONE RECEPTOR ALPHA (C-ERBA-1) GENE	ONCOGENE			English	Article							RETINOIC ACID RECEPTOR; TRANSCRIPTION FACTOR; REGULATED EXPRESSION; NUCLEAR RECEPTORS; RESPONSE ELEMENT; OPPOSITE STRAND; BINDING-SITE; MINUTE VIRUS; BETA-GENE; RAT-CELLS	The thyroid hormone receptor alpha (THRA or c-erbA-1) gene belongs to a family of genes that encode nuclear receptors for various hydrophobic ligands such as steroids, retinoic acid and thyroid hormones. We have previously described the genomic organization of the human THRA gene, which comprises 10 exons distributed along 27 kbp of genomic DNA. We describe here a promoter that initiates THRA transcription. This promoter contains no obvious TATA-like element but is very GC rich and harbors numerous Spl sites. It also contains several sites similar to previously described cis-acting sequences including hormone-responsive elements (HREs). When transfected into cultured HeLa cells, it drives the expression of a CAT reporter gene. The activity of this human THRA promoter is enhanced by the synthetic glucocorticoid dexamethasone but seems unaffected by thyroid hormones.			LAUDET, V (corresponding author), INST PASTEUR, CNRS, URA 1160, 1 RUE CALMETTE, F-59019 LILLE, FRANCE.							AMERO SA, 1992, MOL ENDOCRINOL, V6, P3, DOI 10.1210/me.6.1.3; BAKER BS, 1990, EMBO J, V9, P879, DOI 10.1002/j.1460-2075.1990.tb08185.x; BENBROOK D, 1987, SCIENCE, V238, P788, DOI 10.1126/science.3672126; BEUG H, 1991, NUCLEAR HORMONE RECE, P355; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRADLEY DJ, 1989, P NATL ACAD SCI USA, V86, P7250, DOI 10.1073/pnas.86.18.7250; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRAND NJ, 1990, NUCLEIC ACIDS RES, V18, P6799, DOI 10.1093/nar/18.23.6799; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; Chin W.W., 1991, NUCL HORMONE RECEPTO, P79; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; DEBUIRE B, 1984, SCIENCE, V224, P1456, DOI 10.1126/science.6328658; DENAYER P, 1987, EUR J CLIN INVEST, V17, P106, DOI 10.1111/j.1365-2362.1987.tb02388.x; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DOZIER C, 1991, ONCOGENE, V6, P1307; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; FUJITA T, 1985, CELL, V41, P489, DOI 10.1016/S0092-8674(85)80022-2; GALTON VA, 1990, ENDOCRINOLOGY, V127, P2997, DOI 10.1210/endo-127-6-2997; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREEN S, 1991, NUCLEAR HORMONE RECE, P15; HABER DA, 1992, NEW BIOL, V4, P97; HODIN RA, 1990, J CLIN INVEST, V85, P101, DOI 10.1172/JCI114398; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; IZUMO S, 1990, MOL BIOL CARD SYST, V3, P111; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KANAMORI A, 1992, J BIOL CHEM, V267, P739; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LAUDET V, 1991, NUCLEIC ACIDS RES, V19, P1105, DOI 10.1093/nar/19.5.1105; LAZAR MA, 1990, J BIOL CHEM, V265, P12859; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P479, DOI 10.1210/mend-2-6-479; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; LEE JT, 1991, PANCREAS, V6, P96, DOI 10.1097/00006676-199101000-00013; LUADET V, 1992, CURR BIOL, V2, P93; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MANITATIS T, 1989, MOL CLONING LABORATO; MARTINEZ E, 1991, NUCLEAR HORMONE RECE, P125; MELLSTROM B, 1991, MOL ENDOCRINOL, V5, P1339, DOI 10.1210/mend-5-9-1339; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; MITSUHASHI T, 1989, J BIOL CHEM, V264, P8900; MIYAJIMA N, 1989, CELL, V57, P31, DOI 10.1016/0092-8674(89)90169-4; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOORE D D, 1990, New Biologist, V2, P100; MUCHARDT C, 1992, EMBO J, V11, P2573, DOI 10.1002/j.1460-2075.1992.tb05322.x; NIKI K, 1981, P JPN ACAD B-PHYS, V57, P271, DOI 10.2183/pjab.57.271; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PFAHL M, 1987, NUCLEIC ACIDS RES, V15, P9613, DOI 10.1093/nar/15.22.9613; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; SAMUELS HH, 1977, J BIOL CHEM, V252, P6052; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SPEGELAERE P, 1991, J VIROL, V65, P4919, DOI 10.1128/JVI.65.9.4919-4928.1991; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; VANHILLE B, 1989, VIROLOGY, V171, P89, DOI 10.1016/0042-6822(89)90514-X; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILLS KN, 1991, MOL ENDOCRINOL, V5, P1109, DOI 10.1210/mend-5-8-1109; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	70	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1993	8	4					975	982						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455948				2022-12-17	WOS:A1993KT22000020
J	BAKER, AH; RIDGE, SA; HOY, T; CACHIA, PG; CULLIGAN, D; BAINES, P; WHITTAKER, JA; JACOBS, A; PADUA, RA				BAKER, AH; RIDGE, SA; HOY, T; CACHIA, PG; CULLIGAN, D; BAINES, P; WHITTAKER, JA; JACOBS, A; PADUA, RA			EXPRESSION OF THE COLONY-STIMULATING FACTOR-I RECEPTOR IN B-LYMPHOCYTES	ONCOGENE			English	Article							FMS PROTO-ONCOGENE; FACTOR-I RECEPTOR; C-FMS; CSF-1 RECEPTOR; CELL-LINES; HUMAN-MONOCYTES; PRODUCT; ACTIVATION; TRANSCRIPTION; KINASE	The FMS proto-oncogene encodes for the colony-stimulating factor 1 receptor (CSF-1R), whose expression within the haematopoietic system has previously been thought to be restricted to cells of the mononuclear phagocyte lineage. We have studied the expression of the CSF-1R in peripheral blood mononuclear cells by indirect immunofluorescence and flow cytometry. FMS expression was detected on both monocytes and B lymphocytes from all samples analysed, including 14 haematologically normal individuals and 31 patients (23 in remission following cytotoxic therapy for lymphoma, six with B-cell chronic lymphocytic leukaemia and two with chronic myelomonocytic leukaemia). The level of FMS expression on B lymphocytes was lower than the level of expression detected on monocytes isolated from the same sample. FMS mRNA expression in B lymphocytes has been confirmed by a reverse transcription-polymerase chain reaction (RT-PCR)-based technique and Northern blot analysis. Thus, FMS may play a role in the normal function of B lymphocytes and, because of its potential oncogenic activity, may contribute to the pathogenesis of malignancies of this cell type.	UNIV WALES COLL MED, DEPT HAEMATOL, LEUKAEMIA RES FUND PRELEUKAEMIA UNIT, HEATH PK, CARDIFF CF4 4XN, S GLAM, WALES	Cardiff University			PADUA, Rose Ann/E-8621-2019; Baker, Andy/AAO-5250-2021; Padua, Rose Ann/GVT-5961-2022	PADUA, Rose Ann/0000-0001-9964-7864; Baker, Andy/0000-0003-1441-5576; 				ASHMUN RA, 1989, BLOOD, V73, P827; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BORZILLO GV, 1989, MOL CELL BIOL, V9, P3973, DOI 10.1128/MCB.9.9.3973; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOUDHURY GG, 1991, FEBS LETT, V282, P351, DOI 10.1016/0014-5793(91)80511-Z; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DAS SK, 1982, J BIOL CHEM, V257, P13679; DECINO P, 1988, ONCOGENE RES, V3, P33; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; DOWNING JR, 1991, ONCOGENE, V6, P607; GUILBERT LJ, 1986, J BIOL CHEM, V261, P4024; HEARD JM, 1987, CELL, V51, P663, DOI 10.1016/0092-8674(87)90135-8; HEIDARAN MA, 1992, ONCOGENE, V7, P147; HORIGUCHI J, 1986, BIOCHEM BIOPH RES CO, V141, P924, DOI 10.1016/S0006-291X(86)80131-0; HORIGUCHI J, 1987, BLOOD, V69, P1259; JANOWSKAWIECZOREK A, 1991, BLOOD, V77, P1796; KHALILI K, 1984, J MOL BIOL, V175, P453, DOI 10.1016/0022-2836(84)90179-7; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; MELCHERS F, 1984, CELL, V37, P715, DOI 10.1016/0092-8674(84)90407-0; MULLER R, 1983, MOL CELL BIOL, V3, P1062; OSTER W, 1987, BLOOD, V70, P1700; REGENSTREIF LJ, 1989, DEV BIOL, V133, P284, DOI 10.1016/0012-1606(89)90319-9; REISBACH G, 1989, BLOOD, V74, P959; REISBACH G, 1987, CELL IMMUNOL, V109, P246, DOI 10.1016/0008-8749(87)90308-X; RETTENMIER CW, 1986, J CLIN INVEST, V77, P1740, DOI 10.1172/JCI112496; RIDGE SA, 1990, P NATL ACAD SCI USA, V87, P1377, DOI 10.1073/pnas.87.4.1377; RIDGE SA, 1990, BLOOD S, V1, pA244; ROBERTS WM, 1992, BLOOD, V79, P586; ROBERTS WM, 1991, BLOOD S, V1, pA340; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; Sambrook J., 1989, MOL CLONING LAB MANU; SENGUPTA A, 1988, P NATL ACAD SCI USA, V85, P8062, DOI 10.1073/pnas.85.21.8062; SHERR CJ, 1990, BLOOD, V75, P1; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SORG R, 1991, EXP HEMATOL, V19, P882; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; TOBAL K, 1990, LEUKEMIA, V4, P486; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; VISVADER J, 1989, MOL CELL BIOL, V9, P1336, DOI 10.1128/MCB.9.3.1336; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; [No title captured]	46	25	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					371	378						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426743				2022-12-17	WOS:A1993KN00600016
J	NAIR, APK; HIRSCH, HH; MORONI, C				NAIR, APK; HIRSCH, HH; MORONI, C			MAST-CELLS SENSITIVE TO V-H-RAS TRANSFORMATION ARE HYPERINDUCIBLE FOR INTERLEUKIN-3 EXPRESSION AND HAVE LOST TUMOR-SUPPRESSOR ACTIVITY	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; HEMATOPOIETIC GROWTH-FACTORS; ACUTE LYMPHOCYTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CSF MESSENGER-RNA; GM-CSF; AUTOCRINE GROWTH; FACTOR GENE; MALIGNANT TRANSFORMATION; SIGNAL-TRANSDUCTION	Subcloning of interleukin 3 (IL-3)-dependent PB-3c mastocyte cells revealed two populations, of which only one is sensitive to oncogenic transformation by v-H-ras. The corresponding tumors produce IL-3 and grow in vitro in the absence of exogenous IL-3 [Nair, A.P.K., Diamantis, I.D., Conscience, J.F., Kindler, V., Hofer, P. & Moroni, Ch. (1989). Mol. Cell. Biol., 9, 1183-11901. In the present investigation, IL-3 gene regulation was compared in ras transformable (rT) and ras nontransformable (rNT) lines. We report that upon expression of v-H-ras rT clones but not rNT clones express low levels of IL-3 mRNA as detected by reverse polymerase chain reaction. Treatment with ionomycin, a calcium ionophore, induced high levels of IL-3 expression only in ras-expressing rT clones. Somatic cell fusion between the rNT clone 20 and the IL-3-expressing mastocytoma line V2D1 led to down-regulation of IL-3 expression and to the requirement for exogenous IL-3 for in vitro growth and tumor suppression. In contrast, rT clone 15 lacked tumor-suppressor activity and failed to down-regulate IL-3 expression in somatic hybrids which grew in vitro without added IL-3. Our results indicate that IL-3 gene expression is a critical determinant for the generation of v-H-ras-induced mast cell tumors and show that disturbances in IL-3 gene regulation can be detected already at the premalignant level in v-H-ras transformation-sensitive cells.			NAIR, APK (corresponding author), UNIV BASEL,INST MED MICROBIOL,PETERSPL 10,CH-4003 BASEL,SWITZERLAND.			Hirsch, Hans H./0000-0003-0883-0423				ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; BALL PE, 1983, DIFFERENTIATION, V24, P74, DOI 10.1111/j.1432-0436.1983.tb01305.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BAUMBACH WR, 1987, MOL CELL BIOL, V7, P664, DOI 10.1128/MCB.7.2.664; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CHIAO PJ, 1991, ONCOGENE, V6, P713; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COX PM, 1991, BRIT J CANCER, V63, P651, DOI 10.1038/bjc.1991.151; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DIAMANTIS ID, 1989, P NATL ACAD SCI USA, V86, P9299, DOI 10.1073/pnas.86.23.9299; DUHRSEN U, 1990, EMBO J, V9, P1087, DOI 10.1002/j.1460-2075.1990.tb08214.x; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GAMBKE C, 1984, NATURE, V307, P476, DOI 10.1038/307476a0; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; GOUGH NM, 1984, NATURE, V309, P763, DOI 10.1038/309763a0; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; GRIMALDI JC, 1989, BLOOD, V73, P2081; HAHN S, 1991, ONCOGENE, V6, P2327; HAPEL AJ, 1986, LYMPHOKINE RES, V5, P249; HIRAI H, 1987, NATURE, V327, P430, DOI 10.1038/327430a0; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KOEFFLER HP, 1988, MOL CELL BIOL, V8, P3432, DOI 10.1128/MCB.8.8.3432; KOI M, 1989, P NATL ACAD SCI USA, V86, P8773, DOI 10.1073/pnas.86.22.8773; KRIZMAN DB, 1990, SOMAT CELL MOLEC GEN, V16, P15, DOI 10.1007/BF01650476; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LAKER C, 1989, MOL CELL BIOL, V9, P5746, DOI 10.1128/MCB.9.12.5746; MEEKER TC, 1990, BLOOD, V76, P285; MIYATAKE S, 1985, P NATL ACAD SCI USA, V82, P316, DOI 10.1073/pnas.82.2.316; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUSER J, 1989, ONCOGENE, V4, P1433; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; NEEDLEMAN SW, 1986, BLOOD, V67, P753; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; REIN A, 1985, MOL CELL BIOL, V5, P2257, DOI 10.1128/MCB.5.9.2257; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SENN HP, 1988, INT J CANCER, V41, P59, DOI 10.1002/ijc.2910410112; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; TOKSOZ D, 1987, ONCOGENE, V1, P409; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WISEMAN RW, 1988, J CELL BIOCHEM, V12, pD35; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	56	25	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1963	1972						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408138				2022-12-17	WOS:A1992JP42400009
J	RIM, M; QURESHI, SA; GIUS, D; NHO, J; SUKHATME, VP; FOSTER, DA				RIM, M; QURESHI, SA; GIUS, D; NHO, J; SUKHATME, VP; FOSTER, DA			EVIDENCE THAT ACTIVATION OF THE EGR-1 PROMOTER BY V-RAF INVOLVES SERUM RESPONSE ELEMENTS	ONCOGENE			English	Note							PROTEIN-KINASE-C; SIGNAL TRANSDUCTION; GENE-EXPRESSION; GROWTH-FACTORS; FOS; BINDING; PHOSPHORYLATION; ENCODES; FAMILY; CELLS	The constitutively active serine/threonine kinase encoded by the v-raf oncogene, v-Raf, activates the Egr-1 promoter in transient expression assays. To characterize the v-Raf-responsive transcriptional control elements, deletion mutants of the Egr-1 promoter were used in transient expression assays. A v-Raf expression vector was co-transfected into NIH3T3 cells with reporter chloramphenicol acetyl transferase (CAT) expression vectors under the control of the Egr-1 promoter or the Egr-1 promoter containing various deletions. Responsiveness to v-Raf was restricted to a region that contained repeated CC(A/T)6GG sequences, known as CArG boxes. CArG boxes form the core of serum response elements (SREs). v-Raf-induced Egr-I promoter activation was lost by removal of the four tandemly repeated SREs. This region, between - 425 and - 250, which was necessary for v-Raf responsiveness, was also found to be sufficient for maximal Egr-1 induction by v-Raf when placed upstream from a minimal heterologous promoter. Three out of four SREs from this region were able to respond to v-Raf, however the activation of the individual SREs was lower than the clustered SREs. This cluster of SREs has previously been shown to be responsive to several mitogenic stimuli and the oncogene v-src. Thus, the SREs contained in this cluster may be an important target for cell division signals.	CUNY HUNTER COLL, INST BIOMOLEC STRUCT & FUNCT, 695 PK AVE, NEW YORK, NY 10021 USA; UNIV CHICAGO, DEPT MED MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA; CUNY HUNTER COLL, DEPT BIOL SCI, NEW YORK, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY); University of Chicago; Howard Hughes Medical Institute; University of Chicago; City University of New York (CUNY) System; Hunter College (CUNY)			Sukhatme, Vikas/W-2776-2019		NATIONAL CANCER INSTITUTE [R29CA046677, R01CA046677] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RRO-3037-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; Battey, 1986, BASIC METHODS MOL BI; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; QURESHI SA, 1991, ONCOGENE, V6, P995; RAPP UR, 1991, ONCOGENE, V6, P495; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Treisman R, 1990, Semin Cancer Biol, V1, P47; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2	27	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1992	7	10					2065	2068						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408148				2022-12-17	WOS:A1992JP42400022
J	TANIGUCHI, M; IWAMOTO, T; NAKASHIMA, I; NAKAYAMA, A; OHBAYASHI, M; MATSUYAMA, M; TAKAHASHI, M				TANIGUCHI, M; IWAMOTO, T; NAKASHIMA, I; NAKAYAMA, A; OHBAYASHI, M; MATSUYAMA, M; TAKAHASHI, M			ESTABLISHMENT AND CHARACTERIZATION OF A MALIGNANT MELANOCYTIC TUMOR-CELL LINE EXPRESSING THE RET ONCOGENE	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASES; PROTEINS; CLONING; PI3-KINASE; PRODUCTS; DOMAINS; GENE	We established a cell line (designated Mel-ret) from a melanocytic tumor developed in a metallothionein/ret transgenic mouse. Unlike primary melanocytic tumors, which did not show malignant features, when the Met-ret cells were transplanted into nude mice they invaded into surrounding tissues and had metastatic ability. Although the Ret proteins were expressed at similar levels in the cell fine and the primary tumors, the level of tyrosine phosphorylation in the Mel-ret cells was much higher than that in the primary tumors. In particular, an 85-kDa tyrosine-phosphorylated band was specifically detected in the Mel-ret cells. These results suggest that the increase in tyrosine phosphorylation may be responsible for malignant transformation of the Mel-ret cells. Immunofluorescence and cell fractionation studies showed that the Ret proteins and most of tyrosine-phosphorylated proteins in the Mel-ret cells localized in the membrane fraction. No activation of phosphatidyl-inositol-3 kinase (PI-3 kinase), a target protein for several tyrosine kinases, was detected in the Mel-ret cells.	NAGOYA UNIV,SCH MED,DEPT PATHOL,65 TSURUMAI CHO,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,DEPT IMMUNOL,NAGOYA,AICHI 466,JAPAN	Nagoya University; Nagoya University			Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; 				ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; SCHULTZ RM, 1988, CANCER RES, V48, P5539; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TANIGUCHI M, 1991, BIOCHEM BIOPH RES CO, V181, P416, DOI 10.1016/S0006-291X(05)81435-4	11	25	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1491	1496						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630812				2022-12-17	WOS:A1992JE81300004
J	IIDA, S; YOSHIDA, T; NAITO, K; SAKAMOTO, H; KATOH, O; HIROHASHI, S; SATO, T; ONDA, M; SUGIMURA, T; TERADA, M				IIDA, S; YOSHIDA, T; NAITO, K; SAKAMOTO, H; KATOH, O; HIROHASHI, S; SATO, T; ONDA, M; SUGIMURA, T; TERADA, M			HUMAN HST-2 (FGF-6) ONCOGENE - CDNA CLONING AND CHARACTERIZATION	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; TRANSFORMING GENE; CELL-LINE; NUCLEOTIDE-SEQUENCE; INT-2 GENE; EXPRESSION; RECEPTOR; PROTEIN; ORGANIZATION; PURIFICATION	The hst-2 gene was previously identified by its close homology to the hst-1 gene. Cosmid clones containing the hst-2 gene were cloned from a normal human genomic library. Focus-forming activity was observed for the hst-2 cosmids when NIH3T3 transfection assay was performed in a serum-free medium, whereas induction of morphological transformation was difficult to detect in an ordinary serum-supplemented medium. The hst-2 cDNA was cloned from the NIH3T3 transformant. Nucleotide sequence analysis of the cDNA indicates that the hst-2 gene encodes a 198 amino acid transforming protein containing a signal peptide with the characteristics of a heparin-binding growth factor. The coding sequence was almost identical to the published portion of the exon sequence of the FGF-6 gene, indicating that hst-2 is identical to FGF-6. The hst-2 cDNA fragment, when inserted into an expression vector, was able to transform NIH3T3 cells effectively, and the resulting transformant formed a well-vascularized tumor in nude mice, thus suggesting an angiogenic property similar to some other members of the family. RNA blot analysis revealed the expression of the hst-2 gene in human leukemia cell lines with platelet/megakaryocytic differentiation potential.	NATL CANC CTR,DIV GENET,1-1 TSUKIJI 5-CHOME,CHUO KU,TOKYO 104,JAPAN; NATL CANC CTR,DIV PATHOL,CHUO KU,TOKYO 104,JAPAN; NIPPON MED COLL,DEPT SURG 1,BUNKYO KU,TOKYO 113,JAPAN; TAKEDA CHEM IND LTD,BIOL RES LABS,DIV RES & DEV,YODOGAWA KU,OSAKA 532,JAPAN; CHIBA UNIV,SCH MED,DEPT PEDIAT,CHIBA 280,JAPAN	National Cancer Center - Japan; National Cancer Center - Japan; Nippon Medical School; Takeda Chemical Industries; Chiba University								ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; BAIRD A, 1986, RECENT PROG HORM RES, V42, P143; BROOKES S, 1989, ONCOGENE, V4, P429; BROOKES S, 1989, NUCLEIC ACIDS RES, V17, P4037, DOI 10.1093/nar/17.11.4037; DELAPEYRIERE O, 1990, ONCOGENE, V5, P823; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; Maniatis T., 1982, MOL CLONING; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MARICS I, 1989, ONCOGENE, V4, P335; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MERLO GR, 1990, CELL GROWTH DIFFER, V1, P463; MIYAGAWA K, 1988, ONCOGENE, V3, P383; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; SAKAMOTO H, 1988, BIOCHEM BIOPH RES CO, V151, P965, DOI 10.1016/S0006-291X(88)80460-1; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SATO T, 1989, BRIT J HAEMATOL, V72, P184, DOI 10.1111/j.1365-2141.1989.tb07681.x; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; YOSHIDA T, 1987, BIOCHEM BIOPH RES CO, V142, P1019, DOI 10.1016/0006-291X(87)91516-6; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V155, P1324, DOI 10.1016/S0006-291X(88)81286-5; ZHAN X, 1987, ONCOGENE, V1, P369; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	33	25	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					303	309						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1549352				2022-12-17	WOS:A1992HG98200015
J	MITCHELL, PJ; COOPER, CS				MITCHELL, PJ; COOPER, CS			NUCLEOTIDE-SEQUENCE ANALYSIS OF HUMAN TPR CDNA CLONES	ONCOGENE			English	Note							PROTEIN TYROSINE KINASE; HEAVY-CHAIN GENE; MET ONCOGENE; CELL-LINE; TROPOMYOSIN; ACTIVATION; REARRANGEMENT; POLYPEPTIDE; MECHANISM; DOMAINS	In this study we have characterized cDNA clones corresponding to a gene, called tpr, that has been implicated in the activation of the met and raf proto-oncogenes. Sequencing of tpr clones isolated from an HT1080 human fibrosarcoma cell line cDNA library identified an open reading frame (ORF) of 726 amino acids. In addition we have established that alternative splicing can result in the deletion of a 30 bp sequence that spans the translation termination site of this ORF. This modification generates mRNAs encoding a tpr protein that has an extended C-terminal domain. The 726 amino acid tpr-protein is predicted to have extensive regions of alpha-helix and bas three stretches of a heptad repeat motif that is characteristic of proteins adopting a coiled-coil conformation. The tpr protein exhibits weak homology (28-39%) to the alpha-helical domains of several proteins including tropomyosin, spectrin, laminin B1, the Drosophila glued protein and the tail region of myosin heavy chain.			MITCHELL, PJ (corresponding author), INST CANC RES,MOLEC CARCINOGENESIS SECT,15 COTSWOLD RD,SUTTON SM2 5NG,SURREY,ENGLAND.		Mitchell, Philip J/F-6393-2013					BARLOW DP, 1984, EMBO J, V3, P2355, DOI 10.1002/j.1460-2075.1984.tb02140.x; CHAN AML, 1987, ONCOGENE, V1, P229; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; Favaloro J, 1980, Methods Enzymol, V65, P718; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GARVIN AJ, 1986, AM J PATHOL, V125, P208; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; HAMMER JA, 1987, J CELL BIOL, V105, P913, DOI 10.1083/jcb.105.2.913; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P226; KARN J, 1983, P NATL ACAD SCI-BIOL, V80, P4253, DOI 10.1073/pnas.80.14.4253; KING HWS, 1988, ONCOGENE, V2, P617; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAFLAMME SE, 1988, GENE DEV, V2, P853, DOI 10.1101/gad.2.7.853; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MACLEOD AR, 1986, NUCLEIC ACIDS RES, V14, P8413, DOI 10.1093/nar/14.21.8413; MAHDAVI V, 1982, NATURE, V297, P659, DOI 10.1038/297659a0; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; PARK M, 1986, COLD SPRING HARB SYM, V51, P967, DOI 10.1101/SQB.1986.051.01.110; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; SAEZ L, 1986, NUCLEIC ACIDS RES, V14, P2951, DOI 10.1093/nar/14.7.2951; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOMAN NR, 1990, P NATL ACAD SCI USA, V87, P738, DOI 10.1073/pnas.87.2.738; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; SWAROOP A, 1987, P NATL ACAD SCI USA, V84, P6501, DOI 10.1073/pnas.84.18.6501; TEMPEST PR, 1986, CARCINOGENESIS, V7, P2051, DOI 10.1093/carcin/7.12.2051; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5; WARRICK HM, 1986, P NATL ACAD SCI USA, V83, P9433, DOI 10.1073/pnas.83.24.9433; YAMAWAKIKATAOKA Y, 1987, J BIOL CHEM, V262, P10791	30	25	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					383	388						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1549355				2022-12-17	WOS:A1992HG98200025
J	POLACK, A; STROBL, L; FEEDERLE, R; SCHWEIZER, M; KOCH, E; EICK, D; WIEGAND, H; BORNKAMM, GW				POLACK, A; STROBL, L; FEEDERLE, R; SCHWEIZER, M; KOCH, E; EICK, D; WIEGAND, H; BORNKAMM, GW			THE INTRON ENHANCER OF THE IMMUNOGLOBULIN KAPPA GENE ACTIVATES C-MYC BUT DOES NOT INDUCE THE BURKITT-SPECIFIC PROMOTER SHIFT	ONCOGENE			English	Article							PHOSPHORYLATION-DEPENDENT BINDING; LYMPHOMA CELLS; 1ST EXON; TRANS-ACTIVATION; NEGATIVE AUTOREGULATION; TRANSCRIPTION FACTOR; REGULATORY ELEMENT; V-MYC; EXPRESSION; PROTEIN	In Burkitt's lymphoma cells the c-myc gene locus is consistently fused to the constant region of one of the immunoglobulin genes by chromosomal translocation. The translocated c-myc gene is transcriptionally activated and preferentially transcribed from the P1 promoter whenever the exon-intron structure of c-myc remains intact. In order to define elements involved in this promoter shift we have cloned the translocated c-myc allele from Burkitt's lymphoma cell line BL60, which is characterized by several point mutations. The mutated c-myc allele of BL60 was stably introduced into baby hamster kidney and Burkitt's lymphoma cells. S1 nuclease and RNAase protection mapping experiments demonstrated that the mutated c-myc allele was expressed at a low level and with a normal promoter usage (P2 > P1) in Burkitt's lymphoma and baby hamster kidney cells. Furthermore, we have studied the expression of a construct consisting of the mutated c-myc allele, part of the bvr1 (Burkitt's variant rearranging region 1) locus, the human immunoglobulin kappa constant region, and the kappa intron enhancer after stable transfection into Burkitt's lymphoma cells. Although c-myc expression was about fivefold increased, the transcripts still initiated predominantly at promoter P2. This indicates that 5 kb of the constant kappa light-chain locus including the kappa intron enhancer is not sufficient to induce the Burkitt's lymphoma-specific promoter shift.	INST KLIN MIKROBIOL & HYG,VIROL ABT,W-7800 FREIBURG,GERMANY		POLACK, A (corresponding author), GESELL SCHWERIONENFORSCH GMBH,INST KLIN MOLEK BIOL & TUMORGENET,MARCHIONINISTR 25,W-8000 MUNICH 70,GERMANY.		Strobl, Lothar J/M-7357-2014	Strobl, Lothar J/0000-0001-8389-1862				ALEXANDER WS, 1987, MOL CELL BIOL, V7, P1436, DOI 10.1128/MCB.7.4.1436; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; EICK D, 1988, ONCOGENE, V3, P397; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GOTSCHL M, 1988, BIOCHEM BIOPH RES CO, V157, P379, DOI 10.1016/S0006-291X(88)80058-5; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; HAGMAN J, 1990, GENE DEV, V4, P978, DOI 10.1101/gad.4.6.978; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HENGLEIN B, 1989, MOL CELL BIOL, V9, P2105, DOI 10.1128/MCB.9.5.2105; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KAVATHAS P, 1980, P NATL ACAD SCI-BIOL, V77, P4251, DOI 10.1073/pnas.77.7.4251; KLOBECK HG, 1986, NUCLEIC ACIDS RES, V14, P4591, DOI 10.1093/nar/14.11.4591; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LIPP M, 1989, ONCOGENE, V4, P535; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MEYER KB, 1990, NUCLEIC ACIDS RES, V18, P5609, DOI 10.1093/nar/18.19.5609; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PICARD D, 1984, NATURE, V307, P80, DOI 10.1038/307080a0; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; POLACK A, 1987, EMBO J, V6, P2959, DOI 10.1002/j.1460-2075.1987.tb02601.x; QUEEN C, 1984, MOL CELL BIOL, V4, P1042, DOI 10.1128/MCB.4.6.1042; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RICHMAN A, 1989, MOL CELL BIOL, V9, P4962, DOI 10.1128/MCB.9.11.4962; RICHMAN A, 1989, SCIENCE, V246, P494, DOI 10.1126/science.2683072; SACCA R, 1990, ONCOGENE, V5, P1499; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATT MD, 1990, EMBO J, V9, P481, DOI 10.1002/j.1460-2075.1990.tb08134.x; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SEN R, 1989, IMMUNOGLOBULIN GENES, P327; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; SPENCER CA, 1991, ADV CANCER RES; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; SZAJNERT MF, 1987, NUCLEIC ACIDS RES, V15, P4553, DOI 10.1093/nar/15.11.4553; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; TAUB R, 1984, CELL, V37, P511, DOI 10.1016/0092-8674(84)90381-7; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; TONEGUZZO F, 1986, MOL CELL BIOL, V6, P703, DOI 10.1128/MCB.6.2.703; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; ZAJAC-KAYE M, 1990, J BIOL CHEM, V265, P4547; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510; ZIMBERSTROBL U, 1991, J VIROL, V65, P415, DOI 10.1128/JVI.65.1.415-423.1991; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	65	25	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2033	2040						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1945409				2022-12-17	WOS:A1991GX11900014
J	RADICE, P; SOZZI, G; MIOZZO, M; DEBENEDETTI, V; CARIANI, T; BONGARZONE, I; SPURR, NK; PIEROTTI, MA; DELLAPORTA, G				RADICE, P; SOZZI, G; MIOZZO, M; DEBENEDETTI, V; CARIANI, T; BONGARZONE, I; SPURR, NK; PIEROTTI, MA; DELLAPORTA, G			THE HUMAN TROPOMYOSIN GENE INVOLVED IN THE GENERATION OF THE TRK ONCOGENE MAPS TO CHROMOSOME 1Q31	ONCOGENE			English	Note							THYROID PAPILLARY CARCINOMAS; SOMATIC-CELL HYBRIDS; RET PROTO-ONCOGENE; ASSIGNMENT; EXPRESSION; KINASE; MUSCLE; TISSUE; PTC	The chromosomal localization of hTMnm, a gene coding for a cytoskeletal tropomyosin non-muscle isoform involved in the activation of the TRK proto-oncogene in various human tumors, was determined by Southern blot analysis of a panel of human-rodent somatic cell hybrids. Using as a probe an Alu-free intronic fragment related to the tropomyosin sequence fused to the TRK tyrosine kinase domain, the hTMnm gene was assigned to the long arm of chromosome 1. Subsequently, in situ hybridization of the same probe to human metaphase chromosomes localized the hTMnm gene to 1q31. Since we have recently assigned the TRK locus to chromosome 1q32-q41, the generation of the hybrid transforming sequence tropomyosin-TRK may be due to an intrachromosomal rearrangement of the long arm of chromosome 1.	IST NAZL TUMORI,DIV ONCOL SPERIMENTALE A,VIA G VENEZIAN 1,I-20133 MILAN,ITALY; IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LID,HERTS,ENGLAND	Fondazione IRCCS Istituto Nazionale Tumori Milan			Radice, Paolo/O-3119-2013; Pierotti, Marco Alessandro/AAC-4728-2022; sozzi, gabriella/G-8259-2011; Miozzo, Monica Rosa/AAC-6401-2022; Bongarzone, Italia/B-9544-2017	Radice, Paolo/0000-0001-6298-4111; Pierotti, Marco Alessandro/0000-0002-7431-8332; sozzi, gabriella/0000-0001-9360-6914; Miozzo, Monica Rosa/0000-0002-6523-4575; Bongarzone, Italia/0000-0003-2530-9170				ANDREWS PW, 1985, ANN HUM GENET, V49, P31, DOI 10.1111/j.1469-1809.1985.tb01673.x; BONGARZONE I, 1989, ONCOGENE, V4, P1457; DONGHI R, 1989, ONCOGENE, V4, P521; EDWARDS YH, 1985, ANN HUM GENET, V49, P101, DOI 10.1111/j.1469-1809.1985.tb01681.x; FINE RE, 1975, J MOL BIOL, V95, P447, DOI 10.1016/0022-2836(75)90202-8; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HEISTERKAMP N, 1982, NATURE, V299, P747, DOI 10.1038/299747a0; ISHIZAKA Y, 1989, ONCOGENE, V4, P1519; JONES EA, 1976, SOMAT CELL GENET, V2, P483, DOI 10.1007/BF01542686; KIELTY CM, 1982, ANN HUM GENET, V46, P307, DOI 10.1111/j.1469-1809.1982.tb01582.x; MACLEOD AR, 1988, MOL CELL BIOL, V8, P433, DOI 10.1128/MCB.8.1.433; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MAYALL BH, 1975, AUTOMATION CYTOGENET, P113; MIOZZO M, 1990, ONCOGENE, V5, P1411; NABHOLZ M, 1969, NATURE, V223, P358, DOI 10.1038/223358a0; OLAH E, 1989, CANCER GENET CYTOGEN, V43, P179, DOI 10.1016/0165-4608(89)90029-0; PERRY P, 1974, NATURE, V251, P156, DOI 10.1038/251156a0; POVEY S, 1980, ANN HUM GENET, V43, P241, DOI 10.1111/j.1469-1809.1980.tb01557.x; PULCIANI S, 1982, NATURE, V300, P539, DOI 10.1038/300539a0; REINACH FC, 1986, NATURE, V322, P648, DOI 10.1038/322648a0; SEWELL WA, 1988, IMMUNOGENETICS, V28, P278, DOI 10.1007/BF00345506; SHABTAI F, 1986, HUM GENET, V73, P232, DOI 10.1007/BF00401234; SOLOMON E, 1979, ANN HUM GENET, V42, P273, DOI 10.1111/j.1469-1809.1979.tb00661.x; SOZZI G, 1991, ONCOGENE, V6, P339; VANHEYNINGEN V, 1975, ANN HUM GENET, V38, P295; WHITEHEAD AS, 1982, P NATL ACAD SCI-BIOL, V79, P5021, DOI 10.1073/pnas.79.16.5021	27	25	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2145	2148						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1834975				2022-12-17	WOS:A1991GX11900027
J	LEIBOVITCH, SA; GUILLIER, M; LENORMAND, JL; LEIBOVITCH, MP				LEIBOVITCH, SA; GUILLIER, M; LENORMAND, JL; LEIBOVITCH, MP			ACCUMULATION OF THE C-MOS PROTEIN IS CORRELATED WITH POSTNATAL-DEVELOPMENT OF SKELETAL-MUSCLE	ONCOGENE			English	Article							MURINE SARCOMA-VIRUS; PROTOONCOGENE PRODUCT; ONCOGENE PRODUCT; MOUSE-TISSUES; GENE-PRODUCT; EXPRESSION; SEQUENCE; CELLS; TRANSCRIPTS; HOMOLOG	Previously we reported that c-mos proto-oncogene RNA was developmentally up-regulated during post-natal maturation of the rat skeletal muscle. Using two different site-directed affinity-purified antipeptide antibodies we can observe that c-mos product (p43 c-mos) accumulates increasingly during post-natal development of the skeletal muscle and exhibits protein kinase activity. We find that in adult rat p43 c-mos is 10-fold higher in skeletal muscle than in ovaries, and 20- to 40-fold higher than in heart, lung, testis and liver, and may represent about 0.005% of the total soluble proteins. In addition adult skeletal muscle from Xenopus, mouse and man was found to contain p43 c-mos. These data argue in favour of a novel muscle-specific function of c-mos.			LEIBOVITCH, SA (corresponding author), INST GUSTAVE ROUSSY,CNRS,URA 126,UA1158,ONCOL MOLEC LAB,39 RUE C DESMOULINS,F-94800 VILLEJUIF,FRANCE.		Lenormand, Jean-Luc/ABF-3850-2021; Lenormand, Jean-Luc/M-6644-2014	Lenormand, Jean-Luc/0000-0002-2766-9180				BARTON PJR, 1985, BIOCHEM J, V231, P249, DOI 10.1042/bj2310249; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARRINGTON JC, 1987, NUCLEIC ACIDS RES, V15, P10066, DOI 10.1093/nar/15.23.10066; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4510; HERZOG NK, 1989, ONCOGENE, V4, P1307; HUNTER T, 1986, ENZYMES, V7, P181; KURUTA N, 1989, EMBO J, V8, P457; LEIBOVITCH MP, 1987, EXP CELL RES, V170, P80, DOI 10.1016/0014-4827(87)90118-2; LEIBOVITCH SA, 1986, EXP CELL RES, V166, P526, DOI 10.1016/0014-4827(86)90497-0; LEIBOVITCH SA, 1990, ONCOGENE, V5, P1149; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; OGISO Y, 1986, BIOCHEM BIOPH RES CO, V140, P477, DOI 10.1016/0006-291X(86)90757-6; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PAULES RS, 1988, ONCOGENE, V3, P59; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; PROPST F, 1988, ONCOGENE, V2, P227; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; SHELTON DL, 1984, P NATL ACAD SCI-BIOL, V81, P7951, DOI 10.1073/pnas.81.24.7951; SINGH B, 1990, VIROLOGY, V178, P535, DOI 10.1016/0042-6822(90)90351-Q; SINGH B, 1987, J VIROL, V61, P3625, DOI 10.1128/JVI.61.11.3625-3629.1987; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; VANDERHOORN FA, 1984, NUCLEIC ACIDS RES, V12, P2147, DOI 10.1093/nar/12.4.2147; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; WHALEN RG, 1981, NATURE, V292, P805, DOI 10.1038/292805a0	35	25	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1617	1622						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1833718				2022-12-17	WOS:A1991GX27400017
J	MATSUZAWA, Y; SEMBA, K; KAWAMURATSUZUKU, J; SUDO, T; ISHII, S; TOYOSHIMA, K; YAMAMOTO, T				MATSUZAWA, Y; SEMBA, K; KAWAMURATSUZUKU, J; SUDO, T; ISHII, S; TOYOSHIMA, K; YAMAMOTO, T			CHARACTERIZATION OF THE PROMOTER REGION OF THE C-YES PROTOONCOGENE - THE IMPORTANCE OF THE GC BOXES ON ITS PROMOTER ACTIVITY	ONCOGENE			English	Article							TYROSINE KINASE; TRANSCRIPTION FACTOR; START SITES; GENE; EXPRESSION; SEQUENCE; RECEPTOR; CELLS; PURIFICATION; BINDING	In this study we cloned the 5' flanking sequence of the human c-yes gene and identified its promoter region. A 0.53 kilobase pair (kbp) fragment containing the 5' terminus of the c-yes gene showed strong promoter activity when placed upstream of the bacterial chloramphenicol acetyltransferase (CAT) gene and transfected into monkey CV-1 cells. By nuclease S1 mapping multiple transcriptional start sites were detected within the promoter region. Nucleotide sequence analysis revealed that the c-yes promoter region had high G + C contents (64%) and contained six GC box-like sequences (one at the 5' distal region and five in a cluster at the 5' proximal region), but not a TATA box. These features of the c-yes promoter region are similar to those of other protooncogenes, ras-family genes and c-raf-1, and some housekeeping genes. Deletion analysis suggested that the most downstream 0.21 kbp region is primarily important for the promoter activity. This 0.21 kbp region contains one major and another minor transcriptional start site. Five GC box-like sequences were located within this region, and four of them were shown to bind with purified Sp1 transcription factor. Furthermore, using the base-substituted mutants of the Sp1-binding sites, each GC box in the cluster (GC1 to GC4) was shown to affect the c-yes gene expression.	UNIV TOKYO, INST MED SCI,DEPT ONCOL,4-6-1 SHIROKANEDAI, MINATO KU, TOKYO 108, JAPAN; INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, MOLEC GENET LAB, TSUKUBA, IBARAKI 305, JAPAN; OSAKA UNIV, MICROBIAL DIS RES INST, DEPT ONCOGENE RES, SUITA, OSAKA 565, JAPAN	University of Tokyo; RIKEN; Osaka University			Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; ARAKI E, 1988, NUCLEIC ACIDS RES, V16, P1627, DOI 10.1093/nar/16.4.1627; ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; BECK TW, 1990, MOL CELL BIOL, V10, P3325, DOI 10.1128/MCB.10.7.3325; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER JA, 1990, SRC FAMILY PROTEIN T, P85; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GHYSDAEL J, 1981, P NATL ACAD SCI-BIOL, V78, P2611, DOI 10.1073/pnas.78.4.2611; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENE JM, 1987, CURRENT PROTOCOLS MO, V1; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; ISHII S, 1986, SCIENCE, V232, P1410, DOI 10.1126/science.3012774; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAWAI S, 1980, P NATL ACAD SCI-BIOL, V77, P6199, DOI 10.1073/pnas.77.10.6199; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAVIA P, 1987, EMBO J, V6, P2773, DOI 10.1002/j.1460-2075.1987.tb02572.x; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; MANIATIS T, 1982, NUCLEASE SI MAPPING, P207; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; PATEL M, 1990, ONCOGENE, V5, P201; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SEMBA K, 1985, SCIENCE, V227, P1038, DOI 10.1126/science.2983418; SEMBA K, 1990, STRUCTURE FUNCTION S, P74; SINGERSAM J, 1984, GENE, V32, P409, DOI 10.1016/0378-1119(84)90016-7; SUDOL M, 1989, MOL CELL BIOL, V9, P4545, DOI 10.1128/MCB.9.10.4545; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; SUKEGAWA J, 1990, ONCOGENE, V5, P611; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; TSUKITA S, 1991, IN PRESS J CELL BIOL; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; ZHAO YH, 1990, ONCOGENE, V5, P1629; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	47	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1991	6	9					1561	1567						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923523				2022-12-17	WOS:A1991GX27400010
J	BERNARDS, A				BERNARDS, A			PREDICTED TYK2 PROTEIN CONTAINS 2 TANDEM PROTEIN-KINASE DOMAINS	ONCOGENE			English	Note							TYROSINE KINASES; SIGNAL TRANSDUCTION; CATALYTIC DOMAINS; CLONING; GENES	Tyk2 was recently described as an 1187 amino acid protein with a putative protein-tyrosine kinase domain near its C-terminus and no similarity to other proteins in the approximately 900 amino acids preceding the kinase domain. I report here, however, that tyk2 contains an additional protein kinase domain, and that the two tandem kinase domains are preceded by an SH2-like, putative regulatory domain.			BERNARDS, A (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,DEPT MOLEC GENET,BLDG 149,13TH ST,BOSTON,MA 02129, USA.							BUSS JE, 1984, J VIROL, V53, P7; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; PAWSON T, 1988, ONCOGENE, V3, P491; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; TAN JL, 1990, MOL CELL BIOL, V10, P3578, DOI 10.1128/MCB.10.7.3578; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	13	25	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1185	1187						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861866				2022-12-17	WOS:A1991GV26000013
J	TIEFENBRUN, N; KIMCHI, A				TIEFENBRUN, N; KIMCHI, A			THE INVOLVEMENT OF PROTEIN-KINASE-C IN MEDIATING GROWTH SUPPRESSIVE SIGNALS OF INTERFERONS IN HEMATOPOIETIC-CELLS	ONCOGENE			English	Article							MYC MESSENGER-RNA; DAUDI CELLS; ALPHA-INTERFERON; PHORBOL ESTERS; EXPRESSION; GAMMA; GENE; DIFFERENTIATION; TRANSCRIPTION; TRANSDUCTION	The possible involvement of protein kinase C in transducing the growth suppressive signals of interferons was studied in this work in two different hematopoietic cell lines. Chronic exposure of human Burkitt lymphoma and mouse M1 myeloblastic cell lines to phorbol myristate acetate (PMA), reduced by more than 90% the PKC protein levels and enzymatic activity in cell extracts. The depletion of PKC from cells abrogated the ability of IFN (alpha + beta) to arrest cell growth at the G0/G1 resting phase of the cell cycle. In contrast, other responses to IFN such as the induction of (2'-5') oligoadenylate synthetase gene, continued to take place at the same dose response pattern thus excluding the possibility that early targets in the pathway, such as the number or affinity of IFN cell surface receptors might be affected by PMA. The same prolonged treatment of M1 cells with PMA did not interfere with the ability of another cytokine, transforming growth factor beta (TGF-beta), to induce the normal type of G0/G1 arrest further supporting the specificity of the effect towards IFN responses. Unexpectedly, depletion of PKC from cells did not interfere with the negative effects of IFN on c-myc mRNA and protein expression in spite of the direct involvement of this molecular event in growth responses to IFN. The putative PKC dependent molecular event could therefore function either downstream to or in combination with the reduction in c-myc protein levels, providing a necessary but not a sufficient step to arrest cell cycle progression at the G0/G1 phase.	DEPT MOLEC GENET & VIROL, IL-76100 REHOVOT, ISRAEL		KIMCHI, A (corresponding author), DEPT MOLEC GENET & VIROL, IL-76100 REHOVOT, ISRAEL.							ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; BENECH P, 1985, EMBO J, V4, P2249, DOI 10.1002/j.1460-2075.1985.tb03922.x; CHEBATH J, 1986, TIBS, V11, P166; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; DRON M, 1986, MOL CELL BIOL, V6, P1374, DOI 10.1128/MCB.6.5.1374; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EINAT M, 1988, ONCOGENE, V2, P485; FAN XD, 1988, P NATL ACAD SCI USA, V85, P5122, DOI 10.1073/pnas.85.14.5122; FARRAR WL, 1985, NATURE, V315, P233, DOI 10.1038/315233a0; GATYABLONSKI G, 1990, BIOCHEM J, V270, P679, DOI 10.1042/bj2700679; JEFFREY AM, 1986, P NATL ACAD SCI USA, V83, P241, DOI 10.1073/pnas.83.2.241; JONAK GJ, 1984, P NATL ACAD SCI-BIOL, V81, P1747, DOI 10.1073/pnas.81.6.1747; Kimchi A, 1987, Interferon, V8, P85; KIMCHI A, 1979, P NATL ACAD SCI USA, V76, P3208, DOI 10.1073/pnas.76.7.3208; KIMCHI A, 1981, J INTERFERON RES, V1, P559, DOI 10.1089/jir.1981.1.559; KIMCHI A, 1988, MOL CELL BIOL, V8, P2828, DOI 10.1128/MCB.8.7.2828; KUO JF, 1980, P NATL ACAD SCI-BIOL, V77, P7039, DOI 10.1073/pnas.77.12.7039; LEMEUR M, 1981, CELL, V23, P561, DOI 10.1016/0092-8674(81)90152-5; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOVICK D, 1982, J IMMUNOL, V129, P2244; PFEFFER LM, 1990, P NATL ACAD SCI USA, V87, P6537, DOI 10.1073/pnas.87.17.6537; PFEFFER LM, 1989, J INTERFERON RES S2, V9, P5156; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; RESNITZKY D, 1991, CELL GROWTH DIFFER, V2, P33; RUBINSTEIN M, 1986, CRIT REV BIOCHEM MOL, V21, P249, DOI 10.3109/10409238609113613; SAGIEISENBERG R, 1984, IMMUNOL LETT, V8, P237, DOI 10.1016/0165-2478(84)90002-6; SHANI M, 1981, NUCLEIC ACIDS RES, V9, P579, DOI 10.1093/nar/9.3.579; STABEL S, 1987, J CELL PHYSIOL, V130, P111, DOI 10.1002/jcp.1041300116; TAYLORPAPADIMITRIOU J, 1981, J INTERFERON RES, V1, P401, DOI 10.1089/jir.1981.1.401; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; VANDENBARK GR, 1984, J NATL CANCER I, V73, P1013; YAP WH, 1986, P NATL ACAD SCI USA, V83, P7765, DOI 10.1073/pnas.83.20.7765; YAP WH, 1986, SCIENCE, V234, P355, DOI 10.1126/science.2429366; YARDEN A, 1984, EMBO J, V3, P969, DOI 10.1002/j.1460-2075.1984.tb01915.x; YARDEN A, 1986, SCIENCE, V234, P1419, DOI 10.1126/science.3097823	39	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1991	6	6					1001	1007						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1712443				2022-12-17	WOS:A1991GU62200015
J	CAO, HN; DECKER, S; STERN, DF				CAO, HN; DECKER, S; STERN, DF			TPA INHIBITS THE TYROSINE KINASE-ACTIVITY OF THE NEU PROTEIN INVIVO AND INVITRO	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR-RECEPTOR; EGF RECEPTOR; HUMAN-BREAST; INDEPENDENT MECHANISMS; ONCOGENE; PHOSPHORYLATION; GENE; AMPLIFICATION; C-ERBB-2	P185 is a receptor-like protein encoded by the neu/erbB-2 proto-oncogene. A point mutation in the transmembrane domain renders this protein oncogenic. We report here that incubation of cells with 12-O-tetradecanoylphorbol-13-acetate (TPA) stimulates the phosphorylation of the normal neu protein (p185) and the oncogenic neu protein (p185*). The increased phosphorylation occurs mainly on serine and threonine residues. Phosphate labeling experiments showed that TPA causes a reduction of basal phosphotyrosine in p185 but not p185*. Immunoblotting with antiphosphotyrosine antibody yielded similar results. TPA also inhibited tyrosine phosphorylation of p185* in an in vitro immune complex kinase assay. These data suggest that protein kinase C, the receptor for TPA, regulates p185 function through serine or threonine phosphorylation.	ROCKEFELLER UNIV,NEW YORK,NY 10021	Rockefeller University	CAO, HN (corresponding author), YALE UNIV,SCH MED,DEPT PATHOL,310 CEDAR ST,NEW HAVEN,CT 06510, USA.				NATIONAL CANCER INSTITUTE [R01CA037754, R01CA045708] Funding Source: NIH RePORTER; NCI NIH HHS [CA45708, CA37754] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BROWN KD, 1979, BIOCHEM BIOPH RES CO, V86, P1037, DOI 10.1016/0006-291X(79)90221-3; COCHET C, 1984, J BIOL CHEM, V259, P2553; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DOBASHI K, 1989, DNA-J MOLEC CELL BIO, V8, P723, DOI 10.1089/dna.1989.8.723; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; IWASHITA S, 1984, J BIOL CHEM, V259, P2559; KAMPS MP, 1988, ONCOGENE, V2, P305; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KING CS, 1986, J BIOL CHEM, V261, P10078; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LIVNEH E, 1988, MOL CELL BIOL, V103, P1355; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3400; VENTER DJ, 1987, LANCET, V2, P69, DOI 10.1016/S0140-6736(87)92736-X; WHITELEY B, 1986, J CELL BIOL, V103, P1355, DOI 10.1083/jcb.103.4.1355; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179	38	25	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					705	711						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1675782				2022-12-17	WOS:A1991GT82500004
J	TOURAY, M; RYAN, F; SAURER, S; MARTIN, F; JAGGI, R				TOURAY, M; RYAN, F; SAURER, S; MARTIN, F; JAGGI, R			MOS-INDUCED INHIBITION OF GLUCOCORTICOID RECEPTOR FUNCTION IS MEDIATED BY FOS	ONCOGENE			English	Article							MAMMARY-TUMOR VIRUS; LONG TERMINAL REPEAT; DNA-BINDING DOMAIN; GENE-EXPRESSION; C-FOS; PHORBOL ESTER; RAS ONCOGENE; DEPENDENT TRANSCRIPTION; STEROID-HORMONES; V-MOS	Activation of glucocorticoid hormone-dependent transcription involves the binding of the glucocorticoid hormone to its receptor followed by a specific interaction of the hormone/receptor complex with glucocorticoid responsive elements in the promoter region of hormone-inducible genes. In stably transfected NIH3T3 cells expressing the oncogene product of v-mos or fos, the expression from two glucocorticoid responsive promoters, MMTV LTR and metallothionein IIA (Mt(IIA)), was shown to be impaired and was only transient. Cadmium-dependent Mt(IIA) gene expression was not affected by the expression of v-mos in the cells. In transiently transfected NIH3T3 cells constitutive fos expression also inhibited glucocorticoid hormone-induced expression from the MMTV LTR. However, co-expression of antisense fos (here referred to as sof) inhibited the down-regulatory effect of Fos on glucocorticoid induced gene expression. v-mos expression in NIH3T3 cells induces fos mRNA and functional fos product (Fos) as reflected by its ability to induce expression of a transiently transfected AP-1 dependent reporter plasmid. We show that sof expression inhibits the down-regulatory effect of mos on expression of a transiently transfected pMMTV LTR-CAT. Our findings, thus, strongly suggest that the inhibition of glucocorticoid receptor function in cells expressing the v-mos oncogene is mediated by Fos.	UNIV BERN, DEPT CLIN & EXPTL CANC RES, TIEFENAUSTR 120, CH-3004 BERN, SWITZERLAND; NATL UNIV IRELAND UNIV COLL DUBLIN, DEPT PHARMACOL, DUBLIN 4, IRELAND	University of Bern; University College Dublin			Ryan, Fergus/B-8407-2012					ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BUETTI E, 1983, EMBO J, V2, P1423, DOI 10.1002/j.1460-2075.1983.tb01601.x; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; HAMILTON BJ, 1989, P NATL ACAD SCI USA, V86, P597, DOI 10.1073/pnas.86.2.597; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HOECK W, 1989, J BIOL CHEM, V264, P14396; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; JAGGI R, 1989, CANCER RES, V49, pS2266; JAGGI R, 1988, J STEROID BIOCHEM, V29, P457, DOI 10.1016/0022-4731(88)90179-3; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LEVI BZ, 1988, GENE DEV, V2, P554, DOI 10.1101/gad.2.5.554; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MEDCALF RL, 1986, EMBO J, V5, P2217, DOI 10.1002/j.1460-2075.1986.tb04487.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; PONTA H, 1985, P NATL ACAD SCI USA, V82, P1020, DOI 10.1073/pnas.82.4.1020; PRATT WB, 1988, J BIOL CHEM, V263, P267; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QI M, 1989, MOL ENDOCRINOL, V3, P1279, DOI 10.1210/mend-3-8-1279; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SALMONS B, 1986, GENE, V45, P215, DOI 10.1016/0378-1119(86)90257-X; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHUSTER WA, 1988, EMBO J, V7, P1721, DOI 10.1002/j.1460-2075.1988.tb03001.x; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VACCA A, 1989, MOL ENDOCRINOL, V3, P1659, DOI 10.1210/mend-3-10-1659; VASSALLI JD, 1976, CELL, V8, P271, DOI 10.1016/0092-8674(76)90011-8; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	59	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1991	6	2					211	217						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1847998				2022-12-17	WOS:A1991FZ13400005
J	ITO, E; SWETERLITSCH, LA; TRAN, PBV; RAUSCHER, FJ; NARAYANAN, R				ITO, E; SWETERLITSCH, LA; TRAN, PBV; RAUSCHER, FJ; NARAYANAN, R			INHIBITION OF PC-12 CELL-DIFFERENTIATION BY THE IMMEDIATE EARLY GENE FRA-1	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; PROTO-ONCOGENE FOS; C-FOS; NEURONAL DIFFERENTIATION; ORNITHINE DECARBOXYLASE; PHEOCHROMOCYTOMA CELLS; NEURITE OUTGROWTH; PC12 CELLS; 3T3 CELLS; JUN	The rat pheochromocytoma cell line (PC-12) offers a powerful in vitro model to study the mechanism of growth factor-induced differentiation and proliferation. Within minutes of addition, agents such as nerve growth factor (NGF), epidermal growth factor (EGF), basic fibroblast growth factor (bFGF) and dibutyryl cyclic AMP (db cAMP) rapidly activate cellular immediate early genes such as c-fos, c-jun, jun-B, and egr-1. fra-1, a member of the immediate early gene family, follows a distinctly later time course of induction than c-fos, c-jun, jun-B, and egr-1, suggesting that fra-1 may attenuate the action of genes induced earlier. We demonstrate that constitutive expression of fra-1 in PC-12 cells results in pronounced inhibition of NGF-induced differentiation. Transcriptional activation of c-fos, c-jun, jun-B, and egr-1 by NGF, EGF, and db cAMP was down-regulated to a varying extent whereas NGF-induced ornithine decarboxylase (ODC) was not affected. Expression of jun-D was not affected in PC-12 fra-1 cells. Transfection of fos and egr-1 promoter-chloramphenicol acetyl transferase (CAT) plasmid into these stable fra-1-expressing PC-12 cells revealed that repression of fos and egr-1 was exerted at the promoter level. Thus deregulated fra-1 expression may inhibit PC-12 cell differentiation by altering the patterns of immediate early gene expression.	HOFFMANN LA ROCHE INC,DEPT MOLEC GENET,340 KINGSLAND ST,NUTLEY,NJ 07110; ROCHE INST MOLEC BIOL,DEPT MOLEC ONCOL & VIROL,NUTLEY,NJ 07110	Roche Holding				Ito, Etsuro/0000-0002-0168-2475; Narayanan, Ramaswamy/0000-0001-9346-9083				BOONSTRA J, 1985, BIOCHIMIE, V67, P1177, DOI 10.1016/S0300-9084(85)80117-6; BRTEL DP, 1989, GENE DEV, V3, P304; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CURRAN T, 1987, BIOESSAYS, V7, P255, DOI 10.1002/bies.950070606; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; CURRAN T, 1987, ONCOGENE, V2, P79; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; Curran T, 1988, ONCOGENE HDB, P307; CURRAN T, 1987, UCLA S MOL CELLULAR, V58, P215; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRANZA BR, 1987, ONCOGENE, V1, P213; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENE LA, 1978, NATURE, V276, P191, DOI 10.1038/276191a0; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; HEBY O, 1981, DIFFERENTIATION, V19, P1, DOI 10.1111/j.1432-0436.1981.tb01123.x; HICKOK NJ, 1986, P NATL ACAD SCI USA, V83, P594, DOI 10.1073/pnas.83.3.594; ITO E, 1990, CELL REGUL, V1, P347, DOI 10.1091/mbc.1.4.347; ITO E, 1989, ONCOGENE, V4, P1193; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARUYAMA K, 1987, ONCOGENE, V1, P361; MATSUI M, 1990, ONCOGENE, V5, P249; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; NARAYANAN R, 1989, EXP HEMATOL, V17, P832; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NOMURA N, 1990, NUCLEIC ACIDS RES, V18, P3047, DOI 10.1093/nar/18.10.3047; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDEL RE, 1987, J NEUROSCI, V7, P3639; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	49	25	26	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1990	5	12					1755	1760						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET436	2178237				2022-12-17	WOS:A1990ET43600003
J	SACCA, R; COCHRAN, BH				SACCA, R; COCHRAN, BH			IDENTIFICATION OF A PDGF-RESPONSIVE ELEMENT IN THE MURINE C-MYC GENE	ONCOGENE			English	Article									MIT, CTR CANC RES, 77 MASSACHUSETTS AVE, E17-517, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)				Cochran, Brent/0000-0002-7598-5604	NCI NIH HHS [P01 CA42063] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042063] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; ASSELIN C, 1989, ONCOGENE, V4, P549; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COCHRAN BH, 1988, CELLULAR FACTORS DEV; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DEAN M, 1986, J BIOL CHEM, V261, P9161; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DERSE D, 1986, SCIENCE, V231, P1437, DOI 10.1126/science.3006241; GERONDAKIS S, 1984, CELL, V36, P973, DOI 10.1016/0092-8674(84)90047-3; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALL DJ, 1987, J BIOL CHEM, V262, P15302; HALL DJ, 1990, ONCOGENE, V5, P47; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KAKKIS E, 1987, P NATL ACAD SCI USA, V84, P7031, DOI 10.1073/pnas.84.20.7031; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KELLY K, 1988, J BIOL CHEM, V263, P4828; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MANSOUR SL, 1986, MOL CELL BIOL, V6, P2684, DOI 10.1128/MCB.6.7.2684; MARCU KB, 1988, CURR TOP MICROBIOL, V141, P253; MERRILL GF, 1984, MOL CELL BIOL, V4, P1777, DOI 10.1128/MCB.4.9.1777; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NEPVEU A, 1987, ONCOGENE, V1, P243; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; PAYNE GS, 1982, NATURE, V295, P209, DOI 10.1038/295209a0; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; RICHMAN A, 1989, MOL CELL BIOL, V9, P4962, DOI 10.1128/MCB.9.11.4962; SANTERRE RF, 1984, GENE, V30, P147, DOI 10.1016/0378-1119(84)90115-X; SCHER CD, 1978, J CELL PHYSIOL, V97, P371, DOI 10.1002/jcp.1040970312; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x	68	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1990	5	10					1499	1505						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	2250909				2022-12-17	WOS:A1990EK50200008
J	LOWE, PN; SYDENHAM, M; PAGE, MJ				LOWE, PN; SYDENHAM, M; PAGE, MJ			THE HA-RAS PROTEIN, P21, IS MODIFIED BY A DERIVATIVE OF MEVALONATE AND METHYL-ESTERIFIED WHEN EXPRESSED IN THE INSECT BACULOVIRUS SYSTEM	ONCOGENE			English	Article									WELLCOME BIOTECHNOL,DEPT MOLEC BIOL,BECKENHAM BR3 3BS,KENT,ENGLAND	GlaxoSmithKline	LOWE, PN (corresponding author), WELLCOME RES LABS,DEPT MOLEC SCI,LANGLEY COURT,S EDEN PK RD,BECKENHAM BR3 3BS,KENT,ENGLAND.							ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHELSKY D, 1984, ANAL BIOCHEM, V141, P143, DOI 10.1016/0003-2697(84)90437-8; CHEN ZQ, 1985, J VIROL, V56, P607, DOI 10.1128/JVI.56.2.607-612.1985; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DESCHENES RJ, 1989, J BIOL CHEM, V264, P11865; EDMOND J, 1974, J BIOL CHEM, V249, P66; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; LOWY DR, 1989, NATURE, V341, P384, DOI 10.1038/341384a0; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; SCHAFER WR, 1989, SCIENCE, V245, P376; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x	16	25	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1990	5	7					1045	1048						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	2197592				2022-12-17	WOS:A1990DP41500013
J	KURIE, JM; MORSE, HC; PRINCIPATO, MA; WAX, JS; TROPPMAIR, J; RAPP, UR; POTTER, M; MUSHINSKI, JF				KURIE, JM; MORSE, HC; PRINCIPATO, MA; WAX, JS; TROPPMAIR, J; RAPP, UR; POTTER, M; MUSHINSKI, JF			V-MYC AND V-RAF ACT SYNERGISTICALLY TO INDUCE B-CELL TUMORS IN PRISTANE-PRIMED ADULT BALBC MICE	ONCOGENE			English	Article									NCI, GENET LAB, BLDG 37, ROOM 2B04, BETHESDA, MD 20892 USA; NIAID, IMMUNOPATHOL LAB, BETHESDA, MD 20892 USA; HAZLETON LABS AMERICA INC, ROCKVILLE, MD 20850 USA; NCI, FREDERICK CANC RES FACIL, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Troppmair, Jakob/0000-0002-0611-3837; Morse, Herbert/0000-0002-9331-3705				BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; CLYNES R, 1988, P NATL ACAD SCI USA, V85, P6067, DOI 10.1073/pnas.85.16.6067; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; ENRIETTO PJ, 1987, CANCER SURV, V6, P85; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GILL GW, 1974, ACTA CYTOL, V18, P300; GRAF T, 1982, BIOCHIM BIOPHYS ACTA, V651, P245, DOI 10.1016/0304-419X(82)90014-2; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HOLMES KL, 1986, J EXP MED, V164, P443, DOI 10.1084/jem.164.2.443; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; LANG RB, 1982, NUCLEIC ACIDS RES, V10, P611, DOI 10.1093/nar/10.2.611; MORSE HC, 1986, P NATL ACAD SCI USA, V83, P6868, DOI 10.1073/pnas.83.18.6868; MOUNTZ JD, 1984, SCIENCE, V226, P1087, DOI 10.1126/science.6494925; MUSHINSKI JF, 1988, CELLULAR ONCOGENE AC, P181; OHNO S, 1984, J EXP MED, V159, P1762, DOI 10.1084/jem.159.6.1762; OSSERMAN EF, 1966, J EXP MED, V124, P921, DOI 10.1084/jem.124.5.921; POLSKY F, 1978, ANAL BIOCHEM, V87, P397, DOI 10.1016/0003-2697(78)90689-9; POTTER M, 1987, SCIENCE, V235, P787, DOI 10.1126/science.3810165; PRINCIPATO M, 1988, CURR TOP MICROBIOL, V141, P31; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SCOTT CL, 1982, NATURE, V300, P757, DOI 10.1038/300757a0; SNODGRASS HR, 1985, NATURE, V315, P232, DOI 10.1038/315232a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SYMONDS G, 1989, ONCOGENE, V4, P285; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TROPPMAIR J, 1988, CURR TOP MICROBIOL, V141, P110; TROPPMAIR J, 1989, P NATL ACAD SCI USA, V86, P9941, DOI 10.1073/pnas.86.24.9941; VANNESS BG, 1982, P NATL ACAD SCI-BIOL, V79, P262; VENNSTROM B, 1981, J VIROL, V39, P625; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WEINBERG RA, 1984, BLOOD, V64, P1143; WOLFF L, 1988, J IMMUNOL, V141, P681; YAM LT, 1971, AM J CLIN PATHOL, V55, P283	36	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1990	5	4					577	582						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	2183159				2022-12-17	WOS:A1990DB85300018
J	CHRISTIANSEN, H; CHRISTIANSEN, NM; WAGNER, F; ALTMANNSBERGER, M; LAMPERT, F				CHRISTIANSEN, H; CHRISTIANSEN, NM; WAGNER, F; ALTMANNSBERGER, M; LAMPERT, F			NEUROBLASTOMA - INVERSE RELATIONSHIP BETWEEN EXPRESSION OF N-MYC AND NGF-R	ONCOGENE			English	Note									UNIV GIESSEN,KINDERKLIN,FEULGENSTR 12,W-6300 GIESSEN,GERMANY; UNIV GIESSEN,INST GENET,W-6300 GIESSEN,GERMANY; UNIV GIESSEN,INST PATHOL,W-6300 GIESSEN,GERMANY	Justus Liebig University Giessen; Justus Liebig University Giessen; Justus Liebig University Giessen								BERTHOLD F, 1986, MONOGR PAEDIATR, V18, P206; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1988, J CLIN ONCOL, V6, P1874, DOI 10.1200/JCO.1988.6.12.1874; BUCK CR, 1987, P NATL ACAD SCI USA, V84, P3060, DOI 10.1073/pnas.84.9.3060; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTIANSEN H, 1988, BRIT J CANCER, V57, P121, DOI 10.1038/bjc.1988.24; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DANGIO GJ, 1971, LANCET, V1, P1046; DAVIES AM, 1988, TRENDS GENET, V4, P139, DOI 10.1016/0168-9525(88)90137-0; DAVIES AM, 1987, NATURE, V326, P353, DOI 10.1038/326353a0; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; GRADYLEOPARDI EF, 1986, CANCER RES, V46, P3196; HARMS D, 1979, KLIN PADIATR, V191, P228; HASKELL BE, 1987, CELL TISSUE RES, V247, P67, DOI 10.1007/BF00216548; HERLYN M, 1983, CANCER INVEST, V1, P215, DOI 10.3109/07357908309041361; HUGHES M, 1974, CANCER, V34, P1706, DOI 10.1002/1097-0142(197411)34:5<1706::AID-CNCR2820340519>3.0.CO;2-J; JAKOBOVITS A, 1985, NATURE, V318, P188, DOI 10.1038/318188a0; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; MOOS M, 1983, EMBO J, V2, P757, DOI 10.1002/j.1460-2075.1983.tb01496.x; NISEN PD, 1988, J NATL CANCER I, V80, P633; ROSS AH, 1984, P NATL ACAD SCI-BIOL, V81, P6681, DOI 10.1073/pnas.81.21.6681; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; THIELE CJ, 1988, EXP CELL BIOL, V56, P321	28	25	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					437	440						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	2156211				2022-12-17	WOS:A1990CW41500025
J	MOORE, BE; BOSE, HR				MOORE, BE; BOSE, HR			EXPRESSION OF THE C-REL AND C-MYC PROTO-ONCOGENES IN AVIAN-TISSUES	ONCOGENE			English	Article									UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712; UNIV TEXAS,INST CELL RES,AUSTIN,TX 78712	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin					NATIONAL CANCER INSTITUTE [R01CA026169, R01CA033192] Funding Source: NIH RePORTER; NCI NIH HHS [CA 33192, CA 26169] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARTH CF, 1988, J EXP MED, V167, P89, DOI 10.1084/jem.167.1.89; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BROWNELL E, 1986, AM J HUM GENET, V39, P194; BROWNELL E, 1985, MOL CELL BIOL, V5, P2826, DOI 10.1128/MCB.5.10.2826; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; CHEN ISY, 1981, J VIROL, V40, P800, DOI 10.1128/JVI.40.3.800-811.1981; CHEN ISY, 1983, J VIROL, V45, P104, DOI 10.1128/JVI.45.1.104-113.1983; CHEN L, 1988, P NATL ACAD SCI USA, V85, P549, DOI 10.1073/pnas.85.2.549; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; FRANKLIN RB, 1974, INTERVIROLOGY, V3, P342, DOI 10.1159/000149771; FRANKLIN RB, 1977, VIROLOGY, V83, P313, DOI 10.1016/0042-6822(77)90176-3; GARSON K, 1986, BIOCHEM BIOPH RES CO, V134, P716, DOI 10.1016/S0006-291X(86)80479-X; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; HANNICK M, 1988, 4TH ANN M ONC FRED; HERZOG NK, 1986, P NATL ACAD SCI USA, V83, P812, DOI 10.1073/pnas.83.3.812; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; JONES RE, 1978, VERTEBRATE OVARY COM; KRAWETZ S A, 1984, Biotechniques, V2, P342; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEVINE M, 1988, CELL, V52, P785, DOI 10.1016/0092-8674(88)90418-7; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; REYNOLDS JD, 1987, EUR J IMMUNOL, V17, P503, DOI 10.1002/eji.1830170411; RICE NR, 1986, VIROLOGY, V149, P217, DOI 10.1016/0042-6822(86)90123-6; Romanoff A., 1960, THE AVIAN EMBRYO, V1, P429; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; SEVOIAN M, 1964, AVIAN DIS, V8, P336, DOI 10.2307/1587964; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SIMEK S, 1988, ONCOGENE RES, V2, P103; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STEWARD R, 1988, CELL, V55, P487, DOI 10.1016/0092-8674(88)90035-9; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOIVANEN P, 1974, EUR J IMMUNOL, V4, P405, DOI 10.1002/eji.1830040604; TUNG HYL, 1988, P NATL ACAD SCI USA, V85, P2479, DOI 10.1073/pnas.85.8.2479; WALRO DS, 1987, VIROLOGY, V160, P433, DOI 10.1016/0042-6822(87)90015-8; WHITE BA, 1982, J BIOL CHEM, V257, P8569; WILHELMSEN KC, 1984, J VIROL, V49, P521, DOI 10.1128/JVI.49.2.521-529.1984; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WONG TC, 1981, VIROLOGY, V111, P289, DOI 10.1016/0042-6822(81)90674-7	48	25	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1989	4	7					845	852						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2666905				2022-12-17	WOS:A1989AE58400005
J	BEPLER, G; BADING, H; HEIMANN, B; KIEFER, P; HAVEMANN, K; MOELLING, K				BEPLER, G; BADING, H; HEIMANN, B; KIEFER, P; HAVEMANN, K; MOELLING, K			EXPRESSION OF P64C-MYC AND NEURO-ENDOCRINE PROPERTIES DEFINE 3 SUBCLASSES OF SMALL CELL LUNG-CANCER	ONCOGENE			English	Article									MAX PLANCK INST MOLEC GENET,ABT SCHUSTER,IHNESTR 73,D-1000 BERLIN 33,FED REP GER; UNIV MARBURG,MED CTR,DEPT INTERNAL MED,DIV HEMATOL & ONCOL,D-3550 MARBURG,FED REP GER	Max Planck Society; Philipps University Marburg								BADING H, 1987, ONCOGENE, V1, P395; BADING H, 1988, ONCOGENE, V3, P257; BAILLIEJOHNSON H, 1985, BRIT J CANCER, V52, P495, DOI 10.1038/bjc.1985.220; BAYLIN SB, 1980, CANCER RES, V40, P1990; BEIMLING P, 1985, BIOCHEMISTRY-US, V24, P6349, DOI 10.1021/bi00344a005; BENSCH KG, 1968, CANCER, V22, P1163, DOI 10.1002/1097-0142(196811)22:6<1163::AID-CNCR2820220612>3.0.CO;2-L; BEPLER G, 1987, J CANCER RES CLIN, V113, P253, DOI 10.1007/BF00396382; BEPLER G, 1988, DIFFERENTIATION, V37, P158, DOI 10.1111/j.1432-0436.1988.tb00806.x; BEPLER G, 1987, CANCER RES, V47, P1883; BEPLER G, 1987, J CANCER RES CLIN, V113, P31, DOI 10.1007/BF00389964; BEPLER G, 1986, CANCER RES, V46, P3412; BERGH J, 1985, IMMUNOL SCAND A, V90, P133; BLOBEL GA, 1985, LAB INVEST, V52, P39; CARNEY DN, 1983, CANCER RES, V43, P2806; CARNEY DN, 1985, CANCER RES, V45, P2913; DENHEZ F, 1988, EMBO J, V7, P541, DOI 10.1002/j.1460-2075.1988.tb02843.x; GAZDAR AF, 1985, CANCER RES, V45, P2924; GAZDAR AF, 1985, RECENT RES CANCER, V99, P167; GOULD VE, 1983, PATHOL ANNU, V18, P287; GRIFFIN CA, 1985, RECENT RES CANCER, V99, P237; HAEDER M, 1988, CANCER RES, V48, P1132; KIEFER PE, 1987, CANCER RES, V47, P6236; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LINIAL M, 1982, VIROLOGY, V119, P382, DOI 10.1016/0042-6822(82)90097-6; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MOELLING K, 1987, CONTRIBUTIONS ONCOLO, V24, P76; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; PETTENGILL OS, 1980, CANCER-AM CANCER SOC, V45, P906, DOI 10.1002/1097-0142(19800301)45:5<906::AID-CNCR2820450513>3.0.CO;2-H; RAPP UR, 1987, MODERN TRENDS HUMAN, V7, P450; SORENSON GD, 1981, CANCER, V47, P1289, DOI 10.1002/1097-0142(19810315)47:6<1289::AID-CNCR2820470610>3.0.CO;2-B; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023	36	25	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					45	50						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2536917				2022-12-17	WOS:A1989U567400007
J	Fu, JJ; Su, XR; Li, ZH; Deng, L; Liu, XW; Feng, XC; Peng, J				Fu, Jianjiang; Su, Xiaorui; Li, Zhihua; Deng, Ling; Liu, Xiawei; Feng, Xuancheng; Peng, Juan			HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence	ONCOGENE			English	Review							HEPATOCYTE GROWTH-FACTOR; CELL LUNG-CANCER; EXON 14 MUTATIONS; TYROSINE KINASE INHIBITOR; SCATTER FACTOR HGF/SF; C-MET; BREAST-CANCER; PROGNOSTIC VALUE; FACTOR RECEPTOR; THERAPEUTIC TARGET	This review provides a comprehensive landscape of HGF/c-MET (hepatocyte growth factor (HGF) /mesenchymal-epithelial transition factor (c-MET)) signaling pathway in cancers. First, we generalize the compelling influence of HGF/c-MET pathway on multiple cellular processes. Then, we present the genomic characterization of HGF/c-MET pathway in carcinogenesis. Furthermore, we extensively illustrate the malignant biological behaviors of HGF/c-MET pathway in cancers, in which hyperactive HGF/c-MET signaling is considered as a hallmark. In addition, we investigate the current clinical trials of HGF/c-MET-targeted therapy in cancers. We find that although HGF/c-MET-targeted therapy has led to breakthroughs in certain cancers, monotherapy of targeting HGF/c-MET has failed to demonstrate significant clinical efficacy in most cancers. With the advantage of the combinations of HGF/c-MET-targeted therapy, the exploration of more options of combinational targeted therapy in cancers may be the major challenge in the future.	[Fu, Jianjiang; Su, Xiaorui; Liu, Xiawei; Feng, Xuancheng; Peng, Juan] Guangzhou Med Univ, Affiliated Hosp 3, Dept Pathol, Guangzhou, Peoples R China; [Fu, Jianjiang; Su, Xiaorui; Li, Zhihua; Liu, Xiawei; Feng, Xuancheng; Peng, Juan] Guangzhou Med Univ, Clin Sch 3, Guangzhou, Peoples R China; [Fu, Jianjiang; Su, Xiaorui; Li, Zhihua; Liu, Xiawei; Feng, Xuancheng; Peng, Juan] Key Lab Reprod & Genet Guangdong Higher Educ Inst, Guangzhou, Peoples R China; [Li, Zhihua] Guangzhou Med Univ, Affiliated Hosp 3, Dept Fetal Med & Prenatal Diag, Guangzhou, Peoples R China; [Deng, Ling] Sun Yat Sen Univ Canc Ctr, Dept Mol Diagnost, Guangzhou, Peoples R China	Guangzhou Medical University; Guangzhou Medical University; Guangzhou Medical University; Sun Yat Sen University	Feng, XC; Peng, J (corresponding author), Guangzhou Med Univ, Affiliated Hosp 3, Dept Pathol, Guangzhou, Peoples R China.; Feng, XC; Peng, J (corresponding author), Guangzhou Med Univ, Clin Sch 3, Guangzhou, Peoples R China.; Feng, XC; Peng, J (corresponding author), Key Lab Reprod & Genet Guangdong Higher Educ Inst, Guangzhou, Peoples R China.	2816924339@qq.com; pengjuan1979@yahoo.com	Peng, Juan/GXF-2029-2022	Liu, Xiawei/0000-0001-9508-1832; Feng, Xuancheng/0000-0002-8722-6306; Peng, Juan/0000-0001-6308-3040	National Natural Science Foundation of China [81602631]; Guangdong Natural Science Foundation of China [2016A030310280]; Students' Laboratory Open Project of Guangzhou Medical University [C195015021]; Elite Talents Training Plan of the Third Affiliated Hospital of Guangzhou Medical University; Special Funds for the Cultivation of Guangdong College Students' Scientific and Technological Innovation: "Climbing Program" Special Funds [pdjh2020b0490]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation of China(National Natural Science Foundation of Guangdong Province); Students' Laboratory Open Project of Guangzhou Medical University; Elite Talents Training Plan of the Third Affiliated Hospital of Guangzhou Medical University; Special Funds for the Cultivation of Guangdong College Students' Scientific and Technological Innovation: "Climbing Program" Special Funds	This work has been supported by the National Natural Science Foundation of China (No. 81602631), the Guangdong Natural Science Foundation of China (No. 2016A030310280), the Students' Laboratory Open Project of Guangzhou Medical University (No. C195015021), 2017 Elite Talents Training Plan of the Third Affiliated Hospital of Guangzhou Medical University (J.P.), and Special Funds for the Cultivation of Guangdong College Students' Scientific and Technological Innovation: "Climbing Program" Special Funds (No. pdjh2020b0490).	Abou-Alfa GK, 2018, NEW ENGL J MED, V379, P54, DOI 10.1056/NEJMoa1717002; Aebersold DM, 2003, ONCOGENE, V22, P8519, DOI 10.1038/sj.onc.1206968; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Antonia SJ, 2016, LANCET ONCOL, V17, P883, DOI 10.1016/S1470-2045(16)30098-5; Aparicio T, 2021, TARGET ONCOL, V16, P381, DOI 10.1007/s11523-021-00811-8; Asaoka Y, 2010, BIOCHEM BIOPH RES CO, V394, P1042, DOI 10.1016/j.bbrc.2010.03.120; Awad MM, 2016, J CLIN ONCOL, V34, P721, DOI 10.1200/JCO.2015.63.4600; Baltschukat S, 2019, CLIN CANCER RES, V25, P3164, DOI 10.1158/1078-0432.CCR-18-2814; Bao ZS, 2014, GENOME RES, V24, P1765, DOI 10.1101/gr.165126.113; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Bender S, 2016, NAT MED, V22, P1314, DOI 10.1038/nm.4204; Bertran-Alamillo J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09734-5; Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Burbridge MF, 2013, MOL CANCER THER, V12, P1749, DOI 10.1158/1535-7163.MCT-13-0075; Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]; Catenacci DVT, 2017, CANCER-AM CANCER SOC, V123, P1061, DOI 10.1002/cncr.30437; Chang LL, 2019, ACTA PHARM SIN B, V9, P484, DOI 10.1016/j.apsb.2019.03.001; Charytonowicz E, 2009, CANCER LETT, V279, P126, DOI 10.1016/j.canlet.2008.09.039; Che L, 2020, GUT, V69, P177, DOI 10.1136/gutjnl-2018-317581; Cheng FL, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1269-x; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Choi J, 2018, APPL IMMUNOHISTO M M, V26, P445, DOI 10.1097/PAI.0000000000000448; Choueiri TK, 2015, NEW ENGL J MED, V373, P1814, DOI 10.1056/NEJMoa1510016; Choueiri TK, 2020, J CLIN ONCOL, V38; Choueiri TK, 2017, J CLIN ONCOL, V35, P591, DOI 10.1200/JCO.2016.70.7398; Choueiri TK, 2016, LANCET ONCOL, V17, P917, DOI 10.1016/S1470-2045(16)30107-3; Ciccarese C, 2016, CANCER TREAT REV, V49, P37, DOI 10.1016/j.ctrv.2016.07.003; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Conrotto P, 2004, ONCOGENE, V23, P5131, DOI 10.1038/sj.onc.1207650; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Corso S, 2013, CANCER DISCOV, V3, P978, DOI 10.1158/2159-8290.CD-13-0040; Cui JJ, 2011, J MED CHEM, V54, P6342, DOI 10.1021/jm2007613; Dai L, 2015, BLOOD, V126, P2821, DOI 10.1182/blood-2015-07-658823; Dang H, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1166-4; Daniel SK, 2019, CLIN TRANSL MED, V8, DOI 10.1186/s40169-019-0226-9; Davis IJ, 2010, CANCER RES, V70, P639, DOI 10.1158/0008-5472.CAN-09-1121; De Bacco F, 2011, J NATL CANCER I, V103, P645, DOI 10.1093/jnci/djr093; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Doi T, 2020, INVEST NEW DRUG, V38, P1175, DOI 10.1007/s10637-019-00859-4; Drilon A, 2020, NAT MED, V26, P47, DOI 10.1038/s41591-019-0716-8; Drilon AE, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.108; Du F, 2020, ONCOGENE, V39, P3522, DOI 10.1038/s41388-020-1233-4; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Engstrom LD, 2017, CLIN CANCER RES, V23, P6661, DOI 10.1158/1078-0432.CCR-17-1192; Fan GF, 2016, GENE DEV, V30, P1542, DOI 10.1101/gad.284166.116; Flores-Tellez TNJ, 2017, WORLD J GASTROENTERO, V23, P6750, DOI 10.3748/wjg.v23.i37.6750; Frampton GM, 2015, CANCER DISCOV, V5, P850, DOI 10.1158/2159-8290.CD-15-0285; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GHERARDI E, 1993, SYM SOC EXP BIOL, V47, P163; Gibney GT, 2013, ANN ONCOL, V24, P343, DOI 10.1093/annonc/mds463; Gille J, 1998, J INVEST DERMATOL, V111, P1160, DOI 10.1046/j.1523-1747.1998.00418.x; Gow CH, 2017, LUNG CANCER, V103, P82, DOI 10.1016/j.lungcan.2016.12.001; Goyal L, 2013, CLIN CANCER RES, V19, P2310, DOI 10.1158/1078-0432.CCR-12-2791; Guan XM, 2015, ACTA PHARM SIN B, V5, P402, DOI 10.1016/j.apsb.2015.07.005; Gupta A, 2008, CLIN CANCER RES, V14, P7385, DOI 10.1158/1078-0432.CCR-07-5110; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harding JJ, 2019, CLIN CANCER RES, V25, P2116, DOI 10.1158/1078-0432.CCR-18-2293; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; Hofmann F, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012796.pub2; Huang KH, 2018, ONCOL REP, V40, P294, DOI 10.3892/or.2018.6447; Huang WC, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4529-9; Huang X, 2019, AUTOPHAGY, V15, P1258, DOI 10.1080/15548627.2019.1580105; Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061; Vuong HG, 2018, LUNG CANCER, V123, P76, DOI 10.1016/j.lungcan.2018.07.006; Jagadeeswaran R, 2006, CANCER RES, V66, P352, DOI 10.1158/0008-5472.CAN-04-4567; Jahangiri A, 2017, P NATL ACAD SCI USA, V114, pE8685, DOI 10.1073/pnas.1701821114; Jankowski K, 2003, CANCER RES, V63, P7926; Jeon HM, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2016.12.67; Joo KM, 2012, CANCER RES, V72, P3828, DOI 10.1158/0008-5472.CAN-11-3760; JUCKER M, 1994, LEUKEMIA RES, V18, P7, DOI 10.1016/0145-2126(94)90003-5; Kadoyama K, 2009, NEUROSCI RES, V65, P194, DOI 10.1016/j.neures.2009.06.016; Kelley RK, 2017, ANN ONCOL, V28, P528, DOI 10.1093/annonc/mdw651; Kim H, 2016, J CANCER RES CLIN, V142, P707, DOI 10.1007/s00432-015-2072-5; Kim JH, 2018, J CANCER, V9, P1836, DOI 10.7150/jca.24980; Kim JH, 2017, ONCOTARGET, V8, P90351, DOI 10.18632/oncotarget.20087; Kim JH, 2017, ONCOTARGET, V8, P73098, DOI 10.18632/oncotarget.20392; Kim JH, 2017, ONCOTARGET, V8, P75478, DOI 10.18632/oncotarget.20796; Kondo S, 2013, INT J CLIN ONCOL, V18, P207, DOI 10.1007/s10147-011-0361-9; Kong LR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15318-5; Kong-Beltran M, 2006, CANCER RES, V66, P283, DOI 10.1158/0008-5472.CAN-05-2749; Krishnaswamy S, 2009, CLIN CANCER RES, V15, P5714, DOI 10.1158/1078-0432.CCR-09-0070; Kubo Y, 2019, J DERMATOL SCI, V93, P33, DOI 10.1016/j.jdermsci.2018.10.001; Kurzrock R, 2011, J CLIN ONCOL, V29, P2660, DOI 10.1200/JCO.2010.32.4145; LAGUDA B, 1991, ANN HUM GENET, V55, P213, DOI 10.1111/j.1469-1809.1991.tb00415.x; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Lee SJ, 2018, CLIN COLORECTAL CANC, V17, P165, DOI 10.1016/j.clcc.2018.02.013; Lee SJ, 2013, ANTICANCER RES, V33, P5179; Li A, 2017, CLIN CANCER RES, V23, P4929, DOI 10.1158/1078-0432.CCR-16-3273; Li H, 2019, GASTROENTEROLOGY, V156, P1849, DOI 10.1053/j.gastro.2019.01.252; Li YQ, 2011, P NATL ACAD SCI USA, V108, P9951, DOI 10.1073/pnas.1016912108; Liang QL, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0122-5; Liu XW, 2016, J CLIN ONCOL, V34, P794, DOI 10.1200/JCO.2015.62.0674; Liu Y, 2015, WORLD J GASTROENTERO, V21, P3706, DOI 10.3748/wjg.v21.i12.3706; Lux A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133305; Ma PC, 2008, GENE CHROMOSOME CANC, V47, P1025, DOI 10.1002/gcc.20604; Ma PC, 2005, CANCER RES, V65, P1479, DOI 10.1158/0008-5472.CAN-04-2650; Ma PC, 2003, CANCER RES, V63, P6272; Marona P, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8030272; Maulik G, 2002, CLIN CANCER RES, V8, P620; Michikoshi H, 2013, CANCER LETT, V335, P472, DOI 10.1016/j.canlet.2013.03.008; Miura Y, 2003, BIOCHEM BIOPH RES CO, V305, P160, DOI 10.1016/S0006-291X(03)00725-3; Morell RJ, 2020, J NEUROSCI, V40, P2976, DOI 10.1523/JNEUROSCI.2278-19.2020; Moro-Sibilot D, 2019, ANN ONCOL, V30, P1985, DOI 10.1093/annonc/mdz407; Mujtaba G, 2015, J MED GENET, V52, P548, DOI 10.1136/jmedgenet-2015-103023; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; Nakamura Y, 2008, CANCER SCI, V99, P14, DOI 10.1111/j.1349-7006.2007.00640.x; Nakayama M, 2013, CYTOKINE, V62, P446, DOI 10.1016/j.cyto.2013.04.006; Nassar D, 2016, ANNU REV PATHOL-MECH, V11, P47, DOI 10.1146/annurev-pathol-012615-044438; Nault JC, 2020, HEPATOLOGY, V71, P164, DOI 10.1002/hep.30811; Navis AC, 2015, ACTA NEUROPATHOL, V130, P131, DOI 10.1007/s00401-015-1420-5; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Ou SHI, 2011, J THORAC ONCOL, V6, P942, DOI 10.1097/JTO.0b013e31821528d3; Oyama T, 1998, PATHOL INT, V48, P763, DOI 10.1111/j.1440-1827.1998.tb03835.x; Paik PK, 2020, NEW ENGL J MED, V383, P931, DOI 10.1056/NEJMoa2004407; Park DJ, 2014, ANN SURG ONCOL, V21, P1130, DOI 10.1245/s10434-013-3429-0; Park K, 2021, LUNG CANCER, V155, P127, DOI 10.1016/j.lungcan.2021.03.012; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Peng H, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-1038; Peng JF, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/6594016; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Penuel E, 2013, MOL CANCER THER, V12, P1122, DOI 10.1158/1535-7163.MCT-13-0015; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Previdi S, 2010, EUR J CANCER, V46, P1679, DOI 10.1016/j.ejca.2010.02.036; Puccini A, 2019, DRUG SAFETY, V42, P211, DOI 10.1007/s40264-018-0780-x; Puri N, 2007, CLIN CANCER RES, V13, P2246, DOI 10.1158/1078-0432.CCR-06-0776; Pyo JS, 2016, PATHOL RES PRACT, V212, P710, DOI 10.1016/j.prp.2016.05.006; Rath P, 2013, TRANSL ONCOL, V6, P104, DOI 10.1593/tlo.13127; Ready N, 2019, J THORAC ONCOL, V14, P237, DOI 10.1016/j.jtho.2018.10.003; Recondo G, 2020, CLIN CANCER RES, V26, P2615, DOI 10.1158/1078-0432.CCR-19-3608; Ren JL, 2017, PANMINERVA MED, V59, P97, DOI 10.23736/S0031-0808.16.03228-6; Rodon J, 2017, EUR J CANCER, V81, P142, DOI 10.1016/j.ejca.2017.05.007; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; Roohullah A, 2018, INVEST NEW DRUG, V36, P886, DOI 10.1007/s10637-018-0588-7; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Saltarella I, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-018-0691-4; Saygin C, 2019, CELL STEM CELL, V24, P25, DOI 10.1016/j.stem.2018.11.017; Scarpino S, 2004, J PATHOL, V202, P352, DOI 10.1002/path.1522; Schiefer AI, 2015, HISTOPATHOLOGY, V67, P799, DOI 10.1111/his.12709; Schlumberger M, 2017, ANN ONCOL, V28, P2813, DOI 10.1093/annonc/mdx479; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schoffski P, 2017, ANN ONCOL, V28, P3000, DOI 10.1093/annonc/mdx527; Schultz JM, 2009, AM J HUM GENET, V85, P25, DOI 10.1016/j.ajhg.2009.06.003; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; Shen MQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0839-4; Shojaei F, 2010, CANCER RES, V70, P10090, DOI 10.1158/0008-5472.CAN-10-0489; Skoulidis F, 2019, NAT REV CANCER, V19, P495, DOI 10.1038/s41568-019-0179-8; Skrzypek K, 2015, ONCOTARGET, V6, P31378, DOI 10.18632/oncotarget.5145; Smith DC, 2013, J CLIN ONCOL, V31, P412, DOI 10.1200/JCO.2012.45.0494; Smith M, 2016, J CLIN ONCOL, V34, P3005, DOI 10.1200/JCO.2015.65.5597; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Solomon BJ, 2018, J CLIN ONCOL, V36, P2251, DOI 10.1200/JCO.2017.77.4794; Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034]; SOMAN NR, 1991, P NATL ACAD SCI USA, V88, P4892, DOI 10.1073/pnas.88.11.4892; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Stransky N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5846; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Suzuki M, 2005, J BIOL CHEM, V280, P6409, DOI 10.1074/jbc.M406714200; Szturz P, 2017, ORAL ONCOL, V74, P68, DOI 10.1016/j.oraloncology.2017.09.009; Taulli R, 2006, CANCER RES, V66, P4742, DOI 10.1158/0008-5472.CAN-05-4292; Tavian D, 2000, INT J CANCER, V87, P644, DOI 10.1002/1097-0215(20000901)87:5<644::AID-IJC4>3.3.CO;2-N; THALER FJ, 1985, CANCER RES, V45, P2545; Tong CYK, 2004, J NEUROSURG, V100, P187, DOI 10.3171/ped.2004.100.2.0187; Tsuji T, 2017, ONCOTARGET, V8, P71805, DOI 10.18632/oncotarget.17895; Umeki K, 1999, ONCOLOGY-BASEL, V56, P314, DOI 10.1159/000011985; van den Bent M, 2020, J NEURO-ONCOL, V146, P79, DOI 10.1007/s11060-019-03337-2; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Vsiansky V, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28672-8; Wakelee HA, 2017, CANCER CHEMOTH PHARM, V79, P923, DOI 10.1007/s00280-017-3283-z; Wang F, 2016, BREAST, V28, P45, DOI 10.1016/j.breast.2016.04.016; Wang HY, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00055; Wang Y, 2021, ONCOLOGIST, V26, P178, DOI 10.1002/onco.13545; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; Westover D, 2018, ANN ONCOL, V29, pI10, DOI 10.1093/annonc/mdx703; Wolf J, 2020, NEW ENGL J MED, V383, P944, DOI 10.1056/NEJMoa2002787; Wu F, 2006, DIGEST LIVER DIS, V38, P490, DOI 10.1016/j.dld.2006.03.007; Wu YL, 2020, LANCET RESP MED, V8, P1132, DOI 10.1016/S2213-2600(20)30154-5; Wu YL, 2018, J CLIN ONCOL, V36, P3101, DOI 10.1200/JCO.2018.77.7326; Wu YL, 2018, J THORAC ONCOL, V13, P1539, DOI 10.1016/j.jtho.2018.06.012; Xie Q, 2012, P NATL ACAD SCI USA, V109, P570, DOI 10.1073/pnas.1119059109; Xing F, 2018, CANCER RES, V78, P4316, DOI 10.1158/0008-5472.CAN-18-1102; Yan B, 2018, EXP CELL RES, V371, P63, DOI 10.1016/j.yexcr.2018.07.041; Yan SC, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0296-y; Yao JF, 2019, J BIOCHEM MOL TOXIC, V33, DOI 10.1002/jbt.22316; Zagouri F, 2013, BRIT J CANCER, V108, P1100, DOI 10.1038/bjc.2013.31; Zambelli A, 2021, ADV EXP MED BIOL, V1270, P31, DOI 10.1007/978-3-030-47189-7_2; ZARNEGAR R, 1989, CANCER RES, V49, P3314; Zhang Y, 2014, MOL MED REP, V10, P1013, DOI 10.3892/mmr.2014.2293; Zhang YR, 2020, CANCER RES, V80, P30, DOI 10.1158/0008-5472.CAN-19-1389; Zhang Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0750-2; Zhou L, 2016, ONCOGENE, V35, P2687, DOI 10.1038/onc.2015.343	194	24	25	5	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2021	40	28					4625	4651		10.1038/s41388-021-01863-w	http://dx.doi.org/10.1038/s41388-021-01863-w		JUN 2021	27	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK8LG	34145400				2022-12-17	WOS:000663295300002
J	Lin, CC; Yang, WH; Lin, YT; Tang, XH; Chen, PH; Ding, CKC; Qu, DC; Alvarez, JV; Chi, JT				Lin, Chao-Chieh; Yang, Wen-Hsuan; Lin, Yi-Tzu; Tang, Xiaohu; Chen, Po-Han; Ding, Chien-Kuang Cornelia; Qu, Dan Chen; Alvarez, James V.; Chi, Jen-Tsan			DDR2 upregulation confers ferroptosis susceptibility of recurrent breast tumors through the Hippo pathway	ONCOGENE			English	Article								Recurrent breast cancer presents significant challenges with aggressive phenotypes and treatment resistance. Therefore, novel therapeutics are urgently needed. Here, we report that murine recurrent breast tumor cells, when compared with primary tumor cells, are highly sensitive to ferroptosis. Discoidin Domain Receptor Tyrosine Kinase 2 (DDR2), the receptor for collagen I, is highly expressed in ferroptosis-sensitive recurrent tumor cells and human mesenchymal breast cancer cells. EMT regulators, TWIST and SNAIL, significantly induce DDR2 expression and sensitize ferroptosis in a DDR2-dependent manner. Erastin treatment induces DDR2 upregulation and phosphorylation, independent of collagen I. Furthermore, DDR2 knockdown in recurrent tumor cells reduces clonogenic proliferation. Importantly, both the ferroptosis protection and reduced clonogenic growth may be compatible with the compromised YAP/TAZ upon DDR2 inhibition. Collectively, these findings identify the important role of EMT-driven DDR2 upregulation in recurrent tumors in maintaining growth advantage but activating YAP/TAZ-mediated ferroptosis susceptibility, providing potential strategies to eradicate recurrent breast cancer cells with mesenchymal features.	[Lin, Chao-Chieh; Yang, Wen-Hsuan; Lin, Yi-Tzu; Chen, Po-Han; Ding, Chien-Kuang Cornelia; Qu, Dan Chen; Chi, Jen-Tsan] Duke Univ, Dept Mol Genet & Microbiol, Sch Med, Durham, NC 27710 USA; [Lin, Chao-Chieh; Yang, Wen-Hsuan; Lin, Yi-Tzu; Chen, Po-Han; Ding, Chien-Kuang Cornelia; Qu, Dan Chen; Chi, Jen-Tsan] Duke Univ, Ctr Genom & Computat Biol, Sch Med, Durham, NC 27710 USA; [Tang, Xiaohu] Michigan Technol Univ, Dept Biol Sci, Houghton, MI 49931 USA; [Alvarez, James V.] Duke Univ, Dept Pharmacol & Canc Biol, Sch Med, Durham, NC 27710 USA	Duke University; Duke University; Michigan Technological University; Duke University	Chi, JT (corresponding author), Duke Univ, Dept Mol Genet & Microbiol, Sch Med, Durham, NC 27710 USA.; Chi, JT (corresponding author), Duke Univ, Ctr Genom & Computat Biol, Sch Med, Durham, NC 27710 USA.	jentsan.chi@duke.edu	Yang, Wen-Hsuan/AAY-9158-2021; Yang, Wen-Hsuan/GVU-6615-2022; Yang, Wen-Hsuan/GVU-4518-2022; CHEN, PO-HAN/ABB-6690-2021; Lin, Chao-Chieh/AAC-9102-2022; Tang, Xiaohu/AAX-4577-2021	Yang, Wen-Hsuan/0000-0001-5780-6839; Yang, Wen-Hsuan/0000-0001-5780-6839; CHEN, PO-HAN/0000-0002-9471-4471; Lin, Chao-Chieh/0000-0001-5890-9004; Tang, Mark/0000-0001-6367-4991; Chi, Jen-Tsan/0000-0003-3433-903X	DOD [W81XWH-17-1-0143, W81XWH-15-1-0486, W81XWH-19-1-0842, W81XWH-20-1-0907]; NIH [R01GM124062, R01NS111588-01A1, 1R21-AI149205]	DOD(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We are grateful for technical support from the members of the Chi lab. We also appreciate the generosity of Dr. Everardo Macias for allowing access to the Incucyte S3. We acknowledge the financial support in part by DOD grants (W81XWH-17-1-0143, W81XWH-15-1-0486, W81XWH-19-1-0842, W81XWH-20-1-0907), and NIH grants (R01GM124062, 1R01NS111588-01A1, 1R21-AI149205).	Angeli JPF, 2014, NAT CELL BIOL, V16, P1180, DOI 10.1038/ncb3064; Bayer SVH, 2019, ELIFE, V8, DOI 10.7554/eLife.45508; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Boxer RB, 2004, CANCER CELL, V6, P577, DOI 10.1016/j.ccr.2004.10.013; Burdo J, 2006, J HISTOCHEM CYTOCHEM, V54, P549, DOI 10.1369/jhc.5A6840.2006; Chen PH, 2020, CELL DEATH DIFFER, V27, P1008, DOI 10.1038/s41418-019-0393-7; Chen PH, 2017, MOL CELL ONCOL, V4, DOI 10.1080/23723556.2017.1361501; Chen PH, 2017, EMBO J, V36, P2233, DOI 10.15252/embj.201696113; Come C, 2006, CLIN CANCER RES, V12, P5395, DOI 10.1158/1078-0432.CCR-06-0478; Corsa CAS, 2016, CELL REP, V15, P2510, DOI 10.1016/j.celrep.2016.05.033; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Ding CKC, 2020, NAT METAB, V2, P270, DOI 10.1038/s42255-020-0181-1; Dixon SJ, 2014, ELIFE, V3, DOI 10.7554/eLife.02523; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Doll S, 2017, NAT CHEM BIOL, V13, P91, DOI [10.1038/NCHEMBIO.2239, 10.1038/nchembio.2239]; Du K, 2019, INHIBITING XCT SLC7A, DOI [10.1101/2019.12.23.886259, DOI 10.1101/2019.12.23.886259]; Elloul S, 2005, CANCER-AM CANCER SOC, V103, P1631, DOI 10.1002/cncr.20946; Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915; Fan Y, 2016, AM J TRANSL RES, V8, P2845; Fox DB, 2020, NAT METAB, V2, P318, DOI 10.1038/s42255-020-0191-z; Gao MH, 2015, MOL CELL, V59, P298, DOI 10.1016/j.molcel.2015.06.011; Gonzalez ME, 2017, CELL REP, V18, P1215, DOI 10.1016/j.celrep.2016.12.079; Goswami CP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-970; Grither WR, 2018, P NATL ACAD SCI USA, V115, pE7786, DOI 10.1073/pnas.1805020115; Grither WR, 2018, ONCOGENE, V37, P1714, DOI 10.1038/s41388-017-0043-9; Gunther EJ, 2003, GENE DEV, V17, P488, DOI 10.1101/gad.1051603; Hammerman PS, 2011, CANCER DISCOV, V1, P78, DOI 10.1158/2159-8274.CD-11-0005; Hayano M, 2016, CELL DEATH DIFFER, V23, P270, DOI 10.1038/cdd.2015.93; Huang CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076421; Hwang PY, 2019, CANCER RES, V79, P1899, DOI 10.1158/0008-5472.CAN-18-2828; Ikeda K, 2002, J BIOL CHEM, V277, P19206, DOI 10.1074/jbc.M201078200; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07126-7; Kimbung S, 2015, SEMIN CANCER BIOL, V35, P85, DOI 10.1016/j.semcancer.2015.08.009; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Koo JH, 2020, GENE DEV, V34, P72, DOI 10.1101/gad.331546.119; Lamar JM, 2019, J BIOL CHEM, V294, P2302, DOI 10.1074/jbc.RA118.004364; Li P, 2016, GENE DEV, V30, P798, DOI 10.1101/gad.274951.115; Lin Chao-Chieh, 2020, Oncotarget, V11, P3562, DOI 10.18632/oncotarget.27749; Lin CC, 2020, CELL DEATH DIFFER, V27, P2234, DOI 10.1038/s41418-020-0499-y; Lin CC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03422-6; Linkermann A, 2014, P NATL ACAD SCI USA, V111, P16836, DOI 10.1073/pnas.1415518111; Liu PX, 2011, NAT MED, V17, P1116, DOI 10.1038/nm.2402; Mabe NW, 2018, J CLIN INVEST, V128, P4413, DOI 10.1172/JCI99481; Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Sasaki S, 2017, ANTICANCER RES, V37, P2587, DOI 10.21873/anticanres.11603; Si Y, 2017, CANCER RES, V77, P4868, DOI 10.1158/0008-5472.CAN-17-0391; Skouta R, 2014, J AM CHEM SOC, V136, P4551, DOI 10.1021/ja411006a; Slocum E, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1142-z; Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021; Tang X, 2017, ONCOGENE, V36, P4235, DOI 10.1038/onc.2016.394; Tang XH, 2016, CANCER RES, V76, P1892, DOI 10.1158/0008-5472.CAN-15-2328; Tang XH, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005158; Terai H, 2015, ACS CHEM BIOL, V10, P2687, DOI 10.1021/acschembio.5b00655; Timmerman LA, 2013, CANCER CELL, V24, P450, DOI 10.1016/j.ccr.2013.08.020; Toy KA, 2015, BREAST CANCER RES TR, V150, P9, DOI 10.1007/s10549-015-3285-7; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Tsai MC, 2016, ONCOTARGET, V7, P78918, DOI 10.18632/oncotarget.12912; Tu MM, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav2437; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Walsh LA, 2011, MATRIX BIOL, V30, P243, DOI 10.1016/j.matbio.2011.03.007; Wu J, 2019, NATURE, V572, P402, DOI 10.1038/s41586-019-1426-6; Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158; Yang K, 2005, J BIOL CHEM, V280, P39058, DOI 10.1074/jbc.M506921200; Yang WH, 2020, MOL CELL ONCOL, V7, DOI 10.1080/23723556.2019.1699375; Yang WH, 2020, MOL CANCER RES, V18, P79, DOI 10.1158/1541-7786.MCR-19-0691; Yang WH, 2019, CELL REP, V28, P2501, DOI 10.1016/j.celrep.2019.07.107; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhang K, 2013, NAT CELL BIOL, V15, P677, DOI 10.1038/ncb2743	72	24	25	3	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					2018	2034		10.1038/s41388-021-01676-x	http://dx.doi.org/10.1038/s41388-021-01676-x		FEB 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33603168	Green Accepted			2022-12-17	WOS:000619433100005
J	Kong, DG; Zhou, HB; Neelakantan, D; Hughes, CJ; Hsu, JY; Srinivasan, RR; Lewis, MT; Ford, HL				Kong, Deguang; Zhou, Hengbo; Neelakantan, Deepika; Hughes, Connor J.; Hsu, Jessica Y.; Srinivasan, Ramakrishnan Rajaram; Lewis, Michael T.; Ford, Heide L.			VEGF-C mediates tumor growth and metastasis through promoting EMT-epithelial breast cancer cell crosstalk	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; INTRATUMOR HETEROGENEITY; HEDGEHOG PATHWAY; STEM-CELLS; LYMPHANGIOGENESIS; AXIS; RECEPTOR; CONTRIBUTES; INHIBITION; EXPRESSION	It is well established that a subset of cells within primary breast cancers can undergo an epithelial-to-mesenchymal transition (EMT), although the role of EMT in metastasis remains controversial. We previously demonstrated that breast cancer cells that had undergone an oncogenic EMT could increase metastasis of neighboring cancer cells via non-canonical paracrine-mediated activation of GLI activity that is dependent on SIX1 expression in the EMT cancer cells. However, the mechanism by which these SIX1-expressing EMT cells activate GLI signaling remained unclear. In this study, we demonstrate a novel mechanism for activation of GLI-mediated signaling in epithelial breast tumor cells via EMT cell-induced production and secretion of VEGF-C. We show that VEGF-C, secreted by breast cancer cells that have undergone an EMT, promotes paracrine-mediated increases in proliferation, migration, and invasion of epithelial breast cancer cells, via non-canonical activation of GLI-signaling. We further show that the aggressive phenotypes, including metastasis, imparted by EMT cells on adjacent epithelial cancer cells can be disrupted by either inhibiting VEGF-C in EMT cells or by knocking down NRP2, a receptor which interacts with VEGF-C, in neighboring epithelial cancer cells. Interrogation of TCGA and GEO public datasets supports the relevance of this pathway in human breast cancer, demonstrating that VEGF-C strongly correlates with activation of Hedgehog signaling and EMT in the human disease. Our study suggests that the VEGF-C/NRP2/GLI axis is a novel and conserved paracrine means by which EMT cells enhance metastasis, and provides potential targets for therapeutic intervention in this heterogeneous disease.	[Kong, Deguang; Zhou, Hengbo; Neelakantan, Deepika; Hughes, Connor J.; Hsu, Jessica Y.; Ford, Heide L.] Univ Colorado, Dept Pharmacol, Anschutz Med Campus, Aurora, CO 80045 USA; [Kong, Deguang] Wuhan Univ, Zhongnan Hosp, Dept Gen Surg, Wuhan, Hubei, Peoples R China; [Zhou, Hengbo; Ford, Heide L.] Univ Colorado, Program Canc Biol, Anschutz Med Campus, Aurora, CO 80045 USA; [Neelakantan, Deepika; Ford, Heide L.] Univ Colorado, Program Mol Biol, Anschutz Med Campus, Aurora, CO 80045 USA; [Hughes, Connor J.; Hsu, Jessica Y.; Ford, Heide L.] Univ Colorado, Program Pharmacol, Anschutz Med Campus, Aurora, CO 80045 USA; [Hughes, Connor J.; Ford, Heide L.] Univ Colorado, Med Scientist Training Program, Anschutz Med Campus, Aurora, CO 80045 USA; [Srinivasan, Ramakrishnan Rajaram; Lewis, Michael T.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Wuhan University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Baylor College of Medicine	Ford, HL (corresponding author), Univ Colorado, Dept Pharmacol, Anschutz Med Campus, Aurora, CO 80045 USA.; Ford, HL (corresponding author), Univ Colorado, Program Canc Biol, Anschutz Med Campus, Aurora, CO 80045 USA.; Ford, HL (corresponding author), Univ Colorado, Program Mol Biol, Anschutz Med Campus, Aurora, CO 80045 USA.; Ford, HL (corresponding author), Univ Colorado, Program Pharmacol, Anschutz Med Campus, Aurora, CO 80045 USA.; Ford, HL (corresponding author), Univ Colorado, Med Scientist Training Program, Anschutz Med Campus, Aurora, CO 80045 USA.	Heide.Ford@cuanschutz.edu		Hughes, Connor/0000-0001-6295-8167; Zhou, Hengbo/0000-0002-9948-7909; Ford, Heide/0000-0002-2860-9841	Animal Imaging SR of the University of Colorado Cancer Center [P30CA046934]; Dan L. Duncan Comprehensive Cancer Center (BCM) [P30CA125123]; Cancer Prevention and Research Initiative of Texas (CPRIT) (BCM) [RP170691];  [R01CA224867];  [F99CA234940]	Animal Imaging SR of the University of Colorado Cancer Center; Dan L. Duncan Comprehensive Cancer Center (BCM)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Initiative of Texas (CPRIT) (BCM); ; 	This work was supported by R01CA224867 to HLF and MTL, and F99CA234940 to HZ. We would like to thank the Functional Genomics Shared Resource (SR), the Cell Technologies SR, and the Animal Imaging SR of the University of Colorado Cancer Center (P30CA046934) for help with these studies. We would also like to acknowledge support from The Dan L. Duncan Comprehensive Cancer Center (BCM, P30CA125123) and the Cancer Prevention and Research Initiative of Texas (CPRIT) (BCM, RP170691).	Amakye D, 2013, NAT MED, V19, P1410, DOI 10.1038/nm.3389; Aparicio S, 2013, NEW ENGL J MED, V368, P842, DOI 10.1056/NEJMra1204892; Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021; Blevins MA, 2015, EXPERT OPIN THER TAR, V19, P213, DOI 10.1517/14728222.2014.978860; Borowsky AD, 2005, CLIN EXP METASTAS, V22, P47, DOI 10.1007/s10585-005-2908-5; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Burrell RA, 2013, NATURE, V501, P338, DOI 10.1038/nature12625; Calbo J, 2011, CANCER CELL, V19, P244, DOI 10.1016/j.ccr.2010.12.021; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Chen JC, 2013, INT J MOL SCI, V14, P88, DOI 10.3390/ijms14010088; Dias S, 2002, BLOOD, V99, P2179, DOI 10.1182/blood.V99.6.2179; Drasin DJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3037; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Goel HL, 2013, EMBO MOL MED, V5, P488, DOI 10.1002/emmm.201202078; Jimeno A, 2013, CLIN CANCER RES, V19, P2766, DOI 10.1158/1078-0432.CCR-12-3654; Joukov V, 1996, EMBO J, V15, P290; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kampen KR, 2018, CANCER RES, V78, P5940, DOI 10.1158/0008-5472.CAN-18-0250; Kong DG, 2016, ONCOTARGET, V7, P50755, DOI 10.18632/oncotarget.9394; Lin JM, 2005, CANCER RES, V65, P6901, DOI 10.1158/0008-5472.CAN-05-0408; Lin L, 2019, CANCERS, V11, DOI 10.3390/cancers11081156; Lindstrom LS, 2018, JNCI-J NATL CANCER I, V110, P726, DOI 10.1093/jnci/djx270; Liu D, 2014, CANCER RES, V74, P5597, DOI 10.1158/0008-5472.CAN-13-3598; Liu Q, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0339-1; Lund AW, 2012, CELL REP, V1, P191, DOI 10.1016/j.celrep.2012.01.005; Ma F, 2020, INT J CANCER, V146, P1359, DOI 10.1002/ijc.32536; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Marusyk A, 2014, NATURE, V514, P54, DOI 10.1038/nature13556; McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001; Micalizzi DS, 2010, CANCER RES, V70, P10371, DOI 10.1158/0008-5472.CAN-10-1354; Micalizzi DS, 2009, J CLIN INVEST, V119, P2678, DOI 10.1172/JCI37815; Neelakantan D, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15773; Pietrobono S, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00556; Pinskey JM, 2017, J BIOL CHEM, V292, P15192, DOI 10.1074/jbc.M117.783845; Po A, 2017, ONCOGENE, V36, P4641, DOI 10.1038/onc.2017.91; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Su JL, 2007, BRIT J CANCER, V96, P541, DOI 10.1038/sj.bjc.6603487; Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61; Towers CG, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10077; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608; Wang CA, 2015, EXP BIOL MED, V240, P718, DOI 10.1177/1535370215583802; Wang CA, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0462-2; Wang CA, 2012, J CLIN INVEST, V122, P1895, DOI 10.1172/JCI59858; Wang JW, 2018, CANCER LETT, V418, P176, DOI 10.1016/j.canlet.2018.01.040; Wei T., 2017, R PACKAGECORRPLOTVIS; Xu YL, 2010, J CELL BIOL, V188, P115, DOI 10.1083/jcb.200903137; Yang F, 2017, CARCINOGENESIS, V38, P900, DOI 10.1093/carcin/bgx071; Yang F, 2016, INT J BIOL SCI, V12, P1568, DOI 10.7150/ijbs.16874; Yeh YW, 2017, ONCOTARGET, V8, P5603, DOI 10.18632/oncotarget.13629; Zhang DP, 2010, CANCER RES, V70, P2495, DOI 10.1158/0008-5472.CAN-09-3488; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	54	24	27	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2021	40	5					964	979		10.1038/s41388-020-01539-x	http://dx.doi.org/10.1038/s41388-020-01539-x		DEC 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC5NB	33299122	Green Accepted			2022-12-17	WOS:000599028900001
J	Kaushik, G; Seshacharyulu, P; Rauth, S; Nallasamy, P; Rachagani, S; Nimmakayala, RK; Vengoji, R; Mallya, K; Chirravuri-Venkata, R; Singh, AB; Foster, JM; Ly, QP; Smith, LM; Lele, SM; Malafa, MP; Jain, M; Ponnusamy, MP; Batra, SK				Kaushik, Garima; Seshacharyulu, Parthasarathy; Rauth, Sanchita; Nallasamy, Palanisamy; Rachagani, Satyanarayana; Nimmakayala, Rama Krishna; Vengoji, Raghupathy; Mallya, Kavita; Chirravuri-Venkata, Ramakanth; Singh, Amar B.; Foster, Jason M.; Ly, Quan P.; Smith, Lynette M.; Lele, Subodh M.; Malafa, Mokenge P.; Jain, Maneesh; Ponnusamy, Moorthy P.; Batra, Surinder K.			Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis	ONCOGENE			English	Article							ERBB FAMILY BLOCKER; DRUG-RESISTANCE; POOR-PROGNOSIS; TUMOR-GROWTH; CELLS; AFATINIB; EGFR; DIFFERENTIATION; OVEREXPRESSION; ADENOCARCINOMA	Pancreatic cancer (PC) is difficult to defeat due to mechanism (s) driving metastasis and drug resistance. Cancer stemness is a major challenging phenomenon associated with PC metastasis and limiting therapy efficacy. In this study, we evaluated the pre-clinical and clinical significance of eradicating pancreatic cancer stem cells (PCSC) and its components using a pan-EGFR inhibitor afatinib in combination with gemcitabine. Afatinib in combination with gemcitabine significantly reduced Kras(G12D/+); Pdx-1 Cre (KC) (P < 0.01) and Kras(G12D/+); p53(R172H/+); Pdx-1 Cre (KPC) (P < 0.05) derived mouse tumoroids and KPC-derived murine syngeneic cell line growth compared to gemcitabine/afatinib alone treatment. The drug combination also reduced PC xenograft tumor burden (P < 0.05) and the incidence of metastasis by affecting key stemness markers, as confirmed by co-localization studies. Moreover, the drug combination significantly decreases the growth of various PC patient-derived organoids (P < 0.001). We found that SOX9 is significantly overexpressed in high-grade PC tumors (P < 0.05) and in chemotherapy-treated patients compared to chemo-naive patients (P < 0.05). These results were further validated using publicly available datasets. Moreover, afatinib alone or in combination with gemcitabine decreased stemness and tumorspheres by reducing phosphorylation of EGFR family proteins, ERK, FAK, and CSC markers. Mechanistically, afatinib treatment decreased CSC markers by downregulating SOX9 via FOXA2. Indeed, EGFR and FOXA2 depletion reduced SOX9 expression in PCSCs. Taken together, pan-EGFR inhibition by afatinib impedes PCSCs growth and metastasis via the EGFR/ERK/FOXA2/SOX9 axis. This novel mechanism of pan-EGFR inhibitor and its ability to eradicate CSC may serve as a tailor-made approach to enhance chemotherapeutic benefits in other cancer types.	[Kaushik, Garima; Seshacharyulu, Parthasarathy; Rauth, Sanchita; Nallasamy, Palanisamy; Rachagani, Satyanarayana; Nimmakayala, Rama Krishna; Vengoji, Raghupathy; Mallya, Kavita; Chirravuri-Venkata, Ramakanth; Singh, Amar B.; Jain, Maneesh; Ponnusamy, Moorthy P.; Batra, Surinder K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Foster, Jason M.; Ly, Quan P.] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Div Surg Oncol, Omaha, NE USA; [Smith, Lynette M.] UNMC, Dept Biostat, Omaha, NE USA; [Lele, Subodh M.; Batra, Surinder K.] UNMC, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [Malafa, Mokenge P.] H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Oncol, Tampa, FL USA; [Jain, Maneesh; Ponnusamy, Moorthy P.; Batra, Surinder K.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; H Lee Moffitt Cancer Center & Research Institute; University of Nebraska System; University of Nebraska Medical Center	Ponnusamy, MP; Batra, SK (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.; Batra, SK (corresponding author), UNMC, Dept Pathol & Microbiol, Omaha, NE 68198 USA.; Ponnusamy, MP; Batra, SK (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA.	mpalanim@unmc.edu; sbatra@unmc.edu	Seshacharyulu, Parthasarathy/AGL-7648-2022; Nallasamy, Palanisamy/AAH-7727-2021; Nimmakayala, Rama Krishna/CAG-5670-2022; Kaushik, Garima/AAO-7279-2021	Seshacharyulu, Parthasarathy/0000-0002-2348-3901; Nallasamy, Palanisamy/0000-0001-8962-2487; Nimmakayala, Rama Krishna/0000-0003-4637-4828; Kaushik, Garima/0000-0002-7631-4028	National Institutes of Health [P01 CA217798, R01 CA183459, R01 CA195586, R01 CA206444, R01 CA210637, R01 CA228524, R01 CA247471, U01 CA200466, U01 CA210240]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This research paper is supported, in parts, by grants from the National Institutes of Health (This work was supported, in parts, by the National Institutes of Health (P01 CA217798, R01 CA183459, R01 CA195586, R01 CA206444, R01 CA210637, R01 CA228524, R01 CA247471, U01 CA200466, and U01 CA210240).	Abhold EL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032459; Ardito CM, 2012, CANCER CELL, V22, P304, DOI 10.1016/j.ccr.2012.07.024; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Chen K, 2014, ONCOL REP, V32, P755, DOI 10.3892/or.2014.3245; Clark PA, 2012, NEOPLASIA, V14, P420, DOI 10.1596/neo.12432; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Dalerba P, 2007, CELL STEM CELL, V1, P241, DOI 10.1016/j.stem.2007.08.012; Ding Q, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-15; Engle JA, 2014, AM J HEALTH-SYST PH, V71, P1933, DOI 10.2146/ajhp130654; Fitzgerald Timothy L., 2015, Advances in Biological Regulation, V59, P65, DOI 10.1016/j.jbior.2015.06.003; Fitzgerald Timothy L., 2014, Advances in Biological Regulation, V56, P45, DOI 10.1016/j.jbior.2014.05.001; Furuya T, 2017, J THORAC DIS, V9, pE890, DOI 10.21037/jtd.2017.09.123; Garrido-Laguna I, 2015, NAT REV CLIN ONCOL, V12, P319, DOI 10.1038/nrclinonc.2015.53; Han Haiyong, 2013, Cancer Cell, V23, P424, DOI 10.1016/j.ccr.2013.03.008; Hennig R, 2005, CANCER RES, V65, P6011, DOI 10.1158/0008-5472.CAN-04-4090; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Herreros-Villanueva M, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.23; Hirsh V, 2015, BIODRUGS, V29, P167, DOI 10.1007/s40259-015-0130-9; Ioannou N, 2011, BRIT J CANCER, V105, P1554, DOI 10.1038/bjc.2011.396; Jiang H, 2015, MOL CANCER RES, V13, P1554, DOI 10.1158/1541-7786.MCR-15-0240; Karmakar S, 2017, ONCOTARGET, V8, P14806, DOI 10.18632/oncotarget.14775; Kelley RK, 2008, BIOL-TARGETS THER, V2, P83; Lavon N, 2006, STEM CELLS, V24, P1923, DOI 10.1634/stemcells.2005-0397; Li YW, 2013, CANCER LETT, V338, P94, DOI 10.1016/j.canlet.2012.03.018; Ling SZ, 2011, CANCER RES, V71, P3812, DOI 10.1158/0008-5472.CAN-10-3072; Lynn FC, 2007, P NATL ACAD SCI USA, V104, P10500, DOI 10.1073/pnas.0704054104; Macha MA, 2017, ONCOTARGET, V8, P20961, DOI 10.18632/oncotarget.15468; Majhi PD, 2013, J THORAC ONCOL, V8, P398, DOI 10.1097/JTO.0b013e3182829e06; Modjtahedi H, 2014, N-S ARCH PHARMACOL, V387, P505, DOI 10.1007/s00210-014-0967-3; Mukhopadhyay P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054455; Nimmakayala RK, 2018, GASTROENTEROLOGY, V155, P892, DOI 10.1053/j.gastro.2018.05.041; Nomura A, 2015, ONCOTARGET, V6, P8313, DOI 10.18632/oncotarget.3228; PASSARO A, 2019, ANN ONCOL         S2, V30, pii48, DOI DOI 10.1093/annonc/mdz063.013; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Roy S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013674; Sarkar FH, 2009, MINERVA CHIR, V64, P489; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Seshacharyulu P, 2015, ONCOTARGET, V6, P5164, DOI 10.18632/oncotarget.3286; Seymour Philip A, 2014, Rev Diabet Stud, V11, P51, DOI 10.1900/RDS.2014.11.51; Shroff S, 2014, HUM PATHOL, V45, P456, DOI 10.1016/j.humpath.2013.10.008; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Steelman LS, 2016, CURR PHARM DESIGN, V22, P2358, DOI 10.2174/1381612822666160304151011; Tanase CP, 2014, WORLD J GASTROENTERO, V20, P10790, DOI 10.3748/wjg.v20.i31.10790; Tebbutt N, 2013, NAT REV CANCER, V13, P663, DOI 10.1038/nrc3559; Torres MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080580; Ueda S, 2004, PANCREAS, V29, pE1, DOI 10.1097/00006676-200407000-00061; Van den Broeck A, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-354; Vaz AP, 2014, BRIT J CANCER, V111, P486, DOI 10.1038/bjc.2014.152; Vengoji R, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1264-2; Yang Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097578; Zhou G, 2012, APPL BIOCHEM BIOTECH, V167, P2257, DOI 10.1007/s12010-012-9752-2; Zhou XC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096718	53	24	24	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2021	40	4					848	862		10.1038/s41388-020-01564-w	http://dx.doi.org/10.1038/s41388-020-01564-w		DEC 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA4GO	33288882	Green Accepted			2022-12-17	WOS:000599015000002
J	Liu, YY; Wang, XP; Li, WS; Xu, YJ; Zhuo, YT; Li, MY; He, Y; Wang, XS; Guo, QL; Zhao, L; Qiang, L				Liu, Yunyao; Wang, Xiaoping; Li, Wenshu; Xu, Yujiao; Zhuo, Yating; Li, Mengyuan; He, Yuan; Wang, Xiaosheng; Guo, Qinglong; Zhao, Li; Qiang, Lei			Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1 alpha mediated XPC transcription	ONCOGENE			English	Article							NUCLEOTIDE EXCISION-REPAIR; DNA-DAMAGE RECOGNITION; CELL LUNG-CANCER; MULTIDRUG-RESISTANCE; INDUCIBLE FACTOR-1; TUMOR HYPOXIA; CHEMORESISTANCE; EXPRESSION; SENSITIVITY; PHOSPHORYLATION	Hypoxia is a key concern during the treatment of non-small cell lung cancer (NSCLC), and hypoxia-inducible factor 1 alpha (HIF-1 alpha) has been associated with increased tumor resistance to therapeutic modalities such as cisplatin. Compensatory activation of nucleotide excision repair (NER) pathway is the major mechanism that accounts for cisplatin resistance. In the present study, we suggest a novel strategy to improve the treatment of NSCLC and overcome the hypoxia-induced cisplatin resistance by cotreatment with Oroxylin A, one of the main bioactive flavonoids ofScutellariae radix. Based on the preliminary screening, we found that xeroderma pigmentosum group C (XPC), an important DNA damage recognition protein involved in NER, dramatically increased in hypoxic condition and contributed to hypoxia-induced cisplatin resistance. Further data suggested that Oroxylin A significantly reversed the hypoxia-induced cisplatin resistance through directly binding to HIF-1 alpha bHLH-PAS domain and blocking its binding to HRE3 transcription factor binding sites onXPCpromoter which is important to hypoxia-inducedXPCtranscription. Taken together, our findings not only demonstrate a crucial role of XPC dependent NER in hypoxia-induced cisplatin resistance, but also suggest a previously unrecognized tumor suppressive mechanism of Oroxylin A in NSCLC which through sensitization of cisplatin-mediated growth inhibition and apoptosis under hypoxia.	[Liu, Yunyao; Wang, Xiaoping; Li, Wenshu; Xu, Yujiao; Zhuo, Yating; He, Yuan; Guo, Qinglong; Qiang, Lei] China Pharmaceut Univ, Sch Basic Med & Clin Pharm, State Key Lab Nat Med, Nanjing, Peoples R China; [Li, Mengyuan; Wang, Xiaosheng] China Pharmaceut Univ, Sch Basic Med & Clin Pharm, Biomed Informat Res Lab, Nanjing, Peoples R China; [Zhao, Li] China Pharmaceut Univ, Sch Basic Med & Clin Pharm, Nanjing, Peoples R China	China Pharmaceutical University; China Pharmaceutical University; China Pharmaceutical University	Qiang, L (corresponding author), China Pharmaceut Univ, Sch Basic Med & Clin Pharm, State Key Lab Nat Med, Nanjing, Peoples R China.; Zhao, L (corresponding author), China Pharmaceut Univ, Sch Basic Med & Clin Pharm, Nanjing, Peoples R China.	zhaoli@cpu.edu.cn; lqiang@cpu.edu.cn	Li, Mengyuan/GZM-6335-2022; Qiang, Lei/B-2763-2012; Wang, Xiaosheng/AAN-6410-2020	Li, Mengyuan/0000-0001-6856-6463; Qiang, Lei/0000-0002-7164-3164; Wang, Xiaosheng/0000-0002-7199-7093	China Postdoctoral Science Foundation [2019M652035]; General Program of National Natural Science Foundation of China [81772911, 81974425, 81903648]; Natural Science Foundation of Jiangsu Province [BK20170744]; Six Talent Peaks Project in Jiangsu Province [SWYY-095]	China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); General Program of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Six Talent Peaks Project in Jiangsu Province	This work was supported by the China Postdoctoral Science Foundation Grant (2019M652035); the General Program of National Natural Science Foundation of China (81772911, 81974425, and 81903648); the Natural Science Foundation of Jiangsu Province (BK20170744); the Six Talent Peaks Project in Jiangsu Province (SWYY-095).	Akanji MA, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8547846; An HC, 2018, J MED CHEM, V61, P9266, DOI 10.1021/acs.jmedchem.8b00971; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brown LM, 2006, MOL PHARMACOL, V69, P411, DOI 10.1124/mol.105.015743; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cam H, 2010, MOL CELL, V40, P509, DOI 10.1016/j.molcel.2010.10.030; Chang A, 2011, LUNG CANCER, V71, P3, DOI 10.1016/j.lungcan.2010.08.022; Chun YS, 2002, J KOREAN MED SCI, V17, P581, DOI 10.3346/jkms.2002.17.5.581; Deben C, 2016, CRIT REV ONCOL HEMAT, V99, P63, DOI 10.1016/j.critrevonc.2015.11.019; Furuta T, 2002, CANCER RES, V62, P4899; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Gao HB, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00188; Ha J, 2012, BIOCHEM CELL BIOL, V90, P521, DOI [10.1139/O2012-005, 10.1139/o2012-005]; Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8; Hu LB, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00290; Jin J, 2018, BIOMED PHARMACOTHER, V97, P385, DOI 10.1016/j.biopha.2017.10.140; Jung YW, 2007, CHEM REV, V107, P1387, DOI 10.1021/cr068207j; Kaluz S, 2008, CLIN CHIM ACTA, V395, P6, DOI 10.1016/j.cca.2008.05.002; Kothari S, 2003, ONCOGENE, V22, P4734, DOI 10.1038/sj.onc.1206666; Kwon DY, 2015, J MED CHEM, V58, P7659, DOI 10.1021/acs.jmedchem.5b01220; Lai TC, 2011, ONCOL REP, V25, P1243, DOI 10.3892/or.2011.1184; Lee JY, 2016, EXP THER MED, V12, P151, DOI 10.3892/etm.2016.3320; Lee K, 2007, J MED CHEM, V50, P1675, DOI 10.1021/jm0610292; Li WJ, 2017, MOL CARCINOGEN, V56, P863, DOI 10.1002/mc.22540; Li ZH, 2019, J MED CHEM, V62, P5725, DOI 10.1021/acs.jmedchem.8b01596; Liu RY, 2011, ONCOGENE, V30, P4814, DOI 10.1038/onc.2011.189; Liu YB, 2012, CARCINOGENESIS, V33, P1187, DOI 10.1093/carcin/bgs142; Liu YB, 2018, CELL PHYSIOL BIOCHEM, V46, P1971, DOI 10.1159/000489418; Lu L, 2016, PHYTOTHER RES, V30, P1765, DOI 10.1002/ptr.5694; Martin LP, 2008, CLIN CANCER RES, V14, P1291, DOI 10.1158/1078-0432.CCR-07-2238; Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007; Mazumdar J, 2010, P NATL ACAD SCI USA, V107, P14182, DOI 10.1073/pnas.1001296107; Naik R, 2012, J MED CHEM, V55, P10564, DOI 10.1021/jm301419d; Nardinocchi L, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-1; Olcina MM, 2013, MOL CELL, V52, P758, DOI 10.1016/j.molcel.2013.10.019; Qiang L, 2016, AUTOPHAGY, V12, P357, DOI 10.1080/15548627.2015.1110667; Roberts AM, 2009, CANCER RES, V69, P9056, DOI 10.1158/0008-5472.CAN-09-1770; Selvakumaran M, 2003, CANCER RES, V63, P1311; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Shannon AM, 2003, CANCER TREAT REV, V29, P297, DOI 10.1016/S0305-7372(03)00003-3; Slyskova J, 2018, NUCLEIC ACIDS RES, V46, P9537, DOI 10.1093/nar/gky764; Song XR, 2006, CANCER CHEMOTH PHARM, V58, P776, DOI 10.1007/s00280-006-0224-7; Sowa T, 2017, CANCER MED-US, V6, P288, DOI 10.1002/cam4.991; Teng X, 2019, ONCOL REP, V41, P1875, DOI 10.3892/or.2019.6959; To KKW, 2006, EMBO J, V25, P4784, DOI 10.1038/sj.emboj.7601369; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; Wei M, 2019, J CELL PHYSIOL, V234, P17392, DOI 10.1002/jcp.28361; Wirthner R, 2008, CARCINOGENESIS, V29, P2306, DOI 10.1093/carcin/bgn231; Wohlkoenig C, 2011, CANCER LETT, V308, P134, DOI 10.1016/j.canlet.2011.03.014; Wood RD, 2000, COLD SPRING HARB SYM, V65, P173, DOI 10.1101/sqb.2000.65.173; Xie XQ, 2019, J CANCER, V10, P1039, DOI 10.7150/jca.25814; Yang HY, 2012, MOL CARCINOGEN, V51, P185, DOI 10.1002/mc.20789; Yang SL, 2016, J HUAZHONG U SCI-MED, V36, P321, DOI 10.1007/s11596-016-1586-7; Yohena T, 2009, J THORAC ONCOL, V4, P284, DOI 10.1097/JTO.0b013e31819852d5; Zhou J, 2006, CANCER LETT, V237, P10, DOI 10.1016/j.canlet.2005.05.028; Zhu BB, 2012, TOXICOL APPL PHARM, V259, P387, DOI 10.1016/j.taap.2012.01.019; Zhu LT, 2013, TOXICOL LETT, V219, P107, DOI 10.1016/j.toxlet.2013.01.019	58	24	24	5	30	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2020	39	45					6893	6905		10.1038/s41388-020-01474-x	http://dx.doi.org/10.1038/s41388-020-01474-x		SEP 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ON7IM	32978517				2022-12-17	WOS:000572714000001
J	Talotta, F; Casalino, L; Verde, P				Talotta, Francesco; Casalino, Laura; Verde, Pasquale			The nuclear oncoprotein Fra-1: a transcription factor knocking on therapeutic applications' door	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; P53 SIGNALING PATHWAY; CANCER CELLS; COLORECTAL-CANCER; GENE-EXPRESSION; TUMOR MICROENVIRONMENT; DRUG-ADDICTION; UP-REGULATION; ALPHA-V; BREAST	Among the FOS-related members of the AP-1 dimeric complex, the transcription factor Fra-1, encoded by FOSL1, is crucially involved in human tumor progression and metastasis, thus representing a promising therapeutic target. Here we review the state of the art and discuss the emerging topics and perspectives on FOSL1 and its gene product. First, we summarize the present knowledge on the FOSL1 transcriptional and epigenetic controls, driving Fra-1 accumulation in a variety of human solid tumors. We also present a model on the regulatory interactions between Fra-1, p53, and miRNAs. Then, we outline the multiple roles of Fra-1 posttranslational modifications and transactivation mechanisms of select Fra-1 target genes. In addition to summarizing the Fra-1-dependent gene networks controlling proliferation, survival, and epithelial-mesenchymal transitions (EMT) in multiple cancer cell types, we highlight the roles played by Fra-1 in nonneoplastic cell populations recruited to the tumor microenvironment, and in mouse models of tumorigenesis. Next, we review the prognostic power of the Fra-1-associated gene signatures, and envisage potential strategies aimed at Fra-1 therapeutic inhibition. Finally, we discuss several recent reports showing the emerging roles of Fra-1 in the mechanisms of both resistance and addiction to targeted therapies.	[Talotta, Francesco; Casalino, Laura; Verde, Pasquale] CNR, Inst Genet & Biophys Adriano Buzzati Traverso, Naples, Italy; [Talotta, Francesco] ReiThera Srl, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	Verde, P (corresponding author), CNR, Inst Genet & Biophys Adriano Buzzati Traverso, Naples, Italy.	pasquale.verde@igb.cnr.it	Casalino, Laura/C-1506-2015	Casalino, Laura/0000-0002-2557-0443	Regione Campania Project POR-SATIN	Regione Campania Project POR-SATIN	We wish to thank all the authors whose work was not cited here owing to page limitation. We thank the former members of the lab for fruitful discussions, along with Valerio Costa and Ingram Iaccarino for critical feedback on the paper. We also thank the Regione Campania Project POR-SATIN for financial support.	Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Andreolas C, 2008, INT J CANCER, V122, P1745, DOI 10.1002/ijc.23309; Baker EK, 2015, SCI REP-UK, V5, DOI 10.1038/srep10120; Bakiri L, 2015, CELL DEATH DIFFER, V22, P336, DOI 10.1038/cdd.2014.157; Behan FM, 2019, NATURE, V568, P511, DOI 10.1038/s41586-019-1103-9; Bejjani F, 2019, BBA-REV CANCER, V1872, P11, DOI 10.1016/j.bbcan.2019.04.003; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Belguise K, 2017, CANCER LETT, V385, P97, DOI 10.1016/j.canlet.2016.10.038; Blake DR, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aav7259; Blunsom NJ, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00063; Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018; Casalino L, 2003, MOL CELL BIOL, V23, P4401, DOI 10.1128/MCB.23.12.4401-4415.2003; Casalino L, 2007, EMBO J, V26, P1878, DOI 10.1038/sj.emboj.7601617; Chandran SS, 2019, IMMUNOL REV, V290, P127, DOI 10.1111/imr.12772; Cheng FF, 2016, CANCER LETT, V375, P274, DOI 10.1016/j.canlet.2016.03.010; Racca AC, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00544; Dardenne E, 2014, CELL REP, V7, P1900, DOI 10.1016/j.celrep.2014.05.010; Desmet CJ, 2013, P NATL ACAD SCI USA, V110, P5139, DOI 10.1073/pnas.1222085110; Dhillon AS, 2015, ONCOGENE, V34, P4421, DOI 10.1038/onc.2014.374; Diesch J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088950; Dikshit A, 2018, CANCER RES, V78, P6462, DOI 10.1158/0008-5472.CAN-18-1040; Ding XM, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003884; Dongre A, 2017, CANCER RES, V77, P3982, DOI 10.1158/0008-5472.CAN-16-3292; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Elangovan IM, 2018, AM J RESP CELL MOL, V58, P625, DOI 10.1165/rcmb.2017-0164OC; Esnault C, 2017, MOL CELL, V65, P1081, DOI 10.1016/j.molcel.2017.02.005; Evellin S, 2013, MOL CELL BIOL, V33, P1198, DOI 10.1128/MCB.01054-12; Fleming JD, 2013, GENOME RES, V23, P1195, DOI 10.1101/gr.148080.112; Franco HL, 2018, GENOME RES, V28, P159, DOI 10.1101/gr.226019.117; Gallenne T, 2017, ONCOTARGET, V8, P20572, DOI 10.18632/oncotarget.16244; Gerdes MJ, 2006, CANCER RES, V66, P7578, DOI 10.1158/0008-5472.CAN-06-1247; Grimm J, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0082-2; Hasenfuss SC, 2014, CELL METAB, V19, P84, DOI 10.1016/j.cmet.2013.11.018; He H, 2019, ONCOGENE, V38, P5725, DOI 10.1038/s41388-019-0824-4; He JY, 2015, INT J ONCOL, V47, P1725, DOI 10.3892/ijo.2015.3146; Hong A, 2018, CANCER DISCOV, V8, P74, DOI 10.1158/2159-8290.CD-17-0682; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Iaccarino I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071497; Ibrahim Sherif Abd El-Fattah, 2018, Oncotarget, V9, P34259, DOI 10.18632/oncotarget.26047; Ishay-Ronen D, 2019, CANCER CELL, V35, P17, DOI 10.1016/j.ccell.2018.12.002; Iskit S, 2015, ONCOTARGET, V6, P43146, DOI 10.18632/oncotarget.6454; Jiang XY, 2020, MOL BIOL REP, V47, P737, DOI 10.1007/s11033-019-05123-9; Jin Y, 2011, J BIOL CHEM, V286, P40104, DOI 10.1074/jbc.C111.296707; Kamide D, 2016, CANCER SCI, V107, P666, DOI 10.1111/cas.12914; Kong XJ, 2017, NATURE, V550, P270, DOI 10.1038/nature24037; Kroger C, 2019, MICROBIOL RESOUR ANN, V8, DOI 10.1128/MRA.01700-18; Kurimchak AM, 2019, MOL CANCER RES, V17, P1721, DOI 10.1158/1541-7786.MCR-18-1332; Lau EYT, 2016, CELL REP, V15, P1175, DOI 10.1016/j.celrep.2016.04.019; Lee MH, 2020, AM J TRANSL RES, V12, P409; Leveille N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7520; Li MM, 2012, MOL CELL, V46, P30, DOI 10.1016/j.molcel.2012.01.020; Liu H, 2015, CARCINOGENESIS, V36, P459, DOI 10.1093/carcin/bgv017; Liu WJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep41737; Liu XF, 2016, CELL REP, V14, P1169, DOI 10.1016/j.celrep.2015.12.104; Lockwood WW, 2012, P NATL ACAD SCI USA, V109, P19408, DOI 10.1073/pnas.1216363109; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Luo YP, 2010, ONCOGENE, V29, P662, DOI 10.1038/onc.2009.308; Luo YP, 2003, P NATL ACAD SCI USA, V100, P8850, DOI 10.1073/pnas.1033132100; Luther J, 2011, J CELL SCI, V124, P1465, DOI 10.1242/jcs.079855; Maurus K, 2017, ONCOGENE, V36, P5110, DOI 10.1038/onc.2017.135; Moquet-Torcy G, 2014, NUCLEIC ACIDS RES, V42, P11011, DOI 10.1093/nar/gku814; Natoli G, 2012, ANNU REV GENET, V46, P1, DOI 10.1146/annurev-genet-110711-155459; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; Nikulenkov F, 2012, CELL DEATH DIFFER, V19, P1992, DOI 10.1038/cdd.2012.89; Obenauf AC, 2015, NATURE, V520, P368, DOI 10.1038/nature14336; Qiao YC, 2015, ONCOTARGET, V6, P7804, DOI 10.18632/oncotarget.3158; Ramos-Nino ME, 2008, AM J RESP CELL MOL, V38, P209, DOI 10.1165/rcmb.2007-0206OC; Ramos-Nino ME, 2003, CANCER RES, V63, P3539; Rattanasinchai C, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.44; Roman M, 2019, CANCER RES, V79, P625, DOI 10.1158/0008-5472.CAN-18-1479; Sayan AE, 2012, ONCOGENE, V31, P1493, DOI 10.1038/onc.2011.336; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Shin S, 2007, CANCER RES, V67, P7572, DOI 10.1158/0008-5472.CAN-06-4652; Stinson S, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001538; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Sundqvist A, 2013, ONCOGENE, V32, P3606, DOI 10.1038/onc.2012.370; Tam WL, 2013, CANCER CELL, V24, P347, DOI 10.1016/j.ccr.2013.08.005; Tolza C, 2019, MOL CANCER RES, V17, P1999, DOI 10.1158/1541-7786.MCR-19-0036; Toyozumi T, 2017, ANN SURG ONCOL, V24, P3446, DOI 10.1245/s10434-016-5666-5; Tulchinsky E, 2019, BBA-REV CANCER, V1871, P29, DOI 10.1016/j.bbcan.2018.10.003; Tulchinsky E, 2014, ONCOTARGET, V5, P1; Vallejo A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14294; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Walia V, 2012, ONCOGENE, V31, P2237, DOI 10.1038/onc.2011.392; Walia V, 2009, CANCER RES, V69, P6624, DOI 10.1158/0008-5472.CAN-08-4101; Wang QS, 2010, CELL RES, V20, P701, DOI 10.1038/cr.2010.52; Wang TY, 2019, ONCOGENE, V38, P4932, DOI 10.1038/s41388-019-0763-0; Wu J, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0650-6; Wu JM, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.289; Wu JM, 2012, CARCINOGENESIS, V33, P519, DOI 10.1093/carcin/bgr304; Xiao SS, 2015, INT J ONCOL, V46, P1677, DOI 10.3892/ijo.2015.2873; Yang J, 2014, ONCOGENE, V33, P3014, DOI 10.1038/onc.2013.258; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Yang S, 2013, ONCOGENE, V32, P4294, DOI 10.1038/onc.2012.432; Zanconato F, 2018, NAT MED, V24, P1599, DOI 10.1038/s41591-018-0158-8; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhang K, 2017, ONCOGENE, V36, P5681, DOI 10.1038/onc.2017.177; Zhang L, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20160643; Zhang N, 2016, ONCOTARGETS THER, V9, P6597, DOI 10.2147/OTT.S114609; Zhang XL, 2016, ONCOTARGET, V7, P34371, DOI 10.18632/oncotarget.9110; Zhao CY, 2014, CANCER RES, V74, P3983, DOI 10.1158/0008-5472.CAN-13-3396; Zhong GW, 2016, ONCOL REP, V35, P447, DOI 10.3892/or.2015.4395; Zhou JH, 2017, NAT REV DRUG DISCOV, V16, P181, DOI 10.1038/nrd.2016.199; Zippo A, 2009, CELL, V138, P1122, DOI 10.1016/j.cell.2009.07.031	106	24	24	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	23					4491	4506		10.1038/s41388-020-1306-4	http://dx.doi.org/10.1038/s41388-020-1306-4		MAY 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LU5ZF	32385348				2022-12-17	WOS:000531151100001
J	Wenzel, J; Rose, K; Haghighi, EB; Lamprecht, C; Rauen, G; Freihen, V; Kesselring, R; Boerries, M; Hecht, A				Wenzel, Janna; Rose, Katja; Haghighi, Elham Bavafaye; Lamprecht, Constanze; Rauen, Gilles; Freihen, Vivien; Kesselring, Rebecca; Boerries, Melanie; Hecht, Andreas			Loss of the nuclear Wnt pathway effector TCF7L2 promotes migration and invasion of human colorectal cancer cells	ONCOGENE			English	Article							WNT/BETA-CATENIN PATHWAY; EPHB3 TUMOR-SUPPRESSOR; BETA-CATENIN; HUMAN COLON; COMPETITIVE DISPLACEMENT; ACTIVATION DOMAIN; FEEDBACK LOOP; HUMAN BREAST; STEM-CELLS; TRANSCRIPTION	The transcription factor TCF7L2 is indispensable for intestinal tissue homeostasis where it transmits mitogenic Wnt/beta-Catenin signals in stem and progenitor cells, from which intestinal tumors arise. Yet, TCF7L2 belongs to the most frequently mutated genes in colorectal cancer (CRC), and tumor-suppressive functions of TCF7L2 were proposed. This apparent paradox warrants to clarify the role of TCF7L2 in colorectal carcinogenesis. Here, we investigated TCF7L2 dependence/independence of CRC cells and the cellular and molecular consequences of TCF7L2 loss-of-function. By genome editing we achieved complete TCF7L2 inactivation in several CRC cell lines without loss of viability, showing that CRC cells have widely lost the strict requirement for TCF7L2. TCF7L2 deficiency impaired G1/S progression, reminiscent of the physiological role of TCF7L2. In addition, TCF7L2-negative cells exhibited morphological changes, enhanced migration, invasion, and collagen adhesion, albeit the severity of the phenotypic alterations manifested in a cell-line-specific fashion. To provide a molecular framework for the observed cellular changes, we performed global transcriptome profiling and identified gene-regulatory networks in which TCF7L2 positively regulates the proto-oncogene MYC, while repressing the cell cycle inhibitors CDKN2C/CDKN2D. Consistent with its function in curbing cell motility and invasion, TCF7L2 directly suppresses the pro-metastatic transcription factor RUNX2 and impinges on the expression of cell adhesion molecules. Altogether, we conclude that the proliferation-stimulating activity of TCF7L2 persists in CRC cells. In addition, TCF7L2 acts as invasion suppressor. Despite its negative impact on cell cycle progression, TCF7L2 loss-of-function may thereby increase malignancy, which could explain why TCF7L2 is mutated in a sizeable fraction of colorectal tumors.	[Wenzel, Janna; Rose, Katja; Freihen, Vivien; Hecht, Andreas] Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, Stefan Meier Str 17, D-79104 Freiburg, Germany; [Wenzel, Janna; Rauen, Gilles; Hecht, Andreas] Univ Freiburg, Fac Biol, Schanzlestr 1, D-79104 Freiburg, Germany; [Haghighi, Elham Bavafaye; Boerries, Melanie] Univ Freiburg, Inst Med Bioinformat & Syst Med, Med Ctr, Fac Med, Breisacherstr 153, D-79104 Freiburg, Germany; [Lamprecht, Constanze] Univ Freiburg, Inst Phys, Hermann Herder Str 3a, D-79104 Freiburg, Germany; [Lamprecht, Constanze; Rauen, Gilles; Hecht, Andreas] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, Schanzlestr 18, D-79104 Freiburg, Germany; [Lamprecht, Constanze] Univ Freiburg, Freiburg Ctr Interact Mat & Bioinspired Technol F, Georges Kohler Allee 105, D-79110 Freiburg, Germany; [Kesselring, Rebecca] Univ Freiburg, Dept Gen & Visceral Surg, Ctr Surg, Med Ctr,Fac Med, Hugstetter Str 55, D-79106 Freiburg, Germany; [Boerries, Melanie] German Canc Consortium DKTK, Hugstetter Str 55, D-79106 Freiburg, Germany; [Boerries, Melanie] German Canc Res Ctr, Neuenheimer Feld 280, D-69120 Heidelberg, Germany	University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Hecht, A (corresponding author), Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, Stefan Meier Str 17, D-79104 Freiburg, Germany.; Hecht, A (corresponding author), Univ Freiburg, Fac Biol, Schanzlestr 1, D-79104 Freiburg, Germany.; Hecht, A (corresponding author), Univ Freiburg, BIOSS Ctr Biol Signalling Studies, Schanzlestr 18, D-79104 Freiburg, Germany.	andreas.hecht@mol-med.uni-freiburg.de	Boerries, Melanie/AAM-2602-2021	Lamprecht, Constanze/0000-0002-6005-6239	Deutsche Forschungsgemeinschaft (DFG) [DFG HE2004/11-1, CRC-850, KE2164/2-1, 322977937/GRK2344]; German Federal Ministry of Education and Research (BMBF) [FKZ 01ZX1708F]; Carl-Zeiss-Foundation [Az. 0563-2.8/685/4]; Deutsche Forschungsgemeinschaft Research Training Group GRK2344 "MeInBio-BioInMe"; Projekt DEAL	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Carl-Zeiss-Foundation; Deutsche Forschungsgemeinschaft Research Training Group GRK2344 "MeInBio-BioInMe"(German Research Foundation (DFG)); Projekt DEAL	The authors express their gratitude to K. Geiger, D. Herchenbach, J. Bodinek, and A. Schmitt for exquisite technical assistance, and to the team of the Genomics and Proteomics Core Facility, German Cancer Research Center/DKFZ, Heidelberg, Germany, for sequencing services. The studies reported herein were financially supported by the Deutsche Forschungsgemeinschaft (DFG) (DFG HE2004/11-1 to AH; CRC-850 subprojects B5 to AH, C11 to RK [KE2164/2-1] and Z1 to MB; 322977937/GRK2344 subprojects B02 to MB and B03 to AH), and by the German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept CoNfirm (FKZ 01ZX1708F to MB). CL received a fellowship from the Carl-Zeiss-Foundation (Postdoc Program 2017, Az. 0563-2.8/685/4). JW was additionally supported by the Deutsche Forschungsgemeinschaft Research Training Group GRK2344 "MeInBio-BioInMe". Open access funding provided by Projekt DEAL.	Albers J, 2015, J CLIN INVEST, V125, P1603, DOI 10.1172/JCI79743; Anders Simon, 2010, Genome Biol, V11, pR106, DOI 10.1186/gb-2010-11-10-r106; Angus-Hill ML, 2011, P NATL ACAD SCI USA, V108, P4914, DOI 10.1073/pnas.1102300108; Arrigoni L, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1495; Atcha FA, 2003, J BIOL CHEM, V278, P16169, DOI 10.1074/jbc.M213218200; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Berg KCG, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0691-y; Beumer J, 2016, DEVELOPMENT, V143, P3639, DOI 10.1242/dev.133132; Beyes S, 2019, ONCOGENE, V38, P6647, DOI 10.1038/s41388-019-0905-4; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Bormann F, 2018, CELL REP, V23, P3407, DOI 10.1016/j.celrep.2018.05.045; Cadigan KM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007906; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chai J, 2018, AM J CANCER RES, V8, P538; Clevers H, 2013, CELL, V154, P274, DOI 10.1016/j.cell.2013.07.004; Dang DT, 2003, ONCOGENE, V22, P3424, DOI 10.1038/sj.onc.1206413; de Lau W, 2007, FRONT BIOSCI-LANDMRK, V12, P471, DOI 10.2741/2076; de Sousa e Melo F, 2011, CELL STEM CELL, V9, P476, DOI 10.1016/j.stem.2011.10.008; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Farley FW, 2000, GENESIS, V28, P106, DOI 10.1002/1526-968X(200011/12)28:3/4<106::AID-GENE30>3.0.CO;2-T; Fisher RA, 1922, J R STAT SOC, V85, P87, DOI 10.2307/2340521; Fox J., 2019, R COMPANION APPL REG; Freihen V, 2020, INT J CANCER, V146, P2229, DOI 10.1002/ijc.32644; Frietze S, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-9-r52; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Geoghegan G, 2019, MOL METAB, V24, P44, DOI 10.1016/j.molmet.2019.03.003; Giakountis A, 2016, CELL REP, V15, P2588, DOI 10.1016/j.celrep.2016.05.038; Guo ZJ, 2016, ONCOTARGET, V7, P20999, DOI 10.18632/oncotarget.8236; Hecht A, 2003, J BIOL CHEM, V278, P3776, DOI 10.1074/jbc.M210081200; Holmberg J, 2006, CELL, V125, P1151, DOI 10.1016/j.cell.2006.04.030; Hoverter NP, 2014, NUCLEIC ACIDS RES, V42, P13615, DOI 10.1093/nar/gku1186; Hrckulak D, 2018, GENES-BASEL, V9, DOI 10.3390/genes9090439; Hrckulak D, 2016, CANCERS, V8, DOI 10.3390/cancers8070070; Jagle S, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007109; Jagle S, 2014, P NATL ACAD SCI USA, V111, P4886, DOI 10.1073/pnas.1314523111; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kadem LF, 2016, ADV MATER, V28, P1799, DOI 10.1002/adma.201504394; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Koshizuka K, 2017, CANCER SCI, V108, P1681, DOI 10.1111/cas.13298; Kranz A, 2010, GENESIS, V48, P512, DOI 10.1002/dvg.20641; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Li XQ, 2015, CANCER RES, V75, P3302, DOI 10.1158/0008-5472.CAN-15-0240; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Lv HQ, 2016, ONCOL RES, V23, P283, DOI 10.3727/096504016X14562725373833; Mokry M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015092; Mouradov D, 2014, CANCER RES, V74, P3238, DOI 10.1158/0008-5472.CAN-14-0013; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Neri P, 2011, BLOOD, V117, P6202, DOI 10.1182/blood-2010-06-292243; Ramovs V, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1146-8; Rodilla V, 2009, P NATL ACAD SCI USA, V106, P6315, DOI 10.1073/pnas.0813221106; Ronsch K, 2015, MOL ONCOL, V9, P335, DOI 10.1016/j.molonc.2014.08.016; Ronsch K, 2011, EPIGENETICS-US, V6, P610, DOI 10.4161/epi.6.5.15300; Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026; Sabates-Beliver J, 2007, MOL CANCER RES, V5, P1263, DOI 10.1158/1541-7786.MCR-07-0267; Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Schnappauf O, 2016, BBA-GENE REGUL MECH, V1859, P1353, DOI 10.1016/j.bbagrm.2016.08.002; Schuijers J, 2015, CELL STEM CELL, V16, P158, DOI 10.1016/j.stem.2014.12.006; Seebauer CT, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1242543; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937; Tang W, 2014, BRIT J CANCER, V110, P450, DOI 10.1038/bjc.2013.724; Tang W, 2008, P NATL ACAD SCI USA, V105, P9697, DOI 10.1073/pnas.0804709105; Tuupanen S, 2009, NAT GENET, V41, P885, DOI 10.1038/ng.406; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; van der Flier LG, 2009, CELL, V136, P903, DOI 10.1016/j.cell.2009.01.031; van Es JH, 2012, MOL CELL BIOL, V32, P1918, DOI 10.1128/MCB.06288-11; Varnat F, 2010, EMBO MOL MED, V2, P440, DOI 10.1002/emmm.201000098; Wen DC, 2017, BIOMED PHARMACOTHER, V95, P1314, DOI 10.1016/j.biopha.2017.09.044; Wickham H, 2009, GGPLOT2, DOI DOI 10.1007/978-0-387-98141-3; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Xiang JF, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0367-6; Yochum GS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018966; Yochum GS, 2008, MOL CELL BIOL, V28, P7368, DOI 10.1128/MCB.00744-08; Zhang Y, 2012, J BIOL CHEM, V287, P32494, DOI 10.1074/jbc.M112.368282	79	24	24	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	19					3893	3909		10.1038/s41388-020-1259-7	http://dx.doi.org/10.1038/s41388-020-1259-7		MAR 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LK4OF	32203164	Green Published, hybrid			2022-12-17	WOS:000520614000003
J	Misek, SA; Appleton, KM; Dexheimer, TS; Lisabeth, EM; Lo, RS; Larsen, SD; Gallo, KA; Neubig, RR				Misek, S. A.; Appleton, K. M.; Dexheimer, T. S.; Lisabeth, E. M.; Lo, R. S.; Larsen, S. D.; Gallo, K. A.; Neubig, R. R.			Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells	ONCOGENE			English	Article							SERUM RESPONSE FACTOR; GROWTH-FACTOR; TRANSCRIPTIONAL PATHWAY; ACQUIRED-RESISTANCE; DRIVES RESISTANCE; RAF INHIBITION; COILED-COIL; ACTIN; GTPASES; KINASE	Over half of cutaneous melanoma tumors have BRAF(V600E/K) mutations. Acquired resistance to BRAF inhibitors (BRAFi) remains a major hurdle in attaining durable therapeutic responses. In this study we demonstrate that 50-60% of melanoma cell lines with vemurafenib resistance acquired in vitro show activation of RhoA family GTPases. In BRAFi-resistant melanoma cell lines and tumors, activation of RhoA is correlated with decreased expression of melanocyte lineage genes. Using a machine learning approach, we built gene expression-based models to predict drug sensitivity for 265 common anticancer compounds. We then projected these signatures onto the collection of TCGA cutaneous melanoma and found that poorly differentiated tumors were predicted to have increased sensitivity to multiple Rho kinase (ROCK) inhibitors. Two transcriptional effectors downstream of Rho, MRTF and YAP1, are activated in the Rho(High) BRAFi-resistant cell lines, and resistant cells are more sensitive to inhibition of these transcriptional mechanisms. Taken together, these results support the concept of targeting Rho-regulated gene transcription pathways as a promising therapeutic approach to restore sensitivity to BRAFi-resistant tumors or as a combination therapy to prevent the onset of drug resistance.	[Misek, S. A.; Gallo, K. A.] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; [Appleton, K. M.; Dexheimer, T. S.; Lisabeth, E. M.; Neubig, R. R.] Michigan State Univ, Dept Pharmacol & Toxicol, E Lansing, MI 48824 USA; [Lo, R. S.] Univ Calif Los Angeles, Dept Med, Div Dermatol, Los Angeles, CA 90095 USA; [Lo, R. S.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Lo, R. S.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; [Lo, R. S.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Larsen, S. D.] Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA; [Larsen, S. D.] Univ Michigan, Vahlteich Med Chem Core, Ann Arbor, MI 48109 USA; [Neubig, R. R.] Michigan State Univ, Coll Human Med, Dept Med, Div Dermatol, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Michigan State University; Michigan State University College of Human Medicine	Neubig, RR (corresponding author), Michigan State Univ, Dept Pharmacol & Toxicol, E Lansing, MI 48824 USA.; Neubig, RR (corresponding author), Michigan State Univ, Coll Human Med, Dept Med, Div Dermatol, E Lansing, MI 48824 USA.	rneubig@msu.edu		Neubig, Richard/0000-0003-0501-0008	NIH [R01 AR066049, F31 CA232555]; MSU Gran Fondo Skin Cancer Research Fund; MSUFCU Aitch Foundation Fellowship	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MSU Gran Fondo Skin Cancer Research Fund; MSUFCU Aitch Foundation Fellowship	This work was supported by NIH R01 AR066049 (SDL), the MSU Gran Fondo Skin Cancer Research Fund (RRN), NIH F31 CA232555 (SAM), MSUFCU Aitch Foundation Fellowship (SAM).	Abel EV, 2013, J CLIN INVEST, V123, P2155, DOI 10.1172/JCI65780; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bell JL, 2013, BIOORG MED CHEM LETT, V23, P3826, DOI 10.1016/j.bmcl.2013.04.080; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Esnault C, 2014, GENE DEV, V28, P943, DOI 10.1101/gad.239327.114; Fallahi-Sichani M, 2017, MOL SYST BIOL, V13, DOI 10.15252/msb.20166796; Fisher ML, 2017, ONCOTARGET, V8, P110257, DOI 10.18632/oncotarget.22628; Foster CT, 2017, GENE DEV, V31, P2361, DOI 10.1101/gad.304501.117; Fujisawa K, 1996, J BIOL CHEM, V271, P23022, DOI 10.1074/jbc.271.38.23022; Haak Andrew J., 2016, MOL CANCER THER, V16, P193; Hodge RG, 2016, NAT REV MOL CELL BIO, V17, P496, DOI 10.1038/nrm.2016.67; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hong A, 2018, CANCER DISCOV, V8, P74, DOI 10.1158/2159-8290.CD-17-0682; Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061; Hutchings KM, 2017, BIOORG MED CHEM LETT, V27, P1744, DOI 10.1016/j.bmcl.2017.02.070; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Johnson DB, 2015, EUR J CANCER, V51, P2792, DOI 10.1016/j.ejca.2015.08.022; Kim MH, 2016, EMBO J, V35, P462, DOI 10.15252/embj.201592081; Klein RM, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-114; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Lamar JM, 2019, J BIOL CHEM, V294, P2302, DOI 10.1074/jbc.RA118.004364; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Licciulli S, 2011, AM J PATHOL, V178, P2397, DOI 10.1016/j.ajpath.2011.01.019; Licciulli S, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-5; Lin LP, 2015, NAT GENET, V47, P250, DOI 10.1038/ng.3218; Lisabeth EM, 2018, IDENTIFICATION PIRIN, DOI DOI 10.1101/458554V1; Liu XF, 2016, CELL REP, V14, P1169, DOI 10.1016/j.celrep.2015.12.104; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Medjkane S, 2009, NAT CELL BIOL, V11, P257, DOI 10.1038/ncb1833; Miyazaki I, 2010, NAT CHEM BIOL, V6, P667, DOI [10.1038/NCHEMBIO.423, 10.1038/nchembio.423]; Moriceau G, 2015, CANCER CELL, V27, P240, DOI 10.1016/j.ccell.2014.11.018; Mouilleron S, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001750; Mouilleron S, 2008, EMBO J, V27, P3198, DOI 10.1038/emboj.2008.235; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Nishimura EK, 2010, CELL STEM CELL, V6, P130, DOI 10.1016/j.stem.2009.12.010; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Pan M, 2016, NAT CELL BIOL, V18, P1090, DOI 10.1038/ncb3410; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Pich C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148095; Posern G, 2006, TRENDS CELL BIOL, V16, P588, DOI 10.1016/j.tcb.2006.09.008; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Ramsdale R, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab1111; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026; Routhier A, 2010, ONCOL REP, V23, P861, DOI 10.3892/or_00000708; Ruth MC, 2006, J INVEST DERMATOL, V126, P862, DOI 10.1038/sj.jid.5700211; Saei A, 2018, J EXP MED, V215, P1913, DOI 10.1084/jem.20171960; Seo J, 2018, BMB REP, V51, P151, DOI 10.5483/BMBRep.2018.51.3.012; Shaffer SM, 2017, NATURE, V546, P431, DOI 10.1038/nature22794; Shakhova O, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004877; Shen CH, 2016, NAT MED, V22, P1056, DOI 10.1038/nm.4155; Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642; Shi HB, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1727; Si Y, 2017, CANCER RES, V77, P4868, DOI 10.1158/0008-5472.CAN-17-0391; Sit ST, 2011, J CELL SCI, V124, P679, DOI 10.1242/jcs.064964; Song CY, 2017, CANCER DISCOV, V7, P1248, DOI 10.1158/2159-8290.CD-17-0401; Spiering D, 2011, CELL ADHES MIGR, V5, P170, DOI 10.4161/cam.5.2.14403; Su YP, 2017, P NATL ACAD SCI USA, V114, P13679, DOI 10.1073/pnas.1712064115; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Taglietti V, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.163956; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Tsoi J, 2018, CANCER CELL, V33, P890, DOI 10.1016/j.ccell.2018.03.017; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; van Dijk D, 2018, CELL, V174, P716, DOI 10.1016/j.cell.2018.05.061; Vega FM, 2011, J CELL BIOL, V193, P655, DOI 10.1083/jcb.201011038; Whittaker SR, 2013, CANCER DISCOV, V3, P350, DOI 10.1158/2159-8290.CD-12-0470; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Yang G, 2008, MOL CELL, V32, P554, DOI 10.1016/j.molcel.2008.11.002; Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111; Ye SA, 2018, CANCER RES, V78, P2705, DOI 10.1158/0008-5472.CAN-17-4052; Yin LM, 2007, MOL CANCER THER, V6, P1517, DOI 10.1158/1535-7163.MCT-06-0689; Yui OM, 2018, ONCOGENE, V37, P5492, DOI 10.1038/s41388-018-0301-5; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zuckerbraun BS, 2003, CIRCULATION, V108, P876, DOI 10.1161/01.CIR.0000081947.00070.07	78	24	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1466	1483		10.1038/s41388-019-1074-1	http://dx.doi.org/10.1038/s41388-019-1074-1			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31659259	Green Accepted			2022-12-17	WOS:000513289600006
J	Wang, XW; Wang, YD; Li, L; Xue, XT; Xie, H; Shi, HX; Hu, Y				Wang, Xingwen; Wang, Yudong; Li, Li; Xue, Xuting; Xie, Hui; Shi, Huaxing; Hu, Ying			A lncRNA coordinates with Ezh2 to inhibit HIF-1 alpha transcription and suppress cancer cell adaption to hypoxia	ONCOGENE			English	Article							REPRESSIVE COMPLEX 2; LONG NONCODING RNAS; GROUP PROTEIN EZH2; INDUCIBLE FACTORS; DRUG-RESISTANCE; PROLIFERATION; PROGRESSION; EXPRESSION; PHOSPHORYLATION; INACTIVATION	Hypoxia is a salient feature of the tumor microenvironment. HIF-1 alpha is a master regulator of hypoxic adaption. The polycomb repressor complex 2 (PRC2) molecule Ezh2 is known to play roles in essential cellular processes of cell fate decisions. However, how PRC2-mediated epigenetic dynamic changes take part in hypoxic adaption is not completely understood. Recently, we identified a long non-coding RNA (lncRNA) named HITT (HIF-1 alpha inhibitor at translation levels) that plays roles in modulating hypoxia-mediated angiogenesis and tumor growth in vivo. In this study, we reveal an important activity of HITT in evading hypoxia-induced apoptosis by coordinating with PRC2 activity to regulate HIF-1 alpha transcription. Genetic or chemical inhibition of PRC2 significantly elevates HIF-1 alpha mRNA levels. The occupancy of Ezh2 and its substrate H3K27me3 on the HIF-1 alpha promoter is detected under normoxia, and is reduced by hypoxia. Restoring hypoxia-inhibited HITT expression rescues the association between Ezh2/H3K27me3 and the HIF-1 alpha promoter, which also simultaneously abrogates hypoxia-induced HIF-1 alpha mRNA transcription. Further mechanistic studies revealed that HITT inhibits HIF-1 alpha transcription by guiding Ezh2 through the formation of an RNA-DNA triplex with the HIF-1 alpha promoter. Importantly, HITT/Ezh2-regulated HIF-1 alpha transcription leads to alerted HIF-1 alpha protein output and elicits a significant effect to evade hypoxia-induced apoptosis. Importantly, a close association between HIF-1 alpha mRNA and HITT was further verified in human colon cancer tissues in vivo. Collectively, these findings suggest a model for the epigenetic regulation of hypoxia-induced HIF-1 alpha transcription modulated by lncRNA HITT, which provides important insights into how tumor cells sense and adapt to hypoxic stress.	[Wang, Xingwen; Wang, Yudong; Xue, Xuting; Hu, Ying] Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150001, Heilongjiang, Peoples R China; [Li, Li] Harbin Med Univ, Affiliated Tumor Hosp, Harbin 150001, Heilongjiang, Peoples R China; [Xie, Hui] Harbin Inst Technol, State Key Lab Robot & Syst, 2 Yikuang, Harbin 150001, Peoples R China; [Shi, Huaxing] Harbin Inst Technol, Sch Comp Sci & Technol, 2 Yikuang, Harbin 150001, Peoples R China; [Hu, Ying] Harbin Inst Technol, Shenzhen Grad Sch, Shenzhen 518055, Peoples R China	Harbin Institute of Technology; Harbin Medical University; Harbin Institute of Technology; Harbin Institute of Technology; Harbin Institute of Technology; University Town of Shenzhen	Hu, Y (corresponding author), Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150001, Heilongjiang, Peoples R China.; Hu, Y (corresponding author), Harbin Inst Technol, Shenzhen Grad Sch, Shenzhen 518055, Peoples R China.	huying@hit.edu.cn	xuting, xue/ABD-5584-2020; Xie, Hui/J-6999-2012; Hu, Ying/ABG-2935-2021	xuting, xue/0000-0002-0654-3263; Xie, Hui/0000-0003-4299-2776; Hu, Ying/0000-0003-2469-5604; Wang, Xingwen/0000-0001-7416-142X	National Nature Science Foundation of China [31301131, 31741084, 31871389]; Basic Science Fundation of Science and technology innovation Commission in Shenzhen [JCYJ20170811154452255]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Basic Science Fundation of Science and technology innovation Commission in Shenzhen	This work was funded by the National Nature Science Foundation of China (No. 31301131, 31741084 and 31871389) and Basic Science Fundation of Science and technology innovation Commission in Shenzhen (No. JCYJ20170811154452255).	Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Battistelli C, 2017, ONCOGENE, V36, P942, DOI 10.1038/onc.2016.260; BelAiba RS, 2007, MOL BIOL CELL, V18, P4691, DOI 10.1091/mbc.E07-04-0391; Buske FA, 2012, GENOME RES, V22, P1372, DOI 10.1101/gr.130237.111; Cai BZ, 2020, CELL DEATH DIFFER, V27, P2158, DOI 10.1038/s41418-020-0492-5; Campbell S, 2013, CELL CYCLE, V12, P2675, DOI 10.4161/cc.25795; Chen S, 2016, CANCER LETT, V383, P73, DOI 10.1016/j.canlet.2016.09.027; Cheng YH, 2013, MOL CELL BIOL, V33, P3365, DOI 10.1128/MCB.00438-13; Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533; Comet I, 2016, NAT REV CANCER, V16, P803, DOI 10.1038/nrc.2016.83; Flavahan WA, 2017, SCIENCE, V357, DOI 10.1126/science.aal2380; Grote P, 2013, DEV CELL, V24, P206, DOI 10.1016/j.devcel.2012.12.012; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Guttman M, 2012, NATURE, V482, P339, DOI 10.1038/nature10887; Holoch D, 2017, TRENDS BIOCHEM SCI, V42, P531, DOI 10.1016/j.tibs.2017.04.003; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192; Kikuchi J, 2015, J CLIN INVEST, V125, P4375, DOI 10.1172/JCI80325; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Kinnaird A, 2016, NAT REV CANCER, V16, P694, DOI 10.1038/nrc.2016.82; Li ZW, 2017, CELL DEATH DIFFER, V24, P59, DOI 10.1038/cdd.2016.95; Mahara S, 2016, P NATL ACAD SCI USA, V113, pE3735, DOI 10.1073/pnas.1602079113; Mahmoud F, 2016, CANCER BIOL THER, V17, P579, DOI 10.1080/15384047.2016.1167291; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Mondal T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8743; Ntziachristos P, 2012, NAT MED, V18, P298, DOI 10.1038/nm.2651; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Pang B, 2016, ONCOTARGET, V7, P45134, DOI 10.18632/oncotarget.9761; Perez-Perri JI, 2011, INT J MOL SCI, V12, P4705, DOI 10.3390/ijms12074705; Piunti A, 2016, SCIENCE, V352, DOI 10.1126/science.aad9780; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Pruszko M, 2017, EMBO REP, V18, P1331, DOI 10.15252/embr.201643370; Rohwer N, 2011, DRUG RESIST UPDATE, V14, P191, DOI 10.1016/j.drup.2011.03.001; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Sperandio S, 2009, MOL CARCINOGEN, V48, P38, DOI 10.1002/mc.20454; Su I, 2005, CELL, V121, P425, DOI 10.1016/j.cell.2005.02.029; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Weikert S, 2005, INT J MOL MED, V16, P349; Wen Y, 2019, ONCOGENE, V38, P1845, DOI 10.1038/s41388-018-0552-1; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Zhang YY, 2016, NAT STRUCT MOL BIOL, V23, P522, DOI 10.1038/nsmb.3211; Zhao J, 2008, SCIENCE, V322, P750, DOI 10.1126/science.1163045	49	24	25	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1860	1874		10.1038/s41388-019-1123-9	http://dx.doi.org/10.1038/s41388-019-1123-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31784651				2022-12-17	WOS:000516579800003
J	Zhao, J; Hou, YR; Yin, C; Hu, J; Gao, T; Huang, XJ; Zhang, XH; Xing, JL; An, JZ; Wan, SG; Li, JB				Zhao, Jing; Hou, Yiran; Yin, Chun; Hu, Jing; Gao, Tian; Huang, Xiaojun; Zhang, Xiaohong; Xing, Jinliang; An, Jiaze; Wan, Shaogui; Li, Jibin			Upregulation of histamine receptor H1 promotes tumor progression and contributes to poor prognosis in hepatocellular carcinoma	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; H-1 RECEPTOR; MESENCHYMAL TRANSITION; SIGNALING PATHWAY; ACTIVATION; ALLERGIES; CANCER; RISK; IDENTIFICATION; PROLIFERATION	H1 histamine receptor (H1HR) belongs to the family of rhodopsin-like G-protein-coupled receptors. Recent studies have shown that H1HR expression is increased in several types of cancer. However, its functional roles in tumor progression remain largely unknown, especially in hepatocellular carcinoma (HCC). We found that H1HR is frequently unregulated in HCC, which is significantly associated with both recurrence-free survival and overall survival in HCC patients. Functional experiments revealed that H1HR promoted both the growth and metastasis of HCC cells by inducing cell cycle progression, formation of lamellipodia, production of matrix metalloproteinase 2, and suppression of cell apoptosis. Activation of cyclic adenosine monophosphate-dependent protein kinase A was found to be involved in H1HR-mediated HCC cell growth and metastasis. In addition, we found that overexpression of H1HR was mainly due to the downregulation of miR-940 in HCC cells. Moreover, the H1HR inhibitor terfenadine significantly suppressed tumor growth and metastasis in an HCC xenograft nude mice model. Our findings demonstrate that H1HR plays a critical role in the growth and metastasis of HCC cells, which provides experimental evidence supporting H1HR as a potential drug target for the treatment of HCC.	[Zhao, Jing; Wan, Shaogui] Gannan Med Univ, Affiliated Hosp 1, Ctr Mol Pathol, Ganzhou 341000, Jiangxi, Peoples R China; [Zhao, Jing; Yin, Chun; Hu, Jing; Huang, Xiaojun; Xing, Jinliang; Li, Jibin] Fourth Mil Med Univ, State Key Lab Canc Biol, Xian 710032, Peoples R China; [Zhao, Jing; Yin, Chun; Hu, Jing; Huang, Xiaojun; Xing, Jinliang; Li, Jibin] Fourth Mil Med Univ, Expt Teaching Ctr Basic Med, Xian 710032, Peoples R China; [Hou, Yiran] Yanan Univ, Med Coll, Yanan 716000, Shaanxi, Peoples R China; [Gao, Tian; Zhang, Xiaohong] Fourth Mil Med Univ, Xijing Hosp, Dept Gynecol & Obstet, Xian 710032, Peoples R China; [An, Jiaze] Fourth Mil Med Univ, Xijing Hosp, Dept Hepatobiliary Surg, Xian 710032, Peoples R China	Gannan Medical University; Air Force Military Medical University; Air Force Military Medical University; Yanan University; Air Force Military Medical University; Air Force Military Medical University	Wan, SG (corresponding author), Gannan Med Univ, Affiliated Hosp 1, Ctr Mol Pathol, Ganzhou 341000, Jiangxi, Peoples R China.; Li, JB (corresponding author), Fourth Mil Med Univ, State Key Lab Canc Biol, Xian 710032, Peoples R China.; Li, JB (corresponding author), Fourth Mil Med Univ, Expt Teaching Ctr Basic Med, Xian 710032, Peoples R China.	wansg@gmu.edu.cn; lijibin2006@163.com		, Chun Yin/0000-0002-7299-1929	State Key Laboratory of Cancer Biology Project [CBSKL2017Z01]; National Natural Science Foundation of China [81472298, 81502085, U1604167]; Natural Science Basic Research Plan in Shaanxi Province of China [2018JM7018]	State Key Laboratory of Cancer Biology Project; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Basic Research Plan in Shaanxi Province of China	This work was supported by the State Key Laboratory of Cancer Biology Project (CBSKL2017Z01), National Natural Science Foundation of China (grants 81472298, 81502085 and U1604167) and Natural Science Basic Research Plan in Shaanxi Province of China (Program no. 2018JM7018).	Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Beermann S, 2015, BIOCHEM PHARMACOL, V98, P432, DOI 10.1016/j.bcp.2015.09.011; Cai WK, 2014, EUR J CANCER, V50, P1195, DOI 10.1016/j.ejca.2013.12.025; Capurro M, 2003, GASTROENTEROLOGY, V125, P89, DOI 10.1016/S0016-5085(03)00689-9; Cianchi F, 2005, CLIN CANCER RES, V11, P6807, DOI 10.1158/1078-0432.CCR-05-0675; Cotterchio M, 2014, CANCER EPIDEM BIOMAR, V23, P469, DOI 10.1158/1055-9965.EPI-13-0965; Das AK, 2007, J PHARMACOL SCI, V103, P374, DOI 10.1254/jphs.FP0061411; Davio C, 1995, Inflamm Res, V44 Suppl 1, pS70, DOI 10.1007/BF01674401; de Esch IJP, 2005, TRENDS PHARMACOL SCI, V26, P462, DOI 10.1016/j.tips.2005.07.002; Farso M, 2013, NEUROBIOL AGING, V34, P1971, DOI 10.1016/j.neurobiolaging.2013.02.008; Francis H, 2012, GUT, V61, P753, DOI 10.1136/gutjnl-2011-300007; Gandini S, 2005, CANCER EPIDEM BIOMAR, V14, P1908, DOI 10.1158/1055-9965.EPI-05-0119; GARCIACABALLERO M, 1994, SURG ONCOL, V3, P167, DOI 10.1016/0960-7404(94)90046-9; Hernandez-Angeles A, 2001, J NEURO-ONCOL, V55, P81, DOI 10.1023/A:1013338515229; Kim YS, 2016, MOL BRAIN, V9, DOI 10.1186/s13041-016-0227-1; Lieberman P, 2011, ANN ALLERG ASTHMA IM, V106, pS2, DOI 10.1016/j.anai.2010.08.005; Lin JJ, 2015, ONCOTARGET, V6, P17107, DOI 10.18632/oncotarget.3672; Lipnik-Stangelj M, 2006, BIOCHEM PHARMACOL, V72, P1375, DOI 10.1016/j.bcp.2006.06.028; Liu CJ, 2016, ACM T SENSOR NETWORK, V12, DOI 10.1145/2835180; Mahajan UM, 2018, GASTROENTEROLOGY, V155, P1625, DOI 10.1053/j.gastro.2018.08.009; Medina VA, 2010, BRIT J PHARMACOL, V161, P755, DOI 10.1111/j.1476-5381.2010.00961.x; Megson AC, 2001, MOL PHARMACOL, V59, P1012, DOI 10.1124/mol.59.5.1012; Meng FY, 2011, HEPATOLOGY, V54, P1718, DOI 10.1002/hep.24573; Mu H, 2014, WORLD J GASTROENTERO, V20, P5826, DOI 10.3748/wjg.v20.i19.5826; Ohtsu H, 2017, HANDB EXP PHARMACOL, V241, P333, DOI 10.1007/164_2016_9; Pelekanou V, 2018, CANCER RES, V78; Pino-Angeles A, 2012, J CELL MOL MED, V16, P1947, DOI 10.1111/j.1582-4934.2012.01566.x; Procopiou PA, 2017, BIOORG MED CHEM LETT, V27, P4914, DOI 10.1016/j.bmcl.2017.09.020; Rajendiran S, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-250; Reynolds JL, 1996, MELANOMA RES, V6, P95, DOI 10.1097/00008390-199604000-00003; Schneider Elke, 2011, Front Biosci (Schol Ed), V3, P467, DOI 10.2741/s165; Shadman M, 2013, AM J HEMATOL, V88, P1050, DOI 10.1002/ajh.23564; Shirdel EA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017429; Shiroishi M, 2017, HANDB EXP PHARMACOL, V241, P21, DOI 10.1007/164_2016_10; Sieja K, 2005, BREAST, V14, P236, DOI 10.1016/j.breast.2004.06.012; Suzuki Y, 2011, BIOL PHARM BULL, V34, P507, DOI 10.1248/bpb.34.507; Thomas CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031951; Tomita Kazuyoshi, 2005, Inflammopharmacology, V13, P281, DOI 10.1163/156856005774423917; Wang MH, 2014, INT J MOL MED, V33, P1019, DOI 10.3892/ijmm.2014.1649; Wang ZY, 2010, MOL MED REP, V3, P103, DOI 10.3892/mmr_00000225; Wu XY, 2016, BMC PLANT BIOL, V16, DOI 10.1186/s12870-016-0755-y; Xu TY, 2019, AM J CANCER RES, V9, P250; Xue RD, 2019, CANCER CELL, V35, P932, DOI 10.1016/j.ccell.2019.04.007; Yang CG, 2019, INT J BIOL SCI, V15, P984, DOI 10.7150/ijbs.29836; Yuan B, 2015, CANCER SCI, V106, P819, DOI 10.1111/cas.12688	45	24	24	3	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1724	1738		10.1038/s41388-019-1093-y	http://dx.doi.org/10.1038/s41388-019-1093-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31740780	hybrid, Green Published			2022-12-17	WOS:000514923000008
J	Crawford, NT; McIntyre, AJ; McCormick, A; D'Costa, ZC; Buckley, NE; Mullan, PB				Crawford, N. T.; McIntyre, A. J.; McCormick, A.; D'Costa, Z. C.; Buckley, N. E.; Mullan, P. B.			TBX2 interacts with heterochromatin protein 1 to recruit a novel repression complex to EGR1-targeted promoters to drive the proliferation of breast cancer cells	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; HISTONE H3; EXPRESSION; METHYLATION; MECHANISM; GROWTH; G9A; PROGRESSION; SENESCENCE; BYPASS	Early Growth Response 1 (EGR1) is a stress response transcription factor with multiple tumour suppressor roles in breast tissue, whose expression is often lost in breast cancers. We have previously shown that the breast cancer oncogene TBX2 (T-BOX2) interacts with EGR1 to co-repress EGR1-target genes including the breast tumour suppressor NDRG1. Here, we show the mechanistic basis of this TBX2 repression complex. We show that siRNA knockdown of TBX2, EGR1, Heterochromatin Protein 1 (HP1) isoforms and the generic HP1-associated corepressor protein KAP1 all resulted in growth inhibition of TBX2-expressing breast cancer cells. We show that TBX2 interacts with HP1 through a conserved HP1-binding motif in its N-terminus, which in turn leads to the recruitment of KAP1 and other associated proteins. Mutation of the TBX2 HP1 binding domain abrogates the TBX2-HP1 interaction and loss of repression of target genes such as NDRG1. Chromatin-immunoprecipitation (ChIP) assays showed that TBX2 establishes a repressive chromatin mark, specifically H3K9me3, around the NDRG1 proximal promoter coincident with the recruitment of the DNA methyltransferase DNMT3B and histone methyltransferase (HMT) complex components (G9A, Enhancer of Zeste 2 (EZH2) and Suppressor of Zeste 12 (SUZ12)). Knockdown of G9A, EZH2 or SUZ12 resulted in upregulation of TBX2/EGR1 co-regulated targets accompanied by a dramatic inhibition of cell proliferation. We show that a generic inhibitor of HMT activity, DzNep, phenocopies expression of an inducible dominant negative TBX2. Knockdown of TBX2, KAP1 or HP1 inhibited NDRG1 promoter decoration specifically with the H3K9me3 repression mark. Correspondingly, treatment with a G9A inhibitor effectively reversed TBX2 repression of NDRG1 and synergistically downregulated cell proliferation following TBX2 functional inhibition. These data demonstrate that TBX2 promotes suppression of normal growth control mechanisms through recruitment of a large repression complex to EGR1-responsive promoters leading to the uncontrolled proliferation of breast cancer cells.	[Crawford, N. T.; McIntyre, A. J.; McCormick, A.; D'Costa, Z. C.; Buckley, N. E.; Mullan, P. B.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland	Queens University Belfast	Mullan, PB (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland.	p.mullan@qub.ac.uk		Crawford, Nyree/0000-0003-2258-4687; Buckley, Niamh/0000-0001-9326-8513; McIntyre, Alexander/0000-0002-8411-2581	Breast Cancer Campaign; NEC; AMCI; AMCC; ZCD'C; NEB; PBM	Breast Cancer Campaign; NEC; AMCI; AMCC; ZCD'C; NEB; PBM	Special thanks to Dr James Murray (Trinity College Dublin) for the kind gift of sheep anti-human NDRG1 antibody and Professor Max Costa (University of New York) for NDRG1 promoter luciferase constructs. This work was supported by grants from the Breast Cancer Campaign and Breast Cancer Now (NEC, AMCI, AMCC, ZCD'C, NEB, PBM).	Abrahams A, 2010, IUBMB LIFE, V62, P92, DOI 10.1002/iub.275; Adem C, 2004, GENE CHROMOSOME CANC, V41, P1, DOI 10.1002/gcc.20057; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Barlund M, 2000, CANCER RES, V60, P5340; Buckley NE, 2007, MOL CANCER RES, V5, P261, DOI 10.1158/1541-7786.MCR-06-0250; Chapman DL, 1996, DEV DYNAM, V206, P379, DOI 10.1002/(SICI)1097-0177(199608)206:4<379::AID-AJA4>3.0.CO;2-F; Cowieson NP, 2000, CURR BIOL, V10, P517, DOI 10.1016/S0960-9822(00)00467-X; de Belle I, 1999, ONCOGENE, V18, P3633, DOI 10.1038/sj.onc.1202696; de la Cruz CC, 2007, CHROMOSOME RES, V15, P2007, DOI 10.1007/s10577-007-1126-1; Della Ragione F, 2003, J BIOL CHEM, V278, P23360, DOI 10.1074/jbc.M300771200; Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Frietze S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015082; Granit RZ, 2013, ONCOGENE, V32, P3886, DOI 10.1038/onc.2012.390; Hartman ZC, 2013, CANCER RES, V73, P3470, DOI 10.1158/0008-5472.CAN-12-4524-T; Hosey AM, 2007, J NATL CANCER I, V99, P1683, DOI 10.1093/jnci/djm207; Ismail A, 2009, CANCER LETT, V278, P230, DOI 10.1016/j.canlet.2009.01.006; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Krones-Herzig A, 2003, P NATL ACAD SCI USA, V100, P3233, DOI 10.1073/pnas.2628034100; Kwon SH, 2010, GENE DEV, V24, P2133, DOI 10.1101/gad.1959110; Li YH, 2002, P NATL ACAD SCI USA, V99, P16462, DOI 10.1073/pnas.162371699; Martin N, 2012, EMBO J, V31, P95, DOI 10.1038/emboj.2011.370; Moore HM, 2013, BREAST CANCER RES TR, V138, P741, DOI 10.1007/s10549-013-2498-x; Prince S, 2004, CANCER RES, V64, P1669, DOI 10.1158/0008-5472.CAN-03-3286; Purcell DJ, 2012, J CELL BIOCHEM, V113, P2406, DOI 10.1002/jcb.24114; Redmond KL, 2010, ONCOGENE, V29, P3252, DOI 10.1038/onc.2010.84; Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15; Roylance R, 1999, CANCER RES, V59, P1433; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Sinclair CS, 2002, CANCER RES, V62, P3587; Tirkkonen M, 1997, CANCER RES, V57, P1222; Vance KW, 2010, MOL BIOL CELL, V21, P2770, DOI 10.1091/mbc.E09-12-1029; Vance KW, 2005, CANCER RES, V65, P2260, DOI 10.1158/0008-5472.CAN-04-3045; Vormer TL, 2008, MOL CELL BIOL, V28, P7263, DOI 10.1128/MCB.00313-08; Wang B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041355; Wozniak RJ, 2007, ONCOGENE, V26, P77, DOI 10.1038/sj.onc.1209763; Wu H, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0008570, 10.1371/journal.pone.0013316]; Yu HX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051239	38	24	25	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2019	38	31					5971	5986		10.1038/s41388-019-0853-z	http://dx.doi.org/10.1038/s41388-019-0853-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IT3GE	31253870	Green Accepted			2022-12-17	WOS:000482740000005
J	Mongiardi, MP; Radice, G; Piras, M; Stagni, V; Pacioni, S; Re, A; Putti, S; Ferre, F; Farsetti, A; Pallini, R; Barila, D; Levi, A; Falchetti, ML				Mongiardi, Maria Patrizia; Radice, Giulia; Piras, Maurizia; Stagni, Venturina; Pacioni, Simone; Re, Agnese; Putti, Sabrina; Ferre, Fabrizio; Farsetti, Antonella; Pallini, Roberto; Barila, Daniela; Levi, Andrea; Falchetti, Maria Laura			Axitinib exposure triggers endothelial cells senescence through ROS accumulation and ATM activation	ONCOGENE			English	Article							RECEPTOR TYROSINE KINASES; GROWTH-FACTOR; INHIBITOR; AG-013736; ANTIANGIOGENESIS; ANGIOGENESIS; SECRETION; TARGET; LINES; P53	Inhibitors of Vascular Endothelial Growth Factor target both tumor vasculature and cancer cells that have hijacked VEGF Receptors (VEGFRs) signaling for tumor growth-promoting activities. It is important to get precise insight in the specificity of cell responses to these antiangiogenic drugs to maximize their efficiency and minimize off-target systemic toxicity. Here we report that Axitinib, an inhibitor of VEGFRs currently in use as a second line treatment for advanced renal cell carcinoma, promotes senescence of human endothelial cells in vitro. A one-hour pulse of Axitinib is sufficient for triggering cell senescence. Mechanistically, this requires oxidative stress-dependent activation of the Ataxia Telangiectasia Mutated (ATM) kinase. Axitinib-mediated senescence promoting action is prevented by short-term treatment with antioxidants or ATM inhibitors, which conversely fail to prevent senescence induced by the DNA-damaging drug doxorubicin. Coherently, induction of oxidative stress-related genes distinguishes the response of endothelial cells to Axitinib from that to doxorubicin. Importantly, an Axitinib pulse causes cell senescence in glioblastoma cells. However, neither antioxidants nor ATM inhibitors can reverse this phenotype. Thus, antioxidants may selectively protect endothelial cells from Axitinib by decreasing systemic toxicity and maintaining a functional vascularization necessary for efficient delivery of chemotherapeutic drugs within the tumor mass.	[Mongiardi, Maria Patrizia; Radice, Giulia; Piras, Maurizia; Pacioni, Simone; Re, Agnese; Putti, Sabrina; Farsetti, Antonella; Levi, Andrea; Falchetti, Maria Laura] CNR, Inst Cell Biol & Neurobiol, Rome, Italy; [Stagni, Venturina; Barila, Daniela] Univ Roma Tor Vergata, Dept Biol, Rome, Italy; [Stagni, Venturina; Barila, Daniela] Ist Ricovero & Cura Carattere Sci IRCCS Fdn Santa, Lab Cell Signaling, Rome, Italy; [Pacioni, Simone; Pallini, Roberto] Fdn Policlin Univ A Gemelli, Inst Neurosurg, Rome, Italy; [Ferre, Fabrizio] Univ Bologna Alma Mater, Dept Pharm & Biotechnol, I-40126 Bologna, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia Cellulare e Neurobiologia (IBCN-CNR); University of Rome Tor Vergata; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Bologna	Farsetti, A; Falchetti, ML (corresponding author), CNR, Inst Cell Biol & Neurobiol, Rome, Italy.	antonella.farsetti@cnr.it; marialaura.falchetti@cnr.it	falchetti, maria laura/AAA-5586-2019; Pallini, Roberto/AAA-3760-2019; PALLINI, Roberto/AAA-3747-2019; Farsetti, Antonella/I-8710-2018; Mongiardi, Maria Patrizia/AAA-4668-2019; BARILA', DANIELA/K-8506-2016; PUTTI, SABRINA/H-2574-2019	PALLINI, Roberto/0000-0002-4611-8827; Farsetti, Antonella/0000-0002-8603-7925; mongiardi, maria patrizia/0000-0002-5578-1751; BARILA', DANIELA/0000-0002-6192-1562; PUTTI, SABRINA/0000-0003-3335-043X; stagni, venturina/0000-0002-3971-0398	MIUR-CNR Flagship Invecchiamento [DSB.AD009.001.004]; Associazione Italiana per la Ricerca sul Cancro-AIRC IG2016 [19069]; MIUR-JPI HDHL NUTRICOG MiTyrAge [PRIN_2015LZE9944_005, RF-2016-02362022]; AIRC IG2016 [19069];  [RF-2016-02363460]	MIUR-CNR Flagship Invecchiamento; Associazione Italiana per la Ricerca sul Cancro-AIRC IG2016(Fondazione AIRC per la ricerca sul cancro); MIUR-JPI HDHL NUTRICOG MiTyrAge; AIRC IG2016(Fondazione AIRC per la ricerca sul cancro); 	The study was supported by research grants from: MIUR-CNR Flagship Invecchiamento #DSB.AD009.001.004 to AL and MLF; Associazione Italiana per la Ricerca sul Cancro-AIRC IG2016-n.19069, MIUR-JPI HDHL NUTRICOG MiTyrAge, PRIN_2015LZE9944_005 and RF-2016-02362022 to DB; by RF-2016-02363460 to VS. VS has also been supported by AIRC IG2016-n.19069. We thank Dr Silvia Soddu and Prof Carlo Gaetano for their suggestions on p53 protein detection and ROS measurement, respectively.	Amantini C, 2016, ONCOTARGET, V7, P50180, DOI 10.18632/oncotarget.10326; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Bellesoeur A, 2017, DRUG DES DEV THER, V11, P2801, DOI 10.2147/DDDT.S109640; Bonello-Palot N, 2014, ATHEROSCLEROSIS, V237, P45, DOI 10.1016/j.atherosclerosis.2014.08.036; Chang MWF, 2005, EXP CELL RES, V309, P121, DOI 10.1016/j.yexcr.2005.05.002; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Davalli P, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3565127; Demaria M, 2017, CANCER DISCOV, V7, P165, DOI 10.1158/2159-8290.CD-16-0241; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Elmore LW, 2002, J BIOL CHEM, V277, P35509, DOI 10.1074/jbc.M205477200; Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364; Ferrara N, 2004, ONCOLOGIST, V9, P2, DOI 10.1634/theoncologist.9-suppl_1-2; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Freund A, 2012, MOL BIOL CELL, V23, P2066, DOI 10.1091/mbc.E11-10-0884; Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627; Guo Z, 2010, SCIENCE, V330, P517, DOI 10.1126/science.1192912; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; He SH, 2017, CELL, V169, P1000, DOI 10.1016/j.cell.2017.05.015; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Hovinga KE, 2005, J NEURO-ONCOL, V74, P99, DOI 10.1007/s11060-004-4204-7; Hu-Lowe DD, 2008, CLIN CANCER RES, V14, P7272, DOI 10.1158/1078-0432.CCR-08-0652; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Kang HT, 2017, NAT CHEM BIOL, V13, P616, DOI 10.1038/nchembio.2342; Klaeger S, 2017, SCIENCE, V358, DOI 10.1126/science.aan4368; Lenain C, 2015, CARCINOGENESIS, V36, P1263, DOI 10.1093/carcin/bgv124; Liang YX, 2002, J BIOL CHEM, V277, P20087, DOI 10.1074/jbc.M201766200; Menendez D, 2007, MOL CELL BIOL, V27, P2590, DOI 10.1128/MCB.01742-06; Morelli MB, 2015, ONCOTARGET, V6, P36245, DOI 10.18632/oncotarget.5768; Nair RR, 2015, J CELL SCI, V128, P342, DOI 10.1242/jcs.159517; Passos JF, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.5; Pawlikowski JS, 2013, J CELL SCI, V126, P4061, DOI 10.1242/jcs.109728; Perrigue PM, 2015, MOL CANCER RES, V13, P636, DOI 10.1158/1541-7786.MCR-13-0268; Przybylska D, 2016, ONCOTARGET, V7, P66429, DOI 10.18632/oncotarget.12079; Rugo HS, 2005, J CLIN ONCOL, V23, P5474, DOI 10.1200/JCO.2005.04.192; Song YS, 2005, MECH AGEING DEV, V126, P580, DOI 10.1016/j.mad.2004.11.008; Welti J, 2013, J CLIN INVEST, V123, P3190, DOI 10.1172/JCI70212; White RR, 2016, MOL CELL, V63, P729, DOI 10.1016/j.molcel.2016.08.004; Wilmes LJ, 2007, MAGN RESON IMAGING, V25, P319, DOI 10.1016/j.mri.2006.09.041	39	24	25	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5413	5424		10.1038/s41388-019-0798-2	http://dx.doi.org/10.1038/s41388-019-0798-2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30967634				2022-12-17	WOS:000473842500006
J	Wang, HR; Zhou, YJ; Oyang, LD; Han, YQ; Xia, LZ; Lin, JG; Tang, YY; Su, M; Tan, SM; Tian, YT; Chen, XY; Luo, X; Liang, JX; Rao, S; Wang, Y; Xiong, W; Zeng, ZY; Wang, H; Li, GY; Liao, QJ				Wang, Heran; Zhou, Yujuan; Oyang, Linda; Han, Yaqian; Xia, Longzheng; Lin, Jingguan; Tang, Yanyan; Su, Min; Tan, Shiming; Tian, Yutong; Chen, Xiaoyan; Luo, Xia; Liang, Jiaxin; Rao, Shan; Wang, Ying; Xiong, Wei; Zeng, Zhaoyang; Wang, Hui; Li, Guiyuan; Liao, Qianjin			LPLUNC1 stabilises PHB1 by counteracting TRIM21-mediated ubiquitination to inhibit NF-kappa B activity in nasopharyngeal carcinoma	ONCOGENE			English	Article							PROTEIN-DEGRADATION; CANCER-CELLS; PROHIBITIN; BPIFB1; TRIM21; MICE; IDENTIFICATION; TUMORIGENESIS	Long-palate, lung and nasal epithelium clone 1 (LPLUNC1) is a tumour suppressor gene in nasopharyngeal carcinoma (NPC), and low expression of LPLUNC1 is associated with poor prognosis. Our previous study showed that LPLUNC1 upregulates Prohibitin 1 (PHB1), a pleiotropic protein that functions as a tumour suppressor gene in various cancers. Low expression of PHB1 was also found to be associated with the poor prognosis of NPC patients. However, the mechanisms by which LPLUNC1 upregulates PHB1 and the potential role of PHB1 in NPC are unclear. Here, we found that LPLUNC1 stabilised PHB1 by inhibiting PHB1 ubiquitination, which is mediated by E3 ligase TRIM21. LPLUNC1 competitively impaired the binding of PHB1 to TRIM21 due to its stronger binding affinity to PHB1, suppressing the ubiquitination of PHB1. Therefore, our study indicates that PHB1 acted as a tumour suppressor gene by inhibiting NF-kB activity. Depletion of PHB1 significantly attenuated the anti-tumour effects of LPLUNC1 in NPC cells, and the inhibitory effect of LPLUNC1 on NF-kappa B activity was thus reversed. Together, our findings revealed a novel mechanism underlying the anticancer effect of LPLUNC1 and clarified that PHB1 may represent a novel, promising candidate tumour suppressor gene in NPC, with potential therapeutic target value.	[Wang, Heran; Zhou, Yujuan; Oyang, Linda; Han, Yaqian; Xia, Longzheng; Lin, Jingguan; Tang, Yanyan; Su, Min; Tan, Shiming; Tian, Yutong; Chen, Xiaoyan; Luo, Xia; Liang, Jiaxin; Rao, Shan; Wang, Ying; Wang, Hui; Liao, Qianjin] Cent S Univ, Hunan Canc Hosp, Hunan Key Lab Translat Radiat Oncol, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China; [Wang, Heran; Zhou, Yujuan; Oyang, Linda; Han, Yaqian; Xia, Longzheng; Lin, Jingguan; Tang, Yanyan; Su, Min; Tan, Shiming; Tian, Yutong; Chen, Xiaoyan; Luo, Xia; Liang, Jiaxin; Rao, Shan; Wang, Ying; Wang, Hui; Liao, Qianjin] Cent S Univ, Affiliated Canc Hosp, Hunan Key Lab Translat Radiat Oncol, Xiangya Sch Med, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China; [Xiong, Wei; Zeng, Zhaoyang; Li, Guiyuan] Cent S Univ, Canc Res Inst, Key Lab Carcinogenesis & Canc Invas, Minist Educ, Changsha 410078, Hunan, Peoples R China	Central South University; Central South University; Central South University	Liao, QJ (corresponding author), Cent S Univ, Hunan Canc Hosp, Hunan Key Lab Translat Radiat Oncol, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.; Liao, QJ (corresponding author), Cent S Univ, Affiliated Canc Hosp, Hunan Key Lab Translat Radiat Oncol, Xiangya Sch Med, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.	march-on@126.com	chen, xi/GXH-3653-2022; chen, xia/GYR-3948-2022; chen, xia/GXM-5435-2022	Zhou, Yujuan/0000-0002-5195-8724; Liao, Qianjin/0000-0001-9320-3090	National Natural Science Foundation of China [81472595, 81701510, 81872281]; Natural Science Foundation of Hunan Province [2018JJ1013, 2016JJ4059]; Research Project of the Health and Family Planning Commission of Hunan Province [B20180400, B20180582]; Changsha Science and Technology Board [kq1706045, kq1706043]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hunan Province(Natural Science Foundation of Hunan Province); Research Project of the Health and Family Planning Commission of Hunan Province; Changsha Science and Technology Board	This work was supported by grants from the National Natural Science Foundation of China (81472595, 81701510 and 81872281), the Natural Science Foundation of Hunan Province (2018JJ1013, 2016JJ4059), the Research Project of the Health and Family Planning Commission of Hunan Province (B20180400, B20180582), and the Changsha Science and Technology Board (kq1706045, kq1706043).	Amin H, 2015, ACS MED CHEM LETT, V6, P1071, DOI 10.1021/acsmedchemlett.5b00257; Bingle CD, 2010, HISTOCHEM CELL BIOL, V133, P505, DOI 10.1007/s00418-010-0683-0; Das A, 2015, VIROLOGY, V485, P383, DOI 10.1016/j.virol.2015.08.013; De Smet EG, 2018, INT J CHRONIC OBSTR, V13, P11, DOI 10.2147/COPD.S144136; Donoghue LJ, 2017, GENETICS, V207, P801, DOI 10.1534/genetics.117.300211; El-Etreby NM, 2017, J OVARIAN RES, V10, DOI 10.1186/s13048-017-0325-4; Fan W, 2017, HEPATOLOGY, V65, P1249, DOI 10.1002/hep.28964; Fletcher CE, 2012, HUM MOL GENET, V21, P3112, DOI 10.1093/hmg/dds139; Gao J, 2015, AM J PHYSIOL-LUNG C, V309, pL17, DOI 10.1152/ajplung.00082.2015; Han J, 2014, CELL SIGNAL, V26, P2086, DOI 10.1016/j.cellsig.2014.06.006; Hildesheim A, 2012, SEMIN CANCER BIOL, V22, P107, DOI 10.1016/j.semcancer.2012.01.007; Inobe T, 2014, CURR OPIN STRUC BIOL, V24, P156, DOI 10.1016/j.sbi.2014.02.002; Jin JM, 2016, CELL TISSUE RES, V363, P805, DOI 10.1007/s00441-015-2280-y; Kang DC, 2017, ULTRASON SONOCHEM, V38, P317, DOI 10.1016/j.ultsonch.2017.03.026; Kathiria AS, 2012, CANCER RES, V72, P5778, DOI 10.1158/0008-5472.CAN-12-0603; Koushyar S, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.32; Kumar C, 2017, MEDCHEMCOMM, V8, P2115, DOI 10.1039/c7md00267j; Liao Q, 2014, ONCOGENE, V33, P2098, DOI 10.1038/onc.2013.161; Liao QJ, 2013, EUR J CANCER PREV, V22, P68, DOI 10.1097/CEJ.0b013e328354d351; Mantovani A, 2010, CURR MOL MED, V10, P369, DOI 10.2174/156652410791316968; Mishra S, 2006, J CELL MOL MED, V10, P353, DOI 10.1111/j.1582-4934.2006.tb00404.x; Mishra S, 2010, FEBS J, V277, P3937, DOI 10.1111/j.1742-4658.2010.07809.x; Nguyen JQ, 2017, CANCER BIOL THER, V18, P16, DOI 10.1080/15384047.2016.1252880; Nih LR, 2017, ADV MATER, V29, DOI 10.1002/adma.201606471; Pan JA, 2016, MOL CELL, V61, P720, DOI 10.1016/j.molcel.2016.02.007; Patel N, 2010, P NATL ACAD SCI USA, V107, P2503, DOI 10.1073/pnas.0910649107; Qureshi R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141826; Shin OS, 2011, J INFECT DIS, V204, P1349, DOI 10.1093/infdis/jir544; Shum AK, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006998; Sievers C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012735; Theiss AL, 2011, BBA-MOL CELL RES, V1813, P1137, DOI 10.1016/j.bbamcr.2011.01.033; Theiss AL, 2009, MOL BIOL CELL, V20, P4412, DOI 10.1091/mbc.E09-05-0361; Vargas PA, 2008, ORAL DIS, V14, P613, DOI 10.1111/j.1601-0825.2007.01429.x; Wang HY, 2016, CHIN J CANCER, V35, DOI 10.1186/s40880-016-0103-5; Wang SM, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9343460; Wang T, 2012, J CELL MOL MED, V16, P1134, DOI 10.1111/j.1582-4934.2011.01388.x; Wang XY, 2017, MACROMOL BIOSCI, V17, DOI 10.1002/mabi.201700186; Wei F, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0409-0; Wei F, 2018, BRIT J CANCER, V118, P233, DOI 10.1038/bjc.2017.385; Wu CC, 2018, CANCERS, V10, DOI 10.3390/cancers10040120; Yang LT, 2018, J INVEST DERMATOL, V138, P2568, DOI 10.1016/j.jid.2018.05.016; Yang YX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062869; Ye X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109152; Yuan GJ, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0695-5; Zeng ZY, 2011, SCI CHINA LIFE SCI, V54, P966, DOI 10.1007/s11427-011-4223-5; Zhang BC, 2003, GENE CHROMOSOME CANC, V38, P80, DOI 10.1002/gcc.10247; Zhang L, 2012, ASIAN PAC J CANCER P, V13, P3803, DOI 10.7314/APJCP.2012.13.8.3803; Zhou WQ, 2017, OPEN MED-WARSAW, V12, P299, DOI 10.1515/med-2017-0044; Zhou YJ, 2016, J CANCER, V7, P367, DOI 10.7150/jca.13695	49	24	28	3	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					5062	5075		10.1038/s41388-019-0778-6	http://dx.doi.org/10.1038/s41388-019-0778-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30886235	Green Published, hybrid			2022-12-17	WOS:000472145900013
J	Dang, SW; Zhou, JS; Chen, YJ; Chen, P; Ji, MJ; Shi, BY; Yang, Q; Hou, P				Dang, Siwen; Zhou, Jingshi; Chen, Yijun; Chen, Pu; Ji, Meiju; Shi, Bingyin; Yang, Qi; Hou, Peng			Dynamic expression of ZNF382 and its tumor-suppressor role in hepatitis B virus-related hepatocellular carcinogenesis	ONCOGENE			English	Article							MAJOR SIGNALING PATHWAYS; X-PROTEIN; PROGNOSTIC-SIGNIFICANCE; CANCER STATISTICS; THYROID-CANCER; C-JUN; METHYLATION; GENE; ACTIVATION; GENOME	Hepatitis B virus (HBV) infection is the primary cause of hepatocellular carcinoma (HCC). Zinc-finger protein 382 (ZNF382), which belongs to zinc-finger protein family, has been documented to be downregulated in certain types of cancer. However, its role in HCC remains largely unknown. In this study, we demonstrated that ZNF382 expression was significantly elevated in HBV-infected liver cirrhosis tissues relative to HBV-negative normal liver tissues at protein levels, but not at mRNA levels, and was positively correlated with the levels of HBV DNA and hepatitis B virus X protein (HBx). Further studies revealed that ZNF382 was a target of miR-6867, and HBx promoted the translation of ZNF382 during HBV chronic infection through Erk-mediated miR-6867 inhibition. In addition, our data showed that ZNF382 was frequently downregulated by promoter methylation in HBV-related HCCs relative to HBV-infected liver cirrhosis tissues, and decreased expression of ZNF382 was strongly correlated with poor survival in early-stage HCC patients. Functional studies demonstrated that ZNF382 was a potent tumor suppressor in HCC cells through inhibiting cell proliferation, colony formation, migration, invasion, and tumorigenic potential in nude mice, and inducing cell apoptosis. Mechanistically, ZNF382 exerted its tumor-suppressor functions in HCC through transcriptionally repressing its downstream targets such as Fos proto-oncogene (FOS), Jun proto-oncogene (JUN), disheveled segment polarity protein 2 (DVL2), and frizzled class receptor 1 (FZD1), thereby impairing the activities of activating protein 1 (AP-1) and Wnt/beta-catenin pathways and activating p53 signaling. Altogether, our data show that ZNF382 acts as a tumor suppressor, and is co-regulated by HBx and epigenetic mechanism in HBV-related hepatocellular carcinogenesis.	[Dang, Siwen; Chen, Yijun; Chen, Pu; Shi, Bingyin; Yang, Qi; Hou, Peng] Xi An Jiao Tong Univ, Affiliated Hosp 1, Key Lab Tumor Precis Med Shaanxi Prov, Xian 710061, Shaanxi, Peoples R China; [Dang, Siwen; Chen, Yijun; Chen, Pu; Shi, Bingyin; Yang, Qi; Hou, Peng] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Endocrinol, Xian 710061, Shaanxi, Peoples R China; [Zhou, Jingshi] Fourth Mil Med Univ, Xijing Hosp, Dept Hepatobiliary Surg, Xian 710032, Shaanxi, Peoples R China; [Ji, Meiju] Xi An Jiao Tong Univ, Affiliated Hosp 1, Ctr Translat Med, Xian 710061, Shaanxi, Peoples R China	Xi'an Jiaotong University; Xi'an Jiaotong University; Air Force Military Medical University; Xi'an Jiaotong University	Yang, Q; Hou, P (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Key Lab Tumor Precis Med Shaanxi Prov, Xian 710061, Shaanxi, Peoples R China.; Yang, Q; Hou, P (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Endocrinol, Xian 710061, Shaanxi, Peoples R China.	docqiyang@163.com; phou@xjtu.edu.cn			National Nature Science Foundation of China [81402340, 81572627, 81672645]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Nature Science Foundation of China (no. 81402340, 81572627, and 81672645).	ANTUNOVIC J, 1993, CELL MOL BIOL RES, V39, P463; Arzumanyan A, 2013, NAT REV CANCER, V13, P123, DOI 10.1038/nrc3449; Arzumanyan A, 2012, CANCER RES, V72, P5912, DOI 10.1158/0008-5472.CAN-12-2329; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Berindan-Neagoe I, 2014, CA-CANCER J CLIN, V64, P311, DOI 10.3322/caac.21244; Bui-Nguyen TM, 2010, ONCOGENE, V29, P1179, DOI 10.1038/onc.2009.404; Calvisi DF, 2007, J CLIN INVEST, V117, P2713, DOI 10.1172/JCI31457; Chan SL, 2016, J CLIN ONCOL, V34, P83, DOI 10.1200/JCO.2015.61.5724; Chen JL, 2014, MOL THER, V22, P303, DOI 10.1038/mt.2013.212; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Cheng YD, 2010, CANCER RES, V70, P6516, DOI 10.1158/0008-5472.CAN-09-4566; Chiu CM, 2007, P NATL ACAD SCI USA, V104, P2571, DOI 10.1073/pnas.0609498104; Diao JY, 2001, CYTOKINE GROWTH F R, V12, P189, DOI 10.1016/S1359-6101(00)00034-4; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; Kim DJ, 2014, J CLIN ONCOL, V32, P745, DOI 10.1200/JCO.2013.49.9525; Li YJ, 2018, CANCER RES, V78, P5216, DOI 10.1158/0008-5472.CAN-18-0003; Lim SO, 2008, GASTROENTEROLOGY, V135, P2128, DOI 10.1053/j.gastro.2008.07.027; Liu ZJ, 2014, CLIN CANCER RES, V20, P4598, DOI 10.1158/1078-0432.CCR-13-3380; Luo KM, 2002, BIOCHEM BIOPH RES CO, V299, P606, DOI 10.1016/S0006-291X(02)02700-6; Murata M, 2009, HEPATOLOGY, V49, P1203, DOI 10.1002/hep.22765; Muthukrishnan D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10027; Neuveut C, 2010, J HEPATOL, V52, P594, DOI 10.1016/j.jhep.2009.10.033; Nishida N, 2012, HEPATOLOGY, V56, P994, DOI 10.1002/hep.25706; Niu YD, 2017, HEPATOLOGY, V65, P893, DOI 10.1002/hep.28924; Qiang W, 2014, J CLIN ENDOCR METAB, V99, pE1163, DOI 10.1210/jc.2013-3729; Qiu X, 2013, ONCOGENE, V32, P3296, DOI 10.1038/onc.2013.150; Revill K, 2013, GASTROENTEROLOGY, V145, P1424, DOI 10.1053/j.gastro.2013.08.055; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Schwabe RF, 2003, HEPATOLOGY, V37, P824, DOI 10.1053/jhep.2003.50135; Shan CL, 2010, CELL RES, V20, P563, DOI 10.1038/cr.2010.49; Shi J, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.346; Shi J, 2015, ONCOTARGET, V6, P14344, DOI 10.18632/oncotarget.3852; Shi J, 2012, INT J MOL SCI, V13, P4714, DOI 10.3390/ijms13044714; Shi J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-50; Shi J, 2012, AM J CANCER RES, V2, P116; Shin YJ, 2013, CANCER BIOL THER, V14, P213, DOI 10.4161/cbt.23292; Song K, 2013, HEPATOLOGY, V58, P1681, DOI 10.1002/hep.26514; Sun HL, 2016, CANCER CELL, V30, P723, DOI 10.1016/j.ccell.2016.10.001; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Urrutia R, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-231; Wang C, 2012, HEPATOLOGY, V55, P108, DOI 10.1002/hep.24675; Wang D, 2014, AM J CANCER RES, V4, P725; Xu XJ, 2013, J CLIN INVEST, V123, P630, DOI 10.1172/JCI64265; Ye H, 2014, ONCOGENE, V33, P5133, DOI 10.1038/onc.2013.468; Zhang C, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0604-z; Zhang T, 2012, HEPATOLOGY, V56, P2051, DOI 10.1002/hep.25899; Zhou SJ, 2017, CELL DEATH DIFFER, V24, P1577, DOI 10.1038/cdd.2017.87	48	24	24	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4804	4819		10.1038/s41388-019-0759-9	http://dx.doi.org/10.1038/s41388-019-0759-9			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30804458				2022-12-17	WOS:000471160500011
J	Recio, C; Guerra, B; Guerra-Rodriguez, M; Aranda-Tavio, H; Martin-Rodriguez, P; de Mirecki-Garrido, M; Brito-Casillas, Y; Garcia-Castellano, JM; Estevez-Braun, A; Fernandez-Perez, L				Recio, Carlota; Guerra, Borja; Guerra-Rodriguez, Miguel; Aranda-Tavio, Haidee; Martin-Rodriguez, Patricia; de Mirecki-Garrido, Mercedes; Brito-Casillas, Yeray; Garcia-Castellano, Jose M.; Estevez-Braun, Ana; Fernandez-Perez, Leandro			Signal transducer and activator of transcription (STAT)-5: an opportunity for drug development in oncohematology	ONCOGENE			English	Review							CHRONIC MYELOID-LEUKEMIA; HODGKIN LYMPHOMA; JANUS KINASES; STAT PROTEINS; SELF-RENEWAL; BCR-ABL; CELLS; IMATINIB; MUTATION; PATHWAY	The signal transducer and activator of transcription (STAT) are transcription factors that work via JAK/STAT pathway regulating the expression of genes involved in cell survival, proliferation, differentiation, development, immune response, and, among other essential biological functions, hematopoiesis. JAK/STAT signaling is strictly regulated under normal physiological conditions. However, a large group of diverse diseases has been associated to an aberrant regulation of STAT factors. Erroneous modulation of the pathway leads to constitutive STAT activation, thereby driving proliferation, inflammation, and an uncontrolled immune response. Deregulated STAT5 activation has been found in the development of many hematopoietic tumors, including chronic and acute leukemias, polycythemia vera, and lymphoma. Mutations in the kinases that phosphorylate STAT5, and/or overexpression of the upstream receptor-associated tyrosine kinases have been suggested as the main drivers of constitutive STAT5 activation. Hyper-activated STAT5 leads to the aberrant expression of its target genes including antiapoptotic, proliferative, and pro-inflammatory genes, favouring tumorigenesis. In this review, we intent to discuss the biology of JAK/STAT pathway, with particular focus on STAT5 and its crucial role in the development and progression of hematologic malignancies. Furthermore, we provide a synopsis of potential therapeutic strategies based on STAT5 activity inhibition that may represent an excellent opportunity for drug development in oncohematology.	[Recio, Carlota; Guerra, Borja; Guerra-Rodriguez, Miguel; Aranda-Tavio, Haidee; Martin-Rodriguez, Patricia; de Mirecki-Garrido, Mercedes; Brito-Casillas, Yeray; Garcia-Castellano, Jose M.; Fernandez-Perez, Leandro] Univ Las Palmas Gran Canaria, IUIBS, Farmacol Mol & Traslac BIOPharm, Las Palmas De Gc 35016, Las Palmas, Spain; [Estevez-Braun, Ana] Univ La Laguna, Inst Univ Bioorgan CIBICAN, Dept Quim Organ, E-38206 Tenerife, Spain	Universidad de Las Palmas de Gran Canaria; Universidad de la Laguna	Recio, C (corresponding author), Univ Las Palmas Gran Canaria, IUIBS, Farmacol Mol & Traslac BIOPharm, Las Palmas De Gc 35016, Las Palmas, Spain.	carlota.recio@ulpgc.es	Guerra, Borja/ABE-1138-2021; Guerra, Borja/G-9739-2015; Patricia, Martín Rodríguez/H-3238-2015; Casillas, Yeray Brito/U-6954-2018; Recio, Carlota/ABF-5850-2021; Estevez-Braun, Ana/A-8122-2015; Recio, Carlota/D-2984-2019; Fernandez-Perez, Leandro/H-1493-2015; Guerra Rodriguez, Miguel/R-4283-2018	Guerra, Borja/0000-0003-4355-5682; Guerra, Borja/0000-0003-4355-5682; Patricia, Martín Rodríguez/0000-0002-2378-3242; Casillas, Yeray Brito/0000-0002-0707-7444; Estevez-Braun, Ana/0000-0001-5279-7099; Recio, Carlota/0000-0002-8832-2826; Fernandez-Perez, Leandro/0000-0001-7802-465X; Guerra Rodriguez, Miguel/0000-0002-0047-1131	Spanish Ministry of Economy and Competitivity (MINECO); European Regional Development Fund-European Social Fund [SAF2015-65113-C2-2-R]; Alfredo Martin-Reyes Foundation (Arehucas) - FICIC; MINECO - Juan de la Cierva 2017 program; ULPGC 2017	Spanish Ministry of Economy and Competitivity (MINECO); European Regional Development Fund-European Social Fund; Alfredo Martin-Reyes Foundation (Arehucas) - FICIC; MINECO - Juan de la Cierva 2017 program; ULPGC 2017	We thank all the authors that contributed to the understanding of the role of STAT5 in hematopoiesis and oncohematology. We apologize to those whose work deserves to be cited but unfortunately are not quoted because of space restriction. The research program in the author's lab was supported by grants-in-aid from Spanish Ministry of Economy and Competitivity (MINECO) with the funding of European Regional Development Fund-European Social Fund (SAF2015-65113-C2-2-R) and Alfredo Martin-Reyes Foundation (Arehucas) -FICIC. CR and MMG were supported by postdoctoral grants-in-aid from MINECO - Juan de la Cierva 2017 program and ULPGC 2017, respectively.	Able AA, 2017, BIOLOGY-BASEL, V6, DOI 10.3390/biology6010020; Bibi S, 2014, HAEMATOLOGICA, V99, P417, DOI 10.3324/haematol.2013.098442; Braunstein J, 2003, J BIOL CHEM, V278, P34133, DOI 10.1074/jbc.M304531200; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Campia I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126159; Chatain N, 2013, ONCOGENE, V32, P3587, DOI 10.1038/onc.2012.369; Chun JN, 2018, ONCOTARGET, V9, P3121, DOI 10.18632/oncotarget.23213; Cumaraswamy AA, 2014, ACS MED CHEM LETT, V5, P1202, DOI 10.1021/ml500165r; de Lavallade H, 2008, J CLIN ONCOL, V26, P3358, DOI 10.1200/JCO.2007.15.8154; Dolznig H, 2006, ONCOGENE, V25, P2890, DOI 10.1038/sj.onc.1209308; Dorritie KA, 2014, LEUKEMIA, V28, P248, DOI 10.1038/leu.2013.192; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; Fernandez-Perez L, 2016, RESTRICTED GROWTH CL, P125; Fievez L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000727; Ghoreschi K, 2009, IMMUNOL REV, V228, P273, DOI 10.1111/j.1600-065X.2008.00754.x; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Guerra B, 2017, ONCOTARGET, V8, P29679, DOI 10.18632/oncotarget.11425; Haura EB, 2005, NAT CLIN PRACT ONCOL, V2, P315, DOI 10.1038/ncponc0195; Heltemes-Harris LM, 2012, CURR OPIN IMMUNOL, V24, P146, DOI 10.1016/j.coi.2012.01.015; Hochhaus A, 2009, LEUKEMIA, V23, P1054, DOI 10.1038/leu.2009.38; Hoelbl A, 2006, BLOOD, V107, P4898, DOI 10.1182/blood-2005-09-3596; Hospital MA, 2017, ONCOTARGETS THER, V10, P607, DOI 10.2147/OTT.S103790; Hu XY, 2013, P NATL ACAD SCI USA, V110, P10213, DOI 10.1073/pnas.1221243110; Hughes Katherine, 2012, JAKSTAT, V1, P151, DOI 10.4161/jkst.19691; Joliot V, 2006, ONCOGENE, V25, P4573, DOI 10.1038/sj.onc.1209480; Jona A, 2013, EXP HEMATOL, V41, P995, DOI 10.1016/j.exphem.2013.09.014; Kaymaz BT, 2013, AM J BLOOD RES, V3, P58; Kayser S, 2014, LEUKEMIA LYMPHOMA, V55, P243, DOI 10.3109/10428194.2013.800198; Kemp RA, 2010, IMMUNOL CELL BIOL, V88, P213, DOI 10.1038/icb.2009.95; Kerenyi MA, 2008, BLOOD, V112, P3878, DOI 10.1182/blood-2008-02-138339; Kiu H, 2012, GROWTH FACTORS, V30, P88, DOI 10.3109/08977194.2012.660936; Kosova B, 2010, LEUKEMIA LYMPHOMA, V51, P1895, DOI 10.3109/10428194.2010.507830; Kuppers R, 2002, ADV CANCER RES, V84, P277, DOI 10.1016/S0065-230X(02)84009-X; Linher-Melville K, 2017, MOL CELL ENDOCRINOL, V451, P40, DOI 10.1016/j.mce.2017.02.014; Trung LQ, 2015, MOL NUTR FOOD RES, V59, P2143, DOI 10.1002/mnfr.201500166; Malin S, 2010, NAT IMMUNOL, V11, P171, DOI 10.1038/ni.1827; Martin-Rodriguez P, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01546; Martin-Subero JI, 2002, BLOOD, V99, P1474, DOI 10.1182/blood.V99.4.1474; Melo JV, 2004, HEMATOL ONCOL CLIN N, V18, P545, DOI 10.1016/j.hoc.2004.03.008; Miklossy G, 2013, NAT REV DRUG DISCOV, V12, P611, DOI 10.1038/nrd4088; Moslehi JJ, 2015, J CLIN ONCOL, V33, P4210, DOI 10.1200/JCO.2015.62.4718; Murray PJ, 2007, J IMMUNOL, V178, P2623, DOI 10.4049/jimmunol.178.5.2623; Nelson Erik A, 2012, Genes Cancer, V3, P503, DOI 10.1177/1947601912466555; Nelson EA, 2011, BLOOD, V117, P3421, DOI 10.1182/blood-2009-11-255232; O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev-med-051113-024537; O'Sullivan LA, 2007, MOL IMMUNOL, V44, P2497, DOI 10.1016/j.molimm.2006.11.025; Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192; Park JH, 2010, NAT IMMUNOL, V11, P257, DOI 10.1038/ni.1840; Peixoto F, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01233; Quentmeier H, 2006, LEUKEMIA, V20, P471, DOI 10.1038/sj.leu.2404081; Rawlings JS, 2004, J CELL SCI, V117, P1281, DOI 10.1242/jcs.00963; Re D, 2005, BLOOD, V105, P4553, DOI 10.1182/blood-2004-12-4750; Reich Nancy C, 2013, JAKSTAT, V2, pe27080, DOI 10.4161/jkst.27080; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Rosenwald A, 2003, J EXP MED, V198, P851, DOI 10.1084/jem.20031074; Scheeren FA, 2005, NAT IMMUNOL, V6, P303, DOI 10.1038/ni1172; Scheeren FA, 2008, BLOOD, V111, P4706, DOI 10.1182/blood-2007-08-105643; Schepers H, 2007, BLOOD, V110, P2880, DOI 10.1182/blood-2006-08-039073; Schindler C, 2007, J BIOL CHEM, V282, P20059, DOI 10.1074/jbc.R700016200; Schindler C, 2008, SEMIN CELL DEV BIOL, V19, P311, DOI 10.1016/j.semcdb.2008.08.010; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Socolovsky M, 2001, BLOOD, V98, P3261, DOI 10.1182/blood.V98.12.3261; Sonkin D, 2015, CANCER BIOMARK, V15, P79, DOI 10.3233/CBM-140434; Spivak JL, 2018, CURR TREAT OPTION ON, V19, DOI 10.1007/s11864-018-0529-x; Stark GR, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028555; Sun JP, 2011, LEUKEMIA RES, V35, P1402, DOI 10.1016/j.leukres.2011.06.018; Swaminathan S, 2015, NAT IMMUNOL, V16, P766, DOI 10.1038/ni.3160; Szelag M, 2016, CURR PROTEIN PEPT SC, V17, P135, DOI 10.2174/1389203716666151102103706; Tasian SK, 2012, BLOOD, V120, P833, DOI 10.1182/blood-2011-12-389932; Tsatsanis C, 2000, INT J MOL MED, V5, P583; Tsuruyama T, 2002, P NATL ACAD SCI USA, V99, P8253, DOI 10.1073/pnas.112202899; Vainchenker W, 2008, SEMIN CELL DEV BIOL, V19, P385, DOI 10.1016/j.semcdb.2008.07.002; Van Etten RA, 2007, ONCOGENE, V26, P6738, DOI 10.1038/sj.onc.1210758; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Walters DK, 2006, CANCER CELL, V10, P65, DOI 10.1016/j.ccr.2006.06.002; Walz C, 2012, BLOOD, V119, P3550, DOI 10.1182/blood-2011-12-397554; Wang XF, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0574-7; Wang Zhengqi, 2013, JAKSTAT, V2, pe27159, DOI 10.4161/jkst.27159; Warsch W, 2013, CELL CYCLE, V12, P1813, DOI 10.4161/cc.25116; Warsch W, 2012, ONCOTARGET, V3, P1669; Warsch W, 2011, BLOOD, V117, P3409, DOI 10.1182/blood-2009-10-248211; Wierenga ATJ, 2008, MOL CELL BIOL, V28, P6668, DOI 10.1128/MCB.01025-08; Wingelhofer B, 2018, LEUKEMIA, V32, P1135, DOI 10.1038/s41375-017-0005-9; Wiwi CA, 2004, GROWTH FACTORS, V22, P79, DOI 10.1080/08977190410001715172; Xiao WB, 2008, J CLIN INVEST, V118, P924, DOI 10.1172/JCI34013; Yan DQ, 2012, BLOOD, V119, P3539, DOI 10.1182/blood-2011-03-345215; Yanga S, 2008, EXP CELL RES, V314, P413, DOI 10.1016/j.yexcr.2007.09.002; Yao Z, 2007, BLOOD, V109, P4368, DOI 10.1182/blood-2006-11-055756; Zahn M, 2017, BLOOD, V129, P1480, DOI 10.1182/blood-2016-06-720516; Zhao RX, 2005, J BIOL CHEM, V280, P22788, DOI 10.1074/jbc.C500138200	90	24	24	3	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4657	4668		10.1038/s41388-019-0752-3	http://dx.doi.org/10.1038/s41388-019-0752-3			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30783189				2022-12-17	WOS:000471160500001
J	Yang, J; Guo, YQ; Lu, CJ; Zhang, RH; Wang, YY; Luo, L; Zhang, YL; Chu, CH; Wang, KJ; Obbad, S; Yan, WB; Li, X				Yang, Jian; Guo, Yuqi; Lu, Cuijie; Zhang, Ruohan; Wang, Yaoyu; Luo, Liang; Zhang, Yanli; Chu, Catherine H.; Wang, Katherine J.; Obbad, Sabrine; Yan, Wenbo; Li, Xin			Inhibition of Karyopherin beta 1 suppresses prostate cancer growth	ONCOGENE			English	Article							NF-KAPPA-B; TUMOR-CELL SURVIVAL; IMPORTIN BETA-1; NUCLEAR IMPORT; C-MYC; MESENCHYMAL TRANSITION; TRANSPORT RECEPTOR; METFORMIN TARGETS; POOR-PROGNOSIS; PROTEIN	Prostate cancer (PCa) initiation and progression requires activation of numerous oncogenic signaling pathways. Nuclear-cytoplasmic transport of oncogenic factors is mediated by Karyopherin proteins during cell transformation. However, the role of nuclear transporter proteins in PCa progression has not been well defined. Here, we report that the KPNB1, a key member of Karyopherin beta subunits, is highly expressed in advanced prostate cancers. Further study showed that targeting KPNB1 suppressed the proliferation of prostate cancer cells. The knockdown of KPNB1 reduced nuclear translocation of c-Myc, the expression of downstream cell cycle modulators, and phosphorylation of regulator of chromatin condensation 1 (RCC1), a key protein for spindle assembly during mitosis. Meanwhile, CHIP assay demonstrated the binding of c-Myc to KPNB1 promoter region, which indicated a positive feedback regulation of KPNB1 expression mediated by the c-Myc. In addition, NF-kappa B subunit p50 translocation to nuclei was blocked by KPNB1 inhibition, which led to an increase in apoptosis and a decrease in tumor sphere formation of PCa cells. Furthermore, subcutaneous xenograft tumor models with a stable knockdown of KPNB1 in C42B PCa cells validated that the inhibition of KPNB1 could suppress the growth of prostate tumor in vivo. Moreover, the intravenously administration of importazole, a specific inhibitor for KPNB1, effectively reduced PCa tumor size and weight in mice inoculated with PC3 PCa cells. In summary, our data established the functional link between KPNB1 and PCa prone c-Myc, NF-kB, and cell cycle modulators. More importantly, inhibition of KPNB1 could be a new therapeutic target for PCa treatment.	[Yang, Jian; Guo, Yuqi; Lu, Cuijie; Zhang, Ruohan; Wang, Yaoyu; Luo, Liang; Zhang, Yanli; Chu, Catherine H.; Wang, Katherine J.; Obbad, Sabrine; Yan, Wenbo; Li, Xin] NYU, Coll Dent, Dept Basic Sci & Craniofacial Biol, New York, NY 10010 USA; [Li, Xin] NYU, Langone Med Ctr, Dept Urol, New York, NY 10016 USA; [Li, Xin] NYU, Langone Med Ctr, Perlmutter Canc Inst, New York, NY 10016 USA	New York University; New York University; NYU Langone Medical Center; New York University; NYU Langone Medical Center	Li, X (corresponding author), NYU, Coll Dent, Dept Basic Sci & Craniofacial Biol, New York, NY 10010 USA.; Li, X (corresponding author), NYU, Langone Med Ctr, Dept Urol, New York, NY 10016 USA.; Li, X (corresponding author), NYU, Langone Med Ctr, Perlmutter Canc Inst, New York, NY 10016 USA.	xl15@nyu.edu	yan, wenbo/GXV-2795-2022	Li, Xin/0000-0002-7414-5734	NYU CSCB Pilot Study Award; National Institutes of Health [R01CA180277, R01DE025992, R01DE027074]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE025992, R01DE027074] Funding Source: NIH RePORTER	NYU CSCB Pilot Study Award; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This study was partly supported by NYU CSCB Pilot Study Award to JY, National Institutes of Health grants R01CA180277, R01DE025992 and R01DE027074 to XL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aggarwal A, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/476357; Akinyeke T, 2013, CARCINOGENESIS, V34, P2823, DOI 10.1093/carcin/bgt307; Alshareeda AT, 2015, BRIT J CANCER, V112, P1929, DOI 10.1038/bjc.2015.165; Altan B, 2013, CARCINOGENESIS, V34, P2314, DOI 10.1093/carcin/bgt214; Angus L, 2014, CARCINOGENESIS, V35, P1121, DOI 10.1093/carcin/bgt491; Bretones G, 2015, BBA-GENE REGUL MECH, V1849, P506, DOI 10.1016/j.bbagrm.2014.03.013; Cai YX, 2016, DIGEST DIS SCI, V61, P747, DOI 10.1007/s10620-015-3948-6; Chen T, 2007, NAT CELL BIOL, V9, P596, DOI 10.1038/ncb1572; Elgogary A, 2016, P NATL ACAD SCI USA, V113, pE5328, DOI 10.1073/pnas.1611406113; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Fagerlund R, 2005, J BIOL CHEM, V280, P15942, DOI 10.1074/jbc.M500814200; Gagne B, 2017, TRAFFIC, V18, P362, DOI 10.1111/tra.12480; Ghildyal R, 2005, BIOCHEMISTRY-US, V44, P12887, DOI 10.1021/bi050701e; Gurel B, 2008, MODERN PATHOL, V21, P1156, DOI 10.1038/modpathol.2008.111; Ha S, 2018, CHEMBIOCHEM, V19, P131, DOI 10.1002/cbic.201700489; Hadjebi O, 2008, BBA-MOL CELL RES, V1783, P1467, DOI 10.1016/j.bbamcr.2008.03.015; He XL, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0422-1; Hood FE, 2007, J CELL SCI, V120, P3436, DOI 10.1242/jcs.009092; Huang L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.256; Huang L, 2018, J CANCER, V9, P157, DOI 10.7150/jca.20879; Hutchins JRA, 2004, CURR BIOL, V14, P1099, DOI 10.1016/j.cub.2004.05.021; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Koch HB, 2007, CELL CYCLE, V6, P205, DOI 10.4161/cc.6.2.3742; Kodama M, 2017, P NATL ACAD SCI USA, V114, pE7301, DOI 10.1073/pnas.1705441114; Koh Cheryl M, 2010, Genes Cancer, V1, P617, DOI 10.1177/1947601910379132; Kuusisto HV, 2015, BBA-MOL CELL RES, V1853, P1870, DOI 10.1016/j.bbamcr.2015.05.002; Laurila E, 2014, EXP CELL RES, V322, P159, DOI 10.1016/j.yexcr.2013.11.014; Liang PZ, 2013, TRAFFIC, V14, P1132, DOI 10.1111/tra.12097; Lo HW, 2006, J CELL BIOCHEM, V98, P1570, DOI 10.1002/jcb.20876; Lu T, 2016, BIOCHEM BIOPH RES CO, V478, P1189, DOI 10.1016/j.bbrc.2016.08.093; Lundberg L, 2013, ANTIVIR RES, V100, P662, DOI 10.1016/j.antiviral.2013.10.004; Mahipal A, 2016, PHARMACOL THERAPEUT, V164, P135, DOI 10.1016/j.pharmthera.2016.03.020; Martens-de Kemp SR, 2013, CLIN CANCER RES, V19, P1994, DOI 10.1158/1078-0432.CCR-12-2539; Moore WJ, 2002, CURR BIOL, V12, P1442, DOI 10.1016/S0960-9822(02)01076-X; Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588; Qin ZH, 1999, J NEUROSCI, V19, P4023; Schmitz MHA, 2010, NAT CELL BIOL, V12, P886, DOI 10.1038/ncb2092; Shen SH, 2017, ONCOTARGET, V8, P41432, DOI 10.18632/oncotarget.18186; Soderholm JF, 2011, ACS CHEM BIOL, V6, P700, DOI 10.1021/cb2000296; Stelma T, 2016, IUBMB LIFE, V68, P268, DOI 10.1002/iub.1484; THALMANN GN, 1994, CANCER RES, V54, P2577; van der Watt PJ, 2016, MOL CANCER THER, V15, P560, DOI 10.1158/1535-7163.MCT-15-0052; van der Watt PJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027723; Vuorinen EM, 2017, BBA-MOL BASIS DIS, V1863, P211, DOI 10.1016/j.bbadis.2016.09.015; Wang HJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep13072; Wang J, 2016, ONCOL REP, V36, P441, DOI 10.3892/or.2016.4830; Wang SX, 2015, J PHYSIOL BIOCHEM, V71, P763, DOI 10.1007/s13105-015-0440-x; Watson PA, 2005, CANCER RES, V65, P11565, DOI 10.1158/0008-5472.CAN-05-3441; Winkler J, 2014, HEPATOLOGY, V60, P884, DOI 10.1002/hep.27207; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319; Yan WQ, 2015, CELL SIGNAL, V27, P851, DOI 10.1016/j.cellsig.2015.01.013; Yang J, 2017, ONCOGENE, V36, P2868, DOI 10.1038/onc.2016.440; Yang L, 2015, ASIA PAC J OPER RES, V32, DOI 10.1142/S0217595915400084; Zhang PY, 2014, J PATHOL, V232, P308, DOI 10.1002/path.4294	54	24	26	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4700	4714		10.1038/s41388-019-0745-2	http://dx.doi.org/10.1038/s41388-019-0745-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30742095	Green Accepted			2022-12-17	WOS:000471160500004
J	Zhang, J; Jia, L; Liu, TF; Yip, YL; Tang, WC; Lin, WT; Deng, W; Lo, KW; You, CP; Lung, ML; Lung, HL; Cheung, ALM; Tsao, SW; Tsang, CM				Zhang, Jun; Jia, Lin; Liu, Tengfei; Yip, Yim Ling; Tang, Wing Chung; Lin, Weitao; Deng, Wen; Lo, Kwok Wai; You, Chanping; Lung, Maria Li; Lung, Hong Lok; Cheung, Annie Lai-Man; Tsao, Sai Wah; Tsang, Chi Man			mTORC2-mediated PDHE1 alpha nuclear translocation links EBV-LMP1 reprogrammed glucose metabolism to cancer metastasis in nasopharyngeal carcinoma	ONCOGENE			English	Article							EPSTEIN-BARR-VIRUS; EPITHELIAL-CELLS; EXPRESSION; SNAIL; IMMORTALIZATION; TRANSCRIPTION; GLYCOLYSIS; ACTIVATION; INFECTION; GROWTH	EBV infection of preinvasive nasopharyngeal epithelium is believed to be an initiation step during pathogenesis of nasopharyngeal carcinoma (NPC), but the mechanisms remain poorly understood. Here we report a novel mechanism driving NPC metastasis through the EBV-encoded LMP1-mediated metabolic reprogramming, via activation of IGF1-mTORC2 signaling and nuclear acetylation of the Snail promoter by the PDHE1 alpha, an enzyme involved in glucose metabolism. Mechanistically, EBV-LMP1 increases the cellular secretion of IGF1 which promotes phosphorylation of IGF1R to activate mTORC2/AKT signaling linking glucose metabolism to cell motility. LMP1 expression facilitates translocation of mitochondrial PDHE1a into the nucleus in a phosphorylation-dependent manner at Ser(293) residue. Functionally, nuclear PDHE1a promotes H3K9 acetylation on the Snail promoter to enhance cell motility, thereby driving cancer metastasis. Importantly, the IGF1/mTORC2/PDHE1 alpha/Snail axis correlates significantly with disease progression and poor prognosis in NPC patients. This study highlights the functional importance of IGF1-mTORC2-PDHE1 alpha signaling mediated by EBV-LMP1 in NPC pathogenesis.	[Zhang, Jun; Jia, Lin; Liu, Tengfei; Yip, Yim Ling; Tang, Wing Chung; Lin, Weitao; Deng, Wen; You, Chanping; Cheung, Annie Lai-Man; Tsao, Sai Wah; Tsang, Chi Man] Univ Hong Kong, Sch Biomed Sci, Li Ka Shing Fac Med, Hong Kong, Peoples R China; [Deng, Wen] Univ Hong Kong, Sch Nursing, Li Ka Shing Fac Med, Hong Kong, Peoples R China; [Lo, Kwok Wai] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, State Key Lab Translat Oncol, Hong Kong, Peoples R China; [Lung, Maria Li] Univ Hong Kong, Li Ka Shing Fac Med, Dept Clin Oncol, Hong Kong, Peoples R China; [Lung, Maria Li; Tsao, Sai Wah] Univ Hong Kong, Ctr Canc Res, Hong Kong, Peoples R China; [Lung, Hong Lok] Hong Kong Baptist Univ, Dept Biol, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; Chinese University of Hong Kong; University of Hong Kong; University of Hong Kong; Hong Kong Baptist University	Tsao, SW; Tsang, CM (corresponding author), Univ Hong Kong, Sch Biomed Sci, Li Ka Shing Fac Med, Hong Kong, Peoples R China.; Tsao, SW (corresponding author), Univ Hong Kong, Ctr Canc Res, Hong Kong, Peoples R China.	gswtsao@hku.hk; annatsan@hku.hk	ZHANG, Jun/V-5275-2018	ZHANG, Jun/0000-0002-6523-7573; Lin, Weitao/0000-0003-4385-9897	Research Grants Council, Area of Excellence NPC [AoE/M 06/08]; Theme-Based Research Scheme [T12-401/13-R]; Collaborative Research Fund [C7027-16G, C4001-18GF, C1013-15G]; General Research Fund [14117316, 17161116, 17120814, 779713, 779312, 17110315, 17111516]; Health and Medical Research Fund [04151726, 05162386, 13142201]	Research Grants Council, Area of Excellence NPC; Theme-Based Research Scheme; Collaborative Research Fund; General Research Fund; Health and Medical Research Fund	We acknowledge the Faculty Core Facility members of HKU and Mr. Tony Chan for technical supports. SWT and KWL are funded by the Research Grants Council, Area of Excellence NPC (Grant No. AoE/M 06/08), Theme-Based Research Scheme (T12-401/13-R), Collaborative Research Fund (C7027-16G, C4001-18GF and C1013-15G), General Research Fund (14117316, 17161116, 17120814, 779713, and 779312), and Health and Medical Research Fund (04151726). CMT is funded by the Health and Medical Research Fund (05162386 and 13142201) and General Research Fund (17110315 and 17111516).	Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Cai TT, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006503; Chae YC, 2016, CANCER CELL, V30, P257, DOI 10.1016/j.ccell.2016.07.004; Chua MLK, 2016, LANCET, V387, P1012, DOI 10.1016/S0140-6736(15)00055-0; Dimauro Ivan, 2012, BMC Res Notes, V5, P513, DOI 10.1186/1756-0500-5-513; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hamabe A, 2014, P NATL ACAD SCI USA, V111, P15526, DOI 10.1073/pnas.1407717111; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hecht I, 2015, SCI REP-UK, V5, DOI 10.1038/srep13538; Horikawa T, 2011, BRIT J CANCER, V104, P1160, DOI 10.1038/bjc.2011.38; Levy P, 2016, ONCOGENE, V35, P4155, DOI 10.1038/onc.2015.479; Li HM, 2006, INT J CANCER, V119, P1567, DOI 10.1002/ijc.22032; Li Y., 2017, NAT COMMUN, V8; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Lin WT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06889-5; Liu HP, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002690; Lo AKF, 2018, J PATHOL, V246, P180, DOI 10.1002/path.5130; Lo AKF, 2015, J PATHOL, V237, P238, DOI 10.1002/path.4575; McFadden K, 2016, P NATL ACAD SCI USA, V113, pE782, DOI 10.1073/pnas.1517141113; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; Nagaraj R, 2017, CELL, V168, P210, DOI 10.1016/j.cell.2016.12.026; Niedobitek G, 1992, Diagn Mol Pathol, V1, P103, DOI 10.1097/00019606-199203000-00016; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; Ren XY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14053; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Shair KHY, 2009, CANCER RES, V69, P5734, DOI 10.1158/0008-5472.CAN-09-0468; Sommermann TG, 2011, CANCER RES, V71, P7291, DOI 10.1158/0008-5472.CAN-11-1715; Stacpoole PW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx071; Sutendra G, 2014, CELL, V158, P84, DOI 10.1016/j.cell.2014.04.046; Tsang CM, 2012, P NATL ACAD SCI USA, V109, pE3473, DOI 10.1073/pnas.1202637109; Tsang CM, 2010, INT J CANCER, V127, P1570, DOI 10.1002/ijc.25173; Tsao SW, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0270; Tsao SW, 2015, J PATHOL, V235, P323, DOI 10.1002/path.4448; Tsao SW, 2002, SEMIN CANCER BIOL, V12, P473, DOI 10.1016/S1044579X02000901; Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2; Tworkoski K, 2015, J VIROL, V89, P2590, DOI 10.1128/JVI.02921-14; Wang XM, 2016, CELL RES, V26, P1, DOI 10.1038/cr.2015.134; Wang YF, 2013, CURR CANCER DRUG TAR, V13, P963, DOI 10.2174/15680096113136660102; Xiao L, 2014, ONCOGENE, V33, P4568, DOI 10.1038/onc.2014.32; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Zhang D, 2017, ONCOGENE, V36, P2900, DOI 10.1038/onc.2016.446; Zhang J, 2017, ADV EXP MED BIOL, V1018, P75, DOI 10.1007/978-981-10-5765-6_6; Zhang J, 2017, J VIROL, V91, DOI 10.1128/JVI.02168-16; Zhu DD, 2016, INT J CANCER, V138, P1175, DOI 10.1002/ijc.29850	46	24	25	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4669	4684		10.1038/s41388-019-0749-y	http://dx.doi.org/10.1038/s41388-019-0749-y			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30745576	hybrid, Green Published			2022-12-17	WOS:000471160500002
J	Fischer, M				Fischer, Martin			Conservation and divergence of the p53 gene regulatory network between mice and humans	ONCOGENE			English	Article							CELL-CYCLE CHECKPOINT; DNA-POLYMERASE-ETA; TRANSCRIPTIONAL REPRESSION; BINDING-SITES; CHIP-SEQ; TARGET; MOUSE; DREAM; PATHWAY; IDENTIFICATION	Understanding the p53 tumor suppressor pathway remains crucial for the design of anticancer strategies. Studies in human tumors and mouse models help to unravel the molecular mechanisms that underlie the p53 signaling pathway. Yet, the p53 gene regulatory network (GRN) is not the same in mice and humans. The comparison of the regulatory networks of p53 in mice and humans reveals that gene up-and down-regulation by p53 are distinctly affected during evolution. Importantly, gene up-regulation by p53 underwent more rapid evolution and gene down-regulation has been evolutionarily constrained. This difference stems from the two major mechanisms employed by p53 to regulate gene expression: up-regulation through direct p53 target gene binding and indirect down-regulation through the p53-p21-DREAM pathway. More than 1000 genes have been identified to differ in their p53-dependent expression between mice and humans. Analysis of p53 gene expression profiles and p53 binding data reveal that turnover of p53 binding sites is the major mechanism underlying extensive variation in p53-dependent gene up-regulation. Only a core set of high-confidence genes appears to be directly regulated by p53 in both species. In contrast to up-regulation, p53-induced down-regulation is well conserved between mice and humans and controls cell cycle genes. Here a curated data set is provided that extends the previously established web-atlas at www.targetgenereg.org to assess the p53 response of any human gene of interest and its mouse ortholog. Taken together, the analysis reveals a limited translation potential from mouse models to humans for the p53 GRN.	[Fischer, Martin] Fritz Lipmann Inst, Leibniz Inst Aging, Computat Biol Grp, D-07745 Jena, Germany; [Fischer, Martin] Univ Leipzig, Sch Med, Mol Oncol Grp, D-04103 Leipzig, Germany	Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); Leipzig University	Fischer, M (corresponding author), Fritz Lipmann Inst, Leibniz Inst Aging, Computat Biol Grp, D-07745 Jena, Germany.; Fischer, M (corresponding author), Univ Leipzig, Sch Med, Mol Oncol Grp, D-04103 Leipzig, Germany.	Martin.Fischer@leibniz-fli.de	Fischer, Martin/I-4825-2014	Fischer, Martin/0000-0002-3429-1876	German Research Foundation (DFG) [FI 1993/2-1]; University of Leipzig Medical School; Federal Government of Germany; State or Thuringia; AddOn Fellowship for Interdisciplinary Science in Systems Biology from the Joachim Herz Stiftung	German Research Foundation (DFG)(German Research Foundation (DFG)); University of Leipzig Medical School; Federal Government of Germany; State or Thuringia; AddOn Fellowship for Interdisciplinary Science in Systems Biology from the Joachim Herz Stiftung	This work was supported through research grant FI 1993/2-1 from the German Research Foundation (DFG), a junior research grant from the University of Leipzig Medical School and through an AddOn Fellowship for Interdisciplinary Science in Systems Biology from the Joachim Herz Stiftung. The FLI is a member of the Leibniz Association and is financially supported by the Federal Government of Germany and the State or Thuringia.	Agarwala R, 2018, NUCLEIC ACIDS RES, V46, pD8, DOI [10.1093/nar/gkv1290, 10.1093/nar/gkx1095]; Andrysik Z, 2017, GENOME RES, V27, P1645, DOI 10.1101/gr.220533.117; Assaily W, 2011, MOL CELL, V44, P491, DOI 10.1016/j.molcel.2011.08.038; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bohlig L, 2011, NUCLEIC ACIDS RES, V39, P440, DOI 10.1093/nar/gkq796; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; Broz DK, 2013, GENE DEV, V27, P1016, DOI 10.1101/gad.212282.112; Carvajal LA, 2012, GENE DEV, V26, P1533, DOI 10.1101/gad.184911.111; Chen YW, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-2-r11; Cheng Y, 2014, NATURE, V515, P371, DOI 10.1038/nature13985; Collavin L, 2000, FEBS LETT, V481, P57, DOI 10.1016/S0014-5793(00)01969-4; Conboy CM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001061; Dimitrova N, 2014, MOL CELL, V54, P777, DOI 10.1016/j.molcel.2014.04.025; Engeland K, 2018, CELL DEATH DIFFER, V25, P114, DOI 10.1038/cdd.2017.172; Fischer M, 2017, ONCOGENE, V36, P3943, DOI 10.1038/onc.2016.502; Fischer M, 2017, CRIT REV BIOCHEM MOL, V52, P638, DOI 10.1080/10409238.2017.1360836; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P6070, DOI 10.1093/nar/gkw523; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P164, DOI 10.1093/nar/gkv927; Fischer M, 2015, ONCOTARGET, V6, P41402, DOI 10.18632/oncotarget.6356; Fischer M, 2014, CELL CYCLE, V13, P3037, DOI 10.4161/15384101.2014.949083; Fischer M, 2014, NUCLEIC ACIDS RES, V42, P163, DOI 10.1093/nar/gkt849; Fischer M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063187; Gambino V, 2013, AGING CELL, V12, P435, DOI 10.1111/acel.12060; Horvath MM, 2007, PLOS GENET, V3, P1284, DOI 10.1371/journal.pgen.0030127; Hsieh WJ, 2008, BIOCHEM BIOPH RES CO, V369, P567, DOI 10.1016/j.bbrc.2008.02.047; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Jegga AG, 2008, P NATL ACAD SCI USA, V105, P944, DOI 10.1073/pnas.0704694105; Kaiser AM, 2018, CELL DEATH DIFFER, V25, P93, DOI 10.1038/cdd.2017.171; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Lange SS, 2011, NAT REV CANCER, V11, P96, DOI 10.1038/nrc2998; Lee KH, 2010, P NATL ACAD SCI USA, V107, P69, DOI 10.1073/pnas.0909734107; Lerner LK, 2017, NUCLEIC ACIDS RES, V45, P1270, DOI 10.1093/nar/gkw1196; Lion M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116177; Liu G, 2006, MOL CELL BIOL, V26, P1398, DOI 10.1128/MCB.26.4.1398-1413.2006; Lo PK, 1999, ONCOGENE, V18, P7765, DOI 10.1038/sj.onc.1203167; Lozano G, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001115; Marin-Bejar O, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-9-r104; Mei SL, 2017, NUCLEIC ACIDS RES, V45, pD658, DOI 10.1093/nar/gkw983; Muller GA, 2017, ONCOTARGET, V8, P97736, DOI 10.18632/oncotarget.10888; Muller GA, 2014, NUCLEIC ACIDS RES, V42, P10331, DOI 10.1093/nar/gku696; Muller GA, 2012, NUCLEIC ACIDS RES, V40, P1561, DOI 10.1093/nar/gkr793; Nakaya N, 2007, MOL CELL BIOL, V27, P5430, DOI 10.1128/MCB.00551-06; Nitta KR, 2015, ELIFE, V4, DOI 10.7554/eLife.04837; Quaas M, 2012, CELL CYCLE, V11, P4661, DOI 10.4161/cc.22917; Rutkowski R, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001131; Sanchez-Macedo N, 2013, CELL DEATH DIFFER, V20, P659, DOI 10.1038/cdd.2012.168; Sethi I, 2017, NUCLEIC ACIDS RES, V45, P8208, DOI 10.1093/nar/gkx416; Stergachis AB, 2014, NATURE, V515, P365, DOI 10.1038/nature13972; Stewart AJ, 2012, GENETICS, V192, P973, DOI 10.1534/genetics.112.143370; Stewart-Ornstein J, 2017, CELL SYST, V5, P410, DOI 10.1016/j.cels.2017.09.012; Sullivan KD, 2018, CELL DEATH DIFFER, V25, P133, DOI 10.1038/cdd.2017.174; Tan T, 2002, MOL CELL BIOL, V22, P3247, DOI 10.1128/MCB.22.10.3247-3254.2002; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Timofeev O, 2013, CELL REP, V3, P1512, DOI 10.1016/j.celrep.2013.04.008; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tonelli C, 2015, ONCOTARGET, V6, P24611, DOI 10.18632/oncotarget.5232; Tugrul M, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005639; Velasco-Miguel S, 2003, DNA REPAIR, V2, P91, DOI 10.1016/S1568-7864(02)00189-1; Vierstra J, 2014, SCIENCE, V346, P1007, DOI 10.1126/science.1246426; Wang S, 2013, NAT PROTOC, V8, P2502, DOI 10.1038/nprot.2013.150; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Younger ST, 2015, NUCLEIC ACIDS RES, V43, P4447, DOI 10.1093/nar/gkv284; Yue F, 2014, NATURE, V515, P355, DOI 10.1038/nature13992; Zhang XY, 2013, CELL CYCLE, V12, P1279, DOI 10.4161/cc.24364	64	24	26	3	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4095	4109		10.1038/s41388-019-0706-9	http://dx.doi.org/10.1038/s41388-019-0706-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30710145	Green Published, hybrid			2022-12-17	WOS:000468740200009
J	Jiang, Y; Su, SY; Zhang, YQ; Qian, JY; Liu, PD				Jiang, Yao; Su, Siyuan; Zhang, Yanqiong; Qian, Jiayi; Liu, Pengda			Control of mTOR signaling by ubiquitin	ONCOGENE			English	Review							REGULATES AKT UBIQUITINATION; PROTEIN PHOSPHATASE 2A; E3 LIGASE; TUMOR-SUPPRESSOR; BETA-TRCP; PROTEASOMAL DEGRADATION; MEDIATED DEGRADATION; PTEN; PROMOTES; COMPLEX	The evolutionarily conserved mTOR signaling pathway plays essential roles in cell growth, proliferation, metabolism and responses to cellular stresses. Hyperactivation of the mTOR signaling is observed in virtually all solid tumors and has been an attractive drug target. In addition to changes at genetic levels, aberrant activation of the mTOR signaling is also a result from dysregulated posttranslational modifications on key pathway members, such as phosphorylation that has been extensively studied. Emerging evidence also supports a critical role for ubiquitin-mediated modifications in dynamically regulating the mTOR signaling pathway, while a comprehensive review for relevant studies is missing. In this review, we will summarize characterized ubiquitination events on major mTOR signaling components, their modifying E3 ubiquitin ligases, deubiquitinases and corresponding pathophysiological functions. We will also reveal methodologies that have been used to identify E3 ligases or DUBs to facilitate the search for yet-to-be discovered ubiquitin-mediated regulatory mechanisms in mTOR signaling. We hope that our review and perspectives provide rationales and strategies to target ubiquitination for inhibiting mTOR signaling to treat human diseases.	[Jiang, Yao] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Ctr Canc, Wuhan 430022, Hubei, Peoples R China; [Jiang, Yao; Su, Siyuan; Zhang, Yanqiong; Qian, Jiayi; Liu, Pengda] Univ N Carolina, Dept Biochem & Biophys, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	Huazhong University of Science & Technology; University of North Carolina; University of North Carolina Chapel Hill	Liu, PD (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	pengda_liu@med.unc.edu		Su, Siyuan/0000-0002-8816-9577	NIH [R00CA181342]; V Foundation Research Scholar Grant [V2018-009]; UNC IBM Junior Faculty Development Award; UNC University Cancer Research Fund; NATIONAL CANCER INSTITUTE [R00CA181342] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); V Foundation Research Scholar Grant; UNC IBM Junior Faculty Development Award(International Business Machines (IBM)); UNC University Cancer Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors sincerely apologize to all those colleagues whose important work were not cited in this review owing to space limitations, especially many prominent and pioneer work in the mTOR field. We thank other Liu members for critical reading of the manuscript and helpful discussions. This work was supported by the NIH grants (R00CA181342 to PL), a V Foundation Research Scholar Grant (V2018-009 to PL), a UNC IBM Junior Faculty Development Award (PL) and the UNC University Cancer Research Fund (PL).	Agrawal P, 2012, J BIOL CHEM, V287, P21164, DOI 10.1074/jbc.M111.328021; Bachelder RE, 2001, J BIOL CHEM, V276, P34702, DOI 10.1074/jbc.M102806200; Bae SH, 2012, CELL RES, V22, P873, DOI 10.1038/cr.2012.38; Bar-Peled L, 2013, SCIENCE, V340, P1100, DOI 10.1126/science.1232044; Belova L, 2006, BIOCHEM J, V400, P235, DOI 10.1042/BJ20060905; Bisson JA, 2015, DEV BIOL, V398, P80, DOI 10.1016/j.ydbio.2014.11.015; Brand C, 2010, BBA-MOL CELL RES, V1803, P1265, DOI 10.1016/j.bbamcr.2010.07.006; Bridges CR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00149-0; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Chan CH, 2012, CELL, V149, P1098, DOI 10.1016/j.cell.2012.02.065; Chano T, 2006, INT J MOL MED, V18, P425; Chen J, 2018, NATURE, V557, P585, DOI 10.1038/s41586-018-0128-9; Chen Z, 2018, MOL THER-NUCL ACIDS, V10, P254, DOI 10.1016/j.omtn.2017.12.010; Cheng L, 2018, INT J ONCOL, V53, P203, DOI 10.3892/ijo.2018.4377; Chu J, 2017, MOL PSYCHIATR, V22, P1002, DOI 10.1038/mp.2016.214; Davis RJ, 2014, CANCER CELL, V26, P455, DOI 10.1016/j.ccell.2014.09.013; de Araujo MEG, 2013, J BIOL CHEM, V288, P18228, DOI 10.1074/jbc.M112.349480; Dehan E, 2009, MOL CELL, V33, P109, DOI 10.1016/j.molcel.2008.12.020; Deng L, 2015, MOL CELL, V58, P804, DOI 10.1016/j.molcel.2015.03.033; Dickey CA, 2008, P NATL ACAD SCI USA, V105, P3622, DOI 10.1073/pnas.0709180105; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Duan SS, 2011, MOL CELL, V44, P317, DOI 10.1016/j.molcel.2011.09.005; Emanuele MJ, 2011, CELL, V147, P459, DOI 10.1016/j.cell.2011.09.019; Fan CD, 2013, J BIOL CHEM, V288, P1674, DOI 10.1074/jbc.M112.416339; Gao DM, 2010, MOL CELL, V39, P797, DOI 10.1016/j.molcel.2010.08.016; Ghosh P, 2008, CELL CYCLE, V7, P373, DOI 10.4161/cc.7.3.5267; Guan F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146553; Guo P, 2018, ONCOGENE, V37, P478, DOI 10.1038/onc.2017.349; Hamidi A, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aal4186; Han S, 2008, CELL SIGNAL, V20, P1084, DOI 10.1016/j.cellsig.2008.01.020; Harraz MM, 2016, MOL PSYCHIATR, V21, P313, DOI [10.1038/mp.2015.211, 10.1038/mp.2015211]; Hoffmeister M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116150; Hu J, 2008, GENE DEV, V22, P866, DOI 10.1101/gad.1624008; Hussain S, 2013, MOL CELL BIOL, V33, P1188, DOI 10.1128/MCB.01389-12; Iturrioz X, 2007, FEBS LETT, V581, P1397, DOI 10.1016/j.febslet.2007.02.059; Jiang H, 2018, CELL METAB, V28, P7, DOI 10.1016/j.cmet.2018.06.018; Jin GX, 2015, MOL CELL, V58, P989, DOI 10.1016/j.molcel.2015.05.010; Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304; Joo HM, 2011, EUR J CELL BIOL, V90, P420, DOI 10.1016/j.ejcb.2010.12.001; Kim JH, 2018, EMBO REP, V19, DOI 10.15252/embr.201744378; Kim SY, 2015, ONCOTARGET, V6, P33382, DOI 10.18632/oncotarget.5407; Ko HR, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.79; Koo J, 2015, J BIOL CHEM, V290, P14120, DOI 10.1074/jbc.M114.633057; Kuchay S, 2018, CELL REP, V25, P833, DOI 10.1016/j.celrep.2018.09.088; Kuchay S, 2017, NATURE, V546, P554, DOI 10.1038/nature22965; Kuchay S, 2013, NAT CELL BIOL, V15, P472, DOI 10.1038/ncb2731; Lee MS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8769; Leng SH, 2010, J ENDOCRINOL, V206, P171, DOI 10.1677/JOE-09-0456; Li T, 2017, J NEUROSCI, V37, P12123, DOI 10.1523/JNEUROSCI.1751-17.2017; Li W, 2013, CANCER RES, V73, P6938, DOI 10.1158/0008-5472.CAN-13-0913; Li X, 2009, MOL CELL BIOL, V29, P6192, DOI 10.1128/MCB.00681-09; Lim JH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1776; Linares JF, 2013, MOL CELL, V51, P283, DOI 10.1016/j.molcel.2013.06.020; Liu PD, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aar8133; Liu PD, 2014, NATURE, V508, P541, DOI 10.1038/nature13079; Lu C, 2018, CANCER LETT, V436, P139, DOI 10.1016/j.canlet.2018.07.032; Maddika S, 2011, NAT CELL BIOL, V13, P728, DOI 10.1038/ncb2240; Mao JH, 2008, SCIENCE, V321, P1499, DOI 10.1126/science.1162981; Meszaros B, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aak9982; Nagashima K, 2017, ONCOTARGET, V8, P9947, DOI 10.18632/oncotarget.14221; Oberg EA, 2012, J BIOL CHEM, V287, P43378, DOI 10.1074/jbc.M112.420281; Park D, 2014, CELL SIGNAL, V26, P2122, DOI 10.1016/j.cellsig.2014.06.010; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Ruschmann J, 2010, EXP HEMATOL, V38, P392, DOI 10.1016/j.exphem.2010.03.010; Sacco JJ, 2014, ONCOGENE, V33, P4265, DOI 10.1038/onc.2013.512; Sattler M, 1997, ONCOGENE, V15, P2379, DOI 10.1038/sj.onc.1201422; Schoenebeck B, 2005, MOL CELL NEUROSCI, V30, P249, DOI 10.1016/j.mcn.2005.07.017; Seo G, 2011, FREE RADICAL RES, V45, P389, DOI 10.3109/10715762.2010.535530; Shi J, 2011, DEV CELL, V21, P835, DOI 10.1016/j.devcel.2011.09.011; Shimizu K, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah4117; Skaar JR, 2013, NAT REV MOL CELL BIO, V14, P369, DOI 10.1038/nrm3582; Su CH, 2011, CELL SIGNAL, V23, P1824, DOI 10.1016/j.cellsig.2011.06.018; Suizu F, 2009, DEV CELL, V17, P800, DOI 10.1016/j.devcel.2009.09.007; Sun J, 2018, MOL CELL BIOCHEM, V441, P1, DOI 10.1007/s11010-017-3170-2; Tan MJ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0567-6; Tatebe H, 2017, BIOMOLECULES, V7, DOI 10.3390/biom7040077; Trockenbacher A, 2001, NAT GENET, V29, P287, DOI 10.1038/ng762; Tsun ZY, 2013, MOL CELL, V52, P495, DOI 10.1016/j.molcel.2013.09.016; Uras IZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031003; Van Themsche C, 2009, J BIOL CHEM, V284, P20462, DOI 10.1074/jbc.C109.009522; Wakatsuki S, 2011, NAT CELL BIOL, V13, P1415, DOI 10.1038/ncb2373; Wang B, 2017, NATURE, V545, P365, DOI 10.1038/nature22344; Wang FF, 2017, CANCER LETT, V388, P85, DOI 10.1016/j.canlet.2016.11.031; Wang M, 2017, ONCOTARGET, V8, P89692, DOI 10.18632/oncotarget.21058; Wang ZX, 2016, J BIOL CHEM, V291, P17467, DOI 10.1074/jbc.M116.726083; Wong JJL, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001657; Wu Y, 2014, ANTIOXID REDOX SIGN, V20, P1382, DOI 10.1089/ars.2013.5498; Xiang T, 2008, CANCER RES, V68, P10040, DOI 10.1158/0008-5472.CAN-08-3009; Xu XS, 2008, MOL CELL, V30, P403, DOI 10.1016/j.molcel.2008.03.009; Yang MJ, 2011, J EXP MED, V208, P2099, DOI 10.1084/jem.20102667; Yang WL, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003197; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065; Yoshihara H, 2012, BIOCHEM BIOPH RES CO, V423, P122, DOI 10.1016/j.bbrc.2012.05.093; Yu C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9017; Yuan L, 2015, NAT CELL BIOL, V17, P1169, DOI 10.1038/ncb3218; Zhang JD, 2017, FEBS LETT, V591, P145, DOI 10.1002/1873-3468.12521; Zhang JS, 2013, NAT CELL BIOL, V15, P1486, DOI 10.1038/ncb2874; Zhao LL, 2018, J BIOL CHEM, V293, P4883, DOI 10.1074/jbc.M117.809533; Zhou RF, 2005, J BIOL CHEM, V280, P4518, DOI 10.1074/jbc.M411053200	100	24	24	2	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					3989	4001		10.1038/s41388-019-0713-x	http://dx.doi.org/10.1038/s41388-019-0713-x			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30705402	Green Accepted			2022-12-17	WOS:000468740200002
J	Karvonen, H; Perttila, R; Niininen, W; Hautanen, V; Barker, H; Murumagi, A; Heckman, CA; Ungureanu, D				Karvonen, Hanna; Perttila, Robert; Niininen, Wilhelmiina; Hautanen, Veera; Barker, Harlan; Murumagi, Astrid; Heckman, Caroline A.; Ungureanu, Daniela			Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; STEM-CELLS; DISEASE; IDENTIFICATION; HEMATOPOIESIS; CHEMOTAXIS; MECHANISMS; INHIBITORS; CROSSTALK; PATHWAYS	B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with TCF3-PBX1 fusion gene expression has constitutively elevated levels of Wnt16b and ROR1 (receptor tyrosine kinase-like orphan receptor), a ligand and a receptor from the Wnt signaling pathway, respectively. Although survival rate is usually high after the initial chemotherapy, many TCF3-PBX1 BCP-ALL patients relapse and subsequently develop treatment resistance, resulting in poor prognosis. Here, we aimed to investigate the molecular signaling associated with Wnt16b and ROR1 overexpression in TCF3-PBX1 cell lines and primary samples, and to identify effective treatment options via ROR1 targeting. We detected higher ROR1 expression on TCF3-PBX1 leukemic cells even at a later stage of patient relapse, providing a strong rationale for the use of ROR1-targeted therapy. We found that Wnt5a-ROR1 signaling enhances proliferation of TCF3-PBX1 cells via RhoA/Rac1 GTPases activation and STAT3 upregulation. Wnt16b also activated the RhoA/Rac1 signaling cascade suggesting the activation of a non-canonical Wnt pathway in TCF3-PBX1 cells. Wnt16 could interact with ROR1 but not in TCF3-PBX1 cells, suggesting that Wnt5a is the ligand signaling via ROR1 in TCF3-PBX1 cells. By high throughput drug-sensitivity testing of TCF3-PBX1 cells before and after ROR1 knockdown we found that targeting ROR1 significantly improves the therapeutic efficacy of Bcl-2 family inhibitors venetoclax and navitoclax, and this synergism was confirmed ex vivo using a drug-resistant primary sample from a relapsed TCF3-PBX1 patient. Our work underlines a new type of targeted combination therapy that could be clinically advantageous for patients with TCF3-PBX1 BCP-ALL.	[Karvonen, Hanna; Perttila, Robert; Niininen, Wilhelmiina; Hautanen, Veera; Barker, Harlan; Ungureanu, Daniela] Tampere Univ, BioMediTech Inst, Tampere, Finland; [Karvonen, Hanna; Perttila, Robert; Niininen, Wilhelmiina; Hautanen, Veera; Barker, Harlan; Ungureanu, Daniela] Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland; [Murumagi, Astrid; Heckman, Caroline A.] Univ Helsinki, Helsinki Inst Life Sci, Inst Mol Med Finland FIMM, Helsinki, Finland	Tampere University; Tampere University; University of Helsinki	Ungureanu, D (corresponding author), Tampere Univ, BioMediTech Inst, Tampere, Finland.; Ungureanu, D (corresponding author), Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland.	daniela.ungureanu@tuni.fi	Perttilä, Robert/S-8006-2019	Perttilä, Robert/0000-0001-8030-7077; Karvonen, Hanna/0000-0002-7815-0709; Hautanen, Veera/0000-0002-6278-4109; Murumagi, Astrid/0000-0002-7797-188X; Ungureanu, Daniela/0000-0002-9314-4972; Heckman, Caroline/0000-0002-4324-8706; Barker, Harlan/0000-0003-4125-2522	Doctoral Program in Medicine and Life Sciences at University of Tampere; Academy of Finland; Center of Excellence for Translational Cancer Biology; Sigrid Juselius Foundation	Doctoral Program in Medicine and Life Sciences at University of Tampere; Academy of Finland(Academy of Finland); Center of Excellence for Translational Cancer Biology; Sigrid Juselius Foundation(Sigrid Juselius Foundation)	This work was supported by the Doctoral Program in Medicine and Life Sciences at University of Tampere, Academy of Finland, Center of Excellence for Translational Cancer Biology, and the Sigrid Juselius Foundation.	Asem MS, 2016, CANCERS, V8, DOI 10.3390/cancers8090079; Balakrishnan A, 2016, CLIN CANC RES; Bengoa-Vergniory N, 2017, MOL NEUROBIOL, V54, P6213, DOI 10.1007/s12035-016-0151-5; Berger C, 2015, CANCER IMMUNOL RES, V3, P206, DOI 10.1158/2326-6066.CIR-14-0163; Bicocca VT, 2012, CANCER CELL, V22, P656, DOI 10.1016/j.ccr.2012.08.027; Borcherding N, 2014, PROTEIN CELL, V5, P496, DOI 10.1007/s13238-014-0059-7; Burmeister T, 2010, HAEMATOL-HEMATOL J, V95, P241, DOI 10.3324/haematol.2009.011346; Casagrande G, 2006, HAEMATOLOGICA, V91, P765; CHEN Y, 2017, BLOOD S1, V130; Choi MY, 2018, CELL STEM CELL, V22, P951, DOI 10.1016/j.stem.2018.05.018; Daneshmanesh AH, 2012, LEUKEMIA, V26, P1348, DOI 10.1038/leu.2011.362; Dave H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052655; DeBruine ZJ, 2017, BRIT J PHARMACOL, V174, P4564, DOI 10.1111/bph.14048; Eldfors S, 2017, LEUKEMIA, V31, P51, DOI 10.1038/leu.2016.202; Geng HM, 2015, CANCER CELL, V27, P409, DOI 10.1016/j.ccell.2015.02.003; Grumolato L, 2010, GENE DEV, V24, P2517, DOI 10.1101/gad.1957710; Harvey RC, 2010, BLOOD, V116, P4874, DOI 10.1182/blood-2009-08-239681; Hojjat-Farsangi M, 2018, LEUKEMIA, V32, P2291, DOI 10.1038/s41375-018-0113-1; Hunter JD, 2007, COMPUT SCI ENG, V9, P90, DOI 10.1109/MCSE.2007.55; Janovska P, 2017, BRIT J PHARMACOL, V174, P4701, DOI 10.1111/bph.13949; Janovska P, 2016, CLIN CANCER RES, V22, P459, DOI 10.1158/1078-0432.CCR-15-0154; Kang HN, 2010, BLOOD, V115, P1394, DOI 10.1182/blood-2009-05-218560; Karjalainen R, 2017, BLOOD, V130, P789, DOI 10.1182/blood-2016-02-699363; Karvonen H, 2017, BLOOD ADV, V1, P2257, DOI 10.1182/bloodadvances.2017010215; Karvonen H, 2017, BIOCHEM SOC T, V45, P457, DOI 10.1042/BST20160272; Katoh M, 2007, INT J MOL MED, V19, P273; Li P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011859; Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100; Mazieres J, 2005, ONCOGENE, V24, P5396, DOI 10.1038/sj.onc.1208568; Mendrola JM, 2013, BIOCHEM SOC T, V41, P1029, DOI 10.1042/BST20130104; Mihalyova J, 2018, EXP HEMATOL, V61, P10, DOI 10.1016/j.exphem.2018.02.002; Muschen M, 2015, BLOOD, V125, P3688, DOI 10.1182/blood-2015-01-567842; Murphy JM, 2014, BIOCHEM J, V457, P323, DOI 10.1042/BJ20131174; Nemeth MJ, 2007, P NATL ACAD SCI USA, V104, P15436, DOI 10.1073/pnas.0704747104; Nygren MK, 2009, EXP HEMATOL, V37, P225, DOI 10.1016/j.exphem.2008.10.007; Oliphant TE, 2007, COMPUT SCI ENG, V9, P10, DOI 10.1109/MCSE.2007.58; Pemovska T, 2013, CANCER DISCOV, V3, P1416, DOI 10.1158/2159-8290.CD-13-0350; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Rassenti LZ, 2017, P NATL ACAD SCI USA, V114, P10731, DOI 10.1073/pnas.1708264114; Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257; Schreck C, 2014, ANN NY ACAD SCI, V1310, P32, DOI 10.1111/nyas.12384; Staal FJT, 2005, NAT REV IMMUNOL, V5, P21, DOI 10.1038/nri1529; Sun Y, 2016, ONCOGENE, V35, P4321, DOI 10.1038/onc.2015.494; Teh MT, 2007, J CELL SCI, V120, P330, DOI 10.1242/jcs.03329; Wee S, 2008, P NATL ACAD SCI USA, V105, P13057, DOI 10.1073/pnas.0802655105; Wiederschain D, 2009, CELL CYCLE, V8, P498, DOI 10.4161/cc.8.3.7701; Wilson WH, 2010, LANCET ONCOL, V11, P1149, DOI 10.1016/S1470-2045(10)70261-8; Yadav B, 2014, SCI REP-UK, V4, DOI 10.1038/srep05193; Yu J, 2017, LEUKEMIA, V31, P1333, DOI 10.1038/leu.2016.368; Yu J, 2016, J CLIN INVEST, V126, P585, DOI 10.1172/JCI83535	50	24	24	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3288	3300		10.1038/s41388-018-0670-9	http://dx.doi.org/10.1038/s41388-018-0670-9			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30631148				2022-12-17	WOS:000465557200013
J	Parzych, K; Saavedra-Garcia, P; Valbuena, GN; Al-Sadah, HA; Robinson, ME; Penfold, L; Kuzeva, DM; Ruiz-Tellez, A; Loaiza, S; Holzmann, V; Caputo, V; Johnson, DC; Kaiser, MF; Karadimitris, A; Lam, EWF; Chevet, E; Feldhahn, N; Keun, HC; Auner, HW				Parzych, Katarzyna; Saavedra-Garcia, Paula; Valbuena, Gabriel N.; Al-Sadah, Hibah A.; Robinson, Mark E.; Penfold, Lucy; Kuzeva, Desislava M.; Ruiz-Tellez, Angie; Loaiza, Sandra; Holzmann, Viktoria; Caputo, Valentina; Johnson, David C.; Kaiser, Martin F.; Karadimitris, Anastasios; Lam, Eric W-F; Chevet, Eric; Feldhahn, Niklas; Keun, Hector C.; Auner, Holger W.			The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation	ONCOGENE			English	Article							VALOSIN-CONTAINING PROTEIN; AMINO-ACID DEPRIVATION; AAA-ATPASE CDC48/P97; ELEVATED EXPRESSION; EIF2-ALPHA KINASE; INDUCED AUTOPHAGY; P97; STRESS; ER; DEGRADATION	VCP/p97 regulates numerous cellular functions by mediating protein degradation through its segregase activity. Its key role in governing protein homoeostasis has made VCP/p97 an appealing anticancer drug target. Here, we provide evidence that VCP/p97 acts as a regulator of cellular metabolism. We found that VCP/p97 was tied to multiple metabolic processes on the gene expression level in a diverse range of cancer cell lines and in patient-derived multiple myeloma cells. Cellular VCP/p97 dependency to maintain proteostasis was increased under conditions of glucose and glutamine limitation in a range of cancer cell lines from different tissues. Moreover, glutamine depletion led to increased VCP/p97 expression, whereas VCP/p97 inhibition perturbed metabolic processes and intracellular amino acid turnover. GCN2, an amino acid-sensing kinase, attenuated stress signalling and cell death triggered by VCP/p97 inhibition and nutrient shortages and modulated ERK activation, autophagy, and glycolytic metabolite turnover. Together, our data point to an interconnected role of VCP/p97 and GCN2 in maintaining cancer cell metabolic and protein homoeostasis.	[Parzych, Katarzyna; Saavedra-Garcia, Paula; Al-Sadah, Hibah A.; Penfold, Lucy; Kuzeva, Desislava M.; Ruiz-Tellez, Angie; Loaiza, Sandra; Holzmann, Viktoria; Auner, Holger W.] Imperial Coll London, Canc Cell Prot Metab Grp, Dept Med, Ctr Haematol, London, England; [Valbuena, Gabriel N.; Lam, Eric W-F; Keun, Hector C.] Imperial Coll London, Hammersmith Hosp, Div Canc, Dept Surg & Canc, London, England; [Robinson, Mark E.; Caputo, Valentina; Karadimitris, Anastasios; Feldhahn, Niklas] Imperial Coll London, Dept Med, Ctr Haematol, London, England; [Johnson, David C.; Kaiser, Martin F.] Inst Canc Res, Div Mol Pathfol, Sutton, Surrey, England; [Chevet, Eric] Univ Rennes 1, INSERM, U1242, Chem,Oncogenesis,Stress,Signaling, Rennes, France; [Chevet, Eric] Ctr Lutte Canc Eugene Marquis Rennes, Rennes, France	Imperial College London; Imperial College London; Imperial College London; University of London; Institute of Cancer Research - UK; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes 1	Auner, HW (corresponding author), Imperial Coll London, Canc Cell Prot Metab Grp, Dept Med, Ctr Haematol, London, England.	holger.auner04@imperial.ac.uk	Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576; Saavedra, Paula/0000-0002-9907-475X; Valbuena, Gabriel/0000-0001-6825-7214; Robinson, Mark/0000-0003-2363-6047; Holzmann, Viktoria/0000-0001-5168-1289; Penfold, Lucy/0000-0003-0642-4165; Auner, Holger/0000-0003-4040-0642; Kuzeva, Desislava/0000-0002-7616-3012	Cancer Research UK Clinician Scientist Fellowship [C41494/A15448]; British Society for Haematology Early Stage Research Start-up Grant; Imperial College London National Institute of Health Research-Biomedical Research Centre (NIHR-BRC); Imperial College London Cancer Research UK Centre; Imperial College Healthcare Charity 'Dorothy Cave Legacy Fund'; Cancer Research UK [A22544]; Saudi Arabian Cultural Bureau in the UK; MRC [MR/N012097/1] Funding Source: UKRI	Cancer Research UK Clinician Scientist Fellowship(Cancer Research UK); British Society for Haematology Early Stage Research Start-up Grant; Imperial College London National Institute of Health Research-Biomedical Research Centre (NIHR-BRC); Imperial College London Cancer Research UK Centre; Imperial College Healthcare Charity 'Dorothy Cave Legacy Fund'; Cancer Research UK(Cancer Research UK); Saudi Arabian Cultural Bureau in the UK; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by a Cancer Research UK Clinician Scientist Fellowship (C41494/A15448) and a British Society for Haematology Early Stage Research Start-up Grant to HWA. The work was also supported by grants from the Imperial College London National Institute of Health Research-Biomedical Research Centre (NIHR-BRC), the Imperial College London Cancer Research UK Centre, and the Imperial College Healthcare Charity 'Dorothy Cave Legacy Fund' to HWA. HCK acknowledges support by Cancer Research UK (A22544) and the Imperial College London Cancer Research UK Centre. HAAS was supported by an award from the Saudi Arabian Cultural Bureau in the UK. The authors also acknowledge the excellent technical flow cytometry support provided by Miss Carme Ripoll Fiol.	Anderson DJ, 2015, CANCER CELL, V28, P653, DOI 10.1016/j.ccell.2015.10.002; Anthony TG, 2004, J BIOL CHEM, V279, P36553, DOI 10.1074/jbc.M404559200; B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Behrends V, 2011, ANAL BIOCHEM, V415, P206, DOI 10.1016/j.ab.2011.04.009; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Birsoy K, 2014, NATURE, V508, P108, DOI 10.1038/nature13110; Bunpo P, 2009, J BIOL CHEM, V284, P32742, DOI 10.1074/jbc.M109.047910; Cao K, 2003, CELL, V115, P355, DOI 10.1016/S0092-8674(03)00815-8; Carvalho P, 2006, CELL, V126, P361, DOI 10.1016/j.cell.2006.05.043; Castilho BA, 2014, BBA-MOL CELL RES, V1843, P1948, DOI 10.1016/j.bbamcr.2014.04.006; Chou TF, 2011, P NATL ACAD SCI USA, V108, P4834, DOI 10.1073/pnas.1015312108; Clarke HJ, 2014, CANCER CELL, V25, P563, DOI 10.1016/j.ccr.2014.03.015; Csardi G., 2006, INTERJOURNAL COMPLEX; Davidson SM, 2016, CELL METAB, V23, P517, DOI 10.1016/j.cmet.2016.01.007; Defenouillere Q, 2013, P NATL ACAD SCI USA, V110, P5046, DOI 10.1073/pnas.1221724110; Deshaies RJ, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0094-0; Dickens NJ, 2010, CLIN CANCER RES, V16, P1856, DOI 10.1158/1078-0432.CCR-09-2831; Fessart D, 2013, CANCER LETT, V337, P26, DOI 10.1016/j.canlet.2013.05.030; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hetz C, 2018, MOL CELL, V69, P169, DOI 10.1016/j.molcel.2017.06.017; HILL JM, 1967, J AMER MED ASSOC, V202, P882, DOI 10.1001/jama.202.9.882; Hirayama A, 2009, CANCER RES, V69, P4918, DOI 10.1158/0008-5472.CAN-08-4806; Huber AL, 2013, MOL CELL, V49, P1049, DOI 10.1016/j.molcel.2013.01.009; Ishimura R, 2016, ELIFE, V5, DOI 10.7554/eLife.14295; Janiesch PC, 2007, NAT CELL BIOL, V9, P379, DOI 10.1038/ncb1554; Ju JS, 2008, J BIOL CHEM, V283, P30289, DOI 10.1074/jbc.M805517200; Kamphorst JJ, 2015, CANCER RES, V75, P544, DOI 10.1158/0008-5472.CAN-14-2211; Kind T, 2009, ANAL CHEM, V81, P10038, DOI 10.1021/ac9019522; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Le Moigne R, 2017, MOL CANCER THER, V16, P2375, DOI 10.1158/1535-7163.MCT-17-0233; Magnaghi P, 2013, NAT CHEM BIOL, V9, P548, DOI [10.1038/nchembio.1313, 10.1038/NCHEMBIO.1313]; Martin R, 2013, J CELL SCI, V126, P3010, DOI 10.1242/jcs.118067; Meyer H, 2014, J CELL SCI, V127, P3877, DOI 10.1242/jcs.093831; Meyer H, 2012, NAT CELL BIOL, V14, P117, DOI 10.1038/ncb2407; Moreau P, 2012, BLOOD, V120, P947, DOI 10.1182/blood-2012-04-403733; Muaddi H, 2010, MOL BIOL CELL, V21, P3220, DOI 10.1091/mbc.E10-01-0023; Muller JMM, 2007, BIOCHEM BIOPH RES CO, V354, P459, DOI 10.1016/j.bbrc.2006.12.206; NEUMAN RE, 1956, SCIENCE, V124, P124, DOI 10.1126/science.124.3212.124; Pan M, 2016, NAT CELL BIOL, V18, P1090, DOI 10.1038/ncb3410; Parzych K, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.373; PASIEKA AE, 1959, NATURE, V183, P1201, DOI 10.1038/1831201a0; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Radhakrishnan SK, 2014, ELIFE, V3, DOI [10.7554/elife.01856, 10.7554/eLife.01856]; Ravindran R, 2016, NATURE, V531, P523, DOI 10.1038/nature17186; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Saito Y, 2015, CELL STEM CELL, V17, P585, DOI 10.1016/j.stem.2015.08.019; Sasagawa Y, 2012, J STRUCT BIOL, V179, P104, DOI 10.1016/j.jsb.2012.06.009; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/NMETH.1314, 10.1038/nmeth.1314]; Sha Z, 2014, CURR BIOL, V24, P1573, DOI 10.1016/j.cub.2014.06.004; Shin S, 2015, MOL CELL, V59, P382, DOI 10.1016/j.molcel.2015.06.020; Skrott Z, 2017, NATURE, V552, P194, DOI 10.1038/nature25016; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Steffen J, 2010, MOL CELL, V40, P147, DOI 10.1016/j.molcel.2010.09.012; Sullivan LB, 2016, NAT REV CANCER, V16, P680, DOI 10.1038/nrc.2016.85; Suraweera A, 2012, MOL CELL, V48, P242, DOI 10.1016/j.molcel.2012.08.003; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Nguyen TV, 2017, P NATL ACAD SCI USA, V114, P3565, DOI 10.1073/pnas.1700949114; Tresse E, 2010, AUTOPHAGY, V6, P217, DOI 10.4161/auto.6.2.11014; Tsujimoto Y, 2004, CLIN CANCER RES, V10, P3007, DOI 10.1158/1078-0432.CCR-03-0191; Uchiyama K, 2006, DEV CELL, V11, P803, DOI 10.1016/j.devcel.2006.10.016; Vabulas RM, 2005, SCIENCE, V310, P1960, DOI 10.1126/science.1121925; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039; Verma R, 2013, ELIFE, V2, DOI 10.7554/eLife.00308; Verma R, 2011, MOL CELL, V41, P82, DOI 10.1016/j.molcel.2010.12.017; Vlahakis A, 2014, P NATL ACAD SCI USA, V111, P10586, DOI 10.1073/pnas.1406305111; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wang YG, 2013, NEOPLASIA, V15, P989, DOI 10.1593/neo.13262; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; WEK SA, 1995, MOL CELL BIOL, V15, P4497; Wengrod J, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa0899; Wilson GJ, 2015, AM J PHYSIOL-ENDOC M, V308, pE283, DOI 10.1152/ajpendo.00361.2014; Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003; Yamamoto S, 2003, J CLIN ONCOL, V21, P2537, DOI 10.1200/JCO.2003.12.102; Yamamoto S, 2003, J CLIN ONCOL, V21, P447, DOI 10.1200/JCO.2003.06.068; Ye JB, 2015, GENE DEV, V29, P2331, DOI 10.1101/gad.269324.115; Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Ye YH, 2005, P NATL ACAD SCI USA, V102, P14132, DOI 10.1073/pnas.0505006102; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang PC, 2002, MOL CELL BIOL, V22, P6681, DOI 10.1128/MCB.22.19.6681-6688.2002; Zhou HJ, 2015, J MED CHEM, V58, P9480, DOI 10.1021/acs.jmedchem.5b01346	86	24	25	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3216	3231		10.1038/s41388-018-0651-z	http://dx.doi.org/10.1038/s41388-018-0651-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30626938	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000465557200008
J	Zhu, JL; Huang, G; Hua, XH; Li, Y; Yan, HY; Che, X; Tian, ZX; Liufu, HT; Huang, C; Li, JX; Xu, JH; Dai, W; Huang, HS; Huang, CS				Zhu, Junlan; Huang, Grace; Hua, Xiaohui; Li, Yang; Yan, Huiying; Che, Xun; Tian, Zhongxian; Liufu, Huating; Huang, Chao; Li, Jingxia; Xu, Jiheng; Dai, Wei; Huang, Haishan; Huang, Chuanshu			CD44s is a crucial ATG7 downstream regulator for stem-like property, invasion, and lung metastasis of human bladder cancer (BC) cells	ONCOGENE			English	Article							MALIGNANT-TRANSFORMATION; DOWN-REGULATION; AUTOPHAGY; PROTEINS; USP28; OVEREXPRESSION; MAINTENANCE; INHIBITOR; 5-HYDROXYMETHYLCYTOSINE; PROLIFERATION	Over half a million US residents are suffering with bladder cancer (BC), which costs a total $4 billion in treatment annually. Although recent studies report that autophagy-related gene 7 (ATG7) is overexpressed in BCs, the regulatory effects of ATG7 on cancer stem-like phenotypes and invasion have not been explored yet. Current studies demonstrated that the deficiency of ATG7 by its shRNA dramatically reduced sphere formation and invasion in vitro, as well as lung metastasis in vivo in human invasive BC cells. Further studies indicated that the knockdown of ATG7 attenuated the expression of CD44 standard (CD44s), while ectopic introduction of CD44s, was capable of completely restoring sphere formation, invasion, and lung metastasis in T24T(shATG7) cells. Mechanistic studies revealed that ATG7 overexpression stabilized CD44s proteins accompanied with upregulating USP28 proteins. Upregulated USP28 was able to bind to CD44s and remove the ubiquitin group from CD44s' protein, resulting in the stabilization of CD44s protein. Moreover, ATG7 inhibition stabilized AUF1 protein and thereby reduced tet1 mRNA stability and expression, which was able to demethylate usp28 promoter, reduced USP28 expression, finally promoting CD44s degradation. In addition, CD44s was defined to inhibit degradation of RhoGDI beta, which in turn promotes BC invasion. Our results demonstrate that CD44s is a key ATG7 downstream regulator of the sphere formation, invasion, and lung metastasis of BCs, providing significant insight into understanding the BC invasions, metastasis, and stem-like properties.	[Zhu, Junlan; Huang, Grace; Hua, Xiaohui; Li, Yang; Yan, Huiying; Che, Xun; Tian, Zhongxian; Liufu, Huating; Huang, Chao; Li, Jingxia; Xu, Jiheng; Dai, Wei; Huang, Haishan; Huang, Chuanshu] NYU, Sch Med, Nelson Inst Environm Med, New York, NY 10010 USA	New York University	Huang, HS; Huang, CS (corresponding author), NYU, Sch Med, Nelson Inst Environm Med, New York, NY 10010 USA.	haishan_333@163.com; Chuanshu.huang@nyulangone.org	Xu, Jiheng/AAV-5732-2020	Xu, Jiheng/0000-0002-3538-3174; Huang, Chuanshu/0000-0003-4133-5096; Dai, Wei/0000-0003-0169-8327	NIH/NCI [CA177665, CA165980, CA217923]; NIH/NIEHS [ES000260]; NATIONAL CANCER INSTITUTE [R01CA177665, R01CA217923, P01CA165980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000260] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Dr. Martin Eilers from the Institute of Molecular Biology and Tumor Research, Marburg, Germany, and Dr. James M. Angelastro from the Department of Molecular Biosciences, University of California at Davis for their generous gifts of the Flagtagged USP28 plasmid, the pcDNA3.1/NT-GFP-CD133, and pcDNA3.1/NT-GFP plasmids. We also thank Ms. Nedda Tichi for her critical reading of the manuscript. This work was partially supported by grants from NIH/NCI CA177665, CA165980, CA217923, and NIH/NIEHS ES000260.	Bartakova A., 2017, J OBSTET GYNAECOL, P1; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432; Blaveri E, 2005, CLIN CANCER RES, V11, P4044, DOI 10.1158/1078-0432.CCR-04-2409; Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788; Ceriani M, 2015, EXP CELL RES, V333, P49, DOI 10.1016/j.yexcr.2015.01.019; Chan KS, 2010, CURR OPIN UROL, V20, P393, DOI 10.1097/MOU.0b013e32833cc9df; Chandrasekar T, 2016, INVESTIG CLIN UROL, V57, pS89, DOI 10.4111/icu.2016.57.S1.S89; Chen Q, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.142; Chetty C, 2012, CELL SIGNAL, V24, P549, DOI 10.1016/j.cellsig.2011.10.008; Cho Y, 2015, ONCOTARGET, V6, P8709, DOI 10.18632/oncotarget.3325; Ciesielski P, 2015, POSTEP HIG MED DOSW, V69, P1371; Damrauer JS, 2014, P NATL ACAD SCI USA, V111, P3110, DOI 10.1073/pnas.1318376111; Dickstein RJ, 2012, CANCER BIOL THER, V13, P1325, DOI 10.4161/cbt.21793; Faesen AC, 2012, BIOCHEM SOC T, V40, P539, DOI 10.1042/BST20120004; Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966; Gomez-Puerto MC, 2016, STEM CELLS, V34, P1651, DOI 10.1002/stem.2347; Gong C, 2012, AUTOPHAGY, V8, P1853, DOI 10.4161/auto.21996; Good CR, 2017, NUCLEIC ACIDS RES, V45, P8269, DOI 10.1093/nar/gkx435; Guo GY, 2014, TUMOR BIOL, V35, P4017, DOI 10.1007/s13277-013-1525-1; Han X, 2017, CELL BIOL INT, V41, P405, DOI 10.1002/cbin.10734; Hofner T, 2014, UROL ONCOL-SEMIN ORI, V32, P678, DOI 10.1016/j.urolonc.2014.01.001; Hua XH, 2018, CANCER LETT, V436, P38, DOI 10.1016/j.canlet.2018.08.013; Huang HS, 2016, AUTOPHAGY, V12, P1687, DOI 10.1080/15548627.2016.1196313; Jin BL, 2013, ADV EXP MED BIOL, V754, P3, DOI 10.1007/978-1-4419-9967-2_1; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Kobayashi K, 2016, ONCOL REP, V36, P2852, DOI 10.3892/or.2016.5061; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Lee BH, 2010, NATURE, V467, P179, DOI 10.1038/nature09299; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Li XZ, 2012, ANN SURG ONCOL, V19, P145, DOI 10.1245/s10434-011-1944-4; Liang YG, 2016, AUTOPHAGY, V12, P1229, DOI 10.1080/15548627.2016.1179403; Lin CJ, 2013, INT J ONCOL, V42, P993, DOI 10.3892/ijo.2013.1791; Lin YC, 2016, J UROLOGY, V195, P1126, DOI 10.1016/j.juro.2015.10.128; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Mandelbaum J., 2015, AUTOPHAGY; Mani J, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1239-4; Maycotte P, 2015, MOL CANCER RES, V13, P651, DOI 10.1158/1541-7786.MCR-14-0487; Mizuno E, 2005, MOL BIOL CELL, V16, P5163, DOI 10.1091/mbc.E05-06-0560; Murata A, 2015, ONCOTARGET, V6, P23372, DOI 10.18632/oncotarget.4281; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Nishino M, 2017, J CANCER, V8, P1774, DOI 10.7150/jca.19732; Pastrana E, 2011, CELL STEM CELL, V8, P486, DOI 10.1016/j.stem.2011.04.007; Pei YF, 2016, ONCOTARGET, V7, P31322, DOI 10.18632/oncotarget.8900; Peth A, 2009, MOL CELL, V36, P794, DOI 10.1016/j.molcel.2009.11.015; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Quail DF, 2012, CURR STEM CELL RES T, V7, P197; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Scudder SL, 2014, J NEUROSCI, V34, P16637, DOI 10.1523/JNEUROSCI.2452-14.2014; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Sjodahl G, 2012, CLIN CANCER RES, V18, P3377, DOI 10.1158/1078-0432.CCR-12-0077-T; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Wang XF, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0208-z; Warrick JI, 2016, SCI REP-UK, V6, DOI 10.1038/srep38531; Whelan KA, 2017, ONCOGENE, V36, P4843, DOI 10.1038/onc.2017.102; Wu YD, 2013, CELL REP, V5, P224, DOI 10.1016/j.celrep.2013.08.030; Yang F, 2014, DNA CELL BIOL, V33, P781, DOI 10.1089/dna.2014.2545; Yi B, 2015, ONCOL REP, V33, P1201, DOI 10.3892/or.2015.3707; Yin XT, 2016, ADV EXP MED BIOL, V945, P275, DOI 10.1007/978-3-319-43624-1_12; Ying L, 2013, MOL BIOSYST, V9, P407, DOI 10.1039/c2mb25386k; Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968; Yu G, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0115-4; Zavros Y, 2017, CELL MOL GASTROENTER, V4, P55, DOI 10.1016/j.jcmgh.2017.03.003; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039; Zhou C, 2017, ONCOGENE, V36, P3878, DOI 10.1038/onc.2017.14; Zhou FF, 2017, EMBO J, V36, P1623, DOI 10.15252/embj.201695372; Zhu JL, 2017, NEOPLASIA, V19, P672, DOI 10.1016/j.neo.2017.06.002; Zhu JL, 2017, MOL THER-NUCL ACIDS, V7, P299, DOI 10.1016/j.omtn.2017.04.012; Zhu JL, 2014, CANCER PREV RES, V7, P1270, DOI 10.1158/1940-6207.CAPR-14-0233	70	24	24	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3301	3315		10.1038/s41388-018-0664-7	http://dx.doi.org/10.1038/s41388-018-0664-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30635654	Green Accepted			2022-12-17	WOS:000465557200014
J	Leclerc, J; Garandeau, D; Pandiani, C; Gaudel, C; Bille, K; Nottet, N; Garcia, V; Colosetti, P; Pagnotta, S; Bahadoran, P; Tondeur, G; Mograbi, B; Dalle, S; Caramel, J; Levade, T; Ballotti, R; Andrieu-Abadie, N; Bertolotto, C				Leclerc, Justine; Garandeau, David; Pandiani, Charlotte; Gaudel, Celine; Bille, Karine; Nottet, Nicolas; Garcia, Virginie; Colosetti, Pascal; Pagnotta, Sophie; Bahadoran, Philippe; Tondeur, Garance; Mograbi, Baharia; Dalle, Stephane; Caramel, Julie; Levade, Thierry; Ballotti, Robert; Andrieu-Abadie, Nathalie; Bertolotto, Corine			Lysosomal acid ceramidase ASAH1 controls the transition between invasive and proliferative phenotype in melanoma cells	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; CONFERS RESISTANCE; GENE-EXPRESSION; HIGH-THROUGHPUT; MITF; PATHWAY; SWITCH; PREDISPOSES; METABOLISM; MUTATION	Phenotypic plasticity and subsequent generation of intratumoral heterogeneity underly key traits in malignant melanoma such as drug resistance and metastasis. Melanoma plasticity promotes a switch between proliferative and invasive phenotypes characterized by different transcriptional programs of which MITF is a critical regulator. Here, we show that the acid ceramidase ASAH1, which controls sphingolipid metabolism, acted as a rheostat of the phenotypic switch in melanoma cells. Low ASAH1 expression was associated with an invasive behavior mediated by activation of the integrin alphavbeta5-FAK signaling cascade. In line with that, human melanoma biopsies revealed heterogeneous staining of ASAH1 and low ASAH1 expression at the melanoma invasive front. We also identified ASAH1 as a new target of MITF, thereby involving MITF in the regulation of sphingolipid metabolism. Together, our findings provide new cues to the mechanisms underlying the phenotypic plasticity of melanoma cells and identify new anti-metastatic targets.	[Leclerc, Justine; Pandiani, Charlotte; Gaudel, Celine; Bille, Karine; Bahadoran, Philippe; Ballotti, Robert; Bertolotto, Corine] Univ Cote dAzur, Inserm U1065, Biol & Pathol Melanocytes, Equipe Labellisee ARC 2015,Team 1,C3M, Nice, France; [Garandeau, David; Nottet, Nicolas] Univ Cote dAzur, Inserm U1065, C3M, Nice, France; [Garcia, Virginie; Levade, Thierry; Andrieu-Abadie, Nathalie] Univ Toulouse III, Sphingolipids Metab Cell Death & Tumor Progress, Team 4, Inserm,UMR1037,CRCT, Toulouse, France; [Colosetti, Pascal] INSA Lyon, INRA1397, INSERM U1060, CarMeN Lab, Lyon, France; [Pagnotta, Sophie] Univ Cote dAzur, Ctr Commun Microscop Appl, Nice, France; [Bahadoran, Philippe] CHU NICE, Dept Dermatol, Nice, France; [Tondeur, Garance; Dalle, Stephane; Caramel, Julie] Univ Lyon, Inserm, U1052, CNRS 5286,Equipe Labeillsee Ligue Canc, Lyon, France; [Mograbi, Baharia] INSERM ERI21, EA 4319, F-06107 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm)	Bertolotto, C (corresponding author), Univ Cote dAzur, Inserm U1065, Biol & Pathol Melanocytes, Equipe Labellisee ARC 2015,Team 1,C3M, Nice, France.	bertolot@unice.fr	BALLOTTI, Robert/F-8825-2013; Mograbi, Baharia/N-5531-2018; Dalle, Stephane/E-4552-2018; Colosetti, Pascal/ABH-4585-2020; Carmen, Team2/Y-7383-2019; GARCIA, Virginie/W-8313-2019; Andrieu-Abadie, Nathalie/N-6793-2013; Mograbi, Baharia/Q-7953-2019; Bertolotto, Corine/AAF-6634-2021	Dalle, Stephane/0000-0002-3423-4548; Carmen, Team2/0000-0001-9867-5724; GARCIA, Virginie/0000-0002-9761-7036; Andrieu-Abadie, Nathalie/0000-0003-2698-1970; Bertolotto, Corine/0000-0001-6971-7753; Nottet, Nicolas/0000-0002-8699-6747; Colosetti, Pascal/0000-0002-5848-6053; Leclerc, Justine/0000-0003-3793-458X; Lab, Carmen/0000-0002-5935-3236; Caramel, Julie/0000-0002-8883-918X; BALLOTTI, Robert/0000-0002-7322-4908	INCA [INCA_10573]; la Ligue Nationale contre le Cancer; Inserm, La Societe Francaise de Dermatologie	INCA(Institut National du Cancer (INCA) France); la Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Inserm, La Societe Francaise de Dermatologie	This work was supported by Inserm, La Societe Francaise de Dermatologie, and by a grant from INCA (INCA_10573). CP is a fellowship from la Ligue Nationale contre le Cancer. The authors thank Dr. M Sewer (San Diego, USA) for providing the ASAH1 promoter vector. WM3912, WM8, WM3928 and WM3918 human melanoma cell lines were a kind gift from H Meenhard and G Zhang (Wistar melanoma Institute, Philadelphia, USA).	Bedia C, 2007, CHEMBIOCHEM, V8, P642, DOI 10.1002/cbic.200600533; Bertolotto C, 2011, NATURE, V480, P94, DOI 10.1038/nature10539; Bonet C, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw340; Bonet C, 2012, J BIOL CHEM, V287, P29887, DOI 10.1074/jbc.M112.371682; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Canel M, 2013, J CELL SCI, V126, P393, DOI 10.1242/jcs.100115; Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Cheli Y, 2012, ONCOGENE, V31, P2461, DOI 10.1038/onc.2011.425; Cheli Y, 2011, ONCOGENE, V30, P2307, DOI 10.1038/onc.2010.598; Cheli Y, 2010, PIGM CELL MELANOMA R, V23, P27, DOI 10.1111/j.1755-148X.2009.00653.x; Cheng JC, 2013, J CLIN INVEST, V123, P4344, DOI 10.1172/JCI64791; Colombino M, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-117; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; Desch A, 2012, AM J PATHOL, V181, P693, DOI 10.1016/j.ajpath.2012.04.012; Don AS, 2014, BIOMOLECULES, V4, P315, DOI 10.3390/biom4010315; Elojeimy S, 2007, MOL THER, V15, P1259, DOI 10.1038/sj.mt.6300167; Falletta P, 2017, GENE DEV, V31, P18, DOI 10.1101/gad.290940.116; Fane ME, 2017, EBIOMEDICINE, V16, P63, DOI 10.1016/j.ebiom.2017.01.013; Ferlinz K, 2001, J BIOL CHEM, V276, P35352, DOI 10.1074/jbc.M103066200; Ganapathy-Kanniappan S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-152; Giuliano S, 2010, CANCER RES, V70, P3813, DOI 10.1158/0008-5472.CAN-09-2913; Goodall J, 2008, CANCER RES, V68, P7788, DOI 10.1158/0008-5472.CAN-08-1053; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Kemper K, 2015, EMBO MOL MED, V7, P1104, DOI 10.15252/emmm.201404914; Konieczkowski DJ, 2014, CANCER DISCOV, V4, P816, DOI 10.1158/2159-8290.CD-13-0424; Lai M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07606-w; Larribere L, 2005, GENE DEV, V19, P1980, DOI 10.1101/gad.335905; Lucki N, 2009, BBA-MOL CELL BIOL L, V1791, P706, DOI 10.1016/j.bbalip.2009.03.005; Lucki NC, 2011, J BIOL CHEM, V286, P19399, DOI 10.1074/jbc.M110.195826; Mahdy AEM, 2009, MOL THER, V17, P430, DOI 10.1038/mt.2008.281; Merrill AH, 2005, METHODS, V36, P207, DOI 10.1016/j.ymeth.2005.01.009; Morad SAF, 2013, NAT REV CANCER, V13, P51, DOI 10.1038/nrc3398; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Ohanna M, 2018, GENE DEV, V32, P448, DOI 10.1101/gad.305854.117; Ohanna M, 2011, GENE DEV, V25, P1245, DOI 10.1101/gad.625811; Ohanna M, 2013, ONCOTARGET, V4, P2212, DOI 10.18632/oncotarget.1143; Paillerets BBD, 2014, EUR J CELL BIOL, V93, P71, DOI 10.1016/j.ejcb.2013.10.002; Park JH, 2006, BBA-BIOMEMBRANES, V1758, P2133, DOI 10.1016/j.bbamem.2006.08.019; Pinner S, 2009, CANCER RES, V69, P7969, DOI 10.1158/0008-5472.CAN-09-0781; Rambow F, 2015, CELL REP, V13, P840, DOI 10.1016/j.celrep.2015.09.037; Realini N, 2016, J BIOL CHEM, V291, P2422, DOI 10.1074/jbc.M115.666909; Reinhardt J, 2017, CANCER RES, V77, P4697, DOI 10.1158/0008-5472.CAN-17-0395; Riesenberg S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9755; Ruckhaberle E, 2009, CLIMACTERIC, V12, P502, DOI 10.3109/13697130902939913; Sanger N, 2015, MOL ONCOL, V9, P58, DOI 10.1016/j.molonc.2014.07.016; Shtraizent N, 2008, J BIOL CHEM, V283, P11253, DOI 10.1074/jbc.M709166200; Strub T, 2011, ONCOGENE, V30, P2319, DOI 10.1038/onc.2010.612; Truman JP, 2014, BBA-MOL CELL BIOL L, V1841, P1174, DOI 10.1016/j.bbalip.2013.12.013; Van Allen EM, 2014, PROSTATE CANCER P D, V17, P23, DOI 10.1038/pcan.2013.37; Vazquez F, 2013, CANCER CELL, V23, P287, DOI 10.1016/j.ccr.2012.11.020; Verfaillie A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7683; Vesuna F, 2008, BIOCHEM BIOPH RES CO, V367, P235, DOI 10.1016/j.bbrc.2007.11.151; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Walkley SU, 2009, BBA-MOL CELL RES, V1793, P726, DOI 10.1016/j.bbamcr.2008.11.014; Wang F, 1999, CANCER RES, V59, P6185; WARBURG O, 1956, SCIENCE, V124, P269; Webster MR, 2015, PIGM CELL MELANOMA R, V28, P184, DOI 10.1111/pcmr.12330; Widmer DS, 2012, PIGM CELL MELANOMA R, V25, P343, DOI 10.1111/j.1755-148X.2012.00986.x; Yokoyama S, 2011, NATURE, V480, P99, DOI 10.1038/nature10630; Zhou J, 2012, AM J HUM GENET, V91, P5, DOI 10.1016/j.ajhg.2012.05.001	64	24	24	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1282	1295		10.1038/s41388-018-0500-0	http://dx.doi.org/10.1038/s41388-018-0500-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30254208	Green Submitted			2022-12-17	WOS:000459249800010
J	Munoz-Galvan, S; Lucena-Cacace, A; Perez, M; Otero-Albiol, D; Gomez-Cambronero, J; Carnero, A				Munoz-Galvan, Sandra; Lucena-Cacace, Antonio; Perez, Marco; Otero-Albiol, Daniel; Gomez-Cambronero, Julian; Carnero, Amancio			Tumor cell-secreted PLD increases tumor stemness by senescence-mediated communication with microenvironment	ONCOGENE			English	Article							PHOSPHOLIPASE D2 PLD2; NUCLEOTIDE EXCHANGE; CANCER-CELLS; ACTIVATION; FIBROBLASTS; INVASION; GROWTH; IDENTIFICATION; TRANSFORMATION; TUMORIGENESIS	Cancer cells are in continuous communication with the surrounding microenvironment and this communication can affect tumor evolution. In this work, we show that phospholipase D2 (PLD2) was overexpressed in colon tumors and is secreted by cancer cells, inducing senescence in neighboring fibroblasts. This occurs through its lipase domain. Senescence induced by its product, phosphatidic acid, leads to a senescence-associated secretory phenotype (SASP) able to increase the stem properties of cancer cells. This increase in stemness occurs by Wnt pathway activacion. This closes a feedback loop in which senescence acts as a crosspoint for the generation of CSCs mediated by phospholipid metabolism. We also demonstrate the connexion of both phenomena in mouse models in vivo showing that a high PLD2 expression increased stemness and tumorigenesis. Thus, the patients with colon cancer show high levels of PLD2 and SASP factor genes expression correlating with Wnt pathway activation. Therefore, we demonstrate that tumor cell-secreted PLD2 contributes to tumor development by modifying the microenvironment, making it a possible therapeutic target for cancer treatment. This mechanism may also explain the high levels of Wnt pathway activation in colon cancer.	[Munoz-Galvan, Sandra; Lucena-Cacace, Antonio; Perez, Marco; Otero-Albiol, Daniel; Carnero, Amancio] Univ Seville, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla, CSIC,IBIS, Avda Manuel Siurot S-N, Seville 41013, Spain; [Munoz-Galvan, Sandra; Lucena-Cacace, Antonio; Perez, Marco; Otero-Albiol, Daniel; Carnero, Amancio] Inst Salud Carlos III, CIBER CANC, Madrid, Spain; [Gomez-Cambronero, Julian] Wright State Univ, Sch Med, Dept Biochem & Mol Biol, Dayton, OH 45435 USA	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Instituto de Salud Carlos III; University System of Ohio; Wright State University Dayton	Carnero, A (corresponding author), Univ Seville, Hosp Univ Virgen del Rocio, Inst Biomed Sevilla, CSIC,IBIS, Avda Manuel Siurot S-N, Seville 41013, Spain.; Carnero, A (corresponding author), Inst Salud Carlos III, CIBER CANC, Madrid, Spain.	acarnero-ibis@us.es	Muñoz-Galván, Sandra/K-5827-2015	Carnero, Amancio/0000-0003-4357-3979; Lucena-Cacace, Antonio/0000-0002-1181-2683; Gomez-Cambronero, Julian/0000-0002-7581-9227; Munoz-Galvan, Sandra/0000-0003-0579-325X	ISCIII-Red de Biobancos [PT13/0010/0056]; ISCIII [CD16/00230]; Spanish Ministry of Economy and Competitivity, Plan Estatal de I + D + I 2013-2016, ISCIII [Fis: PI15/00045]; CIBER de Cancer [CD16/12/00275]; FEDER from Regional Development European Funds (European Union); Consejeria de Ciencia e Innovacion [CTS-1848]; Consejeria de Salud of the Junta de Andalucia [PI-0397-2017]; Fundacion BBVA; AECC Foundation; NIH [HL056653-14]	ISCIII-Red de Biobancos; ISCIII(Instituto de Salud Carlos III); Spanish Ministry of Economy and Competitivity, Plan Estatal de I + D + I 2013-2016, ISCIII; CIBER de Cancer; FEDER from Regional Development European Funds (European Union); Consejeria de Ciencia e Innovacion; Consejeria de Salud of the Junta de Andalucia(Junta de Andalucia); Fundacion BBVA(BBVA Foundation); AECC Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank the donors, the HUVR-IBiS Biobank (Andalusian Public Health System Biobank and ISCIII-Red de Biobancos PT13/0010/0056) for the human specimens used in this study, Carolina Castilla for the assistance with IHC assays and Carmen Saez for histological analyses. SM-G was supported by a Sara Borrell grant from ISCIII (CD16/00230). AC lab was supported by grants from the Spanish Ministry of Economy and Competitivity, Plan Estatal de I + D + I 2013-2016, ISCIII (Fis: PI15/00045), and CIBER de Cancer (CD16/12/00275), co-funded by FEDER from Regional Development European Funds (European Union), Consejeria de Ciencia e Innovacion (CTS-1848), and Consejeria de Salud of the Junta de Andalucia (PI-0397-2017). This work was also supported by Fundacion BBVA. Especial thanks to the AECC Foundation for supporting this work. JG-C is supported by Grant HL056653-14 from the NIH.	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Bach JP, 2008, ONCOLOGY-BASEL, V75, P127, DOI 10.1159/000155223; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Burd CE, 2013, CELL, V152, P340, DOI 10.1016/j.cell.2012.12.010; CARNERO A, 1994, J CELL BIOCHEM, V54, P478, DOI 10.1002/jcb.240540415; CARNERO A, 1994, ONCOGENE, V9, P1387; CARNERO A, 1995, MOL CELL BIOL, V15, P1094; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Ferrer I, 2016, ONCOGENE, V35, P2777, DOI 10.1038/onc.2015.341; Foster DA, 2003, MOL CANCER RES, V1, P789; Frankel P, 1999, BIOCHEM BIOPH RES CO, V255, P502, DOI 10.1006/bbrc.1999.0234; Friedlander SYG, 2009, CANCER CELL, V16, P379, DOI 10.1016/j.ccr.2009.09.027; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Gomez-Cambronero J, 2014, J BIOL CHEM, V289, P22557, DOI 10.1074/jbc.R114.574152; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Henkels KM, 2013, ONCOGENE, V32, P5551, DOI 10.1038/onc.2013.207; Henkels KM, 2011, J MOL BIOL, V408, P850, DOI 10.1016/j.jmb.2011.03.017; Herranz N, 2015, NAT CELL BIOL, V17, P1205, DOI 10.1038/ncb3225; Jeon H, 2011, CELL SIGNAL, V23, P1320, DOI 10.1016/j.cellsig.2011.03.014; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kang DW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012109; Kang DW, 2010, CANCER RES, V70, P4233, DOI 10.1158/0008-5472.CAN-09-3470; Knoepp SM, 2008, MOL PHARMACOL, V74, P574, DOI 10.1124/mol.107.040105; Laberge RM, 2015, NAT CELL BIOL, V17, P1049, DOI 10.1038/ncb3195; Lee YH, 2014, FEBS LETT, V588, P3251, DOI 10.1016/j.febslet.2014.07.009; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; Mahankali M, 2012, J BIOL CHEM, V287, P41417, DOI 10.1074/jbc.M112.383596; Mahankali M, 2011, P NATL ACAD SCI USA, V108, P19617, DOI 10.1073/pnas.1114692108; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Nakamura T, 1997, CANCER RES, V57, P3305; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Oshimoto H, 2003, ONCOL RES, V14, P31, DOI 10.3727/000000003108748586; Park JB, 2012, NAT REV CANCER, V12, P782, DOI 10.1038/nrc3379; Perez M, 2016, ONCOTARGET, V7, P33111, DOI 10.18632/oncotarget.8880; Perez-Mancera PA, 2014, NAT REV CANCER, V14, P547, DOI 10.1038/nrc3773; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Saito M, 2007, ONCOL REP, V18, P1329; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; Soria G, 2008, CANCER LETT, V267, P271, DOI 10.1016/j.canlet.2008.03.018; Tsuyada A, 2012, CANCER RES, V72, P2768, DOI 10.1158/0008-5472.CAN-11-3567; Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368; VENABLE ME, 1994, J BIOL CHEM, V269, P26040; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Xu LZ, 2003, MOL CELL BIOL, V23, P645, DOI 10.1128/MCB.23.2.645-654.2003; Zheng Y, 2006, J BIOL CHEM, V281, P15862, DOI 10.1074/jbc.M600660200; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	53	24	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1309	1323		10.1038/s41388-018-0527-2	http://dx.doi.org/10.1038/s41388-018-0527-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30305726				2022-12-17	WOS:000459249800012
J	Coburn, LA; Singh, K; Asim, M; Barry, DP; Allaman, MM; Al-Greene, NT; Hardbower, DM; Polosukhina, D; Williams, CS; Delgado, AG; Piazuelo, MB; Washington, MK; Gobert, AP; Wilson, KT				Coburn, Lori A.; Singh, Kshipra; Asim, Mohammad; Barry, Daniel P.; Allaman, Margaret M.; Al-Greene, Nicole T.; Hardbower, Dana M.; Polosukhina, Dina; Williams, Christopher S.; Delgado, Alberto G.; Piazuelo, M. Blanca; Washington, M. Kay; Gobert, Alain P.; Wilson, Keith T.			Loss of solute carrier family 7 member 2 exacerbates inflammation-associated colon tumorigenesis	ONCOGENE			English	Article							M1 MACROPHAGE ACTIVATION; AMINO-ACID TRANSPORTER-2; NITRIC-OXIDE PRODUCTION; L-ARGININE TRANSPORT; HELICOBACTER-PYLORI; BOWEL-DISEASE; PLASMA ARGININE; COLITIS; CHEMOKINES; ARGINASE	Solute carrier family 7 member 2 (SLC7A2, also known as CAT2) is an inducible transporter of the semi-essential amino acid L-arginine (L-Arg), which has been implicated in wound repair. We have reported that both SLC7A2 expression and L-Arg availability are decreased in colonic tissues from inflammatory bowel disease patients and that mice lacking Slc7a2 exhibit a more severe disease course when exposed to dextran sulfate sodium (DSS) compared to wild-type (WT) mice. Here, we present evidence that SLC7A2 plays a role in modulating colon tumorigenesis in the azoxymethane (AOM)-DSS model of colitis-associated carcinogenesis (CAC). SLC7A2 was localized predominantly to colonic epithelial cells in WT mice. Utilizing the AOM-DSS model, Slc7a2(-/-) mice had significantly increased tumor number, burden, and risk of high-grade dysplasia vs. WT mice. Tumors from Slc7a2(-/-) mice exhibited significantly increased levels of the proinflammatory cytokines/chemokines IL-1 beta, CXCL1, CXCL5, IL-3, CXCL2, CCL3, and CCL4, but decreased levels of IL-4, CXCL9, and CXCL10 compared to tumors from WT mice. This was accompanied by a shift toward pro-tumorigenic M2 macrophage activation in Slc7a2-deficient mice, as marked by increased colonic CD11b(+)F4/80(+)ARG1(+) cells with no alteration in CD11b(+)F4/80(+)NOS2(+) cells by flow cytometry and immunofluorescence microscopy. The shift toward M2 macrophage activation was confirmed in bone marrow-derived macrophages from Slc7a2(-/-) mice. In bone marrow chimeras between Slc7a2(-/-) and WT mice, the recipient genotype drove the CAC phenotype, suggesting the importance of epithelial SLC7A2 in abrogating neoplastic risk. These data reveal that SLC7A2 has a significant role in the protection from CAC in the setting of chronic colitis, and suggest that the decreased SLC7A2 in inflammatory bowel disease (IBD) may contribute to CAC risk. Strategies to enhance L-Arg availability by supplementing L-Arg and/or increasing L-Arg uptake could represent a therapeutic approach in IBD to reduce the substantial long-term risk of colorectal carcinoma.	[Coburn, Lori A.; Williams, Christopher S.; Wilson, Keith T.] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA; [Coburn, Lori A.; Singh, Kshipra; Asim, Mohammad; Barry, Daniel P.; Allaman, Margaret M.; Al-Greene, Nicole T.; Hardbower, Dana M.; Polosukhina, Dina; Williams, Christopher S.; Delgado, Alberto G.; Piazuelo, M. Blanca; Gobert, Alain P.; Wilson, Keith T.] Vanderbilt Univ, Med Ctr, Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37232 USA; [Coburn, Lori A.; Williams, Christopher S.; Piazuelo, M. Blanca; Gobert, Alain P.; Wilson, Keith T.] Vanderbilt Univ, Med Ctr, Ctr Mucosal Inflammat & Canc, Nashville, TN 37232 USA; [Hardbower, Dana M.; Washington, M. Kay; Wilson, Keith T.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Williams, Christopher S.; Wilson, Keith T.] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Wilson, KT (corresponding author), Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA.; Wilson, KT (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37232 USA.; Wilson, KT (corresponding author), Vanderbilt Univ, Med Ctr, Ctr Mucosal Inflammat & Canc, Nashville, TN 37232 USA.; Wilson, KT (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA.; Wilson, KT (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.	keith.wilson@vanderbilt.edu	Allaman, Margaret/GNO-9854-2022; Gobert, Alain P/AHB-1368-2022; /B-5647-2008	Allaman, Margaret M./0000-0002-2803-1365; /0000-0002-3972-3914; Coburn, Lori/0000-0003-3249-9806	National Institutes of Health (NIH) [R01AT004821, 3R01AT004821-02S1, R01DK053620, R01CA190612, P01CA116087, P01CA028842]; Veterans Affairs Merit Review [I01BX001453]; Thomas F. Frist Sr. Endowment; Vanderbilt Center for Mucosal Inflammation and Cancer; NIH [5T32DK007673, P30DK058404]; Vanderbilt Physician Scientist Development Award; Veterans Affairs Career Development Award [1IK2BX002126];  [T32GM008554];  [F31DK10715]; NATIONAL CANCER INSTITUTE [R01CA190612, P01CA116087, P01CA028842] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT004821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007673, P30DK058404, R01DK053620, T32DK007737] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008554] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001453, IK2BX002126] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veterans Affairs Merit Review(US Department of Veterans Affairs); Thomas F. Frist Sr. Endowment; Vanderbilt Center for Mucosal Inflammation and Cancer; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Vanderbilt Physician Scientist Development Award; Veterans Affairs Career Development Award; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	This work was funded by the National Institutes of Health (NIH) grants R01AT004821, 3R01AT004821-02S1, R01DK053620, R01CA190612, P01CA116087, and P01CA028842 (to KTW), Veterans Affairs Merit Review grant I01BX001453 (to KTW), the Thomas F. Frist Sr. Endowment (to KTW), and the Vanderbilt Center for Mucosal Inflammation and Cancer (to KTW). LAC was supported by the NIH training grant 5T32DK007673, a Vanderbilt Physician Scientist Development Award, and a Veterans Affairs Career Development Award 1IK2BX002126. DMH was supported by T32GM008554 and F31DK10715. Additional support was provided by the NIH grant P30DK058404 (Vanderbilt Digestive Disease Research Center). Whole slide imaging and quantification were performed in the Digital Histology Shared Resource at the Vanderbilt University Medical Center (http://www.mc.vanderbilt.edu/dhsr).	ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155; Barrett CW, 2011, CANCER RES, V71, P1302, DOI 10.1158/0008-5472.CAN-10-3317; Baumgart DC, 2007, LANCET, V369, P1627, DOI 10.1016/S0140-6736(07)60750-8; Baumgart DC, 2007, LANCET, V369, P1641, DOI 10.1016/S0140-6736(07)60751-X; Beaugerie L, 2015, NEW ENGL J MED, V372, P1441, DOI 10.1056/NEJMra1403718; Brower V, 2005, J NATL CANCER I, V97, P251, DOI 10.1093/jnci/97.4.251; CASTILLO L, 1994, METABOLISM, V43, P114, DOI 10.1016/0026-0495(94)90166-X; CASTILLO L, 1993, P NATL ACAD SCI USA, V90, P7749, DOI 10.1073/pnas.90.16.7749; Chandrasekar B, 2013, J INFECT DIS, V207, P1556, DOI 10.1093/infdis/jit067; Chaturvedi R, 2010, GASTROENTEROLOGY, V139, P1686, DOI 10.1053/j.gastro.2010.06.060; Coburn LA, 2016, INFLAMM BOWEL DIS, V22, P1847, DOI 10.1097/MIB.0000000000000790; Coburn LA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033546; Coman D, 2008, CLIN NUTR, V27, P489, DOI 10.1016/j.clnu.2008.05.007; Erreni M, 2011, CANCER MICROENVIRON, V4, P141, DOI 10.1007/s12307-010-0052-5; Feagins LA, 2009, NAT REV GASTRO HEPAT, V6, P297, DOI 10.1038/nrgastro.2009.44; Gobert AP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01242; Gobert AP, 2004, J IMMUNOL, V173, P2109, DOI 10.4049/jimmunol.173.3.2109; GRUBBS FE, 1969, TECHNOMETRICS, V11, P1, DOI 10.2307/1266761; Hardbower DM, 2017, ONCOGENE, V36, P3807, DOI 10.1038/onc.2017.23; Hardbower DM, 2017, P NATL ACAD SCI USA, V114, pE751, DOI 10.1073/pnas.1614958114; Hardbower DM, 2016, AMINO ACIDS, V48, P2375, DOI 10.1007/s00726-016-2231-2; Hardbower DM, 2016, J CLIN INVEST, V126, P3296, DOI 10.1172/JCI83585; Herrinton LJ, 2012, GASTROENTEROLOGY, V143, P382, DOI 10.1053/j.gastro.2012.04.054; Hol J, 2010, J LEUKOCYTE BIOL, V87, P501, DOI 10.1189/jlb.0809532; Isidro RA, 2016, AM J PHYSIOL-GASTR L, V311, pG59, DOI 10.1152/ajpgi.00123.2016; Kakuda DK, 1999, BIOCHEM J, V340, P549, DOI 10.1042/0264-6021:3400549; Khor B, 2011, NATURE, V474, P307, DOI 10.1038/nature10209; Martin L, 2006, AM J PHYSIOL-CELL PH, V290, pC1364, DOI 10.1152/ajpcell.00520.2005; Martinez FO, 2014, F1000PRIME REP, V6, P13, DOI DOI 10.12703/P6-13; Mori M, 2007, J NUTR, V137, p1616S, DOI 10.1093/jn/137.6.1616S; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325; Nagy TA, 2011, GASTROENTEROLOGY, V141, P553, DOI 10.1053/j.gastro.2011.05.004; Nicholson B, 2001, J BIOL CHEM, V276, P15881, DOI 10.1074/jbc.M010030200; Porta C, 2009, P NATL ACAD SCI USA, V106, P14978, DOI 10.1073/pnas.0809784106; Rmali KA, 2007, COLORECTAL DIS, V9, P3, DOI 10.1111/j.1463-1318.2006.01089.x; ROSE WC, 1949, FED PROC, V8, P546; Rutter M, 2004, GASTROENTEROLOGY, V126, P451, DOI 10.1053/j.gastro.2003.11.010; Shivashankar R, 2017, CLIN GASTROENTEROL H, V15, P857, DOI 10.1016/j.cgh.2016.10.039; Sierra JC, 2018, GUT, V67, P1247, DOI 10.1136/gutjnl-2016-312888; Singh K, 2018, CANCER RES, V78, P4303, DOI 10.1158/0008-5472.CAN-18-0116; Singh K, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005984; Singh K, 2013, AM J PHYSIOL-GASTR L, V305, pG225, DOI 10.1152/ajpgi.00091.2013; Singh K, 2012, AM J PHYSIOL-GASTR L, V302, pG1061, DOI 10.1152/ajpgi.00544.2011; Singh K, 2011, J BIOL CHEM, V286, P3839, DOI 10.1074/jbc.M110.176719; Sun P, 2017, J NUTR BIOCHEM, V47, P35, DOI 10.1016/j.jnutbio.2017.04.016; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Valbuena G, 2003, AM J PATHOL, V163, P1357, DOI 10.1016/S0002-9440(10)63494-3; Zimmerman NP, 2008, INFLAMM BOWEL DIS, V14, P1000, DOI 10.1002/ibd.20480	49	24	24	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					1067	1079		10.1038/s41388-018-0492-9	http://dx.doi.org/10.1038/s41388-018-0492-9			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30202097	Green Accepted			2022-12-17	WOS:000458624900010
J	Li, YS; Zhang, HY; Zhao, Y; Wang, CY; Cheng, ZG; Tang, LN; Gao, YL; Liu, FR; Li, JB; Li, Y; Li, Y; Geng, NX; Rui, X; Teng, YE; Liu, YP; Cao, L; Kumar, R; Jin, F; Li, F				Li, Yanshu; Zhang, Hongyan; Zhao, Yue; Wang, Chunyu; Cheng, Zhenguo; Tang, Lina; Gao, Yunling; Liu, Furong; Li, Jiabin; Li, Yan; Li, Yang; Geng, Nanxi; Rui, Xue; Teng, Yuee; Liu, Yunpeng; Cao, Liu; Kumar, Rakesh; Jin, Feng; Li, Feng			A mandatory role of nuclear PAK4-LIFR axis in breast-to-bone metastasis of ER alpha-positive breast cancer cells	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; ANDROGEN RECEPTOR; PAK4; INVASION; PROLIFERATION; MIGRATION; PROMOTES; PROTEIN; EXPRESSION; INHIBITOR	The mechanism of estrogen receptor alpha (ER alpha)-positive breast cancer-associated bone metastasis is poorly understood. In this article, we report that nuclear p21-activated kinase 4 (nPAK4) is a novel repressor of ER alpha-mediated transactivation in a 17 beta-estradiol (E2)-dependent manner and promotes PAK4-ER alpha axis-mediated bone metastasis by targeting leukemia inhibitory factor receptor (LIFR) in ER alpha-positive breast cancer. An evaluation of clinical breast cancer samples revealed that nPAK4 is linked to ERa expression and appears to be associated with a poor prognosis in bone metastatic breast cancer. PAK4 bound and co-translocated with ERa from the cytoplasm to the nucleus upon stimulation with E2. nPAK4 enhanced the invasive potential of ER alpha-positive breast cancer cells in vitro and promoted breast cancer metastasis in vivo. Mechanistically, nPAK4 promoted the metastasis of ER alpha-positive breast cancer cells by targeting LIFR, a bone metastasis suppressor. Strikingly, the nuclear accumulation of PAK4 might promote aggressive phenotypes, highlighting nPAK4 as a novel predictive biomarker for ER alpha-positive breast cancer bone metastasis.	[Li, Yanshu; Zhang, Hongyan; Zhao, Yue; Wang, Chunyu; Cheng, Zhenguo; Tang, Lina; Gao, Yunling; Liu, Furong; Li, Jiabin; Li, Yan; Li, Yang; Geng, Nanxi; Cao, Liu; Li, Feng] China Med Univ, Dept Cell Biol, Key Lab Cell Biol, Minist Publ Hlth, 77 Puhe Rd,Shenyang North New Area, Shenyang 110122, Liaoning, Peoples R China; [Li, Yanshu; Zhang, Hongyan; Zhao, Yue; Wang, Chunyu; Cheng, Zhenguo; Tang, Lina; Gao, Yunling; Liu, Furong; Li, Jiabin; Li, Yan; Li, Yang; Geng, Nanxi; Cao, Liu; Li, Feng] China Med Univ, Key Lab Med Cell Biol, Minist Educ, 77 Puhe Rd,Shenyang North New Area, Shenyang 110122, Liaoning, Peoples R China; [Rui, Xue; Jin, Feng] China Med Univ, Dept Surg Oncol, Hosp 1, 155 North Nanjing St, Shenyang 110001, Liaoning, Peoples R China; [Teng, Yuee; Liu, Yunpeng] China Med Univ, Dept Med Oncol, Hosp 1, 155 North Nanjing St, Shenyang 110001, Liaoning, Peoples R China; [Kumar, Rakesh] Rajiv Gandhi Ctr Biotechnol, Canc Res Program, Thiruvananthapuram 695014, Kerala, India	China Medical University; China Medical University; China Medical University; China Medical University; Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB)	Li, F (corresponding author), China Med Univ, Dept Cell Biol, Key Lab Cell Biol, Minist Publ Hlth, 77 Puhe Rd,Shenyang North New Area, Shenyang 110122, Liaoning, Peoples R China.; Li, F (corresponding author), China Med Univ, Key Lab Med Cell Biol, Minist Educ, 77 Puhe Rd,Shenyang North New Area, Shenyang 110122, Liaoning, Peoples R China.; Jin, F (corresponding author), China Med Univ, Dept Surg Oncol, Hosp 1, 155 North Nanjing St, Shenyang 110001, Liaoning, Peoples R China.	jinfeng@cmu.edu.cn; lifeng@cmu.edu.cn	Kumar, Rakesh/ABD-1065-2020	Kumar, Rakesh/0000-0001-7664-0803; Li, Feng/0000-0001-5868-7456	MD Anderson cancer center; National Natural Science Foundation of China [31371424, 31571457, 90813038, 81372337]; Ministry of Education of China [IRT13101]; Basic Research Project of Education Department of Liaoning Province [LZ2015071]	MD Anderson cancer center; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education of China(Ministry of Education, China); Basic Research Project of Education Department of Liaoning Province	We thank Raabe T. for the gifts of the Mbt and Mbt<SUP>P1</SUP> mutants fly stocks. We thank Dr. Yu Tong from MD Anderson cancer center for the gifts of the LIFR plasmids. This research was supported by Grants from the National Natural Science Foundation of China No. 31371424 (Feng Li), No. 31571457 (Feng Li), No. 90813038 (Feng Li), No. 81372337 (Yan Li) and Ministry of Education of China IRT13101 (Liu Cao), and Basic Research Project of Education Department of Liaoning Province, No. LZ2015071 (Feng Li).	Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Ahmed T, 2008, CELL SIGNAL, V20, P1320, DOI 10.1016/j.cellsig.2008.02.021; BERCHUCK A, 1989, CANCER RES, V49, P2091; Bi YQ, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0913-6; Blanco MA, 2012, CELL RES, V22, P1339, DOI 10.1038/cr.2012.89; Cai SW, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0165-2; Chen DH, 2012, NAT MED, V18, P1511, DOI 10.1038/nm.2940; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Choi SW, 2015, J BONE MINER RES, V30, P1494, DOI 10.1002/jbmr.2468; Eswaran J, 2009, CANCER METAST REV, V28, P209, DOI 10.1007/s10555-008-9181-4; Fujiki R, 2005, EMBO J, V24, P3881, DOI 10.1038/sj.emboj.7600853; Guo Q, 2014, ONCOGENE, V33, P3277, DOI 10.1038/onc.2013.296; Johnson RW, 2016, NAT CELL BIOL, V18, P1078, DOI 10.1038/ncb3408; Kobayashi K, 2016, J CLIN PATHOL, V69, P580, DOI 10.1136/jclinpath-2015-203330; Kumar R, 2016, ADV CANCER RES, V130, P137, DOI 10.1016/bs.acr.2016.01.002; Li Y, 2012, BBA-MOL CELL RES, V1823, P465, DOI 10.1016/j.bbamcr.2011.11.013; Li YS, 2013, ANAT REC, V296, P1561, DOI 10.1002/ar.22754; Lindberg MK, 2002, J BONE MINER RES, V17, P2183, DOI 10.1359/jbmr.2002.17.12.2183; Liu FA, 2017, MOL THER-NUCL ACIDS, V8, P370, DOI 10.1016/j.omtn.2017.07.005; Liu Y, 2010, ONCOGENE, V29, P5883, DOI 10.1038/onc.2010.329; Liu YY, 2008, MOL CANCER RES, V6, P1215, DOI 10.1158/1541-7786.MCR-08-0087; Lu W, 2013, NEOPLASMA, V60, P493, DOI 10.4149/neo_2013_064; Melzig J, 1998, CURR BIOL, V8, P1223, DOI 10.1016/S0960-9822(07)00514-3; Menzel N, 2008, BIOCHEM J, V416, P231, DOI 10.1042/BJ20080465; Minden Audrey, 2012, ISRN Oncol, V2012, P694201, DOI 10.5402/2012/694201; Molli PR, 2009, ONCOGENE, V28, P2545, DOI 10.1038/onc.2009.119; Rayala SK, 2006, CANCER RES, V66, P1694, DOI 10.1158/0008-5472.CAN-05-2922; Siu MKY, 2010, P NATL ACAD SCI USA, V107, P18622, DOI 10.1073/pnas.0907481107; Takeyama K, 2002, NEURON, V35, P855, DOI 10.1016/S0896-6273(02)00875-9; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Vershinin Z, 2016, J BIOL CHEM, V291, P6786, DOI 10.1074/jbc.M115.697292; Vesuna F, 2012, ONCOGENE, V31, P3223, DOI 10.1038/onc.2011.483; Wang CY, 2015, NUCLEIC ACIDS RES, V43, P4893, DOI 10.1093/nar/gkv394; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543; Wells CM, 2010, BIOCHEM J, V425, P465, DOI 10.1042/BJ20091173; Wong LE, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.13; Wright LE, 2016, BONEKEY REP, V5, DOI 10.1038/bonekey.2016.31; Xu HT, 2016, CANCER RES, V76, P5732, DOI 10.1158/0008-5472.CAN-15-3373; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1; Zhang HY, 2017, AM J TRANSL RES, V9, P2736; Zhang HJ, 2011, CARCINOGENESIS, V32, P765, DOI 10.1093/carcin/bgr033; Zhang J, 2012, CANCER LETT, V317, P24, DOI 10.1016/j.canlet.2011.11.007; Zhao Y, 2008, MOL CELL, V29, P92, DOI 10.1016/j.molcel.2007.12.011; Zhao Y, 2009, MOL CELL BIOL, V29, P1017, DOI 10.1128/MCB.02123-07; Zhuang T, 2015, ONCOTARGET, V6, P43853, DOI 10.18632/oncotarget.6081	45	24	25	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2019	38	6					808	821		10.1038/s41388-018-0456-0	http://dx.doi.org/10.1038/s41388-018-0456-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK5LC	30177834	Green Published, hybrid			2022-12-17	WOS:000458006300004
J	Rubinstein, TA; Shahmoon, S; Zigmond, E; Etan, T; Merenbakh-Lamin, K; Pasmanik-Chor, M; Har-Zahav, G; Barshack, I; Vainer, GW; Skalka, N; Rosin-Arbesfeld, R; Varol, C; Rubinek, T; Wolf, I				Rubinstein, Tammi Arbel; Shahmoon, Shiri; Zigmond, Ehud; Etan, Tal; Merenbakh-Lamin, Keren; Pasmanik-Chor, Metsada; Har-Zahav, Gil; Barshack, Iris; Vainer, Gilad W.; Skalka, Nir; Rosin-Arbesfeld, Rina; Varol, Chen; Rubinek, Tami; Wolf, Ido			Klotho suppresses colorectal cancer through modulation of the unfolded protein response	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; TRANSCRIPTS ENCODING MEMBRANE; TUMOR-SUPPRESSOR; COLON-CANCER; BREAST-CANCER; BETA-CATENIN; GENE; EXPRESSION; METHYLATION; GROWTH	Klotho is an anti-aging transmembrane protein, which can be shed and function as a hormone. Accumulating data indicate klotho as a tumor suppressor in a wide array of malignancies and indicate the subdomain KL1 as the active region of the protein. We aimed to study the role of klotho as a tumor suppressor in colorectal cancer. Bioinformatics analyses of TCGA datasets indicated reduced klotho mRNA levels in human colorectal cancer, along with negative regulation of klotho expression by hypermethylation of the promoter and 1st exon, and hypomethylation of an area within the gene. Overexpression or treatment with klotho or KL1 inhibited proliferation of colorectal cancer cells in vitro. The in vivo activity of klotho and KL1 was examined using two models recapitulating development of tumors in the normal colonic environment of immune-competent mice. Treatment with klotho inhibited formation of colon polyps induced by the carcinogen azoxymethane, and KL1 treatment slowed growth of orthotopically-implanted colorectal tumors. Gene expression array revealed that klotho and KL1 expression enhanced the unfolded protein response (UPR) and this was further established by increased levels of spliced XBP1, GRP78 and phosphorylated-eIF2 alpha. Furthermore, attenuation of the UPR partially abrogated klotho tumor suppressor activity. In conclusion, this study indicates klotho as a tumor suppressor in colorectal cancer and identifies, for the first time, the UPR as a pathway mediating klotho activities in cancer. These data suggest that administration of exogenous klotho or KL1 may serve as a novel strategy for prevention and treatment of colorectal cancer.	[Rubinstein, Tammi Arbel; Shahmoon, Shiri; Etan, Tal; Merenbakh-Lamin, Keren; Rubinek, Tami; Wolf, Ido] Tel Aviv Sourasky Med Ctr, Inst Oncol, Tel Aviv, Israel; [Rubinstein, Tammi Arbel; Shahmoon, Shiri; Zigmond, Ehud; Etan, Tal; Har-Zahav, Gil; Barshack, Iris; Skalka, Nir; Rosin-Arbesfeld, Rina; Rubinek, Tami; Wolf, Ido] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Zigmond, Ehud; Varol, Chen] Tel Aviv Sourasky Med Ctr, Res Ctr Digest Tract & Liver Dis, Tel Aviv, Israel; [Pasmanik-Chor, Metsada] Tel Aviv Univ, Fac Life Sci, Bioinformat Unit, Tel Aviv, Israel; [Har-Zahav, Gil] Safra Childrens Hosp, Dept Pediat Surg, Sheba Med Ctr, Tel Hashomer, Israel; [Barshack, Iris] Sheba Med Ctr, Inst Pathol, Tel Hashomer, Israel; [Vainer, Gilad W.] Tel Aviv Sourasky Med Ctr, Inst Pathol, Tel Aviv, Israel; [Varol, Chen] Tel Aviv Univ, Sackler Fac Med, Dept Clin Microbiol & Immunol, Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Wolf, I (corresponding author), Tel Aviv Sourasky Med Ctr, Inst Oncol, Tel Aviv, Israel.; Wolf, I (corresponding author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.	wolf-i@inter.net.il	Varol, Chen/ABH-6487-2020; Vainer, Gilad W./ABH-8314-2020; Varol, Chen/AAW-4202-2021	Vainer, Gilad W./0000-0002-8828-8138; 				Abramovitz L, 2011, CLIN CANCER RES, V17, P4254, DOI 10.1158/1078-0432.CCR-10-2749; Banerjee S, 2013, CELL PHYSIOL BIOCHEM, V31, P659, DOI 10.1159/000350085; Berger E, 2011, BIOCHEM BIOPH RES CO, V409, P610, DOI 10.1016/j.bbrc.2011.05.043; Camilli TC, 2011, PIGM CELL MELANOMA R, V24, P175, DOI 10.1111/j.1755-148X.2010.00792.x; Chang Q, 2005, SCIENCE, V310, P490, DOI 10.1126/science.1114245; Chen B, 2012, CANCER BIOL THER, V13, P1221, DOI 10.4161/cbt.21420; Doi S, 2011, J BIOL CHEM, V286, P8655, DOI 10.1074/jbc.M110.174037; Guda K, 2007, CYTOTECHNOLOGY, V54, P85, DOI 10.1007/s10616-007-9083-2; Hanaoka M, 2018, J GASTROENTEROL, V53, P631, DOI 10.1007/s00535-017-1387-1; Hetz C, 2018, MOL CELL, V69, P169, DOI 10.1016/j.molcel.2017.06.017; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Landgraf M, 2018, TRENDS BIOTECHNOL, V36, P242, DOI 10.1016/j.tibtech.2017.12.001; Lee J, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-109; Li XX, 2017, ONCOGENE, V36, P6738, DOI 10.1038/onc.2017.284; Li XX, 2014, INT J ONCOL, V45, P611, DOI 10.3892/ijo.2014.2430; Ligumsky H, 2015, MOL CANCER RES, V13, P1398, DOI 10.1158/1541-7786.MCR-15-0141; Liu QF, 2015, IRAN J KIDNEY DIS, V9, P291; Lojkin I, 2015, CANCER LETT, V362, P149, DOI 10.1016/j.canlet.2015.03.035; Longo PA, 2013, METHOD ENZYMOL, V529, P227, DOI 10.1016/B978-0-12-418687-3.00018-5; Maas NL, 2015, CLIN CANCER RES, V21, P675, DOI 10.1158/1078-0432.CCR-13-3239; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Matsumura Y, 1998, BIOCHEM BIOPH RES CO, V242, P626, DOI 10.1006/bbrc.1997.8019; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Pan J, 2011, TUMOR BIOL, V32, P729, DOI 10.1007/s13277-011-0174-5; Peleg S, 2010, AM J PHYSIOL-GASTR L, V299, pG593, DOI 10.1152/ajpgi.00193.2010; Piton N, 2016, VIRCHOWS ARCH, V469, P145, DOI 10.1007/s00428-016-1961-6; Rubinek T, 2016, VITAM HORM, V101, P197, DOI 10.1016/bs.vh.2016.03.001; Rubinek T, 2012, BREAST CANCER RES TR, V133, P649, DOI 10.1007/s10549-011-1824-4; Shiraki-Iida T, 1998, FEBS LETT, V424, P6, DOI 10.1016/S0014-5793(98)00127-6; Skalka N, 2013, ONCOGENE, V32, P2836, DOI 10.1038/onc.2012.308; Snaebjornsson P, 2017, INT J CANCER, V141, P531, DOI 10.1002/ijc.30766; Song S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082968; Sun HD, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0717-0; Tang X, 2016, DIS ESOPHAGUS, V29, P207, DOI 10.1111/dote.12289; Thornton M, 2013, INT J CANCER, V133, P1408, DOI 10.1002/ijc.28137; Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315; Wang LJ, 2011, AM J CANCER RES, V1, P111; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; Wilhelm-Benartzi CS, 2013, BRIT J CANCER, V109, P1394, DOI 10.1038/bjc.2013.496; Wolf I, 2010, ONCOGENE, V29, P26, DOI 10.1038/onc.2009.301; Wolf I, 2008, ONCOGENE, V27, P7094, DOI 10.1038/onc.2008.292; Xie B, 2013, PATHOL ONCOL RES, V19, P611, DOI 10.1007/s12253-013-9663-8; Xing XM, 2006, CLIN CHIM ACTA, V364, P308, DOI 10.1016/j.cca.2005.07.016; Yang WJ, 2014, TUMOR BIOL, V35, P8267, DOI 10.1007/s13277-014-2100-0; Yang XJ, 2014, CANCER CELL, V26, P577, DOI 10.1016/j.ccr.2014.07.028; Zauber AG, 2012, NEW ENGL J MED, V366, P687, DOI 10.1056/NEJMoa1100370; Zigmond E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028858; Zismanov V, 2009, BRIT J CANCER, V101, P1402, DOI 10.1038/sj.bjc.6605291	50	24	26	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2019	38	6					794	807		10.1038/s41388-018-0489-4	http://dx.doi.org/10.1038/s41388-018-0489-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK5LC	30232408				2022-12-17	WOS:000458006300003
J	Guntuku, L; Gangasani, JK; Thummuri, D; Borkar, RM; Manavathi, B; Ragampeta, S; Vaidya, JR; Sistla, R; Vegi, NGM				Guntuku, Lalita; Gangasani, Jagadeesh Kumar; Thummuri, Dinesh; Borkar, Roshan M.; Manavathi, Bramanandam; Ragampeta, Srinivas; Vaidya, Jayathirtha Rao; Sistla, Ramakrishna; Vegi, Naidu G. M.			IITZ-01, a novel potent lysosomotropic autophagy inhibitor, has single-agent antitumor efficacy in triple-negative breast cancer in vitro and in vivo	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM; APOPTOSIS; DERIVATIVES; LYSOSOMES; PATHWAY; TARGETS; CELLS	Autophagy is a homeostatic process that recycles damaged organelles and long-lived proteins by delivering them in double-membrane vesicles to lysosomes for degradation. Autophagy has a prominent role in survival, proliferation, and resistance of tumors in metabolic and chemotherapeutic stress conditions. Clinical trials with chloroquine-a known autophagy inhibitor -were unable to achieve complete autophagy inhibition in vivo, warranting the search for more potent autophagy inhibitors. In a process of exploring the mechanism of action of previously identified cytotoxic s-triazine analogs, we discovered that both IITZ-01 and IITZ-02 act as potent autophagy inhibitors. Treatment with these compounds resulted in the vacuolated appearance of cells due to their specific accumulation in lysosomes. In addition, these basic compounds also deacidify lysosomes as evidenced by the decrease in lysotracker red staining and inhibit maturation of lysosomal enzymes leading to lysosomal dysfunction. IITZ-01 and IITZ-02 enhance autophagosome accumulation but inhibit autophagosomal degradation by impairing lysosomal function, finally resulting in the inhibition of autophagy. Interestingly, compound IITZ-01 exhibited more than 10-fold potent autophagy inhibition along with 12- to 20-fold better cytotoxic action than CQ. IITZ-01 and IITZ-02 also abolished mitochondrial membrane potential and triggered apoptosis through the mitochondria-mediated pathway. Furthermore, IITZ-01 and IITZ-02 displayed potent antitumor action in vivo through autophagy inhibition and apoptosis induction in MDA-MB-231 breast cancer xenograft model with IITZ-01 exhibiting superior anticancer efficacy. Overall, these data demonstrate that IITZ-01 is potent autophagy inhibitor with single-agent anticancer activity and awaits further preclinical development as potential anticancer therapeutic.	[Guntuku, Lalita; Thummuri, Dinesh; Vegi, Naidu G. M.] Natl Inst Pharmaceut Educ & Res, Dept Pharmacol & Toxicol, Hyderabad, TS, India; [Gangasani, Jagadeesh Kumar; Vaidya, Jayathirtha Rao] CSIR Indian Inst Chem Technol, Crop Protect Chem Div, Hyderabad, TS, India; [Gangasani, Jagadeesh Kumar; Vaidya, Jayathirtha Rao] AcSIR, Training & Dev Complex,CSIR Campus,CSIR Rd, Chennai, TN, India; [Borkar, Roshan M.; Ragampeta, Srinivas] CSIR Indian Inst Chem Technol, Natl Ctr Mass Spectrometry, Hyderabad, TS, India; [Manavathi, Bramanandam] Univ Hyderabad, Sch Life Sci, Dept Biochem, Hyderabad, TS, India; [Sistla, Ramakrishna] CSIR Indian Inst Chem Technol IICT, Med Chem & Pharmacol Div, Hyderabad, TS, India; [Vegi, Naidu G. M.] Natl Inst Pharmaceut Educ & Res, Dept Pharmacol & Toxicol, Gauhati, Assam, India	National Institute of Pharmaceutical Education & Research, Hyderabad; National Institute of Pharmaceutical Education & Research (NIPER); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Technology (IICT); Academy of Scientific & Innovative Research (AcSIR); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Technology (IICT); University of Hyderabad; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Technology (IICT); National Institute of Pharmaceutical Education & Research (NIPER)	Vegi, NGM (corresponding author), Natl Inst Pharmaceut Educ & Res, Dept Pharmacol & Toxicol, Hyderabad, TS, India.; Vegi, NGM (corresponding author), Natl Inst Pharmaceut Educ & Res, Dept Pharmacol & Toxicol, Gauhati, Assam, India.	vgmnaidu@gmail.com	Thummuri, Dinesh/Q-2252-2019; BORKAR, ROSHAN M/J-6995-2019; VAIDYA, JAYATHIRTHA RAO/AET-5302-2022	BORKAR, ROSHAN M/0000-0003-1963-7688; VAIDYA, JAYATHIRTHA RAO/0000-0002-6173-3617; Manavathi, Bramanandam/0000-0002-1797-398X	NIPER-Hyderabad; NIPER-Guwahati; Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India	NIPER-Hyderabad; NIPER-Guwahati; Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India	GL and DT are thankful to Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, and Director of NIPER-Hyderabad and NIPER-Guwahati, for providing fellowship and research activity to the authors. We also acknowledge Dr M Lakshman, Sri Venkateshwara University College of Veterinary Sciences, for his help in processing and acquisition of transmission electron microscopy images. We thank Jaya Lakshmi, Veera Bhadra Swami, and Vasu Penugurti for their technical guidance and support.	Alam MM, 2016, APOPTOSIS, V21, P1191, DOI 10.1007/s10495-016-1277-7; Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Ashoor R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082481; Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622; Cascioferro S, 2017, EUR J MED CHEM, V142, P523, DOI 10.1016/j.ejmech.2017.09.035; Chen C, 2017, MOLECULES, V22, DOI 10.3390/molecules22060891; Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003; Chude CI, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061279; Collignon J, 2016, BREAST CANCER-TARGET, V8, P93, DOI 10.2147/BCTT.S69488; de Castro MAG, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.12; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Endo S, 2017, GASTROENTEROLOGY, V152, P1492, DOI 10.1053/j.gastro.2017.01.010; Farrow JM, 2014, NAT REV UROL, V11, P508, DOI 10.1038/nrurol.2014.196; Fu D, 2014, NAT CHEM, V6, P615, DOI [10.1038/NCHEM.1961, 10.1038/nchem.1961]; Guggilapu SD, 2017, EUR J MED CHEM, V128, P1, DOI 10.1016/j.ejmech.2017.01.026; Han WD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028491; Hardwick JM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008722; Hata AN, 2015, CANCER DISCOV, V5, P475, DOI 10.1158/2159-8290.CD-15-0011; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Hudis CA, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2011-S1-01; Jain K, 2013, AM J CANCER RES, V3, P251; Katsuragi Y, 2015, FEBS J, V282, P4672, DOI 10.1111/febs.13540; Kim EL, 2010, NEURO-ONCOLOGY, V12, P389, DOI 10.1093/neuonc/nop046; Kirkegaard T, 2009, BBA-MOL CELL RES, V1793, P746, DOI 10.1016/j.bbamcr.2008.09.008; Kumar D, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-171; Kumar GJ, 2017, MED CHEM RES, V26, P3072, DOI 10.1007/s00044-017-1978-7; Kumar GJ, 2015, MED CHEM RES, V24, P3991, DOI 10.1007/s00044-015-1430-9; Kumar GJ, 2013, MED CHEM RES, V22, P5973, DOI 10.1007/s00044-013-0584-6; Lefort S, 2014, AUTOPHAGY, V10, P2122, DOI 10.4161/15548627.2014.981788; Liang DH, 2016, CANCER LETT, V376, P249, DOI 10.1016/j.canlet.2016.04.002; Linder S, 2005, DRUG RESIST UPDATE, V8, P199, DOI 10.1016/j.drup.2005.06.004; Liu B. B., 2015, MED CHEM, V5, P131, DOI [10.4172/2161-0444.1000255, DOI 10.4172/2161-0444.1000255]; Lu YY, 2014, AUTOPHAGY, V10, P1895, DOI 10.4161/auto.32200; Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762; Manic G, 2014, MOL CELL ONCOL, V1, DOI 10.4161/mco.29911; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Morissette G, 2004, J PHARMACOL EXP THER, V310, P395, DOI 10.1124/jpet.104.066084; Mowers EE, 2017, ONCOGENE, V36, P1619, DOI 10.1038/onc.2016.333; Nadanaciva S, 2011, TOXICOL IN VITRO, V25, P715, DOI 10.1016/j.tiv.2010.12.010; OHKUMA S, 1981, J CELL BIOL, V90, P656, DOI 10.1083/jcb.90.3.656; Pal S, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-553; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Peterson EA, 2011, BIOORG MED CHEM LETT, V21, P2064, DOI 10.1016/j.bmcl.2011.02.007; POOLE B, 1981, J CELL BIOL, V90, P665, DOI 10.1083/jcb.90.3.665; Ramya PVS, 2018, EUR J MED CHEM, V143, P216, DOI 10.1016/j.ejmech.2017.11.010; Repnik U, 2010, MITOCHONDRION, V10, P662, DOI 10.1016/j.mito.2010.07.008; Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984; Shrivastava S, 2015, EXP MOL PATHOL, V98, P313, DOI 10.1016/j.yexmp.2015.03.031; Shrivastava S, 2014, APOPTOSIS, V19, P1148, DOI 10.1007/s10495-014-0991-2; Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350; Thorburn AM, 2014, MOL PHARM, V114; Wang J, 2014, J BIOL CHEM, V289, P17163, DOI 10.1074/jbc.M114.558288; Welker ME, 2013, BIOORGAN MED CHEM, V21, P4063, DOI 10.1016/j.bmc.2013.04.083; Yaguchi SI, 2006, JNCI-J NATL CANCER I, V98, P545, DOI 10.1093/jnci/djj133; Zhao XJ, 2015, AUTOPHAGY, V11, P1849, DOI 10.1080/15548627.2015.1017185	61	24	24	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2019	38	4					581	595		10.1038/s41388-018-0446-2	http://dx.doi.org/10.1038/s41388-018-0446-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HI6UB	30166591				2022-12-17	WOS:000456589800009
J	Ferrandino, F; Bernardini, G; Tsaouli, G; Grazioli, P; Campese, AF; Noce, C; Ciuffetta, A; Vacca, A; Besharat, ZM; Bellavia, D; Screpanti, I; Felli, MP				Ferrandino, Francesca; Bernardini, Giovanni; Tsaouli, Georgia; Grazioli, Paola; Campese, Antonio Francesco; Noce, Claudia; Ciuffetta, Ambra; Vacca, Alessandra; Besharat, Zein Mersini; Bellavia, Diana; Screpanti, Isabella; Felli, Maria Pia			Intrathymic Notch3 and CXCR4 combinatorial interplay facilitates T-cell leukemia propagation	ONCOGENE			English	Article							NF-KAPPA-B; ACUTE LYMPHOBLASTIC-LEUKEMIA; PRE-TCR; ACTIVATING MUTATIONS; ADRENERGIC-RECEPTOR; SIGNALING PATHWAYS; BONE; EXPRESSION; PROTEIN; BETA	Notch hyperactivation dominates T-cell acute lymphoblastic leukemia development, but the mechanisms underlying "pre-leukemic" cell dissemination are still unclear. Here we describe how deregulated Notch3 signaling enhances CXCR4 cell-surface expression and migratory ability of CD4(+)CD8(+) thymocytes, possibly contributing to "pre-leukemic" cell propagation, early in disease progression. In transgenic mice overexpressing the constitutively active Notch3 intracellular domain, we detect the progressive increase in circulating blood and bone marrow of CD4(+)CD8(+) cells, characterized by high and combined surface expression of Notch3 and CXCR4. We report for the first time that transplantation of such CD4(+)CD8(+) cells reveals their competence in infiltrating spleen and bone marrow of immunocompromised recipient mice. We also show that CXCR4 surface expression is central to the migratory ability of CD4(+)CD8(+) cells and such an expression is regulated by Notch3 through beta-arrestin in human leukemia cells. De novo, we propose that hyperactive Notch3 signaling by boosting CXCR4-dependent migration promotes anomalous egression of CD4(+)CD8(+) cells from the thymus in early leukemia stages. In fact, in vivo CXCR4 antagonism prevents bone marrow colonization by such CD4(+)CD8(+) cells in young Notch3 transgenic mice. Therefore, our data suggest that combined therapies precociously counteracting intrathymic Notch3/CXCR4 crosstalk may prevent dissemination of "pre-leukemic" CD4(+)CD8(+ )cells, by a "thymus-autonomous" mechanism.	[Ferrandino, Francesca; Grazioli, Paola; Vacca, Alessandra; Besharat, Zein Mersini; Felli, Maria Pia] Sapienza Univ, Dept Expt Med, Viale Regina Elena 324, I-00161 Rome, Italy; [Bernardini, Giovanni; Tsaouli, Georgia; Campese, Antonio Francesco; Noce, Claudia; Ciuffetta, Ambra; Bellavia, Diana; Screpanti, Isabella] Sapienza Univ, Dept Mol Med, Viale Regina Elena 291, I-00161 Rome, Italy; [Bernardini, Giovanni] IRCCS Neuromed, Via Atinense 18, I-86077 Pozzilli, IS, Italy	Sapienza University Rome; Sapienza University Rome; IRCCS Neuromed	Felli, MP (corresponding author), Sapienza Univ, Dept Expt Med, Viale Regina Elena 324, I-00161 Rome, Italy.; Screpanti, I (corresponding author), Sapienza Univ, Dept Mol Med, Viale Regina Elena 291, I-00161 Rome, Italy.	isabella.screpanti@uniroma1.it; mariapia.felli@uniroma1.it	BERNARDINI, Giovanni/AAA-8160-2019; Bellavia, Diana/AAO-6348-2021; Ferrandino, Francesca/AAA-4905-2020; Besharat, Zein Mersini/G-5413-2013; Bernardini, Giovanni/GRJ-0070-2022	BERNARDINI, Giovanni/0000-0002-3705-2598; Besharat, Zein Mersini/0000-0003-0317-9854; Bellavia, Diana/0000-0001-5728-2537; FELLI, MARIA PIA/0000-0002-5765-2611	Sapienza University; Ateneo 2015 [C26A15MHEL]; Ateneo 2016 [RP116154CE3A9FA1]	Sapienza University; Ateneo 2015; Ateneo 2016	Dedicated to Alberto Gulino. We thank Maria Pelullo, Giulia Diluvio, and Rebeka Popovic for skillful assistance in experiments, Mr. Alessandro Martini for mouse husbandry and Mr. Fernando Duranti for technical assistance, and Sarah Sturman for help in editing the manuscript. Funding was provided by Sapienza University, Ateneo 2015 (C26A15MHEL), and Ateneo 2016 (RP116154CE3A9FA1) to MPF.	Ara T, 2003, J IMMUNOL, V170, P4649, DOI 10.4049/jimmunol.170.9.4649; Armstrong F, 2009, BLOOD, V113, P1730, DOI 10.1182/blood-2008-02-138172; Barbarulo A, 2011, J IMMUNOL, V186, P6199, DOI 10.4049/jimmunol.1002136; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Bellavia D, 2002, P NATL ACAD SCI USA, V99, P3788, DOI 10.1073/pnas.062050599; Bellavia D, 2007, EMBO J, V26, P1670, DOI 10.1038/sj.emboj.7601626; Ben-Baruch A, 2009, CELL ADHES MIGR, V3, P328, DOI 10.4161/cam.3.4.9211; Bernardini G, 2005, FASEB J, V19, P1305, DOI 10.1096/fj.04-3352fje; Bernardini G, 2008, BLOOD, V111, P3626, DOI 10.1182/blood-2007-08-106203; Bernasconi-Elias P, 2016, ONCOGENE, V35, P6077, DOI 10.1038/onc.2016.133; Campese AF, 2003, SEMIN CELL DEV BIOL, V14, P151, DOI 10.1016/S1084-9521(02)00184-2; Campese AF, 2006, BLOOD, V108, P305, DOI 10.1182/blood-2006-01-0143; Campese AF, 2014, BIOL REPROD, V90, DOI 10.1095/biolreprod.113.113803; Chatterjee S, 2014, ADV CANCER RES, V124, P31, DOI 10.1016/B978-0-12-411638-2.00002-1; Checquolo S, 2010, ONCOGENE, V29, P1463, DOI 10.1038/onc.2009.446; Cyster JG, 2002, J CLIN INVEST, V109, P1011, DOI 10.1172/JCI200215511; Felli MP, 2005, ONCOGENE, V24, P992, DOI 10.1038/sj.onc.1208302; Felli MP, 1999, INT IMMUNOL, V11, P1017, DOI 10.1093/intimm/11.7.1017; Franciosa G, 2016, ONCOGENE, V35, P4741, DOI 10.1038/onc.2016.5; Geminder H, 2001, J IMMUNOL, V167, P4747, DOI 10.4049/jimmunol.167.8.4747; Goertzen CG, 2016, CELL SIGNAL, V28, P165, DOI 10.1016/j.cellsig.2015.12.010; Halkias J, 2013, J CLIN INVEST, V123, P2131, DOI 10.1172/JCI67175; Homminga I, 2011, CANCER CELL, V19, P484, DOI 10.1016/j.ccr.2011.02.008; Hupfeld CJ, 2005, J BIOL CHEM, V280, P1016, DOI 10.1074/jbc.M403674200; Janas ML, 2010, TRENDS IMMUNOL, V31, P370, DOI 10.1016/j.it.2010.07.002; Janas ML, 2010, J EXP MED, V207, P247, DOI 10.1084/jem.20091430; Jost TR, 2016, J LEUKOCYTE BIOL, V99, P1077, DOI 10.1189/jlb.5MA0915-394R; Kuksin CA, 2015, BLOOD, V125, P2087, DOI 10.1182/blood-2014-08-594796; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Lin FT, 1999, J BIOL CHEM, V274, P15971, DOI 10.1074/jbc.274.23.15971; Liu T, 2016, EXP HEMATOL ONCOL, V5, DOI 10.1186/s40164-016-0050-5; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Marchese A, 2013, CELL SIGNAL, V25, P707, DOI 10.1016/j.cellsig.2012.11.024; Martins VC, 2014, NATURE, V509, P465, DOI 10.1038/nature13317; Massimi I, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/607957; Mirandola L, 2012, J PATHOL, V226, P713, DOI 10.1002/path.3015; Parretta E, 2008, J IMMUNOL, V180, P7230, DOI 10.4049/jimmunol.180.11.7230; Passaro D, 2015, CANCER CELL, V27, P769, DOI 10.1016/j.ccell.2015.05.003; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Pelullo M, 2014, NEOPLASIA, V16, P1007, DOI 10.1016/j.neo.2014.10.004; Petrie HT, 2007, ANNU REV IMMUNOL, V25, P649, DOI 10.1146/annurev.immunol.23.021704.115715; Pitt LA, 2015, CANCER CELL, V27, P755, DOI 10.1016/j.ccell.2015.05.002; Plotkin J, 2003, J IMMUNOL, V171, P4521, DOI 10.4049/jimmunol.171.9.4521; Poznansky MC, 2000, NAT MED, V6, P543, DOI 10.1038/75022; Puca L, 2014, J CELL SCI, V127, P1359, DOI 10.1242/jcs.142539; Quaranta R, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.326; Radtke F, 2013, NAT REV IMMUNOL, V13, P427, DOI 10.1038/nri3445; Russell HV, 2004, J PEDIATR SURG, V39, P1506, DOI 10.1016/j.jpedsurg.2004.06.019; Scupoli MT, 2008, HAEMATOLOGICA, V93, P524, DOI 10.3324/haematol.12098; Talora C, 2006, BLOOD, V107, P3313, DOI 10.1182/blood-2005-07-2823; Talora C, 2003, EMBO REP, V4, P1067, DOI 10.1038/sj.embor.7400013; Trampont PC, 2010, NAT IMMUNOL, V11, P162, DOI 10.1038/ni.1830; Uckun FM, 1998, BLOOD, V91, P735; Vacca A, 2006, EMBO J, V25, P1000, DOI 10.1038/sj.emboj.7600996; Van Vlierberghe P, 2012, J CLIN INVEST, V122, P3398, DOI 10.1172/JCI61269; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160	57	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2018	37	49					6285	6298		10.1038/s41388-018-0401-2	http://dx.doi.org/10.1038/s41388-018-0401-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HD3AP	30038265	Green Published, hybrid			2022-12-17	WOS:000452384400001
J	Seo, J; Lee, EW; Shin, J; Seong, D; Nam, YW; Jeong, M; Lee, SH; Lee, C; Song, J				Seo, Jinho; Lee, Eun-Woo; Shin, Jihye; Seong, Daehyeon; Nam, Young Woo; Jeong, Manhyung; Lee, Seon-Hyeong; Lee, Cheolju; Song, Jaewhan			K6 linked polyubiquitylation of FADD by CHIP prevents death inducing signaling complex formation suppressing cell death	ONCOGENE			English	Article							UBIQUITIN LIGASE CHIP; CONTAINING PROTEIN; APOPTOSIS; FAS; PHOSPHORYLATION; KINASE; DOMAIN; CASPASE-8; RECEPTOR; CHAINS	Fas-associated death domain (FADD) is an adaptor protein recruiting complexes of caspase 8 to death ligand receptors to induce extrinsic apoptotic cell death in response to a TNF superfamily member. Although, formation of the complex of FADD and caspase 8 upon death stimuli has been studied in detail, posttranslational modifications fine-tuning these processes have yet to be identified. Here we revealed that K6-linked polyubiquitylation of FADD on lysines 149 and 153 mediated by C terminus HSC70-interacting protein (CHIP) plays an important role in preventing formation of the death inducing signaling complex (DISC), thus leading to the suppression of cell death. Cells depleted of CHIP showed higher sensitivity toward death ligands such as FasL and TRAIL, leading to upregulation of DISC formation composed of a death receptor, FADD, and caspase 8. CHIP was able to bind to FADD, induce K6-linked polyubiquitylation of FADD, and suppress DISC formation. By mass spectrometry, lysines 149 and 153 of FADD were found to be responsible for CHIP-mediated FADD ubiquitylation. FADD mutated at these sites was capable of more potent cell death induction as compared with the wild type and was no longer suppressed by CHIP. On the other hand, CHIP deficient in E3 ligase activity was not capable of suppressing FADD function and of FADD ubiquitylation. CHIP depletion in ME-180 cells induced significant sensitization of these cells toward TRAIL in xenograft analyses. These results imply that K6-linked ubiquitylation of FADD by CHIP is a crucial checkpoint in cytokine-dependent extrinsic apoptosis.	[Seo, Jinho; Seong, Daehyeon; Nam, Young Woo; Jeong, Manhyung; Song, Jaewhan] Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biochem, Seoul 03722, South Korea; [Lee, Eun-Woo] KRIBB, Metab Regulat Res Ctr, Daejeon 34141, South Korea; [Shin, Jihye; Lee, Cheolju] Korea Inst Sci & Technol, Ctr Theragnosis, 5 Hwarang Ro 14 Gil, Seoul 02792, South Korea; [Lee, Seon-Hyeong] Natl Canc Ctr, Canc Cell & Mol Biol Branch, Div Canc Biol, Goyang 10408, South Korea	Yonsei University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Institute of Science & Technology (KIST); National Cancer Center - Korea (NCC)	Song, J (corresponding author), Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biochem, Seoul 03722, South Korea.	jso678@yonsei.ac.kr	Lee, Eun-Woo/AAP-9603-2020	Song, Jaewhan/0000-0001-8152-9210; Lee, Eun-Woo/0000-0002-5156-0003	Ministry of Science, ICT, and Future Planning [2015R1A3A2066581]; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [2017R1A6A3A11035262]; BK21 Plus project of the National Research Foundation of Korea Grant	Ministry of Science, ICT, and Future Planning(Ministry of Science, ICT & Future Planning, Republic of Korea); Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education(National Research Foundation of KoreaMinistry of Education (MOE), Republic of Korea); BK21 Plus project of the National Research Foundation of Korea Grant(National Research Foundation of Korea)	This research was supported by a grant from the Ministry of Science, ICT, and Future Planning (2015R1A3A2066581) (Jaewhan S.) and by the Basic Science Research Program through the National Research Foundation of Korea (NRF) Funded by the Ministry of Education (2017R1A6A3A11035262) (Jinho S.). Additionally, this research was partly supported by the BK21 Plus project of the National Research Foundation of Korea Grant (Jinho S., D.S., M.J., and Y.W. N.), and C.L. acknowledges institutional support by KIST.	Alappat EC, 2005, MOL CELL, V19, P321, DOI 10.1016/j.molcel.2005.06.024; Alappat EC, 2003, J BIOL CHEM, V278, P41585, DOI 10.1074/jbc.C300385200; Alberti S, 2002, J BIOL CHEM, V277, P45920, DOI 10.1074/jbc.M204196200; Algeciras-Schimnich A, 1999, J IMMUNOL, V162, P5205; Arndt V, 2005, MOL BIOL CELL, V16, P5891, DOI 10.1091/mbc.E05-07-0660; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bellail AC, 2012, CANCER DISCOV, V2, P140, DOI 10.1158/2159-8290.CD-11-0172; Ben-Saadon R, 2006, MOL CELL, V24, P701, DOI 10.1016/j.molcel.2006.10.022; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Cursi S, 2006, EMBO J, V25, P1895, DOI 10.1038/sj.emboj.7601085; Durcan TM, 2014, EMBO J, V33, P2473, DOI 10.15252/embj.201489729; Esser C, 2005, J BIOL CHEM, V280, P27443, DOI 10.1074/jbc.M501574200; Fulda S, 2000, CANCER RES, V60, P3947; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Geserick P, 2009, J CELL BIOL, V187, P1037, DOI 10.1083/jcb.200904158; Henry CM, 2017, MOL CELL, V65, P715, DOI 10.1016/j.molcel.2017.01.022; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hospenthal MK, 2013, NAT STRUCT MOL BIOL, V20, P555, DOI 10.1038/nsmb.2547; Hua ZC, 2003, IMMUNITY, V18, P513, DOI 10.1016/S1074-7613(03)00083-9; Jeong M, 2017, ONCOGENE, V36, P458, DOI 10.1038/onc.2016.215; Kalia LV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014695; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim C, 2016, CELL DEATH DIFFER, V23, P333, DOI 10.1038/cdd.2015.103; Kim HT, 2009, EMBO J, V28, P1867, DOI 10.1038/emboj.2009.115; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Lee EW, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1981; Lees MJ, 2003, J BIOL CHEM, V278, P35878, DOI 10.1074/jbc.M302430200; McDonald ER, 2004, P NATL ACAD SCI USA, V101, P6170, DOI 10.1073/pnas.0307459101; Mert U, 2017, CELL MOL LIFE SCI, V74, P245, DOI 10.1007/s00018-016-2321-z; Morgan MJ, 2009, J IMMUNOL, V183, P3278, DOI 10.4049/jimmunol.0803428; Morris JR, 2004, HUM MOL GENET, V13, P807, DOI 10.1093/hmg/ddh095; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Ohta T, 2011, FEBS LETT, V585, P2836, DOI 10.1016/j.febslet.2011.05.005; Paul I, 2015, INT J BIOCHEM CELL B, V58, P37, DOI 10.1016/j.biocel.2014.10.027; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Rochat-Steiner V, 2000, J EXP MED, V192, P1165, DOI 10.1084/jem.192.8.1165; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Scaglione KM, 2011, MOL CELL, V43, P599, DOI 10.1016/j.molcel.2011.05.036; Scott FL, 2009, NATURE, V457, P1019, DOI 10.1038/nature07606; Seo J, 2016, NAT CELL BIOL, V18, P291, DOI 10.1038/ncb3314; Shimamoto S, 2013, J BIOL CHEM, V288, P7158, DOI 10.1074/jbc.M112.436758; Srivastava D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.1; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; Wang LW, 2010, NAT STRUCT MOL BIOL, V17, P1324, DOI 10.1038/nsmb.1920; Wu-Baer F, 2003, J BIOL CHEM, V278, P34743, DOI 10.1074/jbc.C300249200; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899	48	24	25	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2018	37	36					4994	5006		10.1038/s41388-018-0323-z	http://dx.doi.org/10.1038/s41388-018-0323-z			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS6QR	29795330				2022-12-17	WOS:000443823600007
J	He, H; Sinha, I; Fan, RR; Haldosen, LA; Yan, FF; Zhao, CY; Dahlman-Wright, K				He, Huan; Sinha, Indranil; Fan, Rongrong; Haldosen, Lars-Arne; Yan, Feifei; Zhao, Chunyan; Dahlman-Wright, Karin			c-Jun/AP-1 overexpression reprograms ER alpha signaling related to tamoxifen response in ER alpha-positive breast cancer	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; ENDOCRINE RESISTANCE; MATRIX PROTEIN; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; PHOSPHOLIPASE-D; DNA-BINDING; TGF-BETA; CELLS; FOXA1	A critical mechanism that has been proposed for transcription regulation by estrogen receptor a (ER) is the tethering of ER to DNA via other transcription factors, such as AP-1. However, genome-wide assessment of the overlap in chromatin binding repertoires of these two transcription factors has not been reported. Here, we show that the AP-1 transcription factor c-Jun interacts with ER and that c-Jun chromatin binding shows extensive overlap with ER binding at the global level. Further, we show that c-Jun overexpression reprograms ER chromatin binding and modulates ER-mediated gene regulation. Our data are consistent with a mechanism where estrogen/ER-dependent crosstalk with AP-1 at the transcriptional level is mediated through the tethering of ER to DNA bound AP-1. Additionally, in our system c-Jun overexpression causes reduced sensitivity to tamoxifen in ER+ breast cancer cells. Integrated cistrome, transcriptome, and clinical data reveal TGFBI as a candidate gene which may confer tamoxifen resistance by ER and AP-1 crosstalk. Further, we show that TGFBI expression is elevated in breast cancer compared to normal breast. Together, our data provide a novel genome-wide footprint of ER and AP-1 crosstalk and suggest AP-1 and TGFBI signaling as potential therapeutic targets in AP-1-overexpressing ER-positive breast tumors.	[He, Huan; Sinha, Indranil; Fan, Rongrong; Haldosen, Lars-Arne; Yan, Feifei; Zhao, Chunyan; Dahlman-Wright, Karin] Karolinska Inst, Dept Biosci & Nutr, Novum, SE-14183 Huddinge, Sweden	Karolinska Institutet	Zhao, CY (corresponding author), Karolinska Inst, Dept Biosci & Nutr, Novum, SE-14183 Huddinge, Sweden.	chunyan.zhao@ki.se	Fan, Rongrong/AAG-2200-2019; He, Huan/AAF-9644-2019; Fan, Rongrong/N-3446-2017	Fan, Rongrong/0000-0002-5707-1497; Fan, Rongrong/0000-0002-5707-1497; Sinha, Indranil/0000-0002-2513-5927; He, Huan/0000-0001-8123-5765	China Scholarship Council; Karolinska Institutet; Swedish Cancer Society (Cancerfonden)	China Scholarship Council(China Scholarship Council); Karolinska Institutet(Karolinska Institutet); Swedish Cancer Society (Cancerfonden)(Swedish Cancer Society)	The authors thank the Bioinformatic and Expression Analysis core facility at the Karolinska Institute (http://www.bea.ki.se/) for performing the Affymetrix and ChIP-seq assays and Hui Gao for critically reading the manuscript. This work was supported by scholarship from the China Scholarship Council, a PhD student grant (KID) from the Karolinska Institutet and grants from the Swedish Cancer Society (Cancerfonden).	Ahmed AA, 2007, CANCER CELL, V12, P514, DOI 10.1016/j.ccr.2007.11.014; Ali S, 2016, BIOINFORMATION, V12, P135, DOI 10.6026/97320630012135; Biddie SC, 2011, MOL CELL, V43, P145, DOI 10.1016/j.molcel.2011.06.016; Brown HA, 2017, NAT REV DRUG DISCOV, V16, P351, DOI 10.1038/nrd.2016.252; Brunen D, 2013, CELL CYCLE, V12, P2960, DOI 10.4161/cc.26034; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Cheung E, 2005, P NATL ACAD SCI USA, V102, P559, DOI 10.1073/pnas.0407113102; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dahlman-Wright K, 2012, CARCINOGENESIS, V33, P1684, DOI 10.1093/carcin/bgs223; Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8; den Hollander P, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00250; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fu XY, 2016, P NATL ACAD SCI USA, V113, pE6600, DOI 10.1073/pnas.1612835113; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Heldring N, 2011, MOL ENDOCRINOL, V25, P564, DOI 10.1210/me.2010-0425; Hung MS, 2015, ONCOL REP, V34, P3187, DOI 10.3892/or.2015.4324; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ji ZL, 2012, MOL CELL BIOL, V32, P385, DOI 10.1128/MCB.05504-11; Jia M, 2016, CANCER RES, V76, P5634, DOI 10.1158/0008-5472.CAN-15-2910; Jin HJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4972; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Kharman-Biz A, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-441; Kong SL, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.59; Luo M, 2005, MOL CELL BIOL, V25, P7386, DOI 10.1128/MCB.25.16.7386-7398.2005; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Lupien M, 2010, GENE DEV, V24, P2219, DOI 10.1101/gad.1944810; Ma C, 2008, GENE DEV, V22, P308, DOI 10.1101/gad.1632008; Malorni L, 2016, MOL CANCER RES, V14, P470, DOI 10.1158/1541-7786.MCR-15-0423; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Neuzillet C, 2015, PHARMACOL THERAPEUT, V147, P22, DOI 10.1016/j.pharmthera.2014.11.001; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Robinson JLL, 2014, ONCOGENE, V33, P5666, DOI 10.1038/onc.2013.508; Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Schneider D, 2002, BBA-MOL BASIS DIS, V1588, P1, DOI 10.1016/S0925-4439(02)00052-2; Shaulian E, 2010, CELL SIGNAL, V22, P894, DOI 10.1016/j.cellsig.2009.12.008; Shen Q, 2011, J BIOL CHEM, V286, P14554, DOI 10.1074/jbc.M110.165704; Stender JD, 2017, MOL CELL, V65, P1122, DOI 10.1016/j.molcel.2017.02.008; Stender JD, 2010, MOL CELL BIOL, V30, P3943, DOI 10.1128/MCB.00118-10; Sun M, 2012, MOL ENDOCRINOL, V26, P736, DOI 10.1210/me.2011-1158; Theodorou V, 2013, GENOME RES, V23, P12, DOI 10.1101/gr.139469.112; TINIAKOS DG, 1994, J PATHOL, V172, P19, DOI 10.1002/path.1711720106; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Ween MP, 2012, INT J MOL SCI, V13, P10461, DOI 10.3390/ijms130810461; Wright TM, 2014, MOL CANCER RES, V12, P1829, DOI 10.1158/1541-7786.MCR-14-0195; Zhang Y, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-145; Zhao CY, 2007, CANCER RES, V67, P3955, DOI 10.1158/0008-5472.CAN-06-3505; Zhao CY, 2014, CANCER RES, V74, P3983, DOI 10.1158/0008-5472.CAN-13-3396; Zhao CY, 2010, J BIOL CHEM, V285, P39575, DOI 10.1074/jbc.R110.180109; Zhu J, 2014, ONCOGENE, V33, P4340, DOI 10.1038/onc.2013.573	52	24	27	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	19					2586	2600		10.1038/s41388-018-0165-8	http://dx.doi.org/10.1038/s41388-018-0165-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GF3RN	29467493				2022-12-17	WOS:000431873400010
J	Cajal, SRY; Castellvi, J; Hummer, S; Peg, V; Pelletier, J; Sonenberg, N				Ramon y Cajal, Santiago; Castellvi, Josep; Hummer, Stefan; Peg, Vicente; Pelletier, Jerry; Sonenberg, Nahum			Beyond molecular tumor heterogeneity: protein synthesis takes control	ONCOGENE			English	Review							INITIATION-FACTOR 4E; PHOSPHORYLATED 4E-BINDING PROTEIN-1; BREAST-CANCER; EUKARYOTIC TRANSLATION; BINDING-PROTEIN; POOR-PROGNOSIS; 4E-BP1 PHOSPHORYLATION; EIF4E EXPRESSION; MAMMALIAN TARGET; CLONAL EVOLUTION	One of the daunting challenges facing modern medicine lies in the understanding and treatment of tumor heterogeneity. Most tumors show intra-tumor heterogeneity at both genomic and proteomic levels, with marked impacts on the responses of therapeutic targets. Therapeutic target-related gene expression pathways are affected by hypoxia and cellular stress. However, the finding that targets such as eukaryotic initiation factor (eIF) 4E (and its phosphorylated form, p-eIF4E) are generally homogenously expressed throughout tumors, regardless of the presence of hypoxia or other cellular stress conditions, opens the exciting possibility that malignancies could be treated with therapies that combine targeting of eIF4E phosphorylation with immune checkpoint inhibitors or chemotherapy.	[Ramon y Cajal, Santiago; Castellvi, Josep; Hummer, Stefan; Peg, Vicente] Univ Autonoma Barcelona, Vall dHebron Res Inst VHIR, Translat Mol Pathol, Passeig Vall dHebron 119-129, Barcelona 08035, Spain; [Ramon y Cajal, Santiago; Castellvi, Josep; Peg, Vicente] Vall dHebron Hosp, Pathol Dept, Barcelona 08035, Spain; [Ramon y Cajal, Santiago; Castellvi, Josep; Hummer, Stefan; Peg, Vicente] Spanish Biomed Res Network Ctr Oncol CIBERONC, Madrid, Spain; [Pelletier, Jerry; Sonenberg, Nahum] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Pelletier, Jerry; Sonenberg, Nahum] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ, Canada	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Hospital Universitari Vall d'Hebron; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; McGill University; McGill University	Cajal, SRY (corresponding author), Univ Autonoma Barcelona, Vall dHebron Res Inst VHIR, Translat Mol Pathol, Passeig Vall dHebron 119-129, Barcelona 08035, Spain.	sramon@vhebron.net	Ramon y Cajal, Santiago/H-4955-2016; Hümmer, Stefan/J-9861-2013; Peg., Vicente/AAC-9447-2020; Castellvi, Josep/C-5092-2014; Peg, Vicente/E-9160-2018	Ramon y Cajal, Santiago/0000-0002-3867-1390; Hümmer, Stefan/0000-0002-8184-3872; Peg., Vicente/0000-0002-5203-6166; Castellvi, Josep/0000-0001-5745-9996; Peg, Vicente/0000-0002-5203-6166	Fondo de Investigaciones Sanitarias [P1170185, PI 14/01320]; Redes Tematicas de Investigacion Cooperativa en Salud (RTICC) [RD 12/0036/0057]; Generalitat de Catalunya (AGAUR) [1131]; CIBERONC	Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Redes Tematicas de Investigacion Cooperativa en Salud (RTICC); Generalitat de Catalunya (AGAUR)(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)Generalitat de Catalunya); CIBERONC	SRYC acknowledges support from Fondo de Investigaciones Sanitarias (P1170185 and PI 14/01320), Redes Tematicas de Investigacion Cooperativa en Salud (RTICC, RD 12/0036/0057), Generalitat de Catalunya (AGAUR, 2014, 1131), and CIBERONC 2017.	Armengol G, 2007, CANCER RES, V67, P7551, DOI 10.1158/0008-5472.CAN-07-0881; Banerji CRS, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004115; Benavente S, 2009, INT J RADIAT ONCOL, V75, P1316, DOI 10.1016/j.ijrobp.2009.01.004; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Bhat M, 2015, NAT REV DRUG DISCOV, V14, P261, DOI 10.1038/nrd4505; Bordeleau ME, 2008, J CLIN INVEST, V118, P2651, DOI 10.1172/JCI34753; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Buckley NE, 2016, SCI REP-UK, V6, DOI 10.1038/srep23383; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Buxade M, 2008, FRONT BIOSCI-LANDMRK, V13, P5359, DOI 10.2741/3086; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Campbell L, 2015, AM J CANCER RES, V5, P2838; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Castellvi J, 2006, CANCER-AM CANCER SOC, V107, P1801, DOI 10.1002/cncr.22195; Castellvi J, 2009, HUM PATHOL, V40, P1418, DOI 10.1016/j.humpath.2008.12.019; Cencic R, 2011, J VIROL, V85, P6381, DOI 10.1128/JVI.00078-11; Cencic R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005223; Chao MW, 2015, ONCOTARGET, V6, P24092, DOI 10.18632/oncotarget.4483; Chao YK, 2012, J SURG ONCOL, V105, P288, DOI 10.1002/jso.22097; Chen LM, 2012, ONCOTARGET, V3, P869, DOI 10.18632/oncotarget.598; Chen Y, 2017, NEOPLASMA, V64, P787, DOI 10.4149/neo_2017_518; Chen YT, 2017, PATHOL RES PRACT, V213, P490, DOI 10.1016/j.prp.2017.02.004; Coleman LJ, 2009, BRIT J CANCER, V100, P1393, DOI 10.1038/sj.bjc.6605044; Dai XF, 2014, SCI REP-UK, V4, DOI 10.1038/srep06566; Darb-Esfahani S, 2009, J CANCER RES CLIN, V135, P933, DOI 10.1007/s00432-008-0529-5; De Luca A, 2012, EXPERT OPIN THER TAR, V16, pS17, DOI 10.1517/14728222.2011.639361; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; Di Gregorio A, 2016, DEV CELL, V38, P621, DOI 10.1016/j.devcel.2016.08.012; Diab S, 2014, CHEMMEDCHEM, V9, P962, DOI 10.1002/cmdc.201300552; Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738; Doroshow JH, 2014, NAT REV CLIN ONCOL, V11, P649, DOI 10.1038/nrclinonc.2014.158; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Dreas A, 2017, CURR MED CHEM, V24, P3025, DOI 10.2174/0929867324666170203123427; Faes S, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1726078; Fan WB, 2017, J NEURO-ONCOL, V131, P485, DOI 10.1007/s11060-016-2327-2; Fang Z, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0940-5; Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI 10.1001/jamaoncol.2016.5688; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Ghosh B, 2009, ACS CHEM BIOL, V4, P367, DOI 10.1021/cb9000475; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Graff JR, 2008, CANCER RES, V68, P631, DOI 10.1158/0008-5472.CAN-07-5635; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Han M, 2014, J INT MED RES, V42, P976, DOI 10.1177/0300060514527912; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Heikkinen T, 2013, BREAST CANCER RES TR, V141, P79, DOI 10.1007/s10549-013-2671-2; Hong DS, 2011, CLIN CANCER RES, V17, P6582, DOI 10.1158/1078-0432.CCR-11-0430; Hu AX, 2014, TUMORI, V100, P541, DOI 10.1700/1660.18176; Irish JM, 2004, CELL, V118, P217, DOI 10.1016/j.cell.2004.06.028; Jares P, 2012, J CLIN INVEST, V122, P3416, DOI 10.1172/JCI61272; Jiang XM, 2016, J CANCER RES CLIN, V142, P2309, DOI 10.1007/s00432-016-2232-2; Jiao XD, 2013, HEPATO-GASTROENTEROL, V60, P921, DOI 10.5754/hge12865; Karlsson E, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3557; Khosravi S, 2015, J INVEST DERMATOL, V135, P1358, DOI 10.1038/jid.2014.552; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Kolch W, 2015, NAT REV CANCER, V15, P515, DOI 10.1038/nrc3983; Konicek BW, 2011, CANCER RES, V71, P1849, DOI 10.1158/0008-5472.CAN-10-3298; Korkolopoulou P, 2012, HISTOPATHOLOGY, V61, P293, DOI 10.1111/j.1365-2559.2012.04236.x; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; Kuznetsov G, 2009, MOL CANCER THER, V8, P1250, DOI 10.1158/1535-7163.MCT-08-1026; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee HW, 2015, INT J CLIN EXP PATHO, V8, P3955; Lee HW, 2015, PATHOL RES PRACT, V211, P298, DOI 10.1016/j.prp.2014.12.015; Li BDL, 2002, ANN SURG, V235, P732, DOI 10.1097/00000658-200205000-00016; Li ZQ, 2017, ONCOTARGET, V8, P2906, DOI 10.18632/oncotarget.13772; Martinez A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123352; Martinez-Saez E, 2016, CANCER MED-US, V5, P2501, DOI 10.1002/cam4.817; McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Moerke NJ, 2007, CELL, V128, P257, DOI 10.1016/j.cell.2006.11.046; Muz B, 2015, HYPOXIA, V3, P83, DOI 10.2147/HP.S93413; Nasr Z, 2013, ONCOGENE, V32, P861, DOI 10.1038/onc.2012.105; Nishikawa M., 2015, UROL ONCOL, V33, pe9, DOI DOI 10.1016/J.UR0L0NC.2014.12.006; Nishikawa M, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0792-4; O'Reilly KE, 2009, CLIN CANCER RES, V15, P2872, DOI 10.1158/1078-0432.CCR-08-2336; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Pelletier J, 2015, CANCER RES, V75, P250, DOI 10.1158/0008-5472.CAN-14-2789; Polyak K, 2009, TRENDS GENET, V25, P30, DOI 10.1016/j.tig.2008.10.012; Pons B, 2011, INT J ONCOL, V39, P1337, DOI 10.3892/ijo.2011.1118; Qu YY, 2016, SCI REP-UK, V6, DOI 10.1038/srep23594; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ramalingam S, 2014, ONCOTARGET, V5, P530, DOI 10.18632/oncotarget.1528; Cajal SRY, 2014, CLIN TRANSL ONCOL, V16, P937, DOI 10.1007/s12094-014-1203-9; Cajal SRY, 2017, BBA-REV CANCER, V1868, P484, DOI 10.1016/j.bbcan.2017.09.004; Rodon J, 2012, NAT REV CLIN ONCOL, V9, P359, DOI 10.1038/nrclinonc.2012.48; Roh MS, 2015, VIRCHOWS ARCH, V467, P667, DOI 10.1007/s00428-015-1860-2; Rojo F, 2007, CLIN CANCER RES, V13, P81, DOI 10.1158/1078-0432.CCR-06-1560; Rybinski B, 2016, ONCOTARGET, V7, P72322, DOI 10.18632/oncotarget.11875; Scheper GC, 2002, J BIOL CHEM, V277, P3303, DOI 10.1074/jbc.M103607200; Schewe DM, 2009, CANCER RES, V69, P1545, DOI 10.1158/0008-5472.CAN-08-3858; Seki N, 2010, LUNG CANCER, V70, P329, DOI 10.1016/j.lungcan.2010.03.006; Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008; Siddiqui N, 2015, BIOCHEM SOC T, V43, P763, DOI 10.1042/BST20150126; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Singh DK, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.22; Spriggs KA, 2010, MOL CELL, V40, P228, DOI 10.1016/j.molcel.2010.09.028; Svitkin YV, 2001, RNA, V7, P1743; Tabernero J, 2008, J CLIN ONCOL, V26, P1603, DOI 10.1200/JCO.2007.14.5482; Tapia O, 2014, VIRCHOWS ARCH, V465, P25, DOI 10.1007/s00428-014-1588-4; Topisirovic I, 2004, CANCER RES, V64, P8639, DOI 10.1158/0008-5472.CAN-04-2677; Topisirovic I, 2011, WIRES RNA, V2, P277, DOI 10.1002/wrna.52; Tsumuraya T, 2011, BIOCHEM PHARMACOL, V81, P713, DOI 10.1016/j.bcp.2010.12.025; Velasquez C, 2016, P NATL ACAD SCI USA, V113, P8466, DOI 10.1073/pnas.1607768113; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; Wang R, 2009, LUNG CANCER, V66, P237, DOI 10.1016/j.lungcan.2009.02.001; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Webster KR, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-596; Webster RM, 2016, NAT REV DRUG DISCOV, V15, P81, DOI 10.1038/nrd.2016.3; Xu J, 2013, CHEMMEDCHEM, V8, P1483, DOI 10.1002/cmdc.201300231; Yanagiya A, 2012, MOL CELL, V46, P847, DOI 10.1016/j.molcel.2012.04.004; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yeh CJ, 2011, VIRCHOWS ARCH, V458, P171, DOI 10.1007/s00428-010-0994-5; Yong M, 2011, BREAST CANCER RES TR, V129, P495, DOI 10.1007/s10549-011-1475-5; Yu H, 2017, AM J HEMATOL, V92, pE11, DOI 10.1002/ajh.24594; Zheng JY, 2014, ENVIRON RES LETT, V9, DOI 10.1088/1748-9326/9/7/074006; Zochowska M, 2015, NANOMED-NANOTECHNOL, V11, P67, DOI 10.1016/j.nano.2014.07.009	117	24	24	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	19					2490	2501		10.1038/s41388-018-0152-0	http://dx.doi.org/10.1038/s41388-018-0152-0			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GF3RN	29463861	hybrid, Green Published			2022-12-17	WOS:000431873400003
J	Omoto, T; Kim-Kaneyama, J; Lei, XF; Orimo, A; Ohnishi, K; Yoshihara, K; Miyauchi, A; Li, S; Gao, L; Umemoto, T; Tanaka, J; Nakahara, K; Takeya, M; Ishida, F; Kudo, S; Haraguchi, S; Miyazaki, T; Miyazaki, A				Omoto, Tomokatsu; Kim-Kaneyama, Joo-ri; Lei, Xiao-Feng; Orimo, Akira; Ohnishi, Koji; Yoshihara, Kosuke; Miyauchi, Aya; Li, Shuo; Gao, Lin; Umemoto, Takahiro; Tanaka, Junichi; Nakahara, Kenta; Takeya, Motohiro; Ishida, Fumio; Kudo, Shin-ei; Haraguchi, Shogo; Miyazaki, Takuro; Miyazaki, Akira			The impact of stromal Hic-5 on the tumorigenesis of colorectal cancer through lysyl oxidase induction and stromal remodeling	ONCOGENE			English	Article							PROSTATE-CANCER; FIBROBLASTS; ACTIVATION; ROLES; CELLS	Carcinoma-associated fibroblasts (CAFs) influence tumor initiation, progression, and metastasis within the tumor-associated stroma. This suggests that CAFs would be a potential target for tumor therapy. Here we found that Hydrogen peroxide- inducible clone-5 (Hic-5), also named transforming growth factor beta-1-induced transcript 1 protein (Tgfb1i1), was strongly induced in CAFs found in human colorectal cancer. To investigate the role of Hic-5 in CAFs, we isolated CAFs and the control counterpart normal fibroblasts (NFs) from human colorectal cancer and non-cancerous regions, respectively. Hic-5 was highly expressed in isolated human CAFs and strongly induced in NFs in culture by the supernatant from cultured colorectal cancer cells as well as cytokines such as TGF-beta, IL-1 beta and stromal cell-derived factor 1 (SDF-1/CXCL12). Furthermore, tumor growth was inhibited in a co-culture assay with Hic-5 knockdown fibroblasts compared with control fibroblasts. To clarify the function and significance of Hic-5 in colorectal cancer in vivo, we utilized a mouse model of azoxymethane (AOM)-induced colorectal cancer using Hic-5-dehcient mice. Lack of Hic-5 in CAFs completely prevented AOM-induced colorectal cancer development in the colon tissues of mice. Mechanistic investigation revealed that Hic-5 promoted the expression of lysyl oxidase and collagen I in human control counterpart fibroblasts. Taken together, these results demonstrate that Hic-5 in CAFs is responsible for orchestrating or generating a tumor-promoting stroma.	[Omoto, Tomokatsu; Kim-Kaneyama, Joo-ri; Lei, Xiao-Feng; Miyauchi, Aya; Li, Shuo; Gao, Lin; Haraguchi, Shogo; Miyazaki, Takuro; Miyazaki, Akira] Showa Univ, Sch Med, Dept Biochem, Tokyo, Japan; [Orimo, Akira] Juntendo Univ, Sch Med, Dept Pathol & Oncol, Tokyo, Japan; [Ohnishi, Koji; Takeya, Motohiro] Kumamoto Univ, Fac Life Sci, Grad Sch Med Sci, Dept Cell Pathol, Kumamoto, Japan; [Yoshihara, Kosuke] Niigata Univ, Grad Sch Med & Dent Sci, Dept Obstet & Gynecol, Niigata, Japan; [Umemoto, Takahiro; Tanaka, Junichi] Showa Univ, Fujigaoka Hosp, Dept Gastroenterol & Gen Surg, Yokohama, Kanagawa, Japan; [Nakahara, Kenta; Ishida, Fumio; Kudo, Shin-ei] Showa Univ, Northern Yokohama Hosp, Digest Dis Ctr, Tsuzuki Ku, Yokohama, Kanagawa, Japan	Showa University; Juntendo University; Kumamoto University; Niigata University; Showa University; Showa University	Kim-Kaneyama, J (corresponding author), Showa Univ, Sch Med, Dept Biochem, Tokyo, Japan.	shuri@pharm.showa-u.ac.jp	Yoshihara, Kosuke/AAU-9874-2020	Yoshihara, Kosuke/0000-0002-2254-3378; Orimo, Akira/0000-0001-5330-7282; Miyazaki, Takuro/0000-0003-3354-0292; Haraguchi, Shogo/0000-0002-8731-3311	Japan Society for the Promotion of Science [26461149, 16K10553, 17K10713]; Japan-China Medical Association; Takeda Science Foundation; Private University Research Branding Project; MEXT (Ministry of Education, Culture, Sports, Science and Technology)-Supported Program for the Strategic Research Foundation at Private Universities; Grants-in-Aid for Scientific Research [15K15611, 15K14385] Funding Source: KAKEN	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Japan-China Medical Association; Takeda Science Foundation(Takeda Science Foundation (TSF)); Private University Research Branding Project; MEXT (Ministry of Education, Culture, Sports, Science and Technology)-Supported Program for the Strategic Research Foundation at Private Universities; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Grants-in-Aid for Scientific Research (26461149 to J-rK-K; 16K10553 to TO; 17K10713 to X-FL) from Japan Society for the Promotion of Science, a research grant from Japan-China Medical Association (to J-rK-K), a research grant from Takeda Science Foundation (to J-rK-K and X-FL) and Private University Research Branding Project. This work was also supported in part by the MEXT (Ministry of Education, Culture, Sports, Science and Technology)-Supported Program for the Strategic Research Foundation at Private Universities, 2012-2016.	Allaoui R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13050; Arita-Okubo S, 2015, CARDIOVASC RES, V105, P361, DOI 10.1093/cvr/cvv003; Baker AM, 2013, ONCOGENE, V32, P1863, DOI 10.1038/onc.2012.202; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Bonnans C, 2014, NAT REV MOL CELL BIO, V15, P786, DOI 10.1038/nrm3904; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; Cox TR, 2015, NATURE, V522, P106, DOI 10.1038/nature14492; Cox TR, 2011, DIS MODEL MECH, V4, P165, DOI 10.1242/dmm.004077; Csiszar K, 2001, PROG NUCLEIC ACID RE, V70, P1, DOI 10.1016/S0079-6603(01)70012-8; Dabiri G, 2008, J INVEST DERMATOL, V128, P2518, DOI 10.1038/jid.2008.90; Deakin NO, 2011, MOL BIOL CELL, V22, P327, DOI 10.1091/mbc.E10-09-0790; Drori S, 2005, GENE DEV, V19, P362, DOI 10.1101/gad.1240705; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Goreczny GJ, 2017, ONCOGENE, V36, P2693, DOI 10.1038/onc.2016.422; Isella C, 2015, NAT GENET, V47, P312, DOI 10.1038/ng.3224; Jamba A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122773; Kagan HM, 2003, J CELL BIOCHEM, V88, P660, DOI 10.1002/jcb.10413; Kim-Kaneyama J, 2011, J MOL CELL CARDIOL, V50, P77, DOI 10.1016/j.yjmcc.2010.09.024; Kraman M, 2010, SCIENCE, V330, P827, DOI 10.1126/science.1195300; Lei XF, 2016, J HEPATOL, V64, P110, DOI 10.1016/j.jhep.2015.08.026; Lei XF, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000747; Levental I, 2010, J PHYS-CONDENS MAT, V22, DOI 10.1088/0953-8984/22/19/194120; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Shibanuma M, 2003, MOL BIOL CELL, V14, P1158, DOI 10.1091/mbc.02-06-0099; Shola DTN, 2012, ONCOGENE, V31, P2480, DOI 10.1038/onc.2011.422; Solomon JD, 2014, MOL CANCER RES, V12, P1166, DOI 10.1158/1541-7786.MCR-13-0395; Takai K, 2016, ONCOTARGET, V7, P82889, DOI 10.18632/oncotarget.12658; Varney SD, 2016, J CELL SCI, V129, P774, DOI 10.1242/jcs.170589; Vasudev NS, 2014, ANGIOGENESIS, V17, P471, DOI 10.1007/s10456-014-9420-y; Voloshenyuk TG, 2011, CYTOKINE, V55, P90, DOI 10.1016/j.cyto.2011.03.024; Wang TH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010062; Wu JR, 2015, ONCOTARGET, V6, P32526, DOI 10.18632/oncotarget.5322; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Zhou LL, 2015, J CANCER, V6, P717, DOI 10.7150/jca.10865	35	24	24	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	9					1205	1219		10.1038/s41388-017-0033-y	http://dx.doi.org/10.1038/s41388-017-0033-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FY0MK	29242607				2022-12-17	WOS:000426505400006
J	Garcia-Mariscal, A; Li, H; Pedersen, E; Peyrollier, K; Ryan, KM; Stanley, A; Quondamatteo, F; Brakebusch, C				Garcia-Mariscal, A.; Li, H.; Pedersen, E.; Peyrollier, K.; Ryan, K. M.; Stanley, A.; Quondamatteo, F.; Brakebusch, C.			Loss of RhoA promotes skin tumor formation and invasion by upregulation of RhoB	ONCOGENE			English	Article							T-CELL LYMPHOMA; MEMBRANE PROTRUSIONS; CANCER GENOMICS; DISTINCT ROLES; STEM-CELLS; IN-VIVO; GTPASE; MUTATIONS; MIGRATION; ADHESION	Cellular movement is controlled by small GTPases, such as RhoA. Although migration is crucial for cancer cell invasion, the specific role of RhoA in tumor formation is unclear. Inducing skin tumors in mice with a keratinocyte-restricted loss of RhoA, we observed increased tumor frequency, growth and invasion. In vitro invasion assays revealed that in the absence of RhoA cell invasiveness is increased in a Rho-associated protein kinase (ROCK) activation and cell contraction-dependent manner. Surprisingly, loss of RhoA causes increased Rho signaling via overcompensation by RhoB because of reduced lysosomal degradation of RhoB in Gamma-aminobutyric acid receptor-associated protein (GABARAP)+autophagosomes and endosomes. In the absence of RhoA, RhoB relocalized to the plasma membrane and functionally replaced RhoA with respect to invasion, clonogenic growth and survival. Our data demonstrate for the first time that RhoA is a tumor suppressor in 7,12-dimethylbenz[a] anthracene/12-O-tetradecanoylphorbol 13-acetate skin carcinogenesis and identify Rho signaling dependent on RhoA and RhoB as a potent driver of tumor progression.	[Garcia-Mariscal, A.; Li, H.; Pedersen, E.; Peyrollier, K.; Brakebusch, C.] Univ Copenhagen, BRIC, Ole Maaloes Vej 5, Copenhagen, Denmark; [Ryan, K. M.] Beatson Inst, Glasgow, Lanark, Scotland; [Stanley, A.; Quondamatteo, F.] NUI, Skin & Extracellular Matrix Res Grp, Anat, Galway, Ireland	University of Copenhagen; Beatson Institute; Ollscoil na Gaillimhe-University of Galway	Brakebusch, C (corresponding author), Univ Copenhagen, BRIC, Ole Maaloes Vej 5, Copenhagen, Denmark.	cord.brakebusch@bric.ku.dk		Stanley, Alanna/0000-0002-0901-8798; Brakebusch, Cord/0000-0002-9342-1634	Cancer Research UK [15816, 22903] Funding Source: researchfish	Cancer Research UK(Cancer Research UK)		Alfano D, 2012, J CELL SCI, V125, P2369, DOI 10.1242/jcs.091579; Arshad A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115447; Boulter E, 2010, NAT CELL BIOL, V12, P477, DOI 10.1038/ncb2049; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chapman S, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt449; Chrostek A, 2006, MOL CELL BIOL, V26, P6957, DOI 10.1128/MCB.00075-06; Filler Renata B, 2007, CSH Protoc, V2007, DOI 10.1101/pdb.prot4837; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Ho TTG, 2008, J BIOL CHEM, V283, P21588, DOI 10.1074/jbc.M710033200; Howe GA, 2012, VASC CELL, V4, DOI 10.1186/2045-824X-4-1; Iden S, 2008, NAT REV MOL CELL BIO, V9, P846, DOI 10.1038/nrm2521; Jackson B, 2011, MOL BIOL CELL, V22, P593, DOI 10.1091/mbc.E09-10-0859; Jennings RT, 2014, BLOOD, V123, P3635, DOI 10.1182/blood-2014-02-557843; Jensen KB, 2010, NAT PROTOC, V5, P898, DOI 10.1038/nprot.2010.39; Kakiuchi M, 2014, NAT GENET, V46, P583, DOI 10.1038/ng.2984; Karlsson R, 2009, BBA-REV CANCER, V1796, P91, DOI 10.1016/j.bbcan.2009.03.003; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lee Stacey, 2016, F1000Res, V5, DOI 10.12688/f1000research.8800.1; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Mazieres J, 2005, EXP CELL RES, V304, P354, DOI 10.1016/j.yexcr.2004.10.019; Meyer N, 2014, J INVEST DERMATOL, V134, P203, DOI 10.1038/jid.2013.278; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Nagata Y, 2016, BLOOD, V127, P596, DOI 10.1182/blood-2015-06-644948; Nassar D, 2015, NAT MED, V21, P946, DOI 10.1038/nm.3878; Palomero T, 2014, NAT GENET, V46, P166, DOI 10.1038/ng.2873; Pedersen E, 2012, EXP CELL RES, V318, P1779, DOI 10.1016/j.yexcr.2012.05.004; Pedersen E, 2012, METHODS MOL BIOL, V827, P157, DOI 10.1007/978-1-61779-442-1_11; Perez-Sala D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008117; Rath N, 2012, EMBO REP, V13, P900, DOI 10.1038/embor.2012.127; Ridley A, 2013, NAT CELL BIOL, V15, P337, DOI 10.1038/ncb2716; Roberts PJ, 2008, J BIOL CHEM, V283, P25150, DOI 10.1074/jbc.M800882200; Rodrigues P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6458; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sakata-Yanagimoto M, 2014, NAT GENET, V46, P171, DOI 10.1038/ng.2872; Samuel MS, 2011, CANCER CELL, V19, P776, DOI 10.1016/j.ccr.2011.05.008; Schaaf MBE, 2016, FASEB J, V30, P3961, DOI 10.1096/fj.201600698R; Schober M, 2011, P NATL ACAD SCI USA, V108, P10544, DOI 10.1073/pnas.1107807108; Totsukawa G, 2004, J CELL BIOL, V164, P427, DOI 10.1083/jcb.200306172; Valero RA, 2010, TRAFFIC, V11, P1221, DOI 10.1111/j.1600-0854.2010.01091.x; Vallois D, 2016, BLOOD, V128, P1490, DOI 10.1182/blood-2016-02-698977; Vega Francisco M, 2018, Small GTPases, V9, P384, DOI 10.1080/21541248.2016.1253528; Vega FM, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120076; Vega FM, 2011, J CELL BIOL, V193, P655, DOI 10.1083/jcb.201011038; Wang LF, 2010, P NATL ACAD SCI USA, V107, P7317, DOI 10.1073/pnas.1000031107; Wang Z, 2010, ONCOGENE, V29, P3362, DOI 10.1038/onc.2010.95; Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012; Wilhelmsen K, 2006, MOL CELL BIOL, V26, P2877, DOI 10.1128/MCB.26.8.2877-2886.2006; Worthylake RA, 2003, J BIOL CHEM, V278, P13578, DOI 10.1074/jbc.M211584200; Yoo HY, 2014, NAT GENET, V46, P371, DOI 10.1038/ng.2916	49	24	24	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					847	860		10.1038/onc.2017.333	http://dx.doi.org/10.1038/onc.2017.333			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059167				2022-12-17	WOS:000425281800003
J	Zheng, X; Chi, J; Zhi, J; Zhang, H; Yue, D; Zhao, J; Li, D; Li, Y; Gao, M; Guo, J				Zheng, X.; Chi, J.; Zhi, J.; Zhang, H.; Yue, D.; Zhao, J.; Li, D.; Li, Y.; Gao, M.; Guo, J.			Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration	ONCOGENE			English	Article							TUMOR-SUPPRESSOR LKB1; EML4-ALK FUSION GENE; CELL LUNG-CANCER; KINASE INHIBITOR; PROSTATE-CANCER; POOR-PROGNOSIS; AMPK ACTIVITY; SURVIVAL; MLN8237; AURKA	Deletion or loss-of-function mutation of LKB1, frequently occurring in non-small cell lung cancers (NSCLCs), is a predominant caution of NSCLC initiation and progression. However, the upstream signaling pathways governing LKB1 activation are largely unknown. Here, we report that LKB1 undergoes Aurora kinase A (AURKA)-mediated phosphorylation, which largely compromises the LKB1/AMPK signaling axis, in turn leading to the elevation of NSCLC cell proliferation, invasion and migration. Mechanically, AURKA-mediated phosphorylation of LKB1 impairs LKB1 interaction with and phosphorylation of its downstream target AMPKa, which has critical roles in governing cancer cell energy metabolic homeostasis and tumorigenesis. Clinically, AURKA displays high levels in NSCLC patients, and correlates with poor outcome of patients with lung adenocarcinoma. Pathologically, the amplification or activation of AURKA-induced impairment of the LKB1/AMPK signaling pathway contributes to NSCLC initiation and progression, highlighting AURKA as a potential therapeutic target for combatting hyperactive AURKA-driven NSCLCs.	[Zheng, X.; Chi, J.; Zhi, J.; Zhao, J.; Li, D.; Li, Y.; Gao, M.] Tianjin Med Univ, Dept Thyroid & Neck Tumor, Canc Inst & Hosp, Oncol Key Lab Canc Prevent & Therapy,Natl Clin Res, Tianjin, Peoples R China; [Zhang, H.] Tianjin Med Univ, Canc Prevent Ctr, Canc Inst & Hosp, Oncol Key Lab Canc Prevent & Therapy,Natl Clin Res, Tianjin, Peoples R China; [Yue, D.] Tianjin Med Univ, Dept Lung Tumor, Canc Inst & Hosp, Oncol Key Lab Canc Prevent & Therapy,Natl Clin Res, Tianjin, Peoples R China; [Guo, J.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, E CLS 628,3 Blackfan Circle, Boston, MA 02115 USA	Tianjin Medical University; Tianjin Medical University; Tianjin Medical University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Gao, M; Guo, J (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, E CLS 628,3 Blackfan Circle, Boston, MA 02115 USA.	gaoming68@aliyun.com; Jguo3@bidmc.harvard.edu			National Natural Science Foundation of China [81402392, 81472580, 81502322, 81501983]; Tianjin Municipal Science and technology project [15JCQNJC12800]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tianjin Municipal Science and technology project	This work was partially supported by grants from National Natural Science Foundation of China (Grant No. 81402392, 81472580, 81502322 and 81501983) and Tianjin Municipal Science and technology project (Grant No. 15JCQNJC12800).	Al-Khafaji ASK, 2017, ONCOL LETT, V13, P4463, DOI 10.3892/ol.2017.6012; Bach PB, 2003, JNCI-J NATL CANCER I, V95, P470, DOI 10.1093/jnci/95.6.470; Beltran H, 2011, CANCER DISCOV, V1, P487, DOI 10.1158/2159-8290.CD-11-0130; Boudeau J, 2004, J CELL SCI, V117, P6365, DOI 10.1242/jcs.01571; Brose MS, 2002, CANCER RES, V62, P6997; Carretero J, 2007, ONCOGENE, V26, P1616, DOI 10.1038/sj.onc.1209951; Cheng J, 2016, BBA-REV CANCER, V1866, P232, DOI 10.1016/j.bbcan.2016.09.006; Dees EC, 2012, CLIN CANCER RES, V18, P4775, DOI 10.1158/1078-0432.CCR-12-0589; Dorfman J, 2008, MOL BIOL CELL, V19, P1614, DOI 10.1091/mbc.E07-05-0454; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Goos JACM, 2013, BRIT J CANCER, V109, P2445, DOI 10.1038/bjc.2013.608; Guo J, 2013, ONCOGENE, V32, P151, DOI 10.1038/onc.2012.39; Guo JP, 2009, AM J PATHOL, V175, P324, DOI 10.2353/ajpath.2009.080767; Guo JP, 2016, SCIENCE, V353, P929, DOI 10.1126/science.aad5755; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Katayama H, 2010, BBA-GENE REGUL MECH, V1799, P829, DOI 10.1016/j.bbagrm.2010.09.004; Koivunen JP, 2008, CLIN CANCER RES, V14, P4275, DOI 10.1158/1078-0432.CCR-08-0168; Lee SW, 2015, MOL CELL, V57, P1022, DOI 10.1016/j.molcel.2015.01.015; Lens SMA, 2010, NAT REV CANCER, V10, P825, DOI 10.1038/nrc2964; Liu X, 2016, ONCOTARGET, V7, P33152, DOI 10.18632/oncotarget.8888; Lo Iacono M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-100; Luo ZJ, 2005, TRENDS PHARMACOL SCI, V26, P69, DOI 10.1016/j.tips.2004.12.011; Mahadevan D, 2012, CLIN CANCER RES, V18, P2210, DOI 10.1158/1078-0432.CCR-11-2413; Marcus AI, 2010, J THORAC ONCOL, V5, P1883, DOI 10.1097/JTO.0b013e3181fbc28a; Matulonis UA, 2012, GYNECOL ONCOL, V127, P63, DOI 10.1016/j.ygyno.2012.06.040; Nikonova AS, 2013, CELL MOL LIFE SCI, V70, P661, DOI 10.1007/s00018-012-1073-7; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Patel AV, 2012, CLIN CANCER RES, V18, P5020, DOI 10.1158/1078-0432.CCR-12-1072; Pirker R, 2009, LANCET, V373, P1525, DOI 10.1016/S0140-6736(09)60569-9; Pollard JR, 2009, J MED CHEM, V52, P2629, DOI 10.1021/jm8012129; Reiter R, 2006, CLIN CANCER RES, V12, P5136, DOI 10.1158/1078-0432.CCR-05-1650; Ritho J, 2015, CELL REP, V12, P734, DOI 10.1016/j.celrep.2015.07.002; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Shackelford DB, 2013, CANCER CELL, V23, P143, DOI 10.1016/j.ccr.2012.12.008; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Staff S, 2010, ONCOL REP, V23, P307, DOI 10.3892/or_00000637; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500; Zeqiraj E, 2009, SCIENCE, V326, P1707, DOI 10.1126/science.1178377; Zhang LL, 2017, CANCER LETT, V390, P11, DOI 10.1016/j.canlet.2017.01.003; Zheng B, 2009, MOL CELL, V33, P237, DOI 10.1016/j.molcel.2008.12.026; Zheng XQ, 2014, ONCOGENE, V33, P4985, DOI 10.1038/onc.2013.444	47	24	25	1	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2018	37	4					502	511		10.1038/onc.2017.354	http://dx.doi.org/10.1038/onc.2017.354			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT7KP	28967900				2022-12-17	WOS:000423331600008
J	Wang, F; Wang, AY; Chesnelong, C; Yang, Y; Nabbi, A; Thalappilly, S; Alekseev, V; Riabowol, K				Wang, F.; Wang, A. Y.; Chesnelong, C.; Yang, Y.; Nabbi, A.; Thalappilly, S.; Alekseev, V.; Riabowol, K.			ING5 activity in self-renewal of glioblastoma stem cells via calcium and follicle stimulating hormone pathways	ONCOGENE			English	Article							TUMOR-SUPPRESSOR P33(ING1); HISTONE ACETYLTRANSFERASE; NEURAL PROGENITORS; GROWTH-FACTOR; CANCER CELLS; BRAIN; DIFFERENTIATION; GLIOMA; PROLIFERATION; MUTATIONS	Stem cell-like brain tumor initiating cells (BTICs) cause recurrence of glioblastomas, with BTIC 'stemness' affected by epigenetic mechanisms. The ING family of epigenetic regulators (ING1-5) function by targeting histone acetyltransferase (HAT) or histone deacetylase complexes to the H3K4me3 mark to alter histone acetylation and subsequently, gene expression. Here we find that ectopic expression of ING5, the targeting subunit of HBO1, MOZ and MORF HAT complexes increases expression of the Oct4, Olig2 and Nestin stem cell markers, promotes self-renewal, prevents lineage differentiation and increases stem cell pools in BTIC populations. This activity requires the plant homeodomain region of ING5 that interacts specifically with the H3K4me3 mark. ING5 also enhances PI3K/AKT and MEK/ERK activity to sustain self-renewal of BTICs over serial passage of stem cell-like spheres. ING5 exerts these effects by activating transcription of calcium channel and follicle stimulating hormone pathway genes. In silico analyses of The Cancer Genome Atlas data suggest that ING5 is a positive regulator of BTIC stemness, whose expression negatively correlates with patient prognosis, especially in the Proneural and Classical subtypes, and in tumors with low SOX2 expression. These data suggest that altering histone acetylation status and signaling pathways induced by ING5 may provide useful clinical strategies to target tumor resistance and recurrence in glioblastoma.	[Wang, F.; Yang, Y.; Nabbi, A.; Thalappilly, S.; Alekseev, V.; Riabowol, K.] Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB, Canada; [Wang, F.; Wang, A. Y.; Chesnelong, C.; Yang, Y.; Nabbi, A.; Thalappilly, S.; Riabowol, K.] Univ Calgary, Arnie Charbonneau Canc Inst, Cumming Sch Med, Dept Oncol, 311 HMRB,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada; [Wang, A. Y.; Chesnelong, C.] Univ Calgary, Hotchkiss Brain Inst, Dept Cell Biol & Anat, Calgary, AB, Canada; [Yang, Y.] Harbin Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Harbin, Heilongjiang, Peoples R China	University of Calgary; University of Calgary; University of Calgary; Harbin Medical University	Riabowol, K (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB, Canada.; Riabowol, K (corresponding author), Univ Calgary, Arnie Charbonneau Canc Inst, Cumming Sch Med, Dept Oncol, 311 HMRB,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	karl@ucalgary.ca	Alekseev, Vladislav/G-6157-2019	Alekseev, Vladislav/0000-0001-6751-6210; Nabbi, Arash/0000-0002-3195-7361; Thalappilly, Subhash/0000-0003-1766-3057	Alberta Cancer Foundation [26512]; Canadian Institutes of Health Research [MOP-133646]	Alberta Cancer Foundation; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	We are grateful to Dr. Samuel Weiss's group, particularly Dr. Artee Luchman and Rozina Hassam, from the University of Calgary for providing the patient-derived BTIC lines and technical support. We thank Dr. Jennifer Cobb and Dr. Derrick Rancourt from the University of Calgary for valuable experimental insights. This work was funded by the Alberta Cancer Foundation (Project 26512) and Canadian Institutes of Health Research (MOP-133646). This work was funded by grants from the Alberta Cancer Foundation (Project 26512) and Canadian Institutes of Health Research (MOP-133646) to KR.	Ayuso-Sacido A, 2010, J NEURO-ONCOL, V97, P323, DOI 10.1007/s11060-009-0035-x; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bhartiya D, 2015, REPRODUCTION, V149, pR35, DOI 10.1530/REP-14-0220; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Brennan DF, 2011, NATURE, V472, P366, DOI 10.1038/nature09860; Caren H, 2015, STEM CELL REP, V5, P829, DOI 10.1016/j.stemcr.2015.09.014; Chai SJ, 2015, ONCOTARGET, V6, P16069, DOI 10.18632/oncotarget.3866; Chang KC, 2012, BIOESSAYS, V34, P301, DOI 10.1002/bies.201100090; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Clayton-Smith J, 2011, AM J HUM GENET, V89, P675, DOI 10.1016/j.ajhg.2011.10.008; Cusulin C, 2015, STEM CELL REP, V5, P1, DOI 10.1016/j.stemcr.2015.05.010; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Davis FB, 2006, CANCER RES, V66, P7270, DOI 10.1158/0008-5472.CAN-05-4365; Ding XQ, 2017, ONCOTARGET; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Eapen SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040684; FLORES JA, 1990, ENDOCRINOLOGY, V127, P3172, DOI 10.1210/endo-127-6-3172; Fullgrabe J, 2011, ONCOGENE, V30, P3391, DOI 10.1038/onc.2011.121; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gao XF, 2013, CANCER RES, V73, P1481, DOI 10.1158/0008-5472.CAN-12-3429; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Gou WF, 2015, ONCOTARGET, V6, P19552, DOI 10.18632/oncotarget.3735; Guo G, 2010, DEVELOPMENT, V137, P3185, DOI 10.1242/dev.052753; Heddleston JM, 2012, CELL DEATH DIFFER, V19, P428, DOI 10.1038/cdd.2011.109; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Hussein SMI, 2014, NATURE, V516, P198, DOI 10.1038/nature14046; Ignatova TN, 2002, GLIA, V39, P193, DOI 10.1002/glia.10094; Ishiuchi S, 2002, NAT MED, V8, P971, DOI 10.1038/nm746; Kang SS, 2010, CANCER RES, V70, P1173, DOI 10.1158/0008-5472.CAN-09-2886; Kataoka H, 2003, CANCER RES, V63, P5785; Kelly JJP, 2009, STEM CELLS, V27, P1722, DOI 10.1002/stem.98; Kim MS, 2015, FEBS LETT, V589, P941, DOI 10.1016/j.febslet.2015.02.029; Konno D, 2008, NAT CELL BIOL, V10, P93, DOI 10.1038/ncb1673; Kosodo Y, 2004, EMBO J, V23, P2314, DOI 10.1038/sj.emboj.7600223; Kraft M, 2011, J CLIN INVEST, V121, P3479, DOI 10.1172/JCI43428; Lawn S, 2015, J BIOL CHEM, V290, P3814, DOI 10.1074/jbc.M114.599373; Lee J, 2008, CANCER CELL, V13, P69, DOI 10.1016/j.ccr.2007.12.005; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Linzen U, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123736; Liu L, 2015, BIOCHEM BIOPH RES CO, V461, P525, DOI 10.1016/j.bbrc.2015.04.061; Liu LF, 2009, ENDOCRINOLOGY, V150, P3186, DOI 10.1210/en.2008-1447; Liu NS, 2013, CANCER RES, V73, P3749, DOI 10.1158/0008-5472.CAN-12-3684; Liu QH, 2009, J NEURO-ONCOL, V94, P1, DOI 10.1007/s11060-009-9919-z; Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000; Luberg K, 2015, BMC NEUROSCI, V16, DOI 10.1186/s12868-015-0215-x; Mendes-Pereira AM, 2012, P NATL ACAD SCI USA, V109, P2730, DOI 10.1073/pnas.1018872108; Merson TD, 2006, J NEUROSCI, V26, P11359, DOI 10.1523/JNEUROSCI.2247-06.2006; Mulder KW, 2012, NAT CELL BIOL, V14, P753, DOI 10.1038/ncb2520; Niola F, 2013, J CLIN INVEST, V123, P405, DOI 10.1172/JCI63811; Omuro A, 2013, JAMA-J AM MED ASSOC, V310, P1842, DOI 10.1001/jama.2013.280319; Ostrom QT, 2015, NEURO-ONCOLOGY, V17, P1, DOI [10.1093/neuonc/nov189, 10.1093/neuonc/noaa200, 10.1093/neuonc/noab200]; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Peng YH, 2003, ONCOGENE, V22, P4478, DOI 10.1038/sj.onc.1206777; Perez-Campo FM, 2014, STEM CELLS, V32, P1591, DOI 10.1002/stem.1606; Perez-Campo FM, 2009, BLOOD, V113, P4866, DOI 10.1182/blood-2008-04-152017; Pietras A, 2014, CELL STEM CELL, V14, P357, DOI 10.1016/j.stem.2014.01.005; Rajarajacholan UK, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001502; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Ross SE, 2003, NEURON, V39, P13, DOI 10.1016/S0896-6273(03)00365-9; Safa AR, 2015, GENES DIS, V2, P152, DOI 10.1016/j.gendis.2015.02.001; Saito M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015541; Sarkar P, 2016, J PROTEOME RES, V15, P2433, DOI 10.1021/acs.jproteome.5b01118; Schafer A, 2013, GENE DEV, V27, P261, DOI 10.1101/gad.186916.112; Scott M, 2001, J CELL SCI, V114, P3455; Sheikh BN, 2012, J CELL SCI, V125, P295, DOI 10.1242/jcs.077271; Shiseki M, 2003, CANCER RES, V63, P2373; Siegel ET, 2013, REPROD SCI, V20, P211, DOI 10.1177/1933719112461184; Signaroldi E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10753; Simpson MA, 2012, AM J HUM GENET, V90, P290, DOI 10.1016/j.ajhg.2011.11.024; Singh SK, 2003, CANCER RES, V63, P5821; Suva ML, 2014, CELL, V157, P580, DOI 10.1016/j.cell.2014.02.030; Suzuki S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074749; Swartling FJ, 2015, CELL TISSUE RES, V359, P225, DOI 10.1007/s00441-014-2046-y; Tallen G, 2014, FEBS LETT, V588, P2728, DOI 10.1016/j.febslet.2014.03.011; Thomas T, 2000, DEVELOPMENT, V127, P2537; Ullah M, 2008, MOL CELL BIOL, V28, P6828, DOI 10.1128/MCB.01297-08; Velasco I, 2011, CURR TOP MED CHEM, V11, P1684, DOI 10.2174/156802611796117586; Vieyra D, 2003, CLIN CANCER RES, V9, P5952; Vieyra D, 2002, J BIOL CHEM, V277, P29832, DOI 10.1074/jbc.M200197200; Vlismas A, 2016, STEM CELLS DEV, V25, P160, DOI 10.1089/scd.2015.0284; Wang Y, 2012, CELL, V150, P816, DOI 10.1016/j.cell.2012.06.034; Wegner M, 2005, TRENDS NEUROSCI, V28, P583, DOI 10.1016/j.tins.2005.08.008; Woltjen K, 2009, NATURE, V458, P766, DOI 10.1038/nature07863; Yang HM, 2007, J CELL BIOCHEM, V101, P1198, DOI 10.1002/jcb.21244; You LY, 2015, J BIOL CHEM, V290, P7114, DOI 10.1074/jbc.M114.635250; You LY, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005034; Zhang F, 2015, ONCOTARGET, V6, P16239, DOI 10.18632/oncotarget.3842; Zhang FR, 2011, ADV DIFFER EQU-NY, DOI 10.1155/2011/213485; Zhang ZB, 2013, INT J ONCOL, V43, P1194, DOI 10.3892/ijo.2013.2054; Zhao NJ, 2010, ONCOL REP, V23, P1443, DOI 10.3892/or_00000782; Zhao S, 2017, ONCOTARGET, V8, P56558, DOI 10.18632/oncotarget.17802; Zhao S, 2016, ONCOTARGET, V7, P54596, DOI 10.18632/oncotarget.10519	94	24	25	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					286	301		10.1038/onc.2017.324	http://dx.doi.org/10.1038/onc.2017.324			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28925404	Green Published, hybrid			2022-12-17	WOS:000422753900002
J	Chakraborty, D; Benham, V; Bullard, B; Kearney, T; Hsia, HC; Gibbon, D; Demireva, EY; Lunt, SY; Bernard, JJ				Chakraborty, D.; Benham, V.; Bullard, B.; Kearney, T.; Hsia, H. C.; Gibbon, D.; Demireva, E. Y.; Lunt, S. Y.; Bernard, J. J.			Fibroblast growth factor receptor is a mechanistic link between visceral adiposity and cancer	ONCOGENE			English	Article							BODY-MASS INDEX; SQUAMOUS-CELL CARCINOMA; DIET-INDUCED OBESITY; BREAST-CANCER; WAIST CIRCUMFERENCE; NEOPLASTIC TRANSFORMATION; GENE-EXPRESSION; TUMOR-GROWTH; FACTOR FGF-2; SKIN-CANCER	Epidemiological evidence implicates excess adipose tissue in increasing cancer risk. Despite a steeply rising global prevalence of obesity, how adiposity contributes to transformation (stage a non-tumorigenic cell undergoes to become malignant) is unknown. To determine the factors in adipose tissue that stimulate transformation, we used a novel ex vivo system of visceral adipose tissue (VAT)-condition medium-stimulated epithelial cell growth in soft agar. To extend this system in vivo, we used a murine lipectomy model of ultraviolet light B-induced, VAT-promoted skin tumor formation. We found that VAT from mice and obese human donors stimulated growth in soft agar of non-tumorigenic epithelial cells. The difference in VAT activity was associated with fibroblast growth factor-2 (FGF2) levels. Moreover, human and mouse VAT failed to stimulate growth in soft of agar in cells deficient in FGFR-1 (FGF2 receptor). We also demonstrated that circulating levels of FGF2 were associated with non-melanoma tumor formation in vivo. These data implicate FGF2 as a major factor VAT releases to transform epithelial cells-a novel, potential pathway of VAT-enhanced tumorigenesis. Strategies designed to deplete VAT stores of FGF2 or inhibit FGFR-1 in abdominally obese individuals may be important cancer prevention strategies as well as adjuvant therapies for improving outcomes.	[Chakraborty, D.; Benham, V.; Bullard, B.; Bernard, J. J.] Michigan State Univ, Dept Pharmacol & Toxicol, 1355 Bogue St,Life Sci B420, E Lansing, MI 48824 USA; [Kearney, T.] Rutgers Robert Wood Johnson Med Sch, Div Surg Oncol, New Brunswick, NJ USA; [Hsia, H. C.] Yale Sch Med, Sect Plast Surg, Dept Surg, New Haven, CT USA; [Gibbon, D.] Summit Medical4 Grp, Livingston, NJ USA; [Demireva, E. Y.] Michigan State Univ, Off Vice President Res & Grad Studies, E Lansing, MI 48824 USA; [Lunt, S. Y.] Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Yale University; Michigan State University; Michigan State University	Bernard, JJ (corresponding author), Michigan State Univ, Dept Pharmacol & Toxicol, 1355 Bogue St,Life Sci B420, E Lansing, MI 48824 USA.	jbernard@msu.edu	Hsia, Henry/W-6140-2019	Hsia, Henry/0000-0001-8674-9140; Lunt, Sophia/0000-0003-4522-6065; Bernard, Jamie/0000-0002-3800-2576	National Institutes of Health [R00 CA177868]; Michigan State University; Office of the Assistant Secretary of Defense for Health Affairs [W81XWH-15-1-0453]; AACR-Incyte Corporation NextGen Grant [16-20-46-LUNT]; NATIONAL CANCER INSTITUTE [R00CA177868, K99CA177868] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Michigan State University; Office of the Assistant Secretary of Defense for Health Affairs; AACR-Incyte Corporation NextGen Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We acknowledge the MSU Investigative HistoPathology Laboratory, Amy S Porter, HT (ASCP) QIHC and Kathleen A Joseph, HT (ASCP) QIHC. We also thank Dr Karen Liby (MSU) for her consultation and providing antibodies, Dr Richard Neubig (MSU) and Dr Matthew Bernard (MSU) for their consultation and assistance with experimental design and Dr Dalen Agnew (MSU) for his consultation on tumor pathology. JJB is funded by National Institutes of Health Grant R00 CA177868, Michigan State University start-up funds. SYL is funded by the Office of the Assistant Secretary of Defense for Health Affairs, through the Breast Cancer Research Program, under Award No. W81XWH-15-1-0453 and the 2016 AACR-Incyte Corporation NextGen Grant for Transformative Cancer Research, Grant Number 16-20-46-LUNT.	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Aggarwal BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI 10.1016/j.bcp.2006.06.029; Ahmad I, 2012, BBA-MOL CELL RES, V1823, P850, DOI 10.1016/j.bbamcr.2012.01.004; Amstad PA, 1997, MOL CARCINOGEN, V20, P231, DOI 10.1002/(SICI)1098-2744(199710)20:2<231::AID-MC10>3.0.CO;2-B; Arnold M, 2015, LANCET ONCOL, V16, P36, DOI 10.1016/S1470-2045(14)71123-4; Ayala-Lopez N, 2015, AM J PHYSIOL-HEART C, V309, pH1904, DOI 10.1152/ajpheart.00308.2015; Baselga J, 2011, ONCOLOGIST, V16, P12, DOI 10.1634/theoncologist.2011-S1-12; BENARI ET, 1992, MOL CARCINOGEN, V5, P62, DOI 10.1002/mc.2940050111; Berg KK, 2009, SCAND J IMMUNOL, V69, P36, DOI 10.1111/j.1365-3083.2008.02187.x; Bernard Jamie J, 2014, J Carcinog Mutagen, V5, P2157; Binai NA, 2010, INT J CANCER, V127, P55, DOI 10.1002/ijc.25010; Bowden GT, 2004, NAT REV CANCER, V4, P23, DOI 10.1038/nrc1253; Chockalingam R, 2015, J CLIN MED, V4, P1229, DOI 10.3390/jcm4061229; COLBURN NH, 1981, P NATL ACAD SCI-BIOL, V78, P6912, DOI 10.1073/pnas.78.11.6912; Connolly BS, 2002, NUTR CANCER, V44, P127, DOI 10.1207/S15327914NC4402_02; Courneya KS, 2008, CANCER-AM CANCER SOC, V112, P2475, DOI 10.1002/cncr.23455; Cronauer MV, 1997, PROSTATE, V31, P223; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Dutta Deep, 2012, Indian J Endocrinol Metab, V16, pS596, DOI 10.4103/2230-8210.105577; Elsheikh SE, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1665; Font-Burgada J, 2016, CELL METAB, V23, P48, DOI 10.1016/j.cmet.2015.12.015; Freier K, 2007, ORAL ONCOL, V43, P60, DOI 10.1016/j.oraloncology.2006.01.005; Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847; Gabrielsson BG, 2002, OBES RES, V10, P608, DOI 10.1038/oby.2002.83; Garratt M, 2016, AGING CELL, V15, P737, DOI 10.1111/acel.12489; Gaudet MM, 2014, CANCER CAUSE CONTROL, V25, P737, DOI 10.1007/s10552-014-0376-4; Goodwin PJ, 2002, J CLIN ONCOL, V20, P42, DOI 10.1200/JCO.20.1.42; Grazul-Bilska AT, 2002, EXP CLIN ENDOCR DIAB, V110, P176, DOI 10.1055/s-2002-32149; Hajian-Tilaki KO, 2011, MED ONCOL, V28, P1296, DOI 10.1007/s12032-010-9629-6; Hao RH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19868; He ZQ, 2003, J BIOL CHEM, V278, P26435, DOI 10.1074/jbc.M303859200; Hill AL, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000968; Hu MM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147374; Huang Z, 1999, AM J EPIDEMIOL, V150, P1316, DOI 10.1093/oxfordjournals.aje.a009963; Huffman DM, 2013, CANCER PREV RES, V6, P177, DOI 10.1158/1940-6207.CAPR-12-0414; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Ibiebele TI, 2007, AM J CLIN NUTR, V85, P1401, DOI 10.1093/ajcn/85.5.1401; Ibiebele TI, 2009, INT J CANCER, V125, P1678, DOI 10.1002/ijc.24481; Ibrahim MM, 2010, OBES REV, V11, P11, DOI 10.1111/j.1467-789X.2009.00623.x; Itoh N, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00247; Iyengar NM, 2016, CLIN CANCER RES, V22, P2283, DOI 10.1158/1078-0432.CCR-15-2239; JAIN AK, 1989, INDIAN J CHEM A, V28, P992; Jang MH, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3239; Kakudo N, 2007, BIOCHEM BIOPH RES CO, V359, P239, DOI 10.1016/j.bbrc.2007.05.070; Kawaguchi N, 1998, P NATL ACAD SCI USA, V95, P1062, DOI 10.1073/pnas.95.3.1062; Kim S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120073; Kornmann M, 1998, PANCREAS, V17, P169, DOI 10.1097/00006676-199808000-00010; Kuhn MC, 2012, MOL CELL ENDOCRINOL, V349, P180, DOI 10.1016/j.mce.2011.10.018; Larsson A., 2002, Angiogenesis, V5, P107, DOI 10.1023/A:1021588227705; Lau MT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059083; Lepique AP, 2004, J MOL ENDOCRINOL, V33, P623, DOI 10.1677/jme.1.01485; Li HJ, 2013, ONCOL REP, V30, P2153, DOI 10.3892/or.2013.2678; Ligibel JA, 2014, J CLIN ONCOL, V32, P3568, DOI 10.1200/JCO.2014.58.4680; Liu YH, 2001, CARCINOGENESIS, V22, P607, DOI 10.1093/carcin/22.4.607; Logie A, 2005, HUM MOL GENET, V14, P1153, DOI 10.1093/hmg/ddi127; Lu FJ, 2006, CHEM-BIOL INTERACT, V162, P249, DOI 10.1016/j.cbi.2006.07.007; Lu YP, 2012, P NATL ACAD SCI USA, V109, P9065, DOI 10.1073/pnas.1205810109; Malley CO, 2016, BBA CLIN, V5, P29, DOI 10.1016/j.bbacli.2015.11.003; Marshall Fray F, 2002, J Urol, V168, P877; Martin ASG, 2006, AM J CLIN NUTR, V83, p461S, DOI 10.1093/ajcn/83.2.461s; Matsui R, 1999, CELL SIGNAL, V11, P221, DOI 10.1016/S0898-6568(98)00070-9; Miyoshi Y, 2003, CLIN CANCER RES, V9, P5699; Moore LL, 2004, INT J OBESITY, V28, P559, DOI 10.1038/sj.ijo.0802606; Murphy RA, 2014, APPL PHYSIOL NUTR ME, V39, P687, DOI 10.1139/apnm-2013-0360; Mydlo JH, 1998, J UROLOGY, V159, P2159, DOI 10.1016/S0022-5347(01)63298-1; NAKAMOTO T, 1992, CANCER RES, V52, P571; NAKAMURA KD, 1989, MECH AGEING DEV, V48, P199, DOI 10.1016/0047-6374(89)90051-1; NAKAMURA Y, 1988, CARCINOGENESIS, V9, P203, DOI 10.1093/carcin/9.2.203; Nan H, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-172; Neubauer M, 2004, FEBS LETT, V577, P277, DOI 10.1016/j.febslet.2004.10.020; Nunez NP, 2008, NUTR CANCER, V60, P534, DOI 10.1080/01635580801966195; Ogden CL, 2010, JAMA-J AM MED ASSOC, V303, P242, DOI 10.1001/jama.2009.2012; Ortega S, 1998, P NATL ACAD SCI USA, V95, P5672, DOI 10.1073/pnas.95.10.5672; Ouchi N, 2003, CURR OPIN LIPIDOL, V14, P561, DOI 10.1097/00041433-200312000-00003; Ouchi N, 2011, NAT REV IMMUNOL, V11, P85, DOI 10.1038/nri2921; Pan RL, 2015, HEPATOLOGY, V61, P1708, DOI 10.1002/hep.27649; Pothiawala S, 2012, CANCER CAUSE CONTROL, V23, P717, DOI 10.1007/s10552-012-9941-x; QUARTO N, 1989, ONCOGENE RES, V5, P101; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Regad T, 2015, CANCERS, V7, P1758, DOI 10.3390/cancers7030860; Renehan AG, 2015, NAT REV CANCER, V15, P484, DOI 10.1038/nrc3967; SAHL WJ, 1995, INT J DERMATOL, V34, P398, DOI 10.1111/j.1365-4362.1995.tb04440.x; Samaras K, 2010, OBESITY, V18, P884, DOI 10.1038/oby.2009.443; Sarveswaran S, 2015, J BIOL CHEM, V290, P4994, DOI 10.1074/jbc.M114.599035; Sato T, 2009, ONCOL REP, V21, P211, DOI 10.3892/or_00000210; SCHAPIRA DV, 1994, CANCER, V74, P632, DOI 10.1002/1097-0142(19940715)74:2<632::AID-CNCR2820740215>3.0.CO;2-T; SMITH BM, 1986, CANCER RES, V46, P701; SMITH JS, 1992, CARCINOGENESIS, V13, P189, DOI 10.1093/carcin/13.2.189; SRINIVAS L, 1984, CARCINOGENESIS, V5, P515, DOI 10.1093/carcin/5.4.515; Steringer JP, 2015, J MOL BIOL, V427, P1202, DOI 10.1016/j.jmb.2014.07.012; Tsimafeyeu I, 2011, SCAND J UROL NEPHROL, V45, P190, DOI 10.3109/00365599.2011.552436; Turner N, 2010, CANCER RES, V70, P2085, DOI 10.1158/0008-5472.CAN-09-3746; VAGUE J, 1956, AM J CLIN NUTR, V4, P20, DOI 10.1093/ajcn/4.1.20; Vucenik I, 2012, ANN NY ACAD SCI, V1271, P37, DOI 10.1111/j.1749-6632.2012.06750.x; Weber TJ, 2010, J INVEST DERMATOL, V130, P1444, DOI 10.1038/jid.2009.383; Weiss J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001451; Xiao LP, 2010, BONE, V47, P360, DOI 10.1016/j.bone.2010.05.021; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yakar S, 2006, ENDOCRINOLOGY, V147, P5826, DOI 10.1210/en.2006-0311; Zhang DY, 2009, TOXICOL APPL PHARM, V235, P18, DOI 10.1016/j.taap.2008.11.002; Zhang XL, 2012, P NATL ACAD SCI USA, V109, P2790, DOI 10.1073/pnas.1100764108	103	24	25	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2017	36	48					6668	6679		10.1038/onc.2017.278	http://dx.doi.org/10.1038/onc.2017.278			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FO4AJ	28783178	Green Accepted, hybrid, Green Published			2022-12-17	WOS:000416780800002
J	Tsoi, H; Lam, KC; Dong, Y; Zhang, X; Lee, CK; Zhang, J; Ng, SC; Ng, SSM; Zheng, S; Chen, Y; Fang, J; Yu, J				Tsoi, H.; Lam, K. C.; Dong, Y.; Zhang, X.; Lee, C. K.; Zhang, J.; Ng, S. C.; Ng, S. S. M.; Zheng, S.; Chen, Y.; Fang, J.; Yu, J.			Pre-45s rRNA promotes colon cancer and is associated with poor survival of CRC patients	ONCOGENE			English	Article							RNA-POLYMERASE-I; UPSTREAM BINDING-FACTOR; SIGNALING PATHWAY; TRANSCRIPTION; PHOSPHORYLATION; INHIBITION; ACTIVATION; CALCIUM; STRESS; MDM2	One characteristic of cancer cells is the abnormally high rate of cell metabolism to sustain their enhanced proliferation. However, the behind mechanism of this phenomenon is still elusive. Here we find that enhanced precursor 45s ribosomal RNA (pre-45s rRNA) is one of the core mechanisms in promoting the pathogenesis of colorectal cancer (CRC). Pre-45s rRNA expression is significantly higher in primary CRC tumor tissues samples and cancer cell lines compared with the non-tumorous colon tissues, and is associated with tumor sizes. Knockdown of pre-45s rRNA inhibits G1/S cell-cycle transition by stabilizing p53 through inducing murine double minute 2 (MDM2) and ribosomal protein L11 (RpL11) interaction. In addition, we revealed that high rate of cancer cell metabolism triggers the passive release of calcium ion from endoplasmic reticulum to the cytoplasm. The elevated calcium ion in the cytoplasm activates the signaling cascade of calcium/calmodulin-dependent protein kinase II, ribosomal S6 kinase (S6K) and ribosomal S6K (CaMKII-S6K-UBF). The activated UBF promotes the transcription of rDNA, which therefore increases pre-45s rRNA. Disruption of CaMKII-S6K-UBF axis by either RNAi or pharmaceutical approaches leads to reduction of pre-45s rRNA expression, which subsequently suppresses cell proliferation in colon cancer cells by causing cell-cycle arrest. Knockdown of APC activates CaMKII-S6-KUBF cascade and thus enhances pre-45s rRNA expression. Moreover, the high expression level of pre-45s rRNA is associated with poor survival of CRC patients in two independent cohorts. Our study identifies a novel mechanism in CRC pathogenesis mediated by pre-45s rRNA and a prognostic factor of pre-45s rRNA in CRC patients.	[Tsoi, H.; Lam, K. C.; Dong, Y.; Zhang, X.; Lee, C. K.; Zhang, J.; Ng, S. C.; Yu, J.] Chinese Univ Hong Kong, Prince Wales Hosp, Inst Digest Dis, Room 707A,7-F,Li Ka Shing Med Sci Bldg, Shatin, Hong Kong, Peoples R China; [Tsoi, H.; Lam, K. C.; Dong, Y.; Zhang, X.; Lee, C. K.; Zhang, J.; Ng, S. C.; Yu, J.] Chinese Univ Hong Kong, Prince Wales Hosp, CUHK Shenzhen Res Inst,Dept Med & Therapeut, State Key Lab Digest Dis,Li Ka Shing Inst Hlth Sc, Shatin, Hong Kong, Peoples R China; [Ng, S. S. M.] Chinese Univ Hong Kong, Dept Surg, Shatin, Hong Kong, Peoples R China; [Zheng, S.] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Key Lab Canc Prevent & Intervent,China Natl Minis, Hangzhou, Zhejiang, Peoples R China; [Zheng, S.] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Canc Inst, Hangzhou, Zhejiang, Peoples R China; [Chen, Y.; Fang, J.; Yu, J.] Shanghai Jiao Tong Univ, Dept Gastroenterol, Renji Hosp, Sch Med, Shanghai, Peoples R China; [Chen, Y.; Fang, J.; Yu, J.] Shanghai Inst Digest Dis, Shanghai, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Zhejiang University; Zhejiang University; Shanghai Jiao Tong University	Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Inst Digest Dis, Room 707A,7-F,Li Ka Shing Med Sci Bldg, Shatin, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Room 707A,7-F,Li Ka Shing Med Sci Bldg, Shatin, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Ng, Simon S. M./M-1219-2018; ZHANG, Xiang/N-7918-2015; ZHANG, Jingwan/AIC-2560-2022; Ng, Siew Chien/N-4733-2015; Jun, Yu/D-8569-2015	Ng, Simon S. M./0000-0002-5389-9297; ZHANG, Xiang/0000-0002-3222-5824; Ng, Siew Chien/0000-0002-6850-4454; Jun, Yu/0000-0001-5008-2153; tsoi, ho/0000-0003-2037-9575	RGC-GRF Hong Kong [766613, 14106145, 14111216]; HMRF Hong Kong [1196728]; National Key Technology RD Program [2014BAI09B05]; 135 program [2016YFC1303200]; Shenzhen Virtual University	RGC-GRF Hong Kong(Hong Kong Research Grants Council); HMRF Hong Kong; National Key Technology RD Program(National Key Technology R&D Program); 135 program; Shenzhen Virtual University	This project was supported by RGC-GRF Hong Kong (766613, 14106145, 14111216) HMRF Hong Kong (1196728), The National Key Technology R&D Program (2014BAI09B05), 135 program project (2016YFC1303200), and Shenzhen Virtual University Park Support Scheme to CUHK-Shenzhen Research Institute.	Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; De A, 2011, ACTA BIOCH BIOPH SIN, V43, P745, DOI 10.1093/abbs/gmr079; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Fujita T, 2010, LANCET, V376, P331, DOI 10.1016/S0140-6736(10)61183-X; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; Grzmil M, 2012, CANCER RES, V72, P3891, DOI 10.1158/0008-5472.CAN-12-0026; Hannan KM, 2003, MOL CELL BIOL, V23, P8862, DOI 10.1128/MCB.23.23.8862-8877.2003; Hoe KK, 2014, NAT REV DRUG DISCOV, V13, P217, DOI 10.1038/nrd4236; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jimenez-Vidal M, 2010, J BIOL CHEM, V285, P36260, DOI 10.1074/jbc.M110.165555; Kestler HA, 2011, J CELL BIOL, V193, P431, DOI 10.1083/jcb.201103167; Kihm AJ, 1998, P NATL ACAD SCI USA, V95, P14816, DOI 10.1073/pnas.95.25.14816; Kim TH, 2014, ONCOTARGET, V5, P860, DOI 10.18632/oncotarget.1784; Monteith GR, 2007, NAT REV CANCER, V7, P519, DOI 10.1038/nrc2171; Mullineux ST, 2012, BIOCHIMIE, V94, P1521, DOI 10.1016/j.biochi.2012.02.001; Panner A, 2006, CELL CALCIUM, V40, P253, DOI 10.1016/j.ceca.2006.04.029; Panov KI, 2006, EMBO J, V25, P3310, DOI 10.1038/sj.emboj.7601221; Prevarskaya N, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0097; Rodnina MV, 2009, CURR OPIN CELL BIOL, V21, P435, DOI 10.1016/j.ceb.2009.01.023; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Sasaki M, 2011, NAT MED, V17, P944, DOI 10.1038/nm.2392; Schneikert J, 2007, GUT, V56, P417, DOI 10.1136/gut.2006.093310; Shifman JM, 2006, P NATL ACAD SCI USA, V103, P13968, DOI 10.1073/pnas.0606433103; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003	28	24	26	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6109	6118		10.1038/onc.2017.86	http://dx.doi.org/10.1038/onc.2017.86			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28692053	Green Published, hybrid			2022-12-17	WOS:000414249800005
J	Tian, R; Wang, J; Yan, H; Wu, J; Xu, Q; Zhan, X; Gui, Z; Ding, M; He, J				Tian, R.; Wang, J.; Yan, H.; Wu, J.; Xu, Q.; Zhan, X.; Gui, Z.; Ding, M.; He, J.			Differential expression of miR16 in glioblastoma and glioblastoma stem cells: their correlation with proliferation, differentiation, metastasis and prognosis	ONCOGENE			English	Article							MICRORNA-21 EXPRESSION; MIR-125B INHIBITOR; BRAIN-TUMORS; GLIOMA; INVASION; TEMOZOLOMIDE; METAANALYSIS; BIOMARKERS; APOPTOSIS; MIR-16-1	The function of miR16 in multiforme glioblastoma multiforme (GBM) and its stem cells (GSCs) remains elusive. To this end, we investigated the patterns of miR16 expression in these cells and their correlation with malignant behaviors and clinical outcomes. The levels of miR16 and its targeted genes in tumor tissue of GBM and GBM SGH44, U87, U251 cells as well as their stem cell counterparts were measured by qRT-PCR or western blot or immunohistochemistry. Luciferase reporter assay was used to confirm the binding of miR16 to 3'-UTR of its target genes. The effects of miR16 on malignant behaviors were investigated, including tumor cell viability, soft-agar colony formation, GSCs Matrigel colony forming and migration and invasion as well as nude mice xenograft model. Differentially expression patterns of miR16 in glioblastoma cells and GSCs cells were found in this study. Changes of miR16 targeted genes, Bcl2 (B cell lymphoma 2), CDK6 (Cyclin-dependent kinase 6), CCND1 (cyclin D1), CCNE1 (cyclin E1) and SOX5 were confirmed in glioblastoma cell lines and tissue specimens. In vitro and in vivo studies showed that tumor cell proliferation was inhibited by miR16 mimic, but enhanced by miR16 inhibitor. The expression level of miR16 positively correlates with GSCs differentiation, but negatively with the abilities of migration, motility, invasion and colony formation in glioblastoma cells. The inhibitory effects of miR16 on its target genes were also found in nude mice xenograft model. Our findings revealed that the miR16 functions as a tumor suppressor in GSCs and its association with prognosis in GBM.	Anhui Med Univ, Anhui Prov Hosp Affiliated, Dept Pathol, Hefei, Anhui, Peoples R China; [He, J.] Anhui Prov Canc Hosp, 107 Huan Hu Dong Rd, Hefei 230031, Anhui, Peoples R China	Anhui Medical University	He, J (corresponding author), Anhui Prov Canc Hosp, 107 Huan Hu Dong Rd, Hefei 230031, Anhui, Peoples R China.; He, J (corresponding author), Anhui Med Univ, Anhui Prov Hosp Affiliated, 107 Huan Hu Dong Rd, Hefei 230031, Anhui, Peoples R China.	hejie2005g@sina.com			National Natural Science of China [81272800, 81072057, 8152323]	National Natural Science of China(National Natural Science Foundation of China (NSFC))	This study was sponsored by National Natural Science of China (Grant Nos. 81272800, 81072057 and 8152323).	Aqeilan RI, 2010, CELL DEATH DIFFER, V17, P215, DOI 10.1038/cdd.2009.69; Areeb Z, 2015, J NEURO-ONCOL, V125, P237, DOI 10.1007/s11060-015-1912-0; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Blakaj A, 2008, J BIOL CHEM, V283, P9505, DOI 10.1074/jbc.R800002200; Boije M, 2012, CANCER RES S8, V72, P3343; Brower JV, 2014, NEUROCHEM INT, V77, P68, DOI 10.1016/j.neuint.2014.06.002; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Chen J, 2014, TUMOR BIOL, V35, P6293, DOI 10.1007/s13277-014-1821-4; Ciafre SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030; Cuddapah VA, 2014, NAT REV NEUROSCI, V15, P455, DOI 10.1038/nrn3765; Guessous F, 2010, CELL CYCLE, V9, P1031, DOI 10.4161/cc.9.6.10987; He XY, 2016, MOL NEUROBIOL, V53, P1856, DOI 10.1007/s12035-015-9140-3; Krichevsky AM, 2003, RNA, V9, P1274, DOI 10.1261/rna.5980303; Li C, 2016, J NEURO-ONCOL, V130, P11, DOI 10.1007/s11060-016-2233-7; Li XD, 2013, ANAT REC, V296, P427, DOI 10.1002/ar.22626; Li XX, 2016, MOL NEUROBIOL, V53, P577, DOI 10.1007/s12035-014-9017-x; Li YQ, 2009, CANCER RES, V69, P7569, DOI 10.1158/0008-5472.CAN-09-0529; Liu G, 2010, EXP NEUROL, V226, P200, DOI 10.1016/j.expneurol.2010.08.032; Liu Q, 2008, NUCLEIC ACIDS RES, V36, P5391, DOI 10.1093/nar/gkn522; Najbauer J, 2014, PATHOL ONCOL RES, V20, P789, DOI 10.1007/s12253-014-9837-z; Ostrom QT, 2013, NEURO-ONCOLOGY, V15, P1, DOI 10.1093/neuonc/not151; Ouyang Q, 2016, INT J NEUROSCI, V126, P1, DOI 10.3109/00207454.2015.1017881; Pavon LF, 2016, ONCOTARGET, V7, P40546, DOI 10.18632/oncotarget.9658; Rinkenbaugh AL, 2016, ONCOTARGET, V7, P69173, DOI 10.18632/oncotarget.12507; Santhi WS, 2013, ORAL ONCOL, V49, P567, DOI 10.1016/j.oraloncology.2013.01.001; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Shan ZN, 2016, ONCOTARGET, V7, P78813, DOI 10.18632/oncotarget.12385; Shi L, 2014, BIODRUGS, V28, P41, DOI 10.1007/s40259-013-0053-2; Shi L, 2012, NEUROMOL MED, V14, P303, DOI 10.1007/s12017-012-8188-8; Shi L, 2012, INT J ONCOL, V40, P119, DOI 10.3892/ijo.2011.1179; Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14; Suva ML, 2014, CELL, V157, P580, DOI 10.1016/j.cell.2014.02.030; Tchougounova E, 2009, ONCOGENE, V28, P1537, DOI 10.1038/onc.2009.9; Wang Q, 2014, MOL MED REP, V10, P3310, DOI 10.3892/mmr.2014.2583; Wu N, 2012, FEBS LETT, V586, P3831, DOI 10.1016/j.febslet.2012.08.023; Yang TQ, 2014, CANCER SCI, V105, P265, DOI 10.1111/cas.12351; Yue JM, 2010, MAMM GENOME, V21, P88, DOI 10.1007/s00335-009-9240-3; Zhi F, 2010, EUR J CANCER, V46, P1640, DOI 10.1016/j.ejca.2010.02.003	39	24	25	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5861	5873		10.1038/onc.2017.182	http://dx.doi.org/10.1038/onc.2017.182			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28628119	hybrid, Green Published			2022-12-17	WOS:000413292900008
J	Li, W; Hu, M; Wang, C; Lu, H; Chen, F; Xu, J; Shang, Y; Wang, F; Qin, J; Yan, Q; Krueger, BJ; Renne, R; Gao, SJ; Lu, C				Li, W.; Hu, M.; Wang, C.; Lu, H.; Chen, F.; Xu, J.; Shang, Y.; Wang, F.; Qin, J.; Yan, Q.; Krueger, B. J.; Renne, R.; Gao, S-J; Lu, C.			A viral microRNA downregulates metastasis suppressor CD82 and induces cell invasion and angiogenesis by activating the c-Met signaling	ONCOGENE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; HEPATOCYTE GROWTH-FACTOR; PRIMARY EFFUSION LYMPHOMA; LYTIC CYCLE REPLICATION; KAPOSIS-SARCOMA; ENDOTHELIAL-CELLS; ENCODED MICRORNAS; HIV-1 NEF; PROTEIN EXPRESSION; TETRASPANIN CD82	Kaposi's sarcoma (KS) as the most common AIDS-associated malignancy is etiologically caused by KS-associated herpesvirus (KSHV). KS is a highly disseminated and vascularized tumor. KSHV encodes 12 pre-microRNAs that yield 25 mature microRNAs (miRNAs), but their roles in KSHV-induced tumor metastasis and angiogenesis remain largely unclear. KSHV-encoded miR-K12-6 (miR-K6) can generate two mature miRNAs, miR-K6-5p and miR-K6-3p. Recently, we have shown that miR-K6-3p induced cell migration and angiogenesis via directly targeting SH3 domain binding glutamate-rich protein (SH3BGR). Here, by using mass spectrometry, bioinformatics analysis and luciferase reporter assay, we showed that miR-K6-5p directly targeted the coding sequence of CD82 molecule (CD82), a metastasis suppressor. Ectopic expression of miR-K6-5p specifically inhibited the expression of endogenous CD82 and strongly promoted endothelial cells invasion and angiogenesis. Overexpression of CD82 significantly inhibited cell invasion and angiogenesis induced by miR-K6-5p. Mechanistically, CD82 directly interacted with c-Met to inhibit its activation. MiR-K6-5p directly repressed CD82, relieving its inhibition on c-Met activation and inducing cell invasion and angiogenesis. Lack of miR-K6 abrogated KSHV suppression of CD82 resulting in compromised KSHV activation of c-Met pathway, and KSHV induction of cell invasion and angiogenesis. In conclusion, our data show that by reducing CD82, KSHV miR-K6-5p expedites cell invasion and angiogenesis by activating the c-Met pathway. Our findings illustrate that KSHV miRNAs may be critical for the dissemination and angiogenesis of KSHV-induced malignant tumors.	[Li, W.; Lu, C.] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China; [Li, W.; Lu, C.] Nanjing Med Univ, Key Lab Pathogen Biol Jiangsu Prov, Nanjing, Jiangsu, Peoples R China; [Li, W.; Chen, F.; Xu, J.; Shang, Y.; Wang, F.; Qin, J.; Yan, Q.; Lu, C.] Nanjing Med Univ, Dept Microbiol, 101 Longmian Ave, Nanjing 211166, Jiangsu, Peoples R China; [Hu, M.] Xuzhou Med Univ, Dept Pathogen Biol & Immunol, Xuzhou, Peoples R China; [Wang, C.] Nanjing Med Univ, Affiliated Hosp 1, Dept Pathol, Nanjing, Jiangsu, Peoples R China; [Lu, H.] Nanjing Med Univ, Affiliated Hosp 1, Dept Obstet, Nanjing, Jiangsu, Peoples R China; [Krueger, B. J.; Renne, R.] Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL USA; [Gao, S-J] Univ Southern Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA USA	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Xuzhou Medical University; Nanjing Medical University; Nanjing Medical University; State University System of Florida; University of Florida; University of Southern California	Lu, C (corresponding author), Nanjing Med Univ, Dept Microbiol, 101 Longmian Ave, Nanjing 211166, Jiangsu, Peoples R China.	clu@njmu.edu.cn	Gao, Shou-Jiang/B-8641-2012	Gao, Shou-Jiang/0000-0001-6194-1742	National Natural Science Foundation of China [81761128003, 81371824, 81401662]; NIH [R01CA213275, R01CA177377, R01CA132637]; Natural Science Youth Foundation of Jiangsu Province [BK20140908]; NATIONAL CANCER INSTITUTE [R01CA213275, R01CA124332, R01CA197153, R01CA132637, R01CA096512, R01CA177377] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE025465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE017333] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Natural Science Youth Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by grants from National Natural Science Foundation of China (81761128003, 81371824 and 81401662), grants from NIH (R01CA213275, R01CA177377 and R01CA132637), and the Natural Science Youth Foundation of Jiangsu Province (BK20140908).	Abend JR, 2012, J VIROL, V86, P11663, DOI 10.1128/JVI.01147-12; Atabey N, 2001, J BIOL CHEM, V276, P14308, DOI 10.1074/jbc.M010202200; Bandyopadhyay S, 2006, NAT MED, V12, P933, DOI 10.1038/nm1444; Bari R, 2009, AM J PATHOL, V174, P647, DOI 10.2353/ajpath.2009.080685; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bellare P, 2009, CELL HOST MICROBE, V6, P570, DOI 10.1016/j.chom.2009.11.008; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Blankaert D, 1998, J ACQ IMMUN DEF SYND, V18, P203, DOI 10.1097/00042560-199807010-00002; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Brulois KF, 2012, J VIROL, V86, P9708, DOI 10.1128/JVI.01019-12; Cai XZ, 2005, P NATL ACAD SCI USA, V102, P5570, DOI 10.1073/pnas.0408192102; Catrina AM, 2014, PATHOL ONCOL RES, V20, P153, DOI 10.1007/s12253-013-9678-1; Cheung TW, 2004, CANCER INVEST, V22, P774, DOI 10.1081/CNV-200032788; Cullen BR, 2011, GENE DEV, V25, P1881, DOI 10.1101/gad.17352611; Dai L, 2015, BLOOD, V126, P2821, DOI 10.1182/blood-2015-07-658823; Dourmishev LA, 2003, MICROBIOL MOL BIOL R, V67, P175, DOI 10.1128/MMBR.67.2.175-212.2003; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; Feng J, 2015, CANCER METAST REV, V34, P619, DOI 10.1007/s10555-015-9585-x; Fuse N, 2016, GASTRIC CANCER, V19, P183, DOI 10.1007/s10120-015-0471-6; Gottwein E, 2011, CELL HOST MICROBE, V10, P515, DOI 10.1016/j.chom.2011.09.012; Grundhoff A, 2006, RNA, V12, P733, DOI 10.1261/rna.2326106; Guo XZ, 2005, ONCOL REP, V14, P59; Han YL, 2014, ONCOL LETT, V8, P1618, DOI 10.3892/ol.2014.2390; Hanna JA, 2009, ADV CANCER RES, V103, P1, DOI 10.1016/S0065-230X(09)03001-2; Hansen A, 2010, GENE DEV, V24, P195, DOI 10.1101/gad.553410; Hu MM, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005171; Jain V, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8020054; Koo BS, 2014, ANN SURG ONCOL, V21, P2310, DOI 10.1245/s10434-014-3553-5; Lei XF, 2012, J VIROL, V86, P11698, DOI 10.1128/JVI.06855-11; Leo C, 2007, GYNECOL ONCOL, V104, P181, DOI 10.1016/j.ygyno.2006.07.040; Li W, 2016, ONCOTARGET, V7, P32286, DOI 10.18632/oncotarget.8591; Li W, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005605; Li Y, 2013, INT J BIOCHEM CELL B, V45, P2349, DOI 10.1016/j.biocel.2013.08.002; Lin HR, 2011, P NATL ACAD SCI USA, V108, P5148, DOI 10.1073/pnas.1102033108; Lin XZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016224; Liu WM, 2006, CANCER LETT, V240, P183, DOI 10.1016/j.canlet.2005.08.018; Lu CC, 2010, EMBO REP, V11, P784, DOI 10.1038/embor.2010.132; Lu F, 2010, J VIROL, V84, P2697, DOI 10.1128/JVI.01997-09; Marshall V, 2007, J INFECT DIS, V195, P645, DOI 10.1086/511434; Mesri EA, 2010, NAT REV CANCER, V10, P707, DOI 10.1038/nrc2888; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Neuzillet C, 2015, HISTOPATHOLOGY, V67, P664, DOI 10.1111/his.12691; Nishioka C, 2013, INT J CANCER, V132, P2006, DOI 10.1002/ijc.27904; O'Hara AJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000389; Pantanowitz L, 2006, J CUTAN PATHOL, V33, P793, DOI 10.1111/j.1600-0560.2006.00567.x; Poon M, 1997, CIRCULATION, V96, P2514, DOI 10.1161/01.CIR.96.8.2514; Qin D, 2008, CELL MICROBIOL, V10, P713, DOI 10.1111/j.1462-5822.2007.01079.x; Qin J, 2017, TRENDS MICROBIOL, V25, P648, DOI 10.1016/j.tim.2017.02.002; Qin Zhiqiang, 2012, Int J Cell Biol, V2012, P603961, DOI 10.1155/2012/603961; Qin ZQ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000742; Ramalingam D, 2015, J VIROL, V89, P4249, DOI 10.1128/JVI.03687-14; Rosano L, 2003, AM J PATHOL, V163, P753, DOI 10.1016/S0002-9440(10)63702-9; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Ruseva Z, 2009, EXP CELL RES, V315, P1759, DOI 10.1016/j.yexcr.2009.01.007; Sadagopan S, 2009, J VIROL, V83, P3342, DOI 10.1128/JVI.02052-08; Samols MA, 2005, J VIROL, V79, P9301, DOI 10.1128/JVI.79.14.9301-9305.2005; Samols MA, 2007, PLOS PATHOG, V3, P611, DOI 10.1371/journal.ppat.0030065; Sridhar SC, 2006, ONCOGENE, V25, P2367, DOI 10.1038/sj.onc.1209269; Takahashi M, 2007, INT J CANCER, V121, P1919, DOI 10.1002/ijc.22887; Todeschini AR, 2007, J BIOL CHEM, V282, P8123, DOI 10.1074/jbc.M611407200; Tohami T, 2007, FASEB J, V21, P691, DOI 10.1096/fj.06-6610com; Tonoli H, 2005, TRENDS MOL MED, V11, P563, DOI 10.1016/j.molmed.2005.10.002; Wei Q, 2014, CIRCULATION, V130, P1493, DOI 10.1161/CIRCULATIONAHA.114.011096; Xue M, 2014, NUCLEIC ACIDS RES, V42, P9862, DOI 10.1093/nar/gku583; Yan Q, 2014, J VIROL, V88, P4987, DOI 10.1128/JVI.00025-14; Yan SC, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0296-y; Yang XH, 2001, CANCER RES, V61, P5284; Yao SH, 2015, NUCLEIC ACIDS RES, V43, P9362, DOI 10.1093/nar/gkv988; Yoshida S, 2002, J CLIN ENDOCR METAB, V87, P2376, DOI 10.1210/jc.87.5.2376; Zeng Y, 2007, J VIROL, V81, P2401, DOI 10.1128/JVI.02024-06; Zhou F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053145; Zhu X, 2014, ONCOGENE, V33, P1986, DOI 10.1038/onc.2013.136; Zismanov V, 2009, BRIT J CANCER, V101, P1402, DOI 10.1038/sj.bjc.6605291; Zoller M, 2009, NAT REV CANCER, V9, P40, DOI 10.1038/nrc2543	74	24	24	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2017	36	38					5407	5420		10.1038/onc.2017.139	http://dx.doi.org/10.1038/onc.2017.139			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FH7PJ	28534512	Green Accepted			2022-12-17	WOS:000411382100007
J	Kawauchi, D; Ogg, RJ; Liu, L; Shih, DJH; Finkelstein, D; Murphy, BL; Rehg, JE; Korshunov, A; Calabrese, C; Zindy, F; Phoenix, T; Kawaguchi, Y; Gronych, J; Gilbertson, RJ; Lichter, P; Gajjar, A; Kool, M; Northcott, PA; Pfister, SM; Roussel, MF				Kawauchi, D.; Ogg, R. J.; Liu, L.; Shih, D. J. H.; Finkelstein, D.; Murphy, B. L.; Rehg, J. E.; Korshunov, A.; Calabrese, C.; Zindy, F.; Phoenix, T.; Kawaguchi, Y.; Gronych, J.; Gilbertson, R. J.; Lichter, P.; Gajjar, A.; Kool, M.; Northcott, P. A.; Pfister, S. M.; Roussel, M. F.			Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells	ONCOGENE			English	Article							GRANULE NEURON PRECURSORS; CENTRAL-NERVOUS-SYSTEM; CONSTITUTIVE ACTIVATION; GENE-EXPRESSION; BETA-CATENIN; MOUSE MODEL; STEM-CELLS; TUMORS; P53; PROGENITORS	Group3 medulloblastoma (MBG3) that predominantly occur in young children are usually associated with MYC amplification and/or overexpression, frequent metastasis and a dismal prognosis. Physiologically relevant MBG3 models are currently lacking, making inferences related to their cellular origin thus far limited. Using in utero electroporation, we here report that MBG3 mouse models can be developed in situ from different multipotent embryonic cerebellar progenitor cells via conditional expression of Myc and loss of Trp53 function in several Cre driver mouse lines. The Blbp-Cre driver that targets embryonic neural progenitors induced tumors exhibiting a large-cell/anaplastic histopathology adjacent to the fourth ventricle, recapitulating human MBG3. Enforced co-expression of luciferase together with Myc and a dominant-negative form of Trp53 revealed that GABAergic neuronal progenitors as well as cerebellar granule cells give rise to MBG3 with their distinct growth kinetics. Cross-species gene expression analysis revealed that these novel MBG3 models shared molecular characteristics with human MBG3, irrespective of their cellular origin. We here developed MBG3 mouse models in their physiological environment and we show that oncogenic insults drive this MB subgroup in different cerebellar lineages rather than in a specific cell of origin.	[Kawauchi, D.; Liu, L.; Murphy, B. L.; Zindy, F.; Roussel, M. F.] St Jude Childrens Res Hosp SJCRH, Dept Tumor Cell Biol, 262 Danny Thomas Pl, Memphis, TN 38105 USA; [Kawauchi, D.; Kool, M.; Pfister, S. M.] German Canc Res Ctr, Div Pediat Neurooncol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany; [Ogg, R. J.] St Jude Childrens Res Hosp SJCRH, Dept Radiol Sci, 262 Danny Thomas Pl, Memphis, TN 38105 USA; [Shih, D. J. H.] Hosp Sick Children, Peter Gilgan Ctr Res & Learning, Toronto, ON, Canada; [Finkelstein, D.] St Jude Childrens Res Hosp SJCRH, Dept Computat Biol, 262 Danny Thomas Pl, Memphis, TN 38105 USA; [Rehg, J. E.] St Jude Childrens Res Hosp SJCRH, Dept Vet Pathol Core, 262 Danny Thomas Pl, Memphis, TN 38105 USA; [Korshunov, A.] Heidelberg Univ, Dept Neuropathol, German Canc Res Ctr DKFZ, Clin Cooperat Unit Neuropathol, Heidelberg, Germany; [Calabrese, C.] St Jude Childrens Res Hosp SJCRH, Dept Small Anim Imaging Core, 262 Danny Thomas Pl, Memphis, TN 38105 USA; [Phoenix, T.; Gilbertson, R. J.; Northcott, P. A.] St Jude Childrens Res Hosp SJCRH, Dept Dev Neurobiol, 262 Danny Thomas Pl, Memphis, TN 38105 USA; [Kawaguchi, Y.] Kyoto Univ, Ctr iPS Cell Res & Applicat, Dept Clin Applicat, Kyoto, Japan; [Gronych, J.; Lichter, P.] German Canc Res Ctr, Dept Mol Genet, Heidelberg, Germany; [Gajjar, A.] St Jude Childrens Res Hosp SJCRH, Dept Oncol, 262 Danny Thomas Pl, Memphis, TN 38105 USA; [Pfister, S. M.] Heidelberg Univ Hosp, Dept Pediat Hematol & Oncol, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Kyoto University; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Kawauchi, D; Roussel, MF (corresponding author), St Jude Childrens Res Hosp SJCRH, Dept Tumor Cell Biol, 262 Danny Thomas Pl, Memphis, TN 38105 USA.; Kawauchi, D (corresponding author), German Canc Res Ctr, Div Pediat Neurooncol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	d.kawauchi@dkfz.de; martine.roussel@stjude.org	Northcott, Paul A/N-4022-2018; Rehg, Jerold E/N-8111-2018; Pfister, Stefan M/F-6860-2013; Gilbertson, Richard James/ABE-1346-2021; Gajjar, Amar/N-8059-2018; Shih, David J. H./AAE-8726-2019; Roussel, Martine F/F-1469-2016	Northcott, Paul A/0000-0002-1220-5252; Pfister, Stefan M/0000-0002-5447-5322; Gilbertson, Richard James/0000-0001-7539-9472; Shih, David J. H./0000-0002-9802-4937; Roussel, Martine F/0000-0002-1740-8139; Korshunov, Andrey/0000-0002-5257-3623	National Institute of Health [CA-096832, CA-21765, HD-049888, RR-029005]; Anderson fellowship; Deutsche Forschungsgemeinschaft [KA 4472/1-1]; Helmholtz Alliance 'Preclinical Comprehensive Cancer Center' [HA-305]; American Lebanese Syrian Associated Charities of SJCRH; Cancer Research UK [22492] Funding Source: researchfish; The Brain Tumour Charity [GN-000356] Funding Source: researchfish; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD049888] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA096832] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR029005] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Anderson fellowship; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Helmholtz Alliance 'Preclinical Comprehensive Cancer Center'; American Lebanese Syrian Associated Charities of SJCRH(American Lebanese Syrian Associated Charities (ALSAC)); Cancer Research UK(Cancer Research UK); The Brain Tumour Charity; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Drs Y Takahashi (Kyoto University) and K Kawakami (National Institute of Genetics, Japan) for generously providing Tol2 transposon related vectors; L Linke and N Mack (DKFZ), J Grenet, D Farmer, S Wilkerson, S Smith and S Robinson for excellent technical assistance, J Morris and M Loyd for Affymetrix microarray analysis; Drs R Ashmun and A-M Hamilton Easton for fluorescence-activated cell sorting analysis; M Payton and C Winter for in vivo imaging of tumor growth; M Johnson and S Brown for orthotopic transplants; Dr MA Scoggins, L Stokes and A Owens for processing and analysis of human images; Drs O Witt, K Reifenberg, N Denk and K Dell for helpful assistance with animal experiments at DKFZ; Dr C Wright (Vanderbilt University), Y Nakano and M Horiguchi (Kyoto University) for mice; Drs H Liu and W Feng (DKFZ) for sharing R26-LSL-tdTomato mice and helpful discussions; Drs Y Ouyang (SJCRH) and F Bestvater (DKFZ) for Light Microscopy. This work was funded in part by the National Institute of Health Grants CA-096832, CA-21765 (to MFR), HD-049888, RR-029005 (to RJO), the Anderson fellowship and the Deutsche Forschungsgemeinschaft, KA 4472/1-1 (to DK), the Helmholtz Alliance 'Preclinical Comprehensive Cancer Center' Grant HA-305 (to PL, JG and SMP) and the American Lebanese Syrian Associated Charities of SJCRH.	Ashburner J, 1999, HUM BRAIN MAPP, V7, P254, DOI 10.1002/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G; Birks DK, 2013, PEDIATR BLOOD CANCER, V60, P1095, DOI 10.1002/pbc.24481; Bowman T, 1996, GENE DEV, V10, P826, DOI 10.1101/gad.10.7.826; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Brett M., 2005, MNI BRAIN TALAIRACH; Cheng FY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035541; Cho KH, 2011, SURG RADIOL ANAT, V33, P523, DOI 10.1007/s00276-011-0796-8; Dastjerdi FV, 2012, FRONT NEUROANAT, V6, DOI 10.3389/fnana.2012.00010; EVANS AC, 1993, NUCLEAR SCIENCE SYMPOSIUM & MEDICAL IMAGING CONFERENCE, VOLS 1-3, P1813, DOI 10.1109/NSSMIC.1993.373602; Fattet S, 2009, J PATHOL, V218, P86, DOI 10.1002/path.2514; Fedorov A, 2012, MAGN RESON IMAGING, V30, P1323, DOI 10.1016/j.mri.2012.05.001; Gajjar AJ, 2014, NAT REV CLIN ONCOL, V11, P714, DOI 10.1038/nrclinonc.2014.181; Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587; Gilbertson RJ, 2008, ANNU REV PATHOL-MECH, V3, P341, DOI 10.1146/annurev.pathmechdis.3.121806.151518; Hanaford AR, 2016, CLIN CANCER RES, V22, P3903, DOI 10.1158/1078-0432.CCR-15-3011; Hevner RF, 2006, NEUROSCI RES, V55, P223, DOI 10.1016/j.neures.2006.03.004; Hill RM, 2015, CANCER CELL, V27, P72, DOI 10.1016/j.ccell.2014.11.002; Hoshino M, 2005, NEURON, V47, P201, DOI 10.1016/j.neuron.2005.06.007; Hunter NL, 2007, DEVELOPMENT, V134, P3449, DOI 10.1242/dev.003095; Jones DTW, 2012, NATURE, V488, P100, DOI 10.1038/nature11284; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kawauchi D, 2008, DEV BIOL, V322, P345, DOI 10.1016/j.ydbio.2008.08.005; Kawauchi D, 2012, CANCER CELL, V21, P168, DOI 10.1016/j.ccr.2011.12.023; Khandanpour C, 2013, CANCER CELL, V23, P200, DOI 10.1016/j.ccr.2013.01.011; Kool M, 2014, CANCER CELL, V25, P393, DOI 10.1016/j.ccr.2014.02.004; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Li P, 2013, NAT NEUROSCI, V16, P1737, DOI 10.1038/nn.3553; Lorenz A, 2011, MOL CELL BIOL, V31, P3326, DOI 10.1128/MCB.05718-11; McCall MN, 2014, NUCLEIC ACIDS RES, V42, pD938, DOI 10.1093/nar/gkt1204; McCall MN, 2010, BIOSTATISTICS, V11, P242, DOI 10.1093/biostatistics/kxp059; Murphy BL, 2013, CANCER RES, V73, P7068, DOI 10.1158/0008-5472.CAN-13-0927; Northcott PA, 2014, NATURE, V511, P428, DOI 10.1038/nature13379; Northcott PA, 2012, NAT REV NEUROL, V8, P340, DOI 10.1038/nrneurol.2012.78; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Paxinos G., 2008, MOUSE BRAIN STEREOTA; Pei YX, 2012, CANCER CELL, V21, P155, DOI 10.1016/j.ccr.2011.12.021; Perreault S, 2014, AM J NEURORADIOL, V35, P1263, DOI 10.3174/ajnr.A3990; Platt RJ, 2014, CELL, V159, P440, DOI 10.1016/j.cell.2014.09.014; Poschl J, 2013, DEV BIOL, V374, P319, DOI 10.1016/j.ydbio.2012.12.001; Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213; Rogers HA, 2013, BRIT J CANCER, V108, P2130, DOI 10.1038/bjc.2013.170; Roussel MF, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014308; Roussel MF, 2011, CURR TOP DEV BIOL, V94, P235, DOI 10.1016/B978-0-12-380916-2.00008-5; Sato Y, 2007, DEV BIOL, V305, P616, DOI 10.1016/j.ydbio.2007.01.043; Schmahmann J.D., 2000, MRI ATLAS HUMAN CERE; Schuller U, 2008, CANCER CELL, V14, P123, DOI 10.1016/j.ccr.2008.07.005; Sgaier SK, 2005, NEURON, V45, P27, DOI 10.1016/S0896-6273(04)00802-5; Swartling FJ, 2012, CANCER CELL, V21, P601, DOI 10.1016/j.ccr.2012.04.012; Talairach J., 1988, COPLANAR STEREOTAXIC; Uziel T, 2005, GENE DEV, V19, P2656, DOI 10.1101/gad.1368605; Wefers AK, 2014, ACTA NEUROPATHOL, V127, P931, DOI 10.1007/s00401-014-1271-5; Wu Xiaochong, 2011, Chin J Cancer, V30, P442, DOI 10.5732/cjc.011.10040; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Yokota Y, 2011, DEV BIOL, V353, P382, DOI 10.1016/j.ydbio.2011.02.001; Zhu LQ, 2009, NATURE, V457, P603, DOI 10.1038/nature07589; Zindy F, 2007, CANCER RES, V67, P2676, DOI 10.1158/0008-5472.CAN-06-3418; Zuckermann M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8391	57	24	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2017	36	37					5231	5242		10.1038/onc.2017.110	http://dx.doi.org/10.1038/onc.2017.110			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FG8HT	28504719	Green Published, hybrid			2022-12-17	WOS:000410671700002
J	Lin, C; Liao, W; Jian, Y; Peng, Y; Zhang, X; Ye, L; Cui, Y; Wang, B; Wu, X; Xiong, Z; Wu, S; Li, J; Wang, X; Song, L				Lin, C.; Liao, W.; Jian, Y.; Peng, Y.; Zhang, X.; Ye, L.; Cui, Y.; Wang, B.; Wu, X.; Xiong, Z.; Wu, S.; Li, J.; Wang, X.; Song, L.			CGI-99 promotes breast cancer metastasis via autocrine interleukin-6 signaling	ONCOGENE			English	Article							INFLUENZA-VIRUS POLYMERASE; LYMPH-NODE METASTASIS; C14ORF166 OVEREXPRESSION; MONOCLONAL-ANTIBODY; PRECLINICAL MODELS; TUMOR PROGRESSION; MULTIPLE-MYELOMA; CELLULAR-PROTEIN; BINDING PROTEIN; POOR-PROGNOSIS	Metastatic relapse remains largely incurable and a major challenge of clinical management in breast cancer, but the underlying mechanisms are poorly understood. Herein, we report that CGI-99 is overexpressed in breast cancer tissues from patients with metastatic recurrence within 5 years. High CGI-99 significantly predicts poorer 5-year metastasis-free patient survival. We find that CGI-99 increases breast cancer stem cell properties, and potentiates efficient tumor lung colonization and outgrowth in vivo. Furthermore, we demonstrate that CGI-99 activates the autocrine interleukin-6 (IL-6)/STAT3 signaling by increasing the accumulation and activity of RNA polymerase II and p300 cofactor at the proximal promoter of IL-6. Importantly, delivery of the IL-6receptor humanized monoclonal antibody tocilizumab robustly abrogates CGI-99-induced metastasis in vivo. Finally, we find that high levels of CGI-99 are significantly correlated with STAT3 hyperactivation in breast cancer patients. These findings reveal a potential mechanism for constitutive activation of autocrine IL-6/STAT3 signaling and may suggest a novel target for clinical intervention in breast cancer.	[Lin, C.; Zhang, X.; Ye, L.; Cui, Y.; Wang, B.; Wu, X.; Wu, S.; Song, L.] Sun Yat Sen Univ, State Key Lab Oncol South China, Canc Ctr, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China; [Liao, W.; Jian, Y.] Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou, Guangdong, Peoples R China; [Peng, Y.] Guangdong Country Garden Sch, Guangzhou, Guangdong, Peoples R China; [Xiong, Z.; Wang, X.] Sun Yat Sen Univ, Canc Ctr, Dept Breast Surg, Guangzhou 510060, Guangdong, Peoples R China; [Li, J.] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Southern Medical University - China; Sun Yat Sen University; Sun Yat Sen University	Wang, X (corresponding author), Sun Yat Sen Univ, Canc Ctr, Dept Breast Surg, Guangzhou 510060, Guangdong, Peoples R China.; Song, L (corresponding author), Sun Yat Sen Univ, Canc Ctr, Dept Expt Res, State Key Lab Oncol Southern China, 651 Dongfend Rd, Guangzhou 510060, Guangdong, Peoples R China.	wangxi@sysucc.org.cn; songlb@sysucc.org.cn	Song, LB/AAL-1968-2020; Zhang, Xin/C-2464-2017; Lin, Chuyong/AAA-9931-2020; Wang, Bin/AAJ-6007-2020	Zhang, Xin/0000-0001-6036-2685; Lin, Chuyong/0000-0003-4887-5386; Wang, Bin/0000-0002-9093-5381; Ye, Liping/0000-0002-2263-0631	Ministry of Science and Technology of China [973-2014CB910604]; Natural Science Foundation of China [81472546, 81672854, 81530082, 81272198, 81572687, 81325013, 91529301, 81572688]; Science and Technology of Guangdong Province [2016A030308002, 2014A030313008, 2014A030313220]; Science and Technology Program of Guangzhou [15020077]; Guangdong Esophageal Cancer Institute [M201409]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology of Guangdong Province; Science and Technology Program of Guangzhou; Guangdong Esophageal Cancer Institute	This work was supported by the Ministry of Science and Technology of China grant (no. 973-2014CB910604); Natural Science Foundation of China (no. 81472546, 81672854, 81530082, 81272198, 81572687, 81325013, 91529301 and 81572688), the Science and Technology of Guangdong Province (no. 2016A030308002, 2014A030313008 and 2014A030313220), Science and Technology Program of Guangzhou (no. 15020077) and Guangdong Esophageal Cancer Institute (no. M201409).	Ando K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102436; Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518; Blobel GA, 2000, BLOOD, V95, P745, DOI 10.1182/blood.V95.3.745.003k05_745_755; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Cheang TY, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0805-0; Conze D, 2001, CANCER RES, V61, P8851; Coward J, 2011, CLIN CANCER RES, V17, P6083, DOI 10.1158/1078-0432.CCR-11-0945; Cui YZ, 2009, INT J CANCER, V124, P1614, DOI 10.1002/ijc.24163; Deng JH, 2012, CANCER CELL, V21, P642, DOI 10.1016/j.ccr.2012.03.039; Dijkgraaf EM, 2015, ANN ONCOL, V26, P2141, DOI 10.1093/annonc/mdv309; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Grivennikov S, 2008, CANCER CELL, V13, P7, DOI 10.1016/j.ccr.2007.12.020; Guo JH, 2009, CANCER SCI, V100, P2292, DOI 10.1111/j.1349-7006.2009.01324.x; Guryanova OA, 2011, CANCER CELL, V19, P498, DOI 10.1016/j.ccr.2011.03.004; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; He GB, 2013, CELL, V155, P384, DOI 10.1016/j.cell.2013.09.031; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Howng SL, 2004, FEBS LETT, V566, P162, DOI 10.1016/j.febslet.2004.04.024; Huarte M, 2001, J VIROL, V75, P8597, DOI 10.1128/JVI.75.18.8597-8604.2001; Ishizawa K, 2010, CELL STEM CELL, V7, P279, DOI 10.1016/j.stem.2010.08.009; Jeong EG, 2008, CLIN CANCER RES, V14, P3716, DOI 10.1158/1078-0432.CCR-07-4839; Kroon P, 2013, CANCER RES, V73, P5288, DOI 10.1158/0008-5472.CAN-13-0874; Lai CH, 2000, GENOME RES, V10, P703, DOI 10.1101/gr.10.5.703; Larive RM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4881; Lee JW, 2011, J PROTEOME RES, V10, P4522, DOI 10.1021/pr200338d; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Liu SL, 2010, J CLIN ONCOL, V28, P4006, DOI 10.1200/JCO.2009.27.5388; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Perez-Gonzalez A, 2006, J MOL BIOL, V362, P887, DOI 10.1016/j.jmb.2006.07.085; Perez-Gonzalez A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090957; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Rodriguez-Frandsen A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20744; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Song LX, 2011, MOL CANCER THER, V10, P481, DOI 10.1158/1535-7163.MCT-10-0502; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; Trikha M, 2003, CLIN CANCER RES, V9, P4653; Vainchenker W, 2013, ONCOGENE, V32, P2601, DOI 10.1038/onc.2012.347; Voorhees PM, 2007, CLIN CANCER RES, V13, P6469, DOI 10.1158/1078-0432.CCR-07-1293; Voorhees PM, 2009, BRIT J HAEMATOL, V145, P481, DOI 10.1111/j.1365-2141.2009.07647.x; Yang L, 2015, TUMOR BIOL, V36, P7977, DOI 10.1007/s13277-015-3518-8; Yokoe T, 1997, ANTICANCER RES, V17, P695; Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang GJ, 1999, ANTICANCER RES, V19, P1427; Zhang WJ, 2016, TUMOR BIOL, V37, P369, DOI 10.1007/s13277-015-3806-3	48	24	24	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3695	3705		10.1038/onc.2016.525	http://dx.doi.org/10.1038/onc.2016.525			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28166202				2022-12-17	WOS:000404349700005
J	Masilamani, AP; Ferrarese, R; Kling, E; Thudi, NK; Kim, H; Scholtens, DM; Dai, F; Hadler, M; Unterkircher, T; Platania, L; Weyerbrock, A; Prinz, M; Gillespie, GY; Harsh, GR IV; Bredel, M; Carro, MS				Masilamani, A. P.; Ferrarese, R.; Kling, E.; Thudi, N. K.; Kim, H.; Scholtens, D. M.; Dai, F.; Hadler, M.; Unterkircher, T.; Platania, L.; Weyerbrock, A.; Prinz, M.; Gillespie, G. Y.; Harsh, G. R., IV; Bredel, M.; Carro, M. S.			KLF6 depletion promotes NF-kappa B signaling in glioblastoma	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; KRUPPEL-LIKE FACTOR-6; ZINC-FINGER PROTEIN; EXPRESSION; MUTATIONS; CELL; ACTIVATION; TRANSCRIPTION; APOPTOSIS; TARGETS	Dysregulation of the NF-kappa B transcription factor occurs in many cancer types. Kruppel-like family of transcription factors (KLFs) regulate the expression of genes involved in cell proliferation, differentiation and survival. Here, we report a new mechanism of NF kappa B activation in glioblastoma through depletion of the KLF6 tumor suppressor. We show that KLF6 transactivates multiple genes negatively controlling the NF-kappa B pathway and consequently reduces NF-kappa B nuclear localization and downregulates NF-kappa B targets. Reconstitution of KLF6 attenuates their malignant phenotype and induces neural-like differentiation and senescence, consistent with NF-kappa B pathway inhibition. KLF6 is heterozygously deleted in 74.5% of the analyzed glioblastomas and predicts unfavorable patient prognosis suggesting that haploinsufficiency is a clinically relevant means of evading KLF6-dependent regulation of NF-kappa B. Together, our study identifies a new mechanism by which KLF6 regulates NF-kappa B signaling, and how this mechanism is circumvented in glioblastoma through KLF6 loss.	[Masilamani, A. P.; Ferrarese, R.; Kling, E.; Dai, F.; Hadler, M.; Unterkircher, T.; Platania, L.; Weyerbrock, A.; Carro, M. S.] Univ Freiburg, Med Ctr, Dept Neurosurg, Breisacherstr 64, D-79106 Freiburg, Germany; [Masilamani, A. P.; Ferrarese, R.; Kling, E.; Dai, F.; Hadler, M.; Unterkircher, T.; Platania, L.; Weyerbrock, A.; Carro, M. S.] Univ Freiburg, Fac Med, Freiburg, Germany; [Thudi, N. K.; Bredel, M.] Univ Alabama Birmingham, UAB Comprehens Canc Ctr, Sch Med, Dept Radiat Oncol, 1700 6th Ave South Birmingham, Birmingham, AL 35233 USA; [Kim, H.] Jackson Lab Genom Med, Farmington, CT USA; [Scholtens, D. M.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; [Prinz, M.] Univ Freiburg, Inst Neuropathol, Freiburg, Germany; [Prinz, M.] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, Freiburg, Germany; [Gillespie, G. Y.] Univ Alabama Birmingham, UAB Comprehens Canc Ctr, Sch Med, Dept Neurosurg, Birmingham, AL USA; [Harsh, G. R., IV] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA	University of Freiburg; University of Freiburg; University of Alabama System; University of Alabama Birmingham; Jackson Laboratory; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; University of Freiburg; University of Freiburg; University of Alabama System; University of Alabama Birmingham; Stanford University	Carro, MS (corresponding author), Univ Freiburg, Med Ctr, Dept Neurosurg, Breisacherstr 64, D-79106 Freiburg, Germany.; Bredel, M (corresponding author), Univ Alabama Birmingham, UAB Comprehens Canc Ctr, Sch Med, Dept Radiat Oncol, 1700 6th Ave South Birmingham, Birmingham, AL 35233 USA.	mbredel@uab.edu; maria.carro@uniklinik-freiburg.de	Stella, Maria Stella/GVS-1585-2022; Ferrarese, Roberto/GSJ-3449-2022	Ferrarese, Roberto/0000-0003-0625-3319; Carro, Maria Stella/0000-0002-8570-7691; Masilamani, Anie Priscilla/0000-0003-2503-1244; Gillespie, George/0000-0001-6436-9542; Weyerbrock, Astrid/0000-0001-9060-4462	National Cancer Institute [P20 CA151129-01A1/UAB]; German Cancer Aid Grant Award, State of Alabama Investment Pool for Action (IMPACT) funds [107714]	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); German Cancer Aid Grant Award, State of Alabama Investment Pool for Action (IMPACT) funds	This study was supported by National Cancer Institute grant P20 CA151129-01A1/UAB Specialized Program of Research Excellence (SPORE) in Brain Cancer (M Bredel), German Cancer Aid Grant Award (107714, M Bredel), State of Alabama Investment Pool for Action (IMPACT) funds (M Bredel). We thank Jugen Beck (University of Freiburg) for helping in preparing reagents, Maria Oberle (University of Freiburg) for help with mice brain histology, Dr Veerle Baekelandt (University of Leuven) for providing the PCHMWS- eGFP- IRES lentiviral vector, Dr Thomas Brabletz (University of Erlangen) for providing NF-<INF>k</INF>B luciferase vectors and Darren O hAilin (University of Freiburg) and Susanne Nozell (UAB) for editing the manuscript.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Angileri FF, 2008, CANCER-AM CANCER SOC, V112, P2258, DOI 10.1002/cncr.23407; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Bredel M, 2011, NEW ENGL J MED, V364, P627, DOI 10.1056/NEJMoa1006312; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Camacho-Vanegas O, 2007, INT J CANCER, V121, P1390, DOI 10.1002/ijc.22809; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Date D, 2014, J BIOL CHEM, V289, P10318, DOI 10.1074/jbc.M113.526749; Difeo A, 2008, CANCER RES, V68, P965, DOI 10.1158/0008-5472.CAN-07-2604; Difeo A, 2009, CANCER RES, V69, P4733, DOI 10.1158/0008-5472.CAN-08-4282; Difeo A, 2009, DRUG RESIST UPDATE, V12, P1, DOI 10.1016/j.drup.2008.11.001; Dionyssiou MG, 2013, SKELET MUSCLE, V3, DOI 10.1186/2044-5040-3-7; Eckhardt I, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.457; Eom YW, 2005, ONCOGENE, V24, P4765, DOI 10.1038/sj.onc.1208627; Ferrarese R, 2014, J CLIN INVEST, V124, P2861, DOI 10.1172/JCI68836; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Goldmann T, 2015, EMBO J, V34, P1612, DOI 10.15252/embj.201490791; Gurevich I, 2012, BBA-GENE REGUL MECH, V1819, P1, DOI 10.1016/j.bbagrm.2011.09.006; Hatami R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004688; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Hoeferlin L Alexis, 2011, Genes Cancer, V2, P889, DOI 10.1177/1947601911432495; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Jeng YM, 2003, INT J CANCER, V105, P625, DOI 10.1002/ijc.11123; Jennewein C, 2012, ONCOGENE, V31, P1468, DOI 10.1038/onc.2011.333; Jungnickel B, 2000, J EXP MED, V191, P395, DOI 10.1084/jem.191.2.395; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Keung EZ, 2015, J CLIN INVEST, V125, P2965, DOI 10.1172/JCI77976; Kimmelman AC, 2004, ONCOGENE, V23, P5077, DOI 10.1038/sj.onc.1207662; Kohler B, 2004, INT J CANCER, V111, P644, DOI 10.1002/ijc.20302; Koivisto PA, 2004, INT J CANCER, V111, P642, DOI 10.1002/ijc.20301; Kremer-Tal S, 2004, HEPATOLOGY, V40, P1047, DOI 10.1002/hep.20460; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Lai TY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073153; Lee DW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057489; Lee YD, 2014, BMB REP, V47, P262, DOI 10.5483/BMBRep.2014.47.5.172; Masica DL, 2011, CANCER RES, V71, P4550, DOI 10.1158/0008-5472.CAN-11-0180; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Montanini L, 2004, INT J CANCER, V111, P640, DOI 10.1002/ijc.20303; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Narla G, 2008, J CLIN INVEST, V118, P2711, DOI 10.1172/JCI34780; Nogueira L, 2011, ONCOGENE, V30, P3537, DOI 10.1038/onc.2011.74; Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008; Osborne J, 2005, INT J CANCER, V116, P646, DOI 10.1002/ijc.21036; Phan RT, 2004, NATURE, V432, P635, DOI 10.1038/nature03147; Raychaudhuri B, 2007, J NEURO-ONCOL, V85, P39, DOI 10.1007/s11060-007-9390-7; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; Rodriguez E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012639; Sadelain Michel, 2011, Nat Rev Cancer, V12, P51, DOI 10.1038/nrc3179; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Takemura M, 2002, J NEUROSCI, V22, P6972; Tracey L, 2005, J PATHOL, V206, P123, DOI 10.1002/path.1768; Tsunoda Keishi, 2005, Brain Tumor Pathol, V22, P79, DOI 10.1007/s10014-005-0186-1; Varghese F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096801; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Watanabe A, 2006, J NEURO-ONCOL, V77, P25, DOI 10.1007/s11060-005-9010-3; Westhoff MA, 2013, MOL CANCER RES, V11, P1611, DOI 10.1158/1541-7786.MCR-13-0435-T; Yao YL, 2015, CNS NEUROSCI THER, V21, P40, DOI 10.1111/cns.12321; Zhang Y, 2014, J BIOL CHEM, V289, P12876, DOI 10.1074/jbc.M113.535831	61	24	24	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3562	3575		10.1038/onc.2016.507	http://dx.doi.org/10.1038/onc.2016.507			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28166199	Green Published, hybrid			2022-12-17	WOS:000403878600006
J	Hermanns, C; Hampl, V; Holzer, K; Aigner, A; Penkava, J; Frank, N; Martin, DE; Maier, KC; Waldburger, N; Roessler, S; Goppelt-Struebe, M; Akrap, I; Thavamani, A; Singer, S; Nordheim, A; Gudermann, T; Muehlich, S				Hermanns, C.; Hampl, V.; Holzer, K.; Aigner, A.; Penkava, J.; Frank, N.; Martin, D. E.; Maier, K. C.; Waldburger, N.; Roessler, S.; Goppelt-Struebe, M.; Akrap, I.; Thavamani, A.; Singer, S.; Nordheim, A.; Gudermann, T.; Muehlich, S.			The novel MKL target gene myoferlin modulates expansion and senescence of hepatocellular carcinoma	ONCOGENE			English	Article							SERUM RESPONSE FACTOR; TRANSCRIPTIONAL RESPONSE; TUMOR-SUPPRESSOR; ACTIN DYNAMICS; FACTOR SRF; GROWTH; COACTIVATOR; LOCALIZATION; RESISTANCE; REGULATOR	Megakaryoblastic Leukemia 1 and 2 (MKL1/2) are transcriptional coactivators of Serum Response Factor (SRF) with an essential role for hepatocellular carcinoma (HCC) growth and oncogene-induced senescence. In this report, we identified myoferlin as a novel MKL/SRF target gene by gene expression profiling and verification in vivo in HCC xenografts. Myoferlin was overexpressed in human and murine HCCs triggered by conditional expression of constitutively active SRF-VP16 protein in hepatocytes. Furthermore, myoferlin was required for HCC cell invasion, proliferation and anchorage-independent cell growth. We provide evidence that myoferlin is a crucial gene target of MKL1/2 mediating its effect on oncogene-induced senescence by modulating the activation state of the EGFR and downstream MAPK and p16-/Rb pathways. Depletion of myoferlin in tumour cells from SRF-VP16-derived murine HCCs induced a senescence phenotype. These findings identify MKL1/2 and myoferlin as novel therapeutic targets to treat human HCC by a senescence-inducing strategy.	[Hermanns, C.; Hampl, V.; Penkava, J.; Frank, N.; Gudermann, T.; Muehlich, S.] Ludwig Maximilians Univ Munchen, Walther Straub Inst Pharmacol & Toxicol, Goethestr 33, D-80336 Munich, Germany; [Holzer, K.; Waldburger, N.; Roessler, S.; Singer, S.] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany; [Aigner, A.] Univ Leipzig, Rudolf Boehm Inst Pharmacol & Toxicol, Clin Pharmacol, Leipzig, Germany; [Martin, D. E.; Maier, K. C.] Ludwig Maximilians Univ Munchen, Dept Chem & Pharm, Gene Ctr, Munich, Germany; [Goppelt-Struebe, M.] Friedrich Alexander Univ Erlangen Nurnberg, Dept Hypertens & Nephrol, Erlangen, Germany; [Akrap, I.; Thavamani, A.; Nordheim, A.] Tuebingen Univ, Interfac Inst Cell Biol, Tubingen, Germany; [Nordheim, A.] German Canc Consortium DKTK, Heidelberg, Germany; [Nordheim, A.] DKFZ, Heidelberg, Germany	University of Munich; Ruprecht Karls University Heidelberg; Leipzig University; University of Munich; University of Erlangen Nuremberg; Eberhard Karls University of Tubingen; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Muehlich, S (corresponding author), Ludwig Maximilians Univ Munchen, Walther Straub Inst Pharmacol & Toxicol, Goethestr 33, D-80336 Munich, Germany.	susanne.muehlich@lrz.uni-muenchen.de	Aigner, Achim/R-4429-2017; Thavamani, Abhishek/I-3207-2018; Roessler, Stephanie/J-8432-2019	Aigner, Achim/0000-0002-2778-6256; Thavamani, Abhishek/0000-0001-7187-9188; Roessler, Stephanie/0000-0002-5333-5942	NCT; Deutsche Forschungsgemeinschaft [MU 2737/2-2]; Deutsche Krebshilfe [109886]; DKTK (German Cancer Consortium); DFG [Si 1487/3-1]; HRCMM (Heidelberg Research Center for Molecular Medicine) Career Development Fellowship	NCT; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); DKTK (German Cancer Consortium); DFG(German Research Foundation (DFG)); HRCMM (Heidelberg Research Center for Molecular Medicine) Career Development Fellowship	We thank Elizabeth McNally and Alexis Demonbreun for the myoferlin promoter construct, and Veronika Geissler and Esther Herpel from the NCT tissue bank in Heidelberg for their support. Funded by grant MU 2737/2-2 of the Deutsche Forschungsgemeinschaft. Alfred Nordheim was supported by the Deutsche Krebshilfe (grant 109886) and DKTK (German Cancer Consortium). Stephan Singer was supported by DFG (grant Si 1487/3-1), and by an HRCMM (Heidelberg Research Center for Molecular Medicine) Career Development Fellowship.	Bae JS, 2014, INT J ONCOL, V44, P129, DOI 10.3892/ijo.2013.2154; Bai SM, 2009, J BIOL CHEM, V284, P32015, DOI 10.1074/jbc.M109.016774; Cen B, 2003, MOL CELL BIOL, V23, P6597, DOI 10.1128/MCB.23.18.6597-6608.2003; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Descot A, 2009, MOL CELL, V35, P291, DOI 10.1016/j.molcel.2009.07.015; Esnault C, 2014, GENE DEV, V28, P943, DOI 10.1101/gad.239327.114; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giehl K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121589; Hampl V, 2013, EMBO MOL MED, V5, P1367, DOI 10.1002/emmm.201202406; Hobel S, 2010, J GENE MED, V12, P287, DOI 10.1002/jgm.1431; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; Kircher P, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aad2959; Kwon CY, 2010, INT J ONCOL, V37, P837, DOI 10.3892/ijo_00000734; Medjkane S, 2009, NAT CELL BIOL, V11, P257, DOI 10.1038/ncb1833; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Muehlich S, 2012, ONCOGENE, V31, P3913, DOI 10.1038/onc.2011.560; Muehlich S, 2007, AM J PHYSIOL-CELL PH, V292, pC1732, DOI 10.1152/ajpcell.00552.2006; Ohrnberger S, 2015, HEPATOLOGY, V61, P979, DOI 10.1002/hep.27539; Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890; Park MY, 2007, INT J ONCOL, V31, P1309; Reschke M, 2010, HEPATOLOGY, V51, P1383, DOI 10.1002/hep.23428; Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; TAKEDA S, 1992, J BIOL CHEM, V267, P16957; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; Turtoi A, 2013, CANCER RES, V73, P5438, DOI 10.1158/0008-5472.CAN-13-1142; Vartiainen MK, 2007, SCIENCE, V316, P1749, DOI 10.1126/science.1141084; Wang DZ, 2002, P NATL ACAD SCI USA, V99, P14855, DOI 10.1073/pnas.222561499; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; Winkler J, 2014, HEPATOLOGY, V60, P884, DOI 10.1002/hep.27207; Xue W, 2008, GENE DEV, V22, P1439, DOI 10.1101/gad.1672608; Yuan BZ, 1998, CANCER RES, V58, P2196	34	24	24	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3464	3476		10.1038/onc.2016.496	http://dx.doi.org/10.1038/onc.2016.496			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	28114277				2022-12-17	WOS:000403340700010
J	Bruinsma, W; Aprelia, M; Garcia-Santisteban, I; Kool, J; Xu, YJ; Medema, RH				Bruinsma, W.; Aprelia, M.; Garcia-Santisteban, I.; Kool, J.; Xu, Y. J.; Medema, R. H.			Inhibition of Polo-like kinase 1 during the DNA damage response is mediated through loss of Aurora A recruitment by Bora	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITOR; CDK1 PHOSPHORYLATES SPAT-1/BORA; TRCP-DEPENDENT DEGRADATION; MITOTIC ENTRY; PLK1 PHOSPHORYLATION; CHECKPOINT RECOVERY; CELL-CYCLE; ACTIVATION; MITOSIS; PROGRESSION	When cells in G2 phase are challenged with DNA damage, several key mitotic regulators such as Cdk1/Cyclin B, Aurora A and Plk1 are inhibited to prevent entry into mitosis. Here we have studied how inhibition of Plk1 is established after DNA damage. Using a Forster resonance energy transfer (FRET)-based biosensor for Plk1 activity, we show that inhibition of Plk1 after DNA damage occurs with relatively slow kinetics and is entirely dependent on loss of Plk1-T210 phosphorylation. As T210 is phosphorylated by the kinase Aurora A in conjunction with its co-factor Bora, we investigated how they are affected by DNA damage. Interestingly, we find that the interaction between Bora and Plk1 remains intact during the early phases of the DNA damage response (DDR), whereas Plk1 activity is already inhibited at this stage. Expression of an Aurora A mutant that is refractory to inhibition by the DDR failed to prevent inhibition of Plk1 and loss of T210 phosphorylation, suggesting that inhibition of Plk1 may be established by perturbing recruitment of Aurora A by Bora. Indeed, expression of a fusion in which Aurora A was directly coupled to Bora prevented DNA damage-induced inhibition of Plk1 activity, as well as inhibition of T210 phosphorylation. Taken together, these data demonstrate that DNA damage affects the function of Aurora A at multiple levels: both by direct inhibition of Aurora A activity, as well as by perturbing the interaction with its co-activator Bora. We propose that the DDR targets recruitment of Aurora A to the Plk1/Bora complex to prevent activation of Plk1 during DNA damage in G2.	[Bruinsma, W.; Aprelia, M.; Garcia-Santisteban, I.; Medema, R. H.] Netherlands Canc Inst, Dept Cell Biol, Amsterdam, Netherlands; [Bruinsma, W.; Aprelia, M.; Garcia-Santisteban, I.; Medema, R. H.] Netherlands Canc Inst, Canc Genom Ctr CGC Nl, Amsterdam, Netherlands; [Bruinsma, W.; Aprelia, M.; Kool, J.; Xu, Y. J.; Medema, R. H.] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands; [Bruinsma, W.; Aprelia, M.; Kool, J.; Xu, Y. J.; Medema, R. H.] Univ Med Ctr Utrecht, Canc Genom Ctr, Utrecht, Netherlands; [Garcia-Santisteban, I.] Univ Basque Country, Dept Genet Phys Anthropol & Anim Physiol, UPV EHU, Leioa, Spain; [Bruinsma, W.] Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10065 USA	Netherlands Cancer Institute; Netherlands Cancer Institute; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Basque Country; Memorial Sloan Kettering Cancer Center	Medema, RH (corresponding author), Netherlands Canc Inst, Dept Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam Holland, Netherlands.	r.medema@nki.nl	Garcia-Santisteban, Iraia/AAS-1463-2020	Medema, Rene/0000-0002-6754-0381	Netherlands Genomics Initiative of NWO; NWO Gravitation; Basque Country Government (Spain)	Netherlands Genomics Initiative of NWO; NWO Gravitation; Basque Country Government (Spain)(Basque Government)	We thank L. Macurek (IMG, Prague) for the mCherry-Bora construct and members of the Medema laboratory for discussions. RM is supported by the Netherlands Genomics Initiative of NWO and by the NWO Gravitation program CancerGenomics.nl. WB, MA, JK and YJX are supported by the Netherlands Genomics Initiative of NWO. IGS was supported with a postdoctoral fellowship from the Basque Country Government (Spain).	Apweiler R, 2014, NUCLEIC ACIDS RES, V42, pD191, DOI 10.1093/nar/gkt1140; Bassermann F, 2008, CELL, V134, P256, DOI 10.1016/j.cell.2008.05.043; Bruinsma W, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00132; Bruinsma W, 2014, J CELL SCI, V127, P801, DOI 10.1242/jcs.137216; Bruinsma W, 2012, TRENDS BIOCHEM SCI, V37, P534, DOI 10.1016/j.tibs.2012.09.005; Chan EHY, 2008, CHROMOSOMA, V117, P457, DOI 10.1007/s00412-008-0165-5; Chiyoda T, 2012, J CELL BIOL, V197, P625, DOI 10.1083/jcb.201110110; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; Feine O, 2014, CELL CYCLE, V13, DOI 10.4161/cc.28630; Fuller BG, 2008, NATURE, V453, P1132, DOI 10.1038/nature06923; Hutterer A, 2006, DEV CELL, V11, P147, DOI 10.1016/j.devcel.2006.06.002; Ikeda M, 2012, J BIOL CHEM, V287, P27670, DOI 10.1074/jbc.M112.378968; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; Kachaner D, 2012, MOL CELL, V45, P553, DOI 10.1016/j.molcel.2011.12.030; Krystyniak A, 2006, ONCOGENE, V25, P338, DOI 10.1038/sj.onc.1209056; Lee K, 2011, J CELL BIOL, V195, P1093, DOI 10.1083/jcb.201106093; Lee YC, 2013, CELL CYCLE, V12, P953, DOI 10.4161/cc.23945; Lenart P, 2007, CURR BIOL, V17, P304, DOI 10.1016/j.cub.2006.12.046; Lindqvist A, 2009, J CELL BIOL, V185, P193, DOI 10.1083/jcb.200812045; Macurek L, 2008, NATURE, V455, P119, DOI 10.1038/nature07185; Mamely I, 2006, CURR BIOL, V16, P1950, DOI 10.1016/j.cub.2006.08.026; Manfredi MG, 2007, P NATL ACAD SCI USA, V104, P4106, DOI 10.1073/pnas.0608798104; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Qin B, 2013, J BIOL CHEM, V288, P16139, DOI 10.1074/jbc.M113.456780; Reinhardt HC, 2013, NAT REV MOL CELL BIO, V14, P563, DOI 10.1038/nrm3640; Seki A, 2008, SCIENCE, V320, P1655, DOI 10.1126/science.1157425; Seki A, 2008, J CELL BIOL, V181, P65, DOI 10.1083/jcb.200712027; Shaltiel IA, 2015, J CELL SCI, V128, P607, DOI 10.1242/jcs.163766; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Tavernier N, 2015, J CELL BIOL, V208, P661, DOI 10.1083/jcb.201408064; Thomas Y, 2016, CELL REP, V15, P510, DOI 10.1016/j.celrep.2016.03.049; van Vugt MATM, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000287; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Vidanes GM, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000286; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Yamashiro S, 2008, DEV CELL, V14, P787, DOI 10.1016/j.devcel.2008.02.013; Yang XM, 2009, J BIOL CHEM, V284, P18588, DOI 10.1074/jbc.C109.001560; Yata K, 2012, MOL CELL, V45, P371, DOI 10.1016/j.molcel.2011.12.028	41	24	24	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2017	36	13					1840	1848		10.1038/onc.2016.347	http://dx.doi.org/10.1038/onc.2016.347			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EQ5NF	27721411	hybrid, Green Published			2022-12-17	WOS:000398128900009
J	McNair, C; Urbanucci, A; Comstock, CES; Augello, MA; Goodwin, JF; Launchbury, R; Zhao, SG; Schiewer, MJ; Ertel, A; Karnes, J; Davicioni, E; Wang, L; Wang, Q; Mills, IG; Feng, FY; Li, W; Carroll, JS; Knudsen, KE				McNair, C.; Urbanucci, A.; Comstock, C. E. S.; Augello, M. A.; Goodwin, J. F.; Launchbury, R.; Zhao, S. G.; Schiewer, M. J.; Ertel, A.; Karnes, J.; Davicioni, E.; Wang, L.; Wang, Q.; Mills, I. G.; Feng, F. Y.; Li, W.; Carroll, J. S.; Knudsen, K. E.			Cell cycle-coupled expansion of AR activity promotes cancer progression	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; RESISTANT PROSTATE-CANCER; ANDROGEN RECEPTOR; TRANSCRIPTIONAL REGULATION; CERAMIDE 1-PHOSPHATE; SIGNALING PATHWAYS; DNA-REPAIR; IN-VITRO; C-JUN; GROWTH	The androgen receptor (AR) is required for prostate cancer (PCa) survival and progression, and ablation of AR activity is the first line of therapeutic intervention for disseminated disease. While initially effective, recurrent tumors ultimately arise for which there is no durable cure. Despite the dependence of PCa on AR activity throughout the course of disease, delineation of the AR-dependent transcriptional network that governs disease progression remains elusive, and the function of AR in mitotically active cells is not well understood. Analyzing AR activity as a function of cell cycle revealed an unexpected and highly expanded repertoire of AR-regulated gene networks in actively cycling cells. New AR functions segregated into two major clusters: those that are specific to cycling cells and retained throughout the mitotic cell cycle ('Cell Cycle Common'), versus those that were specifically enriched in a subset of cell cycle phases ('Phase Restricted'). Further analyses identified previously unrecognized AR functions in major pathways associated with clinical PCa progression. Illustrating the impact of these unmasked AR-driven pathways, dihydroceramide desaturase 1 was identified as an AR-regulated gene in mitotically active cells that promoted pro-metastatic phenotypes, and in advanced PCa proved to be highly associated with development of metastases, recurrence after therapeutic intervention and reduced overall survival. Taken together, these findings delineate AR function in mitotically active tumor cells, thus providing critical insight into the molecular basis by which AR promotes development of lethal PCa and nominate new avenues for therapeutic intervention.	[McNair, C.; Comstock, C. E. S.; Augello, M. A.; Goodwin, J. F.; Schiewer, M. J.; Ertel, A.; Knudsen, K. E.] Thomas Jefferson Univ, Dept Canc Biol, Sidney Kimmel Canc Ctr, BLSB Room 1008,233 South 10th St, Philadelphia, PA 19107 USA; [Urbanucci, A.; Mills, I. G.] Univ Oslo, Nord EMBL Partnership, Ctr Mol Med Norway NCMM, Prostate Canc Res Grp, Oslo, Norway; [Urbanucci, A.; Mills, I. G.] Oslo Univ Hosp, Oslo, Norway; [Urbanucci, A.; Mills, I. G.] Oslo Univ Hosp, Inst Canc Res, Dept Mol Oncol, Oslo, Norway; [Launchbury, R.] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge Res Inst, Cambridge, England; [Zhao, S. G.] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; [Karnes, J.; Wang, L.] Mayo Clin, Coll Med, Div Biomed Stat & Informat, Rochester, MN USA; [Davicioni, E.] GenomeDx Biosci, San Diego, CA USA; [Wang, Q.] Ohio State Univ, Coll Med, Columbus, OH 43210 USA; [Mills, I. G.] Queens Univ, Ctr Canc Res & Cell Biol, Prostate Canc UK Movember Ctr Excellence Prostat, Belfast, Antrim, North Ireland; [Feng, F. Y.] Univ Calif San Francisco, Dept Radiat Oncol Urol & Med, San Francisco, CA 94143 USA; [Feng, F. Y.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Li, W.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Li, W.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Jefferson University; University of Oslo; University of Oslo; University of Oslo; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Michigan System; University of Michigan; Mayo Clinic; GenomeDx Biosciences; University System of Ohio; Ohio State University; Queens University Belfast; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Baylor College of Medicine; Baylor College of Medicine	Knudsen, KE (corresponding author), Thomas Jefferson Univ, Dept Canc Biol, Sidney Kimmel Canc Ctr, BLSB Room 1008,233 South 10th St, Philadelphia, PA 19107 USA.; Knudsen, KE (corresponding author), Thomas Jefferson Univ, Dept Urol, BLSB Room 1008,233 South 10th St, Philadelphia, PA 19107 USA.; Knudsen, KE (corresponding author), Thomas Jefferson Univ, Dept Radiat Oncol, BLSB Room 1008,233 South 10th St, Philadelphia, PA 19107 USA.	karen.knudsen@jefferson.edu	zhao, shuangling/HCI-6255-2022; Mills, Ian/AAK-9292-2020; Urbanucci, Alfonso/S-4450-2019	Mills, Ian/0000-0001-5347-5083; Urbanucci, Alfonso/0000-0003-2931-3652; Schiewer, Matthew/0000-0002-2325-4228; McNair, Christopher/0000-0003-3204-8482; Carroll, Jason/0000-0003-3643-0080; Knudsen, Karen/0000-0002-1301-890X; Wang, Liguo/0000-0003-2072-4826	PCF; NCI [CA159945, CA176401]; Pennsylvania Department of Health;  [R01HG007538];  [R01CA193466];  [P30-CA056036]; Cancer Research UK [20411] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [P30CA056036, R01CA193466, R01CA176401, R01CA159945] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG007538] Funding Source: NIH RePORTER	PCF; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Pennsylvania Department of Health; ; ; ; Cancer Research UK(Cancer Research UK); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We gratefully thank Mandeep Takhar for her assistance in providing microarray data analysis, K Knudsen lab members for their input, Bin Fang for assistance in creation of motif diagrams and E Schade for graphical support and expertise. This work was supported by grants to WL (R01HG007538 and R01CA193466), SGZ by the PCF, and to KEK by grants from the NCI (CA159945, CA176401), P30-CA056036, and in part by a grant to KEK with the Pennsylvania Department of Health. The Department specifically disclaims responsibility for any analyses, interpretations or conclusions.	Augello MA, 2015, EMBO MOL MED, V7, P628, DOI 10.15252/emmm.201404242; Augello MA, 2014, CANCER METAST REV, V33, P399, DOI 10.1007/s10555-013-9471-3; Balk Steven P, 2008, Nucl Recept Signal, V6, pe001, DOI 10.1621/nrs.06001; Barfeld SJ, 2015, ONCOTARGET, V6, P12587, DOI 10.18632/oncotarget.3494; Barfeld SJ, 2014, ENDOCR-RELAT CANCER, V21, pT57, DOI 10.1530/ERC-13-0515; Beekman KW, 2008, UROL ONCOL-SEMIN ORI, V26, P415, DOI 10.1016/j.urolonc.2007.11.003; Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583; Burd CJ, 2006, P NATL ACAD SCI USA, V103, P2190, DOI 10.1073/pnas.0506281103; Chalfant CE, 2005, J CELL SCI, V118, P4605, DOI 10.1242/jcs.02637; Chen SY, 2006, ONCOGENE, V25, P7212, DOI 10.1038/sj.onc.1209705; Chua SS, 2004, VITAM HORM, V68, P231; Comstock CES, 2013, ONCOGENE, V32, P5481, DOI 10.1038/onc.2013.83; Comstock CES, 2011, J BIOL CHEM, V286, P8117, DOI 10.1074/jbc.M110.170720; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Erho N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066855; Fan L, 2016, ONCOGENE, V35, P2441, DOI 10.1038/onc.2015.309; Fu YT, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000138; Gangoiti P, 2008, CELL SIGNAL, V20, P726, DOI 10.1016/j.cellsig.2007.12.008; Goodwin JF, 2015, CANCER CELL, V28, P97, DOI 10.1016/j.ccell.2015.06.004; Goodwin JF, 2013, CANCER DISCOV, V3, P1254, DOI 10.1158/2159-8290.CD-13-0108; Grabowska MM, 2014, MOL ENDOCRINOL, V28, P949, DOI 10.1210/me.2013-1213; Graham TR, 2008, CANCER RES, V68, P2479, DOI 10.1158/0008-5472.CAN-07-2559; Gudmundsdottir K, 2006, ONCOGENE, V25, P5864, DOI 10.1038/sj.onc.1209874; Gurel B, 2008, MODERN PATHOL, V21, P1156, DOI 10.1038/modpathol.2008.111; He B, 2014, P NATL ACAD SCI USA, V111, P18261, DOI 10.1073/pnas.1421415111; Jian H, 2015, CELL SIGNAL, V27, P1208, DOI 10.1016/j.cellsig.2015.02.027; Karnes RJ, 2013, J UROLOGY, V190, P2047, DOI 10.1016/j.juro.2013.06.017; Knudsen KE, 2011, EXPERT REV ENDOCRINO, V6, P483, DOI 10.1586/EEM.11.33; Knudsen KE, 2010, TRENDS ENDOCRIN MET, V21, P315, DOI 10.1016/j.tem.2010.01.002; Knudsen KE, 2009, CLIN CANCER RES, V15, P4792, DOI 10.1158/1078-0432.CCR-08-2660; Knudsen KE, 1999, CANCER RES, V59, P2297; Koryakina Y, 2015, ENDOCR-RELAT CANCER, V22, P249, DOI 10.1530/ERC-14-0549; Lazarini M, 2013, BBA-MOL BASIS DIS, V1832, P365, DOI 10.1016/j.bbadis.2012.11.010; Lim JTE, 2005, P NATL ACAD SCI USA, V102, P5156, DOI 10.1073/pnas.0501203102; Liu WS, 2015, ONCOTARGET, V6, P8851, DOI 10.18632/oncotarget.3316; Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760; Mallik I, 2008, BBA-MOL CELL RES, V1783, P1737, DOI 10.1016/j.bbamcr.2008.05.006; Martinez ED, 2002, J BIOL CHEM, V277, P29719, DOI 10.1074/jbc.M112134200; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872; Nauseef JT, 2011, NAT REV UROL, V8, P428, DOI 10.1038/nrurol.2011.85; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Palaskas N, 2011, CANCER RES, V71, P5164, DOI 10.1158/0008-5472.CAN-10-4633; Polkinghorn WR, 2013, CANCER DISCOV, V3, P1245, DOI 10.1158/2159-8290.CD-13-0172; Pomerantz MM, 2015, NAT GENET, V47, P1346, DOI 10.1038/ng.3419; Prensner JR, 2014, LANCET ONCOL, V15, P1469, DOI 10.1016/S1470-2045(14)71113-1; Sahu B, 2011, EMBO J, V30, P3962, DOI 10.1038/emboj.2011.328; Schmidt D, 2009, METHODS, V48, P240, DOI 10.1016/j.ymeth.2009.03.001; Schrecengost RS, 2014, CANCER RES, V74, P272, DOI 10.1158/0008-5472.CAN-13-1954; Sharma A, 2010, J CLIN INVEST, V120, P4478, DOI 10.1172/JCI44239; Sharma NL, 2013, CANCER CELL, V23, P35, DOI 10.1016/j.ccr.2012.11.010; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Venant H, 2015, MOL CANCER THER, V14, P2744, DOI 10.1158/1535-7163.MCT-15-0279; Waltering KK, 2009, CANCER RES, V69, P8141, DOI 10.1158/0008-5472.CAN-09-0919; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Williams K, 2012, CANCER RES, V72, P5407, DOI 10.1158/0008-5472.CAN-12-1158; Xu YY, 2006, CANCER RES, V66, P7783, DOI 10.1158/0008-5472.CAN-05-4472; Yamamoto A, 2000, J CELL BIOL, V150, P873, DOI 10.1083/jcb.150.4.873; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Yuan X, 2009, UROL ONCOL-SEMIN ORI, V27, P36, DOI 10.1016/j.urolonc.2008.03.021; Yun EJ, 2015, ONCOGENE, V34, P2741, DOI 10.1038/onc.2014.215; Zaret KS, 2011, GENE DEV, V25, P2227, DOI 10.1101/gad.176826.111; Zhou W, 2009, MOL CARCINOGEN, V48, P886, DOI 10.1002/mc.20533	65	24	24	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1655	1668		10.1038/onc.2016.334	http://dx.doi.org/10.1038/onc.2016.334			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27669432	Green Accepted, Green Submitted			2022-12-17	WOS:000397460600005
J	Wang, Y; Ou, Z; Sun, Y; Yeh, S; Wang, X; Long, J; Chang, C				Wang, Y.; Ou, Z.; Sun, Y.; Yeh, S.; Wang, X.; Long, J.; Chang, C.			Androgen receptor promotes melanoma metastasis via altering the miRNA-539-3p/USP13/MITF/AXL signals	ONCOGENE			English	Article							PROSTATE-CANCER; TRANSCRIPTION FACTOR; BLADDER-CANCER; CELL-MIGRATION; MITF; PROGRESSION; RESISTANCE; THERAPY; SURVIVAL; BEHAVIOR	Early studies demonstrated that male melanoma patients have worse survival than female patients, yet the detailed mechanisms for this gender difference remain unclear. We analyzed around 100 cases of human melanoma and found that androgen receptor (AR) positive melanoma patients have worse survival outcomes compared with AR-negative melanoma patients. Here we report that AR can have positive roles to increase melanoma cell invasion in multiple cell lines in vitro and a mouse model in vivo. Mechanism dissection suggest that AR increases melanoma cell invasion via modulating the MITF-AXL signals via altering the miRNA-539-3p/USP13 signaling to increase MITF protein degradation through a reduction of de-ubiquitination. Restoring MITF can reverse AR-enhanced melanoma cell invasion. Together, our results demonstrate that AR can promote melanoma metastasis via altering the miRNA-539-3p/USP13/MITF/AXL signal and targeting this newly identified signal with AR degradation enhancer ASC-J9 may help us to better suppress the melanoma metastasis.	[Wang, Y.; Ou, Z.; Wang, X.; Long, J.] Cent South Univ, Xiangya Hosp, Dept Plast Surg, Changsha, Hunan, Peoples R China; [Wang, Y.; Ou, Z.; Sun, Y.; Yeh, S.; Chang, C.] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY USA; [Wang, Y.; Ou, Z.; Sun, Y.; Yeh, S.; Chang, C.] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol, Rochester, NY USA; [Wang, Y.; Ou, Z.; Sun, Y.; Yeh, S.; Chang, C.] Univ Rochester, Med Ctr, Wilmot Canc Ctr, Rochester, NY USA; [Chang, C.] China Med Univ Hosp, Sex Hormone Res Ctr, Taichung, Taiwan	Central South University; University of Rochester; University of Rochester; University of Rochester; China Medical University Taiwan; China Medical University Hospital - Taiwan	Long, J; Chang, C (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol,Wilmot Canc Ctr, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.; Long, J; Chang, C (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol,Wilmot Canc Ctr, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.	jianhonglong@126.com; chang@urmc.rochester.edu			NIH [CA155477, CA156700]; George Whipple Professorship Endowment; Taiwan Department of Health Clinical Trial, Research Center of Excellence [DOH99-TD-B-111-004]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); George Whipple Professorship Endowment; Taiwan Department of Health Clinical Trial, Research Center of Excellence	This work was supported by NIH grants (CA155477 and CA156700), George Whipple Professorship Endowment and Taiwan Department of Health Clinical Trial, Research Center of Excellence (DOH99-TD-B-111-004 to China Medical University, Taichung, Taiwan). We thank Karen Wolf for help with preparing the manuscript. ASC-J9 was patented by the University of Rochester, the University of North Carolina, and AndroScience Corp., and then licensed to AndroScience Corp. Both the University of Rochester and C. Chang own royalties and equity in AndroScience Corp.	Bondurand N, 2000, HUM MOL GENET, V9, P1907, DOI 10.1093/hmg/9.13.1907; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Chang C, 2014, ONCOGENE, V33, P3225, DOI 10.1038/onc.2013.274; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Cheli Y, 2012, ONCOGENE, V31, P2461, DOI 10.1038/onc.2011.425; Cheli Y, 2010, PIGM CELL MELANOMA R, V23, P27, DOI 10.1111/j.1755-148X.2009.00653.x; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; CLARK WH, 1969, CANCER RES, V29, P705; Djuranovic S, 2012, SCIENCE, V336, P237, DOI 10.1126/science.1215691; Eccles MR, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00229; Fernandez-Barral A, 2014, NEOPLASIA, V16, P529, DOI 10.1016/j.neo.2014.06.001; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; He DL, 2014, CANCER RES, V74, P4420, DOI 10.1158/0008-5472.CAN-13-2681; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Hsu JW, 2013, AM J PATHOL, V182, P1811, DOI 10.1016/j.ajpath.2013.01.018; Izumi K, 2013, EMBO MOL MED, V5, P1383, DOI 10.1002/emmm.201202367; Javelaud D, 2011, PIGM CELL MELANOMA R, V24, P932, DOI 10.1111/j.1755-148X.2011.00893.x; Jerant AF, 2000, AM FAM PHYSICIAN, V62, P357; Ji SR, 2015, CELL RES, V25, P561, DOI 10.1038/cr.2015.30; Joosse A, 2012, J CLIN ONCOL, V30, P2240, DOI 10.1200/JCO.2011.38.0584; Law MH, 2015, NAT GENET, V47, P987, DOI 10.1038/ng.3373; Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008; Li WQ, 2013, J CLIN ONCOL, V31, P4394, DOI 10.1200/JCO.2013.51.1915; Lin TH, 2013, J BIOL CHEM, V288, P19359, DOI 10.1074/jbc.M113.477216; Long GV, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6694; Ma CL, 2008, GASTROENTEROLOGY, V135, P947, DOI 10.1053/j.gastro.2008.05.046; Ma WL, 2012, HEPATOLOGY, V56, P176, DOI 10.1002/hep.25644; Menzies AM, 2012, DRUG DES DEV THER, V6, P391, DOI 10.2147/DDDT.S38998; Mills IG, 2014, NAT REV CANCER, V14, P187, DOI 10.1038/nrc3678; Miyamoto H, 2007, J NATL CANCER I, V99, P558, DOI 10.1093/jnci/djk113; Mueller DW, 2009, J INVEST DERMATOL, V129, P1740, DOI 10.1038/jid.2008.452; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Niu Y, 2010, ONCOGENE, V29, P3593, DOI 10.1038/onc.2010.121; Obenauf AC, 2015, NATURE, V520, P368, DOI 10.1038/nature14336; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Scoggins CR, 2006, ANN SURG, V243, P693, DOI 10.1097/01.sla.0000216771.81362.6b; Sensi M, 2011, J INVEST DERMATOL, V131, P2448, DOI 10.1038/jid.2011.218; Tas F, 2012, J ONCOL, V2012, DOI 10.1155/2012/647684; Thomsen FB, 2016, INT J CANCER, V138, P2154, DOI 10.1002/ijc.29961; WHITE LP, 1959, NEW ENGL J MED, V260, P789, DOI 10.1056/NEJM195904162601601; Wu MH, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001143; Yajima I, 2011, J SKIN CANCER, V2011, DOI 10.1155/2011/730170; Yang ZM, 2007, NAT MED, V13, P348, DOI 10.1038/nm1547; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Zhao XS, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1421; Zhu G., 2014, UROLOGY, V83, pe19, DOI DOI 10.1016/J.UR0L0GY.2013.10.022	48	24	25	2	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	12					1644	1654		10.1038/onc.2016.330	http://dx.doi.org/10.1038/onc.2016.330			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP6AP	27869170				2022-12-17	WOS:000397460600004
J	Su, Q; Zhang, B; Zhang, L; Dang, T; Rowley, D; Ittmann, M; Xin, L				Su, Q.; Zhang, B.; Zhang, L.; Dang, T.; Rowley, D.; Ittmann, M.; Xin, L.			Jagged1 upregulation in prostate epithelial cells promotes formation of reactive stroma in the Pten null mouse model for prostate cancer	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; DOWN-REGULATION; STEM-CELLS; E-CADHERIN; NOTCH; MECHANISM; TUMORIGENESIS; PROGRESSION; EXPRESSION; MICROENVIRONMENT	The role of Notch signaling in prostate cancer has not been defined definitively. Several large scale tissue microarray studies have revealed that the expression of some Notch signaling components including the Jagged1 ligand are upregulated in advanced human prostate cancer specimens. Jagged1 expressed by tumor cells may activate Notch signaling in both adjacent tumor cells and cells in tumor microenvironment. However, it remains undetermined whether increased Jagged1 expression reflects a cause for or a consequence of tumor progression in vivo. To address this question, we generated a novel R26-LSL-JAG1 mouse model that enables spatiotemporal Jagged1 expression. Prostate specific upregulation of Jagged1 neither interferes with prostate epithelial homeostasis nor significantly accelerates tumor initiation or progression in the prostate-specific Pten deletion mouse model for prostate cancer. However, Jagged1 upregulation results in increased inflammatory foci in tumors and incidence of intracystic adenocarcinoma. In addition, Jagged1 overexpression upregulates Tgf beta signaling in prostate stromal cells and promotes progression of a reactive stromal microenvironment in the Pten null prostate cancer model. Collectively, Jagged1 overexpression does not significantly accelerate prostate cancer initiation and progression in the context of loss-of-function of Pten, but alters tumor histopathology and microenvironment. Our study also highlights an understudied role of Notch signaling in regulating prostatic stromal homeostasis.	[Su, Q.; Zhang, B.; Zhang, L.; Dang, T.; Rowley, D.; Xin, L.] Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza, Houston, TX 77030 USA; [Su, Q.] Baylor Coll Med, Grad Program Integrat Mol & Biomed Sci, Houston, TX 77030 USA; [Rowley, D.; Ittmann, M.; Xin, L.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Ittmann, M.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Ittmann, M.] Baylor Coll Med, Vet Affairs Med Ctr, Michael E DeBakey Dept, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Xin, L (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza, Houston, TX 77030 USA.	xin@bcm.edu			NIH [P30 AI036211, P30 CA125123, S10 RR024574, R01 CA190378, CA196570]; Mouse Embryonic Stem Cell Core at Baylor College of Medicine; NCI; NATIONAL CANCER INSTITUTE [P30CA125123, R21CA196570, R01CA190378] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR024574] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036211] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mouse Embryonic Stem Cell Core at Baylor College of Medicine; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Dr Spyros Artavanis-Tsakonas for providing the human Jagged1 cDNA, the technical support by the Cytometry and Cell Sorting Core at Baylor College of Medicine with funding from the NIH (P30 AI036211, P30 CA125123 and S10 RR024574) and the expert assistance of Joel M. Sederstrom. This work is supported by NIH R01 CA190378 (L.X.), CA196570 (L.X.), NIH P30 CA125123 (the Cancer Center Shared Resources Grant), the Mouse Embryonic Stem Cell Core at Baylor College of Medicine and NCI.	Alme AKB, 2016, UROL ONCOL-SEMIN ORI, V34, P171, DOI 10.1016/j.urolonc.2016.01.006; Ascano JM, 2003, J BIOL CHEM, V278, P8771, DOI 10.1074/jbc.M211427200; Barron DA, 2012, ENDOCR-RELAT CANCER, V19, pR187, DOI 10.1530/ERC-12-0085; Barron DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013751; Bin Hafeez B, 2009, CLIN CANCER RES, V15, P452, DOI 10.1158/1078-0432.CCR-08-1631; Dalrymple S, 2005, CANCER RES, V65, P9269, DOI 10.1158/0008-5472.CAN-04-3989; Danza G, 2013, INT J CANCER, V133, P2577, DOI 10.1002/ijc.28293; del Alamo D, 2011, CURR BIOL, V21, pR40, DOI 10.1016/j.cub.2010.10.034; Demehri S, 2009, CANCER CELL, V16, P55, DOI 10.1016/j.ccr.2009.05.016; Domingo-Domenech J, 2012, CANCER CELL, V22, P373, DOI 10.1016/j.ccr.2012.07.016; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Franklin RA, 2014, SCIENCE, V344, P921, DOI 10.1126/science.1252510; Gibb DR, 2011, J IMMUNOL, V186, P4244, DOI 10.4049/jimmunol.1003318; Ittmann M, 2013, CANCER RES, V73, P2718, DOI 10.1158/0008-5472.CAN-12-4213; Jin CL, 2003, PROSTATE, V57, P160, DOI 10.1002/pros.10283; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Kwon OJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5416; Kwon OJ, 2016, J CLIN INVEST; LaVoie MJ, 2003, J BIOL CHEM, V278, P34427, DOI 10.1074/jbc.M302659200; Lawson DA, 2007, P NATL ACAD SCI USA, V104, P181, DOI 10.1073/pnas.0609684104; Leong KG, 2007, J EXP MED, V204, P2935, DOI 10.1084/jem.20071082; Lu CH, 2007, CANCER RES, V67, P1757, DOI 10.1158/0008-5472.CAN-06-3700; Morrison SJ, 2014, NATURE, V505, P327, DOI 10.1038/nature12984; Mulholland DJ, 2012, CANCER RES, V72, P1878, DOI 10.1158/0008-5472.CAN-11-3132; Njuguna J., 2013, NANOPROD REV J, V1, P1, DOI DOI 10.1074/JBC.M112.443580; Orr B, 2009, ENDOCRINOLOGY, V150, P463, DOI 10.1210/en.2008-0383; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Pedrosa AR, 2015, ONCOTARGET, V6, P24404, DOI 10.18632/oncotarget.4380; Poulos MG, 2013, CELL REP, V4, P1022, DOI 10.1016/j.celrep.2013.07.048; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Ranganathan P, 2011, NAT REV CANCER, V11, P338, DOI 10.1038/nrc3035; Santagata S, 2004, CANCER RES, V64, P6854, DOI 10.1158/0008-5472.CAN-04-2500; Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022; Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414; Shou JY, 2001, CANCER RES, V61, P7291; Steg AD, 2011, CLIN CANCER RES, V17, P5674, DOI 10.1158/1078-0432.CCR-11-0432; Talmadge JE, 2013, NAT REV CANCER, V13, P739, DOI 10.1038/nrc3581; Terada N, 2014, J CELL BIOCHEM, V115, P1505, DOI 10.1002/jcb.24805; Tuxhorn JA, 2001, J UROLOGY, V166, P2472, DOI 10.1016/S0022-5347(05)65620-0; Valdez JM, 2012, CELL STEM CELL, V11, P676, DOI 10.1016/j.stem.2012.07.003; Vallejo DM, 2011, EMBO J, V30, P756, DOI 10.1038/emboj.2010.358; Velasco AM, 2004, ENDOCRINOLOGY, V145, P3913, DOI 10.1210/en.2004-0311; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang Z., 2011, INFORM RES, V2011, P1, DOI DOI 10.1111/J.1365-313X.2011.04659.X; Wang ZW, 2010, J CELL BIOCHEM, V109, P726, DOI 10.1002/jcb.22451; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wu XY, 2011, DEV BIOL, V356, P337, DOI 10.1016/j.ydbio.2011.05.659; Yong T, 2011, J CELL BIOCHEM, V112, P2340, DOI 10.1002/jcb.23157; Yu YC, 2014, ASIAN TEST SYMPOSIUM, P1, DOI 10.1109/ATS.2014.13	49	24	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					618	627		10.1038/onc.2016.232	http://dx.doi.org/10.1038/onc.2016.232			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27345403	Green Accepted			2022-12-17	WOS:000394167700004
J	Sun, H; He, L; Wu, H; Pan, F; Wu, X; Zhao, J; Hu, Z; Sekhar, C; Li, H; Zheng, L; Chen, H; Shen, BH; Guo, Z				Sun, H.; He, L.; Wu, H.; Pan, F.; Wu, X.; Zhao, J.; Hu, Z.; Sekhar, C.; Li, H.; Zheng, L.; Chen, H.; Shen, B. H.; Guo, Z.			The FEN1 L209P mutation interferes with long-patch base excision repair and induces cellular transformation	ONCOGENE			English	Article							DNA-POLYMERASE-BETA; STRAND BREAK REPAIR; HUMAN FLAP ENDONUCLEASE-1; LUNG-CANCER; MUTANT MICE; SACCHAROMYCES-CEREVISIAE; REPLICATION STRESS; TUMOR PROGRESSION; ESCHERICHIA-COLI; MAMMALIAN-CELLS	Flap endonuclease-1 (FEN1) is a multifunctional, structure-specific nuclease that has a critical role in maintaining human genome stability. FEN1 mutations have been detected in human cancer specimens and have been suggested to cause genomic instability and cancer predisposition. However, the exact relationship between FEN1 deficiency and cancer susceptibility remains unclear. In the current work, we report a novel colorectal cancer-associated FEN1 mutation, L209P. This mutant protein lacks the FEN, exonuclease (EXO) and gap endonuclease (GEN) activities of FEN1 but retains DNA-binding affinity. The L209P FEN1 variant interferes with the function of the wild-type FEN1 enzyme in a dominant-negative manner and impairs long-patch base excision repair in vitro and in vivo. Expression of L209P FEN1 sensitizes cells to DNA damage, resulting in endogenous genomic instability and cellular transformation, as well as tumor growth in a mouse xenograft model. These data indicate that human cancer associated genetic alterations in the FEN1 gene can contribute substantially to cancer development.	[Sun, H.; He, L.; Wu, H.; Pan, F.; Zhao, J.; Hu, Z.; Sekhar, C.; Guo, Z.] Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, 1 Wenyuan Rd, Nanjing 210023, Jiangsu, Peoples R China; [Wu, X.] Southeast Univ, Affiliated Hosp 2, Hosp Nanjing 2, Nanjing, Jiangsu, Peoples R China; [Li, H.; Zheng, L.; Shen, B. H.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Med, Duarte, CA 91010 USA; [Li, H.; Zheng, L.; Shen, B. H.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Genet & Epigenet, Duarte, CA USA; [Chen, H.] Shanghai Jiao Tong Univ, RenJi Hosp, Sch Med, Div Gastroenterol & Hepatol, Shanghai 200001, Peoples R China	Nanjing Normal University; Southeast University - China; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; Shanghai Jiao Tong University	Guo, Z (corresponding author), Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, 1 Wenyuan Rd, Nanjing 210023, Jiangsu, Peoples R China.; Shen, BH (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Med, Duarte, CA 91010 USA.; Chen, H (corresponding author), Shanghai Jiao Tong Univ, RenJi Hosp, Sch Med, Div Gastroenterol & Hepatol, Shanghai 200001, Peoples R China.	chenhaoyan@gmail.com; bshen@coh.org; guozgang@gmail.com		k, chandrasekhar/0000-0002-6900-9447; Shen, Binghui/0000-0002-4408-407X	Ministry of Science and Technology of China [2013CB911600]; National Natural Science Foundation of China [31271449]; Jiangsu Provincial Natural Science Foundation [BK20130044, BK20130061, BK2011783]; Research Fund for the Doctoral Program of Higher Education of China (RFDP) [20133207110005]; Program for New Century Excellent Talents in University of Ministry of Education of China [NCET-13-0868]; Priority Academic Program Development Award for Jiangsu Higher Education Institutions; NIH [RO1 CA085344]; NCI-designated cancer center [P30 CA033572]; NATIONAL CANCER INSTITUTE [R01CA085344, R01CA073764, P30CA033572] Funding Source: NIH RePORTER	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Provincial Natural Science Foundation(Natural Science Foundation of Jiangsu Province); Research Fund for the Doctoral Program of Higher Education of China (RFDP)(Research Fund for the Doctoral Program of Higher Education of China (RFDP)Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); Program for New Century Excellent Talents in University of Ministry of Education of China(Program for New Century Excellent Talents in University (NCET)); Priority Academic Program Development Award for Jiangsu Higher Education Institutions; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI-designated cancer center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The work is supported by Ministry of Science and Technology of China (2013CB911600), National Natural Science Foundation of China (31271449), Jiangsu Provincial Natural Science Foundation (BK20130044, BK20130061, BK2011783), The Research Fund for the Doctoral Program of Higher Education of China (RFDP) (20133207110005), The Program for New Century Excellent Talents in University of Ministry of Education of China (NCET-13-0868) and the Priority Academic Program Development Award for Jiangsu Higher Education Institutions. The work was also partially supported by an NIH grant RO1 CA085344 to BHS and NCI-designated cancer center support grant P30 CA033572. We also thank Dr Nancy Linford for her professional editing of the manuscript.	Adams MM, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-19; Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bajpayee M, 2002, MUTAT RES-GEN TOX EN, V520, P83, DOI 10.1016/S1383-5718(02)00175-4; Balakrishnan L, 2013, ANNU REV BIOCHEM, V82, P119, DOI 10.1146/annurev-biochem-072511-122603; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bose R, 2013, CANCER DISCOV, V3, P224, DOI 10.1158/2159-8290.CD-12-0349; Chang JS, 2009, CARCINOGENESIS, V30, P78, DOI 10.1093/carcin/bgn261; Chapados BR, 2004, CELL, V116, P39, DOI 10.1016/S0092-8674(03)01036-5; Chung L, 2015, ONCOGENE, V34, P902, DOI 10.1038/onc.2014.19; David SS, 2007, NATURE, V447, P941, DOI 10.1038/nature05978; Demple B, 2005, DNA REPAIR, V4, P1442, DOI 10.1016/j.dnarep.2005.09.004; Dianova II, 2001, BIOCHEMISTRY-US, V40, P12639, DOI 10.1021/bi011117i; Du JA, 2010, ACTA BIOCH BIOPH SIN, V42, P839, DOI 10.1093/abbs/gmq095; El-Andaloussi N, 2006, MOL CELL, V22, P51, DOI 10.1016/j.molcel.2006.02.013; Fehrmann RSN, 2015, NAT GENET, V47, P115, DOI 10.1038/ng.3173; Figueroa JD, 2007, HUM GENET, V121, P233, DOI 10.1007/s00439-006-0294-y; Frank G, 1998, J BIOL CHEM, V273, P33064, DOI 10.1074/jbc.273.49.33064; Frank G, 2001, J BIOL CHEM, V276, P36295, DOI 10.1074/jbc.M103397200; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Gao J, 2015, APPL BIOCHEM BIOTECH, V176, P454, DOI 10.1007/s12010-015-1587-1; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gembka A, 2007, NUCLEIC ACIDS RES, V35, P2596, DOI 10.1093/nar/gkl1139; Goode EL, 2002, CANCER EPIDEM BIOMAR, V11, P1513; Guo Z, 2012, COCHRANE DB SYST REV, V5, P1; Guo ZG, 2008, MOL CELL BIOL, V28, P4310, DOI 10.1128/MCB.00200-08; Guo ZG, 2008, J MOL BIOL, V377, P679, DOI 10.1016/j.jmb.2007.10.074; Guo ZG, 2009, NUCLEIC ACIDS RES, V37, P3431, DOI 10.1093/nar/gkp201; Henneke G, 2003, ONCOGENE, V22, P4301, DOI 10.1038/sj.onc.1206606; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hosfield DJ, 1998, J BIOL CHEM, V273, P27154, DOI 10.1074/jbc.273.42.27154; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Ivancsits S, 2002, MUTAT RES-GEN TOX EN, V519, P1, DOI 10.1016/S1383-5718(02)00109-2; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Larsen E, 2003, MOL CELL BIOL, V23, P5346, DOI 10.1128/MCB.23.15.5346-5353.2003; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Ling CF, 2015, WORLD J MICROB BIOT, V31, P681, DOI 10.1007/s11274-015-1804-7; Liu P, 2008, MOL CELL BIOL, V28, P4975, DOI 10.1128/MCB.00457-08; Liu Y, 2005, J BIOL CHEM, V280, P3665, DOI 10.1074/jbc.M412922200; Liu Y, 2004, ANNU REV BIOCHEM, V73, P589, DOI 10.1146/annurev.biochem.73.012803.092453; Lukas C, 2011, NAT CELL BIOL, V13, P243, DOI 10.1038/ncb2201; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Narita K, 2006, CANCER RES, V66, P6025, DOI 10.1158/0008-5472.CAN-05-3582; Noon AT, 2011, DNA REPAIR, V10, P1071, DOI 10.1016/j.dnarep.2011.07.012; Nussenzweig A, 2010, CELL, V141, P27, DOI 10.1016/j.cell.2010.03.016; Pascucci B, 2005, NUCLEIC ACIDS RES, V33, P280, DOI 10.1093/nar/gki168; Pascucci B, 1999, J BIOL CHEM, V274, P33696, DOI 10.1074/jbc.274.47.33696; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; Qiu JZ, 2004, J BIOL CHEM, V279, P24394, DOI 10.1074/jbc.M401464200; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007; Roos WP, 2013, CANCER LETT, V332, P237, DOI 10.1016/j.canlet.2012.01.007; Sato M, 2003, ONCOGENE, V22, P7243, DOI 10.1038/sj.onc.1206977; Sattler U, 2003, EMBO REP, V4, P363, DOI 10.1038/sj.embor.embor796; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; SINGH NP, 1991, MUTAT RES, V252, P289, DOI 10.1016/0165-1161(91)90008-V; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Soza S, 2009, MOL CELL BIOL, V29, P2032, DOI 10.1128/MCB.01730-08; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Szczesny B, 2008, J BIOL CHEM, V283, P26349, DOI 10.1074/jbc.M803491200; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tsutakawa SE, 2011, CELL, V145, P198, DOI 10.1016/j.cell.2011.03.004; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Wang YX, 2005, NAT GENET, V37, P750, DOI 10.1038/ng1587; Wu ZX, 2012, MUTAT RES-FUND MOL M, V731, P85, DOI 10.1016/j.mrfmmm.2011.11.009; Xu H, 2011, ONCOGENE, V30, P1072, DOI 10.1038/onc.2010.482; Yamada Y, 2005, ANN NY ACAD SCI, V1049, P9, DOI 10.1196/annals.1334.002; Yang M, 2009, HUM MUTAT, V30, P1320, DOI 10.1002/humu.21060; Yoshioka N, 2006, P NATL ACAD SCI USA, V103, P14519, DOI 10.1073/pnas.0606708103; Zhang B, 2014, NAT GENET, V46, P533, DOI 10.1038/ng.2985; Zharkov DO, 2008, CELL MOL LIFE SCI, V65, P1544, DOI 10.1007/s00018-008-7543-2; Zheng L, 2005, EMBO REP, V6, P83, DOI 10.1038/sj.embor.7400313; Zheng L, 2007, NAT MED, V13, P812, DOI 10.1038/nm1599; Zheng L, 2007, MOL CELL BIOL, V27, P3176, DOI 10.1128/MCB.01652-06; Zheng L, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1825; Zheng L, 2011, CELL RES, V21, P1052, DOI 10.1038/cr.2011.35; Zheng L, 2011, NUCLEIC ACIDS RES, V39, P781, DOI 10.1093/nar/gkq884	83	24	26	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					194	207		10.1038/onc.2016.188	http://dx.doi.org/10.1038/onc.2016.188			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	27270424	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000393938100005
J	Linke, F; Zaunig, S; Nietert, MM; von Bonin, F; Lutz, S; Dullin, C; Janovska, P; Beissbarth, T; Alves, F; Klapper, W; Bryja, V; Pukrop, T; Trumper, L; Wilting, J; Kube, D				Linke, F.; Zaunig, S.; Nietert, M. M.; von Bonin, F.; Lutz, S.; Dullin, C.; Janovska, P.; Beissbarth, T.; Alves, F.; Klapper, W.; Bryja, V.; Pukrop, T.; Truemper, L.; Wilting, J.; Kube, D.			WNT5A: a motility-promoting factor in Hodgkin lymphoma	ONCOGENE			English	Article							PLANAR CELL POLARITY; REED-STERNBERG CELLS; CHRONIC LYMPHOCYTIC-LEUKEMIA; BETA-CATENIN; DISHEVELLED PHOSPHORYLATION; GENE-EXPRESSION; BREAST-CANCER; PROLIFERATION; MIGRATION; PATHOGENESIS	Classical Hodgkin lymphoma (cHL) has a typical clinical manifestation, with dissemination involving functionally neighboring lymph nodes. The factors involved in the spread of lymphoma cells are poorly understood. Here we show that cHL cell lines migrate with higher rates compared with non -Hodgkin lymphoma cell lines. cHL cell migration, invasion and adhesion depend on autocrine WNT signaling as revealed by the inhibition of WNT secretion with the porcupine inhibitors Wnt-059/IWP-2, but did not affect cell proliferation. While application of recombinant WNT5A or WNT5A overexpression stimulates cHL cell migration, neither WNT10A, WNT1OB nor WNT16 did so. Time-lapse studies revealed an amoeboid type of cell migration modulated by WNT5A. Reduced migration distances and velocity of cHL cells, as well as altered movement patterns, were observed using porcupine inhibitor or WNT5A antagonist. Knockdown of Frizzled5 and Dishevelled3 disrupted the WNT5A-mediated RHOA activation and cell migration. Overexpression of DVL3-K435M or inhibition of ROCK (Rho-associated protein kinase) by Y-27632/H1152P disrupted cHL cell migration. In addition to these mechanistic insights into the role of WNT5A in vitro, global gene expression data revealed an increased WNT5A expression in primary HL cells in comparison with normal B-cell subsets and other lymphomas. Furthermore, the activity of both porcupine and WNT5A in cHL cells had an impact on lymphoma development in the chick chorionallantoic membrane assay. Massive bleeding of these lymphomas was significantly reduced after inhibition of WNT secretion by Wnt-059. Therefore, a model is proposed where WNT signaling has an important role in regulating tumor-promoting processes.	[Linke, F.; Zaunig, S.; von Bonin, F.; Alves, F.; Pukrop, T.; Truemper, L.; Kube, D.] Georg August Univ Gottingen, Univ Med Ctr, Clin Hematol & Med Oncol, Robert Koch Str 40, D-37075 Gottingen, Germany; [Nietert, M. M.; Beissbarth, T.] Georg August Univ Gottingen, Univ Med Ctr, Dept Med Stat, Gottingen, Germany; [Lutz, S.] Georg August Univ Gottingen, Univ Med Ctr, Inst Pharmacol, Gottingen, Germany; [Dullin, C.; Alves, F.] Georg August Univ Gottingen, Univ Med Ctr, Inst Diagnost & Intervent Radiol, Gottingen, Germany; [Janovska, P.; Bryja, V.] Masaryk Univ, Inst Expt Biol, Fac Sci, Brno, Czech Republic; [Alves, F.] Max Planck Inst Expt Med, Dept Mol Biol Neuronal Signals, Gottingen, Germany; [Klapper, W.] UKSH Campus Kiel, Hematopathol Sect, Kiel, Germany; [Bryja, V.] Acad Sci Czech Republ, Inst Biophys, Dept Cytokinet, Brno, Czech Republic; [Wilting, J.] Georg August Univ Gottingen, Dept Anat & Cell Biol, Univ Med Ctr, Gottingen, Germany; [Pukrop, T.] Univ Hosp Regensburg, Dept Internal Med Hematol & Internal Oncol 3, Regensburg, Germany	University of Gottingen; University of Gottingen; University of Gottingen; University of Gottingen; Masaryk University Brno; Max Planck Society; University of Kiel; Schleswig Holstein University Hospital; Czech Academy of Sciences; Institute of Biophysics of the Czech Academy of Sciences; University of Gottingen; University of Regensburg	Kube, D (corresponding author), Georg August Univ Gottingen, Univ Med Ctr, Clin Hematol & Med Oncol, Robert Koch Str 40, D-37075 Gottingen, Germany.	dkube@med.uni-goettingen.de	Linke, Franziska/AAD-7600-2022; Janovska, Pavlina/AAM-2683-2020; Bryja, Vítězslav/P-4217-2019; Klapper, Wolfram/S-6314-2016	Linke, Franziska/0000-0002-7005-9687; Bryja, Vítězslav/0000-0002-9136-5085; Nietert, Manuel/0000-0001-5443-7943; Dullin, Christian/0000-0003-4297-8077	Deutsche Forschungsgemeinschaft within the Forschergruppe [Ku 954/12-1, FOR942]	Deutsche Forschungsgemeinschaft within the Forschergruppe(German Research Foundation (DFG))	We thank Moritz Harenberg for evaluating the vascularization of the CAM tumors in a blinded manner. We are very thankful to Mrs S Schwoch, Mrs C Zelent and Mrs S Hellbach for their technical assistance in the histological analysis of the CAM tumors. We kindly acknowledge Dr Aldo Ferrari from the ETH Zurich to provide the sketch on the amoeboid migration type (integrated into Figure 3a). This work was supported by grants of the Deutsche Forschungsgemeinschaft Ku 954/12-1 within the Forschergruppe FOR942.	Aldinucci D, 2008, INT J CANCER, V122, P769, DOI 10.1002/ijc.23119; Aprelikova O, 2013, ONCOGENE, V32, P3246, DOI 10.1038/onc.2012.351; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bernatik O, 2014, J BIOL CHEM, V289, P23520, DOI 10.1074/jbc.M114.590638; Boll B, 2013, J CLIN ONCOL, V31, P4431, DOI 10.1200/JCO.2013.49.8246; Brune V, 2008, J EXP MED, V205, P2251, DOI 10.1084/jem.20080809; Bryja V, 2007, J CELL SCI, V120, P586, DOI 10.1242/jcs.03368; Carragher NO, 2006, ONCOGENE, V25, P5726, DOI 10.1038/sj.onc.1209582; Chiu A, 2007, BLOOD, V109, P729, DOI 10.1182/blood-2006-04-015958; Corrigan PM, 2009, STEM CELLS DEV, V18, P759, DOI 10.1089/scd.2008.0270; Dijksterhuis JP, 2015, J BIOL CHEM, V290, P6789, DOI 10.1074/jbc.M114.612648; Ekstrom EJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-88; Fhu CW, 2014, BLOOD, V124, P2973, DOI 10.1182/blood-2014-05-576140; Florian MC, 2013, NATURE, V503, P392, DOI 10.1038/nature12631; Gentzel M, 2015, MOL BIOL CELL, V26, P966, DOI 10.1091/mbc.E14-06-1089; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; Guermazi A, 2001, RADIOGRAPHICS, V21, P161, DOI 10.1148/radiographics.21.1.g01ja02161; Hecht M, 2005, CARCINOGENESIS, V26, P2105, DOI 10.1093/carcin/bgi192; Hopken UE, 2002, BLOOD, V99, P1109, DOI 10.1182/blood.V99.4.1109; Introcaso CE, 2008, J AM ACAD DERMATOL, V58, P295, DOI 10.1016/j.jaad.2005.11.1055; Janz M, 2006, BLOOD, V107, P2536, DOI 10.1182/blood-2005-07-2694; Jenei V, 2009, P NATL ACAD SCI USA, V106, P19473, DOI 10.1073/pnas.0909409106; Jundt F, 2002, BLOOD, V99, P3398, DOI 10.1182/blood.V99.9.3398; Kafka A, 2014, INT J MOL SCI, V15, P10635, DOI 10.3390/ijms150610635; Kaucka M, 2013, CANCER RES, V73, P1491, DOI 10.1158/0008-5472.CAN-12-1752; Klemm F, 2011, CARCINOGENESIS, V32, P434, DOI 10.1093/carcin/bgq269; Klingenberg M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-339; Kluk MJ, 2013, LAB INVEST, V93, P462, DOI 10.1038/labinvest.2013.7; Koch R, 2014, BLOOD, V123, P2189, DOI 10.1182/blood-2013-08-523886; Kube D, 2001, BLOOD, V98, P762, DOI 10.1182/blood.V98.3.762; Kuppers R, 2012, J CLIN INVEST, V122, P3439, DOI [10.1172/JCI6124.5, 10.1172/JCI61245]; Kurayoshi M, 2006, CANCER RES, V66, P10439, DOI 10.1158/0008-5472.CAN-06-2359; Long A, 2015, CARCINOGENESIS, V36, P598, DOI 10.1093/carcin/bgv025; Lopez-Giral S, 2004, J LEUKOCYTE BIOL, V76, P462, DOI 10.1189/jlb.1203652; MacDonald BT, 2014, J BIOL CHEM, V289, P18122, DOI 10.1074/jbc.M114.575027; MacMillan CD, 2014, SCI REP-UK, V4, DOI 10.1038/srep06315; Malhotra S, 2008, J IMMUNOL, V181, P3955, DOI 10.4049/jimmunol.181.6.3955; Mayor R, 2014, BIOCHEM J, V457, P19, DOI 10.1042/BJ20131182; Najdi R, 2012, DIFFERENTIATION, V84, P203, DOI 10.1016/j.diff.2012.06.004; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; PALS ST, 1989, IMMUNOL REV, V108, P111, DOI 10.1111/j.1600-065X.1989.tb00015.x; Pals ST, 2007, BLOOD, V110, P3102, DOI 10.1182/blood-2007-05-075176; Proffitt KD, 2013, CANCER RES, V73, P502, DOI 10.1158/0008-5472.CAN-12-2258; Qiang YW, 2005, BLOOD, V106, P1786, DOI 10.1182/blood-2005-01-0049; Qin L, 2015, ONCOTARGET, V6, P10239, DOI 10.18632/oncotarget.3518; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Samarzija I, 2009, BIOCHEM BIOPH RES CO, V386, P449, DOI 10.1016/j.bbrc.2009.06.033; Skinnider BF, 2002, BLOOD, V99, P4283, DOI 10.1182/blood-2002-01-0099; Sohlbach K, 2012, LEUKEMIA LYMPHOMA, V53, P996, DOI 10.3109/10428194.2011.634046; Steidl C, 2010, NEW ENGL J MED, V362, P875, DOI 10.1056/NEJMoa0905680; Tiacci E, 2012, BLOOD, V120, P4609, DOI 10.1182/blood-2012-05-428896; van den Berg A, 1999, AM J PATHOL, V154, P1685, DOI 10.1016/S0002-9440(10)65424-7; Vockerodt M, 2001, GENES IMMUN, V2, P433, DOI 10.1038/sj.gene.6363803; Wallingford JB, 2002, DEV CELL, V2, P695, DOI 10.1016/S1534-5807(02)00197-1; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Witze ES, 2008, SCIENCE, V320, P365, DOI 10.1126/science.1151250; Xargay-Torrent S, 2013, CLIN CANCER RES, V19, P586, DOI 10.1158/1078-0432.CCR-12-1935; Yao LL, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/832562; Zepeda-Moreno A, 2014, CELL ADHES MIGR, V5, P215; Zheng B, 2003, BLOOD, V102, P1019, DOI 10.1182/blood-2002-11-3507; Zhu YC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037823	63	24	24	1	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					13	23		10.1038/onc.2016.183	http://dx.doi.org/10.1038/onc.2016.183			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27270428				2022-12-17	WOS:000394069100002
J	Mondal, B; Patil, V; Shwetha, SD; Sravani, K; Hegde, AS; Arivazhagan, A; Santosh, V; Kanduri, M; Somasundaram, K				Mondal, B.; Patil, V.; Shwetha, S. D.; Sravani, K.; Hegde, A. S.; Arivazhagan, A.; Santosh, V.; Kanduri, M.; Somasundaram, K.			Integrative functional genomic analysis identifies epigenetically regulated fibromodulin as an essential gene for glioma cell migration	ONCOGENE			English	Article							TGF-BETA; DNA METHYLATION; BINDING-PROTEIN; GLIOBLASTOMA; TEMOZOLOMIDE; ACTIVATION; EXPRESSION; PROTEOGLYCANS; RADIOTHERAPY; SURVIVAL	An integrative functional genomics study of multiple forms of data are vital for discovering molecular drivers of cancer development and progression. Here, we present an integrated genomic strategy utilizing DNA methylation and transcriptome profile data to discover epigenetically regulated genes implicated in cancer development and invasive progression. More specifically, this analysis identified fibromodulin (FMOD) as a glioblastoma (GBM) upregulated gene because of the loss of promoter methylation. Secreted FMOD promotes glioma cell migration through its ability to induce filamentous actin stress fiber formation. Treatment with cytochalasin D, an actin polymerization inhibitor, significantly reduced the FMOD-induced glioma cell migration. Small interfering RNA and small molecule inhibitor-based studies identified that FMOD-induced glioma cell migration is dependent on integrin-FAK-Src-Rho-ROCK signaling pathway. FMOD lacking C-terminus LRR11 domain (Delta FMOD), which does not bind collagen type I, failed to induce integrin and promote glioma cell migration. Further, FMOD-induced integrin activation and migration was abrogated by a 9-mer wild-type peptide from the FMOD C-terminus. However, the same peptide with mutation in two residues essential for FMOD interaction with collagen type I failed to compete with FMOD, thus signifying the importance of collagen type IFMOD interaction in integrin activation. Chromatin immunoprecipitation-PCR experiments revealed that transforming growth factor beta-1 (TGF-beta 1) regulates FMOD expression through epigenetic remodeling of FMOD promoter that involved demethylation and gain of active histone marks with a simultaneous loss of DNMT3A and EZH2 occupancy, but enrichment of Sma- and Mad related protein-2 (SMAD2) and CBP. FMOD silencing inhibited the TGF-beta 1-mediated glioma cell migration significantly. In univariate and multivariate Cox regression analysis, both FMOD promoter methylation and transcript levels predicted prognosis in GBM. Thus, this study identified several epigenetically regulated alterations responsible for cancer development and progression. Specifically, we found that secreted FMOD as an important regulator of glioma cell migration downstream of TGF-beta 1 pathway and forms a potential basis for therapeutic intervention in GBM.	[Mondal, B.; Patil, V.; Somasundaram, K.] Indian Inst Sci, Dept Microbiol & Cell Biol, CV Raman Ave, Bangalore 560012, Karnataka, India; [Shwetha, S. D.; Sravani, K.; Santosh, V.] Natl Inst Mental Hlth & Neurosci, Dept Neuropathol, Bangalore, Karnataka, India; [Hegde, A. S.] Sri Satya Sai Inst Higher Med Sci, Dept Neurosurg, Bangalore, Karnataka, India; [Arivazhagan, A.] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore, Karnataka, India; [Kanduri, M.] Sahlgrens Univ Hosp, Inst Biomed, Dept Clin Chem & Transfus Med, Gothenburg, Sweden	Indian Institute of Science (IISC) - Bangalore; National Institute of Mental Health & Neurosciences - India; National Institute of Mental Health & Neurosciences - India; Sahlgrenska University Hospital	Somasundaram, K (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, CV Raman Ave, Bangalore 560012, Karnataka, India.	skumar@mcbl.iisc.ernet.in	KANDURI, MEENA/AAI-6169-2021; kanduri, meena/AAG-1813-2019	KANDURI, MEENA/0000-0003-2781-4779; Mondal, Baisakhi/0000-0002-8171-4333	DBT, Government of India; IISc	DBT, Government of India(Department of Biotechnology (DBT) India); IISc	The results published here are in whole or part based upon data generated by The Cancer Genome Atlas (TCGA) pilot project established by the NCI and NHGRI. Information about TCGA and the investigators and institutions, which constitute the TCGA research network, can be found at http://cancergenome.nih.gov/. The use of data sets from Institute NC and GSE22866 is acknowledged. IISc NGS facility is acknowledged for methylation and microarray experiments. KS thanks DBT, Government of India for financial support. KS is a JC Bose Fellow of the Department of Science and Technology. BM acknowledges IISc for the fellowship.	Alblas J, 2001, MOL BIOL CELL, V12, P2137, DOI 10.1091/mbc.12.7.2137; Au SLK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068226; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Beiko J, 2014, NEURO-ONCOLOGY, V16, P81, DOI 10.1093/neuonc/not159; Bevilacqua MA, 2005, J BIOL CHEM, V280, P31809, DOI 10.1074/jbc.M414677200; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chinot OL, 2014, NEW ENGL J MED, V370, P709, DOI 10.1056/NEJMoa1308345; Chopra S, 2015, EXP CELL RES, V334, P246, DOI 10.1016/j.yexcr.2015.03.001; Choudhury A, 2010, BRIT J HAEMATOL, V151, P327, DOI 10.1111/j.1365-2141.2010.08362.x; Colman H, 2010, NEURO-ONCOLOGY, V12, P49, DOI 10.1093/neuonc/nop007; Fernandez AF, 2012, TRENDS GENET, V28, P474, DOI 10.1016/j.tig.2012.05.006; Frattini V, 2013, NAT GENET, V45, P1141, DOI 10.1038/ng.2734; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huttenlocher A, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005074; Ortuno MJ, 2010, J BIOL CHEM, V285, P31985, DOI 10.1074/jbc.M110.123612; Kalamajski S, 2007, J BIOL CHEM, V282, P26740, DOI 10.1074/jbc.M704026200; Kalamajski S, 2010, MATRIX BIOL, V29, P248, DOI 10.1016/j.matbio.2010.01.001; Lin LC, 2014, CLIN EXP METASTAS, V31, P881, DOI 10.1007/s10585-014-9677-y; Lu Y, 2011, ONCOL REP, V25, P1329, DOI 10.3892/or.2011.1195; Luo XR, 2008, J IMMUNOL, V180, P2757, DOI 10.4049/jimmunol.180.5.2757; Mayr C, 2005, BLOOD, V105, P1566, DOI 10.1182/blood-2004-04-1233; Meyer M, 2015, P NATL ACAD SCI USA, V112, P851, DOI 10.1073/pnas.1320611111; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Mouneimne G, 2012, CANCER CELL, V22, P615, DOI 10.1016/j.ccr.2012.09.027; Nathanson DA, 2014, SCIENCE, V343, P72, DOI 10.1126/science.1241328; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Oldberg A, 2007, P NATL ACAD SCI USA, V104, P13966, DOI 10.1073/pnas.0702014104; Pan XD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060335; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Ridley AJ, 2001, J CELL SCI, V114, P2713; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Scherer HJ, 1940, J NEUROL PSYCHIATRY, V3, P147, DOI 10.1136/jnnp.3.2.147; Shukla S, 2014, CURR SCI INDIA, V107, P815; Shukla S, 2013, CANCER RES, V73, P6563, DOI 10.1158/0008-5472.CAN-13-0298; Srinivasan S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017438; Stricker J, 2010, J BIOMECH, V43, P9, DOI 10.1016/j.jbiomech.2009.09.003; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Thillainadesan G, 2012, MOL CELL, V46, P636, DOI 10.1016/j.molcel.2012.03.027; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Vega FM, 2007, CELL, V129, P1430, DOI 10.1016/j.cell.2007.06.021; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Zheng Z, 2011, J INVEST DERMATOL, V131, P769, DOI 10.1038/jid.2010.381	49	24	25	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					71	83		10.1038/onc.2016.176	http://dx.doi.org/10.1038/onc.2016.176			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27212030				2022-12-17	WOS:000394069100007
J	Martinelli, GB; Olivari, D; Cecconi, ADR; Talamini, L; Ottoboni, L; Lecker, SH; Stretch, C; Baracos, VE; Bathe, OF; Resovi, A; Giavazzi, R; Cervo, L; Piccirillo, R				Martinelli, G. B.; Olivari, D.; Cecconi, A. D. Re; Talamini, L.; Ottoboni, L.; Lecker, S. H.; Stretch, C.; Baracos, V. E.; Bathe, O. F.; Resovi, A.; Giavazzi, R.; Cervo, L.; Piccirillo, R.			Activation of the SDF1/CXCR4 pathway retards muscle atrophy during cancer cachexia	ONCOGENE			English	Article							PROTEIN-COUPLED RECEPTOR; SKELETAL-MUSCLE; CHEMOKINE RECEPTOR; PROGENITOR CELLS; WEIGHT-LOSS; CXCR4; INTERLEUKIN-6; DEGRADATION; REGENERATION; EXPRESSION	Cancer cachexia is a life-threatening syndrome that affects most patients with advanced cancers and causes severe body weight loss, with rapid depletion of skeletal muscle. No treatment is available. We analyzed microarray data sets to identify a subset of genes whose expression is specifically altered in cachectic muscles of Yoshida hepatoma-bearing rodents but not in those with diabetes, disuse, uremia or fasting. Ingenuity Pathways Analysis indicated that three genes belonging to the C-X-C motif chemokine receptor 4 (CXCR4) pathway were downregulated only in muscles atrophying because of cancer: stromal cell-derived factor 1 (SDF1), adenylate cyclase 7 (ADCY7), and p21 protein-activated kinase 1 (PAK1). Notably, we found that, in the Rectus Abdominis muscle of cancer patients, the expression of SDF1 and CXCR4 was inversely correlated with that of two ubiquitin ligases induced in muscle wasting, atrogin-1 and MuRF1, suggesting a possible clinical relevance of this pathway. The expression of all main SDF1 isoforms (alpha, beta, gamma) also declined in Tibialis Anterior muscle from cachectic mice bearing murine colon adenocarcinoma or human renal cancer and drugs with anticachexia properties restored their expression. Overexpressing genes of this pathway (that is, SDF1 or CXCR4) in cachectic muscles increased the fiber area by 20%, protecting them from wasting. Similarly, atrophying myotubes treated with either SDF1 alpha or SDF1 beta had greater total protein content, resulting from reduced degradation of overall long-lived proteins. However, inhibiting CXCR4 signaling with the antagonist AMD3100 did not affect protein homeostasis in atrophying myotubes, whereas normal myotubes treated with AMD3100 showed time-and dose-dependent reductions in diameter, until a plateau, and lower total protein content. This further confirms the involvement of a saturable pathway (that is, CXCR4). Overall, these findings support the idea that activating the CXCR4 pathway in muscle suppresses the deleterious wasting associated with cancer.	[Martinelli, G. B.; Olivari, D.; Cecconi, A. D. Re; Talamini, L.; Giavazzi, R.; Piccirillo, R.] IRCCS Mario Negri Inst Pharmacol Res, Dept Oncol, Via G La Masa 19, I-20156 Milan, Italy; [Ottoboni, L.] INSpe, San Raffaele Sci Inst, Milan, Italy; [Lecker, S. H.] Beth Israel Deaconess Med Ctr, Boston, MA USA; [Stretch, C.; Baracos, V. E.] Univ Alberta, Dept Oncol, Edmonton, AB, Canada; [Bathe, O. F.] Univ Calgary, Dept Surg & Oncol, Calgary, AB, Canada; [Resovi, A.] IRCCS Mario Negri Inst Pharmacol Res, Tumor Angiogenesis Unit, Dept Oncol, Bergamo, Italy; [Cervo, L.] IRCCS Mario Negri Inst Pharmacol Res, Dept Neurosci, Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Harvard University; Beth Israel Deaconess Medical Center; University of Alberta; University of Calgary; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Piccirillo, R (corresponding author), IRCCS Mario Negri Inst Pharmacol Res, Dept Oncol, Via G La Masa 19, I-20156 Milan, Italy.	rosanna.piccirillo@marionegri.it	Olivari, Davide/AAC-4733-2022; Piccirillo, Rosanna/K-6619-2016; Resovi, Andrea/ABG-7483-2021; RE CECCONI, ANDREA DAVID/AAG-4949-2021; Piccirillo, Rosanna/AAQ-3653-2020; Giavazzi, Raffaella/J-7424-2018; Cervo, Luigi/AAA-8081-2020; Giavazzi, Raffaella/ABB-9768-2020	Olivari, Davide/0000-0003-0802-6603; Piccirillo, Rosanna/0000-0002-1613-9352; Resovi, Andrea/0000-0001-9560-0815; RE CECCONI, ANDREA DAVID/0000-0003-1502-9108; Piccirillo, Rosanna/0000-0002-1613-9352; Cervo, Luigi/0000-0003-1314-1876; Giavazzi, Raffaella/0000-0001-5249-8208; Stretch, Cynthia/0000-0002-5152-2728; Talamini, Laura/0000-0001-6010-2947	Italian Association for Cancer Research [AIRC Start-UP 11423, AIRC-IG 14532, AIRC 12182]; Union under the Marie Curie International Reintegration Grant [PIRG08-GA-2010-277008]; Fondazione Veronesi; FISM [2012/B/10]; Fondazione Eugenio Morandi	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); Union under the Marie Curie International Reintegration Grant; Fondazione Veronesi(Fondazione Umberto Veronesi); FISM(Fondazione Italiana Sclerosi Multipla (FISM)); Fondazione Eugenio Morandi	We are grateful to the Italian Association for Cancer Research (AIRC Start-UP 11423 to RP and AIRC-IG 14532 and AIRC 12182 to RG) and the Union under the Marie Curie International Reintegration Grant (PIRG08-GA-2010-277008 to RP). LO is the recipient of a training research fellowship from 'Fondazione Veronesi' and of a grant from FISM (2012/B/10). AR is the recipient of a fellowship from 'Fondazione Eugenio Morandi'. We thank JD Baggott for help with the editing.	Argiles JM, 2014, NAT REV CANCER, V14, P754, DOI 10.1038/nrc3829; Bedard N, 2015, FASEB J, V29, P3889, DOI 10.1096/fj.15-270579; Bennani-Baiti N, 2011, SUPPORT CARE CANCER, V19, P1451, DOI 10.1007/s00520-010-0972-0; Bobadilla M, 2014, STEM CELLS DEV, V23, P1417, DOI 10.1089/scd.2013.0491; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Boldajipour B, 2008, CELL, V132, P463, DOI 10.1016/j.cell.2007.12.034; Burns JM, 2006, J EXP MED, V203, P2201, DOI 10.1084/jem.20052144; Chong SW, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-54; Debnath B, 2013, THERANOSTICS, V3, P47, DOI 10.7150/thno.5376; DEWYS WD, 1980, AM J MED, V69, P491, DOI 10.1016/S0149-2918(05)80001-3; FEARON KCH, 1991, ANN SURG, V213, P26, DOI 10.1097/00000658-199101000-00005; Fearon K, 2011, LANCET ONCOL, V12, P489, DOI 10.1016/S1470-2045(10)70218-7; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; He WA, 2013, J CLIN INVEST, V123, P4821, DOI 10.1172/JCI68523; Hernandez PA, 2003, NAT GENET, V34, P70, DOI 10.1038/ng1149; Janowski M, 2009, CELL ADHES MIGR, V3, P243, DOI 10.4161/cam.3.3.8260; Jatoi A, 2007, CANCER, V110, P1396, DOI 10.1002/cncr.22944; Kuroda K, 2007, UROLOGY, V69, P113, DOI 10.1016/j.urology.2006.09.039; Leal MA, 2014, DEV DYNAM, V243, P509, DOI 10.1002/dvdy.24092; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lecker SH, 2006, J AM SOC NEPHROL, V17, P1807, DOI 10.1681/ASN.2006010083; Melchonna R, 2010, MUSCLE NERVE, V41, P828, DOI 10.1002/mus.21611; Mines MA, 2009, J BIOL CHEM, V284, P5742, DOI 10.1074/jbc.M808507200; Minetti GC, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002038; Navegantes LCC, 2002, CURR OPIN CLIN NUTR, V5, P281, DOI 10.1097/00075197-200205000-00007; Oka M, 1996, CANCER RES, V56, P2776; Overington JP, 2006, NAT REV DRUG DISCOV, V5, P993, DOI 10.1038/nrd2199; OVESEN L, 1993, J CLIN ONCOL, V11, P2043, DOI 10.1200/JCO.1993.11.10.2043; Perez AL, 2009, MUSCLE NERVE, V40, P562, DOI 10.1002/mus.21317; Piccirillo R, 2012, EMBO J, V31, P3334, DOI 10.1038/emboj.2012.178; Pillarisetti K, 2001, INFLAMMATION, V25, P293, DOI 10.1023/A:1012808525370; Porporato PE, 2013, J CLIN INVEST, V123, P611, DOI 10.1172/JCI39920; Pretto F, 2015, ONCOTARGET, V6, P3043, DOI 10.18632/oncotarget.2812; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Scott HR, 1996, BRIT J CANCER, V73, P1560, DOI 10.1038/bjc.1996.294; Steen A, 2009, MINI-REV MED CHEM, V9, P1605, DOI 10.2174/138955709791012265; Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x; Tisdale MJ, 2009, PHYSIOL REV, V89, P381, DOI 10.1152/physrev.00016.2008; Toledo M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113931; Toschi A, 2011, MOL ENDOCRINOL, V25, P1661, DOI 10.1210/me.2011-1049; Wang H, 2010, CELL SIGNAL, V22, P1022, DOI 10.1016/j.cellsig.2010.02.005; White JP, 2014, P NATL ACAD SCI USA, V111, P15756, DOI 10.1073/pnas.1417898111; WHITE ME, 1988, J ANIM SCI, V66, P34, DOI 10.2527/jas1988.66134x; Wiedenmann Bertram, 2008, J Support Oncol, V6, P18; Wiegant J, 2002, CANCER GENET CYTOGEN, V139, P126, DOI 10.1016/S0165-4608(02)00623-4; Yu L, 2006, GENE, V374, P174, DOI 10.1016/j.gene.2006.02.001; Zhang LP, 2013, CELL METAB, V18, P368, DOI 10.1016/j.cmet.2013.07.012; Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004; Zheng H, 2007, J CARDIOVASC PHARM, V50, P274, DOI 10.1097/FJC.0b013e318093ec8f	50	24	25	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2016	35	48					6212	6222		10.1038/onc.2016.153	http://dx.doi.org/10.1038/onc.2016.153			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED4YH	27212031				2022-12-17	WOS:000388857700006
J	Muramatsu, T; Kozaki, KI; Imoto, S; Yamaguchi, R; Tsuda, H; Kawano, T; Fujiwara, N; Morishita, M; Miyano, S; Inazawa, J				Muramatsu, T.; Kozaki, K-I; Imoto, S.; Yamaguchi, R.; Tsuda, H.; Kawano, T.; Fujiwara, N.; Morishita, M.; Miyano, S.; Inazawa, J.			The hypusine cascade promotes cancer progression and metastasis through the regulation of RhoA in squamous cell carcinoma	ONCOGENE			English	Article							TRANSLATION INITIATION-FACTOR; FACTOR 5A EIF5A; EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCELLULAR-CARCINOMA; PROTEOMIC ANALYSIS; COLORECTAL-CANCER; PANCREATIC-CANCER; TUMOR-METASTASIS; LIVER-CANCER; IN-VIVO	Metastasis is a critical factor contributing to poor prognosis in cancer, but the underlying mechanisms of metastasis are still poorly understood. We established a highly metastatic cell subline (HOC313-LM) derived from an oral squamous cell carcinoma cell line (HOC313) for uncovering the mechanisms of metastasis, and identified deoxyhypusine synthase (DHPS) as a metastasis-associated gene within the specific amplification at 19p13.2-p13.13 in HOC313-LM. DHPS-mediated hypusine-modification of eukaryotic translation factor 5A facilitated the translation of RhoA, resulting in the activation of the RhoA signaling pathway and leading to not only increased cell motility, invasion and metastasis of cancer cells in vitro, but also increased tumor growth in vivo. Moreover, the use of N1-Guanyl-1,7-diaminoheptane, a DHPS inhibitor, resulted in a significant decrease in tumor formation in vivo. In patients with esophageal squamous cell carcinoma (ESCC), overexpression of DHPS in ESCC tumors was significantly associated with worse recurrence-free survival, and correlated with distant metastasis. The elucidation of these molecular mechanisms within the hypusine cascade suggests opportunities for novel therapeutic targets in SCC.	[Muramatsu, T.; Kozaki, K-I; Fujiwara, N.; Morishita, M.; Inazawa, J.] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Tokyo, Japan; [Muramatsu, T.; Inazawa, J.] Tokyo Med & Dent Univ, Global Ctr Excellence GCOE, Program Frontier Res Mol Destruct & Reconstitut T, Tokyo, Japan; [Muramatsu, T.] Japan Soc Promot Sci, Tokyo, Japan; [Kozaki, K-I; Inazawa, J.] Tokyo Med & Dent Univ, Bioresource Res Ctr, Tokyo, Japan; [Kozaki, K-I] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Dent Pharmacol, Okayama, Japan; [Imoto, S.; Yamaguchi, R.; Miyano, S.] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Dept DNA Informat Anal, Tokyo, Japan; [Tsuda, H.] Natl Def Med Coll, Dept Basic Pathol, Saitama, Japan; [Kawano, T.; Fujiwara, N.] Tokyo Med & Dent Univ, Grad Sch, Dept Surg, Tokyo, Japan; [Inazawa, J.] Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Japan Society for the Promotion of Science; Tokyo Medical & Dental University (TMDU); Okayama University; University of Tokyo; National Defense Medical College - Japan; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp		Imoto, Seiya/0000-0002-2989-308X; Miyano, Satoru/0000-0002-1753-6616	Ministry of Education, Culture, Sports, Science and Technology (MEXT) [22134002, 15H05908, 22240090, 25250019, 15K18401, 26890012]; Tailor-Made Medical Treatment; BioBank Japan Project (BBJ); Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and development [15Ack0106017h0002]; AMED; Global Center of Excellence (GCOE) Program for International Research Center for Molecular Science in Tooth and Bone Diseases; Ministry of Education, Culture, Sports, Science and Technology, Japan	Ministry of Education, Culture, Sports, Science and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Tailor-Made Medical Treatment; BioBank Japan Project (BBJ); Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and development(Japan Agency for Medical Research and Development (AMED)); AMED; Global Center of Excellence (GCOE) Program for International Research Center for Molecular Science in Tooth and Bone Diseases; Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was supported in part by a Grant-in Aid for Scientific Research (KAKENHI) for Innovative Areas (22134002, 15H05908) (Integrative Systems Understanding of Cancer for Advanced Diagnosis, Therapy and Prevention), Scientific Research (A) (22240090, 25250019), Challenging Exploratory Research (B) (15K18401), Research Activity Start-up (26890012), JSPS Fellows from Ministry of Education, Culture, Sports, Science and Technology (MEXT), the Tailor-Made Medical Treatment with the BioBank Japan Project (BBJ) and the Practical Research for Innovative Cancer Control (15Ack0106017h0002) from Japan Agency for Medical Research and development, AMED and Global Center of Excellence (GCOE) Program for International Research Center for Molecular Science in Tooth and Bone Diseases, from the Ministry of Education, Culture, Sports, Science and Technology, Japan. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Balabanov S, 2007, BLOOD, V109, P1701, DOI 10.1182/blood-2005-03-037648; Caraglia M, 2013, AMINO ACIDS, V44, P103, DOI 10.1007/s00726-011-1182-x; Casero RA, 2007, NAT REV DRUG DISCOV, V6, P373, DOI 10.1038/nrd2243; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Cipollini G, 1997, INT J CANCER, V73, P297, DOI 10.1002/(SICI)1097-0215(19971009)73:2<297::AID-IJC22>3.0.CO;2-B; Dong ZZ, 2005, MOL CELL PROTEOMICS, V4, P993, DOI 10.1074/mcp.M500044-MCP200; Eberhard Y, 2009, BLOOD, V114, P3064, DOI 10.1182/blood-2009-03-209965; Fujimura K, 2015, J BIOL CHEM, V290, P29907, DOI 10.1074/jbc.M115.687418; Fujimura K, 2014, CANCER RES, V74, P6671, DOI 10.1158/0008-5472.CAN-14-1031; Giancotti FG, 2013, CELL, V155, P750, DOI 10.1016/j.cell.2013.10.029; Guan XY, 2004, CANCER RES, V64, P4197, DOI 10.1158/0008-5472.CAN-03-3747; Gutierrez E, 2013, MOL CELL, V51, P35, DOI 10.1016/j.molcel.2013.04.021; He XY, 2012, CARCINOGENESIS, V33, P555, DOI 10.1093/carcin/bgs002; Huang YF, 2007, P NATL ACAD SCI USA, V104, P4194, DOI 10.1073/pnas.0611609104; Iden S, 2008, NAT REV MOL CELL BIO, V9, P846, DOI 10.1038/nrm2521; Jasiulionis MG, 2007, CELL BIOCHEM FUNCT, V25, P109, DOI 10.1002/cbf.1351; Kaiser A, 2012, AMINO ACIDS, V42, P679, DOI 10.1007/s00726-011-1042-8; Karlsson R, 2009, BBA-REV CANCER, V1796, P91, DOI 10.1016/j.bbcan.2009.03.003; Lee NP, 2010, INT J CANCER, V127, P968, DOI 10.1002/ijc.25100; Li YJ, 2012, PROCEEDINGS OF INTERNATIONAL SYMPOSIUM ON EMERGENCY MANAGEMENT 2011, P5; Lin DC, 2014, NAT GENET, V46, P467, DOI 10.1038/ng.2935; Lou B, 2013, EXP CELL RES, V319, P2708, DOI 10.1016/j.yexcr.2013.08.010; Lu ZJ, 2014, CELL PHYSIOL BIOCHEM, V33, P859, DOI 10.1159/000358658; Maier B, 2010, J CLIN INVEST, V120, P2156, DOI 10.1172/JCI38924; Mandal A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111800; Memin E, 2014, CANCER RES, V74, P552, DOI 10.1158/0008-5472.CAN-13-0474; Minden MD, 2014, AM J HEMATOL, V89, P363, DOI 10.1002/ajh.23640; Muramatsu T, 2011, CARCINOGENESIS, V32, P389, DOI 10.1093/carcin/bgq254; Nakayama K, 2006, P NATL ACAD SCI USA, V103, P18739, DOI 10.1073/pnas.0604083103; Neeb A, 2012, ONCOGENE, V31, P3796, DOI 10.1038/onc.2011.535; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Ono H, 2012, ONCOGENE, V31, P4923, DOI 10.1038/onc.2011.646; Park MH, 2010, AMINO ACIDS, V38, P491, DOI 10.1007/s00726-009-0408-7; Pickering CR, 2013, CANCER DISCOV, V3, P770, DOI 10.1158/2159-8290.CD-12-0537; Preukschas M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043468; Reymond N, 2013, NAT REV CANCER, V13, P858, DOI 10.1038/nrc3628; Scuoppo C, 2012, NATURE, V487, P244, DOI 10.1038/nature11126; Semenza GL, 2003, NAT REV CANCER, V4, P191; Shih IM, 2011, MODERN PATHOL, V24, P638, DOI 10.1038/modpathol.2010.230; Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176; Straume O, 2012, P NATL ACAD SCI USA, V109, P8699, DOI 10.1073/pnas.1017909109; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Tang DJ, 2010, HEPATOLOGY, V51, P1255, DOI 10.1002/hep.23451; Taylor CA, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-35; Tunca B, 2013, J CANCER RES CLIN, V139, P691, DOI 10.1007/s00432-013-1372-x; Villalonga P, 2006, GROWTH FACTORS, V24, P159, DOI 10.1080/08977190600560651; Wan LL, 2013, NAT MED, V19, P1450, DOI 10.1038/nm.3391; Wang FW, 2013, INT J BIOL SCI, V9, P1013, DOI 10.7150/ijbs.7191; Wei JH, 2014, BRIT J CANCER, V110, P1767, DOI 10.1038/bjc.2014.52; Yap KL, 2012, CANCER RES, V72, P4085, DOI 10.1158/0008-5472.CAN-12-0302; Yasumoto E, 2004, ANTICANCER RES, V24, P755; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zender L, 2008, CELL, V135, P852, DOI 10.1016/j.cell.2008.09.061; Zhou HY, 2010, INT J CANCER, V127, P2467, DOI 10.1002/ijc.25255; Zhu W, 2014, GASTROENTEROLOGY, V146	56	24	26	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2016	35	40					5304	5316		10.1038/onc.2016.71	http://dx.doi.org/10.1038/onc.2016.71			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DZ7NO	27041563				2022-12-17	WOS:000386053000009
J	Jiang, YY; Shang, L; Shi, ZZ; Zhang, TT; Ma, S; Lu, CC; Zhang, Y; Hao, JJ; Shi, C; Shi, F; Xu, X; Cai, Y; Jia, XM; Zhan, QM; Wang, MR				Jiang, Y-Y; Shang, L.; Shi, Z-Z; Zhang, T-T; Ma, S.; Lu, C-C; Zhang, Y.; Hao, J-J; Shi, C.; Shi, F.; Xu, X.; Cai, Y.; Jia, X-M; Zhan, Q-M; Wang, M-R			Microtubule-associated protein 4 is an important regulator of cell invasion/migration and a potential therapeutic target in esophageal squamous cell carcinoma	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; CANCER CELLS; BREAST-CANCER; TUMOR-GROWTH; FACTOR VEGF; P38 MAPK; ANGIOGENESIS; INVASION; PATHWAY; METASTASIS	Cell invasion and migration significantly contribute to tumor metastasis. Microtubule-associated protein 4 (MAP4) protein is one member of microtubule-associate proteins family. It is responsible for stabilization of microtubules by modulation of microtubule dynamics. However, there is little information about the involvement of MAP4 in human cancer. Here we show that MAP4 serves as a regulator of invasion and migration in esophageal squamous cancer cells. By activating the ERK-c-Jun-vascular endothelial growth factor A signaling pathway, MAP4 promotes cell invasion and migration in vitro, tumor growth and metastasis in mouse models. Immunohistochemical staining of operative tissues indicated that MAP4 expression was associated with tumor stage, lymph node metastasis and shorter survival of the patients with esophageal squamous cell carcinoma (ESCC). Multivariate Cox regression analysis showed that MAP4 is an independent prognostic indicator. In the serial sections of ESCC tissues, there was a positive correlation between MAP4 and vascular endothelial growth factor A expression. Notably, an intratumoral injection of MAP4-small interfering RNA (siRNA) remarkably inhibited the growth of the tumors that formed by the MAP4-expressing ESCC cells in nude mice, and a combination of MAP4-siRNA and Bevacizumab significantly enhanced the inhibition effect. Our data suggest that MAP4 is probably a useful prognostic biomarker and a potential therapeutic target for the disease.	[Jiang, Y-Y; Shang, L.; Shi, Z-Z; Zhang, T-T; Ma, S.; Zhang, Y.; Hao, J-J; Shi, C.; Shi, F.; Xu, X.; Cai, Y.; Zhan, Q-M; Wang, M-R] Peking Union Med Coll, Canc Inst Hosp, State Key Lab Mol Oncol, Panjiayuan South 17, Beijing 100021, Peoples R China; [Jiang, Y-Y; Shang, L.; Shi, Z-Z; Zhang, T-T; Ma, S.; Zhang, Y.; Hao, J-J; Shi, C.; Shi, F.; Xu, X.; Cai, Y.; Zhan, Q-M; Wang, M-R] Chinese Acad Med Sci, Panjiayuan South 17, Beijing 100021, Peoples R China; [Lu, C-C; Jia, X-M] Anhui Med Univ, Dept Histol & Embryol, Hefei, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Anhui Medical University	Wang, MR (corresponding author), Peking Union Med Coll, Canc Inst Hosp, State Key Lab Mol Oncol, Panjiayuan South 17, Beijing 100021, Peoples R China.; Wang, MR (corresponding author), Chinese Acad Med Sci, Panjiayuan South 17, Beijing 100021, Peoples R China.	wangmr2015@126.com		WANG, Ming-Rong/0000-0002-8767-9356	National Natural Science Foundation of China [81330052, 81321091]; National High-Tech R&D Program of China [2012AA02A503, 2012AA020206]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High-Tech R&D Program of China(National High Technology Research and Development Program of China)	This work was supported by National Natural Science Foundation of China (81330052 and 81321091) and National High-Tech R&D Program of China (2012AA02A503 and 2012AA020206).	Brock A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007048; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chang W, 2001, J CELL SCI, V114, P2879; Chen HX, 2001, ONCOLOGY-NY, V15, P1017; Darrington E, 2012, ASIAN J ANDROL, V14, P745, DOI 10.1038/aja.2011.197; Deng ZY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036739; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Feng YB, 2009, INT J CANCER, V124, P578, DOI 10.1002/ijc.23990; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Fruchon S, 2012, LEUKEMIA, V26, P795, DOI 10.1038/leu.2011.248; Galliher AJ, 2007, CANCER RES, V67, P3752, DOI 10.1158/0008-5472.CAN-06-3851; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; He Yu-Tong, 2005, Asian Pac J Cancer Prev, V6, P510; Honma N, 2006, LAB INVEST, V86, P687, DOI 10.1038/labinvest.3700427; Hu JY, 2010, CELL MOL LIFE SCI, V67, P321, DOI 10.1007/s00018-009-0187-z; Huang S, 2000, CANCER RES, V60, P5334; Jiang GZ, 2010, GUT, V59, P1535, DOI 10.1136/gut.2009.200105; Kappas NC, 2008, J CELL BIOL, V181, P847, DOI 10.1083/jcb.200709114; Kremer BE, 2005, MOL BIOL CELL, V16, P4648, DOI 10.1091/mbc.E05-03-0267; Lee TH, 2007, PLOS MED, V4, P1101, DOI 10.1371/journal.pmed.0040186; Lee WJ, 2008, TOXICOL APPL PHARM, V226, P178, DOI 10.1016/j.taap.2007.09.013; Luo ML, 2006, CANCER RES, V66, P11690, DOI 10.1158/0008-5472.CAN-06-1484; Monami G, 2006, CANCER RES, V66, P7103, DOI 10.1158/0008-5472.CAN-06-0633; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Nagy JA, 2002, J EXP MED, V196, P1497, DOI 10.1084/jem.20021244; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; OOKATA K, 1995, J CELL BIOL, V128, P849, DOI 10.1083/jcb.128.5.849; Ou Y, 2014, UROL ONCOL, V32, pe21, DOI DOI 10.1016/J.UR0L0NC.2013.06.017; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PARYSEK LM, 1984, J CELL BIOL, V99, P1309, DOI 10.1083/jcb.99.4.1309; Patel V, 2011, CANCER RES, V71, P7103, DOI 10.1158/0008-5472.CAN-10-3192; Permana S, 2005, CELL STRUCT FUNCT, V29, P147, DOI 10.1247/csf.29.147; Shibuya M, 2006, J BIOCHEM MOL BIOL, V39, P469; Tekedereli I, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.45; Weigand Melanie, 2005, Angiogenesis, V8, P197, DOI 10.1007/s10456-005-9010-0; Xu YB, 2013, EUR REV MED PHARMACO, V17, P2486; Zhang Y, 2008, INT J CANCER, V122, P260, DOI 10.1002/ijc.23104; Zhu B, 2012, HEPATO-GASTROENTEROL, V59, P785, DOI 10.5754/hge11427	40	24	25	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2016	35	37					4846	4856		10.1038/onc.2016.17	http://dx.doi.org/10.1038/onc.2016.17			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0LA	26876215				2022-12-17	WOS:000383330700003
J	Moles, A; Butterworth, JA; Sanchez, A; Hunter, JE; Leslie, J; Sellier, H; Tiniakos, D; Cockell, SJ; Mann, DA; Oakley, F; Perkins, ND				Moles, A.; Butterworth, J. A.; Sanchez, A.; Hunter, J. E.; Leslie, J.; Sellier, H.; Tiniakos, D.; Cockell, S. J.; Mann, D. A.; Oakley, F.; Perkins, N. D.			A RelA(p65) Thr505 phospho-site mutation reveals an important mechanism regulating NF-kappa B-dependent liver regeneration and cancer	ONCOGENE			English	Article							ARF TUMOR-SUPPRESSOR; HEPATOCELLULAR-CARCINOMA; GENE-EXPRESSION; CELL-FUNCTION; P65; PHOSPHORYLATION; TRANSACTIVATION; INFLAMMATION; REPRESSION; DISEASE	Post-translational modifications of nuclear factor (NF)-kappa B subunits provide a mechanism to differentially regulate their activity in response to the many stimuli that induce this pathway. However, the physiological significance of these modifications is largely unknown, and it remains unclear if these have a critical role in the normal and pathological functions of NF-kappa B in vivo. Among these, phosphorylation of the RelA(p65) Thr505 residue has been described as an important regulator of NF-kappa B activity in cell lines, but its physiological significance was not known. Therefore, to learn more about the role of this pathway in vivo, we generated a knockin mouse with a RelA T505A mutation. Unlike RelA knockout mice, the RelA T505A mice develop normally but exhibit aberrant hepatocyte proliferation following liver partial hepatectomy or damage resulting from carbon tetrachloride (CCl4) treatment. Consistent with these effects, RelA T505A mice exhibit earlier onset of cancer in the N-nitrosodiethylamine model of hepatocellular carcinoma. These data reveal a critical pathway controlling NF-kappa B function in the liver that acts to suppress the tumour-promoting activities of RelA.	[Moles, A.; Leslie, J.; Tiniakos, D.; Mann, D. A.; Oakley, F.] Newcastle Univ, Fac Med Sci, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England; [Butterworth, J. A.; Sanchez, A.; Hunter, J. E.; Sellier, H.; Perkins, N. D.] Newcastle Univ, Fac Med Sci, Inst Cell & Mol Biosci ICaMB, Newcastle Upon Tyne, Tyne & Wear, England; [Cockell, S. J.] Newcastle Univ, Fac Med Sci, Bioinformat Support Unit, Newcastle Upon Tyne, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Oakley, F; Perkins, ND (corresponding author), Newcastle Univ, Sch Med, Fac Med Sci, Inst Cell & Mol Biosci ICaMB, Catherine Cookson Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	fiona.oakley@ncl.ac.uk; neil.perkins@ncl.ac.uk	Moles, Ana/A-5889-2017; Tiniakos, Dina G/AAA-5708-2020; Sanchez, Ana M/K-4970-2016	Moles, Ana/0000-0002-3915-0060; Sanchez, Ana M/0000-0003-4293-4648; Mann, Derek/0000-0003-0950-243X; Oakley, Fiona/0000-0001-8692-1836; Cockell, Simon/0000-0002-6831-9806	Newcastle University; Wellcome Trust [094409]; Leukaemia Lymphoma Research Grant [11022]; Cancer Research UK Programme Grant [C1443/A12750]; Medical Research Council (MRC) [G0900535]; Welcome Trust Equipment Grant [087961]; MRC [G0900535, MR/K001949/1] Funding Source: UKRI; Cancer Research UK [22095, 12750] Funding Source: researchfish; Medical Research Council [MR/K001949/1, 1367534, G0900535] Funding Source: researchfish; National Centre for the Replacement [NC/K000748/1] Funding Source: researchfish	Newcastle University; Wellcome Trust(Wellcome TrustEuropean Commission); Leukaemia Lymphoma Research Grant; Cancer Research UK Programme Grant(Cancer Research UK); Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Welcome Trust Equipment Grant; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Centre for the Replacement	We would like to thank Adam Moore for technical assistance. We are also grateful to Sonia Rocha, Kirsteen Campbell, Niall Kenneth and all members of the NDP laboratory for helpful advice. AM is a Newcastle University Fellow funded by Newcastle University. JB and HS are funded by the Wellcome Trust Grant 094409, JEH is funded by Leukaemia Lymphoma Research Grant 11022, AS was funded by Cancer Research UK Programme Grant C1443/A12750. FO receives funding from Medical Research Council (MRC) Grant G0900535. The IVIS Spectrum system was funded by Welcome Trust Equipment Grant 087961.	Alexander J, 2013, J GASTROEN HEPATOL, V28, P848, DOI 10.1111/jgh.12116; Algul H, 2007, J CLIN INVEST, V117, P1490, DOI 10.1172/JCI29882; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Campbell KJ, 2006, CANCER RES, V66, P929, DOI 10.1158/0008-5472.CAN-05-2234; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Chariot A, 2009, TRENDS CELL BIOL, V19, P404, DOI 10.1016/j.tcb.2009.05.006; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; Dong J, 2008, GENE DEV, V22, P1159, DOI 10.1101/gad.1657408; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; Ebrahimkhani MR, 2011, NAT MED, V17, P1668, DOI 10.1038/nm.2490; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183; Heindryckx F, 2009, INT J EXP PATHOL, V90, P367, DOI 10.1111/j.1365-2613.2009.00656.x; Hong FX, 2006, BIOINFORMATICS, V22, P2825, DOI 10.1093/bioinformatics/btl476; Hunter JE, 2015, ONCOGENE; Kim HJ, 2006, CELL DEATH DIFFER, V13, P738, DOI 10.1038/sj.cdd.4401877; Luedde T, 2007, CANCER CELL, V11, P119, DOI 10.1016/j.ccr.2006.12.016; Mari M, 2008, GASTROENTEROLOGY, V134, P1507, DOI 10.1053/j.gastro.2008.01.073; Moreno R, 2010, NUCLEIC ACIDS RES, V38, P6029, DOI 10.1093/nar/gkq439; Msaki A, 2011, MOL BIOL CELL, V22, P3032, DOI 10.1091/mbc.E11-04-0280; O'Shea JM, 2008, BIOCHEM SOC T, V36, P603, DOI 10.1042/BST0360603; O'Shea JM, 2010, BIOCHEM J, V426, P345, DOI 10.1042/BJ20091630; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; Papa S, 2009, BIOL CHEM, V390, P965, DOI 10.1515/BC.2009.111; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Ringelhan M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046469; Robinson SM, 2010, CLIN SCI, V118, P691, DOI 10.1042/CS20090549; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608; Seki E, 2012, GASTROENTEROLOGY, V143, P307, DOI 10.1053/j.gastro.2012.06.004; Stein SJ, 2013, BLOOD, V121, P5015, DOI 10.1182/blood-2013-02-486142; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Wilson CL, 2015, NAT COMMUN, V6, DOI [10.1038/ncomms7818, 10.1038/ncomms9901]; Wu ZH, 2008, EMBO J, V27, P1963, DOI 10.1038/emboj.2008.127	39	24	27	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2016	35	35					4623	4632		10.1038/onc.2015.526	http://dx.doi.org/10.1038/onc.2015.526			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU6PE	26853469	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000382336300008
J	Zhou, J; Luo, J; Wu, K; Yun, EJ; Kapur, P; Pong, RC; Du, Y; Wang, B; Authement, C; Hernandez, E; Yang, J; Xiao, G; Cha, TL; Wu, HC; Wu, D; Margulis, V; Lotan, Y; Brugarolas, J; He, D; Hsieh, JT				Zhou, J.; Luo, J.; Wu, K.; Yun, E-j; Kapur, P.; Pong, R-C; Du, Y.; Wang, B.; Authement, C.; Hernandez, E.; Yang, J.; Xiao, G.; Cha, T-L; Wu, H-C; Wu, D.; Margulis, V.; Lotan, Y.; Brugarolas, J.; He, D.; Hsieh, J-T			Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies	ONCOGENE			English	Article							ABERRANT PROMOTER METHYLATION; PROTEIN HDAB2IP GENE; PROSTATE-CANCER; BREAST-CANCER; TUMOR-SUPPRESSOR; HEPATOCELLULAR-CARCINOMA; RENAL-CARCINOMA; DOWN-REGULATION; ACTIVATION; EXPRESSION	Targeted therapies using small-molecule inhibitors (SMIs) are commonly used in metastatic renal cell cancer (mRCC) patients; patients often develop drug resistance and eventually succumb to disease. Currently, understanding of mechanisms leading to SMIs resistance and any identifiable predictive marker(s) are still lacking. We discovered that DAB2IP, a novel Ras-GTPase-activating protein, was frequently epigenetically silenced in RCC, and DAB2IP loss was correlated with the overall survival of RCC patients. Loss of DAB2IP in RCC cells enhances their sensitivities to growth factor stimulation and resistances to SMI (such as mammalian target of rapamycin (mTOR) inhibitors). Mechanistically, loss of DAB2IP results in the activation of extracellular signal-regulated kinase/RSK1 and phosphoinositide-3 kinase/mTOR pathway, which synergizes the induction of hypoxia-inducible factor (HIF)-2 alpha expression. Consequently, elevated HIF-2 alpha suppresses p21/WAF1 expression that is associated with resistance to mTOR inhibitors. Thus combinatorial targeting both pathways resulted in a synergistic tumor inhibition. DAB2IP appears to be a new prognostic/predictive marker for mRCC patients, and its function provides a new insight into the molecular mechanisms of drug resistance to mTOR inhibitors, which also can be used to develop new strategies to overcome drug-resistant mRCC.	[Zhou, J.; Wu, K.; Du, Y.; Wang, B.; Wu, D.; He, D.] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 1, Dept Urol, 277 Yanta West Rd, Xian 710061, Peoples R China; [Zhou, J.; Yun, E-j; Pong, R-C; Authement, C.; Hernandez, E.; Margulis, V.; Lotan, Y.; Hsieh, J-T] Univ Texas Southwestern Med Ctr Dallas, Dept Urol, J8-134,5323 Harry Hines, Dallas, TX 75390 USA; [Luo, J.] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Urol, Guangzhou, Guangdong, Peoples R China; [Kapur, P.] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX USA; [Yang, J.; Xiao, G.] Univ Texas Southwestern Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA; [Cha, T-L] Triserv Gen Hosp, Div Urol, Dept Surg, Natl Def Med Ctr, Taipei, Taiwan; [Wu, H-C] China Med Univ Hosp, Dept Urol, Taichung, Taiwan; [Brugarolas, J.] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX USA	Xi'an Jiaotong University; University of Texas System; University of Texas Southwestern Medical Center Dallas; Sun Yat Sen University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; National Defense Medical Center; Tri-Service General Hospital; China Medical University Taiwan; China Medical University Hospital - Taiwan; University of Texas System; University of Texas Southwestern Medical Center Dallas	He, D (corresponding author), Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 1, Dept Urol, 277 Yanta West Rd, Xian 710061, Peoples R China.; Hsieh, JT (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Urol, J8-134,5323 Harry Hines, Dallas, TX 75390 USA.	hedl@mail.xjtu.edu.cn; jt.hsieh@utsouthwestern.edu			National Natural Science Foundation of China [NSFC 81202014]; Fundamental Research Funds for the Central Universities in China; Endowment for Research in Urologic Oncology	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities in China; Endowment for Research in Urologic Oncology	We thank John Santoyo for editorial assistance. This work was supported in part by Jean H and John T Walter, Jr, Endowment for Research in Urologic Oncology (to J-TH), the National Natural Science Foundation of China (NSFC 81202014 to KW) and the Fundamental Research Funds for the Central Universities in China (to KW).	Abukhdeir AM, 2008, P NATL ACAD SCI USA, V105, P288, DOI 10.1073/pnas.0710887105; [Anonymous], 2013, NATURE, V499, P43, DOI [10.1038/nature12222, DOI 10.1038/NATURE12222, DOI 10.1038/nature12222]; Atkins MB, 2004, J CLIN ONCOL, V22, P909, DOI 10.1200/JCO.2004.08.185; Calvisi DF, 2011, J HEPATOL, V54, P311, DOI 10.1016/j.jhep.2010.06.036; Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200; Chen H, 2003, J BIOL CHEM, V278, P3121, DOI 10.1074/jbc.M208230200; Chen H, 2002, GENOMICS, V79, P573, DOI 10.1006/geno.2002.6739; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; Cole JR, 2009, NUCLEIC ACIDS RES, V37, pD141, DOI 10.1093/nar/gkn879; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Das F, 2010, FEBS LETT, V584, P4268, DOI 10.1016/j.febslet.2010.09.010; Di Lorenzo G, 2009, EUR UROL, V56, P959, DOI 10.1016/j.eururo.2009.09.002; Dote H, 2004, CLIN CANCER RES, V10, P2082, DOI 10.1158/1078-0432.CCR-03-0236; Duggan D, 2007, JNCI-J NATL CANCER I, V99, P1836, DOI 10.1093/jnci/djm250; Escudier B, 2007, LANCET, V370, P2103, DOI 10.1016/S0140-6736(07)61904-7; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Huang D, 2010, CANCER RES, V70, P1063, DOI 10.1158/0008-5472.CAN-09-3965; Julien LA, 2010, MOL CELL BIOL, V30, P908, DOI 10.1128/MCB.00601-09; Kroeger N, 2014, EUR UROL, V65, P1086, DOI 10.1016/j.eururo.2013.07.031; Kucejova B, 2011, MOL CANCER RES, V9, P1255, DOI 10.1158/1541-7786.MCR-11-0302; Laptenko O, 2011, P NATL ACAD SCI USA, V108, P10385, DOI 10.1073/pnas.1105680108; Martinelli E, 2013, INT J CANCER, V133, P2089, DOI 10.1002/ijc.28236; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Omeir RL, 2011, COMPARATIVE MED, V61, P243; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Pena-LlopiS S, 2012, NAT GENET, V44, P751, DOI 10.1038/ng.2323; Qiu GH, 2007, J HEPATOL, V46, P655, DOI 10.1016/j.jhep.2006.11.012; Rini BI, 2009, LANCET ONCOL, V10, P992, DOI 10.1016/S1470-2045(09)70240-2; Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200; RYAN MJ, 1994, KIDNEY INT, V45, P48, DOI 10.1038/ki.1994.6; Sato Y, 2013, NAT GENET, V45, P860, DOI 10.1038/ng.2699; Serra V, 2011, ONCOGENE, V30, P2547, DOI 10.1038/onc.2010.626; Serra V, 2013, J CLIN INVEST, V123, P2551, DOI 10.1172/JCI66343; Shahbazian D, 2006, EMBO J, V25, P2781, DOI 10.1038/sj.emboj.7601166; Shinojima T, 2007, CARCINOGENESIS, V28, P529, DOI 10.1093/carcin/bgl143; Smits M, 2012, CLIN CANCER RES, V18, P4048, DOI 10.1158/1078-0432.CCR-12-0399; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Wang Z, 2002, J BIOL CHEM, V277, P12622, DOI 10.1074/jbc.M110568200; Wu KJ, 2013, CLIN CANCER RES, V19, P4740, DOI 10.1158/1078-0432.CCR-13-0954; Xie DX, 2009, P NATL ACAD SCI USA, V106, P19878, DOI 10.1073/pnas.0908458106; Yano M, 2005, INT J CANCER, V113, P59, DOI 10.1002/ijc.20531; Zhang HF, 2004, J BIOL CHEM, V279, P44955, DOI 10.1074/jbc.M407617200; Zhang XJ, 2012, J GASTROEN HEPATOL, V27, P1117, DOI 10.1111/j.1440-1746.2011.07049.x	50	24	24	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2016	35	35					4663	4674		10.1038/onc.2016.4	http://dx.doi.org/10.1038/onc.2016.4			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU6PE	26876207				2022-12-17	WOS:000382336300012
J	Wang, Y; Xu, J; Gao, G; Li, J; Huang, H; Jin, H; Zhu, J; Che, X; Huang, C				Wang, Y.; Xu, J.; Gao, G.; Li, J.; Huang, H.; Jin, H.; Zhu, J.; Che, X.; Huang, C.			Tumor-suppressor NF kappa B2 p100 interacts with ERK2 and stabilizes PTEN mRNA via inhibition of miR-494	ONCOGENE			English	Article							KAPPA-B PATHWAY; MAP KINASE; CELL PROLIFERATION; SIGNALING PATHWAY; DOWN-REGULATION; PEA-15 REVEALS; PROTEIN; CANCER; EXPRESSION; APOPTOSIS	Emerging evidence from The Cancer Genome Atlas has revealed that nuclear factor kappa B2 (nf kappa b2) gene encoding p100 is genetically deleted or mutated in human cancers, implicating NF kappa B2 as a potential tumor suppressor. However, the molecular mechanism underlying the antitumorigenic action of p100 remains poorly understood. Here we report that p100 inhibits cancer cell anchorageindependent growth, a hallmark of cellular malignancy, by stabilizing the tumor-suppressor phosphatase and tensin homolog (PTEN) mRNA via a mechanism that is independent of p100' s inhibitory role in NF kappa B activation. We further demonstrate that the regulatory effect of p100 on PTEN expression is mediated by its downregulation of miR-494 as a result of the inactivation of extracellular signal-regulated kinase 2 (ERK2), in turn leading to inhibition of c-Jun/ activator protein-1-dependent transcriptional activity. Furthermore, we identify that p100 specifically interacts with non-phosphorylated ERK2 and prevents ERK2 phosphorylation and nuclear translocation. Moreover, the death domain at C-terminal of p100 is identified as being crucial and sufficient for its interaction with ERK2. Taken together, our findings provide novel mechanistic insights into the understanding of the tumor-suppressive role for NF kappa B2 p100.	[Wang, Y.; Xu, J.; Gao, G.; Li, J.; Huang, H.; Jin, H.; Zhu, J.; Che, X.; Huang, C.] NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA	New York University	Huang, C (corresponding author), NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.	chuanshu.huang@nyumc.org		Huang, Chuanshu/0000-0003-4133-5096; Wang, Yulei/0000-0002-6495-3391	 [NIH/NCI CA165980];  [CA177665];  [CA112557];  [NIH/NIEHS ES000260]; NATIONAL CANCER INSTITUTE [P01CA165980, R01CA177665, R01CA112557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000260] Funding Source: NIH RePORTER	; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We greatly appreciate Dr Han-Fei Ding for his generous gifts about constructs expressing p100 and various deletion mutants of p100. We also appreciate Dr Shao-Cong Sun from the Department of Immunology, University of Texas MD Anderson Cancer Center for the gift of constructs expressing p100Ser866/870Ala or p100 Delta DD. This work was supported partially by grants from NIH/NCI CA165980, CA177665 and CA112557, as well as NIH/NIEHS ES000260.	Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556; Arabi A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1975; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Basak S, 2007, CELL, V128, P369, DOI 10.1016/j.cell.2006.12.033; Busino L, 2012, NAT CELL BIOL, V14, P375, DOI 10.1038/ncb2463; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Chen K, 2013, AM J HUM GENET, V93, P812, DOI 10.1016/j.ajhg.2013.09.009; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; Dioletis E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070095; Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6; Fukushima H, 2012, CELL REP, V1, P434, DOI 10.1016/j.celrep.2012.04.002; Fusco AJ, 2008, J BIOL CHEM, V283, P12324, DOI 10.1074/jbc.M707898200; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hettinger K, 2007, CELL DEATH DIFFER, V14, P218, DOI 10.1038/sj.cdd.4401946; Hill JM, 2002, EMBO J, V21, P6494, DOI 10.1093/emboj/cdf641; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Kim WK, 2011, CLIN CANCER RES, V17, P7584, DOI 10.1158/1078-0432.CCR-11-0166; Li J, 1998, CANCER RES, V58, P5667; Li JL, 2004, HYBRIDOMA HYBRIDOM, V23, P1, DOI 10.1089/153685904322771962; Li JX, 2004, J CELL BIOL, V165, P77, DOI 10.1083/jcb.200401004; Liu LH, 2010, LIFE SCI, V86, P192, DOI 10.1016/j.lfs.2009.12.002; Mace PD, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2687; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Montagut C, 2009, CANCER LETT, V283, P125, DOI 10.1016/j.canlet.2009.01.022; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Romagnoli M, 2012, CANCER RES, V72, P6268, DOI 10.1158/0008-5472.CAN-12-2270; Romano G, 2012, P NATL ACAD SCI USA, V109, P16570, DOI 10.1073/pnas.1207917109; Shaulian E, 2010, CELL SIGNAL, V22, P894, DOI 10.1016/j.cellsig.2009.12.008; Shi YJ, 2012, J CELL SCI, V125, P4687, DOI 10.1242/jcs.093765; Skeen JE, 2006, CANCER CELL, V10, P269, DOI 10.1016/j.ccr.2006.08.022; Song L, 2007, MOL CELL BIOL, V27, P2713, DOI 10.1128/MCB.00657-06; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Sun SC, 2012, IMMUNOL REV, V246, P125, DOI 10.1111/j.1600-065X.2011.01088.x; Vasudevan KM, 2004, MOL CELL BIOL, V24, P1007, DOI 10.1128/MCB.24.3.1007-1021.2004; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Wang XH, 2010, CIRCULATION, V122, P1308, DOI 10.1161/CIRCULATIONAHA.110.964684; Wang YQ, 2002, NAT CELL BIOL, V4, P888, DOI 10.1038/ncb872; Wang Z, 2008, J BIOL CHEM, V283, P10698, DOI 10.1074/jbc.M800806200; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Xia DR, 2007, J BIOL CHEM, V282, P3507, DOI 10.1074/jbc.M610141200; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yilmaz ZB, 2014, CELL REP, V9, P1756, DOI 10.1016/j.celrep.2014.11.014; Yu HS, 2013, INT J MOL SCI, V14, P13329, DOI 10.3390/ijms140713329; Yu Y, 2014, ONCOGENE, V33, P996, DOI 10.1038/onc.2013.8; Zhang DY, 2014, J CELL SCI, V127, P2920, DOI 10.1242/jcs.148130; Zhang RW, 2014, J BIOL CHEM, V289, P6394, DOI 10.1074/jbc.M113.513960	50	24	25	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4080	4090		10.1038/onc.2015.470	http://dx.doi.org/10.1038/onc.2015.470			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26686085	Green Accepted			2022-12-17	WOS:000381020900006
J	Han, XR; Zha, Z; Yuan, HX; Feng, X; Xia, YK; Lei, QY; Guan, KL; Xiong, Y				Han, X-R; Zha, Z.; Yuan, H-X; Feng, X.; Xia, Y-K; Lei, Q-Y; Guan, K-L; Xiong, Y.			KDM2B/FBXL10 targets c-Fos for ubiquitylation and degradation in response to mitogenic stimulation	ONCOGENE			English	Article							UBIQUITIN-LIGASE COMPLEX; F-BOX; CPG ISLANDS; CELL; TRANSCRIPTION; PHOSPHORYLATION; DOMAIN; PROTEINS; KINASE; FAMILY	KDM2B (also known as FBXL10) controls stem cell self-renewal, somatic cell reprogramming and senescence, and tumorigenesis. KDM2B contains multiple functional domains, including a JmjC domain that catalyzes H3K36 demethylation and a CxxC zinc-finger that recognizes CpG islands and recruits the polycomb repressive complex 1. Here, we report that KDM2B, via its F-box domain, functions as a subunit of the CUL1-RING ubiquitin ligase (CRL1/SCFKDM2B) complex. KDM2B targets c-Fos for polyubiquitylation and regulates c-Fos protein levels. Unlike the phosphorylation of other SCF (SKP1-CUL1-F-box)/CRL1 substrates that promotes substrates binding to F-box, epidermal growth factor (EGF)-induced c-Fos S374 phosphorylation dissociates c-Fos from KDM2B and stabilizes c-Fos protein. Non-phosphorylatable and phosphomimetic mutations at S374 result in c-Fos protein which cannot be induced by EGF or accumulates constitutively and lead to decreased or increased cell proliferation, respectively. Multiple tumor-derived KDM2B mutations impaired the function of KDM2B to target c-Fos degradation and to suppress cell proliferation. These results reveal a novel function of KDM2B in the negative regulation of cell proliferation by assembling an E3 ligase to targeting c-Fos protein degradation that is antagonized by mitogenic stimulations.	[Han, X-R; Zha, Z.; Yuan, H-X; Feng, X.; Xia, Y-K; Lei, Q-Y; Guan, K-L; Xiong, Y.] Fudan Univ, Minist Educ, Key Lab Mol Med, Shanghai, Peoples R China; [Han, X-R; Zha, Z.; Yuan, H-X; Feng, X.; Xia, Y-K; Guan, K-L; Xiong, Y.] Fudan Univ, Inst Biomed Sci, Mol & Cell Biol Lab, Shanghai, Peoples R China; [Han, X-R; Zha, Z.; Feng, X.; Xia, Y-K; Xiong, Y.] Fudan Univ, Sch Life Sci, Shanghai, Peoples R China; [Lei, Q-Y; Guan, K-L] Fudan Univ, Shanghai Med Coll, Dept Biochem & Mol Biol, Shanghai, Peoples R China; [Guan, K-L] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Guan, K-L] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA; [Xiong, Y.] Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC USA	Fudan University; Fudan University; Fudan University; Fudan University; University of California System; University of California San Diego; University of California System; University of California San Diego	Lei, QY; Guan, KL; Xiong, Y (corresponding author), Univ N Carolina, Lineberger Canc Ctr 22 012, Campus Box 7295, Chapel Hill, NC 27599 USA.	qlei@fudan.edu.cn; kuguan@ucsd.edu; yxiong@email.unc.edu	Lei, Qun-Ying/J-1390-2017; Xia, Yukun/HGT-9369-2022; Guan, Kun-Liang/ADK-7088-2022	Lei, Qun-Ying/0000-0002-8547-8518; Xia, Yukun/0000-0002-8728-9745; Han, Xiaoran/0000-0002-2435-4191	Chinese Ministry of Sciences and Technology 973 [2015CB910401]; NSFC [81225016, 81430057]; Shanghai Key basic research program [12JC1401100]; Shanghai Outstanding Academic Leader [13XD1400600]; Youth Science and Technology Leading Talent by MOST; NIH [EY022611, CA132809, GM067113]; NATIONAL CANCER INSTITUTE [R01CA132809, R01CA068377] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY022611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067113] Funding Source: NIH RePORTER	Chinese Ministry of Sciences and Technology 973; NSFC(National Natural Science Foundation of China (NSFC)); Shanghai Key basic research program; Shanghai Outstanding Academic Leader; Youth Science and Technology Leading Talent by MOST; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the members of the Fudan MCB laboratory for discussions and support throughout this study and Michele Pagano of NYU for providing plasmids expressing full-length human KDM2B cDNA. This work was supported by Chinese Ministry of Sciences and Technology 973 (Grant No. 2015CB910401), NSFC (Grant No. 81225016, 81430057), Shanghai Key basic research program (12JC1401100), Shanghai Outstanding Academic Leader (Grant No. 13XD1400600) and the Youth Science and Technology Leading Talent by MOST (to Q-YL), NIH Grants EY022611 and CA132809 (to K-LG) and GM067113 (to YX).	Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bakiri L, 2011, ONCOGENE, V30, P1506, DOI 10.1038/onc.2010.542; Bartke T, 2010, CELL, V143, P470, DOI 10.1016/j.cell.2010.10.012; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Farcas AM, 2012, ELIFE, V1, DOI 10.7554/eLife.00205; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Furukawa Manabu, 2005, V301, P37; Gearhart MD, 2006, MOL CELL BIOL, V26, P6880, DOI 10.1128/MCB.00630-06; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Gilley R, 2009, CELL SIGNAL, V21, P969, DOI 10.1016/j.cellsig.2009.02.006; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; He J, 2008, NAT STRUCT MOL BIOL, V15, P1169, DOI 10.1038/nsmb.1499; He J, 2013, NAT CELL BIOL, V15, P373, DOI 10.1038/ncb2702; He J, 2011, BLOOD, V117, P3869, DOI 10.1182/blood-2010-10-312736; Kottakis F, 2014, CANCER RES, V74, P3935, DOI 10.1158/0008-5472.CAN-13-2733; Koyama-Nasu R, 2007, NAT CELL BIOL, V9, P1074, DOI 10.1038/ncb1628; Liang GY, 2012, NAT CELL BIOL, V14, P457, DOI 10.1038/ncb2483; Maher VM, 1981, NATL CANCER I MONOGR, V58, P217; Nakakuki T, 2010, CELL, V141, P884, DOI 10.1016/j.cell.2010.03.054; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Pfau R, 2008, P NATL ACAD SCI USA, V105, P1907, DOI 10.1073/pnas.0711865105; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; Sasaki T, 2006, MOL CELL, V24, P63, DOI 10.1016/j.molcel.2006.08.005; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Tzatsos A, 2013, J CLIN INVEST, V123, P727, DOI 10.1172/JCI64535; Wu XD, 2013, MOL CELL, V49, P1134, DOI 10.1016/j.molcel.2013.01.016; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	35	24	25	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	32					4179	4190		10.1038/onc.2015.482	http://dx.doi.org/10.1038/onc.2015.482			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3YY	26725323	Green Accepted, Green Submitted			2022-12-17	WOS:000382149800003
J	Heuser, S; Hufbauer, M; Steiger, J; Marshall, J; Sterner-Kock, A; Mauch, C; Zigrino, P; Akgul, B				Heuser, S.; Hufbauer, M.; Steiger, J.; Marshall, J.; Sterner-Kock, A.; Mauch, C.; Zigrino, P.; Akguel, B.			The fibronectin/alpha 3 beta 1 integrin axis serves as molecular basis for keratinocyte invasion induced by beta HPV	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN-PAPILLOMAVIRUS TYPE-8; SQUAMOUS-CELL CARCINOMA; SKIN TUMOR-FORMATION; TRANSGENIC MICE; E-CADHERIN; UP-REGULATION; STEM-CELLS; ORGANOTYPIC CULTURES; EARLY GENES	Organ-transplant-recipients exhibit cancerization of the skin from which multiple human papillomavirus (HPV)-positive squamous cell carcinomas (SCCs) arise. However, the molecular basis for HPV-induced invasion of skin keratinocytes is not known. We generated a transgenic mouse model expressing the E7 oncoprotein of HPV8 in the murine epidermis under the control of the keratin-14 promoter and showed that E7 is carcinogenic in mice. We further showed that both, the E7-expressing keratinocyte and mesenchymal components of the extracellular matrix as critical in eliciting the invasive behavior. E7 expression in basal keratinocytes, grown on fibronectin, led to epithelial-mesenchymal transition mediated by a cadherin switch. E7-positive keratinocytes displayed enhanced EDA-fibronectin expression and secretion and stimulated dermal fibroblasts to express EDA-fibronectin. Deposition of fibronectin was also detected in the peritumoral stroma of HPV8-positive skin SCC. When grown on fibronectin, E7-positive keratinocytes, in particular stem cell-like cells, exhibited increased cell surface levels of the alpha 3-integrin chain. Functional blocking confirmed alpha 3 as a critical molecule sufficient to induce E7-mediated invasion. This mechanistic link is further supported by expression of an E7-mutant, impaired in targeting alpha 3 to the cell surface. These findings highlight the importance of epithelial-extracellular matrix interaction required for keratinocyte invasion and provide further mechanistic evidence for a role of HPV in skin carcinogenesis.	[Heuser, S.; Hufbauer, M.; Akguel, B.] Univ Cologne, Inst Virol, Furst Puckler Str 56, D-50935 Cologne, Germany; [Steiger, J.; Mauch, C.; Zigrino, P.] Univ Cologne, Dept Dermatol & Venerol, Cologne, Germany; [Marshall, J.] Queen Mary Univ London, Barts Canc Inst, Ctr Tumour Biol, John Vane Sci Ctr, London, England; [Sterner-Kock, A.] Univ Cologne, Univ Hosp, Ctr Med Expt, Cologne, Germany	University of Cologne; University of Cologne; University of London; Queen Mary University London; University of Cologne	Akgul, B (corresponding author), Univ Cologne, Inst Virol, Furst Puckler Str 56, D-50935 Cologne, Germany.	baki.akguel@uk-koeln.de	Akgül, Baki/H-5629-2019; Hufbauer, Martin/AAZ-5473-2020	Akgül, Baki/0000-0002-6564-9412; Zigrino, Paola/0000-0002-7470-0064	Wilhelm-Sander-Stiftung, Germany [2012.105.1, 2012.105.2]; Deutsche Forschungsgemeinschaft [SFB 829]; Deutsche Krebshilfe [111087]	Wilhelm-Sander-Stiftung, Germany; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe)	We thank Herbert Pfister for helpful discussions, Esther Mahabir-Brenner (Animal Facility, Centre of Molecular Medicine Cologne (CMMC)) for generation of the K14-HPV8-E7 mice, John Doorbar for providing HPV8-E4 antibodies and Manuel Koch for collagen IV antibodies. This study was supported by the Wilhelm-Sander-Stiftung, Germany (grant no. 2012.105.1; 2012.105.2) to BA and by the Deutsche Forschungsgemeinschaft through SFB 829 (B4) to CM. MH was supported by the Deutsche Krebshilfe (no. 111087), which was granted to BA.	Aggarwal A, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-459; Akgul B, 2007, EXP DERMATOL, V16, P590, DOI 10.1111/j.1600-0625.2007.00569.x; Akgul B, 2011, J GEN VIROL, V92, P395, DOI 10.1099/vir.0.025064-0; Akgul B, 2006, J PATHOL, V208, P165, DOI 10.1002/path.1893; Akgul B, 2005, CANCER RES, V65, P2216, DOI 10.1158/0008-5472.CAN-04-1952; Benton G, 2011, INT J CANCER, V128, P1751, DOI 10.1002/ijc.25781; Boxman ILA, 2001, J INVEST DERMATOL, V117, P1397, DOI 10.1046/j.0022-202x.2001.01602.x; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chen SH, 2010, ANTICANCER RES, V30, P4177; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; DiPersio CM, 1997, J CELL BIOL, V137, P729, DOI 10.1083/jcb.137.3.729; Euvrard S, 2012, NEW ENGL J MED, V367, P329, DOI 10.1056/NEJMoa1204166; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Hellner K, 2009, VIROLOGY, V391, P57, DOI 10.1016/j.virol.2009.05.036; Howley PM, 2015, VIROLOGY, V479, P290, DOI 10.1016/j.virol.2015.02.004; Hufbauer M, 2010, VIROLOGY, V403, P128, DOI 10.1016/j.virol.2010.04.013; Hufbauer M, 2013, J VIROL, V87, P12158, DOI 10.1128/JVI.01510-13; Hufbauer M, 2011, J DERMATOL SCI, V64, P7, DOI 10.1016/j.jdermsci.2011.06.008; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; Jones SM, 2006, NAT REV CANCER, V6, P175, DOI 10.1038/nrc1817; Kurtz KA, 2006, OTOLARYNG HEAD NECK, V134, P142, DOI 10.1016/j.otohns.2005.08.026; Lazic D, 2011, J DERMATOL SCI, V62, P84, DOI 10.1016/j.jdermsci.2011.02.006; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Leverrier S, 2007, APOPTOSIS, V12, P549, DOI 10.1007/s10495-006-0004-1; Lunt SJ, 2009, CLIN EXP METASTAS, V26, P19, DOI 10.1007/s10585-008-9182-2; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marcuzzi GP, 2014, MED MICROBIOL IMMUN, V203, P155, DOI 10.1007/s00430-014-0327-4; Marcuzzi GP, 2009, J GEN VIROL, V90, P2855, DOI 10.1099/vir.0.012872-0; Margadant C, 2010, FASEB J, V24, P4133, DOI 10.1096/fj.09-151449; Margulis A, 2006, INT J CANCER, V118, P821, DOI 10.1002/ijc.21409; Margulis A, 2005, CANCER RES, V65, P1783, DOI 10.1158/0008-5472.CAN-04-3399; Missan DS, 2014, J INVEST DERMATOL, V134, P2418, DOI 10.1038/jid.2014.166; Missan DS, 2012, CRIT REV EUKAR GENE, V22, P309, DOI 10.1615/CritRevEukarGeneExpr.v22.i4.50; Nystrom ML, 2005, J PATHOL, V205, P468, DOI 10.1002/path.1716; O'Shaughnessy RFL, 2007, CANCER RES, V67, P8207, DOI 10.1158/0008-5472.CAN-07-0755; Owens DM, 2003, NAT REV CANCER, V3, P444, DOI 10.1038/nrc1096; Peh WL, 2005, METH MOLEC MED, V119, P49; Pfefferle R, 2008, J INVEST DERMATOL, V128, P2310, DOI 10.1038/jid.2008.73; Quint KD, 2015, J PATHOL, V235, P342, DOI 10.1002/path.4425; Sachs N, 2012, P NATL ACAD SCI USA, V109, P21468, DOI 10.1073/pnas.1204614110; Schaper ID, 2005, CANCER RES, V65, P1394, DOI 10.1158/0008-5472.CAN-04-3263; Schmidt DS, 2004, EXP CELL RES, V297, P329, DOI 10.1016/j.yexcr.2004.02.023; Sun XJ, 2014, CARCINOGENESIS, V35, P184, DOI 10.1093/carcin/bgt276; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; van Roy F, 2014, NAT REV CANCER, V14, P121, DOI 10.1038/nrc3647; Vasioukhin V, 1999, P NATL ACAD SCI USA, V96, P8551, DOI 10.1073/pnas.96.15.8551; Vinzon SE, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003924; Westphal K, 2009, CELL ONCOL, V31, P213, DOI 10.3233/CLO-2009-0476; Zhang WT, 2006, J CELL SCI, V119, P283, DOI 10.1242/jcs.02738	49	24	24	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	34					4529	4539		10.1038/onc.2015.512	http://dx.doi.org/10.1038/onc.2015.512			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU4AC	26804167				2022-12-17	WOS:000382153100010
J	Yeganeh, M; Gui, Y; Kandhi, R; Bobbala, D; Tobelaim, WS; Saucier, C; Yoshimura, A; Ferbeyre, G; Ramanathan, S; Ilangumaran, S				Yeganeh, M.; Gui, Y.; Kandhi, R.; Bobbala, D.; Tobelaim, W-S; Saucier, C.; Yoshimura, A.; Ferbeyre, G.; Ramanathan, S.; Ilangumaran, S.			Suppressor of cytokine signaling 1-dependent regulation of the expression and oncogenic functions of p21(CIP1/WAF1) in the liver	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; SOCS PROTEINS; EGF RECEPTOR; P21; REGENERATION; CANCER; HEPATOCARCINOGENESIS; PHOSPHORYLATION; P21(WAF1/CIP1); PROLIFERATION	The SOCS1 gene coding for suppressor of cytokine signaling 1 is frequently repressed in hepatocellular carcinoma (HCC), and hence SOCS1 is considered a tumor suppressor in the liver. However, the tumor-suppressor mechanisms of SOCS1 are not yet well understood. SOCS1 is known to inhibit pro-inflammatory cytokine production and signaling and to promote activation of the p53 tumor suppressor. However, we observed that SOCS1-deficient mice developed numerous and large liver tumor nodules following treatment with the hepatocarcinogen diethylnitrosamine (DEN) without showing increased interleukin-6 production or activation of p53. On the other hand, the livers of DEN-treated Socs1-null mice showed elevated levels of p21(CIP1/WAF1) protein (p21). Even though p21 generally functions as a tumor suppressor, paradoxically many cancers, including HCC, are known to express elevated levels of p21 that correlate with poor prognosis. We observed elevated p21 expression also in the regenerating livers of SOCS1-deficient mice and in cisplatin-treated Socs1-null hepatocytes, wherein the p21 protein showed increased stability. We show that SOCS1 interacts with p21 and promotes its ubiquitination and proteasomal degradation. Besides, the DEN-treated livers of Socs1-null mice showed increased nuclear and cytosolic p21 staining, and the latter was associated with growth factor-induced, phosphatidylinositol 3-kinase-dependent phosphorylation of p21 in SOCS1-deficient hepatocytes. Cytosolic p21 is often associated with malignancy and chemo-resistance in many cancers. Accordingly, SOCS1-deficient hepatocytes showed increased resistance to apoptosis that was reversed by shRNA-mediated p21 knockdown. In the regenerating livers of Socs1-null mice, increased p21 expression coincided with elevated cyclinD levels. Correspondingly, SOCS1-deficient hepatocytes showed increased proliferation to growth factor stimulation that was reversed by p21 knockdown. Overall, our findings indicate that the tumor-suppressor functions of SOCS1 in the liver could be mediated, at least partly, via regulation of the expression, stability and subcellular distribution of p21 and its paradoxical oncogenic functions, namely, resistance to apoptosis and increased proliferation.	[Yeganeh, M.; Gui, Y.; Kandhi, R.; Bobbala, D.; Ramanathan, S.; Ilangumaran, S.] Univ Sherbrooke, Fac Med & Hlth Sci, Dept Pediat, Div Immunol, 3001 North 12th Ave, Sherbrooke, PQ J1H 5N4, Canada; [Tobelaim, W-S; Saucier, C.] Univ Sherbrooke, Fac Med & Hlth Sci, Dept Anat & Cell Biol, Sherbrooke, PQ, Canada; [Yoshimura, A.] Keio Univ, Sch Med, Dept Microbiol & Immunol, Tokyo, Japan; [Ferbeyre, G.] Univ Montreal, Dept Biochem, Montreal, PQ, Canada	University of Sherbrooke; University of Sherbrooke; Keio University; Universite de Montreal	Ilangumaran, S (corresponding author), Univ Sherbrooke, Fac Med & Hlth Sci, Dept Pediat, Div Immunol, 3001 North 12th Ave, Sherbrooke, PQ J1H 5N4, Canada.	Subburaj.Ilangumaran@Usherbrooke.ca	Saucier, Caroline/Q-9250-2019; Yoshimura, Akihiko/K-5515-2013	Saucier, Caroline/0000-0001-7678-9886; Ilangumaran, Subburaj/0000-0002-7563-576X	FRQNT graduate scholarship; Canadian Liver Foundation; Faculte de medecine et des sciences de la sante, Universite de Sherbrooke; FRQS; Canadian Institutes of Heath research [MOP-84234]; Cancer Research Society, Montreal, Canada [PIN: 17009]	FRQNT graduate scholarship; Canadian Liver Foundation; Faculte de medecine et des sciences de la sante, Universite de Sherbrooke; FRQS; Canadian Institutes of Heath research(Canadian Institutes of Health Research (CIHR)); Cancer Research Society, Montreal, Canada	MY was a recipient of FRQNT graduate scholarship. YG was supported by a graduate scholarship from the Canadian Liver Foundation. RK is supported by a graduate scholarship from the Faculte de medecine et des sciences de la sante, Universite de Sherbrooke. DB is a recipient of a postdoctoral fellowship from FRQS. CR-CHUS is an FRQS-funded research center. This work was supported by operating grants from the Canadian Institutes of Heath research (to SI, MOP-84234) and Cancer Research Society, Montreal, Canada (to SI and GF, PIN: 17009).	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Anderson P, 2010, NAT REV IMMUNOL, V10, P24, DOI 10.1038/nri2685; Boylan JM, 2005, BIOCHEM BIOPH RES CO, V330, P722, DOI 10.1016/j.bbrc.2005.03.042; Budhu A, 2006, J LEUKOCYTE BIOL, V80, P1197, DOI 10.1189/jlb.0506297; Buitrago-Molina LE, 2013, HEPATOLOGY, V58, P1143, DOI 10.1002/hep.26412; Calabrese V, 2009, MOL CELL, V36, P754, DOI 10.1016/j.molcel.2009.09.044; Chen WM, 2009, MOL CELL, V34, P663, DOI 10.1016/j.molcel.2009.04.029; Dash BC, 2005, MOL CELL BIOL, V25, P3364, DOI 10.1128/MCB.25.8.3364-3387.2005; De la Cueva E, 2006, ONCOGENE, V25, P4128, DOI 10.1038/sj.onc.1209432; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gartel AL, 2006, MOL CANCER THER, V5, P1385, DOI 10.1158/1535-7163.MCT-06-0163; Gartel AL, 2009, BIOFACTORS, V35, P161, DOI 10.1002/biof.26; Gui Y, 2015, ONCOGENE, V34, P5718, DOI 10.1038/onc.2015.20; Gui YR, 2011, J HEPATOL, V55, P1300, DOI 10.1016/j.jhep.2011.03.027; Hui LJ, 2008, J CLIN INVEST, V118, P3943, DOI 10.1172/JCI37156; Iwahori K, 2013, INT J CANCER, V132, P459, DOI 10.1002/ijc.27611; Kazi JU, 2014, CELL MOL LIFE SCI, V71, P3297, DOI 10.1007/s00018-014-1619-y; Kong XN, 2012, HEPATOLOGY, V56, P1150, DOI 10.1002/hep.25744; Lachenmayer A, 2010, DIGEST LIVER DIS, V42, pS264, DOI 10.1016/S1590-8658(10)60515-4; Marhenke S, 2014, GUT, V63, P1501, DOI 10.1136/gutjnl-2013-304829; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Matsuda M, 2005, LAB INVEST, V85, P655, DOI 10.1038/labinvest.3700257; Natarajan A, 2007, P NATL ACAD SCI USA, V104, P17081, DOI 10.1073/pnas.0704126104; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Oh J, 2009, ONCOGENE, V28, P3145, DOI 10.1038/onc.2009.169; Okumura F, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00010; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Rickheim DG, 2002, HEPATOLOGY, V36, P30, DOI 10.1053/jhep.2002.33996; Schneller D, 2011, HEPATOLOGY, V54, P164, DOI 10.1002/hep.24329; Seki E, 2008, J HEPATOL, V48, P237, DOI 10.1016/j.jhep.2007.08.020; Sheng G, 2006, GASTROENTEROLOGY, V131, P153, DOI 10.1053/j.gastro.2006.05.007; Skarpen E, 2005, J CELL PHYSIOL, V202, P707, DOI 10.1002/jcp.20171; Starostina NG, 2012, TRENDS CELL BIOL, V22, P33, DOI 10.1016/j.tcb.2011.10.004; Tanaka K, 2008, J IMMUNOL, V180, P3746, DOI 10.4049/jimmunol.180.6.3746; Taub R, 2004, NAT REV MOL CELL BIO, V5, P836, DOI 10.1038/nrm1489; Velimezi G, 2013, NAT CELL BIOL, V15, P967, DOI 10.1038/ncb2795; Warfel NA, 2013, CURR OPIN ONCOL, V25, P52, DOI 10.1097/CCO.0b013e32835b639e; Wierod L, 2008, ONCOGENE, V27, P2763, DOI 10.1038/sj.onc.1210937; Woelk T, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-11; Yoshida T, 2004, J EXP MED, V199, P1701, DOI 10.1084/jem.20031675; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Yoshimura A, 2007, NAT REV IMMUNOL, V7, P454, DOI 10.1038/nri2093; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	46	24	24	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	32					4200	4211		10.1038/onc.2015.485	http://dx.doi.org/10.1038/onc.2015.485			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3YY	26725321				2022-12-17	WOS:000382149800005
J	Kanu, N; Zhang, T; Burrell, RA; Chakraborty, A; Cronshaw, J; DaCosta, C; Gronroos, E; Pemberton, HN; Anderton, E; Gonzalez, L; Sabbioneda, S; Ulrich, HD; Swanton, C; Behrens, A				Kanu, N.; Zhang, T.; Burrell, R. A.; Chakraborty, A.; Cronshaw, J.; DaCosta, C.; Gronroos, E.; Pemberton, H. N.; Anderton, E.; Gonzalez, L.; Sabbioneda, S.; Ulrich, H. D.; Swanton, C.; Behrens, A.			RAD18, WRNIP1 and ATMIN promote ATM signalling in response to replication stress	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; CELL NUCLEAR ANTIGEN; DNA-DAMAGE; MONOUBIQUITINATED PCNA; ANAPHASE BRIDGES; MAMMALIAN-CELLS; FOCUS FORMATION; ACTIVATION; FORKS; CHECKPOINT	The DNA replication machinery invariably encounters obstacles that slow replication fork progression, and threaten to prevent complete replication and faithful segregation of sister chromatids. The resulting replication stress activates ATR, the major kinase involved in resolving impaired DNA replication. In addition, replication stress also activates the related kinase ATM, which is required to prevent mitotic segregation errors. However, the molecular mechanism of ATM activation by replication stress is not defined. Here, we show that monoubiquitinated Proliferating Cell Nuclear Antigen (PCNA), a marker of stalled replication forks, interacts with the ATM cofactor ATMIN via WRN-interacting protein 1 (WRNIP1). ATMIN, WRNIP1 and RAD18, the E3 ligase responsible for PCNA monoubiquitination, are specifically required for ATM signalling and 53BP1 focus formation induced by replication stress, not ionising radiation. Thus, WRNIP1 connects PCNA monoubiquitination with ATMIN/ATM to activate ATM signalling in response to replication stress and contribute to the maintenance of genomic stability.	[Kanu, N.; Zhang, T.; Chakraborty, A.; Cronshaw, J.; DaCosta, C.; Behrens, A.] Francis Crick Inst, Mammalian Genet Lab, 44 Lincolns Inn Fields, London WC2A 3LY, England; [Burrell, R. A.; Gronroos, E.; Swanton, C.] Francis Crick Inst, Translat Canc Therapeut Lab, London, England; [Pemberton, H. N.; Anderton, E.] Francis Crick Inst, Mol Oncol Lab, London, England; [Gonzalez, L.; Ulrich, H. D.] Francis Crick Inst, DNA Damage Tolerance Lab, London, England; [Sabbioneda, S.] CNR, Ist Genet Mol, Pavia, Italy; [Swanton, C.] UCL Canc Inst, London, England; [Behrens, A.] Kings Coll London, Sch Med, Guys Campus, London, England; [Kanu, N.] UCL Canc Inst, Translat Canc Therapeut Lab, 72 Huntley St, London WC1E 6BT, England; [Zhang, T.] Inst Med Biol, 8 A Biomed Grove,06-06 Immunos, Singapore 138648, Singapore; [Gonzalez, L.; Ulrich, H. D.] Inst Mol Biol, Ackermannweg 4, D-55122 Mainz, Germany; [Chakraborty, A.] AstraZeneca, Li Ka Shing Ctr, Robinson Way, Cambridge CB2 0RE, England	Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of London; University College London; University of London; King's College London; University of London; University College London; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); Institute of Molecular Biology (IMB); AstraZeneca; CRUK Cambridge Institute	Behrens, A (corresponding author), Francis Crick Inst, Mammalian Genet Lab, 44 Lincolns Inn Fields, London WC2A 3LY, England.	axel.behrens@crick.ac.uk	Sabbioneda, Simone/N-7017-2015	Sabbioneda, Simone/0000-0001-8551-5465; Behrens, Axel/0000-0002-1557-1143; Gronroos, Eva/0000-0001-8303-5409; Ulrich, Helle D./0000-0003-0431-2223; Da Costa, Clive/0000-0002-0435-6747; Swanton, Charles/0000-0002-4299-3018	Francis Crick Institute; Breast Cancer Research Foundation; A*STAR NSS-PhD scholarship (Singapore); ERC [281661 ATMINDDR]; Cancer Research UK [15679] Funding Source: researchfish; The Francis Crick Institute [10040, 10039] Funding Source: researchfish	Francis Crick Institute; Breast Cancer Research Foundation; A*STAR NSS-PhD scholarship (Singapore)(Agency for Science Technology & Research (A*STAR)); ERC(European Research Council (ERC)European Commission); Cancer Research UK(Cancer Research UK); The Francis Crick Institute	Support was given from Mass Spectrometry, Bioinformatics and Biostatistics and the Equipment Park in the Cancer Research UK London Research Institute (now part of the Francis Crick Institute). We are grateful to JL Parker in the Ulrich laboratory for preparing ubiquitinated PCNA. R Bish, I Dikic, M Myers, E Soutoglou and A Lehmann kindly provided experimental materials. NK is funded by the Breast Cancer Research Foundation. TZ was financially supported by an A*STAR NSS-PhD scholarship (Singapore). This work was supported by an ERC grant (281661 ATMINDDR) to AB.	Ammazzalorso F, 2010, EMBO J, V29, P3156, DOI 10.1038/emboj.2010.205; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Baumann C, 2007, CELL, V128, P101, DOI 10.1016/j.cell.2006.11.041; Bish RA, 2008, J PROTEOME RES, V7, P3481, DOI 10.1021/pr800217q; Bish RA, 2007, J BIOL CHEM, V282, P23184, DOI 10.1074/jbc.M701042200; Blackford AN, 2012, HUM MOL GENET, V21, P2005, DOI 10.1093/hmg/dds013; Burrell RA, 2013, NATURE, V494, P492, DOI 10.1038/nature11935; Byun TS, 2005, GENE DEV, V19, P1040, DOI 10.1101/gad.1301205; Chan KL, 2011, SEMIN CELL DEV BIOL, V22, P906, DOI 10.1016/j.semcdb.2011.07.001; Chan KL, 2009, NAT CELL BIOL, V11, P753, DOI 10.1038/ncb1882; Chan KL, 2007, EMBO J, V26, P3397, DOI 10.1038/sj.emboj.7601777; Crosetto N, 2008, J BIOL CHEM, V283, P35173, DOI 10.1074/jbc.M803219200; Davalos AR, 2004, CELL CYCLE, V3, P1579, DOI 10.4161/cc.3.12.1286; Derheimer FA, 2010, FEBS LETT, V584, P3675, DOI 10.1016/j.febslet.2010.05.031; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Fugger K, 2015, CELL REP; Gamper AM, 2012, J BIOL CHEM, V287, P12445, DOI 10.1074/jbc.M112.352310; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Harrigan JA, 2011, J CELL BIOL, V193, P97, DOI 10.1083/jcb.201011083; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Kanu N, 2008, CELL CYCLE, V7, P3483, DOI 10.4161/cc.7.22.7044; Kanu N, 2007, EMBO J, V26, P2933, DOI 10.1038/sj.emboj.7601733; Kawabe Y, 2001, J BIOL CHEM, V276, P20364, DOI 10.1074/jbc.C100035200; Lee JH, 2007, ONCOGENE, V26, P7741, DOI 10.1038/sj.onc.1210872; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lilley CE, 2010, EMBO J, V29, P943, DOI 10.1038/emboj.2009.400; Loizou JI, 2011, CANCER CELL, V19, P587, DOI 10.1016/j.ccr.2011.03.022; Lukas C, 2011, NAT CELL BIOL, V13, P243, DOI 10.1038/ncb2201; McNees CJ, 2005, EMBO J, V24, P2447, DOI 10.1038/sj.emboj.7600704; Niimi A, 2008, P NATL ACAD SCI USA, V105, P16125, DOI 10.1073/pnas.0802727105; Olcina MM, 2013, MOL CELL, V52, P758, DOI 10.1016/j.molcel.2013.10.019; Parker Joanne L, 2012, Methods Mol Biol, V920, P569, DOI 10.1007/978-1-61779-998-3_37; Payne BTI, 2006, NUCLEIC ACIDS RES, V34, P5194, DOI 10.1093/nar/gkl682; Saugar I, 2012, NUCLEIC ACIDS RES, V40, P245, DOI 10.1093/nar/gkr738; Schmidt L, 2014, DNA REPAIR, V24, P122, DOI 10.1016/j.dnarep.2014.09.001; Sirbu BM, 2011, GENE DEV, V25, P1320, DOI 10.1101/gad.2053211; Soutoglou E, 2007, NAT CELL BIOL, V9, P675, DOI 10.1038/ncb1591; Trenz K, 2006, EMBO J, V25, P1764, DOI 10.1038/sj.emboj.7601045; Ulrich HD, 2009, DNA REPAIR, V8, P461, DOI 10.1016/j.dnarep.2009.01.006; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Ying SM, 2013, NAT CELL BIOL, V15, P1001, DOI 10.1038/ncb2773; Yoshimura A, 2009, GENES GENET SYST, V84, P171, DOI 10.1266/ggs.84.171; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zhang ZT, 2012, CELL CYCLE, V11, P2128, DOI 10.4161/cc.20595	48	24	24	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					4009	4019		10.1038/onc.2015.427	http://dx.doi.org/10.1038/onc.2015.427			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	26549024	Green Submitted, Green Accepted			2022-12-17	WOS:000381013100012
J	Obermeier, K; Sachsenweger, J; Friedl, TWP; Pospiech, H; Winqvist, R; Wiesmuller, L				Obermeier, K.; Sachsenweger, J.; Friedl, T. W. P.; Pospiech, H.; Winqvist, R.; Wiesmueller, L.			Heterozygous PALB2 c.1592delT mutation channels DNA double-strand break repair into error-prone pathways in breast cancer patients	ONCOGENE			English	Article							FANCONI-ANEMIA PATHWAY; REPLICATION FORKS; BRCA2; SUSCEPTIBILITY; RISK; RECOMBINATION; MECHANISM; PARTNER; PROTEIN; GENES	Hereditary heterozygous mutations in a variety of DNA double-strand break (DSB) repair genes have been associated with increased breast cancer risk. In the Finnish population, PALB2 (partner and localizer of BRCA2) represents a major susceptibility gene for female breast cancer, and so far, only one mutation has been described, c.1592delT, which leads to a sixfold increased disease risk. PALB2 is thought to participate in homologous recombination (HR). However, the effect of the Finnish founder mutation on DSB repair has not been investigated. In the current study, we used a panel of lymphoblastoid cell lines (LCLs) derived from seven heterozygous female PALB2 c.1592delT mutation carriers with variable health status and six wild-type matched controls. The results of our DSB repair analysis showed that the PALB2 mutation causes specific changes in pathway usage, namely increases in error-prone single-strand annealing (SSA) and microhomology-mediated end-joining (MMEJ) compared with wild-type LCLs. These data indicated haploinsufficiency regarding the suppression of error-prone DSB repair in PALB2 mutation carriers. To the contrary, neither reduced HR activities, nor impaired RAD51 filament assembly, nor sensitization to PARP inhibition were consistently observed. Expression of truncated mutant versus wild-type PALB2 verified a causal role of PALB2 c.1592delT in the shift to error-prone repair. Discrimination between healthy and malignancy-presenting PALB2 mutation carriers revealed a pathway shift particularly in the breast cancer patients, suggesting interaction of PALB2 c.1592delT with additional genomic lesions. Interestingly, the studied PALB2 mutation was associated with 53BP1 accumulation in the healthy mutation carriers but not the patients, and 53BP1 was limiting for error-prone MMEJ in patients but not in healthy carriers. Our study identified a rise in error-prone DSB repair as a potential threat to genomic integrity in heterozygous PALB2 mutation carriers. The used phenotypic marker system has the capacity to capture dysfunction caused by polygenic mechanisms and therefore offers new strategies of cancer risk prediction.	[Obermeier, K.; Sachsenweger, J.; Friedl, T. W. P.; Wiesmueller, L.] Univ Ulm, Dept Obstet & Gynecol, Prittwitzstr 43, D-89075 Ulm, Germany; [Pospiech, H.] Univ Oulu, Fac Biochem & Mol Med, Oulu, Finland; [Pospiech, H.] Leibniz Inst Age Res, Fritz Lipmann Inst, Res Grp Biochem, Jena, Germany; [Winqvist, R.] Univ Oulu, Lab Canc Genet & Tumor Biol, Canc & Translat Med Res Unit, Aapistie 5A, SF-90220 Oulu, Finland; [Winqvist, R.] Univ Oulu, Bioctr Oulu, Aapistie 5A, SF-90220 Oulu, Finland; [Winqvist, R.] Northern Finland Lab Ctr NordLab, Oulu, Finland	Ulm University; University of Oulu; Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); University of Oulu; University of Oulu	Wiesmuller, L (corresponding author), Univ Ulm, Dept Obstet & Gynecol, Prittwitzstr 43, D-89075 Ulm, Germany.; Winqvist, R (corresponding author), Univ Oulu, Lab Canc Genet & Tumor Biol, Canc & Translat Med Res Unit, Aapistie 5A, SF-90220 Oulu, Finland.; Winqvist, R (corresponding author), Univ Oulu, Bioctr Oulu, Aapistie 5A, SF-90220 Oulu, Finland.	robert.winqvist@oulu.fi; lisa.wiesmueller@uni-ulm.de	Friedl, Thomas W.P./K-5305-2013	Friedl, Thomas W.P./0000-0002-4773-8067; Wiesmuller, Lisa/0000-0002-2397-5041; Winqvist, Robert/0000-0003-0932-9104	International Graduate School in Molecular Medicine Ulm, Germany; University of Oulu; Finnish Cancer Foundation; Sigrid Juselius Foundation; Academy of Finland Center of Excellence [251314]; Biocenter Oulu; Cancer Foundation Finland sr [150147] Funding Source: researchfish	International Graduate School in Molecular Medicine Ulm, Germany; University of Oulu; Finnish Cancer Foundation; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Academy of Finland Center of Excellence(Academy of Finland); Biocenter Oulu; Cancer Foundation Finland sr	We cordially thank Leena Keskitalo, Annika Vantanen and Meeri Otsukka for the initial preparation and culturing of the Northern Finnish PALB2 mutation carrier and the matched wild-type healthy control LCLs as well as their shipment to Ulm for the current study. We are grateful to Daniela Salles, Ulm, for experimental help during the initial phase of the project, and Jeremy M Stark, Department of Cancer Biology, Division of Radiation Biology, Beckmann Research Institute of the City of Hope, Duarte, CA, USA, for the NHEJ reporter EJ5SceGFP. This project was supported by the International Graduate School in Molecular Medicine Ulm, Germany (to LW). KO was and JS is a member of the International Graduate School in Molecular Medicine Ulm. RW was supported by the University of Oulu and Biocenter Oulu, the Finnish Cancer Foundation, Sigrid Juselius Foundation and the Academy of Finland Center of Excellence funding (grant 251314). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Antoniou AC, 2014, NEW ENGL J MED, V371, P497, DOI [10.1056/NEJMoa1400382, 10.1056/NEJMc1410673]; Bennardo N, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000683; Bohringer M, 2013, ONCOGENE, V32, P5458, DOI 10.1038/onc.2013.38; Bouwman P, 2013, CANCER DISCOV, V3, P1142, DOI 10.1158/2159-8290.CD-13-0094; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Bunting SF, 2010, MOL CELL, V39, P164, DOI 10.1016/j.molcel.2010.07.016; Burkovics P, 2014, NUCLEIC ACIDS RES, V42, P1711, DOI 10.1093/nar/gkt1040; Byrnes GB, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2099; Casadei S, 2011, CANCER RES, V71, P2222, DOI 10.1158/0008-5472.CAN-10-3958; Costantino L, 2014, SCIENCE, V343, P88, DOI 10.1126/science.1243211; Currall Benjamin B, 2013, Curr Genet Med Rep, V1, P81; De Vos M, 2012, BIOCHEM PHARMACOL, V84, P137, DOI 10.1016/j.bcp.2012.03.018; Deng XY, 2009, BIOCHEMISTRY-US, V48, P6633, DOI 10.1021/bi900564k; Do K, 2013, CLIN CANCER RES, V19, P977, DOI 10.1158/1078-0432.CCR-12-0163; Dray E, 2010, NAT STRUCT MOL BIOL, V17, P1255, DOI 10.1038/nsmb.1916; Dumitrescu RG, 2005, J CELL MOL MED, V9, P208, DOI 10.1111/j.1582-4934.2005.tb00350.x; Erkko H, 2008, CLIN CANCER RES, V14, P4667, DOI 10.1158/1078-0432.CCR-08-0210; Erkko H, 2007, NATURE, V446, P316, DOI 10.1038/nature05609; Francis R, 2007, GENE DEV, V21, P1064, DOI 10.1101/gad.1522807; Gagou ME, 2010, MOL BIOL CELL, V21, P739, DOI 10.1091/mbc.E09-07-0618; Guidugli L, 2014, HUM MUTAT, V35, P151, DOI 10.1002/humu.22478; Haanpaa M, 2013, BMC MED GENET, V14, DOI 10.1186/1471-2350-14-82; Heikkinen K, 2006, CARCINOGENESIS, V27, P1593, DOI 10.1093/carcin/bgi360; Ho TV, 2002, ENVIRON MOL MUTAGEN, V51, P552; Hucl T, 2011, PHYSIOL RES, V60, P453, DOI 10.33549/physiolres.932115; Huertas P, 2010, NAT STRUCT MOL BIOL, V17, P11, DOI 10.1038/nsmb.1710; Ireno IC, 2014, CARCINOGENESIS, V35, P2273, DOI 10.1093/carcin/bgu160; Keimling M, 2012, FASEB J, V26, P2094, DOI 10.1096/fj.11-200790; Keimling M, 2011, FASEB J, V25, P3849, DOI 10.1096/fj.11-185546; Keka IS, 2015, NUCLEIC ACIDS RES, V43, P6359, DOI 10.1093/nar/gkv621; Lok BH, 2013, ONCOGENE, V32, P3552, DOI 10.1038/onc.2012.391; Mavaddat N, 2013, JNCI-J NATL CANCER I, V105, P812, DOI 10.1093/jnci/djt095; McKinnon PJ, 2007, ANNU REV GENOM HUM G, V8, P37, DOI 10.1146/annurev.genom.7.080505.115648; Meindl A, 2011, DTSCH ARZTEBL INT, V108, P323, DOI 10.3238/arztebl.2011.0323; Murphy AK, 2014, J CELL BIOL, V206, P493, DOI 10.1083/jcb.201404111; Nikkila J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3578; Panier S, 2014, NAT REV MOL CELL BIO, V15, P7, DOI 10.1038/nrm3719; Park JY, 2014, ONCOGENE, V33, P4803, DOI 10.1038/onc.2013.421; Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021; Rahman N, 2007, NAT GENET, V39, P165, DOI 10.1038/ng1959; Reid S, 2007, NAT GENET, V39, P162, DOI 10.1038/ng1947; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Ribeiro E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066243; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Schlacher K, 2012, CANCER CELL, V22, P106, DOI 10.1016/j.ccr.2012.05.015; Schlacher K, 2011, CELL, V145, P529, DOI 10.1016/j.cell.2011.03.041; Shahid T, 2014, NAT STRUCT MOL BIOL, V21, P962, DOI 10.1038/nsmb.2899; Siaud N, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002409; Sy SMH, 2009, J BIOL CHEM, V284, P21127, DOI 10.1074/jbc.C109.023937; Sy SMH, 2009, P NATL ACAD SCI USA, V106, P7155, DOI 10.1073/pnas.0811159106; Thompson LH, 2009, MUTAT RES-FUND MOL M, V668, P54, DOI 10.1016/j.mrfmmm.2009.02.003; Tischkowitz M, 2010, CANCER RES, V70, P7353, DOI 10.1158/0008-5472.CAN-10-1012; Walsh T, 2007, CANCER CELL, V11, P103, DOI 10.1016/j.ccr.2007.01.010; Walsh T, 2010, P NATL ACAD SCI USA, V107, P12629, DOI 10.1073/pnas.1007983107; Xia B, 2007, NAT GENET, V39, P159, DOI 10.1038/ng1942; Xia B, 2006, MOL CELL, V22, P719, DOI 10.1016/j.molcel.2006.05.022; Zhang F, 2009, FERROALLOYS, V1, P1, DOI DOI 10.1155/2009/514306; Zhang F, 2009, CURR BIOL, V19, P524, DOI 10.1016/j.cub.2009.02.018	59	24	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3796	3806		10.1038/onc.2015.448	http://dx.doi.org/10.1038/onc.2015.448			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26640152	Green Published, hybrid			2022-12-17	WOS:000380753200005
J	Valente, LJ; Grabow, S; Vandenberg, CJ; Strasser, A; Janic, A				Valente, L. J.; Grabow, S.; Vandenberg, C. J.; Strasser, A.; Janic, A.			Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53	ONCOGENE			English	Article							CELL-CYCLE ARREST; TUMOR SUPPRESSION; TRANSGENIC MICE; P21(WAF1/CIP1); GENE; MUTATIONS; P27(KIP1); ABSENCE; CANCER; DELAYS	The tumor suppressor p53 is mutated in similar to 50% of human cancers. P53 is activated by a range of stimuli and regulates several cellular processes, including apoptotic cell death, cell cycle arrest, senescence and DNA repair. P53 induces apoptosis via transcriptional induction of the BH3-only proteins PUMA (p53-upregulated modulator of apoptosis) and NOXA, and cell cycle arrest via p21. Induction of these processes was proposed to be critical for p53-mediated tumor suppression. It is therefore surprising that mice lacking PUMA, NOXA and p21, as well as mice bearing mutations in p53 that impair the transcriptional activation of these genes, are not tumor prone, unlike mice lacking p53 function, which spontaneously develop tumors with 100% incidence. These p53 target genes and the processes they regulate may, however, impact differently on tumor development depending on the oncogenic drivers. For example, loss of PUMA enhances c-MYC-driven lymphoma development in mice, but, interestingly, the acceleration was less impressive compared with that caused by the loss of even a single p53 allele. Different studies have reported that loss of p21 can accelerate, delay or have no impact on tumorigenesis. In an attempt to resolve this controversy, we examined whether loss of p21-mediated cell cycle arrest cooperates with PUMA deficiency in accelerating lymphoma development in E mu-Myc mice (overexpressing c-MYC in B-lymphoid cells). We found that E mu-Myc mice lacking both p21 and PUMA (E mu-Myc; Puma(-/-); p21(-/-)) developed lymphoma at a rate comparable to E mu-Myc; Puma(-/-) animals, notably with considerably longer latency than E mu-Myc; p53(+/-) mice. Loss of p21 had no impact on the numbers, cycling or survival of pre-leukemic E mu-Myc B-lymphoid cells, even when PUMA was lost concomitantly. These results demonstrate that even in the context of deregulated c-MYC expression, p53 must suppress tumor development by activating processes apart from, or in addition to, PUMA-mediated apoptosis and p21-induced cell cycle arrest.	[Valente, L. J.; Grabow, S.; Vandenberg, C. J.; Strasser, A.; Janic, A.] Walter & Eliza Hall Inst Med Res, Mol Genet Canc Div, 1G Royal Parade, Melbourne, Vic 3052, Australia; [Valente, L. J.; Grabow, S.; Vandenberg, C. J.; Strasser, A.; Janic, A.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia; [Valente, L. J.] Stanford Univ, Dept Radiat Oncol, Sch Med, Div Radiat & Canc Biol, Stanford, CA 94305 USA	University of Melbourne; Stanford University	Strasser, A; Janic, A (corresponding author), Walter & Eliza Hall Inst Med Res, Mol Genet Canc Div, 1G Royal Parade, Melbourne, Vic 3052, Australia.	strasser@wehi.edu.au; janic@wehi.edu.au	Strasser, Andreas/C-7581-2013; Janic, Ana/AAR-4783-2020	Strasser, Andreas/0000-0002-5020-4891; Janic, Ana/0000-0002-4200-2560; Valente, Liz J/0000-0002-5591-7700; Grabow, Stephanie/0000-0003-0467-7871	Cancer Council of Victoria; Leukaemia Foundation Australia; Lady Tata Memorial Trust Research Award; Leukemia & Lymphoma Society of America; Beatriu de Pinos Foundation; Cancer Australia; Cure Cancer Australia Foundation [1067571]; National Health and Medical Research Council (NHMRC) [1016701, 1020363]; Leukemia & Lymphoma Society of America (Specialized Center of Research (SCOR)) [7001-13]; Australian Government Independent Medical Research Institutes Infrastructure Support Scheme (IRIISS); Victorian State Government Operational Infrastructure Support (OIS)	Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Leukaemia Foundation Australia; Lady Tata Memorial Trust Research Award; Leukemia & Lymphoma Society of America(Leukemia and Lymphoma Society); Beatriu de Pinos Foundation; Cancer Australia; Cure Cancer Australia Foundation; National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Leukemia & Lymphoma Society of America (Specialized Center of Research (SCOR)); Australian Government Independent Medical Research Institutes Infrastructure Support Scheme (IRIISS)(Australian Government); Victorian State Government Operational Infrastructure Support (OIS)	The authors thank Drs GL Kelly, ARD Delbridge, BJ Aubrey, S Cory and JM Adams for discussions and gifts of mice; K Walker, J Mansheim, C Gatt, G Siciliano and S O'Connor for expert animal care; B Helbert, H Ierino, K Mackwell and C Young for help with genotyping; J Corbin and J McManus for automated blood cell analysis. This work was supported by a PhD scholarship and Postdoctoral Fellowships from the Cancer Council of Victoria to SG and LV, by Postdoctoral Fellowships from the Leukaemia Foundation Australia to SG, from the Lady Tata Memorial Trust Research Award to AJ and SG, from the Leukemia & Lymphoma Society of America and the Beatriu de Pinos Foundation to AJ and by grants from Cancer Australia and Cure Cancer Australia Foundation (grant no. 1067571), the National Health and Medical Research Council (NHMRC; program grant no. 1016701, NHMRC Senior Principal Research Fellow (SPRF) Fellowship 1020363 to AS) and the Leukemia & Lymphoma Society of America (Specialized Center of Research (SCOR) grant no. 7001-13). This work was made possible by operational infrastructure grants through the Australian Government Independent Medical Research Institutes Infrastructure Support Scheme (IRIISS) and the Victorian State Government Operational Infrastructure Support (OIS).	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Aubrey BJ, 2015, CELL REP, V10, P1422, DOI 10.1016/j.celrep.2015.02.002; Barboza JA, 2006, P NATL ACAD SCI USA, V103, P19842, DOI 10.1073/pnas.0606343104; Bearss DJ, 2002, CANCER RES, V62, P2077; Bieging KT, 2012, TRENDS CELL BIOL, V22, P97, DOI 10.1016/j.tcb.2011.10.006; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Garrison SP, 2008, MOL CELL BIOL, V28, P5391, DOI 10.1128/MCB.00907-07; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Hoffman B, 2008, ONCOGENE, V27, P6462, DOI 10.1038/onc.2008.312; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson RJ, 2002, ONCOGENE, V21, P8486, DOI 10.1038/sj.onc.1205946; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jiang DD, 2011, P NATL ACAD SCI USA, V108, P17123, DOI 10.1073/pnas.1111245108; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; McKenzie KE, 1997, CLIN CANCER RES, V3, P1669; Michalak EM, 2009, CELL DEATH DIFFER, V16, P684, DOI 10.1038/cdd.2008.195; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Newbold A, 2014, ONCOGENE, V33, P5415, DOI 10.1038/onc.2013.482; Patino-Garcia A, 1998, PEDIATR RES, V43, P393, DOI 10.1203/00006450-199803000-00014; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Post SM, 2010, ONCOGENE, V29, P1260, DOI 10.1038/onc.2009.423; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strasser A, 1996, EMBO J, V15, P3823, DOI 10.1002/j.1460-2075.1996.tb00756.x; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Valente LJ, 2013, CELL REP, V3, P1339, DOI 10.1016/j.celrep.2013.04.012; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Yang WC, 2001, CANCER RES, V61, P565; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	46	24	25	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2016	35	29					3866	3871		10.1038/onc.2015.457	http://dx.doi.org/10.1038/onc.2015.457			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS4LS	26640149				2022-12-17	WOS:000380753200011
J	Greil, C; Krohs, J; Schnerch, D; Follo, M; Felthaus, J; Engelhardt, M; Wasch, R				Greil, C.; Krohs, J.; Schnerch, D.; Follo, M.; Felthaus, J.; Engelhardt, M.; Waesch, R.			The role of APC/C-Cdh1 in replication stress and origin of genomic instability	ONCOGENE			English	Article							ANAPHASE-PROMOTING COMPLEX; MCM4,6,7 HELICASE ACTIVITY; E3 UBIQUITIN LIGASES; CELL-CYCLE; S-PHASE; TUMOR SUPPRESSION; DNA-REPLICATION; CHROMOSOMAL INSTABILITY; DEPENDENT PROTEOLYSIS; MAMMALIAN-CELLS	It has been proposed that the APC/C-Cdh1 functions as a tumor suppressor by maintaining genomic stability. However, the exact nature of genomic instability following loss of Cdh1 is unclear. Using biochemistry and live cell imaging of single cells we found that Cdh1 knockdown (kd) leads to strong nuclear stabilization of the substrates cyclin A and B and deregulated kinetics of DNA replication. Restoration of the Cdh1-dependent G2 DNA damage checkpoint did not result in G2 arrest but blocked cells in prometaphase, suggesting that these cells enter mitosis despite incomplete replication. This results in DNA double-strand breaks, anaphase bridges, cytokinesis defects and tetraploidization. Tetraploid cells are the source of supernumerary centrosomes following Cdh1-kd, leading to multipolar mitosis or centrosome clustering, in turn resulting in merotelic attachment and lagging chromosomes. Whereas some of these events cause apoptosis during mitosis, surviving cells may accumulate chromosomal aberrations.	[Greil, C.; Krohs, J.; Schnerch, D.; Follo, M.; Felthaus, J.; Engelhardt, M.; Waesch, R.] Univ Med Ctr, Dept Hematol Oncol & Stem Cell Transplanta, Hugstetter Str 55, D-79106 Freiburg, Germany; [Krohs, J.] Univ Freiburg, Fac Biol, Hugstetter Str 55, D-79106 Freiburg, Germany; [Schnerch, D.] Univ Basel, Biozentrum, Basel, Switzerland	University of Freiburg; University of Freiburg; University of Basel	Wasch, R (corresponding author), Univ Med Ctr, Dept Hematol Oncol & Stem Cell Transplanta, Hugstetter Str 55, D-79106 Freiburg, Germany.	ralph.waesch@uniklinik-freiburg.de	Waesch, Ralph/F-6282-2019	Follo, Marie/0000-0002-3090-7442	Deutsche Forschungsgemeinschaft	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work is supported by Deutsche Forschungsgemeinschaft. We thank G Ihorst for statistical advice.	Alver RC, 2014, DNA REPAIR, V19, P182, DOI 10.1016/j.dnarep.2014.03.012; Ayuda-Duran P, 2014, NUCLEIC ACIDS RES, V42, P7057, DOI 10.1093/nar/gku313; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bassermann F, 2008, CELL, V134, P256, DOI 10.1016/j.cell.2008.05.043; Clijsters L, 2013, J CELL BIOL, V201, P1013, DOI 10.1083/jcb.201211019; Diffley JFX, 2004, CURR BIOL, V14, pR778, DOI 10.1016/j.cub.2004.09.019; Drosopoulos K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4686; Eguren M, 2014, CELL REP, V6, P670, DOI 10.1016/j.celrep.2014.01.017; Eguren M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3880; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Engelbert D, 2008, ONCOGENE, V27, P907, DOI 10.1038/sj.onc.1210703; Floyd S, 2008, CURR BIOL, V18, P1649, DOI 10.1016/j.cub.2008.09.058; Fujita M, 1998, J BIOL CHEM, V273, P17095, DOI 10.1074/jbc.273.27.17095; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Garcia-Higuera I, 2008, NAT CELL BIOL, V10, P802, DOI 10.1038/ncb1742; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Harrigan JA, 2011, J CELL BIOL, V193, P97, DOI 10.1083/jcb.201011083; Held M, 2010, NAT METHODS, V7, P747, DOI 10.1038/nmeth.1486; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; Ishimi Y, 2000, J BIOL CHEM, V275, P16235, DOI 10.1074/jbc.M909040199; Ishimi Y, 2001, J BIOL CHEM, V276, P34428, DOI 10.1074/jbc.M104480200; Johansson P, 2014, J BIOL CHEM, V289, P18514, DOI 10.1074/jbc.M114.559930; Kawabata T, 2011, MOL CELL, V41, P543, DOI 10.1016/j.molcel.2011.02.006; Komamura-Kohno Y, 2006, FEBS J, V273, P1224, DOI 10.1111/j.1742-4658.2006.05146.x; Lengronne A, 2002, MOL CELL, V9, P1067, DOI 10.1016/S1097-2765(02)00513-0; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; Moore JD, 2003, SCIENCE, V300, P987, DOI 10.1126/science.1081418; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Neelsen KJ, 2013, J CELL BIOL, V200, P699, DOI 10.1083/jcb.201212058; Nishitani H, 2006, EMBO J, V25, P1126, DOI 10.1038/sj.emboj.7601002; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Pines J, 2011, NAT REV MOL CELL BIO, V12, P427, DOI 10.1038/nrm3132; Qiao XX, 2010, CELL CYCLE, V9, P3904, DOI 10.4161/cc.9.19.13585; Schnerch D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074379; Schnerch D, 2012, CELL CYCLE, V11, P310, DOI 10.4161/cc.11.2.18737; Sigl R, 2009, J CELL SCI, V122, P4208, DOI 10.1242/jcs.054197; Skaar JR, 2008, NAT CELL BIOL, V10, P755, DOI 10.1038/ncb0708-755; Sorensen CS, 2000, MOL CELL BIOL, V20, P7613, DOI 10.1128/MCB.20.20.7613-7623.2000; Steigemann P, 2009, CELL, V136, P473, DOI 10.1016/j.cell.2008.12.020; Sudo T, 2001, EMBO J, V20, P6499, DOI 10.1093/emboj/20.22.6499; Sullivan M, 2007, NAT REV MOL CELL BIO, V8, P894, DOI 10.1038/nrm2276; Torres-Rosell J, 2007, SCIENCE, V315, P1411, DOI 10.1126/science.1134025; Wasch R, 2010, ONCOGENE, V29, P1, DOI 10.1038/onc.2009.325; Wasch R, 2005, ONCOGENE, V24, P1, DOI 10.1038/sj.onc.1208017; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Wheeler LW, 2008, CELL CYCLE, V7, P2179, DOI 10.4161/cc.7.14.6270; Woodward AM, 2006, J CELL BIOL, V173, P673, DOI 10.1083/jcb.200602108; Yuan X, 2014, MOL BIOL CELL, V25, P441, DOI 10.1091/mbc.E13-08-0480; Zhang JF, 2014, BBA-REV CANCER, V1845, P277, DOI 10.1016/j.bbcan.2014.02.001	50	24	25	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					3062	3070		10.1038/onc.2015.367	http://dx.doi.org/10.1038/onc.2015.367			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26455319				2022-12-17	WOS:000377474500011
J	Golmard, L; Delnatte, C; Lauge, A; Moncoutier, V; Lefol, C; Abidallah, K; Tenreiro, H; Copigny, F; Giraudeau, M; Guy, C; Barbaroux, C; Amorim, G; Briaux, A; Guibert, V; Tarabeux, J; Caputo, S; Collet, A; Gesta, P; Ingster, O; Stern, MH; Rouleau, E; De Pauw, A; Gauthier-Villars, M; Buecher, B; Bezieau, S; Stoppa-Lyonnet, D; Houdayer, C				Golmard, L.; Delnatte, C.; Lauge, A.; Moncoutier, V.; Lefol, C.; Abidallah, K.; Tenreiro, H.; Copigny, F.; Giraudeau, M.; Guy, C.; Barbaroux, C.; Amorim, G.; Briaux, A.; Guibert, V.; Tarabeux, J.; Caputo, S.; Collet, A.; Gesta, P.; Ingster, O.; Stern, M-H; Rouleau, E.; De Pauw, A.; Gauthier-Villars, M.; Buecher, B.; Bezieau, S.; Stoppa-Lyonnet, D.; Houdayer, C.			Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations	ONCOGENE			English	Article							DE-NOVO MUTATIONS; ONSET BREAST; HEREDITARY BREAST; GENE BRCA1; PATIENT; WOMAN; SUSCEPTIBILITY; IDENTIFICATION; DIAGNOSTICS; PREVALENCE	BRCA1 and BRCA2 are the two major genes predisposing to breast and ovarian cancer. Whereas high de novo mutation rates have been demonstrated for several genes, only 11 cases of de novo BRCA1/2 mutations have been reported to date and the BRCA1/2 de novo mutation rate remains unknown. The present study was designed to fill this gap based on a series of 12 805 consecutive unrelated patients diagnosed with breast and/or ovarian cancer who met the inclusion criteria for BRCA1/2 gene analysis according to French guidelines. BRCA1/2 mutations were detected in 1527 (12%) patients, and three BRCA1 mutations and one BRCA2 mutation were de novo. The BRCA1/2 de novo mutation rate was estimated to be 0.3% (0.1%; 0.7%). Although rare, it may be useful to take the possibility of de novo BRCA1/2 mutation into account in genetic counseling of relatives and to improve the understanding of complex family histories of breast and ovarian cancers.	[Golmard, L.; Lauge, A.; Moncoutier, V.; Lefol, C.; Abidallah, K.; Tenreiro, H.; Copigny, F.; Giraudeau, M.; Guy, C.; Barbaroux, C.; Amorim, G.; Briaux, A.; Tarabeux, J.; Caputo, S.; Collet, A.; Stern, M-H; Rouleau, E.; De Pauw, A.; Gauthier-Villars, M.; Buecher, B.; Stoppa-Lyonnet, D.; Houdayer, C.] Inst Curie, Dept Biopathol, F-75005 Paris, France; [Golmard, L.; Tarabeux, J.; Stern, M-H; Stoppa-Lyonnet, D.; Houdayer, C.] Inst Curie, INSERM, U830, F-75005 Paris, France; [Delnatte, C.; Guibert, V.; Bezieau, S.] CHU Nantes, Serv Genet Med, F-44035 Nantes 01, France; [Gesta, P.] Oncogenet Poitou Charentes, Pole Oncol, Niort, France; [Ingster, O.] CHU Angers, Serv Genet Med, Angers, France; [Bezieau, S.] Univ Nantes, Fac Med Nantes, Nantes, France; [Stoppa-Lyonnet, D.] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Houdayer, C.] Univ Paris 05, Sorbonne Paris Cite, Fac Sci Pharmaceut & Biol, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; Nantes Universite; CHU de Nantes; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Nantes Universite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Houdayer, C (corresponding author), Inst Curie, Lab Genet Constitut, 26 Rue Ulm, F-75005 Paris, France.	claude.houdayer@curie.fr	Bézieau, stéphane/G-5621-2015; Caputo, Sandrine M/I-7460-2019; De Pauw, Antoine/ABC-6019-2020; Stern, Marc-Henri/A-2728-2011; Caputo, Sandrine M./C-3860-2018; Lambert, Blandine S/O-6002-2016	Bézieau, stéphane/0000-0003-0095-1319; De Pauw, Antoine/0000-0003-3898-073X; Stern, Marc-Henri/0000-0002-8100-2272; Caputo, Sandrine M./0000-0001-5338-9388; Lambert, Blandine S/0000-0002-8429-2404				Antoniou AC, 2006, ONCOGENE, V25, P5898, DOI 10.1038/sj.onc.1209879; Antoniou AC, 2002, BRIT J CANCER, V86, P76, DOI 10.1038/sj.bjc.6600008; Biesecker LG, 2013, NAT REV GENET, V14, P307, DOI 10.1038/nrg3424; Bonaiti B, 2014, J MED GENET, V51, P114, DOI 10.1136/jmedgenet-2013-101674; Caputo S, 2012, NUCLEIC ACIDS RES, V40, pD992, DOI 10.1093/nar/gkr1160; Caux-Moncoutier V, 2011, HUM MUTAT, V32, P325, DOI 10.1002/humu.21414; De Leeneer K, 2012, BREAST CANCER RES TR, V132, P87, DOI 10.1007/s10549-011-1544-9; Delon I, 2013, CLIN GENET, V84, P297, DOI 10.1111/cge.12057; Diez O, 2010, BREAST CANCER RES TR, V121, P221, DOI 10.1007/s10549-009-0494-y; Edwards E, 2009, FAM CANCER, V8, P479, DOI 10.1007/s10689-009-9270-8; Friedman E, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1387; Garcia-Casado Z, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-134; Hansen TVO, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-58; Hodgkinson A, 2011, NAT REV GENET, V12, P756, DOI 10.1038/nrg3098; Houdayer C, 2012, RETINOBLASTOMA UPDAT, P55, DOI [10.5772/34069, DOI 10.5772/34069]; Kwong A, 2011, FAM CANCER, V10, P233, DOI 10.1007/s10689-011-9429-y; Marshall M, 2009, CLIN GENET, V76, P427, DOI 10.1111/j.1399-0004.2009.01246.x; Mavaddat N, 2013, JNCI-J NATL CANCER I, V105, P812, DOI 10.1093/jnci/djt095; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moslehi R, 2010, AM J HUM BIOL, V22, P201, DOI 10.1002/ajhb.20978; Pal T, 2010, FERTIL STERIL, V93, P1805, DOI 10.1016/j.fertnstert.2008.12.052; Ripa R, 2002, EUR J HUM GENET, V10, P631, DOI 10.1038/sj.ejhg.5200853; Robson M, 2002, J MED GENET, V39, P126, DOI 10.1136/jmg.39.2.126; Rouleau E, 2007, CLIN GENET, V72, P199, DOI 10.1111/j.1399-0004.2007.00849.x; Tarabeux J, 2014, EUR J HUM GENET, V22, P535, DOI 10.1038/ejhg.2013.181; Tesoriero A, 1999, AM J HUM GENET, V65, P567, DOI 10.1086/302503; van der Luijt RB, 2001, J MED GENET, V38, P102, DOI 10.1136/jmg.38.2.102; van Minkelen R, 2014, CLIN GENET, V85, P318, DOI 10.1111/cge.12187; Veltman JA, 2012, NAT REV GENET, V13, P565, DOI 10.1038/nrg3241; Walsh T, 2010, P NATL ACAD SCI USA, V107, P12629, DOI 10.1073/pnas.1007983107; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Zhang L, 2011, CLIN GENET, V80, P97, DOI 10.1111/j.1399-0004.2011.01691.x	32	24	24	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1324	1327		10.1038/onc.2015.181	http://dx.doi.org/10.1038/onc.2015.181			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26028024				2022-12-17	WOS:000371763100012
J	Rodriguez, M; Siwko, S; Zeng, L; Li, J; Yi, Z; Liu, M				Rodriguez, M.; Siwko, S.; Zeng, L.; Li, J.; Yi, Z.; Liu, M.			Prostate-specific G-protein-coupled receptor collaborates with loss of PTEN to promote prostate cancer progression	ONCOGENE			English	Article							STROMAL ANDROGEN RECEPTOR; INTRAEPITHELIAL NEOPLASIA; TUMOR-SUPPRESSOR; EXPRESSION; PSGR; GENE; TISSUE; MICROENVIRONMENT; INACTIVATION; INFLAMMATION	Among frequent events in prostate cancer are loss of the tumor-suppressor phosphatase and tensin homologue (PTEN) and overexpression of prostate-specific G-protein-coupled receptor (PSGR), but the potential tumorigenic synergy between these lesions is unknown. Here, we report a new mouse model (PSGR-Pten(Delta/Delta)) combining prostate-specific loss of Pten with probasin promoter-driven PSGR overexpression. By 12 months PSGR-Pten(Delta/Delta) mice developed invasive prostate tumors featuring Akt activation and extensive inflammatory cell infiltration. PSGR-Pten(Delta/Delta) tumors exhibited E-cadherin loss and increased stromal androgen receptor (AR) expression. PSGR overexpression increased LNCaP proliferation, whereas PSGR short hairpin RNA knockdown inhibited proliferation and migration. In conclusion, we demonstrate that PSGR overexpression synergizes with loss of PTEN to accelerate prostate cancer development, and present a novel bigenic mouse model that mimics the human condition, where both PSGR overexpression and loss of PTEN occur concordantly in the majority of advanced prostate cancers, yielding an environment more relevant to studying human prostate cancer.	[Rodriguez, M.; Siwko, S.; Zeng, L.; Liu, M.] Texas A&M Univ, Hlth Sci Ctr, Ctr Canc & Stem Cell Biol, Inst Biosci & Technol,Dept Cellular & Mol Med, 2121 W Holcombe Blvd, Houston, TX 77030 USA; [Li, J.; Yi, Z.; Liu, M.] E China Normal Univ, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200062, Peoples R China; [Li, J.; Yi, Z.; Liu, M.] E China Normal Univ, Sch Life Sci, Shanghai 200062, Peoples R China	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; East China Normal University; East China Normal University	Liu, M (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Ctr Canc & Stem Cell Biol, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	mliu@ibt.tamhsc.edu		Siwko, Stefan/0000-0003-4260-2985	State Key Development Programs of China [2012CB910400]; DOD Prostate Cancer Research Program (PCRP) [W81XWH-10-1-0612, W81XWH-10-10147]; NIH [5R01CA134731]; NATIONAL CANCER INSTITUTE [R01CA134731] Funding Source: NIH RePORTER	State Key Development Programs of China; DOD Prostate Cancer Research Program (PCRP); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Michael Ittmann (Baylor College of Medicine) for his insights and suggestions. We thank Dr Fen Wang (Texas A&M Health Science Center) for the gift of the PTEN<SUP>fl/fl</SUP> Cre mice and for valuable discussions and suggestions, and Dr Dekai Zhang (Texas A&M Health Science Center) for the gift of the RAW264.7 cells. This work was partially supported by grants from the State Key Development Programs of China (2012CB910400), DOD Prostate Cancer Research Program (PCRP, W81XWH-10-1-0612, W81XWH-10-10147) and NIH (5R01CA134731). This work was partially supported by grants from the State Key Development Programs of China (2012CB910400), DOD Prostate Cancer Research Program (PCRP, W81XWH-10-1-0612, W81XWH-10-10147) and NIH (5R01CA134731).	Cairns P, 1997, CANCER RES, V57, P4997; Cano P, 2007, CANCER RES, V67, P511, DOI 10.1158/0008-5472.CAN-06-1478; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Cunha GR, 2003, INT J CANCER, V107, P1, DOI 10.1002/ijc.11335; Giles Graham G, 2003, Methods Mol Med, V81, P1; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gurel B, 2014, CANCER EPIDEM BIOMAR, V23, P847, DOI 10.1158/1055-9965.EPI-13-1126; Kwon OJ, 2014, P NATL ACAD SCI USA, V111, pE592, DOI 10.1073/pnas.1318157111; Lai KP, 2012, EMBO MOL MED, V4, P791, DOI 10.1002/emmm.201101140; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lee JT, 2008, CELL CYCLE, V7, P1745, DOI 10.4161/cc.7.12.6166; Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055; MacKenzie L, 2012, HUM PATHOL, V43, P1491, DOI 10.1016/j.humpath.2011.11.009; McCall P, 2012, BRIT J CANCER, V107, P1554, DOI 10.1038/bjc.2012.372; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12188, DOI 10.1073/pnas.0804701105; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rodriguez M, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.29; Roy AK, 1999, VITAM HORM, V55, P309; Russell Pamela J, 2003, Methods Mol Med, V81, P21; Sanz G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085110; Shen MM, 2007, CANCER RES, V67, P6535, DOI 10.1158/0008-5472.CAN-07-1271; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Vanaja DK, 2003, CANCER RES, V63, P3877; Wang JH, 2006, PROSTATE, V66, P847, DOI 10.1002/pros.20389; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Weng JS, 2005, J CELL BIOCHEM, V96, P1034, DOI 10.1002/jcb.20600; Weng JS, 2005, INT J CANCER, V113, P811, DOI 10.1002/ijc.20635; Wikstrom P, 2009, PROSTATE, V69, P799, DOI 10.1002/pros.20927; Xia CZ, 2001, ONCOGENE, V20, P5903, DOI 10.1038/sj.onc.1204803; Xu LL, 2000, CANCER RES, V60, P6568; Xu LL, 2006, PROSTATE CANCER P D, V9, P56, DOI 10.1038/sj.pcan.4500836; Yoshimoto M, 2007, BRIT J CANCER, V97, P678, DOI 10.1038/sj.bjc.6603924; Yoshimoto M, 2008, MODERN PATHOL, V21, P1451, DOI 10.1038/modpathol.2008.96; Zhang LY, 2009, AM J PATHOL, V175, P489, DOI 10.2353/ajpath.2009.080727; Zhou Y, 2015, J MOL ENDOCRINOL, V54, pR15, DOI 10.1530/JME-14-0203	40	24	24	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1153	1162		10.1038/onc.2015.170	http://dx.doi.org/10.1038/onc.2015.170			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	26028029	Green Accepted			2022-12-17	WOS:000371351700009
J	Yin, N; Qi, X; Tsai, S; Lu, Y; Basir, Z; Oshima, K; Thomas, JP; Myers, CR; Stoner, G; Chen, G				Yin, N.; Qi, X.; Tsai, S.; Lu, Y.; Basir, Z.; Oshima, K.; Thomas, J. P.; Myers, C. R.; Stoner, G.; Chen, G.			p38 gamma MAPK is required for inflammation-associated colon tumorigenesis	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; RAS TRANSFORMATION; ESTROGEN-RECEPTOR; BETA-CATENIN; CANCER; STRESS; CARCINOGENESIS; PIRFENIDONE; EXPRESSION; PATHWAY	Chronic inflammation has long been considered to causatively link to colon cancer development. However, signal transduction pathways involved remain largely unidentified. Here, we report that p38 gamma mitogen-activated protein kinase mediates inflammatory signaling to promote colon tumorigenesis. Inflammation activates p38 gamma in mouse colon tissues and intestinal epithelial cell-specific p38 gamma knockout (KO) attenuates colitis and inhibits pro-inflammatory cytokine expression. Significantly, p38 gamma KO inhibits tumorigenesis in a colitis-associated mouse model. The specific p38 gamma pharmacological inhibitor pirfenidone also suppresses pro-inflammatory cytokine expression and colon tumorigenesis. The tumor-promoting activity of epithelial p38 gamma was further demonstrated by xenograft studies. In addition, p38 gamma is required for beta-catenin/Wnt activities and p38 gamma stimulates Wnt transcription by phosphorylating beta-catenin at Ser605. These results show that p38 gamma activation links inflammation and colon tumorigenesis. Targeting p38 gamma may be a novel strategy for colon cancer prevention and treatment.	[Yin, N.; Qi, X.; Myers, C. R.; Chen, G.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, 8701 Watertown Plank Rd,BSB 660, Milwaukee, WI 53226 USA; [Tsai, S.] Med Coll Wisconsin, Dept Surg, Milwaukee, WI 53226 USA; [Lu, Y.] Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USA; [Basir, Z.; Oshima, K.] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA; [Thomas, J. P.; Stoner, G.] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; [Chen, G.] Med Coll Wisconsin, Zablocki Vet Affairs Med Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	Chen, G (corresponding author), Med Coll Wisconsin, Dept Pharmacol & Toxicol, 8701 Watertown Plank Rd,BSB 660, Milwaukee, WI 53226 USA.	gchen@mcw.edu	Yin, Ning/AAA-7617-2020; Oshima, Kiyoko/CAF-1543-2022	Myers, Charles/0000-0001-7956-3217	Department of Veterans Affairs Merit Review [I01BX002883]; Cancer Center of Medical College of Wisconsin (the State of Wisconsin Tax Check-Off Program); Clinical & Translational Science Institute (CTSI) of Southeast Wisconsin; Veterans Affairs [I01BX002883] Funding Source: NIH RePORTER	Department of Veterans Affairs Merit Review(US Department of Veterans Affairs); Cancer Center of Medical College of Wisconsin (the State of Wisconsin Tax Check-Off Program); Clinical & Translational Science Institute (CTSI) of Southeast Wisconsin; Veterans Affairs(US Department of Veterans Affairs)	We thank Boehringer Ingelheim Pharmaceuticals Inc. and Dr Zhen Yan (University of Virginia) for providing the floxed p38 gamma mice. We also thank former lab members Drs PS Suresh for maintaining mice and conducting some preliminary experiments, and S Hou for generating the p38 gamma-depleted HCT116 cell lines. In addition, we express our gratitude to Drs D Wang (Blood Institute of Wisconsin), A Chan, R Li and J Tichelaar (Medical College of Wisconsin) for useful discussions. We also thank Drs J Han (The Scripps Research Institute), A Cuenda (National Center for Biotechnology-CSIC), NK Tonks (Cold Spring Harbor) and H Howe (South Carolina University) for providing various reagents. This work was in part supported by the grants from the Department of Veterans Affairs Merit Review (I01BX002883), the Cancer Center of Medical College of Wisconsin (the State of Wisconsin Tax Check-Off Program), and Clinical & Translational Science Institute (CTSI) of Southeast Wisconsin (to GC).	Abdollahi T, 2005, APOPTOSIS, V10, P1383, DOI 10.1007/s10495-005-2139-x; Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097-2765(00)00012-5; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; del Reino P, 2014, CANCER RES, V74, P6150, DOI 10.1158/0008-5472.CAN-14-0870; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Gillespie MA, 2009, J CELL BIOL, V187, P991, DOI 10.1083/jcb.200907037; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gupta J, 2014, CANCER CELL, V25, P484, DOI 10.1016/j.ccr.2014.02.019; Hou SW, 2010, CANCER RES, V70, P2901, DOI 10.1158/0008-5472.CAN-09-3229; Hou SW, 2012, J BIOL CHEM, V287, P27895, DOI 10.1074/jbc.M111.335794; Hui LJ, 2007, NAT GENET, V39, P741, DOI 10.1038/ng2033; Kim C, 2008, NAT IMMUNOL, V9, P1019, DOI 10.1038/ni.1640; Korb A, 2006, ARTHRITIS RHEUM, V54, P2745, DOI 10.1002/art.22080; Kozono S, 2013, CANCER RES, V73, P2345, DOI 10.1158/0008-5472.CAN-12-3180; Kyriakis JM, 2012, PHYSIOL REV, V92, P689, DOI 10.1152/physrev.00028.2011; Lee MH, 2009, FASEB J, V23, P3874, DOI 10.1096/fj.08-117804; Liu LX, 2003, WORLD J GASTROENTERO, V9, P683, DOI 10.3748/wjg.v9.i4.683; Loesch M, 2010, J BIOL CHEM, V285, P15149, DOI 10.1074/jbc.M110.105429; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Meng FY, 2011, NEOPLASIA, V13, P472, DOI 10.1593/neo.101748; Moran N, 2011, NAT BIOTECHNOL, V29, P301, DOI 10.1038/nbt0411-301; Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279; Noble PW, 2011, LANCET, V377, P1760, DOI 10.1016/S0140-6736(11)60405-4; Oku H, 2002, EUR J PHARMACOL, V446, P167, DOI 10.1016/S0014-2999(02)01757-0; Otsuka M, 2010, GASTROENTEROLOGY, V138, P1255, DOI 10.1053/j.gastro.2010.01.005; Ozes O, 2008, United States Patent-US, P1, Patent No. [7,407,973, 7407973, US7407973B2]; Pogozelski AR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007934; Qi XM, 2007, J BIOL CHEM, V282, P31398, DOI 10.1074/jbc.M703857200; Qi XM, 2006, CANCER RES, V66, P7540, DOI 10.1158/0008-5472.CAN-05-4639; Qi XM, 2014, ONCOTARGET, V5, P4269, DOI 10.18632/oncotarget.2001; Qi XM, 2012, J BIOL CHEM, V287, P14681, DOI 10.1074/jbc.M112.349357; Qi XM, 2004, J BIOL CHEM, V279, P22138, DOI 10.1074/jbc.M313964200; Rhodes JM, 2002, TRENDS MOL MED, V8, P10, DOI 10.1016/S1471-4914(01)02194-3; Risco A, 2012, P NATL ACAD SCI USA, V109, P11200, DOI 10.1073/pnas.1207290109; Rosenthal DT, 2011, CANCER RES, V71, P6338, DOI 10.1158/0008-5472.CAN-11-1291; Sabio G, 2005, EMBO J, V24, P1134, DOI 10.1038/sj.emboj.7600578; Schreiber S, 2006, CLIN GASTROENTEROL H, V4, P325, DOI 10.1016/j.cgh.2005.11.013; Seril DN, 2003, CARCINOGENESIS, V24, P353, DOI 10.1093/carcin/24.3.353; Suzuki R, 2006, CARCINOGENESIS, V27, P162, DOI 10.1093/carcin/bgi205; Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1; Tang J, 2005, J BIOL CHEM, V280, P23910, DOI 10.1074/jbc.M500699200; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Tian Y, 2013, AM J PATHOL, V182, P2310, DOI 10.1016/j.ajpath.2013.02.037; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Wakeman D, 2012, SURGERY, V152, P286, DOI 10.1016/j.surg.2012.05.009; Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052; Yang K, 2013, SCI REP-UK, V3, DOI 10.1038/srep03021	49	24	24	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2016	35	8					1039	1048		10.1038/onc.2015.158	http://dx.doi.org/10.1038/onc.2015.158			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE7NF	25961922				2022-12-17	WOS:000370823300009
J	Komatsu, Y; Christian, SL; Ho, N; Pongnopparat, T; Licursi, M; Hirasawa, K				Komatsu, Y.; Christian, S. L.; Ho, N.; Pongnopparat, T.; Licursi, M.; Hirasawa, K.			Oncogenic Ras inhibits IRF1 to promote viral oncolysis	ONCOGENE			English	Article							INTERFERON-ALPHA RESISTANCE; TRANSCRIPTION FACTOR; MESSENGER-RNA; ANTIVIRAL RESPONSE; SIGNALING PATHWAY; CANCER-THERAPY; CONSTITUTIVE EXPRESSION; INDUCIBLE GENES; MEASLES-VIRUS; IFN-BETA	Oncolytic viruses exploit common molecular changes in cancer cells, which are not present in normal cells, to target and kill cancer cells. Ras transformation and defects in type I interferon (IFN)-mediated antiviral responses are known to be the major mechanisms underlying viral oncolysis. Previously, we demonstrated that oncogenic RAS/Mitogen-activated protein kinase kinase (Ras/MEK) activation suppresses the transcription of many IFN-inducible genes in human cancer cells, suggesting that Ras transformation underlies type I IFN defects in cancer cells. Here, we investigated how Ras/MEK downregulates IFN-induced transcription. By conducting promoter deletion analysis of IFN-inducible genes, namely guanylate-binding protein 2 and IFN gamma inducible protein 47 (Ifi47), we identified the IFN regulatory factor 1 (IRF1) binding site as the promoter region responsible for the regulation of transcription by MEK. MEK inhibition promoted transcription of the IFN-inducible genes in wild type mouse embryonic fibroblasts (MEFs), but not in IRF1(-/-) MEFs, showing that IRF1 is involved in MEK-mediated downregulation of IFN-inducible genes. Furthermore, IRF1 protein expression was lower in RasV12 cells compared with vector control NIH3T3 cells, but was restored to equivalent levels by inhibition of MEK. Similarly, the restoration of IRF1 expression by MEK inhibition was observed in human cancer cells. IRF1 re-expression in human cancer cells caused cells to become resistant to infection by the oncolytic vesicular stomatitis virus strain. Together, this work demonstrates that Ras/MEK activation in cancer cells downregulates transcription of IFN-inducible genes by targeting IRF1 expression, resulting in increased susceptibility to viral oncolysis.	[Komatsu, Y.; Ho, N.; Pongnopparat, T.; Licursi, M.; Hirasawa, K.] Mem Univ Newfoundland, Fac Med, Div Biomed Sci, St John, NF A1B 3V6, Canada; [Christian, S. L.] Mem Univ Newfoundland, Fac Med, Dept Biochem, St John, NF A1B 3V6, Canada	Memorial University Newfoundland; Memorial University Newfoundland	Hirasawa, K (corresponding author), Mem Univ Newfoundland, Fac Med, Div Biomed Sci, 300 Prince Philip Dr, St John, NF A1B 3V6, Canada.	kensuke@mun.ca		Christian, Sherri/0000-0002-4289-4386	Canadian Institutes for Health Research (CIHR); Regional Development Corporation of Newfoundland and Labrador (RDC); Canadian Breast Cancer Foundation (CBCF); Beatrice Hunter Cancer Research Institute; Cancer Research Training Program as part of The Terry Fox Foundation Strategic Health Research Training Program in Cancer Research at CIHR	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Regional Development Corporation of Newfoundland and Labrador (RDC); Canadian Breast Cancer Foundation (CBCF); Beatrice Hunter Cancer Research Institute; Cancer Research Training Program as part of The Terry Fox Foundation Strategic Health Research Training Program in Cancer Research at CIHR	This work was supported by grants (to KH) from the Canadian Institutes for Health Research (CIHR), the Regional Development Corporation of Newfoundland and Labrador (RDC) and Canadian Breast Cancer Foundation (CBCF). SLC was supported by a post-doctoral award from CIHR and RDC and a separate trainee award from the Beatrice Hunter Cancer Research Institute with funds provided by the Cancer Research Training Program as part of The Terry Fox Foundation Strategic Health Research Training Program in Cancer Research at CIHR. Special thanks to Dr John Bell (Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Canada) for VSV and VSVM51R, and Nebiur E A for graphic design. We thank Susan Wakeham and Rahul-dev Kalsi for technical support.	Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Balachandran S, 2001, J VIROL, V75, P3474, DOI 10.1128/JVI.75.7.3474-3479.2001; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Battcock SA, 2006, J VIROL, V80, P4422, DOI 10.1128/JVI.80.9.4422-4430.2006; Bell J, 2010, MOL THER, V18, P233, DOI 10.1038/mt.2009.314; Bergmann M, 2001, CANCER RES, V61, P8188; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Brien JD, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002230; Cascallo M, 2003, CANCER RES, V63, P5544; Christian SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044267; Christian SL, 2009, J VIROL, V83, P6717, DOI 10.1128/JVI.02213-08; Doherty GM, 2001, ANN SURG, V233, P623, DOI 10.1097/00000658-200105000-00005; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103; Farassati F, 2001, NAT CELL BIOL, V3, P745, DOI 10.1038/35087061; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Goetz C, 2010, MOL THER, V18, P1937, DOI 10.1038/mt.2010.145; GOLDSTEIN D, 1986, CANCER RES, V46, P4315; Iankov I, 2014, MOL THER, V22, pS12; Kanazawa N, 2004, J VIROL, V78, P9713, DOI 10.1128/JVI.78.18.9713-9720.2004; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; Kurokawa C, 2014, MOL THER, V22, pS248; Landolfo S, 2000, Hematol J, V1, P7, DOI 10.1038/sj.thj.6200004; Lian J, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.70; Liu X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058489; Marcato P, 2007, MOL THER, V15, P1522, DOI 10.1038/sj.mt.6300179; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Moriyama Y, 2001, CLIN CANCER RES, V7, P1293; Nguyen TLA, 2008, P NATL ACAD SCI USA, V105, P14981, DOI 10.1073/pnas.0803988105; Norman KL, 2005, DRUG DISCOV TODAY, V10, P847, DOI 10.1016/S1359-6446(05)03483-5; Noser JA, 2007, MOL THER, V15, P1531, DOI 10.1038/sj.mt.6300193; Phillips A, 2008, ONCOGENE, V27, P1645, DOI 10.1038/sj.onc.1210785; PINE R, 1992, J VIROL, V66, P4470, DOI 10.1128/JVI.66.7.4470-4478.1992; Portales-Casamar E, 2010, NUCLEIC ACIDS RES, V38, pD105, DOI 10.1093/nar/gkp950; Puhlmann J, 2010, ONCOGENE, V29, P2205, DOI 10.1038/onc.2009.507; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; Sakai I, 2002, BLOOD, V100, P2926, DOI 10.1182/blood-2002-01-0073; Scheper GC, 2002, J BIOL CHEM, V277, P3303, DOI 10.1074/jbc.M103607200; Shang D, 2007, CANCER SCI, V98, P1259, DOI 10.1111/j.1349-7006.2007.00526.x; Stojdl DF, 2003, CANCER CELL, V4, P263, DOI 10.1016/S1535-6108(03)00241-1; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Sun WH, 1998, BLOOD, V91, P570, DOI 10.1182/blood.V91.2.570.570_570_576; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Topisirovic I, 2004, CANCER RES, V64, P8639, DOI 10.1158/0008-5472.CAN-04-2677; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156	50	24	24	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					3985	3993		10.1038/onc.2014.331	http://dx.doi.org/10.1038/onc.2014.331			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25347735				2022-12-17	WOS:000358544200011
J	Mo, P; Zhou, Q; Guan, L; Wang, Y; Wang, W; Miao, M; Tong, Z; Li, M; Majaz, S; Liu, Y; Su, G; Xu, J; Yu, C				Mo, P.; Zhou, Q.; Guan, L.; Wang, Y.; Wang, W.; Miao, M.; Tong, Z.; Li, M.; Majaz, S.; Liu, Y.; Su, G.; Xu, J.; Yu, C.			Amplified in breast cancer 1 promotes colorectal cancer progression through enhancing notch signaling	ONCOGENE			English	Article							STEROID-RECEPTOR COACTIVATOR-3; CELL-PROLIFERATION; TRANSCRIPTIONAL COACTIVATOR; COLON CARCINOGENESIS; SRC-3 COACTIVATOR; AIB1; ACTIVATION; GROWTH; OVEREXPRESSION; SUPPRESSION	Aberrant activation of Notch signaling has an essential role in colorectal cancer (CRC) progression. Amplified in breast cancer 1 (AIB1), also known as steroid receptor coactivator 3 or NCOA3, is a transcriptional coactivator that promotes cancer cell proliferation and invasiveness. However, AIB1 implication in CRC progression through enhancing Notch signaling is unknown. In this study, we found that several CRC cell lines expressed high levels of AIB1, and knockdown of AIB1 decreased cell proliferation, colony formation and tumorigenesis of these CRC cells. Specifically, knockdown of AIB1 inhibited cell cycle progression at G1 phase by decreasing the mRNA levels of cyclin A2, cyclin B1, cyclin E2 and hairy and enhancer of split (Hes) 1. Furthermore, AIB1 interacted with Notch intracellular domain and Mastermind-like 1 and was recruited to the Hes1 promoter to enhance Notch signaling. Downregulation of AIB1 also decreased CRC cell invasiveness in vitro and lung metastasis in vivo. Besides that, knockout of AIB1 in mice inhibited colon carcinogenesis induced by azoxymethane/dextran sodium sulfate treatment. The mRNA levels of cyclin B1 and Hes5 were downregulated, but p27, ATOH1 and MUC2 were upregulated in the colon tumors from AIB1-deficient mice compared with those from wild-type mice. Thus, our results signify the importance of AIB1 in CRC and demonstrate that AIB1 promotes CRC progression at least in part through enhancing Notch signaling, suggesting that AIB1 is a potential molecular target for CRC treatment.	[Mo, P.; Zhou, Q.; Guan, L.; Wang, Y.; Wang, W.; Miao, M.; Tong, Z.; Li, M.; Majaz, S.; Liu, Y.; Yu, C.] Xiamen Univ, Sch Life Sci, Innovat Ctr Cell Biol, State Key Lab Cellular Stress Biol, Xiamen 361005, Fujian, Peoples R China; [Su, G.] Xiamen Univ, Affiliated Hosp 1, Xiamen 361005, Fujian, Peoples R China; [Xu, J.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Xiamen University; Xiamen University; Baylor College of Medicine	Yu, C (corresponding author), Xiamen Univ, Sch Life Sci, Innovat Ctr Cell Biol, State Key Lab Cellular Stress Biol, Xiamen 361005, Fujian, Peoples R China.	cdyu@xmu.edu.cn	Tong, Zhangwei/V-2475-2019; Zhou, Qiling/AAB-2493-2021		National Natural Science Foundation of China [81071671, 31170819]; Fundamental Research Funds for the Central Universities [2012121038]; New Teachers Award of the Ministry of Education [20110121120004]; 111 Project [B12001]; NIH [CA112403, DK058242]; NATIONAL CANCER INSTITUTE [R01CA112403] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058242, P01DK059820] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); New Teachers Award of the Ministry of Education; 111 Project(Ministry of Education, China - 111 Project); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Dawang Zhou (Xiamen University) for providing HA-NICD, FLAG-NICD and Myc-NICD constructs, and Dr Lizhi Wu (University of Florida) for providing FLAG-MAML1 and pGL3-Hes1-promoter plasmids. This work was supported by grants from the National Natural Science Foundation of China (no. 81071671 and 31170819 to CY), the Fundamental Research Funds for the Central Universities (no. 2012121038 to CY), the New Teachers Award of the Ministry of Education (no. 20110121120004 to PM), and 111 Project B12001. JX is supported by the CA112403 and DK058242 NIH grants.	Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bar Y, 2008, DIABETES, V57, P2413, DOI 10.2337/db07-1323; Chen Q, 2012, HEPATOLOGY, V55, P1820, DOI 10.1002/hep.25549; Christofori G, 2011, CANCER CELL, V19, P6, DOI 10.1016/j.ccr.2011.01.003; Chung ACK, 2007, CANCER RES, V67, P5965, DOI 10.1158/0008-5472.CAN-06-3168; Fereshteh MP, 2008, CANCER RES, V68, P3697, DOI 10.1158/0008-5472.CAN-07-6702; Fernandez-Majada V, 2007, P NATL ACAD SCI USA, V104, P276, DOI 10.1073/pnas.0606476104; Hansson ML, 2009, NUCLEIC ACIDS RES, V37, P2996, DOI 10.1093/nar/gkp163; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kishimoto H, 2005, CARCINOGENESIS, V26, P1706, DOI 10.1093/carcin/bgi137; Kuang SQ, 2005, CANCER RES, V65, P7993, DOI 10.1158/0008-5472.CAN-05-1179; Kuang SQ, 2004, CANCER RES, V64, P1875, DOI 10.1158/0008-5472.CAN-03-3745; Kurooka K, 2000, J BIOL CHEM, V275, P17211, DOI 10.1074/jbc.M000909200; Lin S, 2013, ONCOGENE, V32, P4845, DOI 10.1038/onc.2012.482; Liu YH, 2012, HEPATOLOGY, V56, P1015, DOI 10.1002/hep.25751; Long WW, 2012, J CLIN INVEST, V122, P1869, DOI 10.1172/JCI61492; Long WW, 2010, MOL CELL, V37, P321, DOI 10.1016/j.molcel.2010.01.004; Louet JF, 2006, P NATL ACAD SCI USA, V103, P17868, DOI 10.1073/pnas.0608711103; Louie MC, 2004, MOL CELL BIOL, V24, P5157, DOI 10.1128/MCB.24.12.5157-5171.2004; Miyamoto S, 2013, CARCINOGENESIS, V34, P2415, DOI 10.1093/carcin/bgt191; Monahan P, 2009, ENDOCRINOLOGY, V150, P4386, DOI 10.1210/en.2009-0206; Murata K, 2005, MOL CELL BIOL, V25, P4262, DOI 10.1128/MCB.25.10.4262-4271.2005; Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279; Park KJ, 2005, MOL CELL, V18, P71, DOI 10.1016/j.molcel.2005.03.006; Qiao L, 2009, CARCINOGENESIS, V30, P1979, DOI 10.1093/carcin/bgp236; Qin L, 2008, MOL CELL BIOL, V28, P5937, DOI 10.1128/MCB.00579-08; Ranganathan P, 2011, NAT REV CANCER, V11, P338, DOI 10.1038/nrc3035; Sikandar SS, 2010, CANCER RES, V70, P1469, DOI 10.1158/0008-5472.CAN-09-2557; Tien JCY, 2009, INT J BIOL SCI, V5, P256; Ueo T, 2012, DEVELOPMENT, V139, P1071, DOI 10.1242/dev.069070; Wallberg AE, 2002, MOL CELL BIOL, V22, P7812, DOI 10.1128/MCB.22.22.7812-7819.2002; Wang Y, 2014, CANCER RES, V74, P1506, DOI 10.1158/0008-5472.CAN-13-2939; Wang Y, 2011, MOL ENDOCRINOL, V25, P2041, DOI 10.1210/me.2011-1222; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Xie D, 2005, HUM PATHOL, V36, P777, DOI 10.1016/j.humpath.2005.05.007; Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695; Xu Y, 2010, ONCOGENE, V29, P3386, DOI 10.1038/onc.2010.90; Yan J, 2006, ACTA PHARMACOL SIN, V27, P387, DOI 10.1111/j.1745-7254.2006.00315.x; Yan J, 2008, CANCER RES, V68, P5460, DOI 10.1158/0008-5472.CAN-08-0955; Yan J, 2006, CANCER RES, V66, P11039, DOI 10.1158/0008-5472.CAN-06-2442; Yatim A, 2012, MOL CELL, V48, P445, DOI 10.1016/j.molcel.2012.08.022; Yu CD, 2007, MOL CELL, V25, P765, DOI 10.1016/j.molcel.2007.01.025; Zanotti S, 2010, MOL CELL BIOL, V30, P886, DOI 10.1128/MCB.01285-09; Zhang Y, 2010, CANCER-AM CANCER SOC, V116, P5207, DOI 10.1002/cncr.25449; Zhou HJ, 2005, CANCER RES, V65, P7976, DOI 10.1158/0008-5472.CAN-04-4076	46	24	25	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					3935	3945		10.1038/onc.2014.324	http://dx.doi.org/10.1038/onc.2014.324			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25263446	Green Accepted			2022-12-17	WOS:000358544200006
J	Akaike, Y; Kuwano, Y; Nishida, K; Kurokawa, K; Kajita, K; Kano, S; Masuda, K; Rokutan, K				Akaike, Y.; Kuwano, Y.; Nishida, K.; Kurokawa, K.; Kajita, K.; Kano, S.; Masuda, K.; Rokutan, K.			Homeodomain-interacting protein kinase 2 regulates DNA damage response through interacting with heterochromatin protein 1 gamma	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; TRANSCRIPTION FACTORS; TUMOR-SUPPRESSOR; P53 ACTIVITY; HIPK2; REPAIR; PHOSPHORYLATION; CELLS; HP1; RECRUITMENT	Homeodomain-interacting protein kinase 2 (HIPK2) is a potential tumor suppressor that has a crucial role in the DNA damage response (DDR) by regulating cell-cycle checkpoint activation and apoptosis. However, it is unclear whether HIPK2 exerts distinct roles in DNA damage repair. The aim of this study was to identify novel target molecule(s) of HIPK2, which mediates HIPK2-dependent DNA damage repair. HIPK2-knockdown human colon cancer cells (HCT116) or hipk1/hipk2 double-deficient mouse embryonic fibroblasts could not remove histone H2A.X phosphorylated at Ser139 (gamma H2A.X) after irradiation with a sublethal dose (10 J/m(2)) of ultraviolet (UV)-C, resulting in apoptosis. Knockdown of HIPK2 in p53-null HCT116 cells similarly promoted the UV-C-induced gamma H2A.X accumulation and apoptosis. Proteomic analysis of HIPK2-associated proteins using liquid chromatography-tandem mass spectrometry identified heterochromatin protein 1 gamma (HP1 gamma) as a novel target for HIPK2. Immunoprecipitation experiments with HCT116 cells expressing FLAG-tagged HIPK2 and one of the HA-tagged HP1 family members demonstrated that HIPK2 specifically associated with HP1 gamma, but not with HP1 alpha or HP1 beta, through its chromo-shadow domain. Mutation of the HP1box motif (883-PTVSV-887) within HIPK2 abolished the association. HP1 gamma knockdown also enhanced accumulation of gamma H2A.X and apoptosis after sublethal UV-C irradiation. In vitro kinase assay demonstrated an HP1 gamma-phosphorylating activity of HIPK2. Sublethal UV-C irradiation phosphorylated HP1 gamma. This phosphorylation was absent in endogenous HIPK2-silenced cells with HIPK2 3'UTR siRNA. Overexpression of FLAG-HIPK2, but not the HP1box-mutated or kinase-dead HIPK2 mutant, in the HIPK2-silenced cells increased HP1 gamma binding to trimethylated (Lys9) histone H3 (H3K9me3), rescued the UV-C-induced phosphorylation of HP1 gamma, triggered release of HP1 gamma from histone H3K9me3 and suppressed gamma H2A.X accumulation. Our results suggest that HIPK2-dependent phosphorylation of HP1 gamma may participate in the regulation of dynamic interaction between HP1 gamma and histone H3K9me3 to promote DNA damage repair. This HIPK2/HP1 gamma pathway may uncover a new functional aspect of HIPK2 as a tumor suppressor.	[Akaike, Y.; Kuwano, Y.; Nishida, K.; Kurokawa, K.; Kajita, K.; Kano, S.; Masuda, K.; Rokutan, K.] Univ Tokushima, Grad Sch, Dept Stress Sci, Inst Hlth Biosci, Tokushima 7708503, Japan	Tokushima University	Rokutan, K (corresponding author), Univ Tokushima, Grad Sch, Dept Stress Sci, Inst Hlth Biosci, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	rokutan@tokushima-u.ac.jp	Nishida, Kensei/AAF-2829-2020	Nishida, Kensei/0000-0003-2314-785X	JSPS [24-8354]	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by JSPS KAKENHI Grant Number 24-8354 (to YA).	[Anonymous], ONCOGENE; Ayoub N, 2008, NATURE, V453, P682, DOI 10.1038/nature06875; Baldeyron C, 2011, J CELL BIOL, V193, P81, DOI 10.1083/jcb.201101030; Cann KL, 2011, BIOCHEM CELL BIOL, V89, P45, DOI 10.1139/O10-113; Chiolo I, 2011, CELL, V144, P732, DOI 10.1016/j.cell.2011.02.012; Choi DW, 2013, MOL CELL, V51, P374, DOI 10.1016/j.molcel.2013.06.010; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Di Stefano V, 2005, ONCOGENE, V24, P5431, DOI 10.1038/sj.onc.1208717; Dinant C, 2009, MOL CELL BIOL, V29, P6335, DOI 10.1128/MCB.01048-09; Goodarzi AA, 2008, MOL CELL, V31, P167, DOI 10.1016/j.molcel.2008.05.017; Gresko E, 2006, EMBO J, V25, P1883, DOI 10.1038/sj.emboj.7601077; Grzenda A, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-21; Hiragami-Hamada K, 2011, MOL CELL BIOL, V31, P1186, DOI 10.1128/MCB.01012-10; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Hofmann TG, 2013, BIOESSAYS, V35, P55, DOI 10.1002/bies.201200060; Isono K, 2006, MOL CELL BIOL, V26, P2758, DOI 10.1128/MCB.26.7.2758-2771.2006; Jakob B, 2011, NUCLEIC ACIDS RES, V39, P6489, DOI 10.1093/nar/gkr230; Kim JA, 2007, J CELL BIOL, V178, P209, DOI 10.1083/jcb.200612031; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kuwano Y, 2010, NUCLEIC ACIDS RES, V38, P225, DOI 10.1093/nar/gkp861; Kwon SH, 2008, MOL CELLS, V26, P217; Kwon SH, 2011, BIOESSAYS, V33, P280, DOI 10.1002/bies.201000138; Lee DH, 2011, TRENDS BIOCHEM SCI, V36, P569, DOI 10.1016/j.tibs.2011.08.007; Lee YH, 2013, NUCLEIC ACIDS RES, V41, P5784, DOI 10.1093/nar/gkt231; Leroy G, 2009, MOL CELL PROTEOMICS, V8, P2432, DOI 10.1074/mcp.M900160-MCP200; Lobrich M, 2010, CELL CYCLE, V9, P662, DOI 10.4161/cc.9.4.10764; Lomberk G, 2006, NAT CELL BIOL, V8, P407, DOI 10.1038/ncb1383; Lomberk G, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-228; Luijsterburg MS, 2009, J CELL BIOL, V185, P577, DOI 10.1083/jcb.200810035; Mah LJ, 2010, LEUKEMIA, V24, P679, DOI 10.1038/leu.2010.6; Minc E, 2000, CYTOGENET CELL GENET, V90, P279, DOI 10.1159/000056789; Mund A, 2012, NUCLEIC ACIDS RES, V40, P11363, DOI 10.1093/nar/gks868; Nardinocchi L, 2007, BIOCHEM BIOPH RES CO, V361, P249, DOI 10.1016/j.bbrc.2007.07.031; Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0; Noon AT, 2010, NAT CELL BIOL, V12, P177, DOI 10.1038/ncb2017; Papamichos-Chronakis M, 2013, NAT REV GENET, V14, P62, DOI 10.1038/nrg3345; Pontarin G, 2012, P NATL ACAD SCI USA, V109, P13302, DOI 10.1073/pnas.1211289109; Puca R, 2010, ONCOGENE, V29, P4378, DOI 10.1038/onc.2010.183; Rastogi RP, 2010, J NUCLEIC ACIDS, V2010, DOI 10.4061/2010/592980; Rinaldo C, 2007, BIOCHEM CELL BIOL, V85, P411, DOI 10.1139/O07-071; Rinaldo C, 2012, MOL CELL, V47, P87, DOI 10.1016/j.molcel.2012.04.029; Saul VV, 2013, J MOL CELL BIOL, V5, P27, DOI 10.1093/jmcb/mjs053; Smothers JF, 2000, CURR BIOL, V10, P27, DOI 10.1016/S0960-9822(99)00260-2; Sombroek D, 2009, CELL DEATH DIFFER, V16, P187, DOI 10.1038/cdd.2008.154; Soria G, 2012, MOL CELL, V46, P722, DOI 10.1016/j.molcel.2012.06.002; Wei GW, 2007, P NATL ACAD SCI USA, V104, P13040, DOI 10.1073/pnas.0703213104; Winter M, 2008, NAT CELL BIOL, V10, P812, DOI 10.1038/ncb1743; Yamada D, 2009, ONCOGENE, V28, P2535, DOI 10.1038/onc.2009.109; Yamaguchi T, 2001, CANCER RES, V61, P8256; Zarebski M, 2009, CYTOM PART A, V75A, P619, DOI 10.1002/cyto.a.20734; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X	51	24	25	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3463	3473		10.1038/onc.2014.278	http://dx.doi.org/10.1038/onc.2014.278			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	25151962				2022-12-17	WOS:000356871700011
J	Teneng, I; Tellez, CS; Picchi, MA; Klinge, DM; Yingling, CM; Snider, AM; Liu, Y; Belinsky, SA				Teneng, I.; Tellez, C. S.; Picchi, M. A.; Klinge, D. M.; Yingling, C. M.; Snider, A. M.; Liu, Y.; Belinsky, S. A.			Global identification of genes targeted by DNMT3b for epigenetic silencing in lung cancer	ONCOGENE			English	Article						DNMT3b; lung cancer; DNA methylation; MAL; OLIG2	DE-NOVO METHYLATION; NEURAL STEM-CELLS; DNA METHYLTRANSFERASES; PROMOTER HYPERMETHYLATION; TUMOR-SUPPRESSOR; MAL GENE; EXPRESSION; PROTEIN; EZH2; COMMON	The maintenance cytosine DNA methyltransferase DNMT1 and de novo methyltransferase DNMT3b cooperate to establish aberrant DNA methylation and chromatin complexes to repress gene transcription during cancer development. The expression of DNMT3b was constitutively increased 5-20-fold in hTERT/CDK4-immortalized human bronchial epithelial cells (HBECs) before treatment with low doses of tobacco carcinogens. Overexpression of DNMT3b increased and accelerated carcinogen-induced transformation. Genome-wide profiling of transformed HBECs identified 143 DNMT3b-target genes, many of which were transcriptionally regulated by the polycomb repressive complex 2 (PRC2) complex and silenced through aberrant methylation in non-small-cell lung cancer cell lines. Two genes studied in detail, MAL and OLIG2, were silenced during transformation, initially through enrichment for H3K27me3 and H3K9me2, commonly methylated in lung cancer, and exert tumor suppressor effects in vivo through modulating cancer-related pathways. Re-expression of MAL and OLIG2 to physiological levels dramatically reduced the growth of lung tumor xenografts. Our results identify a key role for DNMT3b in the earliest stages of initiation and provide a comprehensive catalog of genes targeted for silencing by this methyltransferase in non-small-cell lung cancer.	[Teneng, I.; Tellez, C. S.; Picchi, M. A.; Klinge, D. M.; Yingling, C. M.; Snider, A. M.; Liu, Y.; Belinsky, S. A.] Lovelace Resp Res Inst, Lung Canc Program, Albuquerque, NM 87108 USA	Lovelace Respiratory Research Institute	Belinsky, SA (corresponding author), Lovelace Resp Res Inst, 2425 Ridgecrest Dr SE, Albuquerque, NM 87108 USA.	sbelinsk@LRRI.org	Liu, Yushi/A-1533-2014	Liu, Yushi/0000-0003-4185-4187	NIH [R01 ES015262, 1F32 CA157082]; NATIONAL CANCER INSTITUTE [F32CA157082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015262] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Data generated by The Cancer Genome Atlas (TCGA) project established by the NCI and NHGRI were used to validate part of our findings. The dbGaP accession number for TCGA data is phs000178.v8.p7. Information about TCGA and the investigators and institutions that constitute the TCGA research network can be found at http://cancergenome.nih.gov/. We acknowledge the following for technical support: Kieu Do, Randall Willink, Christopher Dagucon and Daniel E Juri. We also thank Dr Shuguang Leng for help with TCGA data acquisition, Dr Xiequn Zhang for help with bioinformatics analyses and Dr Julie Hutt for pathology review of xenografted tumors. This study was supported by NIH Grants R01 ES015262 to SAB and 1F32 CA157082 to IT.	ALONSO MA, 1987, P NATL ACAD SCI USA, V84, P1997, DOI 10.1073/pnas.84.7.1997; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200; Belinsky SA, 2002, CANCER RES, V62, P2370; Belinsky SA, 2003, CANCER RES, V63, P7089; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; Buffart TE, 2008, BRIT J CANCER, V99, P1802, DOI 10.1038/sj.bjc.6604777; Cao W, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-296; Copray S, 2006, STEM CELLS, V24, P1001, DOI 10.1634/stemcells.2005-0239; Damiani LA, 2008, CANCER RES, V68, P9005, DOI 10.1158/0008-5472.CAN-08-1276; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; Fan H, 2012, ONCOGENE, V31, P2298, DOI 10.1038/onc.2011.411; Fatemi M, 2002, EUR J BIOCHEM, V269, P4981, DOI 10.1046/j.1432-1033.2002.03198.x; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gao Q, 2011, P NATL ACAD SCI USA, V108, P18061, DOI 10.1073/pnas.1114946108; Ghoshal K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010338; Girault I, 2003, CLIN CANCER RES, V9, P4415; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; HIRANO T, 1994, AM J PATHOL, V144, P296; Horne HN, 2009, MOL CANCER RES, V7, P199, DOI 10.1158/1541-7786.MCR-08-0314; Janssen-Heijnen MLG, 2003, LUNG CANCER-J IASLC, V41, P245, DOI 10.1016/S0169-5002(03)00230-7; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kim GD, 2002, EMBO J, V21, P4183, DOI 10.1093/emboj/cdf401; KIM T, 1995, J NEUROSCI RES, V42, P413, DOI 10.1002/jnr.490420316; Ligon KL, 2007, NEURON, V53, P503, DOI 10.1016/j.neuron.2007.01.009; Linhart HG, 2007, GENE DEV, V21, P3110, DOI 10.1101/gad.1594007; Marsit CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012334; Mimori K, 2003, ONCOGENE, V22, P3463, DOI 10.1038/sj.onc.1206378; Mokhtari K, 2005, NEUROPATH APPL NEURO, V31, P62, DOI 10.1111/j.1365-2990.2004.00612.x; Niehrs C, 2012, EMBO J, V31, P2705, DOI 10.1038/emboj.2012.124; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pulling LC, 2003, CANCER RES, V63, P4842; Qi W, 2012, P NATL ACAD SCI USA, V109, P21360, DOI 10.1073/pnas.1210371110; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507; Sato M, 2013, MOL CANCER RES, V11, P638, DOI 10.1158/1541-7786.MCR-12-0634-T; Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016; Tabu K, 2006, J CELL SCI, V119, P1433, DOI 10.1242/jcs.02854; Tabu K, 2007, MOL CANCER RES, V5, P1099, DOI 10.1158/1541-7786.MCR-07-0096; Tellez CS, 2011, CANCER RES, V71, P3087, DOI 10.1158/0008-5472.CAN-10-3035; Tessema M, 2010, ONCOGENE, V29, P5159, DOI 10.1038/onc.2010.255; Tessema M, 2013, J THR ONC IN PRESS; Tessema M, 2009, CARCINOGENESIS, V30, P1132, DOI 10.1093/carcin/bgp114; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Winklmeier A, 2009, CANCER SCI, V100, P261, DOI 10.1111/j.1349-7006.2008.01048.x; Yakushiji T, 2003, INT J ONCOL, V22, P1201; Yoo KH, 2012, INT J BIOL SCI, V8, P59, DOI 10.7150/ijbs.8.59; Zi XL, 2005, CANCER RES, V65, P9762, DOI 10.1158/0008-5472.CAN-05-0103	50	24	25	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2015	34	5					621	630		10.1038/onc.2013.580	http://dx.doi.org/10.1038/onc.2013.580			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DD	24469050				2022-12-17	WOS:000348853500009
J	Yun, HM; Park, MH; Kim, DH; Ahn, YJ; Park, KR; Kim, TM; Yun, NY; Jung, YS; Hwang, DY; Yoon, DY; Han, SB; Hong, JT				Yun, H-M; Park, M. H.; Kim, D. H.; Ahn, Y. J.; Park, K-R; Kim, T. M.; Yun, N. Y.; Jung, Y. S.; Hwang, D. Y.; Yoon, D. Y.; Han, S. B.; Hong, J. T.			Loss of presenilin 2 is associated with increased iPLA2 activity and lung tumor development	ONCOGENE			English	Article							AMYLOID PRECURSOR PROTEIN; E-CADHERIN CLEAVAGE; GAMMA-SECRETASE; ALZHEIMERS-DISEASE; PEROXIREDOXIN 6; CANCER-CELLS; INDUCED APOPTOSIS; BRAIN; IDENTIFICATION; TUMORIGENESIS	Presenilins are the enzymatic components of gamma-secretase complex that cleaves amyloid precursor protein, Notch and beta-catenin, which has critical roles in the development of Alzheimer's disease and cancer cell growth. Therefore, in the present study, we studied the effects and mechanisms of PS2 knockout on lung cancer development and possible mechanisms as a key regulator of lung tumor development. We compared carcinogen-induced tumor growth between PS2 knockout mice and wild-type mice. PS2 knockout mice showed increased urethane (1 mg/g)-induced lung tumor incidence when compared with that of wild-type mice with decreased activity of gamma-secretase in the lung tumor tissues. Consequently, iPLA2 activities in lung tumor tissues of PS2 knockout mice were much higher than in tumor tissues of wild-type mice. Furthermore, knockdown of PS2 using PS2 siRNA decreased gamma-secretase activity with increased iPLA2 activity in the lung cancer cells (A549 and NCI-H460), leading to increased lung cancer cell growth. PS2 knockout mice and PS2 knockdown lung cancer cells showed increased DNA-binding activities of nuclear factor kappa-beta, signal transducer and activator of transcription 3 (STAT3) and AP-1 which are critical transcriptional factors of iPLA2 than those of PS2 wild-type mice and control lung cancer cells. Taken together, these results suggest that the loss of PS2 could have a critical role in lung tumor development through the upregulation of iPLA2 activity by reducing gamma-secretase.	[Yun, H-M; Park, M. H.; Kim, D. H.; Ahn, Y. J.; Park, K-R; Yun, N. Y.; Han, S. B.; Hong, J. T.] Chungbuk Natl Univ, Coll Pharm, Cheongju 361763, Chungbuk, South Korea; [Yun, H-M; Park, M. H.; Kim, D. H.; Ahn, Y. J.; Park, K-R; Yun, N. Y.; Han, S. B.; Hong, J. T.] Chungbuk Natl Univ, Med Res Ctr, Cheongju 361763, Chungbuk, South Korea; [Kim, T. M.] Chungbuk Natl Univ, Coll Vet Med, Cheongju 361763, Chungbuk, South Korea; [Jung, Y. S.] Pusan Natl Univ, Coll Pharm, Pusan, South Korea; [Hwang, D. Y.] Pusan Natl Univ, Dept Biomat Sci, Miryang, Kyungnam, South Korea; [Yoon, D. Y.] Konkuk Univ, Bio Mol Informat Ctr, Dept Biosci & Biotechnol, Seoul, South Korea	Chungbuk National University; Chungbuk National University; Chungbuk National University; Pusan National University; Pusan National University; Konkuk University	Hong, JT (corresponding author), Chungbuk Natl Univ, Coll Pharm, 48 Gaeshin Dong, Cheongju 361763, Chungbuk, South Korea.	jinthong@chungbuk.ac.kr			National Research Foundation of Korea (NRF) - Korea Government (MSIP) [MRC, 2008-0062275]	National Research Foundation of Korea (NRF) - Korea Government (MSIP)	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MSIP) (No; MRC, 2008-0062275).	Beel AJ, 2008, CELL MOL LIFE SCI, V65, P1311, DOI 10.1007/s00018-008-7462-2; Bertram L, 2010, NEURON, V68, P270, DOI 10.1016/j.neuron.2010.10.013; Borgegard T, 2012, J BIOL CHEM, V287, P11810, DOI 10.1074/jbc.M111.305227; Boulton ME, 2008, J CELL MOL MED, V12, P781, DOI 10.1111/j.1582-4934.2008.00274.x; Chatterjee S, 2011, J BIOL CHEM, V286, P11696, DOI 10.1074/jbc.M110.206623; Chen FS, 2006, NATURE, V440, P1208, DOI 10.1038/nature04667; Chhunchha B, 2013, AM J PHYSIOL-CELL PH, V304, pC636, DOI 10.1152/ajpcell.00345.2012; Conti A, 2011, AM J PATHOL, V178, P88, DOI 10.1016/j.ajpath.2010.11.035; Das I, 2004, J BIOL CHEM, V279, P30771, DOI 10.1074/jbc.M309252200; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 2010, ANNU REV CELL DEV BI, V26, P235, DOI 10.1146/annurev-cellbio-100109-104117; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; Granville CA, 2005, AM J RESP CELL MOL, V32, P169, DOI 10.1165/rcmb.F290; Jo M, 2013, FREE RADICAL BIO MED, V61, P453, DOI 10.1016/j.freeradbiomed.2013.04.032; Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092-8674(02)00970-4; Kim SY, 2011, CELL DEATH DIFFER, V18, P1573, DOI 10.1038/cdd.2011.21; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Kovacs DM, 1999, J NEUROCHEM, V73, P2278, DOI 10.1046/j.1471-4159.1999.0732278.x; Lehtonen ST, 2004, INT J CANCER, V111, P514, DOI 10.1002/ijc.20294; Liu B, 2012, NEURO-ONCOLOGY, V14, P994, DOI 10.1093/neuonc/nos138; Liu Hai-yan, 2013, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V35, P19, DOI 10.3881/j.issn.1000-503X.2013.01.004; Liu Y, 2004, J PROTEOME RES, V3, P728, DOI 10.1021/pr034127+; McHowat J, 2011, AM J PHYSIOL-CELL PH, V300, pC825, DOI 10.1152/ajpcell.00502.2010; Munter LM, 2007, EMBO J, V26, P1702, DOI 10.1038/sj.emboj.7601616; Murakami D, 2003, ONCOGENE, V22, P1511, DOI 10.1038/sj.onc.1206298; Oh S, 2010, BIOCHEM BIOPH RES CO, V399, P91, DOI 10.1016/j.bbrc.2010.07.047; Olahova M, 2008, P NATL ACAD SCI USA, V105, P19839, DOI 10.1073/pnas.0805507105; Park CS, 2008, TOXICOL SCI, V106, P413, DOI 10.1093/toxsci/kfn197; Rahimi N, 2009, CANCER RES, V69, P2607, DOI 10.1158/0008-5472.CAN-08-2905; Rocher-Ros V, 2010, ONCOGENE, V29, P2950, DOI 10.1038/onc.2010.57; Roe CM, 2005, NEUROLOGY, V64, P895, DOI 10.1212/01.WNL.0000152889.94785.51; Sagi SA, 2011, J BIOL CHEM, V286, P39794, DOI 10.1074/jbc.M111.277228; Schremmer Bruno, 2007, V44, P317; Serrano J, 2010, ONCOGENE, V29, P2165, DOI 10.1038/onc.2009.503; Song X, 2012, HEAD NECK ONCOL, V4, P47; Takahashi T, 2002, ONCOGENE, V21, P6868, DOI 10.1038/sj.onc.1205830; Tanii H, 2000, NEUROSCIENCE, V95, P593; Tarassishin L, 2004, P NATL ACAD SCI USA, V101, P17050, DOI 10.1073/pnas.0408007101; Thun MJ, 2008, PLOS MED, V5, P1357, DOI 10.1371/journal.pmed.0050185; To MD, 2006, ONCOGENE, V25, P3557, DOI 10.1038/sj.onc.1209397; Cespedes MV, 2010, AM J PATHOL, V177, P2067, DOI 10.2353/ajpath.2010.100079; Wakabayashi T, 2008, PHYSIOLOGY, V23, P194, DOI 10.1152/physiol.00009.2008; Wang L, 2008, MOL PHARMACOL, V73, P119, DOI 10.1124/mol.107.040873; Wood WJL, 2003, J COMB CHEM, V5, P869, DOI 10.1021/cc034008r; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; Yan Ke-xia, 2004, Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, V22, P331; Yun HM, 2014, FREE RADICAL BIO MED, V69, P367, DOI 10.1016/j.freeradbiomed.2014.02.001; Zhang WP, 2007, MOL CARCINOGEN, V46, P372, DOI 10.1002/mc.20285; Zhang XZ, 2009, CANCER SCI, V100, P2396, DOI 10.1111/j.1349-7006.2009.01314.x	49	24	26	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2014	33	44					5193	5200		10.1038/onc.2014.128	http://dx.doi.org/10.1038/onc.2014.128			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR9RZ	24858037	hybrid, Green Published			2022-12-17	WOS:000343914900006
J	Dutruel, C; Bergmann, F; Rooman, I; Zucknick, M; Weichenhan, D; Geiselhart, L; Kaffenberger, T; Rachakonda, PS; Bauer, A; Giese, N; Hong, C; Xie, H; Costello, JF; Hoheisel, J; Kumar, R; Rehli, M; Schirmacher, P; Werner, J; Plass, C; Popanda, O; Schmezer, P				Dutruel, C.; Bergmann, F.; Rooman, I.; Zucknick, M.; Weichenhan, D.; Geiselhart, L.; Kaffenberger, T.; Rachakonda, P. S.; Bauer, A.; Giese, N.; Hong, C.; Xie, H.; Costello, J. F.; Hoheisel, J.; Kumar, R.; Rehli, M.; Schirmacher, P.; Werner, J.; Plass, C.; Popanda, O.; Schmezer, P.			Early epigenetic downregulation of WNK2 kinase during pancreatic ductal adenocarcinoma development	ONCOGENE			English	Article						genome-wide screen; CpG island methylation; chronic pancreatitis; pancreatic intraepithelial neoplasia; pancreatic cancer	DNA METHYLATION; CELL TRANSDIFFERENTIATION; INTRAEPITHELIAL NEOPLASIA; ABERRANT METHYLATION; PROTEIN-KINASE; CANCER; BIOLOGY; PROLIFERATION; PROFILE; GENES	Pancreatic ductal adenocarcinoma (PDAC) is usually incurable. Contrary to genetic mechanisms involved in PDAC pathogenesis, epigenetic alterations are ill defined. Here, we determine the contribution of epigenetically silenced genes to the development of PDAC. We analyzed enriched, highly methylated DNAs from PDACs, chronic pancreatitis (CP) and normal tissues using CpG island microarrays and identified WNK2 as a prominent candidate tumor suppressor gene being downregulated early in PDAC development. WNK2 was further investigated in tissue microarrays, methylation analysis of early pancreatic intraepithelial neoplasia (PanIN), mouse models for PDAC and pancreatitis, re-expression studies after demethylation, and cell growth assays using WNK2 overexpression. Demethylation assays confirmed the link between methylation and expression. WNK2 hypermethylation was higher in tumor than in surrounding inflamed tissues and was observed in PanIN lesions as well as in a PDAC mouse model. WNK2 mRNA and protein expressions were lower in PDAC and CP compared with normal tissues both in patients and mouse models. Overexpression of WNK2 led to reduced cell growth, and WNK2 expression in tissues correlated negatively with pERK1/2 expression, a downstream target of WNK2 responsible for cell proliferation. Downregulation of WNK2 by promoter hypermethylation occurs early in PDAC pathogenesis and may support tumor cell growth via the ERK-MAPK pathway.	[Dutruel, C.; Weichenhan, D.; Geiselhart, L.; Kaffenberger, T.; Plass, C.; Popanda, O.; Schmezer, P.] German Canc Res Ctr, Div Epigen & Canc Risk Factors, D-69120 Heidelberg, Germany; [Bergmann, F.; Schirmacher, P.] Univ Heidelberg Hosp, Inst Pathol, Heidelberg, Germany; [Rooman, I.] St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia; [Zucknick, M.] German Canc Res Ctr, Div Biostat, D-69120 Heidelberg, Germany; [Rachakonda, P. S.; Xie, H.; Kumar, R.] German Canc Res Ctr, Div Mol Genet Epidemiol, D-69120 Heidelberg, Germany; [Bauer, A.; Hoheisel, J.] German Canc Res Ctr, D-69120 Heidelberg, Germany; [Giese, N.; Werner, J.] Heidelberg Univ, Dept Gen Visceral & Transplantat Surg, Heidelberg, Germany; [Hong, C.; Costello, J. F.] Univ Calif San Francisco, Dept Neurosurg, Helen Diller Family Comprehens Canc Ctr, Brain Tumor Res Ctr, San Francisco, CA USA; [Rehli, M.] Univ Hosp Regensburg, Dept Hematol & Oncol, Regensburg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Garvan Institute of Medical Research; St Vincents Hospital Sydney; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of Regensburg	Schmezer, P (corresponding author), German Canc Res Ctr, Div Epigen & Canc Risk Factors, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	p.schmezer@dkfz.de	Kumar, Rajiv/H-6431-2019; Rehli, Michael/E-9093-2011; Popanda, Odilia/P-6917-2019	Kumar, Rajiv/0000-0002-6093-0395; Rehli, Michael/0000-0003-3992-932X; Xie, Huaping/0000-0003-1474-2470; Rooman, Ilse/0000-0001-7264-2246; Bauer, Andrea/0000-0002-7919-0497	Cancer Institute New South Wales, Australia [10FRL203]; German Federal Ministry of Education and Research [PKB-01GS08114]; German Federal Ministry of Education and Research as part of the PaCaNct consortium within the NGFN program; Fulbright commission in Germany; US State Department	Cancer Institute New South Wales, Australia; German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); German Federal Ministry of Education and Research as part of the PaCaNct consortium within the NGFN program; Fulbright commission in Germany; US State Department	We would like to thank Reinhard Gliniorz, Oliver Mucke, Jana Petersen; Peter Waas and Otto Zelezny for their technical support, Dr Marta Faryna and Dr Carolin Konermann for discussions regarding the MCIp/microarray assays, Anna Poetsch and Christopher Schmidt for experimental advices; Dr Rainer Claus and Dr Christopher Oakes for stimulating discussions and Dr Ming-Sound Tsao (Ontario Cancer Institute, Toronto, Canada) for providing us the HPDE6-E6E7 cell line. This work is supported by grants from the Cancer Institute New South Wales, Australia (10FRL203 fellowship), from the German Federal Ministry of Education and Research (PKB-01GS08114) and from the German Federal Ministry of Education and Research as part of the PaCaNct consortium within the NGFN program. We thank the Fulbright commission in Germany and the US State Department for providing external funding (TK).	Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Buchholz M, 2005, ONCOGENE, V24, P6626, DOI 10.1038/sj.onc.1208804; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Fukushima N, 2002, AM J PATHOL, V160, P1573, DOI 10.1016/S0002-9440(10)61104-2; Ghaneh P, 2008, POSTGRAD MED J, V84, P478, DOI 10.1136/gut.2006.103333; Goggins M, 2005, J CLIN ONCOL, V23, P4524, DOI 10.1200/JCO.2005.19.711; Gold DV, 2010, CANCER EPIDEM BIOMAR, V19, P2786, DOI 10.1158/1055-9965.EPI-10-0667; Grapin-Botton A, 2005, INT J BIOCHEM CELL B, V37, P504, DOI 10.1016/j.biocel.2004.07.010; Haas BR, 2011, AM J PHYSIOL-CELL PH, V301, pC1150, DOI 10.1152/ajpcell.00203.2011; Hartwig W, 2011, ANN SURG, V254, P311, DOI 10.1097/SLA.0b013e31821fd334; Heller A, 2010, CANCER IMMUNOL IMMUN, V59, P1389, DOI 10.1007/s00262-010-0870-9; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hong CB, 2007, P NATL ACAD SCI USA, V104, P10974, DOI 10.1073/pnas.0700683104; Jansen M, 2002, CANCER BIOL THER, V1, P293, DOI 10.4161/cbt.84; Jensen JN, 2005, GASTROENTEROLOGY, V128, P728, DOI 10.1053/j.gastro.2004.12.008; Jun P, 2009, NEURO-ONCOLOGY, V11, P414, DOI 10.1215/15228517-2008-096; Kong B, 2011, NAT REV GASTRO HEPAT, V8, P467, DOI 10.1038/nrgastro.2011.114; Kuhmann C, 2011, RADIOTHER ONCOL, V101, P116, DOI 10.1016/j.radonc.2011.05.048; Lenertz LY, 2005, J BIOL CHEM, V280, P26653, DOI 10.1074/jbc.M502598200; Liggett T, 2010, CANCER-AM CANCER SOC, V116, P1674, DOI 10.1002/cncr.24893; LOWENFELS AB, 1993, NEW ENGL J MED, V328, P1433, DOI 10.1056/NEJM199305203282001; Matsubayashi H, 2006, CANCER RES, V66, P1208, DOI 10.1158/0008-5472.CAN-05-2664; Means AL, 2005, DEVELOPMENT, V132, P3767, DOI 10.1242/dev.01925; Meloche S, 2007, ONCOGENE, V26, P3227, DOI 10.1038/sj.onc.1210414; Moniz S, 2007, ONCOGENE, V26, P6071, DOI 10.1038/sj.onc.1210706; Moniz S, 2008, CELL SIGNAL, V20, P1762, DOI 10.1016/j.cellsig.2008.06.002; NIEDERAU C, 1985, GASTROENTEROLOGY, V88, P1192, DOI 10.1016/S0016-5085(85)80079-2; Omura Noriyuki, 2008, Proceedings of the American Association for Cancer Research Annual Meeting, V49, P7; Peng DF, 2006, CARCINOGENESIS, V27, P1160, DOI 10.1093/carcin/bgi361; Pinho AV, 2011, GUT, V60, P958, DOI 10.1136/gut.2010.225920; Sato N, 2003, CANCER RES, V63, P3735; Sato N, 2008, MODERN PATHOL, V21, P238, DOI 10.1038/modpathol.3800991; Schilling E, 2007, GENOMICS, V90, P314, DOI 10.1016/j.ygeno.2007.04.011; Sipos B, 2009, PANCREATOLOGY, V9, P45, DOI 10.1159/000178874; Strobel O, 2007, P NATL ACAD SCI USA, V104, P4419, DOI 10.1073/pnas.0605248104; Sun XT, 2006, J NEUROCHEM, V99, P1114, DOI 10.1111/j.1471-4159.2006.04159.x; Vincent A, 2011, CLIN CANCER RES, V17, P4341, DOI 10.1158/1078-0432.CCR-10-3431; Xu BE, 2004, J BIOL CHEM, V279, P7826, DOI 10.1074/jbc.M313465200	39	24	27	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3401	3410		10.1038/onc.2013.312	http://dx.doi.org/10.1038/onc.2013.312			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23912455				2022-12-17	WOS:000338779300007
J	Darr, J; Klochendler, A; Isaac, S; Eden, A				Darr, J.; Klochendler, A.; Isaac, S.; Eden, A.			Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis	ONCOGENE			English	Article						SMARCB1/Snf5; Swi/Snf; malignant rhabdoid tumors	TUMOR-SUPPRESSOR GENE; CHROMATIN REMODELING COMPLEX; FACTOR BINDING-PROTEINS; CELL-CYCLE ARREST; GROWTH-FACTOR; SWI/SNF COMPLEX; RHABDOID TUMORS; BREAST-CANCER; INSULIN; APOPTOSIS	SMARCB1 (Snf5/Ini1/Baf47) is a potent tumor suppressor, the loss of which serves as the diagnostic feature in malignant rhabdoid tumors (MRT) and atypical teratoid/rhabdoid tumors (AT/RT), two highly aggressive forms of pediatric neoplasms. SMARCB1 is a core subunit of Swi/Snf chromatin remodeling complexes, and loss of SMARCB1 or other subunits of these complexes has been observed in a variety of tumor types. Here, we restore Smarcb1 expression in cells derived from Smarcb1-deficient tumors, which developed in Smarcb1 heterozygous p53(-/-) mice. We find that while re-introduction of Smarcb1 does not induce growth arrest, it restores sensitivity to programmed cell death and completely abolishes the ability of the tumor cells to grow as xenografts. We describe persistent activation of AKT signaling in Smarcb1-deficient cells, which stems from PI3K (phosphatidylinositol 3'-kinase)-mediated signaling and which contributes to the survival and proliferation of the tumor cells. We further demonstrate that inhibition of AKT is effective in preventing proliferation of Smarcb1-deficient cells in vitro and inhibits the development of xenografted tumors in vivo. Profiling Smarcb1-dependent gene expression, we find genes that require Smarcb1 and Swi/Snf for their expression to be enriched for extracellular matrix and cell adhesion functions. We find that Smarcb1 is required for transcriptional activation of Igfbp7, a member of the insulin-like growth factor-binding proteins family and a tumor suppressor in itself, and show that re-introduction of Igfbp7 alone can hinder tumor development. Our results define a novel mechanism for Smarcb1-mediated tumorigenesis and highlight potential therapeutic targets.	[Darr, J.; Klochendler, A.; Isaac, S.; Eden, A.] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Cell & Dev Biol, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Eden, A (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Cell & Dev Biol, Edmond J Safra Campus, IL-91904 Jerusalem, Israel.	eden@vms.huji.ac.il		Jonatan, Darr/0000-0002-2992-4448	Israel Cancer Research Fund (ICRF) [2011-3094-PG]; Association for International Cancer Research [AICR 03-109]	Israel Cancer Research Fund (ICRF); Association for International Cancer Research	We thank Dr Ittai Ben-Porath, Professor Eli Keshet and Professor Alex Levitzki for reagents and helpful discussions. This work was funded by the Israel Cancer Research Fund (ICRF, 2011-3094-PG) and by the Association for International Cancer Research (AICR 03-109).	Ae K, 2002, ONCOGENE, V21, P3112, DOI 10.1038/sj.onc.1205414; Aguilar RC, 2005, P NATL ACAD SCI USA, V102, P2679, DOI 10.1073/pnas.0500213102; Ahmed S, 2003, BIOCHEM BIOPH RES CO, V310, P612, DOI 10.1016/j.bbrc.2003.09.058; Arcaro A, 2007, BIOCHEM J, V406, P57, DOI 10.1042/BJ20070309; Barzily-Rokni M, 2011, NUCLEIC ACIDS RES, V39, P1326, DOI 10.1093/nar/gkq994; Beattie J, 2009, BIOCHEM BIOPH RES CO, V381, P572, DOI 10.1016/j.bbrc.2009.02.088; Benatar T, 2012, BREAST CANCER RES TR, V133, P563, DOI 10.1007/s10549-011-1816-4; Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burger AM, 2005, EUR J CANCER, V41, P1515, DOI 10.1016/j.ejca.2005.04.023; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Charboneau A, 2006, J CELL PHYSIOL, V209, P422, DOI 10.1002/jcp.20737; Chen D, 2011, CLIN CANCER RES, V17, P6693, DOI 10.1158/1078-0432.CCR-10-2774; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; CollettSolberg PF, 1996, ENDOCRIN METAB CLIN, V25, P591, DOI 10.1016/S0889-8529(05)70342-X; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Drobic B, 2010, NUCLEIC ACIDS RES, V38, P3196, DOI 10.1093/nar/gkq030; EUHUS DM, 1986, J SURG ONCOL, V31, P229, DOI 10.1002/jso.2930310402; Evdokimova V, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003184; FIGUEROA JA, 1993, J CELL PHYSIOL, V157, P229, DOI 10.1002/jcp.1041570204; Foster K, 2009, CANCER CHEMOTH PHARM, V63, P783, DOI 10.1007/s00280-008-0796-5; Hendricks KB, 2004, MOL CELL BIOL, V24, P362, DOI 10.1128/MCB.24.1.362-376.2004; Hollmann TJ, 2011, AM J SURG PATHOL, V35, pE47, DOI 10.1097/PAS.0b013e31822b325b; Hooper AT, 2009, CIRC RES, V105, P201, DOI 10.1161/CIRCRESAHA.109.196790; Isakoff MS, 2005, P NATL ACAD SCI USA, V102, P17745, DOI 10.1073/pnas.0509014102; Jagani Z, 2010, NAT MED, V16, P1429, DOI 10.1038/nm.2251; Jozwiak J, 2010, FOLIA NEUROPATHOL, V48, P185; Klochendler-Yeivin A, 2006, MOL CELL BIOL, V26, P2661, DOI 10.1128/MCB.26.7.2661-2674.2006; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Lee RS, 2012, J CLIN INVEST, V122, P2983, DOI 10.1172/JCI64400; Medjkane S, 2004, CANCER RES, V64, P3406, DOI 10.1158/0008-5472.CAN-03-3004; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Nocentini S, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-11; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Oruetxebarria I, 2004, J BIOL CHEM, V279, P3807, DOI 10.1074/jbc.M309333200; Pen A, 2011, CANCER BIOL THER, V12, P634, DOI 10.4161/cbt.12.7.17171; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Reincke BS, 2003, J CELL PHYSIOL, V194, P303, DOI 10.1002/jcp.10201; Reisman DN, 2003, CANCER RES, V63, P560; Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; Sato Y, 2007, CANCER SCI, V98, P1055, DOI 10.1111/j.1349-7006.2007.00502.x; Smith MJ, 2012, HUM MOL GENET, V21, P5239, DOI 10.1093/hmg/dds370; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tamura K, 2009, EUR J PHARMACOL, V610, P61, DOI 10.1016/j.ejphar.2009.01.045; Tsikitis M, 2005, P NATL ACAD SCI USA, V102, P12129, DOI 10.1073/pnas.0505300102; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Versteege I, 2002, ONCOGENE, V21, P6403, DOI 10.1038/sj.onc.1205841; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vizioli MG, 2010, ONCOGENE, V29, P3835, DOI 10.1038/onc.2010.136; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Wang L, 2005, MOL CELL BIOL, V25, P7953, DOI 10.1128/MCB.25.18.7953-7965.2005; Wang X, 2009, CANCER RES, V69, P8094, DOI 10.1158/0008-5472.CAN-09-0733; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Xi QR, 2008, J BIOL CHEM, V283, P1146, DOI 10.1074/jbc.M707479200; Yamanaka Y, 1997, J BIOL CHEM, V272, P30729, DOI 10.1074/jbc.272.49.30729; Zhang M, 2007, J BIOL CHEM, V282, P25708, DOI 10.1074/jbc.M701925200; Zhang ZK, 2002, MOL CELL BIOL, V22, P5975, DOI 10.1128/MCB.22.16.5975-5988.2002	63	24	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					3024	3032		10.1038/onc.2013.261	http://dx.doi.org/10.1038/onc.2013.261			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23851500				2022-12-17	WOS:000337232200009
J	Tripathi, P; Wang, Y; Coussens, M; Manda, KR; Casey, AM; Lin, C; Poyo, E; Pfeifer, JD; Basappa, N; Bates, CM; Ma, L; Zhang, H; Pan, M; Ding, L; Chen, F				Tripathi, P.; Wang, Y.; Coussens, M.; Manda, K. R.; Casey, A. M.; Lin, C.; Poyo, E.; Pfeifer, J. D.; Basappa, N.; Bates, C. M.; Ma, L.; Zhang, H.; Pan, M.; Ding, L.; Chen, F.			Activation of NFAT signaling establishes a tumorigenic microenvironment through cell autonomous and non-cell autonomous mechanisms	ONCOGENE			English	Article						NFAT; tumorigenesis; tumor; microenvironment	TRANSCRIPTION FACTOR; CALCINEURIN; EXPRESSION; CANCER; MICE; CA2+/CALCINEURIN; PROLIFERATION; CALCIUM; GENE	NFAT (the nuclear factor of activated T cells) upregulation has been linked to cellular transformation intrinsically, but it is unclear whether and how tissue cells with NFAT activation change the local environment for tumor initiation and progression. Direct evidence showing NFAT activation initiates primary tumor formation in vivo is also lacking. Using inducible transgenic mouse systems, we show that tumors form in a subset of, but not all, tissues with NFATc1 activation, indicating that NFAT oncogenic effects depend on cell types and tissue contexts. In NFATc1-induced skin and ovarian tumors, both cells with NFATc1 activation and neighboring cells without NFATc1 activation have significant upregulation of c-Myc and activation of Stat3. Besides known and suspected NFATc1 targets, such as Spp1 and Osm, we have revealed the early upregulation of a number of cytokines and cytokine receptors, as key molecular components of an inflammatory microenvironment that promotes both NFATc1(+) and NFATc1(-) cells to participate in tumor formation. Cultured cells derived from NFATc1-induced tumors were able to establish a tumorigenic microenvironment, similar to that of the primary tumors, in an NFATc1-dependent manner in nude mice with T-cell deficiency, revealing an addiction of these tumors to NFATc1 activation and downplaying a role for T cells in the NFATc1-induced tumorigenic microenvironment. These findings collectively suggest that beyond the cell autonomous effects on the upregulation of oncogenic proteins, NFATc1 activation has non-cell autonomous effects through the establishment of a promitogenic microenvironment for tumor growth. This study provides direct evidence for the ability of NFATc1 in inducing primary tumor formation in vivo and supports targeting NFAT signaling in anti-tumor therapy.	[Tripathi, P.; Wang, Y.; Coussens, M.; Manda, K. R.; Casey, A. M.; Lin, C.; Ma, L.; Chen, F.] Washington Univ, Sch Med, Dept Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; [Poyo, E.] Washington Univ, Sch Med, Dept Engn, St Louis, MO 63110 USA; [Pfeifer, J. D.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; [Basappa, N.] Univ Maryland, Dept Biol, Baltimore, MD 21201 USA; [Bates, C. M.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; [Zhang, H.] Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; [Pan, M.] Kaiser Permanente Med Ctr, Div Oncol, Santa Clara, CA USA; [Ding, L.] Washington Univ, Sch Med, Genome Inst, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University System of Maryland; University of Maryland Baltimore; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Massachusetts System; University of Massachusetts Worcester; Kaiser Permanente; Washington University (WUSTL)	Chen, F (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Campus Box 8126, St Louis, MO 63110 USA.	fchen@dom.wustl.edu	Pan, Minggui/AAB-7371-2020		Department of Medicine at Washington University School of Medicine; NIH [DK81592, DK67386]; George M. O'Brien Center for Kidney Disease Research at Washington University [George M. O'Brien Center for Kidney Disease Research at Washington University (P30DK079333]; Genome Technology Access Center [P30 CA91842, UL1RR024992]; NATIONAL CANCER INSTITUTE [P30CA091842] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067386, R01DK081592, P30DK079333, R01DK087960] Funding Source: NIH RePORTER	Department of Medicine at Washington University School of Medicine; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); George M. O'Brien Center for Kidney Disease Research at Washington University; Genome Technology Access Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Crabtree for providing the TetO-NFATc1<SUP>Nuc</SUP> mice and Dr Yuan Zhu for helpful discussion of the study. FC is supported in part by institutional funds from the Department of Medicine at Washington University School of Medicine and NIH grants (DK81592 and DK67386). We also thank the George M. O'Brien Center for Kidney Disease Research at Washington University (P30DK079333) for core services. We thank Michael Heinz from the Genome Technology Access Center (P30 CA91842, UL1RR024992) in the Department of Genetics at Washington University School of Medicine for help with gene expression analysis.	ANDERSON B, 1987, GYNECOL ONCOL, V26, P183, DOI 10.1016/0090-8258(87)90272-1; Barriere C, 2007, MOL ONCOL, V1, P72, DOI 10.1016/j.molonc.2007.03.001; Belteki G, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni051; Buchholz M, 2006, EMBO J, V25, P3714, DOI 10.1038/sj.emboj.7601246; Chang CP, 2004, J CLIN INVEST, V113, P1051, DOI 10.1172/JCI200420049; Graef IA, 2001, CURR OPIN GENET DEV, V11, P505, DOI 10.1016/S0959-437X(00)00225-2; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Guo QS, 2011, J UROLOGY, V185, P2320, DOI 10.1016/j.juro.2011.02.044; Horsley V, 2008, CELL, V132, P299, DOI 10.1016/j.cell.2007.11.047; JANIK P, 1975, CANCER RES, V35, P3698; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009; Li SZ, 2007, AM J PHYSIOL-CELL PH, V292, pC1606, DOI 10.1152/ajpcell.00588.2005; Li W, 2009, P NATL ACAD SCI USA, V106, P486, DOI 10.1073/pnas.0804177106; Lin CX, 2009, GENESIS, V47, P352, DOI 10.1002/dvg.20506; Marafiot T, 2005, BRIT J HAEMATOL, V128, P333, DOI 10.1111/j.1365-2141.2004.05313.x; McCormick F, 2011, J SURG ONCOL, V103, P464, DOI 10.1002/jso.21749; McDill BW, 2006, P NATL ACAD SCI USA, V103, P6952, DOI 10.1073/pnas.0602087103; Medyouf H, 2007, NAT MED, V13, P736, DOI 10.1038/nm1588; Muller MR, 2010, NAT REV IMMUNOL, V10, P645, DOI 10.1038/nri2818; Neal JW, 2003, J BIOL CHEM, V278, P17246, DOI 10.1074/jbc.M300528200; Pan MG, CURR MOL ME IN PRESS; Pan MG, 2007, J IMMUNOL, V178, P4315, DOI 10.4049/jimmunol.178.7.4315; Pham LV, 2005, BLOOD, V106, P3940, DOI 10.1182/blood-2005-03-1167; Rao A, 2009, NAT IMMUNOL, V10, P3, DOI 10.1038/ni0109-3; Sansone P, 2011, CURR OPIN GENET DEV, V21, P80, DOI 10.1016/j.gde.2010.11.001; Torti D, 2011, EMBO MOL MED, V3, P623, DOI 10.1002/emmm.201100176; Wang YQ, 2010, J AM SOC NEPHROL, V21, P1657, DOI 10.1681/ASN.2009121253; Wong SY, 2011, P NATL ACAD SCI USA, V108, P4093, DOI 10.1073/pnas.1013098108; Wu H, 2007, TRENDS CELL BIOL, V17, P251, DOI 10.1016/j.tcb.2007.04.006; Yasaka Nami, 1995, Journal of Dermatology (Tokyo), V22, P88; Zhao HT, 2004, DEV BIOL, V276, P403, DOI 10.1016/j.ydbio.2004.09.002	32	24	24	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1840	1849		10.1038/onc.2013.132	http://dx.doi.org/10.1038/onc.2013.132			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23624921	Green Accepted			2022-12-17	WOS:000334345500010
J	Zhu, Y; Das, K; Wu, J; Lee, MH; Tan, P				Zhu, Y.; Das, K.; Wu, J.; Lee, M. H.; Tan, P.			RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells	ONCOGENE			English	Article						HDAC inhibitor; gastric cancer; RNH1; ROS	SUBEROYLANILIDE HYDROXAMIC ACID; RIBONUCLEASE INHIBITOR; HDAC INHIBITORS; ANTICANCER DRUGS; LEUKEMIA-CELLS; SP1 SITES; EXPRESSION; VORINOSTAT; APOPTOSIS; PROTEIN	Histone deacetylase inhibitors (HDACis) are a promising class of anticancer epigenetic drugs, however, molecular factors influencing the responses of individual tumors to HDACi therapies remain obscure. Here, we sought to identify genes associated with HDACi resistance in gastric cancer. Treating a panel of 17 gastric cancer cell lines with multiple HDACi compounds (trichostatin A, SAHA and MS275), we identified two distinct classes of lines exhibiting either HDACi sensitivity or resistance. Genomic comparisons between the sensitive and resistant classes using two independent microarray platforms identified RNH1, encoding a ribonuclease inhibitor, as a gene highly expressed in HDACi-resistant lines. Using genetic knockdown and overexpression assays, we show that RNH1 is both necessary and sufficient to induce HDACi resistance, and that RNH1 is likely to mediate this resistance through the dampening of HDACi-induced reactive oxygen species (ROS) in cancer cells. The discovery of RNH1 as a regulator of HDACi resistance in gastric cancer highlights a functional role for ROS induction in the cellular effects of this important drug class.	[Zhu, Y.; Das, K.; Tan, P.] Duke NUS Grad Med Sch, Singapore 169857, Singapore; [Zhu, Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117595, Singapore; [Wu, J.; Lee, M. H.; Tan, P.] Natl Canc Ctr, Singapore, Singapore; [Tan, P.] Natl Univ Singapore, Yong Loo Lin Sch Med, Canc Sci Inst Singapore, Singapore 117595, Singapore; [Tan, P.] Genome Inst Singapore, Singapore, Singapore	National University of Singapore; National University of Singapore; National Cancer Centre Singapore (NCCS); National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Tan, P (corresponding author), Duke NUS Grad Med Sch, 8 Coll Rd, Singapore 169857, Singapore.	gmstanp@duke-nus.edu.sg		Das, Kakoli/0000-0002-0990-276X	NMRC TCR grant [TCR/001/2007]; Duke-NUS core grant	NMRC TCR grant; Duke-NUS core grant	We thank that Dr Shang Li's lab for the gift of Hela, MCF7, HEPG2 and HCT116 cell lines. This work was funded by NMRC TCR grant TCR/001/2007 and a Duke-NUS core grant.	Alberts SR, 2003, ANN ONCOL, V14, P31, DOI 10.1093/annonc/mdg726; Aresvik DM, 2010, ANTICANCER RES, V30, P3879; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Borbone E, 2010, ONCOGENE, V29, P105, DOI 10.1038/onc.2009.306; Botella-Estrada R, 2001, CANCER GENE THER, V8, P278, DOI 10.1038/sj.cgt.7700302; Bragado P, 2007, APOPTOSIS, V12, P1733, DOI 10.1007/s10495-007-0082-8; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; Carew JS, 2008, CANCER LETT, V269, P7, DOI 10.1016/j.canlet.2008.03.037; Chen GA, 2002, MOL CELL PROTEOMICS, V1, P304, DOI 10.1074/mcp.M200008-MCP200; Chen JX, 2011, MOL CELL BIOCHEM, V349, P83, DOI 10.1007/s11010-010-0663-7; Claerhout S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024662; Cui XY, 2003, FREE RADICAL RES, V37, P1079, DOI 10.1080/10715760310001600408; Dickinson M, 2010, INVEST NEW DRUG, V28, pS3, DOI 10.1007/s10637-010-9596-y; Dickson KA, 2005, PROG NUCLEIC ACID RE, V80, P349, DOI 10.1016/S0079-6603(05)80009-1; Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541-7786.MCR-07-0324; Duvic M, 2007, BLOOD, V109, P31, DOI 10.1182/blood-2006-06-025999; Futami J, 1997, DNA CELL BIOL, V16, P413, DOI 10.1089/dna.1997.16.413; Glaser KB, 2007, BIOCHEM PHARMACOL, V74, P659, DOI 10.1016/j.bcp.2007.04.007; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Hu YM, 2010, BLOOD, V116, P2732, DOI 10.1182/blood-2009-11-256354; Huang CH, 2007, BIOCHEM PHARMACOL, V73, P990, DOI 10.1016/j.bcp.2006.12.013; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Johnson RJ, 2007, BIOCHEMISTRY-US, V46, P13131, DOI 10.1021/bi701521q; Khan O, 2010, P NATL ACAD SCI USA, V107, P6532, DOI 10.1073/pnas.0913912107; Kim JH, 2004, J GASTROEN HEPATOL, V19, P218, DOI 10.1111/j.1440-1746.2004.03336.x; Kim TY, 2008, EXP MOL MED, V40, P639, DOI 10.3858/emm.2008.40.6.639; Klampfer L, 2007, CANCER RES, V67, P8477, DOI 10.1158/0008-5472.CAN-07-0210; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Kobayashi Takanori, 2004, Gastric Cancer, V7, P233, DOI 10.1007/s10120-004-0297-0; Lee JY, 2003, GENOMICS, V82, P78, DOI 10.1016/S0888-7543(03)00098-3; Ma XJ, 2009, DRUGS, V69, P1911, DOI 10.2165/11315680-000000000-00000; Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247; Marks PA, 2010, EXPERT OPIN INV DRUG, V19, P1049, DOI 10.1517/13543784.2010.510514; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Moenner M, 1998, BLOOD CELL MOL DIS, V24, P149, DOI 10.1006/bcmd.1998.0182; Monti DM, 2007, FEBS LETT, V581, P930, DOI 10.1016/j.febslet.2007.01.072; Mutze K, 2010, ANN SURG ONCOL, V17, P3336, DOI 10.1245/s10434-010-1182-1; NADANO D, 1994, ARCH BIOCHEM BIOPHYS, V312, P421, DOI 10.1006/abbi.1994.1328; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Nebbioso A, 2010, J MOL ENDOCRINOL, V45, P219, DOI 10.1677/JME-10-0043; Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434; Ono S, 2002, J EXP CLIN CANC RES, V21, P377; Ree AH, 2010, LANCET ONCOL, V11, P459, DOI 10.1016/S1470-2045(10)70058-9; Rikiishi H, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/830260; Rosato RR, 2003, MOL CANCER THER, V2, P1273; Ruefli AA, 2001, P NATL ACAD SCI USA, V98, P10833, DOI 10.1073/pnas.191208598; Sade H, 2004, CELL DEATH DIFFER, V11, P416, DOI 10.1038/sj.cdd.4401347; Shapiro R, 2001, METHOD ENZYMOL, V341, P611, DOI 10.1016/S0076-6879(01)41180-3; Song SH, 2011, DRUGS, V71, P2391, DOI 10.2165/11596690-000000000-00000; Sowa Y, 1999, ANN NY ACAD SCI, V886, P195, DOI 10.1111/j.1749-6632.1999.tb09415.x; Stevens FE, 2008, ONCOGENE, V27, P1345, DOI 10.1038/sj.onc.1210779; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; SUZUKI Y, 1970, J NEUROCHEM, V17, P1521, DOI 10.1111/j.1471-4159.1970.tb00520.x; Trachootham D, 2008, BLOOD, V112, P1912, DOI 10.1182/blood-2008-04-149815; Ungerstedt JS, 2005, P NATL ACAD SCI USA, V102, P673, DOI 10.1073/pnas.0408732102; VANZANDWIJK N, 1995, J CELL BIOCHEM, P24; Weichert W, 2008, LANCET ONCOL, V9, P139, DOI 10.1016/S1470-2045(08)70004-4; WOJNAR RJ, 1965, CANCER RES, V25, P1913; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930; Zaina S, 2010, CURR GENOMICS, V11, P359, DOI 10.2174/138920210791616662; Zhang XT, 2006, ONCOL REP, V16, P563; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	64	24	25	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1527	1537		10.1038/onc.2013.104	http://dx.doi.org/10.1038/onc.2013.104			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23584480				2022-12-17	WOS:000333244200006
J	Dann, SG; Golas, J; Miranda, M; Shi, C; Wu, J; Jin, G; Rosfjord, E; Upeslacis, E; Klippel, A				Dann, S. G.; Golas, J.; Miranda, M.; Shi, C.; Wu, J.; Jin, G.; Rosfjord, E.; Upeslacis, E.; Klippel, A.			p120 catenin is a key effector of a Ras-PKC epsilon oncogenic signaling axis	ONCOGENE			English	Article						protein kinase C; epithelial to mesenchymal transition; triple negative breast cancer; p120 catenin; drug discovery	PROTEIN-KINASE-C; BREAST-CANCER; CELL-GROWTH; E-CADHERIN; MESENCHYMAL TRANSITION; COMPLEX CONTROLS; GENE-EXPRESSION; PHOSPHORYLATION; P120-CATENIN; PROSTATE	Within the family of protein kinase C (PKC) molecules, the novel isoform PRKCE (PKC epsilon) acts as a bona fide oncogene in in vitro and in vivo models of tumorigenesis. Previous studies have reported expression of PKC epsilon in breast, prostate and lung tumors above that of normal adjacent tissue. Data from the cancer genome atlas suggest increased copy number of PRKCE in triple negative breast cancer (TNBC). We find that overexpression of PKC epsilon in a non-tumorigenic breast epithelial cell line is sufficient to overcome contact inhibition and results in the formation of cellular foci. Correspondingly, inhibition of PKC epsilon in a TNBC cell model results in growth defects in two-dimensional (2D) and three-dimensional (3D) culture conditions and orthotopic xenografts. Using stable isotope labeling of amino acids in a cell culture phosphoproteomic approach, we find that CTNND1/p120ctn phosphorylation at serine 268 (P-S268) occurs in a strictly PKC epsilon-dependent manner, and that loss of PKC epsilon signaling in TNBC cells leads to reversal of mesenchymal morphology and signaling. In a model of Ras activation, inhibition of PKC epsilon is sufficient to block mesenchymal cell morphology. Finally, treatment with a PKC epsilon ATP mimetic inhibitor, PF-5263555, recapitulates genetic loss of function experiments impairing p120ctn phosphorylation as well as compromising TNBC cell growth in vitro and in vivo. We demonstrate PKC epsilon as a tractable therapeutic target for TNBC, where p120ctn phosphorylation may serve as a readout for monitoring patient response.	[Dann, S. G.; Golas, J.; Miranda, M.; Shi, C.; Jin, G.; Rosfjord, E.; Upeslacis, E.; Klippel, A.] Pfizer Oncol Res Unit, Pearl River, NY 10965 USA; [Wu, J.] Pfizer Struct Biol & Biophys, Groton, CT USA	Pfizer; Pfizer	Dann, SG (corresponding author), Pfizer Oncol Res Unit, 401 N Middletown Rd, Pearl River, NY 10965 USA.	stephen.dann@pfizer.com		Rosfjord, Edward/0000-0002-3449-7444				Bellovin DI, 2005, CANCER RES, V65, P10938, DOI 10.1158/0008-5472.CAN-05-1947; Benavides F, 2011, CELL CYCLE, V10, P268, DOI 10.4161/cc.10.2.14469; Bin Hafeez B, 2011, CANCER RES, V71, P2318, DOI 10.1158/0008-5472.CAN-10-4170; Brown MV, 2009, EXP CELL RES, V315, P39, DOI 10.1016/j.yexcr.2008.09.025; CACACE AM, 1993, ONCOGENE, V8, P2095; Cameron AJM, 2009, NAT STRUCT MOL BIOL, V16, P624, DOI 10.1038/nsmb.1606; Craig DW, 2013, MOL CANCER THER, V12, P104, DOI 10.1158/1535-7163.MCT-12-0781; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng127; Doehn U, 2009, MOL CELL, V35, P511, DOI 10.1016/j.molcel.2009.08.002; Dohn MR, 2009, J CELL BIOL, V184, P437, DOI 10.1083/jcb.200807096; Gandellini P, 2009, CANCER RES, V69, P2287, DOI 10.1158/0008-5472.CAN-08-2894; Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577; Gorin MA, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-9; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Ivaska J, 2005, EMBO J, V24, P3834, DOI 10.1038/sj.emboj.7600847; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Leask A, 2008, J CELL SCI, V121, P3459, DOI 10.1242/jcs.029215; Leenders F, 2004, EMBO J, V23, P3303, DOI 10.1038/sj.emboj.7600345; Mackay HJ, 2007, NAT REV CANCER, V7, P554, DOI 10.1038/nrc2168; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Okuzumi T, 2009, NAT CHEM BIOL, V5, P484, DOI 10.1038/nchembio.183; Ozawa M, 2001, J CELL SCI, V114, P503; Paredes J, 2008, J CLIN PATHOL, V61, P856, DOI 10.1136/jcp.2007.052704; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Prashad AS, 2009, BIOORG MED CHEM LETT, V19, P5799, DOI 10.1016/j.bmcl.2009.07.113; Pylayeva Y, 2009, J CLIN INVEST, V119, P252, DOI 10.1172/JCI37160; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; Saurin AT, 2008, NAT CELL BIOL, V10, P891, DOI 10.1038/ncb1749; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Shibata T, 2004, AM J PATHOL, V164, P2269, DOI 10.1016/S0002-9440(10)63783-2; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Soto E, 2008, J CELL BIOL, V183, P737, DOI 10.1083/jcb.200805113; Sternberger M, 2002, ANTISENSE NUCLEIC A, V12, P131, DOI 10.1089/108729002760220734; Tuomi S, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000135; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; Wu J, 2007, J PROTEOME RES, V6, P4684, DOI 10.1021/pr070481m; Xia XB, 2006, EXP CELL RES, V312, P3336, DOI 10.1016/j.yexcr.2006.07.007; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183	40	24	25	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1385	1394		10.1038/onc.2013.91	http://dx.doi.org/10.1038/onc.2013.91			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23542175				2022-12-17	WOS:000332943500006
J	Lahoz, A; Hall, A				Lahoz, A.; Hall, A.			A tumor suppressor role for srGAP3 in mammary epithelial cells	ONCOGENE			English	Article						srGAP; Rac; tumor suppressor; breast cancer; anchorage-independent growth	F-BAR DOMAIN; BREAST-CANCER; GENE-EXPRESSION; RHO-GTPASES; NEURONAL MIGRATION; RAC; MEMBRANE; PROTEINS; WAVE-1; KINASE	srGAP3, a member of the Slit-Robo sub-family of Rho GTPase-activating proteins (Rho GAPs), controls actin and microtubule dynamics through negative regulation of Rac. Here, we describe a potential role for srGAP3 as a tumor suppressor in mammary epithelial cells. We show that RNAi-mediated depletion of srGAP3 promotes Rac dependent, anchorage-independent growth of partially transformed human mammary epithelial cells (HMECs). Furthermore, srGAP3 expression is absent, or significantly reduced in 7/10 breast cancer cell lines compared with normal HMECs. Re-expression of srGAP3 in a subset of these cell lines inhibits both anchorage-independent growth and cell invasion in a GAP-dependent manner, and this is accompanied by an increase in phosphorylation of the ezrin/radixin/moesin (ERM) family proteins and myosin light chain 2 (MLC2). Inhibition of the Rho regulated kinase, ROCK, reduces ERM and MLC2 phosphorylation and restores invasion. We conclude that srGAP3 has tumor suppressor-like activity in HMECs, likely through its activity as a negative regulator of Rac1.	[Lahoz, A.; Hall, A.] Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center	Hall, A (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Programn, 1275 York Ave, New York, NY 10065 USA.	halla@mskcc.org			Fundacion Caja Madrid, Spain; MSKCC Geoffrey Beene Cancer Research Center Grant	Fundacion Caja Madrid, Spain; MSKCC Geoffrey Beene Cancer Research Center Grant	We thank William C Hahn, Dana-Farber Cancer Institute, for providing the cell line HMEC/hTERT/LT/c-myc and John D Scott, University of Washington, for the gift of pCDNA3.1-WRP-V5His and pCDNA3.1-WRP Delta GAP-V5His plasmids. We also thank Memorial Sloan-Kettering Cancer Center Molecular Cytogenetics Core facility for performing the FISH assays, the Bioinformatic Core facility for the analysis of the microarray data and Overholtzer laboratories for critical reading of the manuscript and helpful discussions. This work was supported by Fundacion Caja Madrid, Spain (AL) and by an MSKCC Geoffrey Beene Cancer Research Center Grant (AH).	Aspenstrom P, 2009, INT REV CEL MOL BIO, V272, P1, DOI 10.1016/S1937-6448(08)01601-8; Carlson BR, 2011, J NEUROSCI, V31, P2447, DOI 10.1523/JNEUROSCI.4433-10.2011; Chen K, 2011, CELL MOL NEUROBIOL, V31, P675, DOI 10.1007/s10571-011-9664-7; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; Ellenbroek SIJ, 2007, CLIN EXP METASTAS, V24, P657, DOI 10.1007/s10585-007-9119-1; Endris V, 2002, P NATL ACAD SCI USA, V99, P11754, DOI 10.1073/pnas.162241099; Endris V, 2011, J CELL SCI, V124, P3941, DOI 10.1242/jcs.077081; Guerrier S, 2009, CELL, V138, P990, DOI 10.1016/j.cell.2009.06.047; Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200; Han J, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000684; IKEBE M, 1985, J BIOL CHEM, V260, P27; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kristensen LS, 2009, EUR J PHARMACOL, V625, P131, DOI 10.1016/j.ejphar.2009.10.011; Lazer G, 2011, CELL SIGNAL, V23, P969, DOI 10.1016/j.cellsig.2010.10.022; Lorentzen A, 2011, J CELL SCI, V124, P1256, DOI 10.1242/jcs.074849; Madura T, 2004, MOL BRAIN RES, V123, P76, DOI 10.1016/j.molbrainres.2004.01.002; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Radvanyi L, 2005, P NATL ACAD SCI USA, V102, P11005, DOI 10.1073/pnas.0500904102; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Shuib S, 2009, AM J MED GENET A, V149A, P2099, DOI 10.1002/ajmg.a.32824; Soderling SH, 2007, J NEUROSCI, V27, P355, DOI 10.1523/JNEUROSCI.3209-06.2006; Soderling SH, 2003, P NATL ACAD SCI USA, V100, P1723, DOI 10.1073/pnas.0438033100; Soderling SH, 2002, NAT CELL BIOL, V4, P970, DOI 10.1038/ncb886; Sosa MS, 2010, MOL CELL, V40, P877, DOI 10.1016/j.molcel.2010.11.029; Tang YA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012417; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; Xue W, 2008, GENE DEV, V22, P1439, DOI 10.1101/gad.1672608; Yang CF, 2007, BIOCHEM J, V403, P1, DOI 10.1042/bj20061750; Yang Y, 2006, EXP CELL RES, V312, P2379, DOI 10.1016/j.yexcr.2006.04.001; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	38	24	25	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2013	32	40					4854	4860		10.1038/onc.2012.489	http://dx.doi.org/10.1038/onc.2012.489			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23108406				2022-12-17	WOS:000325274700014
J	Shum, CKY; Lau, ST; Tsoi, LLS; Chan, LK; Yam, JWP; Ohira, M; Nakagawara, A; Tam, PKH; Ngan, ESW				Shum, C. K. Y.; Lau, S. T.; Tsoi, L. L. S.; Chan, L. K.; Yam, J. W. P.; Ohira, M.; Nakagawara, A.; Tam, P. K. H.; Ngan, E. S. W.			Kruppel-like factor 4 (KLF4) suppresses neuroblastoma cell growth and determines non-tumorigenic lineage differentiation	ONCOGENE			English	Article						differentiation; regression; neuroblastoma	CREST STEM-CELLS; BREAST-CANCER; CHILDHOOD NEUROBLASTOMA; GENE AMPLIFICATION; PROGNOSTIC-FACTORS; SERUM FERRITIN; EXPRESSION; PROGRESSION; TUMORS; MYCN	Neuroblastoma (NB) is an embryonal tumor and possesses a unique propensity to exhibit either a spontaneous regression or an unrestrained growth. However, the underlying mechanism for this paradoxical clinical outcome remains largely unclear. Quantitative RT-PCR analysis on 102 primary NB tumors revealed that lower Kruppel-like factor 4 (KLF4) expression is frequently found in the unfavorable NB (Mann-Whitney test, P = 0.027). In particular with the high-risk factors such as age of patient 41 year, MYCN amplification and low TRKA expression, the decreased expression of KLF4 was significantly associated with an unfavorable NB outcome. Despite knockdown of KLF4 alone is not sufficient to increase tumorigenicity of NB cells in vivo, stable expression of KLF4 short hairpin RNA in Be(2)-C cells significantly promoted growth of NB cells and inhibited cell differentiation toward fibromuscular lineage. In concordant with these observations, overexpression of KLF4 in SH-SY-5Y cells profoundly suppressed cell proliferation by direct upregulation of cell-cycle inhibitor protein p21(WAF1/CIP1), and knocking down p21(WAF1/CIP1) could partially rescue the suppressive effect of KLF4. Importantly, KLF4 overexpressing cells have lost their neuroblastic phenotypes, they were epithelial-like, strongly substrate-adherent, expressing smooth muscle marker and became non-tumorigenic, suggesting that KLF4 expression is crucial for lineage determination of NB cells, probably, favoring spontaneous tumor regression. Subsequent global gene expression profiling further revealed that transforming growth factor beta (TGF beta) and cell-cycle pathways are highly dysregulated upon KLF4 overexpression, and myogenic modulators, MEF2A and MYOD1 were found significantly upregulated. Taken together, we have demonstrated that KLF4 contributes to the favorable disease outcome by directly mediating the growth and lineage determination of NB cells.	[Shum, C. K. Y.; Lau, S. T.; Tsoi, L. L. S.; Tam, P. K. H.; Ngan, E. S. W.] Univ Hong Kong, Dept Surg, Pokfulam, Hong Kong, Peoples R China; [Chan, L. K.; Yam, J. W. P.] Univ Hong Kong, Dept Pathol, Pokfulam, Hong Kong, Peoples R China; [Ohira, M.; Nakagawara, A.] Chiba Canc Ctr, Res Inst, Chiba 2608717, Japan; [Tam, P. K. H.; Ngan, E. S. W.] Univ Hong Kong, Li Ka Shing Fac Med, Ctr Reprod Dev & Growth, Pokfulam, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; Chiba Cancer Center; University of Hong Kong	Ngan, ESW (corresponding author), Univ Hong Kong, Dept Surg, Fac Med Bldg,21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	engan@hku.hk	Ngan, Elly/N-1543-2019; Kong, Chan Lo/AAI-9300-2020; /C-4405-2009; Yam, Judy Wai Ping/C-4454-2009	Ngan, Elly/0000-0002-0022-7999; Kong, Chan Lo/0000-0003-3082-1013; /0000-0001-6231-3035; Yam, Judy Wai Ping/0000-0002-5637-121X	University of Hong Kong; Hong Kong Research Grants Council [HKU773909]; Hong Kong Children Cancer Foundation	University of Hong Kong(University of Hong Kong); Hong Kong Research Grants Council(Hong Kong Research Grants Council); Hong Kong Children Cancer Foundation	This study was funded by seed funding grant for basic research from the University of Hong Kong, General Research Grant HKU773909 from the Hong Kong Research Grants Council and research grant from Hong Kong Children Cancer Foundation to ESWN.	Acosta S, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-12; Akaogi K, 2009, ONCOGENE, V28, P2894, DOI 10.1038/onc.2009.151; Beppu Y, 2005, CANCER RES, V65, P4775, DOI 10.1158/0008-5472.CAN-04-3332; Biagiotti T, 2006, STEM CELLS, V24, P443, DOI 10.1634/stemcells.2004-0264; BIEDLER JL, 1978, CANCER RES, V38, P3751; BRESLOW N, 1971, CANCER RES, V31, P2098; Brodeur GM, 2009, CLIN CANCER RES, V15, P3244, DOI 10.1158/1078-0432.CCR-08-1815; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Chen JK, 2011, CELL RES, V21, P205, DOI 10.1038/cr.2010.172; Chen SY, 2006, J BIOL CHEM, V281, P1765, DOI 10.1074/jbc.M507771200; Cordes KR, 2009, NATURE, V460, P705, DOI 10.1038/nature08195; Dang DT, 2003, ONCOGENE, V22, P3424, DOI 10.1038/sj.onc.1206413; Feinberg MW, 2007, EMBO J, V26, P4138, DOI 10.1038/sj.emboj.7601824; Foster KW, 2005, ONCOGENE, V24, P1491, DOI 10.1038/sj.onc.1208307; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Foster KW, 2000, CANCER RES, V60, P6488; HANN HWL, 1985, CANCER RES, V45, P2843; Iehara T, 2006, BRIT J CANCER, V94, P1510, DOI 10.1038/sj.bjc.6603149; Iraci N, 2011, CANCER RES, V71, P404, DOI 10.1158/0008-5472.CAN-10-2627; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Janoueix-Lerosey I, 2010, ONCOGENE, V29, P1566, DOI 10.1038/onc.2009.518; Janoueix-Lerosey I, 2009, J CLIN ONCOL, V27, P1026, DOI 10.1200/JCO.2008.16.0630; Jaubert J, 2003, DEVELOPMENT, V130, P2767, DOI 10.1242/dev.00477; Kaneko M, 2002, J PEDIAT HEMATOL ONC, V24, P613, DOI 10.1097/00043426-200211000-00004; Katz JP, 2002, DEVELOPMENT, V129, P2619; Keshelava N, 2001, CANCER RES, V61, P6185; Lastowska M, 2001, J CLIN ONCOL, V19, P3080; Li RH, 2010, CELL STEM CELL, V7, P51, DOI 10.1016/j.stem.2010.04.014; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; Lutz W, 1998, ONCOGENE, V17, P339, DOI 10.1038/sj.onc.1200201; Mahller YY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004235; Marzi F, 2007, CANCER RES, V67, P2402, DOI 10.1158/0008-5472.CAN-06-3208; McKinsey TA, 2005, J CLIN INVEST, V115, P538, DOI 10.1172/JCI200524144; Michels E, 2007, GENE CHROMOSOME CANC, V46, P1098, DOI 10.1002/gcc.20496; Mosse YP, 2007, GENE CHROMOSOME CANC, V46, P936, DOI 10.1002/gcc.20477; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Ohira M, 2005, CANCER CELL, V7, P337, DOI 10.1016/j.ccr.2005.03.019; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Peterson S, 2004, ONCOGENE, V23, P213, DOI 10.1038/sj.onc.1206980; ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449; Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SHUSTER JJ, 1992, AM J CLIN ONCOL-CANC, V15, P295, DOI 10.1097/00000421-199208000-00004; SILBER JH, 1991, CANCER RES, V51, P1426; Tang XX, 2000, P NATL ACAD SCI USA, V97, P10936, DOI 10.1073/pnas.190123297; Tomioka N, 2008, ONCOGENE, V27, P441, DOI 10.1038/sj.onc.1210661; Tweddle DA, 2001, AM J PATHOL, V158, P2067, DOI 10.1016/S0002-9440(10)64678-0; Tweddle DA, 2001, CANCER RES, V61, P8; Vandesompele J, 2005, J CLIN ONCOL, V23, P2280, DOI 10.1200/JCO.2005.06.104; Walton JD, 2004, NEOPLASIA, V6, P838, DOI 10.1593/neo.04310; Wei DY, 2005, CANCER RES, V65, P2746, DOI 10.1158/0008-5472.CAN-04-3619; Yori JL, 2011, NEOPLASIA, V13, P601, DOI 10.1593/neo.11260; Yori JL, 2010, J BIOL CHEM, V285, P16854, DOI 10.1074/jbc.M110.114546; Yu F, 2011, ONCOGENE, V30, P2161, DOI 10.1038/onc.2010.591; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9	57	24	24	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2013	32	35					4086	4099		10.1038/onc.2012.437	http://dx.doi.org/10.1038/onc.2012.437			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	23045286				2022-12-17	WOS:000323748500004
J	Lin, YH; Huang, YH; Wu, MH; Wu, SM; Chi, HC; Liao, CJ; Chen, CY; Tseng, YH; Tsai, CY; Tsai, MM; Lin, KH				Lin, Y-H; Huang, Y-H; Wu, M-H; Wu, S-M; Chi, H-C; Liao, C-J; Chen, C-Y; Tseng, Y-H; Tsai, C-Y; Tsai, M-M; Lin, K-H			Thyroid hormone suppresses cell proliferation through endoglin-mediated promotion of p21 stability	ONCOGENE			English	Article						thyroid hormome; endoglin; hepatocellular carcinoma; cell proliferation	HEPATOCELLULAR-CARCINOMA; PITUITARY-TUMOR; CANCER-CELLS; CYCLE ARREST; EXPRESSION; RECEPTOR; INVASION; GENE; MIGRATION; BINDING	Hypothyroidism has been associated with significantly elevated risk for hepatocellular carcinoma (HCC), although the precise underlying mechanisms remain unknown at present. Thyroid hormone (T-3) and its receptor (TR) are involved in metabolism and growth. Endoglin is a T-3/TR candidate target gene identified from our previous studies. Here, we demonstrated that T-3 positively regulates endoglin mRNA and protein levels, both in vitro and in vivo. The thyroid hormone response elements of endoglin were identified at positions -2114/-2004 and -2032/-1973 of the promoter region using the electrophoretic mobility shift assay and chromatin immunoprecipitation assay. Endoglin was downregulated in the subgroups of HCC patients and significantly associated with histology grade (negative association, P = 0.001), and this expression level was significantly associated with TR alpha 1 in these HCC patients. Our results clearly indicate that p21 is involved in T-3-mediated suppression of cell proliferation. Knock down of endoglin expression in HCC cells facilitated p21 polyubiquitination and promoted cell proliferation in the presence of T-3. The data collectively suggest that T-3/TR signaling suppresses cell proliferation by upregulating endoglin, in turn, affecting p21 stability. The results indicate that endoglin has a suppressor role to inhibit cell proliferation in HCC cell lines.	[Lin, Y-H; Wu, M-H; Wu, S-M; Chi, H-C; Liao, C-J; Chen, C-Y; Tseng, Y-H; Tsai, C-Y; Lin, K-H] Chang Gung Univ, Dept Biochem, Coll Med, Tao Yuan, Taiwan; [Huang, Y-H] Chang Gung Mem Hosp, Liver Res Ctr, Linkou, Taiwan; [Tsai, M-M] Chang Gung Univ Sci & Technol, Dept Nursing, Tao Yuan, Taiwan	Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University of Science & Technology	Lin, KH (corresponding author), Chang Gung Univ, Dept Biochem, 259 Wen Hwa 1 Rd, Tao Yuan, Taiwan.	khlin@mail.cgu.edu.tw			Chang-Gung University, Taoyuan, Taiwan [CMRPD 34013, NMRP 140511]; National Science Council of the Republic of China [NSC 94-2320-B-182-052]	Chang-Gung University, Taoyuan, Taiwan; National Science Council of the Republic of China(Ministry of Science and Technology, Taiwan)	This work was supported by Grants from Chang-Gung University, Taoyuan, Taiwan (CMRPD 34013, NMRP 140511) and from the National Science Council of the Republic of China (NSC 94-2320-B-182-052).	Aliouat-Denis CM, 2005, MOL CANCER RES, V3, P627, DOI 10.1158/1541-7786.MCR-05-0121; Ando S, 2001, MOL ENDOCRINOL, V15, P1529, DOI 10.1210/me.15.9.1529; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Benetti A, 2008, CANCER RES, V68, P8626, DOI 10.1158/0008-5472.CAN-08-1218; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chamba A, 1996, J CLIN ENDOCR METAB, V81, P360, DOI 10.1210/jc.81.1.360; Chen RN, 2008, ENDOCRINOLOGY, V149, P3817, DOI 10.1210/en.2007-0989; Chen RN, 2008, CANCER RES, V68, P1697, DOI 10.1158/0008-5472.CAN-07-5492; Cheng S Y, 2000, Rev Endocr Metab Disord, V1, P9, DOI 10.1023/A:1010052101214; Craft CS, 2007, ONCOGENE, V26, P7240, DOI 10.1038/sj.onc.1210533; Fonsatti E, 2003, ONCOGENE, V22, P6557, DOI 10.1038/sj.onc.1206813; GOUGOS A, 1988, J IMMUNOL, V141, P1934; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Harvey CB, 2002, THYROID, V12, P441, DOI 10.1089/105072502760143791; Hassan MM, 2009, HEPATOLOGY, V49, P1563, DOI 10.1002/hep.22793; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Henry LA, 2011, ONCOGENE, V30, P1046, DOI 10.1038/onc.2010.488; Huang Ya-Hui, 2008, Chang Gung Med J, V31, P325; Kagawa S, 1999, CELL DEATH DIFFER, V6, P765, DOI 10.1038/sj.cdd.4400549; Kress E, 2010, GASTROENTEROLOGY, V138, P1863, DOI 10.1053/j.gastro.2010.01.041; Laptenko O, 2011, P NATL ACAD SCI USA, V108, P10385, DOI 10.1073/pnas.1105680108; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Lee H, 2006, J BIOL CHEM, V281, P26876, DOI 10.1074/jbc.M605366200; Lee JY, 2007, MOL CELL BIOL, V27, P3187, DOI 10.1128/MCB.01461-06; Li Y, 2002, J BIOL CHEM; Liao CH, 2012, HEPATOLOGY, V55, P910, DOI 10.1002/hep.24740; Liao CH, 2010, ENDOCR-RELAT CANCER, V17, P99, DOI 10.1677/ERC-09-0050; Liao CJ, 2011, CANCER SCI, V102, P2255, DOI 10.1111/j.1349-7006.2011.02102.x; Lin KH, 2000, ENDOCRINOLOGY, V141, P2540, DOI 10.1210/en.141.7.2540; Lin KH, 2001, ENDOCRINOLOGY, V142, P653, DOI 10.1210/en.142.2.653; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; Martinez-Iglesias O, 2009, CANCER RES, V69, P501, DOI 10.1158/0008-5472.CAN-08-2198; Oxmann D, 2008, ONCOGENE, V27, P3567, DOI 10.1038/sj.onc.1211025; Perez-Gomez E, 2007, CANCER RES, V67, P10268, DOI 10.1158/0008-5472.CAN-07-1348; Puzianowska-Kuznicka M, 2002, J CLIN ENDOCR METAB, V87, P1120, DOI 10.1210/jc.87.3.1120; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Wu SM, 2011, ONCOGENE, V30, P2057, DOI 10.1038/onc.2010.585; Yen CC, 2006, J MOL ENDOCRINOL, V36, P9, DOI 10.1677/jme.1.01911; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Yoo YD, 1999, INT J CANCER, V83, P512, DOI 10.1002/(SICI)1097-0215(19991112)83:4<512::AID-IJC13>3.0.CO;2-Z; Yu DC, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-122	44	24	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3904	3914		10.1038/onc.2013.5	http://dx.doi.org/10.1038/onc.2013.5			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	23376845				2022-12-17	WOS:000323210200013
J	Budiu, RA; Elishaev, E; Brozick, J; Lee, M; Edwards, RP; Kalinski, P; Vlad, AM				Budiu, R. A.; Elishaev, E.; Brozick, J.; Lee, M.; Edwards, R. P.; Kalinski, P.; Vlad, A. M.			Immunobiology of human mucin 1 in a preclinical ovarian tumor model	ONCOGENE			English	Article						ovarian cancer; MUC1; Kras; Pten; dendritic cells	CARCINOMA-ASSOCIATED ANTIGEN; MAJOR HISTOCOMPATIBILITY COMPLEX; REGULATORY T-CELLS; MOUSE MODEL; MOLECULAR-CLONING; GENE-EXPRESSION; CANCER; MICE; TOLERANCE; PTEN	Epithelial ovarian cancer is an aggressive malignancy, with a low 5-year median survival. Continued improvement on the development of more effective therapies depends in part on the availability of adequate preclinical models for in vivo testing of treatment efficacy. Mucin 1 (MUC1) glycoprotein is a tumor-associated antigen overexpressed in ovarian cancer cells, making it a potential target for immune therapy. To create a preclinical mouse model for MUC1-positive ovarian tumors, we generated triple transgenic (Tg) mice that heterozygously express human MUC1(+/+) as a transgene, and carry the conditional K-rasG12D oncoallele (loxP-Stop-loxP-K-ras(G12D/+)) and the floxed Pten gene (Pten/(loxP/loxP)). Injection of Cre recombinase-encoding adenovirus (AdCre) in the ovarian bursa of triple (MUC1KrasPten) Tg mice triggers ovarian tumors that, in analogy to human ovarian cancer, express strongly elevated MUC1 levels. The tumors metastasize loco-regionally and are accompanied by high serum MUC1, closely mimicking the human disease. Compared with the KrasPten mice with tumors, the MUC1KrasPten mice show increased loco-regional metastasis and augmented accumulation of CD4+Foxp3+ immune-suppressive regulatory T cells. Vaccination of MUC1KrasPten mice with type 1 polarized dendritic cells (DC1) loaded with a MUC1 peptide (DC1-MUC1) can circumvent tumor-mediated immune suppression in the host, activate multiple immune effector genes and effectively prolong survival. Our studies report the first human MUC1-expressing, orthotopic ovarian tumor model, reveal novel MUC1 functions in ovarian cancer biology and demonstrate its suitability as a target for immune-based therapies.	[Budiu, R. A.; Elishaev, E.; Edwards, R. P.; Vlad, A. M.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA; [Budiu, R. A.; Brozick, J.; Lee, M.; Edwards, R. P.; Vlad, A. M.] Magee Womens Res Inst, Pittsburgh, PA USA; [Elishaev, E.] Univ Pittsburgh, Med Ctr, Dept Pathol, Magee Womens Hosp, Pittsburgh, PA 15213 USA; [Kalinski, P.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; [Kalinski, P.] Univ Pittsburgh, Sch Med, Hillman Canc Ctr, Dept Surg, Pittsburgh, PA 15213 USA; [Kalinski, P.; Vlad, A. M.] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Vlad, AM (corresponding author), Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Magee Womens Res Inst, Room B403,204 Craft Ave, Pittsburgh, PA 15213 USA.	vladam@upmc.edu	Brozick, Joan/AAA-5785-2019		Department of Defense Ovarian Cancer Academy Award; Pennsylvania Department of Health; Scaife Foundation; NIH/NCI [1 R01 CA163462-01]; NATIONAL CANCER INSTITUTE [R01CA163462] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER	Department of Defense Ovarian Cancer Academy Award; Pennsylvania Department of Health; Scaife Foundation; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We would like to thank Dr Daniela Dinulescu for discussion on various aspects of the mouse model, Dr Olivera Finn for critical review of the paper and Julia Thaller for technical assistance with histology work. This study was supported by the Department of Defense Ovarian Cancer Academy Award, Pennsylvania Department of Health, Scaife Foundation and NIH/NCI 1 R01 CA163462-01 (to AMV).	Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Allavena P, 2010, CLIN DEV IMMUNOL, DOI 10.1155/2010/547179; BARND DL, 1989, P NATL ACAD SCI USA, V86, P7159, DOI 10.1073/pnas.86.18.7159; Beatty PL, 2007, J IMMUNOL, V179, P735, DOI 10.4049/jimmunol.179.2.735; Besmer DM, 2011, CANCER RES, V71, P4432, DOI 10.1158/0008-5472.CAN-10-4439; Boyd J, 2005, NEW ENGL J MED, V352, P2240, DOI 10.1056/NEJMcibr051024; Brayman Melissa, 2004, Reprod Biol Endocrinol, V2, P4, DOI 10.1186/1477-7827-2-4; Budiu RA, 2011, CANCER IMMUNOL IMMUN, V60, P975, DOI 10.1007/s00262-011-1010-x; Budiu RA, 2009, DIS MODEL MECH, V2, P593, DOI 10.1242/dmm.002535; Cheever MA, 2009, CLIN CANCER RES, V15, P5323, DOI 10.1158/1078-0432.CCR-09-0737; Chen DS, 2000, BREAST CANCER RES TR, V60, P107, DOI 10.1023/A:1006332009414; Connolly DC, 2003, CANCER RES, V63, P1389; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; Fan HY, 2009, CANCER RES, V69, P6463, DOI 10.1158/0008-5472.CAN-08-3363; Flesken-Nikitin A, 2003, CANCER RES, V63, P3459; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; Giermasz AS, 2009, CANCER IMMUNOL IMMUN, V58, P1329, DOI 10.1007/s00262-008-0648-5; Hiltbold EM, 2000, J IMMUNOL, V165, P3730, DOI 10.4049/jimmunol.165.7.3730; HO SB, 1993, CANCER RES, V53, P641; IOANNIDES CG, 1993, J IMMUNOL, V151, P3693; JEROME KR, 1993, J IMMUNOL, V151, P1654; Kandalaft LE, 2011, J CLIN ONCOL, V29, P925, DOI 10.1200/JCO.2009.27.2369; Karam AK, 2010, NAT REV CLIN ONCOL, V7, P335, DOI 10.1038/nrclinonc.2010.44; KOTERA Y, 1994, CANCER RES, V54, P2856; Kryczek I, 2007, CANCER RES, V67, P8900, DOI 10.1158/0008-5472.CAN-07-1866; Kurman RJ, 2011, HUM PATHOL, V42, P918, DOI 10.1016/j.humpath.2011.03.003; Lau SK, 2004, AM J CLIN PATHOL, V122, P61, DOI 10.1309/9R6673QEC06D86Y4; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; Lu KH, 2004, CLIN CANCER RES, V10, P3291, DOI 10.1158/1078-0432.CCR-03-0409; Matzuk MM, 2005, NAT MED, V11, P24, DOI 10.1038/nm0105-24; Melief CJM, 2008, IMMUNITY, V29, P372, DOI 10.1016/j.immuni.2008.08.004; Mullany LK, 2011, ONCOGENE, V30, P3522, DOI 10.1038/onc.2011.70; Odunsi K, 2008, AM J REPROD IMMUNOL, V59, P62, DOI 10.1111/j.1600-0897.2007.00560.x; Palucka K, 2011, J IMMUNOL, V186, P1325, DOI 10.4049/jimmunol.0902539; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Reinartz S, 2012, EUR J CANCER, V48, P1558, DOI 10.1016/j.ejca.2011.07.004; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Rowse GJ, 1998, CANCER RES, V58, P315; Roy LD, 2011, ONCOGENE, V30, P1449, DOI 10.1038/onc.2010.526; Rustin GJS, 2004, CLIN CANCER RES, V10, P3919, DOI 10.1158/1078-0432.CCR-03-0787; Ryan SO, 2009, BIOL CHEM, V390, P611, DOI 10.1515/BC.2009.070; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Shan WW, 2009, CELL CYCLE, V8, P731, DOI 10.4161/cc.8.5.7848; SPICER AP, 1991, J BIOL CHEM, V266, P15099; Tanwar PS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020715; Theriault C, 2011, GYNECOL ONCOL, V121, P434, DOI 10.1016/j.ygyno.2011.02.020; Tinder TL, 2008, J IMMUNOL, V181, P3116, DOI 10.4049/jimmunol.181.5.3116; Vergara D, 2010, CANCER LETT, V291, P59, DOI 10.1016/j.canlet.2009.09.017; Vlad AM, 2002, J EXP MED, V196, P1435, DOI 10.1084/jem.20020493; Vlad AM, 2006, IMMUNOL RES, V36, P229, DOI 10.1385/IR:36:1:229; Wei CW, 1997, P NATL ACAD SCI USA, V94, P6369, DOI 10.1073/pnas.94.12.6369; Wei XL, 2005, CANCER CELL, V7, P167, DOI 10.1016/j.ccr.2005.01.008; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yang DH, 2006, AM J PATHOL, V169, P258, DOI 10.2353/ajpath.2006.060036	58	24	24	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2013	32	32					3664	3675		10.1038/onc.2012.397	http://dx.doi.org/10.1038/onc.2012.397			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	198EH	22964632	Green Accepted			2022-12-17	WOS:000322904400002
J	Chatain, N; Ziegler, P; Fahrenkamp, D; Jost, E; Moriggl, R; Schmitz-Van de Leur, H; Muller-Newen, G				Chatain, N.; Ziegler, P.; Fahrenkamp, D.; Jost, E.; Moriggl, R.; Schmitz-Van de Leur, H.; Mueller-Newen, G.			Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells	ONCOGENE			English	Article						CML; BCR-ABL; STAT5; Src; inhibitors	CHRONIC MYELOID-LEUKEMIA; DNA-BINDING ACTIVITY; SIGNAL TRANSDUCERS; CONSTITUTIVE ACTIVATION; LYMPHOBLASTIC-LEUKEMIA; PHOSPHORYLATED STAT5; TRANSCRIPTION STAT; INHIBITS APOPTOSIS; TYROSINE KINASE; SURVIVAL	Persistent activation of the Abl tyrosine kinase in the BCR-ABL fusion protein is the major cause of chronic myeloid leukemia (CML). Among many other substrates BCR-ABL phosphorylates STAT5 and Src family kinases (SFK). Activated pSTAT5 is essential for initial transformation and maintenance of the disease. Cytokine-induced phosphorylation on tyrosine 694 typically leads to nuclear accumulation of pSTAT5 and target gene expression. We verified that in BCR-ABL-positive progenitor cells from a CML patient and in K562 cells pSTAT5 is cytoplasmic. However, upon ectopic expression of BCR-ABL p210 in non-myeloid cells, co-transfected STAT5A is phosphorylated on Y694 and localized in the nucleus arguing for an additional factor mediating cytoplasmic retention in CML cells. Expression of the SFK v-Src, Hck or Lyn together with STAT5A results in phosphorylation on Y694 and cytoplasmic retention. Upon coexpression of BCR-ABL and individual SFK the cytoplasmic retention of activated STAT5A mediated by v-Src and Hck but not Lyn is dominant over nuclear translocation induced by BCR-ABL. Cytoplasmic retention depends on the kinase activity of SFK and is mediated through the interaction of the SH2 domain of STAT5A with the SFK. Interestingly, nuclear accumulation of STAT5A as a result of activation by FLT3-ITD, an oncogene found in acute myeloid leukemia, cannot be prevented by coexpression of SFK. Importantly, inhibition of SFK in K562 cells restored nuclear accumulation of pSTAT5A, enhanced STAT5 target gene expression and increased colony formation. Thus, SFK mediate cytoplasmic retention of pSTAT5A in BCR-ABL-positive cells. Cytoplasmic pSTAT5A in CML cells might balance the controversial functions of STAT5 in cellular senescence and differentiation versus G(1)/S progression and survival.	[Chatain, N.; Fahrenkamp, D.; Schmitz-Van de Leur, H.; Mueller-Newen, G.] Rhein Westfal TH Aachen, Inst Biochem & Mol Biol, D-52074 Aachen, NRW, Germany; [Ziegler, P.; Jost, E.] Rhein Westfal TH Aachen, Klin Onkol Hamatol & Stammzelltransplantat, D-52074 Aachen, NRW, Germany; [Moriggl, R.] Ludwig Boltzmann Inst Canc Res LBI CR, Vienna, Austria	RWTH Aachen University; RWTH Aachen University; Ludwig Boltzmann Institute	Muller-Newen, G (corresponding author), Rhein Westfal TH Aachen, Inst Biochem & Mol Biol, Pauwelsstr 30, D-52074 Aachen, NRW, Germany.	mueller-newen@rwth-aachen.de	Moriggl, Richard/H-8118-2019	Moriggl, Richard/0000-0003-0918-9463	Deutsche Forschungsgemeinschaft (DFG) [SFB 542]; Austrian Science Funds (FWF) [SFB F28]; IZKF Aachen (Interdisciplinary Center for Clinical Research within the Faculty of Medicine at RWTH Aachen University); Austrian Science Fund (FWF) [F 2807] Funding Source: researchfish	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Austrian Science Funds (FWF)(Austrian Science Fund (FWF)); IZKF Aachen (Interdisciplinary Center for Clinical Research within the Faculty of Medicine at RWTH Aachen University); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	The research project was supported by grants from the Deutsche Forschungsgemeinschaft (DFG, SFB 542, projects B12 and Z1 to GMN), the Austrian Science Funds (FWF, SFB F28 to RM) and the core facility confocal microscopy of the IZKF Aachen (Interdisciplinary Center for Clinical Research within the Faculty of Medicine at RWTH Aachen University). We would like to thank Frank-D Bohmer, Tim Brummendorf, Michael Huber, Isabelle Maridonneau-Parini, Fred Schaper and Veronika Sexl for their critical discussion and helping us with plasmid constructs.	Baumgartner C, 2009, AM J PATHOL, V175, P2416, DOI 10.2353/ajpath.2009.080953; Bunting KD, 2007, BLOOD, V110, P2775, DOI 10.1182/blood-2007-05-090969; Bunting KD, 2007, FRONT BIOSCI-LANDMRK, V12, P2807, DOI 10.2741/2274; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Choudhary C, 2009, MOL CELL, V36, P326, DOI 10.1016/j.molcel.2009.09.019; Copland M, 2006, BLOOD, V107, P4532, DOI 10.1182/blood-2005-07-2947; Cortes JE, 2011, BLOOD, V118, P4567, DOI 10.1182/blood-2011-05-355594; Costa-Pereira AP, 2002, P NATL ACAD SCI USA, V99, P8043, DOI 10.1073/pnas.122236099; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Ferbeyre G, 2011, BBA-REV CANCER, V1815, P104, DOI 10.1016/j.bbcan.2010.10.004; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harir N, 2007, BLOOD, V109, P1678, DOI 10.1182/blood-2006-01-029918; Heltemes-Harris LM, 2011, ANN NY ACAD SCI, V1217, P18, DOI 10.1111/j.1749-6632.2010.05907.x; Hennighausen L, 2008, GENE DEV, V22, P711, DOI 10.1101/gad.1643908; Herrmann A, 2007, J CELL SCI, V120, P3249, DOI 10.1242/jcs.03482; Hoelbl A, 2006, BLOOD, V107, P4898, DOI 10.1182/blood-2005-09-3596; Hoelbl A, 2010, EMBO MOL MED, V2, P98, DOI 10.1002/emmm.201000062; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; Kotecha N, 2008, CANCER CELL, V14, P335, DOI 10.1016/j.ccr.2008.08.014; Li G, 2010, LEUKEMIA, V24, P1397, DOI 10.1038/leu.2010.131; Li GQ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009152; Li SG, 2005, EXPERT OPIN THER TAR, V9, P329, DOI 10.1517/14728222.9.2.329; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; Lilly M, 1997, CANCER RES, V57, P5348; Lim CP, 2006, MOL BIOSYST, V2, P536, DOI 10.1039/b606246f; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Mallette FA, 2010, ANN NY ACAD SCI, V1197, P142, DOI 10.1111/j.1749-6632.2010.05192.x; Meyn MA, 2006, J BIOL CHEM, V281, P30907, DOI 10.1074/jbc.M605902200; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Nyga R, 2005, BIOCHEM J, V390, P359, DOI 10.1042/BJ20041523; Okutani Y, 2001, ONCOGENE, V20, P6643, DOI 10.1038/sj.onc.1204807; Ozawa Y, 2008, LEUKEMIA RES, V32, P893, DOI 10.1016/j.leukres.2007.11.032; Poincloux R, 2007, J CELL PHYSIOL, V213, P212, DOI 10.1002/jcp.21112; Schenone S, 2010, EXPERT OPIN INV DRUG, V19, P931, DOI 10.1517/13543784.2010.499898; Schmidt-Arras D, 2009, BLOOD, V113, P3568, DOI 10.1182/blood-2007-10-121426; Shiotsu Y, 2009, BLOOD, V114, P1607, DOI 10.1182/blood-2009-01-199307; Shuai K, 1996, ONCOGENE, V13, P247; Silva CM, 2004, ONCOGENE, V23, P8017, DOI 10.1038/sj.onc.1208159; Stanglmaier M, 2003, LEUKEMIA, V17, P283, DOI 10.1038/sj.leu.2402778; Tatton L, 2003, J BIOL CHEM, V278, P4847, DOI 10.1074/jbc.M209321200; Vogt M, 2011, J CELL SCI, V124, P900, DOI 10.1242/jcs.072520; Walz C, 2012, BLOOD, V119, P3550, DOI 10.1182/blood-2011-12-397554; Warmuth M, 2003, BLOOD, V101, P664, DOI 10.1182/blood-2002-01-0288; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Ziegler P, 2007, CURR PROTOC TOXICOL	48	24	24	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2013	32	31					3587	3597		10.1038/onc.2012.369	http://dx.doi.org/10.1038/onc.2012.369			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194MW	22926520				2022-12-17	WOS:000322638400003
J	Schepeler, T; Lamy, P; Hvidberg, V; Laurberg, JR; Fristrup, N; Reinert, T; Bartkova, J; Tropia, L; Bartek, J; Halazonetis, TD; Pan, CC; Borre, M; Dyrskjot, L; Orntoft, TF				Schepeler, T.; Lamy, P.; Hvidberg, V.; Laurberg, J. R.; Fristrup, N.; Reinert, T.; Bartkova, J.; Tropia, L.; Bartek, J.; Halazonetis, T. D.; Pan, C-C; Borre, M.; Dyrskjot, L.; Orntoft, T. F.			A high resolution genomic portrait of bladder cancer: correlation between genomic aberrations and the DNA damage response	ONCOGENE			English	Article						bladder cancer; SNP array; DNA damage response; Timeless	ANTICANCER BARRIER; MAMMALIAN TIMELESS; TIPIN; CHECKPOINT; GENE; INSTABILITY; PROGRESSION; SIGNATURES; ONCOGENE; COMPLEX	One major challenge in cancer research is to understand the complex interplay between the DNA damage response (DDR), genomic integrity, and tumor development. To address these issues, we analyzed 43 bladder tumor genomes from 22 patients using single nucleotide polymorphism (SNP) arrays, and tissue expression of multiple DDR proteins, including Timeless and its interaction partner Tipin. The SNP profiles confirmed and extended known copy number alterations (CNAs) at high resolution, showed clustering of CNAs at nine common fragile sites, and revealed that most metachronous tumors were clonally related. The occurrence of many novel uniparental disomy regions (UPDs) was of potential functional importance in some tumors because UPDs spanned mutated FGFR3 and PIK3CA alleles, and also homozygous deletion of the CDKN2A tumor suppressor locus. The DDR signaling as evaluated by phospho-epitope-specific antibodies against Ser139-phosphorylated H2A histone family member X (gamma H2AX), ataxia telangiectasia mutated (ATM), and ATM- and Rad3-related (ATR) was commonly activated in tumors with both moderate and high extent of accumulated genomic aberrations, the latter tumors showing a more frequent loss of ATM expression. Strikingly, the tumor genomes exhibiting the most complex alterations were associated with a high Ki67-proliferation index, abundant Timeless but not Tipin expression, aberrant p53 expression, and homozygous CDKN2A deletions. Of clinical relevance, evaluation of a tissue microarray (TMA; n = 319) showed that abundant Timeless expression was associated with risk of progression to muscle-invasive disease (P<0.0005; hazard ratio, 2.4; 95% confidence interval, 1.6-3.8) and higher T stage (P<0.05). Univariate analysis confirmed this association (P = 0.006) in an independent cohort (n = 241) but statistical significance was not reached in a multivariate model. Overall, our results are consistent with DDR activation preceding the accumulation of genomic aberrations. Tumors with extensive genomic rearrangements were associated with inactivation of CDKN2A, excessive proliferation, and robust Timeless expression, the latter also correlating with the risk of disease progression. Moreover, we provide evidence to suggest that UPDs likely contribute to bladder tumorigenesis.	[Schepeler, T.; Lamy, P.; Hvidberg, V.; Laurberg, J. R.; Fristrup, N.; Reinert, T.; Dyrskjot, L.; Orntoft, T. F.] Aarhus Univ Hosp, Dept Mol Med, DK-8200 Aarhus N, Denmark; [Bartkova, J.; Bartek, J.] Danish Canc Soc, Res Ctr, Copenhagen, Denmark; [Tropia, L.; Halazonetis, T. D.] Univ Geneva, Dept Mol Biol, CH-1211 Geneva, Switzerland; [Bartek, J.] Palacky Univ, Inst Mol & Translat Med, CR-77147 Olomouc, Czech Republic; [Halazonetis, T. D.] Univ Geneva, Dept Biochem, CH-1211 Geneva, Switzerland; [Pan, C-C] Taipei Vet Gen Hosp, Dept Pathol, Taipei, Taiwan; [Borre, M.] Aarhus Univ Hosp, Dept Urol, DK-8200 Aarhus N, Denmark	Aarhus University; Danish Cancer Society; University of Geneva; Palacky University Olomouc; University of Geneva; Taipei Veterans General Hospital; Aarhus University	Orntoft, TF (corresponding author), Aarhus Univ Hosp, Dept Mol Med, Brendstrupgaardsvej, DK-8200 Aarhus N, Denmark.	orntoft@ki.au.dk	Bartek, Jiri/G-5870-2014	Dyrskjot, Lars/0000-0001-7061-9851; Borre, Michael/0000-0002-1519-9185; Reinert, Thomas/0000-0003-4835-4804	John and Birthe Meyer Foundation; Danish Cancer Society; Danish National Research Foundation; Ministry of Technology and Science; Lundbeck Foundation; European Community's Seventh Framework program [201663]	John and Birthe Meyer Foundation; Danish Cancer Society(Danish Cancer Society); Danish National Research Foundation(Danmarks Grundforskningsfond); Ministry of Technology and Science; Lundbeck Foundation(Lundbeckfonden); European Community's Seventh Framework program(European Commission)	We thank The John and Birthe Meyer Foundation, the Danish Cancer Society, the Danish National Research Foundation, the Ministry of Technology and Science, the Lundbeck Foundation, and the European Community's Seventh Framework program (projects Infla-Care, Biomedreg, DDresponse, and Grant agreement no. 201663).	Aly A, 2011, J MOL CELL BIOL, V3, P66, DOI 10.1093/jmcb/mjq055; Bartek J, 2007, CELL CYCLE, V6, P2344, DOI 10.4161/cc.6.19.4754; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768; Blaveri E, 2005, CLIN CANCER RES, V11, P7012, DOI 10.1158/1078-0432.CCR-05-0177; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Chou DM, 2006, P NATL ACAD SCI USA, V103, P18143, DOI 10.1073/pnas.0609251103; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Dereli-Oz A, 2011, MOL ONCOL, V5, P308, DOI 10.1016/j.molonc.2011.05.002; Dheekollu J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019596; Duggan BJ, 2004, J UROLOGY, V171, P419, DOI 10.1097/01.ju.0000100105.27708.6c; Fu A, 2011, MOL CARCINOG, V17, DOI [10.1002/mc.20862, DOI 10.1002/MC.20862)]; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gotter AL, 2007, J MOL BIOL, V366, P36, DOI 10.1016/j.jmb.2006.10.097; Hafner C, 2002, INT J CANCER, V101, P1, DOI 10.1002/ijc.10544; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Koed K, 2005, CANCER RES, V65, P34; Kompier LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013821; Langbein S, 2002, LAB INVEST, V82, P639, DOI 10.1038/labinvest.3780458; Lapunzina P, 2011, BIOL CELL, V103, P303, DOI 10.1042/BC20110013; Le Tallec B, 2011, NAT STRUCT MOL BIOL, V18, P1421, DOI 10.1038/nsmb.2155; Letessier A, 2011, NATURE, V470, P120, DOI 10.1038/nature09745; Lindgren D, 2010, CANCER RES, V70, P3463, DOI 10.1158/0008-5472.CAN-09-4213; Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760; Lu ML, 2002, CLIN CANCER RES, V8, P171; Martin SA, 2010, J PATHOL, V220, P281, DOI 10.1002/path.2631; McFarlane RJ, 2010, CELL CYCLE, V9, P700, DOI 10.4161/cc.9.4.10676; Mo L, 2007, J CLIN INVEST, V117, P314, DOI 10.1172/JCI30062; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Poulogiannis G, 2010, P NATL ACAD SCI USA, V107, P15145, DOI 10.1073/pnas.1009941107; Reinert T, 2011, CLIN CANCER RES, V17, P5582, DOI 10.1158/1078-0432.CCR-10-2659; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Santarius T, 2010, GENE CHROMOSOME CANC, V49, P711, DOI 10.1002/gcc.20784; Schepeler Troels, 2007, J Mol Signal, V2, P6, DOI 10.1186/1750-2187-2-6; Smith-Roe SL, 2011, CELL CYCLE, V10, P1618, DOI 10.4161/cc.10.10.15613; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Sylvester RJ, 2006, EUR UROL, V49, P466, DOI 10.1016/j.eururo.2005.12.031; Takacova S, 2012, CANCER CELL, V21, P517, DOI 10.1016/j.ccr.2012.01.021; Toledo LI, 2011, NAT STRUCT MOL BIOL, V18, P721, DOI 10.1038/nsmb.2076; Tuna M, 2009, TRENDS MOL MED, V15, P120, DOI 10.1016/j.molmed.2009.01.005; Unsal-Kacmaz K, 2005, MOL CELL BIOL, V25, P3109, DOI 10.1128/MCB.25.8.3109-3116.2005; Unsal-Kacmaz K, 2007, MOL CELL BIOL, V27, P3131, DOI 10.1128/MCB.02190-06; Vetter G, 2010, ONCOGENE, V29, P4436, DOI 10.1038/onc.2010.181; Weaver BAA, 2007, CANCER CELL, V11, P25, DOI 10.1016/j.ccr.2006.12.003; Wu QO, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-16; Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697; Yang XM, 2010, J BIOL CHEM, V285, DOI 10.1074/jbc.M109.050237; Yoshizawa-Sugata N, 2007, J BIOL CHEM, V282, P2729, DOI 10.1074/jbc.M605596200; Zieger K, 2009, INT J CANCER, V125, P2095, DOI 10.1002/ijc.24619; Zieger K, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-149	56	24	26	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2013	32	31					3577	3586		10.1038/onc.2012.381	http://dx.doi.org/10.1038/onc.2012.381			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194MW	22926521				2022-12-17	WOS:000322638400002
J	Kern, F; Doma, E; Rupp, C; Niault, T; Baccarini, M				Kern, F.; Doma, E.; Rupp, C.; Niault, T.; Baccarini, M.			Essential, non-redundant roles of B-Raf and Raf-1 in Ras-driven skin tumorigenesis	ONCOGENE			English	Article						B-Raf; conditional ablation; epidermis; Raf-1; Ras-driven skin tumorigenesis	C-RAF; KERATINOCYTE DIFFERENTIATION; EPIDERMAL NEOPLASIA; BRAF INHIBITION; TUMOR-FORMATION; K-RAS; CARCINOGENESIS; KINASES; CANCER; CELLS	Ras-driven tumorigenesis is assumed to depend on Raf for ERK activation and proliferation; yet, an in vivo requirement for Raf as MEK/ERK activator in this setting has not been demonstrated to date. Here, we show that epidermis-restricted B-Raf ablation restrains the onset and stops the progression of established Ras-driven tumors by limiting MEK/ERK activation and proliferation. Concomitant elimination of B-Raf and Raf-1 enforces the abrupt regression of established tumors owing to the decrease in ERK activation and proliferation caused by B-Raf ablation combined with the ERK-independent increase in Rho-dependent kinase (Rok) signaling and differentiation triggered by Raf-1 inactivation. Thus, B-Raf and Raf-1 have non-redundant functions in Ras-driven tumorigenesis. Of note, Raf kinase inhibitors achieve impressive results in melanomas harboring oncogenic BRAF, but are ineffective against Ras-driven tumors; moreover, therapy-related skin tumors driven by a paradox ERK activation as well as primary and acquired resistance have been reported. Our results suggest that therapies targeting both Raf kinase-dependent and -independent pathways may be effective against a broader range of malignancies and reduce the risks of adverse effects and/or resistance.	[Kern, F.; Doma, E.; Rupp, C.; Niault, T.; Baccarini, M.] Univ Vienna, Dept Microbiol & Immunobiol, Max F Perutz Labs, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Baccarini, M (corresponding author), Univ Vienna, Dept Microbiol & Immunobiol, Max F Perutz Labs, Doktor Bohr Gasse 9, A-1030 Vienna, Austria.	manuela.baccarini@univie.ac.at	Baccarini, Manuela/B-6481-2014	Baccarini, Manuela/0000-0002-3033-391X	European Commission [LSH-CT-2003-506803]; Austrian Research Fund [P19530-B11]	European Commission(European CommissionEuropean Commission Joint Research Centre); Austrian Research Fund(Austrian Science Fund (FWF))	We thank Karin Ehrenreiter and the animal house team for excellent technical help, M Sibilia for the K5-SOS-F mice and P Chambon for the K5-Cre-er(T) animals. This work was supported by European Commission grant LSH-CT-2003-506803 and by Austrian Research Fund grant P19530-B11 (to MB).	Blasco RB, 2011, CANCER CELL, V19, P652, DOI 10.1016/j.ccr.2011.04.002; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Bourcier C, 2006, CANCER RES, V66, P2700, DOI 10.1158/0008-5472.CAN-05-3129; Brower V, 2010, J NATL CANCER I, V102, P214, DOI 10.1093/jnci/djq037; Cichowski K, 2010, NATURE, V464, P358, DOI 10.1038/464358a; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Downward J, 2011, NAT MED, V17, P286, DOI 10.1038/nm0311-286; Dumesic PA, 2009, J CELL BIOL, V185, P409, DOI 10.1083/jcb.200804038; Ehrenreiter K, 2005, J CELL BIOL, V168, P955, DOI 10.1083/jcb.200409162; Ehrenreiter K, 2009, CANCER CELL, V16, P149, DOI 10.1016/j.ccr.2009.06.008; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Galabova-Kovacs G, 2006, P NATL ACAD SCI USA, V103, P1325, DOI 10.1073/pnas.0507399103; Gonzalez-Garcia A, 2005, CANCER CELL, V7, P219, DOI 10.1016/j.ccr.2005.01.029; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Honma M, 2006, MOL BIOL CELL, V17, P1888, DOI 10.1091/mbc.E05-12-1173; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Karreth FA, 2011, CANCER DISCOV, V1, P128, DOI 10.1158/2159-8290.CD-10-0044; Kern F, 2011, BRIT J CANCER, V104, P229, DOI 10.1038/sj.bjc.6606009; Khavari TA, 2007, CELL CYCLE, V6, P2928, DOI 10.4161/cc.6.23.4998; Lichtenberger BM, 2010, CELL, V140, P268, DOI 10.1016/j.cell.2009.12.046; Lock FE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008190; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Maurer G, 2011, ONCOGENE, V30, P3477, DOI 10.1038/onc.2011.160; McMullan R, 2003, CURR BIOL, V13, P2185, DOI 10.1016/S0960-9822(03)00906-0; Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787; Murayama K, 2007, ONCOGENE, V26, P4882, DOI 10.1038/sj.onc.1210274; Niault TS, 2010, CARCINOGENESIS, V31, P1165, DOI 10.1093/carcin/bgp337; Oki-Idouchi CE, 2007, CANCER RES, V67, P276, DOI 10.1158/0008-5472.CAN-06-3080; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Ridky TW, 2004, CELL CYCLE, V3, P621; Riva C, 1995, ORAL ONCOL, V31B, P384, DOI 10.1016/0964-1955(95)00045-3; Scholl FA, 2009, ONCOGENE, V28, P1485, DOI 10.1038/onc.2008.459; Scholl FA, 2007, DEV CELL, V12, P615, DOI 10.1016/j.devcel.2007.03.009; Scholl FA, 2009, CANCER RES, V69, P3772, DOI 10.1158/0008-5472.CAN-08-1963; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; Solit DB, 2011, NEW ENGL J MED, V364, P772, DOI 10.1056/NEJMcibr1013704; Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358; Vitale-Cross L, 2004, CANCER RES, V64, P8804, DOI 10.1158/0008-5472.CAN-04-2623; Wang Z.A., 2010, ONCOGENE; Wimmer R, 2010, TRENDS BIOCHEM SCI, V35, P660, DOI 10.1016/j.tibs.2010.06.001	44	24	24	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2013	32	19					2483	2492		10.1038/onc.2012.254	http://dx.doi.org/10.1038/onc.2012.254			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22733131				2022-12-17	WOS:000318694900012
J	Shanmugasundaram, K; Block, K; Nayak, BK; Livi, CB; Venkatachalam, MA; Sudarshan, S				Shanmugasundaram, K.; Block, K.; Nayak, B. K.; Livi, C. B.; Venkatachalam, M. A.; Sudarshan, S.			PI3K regulation of the SKP-2/p27 axis through mTORC2	ONCOGENE			English	Article						p27; SKP-2; mTOR; RICTOR	RENAL-CELL CARCINOMA; RAPAMYCIN COMPLEX 2; PROTEIN-KINASE B; TISSUE MICROARRAY; SUBCELLULAR-LOCALIZATION; CYTOPLASMIC LOCALIZATION; AKT PHOSPHORYLATION; MAMMALIAN TARGET; UBIQUITIN LIGASE; SKP2	The cyclin-dependent kinase inhibitor p27 is a key regulator of cell-cycle progression. Its expression and localization are altered in several types of malignancies, which has prognostic significance in cancers such as renal cell carcinoma (RCC). S-phase kinase-associated protein 2 (SKP-2) is an F-box protein that is part of the SKP-1/Cul1/F-box ubiquitin ligase complex that targets nuclear p27 among many other cell-cycle proteins for proteosomal degradation. Its overexpression has been observed in several tumor types. Signaling by phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) has previously been shown to regulate the SKP-2/p27 axis. Recent evidence suggests that PI3K signaling may activate mammalian target of rapamycin complex 2 (mTORC2) activity. As PI3K signaling is known to regulate SKP-2 and p27, we sought to determine whether these effects were mediated by mTORC2. Here we provide additional genetic evidence that PI3K signaling activates mTORC2 kinase activity. We also demonstrate a novel role for mTORC2 in the modulation of nuclear p27 levels. In particular, mTORC2 signaling promotes the reduction of nuclear p27 protein levels through the increased protein expression of SKP-2. These are the first data to demonstrate a role for mTOR in the regulation of SKP-2. In concordance with these findings, mTORC2 activity promotes cell proliferation of RCC cells at the G1-S interphase of the cell cycle. Collectively, these data implicate mTORC2 signaling in the regulation of the SKP-2/p27 axis, a signaling node commonly altered in cancer. Oncogene (2013) 32, 2027-2036; doi:10.1038/onc.2012.226; published online 25 June 2012	[Shanmugasundaram, K.; Sudarshan, S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA; [Block, K.; Nayak, B. K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA; [Livi, C. B.] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA; [Venkatachalam, M. A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA; [Block, K.] Audie L Murphy Mem Hosp Div, South Texas Vet Hlth Care Syst, San Antonio, TX USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Sudarshan, S (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, 7703 Floyd Curl Dr,MC 7845, San Antonio, TX 78229 USA.	sudarshan@uthscsa.edu		Livi, Carolina/0000-0001-8389-2830	Cancer Therapy and Research Center (CTRC) at the University of Texas Health Science Center [NIH P30 CA054174-17]; NIH [K08 CA138774, R01 NCI CA131272]; Voelcker Fund Young Investigator Award; AUA Foundation/Astellas Rising Star Award; Veterans Administration Career Development Award [CDA-2]; NATIONAL CANCER INSTITUTE [P30CA054174, K08CA138774, R01CA131272] Funding Source: NIH RePORTER	Cancer Therapy and Research Center (CTRC) at the University of Texas Health Science Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Voelcker Fund Young Investigator Award; AUA Foundation/Astellas Rising Star Award; Veterans Administration Career Development Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the Cancer Therapy and Research Center (CTRC) at the University of Texas Health Science Center (NIH P30 CA054174-17). SS is supported by NIH K08 CA138774, Voelcker Fund Young Investigator Award, AUA Foundation/Astellas Rising Star Award and a special gift from Mr Charles Butt and the employees of HEB. KB is supported by Veterans Administration Career Development Award (CDA-2) and NIH R01 NCI CA131272. We thank Z David Sharp for critical review of the manuscript. We thank William Friedrichs and Korri Weldon for technical assistance.	Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Anastasiadis AG, 2003, ANTICANCER RES, V23, P217; Bashir T, 2010, CELL CYCLE, V9, P971, DOI 10.4161/cc.9.5.10914; Boutonnet C, 2010, CELL CYCLE, V9, P975, DOI 10.4161/cc.9.5.10915; Cho DC, 2010, CLIN CANCER RES, V16, P3628, DOI 10.1158/1078-0432.CCR-09-3022; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Frias MA, 2006, CURR BIOL, V16, P1865, DOI 10.1016/j.cub.2006.08.001; Gan XQ, 2011, J BIOL CHEM, V286, P10998, DOI 10.1074/jbc.M110.195016; Gao DM, 2009, NAT CELL BIOL, V11, P397, DOI 10.1038/ncb1847; Garcia-Martinez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668; Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007; Guertin DA, 2009, CANCER CELL, V15, P148, DOI 10.1016/j.ccr.2008.12.017; Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058; Haitel A, 2001, UROLOGY, V58, P477, DOI 10.1016/S0090-4295(01)01188-8; Hedberg Y, 2003, BRIT J CANCER, V88, P1417, DOI 10.1038/sj.bjc.6600922; Hedberg Y, 2002, INT J CANCER, V102, P601, DOI 10.1002/ijc.10763; Huang JX, 2008, MOL CELL BIOL, V28, P4104, DOI 10.1128/MCB.00289-08; Huang JX, 2009, CANCER RES, V69, P6107, DOI 10.1158/0008-5472.CAN-09-0975; Kim EK, 2011, ONCOGENE, V30, P2954, DOI 10.1038/onc.2011.22; Kim J, 2009, CLIN CANCER RES, V15, P81, DOI 10.1158/1078-0432.CCR-08-0170; Langner C, 2004, VIRCHOWS ARCH, V445, P631, DOI 10.1007/s00428-004-1121-2; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Liu Z, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-51; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Masri J, 2007, CANCER RES, V67, P11712, DOI 10.1158/0008-5472.CAN-07-2223; McDonald PC, 2008, CANCER RES, V68, P1618, DOI 10.1158/0008-5472.CAN-07-5869; Migita T, 2002, CANCER-AM CANCER SOC, V94, P973, DOI 10.1002/cncr.10338; Nogueira V, 2012, EMBO J, V31, P1134, DOI 10.1038/emboj.2011.478; Saito K, 2001, J BIOL CHEM, V276, P16201, DOI 10.1074/jbc.M100873200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sgambato A, 2010, CANCER SCI, V101, P2080, DOI 10.1111/j.1349-7006.2010.01644.x; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Shiota C, 2006, DEV CELL, V11, P583, DOI 10.1016/j.devcel.2006.08.013; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sudarshan S, 2009, MOL CELL BIOL, V29, P4080, DOI 10.1128/MCB.00483-09; Tato I, 2011, J BIOL CHEM, V286, P6128, DOI 10.1074/jbc.M110.166991; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Toschi A, 2008, J BIOL CHEM, V283, P34495, DOI 10.1074/jbc.C800170200; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vervoorts J, 2008, CELL MOL LIFE SCI, V65, P3255, DOI 10.1007/s00018-008-8296-7; Wang HB, 2010, CELL CYCLE, V9, P1021, DOI 10.4161/cc.9.5.10916; Yang Q, 2006, GENE DEV, V20, P2820, DOI 10.1101/gad.1461206	43	24	26	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 18	2013	32	16					2027	2036		10.1038/onc.2012.226	http://dx.doi.org/10.1038/onc.2012.226			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22733130	Green Accepted			2022-12-17	WOS:000317919900004
J	Tsang, YHN; Wu, XW; Lim, JS; Ong, CW; Salto-Tellez, M; Ito, K; Ito, Y; Chen, LF				Tsang, Y-H Nicole; Wu, X-W; Lim, J-S; Ong, C. Wee; Salto-Tellez, M.; Ito, K.; Ito, Y.; Chen, L-F			Prolyl isomerase Pin1 downregulates tumor suppressor RUNX3 in breast cancer	ONCOGENE			English	Article						breast cancer; degradation; Pin1; RUNX3; tumor suppressor; ubiquitination	PROMOTER HYPERMETHYLATION; PHOSPHORYLATION; GENE; ISOMERIZATION; ACETYLATION; BETA; UBIQUITINATION; DEGRADATION; RECEPTOR; ALPHA	Emerging evidence demonstrates that RUNX3 is a tumor suppressor in breast cancer. Inactivation of RUNX3 in mice results in spontaneous mammary gland tumors, and decreased or silenced expression of RUNX3 is frequently found in breast cancer cell lines and human breast cancer samples. However, the underlying mechanism for initiating RUNX3 inactivation in breast cancer remains elusive. Here, we identify prolyl isomerase Pin1, which is often overexpressed in breast cancer, as a key regulator of RUNX3 inactivation. In human breast cancer cell lines and breast cancer samples, expression of Pin1 inversely correlates with the expression of RUNX3. In addition, Pin1 recognizes four phosphorylated Ser/Thr-Pro motifs in RUNX3 via its WW domain. Binding of Pin1 to RUNX3 suppresses the transcriptional activity of RUNX3. Furthermore, Pin1 reduces the cellular levels of RUNX3 in an isomerase activity-dependent manner by inducing the ubiquitination and proteasomal degradation of RUNX3. Knocking down Pin1 enhances the cellular levels and transcriptional activity of RUNX3 by inhibiting the ubiquitination and degradation of RUNX3. Our results identify Pin1 as a new regulator of RUNX3 inactivation in breast cancer. Oncogene (2013) 32, 1488-1496; doi:10.1038/onc.2012.178; published online 14 May 2012	[Tsang, Y-H Nicole; Wu, X-W; Lim, J-S; Chen, L-F] Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; [Tsang, Y-H Nicole; Ito, Y.] Natl Univ Singapore, Inst Mol & Cell Biol, Dept Canc Genet, Singapore 117548, Singapore; [Ong, C. Wee; Salto-Tellez, M.] Natl Univ Singapore, Dept Pathol, Singapore 117548, Singapore; [Ong, C. Wee; Salto-Tellez, M.; Ito, Y.] Natl Univ Singapore, Canc Sci Inst Singapore, Dept Canc Biol, Singapore 117548, Singapore; [Ito, K.] Nagasaki Univ, Grad Sch Biomed Sci, Dept Cell Biol, Nagasaki 852, Japan; [Chen, L-F] Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore; National University of Singapore; Nagasaki University; University of Illinois System; University of Illinois Urbana-Champaign	Chen, LF (corresponding author), Univ Illinois, Coll Med, Dept Biochem, 600 S Matthews Ave,MC-714, Urbana, IL 61801 USA.	lfchen@life.illinois.edu		Salto-Tellez, Manuel/0000-0001-8586-282X	UIUC; NIH [DK-085158]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK085158] Funding Source: NIH RePORTER	UIUC; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Drs Lu KP and Kao HY for the gift of reagents and members in the Chen lab for discussion. This work is supported in part by fund provided by UIUC (to LFC) and NIH grants DK-085158 (to LFC). YHT is an A*STAR-Illinois Partnership fellow.	Bae JS, 2003, BIOCHEM BIOPH RES CO, V305, P1094, DOI 10.1016/S0006-291X(03)00869-6; Bae SC, 2006, GENE, V366, P58, DOI 10.1016/j.gene.2005.10.017; Bao L, 2004, AM J PATHOL, V164, P1727, DOI 10.1016/S0002-9440(10)63731-5; Butt AJ, 2008, ADV EXP MED BIOL, V630, P189; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chen LF, 2012, J CELL BIOCHEM, V113, P1470, DOI 10.1002/jcb.24074; Cheskis BJ, 2007, J CELL PHYSIOL, V213, P610, DOI 10.1002/jcp.21253; Chuang LSH, 2010, ONCOGENE, V29, P2605, DOI 10.1038/onc.2010.88; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Huang B, 2012, ONCOGENE, V31, P527, DOI 10.1038/onc.2011.252; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Hwang KT, 2007, J KOREAN MED SCI, V22, pS24, DOI 10.3346/jkms.2007.22.S.S24; Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755; Jiang Y, 2008, PATHOBIOLOGY, V75, P244, DOI 10.1159/000132385; Jin YH, 2004, J BIOL CHEM, V279, P29409, DOI 10.1074/jbc.M313120200; Katzenellenbogen BS, 2000, BREAST CANCER RES, V2, P335, DOI 10.1186/bcr78; Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369; Lee EYHP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003236; Lim JH, 2011, J BIOL CHEM, V286, P44403, DOI 10.1074/jbc.M111.289512; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; Liou YC, 2011, TRENDS BIOCHEM SCI, V36, P501, DOI 10.1016/j.tibs.2011.07.001; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Lu PJ, 2002, J BIOL CHEM, V277, P2381, DOI 10.1074/jbc.C100228200; Nakano A, 2009, J BIOL CHEM, V284, P6109, DOI 10.1074/jbc.M804659200; Rajbhandari P, 2012, MOL CELL BIOL, V32, P445, DOI 10.1128/MCB.06073-11; Reineke EL, 2008, MOL CELL BIOL, V28, P997, DOI 10.1128/MCB.01848-07; Rustighi A, 2009, NAT CELL BIOL, V11, P133, DOI 10.1038/ncb1822; Schutkowski M, 1998, BIOCHEMISTRY-US, V37, P5566, DOI 10.1021/bi973060z; Subramaniam MM, 2009, BBA-REV CANCER, V1796, P315, DOI 10.1016/j.bbcan.2009.07.004; Subramaniam MM, 2009, BREAST CANCER RES TR, V113, P113, DOI 10.1007/s10549-008-9917-4; Tsang YH, 2010, ONCOGENE, V29, P5643, DOI 10.1038/onc.2010.304; Wulf G, 2003, BREAST CANCER RES, V5, P76, DOI 10.1186/bcr572; Wulf G, 2005, NAT CELL BIOL, V7, P435, DOI 10.1038/ncb0505-435; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yi P, 2005, MOL CELL BIOL, V25, P9687, DOI 10.1128/MCB.25.21.9687-9699.2005; Zhang DH, 2003, LIFE SCI, V73, P3189, DOI 10.1016/j.lfs.2003.05.006; Zhang M, 2009, J CELL SCI, V122, P1382, DOI 10.1242/jcs.040709; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	40	24	24	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2013	32	12					1488	1496		10.1038/onc.2012.178	http://dx.doi.org/10.1038/onc.2012.178			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22580604	Green Accepted			2022-12-17	WOS:000316456000002
J	Donnini, S; Finetti, F; Terzuoli, E; Giachetti, A; Iniguez, MA; Hanaka, H; Fresno, M; Radmark, O; Ziche, M				Donnini, S.; Finetti, F.; Terzuoli, E.; Giachetti, A.; Iniguez, M. A.; Hanaka, H.; Fresno, M.; Radmark, O.; Ziche, M.			EGFR signaling upregulates expression of microsomal prostaglandin E synthase-1 in cancer cells leading to enhanced tumorigenicity	ONCOGENE			English	Article						prostaglandinE-2; mPGES-1; epidermal growth factor; Egr-1; E-cadherin; vimentin	EPIDERMAL-GROWTH-FACTOR; TRANSCRIPTION FACTOR EGR-1; FACTOR-RECEPTOR; LUNG-CANCER; COLORECTAL ADENOMAS; KAPPA-B; ACTIVATION; E-2; GENE; CYCLOOXYGENASE-2	In this report we describe the contribution of prostaglandin E-2 (PGE(2)) derived from the inducible microsomal PGE-synthase type-1 (mPGES-1) to the epidermal growth factor receptor (EGFR) oncogenic drive in tumor epithelial cells and in tumor-bearing mice. EGFR stimulation upregulated expression of mPGES-1 in HT-29, A431 and A549 cancer cells. Egr-1, a transcription factor induced by EGF, mediated this response. The Egr-1 rise provoked the overexpression of mPGES-1 messenger and protein, and enhanced PGE(2) formation. These changes were suppressed either by silencing Egr-1, or by upstream blockade of EGFR or ERK1/2 signals. Further, in a clonogenic assay on tumor cells, EGF induced a florid tumorigenic phenotype, which regressed when mPGES-1 was silenced or knocked down. EGF-induced mPGES-1 overexpression in epithelial cell reduced E-cadherin expression, whereas enhancing that of vimentin, suggesting an incipient mesenchymal phenotype. Additionally, inhibiting the EGFR in mice bearing the A431 tumor, the mPGES-1 expression and the tumor growth, exhibited a parallel decline. In conclusion, these findings provide novel evidence that a tight cooperation between the EGF/EGFR and mPGES-1 leads to a significant tumorigenic gain in epithelial cells, and provide clues for controlling the vicious association. Oncogene (2012) 31, 3457-3466; doi:10.1038/onc.2011.503; published online 14 November 2011	[Donnini, S.; Finetti, F.; Terzuoli, E.; Giachetti, A.; Ziche, M.] Univ Siena, Dept Biotechnol, Pharmacol Sect, I-53100 Siena, Italy; [Donnini, S.; Finetti, F.; Terzuoli, E.; Giachetti, A.; Ziche, M.] ITT, Siena, Italy; [Iniguez, M. A.; Fresno, M.] Univ Autonoma Madrid, CSIC UAM, Ctr Biol Mol Severo Ochoa, Madrid, Spain; [Hanaka, H.; Radmark, O.] Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, Stockholm, Sweden	University of Siena; ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Karolinska Institutet	Ziche, M (corresponding author), Univ Siena, Dept Biotechnol, Pharmacol Sect, Via Aldo Moro 2, I-53100 Siena, Italy.	ziche@unisi.it	Finetti, Federica/J-9089-2016; Donnini, Sandra/K-9252-2019; Peña, Miguel Angel Iñiguez/J-8518-2012; Terzuoli, Erika/M-7346-2016	Donnini, Sandra/0000-0001-6617-1644; Peña, Miguel Angel Iñiguez/0000-0001-8262-6119; Ziche, Marina/0000-0002-9564-214X; Terzuoli, Erika/0000-0001-9248-4505; Fresno Escudero, Manuel/0000-0002-9223-5477	Associazione Italiana della Ricerca sul Cancro (AIRC) [IG10731]; Istituto Toscano Tumori (ITT); Comunidad de Madrid [S-SAL2006/0015]; Ministerio de Ciencia e Innovacion [SAF2010-18733, BFU2010-21055]; Ministerio de Ciencia e Innovacion	Associazione Italiana della Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Istituto Toscano Tumori (ITT); Comunidad de Madrid(Comunidad de Madrid); Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government)	We thank Dr MD Diaz-Munoz for the construction of mPGES-1 plasmids. This work has received financial support from the Associazione Italiana della Ricerca sul Cancro (AIRC) IG10731 (MZ), Istituto Toscano Tumori (ITT) (SD), Comunidad de Madrid S-SAL2006/0015, Ministerio de Ciencia e Innovacion SAF2010-18733 (MF), Ministerio de Ciencia e Innovacion BFU2010-21055 (MAI).	Buchanan FG, 2003, J BIOL CHEM, V278, P35451, DOI 10.1074/jbc.M302474200; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Cheng S, 2004, J BIOL CHEM, V279, P22057, DOI 10.1074/jbc.M402828200; Choe MS, 2005, MOL CANCER THER, V4, P1448, DOI 10.1158/1535-7163.MCT-04-0251; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; Dasari A, 2010, CLIN CANCER RES, V16, P3811, DOI 10.1158/1078-0432.CCR-09-2283; Deckmann K, 2010, BIOCHEM PHARMACOL, V80, P1365, DOI 10.1016/j.bcp.2010.07.032; Diaz-Munoz MD, 2010, CELL SIGNAL, V22, P1427, DOI 10.1016/j.cellsig.2010.05.011; Dohadwala M, 2006, CANCER RES, V66, P5338, DOI 10.1158/0008-5472.CAN-05-3635; Donnini S, 2007, FASEB J, V21, P2418, DOI 10.1096/fj.06-7581com; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Finetti F, 2009, CIRC RES, V105, P657, DOI 10.1161/CIRCRESAHA.109.203760; Golijanin D, 2004, CLIN CANCER RES, V10, P1024, DOI 10.1158/1078-0432.CCR-1032-3; Grotegut S, 2006, EMBO J, V25, P3534, DOI 10.1038/sj.emboj.7601213; Hanaka H, 2009, P NATL ACAD SCI USA, V106, P18757, DOI 10.1073/pnas.0910218106; Johns TG, 2002, INT J CANCER, V98, P398, DOI 10.1002/ijc.10189; Kamei D, 2003, J BIOL CHEM, V278, P19396, DOI 10.1074/jbc.M213290200; Kamei D, 2010, BIOCHEM J, V425, P361, DOI 10.1042/BJ20090045; Leone V, 2007, AM J PHYSIOL-GASTR L, V293, pG673, DOI 10.1152/ajpgi.00584.2006; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Lu D, 2012, ONCOGENE, V31, P842, DOI 10.1038/onc.2011.287; Mann JR, 2006, CANCER RES, V66, P6649, DOI 10.1158/0008-5472.CAN-06-1787; Menter DG, 2010, CLIN CANCER RES, V16, P1384, DOI 10.1158/1078-0432.CCR-09-0788; Nah SS, 2010, RHEUMATOL INT, V30, P443, DOI 10.1007/s00296-009-0976-6; Nakanishi M, 2008, CANCER RES, V68, P3251, DOI 10.1158/0008-5472.CAN-07-6100; Naraba H, 2002, J BIOL CHEM, V277, P28601, DOI 10.1074/jbc.M203618200; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Pignatelli M, 1999, FEBS LETT, V461, P37, DOI 10.1016/S0014-5793(99)01420-9; Pozzi A, 2004, J BIOL CHEM, V279, P29797, DOI 10.1074/jbc.M313989200; Samuelsson B, 2007, PHARMACOL REV, V59, P207, DOI 10.1124/pr.59.3.1; Subbaramaiah K, 2004, J BIOL CHEM, V279, P12647, DOI 10.1074/jbc.M312972200; Tessner TG, 2004, J CLIN INVEST, V114, P1676, DOI 10.1172/JCI200422218; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Wiesner GL, 2001, J NATL CANCER I, V93, P635, DOI 10.1093/jnci/93.8.635; Yoshimatsu K, 2001, CLIN CANCER RES, V7, P3971; Yoshimatsu K, 2001, CLIN CANCER RES, V7, P2669	38	24	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	29					3457	3466		10.1038/onc.2011.503	http://dx.doi.org/10.1038/onc.2011.503			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	976FN	22081067	Green Accepted			2022-12-17	WOS:000306566400006
J	Ratushny, V; Pathak, HB; Beeharry, N; Tikhmyanova, N; Xiao, F; Li, T; Litwin, S; Connolly, DC; Yen, TJ; Weiner, LM; Godwin, AK; Golemis, EA				Ratushny, V.; Pathak, H. B.; Beeharry, N.; Tikhmyanova, N.; Xiao, F.; Li, T.; Litwin, S.; Connolly, D. C.; Yen, T. J.; Weiner, L. M.; Godwin, A. K.; Golemis, E. A.			Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death	ONCOGENE			English	Article						SRC; NEDD9; Aurora; drug; mitosis; attachment	CANCER-CELLS; TARGETED THERAPIES; COLORECTAL-CANCER; CHRONIC-PHASE; PROTEIN HEF1; A KINASE; ACTIVATION; CYTOKINESIS; DASATINIB; ADHESION	Increased activity of SRC family kinases promotes tumor invasion and metastasis, and overexpression of the mitotic regulator Aurora kinase A (AURKA) drives tumor aneuploidy and chromosomal instability. These functions nominate SRC and AURKA as valuable therapeutic targets for cancer, and inhibitors for SRC and Aurora kinases are now being used in the clinic. In this study, we demonstrate potent synergy between multiple inhibitors of Aurora and SRC kinases in ovarian and colorectal cancer cell lines, but not in normal ovarian epithelial cell lines. Combination of Aurora and SRC inhibitors selectively killed cells that have undergone a preceding aberrant mitosis, and was associated with a postmitotic reattachment defect, and selective removal of aneuploid cell populations. Combined inhibition of Aurora kinase and SRC potentiated dasatinib-dependent loss of activated (Y416-phosphorylated) SRC. SRC and AURKA share a common interaction partner, NEDD9, which serves as a scaffolding protein with activities in cell attachment and mitotic control, suggesting SRC and AURKA might interact directly. In vitro, we observed physical interaction and mutual cross-phosphorylation between SRC and AURKA that enhanced SRC kinase activity. Together, these findings suggest that combination of SRC and Aurora-targeting inhibitors in the clinic may be a productive strategy. Oncogene (2012) 31, 1217-1227; doi:10.1038/onc.2011.314; published online 25 July 2011	[Ratushny, V.; Pathak, H. B.; Beeharry, N.; Tikhmyanova, N.; Xiao, F.; Li, T.; Litwin, S.; Connolly, D. C.; Yen, T. J.; Godwin, A. K.; Golemis, E. A.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; [Ratushny, V.] Drexel Univ, Coll Med, Program Mol & Cell Biol & Genet, Philadelphia, PA USA; [Weiner, L. M.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA	Fox Chase Cancer Center; Drexel University; Georgetown University	Golemis, EA (corresponding author), Fox Chase Canc Ctr, 333 Cottman Ave,W406, Philadelphia, PA 19111 USA.	EA_Golemis@fccc.edu		Yen, Tim/0000-0003-2159-0997; Golemis, Erica/0000-0003-3618-3673	Army Materiel Command [DOD W81XWH-07-1-0676]; State of Pennsylvania; Ovarian Cancer Research Fund; Ovarian SPORE [P50 CA083638]; Commonwealth of Pennsylvania; Greenberg Fund; NCI [CA06927]; Pew Charitable Fund; Fox Chase Cancer Center;  [R01-CA63366];  [R01-CA113342];  [R01-CA140323];  [R01-GM86877];  [R01-CA136596];  [R01-CA151374];  [R01-CA50633]; NATIONAL CANCER INSTITUTE [R01CA113342, R01CA136596, R01CA140323, P50CA083638, R01CA151374, P30CA006927, R01CA063366, R01CA050633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM086877] Funding Source: NIH RePORTER	Army Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); State of Pennsylvania; Ovarian Cancer Research Fund; Ovarian SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Commonwealth of Pennsylvania; Greenberg Fund; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Pew Charitable Fund; Fox Chase Cancer Center; ; ; ; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Lisa Vanderveer for assistance with maintaining EOC cell lines; Carolyn Slater for isolating and producing the primary HOSE cultures; Christine Klimowicz for assistance with the drug synergy assays; and Ilya Serebriiskii for assistance with editing the figures. This work was supported by R01-CA63366 and R01-CA113342; DOD W81XWH-07-1-0676 from the Army Materiel Command; and Tobacco Settlement funding from the State of Pennsylvania (to EAG); R01-CA140323 and the Ovarian Cancer Research Fund (to AKG); Ovarian SPORE P50 CA083638 (Project 4, to EAG, AKG, and DCC); R01-GM86877, an appropriation from the Commonwealth of Pennsylvania, and the Greenberg Fund (to TJY); R01-CA136596 and R01-CA151374 (to DCC); R01-CA50633 (to LMW); and by NCI CA06927 and support from the Pew Charitable Fund (to Fox Chase Cancer Center). Additional funds were provided by Fox Chase Cancer Center via institutional support of the Head and Neck Cancer Keystone Program.	Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Astsaturov I, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001083; Bagnyukova T, 2010, CANCER BIOL THER, V10, P843, DOI 10.4161/cbt.10.9.13738; Bellacosa A, 2010, CANCER PREV RES, V3, P48, DOI 10.1158/1940-6207.CAPR-09-0078; BENZEEV A, 1981, CELL, V26, P107, DOI 10.1016/0092-8674(81)90038-6; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Boss DS, 2009, ONCOLOGIST, V14, P780, DOI 10.1634/theoncologist.2009-0019; Brandsma D, 2007, CURR OPIN ONCOL, V19, P598, DOI 10.1097/CCO.0b013e3282f0313b; Cao YH, 2007, ADV CANCER RES, V97, P203, DOI 10.1016/S0065-230X(06)97009-2; Carter TA, 2005, P NATL ACAD SCI USA, V102, P11011, DOI 10.1073/pnas.0504952102; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Dadke D, 2006, MOL BIOL CELL, V17, P1204, DOI 10.1091/mbc.E05-03-0237; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Dutertre S, 2002, ONCOGENE, V21, P6175, DOI 10.1038/sj.onc.1205775; Dyck HG, 1996, INT J CANCER, V69, P429, DOI 10.1002/(SICI)1097-0215(19961220)69:6<429::AID-IJC1>3.0.CO;2-6; Fei F, 2010, MOL CANCER THER, V9, P1318, DOI 10.1158/1535-7163.MCT-10-0069; Fernandez-Miranda G, 2011, DEVELOPMENT, V138, P2661, DOI 10.1242/dev.066381; Friedman A, 2007, CELL, V128, P225, DOI 10.1016/j.cell.2007.01.007; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gautschi O, 2008, CLIN CANCER RES, V14, P1639, DOI 10.1158/1078-0432.CCR-07-2179; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Guan Z, 2007, CANCER RES, V67, P10436, DOI 10.1158/0008-5472.CAN-07-1379; Guarino M, 2010, J CELL PHYSIOL, V223, P14, DOI 10.1002/jcp.22011; Hochhaus A, 2008, LEUKEMIA, V22, P1200, DOI 10.1038/leu.2008.84; Huang X, 2005, CELL CYCLE, V4, P801, DOI 10.4161/cc.4.6.1695; Johnson FM, 2005, CLIN CANCER RES, V11, P6924, DOI 10.1158/1078-0432.CCR-05-0757; Jones RJ, 2002, BRIT J CANCER, V87, P1128, DOI 10.1038/sj.bjc.6600594; Kaestner P, 2009, MOL CANCER THER, V8, P2046, DOI 10.1158/1535-7163.MCT-09-0323; Kantarjian H, 2010, NEW ENGL J MED, V362, P2260, DOI 10.1056/NEJMoa1002315; Kasahara K, 2007, J BIOL CHEM, V282, P5327, DOI 10.1074/jbc.M608396200; Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502; Kopetz S, 2007, CLIN CANCER RES, V13, P7232, DOI 10.1158/1078-0432.CCR-07-1902; Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; MUSTELIN T, 2002, SCI STKE, pPE3; Ng MM, 2005, DEV CELL, V9, P781, DOI 10.1016/j.devcel.2005.11.002; O'Neill GM, 2001, MOL CELL BIOL, V21, P5094, DOI 10.1128/MCB.21.15.5094-5108.2001; Obara Y, 2004, J CELL SCI, V117, P6085, DOI 10.1242/jcs.01527; ORLY J, 1979, CELL, V17, P295, DOI 10.1016/0092-8674(79)90155-7; Pfeiffer P, 2007, ONCOGENE, V26, P3661, DOI 10.1038/sj.onc.1210377; Plotnikova OV, 2011, J CELL BIOL, V193, P1021, DOI 10.1083/jcb.201012061; Plotnikova OV, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1061; Pugacheva EN, 2007, CELL, V129, P1351, DOI 10.1016/j.cell.2007.04.035; Pugacheva EN, 2005, NAT CELL BIOL, V7, P937, DOI 10.1038/ncb1309; Shor AC, 2007, CANCER RES, V67, P2800, DOI 10.1158/0008-5472.CAN-06-3469; Soncini C, 2006, CLIN CANCER RES, V12, P4080, DOI 10.1158/1078-0432.CCR-05-1964; Wong ST, 2009, PHARMACOTHERAPY, V29, P954, DOI 10.1592/phco.29.8.954; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366	50	24	25	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	10					1217	1227		10.1038/onc.2011.314	http://dx.doi.org/10.1038/onc.2011.314			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906KS	21785464	Green Accepted			2022-12-17	WOS:000301344600002
J	Coutts, AS; Pires, IM; Weston, L; Buffa, FM; Milani, M; Li, JL; Harris, AL; Hammond, EM; La Thangue, NB				Coutts, A. S.; Pires, I. M.; Weston, L.; Buffa, F. M.; Milani, M.; Li, J-L; Harris, A. L.; Hammond, E. M.; La Thangue, N. B.			Hypoxia-driven cell motility reflects the interplay between JMY and HIF-1 alpha	ONCOGENE			English	Article						JMY; HIF-1; actin; hypoxia; motility	INDUCIBLE FACTOR-I; P53; COFACTOR; P300; MDM2	Junction-mediating and regulatory protein (JMY) is a novel p53 cofactor that regulates p53 activity during stress. JMY interacts with p300/CBP, which are ubiquitous transcriptional co-activators that interact with a variety of sequence-specific transcription factors, including hypoxia-inducible factor-1 alpha (HIF-1 alpha). In addition, JMY is an actin-nucleating protein, which, through its WH2 domains, stimulates cell motility. In this study, we show that JMY is upregulated during hypoxia in a HIF-1 alpha-dependent manner. The JMY gene contains HIF-responsive elements in its promoter region and HIF-1 alpha is recruited to its promoter during hypoxia. HIF-1 alpha drives transcription of JMY, which accounts for its induction under hypoxia. Moreover, the enhanced cell motility and invasion that occurs during hypoxia requires JMY, as depleting JMY under hypoxic conditions causes decreased cell motility. Our results establish the interplay between JMY and HIF-1 alpha as a new mechanism that controls cell motility under hypoxic stress. Oncogene (2011) 30, 4835-4842; doi: 10.1038/onc.2011.188; published online 30 May 2011	[Coutts, A. S.; Weston, L.; La Thangue, N. B.] Univ Oxford, Dept Oncol, Canc Biol Lab, Oxford OX3 7DQ, Oxon, England; [Pires, I. M.; Hammond, E. M.] Univ Oxford, Dept Oncol, Canc Res UK MRC Gray Inst Radiat Oncol & Biol, Oxford OX3 7DQ, Oxon, England; [Buffa, F. M.; Milani, M.; Li, J-L; Harris, A. L.] Univ Oxford, Dept Oncol, Canc Res UK Mol Oncol Labs, Weatherall Inst Mol Med, Oxford OX3 7DQ, Oxon, England	University of Oxford; Cancer Research UK; University of Oxford; University of Oxford	La Thangue, NB (corresponding author), Univ Oxford, Dept Oncol, Canc Biol Lab, Old Rd Campus,Res Bldg,Roosevelt Dr, Oxford OX3 7DQ, Oxon, England.	nick.lathangue@clinpharm.ox.ac.uk	Harris, Adrian L/ABA-3343-2020; Buffa, Francesca/D-2574-2013	Harris, Adrian L/0000-0003-1376-8409; Buffa, Francesca/0000-0003-0409-406X; Hammond, Ester/0000-0002-2335-3146; Coutts, Amanda/0000-0002-5005-1864; Pires, Isabel/0000-0002-0417-2710	MRC; CRUK [C300/6731, C6415/A9321]; LRF; AICR; MRC [G1000807, G0500905, G9400953] Funding Source: UKRI; Cancer Research UK [13058] Funding Source: researchfish; Medical Research Council [G0500905, G9400953, G1000807] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); CRUK(Cancer Research UK); LRF; AICR; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank the MRC, CRUK, LRF and AICR for support. ASC and LW are funded by MRC and CRUK (grant # C300/6731). IMP and EMH are funded by CRUK (grant # C6415/A9321). We also thank Long Dang, Peter Ratcliffe and Shoumo Bhattacharya for providing invaluable reagents.	Biswas S, 2010, J ONCOL, V2010, DOI 10.1155/2010/757908; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Coutts AS, 2007, EMBO REP, V8, P84, DOI 10.1038/sj.embor.7400855; Coutts AS, 2009, P NATL ACAD SCI USA, V106, P19872, DOI 10.1073/pnas.0906785106; Dang DT, 2006, CANCER RES, V66, P1684, DOI 10.1158/0008-5472.CAN-05-2887; Demonacos C, 2001, MOL CELL, V8, P71, DOI 10.1016/S1097-2765(01)00277-5; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Jansson M, 2008, NAT CELL BIOL, V10, P1431, DOI 10.1038/ncb1802; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Krishnamachary B, 2006, CANCER RES, V66, P2725, DOI 10.1158/0008-5472.CAN-05-3719; Lee K, 2007, J MED CHEM, V50, P1675, DOI 10.1021/jm0610292; Li JL, 2007, CANCER RES, V67, P11244, DOI 10.1158/0008-5472.CAN-07-0969; Marine JC, 2006, CELL DEATH DIFFER, V13, P927, DOI 10.1038/sj.cdd.4401912; Rankin EB, 2008, CELL DEATH DIFFER, V15, P678, DOI 10.1038/cdd.2008.21; Rapisarda A, 2009, CELL CYCLE, V8, P4040, DOI 10.4161/cc.8.24.10145; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Shikama N, 1999, MOL CELL, V4, P365, DOI 10.1016/S1097-2765(00)80338-X; Spinella F, 2007, CANCER RES, V67, P1725, DOI 10.1158/0008-5472.CAN-06-2606; Sullivan R, 2007, CANCER METAST REV, V26, P319, DOI 10.1007/s10555-007-9062-2; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zalmas LP, 2008, EMBO REP, V9, P252, DOI 10.1038/sj.embor.7401158; Zuchero JB, 2009, NAT CELL BIOL, V11, P451, DOI 10.1038/ncb1852	25	24	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	48					4835	4842		10.1038/onc.2011.188	http://dx.doi.org/10.1038/onc.2011.188			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863AH	21625218	Green Published			2022-12-17	WOS:000298134700007
J	Jiang, Y; Scott, KL; Kwak, SJ; Chen, R; Mardon, G				Jiang, Y.; Scott, K. L.; Kwak, S-J; Chen, R.; Mardon, G.			Sds22/PP1 links epithelial integrity and tumor suppression via regulation of myosin II and JNK signaling	ONCOGENE			English	Article						tumor suppressor; epithelial integrity; cell invasion; sds22; protein phosphatase 1	PROTEIN PHOSPHATASE-1; CELL POLARITY; NONMUSCLE MYOSIN; MATRIX METALLOPROTEINASES; DROSOPHILA-MELANOGASTER; NEURAL DEVELOPMENT; INDUCED APOPTOSIS; GENETIC MOSAICS; IMAGINAL DISCS; CANCER	Loss of epithelial integrity often correlates with the progression of malignant tumors. Sds22, a regulatory subunit of protein phosphatase 1 (PP1), has recently been linked to regulation of epithelial polarity in Drosophila. However, its role in tumorigenesis remains obscure. In this study, using Drosophila imaginal tissue as an in vivo model system, we show that sds22 is a new potential tumor suppressor gene in Drosophila. Without sds22, cells lose epithelial architecture, and become invasive and tumorigenic when combined with Ras overexpression; conversely, sds22 overexpression can largely suppress tumorigenic growth of Ras(V12)scrib(-/-) mutant cells. Mechanistically, we show that sds22 prevents cell invasion and metastasis by inhibiting myosin II and Jun N-terminal kinase (JNK) activity downstream of PP1. Loss of this inhibition causes cells to lose epithelial organization and promotes cell invasion. Finally, human Sds22 is focally deleted and downregulated in multiple carcinomas, and this downregulation correlates with tumor progression, suggesting that sds22 inactivation may contribute to tumorigenesis and metastatic potential in human cancers via a similar mechanism. Oncogene (2011) 30, 3248-3260; doi:10.1038/onc.2011.46; published online 14 March 2011	[Jiang, Y.; Scott, K. L.; Chen, R.; Mardon, G.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Kwak, S-J; Mardon, G.] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Chen, R.; Mardon, G.] Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; [Chen, R.; Mardon, G.] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA; [Mardon, G.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; [Mardon, G.] Baylor Coll Med, Dept Ophthalmol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Mardon, G (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.	gmardon@bcm.edu			National Eye Institute [R01 EY011232, EY016853]; Retina Research Foundation; NATIONAL EYE INSTITUTE [R01EY016853, R01EY011232] Funding Source: NIH RePORTER	National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Retina Research Foundation; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	We thank Andreas Bergmann, Yasuyoshi Nishida, Tian Xu, the Bloomington Stock Center, VDRC, and the DSHB for stocks and antibodies. We especially thank Georg Halder, Rui Chen, Mardelle Atkins, Umesh Karandikar, and Nicholas Justice for helpful comments on the manuscript. This work was supported by the National Eye Institute (R01 EY011232 [GM] and EY016853 [RC]) and the Retina Research Foundation (GM).	AGRAWAL N, 1995, DEV BIOL, V172, P218, DOI 10.1006/dbio.1995.0017; Beaucher M, 2007, DEV BIOL, V303, P625, DOI 10.1016/j.ydbio.2006.12.001; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bennett D, 2006, J MOL BIOL, V364, P196, DOI 10.1016/j.jmb.2006.08.094; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brumby AM, 2005, NAT REV CANCER, V5, P626, DOI 10.1038/nrc1671; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Cengiz B, 2007, ORAL ONCOL, V43, P241, DOI 10.1016/j.oraloncology.2006.03.004; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Ceulemans H, 2002, J BIOL CHEM, V277, P47331, DOI 10.1074/jbc.M206838200; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; DOMBRADI V, 1990, EUR J BIOCHEM, V194, P739, DOI 10.1111/j.1432-1033.1990.tb19464.x; DOMBRADI V, 1993, EUR J BIOCHEM, V212, P177, DOI 10.1111/j.1432-1033.1993.tb17648.x; Dow LE, 2007, INT REV CYTOL, V262, P253, DOI 10.1016/S0074-7696(07)62006-3; Grusche FA, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-14; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Jasper H, 2001, DEV CELL, V1, P579, DOI 10.1016/S1534-5807(01)00045-4; Kabbarah O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010770; Kirchner J, 2007, GENETICS, V175, P1741, DOI 10.1534/genetics.106.067488; Kirchner J, 2007, GENETICS, V176, P273, DOI 10.1534/genetics.106.069914; Knox AL, 2002, SCIENCE, V295, P1285, DOI 10.1126/science.1067549; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4; Llano E, 2000, J BIOL CHEM, V275, P35978, DOI 10.1074/jbc.M006045200; MACKELVIE SH, 1995, MOL CELL BIOL, V15, P3777; Martin FA, 2009, INT J DEV BIOL, V53, P1341, DOI 10.1387/ijdb.072447fm; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; McEwen DG, 2005, DEVELOPMENT, V132, P3935, DOI 10.1242/dev.01949; Morais-de-Sa E, 2010, CELL, V141, P509, DOI 10.1016/j.cell.2010.02.040; Narayan G, 2003, ONCOGENE, V22, P3489, DOI 10.1038/sj.onc.1206432; Newsome TP, 2000, DEVELOPMENT, V127, P851; OHKURA H, 1991, CELL, V64, P149, DOI 10.1016/0092-8674(91)90216-L; Page-McCaw A, 2003, DEV CELL, V4, P95, DOI 10.1016/S1534-5807(02)00400-8; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pepple KL, 2008, DEVELOPMENT, V135, P4071, DOI 10.1242/dev.028951; Pohar N, 1999, GENOMICS, V57, P293, DOI 10.1006/geno.1999.5776; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ryoo HD, 2004, DEV CELL, V7, P491, DOI 10.1016/j.devcel.2004.08.019; Shao W, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009938; Singh J, 2010, ONCOGENE, V29, P4033, DOI 10.1038/onc.2010.155; Smith DP, 1999, NEURON, V22, P203, DOI 10.1016/S0896-6273(00)81078-8; Speck O, 2003, NATURE, V421, P83, DOI 10.1038/nature01295; Srivastava A, 2007, P NATL ACAD SCI USA, V104, P2721, DOI 10.1073/pnas.0611666104; STONE EM, 1993, CURR BIOL, V3, P13, DOI 10.1016/0960-9822(93)90140-J; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Traweger A, 2008, P NATL ACAD SCI USA, V105, P10402, DOI 10.1073/pnas.0804102105; Uhlirova M, 2005, P NATL ACAD SCI USA, V102, P13123, DOI 10.1073/pnas.0504170102; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; Vereshchagina N, 2004, MOL BIOL CELL, V15, P4395, DOI 10.1091/mbc.E04-02-0139; Vicente-Manzanares M, 2009, NAT REV MOL CELL BIO, V10, P778, DOI 10.1038/nrm2786; Vidal M, 2006, DEV CELL, V10, P33, DOI 10.1016/j.devcel.2005.11.007; Winter SL, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-85; Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; XU T, 1993, DEVELOPMENT, V117, P1223; Young MRI, 1997, ADV EXP MED BIOL, V407, P311; Zhu MW, 2010, CELL RES, V20, P242, DOI 10.1038/cr.2010.2	64	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	29					3248	3260		10.1038/onc.2011.46	http://dx.doi.org/10.1038/onc.2011.46			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	795VW	21399659	Green Accepted			2022-12-17	WOS:000293006800004
J	Cheung, LWT; Mak, ASC; Cheung, ANY; Ngan, HYS; Leung, PCK; Wong, AST				Cheung, L. W. T.; Mak, A. S. C.; Cheung, A. N. Y.; Ngan, H. Y. S.; Leung, P. C. K.; Wong, A. S. T.			P-cadherin cooperates with insulin-like growth factor-1 receptor to promote metastatic signaling of gonadotropin-releasing hormone in ovarian cancer via p120 catenin	ONCOGENE			English	Article						ovarian cancer; GnRH; P-cadherin; p(120ctn); motility; IGF-1R	TYROSINE PHOSPHORYLATION; PROGNOSTIC-FACTOR; RHO-GTPASES; EXPRESSION; ACTIVATION; ADHESION; KINASE; EPITHELIUM; INDUCTION; INVASION	Gonadotropin-releasing hormone (GnRH) is a potent prometastatic factor in ovarian cancer, but the intracellular signaling events are not well understood. The classical G alpha(q)-phospholipase C signal transduction pathway known to operate in the pituitary is not involved in GnRH actions at non-pituitary targets. Here we showed that GnRH treatment of ovarian cancer cells led to a rapid and remarkable tyrosine phosphorylation of p120 catenin (p120(ctn)), which was mediated by P-cadherin. The use of P-cadherin small interfering RNA or neutralizing antibodies to inhibit P-cadherin expression and function resulted in diminished p120(ctn) activation, confirming that the effect was P-cadherin specific. On exploring how P-cadherin, which lacks intrinsic kinase activity, might regulate the activation of p120ctn, we found that P-cadherin could induce the ligand-independent activation of insulin-like growth factor-1 receptor (IGF-1R). Inhibition of IGF-1R expression or its activity significantly inhibited GnRH-induced p120(ctn) activation, and the subsequent cell migration and invasion. In addition, we showed that IGF-1R regulation by P-cadherin was associated with complex formation between IGF-1R and P-cadherin, and this regulation was also observed to be in vivo correlated with metastasis. Furthermore, using a mouse model of ovarian cancer metastasis, GnRH receptor knockdown was shown to diminish peritoneal dissemination of tumors and ascites formation. These findings suggest for the first time that GnRH can initiate an outside-in p120(ctn) signal transduction through the cross-talk between P-cadherin and IGF-1R, thus providing a novel molecular mechanism by which GnRH may control the high level of aggressiveness and invasion and metastasis potential that are characteristic of ovarian cancer. Oncogene (2011) 30, 2964-2974; doi:10.1038/onc.2011.7; published online 14 February 2011	[Cheung, L. W. T.; Mak, A. S. C.; Wong, A. S. T.] Univ Hong Kong, Sch Biol Sci, Hong Kong, Hong Kong, Peoples R China; [Cheung, A. N. Y.] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Ngan, H. Y. S.] Univ Hong Kong, Dept Obstet & Gynecol, Hong Kong, Hong Kong, Peoples R China; [Leung, P. C. K.] Univ British Columbia, Dept Obstet & Gynecol, Vancouver, BC V5Z 1M9, Canada	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of British Columbia	Wong, AST (corresponding author), Univ Hong Kong, Sch Biol Sci, 4S-14 Kadoorie Biological Sci Bldg,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	awong1@hku.hk	Wong, Alice/AFJ-4595-2022; Cheung, Annie Nga Yin/C-4231-2009	Wong, Alice/0000-0002-0676-6475; Leung, Peter/0000-0003-3152-3800; Cheung, Lydia Wai Ting/0000-0003-1137-3200; Cheung, Annie Nga Yin/0000-0002-1584-7568; Ngan, Hextan Y S/0000-0003-3945-159X	Hong Kong Research Grant Council [778108]; HKU	Hong Kong Research Grant Council(Hong Kong Research Grants Council); HKU(University of Hong Kong)	We thank Dr N Auersperg for cell lines. This work was supported by Hong Kong Research Grant Council 778108 and HKU Outstanding Young Researcher Award (AST Wong).	Alonso L, 2009, CLIN TRANSL ONCOL, V11, P748, DOI 10.1007/s12094-009-0437-4; Brokaw J, 2007, GROWTH FACTORS, V25, P346, DOI 10.1080/08977190701838402; Chen GTC, 2002, MOL REPROD DEV, V62, P289, DOI 10.1002/mrd.10121; Cheung LWT, 2010, ONCOGENE, V29, P2427, DOI 10.1038/onc.2009.523; Cheung LWT, 2008, FEBS J, V275, P5479, DOI 10.1111/j.1742-4658.2008.06677.x; Cheung LWT, 2006, CANCER RES, V66, P10902, DOI 10.1158/0008-5472.CAN-06-2217; Choi JH, 2008, CANCER RES, V68, P5716, DOI 10.1158/0008-5472.CAN-08-0001; Cozzolino M, 2003, MOL BIOL CELL, V14, P1964, DOI 10.1091/mbc.E02-08-0469; Criswell T, 2005, J BIOL CHEM, V280, P14212, DOI 10.1074/jbc.M412569200; Du J, 1996, BIOCHEM BIOPH RES CO, V218, P934, DOI 10.1006/bbrc.1996.0165; Dunn SE, 1998, CANCER RES, V58, P3353; Ellerbroek SM, 2001, CANCER RES, V61, P1855; EMONS G, 1989, EUR J CANCER CLIN ON, V25, P215, DOI 10.1016/0277-5379(89)90011-4; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fagotto F, 1996, DEV BIOL, V180, P445, DOI 10.1006/dbio.1996.0318; GRZES A, 1978, ENDOKRINOLOGIE, V71, P40; HODIVALA KJ, 1994, J CELL BIOL, V124, P589, DOI 10.1083/jcb.124.4.589; Holzman JL, 2007, AM J PHYSIOL-RENAL, V292, pF1219, DOI 10.1152/ajprenal.00214.2006; IRMER G, 1995, CANCER RES, V55, P817; Ishiyama N, 2010, CELL, V141, P117, DOI 10.1016/j.cell.2010.01.017; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; KAWAMURA Y, 1980, FERTIL STERIL, V34, P444; Liao JK, 2003, BIOCHEM SOC T, V31, P66, DOI 10.1042/bst0310066; Morali OG, 2001, ONCOGENE, V20, P4942, DOI 10.1038/sj.onc.1204660; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Patel IS, 2003, INT J CANCER, V106, P172, DOI 10.1002/ijc.11086; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Pennisi PA, 2002, CANCER RES, V62, P6529; Pon YL, 2008, CANCER RES, V68, P6524, DOI 10.1158/0008-5472.CAN-07-6302; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; Sawada K, 2007, CANCER RES, V67, P1670, DOI 10.1158/0008-5472.CAN-06-1147; Shaw TJ, 2004, MOL THER, V10, P1032, DOI 10.1016/j.ymthe.2004.08.013; Soubry A, 2005, CANCER RES, V65, P2224, DOI 10.1158/0008-5472.CAN-04-2020; Spentzos D, 2007, ENDOCR-RELAT CANCER, V14, P781, DOI 10.1677/ERC-06-0073; Spring CM, 2005, EXP CELL RES, V305, P253, DOI 10.1016/j.yexcr.2005.01.007; Steele IA, 2001, ONCOGENE, V20, P5878, DOI 10.1038/sj.onc.1204755; Sundfeldt K, 2003, MOL CELL ENDOCRINOL, V202, P89, DOI 10.1016/S0303-7207(03)00068-6; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Takahari D, 2009, ONCOLOGY-BASEL, V76, P42, DOI 10.1159/000178164; Wilkinson SJ, 2008, HUM PATHOL, V39, P1197, DOI 10.1016/j.humpath.2007.12.011; Wong AST, 1999, INT J CANCER, V81, P180; Yin M, 2009, AM J TRANSL RES, V1, P101	43	24	25	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	26					2964	2974		10.1038/onc.2011.7	http://dx.doi.org/10.1038/onc.2011.7			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	785QZ	21317933				2022-12-17	WOS:000292245100007
J	Draheim, KM; Hermance, N; Yang, Y; Arous, E; Calvo, J; Kelliher, MA				Draheim, K. M.; Hermance, N.; Yang, Y.; Arous, E.; Calvo, J.; Kelliher, M. A.			A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice	ONCOGENE			English	Article						TAL1; Lmo2; E47; HEB; T cell acute lymphoblastic leukemia (T-ALL)	ACUTE LYMPHOBLASTIC-LEUKEMIA; LOOP-HELIX PROTEIN; C-KIT EXPRESSION; TRANSCRIPTION FACTOR; GENE-THERAPY; TRANSGENIC MICE; TRANSACTIVATION DOMAIN; HEMATOPOIETIC-CELLS; COMPLEX; SCL	The most common translocation in childhood T-cell acute lymphoblastic leukemia (T-ALL) involves the LMO2 locus, resulting in ectopic expression of the LMO2 gene in human thymocytes. The LMO2 gene was also activated in patients with X-linked Severe Combined Immune Deficiency treated with gene therapy because of retroviral insertion in the LMO2 locus. The LMO2 insertions predisposed these children to T-ALL, yet how LMO2 contributes to T cell transformation remains unclear. The LIM (Lin 11, Isl-1, Mec-3) domain containing LMO2 protein regulates erythropoiesis as part of a large transcriptional complex consisting of LMO2, TAL1, E47, GATA1 and LDB1 that recognizes bipartite E-box-GATA1 sites on target genes. Similarly, a TAL1/E47/LMO2/LDB1 complex is observed in human T-ALL and Tal1 and Lmo2 expression in mice results in disease acceleration. To address the mechanism(s) of Tal1/Lmo2 synergy in leukemia, we generated Lmo2 transgenic mice and mated them with mice that express wild-type Tal1 or a DNA-binding mutant of TAL1. Tal1/Lmo2 and MutTAL1/Lmo2 bitransgenic mice exhibit perturbations in thymocyte development due to reduced E47/HEB transcriptional activity and develop leukemia with identical kinetics. These data demonstrate that the DNA-binding activity of Tal1 is not required to cooperate with Lmo2 to cause leukemia in mice and suggest that Lmo2 may cooperate with Tal1 to interfere with E47/HEB function(s). Oncogene (2011) 30, 1252-1260; doi:10.1038/onc.2010.495; published online 8 November 2010	[Draheim, K. M.; Hermance, N.; Yang, Y.; Arous, E.; Kelliher, M. A.] UMass Med Sch, Dept Canc Biol, Worcester, MA USA; [Calvo, J.] MIT, Ctr Environm Hlth Sci, Dept Biol Engn, Cambridge, MA 02139 USA	University of Massachusetts System; University of Massachusetts Worcester; Massachusetts Institute of Technology (MIT)	Kelliher, MA (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, 364 Plantat St, Worcester, MA 01605 USA.	Michelle.Kelliher@umassmed.edu			NIH/NCI [CA096899]; Diabetes Endocrinology Research Center [DK32520]; NATIONAL CANCER INSTITUTE [R01CA096899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Diabetes Endocrinology Research Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work is supported by an NIH/NCI CA096899 Grant to MK. Core resources supported by the Diabetes Endocrinology Research Center Grant DK32520 were also used.	ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; Aoyama M, 2005, CANCER RES, V65, P4587, DOI 10.1158/0008-5472.CAN-04-4630; Aplan PD, 1997, EMBO J, V16, P2408, DOI 10.1093/emboj/16.9.2408; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; Berg T, 2002, P NATL ACAD SCI USA, V99, P3830, DOI 10.1073/pnas.062036999; BOEHM T, 1990, ONCOGENE, V5, P1103; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Davenport J, 2000, LEUKEMIA, V14, P1986, DOI 10.1038/sj.leu.2401913; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; FISCH P, 1992, ONCOGENE, V7, P2389; GARCIA IS, 1991, ONCOGENE, V6, P577; Goardon N, 2006, EMBO J, V25, P357, DOI 10.1038/sj.emboj.7600934; Greenbaum S, 2002, SEMIN IMMUNOL, V14, P405, DOI 10.1016/S1044532302000751; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314; Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI 10.1172/JCI35700; Herblot S, 2000, NAT IMMUNOL, V1, P138, DOI 10.1038/77819; Howe SJ, 2008, J CLIN INVEST, V118, P3143, DOI 10.1172/JCI35798; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; Hsu LY, 2003, IMMUNITY, V19, P105, DOI 10.1016/S1074-7613(03)00181-X; Huang EY, 2003, J IMMUNOL, V171, P2296, DOI 10.4049/jimmunol.171.5.2296; Huang S, 2000, MOL CELL BIOL, V20, P2248, DOI 10.1128/MCB.20.6.2248-2259.2000; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Krosl G, 1998, J EXP MED, V188, P439, DOI 10.1084/jem.188.3.439; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lahlil R, 2004, MOL CELL BIOL, V24, P1439, DOI 10.1128/MCB.24.4.1439-1452.2004; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; Lecuyer E, 2002, BLOOD, V100, P2430, DOI 10.1182/blood-2002-02-0568; Nam CH, 2008, ONCOGENE, V27, P4962, DOI 10.1038/onc.2008.130; O'Neil J, 2004, CANCER CELL, V5, P587, DOI 10.1016/j.ccr.2004.05.023; O'Neil J, 2001, ONCOGENE, V20, P3897, DOI 10.1038/sj.onc.1204519; Ono Y, 1997, J BIOL CHEM, V272, P4576, DOI 10.1074/jbc.272.7.4576; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Ryan DP, 2008, PROTEINS, V70, P1461, DOI 10.1002/prot.21638; Schlaeger TM, 2004, MOL CELL BIOL, V24, P7491, DOI 10.1128/MCB.24.17.7491-7502.2004; Sharma VM, 2006, MOL CELL BIOL, V26, P8022, DOI 10.1128/MCB.01091-06; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; Visvader JE, 2001, P NATL ACAD SCI USA, V98, P14452, DOI 10.1073/pnas.251547698; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; Xu ZX, 2003, MOL CELL BIOL, V23, P7585, DOI 10.1128/MCB.23.21.7585-7599.2003; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317	44	24	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	10					1252	1260		10.1038/onc.2010.495	http://dx.doi.org/10.1038/onc.2010.495			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732QD	21057528	Green Accepted			2022-12-17	WOS:000288202400011
J	Song, L; Gao, M; Dong, W; Hu, M; Li, J; Shi, X; Hao, Y; Li, Y; Huang, C				Song, L.; Gao, M.; Dong, W.; Hu, M.; Li, J.; Shi, X.; Hao, Y.; Li, Y.; Huang, C.			p85 alpha mediates p53 K370 acetylation by p300 and regulates its promoter-specific transactivity in the cellular UVB response	ONCOGENE			English	Article						acetylation; p85 alpha; p53; p300; UVB radiation	TUMOR-SUPPRESSOR P53; NF-KAPPA-B; PHOSPHOINOSITIDE 3-KINASE; DNA-DAMAGE; IN-VIVO; POSTTRANSLATIONAL MODIFICATIONS; APOPTOTIC RESPONSE; IKK-BETA; ACTIVATION; BINDING	Inducible acetylation of p53 at lysine residues has a great impact on regulating the transactivation of this protein, which is associated with cell growth arrest and/or apoptosis under various stress conditions. However, the factor(s) for regulating p53 acetylation remains largely unknown. In the current study, we have shown that p85 alpha, the regulatory subunit of phosphatidylinositol-3-kinase, has a critical role in mediating p53 acetylation and promoter-specific transactivation in the ultraviolet B (UVB) response. Depletion of p85 alpha in mouse embryonic fibroblasts significantly impairs UVB-induced apoptosis, as well as p53 transactivation and acetylation at Lys370 (Lys373 of human p53); however, the accumulation, nuclear translocation and phosphorylation of p53 are not affected. Interestingly, p85 alpha binds to p300, promotes the p300-p53 interaction and the subsequent recruitment of the p53/p300 complex to the promoter region of the specific p53 target gene in response to UVB irradiation. Moreover, ablation of p53 acetylation at Lys370 by site-directed mutagenesis dramatically suppresses UVB-induced expression of the specific p53-responsive gene as well as cell apoptosis. Therefore, we conclude that p85 alpha is a novel regulator of p53-mediated response under certain stress conditions, and targeting the p85 alpha-dependent p53 pathway may be promising for cancer therapy. Oncogene (2011) 30, 1360-1371; doi:10.1038/onc.2010.506; published online 8 November 2010	[Song, L.; Gao, M.; Dong, W.; Hu, M.; Hao, Y.; Li, Y.] Beijing Inst Basic Med Sci, Dept Cellular Immunol, Beijing 100850, Peoples R China; [Song, L.; Li, J.; Shi, X.; Huang, C.] NYU, Sch Med, Nelson Inst Environm Med, Dept Environm Med, Tuxedo Pk, NY 10987 USA	Academy of Military Medical Sciences - China; New York University	Song, L (corresponding author), Beijing Inst Basic Med Sci, Dept Cellular Immunol, 27 Taiping Rd, Beijing 100850, Peoples R China.	lunsong@yahoo.com; chuanshu@env.med.nyu.edu		Huang, Chuanshu/0000-0003-4133-5096	NIH/NCI [CA112557, CA119028-05S110]; NIH/NIEHS [ES010344, ES012451]; National Natural Science Foundation of China [30871277, 30970594]; Beijing Natural Science Foundation [5092022, 5102035]; National Key Research and Development Programs on Fundamental Sciences (973 Project) [2011CB503803]; NATIONAL CANCER INSTITUTE [R01CA112557, R01CA119028] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012451, P42ES010344] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation); National Key Research and Development Programs on Fundamental Sciences (973 Project)(National Basic Research Program of China); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We appreciate the technical help from Dr Dan Liu and the helpful discussion provided by Dr Ailing Li. This project is partially supported by NIH/NCI CA112557, CA119028-05S110, NIH/NIEHS ES010344 and ES012451 (to Dr C Huang); and National Natural Science Foundation of China No. 30871277, 30970594, Beijing Natural Science Foundation 5092022 and 5102035 and the National Key Research and Development Programs on Fundamental Sciences (973 Project) 2011CB503803 (to Dr L Song).	An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Brooks CL, 2008, CANCER CELL, V13, P377, DOI 10.1016/j.ccr.2008.04.009; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; CAO CLUS, 2008, J CELL MOL MED, V4, P4; Chao C, 2006, MOL CELL BIOL, V26, P6859, DOI 10.1128/MCB.00062-06; Eischen CM, 2009, CANCER CELL, V15, P161, DOI 10.1016/j.ccr.2009.02.004; Feng LJ, 2005, MOL CELL BIOL, V25, P5389, DOI 10.1128/MCB.25.13.5389-5395.2005; Geering B, 2007, BIOCHEM SOC T, V35, P199, DOI 10.1042/BST0350199; Goodman RH, 2000, GENE DEV, V14, P1553; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kim EJ, 2007, MOL CELL, V28, P277, DOI 10.1016/j.molcel.2007.08.030; Kitagawa M, 2008, MOL CELL, V29, P217, DOI 10.1016/j.molcel.2007.11.036; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kurash JK, 2008, MOL CELL, V29, P392, DOI 10.1016/j.molcel.2007.12.025; Lain S, 2008, CANCER CELL, V13, P454, DOI 10.1016/j.ccr.2008.03.004; Latonen L, 2005, BBA-REV CANCER, V1755, P71, DOI 10.1016/j.bbcan.2005.04.003; Levine AJ, 2006, CELL DEATH DIFFER, V13, P1027, DOI 10.1038/sj.cdd.4401910; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu G, 2006, J CELL BIOCHEM, V97, P448, DOI 10.1002/jcb.20700; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luo J, 2005, J CELL BIOL, V170, P455, DOI 10.1083/jcb.200503088; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Miled N, 2007, SCIENCE, V317, P239, DOI 10.1126/science.1135394; Olsson A, 2007, CELL DEATH DIFFER, V14, P1561, DOI 10.1038/sj.cdd.4402196; Pan X, 2009, P NATL ACAD SCI USA, V106, P3788, DOI 10.1073/pnas.0810147106; Pedeux R, 2005, MOL CELL BIOL, V25, P6639, DOI 10.1128/MCB.25.15.6639-6648.2005; Reczek EE, 2003, MOL CANCER RES, V1, P1048; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sasaki T, 2007, GENE DEV, V21, P848, DOI 10.1101/gad.1534107; Song L, 2008, EXP CELL RES, V314, P2187, DOI 10.1016/j.yexcr.2008.04.002; Song L, 2007, MOL CELL BIOL, V27, P2713, DOI 10.1128/MCB.00657-06; Song L, 2006, J CELL BIOL, V175, P607, DOI 10.1083/jcb.200602149; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Ueki K, 2002, MOL CELL BIOL, V22, P965, DOI 10.1128/MCB.22.3.965-977.2002; Ueki K, 2002, P NATL ACAD SCI USA, V99, P419, DOI 10.1073/pnas.012581799; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang J, 2005, CANCER RES, V65, P6601, DOI 10.1158/0008-5472.CAN-04-4184; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648; Zhao WH, 2008, NATURE, V451, P587, DOI 10.1038/nature06515; Zhu Z, 2009, HEPATOLOGY, V49, P504, DOI 10.1002/hep.22675	52	24	24	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	11					1360	1371		10.1038/onc.2010.506	http://dx.doi.org/10.1038/onc.2010.506			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	736JX	21057544	Green Accepted			2022-12-17	WOS:000288492100010
J	Radulescu, S; Ridgway, RA; Appleton, P; Kroboth, K; Patel, S; Woodgett, J; Taylor, S; Nathke, IS; Sansom, OJ				Radulescu, S.; Ridgway, R. A.; Appleton, P.; Kroboth, K.; Patel, S.; Woodgett, J.; Taylor, S.; Nathke, I. S.; Sansom, O. J.			Defining the role of APC in the mitotic spindle checkpoint in vivo: APC-deficient cells are resistant to Taxol	ONCOGENE			English	Article						APC; WNT signalling; Taxol; mitotic spindle assembly checkpoint	POLYPOSIS-COLI PROTEIN; SUPPRESSOR GENE; CANCER; EXPRESSION; MUTATIONS; PROLIFERATION; MICROTUBULE; HOMEOSTASIS; INSTABILITY; PROGRESSION	Mutations in the adenomatous polyposis coli (APC) tumour suppressor are the key initiating event of colorectal cancer. Although the control of WNT signalling is well established as a central tumour-suppressive function, the significance of APC in regulating chromosome instability is less well established. In this study, we test whether APC-deficient cells have a functional spindle assembly checkpoint (SAC) in vivo by examining the response of these cells to Taxol and Vinorelbine. We also show for the first time that APC deficiency compromises the arrest response to Taxol in vivo. This effect is independent of the role that APC has in WNT signalling. At higher levels of Taxol, APC-deficient cells arrest as efficiently as wild-type cells. Importantly, this dose of Taxol strongly suppresses intestinal tumourigenesis in models of benign (APC(Min/+) mouse) and invasive (AhCreER(+) APC(fl/+) PTENfl/fl) cancer. In contrast to intestinal enterocytes with a general SAC defect because of Bub1 (budding uninhibited by benzimidazole 1) deletion, APC-deficient enterocytes arrest equivalently to wild type when treated with Vinorelbine. This suggests that the failed arrest in response to Taxol is because of a specific defect in microtubule stabilization following Taxol treatment rather than a general role of the APC protein in the mitotic spindle checkpoint. In summary, this study clarifies the role of APC as a mitotic spindle checkpoint protein in vivo and shows that APC-deficient cells have a compromised response to Taxol. Oncogene (2010) 29, 6418-6427; doi:10.1038/onc.2010.373; published online 23 August 2010	[Radulescu, S.; Ridgway, R. A.; Sansom, O. J.] CR UK Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; [Appleton, P.; Kroboth, K.; Nathke, I. S.] Univ Dundee, WTB MSI, Dundee, Scotland; [Patel, S.; Woodgett, J.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; [Taylor, S.] Univ Manchester, Fac Life Sci, Manchester, Lancs, England	Beatson Institute; University of Dundee; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Manchester	Sansom, OJ (corresponding author), CR UK Beatson Inst Canc Res, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	o.sansom@beatson.gla.ac.uk	Woodgett, Jim/F-1087-2010; Taylor, Stephen/GZL-6499-2022	Woodgett, Jim/0000-0003-3731-5797; Sansom, Owen J./0000-0001-9540-3010; Taylor, Stephen/0000-0003-4621-9326; Nathke, Inke/0000-0003-2420-4385	CR-UK; AICR; Cancer Research UK [11913, 12481, 11243] Funding Source: researchfish	CR-UK(Cancer Research UK); AICR; Cancer Research UK(Cancer Research UK)	This work was funded by the CR-UK project and programme grants to Inke Nathke and Owen Sansom. Sorina Radulescu was funded by an AICR grant. Help from Colin Nixon with histology and from Derek Miller and Tom Hamilton with transgenic work was much appreciated.	Baena E, 2005, P NATL ACAD SCI USA, V102, P7286, DOI 10.1073/pnas.0409260102; Caldwell CM, 2007, J CELL BIOL, V178, P1109, DOI 10.1083/jcb.200703186; Dikovskaya D, 2004, MOL BIOL CELL, V15, P2978, DOI 10.1091/mbc.E03-08-0613; Dikovskaya D, 2001, TRENDS CELL BIOL, V11, P378, DOI 10.1016/S0962-8924(01)02069-4; Dikovskaya D, 2007, J CELL BIOL, V176, P183, DOI 10.1083/jcb.200610099; Draviam VM, 2006, EMBO J, V25, P2814, DOI 10.1038/sj.emboj.7601168; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Green RA, 2005, MOL BIOL CELL, V16, P4609, DOI 10.1091/mbc.E05-03-0259; Gregorieff A, 2005, GASTROENTEROLOGY, V129, P626, DOI 10.1053/j.gastro.2005.06.007; Huang HC, 2009, CANCER CELL, V16, P347, DOI 10.1016/j.ccr.2009.08.020; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kemp R, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh090; KRIKORIAN A, 1991, ONKOLOGIE, V14, P7; Kroboth K, 2007, MOL BIOL CELL, V18, P910, DOI 10.1091/mbc.E06-03-0179; LINN SC, 1995, EUR J CANCER, V31A, P1291, DOI 10.1016/0959-8049(95)00278-Q; Marsh V, 2008, NAT GENET, V40, P1436, DOI 10.1038/ng.256; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Patel S, 2008, MOL CELL BIOL, V28, P6314, DOI 10.1128/MCB.00763-08; Perera D, 2007, DEV CELL, V13, P566, DOI 10.1016/j.devcel.2007.08.008; RADULESCU S, BUB1 HAPLOINSU UNPUB; Rusan NM, 2008, J CELL BIOL, V181, P719, DOI 10.1083/jcb.200802107; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; SU LK, 1995, CANCER RES, V55, P2972; Suzuki A, 2003, CANCER RES, V63, P674; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tighe A, 2004, J CELL SCI, V117, P6339, DOI 10.1242/jcs.01556; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014	32	24	24	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	49					6418	6427		10.1038/onc.2010.373	http://dx.doi.org/10.1038/onc.2010.373			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	692FP	20729907	Green Accepted			2022-12-17	WOS:000285138900002
J	Gonfloni, S				Gonfloni, S.			DNA damage stress response in germ cells: role of c-Abl and clinical implications	ONCOGENE			English	Review						c-Abl tyrosine kinase; DNA damage response; germ cells; TAp63; chemotherapy	DOUBLE-STRAND BREAKS; TYROSINE KINASE; IONIZING-RADIATION; BCR-ABL; TUMOR-SUPPRESSOR; DROSOPHILA-MELANOGASTER; DIFFERENTIAL EXPRESSION; APOPTOTIC RESPONSE; CELLULAR-RESPONSE; ATM ACTIVATION	Cells experiencing DNA damage undergo a complex response entailing cell-cycle arrest, DNA repair and apoptosis, the relative importance of the three being modulated by the extent of the lesion. The observation that Abl interacts in the nucleus with several proteins involved in different aspects of DNA repair has led to the hypothesis that this kinase is part of the damage-sensing mechanism. However, the mechanistic details underlying the role of Abl in DNA repair remain unclear. Here, I will review the evidence supporting our current understanding of Abl activation following DNA insults, while focusing on the relevance of these mechanisms in protecting DNA-injured germ cells. Early studies have shown that Abl transcripts are highly expressed in the germ line. Abl-deficient mice exhibit multiple abnormalities, increased perinatal mortality and reduced fertility. Recent findings have implicated Abl in a cisplatin-induced signaling pathway eliciting death of immature oocytes. A p53-related protein, TAp63, is an important immediate downstream effector of this pathway. Of note, pharmacological inhibition of Abl protects the ovarian reserve from the toxic effects of cisplatin. This suggests that the extent of Abl catalytic outputs may shift the balance between survival (likely through DNA repair) and activation of a death response. Taken together, these observations are consistent with the evolutionary conserved relationship between DNA damage and activation of the p53 family of transcription factors, while shedding light on the key role of Abl in dictating the fate of germ cells upon genotoxic insults. Oncogene (2010) 29, 6193-6202; doi:10.1038/onc.2010.410; published online 6 September 2010	Univ Rome, Dept Biol, I-00133 Rome, Italy	Sapienza University Rome	Gonfloni, S (corresponding author), Univ Rome, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.	Stefania.Gonfloni@uniroma2.it		GONFLONI, STEFANIA/0000-0002-9392-4258				Adrian FJ, 2006, NAT CHEM BIOL, V2, P95, DOI 10.1038/nchembio760; Agami R, 1999, NATURE, V399, P809; Backhus Leilah E., 2007, V138, P235; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Belyi VA, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001198; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Brodsky MH, 2004, MOL CELL BIOL, V24, P1219, DOI 10.1128/MCB.24.3.1219-1231.2004; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Burma S, 2004, DNA REPAIR, V3, P909, DOI 10.1016/j.dnarep.2004.03.021; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Chen G, 1999, J BIOL CHEM, V274, P12748, DOI 10.1074/jbc.274.18.12748; Chen XA, 2006, MOL CELL, V22, P489, DOI 10.1016/j.molcel.2006.04.021; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; CHOW CS, 1995, BIOCHEMISTRY-US, V34, P2956, DOI 10.1021/bi00009a027; Collis SJ, 2005, ONCOGENE, V24, P949, DOI 10.1038/sj.onc.1208332; Cong F, 2002, J BIOL CHEM, V277, P34870, DOI 10.1074/jbc.M204416200; David-Cordonnier MH, 1998, BIOCHEMISTRY-US, V37, P6065, DOI 10.1021/bi973030w; Deng XZ, 2004, NAT GENET, V36, P906, DOI 10.1038/ng1396; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; Dery U, 2007, DNA REPAIR, V6, P561, DOI 10.1016/j.dnarep.2006.12.009; Dunn L, 2009, CURR OPIN OBSTET GYN, V21, P68, DOI 10.1097/GCO.0b013e32831e13b9; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Edelmann W, 1999, NAT GENET, V21, P123, DOI 10.1038/5075; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Foray N, 2002, MOL CELL BIOL, V22, P4020, DOI 10.1128/MCB.22.12.4020-4032.2002; Gardino SL, 2010, J ASSIST REPROD GEN, V27, P227, DOI 10.1007/s10815-010-9413-8; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; GODDARD JM, 1986, P NATL ACAD SCI USA, V83, P2172, DOI 10.1073/pnas.83.7.2172; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; Gonfloni S, 2010, CELL CYCLE, V9, P217, DOI 10.4161/cc.9.2.10563; Gonfloni S, 2009, NAT MED, V15, P1179, DOI 10.1038/nm.2033; Gong JG, 1999, NATURE, V399, P806; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gu JJ, 2009, IMMUNOL REV, V228, P170, DOI 10.1111/j.1600-065X.2008.00751.x; Hantschel O, 2004, NAT REV MOL CELL BIO, V5, P33, DOI 10.1038/nrm1280; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Hardin JD, 1996, CELL IMMUNOL, V172, P100, DOI 10.1006/cimm.1996.0220; Her C, 1998, GENOMICS, V52, P50, DOI 10.1006/geno.1998.5374; Her C, 2007, FRONT BIOSCI-LANDMRK, V12, P905, DOI 10.2741/2112; Hulvat MC, 2009, CURR TREAT OPTION ON, V10, P308, DOI 10.1007/s11864-010-0116-2; IWAOKI Y, 1993, EXP CELL RES, V206, P212, DOI 10.1006/excr.1993.1140; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jeruss JS, 2009, NEW ENGL J MED, V360, P902, DOI 10.1056/NEJMra0801454; Johnston RJ, 2009, PEDIATR BLOOD CANCER, V53, P296, DOI 10.1002/pbc.22012; Jones EV, 2007, BIOCHEM J, V405, P617, DOI 10.1042/BJ20061778; Junttila MR, 2009, NAT REV CANCER, V9, P821, DOI 10.1038/nrc2728; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Kharbanda S, 1998, ONCOGENE, V16, P1773, DOI 10.1038/sj.onc.1201934; Kharbanda S, 1997, BBA-REV CANCER, V1333, pO1, DOI 10.1016/S0304-419X(97)00020-6; Kitao H, 2002, J BIOL CHEM, V277, P48944, DOI 10.1074/jbc.M208151200; Kneitz B, 2000, GENE DEV, V14, P1085; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kurita T, 2005, MECH DEVELOP, V122, P1043, DOI 10.1016/j.mod.2005.04.008; Kuriyan J, 2007, NATURE, V450, P983, DOI 10.1038/nature06524; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; LEV Z, 1984, MOL CELL BIOL, V4, P982, DOI 10.1128/MCB.4.5.982; Li BJ, 2000, NAT GENET, V24, P304, DOI 10.1038/73542; Lieber MR, 2004, DNA REPAIR, V3, P817, DOI 10.1016/j.dnarep.2004.03.015; Lobo RA, 2005, NEW ENGL J MED, V353, P64, DOI 10.1056/NEJMra043475; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Maltaris T, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1991; Maltaris T, 2009, IN VIVO, V23, P123; Mandon-Pepin B, 2008, EUR J ENDOCRINOL, V158, P107, DOI 10.1530/EJE-07-0400; MEIJER D, 1987, EMBO J, V6, P4041, DOI 10.1002/j.1460-2075.1987.tb02749.x; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Nagar B, 2007, J NUTR, V137, p1518S, DOI 10.1093/jn/137.6.1518S; Nehme A, 1997, CANCER RES, V57, P3253; Ohndorf UM, 1999, NATURE, V399, P708, DOI 10.1038/21460; Ohren JF, 2006, NAT CHEM BIOL, V2, P63, DOI 10.1038/nchembio0206-63; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; Pandita Tej K, 2003, Expert Rev Mol Med, V5, P1, DOI 10.1017/S1462399403006318; Panier S, 2009, DNA REPAIR, V8, P436, DOI 10.1016/j.dnarep.2009.01.013; Peate M, 2009, BREAST CANCER RES TR, V116, P215, DOI 10.1007/s10549-009-0401-6; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Petrini JHJ, 2003, TRENDS CELL BIOL, V13, P458, DOI 10.1016/S0962-8924(03)00170-3; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; PROPST F, 1988, ONCOGENE, V2, P227; Raina D, 2006, EMBO J, V25, P3774, DOI 10.1038/sj.emboj.7601263; Richardson C, 2004, DNA REPAIR, V3, P1149, DOI 10.1016/j.dnarep.2004.05.007; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rutkowski R, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001131; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schumacher B, 2005, CELL DEATH DIFFER, V12, P153, DOI 10.1038/sj.cdd.4401539; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shaul Y, 2000, CELL DEATH DIFFER, V7, P10, DOI 10.1038/sj.cdd.4400626; Shaul Y, 2005, CELL RES, V15, P33, DOI 10.1038/sj.cr.7290261; SHILO BZ, 1981, P NATL ACAD SCI-BIOL, V78, P6789, DOI 10.1073/pnas.78.11.6789; Shimizu H, 2009, BIOCHEM BIOPH RES CO, V382, P286, DOI 10.1016/j.bbrc.2009.03.020; Sirvent A, 2008, BIOL CELL, V100, P617, DOI 10.1042/BC20080020; Sogame N, 2003, P NATL ACAD SCI USA, V100, P4696, DOI 10.1073/pnas.0736384100; Stojic L, 2004, DNA REPAIR, V3, P1091, DOI 10.1016/j.dnarep.2004.06.006; Suh EK, 2006, NATURE, V444, P624, DOI 10.1038/nature05337; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Takao N, 2000, J BIOL CHEM, V275, P725, DOI 10.1074/jbc.275.2.725; Ting NSY, 2004, DNA REPAIR, V3, P935, DOI 10.1016/j.dnarep.2004.03.026; Tompkins JD, 2009, EXP CELL RES, V315, P2420, DOI 10.1016/j.yexcr.2009.05.004; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; VANDERKAAIJ MAE, 2010, HEMATOL ONCOL; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; Wang JYJ, 2004, NAT CELL BIOL, V6, P3, DOI 10.1038/ncb0104-3; Wang JYJ, 2001, BIOCHEM SOC T, V29, P666, DOI 10.1042/0300-5127:0290666; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/s0079-6603(08)60611-x; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; Weisberg E, 2007, NAT REV CANCER, V7, P345, DOI 10.1038/nrc2126; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; West ER, 2009, PEDIATR BLOOD CANCER, V53, P289, DOI 10.1002/pbc.21999; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Woodruff Teresa K., 2007, V138, P3; Woodruff TK, 2008, NAT MED, V14, P1190, DOI 10.1038/nm1108-1190; Woodruff TK, 2009, NAT MED, V15, P1124, DOI 10.1038/nm1009-1124; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yi W, 2006, CANCER RES, V66, P151, DOI 10.1158/0008-5472.CAN-05-3019; Yi W, 2005, BIOCHEM BIOPH RES CO, V332, P524, DOI 10.1016/j.bbrc.2005.04.154; Yoshida K, 2005, NAT CELL BIOL, V7, P278, DOI 10.1038/ncb1228; Yoshida K, 2008, TRENDS MOL MED, V14, P305, DOI 10.1016/j.molmed.2008.05.003; Yuan JS, 2010, J BIOL CHEM, V285, P1097, DOI 10.1074/jbc.M109.078436; Yuan SSF, 2003, MUTAT RES-FUND MOL M, V525, P85, DOI 10.1016/S0027-5107(03)00009-5; Yuan SSF, 1999, CANCER RES, V59, P3547; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799; Zhang JM, 2010, NATURE, V463, P501, DOI 10.1038/nature08675; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zhu JY, 2004, CURR TOP DEV BIOL, V59, P165, DOI 10.1016/S0070-2153(04)59007-5	141	24	26	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	47					6193	6202		10.1038/onc.2010.410	http://dx.doi.org/10.1038/onc.2010.410			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	685CG	20818431				2022-12-17	WOS:000284601700001
J	Vilgelm, AE; Hong, SM; Washington, MK; Wei, J; Chen, H; El-Rifai, W; Zaika, A				Vilgelm, A. E.; Hong, S-M; Washington, M. K.; Wei, J.; Chen, H.; El-Rifai, W.; Zaika, A.			Characterization of Delta Np73 expression and regulation in gastric and esophageal tumors	ONCOGENE			English	Article						p73; gastric tumor; esophageal tumor	FACTOR-BINDING SITES; FEEDBACK LOOP; P53; CANCER; FAMILY; P73; PROMOTER; TAP73; DEATH; DNP73	p73 is a member of the p53 protein family. Although the tumor suppressor function of p53 is clearly defined, the role of p73 in tumorigenesis is still a matter of debate. A complex pattern of expression of p73 isoforms makes it difficult to unambiguously interpret the experimental results. Previously, we along with others have found that the N-terminally truncated isoform of p73, Delta Np73, has potent anti-apoptotic and oncogenic properties in vitro and in vivo. In this study, we analyzed, for the first time, the regulation of Delta Np73 in a large number of gastric, gastroesophageal junction and esophageal tumors. We found that expression of Delta Np73 mRNA and protein is increased in these neoplasms. Furthermore, the upregulation of the Delta Np73 protein is significantly associated with poor patient survival. Oncogenic properties of Delta Np73 were further confirmed by finding that Delta Np73 facilitates anchorage-independent growth of gastric epithelial cells in soft agar. As little is currently known about the regulation of Delta Np73 transcription, we investigated the alternative p73 gene promoter that mediates the Delta Np73 expression. Analyzing the Delta Np73 promoter in silico as well as by using chromatin immunoprecipitation, site-directed mutagenesis and deletion analyses, we identified the evolutionary conserved region within the Delta Np73 promoter that contains binding sites for HIC1 (hypermethylated in cancer) protein. We found that HIC1 negatively regulates Delta Np73 transcription in mucosal epithelial cells. This leads to a decrease in Delta Np73 protein levels and may normally control the oncogenic potential of the Delta Np73 isoform. Oncogene (2010) 29, 5861-5868; doi: 10.1038/onc.2010.319; published online 2 August 2010	[Vilgelm, A. E.; Wei, J.; El-Rifai, W.; Zaika, A.] Vanderbilt Univ, Dept Surg, Med Ctr, Nashville, TN 37240 USA; [Vilgelm, A. E.; Washington, M. K.; Wei, J.; Chen, H.; El-Rifai, W.; Zaika, A.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA; [Vilgelm, A. E.] Russian Acad Sci, Dept Cell Biol, VA Engelhardt Mol Biol Inst, Moscow, Russia; [Hong, S-M] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; [Washington, M. K.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; [El-Rifai, W.; Zaika, A.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Johns Hopkins University; Johns Hopkins Medicine; Vanderbilt University; Vanderbilt University	Zaika, A (corresponding author), Dept Surg & Canc Biol, 1255 Light Hall,2215 Garland Ave, Nashville, TN 37232 USA.	alexander.zaika@vanderbilt.edu		Hong, Seung-Mo/0000-0002-8888-6007; Vilgelm, Anna/0000-0002-4446-913X	National Cancer Institute [NIH CA108956]; Vanderbilt CTSA [UL1 RR024975]; NATIONAL CANCER INSTITUTE [R01CA138833, R01CA108956] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024975] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Vanderbilt CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported by the National Cancer Institute grant NIH CA108956 and Vanderbilt CTSA grant UL1 RR024975. We thank Dr Castells and Dr Pera of University of Barcelona for their assistance.	Buhlmann S, 2008, BBA-REV CANCER, V1785, P207, DOI 10.1016/j.bbcan.2008.01.002; Cam H, 2006, CANCER CELL, V10, P281, DOI 10.1016/j.ccr.2006.08.024; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993; Chen WY, 2005, CELL CYCLE, V4, P10, DOI 10.4161/cc.4.1.1361; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Kanai Y, 1998, CANCER LETT, V122, P135, DOI 10.1016/S0304-3835(97)00380-7; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Lin KW, 2004, NEOPLASIA, V6, P546, DOI 10.1593/neo.04205; Loots GG, 2004, NUCLEIC ACIDS RES, V32, pW217, DOI 10.1093/nar/gkh383; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Petrenko O, 2003, MOL CELL BIOL, V23, P5540, DOI 10.1128/MCB.23.16.5540-5555.2003; Stiewe T, 2004, CLIN CANCER RES, V10, P626, DOI 10.1158/1078-0432.CCR-0153-03; Tannapfel A, 2008, CARCINOGENESIS, V29, P211, DOI 10.1093/carcin/bgm236; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Vilgelm A, 2008, ONCOGENE, V27, P2170, DOI 10.1038/sj.onc.1210862; Vilgelm A, 2008, DRUG RESIST UPDATE, V11, P152, DOI 10.1016/j.drup.2008.08.001; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494; Zaika AI, 2006, CELL DEATH DIFFER, V13, P935, DOI 10.1038/sj.cdd.4401897	21	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	43					5861	5868		10.1038/onc.2010.319	http://dx.doi.org/10.1038/onc.2010.319			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	672LY	20676143	Green Accepted			2022-12-17	WOS:000283586200011
J	Chock, K; Allison, JMS; ElShamy, WM				Chock, K.; Allison, J. M. S.; ElShamy, W. M.			BRCA1-IRIS overexpression abrogates UV-induced p38MAPK/p53 and promotes proliferation of damaged cells	ONCOGENE			English	Article						BRCA1-IRIS; p53; p38MAPK; WIP1; UVC; etoposide; H2O2	ACTIVATED PROTEIN-KINASE; CYCLIN D1 EXPRESSION; BREAST-CANCER CELLS; NF-KAPPA-B; P38 MAPK; INDUCED PHOSPHORYLATION; FACTOR HUR; P53; WIP1; PHOSPHATASE	Cells' ability to evade cell death and to proliferate post geno-/cell-toxic stresses likely leads to formation of cancer. Activation of p38MAPK and p53 following these stresses helps protect cells against cancer development by initiating apoptosis. The duration of p38MAPK and p53 activation is regulated by the WIP1 phosphatase. BRCA1-IRIS triggers WIP1 expression in a p53-dependent and -independent manner. BRCA1-IRIS triggers the expression and cytoplasmic localization of the mRNA stabilization and translation inducer, HuR, that binds p53 and PPM1D mRNA. Hence, BRCA1-IRIS overexpression inactivates p38MAPK and/or p53 by upregulating WIP1 expression. BRCA1-IRIS abrogation of the homeostatic balance maintained by the p38MAPK-p53-WIP1 pathway suppressed cell death induced by a lethal dose of short-wavelength UV light, and high dosage of etoposide or H2O2, and allowed cells to survive and proliferate post geno-/cell-toxic stresses. This mechanism represents a new link between geno-/cell-toxic stress and aggressive breast cancer formation in p53 wild-type cells. Oncogene (2010) 29, 5274-5285; doi:10.1038/onc.2010.262; published online 12 July 2010	[ElShamy, W. M.] Univ Hawaii, Dept Pathol, John A Burns Sch Med, Honolulu, HI 96813 USA; Canc Ctr Hawaii, Honolulu, HI USA	University of Hawaii System; Cancer Research Center of Hawaii	ElShamy, WM (corresponding author), Univ Hawaii, Dept Pathol, John A Burns Sch Med, 651 Ilalo St,BSB-119A, Honolulu, HI 96813 USA.	welshamy@crch.hawaii.edu	ElShamy, Wael/AAF-2867-2019; ElShamy, Wael M./L-1090-2018		University of Hawaii; Hawaii Community Foundation	University of Hawaii; Hawaii Community Foundation	This research was supported in part by a start-up support from the University of Hawaii, and in part by a Grant from the Hawaii Community Foundation to WMeS. Wael M ElShamy is a Dr Lawrence and Mrs Bo Hing Chen Tsue American Cancer Society Scholar.	Al-Mohanna MA, 2007, NUCLEIC ACIDS RES, V35, P223, DOI 10.1093/nar/gkl1075; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Demuth T, 2007, MOL CANCER THER, V6, P1212, DOI 10.1158/1535-7163.MCT-06-0711; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ElShamy WM, 2004, NAT CELL BIOL, V6, P954, DOI 10.1038/ncb1171; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; FORNACE A, 1999, EMBO J, V18, P6845; Gorospe M, 2003, CELL CYCLE, V2, P412, DOI 10.4161/cc.2.5.491; Hammond EM, 2005, BIOCHEM BIOPH RES CO, V331, P718, DOI 10.1016/j.bbrc.2005.03.154; Hao L, 2007, INT J CANCER, V121, P39, DOI 10.1002/ijc.22597; Harrison M, 2004, TRENDS MOL MED, V10, P359, DOI 10.1016/j.molmed.2004.06.010; Hasegawa H, 2009, BRIT J CANCER, V100, P1943, DOI 10.1038/sj.bjc.6605084; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hickson JA, 2007, MOL REPROD DEV, V74, P821, DOI 10.1002/mrd.20688; Hirasawa A, 2003, CLIN CANCER RES, V9, P1995; Hsieh YH, 2007, CANCER RES, V67, P4320, DOI 10.1158/0008-5472.CAN-06-2486; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Im JS, 2008, J BIOL CHEM, V283, P25171, DOI 10.1074/jbc.M802851200; Jin SQ, 2003, ONCOGENE, V22, P8536, DOI 10.1038/sj.onc.1206907; Junttila MR, 2007, ONCOGENE, V26, P5267, DOI 10.1038/sj.onc.1210332; Kang MJ, 2008, GASTROENTEROLOGY, V135, P2030, DOI 10.1053/j.gastro.2008.08.009; Lafarga V, 2009, MOL CELL BIOL, V29, P4341, DOI 10.1128/MCB.00210-09; Latonen L, 2005, BBA-REV CANCER, V1755, P71, DOI 10.1016/j.bbcan.2005.04.003; LI I, 2007, ACTA BIOCH BIOPH SIN, V39, P181; Licata LA, 2010, BREAST CANCER RES TR, V122, P55, DOI 10.1007/s10549-009-0517-8; Lim SJ, 2009, CANCER RES TREAT, V41, P87, DOI 10.4143/crt.2009.41.2.87; Lowe JM, 2010, J BIOL CHEM, V285, P5249, DOI 10.1074/jbc.M109.034579; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; Marechal R, 2009, EXPERT REV ANTICANC, V9, P1439, DOI [10.1586/era.09.119, 10.1586/ERA.09.119]; Mazan-Mamczarz K, 2003, P NATL ACAD SCI USA, V100, P8354, DOI 10.1073/pnas.1432104100; Mikhailov A, 2004, J CELL BIOL, V166, P517, DOI 10.1083/jcb.200405167; Moll UM, 1998, CRIT REV ORAL BIOL M, V9, P23, DOI 10.1177/10454411980090010101; Nakuci E, 2006, EXP CELL RES, V312, P3120, DOI 10.1016/j.yexcr.2006.06.021; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Rodriguez-Bravo V, 2007, CANCER RES, V67, P11648, DOI 10.1158/0008-5472.CAN-07-3100; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Sakuma T, 2008, J NEURO-ONCOL, V88, P143, DOI 10.1007/s11060-008-9559-8; She QB, 2001, CANCER RES, V61, P1604; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sturgill TW, 2008, BIOCHEM BIOPH RES CO, V371, P1, DOI 10.1016/j.bbrc.2008.04.002; Suarez-Cuervo C, 2004, CLIN EXP METASTAS, V21, P525, DOI 10.1007/s10585-004-3503-x; Sykes SM, 2009, J BIOL CHEM, V284, P20197, DOI 10.1074/jbc.M109.026096; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; Tong X, 2009, MOL CARCINOGEN, V48, P118, DOI 10.1002/mc.20460; Tran H, 2003, MOL CELL BIOL, V23, P7177, DOI 10.1128/MCB.23.20.7177-7188.2003; Wang SL, 2006, CANCER RES, V66, P6982, DOI 10.1158/0008-5472.CAN-06-0511; Yamaguchi H, 2005, BIOCHEMISTRY-US, V44, P5285, DOI 10.1021/bi0476634; YAO KM, 1993, J NEUROBIOL, V24, P723, DOI 10.1002/neu.480240604	51	24	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	38					5274	5285		10.1038/onc.2010.262	http://dx.doi.org/10.1038/onc.2010.262			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	653KE	20622893				2022-12-17	WOS:000282089100006
J	Munro, AF; Cameron, DA; Bartlett, JMS				Munro, A. F.; Cameron, D. A.; Bartlett, J. M. S.			Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge	ONCOGENE			English	Review						HER2; TOP2A; anthracyclines; breast cancer	TOPOISOMERASE-II-ALPHA; IN-SITU HYBRIDIZATION; ADJUVANT CHEMOTHERAPY; GENE AMPLIFICATION; TISSUE INHIBITOR; RANDOMIZED-TRIAL; PREMENOPAUSAL WOMEN; HIGH-RISK; EXPRESSION; HER2	The search for a predictive marker of sensitivity to anthracycline-based chemotherapy has proven challenging. Despite human epidermal growth factor receptor 2 (HER2) being a strong prognostic marker in breast cancer, the only therapies with which there is a recognized functional link to the HER2 oncogene are those directly targeting the molecule itself. Despite this, HER2 has been extensively assessed as a predictive marker in a variety of chemotherapy regimens including anthracyclines. Analysis of anthracycline response in patients with HER2 amplification has given conflicting results. This led to the suggestion that HER2 amplification was acting as a surrogate for the gene encoding topoisomerase II alpha (TOP2A), a direct cellular target of anthracyclines. Despite an attractive functional link between TOP2A and anthracyclines, published studies have failed to show strong evidence of an interaction between TOP2A genetic aberrations and anthracycline response. A number of other biomarkers have also been assessed for their role in predicting anthracycline response, including TP53 (tumour protein 53) and BRCA1 (breast cancer 1, early onset), together with an increasing emergence of gene expression profiling to produce predictive signatures of response. Moreover, recent evidence has emerged from presentations suggesting new candidate markers of response that warrant further investigation: Chr17CEP duplication and tissue inhibitor of metalloproteases 1. This review will discuss research into HER2 and TOP2A as predictive markers of anthracycline response and will focus on current research into other possible candidate predictive markers. Oncogene (2010) 29, 5231-5240; doi:10.1038/onc.2010.286; published online 2 August 2010	[Munro, A. F.; Cameron, D. A.; Bartlett, J. M. S.] Western Gen Hosp, Edinburgh Canc Res Ctr, Endocrine Canc Grp, Edinburgh EH4 2XR, Midlothian, Scotland	University of Edinburgh	Bartlett, JMS (corresponding author), Western Gen Hosp, Edinburgh Canc Res Ctr, Endocrine Canc Grp, Crewe Rd S, Edinburgh EH4 2XR, Midlothian, Scotland.	John.Bartlett@ed.ac.uk	Cameron, David A/C-7781-2013	Cameron, David A/0000-0002-2717-7979				Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Andersen CL, 2002, AM J PATHOL, V161, P73, DOI 10.1016/S0002-9440(10)64158-2; Arriola E, 2008, LAB INVEST, V88, P491, DOI 10.1038/labinvest.2008.19; Bartlett J, 2009, CANCER RES, V69, P45; BARTLETT JM, 2009, CANCER RES, V69, P6059; Bartlett JMS, 2001, J PATHOL, V195, P422, DOI 10.1002/path.971; BARTLETT JMS, 2008, J CLIN ONCOL, V26, P1; Bartlett JMS, 2010, LANCET ONCOL, V11, P266, DOI 10.1016/S1470-2045(10)70006-1; Bertheau P, 2002, LANCET, V360, P852, DOI 10.1016/S0140-6736(02)09969-5; Bertheau P, 2007, PLOS MED, V4, P585, DOI 10.1371/journal.pmed.0040090; Bhargava R, 2005, AM J CLIN PATHOL, V123, P889, DOI 10.1309/PCFK8YTQPYWD534F; Bidard FC, 2008, ANN ONCOL, V19, P1261, DOI 10.1093/annonc/mdn039; Biganzoli L, 2007, CRIT REV ONCOL HEMAT, V62, P1, DOI 10.1016/j.critrevonc.2006.10.004; Bonnefoi Herve, 2007, Lancet Oncol, V8, P1071, DOI 10.1016/S1470-2045(07)70345-5; BORG A, 1991, ONCOGENE, V6, P137; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; CERSOSIMO RJ, 1986, J CLIN ONCOL, V4, P425, DOI 10.1200/JCO.1986.4.3.425; Cheung BW, 2005, CANCER RES, V65, P1450, DOI 10.1158/0008-5472.CAN-04-0567; Cortes-Funes H, 2007, CARDIOVASC TOXICOL, V7, P56, DOI 10.1007/s12012-007-0015-3; Davidsen ML, 2006, BRIT J CANCER, V95, P1114, DOI 10.1038/sj.bjc.6603378; Del Mastro L, 2005, BRIT J CANCER, V93, P7, DOI 10.1038/sj.bjc.6602660; Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370; Di Leo A, 2007, ANN ONCOL, V18, P997, DOI 10.1093/annonc/mdm075; Di Leo A, 2004, BREAST CANCER RES TR, V86, P197, DOI 10.1023/B:BREA.0000036783.88387.47; Di Leo A, 2002, CLIN CANCER RES, V8, P1107; Di Leo A, 2001, ANN ONCOL, V12, P1081, DOI 10.1023/A:1011669223035; Di Leo A, 2009, CANCER RES, V69, P705; Di Leo Angelo, 2003, Clin Breast Cancer, V4, P179; Du YL, 2006, BIOCHEM BIOPH RES CO, V345, P1092, DOI 10.1016/j.bbrc.2006.04.172; Eifel P, 2001, JNCI-J NATL CANCER I, V93, P979; Ejlertsen B, 2010, J CLIN ONCOL, V28, P984, DOI 10.1200/JCO.2009.24.1166; Fedier A, 2003, INT J ONCOL, V22, P1169; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Fraser JA, 2003, BRIT J CANCER, V88, P1263, DOI 10.1038/sj.bjc.6600863; Fung MKL, 2006, BRIT J CANCER, V95, P475, DOI 10.1038/sj.bjc.6603284; Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028; Greenberg RA, 2008, CHROMOSOMA, V117, P305, DOI 10.1007/s00412-008-0154-8; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Holten-Andersen MN, 2000, CLIN CANCER RES, V6, P4292; Hutchins LF, 2005, J CLIN ONCOL, V23, P8313, DOI 10.1200/JCO.2005.08.071; Jarvinen TAH, 2003, CYTOPATHOLOGY, V14, P309, DOI 10.1046/j.0956-5507.2003.00105.x; Jarvinen TAH, 1999, GENE CHROMOSOME CANC, V26, P142; Jarvinen TAH, 2000, AM J PATHOL, V156, P839, DOI 10.1016/S0002-9440(10)64952-8; Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291; JOHN RG, 2003, CANCER, V97, P527; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Kim HT, 2008, MOL CELLS, V25, P457; KLIJN JGM, 1993, ANN NY ACAD SCI, V698, P85, DOI 10.1111/j.1749-6632.1993.tb17193.x; Knoop AS, 2005, J CLIN ONCOL, V23, P7483, DOI 10.1200/JCO.2005.11.007; Levine MN, 2005, J CLIN ONCOL, V23, P5166, DOI 10.1200/JCO.2005.09.423; Levine MN, 1998, J CLIN ONCOL, V16, P2651, DOI 10.1200/JCO.1998.16.8.2651; Lipton A, 2008, J CLIN ONCOL, V26, P2653, DOI 10.1200/JCO.2007.15.4336; McArthur HL, 2009, CANCER RES, V69, P2023; McClendon AK, 2007, MUTAT RES-FUND MOL M, V623, P83, DOI 10.1016/j.mrfmmm.2007.06.009; McCullough Shaun D., 2007, V11, P31; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; Murphy CG, 2010, CANCER J, V16, P39, DOI 10.1097/PPO.0b013e3181cf0204; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nielsen KV, 2008, ACTA ONCOL, V47, P725, DOI 10.1080/02841860801995396; Norton Larry, 2008, Breast Dis, V29, P27; O'Malley FP, 2009, JNCI-J NATL CANCER I, V101, P644, DOI 10.1093/jnci/djp067; Olivier M, 2009, CANCER GENE THER, V16, P1, DOI 10.1038/cgt.2008.69; OMALLEY FP, 2006, ASCO M, V24, P533; Orsetti B, 2004, CANCER RES, V64, P6453, DOI 10.1158/0008-5472.CAN-04-0756; Paik S, 2000, J NATL CANCER I, V92, P1991, DOI 10.1093/jnci/92.24.1991; Paik SM, 1998, JNCI-J NATL CANCER I, V90, P1361, DOI 10.1093/jnci/90.18.1361; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; Pellikainen JM, 2004, CLIN CANCER RES, V10, P7621, DOI 10.1158/1078-0432.CCR-04-1061; Poole CJ, 2006, NEW ENGL J MED, V355, P1851, DOI 10.1056/NEJMoa052084; Pritchard KI, 2008, J CLIN ONCOL, V26, P736, DOI 10.1200/JCO.2007.15.4716; Pritchard KI, 2006, NEW ENGL J MED, V354, P2103, DOI 10.1056/NEJMoa054504; Rahko E, 2003, EUR J CANCER, V39, P447, DOI 10.1016/S0959-8049(02)00499-9; Ree AH, 1997, CLIN CANCER RES, V3, P1623; Reinholz MM, 2007, BREAST CANCER RES TR, V106, pS11; RIED T, 1995, CANCER RES, V55, P5415; Schmidt M, 2009, CANCER RES, V69, P2695, DOI 10.1158/0008-5472.CAN-08-4013; Schrohl AS, 2006, CLIN CANCER RES, V12, P7054, DOI 10.1158/1078-0432.CCR-06-0950; Schrohl AS, 2004, CLIN CANCER RES, V10, P2289, DOI 10.1158/1078-0432.CCR-03-0360; Slamon D, 2005, BREAST CANCER RES TR, V94, pS5; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Small GW, 2003, J PHARMACOL EXP THER, V307, P861, DOI 10.1124/jpet.103.055806; Spencer DMS, 2003, ONCOL RES, V13, P479, DOI 10.3727/000000003108748009; Taatjes DJ, 1999, CHEM RES TOXICOL, V12, P588, DOI 10.1021/tx990008q; Tanner M, 2006, J CLIN ONCOL, V24, P2428, DOI 10.1200/JCO.2005.02.9264; Teschendorff AE, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r157; Todorovic-Rakovic N, 2009, DIS MARKERS, V26, P171, DOI 10.3233/DMA-2009-0628; Tordai A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2088; Tovey SM, 2004, BREAST CANCER RES, V6, pR246, DOI 10.1186/bcr783; Vincent-Salomon A, 2004, EUR J CANCER, V40, P1502, DOI 10.1016/j.ejca.2004.03.014; Wurtz SO, 2008, ACTA ONCOL, V47, P580, DOI 10.1080/02841860802022976	91	24	30	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	38					5231	5240		10.1038/onc.2010.286	http://dx.doi.org/10.1038/onc.2010.286			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	653KE	20676126				2022-12-17	WOS:000282089100002
J	Le, PU; Angers-Loustau, A; de Oliveira, RMW; Ajlan, A; Brassard, CL; Dudley, A; Brent, H; Siu, V; Trinh, G; Molenkamp, G; Wang, J; Sadr, MS; Bedell, B; Del Maestro, RF; Petrecca, K				Le, P. U.; Angers-Loustau, A.; de Oliveira, R. M. W.; Ajlan, A.; Brassard, C. L.; Dudley, A.; Brent, H.; Siu, V.; Trinh, G.; Moelenkamp, G.; Wang, J.; Sadr, M. Seyed; Bedell, B.; Del Maestro, R. F.; Petrecca, K.			DRR drives brain cancer invasion by regulating cytoskeletal-focal adhesion dynamics	ONCOGENE			English	Article						brain cancer; cytoskeleton; cell invasion	CELL INVASION; MYOSIN-II; MIGRATION; MORPHOGENESIS; MICROTUBULES; SRC	Malignant glioma invasion is a primary cause of brain cancer treatment failure, yet the molecular mechanisms underlying its regulation remain elusive. We developed a novel functional-screening strategy and identified downregulated in renal cell carcinoma (DRR) as a regulator of invasion. We show that DRR drives invasion in vitro and in vivo. We found that while DRR is not expressed in normal glial cells, it is highly expressed in the invasive component of gliomas. Exploring underlying mechanisms, we show that DRR associates with and organizes the actin and microtubular cytoskeletons and that these associations are essential for focal adhesion (FA) disassembly and cell invasion. These findings identify DRR as a new cytoskeletal crosslinker that regulates FA dynamics and cell movement. Oncogene (2010) 29, 4636-4647; doi:10.1038/onc.2010.216; published online 14 June 2010	[Le, P. U.; Angers-Loustau, A.; de Oliveira, R. M. W.; Ajlan, A.; Brassard, C. L.; Dudley, A.; Brent, H.; Siu, V.; Trinh, G.; Moelenkamp, G.; Wang, J.; Sadr, M. Seyed; Bedell, B.; Del Maestro, R. F.; Petrecca, K.] McGill Univ, Dept Neurol & Neurosurg, Montreal Neurol Inst & Hosp, Montreal, PQ H3A 2B4, Canada	McGill University	Petrecca, K (corresponding author), McGill Univ, Dept Neurol & Neurosurg, Montreal Neurol Inst & Hosp, 3801 Univ Ave,Suite 109C, Montreal, PQ H3A 2B4, Canada.	kevin.petrecca@mcgill.ca		Angers-Loustau, Alexandre/0000-0003-1425-4143	Goals for Lily; Alex Pavanel Family; Franco Di Giovanni Funds for Brain Tumor Research; Montreal English School Board; B-Strong Foundation; Montreal Neurological Institute; Canadian Institute of Health Research; National Cancer Institute of Canada	Goals for Lily; Alex Pavanel Family; Franco Di Giovanni Funds for Brain Tumor Research; Montreal English School Board; B-Strong Foundation; Montreal Neurological Institute; Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); National Cancer Institute of Canada(Canadian Cancer Society (CCS))	We are grateful to Carmen Sabau for her technical expertise. This work was supported by Goals for Lily, the Alex Pavanel Family, the Franco Di Giovanni Funds for Brain Tumor Research, the Montreal English School Board, the B-Strong Foundation to RFDM, and the Montreal Neurological Institute to KP. RMWO was supported by the Canadian Institute of Health Research doctoral fellowship. AAL was supported by the National Cancer Institute of Canada Terry Fox sStudentship.	Beadle C, 2008, MOL BIOL CELL, V19, P3357, DOI 10.1091/mbc.E08-03-0319; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Del Duca D, 2004, J NEURO-ONCOL, V67, P295, DOI 10.1023/B:NEON.0000024220.07063.70; Dirks PB, 2008, J CLIN ONCOL, V26, P2916, DOI 10.1200/JCO.2008.17.6792; Ezratty EJ, 2005, NAT CELL BIOL, V7, P581, DOI 10.1038/ncb1262; Fernandez C, 2003, NEUROSURGERY, V53, P544, DOI 10.1227/01.NEU.0000079330.01541.6E; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Giese A, 1996, INT J CANCER, V67, P275, DOI 10.1002/(SICI)1097-0215(19960717)67:2<275::AID-IJC20>3.0.CO;2-9; Johnston ALM, 2007, PLOS BIOL, V5, P1723, DOI 10.1371/journal.pbio.0050212; Kaverina I, 1998, J CELL BIOL, V142, P181, DOI 10.1083/jcb.142.1.181; Kaverina I, 1999, J CELL BIOL, V146, P1033, DOI 10.1083/jcb.146.5.1033; Kleihues, 2000, WHO CLASSIFICATION T; Krylyshkina O, 2003, J CELL BIOL, V161, P853, DOI 10.1083/jcb.200301102; Krylyshkina O, 2002, J CELL BIOL, V156, P349, DOI 10.1083/jcb.200105051; LAUUFFENBURGER DA, 1996, CELL, V84, P359; Louis DN, 2002, CANCER CELL, V1, P125, DOI 10.1016/S1535-6108(02)00040-5; Palazzo Alexander F, 2002, Sci STKE, V2002, ppe31, DOI 10.1126/stke.2002.139.pe31; PEDERSEN PH, 1995, INT J CANCER, V62, P767, DOI 10.1002/ijc.2910620620; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703-599; Salhia B, 2006, EXPERT REV MOL DIAGN, V6, P613, DOI 10.1586/14737159.6.4.613; van den Boom J, 2006, INT J CANCER, V119, P2330, DOI 10.1002/ijc.22108; VERKHOVSKY AB, 1995, J CELL BIOL, V131, P989, DOI 10.1083/jcb.131.4.989; Wang L, 2000, GENE CHROMOSOME CANC, V27, P1, DOI 10.1002/(SICI)1098-2264(200001)27:1<1::AID-GCC1>3.0.CO;2-6; Wang LM, 2008, PLOS BIOL, V6, P2496, DOI 10.1371/journal.pbio.0060289; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wu XY, 2008, CELL, V135, P137, DOI 10.1016/j.cell.2008.07.045; Yamana N, 2006, MOL CELL BIOL, V26, P6844, DOI 10.1128/MCB.00283-06; Zijlstra A, 2008, CANCER CELL, V13, P221, DOI 10.1016/j.ccr.2008.01.031	29	24	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2010	29	33					4636	4647		10.1038/onc.2010.216	http://dx.doi.org/10.1038/onc.2010.216			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	641LK	20543869				2022-12-17	WOS:000281127400003
J	Talotta, F; Mega, T; Bossis, G; Casalino, L; Basbous, J; Jariel-Encontre, I; Piechaczyk, M; Verde, P				Talotta, F.; Mega, T.; Bossis, G.; Casalino, L.; Basbous, J.; Jariel-Encontre, I.; Piechaczyk, M.; Verde, P.			Heterodimerization with Fra-1 cooperates with the ERK pathway to stabilize c-Jun in response to the RAS oncoprotein	ONCOGENE			English	Article						c-Jun stability; FRA-1; heterodimerization; RAS transformation	TRANSCRIPTIONAL ACTIVATION; PROTEASOMAL DEGRADATION; THYROID-CELLS; AP-1; FOS; PHOSPHORYLATION; JNK; UBIQUITINATION; TRANSFORMATION; INVASIVENESS	Multiple tumorigenic pathways converge on the activating protein-1 (AP-1) family of dimeric transcription complexes by affecting transcription, mRNA decay, posttranslational modifications, as well as stability of its JUN and FOS components. Several mechanisms have been implicated in the phosphorylation-and ubiquitylation-dependent control of c-Jun protein stability. Although its dimer composition has a major role in the regulation of AP-1, little is known about the influence of heterodimerization partners on the half-life of c-Jun. The FOS family member Fra-1 is overexpressed in various tumors and cancer cell lines wherein it controls motility, invasiveness, cell survival and cell division. Oncogene-induced accumulation of Fra-1 results from both increased transcription and phosphorylation-dependent stabilization of the protein. In this report, we describe a novel role of Fra-1 as a posttranslational regulator of c-Jun. By using both constitutively and inducible transformed rat thyroid cell lines, we found that c-Jun is stabilized in response to RAS oncoprotein expression. This stabilization requires the activity of the extracellular signal-related kinase (ERK) pathway, along with c-Jun heterodimerization with Fra-1. In particular, heterodimerization with Fra-1 inhibits c-Jun breakdown by a mechanism dependent on the phosphorylation of the Fra-1 C-terminal domain that positively controls the stability of the protein in response to ERK signaling. Therefore, Fra-1 modulates AP-1 dimer composition by promoting the accumulation of c-Jun in response to oncogenic RAS signaling. Oncogene (2010) 29, 4732-4740; doi:10.1038/onc.2010.211; published online 14 June 2010	[Talotta, F.; Mega, T.; Casalino, L.; Verde, P.] CNR, Inst Genet & Biophys A Buzzati Traverso, I-80131 Naples, Italy; [Bossis, G.; Basbous, J.; Jariel-Encontre, I.; Piechaczyk, M.] Univ Montpellier I & II, Inst Genet Mol Montpellier, CNRS, UMR 5535, Montpellier, France	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Verde, P (corresponding author), CNR, Inst Genet & Biophys A Buzzati Traverso, I-80131 Naples, Italy.	verde@igb.cnr.it	Basbous, Jihane/AAQ-2040-2021; Casalino, Laura/C-1506-2015; PIECHACZYK, Marc/E-7896-2013; Bossis, Guillaume/C-7172-2012	Basbous, Jihane/0000-0002-3943-627X; Casalino, Laura/0000-0002-2557-0443; PIECHACZYK, Marc/0000-0003-1367-2597; bossis, guillaume/0000-0002-3349-8250	AIRC (Associazione Italiana per la Ricerca sul Cancro); AICR (Association for International Cancer Research, UK); MIUR (Ministero dell'Istruzione, Universita e Ricerca); INCA; PAI 'Galileo'	AIRC (Associazione Italiana per la Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro); AICR (Association for International Cancer Research, UK); MIUR (Ministero dell'Istruzione, Universita e Ricerca)(Ministry of Education, Universities and Research (MIUR)); INCA(Institut National du Cancer (INCA) France); PAI 'Galileo'	We thank Roberto Di Lauro for the FRTL-5<SUP>ER-RAS</SUP> cell line, and Dirk Bohmann, Claus Nerlov and Latifa Bakiri for expression vectors encoding various c-Jun derivatives. We also thank Ingram Iaccarino for critical reading of this paper. This work was supported by grants to Pasquale Verde from AIRC (Associazione Italiana per la Ricerca sul Cancro), AICR (Association for International Cancer Research, UK) and PRIN-MIUR (Ministero dell'Istruzione, Universita e Ricerca). Marc Piechaczyk's group is an 'Equipe Labellisee' of the French 'Ligue Nationale contre le Cancer'. Jihane Basbous was supported by an INCA contract. Exchanges between the two laboratories received support of the PAI 'Galileo'.	Adiseshaiah P, 2008, BIOCHEM BIOPH RES CO, V371, P304, DOI 10.1016/j.bbrc.2008.04.063; Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; Basbous J, 2007, MOL CELL BIOL, V27, P3936, DOI 10.1128/MCB.01776-06; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; Bossis G, 2003, MOL CELL BIOL, V23, P7425, DOI 10.1128/MCB.23.20.7425-7436.2003; Casalino L, 2003, MOL CELL BIOL, V23, P4401, DOI 10.1128/MCB.23.12.4401-4415.2003; Casalino L, 2007, EMBO J, V26, P1878, DOI 10.1038/sj.emboj.7601617; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; De Vita G, 2005, MOL ENDOCRINOL, V19, P76, DOI 10.1210/me.2004-0172; Debinski W, 2005, MOL CANCER RES, V3, P237; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; ELBAHASSI M, 2004, CLIN EXP METASTAS, V21, P293; Ferrara P, 2003, ONCOGENE, V22, P1461, DOI 10.1038/sj.onc.1206266; Fuchs SY, 1999, MOL CELL BIOL, V19, P3289; Fuchs SY, 1996, ONCOGENE, V13, P1531; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Liu H, 2006, EMBO J, V25, P1058, DOI 10.1038/sj.emboj.7601020; Malnou CE, 2007, J BIOL CHEM, V282, P31046, DOI 10.1074/jbc.M702833200; Malnou CE, 2010, J BIOL CHEM, V285, P6552, DOI 10.1074/jbc.M109.032680; Mariani O, 2007, CANCER CELL, V11, P361, DOI 10.1016/j.ccr.2007.02.007; Morton S, 2003, EMBO J, V22, P3876, DOI 10.1093/emboj/cdg388; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Talotta F, 2009, ONCOGENE, V28, P73, DOI 10.1038/onc.2008.370; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Verde P, 2007, CELL CYCLE, V6, P2633, DOI 10.4161/cc.6.21.4850; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005	37	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	33					4732	4740		10.1038/onc.2010.211	http://dx.doi.org/10.1038/onc.2010.211			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	641LK	20543861				2022-12-17	WOS:000281127400012
J	Yousef, AF; Fonseca, GJ; Pelka, P; Ablack, JNG; Walsh, C; Dick, FA; Bazett-Jones, DP; Shaw, GS; Mymryk, JS				Yousef, A. F.; Fonseca, G. J.; Pelka, P.; Ablack, J. N. G.; Walsh, C.; Dick, F. A.; Bazett-Jones, D. P.; Shaw, G. S.; Mymryk, J. S.			Identification of a molecular recognition feature in the E1A oncoprotein that binds the SUMO conjugase UBC9 and likely interferes with polySUMOylation	ONCOGENE			English	Article						E1A; UBC9; SUMO; adenovirus	PML NUCLEAR-BODIES; UBIQUITIN LIGASE; SEQUENCE-ANALYSIS; ADENOVIRUS E1A; PROTEIN; YEAST; MOTIF; RNF4; TRANSFORMATION; SUMOYLATION	Hub proteins have central roles in regulating cellular processes. By targeting a single cellular hub, a viral oncogene may gain control over an entire module in the cellular interaction network that is potentially comprised of hundreds of proteins. The adenovirus E1A oncoprotein is a viral hub that interacts with many cellular hub proteins by short linear motifs/molecular recognition features (MoRFs). These interactions transform the architecture of the cellular protein interaction network and virtually reprogram the cell. To identify additional MoRFs within E1A, we screened portions of E1A for their ability to activate yeast pseudohyphal growth or differentiation. This identified a novel functional region within E1A conserved region 2 comprised of the sequence EVIDLT. This MoRF is necessary and sufficient to bind the N-terminal region of the SUMO conjugase UBC9, which also interacts with SUMO noncovalently and is involved in polySUMOylation. Our results suggest that E1A interferes with polySUMOylation, but not with monoSUMOylation. These data provide the first insight into the consequences of the interaction of E1A with UBC9, which was initially described in 1996. We further demonstrate that polySUMOylation regulates pseudohyphal growth and promyelocytic leukemia body reorganization by E1A. In conclusion, the interaction of the E1A oncogene with UBC9 mimics the normal binding between SUMO and UBC9 and represents a novel mechanism to modulate polySUMOylation. Oncogene (2010) 29, 4693-4704; doi:10.1038/onc.2010.226; published online 14 June 2010	[Yousef, A. F.; Fonseca, G. J.; Ablack, J. N. G.; Walsh, C.; Mymryk, J. S.] Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 4L6, Canada; [Pelka, P.; Dick, F. A.; Mymryk, J. S.] Univ Western Ontario, Dept Oncol, London Reg Canc Program, London, ON N6A 4L6, Canada; [Dick, F. A.; Shaw, G. S.] Univ Western Ontario, Dept Biochem, London, ON N6A 4L6, Canada; [Bazett-Jones, D. P.] Hosp Sick Children, Program Genet & Genome Biol, Toronto, ON M5G 1X8, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Mymryk, JS (corresponding author), Univ Western Ontario, Dept Microbiol, London Reg Canc Program, 790 Commissioners Rd E, London, ON N6A 4L6, Canada.	jmymryk@uwo.ca	Shaw, Gary S./C-7656-2009	Shaw, Gary S./0000-0002-4685-9625; Yousef, Ahmed F./0000-0001-5734-489X	Canadian Institutes of Health Research [MOP-75647]; OGS award; OGSST award	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); OGS award; OGSST award	This work was supported by a grant from the Canadian Institutes of Health Research to JSM (MOP-75647). AFY and PP were supported by CIHR Strategic Training Program in Cancer Research and Technology Transfer awards. GJF and JNA held OGS and OGSST awards. We thank Drs C Brandl, R Hay, J Taylor, K Uzunova, J Dohmen, A Strunnikov, G Fink, E Yeh and O Janne for generously providing reagents essential for this study.	Ansieau S, 2002, J BIOL CHEM, V277, P4906, DOI 10.1074/jbc.M110078200; Avvakumov N, 2004, VIROLOGY, V329, P477, DOI 10.1016/j.virol.2004.08.007; Avvakumov N, 2002, J VIROL, V76, P7968, DOI 10.1128/JVI.76.16.7968-7975.2002; BAYLEY ST, 1994, INT J ONCOL, V5, P425; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Bernardi R, 2007, NAT REV MOL CELL BIO, V8, P1006, DOI 10.1038/nrm2277; Bylebyl GR, 2003, J BIOL CHEM, V278, P44113, DOI 10.1074/jbc.M308357200; Capili AD, 2007, J MOL BIOL, V369, P608, DOI 10.1016/j.jmb.2007.04.006; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; Dunnebier T, 2009, INT J CANCER, V125, P596, DOI 10.1002/ijc.24286; Eskiw CH, 2003, J CELL SCI, V116, P4455, DOI 10.1242/jcs.00758; Ferrari R, 2008, SCIENCE, V321, P1086, DOI 10.1126/science.1155546; Fraser HB, 2002, SCIENCE, V296, P750, DOI 10.1126/science.1068696; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Galanty Y, 2009, NATURE, V462, P935, DOI 10.1038/nature08657; Gandhi TKB, 2006, NAT GENET, V38, P285, DOI 10.1038/ng1747; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Han JDJ, 2004, NATURE, V430, P88, DOI 10.1038/nature02555; Hateboer G, 1996, J BIOL CHEM, V271, P25906, DOI 10.1074/jbc.271.42.25906; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Knipscheer P, 2008, MOL CELL, V31, P371, DOI 10.1016/j.molcel.2008.05.022; Knipscheer P, 2007, EMBO J, V26, P2797, DOI 10.1038/sj.emboj.7601711; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Lin DH, 2002, J BIOL CHEM, V277, P21740, DOI 10.1074/jbc.M108418200; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; Maslov S, 2002, SCIENCE, V296, P910, DOI 10.1126/science.1065103; Mo YY, 2005, EXPERT OPIN THER TAR, V9, P1203, DOI 10.1517/14728222.9.6.1203; Mo YY, 2004, CANCER RES, V64, P2793, DOI 10.1158/0008-5472.CAN-03-2410; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Morris JR, 2009, NATURE, V462, P886, DOI 10.1038/nature08593; Mullen JR, 2008, J BIOL CHEM, V283, P19912, DOI 10.1074/jbc.M802690200; Mymryk JS, 1997, BIOCHEM CELL BIOL, V75, P95, DOI 10.1139/bcb-75-2-95; O'Connor MJ, 1999, J VIROL, V73, P3574; Pelka P, 2008, J VIROL, V82, P7252, DOI 10.1128/JVI.00104-08; Prudden J, 2007, EMBO J, V26, P4089, DOI 10.1038/sj.emboj.7601838; Prudden J, 2009, NAT STRUCT MOL BIOL, V16, P509, DOI 10.1038/nsmb.1582; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Rupp S, 1999, EMBO J, V18, P1257, DOI 10.1093/emboj/18.5.1257; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schwienhorst I, 2000, MOL GEN GENET, V263, P771, DOI 10.1007/s004380000254; Sekiyama N, 2010, PROTEINS, V78, P1491, DOI 10.1002/prot.22667; Song J, 2005, J BIOL CHEM, V280, P40122, DOI 10.1074/jbc.M507059200; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; Stelzl U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029; Sun H, 2007, EMBO J, V26, P4102, DOI 10.1038/sj.emboj.7601839; Tatham MH, 2008, NAT CELL BIOL, V10, P538, DOI 10.1038/ncb1716; TRENTIN JJ, 1962, SCIENCE, V137, P835, DOI 10.1126/science.137.3533.835; Uzunova K, 2007, J BIOL CHEM, V282, P34167, DOI 10.1074/jbc.M706505200; Wang JH, 2007, MOL CELL, V27, P228, DOI 10.1016/j.molcel.2007.05.023; Weisshaar SR, 2008, FEBS LETT, V582, P3174, DOI 10.1016/j.febslet.2008.08.008; Xie Y, 2007, J BIOL CHEM, V282, P34176, DOI 10.1074/jbc.M706025200; Yousef AF, 2008, INT J CANCER, V122, P942, DOI 10.1002/ijc.23174; Zhang ZY, 2001, MOL BIOL CELL, V12, P699, DOI 10.1091/mbc.12.3.699; Zhu S, 2010, ONCOGENE, V29, P1763, DOI 10.1038/onc.2009.459	58	24	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2010	29	33					4693	4704		10.1038/onc.2010.226	http://dx.doi.org/10.1038/onc.2010.226			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	641LK	20543865				2022-12-17	WOS:000281127400008
J	Liu, PS; Jong, TH; Maa, MC; Leu, TH				Liu, P-S; Jong, T-H; Maa, M-C; Leu, T-H			The interplay between Eps8 and IRSp53 contributes to Src-mediated transformation	ONCOGENE			English	Article						IRSp53; Eps8; v-Src; Stat3; oncogenic proteins; cancer cells	TYROSINE KINASE SUBSTRATE; MISSING-IN-METASTASIS; INSULIN-RECEPTOR; STRUCTURAL BASIS; HOMOLOGY DOMAIN; SH3 DOMAIN; V-SRC; EXPRESSION; PHOSPHORYLATION; ACTIVATION	As an oncoprotein, Eps8 participates in v-Src-induced cellular transformation. To delineate the underlying mechanism, we conducted a yeast two-hybrid screening and identified IRSp53S, a protein critical in cell mobilization, as one of the Eps8-binding partners from a human brain cDNA library. The association was mediated by the multiple proline-rich regions of Eps8 and the C-terminal SH3-WWB containing domains of IRSp53S. In this study, we observed that Eps8 modulated the expression of IRSp53 in v-Src-transformed cells (IV5), raising the question of whether Eps8/IRSp53 interaction was crucial in carcinogenesis. To address this issue, we generated IV5-expressing irsp53 siRNA cells. Attenuation of IRSp53 reduced cell proliferation of IV5 in culture dish and tumor formation in mice, which could be partly rescued by ectopically expressed human IRSp53S. In addition, IRSp53 knockdown impaired activity of phosphatidylinositol 3-kinase (as reflected by Pi-Ser473 AKT) and Stat3 (as reflected by Pi-Tyr705 Stat3), and reduced cyclin D1 expression that culminated to impede G(1)-phase cell-cycle progression. Ectopically expressed human IRSp53S, but not its Eps8-binding defective mutants (that is, Delta 363 and PPPDA), rescued these defects and partly restored cell proliferation. Remarkably, through activation of Src, EGF increased the formation of Eps8/IRSp53 complex and Stat3 activation in HeLa cells. With these results, we show for the first time that IRSp53, through its interaction with Eps8, not only affects cell migration but also dictates cellular growth in cancer cells. Oncogene (2010) 29, 3977-3989; doi:10.1038/onc.2010.144; published online 26 April 2010	[Jong, T-H; Leu, T-H] Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan; [Liu, P-S; Leu, T-H] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 70101, Taiwan; [Maa, M-C] China Med Univ, Inst Med Sci, Taichung, Taiwan; [Maa, M-C] China Med Univ, Inst Mol Syst Biomed, Taichung, Taiwan; [Leu, T-H] Natl Cheng Kung Univ, Ctr Gene Regulat & Signal Transduct Res, Tainan 70101, Taiwan	National Cheng Kung University; National Cheng Kung University; China Medical University Taiwan; China Medical University Taiwan; National Cheng Kung University	Leu, TH (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, 1 Univ Rd, Tainan 70101, Taiwan.	mcmaa@mail.cmu.edu.tw; tzengleu@mail.ncku.edu.tw			National Science Council [NSC98-2311-B-039-002-MY3, NSC97-2320-B-006-024-MY3, NSC 94-3112-B-001-003, NSC 94-3112-B-001-018-Y]; NHRI [NHRI-EX-98-9828BI]; Taiwan Department of Health Clinical Trial and Research Center of Excellence [DOH99-TD-B-111-004]; China Medical University [CMU98-C-05]	National Science Council(Ministry of Science and Technology, Taiwan); NHRI(National Health Research Institutes - Taiwan); Taiwan Department of Health Clinical Trial and Research Center of Excellence; China Medical University(China Medical University)	This work was supported by National Science Council grants to M-CM (NSC98-2311-B-039-002-MY3) and T-HL (NSC97-2320-B-006-024-MY3). Additional support came from NHRI (NHRI-EX-98-9828BI to T-H Leu), Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH99-TD-B-111-004 to M-C Maa) and China Medical University (CMU98-C-05 to M-C Maa). The DNA constructs of pLKO.1-mirsp53-b and pLKO.1-mirsp53-c were provided by the National RNAi Core Facility located at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica, supported by the National Research Program for Genomic Medicine Grants of NSC (NSC 94-3112-B-001-003 and NSC 94-3112-B-001-018-Y).	Abbott MA, 1999, J NEUROSCI, V19, P7300, DOI 10.1523/JNEUROSCI.19-17-07300.1999; Aitio O, 2008, J MOL BIOL, V382, P167, DOI 10.1016/j.jmb.2008.07.008; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Chen YJ, 2008, MOL CANCER THER, V7, P1376, DOI 10.1158/1535-7163.MCT-07-2388; Disanza A, 2004, NAT CELL BIOL, V6, P1180, DOI 10.1038/ncb1199; Funato Y, 2004, CANCER RES, V64, P5237, DOI 10.1158/0008-5472.CAN-04-0327; Gallo R, 1997, ONCOGENE, V15, P1929, DOI 10.1038/sj.onc.1201344; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; Lee SH, 2007, STRUCTURE, V15, P145, DOI 10.1016/j.str.2006.12.005; Leu TH, 2004, J BIOL CHEM, V279, P9875, DOI 10.1074/jbc.M309884200; Maa MC, 1998, BIOCHEM BIOPH RES CO, V251, P344, DOI 10.1006/bbrc.1998.9464; Maa MC, 1999, BBA-MOL CELL RES, V1450, P341, DOI 10.1016/S0167-4889(99)00069-5; Maa MC, 2001, ONCOGENE, V20, P106, DOI 10.1038/sj.onc.1204069; Maa MC, 2007, J BIOL CHEM, V282, P19399, DOI 10.1074/jbc.M610280200; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Mattila PK, 2007, J CELL BIOL, V176, P953, DOI 10.1083/jcb.200609176; Millard TH, 2005, EMBO J, V24, P240, DOI 10.1038/sj.emboj.7600535; Miyahara A, 2003, J HUM GENET, V48, P410, DOI 10.1007/s10038-003-0047-x; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Oda K, 1999, CYTOGENET CELL GENET, V84, P75, DOI 10.1159/000015219; Okamura-Oho Y, 1999, HUM MOL GENET, V8, P947, DOI 10.1093/hmg/8.6.947; Okamura-Oho Y, 2001, BIOCHEM BIOPH RES CO, V289, P957, DOI 10.1006/bbrc.2001.6102; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Scita G, 2008, TRENDS CELL BIOL, V18, P52, DOI 10.1016/j.tcb.2007.12.002; Silva CM, 2004, ONCOGENE, V23, P8017, DOI 10.1038/sj.onc.1208159; Suetsugu S, 2006, J BIOL CHEM, V281, P35347, DOI 10.1074/jbc.M606814200; Xu M, 2009, ENDOCRINOLOGY, V150, P2064, DOI 10.1210/en.2008-1265; Yap LF, 2009, ONCOGENE, V28, P2524, DOI 10.1038/onc.2009.105; Yeh TC, 1996, J BIOL CHEM, V271, P2921, DOI 10.1074/jbc.271.6.2921	30	24	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	2010	29	27					3977	3989		10.1038/onc.2010.144	http://dx.doi.org/10.1038/onc.2010.144			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	621SL	20418908				2022-12-17	WOS:000279603200010
J	Fritz, RD; Varga, Z; Radziwill, G				Fritz, R. D.; Varga, Z.; Radziwill, G.			CNK1 is a novel Akt interaction partner that promotes cell proliferation through the Akt-FoxO signalling axis	ONCOGENE			English	Article						CNK1; Akt; FoxO; proliferation; oncogenic signalling; breast cancer	RICTOR-MTOR COMPLEX; PROTEIN-KINASE B; NF-KAPPA-B; SCAFFOLD PROTEIN; RAF ACTIVATION; CANCER; DOWNSTREAM; DROSOPHILA; PATHWAY; TARGET	The scaffold proteins connector enhancer of KSR (CNK) participate in Raf-, Rho-and NF-kappa B-dependent signalling and promote cell differentiation and invasion. In this study, we demonstrate that CNK1 downregulation inhibits, whereas CNK1 overexpression stimulates the proliferation of breast cancer cells and human embryonic kidney cells, respectively. This stimulatory effect depends on a functional phosphatidylinositol-3 kinase (PI3K) pathway because treatment of cells with the PI3K inhibitor, LY294002, abrogates CNK1-induced proliferation. CNK1 interacts with the PI3K effector Akt and knockdown of CNK1 decreases Akt activity in breast cancer cells. CNK1 controls Akt-dependent phosphorylation and transcriptional activity of FoxO, which is a negative regulator of proliferation. Consistent with this, CNK1-induced cell proliferation is blocked by FoxO overexpression. Moreover, CNK1 regulates anchorage-independent proliferation and focus formation of breast cancer cells. CNK1 is predominantly localized at the plasma membrane of breast cancer cells, whereas in non-transformed mammary epithelial cells, CNK1 is cytoplasmatic. Accordingly, CNK1 is found preferentially at the plasma membrane in carcinoma in situ and invasive breast cancer tumours compared with normal breast tissue sections. Analysis of multiple breast cancer samples reveals that CNK1-negative tumours show less Akt activity. Thus, CNK1 promotes oncogenic signalling through Akt in breast cancer cell lines and tumours. Oncogene (2010) 29, 3575-3582; doi:10.1038/onc.2010.104; published online 12 April 2010	[Fritz, R. D.; Radziwill, G.] Univ Zurich, Inst Med Virol, Zurich, Switzerland; [Varga, Z.] Univ Zurich Hosp, Inst Clin Pathol, CH-8091 Zurich, Switzerland; [Radziwill, G.] Univ Freiburg, Fac Biol, Freiburg, Germany	University of Zurich; University of Zurich; University Zurich Hospital; University of Freiburg	Radziwill, G (corresponding author), Univ Freiburg, Fac Biol Biochem, Schaenzlestr 1, D-79104 Freiburg, Germany.	gerald.radziwill@biologie.uni-freiburg.de			Cancer League of Zurich; Centre of Biological Signaling Studies (bioss)	Cancer League of Zurich; Centre of Biological Signaling Studies (bioss)	We thank Dr Thorsten Fritzius for providing the FoxO1 and Akt1 m/p expression constructs and Julia Fritz for help with fractionation experiments and critical reading of the paper. We are grateful to Dr Alexandra Trkola for providing the infrastructure. This work was supported by the Cancer League of Zurich and the Centre of Biological Signaling Studies (bioss).	Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Barnett SF, 2005, BIOCHEM J, V385, P399, DOI 10.1042/BJ20041140; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bumeister R, 2004, CURR BIOL, V14, P439, DOI 10.1016/j.cub.2004.02.037; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Claperon A, 2007, ONCOGENE, V26, P3143, DOI 10.1038/sj.onc.1210408; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Douziech M, 2003, EMBO J, V22, P5068, DOI 10.1093/emboj/cdg506; Fritz RD, 2010, MOL CANCER RES, V8, P395, DOI 10.1158/1541-7786.MCR-09-0296; Fritz RD, 2005, BIOCHEM BIOPH RES CO, V338, P1906, DOI 10.1016/j.bbrc.2005.10.168; Fritzius T, 2008, EMBO J, V27, P1399, DOI 10.1038/emboj.2008.67; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Jaffe AB, 2005, CURR BIOL, V15, P405, DOI 10.1016/j.cub.2004.12.082; Jaffe AB, 2004, MOL CELL BIOL, V24, P1736, DOI 10.1128/MCB.24.4.1736-1746.2004; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kasper G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-12; Laberge G, 2005, EMBO J, V24, P487, DOI 10.1038/sj.emboj.7600558; Lanigan TM, 2003, FASEB J, V17, P2048, DOI 10.1096/fj.02-1096com; Lopez-Ilasaca MA, 2005, FEBS LETT, V579, P648, DOI 10.1016/j.febslet.2004.12.039; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Rabizadeh S, 2004, J BIOL CHEM, V279, P29247, DOI 10.1074/jbc.M401699200; Rocheleau CE, 2005, P NATL ACAD SCI USA, V102, P11757, DOI 10.1073/pnas.0500937102; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; Theurillat JP, 2007, CANCER IMMUNOL IMMUN, V56, P1723, DOI 10.1007/s00262-007-0316-1; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Ziogas A, 2005, J BIOL CHEM, V280, P24205, DOI 10.1074/jbc.M413327200	33	24	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	2010	29	24					3575	3582		10.1038/onc.2010.104	http://dx.doi.org/10.1038/onc.2010.104			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	611QN	20383191	Bronze			2022-12-17	WOS:000278835400012
J	Liu, Y; Yan, S; Wondimu, A; Bob, D; Weiss, M; Sliwinski, K; Villar, J; Notario, V; Sutherland, M; Colberg-Poley, AM; Ladisch, S				Liu, Y.; Yan, S.; Wondimu, A.; Bob, D.; Weiss, M.; Sliwinski, K.; Villar, J.; Notario, V.; Sutherland, M.; Colberg-Poley, A. M.; Ladisch, S.			Ganglioside synthase knockout in oncogene-transformed fibroblasts depletes gangliosides and impairs tumor growth	ONCOGENE			English	Article						ganglioside synthesis; ganglioside depletion; tumor model; c-Myc/H-Ras transformation; tumorigenesis	GLUCOSYLCERAMIDE SYNTHASE; CANCER CELLS; KAPPA-B; ACTIVATION; EXPRESSION; PROLIFERATION; CONVERSION; INHIBITOR; MIGRATION; ADHESION	Biologically active membrane gangliosides, expressed and released by many human tumors, are hypothesized to significantly impact tumor progression. Lack of a model of complete and specific tumor ganglioside depletion in vivo, however, has hampered elucidation of their role. Here, we report the creation of a novel, stable, genetically induced tumor cell system resulting in specific and complete blockade of ganglioside synthesis. Wild-type (WT) and GM3 synthase/GM2 synthase double knockout (DKO) murine embryonic fibroblasts were transformed using amphotropic retrovirus-transduced oncogenes (pBABE-c-Myc(T58A) + H-RasG12V). The transformed cells, WTt and DKOt respectively, evidenced comparable integrated copy numbers and oncogene expression. Ganglioside synthesis was completely blocked in the DKOt cells, importantly without triggering an alternate pathway of ganglioside synthesis. Ganglioside depletion (to <0.5 nmol/10(7) cells from 9 to 11 nmol/10(7) WTt or untransfected normal fibroblasts) did not adversely affect cell proliferation kinetics but did reduce cell migration on fibronectin-coated wells, consistent with our previous observations in ganglioside-depleted normal human fibroblasts. Strikingly, despite similar oncogene expression and growth kinetics, DKOt cells evidenced significantly impaired tumor growth in syngeneic immunocompetent mice, underscoring the pivotal role of tumor cell gangliosides and providing an ideal system for probing their mechanisms of action in vivo. Oncogene (2010) 29, 3297-3306; doi: 10.1038/onc.2010.85; published online 22 March 2010	[Liu, Y.; Yan, S.; Wondimu, A.; Bob, D.; Weiss, M.; Sliwinski, K.; Sutherland, M.; Colberg-Poley, A. M.; Ladisch, S.] Childrens Natl Med Ctr, Ctr Canc & Immunol Res, NW, Washington, DC 20010 USA; [Liu, Y.; Colberg-Poley, A. M.; Ladisch, S.] George Washington Univ, Sch Med & Hlth Sci, Dept Pediat, Washington, DC 20052 USA; [Villar, J.; Notario, V.] Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Radiat Med, Washington, DC 20007 USA; [Colberg-Poley, A. M.; Ladisch, S.] George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Washington, DC 20037 USA	Children's National Health System; George Washington University; Georgetown University; George Washington University	Ladisch, S (corresponding author), Childrens Natl Med Ctr, Ctr Canc & Immunol Res, NW, 111 Michigan Ave NW,Suite 5200, Washington, DC 20010 USA.	sladisch@cnmc.org	/AAB-6461-2022; /AFP-0764-2022		NIH [CA61010, CA42361, CA64472, GM62116]; NATIONAL CANCER INSTITUTE [R01CA042361, R01CA064472, R01CA061010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Rick Proia for the GM3S mice. This work was supported by NIH grants CA61010 and CA42361 to SL, CA64472 to VN, and GM62116 to the Consortium for Functional Glycomics.	Allende ML, 2002, CURR OPIN STRUC BIOL, V12, P587, DOI 10.1016/S0959-440X(02)00376-7; Buggins AGS, 2001, J IMMUNOL, V167, P6021, DOI 10.4049/jimmunol.167.10.6021; Cazet A, 2009, BIOL CHEM, V390, P601, DOI 10.1515/BC.2009.054; Deng W, 2002, GLYCOBIOLOGY, V12, P145, DOI 10.1093/glycob/12.3.145; FLOUTSIS G, 1989, INT J CANCER, V43, P6, DOI 10.1002/ijc.2910430103; Hakomori S, 1973, Adv Cancer Res, V18, P265, DOI 10.1016/S0065-230X(08)60755-1; Hakomori S, 1996, CANCER RES, V56, P5309; Hyuga S, 1999, INT J CANCER, V83, P685, DOI 10.1002/(SICI)1097-0215(19991126)83:5<685::AID-IJC20>3.0.CO;2-4; INOKUCHI JI, 1989, J CELL PHYSIOL, V141, P573, DOI 10.1002/jcp.1041410316; Jeyakumar M, 2002, NEUROPATH APPL NEURO, V28, P343, DOI 10.1046/j.1365-2990.2002.00422.x; Kendall SD, 2005, CANCER RES, V65, P9824, DOI 10.1158/0008-5472.CAN-05-1543; LADISCH S, 1983, CANCER RES, V43, P3808; Ladisch S, 2004, CURR CLIN ONCOL, P145; LADISCH S, 1987, J CLIN INVEST, V79, P1879, DOI 10.1172/JCI113031; LADISCH S, 1985, ANAL BIOCHEM, V146, P220, DOI 10.1016/0003-2697(85)90419-1; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; LEDEEN RW, 1978, J SUPRAMOL STR CELL, V8, P1, DOI 10.1002/jss.400080102; Li RX, 2001, J BIOL CHEM, V276, P42782, DOI 10.1074/jbc.M101481200; LI RX, 1991, BIOCHIM BIOPHYS ACTA, V1083, P57, DOI 10.1016/0005-2760(91)90124-Z; Liu YH, 2004, J BIOL CHEM, V279, P36481, DOI 10.1074/jbc.M402880200; Liu YH, 2008, GLYCOBIOLOGY, V18, P593, DOI 10.1093/glycob/cwn039; Liu YH, 2006, CANCER RES, V66, P10408, DOI 10.1158/0008-5472.CAN-06-1572; Mitsuzuka K, 2005, J BIOL CHEM, V280, P35545, DOI 10.1074/jbc.M505630200; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; Ronnov-Jessen L, 2002, AM J PATHOL, V161, P471, DOI 10.1016/S0002-9440(10)64203-4; Saha S., 2005, Indian Journal of Experimental Biology, V43, P1130; Schenck M, 2007, ARCH BIOCHEM BIOPHYS, V462, P171, DOI 10.1016/j.abb.2007.03.031; Shevchuk NA, 2007, BBA-MOL CELL BIOL L, V1771, P1226, DOI 10.1016/j.bbalip.2007.05.008; Shurin GV, 2001, CANCER RES, V61, P363; Simpson MA, 2004, NAT GENET, V36, P1225, DOI 10.1038/ng1460; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; Todeschini AR, 2008, BBA-GEN SUBJECTS, V1780, P421, DOI 10.1016/j.bbagen.2007.10.008; Uzzo RG, 1999, J CLIN INVEST, V104, P769, DOI 10.1172/JCI6775; VALENTINO L, 1990, BLOOD, V75, P1564; vanEngeland M, 1996, CYTOMETRY, V24, P131, DOI 10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M; Villar J, 2007, CANCER RES, V67, P10859, DOI 10.1158/0008-5472.CAN-07-2041; Yamashita T, 2003, P NATL ACAD SCI USA, V100, P3445, DOI 10.1073/pnas.0635898100; Yamashita T, 2005, P NATL ACAD SCI USA, V102, P2725, DOI 10.1073/pnas.0407785102	38	24	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2010	29	22					3297	3306		10.1038/onc.2010.85	http://dx.doi.org/10.1038/onc.2010.85			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20305696	Green Accepted			2022-12-17	WOS:000278321100012
J	Albano, F; Anelli, L; Zagaria, A; Coccaro, N; D'Addabbo, P; Liso, V; Rocchi, M; Specchia, G				Albano, F.; Anelli, L.; Zagaria, A.; Coccaro, N.; D'Addabbo, P.; Liso, V.; Rocchi, M.; Specchia, G.			Genomic segmental duplications on the basis of the t(9;22) rearrangement in chronic myeloid leukemia	ONCOGENE			English	Article						segmental duplications; chronic myeloid leukemia; microdeletions	DERIVATIVE CHROMOSOME-9 DELETIONS; BREAKPOINT; REGION; TRANSLOCATION; HYBRIDIZATION; ARCHITECTURE; COMMON; GENE	A crucial role of segmental duplications (SDs) of the human genome has been shown in chromosomal rearrangements associated with several genomic disorders. Limited knowledge is yet available on the molecular processes resulting in chromosomal rearrangements in tumors. The t(9;22)(q34;q11) rearrangement causing the 5'BCR/3'ABL gene formation has been detected in more than 90% of cases with chronic myeloid leukemia (CML). In 10-18% of patients with CML, genomic deletions were detected on der(9) chromosome next to translocation breakpoints. The molecular mechanism triggering the t(9; 22) and deletions on der(9) is still speculative. Here we report a molecular cytogenetic analysis of a large series of patients with CML with der(9) deletions, revealing an evident breakpoint clustering in two regions located proximally to ABL and distally to BCR, containing an interchromosomal duplication block (SD_9/22). The deletions breakpoints distribution appeared to be strictly related to the distance from the SD_9/22. Moreover, bioinformatic analyses of the regions surrounding the SD_9/22 revealed a high Alu frequency and a poor gene density, reflecting genomic instability and susceptibility to rearrangements. On the basis of our results, we propose a three-step model for t(9; 22) formation consisting of alignment of chromosomes 9 and 22 mediated by SD_9/22, spontaneous chromosome breakages and misjoining of DNA broken ends. Oncogene (2010) 29, 2509-2516; doi:10.1038/onc.2009.524; published online 25 January 2010	[Albano, F.; Anelli, L.; Zagaria, A.; Coccaro, N.; Liso, V.; Specchia, G.] Univ Bari, Dept Hematol, I-70124 Bari, Italy; [D'Addabbo, P.; Rocchi, M.] Univ Bari, Dept Genet & Microbiol, I-70124 Bari, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Albano, F (corresponding author), Univ Bari, Azienda Osped Univ Policlin, Dept Hematol, Piazza Giulio Cesare 11, I-70124 Bari, Italy.	f.albano@ematba.uniba.it	Albano, Francesco/J-2352-2016; D'Addabbo, Pietro/AAC-7731-2020; D'Addabbo, Pietro/D-8551-2016; Anelli, Luisa/K-2661-2016; Zagaria, Antonella/K-2995-2016; Specchia, Giorgina/K-3084-2016	Albano, Francesco/0000-0001-7926-6052; D'Addabbo, Pietro/0000-0003-3325-4931; Anelli, Luisa/0000-0002-9185-724X; Coccaro, Nicoletta/0000-0003-1327-8186; Zagaria, Antonella/0000-0002-0135-6661; Specchia, Giorgina/0000-0002-2479-9529; Rocchi, Mariano/0000-0002-9451-5616	Associazione Italiana contro le Leucemie (AIL)-BARI	Associazione Italiana contro le Leucemie (AIL)-BARI	We thank Ms MVC Pragnell for language revision of the paper. The financial support of Associazione Italiana contro le Leucemie (AIL)-BARI is gratefully acknowledged.	Albano F, 2007, CANCER GENET CYTOGEN, V174, P121, DOI 10.1016/j.cancergencyto.2006.09.025; Bailey JA, 2006, NAT REV GENET, V7, P552, DOI 10.1038/nrg1895; Barbouti A, 2004, AM J HUM GENET, V74, P1, DOI 10.1086/380648; Darai-Ramqvist E, 2008, GENOME RES, V18, P370, DOI 10.1101/gr.7010208; de Campos MGV, 2007, CANCER GENET CYTOGEN, V178, P49, DOI 10.1016/j.cancergencyto.2007.06.013; Elliott B, 2002, CELL MOL LIFE SCI, V59, P373, DOI 10.1007/s00018-002-8429-3; Fourouclas N, 2006, HAEMATOL-HEMATOL J, V91, P952; Gibcus JH, 2007, HUM GENET, V121, P187, DOI 10.1007/s00439-006-0299-6; Gu Wenli, 2008, Pathogenetics, V1, P4, DOI 10.1186/1755-8417-1-4; Huntly BJP, 2001, BLOOD, V98, P1732, DOI 10.1182/blood.V98.6.1732; Kim PM, 2008, GENOME RES, V18, P1865, DOI 10.1101/gr.081422.108; Kolomietz E, 2003, LEUKEMIA, V17, P1313, DOI 10.1038/sj.leu.2402969; Kolomietz E, 2001, BLOOD, V97, P3581, DOI 10.1182/blood.V97.11.3581; Kreil S, 2007, BLOOD, V110, P1283, DOI 10.1182/blood-2007-02-074252; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LITZ CE, 1993, BLOOD, V81, P1567; Lomiento M, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-12-r173; Mefford HC, 2009, CURR OPIN GENET DEV, V19, P196, DOI 10.1016/j.gde.2009.04.003; Saglio G, 2002, P NATL ACAD SCI USA, V99, P9882, DOI 10.1073/pnas.152171299; Sharp AJ, 2006, NAT GENET, V38, P1038, DOI 10.1038/ng1862; Sinclair PB, 2000, BLOOD, V95, P738, DOI 10.1182/blood.V95.3.738.003k21_738_743; Specchia G, 2004, LEUKEMIA LYMPHOMA, V45, P689, DOI 10.1080/10428190310001623900; Storlazzi CT, 2002, GENE CHROMOSOME CANC, V35, P271, DOI 10.1002/gcc.10116; Yatsenko SA, 2009, HUM MOL GENET, V18, P1924, DOI 10.1093/hmg/ddp114	24	24	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	17					2509	2516		10.1038/onc.2009.524	http://dx.doi.org/10.1038/onc.2009.524			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20101201				2022-12-17	WOS:000277169400006
J	Barbash, O; Egan, E; Pontano, LL; Kosak, J; Diehl, JA				Barbash, O.; Egan, E.; Pontano, L. L.; Kosak, J.; Diehl, J. A.			Lysine 269 is essential for cyclin D1 ubiquitylation by the SCFFbx4/alpha B-crystallin ligase and subsequent proteasome-dependent degradation	ONCOGENE			English	Article						cyclin D1; Fbx4; ubiquitin; alpha B crystallin	MEDIATED DEGRADATION; UBIQUITIN LIGASE; PHOSPHORYLATION; PROTEOLYSIS; MUTATIONS; COMPLEX; CANCER; EXPRESSION; BINDING; PROTEIN	Protein ubiquitylation is a complex enzymatic process that results in the covalent attachment of ubiquitin, through Gly-76 of ubiquitin, to an epsilon NH2 group of an internal lysine residue in a given substrate. Although E3 ligases frequently use lysines adjacent to the degron within the substrate, many substrates can be targeted to the proteasome through the polyubiquitylation of any lysine. We have assessed the role of lysine residues proximal to the cyclin D1 phosphodegron for ubiquitylation by the SCFFbx4/alpha B-crystallin ubiquitin ligase and subsequent proteasome-dependent degradation of cyclin D1. The work described herein reveals a requisite role for Lys-269 (K269) for the rapid polyubiquitin-mediated degradation of cyclin D1. Mutation of Lys-269, which is proximal to the phosphodegron sequence surrounding Thr-286 in cyclin D1, not only stabilizes cyclin D1 but also triggers cyclin D1 accumulation within the nucleus, thereby promoting cell transformation. In addition, D1-K269R is resistant to genotoxic stress-induced degradation, similar to non-phosphorylatable D1-T286A, supporting the critical role for the post-translational regulation of cyclin D1 in response to DNA-damaging agents. Strikingly, although mutation of lysine 269 to arginine inhibits cyclin D1 degradation, it does not inhibit cyclin D1 ubiquitylation in vivo, showing that ubiquitylation of a specific lysine can influence substrate targeting to the 26S proteasome. Oncogene (2009) 28, 4317-4325; doi: 10.1038/onc.2009.287; published online 21 September 2009	[Barbash, O.; Egan, E.; Pontano, L. L.; Kosak, J.; Diehl, J. A.] Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Diehl, JA (corresponding author), Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, 454 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	adiehl@mail.med.upenn.edu			NIH [CA93237]; NATIONAL CANCER INSTITUTE [R01CA093237, P01CA098101] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We wish to thank Serge Fuchs for the plasmids encoding the various ubiquitin lysine-arginine mutants, and Petia Zamfirova and Margarita Romero for their technical assistance. This work was supported by CA93237 (NIH) and a Leukemia & Lymphoma Scholar award (JAD).	Aggarwal P, 2007, GENE DEV, V21, P2908, DOI 10.1101/gad.1586007; Barbash O, 2008, CANCER CELL, V14, P68, DOI 10.1016/j.ccr.2008.05.017; Benzeno S, 2006, ONCOGENE, V25, P6291, DOI 10.1038/sj.onc.1209644; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Feng Q, 2007, ONCOGENE, V26, P5098, DOI 10.1038/sj.onc.1210309; Feng Q, 2008, MOL CANCER THER, V7, P3780, DOI 10.1158/1535-7163.MCT-08-0753; Fung TK, 2005, CELL CYCLE, V4, P1411, DOI 10.4161/cc.4.10.2046; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; Gladden AB, 2006, ONCOGENE, V25, P998, DOI 10.1038/sj.onc.1209147; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P7021, DOI 10.1073/pnas.81.22.7021; KATO J, 1993, GENE DEV, V7, P331; Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007; Lin J, 2004, SEMIN ONCOL, V31, P476, DOI 10.1053/j.seminoncol.2004.04.019; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Moreno-Bueno G, 2003, ONCOGENE, V22, P6115, DOI 10.1038/sj.onc.1206868; Parry D, 1999, MOL CELL BIOL, V19, P1775; Pontano LL, 2008, MOL CELL BIOL, V28, P7245, DOI 10.1128/MCB.01085-08; Sato Y, 1999, J GASTROENTEROL, V34, P486, DOI 10.1007/s005350050301; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Worsley SD, 1996, J CLIN PATHOL-CL MOL, V49, pM46; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	26	24	28	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2009	28	49					4317	4325		10.1038/onc.2009.287	http://dx.doi.org/10.1038/onc.2009.287			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DT	19767775	Green Accepted			2022-12-17	WOS:000272876400001
J	Yuan, BZ; Chapman, J; Reynolds, SH				Yuan, B-Z; Chapman, J.; Reynolds, S. H.			Proteasome inhibitors induce apoptosis in human lung cancer cells through a positive feedback mechanism and the subsequent Mcl-1 protein cleavage	ONCOGENE			English	Article						proteasome inhibitor; non-small cell lung carcinoma; apoptosis; Mcl-1; positive feedback mechanism; protein cleavage	TRAIL; SENSITIZE; EPIDEMIOLOGY; ACTIVATION; BORTEZOMIB; FLICE; NOXA	Proteasome inhibitors (PIs) are promising new therapeutic agents for treating non-small cell lung carcinoma (NSCLC). To investigate the mechanisms of action of PIs, we analyzed the proapoptotic activities of PIs (MG132 or Bortezomib) in NSCLC cells. We found that both MG132 (>1 mu M) and Bortezomib (>0.025 mu M) induced a significant apoptosis in NCI-H1703, a PI-sensitive NSCLC cell line, through initially activating the intrinsic apoptosis pathway, leading to the activation of a positive feedback mechanism (PFM), which then conveyed apoptosis signaling from the intrinsic pathway to the extrinsic pathway with formation of a signaling loop for maximal caspase activation. Mcl-1 and Noxa were identified to be the major anti-apoptotic and proapoptotic proteins, respectively, in PI-induced apoptosis and mutually exclusive in protein stability. Although the Mcl-1 protein was upregulated by proteasome inhibition, it was also subjected to caspase 3-dependent cleavage governed by the PFM. Moreover, it was revealed that Mcl-1 protein cleavage contributed to PFM-governed apoptosis in following inter-related ways: reducing the anti-apoptotic Mcl-1; generating the truncated proapoptotic Mcl-1(S); and inducing a shift of balance between Mcl-1 and Noxa. It was further manifested that tumor necrosis factor-related apoptosis-inducing ligand boosted MG132's proapoptotic activity through strengthening the PFM in both NCI-H1703 and NCI-H358, a PI-resistant NSCLC cell line. Therefore, this study provides a basis for enhancing the efficacy of PIs in treating NSCLC. Oncogene (2009) 28, 3775-3786; doi:10.1038/onc.2009.240; published online 17 August 2009	[Yuan, B-Z; Chapman, J.; Reynolds, S. H.] NIOSH, Mol Genet Lab, Toxicol & Mol Biol Branch, CDC, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Yuan, BZ (corresponding author), NIOSH, Mol Genet Lab, Toxicol & Mol Biol Branch, CDC, 1095 Willowdale Rd,M-S L-3014, Morgantown, WV 26505 USA.	bby1@cdc.gov						Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Das T, 1999, BIOCHEM BIOPH RES CO, V260, P105, DOI 10.1006/bbrc.1999.0712; Davies AM, 2007, CLIN CANCER RES, V13, p4647S, DOI 10.1158/1078-0432.CCR-07-0334; FISKUM G, 1980, P NATL ACAD SCI-BIOL, V77, P3430, DOI 10.1073/pnas.77.6.3430; Green DR, 2006, CANCER CELL, V9, P328, DOI 10.1016/j.ccr.2006.05.004; Hacker G, 2000, CELL TISSUE RES, V301, P5, DOI 10.1007/s004410000193; Hassan M, 2008, ONCOGENE, V27, P4557, DOI 10.1038/onc.2008.90; Henderson CJ, 2005, CELL DEATH DIFFER, V12, P1240, DOI 10.1038/sj.cdd.4401729; Hunter AM, 2007, APOPTOSIS, V12, P1543, DOI 10.1007/s10495-007-0087-3; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jing N, 2005, ANTI-CANCER DRUG, V16, P601, DOI 10.1097/00001813-200507000-00002; Kruyt FAE, 2008, CANCER LETT, V263, P14, DOI 10.1016/j.canlet.2008.02.003; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Liu X, 2006, CANCER RES, V66, P11115, DOI 10.1158/0008-5472.CAN-06-2471; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Milhas D, 2005, J BIOL CHEM, V280, P19836, DOI 10.1074/jbc.M414358200; Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagy K, 2006, PATHOL ONCOL RES, V12, P133, DOI 10.1007/BF02893359; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Saulle E, 2007, APOPTOSIS, V12, P635, DOI 10.1007/s10495-006-0025-9; Steenland K, 1996, AM J IND MED, V30, P495, DOI 10.1002/(SICI)1097-0274(199610)30:4<495::AID-AJIM16>3.3.CO;2-I; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Voortman J, 2007, MOL CANCER THER, V6, P1046, DOI 10.1158/1535-7163.MCT-06-0577; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Weng CJ, 2005, J BIOL CHEM, V280, P10491, DOI 10.1074/jbc.M412819200; Willison HJ, 2005, NAT CLIN PRACT NEURO, V1, P2, DOI 10.1038/ncpneuro0001; Yuan BZ, 2007, EXP CELL RES, V313, P3868, DOI 10.1016/j.yexcr.2007.08.009; Yuan BZ, 2008, TRANSL ONCOL, V1, P129, DOI 10.1593/tlo.08133; Zhang HG, 2004, ONCOGENE, V23, P2009, DOI 10.1038/sj.onc.1207373	34	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	43					3775	3786		10.1038/onc.2009.240	http://dx.doi.org/10.1038/onc.2009.240			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512KT	19684616				2022-12-17	WOS:000271248400002
J	Chin, M; Herscovitch, M; Zhang, N; Waxman, DJ; Gilmore, TD				Chin, M.; Herscovitch, M.; Zhang, N.; Waxman, D. J.; Gilmore, T. D.			Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile	ONCOGENE			English	Article						c-rel; NF-kappa B; malignant transformation; BJAB; lymphoma; microarray	NF-KAPPA-B; EPSTEIN-BARR-VIRUS; TRANSCRIPTION FACTOR REL; TRANSACTIVATION DOMAIN; MOUSE; INDUCTION; CD40; IKK; CHEMOTHERAPY; RESISTANCE	The human REL proto-oncogene encodes a transcription factor in the nuclear factor (NF)-kappa B family. Overexpression of REL is acutely transforming in chicken lymphoid cells, but has not been shown to transform any mammalian lymphoid cell type. In this report, we show that overexpression of a highly transforming mutant of REL (REL Delta TAD1) increases the oncogenic properties of the human B-cell lymphoma BJAB cell line, as shown by increased colony formation in soft agar, tumor formation in SCID (severe combined immunodeficient) mice, and adhesion. BJAB-RELDTAD1 cells also show decreased activation of caspase in response to doxorubicin. BJAB-REL Delta TAD1 cells have increased levels of active nuclear REL protein as determined by immunofluorescence, subcellular fractionation and electrophoretic mobility shift assay. Overexpression of RELDTAD1 in BJAB cells has transformed the gene expression pro. le of BJAB cells from that of a germinal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL) (GCB-DLBCL) to that of an activated B-cell subtype (ABC-DLBCL), as evidenced by increased expression of many ABC-defining mRNAs. Upregulated genes in BJAB-RELDTAD1 cells include several NF-kappa B targets that encode proteins previously implicated in B-cell development or oncogenesis, including BCL2, IRF4, CD40 and VCAM1. The cell system we describe here may be valuable for further characterizing the molecular details of REL-induced lymphoma in humans. Oncogene (2009) 28, 2100-2111; doi:10.1038/onc.2009.74; published online 20 April 2009	[Chin, M.; Herscovitch, M.; Zhang, N.; Waxman, D. J.; Gilmore, T. D.] Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu		Waxman, David/0000-0001-7982-9206	Saarland Ministry of Education, Culture and Science; NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES007381] Funding Source: NIH RePORTER	Saarland Ministry of Education, Culture and Science; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Anna-Maria Bohrer for technical assistance and Martina Sester for support in flow cytometry experiments. This work was supported by a grant of the Saarland Ministry of Education, Culture and Science to HU-S.	Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; Clodfelter KH, 2007, PHYSIOL GENOMICS, V31, P63, DOI 10.1152/physiolgenomics.00055.2007; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Dierlamm J, 2008, HAEMATOLOGICA, V93, P688, DOI 10.3324/haematol.12057; Enberg I, 1983, INT J CANCER, V31, P163; Feuerhake F, 2005, BLOOD, V106, P1392, DOI 10.1182/blood-2004-12-4901; FINKE J, 1992, BLOOD, V80, P459; Gapuzan MER, 2002, ONCOGENE, V21, P2484, DOI 10.1038/sj.onc.1205333; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Gilmore TD, 2003, VIROLOGY, V316, P9, DOI 10.1016/S0042-6822(03)00562-2; Gupta N, 2008, CANCER RES, V68, P808, DOI 10.1158/0008-5472.CAN-07-3169; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Ho L, 2005, BLOOD, V105, P2891, DOI 10.1182/blood-2004-06-2297; Holloway MG, 2008, MOL ENDOCRINOL, V22, P1274, DOI 10.1210/me.2007-0564; Houldsworth J, 2004, BLOOD, V103, P1862, DOI 10.1182/blood-2003-04-1359; Hrdlickova R, 2001, MOL CELL BIOL, V21, P6369; Iqbal J, 2006, J CLIN ONCOL, V24, P961, DOI 10.1200/JCO.2005.03.4264; Kalaitzidis D, 2002, ONCOGENE, V21, P8759, DOI 10.1038/sj.onc.1206033; Kalaitzidis D, 2002, GENE CHROMOSOME CANC, V34, P129, DOI 10.1002/gcc.10051; Lam LT, 2008, P NATL ACAD SCI USA, V105, P20798, DOI 10.1073/pnas.0806491106; Lee HH, 1999, P NATL ACAD SCI USA, V96, P1421, DOI 10.1073/pnas.96.4.1421; Leeman JR, 2008, ONCOGENE, V27, P6770, DOI 10.1038/onc.2008.284; Liang MC, 2003, MOL PHARMACOL, V64, P123, DOI 10.1124/mol.64.1.123; Lucas PC, 2007, ONCOGENE, V26, P5643, DOI 10.1038/sj.onc.1210342; Mainou BA, 2006, J VIROL, V80, P6458, DOI 10.1128/JVI.00135-06; Martin AG, 2001, J BIOL CHEM, V276, P15840, DOI 10.1074/jbc.M011313200; Ngo VN, 2006, NATURE, V441, P106, DOI 10.1038/nature04687; Pavlidis P, 2003, BIOINFORMATICS, V19, P295, DOI 10.1093/bioinformatics/19.2.295; PEREZ JR, 1994, MOL CELL BIOL, V14, P5326, DOI 10.1128/MCB.14.8.5326; Rhodes DR, 2005, NAT GENET, V37, P579, DOI 10.1038/ng1578; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Shaffer AL, 2002, NAT REV IMMUNOL, V2, P920, DOI 10.1038/nri953; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Snow AL, 2006, J IMMUNOL, V177, P3283, DOI 10.4049/jimmunol.177.5.3283; Starczynowski DT, 2007, ONCOGENE, V26, P2685, DOI 10.1038/sj.onc.1210089; Starczynowski DT, 2005, ONCOGENE, V24, P7355, DOI 10.1038/sj.onc.1208902; Starczynowski DT, 2003, ONCOGENE, V22, P6928, DOI 10.1038/sj.onc.1206801; Stoffel A, 2004, P NATL ACAD SCI USA, V101, P9079, DOI 10.1073/pnas.0402415101; van Imhoff GW, 2006, J CLIN ONCOL, V24, P4135, DOI 10.1200/JCO.2006.05.5897; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; Voorzanger-Rousselot N, 1998, BLOOD, V92, P3381, DOI 10.1182/blood.V92.9.3381.421k02_3381_3387; WENNBORG A, 1987, INT J CANCER, V40, P202, DOI 10.1002/ijc.2910400213; Wright G, 2003, P NATL ACAD SCI USA, V100, P9991, DOI 10.1073/pnas.1732008100; Yamamoto N, 2000, FEBS LETT, V484, P153, DOI 10.1016/S0014-5793(00)02145-1; Zarnegar B, 2004, P NATL ACAD SCI USA, V101, P8108, DOI 10.1073/pnas.0402629101	49	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2009	28	20					2100	2111		10.1038/onc.2009.74	http://dx.doi.org/10.1038/onc.2009.74			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	448BI	19377508	Green Accepted			2022-12-17	WOS:000266235800004
J	Ivanova, IA; Nakrieko, KA; Dagnino, L				Ivanova, I. A.; Nakrieko, K-A; Dagnino, L.			Phosphorylation by p38 MAP kinase is required for E2F1 degradation and keratinocyte differentiation	ONCOGENE			English	Article						keratinocyte; E2F; differentiation; p38 mitogen-activated kinase	TRANSCRIPTION FACTORS; NUCLEAR IMPORT; SKIN; EXPRESSION; EXPORT; DYNAMICS; REPAIR	The transcription factor E2F1 plays key roles in skin homeostasis, and is essential for normal keratinocyte proliferation and epidermal regeneration after injury. We have previously established that, in differentiating keratinocytes, E2F1 activity is controlled by nuclear export and subsequent degradation. These events are triggered by differentiation-induced stimulation of protein kinase C and p38 mitogen-activated protein kinase ( MAPK). However, the mechanisms that induce E2F1 export from the nucleus and the role of p38 MAPK in this process are poorly understood. We now describe a novel regulatory pathway for E2F1, which involves phosphorylation by p38. We demonstrate that E2F1 forms complexes with active p38 through regions that exclude the N-terminus of this transcription factor, and that p38 activity is a major contributor to the phosphorylation status of E2F1 in keratinocytes. Using in vitro kinase assays, we identified Ser403 and Thr433 as the residues phosphorylated by p38. The biological significance of these observations is underscored by the inability of E2F1 mutants lacking one or both of these residues to be exported from the nucleus and degraded when keratinocytes receive differentiation stimuli, which results in impaired keratinocyte maturation.	[Ivanova, I. A.; Nakrieko, K-A; Dagnino, L.] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada; [Dagnino, L.] Univ Western Ontario, Regulatory Biol & Funct Genom Res Grp, Siebens Drake Res Inst, London, ON, Canada; [Ivanova, I. A.] Univ Western Ontario, Dept Paediat, Child Hlth Res Inst, London, ON, Canada; [Ivanova, I. A.] Univ Western Ontario, Lawson Hlth Res Inst, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Dagnino, L (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada.	ldagnino@uwo.ca		Dagnino, Lina/0000-0003-1483-5159				Apostolova MD, 2002, J BIOL CHEM, V277, P34471, DOI 10.1074/jbc.M205827200; Balasubramanian S, 1999, INT J ONCOL, V15, P387; Berton TR, 2005, ONCOGENE, V24, P2449, DOI 10.1038/sj.onc.1208462; D'Souza SJA, 2002, J BIOL CHEM, V277, P10626, DOI 10.1074/jbc.M111956200; D'Souza SJA, 2001, J BIOL CHEM, V276, P23531, DOI 10.1074/jbc.M100780200; Dagnino L, 1997, CELL GROWTH DIFFER, V8, P553; Eckert RL, 2004, J INVEST DERMATOL, V123, P13, DOI 10.1111/j.0022-202X.2004.22723.x; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Fuchs E, 1994, Princess Takamatsu Symp, V24, P290; Fuchs E, 2007, NATURE, V445, P834, DOI 10.1038/nature05659; Garcia-Alvarez G, 2007, BBA-MOL CELL RES, V1773, P375, DOI 10.1016/j.bbamcr.2006.09.015; Ivanova IA, 2007, ONCOGENE, V26, P1147, DOI 10.1038/sj.onc.1209894; Ivanova IA, 2006, ONCOGENE, V25, P430, DOI 10.1038/sj.onc.1208999; Ivanova IA, 2007, CELL CYCLE, V6, P2186, DOI 10.4161/cc.6.17.4650; McClellan KA, 2007, CELL CYCLE, V6, P2917, DOI 10.4161/cc.6.23.4997; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Rampalli S, 2007, NAT STRUCT MOL BIOL, V14, P1150, DOI 10.1038/nsmb1316; Vaezi A, 2002, DEV CELL, V3, P367, DOI 10.1016/S1534-5807(02)00259-9; Vandel L, 1999, EMBO J, V18, P4280, DOI 10.1093/emboj/18.15.4280; Vasioukhin V, 2001, CURR OPIN CELL BIOL, V13, P76, DOI 10.1016/S0955-0674(00)00177-0; Zhang XH, 2002, J BIOL CHEM, V277, P45276, DOI 10.1074/jbc.M208063200	22	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					52	62		10.1038/onc.2008.354	http://dx.doi.org/10.1038/onc.2008.354			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18794805				2022-12-17	WOS:000262294100006
J	Markey, M; Berberich, SJ				Markey, M.; Berberich, S. J.			Full-length hdmX transcripts decrease following genotoxic stress	ONCOGENE			English	Article						HdmX; p53; transcription; splicing; microRNAs	TUMOR-SUPPRESSOR P53; UBIQUITIN LIGASE ACTIVITY; EMBRYONIC LETHALITY; ONCOPROTEIN MDM2; REGULATE P53; DNA-DAMAGE; ACTIVATION; EXPRESSION; STABILITY; PROTEIN	Previous studies have suggested that the mdmX gene is constitutively transcribed, and that MdmX protein activity is instead controlled by cellular localization and DNA damage induced Mdm2-mediated ubiquitination leading to proteasomal degradation. In these studies, we report that the human mdmX (hdmX) mRNA is reproducibly decreased in various human cell lines following treatment with various DNA-damaging agents. Repression of hdmX transcripts is observed in DNA-damaged HCT116 colon cancer cells and in isogenic p53(-/-) cells, suggesting that this effect is p53-independent. Reduction in the amount of hdmX transcript occurs in both human tumor cell lines and primary human diploid fibroblasts, and results in a significant reduction of HdmX protein. Examination of hdmX promoter activity suggests that damage-induced repression of hdmX mRNA is not significantly impacted by transcription initiation. In contrast, changes in hdmX mRNA splicing appear to partly explain the reduction in full-length hdmX mRNA levels in tumor cell lines with the destabilization of full-length hdmX transcripts, potentially through microRNA miR-34a regulation, also impacting transcript levels. Taken together, this study uncovers previously unrecognized cellular mechanisms by which hdmX mRNA levels are kept low following genotoxic stress.	[Markey, M.; Berberich, S. J.] Wright State Univ, Boonshoft Sch Med, Dept Biochem & Mol Biol, Dayton, OH 45435 USA	University System of Ohio; Wright State University Dayton	Berberich, SJ (corresponding author), Wright State Univ, Boonshoft Sch Med, Dept Biochem & Mol Biol, 3640 Colonel Glenn Hwy, Dayton, OH 45435 USA.	steven.berberich@wright.edu		Markey, Michael/0000-0002-8593-2290	NIH [CA66430]; NATIONAL CANCER INSTITUTE [R01CA064430] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Berberich laboratory for their insightful discussions. This work was supported by NIH CA66430 (to SJB).	Bartel F, 2005, INT J CANCER, V117, P469, DOI 10.1002/ijc.21206; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Chandler DS, 2006, CANCER RES, V66, P9502, DOI 10.1158/0008-5472.CAN-05-4271; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; de Graaf P, 2003, J BIOL CHEM, V278, P38315, DOI 10.1074/jbc.M213034200; DEOCALUNA R, 1995, NATURE, V0378; Dias CS, 2006, CANCER RES, V66, P9467, DOI 10.1158/0008-5472.CAN-05-3013; Eto I, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-20; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Gentiletti F, 2002, ONCOGENE, V21, P867, DOI 10.1038/sj.onc.1205137; Gertz EM, 2006, BMC BIOL, V4, DOI 10.1186/1741-7007-4-41; Gilkes DM, 2006, EMBO J, V25, P5614, DOI 10.1038/sj.emboj.7601424; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Jackson MW, 1999, DNA CELL BIOL, V18, P693, DOI 10.1089/104454999314971; Jin YT, 2006, EMBO J, V25, P1207, DOI 10.1038/sj.emboj.7601010; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Li CG, 2002, MOL CELL BIOL, V22, P7562, DOI 10.1128/MCB.22.21.7562-7571.2002; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Marine JC, 2005, BIOCHEM BIOPH RES CO, V331, P750, DOI 10.1016/j.bbrc.2005.03.151; Migliorini D, 2002, J BIOL CHEM, V277, P7318, DOI 10.1074/jbc.M108795200; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Ramos YFM, 2001, CANCER RES, V61, P1839; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Rozen S, 2000, Methods Mol Biol, V132, P365; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yamasaki Lili, 2003, Cancer Treat Res, V115, P209	41	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2008	27	52					6657	6666		10.1038/onc.2008.266	http://dx.doi.org/10.1038/onc.2008.266			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368QY	18711402	Green Accepted			2022-12-17	WOS:000260638800004
J	Cid, VJ; Rodriguez-Escudero, I; Andres-Pons, A; Roma-Mateo, C; Gil, A; den Hertog, J; Molina, M; Pulido, R				Cid, V. J.; Rodriguez-Escudero, I.; Andres-Pons, A.; Roma-Mateo, C.; Gil, A.; den Hertog, J.; Molina, M.; Pulido, R.			Assessment of PTEN tumor suppressor activity in nonmammalian models: the year of the yeast	ONCOGENE			English	Review						PTEN; PI3K; tumor suppression; oncogenesis; yeast	CAENORHABDITIS-ELEGANS; SCHIZOSACCHAROMYCES-POMBE; PROTEIN-KINASES; CELL-SIZE; TRASTUZUMAB RESISTANCE; FUNCTIONAL-EVALUATION; PHOSPHATASE-ACTIVITY; REGULATES LONGEVITY; SIGNALING PATHWAY; DAUER FORMATION	Model organisms have emerged as suitable and reliable biological tools to study the properties of proteins whose function is altered in human disease. In the case of the PI3K and PTEN human cancer-related proteins, several vertebrate and invertebrate models, including mouse, fly, worm and amoeba, have been exploited to obtain relevant functional information that has been conserved from these organisms to humans along evolution. The yeast Saccharomyces cerevisiae is an eukaryotic unicellular organism that lacks a canonical mammalian-like PI3K/PTEN pathway and PIP3 as a physiological second messenger, PIP2 being essential for its life. The mammalian PI3K/PTEN pathway can be reconstituted in S. cerevisiae, generating growth alteration phenotypes that can be easily monitored to perform in vivo functional analysis of the molecular constituents of this pathway. Here, we review the current nonmammalian model systems to study PTEN function, summarize our knowledge of PTEN orthologs in yeast species and propose the yeast S. cerevisiae as a sensitive biological sensor of PI3K oncogenicity and PTEN tumor suppressor activity.	[Andres-Pons, A.; Roma-Mateo, C.; Gil, A.; Pulido, R.] Ctr Invest Principe Felipe, Valencia, Spain; [Cid, V. J.; Molina, M.] Univ Complutense Madrid, Dept Microbiol 2, Madrid, Spain; [den Hertog, J.] Hubrecht Inst, Utrecht, Netherlands	Prince Felipe Research Center; Complutense University of Madrid; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Pulido, R (corresponding author), Ctr Invest Principe Felipe, Valencia, Spain.	rpulido@cipf.es	Romá-Mateo, Carlos/B-6640-2016; CID, VICTOR JIMENEZ/I-1240-2015; Rodríguez, Isabel/I-5955-2017; Molina, Maria/ABE-7186-2021; JIMENEZ CID, VICTOR/ABC-4858-2021	Romá-Mateo, Carlos/0000-0002-7981-7157; CID, VICTOR JIMENEZ/0000-0002-3933-2016; Rodríguez, Isabel/0000-0002-1792-1143; Molina, Maria/0000-0003-0074-3309; JIMENEZ CID, VICTOR/0000-0002-3933-2016; Pulido, Rafael/0000-0001-9100-248X; Andres-Pons, Amparo/0000-0001-5801-4024	Ministerio de Educacion y Ciencia [SAF2006-083139, S-SAL-0246-2006]; Instituto de Salud Carlos III [ISCIII-RETIC RD06/0020, CP04/00318]; Spain-FEDER; European Research Training Network [MRTN-CT2006-035830]; Comunidad Autonoma de Madrid, Spain; Ministerio de Educacion y Ciencia; Ayuntamiento de Valencia, Spain	Ministerio de Educacion y Ciencia(Spanish Government); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Spain-FEDER(European Commission); European Research Training Network; Comunidad Autonoma de Madrid, Spain(Comunidad de Madrid); Ministerio de Educacion y Ciencia(Spanish Government); Ayuntamiento de Valencia, Spain	We thank T Maehama (National Institute of Infectious Diseases, Tokyo, Japan) and E Hidalgo (Universitat Pompeu Fabra, Barcelona, Spain) for providing DNA samples. Work at the authors' labs is supported by Grants SAF2006-083139 from Ministerio de Educacion y Ciencia, and Grants ISCIII-RETIC RD06/0020 (to R Pulido) and CP04/00318 (to A Gil) from Instituto de Salud Carlos III, Spain-FEDER; European Research Training Network Grant MRTN-CT2006-035830 (to R Pulido and J den Hertog); and Grants BIO2004-02019 from Ministerio de Educacion y Ciencia, and S-SAL-0246-2006 from Comunidad Autonoma de Madrid, Spain (to M Molina). A Andres-Pons and C Roma-Mateo have been the recipients of predoctoral fellowships from Ministerio de Educacion y Ciencia and Ayuntamiento de Valencia, Spain.	Andres-Pons A, 2007, CANCER RES, V67, P9731, DOI 10.1158/0008-5472.CAN-07-1278; Beeton CA, 2000, BIOCHEM J, V350, P353, DOI 10.1042/0264-6021:3500353; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020; Casamayor A, 1999, CURR BIOL, V9, P186, DOI 10.1016/S0960-9822(99)80088-8; Chen LF, 2007, DEV CELL, V12, P603, DOI 10.1016/j.devcel.2007.03.005; Chow LML, 2006, CANCER LETT, V241, P184, DOI 10.1016/j.canlet.2005.11.042; Croushore JA, 2005, DEV DYNAM, V234, P911, DOI 10.1002/dvdy.20576; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; Faucherre A, 2008, ONCOGENE, V27, P1079, DOI 10.1038/sj.onc.1210730; Fox JA, 2002, J IMMUNOL, V169, P49, DOI 10.4049/jimmunol.169.1.49; Frattini M, 2007, BRIT J CANCER, V97, P1139, DOI 10.1038/sj.bjc.6604009; Friant S, 2001, EMBO J, V20, P6783, DOI 10.1093/emboj/20.23.6783; Fukuyama M, 2006, CURR BIOL, V16, P773, DOI 10.1016/j.cub.2006.02.073; Funaki M, 1999, J BIOL CHEM, V274, P22019, DOI 10.1074/jbc.274.31.22019; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Gao P, 2005, BLOOD, V106, P2619, DOI 10.1182/blood-2004-08-3362; Gao XS, 2000, DEV BIOL, V221, P404, DOI 10.1006/dbio.2000.9680; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Georgescu MM, 2000, CANCER RES, V60, P7033; Gil EB, 1999, P NATL ACAD SCI USA, V96, P2925, DOI 10.1073/pnas.96.6.2925; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Grunwald V, 2002, CANCER RES, V62, P6141; Gupta R, 2002, PLANT CELL, V14, P2495, DOI 10.1105/tpc.005702; Han SY, 2000, CANCER RES, V60, P3147; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Hariharan IK, 2006, ANNU REV GENET, V40, P335, DOI 10.1146/annurev.genet.39.073003.100738; Heymont J, 2000, P NATL ACAD SCI USA, V97, P12672, DOI 10.1073/pnas.97.23.12672; Hoeller O, 2007, CURR BIOL, V17, P813, DOI 10.1016/j.cub.2007.04.004; Huang H, 1999, DEVELOPMENT, V126, P5365; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Iijima M, 2004, J BIOL CHEM, V279, P16606, DOI 10.1074/jbc.M312098200; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Inagaki M, 1999, MOL CELL BIOL, V19, P8344; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Jiang ZB, 2007, CANCER RES, V67, P4467, DOI 10.1158/0008-5472.CAN-06-3398; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; Karakas B, 2006, BRIT J CANCER, V94, P455, DOI 10.1038/sj.bjc.6602970; Kato H, 2000, CLIN CANCER RES, V6, P3937; Kishimoto H, 2003, CELL STRUCT FUNCT, V28, P11; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Lacalle RA, 2004, J CELL SCI, V117, P6207, DOI 10.1242/jcs.01545; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Liu K, 2005, BIOCHEM SOC T, V33, P1170, DOI 10.1042/BST0331170; Liu K, 2005, J BIOL CHEM, V280, P22679, DOI 10.1074/jbc.M502972200; LoPiccolo J, 2008, DRUG RESIST UPDATE, V11, P32, DOI 10.1016/j.drup.2007.11.003; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; Maehama T, 2004, FEBS LETT, V565, P43, DOI 10.1016/j.febslet.2004.03.074; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Mager WH, 2005, TRENDS PHARMACOL SCI, V26, P265, DOI 10.1016/j.tips.2005.03.004; Marone R, 2008, BBA-PROTEINS PROTEOM, V1784, P159, DOI 10.1016/j.bbapap.2007.10.003; Masse I, 2005, DEV BIOL, V286, P91, DOI 10.1016/j.ydbio.2005.07.010; Matsuo T, 2003, EMBO J, V22, P3073, DOI 10.1093/emboj/cdg298; Melese T, 2002, TRENDS PHARMACOL SCI, V23, P544, DOI 10.1016/S0165-6147(02)02097-7; Mihaylova VT, 1999, P NATL ACAD SCI USA, V96, P7427, DOI 10.1073/pnas.96.13.7427; Mitra P, 2004, J CELL BIOL, V166, P205, DOI 10.1083/jcb.200404150; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Niederberger C, 1999, MOL GEN GENET, V261, P177, DOI 10.1007/s004380050955; Nishio M, 2007, NAT CELL BIOL, V9, P36, DOI 10.1038/ncb1515; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Pascual-Ahuir A, 2007, CELL CYCLE, V6, P2445, DOI 10.4161/cc.6.20.4792; Pedruzzi I, 2003, MOL CELL, V12, P1607, DOI 10.1016/S1097-2765(03)00485-4; Pinal N, 2006, CURR BIOL, V16, P140, DOI 10.1016/j.cub.2005.11.068; Pulido R, 2008, FEBS J, V275, P848, DOI 10.1111/j.1742-4658.2008.06250.x; Rodriguez-Escudero I, 2005, BIOCHEM J, V390, P613, DOI 10.1042/BJ20050574; Roelants FM, 2002, MOL BIOL CELL, V13, P3005, DOI 10.1091/mbc.E02-04-0201; Roosen J, 2005, MOL MICROBIOL, V55, P862, DOI 10.1111/j.1365-2958.2004.04429.x; Rouault JP, 1999, CURR BIOL, V9, P329, DOI 10.1016/S0960-9822(99)80143-2; Roux AE, 2006, AGING CELL, V5, P345, DOI 10.1111/j.1474-9726.2006.00225.x; Scanga SE, 2000, ONCOGENE, V19, P3971, DOI 10.1038/sj.onc.1203739; Sharrard RM, 2000, BBA-GENE STRUCT EXPR, V1494, P282, DOI 10.1016/S0167-4781(00)00210-4; Shimodaira H, 1998, NAT GENET, V19, P384, DOI 10.1038/1277; Smith A, 1999, BBA-GENE STRUCT EXPR, V1447, P313, DOI 10.1016/S0167-4781(99)00172-4; Solari F, 2005, ONCOGENE, V24, P20, DOI 10.1038/sj.onc.1207978; Song ZH, 2007, EXP CELL RES, V313, P1161, DOI 10.1016/j.yexcr.2007.01.004; Steelman LS, 2008, ONCOGENE, V27, P4086, DOI 10.1038/onc.2008.49; Stocker H, 2002, SCIENCE, V295, P2088, DOI 10.1126/science. 1068094; Strahl T, 2007, BBA-MOL CELL BIOL L, V1771, P353, DOI 10.1016/j.bbalip.2007.01.015; Subramanian KK, 2007, BLOOD, V109, P4028, DOI 10.1182/blood-2006-10-055319; Sun YD, 2000, MOL CELL BIOL, V20, P4411, DOI 10.1128/MCB.20.12.4411-4419.2000; Suzuki A, 2008, CANCER SCI, V99, P209, DOI 10.1111/j.1349-7006.2007.00670.x; Suzuki T, 1998, GENE CHROMOSOME CANC, V21, P290, DOI 10.1002/(SICI)1098-2264(199804)21:4<290::AID-GCC2>3.0.CO;2-U; Tamguney T, 2007, J CELL SCI, V120, P4071, DOI 10.1242/jcs.015230; Tugendreich S, 2001, GENOME RES, V11, P1899, DOI 10.1101/gr.191601; Ueno S, 2006, DEV BIOL, V297, P274, DOI 10.1016/j.ydbio.2006.06.001; Urban J, 2007, MOL CELL, V26, P663, DOI 10.1016/j.molcel.2007.04.020; Valiente M, 2005, J BIOL CHEM, V280, P28936, DOI 10.1074/jbc.M504761200; Vogt PK, 2007, TRENDS BIOCHEM SCI, V32, P342, DOI 10.1016/j.tibs.2007.05.005; von Stein W, 2005, DEVELOPMENT, V132, P1675, DOI 10.1242/dev.01720; Walther TC, 2007, EMBO J, V26, P4946, DOI 10.1038/sj.emboj.7601933; Wan WZ, 2007, CELL SIGNAL, V19, P2227, DOI 10.1016/j.cellsig.2007.06.007; Wessels D, 2007, J CELL SCI, V120, P2517, DOI 10.1242/jcs.010876; Wu H, 2007, MOL CELL, V28, P886, DOI 10.1016/j.molcel.2007.10.028; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Yu JW, 2004, MOL CELL, V13, P677, DOI 10.1016/S1097-2765(04)00083-8; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	100	24	25	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2008	27	41					5431	5442		10.1038/onc.2008.240	http://dx.doi.org/10.1038/onc.2008.240			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KW	18794878				2022-12-17	WOS:000259280700005
J	Hasegawa, T; Enomoto, A; Kato, T; Kawai, K; Miyamoto, R; Jijiwa, M; Ichihara, M; Ishida, M; Asai, N; Murakumo, Y; Ohara, K; Niwa, Y; Goto, H; Takahashi, M				Hasegawa, T.; Enomoto, A.; Kato, T.; Kawai, K.; Miyamoto, R.; Jijiwa, M.; Ichihara, M.; Ishida, M.; Asai, N.; Murakumo, Y.; Ohara, K.; Niwa, Y.; Goto, H.; Takahashi, M.			Roles of induced expression of MAPK phosphatase-2 in tumor development in RET-MEN2A transgenic mice	ONCOGENE			English	Article						RET; MEN2A; MKP-2; cell proliferation; cell cycle	ACTIVATED PROTEIN-KINASE; CELL-CYCLE ARREST; NEOPLASIA TYPE 2B; RET PROTOONCOGENE; LACKING GDNF; HIRSCHSPRUNGS-DISEASE; TERMINAL KINASE; THYROID-CANCER; 2A MUTATION; GENE	Germline mutations in the RET tyrosine kinase gene are responsible for the development of multiple endocrine neoplasia 2A and 2B (MEN2A and MEN2B). However, knowledge of the fundamental principles that determine the mutant RET-mediated signaling remains elusive. Here, we report increased expression of mitogen-activated protein kinase phosphatase-2 (MKP-2) in carcinomas developed in transgenic mice carrying RET with the MEN2A mutation (RET-MEN2A). The expression of MKP-2 was not only induced by RET-MEN2A or RET-MEN2B mutant proteins but also by the activation of endogenous RET by its ligand, glial cell line-derived neurotrophic factor (GDNF). MKP-2 expression was also evident in the MKK-f cell line, which was established from a mammary tumor developed in a RET- MEN2A transgenic mouse. Inhibition of MKP-2 attenuated the in vitro and in vivo proliferation of MKK-f cells, which was mediated by the suppression of cyclin B1 expression. Furthermore, we found that MKP-2 is highly expressed in medullary thyroid carcinomas derived from MEN2A patients. These findings suggest that the increased expression of MKP-2 may play a crucial role in oncogenic signaling downstream of mutant RET, leading to deregulation of cell cycle.	[Hasegawa, T.; Enomoto, A.; Kato, T.; Kawai, K.; Miyamoto, R.; Jijiwa, M.; Ishida, M.; Asai, N.; Murakumo, Y.; Ohara, K.; Takahashi, M.] Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; [Hasegawa, T.; Ohara, K.; Niwa, Y.; Goto, H.] Nagoya Univ, Grad Sch Med, Dept Gastroenterol, Nagoya, Aichi 4668550, Japan; [Enomoto, A.] Nagoya Univ, Inst Adv Res, Nagoya, Aichi 4668550, Japan; [Ichihara, M.] Chubu Univ, Dept Biomed Sci, Coll Life & Hlth Sci, Kasugai, Aichi 487, Japan; [Takahashi, M.] Nagoya Univ, Grad Sch Med, Div Mol Pathol, Ctr Neurol Dis & Cancer, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University; Nagoya University; Chubu University; Nagoya University	Takahashi, M (corresponding author), Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	mtakaha@med.nagoya-u.ac.jp	Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014; ASAI, Naoya/I-7377-2014; Enomoto, Atsushi/I-7272-2014; Kumi, Kawai/I-6275-2014	Takahashi, Masahide/0000-0002-2803-2683; Enomoto, Atsushi/0000-0002-9206-6116; Kumi, Kawai/0000-0002-7772-2605	21st Century Center of Excellence (COE) Research; Scientific Research (A); Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan	21st Century Center of Excellence (COE) Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Scientific Research (A)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank K Hirose (Nagoya University) for providing the pNAMA shRNA expression vector, S Nakamura (Nagoya University Hospital) for providing sporadic and MEN2A MTC specimens and C Suzuki (Nagoya University) and T Urano (Shimane University) for helpful discussion. We also thank YGotoh (Tokyo University) for providing active MAPKK (pSR alpha-Delta SESE-MAPKK) and MKK6 (pcDNA3.1(+)-MKK6-EE) plasmids. This study was supported by Grants-in-Aid for The 21st Century Center of Excellence (COE) Research, Scientific Research (A) and Scientific Research on Priority Area 'Cancer' commissioned by the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (to MT).	Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Asai N, 2006, PATHOL INT, V56, P164, DOI 10.1111/j.1440-1827.2006.01942.x; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Cadalbert L, 2005, CELL SIGNAL, V17, P1254, DOI 10.1016/j.cellsig.2005.01.003; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Dickinson RJ, 2006, J CELL SCI, V119, P4607, DOI 10.1242/jcs.03266; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; Eng C, 1999, J CLIN ONCOL, V17, P380, DOI 10.1200/JCO.1999.17.1.380; Enomoto A, 2005, DEV CELL, V9, P389, DOI 10.1016/j.devcel.2005.08.001; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Fukuda T, 2005, GENES CELLS, V10, P655, DOI 10.1111/j.1365-2443.2005.00866.x; Gimm O, 1997, J CLIN ENDOCR METAB, V82, P3902, DOI 10.1210/jc.82.11.3902; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Hassan KA, 2002, CANCER RES, V62, P6414; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Kao GD, 1997, CANCER RES, V57, P753; Kawai K, 2000, CANCER RES, V60, P5254; Kawai K, 2003, CANCER SCI, V94, P992, DOI 10.1111/j.1349-7006.2003.tb01390.x; Kodama Y, 2005, CANCER SCI, V96, P143, DOI 10.1111/j.1349-7006.2005.00023.x; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Owens DM, 2007, ONCOGENE, V26, P3203, DOI 10.1038/sj.onc.1210412; Park M, 2000, CANCER RES, V60, P542; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; Porter Lisa A, 2003, Prog Cell Cycle Res, V5, P335; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Rosenthal A, 1999, NEURON, V22, P201, DOI 10.1016/S0896-6273(00)81077-6; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Santana C, 2002, MUTAT RES-FUND MOL M, V508, P49, DOI 10.1016/S0027-5107(02)00172-0; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Shen WH, 2006, CANCER RES, V66, P6033, DOI 10.1158/0008-5472.CAN-05-3878; Shirane D, 2004, NAT GENET, V36, P190, DOI 10.1038/ng1290; Smith DP, 1997, ONCOGENE, V15, P1213, DOI 10.1038/sj.onc.1201481; Soria JC, 2000, CANCER RES, V60, P4000; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Uchida M, 2006, J CELL SCI, V119, P3067, DOI 10.1242/jcs.03043; Wang JL, 2007, J BIOL CHEM, V282, P18521, DOI 10.1074/jbc.M610538200; Watanabe T, 2002, AM J PATHOL, V161, P249, DOI 10.1016/S0002-9440(10)64176-4; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yuan J, 2006, ONCOGENE, V25, P1753, DOI 10.1038/sj.onc.1209202; Yuan JP, 2004, ONCOGENE, V23, P5843, DOI 10.1038/sj.onc.1207757	52	24	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	43					5684	5695		10.1038/onc.2008.182	http://dx.doi.org/10.1038/onc.2008.182			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352HM	18542059				2022-12-17	WOS:000259487100004
J	Nepal, RM; Zaheen, A; Basit, W; Li, L; Berger, SA; Martin, A				Nepal, R. M.; Zaheen, A.; Basit, W.; Li, L.; Berger, S. A.; Martin, A.			AID and RAG1 do not contribute to lymphomagenesis in E mu c-myc transgenic mice	ONCOGENE			English	Article						B cells; hypermutation; activation-induced cytidine deaminase; c-myc; lymphoma; RAG	CYTIDINE DEAMINASE AID; REACTIVE B-LYMPHOCYTES; SOMATIC HYPERMUTATION; CELL LYMPHOMAS; DNA BREAKS; TRANSLOCATIONS; EXPRESSION; REGION; MOUSE; GENE	DNA breaks caused by recombination-activating gene 1 (RAG1) and activation-induced cytidine deaminase (AID) induce c-myc/immunoglobulin (Ig) heavy chain chromosomal translocations and thereby stimulate lymphomagenesis. However, constitutive expression of c-myc alone is not sufficient to induce lymphomas. Because RAG1 and AID activity occurs outside of Ig genes, we assessed whether these enzymes provide the secondary genetic lesions in El c-myc transgenic mice to promote lymphoma development. We found that the tumor incidence and tumor phenotype in E mu c-myc transgenic mice is similar in AID(+/+), AID(+/-) and AID(-/-) backgrounds in both specific pathogen-free and conventional animal facilities, indicating that AID does not contribute to lymphoma development in E mu c-myc transgenic mice. To examine the role of RAG proteins in E mu c-myc mice, we examined E mu c-myc transgenic mice that harbor the Ig-HEL heavy- and light-chain transgenes, and thus have reduced RAG expression in B cells. We found that tumor incidence was not affected by these Ig transgenes. However, we found that RAG1(-/-) E mu c-myc mice exhibited accelerated tumor development compared to controls. This data combined with our finding that E mu c-myc mice lived longer in the conventional facility than in the specific pathogen-free facility suggest an immune-mediated activity that suppresses lymphoma development.	[Nepal, R. M.; Zaheen, A.; Basit, W.; Li, L.; Berger, S. A.; Martin, A.] Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada; [Berger, S. A.] Univ Hlth Network, Arthritis & Autoimmun Res Ctr, Toronto, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Martin, A (corresponding author), Univ Toronto, Dept Immunol, Med Sci Bldg 5265, Toronto, ON M5S 1A8, Canada.	alberto.martin@utoronto.ca		Martin, Alberto/0000-0002-0795-0418				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; CREWS S, 1982, SCIENCE, V218, P1319, DOI 10.1126/science.7146913; Crouch EE, 2007, J EXP MED, V204, P1145, DOI 10.1084/jem.20061952; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Di Nola JM, 2007, ANNU REV BIOCHEM, V76, P1, DOI 10.1146/annurev.biochem.76.061705.090740; Dorsett Y, 2007, J EXP MED, V204, P2225, DOI 10.1084/jem.20070884; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Fang W, 1998, IMMUNITY, V9, P35, DOI 10.1016/S1074-7613(00)80586-5; Franco S, 2006, MOL CELL, V21, P201, DOI 10.1016/j.molcel.2006.01.005; Franco S, 2006, DNA REPAIR, V5, P1030, DOI 10.1016/j.dnarep.2006.05.024; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; Kotani A, 2007, P NATL ACAD SCI USA, V104, P1616, DOI 10.1073/pnas.0610732104; MASON DY, 1992, INT IMMUNOL, V4, P163, DOI 10.1093/intimm/4.2.163; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Muschen M, 2000, J EXP MED, V192, P1833, DOI 10.1084/jem.192.12.1833; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Prasad VS, 1996, CYTOMETRY, V23, P131, DOI 10.1002/(SICI)1097-0320(19960201)23:2<131::AID-CYTO7>3.0.CO;2-N; Raghavan SC, 2004, NATURE, V428, P88, DOI 10.1038/nature02355; Ramiro AR, 2004, CELL, V118, P431, DOI 10.1016/j.cell.2004.08.006; Ramiro AR, 2006, NATURE, V440, P105, DOI 10.1038/nature04495; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Smith DP, 2005, ONCOGENE, V24, P3544, DOI 10.1038/sj.onc.1208399; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9	27	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2008	27	34					4752	4756		10.1038/onc.2008.111	http://dx.doi.org/10.1038/onc.2008.111			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408759				2022-12-17	WOS:000258236300013
J	Greif, PA; Tizazu, B; Krause, A; Kremmer, E; Bohlander, SK				Greif, P. A.; Tizazu, B.; Krause, A.; Kremmer, E.; Bohlander, S. K.			The leukemogenic CALM/AF10 fusion protein alters the subcellular localization of the lymphoid regulator Ikaros	ONCOGENE			English	Article						AF10; CALM/AF10; Ikaros; leukemia; translocation	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; DNA-BINDING PROTEINS; U937 CELL-LINE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; LEUCINE-ZIPPER; FINGER; ISOFORMS; AF10	The t(10; 11)(p13; q14) translocation leads to the fusion of the CALM and AF10 genes. This translocation can be found as the sole cytogenetic abnormality in acute lymphoblastic leukemia, acute myeloid leukemia and in malignant lymphomas. The expression of CALM/AF10 in primary murine bone marrow cells results in the development of an aggressive leukemia in a murine bone marrow transplantation model. Using a yeast two-hybrid screen, we identified the lymphoid regulator Ikaros as an AF10 interacting protein. Interestingly, Ikaros is required for normal development of lymphocytes, and aberrant expression of Ikaros has been found in leukemia. In a murine model, the expression of a dominant negative isoform of Ikaros causes leukemias and lymphomas. The Ikaros interaction domain of AF10 was mapped to the leucine zipper domain of AF10, which is required for malignant transformation both by the CALM/AF10 and the MLL/AF10 fusion proteins. The interaction between AF10 and Ikaros was confirmed by GST pull down and co-immunoprecipitation. Coexpression of CALM/AF10 but not of AF10 alters the subcellular localization of Ikaros in murine fibroblasts. The transcriptional repressor activity of Ikaros is reduced by AF10. These results suggest that CALM/AF10 might interfere with normal Ikaros function, and thereby block lymphoid differentiation in CALM/AF10 positive leukemias.	[Bohlander, S. K.] Univ Munich, Dept Med 3, Klinikum Grosshadern, Med Klin 3, D-81377 Munich, Germany; [Kremmer, E.] GSF Forschungszentrum Umwelt & Gesundheit, Inst Mol Immunol, Munich, Germany; [Greif, P. A.; Tizazu, B.; Krause, A.; Bohlander, S. K.] Univ Munich, GSF, Clin Cooperat Grp Leukemia, D-81377 Munich, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Bohlander, SK (corresponding author), Univ Munich, Dept Med 3, Klinikum Grosshadern, Med Klin 3, Marchioninstr 25, D-81377 Munich, Germany.	sbohlan@gwdg.de	Krause, Alexandre/K-7221-2013	Greif, Philipp/0000-0002-3744-7936; Bohlander, Stefan/0000-0002-2202-9088				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Archangelo LF, 2006, ONCOGENE, V25, P4099, DOI 10.1038/sj.onc.1209438; Arco PGD, 2005, MOL CELL BIOL, V25, P2688, DOI 10.1128/MCB.25.7.2688-2697.2005; Bohlander SK, 2000, LEUKEMIA, V14, P93, DOI 10.1038/sj.leu.2401614; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Caudell D, 2007, CANCER RES, V67, P8022, DOI 10.1158/0008-5472.CAN-06-3749; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; Cobb BS, 2000, GENE DEV, V14, P2146, DOI 10.1101/gad.816400; Debernardi S, 2002, BLOOD, V99, P275, DOI 10.1182/blood.V99.1.275; Deshpande AJ, 2006, CANCER CELL, V10, P363, DOI 10.1016/j.ccr.2006.08.023; DiMartino JF, 2002, BLOOD, V99, P3780, DOI 10.1182/blood.V99.10.3780; Dreyling MH, 1996, P NATL ACAD SCI USA, V93, P4804, DOI 10.1073/pnas.93.10.4804; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; Gomez-del Arco P, 2004, MOL CELL BIOL, V24, P2797, DOI 10.1128/MCB.24.7.2797-2807.2004; HAHM KM, 1994, MOL CELL BIOL, V14, P7111, DOI 10.1128/MCB.14.11.7111; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; KOBAYASHI H, 1995, GENE CHROMOSOME CANC, V13, P217, DOI 10.1002/gcc.2870130312; Koipally J, 2002, J BIOL CHEM, V277, P13007, DOI 10.1074/jbc.M111371200; Linder B, 2000, J MOL BIOL, V299, P369, DOI 10.1006/jmbi.2000.3766; Linder B, 2001, EMBO REP, V2, P211, DOI 10.1093/embo-reports/kve039; Martin DGE, 2006, MOL CELL BIOL, V26, P7871, DOI 10.1128/MCB.00573-06; Mellor J, 2006, CELL, V126, P22, DOI 10.1016/j.cell.2006.06.028; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; Nietfeld W, 1996, IMMUNOL LETT, V49, P139, DOI 10.1016/0165-2478(95)02479-4; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Okada Y, 2006, NAT CELL BIOL, V8, P1017, DOI 10.1038/ncb1464; Olivero S, 2000, BRIT J HAEMATOL, V110, P826, DOI 10.1046/j.1365-2141.2000.02297.x; Payne KJ, 2003, J IMMUNOL, V170, P3091, DOI 10.4049/jimmunol.170.6.3091; Payne KJ, 2001, J IMMUNOL, V167, P1867, DOI 10.4049/jimmunol.167.4.1867; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Rebollo A, 2003, IMMUNOL CELL BIOL, V81, P171, DOI 10.1046/j.1440-1711.2003.01159.x; Ronni T, 2007, J BIOL CHEM, V282, P2538, DOI 10.1074/jbc.M605627200; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; ROWLEY JD, 1990, SEMIN HEMATOL, V27, P122; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; Sun L, 1999, CLIN CANCER RES, V5, P2112; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; Sun L, 1999, J CLIN ONCOL, V17, P3753, DOI 10.1200/JCO.1999.17.12.3753; Tebar F, 1999, MOL BIOL CELL, V10, P2687, DOI 10.1091/mbc.10.8.2687; Trinh LA, 2001, GENE DEV, V15, P1817, DOI 10.1101/gad.905601; Westman BJ, 2002, INT J BIOCHEM CELL B, V34, P1304, DOI 10.1016/S1357-2725(02)00070-5; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Yoshida T, 2006, NAT IMMUNOL, V7, P382, DOI 10.1038/ni1314	47	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2008	27	20					2886	2896		10.1038/sj.onc.1210945	http://dx.doi.org/10.1038/sj.onc.1210945			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18037964				2022-12-17	WOS:000255502500010
J	Kaplan-Lefko, PJ; Sutherland, BW; Evangelou, AI; Hadsell, DL; Barrios, RJ; Foster, BA; DeMayo, F; Greenberg, NM				Kaplan-Lefko, P. J.; Sutherland, B. W.; Evangelou, A. I.; Hadsell, D. L.; Barrios, R. J.; Foster, B. A.; DeMayo, F.; Greenberg, N. M.			Enforced epithelial expression of IGF-1 causes hyperplastic prostate growth while negative selection is requisite for spontaneous metastogenesis	ONCOGENE			English	Article						IGF-1; prostate; transgenic; TRAMP; akt	FACTOR-I-RECEPTOR; TRANSGENIC MICE; BINDING PROTEIN-3; CANCER CELLS; STEM-CELLS; BREAST-CANCER; INSULIN; MOUSE; TUMORS; MODEL	The insulin-like growth factor-1 (IGF-1) signaling axis is important for cell growth, differentiation and survival and increased serum IGF is a risk factor for prostate and other cancers. To study IGF-1 action on the prostate, we created transgenic (PB-Des) mice that specifically express human IGF-1(des) in prostate epithelial cells. This encodes a mature isoform of IGF-1 with decreased affinity for IGF binding proteins (IGFBP) due to a 3-amino acid deletion in the N terminus. Expression of IGF-1des was sufficient to cause hyperplastic lesions in all mice, however the well-differentiated lesions did not progress to adenocarcinoma within a year. Remarkably, crossing the PB-Des mice to an established model of prostate cancer delayed progression of organ-confined tumors and emergence of metastatic lesions in young mice. While dissemination of metastatic lesions was widespread in old bigenic mice we did not detect IGF-1des in poorly differentiated primary tumors or metastatic lesions. Expression of endogenous IGF-1 and levels of P-Akt and P-Erk were reduced independent of age. These data suggest that increased physiologic levels of IGF-1 facilitate the emergence of hyperplastic lesions while imposing a strong IGF-1-dependent differentiation block. Selection against IGF-1 action appears requisite for progression of localized disease and metastogenesis.	[Evangelou, A. I.; Greenberg, N. M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; [Kaplan-Lefko, P. J.; Evangelou, A. I.; Hadsell, D. L.; DeMayo, F.; Greenberg, N. M.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Hadsell, D. L.] Baylor Coll Med, Childrens Nutr Res Ctr, Houston, TX 77030 USA; [Hadsell, D. L.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Barrios, R. J.] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Foster, B. A.] Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; [Greenberg, N. M.] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA; [Greenberg, N. M.] Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Roswell Park Cancer Institute; Baylor College of Medicine; University of Washington; University of Washington Seattle	Greenberg, NM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA.	ngreenberg@fhcrc.org	Hadsell, Darryl/GPF-9037-2022; DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336	NCI NIH HHS [CA84296, CA82807, CA74589] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA084296, R01CA082807, F32CA074589] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahlen J, 2005, CLIN CANCER RES, V11, P206; Bendall SC, 2007, NATURE, V448, P1015, DOI 10.1038/nature06027; Burger PE, 2005, P NATL ACAD SCI USA, V102, P7180, DOI 10.1073/pnas.0502761102; Byrne RL, 1996, BRIT J UROL, V77, P627, DOI 10.1046/j.1464-410X.1996.09721.x; Carboni JM, 2005, CANCER RES, V65, P3781, DOI 10.1158/0008-5472.CAN-04-4602; Chan JM, 2002, J NATL CANCER I, V94, P1099; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chott A, 1999, AM J PATHOL, V155, P1271, DOI 10.1016/S0002-9440(10)65229-7; Colao A, 1999, J CLIN ENDOCR METAB, V84, P1986, DOI 10.1210/jc.84.6.1986; Cunha G R, 1989, Cancer Treat Res, V46, P159; Damon SE, 2001, ENDOCRINOLOGY, V142, P21, DOI 10.1210/en.142.1.21; DiGiovanni J, 2000, CANCER RES, V60, P1561; DiGiovanni J, 2000, P NATL ACAD SCI USA, V97, P3455, DOI 10.1073/pnas.97.7.3455; Evangelou AI, 2004, J CELL BIOCHEM, V91, P671, DOI 10.1002/jcb.10771; Forbes K, 2004, WORLD J UROL, V22, P67, DOI 10.1007/s00345-003-0395-3; Foulstone E, 2005, J PATHOL, V205, P145, DOI 10.1002/path.1712; Gingrich JR, 1996, CANCER RES, V56, P4096; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; Hadsell DL, 1996, ENDOCRINOLOGY, V137, P321, DOI 10.1210/en.137.1.321; Hadsell DL, 2000, ONCOGENE, V19, P889, DOI 10.1038/sj.onc.1203386; Hudson DL, 2004, PROSTATE CANCER P D, V7, P188, DOI 10.1038/sj.pcan.4500745; Huss WJ, 2005, CANCER RES, V65, P6640, DOI 10.1158/0008-5472.CAN-04-2548; Kaplan PJ, 1999, CANCER RES, V59, P2203; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798; Le Roith Derek, 2003, Exp Diabesity Res, V4, P205, DOI 10.1155/EDR.2003.205; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; MacGrogan D, 1997, SEMIN CANCER BIOL, V8, P11, DOI 10.1006/scbi.1997.0048; Majeed N, 2005, ONCOGENE, V24, P4736, DOI 10.1038/sj.onc.1208572; Mehrian-Shai R, 2007, P NATL ACAD SCI USA, V104, P5563, DOI 10.1073/pnas.0609139104; Nakamura M, 2004, CLIN CANCER RES, V10, P8434, DOI 10.1158/1078-0432.CCR-04-0430; OH Y, 1993, ENDOCRINOLOGY, V132, P1337, DOI 10.1210/en.132.3.1337; Platz EA, 2005, CANCER CAUSE CONTROL, V16, P255, DOI 10.1007/s10552-004-3484-8; Plymate SR, 2004, PROSTATE, V61, P276, DOI 10.1002/pros.20099; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Reiss K, 2000, ONCOGENE, V19, P2687, DOI 10.1038/sj.onc.1203587; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Schnarr B, 2000, INT J CANCER, V89, P506, DOI 10.1002/1097-0215(20001120)89:6<506::AID-IJC7>3.0.CO;2-F; Shaneyfelt T, 2000, J CLIN ONCOL, V18, P847, DOI 10.1200/JCO.2000.18.4.847; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Wennbo H, 1997, J CLIN INVEST, V100, P2744, DOI 10.1172/JCI119820; Wennbo H, 1997, ENDOCRINOLOGY, V138, P4410, DOI 10.1210/en.138.10.4410; Wu XC, 2003, CANCER RES, V63, P4936; Xin L, 2005, P NATL ACAD SCI USA, V102, P6942, DOI 10.1073/pnas.0502320102; Yakar S, 2005, ENDOCR DEV, V9, P11, DOI 10.1159/000085718	47	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2008	27	20					2868	2876		10.1038/sj.onc.1210943	http://dx.doi.org/10.1038/sj.onc.1210943			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18026134				2022-12-17	WOS:000255502500008
J	Chinen, Y; Taki, T; Nishida, K; Shimizu, D; Okuda, T; Yoshida, N; Kobayashi, C; Koike, K; Tsuchida, M; Hayashi, Y; Taniwaki, M				Chinen, Y.; Taki, T.; Nishida, K.; Shimizu, D.; Okuda, T.; Yoshida, N.; Kobayashi, C.; Koike, K.; Tsuchida, M.; Hayashi, Y.; Taniwaki, M.			Identification of the novel AML1 fusion partner gene, LAF4, a fusion partner of MLL, in childhood T-cell acute lymphoblastic leukemia with t(2;21)(q11;q22) by bubble PCR method for cDNA	ONCOGENE			English	Article						AML1/RUNX1; LAF4; T-cell acute lymphoblastic leukemia; MLL	ACUTE MYELOID-LEUKEMIA; CHROMOSOMAL TRANSLOCATIONS; PROTEIN; MALIGNANCIES; BREAKPOINTS; RUNXI; HEMATOPOIESIS; AML1/RUNX1; TRANSCRIPT; MUTATIONS	The AML1 gene is frequently rearranged by chromosomal translocations in acute leukemia. We identified that the LAF4 gene on 2q11.2-12 was fused to the AML1 gene on 21q22 in a pediatric patient having T-cell acute lymphoblastic leukemia ( T-ALL) with t(2;21)(q11;q22) using the bubble PCR method for cDNA. The genomic break points were within intron 7 of AML1 and of LAF4, resulting in the in-frame fusion of exon 7 of AML1 and exon 8 of LAF4. The LAF4 gene is a member of the AF4/FMR2 family and was previously identified as a fusion partner of MLL in B-precursor ALL with t(2;11)(q11;q23), although AML1-LAF4 was in T-ALL. LAF4 is the first gene fused with both AML1 and MLL in acute leukemia. Almost all AML1 translocations except for TEL-AML1 are associated with myeloid leukemia; however, AML1-LAF4 was associated with T-ALL as well as AML1-FGA7 in t(4;21)(q28;q22). These findings provide new insight into the common mechanism of AML1 and MLL fusion proteins in the pathogenesis of ALL. Furthermore, we successfully applied bubble PCR to clone the novel AML1-LAF4 fusion transcript. Bubble PCR is a powerful tool for detecting unknown fusion transcripts as well as genomic fusion points.	[Chinen, Y.; Taki, T.; Taniwaki, M.] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Lab Med, Kamigyo Ku, Kyoto 6028566, Japan; [Chinen, Y.; Nishida, K.; Shimizu, D.; Okuda, T.; Yoshida, N.; Taniwaki, M.] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Hematol & Oncol, Kamigyo Ku, Kyoto 6028566, Japan; [Kobayashi, C.; Koike, K.; Tsuchida, M.] Ibaraki Childrens Hosp, Dept Pediat, Mito, Ibaraki, Japan; [Hayashi, Y.] Gunma Childrens Med Ctr, Gunma, Japan	Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine; Gunma Children's Medical Centre	Taki, T (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Lab Med, Kamigyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan.	taki-t@umin.net						Agerstam H, 2007, GENE CHROMOSOME CANC, V46, P635, DOI 10.1002/gcc.20442; Asou N, 2007, BLOOD, V109, P4023, DOI 10.1182/blood-2006-01-031781; Bruch J, 2003, GENE CHROMOSOME CANC, V37, P106, DOI 10.1002/gcc.10187; Chaffanet M, 2000, GENE CHROMOSOME CANC, V28, P138, DOI 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2; Chan EM, 2005, BLOOD, V105, P4523, DOI 10.1182/blood-2004-07-2762; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; ERICKSON P, 1992, BLOOD, V80, P1825; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Hayashi Y, 2000, SEMIN HEMATOL, V37, P368, DOI 10.1016/S0037-1963(00)90017-9; Hiwatari M, 2003, ONCOGENE, V22, P2851, DOI 10.1038/sj.onc.1206389; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Isnard P, 2000, BLOOD, V96, P705; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Kurokawa M, 2003, CANCER SCI, V94, P841, DOI 10.1111/j.1349-7006.2003.tb01364.x; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Ma C, 1996, BLOOD, V87, P734, DOI 10.1182/blood.V87.2.734.bloodjournal872734; Megonigal MD, 2000, P NATL ACAD SCI USA, V97, P9597, DOI 10.1073/pnas.150241797; Mikhail FM, 2004, GENE CHROMOSOME CANC, V39, P110, DOI 10.1002/gcc.10302; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Nguyen TDT, 2006, GENE CHROMOSOME CANC, V45, P918, DOI 10.1002/gcc.20355; OHNISHI H, 1995, BLOOD, V86, P1269, DOI 10.1182/blood.V86.4.1269.bloodjournal8641269; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Paulsson K, 2006, LEUKEMIA, V20, P224, DOI 10.1038/sj.leu.2404076; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; Smith D R, 1992, PCR Methods Appl, V2, P21; Taketani T, 2002, CANCER RES, V62, P33; Taki T, 2006, CURR OPIN ONCOL, V18, P62, DOI 10.1097/01.cco.0000198972.69541.04; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; TANIWAKI M, 1994, BLOOD, V83, P2962, DOI 10.1182/blood.V83.10.2962.2962; VONBERGH AR, 2002, GENE CHROMOSOME CANC, V37, P106; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Yan M, 2004, P NATL ACAD SCI USA, V101, P17468, DOI 10.1073/pnas.0406142101; ZHANG JG, 1995, BRIT J HAEMATOL, V90, P138, DOI 10.1111/j.1365-2141.1995.tb03392.x; Zhang YM, 2004, GENE CHROMOSOME CANC, V40, P365, DOI 10.1002/gcc.20050	41	24	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2008	27	15					2249	2256		10.1038/sj.onc.1210857	http://dx.doi.org/10.1038/sj.onc.1210857			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17968322				2022-12-17	WOS:000254621300016
J	Fontaine, JF; Mirebeau-Prunier, D; Franc, B; Triau, S; Rodien, P; Houlgatte, R; Malthiery, Y; Savagner, F				Fontaine, J-F; Mirebeau-Prunier, D.; Franc, B.; Triau, S.; Rodien, P.; Houlgatte, R.; Malthiery, Y.; Savagner, F.			Microarray analysis refines classification of non-medullary thyroid tumours of uncertain malignancy	ONCOGENE			English	Article						thyroid tumours; microarray analysis; uncertain malignancy; classification	GENE-EXPRESSION PROFILES; FOLLICULAR VARIANT; OBSERVER VARIATION; CARCINOMA; CANCER; REARRANGEMENT; MUTATION; BENIGN; ASSOCIATION; DISCOVERY	Conventional histology failed to classify part of non-medullary thyroid lesions as either benign or malignant. The group of tumours of uncertain malignancy (T-UM) concerns either atypical follicular adenomas or the recently called 'tumours of uncertain malignant potential'. To re. ne this classification we analysed microarray data from 93 follicular thyroid tumours: 10 T-UM, 3 follicular carcinomas, 13 papillary thyroid carcinomas and 67 follicular adenomas, compared to 73 control thyroid tissue samples. The diagnosis potential of 16 selected genes was validated by real-time quantitative RT-PCR on 6 additional T-UM. The gene expression profiles in several groups were examined with reference to the mutational status of the RET/PTC, BRAF and RAS genes. A pathological score (histological and immunohistochemical) was estimate for each of the T-UM involved in the study. The correlation between the T-UM gene profiles and the pathological score allowed a separation of the samples in two groups of benign or malignant tumours. Our analysis confirms the heterogeneity of T-UM and highlighted the molecular similarities between some cases and true carcinomas. We demonstrated the ability of few marker genes to serve as diagnosis tools and the need of a T-UM pathological scoring.	[Fontaine, J-F; Mirebeau-Prunier, D.; Malthiery, Y.; Savagner, F.] CHU Angers, Biochim Lab, INSERM, U694, F-49033 Angers, France; [Fontaine, J-F; Mirebeau-Prunier, D.; Malthiery, Y.; Savagner, F.] Univ Angers, Fac Med, Angers, France; [Franc, B.] Univ Versailles, Hop Ambroise Pare, Serv Pathol, Fac Paris France Ouest, Boulogne, France; [Triau, S.] CHU Angers, Fed Pathol Cellulaire & Tissulaire, F-49033 Angers, France; [Rodien, P.] CHU Angers, Dept Endocrinol & Med Interne, F-49033 Angers, France; [Houlgatte, R.] INSERM, U533, Nantes, France; [Houlgatte, R.] Univ Nantes, Inst Thorax, Fac Med, F-44035 Nantes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Universite d'Angers; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Saclay; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes	Savagner, F (corresponding author), CHU Angers, Biochim Lab, INSERM, U694, 4 Rue Larrey, F-49033 Angers, France.	frsavagner@chu-angers.fr	Prunier, Delphine/K-3301-2015; Houlgatte, Remi/P-3020-2017; Rodien, Patrice/AAT-7909-2021; Fontaine, Jean-Fred/GNP-2904-2022	Fontaine, Jean-Fred/0000-0002-1101-4091				Al-Shahrour F, 2004, BIOINFORMATICS, V20, P578, DOI 10.1093/bioinformatics/btg455; Baris O, 2005, ONCOGENE, V24, P4155, DOI 10.1038/sj.onc.1208578; Baris O, 2004, J CLIN ENDOCR METAB, V89, P994, DOI 10.1210/jc.2003-031238; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bertucci F, 2003, INT J CANCER, V103, P565, DOI 10.1002/ijc.10867; de la Torre NG, 2006, ENDOCR-RELAT CANCER, V13, P931, DOI 10.1677/erc.1.01210; De Micco C, 1999, SURGERY, V126, P1200, DOI 10.1067/msy.2099.101428; Di Cristofaro J, 2006, HUM PATHOL, V37, P824, DOI 10.1016/j.humpath.2006.01.030; Du Villard J, 2000, ONCOGENE, V19, P4896, DOI 10.1038/sj.onc.1203852; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eszlinger M, 2006, J CLIN ENDOCR METAB, V91, P1934, DOI 10.1210/jc.2005-1620; Finley DJ, 2004, ANN SURG, V240, P425, DOI 10.1097/01.sla.0000137128.64978.bc; Finn SP, 2007, VIRCHOWS ARCH, V450, P249, DOI 10.1007/s00428-006-0348-5; Franc B, 2003, HUM PATHOL, V34, P1092, DOI 10.1016/S0046-8177(03)00403-9; GE YC, 2003, TEST, V12, P1, DOI DOI 10.1007/BF02595811; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Giordano TJ, 2005, ONCOGENE, V24, P6646, DOI 10.1038/sj.onc.1208822; Hirokawa M, 2002, AM J SURG PATHOL, V26, P1508, DOI 10.1097/00000478-200211000-00014; Hoffmann S, 2006, ENDOCRINE, V30, P129, DOI 10.1385/ENDO:30:1:129; Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398; Jarzab B, 2005, CANCER RES, V65, P1587, DOI 10.1158/0008-5472.CAN-04-3078; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Lacroix L, 2005, AM J PATHOL, V167, P223, DOI 10.1016/S0002-9440(10)62967-7; Lloyd RV, 2004, AM J SURG PATHOL, V28, P1336, DOI 10.1097/01.pas.0000135519.34847.f6; Lubitz CC, 2005, SURGERY, V138, P1042, DOI 10.1016/j.surg.2005.09.009; Mazzanti C, 2004, CANCER RES, V64, P2898, DOI 10.1158/0008-5472.CAN-03-3811; Mirebeau-Prunier D, 2004, EUR J ENDOCRINOL, V150, P269, DOI 10.1530/eje.0.1500269; More E, 2003, J ENDOCRINOL, V176, P83, DOI 10.1677/joe.0.1760083; Nikiforova MN, 2002, AM J SURG PATHOL, V26, P1016, DOI 10.1097/00000478-200208000-00006; RHODEN KJ, 2003, J CLIN ENDOCR METAB, V91, P2414; Takahashi M, 2003, ONCOGENE, V22, P6810, DOI 10.1038/sj.onc.1206869; Williams ED, 2000, INT J SURG PATHOL, V8, P181, DOI 10.1177/106689690000800304; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	35	24	33	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2008	27	15					2228	2236		10.1038/sj.onc.1210853	http://dx.doi.org/10.1038/sj.onc.1210853			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17968324				2022-12-17	WOS:000254621300013
J	Enomoto, A; Kido, N; Ito, M; Morita, A; Matsumoto, Y; Takamatsu, N; Hosoi, Y; Miyagawa, K				Enomoto, A.; Kido, N.; Ito, M.; Morita, A.; Matsumoto, Y.; Takamatsu, N.; Hosoi, Y.; Miyagawa, K.			Negative regulation of MEKK1/2 signaling by Serine-Threonine kinase 38 (STK38)	ONCOGENE			English	Article						STK38; MEKK1; MEKK2; MAPKKK; signal transduction	ACTIVATED PROTEIN-KINASE; KAPPA-B ACTIVATION; N-TERMINAL KINASE; CELL LINE MOLT-4; MEK KINASE; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; MAP KINASES; JUN KINASES; JNK	Mitogen-activated protein kinases (MAPKs) are activated through the kinase cascades of MAPK, MAPK kinase (MAPKK) and MAPKK kinase (MAPKKK). MAPKKKs phosphorylate and activate their downstream MAPKKs, which in turn phosphorylate and activate their downstream MAPKs. MAPKKK proteins relay upstream signals through the MAPK cascades to induce cellular responses. However, the molecular mechanisms by which given MAPKKKs are regulated remain largely unknown. Here, we found that serine-threonine protein kinase 38, STK38, physically interacts with the MAPKKKs MEKK1 and MEKK2 (MEKK1/2). The carboxy terminus, including the catalytic domain, but not the amino terminus of MEKK1/2 was necessary for the interaction with STK38. STK38 inhibited MEKK1/2 activation without preventing MEKK1/2 binding to its substrate, SEK1. Importantly, STK38 suppressed the autophosphorylation of MEKK2 without interfering with MEKK2 dimer formation, and converted MEKK2 from its phosphorylated to its nonphosphorylated form. The negative regulation of MEKK1/2 was not due to its phosphorylation by STK38. On the other hand, stk38 short hairpin RNA enhanced sorbitol-induced activation of MEKK2 and phosphorylation of the downstream MAPKKs, MKK3/6. Taken together, our results indicate that STK38 negatively regulates the activation of MEKK1/2 by direct interaction with the catalytic domain of MEKK1/2, suggesting a novel mechanism of MEKK1/2 regulation.	[Enomoto, A.; Kido, N.; Matsumoto, Y.; Hosoi, Y.; Miyagawa, K.] Univ Tokyo, Grad Sch Med, Sect Radiol Biol, Ctr Dis Biol & Integrat Med,Bunkyo Ku, Tokyo 1130033, Japan; [Kido, N.] Univ Tokyo, Sch Med, Tokyo 113, Japan; [Ito, M.; Takamatsu, N.] Kitasato Univ, Sch Sci, Dept Biosci, Kanagawa, Japan; [Morita, A.] Tokyo Univ Sci, Fac Sci & Technol, Dept Appl Biol Sci, Chiba, Japan; [Matsumoto, Y.] Tokyo Inst Technol, Nucl Reactors Res Lab, Dept Nucl Engn, Tokyo 152, Japan	University of Tokyo; University of Tokyo; Kitasato University; Tokyo University of Science; Tokyo Institute of Technology	Enomoto, A (corresponding author), Univ Tokyo, Grad Sch Med, Sect Radiol Biol, Ctr Dis & Integrat Med,Bunkyo Ku, 3-7-2001 Hongo, Tokyo 1130033, Japan.	aenomoto@m.u-tokyo.ac.jp	Morita, Akinori/D-1418-2011					Bidlingmaier S, 2001, MOL CELL BIOL, V21, P2449, DOI 10.1128/MCB.21.7.2449-2462.2001; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chayama K, 2001, P NATL ACAD SCI USA, V98, P4599, DOI 10.1073/pnas.081021898; Chen W, 2002, J BIOL CHEM, V277, P49105, DOI 10.1074/jbc.M204934200; Cheng J, 2005, MOL CELL BIOL, V25, P5955, DOI 10.1128/MCB.25.14.5955-5964.2005; Cheng JK, 2005, J BIOL CHEM, V280, P13477, DOI 10.1074/jbc.M414258200; Cheng JK, 2000, MOL CELL BIOL, V20, P2334, DOI 10.1128/MCB.20.7.2334-2342.2000; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deak JC, 1997, BIOCHEM J, V322, P185, DOI 10.1042/bj3220185; Enomoto A, 2000, CANCER LETT, V155, P137, DOI 10.1016/S0304-3835(00)00422-5; Enomoto A, 2003, INT J RADIAT BIOL, V79, P589, DOI 10.1080/09553000310001597273; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Guo ZJ, 2002, MOL CELL BIOL, V22, P5761, DOI 10.1128/MCB.22.16.5761-5768.2002; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hergovich A, 2006, NAT REV MOL CELL BIO, V7, P253, DOI 10.1038/nrm1891; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; ITOM, 1999, MOL CELL BIOL, V19, P7539; JOHNSTON LH, 1990, MOL CELL BIOL, V10, P1358, DOI 10.1128/MCB.10.4.1358; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kesavan K, 2004, J CELL PHYSIOL, V199, P140, DOI 10.1002/jcp.10457; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Manning G, 2002, TRENDS BIOCHEM SCI, V27, P514, DOI 10.1016/S0968-0004(02)02179-5; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Minamino T, 1999, P NATL ACAD SCI USA, V96, P15127, DOI 10.1073/pnas.96.26.15127; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Ryoo K, 2004, J BIOL CHEM, V279, P43589, DOI 10.1074/jbc.M404359200; Su B, 2001, J BIOL CHEM, V276, P14784, DOI 10.1074/jbc.M010134200; Tamaskovic R, 2003, FEBS LETT, V546, P73, DOI 10.1016/S0014-5793(03)00474-5; Verde F, 1998, P NATL ACAD SCI USA, V95, P7526, DOI 10.1073/pnas.95.13.7526; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; YAN MH, 1994, NATURE, V372, P798; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Zhang DY, 2006, EMBO J, V25, P97, DOI 10.1038/sj.emboj.7600913	43	24	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1930	1938		10.1038/sj.onc.1210828	http://dx.doi.org/10.1038/sj.onc.1210828			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17906693				2022-12-17	WOS:000254150600012
J	Iwakuma, T; Tochigi, Y; Van Pelt, CS; Caldwell, LC; Terzian, T; Parant, JM; Chau, GP; Koch, JG; Eischen, CM; Lozano, G				Iwakuma, T.; Tochigi, Y.; Van Pelt, C. S.; Caldwell, L. C.; Terzian, T.; Parant, J. M.; Chau, G. P.; Koch, J. G.; Eischen, C. M.; Lozano, G.			Mtbp haploinsufficiency in mice increases tumor metastasis	ONCOGENE			English	Article						Mdm2; p53; MrpL13	MAMMALIAN MITOCHONDRIAL RIBOSOME; EMBRYONIC LETHALITY; S PHASE; MDM2; P53; EXPRESSION; SPECTRUM; RESCUE; SUPPRESSION; PROTEINS	Mdm2 inhibits the function of the p53 tumor suppressor. Mdm2 is overexpressed in many tumors with wild-type p53 suggesting an alternate mechanism of loss of p53 activity in tumors. An Mdm2-binding protein (MTBP) was identified using a yeast two-hybrid screen. In tissue culture, MTBP inhibits Mdm2 self-ubiquitination, leading to stabilization of Mdm2 and increased degradation of p53. To address the role of MTBP in the regulation of the p53 pathway in vivo, we deleted the Mtbp gene in mice. Homozygous disruption of Mtbp resulted in early embryonic lethality, which was not rescued by loss of p53. Mtbp(+/-) mice were not tumor prone. When mice were sensitized for tumor development by p53 heterozygosity, we found that the Mtbp(+/-)p53(+/-) mice developed significantly more metastatic tumors (18.2%) as compared to p53(+/-) mice (2.6%). Results of in vitro migration and invasion assays support the in vivo findings. Downmodulation of Mtbp in osteosarcoma cells derived from p53(+/-) mice resulted in increased invasiveness, and overexpression of Mtbp in Mtbp(+/-)p53(+/-) osteosarcoma cells inhibited invasiveness. These results suggest that MTBP is a metastasis suppressor. These results advance our understanding of the cellular roles of MTBP and raise the possibility that MTBP is a novel therapeutic target for metastasis.	[Iwakuma, T.; Terzian, T.; Parant, J. M.; Chau, G. P.; Koch, J. G.; Lozano, G.] Univ Texas MD Anderson Canc Ctr, Dept Canc Genet, Houston, TX 77030 USA; [Iwakuma, T.; Tochigi, Y.] Louisiana State Univ, Hlth Sci Ctr, Dept Genet, New Orleans, LA USA; [Van Pelt, C. S.] Univ Texas MD Anderson Canc Ctr, Dept Vet Med, Houston, TX USA; [Koch, J. G.] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA; [Eischen, C. M.] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37212 USA	University of Texas System; UTMD Anderson Cancer Center; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Vanderbilt University	Lozano, G (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	tiwaku@lsuhsc.edu; gglozano@mdanderson.org		Chau, Gilda/0000-0002-7907-3290	NATIONAL CANCER INSTITUTE [R01CA098139] Funding Source: NIH RePORTER; NCI NIH HHS [CA098139] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alt JR, 2003, EMBO J, V22, P1442, DOI 10.1093/emboj/cdg133; BARTEK J, 1991, ONCOGENE, V6, P1699; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Boyd MT, 2000, J BIOL CHEM, V275, P31883, DOI 10.1074/jbc.M004252200; Brady M, 2005, MOL CELL BIOL, V25, P545, DOI 10.1128/MCB.25.2.545-553.2005; Che G, 2006, NEOPLASMA, V53, P530; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Finch RA, 2002, CANCER RES, V62, P3221; Iwakuma T, 2004, ONCOGENE, V23, P7644, DOI 10.1038/sj.onc.1207793; Iwakuma T, 2003, MOL CANCER RES, V1, P993; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jee BK, 2006, BIOCHEM BIOPH RES CO, V342, P655, DOI 10.1016/j.bbrc.2006.01.153; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Koc EC, 2001, J BIOL CHEM, V276, P43958, DOI 10.1074/jbc.M106510200; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; LEVINE AJ, 2004, CELL, V69, pS67; LEVINE HB, 1993, PSYCHOANAL QUART, V62, P651; Lozano G, 2005, J PATHOL, V205, P206, DOI 10.1002/path.1704; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Mendrysa SM, 2006, GENE DEV, V20, P16, DOI 10.1101/gad.1378506; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; PURDIE CA, 1994, ONCOGENE, V9, P603; Reinke V, 1999, CELL GROWTH DIFFER, V10, P147; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; Suzuki T, 2001, J BIOL CHEM, V276, P21724, DOI 10.1074/jbc.M100432200; TSUKADA T, 1993, ONCOGENE, V8, P3313; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991	34	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1813	1820		10.1038/sj.onc.1210827	http://dx.doi.org/10.1038/sj.onc.1210827			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17906694				2022-12-17	WOS:000254150600001
J	Runeberg-Roos, P; Virtanen, H; Saarma, M				Runeberg-Roos, P.; Virtanen, H.; Saarma, M.			RET(MEN 2B) is active in the endoplasmic reticulum before reaching the cell surface	ONCOGENE			English	Article						RET; MEN 2B; precursor; downstream signalling; endoplasmic reticulum	ENDOCRINE NEOPLASIA TYPE-2; RET PROTOONCOGENE PRODUCTS; HIRSCHSPRUNGS-DISEASE; TYROSINE KINASE; THYROID-CELLS; ACTIVATION; MUTATIONS; MECHANISM; RECEPTOR; GDNF	MEN 2B ( multiple endocrine neoplasia type 2B) is an autosomal dominant cancer syndrome caused by an oncogenic form of the receptor tyrosine kinase REarranged during transfection (RET). The MEN 2B syndrome is associated with an abnormal autophosphorylation of the mutated receptor even without ligand-stimulation. Here, we characterize the activation of a RETMEN2B variant carrying the point mutation Met918Thr, and show that the 150 kDa precursor of RETMEN2B becomes phosphorylated already during synthesis in the endoplasmic reticulum (ER). At least three different tyrosine residues (Tyr905, Tyr1062, Tyr1096) of the RETMEN2B precursor are phosphorylated before the oncogenic receptor reaches the cell surface. We also demonstrate that the precursor of RETMEN2B interacts with both growth factor receptor-bound protein and Src homology 2 domain-containing already in the ER, and that this interaction is dependent on the kinase activity of RET. With the aid of two RET mutants (RETMEN2B/S32L and RETMEN2B/ F393L), which accumulate in the ER, we show that the oncogenic precursor of the receptor has the capacity to activate AKT, extracellular signal-regulated kinase and signal transducer and activator of transcription 3 from the ER. Taken together, our data demonstrate that the oncogenic precursor of RETMEN2B is phosphorylated, interacts with adapter proteins and induces downstream signalling from the ER.	[Runeberg-Roos, P.; Virtanen, H.; Saarma, M.] Univ Helsinki, Inst Biotechnol, Viikki Bioctr, FIN-00014 Helsinki, Finland	University of Helsinki	Runeberg-Roos, P (corresponding author), Univ Helsinki, Inst Biotechnol, Viikki Bioctr, Viikinkaari 9,POB 56, FIN-00014 Helsinki, Finland.	pia.runeberg@helsinki.fi						Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Bongarzone I, 1998, ONCOGENE, V16, P2295, DOI 10.1038/sj.onc.1201759; Carlomagno F, 1998, ENDOCRINOLOGY, V139, P3613, DOI 10.1210/en.139.8.3613; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; Cerchia L, 2003, BIOCHEM J, V372, P897, DOI 10.1042/BJ20021530; Chappuis-Flament S, 1998, ONCOGENE, V17, P2851, DOI 10.1038/sj.onc.1202202; Cosma MP, 1998, MOL CELL BIOL, V18, P3321, DOI 10.1128/MCB.18.6.3321; Freche B, 2005, J BIOL CHEM, V280, P36584, DOI 10.1074/jbc.M505707200; Hansford JR, 2000, J MED GENET, V37, P817, DOI 10.1136/jmg.37.11.817; Hwang JH, 2003, MOL ENDOCRINOL, V17, P1155, DOI 10.1210/me.2002-0401; Knauf JA, 2003, ONCOGENE, V22, P4406, DOI 10.1038/sj.onc.1206602; Kodama Y, 2005, CANCER SCI, V96, P143, DOI 10.1111/j.1349-7006.2005.00023.x; Miyagi E, 2004, MOL CARCINOGEN, V41, P98, DOI 10.1002/mc.20042; MIYAZAKI K, 1993, BIOCHEM BIOPH RES CO, V193, P565, DOI 10.1006/bbrc.1993.1661; MULLIGAN LM, 1995, J CLIN ENDOCR METAB, V80, P1989, DOI 10.1210/jc.80.7.1989; Pelet A, 1998, J CLIN INVEST, V101, P1415, DOI 10.1172/JCI375; Salvatore D, 2001, CANCER RES, V61, P1426; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; TAKAHASHI M, 1991, ONCOGENE, V6, P297; Tsui-Pierchala BA, 2002, J BIOL CHEM, V277, P34618, DOI 10.1074/jbc.M203580200; van Weering DHJ, 1998, J BIOL CHEM, V273, P12077, DOI 10.1074/jbc.273.20.12077; Virtanen H, 2005, BIOCHEM J, V387, P817, DOI 10.1042/BJ20041257	24	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2007	26	57					7909	7915		10.1038/sj.onc.1210591	http://dx.doi.org/10.1038/sj.onc.1210591			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599050				2022-12-17	WOS:000252163500009
J	Fischer, U; Meese, E				Fischer, U.; Meese, E.			Glioblastoma multiforme: the role of DSB repair between genotype and phenotype	ONCOGENE			English	Review						gene amplification; XRCC6BP1; temozolomide	COMPARATIVE GENOMIC HYBRIDIZATION; HEMATOPOIETIC STEM-CELLS; KINASE CATALYTIC SUBUNIT; GENE AMPLIFICATION; PROTEIN-KINASE; MALIGNANT GLIOMA; DNA-REPAIR; SECONDARY GLIOBLASTOMA; FRAGILE SITES; EXPRESSION	Glioblastoma is the most frequent primary brain tumor in adults. The average survival time of less than 1 year did not improve notably over the last three decades. The dismal prognosis of glioblastoma patients is largely due to the striking radioresistance of this tumor. Here, we attempt a combined view on the genetics, the repair mechanisms and the radioresistance of glioblastoma. Specifically, we address the role of DNA-PKcs and the novel potential end-joining factor KUB3 in maintaining the radioresistant phenotype, the interrelationship between genetic lesions and repair mechanisms, and new perspectives that emerge from the identification of glioblastoma stem cells.	Univ Saarland, Dept Human Genet, D-66421 Homburg, Germany	Saarland University	Meese, E (corresponding author), Univ Saarland, Dept Human Genet, Bldg 60, D-66421 Homburg, Germany.	hgemee@uniklinik-saarland.de	Meese, Eckart Ulrich/ABD-1983-2021					ALLALUNISTURNER MJ, 1993, RADIAT RES, V134, P349, DOI 10.2307/3578196; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Clarke MF, 2004, NATURE, V432, P281, DOI 10.1038/432281a; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; Daido S, 2005, CANCER RES, V65, P4368, DOI 10.1158/0008-5472.CAN-04-4202; Dibiase SJ, 2000, CANCER RES, V60, P1245; FISCHER U, 1994, EUR J CANCER, V30A, P1124, DOI 10.1016/0959-8049(94)90470-7; Fischer U, 2001, GLIA, V36, P1, DOI 10.1002/glia.1090; Friedman HS, 1997, CANCER RES, V57, P2933; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Hoppe BS, 2000, RADIAT RES, V153, P125, DOI 10.1667/0033-7587(2000)153[0125:COTRMC]2.0.CO;2; KAINA B, 1991, CARCINOGENESIS, V12, P1857; Kasten U, 1999, RADIAT RES, V151, P532, DOI 10.2307/3580029; Koschny R, 2002, CANCER GENET CYTOGEN, V135, P147, DOI 10.1016/S0165-4608(01)00650-1; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Maher EA, 2006, CANCER RES, V66, P11502, DOI 10.1158/0008-5472.CAN-06-2072; McClintock B, 1941, GENETICS, V26, P234; Mondello C, 2001, CANCER RES, V61, P4520; MULERIS M, 1994, ONCOGENE, V9, P2717; Munnia A, 2001, ONCOGENE, V20, P4853, DOI 10.1038/sj.onc.1204650; Nijnik A, 2007, NATURE, V447, P686, DOI 10.1038/nature05875; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Otomo T, 2004, J RADIAT RES, V45, P53, DOI 10.1269/jrr.45.53; Raderschall E, 2002, J CELL SCI, V115, P153; Rattray AJ, 2005, GENE DEV, V19, P1390, DOI 10.1101/gad.1315805; Reifenberger G, 1996, CANCER RES, V56, P5141; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Roos WP, 2007, ONCOGENE, V26, P186, DOI 10.1038/sj.onc.1209785; Rossi DJ, 2007, NATURE, V447, P725, DOI 10.1038/nature05862; Ruano Y, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-39; RUIZ JC, 1988, MOL CELL BIOL, V8, P4302, DOI 10.1128/MCB.8.10.4302; SCHIMKE RT, 1986, P NATL ACAD SCI USA, V83, P2157, DOI 10.1073/pnas.83.7.2157; SCHROCK E, 1994, AM J PATHOL, V144, P1203; Schwartz M, 2005, GENE DEV, V19, P2715, DOI 10.1101/gad.340905; Shen HX, 1998, BBA-GEN SUBJECTS, V1381, P131, DOI 10.1016/S0304-4165(98)00020-8; Short SC, 2007, NEURO-ONCOLOGY, V9, P404, DOI 10.1215/15228517-2007-030; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Slack A, 2006, PLOS GENET, V2, P385, DOI 10.1371/journal.pgen.0020048; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2007, J CLIN ONCOL, V25, P4127, DOI 10.1200/JCO.2007.11.8554; SUTHERLAND GR, 1995, CURR OPIN GENET DEV, V5, P323, DOI 10.1016/0959-437X(95)80046-8; Tanaka H, 2005, NAT GENET, V37, P320, DOI 10.1038/ng1515; Virsik-Kopp P, 2003, INT J RADIAT BIOL, V79, P61, DOI 10.1080/0955300021000038644; Wang HC, 2005, CANCER RES, V65, P4020, DOI 10.1158/0008-5472.CAN-04-3055; Yang CR, 1999, NUCLEIC ACIDS RES, V27, P2165, DOI 10.1093/nar/27.10.2165	46	24	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2007	26	56					7809	7815		10.1038/sj.onc.1210878	http://dx.doi.org/10.1038/sj.onc.1210878			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SL	18066094				2022-12-17	WOS:000251537900012
J	Peng, Y; Stewart, D; Li, W; Hawkins, M; Kulak, S; Ballermann, B; Jahroudi, N				Peng, Y.; Stewart, D.; Li, W.; Hawkins, M.; Kulak, S.; Ballermann, B.; Jahroudi, N.			Irradiation modulates association of NF-Y with histone-modifying cofactors PCAF and HDAC	ONCOGENE			English	Article						NF-Y; HDAC; PCAF; von Willebrand factor; irradiation	WILLEBRAND-FACTOR PROMOTER; PROTEIN PHOSPHATASES; ENDOTHELIAL-CELLS; MDR1 GENE; INDUCTION; RECRUITMENT; ACTIVATION; INHIBITORS	Post-irradiation complications including thrombus formation result from increased procoagulant activity of vascular endothelial cells and elevated levels of von Willebrand factor (VWF) contribute to this process. We have previously demonstrated that irradiation induction of the VWF is mediated through interaction of NF-Y transcription factor with its cognate binding site in the VWF promoter. We have also demonstrated that irradiation increases the association of NF-Y with histone acetyltransferase p300/CBP-associated factor (PCAF). We now report that irradiation decreases the association of NF-Y with histone deacetylase 1 (HDAC1). We demonstrate that irradiation-induced changes in association of NF-Y with HDAC1 and PCAF lead to increased PCAF recruitment to the VWF promoter, increased association of acetylated histone H4 with the VWF promoter and subsequently increased transcription. We also demonstrate that this process is correlated to dephosphorylation of HDAC1 and is inhibited by calyculin A, an inhibitor of protein phosphatase1.	Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada; Albert Einstein Coll Med, Dept Med, Bronx, NY USA	University of Alberta; Yeshiva University; Albert Einstein College of Medicine	Jahroudi, N (corresponding author), Univ Alberta, Dept Med, 370-HMRC, Edmonton, AB T6G 2S2, Canada.	nadia.jahroudi@ualberta.ca	Ballermann, Barbara J/G-5349-2016	Ballermann, Barbara J/0000-0002-8220-6381	NHLBI NIH HHS [HL-67729] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067729] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi N, 2000, GENE, V245, P49, DOI 10.1016/S0378-1119(00)00040-8; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Bertagna A, 2001, THROMB HAEMOSTASIS, V85, P837; Brush MH, 2004, J BIOL CHEM, V279, P7685, DOI 10.1074/jbc.M310997200; Caretti G, 2003, J BIOL CHEM, V278, P30435, DOI 10.1074/jbc.M304606200; Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680; DICHEK D, 1989, IN VITRO CELL DEV B, V25, P289; Edwards E, 2002, CANCER RES, V62, P4671; FAJARDO LF, 1996, VASCULAR BRACHYTHERA, P74; Guo C, 2007, CELL SIGNAL, V19, P504, DOI 10.1016/j.cellsig.2006.08.001; Guo CY, 2002, J BIOL CHEM, V277, P41756, DOI 10.1074/jbc.M207519200; Hu Z, 2000, J BIOL CHEM, V275, P2979, DOI 10.1074/jbc.275.4.2979; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; JAHROUDI N, 1994, MOL CELL BIOL, V14, P999, DOI 10.1128/MCB.14.2.999; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Peng YW, 2002, BLOOD, V99, P2408, DOI 10.1182/blood.V99.7.2408; Peng YW, 2003, J BIOL CHEM, V278, P8385, DOI 10.1074/jbc.M213156200; Rodeghiero F, 2002, HAEMOPHILIA, V8, P292, DOI 10.1046/j.1365-2516.2002.00611.x; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8	24	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7576	7583		10.1038/sj.onc.1210565	http://dx.doi.org/10.1038/sj.onc.1210565			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17599060				2022-12-17	WOS:000251282100010
J	Tang, X; Milyavsky, M; Goldfinger, N; Rotter, V				Tang, X.; Milyavsky, M.; Goldfinger, N.; Rotter, V.			Amyloid-beta precursor-like protein APLP1 is a novel p53 transcriptional target gene that augments neuroblastoma cell death upon genotoxic stress	ONCOGENE			English	Article						p53; APLP1; transcription; apoptosis; senescence; neuroblastoma and Alzheimer's disease	ALZHEIMERS-DISEASE; P53-INDUCED APOPTOSIS; NEURONAL APOPTOSIS; FAMILY-MEMBERS; MOUSE-BRAIN; EXPRESSION; CARCINOMA; CLEAVAGE; DENSITY; IMPAIRS	The tumor suppressor p53 is a key modulator of the cellular stress response, inducing cell-cycle arrest, apoptosis, senescence and cell differentiation. To evaluate further the molecular mechanism underlying p53 function, the transcriptional profiles of proliferating and senescent WI-38 cells, both wild-type p53 expressers and counterparts with an inactivated p53, were compared by DNA microarray analysis. In particular, the amyloid-beta precursor-like protein 1 (APLP1) is induced in senescent cells in a p53-dependent manner. APLP1 was confirmed to be a novel transcriptional target of p53 by in vivo and in vitro characterization of a p53 responsive element found in the first intron of the APLP1 gene locus. APLP1 knockdown experiments demonstrate that APLP1 is required for the proliferation of fibroblastic and epithelial cells. Moreover, depletion of APLP1 expression diminishes stress-induced apoptosis of neural cells, whereas ectopic APLP1 expression augments apoptosis. Based on these data, a mechanism is proposed whereby p53-dependent induction of APLP1 is involved in neural cell death, and which may exacerbate neuronal cell loss in some acute or chronic neurodegenerative disorders.	Weizmann Inst Sci, Dept Mol & Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol & Cell Biol, IL-76100 Rehovot, Israel.	varda.rotter@weizmann.ac.il	Milyavsky, Michael/E-8306-2011					Anandatheerthavarada HK, 2003, J CELL BIOL, V161, P41, DOI 10.1083/jcb.200207030; Attardi LD, 2000, GENE DEV, V14, P704; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bayer TA, 1999, MOL PSYCHIATR, V4, P524, DOI 10.1038/sj.mp.4000552; Bayer TA, 1997, ACTA NEUROPATHOL, V94, P519, DOI 10.1007/s004010050745; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Cregan SP, 1999, J NEUROSCI, V19, P7860; Culmsee C, 2005, BIOCHEM BIOPH RES CO, V331, P761, DOI 10.1016/j.bbrc.2005.03.149; delaMonte SM, 1997, J NEUROL SCI, V152, P73, DOI 10.1016/S0022-510X(97)00131-7; Eggert S, 2004, J BIOL CHEM, V279, P18146, DOI 10.1074/jbc.M311601200; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Galvan V, 2002, J NEUROCHEM, V82, P283, DOI 10.1046/j.1471-4159.2002.00970.x; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Heber S, 2000, J NEUROSCI, V20, P7951; KIM TW, 1995, MOL BRAIN RES, V32, P36, DOI 10.1016/0169-328X(95)00328-P; Ko SY, 2004, INT J CANCER, V111, P727, DOI 10.1002/ijc.20328; LaFerla FM, 1996, J CLIN INVEST, V98, P1626, DOI 10.1172/JCI118957; Li QM, 2004, J BIOL CHEM, V279, P10542, DOI 10.1074/jbc.M310001200; LORENT K, 1995, NEUROSCIENCE, V65, P1009, DOI 10.1016/0306-4522(94)00555-J; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; McNamara MJ, 1998, BRAIN RES, V804, P45, DOI 10.1016/S0006-8993(98)00653-2; Meng JY, 2001, INT J CANCER, V92, P31, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1155>3.3.CO;2-8; Milyavsky M, 2005, CANCER RES, V65, P4530, DOI 10.1158/0008-5472.CAN-04-3880; Moll UM, 1996, MOL CELL BIOL, V16, P1126; Morrison RS, 2000, CELL DEATH DIFFER, V7, P868, DOI 10.1038/sj.cdd.4400741; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Pietrzik CU, 1998, P NATL ACAD SCI USA, V95, P1770, DOI 10.1073/pnas.95.4.1770; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Stambolsky P, 2006, CELL DEATH DIFFER, V13, P2140, DOI 10.1038/sj.cdd.4401965; Takahashi M, 2000, NEURON, V28, P461, DOI 10.1016/S0896-6273(00)00125-2; Tang XH, 2004, ONCOGENE, V23, P5759, DOI 10.1038/sj.onc.1207706; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Ward MW, 2004, J BIOENERG BIOMEMBR, V36, P295, DOI 10.1023/B:JOBB.0000041756.23918.11; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758	37	24	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 15	2007	26	52					7302	7312		10.1038/sj.onc.1210542	http://dx.doi.org/10.1038/sj.onc.1210542			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17533371				2022-12-17	WOS:000250955700002
J	Ji, J; Liu, R; Tong, T; Song, Y; Jin, S; Wu, M; Zhan, Q				Ji, J.; Liu, R.; Tong, T.; Song, Y.; Jin, S.; Wu, M.; Zhan, Q.			Gadd45a regulates beta-catenin distribution and maintains cell-cell adhesion/contact	ONCOGENE			English	Article						Gadd45a; cell-cell adhesion; cell contact; inhibition; beta-catenin	DECREASED DNA-REPAIR; PROTEIN-COMPONENT; STRESS-PROTEIN; EXPRESSION; P53; COMPLEX; KINASE; GROWTH; INHIBITION; TYROSINE	Gadd45a, a growth arrest and DNA-damage gene, plays important roles in the control of cell cycle checkpoints, DNA repair and apoptosis. We show here that Gadd45a is involved in the control of cell contact inhibition and cell cell adhesion. Gadd45a can serve as an adapter to enhance the interaction between beta-catenin and Caveolin-1, and in turn induces beta-catenin translocation to cell membrane for maintaining cell - cell adhesion/contact inhibition. This is coupled with reduction of b-catenin in cytoplasm and nucleus following Gadd45a induction, which is reflected by the downregulation of cyclin D1, one of the beta-catenin targeted genes. Additionally, Gadd45a facilitates ultraviolet radiation-induced degradation of cytoplasmic and nuclear beta-catenin in a p53-dependent manner via activation of p38 kinase. These findings define a novel link that connects Gadd45a to cell - cell adhesion and cell contact inhibition, which might contribute to the role of Gadd45a in inhibiting tumorigenesis.	Chinese Acad Med Sci, Inst Canc, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; Peking Union Med Coll, Beijing 100021, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Zhan, Q (corresponding author), Chinese Acad Med Sci, Inst Canc, State Key Lab Mol Oncol, Beijing 100021, Peoples R China.	zhanqimin@pumc.edu.cn						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Barker N, 2000, BIOESSAYS, V22, P961; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Carrier F, 1999, MOL CELL BIOL, V19, P1673; CARRO MJ, 1994, COLLECT MATH, V45, P53; Dietrich C, 2002, BIOCHEM BIOPH RES CO, V292, P195, DOI 10.1006/bbrc.2002.6625; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Galbiati F, 2000, J BIOL CHEM, V275, P23368, DOI 10.1074/jbc.M002020200; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; Gottardi CJ, 2001, CURR BIOL, V11, pR792, DOI 10.1016/S0960-9822(01)00473-0; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hildesheim J, 2004, ONCOGENE, V23, P1829, DOI 10.1038/sj.onc.1207301; Hildesheim J, 2002, CANCER RES, V62, P7305; Hollander MC, 2001, CANCER RES, V61, P2487; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Jin SQ, 2003, ONCOGENE, V22, P8536, DOI 10.1038/sj.onc.1206907; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Jin SQ, 2002, ONCOGENE, V21, P8696, DOI 10.1038/sj.onc.1206034; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kato Y, 2005, LUNG CANCER, V48, P323, DOI 10.1016/j.lungcan.2004.11.012; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kudo Y, 2004, CLIN CANCER RES, V10, P5455, DOI 10.1158/1078-0432.CCR-04-0372; Leali D, 2001, J BIOL CHEM, V276, P37900; Li G, 1996, AM J PATHOL, V148, P1113; MARCHENKO GN, 2002, BIOCHEM J, V363, P263; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; RICHARD C, 1995, J BIOL CHEM, V270, P24188, DOI 10.1074/jbc.270.41.24188; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Salon C, 2004, HUM PATHOL, V35, P1148, DOI 10.1016/j.humpath.2004.04.015; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Tong T, 2005, MOL CELL BIOL, V25, P4488, DOI 10.1128/MCB.25.11.4488-4500.2005; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vizirianakis IS, 2002, INT J ONCOL, V21, P135; Wang W, 2005, ONCOGENE, V24, P2705, DOI 10.1038/sj.onc.1208464; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Yamasawa K, 2002, CLIN CANCER RES, V8, P2563; Zhan QM, 2005, MUTAT RES-FUND MOL M, V569, P133, DOI 10.1016/j.mrfmmm.2004.06.055; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhang XH, 2003, ONCOGENE, V22, P4166, DOI 10.1038/sj.onc.1206599	49	24	26	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2007	26	44					6396	6405		10.1038/sj.onc.1210469	http://dx.doi.org/10.1038/sj.onc.1210469			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17452974				2022-12-17	WOS:000249737600004
J	Kosmider, O; Denis, N; Dubreuil, P; Moreau-Gachelin, F				Kosmider, O.; Denis, N.; Dubreuil, P.; Moreau-Gachelin, F.			Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate	ONCOGENE			English	Article						erythroleukemia; Kit; SU5416; semaxinib; imatinib mesylate	ACUTE MYELOID-LEUKEMIA; RECEPTOR TYROSINE KINASE; GASTROINTESTINAL STROMAL TUMORS; C-KIT; WILD-TYPE; INHIBITOR; MUTATIONS; MASTOCYTOSIS; ACTIVATION; GROWTH	Activating mutations in the Kit receptor are frequently observed in various malignancies, pointing Kit as a molecule of interest for drug inhibit ion. When mutated on Asp 816 (corresponding to Asp 814 in the mouse), as preferentially found in human mastocytosis and acute myeloid leukemia, Kit became non-sensitive to imatinib mesylate (Gleevec). Erythroleukemic cells isolated from Spi-1/PU.1 transgenic mice express Kit mutated at codon 814 (Kit(D814Y) or Kit(D814V)) or codon 818 (Kit(D818Y)). Using these cells in vitro, we demonstrate that the tyrosine kinase inhibitor SU5416 (Semaxinib) induces growth arrest and apoptosis independent of the mutation type by inhibiting the functions of Kit, including Kit autophosphorylation and activation of Akt, Erk1/Erk2 and Stat3 downstream signaling pathways. These findings indicate that SU5416 may be a promising tool to kill cancer cells driven by Kit oncogenic mutations that are resistant to treatment with imatinib mesylate.	Inst Curie, INSERM, U528, F-75248 Paris 05, France; Inst J Paoli I Calmettes, INSERM, UMR 599, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC)	Moreau-Gachelin, F (corresponding author), Inst Curie, INSERM, U528, 26 Rue Ulm, F-75248 Paris 05, France.	framoreau@curie.fr	dubreuil, patrice/F-5346-2011; Dubreuil, Patrice/V-4816-2019	dubreuil, patrice/0000-0003-1155-1150; Dubreuil, Patrice/0000-0003-1155-1150; KOSMIDER, olivier/0000-0002-6021-4057				Akin C, 2004, BLOOD, V103, P3222, DOI 10.1182/blood-2003-11-3816; Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; Chen H, 2003, INT J CANCER, V105, P130, DOI 10.1002/ijc.11025; Fiedler W, 2003, BLOOD, V102, P2763, DOI 10.1182/blood-2002-10-2998; Fong TAT, 1999, CANCER RES, V59, P99; Giles FJ, 2003, BLOOD, V102, P795, DOI 10.1182/blood-2002-10-3023; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Heymach JV, 2004, CLIN CANCER RES, V10, P5732, DOI 10.1158/1078-0432.CCR-04-0157; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Itokawa T, 2002, MOL CANCER THER, V1, P295; Kosmider O, 2005, CANCER CELL, V8, P467, DOI 10.1016/j.ccr.2005.11.009; Krystal GW, 2001, CANCER RES, V61, P3660; Lennartsson J, 2005, STEM CELLS, V23, P16, DOI 10.1634/stemcells.2004-0117; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Ma YS, 2002, BLOOD, V99, P1741, DOI 10.1182/blood.V99.5.1741; Mesters RM, 2001, BLOOD, V98, P241, DOI 10.1182/blood.V98.1.241; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; O'Farrell AM, 2004, LEUKEMIA RES, V28, P679, DOI 10.1016/j.leukres.2003.11.004; Pignon JM, 1997, BRIT J HAEMATOL, V96, P374, DOI 10.1046/j.1365-2141.1997.d01-2042.x; Smolich BD, 2001, BLOOD, V97, P1413, DOI 10.1182/blood.V97.5.1413; Wang YY, 2005, P NATL ACAD SCI USA, V102, P1104, DOI 10.1073/pnas.0408831102; Yee KWH, 2002, BLOOD, V100, P2941, DOI 10.1182/blood-2002-02-0531; Zermati Y, 2003, ONCOGENE, V22, P660, DOI 10.1038/sj.onc.1206120	24	24	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2007	26	26					3904	3908		10.1038/sj.onc.1210159	http://dx.doi.org/10.1038/sj.onc.1210159			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17173066				2022-12-17	WOS:000247026400014
J	Keller, JW; Haigis, KM; Franklin, JL; Whitehead, RH; Jacks, T; Coffey, RJ				Keller, J. W.; Haigis, K. M.; Franklin, J. L.; Whitehead, R. H.; Jacks, T.; Coffey, R. J.			Oncogenic K-RAS subverts the antiapoptotic role of N-RAS and alters modulation of the N-RAS: gelsolin complex	ONCOGENE			English	Article						K-RAS; N-RAS; survival; gelsolin	PLASMA-MEMBRANE; H-RAS; PROTEIN-KINASE; REGULATORY PROTEIN; CAAX MOTIF; APOPTOSIS; CANCER; TRANSFORMATION; GROWTH; MOUSE	Activating mutations in members of the RAS family of genes are among the most common genetic events in human tumorigenesis. Once thought to be functionally interchangeable, it is increasingly recognized that the classical members of this protein family ( H-RAS, N-RAS and K-RAS4B) exhibit unique and shared functions that are highly context-dependent. Herein, we demonstrate that the presence of an oncogenic KRAS allele results in elevated levels of GTP-bound N-RAS ( N-RAS.GTP) in two human colorectal cancer cell lines, HCT 116 and DLD-1, compared to their isogenic counterparts in which the mutant KRAS allele has been disrupted by homologous recombination. N-RAS subserves an antiapoptotic role in cells expressing wild-type K-RAS; this function is compromised, however, by the presence of mutant K-RAS, and these cells display increased sensitivity to apoptotic stimuli. We additionally identify a physical interaction between N-RAS and gelsolin, a factor that has been shown to promote survival and show that the N-RAS: gelsolin complex is modulated differently in wild-type and mutant K-RAS environments following apoptotic challenge. These findings represent the first biochemical evidence of a functional relationship between endogenous RAS proteins and identify a dynamic physical interaction between endogenous N-RAS and gelsolin that correlates with survival.	Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA; MIT, Canc Res Ctr, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA	Vanderbilt University; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Coffey, RJ (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Suite 4140,MRB3,465 21st Ave S, Nashville, TN 37232 USA.	robert.coffey@vanderbilt.edu			NATIONAL CANCER INSTITUTE [R01CA046413, P50CA095103, U01CA084239] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA046413-19, U01 CA084239-09, P50 CA095103, R01 CA046413, P50 CA095103-06, R01 CA46413, U01 CA084239] Funding Source: Medline; PHS HHS [U01 084239, P50 95103] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Archer SY, 1999, CURR OPIN GENET DEV, V9, P171, DOI 10.1016/S0959-437X(99)80026-4; BOS JL, 1989, CANCER RES, V49, P4682; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Diaz R, 2002, CANCER RES, V62, P4514; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; Hamilton M, 1998, ONCOGENE, V16, P1417, DOI 10.1038/sj.onc.1201653; Hamilton M, 2001, J BIOL CHEM, V276, P29079, DOI 10.1074/jbc.M102001200; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Klampfer L, 2005, ONCOGENE, V24, P3932, DOI 10.1038/sj.onc.1208552; Klampfer L, 2004, J BIOL CHEM, V279, P36680, DOI 10.1074/jbc.M405197200; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; Kusano H, 2000, ONCOGENE, V19, P4807, DOI 10.1038/sj.onc.1203868; Matallanas D, 2006, MOL CELL BIOL, V26, P100, DOI 10.1128/MCB.26.1.100-116.2006; Ohtsu M, 1997, EMBO J, V16, P4650, DOI 10.1093/emboj/16.15.4650; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Prior IA, 2001, J CELL SCI, V114, P1603; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; Roy S, 2005, MOL CELL BIOL, V25, P6722, DOI 10.1128/MCB.25.15.6722-6733.2005; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITEHEAD RH, 1987, IN VITRO CELL DEV B, V23, P436; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; Wolfman JC, 2000, J BIOL CHEM, V275, P19315, DOI 10.1074/jbc.M000250200; Wolfman JC, 2002, MOL CELL BIOL, V22, P1589, DOI 10.1128/MCB.22.5.1589-1606.2002; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0	39	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2007	26	21					3051	3059		10.1038/sj.onc.1210103	http://dx.doi.org/10.1038/sj.onc.1210103			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17130841				2022-12-17	WOS:000246395400010
J	Prost, S; Lu, P; Caldwell, H; Harrison, D				Prost, S.; Lu, P.; Caldwell, H.; Harrison, D.			E2F regulates DDB2: consequences for DNA repair in Rb-deficient cells	ONCOGENE			English	Article						DDB2; retinoblastoma; E2F; transcription factor; hepatocytes; DNA repair	NUCLEOTIDE EXCISION-REPAIR; CYCLOBUTANE PYRIMIDINE DIMERS; BINDING-PROTEIN; IN-VIVO; TRANSCRIPTION FACTORS; UV-IRRADIATION; GENE-PRODUCT; MOUSE CELLS; WILD-TYPE; P53	DDB2, a gene mutated in XPE patients, is involved in global genomic repair especially the repair of cyclobutane pyrimidine dimers (CPDs), and is regulated by p53 in human cells. We show that DDB2 is expressed in mouse tissues and demonstrate, using primary mouse epithelial cells, that mouse DDB2 is regulated by E2F transcription factors. Retinoblastoma (Rb), a tumor suppressor critical for the control of cell cycle progression, regulates E2F activity. Using Cre-Lox technology to delete Rb in primary mouse hepatocytes, we show that DDB2 gene expression increases, leading to elevated DDB2 protein levels. Furthermore, we show that endogenous E2F1 and E2F3 bind to DDB2 promoter and that treatment with E2F1-antisense or E2F1-small interfering RNA (siRNA) decreases DDB2 transcription, demonstrating that E2F1 is a transcriptional regulator for DDB2. This has consequences for global genomic repair: in Rb-null cells, where E2F activity is elevated, global DNA repair is increased and removal of CPDs is more efficient than in wild-type cells. Treatment with DDB2-siRNA decreases DDB2 expression and abolishes the repair phenotype of Rb-null cells. In summary, these results identify a new regulatory pathway for DDB2 by E2F, which does not require but is potentiated by p53, and demonstrate that DDB2 is involved in global repair in mouse epithelial cells.	Univ Edinburgh, Queens Med Res Inst, Edinburgh EH16 4TJ, Midlothian, Scotland	University of Edinburgh	Prost, S (corresponding author), Univ Edinburgh, Queens Med Res Inst, 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland.	s.prost@ed.ac.uk		harrison, david/0000-0001-9041-9988; prost, sandrine/0000-0002-0140-7115	Medical Research Council [G9900991B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Adimoolam S, 2003, DNA REPAIR, V2, P947, DOI 10.1016/S1568-7864(03)00087-9; Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Berton TR, 2005, ONCOGENE, V24, P2449, DOI 10.1038/sj.onc.1208462; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fitch ME, 2003, J BIOL CHEM, V278, P46906, DOI 10.1074/jbc.M307254200; Fitch ME, 2003, CARCINOGENESIS, V24, P843, DOI 10.1093/carcin/bgg031; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P283; Hayes S, 1998, MOL CELL BIOL, V18, P240, DOI 10.1128/MCB.18.1.240; Hwang BJ, 1998, MOL CELL BIOL, V18, P4391, DOI 10.1128/MCB.18.7.4391; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; Lin GY, 1998, VIROLOGY, V249, P189, DOI 10.1006/viro.1998.9317; MORI T, 1991, PHOTOCHEM PHOTOBIOL, V54, P225, DOI 10.1111/j.1751-1097.1991.tb02010.x; MULLER H, 2000, BIOCHIM BIOPHYS ACTA, V1470, P1; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; Nicholson T, 2001, BMC Cardiovasc Disord, V1, P2, DOI 10.1186/1471-2261-1-2; Nishiwaki Y, 2004, J INVEST DERMATOL, V122, P526, DOI 10.1046/j.0022-202X.2004.22226.x; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; Prost S, 1998, FASEB J, V12, P181, DOI 10.1096/fasebj.12.2.181; Prost S, 1998, J BIOL CHEM, V273, P33327, DOI 10.1074/jbc.273.50.33327; Prost S, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.16.e80; PURDIE CA, 1994, ONCOGENE, V9, P603; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Sheahan S, 2004, ONCOGENE, V23, P1489, DOI 10.1038/sj.onc.1207280; Shiyanov P, 1999, MOL CELL BIOL, V19, P4935; Stevceva L, 2004, CURR HIV RES, V2, P1, DOI 10.2174/1570162043485004; Takahashi Y, 2000, GENE DEV, V14, P804; Tan T, 2002, MOL CELL BIOL, V22, P3247, DOI 10.1128/MCB.22.10.3247-3254.2002; Tang J, 2002, DNA REPAIR, V1, P601, DOI 10.1016/S1568-7864(02)00052-6; Vooijs M, 2002, ONCOGENE, V21, P4635, DOI 10.1038/sj.onc.1205575; Wakasugi M, 2002, J BIOL CHEM, V277, P1637, DOI 10.1074/jbc.C100610200; Wang QE, 2004, CARCINOGENESIS, V25, P1033, DOI 10.1093/carcin/bgh085; Zhu QZ, 2000, J BIOL CHEM, V275, P11492, DOI 10.1074/jbc.275.15.11492; Zolezzi F, 2000, GENE, V245, P151, DOI 10.1016/S0378-1119(00)00022-6	37	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2007	26	24					3572	3581		10.1038/sj.onc.1210151	http://dx.doi.org/10.1038/sj.onc.1210151			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17173070				2022-12-17	WOS:000246799200013
J	Neesse, A; Gangeswaran, R; Luettges, J; Feakins, R; Weeks, ME; Lemoine, NR; Crnogorac-Jurcevic, T				Neesse, A.; Gangeswaran, R.; Luettges, J.; Feakins, R.; Weeks, M. E.; Lemoine, N. R.; Crnogorac-Jurcevic, T.			Sperm-associated antigen 1 is expressed early in pancreatic tumorigenesis and promotes motility of cancer cells	ONCOGENE			English	Article						SPAG1; pancreatic adenocarcinoma; PanIN; lesions; motility	TESTIS ANTIGENS; CANCER/TESTIS ANTIGENS; SIGNALING PATHWAY; GENE-EXPRESSION; CARCINOMA; ADENOCARCINOMA; ACTIVATION; MIGRATION; PROTEINS; LINES	Sperm-associated antigen 1 (SPAG1) was recently identified in a rare form of infertility where anti-SPAG1 antibodies derived from the serum of an infertile woman were reported to cause sperm agglutination. Except for its expression and potential role in spermatogenesis, the function of SPAG1 is completely unknown. The unexpected finding of high levels of SPAG1 expression in pancreatic adenocarcinoma compared to normal pancreatic tissue in our previous cDNA array experiments prompted us to look in more detail at the expression and role of this gene in a panel of normal and malignant human tissues as well as in a larger series of pancreatic cancer specimens. We have generated an SPAG1-specific monoclonal antibody and showed high levels of SPAG1 protein in testis and in a large proportion of pancreatic ductal adenocarcinomas (PDAC). In the latter, SPAG1 expression was predominantly cytoplasmic and confined to malignant cells. Furthermore, the extent and intensity of SPAG1 expression was shown to be associated with stage and tumour nodal status, while analysis of precursor lesions, pancreatic intraepithelial neoplasias (PanINs), demonstrated its increased immunoreactivity with increasing PanIN grade, suggesting that SPAG1 is a novel marker of PDAC progression. Immunocytochemical analysis demonstrated colocalization of SPAG1 with microtubules, and their association was confirmed by co-immunoprecipitation; subsequent motility assays further substantiated a potential role of SPAG1 in cancer cell motility. Combined with the finding of its early expression in PDAC development, our data suggest that SPAG1 could contribute to the early spread and poor prognosis of pancreatic adenocarcinoma.	Queen Marys Univ, Barts & London Sch Med & Dent, Canc Res UK, John Vane Sci Ctr,Mol Oncol Unit, London WC1M 6BQ, England; Klinikum Saarbrucken, Dept Pathol, Saarbrucken, Germany; Royal London Hosp, Dept Histopathol, London E1 1BB, England	Cancer Research UK; University of London; Queen Mary University London; Barts Health NHS Trust; Royal London Hospital	Crnogorac-Jurcevic, T (corresponding author), Queen Marys Univ, Barts & London Sch Med & Dent, Canc Res UK, John Vane Sci Ctr,Mol Oncol Unit, Charterhouse Sq, London WC1M 6BQ, England.	t.c.jurcevic@qmul.ac.uk	weeks, Mark/AAT-7258-2021; Feakins, Roger/AAO-5570-2020; /C-2531-2011; Feakins, Roger/J-6782-2019	/0000-0002-6576-8809; 				Coral S, 2002, CLIN CANCER RES, V8, P2690; Crnogorac-Jurcevic T, 2003, J PATHOL, V201, P63, DOI 10.1002/path.1418; Cutillas PR, 2004, AM J PHYSIOL-RENAL, V287, pF353, DOI 10.1152/ajprenal.00018.2004; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Furukawa T, 1996, AM J PATHOL, V148, P1763; Gesierich S, 2005, CLIN CANCER RES, V11, P2840, DOI 10.1158/1078-0432.CCR-04-1935; Giehl K, 2000, ONCOGENE, V19, P2930, DOI 10.1038/sj.onc.1203612; Grutzmann R, 2005, ONCOGENE, V24, P5079, DOI 10.1038/sj.onc.1208696; Hustinx SR, 2004, CANCER BIOL THER, V3, P1254, DOI 10.4161/cbt.3.12.1238; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Kalejs M, 2005, CANCER CELL INT, V5, DOI 10.1186/1475-2867-5-4; Kubuschok B, 2004, INT J CANCER, V109, P568, DOI 10.1002/ijc.20006; Lin W, 2001, MOL HUM REPROD, V7, P811, DOI 10.1093/molehr/7.9.811; Logsdon CD, 2003, CANCER RES, V63, P2649; Michl P, 2005, CANCER CELL, V7, P521, DOI 10.1016/j.ccr.2005.05.018; Missiaglia E, 2005, ONCOGENE, V24, P199, DOI 10.1038/sj.onc.1208018; Missiaglia E, 2004, INT J CANCER, V112, P100, DOI 10.1002/ijc.20376; Old L J, 2001, Cancer Immun, V1, P1; Sawai H, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-37; Scanlan Matthew J, 2004, Cancer Immun, V4, P1; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sigalotti L, 2002, BRIT J CANCER, V86, P979, DOI 10.1038/sj.bjc.6600174; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Small JV, 2002, NAT REV MOL CELL BIO, V3, P957, DOI 10.1038/nrm971; Takimoto M, 2002, BRIT J CANCER, V86, P1757, DOI 10.1038/sj.bjc.6600328; Taniuchi K, 2005, CANCER RES, V65, P3092, DOI 10.1158/0008.5472.CAN-04-3646; Tureci O, 1998, P NATL ACAD SCI USA, V95, P5211, DOI 10.1073/pnas.95.9.5211; Vasiliev JM, 2004, INT J DEV BIOL, V48, P425, DOI 10.1387/ijdb.041806jv; ZHANG ML, 1992, CHINESE MED J-PEKING, V105, P998; Zhang YT, 2004, CHINESE PHYS LETT, V21, P166, DOI 10.1088/0256-307X/21/1/050	30	24	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1533	1545		10.1038/sj.onc.1209961	http://dx.doi.org/10.1038/sj.onc.1209961			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16983343				2022-12-17	WOS:000244782500003
J	Mallakin, A; Taneja, P; Matise, LA; Willingham, MC; Inoue, K				Mallakin, A.; Taneja, P.; Matise, L. A.; Willingham, M. C.; Inoue, K.			Expression of Dmp1 in specific differentiated, nonproliferating cells and its regulation by E2Fs	ONCOGENE			English	Article						Dmp1; Ki67; Arf; E2F; cell cycle; immunohistochemistry	ARF TUMOR-SUPPRESSOR; D-TYPE CYCLINS; TRANSCRIPTION FACTOR DMP1; CELLULAR PROLIFERATION; GENE-EXPRESSION; MYB PROMOTER; IN-VIVO; FAMILY; COMPLEXES; ARREST	Dmp1 is a Myb-like transcription factor that transmits oncogenic Ras-Raf signaling to the Arf-p53 pathway and induces cell cycle arrest. Immunohistochemical staining was performed to identify the pattern of Dmp1 expression in normal murine tissues compared with the proliferation marker, Ki67. In thymus, the nuclei of mature T lymphocytes in the medulla were strongly positive for Dmp1, whereas Ki67 was detected only in the cortex. In intestine, Dmp1 was detected in the nuclei of super. cial layers of the villi, whereas Ki67- positive cells were con. ned to the lower one- third of the crypt. Double staining for Dmp1 and Ki67 revealed that these two proteins were expressed in mutually exclusive fashion in nearly all the tissues examined. Subsets of E2Fs were speci. cally bound to the Dmp1 promoter upon mitogenic signaling and E2Fs 1- 4 inhibited the Dmp1 promoter in a reporter assay. The Dmp1 promoter was repressed when the cells entered the S to G2/ M phase of the cell cycle when both Dmp1 and Arf expressions were downregulated. The Dmp1 mRNA was not downregulated by serum in E2F- DB(+) cells, suggesting that the Dmp1 promoter repression is E2F- dependent. This explains why the Dmp1 and Ki67- positive cells are stained in mutually exclusive fashion in normal tissues.	Wake Forest Univ Hlth Sci, Dept Canc Biol, Winston Salem, NC 27157 USA; Wake Forest Univ Hlth Sci, Dept Pathol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University School of Medicine; Wake Forest University; Wake Forest University School of Medicine	Inoue, K (corresponding author), Wake Forest Univ Hlth Sci, Dept Canc Biol, 2102 Gray Bldg,Med Ctr Blvd, Winston Salem, NC 27157 USA.	kinoue@wfubmc.edu			NATIONAL CANCER INSTITUTE [R01CA106314, R01CA106312, P30CA012197] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA106314-03, CA12197-31, R01 CA106314-02, R01 CA106314, P30 CA012197, R01 CA106314-01, 5R01CA106312-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Barrett KL, 2001, J HISTOCHEM CYTOCHEM, V49, P821, DOI 10.1177/002215540104900703; Bentley HA, 2005, CLIN BIOCHEM, V38, P183, DOI 10.1016/j.clinbiochem.2004.10.009; Bertwistle D, 2004, HYBRIDOMA HYBRIDOM, V23, P293, DOI 10.1089/hyb.2004.23.293; Campanero MR, 1999, MOL CELL BIOL, V19, P8442; Catchpole S, 2002, J BIOL CHEM, V277, P39015, DOI 10.1074/jbc.M202960200; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DeGregori J, 2002, BBA-REV CANCER, V1602, P131, DOI 10.1016/S0304-419X(02)00051-3; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Hirai H, 1996, MOL CELL BIOL, V16, P6457; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Inoue K, 2001, GENE DEV, V15, P2934, DOI 10.1101/gad.929901; Inoue K, 2000, GENE DEV, V14, P1797; INOUE K, 1994, BLOOD, V84, P2672, DOI 10.1182/blood.V84.8.2672.bloodjournal8482672; Inoue K, 1998, J BIOL CHEM, V273, P29188, DOI 10.1074/jbc.273.44.29188; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Joaquin M, 2003, CELL MOL LIFE SCI, V60, P2389, DOI 10.1007/s00018-003-3037-4; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KINDBLOM LG, 1995, VIRCHOWS ARCH, V427, P19; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; LOPEZ F, 1991, CYTOMETRY, V12, P42, DOI 10.1002/cyto.990120107; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Lu Z, 2006, ONCOGENE, V25, P230, DOI 10.1038/sj.onc.1209025; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Quon KC, 2001, GENE DEV, V15, P2917, DOI 10.1101/gad.949001; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sala A, 1999, J CELL PHYSIOL, V179, P245; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sreeramaneni R, 2005, MOL CELL BIOL, V25, P220, DOI 10.1128/MCB.25.1.220-232.2005; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	41	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2006	25	59					7703	7713		10.1038/sj.onc.1209750	http://dx.doi.org/10.1038/sj.onc.1209750			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16878159	Green Accepted			2022-12-17	WOS:000242830800005
J	Zhang, P; Castedo, M; Tao, Y; Violot, D; Metivier, D; Deutsch, E; Kroemer, G; Bourhis, J				Zhang, P.; Castedo, M.; Tao, Y.; Violot, D.; Metivier, D.; Deutsch, E.; Kroemer, G.; Bourhis, Jean			Caspase independence of radio-induced cell death	ONCOGENE			English	Article						apoptosis; delayed cell death; mitotic catastrophe; micronucleation; polyploidization	RADIATION-INDUCED APOPTOSIS; MITOTIC CATASTROPHE; CLONOGENIC SURVIVAL; MITOCHONDRIAL; CANCER; P53; SENESCENCE; EXPRESSION; CHK2	Colon carcinoma cells subjected to gamma-irradiation (4 Gy) manifest signs of apoptosis (caspase activation, chromatin condensation, phosphatidylserine (PS) exposure on the cell surface, sub-diploid DNA content), correlating with their radiosensitivity, which is increased in cells lacking the 14-3-3 sigma protein as compared to wild-type controls. Inhibition of caspases byaddition of Z-Val-Ala-DLAsp (OMe)-fluoromethylketone, by stable transfection with the Baculovirus gene coding for p35, or by Bax knockout reduced all signs of apoptosis, yet failed to suppress radio-induced micro- and multinucleation. Moreover, pharmacological caspase inhibition, p35 expression or Bax knockout had no effect on the clonogenic survival that was reduced by gamma-irradiation and caspase inhibition failed to abolish the increased radiosensitivity of 14-3-3 sigma-deficient cells. Micro- and multinucleation was detectable among non-apoptotic cells lacking PS exposure, as well as among cells undergoing apoptosis. Moreover, a fraction of micro- or multinucleated cells manifested caspase activation, and videomicroscopic analyses revealed that such cells could succumb to caspase-dependent apoptosis. Altogether, these results suggest that genomic instability induced by gamma-irradiation can trigger apoptosis, although apoptosis is dispensable for radio-induced clonogenic death.	Inst Gustave Roussy, Ctr Natl Rech Sci, UMR 8125, F-94805 Villejuif, France; Inst Gustave Roussy, UPRES EA 2710, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Kroemer, G (corresponding author), Inst Gustave Roussy, Ctr Natl Rech Sci, UMR 8125, Pavillon Rech 1,38 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; tao, yungan/0000-0002-6916-5263; Bourhis, Jean/0000-0001-5162-1171; deutsch, eric/0000-0002-8223-3697; Zhang, Ping/0000-0002-3043-8738				Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Albertini RJ, 2000, MUTAT RES-REV MUTAT, V463, P111, DOI 10.1016/S1383-5742(00)00049-1; Andreau K, 2004, J BIOL CHEM, V279, P55937, DOI 10.1074/jbc.M406411200; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Bulavin DV, 1999, ONCOGENE, V18, P5611, DOI 10.1038/sj.onc.1202945; BUSH C, 1993, BRIT J CANCER, V67, P102, DOI 10.1038/bjc.1993.17; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Castedo M, 2004, ONCOGENE, V23, P4353, DOI 10.1038/sj.onc.1207573; Castedo M, 1996, J IMMUNOL, V157, P512; Castedo M, 2006, EMBO J, V25, P2584, DOI 10.1038/sj.emboj.7601127; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Cohen-Jonathan E, 1999, CURR OPIN CHEM BIOL, V3, P77, DOI 10.1016/S1367-5931(99)80014-3; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Date T, 2003, HUM GENE THER, V14, P947, DOI 10.1089/104303403766682214; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Golstein P, 2005, CELL DEATH DIFFER, V12, P1490, DOI 10.1038/sj.cdd.4401607; Gourdier I, 2004, ONCOGENE, V23, P7449, DOI 10.1038/sj.onc.1208047; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; Guo GZ, 1998, INT J RADIAT BIOL, V73, P297, DOI 10.1080/095530098142392; Held KD, 1997, APOPTOSIS, V2, P265, DOI 10.1023/A:1026485003280; Hendry JH, 1997, INT J RADIAT BIOL, V71, P709, DOI 10.1080/095530097143716; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724; Kyprianou N, 1997, INT J CANCER, V70, P341, DOI 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Mariya Y, 1997, RADIAT RES, V147, P29, DOI 10.2307/3579439; Methot N, 2004, J EXP MED, V199, P199, DOI 10.1084/jem.20031791; MULLER WU, 1995, STEM CELLS, V13, P199; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Olive PL, 1997, INT J RADIAT BIOL, V71, P695, DOI 10.1080/095530097143707; Perfettini JL, 2005, J EXP MED, V201, P279, DOI 10.1084/jem.20041502; Prise KM, 2005, LANCET ONCOL, V6, P520, DOI 10.1016/S1470-2045(05)70246-1; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Schulze-Bergkamen H, 2004, SEMIN ONCOL, V31, P90, DOI 10.1053/j.seminoncol.2003.11.006; Stennicke HR, 2002, TRENDS BIOCHEM SCI, V27, P94, DOI 10.1016/S0968-0004(01)02045-X; Vidair CA, 1996, CANCER RES, V56, P4116; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; ZHIVOTOVSKY B, 2004, NAT REV MOL CELL BIO, V117, P4461	46	24	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2006	25	59					7758	7770		10.1038/sj.onc.1209744	http://dx.doi.org/10.1038/sj.onc.1209744			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16862186				2022-12-17	WOS:000242830800010
J	Cerone, MA; Londono-Vallejo, JA; Autexier, C				Cerone, M. A.; Londono-Vallejo, J. A.; Autexier, C.			Mutated telomeres sensitize tumor cells to anticancer drugs independently of telomere shortening and mechanisms of telomere maintenance	ONCOGENE			English	Article						telomeres; telomerase; anticancer drugs; telomere uncapping; mutant template hTR	IMMORTAL HUMAN-CELLS; CANCER-CELLS; REVERSE-TRANSCRIPTASE; MUTANT TELOMERASE; CHROMOSOME SEPARATION; HUMAN FIBROBLASTS; MELANOMA-CELLS; DNA-REPAIR; INHIBITION; RNA	Telomerase is a ribonucleoprotein complex that maintains the stability of chromosome ends and regulates replicative potential. Telomerase is upregulated in over 85% of human tumors, but not in adjacent normal tissues and represents a promising target for anticancer therapy. Most telomerase-based therapies rely on the inhibition of telomerase activity and require extensive telomere shortening before inducing any antiproliferative effect. Disturbances of telomere structure rather than length may be more effective in inducing cell death. Telomerase RNA subunits (hTRs) with mutations in the template region reconstitute active holoenzymes that incorporate mutated telomeric sequences. Here, we analysed the feasibility of an anticancer approach based on the combination of telomere destabilization and conventional chemotherapeutic drugs. We show that a mutant template hTR dictates the synthesis of mutated telomeric repeats in telomerase-positive cancer cells, without significantly affecting their viability and proliferative ability. Nevertheless, the mutant hTR increased sensitivity to anticancer drugs in cells with different initial telomere lengths and mechanisms of telomere maintenance and without requiring overall telomere shortening. This report is the first to show that interfering with telomere structure maintenance in a telomerase-dependent manner may be used to increase the susceptibility of tumor cells to anticancer drugs and may lead to the development of a general therapy for the treatment of human cancers.	McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Anat & Cell Biol,Bloomfield Ctr Res Aging, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3T 1E2, Canada; Inst Curie, UPMC, IC,CNRS, Telomeres & Canc Lab, F-75231 Paris, France	Lady Davis Institute; McGill University; McGill University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite	Autexier, C (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Anat & Cell Biol,Bloomfield Ctr Res Aging, 3755 Cote St Catherine, Montreal, PQ H3T 1E2, Canada.	chantal.autexier@mcgill.ca	Londono-Vallejo, Arturo/ABH-5555-2020	Londono-Vallejo, Arturo/0000-0003-3535-7563				Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Cerone MA, 2001, HUM MOL GENET, V10, P1945, DOI 10.1093/hmg/10.18.1945; Chen Z, 2003, CANCER RES, V63, P5917; Christodoulopoulos G, 1999, CLIN CANCER RES, V5, P2178; Chung HK, 2005, CURR MOL MED, V5, P233, DOI 10.2174/1566524053586635; Cimino-Reale G, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.7.e35; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Folini M, 2000, EUR J CANCER, V36, P2137, DOI 10.1016/S0959-8049(00)00295-1; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kelland LR, 2005, EUR J CANCER, V41, P971, DOI 10.1016/j.ejca.2004.11.024; Kim MM, 2001, P NATL ACAD SCI USA, V98, P7982, DOI 10.1073/pnas.131211098; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; Kondo Y, 1998, ONCOGENE, V16, P2243, DOI 10.1038/sj.onc.1201754; Lee KH, 2001, P NATL ACAD SCI USA, V98, P3381, DOI 10.1073/pnas.051629198; Li S, 2004, CANCER RES, V64, P4833, DOI 10.1158/0008-5472.CAN-04-0953; Lin J, 2004, MOL BIOL CELL, V15, P1623, DOI 10.1091/mbc.E03-10-0740; Ludwig A, 2001, CANCER RES, V61, P3053; Marusic L, 1997, MOL CELL BIOL, V17, P6394, DOI 10.1128/MCB.17.11.6394; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Misawa M, 2002, INT J ONCOL, V21, P1087; Nakamura M, 2005, HUM GENE THER, V16, P859, DOI 10.1089/hum.2005.16.859; Park KH, 1998, INT J ONCOL, V13, P489; Sharma GG, 2003, ONCOGENE, V22, P131, DOI 10.1038/sj.onc.1206063; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shin KH, 2004, CLIN CANCER RES, V10, P2551, DOI 10.1158/1078-0432.CCR-0669-3; Smith CD, 1999, J CELL BIOL, V145, P203, DOI 10.1083/jcb.145.2.203; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tentori L, 2003, MOL PHARMACOL, V63, P192, DOI 10.1124/mol.63.1.192; Ward RJ, 2005, MOL PHARMACOL, V68, P779, DOI 10.1124/mol.105.011494; Wen JP, 1998, HUM MOL GENET, V7, P1137, DOI 10.1093/hmg/7.7.1137; Xu LF, 2004, J CELL BIOL, V167, P819, DOI 10.1083/jcb.200408181; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	46	24	26	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	56					7411	7420		10.1038/sj.onc.1209727	http://dx.doi.org/10.1038/sj.onc.1209727			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16767163				2022-12-17	WOS:000242419100010
J	Huang, L; Watanabe, M; Chikamori, M; Kido, Y; Yamamoto, T; Shibuya, M; Gotoh, N; Tsuchida, N				Huang, L.; Watanabe, M.; Chikamori, M.; Kido, Y.; Yamamoto, T.; Shibuya, M.; Gotoh, N.; Tsuchida, N.			Unique role of SNT-2/FRS2 beta/FRS3 docking/adaptor protein for negative regulation in EGF receptor tyrosine kinase signaling pathways	ONCOGENE			English	Article						SNT-2; FRS2 beta; FRS3; EGF; transformation; ERK2	GROWTH-FACTOR-RECEPTOR; MAP KINASE; PHOSPHORYLATION SITES; TRANSDUCTION PATHWAYS; DOCKING PROTEINS; PC12 CELLS; ACTIVATION; FRS2-ALPHA; FRS2; SHC	The membrane-linked docking protein SNT-2/FRS2b/FRS3 becomes tyrosine phosphorylated in response to fibroblast growth factors (FGFs) and neurotrophins and serves as a platform for recruitment of multiple signaling proteins, including Grb2 and Shp2, to FGF receptors or neurotrophin receptors. We previously reported that SNT-2 is not tyrosine phosphorylated significantly in response to epidermal growth factor (EGF) but that it inhibits ERK activation via EGF stimulation by forming a complex with ERK2. In the present report, we show that expression of SNT-2 suppressed EGF-induced cell transformation and proliferation, and expression level of SNT-2 is down-regulated in cancer. The activities of the major signaling molecules in EGF receptor ( EGFR) signal transduction pathways, including autophosphorylation of EGFR, were attenuated in cells expressing SNT-2 but not in cells expressing SNT-2 mutants lacking the ERK2-binding domain. Furthermore, SNT-2 constitutively bound to EGFR through the phosphotyrosine binding (PTB) domain both with and without EGF stimulation. Treatment of cells with MEK inhibitor U0126 partially restored the phosphorylation levels of MEK and EGFR in cells expressing SNT-2. On the basis of these findings, we propose a novel mechanism of negative control of EGFR tyrosine kinase activity with SNT-2 by recruiting ERK2, which is the site of negative-feedback loop from ERK, ultimately leading to inhibition of EGF-induced cell transformation and proliferation.	Univ Tokyo, Inst Med Sci, Div Genet, Minato Ku, Tokyo 1088639, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Mol Cellular Oncol & Microbiol, Bunkyo Ku, Tokyo, Japan; Univ Tokyo, Inst Med Sci, Div Oncol, Minato Ku, Tokyo, Japan; Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet & Digest & Kidney Dis,Chuo Ku, Kobe, Hyogo, Japan	University of Tokyo; Tokyo Medical & Dental University (TMDU); University of Tokyo; Kobe University	Gotoh, N (corresponding author), Univ Tokyo, Inst Med Sci, Div Genet, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	ngotoh@ims.u-tokyo.ac.jp; tsuchida.mcom@tmd.ac.jp	Huang, Lin/AAI-5740-2020; GOTOH, Noriko/D-8430-2015					BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Dhalluin C, 2000, MOL CELL, V6, P921, DOI 10.1016/S1097-2765(00)00089-7; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; Gotoh N, 2005, MOL CELL BIOL, V25, P4105, DOI 10.1128/MCB.25.10.4105-4116.2005; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Gotoh N, 2004, P NATL ACAD SCI USA, V101, P17144, DOI 10.1073/pnas.0407577101; Gotoh N, 2004, FEBS LETT, V564, P14, DOI 10.1016/S0014-5793(04)00287-X; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Gotoh N, 1995, ONCOGENE, V11, P2525; Habib AA, 2003, MOL CANCER RES, V1, P219; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Harada A, 2005, J BIOL CHEM, V280, P18418, DOI 10.1074/jbc.M411356200; Hirata A, 2005, CANCER RES, V65, P4253, DOI 10.1158/0008-5472.CAN-04-2748; Ho R, 2005, CANCER RES, V65, P9868, DOI 10.1158/0008-5472.CAN-04-2426; Huang L, 2004, BIOCHEM BIOPH RES CO, V324, P1011, DOI 10.1016/j.bbrc.2004.09.152; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Lax I, 2002, MOL CELL, V10, P709, DOI 10.1016/S1097-2765(02)00689-5; LEE M, 1992, JNCI-J NATL CANCER I, V13, P117; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Rubenstein M, 1999, METHOD FIND EXP CLIN, V21, P391, DOI 10.1358/mf.1999.21.6.541918; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Wu YJ, 2003, BIOL CHEM, V384, P1215, DOI 10.1515/BC.2003.134; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	36	24	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2006	25	49					6457	6466		10.1038/sj.onc.1209656	http://dx.doi.org/10.1038/sj.onc.1209656			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16702953				2022-12-17	WOS:000241395100002
J	Dias, SS; Milne, DM; Meek, DW				Dias, S. S.; Milne, D. M.; Meek, D. W.			c-Abl phosphorylates Hdm2 at tyrosine 276 in response to DNA damage and regulates interaction with ARF	ONCOGENE			English	Article						Hdm2; p53; c-Abl; ARF; phosphorylation; DNA damage	POSTTRANSLATIONAL MODIFICATIONS; P53; MDM2; ACTIVATION	The p53 tumour-suppressor protein is tightly regulated through its association with the Hdm2 E3 ligase. Activation of p53 by DNA strand breaks is orchestrated by the ataxia-telangiectasia mutated (ATM) protein kinase and involves interruption of Hdm2-mediated p53 degradation. As part of this mechanism ATM itself, and the ATM-activated protein tyrosine kinase, c-Abl, inhibit Hdm2 function through phosphorylation of serine 395 and tyrosine 394 (Y394), respectively. In the present study, we have identified a novel target of c-Abl in the Hdm2 protein, tyrosine 276 (Y276). We show that c-Abl phosphorylates this residue in vitro and confirm that Y394 is a target of c-Abl. We also show that Y276 is phosphorylated in a c-Abl-dependent manner in cultured cells and provide evidence that Y276 is phosphorylated in response to DNA damage coincident with the activation of c-Abl. Finally, we show that Y276 phosphorylation stimulates interaction with ARF, leading to increased levels of nucleolar Hdm2 and decreased turnover of p53. These data establish Y276 as a physiological target of c-Abl that contributes functionally to the induction of p53.	Univ Dundee, Ninewells Hosp & Med Sch, Mol Signalling Grp, Biomed Res Ctr, Dundee DD1 9SY, Scotland	University of Dundee	Meek, DW (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Mol Signalling Grp, Biomed Res Ctr, Dundee DD1 9SY, Scotland.	david.meek@cancer.org.uk						Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Lu X, 2005, CURR OPIN GENET DEV, V15, P27, DOI 10.1016/j.gde.2004.12.008; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Meek DW, 2003, MOL CANCER RES, V1, P1017; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Shaul Y, 2005, CELL RES, V15, P33, DOI 10.1038/sj.cr.7290261; Sionov RV, 2001, MOL CELL BIOL, V21, P5869; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Wu JJ, 2002, COMB CHEM HIGH T SCR, V5, P83, DOI 10.2174/1386207023330516	16	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6666	6671		10.1038/sj.onc.1209671	http://dx.doi.org/10.1038/sj.onc.1209671			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16702947				2022-12-17	WOS:000241569700011
J	Mizumoto, Y; Kyo, S; Ohno, S; Hashimoto, M; Nakamura, M; Maida, Y; Sakaguchi, J; Takakura, M; Inoue, M; Kiyono, T				Mizumoto, Y.; Kyo, S.; Ohno, S.; Hashimoto, M.; Nakamura, M.; Maida, Y.; Sakaguchi, J.; Takakura, M.; Inoue, M.; Kiyono, T.			Creation of tumorigenic human endometrial epithelial cells with intact chromosomes by introducing defined genetic elements	ONCOGENE			English	Article						endometrial cancer; carcinogenesis; immortalization; tumorigenicity; K-ras	COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN TUMOR-CELLS; MICROSATELLITE INSTABILITY; 3T3-L1 ADIPOCYTES; IN-VITRO; PTEN; SUPPRESSOR; CARCINOGENESIS; CARCINOMA; HYPERPLASIA	Several genetic mutations have been identified in human endometrial cancers, but the specific combinations of mutations required to form endometrial cancer cells remain unknown. In the present study, we established an in vitro model of endometrial carcinogenesis, in which defined genetic elements were introduced into endometrial epithelial cells to create transformed endometrial cells at different stages. Introduction of the human papillomavirus type 16 E6/E7 gene and the human telomerase reverse transcriptase (hTERT) gene into human primary endometrial epithelial cells was sufficient to generate immortalized cells. Introduction of hTERT in early passages stabilized telomeres and created immortalized cells with normal karyotype, whereas introduction of hTERT in later passages generated immortalized cells but with widespread chromosome abnormalities. However, neither of those two immortalized cell lines exhibited tumorigenic phenotypes. Tumorigenic endometrial epithelial cells with invasive capacity were created by introducing a mutant K-ras allele into immortalized cells, keeping their chromosomes intact. Inhibiting the PTEN gene and activating Akt pathways did not create tumorigenic phenotypes, although the latter conferred anchorage-independent growth capacity. These findings suggest that neoplastic transformation of human endometrial cells can occur in the absence of widespread chromosomal abnormality, and that the combination of Rb inactivation, telomerase activation and altered K-ras signaling is sufficient for in vitro neoplastic transformation. The present experimental model can help clarify the genetic requirements for endometrial carcinogenesis, and it is useful for testing and developing specific inhibitors of specific oncogenic pathways.	Kanazawa Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208641, Japan; Natl Canc Ctr, Res Inst, Div Virol, Kanazawa, Ishikawa, Japan	Kanazawa University; National Cancer Center - Japan	Kyo, S (corresponding author), Kanazawa Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.	satoruky@med.kanazawa-u.ac.jp	Kiyono, Tohru/H-5834-2011; Takakura, Masahiro/E-1080-2011					Akoum A, 1996, J REPROD MED, V41, P555; Arnold JT, 2001, HUM REPROD, V16, P836, DOI 10.1093/humrep/16.5.836; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Berger R, 2004, CANCER RES, V64, P8867, DOI 10.1158/0008-5472.CAN-04-2938; Boland CR, 1998, CANCER RES, V58, P5248; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; ClassenLinke I, 1997, CELL TISSUE RES, V287, P171; ENOMOTO T, 1991, CANCER RES, V51, P5308; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hirasawa A, 2003, CLIN CANCER RES, V9, P5675; Inoue M, 2001, INT J GYNECOL CANCER, V11, P339, DOI 10.1046/j.1525-1438.2001.01046.x; Kanaya T, 2005, AM J CLIN PATHOL, V124, P89, DOI 10.1309/PAACLG8DXDK0X2B1; KATABUCHI H, 1995, CANCER RES, V55, P5556; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kyo S, 2003, AM J PATHOL, V163, P2259, DOI 10.1016/S0002-9440(10)63583-3; Levine RL, 1998, CANCER RES, V58, P3254; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maxwell GL, 1998, CANCER RES, V58, P2500; Mutter GL, 1999, J CLIN PATHOL-MOL PA, V52, P257, DOI 10.1136/mp.52.5.257; Niemann TH, 1997, GYNECOL ONCOL, V65, P232, DOI 10.1006/gyno.1997.4664; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sawada M, 2004, CELL DEATH DIFFER, V11, P997, DOI 10.1038/sj.cdd.4401438; Semczuk Andrzej, 2004, Archives of Gynecology and Obstetrics, V269, P104, DOI 10.1007/s00404-002-0449-6; Sonoda G, 1997, GENE CHROMOSOME CANC, V18, P115, DOI 10.1002/(SICI)1098-2264(199702)18:2<115::AID-GCC6>3.0.CO;2-5; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tang XQ, 2005, J BIOL CHEM, V280, P22523, DOI 10.1074/jbc.M501949200; Tashiro H, 1997, CANCER RES, V57, P3935; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6; Zimonjic D, 2001, CANCER RES, V61, P8838	31	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2006	25	41					5673	5682		10.1038/sj.onc.1209575	http://dx.doi.org/10.1038/sj.onc.1209575			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16636665				2022-12-17	WOS:000240599100009
J	Acquaviva, A; Ciccolallo, L; Rondelli, R; Balistreri, A; Ancarola, R; Cozza, R; Hadjistilianou, D; De Francesco, S; Toti, P; Pastore, G; Haupt, R; Carli, M; Santoro, N; Di Cataldo, A; Fiorillo, A; Indolfi, P; Nucci, P; Sandri, A; Porta, F; Porcaro, AB; Tamaro, P; Morgese, G				Acquaviva, A.; Ciccolallo, L.; Rondelli, R.; Balistreri, A.; Ancarola, R.; Cozza, R.; Hadjistilianou, D.; De Francesco, S.; Toti, P.; Pastore, G.; Haupt, R.; Carli, M.; Santoro, N.; Di Cataldo, A.; Fiorillo, A.; Indolfi, P.; Nucci, P.; Sandri, A.; Porta, F.; Porcaro, A. B.; Tamaro, P.; Morgese, G.			Mortality from second tumour among long-term survivors of retinoblastoma: a retrospective analysis of the Italian retinoblastoma registry	ONCOGENE			English	Review						retinoblastoma; second primary neoplasm; chemotherapy; radiotherapy; mortality	NONOCULAR TUMORS; HEREDITARY; NEOPLASMS; MUTATIONS; SPECTRUM; CANCERS; GENE	Survivors of retinoblastoma (Rb) are at high risk of dying from second malignant tumour. The occurrence of second malignant neoplasm ( SMN) and related mortality in a cohort of 1111 cases from the Italian Retinoblastoma Registry was analysed, considering the possible role of both genetic and iatrogenic causes. Rb patients had a greater than 10-fold excess in overall mortality compared with the general population ( standardized mortality ratio ( SMR) 10.73, 95% CI 9.00-12.80). Their excess risk attributable to cancers other than Rb was 14.93 95% CI 10.38 - 21.49). Survivors of hereditary Rb had an SMR for all causes of 16.25 ( 95% CI 13.20 - 20.00), whereas their SMR for all cancers was 25.72 ( 95% CI 17.38 - 38.07). Survivors of unilateral sporadic Rb had an SMR of 4.12 from all cancers ( 95% CI 1.55 - 10.98) and a much higher excess for overall mortality ( SMR 13.34, 95% CI 10.74-16.56). As expected, survivors of hereditary Rb had higher mortality from cancers of the bone ( SMR 391.90, 95% CI 203.90 - 753.20) and soft tissue ( SMR 453.00, 95% CI 203.50 - 1008.40), small intestine ( SMR 1375.50, 95% CI 344.00 - 5499.70), nasal cavity ( SMR 13.71, 95% CI 1.93 - 97.35) and cancers of the brain and central nervous system ( SMR 41.14, 95% CI 13.2 - 127.55)	Univ Siena, Dept Pediat Obstet & Reprod Med, Italian Retinoblastoma Registry, I-53100 Siena, Italy; Ist Nazl Studio & Cura Tumori, Dept Prevent & Predict Med, Epidemiol Unit, I-20133 Milan, Italy; Univ Bologna, Dept Pediat, Bologna, Italy; Univ Siena, Dept Surg & Bioengn, I-53100 Siena, Italy; Bambino Gesu Pediat Hosp, Dept Pediat Oncol, Rome, Italy; Univ Siena, Dept Ophthalmol Sci, I-53100 Siena, Italy; Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy; Univ Turin, Canc Epidemiol Unit, Childhood Canc Registry Piedmont, Turin, Italy; Ist Giannina Gaslini, Dept Hematol Oncol, I-16148 Genoa, Italy; Univ Hosp Padova, Dept Pediat, Div Hematol Oncol, Padua, Italy; Univ Bari, Dept Biomed Childhood, Bari, Italy; Univ Catania, Ctr Paediat Haematol & Oncol, Catania, Italy; Univ Naples Federico II, Dept Pediat, Naples, Italy; Univ Naples 2, Pediat Oncol Serv, Naples, Italy; Univ Milan, San Paola Hosp, Pediat Ophthalmol & Strabismus Unit, Milan, Italy; Univ Turin, Dept Pediat Oncol, Turin, Italy; Univ Brescia, Dept Pediat, Brescia, Italy; Civil Major Hosp, Dept Urol, Verona, Italy; Univ Trieste, Osped Infantile Burlo Garofolo, Dept Pediat, Trieste, Italy	University of Siena; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Bologna; University of Siena; IRCCS Bambino Gesu; University of Siena; University of Siena; University of Turin; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Padua; Azienda Ospedaliera - Universita di Padova; Universita degli Studi di Bari Aldo Moro; University of Catania; University of Naples Federico II; Universita della Campania Vanvitelli; University of Milan; University of Turin; University of Brescia; IRCCS Burlo Garofolo; University of Trieste	Acquaviva, A (corresponding author), Univ Siena, Dept Pediat Obstet & Reprod Med, Italian Retinoblastoma Registry, Viale Bracci 16, I-53100 Siena, Italy.	acquaviva@unisi.it	Toti, Paolo/E-6358-2012; nucci, paolo/J-9523-2016; Haupt, Riccardo/AAA-7437-2020; Ciccolallo, Laura/F-5653-2014; Di Cataldo, Andrea/M-2509-2016; Balistreri, Alberto/P-1173-2018; Porcaro, Antonio/M-2383-2017	Toti, Paolo/0000-0002-1214-5886; nucci, paolo/0000-0002-4036-703X; Haupt, Riccardo/0000-0003-0571-8460; Di Cataldo, Andrea/0000-0002-4509-3066; Balistreri, Alberto/0000-0002-7349-9725; Ciccolallo, Laura/0000-0002-8415-7106; Porcaro, Antonio/0000-0002-7890-040X; Cozza, Raffaele/0000-0002-8502-3310; Hadjistilianou, Theodora/0000-0002-9267-2255				ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; Abramson DH, 2001, OPHTHALMOLOGY, V108, P1868, DOI 10.1016/S0161-6420(01)00713-8; ABRAMSON DH, 1979, AM J OPHTHALMOL, V87, P624, DOI 10.1016/0002-9394(79)90293-9; ACQUAVIVA A, 1985, Bollettino di Oculistica, V64, P141; Aerts I, 2004, EUR J CANCER, V40, P1522, DOI 10.1016/j.ejca.2004.03.023; BLANQUET V, 1995, HUM MOL GENET, V4, P383, DOI 10.1093/hmg/4.3.383; CHAUVEINC L, 2001, OPHTHALMOL GENET, V2, P77; DERKINDEREN DJ, 1987, OPHTHALMIC PAED GEN, V8, P23, DOI 10.3109/13816818709028511; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; Fletcher O, 2004, JNCI-J NATL CANCER I, V96, P357, DOI 10.1093/jnci/djh058; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kaye FJ, 2004, J NATL CANCER I, V96, P342, DOI 10.1093/jnci/djh080; Lohmann DR, 1996, AM J HUM GENET, V58, P940; LUEDER GT, 1986, ARCH OPHTHALMOL-CHIC, V104, P372; Matsumoto H, 2003, PEDIATR INT, V45, P728, DOI 10.1046/j.1442-200x.2003.01821.x; Moll AC, 1996, HUM GENET, V98, P109, DOI 10.1007/s004390050168; ROARTY JD, 1988, OPHTHALMOLOGY, V95, P1583; SAGERMAN RH, 1969, AMER J ROENTGENOL RA, V105, P529, DOI 10.2214/ajr.105.3.529; Stata Corporation, 2006, STAT STAT SOFTW REL; Wong FL, 1997, JAMA-J AM MED ASSOC, V278, P1262, DOI 10.1001/jama.278.15.1262	22	24	24	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5350	5357		10.1038/sj.onc.1209786	http://dx.doi.org/10.1038/sj.onc.1209786			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936757				2022-12-17	WOS:000240064100022
J	Helmbold, H; Deppert, W; Bohn, W				Helmbold, H.; Deppert, W.; Bohn, W.			Regulation of cellular senescence by Rb2/p130	ONCOGENE			English	Review						Rb2; p53; senescence	RETINOBLASTOMA SUSCEPTIBILITY GENE; HUMAN TUMOR-CELLS; CYCLE ARREST; HISTONE DEACETYLASE; FAMILY-MEMBERS; PROTEIN P130; TRANSCRIPTIONAL REPRESSION; DEPENDENT PHOSPHORYLATION; POCKET PROTEINS; E2F1 PROMOTER	Growth regulatory functions of Rb2/p130, which aim at a sustained arrest such as in quiescent or differentiated cells, qualify the protein also to act as a central regulator of growth arrest in cellular senescence. In this respect, Rb2/ p130 functions are connected to signaling pathways induced by p53, which is a master regulator in cellular senescence. Here, we summarize the pathways, which specify pRb2/p130 to control this arrest program and distinguish its functions from those of pRb/p105.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Bohn, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.	wolfgang.bohn@hpi.uni-hamburg.de						Alexander K, 2001, MOL CELL BIOL, V21, P3616, DOI 10.1128/MCB.21.11.3616-3631.2001; Araki K, 2003, ONCOGENE, V22, P7632, DOI 10.1038/sj.onc.1206840; BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Baldi A, 1996, P NATL ACAD SCI USA, V93, P4629, DOI 10.1073/pnas.93.10.4629; Baldi A, 1997, CLIN CANCER RES, V3, P1691; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Bruce JL, 2000, MOL CELL, V6, P737, DOI 10.1016/S1097-2765(00)00072-1; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; Campisi J, 2001, EXP GERONTOL, V36, P607, DOI 10.1016/S0531-5565(00)00230-8; Canhoto AJ, 2000, ONCOGENE, V19, P5116, DOI 10.1038/sj.onc.1203893; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Classon M, 2000, P NATL ACAD SCI USA, V97, P10820, DOI 10.1073/pnas.190343497; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Coisy M, 2004, MOL CELL, V15, P43, DOI 10.1016/j.molcel.2004.06.022; D'Andrilli G, 2004, CLIN CANCER RES, V10, P3098, DOI 10.1158/1078-0432.CCR-03-0524; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dong F, 1998, J BIOL CHEM, V273, P6190, DOI 10.1074/jbc.273.11.6190; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Ghosh MK, 2003, MOL CELL, V12, P255, DOI 10.1016/S1097-2765(03)00225-9; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HAUPT Y, 1995, ONCOGENE, V10, P1563; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; Howard CM, 2000, CANCER RES, V60, P2737; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Iavarone A, 1999, MOL CELL BIOL, V19, P916; Ichimura K, 2000, GENE, V251, P37, DOI 10.1016/S0378-1119(00)00193-1; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kapic A, 2006, CELL DEATH DIFFER, V13, P324, DOI 10.1038/sj.cdd.4401756; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Li Qiang, 2004, Brain Tumor Pathol, V21, P121, DOI 10.1007/BF02482187; Liu DX, 2005, GENE DEV, V19, P719, DOI 10.1101/gad.1296405; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; MAYOL X, 1993, ONCOGENE, V8, P2561; MAYOL X, 1995, ONCOGENE, V11, P801; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; Milde-Langosch K, 2001, BRIT J CANCER, V85, P546, DOI 10.1054/bjoc.2001.1923; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; Nicolas E, 2003, MOL CELL BIOL, V23, P1614, DOI 10.1128/MCB.23.5.1614-1622.2003; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; Psyrri A, 2004, CANCER RES, V64, P3079, DOI 10.1158/0008-5472.CAN-03-3739; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Steiner MS, 2000, ONCOGENE, V19, P1297, DOI 10.1038/sj.onc.1203428; Stiegler P, 1998, CANCER RES, V58, P5049; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Susini T, 2001, HUM PATHOL, V32, P360, DOI 10.1053/hupa.2001.23514; Takahashi Y, 2000, GENE DEV, V14, P804; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Timmermann S, 1998, ONCOGENE, V17, P3445, DOI 10.1038/sj.onc.1202244; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; YEUNG RS, 1993, ONCOGENE, V8, P3465; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	92	24	27	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5257	5262		10.1038/sj.onc.1209613	http://dx.doi.org/10.1038/sj.onc.1209613			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936745				2022-12-17	WOS:000240064100010
J	Soprano, KJ; Purev, E; Vuocolo, S; Soprano, DR				Soprano, K. J.; Purev, E.; Vuocolo, S.; Soprano, D. R.			Rb2/p130 and protein phosphatase 2A: key mediators of ovarian carcinoma cell growth suppression by all-trans retinoic acid	ONCOGENE			English	Review						retinoids; ovarian cancer; protein phosphatase 2A; Rb2/p130	RESTRICTED SYNTHETIC RETINOIDS; LARGE T-ANTIGEN; NUCLEAR-LOCALIZATION; RETINOBLASTOMA PROTEIN; CANCER-CELLS; THYMIDINE KINASE; BINDING-SITE; SUBCELLULAR-LOCALIZATION; PAPILLOMAVIRUS TYPE-1; HISTONE DEACETYLASE	Despite a number of attempts to improve treatment of ovarian cancer, it remains the most common cause of death from gynecological cancers. Thus, it is very important to identify more effective drugs for treatment and prevention of ovarian cancer. All-trans-retinoic acid ( ATRA) has been shown to arrest the growth of ovarian carcinoma cells in G0/G1 and to significantly elevate levels of Rb2/p130 protein, a member of the retinoblastoma family of tumor suppressors. As ATRA treatment leads to a significant increase in the amount of Rb2/p130 protein but not mRNA, the elevated levels of Rb2/p130 protein is likely the result of increased stability. In studies to elucidate the mechanism by which ATRA alters Rb2/p130 stability in ovarian cancer cells, it was determined that PP2A, a serine/threonine phosphatase, binds and dephosphorylates Rb2/p130. Dephosphorylated Rb2/p130 exhibits decreased ubiquitination and thus is not degraded by the proteasome. The sites at which PP2A catalytic subunit (PP2Ac) interacts with Rb2/p130 have been localized to the NLS in the C-terminus of Rb2/p130. These sites are also involved in the interaction of Rb/p130 with importin beta and importin alpha, members of the nuclear transport machinery. It is known that importin a recognizes a NLS on a target protein and importin b binds the nuclear pore complex. Moreover, it has been shown that the binding of importin a to NLS significantly decreases with phosphorylation of NLS. In ATRA-treated ovarian carcinoma cells, PP2A binds to Rb2/p130 and dephosphorylates the NLS of Rb2/p130 leading to the interaction of importin a with Rb2/p130. Importin b then binds to the importin alpha-Rb2/p130 complex, leading to the translocation of the Rb2/p130 to the nucleus where it acts to arrest ovarian cancer cells in G1 and suppress proliferation.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Soprano, KJ (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, 3400 N Broad St, Philadelphia, PA 19140 USA.	sopranok@temple.edu			NATIONAL CANCER INSTITUTE [R01CA064945] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64945] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; BANKS L, 1990, ONCOGENE, V5, P1383; Bhattacharya S, 2003, ONCOGENE, V22, P2443, DOI 10.1038/sj.onc.1206339; Borriello A, 2000, ONCOGENE, V19, P51, DOI 10.1038/sj.onc.1203231; Botz J, 1996, MOL CELL BIOL, V16, P3401; Canhoto AJ, 2000, ONCOGENE, V19, P5116, DOI 10.1038/sj.onc.1203893; Catimel B, 2001, J BIOL CHEM, V276, P34189, DOI 10.1074/jbc.M103531200; Chao WR, 1997, CANCER LETT, V115, P1, DOI 10.1016/S0304-3835(97)04598-9; Chen MH, 2002, MECH DEVELOP, V114, P205, DOI 10.1016/S0925-4773(02)00066-7; Chestukhin A, 2002, MOL CELL BIOL, V22, P453, DOI 10.1128/MCB.22.2.453-468.2002; Cicchillitti L, 2003, J BIOL CHEM, V278, P19509, DOI 10.1074/jbc.M300511200; Cinti C, 2000, CANCER RES, V60, P383; Claudio PP, 1996, CANCER RES, V56, P2003; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Corbeil HB, 1997, ONCOGENE, V15, P657, DOI 10.1038/sj.onc.1201224; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; Daly M, 1998, SEMIN ONCOL, V25, P255; Dawson Marcia I., 1994, P5; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; DELUCA L, 1995, SCI AM, P2; DOU QP, 1994, J BIOL CHEM, V269, P1306; Dunaief JL, 2002, CURR EYE RES, V24, P392, DOI 10.1076/ceyr.24.5.392.8524; Fahrenkrog B, 2004, TRENDS BIOCHEM SCI, V29, P175, DOI 10.1016/j.tibs.2004.02.006; Fan SJ, 2001, ONCOGENE, V20, P4827, DOI 10.1038/sj.onc.1204666; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; FORD D, 1995, AM J HUM GENET, V57, P1457; Fry CJ, 1997, MOL CELL BIOL, V17, P1966, DOI 10.1128/MCB.17.4.1966; Fukuchi K, 1999, BBA-MOL CELL RES, V1451, P206, DOI 10.1016/S0167-4889(99)00081-6; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; GRUNT TW, 1991, J CELL SCI, V100, P657; GUILHOT C, 1993, ONCOGENE, V8, P619; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; HARANT H, 1993, BRIT J CANCER, V68, P530, DOI 10.1038/bjc.1993.381; Harreman MT, 2004, J BIOL CHEM, V279, P20613, DOI 10.1074/jbc.M401720200; Hengstschlager M, 1996, ONCOGENE, V12, P1635; Holmes WF, 2003, J CELL BIOCHEM, V89, P262, DOI 10.1002/jcb.10505; Holmes WF, 2004, J CELL PHYSIOL, V199, P317, DOI 10.1002/jcp.10338; Holmes WF, 2003, ONCOGENE, V22, P6377, DOI 10.1038/sj.onc.1206694; Holmes WF, 2002, J BIOL CHEM, V277, P45408, DOI 10.1074/jbc.M204600200; Holmes WF, 2000, J CELL PHYSIOL, V185, P61, DOI 10.1002/1097-4652(200010)185:1<61::AID-JCP5>3.0.CO;2-0; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1994, RETINOIDS, P592; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; Iavarone A, 1999, MOL CELL BIOL, V19, P916; IQBAL K, 1991, MOL NEUROBIOL, V5, P399, DOI 10.1007/BF02935561; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Kehlenbach RH, 2000, J BIOL CHEM, V275, P17848, DOI 10.1074/jbc.M001455200; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Litovchick L, 2004, MOL CELL BIOL, V24, P8970, DOI 10.1128/MCB.24.20.8970-8980.2004; Liu Y, 2000, J BIOL CHEM, V275, P30894, DOI 10.1074/jbc.M000640200; LUDLOW JW, 1993, ONCOGENE, V8, P331; Mayol X, 1996, ONCOGENE, V13, P237; Mayol X, 1997, Prog Cell Cycle Res, V3, P157; MAYOL X, 1998, FRONT BIOSCI, V3, P11; McGuire WP, 1998, CURR PROB CANCER, V22, P138, DOI 10.1016/S0147-0272(98)90005-8; MISSERO C, 1993, J CELL BIOL, V121, P1109, DOI 10.1083/jcb.121.5.1109; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MJMBY MC, 1993, PHYSIOL REV, V4, P673; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Modugno F, 2003, GYNECOL ONCOL, V91, P15, DOI 10.1016/S0090-8258(03)00254-3; Muller H, 1997, MOL CELL BIOL, V17, P5508; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NIELSCH U, 1991, ONCOGENE, V6, P1031; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Pergolizzi R, 1999, INT J CANCER, V81, P829; Purev E, 2006, J CELL PHYSIOL, V206, P495, DOI 10.1002/jcp.20490; PUREV E, 2006, UNPUB; Putzer BM, 1997, J VIROL, V71, P9538; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Rumpf H, 1999, VIROLOGY, V257, P45, DOI 10.1006/viro.1999.9651; Sabichi AL, 1998, J NATL CANCER I, V90, P597, DOI 10.1093/jnci/90.8.597; SAUNDERS DE, 1995, ANTI-CANCER DRUG, V6, P562, DOI 10.1097/00001813-199508000-00009; SCHMITT A, 1994, J VIROL, V68, P7051, DOI 10.1128/JVI.68.11.7051-7059.1994; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sekimoto T, 2004, EMBO J, V23, P1934, DOI 10.1038/sj.emboj.7600198; SHEIKH MS, 1995, CARCINOGENESIS, V16, P2477, DOI 10.1093/carcin/16.10.2477; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Spitkovsky D, 1997, CELL GROWTH DIFFER, V8, P699; Stiegler P, 1999, ANAL QUANT CYTOL, V21, P363; STOCHAJ U, 1993, J CELL SCI, V104, P89; Strack S, 2002, J BIOL CHEM, V277, P20750, DOI 10.1074/jbc.M202992200; Sueoka N, 1999, CANCER RES, V59, P3838; TortoleroLuna G, 1995, J CELL BIOCHEM, P200; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Um SJ, 2001, CANCER LETT, V174, P127, DOI 10.1016/S0304-3835(01)00697-8; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; Vuocolo S, 2003, J BIOL CHEM, V278, P41881, DOI 10.1074/jbc.M302715200; WADE M, 1995, J BIOL CHEM, V270, P9783, DOI 10.1074/jbc.270.17.9783; Wang P, 1997, Zhonghua Fu Chan Ke Za Zhi, V32, P722; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Wu SJ, 1998, ONCOGENE, V17, P2839, DOI 10.1038/sj.onc.1202208; Wu SJ, 1997, EXP CELL RES, V237, P118, DOI 10.1006/excr.1997.3769; Wu SJ, 1998, J CELL BIOCHEM, V68, P378, DOI 10.1002/(SICI)1097-4644(19980301)68:3<378::AID-JCB8>3.0.CO;2-R; Wu SJ, 1997, EXP CELL RES, V232, P277, DOI 10.1006/excr.1997.3495; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Young M, 2001, PHARMACOECONOMICS, V19, P1227, DOI 10.2165/00019053-200119120-00005; Zacksenhaus E, 1999, BBA-MOL CELL RES, V1451, P288, DOI 10.1016/S0167-4889(99)00103-2; Zhang DM, 2001, ONCOGENE, V20, P7935, DOI 10.1038/sj.onc.1204971; Zhang DM, 2000, J CELL PHYSIOL, V185, P1, DOI 10.1002/1097-4652(200010)185:1<1::AID-JCP1>3.0.CO;2-O	116	24	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5315	5325		10.1038/sj.onc.1209679	http://dx.doi.org/10.1038/sj.onc.1209679			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936753				2022-12-17	WOS:000240064100018
J	Foster, KSJ; McCrary, WJ; Ross, JS; Wright, CF				Foster, K. S. J.; McCrary, W. J.; Ross, J. S.; Wright, C. F.			Members of the hSWI/SNF chromatin remodeling complex associate with. and are phosphorylated by protein kinase B/Akt	ONCOGENE			English	Article						hSWI/SNF; INI1; BAF155; Akt	RHABDOID TUMOR-CELLS; BAF COMPLEX; ENDOTHELIAL-CELLS; SWI/SNF COMPLEX; CYCLE ARREST; BRG1; GENES; INI1; AKT; TRANSCRIPTION	In an adenosine triphosphate (ATP)-dependent process, the hSWI/SNF chromatin remodeling complex functions to alter chromatin structure, thereby regulating transcription factor access to DNA. In addition to interactions with transcription factors and recognition of acetylated histone residues, the chromatin remodeling activity of hSWI/SNF has also been shown to respond to a variety of cell signaling pathways. Our results demonstrate a novel interaction between the serine/threonine kinase Akt and members of the hSWI/SNF chromatin remodeling complex. Activation of Akt in HeLa cells resulted in its association with hSWI/SNF subunits: INI1, BAF155 and BAF170, as well as actin. BAF155 became preferentially recognized by an antibody that detects phosphorylated Akt substrates upon activation of Akt, suggesting that BAF155 may be an in vivo target for phosphorylation by Akt. Gtutathione-S-transferase (GST) pulldown experiments demonstrated that INI1 and BAF155 were both capable of directly interacting with Akt. Finally, in vitro kinase assays provided additional evidence that BAF155 and potentially INI1 are substrates for Akt phosphorylation. These data provide the first evidence that Akt signaling may modulate function of the hSWI/SNF complex.	Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; Med Univ S Carolina, Coll Med, Charleston, SC 29425 USA; Fayetteville State Univ, Dept Nat Sci, Fayetteville, NC USA	Medical University of South Carolina; Medical University of South Carolina; University of North Carolina; Fayetteville State University	Wright, CF (corresponding author), Med Univ S Carolina, Dept Pathol & Lab Med, 165 Ashley Ave,Suite 309,POB 250908, Charleston, SC 29425 USA.	wrightcf@musc.edu		Wright, Cynthia/0000-0003-0442-1665	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T35HL007769] Funding Source: NIH RePORTER; NHLBI NIH HHS [T35 HL007769-14] Funding Source: Medline; NIDDK NIH HHS [T32 DK007431-21] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Banine F, 2005, CANCER RES, V65, P3542, DOI 10.1158/0008-5472.CAN-04-3554; Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412; Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Biegel JA, 1999, CANCER RES, V59, P74; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; Chai JJ, 2005, CANCER RES, V65, P10192, DOI 10.1158/0008-5472.CAN-05-1896; Chen JG, 2005, MOL CELL BIOL, V25, P9016, DOI 10.1128/MCB.25.20.9016-9027.2005; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Craig E, 2002, EMBO J, V21, P31, DOI 10.1093/emboj/21.1.31; Cui KR, 2004, MOL CELL BIOL, V24, P4476, DOI 10.1128/MCB.24.10.4476-4486.2004; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; Doan DN, 2004, ONCOGENE, V23, P3462, DOI 10.1038/sj.onc.1207472; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; FRANKE TF, 1999, NEURAL NOTES, V5, P3; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Gresh L, 2005, EMBO J, V24, P3313, DOI 10.1038/sj.emboj.7600802; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Huang M, 2002, NAT CELL BIOL, V4, P774, DOI 10.1038/ncb855; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; Kang H, 2004, MOL CELL BIOL, V24, P1188, DOI 10.1128/MCB.24.3.1188-1199.2004; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; Link KA, 2005, MOL CELL BIOL, V25, P2200, DOI 10.1128/MCB.25.6.2200-2215.2005; Liu H, 2002, MOL CELL BIOL, V22, P6471, DOI 10.1128/MCB.22.18.6471-6479.2002; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Miyauchi H, 2004, EMBO J, V23, P212, DOI 10.1038/sj.emboj.7600045; Morozov A, 1998, P NATL ACAD SCI USA, V95, P1120, DOI 10.1073/pnas.95.3.1120; Oruetxebarria I, 2004, J BIOL CHEM, V279, P3807, DOI 10.1074/jbc.M309333200; Pattenden SG, 2002, EMBO J, V21, P1978, DOI 10.1093/emboj/21.8.1978; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Rando OJ, 2002, P NATL ACAD SCI USA, V99, P2824, DOI 10.1073/pnas.032662899; Reincke BS, 2003, J CELL PHYSIOL, V194, P303, DOI 10.1002/jcp.10201; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Schonherr E, 2001, J BIOL CHEM, V276, P40687, DOI 10.1074/jbc.M105426200; Simone C, 2004, NAT GENET, V36, P738, DOI 10.1038/ng1378; Versteege I, 2002, ONCOGENE, V21, P6403, DOI 10.1038/sj.onc.1205841; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wu DY, 2002, J BIOL CHEM, V277, P27706, DOI 10.1074/jbc.M200955200; Xu WP, 2003, CANCER RES, V63, P7777; Zhang ZK, 2002, MOL CELL BIOL, V22, P5975, DOI 10.1128/MCB.22.16.5975-5988.2002; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	45	24	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2006	25	33					4605	4612		10.1038/sj.onc.1209496	http://dx.doi.org/10.1038/sj.onc.1209496			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16568092				2022-12-17	WOS:000239457500010
J	Hartl, M; Karagiannidis, AI; Bister, K				Hartl, M.; Karagiannidis, A. I.; Bister, K.			Cooperative cell transformation by Myc/Mil(Raf) involves induction of AP-1 and activation of genes implicated in cell motility and metastasis	ONCOGENE			English	Article						activator protein-1; transcriptional control; gene regulation; osteopontin; target gene; cell transformation	OSTEOPONTIN EXPRESSION; DNA-BINDING; C-MYC; TRANSCRIPTION FACTOR; CHICKEN OSTEOPONTIN; STRUCTURAL-ANALYSIS; MELANOMA-CELLS; BREAST-CANCER; S100 PROTEINS; TARGET GENE	Avian fibroblasts transformed simultaneously by the v-myc and v-mil(raf) oncogenes of acute leukemia and carcinoma virus MH2 contain elevated levels of c-Fos and c-Jun, major components of the transcription factor complex AP-1. To de. ne specific transcriptional targets in these cells, subtractive hybridization techniques were employed leading to the identification of strongly upregulated genes including OPN (osteopontin), 126MRP, and rac2. OPN is a cytokine and cell attachment protein which has been implicated in human tumor progression and metastasis, the calcium binding 126MRP protein is related to the human S100 protein family involved in invasive cell growth, and the Rac2 protein belongs to the Rho family of small GTPases regulating actin reorganization and cell migration. Promoter analysis indicated that OPN activation is mediated by a non-consensus AP-1 binding site located close to the transcription start site. Electrophoretic mobility shift assays, chromatin immuno-precipitation and transcriptional reporter gene analyses showed that c-Fos and c-Jun bind specifically to this site and that c-Fos efficiently transactivates the OPN promoter. High-level expression of OPN, 126MRP, or Rac2 proteins from a retroviral vector led to partial cell transformation, documented by morphological changes and anchorage-independent growth. The specific activation in v-myc/v-mil(raf)-transformed cells of target genes with intrinsic oncogenic potential may provide an explanation for the longstanding observation that concomitant expression of these oncogenes leads to strongly enhanced oncogenicity in vivo and in vitro compared to cell transformation by v-myc or v-mil( raf) alone.	Univ Innsbruck, Inst Biochem, A-6020 Innsbruck, Austria; Univ Innsbruck, CMBI, A-6020 Innsbruck, Austria	University of Innsbruck; University of Innsbruck	Hartl, M (corresponding author), Univ Innsbruck, Inst Biochem, Peter Mayr Str 1A, A-6020 Innsbruck, Austria.	markus.hartl@uibk.ac.at	Bister, Klaus/AFA-9400-2022; Hartl, Markus/O-4655-2014	Hartl, Markus/0000-0001-7447-5920; Bister, Klaus/0000-0001-6545-5653	Austrian Science Fund FWF [P 17041, P 18148] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Bader AG, 2001, ONCOGENE, V20, P7524, DOI 10.1038/sj.onc.1204938; Bidder M, 2002, J BIOL CHEM, V277, P44485, DOI 10.1074/jbc.M206235200; BISTER K, 1986, ADV CANCER RES, V47, P99, DOI 10.1016/S0065-230X(08)60199-2; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CASTAGNOLA P, 1991, J BIOL CHEM, V266, P9944; Chamboredon S, 2003, ONCOGENE, V22, P4047, DOI 10.1038/sj.onc.1206713; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; Dang CV, 1999, MOL CELL BIOL, V19, P1; Denhardt DT, 2001, ANNU REV PHARMACOL, V41, P723, DOI 10.1146/annurev.pharmtox.41.1.723; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; DUESBERG PH, 1977, P NATL ACAD SCI USA, V74, P4320, DOI 10.1073/pnas.74.10.4320; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; El-Tanani M, 2004, J BIOL CHEM, V279, P20794, DOI 10.1074/jbc.M311131200; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hartl M, 1998, ONCOGENE, V17, P2901, DOI 10.1038/sj.onc.1202219; Hartl M, 2003, J MOL BIOL, V333, P33, DOI 10.1016/j.jmb.2003.08.018; Hartl M, 2001, P NATL ACAD SCI USA, V98, P13601, DOI 10.1073/pnas.241451198; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; JANSEN HW, 1983, J VIROL, V48, P61, DOI 10.1128/JVI.48.1.61-73.1983; JANSEN HW, 1983, EMBO J, V2, P1969, DOI 10.1002/j.1460-2075.1983.tb01686.x; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; Kurisu S, 2005, ONCOGENE, V24, P1309, DOI 10.1038/sj.onc.1208177; Kuykindoll RJ, 2000, J EXP BIOL, V203, P273; Lefevre G, 2003, ONCOGENE, V22, P8813, DOI 10.1038/sj.onc.1207099; Marenholz I, 2004, BIOCHEM BIOPH RES CO, V322, P1111, DOI 10.1016/j.bbrc.2004.07.096; Merezak C, 2001, J VIROL, V75, P6977, DOI 10.1128/JVI.75.15.6977-6988.2001; Mi ZY, 2004, J BIOL CHEM, V279, P46659, DOI 10.1074/jbc.M407952200; Moye VE, 2004, BRIT J CANCER, V90, P1796, DOI 10.1038/sj.bjc.6601683; NAKANO T, 1992, ONCOGENE, V7, P527; PATSCHINSKY T, 1988, ONCOGENE, V3, P357; Polsky D, 2003, ONCOGENE, V22, P3087, DOI 10.1038/sj.onc.1206449; RAFIDI K, 1994, GENE, V140, P163, DOI 10.1016/0378-1119(94)90540-1; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; RAPP UR, 1994, ONCOGENE, V9, P3493; Rittling SR, 2004, BRIT J CANCER, V90, P1877, DOI 10.1038/sj.bjc.6601839; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sakata R, 2004, BIOCHEM BIOPH RES CO, V315, P959, DOI 10.1016/j.bbrc.2004.01.152; SENGER DR, 1979, CELL, V16, P885, DOI 10.1016/0092-8674(79)90103-X; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Sherwood DR, 2005, CELL, V121, P951, DOI 10.1016/j.cell.2005.03.031; SHYY JYJ, 1995, P NATL ACAD SCI USA, V92, P8069, DOI 10.1073/pnas.92.17.8069; Simpson PT, 2003, INT J EXP PATHOL, V84, P173, DOI 10.1046/j.1365-2613.2003.00350.x; SORENSEN ES, 1995, PROTEIN SCI, V4, P2040, DOI 10.1002/pro.5560041009; SUTRAVE P, 1984, NATURE, V309, P85, DOI 10.1038/309085a0; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; Teramoto H, 2005, ONCOGENE, V24, P489, DOI 10.1038/sj.onc.1208209; TIKHONENKO AT, 1992, J VIROL, V66, P946, DOI 10.1128/JVI.66.2.946-955.1992; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Vogt PK, 2002, NAT REV CANCER, V2, P465, DOI 10.1038/nrc818; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498	62	24	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2006	25	29					4043	4055		10.1038/sj.onc.1209441	http://dx.doi.org/10.1038/sj.onc.1209441			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16491116				2022-12-17	WOS:000238802400005
J	Sharif, A; Prevot, V; Renault-Mihara, F; Allet, C; Studler, JM; Canton, B; Chneiweiss, H; Junier, MP				Sharif, A.; Prevot, V.; Renault-Mihara, F.; Allet, C.; Studler, J-M; Canton, B.; Chneiweiss, H.; Junier, M-P			Transforming growth factor alpha acts as a gliatrophin for mouse and human astrocytes	ONCOGENE			English	Article						erbB1; apoptosis; survival; trophic factor; oncogenesis; EGF	FEMALE SEXUAL DEVELOPMENT; FACTOR RECEPTOR; TYROSINE KINASE; ERBB RECEPTORS; TGF-ALPHA; PHOSPHATIDYLINOSITOL 3-KINASE; UP-REGULATION; MICE LACKING; RAT-BRAIN; EGF	Astrocyte death has been implicated in several neuropathological diseases, but the identification of molecules susceptible of promoting astrocyte survival has been elusive. We investigated whether transforming growth factor alpha (TGF alpha), an erbB1/EGFR ligand, which promotes glioma progression and affects astrocyte metabolism at embryonic and adult stages, regulates astrocyte survival. Primary serum-free astrocyte cultures from postnatal mouse and fetal human cortices were used. Transforming growth factor alpha protected both species of astrocytes from staurosporine-induced apoptosis. In serum-free medium, mouse astrocytes did not survive beyond 2 months while TGF alpha-treated astrocytes survived up to 12 months. Transforming growth factor alpha also promoted long-term survival of human astrocytes. We additionally extended TGFa proliferative effects to human astrocytes. After 3 days of permanent application, TGFa induced a major downregulation of both erbB1 and erbB2. This downregulation did not impair the functional activation of the receptors, as ascertained by their tyrosine phosphorylation and the continuous stimulation of both ERK/MAPK and PI3K/Akt pathways up to 7 days, the longest time examined. The full cellular effects of TGF alpha required activation of both transduction pathways. Enhanced proliferation and survival thus de. ne TGF alpha as a gliatrophin for mammalian astrocytes. These results demonstrate that in normal, non-transformed astrocytes, sustained and functional erbBs activation is achieved without bypassing ligand-induced receptors downregulation.	INSERM, U752, F-75013 Paris, France; Univ Paris 05, F-75013 Paris, France; INSERM, U114, F-75005 Paris, France; INSERM, U816, F-59000 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Junier, MP (corresponding author), INSERM, U752, F-75013 Paris, France.	marie-pierre.junier@college-de-france.fr	, Renault-Mihara/L-3320-2013; Prevot, Vincent/E-5720-2016; Sharif, Ariane/AGW-8363-2022; herve, chneiweiss/Q-6818-2019	Prevot, Vincent/0000-0001-7185-3615; herve, chneiweiss/0000-0001-7675-5061; ALLET, Cecile/0000-0003-1294-9064; Sharif, Ariane/0000-0003-0810-400X				Bakhiet M, 2001, NAT CELL BIOL, V3, P150, DOI 10.1038/35055057; Barna BP, 2001, CELL IMMUNOL, V208, P18, DOI 10.1006/cimm.2001.1768; Beck G, 2002, NEURON, V33, P673, DOI 10.1016/S0896-6273(02)00619-0; Bergmann A, 2002, DEV CELL, V2, P159, DOI 10.1016/S1534-5807(02)00116-8; Boillee S, 2001, J NEUROSCI, V21, P7079, DOI 10.1523/JNEUROSCI.21-18-07079.2001; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Chakravarti A, 2002, CANCER RES, V62, P4307; Ciardiello F, 2003, EUR J CANCER, V39, P1348, DOI 10.1016/S0959-8049(03)00235-1; Di Iorio P, 2004, GLIA, V46, P356, DOI 10.1002/glia.20002; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Erlich S, 2000, MOL CELL NEUROSCI, V16, P597, DOI 10.1006/mcne.2000.0894; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fernandez PA, 2000, NEURON, V28, P81, DOI 10.1016/S0896-6273(00)00087-8; Francis A, 1999, J NEUROSCI RES, V57, P487, DOI 10.1002/(SICI)1097-4547(19990815)57:4<487::AID-JNR8>3.0.CO;2-W; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Gerecke KM, 2001, J COMP NEUROL, V433, P86, DOI 10.1002/cne.1127; Giffard RG, 2005, GLIA, V50, P299, DOI 10.1002/glia.20167; Hanson MG, 1998, J NEUROSCI, V18, P7361; Hertz L, 2004, TRENDS NEUROSCI, V27, P735, DOI 10.1016/j.tins.2004.10.008; Hidalgo A, 2001, DEV CELL, V1, P679, DOI 10.1016/S1534-5807(01)00074-0; Junier MP, 2000, PROG NEUROBIOL, V62, P443, DOI 10.1016/S0301-0082(00)00017-4; Justicia C, 1999, J CEREBR BLOOD F MET, V19, P128, DOI 10.1097/00004647-199902000-00002; Justman QA, 2002, J BIOL CHEM, V277, P20618, DOI 10.1074/jbc.M111359200; Kari C, 2003, CANCER RES, V63, P1; Kerr DA, 2003, J NEUROSCI, V23, P5131; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; Kornblum HI, 1998, J NEUROSCI RES, V53, P697, DOI 10.1002/(SICI)1097-4547(19980915)53:6<697::AID-JNR8>3.3.CO;2-M; Kornblum HI, 1999, EUR J NEUROSCI, V11, P3236, DOI 10.1046/j.1460-9568.1999.00744.x; KRUEGER BK, 1995, J NEUROSCI, V15, P3366; LEE DC, 1995, PHARMACOL REV, V47, P51; Lemke G, 2001, ANNU REV NEUROSCI, V24, P87, DOI 10.1146/annurev.neuro.24.1.87; LEUTZ A, 1981, CELL TISSUE RES, V220, P393; Levison SW, 2000, GLIA, V32, P328, DOI 10.1002/1098-1136(200012)32:3<328::AID-GLIA110>3.0.CO;2-7; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; MORRISON RS, 1987, SCIENCE, V238, P72, DOI 10.1126/science.3498986; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; PinkasKramarski R, 1997, ONCOGENE, V15, P2803, DOI 10.1038/sj.onc.1201466; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Prevot V, 2005, ENDOCRINOLOGY, V146, P1465, DOI 10.1210/en.2004-1146; Prevot V, 2003, J NEUROSCI, V23, P230; Rabchevsky AG, 1998, J NEUROSCI, V18, P10541, DOI 10.1523/jneurosci.18-24-10541.1998; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rodriguez D, 2001, AM J HUM GENET, V69, P1134, DOI 10.1086/323799; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; Saas P, 2002, NEUROREPORT, V13, P1921, DOI 10.1097/00001756-200210280-00018; Schlessinger J, 2004, SCIENCE, V306, P1506, DOI 10.1126/science.1105396; Schreiner B, 2003, GENE CHROMOSOME CANC, V38, P240, DOI 10.1002/gcc.10285; Schreiner B, 2003, ONCOGENE, V22, P6802, DOI 10.1038/sj.onc.1206836; Sibilia M, 1998, EMBO J, V17, P719, DOI 10.1093/emboj/17.3.719; SORIANO E, 1993, J HISTOCHEM CYTOCHEM, V41, P819, DOI 10.1177/41.6.8315274; Sweeney C, 2004, BRIT J CANCER, V90, P289, DOI 10.1038/sj.bjc.6601500; Takuma K, 2004, PROG NEUROBIOL, V72, P111, DOI 10.1016/j.pneurobio.2004.02.001; Tang P, 1997, J NEURO-ONCOL, V35, P303, DOI 10.1023/A:1005824802617; THOMAS LB, 1995, EXP NEUROL, V133, P265, DOI 10.1006/exnr.1995.1029; Thompson KA, 2001, ANN NEUROL, V49, P745, DOI 10.1002/ana.1011; Tokita Y, 2001, J NEUROSCI, V21, P1257; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; WEICKERT CS, 1995, DEV BRAIN RES, V86, P203, DOI 10.1016/0165-3806(95)00026-A; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; Wu CJ, 2000, ONCOGENE, V19, P3999, DOI 10.1038/sj.onc.1203748; Xian CJ, 1999, MOL NEUROBIOL, V20, P157, DOI 10.1007/BF02742440; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; YOKOYAMA M, 1993, EXP NEUROL, V124, P377, DOI 10.1006/exnr.1993.1209; Zelenaia O, 2000, MOL PHARMACOL, V57, P667, DOI 10.1124/mol.57.4.667	69	24	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2006	25	29					4076	4085		10.1038/sj.onc.1209443	http://dx.doi.org/10.1038/sj.onc.1209443			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16532035				2022-12-17	WOS:000238802400008
J	Chevalier, SA; Meertens, L; Pise-Masison, C; Calattini, S; Park, H; Alhaj, AA; Zhou, M; Gessain, A; Kashanchi, F; Brady, JN; Mahieux, R				Chevalier, S. A.; Meertens, L.; Pise-Masison, C.; Calattini, S.; Park, H.; Alhaj, A. A.; Zhou, M.; Gessain, A.; Kashanchi, F.; Brady, J. N.; Mahieux, R.			The tax protein from the primate T-cell lymphotropic virus type 3 is expressed in vivo and is functionally related to HTLV-1 tax rather than HTLV-2 Tax	ONCOGENE			English	Article						HTLV-3; tax; PDZ; CREB; NF-kappa B	LONG TERMINAL REPEAT; LEUKEMIA-VIRUS; CENTRAL-AFRICA; MOLECULAR EPIDEMIOLOGY; 21-BASE-PAIR REPEATS; CERCOCEBUS-TORQUATUS; VIRAL REPLICATION; ESCHERICHIA-COLI; COACTIVATOR CBP; PAPIO-HAMADRYAS	Human T-cell leukemia virus and simian T-cell leukemia virus ( STLV) form the primate T-cell lymphotropic viruses group. Human T-cell leukemia virus type 1 and type 2 (HTLV-1 and HTLV-2) encode the Tax viral transactivator ( Tax1 and Tax2, respectively). Tax1 possesses an oncogenic potential and is responsible for cell transformation both in vivo and in vitro. We and others have recently discovered the existence of human T-cell lymphotropic virus type 3. However, there is currently no evidence for the presence of a Tax protein in HTLV-3-infected individuals. We show that the serum of an HTLV-3 asymptomatic carrier and the sera of two STLV-3-infected monkeys contain specific anti-Tax3 antibodies. We also show that tax3 mRNA is present in the PBMCs obtained from an STLV-3-infected monkey, demonstrating that Tax3 is expressed in vivo. We further demonstrate that Tax3 intracellular localization is very similar to that of Tax1 and that Tax3 binds to both CBP and p300 coactivators. Using purified Tax3, we show that the protein increases transcription from a 4TxRE G-free cassette plasmid in an in vitro transcription assay. In all cell types tested, including transiently transfected lymphocytes, Tax3 activates its own promoter STLV-3 long terminal repeat (LTR), which contains only two Tax Responsive Elements (TREs), and activates also HTLV-1 and HTLV-2 LTRs. In addition, Tax3 also activates the NF-kappa B pathway. We also show that Tax3 possesses a PDZ-binding sequence at its C-terminal end. Our results demonstrate that Tax3 is a transactivator, and that its properties are more similar to that of Tax1, rather than of Tax2. This suggests the possible occurrence of lymphoproliferative disorders among HTLV-3-infected populations.	Inst Pasteur, Unite Epidemiol & Physiopathol Virus Oncogenes, F-75724 Paris 15, France; NCI, Virus Tumor Biol Sect, NIH, Bethesda, MD USA; George Washington Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); George Washington University	Mahieux, R (corresponding author), Inst Pasteur, Unite Epidemiol & Physiopathol Virus Oncogenes, 28 Rue Dr Roux, F-75724 Paris 15, France.	rmahieux@pasteur.fr	Meertens, Laurent/E-8043-2017	Meertens, Laurent/0000-0003-2811-3675; mahieux, renaud/0000-0002-5129-6804	NIAID NIH HHS [AI43894, AI13969, AI44357] Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC005254, Z01BC005254, Z01BC005691, ZIABC005691] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043894, R29AI044357] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alefantis T, 2003, J BIOL CHEM, V278, P21814, DOI 10.1074/jbc.M211576200; Barnhart MK, 1997, J VIROL, V71, P337, DOI 10.1128/JVI.71.1.337-344.1997; BLAKESLEE JR, 1987, CANCER LETT, V37, P1, DOI 10.1016/0304-3835(87)90139-X; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; Calattini S, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-30; Casoli C, 2004, BLOOD, V103, P995, DOI 10.1182/blood-2003-07-2503; Chen YMA, 1997, INT J CANCER, V71, P196, DOI 10.1002/(SICI)1097-0215(19970410)71:2&lt;196::AID-IJC12&gt;3.0.CO;2-G; COATES SR, 1990, J CLIN MICROBIOL, V28, P1139, DOI 10.1128/JCM.28.6.1139-1142.1990; Courgnaud V, 2004, J VIROL, V78, P4700, DOI 10.1128/JVI.78.9.4700-4709.2004; Deng LW, 2000, VIROLOGY, V277, P278, DOI 10.1006/viro.2000.0593; DUVALL JF, 1995, J VIROL, V69, P5077, DOI 10.1128/JVI.69.8.5077-5086.1995; Endo K, 2002, J VIROL, V76, P2648, DOI 10.1128/JVI.76.6.2648-2653.2002; FROMENT A, 1993, AIDS RES HUM RETROV, V9, P707, DOI 10.1089/aid.1993.9.707; GESSAIN A, 1995, P NATL ACAD SCI USA, V92, P4041, DOI 10.1073/pnas.92.9.4041; GIRI A, 1994, J VIROL, V68, P8392, DOI 10.1128/JVI.68.12.8392-8395.1994; GITLIN SD, 1991, J VIROL, V65, P2612, DOI 10.1128/JVI.65.5.2612-2621.1991; GOUBAU P, 1994, P NATL ACAD SCI USA, V91, P2848, DOI 10.1073/pnas.91.7.2848; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; GUO HG, 1984, SCIENCE, V223, P1195, DOI 10.1126/science.6322297; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Hirata A, 2004, VIROLOGY, V318, P327, DOI 10.1016/j.virol.2003.10.006; Hisada M, 1998, BLOOD, V92, P3557, DOI 10.1182/blood.V92.10.3557.422k09_3557_3561; Hunsmann G, 1984, Princess Takamatsu Symp, V15, P109; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; Kashanchi F, 1998, J BIOL CHEM, V273, P34646, DOI 10.1074/jbc.273.51.34646; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lemasson I, 2001, J BIOL CHEM, V276, P15720, DOI 10.1074/jbc.M100131200; LINDHOLM PF, 1991, J BIOCHEM BIOPH METH, V22, P233, DOI 10.1016/0165-022X(91)90071-4; LIU HF, 1994, LANCET, V344, P265, DOI 10.1016/S0140-6736(94)93032-5; Lu HX, 2002, MOL CELL BIOL, V22, P4450, DOI 10.1128/MCB.22.13.4450-4462.2002; Mahieux R, 1997, J VIROL, V71, P1317, DOI 10.1128/JVI.71.2.1317-1333.1997; Mahieux Renaud, 2003, Rev Clin Exp Hematol, V7, P336; MAUCLERE P, 1993, AIDS, V7, P1394, DOI 10.1097/00002030-199310000-00019; Mauclere P, 1997, J INFECT DIS, V176, P505, DOI 10.1086/514071; Mboudjeka I, 1997, JPN J CANCER RES, V88, P619, DOI 10.1111/j.1349-7006.1997.tb00427.x; Meertens L, 2004, J BIOL CHEM, V279, P43307, DOI 10.1074/jbc.M400497200; Meertens L, 2004, ONCOGENE, V23, P5447, DOI 10.1038/sj.onc.1207719; Meertens L, 2003, J GEN VIROL, V84, P2723, DOI 10.1099/vir.0.19253-0; Meertens L, 2003, J VIROL, V77, P782, DOI 10.1128/JVI.77.1.782-789.2003; Meertens L, 2002, J VIROL, V76, P259, DOI 10.1128/JVI.76.1.259-268.2002; MIYOSHI I, 1982, LANCET, V2, P658; Nerrienet E, 2004, J GEN VIROL, V85, P25, DOI 10.1099/vir.0.19314-0; Nerrienet E, 2001, J GEN VIROL, V82, P2973, DOI 10.1099/0022-1317-82-12-2973; Nicot C, 2004, NAT MED, V10, P197, DOI 10.1038/nm984; Pise-Masison CA, 2005, FRONT BIOSCI-LANDMRK, V10, P919, DOI 10.2741/1586; Pise-Masison CA, 2000, AIDS RES HUM RETROV, V16, P1669, DOI 10.1089/08892220050193128; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Ross TM, 1996, J VIROL, V70, P5194, DOI 10.1128/JVI.70.8.5194-5202.1996; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Scoggin KES, 2001, MOL CELL BIOL, V21, P5520, DOI 10.1128/MCB.21.16.5520-5530.2001; Slattery JP, 1999, GENOME RES, V9, P525; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Takemura T, 2002, J VIROL, V76, P1642, DOI 10.1128/JVI.76.4.1642-1648.2002; Van Brussel M, 1999, REV MED VIROL, V9, P155, DOI 10.1002/(SICI)1099-1654(199907/09)9:3&lt;155::AID-RMV242&gt;3.0.CO;2-3; Van Dooren S, 2004, J GEN VIROL, V85, P507, DOI 10.1099/vir.0.19630-0; Van Dooren S, 2001, J VIROL, V75, P11939, DOI 10.1128/JVI.75.23.11939-11941.2001; VanBrussel M, 1997, J VIROL, V71, P5464; VanBrussel M, 1996, J GEN VIROL, V77, P347, DOI 10.1099/0022-1317-77-2-347; Watanabe M, 2005, BLOOD, V106, P2462, DOI 10.1182/blood-2004-09-3646; Wolfe ND, 2005, P NATL ACAD SCI USA, V102, P7994, DOI 10.1073/pnas.0501734102; Younis I, 2004, J VIROL, V78, P11077, DOI 10.1128/JVI.78.20.11077-11083.2004	63	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	32					4470	4482		10.1038/sj.onc.1209472	http://dx.doi.org/10.1038/sj.onc.1209472			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16532031				2022-12-17	WOS:000239326000010
J	Gronholm, M; Muranen, T; Toby, GG; Utermark, T; Hanemann, CO; Golemis, EA; Carpen, O				Gronholm, M.; Muranen, T.; Toby, G. G.; Utermark, T.; Hanemann, C. O.; Golemis, E. A.; Carpen, O.			A functional association between merlin and HEI10, a cell cycle regulator	ONCOGENE			English	Article						NF2; ERM; HEI10	TUMOR-SUPPRESSOR PROTEIN; NEUROFIBROMATOSIS TYPE-2; GENE-PRODUCT; P21-ACTIVATED KINASE; SCHWANN-CELLS; ERM PROTEINS; NF2 GENE; EZRIN; GROWTH; CYTOSKELETON	Merlin and ezrin are homologous proteins with opposite effects on neoplastic growth. Merlin is a tumor suppressor inactivated in the neurofibromatosis 2 disease, whereas upregulated ezrin expression is associated with increased malignancy. Merlin's tumor suppressor mechanism is not known, although participation in cell cycle regulation has been suggested. To characterize merlin's biological activities, we screened for molecules that would interact with merlin but not ezrin. We identified the cyclin B-binding protein and cell cycle regulator HEI10 as a novel merlin-binding partner. The interaction is mediated by the alpha-helical domain in merlin and the coiled-coil domain in HEI10 and requires conformational opening of merlin. The two proteins show partial subcellular colocalization, which depends on cell cycle stage and cell adhesion. Comparison of Schwann cells and schwannoma cultures demonstrated that the distribution of HEI10 depends on merlin expression. In transfected cells, a constitutively open merlin construct affected HEI10 protein integrity. These results link merlin to the cell cycle control machinery and may help to understand its tumor suppressor function.	Univ Helsinki, Program Neurosci, Biomed Helsinki, Dept Pathol, Helsinki 00014, Finland; Helsinki Univ Hosp, Helsinki 00014, Finland; Fox Chase Canc Ctr, Div Basic Sci, Philadelphia, PA USA; Univ Ulm, Dept Neurol, D-7900 Ulm, Germany; Peninsula Med Sch, Clin Neurobiol, Inst Clin & Biomed Sci, Plymouth, Devon, England; Turku Univ, Dept Pathol, Turku, Finland; Turku Univ Hosp, FIN-20520 Turku, Finland	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Fox Chase Cancer Center; Ulm University; University of Plymouth; University of Turku; University of Turku	Gronholm, M (corresponding author), Univ Helsinki, Program Neurosci, Biomed Helsinki, Dept Pathol, Haartmanink 8,PB 63, Helsinki 00014, Finland.	mikaela.gronholm@helsinki.fi	Gronholm, Mikaela/B-4225-2010; Muranen, Taru/AAM-9349-2021; Hanemann, C Oliver/AAV-6257-2020	Hanemann, C Oliver/0000-0002-1951-1025; Muranen, Taru/0000-0003-4158-9002; Golemis, Erica/0000-0003-3618-3673; Gronholm, Mikaela/0000-0002-2378-8924				Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; ARAKAWA H, 1994, HUM MOL GENET, V3, P565, DOI 10.1093/hmg/3.4.565; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Chambers DN, 2005, BIOCHEMISTRY-US, V44, P3926, DOI 10.1021/bi0480382; DENBAKKER MA, 1995, AM J PATHOL, V147, P1339; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Geiger KD, 2000, AM J PATHOL, V157, P1785, DOI 10.1016/S0002-9440(10)64816-X; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; Gronholm M, 2003, J BIOL CHEM, V278, P41167, DOI 10.1074/jbc.M306149200; Gronholm M, 1999, J CELL SCI, V112, P895; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hanemann CO, 1998, GLIA, V23, P89, DOI 10.1002/(SICI)1098-1136(199806)23:2<89::AID-GLIA1>3.0.CO;2-Z; Hirokawa Y, 2004, CANCER J, V10, P20, DOI 10.1097/00130404-200401000-00006; Huynh DP, 1996, ONCOGENE, V13, P73; Ilmonen S, 2005, MODERN PATHOL, V18, DOI 10.1038/modpathol.3800429; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; LOUIS DN, 1995, BRAIN PATHOL, V5, P163, DOI 10.1111/j.1750-3639.1995.tb00590.x; LUTCHMAN M, 1995, CANCER RES, V55, P2270; Makitie T, 2001, INVEST OPHTH VIS SCI, V42, P2442; McClatchey AI, 2003, NAT REV CANCER, V3, P877, DOI 10.1038/nrc1213; Mine N, 2001, JPN J CANCER RES, V92, P135, DOI 10.1111/j.1349-7006.2001.tb01075.x; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Muranen T, 2005, ONCOGENE, V24, P1150, DOI 10.1038/sj.onc.1208283; Pineau P, 2003, INT J CANCER, V106, P216, DOI 10.1002/ijc.11214; Rosenbaum C, 1998, NEUROBIOL DIS, V5, P55, DOI 10.1006/nbdi.1998.0179; Sainio M, 1997, J CELL SCI, V110, P2249; Schulze KMM, 2002, HUM MOL GENET, V11, P69, DOI 10.1093/hmg/11.1.69; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Smith AP, 2004, CANCER BIOL THER, V3, P104, DOI 10.4161/cbt.3.1.661; Toby GG, 2003, MOL CELL BIOL, V23, P2109, DOI 10.1128/MCB.23.6.2109-2122.2003; Tynninen O, 2004, NEUROPATH APPL NEURO, V30, P472, DOI 10.1111/j.1365-2990.2004.00562.x; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200	38	24	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	32					4389	4398		10.1038/sj.onc.1209475	http://dx.doi.org/10.1038/sj.onc.1209475			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16532029				2022-12-17	WOS:000239326000002
J	Milton, A; Luoto, K; Ingram, L; Munro, S; Logan, N; Graham, AL; Brummelkamp, TR; Hijmans, EM; Bernards, R; La Thangue, NB				Milton, A.; Luoto, K.; Ingram, L.; Munro, S.; Logan, N.; Graham, A. L.; Brummelkamp, T. R.; Hijmans, E. M.; Bernards, R.; La Thangue, N. B.			A functionally distinct member of the DP family of E2F subunits	ONCOGENE			English	Article						cancer; cell cycle; E2F; DP	NUCLEAR ACCUMULATION; TRANSCRIPTION; COMPONENT; PROTEIN; RECOGNITION; MECHANISMS; APOPTOSIS; PARTNER; EXTENDS; PRB	E2F transcription factors regulate genes involved in cell-cycle progression. In mammalian cells, physiological E2F exists as an E2F/DP heterodimer. Currently, eight E2F and two DP subunits have been characterized. We report here the characterization of a new member of the DP family, DP-4. While DP-4 exhibits certain similarities with members of the DP family, it also possesses a number of significant differences. Thus, DP-4 forms a heterodimer with E2F subunits, binds to the E2F site and associates with pocket proteins including pRb. In contrast to DP-1, however, DP-4/E2F-1 complexes exhibit reduced DNA binding activity. Furthermore, DP-4 interferes with E2F-1- dependent transcription and delays cell-cycle progression. These results highlight an emerging complexity in the DP family of E2F subunits, and suggest that DP-4 may endow E2F heterodimers with distinct transcription properties.	Univ Oxford, Canc Biol Lab, Nuffield Dept Clin Lab Sci, Div Med Sci,John Radcliffe Hosp, Oxford, Oxon, England; Netherlands Canc Inst, Amsterdam, Netherlands	University of Oxford; Netherlands Cancer Institute	La Thangue, NB (corresponding author), Univ Oxford, Canc Biol Lab, Nuffield Dept Clin Lab Sci, Div Med Sci, Oxford, Oxon, England.	nick.lathangue@ndcls.ox.ac.uk		Bernards, Rene/0000-0001-8677-3423; Hijmans, Marielle/0000-0003-4847-9412	Cancer Research UK [13058] Funding Source: Medline; Medical Research Council [G9400953, G0500905] Funding Source: Medline; MRC [G9400953, G0500905] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Allen KE, 1997, J CELL SCI, V110, P2819; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; de la Luna S, 1999, EMBO J, V18, P212, DOI 10.1093/emboj/18.1.212; delaLuna S, 1996, J CELL SCI, V109, P2443; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; Kohn MJ, 2004, MOL CELL BIOL, V24, P7197, DOI 10.1128/MCB.24.16.7197-7205.2004; Kohn MJ, 2003, DEVELOPMENT, V130, P1295, DOI 10.1242/dev.00355; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Logan N, 2004, ONCOGENE, V23, P5138, DOI 10.1038/sj.onc.1207649; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; Rogers KT, 1996, P NATL ACAD SCI USA, V93, P7594, DOI 10.1073/pnas.93.15.7594; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; ZHANG YH, 1995, ONCOGENE, V10, P2085; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459	20	24	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3212	3218		10.1038/sj.onc.1209343	http://dx.doi.org/10.1038/sj.onc.1209343			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16418725	Green Published			2022-12-17	WOS:000237951000012
J	Wang, X; Hu, B; Weiss, RS; Wang, Y				Wang, X; Hu, B; Weiss, RS; Wang, Y			The effect of Hus1 on ionizing radiation sensitivity is associated with homologous recombination repair but is independent of nonhomologous end-joining	ONCOGENE			English	Article						Hus1; IR (ionizing radiation); DNA damage; DNA repair; NHEJ (nonhomologous end-joining); HRR (homologous recombination repair)	DNA-DAMAGE; GENOMIC INSTABILITY; MAMMALIAN-CELLS; MOUSE HUS1; HUMAN RAD9; CHECKPOINT; CHK1; PHOSPHORYLATION; ACTIVATION; RESPONSES	Mammalian Hus1 plays an important role in maintaining genomic integrity. Cells lacking mouse Hus1 are hypersensitive to DNA damage inducers including UV and camptothecin ( CPT). By using clonogenic assay, we show here that Hus1 deficient mouse cells are hypersensitive to ionizing radiation ( IR) compared with their Hus1-positive counterparts. However, these cells show similar induction levels and similar rejoining rates of DNA double strand breaks ( DSBs) following IR, indicating that the effect of Hus1 on cell radiosensitivity is independent of nonhomologous end-joining (NHEJ). By combining an I-SceI-induced-DNA DSBs system and a siRNA approach, we also show that knocking down Hus1 decreases the efficiency of homologous recombination repair ( HRR), which is associated with the cellular sensitivity to IR-induced killing. Together, these results indicate that the role of Hus1 affecting the sensitivity of cells to IR-induced killing is independent of NHEJ but might be linked to HRR.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Radiat Oncol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Cornell Univ, Dept Biomed Sci, Ithaca, NY USA; Beijing Inst Biotechnol, Beijing, Peoples R China	Jefferson University; Jefferson University; Cornell University	Wang, Y (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Radiat Oncol, Thompson Bldg Room B-1,1020 Sansom St, Philadelphia, PA 19107 USA.	ya.wang@mail.tju.edu			NCI NIH HHS [R01 CA108773] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA108773] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen MJ, 2001, J BIOL CHEM, V276, P16580, DOI 10.1074/jbc.M008871200; Couedel C, 2004, GENE DEV, V18, P1293, DOI 10.1101/gad.1209204; Golding SE, 2004, J BIOL CHEM, V279, P15402, DOI 10.1074/jbc.M314191200; Hang HY, 2000, GENOMICS, V65, P24, DOI 10.1006/geno.2000.6142; Hopkins KM, 2004, MOL CELL BIOL, V24, P7235, DOI 10.1128/MCB.24.16.7235-7248.2004; Hu BC, 2005, CANCER RES, V65, P8613, DOI 10.1158/0008-5472.CAN-05-1966; Hu BC, 2001, J BIOL CHEM, V276, P17693, DOI 10.1074/jbc.M009340200; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Mills KD, 2004, GENE DEV, V18, P1283, DOI 10.1101/gad.1204304; Nickoloff Jac A, 2004, Methods Mol Biol, V262, P35; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Roos-Mattjus P, 2003, J BIOL CHEM, V278, P24428, DOI 10.1074/jbc.M301544200; Wang HY, 2004, CANCER RES, V64, P7139, DOI 10.1158/0008-5472.CAN-04-1289; Wang X, 2004, NUCLEIC ACIDS RES, V32, P767, DOI 10.1093/nar/gkh243; Weiss RS, 2000, GENE DEV, V14, P1886; Weiss RS, 2003, MOL CELL BIOL, V23, P791, DOI 10.1128/MCB.23.3.791-803.2003; Weiss RS, 2002, CURR BIOL, V12, P73, DOI 10.1016/S0960-9822(01)00626-1	18	24	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1980	1983		10.1038/sj.onc.1209212	http://dx.doi.org/10.1038/sj.onc.1209212			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16278671	Green Submitted			2022-12-17	WOS:000236224800015
J	Takeda, H; Miyoshi, H; Kojima, Y; Oshima, M; Taketo, MM				Takeda, H; Miyoshi, H; Kojima, Y; Oshima, M; Taketo, MM			Accelerated onsets of gastric hamartomas and hepatic adenomas/carcinomas in Lkb1(+/-)p53(-/-) compound mutant mice	ONCOGENE			English	Article						LKB1; p53; Peutz-Jeghers syndrome; hamartoma; HCC	PEUTZ-JEGHERS-SYNDROME; CELL-CYCLE ARREST; INTESTINAL METAPLASIA; KNOCKOUT MICE; LKB1 GENE; CANCER; MUTATIONS; KINASE; P53; CARCINOMA	Germline mutations in the LKB1 gene are responsible for Peutz-Jeghers syndrome (PJS), which is characterized by gastrointestinal hamartomas and increasing risk of cancer. Mice with Lkb1(-/+) mutation develop gastric hamartomas after > 20 weeks of age, and hepatocellular adenomas and carcinomas > 30 weeks. It has been reported that, in PJS patients, carcinomas progressed from hamartomas contain p53 mutations, and that LKB1 regulates p53-dependent apoptosis. To investigate the roles of LKB1 and p53 mutations in tumorigenesis, we constructed compound mutant mice of Lkb1 and p53 genes. In the Lkb1(+/-) p53(-/-) mice, formation of gastric hamartomas and hepatic tumors was accelerated. However, histopathology of hamartomas was similar between Lkb1(+/-) p53(-/-) and Lkb1(+/-) mice, and Lkb1 genotype remained heterozygous, suggesting that the p53 mutation affected hamartoma initiation. Contrary to the heterozygous hamartomas in the stomach and duodenum, the hepatic adenomas in Lkb1(+/-) p53(-/-) mice showed loss of Lkb1 heterozygosity (LOH), suggesting that lack of p53 stimulated Lkb1 LOH and tumor initiation in the liver. Taken together, these results indicate that lack of p53 causes earlier onsets of gastric hamartomas and hepatic tumors in Lkb1(-/-) p53(-/-) mice.	Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Taketo, MM (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan.	taketo@mfour.med.kyoto-u.ac.jp	Oshima, Masanobu/F-9958-2014	Oshima, Masanobu/0000-0002-3304-0004; Miyoshi, Hiroyuki/0000-0001-7400-0714				Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Bronner MP, 2003, MODERN PATHOL, V16, P359, DOI 10.1097/01.MP.0000062992.54036.E4; Crowe SE, 2005, CURR OPIN GASTROEN, V21, P32; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Gruber SB, 1998, CANCER RES, V58, P5267; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Miyaki M, 2000, CANCER RES, V60, P6311; Miyoshi H, 2002, CANCER RES, V62, P2261; Mutoh H, 2004, CANCER RES, V64, P7740, DOI 10.1158/0008-5472.CAN-04-1617; Nakau M, 2002, CANCER RES, V62, P4549; Papageorgiou T, 2002, INT J GYNECOL CANCER, V12, P337, DOI 10.1046/j.1525-1438.2002.01147.x; Seno H, 2002, INT J ONCOL, V21, P769; SPIGELMAN AD, 1989, GUT, V30, P1588, DOI 10.1136/gut.30.11.1588; Takahashi M, 2004, J GASTROENTEROL, V39, P1210, DOI 10.1007/s00535-004-1474-y; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031	23	24	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1816	1820		10.1038/sj.onc.1209207	http://dx.doi.org/10.1038/sj.onc.1209207			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16278673	Green Submitted			2022-12-17	WOS:000236013700014
J	Saha, T; Vardhini, D; Tang, Y; Katuri, V; Jogunoori, W; Volpe, EA; Haines, D; Sidawy, A; Zhou, X; Gallicano, I; Schlegel, R; Mishra, B; Mishra, L				Saha, T; Vardhini, D; Tang, Y; Katuri, V; Jogunoori, W; Volpe, EA; Haines, D; Sidawy, A; Zhou, X; Gallicano, I; Schlegel, R; Mishra, B; Mishra, L			RING finger-dependent ubiquitination by PRAJA is dependent on TGF-beta and potentially defines the functional status of the tumor suppressor ELF	ONCOGENE			English	Article						ELF; PRAJA; TGF-beta; ubiquitination; half-life	LIVER DEVELOPMENT; LIGASE ACTIVITY; PARTIAL-HEPATECTOMY; SIGNALING PATHWAY; CELL-MEMBRANE; I RECEPTOR; DEGRADATION; GROWTH; PROTEIN; CANCER	In gastrointestinal cells, biological signals for transforming growth factor-beta (TGF-beta) are transduced through transmembrane serine/threonine kinase receptors that signal to Smad proteins. Smad4, a tumor suppressor, is often mutated in human gastrointestinal cancers. The mechanism of Smad4 inactivation, however, remains uncertain and could be through E3-mediated ubiquitination of Smad4/adaptor protein complexes. Disruption of ELF (embryonic liver fodrin), a Smad4 adaptor protein, modulates TGF-beta signaling. We have found that PRAJA, a RING-H2 protein, interacts with ELF in a TGF-beta-dependent manner, with a fivefold increase of PRAJA expression and a subsequent decrease in ELF and Smad4 expression, in gastrointestinal cancer cell lines (P < 0.05). Strikingly, PRAJA manifests substantial E3-dependent ubiquitination of ELF and Smad3, but not Smad4. Delta-PRAJA, which has a deleted RING finger domain at the C terminus, abolishes ubiquitination of ELF. A stable cell line that overexpresses PRAJA exhibits low levels of ELF in comparison to a D-PRAJA stable cell line, where ELF expression is high compared to normal controls. The alteration of ELF and/or Smad4 expression and/or function in the TGF-b signaling pathway may be induced by enhancement of ELF degradation, which is mediated by a high-level expression of PRAJA in gastrointestinal cancers. In hepatocytes, half-life (t(1/2)) and rate constant for degradation (k(D)) of ELF is 1.91 hand 21.72 min(-1) when coupled with ectopic expression of PRAJA in cells stimulated by TGF-beta, compared to PRAJA-transfected unstimulated cells (t(1/2) = 4.33 hand k(D) 9.6 min(-1)). These studies reveal a mechanism for tumorigenesis whereby defects in adaptor proteins for Smads, such as ELF, can undergo degradation by PRAJA, through the ubiquitin-mediated pathway.	Georgetown Univ, Lab Dev Mol Biol, Lombardi Comprehens Canc Ctr, Dept Surg Sci, Washington, DC 20007 USA; Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Med, Washington, DC 20007 USA; Temple Univ, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA; Georgetown Univ, Dept Cell Biol, Washington, DC 20007 USA; Georgetown Univ, Dept Pathol, Washington, DC 20007 USA; Dept Vet Affairs Med Ctr, Washington, DC USA	Georgetown University; Georgetown University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Georgetown University; Georgetown University	Mishra, B (corresponding author), Georgetown Univ, Lab Dev Mol Biol, Lombardi Comprehens Canc Ctr, Dept Surg Sci, Med Dent Bldg,Rooms NW210-213,3900 Reservoir Rd,N, Washington, DC 20007 USA.	bm72@georgetown.edu; lm229@georgetown.edu	Volpe, Eugene A./D-2000-2012	Volpe, Eugene A./0000-0002-9128-754X; Mishra, Lopa/0000-0002-6850-0808	NATIONAL CANCER INSTITUTE [R01CA106614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056111] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA106614-01A2] Funding Source: Medline; NIDDK NIH HHS [R01 DK58637, R01 DK56111] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alarcon-Vargas D, 2002, ONCOGENE, V21, P4384, DOI 10.1038/sj.onc.1205543; Asano Y, 2004, J CLIN INVEST, V113, P253, DOI 10.1172/JCI200416269; Bhanumathy CD, 2002, DEV DYNAM, V223, P59, DOI 10.1002/dvdy.1235; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; Brzovic PS, 1998, J BIOL CHEM, V273, P7795, DOI 10.1074/jbc.273.14.7795; Chatterjee-Kishore M, 2000, J BIOL CHEM, V275, P20406, DOI 10.1074/jbc.M001861200; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; Dupont S, 2005, CELL, V121, P87, DOI 10.1016/j.cell.2005.01.033; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Einstein M, 2001, MOL CELL BIOL, V21, P5122, DOI 10.1128/MCB.21.15.5122-5131.2001; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Itoh S, 2003, J BIOL CHEM, V278, P3751, DOI 10.1074/jbc.M208258200; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Janse DM, 2004, J BIOL CHEM, V279, P21415, DOI 10.1074/jbc.M402954200; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Liu XH, 2000, EMBO J, V19, P6759, DOI 10.1093/emboj/19.24.6759; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Mishra L, 1999, ONCOGENE, V18, P353, DOI 10.1038/sj.onc.1202313; Mishra L, 1997, ONCOGENE, V15, P2361, DOI 10.1038/sj.onc.1201405; Mishra L, 1998, INT J DEV BIOL, V42, P221; Miyazono K, 2003, CANCER SCI, V94, P230, DOI 10.1111/j.1349-7006.2003.tb01425.x; Moser MJ, 2001, DIGEST DIS SCI, V46, P907, DOI 10.1023/A:1010791915733; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Pan Y, 1999, CANCER RES, V59, P2064; RUSSELL WE, 1988, P NATL ACAD SCI USA, V85, P5126, DOI 10.1073/pnas.85.14.5126; Sasaki A, 2002, J BIOL CHEM, V277, P22541, DOI 10.1074/jbc.M109728200; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Souchelnytskyi S, 2002, TRENDS CELL BIOL, V12, P304, DOI 10.1016/S0962-8924(02)02300-0; Stroschein SL, 2001, GENE DEV, V15, P2822; Sun Y, 2003, CANCER BIOL THER, V2, P623; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Tang Y, 2005, CANCER RES, V65, P4228, DOI 10.1158/0008-5472.CAN-04-4585; Tang Y, 2003, SCIENCE, V299, P574, DOI 10.1126/science.1075994; Tang Y, 2002, ONCOGENE, V21, P5255, DOI 10.1038/sj.onc.1205548; Wang TW, 2003, FRONT BIOSCI, V8, pD1109, DOI 10.2741/1057; Weinstein M, 2000, CYTOKINE GROWTH F R, V11, P49, DOI 10.1016/S1359-6101(99)00028-3; Wieser R, 2001, CURR OPIN ONCOL, V13, P70, DOI 10.1097/00001622-200101000-00014; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yin YH, 2002, CELL, V109, P181, DOI 10.1016/S0092-8674(02)00721-3; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	61	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					693	705		10.1038/sj.onc.1209123	http://dx.doi.org/10.1038/sj.onc.1209123			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16247473				2022-12-17	WOS:000235068800005
J	Reichman, C; Singh, K; Liu, Y; Singh, S; Li, H; Fajardo, JE; Fiser, A; Birge, RB				Reichman, C; Singh, K; Liu, Y; Singh, S; Li, H; Fajardo, JE; Fiser, A; Birge, RB			Transactivation of Abl by the Crk II adapter protein requires a PNAY sequence in the Crk C-terminal SH3 domain	ONCOGENE			English	Article						Crk; Abl; SH3 domain; atypical; covariation; protein modeling; kinase activation	TERMINAL SH3 DOMAIN; PROLINE-RICH SEQUENCES; SRC HOMOLOGY-3 DOMAIN; C-ABL; TYROSINE KINASE; STRUCTURAL BASIS; HIGH-AFFINITY; ACTIVATION; RECOGNITION; BINDING	To gain a better understanding of how Crk II regulates the function of the Abl tyrosine kinase, we explored the function of the C-terminal linker and SH3 domain, a region of Crk II that is still poorly understood. Molecular modeling, tryptophan. fluorescence, and covariation sequence alignment indicate that the Crk-SH3-C has a unique binding groove and RT loop not observed in typical SH3 domains. Based on these models, we made a series of mutations in the linker and in residues predicted to destabilize the putative binding pocket and RT loop. In Abl transactivation assays, Y222F and P225A mutations in the linker resulted in strong transactivation of Abl by Crk II. However, mutations predicted to be at the surface of the Crk SH3-C were not activators of Abl. Interestingly, combinations of activating mutations of Crk II with mutations in the highly conserved PNAY sequence in the SH3-C inactivated the activating mutations, suggesting that the SH3-C is necessary for activation. Our data provide insight into the role of highly conserved residues in the Crk-SH3-C, suggesting a mechanism for how the linker and the Crk-SH3-C function in the transactivation of the Abl tyrosine kinase.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Yeshiva University; Albert Einstein College of Medicine	Birge, RB (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, 185 S Orange Ave, Newark, NJ 07103 USA.	birgera@umdnj.edu		Li, Hong/0000-0001-5731-5335; Singh, Sukhwinder/0000-0002-7061-0096	NIGMS NIH HHS [GMS55760] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Barber DL, 2001, BLOOD, V97, P2230, DOI 10.1182/blood.V97.8.2230; Barnett P, 2000, EMBO J, V19, P6382, DOI 10.1093/emboj/19.23.6382; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Evans EK, 1997, EMBO J, V16, P230, DOI 10.1093/emboj/16.2.230; FELLER SM, 1995, METHOD ENZYMOL, V255, P369; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Galletta BJ, 1999, GENE, V228, P243, DOI 10.1016/S0378-1119(99)00010-4; Hantschel O, 2004, NAT REV MOL CELL BIO, V5, P33, DOI 10.1038/nrm1280; Harkiolaki M, 2003, EMBO J, V22, P2571, DOI 10.1093/emboj/cdg258; Hemmeryckx B, 2002, ONCOGENE, V21, P3225, DOI 10.1038/sj.onc.1205452; Kami K, 2002, EMBO J, V21, P4268, DOI 10.1093/emboj/cdf428; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Kurakin A, 2002, J BIOMOL STRUCT DYN, V19, P1015, DOI 10.1080/07391102.2002.10506805; Kurakin AV, 2003, J BIOL CHEM, V278, P34102, DOI 10.1074/jbc.M305264200; Larson SM, 2000, J MOL BIOL, V303, P433, DOI 10.1006/jmbi.2000.4146; Larson SM, 2000, PROTEIN SCI, V9, P2170, DOI 10.1110/ps.9.11.2170; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lewitzky M, 2004, J BIOL CHEM, V279, P28724, DOI 10.1074/jbc.M402745200; Lewitzky M, 2001, ONCOGENE, V20, P1052, DOI 10.1038/sj.onc.1204202; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; OGAWA S, 1994, ONCOGENE, V9, P1669; Pires JR, 2003, J MOL BIOL, V326, P1427, DOI 10.1016/S0022-2836(03)00039-1; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Shishido T, 2001, GENES CELLS, V6, P431, DOI 10.1046/j.1365-2443.2001.00431.x; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Smith JJ, 2002, MOL CELL BIOL, V22, P1412, DOI 10.1128/MCB.22.5.1412-1423.2002; Smith KM, 2001, J BIOL CHEM, V276, P24372, DOI 10.1074/jbc.M100786200; Tanis KQ, 2003, MOL CELL BIOL, V23, P3884, DOI 10.1128/MCB.23.11.3884-3896.2003; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; Wang BL, 1996, ONCOGENE, V13, P1379; Wang JYJ, 2004, NAT CELL BIOL, V6, P3, DOI 10.1038/ncb0104-3; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zvara A, 2001, ONCOGENE, V20, P951, DOI 10.1038/sj.onc.1204173	54	24	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8187	8199		10.1038/sj.onc.1208988	http://dx.doi.org/10.1038/sj.onc.1208988			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16158059				2022-12-17	WOS:000233809400010
J	Mao, JH; Li, JZ; Jiang, T; Li, Q; Wu, D; Perez-Losada, J; DelRosario, R; Peterson, L; Balmain, A; Cai, WW				Mao, JH; Li, JZ; Jiang, T; Li, Q; Wu, D; Perez-Losada, J; DelRosario, R; Peterson, L; Balmain, A; Cai, WW			Genomic instability in radiation-induced mouse lymphoma from p53 heterozygous mice	ONCOGENE			English	Article						p53; genomic instability; radiation; thymic lymphoma	IONIZING-RADIATION; CHROMOSOMAL INSTABILITY; P53-DEFICIENT MICE; ARRAY CGH; CANCER; TUMORIGENESIS; GENE; TRANSFORMATION; AMPLIFICATION; IRRADIATION	Although radiation can directly induce DNA damage and is a known human and animal carcinogen, the number of genetic changes in radiation-induced tumors, and the pathways responsible for generating them, are unknown. We have used high-density BAC arrays covering > 95% of the mouse genome for analysis of genomic patterns of aberrations in spontaneous and radiation-induced mouse lymphomas. The majority of radiation-induced tumors exhibit one of three 'signatures' based on gene copy number changes. Some exhibit extensive scrambling of the genome, with very high numbers of recurrent gains and losses. Two other signatures are characterized by excess gains but relatively few losses, or vice versa. Changes in spontaneous tumors often involve whole chromosomes, whereas radiation-induced tumors exhibit a high frequency of localized deletion/amplification events. The number of copy number abnormalities does not correlate with the latency or pathology of the tumors. We propose that specific early events following radiation exposure induce changes in 'caretaker' genes that control specific downstream pathways involved in DNA damage repair. The nature of these early events may determine the overall genomic signature observed in the resulting tumor.	Univ Calif San Francisco, Inst Canc Res, San Francisco, CA 94143 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	University of California System; University of California San Francisco; Baylor College of Medicine; Baylor College of Medicine	Cai, WW (corresponding author), Univ Calif San Francisco, Inst Canc Res, 2340 Sutter St, San Francisco, CA 94143 USA.	abalmain@cc.ucsf.edu; wcai@bcm.tmc.edu	Pérez-Losada, Jesús/A-5883-2019; Mao, Jian-Hua/EIZ-8595-2022	Pérez-Losada, Jesús/0000-0003-2400-624X; Mao, Jian-Hua/0000-0001-9320-6021; Peterson, Leif/0000-0002-1187-0883	NATIONAL CANCER INSTITUTE [U01CA084244] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA84244] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Albertson DG, 2003, BREAST CANCER RES TR, V78, P289, DOI 10.1023/A:1023025506386; ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; Azzam EI, 2003, ONCOGENE, V22, P7050, DOI 10.1038/sj.onc.1206961; BOUFFLER SD, 1995, CANCER RES, V55, P3883; Brenner DJ, 2003, P NATL ACAD SCI USA, V100, P13761, DOI 10.1073/pnas.2235592100; Cai WW, 2002, NAT BIOTECHNOL, V20, P393, DOI 10.1038/nbt0402-393; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gregory SG, 2002, NATURE, V418, P743, DOI 10.1038/nature00957; Hande MP, 2003, AM J HUM GENET, V72, P1162, DOI 10.1086/375041; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; KENNEDY AR, 1984, RADIAT RES, V99, P228, DOI 10.2307/3576368; KENNEDY AR, 1984, NATURE, V307, P85, DOI 10.1038/307085a0; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kinzler KW, 1997, NATURE, V386, P763; Liyanage M, 2000, BLOOD, V96, P1940, DOI 10.1182/blood.V96.5.1940.h8001940_1940_1946; LOEB LA, 1974, CANCER RES, V34, P2311; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Mao JH, 2003, ONCOGENE, V22, P8379, DOI 10.1038/sj.onc.1207083; Marx J, 2002, SCIENCE, V297, P544, DOI 10.1126/science.297.5581.544; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Mitelman F, 2005, MITELMAN DATABASE CH; Okano H, 1999, ONCOGENE, V18, P6677, DOI 10.1038/sj.onc.1203100; Peterson LE, 2002, COMPUT METH PROG BIO, V69, P179, DOI 10.1016/S0169-2607(01)00189-4; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; Saito Y, 2001, ONCOGENE, V20, P5243, DOI 10.1038/sj.onc.1204675; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Sigurdson AJ, 2003, ONCOGENE, V22, P7018, DOI 10.1038/sj.onc.1206989; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UNO M, 1987, INT J CANCER, V40, P540, DOI 10.1002/ijc.2910400418; Volik S, 2003, P NATL ACAD SCI USA, V100, P7696, DOI 10.1073/pnas.1232418100; Watson GE, 1997, INT J RADIAT BIOL, V71, P497, DOI 10.1080/095530097143824	38	24	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7924	7934		10.1038/sj.onc.1208926	http://dx.doi.org/10.1038/sj.onc.1208926			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16116484				2022-12-17	WOS:000233463000011
J	Miccadei, S; Provenzano, C; Mojzisek, M; Natali, PG; Civitareale, D				Miccadei, S; Provenzano, C; Mojzisek, M; Natali, PG; Civitareale, D			Retinoblastoma protein acts as Pax 8 transcriptional coactivator	ONCOGENE			English	Article						Pax 8; retinoblastoma protein; thyroid; transcription; coactivator	CELL-CYCLE; EPITHELIAL-CELLS; FAMILY PROTEINS; RB/E2F PATHWAY; DNA-BINDING; GENE; DIFFERENTIATION; PROMOTER; RB; PRB	Control of cell proliferation and differentiation by the retinoblastoma protein (pRb) depends on its interactions with key cellular substrates. Available data indicate that pRb and the transcription factor Pax 8 play a crucial role in the differentiation of thyroid follicular cells. In this study, we show that pRb takes part in the complex assembled on the thyroperoxidase gene promoter acting as a transcriptional coactivator of Pax 8. Accordingly, pRb interacts with and potentiates Pax 8 transcriptional activity. In addition, we show that the downregulation of pRb gene expression, in thyrocytes, through RNA interference results in a reduction of the thyroperoxidase gene promoter activity mediated by the Pax 8-binding site. In agreement with these results and with the ability of the adenoviral protein E1A to bind pRb, we show that E1A downregulates Pax 8 activity and that such inhibition requires the E1A-Rb interaction. Furthermore, we show that the Pax 8/pRb synergy plays a role on the sodium/iodide symporter gene expression as well.	Italian Natl Council Res, Inst Neurobiol & Mol Med, I-00133 Rome, Italy; Regina Elena Inst Canc Res, Mol Pathol Lab, I-00158 Rome, Italy; Charles Univ Prague, Fac Med Hradec Kralove, Dept Med Biol & Genet, Hradec Kralove 50001, Czech Republic	Consiglio Nazionale delle Ricerche (CNR); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Charles University Prague	Civitareale, D (corresponding author), Italian Natl Council Res, Inst Neurobiol & Mol Med, Via Fosso Cavaliere 100, I-00133 Rome, Italy.	dciv@yahoo.com	, stefaniamiccadei/J-2640-2017; Civitareale, Donato/B-4889-2015	, stefaniamiccadei/0000-0001-8890-6998; Civitareale, Donato/0000-0001-5719-9098				Adams PD, 2001, BBA-REV CANCER, V1471, pM123, DOI 10.1016/S0304-419X(01)00019-1; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BERLINGIERI MT, 1993, ONCOGENE, V8, P249; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; CIVITAREALE D, 1993, MOL ENDOCRINOL, V7, P1589, DOI 10.1210/me.7.12.1589; De Leo R, 2000, J BIOL CHEM, V275, P34100, DOI 10.1074/jbc.M003043200; Decary S, 2002, MOL CELL BIOL, V22, P7877, DOI 10.1128/MCB.22.22.7877-7888.2002; Decesse JT, 2001, ONCOGENE, V20, P962, DOI 10.1038/sj.onc.1204169; Di Palma T, 2003, J BIOL CHEM, V278, P3395, DOI 10.1074/jbc.M205977200; DIMAGLIANO P, 2000, P NATL ACAD SCI USA, V93, P465; Dorfler P, 1996, EMBO J, V15, P1971, DOI 10.1002/j.1460-2075.1996.tb00548.x; Eberhard D, 1999, CANCER RES, V59, p1716S; Esposito C, 1998, BIOCHEM J, V331, P37, DOI 10.1042/bj3310037; Fabbro D, 1998, J MOL ENDOCRINOL, V21, P347, DOI 10.1677/jme.0.0210347; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; Goodman RH, 2000, GENE DEV, V14, P1553; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Iuliano R, 2000, EXP CELL RES, V260, P257, DOI 10.1006/excr.2000.5023; Klenova E, 2002, METHODS, V26, P254, DOI 10.1016/S1046-2023(02)00029-4; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; Macchia PE, 1998, NAT GENET, V19, P83, DOI 10.1038/ng0598-83; MacLellan WR, 2000, MOL CELL BIOL, V20, P8903, DOI 10.1128/MCB.20.23.8903-8915.2000; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; Miccadei S, 2002, MOL ENDOCRINOL, V16, P837, DOI 10.1210/me.16.4.837; Miyake S, 2000, MOL CELL BIOL, V20, P8889, DOI 10.1128/MCB.20.23.8889-8902.2000; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MUSTI AM, 1987, NUCLEIC ACIDS RES, V15, P8149, DOI 10.1093/nar/15.20.8149; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Ohno M, 1999, MOL CELL BIOL, V19, P2051; Perrone L, 2000, BIOCHEM BIOPH RES CO, V275, P203, DOI 10.1006/bbrc.2000.3232; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339-3351.2003; Suzuki K, 1998, MOL CELL BIOL, V18, P7410, DOI 10.1128/MCB.18.12.7410; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Wang XC, 1997, T NONFERR METAL SOC, V7, P45; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Wiggan O, 1998, ONCOGENE, V16, P227, DOI 10.1038/sj.onc.1201534; Yuan SSF, 2002, BIOCHEM BIOPH RES CO, V296, P1019, DOI 10.1016/S0006-291X(02)02032-6; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	52	24	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					6993	7001		10.1038/sj.onc.1208861	http://dx.doi.org/10.1038/sj.onc.1208861			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16007137				2022-12-17	WOS:000232833200001
J	Schwerk, C; Schulze-Osthoff, K				Schwerk, C; Schulze-Osthoff, K			Methyltransferase inhibition induces p53-dependent apoptosis and a novel form of cell death	ONCOGENE			English	Article						adenosine dialdehyde; apoptosis; actin; methyltransferases; p53	DNA-DAMAGE RESPONSE; ACTIN DEPOLYMERIZATION; MEDIATED CYTOTOXICITY; UNDERGO APOPTOSIS; EPITHELIAL-CELLS; IN-VIVO; ROCK-I; METHYLATION; ACTIVATION; P53	We have analysed the importance of proper substrate methylation by S-adenosylmethionine-dependent methyl-transferases for cell survival and cell cycle progression. We show that treatment of cells with the methyltransferase inhibitor adenosine dialdehyde (AdOx) causes cell cycle arrest and death in different cell types. The phenotypical outcome and form of cell death was strikingly dependent on the AdOx concentration. Lower AdOx concentrations led to a G2 arrest and predominantly caused apoptosis, as judged by biochemical and morphological criteria. Apoptotic cell death was largely dependent on the presence of the tumour suppressor p53, but did not require the Bcl-2 family member Bax. Interestingly, higher concentrations of AdOx led to a novel and so far undescribed form of cell death, which was characterized by distinct, caspase-independent alterations of the cell shape including a marked protuberation of the nucleus, cytoplasmic extensions, actin aggregation, and incomplete chromatin condensation. Although this latter form of cell death was clearly distinguishable from apoptosis, early apoptotic features such as Bax activation were detected, indicating a commitment but incomplete execution of apoptosis. Altogether, these data show that methylation reactions play a distinct role in cell survival, which might influence the decision between different phenotypic forms of cell death.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Schwerk, C (corresponding author), Univ Dusseldorf, Inst Mol Med, Bldg 23-12,Univ Str 1, D-40225 Dusseldorf, Germany.	Christian.Scherk@uni-duesseldorf.de	Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				BARTEL RL, 1984, MOL PHARMACOL, V25, P418; BERGMANN S, 1994, J IMMUNOL, V153, P1736; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bursch W, 2000, J CELL SCI, V113, P1189; Chen TP, 2004, CURR TOP DEV BIOL, V60, P55; Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Croft DR, 2005, J CELL BIOL, V168, P245, DOI 10.1083/jcb.200409049; Cuervo AM, 2004, MOL CELL BIOCHEM, V263, P55, DOI 10.1023/B:MCBI.0000041848.57020.57; Di Simone N, 2003, BIOL REPROD, V69, P1129, DOI 10.1095/biolreprod.103.015800; Finkelstein JD, 1998, EUR J PEDIATR, V157, pS40, DOI 10.1007/PL00014300; Grzanka A, 2003, BIOCHEM PHARMACOL, V66, P1611, DOI 10.1016/S0006-2952(03)00532-X; HENNESSEY ES, 1993, BIOCHEM J, V291, P657, DOI 10.1042/bj2910657; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jamison JM, 2002, BIOCHEM PHARMACOL, V63, P1773, DOI 10.1016/S0006-2952(02)00904-8; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; Kruman II, 2004, NEURON, V41, P549, DOI 10.1016/S0896-6273(04)00017-0; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Martin S, 2001, MOL CELL BIOL, V21, P6529, DOI 10.1128/MCB.21.19.6529-6536.2001; Mehlhorn H, 1999, PARASITOL RES, V85, P625, DOI 10.1007/s004360050607; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Proskuryakov SY, 2003, EXP CELL RES, V283, P1, DOI 10.1016/S0014-4827(02)00027-7; Rao JY, 1999, J CELL BIOCHEM, V75, P686, DOI 10.1002/(SICI)1097-4644(19991215)75:4<686::AID-JCB14>3.0.CO;2-F; Ratter F, 1999, INT IMMUNOL, V11, P519, DOI 10.1093/intimm/11.4.519; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Schneider-Stock R, 2005, J PHARMACOL EXP THER, V312, P525, DOI 10.1124/jpet.104.074195; Schubert HL, 2003, TRENDS BIOCHEM SCI, V28, P329, DOI 10.1016/S0968-0004(03)00090-2; Schwerk C, 2003, MOL CELL BIOL, V23, P2981, DOI 10.1128/MCB.23.8.2981-2990.2003; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Sgarra R, 2003, CELL DEATH DIFFER, V10, P386, DOI 10.1038/sj.cdd.4401184; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Song ZY, 2004, HEPATOLOGY, V40, P989, DOI 10.1002/hep.20412; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Stancheva I, 2001, EMBO J, V20, P1963, DOI 10.1093/emboj/20.8.1963; Suarez-Huerta N, 2000, J CELL PHYSIOL, V184, P239, DOI 10.1002/1097-4652(200008)184:2<239::AID-JCP12>3.0.CO;2-R; White SR, 2001, AM J RESP CELL MOL, V24, P282, DOI 10.1165/ajrcmb.24.3.3995; Wyllie AH, 2001, P NATL ACAD SCI USA, V98, P11, DOI 10.1073/pnas.98.1.11; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	42	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2005	24	47					7002	7011		10.1038/sj.onc.1208855	http://dx.doi.org/10.1038/sj.onc.1208855			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	977WC	16007140				2022-12-17	WOS:000232833200002
J	Khalili, P; Arakelian, A; Chen, GP; Singh, G; Rabbani, SA				Khalili, P; Arakelian, A; Chen, GP; Singh, G; Rabbani, SA			Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer	ONCOGENE			English	Article						Her-2; antibody; bone metastases	TRASTUZUMAB HERCEPTIN; ZD1839 IRESSA; NUDE-MICE; IN-VIVO; GROWTH; HER2/NEU; CELLS; BONE; ONCOGENE; KINASE	We examined the effects of Herceptin, a bioengineered monoclonal antibody directed against Her-2/neu oncogene on skeletal metastasis using a xenograft model of breast cancer. Treatment of Her-2 overexpressing human breast cancer cells BT-474 with Herceptin caused a dose-dependent decrease in cell proliferation. In in vivo studies, BT-474 cells (1 x 10(5)) were injected into the left ventricle of female BALB/c nu/nu mice. Intraperitoneal (i.p.) infusion of Herceptin (1 mg/kg twice a week for 5 weeks) from the day of tumor cell inoculation or at the time of radiologically detectable skeletal metastasis either slowed the development or prevented the progression of skeletal metastasis as compared to control groups of animals receiving nonspecific IgG. Bone histological analysis of long bones showed the ability of Herceptin to reduce the ratio of tumor volume to bone volume as well as mitotic index, effects that were more pronounced when Herceptin treatment was initiated from the day of tumor cell inoculation. While immunohistochemical analysis of long bones showed no difference in the production of Her-2, phosphorylated (P) Her-2 and MAPK, a significantly lower level of P-MAPK was seen in bones of Herceptin treated animals. These studies demonstrate the ability of Herceptin to inhibit the development and abrogate the progression of skeletal metastases associated with breast cancer by blocking the HER-2-mediated signaling pathways.	McGill Univ, Ctr Hlth, Dept Med & Oncol, Montreal, PQ H3A 1A1, Canada; Hamilton Reg Canc Ctr, Hamilton, ON L8V 5C2, Canada	McGill University; McMaster University	Rabbani, SA (corresponding author), McGill Univ, Ctr Hlth, Dept Med & Oncol, 687 Pine Ave W,Room H4-61, Montreal, PQ H3A 1A1, Canada.	shafaat.rabbani@mcgill.ca	Singh, Gurmit/C-6744-2014	rabbani, shafaat/0000-0001-5594-3899				ADEWALE A, 2002, CLIN CANCER RES, V8, P1747; Baselga J, 1998, CANCER RES, V58, P2825; Bell R, 2002, ONCOLOGY-BASEL, V63, P39, DOI 10.1159/000066200; Bendre MS, 2002, CANCER RES, V62, P5571; Bernstein L, 2002, J MAMMARY GLAND BIOL, V7, P3, DOI 10.1023/A:1015714305420; Chen CN, 2000, J INF SCI ENG, V16, P1; DiGiovanna MP, 1998, ONCOGENE, V17, P1877, DOI 10.1038/sj.onc.1202091; Duivenvoorden WCM, 2002, CANCER RES, V62, P1588; El Abdaimi K, 2000, CANCER RES, V60, P4412; Esteva FJ, 2001, ONCOLOGIST, V6, P133, DOI 10.1634/theoncologist.6-2-133; KLIJN JGM, 1994, BREAST CANCER RES TR, V29, P73, DOI 10.1007/BF00666183; Kurebayashi  J, 2001, Breast Cancer, V8, P45, DOI 10.1007/BF02967477; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; MARGOLESE TG, 2003, CANC MED, P1879; Masood S, 2002, MICROSC RES TECHNIQ, V59, P102, DOI 10.1002/jemt.10181; Mayfield S, 2001, BREAST CANCER RES TR, V70, P123, DOI 10.1023/A:1012999012192; Moasser MM, 2001, CANCER RES, V61, P7184; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Normanno N, 2002, ANN ONCOL, V13, P65, DOI 10.1093/annonc/mdf020; Park JW, 2002, CLIN CANCER RES, V8, P1172; Rabbani SA, 2005, ENDOCRINOLOGY, V146, P2885, DOI 10.1210/en.2005-0062; ROODMAN DG, 2003, CANCER, V97, P733; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; SHAFIE SM, 1981, J NATL CANCER I, V67, P51; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; van der Pluijm G, 2000, CANCER TREAT REV, V26, P11, DOI 10.1053/ctrv.1999.0143; Yakes FM, 2002, CANCER RES, V62, P4132; Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396; Zhou BP, 2003, SEMIN ONCOL, V30, P38, DOI 10.1053/j.seminoncol.2003.08.006	29	24	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6657	6666		10.1038/sj.onc.1208790	http://dx.doi.org/10.1038/sj.onc.1208790			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16091754				2022-12-17	WOS:000232367800007
J	De Falco, V; Guarino, V; Malorni, L; Cirafici, AM; Troglio, F; Erreni, M; Pelicci, G; Santoro, M; Melillo, RM				De Falco, V; Guarino, V; Malorni, L; Cirafici, AM; Troglio, F; Erreni, M; Pelicci, G; Santoro, M; Melillo, RM			RAI(ShcC/N-Shc)-dependent recruitment of GAB1 to RET oncoproteins potentiates PI3-K signalling in thyroid tumors	ONCOGENE			English	Article						thyroid tumor; RET oncogenes; RAI and GAB1 adaptors	PHOSPHOTYROSINE-BINDING DOMAINS; TERMINAL SH3 DOMAIN; SRC HOMOLOGY 2; ADAPTER PROTEIN; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; N-SHC; ACTIVATION; RECEPTOR; EXPRESSION	RAI, also named ShcC/N-Shc, one of the members of the Shc proteins family, is a substrate of the RET receptor tyrosine kinase. Here, we show that RAI forms a protein complex with both RET/MEN2A and RET/PTC oncoproteins. By coimmunoprecipitation, we found that RAI associates with the Grb2-associated binder1 (GAB1) adapter. This association is constitutive, but, in the presence of RET oncoproteins, both RAI and GAB1 are tyrosine-phosphorylated, and the stoichiometry of this interaction remarkably increases. Consequently, the p85 regulatory subunit of phosphatidylinositol-3 kinase (PI3K) is recruited to the complex, and its downstream effector Akt is activated. We show that human thyroid cancer cell lines derived from papillary or medullary thyroid carcinoma (PTC or MTC) carrying, respectively, RET/PTC and RET/MEN2A oncoproteins express RAI proteins. We also show that human PTC samples express higher levels of RAI, when compared to normal thyroid tissue. In thyroid cells expressing RET/PTC1, ectopic expression of RAI protects cells from apoptosis; on the other hand, the silencing of endogenous RAI by small inhibitory duplex RNAs in a PTC cell line that expresses endogenous RET/PTC1, increases the rate of spontaneous apoptosis. These data suggest that RAI is a critical substrate for RET oncoproteins in thyroid carcinomas.	CNR G Salvatore, Ist Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; European Inst Oncol, Dept Expt Oncol, Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); IRCCS European Institute of Oncology (IEO)	Melillo, RM (corresponding author), CNR G Salvatore, Ist Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, Via S Pansini 5, I-80131 Naples, Italy.	rosmelil@unina.it	Troglio, Flavia/AAQ-4789-2020; Erreni, Marco/K-2522-2016; Malorni, Luca/J-1973-2019; Pelicci, Giuliana/AAA-8921-2022; melillo, rosa marina/O-5255-2015; DE FALCO, VALENTINA/C-2061-2015	Troglio, Flavia/0000-0002-0226-8241; Erreni, Marco/0000-0002-1922-0818; Malorni, Luca/0000-0002-4297-2997; Pelicci, Giuliana/0000-0003-0986-8255; DE FALCO, VALENTINA/0000-0002-8972-7921; MELILLO, Rosa Marina/0000-0002-9233-5275				Basolo F, 2002, INT J CANCER, V97, P608, DOI 10.1002/ijc.10116; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Carlomagno F, 2002, CANCER RES, V62, P1077; Castellone MD, 2003, ONCOGENE, V22, P246, DOI 10.1038/sj.onc.1206112; Cattaneo E, 1998, TRENDS NEUROSCI, V21, P476, DOI 10.1016/S0166-2236(98)01282-X; Celetti A, 2004, ONCOGENE, V23, P109, DOI 10.1038/sj.onc.1206981; Cerutti J, 1996, CLIN CANCER RES, V2, P119; Conti L, 2001, NAT NEUROSCI, V4, P579, DOI 10.1038/88395; COOLEY LD, 1995, CANCER GENET CYTOGEN, V80, P138, DOI 10.1016/0165-4608(94)00185-E; CURCIO F, 1994, P NATL ACAD SCI USA, V91, P9004, DOI 10.1073/pnas.91.19.9004; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ganju P, 1998, EUR J NEUROSCI, V10, P1995, DOI 10.1046/j.1460-9568.1998.00209.x; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Hingorani SR, 2003, CANCER RES, V63, P5198; Jin ZG, 2005, J BIOL CHEM, V280, P12305, DOI 10.1074/jbc.M500294200; Lewitzky M, 2001, ONCOGENE, V20, P1052, DOI 10.1038/sj.onc.1204202; Liu HY, 2002, J BIOL CHEM, V277, P26046, DOI 10.1074/jbc.M111659200; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Luzi L, 2000, CURR OPIN GENET DEV, V10, P668, DOI 10.1016/S0959-437X(00)00146-5; Maeda K, 2004, BIOCHEM BIOPH RES CO, V323, P345, DOI 10.1016/j.bbrc.2004.08.095; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; Nakamura T, 1996, ONCOGENE, V13, P1111; Nakamura T, 1998, J BIOL CHEM, V273, P6960, DOI 10.1074/jbc.273.12.6960; Nakamura T, 2002, ONCOGENE, V21, P22, DOI 10.1038/sj.onc.1205019; Nakazawa T, 2002, J NEUROSCI RES, V68, P668, DOI 10.1002/jnr.10259; Nikiforov YE, 2002, ENDOCR PATHOL, V13, P3, DOI 10.1385/EP:13:1:03; O'Bryan JP, 1998, J BIOL CHEM, V273, P20431, DOI 10.1074/jbc.273.32.20431; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; Ohta K, 2001, J CLIN ENDOCR METAB, V86, P2170, DOI 10.1210/jc.86.5.2170; Pelicci G, 1996, ONCOGENE, V13, P633; Pelicci G, 2002, MOL CELL BIOL, V22, P7351, DOI 10.1128/MCB.22.20.7351-7363.2002; Pierotti MA, 2001, CANCER LETT, V166, P1, DOI 10.1016/S0304-3835(01)00439-6; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; Santoro M, 2004, CELL MOL LIFE SCI, V61, P2954, DOI 10.1007/s00018-004-4276-8; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Tanabe K, 1998, MOL BRAIN RES, V53, P291, DOI 10.1016/S0169-328X(97)00264-7; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Wang JW, 2003, MOL ENDOCRINOL, V17, P1425, DOI 10.1210/me.2003-0041	44	24	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6303	6313		10.1038/sj.onc.1208776	http://dx.doi.org/10.1038/sj.onc.1208776			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	15940252				2022-12-17	WOS:000231877100011
J	Sum, EYM; Shackleton, M; Hahm, K; Thomas, RM; O'Reilly, LA; Wagner, KU; Lindeman, GJ; Visvader, JE				Sum, EYM; Shackleton, M; Hahm, K; Thomas, RM; O'Reilly, LA; Wagner, KU; Lindeman, GJ; Visvader, JE			Loss of the LIM domain protein Lmo4 in the mammary gland during pregnancy impedes lobuloalveolar development	ONCOGENE			English	Article						LIM domain; mammary gland; alveolar development	TRANSGENIC MICE; ONLY PROTEIN; BINDING PROTEIN; ADULT-MOUSE; CELL-CYCLE; GENE; EXPRESSION; IDENTIFICATION; LEUKEMIA; RBTN2	LMO4, a member of the LIM-only family of zinc-finger proteins, is overexpressed in a significant proportion of breast carcinomas and acts as a negative regulator of mammary epithelial differentiation. To delineate cell types within the developing mouse mammary gland that express Lmo4, we analysed different stages of mammopoiesis by immunohistochemistry. Lmo4 was found to be highly expressed in the proliferating cap cells of the terminal end bud and in the ductal and alveolar luminal cells of the mature mammary gland but was negligible or low in myoepithelial cells. To assess the physiological role of Lmo4 in the mammary gland, we generated conditionally targeted mice lacking Lmo4 in the mammary epithelium during pregnancy. Acute loss of Lmo4 in late pregnancy impaired lobuloalveolar development, accompanied by a two-fold reduction in the percentage of BrdU-positive cells. In contrast, germline loss of Lmo4 did not alter lobuloalveolar development arising from transplanted mammary anlagen, implying the existence of a compensatory mechanism in these knockout mice. Thus, the use of a conditional targeting strategy has revealed that Lmo4 is required for proper development of the mammary gland during pregnancy and indicated that Lmo4 acts as a positive regulator of alveolar epithelial proliferation.	Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Bone Marrow Res Labs, Parkville, Vic 3050, Australia; Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA; Univ Nebraska, Med Ctr, Omaha, NE 68198 USA	Walter & Eliza Hall Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Nebraska System; University of Nebraska Medical Center	Visvader, JE (corresponding author), Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Parkville, Vic 3050, Australia.	visvader@wehi.edu.au	Wagner, Kay-Uwe/B-6044-2009	Lindeman, Geoffrey/0000-0001-9386-2416; Wagner, Kay-Uwe/0000-0002-5081-0226				Anderson E, 2004, J MAMMARY GLAND BIOL, V9, P3, DOI 10.1023/B:JOMG.0000023584.01750.16; Andrechek ER, 2004, P NATL ACAD SCI USA, V101, P4984, DOI 10.1073/pnas.0306802101; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Bulchand S, 2003, DEV DYNAM, V226, P460, DOI 10.1002/dvdy.10235; Daniel C. W., 1987, The mammary gland. Development, regulation, and function., P3; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; FISCH P, 1992, ONCOGENE, V7, P2389; Grutz G, 1998, ONCOGENE, V17, P2799, DOI 10.1038/sj.onc.1202502; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hahm KM, 2004, MOL CELL BIOL, V24, P2074, DOI 10.1128/MCB.24.5.2074-2082.2004; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Hermanson O, 1999, CELL MOL BIOL, V45, P677; Hovey RC, 2002, J MAMMARY GLAND BIOL, V7, P17, DOI 10.1023/A:1015766322258; Kenney Nicholas J., 2001, Journal of Biomedicine and Biotechnology, V1, P133, DOI 10.1155/S1110724301000304; Kenny DA, 1998, P NATL ACAD SCI USA, V95, P11257, DOI 10.1073/pnas.95.19.11257; Kudryavtseva EI, 2003, DEV DYNAM, V226, P604, DOI 10.1002/dvdy.10255; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; Li L, 2002, ONCOGENE, V21, P4900, DOI 10.1038/sj.onc.1205634; Manetopoulos C, 2003, BIOCHEM BIOPH RES CO, V307, P891, DOI 10.1016/S0006-291X(03)01298-1; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MEDINA D, 1990, PROTOPLASMA, V159, P77, DOI 10.1007/BF01322591; Mizunuma H, 2003, BRIT J CANCER, V88, P1543, DOI 10.1038/sj.bjc.6600952; Neale Geoffrey A. M., 1997, Leukemia (Basingstoke), V11, P289; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; Racevskis J, 1999, BBA-GENE STRUCT EXPR, V1445, P148, DOI 10.1016/S0167-4781(99)00037-8; ROBINSON GW, 2000, METHODS MAMMARY GLAN, P307; Russo J, 1999, BREAST CANCER RES TR, V53, P217, DOI 10.1023/A:1006186719322; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Silberstein GB, 2001, MICROSC RES TECHNIQ, V52, P155, DOI 10.1002/1097-0029(20010115)52:2<155::AID-JEMT1001>3.0.CO;2-P; Sugihara TM, 1998, P NATL ACAD SCI USA, V95, P15418, DOI 10.1073/pnas.95.26.15418; SUM EY, 2002, J HISTOCHEM CYTOCHEM, V53, P475; Sum EYM, 2002, J BIOL CHEM, V277, P7849, DOI 10.1074/jbc.M110603200; Tse E, 2004, MOL CELL BIOL, V24, P2063, DOI 10.1128/MCB.24.5.2063-2073.2004; Visvader JE, 2003, INT J BIOCHEM CELL B, V35, P1034, DOI 10.1016/S1357-2725(03)00030-X; Visvader JE, 2001, P NATL ACAD SCI USA, V98, P14452, DOI 10.1073/pnas.251547698; Vooijs M, 2001, EMBO REP, V2, P292, DOI 10.1093/embo-reports/kve064; Vu D, 2003, MOL BRAIN RES, V115, P93, DOI 10.1016/S0169-328X(03)00119-0; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wang N, 2004, ONCOGENE, V23, P1507, DOI 10.1038/sj.onc.1207288; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WILLIAMS JM, 1983, DEV BIOL, V97, P274, DOI 10.1016/0012-1606(83)90086-6; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Yamada Y, 2000, P NATL ACAD SCI USA, V97, P320, DOI 10.1073/pnas.97.1.320	45	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4820	4828		10.1038/sj.onc.1208638	http://dx.doi.org/10.1038/sj.onc.1208638			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15856027				2022-12-17	WOS:000230477900009
J	Nister, M; Tang, MJ; Zhang, XQ; Yin, CY; Beeche, M; Hu, XR; Enblad, G; van Dyke, T; Wahl, GM				Nister, M; Tang, MJ; Zhang, XQ; Yin, CY; Beeche, M; Hu, XR; Enblad, G; van Dyke, T; Wahl, GM			p53 must be competent for transcriptional regulation to suppress tumor formation	ONCOGENE			English	Article						p53; transactivation; DNA binding; apoptosis; tumor suppression	IN-VIVO; P53-DEPENDENT APOPTOSIS; DNA-DAMAGE; TRANSGENIC MICE; TERMINAL DOMAIN; EXCISION-REPAIR; MUTANT MICE; WILD-TYPE; ACTIVATION; DEFICIENT	In vitro studies suggest that effective tumor suppression by p53 requires multiple domains to execute transcription-dependent and transcription-independent functions. We generated a mutant p53 allele in mice, p53(W25QL26S) (p53(QS)), containing an inactive transactivation domain to evaluate the importance of transactivation for p53-mediated tumor suppression. Recently, we discovered that the allele also contains a valine substitution for alanine at codon 135, which borders the DNA-binding domain. We found that p53(QSval135) bound to chromatin albeit less well than p53(QSala135), but both were equally deficient in transcriptional regulation, apoptosis induction in mouse embryo fibroblasts (MEFs), and suppression of tumor formation by E1A, Ha-Ras transformed MEFs. p53(QSval135) mice and p53-null mice exhibited identical tumor development kinetics and spectra in spontaneous and oncogene-initiated tumorigenicity assays, when tested in a homo- and heterozygous configuration. The p53(QSval135) allele did not have dominant negative functions and behaved as a null allele. Taken together, these data indicate that effective tumor suppression requires the transcriptional regulation function of p53, and they suggest that transactivation independent functions of p53 are unlikely to contribute significantly to tumor suppression in vivo.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; Karolinska Univ Hosp, Karolinska Inst, Dept Oncol Pathol, S-17176 Stockholm, Sweden; Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, S-75185 Uppsala, Sweden; Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA; Uppsala Univ, Rudbeck Lab, Dept Oncol Radiol & Clin Immunol, S-75185 Uppsala, Sweden	Salk Institute; Karolinska Institutet; Karolinska University Hospital; Uppsala University; University of North Carolina; University of North Carolina Chapel Hill; Uppsala University	Wahl, GM (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	wahl@salk.edu			NCI NIH HHS [CA61449, CA046283] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061449, R01CA046283] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Haupt Ygal, 1997, Leukemia (Basingstoke), V11, P337; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; LOZANO G, 1991, MOL CARCINOGEN, V4, P3, DOI 10.1002/mc.2940040103; Lu XD, 2001, MOL CELL BIOL, V21, P6017, DOI 10.1128/MCB.21.17.6017-6030.2001; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Venkatachalam S, 2001, TOXICOL PATHOL, V29, P147, DOI 10.1080/019262301753178555; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	53	24	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3563	3573		10.1038/sj.onc.1208354	http://dx.doi.org/10.1038/sj.onc.1208354			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15750633				2022-12-17	WOS:000229221800004
J	Kobayashi, S; Nantz, R; Kitamura, T; Higashikubo, R; Horikoshi, N				Kobayashi, S; Nantz, R; Kitamura, T; Higashikubo, R; Horikoshi, N			Combined inhibition of extracellular signal-regulated kinases and HSP90 sensitizes human colon carcinoma cells to ionizing radiation	ONCOGENE			English	Article						nonsteroidal anti-inflammatory drug; MAP kinase; HSP90; radiosensitization	GROWTH-FACTOR RECEPTOR; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TUMOR-CELLS; CYCLIN D1; ACTIVATION; CYCLOOXYGENASE-2; GELDANAMYCIN; RAS; PHOSPHORYLATION; RESVERATROL	Indomethacin, a common nonsteroidal anti-inflammatory drug, has been shown to enhance radiation-mediated cell-killing effect through the activation of p38 mitogen-activated protein kinase ( MAPK). We found that indomethacin strongly reduced the basal level of extracellular signal-regulated kinases 1 and 2 (ERK1/2) in HT-29 human colon carcinoma cells. The inhibition of ERK1/2 by indomethacin was only observed in cells with high basal activities of ERK1/2 such as HT-29 cells, but not in cells with low basal activities, such as HeLa. Cell cycle analysis of HT-29 cells exposed with indomethacin showed a partial G1/S arrest and slow DNA synthesis. However, the treatment with NS398, a specific COX-1/2 inhibitor, failed to show any effect on cell cycle, indicating that the inhibition of COX-1/2 is not responsible for cell cycle arrest. Since U0126, a specific inhibitor for MEK1/2, also induced a partial G1/S arrest, the G1/S arrest induced by indomethacin is, at least in part, caused by the inhibition of ERK1/2. Cell proliferation of HT-29 was inhibited by the treatment of U0126 but not in HeLa cells, and the treatment of HT-29 cells with U0126 enhanced radiation sensitivity possibly due to the accumulation of cells in G1 phase. We found that 17-allylamino-17-demethoxygeldanamycin, a geldanamycin delivative, radiosensitized HT-29 cells at a relatively low dose of irradiation, and indomethacin and U0126 further enhanced this effect. Therefore, tumor cells with elevated ERK1/2 activity can be effectively sensitized to radiation treatment by a combinational inhibition of HSP90 and MAPK activity.	Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Dept Radiat Oncol, St Louis, MO 63108 USA	Washington University (WUSTL)	Horikoshi, N (corresponding author), Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Dept Radiat Oncol, 4511 Forest Pk Blvd, St Louis, MO 65108 USA.	horikoshi@radonc.wustl.edu	Horikoshi, Nobuo/Y-8245-2019	Horikoshi, Nobuo/0000-0001-8464-8178	NATIONAL CANCER INSTITUTE [R01CA098666, P01CA104457] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA104457, R01CA98666] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An WG, 1997, CANCER CHEMOTH PHARM, V40, P60, DOI 10.1007/s002800050626; Barnard J, 2001, GASTROENTEROLOGY, V120, P1872, DOI 10.1053/gast.2001.25297; Bisht KS, 2003, CANCER RES, V63, P8984; Bradbury CM, 2001, CANCER RES, V61, P7689; Brooks P, 1999, RHEUMATOLOGY, V38, P779, DOI 10.1093/rheumatology/38.8.779; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; Fontecave M, 1998, FEBS LETT, V421, P277, DOI 10.1016/S0014-5793(97)01572-X; Gerosa M, 2003, CURR OPIN ONCOL, V15, P188, DOI 10.1097/00001622-200305000-00002; Gupta AK, 2001, CANCER RES, V61, P4278; Hagan M, 2000, RADIAT RES, V153, P371, DOI 10.1667/0033-7587(2000)153[0371:IRIMAP]2.0.CO;2; Joe AK, 2002, CLIN CANCER RES, V8, P893; Jones MK, 1999, NAT MED, V5, P1418; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Keenan SM, 2001, J BIOL CHEM, V276, P22404, DOI 10.1074/jbc.M100409200; Lents NH, 2002, J BIOL CHEM, V277, P47469, DOI 10.1074/jbc.M207425200; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Machida H, 2003, INT J RADIAT BIOL, V79, P973, DOI 10.1080/09553000310001626135; Maloney A, 2002, EXPERT OPIN BIOL TH, V2, P3, DOI 10.1517/14712598.2.1.3; MARNETT LJ, 1995, PREV MED, V24, P103, DOI 10.1006/pmed.1995.1017; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; Maurizi M, 1996, BRIT J CANCER, V74, P1253, DOI 10.1038/bjc.1996.525; Menon SG, 2003, CANCER RES, V63, P2109; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Munster PN, 2001, CANCER RES, V61, P2945; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; O'Dwyer PJ, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.35643; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Phillips-Mason PJ, 2000, J BIOL CHEM, V275, P18046, DOI 10.1074/jbc.M909194199; Purdy JA, 2002, SEMIN RADIAT ONCOL, V12, P199, DOI 10.1053/srao.2002.32432; Rice PL, 2003, CANCER RES, V63, P616; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Roberts RB, 2002, P NATL ACAD SCI USA, V99, P1521, DOI 10.1073/pnas.032678499; Russell JS, 2003, CLIN CANCER RES, V9, P3749; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sheng HM, 1998, J BIOL CHEM, V273, P22120, DOI 10.1074/jbc.273.34.22120; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Sheng HM, 2001, CANCER RES, V61, P2670; Shiff SJ, 1996, EXP CELL RES, V222, P179, DOI 10.1006/excr.1996.0023; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stivala LA, 2001, J BIOL CHEM, V276, P22586, DOI 10.1074/jbc.M101846200; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Wolter F, 2001, J NUTR, V131, P2197, DOI 10.1093/jn/131.8.2197; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhong H, 2004, INT J CANCER, V112, P585, DOI 10.1002/ijc.20438; Zhu A, 1996, INT J RADIAT ONCOL, V34, P809, DOI 10.1016/0360-3016(95)02184-1	50	24	27	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3011	3019		10.1038/sj.onc.1208508	http://dx.doi.org/10.1038/sj.onc.1208508			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735687				2022-12-17	WOS:000228649500010
J	Guerrico, AMG; Jaffer, ZM; Page, RE; Braunewell, KH; Chernoff, J; Klein-Szanto, AJP				Guerrico, AMG; Jaffer, ZM; Page, RE; Braunewell, KH; Chernoff, J; Klein-Szanto, AJP			Visinin-like protein-1 is a potent inhibitor of cell adhesion and migration in squamous carcinoma cells	ONCOGENE			English	Article						visinin-like protein-1 (VILIP-1); squamous cell carcinoma (SCC); adhesion; migraition; integrins	INTEGRIN ALPHA-V-BETA-3; ALPHA-6-BETA-4 INTEGRIN; KINASE-A; EXTRACELLULAR-MATRIX; ALPHA(V) INTEGRINS; LAMELLAE FORMATION; TUMOR INVASION; GROWTH-FACTOR; IN-VITRO; EXPRESSION	Tumor cell invasion is a highly integrated and complex process comprising several biologically distinct functions such as cell adhesion, motility, proteolysis, etc. Visinin-like protein-1 (VILIP-1), a member of the neuronal EF-hand calcium-sensor protein family, plays a role in regulating tumor cell invasiveness of mouse squamous cell carcinoma (SCC). VILIP-1 enhances cyclic adenosine monophosphate levels through PKA induction. However, the mechanism by which VILIP-1 reduces cell invasiveness is not well understood. In this study, we show that VILIP-1 decreased cell adhesion and migration/invasiveness of highly invasive mouse SCC cells. Forced expression of VILIP-1 reduced cell adhesion to fibronectin in parallel to downregulating alpha v and alpha 5 integrin subunit levels. VILIP-1 overexpression also led to decreased migration ability. Conversely, short hairpin RNA-mediated VILIP-1 knock-down of SCC cells' characterized by little or no invasiveness, correlated with increased adhesion to fibro-nectin and enhanced expression of av and %5 integrin subunits together with increased cell migration. Function-blocking assays with inhibitory anti-alpha 5 and anti-alpha v integrin antibodies showed that both subunits contributed to cell adhesion, migration, and invasiveness of highly invasive SCC cell lines. These results point to a critical role of VILIP-1 in regulating cell adhesion and migration by downregulation of fibronectin receptor expression. Decreased or absent VILIP-1 expression in SCC cell subpopulations may lead to a more advanced malignant phenotype characterized by changes in adhesive ability and increased cell motility, suggestive of a tumor suppressor function.	Fox Chase Canc Ctr, Tumor Cell Biol Program, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA; Humboldt Univ, Neurosci Res Ctr, Charite, Fac Med, D-10117 Berlin, Germany	Fox Chase Cancer Center; Fox Chase Cancer Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Klein-Szanto, AJP (corresponding author), Fox Chase Canc Ctr, Tumor Cell Biol Program, 333 Cottman Ave,Room C417, Philadelphia, PA 19111 USA.	aj_klein-szanto@fccc.edu	Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836	NCI NIH HHS [CA06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; Bagutti C, 1998, J PATHOL, V186, P8, DOI 10.1002/(SICI)1096-9896(199809)186:1<8::AID-PATH156>3.0.CO;2-H; Felding-Habermann B, 2002, CLIN EXP METASTAS, V19, P427, DOI 10.1023/A:1016377114119; Gong JG, 1997, CELL GROWTH DIFFER, V8, P83; Haapasalmi K, 1996, J INVEST DERMATOL, V106, P42, DOI 10.1111/1523-1747.ep12327199; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Huang S, 2000, ONCOGENE, V19, P1915, DOI 10.1038/sj.onc.1203509; Hubbard FC, 1997, CANCER RES, V57, P5226; Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576; Jones J, 1997, J ORAL PATHOL MED, V26, P63, DOI 10.1111/j.1600-0714.1997.tb00023.x; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; Kerr JS, 2002, EXPERT OPIN INV DRUG, V11, P1765, DOI 10.1517/13543784.11.12.1765; Kikuchi M, 1997, J Gastrointest Surg, V1, P132, DOI 10.1016/S1091-255X(97)80100-X; Kim S, 2000, J BIOL CHEM, V275, P33920, DOI 10.1074/jbc.M003668200; Koivisto L, 1999, CELL ADHES COMMUN, V7, P245, DOI 10.3109/15419069909010806; Koivisto L, 2000, EXP CELL RES, V255, P10, DOI 10.1006/excr.1999.4769; Koukoulis GK, 1997, HUM PATHOL, V28, P1018, DOI 10.1016/S0046-8177(97)90054-X; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; Li XW, 2001, J CELL SCI, V114, P2665; Ma TY, 1999, J LAB CLIN MED, V134, P363, DOI 10.1016/S0022-2143(99)90150-6; Mahloogi H, 2003, CANCER RES, V63, P4997; Mercurio AM, 2001, SEMIN CANCER BIOL, V11, P129, DOI 10.1006/scbi.2000.0364; Nagaoka K, 2003, J BIOL CHEM, V278, P29048, DOI 10.1074/jbc.M300470200; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Paddison Patrick J, 2004, Methods Mol Biol, V265, P85; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; Reinmuth N, 2003, CANCER RES, V63, P2079; Rolli M, 2003, P NATL ACAD SCI USA, V100, P9482, DOI 10.1073/pnas.1633689100; RUGGERI B, 1991, CANCER RES, V51, P6615; Santibanez JF, 2003, INT J CANCER, V107, P715, DOI 10.1002/ijc.11457; Shiraha H, 2002, MOL CELL BIOL, V22, P2716, DOI 10.1128/MCB.22.8.2716-2727.2002; TAKAHASHI K, 1990, J IMMUNOL, V145, P4371; Thomas GJ, 2001, INT J CANCER, V92, P641, DOI 10.1002/1097-0215(20010601)92:5<641::AID-IJC1243>3.0.CO;2-P; Thomas GJ, 2001, J INVEST DERMATOL, V117, P67, DOI 10.1046/j.0022-202x.2001.01379.x; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F; YASUDA M, 1995, INT IMMUNOL, V7, P251, DOI 10.1093/intimm/7.2.251; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	39	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2307	2316		10.1038/sj.onc.1208476	http://dx.doi.org/10.1038/sj.onc.1208476			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735716				2022-12-17	WOS:000227877400004
J	Kim, E; Rundhaug, JE; Benavides, F; Yang, PY; Newman, RA; Fischer, SM				Kim, E; Rundhaug, JE; Benavides, F; Yang, PY; Newman, RA; Fischer, SM			An antitumorigenic role for murine 8S-lipoxygenase in skin carcinogenesis	ONCOGENE			English	Article						arachidonic acid; lipoxygenase; keratinocytes; differentiation; skin cancer	ARACHIDONIC-ACID METABOLISM; ACTIVATED RECEPTOR-ALPHA; ORNITHINE-DECARBOXYLASE ACTIVITY; PROTEIN-KINASE-C; MOUSE SKIN; TUMOR PROMOTION; KERATINOCYTE DIFFERENTIATION; INDUCE APOPTOSIS; CANCER-CELLS; IN-VIVO	The levels of 8S-lipoxygenase ( 8S-LOX) expression and of its arachidonic acid metabolite, 8-hydroxyeicosatetraenoic acid (8-HETE), are highly elevated in the early stages of mouse skin carcinogenesis. On the other hand, several reports showing that 8-HETE is also closely associated with keratinocyte differentiation raise a question concerning the role of 8S-LOX/8-HETE in skin carcinogenesis. To address that question, here we conducted a series of gain-of-function studies. Skin targeted loricrin 8S-LOX/C57BL/6J transgenic mice showed a more differentiated epidermal phenotype as well as a 64% reduced papilloma development in a two-stage skin carcinogenesis protocol. Forced expression of 8S-LOX in MT1/2 cells, a murine papilloma cell line, also caused a more differentiated appearance as well as keratin 1 expression. Overexpression of 8S-LOX in CH72 cells, a murine carcinoma cell line, inhibited cell proliferation by 30% in vitro and by 86% in in vivo xenografts. Exogenous addition of 5 muM 8-HETE to CH72 cells caused cell cycle arrest at the G1 phase. Finally, immunohistochemical analyses showed 8S-LOX protein expression was strictly confined to the differentiated compartment of mouse skin and throughout tumorigenesis. Collectively, these data suggest that 8S-LOX plays a role as a prodifferentiating, antitumorigenic, and tumor suppressing gene in mouse skin carcinogenesis.	Univ Texas, MD Anderson Canc Ctr, Sci Pk Res Div, Smithville, TX 78957 USA; Univ Texas, MD Anderson Canc Ctr, Pharmaceut Dev Ctr, Houston, TX 77054 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fischer, SM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Sci Pk Res Div, 1808 Pk Rd 1C,POB 389, Smithville, TX 78957 USA.	smfischer@mdanderson.org	Benavides, Fernando/E-7872-2011; Rundhaug, Joyce E/E-9114-2011	Rundhaug, Joyce E/0000-0002-2481-6317; Benavides, Fernando/0000-0003-1275-4320	NCI NIH HHS [CA83794, CA16672, CA100140] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA100140, R01CA083794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bhatia B, 2003, J BIOL CHEM, V278, P25091, DOI 10.1074/jbc.M301920200; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Burger F, 1999, MOL CARCINOGEN, V24, P108, DOI 10.1002/(SICI)1098-2744(199902)24:2<108::AID-MC5>3.0.CO;2-R; CONTI CJ, 1988, CANCER RES, V48, P435; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; DuBois RN, 2003, JNCI-J NATL CANCER I, V95, P1028, DOI 10.1093/jnci/95.14.1028; FISCHER SM, 1989, CANCER RES, V49, P6693; FISCHER SM, 1988, CANCER RES, V48, P658; FISCHER SM, 1982, CARCINOGENESIS, V3, P1243, DOI 10.1093/carcin/3.11.1243; FISCHER SM, 1987, CANCER RES, V47, P3174; Fischer SM, 2004, LIPOXYGENASES TARGET; Fosslien E, 2000, CRIT REV CL LAB SCI, V37, P431, DOI 10.1080/10408360091174286; FURSTENBERGER G, 1991, J BIOL CHEM, V266, P15738; Furstenberger G, 2002, PROSTAG OTH LIPID M, V68-9, P235, DOI 10.1016/S0090-6980(02)00033-3; GSCHWENDT M, 1986, CARCINOGENESIS, V7, P449, DOI 10.1093/carcin/7.3.449; Guo YJ, 1999, MOL CARCINOGEN, V26, P32, DOI 10.1002/(SICI)1098-2744(199909)26:1<32::AID-MC4>3.3.CO;2-5; Hanley K, 1998, J INVEST DERMATOL, V110, P368, DOI 10.1046/j.1523-1747.1998.00139.x; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; Hsi LC, 2002, J BIOL CHEM, V277, P40549, DOI 10.1074/jbc.M203522200; HUITFELDT HS, 1991, CARCINOGENESIS, V12, P2063, DOI 10.1093/carcin/12.11.2063; Jack GS, 2000, HUM PATHOL, V31, P1146, DOI 10.1053/hupa.2000.16670; Jisaka M, 1997, J BIOL CHEM, V272, P24410, DOI 10.1074/jbc.272.39.24410; KARTASOVA T, 1992, MOL CARCINOGEN, V6, P18, DOI 10.1002/mc.2940060105; Kashiwagi M, 2002, J BIOCHEM, V132, P853, DOI 10.1093/oxfordjournals.jbchem.a003297; Kelavkar UP, 2001, CARCINOGENESIS, V22, P1765, DOI 10.1093/carcin/22.11.1765; Kempen EC, 2001, ANAL BIOCHEM, V297, P183, DOI 10.1006/abio.2001.5325; Komuves LG, 2000, J INVEST DERMATOL, V115, P353, DOI 10.1046/j.1523-1747.2000.00073.x; Mahe YF, 1998, INT J DERMATOL, V37, P416, DOI 10.1046/j.1365-4362.1998.00514.x; Marks F, 2000, TOXICOLOGY, V153, P11, DOI 10.1016/S0300-483X(00)00301-2; Muga SJ, 2000, CELL GROWTH DIFFER, V11, P447; Nair J, 2000, CHEM RES TOXICOL, V13, P703, DOI 10.1021/tx000045d; NAITO M, 1989, GENETIC BACKGROUND D; NAKADATE T, 1982, CARCINOGENESIS, V3, P1411, DOI 10.1093/carcin/3.12.1411; NELSON KG, 1982, CANCER RES, V42, P4176; Nie D, 1998, CANCER RES, V58, P4047; NISCHT R, 1988, MOL CARCINOGEN, V1, P96, DOI 10.1002/mc.2940010205; Prigge ST, 1997, BIOCHIMIE, V79, P629, DOI 10.1016/S0300-9084(97)83495-5; Ruckert R, 2000, BRIT J DERMATOL, V143, P1036, DOI 10.1046/j.1365-2133.2000.03784.x; RUZICKA T, 1984, REV PHYSIOL BIOCH P, V100, P121; Shappell SB, 1999, AM J PATHOL, V155, P235, DOI 10.1016/S0002-9440(10)65117-6; Shappell SB, 2001, J INVEST DERMATOL, V117, P36, DOI 10.1046/j.1523-1747.2001.01378.x; Shappell SB, 2001, CANCER RES, V61, P497; Sheu MY, 2002, J INVEST DERMATOL, V118, P94, DOI 10.1046/j.0022-202x.2001.01626.x; Shureiqi I, 2003, P NATL ACAD SCI USA, V100, P9968, DOI 10.1073/pnas.1631086100; Shureiqi I, 2001, CANCER RES, V61, P6307; Shureiqi I, 2001, CANCER RES, V61, P4879; SISSKIN EF, 1982, CARCINOGENESIS, V3, P403, DOI 10.1093/carcin/3.4.403; SLAGA TJ, 1984, MECH INVOLVED 2 STAG; STANBRIDGE EJ, 1982, SCIENCE, V215, P252, DOI 10.1126/science.7053574; Steele VE, 1999, CANCER EPIDEM BIOMAR, V8, P467; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; TANG DG, 1994, ANN NY ACAD SCI, V744, P199, DOI 10.1111/j.1749-6632.1994.tb52738.x; Tang SH, 2002, J BIOL CHEM, V277, P16189, DOI 10.1074/jbc.M111936200; Thuillier P, 2000, MOL CARCINOGEN, V29, P134, DOI 10.1002/1098-2744(200011)29:3<134::AID-MC2>3.0.CO;2-F; TOFTGARD R, 1985, CANCER RES, V45, P5845; VERMA AK, 1980, CANCER RES, V40, P308; Warner TD, 2004, FASEB J, V18, P790, DOI 10.1096/fj.03-0645rev; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; YUSPA SH, 1985, CELLULAR MOL CHANGES; ZIETKIEWICZ E, 1994, GENOMICS, V20, P176, DOI 10.1006/geno.1994.1151	61	24	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1174	1187		10.1038/sj.onc.1208269	http://dx.doi.org/10.1038/sj.onc.1208269			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15558016				2022-12-17	WOS:000226898700005
J	Schramm, A; von Schuetz, V; Christiansen, H; Havers, W; Papoutsi, M; Wilting, JR; Schweigerer, L				Schramm, A; von Schuetz, V; Christiansen, H; Havers, W; Papoutsi, M; Wilting, JR; Schweigerer, L			High activin A-expression in human neuroblastoma: suppression of malignant potential and correlation with favourable clinical outcome	ONCOGENE			English	Article						neuroblastoma; activin A; angiogenesis; outcome	CENTRAL-NERVOUS-SYSTEM; GROWTH-FACTOR; CELL-PROLIFERATION; DOWN-REGULATION; IN-VITRO; INDUCTION; DIFFERENTIATION; ANGIOGENESIS; FOLLISTATIN; INHIBITORS	Amplification of the MYCN oncogene contributes to the malignant progression of human neuroblastomas, but the mechanisms have remained unclear. We have previously demonstrated that N-Myc facilitates angiogenesis by downregulating an angiogenesis inhibitor identified as the inhibin betaA homodimer activin A. Here, we have sought to define the molecular, biological and clinical consequences of activin A expression in human neuroblastoma. We report that enhanced activin A expression suppresses proliferation and colony formation of human neuroblastoma cells with amplified MYCN in vitro; that it inhibits neuroblastoma growth and angiogenesis in vivo; that it is highly expressed in differentiated, but not undifferentiated human neuroblastomas; and that it correlates with favourable outcome of neuroblastoma patients. Our results indicate that high activin A expression plays an important beneficial role in human neuroblastoma.	Klinikum Univ Gottingen, Zentrum Kinderheilkunde & Jugendmed, Abt Padiatr 1, D-37075 Gottingen, Germany; Univ Kinderklin Essen, Abt Hamatol Onkol & Endokrinol, Essen, Germany; Univ Kinderklin Marburg, Marburg, Germany	University of Gottingen; University of Duisburg Essen	Schweigerer, L (corresponding author), Klinikum Univ Gottingen, Zentrum Kinderheilkunde & Jugendmed, Abt Padiatr 1, Robert Koch Str 40, D-37075 Gottingen, Germany.	lothar.schweigerer@med.uni-goettingen.de	Schramm, Alexander/G-5688-2010	Schramm, Alexander/0000-0001-7670-7529				ALTABA AR, 1989, NATURE, V341, P33; ANDREASSON K, 1995, NEUROSCIENCE, V69, P781, DOI 10.1016/0306-4522(95)00245-E; Breit S, 2000, CANCER RES, V60, P4596; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Cantero R, 1999, WORLD J SURG, V23, P1294, DOI 10.1007/s002689900665; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Cinatl J, 2002, INT J ONCOL, V20, P97; Fotsis T, 1997, CANCER RES, V57, P2916; Fotsis T, 1999, EUR J BIOCHEM, V263, P757, DOI 10.1046/j.1432-1327.1999.00575.x; Giusti AF, 2000, EVOL DEV, V2, P294, DOI 10.1046/j.1525-142x.2000.00071.x; Hermanson O, 1999, CELL MOL BIOL, V45, P677; Hubner G, 1996, EXP CELL RES, V228, P106, DOI 10.1006/excr.1996.0305; Iwahori Y, 1997, BRAIN RES, V760, P52, DOI 10.1016/S0006-8993(97)00275-8; Mather JP, 1997, P SOC EXP BIOL MED, V215, P209; Rossler J, 1999, INT J CANCER, V81, P113; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; Tuuri T, 1996, MOL CELL ENDOCRINOL, V121, P1, DOI 10.1016/0303-7207(96)03842-7; Visvader JE, 2001, P NATL ACAD SCI USA, V98, P14452, DOI 10.1073/pnas.251547698; Wai DH, 2002, INT J ONCOL, V20, P441; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; Woodruff TK, 1997, J ENDOCRINOL, V152, P167, DOI 10.1677/joe.0.1520167; Wu DD, 1999, BRAIN RES, V835, P369, DOI 10.1016/S0006-8993(99)01638-8	25	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					680	687		10.1038/sj.onc.1208087	http://dx.doi.org/10.1038/sj.onc.1208087			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580313				2022-12-17	WOS:000226420400015
J	Muyrers-Chen, I; Rozovskaia, T; Lee, N; Kersey, JH; Nakamura, T; Canaani, E; Paro, R				Muyrers-Chen, I; Rozovskaia, T; Lee, N; Kersey, JH; Nakamura, T; Canaani, E; Paro, R			Expression of leukemic MLL fusion proteins in Drosophila affects cell cycle control and chromosome morphology	ONCOGENE			English	Article						Mixed -Lineage Leukemia; trithorax; chromatin; Drosophila	ALL-1 GENE; TRITHORAX; TRANSLOCATIONS; DOMAINS; LINEAGE; MUTANTS; MICE; METHYLTRANSFERASE; PHENOTYPES; HOMOLOG	The Mixed Lineage Leukemia (MLL) gene is involved in lymphoblastic and myeloid leukemia through chromosome translocations leading to fusion of MLL to partner genes, or through internal MLL rearrangements. MLL is the mammalian counterpart of the Drosophila trithorax (trx) gene, involved in maintaining active gene expression states. We have used transgenic Drosophila to assess the molecular targets and cellular processes affected by MLL and two of its leukemic fusion proteins. We find that whereas expression of normal human MLL in flies does not result in phenotypic alterations, overexpressing the human MLL-AF9 and MLL-AF4 proteins causes larval to pupal lethality, which interestingly resembles the phenotypes displayed by certain Drosophila trx mutant alleles. MLL-AF9 and MLL-AF4 transgenic flies exhibit antagonistic alterations in cell cycle progression. Additionally, flies expressing MLL-AF9 display impairment in higher order chromatin integrity, evidenced in decondensation of mitotic figures. The effects of MLL fusion proteins in Drosophila suggest that alteration of chromatin structure by MLL fusion proteins may contribute to the lethal phenotype. Our results indicate that the mode(s) of action of MLL-AF9 in Drosophila varies from that of MLL-AF4. Taken together, the expression of MLL fusion proteins in Drosophila provides a new and powerful system to reveal and characterize biological activities associated with MLL fusion proteins.	Univ Heidelberg, ZMBH, D-69120 Heidelberg, Germany; Weizmann Inst Sci, IL-76100 Rehovot, Israel; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA	Ruprecht Karls University Heidelberg; Weizmann Institute of Science; University of Minnesota System; University of Minnesota Twin Cities; Jefferson University	Paro, R (corresponding author), Univ Heidelberg, ZMBH, D-69120 Heidelberg, Germany.	paro@sun0.urz.uni-heidelberg.de						Asha H, 2003, GENETICS, V163, P203; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Bernardoni R, 1997, DEV BIOL, V191, P118; BRAND AH, 1993, DEVELOPMENT, V118, P401; BREEN TR, 1993, DEVELOPMENT, V117, P119; Breen TR, 1999, GENETICS, V152, P319; CANAANI E, 1995, ADV CANCER RES, V66, P213, DOI 10.1016/S0065-230X(08)60255-9; Collins EC, 2002, MOL CELL BIOL, V22, P7313, DOI 10.1128/MCB.22.20.7313-7324.2002; Collins EC, 2002, TRENDS MOL MED, V8, P436, DOI 10.1016/S1471-4914(02)02397-3; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; CRONMILLER C, 1993, MECH DEVELOP, V42, P159, DOI 10.1016/0925-4773(93)90005-I; Fair K, 2001, MOL CELL BIOL, V21, P3589, DOI 10.1128/MCB.21.10.3589-3597.2001; Forster A, 2003, CANCER CELL, V3, P449, DOI 10.1016/S1535-6108(03)00106-5; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; HIDALGO A, 1995, DEVELOPMENT, V121, P3703; Isnard P, 2000, BLOOD, V96, P705; Ito K, 1997, DEVELOPMENT, V124, P761; Kimbrell DA, 2002, GENESIS, V34, P23, DOI 10.1002/gene.10134; Krause SA, 2001, MOL CELL BIOL, V21, P5156, DOI 10.1128/MCB.21.15.5156-5168.2001; Lebestky T, 2000, SCIENCE, V288, P146, DOI 10.1126/science.288.5463.146; Loupart ML, 2000, CURR BIOL, V10, P1547, DOI 10.1016/S0960-9822(00)00844-7; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; MURRAY MA, 1995, DEV BIOL, V168, P150, DOI 10.1006/dbio.1995.1068; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Pflumm MF, 2001, DEVELOPMENT, V128, P1697; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; Rozovskaia T, 2001, ONCOGENE, V20, P874, DOI 10.1038/sj.onc.1204174; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; van Lohuizen M, 1999, CURR OPIN GENET DEV, V9, P355, DOI 10.1016/S0959-437X(99)80053-7; WILDER EL, 1995, DEVELOPMENT, V121, P477; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	39	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8639	8648		10.1038/sj.onc.1207904	http://dx.doi.org/10.1038/sj.onc.1207904			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15378024				2022-12-17	WOS:000224988800010
J	Edwards, KM; Munger, K				Edwards, KM; Munger, K			Depletion of physiological levels of the human TID1 protein renders cancer cell lines resistant to apoptosis mediated by multiple exogenous stimuli	ONCOGENE			English	Article						apoptosis; DnaJ; tumor suppressor; mitochondria	CYTOCHROME-C RELEASE; HUMAN DNAJ PROTEIN; ENDOPLASMIC-RETICULUM; CONFORMATIONAL-CHANGE; MOLECULAR CHAPERONES; OXIDATIVE STRESS; BAX; DROSOPHILA; GENE; EXPRESSION	The human homologue of the Drosophila tumor suppressor lethal ( 2) tumorous imaginal discs ( l( 2) tid) gene, hTID1, encodes two proteins derived from alternate mRNA splicing. The splice variants TidL and TidS were previously reported from protein overexpression and dominant-negative mutant protein studies to exhibit opposing biological activities in response to exogenous cytotoxic stimuli. TidL was found to promote apoptosis while TidS suppressed it. To elucidate the physiological function of hTID1, we depleted hTID1 proteins using the technique of RNA interference (RNAi). Here, we show that cells essentially lacking expression of hTID1 proteins are protected from cell death in response to multiple stimuli, including cisplatin, tumor necrosis factor alpha/ cycloheximide and mitomycin C. We also generated stable cell populations depleted of hTID1 proteins by RNAi using DNA vectors. In addition to apoptosis resistance, stable hTID1 knockdown cells exhibited an enhanced ability for anchorage-independent growth, as measured by an increase in soft-agar colony formation. These results suggest that hTID1 functions as an important cell death regulator and raise the interesting possibility that hTID1 could exert tumor suppressor activity.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Munger, K (corresponding author), Harvard Univ, Sch Med, Dept Pathol, NRB 0958,77 Ave Louis Pasteur, Boston, MA 02115 USA.	karl_munger@hms.harvard.edu		Munger, Karl/0000-0003-3288-9935	NATIONAL CANCER INSTITUTE [R01CA081135] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056949] Funding Source: NIH RePORTER; NCI NIH HHS [CA-81135] Funding Source: Medline; NHLBI NIH HHS [HL56949] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Benedict CA, 2003, CURR OPIN IMMUNOL, V15, P59, DOI 10.1016/S0952-7915(02)00018-3; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Canamasas I, 2003, J BIOL CHEM, V278, P30952, DOI 10.1074/jbc.M304225200; Cheng H, 2002, J BIOL CHEM, V277, P20605, DOI 10.1074/jbc.M201204200; Cheng H, 2001, CURR BIOL, V11, P1771, DOI 10.1016/S0960-9822(01)00540-1; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eom CY, 2002, P NATL ACAD SCI USA, V99, P1894, DOI 10.1073/pnas.042689499; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Gajkowska B, 2001, CELL BIOL INT, V25, P725, DOI 10.1006/cbir.2001.0768; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Kelley WL, 1999, CURR BIOL, V9, pR305, DOI 10.1016/S0960-9822(99)80185-7; Kondo S, 1997, EUR J IMMUNOL, V27, P1713, DOI 10.1002/eji.1830270718; Kurzik-Dumke U, 1998, CELL STRESS CHAPERON, V3, P12, DOI 10.1379/1466-1268(1998)003<0012:MLATEO>2.3.CO;2; KURZIKDUMKE U, 1992, DIFFERENTIATION, V51, P91, DOI 10.1111/j.1432-0436.1992.tb00685.x; KURZIKDUMKE U, 1995, DEV GENET, V16, P64, DOI 10.1002/dvg.1020160110; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Maroto R, 1997, J NEUROCHEM, V69, P514; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; PFANNER N, 1994, TRENDS BIOCHEM SCI, V19, P368, DOI 10.1016/0968-0004(94)90113-9; Sarkar S, 2001, J BIOL CHEM, V276, P49034, DOI 10.1074/jbc.M103683200; Sasaki S, 2002, ONCOGENE, V21, P5024, DOI 10.1038/sj.onc.1205627; Schilling B, 1998, VIROLOGY, V247, P74, DOI 10.1006/viro.1998.9220; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Sundararajan R, 2001, J BIOL CHEM, V276, P45120, DOI 10.1074/jbc.M106386200; Syken J, 2003, ONCOGENE, V22, P4636, DOI 10.1038/sj.onc.1206569; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Trentin GA, 2001, J BIOL CHEM, V276, P13087, DOI 10.1074/jbc.M009267200; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Yin X, 2001, GENE, V278, P201, DOI 10.1016/S0378-1119(01)00720-X; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	50	24	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8419	8431		10.1038/sj.onc.1207732	http://dx.doi.org/10.1038/sj.onc.1207732			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15156195				2022-12-17	WOS:000224870700002
J	Paz, K; Socci, ND; van Nimwegen, E; Viale, A; Darnell, JE				Paz, K; Socci, ND; van Nimwegen, E; Viale, A; Darnell, JE			Transformation fingerprint: induced STAT3-C, v-Src and Ha-Ras cause small initial changes but similar established profiles in mRNA	ONCOGENE			English	Article						STAT3-C; Src; transformation	MAP KINASE KINASE; MAMMALIAN-CELLS; GENE-EXPRESSION; TRANSCRIPTION; ACTIVATION; PROTEIN; P53; IDENTIFICATION; SYSTEM; SIGNAL	Induced transformation of mouse fibroblasts was carried out by releasing tetracycline-repressed expression of an oncogenic mutant of STAT3, STAT3-C, or of v-Src or Ha-Ras. At 15 days after derepression of each oncogene, DNA microarrays showed elevation (> 3-fold) of a similar group of similar to25 mRNAs compared to untransformed cells. RT - PCR confirmed a number of these mRNA elevations. RNA samples were then analysed at intervals during the first 24 h after doxycycline removal to determine the time of early changes. Extensive changes were not observed by array analysis, except in v-Src-expressing cells where about 10 mRNAs were elevated threefold or more. However, RT - PCR did uncover changes in each derepressed cell type that included some of the changes observed after the 15-day transformation period. In addition, STAT3-C target genes such as BclXI and cyclin D1, which were not observed on array analysis, were elevated by RT - PCR analysis. We conclude, therefore, that early after oncogene induction, transcriptional changes, including those initiated by STAT3-C, may occur only in scarce mRNA and/or to a limited extent. However, with additional time and probably additional cell division, a new epigenetic state is established that is mirrored by a changed transcriptional pro. le emblematic of transformation by each of three oncogenes.	Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Rockefeller Univ, Ctr Studies Phys & Biol, New York, NY 10021 USA	Rockefeller University; Yeshiva University; Albert Einstein College of Medicine; Memorial Sloan Kettering Cancer Center; Rockefeller University	Darnell, JE (corresponding author), Rockefeller Univ, Mol Cell Biol Lab, 1230 York Ave, New York, NY 10021 USA.	darnell@rockefeller.edu	van Nimwegen, Erik/ABF-1085-2021	van Nimwegen, Erik/0000-0001-6338-1312	NIAID NIH HHS [AI32489, AI34420] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032489, R01AI034420, R37AI034420] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ayllon V, 2000, MOL MEMBR BIOL, V17, P65; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; Bar-Sagi D, 2001, MOL CELL BIOL, V21, P1441, DOI 10.1128/MCB.21.5.1441-1443.2001; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOURNE HR, 1990, NATURE, V348, P678, DOI 10.1038/348678a0; BOYNTON AL, 1984, CANCER LETT, V21, P293, DOI 10.1016/0304-3835(84)90008-9; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; CHEN YC, 1977, CELL, V11, P513, DOI 10.1016/0092-8674(77)90069-1; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; DUZGUNES N, 1993, METHOD ENZYMOL, V221, P303, DOI 10.1016/0076-6879(93)21025-4; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Freundlieb S, 1999, J GENE MED, V1, P4, DOI 10.1002/(SICI)1521-2254(199901/02)1:1<4::AID-JGM4>3.0.CO;2-Y; GEIGER B, 1979, P NATL ACAD SCI USA, V76, P2833, DOI 10.1073/pnas.76.6.2833; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Malek RL, 2002, ONCOGENE, V21, P7256, DOI 10.1038/sj.onc.1205900; Naef F, 2003, BIOINFORMATICS, V19, P178, DOI 10.1093/bioinformatics/19.2.178; Naef F, 2002, GENOME BIOL, V3; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Staudt LM, 2003, NEW ENGL J MED, V348, P1777, DOI 10.1056/NEJMra020067; STJOHNSTON D, 1992, CELL, V68, P201; TRAVERSE S, 1993, ONCOGENE, V8, P3175; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; VARMUS HE, 1987, SCIENCE, V238, P1337, DOI 10.1126/science.2825348; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	40	24	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8455	8463		10.1038/sj.onc.1207803	http://dx.doi.org/10.1038/sj.onc.1207803			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378015				2022-12-17	WOS:000224870700006
J	Core, N; Joly, F; Boned, A; Djabali, M				Core, N; Joly, F; Boned, A; Djabali, M			Disruption of E2F signaling suppresses the INK4a-induced proliferative defect in M33-deficient mice	ONCOGENE			English	Article						Pc-G; M33; proliferation; Ink4a	HEMATOPOIETIC STEM-CELLS; RESCUES T-LYMPHOPOIESIS; RECEPTOR-DEFICIENT MICE; POLYCOMB-GROUP GENES; B-CELL; FAMILY-MEMBERS; INK4A LOCUS; EXPRESSION; P16(INK4A); BCL-2	Polycomb group (Pc-G) proteins associate to form large complexes that repress Hox genes, thereby imposing Hox gene expression pattern required for development. However, Pc-G proteins have a Hox-independent function in controlling cell proliferation. Here we show that embryonic fibroblasts derived from M33-deficient mice are impaired in the progression into the S phase of the cell cycle, as shown by a reduced rate of incorporation of bromodeoxyuridine. These cells have a senescent phenotype, associated to an abnormal accumulation of the cyclin-dependent kinase inhibitor p16INK4a protein. We demonstrate that this defect is bypassed in mutant embryonic fibroblasts expressing a transdominant negative form of the cell cycle controlling transcription factor E2F (E2F-DB). In addition, we show that the polycomb protein M33 controls critical expansion of B- and T-lymphocyte precursors. Together, our results emphasize M33-Polycomb protein function in cell cycle control.	CNRS, INSERM, Ctr Immunol, F-13288 Marseille 9, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Djabali, M (corresponding author), CNRS, INSERM, Ctr Immunol, Case 906, F-13288 Marseille 9, France.	djabali@cim1.univ-mrs.fr						Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; Alkema MJ, 1997, J MOL BIOL, V273, P993, DOI 10.1006/jmbi.1997.1372; Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Bel S, 1998, DEVELOPMENT, V125, P3543; Core N, 1997, DEVELOPMENT, V124, P721; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HELIN K, 1994, J VIROL, V68, P5027, DOI 10.1128/JVI.68.8.5027-5035.1994; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kondo M, 1997, IMMUNITY, V7, P155, DOI 10.1016/S1074-7613(00)80518-X; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Lessard J, 1999, GENE DEV, V13, P2691, DOI 10.1101/gad.13.20.2691; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Maraskovsky E, 1997, CELL, V89, P1011, DOI 10.1016/S0092-8674(00)80289-5; Ohta H, 2002, J EXP MED, V195, P759, DOI 10.1084/jem.20011911; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; PENIT C, 1995, J IMMUNOL, V154, P5103; PIRROTTA V, 1995, CURR OPIN GENET DEV, V5, P466, DOI 10.1016/0959-437X(95)90050-Q; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; SCOLLAY R, 1991, CURR OPIN IMMUNOL, V3, P204, DOI 10.1016/0952-7915(91)90051-2; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; Tetsu O, 1998, IMMUNITY, V9, P439, DOI 10.1016/S1074-7613(00)80627-5; VEIS DJ, 1993, J IMMUNOL, V151, P2546; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	35	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7660	7668		10.1038/sj.onc.1207998	http://dx.doi.org/10.1038/sj.onc.1207998			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15377996				2022-12-17	WOS:000224306700007
J	Shan, ZH; Parker, T; Wiest, JS				Shan, ZH; Parker, T; Wiest, JS			Identifying novel homozygous deletions by microsatellite analysis and characterization of tumor suppressor candidate 1 gene, TUSC1, on chromosome 9p in human lung cancer	ONCOGENE			English	Article						homozygous deletion; chromosome 9; lung cancers; TUSC1; expression; tumor suppressor gene	HETEROZYGOSITY; MELANOMA; REGION; METHYLATION; EPIGENETICS; CARCINOMA; 9P21-22; P15	Loss of heterozygosity (LOH) studies indicate that genetic alterations of chromosome 9p occur in numerous tumor types, suggesting the presence of tumor suppressor genes (TSGs) on chromosome 9p critical in carcinogenesis. Our previous LOH analyses in primary lung tumors led us to propose that chromosome 9p harbors other TSGs important in lung tumorigenesis. In this study, 30 non-small-cell lung cancer and 12 small-cell lung cancer cell lines were screened with 55 markers to identify new regions of homozygous deletion (HD) on chromosome 9p. Three novel noncontiguous homozygously deleted regions were detected and ranged in size from 840 kb to 7.4 Mb. One gene identified in the deletion at D9S126, TUSC1 ( tumor suppressor candidate 1), is an intronless gene. Multiplex polymerase chain reaction and Southern blot confirmed the HD of TUSC1. Northern blot analysis of TUSC1 demonstrated two transcripts of approximately 2 and 1.5 kb that are likely generated by alternative polyadenylation signals. Both transcripts are expressed in several human tissues and share an open-reading frame encoding a peptide of 209 amino acids. Analysing cell line cDNAs by reverse transcriptase (RT)-PCR demonstrated downregulation of TUSC1 in cell lines with or without HDs, suggesting that TUSC1 may play a role in lung tumorigenesis.	NCI, Cellular Carcinogenesis & Tumor Promot Lab, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wiest, JS (corresponding author), NCI, Cellular Carcinogenesis & Tumor Promot Lab, Ctr Canc Res, Bldg 37,Room 4008,37 Convent Dr MSC4258, Bethesda, MD 20892 USA.	wiestj@mail.nih.gov		Pritchett, Tracy/0000-0002-3336-9336	Intramural NIH HHS [ZIA BC010448-09] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		An HX, 1996, GENE CHROMOSOME CANC, V17, P14, DOI 10.1002/(SICI)1098-2264(199609)17:1<14::AID-GCC3>3.3.CO;2-Y; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Castellano M, 1997, CANCER RES, V57, P4868; CHENG JQ, 1993, CANCER RES, V53, P4761; COLEMAN A, 1994, CANCER RES, V54, P344; Hamada K, 1998, GENE CHROMOSOME CANC, V22, P232, DOI 10.1002/(SICI)1098-2264(199807)22:3<232::AID-GCC9>3.0.CO;2-X; Hamada K, 2000, GENE CHROMOSOME CANC, V27, P308, DOI 10.1002/(SICI)1098-2264(200003)27:3<308::AID-GCC12>3.0.CO;2-W; HOLLAND EA, 1994, ONCOGENE, V9, P1361; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Mead LJ, 1997, INT J CANCER, V71, P213; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Oh JJ, 2002, CANCER RES, V62, P3207; Pollock PM, 2001, CANCER RES, V61, P1154; QUELLE DE, 1995, CELL, V83, P993; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shan ZH, 2003, GENE, V303, P55, DOI 10.1016/S0378-1119(02)01143-5; Sheu JC, 1999, BRIT J CANCER, V80, P468, DOI 10.1038/sj.bjc.6690380; Stranahan PL, 1996, GLYCOCONJUGATE J, V13, P741, DOI 10.1007/BF00702338; Takeuchi S, 1997, LEUKEMIA, V11, P1636, DOI 10.1038/sj.leu.2400817; Wiest JS, 1997, CANCER RES, V57, P1; XIAO S, 1995, CANCER RES, V55, P2968	26	24	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6612	6620		10.1038/sj.onc.1207857	http://dx.doi.org/10.1038/sj.onc.1207857			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15208665	Green Accepted			2022-12-17	WOS:000223530800008
J	Liu, J; Blackhall, F; Seiden-Long, I; Jurisica, I; Navab, R; Liu, N; Radulovich, N; Wigle, D; Sultan, M; Hu, J; Tsao, MS; Johnston, MR				Liu, J; Blackhall, F; Seiden-Long, I; Jurisica, I; Navab, R; Liu, N; Radulovich, N; Wigle, D; Sultan, M; Hu, J; Tsao, MS; Johnston, MR			Modeling of lung cancer by an orthotopically growing H460SM variant cell line reveals novel candidate genes for systemic metastasis	ONCOGENE			English	Article						lung cancer; orthotopic model; prognostic marker; expression profiling; metastatic model	BREAST-CANCER; ADENOCARCINOMA; EXPRESSION; ESTABLISHMENT; CARCINOMAS; RECEPTOR; NCI-H460-LNM35; ACTIVATION; SURVIVAL; PROFILES	Endobronchial implantation of NCI-H460 cells into the nude rat generates a primary lung tumor with mediastinal lymph node spread, but rarely systemic metastases. We isolated tumor cells from mediastinal nodes, orthotopically reimplanted the cells into nude rats and repeated this four times to derive a cell line, designated H460SM, that spontaneously metastasizes to bone, kidney, brain, soft tissue and contralateral lung. H460SM cells demonstrated higher invasive activity in vitro than parental NCI-H460 cells. Spectral karyotyping revealed a new inversion within 17q and loss of an extra normal copy of chromosome 14 present in parental NCI-H460 cells. Expression pro. ling of orthotopic primary tumors revealed differential expression of 360 genes. Of these, 173 were represented in the probe set of a 19.2K OCI cDNA microarray previously used to pro. le the gene expression of surgically resected lung cancer specimens. We have computationally validated clinical importance of these genes by using in silico analysis of 18 cases of pulmonary adenocarcinoma, which were split into two patient groups with markedly different clinical outcome. The model identifies additional novel candidate genes for the progression of lung cancer to systemic metastases and poor prognosis.	Princess Margaret Hosp, Univ Hlth Network, Div Thorac Surg, Toronto, ON M5G 2M9, Canada; Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Princess Margaret Hosp, Univ Hlth Network, Div Cellular Mol Biol, Toronto, ON M5G 2M9, Canada; Princess Margaret Hosp, Univ Hlth Network, Div Canc Informat, Toronto, ON M5G 2M9, Canada; Univ Toronto, Hosp Sick Children, Res Inst, Toronto, ON M5G 2M9, Canada; Princess Margaret Hosp, Univ Hlth Network, Dept Pathol, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Johnston, MR (corresponding author), Toronto Gen Hosp, Div Thorac Surg, Suite EN10-230,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.	michael.johnston@uhn.on.ca	Tsao, Ming-Sound/M-3503-2017; Tsao, Ming Sound/AFQ-7332-2022; Navab, Roya/AGD-7380-2022; Blackhall, Fiona H/N-2186-2015	Tsao, Ming Sound/0000-0002-9160-5405; Blackhall, Fiona H/0000-0001-8716-3395; Hu, Jim/0000-0001-9134-7103; Sultan, Mujahid/0000-0001-6721-4044				Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; CARNEY DN, 1985, CANCER RES, V45, P2913; Fontao L, 2003, MOL BIOL CELL, V14, P1978, DOI 10.1091/mbc.e02-08-0548; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Gemma A, 2001, EUR J CANCER, V37, P1554, DOI 10.1016/S0959-8049(01)00154-X; Gorogh T, 1999, INT J CANCER, V83, P750, DOI 10.1002/(SICI)1097-0215(19991210)83:6<750::AID-IJC9>3.0.CO;2-V; Howard RB, 1999, CLIN EXP METASTAS, V17, P157, DOI 10.1023/A:1006637712294; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kashima T, 2003, INT J CANCER, V104, P147, DOI 10.1002/ijc.10931; Kozaki K, 2000, CANCER RES, V60, P2535; Kozaki K, 2001, ONCOGENE, V20, P4228, DOI 10.1038/sj.onc.1204561; Liu J, 2002, SURG ONCOL, V11, P217, DOI 10.1016/S0960-7404(02)00053-1; Liu M, 1999, GENOMICS, V55, P296, DOI 10.1006/geno.1998.5644; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; MERCER KE, 2003, BIOCHIM BIOPHYS ACTA, V1653, P23; Miura K, 2002, CANCER RES, V62, P3244; Nakamura H, 2003, CANCER-AM CANCER SOC, V97, P2798, DOI 10.1002/cncr.11406; Rhee J, 2002, NAT CELL BIOL, V4, P798, DOI 10.1038/ncb858; SAIGA T, 1987, IN VITRO CELL DEV B, V23, P850; Sattler M, 2003, SEMIN ONCOL, V30, P57, DOI 10.1053/sonc.2003.50019; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Shindo-Okada N, 2002, JPN J CANCER RES, V93, P50, DOI 10.1111/j.1349-7006.2002.tb01200.x; Shindo-Okada N, 2001, JPN J CANCER RES, V92, P174, DOI 10.1111/j.1349-7006.2001.tb01080.x; Sultan M, 2002, Bioinformatics, V18 Suppl 1, pS111; Tsao MS, 1998, LUNG CANCER, V20, P1, DOI 10.1016/S0169-5002(98)00007-5; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang K, 2002, ONCOGENE, V21, P7598, DOI 10.1038/sj.onc.1205953; Wigle DA, 2002, CANCER RES, V62, P3005; Wigle Dennis A, 2004, Genome Biol, V5, P309, DOI 10.1186/gb-2004-5-2-309	31	24	30	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6316	6324		10.1038/sj.onc.1207795	http://dx.doi.org/10.1038/sj.onc.1207795			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15247903				2022-12-17	WOS:000223399000016
J	Kowolik, CM; Liang, SJ; Yu, Y; Yee, JK				Kowolik, CM; Liang, SJ; Yu, Y; Yee, JK			Cre-mediated reversible immortalization of human renal proximal tubular epithelial cells	ONCOGENE			English	Article						immortalization; lentiviral vector; telomerase; T antigen; kidney	HUMAN-FIBROBLASTS; TELOMERASE ACTIVATION; CELLULAR SENESCENCE; CATALYTIC SUBUNIT; HUMAN HEPATOCYTES; DOME FORMATION; IN-VIVO; EXPRESSION; ONCOGENE; TRANSFORMATION	Primary human renal proximal tubule epithelial cells (RPTECs) are of limited use for basic research and for clinical applications due to their limited lifespan in culture. Here we used two lentivirus vectors carrying the human telomerase (hTERT) and the SV40T antigen (Tag) flanked by loxP sites to reversibly immortalize RPTECs. Transduced RPTEC clones continued to proliferate while retaining biochemical and functional characteristics of primary cells. The clones exhibited contact-inhibited, anchorage- and growth factor-dependent growth and did not form tumors in nude mice, suggesting that the cells were not transformed. Transient Cre expression in these cells led to efficient proviral deletion, upregulation of some renal specific activities, and decreased growth rates. Ultimately, the cells underwent replicative senescence, indicating intact cell cycle control. Thus, reversible immortalization allows the expansion of human RPTECs, leading to large production of RPTECs that retain most tissue-specific properties.	City Hope Natl Med Ctr, Beckman Res Inst, Dept Virol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Yee, JK (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Virol, Miller Bldg 110,1500 E Duarte Rd, Duarte, CA 91010 USA.	jyee@coh.org			NCI NIH HHS [R21 CA101629] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA101629] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berghella L, 1999, HUM GENE THER, V10, P1607, DOI 10.1089/10430349950017617; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Burger AM, 1998, INT J ONCOL, V13, P1043; Condon J, 2002, BIOL REPROD, V67, P506, DOI 10.1095/biolreprod67.2.506; DEYOUNG LM, 1978, CANCER RES, V38, P3697; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DREHER D, 1992, AM J PHYSIOL, V262, pC358, DOI 10.1152/ajpcell.1992.262.2.C358; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HURLIN PJ, 1989, P NATL ACAD SCI USA, V86, P187, DOI 10.1073/pnas.86.1.187; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; JOLY V, 1990, J PHARMACOL EXP THER, V255, P17; Kawano Y, 2003, BLOOD, V101, P532, DOI 10.1182/blood-2002-04-1268; Kim BH, 2000, EXP MOL MED, V32, P29, DOI 10.1038/emm.2000.6; Kim D, 2002, KIDNEY INT, V61, P464, DOI 10.1046/j.1523-1755.2002.00153.x; Kim H, 2002, BIOCHEM J, V365, P765, DOI 10.1042/BJ20011848; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kobayashi N, 2000, SCIENCE, V287, P1258, DOI 10.1126/science.287.5456.1258; Kowolik CM, 2002, MOL THER, V5, P762, DOI 10.1006/mthe.2002.0603; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEVER JE, 1979, P NATL ACAD SCI USA, V76, P1323, DOI 10.1073/pnas.76.3.1323; Montalto MC, 1999, J CELL PHYSIOL, V180, P46, DOI 10.1002/(SICI)1097-4652(199907)180:1<46::AID-JCP5>3.0.CO;2-K; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; O'Hare MJ, 2001, P NATL ACAD SCI USA, V98, P646, DOI 10.1073/pnas.98.2.646; Pfeifer A, 2001, P NATL ACAD SCI USA, V98, P11450, DOI 10.1073/pnas.201415498; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; RABITO CA, 1980, J MEMBRANE BIOL, V54, P31, DOI 10.1007/BF01875374; Racusen LC, 1997, J LAB CLIN MED, V129, P318, DOI 10.1016/S0022-2143(97)90180-3; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; Rudolph AE, 1999, J BIOL CHEM, V274, P11824, DOI 10.1074/jbc.274.17.11824; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RYAN MJ, 1994, KIDNEY INT, V45, P48, DOI 10.1038/ki.1994.6; Sharma GG, 2003, ONCOGENE, V22, P131, DOI 10.1038/sj.onc.1206063; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; Silver DP, 2001, MOL CELL, V8, P233, DOI 10.1016/S1097-2765(01)00295-7; STEVENSON M, 1986, MOL CELL BIOL, V6, P3410, DOI 10.1128/MCB.6.10.3410; Westerman KA, 1996, P NATL ACAD SCI USA, V93, P8971, DOI 10.1073/pnas.93.17.8971; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; YOAKUM GH, 1985, SCIENCE, V227, P1174, DOI 10.1126/science.3975607	40	24	28	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5950	5957		10.1038/sj.onc.1207801	http://dx.doi.org/10.1038/sj.onc.1207801			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208689				2022-12-17	WOS:000222941100009
J	Schreiber, K; Cannon, RE; Karrison, T; Beck-Engeser, G; Huo, DZ; Tennant, RW; Jensen, H; Kast, WM; Krausz, T; Meredith, SC; Chen, LP; Schreiber, H				Schreiber, K; Cannon, RE; Karrison, T; Beck-Engeser, G; Huo, DZ; Tennant, RW; Jensen, H; Kast, WM; Krausz, T; Meredith, SC; Chen, LP; Schreiber, H			Strong synergy between mutant ras and HPV16 E6/E7 in the development of primary tumors	ONCOGENE			English	Article						HPV 16; human papilloma virus 16; E6/E7; vHa ras; transgenic mice; synergy; primary tumors	HUMAN-PAPILLOMAVIRUS TYPE-16; T-LYMPHOCYTE EPITOPE; TRANSGENIC MICE; HA-RAS; CERVICAL-CANCER; K-RAS; HIGH PREVALENCE; UTERINE CERVIX; HIGH-RISK; INTRAEPITHELIAL NEOPLASIA	E6/E7 oncogenes of high-risk human papilloma virus (HPV) subtypes are essential for the development of certain types of cancers. However, these oncogenes are insufficient to transform normal cells into an immortalized or malignant state. Mutant Ha-ras cooperates with E6/E7 of HPV subtype 16 in transformation of cells in vitro and may contribute to some HPV-associated cancers in humans. This study investigates whether HPV16 E6/E7 and v-Ha-ras synergize in vivo. FVB/n mice transgenic for v-Ha-ras gene (R+) were crossed with transgenic C57BL/6 mice that harbor E6/E7 of HPV16 (E+). Beginning at about 3 months of age, the bitransgenic E+R+(C57BL/6 x FVB/n) F1 mice developed mouth, eye and ear tumors. By 6 months, the prevalence of these types of mouth, eye and ear tumors was 100, 71 and 79% respectively in the E+R+ mice. Most tumors grew progressively until the mice had to be killed. The median times for the appearance of the first mouth, eye and ear tumor were 3.6, 4.3 and 4.2 months, respectively. For the two singly transgenic groups of mice, the prevalence of mouth, eye and ear tumors was 0, 0 and 6% (E-R+) and 0, 0 and 0% (E+R-), respectively, and the median time to first tumor was greater than 12 months for singly transgenic mice (E-R+, E+R-). Thus, a remarkable synergy occurred between the v-Ha-ras and HPV16 E6/E7 oncogenes in the development of primary tumors in mice.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; NIEHS, Lab Environm Carcinogenesis & Mutagenesis, Res Triangle Pk, NC 27709 USA; Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA; Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA; Mayo Clin, Dept Immunol, Rochester, MN 55905 USA	University of Chicago; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Chicago; University of Southern California; Mayo Clinic	Schreiber, H (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave,MC 3008, Chicago, IL 60637 USA.	hszz@midway.uchicago.edu		Jensen, Heather/0000-0002-1712-9682; Kast, W Martin/0000-0003-2321-3159	NCI NIH HHS [R01-CA22677, R01-CA37516, P01-CA97296] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022677, P01CA097296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES021175, Z01ES100610] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alonio LV, 2003, J CLIN VIROL, V27, P263, DOI 10.1016/S1386-6532(02)00181-6; Alonio LV, 2000, MEDICINA-BUENOS AIRE, V60, P895; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; BERGMANN K, 1994, INT J CANCER, V59, P463, DOI 10.1002/ijc.2910590405; BRESLOW N, 1970, BIOMETRIKA, V57, P579, DOI 10.1093/biomet/57.3.579; Campo MS, 1998, TRENDS MICROBIOL, V6, P424, DOI 10.1016/S0966-842X(98)01385-7; Coussens LM, 1996, AM J PATHOL, V149, P1899; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; Daniel D, 2003, J EXP MED, V197, P1017, DOI 10.1084/jem.20021047; Dokianakis DN, 1999, ONCOL REP, V6, P1327; DRINKWATER NR, 1991, PROG EXP TUMOR RES, V33, P1; Eiben GL, 2002, CANCER RES, V62, P5792; FELTKAMP MCW, 1995, EUR J IMMUNOL, V25, P2638, DOI 10.1002/eji.1830250935; FELTKAMP MCW, 1993, EUR J IMMUNOL, V23, P2242, DOI 10.1002/eji.1830230929; Gillison, 2000, Br J Surg, V87, P362, DOI 10.1046/j.1365-2168.2000.01383-3.x; Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916; GLOSS B, 1987, EMBO J, V6, P3735, DOI 10.1002/j.1460-2075.1987.tb02708.x; Golijow CD, 1999, GYNECOL ONCOL, V75, P108, DOI 10.1006/gyno.1999.5528; GREENHALGH DA, 1994, CELL GROWTH DIFFER, V5, P667; HANSEN LA, 1994, MOL CARCINOGEN, V9, P143, DOI 10.1002/mc.2940090306; *IARC, 1995, IARC MON EV CARC RIS, V64, P245; *IARC, 1995, IARC MON EV CARC RIS, V64, P65; Janicek MF, 2001, CA-CANCER J CLIN, V51, P92, DOI 10.3322/canjclin.51.2.92; Jin YT, 1997, AM J PATHOL, V150, P1327; Kantz DC, 1999, BIOTECHNIQUES, V27, P278, DOI 10.2144/99272bm13; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Klug SJ, 2001, CANCER EPIDEM BIOMAR, V10, P1009; Klussmann JP, 2001, CANCER-AM CANCER SOC, V92, P2875, DOI 10.1002/1097-0142(20011201)92:11&lt;2875::AID-CNCR10130&gt;3.0.CO;2-7; LAMBERT PF, 1993, P NATL ACAD SCI USA, V90, P5583, DOI 10.1073/pnas.90.12.5583; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Lee JH, 1996, GYNECOL ONCOL, V62, P49, DOI 10.1006/gyno.1996.0188; Lin XH, 1996, J CELL BIOCHEM, V63, P463, DOI 10.1002/(SICI)1097-4644(19961215)63:4<463::AID-JCB8>3.0.CO;2-R; Mazurek S, 2001, ONCOGENE, V20, P6891, DOI 10.1038/sj.onc.1204792; Melero I, 1997, J VIROL, V71, P3998, DOI 10.1128/JVI.71.5.3998-4004.1997; Mouron SA, 2000, MUTAT RES-GEN TOX EN, V469, P127, DOI 10.1016/S1383-5718(00)00066-8; Pedroza-Saavedra A, 2000, ARCH VIROL, V145, P603, DOI 10.1007/s007050050050; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Prokopakis P, 2002, ONCOL REP, V9, P129; RESSING ME, 1995, J IMMUNOL, V154, P5934; Riley RR, 2003, CANCER RES, V63, P4862; Ringstrom E, 2002, CLIN CANCER RES, V8, P3187; RIOU G, 1988, ONCOGENE, V3, P329; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Schlecht NF, 2003, JNCI-J NATL CANCER I, V95, P1336, DOI 10.1093/jnci/djg037; Scott IU, 2002, OPHTHALMOLOGY, V109, P542, DOI 10.1016/S0161-6420(01)00991-5; Siegel CT, 2000, J EXP MED, V191, P1945, DOI 10.1084/jem.191.11.1945; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; Stenzel A, 2001, PATHOL RES PRACT, V197, P597, DOI 10.1016/S0344-0338(04)70133-8; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Thompson KL, 1998, TOXICOL PATHOL, V26, P548, DOI 10.1177/019262339802600411; Tsai ST, 1997, INT J CANCER, V71, P208; WILLIS G, 1993, GYNECOL ONCOL, V49, P359, DOI 10.1006/gyno.1993.1140; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	58	24	26	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3972	3979		10.1038/sj.onc.1207507	http://dx.doi.org/10.1038/sj.onc.1207507			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15077191				2022-12-17	WOS:000221382000009
J	Lee, MS; Igawa, T; Lin, MF				Lee, MS; Igawa, T; Lin, MF			Tyrosine-317 of p52(Shc) mediates androgen-stimulated proliferation signals in human prostate cancer cells	ONCOGENE			English	Article						PAcP; ErbB-2; p52(Shc); androgen sensitivity; human prostate cancer	EPIDERMAL-GROWTH-FACTOR; STEROID-HORMONE RECEPTORS; ACID-PHOSPHATASE-ACTIVITY; ADVANCED BREAST-CANCER; CARCINOMA-CELLS; PROTEIN-PHOSPHORYLATION; ENDOCRINE-THERAPY; INDUCED APOPTOSIS; SHC; EXPRESSION	The involvement of tyrosine phosphorylation signaling pathways in steroid-induced cell proliferation has received much attention. However, the adaptor molecule that mediates this interaction remains to be identified. In this communication, we identify p52(Shc) as the mediator between tyrosine phosphorylation signaling and steroid signaling in steroid-responsive cell proliferation. Although the different LNCaP prostate cancer cells, C-33, C-51 and C-81, express similar levels of functional androgen receptor (AR), they exhibit different levels of androgen sensitivity. C-33 cell proliferation is highly responsive to the presence of androgens, whereas C-51 cell proliferation is comparatively less responsive to androgens. In contrast, C-81 cell proliferation is independent of androgens. In these cells, tyrosine phosphorylation levels of both p52(Shc) and ErbB-2 were greatest in C-81 cells, comparatively less in C-51 cells and weaker in C-33 cells. The levels and activity of protein tyrosine phosphatase, cellular prostatic acid phosphatase, decreased correspondingly in those cells. In both androgen-independent, rapidly growing C-81 and ErbB-2 cDNA-transfected C-33 cells, p52(Shc) was hyperphosphorylated at Tyr317 (Y317). Conversely, p52(Shc) tyrophosphorylation was decreased in prostatic acid phosphatase cDNA-transfected stable subclones of C-81 cells, which restore androgen-sensitive proliferation and leads to slow growth rates. In C-33 cells, androgen-stimulated cell proliferation correlated with tyrophosphorylation of ErbB-2 and increased phosphorylation of p52(Shc) at Y317, but not at Y239, differing from phosphorylation patterns associated with epidermal growth factor (EGF) stimulation. Furthermore, over-expression of a mutant of p52(Shc), that is Y317F, blocks Y317 phosphorylation of endogenous p52(Shc) and abolishes androgen-stimulated proliferation, but not EGF-stimulated proliferation. Thus, Y317 of p52(Shc) serves as an important regulatory site that allows tyrosine phosphorylation pathways to moderate androgen sensitivity in human prostate cancer cells.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Sect Urol Surg, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Lin, MF (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 984525 Nebraska Med Ctr, Omaha, NE 68198 USA.	mlin@unmc.edu		LEE, MING-SHYUE/0000-0002-8673-5088; LEE, MING-SHYUE/0000-0002-5884-4535	NATIONAL CANCER INSTITUTE [R01CA088184] Funding Source: NIH RePORTER; NCI NIH HHS [CA88184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chu TM, 1998, J CLIN LIGAND ASSAY, V21, P24; CHU TM, 1982, BIOCH MARKERS CANC, V117; CULIG Z, 1994, CANCER RES, V54, P5474; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Gao M, 1999, J CELL PHYSIOL, V179, P336, DOI 10.1002/(SICI)1097-4652(199906)179:3<336::AID-JCP11>3.0.CO;2-Q; Gioeli D, 1999, CANCER RES, V59, P279; GLAUBER JG, 1992, SEMIN ONCOL, V19, P308; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; Gresham J, 1998, INT J CANCER, V77, P923, DOI 10.1002/(SICI)1097-0215(19980911)77:6<923::AID-IJC21>3.0.CO;2-0; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Houston SJ, 1999, BRIT J CANCER, V79, P1220, DOI 10.1038/sj.bjc.6690196; Hua WH, 1995, J STEROID BIOCHEM, V55, P279, DOI 10.1016/0960-0760(95)00187-5; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Igawa T, 2003, PROSTATE, V55, P247, DOI 10.1002/pros.10240; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; KAIGHN ME, 1979, INVEST UROL, V17, P16; Karan D, 2003, INT J CANCER, V103, P285, DOI 10.1002/ijc.10813; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Koivisto P, 1997, CANCER RES, V57, P314; Kokontis JM, 1999, VITAM HORM, V55, P219; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; LAI KMV, 1995, MOL CELL BIOL, V15, P4810; Landry F, 1996, J UROLOGY, V155, P386, DOI 10.1016/S0022-5347(01)66665-5; Lee MS, 2003, ONCOGENE, V22, P781, DOI 10.1038/sj.onc.1206066; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; Lin MF, 1996, BIOCHEM BIOPH RES CO, V226, P206, DOI 10.1006/bbrc.1996.1334; LIN MF, 1988, MOL CELL BIOL, V8, P5477, DOI 10.1128/MCB.8.12.5477; LIN MF, 1986, MOL CELL BIOL, V6, P4753, DOI 10.1128/MCB.6.12.4753; LIN MF, 1993, ARCH BIOCHEM BIOPHYS, V300, P384, DOI 10.1006/abbi.1993.1052; LIN MF, 1986, BIOCHEM J, V235, P351, DOI 10.1042/bj2350351; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; LIN MF, 1992, CANCER RES, V52, P4600; LIN MF, 1994, DIFFERENTIATION, V57, P143, DOI 10.1046/j.1432-0436.1994.5720143.x; Lin MF, 2001, J UROLOGY, V166, P1943, DOI 10.1016/S0022-5347(05)65725-4; LIN MF, 1983, BIOCHEMISTRY-US, V22, P1055, DOI 10.1021/bi00274a009; LIN MF, 1987, ADV PROT PHOSPHATASE, V4, P199; LOOR R, 1981, CANCER LETT, V14, P63, DOI 10.1016/0304-3835(81)90010-0; Luzi L, 2000, CURR OPIN GENET DEV, V10, P668, DOI 10.1016/S0959-437X(00)00146-5; Meng TC, 2000, ONCOGENE, V19, P2664, DOI 10.1038/sj.onc.1203576; Meng TC, 1998, J BIOL CHEM, V273, P22096, DOI 10.1074/jbc.273.34.22096; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Osman I, 2001, CLIN CANCER RES, V7, P2643; Patarca R, 1996, CRIT REV ONCOGENESIS, V7, P343, DOI 10.1615/CritRevOncog.v7.i5-6.20; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Price DT, 1999, J UROLOGY, V162, P1537, DOI 10.1016/S0022-5347(05)68354-1; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; RICCI A, 1995, ONCOGENE, V11, P1519; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sadar MD, 1999, ENDOCR-RELAT CANCER, V6, P487, DOI 10.1677/erc.0.0060487; Signoretti S, 2000, JNCI-J NATL CANCER I, V92, P1918, DOI 10.1093/jnci/92.23.1918; SOLIN T, 1990, BIOCHIM BIOPHYS ACTA, V1048, P72, DOI 10.1016/0167-4781(90)90024-V; Stevenson LE, 1998, BREAST CANCER RES TR, V49, P119, DOI 10.1023/A:1006007227747; Stevenson LE, 1999, CELL GROWTH DIFFER, V10, P61; STROHMEYER TG, 1994, J UROLOGY, V151, P1479, DOI 10.1016/S0022-5347(17)35284-9; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; VIHKO P, 1988, FEBS LETT, V236, P275, DOI 10.1016/0014-5793(88)80037-1; VIHKO P, 1993, P NATL ACAD SCI USA, V90, P799, DOI 10.1073/pnas.90.3.799; Walk SF, 1998, EUR J IMMUNOL, V28, P2265, DOI 10.1002/(SICI)1521-4141(199808)28:08<2265::AID-IMMU2265>3.0.CO;2-P; Weigel NL, 1998, J MOL MED, V76, P469, DOI 10.1007/s001090050241; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; WEISS C, 1990, LEUKEMIA RES, V14, P327, DOI 10.1016/0145-2126(90)90159-7; Zelivianski S, 2003, INT J CANCER, V107, P478, DOI 10.1002/ijc.11413; Zhang XQ, 2001, J BIOL CHEM, V276, P2544, DOI 10.1074/jbc.M006661200	68	24	24	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3048	3058		10.1038/sj.onc.1207451	http://dx.doi.org/10.1038/sj.onc.1207451			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	14990987				2022-12-17	WOS:000220845200009
J	Young, AP; Longmore, GD				Young, AP; Longmore, GD			Differential regulation of apoptotic genes by Rb in human versus mouse cells	ONCOGENE			English	Article						Rb; E2F; apoptosis; human versus mouse	RETINOBLASTOMA SUSCEPTIBILITY GENE; TUMOR-SUPPRESSOR; KINASE-ACTIVITY; E2F PROTEINS; IN-VIVO; EXPRESSION; CYCLE; ACTIVATION; MECHANISMS; CANCER	The retinoblastoma protein (Rb) controls cellular proliferation and suppresses tumor formation through its effects upon E2F transcriptional regulation of the cell cycle. Unexpectedly, however, in proliferating human cells, Rb was present at the promoters of eight of eight E2F-regulated apoptotic genes tested, but zero of six E2F-regulated cell cycle genes tested. Binding of apoptotic gene promoters by Rb was constitutive, and inhibition of Rb in human cells by E2Fdb or E1A expression resulted in induction of these apoptotic genes and efficient cell death. E1A induced apoptosis much more efficiently in human fibroblasts than in mouse fibroblasts, suggesting a difference in susceptibility to loss of Rb function between human cells and mouse cells. Abrogation of Rb function in mouse cells did not induce expression of these apoptotic genes. Underlying this species difference in susceptibility to apoptosis following loss of Rb function was the absence of Rb on apoptotic gene promoters in mouse cells. Rb protein levels were 20-35-fold higher in primary human cells than in primary mouse cells. The constitutive repression of a multitude of apoptotic genes by Rb in human cells but not in mouse cells may provide a partial explanation for the well-known difference between human and mouse cells in transformation and tumorigenic potential.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Longmore, GD (corresponding author), Washington Univ, Sch Med, Dept Med, 4940 Parkview Pl, St Louis, MO 63110 USA.	glongmor@im.wustl.edu						Balmain A, 2002, CELL, V108, P145, DOI 10.1016/S0092-8674(02)00622-0; Black EP, 2003, CANCER RES, V63, P3716; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; Bosco G, 2001, NAT CELL BIOL, V3, P289, DOI 10.1038/35060086; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Forsyth NR, 2002, DIFFERENTIATION, V69, P188, DOI 10.1046/j.1432-0436.2002.690412.x; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Fu XY, 1999, CELL DEATH DIFFER, V6, P1201, DOI 10.1038/sj.cdd.4400613; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Ma DD, 2003, J BIOL CHEM, V278, P19358, DOI 10.1074/jbc.M301761200; Marie H, 2003, J BIOL CHEM, V278, P1220, DOI 10.1074/jbc.M205391200; Maronpot R, 1999, PATHOLOGY MOUSE; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Reed SI, 1997, CANCER SURV, V29, P7; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STERNER JM, 1995, J BIOL CHEM, V270, P9281, DOI 10.1074/jbc.270.16.9281; Takahashi Y, 2000, GENE DEV, V14, P804; Tamrakar S, 2000, FRONT BIOSCI-LANDMRK, V5, pD121, DOI 10.2741/Tamrakar; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Wang J, 1996, CELL GROWTH DIFFER, V7, P1471; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264; White E, 2001, ONCOGENE, V20, P7836, DOI 10.1038/sj.onc.1204861; Wright WE, 2000, NAT MED, V6, P849, DOI 10.1038/78592; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Young AP, 2003, ONCOGENE, V22, P7209, DOI 10.1038/sj.onc.1206804; Young AP, 2004, ONCOGENE, V23, P2587, DOI 10.1038/sj.onc.1207330; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6	55	24	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2587	2599		10.1038/sj.onc.1207330	http://dx.doi.org/10.1038/sj.onc.1207330			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	15048095				2022-12-17	WOS:000220714900001
J	Hobbs, SS; Cameron, EM; Hammer, RP; Le, ATD; Gallo, RM; Blommell, EN; Coffing, SL; Chang, H; Riese, DJ				Hobbs, SS; Cameron, EM; Hammer, RP; Le, ATD; Gallo, RM; Blommell, EN; Coffing, SL; Chang, H; Riese, DJ			Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase	ONCOGENE			English	Article						heregulins; neuregulins; ErbB4; HER4	EPIDERMAL-GROWTH-FACTOR; CONSTITUTIVELY ACTIVE ERBB4; FACTOR-ALPHA; DIFFERENTIATION FACTOR; EXTRACELLULAR DOMAIN; CELLULAR-RESPONSE; CRYSTAL-STRUCTURE; HIGH-AFFINITY; EGF RECEPTOR; FAMILY	The neuregulins (NRGs) are members of the epidermal growth factor (EGF) family of peptide growth factors. These hormones are agonists for the ErbB family of receptor tyrosine kinases, a family that includes the epidermal growth factor receptor (EGFR/ErbB1), ErbB2/ Neu/HER2, ErbB3/HER3, and ErbB4/HER4. We recently observed that the EGF family hormone NRG2beta is a potent agonist for ErbB4. In contrast, NRG2alpha, a splicing isoform of the same gene that encodes NRG2beta, is a poor ErbB4 agonist. We hypothesized that carboxyl-terminal residues of NRG2beta are critical for stimulation of ErbB4 tyrosine phosphorylation and coupling to downstream signaling events. Here, we demonstrate that the substitution of a lysine residue for Phe45 in NRG2beta results in reduced ligand potency. We also demonstrate that substitution of a phenylalanine for Lys45 in NRG2alpha: results in increased ligand potency. Finally, analyses of the gain-of-function NRG2alpha Chg5 mutant demonstrate that Gln43, Met47, Asn49, and Phe50 regulate ligand efficacy. Thus, these data indicate that carboxyl-terminal residues of NRG2beta are critical for activation of ErbB4 signaling. Moreover, these NRG2alpha: and NRG2beta mutants reveal new insights into models for ligand-induced ErbB family receptor tyrosine phosphorylation and coupling to downstream signaling events.	Purdue Univ, Dept Med Chem & Mol Pharmacol, Sch Pharm, W Lafayette, IN 47907 USA; Louisiana State Univ, Dept Chem, Baton Rouge, LA 70803 USA; Bristol Myers Squibb Pharmaceut Res Inst, Princeton, NJ 08543 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Louisiana State University System; Louisiana State University; Bristol-Myers Squibb	Riese, DJ (corresponding author), Purdue Univ, Dept Med Chem & Mol Pharmacol, Sch Pharm, 201 S Univ St,HANS 114, W Lafayette, IN 47907 USA.	driese@purdue.edu	Riese, David/AAF-3581-2020	Riese, David/0000-0002-8823-5802	NCI NIH HHS [F33CA085049, R21CA089274, R21CA080770] Funding Source: Medline; NIGMS NIH HHS [T32GM008737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F33CA085049, R21CA089274, R21CA080770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ballinger MD, 1998, J BIOL CHEM, V273, P11675, DOI 10.1074/jbc.273.19.11675; Buonanno A, 2001, CURR OPIN NEUROBIOL, V11, P287, DOI 10.1016/S0959-4388(00)00210-5; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; Domagala T, 2000, GROWTH FACTORS, V18, P11, DOI 10.3109/08977190009003231; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Feroz K, 2002, CELL SIGNAL, V14, P793, DOI 10.1016/S0898-6568(02)00019-0; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Gullick WJ, 2001, ENDOCR-RELAT CANCER, V8, P75, DOI 10.1677/erc.0.0080075; Halgren TA, 1999, J COMPUT CHEM, V20, P720, DOI 10.1002/(SICI)1096-987X(199905)20:7<720::AID-JCC7>3.0.CO;2-X; Harari D, 1999, ONCOGENE, V18, P2681, DOI 10.1038/sj.onc.1202631; Hobbs SS, 2002, ONCOGENE, V21, P8442, DOI 10.1038/sj.onc.1205960; HOYT DW, 1994, BIOCHEMISTRY-US, V33, P11928; Jones JT, 1998, J BIOL CHEM, V273, P11667, DOI 10.1074/jbc.273.19.11667; KLINE TP, 1990, BIOCHEMISTRY-US, V29, P7805, DOI 10.1021/bi00486a005; KOHDA D, 1992, BIOCHEMISTRY-US, V31, P11928, DOI 10.1021/bi00162a036; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; Miura K, 2002, BIOCHEM BIOPH RES CO, V294, P1040, DOI 10.1016/S0006-291X(02)00585-5; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Penington DJ, 2002, CELL GROWTH DIFFER, V13, P247; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Riese DJ, 1998, J BIOL CHEM, V273, P11288, DOI 10.1074/jbc.273.18.11288; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sherrill JM, 1996, BIOCHEMISTRY-US, V35, P5705, DOI 10.1021/bi9602268; Sherrill JM, 1997, BIOCHEMISTRY-US, V36, P12890, DOI 10.1021/bi971418l; Sweeney C, 2000, J BIOL CHEM, V275, P19803, DOI 10.1074/jbc.C901015199; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; VANDEPOLL MLM, 1995, J BIOL CHEM, V270, P22337, DOI 10.1074/jbc.270.38.22337; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Williams EE, 2003, CANCER LETT, V192, P67, DOI 10.1016/S0304-3835(02)00690-0; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	36	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					883	893		10.1038/sj.onc.1207250	http://dx.doi.org/10.1038/sj.onc.1207250			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14661053				2022-12-17	WOS:000188486600003
J	Lahortiga, I; Agirre, X; Belloni, E; Vazquez, I; Larrayoz, MJ; Gasparini, P; Coco, FL; Pelicci, PG; Calasanz, MJ; Odero, MD				Lahortiga, I; Agirre, X; Belloni, E; Vazquez, I; Larrayoz, MJ; Gasparini, P; Coco, FL; Pelicci, PG; Calasanz, MJ; Odero, MD			Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells	ONCOGENE			English	Article						PRDM16/MEL1; RPN1; 1p36; 3q21; MDS (RAEB)	ACUTE MYELOID-LEUKEMIA; HEMATOLOGIC MALIGNANCIES; EVI1 EXPRESSION; GENE; 3Q21; IDENTIFICATION; MDS1/EVI1; 1P36.3; METHYLTRANSFERASES; REARRANGEMENTS	Patients with myeloid malignancies and either the 3q21q26 syndrome or t(1;3)(p36;q21) have been reported to share similar clinicopathological features and a common molecular mechanism for leukemogenesis. Overexpression of MDS1/EVI1 (3q26) or MEL1/PRDM16 (1p36), both members of the PR-domain family, has been directly implicated in the malignant transformation of this subset of neoplasias. The breakpoints in both entities are outside the genes, and the 3q21 region, where RPN1 is located, seems to act as an enhancer. MEL1 has been reported to be expressed in leukemia cells with t(1;3) and in the normal uterus and fetal kidney, but neither in bone marrow (BM) nor in other tissues, suggesting that this gene is specific to t(1;3)-positive MDS/AML. We report the molecular characterization of a t(1;3)(p36;q21) in a patient with MDS (RAEB-2). In contrast to previous studies, we demonstrate that MEL1, the PR-containing form, and MEL1S, the PR-lacking form, are widely expressed in normal tissues, including BM. The clinicopathological features and the breakpoint on 1p36 are different from cases previously described, and MEL1 is not overexpressed, suggesting a heterogeneity in myeloid neoplasias with t(1;3).	Univ Navarra, Dept Genet, Pamplona 31008, Spain; FIRC, Inst Mol Oncol, Milan, Italy; European Inst Oncol, Milan, Italy; Univ Tor Vergata, Dipartimento Biopatol & Diagnost Immagini, Rome, Italy	University of Navarra; IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO); University of Rome Tor Vergata	Odero, MD (corresponding author), Univ Navarra, Dept Genet, C Irunlarrea S-N, Pamplona 31008, Spain.	modero@unav.es	Odero/ABG-9860-2020; Pelicci, Pier Giuseppe/AAL-6572-2020; belloni, elena/H-9909-2013; Agirre, Xabier/ABE-4110-2020; Gasparini, Patrizia/Q-7626-2016; Calasanz, MJ/R-5813-2016	Odero/0000-0002-8858-2054; Gasparini, Patrizia/0000-0002-9548-3724; Calasanz, MJ/0000-0002-0374-3008; Belloni, Elena/0000-0003-3214-0780	Telethon [TGM06S01, TGM03Z03] Funding Source: Medline	Telethon(Fondazione Telethon)		Du Y, 2001, CANCER RES, V61, P8094; FICHELSON S, 1992, LEUKEMIA, V6, P93; Huang S, 2002, NAT REV CANCER, V2, P469, DOI 10.1038/nrc819; Huang Shi, 1999, Frontiers in Bioscience, V4, pd528, DOI 10.2741/Huang; Langabeer SE, 2001, BRIT J HAEMATOL, V112, P208, DOI 10.1046/j.1365-2141.2001.02569.x; Mochizuki N, 2000, BLOOD, V96, P3209, DOI 10.1182/blood.V96.9.3209.h8003209_3209_3214; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; Nishikata I, 2003, BLOOD, V102, P3323, DOI 10.1182/blood-2002-12-3944; Odero MD, 2001, GENE CHROMOSOME CANC, V31, P134, DOI 10.1002/gcc.1127; Pekarsky Y, 1997, CANCER RES, V57, P3914; Rynditch A, 1997, GENE, V193, P49, DOI 10.1016/S0378-1119(97)00076-0; Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2; SECKERWALKER LM, 1995, BRIT J HAEMATOL, V91, P490, DOI 10.1111/j.1365-2141.1995.tb05329.x; Shimizu S, 2000, GENE CHROMOSOME CANC, V27, P229, DOI 10.1002/(SICI)1098-2264(200003)27:3<229::AID-GCC2>3.0.CO;2-0; Soderholm J, 1997, LEUKEMIA, V11, P352, DOI 10.1038/sj.leu.2400584; van Doorn-Khosrovani SBV, 2003, BLOOD, V101, P837, DOI 10.1182/blood-2002-05-1459; Vinatzer U, 2003, GENE CHROMOSOME CANC, V36, P80, DOI 10.1002/gcc.10144; Wieser R, 2002, LEUKEMIA LYMPHOMA, V43, P59, DOI 10.1080/10428190210196; Xinh PT, 2003, GENE CHROMOSOME CANC, V36, P313, DOI 10.1002/gcc.10176	19	24	28	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					311	316		10.1038/sj.onc.1206923	http://dx.doi.org/10.1038/sj.onc.1206923			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712237	Green Published			2022-12-17	WOS:000187895300034
J	Usami, N; Sekido, Y; Maeda, O; Yamamoto, K; Minna, JD; Hasegawa, Y; Yoshioka, H; Imaizumi, M; Ueda, Y; Takahashi, M; Shimokata, K				Usami, N; Sekido, Y; Maeda, O; Yamamoto, K; Minna, JD; Hasegawa, Y; Yoshioka, H; Imaizumi, M; Ueda, Y; Takahashi, M; Shimokata, K			beta-catenin inhibits cell growth of a malignant mesothelioma cell line, NCI-H28, with a 3p21.3 homozygous deletion	ONCOGENE			English	Article						beta-catenin; malignant mesothelioma; chromosome 3; homozygous deletion	HUMAN LUNG-CANCER; HEPATOCELLULAR CARCINOMAS; EPIGENETIC INACTIVATION; ALLELIC LOSS; GENE; ACTIVATION; MUTATIONS; SITES; APOPTOSIS; MULTIPLE	We have found that a malignant mesothelioma cell line, NCI-H28, had a chromosome 3p21.3 homozygous deletion containing the beta-catenin gene (CTNNB1), which suggested that the deletion of beta-catenin might have a growth advantage in the development of this tumor. To determine whether beta-catenin has a growth-inhibitory activity, we transfected wild-type beta-catenin, Ser37Cys mutant beta-catenin as an activated type, and C-terminus deletion mutant beta-catenin that lacks the transcription activity, into the NCI-H28 cells. A non-small cell lung cancer cell line, NCI-H1299, which expressed endogenous beta-catenin, was also studied. We tested the localization of exogenous beta-catenin in the NCI-H28 cells with immunofluorescence, and found that the wild-type beta-catenin and the C-terminus deletion mutant were more strongly expressed in the plasma membrane and cytoplasm than in the nucleus, while the Ser37Cys mutant was more in the nucleus than in the cytoplasm. By using luciferase-reporter assay, the beta-catenin/T-cell factor 4-mediated transactivity of the Ser37Cys mutant was shown to be higher than that of the wild-type beta-catenin in both cell lines. However, the transactivity of the C-terminus deletion mutant was strongly reduced in both. Colony formation of the NCI-H28 cells was reduced by 50% after transfection with the wild-type beta-catenin, and 60% with the Ser37Cys mutant, but only 20% with the C-terminus deletion mutant compared to the vector control. Inhibition of colony formation in NCI-H28 cells was because of apoptosis, manifested by positive staining of Annexin V and TUNEL assays in transfected cells. In contrast, when transfected with the wild-type beta-catenin, no significant reduction in colony formation was seen in beta-catenin wildtype NCI-H1299 cells. In conclusion, our data indicate that inactivation of beta-catenin by a 3p21.3 homozygous deletion might be a crucial event in the development of the mesothelioma NCI-H28 cells. Thus, while beta-catenin is well known to be a positive growth-stimulating factor for many human cancers, it can also act as a potential growth suppressor in some types of human cancer cells.	Nagoya Univ, Sch Med, Dept Clin Prevent Med, Showa Ku, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Thorac Surg, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Internal Med, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Sch Med, Dept Pathol 2, Nagoya, Aichi 4668550, Japan; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA	Nagoya University; Nagoya University; Nagoya University; Nagoya University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sekido, Y (corresponding author), Nagoya Univ, Sch Med, Dept Clin Prevent Med, Showa Ku, Tsurumai Cho 65, Nagoya, Aichi 4668550, Japan.	ysekido@med.nagoya-u.ac.jp	Hasegawa, Yoshinori/I-1277-2012; Takahashi, Masahide/AAN-4770-2020; Sekido, Yoshitaka/P-9756-2015; Maeda, Osamu/Q-1016-2015; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; Maeda, Osamu/0000-0003-4700-6541; Sekido, Yoshitaka/0000-0002-2428-3848	NATIONAL CANCER INSTITUTE [R01CA071618, P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [CA71618, P50 CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Bell DW, 1997, CANCER RES, V57, P4057; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; CHEN JY, 1993, ONCOGENE, V8, P2159; Cheng JQ, 1999, GENE CHROMOSOME CANC, V24, P238, DOI 10.1002/(SICI)1098-2264(199903)24:3<238::AID-GCC9>3.0.CO;2-M; CHENG JQ, 1994, CANCER RES, V54, P5547; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; FLEJTER WL, 1989, GENE CHROMOSOME CANC, V1, P148, DOI 10.1002/gcc.2870010207; Fukuchi T, 1998, CANCER RES, V58, P3526; GIBAS Z, 1986, CANCER GENET CYTOGEN, V20, P191, DOI 10.1016/0165-4608(86)90074-9; HAGEMEIJER A, 1990, CANCER GENET CYTOGEN, V47, P1, DOI 10.1016/0165-4608(90)90258-C; Hasegawa S, 2002, P NATL ACAD SCI USA, V99, P297, DOI 10.1073/pnas.012264999; Hayashi S, 1997, P NATL ACAD SCI USA, V94, P242, DOI 10.1073/pnas.94.1.242; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Iwao K, 1998, CANCER RES, V58, P1021; Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lee WC, 1996, CANCER RES, V56, P4297; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; LU YY, 1994, GENE CHROMOSOME CANC, V9, P76, DOI 10.1002/gcc.2870090114; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Polakis P, 2000, GENE DEV, V14, P1837; POPESCU NC, 1988, CANCER RES, V48, P142; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1999, J BIOL CHEM, V274, P14090, DOI 10.1074/jbc.274.20.14090; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Sekido Y, 2002, CANCER GENET CYTOGEN, V137, P33, DOI 10.1016/S0165-4608(02)00536-8; Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557; Shivapurkar N, 1999, CLIN CANCER RES, V5, P17; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Sunaga N, 2001, GENE CHROMOSOME CANC, V30, P316, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1097>3.0.CO;2-9; TAGUCHI T, 1993, CANCER RES, V53, P4349; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TIAINEN M, 1988, CANCER GENET CYTOGEN, V33, P251, DOI 10.1016/0165-4608(88)90035-0; van Gijn ME, 2001, EXP CELL RES, V265, P46, DOI 10.1006/excr.2001.5174; Wistuba II, 2000, CANCER RES, V60, P1949; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	44	24	25	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2003	22	39					7922	7930		10.1038/sj.onc.1206533	http://dx.doi.org/10.1038/sj.onc.1206533			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970740				2022-12-17	WOS:000185388200007
J	Liang, Y; Mirnics, ZK; Yan, CH; Nylander, KD; Schor, NF				Liang, Y; Mirnics, ZK; Yan, CH; Nylander, KD; Schor, NF			Bcl-2 mediates induction of neural differentiation	ONCOGENE			English	Article						neural differentiation; TrkA; nerve growth factor; Bcl-2; DNA microarray	NERVE GROWTH-FACTOR; NEURONATIN MESSENGER-RNA; EXPRESSION; APOPTOSIS; RECEPTOR; DEATH; CELLS; POTENTIATION; PATHWAYS; SIGNALS	Bcl-2 is an antiapoptotic protein expressed in a wide variety of cell types. We have found that overexpression of bcl-2 in PC12 neural crest tumor cells leads to increased expression of neural differentiation-associated genes and decreased expression of proliferation-related genes. Culture growth rate decreases as well. Overexpression of bcl-2 also leads to increased expression of TrkA and increased phosphorylation of signal transductants in, albeit not specific for, the TrkA-MEK-ERK pathway. Blocking of NGF-mediated signaling through TrkA prevents Bcl-2-associated expression changes in differentiation-associated genes, raising the possibility that Bcl-2 mediates induction of neural differentiation through TrkA/NGF signaling.	Univ Pittsburgh, Div Child Neurol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Pediat Ctr Neurosci, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Schor, NF (corresponding author), Univ Pittsburgh, Div Child Neurol, 3705 5th Ave, Pittsburgh, PA 15213 USA.			Schor, Nina/0000-0002-3817-7376; Korade, Zeljka/0000-0002-8690-4507				Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359-6101(00)00014-9; Bottner M, 2000, J NEUROCHEM, V75, P2227, DOI 10.1046/j.1471-4159.2000.0752227.x; Cortazzo M, 1996, CANCER RES, V56, P1199; Fujita A, 2000, BIOCHEM BIOPH RES CO, V269, P1, DOI 10.1006/bbrc.1999.1893; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; Grellier P, 1998, CANCER RES, V58, P1670; Hamada S, 2001, NEUROSCI RES, V41, P207, DOI 10.1016/S0168-0102(01)00281-4; Huttunen HJ, 2002, J BIOL CHEM, V277, P38635, DOI 10.1074/jbc.M202515200; JOSEPH R, 1995, BRAIN RES, V690, P92, DOI 10.1016/0006-8993(95)00621-V; Joseph R, 1996, BRAIN RES, V738, P32, DOI 10.1016/0006-8993(96)00768-8; Kalaydjieva L, 2000, AM J HUM GENET, V67, P47, DOI 10.1086/302978; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Liang Y, 2002, MOL PHARMACOL, V61, P142, DOI 10.1124/mol.61.1.142; Mani S, 2001, MOL CELL NEUROSCI, V17, P54, DOI 10.1006/mcne.2000.0931; Middleton G, 1998, J NEUROSCI, V18, P3344; Oh YJ, 1996, NEUROSCI LETT, V202, P161, DOI 10.1016/0304-3940(95)12235-4; Rong YP, 2002, ACTA BIOCH BIOPH SIN, V34, P411; Saragovi HU, 1998, J BIOL CHEM, V273, P34933, DOI 10.1074/jbc.273.52.34933; Schor NF, 2000, ONCOGENE, V19, P472, DOI 10.1038/sj.onc.1203324; Schwarz CS, 2002, NEUROREPORT, V13, P2439, DOI 10.1097/00001756-200212200-00013; Suzuki A, 1998, BRAIN RES, V801, P59, DOI 10.1016/S0006-8993(98)00523-X; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Yan CH, 2002, CANCER RES, V62, P4867; Zhang KZ, 1996, P NATL ACAD SCI USA, V93, P4504, DOI 10.1073/pnas.93.9.4504	24	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2003	22	35					5515	5518		10.1038/sj.onc.1206844	http://dx.doi.org/10.1038/sj.onc.1206844			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934111				2022-12-17	WOS:000184735000016
J	Blazek, E; Wasmer, S; Kruse, U; Aronheim, A; Aoki, M; Vogt, PK				Blazek, E; Wasmer, S; Kruse, U; Aronheim, A; Aoki, M; Vogt, PK			Partial oncogenic transformation of chicken embryo fibroblasts by Jun dimerization protein 2, a negative regulator of TRE- and CRE-dependent transcription	ONCOGENE			English	Article						AP-1; JDP2; Jun; repressor; transformation	MAF NUCLEAR ONCOPROTEIN; C-JUN; LEUCINE-ZIPPER; V-JUN; CELL-PROLIFERATION; DELETION MUTANT; AP-1 REPRESSOR; GROWTH-FACTOR; FOS; IDENTIFICATION	Jun dimerization protein 2 (JDP2) was identified as a bZIP protein that forms dimers with Jun proteins. JDP2 represses transcriptional activation of reporter constructs containing 12-O-tetradecanoylphorbol 13-acetate (TPA)-responsive elements (TRE) or cyclic AMP responsive elements (CRE). JDP2, overexpressed by the avian retroviral vector RCAS, induces partial oncogenic transformation of chicken embryo fibroblasts. JDP2-expressing cells form multilayered foci in monolayer cultures but do not show anchorage-independent growth. Both the carboxyl and the amino terminus of JDP2 are required for the transforming activity. Chimeric constructs of JDP2 carrying the leucine zipper domain of Fos, GCN4 or EB1 fail to transform CEF. The leucine zipper of Fos mediates only heterodimerization; it cannot homodimerize. In contrast, the leucine zippers of GCN4 and of EB1 exclusively homodimerize and do not form dimers with other bZip proteins. The results with the JDP2 chimeras suggest that the JDP2 homodimer and the JDP2/Jun heterodimer (or other bZip heterodimers formed with the Fos leucine zipper) are nontransforming, leaving as possible transforming combination the JDP2/Fos heterodimer. The unexpected transforming activity of a negative regulator of TRE- and CRE-dependent transcription raises an important question concerning the mechanisms of transformation by the related bZIP proteins Jun and Fos that address the same target sequences.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Technion Israel Inst Technol, IL-31096 Haifa, Israel	Scripps Research Institute; Technion Israel Institute of Technology	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	pkvogt@scripps.edu	Vogt, Peter K./R-7547-2019; Aoki, Masahiro/A-5149-2016	Vogt, Peter K./0000-0002-4519-7500; Aoki, Masahiro/0000-0003-4316-9490; Aronheim, Ami/0000-0002-8575-4092				Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; Broder YC, 1998, CURR BIOL, V8, P1121, DOI 10.1016/S0960-9822(98)70467-1; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1993, ONCOGENE, V8, P877; Cohen SB, 2001, ONCOGENE, V20, P141, DOI 10.1038/sj.onc.1204077; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gao MH, 1996, CANCER RES, V56, P4229; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; HWANG HC, 2002, P NATL ACAD SCI USA, V31, P31; Jin CY, 2002, MOL CELL BIOL, V22, P4815, DOI 10.1128/MCB.22.13.4815-4826.2002; Jin CY, 2001, FEBS LETT, V489, P34, DOI 10.1016/S0014-5793(00)02387-5; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Kataoka K, 2001, J BIOL CHEM, V276, P36849, DOI 10.1074/jbc.M102234200; Kataoka K, 1996, ONCOGENE, V12, P53; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; MORGAN IM, 1992, ONCOGENE, V7, P1119; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Perez S, 2001, ONCOGENE, V20, P1135, DOI 10.1038/sj.onc.1204200; Piu F, 2001, MOL CELL BIOL, V21, P3012, DOI 10.1128/MCB.21.9.3012-3024.2001; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vasanwala FH, 2002, J IMMUNOL, V169, P1922, DOI 10.4049/jimmunol.169.4.1922; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Vogt PK, 2002, NAT REV CANCER, V2, P465, DOI 10.1038/nrc818; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198	38	24	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2151	2159		10.1038/sj.onc.1206312	http://dx.doi.org/10.1038/sj.onc.1206312			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687017				2022-12-17	WOS:000182066900009
J	Wang, HM; Chakrabarty, S				Wang, HM; Chakrabarty, S			Platelet-activating factor activates mitogen-activated protein kinases, inhibits proliferation, induces differentiation and suppresses the malignant phenotype of human colon carcinoma cells	ONCOGENE			English	Article						PAF; colon; carcinomas	METHOXY HEXADECYL GLYCEROL; EPIDERMAL GROWTH-FACTOR; FACTOR-RECEPTOR; C-ALPHA; EXPRESSION; PAF; SECRETION	Recent studies suggest that the action of platelet-activating factor (PAF), a potent phospholipid modulator of allergic and inflammatory reactions, is diverse and functions as a modulator of a variety of physiological and pathological events in many cell types and tissues. Its role (if any) in modulating the proliferation, transformation and/or differentiation of epithelial colonic cells, however, is not known. In this study, we showed that PAF is biologically active in epithelial-derived human colon carcinoma cells with different phenotypic properties. These cells expressed the PAF receptor. PAF activated three prominent mitogen-activated protein kinase modules (ERK, p38MAPK and Jun N-terminal kinases) in these cells, inhibited proliferation and induced differentiation (measured by the induction of Waf1/p21 and the induction of the differentiation-related marker CEA). The net effect of PAF treatment was the suppression of malignant cell behavior (measured by anchorage-independent growth and cellular invasion). It is concluded that PAF is a modulator of proliferation and differentiation in human epithelial-derived colon carcinoma cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, DIv Pathol & Lab Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Chakrabarty, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, DIv Pathol & Lab Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.							Bazan HEP, 1997, J OCUL PHARMACOL TH, V13, P277, DOI 10.1089/jop.1997.13.277; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; Chakrabarty S, 1998, LAB INVEST, V78, P413; CHAKRABARTY S, 1988, CANCER RES, V48, P4059; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; GUADAGNI F, 1990, CANCER RES, V50, P6248; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HUANG S, 1992, INT J CANCER, V52, P978, DOI 10.1002/ijc.2910520625; Kume K, 1997, J BIOL CHEM, V272, P22898, DOI 10.1074/jbc.272.36.22898; KUNZ D, 1992, J BIOL CHEM, V267, P9101; Marques SA, 2002, J PHARMACOL EXP THER, V300, P1026, DOI 10.1124/jpet.300.3.1026; Mukherjee PK, 1999, J BIOL CHEM, V274, P6493, DOI 10.1074/jbc.274.10.6493; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Reynolds S, 1998, CANCER LETT, V134, P53, DOI 10.1016/S0304-3835(98)00242-0; Reynolds S, 2000, CLIN EXP METASTAS, V18, P309, DOI 10.1023/A:1011071907047; SAITO H, 1992, J LIPID MEDIATOR, V5, P135; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCHROY PC, 1994, J CELL PHYSIOL, V161, P111, DOI 10.1002/jcp.1041610114; Shimada A, 1998, J INVEST DERMATOL, V110, P889, DOI 10.1046/j.1523-1747.1998.00202.x; SMITH CS, 1994, CELL IMMUNOL, V155, P292, DOI 10.1006/cimm.1994.1123; Sperber K, 1998, INFLAMM BOWEL DIS, V4, P12, DOI 10.1097/00054725-199802000-00003; STOLL LL, 1991, J CELL SCI, V100, P145; Sugano T, 2001, MOL HUM REPROD, V7, P475, DOI 10.1093/molehr/7.5.475; Tokutomi T, 2001, NEUROL RES, V23, P605, DOI 10.1179/016164101101199081; Wang H, 1999, J CELL PHYSIOL, V178, P173, DOI 10.1002/(SICI)1097-4652(199902)178:2<173::AID-JCP6>3.3.CO;2-H; Wang HM, 2001, J CELL PHYSIOL, V187, P188, DOI 10.1002/jcp.1068	26	24	25	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2003	22	14					2186	2191		10.1038/sj.onc.1206348	http://dx.doi.org/10.1038/sj.onc.1206348			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687020				2022-12-17	WOS:000182066900012
J	Murray, SA; Zheng, HW; Gu, L; Xiao, ZXJ				Murray, SA; Zheng, HW; Gu, L; Xiao, ZXJ			IGF-1 activates p21 to inhibit UV-induced cell death	ONCOGENE			English	Article						IGF-1; Akt; p53; p21; UV and apoptosis	SERINE-THREONINE KINASE; MYC-INDUCED APOPTOSIS; NF-KAPPA-B; P53-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR; CANCER-CELLS; TRANSCRIPTION FACTOR; GROWTH-FACTORS; DNA-DAMAGE; P53	The insulin-like growth factor-1 (IGF-1) and its downstream effector Akt have been documented as survival factors in response to a variety of stress signals. In this study, we show that IGF-1 activates p21 protein expression in a p53-dependent manner. Inhibition of PI-3 kinase or ectopic expression of a dominant-negative Akt blocks the effect of IGF-1 on the upregulation of p21 expression. In addition, IGF-1 prevents the UV irradiation-mediated suppression of p21 and MDM2 expression. Furthermore, p21 is important for IGF-1-mediated cell survival upon UV irradiation. Taken together, these data indicate that IGF-1 may activate p21 in executing its survival function upon genotoxic insults.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	Boston University; Boston University	Xiao, ZXJ (corresponding author), Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.	jxiao@bu.edu		Zheng, Hongwu/0000-0002-5823-4913	NATIONAL CANCER INSTITUTE [R01CA079804] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA79804] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carter CS, 2002, TRENDS GENET, V18, P295, DOI 10.1016/S0168-9525(02)02696-3; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; GEIER A, 1995, CANCER INVEST, V13, P480, DOI 10.3109/07357909509024911; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Lawlor MA, 2000, J CELL BIOL, V151, P1131, DOI 10.1083/jcb.151.6.1131; Lawrence JW, 2001, J BIOL CHEM, V276, P31521, DOI 10.1074/jbc.M103306200; Lu X, 1996, ONCOGENE, V13, P413; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Ozes ON, 1999, NATURE, V401, P82; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; ROSSIG L, 2002, J BIOL CHEM, V4, P4; Sandhu MS, 2002, J NATL CANCER I, V94, P972; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shimoke K, 1999, DEV BRAIN RES, V112, P245, DOI 10.1016/S0165-3806(98)00172-2; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Xu SQ, 2000, BIOCHEM BIOPH RES CO, V269, P179, DOI 10.1006/bbrc.2000.2247; Zeng XY, 2000, CANCER RES, V60, P6184; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	67	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2003	22	11					1703	1711		10.1038/sj.onc.1206327	http://dx.doi.org/10.1038/sj.onc.1206327			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642873				2022-12-17	WOS:000181580500012
J	Borrmann, L; Seebeck, B; Rogalla, P; Bullerdiek, J				Borrmann, L; Seebeck, B; Rogalla, P; Bullerdiek, J			Human HMGA2 promoter is coregulated by a polymorphic dinucleotide (TC)-repeat	ONCOGENE			English	Article						high-mobility group proteins; HMGA; promoter analysis; cancer; obesity; arteriosclerosis	I-C GENE; TRANSCRIPTION FACTORS; MESENCHYMAL TUMORS; H-DNA; EXPRESSION; ELEMENT; TRIPLEX; REARRANGEMENTS; LIPOMAS; VIVO	HMGA proteins are thought to be causally involved in the progression of different diseases, including benign and malignant tumors, obesity, arteriosclerosis, and restenosis. As HMGA proteins are architectural transcription factors, their binding to DNA leads to changes in DNA-conformation modulating the environment for the assembly and function of transcriptional complexes, thus influencing the expression of a huge variety of genes. Despite the emerging role of HMGA proteins for important diseases, only limited information is available about mechanisms regulating the expression of the HMGA2 gene. In this report, 2240bp of the 5' flanking region of the HMGA2 gene were functionally analyzed by luciferase assay experiments. Besides the identification of novel positive and negative regulatory elements, it was shown that transcription is initiated from two independent promoter regions within cell lines HeLa, MCF7, and L14(TSV40). Furthermore, a functional polymorphic dinucleotide repeat (TCTCT(TC)(n)) 500 bp upstream of the ATG translational start codon was found to regulate strongly the human HMGA2 promoter with an activation pattern that correlates to its TC-repeat length.	Univ Bremen, Ctr Human Genet, D-28359 Bremen, Germany	University of Bremen	Bullerdiek, J (corresponding author), Univ Bremen, Ctr Human Genet, Leobenerstr ZHG, D-28359 Bremen, Germany.							Anand A, 2000, NAT GENET, V24, P377, DOI 10.1038/74207; ASHAR HR, 1995, CELL, V82, P57; Ashar HR, 1996, GENOMICS, V31, P207, DOI 10.1006/geno.1996.0033; Ayoubi TAY, 1999, ONCOGENE, V18, P5076, DOI 10.1038/sj.onc.1202881; Battista S, 1999, CANCER RES, V59, P4793; Borrmann L, 2001, ONCOGENE, V20, P4537, DOI 10.1038/sj.onc.1204577; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Chau KY, 1999, FEBS LETT, V457, P429, DOI 10.1016/S0014-5793(99)01100-X; CHAU KY, 1995, NUCLEIC ACIDS RES, V23, P4262, DOI 10.1093/nar/23.21.4262; Chiappetta G, 1996, ONCOGENE, V13, P2439; Chin MT, 1999, J MOL CELL CARDIOL, V31, P2199, DOI 10.1006/jmcc.1999.1054; Espinas ML, 1996, J BIOL CHEM, V271, P31807, DOI 10.1074/jbc.271.50.31807; FIRULLI AB, 1994, ARCH BIOCHEM BIOPHYS, V310, P236, DOI 10.1006/abbi.1994.1162; Hirning-Folz U, 1998, GENE CHROMOSOME CANC, V23, P350, DOI 10.1002/(SICI)1098-2264(199812)23:4<350::AID-GCC10>3.0.CO;2-E; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; Ishwad CS, 1997, HUM GENET, V99, P103; Kazmierczak B, 1996, ONCOGENE, V12, P515; Kim HG, 1998, BIOCHEMISTRY-US, V37, P2299, DOI 10.1021/bi9718191; LU Q, 1993, MOL CELL BIOL, V13, P2802, DOI 10.1128/MCB.13.5.2802; MEILAHN EN, 1989, MATURITAS, V11, P319, DOI 10.1016/0378-5122(89)90028-5; MICHEL D, 1992, NUCLEIC ACIDS RES, V20, P439, DOI 10.1093/nar/20.3.439; PATEL UA, 1994, BIOCHEM BIOPH RES CO, V201, P63, DOI 10.1006/bbrc.1994.1669; Rogalla P, 1996, AM J PATHOL, V149, P775; Rustighi A, 2002, BIOCHEMISTRY-US, V41, P1229, DOI 10.1021/bi011666o; Rustighi A, 1999, BIOCHEM BIOPH RES CO, V265, P439, DOI 10.1006/bbrc.1999.1680; Scala S, 2000, P NATL ACAD SCI USA, V97, P4256, DOI 10.1073/pnas.070029997; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; Tamimi Y, 1996, BRIT J CANCER, V74, P573, DOI 10.1038/bjc.1996.403; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	31	24	26	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					756	760		10.1038/sj.onc.1206073	http://dx.doi.org/10.1038/sj.onc.1206073			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569368				2022-12-17	WOS:000180642100013
J	Routhier, EL; Donover, PS; Prendergast, GC				Routhier, EL; Donover, PS; Prendergast, GC			hob1+, the fission yeast homolog of Bin1, is dispensable for endocytosis or actin organization, but required for the response to starvation or genotoxic stress	ONCOGENE			English	Article						amphiphysin; Rvs167; endocytosis; Myc; cell cycle; DNA damage	CYCLIN-DEPENDENT KINASE-5; MYC-INTERACTING PROTEIN; TUMOR-SUPPRESSOR BIN1; APOPTOTIC CELL-DEATH; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; AMPHIPHYSIN ISOFORM; ASTROCYTOMA-CELLS; SPLICE VARIANTS; GENE	BAR (Bin/Amphiphysin/Rvs) adapter proteins have been suggested to regulate endocytosis, actin organization, apoptosis, and transcription, but their precise roles are obscure. There are at least five mammalian genes that encode BAR adapter proteins, including the evolutionarily conserved and ubiquitously expressed Bin1/Amphiphysin-II and Bin3 genes. Bin1 holds special interest as certain splice isoforms localize to the nucleus, interact with the c-Ab1 and c-Myc oncoproteins, and display tumor suppressor properties. To obtain functional insights, we embarked upon a genetic analysis of the two BAR adapter proteins expressed in the fission yeast Schizosaccharomyces pombe. In a previous work, a role in actin organization and cytokinesis was identified for the Bin3 homolog hob3+. In this study, a role in stress signaling was defined for the Bin1 homolog, hob1 +. Notably, hoh1 + was dispensable for endocytosis, actin organization, or osmotic sensitivity. Instead, mutation of hob1 + led to slight cell elongation and faulty cell cycle arrest upon nutrient starvation. These defects were complemented by Bin1, but not by Amphiphyrsin-I, arguing that these genes have distinct functions despite their structural similarity. hob1 A mutant cells were also hypersensitive to genotoxic stress. This was not related to faulty checkpoint response, but mutation in the checkpoint gene rad3(+) further exacerbated the sensitivity of hob1Delta mutant cells. Interestingly, mutation of the cell cycle regulator wee1(+) partially relieved the sensitivity defect, suggesting that hob1 + may influence the efficiency of DNA repair or checkpoint release after DNA damage. Genetic and biochemical evidence indicated that hob3 + is epistatic to hob1 + in the response to genotoxic stress. Our findings indicate that the Bin1 homolog hob1 + participates in DNA damage signaling and they suggest a novel role for BAR adapter proteins in stress response processes.	Lankenau Inst Med Res, Wynnewood, PA 19096 USA; DuPont Pharmaceut Co, Glenolden Lab, Canc Res Grp, Glenolden, PA 19036 USA	Lankenau Medical Center; Lankenau Institute for Medical Research; DuPont	Prendergast, GC (corresponding author), Lankenau Inst Med Res, 100 Lancaster Ave, Wynnewood, PA 19096 USA.	prendergastg@mlhs.org						Ahuja HS, 1997, DEV GENET, V21, P258, DOI 10.1002/(SICI)1520-6408(1997)21:4<258::AID-DVG3>3.0.CO;2-6; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Balguerie A, 1999, J CELL SCI, V112, P2529; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; Brazer SCW, 2000, YEAST, V16, P149, DOI 10.1002/(SICI)1097-0061(20000130)16:2<149::AID-YEA514>3.0.CO;2-C; Breeding CS, 1998, MOL BIOL CELL, V9, P3399, DOI 10.1091/mbc.9.12.3399; Breton AM, 1998, CURR GENET, V34, P280, DOI 10.1007/s002940050397; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; Colwill K, 1999, GENETICS, V152, P881; CROUZET M, 1991, YEAST, V7, P727, DOI 10.1002/yea.320070708; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DuHadaway JB, 2001, CANCER RES, V61, P3151; Elliott K, 2000, ONCOGENE, V19, P4669, DOI 10.1038/sj.onc.1203681; FANTES P, 1977, EXP CELL RES, V107, P377, DOI 10.1016/0014-4827(77)90359-7; Galderisi U, 1999, J CELL BIOCHEM, V74, P313, DOI 10.1002/(SICI)1097-4644(19990901)74:3<313::AID-JCB1>3.3.CO;2-Q; Gao C, 2001, J CELL SCI, V114, P1145; Ge K, 2000, INT J CANCER, V86, P155, DOI 10.1002/(SICI)1097-0215(20000415)86:2<155::AID-IJC2>3.0.CO;2-M; Ge K, 1999, P NATL ACAD SCI USA, V96, P9689, DOI 10.1073/pnas.96.17.9689; Ge K, 2000, INT J CANCER, V85, P376; Ge K, 2000, GENOMICS, V67, P210, DOI 10.1006/geno.2000.6216; Hogarty MD, 2000, MED PEDIATR ONCOL, V35, P559, DOI 10.1002/1096-911X(20001201)35:6<559::AID-MPO14>3.3.CO;2-A; Huang DQ, 1999, P NATL ACAD SCI USA, V96, P14445, DOI 10.1073/pnas.96.25.14445; Kanoh J, 1998, MOL BIOL CELL, V9, P3321, DOI 10.1091/mbc.9.12.3321; Lee J, 1998, CURR BIOL, V8, P1310, DOI 10.1016/S0960-9822(07)00561-1; Li FQ, 2000, MOL CELL BIOL, V20, P5129, DOI 10.1128/MCB.20.14.5129-5139.2000; Lila T, 1997, MOL BIOL CELL, V8, P367, DOI 10.1091/mbc.8.2.367; Mao NC, 1999, GENOMICS, V56, P51, DOI 10.1006/geno.1998.5709; MARKS J, 1986, J CELL SCI, P229; Matsumoto T, 1997, MOL CELL BIOL, V17, P742, DOI 10.1128/MCB.17.2.742; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Pelloquin L, 1999, FEBS LETT, V443, P71, DOI 10.1016/S0014-5793(98)01682-2; PRAMANIK A, 1995, CELL MOL BIOL, V41, pS73; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; Routhier EL, 2001, J BIOL CHEM, V276, P21670, DOI 10.1074/jbc.M101096200; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; SAZER S, 1990, J CELL SCI, V97, P509; SIVADON P, 1995, MOL GEN GENET, V246, P485, DOI 10.1007/BF00290452; Tsutsui K, 1997, BIOCHEM BIOPH RES CO, V236, P178, DOI 10.1006/bbrc.1997.6927; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Wechsler-Reya RJ, 1998, MOL CELL BIOL, V18, P566, DOI 10.1128/MCB.18.1.566; WechslerReya R, 1997, J BIOL CHEM, V272, P31453, DOI 10.1074/jbc.272.50.31453; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; Yin MB, 1999, INT J CANCER, V83, P341, DOI 10.1002/(SICI)1097-0215(19991029)83:3<341::AID-IJC9>3.0.CO;2-3; Zhang Q, 1997, DEV BIOL, V183, P222, DOI 10.1006/dbio.1996.8494	51	24	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2003	22	5					637	648		10.1038/sj.onc.1206162	http://dx.doi.org/10.1038/sj.onc.1206162			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569356				2022-12-17	WOS:000180642100001
J	Bachelier, R; Xu, XL; Wang, XY; Li, WM; Naramura, M; Gu, H; Deng, CX				Bachelier, R; Xu, XL; Wang, XY; Li, WM; Naramura, M; Gu, H; Deng, CX			Normal lymphocyte development and thymic lymphoma formation in Brca1 exon-11-deficient mice	ONCOGENE			English	Article						T-lymphoma; Brca1; p53; tumorigenesis	DNA-DAMAGE RESPONSE; DOUBLE-STRAND BREAKS; MAMMARY EPITHELIAL-CELLS; MURINE BRCA1; CANCER SUSCEPTIBILITY; SUBCELLULAR-LOCALIZATION; ATAXIA-TELANGIECTASIA; CHROMOSOME STABILITY; GENETIC INSTABILITY; REPAIR	Breast-cancer-associated gene 1 (BRCA1) is highly expressed in thymus and spleen. In this paper, we have studied lymphocyte development and tumorigenesis in mice carrying mutations in Brca1 and p53. We show that the deletion of Brca1 exon 11 (Brca1-Delta11), which disrupts the full-length isoform, but not the short isoform of Brcal, does not interfere with lymphocyte development. This is true irrespective of p53 status, that is, whether it is wild type, heterozygous or homozygous for a null mutation. These data suggest that the expression of Brcal short isoform alone is enough to maintain normal development of lymphocytes. However, it cannot suppress tumorigenesis as about 30% of Brca1(Delta11/Delta11)p53(+/-) mice develop thymic lymphoma between 3 and 7 months of age. We demonstrate that p53 plays an essential role in Brca1-associated lymphoma, as all the tumors from Brca1(Delta11/Delta11)p53(+/-) mice exhibit LOH of p53 and Brca1(Delta11/Delta)11p53(-/-) mice exhibited accelerated tumorigenesis. We further demonstrate that the Brca1-Delta11 deficiency does not affect thymocyte proliferation; however, it increases genetic instability and triggers gamma-irradiation-induced apoptosis. The loss of p53 attenuates apoptosis and allows accumulation of further mutations in Brca1-Delta11 thymocytes, eventually leading to thymic lymphoma formation.	NIDDK, Genet Dev & Dis Branch, Lab Immunol, Bethesda, MD 20892 USA; NIAID, Lab Immunol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Deng, CX (corresponding author), NIDDK, Genet Dev & Dis Branch, Lab Immunol, 10-9N105,10 Ctr Dr, Bethesda, MD 20892 USA.		deng, chuxia/N-6713-2016	Naramura, Mayumi/0000-0003-3658-0767	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056001, ZIADK056001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Bachelier R, 2000, INT J CANCER, V88, P519, DOI 10.1002/1097-0215(20001115)88:4<519::AID-IJC2>3.0.CO;2-R; Baldeyron C, 2002, ONCOGENE, V21, P1401, DOI 10.1038/sj.onc.1205200; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brodie S G, 2001, Trends Genet, V17, pS18, DOI 10.1016/S0168-9525(01)02451-9; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Brodie SG, 2001, ONCOGENE, V20, P1445, DOI 10.1038/sj.onc.1204222; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chen JJ, 1999, CANCER RES, V59, p1752S; Chen YM, 1996, CANCER RES, V56, P3168; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Deng CX, 2000, BIOESSAYS, V22, P728; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EASTON DF, 1995, AM J HUM GENET, V56, P265; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Elliott B, 2002, CELL MOL LIFE SCI, V59, P373, DOI 10.1007/s00018-002-8429-3; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; GRETZULA JC, 1987, J AM ACAD DERMATOL, V17, P479, DOI 10.1016/S0190-9622(87)70233-3; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953; Huang JR, 2002, NUCLEIC ACIDS RES, V30, P667, DOI 10.1093/nar/30.3.667; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kuschel B, 2001, GENE CHROMOSOME CANC, V31, P96, DOI 10.1002/gcc.1122; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Lu ML, 2000, ONCOGENE, V19, P6351, DOI 10.1038/sj.onc.1204025; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Mak TW, 2000, NAT IMMUNOL, V1, P77, DOI 10.1038/76950; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Moynahan ME, 2001, CANCER RES, V61, P4842; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; SHARAN SK, 1995, HUM MOL GENET, V4, P2275, DOI 10.1093/hmg/4.12.2275; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang Q, 2001, ONCOGENE, V20, P4640, DOI 10.1038/sj.onc.1204625; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Zhong Q, 2002, J BIOL CHEM, V277, P28641, DOI 10.1074/jbc.M200748200; Zhong Q, 2002, CANCER RES, V62, P3966; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	66	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					528	537		10.1038/sj.onc.1206208	http://dx.doi.org/10.1038/sj.onc.1206208			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555066				2022-12-17	WOS:000180538200006
J	Li, WJ; Hu, N; Su, F; Wang, CY; Goldstein, AM; Wang, Y; Emmert-Buck, MR; Roth, MJ; Guo, WJ; Taylor, PR				Li, WJ; Hu, N; Su, F; Wang, CY; Goldstein, AM; Wang, Y; Emmert-Buck, MR; Roth, MJ; Guo, WJ; Taylor, PR			Allelic loss on chromosome 13q14 and mutation in deleted in cancer 1 gene in esophageal squamous cell carcinoma	ONCOGENE			English	Article						DICE1; LOH; SSCP; mutation; polymorphism; esophagus	TUMOR-SUPPRESSOR GENES; SUSCEPTIBILITY GENE; HETEROZYGOSITY; IDENTIFICATION; CHINA; POPULATION; REGIONS	Previous studies have shown frequent allelic loss on chromosome 13 in esophageal squamous cell carcinoma (ESCC). We assessed the frequency of allelic loss on chromosome 13q14 and mutations of deleted in cancer 1 (DICE1) (also found on 13q14) in ESCC patients to determine if this candidate tumor suppressor gene has a role in the development of ESCC, and whether this gene was an inactivation target for allelic loss on chromosome 13q14. Initially, we examined allelic loss at five markers flanking DICE1 in 56 ESCC patients from Shanxi Province, China, and then examined the entire coding sequence of this gene for mutations using polymerase chain reaction-single-strand confirmation polymorphism (PCR-SSCP) analysis and DNA sequencing. Subsequently, we extended our evaluation to an additional 80 ESCC patients and 232 healthy individuals to confirm the germline variant found in the initial 56 ESCC patients. The frequencies of allelic loss were 71, 58, and 75% for D13S325, D13S757, and D13S887, respectively, in the initial 56 ESCC patients studied. Overall, 73% of informative patients had loss of heterozygosity (LOH) for at least one of these three markers. Somatic mutations were identified in three patients (3/56, 5%), and one novel polymorphism was identified in 3% of ESCC patients (4/ 136) and 3% of healthy individuals (6/232). We conclude that DICE1 mutations occur in ESCC but are infrequent. The candidate tumor suppressor gene corresponding to the frequent allelic loss on chromosome 13q14 in ESCC remains unknown.	NCI, Canc Prevent Studies Branch, Ctr Canc Res, Bethesda, MD 20892 USA; Shanxi Canc Hosp & Inst, Taiyuan 030013, Shanxi, Peoples R China; NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Taylor, PR (corresponding author), NCI, Canc Prevent Studies Branch, Ctr Canc Res, 6116 Execut Blvd,Suite 705, Bethesda, MD 20892 USA.							BOYNTON RF, 1991, CANCER RES, V51, P5766; Eiriksdottir G, 1998, EUR J CANCER, V34, P2076, DOI 10.1016/S0959-8049(98)00241-X; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Hu N, 1999, CLIN CANCER RES, V5, P3476; Hu N, 2002, CLIN CANCER RES, V8, P1121; Hu N, 2001, CLIN CANCER RES, V7, P883; HU N, 1992, INT J EPIDEMIOL, V21, P877, DOI 10.1093/ije/21.5.877; Hu N, 2000, GENE CHROMOSOME CANC, V27, P217, DOI 10.1002/(SICI)1098-2264(200003)27:3<217::AID-GCC1>3.0.CO;2-A; Huang J, 2000, CARCINOGENESIS, V21, P2019, DOI 10.1093/carcin/21.11.2019; HUANG Y, 1992, CANCER RES, V52, P6525; Hyytinen ER, 1999, GENE CHROMOSOME CANC, V25, P108, DOI 10.1002/(SICI)1098-2264(199906)25:2<108::AID-GCC6>3.0.CO;2-Y; KUROKI T, 1995, BRIT J CANCER, V72, P383, DOI 10.1038/bjc.1995.342; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Li G, 2001, GENE CHROMOSOME CANC, V31, P390, DOI 10.1002/gcc.1158; MACGEE TL, 1989, GENE, V80, P119; MAESAWA C, 1994, INT J CANCER, V57, P21, DOI 10.1002/ijc.2910570105; Montesano R, 1996, INT J CANCER, V69, P225, DOI 10.1002/(SICI)1097-0215(19960621)69:3<225::AID-IJC13>3.0.CO;2-6; Wieland I, 1999, ONCOGENE, V18, P4530, DOI 10.1038/sj.onc.1202806; Wieland I, 2001, ONCOL RES, V12, P491, DOI 10.3727/096504001108747503; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	20	24	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					314	318		10.1038/sj.onc.1206098	http://dx.doi.org/10.1038/sj.onc.1206098			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527901				2022-12-17	WOS:000180322400017
J	Jishage, M; Fujino, T; Yamazaki, Y; Kuroda, H; Nakamura, T				Jishage, M; Fujino, T; Yamazaki, Y; Kuroda, H; Nakamura, T			Identification of target genes for EWS/ATF-1 chimeric transcription factor	ONCOGENE			English	Article						clear cell sarcoma; EWS/ATF-1; transcription factor; target gene; POSH	RNA-POLYMERASE-II; CHROMOSOME-TRANSLOCATION; MALIGNANT-MELANOMA; HOMEOBOX GENES; SOFT PARTS; ATAXIA-TELANGIECTASIA; DNA-BINDING; FUSION; EWS; RECEPTOR	Chromatin immunoprecipitation is a useful technique to detect in vivo direct interaction between any transcription factor and its binding site on genomic DNA. We applied this skill to identify the direct target gene for EWS/ATF-1 by coupling with a GFP reporter assay. This novel approach isolated 62 of cloned DNA fragments responding upon EWS/ATF-1 expression and 16 of 62 clones included putative ATF-1 binding sites. Further analysis revealed that six of the cloned fragments included possible regulatory regions of ATM, GPP34, ARNT2, NKX6.1, NYD-SP28 and POSH. Most of these clones upregulated reporter activity by overexpression of EWS/ATF-1, suggesting that putative ATF-1 binding sites in these clones are functional elements for ATF-1 in vivo. Consistently, endogenous expression of these genes was upregulated by EWS/ATF-1. Interestingly, the clone containing the promoter region of POSH, which is known to be a strong inducer of apoptosis, repressed reporter activity by overexpression of EWS/ATF-1. Correspondingly, EWS/ATF-1 expression decreased endogenous POSH expression, suggesting that six isolated genes may be involved in direct regulation by EWS/ATF-1. Moreover, induction of POSH brought apoptotic cell death to KAS, the clear cell sarcoma (CCS) cell line, suggesting that repressed expression of POSH in CCS may be relevant to the normal signaling pathway in apoptosis.	Japanese Fdn Canc Res, Inst Canc, Dept Carcinogenesis, Toshima Ku, Tokyo 1708455, Japan; Tokyo Med & Dent Univ, Dept Orthoped, Fac Med, Tokyo 1130034, Japan	Japanese Foundation for Cancer Research; Tokyo Medical & Dental University (TMDU)	Nakamura, T (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Carcinogenesis, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.			Fujino, Takashi/0000-0002-0953-7379				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bell AW, 2001, J BIOL CHEM, V276, P5152, DOI 10.1074/jbc.M006143200; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; BROWN AD, 1995, ONCOGENE, V10, P1749; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; ENZINGER FM, 1995, SOFT TISSUE TUMORS, P889; Fujimura Y, 1996, ONCOGENE, V12, P159; Fujino T, 2001, EXP HEMATOL, V29, P856, DOI 10.1016/S0301-472X(01)00655-5; Gueven N, 2001, J BIOL CHEM, V276, P8884, DOI 10.1074/jbc.M006190200; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hirose K, 1996, MOL CELL BIOL, V16, P1706; JACOBS Y, 1993, MOL CELL BIOL, V13, P7321, DOI 10.1128/MCB.13.12.7321; Jean D, 2000, ONCOGENE, V19, P2721, DOI 10.1038/sj.onc.1203569; KUO MH, 1996, METHODS, V3, P425; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1994, CANCER RES, V54, P2837; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Macaulay VM, 2001, ONCOGENE, V20, P4029, DOI 10.1038/sj.onc.1204565; Maltepe E, 2000, BIOCHEM BIOPH RES CO, V273, P231, DOI 10.1006/bbrc.2000.2928; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; OHNO T, 1994, ONCOGENE, V9, P3087; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Panagopoulos I, 1996, ONCOGENE, V12, P489; Rossow KL, 2001, CANCER RES, V61, P2690; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; RUDNICK A, 1994, P NATL ACAD SCI USA, V91, P12203, DOI 10.1073/pnas.91.25.12203; Sander M, 2000, GENE DEV, V14, P2134, DOI 10.1101/gad.820400; Schaefer KL, 2002, VIRCHOWS ARCH, V440, P476, DOI 10.1007/s00428-001-0558-9; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Watson D K, 2000, Methods Mol Biol, V130, P1; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	40	24	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					41	49		10.1038/sj.onc.1206074	http://dx.doi.org/10.1038/sj.onc.1206074			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527906				2022-12-17	WOS:000180166900005
J	Fukasawa, K				Fukasawa, K			Centrosome - Introduction	ONCOGENE			English	Editorial Material						centrosome; cancer; chromosome instability	P53; INSTABILITY; ORGANIZATION; TUMORS; MICE		Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA	University of Cincinnati	Fukasawa, K (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, 3125 Eden Ave,POB 670521, Cincinnati, OH 45267 USA.							Boveri T., 1914, FRAGE ENTSTEHUNG MAL; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Pihan GA, 1998, CANCER RES, V58, P3974; SCHATTEN H, 1986, CELL MOTIL CYTOSKEL, V6, P163, DOI 10.1002/cm.970060215; VOROBJEV IA, 1987, INT REV CYTOL, V106, P227, DOI 10.1016/S0074-7696(08)61714-3; Wang XJ, 1998, ONCOGENE, V17, P35, DOI 10.1038/sj.onc.1201890	11	24	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	2002	21	40					6140	6145		10.1038/sj.onc.1205771	http://dx.doi.org/10.1038/sj.onc.1205771			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214242				2022-12-17	WOS:000177840500001
J	Masutomi, K; Kaneko, S; Yasukawa, M; Arai, K; Murakami, S; Kobayashi, K				Masutomi, K; Kaneko, S; Yasukawa, M; Arai, K; Murakami, S; Kobayashi, K			Identification of serum anti-human telomerase reverse transcriptase (hTERT) auto-antibodies during progression to hepatocellular carcinoma	ONCOGENE			English	Article						human telomerase reverse transcriptase; auto-antigen; hepatocellular carcinoma	CHRONIC LIVER-DISEASE; CELLS; CANCER; AUTOANTIBODIES; MALIGNANCIES; BREAST	Human telomerase reverse transcriptase, hTERT, is the catalytic component of human telomerase. Expression of hTERT confers telomerase activity, indicating that hTERT is the rate-limiting component of human telomerase. Here we report the detection of anti-hTERT auto-antibodies in the sera derived patients with hepatocellular carcinoma using recombinant, purified hTERT as an antigen in an enzyme linked immunosorbent assay (ELISA). The levels of anti-hTERT antibodies in serum correlated with progression to hepatocellular carcinoma. In contrast, we detected only low levels of anti-hTERT auto-antibodies in the sera derived from 18 normal volunteers. The observation of hTERT auto-antibodies in the sera derived from cancer patients suggests that such auto-antibodies constitute novel and specific tumor marker.	Kanazawa Univ, Grad Sch Med, Dept Gastroenterol, Kanazawa, Ishikawa 9208641, Japan; Kanazawa Univ, Grad Sch Med, Dept Biol Mol, Div Mol Oncol,Canc Res Inst, Kanazawa, Ishikawa 9208641, Japan	Kanazawa University; Kanazawa University	Kaneko, S (corresponding author), Kanazawa Univ, Grad Sch Med, Dept Gastroenterol, Takara Machi 13-1, Kanazawa, Ishikawa 9208641, Japan.							Arai K, 2002, J BIOL CHEM, V277, P8538, DOI 10.1074/jbc.M111068200; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Covini G, 1997, HEPATOLOGY, V25, P75; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hiyama E, 2002, ONCOGENE, V21, P643, DOI 10.1038/sj.onc.1205070; IMAI H, 1992, AM J PATHOL, V140, P859; IMAI H, 1993, J CLIN INVEST, V92, P2419, DOI 10.1172/JCI116848; IMAI H, 1993, CANCER-AM CANCER SOC, V71, P26, DOI 10.1002/1097-0142(19930101)71:1<26::AID-CNCR2820710106>3.0.CO;2-N; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kitamoto M, 1999, CANCER, V85, P245, DOI 10.1002/(SICI)1097-0142(19990101)85:1<245::AID-CNCR37>3.0.CO;2-9; Kojima H, 1997, GASTROENTEROLOGY, V112, P493, DOI 10.1053/gast.1997.v112.pm9024303; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Masutomi K, 2000, J BIOL CHEM, V275, P22568, DOI 10.1074/jbc.M000622200; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; NELSON DS, 1977, PATHOLOGY, V9, P155, DOI 10.3109/00313027709085253; Nouso K, 1996, CANCER, V78, P232, DOI 10.1002/(SICI)1097-0142(19960715)78:2<232::AID-CNCR7>3.0.CO;2-N; Saeboe-Larssen S, 2002, J IMMUNOL METHODS, V259, P191, DOI 10.1016/S0022-1759(01)00506-3; SCHATTNER A, 1983, CANCER-AM CANCER SOC, V52, P2156, DOI 10.1002/1097-0142(19831201)52:11<2156::AID-CNCR2820521130>3.0.CO;2-2; Shay JW, 1996, TRENDS GENET, V12, P129, DOI 10.1016/0168-9525(96)30018-8; TAN EM, 1991, CELL, V67, P841, DOI 10.1016/0092-8674(91)90356-4; Treon SP, 2000, SEMIN ONCOL, V27, P598; Vonderheide RH, 2002, ONCOGENE, V21, P674, DOI 10.1038/sj.onc.1205074; Vonderheide RH, 2001, CANCER RES, V61, P8366; WASSERMAN J, 1975, CLIN EXP IMMUNOL, V19, P417; WINTER SF, 1992, CANCER RES, V52, P4168	26	24	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2002	21	38					5946	5950		10.1038/sj.onc.1205788	http://dx.doi.org/10.1038/sj.onc.1205788			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185596				2022-12-17	WOS:000177520900016
J	Wang, L; Rudert, WA; Loutaev, I; Roginskaya, V; Corey, SJ				Wang, L; Rudert, WA; Loutaev, I; Roginskaya, V; Corey, SJ			Repression of c-Cbl leads to enhanced G-CSF Jak-STAT signaling without increased cell proliferation	ONCOGENE			English	Article						Cbl; Jak; STAT; Lyn; G-CSF	COLONY-STIMULATING FACTOR; UBIQUITIN-PROTEIN LIGASES; SRC KINASE LYN; TYROSINE KINASE; FACTOR-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PROTOONCOGENE PRODUCT; NEGATIVE REGULATOR; ANTIGEN RECEPTOR; PHOSPHOINOSITIDE 3-KINASE	Engagement of the Granulocyte-Colony-Stimulating Factor (G-CSF) receptor activates non-receptor protein tyrosine kinases Lyn and Jak2. We found that Lyn-deficient DT40 cells that express the G-CSF receptor (DT40GR) do not demonstrate G-CSF-induced mitogenic signaling. Lyn associates with and phosphorylates a small set of molecules, including c-Cbl. c-Cbl is an adaptor involved in cell growth and cytoskeletal reorganization, predominantly in hematopoietic cells. Using yeast two-hybrid analysis, we found that c-Cbl directly couples Lyn to PI 3-kinase. We also found that expression of the c-CblY731F mutant, which uncouples PI 3-kinase, resulted in the inhibition of G-CSF-induced proliferative signaling in DT40GR cells. As a complementary strategy, we sought to analyse the effects of c-Cbl deficiency in DT40GR cells. We isolated, cloned and sequenced the full-length cDNA for chicken c-Cbl and constructed antisense vectors. Antisense inhibition of c-Cbl expression in DT40GR cells led to enhanced Jak-STAT activation following G-CSF stimulation. Yet, this enhancement of Jak-STAT activation was associated with decreased G-CSF-induced PI 3-kinase activity and DNA synthesis. PI 3-kinase activity correlated with DNA synthesis and physiological levels of c-Cbl. Together, these data suggest that physiologic level of c-Cbl provides a growth stimulatory pathway for G-CSF and that enhanced Jak-STAT activation is not sufficient for G-CSF-induced growth.	Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Div Hematol Oncol, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Corey, SJ (corresponding author), MD Anderson Canc Ctr, Dept Pediat, 1515 Holcombe Blvd, Houston, TX 77030 USA.							Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; Arron JR, 2001, J BIOL CHEM, V276, P30011, DOI 10.1074/jbc.M100414200; Avalos BR, 1996, BLOOD, V88, P761, DOI 10.1182/blood.V88.3.761.bloodjournal883761; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Corey SJ, 1998, J BIOL CHEM, V273, P3230, DOI 10.1074/jbc.273.6.3230; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DombroskyFerlan PM, 1997, ONCOGENE, V14, P2019, DOI 10.1038/sj.onc.1201031; Elly C, 1999, ONCOGENE, V18, P1147, DOI 10.1038/sj.onc.1202411; Erdreich-Epstein A, 1999, J LEUKOCYTE BIOL, V65, P523, DOI 10.1002/jlb.65.4.523; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Fang D, 2001, J BIOL CHEM, V276, P4872, DOI 10.1074/jbc.M008901200; FELESTEIN J, 1995, PHYLIP PHYLOGENY INF; Finkelstein LD, 2000, BIOCHEM J, V345, P385, DOI 10.1042/0264-6021:3450385; Garcia-Guzman M, 2000, ONCOGENE, V19, P4058, DOI 10.1038/sj.onc.1203750; Grishin A, 2000, ONCOGENE, V19, P97, DOI 10.1038/sj.onc.1203254; Hamilton E, 2001, J BIOL CHEM, V276, P9028, DOI 10.1074/jbc.M009386200; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; Hsueh RC, 2000, ADV IMMUNOL, V75, P283, DOI 10.1016/S0065-2776(00)75007-3; Ikeda M, 2000, VIROLOGY, V268, P178, DOI 10.1006/viro.1999.0166; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kawakami Y, 2000, J IMMUNOL, V165, P1210, DOI 10.4049/jimmunol.165.3.1210; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Kim M, 1999, GENE, V239, P145, DOI 10.1016/S0378-1119(99)00356-X; Lahti JM, 1999, METHODS, V17, P305, DOI 10.1006/meth.1999.0744; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Nishizumi H, 1998, J EXP MED, V187, P1343, DOI 10.1084/jem.187.8.1343; NISHIZUMI H, 1995, IMMUNITY, V3, P549, DOI 10.1016/1074-7613(95)90126-4; Oda H, 1999, P NATL ACAD SCI USA, V96, P9557, DOI 10.1073/pnas.96.17.9557; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Rao NV, 2002, P NATL ACAD SCI USA, V99, P3794, DOI 10.1073/pnas.062055999; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Saci A, 2000, BIOCHEM J, V351, P669, DOI 10.1042/0264-6021:3510669; Satterthwaite AB, 1998, J EXP MED, V188, P833, DOI 10.1084/jem.188.5.833; Sattler M, 1997, J BIOL CHEM, V272, P10248; Scholz G, 2000, J BIOL CHEM, V275, P14615, DOI 10.1074/jbc.275.19.14615; Sinha S, 2001, EXP HEMATOL, V29, P746, DOI 10.1016/S0301-472X(01)00647-6; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; Willeke T, 2000, J LEUKOCYTE BIOL, V68, P284; Yasuda T, 2000, J EXP MED, V191, P641, DOI 10.1084/jem.191.4.641; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	55	24	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 8	2002	21	34					5346	5355		10.1038/sj.onc.1205670	http://dx.doi.org/10.1038/sj.onc.1205670			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579TL	12149655				2022-12-17	WOS:000177193900015
J	Talukder, AH; Wang, RA; Kumar, R				Talukder, AH; Wang, RA; Kumar, R			Expression and transactivating functions of the bZIP transcription factor GADD153 in mammary epithelial cells	ONCOGENE			English	Article						HER2; heregulin; GADD153; differentiation; mammary epithelial cells	FACTOR CHOP GADD153; BINDING PROTEIN; REGULATED EXPRESSION; POINT MUTATION; GROWTH-FACTORS; DNA-BINDING; HEREGULIN; DIFFERENTIATION; STRESS; GENE	Heregulin-beta1 (HRG), a combinatorial ligand for human epidermal growth factor receptor 3 (HER3) and HER4, is a regulatory polypeptide having distinct biological effects, such as growth stimulation, differentiation, invasiveness, and migration in mammary epithelial cells. The mechanism underlying the diverse functions of HRG is not well established but is believed to depend on induced changes in the expression of specific cellular gene products, their modification, or both. Here, we identified the basic leucine zipper transcription factor, the growth-arrest and DNA-damage 153 (GADD153)/ CCAAT-enhancer binding protein (C/EBP) homologous protein (CHOP) as one of the HRG-inducible genes. We demonstrated that HRG stimulation of mammary epithetial cells induces the expression of GADD153 mRNA and protein and transcription of GADD153 promoter. The transcriptional activity of the GADD153 promoter as well as transcription from the C/EBP-activating transcription factor (ATF) composite motif in the GADD153 promoter was also stimulated by HRG-inducible ATF-4 and activated HER2 but not wild-type HER2. GADD153 expression was upregulated by the lactogenic hormones insulin and progesterone and associated with differentiation of normal mammary epithelial cells. Consistent with its role as transcriptional modifier, GADD153 stimulated transcription of beta-casein promoter activity in a STAT5a-sensitive manner in mammary epithelial cells. Analysis of mouse mammary gland development revealed that GADD153 expression was predominantly restricted in the early lactating stages. Because cyclic AMP responsive element and ATF binding sites are present in a variety of growth-regulating cellular genes, these findings suggest that stimulation of GADD153 expression and its transactivating functions may constitute an important mechanism of regulation of putative genes having diverse functions during cell growth and differentiation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Wang, Brian/HGA-9535-2022	Wang, Rui-An/0000-0003-2320-1211	NCI NIH HHS [CA80066, CA65746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065746, R01CA080066, U01CA065746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Ariyoshi K, 2000, J BIOL CHEM, V275, P24407, DOI 10.1074/jbc.M909771199; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Coutts M, 1999, BLOOD, V93, P3369, DOI 10.1182/blood.V93.10.3369.410k11_3369_3378; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Cui KY, 2000, J BIOL CHEM, V275, P7591, DOI 10.1074/jbc.275.11.7591; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; Fitzpatrick VD, 1998, FEBS LETT, V431, P102, DOI 10.1016/S0014-5793(98)00737-6; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Huang QH, 1999, BIOCHEM J, V341, P225, DOI 10.1042/0264-6021:3410225; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; Krane IM, 1996, ONCOGENE, V12, P1781; Kumar R, 1996, CLIN CANCER RES, V2, P1215; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Mandal M, 2001, J BIOL CHEM, V276, P9699, DOI 10.1074/jbc.M008514200; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Reese DM, 1997, STEM CELLS, V15, P1, DOI 10.1002/stem.150001; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SLAMON DJ, 1987, SCIENCE, V235, P77; Talukder AH, 2001, J BIOL CHEM, V276, P5636, DOI 10.1074/jbc.M006824200; Talukder AH, 2000, CANCER RES, V60, P276; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; Vadlamudi RK, 2000, MOL CELL BIOL, V20, P9092, DOI 10.1128/MCB.20.23.9092-9101.2000; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	46	24	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2002	21	27					4289	4300		10.1038/sj.onc.1205529	http://dx.doi.org/10.1038/sj.onc.1205529			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082616				2022-12-17	WOS:000176174200011
J	Wuest, T; Gerlach, E; Banerjee, D; Gerspach, J; Moosmayer, D; Pfizenmaier, K				Wuest, T; Gerlach, E; Banerjee, D; Gerspach, J; Moosmayer, D; Pfizenmaier, K			TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor	ONCOGENE			English	Article						tumor stroma targeting; tumor associated proteases; TNFR2 signaling; juxtatropic membrane TNF like action	FACTOR-ALPHA; FACTOR RECEPTOR; STROMAL FIBROBLASTS; PROTEIN; CANCER; CELLS; INVOLVEMENT; VASCULATURE; EXPRESSION; THERAPY	We describe a TNF fusion protein designated TNF-Selectokine, which is a homo-trimeric molecule comprised of a single chain antibody (scFv) targeting module, a trimerization domain and TINE TNF-Selectokine exerts high bioactivity towards the targeted and adjacent, antigen negative cells. Membrane targeting dependent immobilization of the TNF-Selectokine induced cell death in TNFR1 and TNFR2 dependent manner, thus cell bound TNF-Selectokine mimicks membrane TNF. To restrict TNF activity to the tumor, a prototype of a TNF-Selectokine prodrug was constructed by insertion of a TNFR1 fragment, separated from TNF by a protease-sensitive linker. The prodrug exerts minimal TNF activity, but can be activated in vitro several thousand-fold by proteolytic digest, showing the principal feasibility of this approach. Choice of cleavage site(s) recognized by protease(s) typically associated with a given carcinoma should allow high dose systemic application of the respective TNF prodrug that unveils its specific bioactivity only in targeted tissues.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany	University of Stuttgart	Pfizenmaier, K (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.	klaus.pfizenmaier@po.uni-stuttgart.de						BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Brocks B, 2001, MOL MED, V7, P461, DOI 10.1007/BF03401851; Christ O, 2001, CLIN CANCER RES, V7, P985; CORCORAN AE, 1994, EUR J BIOCHEM, V223, P831, DOI 10.1111/j.1432-1033.1994.tb19059.x; CORTI A, 1992, BIOCHEM J, V284, P905, DOI 10.1042/bj2840905; Curnis F, 2000, NAT BIOTECHNOL, V18, P1185, DOI 10.1038/81183; De Petro G, 1998, CANCER RES, V58, P2234; DeFeo-Jones D, 2000, NAT MED, V6, P1248, DOI 10.1038/81351; Eggermont A M, 2001, Curr Oncol Rep, V3, P359, DOI 10.1007/s11912-001-0090-8; GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235; Gasparri A, 1999, CANCER RES, V59, P2917; Ghiso JAA, 1999, EUR J BIOCHEM, V263, P295, DOI 10.1046/j.1432-1327.1999.00507.x; Grell M, 1998, P NATL ACAD SCI USA, V95, P570, DOI 10.1073/pnas.95.2.570; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Huang PS, 2001, CURR OPIN GENET DEV, V11, P104, DOI 10.1016/S0959-437X(00)00164-7; Kammerer RA, 1998, J BIOL CHEM, V273, P10602, DOI 10.1074/jbc.273.17.10602; KONTERMANN RE, 1995, BIOL CHEM H-S, V376, P473, DOI 10.1515/bchm3.1995.376.8.473; Lejeune FJ, 1998, CURR OPIN IMMUNOL, V10, P573, DOI 10.1016/S0952-7915(98)80226-4; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mersmann M, 2001, INT J CANCER, V92, P240, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1170>3.3.CO;2-L; Nooijen PTGA, 1998, CANCER RES, V58, P4880; Paciucci R, 1998, ONCOGENE, V16, P625, DOI 10.1038/sj.onc.1201564; Park JE, 1999, J BIOL CHEM, V274, P36505, DOI 10.1074/jbc.274.51.36505; ROSENBLUM MG, 1995, CANCER IMMUNOL IMMUN, V40, P322, DOI 10.1007/BF01519633; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; Scherf U, 1996, CLIN CANCER RES, V2, P1523; SCHMID EF, 1995, BLOOD, V86, P1836, DOI 10.1182/blood.V86.5.1836.bloodjournal8651836; Stoelcker B, 2000, AM J PATHOL, V156, P1171, DOI 10.1016/S0002-9440(10)64986-3; Takasaki W, 1997, NAT BIOTECHNOL, V15, P1266, DOI 10.1038/nbt1197-1266; Wajant H, 2001, INT J BIOCHEM CELL B, V33, P19, DOI 10.1016/S1357-2725(00)00064-9	31	24	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2002	21	27					4257	4265		10.1038/sj.onc.1205193	http://dx.doi.org/10.1038/sj.onc.1205193			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082613				2022-12-17	WOS:000176174200008
J	Miller, WH; Waxman, S				Miller, WH; Waxman, S			Differentiation induction as a treatment for hematologic malignancies	ONCOGENE			English	Review						differentiation therapy; acute promyelocytic leukemia; retinoids; arsenic trioxide; transcriptional repression	ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; PML-RAR-ALPHA; ARSENIC TRIOXIDE AS2O3; HISTONE DEACETYLASE; IN-VITRO; MYELOID-LEUKEMIA; RECEPTOR-ALPHA; TRANSCRIPTION FACTORS; COMPLETE REMISSION		Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res & SMBD, Montreal, PQ H3T 1E2, Canada	Icahn School of Medicine at Mount Sinai; Lady Davis Institute; McGill University	Waxman, S (corresponding author), Mt Sinai Sch Med, Dept Med, Box 1178,1 Gustave L Levy Pl, New York, NY 10029 USA.	Samuel.Wadman@mssm.edu			NATIONAL CANCER INSTITUTE [R01CA059936, R01CA085748] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA85748, R01 CA59936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN MJ, 1995, ONCOGENE, V10, P2307; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Atweh GF, 2001, CURR OPIN HEMATOL, V8, P123, DOI 10.1097/00062752-200103000-00010; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; CHEN A, 1994, BLOOD, V84, P2122, DOI 10.1182/blood.V84.7.2122.bloodjournal8472122; Chen GQ, 1997, BLOOD, V89, P3345; Chen GQ, 1996, BLOOD, V88, P1052; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Chikayama S, 1998, HAEMATOLOGIA, V29, P115; COMIC M, 1994, LEUKEMIA, V8, P914; Cote S, 2000, BLOOD, V96, P3200, DOI 10.1182/blood.V96.9.3200.h8003200_3200_3208; CUNNINGHAM ML, 1994, EUR J BIOCHEM, V221, P285, DOI 10.1111/j.1432-1033.1994.tb18740.x; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; Dalla-Favera Riccardo, 1996, P139; Davis AF, 1997, J CELL BIOCHEM, V65, P308, DOI 10.1002/(SICI)1097-4644(19970601)65:3<308::AID-JCB2>3.0.CO;2-W; DAVISON K, 1999, AM ASS CANC RES, V40, P120; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; DELVA L, 1993, BLOOD, V82, P2175; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; Ding W, 1998, BLOOD, V92, P1172, DOI 10.1182/blood.V92.4.1172.416k02_1172_1183; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; Douer D, 2001, BLOOD, V97, P73, DOI 10.1182/blood.V97.1.73; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; Downing JR, 2001, LEUKEMIA, V15, P664, DOI 10.1038/sj.leu.2402035; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FENAUX P, 1994, LEUKEMIA, V8, pS42; Fenaux P, 2001, SEMIN HEMATOL, V38, P13, DOI 10.1053/shem.2001.20862; Ferrari A C, 1994, Cancer Chemother Biol Response Modif, V15, P337; Finch RA, 2000, BLOOD, V96, P2262; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; GambacortiPasserini C, 1996, BLOOD, V88, P1411, DOI 10.1182/blood.V88.4.1411.bloodjournal8841411; GIANNI M, 1995, BLOOD, V85, P3619, DOI 10.1182/blood.V85.12.3619.bloodjournal85123619; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 2001, CURR TOP MICROBIOL, V254, P165; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Han ZT, 1998, P NATL ACAD SCI USA, V95, P5357, DOI 10.1073/pnas.95.9.5357; HASSAN HT, 1991, EUR J CLIN PHARMACOL, V41, P531, DOI 10.1007/BF00314980; Hisatake J, 2001, BLOOD, V97, P2427, DOI 10.1182/blood.V97.8.2427; Hozumi M, 1998, INT J HEMATOL, V68, P107; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Huang YC, 1998, CLIN CANCER RES, V4, P2503; Huang Yicong, 1994, Molecular and Cellular Differentiation, V2, P83; Huang Yicong, 1995, Molecular and Cellular Differentiation, V3, P241; Imaizumi M, 1998, BLOOD, V92, P374, DOI 10.1182/blood.V92.2.374.414a40_374_382; Jansen JH, 1999, BLOOD, V94, P39, DOI 10.1182/blood.V94.1.39.413a26_39_45; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Jing YK, 2000, BLOOD, V96, p309A; Jing YK, 2001, BLOOD, V97, P264, DOI 10.1182/blood.V97.1.264; Kitamura K, 1997, LEUKEMIA, V11, P1950, DOI 10.1038/sj.leu.2400837; Kosugi H, 2001, JPN J CANCER RES, V92, P529, DOI 10.1111/j.1349-7006.2001.tb01126.x; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Makishima M, 1999, BIOCHEM PHARMACOL, V57, P521, DOI 10.1016/S0006-2952(98)00329-3; MANN KK, 2001, JOINT INT C APL DIFF, P44; MATUSHANSKY I, 2000, FRONT BIOSCI, V5, pD4848; Maurer BJ, 1999, JNCI-J NATL CANCER I, V91, P1138, DOI 10.1093/jnci/91.13.1138; Melnick A, 2000, BLOOD, V96, P3939, DOI 10.1182/blood.V96.12.3939.h8003939_3939_3947; Melnick A, 2000, MOL CELL BIOL, V20, P6550, DOI 10.1128/MCB.20.17.6550-6567.2000; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MILLER WH, 1995, BLOOD, V85, P3021, DOI 10.1182/blood.V85.11.3021.bloodjournal85113021; Minucci S, 2001, ONCOGENE, V20, P3110, DOI 10.1038/sj.onc.1204336; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; MUINDI J, 1992, BLOOD, V79, P299; Nervi C, 1998, BLOOD, V92, P2244; Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465; Niitsu N, 1997, BIOCHEM BIOPH RES CO, V238, P100, DOI 10.1006/bbrc.1997.7250; Niitsu N, 1999, LEUKEMIA LYMPHOMA, V34, P261, DOI 10.3109/10428199909050951; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Novick S, 1999, BLOOD, V94, p61A; Novitzky N, 2000, AM J HEMATOL, V63, P212, DOI 10.1002/(SICI)1096-8652(200004)63:4<212::AID-AJH9>3.0.CO;2-D; Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887; RAZA A, 1993, AM J HEMATOL, V42, P147, DOI 10.1002/ajh.2830420202; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Richon VM, 2001, BLOOD CELL MOL DIS, V27, P260, DOI 10.1006/bcmd.2000.0376; Rifkind RA, 1996, PHARMACOL THERAPEUT, V69, P97, DOI 10.1016/0163-7258(95)02044-6; ROWINSKY EK, 1992, LEUKEMIA, V6, P526; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; Saba H I, 2001, Cancer Control, V8, P79; Sanz MA, 2000, BLOOD, V96, P1247; SCHER BM, 1982, CANCER RES, V42, P1300; SCHER W, 1983, CURRENT CONCEPTS ERY, P301; SCHWARTZ EL, 1983, CANCER RES, V43, P2725; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Shiohara M, 2001, CANCER RES, V61, P3361; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; STRAIR RK, 2001, JOINT INT C APL DIFF, P39; SUH N, 1999, CANCER RES, P336; Takeuchi M, 1998, LEUKEMIA LYMPHOMA, V31, P441, DOI 10.3109/10428199809057604; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Teofili L, 2001, BLOOD, V98, P495, DOI 10.1182/blood.V98.2.495; Toyota M, 2001, BLOOD, V97, P2823, DOI 10.1182/blood.V97.9.2823; TRUMP DL, 2001, JOINT INT C APL DIFF, V47; VANDRIEL R, 1991, J CELL BIOCHEM, V47, P311, DOI 10.1002/jcb.240470405; Wang JX, 1999, CANCER RES, V59, P2766; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Wang ZG, 1998, SCIENCE, V279, P1547; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; Waxman S, 2000, LEUKEMIA, V14, P491, DOI 10.1038/sj.leu.2401714; WAXMAN S, 1990, CANCER RES, V50, P3878; WAXMAN S, 2001, JOINT INT C APL DIFF, P22; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WITCHER M, 2001, JOINT INT C APL DIFF, P28; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621; Yang CH, 1999, BRIT J CANCER, V81, P796, DOI 10.1038/sj.bjc.6690766; Zhu J, 2001, BLOOD, V98, P2563, DOI 10.1182/blood.V98.8.2563; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	118	24	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3496	3506		10.1038/sj/onc/1205328	http://dx.doi.org/10.1038/sj/onc/1205328			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032784				2022-12-17	WOS:000175633300019
J	Koike, C; Mizutani, T; Ito, T; Shimizu, Y; Yamamichi, N; Kameda, T; Michimukai, E; Kitamura, N; Okamoto, T; Iba, H				Koike, C; Mizutani, T; Ito, T; Shimizu, Y; Yamamichi, N; Kameda, T; Michimukai, E; Kitamura, N; Okamoto, T; Iba, H			Introduction of wild-type patched gene suppresses the oncogenic potential of human squamous cell carcinoma cell lines including A431	ONCOGENE			English	Article						squamous cell carcinoma; the patched gene; retrovirus vector; human gene therapy; Sonic hedgehog; A431	PSEUDOTYPED RETROVIRUS VECTOR; HEDGEHOG SIGNAL-TRANSDUCTION; SONIC-HEDGEHOG; HUMAN HOMOLOG; GORLIN-SYNDROME; DEVELOPMENTAL DEFECTS; MESSENGER-RNA; MUTATIONS; PATHWAY; INDUCTION	Defects in a developmental signaling pathway involving the mammalian homologue of the Drosophila segment polarity gene, patched are associated with human tumors such as basal cell carcinoma, medulloblastoma and squamous cell carcinoma. Loss of heterozygosity (LOH) in some of these tumor cells suggests that patched functions as a tumor suppressor gene. To evaluate the biological significance of patched mutations in human sporadic tumor cells, we constructed a VSV-G pseudotyped retrovirus vector carrying the wild-type patched gene and transduced it into two human squamous cell carcinoma (SCC) cell lines, A431 and KA, that express only mutant patched mRNA. When SSC cells were transduced with Ptc virus, colony forming activity in soft agar was drastically reduced and these cells recovered anchorage independent growth when Sonic hedgehog (Shh), the ligand of Patched (Ptc), was added into the soft agar culture. Expression of exogenous patched, however, had no effect on anchorage independent growth of Ras-transformed NIH3T3 cells or SCC cell line, NA, which expresses wild-type patched mRNA. Cyclopamine, a specific inhibitor of the Shh/Ptc/Smo signaling pathway, efficiently suppressed anchorage independent growth of A431 and KA cells. These results indicate that loss of patched function plays a major role in the acquisition of oncogenic potential in these SCCs and further that Ptc virus would be an effective reagent for suppressing tumorigenicity of such SCCs.	Univ Tokyo, Dept Microbiol & Immunol, Div Host Parasite Interact, Inst Med Sci,Minato Ku, Tokyo 1088639, Japan; Hiroshima Univ, Dept Mol Oral Med & Maxillofacial Surg 1, Fac Dent, Minami Ku, Hiroshima 7348553, Japan	University of Tokyo; Hiroshima University	Iba, H (corresponding author), Univ Tokyo, Dept Microbiol & Immunol, Div Host Parasite Interact, Inst Med Sci,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.							Ahmadian A, 1998, ONCOGENE, V17, P1837, DOI 10.1038/sj.onc.1202080; Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Altaba ARI, 1998, DEVELOPMENT, V125, P2203; Arai T, 1999, VIROLOGY, V260, P109, DOI 10.1006/viro.1999.9773; Arai T, 1998, J VIROL, V72, P1115, DOI 10.1128/JVI.72.2.1115-1121.1998; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Bale AE, 2000, NATURE, V406, P944, DOI 10.1038/35023197; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; DAHMANE N, 1997, NATURE, V389, P870; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Fan HR, 1997, NAT MED, V3, P788, DOI 10.1038/nm0797-788; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hahn H, 1999, J MOL MED-JMM, V77, P459, DOI 10.1007/s001099900018; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Incardona JP, 2000, DEV BIOL, V224, P440, DOI 10.1006/dbio.2000.9775; Incardona JP, 1998, DEVELOPMENT, V125, P3553; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Johnson RL, 1998, CURR OPIN GENET DEV, V8, P450, DOI 10.1016/S0959-437X(98)80117-2; Karpen HE, 2001, J BIOL CHEM, V276, P19503, DOI 10.1074/jbc.M010832200; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; KWOK TT, 1994, CANCER RES, V54, P2834; Lee J, 1997, DEVELOPMENT, V124, P2537; Lench NJ, 1997, HUM GENET, V100, P497, DOI 10.1007/s004390050541; Levanat S, 1996, NAT GENET, V12, P85, DOI 10.1038/ng0196-85; Liu CZ, 1998, GENE, V209, P1, DOI 10.1016/S0378-1119(97)00668-9; Maesawa C, 1998, GENE CHROMOSOME CANC, V21, P276, DOI 10.1002/(SICI)1098-2264(199803)21:3<276::AID-GCC15>3.3.CO;2-H; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Marigo V, 1996, DEVELOPMENT, V122, P1225; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; Michimukai E, 2001, IN VITRO CELL DEV-AN, V37, P459; Murakami M, 1999, CELL GROWTH DIFFER, V10, P333; Okazaki S, 1998, BIOCHEM BIOPH RES CO, V250, P347, DOI 10.1006/bbrc.1998.9331; OKUNO H, 1991, ONCOGENE, V6, P1491; Palm K, 2000, MOL BRAIN RES, V78, P192, DOI 10.1016/S0169-328X(00)00075-9; Pietsch T, 1997, CANCER RES, V57, P2085; Ping XL, 2001, J INVEST DERMATOL, V116, P614, DOI 10.1046/j.1523-1747.2001.01301.x; Raffel C, 1997, CANCER RES, V57, P842; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Smyth I, 1998, HUM GENET, V102, P598, DOI 10.1007/s004390050747; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Ui M, 1999, GENE THER, V6, P1670, DOI 10.1038/sj.gt.3301009; Ui M, 2000, BIOCHEM BIOPH RES CO, V278, P97, DOI 10.1006/bbrc.2000.3777; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Unden AB, 1997, CANCER RES, V57, P2336; Villavicencio EH, 2000, AM J HUM GENET, V67, P1047, DOI 10.1016/S0002-9297(07)62934-6; Vorechovsky I, 1997, CANCER RES, V57, P4677; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Wetmore C, 2000, CANCER RES, V60, P2239; WOLTER M, 1997, CANCER RES, V57, P2582; Xie JW, 1997, CANCER RES, V57, P2369; Zurawel RH, 2000, GENE CHROMOSOME CANC, V27, P44, DOI 10.1002/(SICI)1098-2264(200001)27:1<44::AID-GCC6>3.0.CO;2-V; Zurawel RH, 2000, GENE CHROMOSOME CANC, V28, P77, DOI 10.1002/(SICI)1098-2264(200005)28:1<77::AID-GCC9>3.0.CO;2-Y	62	24	29	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 18	2002	21	17					2670	2678		10.1038/sj.onc.1205370	http://dx.doi.org/10.1038/sj.onc.1205370			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965540				2022-12-17	WOS:000174996500007
J	Vikis, HG; Stewart, S; Guan, KL				Vikis, HG; Stewart, S; Guan, KL			SmgGDS displays differential binding and exchange activity towards different Ras isoforms	ONCOGENE			English	Article						Ras; Rac; Rho; dominant negative mutants; smgGDS; guanine nucleotide exchange factor	KINASE SUPPRESSOR; PROTEIN; COMPLEX; SIGNAL; FORMS; PURIFICATION; INHIBITION; MUTANTS; GROWTH	Ras family GTPases play central roles in a wide variety of biological responses, including cell proliferation, differentiation, and oncogenic transformation. We searched for novel guanine nucleotide exchange factors of HRas and isolated small G-protein dissociation stimulator (smgGDS), a guanine nucleotide exchange factor known to act on numerous Ras and Rho family GTPases. SmgGDS specifically interacts with both dominant negative and nucleotide free forms of H and NRas, but not with the corresponding oncogenic forms. An effector domain mutant of HRas, HRasN17G37, selectively lost the ability to bind smgGDS. However, smgGDS does not catalyze guanine nucleotide exchange on either H or NRas in vitro. In contrast, substrates of smgGDS, such as KRas, Rac1, and RhoA, bind to smgGDS in both active and inactive forms which requires the presence of poly-basic residues in the C-termini of the GTPases. Our data suggest that the C-terminal poly-basic region of small GTPases is important for both binding and nucleotide exchange by smgGDS. Furthermore, these data underscore the idea that mammalian Ras isoforms are not functionally equivalent.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Guan, KL (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.	kunliang@umich.edu						BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOWMAN EP, 1995, METHOD ENZYMOL, V256, P246; CHEN SY, 1994, ONCOGENE, V9, P2691; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; CHUANG TH, 1994, BIOCHEM J, V303, P761, DOI 10.1042/bj3030761; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NAKANISHI H, 1994, J BIOL CHEM, V269, P15085; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Stewart S, 2000, J BIOL CHEM, V275, P8854, DOI 10.1074/jbc.275.12.8854; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626	24	24	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2425	2432		10.1038/sj.onc.1205306	http://dx.doi.org/10.1038/sj.onc.1205306			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948427				2022-12-17	WOS:000174635600016
J	Sattler, M; Pride, YB; Quinnan, LR; Verma, S; Malouf, NA; Husson, H; Salgia, R; Lipkowitz, S; Griffin, JD				Sattler, M; Pride, YB; Quinnan, LR; Verma, S; Malouf, NA; Husson, H; Salgia, R; Lipkowitz, S; Griffin, JD			Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells	ONCOGENE			English	Article						CBL-B; BCR/ABL; gene expression; cell migration; signal transduction	ADAPTER PROTEINS CRKL; C-CBL; TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; PHOSPHATIDYLINOSITOL 3-KINASE; NEGATIVE REGULATOR; BINDING-PROTEIN; SH2 DOMAIN; RING-TYPE; KINASE	CBL and the related CBL-B protein are two members of a family of RING finger type ubiquitin E3 ligases that are believed to function as negative regulators of signal transduction in hematopoietic and immune cells. In mice, expression of v-Cbl causes lymphomas, and targeted disruption of either the CBL gene or the CBL-B gene can result in a lymphoproliferative disorder or hypersensitivity of lymphocytes. CBL is one of the most prominent targets of the BCR/ABL tyrosine kinase oncogene. We compared the role of CBL and CBL-B in signal transduction of BCR/ABL using pairs of cell lines before and after expression of BCR/ABL. In contrast to CBL, BCR/ABL was found to rapidly downregulate the expression of CBL-B protein. The decrease in CBL-B protein induced by BCR/ABL was associated with down-regulation of CBL-B mRNA. Downregulation and tyrosine phosphorylation of CBL-B required BCR/ABL kinase activity. However, despite their known similarities in structure and function, we found CBL and CBL-B proteins to be involved in distinct signaling complexes. CBL was predominantly in a complex with phosphatidylinositol 3'-kinase and CRKL, while CBL-B was not associated with any significant phosphatidylinositol 3'-kinase activity. A major CBL-B associated protein was identified as mono-ubiquitinated Vav, a nucleotide exchange factor for Rac1. These results demonstrate that BCR/ABL signals differentially through CBL and CBL-B, with downregulation of the CBL-B protein potentially contributing to BCR/ABL-mediated transformation.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Natl Naval Med Ctr, Med Branch, Genet Dept, NCI, Bethesda, MD 20889 USA	Harvard University; Dana-Farber Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walter Reed National Military Medical Center	Sattler, M (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	martin_sattler@dfci.harvard.edu		Pride, Yuri/0000-0002-5884-0964	NCI NIH HHS [CA78348] Funding Source: Medline; NIDDK NIH HHS [DK50654] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Andoniou CE, 1996, ONCOGENE, V12, P1981; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Bartkiewicz M, 1999, J BIOL CHEM, V274, P30887, DOI 10.1074/jbc.274.43.30887; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Ettenberg S A, 1999, Mol Cell Biol Res Commun, V2, P111, DOI 10.1006/mcbr.1999.0157; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Ettenberg SA, 2001, J BIOL CHEM, V276, P27677, DOI 10.1074/jbc.M102641200; Fang D, 2001, J BIOL CHEM, V276, P4872, DOI 10.1074/jbc.M008901200; FREDRICKSON TN, 1984, J NATL CANCER I, V72, P447; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GORDON MY, 1987, NATURE, V328, P342, DOI 10.1038/328342a0; Hamilton E, 2001, J BIOL CHEM, V276, P9028, DOI 10.1074/jbc.M009386200; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Hunter S, 1999, J BIOL CHEM, V274, P2097, DOI 10.1074/jbc.274.4.2097; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Krawczyk C, 2000, IMMUNITY, V13, P463, DOI 10.1016/S1074-7613(00)00046-7; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; MUSHINSKI JF, 1994, ONCOGENE, V9, P2489; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Sattler M, 1999, MOL CELL BIOL, V19, P7473; Sattler M, 1999, BLOOD, V93, P2928; Sattler M, 1996, ONCOGENE, V12, P839; Sattler M, 2001, J BIOL CHEM, V276, P2451, DOI 10.1074/jbc.M006250200; Sattler M, 2001, INT J HEMATOL, V73, P278, DOI 10.1007/BF02981952; Sattler M, 2000, J BIOL CHEM, V275, P24273, DOI 10.1074/jbc.M002094200; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; Uemura N, 1997, LEUKEMIA, V11, P376, DOI 10.1038/sj.leu.2400590; VERFAILLIE CM, 1992, J CLIN INVEST, V90, P1232, DOI 10.1172/JCI115985	49	24	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1423	1433		10.1038/sj.onc.1205202	http://dx.doi.org/10.1038/sj.onc.1205202			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857085				2022-12-17	WOS:000173861000012
J	Yin, XL; Pang, JCS; Ng, HK				Yin, XL; Pang, JCS; Ng, HK			Identification of a region of homozygous deletion on 8p22-23.1 in medulloblastoma	ONCOGENE			English	Article						rnedulloblastoma; chromosome 8p; homozygous deletion; allelotyping	COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR-SUPPRESSOR GENES; SHORT ARM; PROSTATE-CANCER; ALLELIC LOSS; CHROMOSOME 8P; CELL LINES; HETEROZYGOSITY; CARCINOMA; ABNORMALITIES	To identify critical tumor suppressor loci that are associated with the development of medulloblastoma, we performed a comprehensive genome-wide allelotype analysis in a series of 12 medulloblastomas. Non-random allelic imbalances were identified on chromosomes 7q (58.3%), 8p (66.7%), 16q (58.3%), 17p (58.3%) and 17q (66.7%). Comparative genomic hybridization analysis confirmed that allelic imbalances on 8p, 16q and 17p were due to loss of genetic materials. Finer deletion mapping in an expanded series of 23 medulloblastomas localized the common deletion region on 8p to an interval of 18.14 cM on 8p22-23.2. We then searched within the region of loss on 8p for loci that might contain homozygous deletion using comparative duplex PCR. An overlapping homozygous deletion region was identified in a 1.8 cM interval on 8p22-23.1, between markers D8S520 and D8S1130, in two medulloblastomas. This region of homozygous deletion also encompasses the 1.4 cM minimal deletion region detected on 8p in ductal carcinoma in situ of breast. In conclusion, we reported for the first time a detailed deletion mapping on 8p in medulloblastoma and have identified a region of homozygous deletion on 8p22-23.1 that is likely to contain a critical tumor suppressor gene involved in the development of medulloblastoma.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anatom & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital	Ng, HK (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anatom & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China.	hkng@cuhk.edu.hk	Ng, Ho Keung/I-3952-2015; Pang, Jesse CS/H-3549-2013	Pang, Jesse CS/0000-0002-8716-4045				Arbieva ZH, 2000, GENOME RES, V10, P244, DOI 10.1101/gr.10.2.244; Avet-Loiseau H, 1999, BRIT J CANCER, V79, P1843, DOI 10.1038/sj.bjc.6690293; Baffa R, 2000, CLIN CANCER RES, V6, P1372; BIGNER SH, 1988, CANCER GENET CYTOGEN, V30, P91, DOI 10.1016/0165-4608(88)90096-9; Blaeker H, 1996, GENE CHROMOSOME CANC, V15, P54, DOI 10.1002/(SICI)1098-2264(199601)15:1<54::AID-GCC8>3.3.CO;2-4; Bova GS, 1996, GENOMICS, V35, P46, DOI 10.1006/geno.1996.0321; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; Farrington SM, 1996, ONCOGENE, V12, P1803; FUJIWARA Y, 1993, CANCER RES, V53, P1172; GIANGASPERO F, 2000, PATHOLOGY GENETICS T, P129; Gilhuis HJ, 2000, CLIN NEUROL NEUROSUR, V102, P203, DOI 10.1016/S0303-8467(00)00112-8; HEIDEMAN RL, 1997, PRINCIPLES PRACTICE, P651; Ishii H, 1999, P NATL ACAD SCI USA, V96, P3928, DOI 10.1073/pnas.96.7.3928; Ishii H, 2001, P NATL ACAD SCI USA, V98, P10374, DOI 10.1073/pnas.181222898; Ishwad CS, 1999, INT J CANCER, V80, P25, DOI 10.1002/(SICI)1097-0215(19990105)80:1<25::AID-IJC6>3.3.CO;2-7; Jenkins R, 1998, GENE CHROMOSOME CANC, V21, P131, DOI 10.1002/(SICI)1098-2264(199802)21:2<131::AID-GCC9>3.0.CO;2-1; KAGAN J, 1995, ONCOGENE, V11, P2121; Lassus H, 2001, LAB INVEST, V81, P517, DOI 10.1038/labinvest.3780260; Leung YF, 2001, BIOTECHNIQUES, V30, P334, DOI 10.2144/01302tt02; Levy A, 1999, GENE CHROMOSOME CANC, V24, P42, DOI 10.1002/(SICI)1098-2264(199901)24:1<42::AID-GCC6>3.0.CO;2-F; Ng IOL, 2000, CANCER RES, V60, P6581; Nicholson JC, 1999, BRIT J CANCER, V80, P1322, DOI 10.1038/sj.bjc.6690525; Nihei N, 1996, GENE CHROMOSOME CANC, V17, P260, DOI 10.1002/(SICI)1098-2264(199612)17:4<260::AID-GCC8>3.0.CO;2-1; Pineau P, 1999, ONCOGENE, V18, P3127, DOI 10.1038/sj.onc.1202648; Prasad MA, 1998, GENE CHROMOSOME CANC, V23, P255, DOI 10.1002/(SICI)1098-2264(199811)23:3<255::AID-GCC8>3.3.CO;2-Q; Reardon DA, 1997, CANCER RES, V57, P4042; SAYLORS RL, 1991, CANCER RES, V51, P4721; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Sun PC, 1999, GENOMICS, V62, P184, DOI 10.1006/geno.1999.6020; Sunwoo JB, 1999, ONCOGENE, V18, P2651, DOI 10.1038/sj.onc.1202838; Takle LA, 1996, ONCOGENE, V12, P1083; Tanaka K, 1996, ONCOGENE, V12, P405; Tong CYK, 2001, J NEUROSURG, V95, P9, DOI 10.3171/jns.2001.95.1.0009; Vecchione A, 2001, CLIN CANCER RES, V7, P1546; von Deimling A, 2000, J NEUROPATH EXP NEUR, V59, P544, DOI 10.1093/jnen/59.6.544; Wang JC, 1999, GENOMICS, V60, P1, DOI 10.1006/geno.1999.5905; Wilson PJ, 2000, HUM MUTAT, V15, P156, DOI 10.1002/(SICI)1098-1004(200002)15:2<156::AID-HUMU4>3.0.CO;2-4; Wistuba II, 1999, CANCER RES, V59, P1973; Wright K, 1998, ONCOGENE, V17, P1185, DOI 10.1038/sj.onc.1202028; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V; Yin XL, 2000, J NEUROSURG, V93, P77, DOI 10.3171/jns.2000.93.1.0077; Yin XL, 2001, J NEUROSURG, V94, P799, DOI 10.3171/jns.2001.94.5.0799; Yuan BZ, 1998, CANCER RES, V58, P2196	43	24	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1461	1468		10.1038/sj.onc.1205204	http://dx.doi.org/10.1038/sj.onc.1205204			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857089				2022-12-17	WOS:000173861000016
J	Liu, Y; Emilion, G; Mungall, AJ; Dunham, I; Beck, S; Le Meuth-Metzinger, VG; Shelling, AN; Charnock, FML; Ganesan, TS				Liu, Y; Emilion, G; Mungall, AJ; Dunham, I; Beck, S; Le Meuth-Metzinger, VG; Shelling, AN; Charnock, FML; Ganesan, TS			Physical and transcript map of the region between D6S264 and D6S149 on chromosome 6q27, the minimal region of allele loss in sporadic epithelial ovarian cancer	ONCOGENE			English	Article						ovarian cancer chromosome 6q27	SELF-INCOMPATIBILITY GENE; PROTEIN-COUPLED RECEPTOR; DISTINCT REGIONS; NICOTIANA-ALATA; HUMAN DNA; LONG ARM; TUMORS; DELETION; RIBONUCLEASES; CLONING	We have previously shown a high frequency of allele loss at D6S193 (62%) on chromosomal arm 6q27 in ovarian tumours and mapped the minimal region of allele loss between D6S297 and D6S264 (3 cM). We isolated and mapped a single non-chimaeric YAC (17IA12, 260 - 280 kb) containing D6S193 and D6S297. A further extended bacterial contig (between D6S264 and D6S149) has been established using PACs and BACs and a transcript map has been established. We have mapped six new markers to the YAC; three of them are ESTs (WI-15078, WI-8751, and TCP10). We have isolated three cDNA clones of EST WI-15078 and one clone contains a complete open reading frame. The sequence shows homology to a new member of the ribonuclease family. The other two clones are splice variants of this new gene. The gene is expressed ubiquitously in normal tissues. It is expressed in 4/8 ovarian cancer cell lines by Northern analysis. The gene encodes for a 40 kDa protein. Direct sequencing of the gene in all the eight ovarian cancer cell lines did not identify any mutations. Clonogenic assays were performed by transfecting the full-length gene in to ovarian cancer cell lines and no suppression of growth was observed.	John Radcliffe Hosp, Imperial Canc Res Fund, Mol Oncol Labs, Oxford OX3 9DS, England; Sanger Ctr, Cambridge CB10 1SA, England; INRA, UMR Genet Anim, F-35042 Rennes, France; Natl Womens Hosp, Dept Obstet & Gynaecol, Res Ctr Reprod Med, Auckland, New Zealand	University of Oxford; Wellcome Trust Sanger Institute; INRAE	Ganesan, TS (corresponding author), John Radcliffe Hosp, Imperial Canc Res Fund, Mol Oncol Labs, Oxford OX3 9DS, England.	ganesan@icrf.icnet.uk	Meuth, Valérie Metzinger-Le/H-6338-2016; GANESAN, Trivadi Sundaram/AAU-1499-2020; Mungall, Andrew J./U-7067-2018; Shelling, Andrew/E-7496-2010	Meuth, Valérie Metzinger-Le/0000-0003-1718-5083; GANESAN, Trivadi Sundaram/0000-0002-4671-8099; Mungall, Andrew J./0000-0002-0905-2742; Shelling, Andrew/0000-0002-5300-1934; Dunham, Ian/0000-0003-2525-5598; Liu, Ying/0000-0003-3703-2498				Acquati F, 2001, ONCOGENE, V20, P980, DOI 10.1038/sj.onc.1204178; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANAND R, 1990, NUCLEIC ACIDS RES, V18, P1951, DOI 10.1093/nar/18.8.1951; ANDERSON MA, 1989, PLANT CELL, V1, P483, DOI 10.1105/tpc.1.5.483; Baba M, 1997, J BIOL CHEM, V272, P14893, DOI 10.1074/jbc.272.23.14893; BLANCHE H, 1992, GENOMICS, V12, P826, DOI 10.1016/0888-7543(92)90317-L; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; ChenevixTrench G, 1997, GENE CHROMOSOME CANC, V18, P75, DOI 10.1002/(SICI)1098-2264(199702)18:2<75::AID-GCC1>3.0.CO;2-Y; Cooke IE, 1996, GENE CHROMOSOME CANC, V15, P223, DOI 10.1002/(SICI)1098-2264(199604)15:4<223::AID-GCC4>3.3.CO;2-4; Cooke IE, 1996, MAMM GENOME, V7, P157, DOI 10.1007/s003359900040; FRANCESCONI M, 1984, CANCER, V53, P1927, DOI 10.1002/1097-0142(19840501)53:9<1927::AID-CNCR2820530920>3.0.CO;2-#; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; Greaves DR, 1997, J EXP MED, V186, P837, DOI 10.1084/jem.186.6.837; HIME G, 1995, GENE, V158, P203, DOI 10.1016/0378-1119(94)00896-Z; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; ISLAM SD, 1993, HUM MOL GENET, V2, P2075, DOI 10.1093/hmg/2.12.2075; Katso RMT, 1997, CANCER METAST REV, V16, P81, DOI 10.1023/A:1005796307286; Kurihara H, 1996, J MOL BIOL, V255, P310, DOI 10.1006/jmbi.1996.0025; LAVAL S, 1994, CELL GROWTH DIFFER, V5, P1173; Liao F, 1997, BIOCHEM BIOPH RES CO, V236, P212, DOI 10.1006/bbrc.1997.6936; Liao F, 1997, GENOMICS, V40, P175, DOI 10.1006/geno.1996.4544; LIU Y, 2001, IN PRESS RE REPROD; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MCCLURE BA, 1989, NATURE, V342, P955, DOI 10.1038/342955a0; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P286, DOI 10.1002/gcc.2870100411; Mungall AJ, 1997, DNA SEQUENCE, V8, P151, DOI 10.3109/10425179709034066; Obata K, 1998, CANCER RES, V58, P2095; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; Rodriguez C, 2000, GENE CHROMOSOME CANC, V27, P76, DOI 10.1002/(SICI)1098-2264(200001)27:1<76::AID-GCC10>3.0.CO;2-E; SAHA V, 1995, GENE CHROMOSOME CANC, V14, P220, DOI 10.1002/gcc.2870140311; SAITO S, 1992, CANCER RES, V52, P5815; Saito S, 1996, CANCER RES, V56, P5586; Sassa H, 1996, MOL GEN GENET, V252, P222, DOI 10.1007/BF02173225; Schein CH, 1997, NAT BIOTECHNOL, V15, P529, DOI 10.1038/nbt0697-529; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; Tibiletti MB, 2000, CLIN CANCER RES, V6, P1422; Tibiletti MG, 1996, CANCER RES, V56, P4493; Tibiletti MG, 1998, ONCOGENE, V16, P1639, DOI 10.1038/sj.onc.1201654; Trubia M, 1997, GENOMICS, V42, P342, DOI 10.1006/geno.1997.4679; Walter MH, 1996, EUR J BIOCHEM, V239, P281, DOI 10.1111/j.1432-1033.1996.0281u.x; WAN MH, 1994, INT J ONCOL, V5, P1043; Ye ZH, 1996, PLANT MOL BIOL, V30, P697, DOI 10.1007/BF00019005; Zingoni A, 1997, GENOMICS, V42, P519, DOI 10.1006/geno.1997.4754; [No title captured]	46	24	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					387	399		10.1038/sj.onc.1205067	http://dx.doi.org/10.1038/sj.onc.1205067			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821951				2022-12-17	WOS:000173311200007
J	Suraweera, N; Iacopetta, B; Duval, A; Compoint, A; Tubacher, E; Hamelin, R				Suraweera, N; Iacopetta, B; Duval, A; Compoint, A; Tubacher, E; Hamelin, R			Conservation of mononucleotide repeats within 3 ' and 5 ' untranslated regions and their instability in MSI-H colorectal cancer	ONCOGENE			English	Article						5 ' UTR; 3 ' UTR; MSI tumors	MICROSATELLITE INSTABILITY; FRAMESHIFT MUTATIONS; SEQUENCE REPEATS; BINDING PROTEIN; GENE-EXPRESSION; MESSENGER-RNA; COLON CANCERS; CELL-LINES; TRANSCRIPTION; RECEPTOR	Messenger RNA contains untranslated 3' and 5' regions (3' and 5' UTRs) with sequence elements that are essential for the regulation of gene expression. A systematic search of GenBank revealed a large number of mononucleotide repeats within these UTRs. We selected 35 such mononucleotide repeats ranging in length from 15 bp to 32 bp and analysed their size in a series of 60 normal individuals. The conservation of repeats correlated inversely to their length, with longer repeats generally being more polymorphic than shorter repeats, irrespective of 3' or 5' location. Several long repeats were identified however to be monomorphic and we postulate that their conservation may be due to selective pressures relating to a possible functional role. We analysed 19 conserved UTR repeats in 117 colorectal cancers (CRC), 43 of which had defective mismatch repair characterized by widespread microsatellite instability (MSI-H). The UTR repeats were very often deleted in MSI-H tumors, with the length of deletion being proportional to the size of the repeat. Because of the high frequency of deletion observed in the conserved UTR repeats of MSI-H tumors, these could serve as a useful model for the study of possible changes in gene expression resulting from such mutations.	Ctr Etud Polymorphisme Humain, INSERM, U434, F-75010 Paris, France; Univ Western Australia, Dept Surg, Nedlands, WA 6009, Australia	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Western Australia	Hamelin, R (corresponding author), Ctr Etud Polymorphisme Humain, INSERM, U434, 27 Rue Juliette Dodu, F-75010 Paris, France.		Suraweera, Nirosha/E-5912-2012					AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; AHARONI A, 1993, NUCLEIC ACIDS RES, V21, P5221, DOI 10.1093/nar/21.22.5221; BUCHMAN AR, 1990, MOL CELL BIOL, V10, P887, DOI 10.1128/MCB.10.3.887; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; DURET L, 1993, NUCLEIC ACIDS RES, V21, P2315, DOI 10.1093/nar/21.10.2315; Duval A, 1999, CANCER RES, V59, P4213; Duval A, 2001, HUM MOL GENET, V10, P513, DOI 10.1093/hmg/10.5.513; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; GOLLER M, 1994, NUCLEIC ACIDS RES, V22, P1885, DOI 10.1093/nar/22.10.1885; Hoang JM, 1997, CANCER RES, V57, P300; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; Kashi Y, 1997, TRENDS GENET, V13, P74, DOI 10.1016/S0168-9525(97)01008-1; LEVISON G, 1987, MOL BIOL EVOL, V4, P202; LUE NF, 1989, P NATL ACAD SCI USA, V86, P486, DOI 10.1073/pnas.86.2.486; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; NOWAK R, 1994, SCIENCE, V263, P608, DOI 10.1126/science.7508142; Percesepe A, 2000, GENE CHROMOSOME CANC, V27, P424, DOI 10.1002/(SICI)1098-2264(200004)27:4<424::AID-GCC13>3.0.CO;2-M; Pesole G, 1997, GENE, V205, P95, DOI 10.1016/S0378-1119(97)00407-1; Pesole G, 2000, BIOINFORMATICS, V16, P439, DOI 10.1093/bioinformatics/16.5.439; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Sturzeneker R, 2000, HUM MOL GENET, V9, P347, DOI 10.1093/hmg/9.3.347; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thompson MA, 1997, ONCOGENE, V14, P1715, DOI 10.1038/sj.onc.1201007; WINTER E, 1989, EMBO J, V8, P1867, DOI 10.1002/j.1460-2075.1989.tb03583.x; YEE HA, 1991, NUCLEIC ACIDS RES, V19, P949, DOI 10.1093/nar/19.4.949; Zhang L, 2001, CANCER RES, V61, P3801; Zhou XP, 1997, ONCOGENE, V15, P1713, DOI 10.1038/sj.onc.1201337	31	24	28	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2001	20	51					7472	7477		10.1038/sj.onc.1204952	http://dx.doi.org/10.1038/sj.onc.1204952			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709718				2022-12-17	WOS:000171976900003
J	Xin, H; D'Souza, S; Fang, L; Lengyel, P; Choubey, D				Xin, H; D'Souza, S; Fang, L; Lengyel, P; Choubey, D			p202, an interferon-inducible negative regulator of cell growth, is a target of the adenovirus E1A protein	ONCOGENE			English	Article						interferon-inducible p202; cell cycle; pRb; E2Fs; adenovirus E1A	E2F TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR PROTEIN; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; INHIBITION; BINDING; PRB; P53; TRANSFORMATION; PROLIFERATION	Studies have revealed that human adenovirus-encoded E1A protein promotes cell proliferation through the targeted interaction with cellular proteins that act as key negative regulators of cell growth. The targets of E1A protein include the retinoblastoma tumor suppressor protein (pRb). Because p202, an interferon (IFN)inducible murine protein (52-kDa), negatively regulates cell growth in part through the pRb/E2F pathway, we tested whether the p202 is a target of the adenovirus-encoded E1A protein for functional inactivation. Here we report that the expression of E1A protein overcame p202-mediated inhibition of cell growth and this correlated with an alleviation of p202-mediated inhibition of the transcriptional activity of E2F. Furthermore, E1A protein relieved p202-mediated inhibition of the specific DNA-binding activity of E2F complexes, including those containing the pocket proteins. Additionally, the E1A protein bound to p202 both in vitro and in vivo and a deletion of four amino acids in the conserved region 2 (CR2) of E1A protein significantly reduced the binding of E1A to p202. Interestingly, ectopic expression of p202 under reduced serum conditions significantly reduced E1A-mediated apoptosis. Taken together, our observations provide support to the idea that the p202 and adenovirus E1A protein functionally counteract each other and E1A protein targets p202 to promote cell proliferation.	Loyola Univ, Med Ctr, Stritch Sch Med, Dept Radiat Oncol, Maywood, IL 60153 USA; Univ Georgia, Dept Genet, Athens, GA 30602 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Loyola University Chicago; University System of Georgia; University of Georgia; Yale University	Choubey, D (corresponding author), Loyola Univ, Med Ctr, Stritch Sch Med, Dept Radiat Oncol, 2160 S 1st Ave,Bldg 1, Maywood, IL 60153 USA.	dchoube@lumc.edu	Choubey, Divaker/A-4771-2008		NCI NIH HHS [CA69031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA069031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P4387, DOI 10.1093/nar/19.16.4387; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BROCKMANN D, 1995, CURR TOP MICROBIOL, V199, P81; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHOUBEY D, 1992, J CELL BIOL, V116, P1333, DOI 10.1083/jcb.116.6.1333; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; CHOUBEY D, 1993, J INTERFERON RES, V13, P43, DOI 10.1089/jir.1993.13.43; Choubey D, 1997, ONCOGENE, V15, P291, DOI 10.1038/sj.onc.1201184; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Choubey D, 2000, J BIOL REG HOMEOS AG, V14, P187; Condorelli G, 1997, J CELL BIOCHEM, V67, P423, DOI 10.1002/(SICI)1097-4644(19971215)67:4<423::AID-JCB1>3.0.CO;2-U; Cress WD, 1996, CURR TOP MICROBIOL, V208, P63; D'Souza S, 2001, J BIOL CHEM, V276, P298, DOI 10.1074/jbc.M007155200; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; Datta B, 1998, MOL CELL BIOL, V18, P1074, DOI 10.1128/MCB.18.2.1074; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; Geng Y, 2000, J BIOL REG HOMEOS AG, V14, P263; Geng YB, 2000, CELL GROWTH DIFFER, V11, P475; Gutterman JU, 1999, CELL GROWTH DIFFER, V10, P93; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Hertel L, 2000, ONCOGENE, V19, P3598, DOI 10.1038/sj.onc.1203697; JansenDurr P, 1996, TRENDS GENET, V12, P270, DOI 10.1016/0168-9525(96)81455-7; JONES N, 1995, CURR TOP MICROBIOL, V199, P59; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KALVAKOLANU DVR, 1991, P NATL ACAD SCI USA, V88, P7459, DOI 10.1073/pnas.88.17.7459; Koul D, 1998, BIOCHEM BIOPH RES CO, V247, P379, DOI 10.1006/bbrc.1998.8804; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LUDLOW JW, 1995, VIRUS RES, V35, P113, DOI 10.1016/0168-1702(94)00094-S; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; Min W, 1996, MOL CELL BIOL, V16, P359; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; NEVINS JR, 1995, CURR TOP MICROBIOL, V199, P25; NEVINS JR, 1992, SCIENCE, V258, P424; PEEPER DS, 1993, MOL BIOL REP, V17, P197, DOI 10.1007/BF00986728; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; Sang NL, 1997, J CELL PHYSIOL, V170, P182, DOI 10.1002/(SICI)1097-4652(199702)170:2<182::AID-JCP10>3.0.CO;2-K; SCHNEIDER RJ, 1987, ANNU REV BIOCHEM, V56, P317, DOI 10.1146/annurev.biochem.56.1.317; Smith K, 1996, VIROLOGY, V224, P184, DOI 10.1006/viro.1996.0520; WANG H, 2000, J BIOL CHEM, V275, P27366; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHITE E, 1995, CURR TOP MICROBIOL, V199, P33; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; Yan DH, 1999, ONCOGENE, V18, P807, DOI 10.1038/sj.onc.1202369; ZANTEMA A, 1995, CURR TOP MICROBIOL, V199, P1; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	54	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2001	20	47					6828	6839		10.1038/sj.onc.1204844	http://dx.doi.org/10.1038/sj.onc.1204844			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NK	11687962				2022-12-17	WOS:000171641000004
J	Boldrini, L; Faviana, P; Pistolesi, F; Gisfredi, S; Di Quirico, D; Lucchi, M; Mussi, A; Angeletti, CA; Baldinotti, F; Fogli, A; Simi, P; Basolo, F; Fontanini, G				Boldrini, L; Faviana, P; Pistolesi, F; Gisfredi, S; Di Quirico, D; Lucchi, M; Mussi, A; Angeletti, CA; Baldinotti, F; Fogli, A; Simi, P; Basolo, F; Fontanini, G			Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancer	ONCOGENE			English	Article						NSCLC; Fas (CD95/APO-1); p53; mutations	TUMOR-NECROSIS-FACTOR; LIGAND EXPRESSION; IN-VIVO; P53-MEDIATED APOPTOSIS; MEDIATED APOPTOSIS; IMMUNE PRIVILEGE; GROWTH-FACTOR; RECEPTOR; ANTIGEN; ADENOCARCINOMAS	The Fas (APO-1/CD95) system regulates a number of physiological and pathological processes of cell death. The ligand for Fas induces apoptosis by interacting with a transmembrane cell surface Fas receptor. The key role of the Fas system has been studied mostly in the immune system, but Fas mutations, one of the possible mechanisms for resistance to apoptosis signaling, may be involved in the pathogenesis of non-lymphoid malignancies as well. To better understand the potential involvement of Fas system in non-small cell lung cancer (NSCLC) we evaluated Fas and Fas-ligand mRNA expression by polymerase chain reaction in 102 tumor samples and in 44 normal surrounding tissues. Although over 60% of the human NSCLC analysed expressed both genes, they seem to be unable to induce apoptosis in vivo by autocrine suicide. In this regard, we investigated in 79 cases, the promoter and the entire coding region of the Fas gene by polymerase chain reaction, single strand conformation polymorphism and DNA sequencing for detecting putative alterations. Sixteen tumors (20.25%) were found to have Fas alterations, in promoter and/or exon region. In all cases samples carried heterozygous alterations and mostly showed simultaneous mutations of p53 gene. Moreover, the quantitative analysis of Fas mRNA expression showed high levels of Fas messenger associated with p53 wild-type status alone. Taken together, these findings point to an involvement of Fas/Fas-ligand system in the development of NSCLC, suggesting that the loss of its apoptotic function might be linked to p53 alterations which contribute to the self-maintenance of cancer cells.	Univ Pisa, Dept Oncol Transplants & Adv Technol Med, Pisa, Italy; Univ Pisa, Dept Cardiothorac Surg, Pisa, Italy; UO Cytogenet & Mol Genet, Dept Oncol, I-56100 Pisa, Italy	University of Pisa; University of Pisa	Fontanini, G (corresponding author), Dept Oncol, Div Pathol, Via Roma 57, I-56126 Pisa, Italy.		Faviana, Pinuccia/ABA-8436-2021; Basolo, Fulvio/AAC-2727-2019; Fontanini, Gabriella/O-7636-2015; Faviana, Pinuccia/L-5620-2019; FAVIANA, PINUCCIA/R-7928-2017; Lucchi, Marco/K-2140-2019	Faviana, Pinuccia/0000-0003-4283-1083; Basolo, Fulvio/0000-0003-1657-5020; Fontanini, Gabriella/0000-0003-1957-2052; FAVIANA, PINUCCIA/0000-0003-4283-1083; Boldrini, Laura/0000-0001-5904-3708; LUCCHI, MARCO/0000-0001-9909-6820				Beltinger C, 1998, BLOOD, V91, P3943; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bennett MW, 1998, J IMMUNOL, V160, P5669; Boldrini L, 1999, INT J ONCOL, V14, P161; Boussaud V, 1998, EUR RESPIR J, V12, P926, DOI 10.1183/09031936.98.12040926; Butler LM, 2000, BRIT J CANCER, V82, P131; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIRESTEIN GS, 1995, J CLIN INVEST, V96, P1631, DOI 10.1172/JCI118202; Fontanini G, 1999, CLIN CANCER RES, V5, P155; GRATAS C, 1997, BRAIN PATHOL, V7, P853; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; ITOH N, 1993, J BIOL CHEM, V268, P10932; Kashii Y, 1999, J IMMUNOL, V163, P5358; Lee SH, 1999, ONCOGENE, V18, P3754, DOI 10.1038/sj.onc.1202769; Lee SH, 1999, CANCER RES, V59, P3068; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LICHTER P, 1992, GENOMICS, V14, P179, DOI 10.1016/S0888-7543(05)80302-7; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; Midis GP, 1996, CANCER RES, V56, P3870; Mitra D, 1996, IMMUNOLOGY, V87, P581, DOI 10.1046/j.1365-2567.1996.510589.x; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; MUNKER R, 1995, ANN HEMATOL, V70, P15, DOI 10.1007/BF01715376; Munker R, 1996, LEUKEMIA, V10, P1531; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nambu Y, 1998, J CLIN INVEST, V101, P1102, DOI 10.1172/JCI1692; Niehans GA, 1997, CANCER RES, V57, P1007; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; OConnell J, 1997, MOL MED, V3, P294, DOI 10.1007/BF03401808; Rakkar ANS, 1999, CELL DEATH DIFFER, V6, P326, DOI 10.1038/sj.cdd.4400498; RHIN KJ, 2000, J INVEST DERMATOL, V114, P122; Saas P, 1997, J CLIN INVEST, V99, P1173, DOI 10.1172/JCI119273; Shin MS, 1999, AM J PATHOL, V154, P1785, DOI 10.1016/S0002-9440(10)65434-X; Shiraki K, 1997, P NATL ACAD SCI USA, V94, P6420, DOI 10.1073/pnas.94.12.6420; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Ungefroren H, 1998, CANCER RES, V58, P1741; Uramoto H, 1999, EUR J CANCER, V35, P1462, DOI 10.1016/S0959-8049(99)00157-4; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	39	24	25	2	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 4	2001	20	45					6632	6637		10.1038/sj.onc.1204727	http://dx.doi.org/10.1038/sj.onc.1204727			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641789				2022-12-17	WOS:000171404200017
J	Reddy, KB; McGowen, R; Schuger, L; Visscher, D; Sheng, SJ				Reddy, KB; McGowen, R; Schuger, L; Visscher, D; Sheng, SJ			Maspin expression inversely correlates with breast tumor progression in MMTV/TGF-alpha transgenic mouse model	ONCOGENE			English	Article						hyperplasia; carcinoma in situ; invasive carcinoma; immunohistochemistry; in situ hybridization	GROWTH-FACTOR-ALPHA; TGF-ALPHA; PLASMINOGEN-ACTIVATOR; MAMMARY; CELL; CANCER; OVEREXPRESSION; HYPERPLASIA; INHIBITION; NEOPLASIA	Maspin is a novel serine protease inhibitor (serpin) with tumor suppressive activity. To date, despite the mounting evidence implicating the potential diagnostic/prognostic and therapeutic value of maspin in breast and prostate carcinoma, the lack of a suitable animal model hampers the in vivo investigation on the role of maspin at different stages of tumor progression. In this study, we used MMTV/TGF-alpha transgenic mouse model to study the expression profile of maspin in mammary tumor progression. Histopathological examinations of MMTV/TGF-alpha transgenic mice revealed TGF-alpha expression leading to hyperproliferation, hyperplasia, and occasional carcinoma in mammary gland. Interestingly, when MMTV/TGF-alpha transgenic mice were breed to homozygocity, they also developed characteristic skin papillomas. Immunohistochemistry analysis of maspin expression in the breast tissues of TGF-oc transgenic mice showed a direct correlation between down-regulation of maspin expression and tumor progression. The loss of maspin expression was concomitant with the critical transition from carcinoma in situ to invasive carcinoma. Subsequent in-situ hybridization analyses suggest that the down-regulation of maspin expression is primarily a transcriptional event. This data is consistent with the tumor suppressive role of maspin. Furthermore, our data suggests that MMTV/TGF-alpha transgenic mouse model is advantageous for in vivo evaluation of both the expression and the biological function of maspin during the slow multi-stage carcinogenesis of mammary gland.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA	Wayne State University	Sheng, SJ (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield Ave, Detroit, MI 48201 USA.	ssheng@med.wayne.edu			NCI NIH HHS [CA 64248, CA 83964, CA69845] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064248, R01CA083964, R21CA069845] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; GOTTLIEB AB, 1988, J EXP MED, V167, P670, DOI 10.1084/jem.167.2.670; Humphreys RC, 2000, ONCOGENE, V19, P1085, DOI 10.1038/sj.onc.1203278; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Lenferink AEG, 2000, P NATL ACAD SCI USA, V97, P9609, DOI 10.1073/pnas.160564197; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; McGowen R, 2000, CANCER RES, V60, P4771; REDDY KB, 1994, CELL GROWTH DIFFER, V5, P1275; Rose-Hellekant TA, 2000, ONCOGENE, V19, P1092, DOI 10.1038/sj.onc.1203350; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; Sternlicht MD, 1997, CLIN CANCER RES, V3, P1949; Wagner M, 2001, GENE DEV, V15, P286, DOI 10.1101/gad.184701; Xia WY, 2000, ONCOGENE, V19, P2398, DOI 10.1038/sj.onc.1203535; Yamada N, 2000, GENE, V241, P267, DOI 10.1016/S0378-1119(99)00484-9; Zhang M, 1997, MOL MED, V3, P49, DOI 10.1007/BF03401667; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	25	24	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6538	6543		10.1038/sj.onc.1204796	http://dx.doi.org/10.1038/sj.onc.1204796			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641778				2022-12-17	WOS:000171404200006
J	Ludde, T; Kubicka, S; Plumpe, J; Liedtke, C; Manns, MP; Trautwein, C				Ludde, T; Kubicka, S; Plumpe, J; Liedtke, C; Manns, MP; Trautwein, C			Ras adenoviruses modulate cyclin E protein expression and DNA synthesis after partial hepatectomy	ONCOGENE			English	Article						Ras; hepatectomy; liver regeneration; DNA synthesis; cyclin E	RETINOBLASTOMA GENE-PRODUCT; MITOGEN-ACTIVATED PROTEIN; CELL-CYCLE; LIVER-REGENERATION; DIFFERENTIAL REGULATION; DOWN-REGULATION; S PHASE; TRANSCRIPTION; BINDING; GROWTH	Ras-genes encode for proteins important for transmitting extracellular signals from the cytoplasm to the nucleus. In this study we investigated the impact of Ras on cell cycle progression after hepatectomy by using adenoviral vectors (adv) expressing beta -galactosidase (beta -gal), a dominant-negative (Ras N17) or a dominant-active (Ras 61L) form of H-Ras. Partial hepatectomy was performed in mice treated with the different adenoviruses and cell cycle progression was studied by analysing factors involved in cell cycle control during liver regeneration. After hepatectomy, adv Ras 61L increases DNA synthesis significantly in comparison to the other treatment groups. Higher Ras activity results in an early increase of transcriptional active E2F-3, which is associated with higher cyclin E, but almost unchanged cyclin D protein expression. However, Northern blot analysis and cyclin E promoter experiments indicate that, besides transcriptional mechanisms also post-transcriptional mechanisms are involved in regulating cyclin E protein expression after partial hepatectomy in mice treated with adv Ras 61L. Cyclin E phosphorylation studies demonstrate that adv Ras 61L results in hypophosphorylation of cyclin E compared to the control group at early time points after hepatectomy, when cyclin E protein expression strongly increases and there is only a minor effect on cyclin E mRNA levels. Our experiments indicate adv Ras 61L in vivo increases Cyclin E expression by higher transcription via E2F and a post-transcriptional mechanism. These mechanisms result in an earlier activation of an active CDK2/Cyclin E complex which, in turn, triggers DNA synthesis.	Hannover Med Sch, Dept Gastroenterol & Hepatol, D-30625 Hannover, Germany	Hannover Medical School	Trautwein, C (corresponding author), Hannover Med Sch, Dept Gastroenterol & Hepatol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Trautwein.christian@MH-Hannover.de	Liedtke, Christian/DTV-1874-2022; Luedde, Tom/AAE-9135-2022	Liedtke, Christian/0000-0003-4681-7887; Luedde, Tom/0000-0002-6288-8821				AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Botz J, 1996, MOL CELL BIOL, V16, P3401; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; BRENNER DA, 1998, GASTROENTEROL HEPATO, V13, P93; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DAMJANOV I, 1994, BIOCHEM BIOPH RES CO, V201, P994, DOI 10.1006/bbrc.1994.1800; Dealy MJ, 1999, NAT GENET, V23, P245, DOI 10.1038/13886; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Fan JG, 1997, ONCOGENE, V14, P2595, DOI 10.1038/sj.onc.1201105; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; Hayder H, 1999, J IMMUNOL, V163, P1516; Higgins GM, 1931, ARCH PATHOL, V12, P186; Hitomi M, 1999, MOL CELL BIOL, V19, P4623; Kim TH, 1997, HEPATOLOGY, V26, P896, DOI 10.1002/hep.510260415; Kuhnel F, 2000, J BIOL CHEM, V275, P6421, DOI 10.1074/jbc.275.9.6421; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lozier JN, 1999, BLOOD, V94, P3968, DOI 10.1182/blood.V94.12.3968.424k43_3968_3975; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; ROEB E, 1993, HEPATOLOGY, V18, P1437, DOI 10.1016/0270-9139(93)90236-G; Rudolph KL, 1999, HEPATOLOGY, V30, P1159, DOI 10.1002/hep.510300502; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Spector MS, 1997, MOL CELL BIOL, V17, P3556, DOI 10.1128/MCB.17.7.3556; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; Trautwein C, 1999, ONCOGENE, V18, P6443, DOI 10.1038/sj.onc.1203045; Trautwein C, 1996, J BIOL CHEM, V271, P22262, DOI 10.1074/jbc.271.36.22262; Trautwein C, 1996, GASTROENTEROLOGY, V110, P1854, DOI 10.1053/gast.1996.v110.pm8964411; Trautwein C, 1998, J CLIN INVEST, V101, P1960, DOI 10.1172/JCI504; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tulasne D, 1999, MOL BIOL CELL, V10, P551, DOI 10.1091/mbc.10.3.551; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wang YS, 1999, CURR BIOL, V9, P1191, DOI 10.1016/S0960-9822(00)80024-X; Winston JT, 1996, ONCOGENE, V12, P127; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	49	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2001	20	38					5264	5278		10.1038/sj.onc.1204690	http://dx.doi.org/10.1038/sj.onc.1204690			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536040				2022-12-17	WOS:000170575500003
J	Kim, H; You, S; Linda, KF; Farris, J; Foster, DN				Kim, H; You, S; Linda, KF; Farris, J; Foster, DN			The rapid destabilization of p53 mRNA in immortal chicken embryo fibroblast cells	ONCOGENE			English	Article						CEF; cycloheximide; immortalization; mRNA destablization; p53 mRNA; chicken	MESSENGER-RNA DEGRADATION; TUMOR-SUPPRESSOR P53; UNTRANSLATED REGIONS; ELEMENTS; MDM2; GENE; APOPTOSIS; STABILITY; MEDIATOR; PROMOTES	The steady-state levels of p53 mRNA were dramatically lower in immortal chicken embryo fibroblast (CEF) cell lines compared to primary CEF cells. In the presence of cycloheximide (CHX), the steady-state levels of p53 mRNA markedly increased in immortal CEF cell lines, similar to levels found in primary cells. The de novo synthetic rates of p53 mRNA were relatively similar in primary and immortal cells grown in the presence or absence of CHX. Destabilization of p53 mRNA was observed in the nuclei of immortal, but not primary, CEF cells. The half-life of p53 mRNA in primary cells was found to be a relatively long 23 h compared to only 3 It in immortal cells. The expression of transfected p53 cDNA was inhibited in immortal cells, but restored upon CHX treatment. The 5'-region of the p53 mRNA was shown to be involved in the rapid p53 mRNA destabilization in immortal cells by expression analysis of 5'- and 3-deleted p53 cDNAs as well as fusion mRNA constructs of N-terminal p53 and N-terminal deleted LacZ genes. Together, it is suggestive that the downregulation of p53 mRNA in immortal CEF cells occurs through a post-transcriptional destabilizing mechanism.	Univ Minnesota, Dept Anim Sci, St Paul, MN 55108 USA; Seoul Natl Univ, Sch Agr Biotechnol, Suwon 441744, South Korea	University of Minnesota System; University of Minnesota Twin Cities; Seoul National University (SNU)	Foster, DN (corresponding author), 495 AnSci VetMed,1988 Fitch Ave, St Paul, MN 55108 USA.		Kim, Hyunggee/F-2673-2013; You, Seungkwon/H-3067-2015; Kang, Phil Jun/F-4716-2013	Kim, Hyunggee/0000-0002-4738-0990; 				Attardi LD, 2000, GENE DEV, V14, P704; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; D'Erchia AM, 1999, GENOMICS, V58, P50, DOI 10.1006/geno.1999.5794; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; JIANG D, 1993, ONCOGENE, V8, P2805; Kim H, 2001, EXP CELL RES, V265, P339, DOI 10.1006/excr.2001.5207; Kim H, 2001, ONCOGENE, V20, P3306, DOI 10.1038/sj.onc.1204423; Kim H, 2001, ONCOGENE, V20, P2671, DOI 10.1038/sj.onc.1204378; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Madisen L, 1998, MOL CELL BIOL, V18, P6281, DOI 10.1128/MCB.18.11.6281; MIYASHITA T, 1995, CELL, V80, P293; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Yeilding NM, 1998, J BIOL CHEM, V273, P15749, DOI 10.1074/jbc.273.25.15749	26	24	25	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5118	5123		10.1038/sj.onc.1204664	http://dx.doi.org/10.1038/sj.onc.1204664			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526500				2022-12-17	WOS:000170464000005
J	Masuoka, J; Brandner, S; Paulus, W; Soffer, D; Vital, A; Chimelli, L; Jouvet, A; Yonekawa, Y; Kleihues, P; Ohgaki, H				Masuoka, J; Brandner, S; Paulus, W; Soffer, D; Vital, A; Chimelli, L; Jouvet, A; Yonekawa, Y; Kleihues, P; Ohgaki, H			Germline SDHD mutation in paraganglioma of the spinal cord	ONCOGENE			English	Article						SDHD; germline mutation; paraganglioma; cauda equina	FAMILIAL NONCHROMAFFIN PARAGANGLIOMAS; AUTOSOMAL-DOMINANT PARAGANGLIOMA; SUCCINATE-UBIQUINONE REDUCTASE; HEREDITARY PARAGANGLIOMAS; IMPRINTED GENE; GLOMUS TUMORS; CHROMOSOME; OXIDOREDUCTASE; CLONING; DOMAIN	Hereditary paraganglioma of the head and neck is associated with germline mutations in the SDHD gene, which encodes a mitochondrial respirator), chain protein. Paragangliomas of the central nervous system are very rare, occur almost exclusively in the cauda equina of the spinal cord and are considered non-familial. In the present study, we screened 22 apparently sporadic paragangliomas of the cauda equina for SDHD mutations. One spinal paraganglioma and similar cerebellar tumours that developed 22 years later in the same patient contained a missense mutation at codon 12 (GGT --> AGT, Gly --> Ser) and a silent mutation at codon 68 (AGC --> AGT, Ser --> Ser). There was no family history of paragangliomas but DNA from white blood cells of this patient showed the same sequence alterations, indicating the presence of a germline mutation. All other cases of spinal paraganglioma had the wild-type SDHD sequence, except one case with a silent mutation at codon 68 (AGC --> AGT, Ser --> Ser). This is the first observation indicating that inherited SDHD mutations may occasionally cause the development of paragangliomas in the central nervous system.	Int Agcy Res Canc, F-69372 Lyon 08, France; Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland; Univ Hosp, Neuropathol Lab, F-69003 Lyon, France; Fed Univ Rio De Janeiro, Univ Hosp, Div Pathol, BR-21941590 Rio De Janeiro, Brazil; Victor Segalen Univ, Neuropathol Lab, F-33076 Bordeaux, France; Hadassah Univ Hosp, Dept Pathol, IL-91120 Jerusalem, Israel; Univ Munster, Inst Neuropathol, D-48129 Munster, Germany	World Health Organization; International Agency for Research on Cancer (IARC); University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; CHU Lyon; Universidade Federal do Rio de Janeiro; UDICE-French Research Universities; Universite de Bordeaux; Hebrew University of Jerusalem; University of Munster	Ohgaki, H (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.		Brandner, Sebastian/J-4562-2014	Brandner, Sebastian/0000-0002-9821-0342				Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Baysal BE, 1997, AM J HUM GENET, V60, P121; BRODEUR GM, 1998, PHEOCHROMOCYTOMAS PA, P535; GRUFFERMAN S, 1980, CANCER, V46, P2116, DOI 10.1002/1097-0142(19801101)46:9<2116::AID-CNCR2820460934>3.0.CO;2-S; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Hagerhall C, 1996, FEBS LETT, V389, P25, DOI 10.1016/0014-5793(96)00529-7; HEUTINK P, 1992, HUM MOL GENET, V1, P7, DOI 10.1093/hmg/1.1.7; Heutink Peter, 1994, European Journal of Human Genetics, V2, P148; Hirawake H, 1997, CYTOGENET CELL GENET, V79, P132, DOI 10.1159/000134700; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; MARIMAN ECM, 1995, HUM GENET, V95, P56, DOI 10.1007/BF00225075; Niemann S, 1999, NEUROGENETICS, V2, P167, DOI 10.1007/s100480050078; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Oyedotun KS, 1999, FEBS LETT, V442, P203, DOI 10.1016/S0014-5793(98)01657-3; Reis RM, 2000, AM J PATHOL, V156, P425, DOI 10.1016/S0002-9440(10)64746-3; Scheffler IE, 1998, PROG NUCLEIC ACID RE, V60, P267, DOI 10.1016/S0079-6603(08)60895-8; Shenoy SK, 1997, J BIOL CHEM, V272, P17867, DOI 10.1074/jbc.272.28.17867; SOFFER D, 2000, WHO CLASSIFICATION T, P112; SPECTOR GJ, 1975, LARYNGOSCOPE, V85, P1066, DOI 10.1288/00005537-197506000-00016; STROMMER KN, 1995, J NEUROSURG, V83, P166, DOI 10.3171/jns.1995.83.1.0166; van Schothorst EM, 1998, HUM PATHOL, V29, P1045, DOI 10.1016/S0046-8177(98)90411-7; VANBAARS F, 1982, HUM GENET, V60, P305, DOI 10.1007/BF00569208; VANDERMEY AGL, 1989, LANCET, V2, P1291; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x	24	24	25	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					5084	5086		10.1038/sj.onc.1204579	http://dx.doi.org/10.1038/sj.onc.1204579			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526495				2022-12-17	WOS:000170439800020
J	Munnia, A; Schutz, N; Romeike, BFM; Maldener, E; Glass, B; Maas, R; Nastainczyk, W; Feiden, W; Fischer, U; Meese, E				Munnia, A; Schutz, N; Romeike, BFM; Maldener, E; Glass, B; Maas, R; Nastainczyk, W; Feiden, W; Fischer, U; Meese, E			Expression, cellular distribution and protein binding of the glioma amplified sequence (GAS41), a highly conserved putative transcription factor	ONCOGENE			English	Article						amplification; GAS41; glioma; NuMA; ENL; KIAA1009; PFDN1; TFIIF	GENE AMPLIFICATION; MITOTIC SPINDLE; MATRIX; NUMA; OVEREXPRESSION; PREFOLDIN; COMPONENT; DOMAIN	The glioma amplified sequence 41 (GAS41) was previously isolated by microdissection mediated cDNA capture from the glioblastoma multiforme cell line TX3868 and shown to be frequently amplified in human gliomas. We determined the complete cDNA sequence of the GAS41 gene, demonstrated that the GAS41 protein is evolutionarily conserved, specifically at the N-terminus, and identified the yeast transcription factor tf2f domain within the GAS41 sequence. A human multiple-tissue Northern blot revealed ubiquitous expression of GAS41 with the highest expression in human brain. After generating polyclonal antibodies we found GAS41 protein expression in the nucleus of the TX3868 cell line by Western blot analysis and immunofluorescence microscopy. The nuclear localization was confirmed for several human tumors including gliomas of different grades of malignancy. In neuroblastoma however, GAS41 was found in the nucleoli but not in the nucleoplasm. Yeast two-hybrid screening of the TX3868 cell line identified the nuclear mitotic apparatus protein (NuMA), the KIAA1009 protein, and prefoldin subunit 1 (PFDN1) as potential interacting partners of GAS41. We generated a polyclonal antibody against the KIAA1009 protein and we demonstrated that the KIAA1009 protein is a nuclear protein, which appears to be co-localized with the GAS41 protein and NuMA.	Univ Saarlandes Kliniken, Inst Human Genet, D-66421 Homburg, Germany; Univ Saarlandes Kliniken, Abt Neuropathol, D-66421 Homburg, Germany; Univ Saarlandes Kliniken, Inst Med Biochem, D-66421 Homburg, Germany	Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes	Meese, E (corresponding author), Univ Saarland, Dept Human Genet, Bldg 60, D-66421 Homburg, Germany.	hgemee@med-rz.uni-sb.de	Romeike, Bernd/K-8516-2019; , PD Dr. med. Bernd FM Romeike/Q-2600-2019; Meese, Eckart Ulrich/ABD-1983-2021	, PD Dr. med. Bernd FM Romeike/0000-0002-9693-3870; 				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Albrecht EB, 2000, MOL BIOL CELL, V11, P873, DOI 10.1091/mbc.11.3.873; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; COMPTON DA, 1995, J CELL SCI, V108, P621; DINGWALL AK, 1995, MOL BIOL CELL, V6, P777, DOI 10.1091/mbc.6.7.777; Dionne MA, 1999, CELL MOTIL CYTOSKEL, V42, P189, DOI 10.1002/(SICI)1097-0169(1999)42:3<189::AID-CM3>3.0.CO;2-X; Fischer U, 1997, HUM MOL GENET, V6, P1817, DOI 10.1093/hmg/6.11.1817; Fischer U, 1996, HUM GENET, V98, P625, DOI 10.1007/s004390050271; Gelbart WM, 1999, NUCLEIC ACIDS RES, V27, P85, DOI 10.1093/nar/27.1.85; Gueth-Hallonet C, 1998, EXP CELL RES, V243, P434, DOI 10.1006/excr.1998.4178; Hansen WJ, 1999, J CELL BIOL, V145, P265, DOI 10.1083/jcb.145.2.265; Harborth J, 2000, J BIOL CHEM, V275, P31979, DOI 10.1074/jbc.M000994200; Harlow E., 1989, ANTIBODIES LAB MANUA; Heiskanen MA, 2000, CANCER RES, V60, P799; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; KLEIHUES P, 1995, GLIA, V15, P211, DOI 10.1002/glia.440150303; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUDERUS MEE, 1994, MOL CELL BIOL, V14, P6297, DOI 10.1128/MCB.14.9.6297; LYDERSON BK, 1980, CELL               2, V22, P498; MARTIN KJ, 1991, BIOESSAYS, V13, P499, DOI 10.1002/bies.950131003; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Murakami Y, 2000, J VET MED SCI, V62, P783, DOI 10.1292/jvms.62.783; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; Remacle JE, 1997, EMBO J, V16, P5722, DOI 10.1093/emboj/16.18.5722; RICHARD AW, 1997, NAT GENET, V17, P109; Sehgal A, 1998, SEMIN SURG ONCOL, V14, P3; Suzuki SO, 2000, MODERN PATHOL, V13, P548, DOI 10.1038/modpathol.3880095; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang ZH, 1999, ANTICANCER RES, V19, P5445; Zeng CQ, 2000, MICROSC RES TECHNIQ, V49, P467, DOI 10.1002/(SICI)1097-0029(20000601)49:5<467::AID-JEMT9>3.3.CO;2-M	37	24	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2001	20	35					4853	4863		10.1038/sj.onc.1204650	http://dx.doi.org/10.1038/sj.onc.1204650			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521196				2022-12-17	WOS:000170271800009
J	Turturro, F; Frist, AY; Arnold, MD; Seth, P; Pulford, K				Turturro, F; Frist, AY; Arnold, MD; Seth, P; Pulford, K			Biochemical differences between SUDHL-1 and KARPAS 299 cells derived from t(2;5)-positive anaplastic large cell lymphoma are responsible for the different sensitivity to the anti proliferative effect of p27(Kip1)	ONCOGENE			English	Article						cell cycle; adenovirus; p27(Kip1); NPM-ALK; ALCL; PTEN	DEPENDENT KINASE INHIBITOR; NON-HODGKINS-LYMPHOMA; TYROSINE KINASE; TUMOR-CELLS; NPM-ALK; PROTEIN; GENE; EXPRESSION; RECEPTOR; FUSION	An inverse correlation between p27(Kip1) expression and proliferation has been recently established in tissues derived from human lymphomas. The nucleophosminanaplastic lymphoma kinase (NPM-ALK)/phospholipase C-gamma (PLC gamma) complex also appears to play an important role in cell proliferation and malignant transformation of anaplastic large cell lymphoma (ALCL). In this study, we report that SUDHL-1 and KARPAS 299 ALCL-derived cell lines present different sensitivity to the antiproliferative effect of recombinant adenovirus-mediated p27(Kip1) expression or to serum-starvation in culture media. The results indicate that exogenous p27(Kip1) may interact with the NPM-ALK/ PLC;, pathway in SUDHL-1 but not in KARPAS 299 cells. This interaction correlates with changes in cell cycle and cell morphology observed mainly in SUDHL-1 cells. The percentage of SUDHL-1 cells in S phase declines, whereas it is almost unchanged in KARPAS 299 cells as compared to the controls after 96 h of infection with the recombinant adenovirus. Furthermore KARPAS 299 cells are resistant to serum-starvation due to deficient p27(Kip1)-upregulation and G1 arrest, whereas SUDHL-1 cells respond with increased G1 phase and p27(Kip1)-upregulation after 48 h of serum-starvation. Both cell lines express appropriate variation of levels of cyclins E and A, and Rb-phosphorylation as expected by growing them in culture media with different FBS content. Although both cell lines express cyclin D2, SUDHL-1 cells only present high level of cyclin D3. Moreover SUDHL-1 cells express high level of PTEN and the PKB/Akt pathway is constitutively activated in both cell lines. Lastly SUDHL-1 cells show higher levels of phosphotyrosine-containing proteins that is correlated with a higher NPM-ALK-associated autophosphorylation activity compared to KARPAS 299 cells. Our study clearly identifies some of the biochemical differences that may explain the difference in sensitivity to antiproliferative stimuli shown by two cell lines derived from the same type of lymphoma.	Iowa Methodist Med Ctr, John Stoddard Canc Ctr, Human Gene Therapy Res Inst, Des Moines, IA 50309 USA; VA Cent Iowa Hlth Care Syst, Div Hematol Oncol, Des Moines, IA 50309 USA; Des Moines Univ, Univ Res, Des Moines, IA 50312 USA; John Radcliffe Hosp, Nuffield Dept, Clin Sci Lab, Oxford OX3 9DU, England	Iowa Methodist Medical Center; University of Oxford	Turturro, F (corresponding author), Iowa Methodist Med Ctr, John Stoddard Canc Ctr, Human Gene Therapy Res Inst, 1415 Woodland Ave, Des Moines, IA 50309 USA.		Pulford, Karen/B-3609-2009	Pulford, Karen/0000-0002-2989-789X				Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Depoortere F, 2000, MOL BIOL CELL, V11, P1061, DOI 10.1091/mbc.11.3.1061; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; FISCHER P, 1988, BLOOD, V72, P234; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; HARRIS NL, 1994, BLOOD, V84, P1361; Hubinger G, 1999, EXP HEMATOL, V27, P1796, DOI 10.1016/S0301-472X(99)00116-2; Izuishi K, 2000, CANCER RES, V60, P6201; Jiang YH, 2000, P NATL ACAD SCI USA, V97, P10538, DOI 10.1073/pnas.190104497; Jonuleit T, 2000, BLOOD, V96, P1933, DOI 10.1182/blood.V96.5.1933.h8001933_1933_1939; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Mason DY, 1998, CANCER RES, V58, P1057; MORGAN R, 1989, BLOOD, V73, P2155; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Sakai A, 1998, BLOOD, V92, P3410, DOI 10.1182/blood.V92.9.3410.421a06_3410_3415; SanchezBeato M, 1997, AM J PATHOL, V151, P151; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; Sherr CJ, 2000, CANCER RES, V60, P3689; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Suzuki R, 1999, LEUKEMIA, V13, P1335, DOI 10.1038/sj.leu.2401485; Szebeni A, 1999, PROTEIN SCI, V8, P905; Turturro F, 2000, CLIN CANCER RES, V6, P185; Turturro F, 2000, GENE THER, V7, P930, DOI 10.1038/sj.gt.3301186; TURTURRO F, 2000, MOL THER, V1, pS323; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587	36	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2001	20	33					4466	4475		10.1038/sj.onc.1204582	http://dx.doi.org/10.1038/sj.onc.1204582			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494142				2022-12-17	WOS:000170074900004
J	Manos, EJ; Kim, MLH; Kassis, J; Chang, PY; Wells, A; Jones, DA				Manos, EJ; Kim, MLH; Kassis, J; Chang, PY; Wells, A; Jones, DA			Dolichol-phosphate-mannose-3 (DPM3)/prostin-1 is a novel phospholipase C-gamma regulated gene negatively associated with prostate tumor invasion	ONCOGENE			English	Article						prostate; invasion; metastasis; phospholipase; EGF receptor; microarray	EPIDERMAL GROWTH-FACTOR; IN-VITRO INVASIVENESS; EGF RECEPTOR; PLASMINOGEN-ACTIVATOR; FIBROBLAST MIGRATION; CARCINOMA-CELLS; CANCER-CELLS; EXPRESSION; MOTILITY; KINASE	The most ominous development in tumor progression is the transition to an invasive and metastatic phenotype, Little is known, however, about the molecular alterations that cause a tumor to become invasive, in view of this, we have used microarray expression analysis to evaluate the expression profiles of a unique panel of human DU145 prostate cancer sublines that vary in their invasive potential, The three DU145 sublines expressed epidermal growth factor (EGF) receptors that differed in their ability to activate phospholipase C-gamma (PLC gamma). Three-way analyses yielded 11 genes out of 4608 genes screened that associated directly or inversely with invasive potential, The gene whose expression correlated most strongly with lack of invasion was identified as a potential invasion suppressor and called prostin-1. Pharmacological inhibition of PLC gamma (U73122) confirmed that PLC gamma, signaling suppressed prostin-1 in that U73122 treatment caused induction of prostin-1 in PLC gamma, competent cells, The prostin-l gene, conserved through phylogeny, is induced by androgen in LNCaP cells acid encodes a 92 amino acid protein, The protein shares no extensive homologies with other known genes, yet was recently identified as a small stabilizer subunit of the dolichol-phosphate-mannose (DPM) synthase complex, That DPM3/prostin-1 might suppress tumor progression was supported by the finding that exogenous expression in COS cells leads to apoptosis, These findings support the use of model cell lines to identify putative tumor suppressors and promoters.	Univ Utah, Huntsman Canc Inst, Div Mol Pharmacol, Salt Lake City, UT 84112 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA; Univ Wisconsin, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA; Pittsburgh VAMC, Pittsburgh, PA 15260 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Jones, DA (corresponding author), Univ Utah, Huntsman Canc Inst, Div Mol Pharmacol, 2000 Circle Hope,Rm 5242, Salt Lake City, UT 84112 USA.			Wells, Alan/0000-0002-1637-8150				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Barrack ER, 1997, PROSTATE, V31, P61; BAUER J, 1992, J CELL PHYSIOL, V153, P437, DOI 10.1002/jcp.1041530302; Bornfeldt KE, 1995, ANN NY ACAD SCI, V766, P416, DOI 10.1111/j.1749-6632.1995.tb26691.x; BOROS P, 1995, LANCET, V345, P293, DOI 10.1016/S0140-6736(95)90279-1; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; GORDON SR, 1990, CELL MOTIL CYTOSKEL, V16, P47, DOI 10.1002/cm.970160107; Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150; Jacobs W, 1997, J NEURO-ONCOL, V32, P93, DOI 10.1023/A:1005777711567; Kameyama T, 1996, BIOCHEM BIOPH RES CO, V226, P396, DOI 10.1006/bbrc.1996.1367; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Kim HG, 1999, HISTOL HISTOPATHOL, V14, P1175, DOI 10.14670/HH-14.1175; KINDRA V, 1994, ONCOGENE, V9, P1429; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lal A, 1999, CANCER RES, V59, P5403; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Maeda Y, 2000, EMBO J, V19, P2475, DOI 10.1093/emboj/19.11.2475; Maheshwari G, 1999, BIOPHYS J, V76, P2814, DOI 10.1016/S0006-3495(99)77435-7; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; METTLIN C, 1993, CA-CANCER J CLIN, V43, P83, DOI 10.3322/canjclin.43.2.83; MOUL JW, 1996, FED PRACT, V13, P3; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Reuning U, 1998, INT J ONCOL, V13, P893; Rochefort H, 1998, J STEROID BIOCHEM, V65, P163, DOI 10.1016/S0960-0760(98)00010-7; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Schmitt M, 1995, J Obstet Gynaecol (Tokyo 1995), V21, P151; SHULTZ MJ, 1996, FED PRACT, V13, P14; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; Takaoka A, 1998, ONCOGENE, V16, P1443, DOI 10.1038/sj.onc.1201648; Turner T, 1997, CLIN CANCER RES, V3, P2275; Turner T, 1996, CLIN EXP METASTAS, V14, P409, DOI 10.1007/BF00123400; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Ware MF, 1998, J CELL SCI, V111, P2423; Wells A, 1998, MICROSC RES TECHNIQ, V43, P395, DOI 10.1002/(SICI)1097-0029(19981201)43:5<395::AID-JEMT6>3.0.CO;2-T; WENNSTROM S, 1994, ONCOGENE, V9, P651; WHITTEMORE AS, 1991, J NATL CANCER I, V83, P1231, DOI 10.1093/jnci/83.17.1231; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; XIE H, 1995, CLIN EXP METASTAS, V13, P407, DOI 10.1007/BF00118180; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	47	24	26	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2001	20	22					2781	2790		10.1038/sj.onc.1204379	http://dx.doi.org/10.1038/sj.onc.1204379			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420690				2022-12-17	WOS:000168712000006
J	Lin, F; Monaco, G; Sun, T; Liu, JX; Lin, H; Stephens, C; Belmont, J; Arlinghaus, RB				Lin, F; Monaco, G; Sun, T; Liu, JX; Lin, H; Stephens, C; Belmont, J; Arlinghaus, RB			BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model	ONCOGENE			English	Article						Bcr; Bcr-Abl; chronic myelogenous leukemia	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE; 1ST EXON; P160 BCR; IN-VIVO; C-ABL; MICE; SEQUENCES; ONCOGENE	It is well accepted that the Bcr-Abl oncoprotein encoded by the Philadelphia chromosome is responsible for causing chronic myelogenous leukemia (CML), We have previously demonstrated that expression of Bcr interferes with the oncogenic effects of Bcr-Abl, To examine the effects of increased Bcr expression on Bcr-Abl oncogenic effects in a more physiological system, we tested the leukemogenic potential of a clone of K562 cells (K6 K562) containing an inducible BCR gene in NOD/scid mice. In this clone, the BCR gene was placed under the control of a tetracycline (Tet) repression system with a cytomegalovirus (CMV) promoter. Induction of exogenous Bcr protein by removal of Tet from the culture medium caused a dramatic increase in Bcr serine kinase activity, yielding predominantly phosphoserine Bcr, despite the presence of Bcr-Abl in the kinase reaction mixture. Prior to induction, the endogenous Bcr was predominantly in the phosphotyrosine form because of phosphorylation by Bcr-Abl, which we previously have shown suppresses Bcr serine/threonine kinase activity, Injection of K6 K562 cells into NOD/scid mice under conditions where BCR expression was suppressed resulted in death or terminal illness in 100% of the mice within 35 days after injection. These mice had a severe wasting syndrome characterized by atrophy of bone marrow hematopoiesis, and/or neoplasia of liver, bone marrow and spleen. Neoplastic spleens from these mice usually contained b3a2 Bcr-Abl transcripts. In contrast, induction of BCR expression at the time of injection allowed 80% survival; these healthy mice had no detectable microscopic lesions in blood forming organs. This difference in survival was significant with P<0.0001, Of interest, mire that were fed Tet for 19 days to initiate the disease syndrome and then released from the BCR transcriptional block had a significantly better survival pattern than mice exposed to Tet throughout the entire period. Moreover, 30% of these mice (three mice) survived through day 50, We conclude from these findings that BCR gene expression strongly inhibits the oncogenic effects of Bcr-Abl in NOD/scid mice, yielding healthy mice in most cases.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Vet Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Arlinghaus, RB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA.		Belmont, John/AAH-6084-2021; Belmont, John W/AAI-2494-2019	Belmont, John W/0000-0001-7409-3578	NCI NIH HHS [CA49639] Funding Source: Medline; PHS HHS [A16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arlinghaus RB, 1998, CRIT REV ONCOGENESIS, V9, P1; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; CAMPBELL ML, 1990, ONCOGENE, V5, P773; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dazzi F, 1998, BLOOD, V92, P1390, DOI 10.1182/blood.V92.4.1390.416k09_1390_1396; DAZZI F, 1997, BLOOD S1, V90, P8; Gross AW, 1999, MOL CELL BIOL, V19, P6918; Hawk N., 1997, Blood, V90, p277B; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HU AZX, 1997, CANCER RES, V57, P3339; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Lewis ID, 1998, BLOOD, V91, P630, DOI 10.1182/blood.V91.2.630.630_630_640; LI WJ, 1989, ONCOGENE, V4, P127; Lin F, 1996, BLOOD, V87, P4473, DOI 10.1182/blood.V87.10.4473.bloodjournal87104473; Liu JX, 1996, CANCER RES, V56, P5120; Liu JX, 1996, MOL CELL BIOL, V16, P998; LIU JX, 1993, ONCOGENE, V8, P101; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Ma GZ, 1997, ONCOGENE, V14, P2367, DOI 10.1038/sj.onc.1201053; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Wu Y, 1999, ONCOGENE, V18, P4416, DOI 10.1038/sj.onc.1202828; Wu Y, 1998, ONCOGENE, V16, P141, DOI 10.1038/sj.onc.1201524	26	24	28	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2001	20	15					1873	1881		10.1038/sj.onc.1204409	http://dx.doi.org/10.1038/sj.onc.1204409			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	418TX	11313935				2022-12-17	WOS:000167908400008
J	Benaud, CM; Dickson, RB				Benaud, CM; Dickson, RB			Regulation of the expression of c-Myc by beta 1 integrins in epithelial cells	ONCOGENE			English	Article						c-Myc; adhesion; integrin; Src; PKC; MAPK	ACTIVATED PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; BETA(1C) INTEGRIN; EGF RECEPTOR; CYCLIN D1; IN-VIVO; ADHESION; SRC; GROWTH; INDUCTION	Cell adhesion promotes cellular proliferation through the regulation of gene expression, including the immediate early genes. However, the precise role of cell adhesion in the regulation of the c-Myc proto-oncogene is not clear, and the adhesion-dependent signaling pathway(s) regulating the expression of c-Myc has yet to be defined. We now show that integrin signaling directly regulates the expression of c-Myc in the mammary epithelial cell line 184A1N4 (A1N4), Adhesion of quiescent A1N4 cells to fibronectin, and to collagen types IV or I, induces the expression of c-Myc in an ECM concentration-dependent fashion. Cytoskeletal rearrangement, and integrin engagement and integrin clustering are required for the induction of c-Myc by fibronectin. Furthermore, beta1 integrin function-blocking antibodies prevent the adhesion-dependent induction of c-Myc. Adhesion of A1N4 cells results in the activation both of c-Src and of the Erk 1/2 mitogen-activated protein kinase (MAPK), each of which precedes the induction of c-Myc. Pharmacological inhibitors specific for either the c-Src family of kinases or for MEK1 block the adhesion-dependent induction of c-Myc. These observations indicate that pi integrins regulate the expression of c-Myc through the activation of the Src family of tyrosine kinases and the MAI( kinase pathway.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Cell Biol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20007 USA	Georgetown University; Georgetown University; Georgetown University	Dickson, RB (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, 3970 Reservoir Rd NW, Washington, DC 20007 USA.		Benaud, Christelle/M-1178-2018		NIA NIH HHS [R01AG1496] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Aziz N, 1999, MOL CELL BIOL, V19, P1101; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Cheng M, 1999, J BIOL CHEM, V274, P6553, DOI 10.1074/jbc.274.10.6553; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Dike LE, 1996, J CELL SCI, V109, P2855; DIKE LE, 1988, P NATL ACAD SCI USA, V85, P6792, DOI 10.1073/pnas.85.18.6792; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Faraldo MM, 1998, EMBO J, V17, P2139, DOI 10.1093/emboj/17.8.2139; Fornaro M, 1999, J CLIN INVEST, V103, P321, DOI 10.1172/JCI4585; Fornaro M, 1998, AM J PATHOL, V153, P1079, DOI 10.1016/S0002-9440(10)65652-0; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Hakak Y, 1999, MOL CELL BIOL, V19, P6953; Howe AK, 1998, J BIOL CHEM, V273, P27268, DOI 10.1074/jbc.273.42.27268; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; Manzotti M, 2000, AM J PATHOL, V156, P169, DOI 10.1016/S0002-9440(10)64716-5; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; MORTARINI R, 1995, CANCER RES, V55, P4702; Murgia C, 1998, EMBO J, V17, P3940, DOI 10.1093/emboj/17.14.3940; PLOPPER G, 1993, BIOCHEM BIOPH RES CO, V193, P571, DOI 10.1006/bbrc.1993.1662; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; ROUSSEL MF, 1994, ONCOGENE, V9, P405; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; UDAGAWA T, 1995, CLIN EXP METASTAS, V13, P427, DOI 10.1007/BF00118182; VUORI K, 1993, J BIOL CHEM, V268, P21459; WATT R, 1983, NATURE, V303, P231; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; YAMADA KM, 1990, CANCER RES, V50, P4485	43	24	24	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2001	20	6					759	768		10.1038/sj.onc.1204152	http://dx.doi.org/10.1038/sj.onc.1204152			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314009				2022-12-17	WOS:000166806000011
J	Hara, K; Kudoh, H; Enomoto, T; Hashimoto, Y; Masuko, T				Hara, K; Kudoh, H; Enomoto, T; Hashimoto, Y; Masuko, T			Enhanced tumorigenicity caused by truncation of the extracellular domain of GP125/CD98 heavy chain	ONCOGENE			English	Article						CD98; transfectant; extracellular domain	AMINO-ACID-TRANSPORT; GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODY 4F2; CELL-SURFACE ANTIGEN; XENOPUS-LAEVIS OOCYTES; ACTIVATED LYMPHOCYTES; INTEGRIN ACTIVATION; RAS TRANSFORMATION; INHIBIT ACTIVATION; MEMBRANE-PROTEIN	GP125/CD98 is a heterodimeric 125-kDa glycoprotein, which consists of an 85-kDa heavy chain the) and a 40-kDa light chain (Ic), and is strongly expressed on the cell surface of various tumor cells, irrespective of their tissue of origin. We have recently demonstrated that over-expression of the CD98hc cDNA causes malignant transformation of NIH3T3 cells. To investigate the function of the extracellular domain of CD98hc in cell proliferation and malignant transformation, we established two NIH3T3-derived clones transfected with human truncated CD98hc cDNAs, and compared their characteristics with parental NIH3T3 and clones transfected with full-length CD98hc cDNA, Truncated as well as full-length CD98hc-transfected clones grew to a higher saturation density than control cells. Efficiency of colony formation in soft agar was augmented in all CD98hc-transfected clones, and the degrees of augmented colony formation of the transfectants expressing full-length CD98hc of 529 a.a. or truncated CD98hc of 418 a,a, were reduced by anti-human CD98hc antibodies, while that of the transfectant expressing truncated CD98hc of 237 a,a, lacking the epitopes recognized by anti-human CD98hc antibodies was not affected by the addition of antibodies. CD98hc-transfected clones developed tumors in athymic mice, and tumor growth of truncated CD98hc-transfected clones was faster than that of full-length CD98hc-transfected clones.	Kinki Univ, Sch Pharmaceut Sci, Cell Biol Lab, Higashiosaka, Osaka 5778502, Japan; Tohoku Univ, Grad Sch Pharmaceut Sci, Mol Cell Biol Lab, Aoba Ku, Sendai, Miyagi 9808578, Japan; Sasaki Inst, Chikusa Ku, Tokyo 101, Japan	Kindai University (Kinki University); Tohoku University	Masuko, T (corresponding author), Kinki Univ, Sch Pharmaceut Sci, Cell Biol Lab, 4-1 Kowakae 3 Chome, Higashiosaka, Osaka 5778502, Japan.							BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; Bouck N, 1979, Methods Enzymol, V58, P296; Broer S, 1995, BIOCHEM J, V312, P863, DOI 10.1042/bj3120863; COOPER GM, 1980, NATURE, V284, P418, DOI 10.1038/284418a0; DIXON WT, 1990, INT J CANCER, V45, P59, DOI 10.1002/ijc.2910450113; Dong S, 1996, FEBS LETT, V395, P165, DOI 10.1016/0014-5793(96)01031-9; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Hara K, 1999, BIOCHEM BIOPH RES CO, V262, P720, DOI 10.1006/bbrc.1999.1051; Hashimoto Y, 1983, Gan, V74, P819; HAYNES BF, 1981, J IMMUNOL, V126, P1409; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; KAMMA H, 1989, CANCER RES, V49, P5118; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KROUS MH, 1987, EMBO J, V6, P605; LUMADUE JA, 1987, P NATL ACAD SCI USA, V84, P9204, DOI 10.1073/pnas.84.24.9204; MACLEOD CL, 1994, J EXP BIOL, V196, P109; Mannion BA, 1998, J BIOL CHEM, V273, P33127, DOI 10.1074/jbc.273.50.33127; MARTIN GS, 1986, CANCER SURV, V5, P199; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; MASUKO T, 1985, JPN J CANCER RES, V76, P386; MICHALAK M, 1986, J BIOL CHEM, V261, P92; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; OHGIMOTO S, 1995, J IMMUNOL, V155, P3585; PARMACEK MS, 1989, NUCLEIC ACIDS RES, V17, P1915, DOI 10.1093/nar/17.5.1915; PATTERSON JAK, 1984, J INVEST DERMATOL, V83, P210, DOI 10.1111/1523-1747.ep12263581; Pfeiffer R, 1999, EMBO J, V18, P49, DOI 10.1093/emboj/18.1.49; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; POSILLICO JT, 1987, J CLIN ENDOCR METAB, V64, P43, DOI 10.1210/jcem-64-1-43; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QUACKENBUSH E, 1987, P NATL ACAD SCI USA, V84, P6526, DOI 10.1073/pnas.84.18.6526; QUACKENBUSH E, 1987, P NATL ACAD SCI USA, V84, P8618; QUACKENBUSH EJ, 1986, J IMMUNOL, V136, P118; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Rajan DP, 1999, J BIOL CHEM, V274, P29005, DOI 10.1074/jbc.274.41.29005; Rossier G, 1999, J BIOL CHEM, V274, P34948, DOI 10.1074/jbc.274.49.34948; SANG JS, 1995, CANCER RES, V55, P1152; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Schwartz MA, 1996, EMBO J, V15, P6525, DOI 10.1002/j.1460-2075.1996.tb01043.x; Shin S, 1979, Methods Enzymol, V58, P370; Shishido T, 2000, INT J CANCER, V87, P311, DOI 10.1002/1097-0215(20000801)87:3<311::AID-IJC1>3.0.CO;2-W; TANAKA T, 1989, JPN J CANCER RES, V80, P380, DOI 10.1111/j.1349-7006.1989.tb02323.x; TANAKA T, 1988, J BIOCHEM-TOKYO, V103, P644, DOI 10.1093/oxfordjournals.jbchem.a122322; TEIXEIRA S, 1987, J BIOL CHEM, V262, P9574; Tsurudome M, 1999, J IMMUNOL, V162, P2462; Warren AP, 1996, BLOOD, V87, P3676, DOI 10.1182/blood.V87.9.3676.bloodjournal8793676; WELLS RG, 1992, J BIOL CHEM, V267, P15285; YAGITA H, 1986, J IMMUNOL, V136, P2062; YAGITA H, 1986, CANCER RES, V46, P1478; YAGITA H, 1986, J IMMUNOL, V136, P2055; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816	56	24	26	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6209	6215		10.1038/sj.onc.1204019	http://dx.doi.org/10.1038/sj.onc.1204019			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175335				2022-12-17	WOS:000166210500004
J	Pizon, V; Baldacci, G				Pizon, V; Baldacci, G			Rap1A protein interferes with various MAP kinase activating pathways in skeletal myogenic cells	ONCOGENE			English	Article						Rap1A; Ras-like protein; MAP kinases; myogenic differentiation	FIBROBLAST GROWTH-FACTOR; RAS-DEPENDENT ACTIVATION; PHOSPHATIDYLINOSITOL 3-KINASE; MUSCLE DIFFERENTIATION; INDEPENDENT PATHWAYS; HUMAN-PLATELETS; IN-VITRO; C-ZETA; SPECIFICITY; RECEPTOR	Constitutive expression of the activated Rap1A protein inhibits differentiation of myogenic C2 cells whereas the inactivated Rap1A protein favours cell differentiation and induces late endocytic compartments clustering. Although the role of Rap1A in MAPK activation has been analysed in various cell;types, the signalling pathways activated by Rap1A have not been explored in myogenic cells. In this study, me investigated MAP kinase activity in control C2 myoblasts and in stable C2 cell lines expressing mutated Rap1A proteins. We provide evidence that Rap1A mutants promote ERK activation and that the active protein induces a more sustained activation than the inactive protein. In addition, we established that various pathways mediate transient ERK activation in control cells and in cells expressing the inactivated Rap1A protein. In these cells, ERK are activated by a Raf/MEK-dependent pathway, a PI3K/Raf-independent pathway and a third undetermined pathway. In cells expressing the activated Rap1A protein, a PI3K/Raf/MEK-dependent pathway mediates transient ERK activation. However, MAPK activation appears more complex since, according to the state of the myoblasts or the duration of MAPK stimulation, we observed that Rap1A protein could interfere or not with ERK activation.	Inst Andre Lwoff, UPR 1983, F-94801 Villejuif, France; Univ Paris Sud, Inst Curie, UMR 2027, F-91405 Orsay, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Pizon, V (corresponding author), Inst Andre Lwoff, UPR 1983, 7 Rue Guy Moquet,BP8, F-94801 Villejuif, France.		Pizon, Veronique/M-5590-2018	Pizon, Veronique/0000-0003-3596-8313				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; CAMPBELL JS, 1995, P NATL ACAD SCI USA, V92, P870, DOI 10.1073/pnas.92.3.870; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; Dorman CM, 1999, ONCOGENE, V18, P5167, DOI 10.1038/sj.onc.1202907; Dremier S, 2000, BIOCHEM BIOPH RES CO, V267, P7, DOI 10.1006/bbrc.1999.1919; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; Hu CD, 1999, J BIOL CHEM, V274, P48, DOI 10.1074/jbc.274.1.48; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KUDLA AJ, 1995, MOL CELL BIOL, V15, P3238; Kundra A, 1998, J BIOL CHEM, V273, P3848, DOI 10.1074/jbc.273.7.3848; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; LEROSEY I, 1991, BIOCHEM BIOPH RES CO, V175, P430, DOI 10.1016/0006-291X(91)91582-W; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Milasincic DJ, 1996, MOL CELL BIOL, V16, P5964; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; Pinset C, 1997, CR ACAD SCI III-VIE, V320, P367, DOI 10.1016/S0764-4469(97)85024-X; PIZON V, 1994, J CELL SCI, V107, P1661; Pizon V, 1999, EXP CELL RES, V246, P56, DOI 10.1006/excr.1998.4284; Ramocki MB, 1998, J BIOL CHEM, V273, P17696, DOI 10.1074/jbc.273.28.17696; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; TOKER A, 1994, J BIOL CHEM, V269, P32358; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; YANO H, 1993, J BIOL CHEM, V268, P25846; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	47	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2000	19	52					6074	6081		10.1038/sj.onc.1203984	http://dx.doi.org/10.1038/sj.onc.1203984			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146560				2022-12-17	WOS:000165827900015
J	Hosaka, T; Kanoe, H; Nakayama, T; Murakami, H; Yamamoto, H; Nakamata, T; Tsuboyama, T; Oka, M; Kasai, M; Sasaki, MS; Nakamura, T; Toguchida, J				Hosaka, T; Kanoe, H; Nakayama, T; Murakami, H; Yamamoto, H; Nakamata, T; Tsuboyama, T; Oka, M; Kasai, M; Sasaki, MS; Nakamura, T; Toguchida, J			Translin binds to the sequences adjacent to the breakpoints of the TLS and CHOP genes in liposarcomas with translocation t(12;16)	ONCOGENE			English	Article						translin; liposarcoma; translocation; mobility-shift assay	CHROMOSOMAL TRANSLOCATIONS; TOPOISOMERASE-II; RECOMBINATION; PROTEIN; FUSION; REPAIR; MECHANISM; LEUKEMIA; ENDS	Myxoid and round-cell liposarcomas share the translocation t(12;16)(q13;p11) creating the TLS-CHOP fusion gene as a common genetic alteration. We previously reported several unique characteristics of genomic sequences around the breakpoints in the TLS and CHOP loci, and among them was the presence of consensus recognition motifs of Translin, a protein that associates with chromosomal translocations of lymphoid neoplasms. We further extended our search for Translin binding motifs in sequences adjacent to breakpoints and investigated,whether Translin binds to these sequences in vitro by mobility-shift assay. Computer-assisted search found sequences highly homologous (>70%) with Translin binding motifs adjacent to the breakpoints in 10 out of 11 liposarcomas,vith the TLS-CHOP fusion genes. All of 13 oligonucleotides corresponding to the putative binding sequences in these cases bind to Hela cell extract and also recombinant Translin protein, although the binding affinity of each motif showed considerable differences. The DNA-protein complex formation was inhibited by non-labeled competitor or anti-Translin antibody, suggesting the specificity of the complex formation. Considering the high incidence and specific binding property, the presence of Translin binding motif may be one of the important determinants for the location of breakpoints in the TLS and CHOP gents in liposarcomas.	Kyoto Univ, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Dept Orthopaed Surg, Kyoto 6068507, Japan; Kyoto Univ, Ctr Radiat Biol, Kyoto 6068507, Japan; Natl Inst Infect Dis, Dept Immunol, Tokyo 1628640, Japan	Kyoto University; Kyoto University; Kyoto University; National Institute of Infectious Diseases (NIID)	Toguchida, J (corresponding author), Kyoto Univ, Inst Frontier Med Sci, Sakyo Ku, 53 Kawahara Cho, Kyoto 6068507, Japan.							AOKI K, 1995, NAT GENET, V10, P167, DOI 10.1038/ng0695-167; Atlas M, 1998, LEUKEMIA, V12, P1895, DOI 10.1038/sj.leu.2401223; Badge RM, 2000, HUM MOL GENET, V9, P1239, DOI 10.1093/hmg/9.8.1239; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Chalk JG, 1997, ONCOGENE, V15, P1199, DOI 10.1038/sj.onc.1201285; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Gillert E, 1999, ONCOGENE, V18, P4663, DOI 10.1038/sj.onc.1202842; Jeffs AR, 1998, HUM MOL GENET, V7, P767, DOI 10.1093/hmg/7.5.767; Kanoe H, 1999, ONCOGENE, V18, P721, DOI 10.1038/sj.onc.1202364; Kasai M, 1997, J BIOL CHEM, V272, P11402; Obata K, 1999, GENE CHROMOSOME CANC, V25, P6, DOI 10.1002/(SICI)1098-2264(199905)25:1<6::AID-GCC2>3.3.CO;2-D; PANAGOPOULOS I, 1994, CANCER RES, V54, P6500; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Wu XQ, 1997, P NATL ACAD SCI USA, V94, P5640, DOI 10.1073/pnas.94.11.5640; Zucman-Rossi J, 1998, P NATL ACAD SCI USA, V95, P11786, DOI 10.1073/pnas.95.20.11786	18	24	26	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5821	5825		10.1038/sj.onc.1203943	http://dx.doi.org/10.1038/sj.onc.1203943			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126370	Green Submitted			2022-12-17	WOS:000165477700015
J	Zhu, XY; Price-Schiavi, SA; Carraway, KL				Zhu, XY; Price-Schiavi, SA; Carraway, KL			Extracellular regulated kinase (ERK)-dependent regulation of sialomucin complex/rat Muc4 in mammary epithelial cells	ONCOGENE			English	Article						Muc4; ERK; ErbB2; mammary; epithelial; transcript; regulation	GROWTH-FACTOR-I; RECEPTOR TYROSINE KINASE; ADENOCARCINOMA CELLS; MOLECULAR-CLONING; PROTEIN-KINASE; MAP KINASE; DUCTAL MORPHOGENESIS; GLYCOPROTEIN COMPLEX; SIGNAL-TRANSDUCTION; CASEIN GENE	Sialomucin complex (SMC, rat Muc4) is a membrane mucin implicated in the protection of epithelia and the metastasis of some tumors. It is a heterodimeric complex, containing a mucin subunit with anti-adhesive activity and a transmembrane subunit with epidermal growth factor-like domains, one of which acts as an intramembrane ligand for ErbB2, Serum, insulin and insulin-like growth factor, but not epidermal growth factor, induce the expression of sialomucin complex in mammary epithelial cells, Induction correlates,vith sustained, but not transient, activation of extracellular-regulated protein kinase (ERK), MEK inhibitor U0126 blocked the induction, while activated MEK-1 transfected into a rat mammary adenocarcinoma cell line induced a sustained activation of ERK and up-regulated SMC/Muc4 expression, Northern and Western blotting indicated that up-regulation occurred concomitantly at the transcript and protein levels, both of which could be blocked by U0126. These results suggest that expression of SMC/Muc4 in mammary epithelial cells is regulated by selected growth factors through an ERK-dependent pathway at the transcript level.	Univ Miami, Sch Med, Dept Cell Biol & Anat R 124, Miami, FL 33101 USA	University of Miami	Carraway, KL (corresponding author), Univ Miami, Sch Med, Dept Cell Biol & Anat R 124, POB 016960, Miami, FL 33101 USA.				NCI NIH HHS [CA52498] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052498] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1987, J CELL SCI, V99, P407; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CAHILL AL, 1991, J NEUROCHEM, V57, P1832, DOI 10.1111/j.1471-4159.1991.tb06392.x; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; CHEN QM, 1994, J BIOL CHEM, V269, P26602; COLEMAN S, 1990, DEV BIOL, V137, P425, DOI 10.1016/0012-1606(90)90267-M; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Hadsell DL, 1996, ENDOCRINOLOGY, V137, P321, DOI 10.1210/en.137.1.321; HULL SR, 1990, BIOCHEM J, V265, P121, DOI 10.1042/bj2650121; Juang SH, 1996, ONCOGENE, V12, P1033; Kleinberg DL, 1998, BREAST CANCER RES TR, V47, P201, DOI 10.1023/A:1005998832636; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; Komatsu M, 1999, CANCER RES, V59, P2229; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; LEVITZKI A, 1991, METHOD ENZYMOL, V201, P347; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; McNeer RR, 1998, J CELL PHYSIOL, V176, P110, DOI 10.1002/(SICI)1097-4652(199807)176:1<110::AID-JCP13>3.3.CO;2-U; McNeer RR, 1998, BIOCHEM J, V330, P737, DOI 10.1042/bj3300737; MCNEER RR, 1997, FRONT BIOSCI, V2, P449; Merlo GR, 1996, EUR J CELL BIOL, V70, P97; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; Neuenschwander S, 1996, J CLIN INVEST, V97, P2225, DOI 10.1172/JCI118663; NICHOLAS KR, 1983, BIOCHIM BIOPHYS ACTA, V763, P309, DOI 10.1016/0167-4889(83)90139-8; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; Price-Schiavi SA, 1998, J BIOL CHEM, V273, P35228, DOI 10.1074/jbc.273.52.35228; Price-Schiavi SA, 2000, J BIOL CHEM, V275, P17800, DOI 10.1074/jbc.275.23.17800; Price-Schiavi SA, 2000, BIOCHEM J, V349, P641, DOI 10.1042/0264-6021:3490641; PROSSER CG, 1987, ENDOCRINOLOGY, V120, P1411, DOI 10.1210/endo-120-4-1411; Rossi EA, 1996, J BIOL CHEM, V271, P33476, DOI 10.1074/jbc.271.52.33476; Ruan WF, 1999, ENDOCRINOLOGY, V140, P5075, DOI 10.1210/en.140.11.5075; RUAN WF, 1992, P NATL ACAD SCI USA, V89, P10872, DOI 10.1073/pnas.89.22.10872; RUAN WF, 1995, ENDOCRINOLOGY, V136, P1296, DOI 10.1210/en.136.3.1296; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHERBLOM AP, 1980, J BIOL CHEM, V255, P2051; SHERBLOM AP, 1980, J BIOL CHEM, V255, P783; SPITZER E, 1995, J CELL BIOCHEM, V57, P495, DOI 10.1002/jcb.240570315; Swantek JL, 1999, ENDOCRINOLOGY, V140, P3163, DOI 10.1210/en.140.7.3163; TAKETANI Y, 1983, P NATL ACAD SCI-BIOL, V80, P2647, DOI 10.1073/pnas.80.9.2647; TAKETANI Y, 1983, FEBS LETT, V152, P256, DOI 10.1016/0014-5793(83)80391-3; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; VOYTOVICH AE, 1969, P NATL ACAD SCI USA, V63, P213, DOI 10.1073/pnas.63.1.213; Wartmann M, 1996, J BIOL CHEM, V271, P31863, DOI 10.1074/jbc.271.50.31863; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WU K, 1994, J BIOL CHEM, V269, P11950; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	50	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2000	19	38					4354	4361		10.1038/sj.onc.1203781	http://dx.doi.org/10.1038/sj.onc.1203781			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980611				2022-12-17	WOS:000089271900006
J	Primo, L; Roca, C; Ferrandi, C; Lanfrancone, L; Bussolino, F				Primo, L; Roca, C; Ferrandi, C; Lanfrancone, L; Bussolino, F			Human endothelial cells expressing polyoma middle T induce tumors	ONCOGENE			English	Article						hemangioma; middle T; endothelial cells; polyomavirus; human	OPPORTUNISTIC VASCULAR TUMORS; KAPOSIS-SARCOMA; GROWTH-FACTOR; KINASE-ACTIVITY; SRC FAMILY; NUDE-MICE; IN-VITRO; ANTIGEN; ONCOGENE; TRANSFORMATION	The middle T oncogene of murine polyomavirus (PymT) rapidly transforms and immortalizes murine embryonic endothelial cells (EC), leading to the formation of vascular tumors in newborn mice, by recruitment of host, non-transformed EC. These tumors are reminiscent of human vascular tumors like cavernous hemangioma, Kaposi's sarcoma or those characterizing Kasabach-Merrit syndrome. Here we investigate the in vitro and in vivo behavior of human primary umbilical cord vein EC expressing PymT. While PymT has been unable to transform human fibroblasts in earlier experiments or controls done here, mT expressing EC (PymT-EC) derived by infection with pLX-PymT retrovirus induce hemangiomas in nu/nu mice. These tumors contain not only human cells but also recruited mouse EC as shown by the presence of human and murine CD31 positive EC. In vitro analysis shows that PymT-EC retain endothelial specific markers like CD31, Von Willebrand factor, and VE-cadherin, and reach the confluence without signs of overgrowth. They are also responsive to vascular endothelial growth factor-A. However, their proliferation rate is increased. The balance between urokinase-type plasminogen activator and plasminogen activator inhibitor-1 is modified; RNA and catalytic activity for the former are elevated while PAI-1 RN4 is reduced. In contrast with murine model, where the PymT EC cells become immortal, the effects induced by PymT in human EC are transient. After 12-15 passages, human PymT EC stop proliferating, assume a senescent phenotype, and lose the ability to induce hemangiomas, At the same time both the amount of middle T protein and the level of activation of pp60(c-src) lower.	IRCC, I-10060 Turin, Italy; Univ Turin, Sch Med, Dept Genet Biol & Biochem, I-10100 Turin, Italy; European Inst Oncol, Dept Expt Oncol, I-20100 Milan, Italy	University of Turin; IRCCS European Institute of Oncology (IEO)	Bussolino, F (corresponding author), IRCC, Strada Prov 142,Km 3-95, I-10060 Turin, Italy.		Bussolino, Federico/AES-3951-2022; Lanfrancone, Luisa/AAC-8671-2019; Bussolino, Federico/K-2500-2016	Lanfrancone, Luisa/0000-0002-4523-3815; PRIMO, Luca/0000-0002-1294-0441; Bussolino, Federico/0000-0002-5348-1341				AGUZZI A, 1991, ONCOGENE, V6, P113; Albini A, 1997, AIDS, V11, P713, DOI 10.1097/00002030-199706000-00003; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BEATTIE GM, 1982, P NATL ACAD SCI-BIOL, V79, P3033, DOI 10.1073/pnas.79.9.3033; Biancone L, 1999, J IMMUNOL, V162, P5263; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BUSSOLINO F, 1991, J IMMUNOL, V147, P2122; BUSSOLINO F, 1987, J IMMUNOL, V139, P2439; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dong QG, 1996, INT J CANCER, V65, P700, DOI 10.1002/(SICI)1097-0215(19960301)65:5<700::AID-IJC23>3.0.CO;2-9; Drolet BA, 1999, NEW ENGL J MED, V341, P173, DOI 10.1056/NEJM199907153410307; Ensoli B, 1998, CYTOKINE GROWTH F R, V9, P63, DOI 10.1016/S1359-6101(97)00037-3; FIORELLI V, 1995, J CLIN INVEST, V95, P1723, DOI 10.1172/JCI117849; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; GARLANDA C, 1994, P NATL ACAD SCI USA, V91, P7291, DOI 10.1073/pnas.91.15.7291; Garlanda C, 1997, ARTERIOSCL THROM VAS, V17, P1193, DOI 10.1161/01.ATV.17.7.1193; GHIGO D, 1995, J EXP MED, V181, P9, DOI 10.1084/jem.181.1.9; Giraudo E, 1996, J IMMUNOL, V157, P2618; GOLDENBERG DM, 1981, SCIENCE, V212, P65, DOI 10.1126/science.7209521; GOLDENBERG DM, 1982, P NATL ACAD SCI-BIOL, V79, P2389, DOI 10.1073/pnas.79.7.2389; GROSS L, 1983, ONCOGENIC VIRUSES, V2, P737; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HOLMAN PS, 1994, J VIROL, V68, P668, DOI 10.1128/JVI.68.2.668-673.1994; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KORNBLUTH S, 1986, MOL CELL BIOL, V6, P1545, DOI 10.1128/MCB.6.5.1545; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; LEVY JA, 1983, LANCET, V2, P78; LUNARDIISKANDAR Y, 1995, JNCI-J NATL CANCER I, V87, P974, DOI 10.1093/jnci/87.13.974; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MONTESANO R, 1993, J CELL SCI, V105, P1013; Muhlner U, 1999, ONCOGENE, V18, P4200, DOI 10.1038/sj.onc.1203014; Mullane KP, 1998, MOL CELL BIOL, V18, P7556, DOI 10.1128/MCB.18.12.7556; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PARUMS DV, 1990, J CLIN PATHOL, V43, P752, DOI 10.1136/jcp.43.9.752; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; Sabapathy KT, 1997, J CELL BIOL, V137, P953, DOI 10.1083/jcb.137.4.953; SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779; SARTOR O, 1993, J BIOL CHEM, V268, P21014; SCHAFFHAUSEN B, 1981, J VIROL, V40, P184, DOI 10.1128/JVI.40.1.184-196.1981; SCHAFFHAUSEN BS, 1987, J VIROL, V61, P1221, DOI 10.1128/JVI.61.4.1221-1225.1987; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; TARABOLETTI G, 1993, CANCER RES, V53, P3812; TRATTNER A, 1993, CANCER-AM CANCER SOC, V72, P1779, DOI 10.1002/1097-0142(19930901)72:5<1779::AID-CNCR2820720543>3.0.CO;2-M; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WILLIAMS RL, 1988, CELL, V52, P121; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7	56	24	25	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3632	3641		10.1038/sj.onc.1203708	http://dx.doi.org/10.1038/sj.onc.1203708			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951569				2022-12-17	WOS:000088568300009
J	Gillet, R; Grimber, G; Bennoun, M; de Fromentel, CC; Briand, P; Joulin, V				Gillet, R; Grimber, G; Bennoun, M; de Fromentel, CC; Briand, P; Joulin, V			The consequence of p53 overexpression for liver tumor development and the response of transformed murine hepatocytes to genotoxic agents	ONCOGENE			English	Article						transgenic mice; p53; hepatocarcinoma; apoptosis; DNA damage	WILD-TYPE P53; LARGE T-ANTIGEN; BREAST-CANCER CELLS; TRANSGENIC MICE; IN-VIVO; GENE-THERAPY; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVITY; DECREASED SENSITIVITY; SPINDLE CHECKPOINT	To analyse the effect of p53 on liver tumor development, we generated transgenic mice overexpressing wild-type p53 in the liver and crossed them with transgenic mice in which the expression of the SV40 large T antigen (TAg) induces hepatic tumors. Remarkably, whereas preneoplastic TAg liver exhibited anisocaryosis and anisocytosis, TAg/p53 liver never presented any dysplastic cells. Moreover, whereas expression of p53 did not affect hepatic development, its constitutive expression in tumorigenic livers resulted in a significantly enhanced apoptosis once nodules had appeared. In contrast, p53 overexpression did not modify the elevated proliferation of TAg-transformed hepatocytes and had no effect on hepatocarcinoma progression. In vitro analysis of primary hepatocytes exposed to various genotoxic agents showed that p53 failed to sensitize normal or TAg-transformed hepatocytes to apoptosis, except when high doses of doxorubicin, UV-B and UV-C radiation were used. Our results confirmed that the hepatocyte cell type is very resistant to genotoxic agents and showed that constitutive expression of p53 failed to improve their responsiveness. In addition, our results showed that suppression of dysplastic cells, probably by restoring normal cytokinesis and karyokinesis, and enhancement of apoptosis by means of p53 overexpression were insufficient to counteract or delay the TAg-induced liver tumoral progression.	Inst Cochin Genet Mol, INSERM, U380, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Joulin, V (corresponding author), Inst Cochin Genet Mol, INSERM, U380, 22 Rue Mechain, F-75014 Paris, France.		de Fromentel, Claude Caron/Y-9715-2019	de Fromentel, Claude Caron/0000-0001-7566-3958; JOULIN, Virginie/0000-0003-1091-7819				Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Allemand I, 1995, ONCOGENE, V11, P2583; Allemand I, 1999, ONCOGENE, V18, P6521, DOI 10.1038/sj.onc.1203052; Bellamy COC, 1997, J PATHOL, V183, P177, DOI 10.1002/(SICI)1096-9896(199710)183:2<177::AID-PATH909>3.0.CO;2-E; Bellamy COC, 1997, FASEB J, V11, P591, DOI 10.1096/fasebj.11.7.9212083; Bennoun M, 1998, ONCOGENE, V17, P1253, DOI 10.1038/sj.onc.1202047; Blagosklonny MV, 1998, INT J CANCER, V75, P933, DOI 10.1002/(SICI)1097-0215(19980316)75:6<933::AID-IJC17>3.0.CO;2-3; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Conzen SD, 1997, J VIROL, V71, P4536, DOI 10.1128/JVI.71.6.4536-4543.1997; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUBOIS N, 1991, J HEPATOL, V13, P227, DOI 10.1016/0168-8278(91)90819-W; FAN SJ, 1994, CANCER RES, V54, P5824; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FUJIWARA T, 1994, CANCER RES, V54, P2287; FUKASAWA K, 1991, MOL CELL BIOL, V11, P3472, DOI 10.1128/MCB.11.7.3472; Ghebranious N, 1998, HEPATOLOGY, V27, P967, DOI 10.1002/hep.510270411; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Godley LA, 1996, GENE DEV, V10, P836, DOI 10.1101/gad.10.7.836; Goto A, 1998, JPN J CANCER RES, V89, P539, DOI 10.1111/j.1349-7006.1998.tb03295.x; Gudas JM, 1996, CARCINOGENESIS, V17, P1417, DOI 10.1093/carcin/17.7.1417; Gurnani M, 1999, CANCER CHEMOTH PHARM, V44, P143, DOI 10.1007/s002800050959; Hickman ES, 1997, J VIROL, V71, P3710, DOI 10.1128/JVI.71.5.3710-3718.1997; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; Ju JF, 1998, CLIN CANCER RES, V4, P1315; Jung YK, 1997, ONCOGENE, V14, P1207, DOI 10.1038/sj.onc.1200943; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Khan SH, 1998, CANCER RES, V58, P396; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; MacCallum DE, 1996, ONCOGENE, V13, P2575; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; Nielsen LL, 1998, CANCER GENE THER, V5, P52; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; Piovesan B, 1998, ONCOGENE, V17, P2339, DOI 10.1038/sj.onc.1202147; Procopio A, 1998, Monaldi Arch Chest Dis, V53, P241; ROUQUET N, 1995, ONCOGENE, V11, P1061; Seth P, 1997, CANCER GENE THER, V4, P383; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; Song KM, 1997, ONCOL RES, V9, P603; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TREMP GL, 1995, GENE, V156, P199, DOI 10.1016/0378-1119(95)00010-4; Tsai SC, 2000, J BIOL CHEM, V275, P3239, DOI 10.1074/jbc.275.5.3239; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	60	24	27	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3498	3507		10.1038/sj.onc.1203671	http://dx.doi.org/10.1038/sj.onc.1203671			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918608				2022-12-17	WOS:000088346500006
J	Vinos, J; Freeman, M				Vinos, J; Freeman, M			Evidence that Argos is an antagonistic ligand of the EGF receptor	ONCOGENE			English	Article						Argos; EGF receptor; antagonist; receptor; tyrosine kinase; Drosophila; growth factor	DROSOPHILA EYE; ACTIVATION; INHIBITION; PATHWAY; LOOP	Argos, the inhibitor of the Drosophila epidermal growth factor (EGF) receptor, remains the only known extracellular inhibitor of this family of receptors in any organism. The functional domain of Argos includes an atypical EGF domain and it is not clear whether it binds to the EGF receptor or if it acts via a distinct receptor to reduce Egfr activity indirectly. Here we present two lines of evidence that strongly suggest that Argos directly interacts with the EGF receptor. First, Argos is unable to inhibit a chimeric receptor that contains an extracellular domain from an unrelated RTK, indicating the need for the EGF receptor extracellular domain. Second, Argos can inhibit the Drosophila EGF receptor even when expressed in human cells, implying that no other Drosophila protein is necessary for inhibition. We also report that Argos and the Drosophila activating ligand, Spitz, can influence mammalian RTK activation, albeit in a cell-type specific manner. This includes the first evidence that Argos can inhibit signalling in mammalian cells, raising the possibility of engineering an effective human EGF receptor/Erbs antagonist.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Freeman, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.			Freeman, Matthew/0000-0003-0410-5451				Casci T, 1999, CANCER METAST REV, V18, P181, DOI 10.1023/A:1006313122373; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; Golembo M, 1996, DEVELOPMENT, V122, P223; Howes R, 1998, J BIOL CHEM, V273, P4275, DOI 10.1074/jbc.273.7.4275; Lohmeyer M, 1997, INT J ONCOL, V10, P677; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; Stemerdink C, 1997, DEVELOPMENT, V124, P3787; vandePoll MLM, 1997, BIOCHEMISTRY-US, V36, P7425, DOI 10.1021/bi970227f	11	24	25	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3560	3562		10.1038/sj.onc.1203702	http://dx.doi.org/10.1038/sj.onc.1203702			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918615				2022-12-17	WOS:000088346500013
J	Robertson, H; Hime, GR; Lada, H; Bowtell, DDL				Robertson, H; Hime, GR; Lada, H; Bowtell, DDL			A Drosophila analogue of v-Cbl is a dominant-negative oncoprotein in vivo	ONCOGENE			English	Article						cbl; oncogene; Drosophila; ubiquitin; endocytosis; EGFR	GROWTH-FACTOR RECEPTOR; C-CBL; EGF RECEPTOR; TYROSINE KINASE; SH3 DOMAIN; MEDIATED ENDOCYTOSIS; HORMONE RECEPTOR; CELL-DEATH; T-CELLS; PROTEIN	Cells rely on the ability to receive and interpret external signals to regulate growth, differentiation, and death. Positive transduction of these signals to the cytoplasm and nucleus has been extensively characterized, and genetic studies in Drosophila have made major contributions to the understanding of these pathways, Less well understood, but equally important, are the mechanisms underlying signal down-regulation. Here me report biochemical and genetic characterization of the Drosophila homologue of c-Cbl, a negative regulator of signal transduction with ubiquitin-protein ligase activity. A new isoform of D-Cbl, D-CblL, has been identified that contains SH3-binding and UBA domains previously reported to he absent. Genetic analysis demonstrates that Dv-cbl, analogous to the mammalian v-cbl oncogene, is a dominant negative mutation able to enhance signalling from the Drosophila Egfr and cooperate with activating mutations in the sevenless pathway to produce melanotic tumours, In addition, our data show genetic and biochemical links between D-Cbl and proteins involved in endocytosis and ubiquitination, suggesting that v-Cbl may exert its oncogenic effect by enhancing receptor signalling as a consequence of suppressing receptor endocytosis.	Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic 8006, Australia	Peter Maccallum Cancer Center	Bowtell, DDL (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Labs, Locked Bag 1,A Beckett St, Melbourne, Vic 8006, Australia.		Bowtell, David/H-1007-2016; Hime, Gary/B-7162-2015	Bowtell, David/0000-0001-9089-7525; Hime, Gary/0000-0003-4732-3184				ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BEMENT WM, 1994, J MOL BIOL, V243, P356, DOI 10.1006/jmbi.1994.1662; BLAKE TJ, 1991, ONCOGENE, V6, P653; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; BRAND AH, 1993, DEVELOPMENT, V118, P401; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; DIAZBENJUMEA FJ, 1990, P ROY SOC B-BIOL SCI, V242, P36, DOI 10.1098/rspb.1990.0100; Feldmann P, 1999, MOL CELL BIOL, V19, P1928; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Govers R, 1997, EMBO J, V16, P4851, DOI 10.1093/emboj/16.16.4851; HAY BA, 1994, DEVELOPMENT, V120, P2121; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/S0968-0004(96)30015-7; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JONGEWARD GD, 1995, GENETICS, V139, P1553; Karim FD, 1998, DEVELOPMENT, V125, P1; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; LAI KMV, 1995, MOL CELL BIOL, V15, P4810; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Lupher ML, 1998, INT J BIOCHEM CELL B, V30, P439, DOI 10.1016/S1357-2725(97)00075-7; MASUI H, 1991, CANCER RES, V51, P6170; McNiven MA, 1998, CELL, V94, P151, DOI 10.1016/S0092-8674(00)81414-2; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Potter CJ, 2000, TRENDS GENET, V16, P33, DOI 10.1016/S0168-9525(99)01878-8; Robertson H, 1997, BIOCHEM BIOPH RES CO, V240, P46, DOI 10.1006/bbrc.1997.7608; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; Rorth P, 1998, DEVELOPMENT, V125, P1049; Roth AF, 1998, J CELL BIOL, V142, P949, DOI 10.1083/jcb.142.4.949; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Rubin GM, 1997, COLD SPRING HARB SYM, V62, P347; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; Wieschaus E., 1986, P199; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	58	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2000	19	29					3299	3308		10.1038/sj.onc.1203624	http://dx.doi.org/10.1038/sj.onc.1203624			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918586				2022-12-17	WOS:000088019300008
J	Ren, SR; Smith, MJ; Louro, ID; McKie-Bell, P; Bani, MR; Wagner, M; Zochodne, B; Redden, DT; Grizzle, WE; Wang, ND; Smith, DI; Herbst, RA; Bardenheuer, W; Opalka, B; Schutte, J; Trent, JM; Ben-David, Y; Ruppert, JM				Ren, SR; Smith, MJ; Louro, ID; McKie-Bell, P; Bani, MR; Wagner, M; Zochodne, B; Redden, DT; Grizzle, WE; Wang, ND; Smith, DI; Herbst, RA; Bardenheuer, W; Opalka, B; Schutte, J; Trent, JM; Ben-David, Y; Ruppert, JM			The p44(S10) locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma	ONCOGENE			English	Article						proteasome; regulatory particle; p44(S10); gene amplification; melanoma	COMPARATIVE GENOMIC HYBRIDIZATION; GENE AMPLIFICATION; BREAST-CANCER; CELL-LINES; DNA; COMPLEX; DEGRADATION	Gene amplification is frequently present in human tumors, although specific target genes relevant to many amplified loci remain unidentified. An expression cloning assay enabled identification of a candidate oncogene derived from human chromosome 3p14.1, The cDNA retrieved from morphologically transformed cells contained the full-length protein coding region and detected an abundant transcript in the same cells. Sequence analysis revealed identity with the wild-type sequence of p44(S10), a highly conserved subunit of the 26S proteasome that exhibits similarity to the Arabidopsis fus6/cop11 family of signaling molecules. p44(S10) gene copy number and mRNA expression were increased in association with segmental 1.8-11-fold chromosomal gains in cutaneous malignant melanoma cell lines (5/13; 40%) and tumors (2/40; 5%), and in breast cancer MCF-7 cells. Likewise, malignant progression of human radial growth phase WM35 melanoma cells was associated with amplification and increased expression of endogenous p44(S10), and increased expression of p44(S10) was sufficient to induce proliferation of WM35 cells in vivo. The results demonstrate segmental copy number gains within chromosome 3p in cutaneous malignant melanoma and suggest that deregulation of a proteasome regulatory particle subunit may contribute to the malignant phenotype.	Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL USA; Univ Alabama, Dept Med, Div Hematol Oncol, Birmingham, AL USA; Univ Alabama, Ctr Comprehens Canc, Birmingham, AL USA; Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Hannover Med Sch, Dept Dermatol, D-30449 Hannover, Germany; Univ Essen Gesamthsch, Sch Med, Dept Med Oncol Canc Res, W German Canc Ctr Essen, D-45122 Essen, Germany; Natl Human Genome Res Inst, NIH, Bethesda, MD USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Alabama System; University of Alabama Birmingham; Mayo Clinic; Hannover Medical School; University of Duisburg Essen; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Ruppert, JM (corresponding author), Room 570 WTI,1824 6th Ave S, Birmingham, AL 35294 USA.		Bani, Maria Rosa/AAB-3397-2020; Louro, Iuri D/I-8641-2012	Bani, Maria Rosa/0000-0001-8178-1432; Louro, Iuri/0000-0001-5160-9615	NATIONAL CANCER INSTITUTE [R29CA065686, R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [R29CA65686, CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bani MR, 1996, CANCER RES, V56, P3075; Bardenheuer W, 1996, GENOME RES, V6, P176, DOI 10.1101/gr.6.3.176; Barks JH, 1997, GENE CHROMOSOME CANC, V19, P278, DOI 10.1002/(SICI)1098-2264(199708)19:4<278::AID-GCC11>3.3.CO;2-9; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; Bastian BC, 1998, CANCER RES, V58, P2170; Chamovitz DA, 1996, CELL, V86, P115, DOI 10.1016/S0092-8674(00)80082-3; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DESHANE J, 1994, GENE THER, V1, P332; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Montgomery D.C., 1991, DESIGN ANAL EXPT; NEUBAUER A, 1992, ONCOGENE, V7, P1019; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Sozzi G, 1998, ADV CANCER RES, V74, P141, DOI 10.1016/S0065-230X(08)60766-6; VOGELSTEIN B, 1998, GENETIC BIASIS HUMAN; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659	31	24	25	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 9	2000	19	11					1419	1427		10.1038/sj.onc.1203462	http://dx.doi.org/10.1038/sj.onc.1203462			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723133				2022-12-17	WOS:000085942700007
J	Castagnino, P; Lorenzi, MV; Yeh, J; Breckenridge, D; Sakata, H; Munz, B; Werner, S; Bottaro, DP				Castagnino, P; Lorenzi, MV; Yeh, J; Breckenridge, D; Sakata, H; Munz, B; Werner, S; Bottaro, DP			Neu differentiation factor/heregulin induction by hepatocyte and keratinocyte growth factors	ONCOGENE			English	Article						neu differentiation factor; neuregulin; heregulin; hepatocyte growth factor; keratinocyte growth factor; gene induction; tissue repair	FACTOR SCATTER FACTOR; EPITHELIAL-CELLS; FACTOR/SCATTER FACTOR; RECEPTOR EXPRESSION; LIVER-REGENERATION; FACTOR HEREGULIN; MET RECEPTOR; WOUND REPAIR; FACTOR-ALPHA; IN-VIVO	Hepatocyte growth-factor (HGF) is a potent, widely produced, pleiotropic mediator of mesenchymal-epithelial interaction. In a study of changes in gene expression initiated by HGF in Balb/MK keratinocytes, we observed the induction of Neu-differentiation factor (NDF) mRNA (also known as heregulin, or HRG). Further characterization of the regulation of NDF expression in Balb/MK keratinocytes revealed potent induction by keratinocyte growth factor (KGF) and epidermal growth factor (EGF), but not by HGF/NK2, an alternative HGF isoform with motogenic but not mitogenic or morphogenic activities. Sustained treatment (8 h) of Balb/MK cells with KGF stimulated secretion of mature NDF protein into the culture medium, and Balb/MK cells treated with purified recombinant NDF protein showed increased DNA synthesis. We also found evidence of NDF induction in two models of tissue repair in mice: in full-thickness skin wounds, following locally increased KGF production, and in kidney after partial hepatectomy, following elevation of circulating HGF levels. These results reveal that mesenchymally-derived HGF and KGF can activate autocrine NDF signaling in their epithelial targets, and suggest that this mechanism contributes to the coordination of stages of wound repair, and possibly development, where these growth factors act in concert to direct epithelial proliferation, morphogenesis and differentiation.	NCI, DBS, LCMB, Bethesda, MD 20892 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Max Planck Society	Bottaro, DP (corresponding author), NCI, DBS, LCMB, Bldg 37,Room IE24,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.		Bottaro, Donald P/AAF-3853-2020; Bottaro, Donald P/F-8550-2010	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334; Werner, Sabine/0000-0001-7397-8710	DIVISION OF BASIC SCIENCES - NCI [Z01BC005626] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balkovetz DF, 1999, INT REV CYTOL, V186, P225; Bardelli A, 1997, CIBA F SYMP, V212, P133; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Castagnino P, 1998, ONCOGENE, V17, P481, DOI 10.1038/sj.onc.1201957; DANILENKO DM, 1995, J CLIN INVEST, V95, P842, DOI 10.1172/JCI117734; DLUGOSZ AA, 1994, CELL GROWTH DIFFER, V5, P1283; Dunsmore SE, 1996, J BIOL CHEM, V271, P24576, DOI 10.1074/jbc.271.40.24576; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; Ethier SP, 1996, MOL CARCINOGEN, V15, P134; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; Higgins GM, 1931, ARCH PATHOL, V12, P186; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; KINOSHITA T, 1991, BIOCHEM BIOPH RES CO, V177, P330, DOI 10.1016/0006-291X(91)91987-N; KONO S, 1992, BIOCHEM BIOPH RES CO, V186, P991, DOI 10.1016/0006-291X(92)90844-B; Krane IM, 1996, ONCOGENE, V12, P1781; LINDROOS PM, 1991, HEPATOLOGY, V13, P743, DOI 10.1002/hep.1840130422; LORENZI MV, 1995, ONCOGENE, V10, P2051; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; Marikovsky M, 1996, J INVEST DERMATOL, V106, P616, DOI 10.1111/1523-1747.ep12345413; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Munz B, 1997, BIOCHEM J, V326, P579, DOI 10.1042/bj3260579; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; Ozaki M, 1997, NATURE, V390, P691, DOI 10.1038/37795; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RON D, 1993, J BIOL CHEM, V268, P2984; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Sakata H, 1996, CELL GROWTH DIFFER, V7, P1513; Sandrock AW, 1997, SCIENCE, V276, P599, DOI 10.1126/science.276.5312.599; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Schaefer G, 1997, ONCOGENE, V15, P1385, DOI 10.1038/sj.onc.1201317; SCHIMIDT C, 1995, NATURE, V373, P699; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Stahl SJ, 1997, BIOCHEM J, V326, P763, DOI 10.1042/bj3260763; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; TZAAHAR E, 1994, J BIOL CHEM, V269, P25226; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WOJTA J, 1994, BLOOD, V84, P151; Wong VV, 1997, J BIOL CHEM, V272, P5187, DOI 10.1074/jbc.272.8.5187; YANAGITA K, 1993, J BIOL CHEM, V268, P21212; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	54	24	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 3	2000	19	5					640	648		10.1038/sj.onc.1203357	http://dx.doi.org/10.1038/sj.onc.1203357			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZU	10698509				2022-12-17	WOS:000085192000006
J	Ananthaswamy, HN; Ouhtit, A; Evans, RL; Gorny, A; Khaskina, P; Sands, AT; Conti, CJ				Ananthaswamy, HN; Ouhtit, A; Evans, RL; Gorny, A; Khaskina, P; Sands, AT; Conti, CJ			Persistence of p53 mutations and resistance of keratinocytes to apoptosis are associated with the increased susceptibility of mice lacking the XPC gene to UV carcinogenesis	ONCOGENE			English	Article						sunlight; skin cancer; p53; apoptosis; DNA repair	INDUCED SKIN TUMORS; NUCLEOTIDE EXCISION-REPAIR; SQUAMOUS-CELL CARCINOMAS; GROUP-C FIBROBLASTS; XERODERMA-PIGMENTOSUM; ULTRAVIOLET-B; DNA-DAMAGE; HAIRLESS MICE; MOUSE SKIN; SUPPRESSOR GENE	Like xeroderma pigmentosum (XP) patients, transgenic mice lacking nucleotide excision repair (NER) genes such as XPA and XPC are extremely susceptible to ultraviolet (UV)-induced skin cancer, Because the p53 gene is an important target for UV carcinogenesis and because the p53 protein modulates NER, we investigated the consequences of NER deficiency on UV-induced p53 mutations in XPC-/- mouse skin tumors. Thirty-eight (76%) of 50 UV-induced XPC-/- skin tumor analysed displayed C --> T or CC --> TT transitions at dipyrimidine sites on the untranscribed strand of the p53 gene. A major hot spot for p53 mutation occurred at codon 270, which is also a hot spot in UV-induced skin tumors from NER-proficient C3H and SKH-hr 1 mice. Interestingly, codon 270 mutations were induced in both XPC-/- and +/+ mouse skin after 1 week of UV irradiation, but the mutations persisted only in XPC-/- mouse skin after 3-4 weeks of chronic UV, The persistence of UV-induced p53 mutations in XPC-/- mouse skin was associated with decreased apoptosis and increased proliferation of keratinocytes, suggesting that these events may contribute to the accelerated development of UV-induced skin tumors in XPC-/- mice.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Lexicon Genet, The Woodlands, TX 77381 USA; Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center; Lexicon Pharmaceuticals; University of Texas System; UTMD Anderson Cancer Center	Ananthaswamy, HN (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA046523, P30CA016672, R01CA042157] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42157, CA 46523, CA 16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ananthaswamy HN, 1998, PHOTOCHEM PHOTOBIOL, V67, P227, DOI 10.1562/0031-8655(1998)067<0227:MIHSHM>2.3.CO;2; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Berg RJW, 1997, CANCER RES, V57, P581; Berg RJW, 1998, J INVEST DERMATOL, V110, P405, DOI 10.1111/j.1523-1747.1998.00173.x; Brash DE, 1996, J INVEST DERMATOL S, V1, P136; Cheo DL, 1996, CURR BIOL, V6, P1691, DOI 10.1016/S0960-9822(02)70794-X; Cleaver J. E., 1989, METABOLIC BASIS INHE, V2, P2949; CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0; CLEAVER JE, 1989, CARCINOGENESIS, V10, P1691, DOI 10.1093/carcin/10.9.1691; de Vries A, 1998, ONCOGENE, V16, P2205, DOI 10.1038/sj.onc.1201744; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; Dumaz N, 1997, CARCINOGENESIS, V18, P897, DOI 10.1093/carcin/18.5.897; EVANS MK, 1993, CANCER RES, V53, P5377; EVANS MK, 1993, J BIOL CHEM, V268, P4839; FORD JM, 1994, MOL CARCINOGEN, V10, P105, DOI 10.1002/mc.2940100208; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; HOEIJMAKERS JHJ, 1990, CANCER CELL-MON REV, V2, P311; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jiang WD, 1999, ONCOGENE, V18, P4247, DOI 10.1038/sj.onc.1202789; KANJILAL S, 1993, CANCER RES, V53, P2961; KRESS S, 1992, CANCER RES, V52, P6400; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li G, 1996, AM J PATHOL, V148, P1113; Li G, 1997, AM J PATHOL, V150, P1457; Ljungman M, 1996, ONCOGENE, V13, P823; NAKANE H, 1995, NATURE, V377, P165, DOI 10.1038/377165a0; Nataraj AJ, 1996, P NATL ACAD SCI USA, V93, P7961, DOI 10.1073/pnas.93.15.7961; NATARAJ AJ, 1995, PHOTOCHEM PHOTOBIOL, V62, P218, DOI 10.1111/j.1751-1097.1995.tb05262.x; ROBBINS JH, 1988, JAMA-J AM MED ASSOC, V260, P384; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; SETLOW RB, 1969, P NATL ACAD SCI USA, V64, P1035, DOI 10.1073/pnas.64.3.1035; SMITH ML, 1995, ONCOGENE, V10, P1053; Takeuchi S, 1998, CANCER RES, V58, P641; VANKRANEN HJ, 1995, CARCINOGENESIS, V16, P1141; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775	39	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7395	7398		10.1038/sj.onc.1203147	http://dx.doi.org/10.1038/sj.onc.1203147			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602497				2022-12-17	WOS:000084119400027
J	McKay, LM; Carpenter, B; Roberts, SGE				McKay, LM; Carpenter, B; Roberts, SGE			Regulation of the Wilms' tumour suppressor protein transcriptional activation domain	ONCOGENE			English	Article						Wilms' tumour; WT1; transcription	DNA-BINDING SPECIFICITY; GENE-PRODUCT; REPRESSES TRANSCRIPTION; INHIBITOR DOMAIN; SELF-ASSOCIATION; MUTANT PROTEINS; WT1; RNA; EXPRESSION; INTERACTS	The Wilms' tumour suppressor protein WT1 contains a transcriptional regulatory domain that can either activate or repress transcription depending upon its cellular environment. The mechanistic basis for this dichotomy is unclear however. Here, we dissect the transcriptional regulatory domains of WT1. We find that a region within the domain of WT1 attributed to transcriptional repression is a potent suppressor of the activation domain at several promoters and in different cell types. In vitro transcription analysis suggests that the mechanism of suppression of the activation domain occurs at the level of transcription initiation. Furthermore we find that the WT1 suppression domain is able to inhibit a heterologous activation domain when fused in cis. Dissection of this domain resulted in the delineation of a 30 amino acid region that was sufficient to confer suppression of a transcriptional activation domain both in vivo and in vitro. Additionally, we find that the WT1 transcriptional activation domain interacts with the general transcription factor TFIIB and that this interaction is not affected by the suppression domain. Taken together, these studies suggest that the suppression domain of WT1 interacts with a cosuppressor protein to mediate inhibition of the WT1 transcriptional activation domain.	Univ Dundee, Dept Biochem, Div Gene Express, Dundee DD1 5EH, Scotland	University of Dundee	Roberts, SGE (corresponding author), Univ Dundee, Dept Biochem, Div Gene Express, Dundee DD1 5EH, Scotland.		Roberts, Stefan GE/R-5537-2016	Roberts, Stefan GE/0000-0002-7535-6365	Wellcome Trust Funding Source: Medline; Worldwide Cancer Research [02-0275] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission); Worldwide Cancer Research		AUSTIN RJ, 1995, MOL CELL BIOL, V15, P4683; Bardeesy N, 1998, NUCLEIC ACIDS RES, V26, P1784, DOI 10.1093/nar/26.7.1784; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; Cook DM, 1996, ONCOGENE, V13, P1789; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Englert C, 1998, TRENDS BIOCHEM SCI, V23, P389, DOI 10.1016/S0968-0004(98)01277-8; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HASTIE ND, 1994, ANNU REV GENET, V28, P523; Hawkes NA, 1999, J BIOL CHEM, V274, P14337, DOI 10.1074/jbc.274.20.14337; Holmes G, 1997, BIOCHEM BIOPH RES CO, V233, P723, DOI 10.1006/bbrc.1997.6545; JAYARAMAN PS, 1994, EMBO J, V13, P2192, DOI 10.1002/j.1460-2075.1994.tb06496.x; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Johnstone RW, 1998, J BIOL CHEM, V273, P10880, DOI 10.1074/jbc.273.18.10880; Kennedy D, 1996, NAT GENET, V12, P329, DOI 10.1038/ng0396-329; KENT J, 1995, ONCOGENE, V11, P1781; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Li C, 1998, MOL CELL BIOL, V18, P3771, DOI 10.1128/MCB.18.7.3771; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; Liu YZ, 1998, NUCLEIC ACIDS RES, V26, P2464, DOI 10.1093/nar/26.10.2464; MADDEN SL, 1993, ONCOGENE, V8, P1713; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Maheswaran S, 1998, GENE DEV, V12, P1108, DOI 10.1101/gad.12.8.1108; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; Maheswaran S, 1998, ONCOGENE, V16, P2041, DOI 10.1038/sj.onc.1201741; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MOFFETT P, 1995, P NATL ACAD SCI USA, V92, P11105, DOI 10.1073/pnas.92.24.11105; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Novina CD, 1996, TRENDS GENET, V12, P351, DOI 10.1016/0168-9525(96)10034-2; PritchardJones K, 1997, LEUKEMIA LYMPHOMA, V27, P207, DOI 10.3109/10428199709059677; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; REDDY JC, 1995, J BIOL CHEM, V270, P29976; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; REECE RJ, 1993, GENE, V126, P105, DOI 10.1016/0378-1119(93)90596-U; Renshaw J, 1997, GENE CHROMOSOME CANC, V19, P256, DOI 10.1002/(SICI)1098-2264(199708)19:4<256::AID-GCC8>3.0.CO;2-W; ROBERTS SGE, 1995, CURR BIOL, V5, P508, DOI 10.1016/S0960-9822(95)00103-5; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; Thate C, 1998, ONCOGENE, V17, P1287, DOI 10.1038/sj.onc.1202055; UM M, 1995, MOL CELL BIOL, V15, P5007; WANG ZY, 1995, ONCOGENE, V10, P415; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1995, ONCOGENE, V10, P1243	50	24	24	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6546	6554		10.1038/sj.onc.1203046	http://dx.doi.org/10.1038/sj.onc.1203046			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597258				2022-12-17	WOS:000083709200018
J	Mazzaro, G; Bossi, G; Coen, S; Sacchi, A; Soddu, S				Mazzaro, G; Bossi, G; Coen, S; Sacchi, A; Soddu, S			The role of wild-type p53 in the differentiation of primary hemopoietic and muscle cells	ONCOGENE			English	Article						p53; differentiation; satellite cell; bone marrow; transformation	BIOCHEMICAL DIFFERENTIATION; GENE AMPLIFICATION; DNA-SYNTHESIS; EXPRESSION; APOPTOSIS; TUMORS; PROTEIN; TRANSFORMATION; IDENTIFICATION; PROGRESSION	Experiments previously performed on 32D and C2C12 cell lines indicated that wild type p53 (wtp53) protein has a role in granulocyte and myotube differentiation. Since these are immortal cells, we asked whether the inhibition of differentiation induced by the expression of dominant-negative p53 (dnp53) proteins was dependent on the immortalization-determined microenvironment. Thus, we evaluated the effects produced by interfering with the endogenous p53 gene in murine primary hemopoietic and muscle cells. Expression of dnp53 protein reduced the differentiation of bone marrow cells into granulocytes and macrophages. Moreover, p53 activation was measurable during the differentiation process of primary myoblasts, while interference with this activation led to a consistent slow down of terminal differentiation. Since the impairment of the differentiation was not accompanied by alterations in the cell cycle withdrawal and in the rate of apoptosis which are coupled with these types of differentiation, the data here reported support a specific role for p53 in the differentiation process. However, the difference in the intensity of inhibition between immortal and primary cells, i.e., complete versus slow down, respectively, suggests that the immortalization process might render the cells more sensitive to the loss of wtp53 activity for the differentiation process.	CRS, Regina Elena Canc Inst, Mol Oncogenesis Lab, I-00158 Rome, Italy		Soddu, S (corresponding author), CRS, Regina Elena Canc Inst, Mol Oncogenesis Lab, Via Messi Doro 156, I-00158 Rome, Italy.		Soddu, Silvia/ABH-6774-2020; Bossi, Gianluca/G-8375-2016; Bossi, Gianluca/B-9394-2017; Soddu, Silvia/K-2467-2018; Bossi, Gianluca/ABH-6846-2020	Soddu, Silvia/0000-0001-8526-0044; Bossi, Gianluca/0000-0002-2947-1063; Bossi, Gianluca/0000-0002-2947-1063; Soddu, Silvia/0000-0001-8526-0044; Bossi, Gianluca/0000-0002-2947-1063	Telethon [857] Funding Source: Medline	Telethon(Fondazione Telethon)		ALMOG N, 1997, BIOCHIM BIOPHYS ACTA, V1333, P1; CAMPION DR, 1984, INT REV CYTOL, V87, P225, DOI 10.1016/S0074-7696(08)62444-4; CHAMPLIN RE, 1985, BLOOD, V65, P1309; CRESCENZI M, 1994, J CELL BIOL, V125, P1137, DOI 10.1083/jcb.125.5.1137; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FAGIN JA, 1994, THYROID TODAY, V17, P1; FEINSTEIN E, 1991, P NATL ACAD SCI USA, V88, P6293, DOI 10.1073/pnas.88.14.6293; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HUFF CA, 1993, J BIOL CHEM, V268, P377; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; ROBBINS SL, 1989, PATHOLOGIC BASIS DIS; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Scardigli R, 1997, GENE THER, V4, P1371, DOI 10.1038/sj.gt.3300530; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; SCHMID P, 1991, DEVELOPMENT, V113, P857; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SODDU S, 1994, BLOOD, V83, P2230, DOI 10.1182/blood.V83.8.2230.bloodjournal8382230; SUNGRUE MM, 1997, P NATL ACAD SCI USA, V94, P9648; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Wallingford JB, 1997, CURR BIOL, V7, P747, DOI 10.1016/S0960-9822(06)00333-2; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WRIGHT PA, 1991, ONCOGENE, V6, P1693; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	37	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	1999	18	42					5831	5835		10.1038/sj.onc.1202962	http://dx.doi.org/10.1038/sj.onc.1202962			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523864				2022-12-17	WOS:000083095100012
J	Kolzau, T; Hansen, RS; Zahra, D; Reddel, RR; Braithwaite, AW				Kolzau, T; Hansen, RS; Zahra, D; Reddel, RR; Braithwaite, AW			Inhibition of SV40 large T antigen induced apoptosis by small T antigen	ONCOGENE			English	Article						SV40 T antigens; apoptosis	LARGE TUMOR-ANTIGEN; SIMIAN-VIRUS-40 LARGE-T; AMINO-TERMINAL DOMAIN; SIMIAN VIRUS-40; PROTEIN PHOSPHATASE-2A; DNA-REPLICATION; P53 PROTEIN; WILD-TYPE; TRANSFORMATION; FIBROBLASTS	It is well established that the expression of simian virus 40 (SV40) early gene products causes oncogenic transformation of rodent cells, An important aspect of this process is the inactivation of the p53 and retinoblastoma (pRb) tumour suppressor proteins through interaction with the SV40 large tumour antigen (LT). In addition, the SV40 small tumour antigen (ST) may enhance LT induced transformation. Here we show that LT induces apoptotic cell death in rat embryo fibroblast (REF) cells and that ST functions to inhibit this effect by a mechanism which is different from other known anti-apoptotic proteins. Mutational analysis of LT indicates that mutants defective in the pRb-binding domain are unable to induce apoptosis whereas LT mutants defective in the p53-binding domain are still competent to induce apoptosis, Thus, interaction between LT and one or more pRb family members must occur for induction of apoptosis and that binding of p53 by LT is insufficient to inhibit LT induced apoptosis in REFs. The data presented herein suggest that the anti-apoptotic function of ST may explain, at least in part, how ST contributes to SV40 early region induced transformation of REF cells.	Univ Otago, Dunedin Sch Med, Dept Pathol, Dunedin, New Zealand; Childrens Med Res Inst, Sydney, NSW 2145, Australia	University of Otago; Children's Medical Research Institute - Australia; University of Sydney	Braithwaite, AW (corresponding author), Univ Otago, Dunedin Sch Med, Dept Pathol, Box 913, Dunedin, New Zealand.		Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107				AlUbaidi MR, 1997, EXP EYE RES, V64, P573, DOI 10.1006/exer.1996.0240; BELLETT AJD, 1979, J CELL PHYSIOL, V101, P33, DOI 10.1002/jcp.1041010106; BIKEL I, 1986, MOL CELL BIOL, V6, P1172, DOI 10.1128/MCB.6.4.1172; BOUCK N, 1978, P NATL ACAD SCI USA, V75, P2473, DOI 10.1073/pnas.75.5.2473; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BROWN M, 1986, J VIROL, V60, P290, DOI 10.1128/JVI.60.1.290-293.1986; Chen SL, 1998, VIROLOGY, V244, P521, DOI 10.1006/viro.1998.9109; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Endo T, 1998, J CELL SCI, V111, P1081; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; FU XY, 1987, MOL CELL BIOL, V7, P738, DOI 10.1128/MCB.7.2.738; Hansen R, 1995, ONCOGENE, V11, P2535; Hansen RS, 1996, ONCOGENE, V13, P995; HANSEN RS, 1995, THESIS AUSTR NATL U; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; JOG P, 1990, J VIROL, V64, P5649; KRIEGLER M, 1984, CELL, V38, P483, DOI 10.1016/0092-8674(84)90503-8; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; MACLEAN K, 1994, ONCOGENE, V9, P719; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MARCELLUS RC, 1996, J VIROL, V70, P6201; MONTANO X, 1990, P NATL ACAD SCI USA, V87, P7448, DOI 10.1073/pnas.87.19.7448; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PAUCHA E, 1978, P NATL ACAD SCI USA, V75, P2165, DOI 10.1073/pnas.75.5.2165; Reed Michael, 1993, Gene Expression, V3, P95; SAKAMOTO K, 1993, ONCOGENE, V8, P1887; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SOMPAYRAC L, 1992, VIROLOGY, V191, P439, DOI 10.1016/0042-6822(92)90206-5; SOMPAYRAC L, 1989, VIROLOGY, V171, P267, DOI 10.1016/0042-6822(89)90536-9; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SRINIVASAN A, 1994, CELL, V78, P703; TIEMANN F, 1995, J VIROL, V69, P6115, DOI 10.1128/JVI.69.10.6115-6121.1995; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; YANAI N, 1994, EXP CELL RES, V211, P296, DOI 10.1006/excr.1994.1090; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; ZAHRA DG, 1995, THESIS U SYDNEY; ZERRAHN J, 1993, EMBO J, V12, P4739, DOI 10.1002/j.1460-2075.1993.tb06162.x	41	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	1999	18	40					5598	5603		10.1038/sj.onc.1202942	http://dx.doi.org/10.1038/sj.onc.1202942			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523837				2022-12-17	WOS:000082894700013
J	Kogan, SC; Bishop, JM				Kogan, SC; Bishop, JM			Acute promyelocytic leukemia: from treatment to genetics and back	ONCOGENE			English	Article						hematopoiesis; acute promyelocytic leukemia; retinoic acid; pre-clinical testing	RETINOIC ACID RECEPTOR; PML-RAR-ALPHA; ARSENIC TRIOXIDE AS2O3; ZINC FINGER GENE; FUSION PROTEIN; GRANULOCYTIC DIFFERENTIATION; ERYTHROID-DIFFERENTIATION; T(15-17) TRANSLOCATION; HISTONE DEACETYLASE; GROWTH-SUPPRESSOR		Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, GW Hooper Fdn, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kogan, SC (corresponding author), Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.			Kogan, Scott/0000-0002-2395-8479	NCI NIH HHS [CA 4338] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; Borden KLB, 1997, FEBS LETT, V418, P30, DOI 10.1016/S0014-5793(97)01344-6; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BREITMAN TR, 1981, BLOOD, V57, P1000; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Chen GQ, 1997, BLOOD, V89, P3345; Chen GQ, 1996, BLOOD, V88, P1052; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DANIEL MT, 1993, BLOOD, V82, P1858; DEGOS L, 1995, BLOOD, V85, P2643, DOI 10.1182/blood.V85.10.2643.bloodjournal85102643; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Ding W, 1998, BLOOD, V92, P1172, DOI 10.1182/blood.V92.4.1172.416k02_1172_1183; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; DOUER D, 1982, EXP CELL RES, V138, P193, DOI 10.1016/0014-4827(82)90105-7; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRATAS C, 1993, LEUKEMIA, V7, P1156; GRIGNANI F, 1995, CANCER RES, V55, P440; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUANG ME, 1987, CHINESE MED J-PEKING, V100, P949; Imaizumi M, 1998, BLOOD, V92, P374, DOI 10.1182/blood.V92.2.374.414a40_374_382; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; Kitamura K, 1997, LEUKEMIA, V11, P1950, DOI 10.1038/sj.leu.2400837; Kizaki M, 1998, J NATL CANCER I, V90, P1906, DOI 10.1093/jnci/90.24.1906; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Labrecque J, 1998, BLOOD, V92, P607, DOI 10.1182/blood.V92.2.607.414k06_607_615; LAGASSE E, 1992, BLOOD, V79, P1907; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; LANOTTE M, 1991, BLOOD, V77, P1080; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MATTEI MG, 1988, HUM GENET, V80, P186, DOI 10.1007/BF00702866; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Nason-Burchenal K, 1998, ONCOGENE, V17, P1759, DOI 10.1038/sj.onc.1202075; Nervi C, 1998, BLOOD, V92, P2244; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Pollock Jessica L., 1997, Blood, V90, p320A; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; ROUSSELOT P, 1994, ONCOGENE, V9, P545; ROWLEY JD, 1977, LANCET, V1, P549; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Sporn M.B., 1994, RETINOIDS BIOL CHEM; STONE RM, 1990, J CLIN ONCOL, V8, P1913, DOI 10.1200/JCO.1990.8.11.1913; Sun H. D., 1992, CHIN J INTEGRAT CHIN, V12, P170; Testa U, 1998, LEUKEMIA, V12, P563, DOI 10.1038/sj.leu.2400967; Wang ZG, 1998, BLOOD, V92, p479A; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Westervelt P, 1999, BLOOD, V93, P2143, DOI 10.1182/blood.V93.7.2143.407a32_2143_2148; Yoshida H, 1996, CANCER RES, V56, P2945; ZHANG P, 1996, CHIN J HEMATOL, V17, P58; Zhang SY, 1996, BLOOD, V87, P3404, DOI 10.1182/blood.V87.8.3404.bloodjournal8783404	78	24	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	1999	18	38					5261	5267		10.1038/sj.onc.1202996	http://dx.doi.org/10.1038/sj.onc.1202996			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498878				2022-12-17	WOS:000082808400004
J	Sunday, ME; Haley, KJ; Sikorski, K; Graham, SA; Emanuel, RL; Zhang, F; Mu, QQ; Shahsafaei, A; Hatzis, D				Sunday, ME; Haley, KJ; Sikorski, K; Graham, SA; Emanuel, RL; Zhang, F; Mu, QQ; Shahsafaei, A; Hatzis, D			Calcitonin driven v-Ha-ras induces multilineage pulmonary epithelial hyperplasias and neoplasms	ONCOGENE			English	Article						neuroendocrine cells; Clara cells; epithelial cell lineages; carcinoid; adenocarcinoma	CELL LUNG-CANCER; GASTRIN-RELEASING PEPTIDE; NEURO-ENDOCRINE DIFFERENTIATION; MEDULLARY-THYROID CARCINOMA; TRANSGENIC MOUSE MODEL; HUMAN-FETAL LUNG; SV40 T-ANTIGEN; GENE-EXPRESSION; HAMSTER LUNG; CHROMOGRANIN-A	We initiated a transgenic model for primary pulmonary neuroendocrine cell (PNEC) hyperplasia/neoplasia using v-Ha-ras driven by the neural/neuroendocrine (NE)-specific calcitonin promoter (rascal). Previously, we showed that nitrosamine treated rodents develop PNEC hyperplasia but non-NE lung tumors, with variable outcomes presumably reflecting ras activation in multiple cell lineages. Interestingly, all rascal transgenic mouse lineages develop hyperplasias of NE and non-NE cells but mostly non-NE lung carcinomas, with rascal mRNA in differentiated PNECs and tumor cells. Analyses of embryonic lung demonstrate rascal mRNA in undifferentiated epithelium, consistent with expression in a common pluripotent precursor cell. These unexpected observations indicate that v-Ha-ras can lead to both NE and non-NE hyperplasia/neoplasia in vivo, opening new avenues for studies of lung carcinogenesis.	Brigham & Womens Hosp, Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Sunday, ME (corresponding author), Brigham & Womens Hosp, Childrens Hosp, 75 Francis St, Boston, MA 02115 USA.			Sunday, Mary E./0000-0002-6788-1469	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD002911] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050045, R01HL044984] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50045, R01-HL44984] Funding Source: Medline; NICHD NIH HHS [N01-HD02911] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anderson Robert J., 1997, Current Opinion in Oncology, V9, P45; BAETSCHER M, 1991, ONCOGENE, V6, P1133; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BASBAUM C, 1990, AM J PHYSIOL, V259, pL38, DOI 10.1152/ajplung.1990.259.2.L38; BAYLIN SB, 1989, J CLIN ONCOL, V7, P1375, DOI 10.1200/JCO.1989.7.10.1375; BENNETT MM, 1992, ANN NY ACAD SCI, V657, P36, DOI 10.1111/j.1749-6632.1992.tb22755.x; BENSCH KG, 1965, CANCER-AM CANCER SOC, V18, P592, DOI 10.1002/1097-0142(196505)18:5<592::AID-CNCR2820180508>3.0.CO;2-6; BENSCH KG, 1968, CANCER, V22, P1163, DOI 10.1002/1097-0142(196811)22:6<1163::AID-CNCR2820220612>3.0.CO;2-L; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; BERENDSEN HH, 1989, J CLIN ONCOL, V7, P1614, DOI 10.1200/JCO.1989.7.11.1614; BOS JL, 1989, CANCER RES, V49, P4682; BOSTWICK DG, 1984, AM J PATHOL, V117, P195; BRAMBILLA E, 1991, J CLIN ONCOL, V9, P50, DOI 10.1200/JCO.1991.9.1.50; CHEJFEC G, 1985, CANCER, V56, P2683, DOI 10.1002/1097-0142(19851201)56:11<2683::AID-CNCR2820561127>3.0.CO;2-L; DAVIS LG, 1986, BASIC METHODS MOL BI, P1; DEBRUINE AP, 1990, ACTA HISTOCHEM S, V38, pS99; DEMAYO FJ, 1991, AM J PHYSIOL, V261, pL70, DOI 10.1152/ajplung.1991.261.2.L70; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; FALCO JP, 1990, J CLIN INVEST, V85, P1740, DOI 10.1172/JCI114630; FRANCINEMARIE M, 1997, P NATL ACAD SCI USA, V94, P3330; Gardner DG, 1997, ADV INTERNAL MED, V42, P597; GAZDAR AF, 1988, CANCER RES, V48, P4078; GOODWIN G, 1983, P NATL ACAD SCI-BIOL, V80, P3807, DOI 10.1073/pnas.80.12.3807; GOULD VE, 1983, LAB INVEST, V49, P519; HACKETT BP, 1994, AM J RESP CELL MOL, V11, P123, DOI 10.1165/ajrcmb.11.2.8049073; Haley KJ, 1997, MICROSC RES TECHNIQ, V37, P62, DOI 10.1002/(SICI)1097-0029(19970401)37:1<62::AID-JEMT6>3.0.CO;2-Y; HAMID QA, 1987, VIRCHOWS ARCH A, V411, P185, DOI 10.1007/BF00712743; HAMMOND ME, 1985, CANCER, V56, P1624, DOI 10.1002/1097-0142(19851001)56:7<1624::AID-CNCR2820560727>3.0.CO;2-3; HANSBROUGH JR, 1993, J BIOL CHEM, V268, P9762; HAUBOLDREUTER BG, 1993, J NUCL MED, V34, P809; Johnston D, 1998, ONCOGENE, V16, P167, DOI 10.1038/sj.onc.1201478; JONES TC, 1985, MONOGRAPHS PATHOLOGY, P99; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LEBEL M, 1995, CELL GROWTH DIFFER, V6, P1591; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MABRY M, 1989, J CLIN INVEST, V84, P194, DOI 10.1172/JCI114140; Maher J, 1996, LEUKEMIA, V10, P83; MANGUES R, 1990, ONCOGENE, V5, P1491; MARGOLIS B, 1994, J AM SOC NEPHROL, V5, P1288; MARONPOT RR, 1991, EXP LUNG RES, V17, P305, DOI 10.3109/01902149109064420; MENDELSOHN G, 1986, PATHOL ANNU, V21, P91; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; Ogawa K, 1996, CARCINOGENESIS, V17, P341, DOI 10.1093/carcin/17.2.341; OREFFO VIC, 1993, CARCINOGENESIS, V14, P451, DOI 10.1093/carcin/14.3.451; OREFFO VIC, 1992, MOL CARCINOGEN, V6, P199, DOI 10.1002/mc.2940060305; PALADUGU RR, 1985, CANCER, V55, P1303, DOI 10.1002/1097-0142(19850315)55:6<1303::AID-CNCR2820550625>3.0.CO;2-A; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; RODENHUIS S, 1992, CANCER RES, V52, pS2665; SABA SR, 1981, ULTRASTRUCT PATHOL, V2, P131, DOI 10.3109/01913128109064241; SAID JW, 1985, HUM PATHOL, V16, P236, DOI 10.1016/S0046-8177(85)80008-3; SANDMOLLER A, 1995, CELL GROWTH DIFFER, V6, P97; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; STAHLMAN MT, 1987, LAB INVEST, V56, P629; STAHLMAN MT, 1985, LAB INVEST, V52, P52; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; SUNDAY ME, 1991, HUM PATHOL, V22, P1030, DOI 10.1016/0046-8177(91)90011-D; SUNDAY ME, 1995, AM J PATHOL, V147, P740; SUNDAY ME, 1992, CANCER RES, V52, pS2677; SUNDAY ME, 1994, LAB INVEST, V70, P875; TREMBLAY PJ, 1989, MOL CELL BIOL, V9, P854, DOI 10.1128/MCB.9.2.854; TSUTSUMI Y, 1983, LAB INVEST, V48, P623; WARREN WH, 1984, J THORAC CARDIOV SUR, V87, P274; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Wikenheiser KA, 1997, AM J RESP CELL MOL, V16, P713, DOI 10.1165/ajrcmb.16.6.9191473; Willett CG, 1997, J CLIN INVEST, V99, P2979, DOI 10.1172/JCI119493; Wuenschell CW, 1996, J HISTOCHEM CYTOCHEM, V44, P113, DOI 10.1177/44.2.8609367	68	24	26	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	1999	18	30					4336	4347		10.1038/sj.onc.1202810	http://dx.doi.org/10.1038/sj.onc.1202810			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439041				2022-12-17	WOS:000081732700006
J	Fournier, N; Raj, K; Saudan, P; Utzig, S; Sahli, R; Simanis, V; Beard, P				Fournier, N; Raj, K; Saudan, P; Utzig, S; Sahli, R; Simanis, V; Beard, P			Expression of human papillomavirus 16 E2 protein in Schizosaccharomyces pombe delays the initiation of mitosis	ONCOGENE			English	Article						HPV16; mitosis; cdc2 kinase; yeast; cell cycle	FISSION YEAST; CELL-CYCLE; GENETIC-ANALYSIS; CERVICAL-CANCER; S-PHASE; TYPE-16; KINASE; DOMAINS; CLONING; DNA	Infection by some types of human papillomavirus (HPV) is associated with the development of cervical cancer. Analysis of viral DNA from cervical tumours shows that the E2 gene is frequently disrupted during integration into the host cell's DNA, It has therefore been suggested that loss of E2p is an important step in malignant transformation. Expression of E2p in the fission yeast Schizosaccharomyces pombe retards the G2-M transition, by delaying activation of Cdc2p kinase, In contrast, S phase progression, and commitment to cell division in late G1 are not affected. The delay is independent of the transcriptional trans-activation function of E2p, and does not result from E2p DNA binding mimicking DNA damage. Increased expression of E2p also delays mitotic initiation in mammalian cells, S, pombe may thus provide a simple model for the analysis of E2p function.	Swiss Inst Expt Canc Res, Cell Cycle Control Lab, CH-1066 Epalinges, Switzerland; Swiss Inst Expt Canc Res, Dept Virol, CH-1066 Epalinges, Switzerland; CHU Vaudois, Dept Microbiol, CH-1011 Lausanne, Switzerland	Swiss Institute Experimental Cancer Research; Swiss Institute Experimental Cancer Research; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Simanis, V (corresponding author), Swiss Inst Expt Canc Res, Cell Cycle Control Lab, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.		Sahli, Roland/K-6479-2017	Sahli, Roland/0000-0001-7513-1142				ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BENSON JD, 1995, J VIROL, V69, P4364, DOI 10.1128/JVI.69.7.4364-4372.1995; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; CHIANG CM, 1992, P NATL ACAD SCI USA, V89, P5799, DOI 10.1073/pnas.89.13.5799; CORREABORDES J, 1995, CELL, V83, P1001, DOI 10.1016/0092-8674(95)90215-5; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; Creanor J, 1996, J CELL SCI, V109, P1647; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; Daniel B, 1997, J GEN VIROL, V78, P1095, DOI 10.1099/0022-1317-78-5-1095; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; DOWHANICK JJ, 1995, J VIROL, V69, P7791, DOI 10.1128/JVI.69.12.7791-7799.1995; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FANKHAUSER C, 1994, EMBO J, V13, P3011, DOI 10.1002/j.1460-2075.1994.tb06600.x; Frattini MG, 1997, EMBO J, V16, P318, DOI 10.1093/emboj/16.2.318; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; HAGAN I, 1988, J CELL SCI, V91, P587; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HIBMA MH, 1995, EUR J BIOCHEM, V229, P517, DOI 10.1111/j.1432-1033.1995.tb20493.x; Hitt M. M., 1994, CELL BIOL LAB HDB, V1, P479; MACNEILL SA, 1991, MOL GEN GENET, V229, P109, DOI 10.1007/BF00264219; MATSUKURA T, 1995, INT J CANCER, V61, P13, DOI 10.1002/ijc.2910610104; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NASIM A, 1975, GENETICS, V79, P573; NURSE P, 1980, GENETICS, V96, P627; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; REYMOND A, 1992, MOL GEN GENET, V234, P449, DOI 10.1007/BF00538705; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Sakai H, 1996, J VIROL, V70, P1602, DOI 10.1128/JVI.70.3.1602-1611.1996; SALZMAN NP, 1987, PAPOVIRIDEAE, V2; Sambrook J., 1989, MOL CLONING; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shiozaki K, 1997, MOL BIOL CELL, V8, P409, DOI 10.1091/mbc.8.3.409; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; Steger G, 1997, J VIROL, V71, P50, DOI 10.1128/JVI.71.1.50-58.1997; Stern B, 1996, TRENDS GENET, V12, P345; TAN SH, 1994, J VIROL, V68, P6411, DOI 10.1128/JVI.68.10.6411-6420.1994; THURIAUX P, 1980, J GEN MICROBIOL, V116, P525; USHIKAI M, 1994, J VIROL, V68, P6655, DOI 10.1128/JVI.68.10.6655-6666.1994; Vernon SD, 1997, INT J CANCER, V74, P50, DOI 10.1002/(SICI)1097-0215(19970220)74:1<50::AID-IJC9>3.3.CO;2-P	48	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	1999	18	27					4015	4021		10.1038/sj.onc.1202775	http://dx.doi.org/10.1038/sj.onc.1202775			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KU	10435625				2022-12-17	WOS:000081327800012
J	Bond, JA; Webley, K; Wyllie, FS; Jones, CJ; Craig, A; Hupp, T; Wynford-Thomas, D				Bond, JA; Webley, K; Wyllie, FS; Jones, CJ; Craig, A; Hupp, T; Wynford-Thomas, D			p53-dependent growth arrest and altered p53-immunoreactivity following metabolic labelling with P-32 ortho-phosphate in human fibroblasts	ONCOGENE			English	Article						p53; metabolic labelling; DNA damage; phosphorylation; cell cycle	DNA-BINDING FUNCTION; EPITHELIAL-CELLS; MUTANT P53; PROTEIN; DAMAGE; INDUCTION; ACTIVATION; SENESCENCE; EXPRESSION; ANTIBODIES	The tumour suppressor gene p53 plays a major role in the cellular response to DNA damage, mediating growth arrest and/or apoptosis. Phosphorylation of the protein occurs at numerous sites in vivo and is likely to be a major mechanism for modulation of its activity as a transcriptional transactivator. Not surprisingly, therefore, p53 has been intensively studied by P-32 metabolic labelling. Here we show however, using normal human fibroblasts, that typical labelling conditions induce (i) a p53-dependent inhibition of DNA synthesis and (ii) an increase in the cellular content of p53 protein detectable by the phosphorylation-sensitive antibody DO-1 but not by antibody DO-12. These data demonstrate for the first time that P-32 labelling is sufficient to induce biologically-significant, p53-mediated cellular response and strongly suggest that it perturbs the phosphorylation state of p53 which it is being used to measure. This highlights the need to re-evaluate earlier data by nonradioactive approaches using phospho-specific antibodies.	Cardiff Univ, Canc Res Campaign Labs, Dept Pathol, Cardiff CF4 4XN, S Glam, Wales; Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland	Cardiff University; University of Dundee	Wynford-Thomas, D (corresponding author), Cardiff Univ, Canc Res Campaign Labs, Dept Pathol, Cardiff CF4 4XN, S Glam, Wales.			Jones, Christopher/0000-0002-5447-8187				Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; Bond J, 1996, ONCOGENE, V13, P2097; BOND JA, 1995, CANCER RES, V55, P2404; BRADY MAW, 1990, IN SITU HYBRIDIZATIO; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CRAIG AL, 1998, 9 P53 WORKSH CRET, P102; DOVER R, 1994, J CELL SCI, V107, P1181; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HALAZONETIS T, 1998, 9 P53 WORKSH CRET, P52; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; Mundt M, 1997, ONCOGENE, V15, P237, DOI 10.1038/sj.onc.1201174; Shaw P, 1996, ONCOGENE, V12, P921; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; VOJTESEK B, 1995, ONCOGENE, V10, P389; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wyllie FS, 1996, ONCOGENE, V12, P1077; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; WYLLIE FS, 1995, ONCOGENE, V10, P49; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2	29	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	1999	18	25					3788	3792		10.1038/sj.onc.1202733	http://dx.doi.org/10.1038/sj.onc.1202733			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391688				2022-12-17	WOS:000081140200014
J	Chang, CH; Scott, GK; Baldwin, MA; Benz, CC				Chang, CH; Scott, GK; Baldwin, MA; Benz, CC			Exon 4-encoded acidic domain in the epithelium-restricted Ets factor, ESX, confers potent transactivating capacity and binds to TATA-binding protein (TBP)	ONCOGENE			English	Article						ESX; human Ets factor; genomic organization; transactivation domain	TRANSCRIPTION FACTOR; CHROMOSOMAL LOCALIZATION; GENOMIC ORGANIZATION; DNA-BINDING; MOLECULAR-ORGANIZATION; ACTIVATION DOMAINS; GENE FAMILY; EXPRESSION; MEMBER; POLYADENYLATION	The Ets gene family has a complex evolutionary history with many family members known to regulate genetic programs essential for differentiation and development, and some known for their involvement in human tumorigenesis. To understand the biological properties associated with a recently described epithelium-restricted Ets factor ESX, an 11 kb fragment from the 1q32.2 genomically localized human gene was cloned and analysed. Upstream of the ESX promoter region in this genomic fragment lies the terminal exon of a newly identified gene that encodes a ubiquitin-conjugating enzyme variant, UEV-1. Tissues expressing ESX produce a primary 2.2 kb transcript along with a 4.1 kb secondary transcript arising by alternate poly(A) site selection and uniquely recognized by a genomic probe from the 3' terminal region of the 11 kb clone. Endogenous expression of ESX results in a 42 kDa nuclear protein having fivefold greater affinity for the chromatin-nuclear matrix compartment as compared to other endogenous transcription factors like AP-2 and the homologous Ets factor, ELF-1. Exon mapping of the modular structure inferred from ESX cDNA and construction of GAL4(DBD)-ESX expression constructs were used to identify a transactivating domain encoded by exon 4 having comparable potency to the acidic transactivation domain of the viral transcription factor, VP16. This exon 4-encoded 31 amino acid domain in ESX was shown by mutation and deletion analysis to possess a 13 residue acidic transactivation core which, based on modeling and circular dichroism analysis, is predicted to form an amphipathic alpha-helical secondary structure. Using recombinant GST-ESX (exon 4) fusion proteins in an in vitro pull-down assay, this ESX transactivation domain was shown to bind specifically to one component of the general transcription machinery, TATA-binding protein (TBP). Transient transfection experiments confirmed the ability of this TBP-binding transactivation domain in ESX to squelch heterologous promoters independent of any promoter binding as efficiently as the transactivation domain from VP16.	Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Benz, CC (corresponding author), Univ Calif San Francisco, Dept Med, Div Hematol Oncol, Box 1270,3rd & Parnassus, San Francisco, CA 94143 USA.				NATIONAL CANCER INSTITUTE [R01CA036773, P50CA058207, P01CA044768] Funding Source: NIH RePORTER; NCI NIH HHS [CA58207, CA44768, CA36773] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; ASHAR HR, 1995, CELL, V82, P57; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; Baens M, 1996, GENOME RES, V6, P404, DOI 10.1101/gr.6.5.404; BELLACOSA A, 1994, J VIROL, V68, P2320, DOI 10.1128/JVI.68.4.2320-2330.1994; Bochert MA, 1998, BIOCHEM BIOPH RES CO, V246, P176, DOI 10.1006/bbrc.1998.8560; CHANG CB, 1993, MOL CELL BIOL, V13, P7469, DOI 10.1128/MCB.13.12.7469; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chen HM, 1998, GENE, V207, P209, DOI 10.1016/S0378-1119(97)00629-X; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; deCastro CM, 1997, GENOMICS, V42, P227, DOI 10.1006/geno.1997.4730; Defossez PA, 1997, NUCLEIC ACIDS RES, V25, P4455, DOI 10.1093/nar/25.22.4455; Dittmer J, 1998, BBA-REV CANCER, V1377, pF1, DOI 10.1016/S0304-419X(97)00039-5; Grevin D, 1996, GENE, V174, P185, DOI 10.1016/0378-1119(96)00357-5; HROMAS R, 1994, INT J HEMATOL, V59, P257; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; JORCYK CL, 1991, ONCOGENE, V6, P523; KLAMBT C, 1993, DEVELOPMENT, V117, P163; Liu DR, 1997, ONCOGENE, V14, P1445, DOI 10.1038/sj.onc.1200965; Monte D, 1996, GENOMICS, V35, P236, DOI 10.1006/geno.1996.0345; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; Natesan S, 1997, NATURE, V390, P349, DOI 10.1038/37019; Neve R, 1998, FASEB J, V12, P1541, DOI 10.1096/fasebj.12.14.1541; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1997, GENOMICS, V45, P456, DOI 10.1006/geno.1997.4974; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; PRIBYL LJ, 1988, DEV BIOL, V127, P45, DOI 10.1016/0012-1606(88)90187-X; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; PUGH BF, 1997, TRANSCRIPTION FACTOR, P37; Raziuddin A, 1997, J BIOL CHEM, V272, P15715, DOI 10.1074/jbc.272.25.15715; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Sambrook J., 1989, MOL CLONING; Sancho E, 1998, MOL CELL BIOL, V18, P576, DOI 10.1128/MCB.18.1.576; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; VANWIJNEN AJ, 1993, BIOCHEMISTRY-US, V32, P8397, DOI 10.1021/bi00084a003; WASYLYK B, 1997, TRANSCRIPTION FACTOR, P253; WATSON DK, 1988, VIROLOGY, V164, P99, DOI 10.1016/0042-6822(88)90624-1; WATSON DK, 1990, ONCOGENE, V5, P1521	46	24	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	1999	18	25					3682	3695		10.1038/sj.onc.1202674	http://dx.doi.org/10.1038/sj.onc.1202674			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391676				2022-12-17	WOS:000081140200002
J	Aguda, BD				Aguda, BD			Instabilities in phosphorylation-dephosphorylation cascades and cell cycle checkpoints	ONCOGENE			English	Article						cell cycle; phosphorylation-dephosphorylation cascades; G2-M checkpoint	DNA-DAMAGE CHECKPOINT; CDC2; MITOSIS; KINASE; EVENTS; MODEL	The G2-M checkpoint in the cell cycle is identified with a set of phosphorylation-dephosphorylation (PD) cycles involving Cdc25 and the maturation-promoting factor (MPF); these PD cycles are coupled in a way that generates an instability. This instability arises out of a transcritical bifurcation which could be exploited by the G2 DNA damage checkpoint pathway in order to arrest or delay entry into mitosis, The coupling between PD cycles involving Weel and MPF does not lead to an instability and therefore Weel may not be a crucial target of the checkpoint pathway, A set of PD cycles exhibiting transcritical bifurcation also possesses the integrative ability of a checkpoint for 'checking' that prerequisites are satisfied prior to the next cell cycle event. Such a set of coupled PD cycles is suggested to be a core mechanism of cell cycle checkpoints.	Laurentian Univ, Dept Chem & Biochem, Sudbury, ON P3E 2C6, Canada	Laurentian University	Aguda, BD (corresponding author), Laurentian Univ, Dept Chem & Biochem, Sudbury, ON P3E 2C6, Canada.							BASI G, 1995, CELL CYCLE CONTROL, P106; Carr AM, 1996, SCIENCE, V271, P314, DOI 10.1126/science.271.5247.314; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FURNARI B, 1996, SCIENCE, V274, P1495; GOLDBETER A, 1991, P NATL ACAD SCI USA, V88, P9107, DOI 10.1073/pnas.88.20.9107; GOLDBETER A, 1981, P NATL ACAD SCI-BIOL, V78, P6840, DOI 10.1073/pnas.78.11.6840; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY A, 1993, CELL CYCLES; NOVAK B, 1993, J CELL SCI, V106, P1153; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Osmani SA, 1997, TRENDS CELL BIOL, V7, P283, DOI 10.1016/S0962-8924(97)01086-6; PINES J, 1995, CELL CYCLE CONTROL, P144; Poon RYC, 1997, CANCER RES, V57, P5168; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; SHACHTER E, 1986, ENZYMES A, V17, P21; Strogatz SH., 1994, NONLINEAR DYNAMICS C; Thron CD, 1997, ONCOGENE, V15, P317, DOI 10.1038/sj.onc.1201190; Tyson J J, 1995, Prog Cell Cycle Res, V1, P1; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450	22	24	24	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2846	2851		10.1038/sj.onc.1202462	http://dx.doi.org/10.1038/sj.onc.1202462			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362255				2022-12-17	WOS:000080125100007
J	Broome, MA; Galisteo, ML; Schlessinger, J; Courtneidge, SA				Broome, MA; Galisteo, ML; Schlessinger, J; Courtneidge, SA			The proto-oncogene c-Cbl is a negative regulator of DNA synthesis initiated by both receptor and cytoplasmic tyrosine kinases	ONCOGENE			English	Article						c-Cbl; Src; growth-factor-signaling; mitogenesis	PHOSPHOTYROSINE-BINDING DOMAIN; V-CBL; EGF RECEPTOR; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; IN-VIVO; T-CELLS; SRC; ASSOCIATION; PATHWAY	In C, elegans, genetic and biochemical data indicate that the Cbl homolog Sli-1 attenuates Let-23 (EGFR) signaling. To investigate whether c-Cbl might have a role in mammalian growth factor-mediated mitogenic signaling, me microinjected NIH3T3 mouse fibroblasts with expression plasmids encoding wt and G306ECbl (a 'loss of function' mutant identified in C. elegans). We observed inhibition of PDGF BB- and EGF-induced DNA synthesis by wt Cbl but not the mutant. Microinjection of two different affinity purified polyclonal antisera against Cbl boosted a suboptimal PDGF-stimulated mitogenic response. The inhibition of both PDGF BB- and EGF-induced DNA synthesis by,rt Cbl was reversed by co-expression with Myc but not with Fos, DNA synthesis initiated by constitutively activated Src was also blocked by Cbl expression, but curiously by the G306E mutant as well. These data are all consistent with the proposition that Cbl negatively affects mitogenic signaling in mammalian fibroblasts.	SUGEN Inc, S San Francisco, CA 94080 USA; NYU Med Ctr, Dept Pharmacol, New York, NY 10016 USA	Pfizer; New York University	Courtneidge, SA (corresponding author), SUGEN Inc, 230 E Grand Ave, S San Francisco, CA 94080 USA.							BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; KEANE MM, 1995, ONCOGENE, V10, P2367; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Roche S, 1998, CURR BIOL, V8, P975, DOI 10.1016/S0960-9822(98)70400-2; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; SupertiFurga G, 1996, NAT BIOTECHNOL, V14, P600, DOI 10.1038/nbt0596-600; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; YISHIMURA T, 1995, EMBO J, V14, P2816; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	31	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2908	2912		10.1038/sj.onc.1202873	http://dx.doi.org/10.1038/sj.onc.1202873			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362262				2022-12-17	WOS:000080125100014
J	Duncan, EL; Reddel, RR				Duncan, EL; Reddel, RR			Downregulation of metallothionein-IIA expression occurs at immortalization	ONCOGENE			English	Article						metallothionein-IIA; immortalization; senescence; SV40	FRAUMENI SYNDROME FIBROBLASTS; HUMAN-DIPLOID FIBROBLASTS; GENE-EXPRESSION; MESSENGER-RNA; HUMAN-CELLS; P16(INK4) EXPRESSION; TELOMERASE ACTIVITY; EPITHELIAL-CELLS; INDUCTION; ZINC	Metallothioneins (MTs) may modulate a variety of cellular processes by regulating the activity of zinc-binding proteins, These proteins have been implicated in cell growth regulation, and their expression is abnormal in some tumors. In particular, MT-IIA is expressed 27-fold less in human colorectal tumors and tumor cell lines compared with normal tissue (Zhang et al,, 1997), Here we demonstrate that MT-IIA downregulation occurs when human cells become immortal, a key event in tumorigenesis, After immortalization MT-IIA expression remains inducible but the basal activity of the MT-IIA promoter is decreased, MT-IIA downregulation at immortalization is one of the most common immortalization-related changes identified to date, suggesting that MT-IIA has a role in this process.	Childrens Med Res Inst, Sydney, NSW 2145, Australia	Children's Medical Research Institute - Australia; University of Sydney	Reddel, RR (corresponding author), Childrens Med Res Inst, Locked Bag 23, Wentworthville, NSW 2145, Australia.		Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107				ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DESILVA R, 1993, CELL MOL BIOL RES, V39, P101; DESILVA R, 1994, EXP CELL RES, V213, P418, DOI 10.1006/excr.1994.1218; Duncan EL, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1263; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; GONCHAROVA EI, 1994, CANCER RES, V54, P5318; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HEGUY A, 1986, MOL CELL BIOL, V6, P2149, DOI 10.1128/MCB.6.6.2149; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; JAHROUDI N, 1990, J BIOL CHEM, V265, P6506; KAGI JHR, 1991, METHOD ENZYMOL, V205, P613; KARIN M, 1983, P NATL ACAD SCI-BIOL, V80, P4040, DOI 10.1073/pnas.80.13.4040; KARIN M, 1987, MOL CELL BIOL, V7, P606, DOI 10.1128/MCB.7.2.606; KARIN M, 1982, NATURE, V299, P797, DOI 10.1038/299797a0; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KARIN M, 1981, EUR J BIOCHEM, V118, P527, DOI 10.1111/j.1432-1033.1981.tb05551.x; Lechner J F, 1985, J TISSUE CULT METHOD, V9, P43; LECHNER JF, 1985, P NATL ACAD SCI USA, V82, P3884, DOI 10.1073/pnas.82.11.3884; LI Y, 1994, CANCER RES, V54, P6078; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LUCE MC, 1993, EXP GERONTOL, V28, P17, DOI 10.1016/0531-5565(93)90017-8; MACLEAN K, 1994, ONCOGENE, V9, P719; Noble JR, 1996, ONCOGENE, V13, P1259; OFNER D, 1994, VIRCHOWS ARCH, V425, P491; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; SCHMIDT CJ, 1986, P NATL ACAD SCI USA, V83, P3346, DOI 10.1073/pnas.83.10.3346; Shibanuma M, 1997, MOL CELL BIOL, V17, P1224, DOI 10.1128/MCB.17.3.1224; STENNARD FA, 1994, BBA-GENE STRUCT EXPR, V1218, P357, DOI 10.1016/0167-4781(94)90189-9; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; UDOM AO, 1980, BIOCHEM J, V187, P329, DOI 10.1042/bj1870329; VALLEE BL, 1995, NEUROCHEM INT, V27, P23, DOI 10.1016/0197-0186(94)00165-Q; Waalkes MP, 1996, J PHARMACOL EXP THER, V277, P1026; WEST AK, 1990, GENOMICS, V8, P513, DOI 10.1016/0888-7543(90)90038-V; WILSON VL, 1983, SCIENCE, V220, P1054; ZENG J, 1991, FEBS LETT, V279, P310, DOI 10.1016/0014-5793(91)80175-3; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	42	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	1999	18	4					897	903		10.1038/sj.onc.1202370	http://dx.doi.org/10.1038/sj.onc.1202370			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023665				2022-12-17	WOS:000078510600006
J	Joh, T; Hosokawa, Y; Suzuki, R; Takahashi, T; Seto, M				Joh, T; Hosokawa, Y; Suzuki, R; Takahashi, T; Seto, M			Establishment of an inducible expression system of chimeric MLL-LTG9 protein and inhibition of Hox a7, Hox b7 and Hox c9 expression by MLL-LTG9 in 32Dc13 cells	ONCOGENE			English	Article						translocation; 11q23; MLL; LTGB; Hox; leukemogenesis	ACUTE-LEUKEMIA; DROSOPHILA-TRITHORAX; 11Q23 TRANSLOCATIONS; ALL-1 GENE; POLYCOMB; PRODUCTS; MICE; MLL; ABNORMALITIES; HOMOLOG	The MLL (HRX/ALL-1 gene is frequently disrupted in infantile leukemias and therapy-related leukemias and fused to various translocation partner genes, We previously showed that chimeric MLL proteins localize in the nuclei in a fashion similar to that of MLL protein even if the partner gene encodes a cytoplasmic protein and indicated the importance of the IV-terminal portion of MLL common to various MLL translocations, This time we established an inducible expression system for chimeric MLL-LTG9 and truncated N-terminal MLL proteins (MLL-Zf(-)) in 32Dc13 cells. By utilizing this system, we were able to show inhibition of Hox a7, Hox b7 and Hox c9 genes' expression by induced MLL-LTG9 and MLL-Zf(-). Up-regulation of Hox a7, Hox b7 and Hox c9 was observed when 32Dc13 cells were cultured with granulocyte colony stimulating factor (G-CSF) in place of interleukin 3 and induction of MLL-LTG9 and MLL-Zf(-) was shown to suppress this upregulation. At the same time, expression of two mammalian Polycomb group genes, M33 and mel-18, which both reportedly affect Hox genes' expression, was not inhibited by MLL-LTG9 and MLL-Zf(-) induction. These results indicate that MLL has an important effect on the expression of at least some Hox genes in hematopoietic cells and suggest that inhibition of the proper expression of Hox genes by chimeric MLL proteins may dysregulate hematopoietic cell differentiation and proliferation, which then can lead to leukemogenesis.	Aichi Canc Ctr, Res Inst, Lab Chemotherapy, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Immunol Lab, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center; Aichi Cancer Center	Seto, M (corresponding author), Aichi Canc Ctr, Res Inst, Lab Chemotherapy, Nagoya, Aichi 4648681, Japan.			Suzuki, Ritsuro/0000-0002-5974-7614				ABE R, 1984, CANCER GENET CYTOGEN, V13, P121, DOI 10.1016/0165-4608(84)90053-0; Akasaka T, 1996, DEVELOPMENT, V122, P1513; Arakawa H, 1998, P NATL ACAD SCI USA, V95, P4573, DOI 10.1073/pnas.95.8.4573; Core N, 1997, DEVELOPMENT, V124, P721; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; IIDA S, 1993, ONCOGENE, V8, P3085; Joh T, 1997, ONCOGENE, V15, P1681, DOI 10.1038/sj.onc.1201332; Joh T, 1996, ONCOGENE, V13, P1945; KANEKO Y, 1986, BLOOD, V67, P484; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; LAWRENCE HJ, 1992, BLOOD, V80, P2445; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MAVILIO F, 1989, ONCOGENE, V4, P301; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1991, BLOOD, V77, P440; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SCHICHMAN SA, 1994, P NATL ACAD SCI USA, V91, P6236, DOI 10.1073/pnas.91.13.6236; SIMON J, 1992, DEVELOPMENT, V114, P493; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; Waring PM, 1997, CURR TOP MICROBIOL, V220, P1; YAMAMOTO K, 1993, ONCOGENE, V8, P479; YAMAMOTO K, 1993, ONCOGENE, V8, P2617; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	27	24	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1125	1130		10.1038/sj.onc.1202400	http://dx.doi.org/10.1038/sj.onc.1202400			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023690				2022-12-17	WOS:000078510600031
J	Velasco, JA; Avila, MA; Notario, V				Velasco, JA; Avila, MA; Notario, V			The product of the cph oncogene is a truncated, nucleotide-binding protein that enhances cellular survival to stress	ONCOGENE			English	Article						chemical carcinogenesis; Syrian hamster embryo cells; oncogenic activation; nucleotide-binding proteins; stress survival	HAMSTER-EMBRYO FIBROBLASTS; MULTISTEP CARCINOGENESIS; RIBONUCLEOTIDE REDUCTASE; SEQUENCE SIMILARITY; SIGNAL-TRANSDUCTION; EXCHANGE ACTIVITY; MAMMALIAN-CELLS; GROWTH-FACTOR; P53 GENE; RAS	Cph was isolated from neoplastic Syrian hamster embryo fibroblasts initiated by 3-methylcholanthrene (MCA), and was shown to be a single copy gene in the hamster genome, conserved from yeast to human cells, expressed in fetal cells and most adult tissues, and acting synergistically with H-ras in the transformation of murine NIH3T3 fibroblasts, We have now isolated Syrian hamster full-length cDNAs for the cph oncogene and proto-oncogene, Nucleotide sequence analysis revealed that cph was activated in MCA-treated cells by a point-mutational deletion at codon 214, which caused a shift in the normal open reading frame (ORF) and brought a translation termination codon 33 amino acids downstream. While proto-cph encodes a protein (pcph) of 469 amino acids, cpk encodes a truncated protein (cph) of 246 amino acids with a new, hydrophobic C-terminus, Similar mechanisms activated cph in other MCA-treated Syrian hamster cells. The cph and proto-cph proteins have partial sequence homology with two protein families: GDP/GTP exchange factors and nucleotide phosphohydrolases. In vitro translated, gel-purified cph proteins did not catalyze nucleotide exchange for H-ras, but were able to bind nucleotide phosphates, in particular ribonucleotide diphosphates such as UDP and GDP, Steady-state levels of cph mRNA increased 6.7-fold in hamster neoplastic cells, relative to a 2.2-fold increase in normal cells, when they were subjected to a nutritional stress such as serum deprivation, Moreover, cph-transformed NIH3T3 cells showed increased survival to various forms of stress (serum starvation, hyperthermia, ionizing radiation), strongly suggesting that cph participates in cellular mechanisms of response to stress.	Georgetown Univ, Med Ctr, Dept Radiat Med, Washington, DC 20007 USA	Georgetown University	Notario, V (corresponding author), Georgetown Univ, Med Ctr, Dept Radiat Med, Washington, DC 20007 USA.		/AFP-0764-2022; /AAB-6461-2022; Avila, Matias A/Y-6342-2019	Avila, Matias A/0000-0001-6570-3557	NCI NIH HHS [CA64472, P30-CA-51008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064472, P30CA051008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; ALBOR A, 1994, MOL CARCINOGEN, V11, P176, DOI 10.1002/mc.2940110309; ALBOR A, 1994, CANCER RES, V54, P4502; AVILA MA, 1995, ONCOGENE, V10, P963; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERWALD Y, 1965, J NATL CANCER I, V35, P641; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOREK C, 1987, P NATL ACAD SCI USA, V84, P794, DOI 10.1073/pnas.84.3.794; BOS JL, 1989, CANCER RES, V49, P4682; BOYD JA, 1990, PHARMACOL THERAPEUT, V46, P469, DOI 10.1016/0163-7258(90)90028-Z; BRENNER DG, 1989, P NATL ACAD SCI USA, V86, P5517, DOI 10.1073/pnas.86.14.5517; Broach JR, 1997, CURR OPIN GENET DEV, V7, P1, DOI 10.1016/S0959-437X(97)80102-5; BROOKS BJ, 1987, ADV VIRAL ONCOL, V7, P155; BUSTELO XR, 1994, ONCOGENE, V9, P2405; CHAN AML, 1994, ONCOGENE, V9, P1057; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIPAOLO J A, 1986, Toxicologic Pathology, V14, P417; DIPAOLO JA, 1969, SCIENCE, V165, P917, DOI 10.1126/science.165.3896.917; DIPAOLO JA, 1969, J NATL CANCER I, V42, P867; DIPAOLO JA, 1971, NATURE-NEW BIOL, V230, P240, DOI 10.1038/newbio230240a0; DIPAOLO JA, 1983, J NATL CANCER I, V70, P3; FARBER E, 1984, CANCER RES, V44, P4217; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GILMER TM, 1988, MOL CARCINOGEN, V1, P180, DOI 10.1002/mc.2940010306; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; GUSTINCICH S, 1993, CELL GROWTH DIFFER, V4, P753; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HARRIS CC, 1991, CANCER RES, V51, pS5023; HART MJ, 1994, J BIOL CHEM, V269, P62; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KASID U, 1987, SCIENCE, V237, P1039, DOI 10.1126/science.3616625; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Leonardsen L, 1996, ONCOGENE, V13, P2177; Lih CJ, 1996, P NATL ACAD SCI USA, V93, P4617, DOI 10.1073/pnas.93.10.4617; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NOTARIO V, 1990, ONCOGENE, V5, P1425; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1991, NEW BIOL, V3, P372; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SCOVASSI AI, 1984, J BIOL CHEM, V259, P973; SELF AJ, 1995, METHOD ENZYMOL, V256, P67; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SODERMAN K, 1986, ANAL BIOCHEM, V152, P89, DOI 10.1016/0003-2697(86)90124-7; STEVENS CW, 1995, RAD ONCOL INVEST, V2, P212; TOKSOZ D, 1994, ONCOGENE, V9, P621; Velasco JA, 1998, MOL CARCINOGEN, V21, P156, DOI 10.1002/(SICI)1098-2744(199803)21:3<156::AID-MC2>3.0.CO;2-K; Velasco JA, 1996, ONCOGENE, V12, P2713; VELASCO JA, 1993, GENE, V137, P179, DOI 10.1016/0378-1119(93)90004-M; VELASCO JA, 1994, ONCOGENE, V9, P2065; WEINBERG RA, 1989, CANCER RES, V49, P3713; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77	69	24	25	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					689	701		10.1038/sj.onc.1202324	http://dx.doi.org/10.1038/sj.onc.1202324			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989819				2022-12-17	WOS:000078394400014
J	Fogerty, FJ; Juang, JL; Petersen, J; Clark, MJ; Hoffmann, FM; Mosher, DF				Fogerty, FJ; Juang, JL; Petersen, J; Clark, MJ; Hoffmann, FM; Mosher, DF			Dominant effects of the bcr-abl oncogene on Drosophila morphogenesis	ONCOGENE			English	Article						Bcr-Abl; oncogene; Drosophila; tyrosine kinase	TYROSINE KINASE-ACTIVITY; CHRONIC MYELOGENOUS LEUKEMIA; C-ABL; ADAPTER PROTEIN; SUBCELLULAR-LOCALIZATION; SIGNAL-TRANSDUCTION; ECTOPIC EXPRESSION; TRANSGENIC MICE; CELL FATES; SH2 DOMAIN	We targeted expression of human/fly chimeric Bcr-Abl proteins to the developing central nervous system (CNS) and eye imaginal disc of Drosophila melanogaster, Neural expression of human/fly chimeric P210 Bcr-Abl or P185 Bcr-Abl rescued abl mutant flies from pupal lethality, indicating that P210 and P185 Bcr-Abl can substitute functionally for Drosophila Abl during axonogenesis, However, increased levels of neurally expressed P210 or P185 Bcr-Abl but not Drosophila Abl produced CNS defects and lethality. Expression of P210 or P185 in the eye imaginal disc produced a dominant rough eye phenotype that was dependent on dosage of the transgene. Drosophila Enabled, previously identified as a suppressor of the abl mutant phenotype and substrate for Drosophila Abl kinase, had markedly increased phosphotyrosine levels in Bcr-Abl expressing Drosophila, indicating that it is a substrate for Bcr-Abl as well, Drosophila, therefore, is a suitable model system to identify Bcr-Abl interactions important for signal transduction and oncogenesis.	Univ Wisconsin, Dept Med, Madison, WI 53706 USA; Univ Wisconsin, Ctr Comprehens Canc, Madison, WI 53706 USA; Univ Wisconsin, Mcardle Lab Canc Res, Madison, WI 53706 USA; Univ Wisconsin, Genet Lab, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Fogerty, FJ (corresponding author), Univ Wisconsin, Dept Med, 1300 Univ Ave, Madison, WI 53706 USA.		Juang, Jyh-Lyh/E-3944-2010	Hoffmann, F. Michael/0000-0002-2770-9656	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD073263] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021644, P50HL056396] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56396-01, HL21644] Funding Source: Medline; NICHD NIH HHS [N01-HD-7-3263] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHERNDJAMALI SM, 1998, IN PRESS MOL BIOL CE; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BASLER K, 1990, GENE DEV, V4, P728, DOI 10.1101/gad.4.5.728; BENNETT RL, 1992, DEVELOPMENT, V116, P953; BRAND AH, 1993, DEVELOPMENT, V118, P401; BROWN NL, 1991, DEVELOPMENT, V113, P1245; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Comer AR, 1998, MOL CELL BIOL, V18, P152, DOI 10.1128/MCB.18.1.152; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAINSTEIN E, 1989, ONCOGENE, V4, P1477; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1990, SCIENCE, V248, P857, DOI 10.1126/science.2188361; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HENKEMEYER MJ, 1988, MOL CELL BIOL, V8, P843, DOI 10.1128/MCB.8.2.843; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HILL KK, 1995, GENETICS, V141, P595; HOLLAND GD, 1990, J VIROL, V64, P2226, DOI 10.1128/JVI.64.5.2226-2235.1990; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; JUANG JL, 1994, CELL TISSUE RES, V277, P87, DOI 10.1007/BF00303084; KANTARJIAN HM, 1993, BLOOD, V82, P691; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; Laneuville P, 1995, Semin Immunol, V7, P255, DOI 10.1006/smim.1995.0030; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; McWhirter JR, 1997, ONCOGENE, V15, P1625, DOI 10.1038/sj.onc.1201342; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; ODA T, 1995, LEUKEMIA, V9, P295; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Paulson R, 1997, ONCOGENE, V14, P641, DOI 10.1038/sj.onc.1200875; Pendergast AM, 1996, CURR OPIN CELL BIOL, V8, P174, DOI 10.1016/S0955-0674(96)80063-9; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAMAKRISHNA NR, 1993, DEVELOPMENT, P95; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; ROBERTSON HM, 1988, GENETICS, V118, P461; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; SALGIA R, 1995, ONCOGENE, V11, P1149; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; Santamaria P., 1986, DROSOPHILA PRACTICAL, P159; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHEJTER ED, 1985, EMBO J, V4, P407, DOI 10.1002/j.1460-2075.1985.tb03643.x; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Tauchi T, 1997, J BIOL CHEM, V272, P1389, DOI 10.1074/jbc.272.2.1389; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Verfaillie CM, 1997, ACTA HAEMATOL-BASEL, V97, P40; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WONG KK, 1995, ONCOGENE, V10, P705; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	68	24	26	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					219	232		10.1038/sj.onc.1202239	http://dx.doi.org/10.1038/sj.onc.1202239			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926937				2022-12-17	WOS:000078166000024
J	Jenkins, TD; Mueller, A; Odze, R; Shahsafaei, A; Zukerberg, LR; Kent, R; Stoner, GD; Rustgi, AK				Jenkins, TD; Mueller, A; Odze, R; Shahsafaei, A; Zukerberg, LR; Kent, R; Stoner, GD; Rustgi, AK			Cyclin D1 overexpression combined with N-nitrosomethylbenzylamine increases dysplasia and cellular proliferation in murine esophageal squamous epithelium	ONCOGENE			English	Article						cyclin D1; N-nitrosomethylbenzylamine; esophageal squamous dysplasia; transgenic mice	MOUSE SKIN CARCINOGENESIS; RAT ESOPHAGUS; HA-RAS; GENE; EXPRESSION; ONCOGENE; CANCER; MICE; P53; METHYLBENZYLNITROSAMINE	We previously described the oral-esophageal tissue-specific expression of cyclin D1 with the Epstein-Barr virus ED-L2 promoter in transgenic mice, and resulting dysplasia, Given the evidence for an interplay between environmental and genetic factors in esophageal squamous carcinogenesis, the aim of this study was tot determine the potential cooperation of the nitrosamine compound N-nitrosomethylbenzylamine (NMBA), an esophageal specific carcinogen, in the cyclin D1 transgenic mice, NMBA was first demonstrated to induce dysplasia in two strains of inbred mice, C57BL/6 and FVB/N, Subcutaneous NMBA was then administrated to wild type and transgenic mice beginning at 4 weeks of age. Mice were monitered for the duration of the study for general appearance, activity and weight, and were euthanized at 12 and 15 months. Histopathologic analysis revealed increased severity of dysplasia in cyclin D1 mice treated with NMBA compared with treated age-matched wild-type mice and untreated mice. There was also increased proliferating cell nuclear antigen (PCNA) expression in the esophagi of NMBA treated cyclin D1 mice. Taken together, these findings suggest that a genetic alteration, specifically cyclin D1 overexpression and a chemical carinogen, NMBA, may cooperate to increase the severity of esophageal squamous dysplasia, a prominent precursor to carcinoma.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Hematol Oncol Unit, Boston, MA USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA; Forsyth Dent Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Dent Med, Boston, MA 02115 USA; Ohio State Univ, Dept Prevent Med, Canc Etiol & Chemoprevent Lab, Columbus, OH 43210 USA; Ohio State Univ, Arthur James Canc Hosp & Res Inst, Columbus, OH 43210 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Forsyth Institute; Harvard University; Harvard School of Dental Medicine; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Rustgi, AK (corresponding author), Univ Penn, Div Gastroenterol, 6CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053377] Funding Source: NIH RePORTER; NIDCR NIH HHS [P01 DE12467-01A1] Funding Source: Medline; NIDDK NIH HHS [NIDDK K08, DK53377] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERT JM, 1994, J VIROL, V68, P4358; ANTRUP H, 1982, CANCER RES, V42, P1307; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARCH DH, 1986, J NATL CANCER I, V77, P1145; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; CRADDOCK VM, 1987, CARCINOGENESIS, V8, P1129, DOI 10.1093/carcin/8.8.1129; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONIGER J, 1985, P NATL ACAD SCI USA, V82, P421, DOI 10.1073/pnas.82.2.421; DRUCKREY H, 1963, NATURWISSENSCHAFTEN, V50, P100, DOI 10.1007/BF00590822; FONG LYY, 1979, INT J CANCER, V23, P679, DOI 10.1002/ijc.2910230514; Garber SA, 1997, CARCINOGENESIS, V18, P1149, DOI 10.1093/carcin/18.6.1149; HARRIS CC, 1979, CANCER RES, V39, P4401; HODGSON RM, 1982, CANCER RES, V42, P2836; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1992, CANCER RES, V52, P2980; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; LABUC GE, 1982, CANCER RES, V42, P3181; Li M H, 1986, Nutr Cancer, V8, P63, DOI 10.1080/01635588609513877; LIJINSKY W, 1982, J NATL CANCER I, V68, P681; MITSUNAGA SI, 1995, CARCINOGENESIS, V16, P1629, DOI 10.1093/carcin/16.7.1629; MORSE MA, 1993, CARCINOGENESIS, V14, P1737, DOI 10.1093/carcin/14.9.1737; Mueller A, 1997, CANCER RES, V57, P5542; Nakagawa H, 1997, ONCOGENE, V14, P1185, DOI 10.1038/sj.onc.1200937; NAKAGAWA H, 1995, CANCER-AM CANCER SOC, V76, P541, DOI 10.1002/1097-0142(19950815)76:4<541::AID-CNCR2820760402>3.0.CO;2-I; ODELEYE OE, 1992, CARCINOGENESIS, V13, P1811, DOI 10.1093/carcin/13.10.1811; ODELEYE OE, 1992, ANN NY ACAD SCI, V669, P368; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Sheyn I, 1997, HUM PATHOL, V28, P270, DOI 10.1016/S0046-8177(97)90123-4; Siglin JC, 1996, CARCINOGENESIS, V17, P1135, DOI 10.1093/carcin/17.5.1135; STERN MC, 1995, CARCINOGENESIS, V16, P1947, DOI 10.1093/carcin/16.8.1947; STINSON SF, 1978, JNCI-J NATL CANCER I, V61, P1471; VANBENTHEM J, 1992, CARCINOGENESIS, V13, P2101; WALKER EA, 1979, J NATL CANCER I, V63, P947; Wang D, 1996, CARCINOGENESIS, V17, P625, DOI 10.1093/carcin/17.4.625; Wang QS, 1996, MOL CARCINOGEN, V15, P144, DOI 10.1002/(SICI)1098-2744(199602)15:2<144::AID-MC7>3.0.CO;2-J; Wang QS, 1996, CARCINOGENESIS, V17, P1583, DOI 10.1093/carcin/17.8.1583; WANG Y, 1990, CANCER RES, V50, P1591; Yan YX, 1997, J BIOL CHEM, V272, P33181, DOI 10.1074/jbc.272.52.33181; Youssef EM, 1997, JPN J CANCER RES, V88, P18, DOI 10.1111/j.1349-7006.1997.tb00296.x	41	24	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	1999	18	1					59	66		10.1038/sj.onc.1202296	http://dx.doi.org/10.1038/sj.onc.1202296			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926920				2022-12-17	WOS:000078166000007
J	Bauer, R; McGuffin, ME; Mattox, W; Tainsky, MA				Bauer, R; McGuffin, ME; Mattox, W; Tainsky, MA			Cloning and characterization of the Drosophila homologue of the AP-2 transcription factor	ONCOGENE			English	Article						Drosophila; AP-2 transcription factor; development regulation; functional conservation	MOUSE EMBRYOGENESIS; REGULATORY ELEMENTS; MAMMARY-CARCINOMA; RETINOIC ACID; GENE; CELLS; EXPRESSION; ACTIVATION; PROMOTER; BINDING	The AP-2 family of transcription factors (AP-2 alpha, AP-2 beta and AP-2 gamma) is temporally and spatially regulated in mammals and has also been implicated in oncogenesis. Here we report the isolation of genomic and cDNA clones encoding the Drosophila homologue of AP-2, designated DAP-2. The predicted amino acid sequence exhibits 42-45% overall identity with the vertebrate AP-2 proteins, A sequence of 107 amino acids within the DNA binding and dimerization domain of the vertebrate AP-2 proteins is highly conserved (90-92%) with the DAP-2 homologue. An in vitro translation product of DAP-2 cDNA binds specifically to AP-2 consensus binding sites. DAP-2 was also shown to be functionally conserved in vivo because transient transfection of a DAP-2 expression plasmid activated transcription through AP-2 binding sites in both mammalian and Drosophila cell lines. DAP-2 is expressed during early embryogenesis and DAP-2 transcripts are also detected in the adult. Whole-mount in situ hybridizations demonstrated that DAP-2 is expressed initially at stage 9 of Drosophila embryonic development and that DAP-2 transcripts are detected in regions of the brain, eye-antennal disc, optical lobe, antenno-maxillary complex, and in a subset of cells of the ventral nerve cord. The cloning of DAP-2 and the identification of the DAP-2 expression pattern during embryogenesis provides a starting point to address the function of AP-2 during differentiation and development in a well understood model system.	Univ Texas, Md Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Univ Texas, Md Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Tainsky, MA (corresponding author), Wayne State Univ, Karmanos Canc Inst, Detroit, MI 48201 USA.			Tainsky, Michael/0000-0002-0261-831X; Mattox, William/0000-0001-8084-9677	NCI NIH HHS [R01-CA53475] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053475] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BarEli M, 1997, J CELL PHYSIOL, V173, P275, DOI 10.1002/(SICI)1097-4652(199711)173:2<275::AID-JCP35>3.0.CO;2-C; BAUER R, 1994, NUCLEIC ACIDS RES, V22, P1413, DOI 10.1093/nar/22.8.1413; Bisgrove DA, 1997, MOL CELL BIOL, V17, P5935, DOI 10.1128/MCB.17.10.5935; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; BUETTNER R, 1991, MOL CELL BIOL, V11, P3573, DOI 10.1128/MCB.11.7.3573; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHAYETTE B, 1994, NEURON, V12, P977; Chazaud C, 1996, MECH DEVELOP, V54, P83, DOI 10.1016/0925-4773(95)00463-7; CHUNG YT, 1990, MOL CELL BIOL, V10, P6172, DOI 10.1128/MCB.10.12.6172; Doerksen LF, 1996, NUCLEIC ACIDS RES, V24, P2849, DOI 10.1093/nar/24.14.2849; Gilbertson RJ, 1997, CANCER RES, V57, P3272; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hall B. K., 1988, NEURAL CREST; HOLLAND P, 1994, J MAR BIOL ASSOC UK, V75, P49; JAN YN, 1994, CURR OPIN NEUROBIOL, V4, P13; KANNAN P, 1994, GENE DEV, V12, P1258; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEHMANN R, 1994, METHOD CELL BIOL, V44, P575, DOI 10.1016/S0091-679X(08)60933-4; LEWIS RA, 1980, GENETICS, V95, P383; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; Maniatis T., 1989, MOL CLONING LAB MANU; MATTOX W, 1990, GENE DEV, V4, P789, DOI 10.1101/gad.4.5.789; MEIER P, 1995, DEV BIOL, V169, P1, DOI 10.1006/dbio.1995.1121; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; MOUNT SM, 1993, ATLAS DROSOPHILA GEN, P333; OuladAbdelghani M, 1996, EXP CELL RES, V225, P338, DOI 10.1006/excr.1996.0184; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SKINNER A, 1993, ONCOGENE, V8, P3393; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Wang DY, 1997, J BIOL CHEM, V272, P14244, DOI 10.1074/jbc.272.22.14244; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YounossiHartenstein A, 1996, J COMP NEUROL, V370, P313, DOI 10.1002/(SICI)1096-9861(19960701)370:3<313::AID-CNE3>3.0.CO;2-7	41	24	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1911	1922		10.1038/sj.onc.1202114	http://dx.doi.org/10.1038/sj.onc.1202114			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788434				2022-12-17	WOS:000076423500004
J	Liedtke, M; Pandey, P; Kumar, S; Kharbanda, S; Kufe, D				Liedtke, M; Pandey, P; Kumar, S; Kharbanda, S; Kufe, D			Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase	ONCOGENE			English	Article						Bcr-Abl; SHPTP1; SAP kinase transformation	C-ABL; DNA-DAMAGE; IONIZING-RADIATION; STRESS-RESPONSE; ADAPTER PROTEIN; ONCOGENE; GROWTH; FIBROBLASTS; ACTIVATION; PATHWAY	The oncogenic Bcr-Abl variant of the c-Abl tyrosine kinase transforms cells by a mechanism dependent on activation of the stress-activated protein kinase (SAPK). Other work has shown that c-Abl interacts with the SHPTP1 protein tyrosine phosphatase in induction of SAPK activity by genotoxic stress. The present studies demonstrate that Bcr-Abl binds constitutively to SHPTP1. We show that Bcr-Abl phosphorylates SHPTP1 on C-terminal Y536 and Y564 sites. The functional significance of the Bcr-Abl/SHPTP1 interaction is supported by the finding that SHPTP1 regulates Bcr-Abl-induced SAPK activity. Importantly, SHPTP1 also decreases Bcr-Abl-dependent transformation of fibroblasts. These findings indicate that SHPTP1 functions as a tumor suppressor in cells transformed by Bcr-Abl.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Liedtke, M (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [P01CA066996] Funding Source: NIH RePORTER; NCI NIH HHS [CA66996] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; GOGA A, 1995, ONCOGENE, V11, P791; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; PEI DH, 1993, P NATL ACAD SCI USA, V90, P1092, DOI 10.1073/pnas.90.3.1092; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; Raitano AB, 1997, BBA-REV CANCER, V1333, pF201, DOI 10.1016/S0304-419X(97)00023-1; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; YAN MH, 1994, NATURE, V372, P798; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	26	24	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1889	1892		10.1038/sj.onc.1202117	http://dx.doi.org/10.1038/sj.onc.1202117			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788431	Bronze			2022-12-17	WOS:000076423500001
J	Nikiforov, YE; Nikiforova, M; Fagin, JA				Nikiforov, YE; Nikiforova, M; Fagin, JA			Radiation-induced post-Chernobyl pediatric thyroid carcinomas	ONCOGENE			English	Article						minisatellites; microsatellites; radiation; thyroid tumors; Chernobyl; genomic instability	INDUCED GENOMIC INSTABILITY; POLYMERASE CHAIN-REACTION; HUMAN MINISATELLITE; HYPERVARIABLE LOCI; IONIZING-RADIATION; MUTATION PROCESSES; SOMATIC MUTATIONS; RET PROTOONCOGENE; NUCLEAR ACCIDENT; VNTR-LOCUS	Exposure to ionizing radiation induces different forms of genomic instability in cultured cells and experimental animals. A higher rate of germline mutations at human hypervariable minisatellite loci was reported in children born from parents exposed to radiation after Chernobyl, implicating genome destabilization as a possible mechanism responsible for late radiation effects in humans. To test if radiation-induced carcinogenesis in the thyroid gland may be associated with somatic minisatellite instability or microsatellite instability, we utilized a PCR-based approach to study normal and tumor DNA from 17 pediatric post-Chernobyl papillary thyroid carcinomas for mutations at three different minisatellite loci (D1S80, D17S30, ApoB), and 27 microsatellite loci of di-, tri-, or tetranucleotide repeats. Minisatellite instability was found in three (18%) tumors, with one of them exhibiting mutations in all three minisatellite loci, whereas two others showed mutations in one of two informative markers. By contrast, none of 20 sporadic thyroid cancers from patients with no history of radiation exposure was positive for minisatellite instability. Microsatellite analysis of post-Chernobyl tumors revealed a mutation in one (6%) tumor only at the locus of D10S1412, whereas all other 26 microsatellite markers showed identical patterns in each normal/tumor pair. Our results suggest that somatic cell microsatellite instability does not contribute to radiation-induced thyroid carcinogenesis. However, somatic minisatellite mutation events are present in a subset of radiation-induced, but not sporadic, thyroid cancers, suggesting that this type of genomic instability may play a role in radiation-induced tumorigenesis in the thyroid gland.	Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pathol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Fagin, JA (corresponding author), Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Cincinnati, OH 45267 USA.				NATIONAL CANCER INSTITUTE [R01CA072597, R01CA050706, R29CA050706] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50706, CA 72597] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMOUR JAL, 1989, GENOMICS, V4, P328, DOI 10.1016/0888-7543(89)90338-8; BOERWINKLE E, 1989, P NATL ACAD SCI USA, V86, P212, DOI 10.1073/pnas.86.1.212; BOGDANOVA T, 1995, THYROID S1, V5, P28; Dubrova YE, 1996, NATURE, V380, P683, DOI 10.1038/380683a0; DUBROVA YE, 1993, NAT GENET, V5, P92, DOI 10.1038/ng0993-92; FELBER M, 1994, CANCER BIOCHEM BIOPH, V14, P163; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; HOFFOLSEN P, 1995, HUM MUTAT, V5, P329, DOI 10.1002/humu.1380050410; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; IVEY JN, 1994, J FORENSIC SCI, V39, P52; JEFFREYS AJ, 1995, ELECTROPHORESIS, V16, P1577, DOI 10.1002/elps.11501601261; Jeffreys AJ, 1997, HUM MOL GENET, V6, P129, DOI 10.1093/hmg/6.1.129; JEFFREYS AJ, 1987, BIOCHEM SOC T, V15, P309, DOI 10.1042/bst0150309; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JEFFREYS AJ, 1985, NATURE, V316, P76, DOI 10.1038/316076a0; KADHIM MA, 1995, INT J RADIAT BIOL, V67, P287, DOI 10.1080/09553009514550341; KARRAN P, 1995, SCIENCE, V268, P1857, DOI 10.1126/science.7604258; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; Klugbauer S, 1995, ONCOGENE, V11, P2459; KRONENBERG A, 1994, INT J RADIAT BIOL, V66, P603, DOI 10.1080/09553009414551691; LITTLE JB, 1994, RADIAT RES, V140, P299, DOI 10.2307/3579106; MATSUO K, 1991, MOL ENDOCRINOL, V5, P1873, DOI 10.1210/mend-5-12-1873; MINOLETTI F, 1994, GENE CHROMOSOME CANC, V11, P51, DOI 10.1002/gcc.2870110108; MURNANE JP, 1993, SEMIN CANCER BIOL, V4, P93; Nikiforov Y, 1996, J CLIN ENDOCR METAB, V81, P9, DOI 10.1210/jc.81.1.9; NIKIFOROV Y, 1994, CANCER-AM CANCER SOC, V74, P748, DOI 10.1002/1097-0142(19940715)74:2<748::AID-CNCR2820740231>3.0.CO;2-H; Nikiforov YE, 1997, CANCER RES, V57, P1690; Nikiforov YE, 1996, ONCOGENE, V13, P687; PAQUETTE B, 1994, CANCER RES, V54, P3173; PASINI B, 1995, ONCOGENE, V11, P1737; SADAMOTO S, 1994, INT J RADIAT BIOL, V65, P549, DOI 10.1080/09553009414550641; SAJANTILA A, 1992, AM J HUM GENET, V50, P816; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SINGH L, 1995, ELECTROPHORESIS, V16, P1586, DOI 10.1002/elps.11501601262; STSJAZHKO VA, 1995, BMJ-BRIT MED J, V310, P801, DOI 10.1136/bmj.310.6982.801; WOLFF RK, 1988, GENOMICS, V3, P347, DOI 10.1016/0888-7543(88)90126-7; ZEDENIUS J, 1995, HUM GENET, V96, P27, DOI 10.1007/BF00214182	37	24	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 15	1998	17	15					1983	1988		10.1038/sj.onc.1202120	http://dx.doi.org/10.1038/sj.onc.1202120			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788442				2022-12-17	WOS:000076423500012
J	Brake, RL; Kees, UR; Watt, PM				Brake, RL; Kees, UR; Watt, PM			Multiple negative elements contribute to repression of the HOX11 proto-oncogene	ONCOGENE			English	Article						HOX11 promoter; negative element; repressor; silencing; transcription	ACUTE LYMPHOBLASTIC-LEUKEMIA; T-CELL RECEPTOR; BETA-INTERFERON GENE; RNA-POLYMERASE-II; C-MYB EXPRESSION; DROSOPHILA DEVELOPMENT; REGULATORY ELEMENTS; HOMEOBOX GENE; TRANSCRIPTIONAL REPRESSION; CHROMOSOME-TRANSLOCATION	The HOX11 proto-oncogene is normally expressed in embryogenesis where it directs the synthesis of the spleen. In adult tissues, HOX11 expression is silenced by an unknown mechanism. Aberrant expression of HOX11 occurs in T-cell acute lymphoblastic leukaemia (T-ALL), where it is thought to be involved in T-cell immortalization, The deregulated expression of HOX11 is frequently associated with chromosomal translocations which juxtapose a T-cell receptor (TCR) gene upstream of the HOX11 gene. In these cases, it is presumed that the activation of HOX11 expression results from bringing the gene under the control of TCR enhancer elements. However, activation of HOX11 also occurs in the absence of an associated translocation in both T-ALL and erythroleukaemia cells, implying that an alternative activation mechanism may exist, We hypothesized that HOX11 may be repressed in normal T-cells and erythroid cells by the action of negative elements which may be deleted or mutated in leukaemia. We therefore conducted a search for negative elements in the human HOX11 promoter which may function to silence its expression in normal cells of the haematopoietic lineages. Since little sequence of the HOX11 promoter was available, we began our investigation by sequencing over 4.5 kilobases of untranslated DNA from upstream of HOX11, The human sequence that overlaps with the 2.1 kb of murine Hox11 is highly conserved, suggesting that a large region of DNA upstream of HOX11 may have a regulatory function. We then used transfection assays to test the ability of portions of the promoter to drive transcription of a reporter gene. These studies identified four negative elements. Two of them (NRE2 and NRE4) function in all cell lines tested, while the remaining two (NRE1 and NRE3) appear to be cell-type specific. The DNA sequences of three elements are conserved between the human and mouse HOX11/Hox11 promoters, We propose a model in which the combined action of these negative elements contributes to the overall repression of HOX11 expression in normal blood cells.	TVW, Telethon Inst Child Hlth Res, Perth, WA 6872, Australia	Telethon Kids Institute; University of Western Australia	Kees, UR (corresponding author), TVW, Telethon Inst Child Hlth Res, POB 855, Perth, WA 6872, Australia.							ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; Arai Y, 1997, GENE, V193, P73, DOI 10.1016/S0378-1119(97)00088-7; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; BERNARD O, 1992, J EXP MED, V176, P919, DOI 10.1084/jem.176.4.919; BIENZ L, 1995, BIOESSAYS, V17, P775, DOI 10.1002/bies.950170907; BIGGIN MD, 1989, TRENDS GENET, V5, P377, DOI 10.1016/0168-9525(89)90173-X; BROWN WM, 1994, INT J BIOCHEM, V26, P1403, DOI 10.1016/0020-711X(94)90184-8; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DEAR TN, 1995, DEVEL, V121, P2929; DUBE ID, 1991, BLOOD, V78, P2996; Gerard M, 1996, GENE DEV, V10, P2326, DOI 10.1101/gad.10.18.2326; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; Gottgens B, 1997, ONCOGENE, V15, P2419, DOI 10.1038/sj.onc.1201426; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; GUERRA J, 1995, BLOOD, V86, P1873, DOI 10.1182/blood.V86.5.1873.bloodjournal8651873; GUTMAN A, 1994, MOL CELL BIOL, V14, P8143, DOI 10.1128/MCB.14.12.8143; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HAWLEY RG, 1994, ONCOGENE, V9, P1; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; Ip YT, 1997, CURR BIOL, V7, pR216, DOI 10.1016/S0960-9822(06)00104-7; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; KAGAN J, 1989, P NATL ACAD SCI USA, V86, P4161, DOI 10.1073/pnas.86.11.4161; KAGAN J, 1994, CANCER RES, V54, P226; Kees UR, 1998, CANCER GENET CYTOGEN, V100, P159, DOI 10.1016/S0165-4608(97)00030-7; KEES UR, 1994, GENE CHROMOSOME CANC, V9, P129, DOI 10.1002/gcc.2870090209; KEES UR, 1989, BLOOD, V74, P369; KEES UR, 1987, LEUKEMIA RES, V11, P489, DOI 10.1016/0145-2126(87)90082-8; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; LANEY JD, 1996, DEVEL, V122, P2302; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MACINTYRE EA, 1992, BLOOD, V80, P1511; Martin CS, 1996, BIOTECHNIQUES, V21, P520; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MILLER CW, 1984, BLOOD, V63, P195; MING L, 1992, ONCOGENE, V7, P1325; MOTUM PI, 1993, EXP HEMATOL, V21, P852; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; PIRROTTA V, 1991, ADV GENET, V29, P301, DOI 10.1016/S0065-2660(08)60110-8; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; RUTHERFORD T, 1981, P NATL ACAD SCI-BIOL, V78, P348, DOI 10.1073/pnas.78.1.348; SALVATI PD, 1995, ONCOGENE, V11, P1333; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Sullivan J, 1997, J BIOL CHEM, V272, P1943, DOI 10.1074/jbc.272.3.1943; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WOODRUFF KA, 1995, ONCOGENE, V10, P1335; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	59	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	1998	17	14					1787	1795		10.1038/sj.onc.1202078	http://dx.doi.org/10.1038/sj.onc.1202078			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778044				2022-12-17	WOS:000076303300004
J	Fujii, M; Hayashi, K; Niki, M; Chiba, N; Meguro, K; Endo, K; Kameoka, J; Ito, S; Abe, K; Watanabe, T; Satake, M				Fujii, M; Hayashi, K; Niki, M; Chiba, N; Meguro, K; Endo, K; Kameoka, J; Ito, S; Abe, K; Watanabe, T; Satake, M			Overexpression of AML1 renders a T hybridoma resistant to T cell receptor-mediated apoptosis	ONCOGENE			English	Article						AML1/PEBP2 alpha B/CBFA2; T lymphocyte; apoptosis; transcription factor; Fas-ligand	ACUTE MYELOID-LEUKEMIA; CORE-BINDING-FACTOR; PROTEIN-PROTEIN INTERACTIONS; ACUTE LYMPHOBLASTIC-LEUKEMIA; RUNT DOMAIN; TRANSCRIPTION FACTOR; FUSION TRANSCRIPT; DNA-BINDING; PROTOONCOGENE PRODUCT; DELTA-ENHANCER	The AML1 gene, which encodes the DNA binding subunit of the heterodimeric transcription factor, PEBP2/CBF, is involved in several types of chromosomal translocations associated with human acute myeloid leukemia, and has been shown by gene targeting to be essential for the development of definitive hematopoiesis in the murine fetal liver. In addition, the gene is expressed abundantly in T lymphocytes and has been implicated in T cell specific gene expression. In the present study we examined the function of AML1 in T cell receptor (TCR)-mediated, Fas/Fas-ligand dependent apoptosis of a T hybridoma Line, DO11.10, Several independent cell clones overexpressing the AML1 protein were isolated by transfecting AML1 cDNA into these cells. These clones possessed an increased level of PEBP2/CBF DNA binding activity and were found to be resistant to apoptosis induced by anti-CD3 antibody treatment. Northern blot analysis revealed that induction of the Fas-ligand transcript was markedly suppressed in the anti-CD3 treated clones. Instead, expression of IL-2 receptor alpha subunit (IL-2R alpha), which is a manifestation of proliferative TCR signaling, was induced. This was in contrast to the parental, anti-CD3 treated DO11.10 cells where induction of Fas-ligand but not of IL-2R alpha was observed. Resistance of the AML1 overexpressing cell clones to TCR-mediated apoptosis is most likely attributable to the lack of Fas-ligand induction, since simultaneous treatment with anti-CD3 and anti-Fas antibodies caused apoptosis of the clones. The overall results suggest that the AML1 protein may play a pivotal role in switching TCR signaling between apoptosis and cell proliferation in T lymphocytes.	Inst Dev Aging & Canc, Dept Mol Immunol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Sch Med, Dept Internal Med 2, Aoba Ku, Sendai, Miyagi 9808575, Japan	Tohoku University	Satake, M (corresponding author), Inst Dev Aging & Canc, Dept Mol Immunol, Aoba Ku, Seiryo Machi, Sendai, Miyagi 9808575, Japan.		Ito, Sadayoshi/A-3933-2015	Ito, Sadayoshi/0000-0002-5092-3626				BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CALNAN BJ, 1995, IMMUNITY, V3, P273; Chiba N, 1997, ONCOGENE, V14, P2543, DOI 10.1038/sj.onc.1201109; Cui HL, 1996, CELL IMMUNOL, V167, P276, DOI 10.1006/cimm.1996.0036; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; ERICKSON P, 1992, BLOOD, V80, P1825; Frank R, 1995, ONCOGENE, V11, P2667; Fujioka M, 1996, GENES CELLS, V1, P741, DOI 10.1111/j.1365-2443.1996.tb00014.x; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Ito Y, 1996, J CANCER RES CLIN, V122, P266, DOI 10.1007/BF01261402; Ivanov VN, 1997, ONCOGENE, V14, P2455, DOI 10.1038/sj.onc.1201088; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; Latinis KM, 1997, J IMMUNOL, V158, P4602; LEIDEN JM, 1993, ANNU REV IMMUNOL, V11, P539, DOI 10.1146/annurev.iy.11.040193.002543; LENNY N, 1995, ONCOGENE, V11, P1761; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Meyers S, 1996, ONCOGENE, V13, P303; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OKABE T, 1995, J IMMUNOL, V154, P3871; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; SATAKE M, 1992, JPN J CANCER RES, V83, P714, DOI 10.1111/j.1349-7006.1992.tb01971.x; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SHIMIZU A, 1985, NUCLEIC ACIDS RES, V139, P1505; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; SPECK NA, 1990, GENE DEV, V4, P233, DOI 10.1101/gad.4.2.233; SPERISEN P, 1995, J BIOL CHEM, V270, P10743, DOI 10.1074/jbc.270.18.10743; SUN WW, 1995, J VIROL, V69, P4941, DOI 10.1128/JVI.69.8.4941-4949.1995; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Tanaka Y, 1997, ONCOGENE, V15, P677, DOI 10.1038/sj.onc.1201235; Uchida H, 1997, J IMMUNOL, V158, P2251; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WARGNIER A, 1995, P NATL ACAD SCI USA, V92, P6930, DOI 10.1073/pnas.92.15.6930; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WIJMENGA C, 1995, GENOMICS, V26, P611, DOI 10.1016/0888-7543(95)80185-O; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Zhang H, 1996, J AUTOM REASONING, V16, P1, DOI 10.1007/BF00244457	67	24	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1813	1820		10.1038/sj.onc.1202087	http://dx.doi.org/10.1038/sj.onc.1202087			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778047				2022-12-17	WOS:000076303300007
J	Maerz, WJ; Baselga, J; Reuter, VE; Mellado, B; Myers, ML; Bosl, GJ; Spinella, MJ; Dmitrovsky, E				Maerz, WJ; Baselga, J; Reuter, VE; Mellado, B; Myers, ML; Bosl, GJ; Spinella, MJ; Dmitrovsky, E			FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas	ONCOGENE			English	Article						human embryonal carcinomas; fibroblast growth factor-4; all-trans-retinoic acid; differentiation; tumorigenicity	FIBROBLAST GROWTH-FACTOR; GERM-CELL TUMORS; HUMAN TERATOCARCINOMA CELL; K-FGF; FACTOR-IV; RECEPTOR EXPRESSION; TRANSFORMING GENE; F9 CELLS; LINE; FAMILY	A subset of male germ cell cancers presenting with advanced stage abundantly express the fibroblast growth factor-4 (FGF4), FGF4 expression is restricted in vitro to undifferentiated embryonal carcinomas (ECs), During induced differentiation, FGF4 expression is repressed in maturation sensitive but not resistant human ECs, suggesting FGF4 plays an important role in malignant growth or differentiation of ECs, To explore these FGF4 signals in male germ cell cancers, the multipotent human EC NTERA-2 clone D1 (NT2/D1) cell line was studied, All-trans-retinoic acid (RA)-treatment of these cells induces re neuronal phenotype and represses tumorigenicity and FGF4 expression, In contrast, RA-treatment of retinoid resistant lines derived from NT2/D1 cells failed to repress FGF4 expression, This implicated FGF4 directly in regulating human EC growth or differentiation, To evaluate further this FGF4 role, FGF4 was constitutively over-expressed in NT2/D1 cells using a CMV-driven expression vector containing the neomycin resistance gene, Three stable transfectants expressing exogenous FGF4 were studied as was a control transfectant only expressing the neomycin resistance gene, RA-treatment repressed endogenous but not exogenous FGF4 expression, RA-treatment of these transfectants induced morphologic and immunophenotypic maturation, changes in RA-regulated genes, and a G1 cell cycle arrest in a manner similar to parental NT2/D1 cells, This indicated FGF4 over-expression did not block RA-mediiated differentiation, As expected, RA-treatment repressed tumorigenicity of the control transfectant after subcutaneous injection into athymic mice. Despite RA-treatment, this repressed tumorigenicity was overcome in all the transfectants over-expressing FGF4, The histopathology and neovascularization did not appreciably differ between xenograft tumors derived from FGF4 over-expressing versus control transfectants. FGF4 expression studies were extended to patient-derived germ cell tumors using total cellular RNA Northern analysis and an immunohistochemical assay developed to detect FGF4 protein expression, Germ cell tumors with EC components were significantly more likely to express FGF4 mRNA (P less than or equal to 0.0179) than other examined germ cell tumors without EC components, Immunohistochemical results from 43 germ cell tumors demonstrated increased FGF4 expression especially in non-seminomas having EC components, Thus, FGF4 promotes directly malignant growth of cultured ECs, overcomes the antitumorigenic actions of RA, and is selectively expressed in specific histopathologic subsets of germ cell tumors. Taken together, these findings indicate how differentiation and anti-tumorigenic retinoic acid signals can be dissociated in germ cell cancer.	Mem Hosp, Mol Med Lab, New York, NY 10021 USA; Mem Hosp, Dept Med, New York, NY 10021 USA; Mem Hosp, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Mol Pharmacol & Therapeut Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Dmitrovsky, E (corresponding author), Mem Hosp, Mol Med Lab, 1275 York Ave, New York, NY 10021 USA.		Spinella, Michael/B-7210-2014		NATIONAL CANCER INSTITUTE [R01CA054494, U01CA060126, R01CA060126] Funding Source: NIH RePORTER; NCI NIH HHS [1R01 CA 54494-06, CA 60126] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALANKO T, 1994, DEV BIOL, V161, P141, DOI 10.1006/dbio.1994.1016; Alanko T, 1996, EXP CELL RES, V228, P306, DOI 10.1006/excr.1996.0330; Ambrosetti DC, 1997, MOL CELL BIOL, V17, P6321, DOI 10.1128/MCB.17.11.6321; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1984, LAB INVEST, V50, P147; ANDREWS PW, 1990, DIFFERENTIATION, V43, P131, DOI 10.1111/j.1432-0436.1990.tb00439.x; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; Baldassarre G, 1996, INT J CANCER, V66, P538, DOI 10.1002/(SICI)1097-0215(19960516)66:4<538::AID-IJC19>3.0.CO;2-3; BASELGA J, 1993, ONCOGENE, V8, P3257; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CAMPBELL WJ, 1992, IN VITRO CELL DEV-AN, V28A, P61; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; CROUCH GD, 1991, CANCER RES, V51, P4882; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; DAILEY L, 1994, MOL CELL BIOL, V14, P7758, DOI 10.1128/MCB.14.12.7758; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; FENDERSON BA, 1987, DEV BIOL, V122, P21, DOI 10.1016/0012-1606(87)90328-9; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JUNG M, 1994, CANCER RES, V54, P5194; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; Miller K, 1996, CELL GROWTH DIFFER, V7, P203; MILLER WH, 1994, DIFFERENTIATION, V55, P145, DOI 10.1046/j.1432-0436.1994.5520145.x; MILLER WH, 1990, ONCOGENE, V5, P511; MOASSER MM, 1994, ONCOGENE, V9, P833; MOASSER MM, 1995, ONCOGENE, V10, P1537; Moasser MM, 1996, DIFFERENTIATION, V60, P251, DOI 10.1046/j.1432-0436.1996.6040251.x; MUMMERY CL, 1993, BIOCHEM BIOPH RES CO, V191, P188, DOI 10.1006/bbrc.1993.1201; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; PERTOVAARA L, 1993, BIOCHEM BIOPH RES CO, V191, P149, DOI 10.1006/bbrc.1993.1196; Quito FL, 1996, BLOOD, V87, P1282, DOI 10.1182/blood.V87.4.1282.bloodjournal8741282; RUSCH V, 1995, CANCER RES, V55, P1365; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SCHOFIELD PN, 1991, FEBS LETT, V280, P8, DOI 10.1016/0014-5793(91)80192-6; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STROHMEYER T, 1991, CANCER RES, V51, P1811; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TALARICO D, 1993, MOL CELL BIOL, V13, P1998, DOI 10.1128/MCB.13.4.1998; TIESMAN J, 1989, IN VITRO CELL DEV B, V25, P1193; VELCICH A, 1989, ONCOGENE RES, V5, P31; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V157, P618, DOI 10.1016/S0006-291X(88)80295-X; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V155, P1324, DOI 10.1016/S0006-291X(88)81286-5; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	50	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	1998	17	6					761	767		10.1038/sj.onc.1201992	http://dx.doi.org/10.1038/sj.onc.1201992			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	109RP	9715278				2022-12-17	WOS:000075337200011
J	Tsuji, T; Todd, R; Meyer, C; McBride, J; Liao, PH; Huang, MF; Chou, MY; Donoff, RB; Wong, DTW				Tsuji, T; Todd, R; Meyer, C; McBride, J; Liao, PH; Huang, MF; Chou, MY; Donoff, RB; Wong, DTW			Reduction of ornithine decarboxylase antizyme (ODC-Az) level in the 7,12-dimethylbenz(a)anthracene-induced hamster buccal pouch carcinogenesis model	ONCOGENE			English	Article						oral cancer; hamster; ornithine decarboxylase antizyme; proliferation; subtractive hybridization	POLYAMINE LEVELS; NECK-CANCER; GENE; EXPRESSION; HEAD; DEGRADATION; CARCINOMA; LESIONS; TUMORS; TISSUE	Ornithine decarboxylase (ODC) activity is elevated in and necessary for oral carcinogenesis, but the mechanism for its deregulation is unclear. Using subtractive hybridization, a 1029 bp full-length cDNA encoding a 222 amino acid open reading frame has been isolated from normal hamster oral keratinocytes. The hamster cDNA is homologous to the human, mouse and rat ornithine decarboxylase antizyme gene (ODC-Az). The hamster ODC-Az gene demonstrated a restriction fragment length polymorphism (RFLP) upon Southern blot analysis comparing normal and tumor hamster genomic DNA. Northern blot analysis revealed that normal hamster oral keratinocytes express readily detectable level of ODC-Az mRNA. Malignant oral keratinocytes demonstrate reduced expression of the ODC-Az mRNA, In contrast, malignant hamster oral keratinocytes have elevated ODC mRNA levels and lengthened ODC protein half-life when compared to the normal counterparts, This mas corroborated by direct measurement of ODC enzymatic activity. These data support the hypothesis that the reduced and/or loss of expression and function of the ODC-Az gene is an important event for the early de-regulation of cellular proliferation during oral tumor development.	Harvard Univ, Sch Dent Med, Div Oral Pathol, Dept Oral Med & Diagnost Sci, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA	Harvard University; Harvard School of Dental Medicine; Harvard University; Massachusetts General Hospital	Wong, DTW (corresponding author), Harvard Univ, Sch Dent Med, Div Oral Pathol, Dept Oral Med & Diagnost Sci, 188 Longwood Ave, Boston, MA 02115 USA.				NIDCR NIH HHS [P01 DE-12467, DE-00318, DE-08680] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R29DE008680, P01DE012467, R01DE008680, K04DE000318] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Battey, 1986, BASIC METHODS MOL BI; Bedi GC, 1996, CANCER RES, V56, P2484; BOYLE JO, 1992, CANCER EPIDEM BIOMAR, V1, P131; Califano J, 1996, CANCER RES, V56, P2488; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAINES DW, 1988, ANAL BIOCHEM, V174, P88, DOI 10.1016/0003-2697(88)90522-2; GIMENEZCONTI IB, 1993, J CELL BIOCHEM, P83; GIMENEZCONTI IB, 1992, ADV EXP MED BIOL, V320, P63; HAYASHI SI, 1995, BIOCHEM J, V306, P1; HICKOK NJ, 1990, GENE, V93, P257, DOI 10.1016/0378-1119(90)90233-H; KLICKSTEIN LB, 1987, PRODUCTION SUBTRACTE; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LI XQ, 1993, MOL CELL BIOL, V13, P2377, DOI 10.1128/MCB.13.4.2377; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; LINDEN M, 1985, J CELL PHYSIOL, V125, P273, DOI 10.1002/jcp.1041250215; LUNDELL L, 1986, SCAND J GASTROENTERO, V21, P829, DOI 10.3109/00365528609011126; MATSUFUJI S, 1990, J BIOCHEM, V107, P87, DOI 10.1093/oxfordjournals.jbchem.a123018; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; MATSUFUJI S, 1990, J BIOCHEM-TOKYO, V108, P365, DOI 10.1093/oxfordjournals.jbchem.a123207; MEGOSH L, 1995, CANCER RES, V55, P4205; MOROCO JR, 1990, LAB INVEST, V63, P298; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1985, BIOCHEM J, V226, P893, DOI 10.1042/bj2260893; MURAKAMI Y, 1992, J BIOL CHEM, V267, P13138; RADFORD DM, 1990, CANCER RES, V50, P6146; ROM E, 1994, P NATL ACAD SCI USA, V91, P3959, DOI 10.1073/pnas.91.9.3959; ROMANO M, 1986, INT J BIOL MARKER, V2, P77; Roz L, 1996, CANCER RES, V56, P1228; RUSSELL DH, 1981, MED BIOL, V59, P286; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIN DM, 1990, CANCER RES, V50, P2505; SHKLAR G, 1984, EXPT PATHOLOGY ORAL, P41; SLAGA TJ, 1992, NATL CANCER I MONOGR, V13, P55; Svensson F, 1997, P NATL ACAD SCI USA, V94, P397, DOI 10.1073/pnas.94.2.397; TAMORI A, 1994, HEPATOLOGY, V20, P1179, DOI 10.1002/hep.1840200512; TODD R, 1995, FASEB J, V9, P1362, DOI 10.1096/fasebj.9.13.7557027; WEISS RL, 1992, LARYNGOSCOPE, V102, P855, DOI 10.1288/00005537-199208000-00003; WETTERS TV, 1989, NUCLEIC ACIDS RES, V17, P9843, DOI 10.1093/nar/17.23.9843; WILLIAMS HK, 1995, J ORAL PATHOL MED, V24, P322, DOI 10.1111/j.1600-0714.1995.tb01193.x	41	24	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 2	1998	16	26					3379	3385		10.1038/sj.onc.1201887	http://dx.doi.org/10.1038/sj.onc.1201887			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692545				2022-12-17	WOS:000074544100004
J	Dejardin, E; Deregowski, V; Greimers, R; Cai, ZZ; Chouaib, S; Merville, MP; Bours, V				Dejardin, E; Deregowski, V; Greimers, R; Cai, ZZ; Chouaib, S; Merville, MP; Bours, V			Regulation of major histocompatibility complex class I expression by NF-kappa B-related proteins in breast cancer cells	ONCOGENE			English	Article						MHC class I; NF-kappa B, breast cancer	MHC CLASS-I; EMBRYONAL CARCINOMA-CELLS; TRANSCRIPTION FACTORS; GENE-EXPRESSION; DOWN-REGULATION; ONCOPROTEIN BCL-3; ALPHA PROTEOLYSIS; FACTOR BINDING; REL ONCOGENE; TAX-PROTEIN	Downregulation of MHC Class I antigens has been observed in many cancers and usually results from a decreased gene transcription. A reporter CAT gene dependent on the MHC Class I kappa B site or on a longer promoter is transactivated by NF-kappa B complexes containing p65 or RelB. p100 as well as I kappa B-alpha are potent inhibitors of this transcription and p100 sequesters RelB and p65 complexes in the cytoplasm of breast cancer cells. However, although p100 is highly expressed in a number of breast cancer cell lines, MHC Class I antigen expression was observed on all the cell lines we analysed and could be further induced by stimulation with the cytokines IFN-gamma or TNF-alpha. Stable transfection of a unresponsive mutated I kappa B-alpha Ser 32-36 expression vector showed that TNF-alpha induced MHC Cl I expression in an NF-kappa B-dependent way while IFN-gamma did it independently of any NF-kappa B activation.	Univ Liege, Lab Med Chem Med Oncol, B-4000 Liege, Belgium; Univ Liege, Pathol Lab, B-4000 Liege, Belgium; Inst Gustave Roussy, INSERM, CJF Cytokines & Immun Antitumorale 9411, F-94805 Villejuif, France	University of Liege; University of Liege; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	Bours, V (corresponding author), Univ Liege, Lab Med Chem Med Oncol, B-4000 Liege, Belgium.		Dejardin, Emmanuel/AAE-9076-2021; Chouaib, Salem/F-7939-2016					ACCOLLA RS, 1995, IMMUNOL TODAY, V16, P8, DOI 10.1016/0167-5699(95)80063-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BLANCHET O, 1992, P NATL ACAD SCI USA, V89, P3488, DOI 10.1073/pnas.89.8.3488; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; Cai ZZ, 1997, J BIOL CHEM, V272, P96; CORDONCARDO C, 1991, CANCER RES, V51, P6372; DANIELVEDELE F, 1985, IMMUNOGENETICS, V21, P601, DOI 10.1007/BF00395884; DEJARDIN E, 1995, ONCOGENE, V11, P1835; DOBRZANSKI P, 1995, ONCOGENE, V10, P1003; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; Drew PD, 1995, J INTERF CYTOK RES, V15, P1037, DOI 10.1089/jir.1995.15.1037; DREW PD, 1993, J IMMUNOL, V150, P3300; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; Garrido F, 1995, ADV CANCER RES, V67, P155, DOI 10.1016/S0065-230X(08)60713-7; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; ISRAEL A, 1987, P NATL ACAD SCI USA, V84, P2653, DOI 10.1073/pnas.84.9.2653; KANNO T, 1994, P NATL ACAD SCI USA, V91, P12634, DOI 10.1073/pnas.91.26.12634; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; LERNBECHER T, 1994, EMBO J, V13, P4060, DOI 10.1002/j.1460-2075.1994.tb06723.x; Liu XH, 1996, MOL CELL BIOL, V16, P398; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PLASKIN D, 1993, J EXP MED, V177, P1651; POTTER DA, 1993, J BIOL CHEM, V268, P18882; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHOUTEN GJ, 1995, EMBO J, V14, P1498, DOI 10.1002/j.1460-2075.1995.tb07136.x; SEGARS JH, 1993, MOL CELL BIOL, V13, P6157, DOI 10.1128/MCB.13.10.6157; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; VANTVEER LJ, 1993, EMBO J, V12, P195, DOI 10.1002/j.1460-2075.1993.tb05645.x; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; Weih F, 1996, ONCOGENE, V12, P445; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x	55	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3299	3307		10.1038/sj.onc.1201879	http://dx.doi.org/10.1038/sj.onc.1201879			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681829	Green Published			2022-12-17	WOS:000074343600011
J	Willems, L; Grimonpont, C; Kerkhofs, P; Capiau, C; Gheysen, D; Conrath, K; Roussef, R; Mamoun, R; Portetelle, D; Burny, A; Adam, E; Lefebvre, L; Twizere, JC; Heremans, H; Kettmann, R				Willems, L; Grimonpont, C; Kerkhofs, P; Capiau, C; Gheysen, D; Conrath, K; Roussef, R; Mamoun, R; Portetelle, D; Burny, A; Adam, E; Lefebvre, L; Twizere, JC; Heremans, H; Kettmann, R			Phosphorylation of bovine leukemia virus Tax protein is required for in vitro transformation but not for transactivation	ONCOGENE			English	Article						ras cooperation; B lymphocyte; sheep; HTLV	CASEIN KINASE-II; NF-KAPPA-B; HTLV-I; CELLULAR-TRANSFORMATION; VIRAL REPLICATION; BZIP PROTEINS; RAS ONCOGENE; BINDING; SITE; GENE	The Tax proteins of the oncovirinae viruses are phosphorylated transcriptional activators that exhibit oncogenic potential. The role of phosphorylation in their functional activities remains unknown. As a model for the Human T-cell leukemia virus type I (HTLV-I), Bovine Leukemia Virus (BLV) permits the characterization of viral replication and leukemogenesis in vitro. Here, we show that the BLV Tax protein is phosphorylated on serine residues 106 and 293 both in insect and in mammalian cells. These sites can also be efficiently phosphorylated by the cdc2 and MAP kinases in vitro. Mutation of these residues does not affect the capacity of the Tax protein to function as a transactivator. Indeed, the Tax proteins mutated at one or both serines increase LTR-directed viral transcription at levels similar to those obtained with wild-type Tax in cell culture, Moreover, inhibition of Tax phosphorylation by W7, a calmodulin antagonist, does not alter its transactivation activity. Thus, phosphorylation on serines 106 and 293 is not required for transactivation by Tax, However, simultaneous substitution of both serines into alanine residues destroys the capacity of Tax to cooperate with the Haras oncogene to transform primary rat embryo fibroblasts and induce tumors in nude mice, When the serines were replaced with aspartic acid residues, the oncogenic potential of Tax was maintained indicating that the negative charge rather than the phosphate group itself was required for Tax oncogenicity, Finally, to assess the role of the serine residues in vivo, recombinant viruses which express the Tax mutants were constructed and injected into sheep. It appeared that the mutated proviruses replicate at levels similar to the wild-type virus in vivo. We conclude that Tax phosphorylation is dispensable for transactivation and viral replication in vivo but is required for its oncogenic potential in vitro.	Fac Univ Sci Agron, Dept Mol Biol, B-5030 Gembloux, Belgium; Smithkline Beecham, B-1330 Rixensart, Belgium; Inst Natl Rech Vet, Dept Bovine Virol, B-1120 Ucclc, Belgium; Bulgarian Acad Sci, Inst Expt Pathol & Parasitol, Sofia, Bulgaria; Univ Bordeaux 2, INSERM, F-33076 Bordeaux, France; Katholieke Univ Leuven, Rega Inst, B-3000 Louvain, Belgium	University of Liege; GlaxoSmithKline; Bulgarian Academy of Sciences; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; KU Leuven	Willems, L (corresponding author), Fac Univ Sci Agron, Dept Mol Biol, B-5030 Gembloux, Belgium.		robert, mamoun/G-3242-2013; Twizere, Jean-Claude/AAG-3706-2019	TWIZERE, Jean-Claude/0000-0002-8683-705X; Willems, Luc/0000-0002-0563-2213				Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BOROS IM, 1995, VIROLOGY, V214, P207, DOI 10.1006/viro.1995.9939; CHEN G, 1989, VIROLOGY, V172, P343; Cockerell GL, 1996, BLOOD, V87, P1030, DOI 10.1182/blood.V87.3.1030.bloodjournal8731030; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; FONTES JD, 1993, J VIROL, V67, P4436, DOI 10.1128/JVI.67.7.4436-4441.1993; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GREEN PL, 1995, J VIROL, V69, P387, DOI 10.1128/JVI.69.1.387-394.1995; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; HIDAKA H, 1981, P NATL ACAD SCI-BIOL, V78, P4354, DOI 10.1073/pnas.78.7.4354; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; Kettmann R., 1994, RETROVIRIDAE, V3, P39, DOI DOI 10.1007/978-1-4899-1730-0_2; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NYUNOYA H, 1988, VIROLOGY, V167, P538, DOI 10.1016/S0042-6822(88)90116-X; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; PORTETELLE D, 1989, J VIROL METHODS, V23, P211, DOI 10.1016/0166-0934(89)90135-3; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; SEMMES OJ, 1992, J VIROL, V66, P7183, DOI 10.1128/JVI.66.12.7183-7192.1992; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; WILLEMS L, 1992, P NATL ACAD SCI USA, V89, P3957, DOI 10.1073/pnas.89.9.3957; WILLEMS L, 1993, J VIROL, V67, P4078, DOI 10.1128/JVI.67.7.4078-4085.1993; WILLEMS L, 1994, P NATL ACAD SCI USA, V91, P11532, DOI 10.1073/pnas.91.24.11532; WILLEMS L, 1990, EMBO J, V9, P1577, DOI 10.1002/j.1460-2075.1990.tb08277.x; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yoshida M, 1996, J ACQ IMMUN DEF SYND, V13, pS63, DOI 10.1097/00042560-199600001-00012; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	40	24	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2165	2176		10.1038/sj.onc.1201765	http://dx.doi.org/10.1038/sj.onc.1201765			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619825	Green Published			2022-12-17	WOS:000073298000001
J	Agami, R; Shaul, Y				Agami, R; Shaul, Y			The kinase activity of c-Abl but not v-Abl is potentiated by direct interaction with RFXI, a protein that binds the enhancers of several viruses and cell-cycle regulated genes	ONCOGENE			English	Article						EP element; HBV enhancer; c-Abl tyrosine kinase; DNA binding; RFX1; transcription	HEPATITIS-B VIRUS; RNA POLYMERASE-II; TYROSINE KINASE; TRANSCRIPTION FACTORS; TRANSFORMING ACTIVITY; SIGNAL-TRANSDUCTION; ACTIVITY INVITRO; PROMOTER REGION; NUCLEAR-PROTEIN; SH3 DOMAINS	c-Abl, the non-receptor tyrosine kinase is associated with EP, a DNA element found in promoters/enhancers of different viruses and cell-cycle regulated genes. EP-DNA binds RFXI, a member of a novel family of DNA-binding proteins that is conserved through evolution and in yeast, it controls differentiation and exit from the mitotic cycle to G(0). EP-associated proteins are preferentially tyrosine phosphorylated and the associated c-Abl has strong tyrosine kinase activity. Here we investigated the molecular mechanism underlying this c-Abl kinase activity. We show that RFXI and c-Abl are in direct interaction, in vitro and in cell extracts, through the RFXI proline rich (PxxP) motif and the c-Abl SH3 domain. Remarkably, this interaction significantly potentiates c-Abl but not v-Abl auto-kinase activity. Collectively, we describe a novel mechanism of c-Abl recruitment to a defined DNA-cis element with its concomitant kinase activation. We propose that this mechanism may act to regulate cell-cycle control genes.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Shaul, Y (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.		agami, reuven/GOG-8289-2022	Agami, Reuven/0000-0002-2848-2473				ANAFI M, 1992, J BIOL CHEM, V267, P4518; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BIRCHENALLROBERTS MC, 1995, MOL CELL BIOL, V15, P6088; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P3683, DOI 10.1128/MCB.10.7.3683; Dikstein R, 1996, P NATL ACAD SCI USA, V93, P2387, DOI 10.1073/pnas.93.6.2387; Emery P, 1996, NUCLEIC ACIDS RES, V24, P803, DOI 10.1093/nar/24.5.803; FAKTOR O, 1990, J VIROL, V64, P1861, DOI 10.1128/JVI.64.4.1861-1863.1990; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GARCIA AD, 1993, J VIROL, V67, P3940, DOI 10.1128/JVI.67.7.3940-3950.1993; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GHAZAL P, 1988, MOL CELL BIOL, V8, P1809, DOI 10.1128/MCB.8.4.1809; HONIGWACHS J, 1989, J VIROL, V63, P919, DOI 10.1128/JVI.63.2.919-924.1989; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; Katan Y, 1997, NUCLEIC ACIDS RES, V25, P3621, DOI 10.1093/nar/25.18.3621; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; LABRIE C, 1995, NUCLEIC ACIDS RES, V23, P3732, DOI 10.1093/nar/23.18.3732; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; Miao YJ, 1996, J BIOL CHEM, V271, P22823, DOI 10.1074/jbc.271.37.22823; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; OSTAPCHUK P, 1989, MOL CELL BIOL, V9, P2787, DOI 10.1128/MCB.9.7.2787; PAWSON T, 1995, NATURE, V373, P477, DOI 10.1038/373477a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; RAMAKRISHNAN L, 1989, BIOCHIM BIOPHYS ACTA, V989, P209, DOI 10.1016/0304-419X(89)90043-7; REINHOLD W, 1995, MOL CELL BIOL, V15, P3041; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; SAFRANY G, 1995, EUR J BIOCHEM, V230, P1066, DOI 10.1111/j.1432-1033.1995.tb20657.x; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIEGRIST CA, 1993, MOL CELL BIOL, V13, P6375, DOI 10.1128/MCB.13.10.6375; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WANG JYJ, 1994, TRENDS BIOCHEM SCI, V19, P373, DOI 10.1016/0968-0004(94)90114-7; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WU SY, 1995, MOL CELL BIOL, V15, P1479; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZAJAC KM, 1988, SCIENCE, V240, P1176; ZHANG XY, 1991, VIROLOGY, V182, P865, DOI 10.1016/0042-6822(91)90631-K; ZHANG XY, 1990, CANCER RES, V50, P6865; ZHANG XY, 1990, NUCLEIC ACIDS RES, V18, P6253, DOI 10.1093/nar/18.21.6253	67	24	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	1998	16	14					1779	1788		10.1038/sj.onc.1201708	http://dx.doi.org/10.1038/sj.onc.1201708			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZG368	9583676				2022-12-17	WOS:000072994600002
J	Gupta, K; Anand, G; Yin, XY; Grove, L; Prochownik, EV				Gupta, K; Anand, G; Yin, XY; Grove, L; Prochownik, EV			Mmip1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc	ONCOGENE			English	Article						Myc/Mad/leucine; zipper/helix-loop-helix	CELL-CYCLE PROGRESSION; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; OPPOSITE REGULATION; EMBRYO FIBROBLASTS; ONCOGENIC ACTIVITY; REPRESSOR SIN3; IN-VIVO; DIFFERENTIATION; MXI1	C-myc, a member of the basic helix-loop-helix-leucine zipper (bHLH-ZIP) protein family activates target in heterodimeric association with another bHLH-ZIP protein, Max. Max readily homodimerizes, competes with C-myc-Max heterodimers, and represses transcription. Four additional bHLH-ZIP proteins, Mad1, Mxi1, Mad3 and Mad4, heterodimerize with Max and also repress transcription of c-myc-responsive genes. We employed a yeast two-hybid approach to identify proteins which interact with Mxi. We identified a novel ZIP-containing protein, Mmip1 (Mad member-interacting protein 1) that strongly dimerizes with all four Mad members, but not with c-myc, Max, or with unrelated HLH proteins. The Mmip1-Mxi association is mediated by the ZIP domain of each polypeptide and is as strong or stronger than the associations between c-myc and Max or Max and Mxi1. In vitro, Mmip1 can inhibit DNA binding by Max-Mad heterodimers and, in vivo, can reverse the suppressive effects of Mad proteins on c-myc functions. Mmip1 is found in a variety of cells types, is induced by serum stimulation, and can be co-immunoprecipitated from fibroblasts in association with Mxi1. By interfering with the dimerization between Max and Mad family member proteins, Mmip1 can indirectly up-regulate the transcriptional activity of c-myc and suppress the antiproliferative actions of Mad proteins.	Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Hematol Oncol Sect, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Inst Canc, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Hematol Oncol Sect, Pittsburgh, PA 15213 USA.				NHLBI NIH HHS [HL33741] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033741] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ARSURA M, 1995, MOL CELL BIOL, V15, P6702; ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Bartel PL, 1993, CELLULAR INTERACTION, P153; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; EDELHOFF S, 1994, ONCOGENE, V9, P665; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Langlands K, 1997, ANAL BIOCHEM, V249, P250, DOI 10.1006/abio.1997.2184; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; LARSSON LG, 1994, ONCOGENE, V9, P1247; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MIN SY, 1992, ONCOGENE, V7, P1531; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1993, P NATL ACAD SCI USA, V90, P960, DOI 10.1073/pnas.90.3.960; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SHAPIRO DN, 1994, GENOMICS, V23, P282, DOI 10.1006/geno.1994.1496; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; SPENCER CA, 1991, ADV CANCER RES, V56, P1; VANANTWERP ME, 1992, P NATL ACAD SCI USA, V89, P9010, DOI 10.1073/pnas.89.19.9010; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; WECHSLER DS, 1994, GENOMICS, V21, P669, DOI 10.1006/geno.1994.1336; Zeng X, 1997, P NATL ACAD SCI USA, V94, P3673, DOI 10.1073/pnas.94.8.3673; ZERVOS, 1994, CELL, V79, P389; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416; ZHU BY, 1993, PROTEIN SCI, V2, P383	68	24	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	1998	16	9					1149	1159		10.1038/sj.onc.1201634	http://dx.doi.org/10.1038/sj.onc.1201634			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA170	9528857				2022-12-17	WOS:000072336000006
J	Englaro, W; Derijard, B; Ortonne, JP; Ballotti, R				Englaro, W; Derijard, B; Ortonne, JP; Ballotti, R			Solar ultraviolet light activates extracellular signal-regulated kinases and the ternary complex factor in human normal keratinocytes	ONCOGENE			English	Article						ultraviolets A and B; ERKs; SAPKs; TCF/SRF; AP1	SERUM RESPONSE ELEMENT; GROWTH-FACTOR; TYROSINE KINASES; PHOSPHORYLATION; RADIATION; ERK; MECHANISMS; INDUCTION; RECEPTORS; PATHWAYS	Exposure to ultraviolet radiation of solar light is responsible for inflammation, premature skin aging and is the main cause of human skin carcinogenesis. While the noxious consequences of U.V. exposure are known, the molecular events triggered by this radiation are poorly understood. We observed that U.V.-A and U.V.-B irradiation of human keratinocytes induces the activation of tyrosine kinase pathways leading to the tyrosine phosphorylation of several cellular proteins. We also observed a stimulation of the Stress Activated Protein kinases (SAPKs), p38 and JNK, and an activation of the transcription factors AP-1 in response to U.V.-A and U.V.-B radiation. Furthermore, we clearly demonstrated that physiological U.V. doses are able to activate the Extracellular signal-Regulated Kinases, ERK1 and ERK2, which could explain the activation of the Ternary Complex Factor. Thus, in human keratinocytes, solar U.V. light activates multiple signalling pathways that could be involved in skin inflammation following U.V. induced skin injury or in U.V.-induced skin carcinogenesis.	Fac Med Nice, INSERM, U385, F-06107 Nice 2, France; Univ Nice, CNRS, Ctr Biochim, F-06018 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Ballotti, R (corresponding author), Fac Med Nice, INSERM, U385, Ave Valombrose, F-06107 Nice 2, France.		BALLOTTI, Robert/F-8825-2013	BALLOTTI, Robert/0000-0002-7322-4908				ANANTHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119, DOI 10.1111/j.1751-1097.1990.tb08452.x; DELUCA HF, 1982, BIOCHEM SOC T, V10, P147, DOI 10.1042/bst0100147; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DHANWADA KR, 1995, ONCOGENE, V11, P1947; DjavaheriMergny M, 1996, FEBS LETT, V384, P92, DOI 10.1016/0014-5793(96)00294-3; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Gilchrest BA, 1996, PHOTOCHEM PHOTOBIOL, V63, P1, DOI 10.1111/j.1751-1097.1996.tb02988.x; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HOLICK MF, 1980, SCIENCE, V210, P203, DOI 10.1126/science.6251551; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; JEANMOUGIN M, 1983, PHOTODERMATOSES PHOT, P11; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; NAKAZATO Y, 1991, J BIOL CHEM, V266, P14119; PENTLAND AP, 1990, J CLIN INVEST, V86, P566, DOI 10.1172/JCI114746; QIU ZH, 1994, J BIOL CHEM, V269, P19480; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SHAW PE, 1992, EMBO J, V11, P3011, DOI 10.1002/j.1460-2075.1992.tb05371.x; SHEA CR, 1991, PHYSL BIOCH MOL BIOL, P910; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	28	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					661	664		10.1038/sj.onc.1201536	http://dx.doi.org/10.1038/sj.onc.1201536			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482112				2022-12-17	WOS:000071816600011
J	Caruana, G; Cambareri, AC; Gonda, TJ; Ashman, LK				Caruana, G; Cambareri, AC; Gonda, TJ; Ashman, LK			Transformation of NIH3T3 fibroblasts by the c-Kit receptor tyrosine kinase: effect of receptor density and ligand-requirement	ONCOGENE			English	Article						c-Kit; SLF; transformation; anchorage independence; receptor density	STEM-CELL FACTOR; COLONY-STIMULATING FACTOR; ACUTE MYELOID-LEUKEMIA; GROWTH-FACTOR; EGF RECEPTOR; MAST-CELLS; SIGNAL-TRANSDUCTION; PROTO-ONCOGENE; NEURONAL DIFFERENTIATION; MONOCLONAL-ANTIBODIES	Ectopic expression of the normal murine receptor tyrosine kinase, c-Kit, in NIH3T3 cells induced many phenotypic changes characteristic of transformation including anchorage-independent growth, focus formation and tumorigenicity in nude mice, Although transformation was largely dependent on the presence of recombinant murine Steel Factor (SLF), the ligand to the c-Kit receptor, anchorage independent growth did occur at a low frequency in the absence of added factor, and this could not be inhibited by neutralising antibodies or by SLF anti-sense mRNA, Clones from factor-independent colonies in semi-solid agar displayed a narrow range of c-Kit surface protein levels (4.3-6.4 x 10(4) receptors/cell) which was relatively high compared with the pool from which they were derived, Analysis of a larger series of random clones derived from adherent cultures expressing different levels of c-Kit demonstrated a positive correlation between SLF-dependent, anchorage-independent growth and c-Kit protein and mRNA expression levels (respectively, R-S = 0.58, P < 0.01; and R-S = 0.53, P < 0.01) with consistent colony formation observed with clones having > 2.5 x 10(4) receptors/cell, Interestingly, two of the three clones expressing the highest levels of c-Kit protein and mRNA produced few or no colonies in the presence or absence of SLF, Sequential overexpression of human c-KIT in NIH3T3 cells using a dihydrofolate reductase (DHFR)-encoding vector and gene co-amplification through methotrexate selection, which resulted in pools expressing up to 1.5 x 10(5) receptors/cell, confirmed that high receptor densities resulted in a decrease in colony numbers, Thus, analysis of clonal and selected populations has indicated that an optimal level of c-Kit is required for transformation of NIH3T3 cells in the presence of SLF, and that some ligand-independent transformation occurs.	Inst Med & Vet Sci, Div Haematol, Leukaemia Res Unit, Adelaide, SA 5000, Australia; Inst Med & Vet Sci, Div Human Immunol, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia	Institute Medical & Veterinary Science Australia; Institute Medical & Veterinary Science Australia	Ashman, LK (corresponding author), Inst Med & Vet Sci, Div Haematol, Leukaemia Res Unit, Box 14,Rundle Mall PO, Adelaide, SA 5000, Australia.		ASHMAN, LEONIE/G-7631-2013; Gonda, Thomas J/A-3620-2012	ASHMAN, LEONIE/0000-0003-3559-3611; 				ALEXANDER WS, 1991, EMBO J, V10, P3683, DOI 10.1002/j.1460-2075.1991.tb04936.x; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ASHMAN LK, 1988, LEUKEMIA RES, V12, P923, DOI 10.1016/0145-2126(88)90020-3; AYLETT G, 1995, LEUCOCYTE TYPING V W, V2, P1917; BERNSTEIN A, 1991, SEMIN HEMATOL, V28, P138; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BRANDTRAUF PW, 1990, P NATL ACAD SCI USA, V87, P8660, DOI 10.1073/pnas.87.21.8660; CARUANA G, 1993, EXP HEMATOL, V21, P761; CHOO KH, 1986, DNA-J MOLEC CELL BIO, V5, P529, DOI 10.1089/dna.1.1986.5.529; COLE SR, 1989, IMMUNOL CELL BIOL, V67, P377, DOI 10.1038/icb.1989.54; Cole SR, 1996, LEUKEMIA, V10, P288; CONTRERAS MA, 1983, METHOD ENZYMOL, V92, P277; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; FERRAO P, 1997, IN PRESS BLOOD, V90; FUJITA J, 1989, P NATL ACAD SCI USA, V86, P2888, DOI 10.1073/pnas.86.8.2888; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GRAHAM FL, 1980, INTRO MACROMOLECULES, P3; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HERBST R, 1995, ONCOGENE, V10, P369; HIBI K, 1991, ONCOGENE, V6, P2291; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; IRANI AMA, 1992, BLOOD, V80, P3009; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; JOZAKI K, 1991, EXP HEMATOL, V19, P185; KAWAMOTO T, 1984, J BIOL CHEM, V259, P7761; KERN JA, 1990, CANCER RES, V50, P5184; KISS C, 1993, LEUKEMIA, V7, P235; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; LERNER NB, 1991, BLOOD, V77, P1876; LEV S, 1990, MOL CELL BIOL, V10, P6064, DOI 10.1128/MCB.10.11.6064; LIU E, 1992, ONCOGENE, V7, P1027; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MAYRHOFER G, 1987, IMMUNOL CELL BIOL, V65, P241, DOI 10.1038/icb.1987.27; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OCONNOR CG, 1982, J IMMUNOL METHODS, V54, P267, DOI 10.1016/0022-1759(82)90068-0; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; QUI F, 1988, EMBO J, V7, P1003; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; RIEDEL H, 1987, SCIENCE, V236, P197, DOI 10.1126/science.3494307; ROSNET O, 1991, ONCOGENE, V6, P1641; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SASAKI K, 1995, BLOOD, V85, P1220, DOI 10.1182/blood.V85.5.1220.bloodjournal8551220; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; SHERR CJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P225, DOI 10.1016/0304-419X(88)90011-X; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; Zar, 2001, BIOSTAT ANAL	60	24	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					179	190		10.1038/sj.onc.1201494	http://dx.doi.org/10.1038/sj.onc.1201494			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464535				2022-12-17	WOS:000071427100004
J	Sweetser, DA; Kapur, RP; Froelick, GJ; Kafer, KE; Palmiter, RD				Sweetser, DA; Kapur, RP; Froelick, GJ; Kafer, KE; Palmiter, RD			Oncogenesis and altered differentiation induced by activated Ras in neuroblasts of transgenic mice	ONCOGENE			English	Article						Ras; sympathetic nervous system; neuroblastoma	NERVE GROWTH-FACTOR; LACKING GDNF; SYMPATHETIC NEUROBLASTS; ENTERIC NEURONS; NEURAL CREST; CELLS; EXPRESSION; SURVIVAL; ABNORMALITIES; NEUROTROPHINS	Sympathetic neurons, enteric neurons and adrenal chromaffin cells all derive from the neural crest. During development these cells migrate, proliferate, survive and differentiate in a highly controlled fashion influenced by local signals encountered during their migration. Aberrations of these processes are responsible for a variety of developmental defects and malignancies, Many of the environmental signals influencing these precursor cells activate receptor tyrosine kinases that can signal, at least in part, via Ras pathways, To assess the extent to which Ras can alter neuroblast cell number and fate in vivo, we expressed activated H-Ras in transgenic mice using the dopamine-beta-hydroxylase promoter, which directs expression to these cells prior to and after their differentiation. Ganglioneuromas and occasional neuroblastomas formed in the adrenal gland and preaortic sympathetic ganglia. Curiously, neurons of the superior cervical ganglia and the gut were largely unaffected despite demonstrated expression of activated Ras. The sensitivity of preaortic sympathetic neurons and adrenal chromaffin cells to the effects of oncogenes such as Ras may explain the predilection of neuroblastomas in humans to these sites. The ability to analyse neuroblastoma development in these mice may shed light on the molecular basis of certain types of human neuroblastoma.	UNIV WASHINGTON,DIV MED GENET,SEATTLE,WA 98195; UNIV WASHINGTON,DIV PEDIAT HEMATOL & ONCOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PATHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Sweetser, DA (corresponding author), UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT BIOCHEM,BOX 357370,SEATTLE,WA 98195, USA.		Sweetser, David/ABB-9347-2021	Sweetser, David/0000-0002-1621-3284	NCI NIH HHS [T32CA09351] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009351] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALT F, 1990, CRIT REV ONCOGENESIS, V2, P75; ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; BAETGE G, 1990, DEV BIOL, V141, P353, DOI 10.1016/0012-1606(90)90391-U; BALJET B, 1975, STAIN TECHNOL, V50, P31, DOI 10.3109/10520297509117028; BARSAGI D, 1989, ANTICANCER RES, V9, P1427; BESSHO F, 1991, J PEDIATR-US, V119, P237, DOI 10.1016/S0022-3476(05)80733-4; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BRADLEY A, 1987, PRODUCTION ANAL CHIM; BRANDS JHG, 1986, EUR J BIOCHEM, V155, P137; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BRODEUR GM, 1995, METABOLIC MOL BASES, P697; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; BURCHILL SA, 1995, EUR J CANCER, V31A, P476, DOI 10.1016/0959-8049(95)00054-M; BURCHILL SA, 1995, J NEUROL SCI, V133, P3, DOI 10.1016/0022-510X(95)00163-V; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; Davies Alun M., 1994, Progress in Growth Factor Research, V5, P263, DOI 10.1016/0955-2235(94)90010-8; DELATORRE JC, 1980, J NEUROSCI METH, V3, P1, DOI 10.1016/0165-0270(80)90029-1; DICICCOBLOOM E, 1993, NEURON, V11, P1011; Durbec PL, 1996, DEVELOPMENT, V122, P349; EVANS MI, 1978, CLIN CHEM, V24, P567; FOREMAN PJ, 1992, J NEUROSCI RES, V31, P52, DOI 10.1002/jnr.490310108; GAESE F, 1994, DEVELOPMENT, V120, P1613; GOODMAN SN, 1991, AM J DIS CHILD, V145, P1415, DOI 10.1001/archpedi.1991.02160120083024; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HOPEWELL R, 1995, MOL CELL BIOL, V15, P3470; IKEDA Y, 1981, J PEDIATR SURG, V16, P636, DOI 10.1016/0022-3468(81)90019-1; IRELAND CM, 1989, CANCER RES, V49, P5530; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KAPUR RP, 1991, NEURON, V7, P717, DOI 10.1016/0896-6273(91)90275-5; Le Douarin N.M., 1982, NEURAL CREST; Lee T, 1996, DEVELOPMENT, V122, P409; LO L, 1996, NEURON, V15, P527; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MERCER EH, 1991, NEURON, V7, P703, DOI 10.1016/0896-6273(91)90274-4; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; POLUHA W, 1995, ONCOGENE, V10, P185; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SEARLE PF, 1984, MOL CELL BIOL, V4, P1221, DOI 10.1128/MCB.4.7.1221; Silos-Santiago Inmaculada, 1995, Current Opinion in Neurobiology, V5, P42, DOI 10.1016/0959-4388(95)80085-9; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; TANAKA T, 1988, CANCER RES, V48, P1030; TEITELMAN G, 1981, DEV BIOL, V86, P348, DOI 10.1016/0012-1606(81)90192-5; TURKEL SB, 1974, AM J PATHOL, V76, P225; VOGEL KS, 1995, CELL, V82, P733, DOI 10.1016/0092-8674(95)90470-0	48	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2783	2794		10.1038/sj.onc.1201452	http://dx.doi.org/10.1038/sj.onc.1201452			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419969				2022-12-17	WOS:A1997YJ80300004
J	Chen, Q; Turner, J; Watson, AJM; Dive, C				Chen, Q; Turner, J; Watson, AJM; Dive, C			v-Abl protein tyrosine kinase (PTK) mediated suppression of apoptosis is associated with the up-regulation of Bcl-X-L	ONCOGENE			English	Article						apoptosis; v-Abl tyrosine kinase; Bcl-X-L survival signals	PROGRAMMED CELL-DEATH; HEMATOPOIETIC-CELLS; ACTIVATION; INTERLEUKIN-3; GROWTH; GENE; SURVIVAL; LINE; BAX; PHOSPHORYLATION	We demonstrated previously that the activation of v-Abl protein tyrosine kinase (PTK) in IC.DP murine pre-mast cells resulted in suppression of apoptosis after withdrawal of interleukin 3 (IL-3), that protein kinase C (PKC) translocated to the nucleus 6 h after v-Abl PTK activation and that inhibition of PKC restored apoptosis after IL-3 deprivation in the presence of v-Abl PTK activity. Here we demonstrate that v-Abl PTK activation is followed by an approximately twofold increase in mRNA level of Bcl-X-L by 6 h and a corresponding increase in Bcl-X-L protein level by 24 h. Bcl-x(L) RNA and protein decreased in IL-3 deprived cells in the absence of v-Abl PTK activity. Exposure of cells with v-Abl PTK active to the PKC inhbitor calphostin C (125 ng/ml) prevented the increase in Bcl-x(L) protein and resulted in apoptosis. No changes in Bax or Bcl-2 protein level were noted after IL-3 withdrawal and/or activation of v-Abl PTK. Bak was barely detectable and Bad protein level decreased in cells undergoing apoptosis. The data suggest that suppression of apoptosis by v-Abl PTK in the absence of IL-3 is associated with PKC signalling and the upregulation of Bcl-x(L) in IC.DP cells.	UNIV MANCHESTER, SCH BIOL SCI, MOL PHARMACOL GRP, MANCHESTER M13 9PT, LANCS, ENGLAND; UNIV MANCHESTER, DEPT MED, MANCHESTER M13 9PT, LANCS, ENGLAND	University of Manchester; University of Manchester				Dive, Caroline/0000-0002-1726-8850				BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1995, ONCOGENE, V11, P1921; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHAPMAN RS, 1994, CANCER RES, V54, P5131; CHAPMAN RS, 1995, MOL PHARMACOL, V48, P334; CHEN CY, 1995, ONCOGENE, V11, P1487; Chen Q, 1997, J CELL SCI, V110, P379; CHUNG SW, 1995, ONCOGENE, V10, P1261; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Dive C, 1992, Semin Cancer Biol, V3, P417; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; EVANS CA, 1995, J CELL SCI, V108, P2591; EVANS CA, 1993, CANCER RES, V53, P1735; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Guan RJ, 1996, ONCOGENE, V12, P2605; HALDAR S, 1989, NATURE, V342, P195, DOI 10.1038/342195a0; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KAN O, 1994, J EXP MED, V180, P917, DOI 10.1084/jem.180.3.917; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KONOPKA JB, 1985, BIOCHIM BIOPHYS ACTA, V823, P1, DOI 10.1016/0304-419X(85)90012-5; KORSMEYER SJ, 1992, BLOOD, V80, P879; Maniatis T, 1989, MOL CLONING; MAY WS, 1994, J BIOL CHEM, V269, P26865; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWEN PJ, 1993, J BIOL CHEM, V268, P15696; OWENLYNCH PJ, 1995, J BIOL CHEM, V270, P5956, DOI 10.1074/jbc.270.11.5956; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Shuai K, 1996, ONCOGENE, V13, P247; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	43	24	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	1997	15	18					2249	2254		10.1038/sj.onc.1201371	http://dx.doi.org/10.1038/sj.onc.1201371			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YD019	9393984				2022-12-17	WOS:A1997YD01900014
J	Milner, AE; Grand, RJA; Vaughan, ATM; Armitage, RJ; Gregory, CD				Milner, AE; Grand, RJA; Vaughan, ATM; Armitage, RJ; Gregory, CD			Differential effects of BCL-2 on survival and proliferation of human B-lymphoma cells following gamma-irradiation	ONCOGENE			English	Article						apoptosis; CD40; cell cycle; Burkitt lymphoma; gamma-irradiation; Bcl-2	RADIATION-INDUCED APOPTOSIS; BONE-MARROW CELLS; WILD-TYPE P53; CYCLE PROGRESSION; GENE-EXPRESSION; DNA-DAMAGE; DEATH; GROWTH; LINES; PROTECTS	Bcl-2 can inhibit apoptosis induced by a variety of stimuli, including radiation and its presence in tumour cells would be expected to indicate poor prognosis. Bcl-2-expressing tumours, however, are often low-grade and highly responsive to therapy. To investigate this apparent paradox, we analysed in vitro the responses of Burkitt lymphoma (BL) cells to gamma-irradiation in the presence and absence of Bcl-2. High-level expression of Bcl-2 was shown to promote BL cell survival following irradiation. However, a significant proportion of Bcl-2-rescued cells subsequently underwent apoptosis after an extended period in culture. In addition, in different BL lines, Bcl-2 was found either to promote or to inhibit long-term proliferative activity following gamma-irradiation. This differential regulation of proliferation correlated both with differential effects of Bcl-2 on the cell cycle and with differences in p53 status. Thus, by one week after irradiation, BL cells expressing only wild-type p53 (wt/wt) had arrested in G1, whereas those with a mutant allele (wt/mu) were arrested in all phases of the cell cycle. The proportion of Bcl-2-rescued cells subsequently underwent apoptosis was reduced Ligation of CD40 at the time of irradiation in wt/wt BL cells, but not in wt/mu cells, CD40-ligation reduced both G1-arrest and apoptosis in parallel. These results indicate that, whilst Bcl-2 can delay apoptosis in BL cells following gamma-irradiation, the protein can also cause growth-arrest and thereby promote apoptosis, Long-term survival following Bcl-2-mediated rescue of gamma-irradiated cells may depend on p53 status and require additional death-repressing or growth-promoting signals.	UNIV BIRMINGHAM,SCH MED,DEPT IMMUNOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,SCH MED,INST CANC STUDIES,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; IMMUNEX RES & DEV CORP,SEATTLE,WA 98101; LOYOLA UNIV,CARDINAL BERNADINE CANC CTR,CHICAGO,IL 60611	University of Birmingham; University of Birmingham; Loyola University Chicago			Gregory, Chris/C-6927-2019	Gregory, Chris/0000-0002-7553-0132	NCI NIH HHS [CA55840] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055840, R55CA055840] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; BRACEY TS, 1995, ONCOGENE, V10, P2391; CAMPOS L, 1993, BLOOD, V81, P3091; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; Gilbert MS, 1996, CELL DEATH DIFFER, V3, P215; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Herod JJO, 1996, CANCER RES, V56, P2178; HOLDER MJ, 1993, EUR J IMMUNOL, V23, P2368, DOI 10.1002/eji.1830230948; ISHIDA T, 1995, J IMMUNOL, V155, P5527; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KRUMAN II, 1991, J CELL PHYSIOL, V148, P267, DOI 10.1002/jcp.1041480212; Kyprianou N, 1997, INT J CANCER, V70, P341, DOI 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I; LEPELLEY P, 1995, LEUKEMIA, V9, P726; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Lock RB, 1996, CANCER RES, V56, P4006; MARVEL J, 1994, ONCOGENE, V9, P1117; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER AE, 1992, INT J CANCER, V52, P636, DOI 10.1002/ijc.2910520424; MILNER AE, 1993, ONCOGENE, V8, P3385; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OCONNOR PM, 1993, CANCER RES, V53, P4776; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PEZZELLA F, 1992, BRIT J CANCER, V65, P87, DOI 10.1038/bjc.1992.16; PIETENPOL JA, 1994, CANCER RES, V54, P3714; PIRIS MA, 1994, BRIT J CANCER, V69, P337, DOI 10.1038/bjc.1994.61; RADFORD IR, 1994, INT J RADIAT BIOL, V66, P557, DOI 10.1080/09553009414551621; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; Sangfelt O, 1996, INT J CANCER, V67, P106, DOI 10.1002/(SICI)1097-0215(19960703)67:1<106::AID-IJC18>3.0.CO;2-C; SEKI H, 1995, CELL IMMUNOL, V163, P30, DOI 10.1006/cimm.1995.1095; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Silvestrini R, 1996, J CLIN ONCOL, V14, P1604, DOI 10.1200/JCO.1996.14.5.1604; Soldatenkov VA, 1996, INT J ONCOL, V9, P547; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Tewari M, 1996, CURR OPIN GENET DEV, V6, P39, DOI 10.1016/S0959-437X(96)90008-8; Tjalma W, 1997, J CLIN PATHOL, V50, P33, DOI 10.1136/jcp.50.1.33; Walker A, 1997, CANCER RES, V57, P1939; Wang H, 1996, ONCOGENE, V13, P373; Wilson WH, 1997, BLOOD, V89, P601, DOI 10.1182/blood.V89.2.601; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	46	24	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1815	1822		10.1038/sj.onc.1201355	http://dx.doi.org/10.1038/sj.onc.1201355			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362448				2022-12-17	WOS:A1997XZ72500008
J	Ziebold, U; Klempnauer, KH				Ziebold, U; Klempnauer, KH			Linking Myb to the cell cycle: cyclin-dependent phosphorylation and regulation of A-Myb activity	ONCOGENE			English	Article						A-myb; cell cycle; cyclins A and E; phosphorylation; transactivation	DNA-POLYMERASE-ALPHA; PROTEIN-KINASE; RETINOBLASTOMA PROTEIN; S-PHASE; C-MYB; V-MYB; TRANSCRIPTIONAL ACTIVATOR; MAMMALIAN FIBROBLASTS; GENE-EXPRESSION; G(1) CYCLINS	A-myb, a conserved member of the Myb proto-oncogene family, encodes a sequence-specific DNA binding protein (A-Myb) that binds to and transactivates promoters containing myb-binding sites, Previous work has suggested that the C-terminus of A-Myb functions as a regulatory domain, however, the physiological signals that control the activity of A-Myb have not yet been identified, The presence of potential phosphorylation sites for cyclin-dependent kinases in the C-terminus of A-Myb has prompted us to examine the possibility that the function of A-Myb is controlled by the cell cycle. We here show that the transactivation potential of A-Myb is repressed by the C-terminal domain and that phosphorylation of A-Myb, induced by cyclins A and E, relieves this inhibitory effect, Our work provides the first evidence that the function of A-Myb is regulated by the cell cycle machinery and that the carboxy-terminal domain of A-Myb acts as a cell cycle sensor, In addition, we show that A-myb mRNA expression is also cell cycle regulated and attains maximal levels during the late G(1)- and early S-phase, Thus, A-Myb appears to be controlled by two different mechanisms maximal A-Myb activity during the G(1)/S-transition and the S-phase of the cell cycle.	MAX PLANCK INST IMMUNBIOL,HANS SPEMANN LAB,D-79108 FREIBURG,GERMANY; UNIV FREIBURG,KINDERKLIN,D-79106 FREIBURG,GERMANY	Max Planck Society; University of Freiburg			Ziebold, Ulrike/N-4487-2013					AZIZ N, 1993, ONCOGENE, V8, P2259; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FOOS G, 1994, ONCOGENE, V9, P2481; FROST V, 1995, J BIOL CHEM, V270, P26698, DOI 10.1074/jbc.270.44.26698; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Golay J, 1996, BLOOD, V87, P1900; GOLAY J, 1994, ONCOGENE, V9, P2469; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LAM EWF, 1992, ONCOGENE, V7, P1885; Latham KE, 1996, ONCOGENE, V13, P1161; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MASSAGUE J, 1995, CURR OPIN CELL BIOL, V7, P769, DOI 10.1016/0955-0674(95)80059-X; METTUS RV, 1994, ONCOGENE, V9, P3077; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Sitzmann J, 1996, ONCOGENE, V12, P1889; Sitzmann J, 1995, ONCOGENE, V11, P2273; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TRAUTH K, 1994, EMBO J, V13, P5894; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WIMMEL A, 1994, ONCOGENE, V9, P995; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	56	24	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1011	1019		10.1038/sj.onc.1201282	http://dx.doi.org/10.1038/sj.onc.1201282			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285555				2022-12-17	WOS:A1997XT16100002
J	Bauer, A; Ulrich, E; Andersson, M; Beug, H; vonLindern, M				Bauer, A; Ulrich, E; Andersson, M; Beug, H; vonLindern, M			Mechanism of transformation by v-ErbA: Substitution for steroid hormone receptor function in self renewal induction	ONCOGENE			English	Article						leukemogenesis; receptor tyrosine kinases; steroid hormone receptors; thyroid hormone receptor; v-ErbA	AVIAN ERYTHROBLASTOSIS VIRUS; RETINOIC ACID RECEPTORS; GROWTH-FACTOR RECEPTOR; DNA-SEQUENCE SPECIFICITY; THYROID-HORMONE; ESTROGEN-RECEPTOR; C-ERBA; ERYTHROID-DIFFERENTIATION; RESPONSE ELEMENT; BINDING DOMAIN	V-ErbA, a mutated thyroid hormone receptor (TR) alpha cooperates with tyrosine kinase oncoproteins to induce fatal erythroleukemia in chicks, In vitro, v-ErbA employs a similar cooperation to induce sustained proliferation and arrest differentiation of committed erythroid progenitors, V-ErbA has been proposed to function as a dominant-negative c-ErbA/TR alpha, since it lacks an AF-2 transactivation domain and cannot be activated by hormone but retains the capacity to bind corepressors, v-ErbA fails to heterodimerize with the RXR, exhibits an altered DNA binding specificity and fails to suppress the action of coexpressed TR alpha/c-ErbA in erythroblasts, In this paper, we identify a novel mechanism by which v-ErbA contributes to leukemogenesis, Recently, the glucocorticoid receptor (GR) was identified as a key regulator of proliferation and differentiation in normal erythroid progenitors, For this, the GR required to cooperate with endogenous receptor tyrosine kinases (c-Kit) and with the estrogen receptor (ER). Here, we demonstrate that v-ErbA can substitute for the ligand-activated GR and ER, inducing proliferation and arresting differentiation in the presence of specific GR and ER antagonists, Like the GR, v-ErbA required to cooperate with c-Kit for both proliferation induction and differentiation arrest, being devoid of biological activity in the absence of an active c-Kit, In self-renewing erythroblasts, v-ErbA not only repressed known v-ErbA target genes but also maintained high expression of c-myb, These biological activities of v-ErbA depended on distinct mutations in the DNA-binding domain, Additionally, v-ErbA acted as a partial, weak repressor of c-ErbA/TR alpha function in normal erythroblasts, It could be converted into a truly dominant-negative receptor by restoring its ability to heterodimerize with RXR.	VIENNA BIOCTR,INST MOL PATHOL,A-1030 VIENNA,AUSTRIA; KAROLINSKA INST,MED NOBEL INST,DEPT MOL & CELL BIOL,DEV BIOL LAB,S-17177 STOCKHOLM,SWEDEN	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Karolinska Institutet			Andersson Lendahl, Monika/ABE-5981-2021; von Lindern, Marieke/AAH-2350-2020	Andersson Lendahl, Monika/0000-0002-5690-8515				AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1994, CURR OPIN CELL BIOL, V6, P816, DOI 10.1016/0955-0674(94)90050-7; BEUG H, 1995, METHOD ENZYMOL, V254, P41; BEUG H, 1985, MODERN TRENDS HUMA 6, V29, P284; BIGLER J, 1994, MOL CELL BIOL, V14, P7621, DOI 10.1128/MCB.14.11.7621; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; CASINI T, 1995, ONCOGENE, V11, P1019; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CROWE AJ, 1991, J VIROL, V65, P6173; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUERSTENBERG S, 1990, J VIROL, V64, P5891, DOI 10.1128/JVI.64.12.5891-5902.1990; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; GANDRILLON O, 1994, ONCOGENE, V9, P749; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; HAYMAN MJ, 1992, CANCER SURV, V15, P53; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JANSSON M, 1987, ONCOGENE, V1, P167; KAHN P, 1984, P NATL ACAD SCI-BIOL, V81, P7122, DOI 10.1073/pnas.81.22.7122; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MADER S, 1993, J BIOL CHEM, V268, P591; Mellitzer G, 1996, P NATL ACAD SCI USA, V93, P9600, DOI 10.1073/pnas.93.18.9600; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; NAGL SB, 1995, MOL ENDOCRINOL, V9, P1522, DOI 10.1210/me.9.11.1522; NELSON CC, 1994, MOL ENDOCRINOL, V8, P829, DOI 10.1210/me.8.7.829; NIBBS RJB, 1993, MOL CELL BIOL, V13, P5582, DOI 10.1128/MCB.13.9.5582; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SANDE S, 1994, MOL ENDOCRINOL, V8, P1455, DOI 10.1210/me.8.11.1455; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SCHROEDER C, 1992, ONCOGENE, V7, P217; SCHWABE JWR, 1993, STRUCTURE, V1, P187, DOI 10.1016/0969-2126(93)90020-H; SELMI S, 1991, J BIOL CHEM, V266, P11589; SJOBERG M, 1995, MOL CELL BIOL, V15, P4718; SMITMCBRIDE Z, 1994, MOL ENDOCRINOL, V8, P819, DOI 10.1210/me.8.7.819; STEINLEIN P, 1995, CURR BIOL, V5, P191, DOI 10.1016/S0960-9822(95)00040-6; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; TomicCanic M, 1996, J BIOL CHEM, V271, P1416, DOI 10.1074/jbc.271.3.1416; TRUSS M, 1991, MOL CELL BIOL, V11, P3247, DOI 10.1128/MCB.11.6.3247; Wahlstrom GM, 1996, ONCOGENE, V13, P843; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; Wessely O, 1997, EMBO J, V16, P267, DOI 10.1093/emboj/16.2.267; WINBERGER C, 1986, NATURE, V324, P641; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZILLIACUS J, 1992, J BIOL CHEM, V267, P24941; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	82	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 7	1997	15	6					701	715		10.1038/sj.onc.1201208	http://dx.doi.org/10.1038/sj.onc.1201208			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP683	9264411	Bronze			2022-12-17	WOS:A1997XP68300010
J	Shao, ZH; Siegert, JL; Ruppert, S; Robbins, PD				Shao, ZH; Siegert, JL; Ruppert, S; Robbins, PD			Rb interacts with TAF(II)250/TFIID through multiple domains	ONCOGENE			English	Article						retinoblastoma protein; transcription factor TFIID; protein-protein interaction	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR; MOLECULAR-CLONING; TFIID COMPLEX; T-ANTIGEN; PROTEIN; BINDING; EXPRESSION; IDENTIFICATION; ACTIVATION	The retinoblastoma tumor suppressor gene product (Rb) binds directly to the largest TFIID subunit, TATA-binding protein associated factor TAF(II)250, first identified as the cell cycle regulatory protein CCG1. Here we map the domains in Rb and TAF(II)250 important for their interaction in vitro and in vivo. Both the amino terminus and the large pocket of Rb are able to associate independently with TAF(II)250. The binding domain(s) within the large pocket are distinct from the viral oncoprotein and E2F binding region since certain pocket mutations, which abolish E1A binding, do not abolish TAF(II)250 binding. Consistent with the large pocket of Rb binding to TAF(II)250, the large pocket domains of both p107 and p130 are able to bind to TAF(II)250 in vivo. We also demonstrate that at least two regions of TAF(II)250 are able to bind to the large pocket of Rb independently whereas the amino terminus of Rb binds to a distinct domain in TAF(II)250. We further demonstrate that Rb can bind to TFIID in vitro, presumably in part through an interaction with TAF(II)250. Our results suggest a complex interaction between Rb and TAF(II)250 and imply that TAF(II)250, TFIID, and potentially other basal transcription factors are targets for regulation by Rb and Rb-related proteins.	UNIV PITTSBURGH, SCH MED, DEPT MOL GENET & BIOCHEM, PITTSBURGH, PA 15261 USA; GENENTECH INC, DEPT MOL BIOL, San Francisco, CA 94080 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Roche Holding; Genentech					PHS HHS [55227] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Carrozza MJ, 1996, MOL CELL BIOL, V16, P3085; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRYJA TP, 1993, AM J HUM GENET, V52, P1122; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HAYASHIDA T, 1994, GENE, V141, P267; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MAYOL X, 1993, ONCOGENE, V8, P2561; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RUPPERT S, 1995, GENE DEV, V9, P2747, DOI 10.1101/gad.9.22.2747; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SEKIGUCHI T, 1995, EXP CELL RES, V218, P490, DOI 10.1006/excr.1995.1183; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAO Z, 1995, REGULATION TRANSCRIP; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	50	24	24	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	1997	15	4					385	392		10.1038/sj.onc.1201204	http://dx.doi.org/10.1038/sj.onc.1201204			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242374				2022-12-17	WOS:A1997XM23800002
J	Zhang, HT; Zhang, X; Zhao, HZ; Kajino, Y; Weber, BL; Davis, JG; Wang, Q; ORourke, DM; Zhang, HB; Kajino, K; Greene, MI				Zhang, HT; Zhang, X; Zhao, HZ; Kajino, Y; Weber, BL; Davis, JG; Wang, Q; ORourke, DM; Zhang, HB; Kajino, K; Greene, MI			Relationship of p215(BRCA1) to tyrosine kinase signaling pathways and the cell cycle in normal and transformed cells	ONCOGENE			English	Article						BRCA1; neu; EGFR; transformation	BREAST-CANCER; GROWTH-FACTOR; DNA-BINDING; BRCA1; PROTEIN; PHOSPHORYLATION; COMMON; LOCALIZATION; EXPRESSION; ONCOGENE	We have analysed the relationship of the products of two genes, neu and BRCA1, known to be important in human breast cancer, Highly specific antibodies that recognized both the rodent and human form of the BRCA1 gene product (M-r 215 kDa, p215(BRCA1)) were developed to facilitate these efforts, p215(BRCA1) was identified as a tyrosine phosphorylated protein primarily localized in the nucleus of several breast cancer cell lines, In transformed murine and human cells, levels of p215(BRCA1) tyrosine phosphorylation were inversely correlated with the activity of the erbB family receptor-tyrosine-kinases and with the transformed growth features of these cells, Regulation of p215(BRCA1) tyrosine phosphorylation was also related to events in the cell cycle, Increased levels of p215(BRCA1) phosphotyrosine content were observed in NIH3T3 cells arrested at the G(2)/M transition, These findings indicate that the products of BRCA1, neu, and erbB breast cancer genes participate in a common or shared signaling pathway important in cell growth and its regulation.	UNIV PENN,SCH MED,DEPT PATHOL & LAB,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT INTERNAL MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104; UNIV PENN,DIV NEUROSURG,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania			O'Rourke, Donald/AAC-3376-2021; Kajino, Kiichi/F-6873-2012; Wang, Qiang/N-7310-2015	Wang, Qiang/0000-0001-9409-0251; O'Rourke, Donald/0000-0002-8479-7314; Zhang, Hongtao/0000-0001-9173-0049				ABEL KJ, 1995, HUM MOL GENET, V4, P2265, DOI 10.1093/hmg/4.12.2265; ALTSCHUL SF, 1990, J MOL BIOL, V215, P195; Bennett L. M., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P514; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Davis JG, 1997, P NATL ACAD SCI USA, V94, P707, DOI 10.1073/pnas.94.2.707; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; Durocher F, 1996, HUM MOL GENET, V5, P835, DOI 10.1093/hmg/5.6.835; EASTON DF, 1995, AM J HUM GENET, V56, P265; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JARDINES L, 1993, PATHOBIOLOGY, V61, P268, DOI 10.1159/000163805; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Ormerod M.G., 1994, FLOW CYTOMETRY PRACT, P119; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; Qian XL, 1996, ONCOGENE, V13, P2149; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; Rao VN, 1996, ONCOGENE, V12, P523; REIFELMILLER AE, 1994, J BIOL CHEM, V269, P23861; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; Wilson CA, 1996, NAT GENET, V13, P264, DOI 10.1038/ng0796-264; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924	35	24	24	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 19	1997	14	24					2863	2869		10.1038/sj.onc.1201140	http://dx.doi.org/10.1038/sj.onc.1201140			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XF555	9205094				2022-12-17	WOS:A1997XF55500001
J	Simpson, S; Woodworth, CD; DiPaolo, JA				Simpson, S; Woodworth, CD; DiPaolo, JA			Altered expression of Erg and Ets-2 transcription factors is associated with genetic changes at 21q22.2-22.3 in immortal and cervical carcinoma cell lines	ONCOGENE			English	Article						ets and erg; pulsed field gel electrophoresis; papillomavirus HPV-16; cervical carcinoma	HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN EPITHELIAL-CELLS; HUMAN KERATINOCYTES; HUMAN CHROMOSOME-21; NEOPLASTIC TRANSFORMATION; PHYSICAL MAP; TEL GENE; DNA; RAS; TRANSLOCATION	Human Papillomavirus (HPV) type 16 is the most frequently detected HPV in cervical cancer. Although epidemiologic and experimental evidence indicates a prominent role for HPV infection in the development of this disease, other factors are also involved, Altered expression of the sts family transcription factors erg and ets-2 was found associated with the development of cervical carcinoma. Overexpression also occurred in a HPV-16-immortalized cervical cell line, CX16-2, which has HPV integrated at a translocation breakpoint t(19;21) involving 21q22.2-22.3, where these genes have been mapped. Six of 10 cervical carcinoma cell lines overexpressed ets-2 RNA suggesting an association of overexpression with cervical cell neoplasia. A clonally related pair of cervical carcinoma cell lines, C-4I and C-4II, showed differential expression of erg and ets-2. C-4I overexpressed ets-2 RNA compared to normal cervical cells and C-4II, C-4II expressed a 5.3 kb erg transcript not seen in C-4I, ectocervical cells or other cervical carcinoma cell lines examined. Pulsed field gel electrophoresis was used to analyse changes in DNA fragments related to structural changes and to construct a physical map encompassing erg and ets-2. Alterations in erg and ets-2 RNA expression in each of three different cell lines examined were associated,vith translocations. Association between altered expression of erg and ets-2 and altered regional structural suggests that these genes are important targets in cervical carcinogenesis.	NCI,BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BAYLIN SB, 1991, ABNORMAL PATTERNS DN; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BUIJS A, 1995, ONCOGENE, V10, P1511; CARLE GF, 1986, SCIENCE, V232, P65, DOI 10.1126/science.3952500; CHOMCZYNSKI P, 1992, ONE HOUR DOWNWARD AL; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; Crete N., 1993, European Journal of Human Genetics, V1, P51; DEBRAEKELEER M, 1992, CANCER GENET CYTOGEN, V59, P135, DOI 10.1016/0165-4608(92)90207-O; DENDUNNEN JT, 1991, APPL PULSED FIELD GE, P313; DIPAOLO JA, 1989, ONCOGENE, V4, P395; DIPAOLO JA, 1993, CRIT REV ONCOGENESIS, V4, P337; DOERFLER W, 1992, MALIGNANT TRANSFORMA, P143; DOERFLER W, 1983, DNA METHYLATION GENE, P93; DURST M, 1989, VIROLOGY, V173, P767, DOI 10.1016/0042-6822(89)90595-3; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FREEDMAN RS, 1982, IN VITRO CELL DEV B, V18, P719, DOI 10.1007/BF02796428; GARDINER K, 1988, SOMAT CELL MOLEC GEN, V14, P623, DOI 10.1007/BF01535316; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GRAVELL M, 1976, JNCI-J NATL CANCER I, V56, P701, DOI 10.1093/jnci/56.4.701; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HART AH, 1995, ONCOGENE, V10, P1423; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; JAMES GK, 1989, CANCER GENET CYTOGEN, V38, P53, DOI 10.1016/0165-4608(89)90165-9; JEON IS, 1995, ONCOGENE, V10, P1229; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MUNGER K, 1989, J VIROL, V63, P4417; NIBBS RJB, 1993, MOL CELL BIOL, V13, P5582, DOI 10.1128/MCB.13.9.5582; OCHMAN H, 1995, MAMM GENOME, V6, P84, DOI 10.1007/BF00303249; OHARA BM, 1987, MOL CELL BIOL, V7, P2941, DOI 10.1128/MCB.7.8.2941; PATIL N, 1994, HUM MOL GENET, V3, P1811, DOI 10.1093/hmg/3.10.1811; PAULIEN S, 1990, CANCER RES, V50, P7902; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; POPESCU NC, 1990, CANCER RES, V50, P1316; POPESCU NC, 1990, HUM GENET, V84, P383; POPESCU NC, 1995, INT J ONCOL, V7, P279; POPESCU NC, 1990, ONCOGENE RES, V5, P295; POUSTKA A, 1990, Methods (Orlando), V1, P204, DOI 10.1016/S1046-2023(05)80136-7; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; RICKLES R, 1982, P NATL ACAD SCI-BIOL, V79, P749, DOI 10.1073/pnas.79.3.749; RIOU G, 1988, ONCOGENE, V3, P329; ROYERPOKORA B, 1992, GENE CHROMOSOME CANC, V5, P132, DOI 10.1002/gcc.2870050207; Sambrook J., 1989, MOL CLONING; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SHIRASAWA H, 1987, J GEN VIROL, V68, P583, DOI 10.1099/0022-1317-68-2-583; TANZI RE, 1992, GENOMICS, V14, P498, DOI 10.1016/S0888-7543(05)80251-4; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; WATKINS PC, 1985, NUCLEIC ACIDS RES, V13, P6075, DOI 10.1093/nar/13.17.6075; WEN SC, 1995, EXP CELL RES, V217, P8, DOI 10.1006/excr.1995.1057; WOODWORTH CD, 1992, ONCOGENE, V7, P619; WOODWORTH CD, 1993, AM J PATHOL, V142, P1544; WOODWORTH CD, 1988, CANCER RES, V48, P4620; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	63	24	34	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 8	1997	14	18					2149	2157		10.1038/sj.onc.1201058	http://dx.doi.org/10.1038/sj.onc.1201058			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WX938	9174050				2022-12-17	WOS:A1997WX93800003
J	Dazard, JE; Augias, D; Neel, H; Mils, V; Marechal, V; BassetSeguin, N; Piette, J				Dazard, JE; Augias, D; Neel, H; Mils, V; Marechal, V; BassetSeguin, N; Piette, J			MDM-2 protein is expressed in different layers of normal human skin	ONCOGENE			English	Article						MDM-2; p53; keratinocyte; skin	SOFT-TISSUE SARCOMAS; WILD-TYPE P53; CELL-LINES; TRANSCRIPTIONAL ACTIVITY; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; ONCOPROTEIN MDM2; SUPPRESSOR GENE; MUTATIONS; ONCOGENE	MDM-2 is one of the target genes of the p53 tumor suppressor protein. Its best characterized function is found in the inhibition of p53's ability to modulate transcription. Deregulated expression of MDM-2 could thus at least partially substitute for p53 mutation in the process of tumorigenesis. We show here that MDM-2 is highly expressed in biopsies of normal human skin or in vitro reconstituted human skin. The protein is detected in the nucleus of keratinocytes throughout the different layers of the epidermis and in reconstituted skin as early as the two to three cell layer stage. The 90 kiloDalton (kD) protein is one of the major forms detected in Western blot experiments. MDM-2 is detected in skin reconstituted from keratinocytes in which p53 is inactivated by mutation or degradation by E6 protein, providing evidence that MDM-2 expression in the skin can occur in the absence of wild type p53. Moreover, we found no correlation between the p53 status and MDM-2 expression levels in a series of basal and squamous cell carcinomas or Bowen diseases. Our data provide first evidence for the expression of MDM-2 in a differentiated adult tissue.	INST GENET MOL,UMR 5535,F-34033 MONTPELLIER 01,FRANCE; IURC,LAB DERMATOL MOL,F-34033 MONTPELLIER 05,FRANCE; HOP ROTHSCHILD,MICROBIOL LAB,F-75571 PARIS 12,FRANCE	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Rothschild - APHP; UDICE-French Research Universities; Sorbonne Universite			marechal, vincent/P-7719-2017					ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BASSETSEGUIN N, 1990, J INVEST DERMATOL, V94, P418, DOI 10.1111/1523-1747.ep12874493; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CORDONCARDO C, 1994, CANCER RES, V54, P794; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HALL PA, 1993, ONCOGENE, V8, P203; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; LEACH FS, 1993, CANCER RES, V53, P2231; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; LUNA RMD, 1995, NATURE, V378, P203; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MOLES JP, 1993, ONCOGENE, V8, P583; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PARK DJ, 1994, ONCOGENE, V9, P1899; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PRUNIERAS M, 1983, J INVEST DERMATOL, V81, pS28, DOI 10.1111/1523-1747.ep12540324; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REISS M, 1992, ONCOL RES, V4, P349; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SPANDAU DF, 1994, ONCOGENE, V9, P1861; THEILLET C, 1989, ONCOGENE, V4, P915; WABER PG, 1993, CANCER RES, V53, P6028; WATANABE T, 1994, BLOOD, V84, P3158; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	45	24	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 6	1997	14	9					1123	1128		10.1038/sj.onc.1200922	http://dx.doi.org/10.1038/sj.onc.1200922			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070662				2022-12-17	WOS:A1997WM07000015
J	Kenck, C; Bugert, P; Wilhelm, M; Kovacs, G				Kenck, C; Bugert, P; Wilhelm, M; Kovacs, G			Duplication of an approximately 1.5 Mb DNA segment at chromosome 5q22 indicates the locus of a new tumour gene in nonpapillary renal cell carcinomas	ONCOGENE			English	Article						kidney cancer; chromosome 5q22; duplication	LUNG-CANCER; ALLELE LOSS; HEPATOCELLULAR-CARCINOMA; SUPPRESSOR-GENE; LINDAU DISEASE; HETEROZYGOSITY; MUTATIONS; MCC; APC; IDENTIFICATION	Previous karyotyping showed an unbalanced translocation between chromosome 3p11.2-p13 and chromosome 5q22 leading to duplication of chromosome 5q22-qter region in nonpapillary renal cell carcinomas. In order to determine the breakpoint at chromosome 5q22 at the molecular level, we have investigated 50 sporadic nonpapillary renal cell carcinomas from consecutive nephrectomies and 24 renal cell carcinomas obtained from two patients with von Hippel-Lindau disease. We used seven DNA markers mapped to and around the APC and MCC genes to detect allelic imbalance. We observed a duplication of chromosome 5q sequences in 11 of 23 informative sporadic tumours and in 18 of 24 hereditary tumours. We determined a breakpoint cluster between the APC and MCC genes at chromosome 5q22. In addition we have found a partial duplication of the smallest overlapping region of about 1.5 Mb sequences including the MCC gene in seven tumours without visible alteration of chromosome 5q in the karyotype. We suggest that this DNA segment harbours a gene or gene cluster, the altered dosage of which is important for the growth of nonpapillary renal cell carcinomas.	UNIV HEIDELBERG, DEPT UROL, CLIN RES GRP MOL ONCOL, D-69120 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg								AMLER LC, 1995, ONCOGENE, V10, P1095; ASHTONRICKARDT PG, 1991, ONCOGENE, V6, P1881; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P3385, DOI 10.1073/pnas.89.8.3385; CORVI R, 1995, CANCER RES, V55, P3471; CROSSEY PA, 1994, HUM GENET, V93, P53; DAMICO D, 1992, CANCER RES, V52, P1996; FONG KM, 1995, CANCER RES, V55, P220; FOSTER K, 1994, BRIT J CANCER, V69, P230, DOI 10.1038/bjc.1994.44; FUJIMORI M, 1991, CANCER RES, V51, P89; FUJIWARA Y, 1993, CANCER RES, V53, P857; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HORII A, 1992, CANCER RES, V52, P6696; HOSOE S, 1994, CANCER RES, V54, P1787; Kenck C, 1996, J PATHOL, V179, P157, DOI 10.1002/(SICI)1096-9896(199606)179:2<157::AID-PATH557>3.0.CO;2-S; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KOVACS G, 1991, GENE CHROMOSOME CANC, V3, P256, DOI 10.1002/gcc.2870030404; KOVACS G, 1991, P NATL ACAD SCI USA, V88, P194, DOI 10.1073/pnas.88.1.194; KOVACS G, 1989, CANCER RES, V49, P651; KOVACS G, 1993, ADV CANCER RES, V62, P89, DOI 10.1016/S0065-230X(08)60316-4; Moch H, 1996, CANCER RES, V56, P27; MORITA R, 1991, CANCER RES, V51, P5817; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PRESTI JC, 1991, CANCER RES, V51, P1544; THRASHBINGHAM CA, 1995, P NATL ACAD SCI USA, V92, P2854, DOI 10.1073/pnas.92.7.2854; TIAINEN M, 1992, GENE CHROMOSOME CANC, V4, P176, DOI 10.1002/gcc.2870040212; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	27	24	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	1997	14	9					1093	1098		10.1038/sj.onc.1200915	http://dx.doi.org/10.1038/sj.onc.1200915			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070658				2022-12-17	WOS:A1997WM07000011
J	Chen, CH; Nussenzweig, A; Guo, M; Kim, D; Li, GC; Ling, CC				Chen, CH; Nussenzweig, A; Guo, M; Kim, D; Li, GC; Ling, CC			Down-regulation of gadd153 by c-myc in rat fibroblasts and its effect on cell growth and radiation-induced apoptosis	ONCOGENE			English	Article						c-myc; gadd153; growth arrest; apoptosis	DNA-DAMAGING AGENTS; MESSENGER-RNA; DIFFERENTIAL DISPLAY; GENOTOXIC STRESS; EMBRYO CELLS; GENE; PROTEIN; ARREST; BCL-2; INDUCTION	Using differential display reverse transcription PCR (DDRT-PCR), we found that a 360 bp cDNA fragment was absent in several c-myc transfected rat fibroblasts: REC:myc, REC:myc + ras and rat1-myc. These cells also showed enhanced sensitivity to gamma ray-induced apoptosis. This cDNA fragment was present in the parental REC (Rat Embryo Cells) and rat1 cells, and in c-Ha-ras transfected REC (REC:ras), all of which were relatively resistant to gamma ray-induced apoptosis. The cDNA fragment was subsequently cloned and used as a probe to screen a rat1 cDNA library, and identified as one of the growth arrest and DNA damaging-inducible genes, gadd153. In addition to the down-regulation of rat gadd153 in all the c-myc transfectants, methyl methanesulfonate (MMS)-induced transcription of the gadd153 was attenuated. The rat1-myc cells, when successfully transfected with and stably expressing the rat gadd153, showed a significantly longer doubling time compared to the parental cells. However, overexpression of gadd153 in rat1-myc cells did not affect gamma ray-induced apoptosis. Thus, the suppression of gadd153 appears to be inversely correlated with that of myc, but not involved in the myc-dependent apoptotic pathway.	MEM SLOAN KETTERING CANC CTR, DEPT MED PHYS, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Chen, CH (corresponding author), MEM SLOAN KETTERING CANC CTR, LAB RADIAT BIOPHYS, 1275 YORK AVE, NEW YORK, NY 10021 USA.				NATIONAL CANCER INSTITUTE [R01CA052713] Funding Source: NIH RePORTER; NCI NIH HHS [CA52713] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; ASKEW DS, 1991, ONCOGENE, V6, P1915; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BAUER D, 1993, NUCLEIC ACIDS RES, V21, P4272, DOI 10.1093/nar/21.18.4272; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CHEN CH, 1994, RADIAT RES, V139, P307, DOI 10.2307/3578828; CHOI AMK, 1992, EXP CELL RES, V199, P85, DOI 10.1016/0014-4827(92)90464-J; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ENDLICH B, 1992, RADIAT RES, V132, P301, DOI 10.2307/3578238; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FISHER TC, 1993, CANCER RES, V53, P3321; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; GATELY DP, 1994, BRIT J CANCER, V70, P1102, DOI 10.1038/bjc.1994.455; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; JACKMAN J, 1994, CANCER RES, V54, P5656; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KORSMEYER SJ, 1992, CANCER SURV, V15, P105; LAND H, 1983, NATURE, V297, P474; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LING CC, 1989, RADIAT RES, V120, P267, DOI 10.2307/3577713; LOKE SL, 1988, CURR TOP MICROBIOL, V141, P282; LORD KA, 1990, ONCOGENE, V5, P387; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MIYASHITA T, 1993, BLOOD, V81, P151; MIYASHITA T, 1992, CANCER RES, V52, P5407; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; PRICE BD, 1992, CANCER RES, V52, P3814; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SUN Y, 1994, CANCER RES, V54, P1139; WYLLIE AH, 1992, CANCER METAST REV, V11, P95, DOI 10.1007/BF00048057; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	48	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1659	1665						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895511				2022-12-17	WOS:A1996VM88700010
J	Krishnan, K; Yan, H; Lim, JTE; Krolewski, JJ				Krishnan, K; Yan, H; Lim, JTE; Krolewski, JJ			Dimerization of a chimeric CD4-interferon-alpha receptor reconstitutes the signaling events preceding STAT phosphorylation	ONCOGENE			English	Article						interferon; signaling; receptor; tyrosine phosphorylation; STAT	INTERFERON-ALPHA RECEPTOR; PROTEIN-TYROSINE KINASE; GROWTH-FACTOR RECEPTOR; TRANSCRIPTION FACTOR; TRANSDUCTION; CLONING; FAMILY; MEMBER; MPL	Interferon-alpha induces the rapid tyrosine phosphorylation of a number of molecules, including the cognate receptors, JAK-family kinases (Jak1 and tyk2), and latent transcription factors (STATs 1 and 2), Here, we describe the use of chimeric molecules composed of the extracellular domain of CD4 fused to the intracellular domain of the interferon-alpha receptor subunit 1 (IFNaR1), Antibody mediated crosslinking dimerizes the transfected chimeras, activates tyk2 and induces a tyk2-dependent tyrosine phosphorylation of the intracellular domain of the chimera, We further define the major site of IFNaR1 phosphorylation, and show that phosphorylation of this site is required for association with STAT2, Finally, we show that homodimerization of IFNaR1 is not sufficient to activate the STATs, suggesting a role for the IFNaR2 subunit and Jak1 in the transduction of the interferon-alpha signal.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CTR CANC,NEW YORK,NY 10032	Columbia University; Columbia University					NATIONAL CANCER INSTITUTE [R01CA056862] Funding Source: NIH RePORTER; NCI NIH HHS [CA56862] Funding Source: Medline; NIGMS NIH HHS [GM07367] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVICH C, 1994, EMBO J, V13, P5871, DOI 10.1002/j.1460-2075.1994.tb06932.x; BARBIERI G, 1994, EUR J BIOCHEM, V223, P427, DOI 10.1111/j.1432-1033.1994.tb19010.x; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COLAMONICI OR, 1991, PHARMACOL THERAPEUT, V52, P227, DOI 10.1016/0163-7258(91)90010-J; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Davis E, 1996, LEUKEMIA, V10, P543; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GUPTA S, 1996, EMBO J, V15; HANRATTY WP, 1993, MOL GEN GENET, V238, P33, DOI 10.1007/BF00279527; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; LEE AW, 1990, P NATL ACAD SCI USA, V87, P7270, DOI 10.1073/pnas.87.18.7270; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PLATANIAS LC, 1994, J BIOL CHEM, V269, P17761; Sambrook J, 1989, MOL CLONING LAB MANU; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; SOH JM, 1994, J BIOL CHEM, V269, P18102; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; SUDOL M, 1993, NONRECEPTOR TYROSINE, P203; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; UZE G, 1995, J INTERF CYTOK RES, V15, P3, DOI 10.1089/jir.1995.15.3; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; VIGON I, 1993, ONCOGENE, V8, P2607; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; YAN H, 1995, ANAL BIOCHEM, V231, P455, DOI 10.1006/abio.1995.0080; Yan H, 1996, MOL CELL BIOL, V16, P2074	43	24	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					125	133						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700538				2022-12-17	WOS:A1996UX31900014
J	Rohde, M; Warthoe, P; Gjetting, T; Lukas, J; Bartek, J; Strauss, M				Rohde, M; Warthoe, P; Gjetting, T; Lukas, J; Bartek, J; Strauss, M			The retinoblastoma protein modulates expression of genes coding for diverse classes of proteins including components of the extracellular matrix	ONCOGENE			English	Article						retinoblastoma protein; gene regulation; thrombospondin; endothelin; differential display; DDRT-PCR	TRANSFORMING GROWTH FACTOR-BETA-1; CELL-CYCLE; SUSCEPTIBILITY GENE; MESSENGER-RNA; DIFFERENTIAL DISPLAY; BINDING PROTEIN; PRODUCT; TRANSCRIPTION; SEQUENCE; CLONING	The product of the retinoblastoma susceptibility gene, pRb, is a negative regulator of cell growth. It functions by regulating the activity of transcription factors. Rb represses some genes by sequestering or inactivating the positive transcription factor E2F and seems to activate some others by interacting with factors like Spl or ATF-2, However, there are only a few examples of genes which are positively regulated by pRb. In order to find out if there are common mechanisms for promoter regulation by pRb, we were interested to identify more genes which are either stimulated or repressed by pRb, Using the method of differential display (DDRT-PCR) in combination with nuclear run-on analyses we were able to detect a number of genes which are upregulated by ectopic expression of the Rb gene in Rb-deficient mammary carcinoma cells, We could demonstrate not only stimulation of the endogenous mutant Rb gene but also positive regulation of genes coding for diverse classes of proteins, including the endothelial growth and the proteoglycans versican and PG40, As a second approach, we investigated gene expression in cell lines established from Rb deficient heterozygous and homozygous knockout mouse embryos and normal mice, We have identified several genes the expression of which correlates positively or negatively with the presence of Rb. These data provide further evidence for pRb being a master regulator of a complex network of gene activities defining the difference between dividing and resting or differentiated cells.	DANISH CANC SOC,DIV TUMOR BIOL,DEPT CELL CYCLE & CANC,DK-2100 COPENHAGEN,DENMARK; HUMBOLDT UNIV BERLIN,MPG GRP,MAX DELBRUCK CTR MOLEC MED,D-13122 BERLIN,GERMANY	Danish Cancer Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin			Gjetting, Torben/A-6066-2012	Lukas, Jiri/0000-0001-9087-506X; Warthoe, peterwarthoe@gmail.com/0000-0003-3840-5460				BALEY PA, 1990, J CLIN INVEST, V85, P1320, DOI 10.1172/JCI114570; BARTEK J, 1992, ONCOGENE, V7, P101; Bauer D, 1994, PCR Methods Appl, V4, pS97; BAUER D, 1993, NUCLEIC ACIDS RES, V21, P4272, DOI 10.1093/nar/21.18.4272; BLOCH KD, 1989, J BIOL CHEM, V264, P10851; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; ECONOMOS K, 1992, CANCER RES, V52, P554; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; FRAMSON P, 1993, J BIOL CHEM, V268, P4989; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GILL RM, 1994, CELL GROWTH DIFFER, V5, P467; GJETTING T, 1995, BIOL CHEM H-S, V376, P441; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUNG YK, 1987, SCIENCE, V236, P1675; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; INOUE A, 1989, J BIOL CHEM, V264, P14954; IRUELAARISPE ML, 1993, DEV DYNAM, V197, P40, DOI 10.1002/aja.1001970105; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LAHAV J, 1993, BIOCHIM BIOPHYS ACTA, V1182, P1, DOI 10.1016/0925-4439(93)90146-R; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; Lee Hu-Hui, 1995, Gene Expression, V4, P95; LEE ME, 1990, J BIOL CHEM, V265, P10446; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LIANG P, 1995, IN PRESS METHODS ENZ; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NASO MF, 1994, J BIOL CHEM, V269, P32999; PARK K, 1994, J BIOL CHEM, V269, P6083; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SCHONHERR E, 1991, J BIOL CHEM, V266, P17640; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; STRAUSS M, 1990, ONCOGENE, V5, P1223; STRAUSS M, 1995, NAT MED, V1, P1245, DOI 10.1038/nm1295-1245; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; Warthoe Peter, 1995, P421; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WOLF YG, 1994, J CLIN INVEST, V93, P1172, DOI 10.1172/JCI117070; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	70	24	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2393	2401						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649780				2022-12-17	WOS:A1996UQ22000017
J	Aoki, T; Sano, Y; Yamamoto, T; Inoue, J				Aoki, T; Sano, Y; Yamamoto, T; Inoue, J			The ankyrin repeats but not the PEST-like sequences are required for signal-dependent degradation of I kappa B alpha	ONCOGENE			English	Article						ankyrin repeats; degradation; I kappa-B; PEST sequence; phosphorylation	TUMOR-NECROSIS-FACTOR; DNA-BINDING; TRANSCRIPTION FACTORS; PRECURSOR P105; ACTIVATION; REL; PHOSPHORYLATION; I-KAPPA-B/MAD-3; ASSOCIATION; EXPRESSION	The nuclear activity of Rel/NF kappa B transcription factors is tightly regulated from the cytoplasmic compartment by an inhibitory subunit called I kappa B alpha. I kappa B alpha is rapidly phosphorylated and degraded in response to the stimulation through tumor necrosis factor alpha (TNF alpha) receptor, interleukin-1 receptor or CD40. To explore the molecular mechanisms of signal-induced depletion of I kappa B alpha, we have delineated the domain in I kappa B alpha that is required for TNF alpha-induced phosphorylation and rapid degradation of I kappa B alpha. In contrast to the previous reports, the PEST-like sequences, which are present in the carboxyl-terminal region of I kappa B alpha, are demonstrated here to be dispensable for TNF alpha-induced degradation but could be required for signal-independent degradation, as in the case of Cactus, Drosophila homologue of I kappa B. Furthermore, the ankyrin repeats, which are essential for forming a complex with Rel and RelA, are required for TNF alpha-induced degradation suggesting that the putative I kappa B protease could interact with I kappa B alpha in complex with RelA or could recognize the structure of ankyrin repeats. Our data also indicate that neither the ankyrin repeats nor the PEST-like sequences, are essential for TNF alpha-induced phosphorylation.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN	University of Tokyo								ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BAUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141; BAUERLE PA, 1988, SCIENCE, V242, P540; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; ERNST MK, 1995, MOL CELL BIOL, V15, P872; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RODIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	43	24	24	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1159	1164						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649809				2022-12-17	WOS:A1996UA88400026
J	Das, R; Reddy, EP; Chatterjee, D; Andrews, DW				Das, R; Reddy, EP; Chatterjee, D; Andrews, DW			Identification of a novel Bcl-2 related gene, BRAG-1, in human glioma	ONCOGENE			English	Article						apoptosis; Bcl-2; BRAG-1; glioma	APOPTOTIC CELL-DEATH; RNA; PROTEIN	Programmed cell death (apoptosis) plays a major role in embryogenesis, in mature organ homeostasis and in many disease states including cancer. Apoptosis occurs as an orderly cell-intrinsic suicide program regulated by a family of genes related to Bcl-2. Here, we describe the cloning and molecular characterization of a gene homologous to Bcl-2 from a human glioma. This gene named BRAG-1 (for brain-related apoptosis gene) has an open reading frame that encodes for a protein of 31 kDa sharing significant sequence homology with the Bcl-2 family of genes in the BH1 and BH2 regions. Northern blot analyses revealed that BRAG-1 is expressed in human gliomas as a 1.8 kb message. This gene, interestingly, was found to be expressed predominantly in normal human brain as a 4.5 kb transcript which is different in size from the message found in tumor tissues. These results suggest that BRAG-1 may be rearranged in human gliomas leading to its over-expression as a truncated transcript. Utilizing a bacterial expression vector, we produced BRAG-1 protein which was found to cross-react with a Bcl-2 monoclonal antibody, further suggesting structural and immunological similarity to Bcl-2.	THOMAS JEFFERSON UNIV HOSP, WILLS NEUROSENSORY INST, DEPT NEUROSURG, NEUROONCOL LAB, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV HOSP, JEFFERSON CANC INST, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, HLTH SCI CTR, SCH MED, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA	Jefferson University; Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [K11CA001514] Funding Source: NIH RePORTER; NCI NIH HHS [NIHK11-CA01514] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDERSON LM, 1995, CANCER RES, V55, P999; ANDREWS AT, 1986, MONOGRAPHS PHYSICAL; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHOI SS, 1995, ONCOGENE, V11, P1693; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FARWELL J, 1984, NEW ENGL J MED, V311, P749, DOI 10.1056/NEJM198409203111201; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; LIN EY, 1993, J IMMUNOL, V151, P1979; MALONE M, 1986, CANCER, V57, P1979, DOI 10.1002/1097-0142(19860515)57:10<1979::AID-CNCR2820571016>3.0.CO;2-R; Maniatis T., 1982, MOL CLONING; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RICCIARDI RP, 1977, P NATL ACAD SCI USA, V74, P5461; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	28	24	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					947	951						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649811				2022-12-17	WOS:A1996UA88400001
J	Lovric, J; Moelling, K				Lovric, J; Moelling, K			Activation of Mil/Raf protein kinases in mitotic cells	ONCOGENE			English	Article						Mil/Raf kinases; phosphorylation; cell cycle; mitosis	MAP-KINASE; TYROSINE PHOSPHORYLATION; RAF-1 KINASE; V-RAF; C-MYC; ONCOGENE; CYCLE; EXPRESSION; C-RAF-1; DOMAIN	The c-Raf-1 protein kinase is a major element of several signal transduction pathways and thought to be involved in entry into the S phase of the cell cycle. Here we show that c-Raf-1 as well as the transforming viral fusion protein Gag-Mil, in which most of the amino terminal regulatory region of the avian Raf homologue Mil is deleted, are activated five- to sixfold in mitotic cells. Mitotic activation of Mil/Raf kinase activity correlates with reduced electrophoretic mobility caused by hyperphosphorylation at serine/threonine residues located in the carboxy terminal part of c-Raf-1. Mitotic hyperphosphorylation occurs in various cell-lines indicating that it is ubiquitous. Our data suggest a novel function for Mil/Raf kinases in late stages of the cell cycle.	UNIV ZURICH, INST MED VIROL, CH-8028 ZURICH, SWITZERLAND	University of Zurich				Lovric, Josip/0000-0002-0338-6581				ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; BAGRODIA S, 1994, J BIOL CHEM, V269, P10247; BOOTSMA D, 1964, EXP CELL RES, V33, P301, DOI 10.1016/S0014-4827(64)81035-1; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUSCHER D, 1993, ONCOGENE, V8, P3323; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DENHEZ F, 1988, EMBO J, V7, P541, DOI 10.1002/j.1460-2075.1988.tb02843.x; DURKIN JP, 1987, MOL CELL BIOL, V7, P444, DOI 10.1128/MCB.7.1.444; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GUILLOUF C, 1995, ONCOGENE, V10, P2263; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HIROYUKI T, 1992, J BIOL CHEM, V267, P20293; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JAMAL S, 1995, ONCOGENE, V10, P2095; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; LOVRIC J, 1994, FEBS LETT, V343, P15, DOI 10.1016/0014-5793(94)80598-9; MAMON H, 1991, COLD SH Q B, V56, P251; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MUSZYNSKI KW, 1995, J EXP MED, V181, P2189, DOI 10.1084/jem.181.6.2189; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; RADZIWILL G, 1995, P NATL ACAD SCI USA, V92, P1421, DOI 10.1073/pnas.92.5.1421; RAPP UR, 1988, HDB ONCOGENES, P213; SCHRAMM K, 1994, BIOCHEM BIOPH RES CO, V201, P740, DOI 10.1006/bbrc.1994.1763; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SUTRAVE P, 1984, NATURE, V309, P85, DOI 10.1038/309085a0; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; TURNER BC, 1993, P NATL ACAD SCI USA, V90, P5544, DOI 10.1073/pnas.90.12.5544; WARENIUS HM, 1994, EUR J CANCER, V30A, P369, DOI 10.1016/0959-8049(94)90258-5; WEDONG H, 1993, P NATL ACAD SCI USA, V90, P10947; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	44	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					1109	1116						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649803				2022-12-17	WOS:A1996UA88400020
J	Dorin, D; Cohen, L; DelVillar, K; Poullet, P; Mohr, R; Whiteway, M; Witte, O; Tamanoi, F				Dorin, D; Cohen, L; DelVillar, K; Poullet, P; Mohr, R; Whiteway, M; Witte, O; Tamanoi, F			Kir, a novel ras-family G-protein, induces invasive pseudohyphal growth in Saccharomyces cerevisiae	ONCOGENE			English	Article						Ras-family G-protein; Saccharomyces cerevisiae; pseudohyphae; MAP kinase cascade	PHEROMONE RESPONSE PATHWAY; FILAMENTOUS GROWTH; YEAST; SUBUNITS; ELEMENTS; HOMOLOG; DOMAIN; GENE; IRA2	Kir belongs to a novel class of Ras-family G-proteins which includes Gem and Rad, These proteins are unique among Ras super-family G-proteins since their expression is under transcriptional regulation in mammalian cells, To gain insight into the function of Kir, we took advantage of the well-defined signal transduction pathways of yeast, When kir is expressed in Saccharomyces cerevisiae, the transformants form pseudohyphae and exhibit invasive properties characteristic of yeast cells are undergoing a developmental transition induced by GTPase nitrogen starvation, Analysis of pseudohyphal signaling pathway mutants suggests that the Kir-induced pseudohyphae formation requires a MAP kinase cascade involving ste20, ste11, ste7 but not ste5 gene products, Furthermore, our results are consistent with the idea that Kir functions upstream of the STE20 kinase which plays a critical role in two distinct MAP kinase cascades.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90095 USA; NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, MONTREAL, PQ H4P 2R2, CANADA	University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; National Research Council Canada					NATIONAL CANCER INSTITUTE [R01CA041996, R35CA053867] Funding Source: NIH RePORTER; NCI NIH HHS [CA53867, CA41996] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; COHEN L, 1994, P NATL ACAD SCI USA, V91, P12448, DOI 10.1073/pnas.91.26.12448; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; NOMOTO S, 1990, EMBO J, V9, P691, DOI 10.1002/j.1460-2075.1990.tb08161.x; QADOTA H, 1994, P NATL ACAD SCI USA, V91, P9317, DOI 10.1073/pnas.91.20.9317; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; SHERMAN F, 1986, FMETHODS YEAST GENET, P153; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; TANAKA K, 1992, MOL CELL BIOL, V12, P631, DOI 10.1128/MCB.12.2.631; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WRIGHT RM, 1993, CURR GENET, V23, P388, DOI 10.1007/BF00312623; ZHU JH, 1995, J BIOL CHEM, V270, P4805, DOI 10.1074/jbc.270.9.4805	24	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2267	2271						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570176				2022-12-17	WOS:A1995TK70200009
J	MORGAN, IM; HAVARSTEIN, LS; WONG, WY; LUU, P; VOGT, PK				MORGAN, IM; HAVARSTEIN, LS; WONG, WY; LUU, P; VOGT, PK			EFFICIENT INDUCTION OF FIBROSARCOMAS BY V-JUN REQUIRES MUTATIONS IN THE DNA-BINDING REGION AND THE TRANSACTIVATION DOMAIN	ONCOGENE			English	Article							C-JUN; TRANSCRIPTIONAL ACTIVATION; NUCLEAR-PROTEIN; LEUCINE ZIPPER; FOS; TRANSFORMATION; ONCOGENE; AP-1; DELTA	v-jun is the transforming gene of ASV 17, a retrovirus isolated from a spontaneous chicken fibrosarcoma. There are three mutations in the viral Jun protein (v-Jun) as compared to its cellular progenitor c-Jun: a deletion in the transactivation domain (called delta) and two amino acid substitutions in and near the DNA binding region. The effect of each of these mutations on fibrosarcoma development is described. All three mutations contribute towards tumor formation, and their cumulative effect makes v-Jun more tumorigenic compared to Jun proteins that carry only one or two of the mutations. Viruses rescued from tumors induced by c-Jun carrying the two amino acid substitutions in the DNA binding region have increased transforming and tumorigenic potential. These increases are probably due to further mutations that result in the expression of a rearranged Jun protein. Taken together the results show that the evolution of the c-Jun oncoprotein to an efficient carcinogen requires mutations in the transactivation and DNA binding regions.	NLVF, MICROBIAL GENE THERAPY LAB, AS, NORWAY; UNIV SO CALIF, LOS ANGELES CTY MED CTR, DEPT PEDIAT, LOS ANGELES, CA 90033 USA; TULARIK INC, San Francisco, CA 94080 USA	University of Southern California	MORGAN, IM (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500; Havarstein, Leiv Sigve/0000-0001-8250-4322	NCI NIH HHS [CA 42564] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; ANGEL P, 1989, New Biologist, V1, P35; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; FRAME MC, 1991, ONCOGENE, V6, P205; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MORGAN IM, 1993, ONCOGENE, V8, P1135; MORGAN IM, 1992, ONCOGENE, V7, P1119; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIMURA T, 1988, ONCOGENE, V3, P659; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WONG WY, 1992, ONCOGENE, V7, P2077; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	24	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					2793	2797						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084584				2022-12-17	WOS:A1994PG82200004
J	KUNDRA, V; SOKER, S; ZETTER, BR				KUNDRA, V; SOKER, S; ZETTER, BR			EXCESS EARLY SIGNALING ACTIVITY INHIBITS CELLULAR CHEMOTAXIS TOWARD PDGF-BB	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; SIMIAN SARCOMA-VIRUS; V-SIS; PHOSPHATIDYLINOSITOL-3 KINASE; TYROSINE KINASES; PROTEIN-KINASES; TRANSFORMATION; ONCOGENE; SRC; TRANSDUCTION	Chemotaxis, directed migration toward a gradient of a soluble substance, requires a cell to spatially distinguish the concentration of a chemoattractant at one end relative to its opposite end. Platelet-derived growth factor (PDGF) is a potent mitogen and chemoattractant. In the current study, we attempted to interfere with PDGF-BB mediated chemotaxis by abnormal expression of potential early components of the signaling cascade. We find that expression of the PDGF homolog v-Sis prevents cellular migration toward PDGF-BB, indicating that autocrine production of a PDGF receptor ligand will prevent the chemotactic response to exogenously added ligand. In addition, while it is known that PDGF receptor mutants incapable of activating tyrosine kinase activity cannot transduce a signal for mitogenesis or chemotaxis, the effects of excess tyrosine kinase activity on PDGF mediated chemotaxis have not been tested. We demonstrate that cells expressing constitutively active tyrosine kinase genes such as v-fms, v-fes, or v-src fail to migrate toward PDGF-BB whereas expression of the serine/threonine kinase v-mos does not block the chemotactic response. The results demonstrate that chemotaxis may be prevented by excess production of either ligand, receptor activity, or downstream signaling molecule. In addition, our results show that the signals that mediate chemotaxis are separable from those that regulate unstimulated random motility in the same cells.	HARVARD UNIV, CHILDRENS HOSP, SCH MED, PROGRAM BIOL & BIOMED SCI, BOSTON, MA 02115 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT SURG, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA037393, R37CA037393] Funding Source: NIH RePORTER; NCI NIH HHS [CA37393] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; ESCOBEDO JA, 1988, MOL CELL BIOL, V8, P5126, DOI 10.1128/MCB.8.12.5126; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; FUKUI Y, 1991, ONCOGENE, V6, P407; GROTENDORST GR, 1981, P NATL ACAD SCI-BIOL, V78, P3669, DOI 10.1073/pnas.78.6.3669; GROTENDORST GR, 1984, CELL, V36, P279, DOI 10.1016/0092-8674(84)90221-6; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HEIDARAN MA, 1991, MOL CELL BIOL, V11, P134, DOI 10.1128/MCB.11.1.134; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; Kaplan D R, 1992, Cancer Treat Res, V63, P265; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEE BA, 1992, J CELL BIOL, V118, P1057, DOI 10.1083/jcb.118.5.1057; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; QUI F, 1988, EMBO J, V7, P1003; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; SEPPA H, 1982, J CELL BIOL, V92, P584, DOI 10.1083/jcb.92.2.584; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; STROOBANT P, 1984, EMBO J, V3, P2963, DOI 10.1002/j.1460-2075.1984.tb02241.x; SUDOL M, 1993, NEUROCHEM INT, V22, P369, DOI 10.1016/0197-0186(93)90019-2; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; YOUNG JC, 1984, J VIROL, V52, P913, DOI 10.1128/JVI.52.3.913-918.1984	36	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1994	9	5					1429	1435						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152804				2022-12-17	WOS:A1994NH40100015
J	SASSANO, M; GRANUCCI, F; SEVESO, M; MARCONI, G; FOTI, M; RICCIARDICASTAGNOLI, P				SASSANO, M; GRANUCCI, F; SEVESO, M; MARCONI, G; FOTI, M; RICCIARDICASTAGNOLI, P			MOLECULAR-CLONING OF A RECOMBINANT RETROVIRUS CARRYING A MUTATED ENV(AKR)-MYC(MH2) FUSION GENE IMMORTALIZING CELLS OF THE MONOCYTIC-MACROPHAGE LINEAGE	ONCOGENE			English	Note							V-MYC; DNA-BINDING; MYELOMONOCYTIC CELLS; NUCLEOTIDE-SEQUENCE; MURINE RETROVIRUSES; MOUSE MACROPHAGE; LEUKEMIA VIRUSES; TARGET-CELLS; DIFFERENTIATION; ACTIVATION	The VN-11 recombinant retroviruses, originally generated by co-transfection of the avian MH2 and AKRv viral genomes, were molecularly cloned from an infected mouse cell line named N11. The analysis of the proviral genome sequence from one of these recombinants showed a possible env(AKR)-myc(MH2) fusion. Point mutations were also found in this env(AKR)-myc(MH2) gene. The cloned viral genome was co-transfected with the neo gene into the psi 2 packaging cell line. Selected clones were shown to transcribe the viral genome and supernatants from these cultures, containing C-type particles, were used to infect primary cultures from mouse lymphoid tissues and brain. Proliferating macrophages and microglial cell clones were obtained, indicating that various types of cells of the mouse monocytic-macrophage lineage can be immortalized in spite of the absence of selection or special growth conditions.	UNIV MILAN,CTR CYTOPHARMACOL,CNR,I-20129 MILAN,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Milan			GRANUCCI, Francesca/K-6150-2019	FOTI, MARIA/0000-0002-4481-1900; granucci, francesca/0000-0002-7046-4914				ANDERSON SM, 1985, MOL CELL BIOL, V5, P3369, DOI 10.1128/MCB.5.12.3369; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BEUG H, 1979, CELL, V18, P559; BICHENALLROBERT.MC, 1989, ONCOGENE, V4, P731; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; CHISHOLM O, 1992, ONCOGENE, V7, P1827; DUESBERG PH, 1979, P NATL ACAD SCI USA, V76, P1633, DOI 10.1073/pnas.76.4.1633; GAZZOLO L, 1979, CELL, V16, P627, DOI 10.1016/0092-8674(79)90036-9; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; KAN NC, 1984, P NATL ACAD SCI-BIOL, V81, P3000, DOI 10.1073/pnas.81.10.3000; KERKHOFF E, 1991, ONCOGENE, V6, P93; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, EMBO J, V10, P837, DOI 10.1002/j.1460-2075.1991.tb08016.x; MIN SY, 1992, ONCOGENE, V7, P1531; PIRAMI L, 1991, P NATL ACAD SCI USA, V88, P7543, DOI 10.1073/pnas.88.17.7543; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RICCIARDICASTAGNOLI P, 1992, RES IMMUNOL, V143, P101, DOI 10.1016/0923-2494(92)80086-Z; RIGHI M, 1989, ONCOGENE, V4, P223; RIGHI M, 1991, ONCOGENE, V6, P103; SYMONDS G, 1989, ONCOGENE, V4, P285; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7	27	24	25	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1473	1477						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152810				2022-12-17	WOS:A1994NH40100021
J	GRIMES, HL; AMBROSE, MR; GOODENOW, MM				GRIMES, HL; AMBROSE, MR; GOODENOW, MM			C-SKI TRANSCRIPTS WITH AND WITHOUT EXON-2 ARE EXPRESSED IN SKELETAL-MUSCLE AND THROUGHOUT CHICK EMBRYOGENESIS	ONCOGENE			English	Note							ONCOGENE; TRANSFORMATION; GENE; DIFFERENTIATION; ACTIVATION; VIRUSES; QUAIL; CDNAS	Overexpression of v-ski or c-ski cDNAs has a pronounced effect on proliferation, morphological transformation and myogenic differentiation in cells in culture and in transgenic animals. Yet, little is known about expression of the c-ski locus or the relationship between c-ski cDNAs and alternatively spliced c-ski transcripts in chicken tissues, particularly in skeletal muscle or during embryogenesis. We developed a series of probes and oligonucleotide primers specific for the eight coding exons and the long 3' noncoding region found in chicken c-ski mRNAs. The most abundant chicken c-ski mRNAs in a vast array of tissues are 8.5 kb, with additional, but less abundant, mRNAs of 7.5, 6.5 and 4.4 kb. Steady-state levels of c-ski mRNAs, indistinguishable from transcripts in other tissues, accumulate in skeletal muscle from embryonic, newly hatched, and adult chicks. Only exon 2, a small exon of 111 bp, was found to be alternatively spliced in c-ski mRNAs. Transcripts with and without exon 2 appear in all tissues, in somites, and from the earliest stages of chick embryogenesis. Thus, c-ski cDNA sequences, which extend about 4.3 kb, represent either the least abundant form of c-ski mRNAs in tissues or a severely truncated form of the major 8.5 kb transcripts.	UNIV FLORIDA,COLL MED,GRAD PROGRAM IMMUNOL & MOLEC PATHOL,BOX 100275,GAINESVILLE,FL 32610; UNIV FLORIDA,COLL MED,DEPT PATHOL,GAINESVILLE,FL 32610; UNIV FLORIDA,COLL MED,DEPT PEDIAT,DIV IMMUNOL,GAINESVILLE,FL 32610; UNIV FLORIDA,COLL MED,CTR MAMMALIAN GENET,GAINESVILLE,FL 32610	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida				Grimes, H. Leighton/0000-0001-8162-6758	NCI NIH HHS [T32 CA09126] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009126] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEESON D, 1990, EMBO J, V9, P2101, DOI 10.1002/j.1460-2075.1990.tb07378.x; BOTTAZZI ME, 1993, ONCOGENE, V8, P731; BOYER PL, 1993, ONCOGENE, V8, P457; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLAYCOMB WC, 1987, BIOCHEM J, V247, P701, DOI 10.1042/bj2470701; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GOODENOW MM, 1987, J VIROL, V87, P2489; GRIMES HL, 1992, NUCLEIC ACIDS RES, V20, P1511, DOI 10.1093/nar/20.7.1511; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; LARSEN J, 1992, ONCOGENE, V7, P1903; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P435; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; SLEEMAN JP, 1993, ONCOGENE, V8, P67; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; Stavnezer E., 1988, ONCOGENE HDB, P393; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4046; STRATTON MR, 1989, CARCINOGENESIS, V10, P899, DOI 10.1093/carcin/10.5.899; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1989, MOL CELL BIOL, V9, P4046, DOI 10.1128/MCB.9.9.4046; SUTRAVE P, 1991, ONCOGENE, V6, P353; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; WISDOM R, 1992, GENE DEV, V6, P667, DOI 10.1101/gad.6.4.667	32	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2863	2868						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378095				2022-12-17	WOS:A1993LX34300031
J	KUSSICK, SJ; BASLER, K; COOPER, JA				KUSSICK, SJ; BASLER, K; COOPER, JA			RAS1-DEPENDENT SIGNALING BY ECTOPICALLY-EXPRESSED DROSOPHILA-SRC GENE-PRODUCT IN THE EMBRYO AND DEVELOPING EYE	ONCOGENE			English	Article								The cellular functions of the Drosophila src 64B (Dsrc) gene product, Dsrc, and of most vertebrate Src-family kinases, are unknown. We have examined the effects of over-expression of wild type and mutated forms of Dsrc in transgenic Drosophila. Expression of both wild type Dsrc and a C-terminally truncated mutant at high levels during embryonic development induced extensive tyrosine phosphorylation of cellular proteins and caused considerable lethality, correlating with a block to germ-band retraction. Over-expression in the eye imaginal disc led to excess production of photoreceptor cells in the adult ommatidia. In contrast, expression of a kinase-inactive form of Dsrc caused distinct nervous system abnormalities in embryos and decreased the numbers of photoreceptor cells in the adult eye ommatidia. This suggests that active forms of Dsrc alter development by phosphorylation. Both the lethality and the eye roughening caused by activated Dsrc were partially suppressed by mutations in the Drosophila Ras1 gene. These results suggest that over-expressed Dsrc may function through Ras1 to stimulate differentiation in the embryonic nervous system and eye imaginal disc, and that kinase-active Dsrc interferes with these processes.	FRED HUTCHINSON CANC RES CTR, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA; COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA; UNIV WASHINGTON, SCH MED, DEPT PATHOL, SEATTLE, WA 98195 USA	Fred Hutchinson Cancer Center; Columbia University; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle				Basler, Konrad/0000-0003-3534-1529	NATIONAL CANCER INSTITUTE [R01CA041072, R37CA041072] Funding Source: NIH RePORTER; NCI NIH HHS [CA-41072] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BASLER K, 1990, GENE DEV, V4, P728, DOI 10.1101/gad.4.5.728; BASLER K, 1989, EMBO J, V8, P2381, DOI 10.1002/j.1460-2075.1989.tb08367.x; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BISHOP JG, 1988, GENE DEV, V2, P567, DOI 10.1101/gad.2.5.567; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHENG SH, 1991, J VIROL, V65, P170, DOI 10.1128/JVI.65.1.170-179.1991; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; HAFEN E, 1991, DEVELOPMENT, P123; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KUSSICK SJ, 1992, ONCOGENE, V7, P2461; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANO H, 1990, ONCOGENE, V5, P1781; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; Roberts D. B, 1986, DROSOPHILA PRACTICAL; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1983, NATURE, V302, P837, DOI 10.1038/302837a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SIMON MA, 1987, THESIS U CALIFORNIA; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRECKER TR, 1991, P NATL ACAD SCI USA, V88, P5824, DOI 10.1073/pnas.88.13.5824; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; ZIEGLER SF, 1989, MOL CELL BIOL, V9, P2724, DOI 10.1128/MCB.9.6.2724	74	24	25	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2791	2803						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378088				2022-12-17	WOS:A1993LX34300021
J	WEISSKER, SN; MULLER, BF; HOMFELD, A; DEPPERT, W				WEISSKER, SN; MULLER, BF; HOMFELD, A; DEPPERT, W			SPECIFIC AND COMPLEX INTERACTIONS OF MURINE P53 WITH DNA	ONCOGENE			English	Article							LARGE-T-ANTIGEN; TRANSFORMATION-RELATED PROTEIN; CELL-CYCLE CONTROL; A MOUSE CELLS; WILD-TYPE P53; MONOCLONAL-ANTIBODY; MUTANT P53; TRANSCRIPTIONAL ACTIVATION; NUCLEAR-LOCALIZATION; BINDING-PROTEIN	Biologically active mutant p53 from Balb/c mouse tumor cells (Meth A) was analysed for its specific interaction with DNA. Restricted phage lambda-DNA, representing DNA of high complexity with regard to sequence and secondary structure, was used to probe for such an activity in a target-bound DNA-binding assay, using doubly immunopurified p53. A single lambda-DNA fragment was specifically retained with very high affinity (K(D) = 10(-10) M). Specific DNA binding was shown to be an intrinsic property of p53, as it could be blocked with p53-specific monoclonal antibodies PAb122 and PAb421. The characteristics of the DNA binding of p53 to this lambda-DNA fragment, as well as the structural properties of this fragment, suggested the possibility that p53 might be able to interact with nuclear matrix attachment region (MAR) DNA. Indeed, established genomic MAR elements were specifically bound by Meth A p53, whereas no binding was observed to an AT-rich control DNA. The interaction of p53 with MAR elements in vitro is compatible with the idea that p53 in vivo is involved in the regulation of replication and/or expression of cellular DNA. Complex DNA interactions were not restricted to mutant p53 from Meth A cells. Mutant p53 of a different conformational phenotype (PAb246+ 'wild-type' as opposed to PAb246- 'mutant' for p53 from Meth A cells) from minimally transformed T3T3 cells, as well as genotypic wild-type p53 expressed by a recombinant baculovirus in insect cells, exhibited similar DNA-binding properties.	UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY	Heinrich Pette Institute; University of Hamburg								AMATI B, 1990, MOL CELL BIOL, V10, P5442, DOI 10.1128/MCB.10.10.5442; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BADING H, 1987, ONCOGENE, V1, P395; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BARTEK J, 1990, ONCOGENE, V5, P893; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BRUN C, 1990, MOL CELL BIOL, V10, P5453; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P159; CASEY G, 1991, ONCOGENE, V6, P1791; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; DEFROMENTEL CC, 1986, EXP CELL RES, V164, P35, DOI 10.1016/0014-4827(86)90452-0; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1990, ONCOGENE, V5, P1701; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GETZENBERG RH, 1991, J CELL BIOCHEM, V47, P289, DOI 10.1002/jcb.240470402; GILLESPIE PG, 1991, P NATL ACAD SCI USA, V88, P2563, DOI 10.1073/pnas.88.6.2563; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HERBOMEL P, 1990, New Biologist, V2, P937; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINZPETER M, 1986, VIROLOGY, V148, P159, DOI 10.1016/0042-6822(86)90411-3; HINZPETER M, 1987, ONCOGENE, V1, P119; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1983, CELL BIOL INT REP, V7, P513, DOI 10.1016/0309-1651(83)90154-6; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1990, ONCOGENE, V5, P973; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OROURKE RW, 1990, ONCOGENE, V5, P1829; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; PHIVAN L, 1990, PROG MOL SUBCELL BIO, V11, P1; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHIRMBECK R, 1988, VIROLOGY, V165, P527, DOI 10.1016/0042-6822(88)90597-1; SCHIRMBECK R, 1989, J VIROL, V63, P2308, DOI 10.1128/JVI.63.5.2308-2316.1989; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHOHATFOORD O, 1991, NUCLEIC ACIDS RES, V19, P5191; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STEINMEYER K, 1988, ONCOGENE, V3, P501; Summers MD, 1987, TEXAS AGR EXPT STATI; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YOUISHROUACH E, 1991, NATURE, V352, P345; ZERRAHN J, 1992, IN PRESS ONCOGENE	62	24	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1921	1932						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408133				2022-12-17	WOS:A1992JP42400004
J	BRUGGEMAN, LA; BURBELO, PD; YAMADA, Y; KLOTMAN, PE				BRUGGEMAN, LA; BURBELO, PD; YAMADA, Y; KLOTMAN, PE			A NOVEL SEQUENCE IN THE TYPE-IV COLLAGEN PROMOTER BINDS NUCLEAR PROTEINS FROM ENGELBRETH-HOLM-SWARM TUMOR	ONCOGENE			English	Article							HEAD-TO-HEAD; BASEMENT-MEMBRANE; EXTRACELLULAR-MATRIX; TRANSCRIPTIONAL REGULATION; BIDIRECTIONAL PROMOTER; GENE-REGULATION; CHAIN; CELLS; IDENTIFICATION; ALPHA-1(IV)	The production of extracellular matrix proteins is an important element of tumor formation, and alterations in matrix protein metabolism may be critical to the process of tumor metastasis. Abundant expression of type IV collagen, the major structural protein of the basement membrane, is characteristic of the Engelbreth-Holm-Swarm (EHS) mouse sarcoma. In the present study, we evaluated mechanisms of transcriptional regulation of type IV collagen genes by analysing nuclear factors that bind to the promoter region. Gel mobility-shift assays indicated that specific proteins from EHS tumor bound the promoter and generated several unique shift patterns. The specific sequences to which these proteins bound were determined using DNAase I protection assays. DNA-binding proteins protected two regions from DNAase I digestion. The first region was similar to a GC box, the binding site for the transcription factor Spl. The other footprint was a 30-bp region that contained the novel sequence motif, `CCCTCCC' present in several other extracellular matrix promoters. Nuclear extracts isolated from tissues that variably express type IV collagen bound to this protected sequence with distinctly different shift patterns. Furthermore, in highly expressing tissues, unlabeled oligonucleotides containing the `CCCTCCC' motif effectively inhibited nuclear protein binding with the entire promoter. Thus, it is likely that a novel protein or protein complex binds to these sequences. Furthermore, these sequences appear to be unique to the genes that encode basement membrane proteins, suggesting a specific role in their regulation.	NIH,DEV BIOL LAB,9000 ROCKVILLE PIKE,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA			Burbelo, Peter D./B-1027-2009					ABEL T, 1989, NATURE, V341, P24, DOI 10.1038/341024a0; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BACHINGER HP, 1982, J BIOL CHEM, V257, P9796; BRUGGEMAN LA, 1991, AM J KIDNEY DIS, V18, P134, DOI 10.1016/S0272-6386(12)80305-2; BURBELO PD, 1990, J BIOL CHEM, V265, P4839; BURBELO PD, 1988, P NATL ACAD SCI USA, V85, P9679, DOI 10.1073/pnas.85.24.9679; DEAN DC, 1989, MOL CELL BIOL, V9, P1498, DOI 10.1128/MCB.9.4.1498; DYAN WS, 1985, NATURE, V316, P774; DYNAN WS, 1989, CELL, V58, P1, DOI 10.1016/0092-8674(89)90393-0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KALLUNKI T, 1991, J BIOL CHEM, V266, P221; KAYTES P, 1988, J BIOL CHEM, V263, P19274; KILLEN PD, 1988, J BIOL CHEM, V263, P12310; KLEINMAN HK, 1987, DEV BIOL, V122, P373, DOI 10.1016/0012-1606(87)90302-2; LIOTTA LA, 1983, LAB INVEST, V49, P636; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MEYERS JC, 1987, COLLAGEN REL RES, V7, P149; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRISON KE, 1991, J BIOL CHEM, V266, P34; OGAWA K, 1988, J BIOL CHEM, V263, P8384; OGAWA K, 1986, CANCER, V58, P269, DOI 10.1002/1097-0142(19860715)58:2<269::AID-CNCR2820580212>3.0.CO;2-7; ORKIN RW, 1977, J EXP MED, V145, P204, DOI 10.1084/jem.145.1.204; OSBORNE TF, 1987, P NATL ACAD SCI USA, V84, P3614, DOI 10.1073/pnas.84.11.3614; PATEL RS, 1987, EMBO J, V6, P2565, DOI 10.1002/j.1460-2075.1987.tb02545.x; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RUTKA JT, 1987, CAN J NEUROL SCI, V14, P25; SAKR WA, 1987, HUM PATHOL, V18, P1043, DOI 10.1016/S0046-8177(87)80221-6; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SOININEN R, 1988, J BIOL CHEM, V263, P17217; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TIMPL R, 1986, INT REV EXP PATHOL, V29, P1	36	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1497	1502						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630813				2022-12-17	WOS:A1992JE81300005
J	MICHALSKI, AJ; COTTER, FE; COWELL, JK				MICHALSKI, AJ; COTTER, FE; COWELL, JK			ISOLATION OF CHROMOSOME-SPECIFIC DNA-SEQUENCES FROM AN ALU POLYMERASE CHAIN-REACTION LIBRARY TO DEFINE THE BREAKPOINT IN A PATIENT WITH A CONSTITUTIONAL TRANSLOCATION T(1,13) (Q22,Q12) AND GANGLIONEUROBLASTOMA	ONCOGENE			English	Article							SOMATIC-CELL HYBRID; NEURO-BLASTOMA; HUMAN NEUROBLASTOMAS; WILMS-TUMOR; RAPID ISOLATION; HUMAN GENOME; SHORT ARM; GENE; RETINOBLASTOMA; HETEROZYGOSITY	We describe the cytogenetic and molecular characterization of a t(1;13)(q22;q12) constitutional rearrangement occurring in a patient with a relatively benign form of neuroblastoma, called gangtioneuroblastoma. Somatic cell hybrids were generated between mouse 3T3 cells and a lymphoblastoid cell line from this patient, D.G. One isolated subclone, DGF27C11, contained the derivative chromosome, 1pter-q22 = 13q12-qter, but no other material from either chromosome 1 or 13. Using available DNA probes the 13 breakpoint was assigned proximal to all reported markers. In order to generate flanking markers to define this translocation further, an Alu polymerase chain reaction library was constructed from a somatic cell hybrid containing only the proximal, 13pter-13q14, region of chromosome 13. Seven unique sequences have been isolated from the library, three of which lie below and four of which lie above the 13q12 breakpoint. More precise mapping of the distal markers was achieved using a panel of somatic cell hybrids with overlapping deletions of chromosome 13. The paucity of probes in the 1q22 region has made a precise assignment of this breakpoint difficult, however it has been shown to lie distal to c-SKI and proximal to APOA2. This refined characterization of the breakpoint is a prerequisite for its cloning, which may yield genes important in the pathogenesis of ganglioneuroblastoma.	INST CHILD HLTH,IMPERIAL CANC RES FDN,MOLEC ONCOL GRP,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND	University of London; University College London				Cowell, John/0000-0002-2079-5950				BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; BROOKSWILSON AR, 1990, GENOMICS, V7, P614, DOI 10.1016/0888-7543(90)90207-B; CAVENEE W, 1984, AM J HUM GENET, V36, P10; CHRISTIANSEN H, 1988, BRIT J CANCER, V57, P121, DOI 10.1038/bjc.1988.24; COLE CG, 1991, GENOMICS, V10, P816, DOI 10.1016/0888-7543(91)90468-T; COTTER FE, 1991, GENOMICS, V9, P473, DOI 10.1016/0888-7543(91)90413-9; COTTER FE, 1990, GENOMICS, V7, P257, DOI 10.1016/0888-7543(90)90548-9; COWELL JK, 1980, J NATL CANCER I, V65, P955; COWELL JK, 1989, CYTOGENET CELL GENET, V52, P1, DOI 10.1159/000132827; COWELL JK, 1986, HUMAN CYTOGENETICS P, P202; DRYJA TP, 1984, HUM GENET, V65, P320, DOI 10.1007/BF00291555; FLOYDSMITH G, 1986, IMMUNOGENETICS, V24, P171; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FOUNTAIN JW, 1989, SCIENCE, V244, P1085, DOI 10.1126/science.2543076; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GENDLER SJ, 1987, P NATL ACAD SCI USA, V84, P6060, DOI 10.1073/pnas.84.17.6060; GILBERT F, 1984, CANCER RES, V44, P5444; GREEN ED, 1990, SCIENCE, V250, P94, DOI 10.1126/science.2218515; GRUNDY P, 1988, NATURE, V336, P375; GUZZETTA V, 1991, GENOMICS, V9, P31, DOI 10.1016/0888-7543(91)90217-3; HIGGINS MJ, 1989, MOL CELL BIOL, V9, P1; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; HUNT JD, 1990, GENE CHROMOSOME CANC, V2, P137, DOI 10.1002/gcc.2870020210; JELINEK WR, 1982, ANNU REV BIOCHEM, V51, P813, DOI 10.1146/annurev.bi.51.070182.004121; KARIYA Y, 1987, GENE, V53, P1, DOI 10.1016/0378-1119(87)90087-4; KNUDSON AG, 1972, AM J HUM GENET, V24, P514; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KUSHNER BH, 1986, CANCER-AM CANCER SOC, V57, P1887, DOI 10.1002/1097-0142(19860501)57:9<1887::AID-CNCR2820570931>3.0.CO;2-7; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; LEISTER I, 1990, CANCER RES, V50, P7232; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MARTINSSON T, 1989, GENE CHROMOSOME CANC, V1, P67, DOI 10.1002/gcc.2870010111; MIDDLETONPRICE HR, 1988, HUM GENET, V79, P283, DOI 10.1007/BF00366253; MITCHELL CD, 1991, ONCOGENE, V6, P89; MITCHELL CD, 1989, ONCOGENE, V4, P253; MOORE JW, 1986, HUM GENET, V72, P297, DOI 10.1007/BF00290952; MOORHEAD PS, 1980, ADV NEUROBLASTOMA RE, P109; MOYZIS RK, 1989, GENOMICS, V4, P273, DOI 10.1016/0888-7543(89)90331-5; NAGANO H, 1980, JPN J HUM GENET, V25, P39, DOI 10.1007/BF01876544; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; OCONNELL P, 1989, SCIENCE, V244, P1087, DOI 10.1126/science.2543077; RAY PN, 1985, NATURE, V318, P672, DOI 10.1038/318672a0; RICCARDI VM, 1978, PEDIATRICS, V61, P604; SANGER WG, 1984, CANCER GENET CYTOGEN, V11, P153, DOI 10.1016/0165-4608(84)90109-2; SCHEFFER H, 1986, CYTOGENET CELL GENET, V52, P971; SPARKES RS, 1983, SCIENCE, V219, P971, DOI 10.1126/science.6823558; SUZUKI T, 1989, CANCER RES, V49, P1095; VARESCO L, 1989, P NATL ACAD SCI USA, V86, P10118, DOI 10.1073/pnas.86.24.10118; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WADEY RB, 1990, ONCOGENE, V5, P901; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; YUNIS JJ, 1978, AM J DIS CHILD, V132, P161, DOI 10.1001/archpedi.1978.02120270059012	55	24	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1595	1602						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630820				2022-12-17	WOS:A1992JE81300016
J	NEGISHI, Y; IGUCHIARIGA, SMM; ARIGA, H				NEGISHI, Y; IGUCHIARIGA, SMM; ARIGA, H			PROTEIN COMPLEXES BEARING MYC-LIKE ANTIGENICITY RECOGNIZE 2 DISTINCT DNA-SEQUENCES	ONCOGENE			English	Article							HEAVY-CHAIN PROMOTER; TRANSCRIPTIONAL ENHANCER; REPLICATION; BINDING; INITIATION; CELLS; GENE; ELEMENTS; ORIGIN; SYSTEM	The products of the myc proto-oncogene family have been suggested to carry functions important for cell proliferation, differentiation and neoplasia, but the molecular mechanisms of such biological effects have not vet been clarified. We have previously reported that the c-myc protein or protein(s) complexed with the c-myc protein bind to a specific sequence in the region upstream of the c-myc gene, where there exist an origin of cellular DNA replication (ori) and also a transcriptional enhancer. It was recently reported that the c-myc protein forms complexes with a novel helix-loop-helix leucine zipper protein (Max), and that the Myc-Max complex specifically recognizes a DNA sequence different from the sequence we have defined in the c-myc gene. In this report we examine the nuclear extract prepared from human Raji cells for binding to the two different sequences which have been reported as specific binding sequences for c-myc protein or c-myc protein complexes. The binding to one sequence was inhibited in the presence of excess amount of the other sequence, suggesting that the same protein(s) may be necessary for binding to either of the two sequences. Since binding to both sequences was cancelled by pretreatment of the Raji extract with an anti-c-myc protein antibody, it is suggested that proteins carrying myc-like antigenicity are necessary for efficient binding of the nucleoprotein complexes to the two distinct DNA sequences.	HOKKAIDO UNIV,FAC PHARMACEUT SCI,KITA 12 NISHI 6,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,COLL MED TECHNOL,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University; Hokkaido University			Ariga, Hiroyoshi/B-5895-2013	Ariga, Hiroyoshi/0000-0001-7384-2143				ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; ARIIZUMI K, 1989, MOL CELL BIOL, V9, P4032, DOI 10.1128/MCB.9.9.4032; ARIIZUMI K, 1989, MOL CELL BIOL, V9, P4026, DOI 10.1128/MCB.9.9.4026; BAKKER O, 1991, NUCLEIC ACIDS RES, V19, P1213, DOI 10.1093/nar/19.6.1213; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6501; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; IGUCHIARIGA SMM, 1987, NUCLEIC ACIDS RES, V15, P4889, DOI 10.1093/nar/15.12.4889; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; KITAURA H, 1991, FEBS LETT, V290, P147, DOI 10.1016/0014-5793(91)81246-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; POELLINGER L, 1989, MOL CELL BIOL, V9, P747, DOI 10.1128/MCB.9.2.747; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; SUDO K, 1990, NUCLEIC ACIDS RES, V18, P5425, DOI 10.1093/nar/18.18.5425; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787	24	24	24	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					543	548						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549367				2022-12-17	WOS:A1992HK00500021
J	BORRELLO, MG; PIEROTTI, MA; TAMBORINI, E; BIASSONI, D; RIZZETTI, MG; PILOTTI, S; DELLAPORTA, G				BORRELLO, MG; PIEROTTI, MA; TAMBORINI, E; BIASSONI, D; RIZZETTI, MG; PILOTTI, S; DELLAPORTA, G			DNA METHYLATION OF CODING AND NONCODING REGIONS OF THE HUMAN H-RAS GENE IN NORMAL AND TUMOR-TISSUES	ONCOGENE			English	Article							ONCOGENE; EXPRESSION; HYPOMETHYLATION; CHROMOSOME; CHROMATIN; ISLANDS; GENOME; LOCUS	To study a possible role of DNA methylation in the regulation of expression of the human H-RAS gene in vivo, 41 samples of different normal tissues and 33 tumors of various histotypes were analysed for DNA methylation. In a subset of normal tissues the RNA expression was also examined. The promoter region of the gene showed the features of a CpG island being CpG rich and unmethylated in all the normal tissues and tumors. The coding region displayed an intermediate level of methylation in the majority of normal and tumor tissues. Among the normal tissues only thymus DNA was found to be hypermethylated, while testes and sperm cells DNAs were hypomethylated. The 3' region was found to he completely methylated only in sperm cells and was never completely demethylated. The majority of the tissues showed an intermediate level of methylation, and a certain tissue specificity emerged by comparing tissues of the same and different histotypes. However, the overall methylation of both coding and 3' regions did not correlate with the levels of tissue-specific RNA expression. In heterozygous individuals, allelic methylation of the 3' region showed either perfectly balanced or slightly unbalanced methylation of the two alleles in normal tissues, while an allele-specific methylation was found in 5 out of 12 fresh tumor samples.	IST NAZL TUMORI,DIV ONCOL SPERIMENTALE A,VIA G VENEZIAN 1,I-20133 MILAN,ITALY; IST NAZL TUMORI,DIV ANAT PATOL & CITOL,I-20133 MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan			Tamborini, Elena/C-3307-2017; Borrello, Maria Grazia/C-3161-2017	Tamborini, Elena/0000-0002-3819-8687; Borrello, Maria Grazia/0000-0002-6854-2848; Pierotti, Marco Alessandro/0000-0002-7431-8332				BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; BIRD AP, 1987, EMBO J, V6, P999, DOI 10.1002/j.1460-2075.1987.tb04851.x; BORRELLO MG, 1988, ONCOGENE RES, V2, P197; BORRELLO MG, 1987, CANCER RES, V47, P75; BROWETT PJ, 1989, ONCOGENE, V4, P1029; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHANDLER LA, 1987, CELL, V50, P711, DOI 10.1016/0092-8674(87)90329-1; DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693; EDWARDS YN, 1985, MOL CELL BIOL, V5, P2147, DOI 10.1128/MCB.5.8.2147; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GROUDINE M, 1985, SCIENCE, V228, P1061, DOI 10.1126/science.2986289; HELLER DL, 1988, MOL CELL BIOL, V8, P2797, DOI 10.1128/MCB.8.7.2797; JONES PA, 1986, CANCER RES, V46, P461; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; METTER J, 1989, NUCLEIC ACIDS RES, V17, P7089, DOI 10.1093/nar/17.17.7089; MONK M, 1987, NATURE, V328, P203, DOI 10.1038/328203a0; MULLINS LJ, 1987, MOL CELL BIOL, V7, P3916, DOI 10.1128/MCB.7.11.3916; PERFETTI V, 1991, IN PRESS LEUKEMIA; PIEROTTI MA, 1986, CYTOGENET CELL GENET, V43, P174, DOI 10.1159/000132317; SALUZ HP, 1988, P NATL ACAD SCI USA, V85, P6697, DOI 10.1073/pnas.85.18.6697; SILVA AJ, 1988, TRENDS GENET, V4, P59; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806; WOLF SF, 1985, NATURE, V314, P467, DOI 10.1038/314467a0	30	24	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					269	275						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1549348				2022-12-17	WOS:A1992HG98200010
J	AXELSON, H; PANDA, CK; SILVA, S; SUGIYAMA, H; WIENER, F; KLEIN, G; SUMEGI, J				AXELSON, H; PANDA, CK; SILVA, S; SUGIYAMA, H; WIENER, F; KLEIN, G; SUMEGI, J			A NEW VARIANT 15-16 TRANSLOCATION IN MOUSE PLASMACYTOMA LEADS TO THE JUXTAPOSITION OF C-MYC AND IMMUNOGLOBULIN-LAMBDA	ONCOGENE			English	Article							MURINE LEUKEMIA-VIRUS; CHROMOSOME TRANSLOCATIONS; GENE; LOCUS; ONCOGENE; LYMPHOMAS; ENHANCER; REGION; CELLS; MICE	Mouse plasmacytomas (MPCs) induced by pristane oil, or by a combination of pristane oil and Abelson virus, carry one of two chromosomal translocations. The typical 12; 15 translocation leads to the juxtaposition of c-myc and immunoglobulin heavy-chain sequences, whereas the 6; 15 translocation links the kappa light-chain locus with the pyt-1 (plasmacytoma variant translocation) locus, located al least 75 kb 3' of c-myc [Cory, S., Graham, M., Webb, E., Corcoran, L. & Adams, J. (1985). EMBO J., 4, 675-681]. Unlike the human Burkitt's lymphoma-associated translocation, the lambda/myc juxtaposed variant translocation has not been found previously in MPCs. Using unconventional MPC induction systems in which the tumor precursor cell was induced to proliferate in a secondary host, we have recently identified a 15; 16 Translocation in six of the derived MPCs [Wiener, F., Silva, S., Sugiyama, H., Babonits, M. & Klein, G. (1990). Genes Chromosomes Cancer, 2, 36-43]. Chromosome 16 harbors the lambda light-chain gene. To explore whether the 15; 16 translocation represents the lambda/myc juxtaposition, we have mapped the breakpoints on chromosomes 15 and 16 by pulsed-field gel electrophoresis (PFGE). The pvt-1 region was mapped to approximately 220 kb 3' of c-myc. The breakpoint on chromosome 15 in ABPC-Ch-163-10, one of the six 15; 16 translocation-carrying carrying MPCs, was situated approximately 80 kb 3' of c-myc and 140 kb 5' of pvt-1b, the major breakpoint cluster region of the previously analysed 6; 15 variant MPCs. The breakpoint on chromosone 16 was found to cut between the V1 and C3 regions of the lambda locus. Co-migration experiments showed that the C3 and the myc gene were juxtaposed head to tail on the 15; 16 translocation chromosome. On the reciprocal product V1 was juxtaposed to pvt-1.			AXELSON, H (corresponding author), KAROLINSKA INST,DEPT TUMOR BIOL,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN.				NCI NIH HHS [3R01CA4054] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1983, P NATL ACAD SCI-BIOL, V80, P1982, DOI 10.1073/pnas.80.7.1982; BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; CARSON S, 1989, IMMUNOGENETICS, V29, P173, DOI 10.1007/BF00373642; CAZENAVE A, 1990, EMBO J, V9, P435; CORY S, 1985, EMBO J, V4, P675, DOI 10.1002/j.1460-2075.1985.tb03682.x; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; ECCLES S, 1990, New Biologist, V2, P801; EISEN HN, 1985, ANNU REV IMMUNOL, V3, P337, DOI 10.1146/annurev.iy.03.040185.002005; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRANCKE U, 1982, CYTOGENET CELL GENET, V33, P267, DOI 10.1159/000131769; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GRAHAM M, 1985, NATURE, V314, P740, DOI 10.1038/314740a0; HAGMAN J, 1990, GENE DEV, V4, P978, DOI 10.1101/gad.4.6.978; HENGLEIN B, 1989, MOL CELL BIOL, V9, P2105, DOI 10.1128/MCB.9.5.2105; HUPPI K, 1990, CURR TOP MICROBIOL, V166, P233; KLEIN G, 1985, IMMUNOL TODAY, V6, P208, DOI 10.1016/0167-5699(85)90036-2; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MARCU KB, 1983, P NATL ACAD SCI-BIOL, V80, P519, DOI 10.1073/pnas.80.2.519; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; NADEL B, 1990, EMBO J, V9, P435, DOI 10.1002/j.1460-2075.1990.tb08128.x; OHNO S, 1979, CELL, V18, P1001, DOI 10.1016/0092-8674(79)90212-5; PEAR WS, 1988, MOL CELL BIOL, V8, P441, DOI 10.1128/MCB.8.1.441; PICARD D, 1984, NATURE, V307, P80, DOI 10.1038/307080a0; POTTER M, 1987, SCIENCE, V235, P787, DOI 10.1126/science.3810165; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; SHTIVELMAN E, 1990, MOL CELL BIOL, V10, P1835, DOI 10.1128/MCB.10.4.1835; SILVA S, 1989, INT J CANCER, V44, P337, DOI 10.1002/ijc.2910440225; STORB U, 1989, MOL CELL BIOL, V9, P711, DOI 10.1128/MCB.9.2.711; SUGIYAMA H, 1989, INT J CANCER, V44, P348, DOI 10.1002/ijc.2910440227; TSICHLIS PN, 1989, P NATL ACAD SCI USA, V86, P5487, DOI 10.1073/pnas.86.14.5487; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WIENER F, 1990, GENE CHROMOSOME CANC, V2, P36, DOI 10.1002/gcc.2870020107; WIRSCHUBSKY Z, 1986, INT J CANCER, V38, P739, DOI 10.1002/ijc.2910380518; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x	36	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2263	2270						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766673				2022-12-17	WOS:A1991GX73500013
J	NIMMO, ER; SANDERS, PG; PADUA, RA; HUGHES, D; WILLIAMSON, R; JOHNSON, KJ				NIMMO, ER; SANDERS, PG; PADUA, RA; HUGHES, D; WILLIAMSON, R; JOHNSON, KJ			THE MEL GENE - A NEW MEMBER OF THE RAB/YPT CLASS OF RAS-RELATED GENES	ONCOGENE			English	Article							GTP-BINDING-PROTEINS; HUMAN-MALIGNANT MELANOMA; CELL-LINE; MOLECULAR-CLONING; DNA-BINDING; YEAST YPT1; C-MEL; TRANSLOCATION; CHROMOSOME-19; FAMILY	The MEL gene was identified following transfection of NIH3T3 mouse fibroblasts with DNA from a human melanoma cell line. The human MEL gene has been localized to 19cen-p13.2, a region in which translocation breakpoints occur in a number of malignancies. We have identified and sequenced human and mouse MEL cDNA clones which show homology of 92% and 96% at the nucleotide and amino acid levels respectively. The predicted human MEL protein shows only six amino acid differences between it and the recently described dog RAB8 protein. All of these changes occur in the 30 amino acids at the C-terminal of these proteins. MEL is similar to the RAB/YPT proteins in the region corresponding to the putative effector domain, suggesting that they may interact with the same cellular substrates. However, MEL contains a C-terminal CAAX motif in common with the majority of the RAS superfamily, unlike YPT1 and the majority of the RAB proteins.	CHARING CROSS & WESTMINSTER MED SCH,DEPT ANAT,LONDON W6 8RF,ENGLAND; UNIV LONDON IMPERIAL COLL SCI & TECHNOL,ST MARYS HOSP,SCH MED,BIOCHEM & MOLEC GENET,LONDON W2 1PG,ENGLAND; HEATH PK HOSP,DEPT HAEMATOL,LRF PRELEUKAEMIA UNIT,CARDIFF CF4 4XN,WALES; UNIV SURREY,DEPT MICROBIOL,GUILDFORD GU2 5XH,SURREY,ENGLAND	Imperial College London; Imperial College London; University of Surrey			Padua, Rose Ann/GVT-5961-2022; PADUA, Rose Ann/E-8621-2019	PADUA, Rose Ann/0000-0001-9964-7864; johnson, keith/0000-0002-8578-5921				BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; CAVANNA JS, 1990, GENOMICS, V7, P12, DOI 10.1016/0888-7543(90)90513-T; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HAUBRUCK H, 1987, EMBO J, V6, P4049, DOI 10.1002/j.1460-2075.1987.tb02750.x; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NIMMO E, 1989, HUM GENET, V81, P382, DOI 10.1007/BF00283697; PADUA RA, 1984, NATURE, V311, P671, DOI 10.1038/311671a0; PARMITER AH, 1986, CANCER RES, V46, P1526; ROUSSEAUMERCK MF, 1989, GENOMICS, V5, P694, DOI 10.1016/0888-7543(89)90110-9; SALTMAN DL, 1990, GENE CHROMOSOME CANC, V2, P259, DOI 10.1002/gcc.2870020402; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; SPURR NK, 1986, SOMAT CELL MOLEC GEN, V12, P637, DOI 10.1007/BF01671949; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394; ZAHRAOUI A, 1988, NUCLEIC ACIDS RES, V16, P1204, DOI 10.1093/nar/16.3.1204	33	24	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1347	1351						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886711				2022-12-17	WOS:A1991GX27200009
J	DOBASHI, Y; STERN, DF				DOBASHI, Y; STERN, DF			MEMBRANE-ANCHORED FORMS OF EGF STIMULATE FOCUS FORMATION AND INTERCELLULAR COMMUNICATION	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; STOMATITIS-VIRUS GLYCOPROTEIN; ALTERED CYTOPLASMIC DOMAINS; CELL-SURFACE; FACTOR PRECURSOR; FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; SECRETORY PROTEIN; FACTOR-ALPHA; TRANSPORT	Epidermal growth factor (EGF) is the prototype for a small family of soluble proteins that bind to and activate the EGF receptor. These proteins are derived from larger propeptides that are anchored to the plasma membrane. Although the signalling properties of soluble EGF are well-characterized, the signalling potential of the membrane-anchored form had not been determined. We therefore investigated whether membrane-anchored EGF can stimulate the EGF receptor. An EGF mini-gene expression system that we had previously constructed for expression of soluble EGF was modified to encode anchored forms of EGF. In the encoded proteins EGF was fused to the spacer in the EGF propeptide that separates EGF from the transmembrane domain. The spacer was followed by vesicular stomatitis virus G protein transmembrane and cytoplasmic domain sequences. Three forms of EGF/G fusion protein were expressed in rat fibroblasts. The plasmids for expression of anchored EGF induced focus formation in rat fibroblasts, indicating that anchored EGF can cause autocrine transformation. When mixed with indicator HeLa cells, cell lines expressing EGF/G fusion proteins activated the HeLa EGF receptor. This activation was mediated by cell-associated, rather than soluble EGF. The finding that membrane-anchored EGF is capable of activating the EGF receptor on neighboring cells has broad implications for the functions of EGF in the organism.	YALE UNIV,SCH MED,DEPT PATHOL,310 CEDAR ST,POB 3333,NEW HAVEN,CT 06510	Yale University	STERN, DF (corresponding author), YALE UNIV,SCH MED,DEPT PATHOL,310 CEDAR ST,POB 3333,NEW HAVEN,CT 06510, USA.			Dobashi, Yoh/0000-0003-0507-3332	NATIONAL CANCER INSTITUTE [R01CA045708] Funding Source: NIH RePORTER; NCI NIH HHS [CA45708] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; BROWN JP, 1985, NATURE, V313, P491, DOI 10.1038/313491a0; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; DAVIS C G, 1990, New Biologist, V2, P410; DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; GUAN JL, 1988, MOL CELL BIOL, V8, P2869, DOI 10.1128/MCB.8.7.2869; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; GUAN JL, 1985, CELL, V42, P489, DOI 10.1016/0092-8674(85)90106-0; GUAN JL, 1988, J BIOL CHEM, V263, P5306; KAMPS MP, 1988, ONCOGENE, V2, P305; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MROCZKOWSKI B, 1989, MOL CELL BIOL, V9, P2771, DOI 10.1128/MCB.9.7.2771; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; RALL LB, 1985, NATURE, V313, P228, DOI 10.1038/313228a0; ROSE JK, 1983, CELL, V34, P513, DOI 10.1016/0092-8674(83)90384-7; SCOTT J, 1983, SCIENCE, V221, P236, DOI 10.1126/science.6602382; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; STEIN J, 1990, BLOOD, V76, P1308, DOI 10.1182/blood.V76.7.1308.bloodjournal7671308; STERN DF, 1987, SCIENCE, V235, P321, DOI 10.1126/science.3492043; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TWARDZIK DR, 1985, P NATL ACAD SCI USA, V82, P5300, DOI 10.1073/pnas.82.16.5300; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WHITT MA, 1989, J VIROL, V63, P3569, DOI 10.1128/JVI.63.9.3569-3578.1989; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	39	24	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1151	1159						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861865				2022-12-17	WOS:A1991GV26000009
J	HANNIG, G; OTTILIE, S; SCHARTL, M				HANNIG, G; OTTILIE, S; SCHARTL, M			CONSERVATION OF STRUCTURE AND EXPRESSION OF THE C-YES AND FYN GENES IN LOWER-VERTEBRATES	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; CELLULAR SRC GENE; MESSENGER-RNA; DIFFERENTIAL EXPRESSION; TRANSFORMED-CELLS; SEQUENCE; XIPHOPHORUS; ONCOGENE; PRODUCT; ADULT	The src-gene family in mammals and birds consists of 9 closely related protein tyrosine kinases. We have cloned the c-yes and fyn homologues of the src-family from the teleost fish Xiphophorus helleri. Both genes show a high degree of sequence conservation and exhibit all structural motifs diagnostic for functional src-like protein tyrosine kinases. Sequence comparisons revealed three domains (exon 2, exons 3-6, exons 7-12) which evolve at different rates. Both genes exhibit an identical expression pattern, with preferential expression in neural tissues. No transcripts of c-yes were found in liver which is contrary to the situation in higher vertebrates. In malignant melanoma, elevated levels of c-yes and fyn were detected indicating a possible function during secondary steps of tumor progression for src-related tyrosine kinases.	MAX PLANCK INST BIOCHEM,CTR GENE,KLOPFERSPITZ 18A,W-8033 MARTINSRIED,GERMANY	Max Planck Society				Schartl, Manfred/0000-0001-9882-5948				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARNEKOW A, 1984, MOL CELL BIOL, V4, P1179, DOI 10.1128/MCB.4.6.1179; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; Dayhoff M.O., 1978, ATLAS PROTEIN SEQ ST; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GESSLER M, 1984, BIOSCIENCE REP, V4, P757, DOI 10.1007/BF01128817; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; IOTHARA S, 1978, JAPANESE J CANCER RE, V69, P825; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KHANDJIAN EW, 1986, MOL BIOL REP, V11, P105; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAUELER W, 1988, ONCOGENE, V3, P113; MAUELER W, 1988, ONCOGENE, V2, P421; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MONTELL C, 1983, NATURE, V305, P600, DOI 10.1038/305600a0; OHNO S, 1968, HEREDITAS-GENETISK A, V59, P169; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RAULF F, 1989, ONCOGENE RES, V5, P39; RAULF F, 1989, J NEUROSCI RES, V24, P81, DOI 10.1002/jnr.490240112; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARTL M, 1982, DIFFERENTIATION, V23, P109, DOI 10.1111/j.1432-0436.1982.tb01273.x; SCHARTL M, 1989, ONCOGENE, V4, P1185; SCHARTL M, 1985, INT J CANCER, V36, P199, DOI 10.1002/ijc.2910360212; SCHARTL M, 1984, DEV BIOL, V105, P415, DOI 10.1016/0012-1606(84)90298-7; SEKI T, 1985, JPN J CANCER RES, V76, P907; SEMBA K, 1985, SCIENCE, V227, P1038, DOI 10.1126/science.2983418; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SHIBUYA M, 1982, J VIROL, V42, P143, DOI 10.1128/JVI.42.1.143-152.1982; STEELE RE, 1989, ONCOGENE RES, V4, P223; STEELE RE, 1990, ONCOGENE, V5, P369; SUDOL M, 1988, ONCOGENE RES, V2, P345; SUDOL M, 1988, NUCLEIC ACIDS RES, V16, P9876, DOI 10.1093/nar/16.20.9876; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; Tavolga W. N., 1949, Bulletin of the American Museum of Natural History, V94, P163; WALLBANK AM, 1966, NATURE, V209, P1265, DOI 10.1038/2091265a0; WILSON AC, 1987, TRENDS GENET, V3, P241, DOI 10.1016/0168-9525(87)90257-5; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHENG XF, 1989, ONCOGENE, V4, P99	50	24	29	2	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					361	369						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1707152				2022-12-17	WOS:A1991FT34400003
J	WILSON, LK; PARSONS, SJ				WILSON, LK; PARSONS, SJ			ENHANCED EGF MITOGENIC RESPONSE IS ASSOCIATED WITH ENHANCED TYROSINE PHOSPHORYLATION OF SPECIFIC CELLULAR PROTEINS IN FIBROBLASTS OVEREXPRESSING C-SRC	ONCOGENE			English	Article									UNIV VIRGINIA, HLTH SCI CTR,SCH MED,CANC RES CTR,DEPT MICROBIOL, BOX 441, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, INST MOLEC BIOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NCI NIH HHS [CA 40042, CA 39438] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040042, R01CA039438] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHAPRON Y, 1989, BIOCHEM BIOPH RES CO, V158, P527, DOI 10.1016/S0006-291X(89)80081-6; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COHEN S, 1980, J BIOL CHEM, V255, P4834; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; EARP HS, 1988, J BIOL CHEM, V263, P13868; FAVA RA, 1984, J BIOL CHEM, V259, P2636; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HUNTER T, 1981, CELL, V24, P741, DOI 10.1016/0092-8674(81)90100-8; JOHANSEN JW, 1986, P NATL ACAD SCI USA, V83, P207, DOI 10.1073/pnas.83.2.207; JOHNSON RM, 1989, SCIENCE, V246, P121, DOI 10.1126/science.2506643; KAMPS MP, 1988, ONCOGENE, V2, P305; KANNER SB, 1989, ONCOGENE, V4, P295; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCUNE BK, 1989, J BIOL CHEM, V264, P15501; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOOLENAAR WH, 1986, J BIOL CHEM, V261, P279; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MULDOON LL, 1988, J BIOL CHEM, V263, P18834; NAKAMURA KD, 1983, MOL CELL BIOL, V3, P380, DOI 10.1128/MCB.3.3.380; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PASQUALE EB, 1988, J CELL PHYSIOL, V137, P146, DOI 10.1002/jcp.1041370118; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; PHILLIPS SA, 1987, FEBS LETT, V212, P141, DOI 10.1016/0014-5793(87)81573-9; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; ROTHENBERG P, 1983, J BIOL CHEM, V258, P2644; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SQUINTO SP, 1989, MOL ENDOCRINOL, V3, P433, DOI 10.1210/mend-3-3-433; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; WASILENKO WJ, 1990, MOL CELL BIOL, V10, P1254, DOI 10.1128/MCB.10.3.1254; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536	46	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1990	5	10					1471	1480						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	1701230				2022-12-17	WOS:A1990EK50200005
J	WESTIN, EH; GORSE, KM; CLARKE, MF				WESTIN, EH; GORSE, KM; CLARKE, MF			ALTERNATIVE SPLICING OF THE HUMAN C-MYB GENE	ONCOGENE			English	Article									VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,DIV HEMATOL ONCOL,RICHMOND,VA 23298; UNIV MICHIGAN,DEPT MED,DIV HEMATOL ONCOL,ANN ARBOR,MI 48109	Virginia Commonwealth University; University of Michigan System; University of Michigan								ALBRETSEN C, 1988, ANAL BIOCHEM, V170, P193, DOI 10.1016/0003-2697(88)90108-X; BADING H, 1987, ONCOGENE, V1, P395; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; EVINGERHODGES MJ, 1987, LEUKEMIA, V1, P597; FRANCHINI G, 1983, P NATL ACAD SCI-BIOL, V80, P7385, DOI 10.1073/pnas.80.24.7385; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GOODWIN RG, 1986, MOL CELL BIOL, V6, P3128, DOI 10.1128/MCB.6.9.3128; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; ISHIKURA H, 1987, CANCER RES, V47, P1052; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; KORNELUK RG, 1985, GENE, V40, P317, DOI 10.1016/0378-1119(85)90055-1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTONI MJ, 1989, EMBO J, V8, P385, DOI 10.1002/j.1460-2075.1989.tb03389.x; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANTON LW, 1987, MOL CELL BIOL, V7, P4266, DOI 10.1128/MCB.7.12.4266; STRAUSS EC, 1986, ANAL BIOCHEM, V154, P353, DOI 10.1016/0003-2697(86)90536-1; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	45	24	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1990	5	8					1117	1124						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	2202948				2022-12-17	WOS:A1990DX36100002
J	BHAT, GV; TEMIN, HM				BHAT, GV; TEMIN, HM			MUTATIONAL ANALYSIS OF V-REL, THE ONCOGENE OF RETICULOENDOTHELIOSIS VIRUS STRAIN-T	ONCOGENE			English	Article									UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NCI NIH HHS [CA-22443, CA-07175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA007175, P01CA022443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BISHOP JM, 1983, ANN REV BIOCH, V52, P501; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; CAPOBIANCO AJ, 1990, IN PRESS ONCOGENE; CHEN ISY, 1982, CELL, V31, P111, DOI 10.1016/0092-8674(82)90410-X; CHEN ISY, 1981, J VIROL, V40, P800, DOI 10.1128/JVI.40.3.800-811.1981; CHEN ISY, 1983, J VIROL, V45, P104, DOI 10.1128/JVI.45.1.104-113.1983; CICHUTEK K, 1986, P NATL ACAD SCI USA, V83, P2340, DOI 10.1073/pnas.83.8.2340; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOSTER DA, 1985, CELL, V42, P105, DOI 10.1016/S0092-8674(85)80106-9; FOSTER DA, 1983, J VIROL, V48, P744, DOI 10.1128/JVI.48.3.744-751.1983; FRANKLIN RB, 1974, INTERVIROLOGY, V3, P342, DOI 10.1159/000149771; GARSON K, 1986, BIOCHEM BIOPH RES CO, V134, P716, DOI 10.1016/S0006-291X(86)80479-X; GELINAS C, 1986, P NATL ACAD SCI USA, V83, P9211, DOI 10.1073/pnas.83.23.9211; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANNINK M, 1984, SCIENCE, V226, P1197, DOI 10.1126/science.6095451; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HERZOG NK, 1986, J VIROL, V57, P371, DOI 10.1128/JVI.57.1.371-375.1986; HERZOG NK, 1986, P NATL ACAD SCI USA, V83, P812, DOI 10.1073/pnas.83.3.812; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOELZER JD, 1980, VIROLOGY, V100, P462, DOI 10.1016/0042-6822(80)90536-X; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; Maniatis T., 1982, MOL CLONING; MILLER AD, 1984, CELL, V36, P51; MILLER CK, 1986, J VIROL, V58, P75, DOI 10.1128/JVI.58.1.75-80.1986; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; PRYWES R, 1983, CELL, V34, P569, DOI 10.1016/0092-8674(83)90389-6; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; RICE NR, 1982, J VIROL, V42, P237, DOI 10.1128/JVI.42.1.237-252.1982; RICE NR, 1986, VIROLOGY, V149, P217, DOI 10.1016/0042-6822(86)90123-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBUYA T, 1982, CANCER RES, V42, P2722; SIMEK S, 1988, ONCOGENE RES, V2, P103; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; TEMIN HM, 1984, CANCER SURV, V3, P229; TEMIN HM, 1974, J VIROL, V13, P291, DOI 10.1128/JVI.13.2.291-297.1974; THEILEN GH, 1966, J NATL CANCER I, V37, P731; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WALRO DS, 1987, VIROLOGY, V160, P433, DOI 10.1016/0042-6822(87)90015-8; WILHELMSEN KC, 1984, J VIROL, V49, P521, DOI 10.1128/JVI.49.2.521-529.1984; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	49	24	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1990	5	5					625	634						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG374	2189101				2022-12-17	WOS:A1990DG37400001
J	BRUSKIN, A; JACKSON, J; BISHOP, JM; MCCARLEY, DJ; SCHATZMAN, RC				BRUSKIN, A; JACKSON, J; BISHOP, JM; MCCARLEY, DJ; SCHATZMAN, RC			6 AMINO-ACIDS FROM THE RETROVIRAL GENE GAG GREATLY ENHANCE THE TRANSFORMING POTENTIAL OF THE ONCOGENE V-ERB-B	ONCOGENE			English	Article									SYNTEX INC,53-1,3401 HILLVIEW AVE,PALO ALTO,CA 94304; UNIV CALIF SAN FRANCISCO,GEORGE WILLIAMS HOOPER FDN,SAN FRANCISCO,CA 94143	Syntex Corporation; University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [R35CA044338, R01CA012705] Funding Source: NIH RePORTER; NCI NIH HHS [CA12705, CA44338] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; ANDERSON SM, 1980, J VIROL, V36, P676, DOI 10.1128/JVI.36.3.676-683.1980; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BASSIRI M, 1986, J VIROL, V58, P525; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; BISHOP JM, 1985, RNA TUMOR VIRUSES S, V2, P249; BISTER K, 1980, P NATL ACAD SCI-BIOL, V77, P7142, DOI 10.1073/pnas.77.12.7142; BISTER K, 1979, P NATL ACAD SCI USA, V76, P5023, DOI 10.1073/pnas.76.10.5023; BROWN AMC, 1987, DNA CLONING, V3, P189; DAVIS AR, 1981, P NATL ACAD SCI-BIOL, V78, P5376, DOI 10.1073/pnas.78.9.5376; DEBUIRE B, 1984, SCIENCE, V224, P1456, DOI 10.1126/science.6328658; EDMONDS M, 1971, P NATL ACAD SCI USA, V68, P1336, DOI 10.1073/pnas.68.6.1336; FREEMAN AE, 1973, P NATL ACAD SCI USA, V70, P2415, DOI 10.1073/pnas.70.8.2415; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUNG YKT, 1983, CELL, V33, P357, DOI 10.1016/0092-8674(83)90417-8; GAMETT DC, 1986, P NATL ACAD SCI USA, V83, P6053, DOI 10.1073/pnas.83.16.6053; GAZIT A, 1986, J VIROL, V60, P19, DOI 10.1128/JVI.60.1.19-28.1986; GOLDBERG DA, 1980, P NATL ACAD SCI-BIOL, V77, P5794, DOI 10.1073/pnas.77.10.5794; GRAF T, 1976, VIROLOGY, V71, P423, DOI 10.1016/0042-6822(76)90370-6; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HAYMAN MJ, 1979, VIROLOGY, V92, P31, DOI 10.1016/0042-6822(79)90212-5; HAYMAN MJ, 1983, CELL, V32, P579, DOI 10.1016/0092-8674(83)90477-4; HENRY C, 1985, VIROLOGY, V140, P179, DOI 10.1016/0042-6822(85)90457-X; HJELLE B, 1988, P NATL ACAD SCI USA, V85, P4355, DOI 10.1073/pnas.85.12.4355; HU SSF, 1978, VIROLOGY, V89, P162, DOI 10.1016/0042-6822(78)90049-1; ISHIZAKI R, 1979, CANCER RES, V30, P2827; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1983, J VIROL, V48, P565, DOI 10.1128/JVI.48.3.565-572.1983; KLINKEN SP, 1988, ONCOGENE RES, V3, P187; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; LAI MMC, 1980, VIROLOGY, V100, P475, DOI 10.1016/0042-6822(80)90537-1; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; MANIATIS T, 1982, MOL CLONING LABORATO, P157; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MAXIM AM, 1977, P NATL ACAD SCI USA, V74, P560; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; PAWSON T, 1980, J VIROL, V34, P280, DOI 10.1128/JVI.34.1.280-284.1980; PIERCE JH, 1986, CURR TOP MICROBIOL, V132, P55; PRIVALSKY ML, 1982, P NATL ACAD SCI-BIOL, V79, P3958, DOI 10.1073/pnas.79.13.3958; PRIVALSKY ML, 1984, P NATL ACAD SCI-BIOL, V81, P704, DOI 10.1073/pnas.81.3.704; PRIVALSKY ML, 1983, CELL, V32, P1257, DOI 10.1016/0092-8674(83)90307-0; RAINES MA, 1985, P NATL ACAD SCI USA, V82, P2287, DOI 10.1073/pnas.82.8.2287; RETTENMIER CW, 1979, J VIROL, V32, P749, DOI 10.1128/JVI.32.3.749-761.1979; RUSHLOW KE, 1982, SCIENCE, V216, P1421, DOI 10.1126/science.6283631; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHATZMAN RC, 1986, MOL CELL BIOL, V6, P1329, DOI 10.1128/MCB.6.4.1329; SEALY L, 1983, VIROLOGY, V130, P155, DOI 10.1016/0042-6822(83)90125-3; SEALY L, 1983, VIROLOGY, V130, P179, DOI 10.1016/0042-6822(83)90126-5; SHEINESS D, 1981, CELL, V23, P291, DOI 10.1016/0092-8674(81)90293-2; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; VENNSTROM B, 1980, J VIROL, V36, P575; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WELLS A, 1988, P NATL ACAD SCI USA, V85, P7597, DOI 10.1073/pnas.85.20.7597; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X	61	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1990	5	1					15	24						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM620	1969616				2022-12-17	WOS:A1990CM62000003
J	REISMAN, D; ROTTER, V				REISMAN, D; ROTTER, V			2 PROMOTERS THAT MAP TO 5'-SEQUENCES OF THE HUMAN P53 GENE ARE DIFFERENTIALLY REGULATED DURING TERMINAL DIFFERENTIATION OF HUMAN MYELOID LEUKEMIC-CELLS	ONCOGENE			English	Article											REISMAN, D (corresponding author), WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL.				NCI NIH HHS [IR01 CA4003] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTON NK, 1979, NATURE, V282, P861; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ATCHISON ML, 1987, CELL, V48, P121, DOI 10.1016/0092-8674(87)90362-X; BENDORI R, 1987, VIROLOGY, V161, P607, DOI 10.1016/0042-6822(87)90159-0; BENYAJATI C, 1983, CELL, V33, P125, DOI 10.1016/0092-8674(83)90341-0; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BROCK ML, 1983, CELL, V34, P207, DOI 10.1016/0092-8674(83)90151-4; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHEN CN, 1987, NATURE, V329, P721, DOI 10.1038/329721a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; COLLINS SJ, 1987, BLOOD, V70, P1233; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KOEFFLER HP, 1986, P NATL ACAD SCI USA, V83, P4035, DOI 10.1073/pnas.83.11.4035; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUBBERT M, 1988, J EXP MED, V167, P873, DOI 10.1084/jem.167.3.873; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; PAEK I, 1987, MOL CELL BIOL, V7, P1496, DOI 10.1128/MCB.7.4.1496; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PROKOCIMER M, 1986, BLOOD, V68, P113; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REISMAN D, 1988, P NATL ACAD SCI USA, V85, P5146, DOI 10.1073/pnas.85.14.5146; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; ROTTER V, 1983, P NATL ACAD SCI-BIOL, V80, P2613, DOI 10.1073/pnas.80.9.2613; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SHEN DW, 1983, P NATL ACAD SCI-BIOL, V80, P5919, DOI 10.1073/pnas.80.19.5919; SHOHAT O, 1987, ONCOGENE, V1, P277; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STURZBECHER HW, 1988, ONCOGENE, V3, P405; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; THOMPSON NL, 1986, CANCER RES, V46, P3111; TODARO GJ, 1966, SCIENCE, V153, P1252, DOI 10.1126/science.153.3741.1252; WOLF D, 1985, MOL CELL BIOL, V5, P1887, DOI 10.1128/MCB.5.8.1887; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YEN A, 1985, EXP CELL RES, V156, P198, DOI 10.1016/0014-4827(85)90274-5	57	24	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					945	953						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297	2668845				2022-12-17	WOS:A1989AJ29700001
J	GREEN, SM; LOWE, AD; PARRINGTON, J; KARN, J				GREEN, SM; LOWE, AD; PARRINGTON, J; KARN, J			TRANSFORMATION OF GROWTH FACTOR-DEPENDENT MYELOID STEM-CELLS WITH RETROVIRAL VECTORS CARRYING C-MYC	ONCOGENE			English	Article									MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology								ALLEN TD, 1984, EXP HEMATOL, V12, P517; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BAZILL GW, 1983, BIOCHEM J, V210, P747, DOI 10.1042/bj2100747; BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; CROCKER PR, 1985, J EXP MED, V162, P993, DOI 10.1084/jem.162.3.993; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; DICK JE, 1985, CELL, V42, P71, DOI 10.1016/S0092-8674(85)80102-1; DZIERZAK EA, 1988, NATURE, V331, P35, DOI 10.1038/331035a0; FUNG MC, 1984, NATURE, V307, P233, DOI 10.1038/307233a0; GORMAN CM, 1985, CELL, V42, P519, DOI 10.1016/0092-8674(85)90109-6; GOUGH NM, 1984, NATURE, V309, P763, DOI 10.1038/309763a0; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GRUBER HE, 1985, SCIENCE, V230, P1057, DOI 10.1126/science.3864246; HO DD, 1986, J CLIN INVEST, V77, P1712, DOI 10.1172/JCI112491; HUNT P, 1987, CELL, V48, P997, DOI 10.1016/0092-8674(87)90708-2; IHLE JN, 1983, J IMMUNOL, V131, P282; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KELLER G, 1986, COLD SPRING HARB SYM, V51, P1052; KINCADE PW, 1981, J IMMUNOL, V127, P2262; KKARN J, 1989, ONCOGENE, V4, P773; KUNG JT, 1981, J IMMUNOL, V127, P873; LAHER C, 1987, P NATL ACAD SCI USA, V84, P8458; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; LEMISCHKA IR, 1986, CELL, V45, P917, DOI 10.1016/0092-8674(86)90566-0; LY IA, 1974, J IMMUNOL METHODS, V5, P239, DOI 10.1016/0022-1759(74)90108-2; MAGLI MC, 1987, P NATL ACAD SCI USA, V84, P789, DOI 10.1073/pnas.84.3.789; MARSHAKROTHSTEIN A, 1979, J IMMUNOL, V122, P2491; METCALF D, 1980, BLOOD, V55, P138; MOCHIZUKI DY, 1987, P NATL ACAD SCI USA, V84, P5267, DOI 10.1073/pnas.84.15.5267; MORSE HC, 1986, P NATL ACAD SCI USA, V83, P6868, DOI 10.1073/pnas.83.18.6868; MULLERSIEBURG CE, 1986, CELL, V44, P653, DOI 10.1016/0092-8674(86)90274-6; NICOLA NA, 1983, J BIOL CHEM, V258, P9017; NUSSENZWEIG MC, 1981, J EXP MED, V154, P168, DOI 10.1084/jem.154.1.168; Oi V T, 1978, Curr Top Microbiol Immunol, V81, P115; ROSEN H, 1987, J EXP MED, V166, P1685, DOI 10.1084/jem.166.6.1685; SANCHEZMADRID F, 1983, J EXP MED, V158, P586, DOI 10.1084/jem.158.2.586; SNODGRASS R, 1987, EMBO J, V6, P3955, DOI 10.1002/j.1460-2075.1987.tb02737.x; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; SPRINGER TA, 1981, J BIOL CHEM, V256, P3833; STANLEY ER, 1981, J IMMUNOL METHODS, V42, P253, DOI 10.1016/0022-1759(81)90156-3; STANLEY ER, 1986, CELL, V45, P667, DOI 10.1016/0092-8674(86)90781-6; STEINMAN RM, 1983, J EXP MED, V157, P613, DOI 10.1084/jem.157.2.613; STEINMAN RM, 1980, J EXP MED, V152, P1248, DOI 10.1084/jem.152.5.1248; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; WHITE JG, 1987, J CELL BIOL, V105, P41, DOI 10.1083/jcb.105.1.41; WHITLOCK CA, 1987, CELL, V48, P1009, DOI 10.1016/0092-8674(87)90709-4; WILLIAMS DA, 1984, NATURE, V310, P476, DOI 10.1038/310476a0	54	24	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1989	4	6					737	751						15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2660072				2022-12-17	WOS:A1989AA66000010
J	RAY, R; THOMAS, S; MILLER, DM				RAY, R; THOMAS, S; MILLER, DM			MOUSE FIBROBLASTS TRANSFORMED WITH THE HUMAN C-MYC GENE EXPRESS A HIGH-LEVEL OF MESSENGER-RNA BUT A LOW-LEVEL OF C-MYC PROTEIN AND ARE NON-TUMORIGENIC IN NUDE-MICE	ONCOGENE			English	Article									UNIV ALABAMA,CTR COMPREHENS CANC,DEPT INTERNAL MED,288 BHSB,BIRMINGHAM,AL 35294; UNIV ALABAMA,CTR COMPREHENS CANC,DEPT BIOCHEM,BIRMINGHAM,AL 35294; VET ADM MED CTR,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NCI NIH HHS [R01 CA42337, R01 CA42664] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042337, R01CA042664] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLAIR DG, 1982, SCIENCE, V218, P1122, DOI 10.1126/science.6293052; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPELAND NG, 1980, J VIROL, V33, P1199, DOI 10.1128/JVI.33.3.1199-1202.1980; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIALLONGO A, 1983, SCIENCE, V222, P430, DOI 10.1126/science.6604943; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.ge.21.120187.001541; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; JOHNSON BE, 1986, J CLIN INVEST, V78, P525, DOI 10.1172/JCI112604; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.iy.04.040186.001533; KLEIN G, 1983, CELL, V32, P311, DOI 10.1016/0092-8674(83)90449-X; KOLLER CA, 1985, J CLIN INVEST, V76, P365, DOI 10.1172/JCI111970; KOLLER CA, 1986, NEW ENGL J MED, V315, P1433, DOI 10.1056/NEJM198612043152301; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAUTENBERGER JA, 1981, P NATL ACAD SCI-BIOL, V78, P1518, DOI 10.1073/pnas.78.3.1518; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; Maniatis T., 1982, MOL CLONING; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MORSE B, 1989, MOL CELL BIOL, V9, P74, DOI 10.1128/MCB.9.1.74; NEPVEU A, 1985, NATURE, V317, P440, DOI 10.1038/317440a0; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PERRY RP, 1983, CELL, V33, P647, DOI 10.1016/0092-8674(83)90006-5; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; SCHAWB M, 1984, CANCER CELLS, V2, P215; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPECTOR DL, 1987, ONCOGENE, V1, P5; STUDZINSKI GP, 1986, SCIENCE, V234, P467, DOI 10.1126/science.3532322; SULLIVAN N, 1986, CURR TOP MICROBIOL, V132, P355; VANBENEDEN RJ, 1986, P NATL ACAD SCI USA, V83, P3698; VENNSTROM B, 1987, ONCOGENE, V1, P271; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; WURM FM, 1986, P NATL ACAD SCI USA, V83, P5414, DOI 10.1073/pnas.83.15.5414; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363	53	24	24	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1989	4	5					593	600						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2657574				2022-12-17	WOS:A1989U768800009
J	TROTTER, J; BOULTER, CA; SONTHEIMER, H; SCHACHNER, M; WAGNER, EF				TROTTER, J; BOULTER, CA; SONTHEIMER, H; SCHACHNER, M; WAGNER, EF			EXPRESSION OF V-SRC ARRESTS MURINE GLIAL-CELL DIFFERENTIATION	ONCOGENE			English	Article									EUROPEAN MOLEC BIOL LAB,D-6900 HEIDELBERG,FED REP GER	European Molecular Biology Laboratory (EMBL)	TROTTER, J (corresponding author), UNIV HEIDELBERG,DEPT NEUROBIOL,NEUENHEIMER FELD 364,D-6900 HEIDELBERG,FED REP GER.		Boulter, Catherine/A-6607-2010	Sontheimer, Harald/0000-0002-5843-9871; Wagner, Erwin F/0000-0001-7872-0196				ABNEY ER, 1983, DEV BIOL, V100, P166, DOI 10.1016/0012-1606(83)90207-5; BARRES BA, 1988, GLIA, V1, P10, DOI 10.1002/glia.440010104; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BOULTER CA, 1988, ONCOGENE, V2, P207; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; DUBOISDALCQ M, 1987, EMBO J, V6, P2587, DOI 10.1002/j.1460-2075.1987.tb02549.x; EDELMAN GM, 1985, ANNU REV BIOCHEM, V54, P135, DOI 10.1146/annurev.bi.54.070185.001031; EISENBARTH GS, 1979, P NATL ACAD SCI USA, V76, P4913, DOI 10.1073/pnas.76.10.4913; FAISSNER A, 1985, EMBO J, V4, P3105, DOI 10.1002/j.1460-2075.1985.tb04052.x; FAISSNER A, 1988, DIFFERENTIATION, V37, P104, DOI 10.1111/j.1432-0436.1988.tb00802.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIOTTA GJ, 1982, DEV BRAIN RES, V4, P209, DOI 10.1016/0165-3806(82)90043-8; GIOTTA GJ, 1981, J CELL PHYSIOL, V107, P219, DOI 10.1002/jcp.1041070207; GIOTTA GJ, 1980, BRAIN RES, V202, P445, DOI 10.1016/0006-8993(80)90154-7; GREENBERG ME, 1984, P NATL ACAD SCI-BIOL, V81, P969, DOI 10.1073/pnas.81.3.969; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIRN M, 1981, BRAIN RES, V214, P433, DOI 10.1016/0006-8993(81)91208-7; KAHN P, 1986, ONCOGENES GROWTH CON; KEANE RW, 1984, DEV BIOL, V103, P38, DOI 10.1016/0012-1606(84)90005-8; KEILHAUER G, 1985, NATURE, V316, P728, DOI 10.1038/316728a0; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KELLER G, 1987, COLD SPRING HARBOR S, V51; KRUSE J, 1985, NATURE, V316, P146, DOI 10.1038/316146a0; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; Maniatis T., 1982, MOL CLONING; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MIRSKY R, 1978, BRAIN RES, V148, P251, DOI 10.1016/0006-8993(78)90399-2; NAGATA I, 1986, DEV BRAIN RES, V24, P217, DOI 10.1016/0165-3806(86)90190-2; NOWAK L, 1987, J NEUROSCI, V7, P101; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; RUTISCHAUSER U, 1986, TRENDS GENET, V22, P72; SCHACHNER M, 1981, DEV BIOL, V83, P328, DOI 10.1016/0012-1606(81)90478-4; SCHNITZER J, 1982, CELL TISSUE RES, V224, P625; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; SONTHEIMER GM, 1988, 16TH P GOTT NEUR C E; SONTHEIMER H, 1989, IN PRESS NEURON; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; TEMPLE S, 1985, NATURE, V313, P223, DOI 10.1038/313223a0; TROTTER J, 1989, IN PRESS DEV BRAIN R; TROTTER J, 1989, IN PRESS J NEUROSCI; WIESTLER OD, 1988, MOL CELL BIOL, V8, P502, DOI 10.1128/MCB.8.1.502	44	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1989	4	4					457	464						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5677	2497422				2022-12-17	WOS:A1989U567700010
J	EAGER, KB; PFIZENMAIER, K; RICCIARDI, RP				EAGER, KB; PFIZENMAIER, K; RICCIARDI, RP			MODULATION OF MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS-I GENES IN ADENOVIRUS-12 TRANSFORMED-CELLS - INTERFERON-GAMMA INCREASES CLASS-I EXPRESSION BY A MECHANISM THAT CIRCUMVENTS E1A INDUCED-REPRESSION AND TUMOR NECROSIS FACTOR ENHANCES THE EFFECT OF INTERFERON-GAMM	ONCOGENE			English	Article									WISTAR INST ANAT & BIOL,36TH & SPRUCE ST,PHILADELPHIA,PA 19104; UNIV GOTTINGEN,MAX PLANCK SOC,CLIN RES GRP,D-3400 GOTTINGEN,FED REP GER	The Wistar Institute; Max Planck Society; University of Gottingen					NCI NIH HHS [CA-29797, CA-09171] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029797, T32CA009171] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BONNER WM, 1974, EUR J BIOCHEM, V46, P83; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CHEN E, 1986, MOL CELL BIOL, V6, P1698, DOI 10.1128/MCB.6.5.1698; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; COLLINS T, 1986, P NATL ACAD SCI USA, V83, P446, DOI 10.1073/pnas.83.2.446; CROCE CM, 1981, P NATL ACAD SCI-BIOL, V78, P5754, DOI 10.1073/pnas.78.9.5754; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; EAGER KB, 1985, P NATL ACAD SCI USA, V82, P5525, DOI 10.1073/pnas.82.16.5525; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EVANS GA, 1982, P NATL ACAD SCI-BIOL, V79, P1994, DOI 10.1073/pnas.79.6.1994; FELLOUS M, 1982, P NATL ACAD SCI-BIOL, V79, P3082, DOI 10.1073/pnas.79.10.3082; FRIEDMAN DJ, 1988, VIROLOGY, V165, P303, DOI 10.1016/0042-6822(88)90689-7; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; FRIEDMAN RM, 1983, ADV IMMUNOL, V34, P97, DOI 10.1016/S0065-2776(08)60378-8; GRAY PW, 1983, P NATL ACAD SCI-BIOL, V80, P5842, DOI 10.1073/pnas.80.19.5842; HAYASHI H, 1985, CELL, V43, P263, DOI 10.1016/0092-8674(85)90031-5; HELSON L, 1975, NATURE, V258, P731, DOI 10.1038/258731a0; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; ISRAEL A, 1986, NATURE, V322, P743, DOI 10.1038/322743a0; JONAK GJ, 1984, P NATL ACAD SCI-BIOL, V81, P1747, DOI 10.1073/pnas.81.6.1747; KHALILI K, 1983, GENE, V21, P9, DOI 10.1016/0378-1119(83)90142-7; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KNIGHT E, 1985, P NATL ACAD SCI USA, V82, P1151, DOI 10.1073/pnas.82.4.1151; KNOWLES BB, 1979, J IMMUNOL, V122, P1798; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; KRONKE M, 1987, P NATL ACAD SCI USA, V84, P469, DOI 10.1073/pnas.84.2.469; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; Maniatis T., 1982, MOL CLONING; MAY LT, 1986, P NATL ACAD SCI USA, V83, P8957, DOI 10.1073/pnas.83.23.8957; MIYAZAKI J, 1986, P NATL ACAD SCI USA, V83, P9537, DOI 10.1073/pnas.83.24.9537; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PARNES JR, 1981, P NATL ACAD SCI-BIOL, V78, P2253, DOI 10.1073/pnas.78.4.2253; PFEFFER LM, 1982, GENETIC EXPRESSION C, P289; PFIZENMAIER K, 1987, J IMMUNOL, V138, P975; ROSENTHAL A, 1984, NATURE, V310, P415, DOI 10.1038/310415a0; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHEURICH P, 1987, J IMMUNOL, V138, P1786; SCHEURICH P, 1986, INT J CANCER, V38, P127, DOI 10.1002/ijc.2910380120; SCHEURICH P, 1986, IMMUNOBIOLOGY, V172, P281; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SCOTT MO, 1984, J VIROL, V50, P895, DOI 10.1128/JVI.50.3.895-903.1984; SHIRAYOSHI Y, 1987, MOL CELL BIOL, V7, P4542, DOI 10.1128/MCB.7.12.4542; STALLCUP KC, 1981, J IMMUNOL, V127, P923; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TANAKA K, 1985, SCIENCE, V228, P26, DOI 10.1126/science.3975631; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; VASAVADA R, 1986, P NATL ACAD SCI USA, V83, P5257, DOI 10.1073/pnas.83.14.5257; VOGEL J, 1986, MOL CELL BIOL, V6, P3550, DOI 10.1128/MCB.6.10.3550; WAN YJY, 1987, J CELL PHYSIOL, V130, P276, DOI 10.1002/jcp.1041300214; WEIL J, 1983, NATURE, V301, P437, DOI 10.1038/301437a0; WONG GHW, 1984, EUR J IMMUNOL, V14, P52, DOI 10.1002/eji.1830140110; YARDEN A, 1986, SCIENCE, V234, P1419, DOI 10.1126/science.3097823	59	24	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					39	44						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2521704				2022-12-17	WOS:A1989U567400006
J	VONLINDERN, M; VANAGTHOVEN, T; HAGEMEIJER, A; ADRIAANSEN, H; GROSVELD, G				VONLINDERN, M; VANAGTHOVEN, T; HAGEMEIJER, A; ADRIAANSEN, H; GROSVELD, G			THE HUMAN PIM-1 GENE IS NOT DIRECTLY ACTIVATED BY THE TRANSLOCATION (6-9) IN ACUTE NONLYMPHOCYTIC LEUKEMIA	ONCOGENE			English	Article									ACAD HOSP DIJKZIGT,DEPT IMMUNOL,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC	VONLINDERN, M (corresponding author), ERASMUS UNIV,DEPT CELL BIOL & GENET,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.		von Lindern, Marieke/AAH-2350-2020					ADRIAANSEN HJ, 1988, LEUKEMIA, V2, P136; CARLE GF, 1986, SCIENCE, V232, P65, DOI 10.1126/science.3952500; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CUYPERS HT, 1984, CELL, V37, P141; DOMEN J, 1987, ONCOGENE RES, V1, P103; FEINBERG A, 1982, ANAL BIOCHEM, V132, P6; HEIM S, 1986, CANCER GENET CYTOGEN, V22, P195, DOI 10.1016/0165-4608(86)90155-X; HEISTERKAMP N, 1982, NATURE, V299, P747, DOI 10.1038/299747a0; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; JEFFREYS AJ, 1977, CELL, V12, P429, DOI 10.1016/0092-8674(77)90119-2; KAMATA T, 1987, ONCOGENE, V1, P19; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; LARSON RA, 1983, CANCER GENET CYTOGEN, V10, P219, DOI 10.1016/0165-4608(83)90050-X; LEACH R, 1986, P NATL ACAD SCI USA, V83, P3909, DOI 10.1073/pnas.83.11.3909; LEBEAU MM, 1984, CANCER SURV, V3, P371; Maniatis T., 1982, MOL CLONING; MEEKER TC, 1987, ONCOGENE RES, V1, P87; NAGARAJAN L, 1986, P NATL ACAD SCI USA, V83, P2556, DOI 10.1073/pnas.83.8.2556; PEARSON MG, 1985, AM J HEMATOL, V18, P393, DOI 10.1002/ajh.2830180409; ROWLEY JD, 1976, BLOOD, V47, P705; ROWLEY JD, 1977, LANCET, V1, P549; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; TELERMAN A, 1988, MOL CELL BIOL, V8, P1498, DOI 10.1128/MCB.8.4.1498; VANKESSEL AHMG, 1981, CYTOGENET CELL GENET, V30, P83; WESTBROOK CA, 1985, P NATL ACAD SCI USA, V82, P8742, DOI 10.1073/pnas.82.24.8742; WESTBROOK CA, 1987, P NATL ACAD SCI USA, V84, P251, DOI 10.1073/pnas.84.1.251; YUNIS JJ, 1984, CANCER GENET CYTOGEN, V11, P125, DOI 10.1016/0165-4608(84)90106-7	30	24	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					75	79						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2644612				2022-12-17	WOS:A1989U567400011
J	SHAW, APW; POIRIER, V; TYLER, S; MOTT, M; BERRY, J; MAITLAND, NJ				SHAW, APW; POIRIER, V; TYLER, S; MOTT, M; BERRY, J; MAITLAND, NJ			EXPRESSION OF THE N-MYC ONCOGENE IN WILMS TUMOR AND RELATED-TISSUES	ONCOGENE			English	Article									UNIV BRISTOL,DEPT PATHOL,BRISTOL BS8 1TD,AVON,ENGLAND; UNIV BRISTOL,DEPT CHILD HLTH,BRISTOL BS8 1TD,AVON,ENGLAND	University of Bristol; University of Bristol	SHAW, APW (corresponding author), UNIV BRISTOL,CANC & LEUKAEMIA CHILDHOOD TRUST RES UNIT,BRISTOL BS8 1TD,AVON,ENGLAND.							BERNARDS R, 1987, TRENDS GENET, V3, P298, DOI 10.1016/0168-9525(87)90272-1; Bolande R P, 1973, Perspect Pediatr Pathol, V1, P227; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRADY EF, 1987, CANCER RES, V47, P2931; GREENWOOD MF, 1984, WILMS TUMOUR CLIN BI; HOEFLER H, 1986, HISTOCHEM J, V18, P597, DOI 10.1007/BF01675295; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KNUDSON AG, 1985, CANCER RES, V45, P1435; KONECKI DS, 1982, NUCLEIC ACIDS RES, V10, P6763, DOI 10.1093/nar/10.21.6763; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; MACHIN GA, 1984, WILMS TUMOUR CLIN BI, P236; MAITLAND NJ, 1987, J ORAL PATHOL MED, V16, P199; MAITLAND NJ, 1981, J GEN VIROL, V55, P123, DOI 10.1099/0022-1317-55-1-123; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIERAU GW, 1987, ULTRASTRUCT PATHOL, V11, P313, DOI 10.3109/01913128709048329; NISEN PD, 1986, CANCER RES, V46, P6217; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SNYDER HM, 1981, J UROLOGY, V126, P513, DOI 10.1016/S0022-5347(17)54601-7; SOOD AK, 1981, P NATL ACAD SCI-BIOL, V78, P616, DOI 10.1073/pnas.78.1.616; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	28	24	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1988	3	2					143	149						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	2842712				2022-12-17	WOS:A1988Q053400003
J	CAVALIERI, F; GOLDFARB, M				CAVALIERI, F; GOLDFARB, M			N-MYC PROTO-ONCOGENE EXPRESSION CAN INDUCE DNA-REPLICATION IN BALB/C 3T3 FIBROBLASTS	ONCOGENE			English	Article											CAVALIERI, F (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,630 W 168 ST,NEW YORK,NY 10032, USA.				NATIONAL CANCER INSTITUTE [P01CA022376] Funding Source: NIH RePORTER; NCI NIH HHS [CA22376] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; ARMELIN HA, 1984, NATURE, V310, P656; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; CAVALIERI F, 1987, MOL CELL BIOL, V7, P3554, DOI 10.1128/MCB.7.10.3554; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HUBERMAN JA, 1981, CELL, V23, P647, DOI 10.1016/0092-8674(81)90426-8; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KELLY K, 1986, ANNU REV IMMUNOL, V4, P327; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; SHARP PA, 1974, COLD SPRING HARB SYM, V39, P457, DOI 10.1101/SQB.1974.039.01.058; SLAMON DJ, 1986, SCIENCE, V232, P768, DOI 10.1126/science.3008339; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	24	24	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					289	291						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	3281096				2022-12-17	WOS:A1988M593100013
J	HOHNE, M; PIASECKI, A; UMMELMANN, E; PAUL, D				HOHNE, M; PIASECKI, A; UMMELMANN, E; PAUL, D			TRANSFORMATION OF DIFFERENTIATED NEONATAL RAT HEPATOCYTES IN PRIMARY CULTURE BY POLYOMA-VIRUS EARLY REGION SEQUENCES	ONCOGENE			English	Article									UNIV HAMBURG,SCH MED,DEPT TOXICOL,GRINDELALLEE 117,D-2000 HAMBURG 13,FED REP GER; FRAUNHOFER INST TOXICOL,DEPT CELL BIOL,D-3000 HANNOVER 61,FED REP GER	University of Hamburg; Fraunhofer Gesellschaft								ARMATO U, 1983, CHEM-BIOL INTERACT, V45, P203, DOI 10.1016/0009-2797(83)90069-8; BARGMANN CI, 1986, NATURE, V319, P230; BUCHER NLR, 1978, CIBA F S, V55, P95; CAPETANAKI YG, 1982, MOL CELL BIOL, V2, P258, DOI 10.1128/MCB.2.3.258; CHEAH MSC, 1986, NATURE, V319, P238, DOI 10.1038/319238a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; CLAYTON DF, 1983, MOL CELL BIOL, V3, P1552, DOI 10.1128/MCB.3.9.1552; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; Cowley GO, 1984, CANCER CELL, V1, P5; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; DRAGHI E, 1980, J CELL PHYSIOL, V103, P129, DOI 10.1002/jcp.1041030118; ENAT R, 1984, P NATL ACAD SCI-BIOL, V81, P1411, DOI 10.1073/pnas.81.5.1411; FRANCAVILLA A, 1986, CANCER RES, V46, P1318; FRIEDMAN DL, 1981, EXP CELL RES, V135, P283, DOI 10.1016/0014-4827(81)90164-6; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GEORGOFF I, 1984, J BIOL CHEM, V259, P9595; GOSPODAROWICZ D, 1974, P NATL ACAD SCI USA, V71, P4584, DOI 10.1073/pnas.71.11.4584; HOFFMANN B, 1987, UNPUB EXP CELL RES; HUANG DP, 1985, NUCLEIC ACIDS RES, V13, P3873, DOI 10.1093/nar/13.11.3873; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; INNIS MA, 1979, ARCH BIOCHEM BIOPHYS, V195, P128, DOI 10.1016/0003-9861(79)90334-5; ISOM HC, 1985, P NATL ACAD SCI USA, V82, P3252, DOI 10.1073/pnas.82.10.3252; ISOM HC, 1984, P NATL ACAD SCI-BIOL, V81, P6378, DOI 10.1073/pnas.81.20.6378; JEFFERSON DM, 1984, MOL CELL BIOL, V4, P1929, DOI 10.1128/MCB.4.9.1929; KAPLAN PL, 1982, VIROLOGY, V123, P372, DOI 10.1016/0042-6822(82)90270-7; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; LEFFERT HL, 1972, J CELL BIOL, V52, P559, DOI 10.1083/jcb.52.3.559; LIEBERMAN TA, 1985, NATURE, V313, P144; LIN QX, 1984, J CELL PHYSIOL, V119, P267, DOI 10.1002/jcp.1041190304; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; MASSAGUE J, 1983, J BIOL CHEM, V258, P3606; MCGOWAN JA, 1981, J CELL PHYSIOL, V108, P353, DOI 10.1002/jcp.1041080309; MIRANDA AF, 1983, P NATL ACAD SCI-BIOL, V80, P6581, DOI 10.1073/pnas.80.21.6581; PALMITER RD, 1985, NATURE, V316, P457, DOI 10.1038/316457a0; PAUL D, 1984, EXP CELL RES, V154, P95, DOI 10.1016/0014-4827(84)90670-0; PAUL D, 1987, IN PRESS EXP CELL RE; PINET F, 1985, P NATL ACAD SCI USA, V82, P8503, DOI 10.1073/pnas.82.24.8503; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHNEIDER CA, 1986, P NATL ACAD SCI USA, V83, P333, DOI 10.1073/pnas.83.2.333; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SHINOMIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P1346, DOI 10.1073/pnas.81.5.1346; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; TSAO MS, 1986, J CELL PHYSIOL, V126, P167, DOI 10.1002/jcp.1041260204; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YASUMOTO S, 1984, MOL CELL BIOL, V4, P712, DOI 10.1128/MCB.4.4.712	56	24	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	4					337	345						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	K7483	2838782				2022-12-17	WOS:A1987K748300001
J	Saraon, P; Pathmanathan, S; Snider, J; Lyakisheva, A; Wong, V; Stagljar, I				Saraon, Punit; Pathmanathan, Shivanthy; Snider, Jamie; Lyakisheva, Anna; Wong, Victoria; Stagljar, Igor			Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches	ONCOGENE			English	Review							TARGETED PROTEIN-DEGRADATION; ANTITUMOR-ACTIVITY; EGFR MUTANTS; ACTIVATION; GROWTH; MET; RESISTANCE; INHIBITION; DRIVEN; CELLS	Receptor tyrosine kinases (RTKs) are transmembrane receptors of great clinical interest due to their role in disease, notably cancer. Since their discovery, several mechanisms of RTK dysregulation have been identified, resulting in multiple cancer types displaying 'oncogenic addiction' to RTKs. As a result, RTKs have represented a major class for targeted therapeutics over the past two decades, with numerous small molecule-based tyrosine kinase inhibitor (TKI) therapeutics having been developed and clinically approved for several cancers. However, many of the current RTK inhibitor treatments eventually result in the rapid development of acquired resistance and subsequent tumor relapse. Recent technological advances and tools are being generated for the identification of novel RTK small molecule therapeutics. These newer technologies will be important for the identification of diverse types of RTK inhibitors, targeting both the receptors themselves as well as key cellular factors that play important roles in the RTK signaling cascade.	[Saraon, Punit] Ontario Inst Canc Res, Drug Discovery Program, Toronto, ON, Canada; [Pathmanathan, Shivanthy; Snider, Jamie; Lyakisheva, Anna; Wong, Victoria; Stagljar, Igor] Univ Toronto, Donnelly Ctr, Toronto, ON, Canada; [Pathmanathan, Shivanthy; Stagljar, Igor] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada; [Stagljar, Igor] Univ Toronto, Dept Biochem, Toronto, ON, Canada; [Stagljar, Igor] Mediterranean Inst Life Sci, Split, Croatia; [Stagljar, Igor] Univ Split, Sch Med, Split, Croatia	Ontario Institute for Cancer Research; University of Toronto; University Toronto Affiliates; University of Toronto; University of Toronto; University of Toronto; University of Split	Stagljar, I (corresponding author), Univ Toronto, Donnelly Ctr, Toronto, ON, Canada.; Stagljar, I (corresponding author), Univ Toronto, Dept Mol Genet, Toronto, ON, Canada.; Stagljar, I (corresponding author), Univ Toronto, Dept Biochem, Toronto, ON, Canada.; Stagljar, I (corresponding author), Mediterranean Inst Life Sci, Split, Croatia.; Stagljar, I (corresponding author), Univ Split, Sch Med, Split, Croatia.	igor.stagljar@utoronto.ca						Alshareef A, 2016, SCI REP-UK, V6, DOI 10.1038/srep33710; Baro M, 2019, CLIN CANCER RES, V25, P784, DOI 10.1158/1078-0432.CCR-18-0792; Bender S, 2016, NAT MED, V22, P1314, DOI 10.1038/nm.4204; Bhargava R, 2005, MODERN PATHOL, V18, P1027, DOI 10.1038/modpathol.3800438; Bhullar KS, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0804-2; Bondeson DP, 2018, CELL CHEM BIOL, V25, P78, DOI 10.1016/j.chembiol.2017.09.010; Bondeson DP, 2015, NAT CHEM BIOL, V11, P611, DOI [10.1038/NCHEMBIO.1858, 10.1038/nchembio.1858]; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Burslem GM, 2020, CELL, V181, P102, DOI 10.1016/j.cell.2019.11.031; Burslem GM, 2019, CANCER RES, V79, P4744, DOI 10.1158/0008-5472.CAN-19-1236; Burslem GM, 2018, J AM CHEM SOC, V140, P16428, DOI 10.1021/jacs.8b10320; Burslem GM, 2018, CELL CHEM BIOL, V25, P67, DOI 10.1016/j.chembiol.2017.09.009; Castelli MS, 2019, PHARMACOL RES PERSPE, V7, DOI 10.1002/prp2.535; Charest A, 2003, P NATL ACAD SCI USA, V100, P916, DOI 10.1073/pnas.242741799; Chen CHB, 2003, P NATL ACAD SCI USA, V100, P9226, DOI 10.1073/pnas.1332660100; Chen YNP, 2016, NATURE, V535, P148, DOI 10.1038/nature18621; Cheng HY, 2015, CANCER RES, V75, P2737, DOI 10.1158/0008-5472.CAN-15-0370; Choudhary C, 2009, MOL CELL, V36, P326, DOI 10.1016/j.molcel.2009.09.019; Chung BM, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-84; Citri A, 2004, EMBO REP, V5, P1165, DOI 10.1038/sj.embor.7400300; Cocco E, 2018, NAT REV CLIN ONCOL, V15, P731, DOI 10.1038/s41571-018-0113-0; Comoglio PM, 2018, NAT REV CANCER, V18, P341, DOI 10.1038/s41568-018-0002-y; Contessa JN, 2008, CANCER RES, V68, P3803, DOI 10.1158/0008-5472.CAN-07-6389; Contessa JN, 2010, CLIN CANCER RES, V16, P3205, DOI 10.1158/1078-0432.CCR-09-3331; Cromm PM, 2018, J AM CHEM SOC, V140, P17019, DOI 10.1021/jacs.8b08008; Dance M, 2008, CELL SIGNAL, V20, P453, DOI 10.1016/j.cellsig.2007.10.002; Dart ML, 2018, ACS MED CHEM LETT, V9, P546, DOI 10.1021/acsmedchemlett.8b00081; Daver N, 2019, LEUKEMIA, V33, P299, DOI 10.1038/s41375-018-0357-9; De Meyts P, 2015, BIOESSAYS, V37, P389, DOI 10.1002/bies.201400190; Drilon A, 2020, NAT MED, V26, P47, DOI 10.1038/s41591-019-0716-8; Du ZF, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0782-4; Ducray SP, 2019, CANCERS, V11, DOI 10.3390/cancers11081074; Esposito CL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024071; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Flavahan WA, 2016, NATURE, V529, P110, DOI 10.1038/nature16490; Foster SA, 2016, CANCER CELL, V29, P477, DOI 10.1016/j.ccell.2016.02.010; Gan HK, 2013, FEBS J, V280, P5350, DOI 10.1111/febs.12393; Goh LK, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a017459; Griffith J, 2004, MOL CELL, V13, P169, DOI 10.1016/S1097-2765(03)00505-7; Gujral TS, 2006, CANCER RES, V66, P10741, DOI 10.1158/0008-5472.CAN-06-3329; Harbinski F, 2012, CANCER DISCOV, V2, P948, DOI 10.1158/2159-8290.CD-12-0237; Heldin J, 2019, EXP CELL RES, V380, P69, DOI 10.1016/j.yexcr.2019.04.004; Henderson MJ, 2020, SLAS DISCOV, V25, P137, DOI 10.1177/2472555219877183; IM J, 2020, NAT COMMUN, V11; Jafari R, 2014, NAT PROTOC, V9, P2100, DOI 10.1038/nprot.2014.138; Jia Y, 2016, NATURE, V534, P129, DOI 10.1038/nature17960; Joffre C, 2011, NAT CELL BIOL, V13, P827, DOI 10.1038/ncb2257; Katoh M, 2019, NAT REV CLIN ONCOL, V16, P105, DOI 10.1038/s41571-018-0115-y; Kentsis A, 2012, NAT MED, V18, P1118, DOI 10.1038/nm.2819; Kilpatrick LE, 2017, BIOCHEM PHARMACOL, V136, P62, DOI 10.1016/j.bcp.2017.04.006; Klaver E, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.039602; Kobayashi H, 2019, NAT PROTOC, V14, P1084, DOI 10.1038/s41596-019-0129-7; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Lopez-Sambrooks C, 2016, NAT CHEM BIOL, V12, P1023, DOI 10.1038/nchembio.2194; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Macdonald JL, 2008, P NATL ACAD SCI USA, V105, P112, DOI 10.1073/pnas.0707080105; Macdonald-Obermann JL, 2014, J BIOL CHEM, V289, P26178, DOI 10.1074/jbc.M114.586826; Machleidt T, 2015, ACS CHEM BIOL, V10, P1797, DOI 10.1021/acschembio.5b00143; Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002; Mak HHL, 2007, ONCOGENE, V26, P7213, DOI 10.1038/sj.onc.1210522; Mellman I, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a016949; Menard L, 2018, CANCER RES, V78, P3267, DOI 10.1158/0008-5472.CAN-17-2195; Molhoek KR, 2011, MELANOMA RES, V21, P274, DOI 10.1097/CMR.0b013e328343a1d6; Molina DM, 2013, SCIENCE, V341, P84, DOI 10.1126/science.1233606; Mulligan LM, 2014, NAT REV CANCER, V14, P173, DOI 10.1038/nrc3680; Niederst MJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004652; Oh DY, 2020, NAT REV CLIN ONCOL, V17, P33, DOI 10.1038/s41571-019-0268-3; Ohashi Y, 2018, ONCOTARGET, V9, P1641, DOI 10.18632/oncotarget.22895; Ohashi Y, 2016, CANCER RES, V76, P3895, DOI 10.1158/0008-5472.CAN-15-2220; ORCI L, 1991, CELL, V64, P1183; OSTRANDER GK, 1988, CANCER RES, V48, P1091; Paiva SL, 2019, CURR OPIN CHEM BIOL, V50, P111, DOI 10.1016/j.cbpa.2019.02.022; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Perrin J, 2020, NAT BIOTECHNOL, V38, P303, DOI 10.1038/s41587-019-0388-4; Petschnigg J, 2017, J MOL BIOL, V429, P280, DOI 10.1016/j.jmb.2016.12.006; Petschnigg J, 2014, NAT METHODS, V11, P585, DOI [10.1038/NMETH.2895, 10.1038/nmeth.2895]; Pietras K, 2008, PLOS MED, V5, P123, DOI 10.1371/journal.pmed.0050019; Robertson MJ, 2014, NAT PROTOC, V9, P1592, DOI 10.1038/nprot.2014.106; Rosendale M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12434-9; Sakamoto KM, 2001, P NATL ACAD SCI USA, V98, P8554, DOI 10.1073/pnas.141230798; Salami J, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0105-8; Sambrooks CL, 2018, CANCER RES, V78, P5094, DOI 10.1158/0008-5472.CAN-18-0505; Saraon P, 2020, NAT CHEM BIOL, V16, P577, DOI 10.1038/s41589-020-0484-2; Savitski MM, 2018, CELL, V173, P260, DOI 10.1016/j.cell.2018.02.030; Savitski MM, 2014, SCIENCE, V346, P55, DOI 10.1126/science.1255784; Schapira M, 2019, NAT REV DRUG DISCOV, V18, P949, DOI 10.1038/s41573-019-0047-y; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sholl LM, 2009, CANCER RES, V69, P8341, DOI 10.1158/0008-5472.CAN-09-2477; Shtiegman K, 2007, ONCOGENE, V26, P6968, DOI 10.1038/sj.onc.1210503; Singh D, 2012, SCIENCE, V337, P1231, DOI 10.1126/science.1220834; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748; Stoddart LA, 2018, TRENDS PHARMACOL SCI, V39, P136, DOI 10.1016/j.tips.2017.10.006; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Tamirat MZ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222814; Tape CJ, 2016, CELL, V165, P1818, DOI [10.1016/j.cell.2016.03.029, 10.1016/j.cell.2016.05.079]; Tejada ML, 2006, CLIN CANCER RES, V12, P2676, DOI 10.1158/1078-0432.CCR-05-1770; Thress KS, 2015, NAT MED, V21, P560, DOI 10.1038/nm.3854; To C, 2019, CANCER DISCOV, V9, P926, DOI 10.1158/2159-8290.CD-18-0903; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; Villasenor R, 2016, CURR OPIN CELL BIOL, V39, P53, DOI 10.1016/j.ceb.2016.02.002; Villasenor R, 2015, ELIFE, V4, DOI 10.7554/eLife.06156; von Kleist L, 2011, CELL, V146, P471, DOI 10.1016/j.cell.2011.06.025; Wang L, 2020, J MED CHEM, V63, P1281, DOI 10.1021/acs.jmedchem.9b01659; Wang YN, 2010, BIOCHEM BIOPH RES CO, V399, P498, DOI 10.1016/j.bbrc.2010.07.096; Yano S, 2008, CANCER RES, V68, P9479, DOI 10.1158/0008-5472.CAN-08-1643; Yao Z, 2017, MOL CELL, V65, P347, DOI 10.1016/j.molcel.2016.12.004; Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017; Zhao P, 2018, BIOCHEM BIOPH RES CO, V502, P332, DOI 10.1016/j.bbrc.2018.05.154; Zhao Q, 2017, J AM CHEM SOC, V139, P680, DOI 10.1021/jacs.6b08536; Zsebik B, 2006, IMMUNOL LETT, V104, P146, DOI 10.1016/j.imlet.2005.11.018	113	23	23	4	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2021	40	24					4079	4093		10.1038/s41388-021-01841-2	http://dx.doi.org/10.1038/s41388-021-01841-2		JUN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SU3OE	34079087				2022-12-17	WOS:000657217400008
J	Pantano, F; Croset, M; Driouch, K; Bednarz-Knoll, N; Iuliani, M; Ribelli, G; Bonnelye, E; Wikman, H; Geraci, S; Bonin, F; Simonetti, S; Vincenzi, B; Hong, SS; Sousa, S; Pantel, K; Tonini, G; Santini, D; Clezardin, P				Pantano, Francesco; Croset, Martine; Driouch, Keltouma; Bednarz-Knoll, Natalia; Iuliani, Michele; Ribelli, Giulia; Bonnelye, Edith; Wikman, Harriet; Geraci, Sandra; Bonin, Florian; Simonetti, Sonia; Vincenzi, Bruno; Hong, Saw See; Sousa, Sofia; Pantel, Klaus; Tonini, Giuseppe; Santini, Daniele; Clezardin, Philippe			Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions	ONCOGENE			English	Article							CELL-MIGRATION; OSTEOBLAST DIFFERENTIATION; TUMOR-CELLS; EXPRESSION; LUNG; VOLOCIXIMAB; SURVIVAL; GROWTH; COLONIZATION; INHIBITION	Bone metastasis remains a major cause of mortality and morbidity in breast cancer. Therefore, there is an urgent need to better select high-risk patients in order to adapt patient's treatment and prevent bone recurrence. Here, we found that integrin alpha5 (ITGA5) was highly expressed in bone metastases, compared to lung, liver, or brain metastases. High ITGA5 expression in primary tumors correlated with the presence of disseminated tumor cells in bone marrow aspirates from early stage breast cancer patients (n = 268; p = 0.039). ITGA5 was also predictive of poor bone metastasis-free survival in two separate clinical data sets (n = 855, HR = 1.36, p = 0.018 and n = 427, HR = 1.62, p = 0.024). This prognostic value remained significant in multivariate analysis (p = 0.028). Experimentally, ITGA5 silencing impaired tumor cell adhesion to fibronectin, migration, and survival. ITGA5 silencing also reduced tumor cell colonization of the bone marrow and formation of osteolytic lesions in vivo. Conversely, ITGA5 overexpression promoted bone metastasis. Pharmacological inhibition of ITGA5 with humanized monoclonal antibody M200 (volociximab) recapitulated inhibitory effects of ITGA5 silencing on tumor cell functions in vitro and tumor cell colonization of the bone marrow in vivo. M200 also markedly reduced tumor outgrowth in experimental models of bone metastasis or tumorigenesis, and blunted cancer-associated bone destruction. ITGA5 was not only expressed by tumor cells but also osteoclasts. In this respect, M200 decreased human osteoclast-mediated bone resorption in vitro. Overall, this study identifies ITGA5 as a mediator of breast-to-bone metastasis and raises the possibility that volociximab/M200 could be repurposed for the treatment of ITGA5-positive breast cancer patients with bone metastases.	[Pantano, Francesco; Croset, Martine; Bonnelye, Edith; Geraci, Sandra; Sousa, Sofia; Clezardin, Philippe] INSERM, UMR S1033, LYOS, Lyon, France; [Pantano, Francesco; Croset, Martine; Bonnelye, Edith; Geraci, Sandra; Hong, Saw See; Sousa, Sofia; Clezardin, Philippe] Univ Lyon, Villeurbanne, France; [Pantano, Francesco; Iuliani, Michele; Ribelli, Giulia; Simonetti, Sonia; Vincenzi, Bruno; Tonini, Giuseppe; Santini, Daniele] Campus Biomed Univ Rome, Dept Med Oncol, Rome, Italy; [Driouch, Keltouma; Bonin, Florian] Inst Curie, Serv Genet, Unite Pharmacogen, Paris, France; [Bednarz-Knoll, Natalia; Wikman, Harriet; Pantel, Klaus] Univ Med Ctr Hamburg Eppendorf, Dept Tumor Biol, Hamburg, Germany; [Bednarz-Knoll, Natalia] Med Univ Gdansk, Lab Translat Oncol, Gdansk, Poland; [Hong, Saw See] INRA, UMR 754, Lyon, France; [Clezardin, Philippe] Univ Sheffield, Oncol & Metab Dept, Sheffield, S Yorkshire, England	Institut National de la Sante et de la Recherche Medicale (Inserm); University Campus Bio-Medico - Rome Italy; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Hamburg; University Medical Center Hamburg-Eppendorf; Fahrenheit Universities; Medical University Gdansk; INRAE; University of Sheffield	Clezardin, P (corresponding author), INSERM, UMR S1033, LYOS, Lyon, France.; Clezardin, P (corresponding author), Univ Lyon, Villeurbanne, France.; Clezardin, P (corresponding author), Univ Sheffield, Oncol & Metab Dept, Sheffield, S Yorkshire, England.	philippe.clezardin@inserm.fr	Pantano, Francesco/D-8459-2012; Bonnelye, Edith/AAT-9134-2021; Clezardin, Philippe/M-8071-2014	Pantano, Francesco/0000-0002-2894-9686; Wikman, Harriet/0000-0001-6862-0888; Clezardin, Philippe/0000-0003-0149-4463; Bednarz-Knoll, Natalia/0000-0001-9506-942X	"Ligue contre le cancer" cd69, 2016; Breast Cancer Research Foundation (BCRF, USA) [BCRF-16-096]; Deutsche Forschungsgemeinschaft, SPP microBONE; INSERM, University Claude Bernard Lyon 1; "Project LIA/LEA 2016" of the University of Lyon, within the program "Investissements d'Avenir" [ASC17018CSA, ANR-11-IDEX-0007]; LabEX DEVweCAN of the University of Lyon, within the program "Investissements d'Avenir" [ANR-11-IDEX-0007, ANR-10-LABX-61]; Inca [Transla09-112]	"Ligue contre le cancer" cd69, 2016; Breast Cancer Research Foundation (BCRF, USA); Deutsche Forschungsgemeinschaft, SPP microBONE(German Research Foundation (DFG)); INSERM, University Claude Bernard Lyon 1; "Project LIA/LEA 2016" of the University of Lyon, within the program "Investissements d'Avenir"(French National Research Agency (ANR)); LabEX DEVweCAN of the University of Lyon, within the program "Investissements d'Avenir"(French National Research Agency (ANR)); Inca(Institut National du Cancer (INCA) France)	MC acknowledges the support of "Ligue contre le cancer" cd69, 2016. KD acknowledges the support of Inca (Grant No. Transla09-112). FB is supported by the Breast Cancer Research Foundation (BCRF, USA) (BCRF-16-096, 2016-2017). KP is supported by the Deutsche Forschungsgemeinschaft, SPP microBONE. PC is supported by INSERM, University Claude Bernard Lyon 1, the "Project LIA/LEA 2016" (Grant No.: ASC17018CSA), and the LabEX DEVweCAN (ANR-10-LABX-61) of the University of Lyon, within the program "Investissements d'Avenir" (ANR-11-IDEX-0007) operated by the French National Research Agency (ANR).	Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Almokadem S, 2012, EXPERT OPIN BIOL TH, V12, P251, DOI 10.1517/14712598.2012.646985; Anderson JA, 2007, BRIT J CANCER, V96, P1394, DOI 10.1038/sj.bjc.6603720; Bartkowiak K, 2015, CANCER RES, V75, P5367, DOI 10.1158/0008-5472.CAN-14-3728; Bednarz-Knoll N, 2015, ONCOTARGET, V6, P26789, DOI 10.18632/oncotarget.4628; Bell-McGuinn KM, 2011, GYNECOL ONCOL, V121, P273, DOI 10.1016/j.ygyno.2010.12.362; Besse B, 2013, ANN ONCOL, V24, P90, DOI 10.1093/annonc/mds281; Bieche I, 2001, CANCER RES, V61, P1652; Bonnelye E, 2001, J CELL BIOL, V153, P971, DOI 10.1083/jcb.153.5.971; Braun S, 2000, NEW ENGL J MED, V342, P525, DOI 10.1056/NEJM200002243420801; Cerami E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008918; Coleman RE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-00216-3; Croset M, 2018, CANCER RES, V78, P5259, DOI 10.1158/0008-5472.CAN-17-3058; Croset M, 2014, J BONE MINER RES, V29, P1886, DOI 10.1002/jbmr.2215; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Duffy MJ, 2008, CLIN CHEM, V54, P1770, DOI 10.1373/clinchem.2008.110056; Fan LC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162933; Fehm T, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1869; FIDLER IJ, 1973, EUR J CANCER, V9, P223, DOI 10.1016/S0014-2964(73)80022-2; Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767; Hamidi H, 2018, NAT REV CANCER, V18, P532, DOI 10.1038/s41568-018-0038-z; Hamidouche Z, 2009, P NATL ACAD SCI USA, V106, P18587, DOI 10.1073/pnas.0812334106; Harrell JC, 2012, BREAST CANCER RES TR, V132, P523, DOI 10.1007/s10549-011-1619-7; Hosseini H, 2016, NATURE, V540, P552, DOI 10.1038/nature20785; HUGHES DE, 1993, J BONE MINER RES, V8, P527; Imanishi Y, 2007, CANCER RES, V67, P4254, DOI 10.1158/0008-5472.CAN-06-4100; Iuliani M, 2015, ONCOTARGET, V6, P12520, DOI 10.18632/oncotarget.3724; Jami MS, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-194; Ju JLA, 2017, MOL CANCER RES, V15, P723, DOI 10.1158/1541-7786.MCR-16-0338; Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820; Khalili P, 2006, MOL CANCER THER, V5, P2271, DOI 10.1158/1535-7163.MCT-06-0100; Korah R, 2004, CANCER RES, V64, P4514, DOI 10.1158/0008-5472.CAN-03-3853; Landemaine T, 2008, CANCER RES, V68, P6092, DOI 10.1158/0008-5472.CAN-08-0436; Lehtinen L, 2012, J PATHOL, V226, P674, DOI 10.1002/path.3956; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Oudin MJ, 2016, CANCER DISCOV, V6, P516, DOI 10.1158/2159-8290.CD-15-1183; Pantel K, 1994, J Hematother, V3, P165, DOI 10.1089/scd.1.1994.3.165; Pecheur I, 2002, FASEB J, V16, P1266, DOI 10.1096/fj.01-0911fje; Peyruchaud O, 2001, J BONE MINER RES, V16, P2027, DOI 10.1359/jbmr.2001.16.11.2027; Pignatelli J, 2012, J CELL BIOL, V197, P421, DOI 10.1083/jcb.201108143; Qin L, 2011, CANCER RES, V71, P1742, DOI 10.1158/0008-5472.CAN-10-3453; Reynaud C, 2017, CANCER RES, V77, P268, DOI 10.1158/0008-5472.CAN-15-2621; Ricart AD, 2008, CLIN CANCER RES, V14, P7924, DOI 10.1158/1078-0432.CCR-08-0378; Schnitt SJ, 2010, MODERN PATHOL, V23, pS60, DOI 10.1038/modpathol.2010.33; Simon KO, 1997, J BIOL CHEM, V272, P29380, DOI 10.1074/jbc.272.46.29380; Sin S, 2011, J NATL CANCER I, V103, P1323, DOI 10.1093/jnci/djr290; Truong HH, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004751; VanderVeldeZimmermann D, 1997, EXP CELL RES, V230, P111, DOI 10.1006/excr.1996.3405; Wiedswang G, 2003, CYTOTHERAPY, V5, P40, DOI 10.1080/14653240310000065; Wu ZG, 2018, BIOCHEM BIOPH RES CO, V498, P495, DOI 10.1016/j.bbrc.2018.03.007; Yao HR, 2016, BREAST CANCER RES TR, V157, P489, DOI 10.1007/s10549-016-3844-6; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017; Zhang ZZ, 2015, AM J CANCER RES, V5, P772; Zhao YS, 2007, CANCER RES, V67, P5821, DOI 10.1158/0008-5472.CAN-06-4499; Zuo T, 2018, TRANSL ONCOL, V11, P346, DOI 10.1016/j.tranon.2018.01.021	55	23	23	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1284	1299		10.1038/s41388-020-01603-6	http://dx.doi.org/10.1038/s41388-020-01603-6		JAN 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420367	hybrid, Green Submitted, Green Published, Green Accepted			2022-12-17	WOS:000607346000004
J	Song, YF; Wang, MF; Tong, H; Tan, Y; Hu, X; Wang, K; Wan, XP				Song, Yunfeng; Wang, Mengfei; Tong, Huan; Tan, Yuan; Hu, Xiang; Wang, Kai; Wan, Xiaoping			Plasma exosomes from endometrial cancer patients contain LGALS3BP to promote endometrial cancer progression	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; SIGNALING PATHWAY; BINDING-PROTEIN; TUMOR-GROWTH; EXPRESSION; SUPERFAMILY; BIOMARKER; VESICLES; MEMBER; CELLS	Endometrial cancer (EC) is a common gynaecological cancer worldwide. Exosomes, secreted by living cells and detected in various body fluids, can exchange information between organs and compartments to affect cellular functions, such as proliferation, apoptosis, migration and angiogenesis. We hypothesise that plasma exosomal contents are altered during cancer progression and promote cancer growth and angiogenesis by delivering biomolecules to cancer and vascular endothelial cells. In this study, circulating exosomes derived from EC patients and age-matched healthy people were acquired by commercial kits. Cell counting kit-8, Transwell and Matrigel tube formation assays showed that circulating exosomes from EC patients promote EC cell growth and human umbilical vein endothelial cell (HUVEC) angiogenesis. Next, proteomic analysis and ELISA revealed that plasma exosomal lectin galactoside-binding soluble 3 binding protein (LGALS3BP) increased during EC progression. Moreover, to explore the function of exosomal LGALS3BP, we acquired exosomes containing high levels of LGALS3BP by overexpressing LGALS3BP in human embryonic kidney 293 cells, and we demonstrated that highly contained exosomal LGALS3BP contributed to EC cell proliferation and migration and HUVEC functions via the activation of the PI3K/AKT/VEGFA signalling pathway both in vitro and in vivo. Finally, high LGALS3BP expression was observed in human EC tissue, which indicated a poor prognosis. In addition, immunohistochemical analysis of human EC tissues revealed that LGALS3BP expression was correlated with VEGFA expression and blood vessel density. Hence, we proposed that plasma exosomes containing LGALS3BP contributed to EC growth and angiogenesis during EC progression, which also provided a novel perspective on EC diagnosis and prognosis.	[Song, Yunfeng; Wang, Mengfei; Tong, Huan; Tan, Yuan; Hu, Xiang; Wan, Xiaoping] Tongji Univ, Shanghai Matern & Infant Hosp 1, Dept Gynaecol, Sch Med, Shanghai, Peoples R China; [Wang, Kai] Tongji Univ, Shanghai Matern & Infant Hosp 1, Clin & Translat Res Ctr, Sch Med, Shanghai, Peoples R China	Tongji University; Tongji University	Wan, XP (corresponding author), Tongji Univ, Shanghai Matern & Infant Hosp 1, Dept Gynaecol, Sch Med, Shanghai, Peoples R China.; Wang, K (corresponding author), Tongji Univ, Shanghai Matern & Infant Hosp 1, Clin & Translat Res Ctr, Sch Med, Shanghai, Peoples R China.	kaiwangcn@yahoo.com; wanxiaoping@tongji.edu.cn		wang, kai/0000-0003-2298-4816; Song, yunfeng/0000-0002-7373-3198; wan, xiaoping/0000-0001-6079-631X	Shanghai Science and Technology Commission Innovation Plan [17411951600]; National Natural Science Foundation of China [81672574, 81972438]; Shanghai Key Clinical Specialty Programme [2017ZZ02015]	Shanghai Science and Technology Commission Innovation Plan; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Key Clinical Specialty Programme	This work was supported by Shanghai Science and Technology Commission Innovation Plan (No. 17411951600), the National Natural Science Foundation of China (Nos. 81672574 and 81972438) and Shanghai Key Clinical Specialty Programme (No. 2017ZZ02015).	Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Bhagirath D, 2018, CANCER RES, V78, P1833, DOI 10.1158/0008-5472.CAN-17-2069; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Caby MP, 2005, INT IMMUNOL, V17, P879, DOI 10.1093/intimm/dxh267; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chatterjee S, 2013, J CLIN INVEST, V123, P1732, DOI 10.1172/JCI65385; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; IACOBELLI S, 1986, CANCER RES, V46, P3005; Jiang Y, 2019, BRAIN RES, V1722, DOI 10.1016/j.brainres.2019.146331; Jiang ZY, 2002, J BIOL CHEM, V277, P509, DOI 10.1074/jbc.M108280200; KOTHS K, 1993, J BIOL CHEM, V268, P14245; Ludwig AK, 2012, INT J BIOCHEM CELL B, V44, P11, DOI 10.1016/j.biocel.2011.10.005; Mariscal J, 2019, J PROTEOME RES, V18, P1043, DOI 10.1021/acs.jproteome.8b00750; Matei I, 2017, CELL, V170, P223, DOI 10.1016/j.cell.2017.06.047; Melo SA, 2015, NATURE, V523, P177, DOI 10.1038/nature14581; Ozaki Y, 2004, ONCOL REP, V12, P1071; Pan C, 2018, MOL ONCOL, V12, P1935, DOI 10.1002/1878-0261.12371; Peng S, 2014, HEPATOLOGY, V60, P1264, DOI 10.1002/hep.27236; Piccolo E, 2013, J MOL MED, V91, P83, DOI 10.1007/s00109-012-0936-6; Pisitkun T, 2004, P NATL ACAD SCI USA, V101, P13368, DOI 10.1073/pnas.0403453101; Pore N, 2004, MOL BIOL CELL, V15, P4841, DOI 10.1091/mbc.E04-05-0374; Pramanik KC, 2013, CARCINOGENESIS, V34, P2061, DOI 10.1093/carcin/bgt154; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Stampolidis P, 2015, ONCOGENE, V34, P39, DOI 10.1038/onc.2013.548; Teng Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14448; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Wahlgren J, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks463; Wang JJ, 2018, CANCER BIOMARK, V21, P805, DOI 10.3233/CBM-170738; Wang M, 2018, CLIN TRANSL ONCOL, V20, P906, DOI 10.1007/s12094-017-1805-0; Weiderpass E, 2015, INT J EPIDEMIOL, V44, P3; Wen XL, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0170-6; Zhang XX, 2019, CELL SIGNAL, V63, DOI 10.1016/j.cellsig.2019.109359; Zhong H, 2000, CANCER RES, V60, P1541; Zhou H, 2006, KIDNEY INT, V69, P1471, DOI 10.1038/sj.ki.5000273	35	23	23	3	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					633	646		10.1038/s41388-020-01555-x	http://dx.doi.org/10.1038/s41388-020-01555-x		NOV 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33208911				2022-12-17	WOS:000590925500002
J	Qian, WL; Li, Q; Wu, XL; Li, WG; Li, QW; Zhang, J; Li, MY; Zhang, D; Zhao, HX; Zou, XQ; Jia, H; Zhang, LQ; Yang, XD; Hou, ZY				Qian, Wenli; Li, Qi; Wu, Xinglong; Li, Wenguo; Li, Qiwei; Zhang, Jie; Li, Mengying; Zhang, Dan; Zhao, Hongxia; Zou, Xiuqun; Jia, Hao; Zhang, Lingqiang; Yang, Xiao-Dong; Hou, Zhaoyuan			Deubiquitinase USP29 promotes gastric cancer cell migration by cooperating with phosphatase SCP1 to stabilize Snail protein	ONCOGENE			English	Article							TERMINAL DOMAIN PHOSPHATASE; E-CADHERIN REPRESSION; DNA-REPLICATION; GENE; TRANSCRIPTION; PHOSPHORYLATION; RECRUITMENT; METASTASIS; DROSOPHILA; DISTINCT	Snail is a master inducer of epithelial-mesenchymal transition (EMT) and metastasis, however, Snail protein is labile and is quickly degraded through the predominate ubiquitination-mediated proteasome pathway. Deubiquitinases (DUBs) can counteract the Snail degradation process to maintain high level of Snail protein in cancer cells. In this study, we screened a cDNA library containing 79 DUBs, and discovered that a panel of DUBs consisting of USP13, USP28, USP29, USP37, OTUD6A, and DUB3 can markedly stabilize Snail protein, with USP29 displaying the strongest activity to prevent Snail degradation. Mechanistically, USP29 enhances the interaction of Snail and SCP1, resulting in simultaneous dephosphorylation and deubiquitination of Snail and thereafter cooperative prevention of Snail degradation. Biologically, ectopic expression of USP29 promotes gastric cancer cell migration, and depletion of Snail abolishes USP29-mediated cell migration; and USP29 can be induced by major EMT and metastatic inducing factors such as TGF beta, TNF alpha, and hypoxia. More importantly, high expression levels of Snail, USP29, and SCP1 are associated with poor survival and prognosis. Collectively, these data indicate that Snail is a crucial substrate for USP29 to promote cell migration and USP29/SCP1 complex may be new therapeutic targets to treat metastatic cancer.	[Qian, Wenli; Li, Qi; Zhang, Jie; Li, Mengying; Zhang, Dan; Zou, Xiuqun; Jia, Hao; Hou, Zhaoyuan] Shanghai Jiao Tong Univ, Hongqiao Inst Med, Tongren Hosp, Fac Basic Med,Sch Med, Shanghai 200025, Peoples R China; [Li, Qi] Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, State Key Lab Drug Res, Shanghai 201203, Peoples R China; [Wu, Xinglong; Hou, Zhaoyuan] Lanling Peoples Hosp, Cent Clin Lab, Lanling Cty 277700, Shandong, Peoples R China; [Li, Wenguo; Yang, Xiao-Dong] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Immunol, Dept Immunol & Microbiol, Shanghai 200025, Peoples R China; [Li, Wenguo; Yang, Xiao-Dong] Shanghai Jiao Tong Univ, Sch Med, Minist Educ, Key Lab Cell Death & Differentiat, Shanghai 200025, Peoples R China; [Li, Qiwei] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Biliary Pancreat Surg, Shanghai 200127, Peoples R China; [Zhao, Hongxia] Univ Helsinki, Fac Biol & Environm Sci, Helsinki, Finland; [Zhang, Lingqiang] Beijing Inst Life, Natl Ctr Prot Sci Beijing, State Key Lab Prote, Beijing 100850, Peoples R China; [Hou, Zhaoyuan] Shanghai Jiao Tong Univ, Dept Biochem & Mol Cell Biol, Shanghai Key Lab Tumor Microenvironm & Inflammat, Sch Med, Shanghai 200025, Peoples R China	Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Chinese Academy of Sciences; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; University of Helsinki; Shanghai Jiao Tong University	Hou, ZY (corresponding author), Shanghai Jiao Tong Univ, Hongqiao Inst Med, Tongren Hosp, Fac Basic Med,Sch Med, Shanghai 200025, Peoples R China.; Hou, ZY (corresponding author), Lanling Peoples Hosp, Cent Clin Lab, Lanling Cty 277700, Shandong, Peoples R China.; Yang, XD (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Immunol, Dept Immunol & Microbiol, Shanghai 200025, Peoples R China.; Yang, XD (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Minist Educ, Key Lab Cell Death & Differentiat, Shanghai 200025, Peoples R China.; Zhang, LQ (corresponding author), Beijing Inst Life, Natl Ctr Prot Sci Beijing, State Key Lab Prote, Beijing 100850, Peoples R China.; Hou, ZY (corresponding author), Shanghai Jiao Tong Univ, Dept Biochem & Mol Cell Biol, Shanghai Key Lab Tumor Microenvironm & Inflammat, Sch Med, Shanghai 200025, Peoples R China.	zhanglq@nic.bmi.ac.cn; xdyang@shsmu.edu.cn; houzy@sjtu.edu.cn		YANG, XIAO-DONG/0000-0001-6895-0713	National Natural Science Foundation of China [81872131, 31671415, 31570770, 31770818]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Natural Science Foundation of China to ZH (81872131 and 31671415) and to XDY (31570770 and 31770818).	ALBERGA A, 1991, DEVELOPMENT, V111, P983; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Chen JZ, 2014, CANCER RES, V74, P4353, DOI 10.1158/0008-5472.CAN-14-0181; Clague MJ, 2013, PHYSIOL REV, V93, P1289, DOI 10.1152/physrev.00002.2013; Deep G, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-37; Do Kim J, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-108; Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349; Hou ZY, 2008, MOL CELL BIOL, V28, P3198, DOI 10.1128/MCB.01435-07; Hsu DSS, 2014, CANCER CELL, V26, P534, DOI 10.1016/j.ccell.2014.09.002; Huang Z, 2019, SCI CHINA LIFE SCI, V62, P544, DOI 10.1007/s11427-018-9469-4; Kim J, 2000, GENOME RES, V10, P1138, DOI 10.1101/gr.10.8.1138; Kim J, 2003, HUM MOL GENET, V12, P233, DOI 10.1093/hmg/ddg028; Knockaert M, 2006, P NATL ACAD SCI USA, V103, P11940, DOI 10.1073/pnas.0605133103; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(05)00092-4; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lee JH, 2017, NAT CELL BIOL, V19, P1260, DOI 10.1038/ncb3609; Li Q, 2016, CELL DEATH DIFFER, V23, P158, DOI 10.1038/cdd.2015.83; Liu JH, 2011, EMBO J, V30, P846, DOI 10.1038/emboj.2011.11; Martin Y, 2015, ONCOGENE, V34, P1058, DOI 10.1038/onc.2014.38; Meinhart A, 2005, GENE DEV, V19, P1401, DOI 10.1101/gad.1318105; Mevissen TET, 2017, ANNU REV BIOCHEM, V86, P159, DOI 10.1146/annurev-biochem-061516-044916; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Nesti E, 2014, P NATL ACAD SCI USA, V111, pE3929, DOI 10.1073/pnas.1414770111; NIETO MA, 1992, DEVELOPMENT, V116, P227; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Park SY, 2010, EMBO J, V29, P3787, DOI 10.1038/emboj.2010.254; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Rehman SAA, 2016, MOL CELL, V63, P146, DOI 10.1016/j.molcel.2016.05.009; Reyes-Turcu FE, 2009, ANNU REV BIOCHEM, V78, P363, DOI 10.1146/annurev.biochem.78.082307.091526; Sapkota G, 2006, J BIOL CHEM, V281, P40412, DOI 10.1074/jbc.M610172200; Vinas-Castells R, 2014, NUCLEIC ACIDS RES, V42, P1079, DOI 10.1093/nar/gkt935; Vinas-Castells R, 2010, J BIOL CHEM, V285, P3794, DOI 10.1074/jbc.M109.065995; Wrighton KH, 2006, J BIOL CHEM, V281, P38365, DOI 10.1074/jbc.M607246200; Wu YD, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14228; Wu YD, 2009, J BIOL CHEM, V284, P640, DOI 10.1074/jbc.M806916200; Xu BH, 2019, NUCLEIC ACIDS RES, V47, P2322, DOI 10.1093/nar/gky1306; Yeo M, 2003, J BIOL CHEM, V278, P26078, DOI 10.1074/jbc.M301791200; Yeo M, 2005, SCIENCE, V307, P596, DOI 10.1126/science.1100801; Yuan L, 2015, NAT CELL BIOL, V17, P1169, DOI 10.1038/ncb3218; Zhang MM, 2010, PROTEIN SCI, V19, P974, DOI 10.1002/pro.375; Zhang YH, 2019, CELL DEATH DIFFER, V26, P565, DOI 10.1038/s41418-018-0147-y; Zheng HQ, 2014, CANCER CELL, V26, P358, DOI 10.1016/j.ccr.2014.07.022; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhou HH, 2018, ONCOGENE, V37, P3356, DOI 10.1038/s41388-018-0224-1	46	23	25	2	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2020	39	44					6802	6815		10.1038/s41388-020-01471-0	http://dx.doi.org/10.1038/s41388-020-01471-0		SEP 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OH9QS	32973332				2022-12-17	WOS:000572607300002
J	Doheny, D; Sirkisoon, S; Carpenter, RL; Aguayo, NR; Regua, AT; Anguelov, M; Manore, SG; Arrigo, A; Abu Jalboush, S; Wong, GL; Yu, Y; Wagner, CJ; Chan, M; Ruiz, J; Thomas, A; Strowd, R; Lin, J; Lo, HW				Doheny, Daniel; Sirkisoon, Sherona; Carpenter, Richard L.; Aguayo, Noah Reeve; Regua, Angelina T.; Anguelov, Marlyn; Manore, Sara G.; Arrigo, Austin; Jalboush, Sara Abu; Wong, Grace L.; Yu, Yang; Wagner, Calvin J.; Chan, Michael; Ruiz, Jimmy; Thomas, Alexandra; Strowd, Roy; Lin, Jiayuh; Lo, Hui-Wen			Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis	ONCOGENE			English	Article							SIGNALING PATHWAY; SONIC HEDGEHOG; THERAPEUTIC TARGET; GENE-EXPRESSION; FACTOR RECEPTOR; SPLICE VARIANT; UP-REGULATION; SELF-RENEWAL; STAT3; ACTIVATION	Triple-negative breast cancer (TNBC) and HER2-positive breast cancer are particularly aggressive and associated with unfavorable prognosis. TNBC lacks effective treatments. HER2-positive tumors have treatment options but often acquire resistance to HER2-targeted therapy after initial response. To address these challenges, we determined whether novel combinations of JAK2-STAT3 and SMO-GLI1/tGLI1 inhibitors synergistically target TNBC and HER2 breast cancer since these two pathways are concurrently activated in both tumor types and enriched in metastatic tumors. Herein, we show that novel combinations of JAK2 inhibitors (ruxolitinib and pacritinib) with SMO inhibitors (vismodegib and sonidegib) synergistically inhibited in vitro growth of TNBC and HER2-positive trastuzumab-resistant BT474-TtzmR cells. Synergy was also observed against breast cancer stem cells. To determine if the combination is efficacious in inhibiting metastasis, we treated mice with intracardially inoculated TNBC cells and found the combination to inhibit lung and liver metastases, and prolong host survival without toxicity. The combination inhibited orthotopic growth, VEGF-A expression, and tumor vasculature of both TNBC and HER2-positive trastuzumab-refractory breast cancer. Lung metastasis of orthotopic BT474-TtzmR xenografts was suppressed by the combination. Together, our results indicated that dual targeting of JAK2 and SMO resulted in synergistic suppression of breast cancer growth and metastasis, thereby supporting future clinical testing.	[Doheny, Daniel; Sirkisoon, Sherona; Carpenter, Richard L.; Aguayo, Noah Reeve; Regua, Angelina T.; Anguelov, Marlyn; Manore, Sara G.; Arrigo, Austin; Jalboush, Sara Abu; Wong, Grace L.; Yu, Yang; Wagner, Calvin J.; Lo, Hui-Wen] Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27103 USA; [Chan, Michael; Ruiz, Jimmy; Thomas, Alexandra; Strowd, Roy; Lo, Hui-Wen] Wake Forest Univ, Bowman Gray Sch Med, Wake Forest Comprehens Canc Ctr, Winston Salem, NC 27103 USA; [Chan, Michael] Wake Forest Univ, Bowman Gray Sch Med, Dept Radiat Oncol, Winston Salem, NC USA; [Ruiz, Jimmy; Thomas, Alexandra] Wake Forest Univ, Bowman Gray Sch Med, Dept Hematol & Oncol, Winston Salem, NC USA; [Strowd, Roy] Wake Forest Univ, Bowman Gray Sch Med, Dept Neurol, Winston Salem, NC 27103 USA; [Lin, Jiayuh] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; [Carpenter, Richard L.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, JH 308 1001 E 3rd St, Bloomington, IN 47405 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; University System of Maryland; University of Maryland Baltimore; Indiana University System; Indiana University Bloomington	Lo, HW (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27103 USA.; Lo, HW (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Wake Forest Comprehens Canc Ctr, Winston Salem, NC 27103 USA.	hlo@wakehealth.edu		Doheny, Daniel/0000-0002-1455-3090; Manore, Sara/0000-0003-1962-5505; Regua, Angelina/0000-0003-2595-8242	NIH [R01NS087169, T32CA079448, R01NS087169-3S1, 1T32CA247819-01, P30CA012197, 1R01CA228137-01A1]; DoD [W81XWH-17-1-0044, W81XWH-19-1-0072, W81XWH-19-1-0753, W81XWH-20-1-0044]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DoD(United States Department of Defense)	We would like to acknowledge the Massague laboratory for gifting the 231-BoM and 231-BrM breast cancer cell lines and Dr. Dihua Yu for gifting the BT474-TtzmR cell line. We acknowledge funding support for this project from NIH grants, R01NS087169 (HWL), T32CA079448 (RLC), R01NS087169-3S1 (HWL and SS), 1T32CA247819-01 (ATR), P30CA012197 (BP), 1R01CA228137-01A1 (HWL), as well as, DoD grants, W81XWH-17-1-0044 (HWL), W81XWH-19-1-0072 (HWL), W81XWH-19-1-0753 (HWL), and W81XWH-20-1-0044 (HWL and JL).	Ackerman Z, 2015, BIOL TRACE ELEM RES, V163, P169, DOI 10.1007/s12011-014-0110-9; Aditya Suruchi, 2013, Indian Dermatol Online J, V4, P365, DOI 10.4103/2229-5178.120685; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Al-Mahmood S, 2018, DRUG DELIV TRANSL RE, V8, P1483, DOI 10.1007/s13346-018-0551-3; Atwood SX, 2015, CANCER CELL, V27, P342, DOI 10.1016/j.ccell.2015.02.002; Balko JM, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad3001; Balko JM, 2014, CANCER DISCOV, V4, P232, DOI 10.1158/2159-8290.CD-13-0286; Baron JM, 2015, J ONCOL PHARM PRACT, V21, P132, DOI 10.1177/1078155214527144; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Bourguignon LYW, 2008, J BIOL CHEM, V283, P17635, DOI 10.1074/jbc.M800109200; Cao X, 2012, ONCOGENE, V31, P104, DOI 10.1038/onc.2011.219; Carpenter RL, 2015, ONCOTARGET, V6, P22653, DOI 10.18632/oncotarget.4248; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Carpenter RL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078836; Carpenter RL, 2013, J CARCINOG MUTAGEN, P2013; Chen WW, 2011, P NATL ACAD SCI USA, V108, P9589, DOI 10.1073/pnas.1017945108; Choi HJ, 2012, BBA-MOL CELL RES, V1823, P1082, DOI 10.1016/j.bbamcr.2012.03.015; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Epstein EH, 2008, NAT REV CANCER, V8, P743, DOI 10.1038/nrc2503; Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Fiaschi M, 2009, CANCER RES, V69, P4810, DOI 10.1158/0008-5472.CAN-08-3938; Foshay KM, 2008, STEM CELLS DEV, V17, P269, DOI 10.1089/scd.2007.0098; Gruber R, 2016, GASTROENTEROLOGY, V151, P526, DOI 10.1053/j.gastro.2016.05.006; Guo CC, 2012, P NATL ACAD SCI USA, V109, P17603, DOI 10.1073/pnas.1208807109; Han W, 2013, CANC HALLMARKS, V1, P28, DOI DOI 10.1166/CH.2013.1006; Hindley C, 2013, BIOCHEM J, V451, P135, DOI 10.1042/BJ20121627; Howie LJ, 2019, CLIN CANCER RES, V25, P2949, DOI 10.1158/1078-0432.CCR-18-3003; Howlader NNA, 2019, SEER CANC STAT REV 1, V2020, P1975; Hsu TH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04052-6; Jain S, 2017, ONCOTARGETS THER, V10, DOI 10.2147/OTT.S130910; Jiao X, 2012, GENE CHROMOSOME CANC, V51, P480, DOI 10.1002/gcc.21935; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Kameda C, 2009, ANTICANCER RES, V29, P871; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Kuba S, 2014, JPN J CLIN ONCOL, V44, P1025, DOI 10.1093/jjco/hyu126; Kusaba T, 2006, ONCOL REP, V15, P1445; Lebert JM, 2018, CURR ONCOL, V25, pS142, DOI 10.3747/co.25.3954; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Lo HW, 2008, CLIN CANCER RES, V14, P6042, DOI 10.1158/1078-0432.CCR-07-4923; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Lo HW, 2010, MOL CANCER RES, V8, P232, DOI 10.1158/1541-7786.MCR-09-0391; Lo HW, 2009, CANCER RES, V69, P6790, DOI 10.1158/0008-5472.CAN-09-0886; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Loh CY, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00048; Machold R, 2003, NEURON, V39, P937, DOI 10.1016/S0896-6273(03)00561-0; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Merchant AA, 2010, CLIN CANCER RES, V16, P3130, DOI 10.1158/1078-0432.CCR-09-2846; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Okumura F, 2011, BBA-MOL CELL RES, V1813, P1784, DOI 10.1016/j.bbamcr.2011.05.013; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; Palmieri C, 2010, NAT REV CLIN ONCOL, V7, P561, DOI 10.1038/nrclinonc.2010.122; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Qin JJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1206-z; Ramos A, 2012, TRENDS CELL BIOL, V22, P339, DOI 10.1016/j.tcb.2012.04.006; Rimkus TK, 2018, CANCER RES, V78, P2589, DOI 10.1158/0008-5472.CAN-17-2933; Rimkus TK, 2016, CANCERS, V8, DOI 10.3390/cancers8020022; Riobo-Del Galdo NA, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040375; Ruiz-Borrego M, 2019, INVEST NEW DRUG, V37, P98, DOI 10.1007/s10637-018-0614-9; Ryan Q, 2008, ONCOLOGIST, V13, P1114, DOI 10.1634/theoncologist.2008-0816; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sirkisoon SR, 2020, ONCOGENE, V39, P64, DOI 10.1038/s41388-019-0959-3; Sirkisoon SR, 2018, ONCOGENE, V37, P2502, DOI 10.1038/s41388-018-0132-4; Snigdha K, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00085; Tavallai M, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00142; Teperino R, 2014, SEMIN CELL DEV BIOL, V33, P81, DOI 10.1016/j.semcdb.2014.05.007; Wang T, 2015, ONCOTARGET, V6, P44191, DOI 10.18632/oncotarget.6176; Wang Y, 2018, CANCER LETT, V415, P117, DOI 10.1016/j.canlet.2017.12.003; Xie JW, 1997, CANCER RES, V57, P2369; Zaidi AH, 2013, CANCER INVEST, V31, P480, DOI 10.3109/07357907.2013.820317; Zbinden M, 2010, EMBO J, V29, P2659, DOI 10.1038/emboj.2010.137; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309; Zhu C, 2015, ACTA BIOCH BIOPH SIN, V47, P16, DOI 10.1093/abbs/gmu110; Zhu H, 2014, CANCER LETT, V343, P51, DOI 10.1016/j.canlet.2013.09.014	80	23	25	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2020	39	42					6589	6605		10.1038/s41388-020-01454-1	http://dx.doi.org/10.1038/s41388-020-01454-1		SEP 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA9HI	32929154	Green Accepted			2022-12-17	WOS:000569499000002
J	Li, YL; Wu, LW; Zeng, LH; Zhang, ZY; Wang, W; Zhang, C; Lin, NM				Li, Yang-ling; Wu, Lin-wen; Zeng, Ling-hui; Zhang, Zuo-yan; Wang, Wei; Zhang, Chong; Lin, Neng-ming			ApoC1 promotes the metastasis of clear cell renal cell carcinoma via activation of STAT3	ONCOGENE			English	Article							APOLIPOPROTEIN C1 APOC1; SH2 DOMAIN; CANCER; SURVIVAL; PROGRESSION; EXPRESSION; THERAPY	Clear cell renal cell carcinoma (ccRCC) is the most common renal cancer and frequently diagnosed at an advanced stage. It is prone to develop unpredictable metastases even with proper treatment. Antiangiogenic therapy is the most effective medical treatment for metastatic ccRCC. Thus, exploration of novel approaches to inhibit angiogenesis and metastasis may potentially lead to a better therapeutic option for ccRCC. Among all the types of cancer, renal cancer samples exhibited the maximum upregulation of ApoC1 as referred to in the Oncomine database. The expression of ApoC1 was increased accompanied by ccRCC progression. A high level of ApoC1 was closely related to poor survival time in ccRCC patients. Furthermore, ApoC1 was over-expressed in the highly invasive ccRCC cells as compared to that in the low-invasive ccRCC cells. Besides, ApoC1 promoted metastasis of ccRCC cells via EMT pathway, whereas depletion of ApoC1 alleviated these effects. ApoC1 as a novel pro-metastatic factor facilitates the activation of STAT3 and enhances the metastasis of ccRCC cells. Meanwhile, ApoC1 in the exosomes were transferred from the ccRCC cells to the vascular endothelial cells and promoted metastasis of the ccRCC cells via activating STAT3. Finally, the metastatic potential of the ccRCC cells driven by ApoC1 was suppressed by DPP-4 inhibition. Our study not only identifies a novel ApoC1-STAT3 pathway in ccRCC metastasis but also provides direction for the exploration of novel strategies to predict and treat metastatic ccRCC in the future.	[Li, Yang-ling; Lin, Neng-ming] Zhejiang Univ, Dept Clin Pharmacol, Key Lab Clin Canc Pharmacol & Toxicol Res Zhejian, Affiliated Hangzhou Peoples Hosp 1,Sch Med, Hangzhou 310006, Zhejiang, Peoples R China; [Wu, Lin-wen; Zeng, Ling-hui; Zhang, Zuo-yan; Zhang, Chong] Zhejiang Univ City Coll, Sch Med, Hangzhou 310015, Zhejiang, Peoples R China; [Wu, Lin-wen; Zhang, Zuo-yan] Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China; [Wang, Wei] Zhejiang Univ, Sch Med, Affiliated Hangzhou Peoples Hosp 1, Dept Pathol, Hangzhou 310058, Zhejiang, Peoples R China; [Lin, Neng-ming] Zhejiang Univ, Key Lab Clin Canc Pharmacol & Toxicol Res Zhejian, Hangzhou Translat Med Res Ctr, Affiliated Hangzhou Peoples Hosp 1,Sch Med, Hangzhou 310058, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University City College; Zhejiang University; Zhejiang University; Zhejiang University	Lin, NM (corresponding author), Zhejiang Univ, Dept Clin Pharmacol, Key Lab Clin Canc Pharmacol & Toxicol Res Zhejian, Affiliated Hangzhou Peoples Hosp 1,Sch Med, Hangzhou 310006, Zhejiang, Peoples R China.; Zhang, C (corresponding author), Zhejiang Univ City Coll, Sch Med, Hangzhou 310015, Zhejiang, Peoples R China.; Lin, NM (corresponding author), Zhejiang Univ, Key Lab Clin Canc Pharmacol & Toxicol Res Zhejian, Hangzhou Translat Med Res Ctr, Affiliated Hangzhou Peoples Hosp 1,Sch Med, Hangzhou 310058, Zhejiang, Peoples R China.	zhangchong@zucc.edu.cn; lnm1013@zju.edu.cn		wang, Wei/0000-0001-6060-8665; ZUOYAN, ZHANG/0000-0003-0883-6016; Zhang, Chong/0000-0002-8113-5585	National Natural Science Foundation of China [81702887, 81272473]; Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province [2020E10021]; Key Medical Discipline of Zhejiang Province [2018-2-3]; Key Medical Discipline of Hangzhou City [2017-51-07]; Zhejiang Provincial Foundation of Natural Science [LY19H310004]; Hangzhou Major Science and Technology Project [20172016A01]; High-level Talents Coming Back from Abroad Innovation and Entrepreneurship Program in Hangzhou, Scientific and Technological Developing Scheme of Hangzhou City [20191203B49]; Science Research Foundation of Zhejiang Health Bureau [2020RC026]; Teachers Research Fund of Zhejiang University City College [J-19006]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province; Key Medical Discipline of Zhejiang Province; Key Medical Discipline of Hangzhou City; Zhejiang Provincial Foundation of Natural Science(Natural Science Foundation of Zhejiang Province); Hangzhou Major Science and Technology Project; High-level Talents Coming Back from Abroad Innovation and Entrepreneurship Program in Hangzhou, Scientific and Technological Developing Scheme of Hangzhou City; Science Research Foundation of Zhejiang Health Bureau; Teachers Research Fund of Zhejiang University City College	This study was funded by National Natural Science Foundation of China (81702887, 81272473), Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province (2020E10021), Key Medical Discipline of Zhejiang Province (2018-2-3), Key Medical Discipline of Hangzhou City (2017-51-07), Zhejiang Provincial Foundation of Natural Science (LY19H310004), Hangzhou Major Science and Technology Project (20172016A01), High-level Talents Coming Back from Abroad Innovation and Entrepreneurship Program in Hangzhou, Scientific and Technological Developing Scheme of Hangzhou City (20191203B49), Science Research Foundation of Zhejiang Health Bureau (2020RC026), and Teachers Research Fund of Zhejiang University City College (J-19006).	Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Barata PC, 2017, CA-CANCER J CLIN, V67, P507, DOI 10.3322/caac.21411; Beebe JD, 2018, PHARMACOL THERAPEUT, V191, P74, DOI 10.1016/j.pharmthera.2018.06.006; Bielecka Zofia F, 2014, Curr Signal Transduct Ther, V8, P218; Bouillet B, 2016, DIABETES METAB, V42, P263, DOI 10.1016/j.diabet.2016.01.003; Bouillet B, 2014, DIABETES CARE, V37, P1148, DOI 10.2337/dc13-1467; Bus P, 2017, J PATHOL, V241, P589, DOI 10.1002/path.4859; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Choueiri TK, 2017, NEW ENGL J MED, V376, P354, DOI 10.1056/NEJMra1601333; de Palma M, 2017, NAT REV CANCER, V17, P457, DOI 10.1038/nrc.2017.51; Desroses M, 2018, J PHARMACEUT BIOMED, V160, P80, DOI 10.1016/j.jpba.2018.07.018; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Harshman LC, 2012, LANCET ONCOL, V13, P927, DOI 10.1016/S1470-2045(12)70285-1; Horiguchi A, 2002, J UROLOGY, V168, P762, DOI 10.1016/S0022-5347(05)64741-6; Hsieh JJ, 2018, J CLIN ONCOL, V36, P3533, DOI 10.1200/JCO.2018.79.2549; Hsieh JJ, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.9; Huang YP, 2012, EUR J OBSTET GYN R B, V165, P96, DOI 10.1016/j.ejogrb.2012.06.031; Huynh J, 2019, NAT REV CANCER, V19, P82, DOI 10.1038/s41568-018-0090-8; Ko HL, 2014, THORAC CANCER, V5, P500, DOI 10.1111/1759-7714.12117; Li X, 2018, ONCOGENE, V37, P2469, DOI 10.1038/s41388-017-0076-0; Mathieu M, 2019, NAT CELL BIOL, V21, P9, DOI 10.1038/s41556-018-0250-9; McPherson A, 2019, J LIPID RES, V60, P400, DOI 10.1194/jlr.M089441; Patard JJ, 2009, BRIT J CANCER, V101, P1417, DOI 10.1038/sj.bjc.6605298; Ren H, 2019, CANCER MANAG RES, V11, P4917, DOI 10.2147/CMAR.S192529; Sanchez-Gastaldo A, 2017, CANCER TREAT REV, V60, P77, DOI 10.1016/j.ctrv.2017.08.010; Schokrpur S, 2016, SCI REP-UK, V6, DOI 10.1038/srep29032; Shen C, 2013, SEMIN CANCER BIOL, V23, P18, DOI 10.1016/j.semcancer.2012.06.001; Sirkisoon SR, 2018, ONCOGENE, V37, P2502, DOI 10.1038/s41388-018-0132-4; Skinner NEB, 2015, DIABETES THER, V6, P395, DOI 10.1007/s13300-015-0123-1; Srivastava J, 2016, MOL CARCINOGEN, V55, P1889, DOI 10.1002/mc.22438; Su WP, 2018, J BIOCHEM MOL TOXIC, V32, DOI 10.1002/jbt.22158; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Wang XK, 2019, J CELL BIOCHEM, V120, P18246, DOI 10.1002/jcb.29131; Wang XG, 2019, J CELL BIOCHEM, V120, P1492, DOI 10.1002/jcb.27347; Wu LW, 2019, BIOCHEM BIOPH RES CO, V512, P852, DOI 10.1016/j.bbrc.2019.03.154; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Yusenko MV, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-152; Zhang RJ, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-018-0725-5; Zhao W, 2010, J BIOL CHEM, V285, P35855, DOI 10.1074/jbc.M110.154088; Zheng PM, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0465-5; Zhou Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087017	42	23	23	4	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2020	39	39					6203	6217		10.1038/s41388-020-01428-3	http://dx.doi.org/10.1038/s41388-020-01428-3		AUG 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NS8XO	32826950				2022-12-17	WOS:000561519300001
J	Zhu, YX; Li, JJ; Bo, H; He, D; Xiao, MQ; Xiang, L; Gong, L; Hu, Y; Zhang, YY; Cheng, YX; Deng, LP; Zhu, RR; Ma, YN; Cao, K				Zhu, Yuxing; Li, Jingjing; Bo, Hao; He, Dong; Xiao, Mengqing; Xiang, Liang; Gong, Lian; Hu, Yi; Zhang, Yeyu; Cheng, Yaxin; Deng, Liping; Zhu, Rongrong; Ma, Yanni; Cao, Ke			LINC00467 is up-regulated by TDG-mediated acetylation in non-small cell lung cancer and promotes tumor progression	ONCOGENE			English	Article								The long non-coding RNA (LncRNA) abnormally expresses in several cancers including non-small cell lung cancer (NSCLC). To better understand the role of key lncRNA involving cancer progress, we conduct a comprehensive data mining on LINC00467 and determine its molecular mechanisms. We identified LINC00467 was the up-regulated lncRNA that common significantly differentially expressed in NSCLC and CRC tissues from GEO database. LINC00467 highly expressed in NSCLC tissues and associated with advanced clinical stages and poor outcome. Knockdown of LINC00467 inhibited cell growth and metastasis via regulating the Akt signaling pathway. Finally, we demonstrated that TDG mediated acetylation is the key factor controlling LINC00467 expression. In conclusion, LINC00467 promotes NSCLC progression via Akt signal pathway. The identified LINC00467 may serve as a valuable diagnostic and prognostic biomarker as well as a therapeutic target for NSCLC.	[Zhu, Yuxing; Li, Jingjing; Xiao, Mengqing; Xiang, Liang; Gong, Lian; Hu, Yi; Zhang, Yeyu; Cheng, Yaxin; Deng, Liping; Zhu, Rongrong; Ma, Yanni; Cao, Ke] Cent South Univ, Dept Oncol, Xiangya Hosp 3, Changsha 410013, Peoples R China; [Li, Jingjing] Cent South Univ, Dept Plast Surg, Xiangya Hosp, Changsha 410008, Peoples R China; [Bo, Hao] Reprod & Genet Hosp CITIC Xiangya, Clin Res Ctr Reprod & Genet Hunan Prov, Changsha 410078, Peoples R China; [Bo, Hao] Cent South Univ, Key Lab Reprod & Stem Cell Engn, Natl Hlth & Family Planning Commiss, Inst Reprod & Stem Cell Engn,Basic Med Coll, Changsha 410078, Peoples R China; [He, Dong] Second Peoples Hosp Hunan Prov, Dept Resp, Chansha 410007, Peoples R China	Central South University; Central South University; Central South University; Central South University	Cao, K (corresponding author), Cent South Univ, Dept Oncol, Xiangya Hosp 3, Changsha 410013, Peoples R China.	csucaoke@163.com	Li, Jing/GYU-5036-2022	Cao, Ke/0000-0001-5392-2306	National Natural Science Foundation of China [81874137]; Outstanding Youth Foundation of Hunan Province [2018JJ1047]; Huxiang Young Talent Project [2016RS3022]; Hunan Province Science and technology talent promotion project [2019TJ-Q10]; Project of scientific research plan of health and Family Planning Commission of Hunan Province [c20180476]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Outstanding Youth Foundation of Hunan Province; Huxiang Young Talent Project; Hunan Province Science and technology talent promotion project; Project of scientific research plan of health and Family Planning Commission of Hunan Province	This work was supported by the National Natural Science Foundation of China (81874137), the Outstanding Youth Foundation of Hunan Province (2018JJ1047), the Huxiang Young Talent Project (2016RS3022). the Hunan Province Science and technology talent promotion project (2019TJ-Q10), the Project of scientific research plan of health and Family Planning Commission of Hunan Province (c20180476).	Chen J, 2019, INT J BIOL SCI, V15, P1802, DOI 10.7150/ijbs.34785; Chen TY, 2019, MOL GENET GENOM MED, V7, DOI 10.1002/mgg3.757; Chu Ci, 2012, J Vis Exp, DOI 10.3791/3912; Guan HY, 2019, P NATL ACAD SCI USA, V116, P14019, DOI 10.1073/pnas.1900997116; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Herreros-Pomares A, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1898-1; Hirsch FR, 2016, LANCET, V388, P1012, DOI 10.1016/S0140-6736(16)31473-8; Hua JT, 2018, CELL, V174, P564, DOI 10.1016/j.cell.2018.06.014; Huang ZW, 2018, J CELL PHYSIOL, V233, P6768, DOI 10.1002/jcp.26530; Loewen G, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0090-4; Oka H, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-018-5375-5; Peterson AC, 2012, MOL CELL PROTEOMICS, V11, P1475, DOI 10.1074/mcp.O112.020131; Rizvi NA, 2017, NEW ENGL J MED, V377, P1986, DOI 10.1056/NEJMe1711430; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tini M, 2002, MOL CELL, V9, P265, DOI 10.1016/S1097-2765(02)00453-7; Wang XH, 2019, MOL MED REP, V20, P640, DOI 10.3892/mmr.2019.10292; Wei SQ, 2019, INT J IMMUNOPATH PH, V33, DOI 10.1177/2058738419859699; Xiong RF, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1550-4; Xue YN, 2019, J CELL BIOCHEM, V120, P19087, DOI 10.1002/jcb.29232; Yang F, 2013, MOL CELL, V49, P1083, DOI 10.1016/j.molcel.2013.01.010; Yang JL, 2019, BIOCHEM BIOPH RES CO, V514, P118, DOI 10.1016/j.bbrc.2019.04.107; Yin DD, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0836-7; Zhu YX, 2019, ONCOGENE, V38, P6065, DOI 10.1038/s41388-019-0858-7	24	23	23	2	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2020	39	38					6071	6084		10.1038/s41388-020-01421-w	http://dx.doi.org/10.1038/s41388-020-01421-w		AUG 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NQ9JF	32796958				2022-12-17	WOS:000559718800001
J	Yang, H; Geng, YH; Wang, P; Yang, H; Zhou, YT; Zhang, HQ; He, HY; Fang, WG; Tian, XX				Yang, Hui; Geng, Yue-Hang; Wang, Peng; Yang, Han; Zhou, Yan-Ting; Zhang, Hong-Quan; He, Hui-Ying; Fang, Wei-Gang; Tian, Xin-Xia			Extracellular ATP promotes breast cancer invasion and chemoresistance via SOX9 signaling	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; PURINERGIC RECEPTORS; CELL INVASION; LEADING ROLE; METASTASIS; ACTIVATION; INFLAMMATION; EPITHELIUM; IMMUNITY; FAMILY	Our previous research demonstrated that extracellular adenosine 5 '-triphosphate (ATP) could promote breast cancer cell invasion. However, the impact of extracellular ATP on chemoresistance and the mechanisms behind ATP pro-invasion and pro-chemoresistance remain unclear. Here we aimed to determine the molecules or signaling pathways involved. cDNA microarray was performed to identify the differentially expressed genes before and after ATP treatment. As a result, Sex-determining region Y-box 9 (SOX9) was up-regulated after ATP treatment in breast cancer cells. In vitro invasion and migration assays demonstrated that knocking down SOX9 attenuated ATP-driven invasive capability. Mass spectrometry and co-IP revealed that SOX9 interacted with Janus kinase 1 (JAK1). Afterward, IL-6-JAK1-STAT3 signaling was demonstrated to promote SOX9 expression and invasion following ATP treatment. Notably, ATP-IL-6-SOX9 signaling was shown to stimulate chemoresistance in breast cancer cells. ChIP assays identified some potential SOX9 target genes, among which carcinoembryonic antigen-related cell adhesion molecule 5/6 (CEACAM5/6) was demonstrated to mediate ATP pro-invasive function, while ATP-binding cassette subfamily B member 1 (ABCB1) and ATP-binding cassette subfamily G member 2 (ABCG2) mediated ATP-driven chemoresistance. In addition, SOX9-knockdown and apyrase (an ATP hydrolase)-treated MDA-MB-231 cells illustrated decreased tumor growth and enhanced drug sensitivity in nude mice. In vitro spheroid formation assays also proved the significance of ATP-SOX9 in mediating chemoresistance. Moreover, molecules involved in ATP-SOX9 signaling were up-regulated in human breast carcinoma specimens and were associated with poor prognosis. Altogether, SOX9 signaling is vital in ATP-driven invasion and chemoresistance, which may serve as a potential target for breast cancer therapies.	[Yang, Hui; Geng, Yue-Hang; Yang, Han; Zhou, Yan-Ting; He, Hui-Ying; Fang, Wei-Gang; Tian, Xin-Xia] Peking Univ, Dept Pathol, Key Lab Carcinogenesis & Translat Res, Minist Educ,Sch Basic Med Sci,Hosp 3,Hlth Sci Ctr, Beijing 100191, Peoples R China; [Wang, Peng; Zhang, Hong-Quan] Peking Univ, Hlth Sci Ctr, Dept Anat Histol & Embryol, Beijing 100191, Peoples R China	Peking University; Peking University	Fang, WG; Tian, XX (corresponding author), Peking Univ, Dept Pathol, Key Lab Carcinogenesis & Translat Res, Minist Educ,Sch Basic Med Sci,Hosp 3,Hlth Sci Ctr, Beijing 100191, Peoples R China.	wgfang@bjmu.edu.cn; tianxinxia@bjmu.edu.cn		Wang, Peng/0000-0002-2558-292X; Yang, Hui/0000-0002-9138-1325; Tian, Xin-Xia/0000-0002-1593-4987	National Natural Science Foundation of China [81872382, 81621063]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants to XXT and WGF from the National Natural Science Foundation of China (No 81872382 and 81621063).	Abbosh C, 2017, NATURE, V545, P446, DOI 10.1038/nature22364; Antonioli L, 2013, NAT REV CANCER, V13, P842, DOI 10.1038/nrc3613; Atarashi K, 2008, NATURE, V455, P808, DOI 10.1038/nature07240; Auger R, 2005, J BIOL CHEM, V280, P28142, DOI 10.1074/jbc.M501290200; Cai CM, 2013, J CLIN INVEST, V123, P1109, DOI 10.1172/JCI66666; Chen H, 2017, CLIN CANCER RES, V23, P5176, DOI 10.1158/1078-0432.CCR-17-0177; Chen L, 2004, CANCER LETT, V215, P239, DOI 10.1016/j.canlet.2004.05.023; Crystal AS, 2014, SCIENCE, V346, P1480, DOI 10.1126/science.1254721; Di Virgilio F, 2017, ONCOGENE, V36, P293, DOI 10.1038/onc.2016.206; Di Virgilio F, 2016, CURR OPIN PHARMACOL, V29, P17, DOI 10.1016/j.coph.2016.05.001; Di Virgilio F, 2012, CANCER RES, V72, P5441, DOI 10.1158/0008-5472.CAN-12-1600; Eguchi Y, 1997, CANCER RES, V57, P1835; FANG WG, 1992, J CLIN INVEST, V89, P191, DOI 10.1172/JCI115562; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Galluzzi L, 2015, CELL REP, V11, P1501, DOI 10.1016/j.celrep.2015.05.041; Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028; Gilbert SM, 2019, ONCOGENE, V38, P194, DOI 10.1038/s41388-018-0426-6; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Kumar S, 2015, CELL REP, V12, P1325, DOI 10.1016/j.celrep.2015.07.034; Larsimont JC, 2015, CELL STEM CELL, V17, P60, DOI 10.1016/j.stem.2015.05.008; Leung CON, 2016, ONCOTARGET, V7, P29371, DOI 10.18632/oncotarget.8835; Li WH, 2013, BRIT J CANCER, V109, P1666, DOI 10.1038/bjc.2013.484; Li WH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133165; Liu Y, 2018, CANCER LETT, V430, P1, DOI 10.1016/j.canlet.2018.04.043; McKenney RJ, 2014, SCIENCE, V345, P337, DOI 10.1126/science.1254198; Nagy A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27521-y; Patel A, 2017, SCIENCE, V356, P753, DOI 10.1126/science.aaf6846; Pearson RA, 2005, NEURON, V46, P731, DOI 10.1016/j.neuron.2005.04.024; Prevostel C, 2017, EUR J CANCER, V86, P150, DOI 10.1016/j.ejca.2017.08.037; Putoczki T, 2010, J LEUKOCYTE BIOL, V88, P1109, DOI 10.1189/jlb.0410226; Qiu ML, 2020, EXP CELL RES, V392, DOI 10.1016/j.yexcr.2020.112002; Qiu Y, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.011437, DOI 10.1371/JOURNAL.PONE.011437]; Qiu Y, 2018, ONCOL REP, V39, P138, DOI 10.3892/or.2017.6081; Roger S, 2011, EXPERT OPIN INV DRUG, V20, P875, DOI 10.1517/13543784.2011.583918; Santos JC, 2016, CANCER RES, V76, P6735, DOI 10.1158/0008-5472.CAN-16-1120; Shan L, 2016, CANCER CELL, V30, P708, DOI 10.1016/j.ccell.2016.09.010; Solini A, 1999, J CELL SCI, V112, P297; Verhalen B, 2017, NATURE, V543, P738, DOI 10.1038/nature21414; Wang H, 2015, CANCER CELL, V27, P193, DOI 10.1016/j.ccell.2014.11.017; Wang H, 2008, CANCER RES, V68, P1625, DOI 10.1158/0008-5472.CAN-07-5915; Wang X, 2017, ONCOTARGET, V8, P87860, DOI 10.18632/oncotarget.21231; Wilson M, 2002, CURR OPIN GENET DEV, V12, P441, DOI 10.1016/S0959-437X(02)00323-4; Xia MS, 2015, J MOL NEUROSCI, V55, P131, DOI 10.1007/s12031-014-0393-5; Yang H, 2019, CANCER SCI, V110, P2456, DOI 10.1111/cas.14086; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zalzali H, 2008, ONCOGENE, V27, P7131, DOI 10.1038/onc.2008.331; Zeng HL, 2016, CANCER CELL, V30, P459, DOI 10.1016/j.ccell.2016.08.001; Zhang JL, 2017, CANCER SCI, V108, P1318, DOI 10.1111/cas.13273; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	50	23	23	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2020	39	35					5795	5810		10.1038/s41388-020-01402-z	http://dx.doi.org/10.1038/s41388-020-01402-z		JUL 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NF2QB	32724162				2022-12-17	WOS:000553333400001
J	Pellarin, I; Dall'Acqua, A; Gambelli, A; Pellizzari, I; D'Andrea, S; Sonego, M; Lorenzon, I; Schiappacassi, M; Belletti, B; Baldassarre, G				Pellarin, Ilenia; Dall'Acqua, Alessandra; Gambelli, Alice; Pellizzari, Ilenia; D'Andrea, Sara; Sonego, Maura; Lorenzon, Ilaria; Schiappacassi, Monica; Belletti, Barbara; Baldassarre, Gustavo			Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity	ONCOGENE			English	Article							RNA-BINDING PROTEIN; REPAIR; PSF; EXPRESSION; APOPTOSIS; NONO; RESISTANCE; VARIANT; DOMAIN; ERCC1	In epithelial ovarian cancer (EOC), response to platinum (PT)-based chemotherapy dictates subsequent treatments and predicts patients' prognosis. Alternative splicing is often deregulated in human cancers and can be altered by chemotherapy. Whether and how changes in alternative splicing regulation could impact on the response of EOC to PT-based chemotherapy is still not clarified. We identified the splicing factor proline and glutamine rich (SFPQ) as a critical mediator of response to PT in an unbiased functional genomic screening in EOC cells and, using a large cohort of primary and recurrent EOC samples, we observed that it is frequently overexpressed in recurrent PT-treated samples and that its overexpression correlates with PT resistance. At mechanistic level, we show that, under PT treatment, SFPQ, in complex with p54(nrb), binds and regulates the activity of the splicing factor SRSF2. SFPQ/p54(nrb) complex decreases SRSF2 binding to caspase-9 RNA, favoring the expression of its alternative spliced antiapoptotic form. As a consequence, SFPQ/p54(nrb) protects cells from PT-induced death, eventually contributing to chemoresistance. Overall, our work unveils a previously unreported SFPQ/p54(nrb)/SRSF2 pathway that in EOC cells plays a central role in regulating alternative splicing and PT-induced apoptosis and that could result in the design of new possible ways of intervention to overcome PT resistance.	[Pellarin, Ilenia; Dall'Acqua, Alessandra; Gambelli, Alice; Pellizzari, Ilenia; D'Andrea, Sara; Sonego, Maura; Lorenzon, Ilaria; Schiappacassi, Monica; Belletti, Barbara; Baldassarre, Gustavo] NCI, IRCCS, Ctr Riferimento Oncol Aviano CRO, Div Mol Oncol, I-33081 Aviano, PN, Italy	IRCCS Aviano (CRO)	Baldassarre, G (corresponding author), NCI, IRCCS, Ctr Riferimento Oncol Aviano CRO, Div Mol Oncol, I-33081 Aviano, PN, Italy.	gbaldassarre@cro.it	Sonego, Maura/AAX-5529-2020; Baldassarre, Gustavo/K-1350-2016; Pellarin, Ilenia/AAY-2238-2020; Dall'Acqua, Alessandra/ABF-8020-2020; Lorenzon, Ilaria/AAY-6372-2020; Belletti, Barbara/J-2028-2018; GAMBELLI, ALICE/ABD-4280-2020; Schiappacassi, Monica/AAX-5505-2020	Sonego, Maura/0000-0002-9505-9771; Baldassarre, Gustavo/0000-0002-9750-8825; Pellarin, Ilenia/0000-0002-1041-1722; Dall'Acqua, Alessandra/0000-0003-2297-1361; Lorenzon, Ilaria/0000-0001-6336-4678; Belletti, Barbara/0000-0003-2249-0285; GAMBELLI, ALICE/0000-0003-0223-9798; Schiappacassi, Monica/0000-0003-4804-4291	Ministero della Salute [RCR-2019-23669115, RF-2016-02361040, GR-2016-02361041]; Ministero degli Affari Esteri e Cooperazione Internazionale [PGR01036]; CRO-Ricerca Corrente core grant (linea 1); 5x1000 CRO Intramural; Regione Friuli Venezia Giulia (POR-FERS TICHEP grant)	Ministero della Salute(Ministry of Health, Italy); Ministero degli Affari Esteri e Cooperazione Internazionale; CRO-Ricerca Corrente core grant (linea 1); 5x1000 CRO Intramural; Regione Friuli Venezia Giulia (POR-FERS TICHEP grant)	We are grateful to the patients who consented to donating their samples. We thank Dr Benjamin Blencowe for providing the p54<SUP>nrb</SUP> and the SFPQ wild type and mutant expression vectors (through Addgene) and Dr Beatrice Eymin for providing the SRSF2 vector. We like to thank all members of the SCICC lab for fruitful scientific discussion, Dr Riccardo Bomben for helping us with the analysis of gene expression profiles and Dr Francesca Rossi for FACS analyses. This work was supported by grants from Ministero della Salute (RCR-2019-23669115 and RF-2016-02361040 to GB and GR-2016-02361041 to MS); Ministero degli Affari Esteri e Cooperazione Internazionale (PGR01036 to GB), CRO-Ricerca Corrente core grant (linea 1); 5x1000 CRO Intramural to GB and Regione Friuli Venezia Giulia (POR-FERS TICHEP grant to GB).	Dall'Acqua A, 2017, EMBO MOL MED, V9, P1415, DOI 10.15252/emmm.201607012; Edmond V, 2011, EMBO J, V30, P510, DOI 10.1038/emboj.2010.333; Fischer DC, 2004, ONCOL REP, V11, P1085; Freimund AE, 2018, HEMATOL ONCOL CLIN N, V32, P983, DOI 10.1016/j.hoc.2018.07.007; Gabriel M, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1259-0; Heyd F, 2010, MOL CELL, V40, P126, DOI 10.1016/j.molcel.2010.09.013; Jaafar L, 2017, NUCLEIC ACIDS RES, V45, P1848, DOI 10.1093/nar/gkw1209; Jayson GC, 2014, LANCET, V384, P1376, DOI 10.1016/S0140-6736(13)62146-7; Kedzierska H, 2017, CANCER LETT, V396, P53, DOI 10.1016/j.canlet.2017.03.013; Knott GJ, 2016, NUCLEIC ACIDS RES, V44, P3989, DOI 10.1093/nar/gkw271; Konstantinopoulos PA, 2018, HEMATOL ONCOL CLIN N, V32, P997, DOI 10.1016/j.hoc.2018.07.006; Lambert CA, 2017, INT J BIOCHEM CELL B, V91, P84, DOI 10.1016/j.biocel.2017.04.006; Lee SCW, 2016, NAT MED, V22, P976, DOI 10.1038/nm.4165; Lee SCW, 2016, NAT MED, V22, P672, DOI 10.1038/nm.4097; Lheureux S, 2019, LANCET, V393, P1240, DOI 10.1016/S0140-6736(18)32552-2; Li SY, 2017, DNA REPAIR, V51, P70, DOI 10.1016/j.dnarep.2017.02.002; Lorenzon I, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010036; Marzec M, 2008, P NATL ACAD SCI USA, V105, P20852, DOI 10.1073/pnas.0810958105; Merdzhanova G, 2008, CELL DEATH DIFFER, V15, P1815, DOI 10.1038/cdd.2008.135; Meyer S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.264; Nicoloso MS, 2017, CANC BREAK NEWS, P25, DOI DOI 10.19156/CBN.2017.0056; Rosonina E, 2005, MOL CELL BIOL, V25, P6734, DOI 10.1128/MCB.25.15.6734-6746.2005; Segatto I, 2019, CANCER RES, V79, P397, DOI 10.1158/0008-5472.CAN-18-2488; Seiler M, 2018, NAT MED, V24, P497, DOI 10.1038/nm.4493; Sevcik J, 2013, CELL SIGNAL, V25, P1186, DOI 10.1016/j.cellsig.2013.02.008; Sevcik J, 2012, CELL SIGNAL, V24, P1023, DOI 10.1016/j.cellsig.2011.12.023; Shav-Tal Y, 2002, FEBS LETT, V531, P109, DOI 10.1016/S0014-5793(02)03447-6; Shav-Tal Y, 2001, MOL BIOL CELL, V12, P2328, DOI 10.1091/mbc.12.8.2328; Sonego M, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav3235; Sonego M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07005-1; Sonego M, 2013, EMBO MOL MED, V5, P707, DOI 10.1002/emmm.201201504; Sun YH, 2009, CANCER INVEST, V27, P891, DOI 10.3109/07357900902744536; Takayama K, 2017, P NATL ACAD SCI USA, V114, P10461, DOI 10.1073/pnas.1706076114; Tsukahara T, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/204973; Wu W, 2010, MUTAT RES-FUND MOL M, V691, P1, DOI 10.1016/j.mrfmmm.2010.06.002; Yarosh CA, 2015, WIRES RNA, V6, P351, DOI 10.1002/wrna.1280; Yu JJ, 1998, INT J MOL MED, V1, P617; Zhang GL, 2012, MUTAT RES-GEN TOX EN, V746, P66, DOI 10.1016/j.mrgentox.2012.03.004; Zhu JY, 2018, GYNECOL ONCOL, V148, P368, DOI 10.1016/j.ygyno.2017.11.028	39	23	24	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	22					4390	4403		10.1038/s41388-020-1292-6	http://dx.doi.org/10.1038/s41388-020-1292-6		APR 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LR9IT	32332923	Green Published, hybrid			2022-12-17	WOS:000528417800001
J	He, ZS; Thorrez, L; Siegfried, G; Meulemans, S; Evrard, S; Tejpar, S; Khatib, AM; Creemers, JWM				He, Zongsheng; Thorrez, Lieven; Siegfried, Geraldine; Meulemans, Sandra; Evrard, Serge; Tejpar, Sabine; Khatib, Abdel-Majid; Creemers, John W. M.			The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer	ONCOGENE			English	Article							HUMAN COLON; TUMOR PROGRESSION; GROWTH; EXPRESSION; CELLS; PROLIFERATION; ACTIVATION; RESISTANCE; INHIBITORS; MUTATIONS	Mutations in KRAS and/or BRAF that activate the ERK kinase are frequently found in colorectal cancer (CRC) and drive resistance to targeted therapies. Therefore, the identification of therapeutic targets that affect multiple signaling pathways simultaneously is crucial for improving the treatment of patients with KRAS or BRAF mutations. The proprotein convertase furin activates several oncogenic protein precursors involved in the ERK-MAPK pathway by endoproteolytic cleavage. Here we show that genetic inactivation of furin suppresses tumorigenic growth, proliferation, and migration in KRAS or BRAF mutant CRC cell lines but not in wild-type KRAS and BRAF cells. In a mouse xenograft model, these KRAS or BRAF mutant cells lacking furin displayed reduced growth and angiogenesis, and increased apoptosis. Mechanistically, furin inactivation prevents the processing of various protein pecursors including proIGF1R, proIR, proc-MET, proTGF-beta 1 and NOTCH1 leading to potent and durable ERK-MAPK pathway suppression in KRAS or BRAF mutant cells. Furthermore, we identified genes involved in activating the ERK-MAPK pathway, such as PTGS2, which are downregulated in the KRAS or BRAF mutant cells after furin inactivation but upregulated in wild-type KRAS and BRAF cells. Analysis of human colorectal tumor samples reveals a positive correlation between enhanced furin expression and KRAS or BRAF expression. These results indicate that furin plays an important role in KRAS or BRAF-associated ERK-MAPK pathway activation and tumorigenesis, providing a potential target for personalized treatment.	[He, Zongsheng; Meulemans, Sandra; Creemers, John W. M.] Katholieke Univ Leuven, Dept Human Genet, Lab Biochem Neuroendocrinol, Leuven, Belgium; [Thorrez, Lieven] Katholieke Univ Leuven, Dept Dev & Regenerat, Interdisciplinary Res Facil, Campus Kulak Kortrijk, Kortrijk, Belgium; [Siegfried, Geraldine; Evrard, Serge; Khatib, Abdel-Majid] INSERM, UMR, LAMC, Allee Geoffroy St Hilaire 1029, Pessac, France; [Evrard, Serge] Inst Bergonie, Bordeaux, France; [Tejpar, Sabine] Univ Hosp Leuven, Dept Oncol, Digest Oncol Unit, Leuven, Belgium	KU Leuven; KU Leuven; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Bergonie; KU Leuven; University Hospital Leuven	Creemers, JWM (corresponding author), Katholieke Univ Leuven, Dept Human Genet, Lab Biochem Neuroendocrinol, Leuven, Belgium.	john.creemers@kuleuven.be	Thorrez, Lieven/A-2583-2011; KHATIB, Abdel-Majid/A-9948-2015	Thorrez, Lieven/0000-0002-5896-6823; KHATIB, Abdel-Majid/0000-0001-6957-0384; siegfried, geraldine/0000-0002-6346-5206	SIRIC BRIO, France; La Ligue Contre le Cancer, France; FWO Vlaanderen [G.0738.15]; Chinese Government Scholarship [201409110101]	SIRIC BRIO, France; La Ligue Contre le Cancer, France; FWO Vlaanderen(FWO); Chinese Government Scholarship	We would like to thank Maria Francesca Baietti for providing help with the soft agar assay, and Rudra Kashyap for providing help with the wound healing migration assay. We would also like to thank Alvaro Cortes Calabuig for the RNA-seq data analysis. This work was supported in part by SIRIC BRIO and La Ligue Contre le Cancer to AMK, France. We acknowledge grant support from FWO Vlaanderen (Grant nr. G.0738.15) to JC. ZH was supported by a Chinese Government Scholarship (Nr. 201409110101).	Artenstein AW, 2011, NEW ENGL J MED, V365, P2507, DOI 10.1056/NEJMra1106700; Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558; Bassi DE, 2001, MOL CARCINOGEN, V31, P224, DOI 10.1002/mc.1057; Batlle E, 2019, IMMUNITY, V50, P924, DOI 10.1016/j.immuni.2019.03.024; Benvenuti S, 2007, CANCER RES, V67, P2643, DOI 10.1158/0008-5472.CAN-06-4158; Blommaert E, 2019, P NATL ACAD SCI USA, V116, P9865, DOI 10.1073/pnas.1817815116; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Buck E, 2010, MOL CANCER THER, V9, P2652, DOI 10.1158/1535-7163.MCT-10-0318; Chisanga D, 2016, NUCLEIC ACIDS RES, V44, pD969, DOI 10.1093/nar/gkv1097; Cordova ZM, 2016, ONCOTARGET, V7, P54392, DOI 10.18632/oncotarget.11106; Couture F, 2015, EXPERT OPIN THER PAT, V25, P379, DOI 10.1517/13543776.2014.1000303; Creemers JWM, 2008, FRONT BIOSCI-LANDMRK, V13, P4960, DOI 10.2741/3055; Dahms SO, 2016, SCI REP-UK, V6, DOI 10.1038/srep34303; De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6; Declercq J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/148651; Duguay SJ, 1998, J BIOL CHEM, V273, P18443, DOI 10.1074/jbc.273.29.18443; Duguay SJ, 1997, J BIOL CHEM, V272, P6663, DOI 10.1074/jbc.272.10.6663; Erdogan B, 2017, BIOCHEM SOC T, V45, P229, DOI 10.1042/BST20160387; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Ghisoli M, 2016, MOL THER, V24, P1478, DOI 10.1038/mt.2016.86; Ginefra P, 2018, CELL REP, V22, P2176, DOI 10.1016/j.celrep.2018.02.005; Grabocka E, 2016, CELL, V167, P1803, DOI 10.1016/j.cell.2016.11.035; Guo SC, 2011, BBA-REV CANCER, V1815, P197, DOI 10.1016/j.bbcan.2010.12.002; Hardes K, 2015, CHEMMEDCHEM, V10, P1218, DOI 10.1002/cmdc.201500103; Henrich S, 2005, J MOL BIOL, V345, P211, DOI 10.1016/j.jmb.2004.10.050; Holderfield M, 2014, NAT REV CANCER, V14, P455, DOI 10.1038/nrc3760; Huang YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030638; Jaaks P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161396; Jin M, 2018, PATHOL ONCOL RES, V24, P45, DOI 10.1007/s12253-017-0195-5; Khatib AM, 2001, J BIOL CHEM, V276, P30686, DOI 10.1074/jbc.M101725200; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Kosumi K, 2019, EUR J CANCER, V111, P82, DOI 10.1016/j.ejca.2019.01.022; Krysan K, 2005, CANCER RES, V65, P6275, DOI 10.1158/0008-5472.CAN-05-0216; Liu DX, 2007, J CLIN ENDOCR METAB, V92, P2264, DOI 10.1210/jc.2006-1613; Liu XL, 2011, AM J CLIN PATHOL, V135, P245, DOI 10.1309/AJCP7FO2VAXIVSTP; Low K, 2019, FEBS J, V286, P4597, DOI 10.1111/febs.14979; Lopez de Cicco R, 2002, Acta Odontol Latinoam, V15, P29; Louagie E, 2008, P NATL ACAD SCI USA, V105, P12319, DOI 10.1073/pnas.0800340105; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Oh J, 2016, GYNECOL ONCOL, V143, P504, DOI 10.1016/j.ygyno.2016.09.018; Page RE, 2007, CELL ONCOL, V29, P289; Ramirez C, 2019, NATURE, V576, P477, DOI 10.1038/s41586-019-1831-x; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Roebroek AJM, 2004, J BIOL CHEM, V279, P53442, DOI 10.1074/jbc.M407152200; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Sarac MS, 2002, INFECT IMMUN, V70, P7136, DOI 10.1128/IAI.70.12.7136-7139.2002; Scamuffa N, 2008, J CLIN INVEST, V118, P352, DOI 10.1172/JCI32040; Scamuffa N, 2014, CARCINOGENESIS, V35, P528, DOI 10.1093/carcin/bgt345; Shimura T, 2020, CARCINOGENESIS, V41, P751, DOI 10.1093/carcin/bgz195; Siegfried G, 2005, ONCOGENE, V24, P6925, DOI 10.1038/sj.onc.1208838; Siegfried G, 2003, J CLIN INVEST, V111, P1723, DOI 10.1172/JCI200317220; Siegfried G, 2020, CANCER LETT, V473, P50, DOI 10.1016/j.canlet.2019.12.027; Susan-Resiga D, 2011, J BIOL CHEM, V286, P22785, DOI 10.1074/jbc.M111.233577; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tome M, 2019, CANCER RES, V79, P5008, DOI 10.1158/0008-5472.CAN-19-0086; Tripathi S, 2015, CELL HOST MICROBE, V18, P723, DOI 10.1016/j.chom.2015.11.002; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Ulanet DB, 2010, P NATL ACAD SCI USA, V107, P10791, DOI 10.1073/pnas.0914076107; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Van Schaeybroeck S, 2014, CELL REP, V7, P1940, DOI 10.1016/j.celrep.2014.05.032; Vartanian S, 2013, J BIOL CHEM, V288, P2403, DOI 10.1074/jbc.M112.394130; Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Zhang DX, 2015, CELL REP, V10, P1335, DOI 10.1016/j.celrep.2015.02.006; Zhang YL, 2017, INT J ONCOL, V50, P1352, DOI 10.3892/ijo.2017.3896	65	23	23	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3571	3587		10.1038/s41388-020-1238-z	http://dx.doi.org/10.1038/s41388-020-1238-z		MAR 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32139876	Green Published			2022-12-17	WOS:000518240400001
J	Li, ZY; Philip, M; Ferrell, PB				Li, Zhuoyan; Philip, Mary; Ferrell, P. Brent			Alterations of T-cell-mediated immunity in acute myeloid leukemia	ONCOGENE			English	Review							ISOCITRATE DEHYDROGENASE MUTATIONS; INDOLEAMINE 2,3-DIOXYGENASE; CD200 EXPRESSION; SPONTANEOUS REMISSION; INCREASED FREQUENCY; PROGNOSTIC-FACTOR; PERIPHERAL-BLOOD; POOR-PROGNOSIS; PROLIFERATION; IMMUNOCOMPETENCE	Acute myeloid leukemia (AML) is a systemic, heterogeneous hematologic malignancy with poor overall survival. While some malignancies have seen improvements in clinical outcomes with immunotherapy, success of these agents in AML remains elusive. Despite limited progress, stem cell transplantation and donor lymphocyte infusions show that modulation of the immune system can improve overall survival of AML patients. Understanding the causes of immune evasion and disease progression will identify potential immune-mediated targets in AML. This review explores immunosuppressive mechanisms that alter T-cell-mediated immunity in AML.	[Li, Zhuoyan; Philip, Mary; Ferrell, P. Brent] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol & Oncol, Nashville, TN 37232 USA	Vanderbilt University	Ferrell, PB (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol & Oncol, Nashville, TN 37232 USA.	brent.ferrell@vumc.org		Li, Zhuoyan/0000-0003-2658-9071	 [K23HL138291];  [T32CA217834]	; 	The authors are supported by K23HL138291(PBF) and T32CA217834 (ZL).	Almosailleakh M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020453; Arandi N, 2018, BLOOD RES, V53, P294, DOI 10.5045/br.2018.53.4.294; Austin R, 2016, CRIT REV ONCOL HEMAT, V103, P62, DOI 10.1016/j.critrevonc.2016.04.020; Barosi G, 2014, CURR HEMATOL MALIG R, V9, P331, DOI 10.1007/s11899-014-0227-0; Boddu P, 2018, LEUKEMIA LYMPHOMA, V59, P790, DOI 10.1080/10428194.2017.1344905; Buggins AGS, 2001, J IMMUNOL, V167, P6021, DOI 10.4049/jimmunol.167.10.6021; Bunse L, 2018, NAT MED, V24, P1192, DOI 10.1038/s41591-018-0095-6; Cerrano M, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0764-8; Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2; Chamuleau MED, 2008, HAEMATOL-HEMATOL J, V93, P1894, DOI 10.3324/haematol.13113; Christopher MJ, 2018, NEW ENGL J MED, V379, P2330, DOI 10.1056/NEJMoa1808777; Coles SJ, 2012, LEUKEMIA, V26, P2146, DOI 10.1038/leu.2012.75; Coles SJ, 2012, LEUKEMIA, V26, P2148, DOI 10.1038/leu.2012.77; Corm S, 2009, LEUKEMIA RES, V33, P490, DOI 10.1016/j.leukres.2008.06.014; Curti A, 2007, LEUKEMIA, V21, P353, DOI 10.1038/sj.leu.2404485; Curti A, 2007, BLOOD, V109, P2871, DOI 10.1182/blood-2006-07-036863; Dama P, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0611-3; Damiani D, 2015, ONCOTARGET, V6, P30212, DOI 10.18632/oncotarget.4901; Daver N, 2019, CANCER DISCOV, V9, P370, DOI 10.1158/2159-8290.CD-18-0774; Deng M, 2018, NATURE, V562, P605, DOI 10.1038/s41586-018-0615-z; DiNardo CD, 2013, BLOOD, V121, P4917, DOI 10.1182/blood-2013-03-493197; Dobrowolska H, 2013, CYTOM PART B-CLIN CY, V84B, P21, DOI 10.1002/cyto.b.21050; Ersvaer Elisabeth, 2010, BMC Immunol, V11, P38, DOI 10.1186/1471-2172-11-38; Fozza C, 2016, CRIT REV ONCOL HEMAT, V107, P90, DOI 10.1016/j.critrevonc.2016.08.016; Frumento G, 2002, J EXP MED, V196, P459, DOI 10.1084/jem.20020121; Fukuno K, 2015, LEUKEMIA LYMPHOMA, V56, P1398, DOI 10.3109/10428194.2014.953150; Han YX, 2014, CANCER SCI, V105, P933, DOI 10.1111/cas.12459; Hasegawa K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144594; HERSH EM, 1974, J CLIN INVEST, V54, P401, DOI 10.1172/JCI107775; HERSH EM, 1971, NEW ENGL J MED, V285, P1211, DOI 10.1056/NEJM197111252852201; HOROWITZ MM, 1990, BLOOD, V75, P555; Howlader N., SEER CANC STAT REV 1; Jia B, 2019, CANC RES; Jia B, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0069-4; Kanakry CG, 2011, BLOOD, V117, P608, DOI 10.1182/blood-2010-04-277939; Kang XL, 2016, CELL CYCLE, V15, P25, DOI 10.1080/15384101.2015.1121324; Kawasaki BT, 2008, TRENDS IMMUNOL, V29, P464, DOI 10.1016/j.it.2008.07.005; Kelderman S, 2014, MOL ONCOL, V8, P1132, DOI 10.1016/j.molonc.2014.07.011; Kittang AO, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1062208; Klco JM, 2014, CANCER CELL, V25, P379, DOI 10.1016/j.ccr.2014.01.031; Knaus HA, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120974; Kretz-Rommel A, 2007, J IMMUNOL, V178, P5595, DOI 10.4049/jimmunol.178.9.5595; LaBelle JL, 2002, BLOOD, V99, P2146, DOI 10.1182/blood.V99.6.2146; Lamble AJ, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00213; Le Dieu R, 2009, BLOOD, V114, P3909, DOI 10.1182/blood-2009-02-206946; Lee JB, 2019, BLOOD REV, V35, P18, DOI 10.1016/j.blre.2019.02.001; Lichtenegger FS, 2014, LEUKEMIA RES, V38, P964, DOI 10.1016/j.leukres.2014.05.014; Liu YX, 2019, BLOOD REV, V34, P67, DOI 10.1016/j.blre.2018.12.001; Losman JA, 2013, SCIENCE, V339, P1621, DOI 10.1126/science.1231677; Masarova L, 2018, ADV EXP MED BIOL, V995, P97, DOI 10.1007/978-3-030-02505-2_4; Medeiros BC, 2017, LEUKEMIA, V31, P272, DOI 10.1038/leu.2016.275; Menter T, 2018, BRIT J HAEMATOL, V182, P581, DOI 10.1111/bjh.14819; Moreaux J, 2008, BIOCHEM BIOPH RES CO, V366, P117, DOI 10.1016/j.bbrc.2007.11.103; Moreaux J, 2006, BLOOD, V108, P4194, DOI 10.1182/blood-2006-06-029355; Muller-Schmah C, 2012, ANN HEMATOL, V91, P27, DOI 10.1007/s00277-011-1332-y; Mussai F, 2019, INT J CANCER, V145, P2201, DOI 10.1002/ijc.32028; Mussai F, 2013, BLOOD, V122, P749, DOI 10.1182/blood-2013-01-480129; Musuraca G, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0590-1; Orleans-Lindsay JK, 2001, CLIN EXP IMMUNOL, V126, P403, DOI 10.1046/j.1365-2249.2001.01692.x; Paley MA, 2012, SCIENCE, V338, P1220, DOI 10.1126/science.1229620; Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192; Philip M, 2017, NATURE, V545, P452, DOI 10.1038/nature22367; Pollyea DA, 2018, HEMATOL-AM SOC HEMAT, P45, DOI 10.1182/asheducation-2018.1.45; Radpour R, 2019, LEUKEMIA, V33, P2379, DOI 10.1038/s41375-019-0441-9; Rashidi A, 2015, LEUKEMIA LYMPHOMA, V56, P1727, DOI 10.3109/10428194.2014.970545; Schnorfeil FM, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0189-2; Sun YX, 2014, HUM IMMUNOL, V75, P113, DOI 10.1016/j.humimm.2013.11.014; Szczepanski MJ, 2009, CLIN CANCER RES, V15, P3325, DOI 10.1158/1078-0432.CCR-08-3010; Teague RM, 2013, J IMMUNOTHER CANCER, V1, DOI 10.1186/2051-1426-1-13; Tian T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131761; Tian T, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/915873; Tikhonova AN, 2019, NATURE, V569, P222, DOI 10.1038/s41586-019-1104-8; Tonks A, 2007, LEUKEMIA, V21, P566, DOI 10.1038/sj.leu.2404559; Ustun C, 2011, BLOOD, V118, P5084, DOI 10.1182/blood-2011-07-365817; van Galen P, 2019, CELL, V176, P1265, DOI 10.1016/j.cell.2019.01.031; Wang MJ, 2018, CLIN IMMUNOL, V190, P64, DOI 10.1016/j.clim.2017.08.021; Wang XB, 2005, EUR J HAEMATOL, V75, P468, DOI 10.1111/j.1600-0609.2005.00537.x; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Williams M, 2018, CANCERS, V10, DOI 10.3390/cancers10050129; Wouters BJ, 2016, BLOOD, V127, P42, DOI 10.1182/blood-2015-07-604512; Wu C, 2009, CLIN EXP IMMUNOL, V158, P199, DOI 10.1111/j.1365-2249.2009.04011.x; Xu T, 2017, NATURE, V548, P228, DOI 10.1038/nature23475; Zahran AM, 2018, CANCER BIOMARK, V22, P587, DOI 10.3233/CBM-181368; Zhang LJ, 2018, CLIN CANCER RES, V24, P5381, DOI 10.1158/1078-0432.CCR-17-3855; Zhang L, 2013, J CLIN INVEST, V123, P1999, DOI 10.1172/JCI63980; Zhang SH, 2011, INT J CANCER, V129, P1373, DOI 10.1002/ijc.25791; Zhou Q, 2011, BLOOD, V117, P4501, DOI 10.1182/blood-2010-10-310425; Zhou Q, 2009, BLOOD, V114, P3793, DOI 10.1182/blood-2009-03-208181; Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806	89	23	23	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3611	3619		10.1038/s41388-020-1239-y	http://dx.doi.org/10.1038/s41388-020-1239-y		MAR 2020	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32127646	Green Accepted			2022-12-17	WOS:000517861800001
J	Zhou, QQ; Huang, TT; Jiang, ZY; Ge, C; Chen, XX; Zhang, LL; Zhao, FY; Zhu, MX; Chen, TY; Cui, Y; Li, H; Yao, M; Li, JJ; Tian, H				Zhou, Qingqing; Huang, Tingting; Jiang, Zhiyuan; Ge, Chao; Chen, Xiaoxia; Zhang, Lili; Zhao, Fangyu; Zhu, Miaoxin; Chen, Taoyang; Cui, Ying; Li, Hong; Yao, Ming; Li, Jinjun; Tian, Hua			Upregulation of SNX5 predicts poor prognosis and promotes hepatocellular carcinoma progression by modulating the EGFR-ERK1/2 signaling pathway	ONCOGENE			English	Article							SORTING NEXIN 5; TARGETED THERAPIES; CANCER; EGFR; ENDOCYTOSIS; DEGRADATION; PROTEINS; DOMAINS	Endocytosis is an essential component of cell motility, which facilitates the malignant behavior of cancer. Sorting nexin (SNX) family members are associated with tumor progression. However, the role and mechanism of SNX5 in hepatocellular carcinoma (HCC) progression remain largely unknown. In this study, we investigated the clinical significance and possible involvement of SNX5 in the progression of HCC. Here, we showed that SNX5 was upregulated in tumors compared with adjacent nontumorous tissues in HCC patients. The upregulation of SNX5 in HCC was associated with vascular invasion, intrahepatic metastasis, and poor prognosis. The overexpression of SNX5 promoted HCC cell proliferation, migration, invasion, and metastasis, whereas silencing SNX5 expression resulted in decreased cell proliferation, migration, and invasion. Knockdown of SNX5 significantly inhibited HCC cell proliferation by inducing G1/S transition arrest. Mechanistically, we demonstrated that SNX5 promoted cell proliferation, migration, and invasion via the activation of the EGFR-ERK1/2 pathway by blocking EGF-mediated EGFR internalization. We found that SNX5 interacted with EGFR in HCC cells. Moreover, SNX5-induced cell proliferation, migration, and invasion were partially reversed by the knockdown of EGFR or by ERK1/2 inhibitors. In addition, we demonstrated that SNX5 knockdown sensitized HCC cells to tyrosine kinase inhibitors, including erlotinib and sorafenib. Taken together, our results indicate that SNX5 promotes HCC cell proliferation and metastasis via inhibiting the endocytosis and degradation of EGFR, thereby activating the ERK1/2 signaling pathway. Our work also suggests that SNX5 is a potential therapeutic target for HCC.	[Zhou, Qingqing; Huang, Tingting; Jiang, Zhiyuan; Ge, Chao; Chen, Xiaoxia; Zhang, Lili; Zhao, Fangyu; Zhu, Miaoxin; Li, Hong; Yao, Ming; Li, Jinjun; Tian, Hua] Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst,Renji Hosp, Shanghai, Peoples R China; [Chen, Taoyang] Qi Dong Liver Canc Inst, Qi Dong, Jiangsu, Peoples R China; [Cui, Ying] Canc Inst Guangxi, Nanning, Peoples R China	Shanghai Jiao Tong University	Tian, H (corresponding author), Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst,Renji Hosp, Shanghai, Peoples R China.	htian@shsci.org	huang, ting/GRR-3141-2022		National Natural Science Foundation of China [81972581, 81472570]; National Key Sci-Tech Special Project of China [2018ZX10723204-006]; Natural Science Foundation of Shanghai [19ZR1452800]; Foundation of Shanghai Municipal Health Commission [201940429]; SKLORG Research Foundation [91-17-29]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Sci-Tech Special Project of China; Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); Foundation of Shanghai Municipal Health Commission; SKLORG Research Foundation	This work was supported by grants from the National Natural Science Foundation of China (81972581, 81472570), the National Key Sci-Tech Special Project of China (2018ZX10723204-006), Natural Science Foundation of Shanghai (19ZR1452800), Foundation of Shanghai Municipal Health Commission (201940429) and the SKLORG Research Foundation (91-17-29).	Ara S, 2012, CANCER SCI, V103, P1356, DOI 10.1111/j.1349-7006.2012.02296.x; Bendris N, 2016, J CELL SCI, V129, P2804, DOI 10.1242/jcs.188045; Bokel C, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a017020; Brunt L, 2018, CELL MOL LIFE SCI, V75, P785, DOI 10.1007/s00018-017-2654-2; Choi E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09318-3; Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Cullen PJ, 2012, NAT CELL BIOL, V14, P29, DOI 10.1038/ncb2374; Fu J, 2018, CANCER LETT, V412, P283, DOI 10.1016/j.canlet.2017.10.008; Fuchs BC, 2014, HEPATOLOGY, V59, P1577, DOI 10.1002/hep.26898; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heucken N, 2018, J CELL SCI, V131, DOI 10.1242/jcs.203695; Hirsch FR, 2009, ONCOGENE, V28, pS32, DOI 10.1038/onc.2009.199; Hou HL, 2018, CANCER SCI, V109, P1088, DOI 10.1111/cas.13518; Hu PF, 2018, ACTA BIOCH BIOPH SIN, V50, P1075, DOI 10.1093/abbs/gmy110; Jiang ZY, 2019, CANCER LETT, V447, P1, DOI 10.1016/j.canlet.2019.01.020; Jitsukawa S, 2017, J PATHOL, V243, P342, DOI 10.1002/path.4951; Joffre C, 2011, NAT CELL BIOL, V13, P827, DOI 10.1038/ncb2257; Kaksonen M, 2018, NAT REV MOL CELL BIO, V19, P313, DOI 10.1038/nrm.2017.132; Kim N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08533-2; Lanaya H, 2014, NAT CELL BIOL, V16, P972, DOI 10.1038/ncb3031; Liu H, 2006, BIOCHEM BIOPH RES CO, V342, P537, DOI 10.1016/j.bbrc.2006.01.179; Liu ZC, 2018, J CELL BIOCHEM, V119, P4170, DOI 10.1002/jcb.26625; Llovet JM, 2008, HEPATOLOGY, V48, P1312, DOI 10.1002/hep.22506; Menard JA, 2016, CANCER RES, V76, P4828, DOI 10.1158/0008-5472.CAN-15-2831; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Mygind KJ, 2018, J BIOL CHEM, V293, P8077, DOI 10.1074/jbc.RA117.001077; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Nothwehr SF, 2000, J CELL BIOL, V151, P297, DOI 10.1083/jcb.151.2.297; Nothwehr SF, 1999, MOL BIOL CELL, V10, P875, DOI 10.1091/mbc.10.4.875; Roskoski R, 2019, PHARMACOL RES, V144, P19, DOI 10.1016/j.phrs.2019.03.006; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sigismund S, 2018, MOL ONCOL, V12, P3, DOI 10.1002/1878-0261.12155; Sun Y, 2013, DEV CELL, V25, P144, DOI 10.1016/j.devcel.2013.03.010; Tanigawa K, 2019, J CELL PHYSIOL, V234, P17280, DOI 10.1002/jcp.28346; Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263; Villanueva A, 2011, GASTROENTEROLOGY, V140, P1410, DOI 10.1053/j.gastro.2011.03.006; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; Xu MJ, 2017, CANCER METAST REV, V36, P463, DOI 10.1007/s10555-017-9687-8; Zhang SL, 2018, CANCER LETT, V419, P116, DOI 10.1016/j.canlet.2018.01.045; Zhu AX, 2015, J CLIN ONCOL, V33, P559, DOI 10.1200/JCO.2013.53.7746	41	23	23	6	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2140	2155		10.1038/s41388-019-1131-9	http://dx.doi.org/10.1038/s41388-019-1131-9			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31819169				2022-12-17	WOS:000518584000009
J	Saliakoura, M; Reynoso-Moreno, I; Pozzato, C; Sebastiano, MR; Galie, M; Gertsch, J; Konstantinidou, G				Saliakoura, Maria; Reynoso-Moreno, Ines; Pozzato, Chiara; Rossi Sebastiano, Matteo; Galie, Mirco; Gertsch, Jurg; Konstantinidou, Georgia			The ACSL3-LPIAT1 signaling drives prostaglandin synthesis in non-small cell lung cancer	ONCOGENE			English	Article							GENE-EXPRESSION; PHOSPHOLIPASE A(2); GROWTH-FACTOR; FATTY-ACIDS; CYCLOOXYGENASE-2; PHOSPHATIDYLINOSITOL; INDUCTION; LIPIDOME; BREAST; PROGRESSION	Enhanced prostaglandin production promotes the development and progression of cancer. Prostaglandins are generated from arachidonic acid (AA) by the action of cyclooxygenase (COX) isoenzymes. However, how cancer cells are able to maintain an elevated supply of AA for prostaglandin production remains unclear. Here, by using lung cancer cell lines and clinically relevant Kras(G12D)-driven mouse models, we show that the long-chain acyl-CoA synthetase (ACSL3) channels AA into phosphatidylinositols to provide the lysophosphatidylinositol-acyltransferase 1 (LPIAT1) with a pool of AA to sustain high prostaglandin synthesis. LPIAT1 knockdown suppresses proliferation and anchorage-independent growth of lung cancer cell lines, and hinders in vivo tumorigenesis. In primary human lung tumors, the expression of LPIAT1 is elevated compared with healthy tissue, and predicts poor patient survival. This study uncovers the ACSL3-LPIAT1 axis as a requirement for the sustained prostaglandin synthesis in lung cancer with potential therapeutic value.	[Saliakoura, Maria; Pozzato, Chiara; Rossi Sebastiano, Matteo; Konstantinidou, Georgia] Univ Bern, Inst Pharmacol, CH-3010 Bern, Switzerland; [Reynoso-Moreno, Ines; Gertsch, Jurg] Univ Bern, Inst Biochem & Mol Med, CH-3012 Bern, Switzerland; [Galie, Mirco] Univ Verona, Dept Neurosci Biomed & Movement, I-37134 Verona, Italy	University of Bern; University of Bern; University of Verona	Konstantinidou, G (corresponding author), Univ Bern, Inst Pharmacol, CH-3010 Bern, Switzerland.	georgia.konstantinidou@pki.unibe.ch	Konstantinidou, Georgia/O-9192-2016	Konstantinidou, Georgia/0000-0001-9513-0286; Saliakoura, Maria/0000-0001-9021-2151; Reynoso Moreno, Ines del Carmen/0000-0001-7672-8282; Gertsch, Jurg/0000-0003-0978-1555; GALIE', Mirco/0000-0002-6441-8313; Rossi Sebastiano, Matteo/0000-0002-9925-1904	Swiss National Science Foundation (SNSF) [PP00P3_163929]; Novartis Foundation for medical-biological research [16C190]; UniBern Forschungsstiftung; SNSF [163359]	Swiss National Science Foundation (SNSF)(Swiss National Science Foundation (SNSF)); Novartis Foundation for medical-biological research; UniBern Forschungsstiftung; SNSF(Swiss National Science Foundation (SNSF))	The authors wish to thank Prof. Hiroyuki Arai (University of Tokyo, Japan) for providing the LPIAT1 antibody [39]. The NSCLC cell lines were a kind gift from Prof. John D. Minna (University of Southwestern Medical Center at Dallas, Texas, USA). Human tissues were provided by the Tissue Bank Bern. We thank Dr. Alexis Traynor-Kaplan (University of Washington, Medicinal Chemistry Mass Spectrometry Center, Washington, USA) for help with MS analysis. This study was supported by the Swiss National Science Foundation (SNSF) professorship PP00P3_163929, Novartis Foundation for medical-biological research #16C190, UniBern Forschungsstiftung (to GK), and SNSF research grant #163359 (to JG).	Balsinde J, 2002, FEBS LETT, V531, P2, DOI 10.1016/S0014-5793(02)03413-0; Baratelli F, 2005, J IMMUNOL, V175, P1483, DOI 10.4049/jimmunol.175.3.1483; Blaine SA, 2001, J BIOL CHEM, V276, P42737, DOI 10.1074/jbc.M107773200; Borer JS, 2005, ARTHRITIS RES THER, V7, pS14, DOI 10.1186/ar1794; Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]; Chicca A, 2017, P NATL ACAD SCI USA, V114, pE5006, DOI 10.1073/pnas.1704065114; D'Souza K, 2014, BBA-BIOMEMBRANES, V1838, P1501, DOI 10.1016/j.bbamem.2013.10.003; Dannenberg AJ, 2003, CANCER CELL, V4, P431, DOI 10.1016/S1535-6108(03)00310-6; Ejsing CS, 2009, P NATL ACAD SCI USA, V106, P2136, DOI 10.1073/pnas.0811700106; Ferrer I, 2018, LUNG CANCER, V124, P53, DOI 10.1016/j.lungcan.2018.07.013; Goldman M, 2018, PREPRINT, DOI DOI 10.1101/326470V3; Harris R. E., 2009, Inflammopharmacology, V17, P55, DOI 10.1007/s10787-009-8049-8; Herzog R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029851; Herzog R, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r8; HOLUB BJ, 1971, J LIPID RES, V12, P699; Howe LR, 2002, CANCER RES, V62, P5405; Huang M, 1998, CANCER RES, V58, P1208; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; JUNGALWALA FB, 1984, J LIPID RES, V25, P738; Kaminska K, 2014, FUTURE ONCOL, V10, P2177, DOI 10.2217/fon.14.152; Kamphorst JJ, 2013, P NATL ACAD SCI USA, V110, P8882, DOI 10.1073/pnas.1307237110; LANDS WEM, 1958, J BIOL CHEM, V231, P883; Lee HC, 2008, MOL BIOL CELL, V19, P1174, DOI 10.1091/mbc.E07-09-0893; Lee HC, 2012, MOL BIOL CELL, V23, P4689, DOI 10.1091/mbc.E12-09-0673; Marino S, 2000, GENE DEV, V14, P994; Mashek DG, 2007, FUTURE LIPIDOL, V2, P465, DOI 10.2217/17460875.2.4.465; Meehan TF, 2015, NUCLEIC ACIDS RES, V43, pD1171, DOI 10.1093/nar/gku1193; Oliver TG, 2010, GENE DEV, V24, P837, DOI 10.1101/gad.1897010; Padanad MS, 2016, CELL REP, V16, P1614, DOI 10.1016/j.celrep.2016.07.009; Park JY, 2006, CLIN IMMUNOL, V119, P229, DOI 10.1016/j.clim.2006.01.016; PATTON GM, 1982, J LIPID RES, V23, P190; Perez R, 2006, J LIPID RES, V47, P484, DOI 10.1194/jlr.M500397-JLR200; Phelps RM, 1996, J CELL BIOCHEM, P32; Poligone B, 2001, J BIOL CHEM, V276, P38658, DOI 10.1074/jbc.M106599200; Quach ND, 2014, BIOCHEM PHARMACOL, V90, P338, DOI 10.1016/j.bcp.2014.05.022; Sampaio JL, 2011, P NATL ACAD SCI USA, V108, P1903, DOI 10.1073/pnas.1019267108; Sheng HM, 1998, J BIOL CHEM, V273, P22120, DOI 10.1074/jbc.273.34.22120; Slatter DA, 2016, CELL METAB, V23, P930, DOI 10.1016/j.cmet.2016.04.001; Smakman N, 2005, CLIN CANCER RES, V11, P41; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Stolina M, 2000, J IMMUNOL, V164, P361, DOI 10.4049/jimmunol.164.1.361; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; Surette ME, 1999, CARCINOGENESIS, V20, P757, DOI 10.1093/carcin/20.5.757; Tanaka T, 2003, EUR J BIOCHEM, V270, P1466, DOI 10.1046/j.1432-1033.2003.03512.x; Traynor-Kaplan A, 2017, BBA-MOL CELL BIOL L, V1862, P513, DOI 10.1016/j.bbalip.2017.02.002; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; Wang D, 2006, GUT, V55, P115, DOI 10.1136/gut.2004.047100; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Wang Z, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/132320; Wymann MP, 2008, NAT REV MOL CELL BIO, V9, P162, DOI 10.1038/nrm2335; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742	53	23	24	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					2948	2960		10.1038/s41388-020-1196-5	http://dx.doi.org/10.1038/s41388-020-1196-5		FEB 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32034305	Green Published, hybrid			2022-12-17	WOS:000511752600003
J	Timaner, M; Kotsofruk, R; Raviv, Z; Magidey, K; Shechter, D; Kan, T; Nevelsky, A; Daniel, S; de Vries, EGE; Zhang, TW; Kaidar-Person, O; Kerbel, RS; Shaked, Y				Timaner, Michael; Kotsofruk, Ruslana; Raviv, Ziv; Magidey, Ksenia; Shechter, Dvir; Kan, Tal; Nevelsky, Alexander; Daniel, Shahar; de Vries, Elisabeth G. E.; Zhang, Tongwu; Kaidar-Person, Orit; Kerbel, Robert S.; Shaked, Yuval			Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1	ONCOGENE			English	Article							CANCER-THERAPY; RADIOTHERAPY; CELLS; MECHANISMS; EXPRESSION; MEDIATORS; RESPONSES; ASSAY; MICROENVIRONMENT; MICROVESICLES	Radiotherapy induces immune-related responses in cancer patients by various mechanisms. Here, we investigate the immunomodulatory role of tumor-derived microparticles (TMPs)-extracellular vesicles shed from tumor cells-following radiotherapy. We demonstrate that breast carcinoma cells exposed to radiation shed TMPs containing elevated levels of immune-modulating proteins, one of which is programmed death-ligand 1 (PD-L1). These TMPs inhibit cytotoxic T lymphocyte (CTL) activity both in vitro and in vivo, and thus promote tumor growth. Evidently, adoptive transfer of CTLs pre-cultured with TMPs from irradiated breast carcinoma cells increases tumor growth rates in mice recipients in comparison with control mice receiving CTLs pre-cultured with TMPs from untreated tumor cells. In addition, blocking the PD-1-PD-L1 axis, either genetically or pharmacologically, partially alleviates TMP-mediated inhibition of CTL activity, suggesting that the immunomodulatory effects of TMPs in response to radiotherapy is mediated, in part, by PD-L1. Overall, our findings provide mechanistic insights into the tumor immune surveillance state in response to radiotherapy and suggest a therapeutic synergy between radiotherapy and immune checkpoint inhibitors.	[Timaner, Michael; Kotsofruk, Ruslana; Raviv, Ziv; Magidey, Ksenia; Shechter, Dvir; Kan, Tal; Shaked, Yuval] Technion, Cell Biol & Canc Sci, Rappaport Fac Med, Haifa, Israel; [Nevelsky, Alexander; Daniel, Shahar; Kaidar-Person, Orit] Rambam Hlth Care Campus, Radiat Oncol Unit, Oncol Inst, Haifa, Israel; [de Vries, Elisabeth G. E.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands; [Zhang, Tongwu] NCI, Div Canc Epidemiol & Genet, Integrat Tumor Epidemiol Branch, NIH, Bethesda, MD USA; [Kerbel, Robert S.] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Rambam Health Care Campus; University of Groningen; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Shaked, Y (corresponding author), Technion, Cell Biol & Canc Sci, Rappaport Fac Med, Haifa, Israel.	yshaked@tx.technion.ac.il		de Vries, Elisabeth/0000-0002-8949-7425; Zhang, Tongwu/0000-0003-2124-2706; Kaidar-Person, Orit/0000-0003-4023-1869	Israel Cancer Research Fund; European Research Council [771112]; Rappaport funds	Israel Cancer Research Fund; European Research Council(European Research Council (ERC)European Commission); Rappaport funds	This study was supported by grants from the Israel Cancer Research Fund supported the Buckstein Family to YS and RSK, the European Research Council (no. 771112) and Rappaport funds to YS.	Ahn GO, 2008, CANCER CELL, V13, P193, DOI 10.1016/j.ccr.2007.11.032; Al-Nedawi K, 2009, CELL CYCLE, V8, P2014, DOI 10.4161/cc.8.13.8988; Barcellos-Hoff MH, 2005, NAT REV CANCER, V5, P867, DOI 10.1038/nrc1735; Barcellos-Hoff MH, 2005, SEMIN CANCER BIOL, V15, P138, DOI 10.1016/j.semcancer.2004.08.010; Barker HE, 2015, NAT REV CANCER, V15, P409, DOI 10.1038/nrc3958; Chen G, 2018, NATURE, V560, P382, DOI 10.1038/s41586-018-0392-8; Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591; De Palma M, 2013, CANCER CELL, V23, P277, DOI 10.1016/j.ccr.2013.02.013; Deng LF, 2014, J CLIN INVEST, V124, P687, DOI 10.1172/JCI67313; Dovedi SJ, 2014, CANCER RES, V74, P5458, DOI 10.1158/0008-5472.CAN-14-1258; EHLERS G, 1973, BRIT J RADIOL, V46, P220, DOI 10.1259/0007-1285-46-543-220; Formenti SC, 2009, LANCET ONCOL, V10, P718, DOI 10.1016/S1470-2045(09)70082-8; Fremder E, 2014, INT J CANCER, V135, P270, DOI 10.1002/ijc.28678; FU YX, 1990, CANCER RES, V50, P227; GENOVESI EV, 1984, CANCER RES, V44, P1489; Hutchinson Lisa, 2011, Nat Rev Clin Oncol, V8, P508, DOI 10.1038/nrclinonc.2011.112; Issman L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083680; Jaiswal R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061515; Kang J, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0156-7; Keklikoglou I, 2019, NAT CELL BIOL, V21, P190, DOI 10.1038/s41556-018-0256-3; Koller KM, 2017, CANCER BIOL THER, V18, P36, DOI 10.1080/15384047.2016.1264543; Lee TH, 2011, SEMIN IMMUNOPATHOL, V33, P455, DOI 10.1007/s00281-011-0250-3; Ma RH, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1118599; Makinde AY, 2016, SEMIN RADIAT ONCOL, V26, P254, DOI 10.1016/j.semradonc.2016.07.001; Matsumura S, 2008, J IMMUNOL, V181, P3099, DOI 10.4049/jimmunol.181.5.3099; Mege D, 2018, METHODS MOL BIOL, V1765, P271, DOI 10.1007/978-1-4939-7765-9_17; Mell LK, 2017, INT J RADIAT ONCOL, V97, P536, DOI 10.1016/j.ijrobp.2016.11.027; Meng YR, 2010, MOL THER, V18, P912, DOI 10.1038/mt.2010.18; Palayoor ST, 2014, MOL CANCER RES, V12, P1002, DOI 10.1158/1541-7786.MCR-13-0623; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Peinado H, 2017, NAT REV CANCER, V17, P302, DOI 10.1038/nrc.2017.6; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358; Rak J, 2010, SEMIN THROMB HEMOST, V36, P888, DOI 10.1055/s-0030-1267043; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Reynders K, 2015, PROG TUMOR RES, V42, P67, DOI 10.1159/000437185; Ricklefs FL, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar2766; Rose B, 2017, PRACT RADIAT ONCOL, V7, pE291, DOI 10.1016/j.prro.2017.03.008; Russell JS, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00157; Shaked Y, 2016, NAT REV CLIN ONCOL, V13, P611, DOI 10.1038/nrclinonc.2016.57; Sharabi AB, 2015, LANCET ONCOL, V16, pE498, DOI 10.1016/S1470-2045(15)00007-8; Sharma P, 2015, CELL, V161, P205, DOI 10.1016/j.cell.2015.03.030; STONE HB, 1979, JNCI-J NATL CANCER I, V63, P1229; Tang K, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2282; Timaner Michael, 2016, Curr Protoc Cell Biol, V70, DOI 10.1002/0471143030.cb1918s70; Timaner M, 2015, ONCOTARGET, V6, P27537, DOI 10.18632/oncotarget.4826; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Tyanova S, 2018, METHODS MOL BIOL, V1711, P133, DOI 10.1007/978-1-4939-7493-1_7; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Voloshin T, 2014, CANCER MICROENVIRON, V7, P11, DOI 10.1007/s12307-014-0144-8; Wargo JA, 2015, SEMIN ONCOL, V42, P601, DOI 10.1053/j.seminoncol.2015.05.007; Wersall PJ, 2006, ACTA ONCOL, V45, P493, DOI 10.1080/02841860600604611; WINN HJ, 1961, J IMMUNOL, V86, P228; Wolford CC, 2013, J CLIN INVEST, V123, P2893, DOI 10.1172/JCI64410; Zhao LL, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0328-9	55	23	25	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					187	203		10.1038/s41388-019-0971-7	http://dx.doi.org/10.1038/s41388-019-0971-7			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31467431	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000509849200013
J	Wei, TT; Lin, YT; Tang, SP; Luo, CK; Tsai, CT; Shun, CT; Chen, CC				Wei, Tzu-Tang; Lin, Yi-Ting; Tang, Shao-Pu; Luo, Cong-Kai; Tsai, Chiou-Tsun; Shun, Chia-Tung; Chen, Ching-Chow			Metabolic targeting of HIF-1 alpha potentiates the therapeutic efficacy of oxaliplatin in colorectal cancer	ONCOGENE			English	Article							HYPOXIA-INDUCIBLE FACTORS; TUMOR HYPOXIA; HISTONE DEACETYLASE; DRUG-RESISTANCE; HIF-1; INFLAMMATION; CHEMORESISTANCE; ANGIOGENESIS; CHEMOTHERAPY; VASCULATURE	Drug resistance is a major problem limiting the efficacy of chemotherapy in cancer treatment, and the hypoxia-induced stabilization of HIF-1 alpha plays a role in this process. HIF-1 alpha overexpression has been observed in a variety of human cancers, including colorectal cancer (CRC). Therefore, targeting HIF-1 alpha is a promising strategy for overcoming chemoresistance to enhance the efficacy of chemotherapies in CRC. Here, we show that DNMT inhibitors can induce HIF-1 alpha degradation to overcome oxaliplatin resistance and enhance anti-CRC therapy. We found that a low-toxicity DNMT inhibitor, zebularine, could downregulate HIF-1 alpha expression and overcome hypoxia-induced oxaliplatin resistance in HCT116 cells and showed efficacy in HCT116 xenograft models and AOM/DSS-induced CRC mouse models. Zebularine could induce the degradation of HIF-1 alpha protein through hydroxylation. LC-MS analysis showed a decrease in succinate in various CRC cells under hypoxia and in colon tissues of AOM/DSS-induced CRC mice. The decrease was reversed by zebularine. Tumor angiogenesis was also reduced by zebularine. Furthermore, zebularine potentiated the anticancer effect of oxaliplatin in AOM/DSS-induced CRC models. This finding provides a new strategy in which an increase in HIF-1 alpha hydroxylation could overcome oxaliplatin resistance to enhance anti-CRC therapy.	[Wei, Tzu-Tang; Lin, Yi-Ting; Tang, Shao-Pu; Luo, Cong-Kai; Tsai, Chiou-Tsun; Chen, Ching-Chow] Natl Taiwan Univ, Dept Pharmacol, Coll Med, Taipei 100, Taiwan; [Wei, Tzu-Tang; Lin, Yi-Ting; Tang, Shao-Pu; Luo, Cong-Kai; Tsai, Chiou-Tsun; Shun, Chia-Tung; Chen, Ching-Chow] Natl Taiwan Univ, Grad Inst Forens Med, Coll Med, Taipei 100, Taiwan; [Shun, Chia-Tung] Natl Taiwan Univ Hosp, Dept Pathol, Taipei 106, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital	Chen, CC (corresponding author), Natl Taiwan Univ, Dept Pharmacol, Coll Med, Taipei 100, Taiwan.; Chen, CC (corresponding author), Natl Taiwan Univ, Grad Inst Forens Med, Coll Med, Taipei 100, Taiwan.	chingchowchen@ntu.edu.tw	Tsai, Chiou-Tsun/AAO-6782-2021; WEI, TZU-TANG/AAT-8447-2020	SHUN, CHIA-TUNG/0000-0002-0468-4468	National Science Council of Taiwan; Institute of Biomedical Sciences, Academia Sinica [IBMS-CRC103-P02]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Institute of Biomedical Sciences, Academia Sinica(Academia Sinica - Taiwan)	This work was supported by a research grant from the National Science Council of Taiwan and the Institute of Biomedical Sciences, Academia Sinica (IBMS-CRC103-P02).	Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Berchner-Pfannschmidt U, 2008, J BIOL CHEM, V283, P31745, DOI 10.1074/jbc.M804390200; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Chan DA, 2005, MOL CELL BIOL, V25, P6415, DOI 10.1128/MCB.25.15.6415-6426.2005; Chan DA, 2009, CANCER CELL, V15, P527, DOI 10.1016/j.ccr.2009.04.010; Chen CC, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0248-3; Cheng JC, 2004, CANCER CELL, V6, P151, DOI 10.1016/j.ccr.2004.06.023; Colgan SP, 2010, NAT REV GASTRO HEPAT, V7, P281, DOI 10.1038/nrgastro.2010.39; Fong GH, 2008, CELL DEATH DIFFER, V15, P635, DOI 10.1038/cdd.2008.10; Foxler DE, 2012, NAT CELL BIOL, V14, P201, DOI 10.1038/ncb2424; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kim MS, 2010, CANCER METAST REV, V29, P181, DOI 10.1007/s10555-010-9207-6; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Lee K, 2009, P NATL ACAD SCI USA, V106, P17910, DOI 10.1073/pnas.0909353106; Lendahl U, 2009, NAT REV GENET, V10, P821, DOI 10.1038/nrg2665; Liu LL, 2008, CANCER SCI, V99, P121, DOI 10.1111/j.1349-7006.2007.00643.x; Ma J, 2008, MOL CANCER THER, V7, P3670, DOI 10.1158/1535-7163.MCT-08-0715; Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1; Meneses AM, 2016, HYPOXIA, V4, P53, DOI 10.2147/HP.S53576; Pientka FK, 2012, J CELL SCI, V125, P5168, DOI 10.1242/jcs.109041; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Rapisarda A, 2012, NAT REV CLIN ONCOL, V9, P378, DOI 10.1038/nrclinonc.2012.64; Remels AHV, 2015, ENDOCRINOLOGY, V156, P1770, DOI 10.1210/en.2014-1591; Rohwer N, 2011, DRUG RESIST UPDATE, V14, P191, DOI 10.1016/j.drup.2011.03.001; Samanta D, 2014, P NATL ACAD SCI USA, V111, pE5429, DOI 10.1073/pnas.1421438111; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Thienpont B, 2016, NATURE, V537, P63, DOI 10.1038/nature19081; Tredan O, 2007, J NATL CANCER I, V99, P1441, DOI 10.1093/jnci/djm135; Ullman TA, 2011, GASTROENTEROLOGY, V140, P1807, DOI 10.1053/j.gastro.2011.01.057; Wei TT, 2016, EBIOMEDICINE, V10, P124, DOI 10.1016/j.ebiom.2016.07.019; Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988; Wilson TR, 2006, ANN ONCOL, V17, pX315, DOI 10.1093/annonc/mdl280; Yang PM, 2013, SCI REP-UK, V3, DOI 10.1038/srep03219; Zhong H, 1999, CANCER RES, V59, P5830	47	23	29	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					414	427		10.1038/s41388-019-0999-8	http://dx.doi.org/10.1038/s41388-019-0999-8			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31477841				2022-12-17	WOS:000507766400012
J	Cao, SB; Ma, TF; Ungerleider, N; Roberts, C; Kobelski, M; Jin, LJ; Concha, M; Wang, X; Baddoo, M; Nguyen, HM; Corey, E; Fazli, L; Ledet, E; Zhang, RB; Silberstein, JL; Zhang, WS; Zhang, K; Sartor, O; Dong, XS; Flemington, EK; Dong, Y				Cao, Subing; Ma, Tianfang; Ungerleider, Nathan; Roberts, Claire; Kobelski, Margaret; Jin, Lianjin; Concha, Monica; Wang, Xia; Baddoo, Melody; Nguyen, Holly M.; Corey, Eva; Fazli, Ladan; Ledet, Elisa; Zhang, Rubin; Silberstein, Jonathan L.; Zhang, Wensheng; Zhang, Kun; Sartor, Oliver; Dong, Xuesen; Flemington, Erik K.; Dong, Yan			Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer	ONCOGENE			English	Article							TRANSLATION; EXPRESSION; PROGRESSION; LANDSCAPE	Deregulated expression of circular RNAs (circRNAs) is associated with various human diseases, including many types of cancer. Despite their growing links to cancer, there has been limited characterization of circRNAs in metastatic castration-resistant prostate cancer, the major cause of prostate cancer mortality. Here, through the analysis of an exome-capture RNA-seq dataset from 47 metastatic castration-resistant prostate cancer samples and ribodepletion and RNase R RNA-sequencing of patient-derived xenografts (PDXs) and cell models, we identified 13 circRNAs generated from the key prostate cancer driver gene-androgen receptor (AR). We validated and characterized the top four most abundant, clinically relevant AR circRNAs. Expression of these AR circRNAs was upregulated during castration-resistant progression of PDXs. The upregulation was not due to global increase of circRNA formation in these tumors. Instead, the levels of AR circRNAs correlated strongly with that of the linear AR transcripts (both AR and AR variants) in clinical samples and PDXs, indicating a transcriptional mechanism of regulation. In cultured cells, androgen suppressed the expression of these AR circRNAs and the linear AR transcripts, and the suppression was attenuated by an antiandrogen. Using nuclear/cytoplasmic fractionation and RNA in-situ hybridization assays, we demonstrated predominant cytoplasmic localization of these AR circRNAs, indicating likely cytoplasmic functions. Overall, this is the first comprehensive characterization of circRNAs arising from the AR gene. With greater resistance to exoribonuclease compared to the linear AR transcripts and detectability of AR circRNAs in patient plasma, these AR circRNAs may serve as surrogate circulating markers for AR/AR-variant expression and castration-resistant prostate cancer progression.	[Cao, Subing; Ma, Tianfang; Kobelski, Margaret; Jin, Lianjin; Dong, Yan] Tulane Univ, Sch Med, Dept Struct & Cellular Biol, Tulane Canc Ctr, 1430 Tulane Ave, New Orleans, LA 70112 USA; [Ungerleider, Nathan; Roberts, Claire; Concha, Monica; Wang, Xia; Baddoo, Melody; Flemington, Erik K.] Tulane Univ, Sch Med, Dept Pathol, Tulane Canc Ctr, New Orleans, LA 70112 USA; [Nguyen, Holly M.; Corey, Eva] Univ Washington, Dept Urol, Seattle, WA 98195 USA; [Fazli, Ladan; Dong, Xuesen] Univ British Columbia, Vancouver Prostate Ctr, Dept Urol Sci, Vancouver, BC, Canada; [Ledet, Elisa; Zhang, Rubin; Silberstein, Jonathan L.; Sartor, Oliver] Tulane Univ, Sch Med, Dept Med, Tulane Canc Ctr, New Orleans, LA 70112 USA; [Zhang, Wensheng; Zhang, Kun] Xavier Univ Louisiana, Dept Comp Sci, Bioinformat Facil, Xavier RCMI Ctr Canc Res, New Orleans, LA USA	Tulane University; Tulane University; University of Washington; University of Washington Seattle; University of British Columbia; Tulane University; Xavier University of Louisiana	Dong, Y (corresponding author), Tulane Univ, Sch Med, Dept Struct & Cellular Biol, Tulane Canc Ctr, 1430 Tulane Ave, New Orleans, LA 70112 USA.; Flemington, EK (corresponding author), Tulane Univ, Sch Med, Dept Pathol, Tulane Canc Ctr, New Orleans, LA 70112 USA.	erik@tulane.edu; ydong@tulane.edu	Dong, Xuesen/AGF-9228-2022	Kobelski, Margaret/0000-0002-8829-4562; Dong, Yan/0000-0003-1622-5354; Ma, Tianfang/0000-0003-4161-882X	National Institutes of Health [R01CA188609, R01AI101046, R01AI106676, P01CA214091]; PNW Prostate Cancer SPORE [P50CA097186, P01CA163227, RCMI 2U54MD007595, 5P20GM103424-17]; Department of Defense [W81XWH-15-10439, W81XWH-16-1-0317, W81XWH-16-1-0318]; Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE [P01CA214091, R21CA236549, P50CA097186, R01CA188609, R01CA243793, P01CA163227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI101046, R01AI106676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103424] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [U54MD007595] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); PNW Prostate Cancer SPORE; Department of Defense(United States Department of Defense); Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	This work was supported by the following grants: the National Institutes of Health grants R01CA188609, R01AI101046, R01AI106676, P01CA214091, PNW Prostate Cancer SPORE P50CA097186, P01CA163227, RCMI 2U54MD007595, and 5P20GM103424-17; Department of Defense grants W81XWH-15-10439, W81XWH-16-1-0317, and W81XWH-16-1-0318; The Prostate Cancer Foundation. The Richard M. Lucas Foundation supported the development of the LuCaP models. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.	Abdelmohsen K, 2017, RNA BIOL, V14, P361, DOI 10.1080/15476286.2017.1279788; Abe N, 2015, SCI REP-UK, V5, DOI 10.1038/srep16435; Abe N, 2013, ANGEW CHEM INT EDIT, V52, P7004, DOI 10.1002/anie.201302044; Ashwal-Fluss R, 2014, MOL CELL, V56, P55, DOI 10.1016/j.molcel.2014.08.019; Bach DH, 2019, MOL THER-NUCL ACIDS, V16, P118, DOI 10.1016/j.omtn.2019.02.005; Burd CE, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001233; Burnstein KL, 2005, J CELL BIOCHEM, V95, P657, DOI 10.1002/jcb.20460; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Cao SB, 2016, ENDOCR-RELAT CANCER, V23, pT199, DOI 10.1530/ERC-16-0298; Chen S, 2019, CANCER CELL, V176, pe822; Dai YQ, 2018, MED SCI MONITOR, V24, P3462, DOI 10.12659/MSM.908009; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dong Y, 2004, CANCER RES, V64, P19, DOI 10.1158/0008-5472.CAN-03-2789; Egan A, 2014, CANCER TREAT REV, V40, P426, DOI 10.1016/j.ctrv.2013.09.011; Hamilton MP, 2016, NEOPLASIA, V18, P356, DOI 10.1016/j.neo.2016.04.008; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Holdt LM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12429; Huang H, 2002, CRIT REV EUKAR GENE, V12, P193, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i3.30; Jie ST, 2019, INT J BIOL MACROMOL, V122, P1235, DOI 10.1016/j.ijbiomac.2018.09.076; Kahn B, 2014, INT J BIOL SCI, V10, P588, DOI 10.7150/ijbs.8671; Kong Z, 2017, BIOCHEM BIOPH RES CO, V493, P1217, DOI 10.1016/j.bbrc.2017.07.162; Kotake Y, 2011, ONCOGENE, V30, P1956, DOI 10.1038/onc.2010.568; Kristensen LS, 2018, ONCOGENE, V37, P555, DOI 10.1038/onc.2017.361; Legnini I, 2017, MOL CELL, V66, P22, DOI 10.1016/j.molcel.2017.02.017; Li SL, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0629-7; Li Y, 2012, ONCOGENE, V31, P4759, DOI 10.1038/onc.2011.637; Li Y, 2015, CELL RES, V25, P981, DOI 10.1038/cr.2015.82; Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959; Liang DM, 2014, GENE DEV, V28, P2233, DOI 10.1101/gad.251926.114; Markowski MC, 2017, JCO PRECIS ONCOL, V1; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Nyquist MD, 2013, P NATL ACAD SCI USA, V110, P17492, DOI 10.1073/pnas.1308587110; Pamudurti NR, 2017, MOL CELL, V66, P9, DOI 10.1016/j.molcel.2017.02.021; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Shand RL, 2006, CURR OPIN UROL, V16, P123, DOI 10.1097/01.mou.0000193384.39351.64; Ungerleider N, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2865-7; Ungerleider N, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007206; Ungerleider NA, 2019, J VIROL, V93, DOI 10.1128/JVI.01952-18; Vo JN, 2019, CELL, V176, P869, DOI 10.1016/j.cell.2018.12.021; Xia QL, 2018, CELL PHYSIOL BIOCHEM, V50, P1903, DOI 10.1159/000494870; Xu HY, 2015, SCI REP-UK, V5, DOI 10.1038/srep12453; Yang Y, 2017, CELL RES, V27, P626, DOI 10.1038/cr.2017.31; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Zhang Y, 2013, MOL CELL, V51, P792, DOI 10.1016/j.molcel.2013.08.017; Zheng QP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11215	45	23	24	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2019	38	45					7060	7072		10.1038/s41388-019-0947-7	http://dx.doi.org/10.1038/s41388-019-0947-7			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JL9XI	31409897	Green Accepted			2022-12-17	WOS:000495878400003
J	Dayan, A; Fleminger, G; Ashur-Fabian, O				Dayan, Avraham; Fleminger, Gideon; Ashur-Fabian, Osnat			Targeting the Achilles' heel of cancer cells via integrin-mediated delivery of ROS-generating dihydrolipoamide dehydrogenase	ONCOGENE			English	Article							ALPHA-KETOGLUTARATE DEHYDROGENASE; LIPOAMIDE DEHYDROGENASE; COMPLEX; STRATEGIES; SUBSTRATE; SEQUENCE; SUBUNIT; IMPORT; STRAIN	Cancer cells frequently exhibit higher levels of reactive oxygen species (ROS) than normal cells and when ROS levels increase beyond a cellular tolerability threshold, cancer cell death is enhanced. The mitochondrial dihydrolipoamide dehydrogenase (DLDH) is an enzyme which produces ROS in association with its oxidoreductive activity and may be thus utilized as an exogenous anticancer agent. As cancer cells often overexpress integrins that recognize RGD-containing proteins, we have bioengineered the human DLDH with RGD motifs (DLDHRGD) for integrin-mediated drug delivery. The modified protein fully retained its enzyme activity and ROS-production capability. DLDHRGD uptake by cells was shown to depend on the presence of cell-associated integrin alpha v beta 3, as comparatively demonstrated with normal kidney cells (HEK293) transfected with either beta 1 (alpha v beta 1 positive) or beta 3 integrins (alpha v beta 3 positive). The interaction with beta 3 integrins was shown to be competitively inhibited by an RGD peptide. In mice melanoma cells (B16F10), which highly express an endogenous alpha v beta 3 integrin, fast cellular uptake of DLDHRGD which resulted in cell number reduction, apoptosis induction, and a parallel intracellular ROS production was shown. Similar results were obtained with additional human melanoma cell models (A375, WM3314, and WM3682). In contrast, HEK293 beta 3 cells remained intact following DLDHRGD uptake. The high pharmacological safety profile of DLDHRGD has been observed by several modes of administrations in BALB/C or C57B1/6 mouse strains. Treatments with DLDHRGD in a subcutaneous melanoma mice model resulted in significant tumor inhibition. Our study demonstrated, in vitro and in vivo, the development of a unique platform, which targets cancer cells via integrin-mediated drug delivery of an exogenous ROS-generating drug.	[Dayan, Avraham; Fleminger, Gideon] Tel Aviv Univ, George S Wise Fac Life Sci, Sch Mol Cell Biol & Biotechnol, Tel Aviv, Israel; [Ashur-Fabian, Osnat] Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, Tel Aviv, Israel	Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Ashur-Fabian, O (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, Tel Aviv, Israel.	osnataf@gmail.com	Ashur, Osnat/AAC-1417-2020	Ashur-Fabian, Osnat/0000-0001-8624-3182	Israeli Ministry of Economics [52679, 55869]	Israeli Ministry of Economics	The authors wish to thank Mrs. Ronit Hollander for the graphics assistance and the table of contents illustration. This research was supported by the Israeli Ministry of Economics (Projects 52679 and 55869).	Ambrus A, 2018, NEUROCHEM INT, V117, P5, DOI 10.1016/j.neuint.2017.05.018; Ambrus A, 2013, ARCH BIOCHEM BIOPHYS, V538, P145, DOI 10.1016/j.abb.2013.08.015; Babu A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15012-5; Bender T, 2016, BBA-MOL CELL RES, V1863, P2436, DOI 10.1016/j.bbamcr.2016.01.017; Bolley J, 2013, NANOSCALE, V5, P11478, DOI 10.1039/c3nr03763k; Bui T, 2006, CANCER CELL, V9, P419, DOI 10.1016/j.ccr.2006.05.012; Caswell P, 2008, TRENDS CELL BIOL, V18, P257, DOI 10.1016/j.tcb.2008.03.004; Chen W, 2017, SMALL, V13, DOI 10.1002/smll.201601997; Chiarugi A, 2012, NAT REV CANCER, V12, P741, DOI 10.1038/nrc3340; CUNNINGHAM ML, 1985, PHOTOCHEM PHOTOBIOL, V42, P125, DOI 10.1111/j.1751-1097.1985.tb01549.x; DAHL HHM, 1987, J BIOL CHEM, V262, P7398; Danhier F, 2012, MOL PHARMACEUT, V9, P2961, DOI 10.1021/mp3002733; Dayan A, 2018, RSC ADV, V8, P9112, DOI 10.1039/c7ra13777j; Dayan A, 2017, J MOL RECOGNIT, V30, DOI 10.1002/jmr.2617; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Diebold L, 2016, FREE RADICAL BIO MED, V100, P86, DOI 10.1016/j.freeradbiomed.2016.04.198; FLEMINGER G, 1995, APPL ENVIRON MICROB, V61, P4357, DOI 10.1128/AEM.61.12.4357-4361.1995; Fu Q, 2016, INT J EXP PATHOL, V97, P351, DOI 10.1111/iep.12192; Galadari S, 2017, FREE RADICAL BIO MED, V104, P144, DOI 10.1016/j.freeradbiomed.2017.01.004; Gandioso A, 2016, J ORG CHEM, V81, P11556, DOI 10.1021/acs.joc.6b02415; Hu ZW, 2000, P NATL ACAD SCI USA, V97, P9221, DOI 10.1073/pnas.97.16.9221; Jezek J, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7010013; Kapp TG, 2017, SCI REP-UK, V7, DOI 10.1038/srep39805; Klyachko NL, 2005, J BIOL CHEM, V280, P16106, DOI 10.1074/jbc.M414285200; Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007; McCartney RG, 1998, J BIOL CHEM, V273, P24158, DOI 10.1074/jbc.273.37.24158; Nicco C, 2018, MOLECULES, V23, DOI 10.3390/molecules23010084; Nogueira V, 2013, CLIN CANCER RES, V19, P4309, DOI 10.1158/1078-0432.CCR-12-1424; Omura T, 1998, J BIOCHEM-TOKYO, V123, P1010; Poprac P, 2017, TRENDS PHARMACOL SCI, V38, P592, DOI 10.1016/j.tips.2017.04.005; Ralph SJ, 2011, PHARM RES-DORDR, V28, P2695, DOI 10.1007/s11095-011-0566-7; Raza MH, 2017, J CANCER RES CLIN, V143, P1789, DOI 10.1007/s00432-017-2464-9; Schaffner P, 2003, CELL MOL LIFE SCI, V60, P119, DOI 10.1007/s000180300008; Schiffelers RM, 2003, J CONTROL RELEASE, V91, P115, DOI 10.1016/S0168-3659(03)00240-2; Schito L, 2016, TRENDS CANCER, V2, P758, DOI 10.1016/j.trecan.2016.10.016; Schumacker PT, 2006, CANCER CELL, V10, P175, DOI 10.1016/j.ccr.2006.08.015; Sheldrake HM, 2014, J MED CHEM, V57, P6301, DOI 10.1021/jm5000547; STAMBAUGH R, 1966, J BIOL CHEM, V241, P1462; Starkov AA, 2004, J NEUROSCI, V24, P7779, DOI 10.1523/JNEUROSCI.1899-04.2004; Sun Y, 2017, DRUG DEVELOP RES, V78, P283, DOI 10.1002/ddr.21399; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Tretter L, 2004, J NEUROSCI, V24, P7771, DOI 10.1523/JNEUROSCI.1842-04.2004; TSAI CS, 1981, ARCH BIOCHEM BIOPHYS, V206, P77, DOI 10.1016/0003-9861(81)90068-0; Vanderperre B, 2015, CURR OPIN CELL BIOL, V33, P35, DOI 10.1016/j.ceb.2014.10.008; Wang J, 2008, CANCER BIOL THER, V7, P1875, DOI 10.4161/cbt.7.12.7067; Wang YC, 2007, J BIOMED SCI, V14, P203, DOI 10.1007/s11373-006-9136-0; Yu YP, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-78; Zhou ZH, 2001, P NATL ACAD SCI USA, V98, P14802, DOI 10.1073/pnas.011597698; Zundorf G, 2009, NEUROSCIENCE, V158, P610, DOI 10.1016/j.neuroscience.2008.10.015	49	23	23	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					5050	5061		10.1038/s41388-019-0775-9	http://dx.doi.org/10.1038/s41388-019-0775-9			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30872792				2022-12-17	WOS:000472145900012
J	Zhu, SM; Tian, H; Niu, XD; Wang, J; Li, X; Jiang, N; Wen, SM; Chen, XR; Ren, SC; Xu, CL; Chang, CS; Flores-Morales, A; Shang, ZQ; Sun, YH; Niu, YJ				Zhu, Shimiao; Tian, Hao; Niu, Xiaodan; Wang, Jiang; Li, Xing; Jiang, Ning; Wen, Simeng; Chen, Xuanrong; Ren, Shancheng; Xu, Chuanliang; Chang, Chawnshang; Flores-Morales, Amilcar; Shang, Zhiqun; Sun, Yinghao; Niu, Yuanjie			Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer	ONCOGENE			English	Article							ANDROGEN-DEPRIVATION THERAPY; TUMOR-CELLS; INCREASED SURVIVAL; DIFFERENTIATION; ADENOCARCINOMA; PHENOTYPE; RESISTANCE; MECHANISM; BIOLOGY	Castration-resistant prostate cancer (CRPC) with neuroendocrine differentiation (NED) is a lethal disease for which effective therapies are urgently needed. The mechanism underlying development of CRPC with NED, however, remains largely uncharacterized. In this study, we explored and characterized the functional role of neurotensin (NTS) in cell line and animal models of CRPC with NED. NTS was acutely induced by androgen deprivation in animal models of prostate cancer (PCa) and activated downstream signaling leading to NED through activation of neurotensin receptor 1 (NTSR1) and neurotensin receptor 3 (NTSR3), but not neurotensin receptor 2 (NTSR2). Our findings also revealed the existence of a CK8(+)/CK14(+) subpopulation in the LNCaP cell line that expresses high levels of both NTSR1 and NTSR3, and displays an enhanced susceptibility to develop neuroendocrine-like phenotypes upon treatment with NTS. More importantly, NTSR1 pathway inhibition prevented the development of NED and castration resistance in vivo. We propose a novel role of NTS in the development of CRPC with NED, and a possible strategy to prevent the onset of NED by targeting the NTS signaling pathway.	[Zhu, Shimiao; Tian, Hao; Wang, Jiang; Li, Xing; Jiang, Ning; Wen, Simeng; Chen, Xuanrong; Shang, Zhiqun; Niu, Yuanjie] Tianjin Med Univ, Hosp 2, Tianjin Inst Urol, Dept Urol, Tianjin 300211, Peoples R China; [Niu, Xiaodan] Univ Minnesota, Minneapolis, MN 55455 USA; [Ren, Shancheng; Xu, Chuanliang; Sun, Yinghao] Second Mil Med Univ, Changhai Hosp, Dept Urol, Shanghai 200433, Peoples R China; [Chang, Chawnshang] Univ Rochester, Dept Pathol, Rochester, NY 14620 USA; [Flores-Morales, Amilcar] Univ Copenhagen, Dept Hlth Sci, Fac Hlth & Med Sci, DK-2200 Copenhagen, Denmark	Tianjin Medical University; University of Minnesota System; University of Minnesota Twin Cities; Naval Medical University; University of Rochester; University of Copenhagen	Shang, ZQ; Niu, YJ (corresponding author), Tianjin Med Univ, Hosp 2, Tianjin Inst Urol, Dept Urol, Tianjin 300211, Peoples R China.; Sun, YH (corresponding author), Second Mil Med Univ, Changhai Hosp, Dept Urol, Shanghai 200433, Peoples R China.	zhiqun_shang@tmu.edu.cn; sunyh@medmail.com.cn; niuyuanjie9317@163.com		Wen, Simeng/0000-0001-7989-7700	National Basic Research Program of China [2012CB518304]; National Natural Science Foundation of China [81802573, 81472682, 81772756]; Natural Science Foundation of Tianjin [17JCZDJC35300, 15JCZDJC35400, 15JCYBJC27200]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Tianjin(Natural Science Foundation of Tianjin)	This work was supported by National Basic Research Program of China (2012CB518304), National Natural Science Foundation of China (81802573, 81472682, and 81772756), and Natural Science Foundation of Tianjin (17JCZDJC35300, 15JCZDJC35400, and 15JCYBJC27200).	Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Azzouni F, 2012, UROL CLIN N AM, V39, P435, DOI 10.1016/j.ucl.2012.07.002; Beltran H, 2012, J CLIN ONCOL, V30, pE386, DOI 10.1200/JCO.2011.41.5166; Cindolo L, 2007, UROL INT, V79, P287, DOI 10.1159/000109711; Davies AH, 2018, NAT REV UROL, V15, P271, DOI 10.1038/nrurol.2018.22; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Delk NA, 2012, AUTOPHAGY, V8, P650, DOI 10.4161/auto.19226; Fiaschi T, 2012, CANCER RES, V72, P5130, DOI 10.1158/0008-5472.CAN-12-1949; Friedlander TW, 2012, UROL CLIN N AM, V39, P453, DOI 10.1016/j.ucl.2012.07.003; Gingrich JR, 1997, CANCER RES, V57, P4687; Hashimoto K, 2015, LAB INVEST, V95, P283, DOI 10.1038/labinvest.2014.165; Huang JT, 2006, PROSTATE, V66, P1399, DOI 10.1002/pros.20434; Ito T, 2001, ONCOL REP, V8, P1221; Jiang N, 2015, ONCOGENE, V34, P2764, DOI 10.1038/onc.2014.206; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Lapuk AV, 2012, J PATHOL, V227, P286, DOI 10.1002/path.4047; Li P, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-55; Li YA, 2017, EUR UROL, V71, P68, DOI 10.1016/j.eururo.2016.04.028; Lorente D, 2015, NAT REV UROL, V12, P37, DOI 10.1038/nrurol.2014.345; Martin S, 2002, GASTROENTEROLOGY, V123, P1135, DOI 10.1053/gast.2002.36000; Niu Y, 2010, ONCOGENE, V29, P3593, DOI 10.1038/onc.2010.121; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Palapattu GS, 2009, PROSTATE, V69, P787, DOI 10.1002/pros.20928; Qi JF, 2010, CANCER CELL, V18, P23, DOI 10.1016/j.ccr.2010.05.024; Sauer CG, 2006, PROSTATE, V66, P227, DOI 10.1002/pros.20338; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; SEHGAL I, 1994, P NATL ACAD SCI USA, V91, P4673, DOI 10.1073/pnas.91.11.4673; Sella A, 2000, EUR UROL, V38, P250, DOI 10.1159/000020289; Tyler-McMahon BM, 2000, REGUL PEPTIDES, V93, P125, DOI 10.1016/S0167-0115(00)00183-X; Valerie NCK, 2011, CANCER RES, V71, P6817, DOI 10.1158/0008-5472.CAN-11-1646; Vashchenko N, 2005, EUR UROL, V47, P147, DOI 10.1016/j.eururo.2004.09.007; Vincent JP, 1999, TRENDS PHARMACOL SCI, V20, P302, DOI 10.1016/S0165-6147(99)01357-7; Wu Zherui, 2012, Front Endocrinol (Lausanne), V3, P184, DOI 10.3389/fendo.2012.00184; Yuan TC, 2007, ENDOCR-RELAT CANCER, V14, P531, DOI 10.1677/ERC-07-0061; Yuan TC, 2006, ENDOCR-RELAT CANCER, V13, P151, DOI 10.1677/erc.1.01043; Zou M, 2017, CANCER DISCOV, V7, P736, DOI 10.1158/2159-8290.CD-16-1174	37	23	23	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4875	4884		10.1038/s41388-019-0750-5	http://dx.doi.org/10.1038/s41388-019-0750-5			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30770901	Green Published, hybrid			2022-12-17	WOS:000471160500015
J	Zhou, XL; Zhu, CY; Wu, ZG; Guo, X; Zou, W				Zhou, Xiao-Lei; Zhu, Chong-Yue; Wu, Zhi-Gang; Guo, Xin; Zou, Wei			The oncoprotein HBXIP competitively binds KEAP1 to activate NRF2 and enhance breast cancer cell growth and metastasis	ONCOGENE			English	Article							TRANSCRIPTION FACTOR NRF2; PROMOTE PROLIFERATION; FACTOR SP1; MIGRATION; PROTEIN; PATHWAY; DYSREGULATION; DEGRADATION; MECHANISMS; MUTATIONS	The nuclear factor E2-related factor 2 (NRF2)-Kelch-like ECH-associated protein 1 (KEAP1) signaling cascades is a key transcriptional pathway governing cellular oxidative stress and tumor development. Mammalian hepatitis B X-interacting protein (HBXIP) has critical roles in modulating cancer malignance and tumor progression. However, whether HBXIP interacts with KEAP1 and NRF2 is unclear. Here, we found that HBXIP can effectually compete with NRF2 for binding with KEAP1 protein via its highly conserved GLNLG motif. The HBXIP-mediated reduction in NRF2-KEAP1 complexes promotes NRF2 accumulation and nuclear entry, which facilities the activation of antioxidant response element (ARE)dependent signaling cascades, thereby reducing the accumulation of endogenous cellular reactive oxygen species (ROS). We also found a strong positive correlation between HBXIP expression and NRF2 expression in breast cancer cells, tissue microarrays and clinical breast cancer tissues. Furthermore, this positive correlation was further confirmed via analysis of 1905 clinical cases of breast carcinoma provided by the cancer genomics database cBioPortal. Strikingly, disrupting the HBXIP-KEAP1 axis via mutating the GLNLG motif of HBXIP leads to potent inhibition of the malignancy of breast carcinoma both in vivo and in vitro. Our findings broaden our understanding of HBXIP as a modulation factor of cellular oxidative stress and address a novel regulatory mechanism governing redox homeostasis and the progression of breast carcinoma.	[Zhou, Xiao-Lei; Zhu, Chong-Yue; Wu, Zhi-Gang; Zou, Wei] Hebei Univ Sci & Technol, Publ R&D Ctr Biomanufacture, Shijiazhuang 050018, Hebei, Peoples R China; [Guo, Xin] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Mol & Cellular Pathol, 8-35-1 Sakuragaoka, Kagoshima 8908544, Japan	Hebei University of Science & Technology; Kagoshima University	Zhou, XL (corresponding author), Hebei Univ Sci & Technol, Publ R&D Ctr Biomanufacture, Shijiazhuang 050018, Hebei, Peoples R China.	foxlei@live.cn			National Natural Scientific Foundation [81602428]; Colleges and Universities in Hebei Province Science and Technology Research Project [QN2016020]; Science and Technology Research and Developmental Guidance Program of Shijiazhuang City [171201073 A]	National Natural Scientific Foundation(National Natural Science Foundation of China (NSFC)); Colleges and Universities in Hebei Province Science and Technology Research Project; Science and Technology Research and Developmental Guidance Program of Shijiazhuang City	This project was supported by grants from the National Natural Scientific Foundation (No. 81602428), the Colleges and Universities in Hebei Province Science and Technology Research Project (No. QN2016020), and the Science and Technology Research and Developmental Guidance Program of Shijiazhuang City (No. 171201073 A)	Bar-Peled L, 2012, CELL, V150, P1196, DOI 10.1016/j.cell.2012.07.032; Bauer AK, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/746432; Camp ND, 2012, J BIOL CHEM, V287, P6539, DOI 10.1074/jbc.M111.316471; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen WM, 2009, MOL CELL, V34, P663, DOI 10.1016/j.molcel.2009.04.029; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giudice A, 2006, BIOESSAYS, V28, P169, DOI 10.1002/bies.20359; Hast BE, 2014, CANCER RES, V74, P808, DOI 10.1158/0008-5472.CAN-13-1655; Hu N, 2011, J BIOL CHEM, V286, P13714, DOI 10.1074/jbc.M110.204131; Kansanen E, 2013, REDOX BIOL, V1, P45, DOI 10.1016/j.redox.2012.10.001; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021; Leinonen HM, 2015, BIOCHEM SOC T, V43, P645, DOI 10.1042/BST20150048; Li H, 2018, J BIOL CHEM, V293, P2053, DOI 10.1074/jbc.M117.809582; Li H, 2015, J BIOL CHEM, V290, P22649, DOI 10.1074/jbc.M115.658468; Li LL, 2015, BIOCHEM BIOPH RES CO, V458, P720, DOI 10.1016/j.bbrc.2015.02.036; Li YH, 2014, CANCER LETT, V355, P288, DOI 10.1016/j.canlet.2014.09.047; Liu BW, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0577-5; Liu Q, 2013, INT J CANCER, V133, P1310, DOI 10.1002/ijc.28154; Liu SP, 2012, J BIOL CHEM, V287, P30228, DOI 10.1074/jbc.M112.343947; Ma JL, 2012, MOL CELL BIOL, V32, P1506, DOI 10.1128/MCB.06271-11; Marusawa H, 2003, EMBO J, V22, P2729, DOI 10.1093/emboj/cdg263; Melegari M, 1998, J VIROL, V72, P1737, DOI 10.1128/JVI.72.3.1737-1743.1998; Nagy A, 2000, GENESIS, V26, P99, DOI 10.1002/(SICI)1526-968X(200002)26:2<99::AID-GENE1>3.0.CO;2-B; Onodera Y, 2014, ENDOCR-RELAT CANCER, V21, P241, DOI 10.1530/ERC-13-0234; Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Shi H, 2016, BIOCHEM BIOPH RES CO, V471, P89, DOI 10.1016/j.bbrc.2016.01.174; Shibata T, 2008, GASTROENTEROLOGY, V135, P1358, DOI 10.1053/j.gastro.2008.06.082; Stacy DR, 2006, HEAD NECK-J SCI SPEC, V28, P813, DOI 10.1002/hed.20430; Taguchi K, 2011, GENES CELLS, V16, P123, DOI 10.1111/j.1365-2443.2010.01473.x; Tong KI, 2007, MOL CELL BIOL, V27, P7511, DOI 10.1128/MCB.00753-07; Torrente L, 2017, ONCOGENE, V36, P6204, DOI 10.1038/onc.2017.221; Virostko J, 2010, MOL IMAGING BIOL, V12, P42, DOI 10.1007/s11307-009-0240-1; Wang J, 2008, CANCER BIOL THER, V7, P1875, DOI 10.4161/cbt.7.12.7067; Xu FQ, 2013, CANCER LETT, V333, P124, DOI 10.1016/j.canlet.2013.01.029; Yamamoto T, 2008, MOL CELL BIOL, V28, P2758, DOI 10.1128/MCB.01704-07; Zhang YY, 2013, J BIOL CHEM, V288, P18961, DOI 10.1074/jbc.M113.458638; Zhang YY, 2013, BIOCHEM BIOPH RES CO, V434, P305, DOI 10.1016/j.bbrc.2013.02.123; Zhao Y, 2016, CANCER RES, V76, P4696, DOI 10.1158/0008-5472.CAN-15-1734; Zhou XL, 2018, ACTA PHARMACOL SIN, V39, P459, DOI 10.1038/aps.2017.157; Zipper LM, 2002, J BIOL CHEM, V277, P36544, DOI 10.1074/jbc.M206530200	45	23	25	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4028	4046		10.1038/s41388-019-0698-5	http://dx.doi.org/10.1038/s41388-019-0698-5			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30692632				2022-12-17	WOS:000468740200005
J	Tang, B; Wu, J; Zhu, MX; Sun, XM; Liu, JJ; Xie, R; Dong, TX; Xiao, YF; Carethers, JM; Yang, SM; Dong, H				Tang, Bo; Wu, Jilin; Zhu, Michael X.; Sun, Xuemei; Liu, Jingjing; Xie, Rui; Dong, Tobias Xiao; Xiao, Yufeng; Carethers, John M.; Yang, Shiming; Dong, Hui			VPAC1 couples with TRPV4 channel to promote calcium-dependent gastric cancer progression via a novel autocrine mechanism	ONCOGENE			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; CELL-PROLIFERATION; CA2+; VIP; RECEPTOR; ACTIVATION; OVEREXPRESSION; EXPRESSION; SECRETION; CATENIN	Although VPAC1 and its ligand vasoactive intestinal peptide (VIP) are important in gastrointestinal physiology, their involvements in progression of gastrointestinal tumor have not been explored. Here, we found that higher expression of VIP/VPAC1 was observed in gastric cancer compared to the adjacent normal tissues. The increased expression of VIP/VPAC1 in gastric cancer correlated positively with invasion, tumor stage, lymph node, distant metastases, and poor survival. Moreover, high expression of VIP and VPAC1, advanced tumor stage and distant metastasis were independent prognostic factors. VPAC1 activation by VIP markedly induced TRPV4-mediated Ca2+ entry, and eventually promoted gastric cancer progression in a Ca2+ signaling-dependent manner. Inhibition of VPAC1 and its signaling pathway could block the progressive responses. VPAC1/TRPV4/Ca2+ signaling in turn enhanced the expression and secretion of VIP in gastric cancer cells, enforcing a positive feedback regulation mechanism. Taken together, our study demonstrate that VPAC1 is significantly overexpressed in gastric cancer and VPAC1/TRPV4/Ca2+ signaling axis could enforce a positive feedback regulation in gastric cancer progression. VIP/VPAC1 may serve as potential prognostic markers and therapeutic targets for gastric cancer.	[Tang, Bo; Sun, Xuemei; Liu, Jingjing; Xie, Rui; Xiao, Yufeng; Yang, Shiming; Dong, Hui] Third Mil Med Univ, Xinqiao Hosp, Dept Gastroenterol, Chongqing, Peoples R China; [Tang, Bo; Dong, Tobias Xiao; Dong, Hui] Univ Calif San Diego, Sch Med, Dept Med, San Diego, CA 92103 USA; [Wu, Jilin; Zhu, Michael X.] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai, Peoples R China; [Wu, Jilin] Univ Chinese Acad Sci, Beijing, Peoples R China; [Zhu, Michael X.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Xie, Rui] Zunyi Med Coll, Affiliated Hosp, Dept Gastroenterol, Zunyi, Peoples R China; [Carethers, John M.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	Army Medical University; University of California System; University of California San Diego; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; University of Texas System; University of Texas Health Science Center Houston; Zunyi Medical University; University of Michigan System; University of Michigan	Yang, SM; Dong, H (corresponding author), Third Mil Med Univ, Xinqiao Hosp, Dept Gastroenterol, Chongqing, Peoples R China.; Dong, H (corresponding author), Univ Calif San Diego, Sch Med, Dept Med, San Diego, CA 92103 USA.	shimingyang@yahoo.com; h2dong@ucsd.edu		Dong, Xiao/0000-0001-5500-7099	National Key Research and Development Program of China [2016YFC1302200]; National Natural Science Foundation of China [81602577]; Basic Science and Frontier Technology Research Project of Chongqing [cstc2017jcyjAX0149]; NATIONAL CANCER INSTITUTE [R01CA206010] Funding Source: NIH RePORTER	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Basic Science and Frontier Technology Research Project of Chongqing; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Key Research and Development Program of China (No. 2016YFC1302200 to HD), National Natural Science Foundation of China (No. 81602577 to BT), and Basic Science and Frontier Technology Research Project of Chongqing (No. cstc2017jcyjAX0149 to BT).	Andrikopoulos P, 2015, J BIOL CHEM, V290, P18412, DOI 10.1074/jbc.M114.628156; Badgwell B, 2016, LANCET ONCOL, V17, P1628, DOI 10.1016/S1470-2045(16)30521-6; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Chen F, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0278-7; Chen YF, 2016, BBA-MOL CELL RES, V1863, P1427, DOI 10.1016/j.bbamcr.2015.11.030; Chen YF, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-23; D'Aldebert E, 2011, GASTROENTEROLOGY, V140, P275, DOI 10.1053/j.gastro.2010.09.045; Deliot N, 2015, BBA-BIOMEMBRANES, V1848, P2512, DOI 10.1016/j.bbamem.2015.06.009; Dickson L, 2009, PHARMACOL THERAPEUT, V121, P294, DOI 10.1016/j.pharmthera.2008.11.006; Evans AM, 2016, SCI CHINA LIFE SCI, V59, P749, DOI 10.1007/s11427-016-5071-0; Favia A, 2014, P NATL ACAD SCI USA, V111, pE4706, DOI 10.1073/pnas.1406029111; Fernandez-Martinez AB, 2012, HISTOL HISTOPATHOL, V27, P1093, DOI 10.14670/HH-27.1093; Galione A, 2002, CELL CALCIUM, V32, P343, DOI 10.1016/S0143416002001902; Hagen BM, 2006, AM J PHYSIOL-CELL PH, V291, pC375, DOI 10.1152/ajpcell.00495.2005; Hahm SH, 1998, ANN NY ACAD SCI, V865, P10, DOI 10.1111/j.1749-6632.1998.tb11158.x; Hejna M, 2001, ANTICANCER RES, V21, P1183; Herrera JL, 2009, J CELL MOL MED, V13, P3209, DOI 10.1111/j.1582-4934.2009.00662.x; Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154; Hogan PG, 2017, CELL CALCIUM, V63, P66, DOI 10.1016/j.ceca.2017.01.014; Holzer P, 2011, CURR PHARM BIOTECHNO, V12, P24, DOI 10.2174/138920111793937862; Kodama D, 2013, BIOCHEM BIOPH RES CO, V437, P239, DOI 10.1016/j.bbrc.2013.06.047; Leuner K, 2010, MOL PHARMACOL, V77, P368, DOI 10.1124/mol.109.057513; Li D, 2013, INVEST OPHTH VIS SCI, V54, P2872, DOI 10.1167/iovs.12-11264; Liu F, 2015, ONCOTARGET, V6, P11585, DOI 10.18632/oncotarget.3412; Liu SH, 2014, TUMOR BIOL, V35, P6397, DOI 10.1007/s13277-014-1852-x; Ma YL, 2016, GUT, V65, P1494, DOI 10.1136/gutjnl-2014-308392; Monteith GR, 2012, J BIOL CHEM, V287, P31666, DOI 10.1074/jbc.R112.343061; Pla AF, 2012, ONCOGENE, V31, P200, DOI 10.1038/onc.2011.231; Reubi JC, 2000, CANCER RES, V60, P3105; Schwarz EC, 2013, BBA-MOL CELL RES, V1833, P1603, DOI 10.1016/j.bbamcr.2012.11.016; Seoane IV, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149141; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Song WQ, 2014, CANCER RES, V74, P2444, DOI 10.1158/0008-5472.CAN-13-2136; Storch U, 2017, P NATL ACAD SCI USA, V114, pE37, DOI 10.1073/pnas.1612263114; Tabuchi A, 2002, J BIOL CHEM, V277, P35920, DOI 10.1074/jbc.M204784200; Tan P, 2015, GASTROENTEROLOGY, V149, P1153, DOI 10.1053/j.gastro.2015.05.059; Thrasivoulou C, 2013, J BIOL CHEM, V288, P35651, DOI 10.1074/jbc.M112.437913; Tompkins JD, 2010, J MOL NEUROSCI, V42, P390, DOI 10.1007/s12031-010-9367-4; Vacas E, 2013, CANCER LETT, V336, P196, DOI 10.1016/j.canlet.2013.04.033; Vacas E, 2013, MOL CELL ENDOCRINOL, V365, P212, DOI 10.1016/j.mce.2012.10.021; Valdehita A, 2007, REGUL PEPTIDES, V144, P101, DOI 10.1016/j.regpep.2007.06.006; Valdehita A, 2009, MOL CELL ENDOCRINOL, V302, P41, DOI 10.1016/j.mce.2008.11.024; Wei CL, 2009, NATURE, V457, P901, DOI 10.1038/nature07577; White CM, 2010, CNS NEUROL DISORD-DR, V9, P661; Woo DH, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-42; Xiao G, 2015, ONCOTARGET, V6, P14165, DOI 10.18632/oncotarget.3690; Xie R, 2017, CANCER RES, V77, P6499, DOI 10.1158/0008-5472.CAN-17-0360; Yin YL, 2016, P NATL ACAD SCI USA, V113, pE3773, DOI 10.1073/pnas.1604519113; Zhang SA, 2010, J PHYSIOL SCI, V60, P389, DOI 10.1007/s12576-010-0107-x; Zhou ZC, 2014, GASTROENTEROLOGY, V147, P1043, DOI 10.1053/j.gastro.2014.07.021; Zhu MX, 2016, SCI CHINA LIFE SCI, V59, P743, DOI 10.1007/s11427-016-5098-2	51	23	23	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3946	3961		10.1038/s41388-019-0709-6	http://dx.doi.org/10.1038/s41388-019-0709-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30692637	Green Submitted			2022-12-17	WOS:000468035600013
J	Jang, D; Kwon, H; Choi, M; Lee, J; Pak, Y				Jang, Donghwan; Kwon, Hayeong; Choi, Moonjeong; Lee, Jaewoong; Pak, Yunbae			Sumoylation of Flotillin-1 promotes EMT in metastatic prostate cancer by suppressing Snail degradation	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; NUCLEAR TRANSLOCATION; SIGNALING PATHWAY; BREAST-CANCER; UP-REGULATION; ACTIVATION; KINASE; CAVEOLIN-2; PROTEIN; MEMBRANE	Flotillin-1 (Flot-1) has been shown to regulate cancer progression, but the regulatory role of post-translational modifications of Flot-1 on cancers remains elusive. Herein, we show that up-regulated E2 conjugating enzyme UBC9 sumoylates Flot-1 at Lys-51 and Lys-195 with small ubiquitin-like modifier (SUMO)-2/3 modification in metastatic prostate cancer. Mitogen induced the sumoylation and nuclear translocation of Flot-1. The nuclear-targeted Flot-1 physically interacted with Snail, and inhibited Snail degradation through the proteasome in a sumoylation-dependent manner, thereby promoting epithelial-to-mesenchymal transition (EMT). Sumoylation of Flot-1 by up-regulated UBC9 in human metastatic prostate cancer tissues and prostate cancer cells with high metastatic potential positively correlated with the stabilization of Snail and the induction of Snail-mediated EMT genes in the metastatic prostate cancer. Our study reveals a new mechanism of sumoylated Flot-1-mediating Snail stabilization, and identifies a novel sumoylated Flot-1-Snail signaling axis in EMT of metastatic prostate cancer.	[Jang, Donghwan; Kwon, Hayeong; Choi, Moonjeong; Lee, Jaewoong; Pak, Yunbae] Gyeongsang Natl Univ, BK21 Plus Program, Div Life Sci, Grad Sch Appl Life Sci,PMBBRC, Jinju 52828, South Korea	Gyeongsang National University	Pak, Y (corresponding author), Gyeongsang Natl Univ, BK21 Plus Program, Div Life Sci, Grad Sch Appl Life Sci,PMBBRC, Jinju 52828, South Korea.	ybpak@gnu.ac.kr	Pak, Yunbae/Q-5783-2019	Pak, Yunbae/0000-0002-8594-5673; Kwon, Hayeong/0000-0002-8828-6060; Jang, Donghwan/0000-0002-4639-1102	National Research Foundation of Korea [NRF-2015R1D1A3A01016537, NRF-2018R1D1A1B07045995, NRF-2015R1D1A4A01017437, NRF-2018R1C1B6006816]; National R&D Program for Cancer Control of Korea [1631090]; Next-Generation BioGreen 21 Program of Korea SSAC [PJ01317301]; Global Ph.D. Fellowship Program [NRF-2013H1A2A1034489]; the BK21 Plus Program	National Research Foundation of Korea(National Research Foundation of Korea); National R&D Program for Cancer Control of Korea; Next-Generation BioGreen 21 Program of Korea SSAC; Global Ph.D. Fellowship Program; the BK21 Plus Program	This work was supported by grants from the National Research Foundation of Korea (NRF-2015R1D1A3A01016537 and NRF-2018R1D1A1B07045995 to YP and NRF-2015R1D1A4A01017437 and NRF-2018R1C1B6006816 to HK), the National R&D Program for Cancer Control of Korea (1631090 to HK), and the Next-Generation BioGreen 21 Program of Korea SSAC, Project No. PJ01317301 to HK. DJ is a recipient of the Global Ph.D. Fellowship Program (NRF-2013H1A2A1034489). MC was supported by a scholarship from the BK21 Plus Program.	Amaddii M, 2012, J BIOL CHEM, V287, P7265, DOI 10.1074/jbc.M111.287599; Baulida J, 2015, BBA-REV CANCER, V1856, P55, DOI 10.1016/j.bbcan.2015.05.005; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bettermann K, 2012, CANCER LETT, V316, P113, DOI 10.1016/j.canlet.2011.10.036; Chaffer CL, 2016, CANCER METAST REV, V35, P645, DOI 10.1007/s10555-016-9648-7; Christofori G, 2003, EMBO J, V22, P2318, DOI 10.1093/emboj/cdg228; Du C, 2010, CANCER RES, V70, P7810, DOI 10.1158/0008-5472.CAN-09-4481; Escriva M, 2008, MOL CELL BIOL, V28, P1528, DOI 10.1128/MCB.02061-07; Garbis SD, 2008, J PROTEOME RES, V7, P3146, DOI 10.1021/pr800060r; Glebov OO, 2006, NAT CELL BIOL, V8, P46, DOI 10.1038/ncb1342; Gomez V, 2010, J BIOL CHEM, V285, P20683, DOI 10.1074/jbc.M110.130591; Green J. R, 2006, CAN MED BIOL ENG C, DOI [10.13140/2.1.1621.3446, DOI 10.13140/2.1.1621.3446]; Guillaume E, 2013, J CELL SCI, V126, P5293, DOI 10.1242/jcs.133975; Jang D, 2015, J CELL SCI, V128, P2179, DOI 10.1242/jcs.169409; Jeong K, 2012, TRAFFIC, V13, P1218, DOI 10.1111/j.1600-0854.2012.01378.x; Kaufhold S, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0062-0; Koh M, 2016, INT J CANCER, V138, P1232, DOI 10.1002/ijc.29869; Kuhne S, 2015, INT J MOL SCI, V16, P6447, DOI 10.3390/ijms16036447; Kwon H, 2015, BBA-MOL CELL RES, V1853, P1022, DOI 10.1016/j.bbamcr.2015.02.002; Kwon H, 2013, BBA-MOL CELL RES, V1833, P2176, DOI 10.1016/j.bbamcr.2013.05.003; Kwon H, 2011, J CELL MOL MED, V15, P888, DOI 10.1111/j.1582-4934.2010.01079.x; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Limpert AS, 2007, MOL CELL BIOL, V27, P5686, DOI 10.1128/MCB.01109-06; Lin CY, 2011, CLIN CANCER RES, V17, P3089, DOI 10.1158/1078-0432.CCR-10-3068; Liu J, 2005, J BIOL CHEM, V280, P1432, DOI 10.1074/jbc.M409740200; Meister M, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.47; Morrow IC, 2002, J BIOL CHEM, V277, P48834, DOI 10.1074/jbc.M209082200; Neumann-Giesen C, 2004, BIOCHEM J, V378, P509, DOI 10.1042/BJ20031100; Osorio LA, 2016, MOL MED REP, V13, P778, DOI 10.3892/mmr.2015.4585; Poblete CE, 2014, INT J ONCOL, V44, P647, DOI 10.3892/ijo.2014.2254; Pulukuri SM, 2005, J BIOL CHEM, V280, P36529, DOI 10.1074/jbc.M503111200; Randle DD, 2013, ONCOL LETT, V6, P1767, DOI 10.3892/ol.2013.1635; Ren ZX, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150070; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Santamaria A, 2005, MOL CELL BIOL, V25, P1900, DOI 10.1128/MCB.25.5.1900-1911.2005; Sehat B, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000628; Song LB, 2012, GASTROENTEROLOGY, V143, P995, DOI 10.1053/j.gastro.2012.06.033; Tomasovic A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029739; Tulloch LB, 2011, J BIOL CHEM, V286, P36020, DOI 10.1074/jbc.M111.282145; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Yan Y, 2014, TUMOR BIOL, V35, P10479, DOI 10.1007/s13277-014-2343-9; Zhang YY, 2014, MOL MED REP, V10, P860, DOI 10.3892/mmr.2014.2310; Zhao Q, 2014, NUCLEIC ACIDS RES, V42, pW325, DOI 10.1093/nar/gku383; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	44	23	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3248	3260		10.1038/s41388-018-0641-1	http://dx.doi.org/10.1038/s41388-018-0641-1			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30631151	hybrid, Green Published			2022-12-17	WOS:000465557200010
J	Nie, E; Miao, F; Jin, X; Wu, WN; Zhou, X; Zeng, AL; Yu, TF; Zhi, TL; Shi, ZM; Wang, YY; Zhang, JX; Liu, N; You, YP				Nie, Er; Miao, Faan; Jin, Xin; Wu, Weining; Zhou, Xu; Zeng, Ailiang; Yu, Tianfu; Zhi, Tongle; Shi, Zhumei; Wang, Yingyi; Zhang, Junxia; Liu, Ning; You, Yongping			Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma	ONCOGENE			English	Article							FOLLISTATIN-LIKE 1; GENE O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; HISTONE DEACETYLATION; PROMOTER METHYLATION; BINDING-PROTEIN; EXPRESSION; MGMT; REPAIR; FSTL1; HDAC2	Temozolomide was recognized as the first-line therapy for glioblastoma to prolong the survival of patients noticeably, while recent clinical studies found that some patients were not sensitive to temozolomide treatment. The possible mechanisms seemed to be methylguanine-DNA-methyltransferase (MGMT), mismatch repair, PARP, etc. And the abnormal expression of MGMT might be the most direct factor. In this study, we provide evidence that Fstl1 plays a vital role in temozolomide resistance by sequentially regulating DIP2A protein distribution, H3K9 acetylation (H3K9Ac), and MGMT transcription. As a multifunctional protein widely distributed in cells, DIP2A cooperates with the HDAC2-DMAP1 complex to enhance H3K9Ac deacetylation, prevent MGMT transcription, and increase temozolomide sensitivity. Fstl1, a glycoprotein highly expressed in glioblastoma, competitively binds DIP2A to block DIP2A nuclear translocation, so as to hinder DIP2A from binding the HDAC2-DMAP1 complex. The overexpression of Fstl1 promoted the expression of MGMT in association with increased promoter H3K9Ac. Upregulation of Fstl1 enhanced temozolomide resistance, whereas Fstl1 silencing obviously sensitized GBM cells to temozolomide both in vivo and in vitro. Moreover, DIP2A depletion abolished the effects of Fstl1 on MGMT expression and temozolomide resistance. These findings highlight an important role of Fstl1 in the regulation of temozolomide resistance by modulation of DIP2A/MGMT signaling.	[Nie, Er; Miao, Faan; Jin, Xin; Wu, Weining; Zhou, Xu; Zeng, Ailiang; Yu, Tianfu; Zhi, Tongle; Shi, Zhumei; Wang, Yingyi; Zhang, Junxia; Liu, Ning; You, Yongping] Nanjing Med Univ, Dept Neurosurg, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China; [Shi, Zhumei] Nanjing Med Univ, State Key Lab Reprod Med, Collaborat Innovat Ctr Canc Personalized Med, Dept Pathol,Canc Ctr, Nanjing 210029, Jiangsu, Peoples R China; [Liu, Ning; You, Yongping] CGCG, Nanjing 210029, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University	Liu, N; You, YP (corresponding author), Nanjing Med Univ, Dept Neurosurg, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China.; Liu, N; You, YP (corresponding author), CGCG, Nanjing 210029, Jiangsu, Peoples R China.	liuning0853@126.com; yypl9@njmu.edu.cn	zeng, ailiang/AAF-4498-2020	Zeng, Ailiang/0000-0003-2869-9899	Research Special Fund for Public Welfare Industry of Health [201402008]; National Key Research and Development Plan [2016YFC0902500]; National Natural Science Foundation of China [81672501, 81472362, 81372709]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	Research Special Fund for Public Welfare Industry of Health; National Key Research and Development Plan; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This work was supported by grants from the Research Special Fund for Public Welfare Industry of Health (201402008), the National Key Research and Development Plan (2016YFC0902500), National Natural Science Foundation of China (81672501, 81472362, and 81372709), and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Bae K, 2016, ONCOTARGET, V7, P18076, DOI 10.18632/oncotarget.6729; Bhakat KK, 2000, J BIOL CHEM, V275, P34197, DOI 10.1074/jbc.M005447200; Boldogh I, 1998, CANCER RES, V58, P3950; Bradshaw AD, 2012, INT J BIOCHEM CELL B, V44, P480, DOI 10.1016/j.biocel.2011.12.021; Chan QKY, 2009, CARCINOGENESIS, V30, P114, DOI 10.1093/carcin/bgn215; Choi YB, 2004, J BIOL CHEM, V279, P50930, DOI 10.1074/jbc.M406831200; COSTELLO JF, 1994, MOL CELL BIOL, V14, P6515, DOI 10.1128/MCB.14.10.6515; Danam RP, 2005, MOL CANCER THER, V4, P61; Esteller M, 1999, CANCER RES, V59, P793; Fiskus W, 2014, MOL CANCER THER, V13, P1142, DOI 10.1158/1535-7163.MCT-13-0770; Friedman HS, 2000, CLIN CANCER RES, V6, P2585; Geng Y, 2011, P NATL ACAD SCI USA, V108, P7058, DOI 10.1073/pnas.1007293108; Gerace E, 2015, METHOD ENZYMOL, V559, P99, DOI 10.1016/bs.mie.2014.11.010; Gerson SL, 2002, J CLIN ONCOL, V20, P2388, DOI 10.1200/JCO.2002.06.110; Gerson SL, 2004, NAT REV CANCER, V4, P296, DOI 10.1038/nrc1319; Hambrock HO, 2004, J BIOL CHEM, V279, P11727, DOI 10.1074/jbc.M309318200; Hambrock HO, 2003, J BIOL CHEM, V278, P11351, DOI 10.1074/jbc.M212291200; Hegi ME, 2004, CLIN CANCER RES, V10, P1871, DOI 10.1158/1078-0432.CCR-03-0384; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Hegi ME, 2008, J CLIN ONCOL, V26, P4189, DOI 10.1200/JCO.2007.11.5964; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; Kim HJ, 2016, CELL SIGNAL, V28, P1137, DOI 10.1016/j.cellsig.2016.05.018; Kitange GJ, 2016, CELL REP, V14, P2587, DOI 10.1016/j.celrep.2016.02.045; Kitange GJ, 2012, CLIN CANCER RES, V18, P4070, DOI 10.1158/1078-0432.CCR-12-0560; Kramer OH, 2009, TRENDS PHARMACOL SCI, V30, P647, DOI 10.1016/j.tips.2009.09.007; Kudo-Saito C, 2013, CANCER RES, V73, P6185, DOI 10.1158/0008-5472.CAN-13-1364; Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190; Lavon I, 2007, CANCER RES, V67, P8952, DOI 10.1158/0008-5472.CAN-06-3820; Liu S, 2006, EXP MOL PATHOL, V80, P132, DOI 10.1016/j.yexmp.2005.07.005; Liu S, 2010, AM J PHYSIOL-ENDOC M, V299, pE351, DOI 10.1152/ajpendo.00005.2010; Luo H, 2015, BRAIN, V138, P3654, DOI 10.1093/brain/awv287; Ma XY, 2009, J CLIN NEUROSCI, V16, P1595, DOI 10.1016/j.jocn.2009.02.036; Mukhopadhyay M, 2002, GENE, V293, P59, DOI 10.1016/S0378-1119(02)00694-7; Murakami K, 2012, FEBS LETT, V586, P319, DOI 10.1016/j.febslet.2012.01.010; Nakagawachi T, 2003, ONCOGENE, V22, P8835, DOI 10.1038/sj.onc.1207183; Nie E, 2017, J NEURO-ONCOL, V133, P59, DOI 10.1007/s11060-017-2425-9; Nie E, 2016, SCI REP-UK, V6, DOI 10.1038/srep39743; Oshima Y, 2008, CIRCULATION, V117, P3099, DOI 10.1161/CIRCULATIONAHA.108.767673; Ouchi N, 2010, J BIOL CHEM, V285, P7127, DOI 10.1074/jbc.M109.069468; Park HG, 2014, INT J NEUROPSYCHOPH, V17, P1487, DOI 10.1017/S1461145714000248; Pistollato F, 2010, STEM CELLS, V28, P851, DOI 10.1002/stem.415; Poelmans G, 2011, MOL PSYCHIATR, V16, P365, DOI 10.1038/mp.2010.105; Reddy SP, 2008, CLIN CANCER RES, V14, P2978, DOI 10.1158/1078-0432.CCR-07-4821; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Sarkaria JN, 2008, CLIN CANCER RES, V14, P2900, DOI 10.1158/1078-0432.CCR-07-1719; Serao NVL, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-49; SHIBANUMA M, 1993, EUR J BIOCHEM, V217, P13, DOI 10.1111/j.1432-1033.1993.tb18212.x; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sundaram GM, 2013, NATURE, V495, P103, DOI 10.1038/nature11890; Tai IT, 2008, DRUG RESIST UPDATE, V11, P231, DOI 10.1016/j.drup.2008.08.005; Tanaka M, 2010, FEBS J, V277, P4278, DOI 10.1111/j.1742-4658.2010.07816.x; Torres S, 2013, CLIN CANCER RES, V19, P6006, DOI 10.1158/1078-0432.CCR-13-1130; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; Turtoi A, 2012, J PROTEOME RES, V11, P5011, DOI 10.1021/pr3005698; Vannahme C, 2003, BIOCHEM J, V373, P805, DOI 10.1042/BJ20030532; Venneti S, 2013, BRAIN PATHOL, V23, P558, DOI 10.1111/bpa.12042; Wilting RH, 2012, DRUG RESIST UPDATE, V15, P21, DOI 10.1016/j.drup.2012.01.008; Yang JH, 2016, ONCOL REP, V35, P3566, DOI 10.3892/or.2016.4757	58	23	23	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2706	2721		10.1038/s41388-018-0596-2	http://dx.doi.org/10.1038/s41388-018-0596-2			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30542120	Green Published, hybrid			2022-12-17	WOS:000464121600003
J	Asnaghi, L; Whiten, DT; Key, N; Choi, JH; Mahale, A; Alkatan, H; Edward, DP; Elkhamary, SM; Al-Mesfer, S; Maktabi, A; Hurtado, CG; Leen, GY; Carcaboso, AM; Mumm, JS; Abu Safieh, L; Eberhart, CG				Asnaghi, Laura; Whiten, David T.; Key, Nolan; Choi, Joshua; Mahale, Alka; Alkatan, Hind; Edward, Deepak P.; Elkhamary, Sahar M.; Al-Mesfer, Saleh; Maktabi, Azza; Hurtado, Christopher G.; Leen, Grace Y.; Carcaboso, Angel M.; Mumm, Jeff S.; Abu Safieh, Leen; Eberhart, Charles G.			ACVR1C/SMAD2 signaling promotes invasion and growth in retinoblastoma	ONCOGENE			English	Article							TGF-BETA; TUMORIGENIC PHENOTYPE; CELL-GROWTH; ACTIVIN-A; CANCER; RECEPTOR; PROTEINS; DIFFERENTIATION; EXPRESSION; REVEALS	Retinoblastoma is the most common intraocular cancer in children. While the primary tumor can often be treated by local or systemic chemotherapy, metastatic dissemination is generally resistant to therapy and remains a leading cause of pediatric cancer death in much of the world. In order to identify new therapeutic targets in aggressive tumors, we sequenced RNA transcripts in five snap frozen retinoblastomas which invaded the optic nerve and five which did not. A three-fold increase was noted in mRNA levels of ACVR1C/ALK7, a type I receptor of the TGF-beta family, in invasive retinoblastomas, while downregulation of DACT2 and LEFTY2, negative modulators of the ACVR1C signaling, was observed in most invasive tumors. A two-to three-fold increase in ACVR1C mRNA was also found in invasive WERI Rb1 and Y79 cells as compared to non-invasive cells in vitro. Transcripts of ACVR1C receptor and its ligands (Nodal, Activin A/B, and GDF3) were expressed in six retinoblastoma lines, and evidence of downstream SMAD2 signaling was present in all these lines. Pharmacological inhibition of ACVR1C signaling using SB505124, or genetic downregulation of the receptor using shRNA potently suppressed invasion, growth, survival, and reduced the protein levels of the mesenchymal markers ZEB1 and Snail. The inhibitory effects on invasion, growth, and proliferation were recapitulated by knocking down SMAD2, but not SMAD3. Finally, in an orthotopic zebrafish model of retinoblastoma, a 55% decrease in tumor spread was noted (p = 0.0026) when larvae were treated with 3 mu M of SB505124, as compared to DMSO. Similarly, knockdown of ACVR1C in injected tumor cells using shRNA also resulted in a 54% reduction in tumor dissemination in the zebrafish eye as compared to scrambled shRNA control (p = 0.0005). Our data support a role for the ACVR1C/SMAD2 pathway in promoting invasion and growth of retinoblastoma.	[Asnaghi, Laura; Key, Nolan; Choi, Joshua; Eberhart, Charles G.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Whiten, David T.; Edward, Deepak P.; Hurtado, Christopher G.; Leen, Grace Y.; Mumm, Jeff S.; Eberhart, Charles G.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA; [Mahale, Alka; Alkatan, Hind; Edward, Deepak P.; Elkhamary, Sahar M.; Al-Mesfer, Saleh; Maktabi, Azza; Abu Safieh, Leen] King Khalid Eye Specialist Hosp, Riyadh, Saudi Arabia; [Edward, Deepak P.] Univ Illinois, Eye & Ear Infirm, Chicago, IL 60612 USA; [Elkhamary, Sahar M.] Mansoura Fac Med, Dept Diagnost Radiol, Mansoura, Egypt; [Carcaboso, Angel M.] Inst Rec St Joan de Deu, Barcelona, Spain; [Eberhart, Charles G.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Alkatan, Hind] King Saud Univ, Coll Med, Dept Ophthalmol, Riyadh, Saudi Arabia	Johns Hopkins University; Johns Hopkins University; King Khaled Eye Specialist Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Egyptian Knowledge Bank (EKB); Mansoura University; Johns Hopkins University; King Saud University	Eberhart, CG (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.; Eberhart, CG (corresponding author), Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.; Abu Safieh, L (corresponding author), King Khalid Eye Specialist Hosp, Riyadh, Saudi Arabia.; Eberhart, CG (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.	leensafieh@yahoo.co.uk; ceberha@jhmi.edu	ALKATAN, HIND M/AAU-3752-2021; Elkhamary, Sahar M/Z-1797-2018; Mumm, Jeff S/F-3125-2013; Elkhamary, Sahar M/R-2021-2017; Elkhamary, Sahar M/AAR-6991-2020	ALKATAN, HIND M/0000-0002-9968-4099; Elkhamary, Sahar M/0000-0001-8694-4376; Elkhamary, Sahar M/0000-0001-8694-4376; Elkhamary, Sahar M/0000-0001-8694-4376; Lee, Grace/0000-0003-1999-0836; Carcaboso, Angel/0000-0002-8485-426X; Mumm, Jeff/0000-0002-2575-287X	King Khaled Eye Specialist Hospital (KKESH)-Wilmer Eye Institute (WEI) Collaborative Research Grant; NIH [R21CA229919]; Jenny Fund; ISCIII-FEDER [CP13/00189]; MINECO (Retos program; Cure4RB project) [RTC-2015-4319-1];  [EY001765]; NATIONAL CANCER INSTITUTE [R21CA229919] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY001765, T32EY007143] Funding Source: NIH RePORTER	King Khaled Eye Specialist Hospital (KKESH)-Wilmer Eye Institute (WEI) Collaborative Research Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Jenny Fund; ISCIII-FEDER; MINECO (Retos program; Cure4RB project); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	King Khaled Eye Specialist Hospital (KKESH)-Wilmer Eye Institute (WEI) Collaborative Research Grant, NIH Grant R21CA229919, the core grant EY001765, and The Jenny Fund. AMC acknowledges funding from ISCIII-FEDER (CP13/00189) and MINECO (Retos program; Cure4RB project RTC-2015-4319-1).	Arima Y, 2012, J BIOL CHEM, V287, P7896, DOI 10.1074/jbc.M111.313759; Asnaghi L, 2016, ONCOTARGET, V7, P70028, DOI 10.18632/oncotarget.12142; Asnaghi L, 2013, INVEST OPHTH VIS SCI, V54, P295, DOI 10.1167/iovs.12-10209; Badhu B, 2005, CLIN EXP OPHTHALMOL, V33, P386, DOI 10.1111/j.1442-9071.2005.01010.x; Bashir M, 2015, NPJ BREAST CANCER, V1, DOI 10.1038/npjbcancer.2015.7; Bertacchi M, 2015, STEM CELL REP, V5, P532, DOI 10.1016/j.stemcr.2015.08.011; Bondestam J, 2001, CYTOGENET CELL GENET, V95, P157, DOI 10.1159/000059339; Busch M, 2018, ONCOL REP, V39, P160, DOI 10.3892/or.2017.6100; Byfield SD, 2004, MOL PHARMACOL, V65, P744, DOI 10.1124/mol.65.3.744; Chantada GL, 2011, PEDIATR BLOOD CANCER, V56, P341, DOI 10.1002/pbc.22843; Chawla B, 2016, OPHTHALMOLOGY, V123, P1933, DOI 10.1016/j.ophtha.2016.05.034; Chen XY, 2015, SCI REP-UK, V5, DOI 10.1038/srep10351; Chung IC, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-348; Condro MC, 2016, J COMP NEUROL, V524, P3827, DOI 10.1002/cne.24035; Gong WC, 2016, ONCOTARGET, V7, P70152, DOI 10.18632/oncotarget.12161; Gray PC, 2012, FEBS LETT, V586, P1836, DOI 10.1016/j.febslet.2012.01.051; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Hamilton L, 2016, ZEBRAFISH, V13, P523, DOI 10.1089/zeb.2016.1339; Honavar Santosh G, 2005, Ophthalmol Clin North Am, V18, P65, DOI 10.1016/j.ohc.2004.09.001; Hu TT, 2017, ANTICANCER RES, V37, P3441, DOI 10.21873/anticanres.11712; James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706; Joseph JV, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.395; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kanno C, 2009, CURR EYE RES, V34, P652, DOI 10.1080/02713680903007147; Kirsammer G, 2014, SEMIN CANCER BIOL, V29, P40, DOI 10.1016/j.semcancer.2014.07.007; Lawrence MG, 2011, PROSTATE, V71, P1198, DOI 10.1002/pros.21335; Leal-Leal Carlos A, 2006, Clin Transl Oncol, V8, P39, DOI 10.1007/s12094-006-0093-x; Liu CH, 2003, J BIOL CHEM, V278, P11721, DOI 10.1074/jbc.M207728200; Liu Y, 2017, INT J MOL MED, V40, P1172, DOI 10.3892/ijmm.2017.3102; Liu YQ, 2013, J BIOL CHEM, V288, P11572, DOI 10.1074/jbc.M112.434951; Lonardo E, 2011, CELL STEM CELL, V9, P433, DOI 10.1016/j.stem.2011.10.001; Loomans HA, 2016, AM J CANCER RES, V6, P2431; Lv FZ, 2015, INT J IMMUNOPATH PH, V28, P77, DOI 10.1177/0394632015572557; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; MCFALL RC, 1977, CANCER RES, V37, P1003; Morini M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-649; Pacifici M, 2016, CYTOKINE GROWTH F R, V27, P93, DOI 10.1016/j.cytogfr.2015.12.007; Pascual-Pasto G, 2016, CANCER LETT, V380, P10, DOI 10.1016/j.canlet.2016.06.012; Peng L, 2017, ONCOTARGET, V8, P34387, DOI 10.18632/oncotarget.16166; Postovit LM, 2008, P NATL ACAD SCI USA, V105, P4329, DOI 10.1073/pnas.0800467105; REID TW, 1974, J NATL CANCER I, V53, P347, DOI 10.1093/jnci/53.2.347; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Sakami S, 2008, MECH DEVELOP, V125, P106, DOI 10.1016/j.mod.2007.10.001; Schmierer B, 2003, J BIOL CHEM, V278, P21197, DOI 10.1074/jbc.M212425200; Schubert FR, 2014, BMC EVOL BIOL, V14, DOI 10.1186/1471-2148-14-157; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Strizzi Luigi, 2009, Expert Rev Dermatol, V4, P67, DOI 10.1586/17469872.4.1.67; Tanaka K, 2007, ONCOGENE, V26, P6456, DOI 10.1038/sj.onc.1210459; Teng Y, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-453; Theodoropoulou S, 2010, FASEB J, V24, P2620, DOI 10.1096/fj.09-152546; Topczewska JM, 2006, NAT MED, V12, P925, DOI 10.1038/nm1448; Tsuchida K, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-15; Villegas VM, 2013, CURR OPIN OPHTHALMOL, V24, P581, DOI 10.1097/ICU.0000000000000002; Weingart MF, 2015, ONCOTARGET, V6, P3165, DOI 10.18632/oncotarget.3078; White CD, 2009, FEBS LETT, V583, P1817, DOI 10.1016/j.febslet.2009.05.007; White DT, 2017, P NATL ACAD SCI USA, V114, pE3719, DOI 10.1073/pnas.1617721114; Wickham H, 2016, GGPLOT2 ELEGANT GRAP; Yang Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097578; Yoshinaga K, 2004, CLIN CANCER RES, V10, P5702, DOI 10.1158/1078-0432.CCR-03-0262	59	23	23	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2056	2075		10.1038/s41388-018-0543-2	http://dx.doi.org/10.1038/s41388-018-0543-2			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30401983	Green Accepted			2022-12-17	WOS:000461822600005
J	Fedorova, O; Petukhov, A; Daks, A; Shuvalov, O; Leonova, T; Vasileva, E; Aksenov, N; Melino, G; Barlev, NA				Fedorova, Olga; Petukhov, Alexey; Daks, Alexandra; Shuvalov, Oleg; Leonova, Tatyana; Vasileva, Elena; Aksenov, Nikolai; Melino, Gerry; Barlev, Nikolai A.			Orphan receptor NR4A3 is a novel target of p53 that contributes to apoptosis	ONCOGENE			English	Article							TUMOR-SUPPRESSOR P53; NUCLEAR RECEPTORS; MESSENGER-RNA; CANCER-CELLS; BCL-2; EXPRESSION; TRANSCRIPTION; PROTEASOME; FAMILY; GENES	Major tumor suppressor and transcription factor p53 coordinates expression of many genes hence affecting critical cellular functions including cell cycle, senescence, and apoptosis. The NR4A family of orphan receptors (NR4A1-3) belongs to the superfamily of nuclear receptors. They regulate genes involved in proliferation, cell migration, and apoptosis. In this study, we report an identification of NR4A3 as a direct transcriptional target of p53. Using various techniques, we showed that p53 directly bound the promoter of NR4A3 gene and induced its transcription. Functionally, over-expression of NR4A3 attenuated proliferation of cancer cells and promoted apoptosis by augmenting the expression of pro-apoptotic genes, PUMA and Bax. Knockdown of NR4A3 reversed these phenotypes. Importantly, NR4A3 exhibited tumor suppressive functions both in p53-dependent and independent manner. In addition, NR4A3 physically interacted with an anti-apoptotic Bcl-2 protein hence sequestering it from blunting apoptosis. These observations were corroborated by the bioinformatics analysis, which demonstrated a correlation between high levels of NR4A3 expression and better survival of breast and lung cancer patients. Collectively, our studies revealed a novel transcriptional target of p53, NR4A3, which triggers apoptosis and thus likely has a tumor suppressive role in breast and lung cancers.	[Fedorova, Olga; Petukhov, Alexey; Daks, Alexandra; Shuvalov, Oleg; Leonova, Tatyana; Vasileva, Elena; Aksenov, Nikolai; Barlev, Nikolai A.] Inst Cytol, Gene Express Program, St Petersburg 194064, Russia; [Petukhov, Alexey] Almazov Natl Med Res Ctr, St Petersburg 197341, Russia; [Melino, Gerry] MRC Toxicol Unit, Leicester LE1 9HN, Leics, England; [Barlev, Nikolai A.] Moscow Inst Technol & Phys, Dolgoprudnyi 141700, Moscow Region, Russia	Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS; Almazov National Medical Research Centre; Moscow Institute of Physics & Technology	Barlev, NA (corresponding author), Inst Cytol, Gene Express Program, St Petersburg 194064, Russia.; Barlev, NA (corresponding author), Moscow Inst Technol & Phys, Dolgoprudnyi 141700, Moscow Region, Russia.	nick.a.barlev@gmail.com	Leonova, Tatiana/V-3589-2019; Petukhov, Alexey/ABA-7903-2020; Fedorova, Olga/ABI-4862-2020; Barlev, Nikolai A/K-5268-2017; Shuvalov, Oleg/AAF-3535-2021; Daks, Alexandra/F-1191-2017	Petukhov, Alexey/0000-0002-7298-5238; Barlev, Nikolai A/0000-0001-7111-2446; Daks, Alexandra/0000-0003-0495-1244; Fedorova, Olga/0000-0003-1382-4204	RCF [18-75-10076]; RFBR [18-29-09144]; MRC [MC_UU_00025/2, MC_U132670600] Funding Source: UKRI	RCF; RFBR(Russian Foundation for Basic Research (RFBR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	O.F., A.P. and E.V. carried out chromatin immunoprecipitation, Luciferase assay, quantitative PCR, cell-cycle analysis, colony formation assay, immunofluorescence, wound-healing and real-time cell migration assay and acknowledge the support from RCF grant 18-75-10076. A.D., O.S., N.B. carried out annexin V, coimmunoprecipitation interaction assay and the bioinformatics analysis and acknowledge the support from RFBR grant 18-29-09144. We appreciate Dr Mikhal Maliewitz (MRC Toxicology, Leicester) for a gift of NR4A1 and NR4A2 antibodies.	Althubiti M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.489; Amelio I, 2016, CELL DEATH DIFFER, V23, P912, DOI 10.1038/cdd.2016.12; Amelio I, 2015, TRENDS BIOCHEM SCI, V40, P425, DOI 10.1016/j.tibs.2015.04.007; Angeloni SV, 2004, J ENDOCRINOL, V180, P497, DOI 10.1677/joe.0.1800497; Antonov AV, 2011, NUCLEIC ACIDS RES, V39, pW323, DOI 10.1093/nar/gkr372; Barlev NA, 2010, CELL DEATH DIFFER, V17, P373, DOI 10.1038/cdd.2009.73; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Beard JA, 2016, SCI REP-UK, V6, DOI 10.1038/srep25108; Charni M, 2016, CELL DEATH DIFFER, V23, P509, DOI 10.1038/cdd.2015.119; Cronauer MV, 2004, ONCOGENE, V23, P3541, DOI 10.1038/sj.onc.1207346; Deutsch AJA, 2017, CANCER RES, V77, P2375, DOI 10.1158/0008-5472.CAN-16-2320; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elias A, 2013, MOL PHARMACOL, V83, P1229, DOI 10.1124/mol.113.085092; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Fedorova OA, 2011, BIOCHEM BIOPH RES CO, V416, P258, DOI 10.1016/j.bbrc.2011.10.126; Feng ZH, 2011, J MOL CELL BIOL, V3, P44, DOI 10.1093/jmcb/mjq040; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Gao WN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091462; Gibson LF, 1999, BREAST CANCER RES TR, V55, P107, DOI 10.1023/A:1006175811676; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hamroun D, 2006, HUM MUTAT, V27, P14, DOI 10.1002/humu.20269; Hermeking H, 2007, CANCER CELL, V12, P414, DOI 10.1016/j.ccr.2007.10.028; Innocente SA, 2005, FEBS LETT, V579, P1001, DOI 10.1016/j.febslet.2004.12.073; Iwano S, 2006, FEBS LETT, V580, P890, DOI 10.1016/j.febslet.2006.01.009; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kitagawa H, 2007, MOL CELL BIOL, V27, P7486, DOI 10.1128/MCB.00409-07; Kurakula K, 2014, BBA-MOL CELL RES, V1843, P2543, DOI 10.1016/j.bbamcr.2014.06.010; Lee SO, 2011, EXPERT OPIN THER TAR, V15, P195, DOI 10.1517/14728222.2011.547481; Levrero M, 2000, J CELL SCI, V113, P1661; Lezina L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.483; Lezina L, 2015, ONCOTARGET, V6, P25843, DOI 10.18632/oncotarget.4584; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Malewicz M, 2011, GENE DEV, V25, P2031, DOI 10.1101/gad.16872411; Marouco D, 2013, ONCOTARGET, V4, P1556, DOI 10.18632/oncotarget.1436; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Moiseeva TN, 2013, ONCOTARGET, V4, P1338, DOI 10.18632/oncotarget.1060; Murray-Zmijewski F, 2008, NAT REV MOL CELL BIO, V9, P702, DOI 10.1038/nrm2451; Olefsky JM, 2001, J BIOL CHEM, V276, P36863, DOI 10.1074/jbc.R100047200; Pant V, 2014, GENE DEV, V28, P1739, DOI 10.1101/gad.247452.114; Shibue T, 2006, EMBO J, V25, P4952, DOI 10.1038/sj.emboj.7601359; Stark AM, 2006, NEUROL RES, V28, P787, DOI 10.1179/016164106X110364; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Yeh CM, 2016, SCI REP-UK, V6, DOI 10.1038/srep31690; Yu CL, 1997, BIOCHEM BIOPH RES CO, V239, P617, DOI 10.1006/bbrc.1997.7522; Yu CL, 1997, CANCER LETT, V116, P191, DOI 10.1016/S0304-3835(97)00186-9; Yu J, 2008, ONCOGENE, V27, pS71, DOI 10.1038/onc.2009.45; Zhao BX, 2006, EMBO J, V25, P5703, DOI 10.1038/sj.emboj.7601435; Zhao Y, 2010, ARTERIOSCL THROM VAS, V30, P1535, DOI 10.1161/ATVBAHA.109.191163; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	54	23	23	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2108	2122		10.1038/s41388-018-0566-8	http://dx.doi.org/10.1038/s41388-018-0566-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30455429				2022-12-17	WOS:000461822600008
J	Smirnov, A; Lena, AM; Cappello, A; Panatta, E; Anemona, L; Bischetti, S; Annicchiarico-Petruzzelli, M; Mauriello, A; Melino, G; Candi, E				Smirnov, Artem; Lena, Anna Maria; Cappello, Angela; Panatta, Emanuele; Anemona, Lucia; Bischetti, Simone; Annicchiarico-Petruzzelli, Margherita; Mauriello, Alessandro; Melino, Gerry; Candi, Eleonora			ZNF185 is a p63 target gene critical for epidermal differentiation and squamous cell carcinoma development	ONCOGENE			English	Article							E-CADHERIN; LIM DOMAIN; P53 HOMOLOG; ADHESION; EXPRESSION; REVEALS; TRANSCRIPTION; PROTEIN; SKIN; PROLIFERATION	Development and maintenance of healthy stratified epithelia require the coordination of complex transcriptional programmes. The transcription factor p63, a member of the p53 family, plays a crucial role in epithelial development and homeostasis. Analysis of the p63-dependent transcriptome indicated that one important aspect of p63 functions in epithelial development is the regulation of cell-cell and cell-matrix adhesion programmes. However, limited knowledge exists on the relevant cell-cell adhesion molecules involved in physiological epithelial formation. Similarly, limited data are available to understand if deregulation of the cell-cell adhesion programme is important in tumour formation. Here, using the epidermis as an experimental model with the RNA sequencing approach, we identify a novel p63-regulated gene induced during differentiation, ZNF185. ZNF185 is an actin-cytoskeleton-associated Lin-l 1, Isl-1 and Mec-3 (LIM) domain containing protein, whose function is poorly known. We found that p63 binds to a specific enhancer region, promoting its expression to sustain epithelial differentiation. ZNF185 silencing strongly impaired keratinocyte differentiation according to gene array analysis. ZNF185 is detected at the cell-cell periphery where it physically interacts with E-cadherin, indicating that it is important to maintain epithelial integrity beyond its pro-differentiation role. Interestingly, poorly differentiated, including head and neck, cervical and oesophageal, squamous cell carcinomas display loss of ZNF185 expression. Together, these studies reinforce that p63 is a crucial gene for maintaining epithelial tissue integrity and support the deregulation of the cell-cell adhesion programme,which plays a critical role in carcinoma development.	[Smirnov, Artem; Lena, Anna Maria; Cappello, Angela; Panatta, Emanuele; Anemona, Lucia; Bischetti, Simone; Mauriello, Alessandro; Melino, Gerry; Candi, Eleonora] Univ Roma Tor Vergata, Dept Expt Med & Surg, Via Montpellier 1, I-00133 Rome, Italy; [Annicchiarico-Petruzzelli, Margherita; Candi, Eleonora] Ist Dermopat Immacolata IRCCS, Via Monti Creta 104, I-00163 Rome, Italy; [Melino, Gerry] Univ Cambridge, MRC Toxicol Unit, Hodgkin Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England	University of Rome Tor Vergata; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Cambridge	Melino, G; Candi, E (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Surg, Via Montpellier 1, I-00133 Rome, Italy.; Candi, E (corresponding author), Ist Dermopat Immacolata IRCCS, Via Monti Creta 104, I-00163 Rome, Italy.; Melino, G (corresponding author), Univ Cambridge, MRC Toxicol Unit, Hodgkin Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England.	gerry.melino@uniroma2.it; candi@uniroma2.it	Lena, Anna Maria/AAI-5042-2020; Smirnov, Artem/AAB-3496-2020; Anemona, lucia/AAB-3491-2022; Annicchiarico-Petruzzelli, Margherita/AAG-7746-2020; Cappello, Angela/AAL-6109-2021	Smirnov, Artem/0000-0002-1575-8725; Anemona, lucia/0000-0002-3711-2714; Annicchiarico-Petruzzelli, Margherita/0000-0002-4717-4740; Panatta, Emanuele/0000-0001-8723-9564	AIRC [IG-15653]; IDI-IRCCS;  [RF-2016-02362541]; MRC [MC_U132670600, MC_UU_00025/2] Funding Source: UKRI	AIRC(Fondazione AIRC per la ricerca sul cancro); IDI-IRCCS; ; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The authors thank Dr. Ivano Amelio for his assistance with the gene microarray analysis, Dr. Alessandro Terrinoni for his assistance with RNA seq experiment, and Dr. Alessandra Gambacurta for reagents and scientific discussion. The authors also thank all laboratory members for their helpful discussion. This work has been partially supported by AIRC Grant IG-15653 to GM. This work has been mainly supported by IDI-IRCCS (RC to EC and GM) and RF-2016-02362541 (to EC).	Amelio I, 2012, J CELL BIOL, V199, P347, DOI 10.1083/jcb.201203134; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Bao XM, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0840-9; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Beaudry VG, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001168; Beck Tim N, 2016, Cancers Head Neck, V1, DOI 10.1186/s41199-016-0003-z; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Carroll DK, 2007, CELL CYCLE, V6, P255, DOI 10.4161/cc.6.3.3799; Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420; Cassandri M, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.71; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Cavazza A, 2016, STEM CELL REP, V6, P618, DOI 10.1016/j.stemcr.2016.03.003; Davis MA, 2006, DEV CELL, V10, P21, DOI 10.1016/j.devcel.2005.12.004; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Ferone G, 2013, HUM MOL GENET, V22, P531, DOI 10.1093/hmg/dds464; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Fuchs E, 2007, NATURE, V445, P834, DOI 10.1038/nature05659; Gallant-Behm CL, 2013, CELL CYCLE, V12, P409, DOI 10.4161/cc.23593; Gonzalez HE, 2003, ARCH OTOLARYNGOL, V129, P754, DOI 10.1001/archotol.129.7.754; Guo ZH, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005473; Hatzfeld M, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a029157; Heiss NS, 1997, GENOMICS, V43, P329, DOI 10.1006/geno.1997.4810; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Kadrmas JL, 2004, NAT REV MOL CELL BIO, V5, P920, DOI 10.1038/nrm1499; Koster MI, 2006, DEV BIOL, V289, P253, DOI 10.1016/j.ydbio.2005.10.041; Kouwenhoven EN, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001065; Kroigard AB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0189887; Laurikkala J, 2006, DEVELOPMENT, V133, P1553, DOI 10.1242/dev.02325; Luxenburg C, 2015, NAT CELL BIOL, V17, P592, DOI 10.1038/ncb3146; McDade SS, 2014, NUCLEIC ACIDS RES, V42, P6270, DOI 10.1093/nar/gku299; Medina PP, 2005, HUM MOL GENET, V14, P973, DOI 10.1093/hmg/ddi091; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Niessen CM, 2008, BBA-BIOMEMBRANES, V1778, P562, DOI 10.1016/j.bbamem.2007.12.015; Niessen CM, 2007, J INVEST DERMATOL, V127, P2525, DOI 10.1038/sj.jid.5700865; Osada M, 2005, MOL CELL BIOL, V25, P6077, DOI 10.1128/MCB.25.14.6077-6089.2005; Osada M, 2005, J INVEST DERMATOL, V125, P52, DOI 10.1111/j.0022-202X.2005.23801.x; Oti M, 2015, GENOM DATA, V5, P159, DOI 10.1016/j.gdata.2015.06.002; Perez-Moreno M, 2008, P NATL ACAD SCI USA, V105, P15399, DOI 10.1073/pnas.0807301105; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Saladi SV, 2017, CANCER CELL, V31, P35, DOI 10.1016/j.ccell.2016.12.001; Shalom-Feuerstein R, 2011, CELL DEATH DIFFER, V18, P887, DOI 10.1038/cdd.2010.159; Shimomura Y, 2008, DEVELOPMENT, V135, P743, DOI 10.1242/dev.006718; Vaezi A, 2002, DEV CELL, V3, P367, DOI 10.1016/S1534-5807(02)00259-9; van Roy F, 2014, NAT REV CANCER, V14, P121, DOI 10.1038/nrc3647; Vanaja DK, 2003, CANCER RES, V63, P3877; Vasilaki E, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aag3232; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Warner SMB, 2013, AM J RESP CELL MOL, V49, P978, DOI 10.1165/rcmb.2012-0447OC; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Wu N, 2012, J BIOL CHEM, V287, P5627, DOI 10.1074/jbc.M111.328120; Xu JF, 1998, NAT GENET, V20, P175, DOI 10.1038/2477; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zarnegar BJ, 2012, AM J HUM GENET, V91, P435, DOI 10.1016/j.ajhg.2012.07.007; Zhang JS, 2007, ONCOGENE, V26, P111, DOI 10.1038/sj.onc.1209769	57	23	24	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1625	1638		10.1038/s41388-018-0509-4	http://dx.doi.org/10.1038/s41388-018-0509-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30337687	Green Published, hybrid			2022-12-17	WOS:000460423800004
J	Swaroop, A; Oyer, JA; Will, CM; Huang, XX; Yu, WB; Troche, C; Bulic, M; Durham, BH; Wen, QJ; Crispino, JD; MacKerell, AD; Bennett, RL; Kelleher, NL; Licht, JD				Swaroop, Alok; Oyer, Jon A.; Will, Christine M.; Huang, Xiaoxiao; Yu, Wenbo; Troche, Catalina; Bulic, Marinka; Durham, Benjamin H.; Wen, Qiang Jeremy; Crispino, John D.; MacKerell, Alexander D., Jr.; Bennett, Richard L.; Kelleher, Neil L.; Licht, Jonathan D.			An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia	ONCOGENE			English	Article							MULTIPLE-MYELOMA; GENE-EXPRESSION; LYSINE 36; SOMATIC MUTATIONS; IN-VIVO; METHYLATION; MMSET; H3; EZH2; LANDSCAPE	NSD2, a histone methyltransferase specific for methylation of histone 3 lysine 36 (H3K36), exhibits a glutamic acid to lysine mutation at residue 1099 (E1099K) in childhood acute lymphocytic leukemia (ALL), and cells harboring this mutation can become the predominant clone in relapsing disease. We studied the effects of this mutant enzyme in silico, in vitro, and in vivo using gene edited cell lines. The E1099K mutation altered enzyme/substrate binding and enhanced the rate of H3K36 methylation. As a result, cell lines harboring E1099K exhibit increased H3K36 dimethylation and reduced H3K27 trimethylation, particularly on nucleosomes containing histone H3.1. Mutant NSD2 cells exhibit reduced apoptosis and enhanced proliferation, clonogenicity, adhesion, and migration. In mouse xenografts, mutant NSD2 cells are more lethal and brain invasive than wildtype cells. Transcriptional profiling demonstrates that mutant NSD2 aberrantly activates factors commonly associated with neural and stromal lineages in addition to signaling and adhesion genes. Identification of these pathways provides new avenues for therapeutic interventions in NSD2 dysregulated malignancies.	[Swaroop, Alok; Huang, Xiaoxiao; Troche, Catalina; Bennett, Richard L.; Licht, Jonathan D.] Univ Florida, Div Hematol Oncol, Hlth Canc Ctr, Gainesville, FL 32611 USA; [Swaroop, Alok; Oyer, Jon A.; Will, Christine M.; Huang, Xiaoxiao; Bulic, Marinka; Wen, Qiang Jeremy; Crispino, John D.; Licht, Jonathan D.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Chicago, IL 60611 USA; [Huang, Xiaoxiao; Kelleher, Neil L.] Northwestern Univ, Dept Chem, Chem Life Proc Inst, Evanston, IL USA; [Huang, Xiaoxiao] Northwestern Univ, Dept Mol Biosci, Chem Life Proc Inst, Evanston, IL USA; [Yu, Wenbo; MacKerell, Alexander D., Jr.] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Comp Aided Drug Design Ctr, Baltimore, MD 21201 USA; [Durham, Benjamin H.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA	State University System of Florida; University of Florida; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Northwestern University; University System of Maryland; University of Maryland Baltimore; Memorial Sloan Kettering Cancer Center	Licht, JD (corresponding author), Univ Florida, Div Hematol Oncol, Hlth Canc Ctr, Gainesville, FL 32611 USA.; Licht, JD (corresponding author), Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Chicago, IL 60611 USA.	jdlicht@ufl.edu	Huang, Xiaoxiao/ABG-2564-2020; MacKerell, Alex/AAA-2560-2020; Licht, Jonathan/AAL-9184-2020; Bennett, Richard/ABF-9211-2021	Huang, Xiaoxiao/0000-0002-4623-2005; Licht, Jonathan/0000-0002-3942-1369; Bennett, Richard/0000-0002-0243-2443; Swaroop, Alok/0000-0003-0317-6688; Durham, Benjamin/0000-0001-8090-5448; Crispino, John/0000-0002-8182-8306; Yu, Wenbo/0000-0001-6962-5314; Oyer, Jon/0000-0002-5479-3400	Leukemia and Lymphoma Society Specialized Center of Excellence grant; Samuel Waxman Cancer Research Foundation; Celgene [P41 GM108569, R01 GM067193]; Lauri Strauss Leukemia Foundation;  [T32 CA009560];  [F30 CA203292];  [R01 CA195732];  [R01 GM051501]; NATIONAL CANCER INSTITUTE [R01CA195732, T32CA009560, F30CA203292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008152, P41GM108569, R01GM067193, R01GM051501] Funding Source: NIH RePORTER	Leukemia and Lymphoma Society Specialized Center of Excellence grant(Leukemia and Lymphoma Society); Samuel Waxman Cancer Research Foundation; Celgene(Bristol-Myers SquibbCelgene Corporation); Lauri Strauss Leukemia Foundation; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by T32 CA009560 (AS), F30 CA203292 (AS), R01 CA195732 (JDL), R01 GM051501 (ADM), a Leukemia and Lymphoma Society Specialized Center of Excellence grant (JDL), the Samuel Waxman Cancer Research Foundation (ADM and JDL) and Celgene (JDL), P41 GM108569 and R01 GM067193 (NLK) and the Lauri Strauss Leukemia Foundation (JAO, CT).	[Anonymous], 2016, CANC FACTS FIG 2016; Bea S, 2013, P NATL ACAD SCI USA, V110, P18250, DOI 10.1073/pnas.1314608110; Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005; Best RB, 2012, J CHEM THEORY COMPUT, V8, P3257, DOI 10.1021/ct300400x; Brennan D, 2007, J CELL SCI, V120, P758, DOI 10.1242/jcs.03392; Brito JLR, 2009, HAEMATOL-HEMATOL J, V94, P78, DOI 10.3324/haematol.13426; Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287; Broyl A, 2010, BLOOD, V116, P2543, DOI 10.1182/blood-2009-12-261032; Campos-Sanchez E, 2017, CELL REP, V19, P1586, DOI 10.1016/j.celrep.2017.04.069; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Chen BH, 2013, CELL, V155, P1479, DOI 10.1016/j.cell.2013.12.001; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Damgaard T, 2009, LEUKEMIA LYMPHOMA, V50, P236, DOI 10.1080/10428190802699332; Ding LW, 2017, CANCER RES, V77, P390, DOI 10.1158/0008-5472.CAN-16-1303; Ezponda T, 2013, ONCOGENE, V32, P2882, DOI 10.1038/onc.2012.297; Fabbri G, 2011, J EXP MED, V208, P1389, DOI 10.1084/jem.20110921; Faderl SH, 2008, HEMATOL MALIG, P1, DOI 10.1007/978-3-540-72304-2; Garcia BA, 2007, NAT PROTOC, V2, P933, DOI 10.1038/nprot.2007.106; Golub TR, 2007, NATURE, V446, P739, DOI 10.1038/446739a; Hake SB, 2006, P NATL ACAD SCI USA, V103, P6428, DOI 10.1073/pnas.0600803103; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hart K, 2012, J CHEM THEORY COMPUT, V8, P348, DOI 10.1021/ct200723y; Heng TSP, 2008, NAT IMMUNOL, V9, P1091, DOI 10.1038/ni1008-1091; HOLM S, 1979, SCAND J STAT, V6, P65; Huang Z, 2013, CANCER RES, V73, P6277, DOI 10.1158/0008-5472.CAN-13-1000; Jaffe JD, 2013, NAT GENET, V45, P1386, DOI 10.1038/ng.2777; Jinek M, 2013, ELIFE, V2, DOI 10.7554/eLife.00471; Keats JJ, 2005, BLOOD, V105, P4060, DOI 10.1182/blood-2004-09-3704; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Kim SM, 2006, BIOCHEM BIOPH RES CO, V345, P318, DOI 10.1016/j.bbrc.2006.04.095; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Kuo AJ, 2011, MOL CELL, V44, P609, DOI 10.1016/j.molcel.2011.08.042; LaFave LM, 2013, NAT GENET, V45, P1269, DOI 10.1038/ng.2808; Lauring J, 2008, BLOOD, V111, P856, DOI 10.1182/blood-2007-05-088674; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lee MS, 2002, J CHEM PHYS, V116, P10606, DOI 10.1063/1.1480013; Li Y, 2009, J BIOL CHEM, V284, P34283, DOI 10.1074/jbc.M109.034462; Loh ML, 2013, BLOOD, V122, P824; Lucio-Eterovic AK, 2010, P NATL ACAD SCI USA, V107, P16952, DOI 10.1073/pnas.1002653107; Ma XT, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7604; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; MacLean B, 2010, BIOINFORMATICS, V26, P966, DOI 10.1093/bioinformatics/btq054; Martinez-Garcia E, 2011, BLOOD, V117, P211, DOI 10.1182/blood-2010-07-298349; Matsuda T, 2004, P NATL ACAD SCI USA, V101, P16, DOI 10.1073/pnas.2235688100; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Mueller F, 2012, METHODS MOL BIOL, V833, P153, DOI 10.1007/978-1-61779-477-3_11; Mullighan CG, 2013, BLOOD, V122, P3899, DOI 10.1182/blood-2013-08-460311; Oyer JA, 2014, LEUKEMIA, V28, P198, DOI 10.1038/leu.2013.204; Pierce BG, 2014, BIOINFORMATICS, V30, P1771, DOI 10.1093/bioinformatics/btu097; Popovic R, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004566; Qiao Q, 2011, J BIOL CHEM, V286, P8361, DOI 10.1074/jbc.M110.204115; Ravandi F, 2002, LEUKEMIA RES, V26, P643, DOI 10.1016/S0145-2126(01)00188-6; Rotenberg M., 1970, METHODS COMPUTATIONA; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Schmitges FW, 2011, MOL CELL, V42, P330, DOI 10.1016/j.molcel.2011.03.025; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sneeringer CJ, 2010, P NATL ACAD SCI USA, V107, P20980, DOI 10.1073/pnas.1012525107; Society AC, 2014, CANC FACTS FIG 2014; Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369; Szenker E, 2011, CELL RES, V21, P421, DOI 10.1038/cr.2011.14; Tisi D, 2016, ACS CHEM BIOL, V11, P3093, DOI 10.1021/acschembio.6b00308; Van Rechem C, 2014, BBA-GENE REGUL MECH, V1839, P1463, DOI 10.1016/j.bbagrm.2014.05.014; Wagner EJ, 2012, NAT REV MOL CELL BIO, V13, P115, DOI 10.1038/nrm3274; Word JM, 1999, J MOL BIOL, V285, P1735, DOI 10.1006/jmbi.1998.2401; Wynn RF, 2010, ACUTE LYMPHOBLASTIC, P75; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725; Zheng YP, 2014, PROTEOMICS, V14, P2190, DOI 10.1002/pmic.201400060; Zheng YP, 2012, P NATL ACAD SCI USA, V109, P13549, DOI 10.1073/pnas.1205707109; Zhu L, 2016, CANCER DISCOV, V6, P770, DOI 10.1158/2159-8290.CD-16-0058	70	23	24	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2019	38	5					671	686		10.1038/s41388-018-0474-y	http://dx.doi.org/10.1038/s41388-018-0474-y			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HJ6LI	30171259	Green Accepted			2022-12-17	WOS:000457300300005
J	Wong, D; Lounsbury, K; Lum, A; Song, J; Chan, S; LeBlanc, V; Chittaranjan, S; Marra, M; Yip, S				Wong, Derek; Lounsbury, Kohl; Lum, Amy; Song, Jungeun; Chan, Susanna; LeBlanc, Veronique; Chittaranjan, Suganthi; Marra, Marco; Yip, Stephen			Transcriptomic analysis of CIC and ATXN1L reveal a functional relationship exploited by cancer	ONCOGENE			English	Article							CELL-PROLIFERATION; DOWN-REGULATION; CAPICUA; ATAXIN-1; MUTATIONS; PROTEIN; REPRESSOR; PATHWAY; COMPLEX; TUMORS	Aberrations in Capicua (CIC) have recently been implicated as a negative prognostic factor in a multitude of cancer types through activation of the MAPK signalling cascade and derepression of oncogenic ETS transcription factors. The Ataxin-family protein ATXN1L has previously been reported to interact with CIC in developmental and disease contexts to facilitate the repression of CIC target genes. To further investigate this relationship, we performed functional in vitro studies utilizing ATX/V/L-KO and CICKO human cell lines and characterized a reciprocal functional relationship between CIC and ATXN1L. Transcriptomic interrogation of the CIC-ATXN1-ATXN1L axis in low-grade glioma, prostate adenocarcinoma and stomach adenocarcinoma TCGA cohorts revealed context-dependent convergence of gene sets and pathways related to mitotic cell cycle and division. This study highlights the CIC-ATXN1-ATXN1L axis as a more potent regulator of the cell cycle than previously appreciated.	[Wong, Derek; Yip, Stephen] Univ British Columbia, Pathol & Lab Med, Vancouver, BC, Canada; [Wong, Derek; Lum, Amy; Yip, Stephen] BC Canc, Mol Oncol, Vancouver, BC, Canada; [Lounsbury, Kohl] Univ British Columbia, Cellular & Physiol Sci, Vancouver, BC, Canada; [Song, Jungeun; Chan, Susanna; LeBlanc, Veronique; Chittaranjan, Suganthi; Marra, Marco] BC Canc, Canadas Michael Smith Genome Sci Ctr, Vancouver, BC, Canada; [Marra, Marco] Univ British Columbia, Med Genet, Vancouver, BC, Canada	University of British Columbia; University of British Columbia; University of British Columbia	Yip, S (corresponding author), Univ British Columbia, Pathol & Lab Med, Vancouver, BC, Canada.; Yip, S (corresponding author), BC Canc, Mol Oncol, Vancouver, BC, Canada.	Stephen.Yip@vch.ca	Wong, Derek/AAF-8587-2020; Marra, Marco A/B-5987-2008; Yip, Stephen/E-9994-2012	Wong, Derek/0000-0003-2607-5265; Marra, Marco A/0000-0001-7146-7175; Yip, Stephen/0000-0002-8514-9861	VCHRI mentored scientist award; Canada Research Chairs program; Canadian Institutes of Health Research (CIHR) [FDN-143288]	VCHRI mentored scientist award; Canada Research Chairs program(Canada Research Chairs); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	We thank Dr Gregory Cairncross, Dr Jennifer Chan, Dr Kenneth Aldape, Dr Severa Bunda, and members of the David Huntsman and Marco Marra laboratory for helpful discussions. SY is supported by a VCHRI mentored scientist award. MM acknowledges support from the Canada Research Chairs program and the Canadian Institutes of Health Research (CIHR; FDN-143288). We would also like to acknowledge the ongoing support from BrainCare BC, the BC Cancer Foundation, BC Cancer Agency, and the University of British Columbia. The results published here are in part based upon data generated by The Cancer Genome Atlas managed by the NCI and NHGRI. Information about TCGA can be found at http://cancergenome.nih.gov.	Alonso MM, 2008, CANCER LETT, V263, P157, DOI 10.1016/j.canlet.2008.02.001; Astigarraga S, 2007, EMBO J, V26, P668, DOI 10.1038/sj.emboj.7601532; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bettegowda C, 2011, SCIENCE, V333, P1453, DOI 10.1126/science.1210557; Bowman AB, 2007, NAT GENET, V39, P373, DOI 10.1038/ng1977; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Brat DJ, 2015, NEW ENGL J MED, V372, P2481, DOI 10.1056/NEJMoa1402121; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan AKY, 2014, MODERN PATHOL, V27, P332, DOI 10.1038/modpathol.2013.165; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Chittaranjan S, 2014, ONCOTARGET, V5, P7960, DOI 10.18632/oncotarget.2401; Choi N, 2015, ONCOTARGET, V6, P23533, DOI 10.18632/oncotarget.4372; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Crespo-Barreto J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001021; Crosby ME, 2004, CANCER BIOL THER, V3, P1208, DOI 10.4161/cbt.3.12.1494; Dalerba P, 2011, NAT BIOTECHNOL, V29, P1120, DOI 10.1038/nbt.2038; Dalman MR, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S2-S11; de Chiara C, 2003, FEBS LETT, V551, P107, DOI 10.1016/S0014-5793(03)00818-4; Eisenreich S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076623; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gleize V, 2015, ANN NEUROL, V78, P355, DOI 10.1002/ana.24443; Goukassian D, 2001, BRIT J PHARMACOL, V132, P1597, DOI 10.1038/sj.bjp.0703945; Han FX, 2018, ONCOL LETT, V15, P1459, DOI 10.3892/ol.2017.7460; Huang L, 2017, BIOCHEM BIOPH RES CO, V490, P707, DOI 10.1016/j.bbrc.2017.06.105; Iglesias-Ara A, 2015, CELL DEATH DIFFER, V22, P1577, DOI 10.1038/cdd.2015.4; Jimenez G, 2000, GENE DEV, V14, P224; Jimenez G, 2012, J CELL SCI, V125, P1383, DOI 10.1242/jcs.092965; Jin YH, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005634; Johnson J, 2016, ONCOGENE, V35, P4829, DOI 10.1038/onc.2016.32; Kahle JJ, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003359; Kawamura-Saito M, 2006, HUM MOL GENET, V15, P2125, DOI 10.1093/hmg/ddl136; Kim E, 2018, HEPATOLOGY, V67, P2287, DOI 10.1002/hep.29738; Kim E, 2015, SCI REP-UK, V5, DOI 10.1038/srep08272; Kim E, 2013, GENE DEV, V27, P590, DOI 10.1101/gad.212068.112; Lam YC, 2006, CELL, V127, P1335, DOI 10.1016/j.cell.2006.11.038; LeBlanc VG, 2017, J PATHOL, V242, P206, DOI 10.1002/path.4894; Lee CJ, 2002, MOL BRAIN RES, V106, P151, DOI 10.1016/S0169-328X(02)00439-4; Lee Y, 2011, DEV CELL, V21, P746, DOI 10.1016/j.devcel.2011.08.017; Liao SD, 2017, GENE DEV, V31, P184, DOI 10.1101/gad.291948.116; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lu HC, 2017, NAT GENET, V49, P527, DOI 10.1038/ng.3808; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; Mizutani A, 2005, EMBO J, V24, P3339, DOI 10.1038/sj.emboj.7600785; Muller M, 2016, STEM CELL RES, V16, P349, DOI 10.1016/j.scr.2016.02.005; Okimoto RA, 2017, NAT GENET, V49, P87, DOI 10.1038/ng.3728; Padul V, 2015, GENE CHROMOSOME CANC, V54, P725, DOI 10.1002/gcc.22283; Pasini D, 2014, CELL CYCLE, V3, P394; POST GR, 1992, MOL CHEM NEUROPATHOL, V16, P303, DOI 10.1007/BF03159976; Roch F, 2002, DEVELOPMENT, V129, P993; Rousseaux MWC, 2018, NEURON, V97, P1235, DOI 10.1016/j.neuron.2018.02.013; Sahm F, 2012, ACTA NEUROPATHOL, V123, P853, DOI 10.1007/s00401-012-0993-5; Seim I, 2017, G3-GENES GENOM GENET, V7, P1731, DOI 10.1534/g3.117.039909; Simon-Carrasco L, 2017, GENE DEV, V31, P1456, DOI 10.1101/gad.300244.117; Sonoda Y, 2001, CANCER RES, V61, P4956; Specht K, 2014, GENE CHROMOSOME CANC, V53, P622, DOI 10.1002/gcc.22172; Suzuki H, 2015, NAT GENET, V47, P458, DOI 10.1038/ng.3273; Tong X, 2011, EMBO REP, V12, P428, DOI 10.1038/embor.2011.49; Tseng ASK, 2007, CURR BIOL, V17, P728, DOI 10.1016/j.cub.2007.03.023; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; Wang B, 2017, CELL REP, V18, P1543, DOI 10.1016/j.celrep.2017.01.031; Yang L, 2016, P NATL ACAD SCI USA, V113, P10583, DOI 10.1073/pnas.1609417113; Yip S, 2012, J PATHOL, V226, P7, DOI 10.1002/path.2995	65	23	23	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2019	38	2					273	290		10.1038/s41388-018-0427-5	http://dx.doi.org/10.1038/s41388-018-0427-5			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG9XX	30093628				2022-12-17	WOS:000455366700009
J	Chow, RD; Chen, SD				Chow, Ryan D.; Chen, Sidi			Sno-derived RNAs are prevalent molecular markers of cancer immunity	ONCOGENE			English	Article							SMALL NUCLEOLAR RNAS; LONG NONCODING RNAS; INTRATUMOR HETEROGENEITY; MICRORNA; SNORNAS; EXPRESSION; RESISTANCE; PATTERNS; ANTIBODY; PLATFORM	Small nucleolar RNAs (snoRNAs) constitute a family of noncoding RNAs that are classically known as guide RNAs for processing and modification of ribosomal RNAs. Recently, it was discovered that snoRNAs can be further processed into sno-derived RNAs (sdRNAs), some of which are known to exhibit microRNA-like properties. SdRNAs have been implicated in human cancer; however, a systems-level sdRNA landscape in human cancers is lacking. Through integrative analysis of similar to 22 nt size-selected smRNA-seq datasets from 10,262 patient samples across 32 cancer types, we mapped a pan-cancer sdRNAome and interrogated its signatures in multiple clinically relevant features, particularly cancer immunity and clinical outcome. Aggregating sdRNA abundances by parental snoRNAs, these expression signatures alone are sufficient to distinguish patients with distinct cancer types. Interestingly, a large panel of sdRNAs are significantly correlated with features of the tumor-immune microenvironment, such as immunosuppressive markers, CD8(+) T cell infiltration, cytolytic T cell activity, and tumor vasculature. A set of individual sdRNAs with tumor-immune signatures can also stratify patient survival. These findings implicate snoRNAs and their derivative sdRNAs as a class of prevalent noncoding molecular markers of human cancer immunity.	[Chow, Ryan D.; Chen, Sidi] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; [Chow, Ryan D.; Chen, Sidi] Yale Univ, Sch Med, Syst Biol Inst, West Haven, CT 06516 USA; [Chow, Ryan D.; Chen, Sidi] Yale Univ, Sch Med, Med Scientist Training Program, New Haven, CT 06520 USA; [Chen, Sidi] Yale Univ, Sch Med, Biol & Biomed Sci Program, New Haven, CT 06520 USA; [Chen, Sidi] Yale Univ, Sch Med, Immunobiol Program, New Haven, CT 06520 USA; [Chen, Sidi] Yale Univ, Sch Med, Comprehens Canc Ctr, New Haven, CT 06510 USA; [Chen, Sidi] Yale Univ, Sch Med, Stem Cell Ctr, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University; Yale University; Yale University; Yale University	Chen, SD (corresponding author), Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA.; Chen, SD (corresponding author), Yale Univ, Sch Med, Syst Biol Inst, West Haven, CT 06516 USA.; Chen, SD (corresponding author), Yale Univ, Sch Med, Med Scientist Training Program, New Haven, CT 06520 USA.; Chen, SD (corresponding author), Yale Univ, Sch Med, Biol & Biomed Sci Program, New Haven, CT 06520 USA.; Chen, SD (corresponding author), Yale Univ, Sch Med, Immunobiol Program, New Haven, CT 06520 USA.; Chen, SD (corresponding author), Yale Univ, Sch Med, Comprehens Canc Ctr, New Haven, CT 06510 USA.; Chen, SD (corresponding author), Yale Univ, Sch Med, Stem Cell Ctr, New Haven, CT 06520 USA.	sidi.chen@yale.edu	Chow, Ryan/ABF-1119-2021; CHEN, SIDI/D-8284-2016	Chow, Ryan/0000-0002-1872-6307; CHEN, SIDI/0000-0002-3819-5005	Yale SBI/Genetics Startup Fund, Damon Runyon [DRG-2117-12, DFS-13-15]; Melanoma Research Alliance [412806, 16-003524]; St.-Baldrick's Foundation [426685]; Breast Cancer Alliance; Cancer Research Institute (CLIP); AACR [499395, 17-20-01-CHEN]; Mary Kay Foundation [017-81]; V Foundation [V2017-022]; DoD [W81XWH-17-1-0235]; NIH/NCI [1U54CA209992, 5P50CA196530-A10805, 4P50CA121974-A08306]; NIH MSTP training grant [T32GM007205]; Ludwig Family Foundation; NATIONAL CANCER INSTITUTE [U54CA209992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007205] Funding Source: NIH RePORTER	Yale SBI/Genetics Startup Fund, Damon Runyon; Melanoma Research Alliance; St.-Baldrick's Foundation; Breast Cancer Alliance; Cancer Research Institute (CLIP); AACR; Mary Kay Foundation; V Foundation; DoD(United States Department of Defense); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH MSTP training grant; Ludwig Family Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank all members in Chen laboratory for their support. We thank Yale High Performance Computing staff for assistance. S.C. is supported by Yale SBI/Genetics Startup Fund, Damon Runyon (DRG-2117-12 and DFS-13-15), Melanoma Research Alliance (412806 and 16-003524), St.-Baldrick's Foundation (426685), Breast Cancer Alliance, Cancer Research Institute (CLIP), AACR (499395, 17-20-01-CHEN), The Mary Kay Foundation (017-81), The V Foundation (V2017-022), Ludwig Family Foundation, DoD (W81XWH-17-1-0235) and NIH/NCI (1U54CA209992, 5P50CA196530-A10805, and 4P50CA121974-A08306). R.D.C. is supported by the NIH MSTP training grant (T32GM007205).	Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Babiarz JE, 2008, GENE DEV, V22, P2773, DOI 10.1101/gad.1705308; Brameier M, 2011, NUCLEIC ACIDS RES, V39, P675, DOI 10.1093/nar/gkq776; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chu A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv808; Dupuis-Sandoval F, 2015, WIRES RNA, V6, P381, DOI 10.1002/wrna.1284; Ender C, 2008, MOL CELL, V32, P519, DOI 10.1016/j.molcel.2008.10.017; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Falaleeva M, 2013, BIOESSAYS, V35, P46, DOI 10.1002/bies.201200117; Freedman JE, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11106; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gong J, 2017, CELL REP, V21, P1968, DOI 10.1016/j.celrep.2017.10.070; Heneghan HM, 2010, ANN SURG, V251, P499, DOI 10.1097/SLA.0b013e3181cc939f; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hsieh CL, 2014, P NATL ACAD SCI USA, V111, P7319, DOI 10.1073/pnas.1324151111; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Jackowiak P, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3891-3; Jacobsen A, 2013, NAT STRUCT MOL BIOL, V20, P1325, DOI 10.1038/nsmb.2678; Jorjani H, 2016, NUCLEIC ACIDS RES, V44, P5068, DOI 10.1093/nar/gkw386; Kishore S, 2006, SCIENCE, V311, P230, DOI 10.1126/science.1118265; Kishore S, 2010, HUM MOL GENET, V19, P1153, DOI 10.1093/hmg/ddp585; Kiss T, 2002, CELL, V109, P145, DOI 10.1016/S0092-8674(02)00718-3; Kiss T, 2010, MOL CELL, V37, P597, DOI 10.1016/j.molcel.2010.01.032; Krishnan P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162622; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li JQ, 2015, AM J CANCER RES, V5, P472; Li ZH, 2012, NUCLEIC ACIDS RES, V40, P6787, DOI 10.1093/nar/gks307; Liao JP, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-198; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Mannoor K, 2012, BBA-REV CANCER, V1826, P121, DOI 10.1016/j.bbcan.2012.03.005; Martens-Uzunova ES, 2013, CANCER LETT, V340, P201, DOI 10.1016/j.canlet.2012.11.058; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001; Mei YP, 2012, ONCOGENE, V31, P2794, DOI 10.1038/onc.2011.449; Michel CI, 2011, CELL METAB, V14, P33, DOI 10.1016/j.cmet.2011.04.009; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Morris GE, 2008, BBA-MOL CELL RES, V1783, P2108, DOI 10.1016/j.bbamcr.2008.07.016; Ono M, 2011, NUCLEIC ACIDS RES, V39, P3879, DOI 10.1093/nar/gkq1355; Orom UA, 2013, CELL, V154, P1190, DOI 10.1016/j.cell.2013.08.028; Patterson DG, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0032-8; Pundhir S, 2015, SCI REP-UK, V5, DOI 10.1038/srep12062; Ramirez F, 2014, NUCLEIC ACIDS RES, V42, pW187, DOI 10.1093/nar/gku365; Ribas A, 2015, CANCER DISCOV, V5, P915, DOI 10.1158/2159-8290.CD-15-0563; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Sahoo T, 2008, NAT GENET, V40, P719, DOI 10.1038/ng.158; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Schubert T, 2012, MOL CELL, V48, P434, DOI 10.1016/j.molcel.2012.08.021; Scott MS, 2012, NUCLEIC ACIDS RES, V40, P3676, DOI 10.1093/nar/gkr1233; Scott MS, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000507; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Siprashvili Z, 2016, NAT GENET, V48, P53, DOI 10.1038/ng.3452; Starega-Roslan J, 2011, NUCLEIC ACIDS RES, V39, P257, DOI 10.1093/nar/gkq727; Taft RJ, 2009, RNA, V15, P1233, DOI 10.1261/rna.1528909; Tata PR, 2018, DEV CELL, V44, P679, DOI 10.1016/j.devcel.2018.02.024; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; van der Maaten L, 2008, J MACH LEARN RES, V9, P2579; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang QY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10966; Watson IR, 2013, NAT REV GENET, V14, P703, DOI 10.1038/nrg3539; Williams GT, 2012, NAT REV CANCER, V12, P84, DOI 10.1038/nrc3195; Xu B, 2017, ONCOTARGET, V8, P43953, DOI 10.18632/oncotarget.16693; Yoshida K, 2017, EBIOMEDICINE, V22, P68, DOI 10.1016/j.ebiom.2017.07.009; Zhou FB, 2017, NAT CELL BIOL, V19, P844, DOI 10.1038/ncb3563	71	23	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2018	37	50					6442	6462		10.1038/s41388-018-0420-z	http://dx.doi.org/10.1038/s41388-018-0420-z			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HE0WA	30072739	Green Accepted			2022-12-17	WOS:000452989100005
J	Golfmann, K; Meder, L; Koker, M; Volz, C; Borchmann, S; Tharun, L; Dietlein, F; Malchers, F; Florin, A; Buttner, R; Rosen, N; Rodrik-Outmezguine, V; Hallek, M; Ullrich, RT				Golfmann, Kristina; Meder, Lydia; Koker, Mirjam; Volz, Caroline; Borchmann, Sven; Tharun, Lars; Dietlein, Felix; Malchers, Florian; Florin, Alexandra; Buettner, Reinhard; Rosen, Neal; Rodrik-Outmezguine, Vanessa; Hallek, Michael; Ullrich, Roland T.			Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer	ONCOGENE			English	Article							ACQUIRED-RESISTANCE; CARCINOMA-CELLS; GROWTH; RECEPTOR; ACTIVATION; SURVIVAL; BGJ398; TUMORS; AKT	FGFR1 amplification has been found in 15% of patients with breast cancer and has been postulated as a promising marker to predict response against FGFR inhibitors. However, early phase clinical trials of selective FGFR inhibitors demonstrated only limited efficacy in FGFR1-amplified breast cancer patients. We found that BGJ398, an FGFR inhibitor, effectively inhibited phosphorylation of FGFR1 and MEK/ERK signaling in FGFR1-amplified breast cancer without affecting tumor cell proliferation. However, FGFR1 knockout inhibited tumor angiogenesis in vivo. We unraveled that FGFR1 regulates the secretion of the proangiogenic vascular endothelial growth factor (VEGF) in a MAPK-dependent manner. We further found that FGF-FGFR1 signaling induces an autocrine activation of VEGF-VEGFR1 pathway that again amplifies VEGF secretion via VEGF-VEGFR1-AKT signaling. Targeting both VEGFR1 and FGFR1 resulted in synergistic anti-angiogenic treatment effects in vivo. We thus postulate synergistic treatment effects in FGFR1/VEGFR1-positive breast cancer patients by dual targeting of FGFR and VEGFR.	[Golfmann, Kristina; Meder, Lydia; Koker, Mirjam; Volz, Caroline; Borchmann, Sven; Hallek, Michael; Ullrich, Roland T.] Univ Hosp Cologne, Dept Internal Med 1, Kerpener Str 62, D-50937 Cologne, Germany; [Golfmann, Kristina; Meder, Lydia; Koker, Mirjam; Volz, Caroline; Borchmann, Sven; Buettner, Reinhard; Hallek, Michael; Ullrich, Roland T.] Univ Cologne, Ctr Mol Med Cologne, Robert Koch Str 21, D-50931 Cologne, Germany; [Borchmann, Sven] Univ Hosp Cologne, Dept Internal Med 1, German Hodgkin Study Grp, Kerpener Str 62, D-50937 Cologne, Germany; [Borchmann, Sven; Dietlein, Felix] Univ Hosp Cologne, Else Kroner Forsch Kolleg Clonal Evolut Canc, D-50931 Cologne, Germany; [Tharun, Lars; Florin, Alexandra; Buettner, Reinhard] Univ Hosp Cologne, Inst Pathol, Kerpener Str 62, D-50937 Cologne, Germany; [Dietlein, Felix] Dana Faber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Dietlein, Felix] Broad Inst MIT & Harvard, Canc Program, Cambridge, MA 02142 USA; [Malchers, Florian] Univ Hosp Cologne, Dept Translat Genom, Weyertal 115b, D-50931 Cologne, Germany; [Malchers, Florian; Hallek, Michael; Ullrich, Roland T.] Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, Kerpener Str 62, D-50937 Cologne, Germany; [Rosen, Neal; Rodrik-Outmezguine, Vanessa] Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol, 1275 York Ave, New York, NY 10021 USA	University of Cologne; University of Cologne; University of Cologne; University of Cologne; University of Cologne; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; University of Cologne; University of Cologne; Memorial Sloan Kettering Cancer Center	Ullrich, RT (corresponding author), Univ Hosp Cologne, Dept Internal Med 1, Kerpener Str 62, D-50937 Cologne, Germany.; Ullrich, RT (corresponding author), Univ Cologne, Ctr Mol Med Cologne, Robert Koch Str 21, D-50931 Cologne, Germany.; Ullrich, RT (corresponding author), Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, Kerpener Str 62, D-50937 Cologne, Germany.	roland.ullrich@uk-koeln.de	Hallek, Michael/Y-3191-2019; Borchmann, Sven/ABB-5244-2021; Rosen, Neal/ABF-2677-2020	Hallek, Michael/0000-0002-7425-4455; Borchmann, Sven/0000-0001-6662-6864; Malchers, Florian/0000-0002-3443-4419; Meder, Lydia/0000-0002-9547-5812	Thyssen Foundation [10.16.1.028MN]; Nachwuchsforschungsgruppen-NRW [1411ng005]; Deutsche Forschungsgemeinschaft (DFG) [UL379/1-1]; Deutsche Krebshilfe [70113009]	Thyssen Foundation; Nachwuchsforschungsgruppen-NRW; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe)	This work was supported by the Thyssen Foundation (Grant No.: 10.16.1.028MN to RTU), by the Nachwuchsforschungsgruppen-NRW (Grant No.: 1411ng005 to RTU), by the Deutsche Forschungsgemeinschaft (DFG) (Grant No.: UL379/1-1 to RTU) and by the Deutsche Krebshilfe (Grant No.: 70113009 to RTU).	Andre F, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.tps1134; Andre F, 2015, BREAST CANCER RES TR, V150, P1, DOI 10.1007/s10549-015-3301-y; Chatterjee S, 2013, J CLIN INVEST, V123, P1732, DOI 10.1172/JCI65385; Dales JP, 2003, ANN PATHOL, V23, P297; Datta J, 2017, MOL CANCER THER, V16, P614, DOI 10.1158/1535-7163.MCT-15-1010; Goyal L, 2017, CANCER DISCOV, V7, P252, DOI 10.1158/2159-8290.CD-16-1000; Helsten T, 2016, CLIN CANCER RES, V22, P259, DOI 10.1158/1078-0432.CCR-14-3212; Herrera-Abreu MT, 2013, CANCER DISCOV, V3, P1058, DOI 10.1158/2159-8290.CD-12-0569; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kopetz S, 2010, J CLIN ONCOL, V28, P453, DOI 10.1200/JCO.2009.24.8252; Kut C, 2007, BRIT J CANCER, V97, P978, DOI 10.1038/sj.bjc.6603923; Lee TH, 2007, PLOS MED, V4, P1101, DOI 10.1371/journal.pmed.0040186; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Malchers F, 2017, CLIN CANCER RES, V23, P5527, DOI 10.1158/1078-0432.CCR-17-0478; Malchers F, 2014, CANCER DISCOV, V4, P246, DOI 10.1158/2159-8290.CD-13-0323; Musolino A, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0807-8; Mylona E, 2007, GYNECOL ONCOL, V104, P557, DOI 10.1016/j.ygyno.2006.09.031; Nogova L, 2017, J CLIN ONCOL, V35, P157, DOI 10.1200/JCO.2016.67.2048; Ocana A, 2017, ONCOTARGET, V8, P22218, DOI 10.18632/oncotarget.14731; Packer LM, 2017, MOL CANCER THER, V16, P637, DOI 10.1158/1535-7163.MCT-16-0415; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Terry S, 2015, ONCOTARGET, V6, P11994, DOI 10.18632/oncotarget.2740; Turner N, 2010, CANCER RES, V70, P2085, DOI 10.1158/0008-5472.CAN-09-3746; Weiss J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001451; Wu Y, 2006, INT J CANCER, V119, P1519, DOI 10.1002/ijc.21865	25	23	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2018	37	42					5682	5693		10.1038/s41388-018-0380-3	http://dx.doi.org/10.1038/s41388-018-0380-3			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX3JJ	29970903				2022-12-17	WOS:000447619100007
J	Kim, Y; Shiba-Ishii, A; Nakagawa, T; Iemura, S; Natsume, T; Nakano, N; Matsuoka, R; Sakashita, S; Lee, S; Kawaguchi, A; Sato, Y; Noguchi, M				Kim, Yunjung; Shiba-Ishii, Aya; Nakagawa, Tomoki; Iemura, Shun-Ichiro; Natsume, Tohru; Nakano, Noriyuki; Matsuoka, Ryota; Sakashita, Shingo; Lee, SangJoon; Kawaguchi, Atsushi; Sato, Yukio; Noguchi, Masayuki			Stratifin regulates stabilization of receptor tyrosine kinases via interaction with ubiquitin-specific protease 8 in lung adenocarcinoma	ONCOGENE			English	Article							STRUCTURAL BASIS; UBPY; USP8; 14-3-3-SIGMA; STABILITY; CANCER; ENZYME; DEUBIQUITINATION; CLASSIFICATION; TRAFFICKING	Previously we have reported that stratifin (SFN, 14-3-3 sigma) acts as a novel oncogene, accelerating the tumor initiation and progression of lung adenocarcinoma. Here, pull-down assay and LC-MS/MS analysis revealed that ubiquitin-specific protease 8 (USP8) specifically bound to SFN in lung adenocarcinoma cells. Both USP8 and SFN showed higher expression in human lung adenocarcinoma than in normal lung tissue, and USP8 expression was significantly correlated with SFN expression. Expression of SFN, but not of USP8, was associated with histological subtype, pathological stage, and poor prognosis. USP8 stabilizes receptor tyrosine kinases (RTKs) such as EGFR and MET by deubiquitination, contributing to the proliferative activity of many human cancers including non-small cell lung cancer. In vitro, USP8 binds to SFN and they co-localize at the early endosomes in lung adenocarcinoma cells. Moreover, USP8 or SFN knockdown leads to downregulation of tumor cellular proliferation and upregulation of apoptosis, p-EGFR or p-MET, which are related to the degradation pathway, and accumulation of ubiquitinated RTKs, leading to lysosomal degradation. Additionally, mutant USP8, which is unable to bind to SFN, reduces the expression of RTKs and p-STAT3. We also found that interaction with SFN is critical for USP8 to exert its auto-deubiquitination function and avoid dephosphorylation by PP1. Our findings demonstrate that SFN enhances RTK stabilization through abnormal USP8 regulation in lung adenocarcinoma, suggesting that SFN could be a more suitable therapeutic target for lung adenocarcinoma than USP8.	[Kim, Yunjung; Shiba-Ishii, Aya; Nakano, Noriyuki; Matsuoka, Ryota; Sakashita, Shingo; Noguchi, Masayuki] Univ Tsukuba, Dept Pathol, Fac Med, Ibaraki, Japan; [Nakagawa, Tomoki] Univ Tsukuba, Doctoral Program Biomed Sci, Grad Sch Comprehens Human Sci, Ibaraki, Japan; [Iemura, Shun-Ichiro] Fukushima Med Univ, Translat Res Ctr, Fukushima, Japan; [Natsume, Tohru] Natl Inst Adv Ind Sci & Technol, Mol Profiling Res Ctr Drug Discovery, Tokyo, Japan; [Lee, SangJoon] Univ Tsukuba, PhD Program Human Biol, Sch Integrat & Global Majors, Ibaraki, Japan; [Kawaguchi, Atsushi] Univ Tsukuba, Dept Infect Biol, Fac Med, Ibaraki, Japan; [Sato, Yukio] Univ Tsukuba, Dept Thorac Surg, Fac Med, Ibaraki, Japan	University of Tsukuba; University of Tsukuba; Fukushima Medical University; National Institute of Advanced Industrial Science & Technology (AIST); University of Tsukuba; University of Tsukuba; University of Tsukuba	Shiba-Ishii, A; Noguchi, M (corresponding author), Univ Tsukuba, Dept Pathol, Fac Med, Ibaraki, Japan.	aya_shiba@md.tsukuba.ac.jp; nmasayuk@md.tsukuba.ac.jp	Lee, SangJoon/AAL-3341-2021; Kim, Yunjung/AAF-9373-2020	Lee, SangJoon/0000-0001-7500-782X; KIM, Yunjung/0000-0003-3922-3642				Aghazadeh Y, 2016, DRUG DISCOV TODAY, V21, P278, DOI 10.1016/j.drudis.2015.09.012; Alwan HAJ, 2007, J BIOL CHEM, V282, P1658, DOI 10.1074/jbc.M604711200; Ballif BA, 2006, J PROTEOME RES, V5, P2372, DOI 10.1021/pr060206k; Bansal P, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00112; Benzinger A, 2005, MOL CELL PROTEOMICS, V4, P785, DOI 10.1074/mcp.M500021-MCP200; Byun S, 2013, CLIN CANCER RES, V19, P3894, DOI 10.1158/1078-0432.CCR-12-3696; Clague MJ, 2006, TRENDS CELL BIOL, V16, P551, DOI 10.1016/j.tcb.2006.09.002; Devarakonda S, 2015, LANCET ONCOL, V16, pE342, DOI 10.1016/S1470-2045(15)00077-7; Dougherty MK, 2004, J CELL SCI, V117, P1875, DOI 10.1242/jcs.01171; Dufner A, 2015, NAT IMMUNOL, V16, P950, DOI 10.1038/ni.3230; Fraile JM, 2012, ONCOGENE, V31, P2373, DOI 10.1038/onc.2011.443; Guo L, 2003, J AM SOC MASS SPECTR, V14, P1022, DOI 10.1016/S1044-0305(03)00206-X; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; Huang WG, 2010, INT J BIOCHEM CELL B, V42, P137, DOI 10.1016/j.biocel.2009.10.001; Kakinuma R, 2016, J THORAC ONCOL, V11, P1012, DOI 10.1016/j.jtho.2016.04.006; Kim JO, 2015, ONCOTARGET, V6, P36551, DOI 10.18632/oncotarget.5336; Kim Y, 2017, PATHOL INT, V67, P292, DOI 10.1111/pin.12546; Komada Masayuki, 2008, Curr Drug Discov Technol, V5, P78, DOI 10.2174/157016308783769469; Ledda F, 2007, BIOMARK INSIGHTS, V2, P45; Li ZM, 2009, AM J TRANSL RES, V1, P326; Ma ZY, 2015, CELL RES, V25, P306, DOI 10.1038/cr.2015.20; Mei Yide, 2011, J Biol Chem, V286, P35380, DOI 10.1074/jbc.M111.282020; Meijer IMJ, 2013, CELL SIGNAL, V25, P919, DOI 10.1016/j.cellsig.2013.01.003; Meijer IMJ, 2011, CELL SIGNAL, V23, P458, DOI 10.1016/j.cellsig.2010.10.023; Mizuno E, 2005, MOL BIOL CELL, V16, P5163, DOI 10.1091/mbc.E05-06-0560; Mizuno E, 2007, EXP CELL RES, V313, P3624, DOI 10.1016/j.yexcr.2007.07.028; Mukai A, 2010, EMBO J, V29, P2114, DOI 10.1038/emboj.2010.100; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; Niendorf S, 2007, MOL CELL BIOL, V27, P5029, DOI 10.1128/MCB.01566-06; NOGUCHI M, 1995, CANCER-AM CANCER SOC, V75, P2844, DOI 10.1002/1097-0142(19950615)75:12<2844::AID-CNCR2820751209>3.0.CO;2-#; Panner A, 2010, CANCER RES, V70, P5046, DOI 10.1158/0008-5472.CAN-09-3979; Pareja F, 2012, ONCOGENE, V31, P4599, DOI 10.1038/onc.2011.587; Perez-Rivas LG, 2015, J CLIN ENDOCR METAB, V100, pE997, DOI 10.1210/jc.2015-1453; Reincke M, 2015, NAT GENET, V47, P31, DOI 10.1038/ng.3166; Row PE, 2006, J BIOL CHEM, V281, P12618, DOI 10.1074/jbc.M512615200; Sato T, 2017, CANCER SCI, V108, P536, DOI 10.1111/cas.13148; Savio MG, 2016, CURR BIOL, V26, P173, DOI 10.1016/j.cub.2015.11.050; Sbiera S, 2015, TRENDS ENDOCRIN MET, V26, P573, DOI 10.1016/j.tem.2015.08.003; Shiba-Ishii A, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0414-1; Shiba-Ishii A, 2012, AM J PATHOL, V180, P1653, DOI 10.1016/j.ajpath.2011.12.014; Shiba-Ishii A, 2011, INT J CANCER, V129, P2445, DOI 10.1002/ijc.25907; Shimada A, 2005, CANCER SCI, V96, P668, DOI 10.1111/j.1349-7006.2005.00100.x; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smith AJ, 2011, PHYSIOLOGY, V26, P181, DOI 10.1152/physiol.00042.2010; Smith GA, 2016, TRAFFIC, V17, P53, DOI 10.1111/tra.12341; Takeuchi K, 2011, BIOL PHARM BULL, V34, P1774, DOI 10.1248/bpb.34.1774; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Wilker EW, 2005, J BIOL CHEM, V280, P18891, DOI 10.1074/jbc.M500982200; Wu XL, 2004, MOL CELL BIOL, V24, P7748, DOI 10.1128/MCB.24.17.7748-7757.2004; Xia RH, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001238; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	52	23	23	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2018	37	40					5387	5402		10.1038/s41388-018-0342-9	http://dx.doi.org/10.1038/s41388-018-0342-9			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV7MY	29880877				2022-12-17	WOS:000446312900002
J	Xiao, P; Guo, Y; Zhang, H; Zhang, X; Cheng, H; Cao, Q; Ke, Y				Xiao, P.; Guo, Y.; Zhang, H.; Zhang, X.; Cheng, H.; Cao, Q.; Ke, Y.			Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN-gamma production in tumor microenvironment	ONCOGENE			English	Article							ELECTROPORATION GENE-THERAPY; DENDRITIC CELLS; BREAST-CANCER; ALTERNATIVE ACTIVATION; CXCR3 LIGANDS; LUNG-CANCER; T-CELLS; CHEMOKINE; MACROPHAGES; CARCINOMA	The Src homology 2 domain-containing protein tyrosine phosphatase 2 (Shp2) is generally considered to be an oncogene owing to its ability in enhancing the malignancy of multiple types of tumor cells; however, its role in modulating tumor immunity remains largely elusive. Here, we reported that myeloid-restricted ablation of Shp2 suppressed melanoma growth. Mechanistically, loss of Shp2 potentiates macrophage production of CXCL9 in response to IFN-gamma and tumor cell-derived cytokines, thereby facilitating the tumor infiltration of IFN-gamma-producing T cells that could in turn support CXCL9 production within tumor microenvironment. Collectively, our findings highlight a causative role of myeloid Shp2 in dampening T cell-mediated antitumor immunity by restraining the macrophage/CXCL9-T cell/IFN-gamma feedback loop. Thus, targeting macrophage Shp2 may help to create a Th1-dominant tumor immune microenvironment.	[Xiao, P.; Cao, Q.] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Pathol & Pathophysiol, Hangzhou 310058, Zhejiang, Peoples R China; [Xiao, P.; Cao, Q.] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Gastroenterol, Hangzhou 310058, Zhejiang, Peoples R China; [Guo, Y.; Zhang, H.; Zhang, X.; Cheng, H.; Ke, Y.] Zhejiang Univ, Sch Med, Dept Pathol & Pathophysiol, Program Mol Cell Biol, Hangzhou 310058, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University	Cao, Q (corresponding author), Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Pathol & Pathophysiol, Hangzhou 310058, Zhejiang, Peoples R China.; Cao, Q (corresponding author), Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Gastroenterol, Hangzhou 310058, Zhejiang, Peoples R China.; Ke, Y (corresponding author), Zhejiang Univ, Sch Med, Dept Pathol & Pathophysiol, Program Mol Cell Biol, Hangzhou 310058, Zhejiang, Peoples R China.	0000232@zju.edu.cn; yke@zju.edu.cn		Xiao, Peng/0000-0003-0075-581X	National Natural Science Foundation of China [81702807]; Key Project of the National Natural Science Foundation of China [81530001]; Key Research and Development Project of Ministry of Science and Technology of China [2016FYA0501800]; Natural Science Foundation of Zhejiang Province [LY16H030009]; Foundation of Health and Family Planning Commission of Zhejiang Province [2016134143]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Project of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Research and Development Project of Ministry of Science and Technology of China; Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province); Foundation of Health and Family Planning Commission of Zhejiang Province	We thank G. Feng (University of California, San Diego, CA) for providing the Shp2 flox/flox mice. This study was supported by National Natural Science Foundation of China (81702807 to P. Xiao), Key Project of the National Natural Science Foundation of China (81530001 to Y. Ke), Key Research and Development Project of Ministry of Science and Technology of China (2016FYA0501800 to Y. Ke), Natural Science Foundation of Zhejiang Province (LY16H030009 to Q. Cao), and Foundation of Health and Family Planning Commission of Zhejiang Province (2016134143 to Q. Cao).	Aceto N, 2012, NAT MED, V18, P529, DOI 10.1038/nm.2645; Addison CL, 2000, HUM GENE THER, V11, P247, DOI 10.1089/10430340050015996; Andersson A, 2011, CLIN CANCER RES, V17, P3660, DOI 10.1158/1078-0432.CCR-10-3346; Antonelli A, 2010, CYTOKINE, V50, P260, DOI 10.1016/j.cyto.2010.01.009; Bard-Chapeau EA, 2011, CANCER CELL, V19, P629, DOI 10.1016/j.ccr.2011.03.023; Bedognetti D, 2013, BRIT J CANCER, V109, P2412, DOI 10.1038/bjc.2013.557; Bronger H, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3115; Caso G, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-7; Cero FT, 2012, EXP LUNG RES, V38, P406, DOI 10.3109/01902148.2012.716903; Chauhan D, 2000, J BIOL CHEM, V275, P27845; Chen YNP, 2016, NATURE, V535, P148, DOI 10.1038/nature18621; Coma G, 2006, CLIN EXP IMMUNOL, V145, P535, DOI 10.1111/j.1365-2249.2006.03145.x; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370; Ding Q, 2016, CANCER MED-US, V5, P3246, DOI 10.1002/cam4.934; Fang L, 2008, J LEUKOCYTE BIOL, V84, P965, DOI 10.1189/jlb.1107776; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; Fuertes MB, 2011, J EXP MED, V208, P2005, DOI 10.1084/jem.20101159; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Gustafsson K, 2011, SCAND J IMMUNOL, V74, P318, DOI 10.1111/j.1365-3083.2011.02580.x; Hannesdottir L, 2013, EUR J IMMUNOL, V43, P2718, DOI 10.1002/eji.201242505; Harlin H, 2009, CANCER RES, V69, P3077, DOI 10.1158/0008-5472.CAN-08-2281; Howe LR, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1678; Kunz M, 1999, J PATHOL, V189, P552, DOI 10.1002/(SICI)1096-9896(199912)189:4<552::AID-PATH469>3.0.CO;2-I; Langlais D, 2016, J EXP MED, V213, P585, DOI 10.1084/jem.20151764; Lazzara MJ, 2010, CANCER RES, V70, P3843, DOI 10.1158/0008-5472.CAN-09-3421; Li S, 2002, GENE THER, V9, P390, DOI 10.1038/sj.gt.3301645; Li SM, 2014, J BIOL CHEM, V289, P34152, DOI 10.1074/jbc.M113.546077; Li SL, 2004, MOL THER, V9, P347, DOI 10.1016/j.ymthe.2003.11.022; Mantovani A, 2015, J EXP MED, V212, P435, DOI 10.1084/jem.20150295; Mikucki ME, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8458; Molon B, 2011, J EXP MED, V208, P1949, DOI 10.1084/jem.20101956; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Pardee AD, 2010, CANCER RES, V70, P9041, DOI 10.1158/0008-5472.CAN-10-1369; Park JH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07316-3; Petro M, 2013, J IMMUNOL, V190, P832, DOI 10.4049/jimmunol.1201906; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ran H, 2016, CANCER CELL, V30, P194, DOI 10.1016/j.ccell.2016.07.010; Reckamp KL, 2007, J IMMUNOTHER, V30, P417, DOI 10.1097/CJI.0b013e31802e089a; Reid-Yu SA, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004648; Roccograndi L, 2017, J NEURO-ONCOL, V135, P487, DOI 10.1007/s11060-017-2610-x; Sausgruber N, 2015, ONCOGENE, V34, P2272, DOI 10.1038/onc.2014.170; Sharma S, 2003, HUM GENE THER, V14, P1511, DOI 10.1089/104303403322495025; Specht K, 2009, BREAST CANCER RES TR, V118, P45, DOI 10.1007/s10549-008-0207-y; Szabo A, 2012, MELANOMA RES, V22, P351, DOI 10.1097/CMR.0b013e328357076c; Tao B, 2014, J IMMUNOL, V193, P2801, DOI 10.4049/jimmunol.1303463; Thapa M, 2008, J VIROL, V82, P10295, DOI 10.1128/JVI.00931-08; Voena C, 2007, CANCER RES, V67, P4278, DOI 10.1158/0008-5472.CAN-06-4350; Wu ZQ, 2016, BIOMED PHARMACOTHER, V78, P8, DOI 10.1016/j.biopha.2015.12.021; Xie M, 2015, J ALLERGY CLIN IMMUN, V135, P386, DOI 10.1016/j.jaci.2014.08.023; Xu JQ, 2017, J IMMUNOL, V199, P2323, DOI 10.4049/jimmunol.1601696; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Yun JJ, 2002, AM J PATHOL, V161, P1307, DOI 10.1016/S0002-9440(10)64407-0; Zhang J, 2015, J CELL MOL MED, V19, P2075, DOI 10.1111/jcmm.12618; Zhang R, 2006, GENE THER, V13, P1263, DOI 10.1038/sj.gt.3302756; Zhou XD, 2008, CELL DEATH DIFFER, V15, P988, DOI 10.1038/cdd.2008.54	57	23	25	2	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2018	37	37					5088	5100		10.1038/s41388-018-0337-6	http://dx.doi.org/10.1038/s41388-018-0337-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT3LT	29795405				2022-12-17	WOS:000444405300005
J	Chang, JW; Kuo, WH; Lin, CM; Chen, WL; Chan, SH; Chiu, MF; Chang, IS; Jiang, SS; Tsai, FY; Chen, CH; Huang, PH; Chang, KJ; Lin, KT; Lin, SC; Wang, MY; Uen, YH; Tu, CW; Hou, MF; Tsai, SF; Shen, CY; Tung, SL; Wang, LH				Chang, Jer-Wei; Kuo, Wen-Hung; Lin, Chiao-Mei; Chen, Wen-Ling; Chan, Shih-Hsuan; Chiu, Meng-Fan; Chang, I-Shou; Jiang, Shih-Sheng; Tsai, Fang-Yu; Chen, Chung-Hsing; Huang, Pei-Hsin; Chang, King-Jen; Lin, Kai-Ti; Lin, Sheng-Chieh; Wang, Ming-Yang; Uen, Yih-Huei; Tu, Chi-Wen; Hou, Ming-Feng; Tsai, Shih-Feng; Shen, Chen-Yang; Tung, Shiao-Lin; Wang, Lu-Hai			Wild-type p53 upregulates an early onset breast cancer-associated gene GAS7 to suppress metastasis via GAS7-CYFIP1-mediated signaling pathway	ONCOGENE			English	Article							YOUNG AGE; PROTEIN; ACTIN; DIAGNOSIS; PROGNOSIS; PATTERNS; IDENTIFICATION; PROGRESSION; ABNORMALITY; FEATURES	The early onset breast cancer patients (age <= 40) often display higher incidence of axillary lymph node metastasis, and poorer five-year survival than the late-onset patients. To identify the genes and molecules associated with poor prognosis of early onset breast cancer, we examined gene expression profiles from paired breast normal/tumor tissues, and coupled with Gene Ontology and public data base analysis. Our data showed that the expression of GAS7b gene was lower in the early onset breast cancer patients as compared to the elder patients. We found that GAS7 was associated with CYFIP1 and WAVE2 complex to suppress breast cancer metastasis via blocking CYFIP1 and Rac1 protein interaction, actin polymerization, and beta 1-integrin/FAK/Src signaling. We further demonstrated that p53 directly regulated GAS7 gene expression, which was inversely correlated with p53 mutations in breast cancer specimens. Our study uncover a novel regulatory mechanism of p53 in early onset breast cancer progression through GAS7-CYFIP1-mediated signaling pathways.	[Chang, Jer-Wei; Lin, Chiao-Mei; Chen, Wen-Ling; Chan, Shih-Hsuan; Chiu, Meng-Fan; Tsai, Shih-Feng; Wang, Lu-Hai] Natl Hlth Res Inst, Inst Mol & Genom Med, Miaoli, Taiwan; [Kuo, Wen-Hung; Chang, King-Jen; Wang, Ming-Yang] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan; [Chan, Shih-Hsuan] Natl Tsing Hua Univ, Inst Mol Med, Coll Life Sci, Hsinchu, Taiwan; [Chan, Shih-Hsuan] China Med Univ, Grad Inst Integrated Med, Coll Chinese Med, Taichung, Taiwan; [Chang, I-Shou; Jiang, Shih-Sheng; Tsai, Fang-Yu; Chen, Chung-Hsing] Natl Hlth Res Inst, Natl Inst Canc Res, Miaoli, Taiwan; [Huang, Pei-Hsin] Natl Taiwan Univ, Dept Pathol, Coll Med, Taipei, Taiwan; [Chang, King-Jen] Taiwan Adventist Hosp, Taipei, Taiwan; [Lin, Kai-Ti] Natl Tsing Hua Univ, Inst Biotechnol, Coll Life Sci, Hsinchu, Taiwan; [Lin, Sheng-Chieh; Wang, Lu-Hai] China Med Univ, Coll Chinese Med, Taichung, Taiwan; [Uen, Yih-Huei] Asia Univ Hosp, Dept Surg, Taichung, Taiwan; [Tu, Chi-Wen] Ditmanson Med Fdn, Dept Gen Surg, Chia Yi Christian Hosp, Chiayi, Taiwan; [Hou, Ming-Feng] Kaohsiung Med Univ, Dept Surg, Coll Med, Kaohsiung, Taiwan; [Hou, Ming-Feng] Kaohsiung Municipal Hsiaokang Hosp, Dept Surg, Kaohsiung, Taiwan; [Hou, Ming-Feng] Kaohsiung Med Univ Hosp, Div Breast Surg, Kaohsiung, Taiwan; [Shen, Chen-Yang] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [Tung, Shiao-Lin] Ton Yen Gen Hosp, Dept Hematol & Oncol, Hsinchu, Taiwan	National Health Research Institutes - Taiwan; National Taiwan University; National Taiwan University Hospital; National Tsing Hua University; China Medical University Taiwan; National Health Research Institutes - Taiwan; National Taiwan University; National Tsing Hua University; China Medical University Taiwan; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Municipal Siao-Gang Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Academia Sinica - Taiwan	Wang, LH (corresponding author), Natl Hlth Res Inst, Inst Mol & Genom Med, Miaoli, Taiwan.; Wang, LH (corresponding author), China Med Univ, Coll Chinese Med, Taichung, Taiwan.	luhaiwang@mail.cmu.edu.tw	Jiang, Shih Sheng/J-9671-2019; Chan, Shih-Hsuan/AAD-4317-2021; Shen, CY/F-6271-2010; Chan, Shih-Hsuan/AAW-6857-2020; Lin, Kai-Ti/B-3840-2016	Jiang, Shih Sheng/0000-0003-1909-437X; Lin, Kai-Ti/0000-0001-8656-5755; KUO, WEN-HUNG/0000-0002-9881-4605; Tung, Shiao-Lin/0000-0002-6241-6293; Chen, Chung-Hsing/0000-0002-1205-7368; Hou, Ming-Feng/0000-0001-6030-9702; Chan, Shih-Hsuan/0000-0002-8703-5139; Chang, King jen/0000-0001-9811-3422	Advance Medical Plan from Ministry of Health and Welfare, Taiwan [107-0324-01-19-03];  [CA-105-SP-01];  [MOHW105-TDU-B-212-112017]	Advance Medical Plan from Ministry of Health and Welfare, Taiwan; ; 	This work was supported by grants (CA-105-SP-01 and MOHW105-TDU-B-212-112017) and Advance Medical Plan (107-0324-01-19-03) from Ministry of Health and Welfare, Taiwan.	ADAMI HO, 1986, NEW ENGL J MED, V315, P559, DOI 10.1056/NEJM198608283150906; Anders CK, 2008, J CLIN ONCOL, V26, P3324, DOI 10.1200/JCO.2007.14.2471; Anders CK, 2011, J CLIN ONCOL, V29, pE18, DOI 10.1200/JCO.2010.28.9199; Anders CK, 2009, SEMIN ONCOL, V36, P237, DOI 10.1053/j.seminoncol.2009.03.001; Azim HA, 2012, CLIN CANCER RES, V18, P1341, DOI 10.1158/1078-0432.CCR-11-2599; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; BONNIER P, 1995, INT J CANCER, V62, P138, DOI 10.1002/ijc.2910620205; BRENNER DG, 1989, P NATL ACAD SCI USA, V86, P5517, DOI 10.1073/pnas.86.14.5517; Chan SH, 2014, ONCOGENE, V33, P4496, DOI 10.1038/onc.2014.10; Chao CCK, 2005, J NEUROSCI RES, V81, P153, DOI 10.1002/jnr.20552; Chen FM, 2004, CANCER LETT, V207, P59, DOI 10.1016/j.canlet.2003.12.005; Cheng SH, 2000, BREAST CANCER RES TR, V63, P213, DOI 10.1023/A:1006468514396; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; DELAROCHEFORDIERE A, 1993, LANCET, V341, P1039, DOI 10.1016/0140-6736(93)92407-K; El Saghir NS, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-194; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hu JH, 2011, J CELL SCI, V124, P1739, DOI 10.1242/jcs.078014; Ingham RJ, 2005, MOL CELL BIOL, V25, P7092, DOI 10.1128/MCB.25.16.7092-7106.2005; Jong YJ, 2004, CANCER GENET CYTOGEN, V148, P55, DOI 10.1016/S0165-4608(03)00205-X; Ju YT, 1998, P NATL ACAD SCI USA, V95, P11423, DOI 10.1073/pnas.95.19.11423; Kobayashi K, 1998, J BIOL CHEM, V273, P291, DOI 10.1074/jbc.273.1.291; Kuo WH, 2006, BREAST CANCER RES TR, V99, P221, DOI 10.1007/s10549-006-9194-z; Kurisu S, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-226; Lin KT, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6917; Lin KT, 2012, CANCER RES, V72, P3000, DOI 10.1158/0008-5472.CAN-11-2502; Liu SX, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0144-2; Lortie K, 2005, BRAIN RES, V1036, P27, DOI 10.1016/j.brainres.2004.12.024; Lou MA, 1997, BRIT J CANCER, V75, P746, DOI 10.1038/bjc.1997.132; Melhem-Bertrandt A, 2012, CANCER-AM CANCER SOC, V118, P908, DOI 10.1002/cncr.26377; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; NIXON AJ, 1994, J CLIN ONCOL, V12, P888, DOI 10.1200/JCO.1994.12.5.888; Saengsawang W, 2012, CURR BIOL, V22, P494, DOI 10.1016/j.cub.2012.01.038; Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206; She BR, 2002, EXP CELL RES, V273, P34, DOI 10.1006/excr.2001.5435; Shen YC, 2005, CANCER EPIDEM BIOMAR, V14, P1986, DOI 10.1158/1055-9965.EPI-04-0932; Tseng RC, 2008, LUNG CANCER, V59, P332, DOI 10.1016/j.lungcan.2007.08.038; Tseng RC, 2015, ONCOTARGET, V6, P44207, DOI 10.18632/oncotarget.6229; Xu GW, 2005, INT J CANCER, V116, P187, DOI 10.1002/ijc.21071; Yan C, 2003, EMBO J, V22, P3602, DOI 10.1093/emboj/cdg350; You JJ, 2010, J BIOL CHEM, V285, P11652, DOI 10.1074/jbc.M109.051094; Zhou P, 2004, CANCER-AM CANCER SOC, V101, P1264, DOI 10.1002/cncr.20523	42	23	23	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 26	2018	37	30					4137	4150		10.1038/s41388-018-0253-9	http://dx.doi.org/10.1038/s41388-018-0253-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GO2YI	29706651	Green Published, hybrid			2022-12-17	WOS:000439847000007
J	Ji, CD; Yang, L; Yi, WJ; Xiang, DF; Wang, YX; Zhou, ZH; Qian, F; Ren, Y; Cui, W; Zhang, X; Zhang, P; Wang, JM; Cui, YH; Bian, XW				Ji, Chengdong; Yang, Lang; Yi, Weijing; Xiang, Dongfang; Wang, Yanxia; Zhou, Zhihua; Qian, Feng; Ren, Yong; Cui, Wei; Zhang, Xia; Zhang, Peng; Wang, Ji Ming; Cui, Youhong; Bian, Xiuwu			Capillary morphogenesis gene 2 maintains gastric cancer stem-like cell phenotype by activating a Wnt/beta-catenin pathway	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; ANTHRAX TOXIN RECEPTOR; GENERATES CELLS; MARKER CD44; WNT; PROGRESSION; DIFFERENTIATION; OVEREXPRESSION; IDENTIFICATION; ANGIOGENESIS	A growing body of evidence shows that the development and progression of gastric cancer (GC) is mainly associated to the presence of gastric cancer stem-like cells (GCSLCs). However, it is unclear how GCSLC population is maintained. This study aimed to explore the role of capillary morphogenesis gene 2 (CMG2) in GCSLC maintenance and the relevance to GC progression. We found that CMG2 was highly expressed in GC tissues and the expression levels were associated with the invasion depth and lymph node metastasis of GC, and inversely correlated with the survival of GC patients. Sorted CMG2(High) GC cells preferentially clustered in CD44(High) stem-like cell population, which expressed high levels of stemness-related genes with increased capabilities of self-renewal and tumorigenicity. Depletion of CMG2 gene resulted in reduction of GCSLC population with attenuated stemness and decrease of invasive and metastatic capabilities with subdued epithelial-mesenchymal transition phenotype in GC cells. Mechanistically, CMG2 interacted with LRP6 in GCSLCs to activate a Wnt/beta-catenin pathway. Thus, our results demonstrate that CMG2 promotes GC progression by maintaining GCSLCs and can serve as a new prognostic indicator and a target for human GC therapy.	[Ji, Chengdong; Yang, Lang; Yi, Weijing; Xiang, Dongfang; Wang, Yanxia; Zhou, Zhihua; Ren, Yong; Cui, Wei; Zhang, Xia; Zhang, Peng; Cui, Youhong; Bian, Xiuwu] Third Mil Med Univ, Army Med Univ, Southwest Hosp, Inst Pathol, Chongqing 400038, Peoples R China; [Ji, Chengdong; Yang, Lang; Yi, Weijing; Xiang, Dongfang; Wang, Yanxia; Zhou, Zhihua; Ren, Yong; Cui, Wei; Zhang, Xia; Zhang, Peng; Cui, Youhong; Bian, Xiuwu] Third Mil Med Univ, Army Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing 400038, Peoples R China; [Ji, Chengdong; Yang, Lang; Yi, Weijing; Xiang, Dongfang; Wang, Yanxia; Zhou, Zhihua; Ren, Yong; Cui, Wei; Zhang, Xia; Zhang, Peng; Cui, Youhong; Bian, Xiuwu] Third Mil Med Univ, Army Med Univ, Southwest Hosp, Minist Educ China,Key Lab Tumor Immunopathol, Chongqing 400038, Peoples R China; [Zhou, Zhihua] 101 Hosp Peoples Liberat Army, Dept Pathol, Wuxi 214000, Jiangsu, Peoples R China; [Qian, Feng] Third Mil Med Univ, Southwest Hosp, Dept Gen Surg, Chongqing 400038, Peoples R China; [Wang, Ji Ming] Natl Canc Inst Frederick, Ctr Canc Res, Canc & Inflammat Program, Frederick, MD 21702 USA	Army Medical University; Army Medical University; Army Medical University; Ministry of Education, China; Army Medical University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cui, YH; Bian, XW (corresponding author), Third Mil Med Univ, Army Med Univ, Southwest Hosp, Inst Pathol, Chongqing 400038, Peoples R China.; Cui, YH; Bian, XW (corresponding author), Third Mil Med Univ, Army Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing 400038, Peoples R China.; Cui, YH; Bian, XW (corresponding author), Third Mil Med Univ, Army Med Univ, Southwest Hosp, Minist Educ China,Key Lab Tumor Immunopathol, Chongqing 400038, Peoples R China.	cuiyouhongx@yahoo.com; bianxiuwu@263.net	Bian, Xiu-Wu/D-4736-2017; Yang, Lang/AAL-3025-2020; yang, lang/ABA-2517-2021; Zhang, Xia/B-8152-2008	Bian, Xiu-Wu/0000-0003-4383-0197; Yang, Lang/0000-0002-5234-7394; Zhang, Xia/0000-0002-9040-1486	National Natural Science Foundation of China [81372555]; NATIONAL CANCER INSTITUTE [ZIABC010015] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the National Natural Science Foundation of China (81372555) to YC.	Ajani JA, 2016, J NATL COMPR CANC NE, V14, P1286, DOI 10.6004/jnccn.2016.0137; Bekaii-Saab T, 2017, CANCER-AM CANCER SOC, V123, P1303, DOI 10.1002/cncr.30538; Bell SE, 2001, J CELL SCI, V114, P2755; Bessede E, 2014, ONCOGENE, V33, P4123, DOI 10.1038/onc.2013.380; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Brown SD, 1998, BIOCHEM BIOPH RES CO, V248, P879, DOI 10.1006/bbrc.1998.9061; Burgi J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15861; Cai C, 2012, MOL MED REP, V5, P1191, DOI 10.3892/mmr.2012.802; Cao SG, 2012, BIOORG MED CHEM LETT, V22, P5885, DOI 10.1016/j.bmcl.2012.07.075; Castanon I, 2013, NAT CELL BIOL, V15, P28, DOI 10.1038/ncb2632; Cervantes A, 2013, CANCER TREAT REV, V39, P60, DOI 10.1016/j.ctrv.2012.09.007; Chen KH, 2016, J BIOL CHEM, V291, P22021, DOI 10.1074/jbc.M116.753301; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Cryan LM, 2013, J MED CHEM, V56, P1940, DOI 10.1021/jm301558t; Demitrack ES, 2015, EMBO J, V34, P2522, DOI 10.15252/embj.201490583; Deuquet J, 2012, EMBO J, V31, P3, DOI 10.1038/emboj.2011.442; Fan F, 2012, CANCER MED-US, V1, P5, DOI 10.1002/cam4.4; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gao YH, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0548-8; Guo ZJ, 2016, ONCOTARGET, V7, P20999, DOI 10.18632/oncotarget.8236; Haraguchi N, 2006, STEM CELLS, V24, P506, DOI 10.1634/stemcells.2005-0282; Huang L, 2015, AM J TRANSL RES, V7, P2141; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Ishimoto T, 2010, CANCER SCI, V101, P673, DOI 10.1111/j.1349-7006.2009.01430.x; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Jiang Y, 2012, GASTRIC CANCER, V15, P440, DOI 10.1007/s10120-012-0140-y; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316; Kodama H, 2017, BRIT J CANCER, V116, P186, DOI 10.1038/bjc.2016.401; Kong DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012445; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Li LC, 2015, ONCOL LETT, V10, P3293, DOI 10.3892/ol.2015.3727; Li YH, 2001, MOL NEUROBIOL, V23, P53; Liu JJ, 2016, CANCER LETT, V376, P110, DOI 10.1016/j.canlet.2016.03.035; Liu SH, 2016, P NATL ACAD SCI USA, V113, pE4079, DOI 10.1073/pnas.1600982113; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Nishii T, 2009, CANCER SCI, V100, P1397, DOI 10.1111/j.1349-7006.2009.01211.x; Park JY, 2014, CLIN ENDOSC, V47, P478, DOI 10.5946/ce.2014.47.6.478; Peng Z, 2014, WORLD J GASTROENTERO, V20, P5403, DOI 10.3748/wjg.v20.i18.5403; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Rao J, 2015, CANCER LETT, V358, P76, DOI 10.1016/j.canlet.2014.12.040; Rasheed ZA, 2010, JNCI-J NATL CANCER I, V102, P340, DOI 10.1093/jnci/djp535; Reeves CV, 2010, ONCOGENE, V29, P789, DOI 10.1038/onc.2009.383; Rogers MS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039911; Ryu HS, 2012, HUM PATHOL, V43, P520, DOI 10.1016/j.humpath.2011.07.003; Savagner P, 1994, Cancer Treat Res, V71, P229; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; Simon E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035486; Singh SR, 2013, CANCER LETT, V338, P110, DOI 10.1016/j.canlet.2013.03.035; Song Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017687; Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30; Thiery JP, 1999, CANCER METAST REV, V18, P31, DOI 10.1023/A:1006256219004; Varga J, 2014, FEBS LETT, V588, P2422, DOI 10.1016/j.febslet.2014.06.019; Wang B, 2013, J GASTROENTEROL, V48, P798, DOI 10.1007/s00535-012-0711-z; Wang T, 2011, BRIT J CANCER, V105, P658, DOI 10.1038/bjc.2011.287; Wang W, 2014, INT J CLIN EXP MED, V7, P5059; Wei W, 2006, CELL, V124, P1141, DOI 10.1016/j.cell.2005.12.045; Xu GH, 2013, J GASTROENTEROL, V48, P781, DOI 10.1007/s00535-012-0712-y; Yang L, 2011, CANCER LETT, V310, P46, DOI 10.1016/j.canlet.2011.06.003; Ye L, 2014, INT J ONCOL, V45, P1565, DOI 10.3892/ijo.2014.2533; Ye L, 2014, ONCOL LETT, V7, P2149, DOI 10.3892/ol.2014.2038; Ye L, 2014, J CANCER RES CLIN, V140, P957, DOI 10.1007/s00432-014-1650-2; Yu D, 2014, ONCOL REP, V31, P673, DOI 10.3892/or.2013.2893; Zhang CJ, 2011, J CANCER RES CLIN, V137, P1679, DOI 10.1007/s00432-011-1038-5; Zhu L, 2017, ONCOTARGET, V8, P37633, DOI 10.18632/oncotarget.16839; Zou JW, 2014, BIOCHEM BIOPH RES CO, V452, P186, DOI 10.1016/j.bbrc.2014.06.001	67	23	23	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2018	37	29					3953	3966		10.1038/s41388-018-0226-z	http://dx.doi.org/10.1038/s41388-018-0226-z			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GN5LP	29662192	Green Published, hybrid			2022-12-17	WOS:000439101300004
J	Tang, QL; Lu, JC; Zou, CY; Shao, Y; Chen, Y; Narala, S; Fang, H; Xu, HY; Wang, J; Shen, JN; Khokha, R				Tang, Qinglian; Lu, Jinchang; Zou, Changye; Shao, Yang; Chen, Yan; Narala, Swami; Fang, Hui; Xu, Huaiyuan; Wang, Jin; Shen, Jingnan; Khokha, Rama			CDH4 is a novel determinant of osteosarcoma tumorigenesis and metastasis	ONCOGENE			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; TYPHIMURIUM A1-R REGRESSES; CADHERIN EXPRESSION; PEDIATRIC OSTEOSARCOMA; OSTEOBLAST LINEAGE; LUNG METASTASIS; TUMOR-GROWTH; C-JUN; CELLS; CANCER	The era of cancer genomics now provides an opportunity to discover novel determinants of osteosarcoma (OS), the most common primary bone cancer in children and adolescents known for its poor prognosis due to lung metastasis. Here, we identify CDH4 amplification in 43.6% of human osteosarcoma using array CGH and demonstrate its critical role in osteosarcoma development and progression. Gain or loss-of-function of CDH4, which encodes R-cadherin, causally impacts multiple features of human OS cells including cell migration and invasion, osteogenic differentiation, and stemness. CDH4 overexpression activates c-Jun via the JNK pathway, while CDH4 knockdown suppresses both tumor xenograft growth and lung colonization. In OS patient specimens, high CDH4 expression associates with lung metastases and poor prognosis. Collectively, our bioinformatics, functional, molecular, and clinical analyses uncover an oncogenic function of CDH4 in osteosarcoma and its relationship with patient outcome.	[Tang, Qinglian; Lu, Jinchang; Shao, Yang; Chen, Yan; Narala, Swami; Fang, Hui; Khokha, Rama] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON M5G 0A3, Canada; [Tang, Qinglian; Lu, Jinchang; Zou, Changye; Xu, Huaiyuan; Wang, Jin; Shen, Jingnan] Sun Yat Sen Univ, Dept Orthoped Oncol, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Sun Yat Sen University	Khokha, R (corresponding author), Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON M5G 0A3, Canada.; Shen, JN (corresponding author), Sun Yat Sen Univ, Dept Orthoped Oncol, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China.	shenjingnan@126.com; rama.khokha@utoronto.ca			Canadian Institutes of Health Research (CIHR); Canadian Cancer Society Research Institute (CCSRI); International Science & Technology Cooperation Program of Guangzhou [201704030008]; Graduate Student Overseas Study Program of China Scholarship Council; National Natural Science Foundation of China [81502324]; National Postdoctoral Program for Innovative Talents [BX201600196]	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society Research Institute (CCSRI)(Canadian Cancer Society (CCS)); International Science & Technology Cooperation Program of Guangzhou; Graduate Student Overseas Study Program of China Scholarship Council; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Postdoctoral Program for Innovative Talents	This study is supported by funding from the Canadian Institutes of Health Research (CIHR) and the Canadian Cancer Society Research Institute (CCSRI) to RK, and International Science & Technology Cooperation Program of Guangzhou to JS (201704030008). Q.T. and J.L. are supported by Graduate Student Overseas Study Program of China Scholarship Council. Q.T. is also supported by National Natural Science Foundation of China (81502324), and J.L. is supported by National Postdoctoral Program for Innovative Talents (BX201600196).	Agiostratidou G, 2009, CANCER RES, V69, P5030, DOI 10.1158/0008-5472.CAN-08-4007; Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb-76-6-899; Biermann J Sybil, 2007, J Natl Compr Canc Netw, V5, P420; Bjornland K, 2005, J SURG RES, V127, P151, DOI 10.1016/j.jss.2004.12.016; Both J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030907; Briccoli A, 2010, SURG ONCOL, V19, P193, DOI 10.1016/j.suronc.2009.05.002; Bubici C, 2014, BRIT J PHARMACOL, V171, P24, DOI 10.1111/bph.12432; Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003; Fromigue O, 2008, J BIOL CHEM, V283, P30549, DOI 10.1074/jbc.M801436200; Gustems M, 2014, NUCLEIC ACIDS RES, V42, P3059, DOI 10.1093/nar/gkt1323; Gvozdenovic A, 2013, J BONE MINER RES, V28, P838, DOI 10.1002/jbmr.1817; Ibrahim EE, 2012, STEM CELLS, V30, P2076, DOI 10.1002/stem.1182; Igarashi K, 2017, CELL CYCLE, V16, P1164, DOI 10.1080/15384101.2017.1317417; Kashima T, 2003, INT J CANCER, V104, P147, DOI 10.1002/ijc.10931; Kashima T, 1999, AM J PATHOL, V155, P1549, DOI 10.1016/S0002-9440(10)65471-5; Kawaguchi J, 2001, J BONE MINER RES, V16, P260, DOI 10.1359/jbmr.2001.16.2.260; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kimura R, 2011, BBA-MOL CELL RES, V1813, P1543, DOI 10.1016/j.bbamcr.2011.04.008; Kitajima H, 2013, CANCER MED-US, V2, P267, DOI 10.1002/cam4.67; Kresse SH, 2009, GENE CHROMOSOME CANC, V48, P679, DOI 10.1002/gcc.20675; Krueger S, 2001, CANCER GENE THER, V8, P522, DOI 10.1038/sj.cgt.7700341; Kucharczak J, 2008, CANCER RES, V68, P6559, DOI 10.1158/0008-5472.CAN-08-0196; Lin YH, 2017, TRENDS MOL MED, V23, P737, DOI 10.1016/j.molmed.2017.06.004; Lorenz S, 2016, ONCOTARGET, V7, P5273, DOI 10.18632/oncotarget.6567; Lu J, 2017, ONCOGENE, V36, P231, DOI 10.1038/onc.2016.194; Lu JC, 2015, J CLIN INVEST, V125, P1839, DOI 10.1172/JCI78437; Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006; Martin Jeff W., 2012, Sarcoma, V2012, P627254, DOI 10.1155/2012/627254; Mathisen B, 2003, CLIN EXP METASTAS, V20, P701, DOI 10.1023/B:CLIN.0000006819.21361.03; Miotto E, 2004, CANCER RES, V64, P8156, DOI 10.1158/0008-5472.CAN-04-3000; Murakami T, 2017, ONCOTARGET, V8, P8035, DOI 10.18632/oncotarget.14040; Ozaki T, 2002, INT J CANCER, V102, P355, DOI 10.1002/ijc.10709; Papachristou DJ, 2003, BONE, V32, P364, DOI 10.1016/S8756-3282(03)00026-7; Pohlig F, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1315-6; Poos K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123082; Shin CS, 2000, J CELL BIOCHEM, V78, P566, DOI 10.1002/1097-4644(20000915)78:4<566::AID-JCB6>3.0.CO;2-K; Smida J, 2017, INT J CANCER, V141, P816, DOI 10.1002/ijc.30778; Smida J, 2010, CLIN CANCER RES, V16, P4256, DOI 10.1158/1078-0432.CCR-10-0284; Squire JA, 2003, GENE CHROMOSOME CANC, V38, P215, DOI 10.1002/gcc.10273; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999-008-0335-z; Wheelock MJ, 2008, J CELL SCI, V121, P727, DOI 10.1242/jcs.000455; Xie L, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/762098; Yoon CH, 2012, ONCOGENE, V31, P4655, DOI 10.1038/onc.2011.634; Zhang GY, 2011, ASIAN PAC J CANCER P, V12, P2075	45	23	25	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 5	2018	37	27					3617	3630		10.1038/s41388-018-0231-2	http://dx.doi.org/10.1038/s41388-018-0231-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GM3CM	29610525				2022-12-17	WOS:000437975200001
J	Monterisi, S; Lo Riso, P; Russo, K; Bertalot, G; Vecchi, M; Testa, G; Di Fiore, PP; Bianchi, F				Monterisi, Simona; Lo Riso, Pietro; Russo, Karin; Bertalot, Giovanni; Vecchi, Manuela; Testa, Giuseppe; Di Fiore, Pier Paolo; Bianchi, Fabrizio			HOXB7 overexpression in lung cancer is a hallmark of acquired stem-like phenotype	ONCOGENE			English	Article							CELL-PROLIFERATION; BREAST-CANCER; MALIGNANT PROGRESSION; SURVIVAL PREDICTION; GROWTH-FACTOR; EXPRESSION; GENE; LET-7; CARCINOMA; OCT4	HOXB7 is a homeodomain (HOX) transcription factor involved in regional body patterning of invertebrates and vertebrates. We previously identified HOXB7 within a ten-gene prognostic signature for lung adenocarcinoma, where increased expression of HOXB7 was associated with poor prognosis. This raises the question of how HOXB7 overexpression can influence the metastatic behavior of lung adenocarcinoma. Here, we analyzed publicly available microarray and RNA-seq lung cancer expression datasets and found that HOXB7-overexpressing tumors are enriched in gene signatures characterizing adult and embryonic stem cells (SC), and induced pluripotent stem cells (iPSC). Experimentally, we found that HOXB7 upregulates several canonical SC/iPSC markers and sustains the expansion of a subpopulation of cells with SC characteristics, through modulation of LIN28B, an emerging cancer gene and pluripotency factor, which we discovered to be a direct target of HOXB7. We validated this new circuit by showing that HOXB7 enhances reprogramming to iPSC with comparable efficiency to LIN28B or its target c-MYC, which is a canonical reprogramming factor.	[Monterisi, Simona; Bertalot, Giovanni; Di Fiore, Pier Paolo; Bianchi, Fabrizio] European Inst Oncol, Mol Med Program, I-20141 Milan, Italy; [Monterisi, Simona; Russo, Karin; Vecchi, Manuela; Di Fiore, Pier Paolo] Mol Oncol Fdn, FIRC Inst, IFOM, I-20139 Milan, Italy; [Lo Riso, Pietro; Testa, Giuseppe] European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; [Testa, Giuseppe; Di Fiore, Pier Paolo] Univ Milan, Dept Oncol & Hematooncol, DIPO, I-20122 Milan, Italy; [Bianchi, Fabrizio] Regenerat Med & Innovat Therapies IRCCS Casa Soll, Inst Stem Cell Biol, ISBREMIT, I-71013 San Giovanni Rotondo, FG, Italy; [Monterisi, Simona] Humanitas Clin & Res Ctr, I-20089 Rozzano, MI, Italy	IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO); University of Milan; IRCCS Humanitas Research Hospital	Bianchi, F (corresponding author), European Inst Oncol, Mol Med Program, I-20141 Milan, Italy.; Bianchi, F (corresponding author), Regenerat Med & Innovat Therapies IRCCS Casa Soll, Inst Stem Cell Biol, ISBREMIT, I-71013 San Giovanni Rotondo, FG, Italy.	f.bianchi@operapadrepio.it	Bertalot, Giovanni/O-8878-2017; Bianchi, Fabrizio/B-5995-2017; Di Fiore, Pier Paolo/K-2130-2012; Bertalot, Giovanni/AAV-8788-2021; Bianchi, Fabrizio/W-7037-2019	Bianchi, Fabrizio/0000-0001-7412-8638; Di Fiore, Pier Paolo/0000-0002-2252-0950; Bianchi, Fabrizio/0000-0001-7412-8638; Bertalot, Giovanni/0000-0002-4862-7705; LO RISO, PIETRO/0000-0003-2542-0637; Testa, Giuseppe/0000-0002-9104-0918	Associazione Italiana per la Ricerca sul Cancro (AIRC) [MFAG17568, IG 10349, 14040, MCO 10.000]; Monzino Foundation	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Monzino Foundation	We thank Bruno Amati for kindly providing the pBABE-MYC plasmid. We are indebted to Giuseppina Bonizzi, Giovanna Jodice, Elena Belloni, Elena Marino, Francesca De Santis, Stefania Pirroni, Pietro Vella, Valentina Melocchi, Davide Disalvatore and Stefano Freddi for technical support. We thank Ugo Cavallaro for inspiring discussions and comments on the paper. This work was supported by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC) (MFAG17568 to FB; IG 10349 and 14040 and MCO 10.000 to PPDF) and from the Monzino Foundation (to PPDF).	Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Kovochich AN, 2013, CANCER-AM CANCER SOC, V119, P529, DOI 10.1002/cncr.27725; Berger MF, 2008, CELL, V133, P1266, DOI 10.1016/j.cell.2008.05.024; Bianchi F, 2007, J CLIN INVEST, V117, P3436, DOI 10.1172/JCI32007; Care A, 1998, ONCOGENE, V16, P3285, DOI 10.1038/sj.onc.1201875; Care A, 1996, MOL CELL BIOL, V16, P4842; Care A, 1999, ONCOGENE, V18, P1993, DOI 10.1038/sj.onc.1202498; Chang TC, 2009, P NATL ACAD SCI USA, V106, P3384, DOI 10.1073/pnas.0808300106; Chien CS, 2015, CANCER RES, V75, P2553, DOI 10.1158/0008-5472.CAN-14-2215; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Copley MR, 2013, NAT CELL BIOL, V15, P916, DOI 10.1038/ncb2783; Dama E, 2017, CLIN CANCER RES, V23, P62, DOI 10.1158/1078-0432.CCR-15-3005; Destro MFDS, 2010, INT J ONCOL, V36, P141, DOI 10.3892/ijo_00000485; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Errico MC, 2016, CANCER RES, V76, P2857, DOI 10.1158/0008-5472.CAN-15-3444; Hammachi F, 2012, CELL REPORTS, V1, P99, DOI 10.1016/j.celrep.2011.12.002; He XJ, 2017, ONCOTARGET, V8, P1247, DOI 10.18632/oncotarget.13604; Huan HB, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0559-4; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Jin K, 2012, P NATL ACAD SCI USA, V109, P2736, DOI 10.1073/pnas.1018859108; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; KORNBERG TB, 1993, J BIOL CHEM, V268, P26813; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Lengner CJ, 2007, CELL STEM CELL, V1, P403, DOI 10.1016/j.stem.2007.07.020; Liao WT, 2011, CLIN CANCER RES, V17, P3569, DOI 10.1158/1078-0432.CCR-10-2533; Liu S, 2015, CANCER RES, V75, P709, DOI 10.1158/0008-5472.CAN-14-3100; Liu YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083083; Lu HH, 2014, NAT CELL BIOL, V16, P1105, DOI 10.1038/ncb3041; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Morgan R, 2006, TRENDS GENET, V22, P67, DOI 10.1016/j.tig.2005.11.004; Newman MA, 2008, RNA, V14, P1539, DOI 10.1261/rna.1155108; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Pearson JC, 2005, NAT REV GENET, V6, P893, DOI 10.1038/nrg1726; RIDDIHOUGH G, 1992, NATURE, V357, P643, DOI 10.1038/357643a0; Shao YB, 2015, AM J CANCER RES, V5, P2643; Shedden K, 2008, NAT MED, V14, P822, DOI 10.1038/nm.1790; Stadtfeld M, 2010, NAT METHODS, V7, P53, DOI [10.1038/NMETH.1409, 10.1038/nmeth.1409]; Storti P, 2011, LEUKEMIA, V25, P527, DOI 10.1038/leu.2010.270; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suva ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Viswanathan SR, 2010, CELL, V140, P445, DOI 10.1016/j.cell.2010.02.007; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Wang PH, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0052088, 10.1371/journal.pone.0057020]; Wang XR, 2012, ONCOL LETT, V3, P955, DOI 10.3892/ol.2012.609; Wernig M, 2008, CELL STEM CELL, V2, P10, DOI 10.1016/j.stem.2007.12.001; Wesselschmidt RL, 2011, METHODS MOL BIOL, V767, P231, DOI 10.1007/978-1-61779-201-4_17; Wetzel A, 2004, J IMMUNOL, V172, P3850, DOI 10.4049/jimmunol.172.6.3850; Whitfield TW, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-9-r50; Wu XY, 2006, CANCER RES, V66, P9527, DOI 10.1158/0008-5472.CAN-05-4470; Yamanaka S, 2011, GOOGLE PATENTS; Yamauchi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043923; Yan XP, 2013, ONCOL REP, V30, P2733, DOI 10.3892/or.2013.2784; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Yuan WW, 2014, MOL CARCINOGEN, V53, P49, DOI 10.1002/mc.21947	57	23	24	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	26					3575	3588		10.1038/s41388-018-0229-9	http://dx.doi.org/10.1038/s41388-018-0229-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TM	29576613				2022-12-17	WOS:000436412500008
J	Oyinlade, O; Wei, S; Lal, B; Laterra, J; Zhu, H; Goodwin, CR; Wang, SY; Ma, D; Wan, J; Xia, SL				Oyinlade, Olutobi; Wei, Shuang; Lal, Bachchu; Laterra, John; Zhu, Heng; Goodwin, C. Rory; Wang, Shuyan; Ma, Ding; Wan, Jun; Xia, Shuli			Targeting UDP-alpha-D-glucose 6-dehydrogenase inhibits glioblastoma growth and migration	ONCOGENE			English	Article							STEM-LIKE CELLS; CANCER PROGRESSION; HYALURONAN; INVASION; DEHYDROGENASE; MULTIFORME	UDP-glucose 6-dehydrogenase (UGDH) produces UDP-alpha-D-glucuronic acid, the precursors for glycosaminoglycans (GAGs) and proteoglycans of the extracellular matrix. Elevated GAG formation has been implicated in a variety of human diseases, including glioblastoma (GBM). In our previous study, we found that Kruppel-like factor 4 (KLF4) promotes GBM cell migration by binding to methylated DNA, mainly methylated CpGs (mCpG) and transactivating gene expression. We identified UDGH as one of the downstream targets of KLF4-mCpG binding activity. In this study, we show that KLF4 upregulates UGDH expression in a mCpG-dependent manner, and UGDH is required for KLF4-induced cell migration in vitro. UGDH knockdown decreases GAG abundance in GBM cells, as well as cell proliferation and migration in vitro. In intracranial xenografts, reduced UGDH inhibits tumor growth and migration, accompanied by a decrease in the expression of extracellular matrix proteins such as tenascin C, brevican. Our studies demonstrate a novel DNA methylation-dependent UGDH upregulation by KLF4. Developing UGDH antagonists to decrease the synthesis of extracellular matrix components will be a useful strategy for GBM therapy.	[Oyinlade, Olutobi; Wei, Shuang; Lal, Bachchu; Laterra, John; Wang, Shuyan; Ma, Ding; Xia, Shuli] Hugo W Moser Res Inst Kennedy Krieger, Baltimore, MD 21205 USA; [Oyinlade, Olutobi; Zhu, Heng] Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; [Wei, Shuang; Lal, Bachchu; Laterra, John; Wang, Shuyan; Ma, Ding; Xia, Shuli] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Wei, Shuang] Huazhong Univ Sci & Technol, Dept Resp & Crit Care Med, Tongji Med Coll, Tongji Hosp, Wuhan 430030, Hubei, Peoples R China; [Laterra, John] Johns Hopkins Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA; [Laterra, John] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Zhu, Heng] Johns Hopkins Sch Med, High Throughput Biol Ctr, Baltimore, MD 21205 USA; [Goodwin, C. Rory] Duke Univ, Med Ctr, Dept Neurosurg, Durham, NC 27710 USA; [Wan, Jun] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Huazhong University of Science & Technology; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Duke University; Indiana University System; Indiana University Bloomington	Xia, SL (corresponding author), Hugo W Moser Res Inst Kennedy Krieger, Baltimore, MD 21205 USA.; Xia, SL (corresponding author), Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD 21205 USA.	xia@kennedykrieger.org	Wei, Shuang/AAA-4031-2019; Wan, Jun/AAN-1337-2020	Wan, Jun/0000-0001-9286-6562	NIH [R01NS091165, R01 NS096754, NS076759, GM111514, R01 GM111514, R33CA186790, U54 HG006434, U24 CA160036, T32 GM007445]; Ford Foundation pre-doctoral fellowship program; Duke SPORE CEP Award; NIH/NINDS; Burroughs Wellcome Fund; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007445] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS073611, R01NS096754, R01NS091165] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ford Foundation pre-doctoral fellowship program; Duke SPORE CEP Award; NIH/NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Burroughs Wellcome Fund(Burroughs Wellcome Fund); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by grants from NIH R01NS091165 (to SX), NIH R01 NS096754 (to JL), NS076759 (to JL), NIH GM111514 (to HZ), NIH R01 GM111514 (to HZ), NIH R33CA186790 (to HZ), NIH U54 HG006434 (to HZ), NIH U24 CA160036 (to HZ), Ford Foundation pre-doctoral fellowship program (to OO) and NIH T32 GM007445 (to OO), NIH/NINDS K12 Physician Scientist Award, Burroughs Wellcome Fund, and Duke SPORE CEP Award (to CRG).	Adamson C, 2009, EXPERT OPIN INV DRUG, V18, P1061, DOI 10.1517/13543780903052764; Afratis N, 2012, FEBS J, V279, P1177, DOI 10.1111/j.1742-4658.2012.08529.x; Barbosa I, 2003, GLYCOBIOLOGY, V13, P647, DOI 10.1093/glycob/cwg082; Batash R., 2017, RECENT LIT REV CURR, V24, P3002, DOI DOI 10.2174/0929867324666170516123206; Clarkin CE, 2011, J CELL PHYSIOL, V226, P749, DOI 10.1002/jcp.22393; CRAIG JM, 1994, NAT GENET, V7, P376, DOI 10.1038/ng0794-376; Egger S, 2010, BIOCHEM SOC T, V38, P1378, DOI 10.1042/BST0381378; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Hu SH, 2013, ELIFE, V2, DOI 10.7554/eLife.00726; Lu PF, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005058; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Medvedeva YA, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-119; Nutt CL, 2001, CANCER RES, V61, P7056; Rath P, 2013, TRANSL ONCOL, V6, P104, DOI 10.1593/tlo.13127; Reznik TE, 2008, MOL CANCER RES, V6, P139, DOI 10.1158/1541-7786.MCR-07-0236; Tilghman J, 2014, CANCER RES, V74, P3168, DOI 10.1158/0008-5472.CAN-13-2103; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Venning FA, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00224; Wade A, 2013, FEBS J, V280, P2399, DOI 10.1111/febs.12109; Wan J, 2017, ELIFE, V6, DOI 10.7554/eLife.20068; Wang SD, 2012, ONCOGENE, V31, P5132, DOI 10.1038/onc.2012.16; Wen YX, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075-014-0484-2; Wiranowska MR, 2011, GLIOMA EXPLORING ITS, P257; Wu YJ, 2012, CANCER SCI, V103, P1028, DOI 10.1111/j.1349-7006.2012.02260.x; Xia SL, 2016, NEURO-ONCOLOGY, V18, P507, DOI 10.1093/neuonc/nov171; Ying MY, 2014, J BIOL CHEM, V289, DOI 10.1074/jbc.M114.588988; Yu F, 2011, ONCOGENE, V30, P2161, DOI 10.1038/onc.2010.591	28	23	24	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	20					2615	2629		10.1038/s41388-018-0138-y	http://dx.doi.org/10.1038/s41388-018-0138-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG2TH	29479058	Green Accepted, Green Submitted			2022-12-17	WOS:000432545100001
J	Zhang, YH; Wester, L; He, JC; Geiger, T; Moerkens, M; Siddappa, R; Helmijr, JA; Timmermans, MM; Look, MP; van Deurzen, CHM; Martens, JWM; Pont, C; de Graauw, M; Danen, EHJ; Berns, EMJJ; Meerman, JHN; Jansen, MPHM; van de Water, B				Zhang, Yinghui; Wester, Lynn; He, Jichao; Geiger, Tamar; Moerkens, Marja; Siddappa, Ram; Helmijr, Jean A.; Timmermans, Mieke M.; Look, Maxime P.; van Deurzen, Caroline H. M.; Martens, John W. M.; Pont, Chantal; de Graauw, Marjo; Danen, Erik H. J.; Berns, Els M. J. J.; Meerman, John H. N.; Jansen, Maurice P. H. M.; van de Water, Bob			IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer	ONCOGENE			English	Article							TAMOXIFEN RESISTANCE; P21-ACTIVATED-KINASE-1 PAK1; ENDOCRINE RESISTANCE; CELL-PROLIFERATION; NEURITE OUTGROWTH; GROWTH-FACTORS; BETA-CATENIN; I RECEPTOR; EXPRESSION; PATHWAY	Antiestrogen resistance in estrogen receptor positive (ER+) breast cancer is associated with increased expression and activity of insulin-like growth factor 1 receptor (IGF1R). Here, a kinome siRNA screen has identified 10 regulators of IGF1R-mediated antiestrogen with clinical significance. These include the tamoxifen resistance suppressors BMPR1B, CDK10, CDK5, EIF2AK1, and MAP2K5, and the tamoxifen resistance inducers CHEK1, PAK2, RPS6KC1, TTK, and TXK. The p21-activated kinase 2, PAK2, is the strongest resistance inducer. Silencing of the tamoxifen resistance inducing genes, particularly PAK2, attenuates IGF1R-mediated resistance to tamoxifen and fulvestrant. High expression of PAK2 in ER+ metastatic breast cancer patients is correlated with unfavorable outcome after first-line tamoxifen monotherapy. Phospho-proteomics has defined PAK2 and the PAK-interacting exchange factors PIX alpha/beta as downstream targets of IGF1R signaling, which are independent from PI3K/ATK and MAPK/ERK pathways. PAK2 and PIX alpha/beta modulate IGF1R signaling-driven cell scattering. Targeting PIX alpha/beta entirely mimics the effect of PAK2 silencing on antiestrogen re-sensitization. These data indicate PAK2/PIX as an effector pathway in IGF1R-mediated antiestrogen resistance.	[Zhang, Yinghui; Wester, Lynn; He, Jichao; Moerkens, Marja; Siddappa, Ram; Pont, Chantal; de Graauw, Marjo; Danen, Erik H. J.; Meerman, John H. N.; van de Water, Bob] Leiden Univ, Leiden Acad Ctr Drug Res, Div Toxicol, Leiden, Netherlands; [Geiger, Tamar] Tel Aviv Univ, Dept Human Mol Genet & Biochem, Sackler Fac Med, Tel Aviv, Israel; [Helmijr, Jean A.; Timmermans, Mieke M.; Look, Maxime P.; van Deurzen, Caroline H. M.; Martens, John W. M.; Berns, Els M. J. J.; Jansen, Maurice P. H. M.] Dept Med Oncol & Canc Genom Netherlands, Rotterdam, Netherlands; [van Deurzen, Caroline H. M.] Erasmus Univ, Erasmus MC Canc Inst, Dept Pathol, Med Ctr, Rotterdam, Netherlands	Leiden University; Leiden University - Excl LUMC; Tel Aviv University; Sackler Faculty of Medicine; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	Zhang, YH; van de Water, B (corresponding author), Leiden Univ, Leiden Acad Ctr Drug Res, Div Toxicol, Leiden, Netherlands.	y.zhang@lacdr.leidenuniv.nl; b.water@lacdr.leidenuniv.nl	jansen, maurice/E-9927-2013	Geiger, Tamar/0000-0002-9526-197X; danen, erik/0000-0002-0491-6345; Zhang, Yinghui/0000-0003-1635-0278	Top Institute Pharma (Leiden, The Netherlands) [T3-107]; Dutch Cancer Society [UL-2011-5124]	Top Institute Pharma (Leiden, The Netherlands)(Netherlands Government); Dutch Cancer Society(KWF Kankerbestrijding)	This study was supported by the research project of Top Institute Pharma (Leiden, The Netherlands) "Nuclear Receptors in Targeted Cancer Therapy" (T3-107) and the research project of Dutch Cancer Society "Novel Protein Kinase Targets in Receptor Tyrosine Kinase-mediated Drug Resistant Breast Cancer" (UL-2011-5124).	Arias-Romero LE, 2013, CANCER RES, V73, P3671, DOI 10.1158/0008-5472.CAN-12-4453; Arnaldez FI, 2012, HEMATOL ONCOL CLIN N, V26, P527, DOI 10.1016/j.hoc.2012.01.004; Beeser A, 2005, J BIOL CHEM, V280, P36609, DOI 10.1074/jbc.M502306200; Birmingham A, 2009, NAT METHODS, V6, P569, DOI 10.1038/nmeth.1351; Cleator SJ, 2009, CLIN BREAST CANCER, V9, pS6, DOI 10.3816/CBC.2009.s.001; Feng QY, 2010, J BIOL CHEM, V285, P18806, DOI 10.1074/jbc.M109.098079; Fox EM, 2011, CANCER RES, V71, P6773, DOI 10.1158/0008-5472.CAN-11-1295; Frank SR, 2012, CURR BIOL, V22, P1747, DOI 10.1016/j.cub.2012.07.011; Gao CC, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-55; Gonzalez-Malerva L, 2011, P NATL ACAD SCI USA, V108, P2058, DOI 10.1073/pnas.1018157108; Heskamp S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117745; Holm C, 2006, JNCI-J NATL CANCER I, V98, P671, DOI 10.1093/jnci/djj185; Hsu RM, 2010, MOL BIOL CELL, V21, P287, DOI 10.1091/mbc.E09-03-0232; Iorns E, 2008, CANCER CELL, V13, P91, DOI 10.1016/j.ccr.2008.01.001; JAIYESIMI IA, 1995, J CLIN ONCOL, V13, P513, DOI 10.1200/JCO.1995.13.2.513; Jansen MPHM, 2005, J CLIN ONCOL, V23, P732, DOI 10.1200/JCO.2005.05.145; Jin K, 2015, CANCER DISCOV, V5, P944, DOI 10.1158/2159-8290.CD-15-0090; Jin K, 2012, P NATL ACAD SCI USA, V109, P2736, DOI 10.1073/pnas.1018859108; Kok M, 2011, BREAST CANCER RES TR, V125, P1, DOI 10.1007/s10549-010-0798-y; Kok M, 2009, BREAST CANCER RES TR, V113, P275, DOI 10.1007/s10549-008-9939-y; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Lacombe J, 2014, CANCER EPIDEM BIOMAR, V23, P1834, DOI 10.1158/1055-9965.EPI-14-0267; Law JH, 2008, CANCER RES, V68, P10238, DOI 10.1158/0008-5472.CAN-08-2755; Luey BC, 2016, MOL CANCER, V15, DOI 10.1186/s12943-015-0482-2; Lundgren K, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2150; Macek B, 2009, ANNU REV PHARMACOL, V49, P199, DOI 10.1146/annurev.pharmtox.011008.145606; Mann M, 2006, NAT REV MOL CELL BIO, V7, P952, DOI 10.1038/nrm2067; McShane LM, 2006, BREAST CANCER RES TR, V100, P229, DOI 10.1007/s10549-006-9242-8; Mendes-Pereira AM, 2012, P NATL ACAD SCI USA, V109, P2730, DOI 10.1073/pnas.1018872108; Meng SD, 2004, P NATL ACAD SCI USA, V101, P9393, DOI 10.1073/pnas.0402993101; Menges CW, 2012, MOL CANCER RES, V10, P1178, DOI 10.1158/1541-7786.MCR-12-0082; Moerkens M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-283; Molli PR, 2009, ONCOGENE, V28, P2545, DOI 10.1038/onc.2009.119; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nheu T, 2004, CELL CYCLE, V3, P71; Ong CC, 2011, P NATL ACAD SCI USA, V108, P7177, DOI 10.1073/pnas.1103350108; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; OSBORNE CK, 1980, CANCER-AM CANCER SOC, V46, P2884, DOI 10.1002/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U; Padala RR, 2017, MOL BIOSYST, V13, P830, DOI 10.1039/c6mb00786d; Puigvert JC, 2010, CURRENT PROTOCOLS CE; Puto LA, 2003, J BIOL CHEM, V278, P9388, DOI 10.1074/jbc.M208414200; Radu M, 2014, NAT REV CANCER, V14, P13, DOI 10.1038/nrc3645; Reijm EA, 2014, ANN ONCOL, V25, P2185, DOI 10.1093/annonc/mdu391; Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776; Sachdev D, 2008, J MAMMARY GLAND BIOL, V13, P431, DOI 10.1007/s10911-008-9105-5; Santiago-Medina M, 2013, J CELL SCI, V126, P1122, DOI 10.1242/jcs.112607; Shin EY, 2002, J BIOL CHEM, V277, P44417, DOI 10.1074/jbc.M203754200; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Tabusa H, 2013, MOL CANCER RES, V11, P109, DOI 10.1158/1541-7786.MCR-12-0466; Vadlakondalf L, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00085; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wang Z, 2010, ONCOGENE, V29, P3362, DOI 10.1038/onc.2010.95; Wang ZP, 2013, J BIOL CHEM, V288, P20093, DOI 10.1074/jbc.M112.426023; Werner Haim, 2009, Archives of Physiology and Biochemistry, V115, P58, DOI 10.1080/13813450902783106; Williams N, 2008, LANCET ONCOL, V9, P45, DOI 10.1016/S1470-2045(07)70385-6; Winder T, 2014, PHARMACOGENOMICS J, V14, P28, DOI 10.1038/tpj.2013.8; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/nmeth.1322, 10.1038/NMETH.1322]; Ye P, 2010, GLIA, V58, P1031, DOI 10.1002/glia.20984; Zhang YH, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2883; Zhou L, 2011, NEOPLASIA, V13, P1101, DOI 10.1593/neo.111060	60	23	27	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	14					1869	1884		10.1038/s41388-017-0027-9	http://dx.doi.org/10.1038/s41388-017-0027-9			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GB8CU	29353882	Green Published			2022-12-17	WOS:000429303300005
J	Liu, GH; Feng, S; Jia, L; Wang, CY; Fu, Y; Luo, YZ				Liu, Guanghua; Feng, Shi; Jia, Lin; Wang, Chunying; Fu, Yan; Luo, Yongzhang			Lung fibroblasts promote metastatic colonization through upregulation of stearoyl-CoA desaturase 1 in tumor cells	ONCOGENE			English	Article							CATHEPSIN-B; CYSTEINE CATHEPSINS; THERAPEUTIC TARGET; CANCER-CELLS; PROGRESSION; PROLIFERATION; SURVIVAL; NETWORK; MTOR; LIPOGENESIS	As a rate-limiting step in metastasis, metastatic colonization requires survival signals from supportive stroma. However, the mechanisms driving this process are incompletely understood. Here, we showed that the proliferation of B16F10 cells was promoted when cocultured with lung fibroblasts. Meanwhile, co-injection of B16F10 tumor cells with mouse lung fibroblasts significantly increased lung metastasis. Based on GEO database, we identified stearoyl-CoA desaturase 1 (SCD1) as a novel factor promoting metastatic colonization. Importantly, we found that fibroblast-secreted cathepsin B (CTSB) induced the upregulation of SCD1 in B16F10 through Annexin A2 (ANXA2) and PI3K/Akt/mTOR pathway. The elevated SCD1 induced a higher ratio of monounsaturated fatty acids to saturated fatty acids in B16F10 cells. The changes in fatty acid composition contributed to tumor cell proliferation and metastatic colonization. Furthermore, targeting SCD1 effectively inhibited lung metastasis and prolonged the overall survival of mice. Meanwhile, the expression of SCD1 was negatively correlated with disease-free survival in five types of cancer patients. Collectively, our study identifies SCD1 as a critical modulator of tumor cell proliferation that is activated by cathepsin B, secreted by lung fibroblasts at the metastatic niche. Our novel findings provide potential therapeutic targets to prevent tumor metastasis.	[Liu, Guanghua; Feng, Shi; Jia, Lin; Wang, Chunying; Fu, Yan; Luo, Yongzhang] Tsinghua Univ, Natl Engn Lab Antitumor Prot Therapeut, Beijing, Peoples R China; [Liu, Guanghua; Feng, Shi; Jia, Lin; Wang, Chunying; Fu, Yan; Luo, Yongzhang] Tsinghua Univ, Beijing Key Lab Prot Therapeut, Beijing, Peoples R China; [Liu, Guanghua; Feng, Shi; Jia, Lin; Wang, Chunying; Fu, Yan; Luo, Yongzhang] Tsinghua Univ, Sch Life Sci, Canc Biol Lab, Beijing, Peoples R China	Tsinghua University; Tsinghua University; Tsinghua University	Luo, YZ (corresponding author), Tsinghua Univ, Natl Engn Lab Antitumor Prot Therapeut, Beijing, Peoples R China.; Luo, YZ (corresponding author), Tsinghua Univ, Beijing Key Lab Prot Therapeut, Beijing, Peoples R China.; Luo, YZ (corresponding author), Tsinghua Univ, Sch Life Sci, Canc Biol Lab, Beijing, Peoples R China.	yluo@mail.tsinghua.edu.cn			General Programs of the National Natural Science Foundation of China [81672865, 81472667, 81461148021, 81272529]; Major Scientific and Technological Special Project for "significant new drugs creation" [2013ZX09509103]	General Programs of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Major Scientific and Technological Special Project for "significant new drugs creation"	This work was supported in part by the General Programs of the National Natural Science Foundation of China (Nos. 81672865, 81472667, 81461148021, and 81272529) and the Major Scientific and Technological Special Project for "significant new drugs creation" (No. 2013ZX09509103).	AbuAli G, 2015, ONCOGENE, V34, P1718, DOI 10.1038/onc.2014.93; Aggarwal N, 2014, PROTEOM CLIN APPL, V8, P427, DOI 10.1002/prca.201300105; Atilla-Gokcumen GE, 2014, CELL, V156, P428, DOI 10.1016/j.cell.2013.12.015; Bansal S, 2014, J SURG RES, V186, P29, DOI 10.1016/j.jss.2013.07.001; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen Q, 2011, CANCER CELL, V20, P538, DOI 10.1016/j.ccr.2011.08.025; Chen Y, 2015, INT J CANCER, V136, P182, DOI 10.1002/ijc.28950; Du XN, 2012, CANCER RES, V72, P5843, DOI 10.1158/0008-5472.CAN-12-1329; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Fellmann C, 2013, CELL REP, V5, P1704, DOI 10.1016/j.celrep.2013.11.020; Fritz V, 2010, MOL CANCER THER, V9, P1740, DOI 10.1158/1535-7163.MCT-09-1064; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Hagiwara A, 2012, CELL METAB, V15, P725, DOI 10.1016/j.cmet.2012.03.015; Harbeck N, 2001, CLIN CANCER RES, V7, P2757; Huang GM, 2015, CANCER LETT, V358, P180, DOI 10.1016/j.canlet.2014.12.036; Huang J, 2016, ONCOTARGET, V7, P39970, DOI 10.18632/oncotarget.9461; Huang YJ, 2009, CANCER RES, V69, P7529, DOI 10.1158/0008-5472.CAN-08-4382; Igal RA, 2016, BBA-MOL CELL BIOL L, V1861, P1865, DOI 10.1016/j.bbalip.2016.09.009; Igal RA, 2010, CARCINOGENESIS, V31, P1509, DOI 10.1093/carcin/bgq131; Jedeszko C, 2004, BIOL CHEM, V385, P1017, DOI 10.1515/BC.2004.132; Jia L, 2017, J PATHOL, V243, P255, DOI 10.1002/path.4952; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kamphorst JJ, 2013, P NATL ACAD SCI USA, V110, P8882, DOI 10.1073/pnas.1307237110; Kim M, 2010, ANTIVIR THER, V15, P897, DOI 10.3851/IMP1646; Lewis CA, 2015, ONCOGENE, V34, P5128, DOI 10.1038/onc.2014.439; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; Liu GH, 2015, J PATHOL, V237, P190, DOI 10.1002/path.4564; Luyimbazi D, 2010, MOL CANCER THER, V9, P2770, DOI 10.1158/1535-7163.MCT-09-0980; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; Miranda F, 2016, CANCER CELL, V30, P273, DOI 10.1016/j.ccell.2016.06.020; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Nodomi S, 2016, ONCOGENE, V35, P5317, DOI 10.1038/onc.2016.72; Noto A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.444; Oberle C, 2010, CELL DEATH DIFFER, V17, P1167, DOI 10.1038/cdd.2009.214; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Qi FF, 2015, CLIN CANCER RES, V21, P3071, DOI 10.1158/1078-0432.CCR-14-2785; Qiang L, 2015, CELL REP, V11, P1797, DOI 10.1016/j.celrep.2015.05.025; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ricoult SJH, 2013, EMBO REP, V14, P242, DOI 10.1038/embor.2013.5; Roy D, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-13; Shimobayashi M, 2014, NAT REV MOL CELL BIO, V15, P155, DOI 10.1038/nrm3757; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007; Vasiljeva O, 2008, ONCOGENE, V27, P4191, DOI 10.1038/onc.2008.59; Vasiljeva O, 2006, CANCER RES, V66, P5242, DOI 10.1158/0008-5472.CAN-05-4463; von Roemeling CA, 2013, CLIN CANCER RES, V19, P2368, DOI 10.1158/1078-0432.CCR-12-3249; Wang H, 2015, DIABETES, V64, P2442, DOI 10.2337/db14-0528; Wang JQ, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5692852; Wculek SK, 2015, NATURE, V528, P413, DOI 10.1038/nature16140; Wu JB, 2017, CANCER CELL, V31, P368, DOI 10.1016/j.ccell.2017.02.003; Zhang L, 2016, ONCOGENE, V35, P5641, DOI 10.1038/onc.2016.100	53	23	24	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	11					1519	1533		10.1038/s41388-017-0062-6	http://dx.doi.org/10.1038/s41388-017-0062-6			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ3AZ	29326439				2022-12-17	WOS:000427459500009
J	Peng, F; Wang, JH; Fan, WJ; Meng, YT; Li, MM; Li, TT; Cui, B; Wang, HF; Zhao, Y; An, F; Guo, T; Liu, XF; Zhang, L; Lv, L; Lv, DK; Xu, LZ; Xie, JJ; Lin, WX; Lam, EWF; Xu, J; Liu, Q				Peng, F.; Wang, J-H; Fan, W-J; Meng, Y-T; Li, M-M; Li, T-T; Cui, B.; Wang, H-F; Zhao, Y.; An, F.; Guo, T.; Liu, X-F; Zhang, L.; Lv, L.; Lv, D-K; Xu, L-Z; Xie, J-J; Lin, W-X; Lam, E. W-F; Xu, J.; Liu, Q.			Glycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia (vol 37, pg 1062, 2017)	ONCOGENE			English	Correction													Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576	MRC [MR/N012097/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BBS/B/03785, 1243234] Funding Source: researchfish; Cancer Research UK [12011] Funding Source: researchfish; Medical Research Council [MR/N012097/1] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Peng F, 2018, ONCOGENE, V37, P1062, DOI 10.1038/onc.2017.368	1	23	23	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					1119	1119		10.1038/onc.2017.407	http://dx.doi.org/10.1038/onc.2017.407			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29251717	Green Published, hybrid			2022-12-17	WOS:000425905700014
J	Mitamura, T; Pradeep, S; McGuire, M; Wu, SY; Ma, S; Hatakeyama, H; Lyons, YA; Hisamatsu, T; Noh, K; Villar-Prados, A; Chen, X; Ivan, C; Rodriguez-Aguayo, C; Hu, W; Lopez-Berestein, G; Coleman, RL; Sood, AK				Mitamura, T.; Pradeep, S.; McGuire, M.; Wu, S. Y.; Ma, S.; Hatakeyama, H.; Lyons, Y. A.; Hisamatsu, T.; Noh, K.; Villar-Prados, A.; Chen, X.; Ivan, C.; Rodriguez-Aguayo, C.; Hu, W.; Lopez-Berestein, G.; Coleman, R. L.; Sood, A. K.			Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP)	ONCOGENE			English	Article							OVARIAN-CANCER; BEVACIZUMAB; ANGIOGENESIS; CARCINOMA; PROTEIN; PANOBINOSTAT; UPDATE; GENES; TRIAL; CTCF	Anti-vascular endothelial growth factor (VEGF) therapy has demonstrated efficacy in treating human metastatic cancers, but therapeutic resistance is a practical limitation and most tumors eventually become unresponsive. To identify microenvironmental factors underlying the resistance of cancer to antiangiogenesis therapy, we conducted genomic analyses of intraperitoneal ovarian tumors in which adaptive resistance to anti-VEGF therapy (B20 antibody) developed. We found that expression of the microseminoprotein, prostate-associated (MSMP) gene was substantially upregulated in resistant compared with control tumors. MSMP secretion from cancer cells was induced by hypoxia, triggering MAPK signaling in endothelial cells to promote tube formation in vitro. Recruitment of the transcriptional repressor CCCTC-binding factor (CTCF) to the MSMP enhancer region was decreased by histone acetylation under hypoxic conditions in cancer cells. MSMP siRNA, delivered in vivo using the DOPC nanoliposomes, restored tumor sensitivity to anti-VEGF therapy. In ovarian cancer patients treated with bevacizumab, serum MSMP concentration increased significantly only in non-responders. These findings imply that MSMP inhibition combined with the use of antiangiogenesis drugs may be a new strategy to overcome resistance to antiangiogenesis therapy.	[Mitamura, T.; Pradeep, S.; McGuire, M.; Wu, S. Y.; Ma, S.; Hatakeyama, H.; Lyons, Y. A.; Hisamatsu, T.; Noh, K.; Villar-Prados, A.; Chen, X.; Hu, W.; Coleman, R. L.; Sood, A. K.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA; [Mitamura, T.] Hokkaido Univ, Grad Sch Med, Dept Obstet & Gynecol, Sapporo, Hokkaido, Japan; [Pradeep, S.] Med Coll Wisconsin, Dept Obstet & Gynecol, Milwaukee, WI 53226 USA; [Noh, K.] Korea Res Inst Bioscience & Biotechnol, Gene Therapy Res Unit, Daejeon, South Korea; [Ivan, C.; Rodriguez-Aguayo, C.; Lopez-Berestein, G.; Sood, A. K.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Ivan, C.; Rodriguez-Aguayo, C.; Lopez-Berestein, G.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNAs, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Hokkaido University; Medical College of Wisconsin; Korea Research Institute of Bioscience & Biotechnology (KRIBB); University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Sood, AK (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Unit 1362, 1515 Holcombe Blvd, Houston, TX 77030 USA.	asood@mdanderson.org	Chen, Xiuhui/CAE-9641-2022; Coleman, Robert/E-4346-2019; Hatakeyama, Hiroto/V-9987-2017; Sood, Anoop Kumar/A-7344-2013	Hatakeyama, Hiroto/0000-0003-3899-0508; Sood, Anoop Kumar/0000-0001-5702-4108; RODRIGUEZ-AGUAYO, CRISTIAN/0000-0002-7880-7723; Ivan, Cristina/0000-0002-4848-0168	Foundation for Women's Cancer grant; Ovarian Cancer Research Fund Alliance; Foundation for Women's Cancer; Texas Center for Cancer Nanomedicine; Cancer Prevention and Research Institute of Texas training grants [RP101502, RP101489]; Ovarian Cancer Research Fund Alliance [292015]; KRIBB Research Initiative Program; Uehara Memorial Foundation Research Fellowships for Research Abroad; National Institutes of Health [CA016672, CA109298, P50 CA083639, P50 CA098258, UH3 TR000943]; Ovarian Cancer Research Fund, Inc. (Program Project Development Grant); American Cancer Society Research Professor Award; Blanton-Davis Ovarian Cancer Research Program; RGK Foundation; Frank McGraw Memorial Chair in Cancer Research; NATIONAL CANCER INSTITUTE [R01CA109298, P30CA016672, P50CA083639, P50CA098258] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UH3TR000943] Funding Source: NIH RePORTER	Foundation for Women's Cancer grant; Ovarian Cancer Research Fund Alliance; Foundation for Women's Cancer; Texas Center for Cancer Nanomedicine; Cancer Prevention and Research Institute of Texas training grants; Ovarian Cancer Research Fund Alliance; KRIBB Research Initiative Program; Uehara Memorial Foundation Research Fellowships for Research Abroad; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ovarian Cancer Research Fund, Inc. (Program Project Development Grant); American Cancer Society Research Professor Award(American Cancer Society); Blanton-Davis Ovarian Cancer Research Program; RGK Foundation; Frank McGraw Memorial Chair in Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	SP is supported by a Foundation for Women's Cancer grant and Ovarian Cancer Research Fund Alliance. SW is supported by Ovarian Cancer Research Fund Alliance, Foundation for Women's Cancer, Texas Center for Cancer Nanomedicine, and Cancer Prevention and Research Institute of Texas training grants (RP101502 and RP101489, respectively). KN is supported by the Ovarian Cancer Research Fund Alliance (grant 292015) and KRIBB Research Initiative Program. TH is supported by Uehara Memorial Foundation Research Fellowships for Research Abroad. Portions of this work were supported by the National Institutes of Health grants (CA016672, CA109298, P50 CA083639, P50 CA098258 and UH3 TR000943), Ovarian Cancer Research Fund, Inc. (Program Project Development Grant), American Cancer Society Research Professor Award, Blanton-Davis Ovarian Cancer Research Program, RGK Foundation and the Frank McGraw Memorial Chair in Cancer Research.	BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; BUICK RN, 1985, CANCER RES, V45, P3668; Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390; Drappatz J, 2012, J NEURO-ONCOL, V107, P133, DOI 10.1007/s11060-011-0717-z; Friedman HS, 2009, J CLIN ONCOL, V27, P4733, DOI 10.1200/JCO.2008.19.8721; Ghirlando R, 2016, GENE DEV, V30, P881, DOI 10.1101/gad.277863.116; Hillen F, 2007, CANCER METAST REV, V26, P489, DOI 10.1007/s10555-007-9094-7; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507; Landen CN, 2008, NEOPLASIA, V10, P1259, DOI 10.1593/neo.08740; LAU DHM, 1991, CANCER RES, V51, P5181; Lee EQ, 2015, NEURO-ONCOLOGY, V17, P862, DOI 10.1093/neuonc/nou350; Pei XL, 2014, J IMMUNOL, V192, P1878, DOI 10.4049/jimmunol.1300758; Perren TJ, 2011, NEW ENGL J MED, V365, P2484, DOI 10.1056/NEJMoa1103799; Pujade-Lauraine E, 2014, J CLIN ONCOL, V32, P1302, DOI 10.1200/JCO.2013.51.4489; Rini BI, 2008, J CLIN ONCOL, V26, P5422, DOI 10.1200/JCO.2008.16.9847; Rosenbloom KR, 2015, NUCLEIC ACIDS RES, V43, pD670, DOI 10.1093/nar/gku1177; Rosenbloom KR, 2013, NUCLEIC ACIDS RES, V41, pD56, DOI 10.1093/nar/gks1172; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Strickler JH, 2012, CANCER CHEMOTH PHARM, V70, P251, DOI 10.1007/s00280-012-1911-1; Uhlen M, 2010, NAT BIOTECHNOL, V28, P1248, DOI 10.1038/nbt1210-1248; Valtonen-Andre C, 2007, BIOL CHEM, V388, P289, DOI 10.1515/BC.2007.032; Weth O, 2014, NUCLEIC ACIDS RES, V42, P11941, DOI 10.1093/nar/gku937; Yoneda J, 1998, JNCI-J NATL CANCER I, V90, P447, DOI 10.1093/jnci/90.6.447	25	23	23	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2018	37	6					722	731		10.1038/onc.2017.348	http://dx.doi.org/10.1038/onc.2017.348			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FV5ND	29059175	Green Accepted, Green Submitted			2022-12-17	WOS:000424628100004
J	Chiodelli, P; Rezzola, S; Urbinati, C; Signori, FF; Monti, E; Ronca, R; Presta, M; Rusnati, M				Chiodelli, P.; Rezzola, S.; Urbinati, C.; Signori, F. Federici; Monti, E.; Ronca, R.; Presta, M.; Rusnati, M.			Contribution of vascular endothelial growth factor receptor-2 sialylation to the process of angiogenesis	ONCOGENE			English	Article							CHORIOALLANTOIC MEMBRANE; ALPHA(V)BETA(3) INTEGRIN; LECTIN HISTOCHEMISTRY; CELL ADHESION; SIALIC ACIDS; EXPRESSION; SURFACE; GLYCOSYLATION; ACTIVATION; PROTEOGLYCAN	Vascular endothelial growth factor receptor-2 (VEGFR2) is the main pro-angiogenic receptor expressed by endothelial cells (ECs). Using surface plasmon resonance, immunoprecipitation, enzymatic digestion, immunofluorescence and cross-linking experiments with specific sugar-binding lectins, we demonstrated that VEGFR2 bears both alpha,1-fucose and alpha(2,6)-linked sialic acid (NeuAc). However, only the latter is required for VEGF binding to VEGFR2 and consequent VEGF-dependent VEGFR2 activation and motogenic response in ECs. Notably, downregulation of beta-galactoside alpha(2,6)-sialyltransferase expression by short hairpin RNA transduction inhibits VEGFR2 alpha(2,6) sialylation that is paralleled by an increase of beta-galactoside alpha(2,3)-sialyltransferase expression. This results in an ex-novo alpha(2,3)-NeuAc sialylation of the receptor that functionally replaces the lacking alpha(2,6)-NeuAc, thus allowing VEGF/VEGFR2 interaction. In keeping with the role of VEGFR2 sialylation in angiogenesis, the alpha(2,6)-NeuAc-binding lectin Sambucus nigra (SNA) prevents VEGF-dependent VEGFR2 autophosphorylation and EC motility, proliferation and motogenesis. In addition, SNA exerts a VEGF-antagonist activity in tridimensional angiogenesis models in vitro and in the chick-embryo chorioallantoic membrane neovascularization assay and mouse matrigel plug assay in vivo. In conclusion, VEGFR2-associated NeuAc plays an important role in modulating VEGF/VEGFR2 interaction, EC pro-angiogenic activation and neovessel formation. VEGFR2 sialylation may represent a target for the treatment of angiogenesis-dependent diseases.	[Chiodelli, P.; Rezzola, S.; Urbinati, C.; Signori, F. Federici; Ronca, R.; Presta, M.; Rusnati, M.] Univ Brescia, Unit Expt Oncol, Brescia, Italy; [Chiodelli, P.; Rezzola, S.; Urbinati, C.; Signori, F. Federici; Ronca, R.; Presta, M.; Rusnati, M.] Univ Brescia, Unit Immunol, Brescia, Italy; [Monti, E.] Univ Brescia, Unit Biotechnol, Dept Mol & Translat Med, Brescia, Italy	University of Brescia; University of Brescia; University of Brescia	Chiodelli, P; Rusnati, M (corresponding author), Dept Mol & Translat Med, Expt Oncol & Immunol, Viale Europa 11, I-25123 Brescia, Italy.	paola.chiodelli@unibs.it; marco.rusnati@unibs.it	Rezzola, Sara/AAE-8980-2020; Rezzola, Sara/AAA-2745-2019; Ronca, Roberto/AAC-6470-2022; Rusnati, Marco/F-1168-2010	Rezzola, Sara/0000-0003-1193-8929; Ronca, Roberto/0000-0001-8979-7068; Rusnati, Marco/0000-0001-9968-5908; PRESTA, Marco/0000-0002-4398-8376; Urbinati, Chiara Eva/0000-0002-0138-7871	Ministero dell'Istruzione, Universita e Ricerca (MIUR); Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG 18943, MFAG 18459]; AIRC	Ministero dell'Istruzione, Universita e Ricerca (MIUR)(Ministry of Education, Universities and Research (MIUR)); Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); AIRC(Fondazione AIRC per la ricerca sul cancro)	This work was supported by grant from Ministero dell'Istruzione, Universita e Ricerca (MIUR) (ex 60%) to MR and by IG 18943 and MFAG 18459 grants from Associazione Italiana per la Ricerca sul Cancro (AIRC) to MP and RR, respectively. PC and SR were supported by AIRC Fellowships.	Abe Y, 1999, J IMMUNOL, V163, P2867; Antony P, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-901; BORN GVR, 1985, BRIT J EXP PATHOL, V66, P543; Brambilla A, 2015, INT J BIOCHEM CELL B, V69, P95, DOI 10.1016/j.biocel.2015.10.005; Brozzo MS, 2012, BLOOD, V119, P1781, DOI 10.1182/blood-2011-11-390922; Bugatti A, 2013, J BIOL CHEM, V288, P1150, DOI 10.1074/jbc.M112.400077; Cai J, 2012, EMBO MOL MED, V4, P980, DOI 10.1002/emmm.201101084; Chandler KB, 2017, J PROTEOME RES, V16, P677, DOI 10.1021/acs.jproteome.6b00738; Chen JY, 2011, CANCER RES, V71, P473, DOI 10.1158/0008-5472.CAN-10-1303; Chiodelli P, 2012, J BIOL CHEM, V287, P20456, DOI 10.1074/jbc.M111.337139; Chiodelli P, 2011, ARTERIOSCL THROM VAS, V31, pE116, DOI 10.1161/ATVBAHA.111.235184; Chuang IC, 2015, LIFE SCI, V139, P52, DOI 10.1016/j.lfs.2015.08.002; Cioffi DL, 2012, AM J PHYSIOL-LUNG C, V302, pL1067, DOI 10.1152/ajplung.00190.2011; Claesson-Welsh L, 2013, J INTERN MED, V273, P114, DOI 10.1111/joim.12019; Coltrini D, 2013, ANGIOGENESIS, V16, P469, DOI 10.1007/s10456-012-9324-7; Croci DO, 2014, GLYCOBIOLOGY, V24, P1283, DOI 10.1093/glycob/cwu083; Croci DO, 2014, CELL, V156, P744, DOI 10.1016/j.cell.2014.01.043; DENG X, 2017, SCI REP UK, V7; Doiron AL, 2004, TECH PAPERS ISA, V449, P331; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; Franklin MC, 2011, STRUCTURE, V19, P1097, DOI 10.1016/j.str.2011.01.019; Fuh G, 2000, J BIOL CHEM, V275, P26690; Garcia-Vallejo JJ, 2006, J CELL PHYSIOL, V206, P203, DOI 10.1002/jcp.20458; Cabral MG, 2010, IMMUNOL LETT, V131, P89, DOI 10.1016/j.imlet.2010.02.009; Harduin-Lepers A, 2001, BIOCHIMIE, V83, P727, DOI 10.1016/S0300-9084(01)01301-3; Henry CBS, 1996, TISSUE CELL, V28, P449, DOI 10.1016/S0040-8166(96)80030-9; Hutchings H, 2003, FASEB J, V17, P1520, DOI 10.1096/fj.02-0691fje; Kitazume S, 2014, J BIOL CHEM, V289, P27604, DOI 10.1074/jbc.M114.563585; Koch S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006502; Lauder H, 1998, Angiogenesis, V2, P67, DOI 10.1023/A:1009006527462; Lee C, 2014, J BIOL CHEM, V289, P9121, DOI 10.1074/jbc.M114.555888; Lee JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056211; Leppanen VM, 2010, P NATL ACAD SCI USA, V107, P2425, DOI 10.1073/pnas.0914318107; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Manning JC, 2004, HISTOL HISTOPATHOL, V19, P1043, DOI 10.14670/HH-19.1043; Marino K, 2010, NAT CHEM BIOL, V6, P713, DOI [10.1038/nchembio.437, 10.1038/NCHEMBIO.437]; Markowska AI, 2011, J BIOL CHEM, V286, P29913, DOI 10.1074/jbc.M111.226423; Mitola S, 2008, BLOOD, V112, P1154, DOI 10.1182/blood-2007-09-111450; Miyagawa S, 2010, XENOTRANSPLANTATION, V17, P61, DOI 10.1111/j.1399-3089.2009.00565.x; Monaco L, 1996, CYTOTECHNOLOGY, V22, P197, DOI 10.1007/BF00353939; Nacev BA, 2011, J BIOL CHEM, V286, P44045, DOI 10.1074/jbc.M111.278754; PEVERALI FA, 1994, J CELL PHYSIOL, V161, P1, DOI 10.1002/jcp.1041610102; Presta M, 2005, CYTOKINE GROWTH F R, V16, P159, DOI 10.1016/j.cytogfr.2005.01.004; Rahimi N, 2015, PROTEOMICS, V15, P300, DOI 10.1002/pmic.201400183; Ravelli C, 2013, ANGIOGENESIS, V16, P235, DOI 10.1007/s10456-012-9309-6; Rezzola S, 2013, EXP EYE RES, V112, P51, DOI 10.1016/j.exer.2013.04.014; Ribatti D, 2012, METHODS MOL BIOL, V843, P47, DOI 10.1007/978-1-61779-523-7_5; Roskoski R, 2008, BIOCHEM BIOPH RES CO, V375, P287, DOI 10.1016/j.bbrc.2008.07.121; Safina G, 2012, ANAL CHIM ACTA, V712, P9, DOI 10.1016/j.aca.2011.11.016; Schauer R, 2009, CURR OPIN STRUC BIOL, V19, P507, DOI 10.1016/j.sbi.2009.06.003; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; Stabile H, 2007, BLOOD, V109, P1834, DOI 10.1182/blood-2006-06-032276; TAATJES DJ, 1988, J BIOL CHEM, V263, P6302; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Tao Q, 2001, J BIOL CHEM, V276, P21916, DOI 10.1074/jbc.M100763200; Tatsuzuki A, 2009, ARCH HISTOL CYTOL, V72, P35, DOI 10.1679/aohc.72.35; Urbinati C, 2004, FEBS LETT, V568, P171, DOI 10.1016/j.febslet.2004.05.033; WANG WC, 1988, J BIOL CHEM, V263, P4576; Windwarder M, 2016, GLYCOCONJUGATE J, V33, P387, DOI 10.1007/s10719-015-9602-x	61	23	24	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 23	2017	36	47					6531	6541		10.1038/onc.2017.243	http://dx.doi.org/10.1038/onc.2017.243			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FN5LN	28783175				2022-12-17	WOS:000416049200003
J	Teo, Z; Sng, MK; Chan, JSK; Lim, MMK; Li, Y; Li, L; Phua, T; Lee, JYH; Tan, ZW; Zhu, P; Tan, NS				Teo, Z.; Sng, M. K.; Chan, J. S. K.; Lim, M. M. K.; Li, Y.; Li, L.; Phua, T.; Lee, J. Y. H.; Tan, Z. W.; Zhu, P.; Tan, N. S.			Elevation of adenylate energy charge by angiopoietin-like 4 enhances epithelial-mesenchymal transition by inducing 14-3-3 gamma expression	ONCOGENE			English	Article							TUMOR MICROENVIRONMENT; CANCER; HYPOXIA; METASTASIS; METABOLISM; CADHERIN; ANGPTL4; PROTEIN; GLYCOLYSIS; INTERACTS	Metastatic cancer cells acquire energy-intensive processes including increased invasiveness and chemoresistance. However, how the energy demand is met and the molecular drivers that coordinate an increase in cellular metabolic activity to drive epithelial-mesenchymal transition (EMT), the first step of metastasis, remain unclear. Using different in vitro and in vivo EMT models with clinical patient's samples, we showed that EMT is an energy-demanding process fueled by glucose metabolism-derived adenosine triphosphate (ATP). We identified angiopoietin-like 4 (ANGPTL4) as a key player that coordinates an increase in cellular energy flux crucial for EMT via an ANGPTL4/14-3-3. signaling axis. This augmented cellular metabolic activity enhanced metastasis. ANGPTL4 knockdown suppresses an adenylate energy charge elevation, delaying EMT. Using an in vivo dualinducible EMT model, we found that ANGPTL4 deficiency reduces cancer metastasis to the lung and liver. Unbiased kinase inhibitor screens and Ingenuity Pathway Analysis revealed that ANGPTL4 regulates the expression of 14-3-3. adaptor protein via the phosphatidylinositol-3-kinase/AKT and mitogen-activated protein kinase signaling pathways that culminate to activation of transcription factors, CREB, cFOS and STAT3. Using a different mode of action, as compared with protein kinases, the ANGPTL4/14-3-3. signaling axis consolidated cellular bioenergetics and stabilized critical EMT proteins to coordinate energy demand and enhanced EMT competency and metastasis, through interaction with specific phosphorylation signals on target proteins.	[Teo, Z.; Sng, M. K.; Chan, J. S. K.; Lim, M. M. K.; Li, Y.; Li, L.; Phua, T.; Lee, J. Y. H.; Tan, Z. W.; Zhu, P.; Tan, N. S.] Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore; [Phua, T.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [Tan, N. S.] Nanyang Technol, Lee Kong Chian Sch Med, Singapore, Singapore; [Tan, N. S.] Inst Mol & Cell Biol, Singapore, Singapore; [Tan, N. S.] KK Womens & Childrens Hosp, KK Res Ctr, Singapore, Singapore	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Karolinska Institutet; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); KK Women's & Children's Hospital	Teo, Z; Zhu, P; Tan, NS (corresponding author), Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.	zqteo@ntu.edu.sg; PCZhu@ntu.edu.sg; nstan@ntu.edu.sg	Tan, Nguan Soon/A-2220-2011; Sng, Ming Keat/J-7266-2013	Tan, Nguan Soon/0000-0003-0136-7341; Sng, Ming Keat/0000-0002-5529-4371	Ministry of Education, Singapore [MOE2014-T2-1-012, 2012-T1-001-036]	Ministry of Education, Singapore(Ministry of Education, Singapore)	This work was supported by grants from Ministry of Education, Singapore (MOE2014-T2-1-012 and 2012-T1-001-036).	Allalou A, 2009, COMPUT METH PROG BIO, V94, P58, DOI 10.1016/j.cmpb.2008.08.006; ATKINSON DE, 1967, J BIOL CHEM, V242, P3239; Bridges Dave, 2004, Sci STKE, V2004, pre10, DOI 10.1126/stke.2422004re10; Cai SL, 2006, J CELL BIOL, V173, P279, DOI 10.1083/jcb.200507119; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Chu K, 2013, ONCOTARGET, V4, P446, DOI 10.18632/oncotarget.872; Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112; Dang CV, 1997, J BIOENERG BIOMEMBR, V29, P345, DOI 10.1023/A:1022446730452; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Finger EC, 2010, CANCER METAST REV, V29, P285, DOI 10.1007/s10555-010-9224-5; Goh YY, 2010, AM J PATHOL, V177, P2791, DOI 10.2353/ajpath.2010.100129; Goh YY, 2010, J BIOL CHEM, V285, P32999, DOI 10.1074/jbc.M110.108175; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hou ZY, 2010, CANCER RES, V70, P4385, DOI 10.1158/0008-5472.CAN-10-0070; Hu H, 2016, CELL, V164, P433, DOI 10.1016/j.cell.2015.12.042; Hu K, 2016, ONCOTARGET, V7, P7816, DOI 10.18632/oncotarget.6868; Huang RL, 2011, BLOOD, V118, P3990, DOI 10.1182/blood-2011-01-328716; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Khong TL, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-518; Klymkowsky MW, 2009, AM J PATHOL, V174, P1588, DOI 10.2353/ajpath.2009.080545; Li H, 2011, HEPATOLOGY, V54, P910, DOI 10.1002/hep.24479; Liang JY, 2013, CANCER RES, V73, P2929, DOI 10.1158/0008-5472.CAN-12-3876; LIVE TR, 1975, J BIOL CHEM, V250, P1786; Lunt SJ, 2009, CLIN EXP METASTAS, V26, P19, DOI 10.1007/s10585-008-9182-2; Mak BC, 2004, CANCER INVEST, V22, P588, DOI 10.1081/CNV-200027144; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Montagner A, 2014, EMBO MOL MED, V6, P80, DOI 10.1002/emmm.201302666; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; RIDGE JW, 1972, BIOCHEM J, V127, P351, DOI 10.1042/bj1270351; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Schito L, 2017, BBA-REV CANCER, V1868, P239, DOI 10.1016/j.bbcan.2017.05.004; Shiraishi T, 2015, ONCOTARGET, V6, P130, DOI 10.18632/oncotarget.2766; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Sousa B, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-734; Steeg PS, 2008, NAT CLIN PRACT ONCOL, V5, P206, DOI 10.1038/ncponc1066; Tan MJ, 2012, MOL CANCER RES, V10, P677, DOI 10.1158/1541-7786.MCR-11-0519; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tinti M, 2014, DATABASE-OXFORD, DOI 10.1093/database/bat085; Tsai YP, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-102; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Yang NC, 2002, ANAL BIOCHEM, V306, P323, DOI 10.1006/abio.2002.5698; Yeung YG, 2009, ANAL BIOCHEM, V389, P89, DOI 10.1016/j.ab.2009.03.017; Zadra G, 2015, MOL CANCER RES, V13, P1059, DOI 10.1158/1541-7786.MCR-15-0068; Zhang H, 2012, ONCOGENE, V31, P1757, DOI 10.1038/onc.2011.365; Zhu PC, 2012, BIOSCIENCE REP, V32, P211, DOI 10.1042/BSR20110102; Zhu PC, 2011, CANCER CELL, V19, P401, DOI 10.1016/j.ccr.2011.01.018; Zhu XM, 2016, LUNG, V194, P637, DOI 10.1007/s00408-016-9895-y	48	23	24	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6408	6419		10.1038/onc.2017.244	http://dx.doi.org/10.1038/onc.2017.244			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28745316	Green Published, hybrid			2022-12-17	WOS:000415622900005
J	Suleymanova, N; Crudden, C; Shibano, T; Worrall, C; Oprea, I; Tica, A; Calin, GA; Girnita, A; Girnita, L				Suleymanova, N.; Crudden, C.; Shibano, T.; Worrall, C.; Oprea, I.; Tica, A.; Calin, G. A.; Girnita, A.; Girnita, L.			Functional antagonism of beta-arrestin isoforms balance IGF-1R expression and signalling with distinct cancer-related biological outcomes	ONCOGENE			English	Article							FACTOR-I RECEPTOR; PROTEIN-COUPLED RECEPTOR; CLATHRIN-MEDIATED ENDOCYTOSIS; GROWTH-FACTOR RECEPTOR; BIASED AGONISM; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; 7-TRANSMEMBRANE RECEPTORS; G(BETA-GAMMA) SUBUNITS; PICROPODOPHYLLIN PPP; ADRENERGIC-RECEPTOR	With very similar 3D structures, the widely expressed beta-arrestin isoforms 1 and 2 play at times identical, distinct or even opposing roles in regulating various aspects of G protein-coupled receptors (GPCR) expression and signalling. Recent evidence recognizes the beta-arrestin system as a key regulator of not only GPCRs, but also receptor tyrosine kinases, including the highly cancer relevant insulin-like growth factor type 1 receptor (IGF-1R). Binding of beta-arrestin1 to IGF-1R leads to ligand-dependent degradation of the receptor and generates additional MAPK/ERK signalling, protecting cancer cells against anti-IGF-1R therapy. Because the interplay between beta-arrestin isoforms governs the biological effects for most GPCRs, as yet unexplored for the IGF-1R, we sought to investigate specifically the regulatory roles of the beta-arrestin2 isoform on expression and function of the IGF-1R. Results from controlled expression of either beta-arrestin isoform demonstrate that beta-arrestin2 acts in an opposite manner to beta-arrestin1 by promoting degradation of an unstimulated IGF-1R, but protecting the receptor against agonist-induced degradation. Although both isoforms co-immunoprecipitate with IGF-1R, the ligand-occupied receptor has greater affinity for beta-arrestin1; this association lasts longer, sustains MAPK/ERK signalling and mitigates p53 activation. Conversely, beta-arrestin2 has greater affinity for the ligand-unoccupied receptor; this interaction is transient, triggers receptor ubiquitination and degradation without signalling activation, and leads to a lack of responsiveness to IGF-1, cell cycle arrest and decreased viability of cancer cells. This study reveals contrasting abilities of IGF-1R to interact with each beta-arrestin isoform, depending on the presence of the ligand and demonstrates the antagonism between the two beta-arrestin isoforms in controlling IGF-1R expression and function, which could be developed into a practical anti-IGF-1R strategy for cancer therapy.	[Suleymanova, N.; Crudden, C.; Shibano, T.; Worrall, C.; Oprea, I.; Girnita, A.; Girnita, L.] Karolinska Inst, Canc Ctr Karolinska, Dept Oncol & Pathol, S-17176 Stockholm, Sweden; [Suleymanova, N.; Crudden, C.; Shibano, T.; Worrall, C.; Oprea, I.; Girnita, A.; Girnita, L.] Karolinska Univ Hosp, S-17176 Stockholm, Sweden; [Tica, A.] Univ Med & Pharm Craiova, Dept Pharmacol, Craiova, Romania; [Calin, G. A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Calin, G. A.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNAs, Houston, TX 77030 USA; [Girnita, A.] Karolinska Univ Hosp, Dermatol Dept, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; University of Medicine & Pharmacy of Craiova; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Karolinska Institutet; Karolinska University Hospital	Girnita, L (corresponding author), Karolinska Inst, Canc Ctr Karolinska, Dept Oncol & Pathol, S-17176 Stockholm, Sweden.; Girnita, L (corresponding author), Karolinska Univ Hosp, S-17176 Stockholm, Sweden.	Leonard.Girnita@ki.se	Crudden, Caitrin/Q-5172-2018; Calin, George/E-9390-2011; TICA, ANDREI/AAK-8573-2020; 柴野, 卓志/AHB-7015-2022; Girnita, Leonard/A-4168-2008; Girnita, Ada/AAC-4518-2020	Crudden, Caitrin/0000-0002-7786-112X; Girnita, Leonard/0000-0003-0280-9500; Calin, George/0000-0001-6704-5615; TICA, ANDREI ADRIAN/0000-0002-3821-4018; Calin, George/0000-0002-7427-0578	Swedish Research Council; Swedish Cancer Society; Swedish Childhood Cancer Foundation; Crown Princess Margareta's Foundation for the Visually Impaired; Welander Finsen Foundation; King Gustaf V Jubilee Foundation; Stockholm Cancer Society, Stockholm County; Karolinska Institute; NATIONAL CANCER INSTITUTE [R01CA182905] Funding Source: NIH RePORTER	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Swedish Childhood Cancer Foundation(European Commission); Crown Princess Margareta's Foundation for the Visually Impaired; Welander Finsen Foundation; King Gustaf V Jubilee Foundation; Stockholm Cancer Society, Stockholm County; Karolinska Institute(Karolinska Institutet); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Robert J Lefkowitz and Dr Renato Baserga for generously providing reagents and cell lines. Research support was received from the Swedish Research Council, Swedish Cancer Society, The Swedish Childhood Cancer Foundation, Crown Princess Margareta's Foundation for the Visually Impaired, Welander Finsen Foundation, King Gustaf V Jubilee Foundation, Stockholm Cancer Society, Stockholm County and Karolinska Institute.	Ahn S, 2004, J BIOL CHEM, V279, P7807, DOI 10.1074/jbc.C300443200; BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Boularan C, 2007, P NATL ACAD SCI USA, V104, P18061, DOI 10.1073/pnas.0705550104; Bowen-Pidgeon D, 2001, MOL PHARMACOL, V59, P1395, DOI 10.1124/mol.59.6.1395; CASTRO J, 1993, CYTOMETRY, V14, P793, DOI 10.1002/cyto.990140712; Conner DA, 1997, CIRC RES, V81, P1021; Crudden C, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00064; Crudden C, 2015, GROWTH HORM IGF RES, V25, P2, DOI 10.1016/j.ghir.2014.10.002; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749; Economou MA, 2008, INVEST OPHTH VIS SCI, V49, P2620, DOI 10.1167/iovs.07-0742; Economou MA, 2008, INVEST OPHTH VIS SCI, V49, P2337, DOI 10.1167/iovs.07-0819; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Girnita A, 2012, ONCOGENE, V31, P352, DOI 10.1038/onc.2011.239; Girnita L, 2000, CANCER RES, V60, P5278; Girnita L, 2016, PROG MOL BIOL TRANSL, V141, P277, DOI 10.1016/bs.pmbts.2016.04.001; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Girnita L, 2005, J BIOL CHEM, V280, P24412, DOI 10.1074/jbc.M501129200; Girnita L, 2007, J BIOL CHEM, V282, P11329, DOI 10.1074/jbc.M611526200; Girnita L, 2014, CELL MOL LIFE SCI, V71, P2403, DOI 10.1007/s00018-013-1514-y; Gurevich VV, 2013, PROG MOL BIOL TRANSL, V118, P57, DOI 10.1016/B978-0-12-394440-5.00003-6; Hallak H, 2000, J BIOL CHEM, V275, P2255, DOI 10.1074/jbc.275.4.2255; Hara MR, 2013, CELL CYCLE, V12, P219, DOI 10.4161/cc.23368; Hara MR, 2011, NATURE, V477, P349, DOI 10.1038/nature10368; Hongo A, 1996, ONCOGENE, V12, P1231; Hoshino R, 2001, J BIOL CHEM, V276, P2686, DOI 10.1074/jbc.M006132200; Hupfeld CJ, 2007, ANNU REV PHYSIOL, V69, P561, DOI 10.1146/annurev.physiol.69.022405.154626; Ibrahim IAAEH, 2012, J PHARMACOL SCI, V118, P408, DOI 10.1254/jphs.11R10CP; Kim J, 2005, P NATL ACAD SCI USA, V102, P1442, DOI 10.1073/pnas.0409532102; Larsson O, 2005, BRIT J CANCER, V92, P2097, DOI 10.1038/sj.bjc.6602627; Lee MH, 2008, J BIOL CHEM, V283, P2088, DOI 10.1074/jbc.M706892200; Lefkowitz RJ, 2013, PROG MOL BIOL TRANSL, V118, P3, DOI 10.1016/B978-0-12-394440-5.00001-2; Lefkowitz RJ, 2006, MOL CELL, V24, P643, DOI 10.1016/j.molcel.2006.11.007; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Park JY, 2016, ARCH PHARM RES, V39, P293, DOI 10.1007/s12272-016-0712-1; Povsic TJ, 2003, J BIOL CHEM, V278, P51334, DOI 10.1074/jbc.M309968200; Reiter E, 2012, ANNU REV PHARMACOL, V52, P179, DOI 10.1146/annurev.pharmtox.010909.105800; Ren XR, 2005, P NATL ACAD SCI USA, V102, P1448, DOI 10.1073/pnas.0409534102; Sanni SJ, 2010, BRIT J PHARMACOL, V161, P150, DOI 10.1111/j.1476-5381.2010.00875.x; Sehat B, 2008, CANCER RES, V68, P5669, DOI 10.1158/0008-5472.CAN-07-6364; Sehat B, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000340; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Shenoy Sudha K, 2005, Sci STKE, V2005, pcm10, DOI 10.1126/stke.2005/308/cm10; Shenoy SK, 2011, TRENDS PHARMACOL SCI, V32, P521, DOI 10.1016/j.tips.2011.05.002; Shukla AK, 2014, NATURE, V512, P218, DOI 10.1038/nature13430; Shukla AK, 2013, NATURE, V497, P137, DOI 10.1038/nature12120; Srivastava A, 2015, TRENDS ENDOCRIN MET, V26, P628, DOI 10.1016/j.tem.2015.09.001; Vasilcanu D, 2006, ONCOGENE, V25, P3186, DOI 10.1038/sj.onc.1209339; Vasilcanu R, 2008, MOL PHARMACOL, V73, P930, DOI 10.1124/mol.107.040014; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100; Whalen EJ, 2011, TRENDS MOL MED, V17, P126, DOI 10.1016/j.molmed.2010.11.004; Wisler JW, 2014, CURR OPIN CELL BIOL, V27, P18, DOI 10.1016/j.ceb.2013.10.008; Worrall C, 2017, ONCOGENE, V36, P3274, DOI 10.1038/onc.2016.472; Zhang MF, 2010, DEV BIOL, V339, P407, DOI 10.1016/j.ydbio.2009.12.042; Zheng HY, 2012, P NATL ACAD SCI USA, V109, P20620, DOI 10.1073/pnas.1216348110; Zheng HY, 2012, P NATL ACAD SCI USA, V109, P7055, DOI 10.1073/pnas.1118359109; Zwang YR, 2011, MOL CELL, V42, P524, DOI 10.1016/j.molcel.2011.04.017	70	23	23	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2017	36	41					5734	5744		10.1038/onc.2017.179	http://dx.doi.org/10.1038/onc.2017.179			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FJ6DJ	28581517	Green Published, hybrid			2022-12-17	WOS:000412843900007
J	Semenova, G; Stepanova, DS; Dubyk, C; Handorf, E; Deyev, SM; Lazar, AJ; Chernoff, J				Semenova, G.; Stepanova, D. S.; Dubyk, C.; Handorf, E.; Deyev, S. M.; Lazar, A. J.; Chernoff, J.			Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis	ONCOGENE			English	Article							SCHWANN-CELL TRANSFORMATION; NEUROFIBROMATOSIS TYPE-1; SIGNALING PATHWAY; PAK1 INHIBITOR; MEK INHIBITOR; BETA-CATENIN; ACTIVATION; CANCER; MAPK; TUMORIGENESIS	Malignant peripheral nerve sheath tumors (MPNSTs) are devastating sarcomas for which no effective medical therapies are available. Over 50% of MPSNTs are associated with mutations in NF1 tumor suppressor gene, resulting in activation of Ras and its effectors, including the Raf/Mek/Erk and PI3K/Akt/mTORC1 signaling cascades, and also the WNT/beta-catenin pathway. As Group I p21-activated kinases (Group I Paks, PAK1/2/3) have been shown to modulate Ras-driven oncogenesis, we asked if these enzymes might regulate signaling in MPNSTs. In this study we found a strong positive correlation between the activity of PAK1/2/3 and the stage of human MPNSTs. We determined that reducing Group I Pak activity diminished MPNST cell proliferation and motility, and that these effects were not accompanied by significant blockade of the Raf/Mek/Erk pathway, but rather by reductions in Akt and beta-catenin activity. Using the small molecule PAK1/2/3 inhibitor Frax1036 and the MEK1/2 inhibitor PD0325901, we showed that the combination of these two agents synergistically inhibited MPNST cell growth in vitro and dramatically decreased local and metastatic MPNST growth in animal models. Taken together, these data provide new insights into MPNST signaling deregulation and suggest that co-targeting of PAK1/2/3 and MEK1/2 may be effective in the treatment of patients with MPNSTs.	[Semenova, G.; Deyev, S. M.] Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow, Russia; [Semenova, G.; Stepanova, D. S.; Chernoff, J.] Fox Chase Canc Ctr, Canc Biol Program, 333 Cottman Ave W451, Philadelphia, PA 19111 USA; [Stepanova, D. S.] Russian Natl Res Med Univ, Moscow, Russia; [Dubyk, C.] Fox Chase Canc Ctr, Biosample Repository, 333 Cottman Ave W451, Philadelphia, PA 19111 USA; [Handorf, E.] Fox Chase Canc Ctr, Biostat & Bioinformat, 333 Cottman Ave W451, Philadelphia, PA 19111 USA; [Deyev, S. M.] Natl Res Tomsk Polytech Univ, Tomsk, Russia; [Lazar, A. J.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Fox Chase Cancer Center; Pirogov Russian National Research Medical University; Fox Chase Cancer Center; Fox Chase Cancer Center; Tomsk Polytechnic University; University of Texas System; UTMD Anderson Cancer Center	Chernoff, J (corresponding author), Fox Chase Canc Ctr, Canc Biol Program, 333 Cottman Ave W451, Philadelphia, PA 19111 USA.	Jonathan.Chernoff@fccc.edu	Chernoff, Jonathan/I-7631-2014; Stepanova, Dina/T-3999-2019; Lazar, Alexander J/A-3416-2008; Deyev, Sergey/F-8191-2014	Chernoff, Jonathan/0000-0002-4803-7836; Lazar, Alexander J/0000-0002-6395-4499; Stepanova, Dina/0000-0001-6138-8502; Deyev, Sergey/0000-0002-3952-0631	NIH [RO1 CA142928]; Children's Tumor Foundation [2011-15-012]; NIH CORE Grant [P30 CA006927]; RSF grant [14-24-00106]; state of Pennsylvania; Russian Science Foundation [17-24-00006] Funding Source: Russian Science Foundation; NATIONAL CANCER INSTITUTE [R01CA142928, P30CA006927] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Tumor Foundation; NIH CORE Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); RSF grant(Russian Science Foundation (RSF)); state of Pennsylvania; Russian Science Foundation(Russian Science Foundation (RSF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Timothy Cripe and Nancy Ratner for providing MPNST cell lines, Ahmet Hoke for providing immortalized HSC, Maureen Murphy for providing construct pWZL-Luc, Genentech for providing Frax1036, and Erica Golemis for commentary. This work was supported by grants from the NIH (RO1 CA142928), and the Children's Tumor Foundation (2011-15-012) to Jonathan Chernoff, NIH CORE Grant P30 CA006927 and an appropriation fromthe state of Pennsylvania to the Fox Chase Cancer Center. In vitro studies were supported by RSF grant 14-24-00106.	Arias-Romero LE, 2013, CANCER RES, V73, P3671, DOI 10.1158/0008-5472.CAN-12-4453; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Barker Nick, 2008, V468, P5, DOI 10.1007/978-1-59745-249-6_1; Beeser A, 2005, J BIOL CHEM, V280, P36609, DOI 10.1074/jbc.M502306200; Brown AP, 2007, CANCER CHEMOTH PHARM, V59, P671, DOI 10.1007/s00280-006-0323-5; Carroll SL, 2008, GLIA, V56, P1590, DOI 10.1002/glia.20776; Carroll SL, 2012, ACTA NEUROPATHOL, V123, P321, DOI 10.1007/s00401-011-0928-6; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Chow HY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013791; Chow HY, 2015, ONCOTARGET, V6, P1981, DOI 10.18632/oncotarget.2810; Connolly DC, 2009, CURRENT PROTOC PHARM, V45, P14, DOI DOI 10.1002/0471141755.ph1412s45; Crawford AT, 2008, GLIA, V56, P1637, DOI 10.1002/glia.20716; Dasgupta B, 2005, CANCER RES, V65, P236; Deacon SW, 2008, CHEM BIOL, V15, P322, DOI 10.1016/j.chembiol.2008.03.005; Endo M, 2013, CLIN CANCER RES, V19, P450, DOI 10.1158/1078-0432.CCR-12-1067; Eswaran J, 2008, TRENDS BIOCHEM SCI, V33, P394, DOI 10.1016/j.tibs.2008.06.002; Haura EB, 2010, CLIN CANCER RES, V16, P2450, DOI 10.1158/1078-0432.CCR-09-1920; He H, 2012, CANCER LETT, V317, P65, DOI 10.1016/j.canlet.2011.11.014; Ingram DA, 2001, J EXP MED, V194, P57, DOI 10.1084/jem.194.1.57; Jessen WJ, 2013, J CLIN INVEST, V123, P340, DOI 10.1172/JCI60578; Johansson G, 2008, MOL CANCER THER, V7, P1237, DOI 10.1158/1535-7163.MCT-07-2335; Karpov AS, 2015, ACS MED CHEM LETT, V6, P776, DOI 10.1021/acsmedchemlett.5b00102; Katz D, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001227; Kolberg M, 2013, NEURO-ONCOLOGY, V15, P135, DOI 10.1093/neuonc/nos287; LoRusso PM, 2010, CLIN CANCER RES, V16, P1924, DOI 10.1158/1078-0432.CCR-09-1883; Luscan A, 2014, CLIN CANCER RES, V20, P358, DOI 10.1158/1078-0432.CCR-13-0780; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Malone CF, 2014, CANCER DISCOV, V4, P1062, DOI 10.1158/2159-8290.CD-14-0159; Mo W, 2013, CELL, V152, P1077, DOI 10.1016/j.cell.2013.01.053; Ndubaku CO, 2015, ACS MED CHEM LETT, V6, P1241, DOI 10.1021/acsmedchemlett.5b00398; Packer RJ, 2002, J CHILD NEUROL, V17, P638, DOI 10.1177/088307380201700816; Prudnikova TY, 2016, ONCOGENE, V35, P2178, DOI 10.1038/onc.2015.278; Radu M, 2014, NAT REV CANCER, V14, P13, DOI 10.1038/nrc3645; Shrestha Y, 2012, ONCOGENE, V31, P3397, DOI 10.1038/onc.2011.515; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Tang Y, 1998, P NATL ACAD SCI USA, V95, P5139, DOI 10.1073/pnas.95.9.5139; Tonsgard James H, 2006, Semin Pediatr Neurol, V13, P2, DOI 10.1016/j.spen.2006.01.005; Torres KE, 2011, CLIN CANCER RES, V17, P3943, DOI 10.1158/1078-0432.CCR-11-0193; Upadhyaya M, 2012, HUM MUTAT, V33, P763, DOI 10.1002/humu.22044; Watson AL, 2014, ONCOTARGET, V5, P1502, DOI 10.18632/oncotarget.1609; Watson AL, 2013, CANCER DISCOV, V3, P674, DOI 10.1158/2159-8290.CD-13-0081; Widemann BC, 2009, CURR ONCOL REP, V11, P322, DOI 10.1007/s11912-009-0045-z; Yang JL, 2014, EUR J CANCER, V50, P593, DOI 10.1016/j.ejca.2013.11.006; Ye Diana Zi, 2012, Cell Logist, V2, P105	45	23	23	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2017	36	38					5421	5431		10.1038/onc.2017.143	http://dx.doi.org/10.1038/onc.2017.143			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FH7PJ	28534510	Green Accepted			2022-12-17	WOS:000411382100008
J	Moyo, TK; Wilson, CS; Moore, DJ; Eischen, CM				Moyo, T. K.; Wilson, C. S.; Moore, D. J.; Eischen, C. M.			Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; ANTIGEN RECEPTOR; C-MYC; FOLLICULAR LYMPHOMA; TARGETING BTK; SYK; IBRUTINIB; ACTIVATION; PCI-32765; SURVIVAL	Dysregulation of the oncogenic transcription factor MYC induces B-cell transformation and is a driver for B-cell non-Hodgkin lymphoma (B-NHL). MYC overexpression in B-NHL is associated with more aggressive phenotypes and poor prognosis. Although genomic studies suggest a link between MYC overexpression and B-cell receptor (BCR) signaling molecules in B-NHL, signaling pathways essential to Myc-mediated B-cell transformation have not been fully elucidated. We utilized intracellular phospho-flow cytometry to investigate the relationship between Myc and BCR signaling in pre-malignant B cells. Utilizing the E mu-myc mouse model, where Myc is overexpressed specifically in B cells, both basal and stimulated BCR signaling were increased in precancerous B lymphocytes from E mu-myc mice compared with wild-type littermates. B cells overexpressing Myc displayed constitutively higher levels of activated CD79a, Btk, Plc gamma 2 and Erk1/2. Notably, Myc-overexpressing B cells maintained elevated BCR signaling despite treatment with ibrutinib, a Bruton's tyrosine kinase inhibitor. Furthermore, PI3K/Akt pathway signaling was also increased in E mu-myc B cells, and this increase was partially suppressed with ibrutinib. In addition, experiments with Btk-null B cells revealed off-target effects of ibrutinib on BCR signaling. Our data show that in pre-malignant B cells, Myc overexpression is sufficient to activate BCR and PI3K/Akt signaling pathways and further enhances signaling following BCR ligation. Therefore, our results indicate that precancerous B cells have already acquired enhanced survival and growth capabilities before transformation, and that elevated MYC levels confer resistance to pharmacologic inhibitors of BCR signaling, which has significant implications for B-NHL treatment.	[Moyo, T. K.] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA; [Wilson, C. S.; Moore, D. J.; Eischen, C. M.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Med Ctr, Nashville, TN 37232 USA; [Moore, D. J.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA; [Eischen, C. M.] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Dept Canc Biol, 233 South 10th St,Bluemle Life Sci Bldg,Room 650, Philadelphia, PA 19107 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Jefferson University	Eischen, CM (corresponding author), Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Dept Canc Biol, 233 South 10th St,Bluemle Life Sci Bldg,Room 650, Philadelphia, PA 19107 USA.	christine.eischen@jefferson.edu	Moore, Daniel/V-6145-2019; Moore, Daniel J/A-4924-2008	Moore, Daniel/0000-0002-6889-9345; Moore, Daniel J/0000-0002-6889-9345	NIH/NCI [R21CA184352]; Hematology Helping Hands Research Award; NCI Cancer Center [P30CA68485, P30CA056036]; NATIONAL CANCER INSTITUTE [R21CA184352, P30CA068485, P30CA056036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM062459] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Hematology Helping Hands Research Award; NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Peggy Kendall for providing Btk<SUP>-/-</SUP> mice and members of the Eischen laboratory and Dr Jonathan Irish for their advice. This work was supported by NIH/NCI R21CA184352 (CME), the Hematology Helping Hands Research Award (TKM) and the NCI Cancer Center support grant P30CA68485 that supports the Vanderbilt Flow Cytometry Shared Resource and the NCI Cancer Center support grant P30CA056036.	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Advani RH, 2013, J CLIN ONCOL, V31, P88, DOI 10.1200/JCO.2012.42.7906; Baba Y, 2001, P NATL ACAD SCI USA, V98, P2582, DOI 10.1073/pnas.051626198; Beitz LO, 1999, J BIOL CHEM, V274, P32662, DOI 10.1074/jbc.274.46.32662; Bye AP, 2015, ARTERIOSCL THROM VAS, V35, P2326, DOI 10.1161/ATVBAHA.115.306130; Byrd JC, 2016, NEW ENGL J MED, V374, P323, DOI 10.1056/NEJMoa1509981; Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637; Chen LF, 2008, BLOOD, V111, P2230, DOI 10.1182/blood-2007-07-100115; Christie L, 2008, LEUKEMIA LYMPHOMA, V49, P470, DOI 10.1080/10428190701836845; Dal Porto JM, 2004, MOL IMMUNOL, V41, P599, DOI 10.1016/j.molimm.2004.04.008; Davis RE, 2010, NATURE, V463, P88, DOI 10.1038/nature08638; Ding JY, 2000, J BIOL CHEM, V275, P30873, DOI 10.1074/jbc.M004813200; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Geahlen RL, 2009, BBA-MOL CELL RES, V1793, P1115, DOI 10.1016/j.bbamcr.2009.03.004; Gramling MW, 2012, CELL DEATH DIFFER, V19, P1220, DOI 10.1038/cdd.2012.1; Honigberg LA, 2010, P NATL ACAD SCI USA, V107, P13075, DOI 10.1073/pnas.1004594107; Huh YO, 2008, BRIT J HAEMATOL, V142, P36, DOI 10.1111/j.1365-2141.2008.07152.x; Irish JM, 2006, J IMMUNOL, V177, P1581, DOI 10.4049/jimmunol.177.3.1581; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; Kraus M, 2004, CELL, V117, P787, DOI 10.1016/j.cell.2004.05.014; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Love C, 2012, NAT GENET, V44, P1321, DOI 10.1038/ng.2468; Manne BK, 2015, J BIOL CHEM, V290, P11557, DOI 10.1074/jbc.M114.629527; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Pan ZY, 2007, CHEMMEDCHEM, V2, P58, DOI 10.1002/cmdc.200600221; Pede V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060275; Ponader S, 2012, BLOOD, V119, P1182, DOI 10.1182/blood-2011-10-386417; Psathas JN, 2013, BLOOD, V122, P4220, DOI 10.1182/blood-2012-12-473090; Refaeli Y, 2008, PLOS BIOL, V6, P1208, DOI 10.1371/journal.pbio.0060152; Richter J, 2012, NAT GENET, V44, P1316, DOI 10.1038/ng.2469; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Satterthwaite AB, 1997, P NATL ACAD SCI USA, V94, P13152, DOI 10.1073/pnas.94.24.13152; Schmitz R, 2012, NATURE, V490, P116, DOI 10.1038/nature11378; Shaffer AL, 2012, ANNU REV IMMUNOL, V30, P565, DOI 10.1146/annurev-immunol-020711-075027; Speich HE, 2008, AM J PHYSIOL-CELL PH, V295, pC1045, DOI 10.1152/ajpcell.90644.2007; Wang ML, 2013, NEW ENGL J MED, V369, P507, DOI 10.1056/NEJMoa1306220; Woyach JA, 2012, BLOOD, V120, P1175, DOI 10.1182/blood-2012-02-362624; Xu XX, 2013, INT J CLIN EXP PATHO, V6, P788; Yeomans A, 2016, BLOOD, V127, P449, DOI 10.1182/blood-2015-07-660969; Young KH, 2008, AM J CLIN PATHOL, V129, P157, DOI 10.1309/NKK3FEX2BE5L7EKB	42	23	24	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4653	4661		10.1038/onc.2017.95	http://dx.doi.org/10.1038/onc.2017.95			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368423	Green Accepted			2022-12-17	WOS:000407246200012
J	Hu, X; Zhao, Y; Wei, L; Zhu, B; Song, D; Wang, J; Yu, L; Wu, J				Hu, X.; Zhao, Y.; Wei, L.; Zhu, B.; Song, D.; Wang, J.; Yu, L.; Wu, J.			CCDC178 promotes hepatocellular carcinoma metastasis through modulation of anoikis	ONCOGENE			English	Article							NF-KAPPA-B; ACTIVATION; PROTEIN; GROWTH; CANCER; PATHWAY; GENOME; BIM	Hepatocellular carcinoma (HCC) is one of the most malignant tumors with high rate of recurrence and metastasis. Coiled-coil domain-containing protein 178 (CCDC178) has been reported to be mutated in HCC, whereas its role in physiological and pathologic process, including in human cancer, remains largely unknown. Here, we found that CCDC178 is upregulated in HCC tissues and its overexpression is correlated with pathological stage (P = 0.003). CCDC178 deficiency reduced the anchorageindependent growth and anoikis resistance of HCC cells, and inhibited the HCC metastasis in vivo. Mechanistically, CCDC178 associated with BRCA1-associated protein 2 (BRAP2), a negative regulator of extracellular signal-regulated kinase (ERK) pathway, and promoted its degradation. Moreover, CCDC178 deficiency impaired the ERK activation, which is dependent on BRAP2. In conclusion, we identify CCDC178 as a novel candidate oncogene involved in anoikis resistance and HCC metastasis, and raise the possibility that CCDC178 may be a new therapeutic target for HCC.	[Hu, X.; Zhao, Y.; Zhu, B.; Song, D.; Wang, J.; Yu, L.; Wu, J.] Fudan Univ, Zhongshan Hosp, State Key Lab Genet Engn, 2005 SongHu Rd, Shanghai 200438, Peoples R China; [Hu, X.; Zhao, Y.; Zhu, B.; Song, D.; Wang, J.; Yu, L.; Wu, J.] Fudan Univ, Sch Life Sci, 2005 SongHu Rd, Shanghai 200438, Peoples R China; [Wei, L.] 401 Hosp PLA, Dept Oncol, Qingdao, Peoples R China	Fudan University; Fudan University	Wu, J (corresponding author), Fudan Univ, Zhongshan Hosp, State Key Lab Genet Engn, 2005 SongHu Rd, Shanghai 200438, Peoples R China.; Wu, J (corresponding author), Fudan Univ, Sch Life Sci, 2005 SongHu Rd, Shanghai 200438, Peoples R China.	jiaxue@fudan.edu.cn	wang, juanjuan/GYV-5540-2022	Wang, Juanjuan/0000-0001-5477-8860; Hu, xiaoding/0000-0002-3144-1859	National Key Research and Development Plan [2016YFC0902401]; National Key Sci-Tech Special Project of China [2013ZX10002010-08]; National Natural Science Foundation of China [81272250, 81472619]	National Key Research and Development Plan; National Key Sci-Tech Special Project of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Yongjun Dang at School of Basic Medical Science, Fudan University for fruitful scientific discussions and sharing some reagents. This work was supported by National Key Research and Development Plan (2016YFC0902401 to JW); the National Key Sci-Tech Special Project of China (2013ZX10002010-08 to JW) and the National Natural Science Foundation of China (81272250 and 81472619 to JW).	Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chen C, 2008, J BIOL CHEM, V283, P12789, DOI 10.1074/jbc.M709305200; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Eccles SA, 2007, LANCET, V369, P1742, DOI 10.1016/S0140-6736(07)60781-8; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Galante JM, 2009, J SURG RES, V152, P18, DOI 10.1016/j.jss.2008.05.017; Geiger TR, 2009, BBA-REV CANCER, V1796, P293, DOI 10.1016/j.bbcan.2009.07.006; Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hauck CR, 2000, J BIOL CHEM, V275, P41092, DOI 10.1074/jbc.M005450200; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Huang J, 2012, NAT GENET, V44, P1117, DOI 10.1038/ng.2391; Hubner A, 2008, MOL CELL, V30, P415, DOI 10.1016/j.molcel.2008.03.025; Kairouz-Wahbe R, 2008, P NATL ACAD SCI USA, V105, P1528, DOI 10.1073/pnas.0711357105; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Lassus P, 2000, ONCOGENE, V19, P2377, DOI 10.1038/sj.onc.1203553; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; Liotta LA, 2004, NATURE, V430, P973, DOI 10.1038/430973a; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]; Malin D, 2015, ONCOGENE, V34, P5626, DOI 10.1038/onc.2015.12; Matheny SA, 2004, NATURE, V427, P256, DOI 10.1038/nature02237; Matheny SA, 2006, METHOD ENZYMOL, V407, P237, DOI 10.1016/S0076-6879(05)07020-5; Matheny SA, 2009, J BIOL CHEM, V284, P11007, DOI 10.1074/jbc.R800082200; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Taddei ML, 2012, J PATHOL, V226, P380, DOI 10.1002/path.3000; Takashima O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058911; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Yan SR, 2005, ONCOGENE, V24, P6482, DOI 10.1038/sj.onc.1208810; Zhang J, 2015, SCI REP-UK, V5, DOI 10.1038/srep13750; Zhou FF, 2011, FEBS J, V278, P403, DOI 10.1111/j.1742-4658.2010.07965.x	35	23	24	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					4047	4059		10.1038/onc.2017.10	http://dx.doi.org/10.1038/onc.2017.10			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28319061				2022-12-17	WOS:000405379900010
J	Janakiraman, H; House, RP; Talwar, S; Courtney, SM; Hazard, ES; Hardiman, G; Mehrotra, S; Howe, PH; Gangaraju, V; Palanisamy, V				Janakiraman, H.; House, R. P.; Talwar, S.; Courtney, S. M.; Hazard, E. S.; Hardiman, G.; Mehrotra, S.; Howe, P. H.; Gangaraju, V.; Palanisamy, V.			Repression of caspase-3 and RNA-binding protein HuR cleavage by cyclooxygenase-2 promotes drug resistance in oral squamous cell carcinoma	ONCOGENE			English	Article							COX-2 EXPRESSION; POSTTRANSCRIPTIONAL REGULATION; MEDIATED CLEAVAGE; PROSTATE-CANCER; CYCLO-OXYGENASE-2; OVEREXPRESSION; APOPTOSIS; LESIONS	A well-studied RNA-binding protein Hu Antigen-R (HuR), controls post-transcriptional gene regulation and undergoes stress-activated caspase-3 dependent cleavage in cancer cells. The cleavage products of HuR are known to promote cell death; however, the underlying molecular mechanisms facilitating caspase-3 activation and HuR cleavage remains unknown. Here, we show that HuR cleavage associated with active caspase-3 in oral cancer cells treated with ionizing radiation and chemotherapeutic drug, paclitaxel. We determined that oral cancer cells overexpressing cyclooxygenase-2 (COX-2) limited the cleavage of caspase-3 and HuR, which reduced the rate of cell death in paclitaxel resistant oral cancer cells. Specific inhibition of COX-2 by celecoxib, promoted apoptosis through activation of caspase-3 and cleavage of HuR in paclitaxel-resistant oral cancer cells, both in vitro and in vivo. In addition, oral cancer cells overexpressing cellular HuR increased the half-life of COX-2 mRNA, promoted COX-2 protein expression and exhibited enhanced tumor growth in vivo in comparison with cells expressing a cleavable form of HuR. Finally, our ribonucleoprotein immunoprecipitation and sequencing (RIP-seq) analyses of HuR in oral cancer cells treated with ionizing radiation (IR), determined that HuR cleavage product-1 (HuR-CP1) bound and promoted the expression of mRNAs encoding proteins involved in apoptosis. Our results indicated that, cellular non-cleavable HuR controls COX-2 mRNA expression and enzymatic activity. In addition, overexpressed COX-2 protein repressed the cleavage of caspase-3 and HuR to promote drug resistance and tumor growth. Altogether, our observations support the use of the COX-2 inhibitor celecoxib, in combination with paclitaxel, for the management of paclitaxel resistant oral cancer cells.	[Janakiraman, H.; House, R. P.; Talwar, S.; Palanisamy, V.] Med Univ South Carolina, Coll Dent Med, Dept Oral Hlth Sci, Charleston, SC 29425 USA; [Janakiraman, H.; House, R. P.; Talwar, S.; Palanisamy, V.] Med Univ South Carolina, Coll Dent Med, Ctr Oral Hlth Res, Charleston, SC 29425 USA; [Courtney, S. M.; Hazard, E. S.; Hardiman, G.] Med Univ South Carolina, Ctr Genom Med, Charleston, SC 29425 USA; [Courtney, S. M.] Med Univ South Carolina, Dept Pathol, Charleston, SC 29425 USA; [Hazard, E. S.] Med Univ South Carolina, Lib Sci & Informat, Charleston, SC 29425 USA; [Hardiman, G.] Med Univ South Carolina, Dept Med, Charleston, SC 29425 USA; [Hardiman, G.] Med Univ South Carolina, Dept Publ Hlth, Charleston, SC 29425 USA; [Mehrotra, S.] Med Univ South Carolina, Dept Surg, Charleston, SC 29425 USA; [Howe, P. H.; Gangaraju, V.; Palanisamy, V.] Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Palanisamy, V (corresponding author), Med Univ South Carolina, Dept Oral Hlth Sci, BSB 230-F, Charleston, SC 29425 USA.	visu@musc.edu		Janakiraman, Harinarayanan/0000-0002-3043-2352; Hardiman, Gary/0000-0003-4558-0400	National Institutes of Health [R01DE022776, R01DE022776S1]; NIH grant [P30 GM103331]; NATIONAL CANCER INSTITUTE [R01CA154663, P30CA138313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE022776] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103331] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We acknowledge the funding source from the National Institutes of Health R01DE022776 and R01DE022776S1 to VP. We acknowledge the Center for Oral Health Research (L-COHR) which is supported by the NIH grant P30 GM103331.	Abdelmohsen K, 2010, WIRES RNA, V1, P214, DOI 10.1002/wrna.4; Barbisan F, 2009, EUR UROL, V56, P105, DOI 10.1016/j.eururo.2008.04.043; Beauchamp P, 2010, CELL DEATH DIFFER; Bombard Y, 2013, J NATL COMPR CANC NE, V11, P1343, DOI 10.6004/jnccn.2013.0158; Brenner JC, 2010, HEAD NECK-J SCI SPEC, V32, P417, DOI 10.1002/hed.21198; Brody JR, 2011, WIRES RNA, V2, P435, DOI 10.1002/wrna.62; Chen DY, 2002, J BIOL CHEM, V277, P15985, DOI 10.1074/jbc.M108675200; Costantino CL, 2009, CANCER RES, V69, P4567, DOI 10.1158/0008-5472.CAN-09-0371; Dandekar DS, 2005, INT J CANCER, V115, P484, DOI 10.1002/ijc.20878; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Devarajan E, 2002, ONCOGENE, V21, P8843, DOI 10.1038/sj.onc.1206044; Do SI, 2008, TUMORI, V94, P347; Ferrandina G, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-182; Filippova N, 2011, MOL CANCER RES, V9, P648, DOI 10.1158/1541-7786.MCR-10-0325; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Hague A, 2004, J PATHOL, V204, P175, DOI 10.1002/path.1630; Hida T, 1998, CANCER RES, V58, P3761; Hulsen T, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-488; Idro R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014001; Itoh S, 2003, ORAL ONCOL, V39, P829, DOI 10.1016/S1368-8375(03)00105-2; KARGMAN SL, 1995, CANCER RES, V55, P2556; Katsanou V, 2009, MOL CELL BIOL, V29, P2762, DOI 10.1128/MCB.01393-08; Kozak I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074712; KULMACZ RJ, 1983, PROSTAGLANDINS, V25, P531, DOI 10.1016/0090-6980(83)90025-4; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; Li M, 2014, SCI REP-UK, V4, DOI 10.1038/srep07380; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mazroui R, 2008, J CELL BIOL, V180, P113, DOI 10.1083/jcb.200709030; McIlwain DR, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008656; Mohammad Shadab, 2011, Natl J Maxillofac Surg, V2, P17, DOI 10.4103/0975-5950.85848; Mukherjee N, 2011, MOL CELL, V43, P327, DOI 10.1016/j.molcel.2011.06.007; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Niesporek S, 2008, INT J ONCOL, V32, P341; Olsson M, 2011, CELL DEATH DIFFER, V18, P1441, DOI 10.1038/cdd.2011.30; Paolini P, 2014, PHARMACOGENOMICS, V15, P759, DOI [10.2217/PGS.14.39, 10.2217/pgs.14.39]; Papadaki O, 2009, J IMMUNOL, V182, P6779, DOI 10.4049/jimmunol.0900377; Renkonen J, 2002, VIRCHOWS ARCH, V440, P594, DOI 10.1007/s00428-002-0616-y; Ristimaki A, 1997, CANCER RES, V57, P1276; Sakurai K, 2007, HEAD NECK-J SCI SPEC, V29, P1002, DOI 10.1002/hed.20627; Shirahama T, 2000, CLIN CANCER RES, V6, P2424; Subbaramaiah K, 2003, J BIOL CHEM, V278, P37637, DOI 10.1074/jbc.M301481200; Sudbo J, 2003, ORAL ONCOL, V39, P497, DOI 10.1016/S1368-8375(03)00012-5; Talwar S, 2014, J BIOL CHEM, V289, P3487, DOI 10.1074/jbc.M113.504951; Talwar S, 2011, J BIOL CHEM, V286, P32333, DOI 10.1074/jbc.M111.255927; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; von Roretz C, 2013, CELL DEATH DIFFER, V20, P154, DOI 10.1038/cdd.2012.111; von Roretz C, 2010, J BIOL CHEM, V285, P16806, DOI 10.1074/jbc.M109.087320; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Yoshimura R, 2000, CANCER-AM CANCER SOC, V89, P589, DOI 10.1002/1097-0142(20000801)89:3<589::AID-CNCR14>3.0.CO;2-C; Young LE, 2010, CURR COLORECT CANC R, V6, P60, DOI 10.1007/s11888-010-0044-3; Zimmermann KC, 1999, CANCER RES, V59, P198	51	23	23	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2017	36	22					3137	3148		10.1038/onc.2016.451	http://dx.doi.org/10.1038/onc.2016.451			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW6KA	27941877	Green Accepted			2022-12-17	WOS:000402617900006
J	Jiang, C; Zhu, Y; Zhou, Z; Gumin, J; Bengtsson, L; Wu, W; Songyang, Z; Lang, FF; Lin, X				Jiang, C.; Zhu, Y.; Zhou, Z.; Gumin, J.; Bengtsson, L.; Wu, W.; Songyang, Z.; Lang, F. F.; Lin, X.			TMEM43/LUMA is a key signaling component mediating EGFR-induced NF-kappa B activation and tumor progression	ONCOGENE			English	Article							GROWTH-FACTOR-RECEPTOR; NECROSIS-FACTOR-ALPHA; PATHWAYS; FAMILY; CELLS; PROTEINS; COMPLEX; CARMA3	Epidermal growth factor receptor (EGFR) family members play pivotal roles in cell proliferation, differentiation and survival. Overexpression and mutations of EGFRs, or aberrant EGFR signaling are commonly associated with the development of various cancers, where constitutive NF-kappa B activation is often found to promote the expression of various proteins involved in the proliferation, survival, migration and epithelial-to-mesenchymal transition of cancer cells. However, the mechanism of EGFR-induced NF-kappa B activation is not fully defined. Here, we used a Bimolecular Fluorescence Complementation-based functional genomics method to perform a high throughput screening and identified TMEM43/LUMA as a critical component in EGFR signaling network, mediating EGFR-induced NF-kappa B activation. Our data show that EGFR recruits TMEM43 following EGF stimulation. TMEM43 interacts with the scaffold protein CARMA3 and its associating complex to induce downstream NF-kappa B activation, and plays a critical role in controlling cell survival. TMEM43 deficiency significantly affects colony formation, survival of anoikis-induced cell death, migration and invasion of cancer cells in vitro, as well as tumor progression in vivo. Importantly, higher expression of TMEM43 closely correlates with brain tumor malignancy, and suppression of TMEM43 expression in brain tumor cells inhibited their growth both in vitro and in vivo. Altogether, our studies reveal a crucial link of EGF receptor to NF-kappa B activation and tumor progression.	[Jiang, C.; Zhu, Y.; Zhou, Z.; Wu, W.; Lin, X.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Unit 108, Houston, TX 77030 USA; [Gumin, J.; Lang, F. F.] Univ Texas MD Anderson Canc Ctr, Div Surg, Dept Neurosurg, Houston, TX 77030 USA; [Bengtsson, L.] Max Delbrueck Ctr Mol Med, Berlin, Germany; [Songyang, Z.] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Lin, X.] Tsinghua Univ, Sch Med, Dept Basic Med Sci, Inst Immunol, Beijing, Peoples R China; [Zhu, Y.] Sun Yet San Univ, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China; [Wu, W.] Nankai Univ, Dept Microbiol, Coll Life Sci, Tianjin, Peoples R China	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Baylor College of Medicine; Tsinghua University; Sun Yat Sen University; Nankai University	Jiang, C; Lin, X (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Unit 108, Houston, TX 77030 USA.	cjiang@mdanderson.org; linxin307@tsinghua.edu.cn	Jiang, Changying/AAL-3711-2020	Jiang, Changying/0000-0003-3778-4438; Bengtsson, Luiza/0000-0001-6048-3743	National Natural Science Foundation of China [81570211]; Cancer Prevention Research Institute of Texas [RP120316]; National Institutes of Health [R01 AI116722]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Cancer Prevention Research Institute of Texas; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was partially supported by grants from the National Natural Science Foundation of China (81570211), Cancer Prevention Research Institute of Texas (RP120316) and National Institutes of Health (R01 AI116722) to X Lin.	Ando K, 2005, CLIN CANCER RES, V11, P8872, DOI 10.1158/1078-0432.CCR-05-0811; Bancroft CC, 2002, INT J CANCER, V99, P538, DOI 10.1002/ijc.10398; Bengtsson L, 2008, J CELL SCI, V121, P536, DOI 10.1242/jcs.019281; Bhat-Nakshatri P, 2002, ONCOGENE, V21, P2066, DOI 10.1038/sj.onc.1205243; Biswas DK, 2006, J CELL PHYSIOL, V209, P645, DOI 10.1002/jcp.20785; Biswas Debajit K, 2005, Sci STKE, V2005, ppe27, DOI 10.1126/stke.2882005pe27; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Biswas DK, 2003, CANCER RES, V63, P290; Blonska M, 2005, J BIOL CHEM, V280, P43056, DOI 10.1074/jbc.M507807200; Blonska M, 2011, CELL RES, V21, P55, DOI 10.1038/cr.2010.182; Dreger M, 2001, P NATL ACAD SCI USA, V98, P11943, DOI 10.1073/pnas.211201898; Driskell OJ, 2007, NAT CELL BIOL, V9, P113, DOI 10.1038/ncb1525; Grabiner BC, 2007, GENE DEV, V21, P984, DOI 10.1101/gad.1502507; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Haywood AFM, 2013, EUR HEART J, V34, P1002, DOI 10.1093/eurheartj/ehs383; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Jiang T, 2011, CANCER RES, V71, P2183, DOI 10.1158/0008-5472.CAN-10-3626; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kerppola TK, 2009, CHEM SOC REV, V38, P2876, DOI 10.1039/b909638h; Lal S, 2000, J NEUROSURG, V92, P326, DOI 10.3171/jns.2000.92.2.0326; Le Page C, 2005, PROSTATE, V65, P130, DOI 10.1002/pros.20234; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Marciniak DJ, 2004, MOL CANCER THER, V3, P1615; Merner ND, 2008, AM J HUM GENET, V82, P809, DOI 10.1016/j.ajhg.2008.01.010; Nakamizo A, 2005, CANCER RES, V65, P3307, DOI 10.1158/0008-5472.CAN-04-1874; Pan D, 2016, ONCOGENE, V35, P919, DOI 10.1038/onc.2015.146; Pan D, 2016, MOL CANCER RES, V14, P93, DOI 10.1158/1541-7786.MCR-15-0229-T; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Shimizu M, 2005, CLIN CANCER RES, V11, P2735, DOI 10.1158/1078-0432.CCR-04-2014; Sun JY, 2008, P NATL ACAD SCI USA, V105, P17085, DOI 10.1073/pnas.0802701105; Thornburg NJ, 2003, CANCER RES, V63, P8293; Vanderschuren KLA, 2013, GENET RES INT, V2013, DOI 10.1155/2013/460805; Wang HM, 2004, LAB INVEST, V84, P941, DOI 10.1038/labinvest.3700123; Wang ZW, 2006, CANCER RES, V66, P7653, DOI 10.1158/0008-5472.CAN-06-1019	36	23	24	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2813	2823		10.1038/onc.2016.430	http://dx.doi.org/10.1038/onc.2016.430			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	27991920				2022-12-17	WOS:000401697800004
J	Luo, C; Shu, Y; Luo, J; Liu, D; Huang, DS; Han, Y; Chen, C; Li, YC; Zou, JM; Qin, J; Wang, Y; Li, D; Wang, SS; Zhang, GM; Chen, J; Feng, ZH				Luo, C.; Shu, Y.; Luo, J.; Liu, D.; Huang, D-S; Han, Y.; Chen, C.; Li, Y-C; Zou, J-M; Qin, J.; Wang, Y.; Li, D.; Wang, S-S; Zhang, G-M; Chen, J.; Feng, Z-H			Intracellular IL-37b interacts with Smad3 to suppress multiple signaling pathways and the metastatic phenotype of tumor cells	ONCOGENE			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; TGF-BETA; CANCER-CELLS; INNATE INFLAMMATION; GENE-EXPRESSION; IN-VITRO; IL-1; RECEPTOR; ACTIVATION; INHIBITION	Multiple signaling pathways that promote tumor cell metastasis are differentially activated in low/non-metastatic and metastatic tumor cells, resulting in the differential expression of metastasis-related genes. The underlying mechanism may involve the alterations of the intrinsic negative regulation in tumor cells. Here we report that the differential expression of interleukin-37b (IL-37b) in tumor cells alters the intrinsic negative regulation of signaling pathways, resulting in the difference of metastatic capacity. IL-37b could bind Smad3 and suppress Smad pathway by interfering with the formation and nuclear translocation of Smad2/3/4 complex. In turn, Smad3 could function as a co-regulator, enabling IL-37b to suppress multiple non-Smad pathways. IL-37b-Smad3 translocated into nucleus to upregulate the expression of non-receptor protein tyrosine phosphatases (PTPNs), thus promoting dephosphorylation to suppress the activation of tyrosine phosphorylation-dependent signaling pathways such as ERK, p38 MAPK, JNK, PI3K, NF-kappa B, and STAT3 pathways. Intriguingly, 13 of 17 PTPNs, most of which are metastasis suppressors, were downregulated in metastatic tumor cells because of the low expression of IL-37b. The marked decrease of intracellular IL-37b attenuated the intrinsic negative regulation in tumor cells, resulting in the enhanced activation of multiple signaling pathways and the increased capacity of invasiveness and metastatic colonization. Consistently, low expression of IL-37b in tumors was significantly associated with poor prognosis of cancer patients. Taken together, these findings reveal that intracellular IL-37b is a critical factor in the negative regulation of multiple signaling pathways that modulate the expression of metastasis-related genes, and suggest that IL-37b expression in tumor cells can potentially be a histopathological prognostic parameter for cancer patients and a therapeutic target for preventing tumor metastasis.	[Luo, C.; Shu, Y.; Luo, J.; Li, Y-C; Zou, J-M; Qin, J.; Wang, Y.; Li, D.; Wang, S-S; Zhang, G-M; Chen, J.; Feng, Z-H] Huazhong Univ Sci & Technol, Sch Basic Med, Dept Biochem & Mol Biol, Tongji Med Coll, Wuhan 430030, Peoples R China; [Liu, D.] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Canc Biol Res Ctr, Wuhan, Peoples R China; [Huang, D-S; Han, Y.] Zhejiang Prov Peoples Hosp, Clin Res Inst, Hangzhou, Zhejiang, Peoples R China; [Chen, C.] Wuhan Univ, Renmin Hosp, Res Inst Otolaryngol Head & Neck Surg, Wuhan 430060, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Zhejiang Provincial People's Hospital; Wuhan University	Chen, J (corresponding author), Huazhong Univ Sci & Technol, Sch Basic Med, Dept Biochem & Mol Biol, Tongji Med Coll, Wuhan 430030, Peoples R China.	chenjuanlinda69@163.com; fengzhg_tj@163.com			National Natural Science Foundation of China [81472704, 30830095, 81272314]; National Development Program (973) For Key Basic Research of China [2009CB521806]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Development Program (973) For Key Basic Research of China(National Basic Research Program of China)	We thank Zhi-Hui Liang, Hui-Fen Zhu, Sheng-Hong Liu for technical assistance; Professor Guan-Xin Shen, Xiong-Wen Wu, Xin-Xing Wu, Zhan-Qiu Yang for their valuable comments and critical review of the manuscript. This work was supported by National Natural Science Foundation of China (no. 81472704 and 30830095 to Z-HF, and 81272314 to G-MZ), and National Development Program (973) For Key Basic Research of China (no. 2009CB521806 to Z-HF).	Abdel-Ghany M, 2002, J BIOL CHEM, V277, P34391, DOI 10.1074/jbc.M205307200; Apte RN, 2006, CANCER METAST REV, V25, P387, DOI 10.1007/s10555-006-9004-4; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Bettaieb A, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/1478-811X-12-13; Boraschi D, 2011, EUR CYTOKINE NETW, V22, P127, DOI 10.1684/ecn.2011.0288; Brown KA, 2004, BREAST CANCER RES, V6, pR215, DOI 10.1186/bcr778; Bulau AM, 2014, P NATL ACAD SCI USA, V111, P2650, DOI 10.1073/pnas.1324140111; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Dinarello CA, 2016, EUR J IMMUNOL, V46, P1067, DOI 10.1002/eji.201545828; Fekete T, 2012, INT J CANCER, V131, P95, DOI 10.1002/ijc.26364; Feng XX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079857; Gallego MI, 2003, ONCOGENE, V22, P8498, DOI 10.1038/sj.onc.1207063; Gao ZH, 2014, NATURE, V516, P349, DOI 10.1038/nature13921; Gong W, 2008, INT J CANCER, V123, P702, DOI 10.1002/ijc.23553; Ida M, 1996, BIOCHEM PHARMACOL, V51, P1061, DOI 10.1016/0006-2952(95)02438-7; Jiang YZ, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0695-7; Jinnin M, 2006, MOL PHARMACOL, V69, P597, DOI 10.1124/mol.105.017483; Julien SG, 2011, NAT REV CANCER, V11, P35, DOI 10.1038/nrc2980; Kowanetz M, 2010, P NATL ACAD SCI USA, V107, P21248, DOI 10.1073/pnas.1015855107; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; Kumar S, 2002, CYTOKINE, V18, P61, DOI 10.1006/cyto.2002.0873; Kuwada Y, 2003, INT J ONCOL, V22, P765; Lane AE, 2010, BIOCHEM J, V430, P161, DOI 10.1042/BJ20100082; Lee K, 2002, FREE RADICAL BIO MED, V33, P1121, DOI 10.1016/S0891-5849(02)01000-6; Li S, 2012, CANCER RES, V72, P865, DOI 10.1158/0008-5472.CAN-11-1357; Li SZ, 2015, P NATL ACAD SCI USA, V112, P2497, DOI 10.1073/pnas.1424626112; Li Y, 2010, ENDOCRINOLOGY, V151, P5146, DOI 10.1210/en.2009-1506; Liao SJ, 2012, BREAST CANCER RES TR, V133, P853, DOI 10.1007/s10549-011-1844-0; Liu D, 2014, CANCER RES, V74, P5597, DOI 10.1158/0008-5472.CAN-13-3598; Liu DW, 2012, INT J MOL SCI, V13, P828, DOI 10.3390/ijms13010828; Ludyga N, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-28; Marshall JC, 2009, MOL CELL BIOCHEM, V329, P115, DOI 10.1007/s11010-009-0116-3; Marshall JCA, 2012, JNCI-J NATL CANCER I, V104, P1306, DOI 10.1093/jnci/djs319; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; McCarty Mark F, 2004, Integr Cancer Ther, V3, P349, DOI 10.1177/1534735404270757; Meulmeester E, 2011, J PATHOL, V223, P205, DOI 10.1002/path.2785; Nold MF, 2010, NAT IMMUNOL, V11, P1014, DOI 10.1038/ni.1944; Nold-Petry CA, 2015, NAT IMMUNOL, V16, P354, DOI 10.1038/ni.3103; Ozaki I, 2011, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00078; Palmieri D, 2006, J BIOENERG BIOMEMBR, V38, P151, DOI 10.1007/s10863-006-9039-9; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Pickup M, 2013, NAT REV CANCER, V13, P788, DOI 10.1038/nrc3603; Sastry SK, 2011, BIOCHEM PHARMACOL, V82, P435, DOI 10.1016/j.bcp.2011.06.016; Schneider MA, 2015, CLIN CANCER RES, V21, P3529, DOI 10.1158/1078-0432.CCR-14-2464; Sharma S, 2008, J IMMUNOL, V180, P5477, DOI 10.4049/jimmunol.180.8.5477; Shibue T, 2009, P NATL ACAD SCI USA, V106, P10290, DOI 10.1073/pnas.0904227106; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; Wang ZH, 2013, J IMMUNOL, V190, P2415, DOI 10.4049/jimmunol.1202535; Wu WS, 2008, CANCER METAST REV, V27, P303, DOI 10.1007/s10555-008-9112-4; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; You M, 2001, J EXP MED, V193, P101, DOI 10.1084/jem.193.1.101; Zhang P, 2013, J IMMUNOL, V190, P1685, DOI 10.4049/jimmunol.1202384; Zhou YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065906	54	23	25	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2889	2899		10.1038/onc.2016.444	http://dx.doi.org/10.1038/onc.2016.444			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	28092676				2022-12-17	WOS:000401697800011
J	Bucay, N; Sekhon, K; Yang, T; Majid, S; Shahryari, V; Hsieh, C; Mitsui, Y; Deng, G; Tabatabai, ZL; Yamamura, S; Calin, GA; Dahiya, R; Tanaka, Y; Saini, S				Bucay, N.; Sekhon, K.; Yang, T.; Majid, S.; Shahryari, V.; Hsieh, C.; Mitsui, Y.; Deng, G.; Tabatabai, Z. L.; Yamamura, S.; Calin, G. A.; Dahiya, R.; Tanaka, Y.; Saini, S.			MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer	ONCOGENE			English	Article							TUMOR-INITIATING CELLS; STEM-CELLS; INTEGRATIVE ANALYSIS; DOWN-REGULATION; CYCLE ARREST; GLIOMA-CELLS; EXPRESSION; CARCINOMA; DELETIONS; PROGRESSION	A major genomic alteration in prostate cancer (PCa) is frequent loss of chromosome (chr) 8p with a common region of loss of heterozygosity (LOH) at chr8p22 locus. Genomic studies implicate this locus in the initiation of clinically significant PCa and with progression to metastatic disease. However, the genes within this region have not been fully characterized to date. Here we demonstrate for the first time that a microRNA component of this region-miR-383- is frequently downregulated in prostate cancer, has a critical role in determining tumor- initiating potential and is involved in prostate cancer metastasis via direct regulation of CD44, a ubiquitous marker of PCa tumor- initiating cells (TICs)/stem cells. Expression analyses of miR-383 in PCa clinical tissues established that low miR-383 expression is associated with poor prognosis. Functional data suggest that miR-383 regulates PCa tumor-initiating/stem-like cells via CD44 regulation. Ectopic expression of miR-383 inhibited tumor- initiating capacity of CD44+ PCa cells. Also, 'anti-metastatic' effects of ectopic miR-383 expression were observed in a PCa experimental metastasis model. In view of our results, we propose that frequent loss of miR-383 at chr8p22 region leads to tumor initiation and prostate cancer metastasis. Thus, we have identified a novel finding that associates a long observed genomic alteration to PCa stemness and metastasis. Our data suggest that restoration of miR-383 expression may be an effective therapeutic modality against PCa. Importantly, we identified miR-383 as a novel PCa tissue diagnostic biomarker with a potential that outperforms that of serum PSA.	[Bucay, N.; Sekhon, K.; Yang, T.; Majid, S.; Shahryari, V.; Hsieh, C.; Mitsui, Y.; Deng, G.; Tabatabai, Z. L.; Yamamura, S.; Dahiya, R.; Tanaka, Y.; Saini, S.] Vet Affairs Med Ctr, Dept Urol, 4150 Clement St, San Francisco, CA 94121 USA; [Bucay, N.; Sekhon, K.; Yang, T.; Majid, S.; Shahryari, V.; Hsieh, C.; Mitsui, Y.; Deng, G.; Tabatabai, Z. L.; Yamamura, S.; Dahiya, R.; Tanaka, Y.; Saini, S.] Univ Calif San Francisco, 4150 Clement St, San Francisco, CA 94121 USA; [Calin, G. A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Noncoding RNA Ctr, Houston, TX 77030 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of Texas System; UTMD Anderson Cancer Center	Saini, S (corresponding author), Vet Affairs Med Ctr, Dept Urol, 4150 Clement St, San Francisco, CA 94121 USA.; Saini, S (corresponding author), Univ Calif San Francisco, 4150 Clement St, San Francisco, CA 94121 USA.; Saini, S (corresponding author), Univ Calif San Francisco, 4150 Clement St, San Francisco, CA 94121 USA.	Sharanjot.Saini@ucsf.edu	Calin, George/E-9390-2011	Calin, George/0000-0001-6704-5615; Calin, George/0000-0002-7427-0578	National Cancer Institute at the National Institutes of Health [RO1CA177984, RO1CA138642]; VA program project on PCa [BX001604]; NATIONAL CANCER INSTITUTE [R01CA182905, R01CA138642, R01CA177984] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002690, IP1BX001604] Funding Source: NIH RePORTER	National Cancer Institute at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); VA program project on PCa; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	We thank Dr Roger Erickson for his support and assistance with preparation of the manuscript. We acknowledge UCSF CTSI (Dr Iryna V. Lobach) for help with statistical analysis. This work was supported by the National Cancer Institute at the National Institutes of Health (Grant Number RO1CA177984, RO1CA138642), VA program project on PCa (BX001604).	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; BOVA GS, 1993, CANCER RES, V53, P3869; Brooks DD, 2010, J NATL MED ASSOC, V102, P423, DOI 10.1016/S0027-9684(15)30578-2; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; El Gammal AT, 2010, CLIN CANCER RES, V16, P56, DOI 10.1158/1078-0432.CCR-09-1423; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Han SL, 2015, CANCER LETT, V366, P61, DOI 10.1016/j.canlet.2015.06.004; He ZW, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0557-0; Hsieh IS, 2013, CARCINOGENESIS, V34, P530, DOI 10.1093/carcin/bgs371; Huang HL, 2014, CELL SIGNAL, V26, P903, DOI 10.1016/j.cellsig.2014.01.016; KAGAN J, 1995, ONCOGENE, V11, P2121; Kim JH, 2007, CANCER RES, V67, P8229, DOI 10.1158/0008-5472.CAN-07-1297; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lapointe J, 2007, CANCER RES, V67, P8504, DOI 10.1158/0008-5472.CAN-07-0673; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Li H, 2008, CANCER RES, V68, P1820, DOI 10.1158/0008-5472.CAN-07-5878; Li HW, 2011, J SURG ONCOL, V103, P558, DOI 10.1002/jso.21806; Lian J, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.70; Liao XH, 2015, CELL SIGNAL, V27, P2285, DOI 10.1016/j.cellsig.2015.08.005; Lieberfarb ME, 2003, CANCER RES, V63, P4781; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Lu W, 2006, GENE CHROMOSOME CANC, V45, P509, DOI 10.1002/gcc.20314; MACOSKA JA, 1995, CANCER RES, V55, P5390; Matsuyama H, 2003, AKTUEL UROL, V34, P247; Matsuyama H, 2003, PROSTATE, V54, P103, DOI 10.1002/pros.10173; Matsuyama H, 2007, CANCER GENET CYTOGEN, V174, P24, DOI 10.1016/j.cancergencyto.2006.11.008; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Patrawala L, 2007, CANCER RES, V67, P6796, DOI 10.1158/0008-5472.CAN-07-0490; Perner S, 2006, CANCER RES, V66, P8337, DOI 10.1158/0008-5472.CAN-06-1482; Piovani G, 2014, MOL CYTOGENET, V7, DOI 10.1186/1755-8166-7-25; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Saini S, 2016, CELL ONCOL, V39, P97, DOI 10.1007/s13402-016-0268-6; Saini S, 2012, CANCER RES, V72, P3618, DOI 10.1158/0008-5472.CAN-12-0540; Saini S, 2011, CLIN CANCER RES, V17, P5287, DOI 10.1158/1078-0432.CCR-10-2619; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Tang DG, 2007, MOL CARCINOGEN, V46, P1, DOI 10.1002/mc.20255; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Wicha MS, 2011, NAT MED, V17, P162, DOI 10.1038/nm0211-162; Wolf AMD, 2010, CA-CANCER J CLIN, V60, P70, DOI 10.3322/caac.20066; Xu DW, 2015, TUMOR BIOL, V36, P7743, DOI 10.1007/s13277-015-3378-2; Xu Z, 2014, BIOCHEM BIOPH RES CO, V453, P833, DOI 10.1016/j.bbrc.2014.10.047; Yang K, 2010, AM J TRANSL RES, V2, P88; Yang K, 2009, INT J CLIN EXP PATHO, V2, P361; Yin MM, 2014, J BIOL CHEM, V289, P18239, DOI 10.1074/jbc.M113.546044; Zhao L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110472	52	23	23	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2667	2679		10.1038/onc.2016.419	http://dx.doi.org/10.1038/onc.2016.419			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27893706	Green Accepted, Green Submitted			2022-12-17	WOS:000401120900005
J	McCurdy, SR; Pacal, M; Ahmad, M; Bremner, R				McCurdy, S. R.; Pacal, M.; Ahmad, M.; Bremner, R.			A CDK2 activity signature predicts outcome in CDK2-low cancers	ONCOGENE			English	Article							CYCLIN-DEPENDENT KINASES; TERMINAL DOMAIN CTD; CELL-CYCLE; TUMOR SUPPRESSION; TARGET GENES; IDENTIFICATION; PHOSPHORYLATION; CARCINOMA; MICE; RETINOBLASTOMA	The role of cyclin-dependent kinase 2 (CDK2) in cancer is controversial. A major hurdle is the availability of tools to easily assess its activity across many samples. Here, we introduce a transcriptional signature to specifically track CDK2 activity. It responds to genetic and chemical perturbations in the CDK-RB-E2F axis, correlates with mitotic rate in vitro and in vivo and reacts rapidly to changes in CDK2 activity during cell cycle progression. We find that CDK2 activity is specifically elevated in human testes, mirroring its critical function in mice, and report very distinct profiles across human cancers. Increased CDK2 activity decreases risk in colon cancer, but elevates poor outcome two-to fivefold in specific tumors, including low grade glioma, kidney, thyroid, adrenocortical and prostate cancer. These are typically 'CDK2-low' cancers, suggesting that above a certain threshold CDK2 promotes progression, but further increases do not influence outcome. Multivariate analysis revealed that the CDK2 signature is the most important predictive feature in these cancers versus dozens of other clinical parameters, such as tumor grade or mitotic index. Thus, transcriptome data provides a novel, straightforward method to monitor CDK2 activity, implicates key roles for the kinase in a subset of human tissues and tumors and enhances cancer risk prediction. The strategy used here for CDK2 could be applied to other kinases that influence transcription.	[McCurdy, S. R.; Pacal, M.; Ahmad, M.; Bremner, R.] Sinai Hlth Syst, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Room 840 600 Univ Ave, Toronto, ON M5G 1X5, Canada; [McCurdy, S. R.; Bremner, R.] Univ Toronto, Dept Lab Med & Pathobiol, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Bremner, R (corresponding author), Sinai Hlth Syst, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Room 840 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	bremner@lunenfeld.ca	Bremner, Rod/I-6490-2012	Bremner, Rod/0000-0001-9184-7212	Canadian Institutes for Health Research (CIHR); Foundation Fighting Blindness Canada; Ontario Institute for Cancer Research through Government of Ontario; Terry Fox Research Institute; Peterborough KM Hunter Foundation; CIHR (Vanier Graduate Scholarship); CIHR Biological Therapeutics Program; Krembil Foundation	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Foundation Fighting Blindness Canada; Ontario Institute for Cancer Research through Government of Ontario; Terry Fox Research Institute; Peterborough KM Hunter Foundation; CIHR (Vanier Graduate Scholarship)(Canadian Institutes of Health Research (CIHR)); CIHR Biological Therapeutics Program(Canadian Institutes of Health Research (CIHR)); Krembil Foundation	We thank G Bader, F Roth and J Wrana for helpful comments. This project was funded by grants to RB from the Canadian Institutes for Health Research (CIHR), Foundation Fighting Blindness Canada, Krembil Foundation, Ontario Institute for Cancer Research through funding provided by the Government of Ontario and the Terry Fox Research Institute. SRM was supported by scholarships from Peterborough KM Hunter Foundation, CIHR (Vanier Graduate Scholarship) and the CIHR Biological Therapeutics Program.	Adler AS, 2012, CANCER RES, V72, P2129, DOI 10.1158/0008-5472.CAN-11-3886; Akli S, 2011, CANCER RES, V71, P3377, DOI 10.1158/0008-5472.CAN-10-4086; Aleem E, 2005, NAT CELL BIOL, V7, P831, DOI 10.1038/ncb1284; Anastassiadis T, 2011, NAT BIOTECHNOL, V29, P1039, DOI 10.1038/nbt.2017; Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504; Assie G, 2014, NAT GENET, V46, P607, DOI 10.1038/ng.2953; Berkofsky-Fessler W, 2009, MOL CANCER THER, V8, P2517, DOI 10.1158/1535-7163.MCT-09-0083; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Campaner S, 2010, NAT CELL BIOL, V12, P54, DOI 10.1038/ncb2004; Chen SA, 2010, NAT CELL BIOL, V12, P1108, DOI 10.1038/ncb2116; Chi Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-10-r149; Cline MS, 2013, SCI REP-UK, V3, DOI 10.1038/srep02652; Deng LW, 2002, J BIOL CHEM, V277, P33922, DOI 10.1074/jbc.M111349200; Firestein R, 2008, NATURE, V455, P547, DOI 10.1038/nature07179; Galbraith MD, 2013, CELL, V153, P1327, DOI 10.1016/j.cell.2013.04.048; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Gillam MP, 2014, ONCOGENE, V124, P1056; Heaton JH, 2012, AM J PATHOL, V181, P1017, DOI 10.1016/j.ajpath.2012.05.026; Hongo F, 2014, UROL ONCOL-SEMIN ORI, V32, P1240, DOI 10.1016/j.urolonc.2014.05.006; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Ishihara H, 2005, BBA-MOL BASIS DIS, V1741, P226, DOI 10.1016/j.bbadis.2005.06.001; Kim SJ, 2008, ANN ONCOL, V19, P68, DOI 10.1093/annonc/mdm358; Kim SJ, 2012, ANN ONCOL, V23, P891, DOI 10.1093/annonc/mdr340; Kronja I, 2011, PHILOS T R SOC B, V366, P3638, DOI 10.1098/rstb.2011.0084; Kubo H, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-755; Lee JK, 2007, P NATL ACAD SCI USA, V104, P13086, DOI 10.1073/pnas.0610292104; Li JQ, 2001, HUM PATHOL, V32, P945, DOI 10.1053/hupa.2001.27116; Lim SH, 2013, DEVELOPMENT, V140, P3079, DOI 10.1242/dev.091744; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Macias E, 2007, CANCER RES, V67, P9713, DOI 10.1158/0008-5472.CAN-07-2119; Malumbres M, 2009, NAT CELL BIOL, V11, P1275, DOI 10.1038/ncb1109-1275; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Martin A, 2005, CANCER CELL, V7, P591, DOI 10.1016/j.ccr.2005.05.006; Molenaar JJ, 2009, P NATL ACAD SCI USA, V106, P12968, DOI 10.1073/pnas.0901418106; Morris EJ, 2008, NATURE, V455, P552, DOI 10.1038/nature07310; Nekhai S, 2002, BIOCHEM J, V364, P649, DOI 10.1042/BJ20011191; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Padmakumar VC, 2009, MOL CELL BIOL, V29, P2582, DOI 10.1128/MCB.00952-08; Palancade B, 2003, EUR J BIOCHEM, V270, P3859, DOI 10.1046/j.1432-1033.2003.03794.x; Puyol M, 2010, CANCER CELL, V18, P63, DOI 10.1016/j.ccr.2010.05.025; Ray D, 2011, NEOPLASIA, V13, P439, DOI 10.1593/neo.101704; Sakaue-Sawano A, 2008, CELL, V132, P487, DOI 10.1016/j.cell.2007.12.033; Sangwan M, 2012, ONCOGENE, V31, P5019, DOI 10.1038/onc.2011.654; Satyanarayana A, 2009, ONCOGENE, V28, P2925, DOI 10.1038/onc.2009.170; Spencer SL, 2013, CELL, V155, P369, DOI 10.1016/j.cell.2013.08.062; Stojadinovic A, 2003, MODERN PATHOL, V16, P742, DOI 10.1097/01.MP.0000081730.72305.81; Stojadinovic A, 2002, J CLIN ONCOL, V20, P941, DOI 10.1200/JCO.2002.20.4.941; Tsutsui T, 2011, GENES CELLS, V16, P1208, DOI 10.1111/j.1365-2443.2011.01565.x; Wang L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034247; WEISS LM, 1989, AM J SURG PATHOL, V13, P202, DOI 10.1097/00000478-198903000-00004; WEISS LM, 1984, AM J SURG PATHOL, V8, P163, DOI 10.1097/00000478-198403000-00001; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Zhang W, 2006, MOL CANCER RES, V4, P935, DOI 10.1158/1541-7786.MCR-06-0253; Zhu JC, 2009, NAT METHODS, V6, P239, DOI 10.1038/nmeth0409-239	59	23	24	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2491	2502		10.1038/onc.2016.409	http://dx.doi.org/10.1038/onc.2016.409			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27819669				2022-12-17	WOS:000400597300001
J	Zhu, W; Gliddon, BL; Jarman, KE; Moretti, PAB; Tin, T; Parise, LV; Woodcock, JM; Powell, JA; Ruszkiewicz, A; Pitman, MR; Pitson, SM				Zhu, W.; Gliddon, B. L.; Jarman, K. E.; Moretti, P. A. B.; Tin, T.; Parise, L. V.; Woodcock, J. M.; Powell, J. A.; Ruszkiewicz, A.; Pitman, M. R.; Pitson, S. M.			CIB1 contributes to oncogenic signalling by Ras via modulating the subcellular localisation of sphingosine kinase 1	ONCOGENE			English	Article							BREAST-CANCER; CYTOPLASMIC DOMAIN; BINDING PROTEIN; PHOSPHORYLATION; CELLS; IDENTIFICATION; TRANSLOCATION; ACTIVATION; PATHWAYS; SURVIVAL	CIB1 (calcium and integrin binding protein 1) is a small intracellular protein with numerous interacting partners, and hence has been implicated in various cellular functions. Recent studies have revealed emerging roles of CIB1 in regulating cancer cell survival and angiogenesis, although the mechanisms involved have remained largely undefined. In investigating the oncogenic function of CIB1, we initially found that CIB1 is widely up-regulated across a diverse range of cancers, with this upregulation frequently correlating with oncogenic mutations of KRas. Consistent with this, we found that ectopic expression of oncogenic KRas and HRas in cells resulted in elevated CIB1 expression. We previously described the Ca2+-myristoyl switch function of CIB1, and its ability to facilitate agonist-induced plasma membrane localisation of sphingosine kinase 1 (SK1), a location where SK1 is known to elicit oncogenic signalling. Thus, we examined the role this may play in oncogenesis. Consistent with these findings, we demonstrated here that over-expression of CIB1 by itself is sufficient to drive localisation of SK1 to the plasma membrane and enhance the membrane-associated enzymatic activity of SK1, as well as its oncogenic signalling. We subsequently demonstrated that elevated levels of CIB1 resulted in full neoplastic transformation, in a manner dependent on SK1. In agreement with our previous findings that SK1 is a downstream mediator of oncogenic signalling by Ras, we found that targeting CIB1 also inhibited neoplastic growth of cells induced by oncogenic Ras, suggesting an important pro-tumorigenic role for CIB1. Thus, we have demonstrated for the first time a role for CIB1 in neoplastic transformation, and revealed a novel mechanism facilitating oncogenic signalling by Ras and SK1.	[Zhu, W.; Gliddon, B. L.; Jarman, K. E.; Moretti, P. A. B.; Tin, T.; Woodcock, J. M.; Powell, J. A.; Ruszkiewicz, A.; Pitman, M. R.; Pitson, S. M.] Univ South Australia, Ctr Canc Biol, SA Pathol Bldg,Frome Rd, Adelaide, SA 5000, Australia; [Zhu, W.; Gliddon, B. L.; Jarman, K. E.; Moretti, P. A. B.; Tin, T.; Woodcock, J. M.; Powell, J. A.; Ruszkiewicz, A.; Pitman, M. R.; Pitson, S. M.] SA Pathol, SA Pathol Bldg,Frome Rd, Adelaide, SA 5000, Australia; [Zhu, W.; Jarman, K. E.; Pitson, S. M.] Univ Adelaide, Sch Biol Sci, Adelaide, SA, Australia; [Parise, L. V.] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC USA; [Powell, J. A.; Pitson, S. M.] Univ Adelaide, Sch Med, Adelaide, SA, Australia	Centre for Cancer Biology; SA Pathology; University of South Australia; SA Pathology; University of Adelaide; University of North Carolina; University of North Carolina Chapel Hill; University of Adelaide	Pitson, SM (corresponding author), Univ South Australia, Ctr Canc Biol, SA Pathol Bldg,Frome Rd, Adelaide, SA 5000, Australia.; Pitson, SM (corresponding author), SA Pathol, SA Pathol Bldg,Frome Rd, Adelaide, SA 5000, Australia.	stuart.pitson@unisa.edu.au	Pitson, Stuart/B-9342-2009	Pitson, Stuart/0000-0002-9527-2740; Pitman, Melissa/0000-0002-9587-3837; Moretti, Paul/0000-0002-3523-1496; Zhu, Layla/0000-0002-6413-699X; Woodcock, Joanna/0000-0001-5127-9687; Powell, jason/0000-0001-8493-9178; Gliddon, Briony/0000-0003-3928-7478	Fay Fuller Foundation [1004695]; National Health and Medical Research Council of Australia [508098, 1042589]; University of Adelaide Graduate Research and Research Training Scheme Scholarships, an Australian Postgraduate Award and Royal Adelaide Hospital (RAH) Dawes Scholarship; RAH Research Foundation Early Career Fellowship; Imperial Cancer Research Fund, London; Institute for Molecular Bioscience, Brisbane; Osaka University;  [NIH 1R01HL092544]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL092544] Funding Source: NIH RePORTER	Fay Fuller Foundation; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); University of Adelaide Graduate Research and Research Training Scheme Scholarships, an Australian Postgraduate Award and Royal Adelaide Hospital (RAH) Dawes Scholarship; RAH Research Foundation Early Career Fellowship; Imperial Cancer Research Fund, London; Institute for Molecular Bioscience, Brisbane; Osaka University; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the Fay Fuller Foundation, Project Grant (1004695) and Senior Research Fellowships (508098 and 1042589) from the National Health and Medical Research Council of Australia (to SMP), NIH 1R01HL092544 (to LVP), University of Adelaide Graduate Research and Research Training Scheme Scholarships (to WZ), an Australian Postgraduate Award and Royal Adelaide Hospital (RAH) Dawes Scholarship (to KEJ) and a RAH Research Foundation Early Career Fellowship (to MRP). We thank J Downward (Imperial Cancer Research Fund, London) and R Parton (Institute for Molecular Bioscience, Brisbane) for providing the H- and KRas plasmids, respectively, and M Okabe (Osaka University) for providing the pCX-EGFP plasmid. Some of the data shown are based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/.	Adams DR, 2016, TRENDS BIOCHEM SCI, V41, P395, DOI 10.1016/j.tibs.2016.02.007; Al-Jehani RM, 1998, J NATL CANCER I, V90, P540, DOI 10.1093/jnci/90.7.540; Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; Armacki M, 2014, ONCOGENE, V33, P1167, DOI 10.1038/onc.2013.43; Black JL, 2015, BREAST CANCER RES TR, V152, P337, DOI 10.1007/s10549-015-3458-4; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; Di Fiore F, 2007, BRIT J CANCER, V96, P1166, DOI 10.1038/sj.bjc.6603685; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; French KJ, 2003, CANCER RES, V63, P5962; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Gault CR, 2012, J BIOL CHEM, V287, P31794, DOI 10.1074/jbc.M112.385765; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Heffernan-Stroud LA, 2013, ADV CANCER RES, V117, P201, DOI 10.1016/B978-0-12-394274-6.00007-8; IKAWA M, 1995, FEBS LETT, V375, P125, DOI 10.1016/0014-5793(95)01162-8; Jarman KE, 2010, J BIOL CHEM, V285, P483, DOI 10.1074/jbc.M109.068395; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Leisner TM, 2013, ONCOGENE, V32, P4017, DOI 10.1038/onc.2012.408; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Meyer T, 1999, NAT CELL BIOL, V1, pE93, DOI 10.1038/12090; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nagayoshi Y, 2014, ANN SURG ONCOL, V21, P459, DOI 10.1245/s10434-014-3574-0; Naik MU, 2009, J THROMB HAEMOST, V7, P1906, DOI 10.1111/j.1538-7836.2009.03581.x; Naik MU, 2011, J CELL BIOCHEM, V112, P3289, DOI 10.1002/jcb.23255; Naik MU, 2011, INT J CANCER, V128, P587, DOI 10.1002/ijc.25388; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; Paugh SW, 2008, BLOOD, V112, P1382, DOI 10.1182/blood-2008-02-138958; Pitman MR, 2015, ONCOTARGET, V6, P7065, DOI 10.18632/oncotarget.3178; Pitman Melissa R, 2012, Methods Mol Biol, V874, P21, DOI 10.1007/978-1-61779-800-9_2; Pitman MR, 2011, INT J BIOCHEM CELL B, V43, P342, DOI 10.1016/j.biocel.2010.11.001; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Pitson SM, 2011, TRENDS BIOCHEM SCI, V36, P97, DOI 10.1016/j.tibs.2010.08.001; Plowman SJ, 2008, MOL CELL BIOL, V28, P4377, DOI 10.1128/MCB.00050-08; Powell JA, 2009, BLOOD, V114, P4859, DOI 10.1182/blood-2009-02-204818; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shock DD, 1999, BIOCHEM J, V342, P729, DOI 10.1042/0264-6021:3420729; Tong JR, 2011, J BIOSCIENCES, V36, P659, DOI 10.1007/s12038-011-9101-6; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Yamniuk AP, 2006, CALCIUM BINDING PROT, V1, P150; Yoon KW, 2009, P NATL ACAD SCI USA, V106, P17389, DOI 10.1073/pnas.0812259106; Yuan W, 2006, MOL CELL BIOL, V26, P8507, DOI 10.1128/MCB.01488-06; Zayed MA, 2007, CIRC RES, V101, P1185, DOI 10.1161/CIRCRESAHA.107.157586; Zayed MA, 2010, VASC CELL, V2, DOI 10.1186/2040-2384-2-17	48	23	23	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2619	2627		10.1038/onc.2016.428	http://dx.doi.org/10.1038/onc.2016.428			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27941888	Green Submitted, Green Accepted			2022-12-17	WOS:000400597300012
J	Su, X; Napoli, M; Abbas, HA; Venkatanarayan, A; Bui, NHB; Coarfa, C; Gi, YJ; Kittrell, F; Gunaratne, PH; Medina, D; Rosen, JM; Behbod, F; Flores, ER				Su, X.; Napoli, M.; Abbas, H. A.; Venkatanarayan, A.; Bui, N. H. B.; Coarfa, C.; Gi, Y. J.; Kittrell, F.; Gunaratne, P. H.; Medina, D.; Rosen, J. M.; Behbod, F.; Flores, E. R.			TAp63 suppresses mammary tumorigenesis through regulation of the Hippo pathway	ONCOGENE			English	Article							STEM-CELL MARKERS; BREAST-CANCER; EPITHELIAL MIGRATION; GLAND DEVELOPMENT; SELF-RENEWAL; P63; EXPRESSION; MORPHOGENESIS; POLARITY; DELTA-NP63	Mechanisms regulating the transition of mammary epithelial cells (MECs) to mammary stem cells (MaSCs) and to tumor-initiating cells (TICs) have not been entirely elucidated. The p53 family member, p63, is critical for mammary gland development and contains transactivation domain isoforms, which have tumor-suppressive activities, and the Delta N isoforms, which act as oncogenes. In the clinic, p63 is often used as a diagnostic marker, and further analysis of the function of TAp63 in the mammary gland is critical for improved diagnosis and patient care. Loss of TAp63 in mice leads to the formation of aggressive metastatic mammary adenocarcinoma at 9-16 months of age. Here we show that TAp63 is crucial for the transition of mammary cancer cells to TICs. When TAp63 is lost, MECs express embryonic and MaSC signatures and activate the Hippo pathway. These data indicate a crucial role for TAp63 in mammary TICs and provide a mechanism for its role as a tumor-and metastasis-suppressor in breast cancer.	[Su, X.; Napoli, M.; Abbas, H. A.; Venkatanarayan, A.; Bui, N. H. B.; Gi, Y. J.; Flores, E. R.] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA; [Su, X.; Napoli, M.; Abbas, H. A.; Venkatanarayan, A.; Bui, N. H. B.; Gi, Y. J.; Flores, E. R.] H Lee Moffitt Canc Ctr & Res Inst, Dept Cutaneous Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA; [Venkatanarayan, A.; Bui, N. H. B.; Kittrell, F.; Flores, E. R.] H Lee Moffitt Canc Ctr & Res Inst, Canc Biol & Evolut Program, 12902 Magnolia Dr, Tampa, FL 33612 USA; [Coarfa, C.; Medina, D.; Rosen, J. M.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Gunaratne, P. H.] Univ Houston, Dept Biol & Biochem, Houston, TX USA; [Behbod, F.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA	H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; Baylor College of Medicine; University of Houston System; University of Houston; University of Kansas; University of Kansas Medical Center	Flores, ER (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	elsa.flores@moffitt.org		Napoli, Marco/0000-0001-7192-5252; Bui, Ngoc/0000-0001-5161-1133	National Cancer Institute (NCI) [R35CA197452, R01CA160394, R01CA134796]; Cancer Prevention & Research Institute of Texas (CPRIT) [RP120124, RP150094]; Hildegardo E and Olga M. Flores Foundation; NCI-Cancer Center Core Grant (University of Texas MD Anderson Cancer Center) [CA-16672]; Cancer Prevention and Research Institute of Texas [RP140106]; American Cancer Society grant [IRG-09-062-01];  [R01CA16303]; NATIONAL CANCER INSTITUTE [R35CA197452, P30CA016672, R01CA134796, R01CA160394] Funding Source: NIH RePORTER	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Prevention & Research Institute of Texas (CPRIT); Hildegardo E and Olga M. Flores Foundation; NCI-Cancer Center Core Grant (University of Texas MD Anderson Cancer Center); Cancer Prevention and Research Institute of Texas; American Cancer Society grant(American Cancer Society); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the work of Henry P Adams, Microscopy Core of the Genetics Department. We also thank Leif Ellisen for the kind gift of the TAp63 shRNA. This study was funded by R35CA197452, R01CA160394 and R01CA134796 from the National Cancer Institute (NCI) and RP120124 and RP150094 from the Cancer Prevention & Research Institute of Texas (CPRIT) and funding from the Hildegardo E and Olga M. Flores Foundation to ERF, NCI-Cancer Center Core Grant (CA-16672) (University of Texas MD Anderson Cancer Center) and R01CA16303 to JMR. ERF is an NCI Outstanding Investigator, a Moffitt Distinguished Scholar, a scholar of the Leukemia and Lymphoma Society, the Rita Allen Foundation and the V Foundation for Cancer Research. MN is a CPRIT-TRIUMPH Scholar and was supported by a Research Training Award from the Cancer Prevention and Research Institute of Texas (RP140106). HAA is an Odyssey Fellow at MD Anderson Cancer Center. FB was supported in part by an American Cancer Society grant (IRG-09-062-01), awarded to the University of Kansas Medical Center.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Amin N, 2012, FRONT BIOSCI-LANDMRK, V17, P784, DOI 10.2741/3957; Anastas JN, 2012, ONCOGENE, V31, P3696, DOI 10.1038/onc.2011.528; Bartucci M, 2015, ONCOGENE, V34, P681, DOI 10.1038/onc.2014.5; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Biernaskie J, 2009, CELL STEM CELL, V5, P610, DOI 10.1016/j.stem.2009.10.019; Chakravarti D, 2014, P NATL ACAD SCI USA, V111, pE572, DOI 10.1073/pnas.1319743111; Chalcrabarti R, 2014, NAT CELL BIOL, V16, P1004, DOI 10.1038/ncb3040; Chen Q, 2014, GENE DEV, V28, P432, DOI 10.1101/gad.233676.113; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dow LE, 2007, ONCOGENE, V26, P2272, DOI 10.1038/sj.onc.1210016; Ewald AJ, 2008, DEV CELL, V14, P570, DOI 10.1016/j.devcel.2008.03.003; Forster N, 2014, DEV CELL, V28, P147, DOI 10.1016/j.devcel.2013.11.019; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Gurumurthy S, 2010, NATURE, V468, P659, DOI 10.1038/nature09572; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hiemer SE, 2013, BBA-GEN SUBJECTS, V1830, P2323, DOI 10.1016/j.bbagen.2012.07.005; Koker MM, 2004, AM J SURG PATHOL, V28, P1506, DOI 10.1097/01.pas.0000138183.97366.fd; Kostera MI, 2004, J DERMATOL SCI, V34, P3, DOI 10.1016/j.jdermsci.2003.10.003; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Li J, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0070-0; Li N, 2008, STEM CELLS, V26, P1253, DOI 10.1634/stemcells.2007-0691; Memmi EM, 2015, P NATL ACAD SCI USA, V112, P3499, DOI 10.1073/pnas.1500762112; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mohseni M, 2014, NAT CELL BIOL, V16, P108, DOI 10.1038/ncb2884; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Muller PAJ, 2014, J BIOL CHEM, V289, P122, DOI 10.1074/jbc.M113.502138; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Nguyen-Ngoc KV, 2015, METHODS MOL BIOL, V1189, P135, DOI 10.1007/978-1-4939-1164-6_10; Nusse R, 2008, CELL RES, V18, P523, DOI 10.1038/cr.2008.47; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003; Ricardo S, 2011, J CLIN PATHOL, V64, P937, DOI 10.1136/jcp.2011.090456; Romano RA, 2012, DEVELOPMENT, V139, P772, DOI 10.1242/dev.071191; Shi PG, 2015, ACTA BIOCH BIOPH SIN, V47, P53, DOI 10.1093/abbs/gmu114; Skibinski A, 2014, CELL REP, V6, P1059, DOI 10.1016/j.celrep.2014.02.038; Smith GH, 1996, BREAST CANCER RES TR, V39, P21, DOI 10.1007/BF01806075; Su XH, 2013, NAT REV CANCER, V13, P136, DOI 10.1038/nrc3446; Su XH, 2012, CELL METAB, V16, P511, DOI 10.1016/j.cmet.2012.09.006; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Su XH, 2009, CELL STEM CELL, V5, P64, DOI 10.1016/j.stem.2009.04.003; Tsang JYS, 2012, BREAST CANCER RES TR, V136, P407, DOI 10.1007/s10549-012-2271-6; Vaira V, 2011, AM J PATHOL, V178, P2478, DOI 10.1016/j.ajpath.2011.02.028; Venkatanarayan A, 2015, NATURE, V517, P626, DOI 10.1038/nature13910; Yamben IF, 2013, DEV BIOL, V384, P41, DOI 10.1016/j.ydbio.2013.09.027; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2006, MOL CELL, V24, P593, DOI 10.1016/j.molcel.2006.10.018; Yates LL, 2013, DEV BIOL, V373, P267, DOI 10.1016/j.ydbio.2012.11.012; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Zhao R, 2014, DEV CELL, V30, P151, DOI 10.1016/j.devcel.2014.06.004	51	23	24	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2017	36	17					2377	2393		10.1038/onc.2016.388	http://dx.doi.org/10.1038/onc.2016.388			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET4QE	27869165	Green Published, hybrid			2022-12-17	WOS:000400268900005
J	Mimoto, R; Imawari, Y; Hirooka, S; Takeyama, H; Yoshida, K				Mimoto, R.; Imawari, Y.; Hirooka, S.; Takeyama, H.; Yoshida, K.			Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL-TRANSITION; DOWN-REGULATION; DNA-DAMAGE; CELLS; PHOSPHORYLATION; PROGRESSION; P53; DIFFERENTIATION; PROLIFERATION; CHEMOTHERAPY	Whereas accumulating studies have supported the cancer stem cell theory, a specific therapy targeting a cancer stem cell subpopulation has not been established. Here, we show that dual-specificity tyrosine phosphorylation-kinase 2 (DYRK2) is a novel negative regulator for formation of breast cancer stem cells. Downregulation of DYRK2 promotes cancer stem-like traits in vitro, tumourigenesis in vivo and the proportion of the cancer stem cell population in human breast cancer tissues. We found that Krupple-like factor 4 (KLF4) serves as a key mediator of DYRK2's control over the cancer stem phenotype. Reduced DYRK2 expression increases KLF4 expression, which induces cancer stem-like properties. We identified androgen receptor (AR) as a transcription factor binding to the KLF4 promoter region; this process is dependent on DYRK2 kinase activity. Our findings delineate a mechanism of cancer stem cell regulation by the DYRK2-AR-KLF4 axis in breast cancer. Targeting of this pathway may be a promising strategy against breast cancer stem cells.	[Mimoto, R.; Imawari, Y.; Yoshida, K.] Jikei Univ, Sch Med, Dept Biochem, Tokyo, Japan; [Mimoto, R.; Imawari, Y.; Takeyama, H.] Jikei Univ, Sch Med, Dept Surg, Tokyo, Japan; [Hirooka, S.] Jikei Univ, Sch Med, Dept Pathol, Tokyo, Japan	Jikei University; Jikei University; Jikei University	Yoshida, K (corresponding author), Jikei Univ, Sch Med, Dept Biochem, Minato Ku, 3-25-8 Nishi Shinbashi, Tokyo 1058461, Japan.	kyoshida@jikei.ac.jp		Kudo, Rei/0000-0003-0702-5828	JSPS KAKENHI [26290041, 26861056]; Takeda Science Foundation; Vehicle Racing Commemorative Foundation; Research Grant of the Princess Takamatsu Cancer Research Fund	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Vehicle Racing Commemorative Foundation; Research Grant of the Princess Takamatsu Cancer Research Fund	The authors appreciate all patients who provided the clinical samples for the study. We thank Naoe T Nihira for microarray analysis, Mamiko Owada for immunohistochemistry, Minori Kamada for FACS analysis and Noriko Yamaguchi for xenograft experiments. This work was supported by grants from JSPS KAKENHI Grant Number 26290041 and 26861056, Takeda Science Foundation, the Vehicle Racing Commemorative Foundation and Research Grant of the Princess Takamatsu Cancer Research Fund.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Aranda S, 2011, FASEB J, V25, P449, DOI 10.1096/fj.10-165837; Bolton EC, 2007, GENE DEV, V21, P2005, DOI 10.1101/gad.1564207; Chen XM, 2003, J MOL BIOL, V326, P665, DOI 10.1016/S0022-2836(02)01449-3; Choi BJ, 2006, PATHOL RES PRACT, V202, P585, DOI 10.1016/j.prp.2006.05.001; Enomoto Y, 2014, TUMOR BIOL, V35, P11021, DOI 10.1007/s13277-014-2413-z; Foster KW, 2005, ONCOGENE, V24, P1491, DOI 10.1038/sj.onc.1208307; Hiyama E, 2007, BRIT J CANCER, V96, P1020, DOI 10.1038/sj.bjc.6603671; Jung HY, 2013, J BIOL CHEM, V288, P7252, DOI 10.1074/jbc.M112.416792; Li RH, 2010, CELL STEM CELL, V7, P51, DOI 10.1016/j.stem.2010.04.014; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marinescu VD, 2005, NUCLEIC ACIDS RES, V33, pD91, DOI 10.1093/nar/gki103; Mimoto R, 2014, BREAST CANCER RES TR, V147, P317, DOI 10.1007/s10549-014-3111-7; Mimoto R, 2013, CANCER LETT, V339, P214, DOI 10.1016/j.canlet.2013.06.005; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Nomura S, 2015, BMC UROL, V15, DOI 10.1186/s12894-015-0040-7; Pandya AY, 2004, CLIN CANCER RES, V10, P2709, DOI 10.1158/1078-0432.CCR-03-0484; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Taira N, 2007, MOL CELL, V25, P725, DOI 10.1016/j.molcel.2007.02.007; Taira N, 2014, P NATL ACAD SCI USA, V111, P717, DOI 10.1073/pnas.1313675111; Taira N, 2012, J CLIN INVEST, V122, P859, DOI 10.1172/JCI60818; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tomaskovic-Crook E, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2416; Wang YC, 2015, INT J BIOL MACROMOL, V81, P809, DOI 10.1016/j.ijbiomac.2015.08.067; Wei DY, 2005, CANCER RES, V65, P2746, DOI 10.1158/0008-5472.CAN-04-3619; Wei Z, 2009, STEM CELLS, V27, P2969, DOI 10.1002/stem.231; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Yamaguchi N, 2015, TUMOR BIOL, V36, P5913, DOI 10.1007/s13277-015-3264-y; Yamashita SI, 2009, ANTICANCER RES, V29, P2753; Yori JL, 2011, NEOPLASIA, V13, P601, DOI 10.1593/neo.11260; Yu F, 2011, ONCOGENE, V30, P2161, DOI 10.1038/onc.2010.591	33	23	23	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2017	36	13					1862	1872		10.1038/onc.2016.349	http://dx.doi.org/10.1038/onc.2016.349			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EQ5NF	27721402				2022-12-17	WOS:000398128900011
J	Jang, JW; Kim, MK; Lee, YS; Lee, JW; Kim, DM; Song, SH; Lee, JY; Choi, BY; Min, B; Chi, XZ; Bae, SC				Jang, J-W; Kim, M-K; Lee, Y-S; Lee, J-W; Kim, D-M; Song, S-H; Lee, J-Y; Choi, B-Y; Min, B.; Chi, X-Z; Bae, S-C			RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3	ONCOGENE			English	Article							TUMOR-SUPPRESSOR PATHWAY; HIPPO PATHWAY; TRANSCRIPTIONAL COACTIVATOR; TEAD/TEF FAMILY; DROSOPHILA EYE; PROTEIN-KINASE; GROWTH-CONTROL; TISSUE-GROWTH; SIZE-CONTROL; CANCER	The tumor-suppressor RUNX3 has a critical role in a lineage determination, cell cycle arrest and apoptosis. Lozenge (Lz), a Drosophila homolog of mammalian RUNX family members, has integral roles in these processes and specifically in eye cell fate determination. To elucidate the genetic modifiers of Lz/RUNX3, we performed a large-scale functional screen in a fly mutant library. The screen revealed genetic interactions between the Lz, Rac and Hippo pathways. Analysis of interactions among these genes revealed that the defective phenotype resulting from activation of Yki, an end point effector of the Hippo pathway, was suppressed by Lz and enhanced by Rac-Trio. Molecular biological analysis using mammalian homologs reveled that LATS1/2-mediated YAP phosphorylation-facilitated dissociation of the YAP-TEAD4 complex and association of the YAP-RUNX3 complex. When cells were stimulated to proliferate, activated RAC-TRIO signaling inhibited LATS1/2-mediated YAP phosphorylation; consequently, YAP dissociated from RUNX3 and associated with TEAD, thereby replacing the YAP-RUNX3 complex with YAP-TEAD. RUNX3 contributed to both association and dissociation of YAP-TEAD complex, most likely through the formation of the YAP-TEAD-RUNX3 ternary complex. Ectopic expression of RUNX3 in MKN28 gastric cancer cells reduced tumorigenicity, and the tumor-suppressive activity of RUNX3 was associated with its ability to interact with YAP. These results identify a novel regulatory mechanism, mediated by the Hippo and RAC-TRIO pathways, that changes the binding partner of YAP.	[Jang, J-W; Kim, M-K; Lee, Y-S; Lee, J-W; Kim, D-M; Song, S-H; Lee, J-Y; Choi, B-Y; Min, B.; Chi, X-Z; Bae, S-C] Chungbuk Natl Univ, Dept Biochem, Coll Med, Cheongju, South Korea	Chungbuk National University	Bae, SC (corresponding author), Chungbuk Natl Univ, Dept Biochem, Sch Med, Cheongju 28644, South Korea.; Bae, SC (corresponding author), Chungbuk Natl Univ, Inst Tumor Res, Cheongju 28644, South Korea.	scbae@chungbuk.ac.kr		Bae, Sang-Cheol/0000-0003-4658-1093	National Research Foundation (NRF) of Korea [2014R1A3A2030690]; Chungbuk National University; Basic Science Research Program through the NRF - Ministry of Education of Korea [2014R1A1A2009492]	National Research Foundation (NRF) of Korea(National Research Foundation of Korea); Chungbuk National University; Basic Science Research Program through the NRF - Ministry of Education of Korea	S-CB is supported by a Creative Research Grant (2014R1A3A2030690) through the National Research Foundation (NRF) of Korea and a Research Grant of Chungbuk National University in 2012. J-WJ is supported by Basic Science Research Program (2014R1A1A2009492) through the NRF funded by the Ministry of Education of Korea.	Adler JJ, 2013, P NATL ACAD SCI USA, V110, P17368, DOI 10.1073/pnas.1308236110; Boggiano JC, 2011, DEV CELL, V21, P888, DOI 10.1016/j.devcel.2011.08.028; Bouquier N, 2009, CHEM BIOL, V16, P657, DOI 10.1016/j.chembiol.2009.04.012; Canon J, 2000, SEMIN CELL DEV BIOL, V11, P327, DOI 10.1006/scdb.2000.0185; Daga A, 1996, GENE DEV, V10, P1194, DOI 10.1101/gad.10.10.1194; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Flores GV, 1998, DEVELOPMENT, V125, P3681; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Goulev Y, 2008, CURR BIOL, V18, P435, DOI 10.1016/j.cub.2008.02.034; Ito Y, 2015, NAT REV CANCER, V15, P81, DOI 10.1038/nrc3877; Lee JH, 2007, NATURE, V447, P1017, DOI 10.1038/nature05828; Lee YS, 2016, ONCOGENE, V35, P827, DOI 10.1038/onc.2015.153; Lee YS, 2013, CANCER CELL, V24, P603, DOI 10.1016/j.ccr.2013.10.003; Levy D, 2008, J BIOL CHEM, V283, P27462, DOI 10.1074/jbc.M803941200; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Miller E, 2012, CHEM BIOL, V19, P955, DOI 10.1016/j.chembiol.2012.07.005; Mo JS, 2015, NAT CELL BIOL, V17, P500, DOI 10.1038/ncb3111; Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638; Oh H, 2008, DEVELOPMENT, V135, P1081, DOI 10.1242/dev.015255; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Poon CLC, 2011, DEV CELL, V21, P896, DOI 10.1016/j.devcel.2011.09.012; Qiao Y, 2016, ONCOGENE, V35, P2664, DOI 10.1038/onc.2015.338; Ren FF, 2010, DEV BIOL, V337, P303, DOI 10.1016/j.ydbio.2009.10.046; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; Sorrentino G, 2014, NAT CELL BIOL, V16, P357, DOI 10.1038/ncb2936; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Wada KI, 2011, DEVELOPMENT, V138, P3907, DOI 10.1242/dev.070987; Wang ZY, 2014, P NATL ACAD SCI USA, V111, pE89, DOI 10.1073/pnas.1319190110; Wildonger J, 2005, DEVELOPMENT, V132, P2263, DOI 10.1242/dev.01824; Wu S, 2008, DEV CELL, V14, P388, DOI 10.1016/j.devcel.2008.01.007; XU TA, 1995, DEVELOPMENT, V121, P1053; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Zaidi SK, 2004, EMBO J, V23, P790, DOI 10.1038/sj.emboj.7600073; Zhang L, 2008, DEV CELL, V14, P377, DOI 10.1016/j.devcel.2008.01.006; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907	38	23	24	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					999	1011		10.1038/onc.2016.266	http://dx.doi.org/10.1038/onc.2016.266			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27425596				2022-12-17	WOS:000394169100012
J	Fife, CM; Sagnella, SM; Teo, WS; Po'uha, ST; Byrne, FL; Yeap, YYC; Ng, DCH; Davis, TP; McCarroll, JA; Kavallaris, M				Fife, C. M.; Sagnella, S. M.; Teo, W. S.; Po'uha, S. T.; Byrne, F. L.; Yeap, Y. Y. C.; Ng, D. C. H.; Davis, T. P.; McCarroll, J. A.; Kavallaris, M.			Stathmin mediates neuroblastoma metastasis in a tubulin-independent manner via RhoA/ROCK signaling and enhanced transendothelial migration	ONCOGENE			English	Article							CELL LUNG-CANCER; DEPENDENT PROTEIN-KINASE; POTENTIAL TARGET; RHOA ACTIVATION; POOR-PROGNOSIS; LIVING CELLS; IN-VITRO; EXPRESSION; PHOSPHOPROTEIN; PHOSPHORYLATION	Neuroblastoma, the most common solid tumor of young children, frequently presents with aggressive metastatic disease and for these children the 5-year survival rates are dismal. Metastasis, the movement of cancer cells from one site to another, involves remodeling of the cytoskeleton including altered microtubule dynamics. The microtubule-destabilizing protein, stathmin, has recently been shown to mediate neuroblastoma metastasis although precise functions remain poorly defined. In this study we investigated stathmin's contribution to the metastatic process and potential mechanism(s) by which it exerts these effects. Stathmin suppression significantly reduced neuroblastoma cell invasion of 3D tumor spheroids into an extracellular matrix. Moreover, inhibiting stathmin expression significantly reduced transendothelial migration in two different neuroblastoma cell lines in vitro. Inhibition of ROCK, a key regulator of cell migration, in neuroblastoma cells highlighted that stathmin regulates transendothelial migration through ROCK signaling. Reduced stathmin expression in neuroblastoma cells significantly increased the activation of the RhoA small GTPase. Notably, re-expression of either wild type or a phospho-mimetic stathmin mutant (4E) made defective in tubulin binding returned cell migration and transendothelial migration back to control levels, indicating that stathmin may influence these processes in neuroblastoma cells independent of tubulin binding. Finally, stathmin suppression in neuroblastoma cells significantly reduced whole body, lung, kidney and liver metastases in an experimental metastases mouse model. In conclusion, stathmin suppression interferes with the metastatic process via RhoA/ROCK signaling in neuroblastoma cells. These findings highlight the importance of stathmin to the metastatic process and its potential as a therapeutic target for the treatment of neuroblastoma.	[Fife, C. M.; Sagnella, S. M.; Teo, W. S.; Po'uha, S. T.; McCarroll, J. A.; Kavallaris, M.] UNSW Australia, Childrens Canc Inst, Lowy Canc Res Ctr, Tumour Biol & Targeting Program, Sydney, NSW, Australia; [Fife, C. M.; Sagnella, S. M.; Teo, W. S.; Po'uha, S. T.; McCarroll, J. A.; Kavallaris, M.] UNSW Australia, ARC Ctr Excellence Convergent Bionano Sci & Techn, Sydney, NSW, Australia; [Fife, C. M.; Sagnella, S. M.; Teo, W. S.; Po'uha, S. T.; McCarroll, J. A.; Kavallaris, M.] UNSW Australia, Australian Ctr NanoMed, Sydney, NSW, Australia; [Byrne, F. L.] UNSW Australia, Biotechnol & Biomol Sci, Sydney, NSW, Australia; [Yeap, Y. Y. C.; Ng, D. C. H.] Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic, Australia; [Yeap, Y. Y. C.; Ng, D. C. H.] Univ Queensland, Sch Biomed Sci, Brisbane, Qld, Australia; [Davis, T. P.] Monash Univ, Monash Inst Pharmaceut Sci, ARC Ctr Convergent Bionanosci & Technol, Melbourne, Vic, Australia; [Davis, T. P.] Univ Warwick, Dept Chem, Coventry, W Midlands, England	Children's Cancer Institute; University of New South Wales Sydney; University of New South Wales Sydney; University of New South Wales Sydney; University of New South Wales Sydney; University of Melbourne; University of Queensland; Monash University; University of Warwick	McCarroll, JA; Kavallaris, M (corresponding author), UNSW Australia, Lowy Canc Res Ctr, Childrens Canc Inst, Tumour Biol & Targeting Program, POB 81, Randwick, NSW 2031, Australia.	jmccarroll@ccia.unsw.edu.au; m.kavallaris@ccia.unsw.edu.au	Davis, Thomas/B-6395-2008; McCarroll, Joshua/E-8481-2010; Byrne, Frances/AAW-7748-2020; Ng, Dominic/C-7291-2015	Davis, Thomas/0000-0003-2581-4986; McCarroll, Joshua/0000-0001-8807-3623; Byrne, Frances/0000-0002-8897-8438; Ng, Dominic/0000-0003-4657-159X	Cancer Council New South Wales; Kids Cancer Project; ARC Future Fellowship [FT120100193]; Hope Funds for Cancer Research Fellowship [HFCR-14-06-04]; Cancer Institute NSW Career Development Fellowship [15/CDF/1-02]; NHMRC Senior Research Fellowships [APP1058299]; Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology [CE140100036]; Cancer Institute of New South Wales	Cancer Council New South Wales(Cancer Council New South Wales); Kids Cancer Project; ARC Future Fellowship(Australian Research Council); Hope Funds for Cancer Research Fellowship; Cancer Institute NSW Career Development Fellowship; NHMRC Senior Research Fellowships(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology(Australian Research Council); Cancer Institute of New South Wales	We thank the Children's Cancer Institute, which is affiliated with the University of New South Wales (UNSW Australia), and Sydney Children's Hospital Network and by grants from the Cancer Council New South Wales (to MK), Kids Cancer Project (to MK), ARC Future Fellowship (to DCHN; FT120100193), Hope Funds for Cancer Research Fellowship (to FLB; HFCR-14-06-04), Cancer Institute NSW Career Development Fellowship (15/CDF/1-02) and NHMRC Senior Research Fellowships (to MK; APP1058299). MK and TPD are funded by the Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology (project number CE140100036). This research was supported by a Cancer Institute of New South Wales infrastructure award.	ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Amayed P, 2002, J BIOL CHEM, V277, P22718, DOI 10.1074/jbc.M111605200; Ara T, 2006, CANCER METAST REV, V25, P645, DOI 10.1007/s10555-006-9028-9; Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; Belletti B, 2005, CURR MED CHEM, V12, P1589, DOI 10.2174/0929867054367149; Belletti B, 2008, MOL BIOL CELL, V19, P2003, DOI 10.1091/mbc.E07-09-0894; Belletti B, 2011, EXPERT OPIN THER TAR, V15, P1249, DOI 10.1517/14728222.2011.620951; Belletti B, 2010, MOL CELL BIOL, V30, P2229, DOI 10.1128/MCB.00723-09; BERETTA L, 1993, J BIOL CHEM, V268, P20076; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Bieche I, 2003, GENOMICS, V81, P400, DOI 10.1016/S0888-7543(03)00031-4; Budde PP, 2001, J CELL BIOL, V153, P149, DOI 10.1083/jcb.153.1.149; Byrne FL, 2014, ONCOGENE, V33, P882, DOI 10.1038/onc.2013.11; CHNEIWEISS H, 1989, J NEUROCHEM, V53, P856, DOI 10.1111/j.1471-4159.1989.tb11783.x; Curmi PA, 1999, CELL STRUCT FUNCT, V24, P345; Daniel C, 2004, LAB INVEST, V84, P588, DOI 10.1038/labinvest.3700078; Delaloy C, 2010, CELL STEM CELL, V6, P323, DOI 10.1016/j.stem.2010.02.015; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FEUERSTEIN N, 1983, J BIOL CHEM, V258, P786; Fife CM, 2014, BRIT J PHARMACOL, V171, P5507, DOI 10.1111/bph.12704; Giampietro C, 2005, ENDOCRINOLOGY, V146, P1825, DOI 10.1210/en.2004-0972; Goukassian D, 2001, FASEB J, V15, P1877, DOI 10.1096/fj.01-0065com; Gutierrez JC, 2007, PEDIATR SURG INT, V23, P637, DOI 10.1007/s00383-007-1933-7; HAILAT N, 1990, ONCOGENE, V5, P1615; Hall A, 2012, BIOCHEM SOC T, V40, P1378, DOI 10.1042/BST20120103; HANASH SM, 1988, J BIOL CHEM, V263, P12813; Hsieh SY, 2010, MOL CARCINOGEN, V49, P476, DOI 10.1002/mc.20627; Jeon TY, 2010, BRIT J CANCER, V102, P710, DOI 10.1038/sj.bjc.6605537; Jin KL, 2004, FASEB J, V18, P287, DOI 10.1096/fj.03-0973com; KOPPEL J, 1990, J BIOL CHEM, V265, P3703; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Kurokawa K, 2005, MOL BIOL CELL, V16, P4294, DOI 10.1091/mbc.E04-12-1076; Machacek M, 2009, NATURE, V461, P99, DOI 10.1038/nature08242; Maris JM, N ENGL J MED, V362, P2202; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; McCarroll JA, 2015, CANCER RES, V75, P415, DOI 10.1158/0008-5472.CAN-14-2740; McCarroll JA, 2010, CANCER RES, V70, P4995, DOI 10.1158/0008-5472.CAN-09-4487; Mistry SJ, 2007, MOL CANCER RES, V5, P773, DOI 10.1158/1541-7786.MCR-06-0290; Nalbant P, 2004, SCIENCE, V305, P1615, DOI 10.1126/science.1100367; Ng DCH, 2006, J CELL BIOL, V172, P245, DOI 10.1083/jcb.200503021; Niethammer P, 2004, SCIENCE, V303, P1862, DOI 10.1126/science.1094108; Ozon S, 2002, MOL BIOL CELL, V13, P698, DOI 10.1091/mbc.01-07-0362; PASMANTIER R, 1986, ENDOCRINOLOGY, V119, P1229, DOI 10.1210/endo-119-3-1229; Pertz O, 2006, NATURE, V440, P1069, DOI 10.1038/nature04665; Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104; Sadow PM, 2008, ENDOCR PATHOL, V19, P97, DOI 10.1007/s12022-008-9028-0; SCHUBART UK, 1992, DIFFERENTIATION, V51, P21, DOI 10.1111/j.1432-0436.1992.tb00676.x; Singer S, 2009, CANCER RES, V69, P2234, DOI 10.1158/0008-5472.CAN-08-3338; SOBEL A, 1989, J BIOL CHEM, V264, P3765; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Steinmetz MO, 2007, J STRUCT BIOL, V158, P137, DOI 10.1016/j.jsb.2006.07.018; Sun J, 2001, CIRCULATION, V103, P2967, DOI 10.1161/01.CIR.103.24.2967; Trovik J, 2011, CLIN CANCER RES, V17, P3368, DOI 10.1158/1078-0432.CCR-10-2412; Van Sluis GL, 2009, BLOOD, V114, P1968, DOI 10.1182/blood-2009-04-217679; Verma NK, 2009, J BIOL CHEM, V284, P12349, DOI 10.1074/jbc.M807761200; Vinci M, 2012, BMC BIOL, V10, DOI 10.1186/1741-7007-10-29	56	23	24	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					501	511		10.1038/onc.2016.220	http://dx.doi.org/10.1038/onc.2016.220			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27321182				2022-12-17	WOS:000394166700007
J	Dong, H; Ma, L; Gan, J; Lin, W; Chen, C; Yao, Z; Du, L; Zheng, L; Ke, C; Huang, X; Song, H; Kumar, R; Yeung, SC; Zhang, H				Dong, H.; Ma, L.; Gan, J.; Lin, W.; Chen, C.; Yao, Z.; Du, L.; Zheng, L.; Ke, C.; Huang, X.; Song, H.; Kumar, R.; Yeung, S. C.; Zhang, H.			PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2	ONCOGENE			English	Article							PROTEIN-TYROSINE PHOSPHATASES; TUMOR-SUPPRESSOR; EPITHELIAL-CELLS; MAMMARY TUMORIGENESIS; CANCER PATIENTS; RECEPTOR; ACTIVATION; EXPRESSION; TRANSFORMATION; THERAPY	The plasma membrane-associated tyrosine phosphatase PTPRO is frequently transcriptionally repressed in cancers and signifies poor prognosis of breast cancer patients. In this study, deletion of Ptpro in MMTV-Erbb2 transgenic mice dramatically shortened the mammary tumor latency and accelerated tumor growth due to loss of Ptpro within the breast cancer cells but not in surrounding tissue as confirmed by hetero-transplantation studies. Both in vitro and in vivo data demonstrated that the phosphatase activity was required for the inactivation of ERBB2 and its downstream signaling. PTPRO regulated the phosphorylation status of ERBB2 at Y1248. Co-immunoprecipitation and proximity ligation assay (Duolink) indicated that PTPRO directly physically interacted with ERBB2. Moreover, PTPRO phosphatase activity shortened the half-life of ERBB2 by increasing endocytotic degradation. PTPRO reexpression by demethylation treatment using 5-azacytidine reduced the proliferation and colony formation potential in ERBB2positive breast cancer cells. Taken together, PTPRO inhibited ERBB2-driven breast cancer through dephosphorylation leading to dual effects of ERBB2 signaling suppression and endosomal internalization of ERBB2, Therefore, reexpression of PTPRO may be a potential therapy for ERBB2-overexpressing breast cancer.	[Dong, H.; Gan, J.; Lin, W.; Chen, C.; Yao, Z.; Du, L.; Zheng, L.; Ke, C.; Yeung, S. C.; Zhang, H.] Shantou Univ, Canc Res Ctr, Coll Med, Xinling Rd 22, Shantou 515041, Peoples R China; [Ma, L.] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol, Houston, TX 77030 USA; [Huang, X.] Nanjing Univ, Model Anim Res Ctr, MOE Key Lab Model Anim Dis Study, Nanjing, Peoples R China; [Song, H.] Xi An Jiao Tong Univ, Dept Cell Biol, Suzhou Acad, Suzhou, Peoples R China; [Kumar, R.] George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Med, Washington, DC 20037 USA; [Yeung, S. C.] Univ Texas MD Anderson Canc Ctr, Dept Emergency Med, Houston, TX 77030 USA; [Yeung, S. C.] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Zhang, H.] Shantou Univ, Coll Med, Affiliated Canc Hosp, Dept Biotherapy, Shantou, Peoples R China	Shantou University; University of Texas System; UTMD Anderson Cancer Center; Nanjing University; Xi'an Jiaotong University; George Washington University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Shantou University	Zhang, H (corresponding author), Shantou Univ, Canc Res Ctr, Coll Med, Xinling Rd 22, Shantou 515041, Peoples R China.; Yeung, SC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, 1515 Holcombe Blvd, Houston, TX 77030 USA.	syeung@mdanderson.org; haozhang@stu.edu.cn	Yeung, Sai-Ching/AAP-8079-2020; Kumar, Rakesh/ABD-1065-2020; Yeung, Sai-Ching/AAI-6178-2021	Kumar, Rakesh/0000-0001-7664-0803; Yeung, Sai-Ching/0000-0001-5170-0822; huang, xingxu/0000-0001-8934-1247; Du, Liang/0000-0002-1191-2465	National Natural Science Foundation of China NSFC [81071736, 30973508, 81572876, 31271495]; Department of Education, Guangdong Government under the Top-tier University Development Scheme for Research and Control of Infectious Diseases	National Natural Science Foundation of China NSFC(National Natural Science Foundation of China (NSFC)); Department of Education, Guangdong Government under the Top-tier University Development Scheme for Research and Control of Infectious Diseases	This work was supported in part by National Natural Science Foundation of China NSFC (81071736, 30973508 and 81572876 to HZ and 31271495 to HS), the funding for Collaborative and Creative Center, Molecular Diagnosis and Personalized Medicine, Shantou University, Guangdong Province, and the funding from the Department of Education, Guangdong Government under the Top-tier University Development Scheme for Research and Control of Infectious Diseases. We thank Dr Stanley Lin for the careful reading the manuscript.	Aceto N, 2012, NAT MED, V18, P529, DOI 10.1038/nm.2645; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Anthis NJ, 2009, J BIOL CHEM, V284, P36700, DOI 10.1074/jbc.M109.061275; Arias-Romero LE, 2009, CANCER RES, V69, P4582, DOI 10.1158/0008-5472.CAN-08-4001; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Asbagh LA, 2014, ONCOTARGET, V5, P10070, DOI 10.18632/oncotarget.2458; Bard-Chapeau EA, 2011, CANCER CELL, V19, P629, DOI 10.1016/j.ccr.2011.03.023; Barr AJ, 2009, CELL, V136, P352, DOI 10.1016/j.cell.2008.11.038; Chaturvedi P, 2008, CANCER RES, V68, P2065, DOI 10.1158/0008-5472.CAN-07-6041; Chen B, 2005, J NEUROSCI, V25, P880, DOI 10.1523/JNEUROSCI.4365-04.2005; Cicenas J, 2006, EUR J CANCER, V42, P636, DOI 10.1016/j.ejca.2005.11.012; Dankort D, 2001, J BIOL CHEM, V276, P38921, DOI 10.1074/jbc.M106239200; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gensler M, 2004, J BIOL CHEM, V279, P12110, DOI 10.1074/jbc.M309527200; Gradishar WJ, 2013, ANN ONCOL, V24, P2492, DOI 10.1093/annonc/mdt217; Hayashi N, 2011, ONCOLOGIST, V16, P956, DOI 10.1634/theoncologist.2010-0409; Hou JJ, 2013, HEPATOLOGY, V57, P678, DOI 10.1002/hep.25980; Huang YT, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-245; Hudelist G, 2006, INT J CANCER, V118, P1126, DOI 10.1002/ijc.21492; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Julien SG, 2007, NAT GENET, V39, P338, DOI 10.1038/ng1963; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lui VWY, 2014, P NATL ACAD SCI USA, V111, P1114, DOI 10.1073/pnas.1319551111; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Meyer DS, 2014, ONCOGENE, V33, P398, DOI 10.1038/onc.2012.585; Miaczynska M, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009035; Monast CS, 2012, BIOPHYS J, V102, P2012, DOI 10.1016/j.bpj.2012.03.037; Mori Y, 2004, CANCER RES, V64, P2434, DOI 10.1158/0008-5472.CAN-03-3508; Motiwala T, 2004, P NATL ACAD SCI USA, V101, P13844, DOI 10.1073/pnas.0405451101; Motiwala T, 2003, ONCOGENE, V22, P6319, DOI 10.1038/sj.onc.1206750; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Ramaswamy B, 2009, MOL ENDOCRINOL, V23, P176, DOI 10.1210/me.2008-0211; Ramsauer VP, 2006, MOL BIOL CELL, V17, P2931, DOI 10.1091/mbc.E05-09-0895; Ramsauer VP, 2003, J BIOL CHEM, V278, P30142, DOI 10.1074/jbc.M303220200; Roepstorff K, 2008, HISTOCHEM CELL BIOL, V129, P563, DOI 10.1007/s00418-008-0401-3; Schneeberger VE, 2015, ONCOTARGET, V6, P6191, DOI 10.18632/oncotarget.3356; Stepanek L, 2001, J CELL BIOL, V154, P867, DOI 10.1083/jcb.200105019; Stern HM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3001539; Sun TT, 2011, CELL, V144, P703, DOI 10.1016/j.cell.2011.02.003; Taniyama K, 2008, BREAST CANCER-TOKYO, V15, P231, DOI 10.1007/s12282-007-0026-8; Veeriah S, 2009, P NATL ACAD SCI USA, V106, P9435, DOI 10.1073/pnas.0900571106; Wang HM, 2014, CELL RES, V24, P1067, DOI 10.1038/cr.2014.99; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Weibrecht I, 2010, EXPERT REV PROTEOMIC, V7, P401, DOI 10.1586/EPR.10.10; You YJ, 2012, CANCER LETT, V315, P138, DOI 10.1016/j.canlet.2011.08.032; Yu M, 2012, MOL CELL BIOL, V32, P3913, DOI 10.1128/MCB.00068-12; Yuan TC, 2010, J BIOL CHEM, V285, P14861, DOI 10.1074/jbc.M109.099879; Zhang H, 2004, CANCER RES, V64, P7169, DOI 10.1158/0008-5472.CAN-04-1176; Zhang H, 2006, GENE DEV, V20, P2943, DOI 10.1101/gad.1461706; Zhao S, 2015, ONCOGENE, V34, P3885, DOI 10.1038/onc.2014.326; Zhu JH, 2008, ONCOGENE, V27, P2525, DOI 10.1038/sj.onc.1210922	53	23	23	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	2017	36	3					410	422		10.1038/onc.2016.213	http://dx.doi.org/10.1038/onc.2016.213			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IB	27345410	Green Published, hybrid			2022-12-17	WOS:000394166000010
J	Shen, J; Tsoi, H; Liang, Q; Chu, ESH; Liu, D; Yu, ACS; Chan, TF; Li, X; Sung, JJY; Wong, VWS; Yu, J				Shen, J.; Tsoi, H.; Liang, Q.; Chu, E. S. H.; Liu, D.; Yu, A. C-S; Chan, T. F.; Li, X.; Sung, J. J. Y.; Wong, V. W. S.; Yu, J.			Oncogenic mutations and dysregulated pathways in obesity-associated hepatocellular carcinoma	ONCOGENE			English	Article							CARBOXYL ESTER LIPASE; FATTY LIVER-DISEASE; CELL-PROLIFERATION; CHOLESTERYL ESTERS; SEQUENCING DATA; DOWN-REGULATION; INHIBITORY ROLE; BILIARY-TRACT; IN-VITRO; CANCER	Epidemiological studies showed that obesity and its related non-alcoholic fatty liver disease (NAFLD) promote hepatocellular carcinoma (HCC) development. We aimed to uncover the genetic alterations of NAFLD-HCC using whole-exome sequencing. We compared HCC development in genetically obese mice and dietary obese mice with wild-type lean mice fed a normal chow after treatment with diethylnitrosamine. HCC tumor and adjacent normal samples from obese and lean mice were then subjected to whole-exome sequencing. Functional and mechanistic importance of the identified mutations in Carboxyl ester lipase (Cel) gene and Harvey rat sarcoma virus oncogene 1 (Hras) was further elucidated. We demonstrated significantly higher incidences of HCC in both genetic and dietary obese mice with NAFLD development as compared with lean mice without NAFLD. The mutational signatures of NAFLD-HCC and lean HCC were distinct, with o3% overlapped. Eight metabolic or oncogenic pathways were found to be significantly enriched by mutated genes in NAFLD-HCC, but only two of these pathways were dysregulated by mutations in lean HCC. In particular, Cel was mutated significantly more frequently in NAFLD-HCC than in lean HCC. The multiple-site mutations in Cel are loss-of-function mutations, with effects similar to Cel knock-down. Mutant Cel caused accumulation of cholesteryl ester in liver cells, which led to induction of endoplasmic reticulum stress and consequently activated the IRE1a/c-Jun N-terminal kinase (JNK)/cJun/ activating protein-1 (AP-1) signaling cascade to promote liver cell growth. In addition, single-site mutations in Hras at codon 61 were found in NAFLD-HCC but none in lean HCC. The gain-of-function mutations in Hras (Q61R and Q61K) significantly promoted liver cell growth through activating the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/3-phosphoinositide-dependent protein kinase-1 (PDK1)/Akt pathways. In conclusion, we have identified mutation signature and pathways in NAFLD-associated HCC. Mutations in Cel and Hras have important roles in NAFLD-associated hepatocellular carcinogenesis.	[Shen, J.; Tsoi, H.; Liang, Q.; Chu, E. S. H.; Liu, D.; Li, X.; Sung, J. J. Y.; Wong, V. W. S.; Yu, J.] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Shen, J.; Tsoi, H.; Liang, Q.; Chu, E. S. H.; Liu, D.; Li, X.; Sung, J. J. Y.; Wong, V. W. S.; Yu, J.] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Yu, A. C-S; Chan, T. F.] Chinese Univ Hong Kong, Sch Life Sci, Hong Kong, Hong Kong, Peoples R China; [Yu, A. C-S; Chan, T. F.] Chinese Univ Hong Kong, State Key Lab Agrobiotechnol, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	Wong, VWS; Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Room 707A,7-F,Li Ka Shing Med Sci Bldg, Shatin, Hong Kong, Peoples R China.	wongv@cuhk.edu.hk; junyu@cuhk.edu.hk	Sung, Joseph J. Y./R-3203-2018; Liang, Qiaoyi Jessie/G-9612-2019; Wong, Vincent WS/K-3864-2014; Liu, Dabin/GNH-2648-2022; Wong, Grace LH/L-8586-2014; Li, Xiao-xing/B-9114-2008; Chan, TingFung/A-6161-2013; Jun, Yu/D-8569-2015	Sung, Joseph J. Y./0000-0003-3125-5199; Liang, Qiaoyi Jessie/0000-0001-8496-3442; Wong, Vincent WS/0000-0003-2215-9410; Wong, Grace LH/0000-0002-2863-9389; Li, Xiao-xing/0000-0001-8791-7505; Chan, TingFung/0000-0002-0489-3884; Liu, Dabin/0000-0002-3811-8317; Jun, Yu/0000-0001-5008-2153; Yu, Allen Chi-Shing/0000-0002-9568-8316; tsoi, ho/0000-0003-2037-9575	RGC-GRF Hong Kong [14106415]; RGC-CRF Hong Kong [CUHK3/CRF/12R, HKU3/CRF11R]; National Basic Research Program of China (973 Program) [2013CB531401]; RGC-Theme-based Research Scheme Hong Kong [T12-403-11]; Shenzhen Virtual University Park Support Scheme	RGC-GRF Hong Kong(Hong Kong Research Grants Council); RGC-CRF Hong Kong; National Basic Research Program of China (973 Program)(National Basic Research Program of China); RGC-Theme-based Research Scheme Hong Kong; Shenzhen Virtual University Park Support Scheme	The project was supported by the RGC-GRF Hong Kong (14106415); RGC-CRF Hong Kong (CUHK3/CRF/12R; HKU3/CRF11R); National Basic Research Program of China (973 Program, 2013CB531401); RGC-Theme-based Research Scheme Hong Kong (T12-403-11); Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute. The results shown here are in part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/.	Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Borena W, 2012, INT J CANCER, V131, P193, DOI 10.1002/ijc.26338; Camarota LM, 2004, J BIOL CHEM, V279, P27599, DOI 10.1074/jbc.M402946200; Castellano Esther, 2011, Genes Cancer, V2, P261, DOI 10.1177/1947601911408079; Castellano E, 2010, CURR TOP MICROBIOL, V346, P143, DOI 10.1007/82_2010_56; Chang TY, 2009, AM J PHYSIOL-ENDOC M, V297, pE1, DOI 10.1152/ajpendo.90926.2008; Chang WC, 2006, ACTA PHARMACOL SIN, V27, P813, DOI 10.1111/j.1745-7254.2006.00395.x; Chanson M, 2005, BBA-BIOMEMBRANES, V1711, P197, DOI 10.1016/j.bbamem.2004.10.005; Chen HF, 2010, HEPATOLOGY, V52, P155, DOI 10.1002/hep.23641; Cianciola NL, 2013, MOL BIOL CELL, V24, P3309, DOI 10.1091/mbc.E12-10-0760; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Guo GW, 2013, NAT GENET, V45, P1459, DOI 10.1038/ng.2798; Hui DY, 2002, J LIPID RES, V43, P2017, DOI 10.1194/jlr.R200013-JLR200; Hui LJ, 2008, J CLIN INVEST, V118, P3943, DOI 10.1172/JCI37156; Keane MP, 2000, CRIT CARE MED, V28, pN13, DOI 10.1097/00003246-200004001-00003; Larsson SC, 2007, BRIT J CANCER, V97, P1005, DOI 10.1038/sj.bjc.6603932; Leithe Edward, 2006, Critical Reviews in Oncogenesis, V12, P225; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Limonta P, 2012, ENDOCR REV, V33, P784, DOI 10.1210/er.2012-1014; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mohit E, 2012, IMMUNOTHERAPY-UK, V4, P807, DOI [10.2217/IMT.12.72, 10.2217/imt.12.72]; Nakagawa H, 2014, CANCER CELL, V26, P331, DOI 10.1016/j.ccr.2014.07.001; Osaki LH, 2013, INT J MOL SCI, V14, P10143, DOI 10.3390/ijms140510143; Otoda T, 2013, DIABETES, V62, P811, DOI 10.2337/db11-1652; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Petit V, 2000, BIOL CELL, V92, P477, DOI 10.1016/S0248-4900(00)01101-1; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Raeder H, 2006, NAT GENET, V38, P54, DOI 10.1038/ng1708; Renauld JC, 2003, NAT REV IMMUNOL, V3, P667, DOI 10.1038/nri1153; Schlesinger S, 2013, INT J CANCER, V132, P645, DOI 10.1002/ijc.27645; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Swami M, 2010, NAT REV CANCER, V10, P738, DOI 10.1038/nrc2956; Turati F, 2013, BRIT J CANCER, V108, P222, DOI 10.1038/bjc.2012.492; VOGEL MJ, 1971, IBM J RES DEV, V15, P52, DOI 10.1147/rd.151.0052; Wang J, 2013, J PATHOL, V230, P441, DOI 10.1002/path.4206; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; White DL, 2012, CLIN GASTROENTEROL H, V10, P1342, DOI 10.1016/j.cgh.2012.10.001; Wong VWS, 2013, J GASTROEN HEPATOL, V28, P18, DOI 10.1111/jgh.12011; Ximing DU, 2011, [Frontiers in Biology, 生物学前沿], V6, P190; Yu J, 2010, HEPATOLOGY, V51, P2008, DOI 10.1002/hep.23550; Yue SH, 2014, CELL METAB, V19, P393, DOI 10.1016/j.cmet.2014.01.019	43	23	23	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2016	35	49					6271	6280		10.1038/onc.2016.162	http://dx.doi.org/10.1038/onc.2016.162			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TJ	27132506	Green Published, hybrid			2022-12-17	WOS:000390247000001
J	Paul, PJ; Raghu, D; Chan, AL; Gulati, T; Lambeth, L; Takano, E; Herold, MJ; Hagekyriakou, J; Vessella, RL; Fedele, C; Shackleton, M; Williams, ED; Fox, S; Williams, S; Haupt, S; Gamell, C; Haupt, Y				Paul, P. J.; Raghu, D.; Chan, A-L; Gulati, T.; Lambeth, L.; Takano, E.; Herold, M. J.; Hagekyriakou, J.; Vessella, R. L.; Fedele, C.; Shackleton, M.; Williams, E. D.; Fox, S.; Williams, S.; Haupt, S.; Gamell, C.; Haupt, Y.			Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP	ONCOGENE			English	Article							PROTEASOME INHIBITOR BORTEZOMIB; PML-INDUCED SENESCENCE; DRIVEN; CELLS; FIBROBLASTS; PROGRESSION; MOUSE; DEATH	Restoration of tumor suppression is an attractive onco-therapeutic approach. It is particularly relevant when a tumor suppressor is excessively degraded by an overactive oncogenic E3 ligase. We previously discovered that the E6-associated protein (E6AP; as classified in the human papilloma virus context) is an E3 ligase that has an important role in the cellular stress response, and it directly targets the tumor-suppressor promyelocytic leukemia protein (PML) for proteasomal degradation. In this study, we have examined the role of the E6AP-PML axis in prostate cancer (PC). We show that knockdown (KD) of E6AP expression attenuates growth of PC cell lines in vitro. We validated this finding in vivo using cell line xenografts, patient-derived xenografts and mouse genetics. We found that KD of E6AP attenuates cancer cell growth by promoting cellular senescence in vivo, which correlates with restoration of tumor suppression by PML. In addition, we show that KD of E6AP sensitizes cells to radiation-induced death. Overall, our findings demonstrate a role for E6AP in the promotion of PC and support E6AP targeting as a novel approach for PC treatment, either alone or in combination with radiation.	[Paul, P. J.; Raghu, D.; Gulati, T.; Haupt, Y.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Paul, P. J.; Raghu, D.; Chan, A-L; Gulati, T.; Lambeth, L.; Haupt, S.; Gamell, C.; Haupt, Y.] Peter MacCallum Canc Ctr, Tumor Suppress Lab, St Andrews Pl, Melbourne, Vic 3002, Australia; [Takano, E.; Fedele, C.; Shackleton, M.; Fox, S.] Peter MacCallum Canc Ctr, Dept Pathol, Melbourne, Vic, Australia; [Herold, M. J.] Walter & Eliza Hall Inst Med Res, Mol Genet Canc, Parkville, Vic, Australia; [Herold, M. J.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia; [Hagekyriakou, J.] Peter MacCallum Canc Ctr, Dept Phys Sci, Melbourne, Vic, Australia; [Vessella, R. L.] Univ Washington, Dept Urol, Seattle, WA 98195 USA; [Fedele, C.; Shackleton, M.] Peter MacCallum Canc Ctr, Canc Dev & Treatment Lab, Melbourne, Vic, Australia; [Fedele, C.; Shackleton, M.; Williams, S.; Haupt, Y.] Peter MacCallum Canc Ctr, Div Radiat Oncol & Canc Imaging, Melbourne, Vic, Australia; [Williams, E. D.] Queensland Univ Technol, Australian Prostate Canc Res Ctr, Brisbane, Qld, Australia; [Haupt, Y.] Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic, Australia; [Haupt, Y.] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia; [Paul, P. J.] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Tumor Pathol Dept, Gliwice Branch, Gliwice, Poland; [Chan, A-L] Monash Univ, Australian Regenerat Med Inst, Melbourne, Vic, Australia; [Lambeth, L.] Murdoch Childrens Res Inst, Parkville, Vic, Australia	Peter Maccallum Cancer Center; University of Melbourne; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; Walter & Eliza Hall Institute; University of Melbourne; Peter Maccallum Cancer Center; University of Washington; University of Washington Seattle; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; Queensland University of Technology (QUT); Monash University; University of Melbourne; Maria Sklodowska-Curie National Research Institute of Oncology; Australian Regenerative Medicine Institute; Monash University; Murdoch Children's Research Institute	Gamell, C (corresponding author), Peter MacCallum Canc Ctr, Tumor Suppress Lab, St Andrews Pl, Melbourne, Vic 3002, Australia.	Cristina.Gamell@petermac.org	Williams, Elizabeth D/B-1538-2008; Herold, Marco J/C-8039-2013; Fox, Stephen/G-9719-2016	Williams, Elizabeth D/0000-0002-3364-6655; Herold, Marco J/0000-0001-7539-7581; Paul, Piotr Jan/0000-0002-2319-224X; Fox, Stephen/0000-0002-7648-8896; Raghu, Dinesh/0000-0002-8960-6222; Gulati, Twishi/0000-0003-3841-8392; Chan, Ai-Leen/0000-0003-3553-7249; Gamell, Cristina/0000-0003-0720-2652; Haupt, Ygal/0000-0001-5925-0096	NHMRC [1049179, 1063389, 9628426, 1049720]; PCF creativity grant; CCV grant [1085154]; VCA Richard Pratt Fellowship in Prostate Cancer Research; PCFA grant [NDDA-1811]; Pfizer Australia; Veski foundings; Foundation of the Peter MacCallum Cancer Centre	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); PCF creativity grant; CCV grant(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); VCA Richard Pratt Fellowship in Prostate Cancer Research; PCFA grant; Pfizer Australia(PfizerPfizer Australia); Veski foundings; Foundation of the Peter MacCallum Cancer Centre	This work was supported by NHMRC project grants (1049179 and 1063389) and NHMRC Fellowship to YH (9628426), NHMRC project grant to MJH (1049720), PCF creativity grant to SW and YH, CCV grant (1085154), VCA Richard Pratt Fellowship in Prostate Cancer Research to CG, the PCFA grant (NDDA-1811) to EW, Pfizer Australia, NHMRC and Veski foundings to MS, and a prostate initiative grant from the Foundation of the Peter MacCallum Cancer Centre. PrEC line was a generous gift from Dr Patrick Humbert and Helen Pearson at Peter MacCallum Cancer Centre.	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alimonti A, 2010, J CLIN INVEST, V120, P681, DOI 10.1172/JCI40535; Beaudenon S, 2008, BMC BIOCHEM, V9, DOI 10.1186/1471-2091-9-S1-S4; Birch SE, 2014, ANN ONCOL, V25, P2392, DOI 10.1093/annonc/mdu454; Chen RH, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-81; Christian PA, 2009, CANCER BIOL THER, V8, P73, DOI 10.4161/cbt.8.1.7132; Corey E, 2003, PROSTATE, V55, P239, DOI 10.1002/pros.10198; de The H, 2012, J CELL BIOL, V198, P11, DOI 10.1083/jcb.201112044; Dreicer R, 2007, CLIN CANCER RES, V13, P1208, DOI 10.1158/1078-0432.CCR-06-2046; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Gamell C, 2014, FEBS LETT, V588, P2653, DOI 10.1016/j.febslet.2014.02.007; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Herold MJ, 2008, P NATL ACAD SCI USA, V105, P18507, DOI 10.1073/pnas.0806213105; Hurwitz A. A., 2001, CURR PROTOC IMMUNOL, DOI [10.1002/0471142735.im2005s45, DOI 10.1002/0471142735.IM2005S45]; Ivanschitz L, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00171; Khan OY, 2006, MOL ENDOCRINOL, V20, P544, DOI 10.1210/me.2005-0110; Kraft AS, 2011, CANCER BIOL THER, V12, P119, DOI 10.4161/cbt.12.2.15723; Levav-Cohen Y, 2012, ONCOGENE, V31, P2199, DOI 10.1038/onc.2011.402; Li Z, 2013, ASIAN J ANDROL, V15, P328, DOI 10.1038/aja.2013.7; Louria-Hayon I, 2009, CELL DEATH DIFFER, V16, P1156, DOI 10.1038/cdd.2009.31; Mallette FA, 2004, ONCOGENE, V23, P91, DOI 10.1038/sj.onc.1206886; Oh W, 2009, J CELL SCI, V122, P2613, DOI 10.1242/jcs.048066; Papandreou CN, 2004, J CLIN ONCOL, V22, P2108, DOI 10.1200/JCO.2004.02.106; Papandreou CN, 2004, CANCER RES, V64, P5036, DOI 10.1158/0008-5472.CAN-03-2707; Pernicova Z, 2011, NEOPLASIA, V13, P526, DOI 10.1593/neo.11182; Price Nancy, 2004, Clin Prostate Cancer, V3, P141; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Salomoni P, 2008, CELL RES, V18, P620, DOI 10.1038/cr.2008.58; Srinivasan S, 2011, BBA-GENE REGUL MECH, V1809, P119, DOI 10.1016/j.bbagrm.2010.08.011; Steiner MS, 2000, ONCOGENE, V19, P1297, DOI 10.1038/sj.onc.1203428; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Wolyniec K, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00124; Wolyniec K, 2012, CELL CYCLE, V11, P3705, DOI 10.4161/cc.22043; Wolyniec K, 2012, BLOOD, V120, P822, DOI 10.1182/blood-2011-10-387647; Yamagishi Y, 2011, CHEM BIOL, V18, P1562, DOI 10.1016/j.chembiol.2011.09.013	38	23	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2016	35	48					6235	6245		10.1038/onc.2016.159	http://dx.doi.org/10.1038/onc.2016.159			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED4YH	27641331				2022-12-17	WOS:000388857700008
J	Si, H; Lu, H; Yang, X; Mattox, A; Jang, M; Bian, Y; Sano, E; Viadiu, H; Yan, B; Yau, C; Ng, S; Lee, SK; Romano, RA; Davis, S; Walker, RL; Xiao, W; Sun, H; Wei, L; Sinha, S; Benz, CC; Stuart, JM; Meltzer, PS; Van Waes, C; Chen, Z				Si, H.; Lu, H.; Yang, X.; Mattox, A.; Jang, M.; Bian, Y.; Sano, E.; Viadiu, H.; Yan, B.; Yau, C.; Ng, S.; Lee, S. K.; Romano, R-A; Davis, S.; Walker, R. L.; Xiao, W.; Sun, H.; Wei, L.; Sinha, S.; Benz, C. C.; Stuart, J. M.; Meltzer, P. S.; Van Waes, C.; Chen, Z.			TNF-alpha modulates genome-wide redistribution of Delta Np63 alpha/TAp73 and NF-kappa B cREL interactive binding on TP53 and AP-1 motifs to promote an oncogenic gene program in squamous cancer	ONCOGENE			English	Article							CELL CARCINOMA; C-JUN; TRANSCRIPTION FACTORS; TUMOR SUPPRESSION; SIGNAL PATHWAYS; GROWTH-FACTOR; NECK-CANCER; P53 HOMOLOG; HUMAN HEAD; P63	The Cancer Genome Atlas (TCGA) network study of 12 cancer types (PanCancer 12) revealed frequent mutation of TP53, and amplification and expression of related TP63 isoform Delta Np63 in squamous cancers. Further, aberrant expression of inflammatory genes and TP53/p63/p73 targets were detected in the PanCancer 12 project, reminiscent of gene programs comodulated by cREL/Delta Np63/TAp73 transcription factors we uncovered in head and neck squamous cell carcinomas (HNSCCs). However, how inflammatory gene signatures and cREL/p63/p73 targets are comodulated genome wide is unclear. Here, we examined how the inflammatory factor tumor necrosis factor-alpha (TNF-alpha) broadly modulates redistribution of cREL with Delta Np63 alpha/TAp73 complexes and signatures genome wide in the HNSCC model UM-SCC46 using chromatin immunoprecipitation sequencing (ChIP-seq). TNF-alpha enhanced genome-wide co-occupancy of cREL with Delta Np63 alpha on TP53/p63 sites, while unexpectedly promoting redistribution of TAp73 from TP53 to activator protein-1 (AP-1) sites. cREL, Delta Np63 alpha and TAp73 binding and oligomerization on NF-kappa B-, TP53- or AP-1-specific sequences were independently validated by ChIP-qPCR (quantitative PCR), oligonucleotide-binding assays and analytical ultracentrifugation. Function of the binding activity was confirmed using TP53-, AP-1- and NF-kappa B-specific REs or p21, SERPINE1 and IL-6 promoter luciferase reporter activities. Concurrently, TNF-alpha regulated a broad gene network with cobinding activities for cREL, Delta Np63 alpha and TAp73 observed upon array profiling and reverse transcription-PCR. Overlapping target gene signatures were observed in squamous cancer subsets and in inflamed skin of transgenic mice overexpressing Delta Np63 alpha. Furthermore, multiple target genes identified in this study were linked to TP63 and TP73 activity and increased gene expression in large squamous cancer samples from PanCancer 12 TCGA by CircleMap. PARADIGM inferred pathway analysis revealed the network connection of TP63 and NF-kappa B complexes through an AP-1 hub, further supporting our findings. Thus, inflammatory cytokine TNF-a mediates genome-wide redistribution of the cREL/p63/p73, and AP-1 interactome, to diminish TAp73 tumor suppressor function and reciprocally activate NF-kappa B and AP-1 gene programs implicated in malignancy.	[Si, H.; Lu, H.; Yang, X.; Mattox, A.; Jang, M.; Bian, Y.; Lee, S. K.; Van Waes, C.; Chen, Z.] NIDCD, Tumor Biol Sect, Head & Neck Surg Branch, NIH, Bethesda, MD USA; [Lu, H.] Zhujiang Hosp Guangzhou, Orthopaed Ctr, Guangzhou, Guangdong, Peoples R China; [Sano, E.] Univ Calif San Diego, Dept Chem & Biochem, San Diego, CA 92103 USA; [Viadiu, H.] Univ Nacl Autonoma Mexico, Inst Quim, Ciudad Univ, Mexico City, DF, Mexico; [Yan, B.] Univ Hong Kong, LKS Fac Med, Hong Kong, Hong Kong, Peoples R China; [Yan, B.] Univ Hong Kong, LKS Fac Med, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Yan, B.] Univ Hong Kong, Ctr Genome Sci, Hong Kong, Hong Kong, Peoples R China; [Yau, C.; Benz, C. C.] Buck Inst Res Aging, Novato, CA USA; [Ng, S.; Stuart, J. M.] Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Dept Biomol Engn, Santa Cruz, CA 95064 USA; [Romano, R-A; Sinha, S.] SUNY Buffalo, Ctr Excellence Bioinformat & Life Sci, Dept Biochem, Buffalo, NY USA; [Davis, S.; Walker, R. L.] NCI, Canc Genet Branch, Bethesda, MD 20892 USA; [Xiao, W.] US FDA, Natl Ctr Toxicol Res, Div Bioinformat & Biostat, Jefferson, AK USA; [Sun, H.] NIAMSD, Biodata Min & Discovery Sect, Bethesda, MD 20892 USA; [Wei, L.] NEI, Clin Immunol Sect, NIH, Bethesda, MD 20892 USA; [Wei, L.] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Guangdong, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Southern Medical University - China; University of California System; University of California San Diego; Universidad Nacional Autonoma de Mexico; University of Hong Kong; University of Hong Kong; University of Hong Kong; Buck Institute for Research on Aging; University of California System; University of California Santa Cruz; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Sun Yat Sen University	Van Waes, C (corresponding author), NIDCD, NIH, Bldg 10-CRC,4-2732,10 Ctr Dr, Bethesda, MD 20892 USA.; Chen, Z (corresponding author), NIDCD, Clin Genom Unit, Head & Neck Surg Branch, NIH, Bldg 10-5D55,10 Ctr Dr, Bethesda, MD 20892 USA.	vanwaesc@nidcd.nih.gov; chenz@nidcd.nih.gov	Davis, Sean/AAD-1801-2021	Davis, Sean/0000-0002-8991-6458; Walker, Robert/0000-0001-8235-4686; Stuart, Joshua/0000-0002-2171-565X; /0000-0002-2168-3379; Lu, Hai/0000-0002-4212-3282	NIH [R01AR049238]; NCI [R01-CA180778, U24-CA143858]; Stand Up to Cancer; Prostate Cancer Foundation; Movember Foundation;  [ZIA-DC-000073];  [ZIA-DC-000074]; NATIONAL CANCER INSTITUTE [U24CA210990, U24CA143858, R01CA180778, ZIABC011091] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG006097] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM109031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000073, Z01DC000073, ZIADC000016, ZIADC000074] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Stand Up to Cancer; Prostate Cancer Foundation; Movember Foundation; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	We thank Dr Fan Yang (NCI/NIH), Dr Kairong Cui (NHLBI/NIH), Dr Bingmei Zhu (NIDDK/NIH), Jeffery Burnett (NIDCD/NIH), Jamie Coupar (NIDCD/NIH), Guanmei Liang (Thomas Jefferson High School for Science and Technology, Alexandria, VA, USA) and Eric Nicolson (Ithaca High School, Ithaca, New York, NY, USA) for their technical assistance and suggestions. The authors express appreciation to Drs James W Rocco and Leif W Ellisen (Harvard University) for providing Delta Np63 and TAp63 expression vectors, Dr Thomas Gilmore (Boston University) for cRel expression plasmids, Professor Gerry Melino (University of Leicester) for TAp73 alpha expression plasmids, Dr J Silvio Gutkind (NIDCR/NIH) for IL-6 promoter reporter plasmids, Dr Gourisankar Ghosh (UCSD) for the cRel expression plasmid, and Drs Michal Karin (University of California, San Diego), Cheng-Ming Chiang (University of Texas, Southwestern) and Xuan Liu (University of California, Riverside) for critique of and helpful suggestions for the manuscript. HL, HS, XY, AM, MJ, YB, CVW and ZC are supported by intramural projects ZIA-DC-000073, ZIA-DC-000074 and RAR and SS are supported by a grant from NIH (R01AR049238). JMS acknowledges support from NCI (R01-CA180778 and U24-CA143858), Stand Up to Cancer, Prostate Cancer Foundation and the Movember Foundation.	Andreasen PA, 2007, CURR DRUG TARGETS, V8, P1030, DOI 10.2174/138945007781662346; Bancroft CC, 2001, CLIN CANCER RES, V7, P435; Barenco M, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.84; Belyi VA, 2009, P NATL ACAD SCI USA, V106, P17609, DOI 10.1073/pnas.0910634106; Bid HK, 2014, CANCER RES, V74, P320, DOI 10.1158/0008-5472.CAN-13-0894; Boccaccio C, 2005, NATURE, V434, P396, DOI 10.1038/nature03357; Bunting K, 2007, J IMMUNOL, V178, P7097, DOI 10.4049/jimmunol.178.11.7097; Chatterjee A, 2010, CANCER RES, V70, P1419, DOI 10.1158/0008-5472.CAN-09-2613; Collavin L, 2010, CELL DEATH DIFFER, V17, P901, DOI 10.1038/cdd.2010.35; Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; DeYoung MP, 2007, ONCOGENE, V26, P5169, DOI 10.1038/sj.onc.1210337; Dong G, 2004, ONCOGENE, V23, P6199, DOI 10.1038/sj.onc.1207851; Dong G, 2001, CANCER RES, V61, P5911; Du JH, 2014, J PATHOL, V232, P356, DOI 10.1002/path.4302; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049; Jiang H, 2010, BIOINFORMATICS, V26, P1781, DOI 10.1093/bioinformatics/btq286; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; King KE, 2008, CANCER RES, V68, P5122, DOI 10.1158/0008-5472.CAN-07-6123; Koeppel M, 2011, NUCLEIC ACIDS RES, V39, P6069, DOI 10.1093/nar/gkr028; Koshiba S, 2008, J PATHOL, V214, P75, DOI 10.1002/path.2266; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Leong CO, 2007, J CLIN INVEST, V117, P1370, DOI 10.1172/JCI30866; Leslie M, 2011, SCIENCE, V331, P1551, DOI 10.1126/science.331.6024.1551; Lu H, 2011, CANCER RES, V71, P6867, DOI 10.1158/0008-5472.CAN-11-2460; Machanick P, 2011, BIOINFORMATICS, V27, P1696, DOI 10.1093/bioinformatics/btr189; Marcel V, 2011, CELL DEATH DIFFER, V18, P1815, DOI 10.1038/cdd.2011.120; Natan E, 2012, J MOL BIOL, V415, P503, DOI 10.1016/j.jmb.2011.11.007; Ng S, 2012, BIOINFORMATICS, V28, pI640, DOI 10.1093/bioinformatics/bts402; Nottingham LK, 2014, ONCOGENE, V33, P1135, DOI 10.1038/onc.2013.49; O'Donnell RK, 2005, ONCOGENE, V24, P1244, DOI 10.1038/sj.onc.1208285; Ondrey FG, 1999, MOL CARCINOGEN, V26, P119, DOI 10.1002/(SICI)1098-2744(199910)26:2<119::AID-MC6>3.0.CO;2-N; Ortt K, 2006, FEBS LETT, V580, P4544, DOI 10.1016/j.febslet.2006.07.004; Perez CA, 2007, CELL CYCLE, V6, P246, DOI 10.4161/cc.6.3.3801; Rickman DS, 2008, ONCOGENE, V27, P6607, DOI 10.1038/onc.2008.251; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Romano RA, 2011, INDIAN J EXP BIOL, V49, P721; Romano RA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005623; Rosenbluth JM, 2011, P NATL ACAD SCI USA, V108, P2076, DOI 10.1073/pnas.1011936108; Seiwert TY, 2015, CLIN CANCER RES, V21, P632, DOI 10.1158/1078-0432.CCR-13-3310; Sethi G, 2012, BIOSCIENCE REP, V32, P1, DOI 10.1042/BSR20100136; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shin HJ, 2009, BIOINFORMATICS, V25, P2605, DOI 10.1093/bioinformatics/btp479; Smeenk L, 2008, NUCLEIC ACIDS RES, V36, P3639, DOI 10.1093/nar/gkn232; Soussi T, 2007, CANCER CELL, V12, P303, DOI 10.1016/j.ccr.2007.10.001; Toh WH, 2004, J BIOL CHEM, V279, P44713, DOI 10.1074/jbc.M407672200; Vaske CJ, 2010, BIOINFORMATICS, V26, pi237, DOI 10.1093/bioinformatics/btq182; Vayssade M, 2005, INT J CANCER, V116, P860, DOI 10.1002/ijc.21033; Vikhanskaya F, 2007, NAT CELL BIOL, V9, P698, DOI 10.1038/ncb1598; Wong CK, 2013, NUCLEIC ACIDS RES, V41, pW218, DOI 10.1093/nar/gkt473; Yang A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011572; Yang XP, 2011, CANCER RES, V71, P3688, DOI 10.1158/0008-5472.CAN-10-3445; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	55	23	24	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2016	35	44					5781	5794		10.1038/onc.2016.112	http://dx.doi.org/10.1038/onc.2016.112			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XQ	27132513	Green Accepted, Green Submitted			2022-12-17	WOS:000386998400009
J	Powley, IR; Hughes, MA; Cain, K; MacFarlane, M				Powley, I. R.; Hughes, M. A.; Cain, K.; MacFarlane, M.			Caspase-8 tyrosine-380 phosphorylation inhibits CD95 DISC function by preventing procaspase-8 maturation and cycling within the complex	ONCOGENE			English	Article							SIGNALING COMPLEX; CELL-DEATH; APOPTOSIS; MUTATIONS; RECONSTITUTION; ACTIVATION; MECHANISM; SURVIVAL; REVEALS; KINASES	Caspase-8 is a key initiator of apoptotic cell death where it functions as the apical protease in death receptor-mediated apoptosis triggered via the death-inducing signalling complex (DISC). However, the observation that caspase-8 is upregulated in many common tumour types led to the discovery of alternative non-apoptotic, pro-survival functions, many of which are contingent on phosphorylation of a tyrosine residue (Y380) found in the linker region between the two catalytic domains of the enzyme. Furthermore, Src-mediated Y380 phosphorylation leads to increased resistance to CD95-induced apoptosis; however, the mechanism underlying this impaired response to extrinsic apoptotic stimuli has not been identified. Consequently, we have employed a number of model systems to further dissect this protective mechanism. First, using an in vitro DISC model together with recombinant procaspase-8 variants, we show that Y380 phosphorylation inhibits procaspase-8 activation at the CD95 DISC, thereby preventing downstream activation of the caspase cascade. Second, we validated this finding in a cellular context using transfected neuroblastoma cell lines deficient in caspase-8. Reconstitution of these lines with phosphomimetic-caspase-8 results in increased resistance to CD95-mediated apoptosis and enhanced cell migration. When the in vitro DISC is assembled in the presence of cell lysate, caspase-8 Y380 phosphorylation attenuates DISC activity by inhibiting procaspase-8 autoproteolytic activity but not recruitment or homodimerization of caspase-8 within the complex. Once incorporated into the DISC, phosphorylated caspase-8 is unable to be released from the complex; this inhibits further cycling and release of active catalytic subunits into the cytoplasm, thus resulting in increased apoptotic resistance. Taken together, our novel findings expand our understanding of the key mechanisms underlying the anti-apoptotic functions of caspase-8 which may act as a critical block to existing antitumour therapies. Importantly, reversal or inhibition of caspase-8 phosphorylation may prove a valuable avenue to explore for sensitization of resistant tumours to extrinsic apoptotic stimuli.	[Powley, I. R.; Hughes, M. A.; Cain, K.; MacFarlane, M.] MRC, Toxicol Unit, Hodgkin Budding,POB 138,Lancaster Rd, Leicester LE1 9HN, Leics, England	University of Leicester	MacFarlane, M (corresponding author), MRC, Toxicol Unit, Hodgkin Budding,POB 138,Lancaster Rd, Leicester LE1 9HN, Leics, England.	mm21@le.ac.uk			UK Medical Research Council (MRC); MRC [MC_U132685863] Funding Source: UKRI; Medical Research Council [MC_U132685863] Funding Source: researchfish	UK Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We would like to thank Dr T Chernova for her valuable advice regarding qRT-PCR design and analysis. This work was supported by the UK Medical Research Council (MRC).	Alvarado-Kristensson M, 2004, J EXP MED, V199, P449, DOI 10.1084/jem.20031771; Ando M, 2013, CANCER SCI, V104, P1002, DOI 10.1111/cas.12191; Creedon Helen, 2012, Critical Reviews in Oncogenesis, V17, P145; Cursi S, 2006, EMBO J, V25, P1895, DOI 10.1038/sj.emboj.7601085; Dickens LS, 2012, MOL CELL, V47, P291, DOI 10.1016/j.molcel.2012.05.004; Dickens LS, 2012, EXP CELL RES, V318, P1269, DOI 10.1016/j.yexcr.2012.04.005; Frisch SM, 2008, CANCER RES, V68, P4491, DOI 10.1158/0008-5472.CAN-08-0952; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; Hughes MA, 2015, COLD SPRING HARB PRO, V12; Hughes MA, 2013, METHODS, V61, P98, DOI 10.1016/j.ymeth.2013.02.006; Hughes MA, 2009, MOL CELL, V35, P265, DOI 10.1016/j.molcel.2009.06.012; Jia SH, 2008, J BIOL CHEM, V283, P5402, DOI 10.1074/jbc.M706462200; Keller N, 2010, CELL DEATH DIFFER, V17, P710, DOI 10.1038/cdd.2009.155; Keller N, 2009, STRUCTURE, V17, P438, DOI 10.1016/j.str.2008.12.019; Kim HS, 2003, GASTROENTEROLOGY, V125, P708, DOI 10.1016/S0016-5085(03)01059-X; Kurokawa M, 2009, CELL, V138, P838, DOI 10.1016/j.cell.2009.08.021; Langlais C, 2015, COLD SPRING HARB PRO, V12; MacFarlane M, 1997, J CELL BIOL, V137, P469, DOI 10.1083/jcb.137.2.469; Mandal R, 2014, MOL ONCOL, V8, P232, DOI 10.1016/j.molonc.2013.11.003; Matthess Y, 2014, MOL ONCOL, V8, P596, DOI 10.1016/j.molonc.2013.12.013; Oberst A, 2010, J BIOL CHEM, V285, P16632, DOI 10.1074/jbc.M109.095083; Parrish A.B., 2013, COLD SPRING HARB PER, V5, P5, DOI DOI 10.1101/CSHPERSPECT.A008672; Salvesen GS, 2014, SEMIN IMMUNOL, V26, P246, DOI 10.1016/j.smim.2014.03.005; Schleich K, 2012, MOL CELL, V47, P306, DOI 10.1016/j.molcel.2012.05.006; Senft J, 2007, CANCER RES, V67, P11505, DOI 10.1158/0008-5472.CAN-07-5755; Soung YH, 2005, CANCER RES, V65, P815; Torres VA, 2008, J BIOL CHEM, V283, P36280, DOI 10.1074/jbc.M805878200; Xu J, 2013, J BIOL CHEM, V288, P33263, DOI 10.1074/jbc.M113.508093; Zhang SY, 2012, TRENDS PHARMACOL SCI, V33, P122, DOI 10.1016/j.tips.2011.11.002; Zonta F, 2014, BLOOD, V123, P875, DOI 10.1182/blood-2013-02-485540	30	23	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2016	35	43					5629	5640		10.1038/onc.2016.99	http://dx.doi.org/10.1038/onc.2016.99			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XP	27109099	Green Published, hybrid			2022-12-17	WOS:000386998300006
J	Zhu, L; Cheng, X; Shi, J; Lin, J; Chen, G; Jin, H; Liu, AB; Pyo, H; Ye, J; Zhu, Y; Wang, H; Chen, H; Fang, J; Cai, L; Wang, TC; Yang, CS; Tu, SP				Zhu, L.; Cheng, X.; Shi, J.; Lin, J.; Chen, G.; Jin, H.; Liu, A. B.; Pyo, H.; Ye, J.; Zhu, Y.; Wang, H.; Chen, H.; Fang, J.; Cai, L.; Wang, T. C.; Yang, C. S.; Tu, S. P.			Crosstalk between bone marrow-derived myofibroblasts and gastric cancer cells regulates cancer stemness and promotes tumorigenesis	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; TUMOR-GROWTH; EXPRESSION; MICROENVIRONMENT; FIBROBLASTS; INITIATION; NICHE; STAT3; MICE; IL-6	Bone marrow-derived cells have important roles in cancer development and progression. Our previous studies demonstrated that murine bone marrow-derived myofibroblasts (BMFs) enhanced tumor growth. In this study, we investigated the mechanisms of BMF actions. We found that co-injection of BMFs with gastric cancer cells markedly promoted tumorigenesis. Co-cultured BMFs or BMF-conditioned medium (BMF-CM) induced the formation of spheres, which expressed stem cell signatures and exhibited features of self-renewal, epithelial-to-mesenchymal transition and tumor initiation. Furthermore, CD44(+) fractions in spheres were able to initiate tumorigenesis and re-establish tumors in serially passaged xenografts. In co-culture systems, BMFs secreted high levels of murine interleukin-6 (IL-6) and hepatocyte growth factor (HGF), whereas cancer cells produced high level of transformation growth factor-beta 1 (TGF-beta 1). BMF-CM and IL-6 activated BMFs to produce mHGF, which activated signal transducer and activator of transcription 3 (STAT3) and upregulated TGF-beta 1 in human cancer cells. In return, cancer cell-CM stimulated BMFs to produce IL-6, which was inhibited by anti-TGF-beta 1 neutralizing antibody. Blockade of HGF/Met, Janus kinase 2 (JAK2)/STAT3 and TGF-beta 1 signaling by specific inhibitors inhibited BMF-induced sphere formation. STAT3 knockdown in cancer cells also inhibited BMF-induced sphere formation and tumorigenesis. Moreover, TGF-beta 1 overexpression in cancer cells was co-related with IL-6 and HGF overexpression in stromal cells in human gastric cancer tissues. Our results show that BMF-derived IL-6/HGF and cancer cell-derived TGF-beta 1 mediate the interactions between BMFs and gastric cancer cells, which regulate cancer stemness and promote tumorigenesis. Targeting inhibition of the interactions between BMFs and cancer cells may be a new strategy for cancer therapy.	[Zhu, L.; Cheng, X.; Lin, J.; Chen, G.; Tu, S. P.] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Oncol, Shanghai, Peoples R China; [Zhu, L.; Shi, J.; Chen, G.; Jin, H.; Liu, A. B.; Pyo, H.; Wang, H.; Yang, C. S.; Tu, S. P.] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Biol Chem, Piscataway, NJ 08854 USA; [Ye, J.] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Emergency Med, Shanghai, Peoples R China; [Zhu, Y.] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Pathol, Shanghai, Peoples R China; [Chen, H.; Fang, J.] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Gastroenterol, Shanghai, Peoples R China; [Cai, L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ USA; [Wang, T. C.] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA	Shanghai Jiao Tong University; Rutgers State University New Brunswick; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Rutgers State University New Brunswick; Columbia University	Tu, SP (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Oncol, Shanghai, Peoples R China.; Yang, CS; Tu, SP (corresponding author), Rutgers State Univ, Ernest Mario Sch Pharm, Dept Biol Chem, Piscataway, NJ 08854 USA.	csyang@pharmacy.rutgers.edu; tushuiping@yahoo.com	LIN, JIACHENG/ABG-9209-2021	Cai, Li/0000-0003-3344-337X; Wang, Timothy/0000-0001-5730-3019; LIN, JIACHENG/0000-0002-6132-9163	NIH [R21CA149865, RO1 CA133021]; NSFC [81172159, 81272403, 81472727, 91029718, 91429307]; Shanghai Education Committee Key Discipline and Specialty Foundation [J50208]; Science and Technology Commission of Shanghai Municipality [15JC1403100]; NATIONAL CANCER INSTITUTE [R21CA149865, R01CA133021] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSFC(National Natural Science Foundation of China (NSFC)); Shanghai Education Committee Key Discipline and Specialty Foundation; Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The project was supported by NIH R21CA149865, NSFC 81172159, NSFC 81272403, NSFC 81472727, NSFC 91029718, NSFC 91429307 and NIH RO1 CA133021; Shanghai Education Committee Key Discipline and Specialty Foundation (J50208), Science and Technology Commission of Shanghai Municipality (15JC1403100). National Laboratory of Oncogene and Cancer-related Genes foundation (90-15-05).	Beppu H, 2008, ONCOGENE, V27, P1063, DOI 10.1038/sj.onc.1210720; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Birkenkamp-Demtroder K, 2011, BRIT J CANCER, V105, P552, DOI 10.1038/bjc.2011.268; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Castano Z, 2012, SEMIN CANCER BIOL, V22, P462, DOI 10.1016/j.semcancer.2012.04.006; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Giraud AS, 2012, EXPERT OPIN THER TAR, V16, P889, DOI 10.1517/14728222.2012.709238; Gomes I, 2005, J ALLERGY CLIN IMMUN, V116, P796, DOI 10.1016/j.jaci.2005.06.031; Hamerlik P, 2012, J EXP MED, V209, P507, DOI 10.1084/jem.20111424; HAMMACHER A, 1994, PROTEIN SCI, V3, P2280, DOI 10.1002/pro.5560031213; Hawinkels LJ, 2012, ONCOGENE, V33, P97, DOI [DOI 10.1038/ONC.2012.536, DOI 10.1038/onc.2012.536]; Hayward SW, 2001, CANCER RES, V61, P8135; Jinushi M, 2011, P NATL ACAD SCI USA, V108, P12425, DOI 10.1073/pnas.1106645108; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kaplan RN, 2006, CANCER RES, V66, P11089, DOI 10.1158/0008-5472.CAN-06-2407; Lecomte J, 2012, NEOPLASIA, V14, P943, DOI 10.1593/neo.121092; Lee BS, 2009, CELL SIGNAL, V21, P419, DOI 10.1016/j.cellsig.2008.11.010; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Liu XD, 2008, EXPERT OPIN INV DRUG, V17, P997, DOI [10.1517/13543784.17.7.997, 10.1517/13543784.17.7.997 ]; Maguer-Satta V, 2011, STEM CELLS, V29, P389, DOI 10.1002/stem.592; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Powell DW, 2005, AM J PHYSIOL-GASTR L, V289, pG2, DOI 10.1152/ajpgi.00075.2005; Quante M, 2011, CANCER CELL, V19, P257, DOI 10.1016/j.ccr.2011.01.020; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30; Tsai KS, 2011, GASTROENTEROLOGY, V141, P1046, DOI 10.1053/j.gastro.2011.05.045; Tu S, 2008, CANCER CELL, V14, P408, DOI 10.1016/j.ccr.2008.10.011; Tu SP, 2003, CANCER RES, V63, P7724; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Watabe T, 2009, CELL RES, V19, P103, DOI 10.1038/cr.2008.323; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5	33	23	24	3	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2016	35	41					5388	5399		10.1038/onc.2016.76	http://dx.doi.org/10.1038/onc.2016.76			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA5QU	27109105	Green Accepted			2022-12-17	WOS:000386677800005
J	Jones, KB; Barrott, JJ; Xie, M; Haldar, M; Jin, H; Zhu, JF; Monument, MJ; Mosbruger, TL; Langer, EM; Randall, RL; Wilson, RK; Cairns, BR; Ding, L; Capecchi, MR				Jones, K. B.; Barrott, J. J.; Xie, M.; Haldar, M.; Jin, H.; Zhu, J-F; Monument, M. J.; Mosbruger, T. L.; Langer, E. M.; Randall, R. L.; Wilson, R. K.; Cairns, B. R.; Ding, L.; Capecchi, M. R.			The impact of chromosomal translocation locus and fusion oncogene coding sequence in synovial sarcomagenesis	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; RETROSPECTIVE ANALYSIS; PROGNOSTIC IMPLICATION; MULTIGENE FAMILY; GENE-EXPRESSION; MOUSE MODEL; RT-PCR; SSX; SYT; TRANSCRIPTS	Synovial sarcomas are aggressive soft-tissue malignancies that express chromosomal translocation-generated fusion genes, SS18-SSX1 or SS18-SSX2 in most cases. Here, we report a mouse sarcoma model expressing SS18-SSX1, complementing our prior model expressing SS18-SSX2. Exome sequencing identified no recurrent secondary mutations in tumors of either genotype. Most of the few mutations identified in single tumors were present in genes that were minimally or not expressed in any of the tumors. Chromosome 6, either entirely or around the fusion gene expression locus, demonstrated a copy number gain in a majority of tumors of both genotypes. Thus, by fusion oncogene coding sequence alone, SS18-SSX1 and SS18-SSX2 can each drive comparable synovial sarcomagenesis, independent from other genetic drivers. SS18-SSX1 and SS18-SSX2 tumor transcriptomes demonstrated very few consistent differences overall. In direct tumorigenesis comparisons, SS18-SSX2 was slightly more sarcomagenic than SS18-SSX1, but equivalent in its generation of biphasic histologic features. Meta-analysis of human synovial sarcoma patient series identified two tumor-gentoype-phenotype correlations that were not modeled by the mice, namely a scarcity of male hosts and biphasic histologic features among SS18-SSX2 tumors. Re-analysis of human SS18-SSX1 and SS18-SSX2 tumor transcriptomes demonstrated very few consistent differences, but highlighted increased native SSX2 expression in SS18-SSX1 tumors. This suggests that the translocated locus may drive genotypephenotype differences more than the coding sequence of the fusion gene created. Two possible roles for native SSX2 in synovial sarcomagenesis are explored. Thus, even specific partial failures of mouse genetic modeling can be instructive to human tumor biology.	[Jones, K. B.; Barrott, J. J.; Jin, H.; Zhu, J-F; Monument, M. J.; Randall, R. L.] Univ Utah, Dept Orthopaed, 2000 Circle Hope Dr,Room 4263, Salt Lake City, UT 84112 USA; [Jones, K. B.; Barrott, J. J.; Jin, H.; Zhu, J-F; Cairns, B. R.] Univ Utah, Dept Oncol Sci, Salt Lake City, UT USA; [Jones, K. B.; Barrott, J. J.; Jin, H.; Zhu, J-F; Monument, M. J.; Mosbruger, T. L.; Randall, R. L.; Cairns, B. R.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA; [Xie, M.; Wilson, R. K.; Ding, L.] Washington Univ, Dept Med, St Louis, MO USA; [Haldar, M.; Langer, E. M.; Capecchi, M. R.] Univ Utah, Dept Human Genet, Salt Lake City, UT USA; [Mosbruger, T. L.] Univ Utah, Dept Bioinformat, Salt Lake City, UT USA; [Wilson, R. K.; Ding, L.] Washington Univ, McDonnell Genome Inst, St Louis, MO USA; [Wilson, R. K.; Ding, L.] Washington Univ, Dept Genet, St Louis, MO 63110 USA; [Wilson, R. K.; Ding, L.] Washington Univ, Siteman Canc Ctr, St Louis, MO USA; [Cairns, B. R.] Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Washington University (WUSTL); Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Washington University (WUSTL); Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	Jones, KB (corresponding author), Univ Utah, Dept Orthopaed, 2000 Circle Hope Dr,Room 4263, Salt Lake City, UT 84112 USA.; Jones, KB (corresponding author), Univ Utah, Ctr Childrens Canc Res, Huntsman Canc Inst, 2000 Circle Hope Dr,Room 4263, Salt Lake City, UT 84112 USA.	kevin.jones@hci.utah.edu	Wilson, Richard K./AAF-4139-2019	Wilson, Richard K./0000-0002-1992-1358; Barrott, Jared/0000-0001-6059-9009	Paul Nabil Bustany Memorial Fund for Synovial Sarcoma Research; Damon Runyon Cancer Research Foundation; National Cancer Institute/National Institutes of Health (NCI/NIH) [R01CA180006]; National Human Genome Research Institute/NIH [U01HG006517, U54HG003079]; NCI/NIH [K08CA138764]; National Cancer Institute [P30CA042014]; Huntsman Cancer Foundation; NATIONAL CANCER INSTITUTE [R01CA210165, P30CA042014, K08CA138764, R01CA180006] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U01HG006517, U54HG003079] Funding Source: NIH RePORTER	Paul Nabil Bustany Memorial Fund for Synovial Sarcoma Research; Damon Runyon Cancer Research Foundation; National Cancer Institute/National Institutes of Health (NCI/NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Human Genome Research Institute/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Huntsman Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We thank Matt Hockin for provision of the TATCre and Marc Ladanyi, Louis Guillo, Jean- Michel Coindre, Fernanda Amary, Alessandro Gronchi, Ira Kokovic, Satoshi Takenaka and Takafumi Ueda for sharing raw data from their previously published patient series. This work was directly supported by the Paul Nabil Bustany Memorial Fund for Synovial Sarcoma Research and the Damon Runyon Cancer Research Foundation to KBJ, National Cancer Institute/National Institutes of Health (NCI/NIH) grant R01CA180006 to LD and National Human Genome Research Institute/NIH grants U01HG006517 to LD and U54HG003079 to RKW. KBJ received additional career development support from NCI/NIH K08CA138764. This work was also partly supported by P30CA042014 from the National Cancer Institute and the Huntsman Cancer Foundation.	Amary MFC, 2007, MODERN PATHOL, V20, P482, DOI 10.1038/modpathol.3800761; Badea TC, 2003, J NEUROSCI, V23, P2314; Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619; Barrott JJ, 2015, ONCOTARGET, V6, P22758, DOI 10.18632/oncotarget.4283; Begueret H, 2005, AM J SURG PATHOL, V29, P339; Bijwaard KE, 2002, J MOL DIAGN, V4, P59, DOI 10.1016/S1525-1578(10)60681-2; Billings SD, 2004, MODERN PATHOL, V17, P141, DOI 10.1038/modpathol.3800042; Breslin A, 2007, BIOCHEM BIOPH RES CO, V363, P462, DOI 10.1016/j.bbrc.2007.09.052; Carrel L, 2005, NATURE, V434, P400, DOI 10.1038/nature03479; Chen L, 2012, INT J ONCOL, V40, P1986, DOI 10.3892/ijo.2012.1369; Chen YT, 2003, GENOMICS, V82, P628, DOI 10.1016/S0888-7543(03)00183-6; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; D'Arcy P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095136; de Bruijn DRH, 2002, GENE CHROMOSOME CANC, V34, P285, DOI 10.1002/gcc.10073; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; Fernebro J, 2006, INT J CANCER, V118, P1165, DOI 10.1002/ijc.21475; Francis JC, 2015, J PATHOL, V236, P186, DOI 10.1002/path.4517; Goodwin ML, 2014, CANCER CELL, V26, P851, DOI 10.1016/j.ccell.2014.10.003; Guillou L, 2004, J CLIN ONCOL, V22, P4040, DOI 10.1200/JCO.2004.11.093; Gure AO, 2002, INT J CANCER, V101, P448, DOI 10.1002/ijc.10634; Gure AO, 1997, INT J CANCER, V72, P965, DOI 10.1002/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N; Haldar M, 2007, CANCER CELL, V11, P375, DOI 10.1016/j.ccr.2007.01.016; Haldar M, 2009, CANCER RES, V69, P3657, DOI 10.1158/0008-5472.CAN-08-4127; Herzog CE, 2005, J PEDIAT HEMATOL ONC, V27, P215, DOI 10.1097/01.mph.0000161762.53175.e4; Hori A, 2015, MOL BIOL CELL, V26, P2005, DOI 10.1091/mbc.E14-11-1561; Hur K, 2014, GUT, V63, P635, DOI 10.1136/gutjnl-2012-304219; Inagaki H, 2000, MODERN PATHOL, V13, P482, DOI 10.1038/modpathol.3880083; Joseph CG, 2014, GENE CHROMOSOME CANC, V53, P15, DOI 10.1002/gcc.22114; Kadoch C, 2013, CELL, V153, P71, DOI 10.1016/j.cell.2013.02.036; Kawai A, 1998, NEW ENGL J MED, V338, P153, DOI 10.1056/NEJM199801153380303; Kim SK, 2014, INT J CANCER, V134, P1067, DOI 10.1002/ijc.28445; Kokovic I, 2004, CANCER DETECT PREV, V28, P294, DOI 10.1016/j.cdp.2004.06.002; Kubo T, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1168-3; Ladanyi M, 2002, CANCER RES, V62, P135; LEROY H, 1993, GENE CHROMOSOME CANC, V6, P156; Li C, 2001, GENOME BIOL, V2, DOI DOI 10.1186/GB-2001-2-8-RESEARCH0032; McFadden DG, 2014, CELL, V156, P1298, DOI 10.1016/j.cell.2014.02.031; Mezzelani A, 2001, BRIT J CANCER, V85, P1535, DOI 10.1054/bjoc.2001.2088; Nakayama R, 2010, AM J SURG PATHOL, V34, P1599, DOI 10.1097/PAS.0b013e3181f7ce2c; Ogawa K, 1999, CARCINOGENESIS, V20, P2083, DOI 10.1093/carcin/20.11.2083; Perani M, 2003, ONCOGENE, V22, P8156, DOI 10.1038/sj.onc.1207031; Przybyl J, 2014, INT J BIOCHEM CELL B, V53, P505, DOI 10.1016/j.biocel.2014.05.006; Ren T, 2013, BRIT J CANCER, V109, P2279, DOI 10.1038/bjc.2013.547; Sandberg AA, 2002, CANCER GENET CYTOGEN, V133, P1, DOI 10.1016/S0165-4608(01)00626-4; Straessler KM, 2013, CANCER CELL, V23, P215, DOI 10.1016/j.ccr.2012.12.019; Su L, 2012, CANCER CELL, V21, P333, DOI 10.1016/j.ccr.2012.01.010; Sun Y, 2009, CANCER SCI, V100, P1018, DOI 10.1111/j.1349-7006.2009.01134.x; Takenaka S, 2008, ONCOL REP, V19, P467; Tang SHE, 2002, GENESIS, V32, P199, DOI 10.1002/gene.10030; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; Tvrdik D, 2005, MED SCI MONITOR, V11, pMT1; Varela I, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r100; Wartman LD, 2011, J CLIN INVEST, V121, P1445, DOI 10.1172/JCI45284; Wei YK, 2002, CHINESE MED J-PEKING, V115, P1043; Westcott PMK, 2015, NATURE, V517, P489, DOI 10.1038/nature13898; Xu Z, 2001, Zhonghua Bing Li Xue Za Zhi, V30, P431; Yuan W, 2013, ONCOGENE, V32, P318, DOI 10.1038/onc.2012.53	58	23	23	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2016	35	38					5021	5032		10.1038/onc.2016.38	http://dx.doi.org/10.1038/onc.2016.38			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW9GT	26947017	Green Submitted, Green Accepted			2022-12-17	WOS:000383965300006
J	Roth, I; Campbell, H; Rubio, C; Vennin, C; Wilson, M; Wiles, A; Williams, G; Woolley, A; Timpson, P; Berridge, MV; Fleming, N; Baird, M; Braithwaite, AW				Roth, I.; Campbell, H.; Rubio, C.; Vennin, C.; Wilson, M.; Wiles, A.; Williams, G.; Woolley, A.; Timpson, P.; Berridge, M. V.; Fleming, N.; Baird, M.; Braithwaite, A. W.			The Delta 133p53 isoform and its mouse analogue Delta 122p53 promote invasion and metastasis involving pro-inflammatory molecules interleukin-6 and CCL2	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; P53 ISOFORMS; ANGIOGENESIS; EXPRESSION; CANCER; INHIBITOR; MIGRATION; MOTILITY; MUTANT	A number of naturally occurring isoforms of the tumour suppressor protein p53 have been discovered, which appear to have differing roles in tumour prevention or promotion. We are investigating the tumour-promoting activities of the Delta 133p53 isoform using our mouse model of Delta 133p53 (Delta 122p53). Here, we report that tumours from Delta 122p53 homozygous mice show evidence of invasion and metastasis and that Delta 122p53 promotes migration though a 3-dimensional collagen matrix. We also show that Delta 122p53 and Delta 133p53 promote cell migration in scratch wound and Transwell assays, similar to the 'gain-of-function' phenotypes seen with mutant p53. Using the well-defined B16 mouse melanoma metastatic model, we show that Delta 122p53 leads to faster generation of lung metastases. The increased migratory phenotypes are dependent on secreted factors, including the cytokine interleukin-6 and the chemokine CCL2. We propose that Delta 122p53 (and Delta 133p53) acts in a similar manner to 'gain-of-function' mutant p53 proteins to promote migration, invasion and metastasis, which may contribute to poor survival in patients with Delta 133p53-expressing tumours.	[Roth, I.; Wilson, M.; Wiles, A.; Williams, G.; Woolley, A.; Fleming, N.; Baird, M.; Braithwaite, A. W.] Univ Otago, Dunedin Sch Med, Dept Pathol, 58 Hanover St, Dunedin, New Zealand; [Roth, I.; Baird, M.; Braithwaite, A. W.] Univ Auckland, Sch Biol Sci, Maurice Wilkins Ctr Mol Biodiscovery, Auckland, New Zealand; [Campbell, H.; Rubio, C.; Braithwaite, A. W.] Univ Sydney, Childrens Med Res Inst, Sydney, NSW, Australia; [Vennin, C.; Timpson, P.] Garvan Inst Med Res, Sydney, NSW, Australia; [Berridge, M. V.] Malaghan Inst Med Res, Wellington, New Zealand	University of Otago; University of Auckland; Children's Medical Research Institute - Australia; University of Sydney; Garvan Institute of Medical Research; Malaghan Institute; Victoria University Wellington	Braithwaite, AW (corresponding author), Univ Otago, Dunedin Sch Med, Dept Pathol, 58 Hanover St, Dunedin, New Zealand.	antony.braithwaite@otago.ac.nz	Timpson, Paul/A-9429-2016	Berridge, Michael/0000-0003-2619-7473; Vennin, Claire/0000-0001-9088-4177; Timpson, Paul/0000-0002-5514-7080	Health Research Council of New Zealand; Marsden Fund; Maurice Wilkins Centre for Molecular Biodiscovery; Cancer Council NSW; National Health and Medical Research Council	Health Research Council of New Zealand(Health Research Council of New Zealand); Marsden Fund(Royal Society of New ZealandMarsden Fund (NZ)); Maurice Wilkins Centre for Molecular Biodiscovery; Cancer Council NSW(Cancer Council New South Wales); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by the Health Research Council of New Zealand, Marsden Fund, Maurice Wilkins Centre for Molecular Biodiscovery, Cancer Council NSW and National Health and Medical Research Council.	Alexandrova A, 2000, ONCOGENE, V19, P5826, DOI 10.1038/sj.onc.1203944; Anensen N, 2006, CLIN CANCER RES, V12, P3985, DOI 10.1158/1078-0432.CCR-05-1970; Avery-Kiejda KA, 2008, CLIN CANCER RES, V14, P1659, DOI 10.1158/1078-0432.CCR-07-1422; Bernard H, 2013, ONCOGENE, V32, P2150, DOI 10.1038/onc.2012.242; BLAY JY, 1992, CANCER RES, V52, P3317; Boldrup L, 2007, EUR J CANCER, V43, P617, DOI 10.1016/j.ejca.2006.10.019; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Bystry RS, 2001, NAT IMMUNOL, V2, P1126, DOI 10.1038/ni735; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; DAVATELIS G, 1988, J EXP MED, V167, P1939, DOI 10.1084/jem.167.6.1939; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Gadea G, 2002, EMBO J, V21, P2373, DOI 10.1093/emboj/21.10.2373; Gadea G, 2007, J CELL BIOL, V178, P23, DOI 10.1083/jcb.200701120; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Gudkov Andrei V, 2011, Genes Cancer, V2, P503, DOI 10.1177/1947601911409747; Guo FK, 2004, ONCOGENE, V23, P5577, DOI 10.1038/sj.onc.1207752; Guo FK, 2003, J BIOL CHEM, V278, P14414, DOI 10.1074/jbc.M300341200; Hafsi H, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-134; Hofstetter G, 2010, ONCOGENE, V29, P1997, DOI 10.1038/onc.2009.482; JOHNSON RK, 1979, INT J RADIAT ONCOL, V5, P1605, DOI 10.1016/0360-3016(79)90782-X; Marcel V, 2011, CELL DEATH DIFFER, V18, P1815, DOI 10.1038/cdd.2011.120; Muller PAJ, 2011, J CELL BIOL, V192, P209, DOI 10.1083/jcb.201009059; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Nutthasirikul N, 2013, INT J ONCOL, V42, P1181, DOI 10.3892/ijo.2013.1818; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; Ravi R, 2000, GENE DEV, V14, P34; Senturk S, 2014, P NATL ACAD SCI USA, V111, pE3287, DOI 10.1073/pnas.1321640111; Slatter TL, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.149; Slatter TL, 2011, BLOOD, V117, P5166, DOI 10.1182/blood-2010-11-321851; Song W, 2009, CHINESE MED J-PEKING, V122, P921, DOI 10.3760/cma.j.issn.0366-6999.2009.08.008; Timpson P, 2011, JOVE-J VIS EXP, DOI 10.3791/3089	33	23	23	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2016	35	38					4981	4989		10.1038/onc.2016.45	http://dx.doi.org/10.1038/onc.2016.45			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW9GT	26996665				2022-12-17	WOS:000383965300003
J	Dayde, D; Guerard, M; Perron, P; Hatat, AS; Barrial, C; Eymin, B; Gazzeri, S				Dayde, D.; Guerard, M.; Perron, P.; Hatat, A-S; Barrial, C.; Eymin, B.; Gazzeri, S.			Nuclear trafficking of EGFR by Vps34 represses Arf expression to promote lung tumor cell survival	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; SIGNALING NETWORK; PROGNOSTIC VALUE; P14(ARF) EXPRESSION; IONIZING-RADIATION; PROTEIN EXPRESSION; CANCER; MUTATIONS; MECHANISMS; GEFITINIB	Epidermal growth factor receptor (EGFR) is a cell surface receptor that has an essential role in cell proliferation and survival, and overexpression of EGFR is a common feature of human cancers. In Non-small-cell lung cancer (NSCLC), activating mutations of EGFR have also been described. We recently showed that mutant EGFR-L858R inhibits the expression of the p14ARF tumor-suppressor protein to promote cell survival. In this study, we defined the molecular bases by which EGFR controls Arf expression. Using various lung tumor models, we showed that EGF stimulation inhibits Arf transcription by a mechanism involving the nuclear transport and recruitment of EGFR to the Arf promoter. We unraveled the vesicular trafficking protein Vps34 as a mediator of EGFR nuclear trafficking and showed that its neutralization prevents the accumulation of EGFR to the Arf promoter in response to ligand activation. Finally, in lung tumor cells that carry mutant EGFR-L858R, we demonstrated that inhibition of Vps34 using small interfering RNA restrains nuclear EGFR location and restores Arf expression leading to apoptosis. These findings identify the Arf tumor suppressor as a new transcriptional target of nuclear EGFR and highlight Vps34 as an important regulator of the nuclear EGFR/Arf survival pathway. As a whole, they provide a mechanistic explanation to the inverse correlation between nuclear expression of EGFR and overall survival in NSCLC patients.	[Dayde, D.; Guerard, M.; Perron, P.; Hatat, A-S; Barrial, C.; Eymin, B.; Gazzeri, S.] INSERM, Ctr Rech, Equipe Bases Mol Progress Canc Poumo, U823, Grenoble, France; [Dayde, D.; Guerard, M.; Perron, P.; Hatat, A-S; Barrial, C.; Eymin, B.; Gazzeri, S.] Univ Grenoble 1, Inst Albert Bonniot, Grenoble, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Gazzeri, S (corresponding author), Inst Albert Bonniot, INSERM, Ctr Rech, Equipe Bases Mol Progress Canc Poumon,U823, F-38042 Grenoble, France.	Sylvie.Gazzeri@ujf-grenoble.fr	eymin, beatrice/U-4670-2019; Eymin, Beatrice/M-1962-2013; gazzeri, sylvie/U-4669-2019; gazzeri, sylvie/M-1961-2013	eymin, beatrice/0000-0002-7311-3810; Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; gazzeri, sylvie/0000-0001-5817-1839	Institut National de la Sante et de la Recherche Medicale [U823]; Fondation ARC pour la recherche sur le cancer [20131200109]; Fondation de France; Ligue Nationale contre Le Cancer Comite de Savoie; Fond de Dotation pour la Recherche en Sante Respiratoire; Fondation ARC pour la recherche sur le cancer; le Fonds Agir pour les Maladies Chroniques; French Research Ministry	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Fondation ARC pour la recherche sur le cancer(Fondation ARC pour la Recherche sur le Cancer); Fondation de France(Fondation de France); Ligue Nationale contre Le Cancer Comite de Savoie; Fond de Dotation pour la Recherche en Sante Respiratoire; Fondation ARC pour la recherche sur le cancer(Fondation ARC pour la Recherche sur le Cancer); le Fonds Agir pour les Maladies Chroniques; French Research Ministry(Ministry of Research, France)	We thank Professor A Gazdar for providing us with the H1719, HCC827 and H1975 cellular models and Dr MC Hung for the CHO-EGFR and CHO-EGFR-pNLS cells. This work was supported by Institut National de la Sante et de la Recherche Medicale U823, the Fondation ARC pour la recherche sur le cancer (grant no. 20131200109), the Fondation de France and the Ligue Nationale contre Le Cancer Comite de Savoie. DD was supported by the Fond de Dotation pour la Recherche en Sante Respiratoire 2010 and the Fondation ARC pour la recherche sur le cancer. MG was supported by le Fonds Agir pour les Maladies Chroniques. A-SH was supported by the French Research Ministry.	Abhold EL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032459; Aggarwal H, 2011, EXP MOL PATHOL, V91, P496, DOI 10.1016/j.yexmp.2011.05.006; Backer JM, 2008, BIOCHEM J, V410, P1, DOI 10.1042/BJ20071427; Brand TM, 2011, DISCOV MED, V12, P419; Burda P, 2002, J CELL SCI, V115, P3889, DOI 10.1242/jcs.00090; Carpenter G, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008979; Chen DJ, 2007, CLIN CANCER RES, V13, P6555, DOI 10.1158/1078-0432.CCR-07-1610; Cortot AB, 2014, CLIN LUNG CANCER, V15, P124, DOI 10.1016/j.cllc.2013.08.003; Dittmann K, 2010, FEBS LETT, V584, P3878, DOI 10.1016/j.febslet.2010.08.005; Dovey JS, 2008, P NATL ACAD SCI USA, V105, P11857, DOI 10.1073/pnas.0803574105; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; Huang WC, 2011, J BIOL CHEM, V286, P20558, DOI 10.1074/jbc.M111.240796; Hung LY, 2008, NUCLEIC ACIDS RES, V36, P4337, DOI 10.1093/nar/gkn417; Jaganathan S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019605; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389; Li C, 2009, ONCOGENE, V28, P3801, DOI 10.1038/onc.2009.234; Liccardi G, 2011, CANCER RES, V71, P1103, DOI 10.1158/0008-5472.CAN-10-2384; Lill NL, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003341; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lo HW, 2010, DISCOV MED, V10, P44; Lo HW, 2010, MOL CANCER RES, V8, P232, DOI 10.1158/1541-7786.MCR-09-0391; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Lo HW, 2005, CANCER RES, V65, P338; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maggi LB, 2014, BBA-MOL BASIS DIS, V1842, P831, DOI 10.1016/j.bbadis.2014.01.016; MAO L, 1995, CANCER RES, V55, P2995; Marsh T, 2015, NAT CELL BIOL, V17, P1, DOI 10.1038/ncb3089; Massie C, 2006, NAT REV CANCER, V6, P403, DOI 10.1038/nrc1882; Meng XX, 2012, LUNG CANCER, V77, P24, DOI 10.1016/j.lungcan.2012.02.015; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Mounawar M, 2007, CANCER RES, V67, P5667, DOI 10.1158/0008-5472.CAN-06-4229; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Ozenne P, 2013, ONCOGENE, V32, P1050, DOI 10.1038/onc.2012.107; Ozenne P, 2010, INT J CANCER, V127, P2239, DOI 10.1002/ijc.25511; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Psyrri A, 2005, CLIN CANCER RES, V11, P5856, DOI 10.1158/1078-0432.CCR-05-0420; QUELLE DE, 1995, CELL, V83, P993; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Simonsen A, 2009, J CELL BIOL, V186, P773, DOI 10.1083/jcb.200907014; Tao YG, 2005, EXP CELL RES, V303, P240, DOI 10.1016/j.yexcr.2004.09.030; Traynor AM, 2013, LUNG CANCER, V81, P138, DOI 10.1016/j.lungcan.2013.03.020; Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882; Vonlanthen S, 2001, BRIT J CANCER, V84, P1372, DOI 10.1054/bjoc.2001.1791; Wang YN, 2010, ONCOGENE, V29, P3997, DOI 10.1038/onc.2010.157; Wang YN, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-13; Xia WY, 2009, MOL CARCINOGEN, V48, P610, DOI 10.1002/mc.20504; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhao ZH, 2008, LUNG CANCER, V62, P113, DOI 10.1016/j.lungcan.2008.02.014	54	23	24	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2016	35	30					3986	3994		10.1038/onc.2015.480	http://dx.doi.org/10.1038/onc.2015.480			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8DJ	26686095	Green Submitted			2022-12-17	WOS:000381013100010
J	Shigeta, S; Toyoshima, M; Kitatani, K; Ishibashi, M; Usui, T; Yaegashi, N				Shigeta, S.; Toyoshima, M.; Kitatani, K.; Ishibashi, M.; Usui, T.; Yaegashi, N.			Transferrin facilitates the formation of DNA double-strand breaks via transferrin receptor 1: the possible involvement of transferrin in carcinogenesis of high-grade serous ovarian cancer	ONCOGENE			English	Article							FALLOPIAN-TUBE EPITHELIUM; HUMAN FOLLICULAR-FLUID; CANDIDATE PRECURSOR; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; DAMAGE RESPONSE; IRON; INFLAMMATION; WOMEN; MODEL	Fallopian tubal epithelium is a candidate for the origin of high-grade serous ovarian cancer. Transferrin-containing follicular fluid and/or retrograde menstrual blood are possible risk factors for carcinogenesis. Accumulation of DNA double-strand breaks (DNA-DSBs) in the fallopian tubal epithelium is considered to play an important role in the development of cancer. However, the mechanisms by which DNA-DSBs accumulate have not yet been fully elucidated. The hydroxyl radical, which is produced in a Fenton reaction catalyzed by an iron ion, serves as a potent DNA-DSB-inducing molecule, raising the potential of an iron ion transporter of transferrin in the formation of DNA-DSBs. We studied the potential involvement of transferrin in DNA damage and the development of ovarian cancer. Treatment with transferrin facilitated the formation of histone 2AX phosphorylated at Serine 139 (gamma H2AX), which is known as a DNA-DSB marker, in human fallopian tube secretory epithelial cells and A2780 ovarian cancer cells. Knockdown of transferrin receptor 1 (TfR1), but not transferrin receptor 2, suppressed the transferrin uptake and consequent formation of gamma H2AX. As hydroxyl radicals in reactive oxygen species (ROS) are involved in DNA-DSBs, the formation of ROS was determined. Treatment with TfR1-specific small interference RNAs significantly diminished transferrin-induced formation of ROS. Moreover, TfR1-dependent uptake of transferrin was revealed to augment the formation of DNA-DSBs in the presence of hydrogen peroxide, which served as a substrate for the Fenton reaction. An ex vivo study with murine fallopian tubes further demonstrated that transferrin treatment introduced DNA-DSBs in the fallopian tubal epithelium. Collectively, these data suggested that the transferrin-TfR1 axis accounts for the induction of DNA-DSBs that potentially lead to DNA damage/genome instability. These findings also suggested that exposure to transferrin initiates and promotes the development of ovarian cancer by aiding the accumulation of DNA-DSBs in the fallopian tubal epithelium.	[Shigeta, S.; Toyoshima, M.; Kitatani, K.; Ishibashi, M.; Yaegashi, N.] Tohoku Univ, Sch Med, Dept Obstet & Gynecol, Sendai, Miyagi, Japan; [Toyoshima, M.] Sendai Med Ctr, Dept Obstet & Gynecol, Sendai, Miyagi, Japan; [Kitatani, K.; Usui, T.] Tohoku Univ, Tohoku Med Megabank Org, Sendai, Miyagi, Japan	Tohoku University; Tohoku University	Toyoshima, M (corresponding author), Tohoku Univ, Sch Med, Dept Obstet & Gynecol, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.; Kitatani, K (corresponding author), Tohoku Univ, Tohoku Med Megabank Org, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9800873, Japan.	m-toyo@med.tohoku.ac.jp; kitatani@med.tohoku.ac.jp	Kitatani, Kazuyuki/H-7100-2019	Kitatani, Kazuyuki/0000-0002-8516-6135; xing zhi, shi zhi/0000-0003-3289-5681	JSPS KAKENHI [23791801, 26462509, 23790366, 26861304, 40539235, 24390375, 26670710]; Health Labor Sciences Research Grant [201221019A]; Kurokawa Cancer Research Foundation; Japan Society of Gynecologic Oncology; Foundation for Promotion of Cancer Research; Tohoku University Graduate School of Medicine United Center for Advanced Research and Translational Medicine; Grants-in-Aid for Scientific Research [26462509, 26670710] Funding Source: KAKEN	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Health Labor Sciences Research Grant; Kurokawa Cancer Research Foundation(Kurokawa Cancer Research Foundation); Japan Society of Gynecologic Oncology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Foundation for Promotion of Cancer Research; Tohoku University Graduate School of Medicine United Center for Advanced Research and Translational Medicine; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Drs Ronny Drapkin and Alison M Karst for kindly providing FTSECs established in their laboratory. This study was supported in part by the JSPS KAKENHI Grants (23791801 and 26462509 to MT, 23790366, 26861304 and 40539235 to KK, 24390375 and 26670710 to NY), a Health Labor Sciences Research Grant (201221019A to NY), the Kurokawa Cancer Research Foundation (MT), the Japan Society of Gynecologic Oncology (MT), the Foundation for Promotion of Cancer Research (MT) and Tohoku University Graduate School of Medicine United Center for Advanced Research and Translational Medicine (MT).	Bahar-Shany K, 2014, GYNECOL ONCOL, V132, P322, DOI 10.1016/j.ygyno.2013.12.015; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bowtell DDL, 2010, NAT REV CANCER, V10, P803, DOI 10.1038/nrc2946; Briggs DA, 1999, MOL HUM REPROD, V5, P1107, DOI 10.1093/molehr/5.12.1107; Calzolari A, 2007, BLOOD CELL MOL DIS, V39, P82, DOI 10.1016/j.bcmd.2007.02.003; CANNISTRA SA, 1993, NEW ENGL J MED, V329, P1550, DOI 10.1056/NEJM199311183292108; Carbone MC, 2003, MOL HUM REPROD, V9, P639, DOI 10.1093/molehr/gag090; CASAGRANDE JT, 1979, LANCET, V2, P170; Chen EY, 2010, J PATHOL, V222, P110, DOI 10.1002/path.2739; Dizdaroglu M, 2002, FREE RADICAL BIO MED, V32, P1102, DOI 10.1016/S0891-5849(02)00826-2; Elizur SE, 2014, GYNECOL ENDOCRINOL, V30, P705, DOI 10.3109/09513590.2014.924100; ENTMAN SS, 1987, J IN VITRO FERTIL EM, V4, P98, DOI 10.1007/BF01555447; Falconer H, 2015, J NATL CANC IN PRESS, V107; FATHALLA MF, 1971, LANCET, V2, P163; Federico A, 2007, INT J CANCER, V121, P2381, DOI 10.1002/ijc.23192; Folkins AK, 2008, GYNECOL ONCOL, V109, P168, DOI 10.1016/j.ygyno.2008.01.012; Fridlich R, 2015, DNA REPAIR, V30, P11, DOI 10.1016/j.dnarep.2015.03.002; Garcia-Canton C, 2012, TOXICOL IN VITRO, V26, P1075, DOI 10.1016/j.tiv.2012.06.006; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gupta S, 2011, REPROD FERT DEVELOP, V23, P673, DOI 10.1071/RD10270; Havrilesky LJ, 2013, OBSTET GYNECOL, V122, P139, DOI 10.1097/AOG.0b013e318291c235; Hennet ML, 2013, J ASSIST REPROD GEN, V30, P333, DOI 10.1007/s10815-012-9925-5; Herbison CE, 2009, AM J PHYSIOL-CELL PH, V297, pC1567, DOI 10.1152/ajpcell.00649.2008; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Karst AM, 2012, NAT PROTOC, V7, P1755, DOI 10.1038/nprot.2012.097; Kawabata H, 1999, J BIOL CHEM, V274, P20826, DOI 10.1074/jbc.274.30.20826; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kumari A, 2004, ONCOGENE, V23, P2324, DOI 10.1038/sj.onc.1207379; Kurman RJ, 2011, HUM PATHOL, V42, P918, DOI 10.1016/j.humpath.2011.03.003; Kurman RJ, 2010, AM J SURG PATHOL, V34, P433, DOI 10.1097/PAS.0b013e3181cf3d79; Lau A, 2014, EXP BIOL MED, V239, P24, DOI 10.1177/1535370213508216; Lee Y, 2007, J PATHOL, V211, P26, DOI 10.1002/path.2091; Levanon K, 2010, ONCOGENE, V29, P1103, DOI 10.1038/onc.2009.402; Madsen C, 2015, ACTA OBSTET GYN SCAN, V94, P86, DOI 10.1111/aogs.12516; Mashiko S, 2015, CANCER BIOL THER, V16, P253, DOI 10.1080/15384047.2014.1001271; Meneghini R, 1997, FREE RADICAL BIO MED, V23, P783, DOI 10.1016/S0891-5849(97)00016-6; Modugno F, 2012, INT J GYNECOL CANCER, V22, pS45, DOI 10.1097/IGC.0b013e31826bd1f2; Narod SA, 2001, LANCET, V357, P1467, DOI 10.1016/S0140-6736(00)04642-0; NASCIMENTO ALTO, 1995, CARCINOGENESIS, V16, P1335, DOI 10.1093/carcin/16.6.1335; Ohshima H, 2003, ARCH BIOCHEM BIOPHYS, V417, P3, DOI 10.1016/S0003-9861(03)00283-2; Oyawoye O, 2003, HUM REPROD, V18, P2270, DOI 10.1093/humrep/deg450; Ponka P, 1999, INT J BIOCHEM CELL B, V31, P1111, DOI 10.1016/S1357-2725(99)00070-9; Pra D, 2012, MUTAT RES-FUND MOL M, V733, P92, DOI 10.1016/j.mrfmmm.2012.02.001; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sabatini L, 1999, FERTIL STERIL, V72, P1027, DOI 10.1016/S0015-0282(99)00411-2; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shaw PA, 2009, MODERN PATHOL, V22, P1133, DOI 10.1038/modpathol.2009.89; Shih IM, 2004, AM J PATHOL, V164, P1511, DOI 10.1016/S0002-9440(10)63708-X; Squires S, 2004, CELL CYCLE, V3, P1543, DOI 10.4161/cc.3.12.1272; Takabayashi H, 2013, HUM PATHOL, V44, P1038, DOI 10.1016/j.humpath.2012.09.006; Vercellini P, 2011, HUM REPROD, V26, P2262, DOI 10.1093/humrep/der211; West AP, 2000, J BIOL CHEM, V275, P38135, DOI 10.1074/jbc.C000664200	53	23	23	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3577	3586		10.1038/onc.2015.425	http://dx.doi.org/10.1038/onc.2015.425			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26549031				2022-12-17	WOS:000379621500010
J	Liu, XS; Liu, Z; Gerarduzzi, C; Choi, DE; Ganapathy, S; Pandolfi, PP; Yuan, ZM				Liu, X-S; Liu, Z.; Gerarduzzi, C.; Choi, D. E.; Ganapathy, S.; Pandolfi, P. P.; Yuan, Z-M			Somatic human ZBTB7A zinc finger mutations promote cancer progression	ONCOGENE			English	Article							TRANSCRIPTIONAL REPRESSOR; POZ DOMAIN; GENE; PROTEINS; LRF	We recently reported that ZBTB7A is a bona fide transcription repressor of key glycolytic genes and its downregulation in human cancer contributes to tumor metabolism. As reduced expression of ZBTB7A is found only in a subset of human cancers, we explored alternative mechanisms of its inactivation by mining human cancer genome databases. We discovered recurrent somatic mutations of ZBTB7A in multiple types of human cancers with a marked enrichment of mutations within the zinc finger domain. Functional characterization of the mutants demonstrated that mutations within the zinc finger region of ZBTB7A invariably resulted in loss of function. As a consequence, the glycolytic genes were markedly upregulated in cancer cells harboring ZBTB7A zinc finger mutation, leading to increased glycolysis and proliferation. Our study uncovers the loss-of-function mutation in ZBTB7A as a novel mechanism causing elevated glycolysis in human cancer, which carries important therapeutic implication.	[Liu, X-S; Gerarduzzi, C.; Choi, D. E.; Ganapathy, S.; Yuan, Z-M] Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA; [Liu, X-S] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201203, Peoples R China; [Liu, Z.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Pandolfi, P. P.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med,Dept Med, Canc Genet Program,Beth Israel Deaconess Canc Ctr, Boston, MA 02215 USA; [Pandolfi, P. P.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med,Dept Pathol, Canc Genet Program,Beth Israel Deaconess Canc Ctr, Boston, MA 02215 USA	Harvard University; Harvard T.H. Chan School of Public Health; ShanghaiTech University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Yuan, ZM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA.	zyuan@hsph.harvard.edu	Liu, Xue-Song/ADF-2183-2022	Liu, Xue-Song/0000-0002-7736-0077; Liu, Zhonghua/0000-0003-3048-9823; Gerarduzzi, Casimiro/0000-0001-7098-1455; Pandolfi, Pier Paolo/0000-0002-5352-5295	Morningside Foundation; NIH/NCI [R01CA085679, RO1CA167814, RO1CA125144]; NATIONAL CANCER INSTITUTE [R01CA167814, R01CA085679, R01CA125144, R01CA183074] Funding Source: NIH RePORTER	Morningside Foundation; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to current and former members of the Yuan lab for experimental support, advice and helpful discussions. This work was supported in part by the Morningside Foundation and grants from NIH/NCI (R01CA085679, RO1CA167814 and RO1CA125144).	Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Costoya Jose A., 2007, Briefings in Functional Genomics & Proteomics, V6, P8, DOI 10.1093/bfgp/elm002; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987; Kelly KF, 2006, TRENDS CELL BIOL, V16, P578, DOI 10.1016/j.tcb.2006.09.003; Kukita A, 1999, BLOOD, V94, P1987, DOI 10.1182/blood.V94.6.1987.418k26_1987_1997; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lee SU, 2012, IMMUNOL REV, V247, P107, DOI 10.1111/j.1600-065X.2012.01116.x; Liu CJ, 2004, J BIOL CHEM, V279, P47081, DOI 10.1074/jbc.M405288200; Liu XS, 2014, GENE DEV, V28, P1917, DOI 10.1101/gad.245910.114; LOCOCO F, 1994, BLOOD, V83, P1757, DOI 10.1182/blood.V83.7.1757.bloodjournal8371757; Maeda T, 2005, NATURE, V433, P278, DOI 10.1038/nature03203; Maeda T, 2007, SCIENCE, V316, P860, DOI 10.1126/science.1140881; Maeda T, 2009, DEV CELL, V17, P527, DOI 10.1016/j.devcel.2009.09.005; Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27; Pessler F, 1997, MOL CELL BIOL, V17, P3786, DOI 10.1128/MCB.17.7.3786; Sakurai N, 2011, J CLIN INVEST, V121, P2583, DOI 10.1172/JCI45682; Stogios PJ, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-10-r82; Wang GC, 2013, NAT GENET, V45, P739, DOI 10.1038/ng.2654; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760	24	23	24	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					3071	3078		10.1038/onc.2015.371	http://dx.doi.org/10.1038/onc.2015.371			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26455326	Green Accepted			2022-12-17	WOS:000377474500012
J	Timsah, Z; Ahmed, Z; Ivan, C; Berrout, J; Gagea, M; Zhou, Y; Pena, GNA; Hu, X; Vallien, C; Kingsley, CV; Lu, Y; Hancock, JF; Liu, J; Gladden, AB; Mills, GB; Lopez-Berestein, G; Hung, MC; Sood, AK; Bogdanov, M; Ladbury, JE				Timsah, Z.; Ahmed, Z.; Ivan, C.; Berrout, J.; Gagea, M.; Zhou, Y.; Pena, G. N. A.; Hu, X.; Vallien, C.; Kingsley, C. V.; Lu, Y.; Hancock, J. F.; Liu, J.; Gladden, A. B.; Mills, G. B.; Lopez-Berestein, G.; Hung, M-C; Sood, A. K.; Bogdanov, M.; Ladbury, J. E.			Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer	ONCOGENE			English	Article							PI3K/AKT/MTOR INHIBITORS; SIGNALING PATHWAY; PHOSPHORYLATION; FGFR2; PHOSPHATASE; ACTIVATION; QUANTIFICATION; MUTATIONS; KINASE; RAS	In the absence of extracellular stimulation the adaptor protein growth factor receptor-bound protein (Grb2) and the phospholipase Plc gamma 1 compete for the same binding site on fibroblast growth factor receptor 2 (FGFR2). Reducing cellular Grb2 results in upregulation of Plc gamma 1 and depletion of the phospholipid PI(4,5)P-2. The functional consequences of this event on signaling pathways are unknown. We show that the decrease in PI(4,5)P-2 level under non-stimulated conditions inhibits PTEN activity leading to the aberrant activation of the oncoprotein Akt. This results in excessive cell proliferation and tumor progression in a xenograft mouse model. As well as defining a novel mechanism of Akt phosphorylation with important therapeutic consequences, we also demonstrate that differential expression levels of FGFR2, Plc gamma 1 and Grb2 correlate with patient survival. Oncogenesis through fluctuation in the expression levels of these proteins negates extracellular stimulation or mutation and defines them as novel prognostic markers in ovarian cancer.	[Timsah, Z.; Ahmed, Z.; Ladbury, J. E.] Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Unit 1000, Houston, TX 77030 USA; [Timsah, Z.; Berrout, J.; Ladbury, J. E.] Univ Leeds, Sch Mol & Cellular Biol, Miall Bldg, Leeds LS2 9JT, W Yorkshire, England; [Ahmed, Z.; Ladbury, J. E.] Univ Texas MD Anderson Canc Ctr, Ctr Biomol Struct & Funct, Unit 1000, Houston, TX 77030 USA; [Ivan, C.; Pena, G. N. A.; Lopez-Berestein, G.; Sood, A. K.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA; [Ivan, C.; Lopez-Berestein, G.; Sood, A. K.] Univ Texas MD Anderson Canc Ctr, Ctr RNAi & Noncoding RNA, Houston, TX 77030 USA; [Berrout, J.] Baylor Coll Med, Ctr Cell & Gene Therapy, Stem Cells & Regenerat Med Ctr, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Gagea, M.; Vallien, C.] Univ Texas MD Anderson Canc Ctr, Dept Vet Med & Surg, Unit 63, Houston, TX 77030 USA; [Zhou, Y.; Hancock, J. F.] Univ Texas Hlth Sci Ctr Houston, Sch Med, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; [Hu, X.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Kingsley, C. V.] Univ Texas MD Anderson Canc Ctr, Dept Imaging Phys, Unit 1472, Houston, TX 77030 USA; [Lu, Y.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Liu, J.] Univ Texas MD Anderson Canc Ctr, Dept Pathol Lab Med, Div Pathol Lab Med, Houston, TX 77030 USA; [Gladden, A. B.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Unit 1010, Houston, TX 77030 USA; [Lopez-Berestein, G.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Sood, A. K.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Bogdanov, M.] Univ Texas Hlth Sci Ctr Houston, Dept Biochem & Mol Biol, Sch Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Leeds; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Ladbury, JE (corresponding author), Univ Leeds, Sch Mol & Cellular Biol, Miall Bldg, Leeds LS2 9JT, W Yorkshire, England.	J.E.Ladbury@leeds.ac.uk	Hung, Mien-Chie/ABD-5911-2021; Bogdanov, Mikhail/J-3695-2017; Sood, Anoop Kumar/A-7344-2013	Hung, Mien-Chie/0000-0003-4317-4740; Sood, Anoop Kumar/0000-0001-5702-4108; Armaiz-Pena, Guillermo N/0000-0002-9081-5339; Ladbury, John/0000-0002-6328-7200; Ivan, Cristina/0000-0002-4848-0168; Zhou, Yong/0000-0002-0214-8151; Hancock, John/0000-0003-0542-4710	G. Harold and Leila Y. Mathers Charitable Foundation; NIH [U54CA151668, P50 CA083639, P50 CA098258]; RGK Foundation; Gilder Foundation; NATIONAL CANCER INSTITUTE [P50CA083639, P30CA016672, P50CA098258, U54CA151668] Funding Source: NIH RePORTER	G. Harold and Leila Y. Mathers Charitable Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); RGK Foundation; Gilder Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by the G. Harold and Leila Y. Mathers Charitable Foundation. This work was supported by NIH grants U54CA151668, P50 CA083639, P50 CA098258 and by the RGK Foundation and the Gilder Foundation.	Ahmed Z, 2013, J CELL BIOL, V200, P493, DOI 10.1083/jcb.201204106; Ahmed Z, 2010, CELL SIGNAL, V22, P23, DOI 10.1016/j.cellsig.2009.08.011; Ahmed Z, 2008, BIOCHEM J, V413, P37, DOI 10.1042/BJ20071594; Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721; Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Byron SA, 2009, FUTURE ONCOL, V5, P27, DOI 10.2217/14796694.5.1.27; Campbell RB, 2003, J BIOL CHEM, V278, P33617, DOI 10.1074/jbc.C300296200; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Ching JK, 2010, AM J PHYSIOL-CELL PH, V299, pC1171, DOI 10.1152/ajpcell.00514.2009; Clark J, 2011, NAT METHODS, V8, P267, DOI 10.1038/NMETH.1564; Cole C, 2010, CANCER BIOL THER, V10, DOI 10.4161/cbt.10.5.12585; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fry Michael J., 2009, V462, P345, DOI 10.1007/978-1-60327-115-8_22; Gauglhofer C, 2011, HEPATOLOGY, V53, P854, DOI 10.1002/hep.24099; Janku F, 2012, J CLIN ONCOL, V30, P777, DOI 10.1200/JCO.2011.36.1196; Katoh Y, 2009, INT J MOL MED, V23, P307, DOI 10.3892/ijmm_00000132; Khan KH, 2013, CHIN J CANCER, V32, P253, DOI 10.5732/cjc.013.10057; Konig S, 2008, ANAL BIOCHEM, V378, P197, DOI 10.1016/j.ab.2008.03.052; Lin CC, 2012, CELL, V149, P1514, DOI 10.1016/j.cell.2012.04.033; Matsuda Yoko, 2012, Patholog Res Int, V2012, P574768, DOI 10.1155/2012/574768; Mazzoletti M, 2010, CURR MED CHEM, V17, P4433, DOI 10.2174/092986710794182999; Ooms Lisa M., 2009, V462, P223, DOI 10.1007/978-1-60327-115-8_15; Pan JJ, 2010, CHEM RES TOXICOL, V23, P568, DOI 10.1021/tx9003193; Pirkmajer S, 2011, AM J PHYSIOL-CELL PH, V301, pC272, DOI 10.1152/ajpcell.00091.2011; Redfern RE, 2008, BIOCHEMISTRY-US, V47, P2162, DOI 10.1021/bi702114w; Risbud MV, 2005, SPINE, V30, P2503, DOI 10.1097/01.brs.0000186326.82747.13; Rodriguez EF, 2011, ACTA NEUROPATHOL, V121, P407, DOI 10.1007/s00401-010-0784-9; Rotblat B, 2004, MOL CELL BIOL, V24, P6799, DOI 10.1128/MCB.24.15.6799-6810.2004; Sato K., 2012, J SIGNAL TRANSDUCT, V2012; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Srinivasan S, 2003, J CELL BIOL, V160, P375, DOI 10.1083/jcb.200208179; Storz P, 2009, MOL CELL BIOL, V29, P4906, DOI 10.1128/MCB.00077-09; Thapa N, 2012, DEV CELL, V22, P116, DOI 10.1016/j.devcel.2011.10.030; Timsah Z, 2014, NAT STRUCT MOL BIOL, V21, P180, DOI 10.1038/nsmb.2752; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Troncoso R, 2012, CARDIOVASC RES, V93, P320, DOI 10.1093/cvr/cvr321; Turke AB, 2012, CANCER RES, V72, P3228, DOI 10.1158/0008-5472.CAN-11-3747; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Yamamoto N, 2006, J CELL SCI, V119, P4623, DOI 10.1242/jcs.03236; Yang K, 2011, METABOLITES, V1, P21, DOI 10.3390/metabo1010021; Zhou Y, 2014, MOL CELL BIOL, V34, P862, DOI 10.1128/MCB.01227-13	45	23	23	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2016	35	17					2186	2196		10.1038/onc.2015.279	http://dx.doi.org/10.1038/onc.2015.279			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DK5UK	26212011	Green Published, Green Accepted			2022-12-17	WOS:000374986000005
J	Goodman, CR; Sato, T; Peck, AR; Girondo, MA; Yang, N; Liu, C; Yanac, AF; Kovatich, AJ; Hooke, JA; Shriver, CD; Mitchell, EP; Hyslop, T; Rui, H				Goodman, C. R.; Sato, T.; Peck, A. R.; Girondo, M. A.; Yang, N.; Liu, C.; Yanac, A. F.; Kovatich, A. J.; Hooke, J. A.; Shriver, C. D.; Mitchell, E. P.; Hyslop, T.; Rui, H.			Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism	ONCOGENE			English	Article							MEDROXYPROGESTERONE ACETATE; SIGNAL TRANSDUCER; BCL6 EXPRESSION; PROLACTIN; STAT5; DIFFERENTIATION; INHIBITION; PROGESTERONE; ACTIVATOR; SURVIVAL	Therapy resistance remains a major problem in estrogen receptor-alpha (ER alpha)-positive breast cancer. A subgroup of ER alpha-positive breast cancer is characterized by mosaic presence of a minor population of ER alpha-negative cancer cells expressing the basal cytokeratin-5 (CK5). These CK5-positive cells are therapy resistant and have increased tumor-initiating potential. Although a series of reports document induction of the CK5-positive cells by progestins, it is unknown if other 3-ketosteroids share this ability. We now report that glucocorticoids and mineralocorticoids effectively expand the CK5-positive cell population. CK5-positive cells induced by 3-ketosteroids lacked ER alpha and progesterone receptors, expressed stem cell marker, CD44, and displayed increased clonogenicity in soft agar and broad drug-resistance in vitro and in vivo. Upregulation of CK5-positive cells by 3-ketosteroids required induction of the transcriptional repressor BCL6 based on suppression of BCL6 by two independent BCL6 small hairpin RNAs or by prolactin. Prolactin also suppressed 3-ketosteroid induction of CK5+ cells in T47D xenografts in vivo. Survival analysis with recursive partitioning in node-negative ER alpha-positive breast cancer using quantitative CK5 and BCL6 mRNA or protein expression data identified patients at high or low risk for tumor recurrence in two independent patient cohorts. The data provide a mechanism by which common pathophysiological or pharmacologic elevations in glucocorticoids or other 3-ketosteroids may adversely affect patients with mixed ER alpha+/CK5+ breast cancer. The observations further suggest a cooperative diagnostic utility of CK5 and BCL6 expression levels and justify exploring efficacy of inhibitors of BCL6 and 3-ketosteroid receptors for a subset of ER alpha-positive breast cancers.	[Goodman, C. R.; Sato, T.; Peck, A. R.; Girondo, M. A.; Yang, N.; Liu, C.; Yanac, A. F.; Rui, H.] Thomas Jefferson Univ, Dept Canc Biol, 233 S 10th St,BLSB 330, Philadelphia, PA 19107 USA; [Kovatich, A. J.; Hooke, J. A.; Shriver, C. D.] Walter Reed Natl Mil Med Ctr, John P Murtha Canc Ctr, Bethesda, MD USA; [Mitchell, E. P.; Rui, H.] Thomas Jefferson Univ, Dept Med Oncol, Philadelphia, PA 19107 USA; [Hyslop, T.] Duke Univ, Duke Canc Inst, Dept Biostat & Bioinformat, Durham, NC USA; [Rui, H.] Thomas Jefferson Univ, Dept Pathol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University; Walter Reed National Military Medical Center; Jefferson University; Duke University; Jefferson University	Rui, H (corresponding author), Thomas Jefferson Univ, Dept Canc Biol, 233 S 10th St,BLSB 330, Philadelphia, PA 19107 USA.	hallgeir.rui@jefferson.edu		Kovatich, Albert/0000-0002-5169-4087; Rui, Hallgeir/0000-0002-8778-261X; Goodman, Chelain/0000-0001-9083-3652	Susan G Komen [KG091116]; Ladies of Port Richmond; NCI [CA185918, CA188575, 1P30CA56036]; Commonwealth University Research Enhancement Program grant with the Pennsylvania Department of Health; NATIONAL CANCER INSTITUTE [R01CA188575, P30CA056036, R21CA185918] Funding Source: NIH RePORTER	Susan G Komen(Susan G. Komen Breast Cancer Foundation); Ladies of Port Richmond; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Commonwealth University Research Enhancement Program grant with the Pennsylvania Department of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by grants from Susan G Komen (KG091116), Ladies of Port Richmond and NCI (CA185918, CA188575; Support Grant 1P30CA56036), and in part, under a Commonwealth University Research Enhancement Program grant with the Pennsylvania Department of Health. The Department specifically disclaims responsibility for any analyses, interpretations or conclusions. We thank Colleen Lord for expert editorial assistance.	Anderson WF, 2002, BREAST CANCER RES TR, V76, P27, DOI 10.1023/A:1020299707510; Axlund SD, 2013, HORM CANCER-US, V4, P36, DOI 10.1007/s12672-012-0127-5; Bentel JM, 1999, MOL CELL ENDOCRINOL, V154, P11, DOI 10.1016/S0303-7207(99)00109-4; Byrne MJ, 1997, J CLIN ONCOL, V15, P3141, DOI 10.1200/JCO.1997.15.9.3141; Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658; Chida Y, 2008, NAT CLIN PRACT ONCOL, V5, P466, DOI 10.1038/ncponc1134; Cittelly DM, 2013, ONCOGENE, V32, P2555, DOI 10.1038/onc.2012.275; Conde I, 2008, HISTOL HISTOPATHOL, V23, P77, DOI 10.14670/HH-23.77; Costanzo ES, 2011, IMMUNOL ALLERGY CLIN, V31, P109, DOI 10.1016/j.iac.2010.09.001; Duy C, 2011, NATURE, V473, P384, DOI 10.1038/nature09883; El-Rehim DMA, 2004, J PATHOL, V203, P661, DOI 10.1002/path.1559; Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1; Haughian JM, 2012, P NATL ACAD SCI USA, V109, P2742, DOI 10.1073/pnas.1106509108; Horwitzt KB, 2008, P NATL ACAD SCI USA, V105, P5774, DOI 10.1073/pnas.0706216105; Hothorn T, 2006, J COMPUT GRAPH STAT, V15, P651, DOI 10.1198/106186006X133933; Joensuu K, 2013, BREAST CANCER-BASIC, V7, P23, DOI 10.4137/BCBCR.S10701; Johnson KJ, 2010, AM J PATHOL, V177, P2971, DOI 10.2353/ajpath.2010.090399; Kabos P, 2011, BREAST CANCER RES TR, V128, P45, DOI 10.1007/s10549-010-1078-6; Knox AJ, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0418-6; Li XT, 2003, MOL CELL BIOL, V23, P3763, DOI 10.1128/MCB.23.11.3763-3773.2003; Logarajah S, 2003, ONCOGENE, V22, P5572, DOI 10.1038/sj.onc.1206689; Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522; Neilson LM, 2007, MOL ENDOCRINOL, V21, P2218, DOI 10.1210/me.2007-0173; Nelson CC, 1999, MOL ENDOCRINOL, V13, P2090, DOI 10.1210/me.13.12.2090; Nevalainen MT, 2004, J CLIN ONCOL, V22, P2053, DOI 10.1200/JCO.2004.11.046; Nouhi Z, 2006, CANCER RES, V66, P1824, DOI 10.1158/0008-5472.CAN-05-2292; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Ouatas T, 2003, CLIN CANCER RES, V9, P3763; Palesh O, 2007, J PSYCHOSOM RES, V63, P233, DOI 10.1016/j.jpsychores.2007.05.012; Pang D, 2006, CANCER BIOL THER, V5, P933, DOI 10.4161/cbt.5.8.2875; Paredes J, 2007, VIRCHOWS ARCH, V450, P73, DOI 10.1007/s00428-006-0334-y; Peck AR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3328; Peck AR, 2011, J CLIN ONCOL, V29, P2448, DOI 10.1200/JCO.2010.30.3552; Plotnikov A, 2009, CANCER RES, V69, P3165, DOI 10.1158/0008-5472.CAN-08-4033; Rakha EA, 2007, HISTOPATHOLOGY, V50, P434, DOI 10.1111/j.1365-2559.2007.02638.x; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sartorius CA, 2005, CANCER RES, V65, P9779, DOI 10.1158/0008-5472.CAN-05-0505; Sasano H, 1997, ANTICANCER RES, V17, P2001; Sato T, 2014, ONCOGENE, V33, P2215, DOI 10.1038/onc.2013.172; Sato T, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-59; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Sultan AS, 2008, CANCER SCI, V99, P272, DOI 10.1111/j.1349-7006.2007.00685.x; Sultan AS, 2005, ONCOGENE, V24, P746, DOI 10.1038/sj.onc.1208203; Tran TH, 2010, CANCER RES, V70, P1711, DOI 10.1158/0008-5472.CAN-09-2314; Voduc KD, 2010, J CLIN ONCOL, V28, P1684, DOI 10.1200/JCO.2009.24.9284; Volden PA, 2013, BRAIN BEHAV IMMUN, V30, pS26, DOI 10.1016/j.bbi.2012.10.022; Wagner SD, 2011, BRIT J HAEMATOL, V152, P3, DOI 10.1111/j.1365-2141.2010.08420.x; Walker SR, 2007, ONCOGENE, V26, P224, DOI 10.1038/sj.onc.1209775; Wan YH, 2002, MOL ENDOCRINOL, V16, P1204, DOI 10.1210/me.16.6.1204; Wu Q, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-418; Wu W, 2004, CANCER RES, V64, P1757, DOI 10.1158/0008-5472.CAN-03-2546; Yamashita H, 2006, ENDOCR-RELAT CANCER, V13, P885, DOI 10.1677/erc.1.01095; Yang N, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3467; Yin P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029021; Yoo BH, 2012, J BIOMOL SCREEN, V17, P1211, DOI 10.1177/1087057112452138; Zhang C, 2007, CANCER BIOL THER, V6, P278, DOI 10.4161/cbt.6.2.3652	56	23	23	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2016	35	11					1373	1385		10.1038/onc.2015.193	http://dx.doi.org/10.1038/onc.2015.193			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG6LQ	26096934	hybrid, Green Published			2022-12-17	WOS:000372196400004
J	Cao, H; Eppinga, RD; Razidlo, GL; Krueger, EW; Chen, J; Qiang, L; McNiven, MA				Cao, H.; Eppinga, R. D.; Razidlo, G. L.; Krueger, E. W.; Chen, J.; Qiang, L.; McNiven, M. A.			Stromal fibroblasts facilitate cancer cell invasion by a novel invadopodia-independent matrix degradation process	ONCOGENE			English	Article							CARCINOMA-ASSOCIATED FIBROBLASTS; CLATHRIN-COATED PITS; MEDIATED ENDOCYTOSIS; PANCREATIC-CANCER; MAMMALIAN-CELLS; TUMOR-GROWTH; DYNAMIN; METASTASIS; EXPRESSION; METALLOPROTEINASE	Metastatic invasion of tumors into peripheral tissues is known to rely upon protease-mediated degradation of the surrounding stroma. This remodeling process uses complex, actin-based, specializations of the plasma membrane termed invadopodia that act both to sequester and release matrix metalloproteinases. Here we report that cells of mesenchymal origin, including tumor-associated fibroblasts, degrade substantial amounts of surrounding matrix by a mechanism independent of conventional invadopodia. These degradative sites lack the punctate shape of conventional invadopodia to spread along the cell base and are reticular and/or fibrous in character. In marked contrast to invadopodia, this degradation does not require the action of Src kinase, Cdc42 or Dyn2. Rather, inhibition of Dyn2 causes a marked upregulation of stromal matrix degradation. Further, expression and activity of matrix metalloproteinases are differentially regulated between tumor cells and stromal fibroblasts. This matrix remodeling by fibroblasts increases the invasive capacity of tumor cells, thereby illustrating how the tumor microenvironment can contribute to metastasis. These findings provide evidence for a novel matrix remodeling process conducted by stromal fibroblasts that is substantially more effective than conventional invadopodia, distinct in structural organization and regulated by disparate molecular mechanisms.	[Cao, H.; Eppinga, R. D.; Razidlo, G. L.; Krueger, E. W.; Chen, J.; McNiven, M. A.] Mayo Clin, Div Gastroenterol & Hepatol, 200 First St SW, Rochester, MN 55905 USA; [Cao, H.; Razidlo, G. L.; Qiang, L.; McNiven, M. A.] Mayo Clin, Dept Biochem & Mol Biol, 200 First St SW, Rochester, MN 55905 USA; [Eppinga, R. D.] Dordt Coll, Dept Biol, Sioux Ctr, IA USA	Mayo Clinic; Mayo Clinic	McNiven, MA (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, 200 First St SW, Rochester, MN 55905 USA.; McNiven, MA (corresponding author), Mayo Clin, Ctr Basic Res Digest Dis, 200 First St SW, Rochester, MN 55905 USA.	mmcniven@mayo.edu		Razidlo, Gina/0000-0002-9042-2738	Mayo Clinic Center for Cell Signaling in Gastroenterology [R01 CA104125, P30DK084567]; Mayo Clinic SPORE in Pancreatic Cancer [P50 CA102701];  [T32 DK007198]; NATIONAL CANCER INSTITUTE [P50CA102701, R01CA104125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007198, P30DK084567] Funding Source: NIH RePORTER	Mayo Clinic Center for Cell Signaling in Gastroenterology; Mayo Clinic SPORE in Pancreatic Cancer; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by R01 CA104125 to MAM, P30DK084567 (Mayo Clinic Center for Cell Signaling in Gastroenterology), T32 DK007198 (to RDE), and P50 CA102701 (Mayo Clinic SPORE in Pancreatic Cancer, to GLR).	Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177; Baldassarre M, 2003, MOL BIOL CELL, V14, P1074, DOI 10.1091/mbc.E02-05-0308; Boateng LR, 2012, EUR J CELL BIOL, V91, P878, DOI 10.1016/j.ejcb.2012.06.003; Brentnall TA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030219; Buccione R, 2004, NAT REV MOL CELL BIO, V5, P647, DOI 10.1038/nrm1436; Calon A, 2014, SEMIN CANCER BIOL, V25, P15, DOI 10.1016/j.semcancer.2013.12.008; Cao H, 2000, J CELL SCI, V113, P1993; Cao H, 2003, MOL CELL BIOL, V23, P2162, DOI 10.1128/MCB.23.6.2162-2170.2003; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; CHEN WT, 1985, NATURE, V316, P156, DOI 10.1038/316156a0; De Wever O, 2014, SEMIN CANCER BIOL, V25, P33, DOI 10.1016/j.semcancer.2013.12.009; Destaing O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077956; Egeblad M, 2005, COLD SH Q B, V70, P383, DOI 10.1101/sqb.2005.70.007; Eppinga RD, 2012, ONCOGENE, V31, P1228, DOI 10.1038/onc.2011.329; Ferguson S, 2009, DEV CELL, V17, P811, DOI 10.1016/j.devcel.2009.11.005; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Goicoechea SM, 2014, ONCOGENE, V33, P1265, DOI 10.1038/onc.2013.68; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Karagiannis GS, 2012, MOL CANCER RES, V10, P1403, DOI 10.1158/1541-7786.MCR-12-0307; Luga V, 2013, CANCER RES, V73, P6843, DOI 10.1158/0008-5472.CAN-13-1791; Martinez-Outschoorn UE, 2014, SEMIN CANCER BIOL, V25, P47, DOI 10.1016/j.semcancer.2014.01.005; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Mishra P, 2011, J LEUKOCYTE BIOL, V89, P31, DOI 10.1189/jlb.0310182; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Nakahara H, 2003, GENES CELLS, V8, P1019, DOI 10.1111/j.1365-2443.2003.00695.x; Ohlund D, 2014, J EXP MED, V211, P1503, DOI 10.1084/jem.20140692; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Okada A, 1997, J CELL BIOL, V137, P67, DOI 10.1083/jcb.137.1.67; Razidlo GL, 2014, CURR BIOL, V24, P86, DOI 10.1016/j.cub.2013.11.013; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Ries C, 2007, BLOOD, V109, P4055, DOI 10.1182/blood-2006-10-051060; Sato H, 1996, FEBS LETT, V385, P238, DOI 10.1016/0014-5793(96)00389-4; Waghray M, 2013, CURR OPIN GASTROEN, V29, P537, DOI 10.1097/MOG.0b013e328363affe; Wang Y, 2012, J CELL BIOL, V196, P375, DOI 10.1083/jcb.201105153; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Yu XZ, 2012, J CELL BIOL, V199, P527, DOI 10.1083/jcb.201203025	37	23	23	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1099	1110		10.1038/onc.2015.163	http://dx.doi.org/10.1038/onc.2015.163			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	25982272	Green Accepted, Green Published			2022-12-17	WOS:000371351700004
J	Katara, GK; Kulshrestha, A; Jaiswal, MK; Pamarthy, S; Gilman-Sachs, A; Beaman, KD				Katara, G. K.; Kulshrestha, A.; Jaiswal, M. K.; Pamarthy, S.; Gilman-Sachs, A.; Beaman, K. D.			Inhibition of vacuolar ATPase subunit in tumor cells delays tumor growth by decreasing the essential macrophage population in the tumor microenvironment	ONCOGENE			English	Article							BREAST-CANCER CELLS; H+-ATPASE; IN-VITRO; V-ATPASE; DIFFERENTIATION; POLARIZATION; METASTASIS; EXPRESSION; ISOFORM	In cancer cells, vacuolar ATPase (V-ATPase), a multi-subunit enzyme, is expressed on the plasma as well as vesicular membranes and critically influences metastatic behavior. The soluble, cleaved N-terminal domain of V-ATPase a2 isoform is associated with in vitro induction of tumorigenic characteristics in macrophages. This activity led us to further investigate its in vivo role in cancer progression by inhibition of a2 isoform (a2V) in tumor cells and the concomitant effect on tumor microenvironment in the mouse 4T-1 breast cancer model. Results showed that macrophages cocultivated with a2V knockdown (sh-a2) 4T-1 cells produce lower amounts of tumorigenic factors in vitro and have reduced ability to suppress T-cell activation and proliferation compared with control 4T-1 cells. Data analysis showed a delayed mammary tumor growth in Balb/c mice inoculated with sh-a2 4T-1 cells compared with control. The purified CD11b(+) macrophages from sh-a2 tumors showed a reduced expression of mannose receptor-1 (CD206), interleukin-10, transforming growth factor-beta, arginase-1, matrix metalloproteinase and vascular endothelial growth factor. Flow cytometric analysis of tumor-infiltrated macrophages showed a significantly low number of F4/80(+) CD11c(+) CD206(+) macrophages in sh-a2 tumors compared with control. In sh-a2 tumors, most of the macrophages were F4/80(+) CD11c(+) (antitumor M1 macrophages) suggesting it to be the reason behind delayed tumor growth. Additionally, tumor-infiltrating macrophages from sh-a2 tumors showed a reduced expression of CD206 compared with control whereas CD11c expression was unaffected. These findings demonstrate that in the absence of a2V in tumor cells, the resident macrophage population in the tumor microenvironment is altered which affects in vivo tumor growth. We suggest that by involving the host immune system, tumor growth can be controlled through targeting of a2V on tumor cells.	[Katara, G. K.; Kulshrestha, A.; Jaiswal, M. K.; Pamarthy, S.; Gilman-Sachs, A.; Beaman, K. D.] Rosalind Franklin Univ Med & Sci, Dept Microbiol & Immunol, 3333 Green Bay Rd, N Chicago, IL 60064 USA	Rosalind Franklin University Medical & Science	Beaman, KD (corresponding author), Rosalind Franklin Univ Med & Sci, Dept Microbiol & Immunol, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	kenneth.beaman@rosalindfranklin.edu		Pamarthy, Sahithi/0000-0003-2692-4829	Clinical Immunology Laboratory, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA	Clinical Immunology Laboratory, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA	We thank Robert Dickinson for technical assistance and the Rosalind Franklin University of Medicine and Science Flow Cytometry Core Facility. This work was supported by the grants from the Clinical Immunology Laboratory, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA.	Conejo-Garcia JR, 2004, NAT MED, V10, P950, DOI 10.1038/nm1097; Feng SM, 2013, INT J BIOL SCI, V9, P853, DOI 10.7150/ijbs.6030; Forgac M, 2007, NAT REV MOL CELL BIO, V8, P917, DOI 10.1038/nrm2272; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Granata F, 2010, J IMMUNOL, V184, P5232, DOI 10.4049/jimmunol.0902501; Hinton A, 2009, J BIOL CHEM, V284, P16400, DOI 10.1074/jbc.M901201200; Jaiswal MK, 2013, J IMMUNOL, V191, P5702, DOI 10.4049/jimmunol.1301604; Jaiswal MK, 2012, REPRODUCTION, V143, P713, DOI 10.1530/REP-12-0036; Katara GK, 2014, ONCOGENE, V33, P5649, DOI 10.1038/onc.2013.532; Kwong C, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22978; Kwong C, 2011, J IMMUNOL, V186, P1781, DOI 10.4049/jimmunol.1002998; Lu YD, 2005, CANCER RES, V65, P6843, DOI 10.1158/0008-5472.CAN-04-3822; Luo YP, 2006, J CLIN INVEST, V116, P2132, DOI 10.1172/JCI27648; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; Motz GT, 2013, IMMUNITY, V39, P61, DOI 10.1016/j.immuni.2013.07.005; Movahedi K, 2010, CANCER RES, V70, P5728, DOI 10.1158/0008-5472.CAN-09-4672; Nishisho T, 2011, MOL CANCER RES, V9, P845, DOI 10.1158/1541-7786.MCR-10-0449; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Ntrivalas E, 2007, AM J REPROD IMMUNOL, V57, P201, DOI 10.1111/j.1600-0897.2006.00463.x; Ostrand-Rosenberg S, 2010, CANCER IMMUNOL IMMUN, V59, P1593, DOI 10.1007/s00262-010-0855-8; Sennoune SR, 2004, AM J PHYSIOL-CELL PH, V286, pC1443, DOI 10.1152/ajpcell.00407.2003; Sennoune SR, 2004, CELL BIOCHEM BIOPHYS, V40, P185, DOI 10.1385/CBB:40:2:185; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422; Torigoe T, 2002, J BIOL CHEM, V277, P36534, DOI 10.1074/jbc.M202605200; Umemura N, 2008, J LEUKOCYTE BIOL, V83, P1136, DOI 10.1189/jlb.0907611; Watkins SK, 2007, J IMMUNOL, V178, P1357, DOI 10.4049/jimmunol.178.3.1357	28	23	24	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2016	35	8					1058	1065		10.1038/onc.2015.159	http://dx.doi.org/10.1038/onc.2015.159			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE7NF	25961933				2022-12-17	WOS:000370823300011
J	Ma, X; Chen, Y; Zhang, S; Xu, W; Shao, Y; Yang, Y; Li, W; Li, M; Xue, L				Ma, X.; Chen, Y.; Zhang, S.; Xu, W.; Shao, Y.; Yang, Y.; Li, W.; Li, M.; Xue, L.			Rho1-Wnd signaling regulates loss-of-cell polarity-induced cell invasion in Drosophila	ONCOGENE			English	Article							MAP KINASE; TUMOR-SUPPRESSOR; JNK ACTIVATION; APOPTOTIC CELLS; ONCOGENIC RAS; RHO-GTPASES; CANCER; DEATH; PATHWAY; MIGRATION	Both cell polarity and c-Jun N-terminal kinase (JNK) activity are essential to the maintenance of tissue homeostasis, and disruption of either is commonly seen in cancer progression. Despite the established connection between loss-of-cell polarity and JNK activation, much less is known about the molecular mechanism by which aberrant cell polarity induces JNK-mediated cell migration and tumor invasion. Here we show results from a genetic screen using an in vivo invasion model via knocking down cell polarity gene in Drosophila wing discs, and identify Rho1-Wnd signaling as an important molecular link that mediates loss-of-cell polarity-triggered JNK activation and cell invasion. We show that Wallenda (Wnd), a protein kinase of the mitogen-activated protein kinase kinase kinase family, by forming a complex with the GTPase Rho1, is both necessary and sufficient for Rho1-induced JNK-dependent cell invasion, MMP1 activation and epithelial-mesenchymal transition. Furthermore, Wnd promotes cell proliferation and tissue growth through wingless production when apoptosis is inhibited by p35. Finally, Wnd shows oncogenic cooperation with Ras(V12) to trigger tumor growth in eye discs and causes invasion into the ventral nerve cord. Together, our data not only provides a novel mechanistic insight on how cell polarity loss contributes to cell invasion, but also highlights the value of the Drosophila model system to explore human cancer biology.	[Ma, X.; Chen, Y.; Zhang, S.; Shao, Y.; Yang, Y.; Li, W.; Li, M.; Xue, L.] Tongji Univ, Inst Intervent Vessel, Shanghai Peoples Hosp 10, Shanghai Key Lab Signaling & Dis Res,Sch Life Sci, 1239 Siping Rd, Shanghai 200092, Peoples R China; [Ma, X.] Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Howard Hughes Med Inst, Baltimore, MD 21205 USA; [Xu, W.] Tongji Univ, Sch Life Sci & Technol, Shanghai 200092, Peoples R China	Tongji University; Howard Hughes Medical Institute; Johns Hopkins University; Tongji University	Li, M; Xue, L (corresponding author), Tongji Univ, Inst Intervent Vessel, Shanghai Peoples Hosp 10, Shanghai Key Lab Signaling & Dis Res,Sch Life Sci, 1239 Siping Rd, Shanghai 200092, Peoples R China.; Ma, X (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Howard Hughes Med Inst, Baltimore, MD 21205 USA.	XianjueMa@jhmi.eduor; cjr.limaoquan@vip.163.com; lei.xue@tongji.edu.cn		Ma, Xianjue/0000-0003-4360-3947	National Basic Research Program of China (973 Program) [2011CB943903]; National Natural Science Foundation of China [31071294, 31171413, 31371490]; Specialized Research Fund for the Doctoral Program of Higher Education of China [20120072110023, 20120072120030]; Shanghai Committee of Science and Technology [09DZ2260100, 14JC1406000]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Specialized Research Fund for the Doctoral Program of Higher Education of China(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); Shanghai Committee of Science and Technology(Shanghai Science & Technology Committee)	We thank Drs Duojia Pan, Tian Xu, Helena Richardson, Aaron DiAntonio, Bloomington, VDRC and NIG stock centers for fly stocks and reagents, Dr Margaret Ho and members of Xue lab for discussion and comments, Dr Jonathan Phillips for critically reading the manuscript. This research was supported by the National Basic Research Program of China (973 Program) (2011CB943903), National Natural Science Foundation of China (31071294, 31171413, 31371490), the Specialized Research Fund for the Doctoral Program of Higher Education of China (20120072110023, 20120072120030), and Shanghai Committee of Science and Technology (09DZ2260100, 14JC1406000). Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).	Baek SH, 2010, BIOCHEM BIOPH RES CO, V394, P488, DOI 10.1016/j.bbrc.2010.02.124; Bergstralh DT, 2012, ESSAYS BIOCHEM, V53, P129, DOI [10.1042/BSE0530129, 10.1042/bse0530129]; Billuart P, 2001, CELL, V107, P195, DOI 10.1016/S0092-8674(01)00522-0; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Brumby AM, 2011, GENETICS, V188, P105, DOI 10.1534/genetics.111.127910; Collins CA, 2006, NEURON, V51, P57, DOI 10.1016/j.neuron.2006.05.026; Cordero JB, 2010, DEV CELL, V18, P999, DOI 10.1016/j.devcel.2010.05.014; Cuevas BD, 2007, ONCOGENE, V26, P3159, DOI 10.1038/sj.onc.1210409; Ebelt Nancy D, 2013, Genes Cancer, V4, P378, DOI 10.1177/1947601913485413; Elsum I, 2012, ESSAYS BIOCHEM, V53, P141, DOI [10.1042/BSE0530141, 10.1042/bse0530141]; Fernandez BG, 2014, ONCOGENE, V33, P2027, DOI 10.1038/onc.2013.155; Gaspar P, 2014, CURR OPIN CELL BIOL, V31, P74, DOI 10.1016/j.ceb.2014.09.003; Geuking P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007709; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; Gonzalez C, 2013, NAT REV CANCER, V13, P172, DOI 10.1038/nrc3461; Grifoni D, 2004, ONCOGENE, V23, P8688, DOI 10.1038/sj.onc.1208023; Hammarlund M, 2009, SCIENCE, V323, P802, DOI 10.1126/science.1165527; Hirai S, 2006, J NEUROSCI, V26, P11992, DOI 10.1523/JNEUROSCI.2272-06.2006; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Itoh A, 2011, J NEUROSCI, V31, P7223, DOI 10.1523/JNEUROSCI.5947-10.2011; Khoo P, 2013, DIS MODEL MECH, V6, P661, DOI 10.1242/dmm.010066; Kulshammer E, 2013, J CELL SCI, V126, P927, DOI 10.1242/jcs.114462; Lee MH, 2008, J CELL SCI, V121, P1141, DOI 10.1242/jcs.016634; Lesch C, 2010, GENETICS, V186, P943, DOI 10.1534/genetics.110.121822; Lewcock JW, 2007, NEURON, V56, P604, DOI 10.1016/j.neuron.2007.09.009; Ma X, 2014, CELL DEATH DIFFER, V21, P407, DOI 10.1038/cdd.2013.154; Ma X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.392; Ma XJ, 2014, AIMS GENET, V1, P20, DOI 10.3934/genet.2014.1.20; Ma XJ, 2015, P NATL ACAD SCI USA, V112, P1065, DOI 10.1073/pnas.1415020112; Ma XJ, 2013, DEV BIOL, V380, P211, DOI 10.1016/j.ydbio.2013.05.013; Ma XJ, 2012, CELL RES, V22, P425, DOI 10.1038/cr.2011.135; Macara IG, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2013.0012; Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169; McGuire SE, 2003, SCIENCE, V302, P1765, DOI 10.1126/science.1089035; Miles WO, 2011, DIS MODEL MECH, V4, P753, DOI 10.1242/dmm.006908; Morata G, 2011, DEV GROWTH DIFFER, V53, P168, DOI 10.1111/j.1440-169X.2010.01225.x; Muthuswamy SK, 2012, ANNU REV CELL DEV BI, V28, P599, DOI 10.1146/annurev-cellbio-092910-154244; Neisch AL, 2010, J CELL BIOL, V189, P311, DOI 10.1083/jcb.200912010; Ohsawa S, 2012, NATURE, V490, P547, DOI 10.1038/nature11452; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-23; Pearson HB, 2011, J CLIN INVEST, V121, P4257, DOI 10.1172/JCI58509; Pichon S, 2004, J CELL SCI, V117, P2569, DOI 10.1242/jcs.01110; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Rauskolb C, 2014, CELL, V158, P143, DOI 10.1016/j.cell.2014.05.035; Royer C, 2011, CELL DEATH DIFFER, V18, P1470, DOI 10.1038/cdd.2011.60; Rudrapatna VA, 2014, ONCOGENE, V33, P2801, DOI 10.1038/onc.2013.232; Rudrapatna VA, 2013, EMBO REP, V14, P172, DOI 10.1038/embor.2012.217; Rudrapatna VA, 2012, DEV DYNAM, V241, P107, DOI 10.1002/dvdy.22771; Ryoo HD, 2004, DEV CELL, V7, P491, DOI 10.1016/j.devcel.2004.08.019; Srivastava A, 2007, P NATL ACAD SCI USA, V104, P2721, DOI 10.1073/pnas.0611666104; Tedeschi A, 2013, EMBO REP, V14, P605, DOI 10.1038/embor.2013.64; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Uhlirova M, 2005, P NATL ACAD SCI USA, V102, P13123, DOI 10.1073/pnas.0504170102; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; Vaira V, 2011, AM J PATHOL, V178, P2478, DOI 10.1016/j.ajpath.2011.02.028; Vidal M, 2006, DEV CELL, V10, P33, DOI 10.1016/j.devcel.2005.11.007; Xiong X, 2012, J NEUROSCI, V32, P610, DOI 10.1523/JNEUROSCI.3586-11.2012; Xue L, 2007, DEV CELL, V13, P446, DOI 10.1016/j.devcel.2007.07.012; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045; Zhang L, 2008, DEV CELL, V14, P377, DOI 10.1016/j.devcel.2008.01.006; Zhang SY, 2012, TRENDS PHARMACOL SCI, V33, P122, DOI 10.1016/j.tips.2011.11.002	62	23	23	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					846	855		10.1038/onc.2015.137	http://dx.doi.org/10.1038/onc.2015.137			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	25961917				2022-12-17	WOS:000370332200005
J	Carvalho, S; Lindzen, M; Lauriola, M; Shirazi, N; Sinha, S; Abdul-Hai, A; Levanon, K; Korach, J; Barshack, I; Cohen, Y; Onn, A; Mills, G; Yarden, Y				Carvalho, S.; Lindzen, M.; Lauriola, M.; Shirazi, N.; Sinha, S.; Abdul-Hai, A.; Levanon, K.; Korach, J.; Barshack, I.; Cohen, Y.; Onn, A.; Mills, G.; Yarden, Y.			An antibody to amphiregulin, an abundant growth factor in patients' fluids, inhibits ovarian tumors	ONCOGENE			English	Article							FACTOR RECEPTOR; ERBB RECEPTORS; EGFR LIGANDS; CANCER; AUTOCRINE; EXPRESSION; COMBINATIONS; GEFITINIB; CARCINOMA; PARACRINE	Growth factors of the epidermal growth factor (EGF)/neuregulin family are involved in tumor progression and, accordingly, antibodies that intercept a cognate receptor, epidermal growth factor receptor ( EGFR)/ERBB1, or a co-receptor, HER2, have been approved for cancer therapy. Although they might improve safety and delay onset of chemoresistance, no anti-ligand antibodies have been clinically approved. To identify suitable ligands, we surveyed fluids from ovarian and lung cancer patients and found that amphiregulin (AREG) is the most abundant and generalized ligand secreted by advanced tumors. AREG is a low affinity EGFR ligand, which is upregulated following treatment with chemotherapeutic drugs. Because AREG depletion retarded growth of xenografted ovarian tumors in mice, we generated a neutralizing monoclonal anti-AREG antibody. The antibody inhibited growth of ovarian cancer xenografts and strongly enhanced chemotherapy efficacy. Taken together, these results raise the possibility that AREG and other low-or high-affinity binders of EGFR might serve as potential targets for cancer therapy.	[Carvalho, S.; Lindzen, M.; Lauriola, M.; Shirazi, N.; Sinha, S.; Yarden, Y.] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; [Abdul-Hai, A.] Kaplan Med Ctr, Rehovot, Israel; [Levanon, K.] Chaim Sheba Med Ctr, Dr Pinchas Borenstein Talpiot Med Leadership Prog, Ramat Gan, Israel; [Levanon, K.] Chaim Sheba Med Ctr, Inst Oncol, Ramat Gan, Israel; [Korach, J.] Chaim Sheba Med Ctr, Dept Gynecol Oncol, Ramat Gan, Israel; [Barshack, I.] Sheba Med Ctr, Dept Pathol, Ramat Gan, Israel; [Cohen, Y.] Sheba Med Ctr, Inst Tissue Banks, Ramat Gan, Israel; [Onn, A.] Chaim Sheba Med Ctr, Inst Pulm Oncol, Ramat Gan, Israel; [Mills, G.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Lauriola, M.] Univ Bologna, Dept Expt Diagnost & Specialty Med, Unit Histol Embryol & Appl Biol, I-40126 Bologna, Italy	Weizmann Institute of Science; Hebrew University of Jerusalem; Kaplan Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; University of Texas System; UTMD Anderson Cancer Center; University of Bologna	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	lauriola, mattia/N-6435-2014	Levanon, Keren/0000-0002-5122-064X; lauriola, mattia/0000-0002-7966-0065	Merck KGaA; Israel Cancer Research Fund; Dr Miriam and Sheldon G Adelson Medical Research Foundation; MD Moross Institute for Cancer Research; Flight Attendants Medical Research Institute (FAMRI); NATIONAL CANCER INSTITUTE [P50CA098258] Funding Source: NIH RePORTER	Merck KGaA(Merck & Company); Israel Cancer Research Fund; Dr Miriam and Sheldon G Adelson Medical Research Foundation; MD Moross Institute for Cancer Research; Flight Attendants Medical Research Institute (FAMRI); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Julian Downward for lung cell lines. This work was performed at the Marvin Tanner Laboratory for Cancer Research and it was supported, in part, by Merck KGaA. The research in our laboratory is supported by the Israel Cancer Research Fund and the Dr Miriam and Sheldon G Adelson Medical Research Foundation and by the MD Moross Institute for Cancer Research. YY is the incumbent of the Harold and Zelda Goldenberg Professorial Chair. The Sheba Institutional Tissue Banks have received financial support from the Flight Attendants Medical Research Institute (FAMRI).	Amit I, 2007, NAT GENET, V39, P503, DOI 10.1038/ng1987; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Baldys A, 2009, BIOCHEMISTRY-US, V48, P1462, DOI 10.1021/bi801771g; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Berasain C, 2014, SEMIN CELL DEV BIOL, V28, P31, DOI 10.1016/j.semcdb.2014.01.005; Blivet-Van Eggelpoel MJ, 2012, J HEPATOL, V57, P108, DOI 10.1016/j.jhep.2012.02.019; Brustmann H, 2008, INT J GYNECOL PATHOL, V27, P380, DOI 10.1097/PGP.0b013e31815d060d; Burgess AW, 2008, GROWTH FACTORS, V26, P263, DOI 10.1080/08977190802312844; Ciarloni L, 2007, P NATL ACAD SCI USA, V104, P5455, DOI 10.1073/pnas.0611647104; DeWitt A, 2002, DEV BIOL, V250, P305, DOI 10.1006/dbio.2002.0807; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; Eckstein N, 2008, J BIOL CHEM, V283, P739, DOI 10.1074/jbc.M706287200; Esposito CL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024071; Friedman LM, 2005, P NATL ACAD SCI USA, V102, P1915, DOI 10.1073/pnas.0409610102; Frosi Y, 2010, J CELL BIOL, V189, P557, DOI 10.1083/jcb.201002032; Gui T, 2012, CANCER EPIDEMIOL, V36, P490, DOI 10.1016/j.canep.2012.06.005; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Higginbotham JN, 2011, CURR BIOL, V21, P779, DOI 10.1016/j.cub.2011.03.043; Hsu D, 2010, LAB INVEST, V90, P1295, DOI 10.1038/labinvest.2010.100; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; Keyse SM, 2008, CANCER METAST REV, V27, P253, DOI 10.1007/s10555-008-9123-1; Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437; Kochupurakkal BS, 2005, J BIOL CHEM, V280, P8503, DOI 10.1074/jbc.M413919200; Lassus H, 2006, J MOL MED-JMM, V84, P671, DOI 10.1007/s00109-006-0054-4; Lazzara MJ, 2009, EXP CELL RES, V315, P717, DOI 10.1016/j.yexcr.2008.10.033; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Lindzen M, 2012, ONCOGENE, V31, P3505, DOI 10.1038/onc.2011.518; Lindzen M, 2010, P NATL ACAD SCI USA, V107, P12559, DOI 10.1073/pnas.1006218107; Lopez J, 2013, ANN ONCOL, V24, P69, DOI 10.1093/annonc/mdt475; Murphy M, 2011, DRUG RESIST UPDATE, V14, P177, DOI 10.1016/j.drup.2011.02.004; Normanno N, 2005, CURR DRUG TARGETS, V6, P243, DOI 10.2174/1389450053765879; Panupinthu N, 2014, ONCOGENE, V33, P2846, DOI 10.1038/onc.2013.259; Pedersen MW, 2010, CANCER RES, V70, P588, DOI 10.1158/0008-5472.CAN-09-1417; Reddy CC, 1996, NAT BIOTECHNOL, V14, P1696, DOI 10.1038/nbt1296-1696; Roepstorff K, 2009, TRAFFIC, V10, P1115, DOI 10.1111/j.1600-0854.2009.00943.x; Sato S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051964; Sauer L, 2010, ONCOGENE, V29, P2628, DOI 10.1038/onc.2010.24; Sheng Q, 2010, CANCER CELL, V17, P298, DOI 10.1016/j.ccr.2009.12.047; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; Siwak DR, 2010, J ONCOL, V2010, DOI 10.1155/2010/568938; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; Stern KA, 2008, BIOCHEM J, V410, P585, DOI 10.1042/BJ20071505; Sternlicht MD, 2005, DEVELOPMENT, V132, P3923, DOI 10.1242/dev.01966; Tzahar E, 1998, EMBO J, V17, P5948, DOI 10.1093/emboj/17.20.5948; Van Zoelen E J, 2000, Vitam Horm, V59, P99, DOI 10.1016/S0083-6729(00)59005-0; Willmarth NE, 2006, J BIOL CHEM, V281, P37728, DOI 10.1074/jbc.M606532200; Wilson KJ, 2012, GROWTH FACTORS, V30, P107, DOI 10.3109/08977194.2011.649918; Witsch E, 2010, PHYSIOLOGY, V25, P85, DOI 10.1152/physiol.00045.2009; Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309; Yonesaka K, 2008, CLIN CANCER RES, V14, P6963, DOI 10.1158/1078-0432.CCR-08-0957; Zwang Yaara, 2009, Traffic, V10, P349, DOI 10.1111/j.1600-0854.2008.00870.x	52	23	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2016	35	4					438	447		10.1038/onc.2015.93	http://dx.doi.org/10.1038/onc.2015.93			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OT	25915843				2022-12-17	WOS:000369056700004
J	Fleisig, HB; Hukezalie, KR; Thompson, CAH; Au-Yeung, TTT; Ludlow, AT; Zhao, CR; Wong, JMY				Fleisig, H. B.; Hukezalie, K. R.; Thompson, C. A. H.; Au-Yeung, T. T. T.; Ludlow, A. T.; Zhao, C. R.; Wong, J. M. Y.			Telomerase reverse transcriptase expression protects transformed human cells against DNA-damaging agents, and increases tolerance to chromosomal instability	ONCOGENE			English	Article							CATALYTIC SUBUNIT; HTERT; LENGTH; MAINTENANCE; BIOGENESIS; VARIANT; APOPTOSIS; CHROMATIN; TARGET; CANCER	Reactivation of telomerase reverse transcriptase (TERT) expression is found in more than 85% of human cancers. The remaining cancers rely on the alternative lengthening of telomeres (ALT), a recombination-based mechanism for telomere-length maintenance. Prevalence of TERT reactivation over the ALT mechanism was linked to secondary TERT function unrelated to telomere length maintenance. To characterize this non-canonical function, we created a panel of ALT cells with recombinant expression of TERT and TERT variants: TERT-positive ALT cells showed higher tolerance to genotoxic insults compared with their TERT-negative counterparts. We identified telomere synthesis-defective TERT variants that bestowed similar genotoxic stress tolerance, indicating that telomere synthesis activity is dispensable for this survival phenotype. TERT expression improved the kinetics of double-strand chromosome break repair and reduced DNA damage-related nuclear division abnormalities, a phenotype associated with ALT tumors. Despite this reduction in cytological abnormalities, surviving TERT-positive ALT cells were found to have gross chromosomal instabilities. We sorted TERT-positive cells with cytogenetic changes and followed their growth. We found that the chromosome-number changes persisted, and TERT-positive ALT cells surviving genotoxic events propagated through subsequent generations with new chromosome numbers. Our data confirm that telomerase expression protects against doublestrand DNA (dsDNA)-damaging events, and show that this protective function is uncoupled from its role in telomere synthesis. TERT expression promotes oncogene-transformed cell growth by reducing the inhibitory effects of cell-intrinsic (telomere attrition) and cell-extrinsic (chemical-or metabolism-induced genotoxic stress) challenges. These data provide the impetus to develop new therapeutic interventions for telomerase-positive cancers through simultaneous targeting of multiple telomerase activities.	[Fleisig, H. B.; Hukezalie, K. R.; Thompson, C. A. H.; Au-Yeung, T. T. T.; Zhao, C. R.; Wong, J. M. Y.] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC V6T 1Z3, Canada; [Ludlow, A. T.] Univ Texas SW Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA	University of British Columbia; University of Texas System; University of Texas Southwestern Medical Center Dallas	Wong, JMY (corresponding author), Univ British Columbia, Fac Pharmaceut Sci, 2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	judy.wong@ubc.ca	Wong, Judy/AAG-1868-2021	Wong, Judy/0000-0001-5572-4143	Canadian Cancer Society Research Institute [019250]; Research Reinvestment Funds from the Faculty of Pharmaceutical Sciences at UBC; Michael Smith Foundation for Health Research Career Development program	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Research Reinvestment Funds from the Faculty of Pharmaceutical Sciences at UBC; Michael Smith Foundation for Health Research Career Development program	We thank members of Judy Wong's laboratory for providing helpful insights. Kathleen Collins and Bill Hahn kindly provided reagents. Shirley Yeung, Irene Iu and Arthur Chan assisted with method development. Nigel O'Neil assisted with optimization of the chromosomal healing assay. Andy Johnson from the UBC Flow-Cytometry Facility provided expertise with FACS procedures. We thank them for their assistance. Financial support for this work was provided by the Canadian Cancer Society Research Institute (operating grant #019250), and Research Reinvestment Funds from the Faculty of Pharmaceutical Sciences at UBC. JMYW is supported by the Michael Smith Foundation for Health Research Career Development program.	Armbruster BN, 2003, MOL CELL BIOL, V23, P3237, DOI 10.1128/MCB.23.9.3237-3246.2003; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Bryant Helen E, 2012, Methods Mol Biol, V920, P315, DOI 10.1007/978-1-61779-998-3_22; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; Egan ED, 2012, RNA, V18, P1747, DOI 10.1261/rna.034629.112; Fasching CL, 2005, CANCER RES, V65, P2722, DOI 10.1158/0008-5472.CAN-04-2881; Fenech M, 2007, NAT PROTOC, V2, P1084, DOI 10.1038/nprot.2007.77; Fleisig HB, 2012, ONCOGENE, V31, P954, DOI 10.1038/onc.2011.292; Fleisig HB, 2007, EXP GERONTOL, V42, P102, DOI 10.1016/j.exger.2006.05.011; Fu D, 2007, MOL CELL, V28, P773, DOI 10.1016/j.molcel.2007.09.023; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Hukezalie KR, 2013, FEBS J, V280, P3194, DOI 10.1111/febs.12272; Lincz LF, 2008, NEOPLASIA, V10, P1131, DOI 10.1593/neo.08644; Listerman I, 2013, CANCER RES, V73, P2817, DOI 10.1158/0008-5472.CAN-12-3082; Lovejoy CA, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002772; Martinez P, 2011, NAT REV CANCER, V11, P161, DOI 10.1038/nrc3025; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; Okamoto N, 2011, P NATL ACAD SCI USA, V108, P20388, DOI 10.1073/pnas.1015171108; Park JI, 2009, NATURE, V460, P66, DOI 10.1038/nature08137; Perrem K, 2001, MOL CELL BIOL, V21, P3862, DOI 10.1128/MCB.21.12.3862-3875.2001; Poon SSS, 2001, METHOD CELL BIOL, V64, P69; Robin JD, 2014, GENE DEV, V28, P2464, DOI 10.1101/gad.251041.114; Sharma GG, 2003, ONCOGENE, V22, P131, DOI 10.1038/sj.onc.1206063; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Tamakawa RA, 2010, CANCER RES, V70, P8684, DOI 10.1158/0008-5472.CAN-10-2227; Ulaner GA, 1998, CANCER RES, V58, P4168; Wong JMY, 2003, LANCET, V362, P983, DOI 10.1016/S0140-6736(03)14369-3; Wright WE, 1996, DEV GENET, V18, P173; Yi XM, 2000, NEOPLASIA, V2, P433, DOI 10.1038/sj.neo.7900113	30	23	23	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2016	35	2					218	227		10.1038/onc.2015.75	http://dx.doi.org/10.1038/onc.2015.75			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB0JH	25893297				2022-12-17	WOS:000368193900008
J	Barakat, DJ; Zhang, J; Barberi, T; Denmeade, SR; Friedman, AD; Paz-Priel, I				Barakat, D. J.; Zhang, J.; Barberi, T.; Denmeade, S. R.; Friedman, A. D.; Paz-Priel, I.			CCAAT/Enhancer binding protein beta controls androgen-deprivation-induced senescence in prostate cancer cells	ONCOGENE			English	Article							TRANSCRIPTION FACTOR SP1; C/EBP-BETA; GENE-EXPRESSION; SECRETORY PHENOTYPE; RECEPTOR; PROLIFERATION; DIFFERENTIATION; THERAPY; ALPHA; OVEREXPRESSION	The processes associated with transition to castration-resistant prostate cancer (PC) growth are not well understood. Cellular senescence is a stable cell cycle arrest that occurs in response to sublethal stress. It is often overcome in malignant transformation to confer a survival advantage. CCAAT/Enhancer Binding Protein (C/EBP) beta function is frequently deregulated in human malignancies and interestingly, androgen-sensitive PC cells express primarily the liver-enriched inhibitory protein isoform. We found that C/EBP beta expression is negatively regulated by androgen receptor (AR) activity and that treatment of androgen-sensitive cell lines with anti-androgens increases C/EBP beta mRNA and protein levels. Accordingly, we also find that C/EBP beta levels are significantly elevated in primary PC samples from castration-resistant compared with therapy-naive patients. Chromatin immunoprecipitation demonstrated enhanced binding of the AR to the proximal promoter of the CEBPB gene in the presence of dihydroxytestosterone. Upon androgen deprivation, induction of C/EBP beta is facilitated by active transcription as evident by increased histone 3 acetylation at the C/EBP beta promoter. Also, the androgen agonist R1881 suppresses the activity of a CEBPB promoter reporter. Loss of C/EBP beta expression prevents growth arrest following androgen deprivation or anti-androgen challenge. Accordingly, suppression of C/EBP beta under low androgen conditions results in reduced expression of senescence-associated secretory genes, significantly decreased number of cells displaying heterochromatin foci and increased numbers of Ki67-positive cells. Ectopic expression of C/EBP beta caused pronounced morphological changes, reduced PC cell growth and increased the number of senescent LNCaP cells. Lastly, we found that senescence contributes to PC cell survival under androgen deprivation, and C/EBP beta-deficient cells were significantly more susceptible to killing by cytotoxic chemotherapy following androgen deprivation. Our data demonstrate that upregulation of C/EBP beta is critical for complete maintenance of androgen deprivation-induced senescence and that targeting C/EBP beta expression may synergize with anti-androgen or chemotherapy in eradicating PC.	[Barakat, D. J.; Zhang, J.; Barberi, T.; Friedman, A. D.; Paz-Priel, I.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Div Pediat Oncol, Baltimore, MD 21231 USA; [Denmeade, S. R.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Div Med Oncol, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Paz-Priel, I (corresponding author), Johns Hopkins Univ, Bunting Blaustein Canc Res Bldg 1,Room 208,1650 O, Baltimore, MD 21231 USA.	ipazpri1@jhmi.edu		Barakat, David/0000-0001-7057-178X	St Baldrick's Foundation; Mitchell Foundation; Walsh Prostate Cancer Research Fund; Samuel Waxman Cancer Research Foundation; Department of Defense [PC131609]; National Institutes of Health [T32 CA60441]; Giant Food Children's Cancer Research Fund;  [P30 CA006973]; NATIONAL CANCER INSTITUTE [P30CA006973, T32CA060441] Funding Source: NIH RePORTER	St Baldrick's Foundation; Mitchell Foundation; Walsh Prostate Cancer Research Fund; Samuel Waxman Cancer Research Foundation; Department of Defense(United States Department of Defense); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Giant Food Children's Cancer Research Fund; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by grants from the St Baldrick's Foundation (to IP-P), the Mitchell Foundation (to IP-P), the Walsh Prostate Cancer Research Fund (to IP-P and ADF), the Samuel Waxman Cancer Research Foundation (to ADF), Department of Defense grant PC131609 (to DJB), National Institutes of Health T32 CA60441 (to TB), the Giant Food Children's Cancer Research Fund and P30 CA006973.	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; American Cancer Society, 2013, CANC FACTS FIG 2013; Bagchi MK, 2006, CELL CYCLE, V5, P922, DOI 10.4161/cc.5.9.2712; Baretton GB, 1999, BRIT J CANCER, V80, P546, DOI 10.1038/sj.bjc.6690390; Bavik C, 2006, CANCER RES, V66, P794, DOI 10.1158/0008-5472.CAN-05-1716; Bedell VM, 2012, NATURE, V491, P114, DOI 10.1038/nature11537; Boruk M, 1998, MOL ENDOCRINOL, V12, P1749, DOI 10.1210/me.12.11.1749; Burton DGA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068003; Cahu J, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.183; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Calkhoven CF, 2000, GENE DEV, V14, P1920; Cermak T, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr218; Christenson LK, 1999, J BIOL CHEM, V274, P26591, DOI 10.1074/jbc.274.37.26591; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Dean JP, 2008, BRIT J CANCER, V98, P245, DOI 10.1038/sj.bjc.6604087; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Denmeade S R, 1996, Adv Pharmacol, V35, P281, DOI 10.1016/S1054-3589(08)60278-1; Denmeade SR, 1996, PROSTATE, V28, P251; Ewald JA, 2013, PROSTATE, V73, P337, DOI 10.1002/pros.22571; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Henshall SM, 2001, CLIN CANCER RES, V7, P544; Jia L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003645; Kawabata R, 2011, INT J ONCOL, V38, P1489, DOI 10.3892/ijo.2011.991; Kim MH, 2008, PROSTATE, V68, P1362, DOI 10.1002/pros.20801; Kim MH, 2009, PROSTATE, V69, P1435, DOI 10.1002/pros.20993; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kurz DJ, 2000, J CELL SCI, V113, P3613; Lee CT, 1999, CLIN CANCER RES, V5, P977; Lehmann BD, 2008, CANCER RES, V68, P7864, DOI 10.1158/0008-5472.CAN-07-6538; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; MacManus CF, 2007, MOL CANCER RES, V5, P737, DOI 10.1158/1541-7786.MCR-07-0032; Manna S, 2013, J IMMUNOL, V191, P2837, DOI 10.4049/jimmunol.1300895; Mantena SR, 2006, P NATL ACAD SCI USA, V103, P1870, DOI 10.1073/pnas.0507261103; Martinez LA, 2002, CARCINOGENESIS, V23, P1289, DOI 10.1093/carcin/23.8.1289; Mehta HH, 2011, CANCER RES, V71, P5154, DOI 10.1158/0008-5472.CAN-10-4513; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Orjalo AV, 2009, P NATL ACAD SCI USA, V106, P17031, DOI 10.1073/pnas.0905299106; Paz-Priel I, 2011, BLOOD, V117, P4085, DOI 10.1182/blood-2010-07-294470; Pernicova Z, 2011, NEOPLASIA, V13, P526, DOI 10.1593/neo.11182; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Seaton A, 2008, CARCINOGENESIS, V29, P1148, DOI 10.1093/carcin/bgn109; Sebastian T, 2005, EMBO J, V24, P3301, DOI 10.1038/sj.emboj.7600789; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Sharma NL, 2013, CANCER CELL, V23, P35, DOI 10.1016/j.ccr.2012.11.010; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Steinman RA, 2000, MOL MED, V6, P736, DOI 10.1007/BF03402190; Svensson C, 2014, NUCLEIC ACIDS RES, V42, P999, DOI 10.1093/nar/gkt921; Tanabe A, 2000, BIOL PHARM BULL, V23, P1424, DOI 10.1248/bpb.23.1424; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P4517, DOI 10.1093/nar/27.22.4517; Wang WZ, 2007, PROSTATE, V67, P1238, DOI 10.1002/pros.20595; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Yuan HQ, 2005, CARCINOGENESIS, V26, P793, DOI 10.1093/carcin/bgi021; Yusa K, 2011, P NATL ACAD SCI USA, V108, P1531, DOI 10.1073/pnas.1008322108; Zhang ZH, 2006, MODERN PATHOL, V19, P1339, DOI 10.1038/modpathol.3800655; Zhou JF, 2001, CANCER RES, V61, P2328	57	23	23	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2015	34	48					5912	5922		10.1038/onc.2015.41	http://dx.doi.org/10.1038/onc.2015.41			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CX1CO	25772238	Green Accepted			2022-12-17	WOS:000365434000006
J	Spring, K; Fournier, P; Lapointe, L; Chabot, C; Roussy, J; Pommey, S; Stagg, J; Royal, I				Spring, K.; Fournier, P.; Lapointe, L.; Chabot, C.; Roussy, J.; Pommey, S.; Stagg, J.; Royal, I.			The protein tyrosine phosphatase DEP-1/PTPRJ promotes breast cancer cell invasion and metastasis	ONCOGENE			English	Article							C-SRC; KINASE INHIBITOR; BONE METASTASIS; IN-VITRO; CORTACTIN; GROWTH; ACTIVATION; MIGRATION; RECEPTOR; PHOSPHORYLATION	DEP-1/PTPRJ is a receptor-like protein tyrosine phosphatase mainly known for its antiproliferative and tumor-suppressive functions. Many identified substrates are growth factor receptors, and DEP-1 is deleted and/or mutated in human cancers including that of the breast. However, DEP-1 was also identified as a promoter of Src activation and proinvasive functions in the endothelium, suggesting it could perhaps mediate breast cancer invasiveness that is likewise driven by Src family kinases. We show here that DEP-1 expression was greater in highly invasive breast cancer cells (MDA-MB-231, Hs578T, BT-549) than in the less invasive or untransformed cell lines tested (MCF-7, T47D, SK-BR3 and MCF10A). DEP-1 silencing experiments in invasive cells demonstrated that moderately expressed and catalytically active DEP-1 was required, in collaboration with basal epidermal growth factor receptor activity, for Src activation and the phosphorylation of its substrate Cortactin, and for their colocalization at the cell's leading edge. This correlated with an increased number of cell protrusions, and an enhanced capacity of the cells to migrate and invade. Similarly, moderate overexpression of DEP-1 in the low-invasive cells resulted in the promotion of their invasiveness in an Src-dependent manner. Consistent with these data, the expression of endogenous DEP-1 was elevated in a bone metastatic cell line derived from MDA-MB-231 cells, and promoted increased Src Y418 and Cortactin Y421 phosphorylation, as well as pro-MMP9 secretion and Matrigel invasion. Importantly, the silencing of DEP-1 in MDA-MB-231 cells greatly decreased their ability to metastasize, despite having no effect on tumor growth or angiogenesis. Hence, we found that moderate expression of DEP-1 was associated with the increased relapse and decreased survival of breast cancer patients. These results therefore identify a new and unsuspected role for DEP-1 as a mediator of an invasive cell program implicating Src activation and the promotion of breast cancer progression.	[Spring, K.; Fournier, P.; Lapointe, L.; Chabot, C.; Roussy, J.; Pommey, S.; Stagg, J.; Royal, I.] CHUM, Ctr Rech, Inst Canc Montreal, Montreal, PQ H2X 0A9, Canada; [Stagg, J.] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada; [Royal, I.] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal	Royal, I (corresponding author), CHUM, Ctr Rech, 900 Rue St Denis, Montreal, PQ H2X 0A9, Canada.	isabelle.royal@umontreal.ca		Royal, Isabelle/0000-0002-7548-1182; Spring, Kathleen/0000-0001-6747-7725	Cancer Research Society/Quebec Breast Cancer Foundation; FRQS [25988]; CIHR [292353]	Cancer Research Society/Quebec Breast Cancer Foundation; FRQS; CIHR(Canadian Institutes of Health Research (CIHR))	We thank our colleagues for their generous gifts of plasmid DNAs and cell lines. This work was supported by a Cancer Research Society/Quebec Breast Cancer Foundation grant (to IR). KS and CC held partial studentships from Universite de Montreal. PF was supported by FRQS (25988) and CIHR (292353) studentships. KS, PF, CC and JR also held partial studentships from the Montreal Cancer Institute.	Aceto N, 2012, NAT MED, V18, P529, DOI 10.1038/nm.2645; Arora D, 2011, J BIOL CHEM, V286, P10918, DOI 10.1074/jbc.M110.205021; Aya-Bonilla C, 2013, GENE CHROMOSOME CANC, V52, P467, DOI 10.1002/gcc.22044; Balavenkatraman KK, 2006, ONCOGENE, V25, P6319, DOI 10.1038/sj.onc.1209647; Bentires-Alj M, 2007, CANCER RES, V67, P2420, DOI 10.1158/0008-5472.CAN-06-4610; Berset TA, 2005, GENE DEV, V19, P1328, DOI 10.1101/gad.333505; Bertos NR, 2011, J CLIN INVEST, V121, P3789, DOI 10.1172/JCI57100; Bryce NS, 2005, CURR BIOL, V15, P1276, DOI 10.1016/j.cub.2005.06.043; Chabot C, 2009, MOL CELL BIOL, V29, P241, DOI 10.1128/MCB.01374-08; Chiorean R, 2013, BREAST, V22, P1026, DOI 10.1016/j.breast.2013.08.007; Clark ES, 2008, EUR J CELL BIOL, V87, P581, DOI 10.1016/j.ejcb.2008.01.008; Clark ES, 2007, CANCER RES, V67, P4227, DOI 10.1158/0008-5472.CAN-06-3928; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Eccles SA, 2011, INT J DEV BIOL, V55, P685, DOI 10.1387/ijdb.113396se; Eckert LB, 2004, CANCER RES, V64, P4585, DOI 10.1158/0008-5472.CAN-04-0396; Elias D, 2014, ONCOGENE, P1; Ellinghaus E, 2012, LEUKEMIA, V26, P902, DOI 10.1038/leu.2011.302; Foley John, 2010, Semin Cell Dev Biol, V21, P951, DOI 10.1016/j.semcdb.2010.08.009; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Guarino M, 2010, J CELL PHYSIOL, V223, P14, DOI 10.1002/jcp.22011; Hardy S, 2010, CANCER RES, V70, P8959, DOI 10.1158/0008-5472.CAN-10-2041; Hiscox S, 2006, BREAST CANCER RES TR, V97, P263, DOI 10.1007/s10549-005-9120-9; Hochgrafe F, 2010, CANCER RES, V70, P9391, DOI 10.1158/0008-5472.CAN-10-0911; Holsinger LJ, 2002, ONCOGENE, V21, P7067, DOI 10.1038/sj.onc.1205858; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Iuliano R, 2004, ONCOGENE, V23, P8432, DOI 10.1038/sj.onc.1207766; Iuliano R, 2010, ENDOCR-RELAT CANCER, V17, P1001, DOI 10.1677/ERC-10-0143; Jallal H, 2007, CANCER RES, V67, P1580, DOI 10.1158/0008-5472.CAN-06-2027; Julien SG, 2007, NAT GENET, V39, P338, DOI 10.1038/ng1963; Julien SG, 2011, NAT REV CANCER, V11, P35, DOI 10.1038/nrc2980; Keane MM, 1996, CANCER RES, V56, P4236; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; Lai FPL, 2009, MOL BIOL CELL, V20, P3209, DOI 10.1091/mbc.E08-12-1180; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Le Pera I, 2005, ONCOGENE, V24, P3187, DOI 10.1038/sj.onc.1208510; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Lesueur F, 2005, HUM MOL GENET, V14, P2349, DOI 10.1093/hmg/ddi237; Li YS, 2001, CANCER RES, V61, P6906; Ma JG, 2011, BREAST CANCER RES TR, V130, P85, DOI 10.1007/s10549-010-1302-4; MacGrath SM, 2012, J CELL SCI, V125, P1621, DOI 10.1242/jcs.093781; Majumder S, 2014, ARTERIOSCL THROM VAS, V34, P419, DOI 10.1161/ATVBAHA.113.302689; Mezi S, 2012, INT J ONCOL, V41, P2128, DOI 10.3892/ijo.2012.1642; Mita Y, 2010, J CANCER RES CLIN, V136, P249, DOI 10.1007/s00432-009-0656-7; Myoui A, 2003, CANCER RES, V63, P5028; Nam JS, 2002, CLIN CANCER RES, V8, P2430; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Petermann A, 2011, BRAIN PATHOL, V21, P405, DOI 10.1111/j.1750-3639.2010.00464.x; Podo F, 2010, MOL ONCOL, V4, P209, DOI 10.1016/j.molonc.2010.04.006; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rucci N, 2006, J PHARMACOL EXP THER, V318, P161, DOI 10.1124/jpet.106.102004; Ruivenkamp C, 2003, ONCOGENE, V22, P3472, DOI 10.1038/sj.onc.1206246; Sabe H, 2008, CELL ADHES MIGR, V2, P71, DOI 10.4161/cam.2.2.6191; Sallee JL, 2009, J BIOL CHEM, V284, P14997, DOI 10.1074/jbc.M901901200; Senis YA, 2009, BLOOD, V113, P4942, DOI 10.1182/blood-2008-08-174318; Shields BJ, 2013, MOL CELL BIOL, V33, P557, DOI 10.1128/MCB.01016-12; Shor AC, 2007, CANCER RES, V67, P2800, DOI 10.1158/0008-5472.CAN-06-3469; Sihto H, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2944; Smart CE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040742; Smid M, 2008, CANCER RES, V68, P3108, DOI 10.1158/0008-5472.CAN-07-5644; Spring K, 2014, CELL SIGNAL, V26, P1283, DOI 10.1016/j.cellsig.2014.02.008; Spring K, 2012, BLOOD, V120, P2745, DOI 10.1182/blood-2011-12-398040; Sun TT, 2011, CELL, V144, P703, DOI 10.1016/j.cell.2011.02.003; Sung BH, 2011, CURR BIOL, V21, P1460, DOI 10.1016/j.cub.2011.06.065; Takahashi K, 1996, EXP CELL RES, V226, P214, DOI 10.1006/excr.1996.0221; Takahashi T, 1999, J AM SOC NEPHROL, V10, P2135; Tarcic G, 2009, CURR BIOL, V19, P1788, DOI 10.1016/j.cub.2009.09.048; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Tehrani S, 2007, P NATL ACAD SCI USA, V104, P11933, DOI 10.1073/pnas.0701077104; Tonks NK, 2013, FEBS J, V280, P346, DOI 10.1111/febs.12077; Trapasso F, 2004, CARCINOGENESIS, V25, P2107, DOI 10.1093/carcin/bgh224; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; Yu M, 2012, MOL CELL BIOL, V32, P3913, DOI 10.1128/MCB.00068-12; Zhang L, 1997, EXP CELL RES, V235, P62, DOI 10.1006/excr.1997.3659; Zhang SY, 2012, TRENDS PHARMACOL SCI, V33, P122, DOI 10.1016/j.tips.2011.11.002; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017; Zhu JW, 2008, IMMUNITY, V28, P183, DOI 10.1016/j.immuni.2007.11.024	79	23	23	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2015	34	44					5536	5547		10.1038/onc.2015.9	http://dx.doi.org/10.1038/onc.2015.9			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9FX	25772245				2022-12-17	WOS:000364594000003
J	Kumar, S; Das, S; Rachagani, S; Kaur, S; Joshi, S; Johansson, SL; Ponnusamy, MP; Jain, M; Batra, SK				Kumar, S.; Das, S.; Rachagani, S.; Kaur, S.; Joshi, S.; Johansson, S. L.; Ponnusamy, M. P.; Jain, M.; Batra, S. K.			NCOA3-mediated upregulation of mucin expression via transcriptional and post-translational changes during the development of pancreatic cancer	ONCOGENE			English	Article							NUCLEAR RECEPTOR COACTIVATOR; GENE-EXPRESSION; RETINOIC ACID; BREAST-CANCER; POTENTIAL ROLE; GROWTH; ACTIVATION; SRC-3; AIB1; PROGRESSION	Pancreatic cancer (PC) is characterized by aberrant overexpression of mucins that contribute to its pathogenesis. Although the inflammatory cytokines contribute to mucin overexpression, the mucin profile of PC is markedly distinct from that of normal or inflamed pancreas. We postulated that de novo expression of various mucins in PC involves chromatin modifications. Analysis of chromatin modifying enzymes by PCR array identified differential expression of NCOA3 in MUC4-expressing PC cell lines. Immunohistochemistry analysis in tumor tissues from patients and spontaneous mouse models, and microarray analysis following the knockdown of NCOA3 were performed to elucidate its role in mucin regulation and overall impact on PC. Silencing of NCOA3 in PC cell lines resulted in significant downregulation of two most differentially expressed mucins in PC, MUC4 and MUC1 (P<0.01). Immunohistochemistry analysis in PC tissues and metastatic lesions established an association between NCOA3 and mucin (MUC1 and MUC4) expression. Spontaneous mouse model of PC (K-rasG12D; Pdx-1cre) showed early expression of Ncoa3 during preneoplastic lesions. Mechanistically, NCOA3 knockdown abrogated retinoic acid-mediated MUC4 upregulation by restricting MUC4 promoter accessibility as demonstrated by micrococcus nuclease digestion (P<0.05) and chromatin immuno-precipitation analysis. NCOA3 also created pro-inflammatory conditions by upregulating chemokines like CXCL1, 2, 5 and CCL20 (P<0.001). AKT, ubiquitin C, ERK1/2 and NF-kappa B occupied dominant nodes in the networks significantly modulated after NCOA3 silencing. In addition, NCOA3 stabilized mucins post translationally through fucosylation by FUT8, as the knockdown of FUT8 resulted in the downregulation of MUC4 and MUC1 at protein levels.	[Kumar, S.; Das, S.; Rachagani, S.; Kaur, S.; Joshi, S.; Ponnusamy, M. P.; Jain, M.; Batra, S. K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Johansson, S. L.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [Jain, M.; Batra, S. K.] Univ Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE 68198 USA; [Batra, S. K.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Batra, SK (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	sbatra@unmc.edu	Das, Srustidhar/GVU-1044-2022	Palanimuthu Ponnusamy, Moorthy/0000-0001-5744-193X	NIH [TMEN U54 CA163120, RO1 CA183459, EDRN UO1, CA111294, SPORE P50 CA127297, RO3 CA167342]; NATIONAL CANCER INSTITUTE [R01CA183459, P50CA127297, R03CA167342, U01CA111294, U54CA163120] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Lynette Smith, Dr Joshua Souchek, Ms Kavita Mallya, Dr Neeru Sharma and Dr Parama Dey for help in statistical analysis and technical support. Microarray analysis was performed using BRB-Array Tools developed by Dr. Richard Simon and BRB-Array Development Team. The work was supported, in parts, by grants from the NIH (TMEN U54 CA163120, RO1 CA183459, EDRN UO1, CA111294, SPORE P50 CA127297 and RO3 CA167342).	Al-Otaiby M, 2012, AM J PATHOL, V180, P1474, DOI 10.1016/j.ajpath.2011.12.032; Andrianifahanana M, 2005, ONCOGENE, V24, P6143, DOI 10.1038/sj.onc.1208756; Andrianifahanana M, 2001, CLIN CANCER RES, V7, P4033; Barry-Hamilton V, 2010, NAT MED, V16, P1009, DOI 10.1038/nm.2208; Bautista S, 1998, CLIN CANCER RES, V4, P2925; Borchers MT, 1999, AM J PHYSIOL-LUNG C, V276, pL549, DOI 10.1152/ajplung.1999.276.4.L549; Braat H, 2012, CANCER LETT, V318, P1, DOI 10.1016/j.canlet.2011.11.034; Brown K, 2003, J BIOL CHEM, V278, P39402, DOI 10.1074/jbc.M307832200; Carson DD, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.127pe35; Chakraborty S, 2010, J CLIN PATHOL, V63, P579, DOI 10.1136/jcp.2010.076125; Chaturvedi P, 2008, CANCER RES, V68, P2065, DOI 10.1158/0008-5472.CAN-07-6041; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Dey P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026926; Dharmaraj N, 2010, MOL ENDOCRINOL, V24, P2253, DOI 10.1210/me.2009-0448; Fereshteh MP, 2008, CANCER RES, V68, P3697, DOI 10.1158/0008-5472.CAN-07-6702; Ghadimi BM, 1999, AM J PATHOL, V154, P525, DOI 10.1016/S0002-9440(10)65298-4; Grzesiak JJ, 2007, PANCREAS, V35, P293, DOI 10.1097/mpa.0b013e31811f4526; Haridas D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026839; Harigopal M, 2009, BREAST CANCER RES TR, V115, P77, DOI 10.1007/s10549-008-0063-9; Hawker NP, 2007, J INVEST DERMATOL, V127, P874, DOI 10.1038/sj.jid.5700624; Henke RT, 2004, CLIN CANCER RES, V10, P6134, DOI 10.1158/1078-0432.CCR-04-0561; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; HOLLINGSWORTH MA, 1994, INT J CANCER, V57, P198, DOI 10.1002/ijc.2910570212; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kawano T, 2008, INT J ONCOL, V33, P153; Koo JS, 2002, EXP LUNG RES, V28, P315, DOI 10.1080/01902140252964393; Kuang SQ, 2004, CANCER RES, V64, P1875, DOI 10.1158/0008-5472.CAN-03-3745; Lahusen T, 2007, CANCER RES, V67, P7256, DOI 10.1158/0008-5472.CAN-07-1013; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Li J, 2012, MOL CELL BIOCHEM, V364, P29, DOI 10.1007/s11010-011-1201-y; Li X, 2003, J DENT RES, V82, P883, DOI 10.1177/154405910308201107; Li Z, 2012, WORLD J GASTROENTERO, V18, P855, DOI 10.3748/wjg.v18.i8.855; Lin HL, 2011, AM J PHYSIOL-RENAL, V300, pF1017, DOI 10.1152/ajprenal.00426.2010; Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006; Liu YC, 2011, P NATL ACAD SCI USA, V108, P11332, DOI 10.1073/pnas.1107385108; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McAllister F, 2014, CANCER CELL, V25, P621, DOI 10.1016/j.ccr.2014.03.014; McCarroll JA, 2006, GUT, V55, P79, DOI 10.1136/gut.2005.064543; Mejias-Luque R, 2010, ONCOGENE, V29, P1753, DOI 10.1038/onc.2009.467; Moniaux N, 2008, BRIT J CANCER, V98, P1540, DOI 10.1038/sj.bjc.6604329; Nakles RE, 2011, MOL ENDOCRINOL, V25, P549, DOI 10.1210/me.2010-0114; Navas C, 2012, CANCER CELL, V22, P318, DOI 10.1016/j.ccr.2012.08.001; Okuyama N, 2006, INT J CANCER, V118, P2803, DOI 10.1002/ijc.21728; Percharde M, 2013, CELL CYCLE, V12, P195, DOI 10.4161/cc.23377; Rachagani S, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-68; Reid G, 2009, INT J BIOCHEM CELL B, V41, P155, DOI 10.1016/j.biocel.2008.08.028; Rieder S, 2011, ANTI-CANCER AGENT ME, V11, P427, DOI 10.2174/187152011795677454; Saitou M, 2005, J CLIN PATHOL, V58, P845, DOI 10.1136/jcp.2004.023572; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Wang Y, 2014, CANCER RES, V74, P1506, DOI 10.1158/0008-5472.CAN-13-2939; Wang Y, 2011, MOL ENDOCRINOL, V25, P2041, DOI 10.1210/me.2011-1222; Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695; York B, 2010, P NATL ACAD SCI USA, V107, P11122, DOI 10.1073/pnas.1005262107; Yu CD, 2007, MOL CELL, V25, P765, DOI 10.1016/j.molcel.2007.01.025; Zhao C, 2003, CANCER, V98, P18, DOI 10.1002/cncr.11482	57	23	24	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2015	34	37					4879	4889		10.1038/onc.2014.409	http://dx.doi.org/10.1038/onc.2014.409			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR0YP	25531332	Green Accepted			2022-12-17	WOS:000361050000008
J	Dembowy, J; Adissu, HA; Liu, JC; Zacksenhaus, E; Woodgett, JR				Dembowy, J.; Adissu, H. A.; Liu, J. C.; Zacksenhaus, E.; Woodgett, J. R.			Effect of glycogen synthase kinase-3 inactivation on mouse mammary gland development and oncogenesis	ONCOGENE			English	Article							HEDGEHOG SIGNALING PATHWAY; BREAST-CANCER; BETA-CATENIN; STEM-CELLS; PROGENITOR CELLS; SUBCELLULAR-DISTRIBUTION; METAPLASTIC CARCINOMAS; CUBITUS INTERRUPTUS; TRANSGENIC MICE; SELF-RENEWAL	Many components of the Wnt/beta-catenin signaling pathway have critical functions in mammary gland development and tumor formation, yet the contribution of glycogen synthase kinase-3 (GSK-3 alpha and GSK-3 beta) to mammopoiesis and oncogenesis is unclear. Here, we report that WAP-Cre-mediated deletion of GSK-3 in the mammary epithelium results in activation of Wnt/beta-catenin signaling and induces mammary intraepithelial neoplasia that progresses to squamous transdifferentiation and development of adenosquamous carcinomas at 6 months. To uncover possible beta-catenin-independent activities of GSK-3, we generated mammary-specific knockouts of GSK-3 and beta-catenin. Squamous transdifferentiation of the mammary epithelium was largely attenuated, however, mammary epithelial cells lost the ability to form mammospheres suggesting perturbation of stem cell properties unrelated to loss of beta-catenin alone. At 10 months, adenocarcinomas that developed in glands lacking GSK-3 and beta-catenin displayed elevated levels of gamma-catenin/plakoglobin as well as activation of the Hedgehog and Notch pathways. Collectively, these results establish the two isoforms of GSK-3 as essential integrators of multiple developmental signals that act to maintain normal mammary gland function and suppress tumorigenesis.	[Dembowy, J.; Woodgett, J. R.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada; [Dembowy, J.; Zacksenhaus, E.; Woodgett, J. R.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Adissu, H. A.] Toronto Ctr Phenogen, Ctr Modelling Human Dis, Pathol Core, Toronto, ON, Canada; [Adissu, H. A.; Zacksenhaus, E.] Toronto Gen Hosp, Res Inst, Toronto, ON, Canada; [Liu, J. C.; Zacksenhaus, E.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto	Woodgett, JR (corresponding author), Mt Sinai Hosp, Room 982,600 Univ Ave, Toronto, ON M5G 1X5, Canada.	woodgett@lunenfeld.ca	Woodgett, Jim/F-1087-2010; adissu, hibret a/R-3282-2018; Zacksenhaus, Eldad/AAD-3584-2020	Woodgett, Jim/0000-0003-3731-5797; adissu, hibret a/0000-0003-3365-7466; 	CBCRA; CIHR [MOP74711]; Terry Fox Foundation; CBCF (Ontario) doctoral fellowship	CBCRA; CIHR(Canadian Institutes of Health Research (CIHR)); Terry Fox Foundation; CBCF (Ontario) doctoral fellowship	We thank Tao Deng, Hartland W Jackson and Purna A Joshi for assistance with mammary gland manipulation and Katrina MacAulay, Brad Doble and Satish Patel for their generation of mice harboring floxed GSK-3 alleles. We wish to thank Tara Paton of The Centre for Applied Genomics (TCAG), The Hospital for Sick Children, Toronto, for assistance with Sanger sequencing and Yanchun Wang of the Centre for Modeling Human Disease Pathology (CMHD) and Cryopreservation Core at the Toronto Centre for Phenogenomics for laser-capture microdissection. This work was supported by grants to JRW from the CBCRA, CIHR (MOP74711) and Terry Fox Foundation team grant to EZ. JD was partially supported by a CBCF (Ontario) doctoral fellowship.	Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379; Aktary Zackie, 2012, Int J Cell Biol, V2012, P189521, DOI 10.1155/2012/189521; Booth BW, 2007, J CELL PHYSIOL, V212, P729, DOI 10.1002/jcp.21071; Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001; Bu W, 2011, ONCOGENE, V30, P4399, DOI 10.1038/onc.2011.147; Callahan R, 2004, J MAMMARY GLAND BIOL, V9, P145, DOI 10.1023/B:JOMG.0000037159.63644.81; Chen Y, 2011, J BIOL CHEM, V286, P13502, DOI 10.1074/jbc.M110.217604; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Dolled-Filhart M, 2006, CANCER RES, V66, P5487, DOI 10.1158/0008-5472.CAN-06-0100; Dontu G, 2005, J MAMMARY GLAND BIOL, V10, P75, DOI 10.1007/s10911-005-2542-5; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Espinosa L, 2003, J BIOL CHEM, V278, P32227, DOI 10.1074/jbc.M304001200; Fiaschi M, 2007, J BIOL CHEM, V282, P36090, DOI 10.1074/jbc.M704280200; Fiaschi M, 2009, CANCER RES, V69, P4810, DOI 10.1158/0008-5472.CAN-08-3938; Foltz DR, 2002, CURR BIOL, V12, P1006, DOI 10.1016/S0960-9822(02)00888-6; Franzen CA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042132; Gallagher RCJ, 2002, ONCOGENE, V21, P6446, DOI 10.1038/sj.onc.1205892; Gauger KJ, 2009, CANCER CELL INT, V9, DOI 10.1186/1475-2867-9-11; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hayes MJ, 2008, CLIN CANCER RES, V14, P4038, DOI 10.1158/1078-0432.CCR-07-4379; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Hui M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3401; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Jia JH, 2002, NATURE, V416, P548, DOI 10.1038/nature733; Jin YH, 2009, MOL CELLS, V27, P15, DOI 10.1007/s10059-009-0001-7; Kameda C, 2010, BRIT J CANCER, V102, P738, DOI 10.1038/sj.bjc.6605517; Kasper M, 2009, CARCINOGENESIS, V30, P903, DOI 10.1093/carcin/bgp048; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Kim WY, 2009, NAT NEUROSCI, V12, P1390, DOI 10.1038/nn.2408; Kise Y, 2009, BIOCHEM BIOPH RES CO, V387, P569, DOI 10.1016/j.bbrc.2009.07.087; Kubo M, 2004, CANCER RES, V64, P6071, DOI 10.1158/0008-5472.CAN-04-0416; Kuraguchi M, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000367; Lacroix-Triki M, 2010, MODERN PATHOL, V23, P1438, DOI 10.1038/modpathol.2010.141; Lam L, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.4; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Li LJ, 2007, MOL CARCINOGEN, V46, P824, DOI 10.1002/mc.20310; Li N, 2008, STEM CELLS, V26, P1253, DOI 10.1634/stemcells.2007-0691; Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Ling H, 2010, ONCOGENE, V29, P4543, DOI 10.1038/onc.2010.186; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; MacAulay K, 2007, CELL METAB, V6, P329, DOI 10.1016/j.cmet.2007.08.013; Mahendram S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065320; Makarem M, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001630; Makarem M, 2013, J MAMMARY GLAND BIOL, V18, P209, DOI 10.1007/s10911-013-9284-6; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; Miyoshi K, 2003, BREAST CANCER RES, V5, P63, DOI 10.1186/bcr566; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; Moraes RC, 2007, DEVELOPMENT, V134, P1231, DOI 10.1242/dev.02797; O'Toole SA, 2011, CANCER RES, V71, P4002, DOI 10.1158/0008-5472.CAN-10-3738; Ozaki S, 2005, ONCOL REP, V14, P1437; Parr C, 2004, INT J MOL MED, V14, P779; Patel S, 2008, MOL CELL BIOL, V28, P6314, DOI 10.1128/MCB.00763-08; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Radulescu S, 2013, ONCOGENE, V32, P2048, DOI 10.1038/onc.2012.224; Raouf A, 2008, CELL STEM CELL, V3, P109, DOI 10.1016/j.stem.2008.05.018; Renou JP, 2003, ONCOGENE, V22, P4594, DOI 10.1038/sj.onc.1206596; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Rieger-Christ KM, 2005, BRIT J CANCER, V92, P2153, DOI 10.1038/sj.bjc.6602651; Robinson DR, 2011, NAT MED, V17, P1646, DOI 10.1038/nm.2580; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; Sale S, 2013, NAT CELL BIOL, V15, P451, DOI 10.1038/ncb2725; Sun P, 2010, HISTOCHEM CELL BIOL, V133, P213, DOI 10.1007/s00418-009-0662-5; Taelman VF, 2010, CELL, V143, P1136, DOI 10.1016/j.cell.2010.11.034; Teuliere J, 2005, DEVELOPMENT, V132, P267, DOI 10.1242/dev.01583; van Amerongen R, 2012, CELL STEM CELL, V11, P387, DOI 10.1016/j.stem.2012.05.023; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Wagner KU, 2002, DEVELOPMENT, V129, P1377; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Winn RA, 2002, ONCOGENE, V21, P7497, DOI 10.1038/sj.onc.1205963; Wong SCC, 2002, J PATHOL, V196, P145, DOI 10.1002/path.1035; Xu LS, 2010, BREAST CANCER RES TR, V123, P59, DOI 10.1007/s10549-009-0617-5; Yalcin-Ozuysal O, 2010, CELL DEATH DIFFER, V17, P1600, DOI 10.1038/cdd.2010.37; Yin TF, 2005, P NATL ACAD SCI USA, V102, P5420, DOI 10.1073/pnas.0501676102; Zeng YA, 2010, CELL STEM CELL, V6, P568, DOI 10.1016/j.stem.2010.03.020	78	23	24	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	27					3514	3526		10.1038/onc.2014.279	http://dx.doi.org/10.1038/onc.2014.279			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM1IQ	25195860	Green Submitted, Green Published, Green Accepted, hybrid			2022-12-17	WOS:000357434900004
J	Riemer, P; Sreekumar, A; Reinke, S; Rad, R; Schafer, R; Sers, C; Blaker, H; Herrmann, BG; Morkel, M				Riemer, P.; Sreekumar, A.; Reinke, S.; Rad, R.; Schaefer, R.; Sers, C.; Blaeker, H.; Herrmann, B. G.; Morkel, M.			Transgenic expression of oncogenic BRAF induces loss of stem cells in the mouse intestine, which is antagonized by beta-catenin activity	ONCOGENE			English	Article							WNT/BETA-CATENIN; ACQUIRED-RESISTANCE; TUMOR PROGRESSION; SERRATED PATHWAY; SENESCENCE; GENE; KINASE; COLON; WNT; ADENOMA	Colon cancer cells frequently carry mutations that activate the beta-catenin and mitogen-activated protein kinase (MAPK) signaling cascades. Yet how oncogenic alterations interact to control cellular hierarchies during tumor initiation and progression is largely unknown. We found that oncogenic BRAF modulates gene expression associated with cell differentiation in colon cancer cells. We therefore engineered a mouse with an inducible oncogenic BRAF transgene, and analyzed BRAF effects on cellular hierarchies in the intestinal epithelium in vivo and in primary organotypic culture. We demonstrate that transgenic expression of oncogenic BRAF in the mouse strongly activated MAPK signal transduction, resulted in the rapid development of generalized serrated dysplasia, but unexpectedly also induced depletion of the intestinal stem cell (ISC) pool. Histological and gene expression analyses indicate that ISCs collectively converted to short-lived progenitor cells after BRAF activation. As Wnt/beta-catenin signals encourage ISC identity, we asked whether beta-catenin activity could counteract oncogenic BRAF. Indeed, we found that intestinal organoids could be partially protected from deleterious oncogenic BRAF effects by Wnt3a or by small-molecule inhibition of GSK3 beta. Similarly, transgenic expression of stabilized beta-catenin in addition to oncogenic BRAF partially prevented loss of stem cells in the mouse intestine. We also used BRAF(V637E) knock-in mice to follow changes in the stem cell pool during serrated tumor progression and found ISC marker expression reduced in serrated hyperplasia forming after BRAF activation, but intensified in progressive dysplastic foci characterized by additional mutations that activate the Wnt/beta-catenin pathway. Our study suggests that oncogenic alterations activating the MAPK and Wnt/beta-catenin pathways must be consecutively and coordinately selected to assure stem cell maintenance during colon cancer initiation and progression. Notably, loss of stem cell identity upon induction of BRAF/MAPK activity may represent a novel fail-safe mechanism protecting intestinal tissue from oncogene activation.	[Riemer, P.; Sreekumar, A.; Schaefer, R.; Sers, C.; Morkel, M.] Charite, Lab Mol Tumor Pathol, Inst Pathol, D-10117 Berlin, Germany; [Riemer, P.; Sreekumar, A.; Reinke, S.; Herrmann, B. G.; Morkel, M.] Max Planck Inst Mol Genet, Dept Dev Genet, D-14195 Berlin, Germany; [Rad, R.] Tech Univ Munich, Klinikum Rechts Isar, Dept Med 2, D-80290 Munich, Germany; [Rad, R.; Schaefer, R.; Sers, C.] German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany; [Blaeker, H.] Charite, Dept Gen Pathol, Inst Pathol, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society; Technical University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Morkel, M (corresponding author), Charite, Lab Mol Tumor Pathol, Inst Pathol, CCM, Charitepl 1, D-10117 Berlin, Germany.	markus.morkel@charite.de	Sers, Christine/B-5438-2010; Schäfer, Reinhold/AAB-5110-2021	Riemer, Pamela/0000-0003-3231-7056; Schafer, Reinhold/0000-0001-7952-2124; Reinke, Soren/0000-0003-2412-385X; Sers, christine/0000-0002-6219-1514; Morkel, Markus/0000-0002-2553-9999	NGFNplus grant [PKM-01GS08105]; eBio grant [0316184A]	NGFNplus grant; eBio grant	This work was funded in part by NGFNplus grant PKM-01GS08105 to MM and BGH and eBio grant 0316184A to MM. We gratefully acknowledge Judith Seidemann (Charite Berlin), Gaby Blass and Karol Macura (MPI-MG Berlin) for excellent technical assistance, Sonja Banko (animal facility, MPI-MG) for maintainance of the mice, Jan Dorr (Charite Berlin) for SA-beta-Galactosidase stainings, Tilman Brummer (University of Freiburg) for the gift of Caco2-tet cells and Julian Heuberger (Max-Delbruck-Center for Molecular Medicine, Berlin) for the gift of the ITF antibody.	Azzolin L, 2012, CELL, V151, P1443, DOI 10.1016/j.cell.2012.11.027; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2014, NAT REV MOL CELL BIO, V15, P19, DOI 10.1038/nrm3721; Bennecke M, 2010, CANCER CELL, V18, P135, DOI 10.1016/j.ccr.2010.06.013; Bettington M, 2013, HISTOPATHOLOGY, V62, P367, DOI 10.1111/his.12055; Biechele TL, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002274; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Carragher LAS, 2010, EMBO MOL MED, V2, P458, DOI 10.1002/emmm.201000099; Corcoran RB, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001148; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; El-Osta H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025806; Farin HF, 2012, GASTROENTEROLOGY, V143, P1518, DOI 10.1053/j.gastro.2012.08.031; Farrall AL, 2012, INT J CANCER, V131, P2242, DOI 10.1002/ijc.27500; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d; Fritsche-Guenther R, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.27; Gonzalo DH, 2013, J PATHOL, V230, P420, DOI 10.1002/path.4200; Guardavaccaro D, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002921; Herr R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-17; Jeong WJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002242; Jurchott K, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001231; Kimura T, 2012, AM J GASTROENTEROL, V107, P460, DOI 10.1038/ajg.2011.457; Laiho P, 2007, ONCOGENE, V26, P312, DOI 10.1038/sj.onc.1209778; Lao VV, 2011, NAT REV GASTRO HEPAT, V8, P686, DOI 10.1038/nrgastro.2011.173; Little AS, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001752; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Moon BS, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt373; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; Murray JT, 2004, BIOCHEM J, V384, P477, DOI 10.1042/BJ20041057; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; Osaki LH, 2013, INT J MOL SCI, V14, P10143, DOI 10.3390/ijms140510143; Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Rad R, 2013, CANCER CELL, V24, P15, DOI 10.1016/j.ccr.2013.05.014; Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Snover DC, 2011, HUM PATHOL, V42, P1, DOI 10.1016/j.humpath.2010.06.002; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takahashi M, 2000, CARCINOGENESIS, V21, P1117, DOI 10.1093/carcin/21.6.1117; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Van Der Flier LG, 2007, GASTROENTEROLOGY, V132, P628, DOI 10.1053/j.gastro.2006.08.039; van Es JH, 2012, MOL CELL BIOL, V32, P1918, DOI 10.1128/MCB.06288-11; Vermeulen L, 2013, SCIENCE, V342, P995, DOI 10.1126/science.1243148; Vidigal JA, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq199; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wu JM, 2008, AM J CLIN PATHOL, V129, P416, DOI 10.1309/603UQKM7C2KELGJU; Yachida S, 2009, AM J SURG PATHOL, V33, P1823, DOI 10.1097/PAS.0b013e3181b6da19; Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078-0432.CCR-06-1150; Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968	55	23	24	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2015	34	24					3164	3175		10.1038/onc.2014.247	http://dx.doi.org/10.1038/onc.2014.247			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3FD	25109331	Green Published			2022-12-17	WOS:000356101100008
J	Bardot, B; Bouarich-Bourimi, R; Leemput, J; Lejour, V; Hamon, A; Plancke, L; Jochemsen, AG; Simeonova, I; Fang, M; Toledo, F				Bardot, B.; Bouarich-Bourimi, R.; Leemput, J.; Lejour, V.; Hamon, A.; Plancke, L.; Jochemsen, A. G.; Simeonova, I.; Fang, M.; Toledo, F.			Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity	ONCOGENE			English	Article							ACTIVITY IN-VIVO; THERAPEUTIC TARGET; MESSENGER-RNA; HDMX GENE; CANCER; REVEALS; PATHWAY; DOMAIN; CELLS; AMPLIFICATION	Mdm4, a protein related to the ubiquitin-ligase Mdm2, is an essential inhibitor of tumor suppressor protein p53. In both human and mouse cells, the Mdm4 gene encodes two major transcripts: one encodes the full-length oncoprotein (designated below as Mdm4-FL), whereas the other, resulting from a variant splicing that skips exon 6, encodes the shorter isoform Mdm4-S. Importantly, increased Mdm4-S mRNA levels were observed in several human cancers, and correlated with poor survival. However, the role of Mdm4-S in cancer progression remains controversial, because the Mdm4-S protein appeared to be a potent p53 inhibitor when overexpressed, but the splice variant also leads to a decrease in Mdm4-FL expression. To unambiguously determine the physiological impact of the Mdm4-S splice variant, we generated a mouse model with a targeted deletion of the Mdm4 exon 6, thereby creating an obligatory exon skipping. The mutant allele (Mdm4(Delta E6)) prevented the expression of Mdm4-FL, but also led to increased Mdm4-S mRNA levels. Mice homozygous for this allele died during embryonic development, but were rescued by a concomitant p53 deficiency. Furthermore in a hypomorphic p53(Delta P/Delta P) context, the Mdm4(Delta E6) allele led to p53 activation and delayed the growth of oncogene-induced tumors. We next determined the effect of Mdm4(+/Delta E6) heterozygosity in a hypermorphic p53(+/Delta 31) genetic background, recently shown to be extremely sensitive to Mdm4 activity. Mdm4(+/Delta E6) p53(+/Delta 31) pups were born, but suffered from aplastic anemia and died before weaning, again indicating an increased p53 activity. Our results demonstrate that the main effect of a skipping of Mdm4 exon 6 is not the synthesis of the Mdm4-S protein, but rather a decrease in Mdm4-FL expression. These and other data suggest that increased Mdm4-S mRNA levels might correlate with more aggressive cancers without encoding significant amounts of a potential oncoprotein. Hypotheses that may account for this apparent paradox are discussed.	[Bardot, B.; Bouarich-Bourimi, R.; Leemput, J.; Lejour, V.; Hamon, A.; Plancke, L.; Simeonova, I.; Fang, M.; Toledo, F.] Inst Curie, Ctr Rech, Genet Tumor Suppress Equipe Labellisee Ligue 2014, F-75248 Paris 05, France; [Bardot, B.; Bouarich-Bourimi, R.; Leemput, J.; Lejour, V.; Hamon, A.; Plancke, L.; Simeonova, I.; Fang, M.; Toledo, F.] Univ Paris 06, Paris, France; [Bardot, B.; Bouarich-Bourimi, R.; Leemput, J.; Lejour, V.; Hamon, A.; Plancke, L.; Simeonova, I.; Fang, M.; Toledo, F.] CNRS, UMR 3244, Paris, France; [Jochemsen, A. G.] Leiden Univ, Med Ctr, Leiden, Netherlands	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie; Universite Paris Cite; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Toledo, F (corresponding author), Inst Curie, Ctr Rech, UMR 3244, Genet Tumor Suppress, F-75248 Paris 05, France.	franck.toledo@curie.fr	Simeonova, Iva/Y-9412-2019; Hamon, Annaïg/AAG-4899-2021	Hamon, Annaïg/0000-0002-1662-1405; Leemput, Julia/0000-0001-8732-0741; Bardot, Boris/0000-0003-4976-9593; Toledo, Franck/0000-0003-3798-4106	Ligue Nationale contre le Cancer; Fondation de France (Comite Tumeurs); Ligue Nationale contre le Cancer (Comite Ile de France); Fondation ARC; Canceropole Ile de France	Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Fondation de France (Comite Tumeurs); Ligue Nationale contre le Cancer (Comite Ile de France); Fondation ARC; Canceropole Ile de France(Region Ile-de-France)	We thank members of the Curie technological platforms for their contribution to this study: I Grandjean, C Daviaud and M Verlhac from the Animal facility, C Alberti, E Belloir and N Mebirouk from the transgenesis platform, M Richardson, A Nicolas, R Leclere and M Huerre from the pathology service. Our lab received funding as an Equipe Labellisee by the Ligue Nationale contre le Cancer. The project was initiated by grants from the Fondation de France (Comite Tumeurs), the Ligue Nationale contre le Cancer (Comite Ile de France) and the Fondation ARC. JL was supported by a post-doctoral fellowship from the Canceropole Ile de France.	Bartel F, 2005, INT J CANCER, V117, P469, DOI 10.1002/ijc.21206; Bernal F, 2010, CANCER CELL, V18, P411, DOI 10.1016/j.ccr.2010.10.024; Bezzi M, 2013, GENE DEV, V27, P1903, DOI 10.1101/gad.219899.113; Bista M, 2013, P NATL ACAD SCI USA, V110, P17814, DOI 10.1073/pnas.1317398110; Fang M, 2014, ONCOGENE, V33, P1336, DOI 10.1038/onc.2013.62; Finch RA, 2002, CANCER RES, V62, P3221; Garcia D, 2011, GENE DEV, V25, P1746, DOI 10.1101/gad.16722111; Gembarska A, 2012, NAT MED, V18, P1239, DOI 10.1038/nm.2863; Huang L, 2011, P NATL ACAD SCI USA, V108, P12001, DOI 10.1073/pnas.1102309108; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Lenos K, 2012, CANCER RES, V72, P4074, DOI 10.1158/0008-5472.CAN-12-0215; Lenos K, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/876173; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Mancini F, 2009, CURR GENOMICS, V10, P42, DOI 10.2174/138920209787581280; Marine JC, 2011, CURR TOP DEV BIOL, V94, P45, DOI 10.1016/B978-0-12-380916-2.00003-6; Matijasevic Z, 2008, MOL CELL BIOL, V28, P1265, DOI 10.1128/MCB.01108-07; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Okada N, 2014, GENE DEV, V28, P438, DOI 10.1101/gad.233585.113; Pajares MJ, 2007, LANCET ONCOL, V8, P349, DOI 10.1016/S1470-2045(07)70104-3; Pant V, 2011, P NATL ACAD SCI USA, V108, P11995, DOI 10.1073/pnas.1102241108; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Phillips A, 2010, J BIOL CHEM, V285, P29111, DOI 10.1074/jbc.M110.129726; Prodosmo A, 2008, J MOL MED-JMM, V86, P585, DOI 10.1007/s00109-008-0322-6; Prophet E, 1992, AFIP LAB METHODS HIS; Rallapalli R, 2003, J CELL BIOCHEM, V89, P563, DOI 10.1002/jcb.10535; Rallapalli R, 1999, J BIOL CHEM, V274, P8299, DOI 10.1074/jbc.274.12.8299; Ramos YFM, 2001, CANCER RES, V61, P1839; Riemenschneider MJ, 2003, INT J CANCER, V104, P752, DOI 10.1002/ijc.11023; Simeonova I, 2013, CELL REP, V3, P2046, DOI 10.1016/j.celrep.2013.05.028; Simeonova I, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002731; Steinman HA, 2005, ONCOGENE, V24, P7935, DOI 10.1038/sj.onc.1208930; Steinman HA, 2004, ONCOGENE, V23, P303, DOI 10.1038/sj.onc.1206925; Toledo F, 2006, CANCER CELL, V9, P273, DOI 10.1016/j.ccr.2006.03.014; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Vandenbroucke I I, 2001, Nucleic Acids Res, V29, pE68, DOI 10.1093/nar/29.13.e68; Wang YYV, 2011, GENE DEV, V25, P1426, DOI 10.1101/gad.2024411; Wang YYV, 2009, CANCER CELL, V16, P33, DOI 10.1016/j.ccr.2009.05.008	38	23	23	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2943	2948		10.1038/onc.2014.230	http://dx.doi.org/10.1038/onc.2014.230			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25088193				2022-12-17	WOS:000355324300013
J	Spaargaren, M; de Rooij, MFM; Kater, AP; Eldering, E				Spaargaren, M.; de Rooij, M. F. M.; Kater, A. P.; Eldering, E.			BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future	ONCOGENE			English	Review							BRUTONS TYROSINE KINASE; B-CELL-RECEPTOR; X-LINKED AGAMMAGLOBULINEMIA; TOLL-LIKE-RECEPTOR; FACTOR-KAPPA-B; BETA-GAMMA-SUBUNITS; MEDIATED ACTIVATION; NUCLEAR-FACTOR; PHASE-II; PHOSPHOLIPASE C-GAMMA-2	The treatment of chronic lymphocytic leukemia (CLL) with inhibitors targeting B cell receptor signaling and other survival mechanisms holds great promise. Especially the early clinical success of Ibrutinib, an irreversible inhibitor of Bruton's tyrosine kinase (BTK), has received widespread attention. In this review we will focus on the fundamental and clinical aspects of BTK inhibitors in CLL, with emphasis on Ibrutinib as the best studied of this class of drugs. Furthermore, we summarize recent laboratory as well as clinical findings relating to the first cases of Ibrutinib resistance. Finally, we address combination strategies with Ibrutinib, and attempt to extrapolate its current status to the near future in the clinic.	[Spaargaren, M.; de Rooij, M. F. M.] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; [Spaargaren, M.; Kater, A. P.; Eldering, E.] Univ Amsterdam, Acad Med Ctr, Lymphoma & Myeloma Ctr Amsterdam LYMMCARE, NL-1105 AZ Amsterdam, Netherlands; [Kater, A. P.] Univ Amsterdam, Acad Med Ctr, Dept Hematol, NL-1105 AZ Amsterdam, Netherlands; [Eldering, E.] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Spaargaren, M (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Pathol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	marcel.spaargaren@amc.uva.nl; e.eldering@amc.uva.nl	Spaargaren, Marcel/AAU-1298-2021	Spaargaren, Marcel/0000-0002-3135-5109	Pharmacyclics	Pharmacyclics	MS has received research support from Pharmacyclics. The other authors declare no conflict of interest.	Advani R, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.8012; Advani RH, 2013, J CLIN ONCOL, V31, P88, DOI 10.1200/JCO.2012.42.7906; Amrein PC, 2011, CLIN CANCER RES, V17, P2977, DOI 10.1158/1078-0432.CCR-10-2879; Anderson MA, 2013, BLOOD, V122; Antony P, 2004, BIOCHEM SOC T, V32, P113, DOI 10.1042/BST0320113; Apor E, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.4163.4163; Ashworth T, 2007, J IMMUNOL, V178, P2631, DOI 10.4049/jimmunol.178.5.2631; Axelrod M, 2014, LEUKEMIA, V28, P407, DOI 10.1038/leu.2013.249; Bagnara D, 2011, BLOOD, V117, P5463, DOI 10.1182/blood-2010-12-324210; Brown JR, 2014, BLOOD, V123, P3390, DOI 10.1182/blood-2013-11-535047; Brown JR, 2013, BLOOD, V122; Burger JA, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.866.866; Burger JA, 2014, SEMIN CANCER BIOL, V24, P71, DOI 10.1016/j.semcancer.2013.08.011; Burger JA, 2011, HEMATOL-AM SOC HEMAT, P96, DOI 10.1182/asheducation-2011.1.96; Byrd JC, 2013, NEW ENGL J MED, V369, P32, DOI 10.1056/NEJMoa1215637; CAMPANA D, 1990, J IMMUNOL, V145, P1675; Chang BY, 2013, BLOOD, V122, P2412, DOI 10.1182/blood-2013-02-482125; Cheng S, 2014, LEUKEMIA, V28, P649, DOI 10.1038/leu.2013.358; Cheson BD, 2012, J CLIN ONCOL, V30, P2820, DOI 10.1200/JCO.2012.43.3748; Coelho V, 2013, BLOOD, V122, P2664, DOI 10.1182/blood-2013-02-485425; Conley ME, 2009, ANNU REV IMMUNOL, V27, P199, DOI 10.1146/annurev.immunol.021908.132649; Cramer P, 2011, NAT REV CLIN ONCOL, V8, P38, DOI 10.1038/nrclinonc.2010.167; Cyster JG, 2005, ANNU REV IMMUNOL, V23, P127, DOI 10.1146/annurev.immunol.23.021704.115628; DAZZI F, 1995, CLIN IMMUNOL IMMUNOP, V75, P26, DOI 10.1006/clin.1995.1048; de Diego RP, 2006, J ALLERGY CLIN IMMUN, V117, P1462, DOI 10.1016/j.jaci.2006.01.037; de Gorter DJJ, 2007, IMMUNITY, V26, P93, DOI 10.1016/j.immuni.2006.11.012; de Gorter DJJ, 2007, J IMMUNOL, V178, P1405, DOI 10.4049/jimmunol.178.3.1405; de Rooij MFM, 2012, BLOOD, V119, P2590, DOI 10.1182/blood-2011-11-390989; de Weerdt I, 2013, LEUKEMIA RES, V37, P838, DOI 10.1016/j.leukres.2013.03.011; DEWEERS M, 1993, EUR J IMMUNOL, V23, P3109, DOI 10.1002/eji.1830231210; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Dubovsky JA, 2013, BLOOD, V122, P2539, DOI 10.1182/blood-2013-06-507947; Duhren-von Minden M, 2012, NATURE, V489, P309, DOI 10.1038/nature11309; Ellmeier W, 2000, J EXP MED, V192, P1611, DOI 10.1084/jem.192.11.1611; Faderl S, 2006, CANCER-AM CANCER SOC, V107, P916, DOI 10.1002/cncr.22097; FEARON ER, 1987, NEW ENGL J MED, V316, P427, DOI 10.1056/NEJM198702193160802; Fowler N, 2010, BLOOD, V116, P425; Furman RR, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.4914.4914; Furman RR, 2014, NEW ENGL J MED, V370, P997, DOI 10.1056/NEJMoa1315226; Futatani T, 2001, BRIT J HAEMATOL, V114, P141, DOI 10.1046/j.1365-2141.2001.02905.x; Gagliardi MC, 2003, CLIN EXP IMMUNOL, V133, P115, DOI 10.1046/j.1365-2249.2003.t01-1-02178.x; GENEVIER HC, 1994, EUR J IMMUNOL, V24, P3100, DOI 10.1002/eji.1830241228; Genevier HC, 1997, CLIN EXP IMMUNOL, V110, P386, DOI 10.1046/j.1365-2249.1997.4581478.x; Ghia P, 2007, AUTOIMMUN REV, V7, P127, DOI 10.1016/j.autrev.2007.02.014; Goede V, 2014, NEW ENGL J MED, V370, P1101, DOI 10.1056/NEJMoa1313984; Hallaert DYH, 2008, BLOOD, V112, P5141, DOI 10.1182/blood-2008-03-146704; Hallek M, 2010, LANCET, V376, P1164, DOI 10.1016/S0140-6736(10)61381-5; Hallek M, 2013, BLOOD, V122, P3723, DOI 10.1182/blood-2013-05-498287; Hantschel O, 2007, P NATL ACAD SCI USA, V104, P13283, DOI 10.1073/pnas.0702654104; Hata D, 1998, J EXP MED, V187, P1235, DOI 10.1084/jem.187.8.1235; Herishanu Y, 2011, BLOOD, V117, P563, DOI 10.1182/blood-2010-05-284984; Herman SEM, 2014, LEUKEMIA, V28, P2188, DOI 10.1038/leu.2014.122; Herman SEM, 2013, LEUKEMIA, V27, P2311, DOI 10.1038/leu.2013.131; Herman SEM, 2014, BLOOD, V123, P3286, DOI 10.1182/blood-2014-02-548610; Herman SEM, 2011, BLOOD, V117, P6287, DOI 10.1182/blood-2011-01-328484; Honigberg LA, 2010, P NATL ACAD SCI USA, V107, P13075, DOI 10.1073/pnas.1004594107; Hoogeboom R, 2013, J EXP MED, V210, P59, DOI 10.1084/jem.20121801; Horwood NJ, 2006, J IMMUNOL, V176, P3635, DOI 10.4049/jimmunol.176.6.3635; Horwood NJ, 2003, J EXP MED, V197, P1603, DOI 10.1084/jem.20021845; Improgo R, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.670.670; Jefferies CA, 2004, IMMUNOL LETT, V92, P15, DOI 10.1016/j.imlet.2003.11.017; Jefferies CA, 2003, J BIOL CHEM, V278, P26258, DOI 10.1074/jbc.M301484200; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Jongstra-Bilen J, 2008, J IMMUNOL, V181, P288, DOI 10.4049/jimmunol.181.1.288; Kang SW, 2001, EMBO J, V20, P5692, DOI 10.1093/emboj/20.20.5692; Karlin L, 2013, ASH ANN M, V122, P676; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; Kelley TW, 2004, LEUKEMIA RES, V28, P845, DOI 10.1016/j.leukres.2003.12.010; Kil LP, 2013, AM J BLOOD RES, V3, P71; Kil LP, 2012, BLOOD, V119, P3744, DOI 10.1182/blood-2011-12-397919; Kim YJ, 2004, MOL CELL BIOL, V24, P9986, DOI 10.1128/MCB.24.22.9986-9999.2004; Kohrt HE, 2014, BLOOD, V123, P1957, DOI 10.1182/blood-2014-01-547869; Kremer AN, 2014, BIOL BLOOD MARROW TR, V20, P742, DOI 10.1016/j.bbmt.2014.02.005; Kurosaki T, 1997, J BIOL CHEM, V272, P15595, DOI 10.1074/jbc.272.25.15595; Landau DA, 2013, CELL, V152, P714, DOI 10.1016/j.cell.2013.01.019; LeBien TW, 2008, BLOOD, V112, P1570, DOI 10.1182/blood-2008-02-078071; Lo CG, 2005, J EXP MED, V201, P291, DOI 10.1084/jem.20041509; Lowry WE, 2002, J BIOL CHEM, V277, P1488, DOI 10.1074/jbc.M110390200; Martensson IL, 2002, SEMIN IMMUNOL, V14, P335, DOI 10.1016/S1044-5323(02)00066-0; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; MENSINK EJBM, 1986, EUR J IMMUNOL, V16, P963, DOI 10.1002/eji.1830160815; Messina M, 2014, BLOOD, V123, P2378, DOI 10.1182/blood-2013-10-534271; Messmer BT, 2004, J EXP MED, V200, P519, DOI 10.1084/jem.20040544; Messmer BT, 2005, J CLIN INVEST, V115, P755, DOI 10.1172/JCI23409; Middendorp S, 2003, J IMMUNOL, V171, P5988, DOI 10.4049/jimmunol.171.11.5988; Monroe JG, 2008, IMMUNITY, V28, P729, DOI 10.1016/j.immuni.2008.05.006; Novina CD, 1999, MOL CELL BIOL, V19, P5014; O'Connor OA, 2005, J CLIN ONCOL, V23, P676, DOI 10.1200/JCO.2005.02.050; Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood-2005-08-3531; Oda A, 2000, BLOOD, V95, P1663; Ouillette P, 2013, CLIN CANCER RES, V19, P2893, DOI 10.1158/1078-0432.CCR-13-0138; Pan ZY, 2007, CHEMMEDCHEM, V2, P58, DOI 10.1002/cmdc.200600221; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Pascutti MF, 2013, BLOOD, V122, P3010, DOI 10.1182/blood-2012-11-467670; Peng SL, 2005, CURR OPIN IMMUNOL, V17, P230, DOI 10.1016/j.coi.2005.03.003; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; Petro JB, 2001, J BIOL CHEM, V276, P1715, DOI 10.1074/jbc.M009137200; Ponader S, 2012, BLOOD, V119, P1182, DOI 10.1182/blood-2011-10-386417; Pospisilova S, 2012, LEUKEMIA, V26, P1458, DOI 10.1038/leu.2012.25; Rajaiya J, 2005, MOL CELL BIOL, V25, P2073, DOI 10.1128/MCB.25.6.2073-2084.2005; Rajaiya J, 2006, MOL CELL BIOL, V26, P4758, DOI 10.1128/MCB.02009-05; Ramadani F, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001104; Rawlings DJ, 1999, CLIN IMMUNOL, V91, P243, DOI 10.1006/clim.1999.4732; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Ricks JL, 2013, J CLIN ONCOL, V31, DOI 10.1200/jco.2013.31.31_suppl.7; Ridderstad A, 1996, J IMMUNOL, V157, P3357; Rock J, 2007, EUR J IMMUNOL, V37, P3564, DOI 10.1002/eji.200737711; Rossi D, 2014, BLOOD, V123, P2139, DOI 10.1182/blood-2013-11-539726; Rozkova D, 2010, INT J CANCER, V126, P1132, DOI 10.1002/ijc.24832; Saito K, 2003, IMMUNITY, V19, P669, DOI 10.1016/S1074-7613(03)00297-8; Saito K, 2001, J BIOL CHEM, V276, P16201, DOI 10.1074/jbc.M100873200; SCHMID C, 1994, HISTOPATHOLOGY, V24, P445, DOI 10.1111/j.1365-2559.1994.tb00553.x; Schulzke JD, 2009, ANN NY ACAD SCI, V1165, P294, DOI 10.1111/j.1749-6632.2009.04062.x; Seymour JF, 2013, BLOOD, V122; Sharma S, 2009, J IMMUNOL, V182, P329, DOI 10.4049/jimmunol.182.1.329; Shinohara M, 2008, CELL, V132, P794, DOI 10.1016/j.cell.2007.12.037; Shiow LR, 2006, NATURE, V440, P540, DOI 10.1038/nature04606; Smit LA, 2007, BLOOD, V109, P1660, DOI 10.1182/blood-2006-05-021683; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Souwer Y, 2009, BRIT J HAEMATOL, V145, P334, DOI 10.1111/j.1365-2141.2009.07625.x; Spaargaren M, 2003, J EXP MED, V198, P1539, DOI 10.1084/jem.20011866; Spaner DE, 2007, LEUKEMIA, V21, P53, DOI 10.1038/sj.leu.2404456; Stevenson FK, 2011, BLOOD, V118, P4313, DOI 10.1182/blood-2011-06-338855; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; van Gent R, 2008, CANCER RES, V68, P10137, DOI 10.1158/0008-5472.CAN-08-2325; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; Wang ML, 2013, NEW ENGL J MED, V369, P507, DOI 10.1056/NEJMoa1306220; Webb CF, 2000, J IMMUNOL, V165, P6956, DOI 10.4049/jimmunol.165.12.6956; Wierda WG, 2010, J CLIN ONCOL, V28, P1749, DOI 10.1200/JCO.2009.25.3187; Wiestner A, 2012, BLOOD, V120, P4684, DOI 10.1182/blood-2012-05-423194; Wolska A, 2013, LEUKEMIA LYMPHOMA, V54, P1268, DOI 10.3109/10428194.2012.741233; Woyach JA, 2014, BLOOD, V123, P1810, DOI 10.1182/blood-2013-09-527853; Woyach JA, 2014, BLOOD, V123, P1207, DOI 10.1182/blood-2013-07-515361; Yang G, 2013, BLOOD, V122, P1222, DOI 10.1182/blood-2012-12-475111; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; Yu L, 2008, BLOOD, V111, P4617, DOI 10.1182/blood-2007-10-121137; Zenz T, 2008, BLOOD, V112, P3322, DOI 10.1182/blood-2008-04-154070; Zenz T, 2009, BLOOD, V114, P2589, DOI 10.1182/blood-2009-05-224071; Zorn CN, 2009, CELL SIGNAL, V21, P79, DOI 10.1016/j.cellsig.2008.09.010	144	23	23	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2015	34	19					2426	2436		10.1038/onc.2014.181	http://dx.doi.org/10.1038/onc.2014.181			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH7BK	24954503				2022-12-17	WOS:000354190400002
J	Yan, Y; Hein, AL; Greer, PM; Wang, Z; Kolb, RH; Batra, SK; Cowan, KH				Yan, Y.; Hein, A. L.; Greer, P. M.; Wang, Z.; Kolb, R. H.; Batra, S. K.; Cowan, K. H.			A novel function of HER2/Neu in the activation of G2/M checkpoint in response to gamma-irradiation	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; DNA-DAMAGE CHECKPOINT; TYROSINE KINASE INHIBITION; CELL-CYCLE CHECKPOINTS; SIGNALING PATHWAY; CANCER-CELLS; PHOSPHORYLATION; RADIATION; EGFR; PROTEIN	In response to gamma-irradiation (IR)-induced DNA damage, activation of cell cycle checkpoints results in cell cycle arrest, allowing time for DNA repair before cell cycle re-entry. Human cells contain G1 and G2 cell cycle checkpoints. While G1 checkpoint is defective in most cancer cells, commonly due to mutations and/or alterations in the key regulators of G1 checkpoint (for example, p53, cyclin D), G2 checkpoint is rarely impaired in cancer cells, which is important for cancer cell survival. G2 checkpoint activation involves activation of ataxia telangiectasia-mutated (ATM)/ATM- and rad3-related (ATR) signalings, which leads to the inhibition of Cdc2 kinase and subsequent G2/M cell cycle arrest. Previous studies from our laboratory show that G2 checkpoint activation following IR exposure of MCF-7 breast cancer cells is dependent on the activation of extracellular signal-regulated protein kinase 1 and 2 (ERK1/2) signaling. As HER receptor tyrosine kinases (RTKs), which have important roles in cell proliferation and survival, have been shown to activate ERK1/2 signaling in response to various stimuli, we investigated the role of HER RTKs in IR-induced G2/M checkpoint response in breast cancer cells. Results of the present studies indicate that IR exposure resulted in a striking increase in the phosphorylation of HER1, HER2, HER3 and HER4 in MCF-7 cells, indicative of activation of these proteins. Furthermore, specific inhibition of HER2 using an inhibitor, short hairpin RNA and dominant-negative mutant HER2 abolished IR-induced activation of ATM/ATR signaling, phosphorylation of Cdc2-Y15 and subsequent induction of G2/M arrest. Moreover, the inhibition of HER2 also abrogated IR-induced ERK1/2 phosphorylation. In contrast, inhibition of HER1 using specific inhibitors or decreasing expression of HER3 or HER4 using short hairpin RNAs did not block the induction of G2/M arrest following IR. These results suggest an important role of HER2 in the activation of G2/M checkpoint response following IR.	[Yan, Y.; Hein, A. L.; Greer, P. M.; Wang, Z.; Kolb, R. H.; Cowan, K. H.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; [Batra, S. K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Yan, Y (corresponding author), Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, 986805 Nebraska Med Ctr, Omaha, NE 68198 USA.	yyan@unmc.edu; kcowan@unmc.edu		Hein, Ashley/0000-0002-3309-2218	Nebraska [DHHS-LB506]; NCI [NCI T32 CA009476]; NCI Cancer Center [P30CA036727]; NATIONAL CANCER INSTITUTE [P30CA036727, T32CA009476] Funding Source: NIH RePORTER	Nebraska; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI Cancer Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Helen Piwnica-Worms for the GST-Cdc25C construct, Dr Ming-Fong Lin for the HER2-mut, wild-type HER2 and control constructs, Victoria Smith and Dr Charles Kuzynski for assistance with FACS analysis and Dr Janina Baranowska-Kortylewicz for assistance with the Mark I 68A Cesium-137 Irradiator. This work was supported by Nebraska DHHS-LB506 Grant 2010-40 to YY, NCI Training Grant (NCI T32 CA009476) to RK and NCI Cancer Center Support Grant (P30CA036727) to KC.	Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Baselga J, 2005, J CLIN ONCOL, V23, P2445, DOI 10.1200/JCO.2005.11.890; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.3.CO;2-S; Bulavin DV, 2003, NAT CELL BIOL, V5, P545, DOI 10.1038/ncb994; Dhomen Nathalie S., 2012, Critical Reviews in Oncogenesis, V17, P31; Geoerger B, 2008, INT J CANCER, V123, P209, DOI 10.1002/ijc.23488; Goldkorn T, 1997, BBA-MOL CELL RES, V1358, P289, DOI 10.1016/S0167-4889(97)00063-3; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hersey P, 2006, INT REV CYTOL, V251, P131, DOI 10.1016/S0074-7696(06)51004-6; Jani JP, 2007, CANCER RES, V67, P9887, DOI 10.1158/0008-5472.CAN-06-3559; KASTAN MB, 1991, CANCER RES, V51, P6304; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; KHARBANDA S, 1994, CANCER RES, V54, P1412; Kiyozuka M, 2013, ANTICANCER RES, V33, P4337; Kolb RH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050281; Kuntz K, 2009, CANCER BIOL THER, V8, P1433, DOI 10.4161/cbt.8.15.9081; Leach JK, 2001, CANCER RES, V61, P3894; Lee HC, 2008, MOL CANCER RES, V6, P996, DOI 10.1158/1541-7786.MCR-08-0113; Lee MS, 2003, ONCOGENE, V22, P781, DOI 10.1038/sj.onc.1206066; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liang K, 2003, MOL CANCER THER, V2, P1113; Linggi B, 2006, TRENDS CELL BIOL, V16, P649, DOI 10.1016/j.tcb.2006.10.008; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; Navolanic PM, 2003, INT J ONCOL, V22, P237; Nyati MK, 2004, CLIN CANCER RES, V10, P691, DOI 10.1158/1078-0432.CCR-1041-03; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Prigent C, 2003, J CELL SCI, V116, P3677, DOI 10.1242/jcs.00735; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; Rexer Brent N., 2012, Critical Reviews in Oncogenesis, V17, P1; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Sauve DM, 1999, J CELL BIOL, V145, P225, DOI 10.1083/jcb.145.2.225; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; Slichenmyer WJ, 2001, SEMIN ONCOL, V28, P80, DOI 10.1016/S0093-7754(01)90285-4; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Subik K, 2010, BREAST CANCER-BASIC, V4, P35; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Turke AB, 2012, CANCER RES, V72, P3228, DOI 10.1158/0008-5472.CAN-11-3747; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu Bo, 2004, Methods Mol Biol, V281, P283; Yamaguchi H, 2014, ONCOGENE, V33, P1073, DOI 10.1038/onc.2013.74; Yan Y, 2007, ONCOGENE, V26, P4689, DOI 10.1038/sj.onc.1210268; Yan Y, 2010, ONCOGENE, V29, P4317, DOI 10.1038/onc.2010.187; Yan Y, 2005, ONCOGENE, V24, P3285, DOI 10.1038/sj.onc.1208492; Yan Y, 2002, J BIOL CHEM, V277, P33422, DOI 10.1074/jbc.M201147200; Yan Y, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3164	51	23	26	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2015	34	17					2215	2226		10.1038/onc.2014.167	http://dx.doi.org/10.1038/onc.2014.167			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG7HG	24909175	Green Accepted			2022-12-17	WOS:000353473000007
J	Appolloni, I; Barilari, M; Caviglia, S; Gambini, E; Reisoli, E; Malatesta, P				Appolloni, I.; Barilari, M.; Caviglia, S.; Gambini, E.; Reisoli, E.; Malatesta, P.			A cadherin switch underlies malignancy in high-grade gliomas	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; PDGF-INDUCED OLIGODENDROGLIOMA; GROWTH-FACTOR RECEPTOR; CELL-CELL-ADHESION; CONTACT INHIBITION; R-CADHERIN; TUMOR PROGRESSION; NEURAL PROGENITORS; BREAST-CANCER; B-CHAIN	Although the infiltrative behavior of malignant gliomas is one of their most critical aspects, the mechanisms underlying it have not yet been elucidated. To migrate in the brain parenchyma, malignant glioma cells need to bypass the cell-cell contact inhibitory signals. Here we propose that the blinding of cell-cell contact sensing in gliomas is caused by an unusual mechanism of cadherin switch, involving the replacement of N-cadherin with R-cadherin (Rcad) at the cell-cell junctions and the activation of ERK and p27. In our model of malignant glioma, we found that Rcad expression is necessary and sufficient to release cells from contact inhibition of proliferation, and is necessary, although not sufficient, for overriding contact inhibition of migration and for tumorigenicity. Altogether, these observations suggest that Rcad is a potential target for malignant glioma therapies.	[Appolloni, I.; Barilari, M.; Reisoli, E.; Malatesta, P.] IRCCS AOU San Martino IST, UO Trasferimento Genico, I-16132 Genoa, Italy; [Caviglia, S.; Gambini, E.; Malatesta, P.] Univ Genoa, Dept Expt Med DiMES, Genoa, Italy	University of Genoa; IRCCS AOU San Martino IST; University of Genoa	Malatesta, P (corresponding author), IRCCS AOU San Martino IST, UO Trasferimento Genico, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.	paolo.malatesta@unige.it	Malatesta, Paolo/J-3570-2012; Appolloni, Irene/AAC-1629-2019	Malatesta, Paolo/0000-0003-3045-3361; Caviglia, Sara/0000-0001-9832-2566	NUSUG grant from AIRC; Ministero della Salute [GR-2008-1135643]; Fondazione S. Paolo (Molecular and cellular basis of glioma); Fondazione CARIGE; FIRC fellowship [9887]	NUSUG grant from AIRC(Fondazione AIRC per la ricerca sul cancro); Ministero della Salute(Ministry of Health, Italy); Fondazione S. Paolo (Molecular and cellular basis of glioma); Fondazione CARIGE(Fondazione Carige); FIRC fellowship(Fondazione AIRC per la ricerca sul cancro)	We thank Dr Magdalena Gotz (Institute of Stem Cell Research-Helmholtz Centre Munich, Germany) for providing access to the time lapse equipment and Dr Masatoshi Takeichi (RIKEN Center for developmental biology, Kobe, Japan) for sharing plasmids. We acknowledge Dr Paola Briata, Dr Filippo Calzolari, Dr Federico Cremisi and Dr Roberto Gherzi for helpful comments on the manuscript. This work was supported by a NUSUG grant from AIRC, by the GR-2008-1135643 grant from Ministero della Salute, by Fondazione S. Paolo (Molecular and cellular basis of glioma) and by Fondazione CARIGE. ER salary was funded by the FIRC fellowship 9887.	Agiostratidou G, 2009, CANCER RES, V69, P5030, DOI 10.1158/0008-5472.CAN-08-4007; Appolloni I, 2012, INT J MOL SCI, V13, P14667, DOI 10.3390/ijms131114667; Appolloni I, 2012, INT J CANCER, V131, pE1078, DOI 10.1002/ijc.27606; Appolloni I, 2009, INT J CANCER, V124, P2251, DOI 10.1002/ijc.24206; Assanah M, 2006, J NEUROSCI, V26, P6781, DOI 10.1523/JNEUROSCI.0514-06.2006; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Baum B, 2008, SEMIN CELL DEV BIOL, V19, P294, DOI 10.1016/j.semcdb.2008.02.001; Brennan C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007752; Calzolari F, 2008, NEOPLASIA, V10, P1373, DOI 10.1593/neo.08814; Charrasse S, 2002, J CELL BIOL, V158, P953, DOI 10.1083/jcb.200202034; Chin YR, 2009, CELL SIGNAL, V21, P470, DOI 10.1016/j.cellsig.2008.11.015; Cooper LAD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012548; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; De Donatis A, 2008, J BIOL CHEM, V283, P19948, DOI 10.1074/jbc.M709428200; Du CP, 2011, CANCER LETT, V309, P54, DOI 10.1016/j.canlet.2011.05.016; Gambini E, 2012, MOL THER, V20, P994, DOI 10.1038/mt.2012.22; Gravdal K, 2007, CLIN CANCER RES, V13, P7003, DOI 10.1158/1078-0432.CCR-07-1263; Gravendeel LAM, 2009, CANCER RES, V69, P9065, DOI 10.1158/0008-5472.CAN-09-2307; HERMANSSON M, 1988, P NATL ACAD SCI USA, V85, P7748, DOI 10.1073/pnas.85.20.7748; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Hsu YM, 2007, CANCER RES, V67, P11064, DOI 10.1158/0008-5472.CAN-07-2443; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; INUZUKA H, 1991, NEURON, V7, P69, DOI 10.1016/0896-6273(91)90075-B; Johnson E, 2004, J BIOL CHEM, V279, P31041, DOI 10.1074/jbc.M400024200; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim EK, 2010, BBA-MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009; Kim NG, 2011, P NATL ACAD SCI USA, V108, P11930, DOI 10.1073/pnas.1103345108; Kucharczak J, 2008, CANCER RES, V68, P6559, DOI 10.1158/0008-5472.CAN-08-0196; KUPFER A, 1982, P NATL ACAD SCI-BIOL, V79, P2603, DOI 10.1073/pnas.79.8.2603; Le Bras GF, 2012, CELL ADHES MIGR, V6, P365, DOI 10.4161/cam.21326; Lei L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020041; Levenberg S, 1999, ONCOGENE, V18, P869, DOI 10.1038/sj.onc.1202396; Lien WH, 2006, CURR OPIN CELL BIOL, V18, P499, DOI 10.1016/j.ceb.2006.07.001; Lim J, 2012, DEVELOPMENT, V139, P3471, DOI 10.1242/dev.071209; Maeda M, 2006, ONCOGENE, V25, P4595, DOI 10.1038/sj.onc.1209396; Mayor R, 2013, DEVELOPMENT, V140, P2247, DOI 10.1242/dev.091751; Mayor R, 2010, TRENDS CELL BIOL, V20, P319, DOI 10.1016/j.tcb.2010.03.005; McClatchey AI, 2012, CURR OPIN CELL BIOL, V24, P685, DOI 10.1016/j.ceb.2012.06.009; McKinnon RD, 2005, J NEUROSCI, V25, P3499, DOI 10.1523/JNEUROSCI.5049-04.2005; Miotto E, 2004, CANCER RES, V64, P8156, DOI 10.1158/0008-5472.CAN-04-3000; Motti ML, 2005, CARCINOGENESIS, V26, P1021, DOI 10.1093/carcin/bgi050; Nabi IR, 1999, J CELL SCI, V112, P1803; Puliafito A, 2012, P NATL ACAD SCI USA, V109, P739, DOI 10.1073/pnas.1007809109; Redies C, 2000, PROG NEUROBIOL, V61, P611, DOI 10.1016/S0301-0082(99)00070-2; Sheehan KM, 2008, ONCOGENE, V27, P323, DOI 10.1038/sj.onc.1210647; Siletz A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057180; Smith CL, 2010, CELL ADHES MIGR, V4, P561, DOI 10.4161/cam.4.4.12829; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; Szerlip NJ, 2012, P NATL ACAD SCI USA, V109, P3041, DOI 10.1073/pnas.1114033109; Terrile M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-550; Theisen U, 2012, DEV CELL, V23, P1153, DOI 10.1016/j.devcel.2012.11.005; Theveneau E, 2012, CURR OPIN CELL BIOL, V24, P677, DOI 10.1016/j.ceb.2012.08.002; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Uhrbom L, 1998, CANCER RES, V58, P5275; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wheelock MJ, 2008, J CELL SCI, V121, P727, DOI 10.1242/jcs.000455; Yoeli-Lerner M, 2006, CELL CYCLE, V5, P603, DOI 10.4161/cc.5.6.2561; Zou L, 2009, CELL MOTIL CYTOSKEL, V66, P1048, DOI 10.1002/cm.20407	59	23	24	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1991	2002		10.1038/onc.2014.122	http://dx.doi.org/10.1038/onc.2014.122			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24858041				2022-12-17	WOS:000352725600013
J	Macha, MA; Rachagani, S; Pai, P; Gupta, S; Lydiatt, WM; Smith, RB; Johansson, SL; Lele, SM; Kakar, SS; Lee, JH; Meza, J; Ganti, AK; Jain, M; Batra, SK				Macha, M. A.; Rachagani, S.; Pai, P.; Gupta, S.; Lydiatt, W. M.; Smith, R. B.; Johansson, S. L.; Lele, S. M.; Kakar, S. S.; Lee, J. H.; Meza, J.; Ganti, A. K.; Jain, M.; Batra, S. K.			MUC4 regulates cellular senescence in head and neck squamous cell carcinoma through p16/Rb pathway	ONCOGENE			English	Article							PANCREATIC-CANCER; HUMAN-PAPILLOMAVIRUS; MUCINS MUC1; EXPRESSION; GROWTH; PROLIFERATION; METASTASIS; OVEREXPRESSION; SURVIVAL; BIOLOGY	The limited effectiveness of therapy for patients with advanced stage head and neck squamous cell carcinoma (HNSCC) or recurrent disease is a reflection of an incomplete understanding of the molecular basis of HNSCC pathogenesis. MUC4, a high molecular weight glycoprotein, is differentially overexpressed in many human cancers and implicated in cancer progression and resistance to several chemotherapies. However, its clinical relevance and the molecular mechanisms through which it mediates HNSCC progression are not well understood. This study revealed a significant upregulation of MUC4 in 78% (68/87) of HNSCC tissues compared with 10% positivity (1/10) in benign samples (P = 0.006, odds ratio (95% confidence interval) = 10.74 (2.0-57.56). MUC4 knockdown (KD) in SCC1 and SCC10B HNSCC cell lines resulted in significant inhibition of growth in vitro and in vivo, increased senescence as indicated by an increase in the number of flat, enlarged and senescence-associated beta-galactosidase (SA-beta-Gal)positive cells. Decreased cellular proliferation was associated with G(0)/G(1) cell cycle arrest and decrease expression of cell cycle regulatory proteins like cyclin E, cyclin D1 and decrease in BrdU incorporation. Mechanistic studies revealed upregulation of p16, pRb dephosphorylation and its interaction with histone deacetylase 1/2. This resulted in decreased histone acetylation (H3K9) at cyclin E promoter leading to its downregulation. Orthotopic implantation of MUC4 KD SCC1 cells into the floor of the mouth in nude mice resulted in the formation of significantly smaller tumors (170 +/- 18.30 mg) compared to those (375 +/- 17.29 mg) formed by control cells (P = 0.00007). In conclusion, our findings showed that MUC4 overexpression has a critical role by regulating proliferation and cellular senescence of HNSCC cells. Downregulation of MUC4 may be a promising therapeutic approach for treating HNSCC patients.	[Macha, M. A.; Rachagani, S.; Pai, P.; Gupta, S.; Jain, M.; Batra, S. K.] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; [Lydiatt, W. M.; Smith, R. B.] Univ Nebraska, Med Ctr, Dept Otolaryngol, Omaha, NE 68198 USA; [Johansson, S. L.; Lele, S. M.] Univ Nebraska, Med Ctr, Dept Pathol, Omaha, NE 68198 USA; [Kakar, S. S.] Univ Louisville, Dept Physiol & Biophys, Louisville, KY 40292 USA; [Lee, J. H.] Sanford Canc Res Ctr, Sanford ENT Head & Neck Surg, Sioux Falls, SD USA; [Meza, J.] Univ Nebraska, Med Ctr, Coll Publ Hlth, Dept Biostat, Omaha, NE 68198 USA; [Ganti, A. K.] VA Nebraska Western Iowa Hlth Care Syst, Dept Internal Med, Omaha, NE USA; [Ganti, A. K.] Univ Nebraska, Med Ctr, Omaha, NE 68198 USA; [Jain, M.; Batra, S. K.] Buffett Canc Ctr, Omaha, NE USA; [Batra, S. K.] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Louisville; Sanford Health; University of Nebraska System; University of Nebraska Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Jain, M (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	mjain@unmc.edu; sbatra@unmc.edu	MACHA, MUZAFAR AHMAD/AAN-5735-2020; Ganti, Apar Kishor/D-5498-2015	MACHA, MUZAFAR AHMAD/0000-0003-4468-4435; Ganti, Apar Kishor/0000-0003-3724-2671	National Institutes of Health [RO1 CA133774, U54 CA163120, UO1 CA111294, P50 CA 127297, R21 CA156037, P20 RR021937]; NATIONAL CANCER INSTITUTE [U01CA111294, P50CA127297, R21CA156037, U54CA163120, R01CA133774] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR021937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103480] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We acknowledge the invaluable technical support from Ms Kavita Mallya and Hanan I Farghaly. We also thank Janice A Taylor and James R Talaska of the confocal laser scanning microscope core facility at UNMC for their support. This work was supported, in part, by the grants from National Institutes of Health (RO1 CA133774, U54 CA163120, UO1 CA111294, P50 CA 127297, R21 CA156037 and P20 RR021937).	Alos L, 2005, AM J SURG PATHOL, V29, P806, DOI 10.1097/01.pas.0000155856.84553.c9; Argiris A, 2008, LANCET, V371, P1695, DOI 10.1016/S0140-6736(08)60728-X; Bafna S, 2008, CANCER RES, V68, P9231, DOI 10.1158/0008-5472.CAN-08-3135; Bandyopadhyay D, 2002, CANCER RES, V62, P6231; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cai Yang, 2007, Chinese Journal of Pathology, V36, P375; Califano J, 1996, CANCER RES, V56, P2488; Cammarano MS, 2005, MOL CELL BIOL, V25, P9532, DOI 10.1128/MCB.25.21.9532-9542.2005; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chakraborty Subhankar, 2008, Expert Opin Med Diagn, V2, P891, DOI 10.1517/17530059.2.8.891; Chaturvedi P, 2008, FASEB J, V22, P966, DOI 10.1096/fj.07-9673rev; Chaturvedi P, 2007, MOL CANCER RES, V5, P309, DOI 10.1158/1541-7786.MCR-06-0353; Chung IS, 2008, ORAL ONCOL, V44, P1118, DOI 10.1016/j.oraloncology.2008.01.017; Dey P, 2012, CLIN CANCER RES, V18, P6188, DOI 10.1158/1078-0432.CCR-12-1789; DIMRI GP, 1994, COLD SPRING HARB SYM, V59, P67, DOI 10.1101/SQB.1994.059.01.010; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fakhry C, 2008, JNCI-J NATL CANCER I, V100, P261, DOI 10.1093/jnci/djn011; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Gil Z, 2009, ISR MED ASSOC J, V11, P296; Hamada T, 2012, INT J CANCER, V130, P1768, DOI 10.1002/ijc.26187; Hammarstedt L, 2006, INT J CANCER, V119, P2620, DOI 10.1002/ijc.22177; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Kaur S, 2013, NAT REV GASTRO HEPAT, V10, P607, DOI 10.1038/nrgastro.2013.120; Ke XS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004687; Kitazono I, 2013, PANCREAS, V42, P1120, DOI 10.1097/MPA.0b013e3182965915; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Liggett WH, 1996, CANCER RES, V56, P4119; LLeonart ME, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-3; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Macha MA, CANC LETT, V341, P166; Majhi PD, 2013, J THORAC ONCOL, V8, P398, DOI 10.1097/JTO.0b013e3182829e06; Moniaux N, 2004, J HISTOCHEM CYTOCHEM, V52, P253, DOI 10.1177/002215540405200213; Mukhopadhyay P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054455; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nichols Anthony C, 2012, ISRN Oncol, V2012, P809370, DOI 10.5402/2012/809370; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Peeper DS, 2002, NAT CELL BIOL, V4, P148, DOI 10.1038/ncb742; Ponnusamy MP, 2008, BRIT J CANCER, V99, P520, DOI 10.1038/sj.bjc.6604517; Ponnusamy MP, 2010, ONCOGENE, V29, P5741, DOI 10.1038/onc.2010.309; Ponnusamy MP, 2008, J OVARIAN RES, V1, DOI 10.1186/1757-2215-1-4; Rabassa ME, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-253; Rachagani S, 2012, CARCINOGENESIS, V33, P1953, DOI 10.1093/carcin/bgs225; Rakha EA, 2005, MODERN PATHOL, V18, P1295, DOI 10.1038/modpathol.3800445; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Sano D, 2011, CLIN CANCER RES, V17, P6658, DOI 10.1158/1078-0432.CCR-11-0046; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Tanaka K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0027922; Tang AL, 2012, HEAD NECK-J SCI SPEC, V34, P1480, DOI 10.1002/hed.21962; Urnov FD, 2001, ONCOGENE, V20, P2991, DOI 10.1038/sj.onc.1204323; Weed DT, 2001, OTOLARYNG HEAD NECK, V124, P127, DOI 10.1067/mhn.2001.112575; Zhang XW, 2006, MOL CELL BIOL, V26, P8252, DOI 10.1128/MCB.00604-06	56	23	24	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1698	1708		10.1038/onc.2014.102	http://dx.doi.org/10.1038/onc.2014.102			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24747969	Green Accepted			2022-12-17	WOS:000351848400010
J	Nopparat, J; Zhang, J; Lu, JP; Chen, YH; Zheng, D; Neufer, PD; Fan, JM; Hong, H; Boykin, C; Lu, Q				Nopparat, J.; Zhang, J.; Lu, J-P; Chen, Y-H; Zheng, D.; Neufer, P. D.; Fan, J. M.; Hong, H.; Boykin, C.; Lu, Q.			delta-Catenin, a Wnt/beta-catenin modulator, reveals inducible mutagenesis promoting cancer cell survival adaptation and metabolic reprogramming	ONCOGENE			English	Article							E-CADHERIN; ARMADILLO PROTEIN; PROSTATE; MEMBER; KAISO; GENE; MORPHOGENESIS; P190RHOGEF; EXPRESSION; MUTATIONS	Mutations of Wnt/beta-catenin signaling pathway has essential roles in development and cancer. Although beta-catenin and adenomatous polyposis coli (APC) gene mutations are well established and are known to drive tumorigenesis, discoveries of mutations in other components of the pathway lagged, which hinders the understanding of cancer mechanisms. Here we report that delta-catenin (gene designation: CTNND2), a primarily neural member of the beta-catenin superfamily that promotes canonical Wnt/beta-catenin/LEF-1-mediated transcription, displays exonic mutations in human prostate cancer and promotes cancer cell survival adaptation and metabolic reprogramming. When overexpressed in cells derived from prostate tumor xenografts, delta-catenin gene invariably gives rise to mutations, leading to sequence disruptions predicting functional alterations. Ectopic delta-catenin gene integrating into host chromosomes is locus nonselective. delta-Catenin mutations promote tumor development in mouse prostate with probasin promoter (ARR(2)PB)-driven, prostate-specific expression of Myc oncogene, whereas mutant cells empower survival advantage upon overgrowth and glucose deprivation. Reprogramming energy utilization accompanies the downregulation of glucose transporter-1 and poly (ADP-ribose) polymerase cleavage while preserving tumor type 2 pyruvate kinase expression. delta-Catenin mutations increase beta-catenin translocation to the nucleus and hypoxia-inducible factor 1 alpha (HIF-1 alpha) expression. Therefore, introducing delta-catenin mutations is an important milestone in prostate cancer metabolic adaptation by modulating beta-catenin and HIF-1 alpha signaling under glucose shortage to amplify its tumor-promoting potential.	[Nopparat, J.; Zhang, J.; Lu, J-P; Fan, J. M.; Boykin, C.; Lu, Q.] E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, Greenville, NC 27834 USA; [Lu, J-P] Zhejiang Univ, Coll Life Sci, Hangzhou 310003, Zhejiang, Peoples R China; [Chen, Y-H; Lu, Q.] E Carolina Univ, Brody Sch Med, Leo Jenkins Canc Ctr, Greenville, NC 27834 USA; [Chen, Y-H; Lu, Q.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Zheng, D.; Neufer, P. D.] E Carolina Univ, Dept Kinesiol, Greenville, NC 27834 USA; [Zheng, D.; Neufer, P. D.] E Carolina Univ, East Carolina Diabet & Obes Inst, Greenville, NC 27834 USA; [Neufer, P. D.] E Carolina Univ, Brody Sch Med, Dept Physiol, Greenville, NC 27834 USA; [Hong, H.] E Carolina Univ, Brody Sch Med, Dept Pathol & Lab Med, Greenville, NC 27834 USA	University of North Carolina; East Carolina University; Zhejiang University; University of North Carolina; East Carolina University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; University of North Carolina; East Carolina University	Lu, Q (corresponding author), E Carolina Univ, Brody Sch Med, Dept Anat & Cell Biol, 7N72A Brody Sci Bldg,600 Moye Blvd, Greenville, NC 27834 USA.	luq@ecu.edu	Nopparat, Jongdee/AAX-1690-2020; Lu, Jianping/AFL-6811-2022	Nopparat, Jongdee/0000-0003-3532-1405; Lu, Jianping/0000-0001-9601-0040	DOD [PC040569]; NIH [CA111891, CA165202, ES016888, DK073488, DK074825]; NATIONAL CANCER INSTITUTE [R15CA165202, R01CA111891] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073488, R01DK096907, R01DK074825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R03ES016888] Funding Source: NIH RePORTER	DOD(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Joani Zary Oswald for technical assistance. This work was supported, in part, by DOD Grant PC040569 (to QL), NIH Grants CA111891 and CA165202 (to QL), ES016888 (to Y-HC) and DK073488 and DK074825 (to PDN).	Bareiss S, 2010, J NEUROSCI RES, V88, P2350, DOI 10.1002/jnr.22414; Baum C, 2004, MOL THER, V9, P5, DOI 10.1016/j.ymthe.2003.10.013; Burger MJ, 2002, INT J CANCER, V100, P228, DOI 10.1002/ijc.10468; Dai SD, 2011, CANCER SCI, V102, P95, DOI 10.1111/j.1349-7006.2010.01766.x; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Deng W, 2003, CYTOM PART A, V51A, P46, DOI 10.1002/cyto.a.10004; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Fang Y, 2004, J CANCER RES CLIN, V138, P1769; Gu DM, 2009, J CELL SCI, V122, P4049, DOI 10.1242/jcs.031948; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hirsch D, 2013, CANCER RES, V73, P1454, DOI 10.1158/0008-5472.CAN-12-0928; Huang XT, 2007, GENES GENET SYST, V82, P257, DOI 10.1266/ggs.82.257; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Israely I, 2004, CURR BIOL, V14, P1657, DOI 10.1016/j.cub.2004.08.065; Jun G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043728; Kim H, 2008, J BIOL CHEM, V283, P977, DOI 10.1074/jbc.M707158200; Kim H, 2012, BBA-MOL BASIS DIS, V1822, P509, DOI 10.1016/j.bbadis.2011.12.015; Kim H, 2008, BIOCHEM BIOPH RES CO, V377, P636, DOI 10.1016/j.bbrc.2008.10.030; Kim JS, 2006, BIOCHEM BIOPH RES CO, V351, P903, DOI 10.1016/j.bbrc.2006.10.135; Kim K, 2002, EXP CELL RES, V275, P171, DOI 10.1006/excr.2002.5503; Kim SW, 2004, NAT CELL BIOL, V6, P1212, DOI 10.1038/ncb1191; Kouchi Z, 2009, J BIOL CHEM, V284, P1954, DOI 10.1074/jbc.M806250200; Lu BY, 2011, INVEST OPHTH VIS SCI, V52, P8258, DOI 10.1167/iovs.11-7914; Lu Q, 2005, HUM PATHOL, V36, P1037, DOI 10.1016/j.humpath.2005.07.012; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; Lu Q, 2010, J PATHOL, V222, P119, DOI 10.1002/path.2755; Martinez MC, 2003, J CELL BIOL, V162, P99, DOI 10.1083/jcb.200211025; Mathupala SP, 2006, ONCOGENE, V25, P4777, DOI 10.1038/sj.onc.1209603; Oh M, 2009, J BIOL CHEM, V284, P28579, DOI 10.1074/jbc.M109.002659; Paffenholz R, 1997, DIFFERENTIATION, V61, P293, DOI 10.1046/j.1432-0436.1997.6150293.x; Papadopoulos N, 2006, NAT BIOTECHNOL, V24, P985, DOI 10.1038/nbt1234; Rios-Doria J, 2003, J BIOL CHEM, V278, P1372, DOI 10.1074/jbc.M208772200; Rodova M, 2004, MOL CELL BIOL, V24, P7188, DOI 10.1128/MCB.24.16.7188-7196.2004; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang T, 2009, ONCOGENE, V28, P555, DOI 10.1038/onc.2008.399; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Wilson KF, 2013, TRENDS MOL MED, V19, P74, DOI 10.1016/j.molmed.2012.10.011; Wolf A, 2006, NAT CELL BIOL, V8, P1432, DOI 10.1038/ncb1504; Wu M, 2007, AM J PHYSIOL-CELL PH, V292, pC125, DOI 10.1152/ajpcell.00247.2006; Yuan H, 2009, AM J PHYSIOL-HEART C, V296, pH470, DOI 10.1152/ajpheart.01051.2008; Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229; Zeng Y, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-19; Zhang H, 2013, TARGET ONCOL, DOI [10.1007/s11523-013-0269-6, DOI 10.1007/S11523-013-0269-6)]; Zhang JY, 2010, J PATHOL, V222, P76, DOI 10.1002/path.2742; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	48	23	24	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	2015	34	12					1542	1552		10.1038/onc.2014.89	http://dx.doi.org/10.1038/onc.2014.89			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD9KI	24727894	Green Accepted, Green Submitted			2022-12-17	WOS:000351416800007
J	Xu, S; Wen, Z; Jiang, Q; Zhu, L; Feng, S; Zhao, Y; Wu, J; Dong, Q; Mao, J; Zhu, Y				Xu, S.; Wen, Z.; Jiang, Q.; Zhu, L.; Feng, S.; Zhao, Y.; Wu, J.; Dong, Q.; Mao, J.; Zhu, Y.			CD58, a novel surface marker, promotes self-renewal of tumor-initiating cells in colorectal cancer	ONCOGENE			English	Article							STEM-CELLS; PROSPECTIVE IDENTIFICATION; METASTATIC CAPACITY; ADHESION MOLECULES; DRUG-RESISTANCE; COLON; EXPRESSION; DIFFERENTIATION; SUBPOPULATION; CONTRIBUTE	Colorectal tumor-initiating cells (CT-ICs) have self-renewal capabilities and have an important role in tumorigenesis, metastasis, recurrence and treatment resistance in colorectal cancer. Multiple cell-surface molecules targeting CT-ICs, possibly representing different CT-IC subpopulations, have been reported. However, whether new surface markers exist, as well as the mechanisms by which the markers regulate self-renewal, remain unclear. In this study, we enriched a CT-IC population through a serum-free low-adhesion system in vitro. Within this population, we found that CD58 and CD44 were upregulated using a cDNA GeneChip, and CD44(high)CD58(high) cancer cells, the common existence of which was demonstrated by flow cytometry in multiple colon cancer cell lines and primary specimens, exhibited enhanced self-renewal ability, epithelial-mesenchymal transition ability and tumorigenicity, both in vitro and in vivo. Furthermore, activated CD58 upregulated the Wnt/beta-catenin pathway and thus promoted self-renewal of CT-ICs; conversely, knockdown of CD58 significantly impaired sphere formation and tumor growth. With immunoprecipitation and western blotting approaches, CD58 was found to upregulate the Wnt pathway by degradation of Dickkopf 3. These results indicate that CD58 is a novel cell-surface marker that functionally regulates self-renewal of CT-ICs, which may provide an intriguing therapeutic target for the efficient killing and elimination of CT-ICs.	[Xu, S.; Wen, Z.; Zhu, L.; Feng, S.; Zhao, Y.; Wu, J.; Mao, J.; Zhu, Y.] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Lab Gastroenterol, Hangzhou 310009, Zhejiang, Peoples R China; [Jiang, Q.] Tongde Hosp Zhejiang Prov, Dept Gastroenterol, Hangzhou 310012, Zhejiang, Peoples R China; [Dong, Q.; Zhu, Y.] Zhejiang Univ, Sch Med, Inst Canc, Hangzhou 310009, Zhejiang, Peoples R China; [Dong, Q.; Zhu, Y.] Zhejiang Univ, Sch Med, Key Lab Canc Prevent & Intervent, Educ Minist, Hangzhou 310009, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University	Zhu, Y (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Lab Gastroenterol, Hangzhou 310009, Zhejiang, Peoples R China.	zhuyongliangch@gmail.com			National Science of Foundation Committee of China [81071768, 81071619, 31090361, 81372348]; Natural Science of Foundation of Zhejiang Province [R2090074, Y2110246]; Foundation of Scientific Technology Bureau of Zhejiang Province [2010C33118, 2011C23091, 2013C33129]	National Science of Foundation Committee of China; Natural Science of Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province); Foundation of Scientific Technology Bureau of Zhejiang Province	We thank Mr Qinghua Lu (Cancer Institute and Education Ministry Key Laboratory of Cancer Prevention and Intervention, Zhejiang University School of Medicine) for FCM analysis. This work was supported by grants from the National Science of Foundation Committee of China (81071768, 81071619, 31090361, 81372348), the Natural Science of Foundation of Zhejiang Province (R2090074, Y2110246) and the Foundation of Scientific Technology Bureau of Zhejiang Province (2010C33118, 2011C23091, 2013C33129).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ariel O, 2009, CELL SIGNAL, V21, P1100, DOI 10.1016/j.cellsig.2009.02.022; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bruno S, 2006, AM J PATHOL, V169, P2223, DOI 10.2353/ajpath.2006.060498; Challa-Malladi M, 2011, CANCER CELL, V20, P728, DOI 10.1016/j.ccr.2011.11.006; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Douard R, 2006, SURGERY, V139, P665, DOI 10.1016/j.surg.2005.10.012; Dreesen O, 2007, STEM CELL REV, V3, P7, DOI 10.1007/s12015-007-0004-8; Du L, 2008, CLIN CANCER RES, V14, P6751, DOI 10.1158/1078-0432.CCR-08-1034; Du L, 2013, CANCER RES, V73, P2682, DOI 10.1158/0008-5472.CAN-12-3759; DUSTIN ML, 1987, NATURE, V329, P846, DOI 10.1038/329846a0; Ebert EC, 2009, AM J PHYSIOL-GASTR L, V296, pG671, DOI 10.1152/ajpgi.90497.2008; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Gerger A, 2011, CLIN CANCER RES, V17, P6934, DOI 10.1158/1078-0432.CCR-11-1180; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952; Kolligs FT, 2002, DIGESTION, V66, P131, DOI 10.1159/000066755; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; KVALE D, 1992, SCAND J IMMUNOL, V35, P669, DOI 10.1111/j.1365-3083.1992.tb02973.x; LaBarge MA, 2008, J CLIN INVEST, V118, P2021, DOI 10.1172/JCI36046; Lee JL, 2009, J CELL BIOL, V185, P949, DOI 10.1083/jcb.200812060; Lee RV, 2005, AM J CLIN PATHOL, V123, P119, DOI 10.1309/X5VV-6FKJ-Q6MU-BLPX; Li DW, 2011, ANN SURG ONCOL, V18, P2074, DOI 10.1245/s10434-011-1567-9; Lombardo Y, 2011, GASTROENTEROLOGY, V140, P297, DOI 10.1053/j.gastro.2010.10.005; Mayer B, 1995, INT J CANCER, V64, P415, DOI 10.1002/ijc.2910640611; Morrison SJ, 2006, NATURE, V441, P1068, DOI 10.1038/nature04956; Munz M, 2009, CANCER RES, V69, P5627, DOI 10.1158/0008-5472.CAN-09-0654; Najdi Rani, 2011, J Carcinog, V10, P5, DOI 10.4103/1477-3163.78111; Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Pang R, 2010, CELL STEM CELL, V6, P603, DOI 10.1016/j.stem.2010.04.001; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Sagiv E, 2006, GASTROENTEROLOGY, V131, P630, DOI 10.1053/j.gastro.2006.04.028; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Shenoy AK, 2012, CANCER RES, V72, P5091, DOI 10.1158/0008-5472.CAN-12-1806; Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401; Sikandar SS, 2010, CANCER RES, V70, P1469, DOI 10.1158/0008-5472.CAN-09-2557; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Singh SK, 2003, CANCER RES, V63, P5821; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; Su YJ, 2011, EMBO J, V30, P3186, DOI 10.1038/emboj.2011.211; Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196; Tamada M, 2012, CANCER RES, V72, P1438, DOI 10.1158/0008-5472.CAN-11-3024; Todaro M, 2010, GASTROENTEROLOGY, V138, P2151, DOI 10.1053/j.gastro.2009.12.063; Vermeulen L, 2008, P NATL ACAD SCI USA, V105, P13427, DOI 10.1073/pnas.0805706105; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; Wang YZ, 2010, SCIENCE, V327, P1650, DOI 10.1126/science.1186624; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Yue W, 2008, CARCINOGENESIS, V29, P84, DOI 10.1093/carcin/bgm267; Zhu LQ, 2009, NATURE, V457, P603, DOI 10.1038/nature07589	55	23	24	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	2015	34	12					1520	1531		10.1038/onc.2014.95	http://dx.doi.org/10.1038/onc.2014.95			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD9KI	24727892				2022-12-17	WOS:000351416800005
J	Kim, B; Wang, S; Lee, JM; Jeong, Y; Ahn, T; Son, DS; Park, HW; Yoo, HS; Song, YJ; Lee, E; Oh, YM; Lee, SB; Choi, J; Murray, JC; Zhou, Y; Song, PH; Kim, KA; Weiner, LM				Kim, B.; Wang, S.; Lee, J. M.; Jeong, Y.; Ahn, T.; Son, D-S; Park, H. W.; Yoo, H-s; Song, Y-J; Lee, E.; Oh, Y. M.; Lee, S. B.; Choi, J.; Murray, J. C.; Zhou, Y.; Song, P. H.; Kim, K-A; Weiner, L. M.			Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; TYROSINE KINASE; HEPATOCYTE GROWTH; C-MET; GEFITINIB RESISTANCE; ACTIVATING MUTATIONS; MEDIATES RESISTANCE; SIGNALING PATHWAY; DRUG-RESISTANCE	Met is a receptor tyrosine kinase that promotes cancer progression. In addition, Met has been implicated in resistance of tumors to various targeted therapies such as epidermal growth factor receptor inhibitors in lung cancers, and has been prioritized as a key molecular target for cancer therapy. However, the underlying mechanism of resistance to Met-targeting drugs is poorly understood. Here, we describe screening of 1310 genes to search for key regulators related to drug resistance to an anti-Met therapeutic antibody (SAIT301) by using a small interfering RNA-based synthetic lethal screening method. We found that knockdown of 69 genes in Met-amplified MKN45 cells sensitized the antitumor activity of SAIT301. Pathway analysis of these 69 genes implicated fibroblast growth factor receptor (FGFR) as a key regulator for antiproliferative effects of Met-targeting drugs. Inhibition of FGFR3 increased target cell apoptosis through the suppression of Bcl-xL expression, followed by reduced cancer cell growth in the presence of Met-targeting drugs. Treatment of cells with the FGFR inhibitors substantially restored the efficacy of SAIT301 in SAIT301-resistant cells and enhanced the efficacy in SAIT301-sensitive cells. In addition to FGFR3, integrin beta 3 is another potential target for combination treatment with SAIT301. Suppression of integrin beta 3 decreased AKT phosphorylation in SAIT301-resistant cells and restored SAIT301 responsiveness in HCC1954 cells, which are resistant to SAIT301. Gene expression analysis using CCLE database shows that cancer cells with high levels of FGFR and integrin beta 3 are resistant to crizotinib treatment, suggesting that FGFR and integrin beta 3 could be used as predictive markers for Met-targeted therapy and provide a potential therapeutic option to overcome acquired and innate resistance for the Met-targeting drugs.	[Kim, B.; Lee, J. M.; Jeong, Y.; Ahn, T.; Son, D-S; Park, H. W.; Yoo, H-s; Song, Y-J; Lee, E.; Oh, Y. M.; Lee, S. B.; Choi, J.; Song, P. H.; Kim, K-A] SAIT, BioTherapeut Lab, Yongin 446712, Gyeonggi Do, South Korea; [Wang, S.; Murray, J. C.; Weiner, L. M.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20007 USA; [Zhou, Y.] Fox Chase Canc Ctr, Biostat & Bioinformat Fac, Philadelphia, PA 19111 USA	Samsung; Georgetown University; Fox Chase Cancer Center	Kim, KA (corresponding author), SAIT, BioTherapeut Lab, 95 Samsung2 Ro, Yongin 446712, Gyeonggi Do, South Korea.	ka10.kim@samsung.com	Murray, Joseph C/J-8916-2014; Lee, Ji Min/ABE-7494-2021; Jeong, Yunju/GRS-0008-2022	Murray, Joseph C/0000-0001-6159-7814; Lee, Ji Min/0000-0003-2978-2440; Wang, Shangzi/0000-0002-8936-6572	NCI [CA51008, CA50633]; Lombardi Comprehensive Cancer Center's Genomics and Epigenomics Shared Resource; NATIONAL CANCER INSTITUTE [P30CA051008, T32CA009686, R01CA050633] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Lombardi Comprehensive Cancer Center's Genomics and Epigenomics Shared Resource; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	LMW, SW and JCM are supported in part by NCI Grants CA51008 and CA50633. We thank Sandra A Jablonski, Wei Xu and Kyutaeg Lee for technical assistance. We are grateful for the support of the Lombardi Comprehensive Cancer Center's Genomics and Epigenomics Shared Resource.	Astsaturov I, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001083; Bachleitner-Hofmann T, 2008, MOL CANCER THER, V7, P3499, DOI 10.1158/1535-7163.MCT-08-0374; Basilico C, 2013, CLIN CANCER RES, V19, P2381, DOI 10.1158/1078-0432.CCR-12-3459; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Burke PA, 2002, CANCER RES, V62, P4263; Cecchi F, 2012, EXPERT OPIN THER TAR, V16, P553, DOI 10.1517/14728222.2012.680957; Cepero V, 2010, CANCER RES, V70, P7580, DOI 10.1158/0008-5472.CAN-10-0436; Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007; Corso S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-121; Dechantsreiter MA, 1999, J MED CHEM, V42, P3033, DOI 10.1021/jm970832g; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fong JT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078398; Garcia S, 2007, HUM PATHOL, V38, P830, DOI 10.1016/j.humpath.2006.11.015; Guagnano V, 2011, J MED CHEM, V54, P7066, DOI 10.1021/jm2006222; Harbinski F, 2012, CANCER DISCOV, V2, P948, DOI 10.1158/2159-8290.CD-12-0237; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Huang C, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2936; Iida Mari, 2013, Cancer Biol Ther, V14, P481, DOI 10.4161/cbt.24342; Janne PA, 2009, NAT REV DRUG DISCOV, V8, P709, DOI 10.1038/nrd2871; Ju LX, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-15; Kentsis A, 2012, NAT MED, V18, P1118, DOI 10.1038/nm.2819; Landi L, 2013, CURR OPIN ONCOL, V25, P130, DOI 10.1097/CCO.0b013e32835daf37; Langsenlehner U, 2006, BREAST CANCER RES TR, V97, P67, DOI 10.1007/s10549-005-9089-4; Lee HE, 2012, BRIT J CANCER, V107, P325, DOI 10.1038/bjc.2012.237; Lee JM, 2014, ONCOGENE, V33, P34, DOI 10.1038/onc.2012.551; Lee NV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039653; Lennerz JK, 2011, J CLIN ONCOL, V29, P4803, DOI 10.1200/JCO.2011.35.4928; Lesniak D, 2009, CANCER RES, V69, P8620, DOI 10.1158/0008-5472.CAN-09-1591; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; Morse DL, 2010, BIOCHEM PHARMACOL, V80, P731, DOI 10.1016/j.bcp.2010.04.011; Nagilla M, 2012, ADV THER, V29, P925, DOI 10.1007/s12325-012-0060-6; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Ou SHI, 2011, J THORAC ONCOL, V6, P942, DOI 10.1097/JTO.0b013e31821528d3; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Scagliotti GV, 2013, CANCER TREAT REV, V39, P793, DOI 10.1016/j.ctrv.2013.02.001; Sequist LV, 2011, J CLIN ONCOL, V29, P3307, DOI 10.1200/JCO.2010.34.0570; Singleton KR, 2013, MOL PHARMACOL, V83, P882, DOI 10.1124/mol.112.084111; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Surati M, 2011, EXPERT OPIN BIOL TH, V11, P1655, DOI 10.1517/14712598.2011.626762; Tiedt R, 2011, CANCER RES, V71, P5255, DOI 10.1158/0008-5472.CAN-10-4433; Tuck AB, 2000, J CELL BIOCHEM, V78, P465, DOI 10.1002/1097-4644(20000901)78:3<465::AID-JCB11>3.0.CO;2-C; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; Vogler M, 2010, CLIN CANCER RES, V16, P4217, DOI 10.1158/1078-0432.CCR-10-0777; Wickramasinghe D, 2005, CELL CYCLE, V4, P683, DOI 10.4161/cc.4.5.1688; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Yadav V, 2012, J BIOL CHEM, V287, P28087, DOI 10.1074/jbc.M112.377218; Yano S, 2008, CANCER RES, V68, P9479, DOI 10.1158/0008-5472.CAN-08-1643; Zhang Y, 2010, IDRUGS, V13, P112; Zhang YW, 2010, CANCER RES, V70, P6880, DOI 10.1158/0008-5472.CAN-10-0898; Zhu LJ, 2005, MOL CANCER THER, V4, P787, DOI 10.1158/1535-7163.MCT-04-0330	51	23	24	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2015	34	9					1083	1093		10.1038/onc.2014.51	http://dx.doi.org/10.1038/onc.2014.51			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RY	24662823	Green Accepted			2022-12-17	WOS:000350122100002
J	Dekanty, A; Barrio, L; Milan, M				Dekanty, A.; Barrio, L.; Milan, M.			Contributions of DNA repair, cell cycle checkpoints and cell death to suppressing the DNA damage-induced tumorigenic behavior of Drosophila epithelial cells	ONCOGENE			English	Article							DEPENDENT KINASE INHIBITOR; APOPTOSIS; PROLIFERATION; MORPHOGENESIS; ANEUPLOIDY; ABSENCE; MELANOGASTER; EXPRESSION; RADIATION; TRIBBLES	When exposed to DNA-damaging agents, components of the DNA damage response (DDR) pathway trigger apoptosis, cell cycle arrest and DNA repair. Although failures in this pathway are associated with cancer development, the tumor suppressor roles of cell cycle arrest and apoptosis have recently been questioned in mouse models. Using Drosophila epithelial cells that are unable to activate the apoptotic program, we provide evidence that ionizing radiation (IR)-induced DNA damage elicits a tumorigenic behavior in terms of E-cadherin delocalization, cell delamination, basement membrane degradation and neoplasic overgrowth. The tumorigenic response of the tissue to IR is enhanced by depletion of Okra/DmRAD54 or spnA/DmRAD51-genes required for homologous recombination (HR) repair of DNA double-strand breaks in G2-and it is independent of the activity of Lig4, a ligase required for nonhomologous end-joining repair in G1. Remarkably, depletion of Grapes/DmChk1 or Mei-41/dATR-genes affecting DNA damage-induced cell cycle arrest in G2-compromised DNA repair and enhanced the tumorigenic response of the tissue to IR. On the contrary, DDR-independent lengthening of G2 had a positive impact on the dynamics of DNA repair and suppressed the tumorigenic response of the tissue to IR. Our results support a tumor suppressor role of apoptosis, DNA repair by HR and cell cycle arrest in G2 in simple epithelia subject to IR-induced DNA damage.	[Dekanty, A.; Barrio, L.; Milan, M.] IRB Barcelona, Barcelona 08028, Spain; [Milan, M.] ICREA, Barcelona, Spain	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; ICREA	Milan, M (corresponding author), IRB Barcelona, Dept Cell & Dev Biol, Baldiri Reixac 10-12, Barcelona 08028, Spain.	marco.milan@irbbarcelona.org	Dekanty, Andres/C-3925-2018; Milan, Marco/H-1450-2015; Barrio Guerrero, Lara/F-4155-2016	Dekanty, Andres/0000-0002-0587-0449; Milan, Marco/0000-0002-7111-6444; Barrio Guerrero, Lara/0000-0001-7347-3114	Juan de la Cierva post-doctoral contract; Ministerio de Economia y Competitividad [BFU2010-21123, CSD2007-00008]; Generalitat de Catalunya [2005 SGR 00118]; EMBO Young Investigator Programme; ICREA Funding Source: Custom	Juan de la Cierva post-doctoral contract; Ministerio de Economia y Competitividad(Spanish Government); Generalitat de Catalunya(Generalitat de Catalunya); EMBO Young Investigator Programme(European Molecular Biology Organization (EMBO)); ICREA(ICREA)	We thank B Edgar and I Hariharan for flies and reagents, T Yates for help in editing the manuscript, and M Clemente-Ruiz for comments on the manuscript. AD is funded by a Juan de la Cierva post-doctoral contract and LB by a pre-doctoral fellowship (Ministerio de Economia y Competitividad), MM is an ICREA Research Professor and MM's laboratory was funded by Grants from the Ministerio de Economia y Competitividad (BFU2010-21123 and CSD2007-00008), the Generalitat de Catalunya (2005 SGR 00118), intramural funds and the EMBO Young Investigator Programme.	Beaucher M, 2007, DEV BIOL, V303, P625, DOI 10.1016/j.ydbio.2006.12.001; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Dar AC, 2012, NATURE, V486, P80, DOI 10.1038/nature11127; Dekanty A, 2012, P NATL ACAD SCI USA, V109, P20549, DOI 10.1073/pnas.1206675109; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; Foster SS, 2012, P NATL ACAD SCI USA, V109, P9953, DOI 10.1073/pnas.1120476109; Garcia AM, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-12-r121; Garcia AM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000950; Grosshans J, 2000, CELL, V101, P523, DOI 10.1016/S0092-8674(00)80862-4; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HAY BA, 1994, DEVELOPMENT, V120, P2121; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jaklevic BR, 2004, CURR BIOL, V14, P23, DOI 10.1016/j.cub.2003.12.032; Joyce EF, 2011, J CELL BIOL, V195, P359, DOI 10.1083/jcb.201104121; Kooistra R, 1997, MOL CELL BIOL, V17, P6097, DOI 10.1128/MCB.17.10.6097; Kusano K, 2001, SCIENCE, V291, P2600, DOI 10.1126/science.291.5513.2600; Lane D, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000893; Lane ME, 1996, CELL, V87, P1225, DOI 10.1016/S0092-8674(00)81818-8; Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Mata J, 2000, CELL, V101, P511, DOI 10.1016/S0092-8674(00)80861-2; McVey M, 2004, P NATL ACAD SCI USA, V101, P15694, DOI 10.1073/pnas.0406157101; McVey M, 2004, GENETICS, V167, P699, DOI 10.1534/genetics.103.025411; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Ohsawa S, 2012, NATURE, V490, P547, DOI 10.1038/nature11452; Oromendia AB, 2012, GENE DEV, V26, P2696, DOI 10.1101/gad.207407.112; Pacquelet A, 2005, J CELL BIOL, V170, P803, DOI 10.1083/jcb.200506131; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Perez-Garijo A, 2004, DEVELOPMENT, V131, P5591, DOI 10.1242/dev.01432; Peters M, 2002, P NATL ACAD SCI USA, V99, P11305, DOI 10.1073/pnas.172382899; Reis T, 2004, CELL, V117, P253, DOI 10.1016/S0092-8674(04)00247-8; Romeijn RJ, 2005, GENETICS, V169, P795, DOI 10.1534/genetics.104.033464; Salomon RN, 2008, FLY, V2, P265, DOI 10.4161/fly.7396; Seher TC, 2000, CURR BIOL, V10, P623, DOI 10.1016/S0960-9822(00)00502-9; Song YH, 2005, MOL CELLS, V19, P167; Song YH, 2004, CURR BIOL, V14, P1354, DOI 10.1016/j.cub.2004.06.064; Srivastava A, 2007, P NATL ACAD SCI USA, V104, P2721, DOI 10.1073/pnas.0611666104; Srivastava N, 2009, MUTAT RES-REV MUTAT, V681, P180, DOI 10.1016/j.mrrev.2008.08.003; Staeva-Vieira E, 2003, EMBO J, V22, P5863, DOI 10.1093/emboj/cdg564; Stingele S, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2012.40; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; Valente LJ, 2013, CELL REP, V3, P1339, DOI 10.1016/j.celrep.2013.04.012; Warner SJ, 2010, CURR BIOL, V20, P677, DOI 10.1016/j.cub.2010.03.025	50	23	24	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					978	985		10.1038/onc.2014.42	http://dx.doi.org/10.1038/onc.2014.42			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632609				2022-12-17	WOS:000350121300004
J	Chung, L; Onyango, D; Guo, Z; Jia, P; Dai, H; Liu, S; Zhou, M; Lin, W; Pang, I; Li, H; Yuan, YC; Huang, Q; Zheng, L; Lopes, J; Nicolas, A; Chai, W; Raz, D; Reckamp, KL; Shen, B				Chung, L.; Onyango, D.; Guo, Z.; Jia, P.; Dai, H.; Liu, S.; Zhou, M.; Lin, W.; Pang, I.; Li, H.; Yuan, Y-C; Huang, Q.; Zheng, L.; Lopes, J.; Nicolas, A.; Chai, W.; Raz, D.; Reckamp, K. L.; Shen, B.			The FEN1 E359K germline mutation disrupts the FEN1-WRN interaction and FEN1 GEN activity, causing aneuploidy-associated cancers	ONCOGENE			English	Article							OKAZAKI FRAGMENT MATURATION; DNA-DAMAGE RESPONSE; FLAP ENDONUCLEASE-1; REPLICATION FORK; CHROMOSOMAL INSTABILITY; SECONDARY STRUCTURES; TELOMERE STABILITY; TUMOR PROGRESSION; STRUCTURAL BASIS; MUTANT MICE	Polymorphisms and somatic mutations in Flap Endonuclease 1 (FEN1), an essential enzyme involved in DNA replication and repair, can lead to functional deficiencies of the FEN1 protein and a predisposition to cancer. We identified a FEN1 germline mutation that changed residue E359 to K in a patient whose family had a history of breast cancer. We determined that the E359K mutation, which is in the protein-protein domain of FEN1, abolished the interaction of FEN1 with Werner syndrome protein (WRN), an interaction that is critical for resolving stalled DNA replication forks. Furthermore, although the flap endonuclease activity of FEN1 E359K was unaffected, it failed to resolve bubble structures, which require the FEN1 gap-dependent endonuclease activity. To determine the etiological significance of E359K, we established a mouse model containing this mutation. E359K mouse embryonic fibroblasts (MEF) were more sensitive to DNA crosslinking agents that cause replication forks to stall. Cytological analysis suggested that the FEN1-WRN interaction was also required for telomere stability; mutant cell lines had fragile telomeres, increased numbers of spontaneous chromosomal anomalies and higher frequencies of transformation. Moreover, the incidence of cancer was significantly higher in mice homozygous for FEN1 E359K than in wild-type mice, suggesting that the FEN1 E359K mutation is oncogenic.	[Chung, L.; Onyango, D.; Guo, Z.; Dai, H.; Liu, S.; Zhou, M.; Lin, W.; Pang, I.; Zheng, L.; Shen, B.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Radiat Oncol, Duarte, CA 91010 USA; [Guo, Z.] Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, Nanjing, Jiangsu, Peoples R China; [Jia, P.; Chai, W.] Washington State Univ, Sch Mol Biosci, WWAMI Med Educ Program, Spokane, WA USA; [Liu, S.] Zhejiang Univ, Coll Life Sci, Hangzhou 310058, Zhejiang, Peoples R China; [Li, H.; Yuan, Y-C] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Med, Duarte, CA 91010 USA; [Huang, Q.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Pathol, Duarte, CA 91010 USA; [Lopes, J.; Nicolas, A.] CNRS, Inst Curie, Sect Rech Inst, Paris, France; [Lopes, J.] Museum Natl Hist Nat, INSERM U565, USM 503, UMR7196, F-75231 Paris, France; [Raz, D.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Surg, Duarte, CA 91010 USA; [Reckamp, K. L.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; Nanjing Normal University; Washington State University; Zhejiang University; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN); City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Reckamp, KL (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Med Oncol & Therapeut Res, 107 East Duarte Rd, Duarte, CA 91010 USA.	kreckamp@coh.org; bshen@coh.org	Li, Hongzhi/E-8530-2012; Brodie, Matthew A D/ABG-1640-2020; Chai, Weihang/AAG-5194-2021; Brodie, Matthew Andrew/HDN-0096-2022; Lopes, Judith/K-3788-2017; LIU, SONGBAI/AFL-6448-2022	Brodie, Matthew A D/0000-0002-5711-3458; Brodie, Matthew Andrew/0000-0002-5711-3458; Lopes, Judith/0000-0003-4907-6797; Shen, Binghui/0000-0002-4408-407X; liu, songbai/0000-0002-3920-1032; Reckamp, Karen/0000-0002-9213-0325	NIH [R01 CA073764]; Ligue Nationale contre le Cancer [EL2007/LNCC, EL2010/LNCC]; NATIONAL CANCER INSTITUTE [R29CA073764, R01CA073764, P30CA033572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM112864] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the City of Hope Pathology Core Facility for technical assistance with characterization of mouse cancer specimens (P30CA033572). We thank M Lee and B Armstrong in the City of Hope Microscopy Core Facility for assistance with characterization of chromosomal aberrations and D Stoppa-Lyonnet (Institut Curie) to provide the breast cancer patient DNA. This work was supported by NIH grant R01 CA073764 and Ligue Nationale contre le Cancer (EL2007/LNCC and EL2010/LNCC).	Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770; Ayyagari R, 2003, J BIOL CHEM, V278, P1618, DOI 10.1074/jbc.M209801200; Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bernstein DA, 2003, EMBO J, V22, P4910, DOI 10.1093/emboj/cdg500; Blackburn EH, 2006, NAT MED, V12, P1133, DOI 10.1038/nm1006-1133; Bochman ML, 2012, NAT REV GENET, V13, P770, DOI 10.1038/nrg3296; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Branzei D, 2010, NAT REV MOL CELL BIO, V11, P208, DOI 10.1038/nrm2852; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; de Lange T, 2011, COLD SPRING HARB SYM, V75, P167; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Gilson E, 2007, NAT REV MOL CELL BIO, V8, P825, DOI 10.1038/nrm2259; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Guo ZG, 2008, J MOL BIOL, V377, P679, DOI 10.1016/j.jmb.2007.10.074; Kitano K, 2010, STRUCTURE, V18, P177, DOI 10.1016/j.str.2009.12.011; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; Larsen E, 2003, MOL CELL BIOL, V23, P5346, DOI 10.1128/MCB.23.15.5346-5353.2003; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Liu R, 2006, NUCLEIC ACIDS RES, V34, P1772, DOI 10.1093/nar/gkl106; Lo AWI, 2002, NEOPLASIA, V4, P531, DOI 10.1038/sj.neo.7900267; Lopes J, 2006, MOL CELL BIOL, V26, P6675, DOI 10.1128/MCB.00649-06; Michel B, 2004, P NATL ACAD SCI USA, V101, P12783, DOI 10.1073/pnas.0401586101; Murnane JP, 2010, CANCER RES, V70, P4255, DOI 10.1158/0008-5472.CAN-09-4357; Nussenzweig A, 2010, CELL, V141, P27, DOI 10.1016/j.cell.2010.03.016; O'Sullivan RJ, 2010, NAT REV MOL CELL BIO, V11, P171, DOI 10.1038/nrm2848; Pierce BG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024657; Saharia A, 2008, CURR BIOL, V18, P496, DOI 10.1016/j.cub.2008.02.071; Saharia A, 2010, J BIOL CHEM, V285, P27057, DOI 10.1074/jbc.M110.112276; Sakurai S, 2005, EMBO J, V24, P683, DOI 10.1038/sj.emboj.7600519; Sampathi S, 2009, J BIOL CHEM, V284, P3682, DOI 10.1074/jbc.M805362200; Schvartzman JM, 2010, NAT REV CANCER, V10, P102, DOI 10.1038/nrc2781; Singh P, 2007, J BIOL CHEM, V282, P3465, DOI 10.1074/jbc.M606582200; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1; Sweasy JB, 2005, P NATL ACAD SCI USA, V102, P14350, DOI 10.1073/pnas.0505166102; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tsutakawa SE, 2011, CELL, V145, P198, DOI 10.1016/j.cell.2011.03.004; Wang YX, 2005, NAT GENET, V37, P750, DOI 10.1038/ng1587; Wu ZX, 2012, MUTAT RES-FUND MOL M, V731, P85, DOI 10.1016/j.mrfmmm.2011.11.009; Xu H, ONCOGENE, V30, P1072; Zheng L, 2005, EMBO REP, V6, P83, DOI 10.1038/sj.embor.7400313; Zheng L, 2007, NAT MED, V13, P812, DOI 10.1038/nm1599; Zheng L, 2007, MOL CELL BIOL, V27, P3176, DOI 10.1128/MCB.01652-06; Zheng L, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1825; Zheng L, 2011, CELL RES, V21, P1052, DOI 10.1038/cr.2011.35; Zheng L, 2011, NUCLEIC ACIDS RES, V39, P781, DOI 10.1093/nar/gkq884; Zheng L, 2011, J MOL CELL BIOL, V3, P23, DOI 10.1093/jmcb/mjq048	49	23	24	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					902	911		10.1038/onc.2014.19	http://dx.doi.org/10.1038/onc.2014.19			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	24608430	Green Accepted			2022-12-17	WOS:000349472000010
J	Kuhnemuth, B; Muhlberg, L; Schipper, M; Griesmann, H; Neesse, A; Milosevic, N; Wissniowski, T; Buchholz, M; Gress, TM; Michl, P				Kuehnemuth, B.; Muehlberg, L.; Schipper, M.; Griesmann, H.; Neesse, A.; Milosevic, N.; Wissniowski, T.; Buchholz, M.; Gress, T. M.; Michl, P.			CUX1 modulates polarization of tumor-associated macrophages by antagonizing NF-kappa B signaling	ONCOGENE			English	Article						CUX1; macrophage polarization; NF-kappa B; pancreatic cancer	GROWTH-FACTOR-BETA; TRANSCRIPTION FACTOR; PANCREATIC-CANCER; PROTEIN FUNCTION; MOUSE MODELS; GENE; ACTIVATION; DISTINCT; INFLAMMATION; EXPRESSION	Many solid cancers including pancreatic ductal adenocarcinoma (PDAC) are characterized by an extensive stromal reaction that is accompanied by infiltrating tumor-associated macrophages (TAMs). The role of TAMs in malignant tumors is only partially understood. Previously, we identified the transcription factor CUX1 as an important mediator of tumor progression in PDAC. Interestingly, we found that CUX1 is highly expressed not only in tumor cells but also in TAMs. On the basis of these data, we aimed to elucidate the effects of CUX1 in TAMs in vitro and in vivo. We analyzed the effects of CUX1 on cytokine expression using overexpression and knockdown strategies. The cytokine regulation by CUX1 was further assessed by reporter assays, DNA pulldown experiments and chromatin-immunoprecipitation. CUX1 expression in TAMs was analyzed in human pancreatic cancer tissues and in a genetic mouse model. Immunohistochemical analysis revealed strong expression levels of CUX1 in a distinct subset of TAMs in human PDAC tissues. Furthermore, its expression increased during tumor progression in a genetic mouse model of PDAC. Profiling experiments showed that CUX1 downregulates several NF-kappa B-regulated chemokines such as CXCL10, which have been associated with M1 polarization and inhibition of angiogenesis and tumor progression. We could demonstrate that CUX1 interacts with NF-kappa B p65, leading to reduced binding of NF-kappa B p65 to the chemokine promoters. In addition, CUX1 reduces acetylation of NF-kappa B p65 at K310 by recruiting HDAC1. Functionally, CUX1 expression in TAMs antagonizes T-cell attraction and enhances angiogenesis in vitro. We identified CUX1 as an important modulator of the TAMs phenotype and function by modulating NF-kappa B-dependent cytokines.	[Kuehnemuth, B.; Muehlberg, L.; Griesmann, H.; Neesse, A.; Milosevic, N.; Wissniowski, T.; Buchholz, M.; Gress, T. M.; Michl, P.] Univ Marburg, Univ Hosp, Dept Gastroenterol & Endocrinol, D-35043 Marburg, Germany; [Schipper, M.] Univ Marburg, Sch Med, Dept Biol, D-35043 Marburg, Germany	Philipps University Marburg; Philipps University Marburg	Michl, P (corresponding author), Univ Marburg, Dept Gastroenterol, Baldinger Str, D-35043 Marburg, Germany.	michlp@med.uni-marburg.de	Michl, Patrick/AAG-3987-2021; Michl, Patrick/HDN-4172-2022	Gress, Thomas/0000-0002-9333-5461	European Commisson FP7 (Collaborative Project 'EPC-TM-Net); Deutsche Forschungsgemeinschaft (DFG); LOEWE initiative of the state of Hessen; Behring-Roentgen Foundation; Deutsche Krebshilfe	European Commisson FP7 (Collaborative Project 'EPC-TM-Net); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); LOEWE initiative of the state of Hessen; Behring-Roentgen Foundation; Deutsche Krebshilfe(Deutsche Krebshilfe)	This work was supported in part by grants of the European Commisson FP7 grant (Collaborative Project 'EPC-TM-Net, to PM, AN and TMG), Deutsche Forschungsgemeinschaft (DFG) (to PM), the LOEWE initiative of the state of Hessen, the Behring-Roentgen Foundation (to PM), and the Deutsche Krebshilfe (to PM). This publication reflects only the authors' views. The European Community is not liable for any use that may be made of the information herein.	Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Baumgart S, 2012, GASTROENTEROLOGY, V142, P388, DOI 10.1053/j.gastro.2011.11.001; Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Beatty GL, 2011, SCIENCE, V331, P1612, DOI 10.1126/science.1198443; Benson DD, 2012, AM J PHYSIOL-REG I, V302, pR1067, DOI 10.1152/ajpregu.00320.2011; Biswas SK, 2006, BLOOD, V107, P2112, DOI 10.1182/blood-2005-01-0428; Biswas SK, 2008, J IMMUNOL, V180, P2011, DOI 10.4049/jimmunol.180.4.2011; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; BOGDAN C, 1992, J BIOL CHEM, V267, P23301; Cadieux C, 2009, CANCER RES, V69, P7188, DOI 10.1158/0008-5472.CAN-08-4899; Catt D, 1999, BLOOD, V94, P3151, DOI 10.1182/blood.V94.9.3151.421k38_3151_3160; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chen LF, 2003, J MOL MED, V81, P549, DOI 10.1007/s00109-003-0469-0; Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175; Clark CE, 2009, CANCER LETT, V279, P1, DOI 10.1016/j.canlet.2008.09.037; Darsigny M, 2010, INFLAMM BOWEL DIS, V16, P1739, DOI 10.1002/ibd.21274; De Vos J, 2002, ONCOGENE, V21, P6848, DOI 10.1038/sj.onc.1205868; Fragiadaki M, 2011, MOL BIOL CELL, V22, P1836, DOI 10.1091/mbc.E10-08-0669; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; HARADA R, 1994, J BIOL CHEM, V269, P2062; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Huang LY, 2009, J CLIN MICROBIOL, V47, P3427, DOI 10.1128/JCM.00373-09; Huth J, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-24; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kedinger V, 2009, J BIOL CHEM, V284, P27701, DOI 10.1074/jbc.M109.031849; Kleeff J, 2007, INT J CANCER, V121, P699, DOI 10.1002/ijc.22871; Kurahara H, 2011, J SURG RES, V167, pE211, DOI 10.1016/j.jss.2009.05.026; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; Li SD, 2000, P NATL ACAD SCI USA, V97, P7166, DOI 10.1073/pnas.130028697; Liu ML, 2011, ONCOL LETT, V2, P583, DOI 10.3892/ol.2011.300; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Mahadevan D, 2007, MOL CANCER THER, V6, P1186, DOI 10.1158/1535-7163.MCT-06-0686; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Menen RS, 2012, IN VIVO, V26, P565; Michl P, 2005, CANCER CELL, V7, P521, DOI 10.1016/j.ccr.2005.05.018; Mihaly Z, 2013, BREAST CANCER RES TR, V140, P219, DOI 10.1007/s10549-013-2622-y; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Neesse A, 2013, P NATL ACAD SCI USA, V110, P12325, DOI 10.1073/pnas.1300415110; Nepveu A, 2001, GENE, V270, P1, DOI 10.1016/S0378-1119(01)00485-1; Nirodi C, 2001, J BIOL CHEM, V276, P26122, DOI 10.1074/jbc.M102872200; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Ripka S, 2010, GUT, V59, P1101, DOI 10.1136/gut.2009.189720; Saccani A, 2006, CANCER RES, V66, P11432, DOI 10.1158/0008-5472.CAN-06-1867; Sansregret L, 2008, GENE, V412, P84, DOI 10.1016/j.gene.2008.01.017; Schmitz ML, 2004, CHEMBIOCHEM, V5, P1348, DOI 10.1002/cbic.200400144; Sharma M, 2009, GENE, V439, P87, DOI 10.1016/j.gene.2009.03.014; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Sica A, 2000, J IMMUNOL, V164, P762, DOI 10.4049/jimmunol.164.2.762; Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; Ueda Y, 2007, MELANOMA RES, V17, P91, DOI 10.1097/CMR.0b013e3280a60888; Werner F, 2000, J BIOL CHEM, V275, P36653, DOI 10.1074/jbc.M004536200; Yoshikawa K, 2012, CANCER SCI, V103, P2012, DOI 10.1111/j.1349-7006.2012.02411.x; Zhang WZ, 2002, AM J PHYSIOL-RENAL, V283, pF904, DOI 10.1152/ajprenal.00156.2002	60	23	24	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					177	187		10.1038/onc.2013.530	http://dx.doi.org/10.1038/onc.2013.530			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24336331				2022-12-17	WOS:000347790500005
J	Pham, DH; Powell, JA; Gliddon, BL; Moretti, PAB; Tsykin, A; Van der Hoek, M; Kenyon, R; Goodall, GJ; Pitson, SM				Pham, D. H.; Powell, J. A.; Gliddon, B. L.; Moretti, P. A. B.; Tsykin, A.; Van der Hoek, M.; Kenyon, R.; Goodall, G. J.; Pitson, S. M.			Enhanced expression of transferrin receptor 1 contributes to oncogenic signalling by sphingosine kinase 1	ONCOGENE			English	Article						expression profiling; DNA microarray; neoplastic transformation; sphingosine kinase; transferrin receptor	CANCER-CELLS; IN-VITRO; C-MYC; 1-PHOSPHATE; GROWTH; SPHINGOSINE-1-PHOSPHATE; ACTIVATION; CARCINOMA; APOPTOSIS; HEAT-SHOCK-PROTEIN-105	Sphingosine kinase 1 (SK1) is a lipid kinase that catalyses the formation of sphingosine-1-phosphate (S1P). Considerable evidence has implicated elevated cellular SK1 in tumour development, progression and disease severity. In particular, SK1 has been shown to enhance cell survival and proliferation and induce neoplastic transformation. Although S1P has been found to have both cellsurface G-protein-coupled receptors and intracellular targets, the specific downstream pathways mediating oncogenic signalling by SK1 remain poorly defined. Here, using a gene expression array approach, we have demonstrated a novel mechanism whereby SK1 regulates cell survival, proliferation and neoplastic transformation through enhancing expression of transferrin receptor 1 (TFR1). We showed that elevated levels of SK1 enhanced total as well as cell-surface TFR1 expression, resulting in increased transferrin uptake into cells. Notably, we also found that SK1 activation and localization to the plasma membrane, which are critical for its oncogenic effects, are necessary for regulation of TFR1 expression specifically through engagement of the S1P G-protein coupled receptor, S1P(2). Furthermore, we showed that blocking TFR1 function with a neutralizing antibody inhibits SK1-induced cell proliferation, survival and neoplastic transformation of NIH3T3 fibroblasts. Similar effects were observed following antagonism of S1P2. Together these findings suggest that TFR1 has an important role in SK1-mediated oncogenesis.	[Pham, D. H.; Powell, J. A.; Gliddon, B. L.; Moretti, P. A. B.; Tsykin, A.; Goodall, G. J.; Pitson, S. M.] SA Pathol, Ctr Canc Biol, Frome Rd, Adelaide, SA 5000, Australia; [Pham, D. H.; Tsykin, A.; Goodall, G. J.; Pitson, S. M.] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA, Australia; [Van der Hoek, M.; Kenyon, R.] SA Pathol, Adelaide Microarray Facil, Adelaide, SA, Australia; [Goodall, G. J.; Pitson, S. M.] Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia	Centre for Cancer Biology; SA Pathology; University of Adelaide; SA Pathology; University of South Australia	Pitson, SM (corresponding author), SA Pathol, Ctr Canc Biol, Frome Rd, Adelaide, SA 5000, Australia.	stuart.pitson@health.sa.gov.au	Pitson, Stuart/B-9342-2009; Pham, Duyen/V-6101-2019	Pitson, Stuart/0000-0002-9527-2740; Pham, Duyen/0000-0003-0664-4133; Powell, jason/0000-0001-8493-9178; Goodall, Gregory/0000-0003-1294-0692; Moretti, Paul/0000-0002-3523-1496; Tsykin, Anna/0000-0001-5965-6803; Gliddon, Briony/0000-0003-3928-7478	Fay Fuller Foundation; University of Adelaide Postgraduate Scholarship; National Health and Medical Research Council of Australia [626936];  [508098];  [1042589]	Fay Fuller Foundation; University of Adelaide Postgraduate Scholarship; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); ; 	This work was supported by the Fay Fuller Foundation, a University of Adelaide Postgraduate Scholarship (to DHP), Senior Research Fellowships (508098 and 1042589) and Project Grant (626936) from the National Health and Medical Research Council of Australia (to SMP). We thank Julia Zebol for technical assistance and Andrew Bert for assistance with Figure preparation.	Ader I, 2008, CANCER RES, V68, P8635, DOI 10.1158/0008-5472.CAN-08-0917; Ader I, 2009, CANCER RES, V69, P3723, DOI 10.1158/0008-5472.CAN-09-0389; Baran Y, 2007, J BIOL CHEM, V282, P10922, DOI 10.1074/jbc.M610157200; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bianchi L, 1999, NUCLEIC ACIDS RES, V27, P4223, DOI 10.1093/nar/27.21.4223; Callens C, 2008, LEUKEMIA, V22, P42, DOI 10.1038/sj.leu.2404958; Cattoretti G, 2009, CANCER RES, V69, P8686, DOI 10.1158/0008-5472.CAN-09-1110; Chan HS, 2013, BBA-MOL CELL BIOL L, V1831, P147, DOI 10.1016/j.bbalip.2012.07.005; Daniels TR, 2006, CLIN IMMUNOL, V121, P144, DOI 10.1016/j.clim.2006.06.010; Das Gupta A, 1990, Hematol Pathol, V4, P37; El-Shewy HM, 2006, J BIOL CHEM, V281, P31399, DOI 10.1074/jbc.M605339200; French KJ, 2003, CANCER RES, V63, P5962; Habashy HO, 2010, BREAST CANCER RES TR, V119, P283, DOI 10.1007/s10549-009-0345-x; HABESHAW JA, 1983, LANCET, V1, P498; Helpman L, 2009, AM J OBSTET GYNECOL, V201, DOI 10.1016/j.ajog.2009.05.013; Heringdorf DMZ, 2001, EUR J PHARMACOL, V414, P145, DOI 10.1016/S0014-2999(01)00789-0; Hosaka S, 2006, CANCER SCI, V97, P623, DOI 10.1111/j.1349-7006.2006.00217.x; Huang WJ, 2009, INT J CANCER, V124, P298, DOI 10.1002/ijc.23906; Jarman KE, 2010, J BIOL CHEM, V285, P483, DOI 10.1074/jbc.M109.068395; Jiang XP, 2010, ANTICANCER RES, V30, P759; Jose-Eneriz ES, 2008, BRIT J HAEMATOL, V142, P571, DOI 10.1111/j.1365-2141.2008.07221.x; Kawamori T, 2006, FASEB J, V20, P386, DOI 10.1096/fj.05-4331fje; Kawamori T, 2009, FASEB J, V23, P405, DOI 10.1096/fj.08-117572; Kohno M, 2006, MOL CELL BIOL, V26, P7211, DOI 10.1128/MCB.02341-05; Le Scolan E, 2005, BLOOD, V106, P1808, DOI 10.1182/blood-2004-12-4832; Li MH, 2009, J UROLOGY, V181, P1347, DOI 10.1016/j.juro.2008.10.140; Long JS, 2010, J BIOL CHEM, V285, P35957, DOI 10.1074/jbc.M110.117945; Loveridge C, 2010, J BIOL CHEM, V285, P38841, DOI 10.1074/jbc.M110.127993; Michaud MD, 2009, ARTERIOSCL THROM VAS, V29, P902, DOI 10.1161/ATVBAHA.109.185280; Muchemwa FC, 2006, BRIT J DERMATOL, V155, P582, DOI 10.1111/j.1365-2133.2006.07362.x; Muchemwa FC, 2008, MELANOMA RES, V18, P166, DOI 10.1097/CMR.0b013e3282fe9a16; O'Donnell KA, 2006, MOL CELL BIOL, V26, P2373, DOI 10.1128/MCB.26.6.2373-2386.2006; Okazaki F, 2010, CANCER RES, V70, P6238, DOI 10.1158/0008-5472.CAN-10-0184; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Pantopoulos K, 2004, ANN NY ACAD SCI, V1012, P1, DOI 10.1196/annals.1306.001; Park HS, 2009, J CUTAN PATHOL, V36, P511, DOI 10.1111/j.1600-0560.2008.01085.x; Pchejetski D, 2005, CANCER RES, V65, P11667, DOI 10.1158/0008-5472.CAN-05-2702; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Pham DH, 2008, BIOTECHNIQUES, V45, P155, DOI 10.2144/000112896; Pitman MR, 2010, CURR CANCER DRUG TAR, V10, P354, DOI 10.2174/156800910791208599; Pitman Melissa R, 2012, Methods Mol Biol, V874, P21, DOI 10.1007/978-1-61779-800-9_2; Pitman MR, 2011, INT J BIOCHEM CELL B, V43, P342, DOI 10.1016/j.biocel.2010.11.001; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; Pitson SM, 2000, BIOCHEM J, V350, P429, DOI 10.1042/0264-6021:3500429; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Pitson SM, 2011, ANTI-CANCER AGENT ME, V11, P799; Pitson SM, 2011, TRENDS BIOCHEM SCI, V36, P97, DOI 10.1016/j.tibs.2010.08.001; Ponnusamy S, 2012, EMBO MOL MED, V4, P761, DOI 10.1002/emmm.201200244; PRIOR R, 1990, VIRCHOWS ARCH A, V416, P491, DOI 10.1007/BF01600299; Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875; Ryschich E, 2004, EUR J CANCER, V40, P1418, DOI 10.1016/j.ejca.2004.01.036; Salas A, 2011, BLOOD, V117, P5941, DOI 10.1182/blood-2010-08-300772; Salomone S, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00009; Schwock J, 2008, CANCER CHEMOTH PHARM, V61, P669, DOI 10.1007/s00280-007-0522-8; Shen X, 2008, INT IMMUNOPHARMACOL, V8, P1813, DOI 10.1016/j.intimp.2008.08.022; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Strub GM, 2010, ADV EXP MED BIOL, V688, P141; Sun J, 2010, CANCER BIOTHER RADIO, V25, P155, DOI 10.1089/cbr.2009.0664; Takeshita A, 2000, J BIOL CHEM, V275, P32220, DOI 10.1074/jbc.M002569200; Takuwa N, 2011, AM J CANCER RES, V1, P460; Tran PLCHB, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-276; TROWBRIDGE IS, 1982, P NATL ACAD SCI-BIOL, V79, P1175, DOI 10.1073/pnas.79.4.1175; TROWBRIDGE IS, 1986, BIOCHEM SOC SYMP, P117; van Dam EM, 2002, J BIOL CHEM, V277, P48876, DOI 10.1074/jbc.M206271200; Wirth GJ, 2006, ONCOLOGY-BASEL, V71, P86, DOI 10.1159/000100476; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Yang Y H, 2001, Brief Bioinform, V2, P341, DOI 10.1093/bib/2.4.341; Young JC, 2003, TRENDS BIOCHEM SCI, V28, P541, DOI 10.1016/j.tibs.2003.08.009; Zhou HJ, 2008, ANTI-CANCER DRUG, V19, P247, DOI 10.1097/CAD.0b013e3282f3f152	72	23	23	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2014	33	48					5559	5568		10.1038/onc.2013.502	http://dx.doi.org/10.1038/onc.2013.502			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZO	24276247				2022-12-17	WOS:000346087900008
J	Bhattacharyya, S; Feferman, L; Tobacman, JK				Bhattacharyya, S.; Feferman, L.; Tobacman, J. K.			Arylsulfatase B regulates versican expression by galectin-3 and AP-1 mediated transcriptional effects	ONCOGENE			English	Article						chondroitin sulfate; arylsulfatase B; galectin-3; versican; glycosaminoglycan	FORMYLGLYCINE-GENERATING ENZYME; GROWTH-FACTOR RECEPTOR; STAGE PROSTATE-CANCER; EPITHELIAL-CELLS; BINDING SITE; IN-VITRO; ACTIVATION; N-ACETYLGALACTOSAMINE-4-SULFATASE; OVEREXPRESSION; PROGRESSION	Arylsulfatase B (N-acetylgalactosamine-4-sulfatase; ARSB) removes 4-sulfate groups from chondroitin-4-sulfate (C4S) and dermatan sulfate and is required for their degradation. In human prostate stromal and epithelial cells, when ARSB was silenced, C4S, versican and versican promoter activity increased, and the galectin-3 that co-immunoprecipitated with C4S declined. Galectin-3 silencing inhibited the ARSB-silencing-induced increases in versican and versican promoter due to effects on the AP-1-binding site in the versican promoter. These findings demonstrate for the first time the transcriptional mechanism whereby ARSB can regulate expression of an extracellular matrix proteoglycan with C4S attachments. In addition, following ARSB silencing, C4S that co-immunoprecipitated with versican increased, whereas co-immunoprecipitated EGFR declined, total EGFR increased and exogenous EGF-induced cell proliferation increased, suggesting profound effects of ARSB on vital cell processes.	[Bhattacharyya, S.; Feferman, L.; Tobacman, J. K.] Univ Illinois, Dept Med, Chicago, IL 60612 USA; [Bhattacharyya, S.; Feferman, L.; Tobacman, J. K.] Jesse Brown VA Med Ctr, Chicago, IL USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Tobacman, JK (corresponding author), Univ Illinois, Dept Med, 840 South Wood St,CSN 440 M-C 718, Chicago, IL 60612 USA.	jkt@uic.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR029879] Funding Source: NIH RePORTER; NCRR NIH HHS [UL1 RR029879] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bhattacharyya S, 2008, J BIOL CHEM, V283, P9523, DOI 10.1074/jbc.M707967200; Bhattacharyya S, 2008, J NUTR, V138, P469, DOI 10.1093/jn/138.3.469; Bhattacharyya S, 2007, CLIN CHIM ACTA, V380, P122, DOI 10.1016/j.cca.2007.01.021; Bhattacharyya S, 2007, J STEROID BIOCHEM, V103, P20, DOI 10.1016/j.jsbmb.2006.08.002; Bhattacharyya S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033250; Bhattacharyya S, 2010, BBA-MOL BASIS DIS, V1802, P472, DOI 10.1016/j.bbadis.2010.01.014; Bhattacharyya S, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-303; Bhattacharyya S, 2010, AM J RESP CELL MOL, V42, P51, DOI 10.1165/rcmb.2008-0482OC; Bhattacharyya S, 2009, CLIN EXP METASTAS, V26, P535, DOI 10.1007/s10585-009-9253-z; Christianson TM, 2004, BIOCHEM J, V382, P581, DOI 10.1042/BJ20040447; Domenzain-Reyna C, 2009, J BIOL CHEM, V284, P12306, DOI 10.1074/jbc.M807108200; Du WW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013828; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; Feferman L, 2013, PROSTATE CANCER P D, V16, P277, DOI 10.1038/pcan.2013.18; Ferrero GB, 2008, MOL GENET METAB, V94, P139, DOI 10.1016/j.ymgme.2007.10.010; Hann A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020859; Harmatz P, 2004, J PEDIATR-US, V144, P574, DOI 10.1016/j.jpeds.2004.03.018; Holzberg D, 2003, J BIOL CHEM, V278, P40213, DOI 10.1074/jbc.M304058200; Iwaki J, 2008, BIOCHEM BIOPH RES CO, V373, P206, DOI 10.1016/j.bbrc.2008.05.190; Kischel P, 2010, INT J CANCER, V126, P640, DOI 10.1002/ijc.24812; Kotlo K, 2013, GLYCOCONJUGATE J, V30, P667, DOI 10.1007/s10719-013-9468-8; Mitsunaga-Nakatsubo K, 2009, MED MOL MORPHOL, V42, P63, DOI 10.1007/s00795-009-0447-x; Prabhu SV, 2011, J HISTOCHEM CYTOCHEM, V59, P328, DOI 10.1369/0022155410395511; Rao GJ, 1994, BIOCHIM BIOPHYS ACTA, V788, P58; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; Ricciardelli C, 1997, CLIN CANCER RES, V3, P983; Ricciardelli C, 1998, CLIN CANCER RES, V4, P963; Ricciardelli C, 2009, CANCER METAST REV, V28, P233, DOI 10.1007/s10555-009-9182-y; Roeser D, 2006, P NATL ACAD SCI USA, V103, P81, DOI 10.1073/pnas.0507592102; Roeser D, 2007, ACTA CRYSTALLOGR D, V63, P621, DOI 10.1107/S0907444907009961; Sakko AJ, 2003, CANCER RES, V63, P4786; Sharma G, 2013, PEDIATR PULM, V48, P236, DOI 10.1002/ppul.22567; Song SM, 2005, GASTROENTEROLOGY, V129, P1581, DOI 10.1053/j.gastro.2005.09.002; Wang H, 2008, J CELL SCI, V121, P3083, DOI 10.1242/jcs.032649; WANG L, 1995, BIOCHEM BIOPH RES CO, V217, P292, DOI 10.1006/bbrc.1995.2777; Wang Y, 2009, AM J PATHOL, V174, P1515, DOI 10.2353/ajpath.2009.080816; WOJCZYK B, 1986, BIOL CELL, V57, P147, DOI 10.1111/j.1768-322X.1986.tb00471.x; Wu YJ, 2004, J CELL SCI, V117, P2227, DOI 10.1242/jcs.01057; Xiang YY, 2006, J BIOL CHEM, V281, P19358, DOI 10.1074/jbc.M512980200; Yoo BC, 2009, CELL MOL LIFE SCI, V66, P350, DOI 10.1007/s00018-009-8562-3; Yoo M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057415	41	23	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2014	33	47					5467	5476		10.1038/onc.2013.483	http://dx.doi.org/10.1038/onc.2013.483			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MG	24240681	Green Accepted			2022-12-17	WOS:000345120700009
J	Fogarty, FM; O'Keeffe, J; Zhadanov, A; Papkovsky, D; Ayllon, V; O'Connor, R				Fogarty, F. M.; O'Keeffe, J.; Zhadanov, A.; Papkovsky, D.; Ayllon, V.; O'Connor, R.			HRG-1 enhances cancer cell invasive potential and couples glucose metabolism to cytosolic/extracellular pH gradient regulation by the vacuolar-H+ ATPase	ONCOGENE			English	Article						V-ATPase; HRG-1; glucose metabolism; pH; IGF-1	PROTON PUMPS; PHOSPHATIDYLINOSITOL 3-KINASE; PLASMA-MEMBRANE; CYTOSOLIC PH; A3 ISOFORM; V-ATPASES; SUBUNIT; TRANSLOCATION; EXPRESSION; TRANSPORTERS	Haeme-responsive gene (HRG)-1 encodes a 16-kDa transmembrane protein that is induced by insulin-like growth factor-1 (IGF-1) and associates with the vacuolar-(H+) ATPase (V-ATPase). We previously reported that HRG-1 is essential for V-ATPase activity in endosomal acidification and receptor trafficking. Here, we show that in highly invasive and migratory cancer cell lines, HRG-1 and the V-ATPase are co-expressed at the plasma membrane, whereas in less invasive cell lines and non-transformed cells HRG-1 overexpression remains confined to intracellular compartments. Stable suppression of HRG-1 in invasive breast cancer MDA-MB-231 cells decreases extracellular pH, cell growth, migration and invasion. Ectopic expression of HRG-1 in non-invasive MCF-7 cells enhances V-ATPase activity, lowers the extracellular pH and increases the pH-dependent activity of MMP2 and MMP9 matrix metalloproteinases. HRG-1 enhances trafficking of the glucose transporter-1 (GLUT-1) with a concomitant increase in glucose uptake and lactate production. HRG-1 also promotes trafficking of the insulin-like growth factor I receptor (IGF-1R), beta 1-integrin and IGF-1 signalling. Taken together, our findings indicate that HRG-1 expression at the plasma membrane enhances V-ATPase activity, drives glycolytic flux and facilitates cancer cell growth, migration and invasion. Thus, HRG-1 may represent a novel target for selectively disrupting V-ATPase activity and the metastatic potential of cancer cells.	[Fogarty, F. M.; O'Keeffe, J.; Ayllon, V.; O'Connor, R.] Natl Univ Ireland Univ Coll Cork, BioSci Inst, Cell Biol Lab, Cork, Ireland; [Zhadanov, A.; Papkovsky, D.] Natl Univ Ireland Univ Coll Cork, BioSci Inst, Dept Biochem, Lab Biophys & Bioanal, Cork, Ireland	University College Cork; University College Cork	O'Connor, R (corresponding author), Natl Univ Ireland Univ Coll Cork, BioSci Inst, Dept Biochem, Lab Biophys & Bioanal, Coll Rd, Cork, Ireland.	r.oconnor@ucc.ie	O'Connor, Rosemary/B-7902-2014; Ayllon, Veronica/L-7069-2014	O'Connor, Rosemary/0000-0002-0687-3422; Ayllon, Veronica/0000-0002-7322-9282; Papkovsky, Dmitri/0000-0003-1556-1145	Health Research Board (PhD Scholars Programme in Cancer Biology(FF)); Science Foundation Ireland (PI) [06/INI/B107]	Health Research Board (PhD Scholars Programme in Cancer Biology(FF)); Science Foundation Ireland (PI)(Science Foundation Ireland)	We are grateful to our colleagues in the Cell Biology Laboratory and Dr Kellie Dean for helpful discussions, and to Kurt Tidmore for preparing illustrations. This work was supported by the Health Research Board (PhD Scholars Programme in Cancer Biology (FF)) and Science Foundation Ireland (PI Award: 06/INI/B107).	Balgi AD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021549; Beyenbach KW, 2006, J EXP BIOL, V209, P577, DOI 10.1242/jeb.02014; Cardone RA, 2005, NAT REV CANCER, V5, P786, DOI 10.1038/nrc1713; Chiche J, 2012, INT J CANCER, V130, P1511, DOI 10.1002/ijc.26125; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; Dechant R, 2010, EMBO J, V29, P2515, DOI 10.1038/emboj.2010.138; Forgac M, 2007, NAT REV MOL CELL BIO, V8, P917, DOI 10.1038/nrm2272; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hernandez A, 2012, CURR PHARM DESIGN, V18, P1383, DOI 10.2174/138161212799504821; Hinton A, 2009, J BIOL CHEM, V284, P16400, DOI 10.1074/jbc.M901201200; Kubota S, 2000, BIOCHEM BIOPH RES CO, V278, P390, DOI 10.1006/bbrc.2000.3802; Lu M, 2004, J BIOL CHEM, V279, P8732, DOI 10.1074/jbc.M303871200; Lu X, 2005, CANCER RES, V65, P6843; Martinez-Munoz GA, 2008, J BIOL CHEM, V283, P20309, DOI 10.1074/jbc.M710470200; Martinez-Zaguilan R, 1999, BIOCHEM PHARMACOL, V57, P1037, DOI 10.1016/S0006-2952(99)00022-2; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; Murakami T, 2001, INT J CANCER, V93, P869, DOI 10.1002/ijc.1418; Nilsson Cathrine, 2003, Methods Cell Sci, V25, P185; Nishisho T, 2011, MOL CANCER RES, V9, P845, DOI 10.1158/1541-7786.MCR-10-0449; O'Callaghan KM, 2010, J BIOL CHEM, V285, P381, DOI 10.1074/jbc.M109.063248; Ohta T, 1998, J PATHOL, V185, P324, DOI 10.1002/(SICI)1096-9896(199807)185:3<324::AID-PATH72>3.0.CO;2-9; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; Pastor-Soler N, 2005, PHYSIOLOGY, V20, P417, DOI 10.1152/physiol.00036.2005; Perez-Sayans M, 2012, BRAZ J BIOL, V72, P189, DOI 10.1590/S1519-69842012000100023; Perez-Sayans M, 2009, CANCER TREAT REV, V35, P707, DOI 10.1016/j.ctrv.2009.08.003; Samih N, 2000, ENDOCRINOLOGY, V141, P4146, DOI 10.1210/en.141.11.4146; Sautin YY, 2005, MOL CELL BIOL, V25, P575, DOI 10.1128/MCB.25.2.575-589.2005; Sennoune SR, 2012, CURR PROTEIN PEPT SC, V13, P152; Sennoune SR, 2004, AM J PHYSIOL-CELL PH, V286, pC1443, DOI 10.1152/ajpcell.00407.2003; Spugnini EP, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-44; Su Y, 2003, J BIOL CHEM, V278, P20013, DOI 10.1074/jbc.M210077200; Swietach P, 2010, ONCOGENE, V29, P6509, DOI 10.1038/onc.2010.455; Thomsen P, 1999, BBA-MOL CELL RES, V1452, P285, DOI 10.1016/S0167-4889(99)00132-9; Toei M, 2010, BIOCHEMISTRY-US, V49, P4715, DOI 10.1021/bi100397s; Toyomura T, 2003, J BIOL CHEM, V278, P22023, DOI 10.1074/jbc.M302436200; Wagner CA, 2004, PHYSIOL REV, V84, P1263, DOI 10.1152/physrev.00045.2003; Webb BA, 2011, NAT REV CANCER, V11, P671, DOI 10.1038/nrc3110; Yanatori I, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-39; Zhdanov AV, 2013, BBA-GEN SUBJECTS, V1830, P3553, DOI 10.1016/j.bbagen.2013.02.016	39	23	25	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2014	33	38					4653	4663		10.1038/onc.2013.403	http://dx.doi.org/10.1038/onc.2013.403			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3VX	24141772				2022-12-17	WOS:000342007200004
J	Niedan, S; Kauer, M; Aryee, DNT; Kofler, R; Schwentner, R; Meier, A; Potschger, U; Kontny, U; Kovar, H				Niedan, S.; Kauer, M.; Aryee, D. N. T.; Kofler, R.; Schwentner, R.; Meier, A.; Poetschger, U.; Kontny, U.; Kovar, H.			Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma	ONCOGENE			English	Article						CDK2; Ewing sarcoma; EWS-FLI1; FOXO1	CELL-CYCLE ARREST; METHYLSELENINIC ACID; GENE-EXPRESSION; TUMOR-CELLS; IN-VITRO; CANCER; EWS/FLI-1; TRANSFORMATION; INHIBITION; PATHWAYS	The Ewing sarcoma (ES) EWS-FLI1 chimeric oncoprotein is a prototypic aberrant ETS transcription factor with activating and repressive regulatory functions. We report that EWS-FLI1-repressed promoters are enriched in forkhead box ( FOX) recognition motifs, and identify FOXO1 as a EWS-FLI1-suppressed regulator orchestrating a major subset of EWS-FLI1-repressed genes. In addition to FOXO1 regulation by direct promoter binding of EWS-FLI1, its subcellular localization and activity is regulated by cyclin-dependent kinase 2- and AKT-mediated phosphorylation downstream of EWS-FLI1. Restoration of nuclear FOXO1 expression in ES cells impaired proliferation and significantly reduced clonogenicity. Gene-expression profiling revealed a significant overlap between EWS-FLI1-repressed and FOXO1-activated genes. As a proof of principle for a potential therapeutic application of our findings, the treatment of ES cell lines with methylseleninic acid (MSA) reactivated endogenous FOXO1 in the presence of EWS-FLI1 in a dose- and time-dependent manner and induced massive cell death dependent on FOXO1. In an orthotopic xenograft mouse model, MSA increased FOXO1 expression in the tumor paralleled by a significant decrease in ES tumor growth. FOXO1 reactivation by small molecules may therefore serve as a promising strategy for a future ES-specific therapy.	[Niedan, S.; Kauer, M.; Aryee, D. N. T.; Schwentner, R.; Poetschger, U.; Kovar, H.] St Anna Kinderkrebsforschung, Childrens Canc Res Inst, A-1090 Vienna, Austria; [Aryee, D. N. T.; Kovar, H.] Med Univ, Dept Pediat, Vienna, Austria; [Kofler, R.] Med Univ Innsbruck, Div Mol Pathophysiol Bioctr, Innsbruck, Austria; [Meier, A.; Kontny, U.] Univ Med Ctr, Dept Pediat & Adolescent Med, Div Pediat Hematol Oncol, Freiburg, Germany	Saint Anna Children's Hospital; Medical University of Innsbruck; University of Freiburg	Kovar, H (corresponding author), St Anna Kinderkrebsforschung, Childrens Canc Res Inst, Zimmermannplatz 10, A-1090 Vienna, Austria.	heinrich.kovar@ccri.at		Schwentner, Raphaela/0000-0001-6839-0322; Kovar, Heinrich/0000-0001-6873-9109; Potschger, Ulrike/0000-0001-7024-7082	Austrian Science Fund (FWF) [22328-B09]; 7th framework program of the European Commission [259348]; Austrian Academy of Sciences; Austrian Science Fund (FWF) [P 22328] Funding Source: researchfish	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); 7th framework program of the European Commission(European Commission); Austrian Academy of Sciences; Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	We thank Lukas Kenner for processing tumor sections and hematoxylin and eosin stainings. This study was supported in part by the Austrian Science Fund (FWF), grant 22328-B09, and by the 7th framework program of the European Commission, grant 259348 ('ASSET'). Raphaela Schwentner is a recipient of a DOC-fFORTE fellowship of the Austrian Academy of Sciences.	Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Aryee DNT, 2010, CANCER RES, V70, P4015, DOI 10.1158/0008-5472.CAN-09-4333; Bernstein M, 2006, ONCOLOGIST, V11, P503, DOI 10.1634/theoncologist.11-5-503; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Dong Y, 2003, CANCER RES, V63, P52; Duffield-Lillico AJ, 2003, JNCI-J NATL CANCER I, V95, P1477, DOI 10.1093/jnci/djg061; France KA, 2011, J BIOL CHEM, V286, P22750, DOI 10.1074/jbc.M111.225433; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gonzalez-Moreno O, 2007, INT J CANCER, V121, P1197, DOI 10.1002/ijc.22764; Hancock JD, 2008, CELL CYCLE, V7, P250, DOI 10.4161/cc.7.2.5229; Hotfilder M, 2005, BRIT J CANCER, V92, P705, DOI 10.1038/sj.bjc.6602384; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Huang HJ, 2006, SCIENCE, V314, P294, DOI 10.1126/science.1130512; Kauer M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005415; Kelland LR, 2004, EUR J CANCER, V40, P827, DOI 10.1016/j.ejca.2003.11.028; Kinsey M, 2009, CANCER RES, V69, P9047, DOI 10.1158/0008-5472.CAN-09-1540; Kovar H, 2005, SEMIN CANCER BIOL, V15, P189, DOI 10.1016/j.semcancer.2005.01.004; KOVAR H, 1993, ONCOGENE, V8, P2683; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; KOZIOL JA, 1981, BIOMETRICS, V37, P383, DOI 10.2307/2530427; Li QX, 2008, CELL DEATH DIFFER, V15, P1197, DOI 10.1038/cdd.2008.48; Maiese K, 2009, MED RES REV, V29, P395, DOI 10.1002/med.20139; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Owen LA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001965; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pW249, DOI 10.1093/nar/gkh372; Sankar S, 2013, ONCOGENE, V32, P5089, DOI 10.1038/onc.2012.525; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Siligan C, 2005, ONCOGENE, V24, P2512, DOI 10.1038/sj.onc.1208455; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Teixeira CC, 2010, J BIOL CHEM, V285, P31055, DOI 10.1074/jbc.M109.079962; Tirado OM, 2006, CANCER RES, V66, P9937, DOI 10.1158/0008-5472.CAN-06-0927; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; Toretsky JA, 1999, CANCER RES, V59, P5745; Uren Aykut, 2005, Future Oncol, V1, P521, DOI 10.2217/14796694.1.4.521; Weidinger C, 2008, ENDOCR-RELAT CANCER, V15, P917, DOI 10.1677/ERC-08-0153; Wettenhall JM, 2004, BIOINFORMATICS, V20, P3705, DOI 10.1093/bioinformatics/bth449; Winter GE, 2011, MOL CANCER THER, V10, P1846, DOI 10.1158/1535-7163.MCT-11-0100; Wu Y, 2005, CANCER RES, V65, P9073, DOI 10.1158/0008-5472.CAN-05-2016; Yang L, 2010, BIOCHEM BIOPH RES CO, V402, P129, DOI 10.1016/j.bbrc.2010.09.129; Zhang Haitao, 2005, Cancer Genomics & Proteomics, V2, P97; Zhu ZJ, 2002, CANCER RES, V62, P156	50	23	26	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					3927	3938		10.1038/onc.2013.361	http://dx.doi.org/10.1038/onc.2013.361			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	23995784	Green Published, hybrid			2022-12-17	WOS:000339394700005
J	Bjerke, GA; Yang, CS; Frierson, HF; Paschal, BM; Wotton, D				Bjerke, G. A.; Yang, C-S; Frierson, H. F.; Paschal, B. M.; Wotton, D.			Activation of Akt signaling in prostate induces a TGF beta-mediated restraint on cancer progression and metastasis	ONCOGENE			English	Article						TGF beta; Akt; Pten; prostate cancer; signaling	TUMOR-SUPPRESSOR GENE; INTRAEPITHELIAL NEOPLASIA; CELL-PROLIFERATION; II RECEPTORS; PTEN; GROWTH; MOUSE; INACTIVATION; PTEN/MMAC1; EXPRESSION	Mutations in the PTEN tumor suppressor gene are found in a high proportion of human prostate cancers, and in mice, Pten deletion induces high-grade prostate intraepithelial neoplasia (HGPIN). However, progression from HGPIN to invasive cancer occurs slowly, suggesting that tumorigenesis is subject to restraint. We show that Pten deletion, or constitutive activation of the downstream kinase AKT, activates the transforming growth factor (TGF)beta pathway in prostate epithelial cells. TGF beta signaling is known to have a tumor suppressive role in many cancer types, and reduced expression of TGF beta receptors correlates with advanced human prostate cancer. We demonstrate that in combination either with loss of Pten or expression of constitutively active AKT1, inactivation of TGF beta signaling by deletion of the TGF beta type II receptor gene relieves a restraint on tumorigenesis. This results in rapid progession to lethal prostate cancer, including metastasis to lymph node and lung. In prostate epithelium, inactivation of TGF beta signaling alone is insufficient to initiate tumorigenesis, but greatly accelerates cancer progression. The activation of TGF beta signaling by Pten loss or AKT activation suggests that the same signaling events that have key roles in tumor initiation also induce the activity of a pathway that restrains disease progression.	[Bjerke, G. A.; Yang, C-S; Paschal, B. M.; Wotton, D.] Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; [Bjerke, G. A.; Yang, C-S; Paschal, B. M.; Wotton, D.] Univ Virginia, Ctr Cell Signaling, Charlottesville, VA 22908 USA; [Frierson, H. F.] Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Wotton, D (corresponding author), Univ Virginia, Dept Biochem & Mol Genet, Ctr Cell Signaling, Box 800577, Charlottesville, VA 22908 USA.	dw2p@virginia.edu		Wotton, David/0000-0002-4652-5350	National Cancer Institute [2P01CA104106]; UVA Cancer Center; James and Rebecca Craig Foundation [CCSG P30 CA44579]; UVA Women's Oncology fund; NATIONAL CANCER INSTITUTE [P01CA104106, P30CA044579] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); UVA Cancer Center; James and Rebecca Craig Foundation; UVA Women's Oncology fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Sharon Birdsall and Marya Brown for technical assistance, Doug DeSimone for use of the Zeiss microscope, Anindya Dutta and Dan Gioeli for helpful discussions and Tiffany Melhuish for expert advice and assistance. This work was supported by a Program Project Grant from the National Cancer Institute (2P01CA104106 to B Paschal and D Wotton), and by a pilot grant from the UVA Cancer Center (funded from the CCSG P30 CA44579, the James and Rebecca Craig Foundation, and UVA Women's Oncology fund) to D Wotton.	Aitchison AA, 2008, PROSTATE, V68, P661, DOI 10.1002/pros.20730; Bartholin L, 2008, DEV BIOL, V319, P285, DOI 10.1016/j.ydbio.2008.04.027; Bayascas JR, 2005, CURR BIOL, V15, P1839, DOI 10.1016/j.cub.2005.08.066; Cairns P, 1997, CANCER RES, V57, P4997; Chen ML, 2006, GENE DEV, V20, P1569, DOI 10.1101/gad.1395006; Chytil A, 2002, GENESIS, V32, P73, DOI 10.1002/gene.10046; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Ding ZH, 2012, CELL, V148, P896, DOI 10.1016/j.cell.2012.01.039; Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677; Galgano MT, 2009, HUM PATHOL, V40, P1434, DOI 10.1016/j.humpath.2009.02.008; Guo YP, 1997, INT J CANCER, V71, P573, DOI 10.1002/(SICI)1097-0215(19970516)71:4<573::AID-IJC11>3.3.CO;2-1; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Kim IY, 1996, CLIN CANCER RES, V2, P1255; Kim J, 2012, ONCOGENE, V31, P322, DOI 10.1038/onc.2011.236; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; Ma XQ, 2005, CANCER RES, V65, P5730, DOI 10.1158/0008-5472.CAN-04-4519; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Majumder PK, 2008, CANCER CELL, V14, P146, DOI 10.1016/j.ccr.2008.06.002; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Powers SE, 2010, DEVELOPMENT, V137, P249, DOI 10.1242/dev.040782; Sorrentino A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Suzuki H, 1998, CANCER RES, V58, P204; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Truett GE, 2000, BIOTECHNIQUES, V29, P52, DOI 10.2144/00291bm09; Wang SI, 1998, CLIN CANCER RES, V4, P811; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Williams RH, 1996, CLIN CANCER RES, V2, P635; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Yamada KM, 2001, J CELL SCI, V114, P2375; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhao H, 2005, CANCER-AM CANCER SOC, V104, P44, DOI 10.1002/cncr.21135	42	23	23	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3660	3667		10.1038/onc.2013.342	http://dx.doi.org/10.1038/onc.2013.342			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	23995785	Green Accepted			2022-12-17	WOS:000338942900005
J	Jiang, CC; Croft, A; Tseng, HY; Guo, ST; Jin, L; Hersey, P; Zhang, XD				Jiang, C. C.; Croft, A.; Tseng, H-Y; Guo, S. T.; Jin, L.; Hersey, P.; Zhang, X. D.			Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma	ONCOGENE			English	Article						miR-768-3p; eIF4E; mRNA translation; melanoma; RAF/MEK/ERK	CAP-BINDING PROTEIN; INCREASED EXPRESSION; CYCLIN D1; INITIATION; EIF4E; EIF-4E; CELLS; TRANSFORMATION; INHIBITION; DEREGULATION	Increased global protein synthesis and selective translation of mRNAs encoding proteins contributing to malignancy is common in cancer cells. This is often associated with elevated expression of eukaryotic translation initiation factor 4 (eIF4E), the rate-limiting factor of cap-dependent translation initiation. We report here that in human melanoma downregulation of miR-768-3p as a result of activation of the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway has an important role in the upregulation of eIF4E and enhancement in protein synthesis. Melanoma cells displayed increased nascent protein production and elevated eIF4E expression, which was associated with the downregulation of miR-768-3p that was predicted to target the 30-untranslated region of the eIF4E mRNA. Overexpression of miR-768-3p led to the downregulation of the endogenous eIF4E protein, reduction in nascent protein synthesis and inhibition of cell survival and proliferation. These effects were efficiently reversed when eIF4E was co-overexpressed in melanoma cells. On the other hand, introduction of anti-miR-768-3p into melanocytes upregulated endogenous eIF4E protein expression and increased global protein synthesis. Downregulation of miR-768-3p appeared to be mediated by activation of the MEK/ERK pathway, in that treatment of BRAFV600E melanoma cells with the mutant BRAF inhibitor PLX4720 or exposure of either BRAFV600E or wild-type BRAF melanoma cells to the MEK inhibitor U0126 resulted in the upregulation of miR-768-3p and inhibition of nascent protein synthesis. This inhibition was partially blocked in cells cointroduced with anti-miR-768-3p. Significantly, miR-768-3p was similarly downregulated, which was inversely associated with the expression levels of eIF4E in fresh melanoma isolates. Taken together, these results identify downregulation of miR-768-3p and subsequent upregulation of eIF4E as an important mechanism in addition to phosphorylation of eIF4E responsible for MEK/ERK-mediated enhancement of protein synthesis in melanoma.	[Jiang, C. C.; Croft, A.; Tseng, H-Y; Zhang, X. D.] Univ Newcastle, Prior Res Ctr Canc Res, Callaghan, NSW 2308, Australia; [Jiang, C. C.; Tseng, H-Y; Zhang, X. D.] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia; [Croft, A.] Calvary Mater Newcastle Hosp, Oncol & Immunol Unit, Waratah, NSW, Australia; [Guo, S. T.; Zhang, X. D.] Shanxi Canc Hosp & Inst, Dept Mol Biol, Taiyuan, Shanxi, Peoples R China; [Jin, L.; Hersey, P.] Univ Sydney, Kolling Inst Med Res, St Leonards, NSW, Australia	University of Newcastle; University of Newcastle; Calvary Mater Newcastle Hospital; University of Sydney; Kolling Institute of Medical Research	Zhang, XD (corresponding author), Univ Newcastle, Sch Med & Publ Hlth, Prior Res Ctr Canc Res, LS3-49,Life Sci Bldg, Callaghan, NSW 2308, Australia.	Xu.Zhang@newcastle.edu.au	Tseng, Cindy Hsin-Yi/AAB-8958-2022; Jin, Lei/K-2315-2019; zhang, xu/GYE-3558-2022; zhang, xian/GYA-0290-2022; Zhang, xiaoyu/GXA-3206-2022; zhang, xu/GRX-9733-2022; Jin, Lei/J-1896-2019	Tseng, Cindy Hsin-Yi/0000-0002-7499-7515; Jin, Lei/0000-0001-7187-9671; Zhang, Xu Dong/0000-0001-9457-8003	NSW State Cancer Council, Cancer Institute NSW; National Health and Medical Research Council (NHMRC), Australia; NHMRC	NSW State Cancer Council, Cancer Institute NSW(Cancer Council New South Wales); National Health and Medical Research Council (NHMRC), Australia(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by the NSW State Cancer Council, Cancer Institute NSW, and National Health and Medical Research Council (NHMRC), Australia. CCJ is a recipient of postdoctoral training Fellowship of NHMRC. XDZ is supported by a senior research fellowship of NHMRC.	Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Bemis LT, 2008, CANCER RES, V68, P1362, DOI 10.1158/0008-5472.CAN-07-2912; Bilanges B, 2007, ONCOGENE, V26, P5973, DOI 10.1038/sj.onc.1210431; Bitterman PB, 2012, CELL CYCLE, V11, P1097, DOI 10.4161/cc.11.6.19610; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Bonazzi VF, 2012, MELANOMA RES, V22, P101, DOI 10.1097/CMR.0b013e32834f6fbb; Caramuta S, 2010, J INVEST DERMATOL, V130, P2062, DOI 10.1038/jid.2010.63; Coleman LJ, 2009, BRIT J CANCER, V100, P1393, DOI 10.1038/sj.bjc.6605044; Couts KL, 2013, ONCOGENE, V32, P1959, DOI 10.1038/onc.2012.209; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Dong L, 2011, ONCOGENE, V30, P3716, DOI 10.1038/onc.2011.87; Felicetti F, 2008, CANCER RES, V68, P2745, DOI 10.1158/0008-5472.CAN-07-2538; Graff JR, 2008, CANCER RES, V68, P631, DOI 10.1158/0008-5472.CAN-07-5635; Grzmil M, 2012, CANCER RES, V72, P3891, DOI 10.1158/0008-5472.CAN-12-0026; Guo ST, 2013, ONCOGENE, V32, P1910, DOI 10.1038/onc.2012.214; Haflidadottir BS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011574; HE L, 2004, NAT REV GENET, V5, P522; Hong DS, 2011, CLIN CANCER RES, V17, P6582, DOI 10.1158/1078-0432.CCR-11-0430; Hou JQ, 2012, ONCOTARGET, V3, P118; Humphreys DT, 2005, P NATL ACAD SCI USA, V102, P16961, DOI 10.1073/pnas.0506482102; Ibrahim AF, 2011, CANCER RES, V71, P5214, DOI 10.1158/0008-5472.CAN-10-4645; Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317; Jackson RJ, 2010, NAT REV MOL CELL BIO, V11, P113, DOI 10.1038/nrm2838; Jiang CC, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.48; Jin L, 2011, P NATL ACAD SCI USA, V108, P15840, DOI 10.1073/pnas.1019312108; Kiss T, 2004, J CELL SCI, V117, P5949, DOI 10.1242/jcs.01487; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; Larsson O, 2007, CANCER RES, V67, P6814, DOI 10.1158/0008-5472.CAN-07-0752; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Li SC, 2007, DNA CELL BIOL, V26, P195, DOI 10.1089/dna.2006.0558; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; Mamane Y, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000242; Mathonnet G, 2007, SCIENCE, V317, P1764, DOI 10.1126/science.1146067; Miyoshi K, 2010, MOL GENET GENOMICS, V284, P95, DOI 10.1007/s00438-010-0556-1; Moerke NJ, 2007, CELL, V128, P257, DOI 10.1016/j.cell.2006.11.046; Mueller DW, 2010, PIGM CELL MELANOMA R, V23, P620, DOI 10.1111/j.1755-148X.2010.00734.x; Phillips A, 2008, ONCOGENE, V27, P1645, DOI 10.1038/sj.onc.1210785; Platz A, 2008, MOL ONCOL, V1, P395, DOI 10.1016/j.molonc.2007.12.003; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rosenwald IB, 2004, ONCOGENE, V23, P3230, DOI 10.1038/sj.onc.1207552; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Stumpf CR, 2011, CURR OPIN GENET DEV, V21, P474, DOI 10.1016/j.gde.2011.03.007; Takatsu H, 1998, J BIOL CHEM, V273, P24693, DOI 10.1074/jbc.273.38.24693; Valleron W, 2012, BLOOD, V120, P3997, DOI 10.1182/blood-2012-06-438135; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; Wilmott JS, 2011, PATHOLOGY, V43, P657, DOI 10.1097/PAT.0b013e32834a7358; Wulfken LM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025787; Yanagiya A, 2012, MOL CELL, V46, P847, DOI 10.1016/j.molcel.2012.04.004; Yang SX, 2007, ONCOL REP, V17, P281	54	23	24	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2577	2588		10.1038/onc.2013.237	http://dx.doi.org/10.1038/onc.2013.237			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23770856	Green Submitted			2022-12-17	WOS:000336502700004
J	Ai, J; Pascal, LE; O'Malley, KJ; Dar, JA; Isharwal, S; Qiao, Z; Ren, B; Rigatti, LH; Dhir, R; Xiao, W; Nelson, JB; Wang, Z				Ai, J.; Pascal, L. E.; O'Malley, K. J.; Dar, J. A.; Isharwal, S.; Qiao, Z.; Ren, B.; Rigatti, L. H.; Dhir, R.; Xiao, W.; Nelson, J. B.; Wang, Z.			Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model	ONCOGENE			English	Article						prostate cancer; EAF2/U19; Pten; knockout	INTRAEPITHELIAL NEOPLASIA; TUMOR ANGIOGENESIS; SUPPRESSOR GENE; CELL-SURVIVAL; CANCER; MICE; AKT; CARCINOMA; PATHWAY; ADENOCARCINOMA	Multiple genetic alterations are associated with prostate carcinogenesis. Tumor-suppressor genes phosphatase and tensin homolog deleted on chromosome 10 (Pten) and androgen upregulated gene 19 (U19), which encodes ELL-associated factor 2 (EAF2), are frequently inactivated or downregulated in advanced prostate cancers. Previous studies showed that EAF2 knockout caused tumors in multiple organs and prostatic intraepithelial neoplasia (PIN) in mice. However, EAF2-knockout mice did not develop prostate cancer even at 2 years of age. To further define the roles of EAF2 in prostate carcinogenesis, we crossed the Pten +/- and EAF2 +/- mice in the C57/BL6 background to generate EAF2 -/- Pten +/-, Pten +/-, EAF2 -/- and wild-type mice. The prostates from virgin male mice with the above four genotypes were analyzed at 7 weeks, 19 weeks and 12 months of age. Concomitant loss of EAF2 function and inactivation of one Pten allele induced spontaneous prostate cancer in 33% of the mice. Prostatic tissues from intact EAF2 -/- Pten +/- mice exhibited higher levels of phospho-Akt, -p44/42 and microvessel density. Moreover, phospho-Akt remained high after castration. Consistently, there was a synergistic increase in prostate epithelial proliferation in both intact and castrated EAF2 -/- Pten +/- mice. Using laser-capture microdissection coupled with real-time reverse transcription-PCR, we confirmed that co-downregulation of EAF2 and Pten occurred in > 50% clinical prostate cancer specimens with Gleason scores of 8-9 (n = 11), which is associated with poor prognosis. The above findings together demonstrated synergistic functional interactions and clinical relevance of concurrent EAF2 and Pten downregulation in prostate carcinogenesis.	[Ai, J.; Pascal, L. E.; O'Malley, K. J.; Dar, J. A.; Isharwal, S.; Ren, B.; Nelson, J. B.; Wang, Z.] Univ Pittsburgh, Sch Med, Dept Urol, Pittsburgh, PA 15232 USA; [Qiao, Z.] Harbin Med Univ, Affiliated Hosp 3, Dept Urol, Harbin, Peoples R China; [Rigatti, L. H.] Univ Pittsburgh, Sch Med, Div Lab Anim Resources, Pittsburgh, PA 15232 USA; [Dhir, R.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15232 USA; [Xiao, W.] Chinese Acad Sci, Inst Hydrobiol, Wuhan, Peoples R China; [Wang, Z.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15232 USA; [Wang, Z.] Univ Pittsburgh, Sch Med, Inst Canc, Pittsburgh, PA 15232 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harbin Medical University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese Academy of Sciences; Institute of Hydrobiology, CAS; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wang, Z (corresponding author), Univ Pittsburgh, Sch Med, Dept Urol, Suite G40,5200 Ctr Ave, Pittsburgh, PA 15232 USA.	wangz2@upmc.edu	Isharwal, Sudhir/I-4347-2019; Dar, Javid/D-6276-2015; Pascal, Laura E./AAH-5743-2019; Xiao, Wuhan/GLU-7352-2022	Dar, Javid/0000-0002-4102-6202; Pascal, Laura E./0000-0003-3840-1662; 	National Institutes of Health Grants [R01 CA 120386, 5 R37 DK51193, 1 P50 CA90386, T32 DK007774];  [P30CA047904]; NATIONAL CANCER INSTITUTE [R01CA120386, P50CA090386, P30CA047904] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007774, R37DK051193] Funding Source: NIH RePORTER	National Institutes of Health Grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This investigation was supported in part by the National Institutes of Health Grants R01 CA 120386, 5 R37 DK51193, 1 P50 CA90386 and T32 DK007774. This project used the UPCI Animal Facility and Tissue and Research Pathology Services (TARPS), and was supported in part by award P30CA047904. We thank Marie Acquafondata, Aiyuan Zhang, Katie Leschak and Dawn Everard (University of Pittsburgh, Pittsburgh, PA) for excellent technical assistance. We also thank all members of the Wang laboratory for insightful discussion and critical reading of the manuscript. LEP is a Tippins Foundation Scholar.	Abate-Shen C, 2003, CANCER RES, V63, P3886; Ahmad Imran, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000689; Backman SA, 2004, P NATL ACAD SCI USA, V101, P1725, DOI 10.1073/pnas.0308217100; Bedolla R, 2007, CLIN CANCER RES, V13, P3860, DOI 10.1158/1078-0432.CCR-07-0091; Bostwick DG, 1996, CANCER, V78, P330, DOI 10.1002/(SICI)1097-0142(19960715)78:2<330::AID-CNCR22>3.0.CO;2-W; BOSTWICK DG, 1987, CANCER, V59, P788, DOI 10.1002/1097-0142(19870215)59:4<788::AID-CNCR2820590421>3.0.CO;2-I; Chung JH, 2005, CANCER RES, V65, P8096, DOI 10.1158/0008-5472.CAN-05-1888; Coffer PJ, 1998, BIOCHEM J, V335, P1; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Hamada K, 2005, GENE DEV, V19, P2054, DOI 10.1101/gad.1308805; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kim MJ, 2002, P NATL ACAD SCI USA, V99, P2884, DOI 10.1073/pnas.042688999; Kinkade CW, 2008, J CLIN INVEST, V118, P3051, DOI 10.1172/JCI34764; Knobbe CB, 2008, ONCOGENE, V27, P5398, DOI 10.1038/onc.2008.238; Koul HK, 2004, ANN NY ACAD SCI, V1030, P243, DOI 10.1196/annals.1329.030; Leslie NR, 2004, BIOCHEM J, V382, P1, DOI 10.1042/BJ20040825; Liu JX, 2009, J BIOL CHEM, V284, P16679, DOI 10.1074/jbc.M109.009654; Ma XQ, 2005, CANCER RES, V65, P5730, DOI 10.1158/0008-5472.CAN-04-4519; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Maurus D, 2005, EMBO J, V24, P1181, DOI 10.1038/sj.emboj.7600603; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; Pascal LE, 2011, ANGIOGENESIS, V14, P331, DOI 10.1007/s10456-011-9217-1; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stiles B, 2004, DEV BIOL, V273, P175, DOI 10.1016/j.ydbio.2004.06.008; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Vivanco I, 2007, CANCER CELL, V11, P555, DOI 10.1016/j.ccr.2007.04.021; Wan XY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009118; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; WEIDNER N, 1995, BREAST CANCER RES TR, V36, P169, DOI 10.1007/BF00666038; WEIDNER N, 1993, AM J PATHOL, V143, P401; Xiao W, 2008, ONCOGENE, V27, P1536, DOI 10.1038/sj.onc.1210786; Xiao WH, 2003, CANCER RES, V63, P4698	41	23	24	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2286	2294		10.1038/onc.2013.190	http://dx.doi.org/10.1038/onc.2013.190			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23708662	Green Accepted			2022-12-17	WOS:000335451800002
J	Medjkane, S; Perichon, M; Marsolier, J; Dairou, J; Weitzman, JB				Medjkane, S.; Perichon, M.; Marsolier, J.; Dairou, J.; Weitzman, J. B.			Theileria induces oxidative stress and HIF1 alpha activation that are essential for host leukocyte transformation	ONCOGENE			English	Article						leukocyte transformation; Warburg effect; metabolism; Theileria; host-parasite interactions	GLUCOSE-METABOLISM; CANCER; CELLS; ANNULATA; PARVA; HIF-1; TUMOR; SURVIVAL; HYPOXIA; GROWTH	Complex links between infection and cancer suggest that we still can learn much about tumorigenesis by studying how infectious agents hijack the host cell machinery. We studied the effects of an intracellular parasite called Theileria that infects bovine leukocytes and turns them into invasive cancer-like cells. We investigated the host cells pathways that are deregulated in infected leukocytes and might link infection and lymphoproliferative disease. We show that intracellular Theileria parasites drive a Warburg-like phenotype in infected host leukocytes, characterized by increased expression of metabolic regulators, increased glucose uptake and elevated lactate production, which were lost when the parasite was eliminated. The cohabitation of the parasites within the host cells leads to disruption of the redox balance (as measured by reduced/oxidized glutathione ratio) and elevated ROS (reactive oxygen species) levels, associated with chronic stabilization of the hypoxia-inducible factor 1 alpha (HIF1 alpha). Inhibition of HIF1 alpha (pharmacologically or genetically), or treatment with antioxidants, led to a marked reduction in expression of aerobic glycolytic genes and inhibited the transformed phenotype. These data show that stabilization of HIF1a, following increased ROS production, modulates host glucose metabolism and is critical for parasite-induced transformation. Our study expands knowledge about the molecular strategy used by the parasite Theileria to induce the transformed phenotypes of infected cells via reprogramming of glucose metabolism and redox signaling.	[Medjkane, S.; Perichon, M.; Marsolier, J.; Weitzman, J. B.] Univ Paris Diderot, Sorbonne Paris Cite, UMR 7216 CNRS, F-75013 Paris, France; [Dairou, J.] Univ Paris Diderot, Sorbonne Paris Cite, Lab Biol Fonctionnelle & Adaptat, Equipe RMCX, F-75013 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Weitzman, JB (corresponding author), Univ Paris Diderot, Sorbonne Paris Cite, UMR 7216 CNRS, Batiment Lamarck,35 Rue Helene Brion, F-75013 Paris, France.	jonathan.weitzman@univ-paris-diderot.fr		Marsolier, Justine/0000-0001-8464-9306; Medjkane, Souhila/0000-0001-7973-7707	Association pour la Recherche contre le Cancer (ARC) [4975, 7990]; Association for International Cancer Research (AICR) [08-0111]; appel d'offre 'Actions Specifiques Universite Paris Diderot	Association pour la Recherche contre le Cancer (ARC)(Fondation ARC pour la Recherche sur le CancerFrench National Research Agency (ANR)); Association for International Cancer Research (AICR); appel d'offre 'Actions Specifiques Universite Paris Diderot	We thank Slimane Ait-Si-Ali and Pierre-Antoine Defossez for critical reading of the manuscript and members of the UMR 7216 for helpful discussions. We thank Gordon Langsley for the generous gift of reagents, the Theileria-infected cell lines, the AP1-Luciferase reporter and for helpful discussions about our work. We thank Peter Staller (Biotech Research & Innovation Center, Denmark) for kindly providing the 5xHRE-luciferase constructs and Sebastien Jauliac for providing the NF-kappa B-Luciferase reporter. We also thank the Bioprofiler facility (Universite Paris Diderot) for HPLC analysis. We thank Ayad Eddaoudi (Institute of Child Health, London, UK) for expert technical support in flow cytometry analysis. This work was supported by grants from the Association pour la Recherche contre le Cancer (ARC no. 4975 and 7990) (JBW), the Association for International Cancer Research (AICR, no. 08-0111) (JBW) and appel d'offre 'Actions Specifiques 2012' Universite Paris Diderot. All infected bovine cell lines used in this study have been previously characterized and published.	Ballatori N, 2009, BIOL CHEM, V390, P191, DOI 10.1515/BC.2009.033; Baumgartner M, 2000, CELL MICROBIOL, V2, P329, DOI 10.1046/j.1462-5822.2000.00062.x; Chaussepied M, 1996, RES IMMUNOL, V147, P127, DOI 10.1016/0923-2494(96)83165-8; Chaussepied M, 1998, MOL BIOCHEM PARASIT, V94, P215, DOI 10.1016/S0166-6851(98)00070-X; Chaussepied M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001197; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Dessauge G, 2005, ONCOGENE, V24, P1075, DOI 10.1038/sj.onc.1208314; Dobbelaere D, 1999, ANNU REV MICROBIOL, V53, P1, DOI 10.1146/annurev.micro.53.1.1; DOBBELAERE DAE, 1988, P NATL ACAD SCI USA, V85, P4730, DOI 10.1073/pnas.85.13.4730; Dobbelaere DAE, 2003, CURR OPIN MICROBIOL, V6, P377, DOI 10.1016/S1369-5274(03)00085-7; Favier J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007094; Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082; Galley Y, 1997, P NATL ACAD SCI USA, V94, P5119, DOI 10.1073/pnas.94.10.5119; Gao P, 2007, CANCER CELL, V12, P230, DOI 10.1016/j.ccr.2007.08.004; Gatenby RA, 2006, CANCER RES, V66, P5216, DOI 10.1158/0008-5472.CAN-05-4193; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gillies RJ, 2008, J NUCL MED, V49, p24S, DOI 10.2967/jnumed.107.047258; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; HUDSON AT, 1985, PARASITOLOGY, V90, P45, DOI 10.1017/S0031182000049003; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Lizundia R, 2006, CANCER RES, V66, P6105, DOI 10.1158/0008-5472.CAN-05-3861; Lopez-Lazaro M, 2007, CANCER LETT, V252, P1, DOI 10.1016/j.canlet.2006.10.029; Lopez-Lazaro M, 2007, INT J CANCER, V120, P1378, DOI 10.1002/ijc.22493; Masella R, 2005, J NUTR BIOCHEM, V16, P577, DOI 10.1016/j.jnutbio.2005.05.013; Mentis AFA, 2010, ASIAN PAC J CANCER P, V11, P1437; Moreau MF, 1999, INFECT IMMUN, V67, P6678; Muraguri GR, 1999, VET PARASITOL, V87, P25, DOI 10.1016/S0304-4017(99)00154-5; Narayanan BA, 2006, CURR CANCER DRUG TAR, V6, P711, DOI 10.2174/156800906779010218; OLOBO JO, 1989, VET IMMUNOL IMMUNOP, V20, P165, DOI 10.1016/0165-2427(89)90096-2; Poyton RO, 2009, TRENDS ENDOCRIN MET, V20, P332, DOI 10.1016/j.tem.2009.04.001; Ralph SJ, 2010, MOL ASPECTS MED, V31, P145, DOI 10.1016/j.mam.2010.02.008; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2007, J BIOENERG BIOMEMBR, V39, P231, DOI 10.1007/s10863-007-9081-2; Seyfried TN, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-7; Shaw RJ, 2006, CURR OPIN CELL BIOL, V18, P598, DOI 10.1016/j.ceb.2006.10.005; Shiels B, 2006, INT J PARASITOL, V36, P9, DOI 10.1016/j.ijpara.2005.09.002; SHIELS BR, 1986, PARASITE IMMUNOL, V8, P69, DOI 10.1111/j.1365-3024.1986.tb00834.x; Somerville RPT, 1998, PARASITOLOGY, V116, P223, DOI 10.1017/S0031182097002151; Spear W, 2006, CELL MICROBIOL, V8, P339, DOI 10.1111/j.1462-5822.2005.00628.x; THEILEN GH, 1968, JNCI-J NATL CANCER I, V40, P737; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wellen KE, 2010, MOL CELL, V40, P323, DOI 10.1016/j.molcel.2010.10.004; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12; Wiley M, 2010, J BIOL CHEM, V285, P26852, DOI 10.1074/jbc.M110.147041; Yeung SJ, 2008, CELL MOL LIFE SCI, V65, P3981, DOI 10.1007/s00018-008-8224-x; Zhang HF, 2008, P NATL ACAD SCI USA, V105, P19579, DOI 10.1073/pnas.0809763105	50	23	24	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1809	1817		10.1038/onc.2013.134	http://dx.doi.org/10.1038/onc.2013.134			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23665677				2022-12-17	WOS:000334345500007
J	Ui, A; Ogiwara, H; Nakajima, S; Kanno, S; Watanabe, R; Harata, M; Okayama, H; Harris, CC; Yokota, J; Yasui, A; Kohno, T				Ui, A.; Ogiwara, H.; Nakajima, S.; Kanno, S.; Watanabe, R.; Harata, M.; Okayama, H.; Harris, C. C.; Yokota, J.; Yasui, A.; Kohno, T.			Possible involvement of LKB1-AMPK signaling in non-homologous end joining	ONCOGENE			English	Article						LKB1-AMPK signaling; non-homologous end joining; chromatin remodeling; tumor suppressor gene; genome instability	DOUBLE-STRAND BREAKS; ACTIVATED PROTEIN-KINASE; DNA-DAMAGE RESPONSE; CANCER CELL-LINES; HISTONE ACETYLATION; REPAIR PROTEINS; LKB1; LUNG; PHOSPHORYLATION; COMPLEX	LKB1/STK11 is a tumor suppressor gene responsible for Peutz-Jeghers syndrome, an inherited cancer disorder associated with genome instability. The LKB1 protein functions in the regulation of cell proliferation, polarization and differentiation. Here, we suggest a role of LKB1 in non-homologous end joining (NHEJ), a major DNA double-strand break (DSB) repair pathway. LKB1 localized to DNA ends upon the generation of micro-irradiation and I-SceI endonuclease-induced DSBs. LKB1 inactivation either by RNA interference or by kinase-dead mutation compromised NHEJ-mediated DNA repair by suppressing the accumulation of BRM, a catalytic subunit of the SWI/SNF complex, at DSB sites, which promotes the recruitment of an essential NHEJ factor, KU70. AMPK2, a major substrate of LKB1 and a histone H2B kinase, was recruited to DSBs in an LKB1-dependent manner. AMPK2 depletion and a mutation of H2B that disrupted the AMPK2 phoshorylation site impaired KU70 and BRM recruitment to DSB sites. LKB1 depletion induced the formation of chromosome breaks and radials. These results suggest that LKB1-AMPK signaling controls NHEJ and contributes to genome stability.	[Ui, A.; Ogiwara, H.; Kohno, T.] Natl Canc Ctr, Res Inst, Div Genome Biol, Chuo Ku, Tokyo 1040045, Japan; [Ui, A.; Kanno, S.; Watanabe, R.; Yasui, A.] Tohoku Univ, Inst Dev Aging & Canc, Div Dynam Proteome, Sendai, Miyagi 980, Japan; [Nakajima, S.; Yasui, A.] Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, Sendai, Miyagi 980, Japan; [Harata, M.] Tohoku Univ, Grad Sch Agr Sci, Dept Mol & Cell Biol, Div Life Sci,Lab Mol Biol, Sendai, Miyagi 980, Japan; [Okayama, H.; Harris, C. C.] NCI, Ctr Canc Res, Human Carcinogenesis Lab, NIH, Bethesda, MD USA; [Yokota, J.] Natl Canc Ctr, Res Inst, Div Multistage Carcinogenesis, Tokyo 104, Japan	National Cancer Center - Japan; Tohoku University; Tohoku University; Tohoku University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Cancer Center - Japan	Kohno, T (corresponding author), Natl Canc Ctr, Res Inst, Div Genome Biol, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan.	tkkohno@ncc.go.jp	Harata, Masahiko/T-5281-2019; Kanno, Shin-ichiro/AAE-4549-2019; Ui, Ayako/GON-4666-2022	Ui, Ayako/0000-0001-6698-7168; Okayama, Hirokazu/0000-0003-0966-4746; Ogiwara, Hideaki/0000-0003-0860-1807	Ministry of Education, Culture, Sports, Science and Technology of Japan for Scientific Research on Innovative Areas [22131006, 22131005]; Japan Society for the Promotion of Science for Young Scientists (B) KAKENHI [23701110, 24710057]; Government to the National Cancer Center; Grants-in-Aid for Scientific Research [24710057] Funding Source: KAKEN; NATIONAL CANCER INSTITUTE [Z01BC005480, ZIABC011492] Funding Source: NIH RePORTER	Ministry of Education, Culture, Sports, Science and Technology of Japan for Scientific Research on Innovative Areas; Japan Society for the Promotion of Science for Young Scientists (B) KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Government to the National Cancer Center; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan for Scientific Research on Innovative Areas (22131006 to TK and HO; and 22131005 to AY), from the Japan Society for the Promotion of Science for Young Scientists (B) KAKENHI (23701110 to HO and 24710057 to AU) and Management Expenses Grants from the Government to the National Cancer Center. A part of this work was carried out under the Cooperative Research Project Program of the Institute of Development, Aging and Cancer, Tohoku University.	Blanco R, 2009, HUM MUTAT, V30, P1199, DOI 10.1002/humu.21028; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Bungard D, 2010, SCIENCE, V329, P1201, DOI 10.1126/science.1191241; Burma S, 2006, DNA REPAIR, V5, P1042, DOI 10.1016/j.dnarep.2006.05.026; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Kim J, 2009, CELL, V137, P459, DOI 10.1016/j.cell.2009.02.027; Lan L, 2005, J CELL SCI, V118, P4153, DOI 10.1242/jcs.02544; Lan L, 2010, MOL CELL, V40, P976, DOI 10.1016/j.molcel.2010.12.003; Lieber MR, 2008, J BIOL CHEM, V283, P1, DOI 10.1074/jbc.R700039200; Marignani PA, 2001, J BIOL CHEM, V276, P32415, DOI 10.1074/jbc.C100207200; Matsumoto S, 2007, ONCOGENE, V26, P5911, DOI 10.1038/sj.onc.1210418; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Mehenni H, 1998, AM J HUM GENET, V63, P1641, DOI 10.1086/302159; Miller KM, 2010, NAT STRUCT MOL BIOL, V17, P1144, DOI 10.1038/nsmb.1899; Mladenov E, 2011, MUTAT RES-FUND MOL M, V711, P61, DOI 10.1016/j.mrfmmm.2011.02.005; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Nakajima S, 2006, J BIOL CHEM, V281, P34687, DOI 10.1074/jbc.M605545200; Ogiwara H, 2011, ONCOGENE, V30, P2135, DOI [10.1038/onc.2010.592, 10.1038/onc.2010.592;]; Ogiwara H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028756; Osley MA, 2006, TRENDS GENET, V22, P671, DOI 10.1016/j.tig.2006.09.007; Park JH, 2006, EMBO J, V25, P3986, DOI 10.1038/sj.emboj.7601291; Peng G, 2009, NAT CELL BIOL, V11, P865, DOI 10.1038/ncb1895; Perez-Cadahia B, 2010, CURR OPIN DRUG DISC, V13, P613; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; RICHARD F, 1994, CANCER GENET CYTOGEN, V73, P23, DOI 10.1016/0165-4608(94)90178-3; Rodrigue A, 2006, EMBO J, V25, P222, DOI 10.1038/sj.emboj.7600914; Roy BC, 2010, LUNG CANCER, V70, P136, DOI 10.1016/j.lungcan.2010.02.004; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sapkota GP, 2002, BIOCHEM J, V368, P507, DOI 10.1042/BJ20021284; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shim EY, 2005, MOL CELL BIOL, V25, P3934, DOI 10.1128/MCB.25.10.3934-3944.2005; van Attikum H, 2007, EMBO J, V26, P4113, DOI 10.1038/sj.emboj.7601835; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Wingo SN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005137; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031	38	23	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1640	1648		10.1038/onc.2013.125	http://dx.doi.org/10.1038/onc.2013.125			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23584481	Green Accepted			2022-12-17	WOS:000334344700004
J	Zhang, Y; Yan, W; Chen, X				Zhang, Y.; Yan, W.; Chen, X.			P63 regulates tubular formation via epithelial-to-mesenchymal transition	ONCOGENE			English	Article						p63; the p53 family; tubular formation; epithelial-to-mesenchymal transition; cell proliferation; migration and invasion	P53 HOMOLOG; MIR-200 FAMILY; CELL CARCINOMA; GENE-MUTATIONS; EEC-SYNDROME; E-CADHERIN; IN-VIVO; TARGET; KIDNEY; GROWTH	P63, a p53 family member, is expressed as Delta A and DN isoforms. Interestingly, both TAp63 and Delta Np63 are transcription factors, and regulate both common and distinct sets of target genes. p63 is required for survival of some epithelial cell lineages, and lack of p63 leads to loss of epidermis and other epithelia in humans and mice. Here, we explored the role of p63 isoforms in cell proliferation, migration and tubulogenesis by using Madin-Darby Canine Kidney (MDCK) tubular epithelial cells in two-or three-dimensional (2-D or 3-D) culture. We found that like downregulation of p53, downregulation of p63 and TAp63 decreases expression of growth-suppressing genes, including p21, PUMA and MIC-1, and consequently promotes cell proliferation and migration in 2-D culture. However, in 3-D culture, downregulation of p63, especially TAp63, but not p53, decapacitates MDCK cells to form a cyst structure through enhanced epithelial-to-mesenchymal transition (EMT). In contrast, downregulation of DNp63 inhibits MDCK cell proliferation and migration in 2-D culture, and delays but does not block MDCK cell cyst formation and tubulogenesis in 3-D culture. Consistent with this, downregulation of DNp63 markedly upregulates growth-suppressing genes, including p21, PUMA and MIC-1. Taken together, these data suggest that TAp63 is the major isoform required for tubulogenesis by maintaining an appropriate level of EMT, whereas DNp63 fine-tunes the rate of cyst formation and tubulogenesis by maintaining an appropriate expression level of genes involved in cell cycle arrest and apoptosis.	[Chen, X.] Univ Calif Davis, Ctr Comparat Oncol, Sch Med, Davis, CA 95616 USA; [Chen, X.] Univ Calif Davis, Ctr Comparat Oncol, Sch Vet Med, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Chen, X (corresponding author), Univ Calif Davis, Ctr Comparat Oncol, Sch Med, 2128 Tupper Hall, Davis, CA 95616 USA.	xbchen@ucdavis.edu			National Institutes of Health [CA102188, CA108122, CA076069]; NATIONAL CANCER INSTITUTE [R01CA102188, R01CA076069, R29CA076069, R01CA123227, R01CA081237] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the National Institutes of Health grants CA102188, CA108122 and CA076069. We thank Jin Zhang for helpful comments on this manuscript.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Allen LM, 2008, J ULTRAS MED, V27, P149, DOI 10.7863/jum.2008.27.1.149; Bakkers J, 2002, DEV CELL, V2, P617, DOI 10.1016/S1534-5807(02)00163-6; Brunner HG, 2002, AM J MED GENET, V112, P284, DOI 10.1002/ajmg.10778; Cao Y, 2008, CANCER RES, V68, P8667, DOI 10.1158/0008-5472.CAN-08-2614; Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Cook HT, 2010, AM J PATHOL, V176, P22, DOI 10.2353/ajpath.2010.090898; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Dressler GR, 2002, TRENDS CELL BIOL, V12, P390, DOI 10.1016/S0962-8924(02)02334-6; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Guo XC, 2009, NAT CELL BIOL, V11, P1451, DOI 10.1038/ncb1988; Herfs M, 2010, AM J PATHOL, V176, P1941, DOI 10.2353/ajpath.2010.090804; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Jia LW, 2011, MOL BIOL CELL, V22, P2031, DOI 10.1091/mbc.E11-01-0038; Keyes WM, 2005, GENE DEV, V19, P1986, DOI 10.1101/gad.342305; Kim D, 2005, J AM SOC NEPHROL, V16, P3527, DOI 10.1681/ASN.2005050544; Lee H, 2002, DEV CELL, V2, P607, DOI 10.1016/S1534-5807(02)00166-1; LEIGHTON J, 1970, CANCER-AM CANCER SOC, V26, P1022, DOI 10.1002/1097-0142(197011)26:5<1022::AID-CNCR2820260509>3.0.CO;2-M; Lindsay J, 2011, J BIOL CHEM, V286, P3915, DOI 10.1074/jbc.M110.162511; Lipschutz JH, 2000, MOL BIOL CELL, V11, P4259, DOI 10.1091/mbc.11.12.4259; Liu G, 2006, MOL CELL BIOL, V26, P1398, DOI 10.1128/MCB.26.4.1398-1413.2006; Lo Iacono M, 2006, CELL CYCLE, V5, P78; Massion PP, 2003, CANCER RES, V63, P7113; MCATEER JA, 1987, ANAT REC, V217, P229, DOI 10.1002/ar.1092170303; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; O'Brien LE, 2006, METHOD ENZYMOL, V406, P676, DOI 10.1016/S0076-6879(06)06053-8; O'Brien LE, 2004, DEV CELL, V7, P21, DOI 10.1016/j.devcel.2004.06.001; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Park BJ, 2000, CANCER RES, V60, P3370; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pollack AL, 1998, DEV BIOL, V204, P64, DOI 10.1006/dbio.1998.9091; Prindull G, 2004, BLOOD, V103, P2892, DOI 10.1182/blood-2003-08-2807; Rinne T, 2006, AM J MED GENET A, V140A, P1396, DOI 10.1002/ajmg.a.31271; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Saxen L., 1987, Developmental and Cell Biology Series, V19, P1; Sensen CW, 1998, EXTREMOPHILES, V2, P305, DOI 10.1007/s007920050073; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; Sniezek JC, 2004, LARYNGOSCOPE, V114, P2063, DOI 10.1097/01.mlg.0000149437.35855.4b; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Su XH, 2009, CELL STEM CELL, V5, P64, DOI 10.1016/j.stem.2009.04.003; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tucci P, 2012, P NATL ACAD SCI USA, V109, P15312, DOI 10.1073/pnas.1110977109; van Bokhoven H, 2001, AM J HUM GENET, V69, P481, DOI 10.1086/323123; Vanbokhoven H, 2011, J INVEST DERMATOL, V131, P1196, DOI 10.1038/jid.2011.84; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zeisberg M, 2005, J BIOL CHEM, V280, P8094, DOI 10.1074/jbc.M413102200; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang J, 2009, MOL CANCER RES, V7, P67, DOI 10.1158/1541-7786.MCR-08-0347; Zhang YH, 2008, J BIOL CHEM, V283, P30689, DOI 10.1074/jbc.M801711200; Zhang YH, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.214585; Zheng Z, 2010, J CELL BIOL, V189, P275, DOI 10.1083/jcb.200910021; Zimmers TA, 2005, SHOCK, V23, P543, DOI 10.1097/01.shk.0000163393.55350.70	58	23	23	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1548	1557		10.1038/onc.2013.101	http://dx.doi.org/10.1038/onc.2013.101			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23542170	Green Accepted			2022-12-17	WOS:000333244200008
J	Liu, Z; Li, T; Reinhold, MI; Naski, MC				Liu, Z.; Li, T.; Reinhold, M. I.; Naski, M. C.			MEK1-RSK2 contributes to hedgehog signaling by stabilizing GLI2 transcription factor and inhibiting ubiquitination	ONCOGENE			English	Article						Hedgehog; GLI2; MEK1; RSK2; ubiquitination; multiple myeloma	CARCINOMA-CELLS; DOWN-REGULATION; CANCER; DEGRADATION; ACTIVATION; PROLIFERATION; METASTASIS; MECHANISMS; EXPRESSION; PROTEINS	The transcription factor GLI2 has an important role in the transduction of Hedgehog signaling and thereby regulates tumorigenesis in a wide variety of human tumors. However, the mechanisms controlling GLI2 protein expression and stabilization are incompletely understood. In this study, we show that the mitogen-activated protein kinase MEK1 modulates GLI2 both at the mRNA and protein level. Constitutively activated MEK1 prolonged the half-life of GLI2 and increased its nuclear translocation, accompanied by attenuated ubiquitination of GLI2 protein. RSK2, a protein kinase lying downstream of MEK-ERK cascade, mimicked the effect of MEK on GLI2 stabilization. MEK1 and RSK2 failed to augment the half-life of GLI2 lacking GSK-3 beta phosphorylation sites, indicating that MEK-RSK stabilizes GLI2 by controlling targeting GSK-3 beta-mediated phosphorylation and ubiquitination of GLI2. The significance of MEK-RSK stabilization was demonstrated in experiments showing that activation of MEK-RSK paralleled higher protein level of GLI2 in several multiple myelomas (MM) cells relative to normal B cells. Moreover, combined treatment with RSK and GLI inhibitors led to an enhanced apoptosis of MM cells. Thus, our results indicate that MEK-RSK cascade positively regulates GLI2 stabilization and represses its degradation via inhibiting GSK-3 beta-dependent phosphorylation and ubiquitination of GLI2.	[Liu, Z.; Reinhold, M. I.; Naski, M. C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA; [Liu, Z.] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA; [Li, T.] Zhejiang Normal Univ, Coll Chem & Life Sci, Dept Biol, Jinhua, Peoples R China; [Reinhold, M. I.] Grand Valley State Univ, Dept Phys Assistant Studies, Grand Rapids, MI USA; [Naski, M. C.] St Marys Hlth Care, Dept Pathol, Grand Rapids, MI USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; UTMD Anderson Cancer Center; Zhejiang Normal University; Grand Valley State University	Liu, Z (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA.	zliu2@mdanderson.org; mikenaski@yahoo.com	Liu, Zhiqiang/E-6950-2014	Liu, Zhiqiang/0000-0002-0677-8097	National Institutes of Health [R01 (AR053100)]; National Natural Sciences Foundation of China [31101057]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053100] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by National Institutes of Health R01 (AR053100) (M C Naski), the National Natural Sciences Foundation of China (31101057), and the Sciences Foundation of Zhejiang Normal University (ZC304009172). We thank Dr Natalia Riobo from Thomas Jefferson University; Dr John Blenis from Department of Cell Biology of Harvard Medical School; Dr Richard L Huganir from the Department of Neuroscience of Howard Hughes Medical Institute; Dr Fritz Aberger, University of Salzburg; and Dr Baolin Wang, Associate Professor of Cell and Developmental Biology Weill Cornell Medical College, for their generous contributions of the plasmids used in this study.	Alexaki VI, 2010, JNCI-J NATL CANCER I, V102, P1148, DOI 10.1093/jnci/djq257; Aza-Blanc P, 2000, DEVELOPMENT, V127, P4293; Bhatia N, 2006, J BIOL CHEM, V281, P19320, DOI 10.1074/jbc.M513203200; Cai Jiaqin, 2010, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V24, P993; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; Fujii Katsunori, 2009, No To Hattatsu, V41, P247; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Javelaud D, 2011, CANCER RES, V71, P5606, DOI 10.1158/0008-5472.CAN-11-1194; Jiang J, 2008, DEV CELL, V15, P801, DOI 10.1016/j.devcel.2008.11.010; Jiao X, 2012, GENE CHROMOSOME CANC, V51, P480, DOI 10.1002/gcc.21935; Keshet Y, 2010, METHODS MOL BIOL, V661, P3, DOI 10.1007/978-1-60761-795-2_1; Kim J, 2009, P NATL ACAD SCI USA, V106, P21666, DOI 10.1073/pnas.0912180106; Kim Y, 2007, CANCER RES, V67, P3583, DOI 10.1158/0008-5472.CAN-06-3040; Kump E, 2008, ONCOGENE, V27, P3856, DOI 10.1038/onc.2008.5; Lauth M, 2007, CELL CYCLE, V6, P2458, DOI 10.4161/cc.6.20.4808; Lewis M T, 2006, Ernst Schering Found Symp Proc, P181; Liu ZQ, 2009, BBA-MOL CELL RES, V1793, P300, DOI 10.1016/j.bbamcr.2008.08.013; Marini KD, 2011, GROWTH FACTORS, V29, P221, DOI 10.3109/08977194.2011.610756; Onishi H, 2011, CANCER SCI, V102, P1756, DOI 10.1111/j.1349-7006.2011.02010.x; Pan Y, 2006, MOL CELL BIOL, V26, P3365, DOI 10.1128/MCB.26.9.3365-3377.2006; Pan Y, 2009, DEV BIOL, V326, P177, DOI 10.1016/j.ydbio.2008.11.009; Reinhold MI, 2006, J BIOL CHEM, V281, P1381, DOI 10.1074/jbc.M504875200; Tam Michael, 2010, J Assoc Genet Technol, V36, P111; Teichert AE, 2011, J INVEST DERMATOL, V131, P2289, DOI 10.1038/jid.2011.196; Thiyagarajan S, 2007, CANCER RES, V67, P10642, DOI 10.1158/0008-5472.CAN-07-2015; Thomas GM, 2005, P NATL ACAD SCI USA, V102, P15006, DOI 10.1073/pnas.0507476102; Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608	28	23	24	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					65	73		10.1038/onc.2012.544	http://dx.doi.org/10.1038/onc.2012.544			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23208494				2022-12-17	WOS:000329212000008
J	Yang, WC; Shih, HM				Yang, W-C; Shih, H-M			The deubiquitinating enzyme USP37 regulates the oncogenic fusion protein PLZF/RARA stability	ONCOGENE			English	Article						acute promyelocytic leukemia; deubiquitinating enzyme; USP37; PLZF; RARA	ACUTE PROMYELOCYTIC LEUKEMIA; SMALL-MOLECULE INHIBITOR; PML-RAR-ALPHA; CELLS; PLZF; PATHWAY; CYCLIN; DIFFERENTIATION; PATHOGENESIS; APOPTOSIS	Acute promyelocytic leukemia (APL) is predominantly characterized by chromosomal translocations between the retinoic acid receptor, alpha (RARA) gene and the promyelocytic leukemia (PML) or promyelocytic leukemia zinc finger (PLZF) gene. In APL cells with PML/RARA fusions, arsenic trioxide and all-trans retinoic acid treatments specifically target the fusion protein for proteasome-dependent degradation, thereby promoting cellular differentiation and clinical remission of disease. In contrast, APL cells expressing PLZF/RARA fusion proteins are largely resistant to similar treatments and prognosis for patients with this translocation is poor. Understanding the molecular mechanisms regulating PLZF/RARA protein stability would provide novel therapeutic targets for PLZF/RARA-associated APL. Toward this end, we have performed an RNAi-based screen to identify factors affecting PLZF/RARA stability. Among the factors identified was the ubiquitin-specific peptidase 37 (USP37). We showed that USP37 interacted with PLZF/RARA through the PLZF moiety and sustained PLZF/RARA steady state levels. Domain mapping study revealed that N-terminal domain of USP37 is required for the PLZF/RARA interaction and protein regulation. Furthermore, overexpression or depletion of USP37 caused an increase or decrease of PLZF/RARA protein half-life, correlating with down-or upregulation of PLZF/RARA poly-ubiquitination, respectively. By PLZF/RARA-transduced primary mouse hematopoietic progenitor cells, we demonstrated that Usp37 knockdown alleviated PLZF/RARA-mediated target gene suppression and cell transformation potential. Altogether, our findings of USP37-modulating PLZF/RARA stability and cell transformation suggest that USP37 is a potential therapeutic target for PLZF/RARA-associated APL.	[Yang, W-C; Shih, H-M] Acad Sinica, Taiwan Int Grad Program TIGP, Mol Med Program, Taipei 115, Taiwan; [Yang, W-C; Shih, H-M] Natl Yang Ming Univ, Sch Life Sci, Inst Biochem & Mol Biol, Taipei 112, Taiwan; [Yang, W-C; Shih, H-M] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Shih, HM (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Sec 2,Acad Rd, Taipei 115, Taiwan.	hmshih@ibms.sinica.edu.tw	Shih, Hsiu-Ming/S-7023-2018		NSC [NSC100-2321-B-001-004, NSC100-3112-B-001-004]; Academia Sinica Investigator Award	NSC(Ministry of Science and Technology, Taiwan); Academia Sinica Investigator Award(Academia Sinica - Taiwan)	We thank Dr. J Wade Harper for USP37, OTUD6B and USP2 cDNA constructs, Dr Sheng-Chung Lee for anti-ubiquitin antibody, and Dr Yen-Sung Huang for mouse preparation. We also thank for the NRPGM Core RNAi by providing lentiviral constructs for TetOn system and shRNAs of DUBs. We are grateful to Dr Michael J Matunis for comments on the paper. The work was supported by NSC Grants (NSC100-2321-B-001-004; NSC100-3112-B-001-004) and an Academia Sinica Investigator Award to H-M Shih.	Buaas FW, 2004, NAT GENET, V36, P647, DOI 10.1038/ng1366; Chang CC, 2011, MOL CELL, V42, P62, DOI 10.1016/j.molcel.2011.02.022; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Colland F, 2009, MOL CANCER THER, V8, P2286, DOI 10.1158/1535-7163.MCT-09-0097; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Doulatov S, 2009, GENE DEV, V23, P2076, DOI 10.1101/gad.1788109; Duprez E, 2003, EMBO J, V22, P5806, DOI 10.1093/emboj/cdg556; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Guibal FC, 2009, BLOOD, V114, P5415, DOI 10.1182/blood-2008-10-182071; Huang XD, 2011, MOL CELL, V42, P511, DOI 10.1016/j.molcel.2011.03.027; Ji P, 2005, ONCOGENE, V24, P2739, DOI 10.1038/sj.onc.1208356; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Lee BH, 2010, NATURE, V467, P179, DOI 10.1038/nature09299; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Lin DY, 2006, MOL CELL, V24, P341, DOI 10.1016/j.molcel.2006.10.019; Lin RJ, 2001, ONCOGENE, V20, P7204, DOI 10.1038/sj.onc.1204853; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mistry AR, 2003, BLOOD REV, V17, P71, DOI 10.1016/S0268-960X(02)00075-9; Muller C, 2000, BLOOD, V96, P3894, DOI 10.1182/blood.V96.12.3894.h8003894_3894_3899; Nasr R, 2009, CLIN CANCER RES, V15, P6321, DOI 10.1158/1078-0432.CCR-09-0209; Nasr R, 2008, NAT MED, V14, P1333, DOI 10.1038/nm.1891; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Schwickart M, 2010, NATURE, V463, P103, DOI 10.1038/nature08646; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Ventii KH, 2008, BIOCHEM J, V414, P161, DOI 10.1042/BJ20080798; Wang ZY, 2008, BLOOD, V111, P2505, DOI 10.1182/blood-2007-07-102798; Yang R, 1999, BLOOD, V93, P2067; Zhang XW, 2010, SCIENCE, V328, P240, DOI 10.1126/science.1183424	32	23	24	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2013	32	43					5167	5175		10.1038/onc.2012.537	http://dx.doi.org/10.1038/onc.2012.537			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240JY	23208507				2022-12-17	WOS:000326093200004
J	Choi, HJ; Kim, J; Do, KH; Park, SH; Moon, Y				Choi, H. J.; Kim, J.; Do, K. H.; Park, S-H; Moon, Y.			Enteropathogenic Escherichia coli-induced macrophage inhibitory cytokine 1 mediates cancer cell survival: an in vitro implication of infection-linked tumor dissemination	ONCOGENE			English	Article						epithelial tumor cell survival; enteropathogenic Escherichia coli; macrophage inhibitory cytokine 1	INFLAMMATORY-BOWEL-DISEASE; ACTIN PEDESTAL FORMATION; GENE-EXPRESSION; PROGNOSTIC-SIGNIFICANCE; RHO-GTPASES; MIC-1; APOPTOSIS; INVASION; PROSTATE; RISK	Mucosally adherent Escherichia coli is frequently observed in intestinal surface of patients with colorectal cancer, but rarely in healthy control. Particularly, enteropathogenic Escherichia coli (EPEC) is known to be closely associated with colorectal carcinogenesis in human. In this study, one consequence of EPEC infection in human intestinal cancer cells was induction of macrophage inhibitory cytokine 1 (MIC-1), which is a multifunctional cytokine with biological activities involved in cancer cell growth, differentiation and migration. The present investigation assessed the involvement of MIC-1 protein in EPEC infectionmediated cancer cell survival. The challenge with EPEC induced cancer cell detachment via cytoskeleton rearrangement, which was positively associated with induced MIC-1 expression. Moreover, MIC-1 also mediated RhoA GTPase-linked survival of the detached cancer cells. Blocking of MIC-1 or RhoA activity increased cellular apoptosis of the detached cancer cells. In terms of signaling pathway, MIC-1 triggered transforming growth factorb-activated kinase 1 (TAK1), which enhanced expression of RhoA GTPase. We conclude that EPEC enhances MIC-1 gene expression in the human intestinal cancer cells, which can be associated with enhanced tumor cell resistance to anchorage-dependent tumor cell death via enhanced TAK1 and RhoA GTPase.	[Choi, H. J.; Kim, J.; Do, K. H.; Park, S-H; Moon, Y.] Pusan Natl Univ, Sch Med, Dept Microbiol & Immunol, Lab Mucosal Exposome & Biomodulat, Yangsan 626870, Kyungnam, South Korea; [Choi, H. J.; Kim, J.; Do, K. H.; Park, S-H; Moon, Y.] Pusan Natl Univ, Sch Med, Med Res Inst, Yangsan 626870, Kyungnam, South Korea; [Moon, Y.] Pusan Natl Univ, Res Inst Basic Sci, Pusan, South Korea; [Moon, Y.] Pusan Natl Univ, Med Res Inst, Pusan, South Korea	Pusan National University; Pusan National University Hospital; Pusan National University; Pusan National University Hospital; Pusan National University; Pusan National University	Moon, Y (corresponding author), Pusan Natl Univ, Sch Med, Dept Microbiol & Immunol, Lab Mucosal Exposome & Biomodulat, Room 704, Yangsan 626870, Kyungnam, South Korea.	moon@pnu.edu	Yuseok Moon, ATS/AAE-4364-2020	MOON, YUSEOK/0000-0001-8686-8166	Basic Science Research Program through the National Research Foundation of Korea; Ministry of Education, Science and Technology [2012R1A1A2005837]	Basic Science Research Program through the National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by the Basic Science Research Program through the National Research Foundation of Korea, funded by Ministry of Education, Science and Technology Grant 2012R1A1A2005837.	Aepfelbacher M, 2005, CURR TOP MICROBIOL, V291, P167; Agarwal MK, 2006, P NATL ACAD SCI USA, V103, P16278, DOI 10.1073/pnas.0607210103; BARTHOLD SW, 1977, CANCER RES, V37, P4352; Batchelor M, 2004, EMBO REP, V5, P104, DOI 10.1038/sj.embor.7400038; Bellizzi A, 2008, INT J MOL MED, V22, P25; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Borthakur A, 2006, AM J PHYSIOL-GASTR L, V290, pG30, DOI 10.1152/ajpgi.00302.2005; Braga V, 2000, EXP CELL RES, V261, P83, DOI 10.1006/excr.2000.5050; Brown DA, 2003, CLIN CANCER RES, V9, P2642; Brown DA, 2002, LANCET, V359, P2159, DOI 10.1016/S0140-6736(02)09093-1; Campellone KG, 2003, CURR OPIN MICROBIOL, V6, P82, DOI 10.1016/S1369-5274(03)00005-5; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Crane JK, 1999, INFECT IMMUN, V67, P2575, DOI 10.1128/IAI.67.5.2575-2584.1999; Dean P, 2006, P NATL ACAD SCI USA, V103, P1876, DOI 10.1073/pnas.0509451103; Detrich R E, 1976, J Maine Med Assoc, V67, P52; Dittert DD, 2008, HUM PATHOL, V39, P1002, DOI 10.1016/j.humpath.2007.11.016; Fairlie WD, 1999, J LEUKOCYTE BIOL, V65, P2, DOI 10.1002/jlb.65.1.2; Faried A, 2007, ANN SURG ONCOL, V14, P3593, DOI 10.1245/s10434-007-9562-x; Gotoh T, 2002, J BIOL CHEM, V277, P12343, DOI 10.1074/jbc.M107988200; Gradel KO, 2009, GASTROENTEROLOGY, V137, P495, DOI 10.1053/j.gastro.2009.04.001; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hecht G, 2001, AM J PHYSIOL-GASTR L, V281, pG1, DOI 10.1152/ajpgi.2001.281.1.G1; Iczkowski KA, 2003, INT J SURG PATHOL, V11, P159, DOI 10.1177/106689690301100302; Kim KS, 2002, GASTROENTEROLOGY, V122, P1388, DOI 10.1053/gast.2002.32972; Lee DH, 2003, CANCER RES, V63, P4648; Lieberman D, 2009, CURR OPIN GASTROEN, V25, P422, DOI 10.1097/MOG.0b013e32832d1e2a; Lim DY, 2009, AM J PHYSIOL-GASTR L, V296, pG1060, DOI 10.1152/ajpgi.90490.2008; Liu T, 2003, CANCER RES, V63, P5034; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Maddocks ODK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005517; Mager DL, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-14; Mahida YR, 2004, CLIN SCI, V107, P331, DOI 10.1042/CS20040136; Martin HM, 2004, GASTROENTEROLOGY, V127, P80, DOI 10.1053/j.gastro.2004.03.054; Matsuzawa T, 2004, EMBO J, V23, P3570, DOI 10.1038/sj.emboj.7600359; MOSCOW JA, 1994, ONCOGENE, V9, P189; Mylonaki M, 2005, INFLAMM BOWEL DIS, V11, P481, DOI 10.1097/01.MIB.0000159663.62651.4f; Nagai T, 2005, J BIOL CHEM, V280, P2998, DOI 10.1074/jbc.M411550200; Newman JV, 2001, J INFECT DIS, V184, P227, DOI 10.1086/321998; Nougayrede JP, 2007, CELL MICROBIOL, V9, P680, DOI 10.1111/j.1462-5822.2006.00820.x; Oliva C A, 1997, Rev Assoc Med Bras (1992), V43, P283; POTTER JD, 1993, EPIDEMIOL REV, V15, P499, DOI 10.1093/oxfordjournals.epirev.a036132; Rathinam R, 2011, FRONT BIOSCI-LANDMRK, V16, P2561, DOI 10.2741/3872; Rihet S, 2001, J CANCER RES CLIN, V127, P733; Rogers AB, 2004, AM J PHYSIOL-GASTR L, V286, pG361, DOI 10.1152/ajpgi.00499.2003; Rogers Arlin B., 2009, V511, P267, DOI 10.1007/978-1-59745-447-6_11; ROTHBAUM R, 1982, GASTROENTEROLOGY, V83, P441; Struckhoff AP, 2011, FRONT BIOSCI-LANDMRK, V16, P1915, DOI 10.2741/3830; Stypulkowska-Misiurewicz H, 1984, Przegl Epidemiol, V38, P19; Swidsinski A, 1998, GASTROENTEROLOGY, V115, P281, DOI 10.1016/S0016-5085(98)70194-5; Thomas R, 2001, INT J CANCER, V93, P47, DOI 10.1002/ijc.1291; Thompson Patricia A, 2009, Expert Rev Gastroenterol Hepatol, V3, P369, DOI 10.1586/egh.09.28; Tomson FL, 2005, MOL MICROBIOL, V56, P447, DOI 10.1111/j.1365-2958.2005.04571.x; Tong S, 2004, LANCET, V363, P129, DOI 10.1016/S0140-6736(03)15265-8; Triantafillidis JK, 2009, ANTICANCER RES, V29, P2727; ULSHEN MH, 1980, NEW ENGL J MED, V302, P99, DOI 10.1056/NEJM198001103020207; Vermeulen SJ, 1999, CLIN EXP METASTAS, V17, P663, DOI 10.1023/A:1006724300022; Vermeulen SJ, 1997, ANN NY ACAD SCI, V833, P186, DOI 10.1111/j.1749-6632.1997.tb48607.x; Viswanathan VK, 2004, CELL MICROBIOL, V6, P987, DOI 10.1111/j.1462-5822.2004.00416.x; Welsh JB, 2003, P NATL ACAD SCI USA, V100, P3410, DOI 10.1073/pnas.0530278100; Wollmann W, 2005, CARCINOGENESIS, V26, P900, DOI 10.1093/carcin/bgi031; Yang H, 2009, BIOCHEM PHARMACOL, V78, P1205, DOI 10.1016/j.bcp.2009.06.012	61	23	24	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4960	4969		10.1038/onc.2012.508	http://dx.doi.org/10.1038/onc.2012.508			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23503457				2022-12-17	WOS:000325717800012
J	Li, D; Takao, T; Tsunematsu, R; Morokuma, S; Fukushima, K; Kobayashi, H; Saito, T; Furue, M; Wake, N; Asanoma, K				Li, D.; Takao, T.; Tsunematsu, R.; Morokuma, S.; Fukushima, K.; Kobayashi, H.; Saito, T.; Furue, M.; Wake, N.; Asanoma, K.			Inhibition of AHR transcription by NF1C is affected by a single-nucleotide polymorphism, and is involved in suppression of human uterine endometrial cancer	ONCOGENE			English	Article						NF1C; AHR; single-nucleotide polymorphism; uterine endometrial cancer	ARYL-HYDROCARBON-RECEPTOR; ADENOVIRUS DNA-REPLICATION; MAMMARY-GLAND; CYP1A1 LEVELS; LUNG-CANCER; FACTOR 1-C2; IN-VIVO; EXPRESSION; GENE; OVEREXPRESSION	Involvement of the aryl hydrocarbon receptor (AHR) in carcinogenesis has been suggested in many studies. Upregulation of AHR has been reported in some cancer species, and an association between single-nucleotide polymorphisms (SNPs) of AHR and cancer risk or cancer development has also been reported. This evidence suggests the involvement of some specific SNPs in AHR transcriptional regulation in the process of carcinogenesis or cancer development, but there have been no studies to elucidate the mechanism involved. In this study, we identified the transcription factor Nuclear Factor 1-C (NF1C) as a candidate to regulate AHR transcription in a polymorphism-dependent manner. SNP rs10249788 was included in a consensus binding site for NF1C. Our results suggested that NF1C preferred the C allele to the T allele at rs10249788 for binding. Forced expression of NF1C suppressed the activity of the AHR promoter with C at rs10249788 stronger than that with T. Moreover, expression analysis of human uterine endometrial cancer (HEC) specimens showed greater upregulation of AHR and downregulation of NF1C than those of normal endometrium specimens. Sequence analysis showed HEC patients at advanced stages tended to possess T/T alleles more frequently than healthy women. We also demonstrated that NF1C suppressed proliferation, motility and invasion of HEC cells. This function was at least partially mediated by AHR. This study is the first to report that a polymorphism on the AHR regulatory region affected transcriptional regulation of the AHR gene in vitro. Because NF1C is a tumor suppressor, our new insights into AHR deregulation and its polymorphisms could reveal novel mechanisms of genetic susceptibility to cancer.	[Li, D.; Tsunematsu, R.; Fukushima, K.; Kobayashi, H.; Wake, N.; Asanoma, K.] Kyushu Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Fukuoka 8128582, Japan; [Takao, T.; Morokuma, S.; Wake, N.] Kyushu Univ, Grad Sch Med Sci, Res Ctr Environm & Dev Med Sci, Dept Genom Epidemiol, Fukuoka 8128582, Japan; [Saito, T.] Kyushu Natl Canc Ctr, Dept Gynecol, Fukuoka, Japan; [Furue, M.] Kyushu Univ, Grad Sch Med Sci, Dept Dermatol, Fukuoka 8128582, Japan	Kyushu University; Kyushu University; Kyushu University	Asanoma, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	asanoma@med.kyushu-u.ac.jp	Takao, Tomoka/K-1568-2015	Takao, Tomoka/0000-0002-6519-2301	Ministry of Education, Culture, Sports, Science and Technology, Japan [23249075, 23591596, 23791847, 23592405]; Ministry of Health, Labor and Welfare; Environment Technology Development Fund of the Ministry of the Environment, Japan; Grants-in-Aid for Scientific Research [23592405] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labor and Welfare(Ministry of Health, Labour and Welfare, Japan); Environment Technology Development Fund of the Ministry of the Environment, Japan; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr Suminori Kono at the Division of Environmental and Social Medicine, Kyushu University for kindly providing us with DNA from blood samples. We appreciate the technical support from Kanako Okamoto, Dr Tomoko Yoneda and the Research Support Center, Graduate School of Medical Sciences, Kyushu University. We also thank Drs Kiyoko Kato and Kiyomi Tsukimori for their valuable discussions. This work was supported by a Grant-in-Aid (23249075, 23591596, 23791847 and 23592405) from the Ministry of Education, Culture, Sports, Science and Technology, Japan. This work was also partly supported by grants from The Ministry of Health, Labor and Welfare, and the Environment Technology Development Fund of the Ministry of the Environment, Japan.	ABBOTT BD, 1995, DEV DYNAM, V204, P133, DOI 10.1002/aja.1002040204; Andersson P, 2002, P NATL ACAD SCI USA, V99, P9990, DOI 10.1073/pnas.152706299; Anttila S, 2001, PHARMACOGENETICS, V11, P501, DOI 10.1097/00008571-200108000-00005; Asanoma K, 2012, J BIOL CHEM, V287, P2257, DOI 10.1074/jbc.M111.287128; Belguise K, 2007, CANCER RES, V67, P11742, DOI 10.1158/0008-5472.CAN-07-2730; Bradshaw TD, 2002, CURR PHARM DESIGN, V8, P2475, DOI 10.2174/1381612023392784; Cauchi S, 2001, CARCINOGENESIS, V22, P1819, DOI 10.1093/carcin/22.11.1819; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; EGUCHI H, 1994, BIOCHEM BIOPH RES CO, V203, P615, DOI 10.1006/bbrc.1994.2227; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; HAY RT, 1985, EMBO J, V4, P421, DOI 10.1002/j.1460-2075.1985.tb03645.x; Higasa K, 2007, NUCLEIC ACIDS RES, V35, pD685, DOI 10.1093/nar/gkl848; Ikuta T, 2006, EXP CELL RES, V312, P3585, DOI 10.1016/j.yexcr.2006.08.002; Innocentin YLS, 2011, CELL, V147, P629, DOI 10.1016/j.cell.2011.09.025; Johansson EM, 2003, ONCOGENE, V22, P6061, DOI 10.1038/sj.onc.1206884; Khorram O, 2002, MOL HUM REPROD, V8, P75, DOI 10.1093/molehr/8.1.75; Kim JH, 2007, LUNG CANCER, V56, P9, DOI 10.1016/j.lungcan.2006.11.010; Kiss EA, 2011, SCIENCE, V334, P1561, DOI 10.1126/science.1214914; Koliopanos A, 2002, ONCOGENE, V21, P6059, DOI 10.1038/sj.onc.1205633; Kondo H, 2004, INVEST OPHTH VIS SCI, V45, P4433, DOI 10.1167/iovs.04-0544; Kuchenhoff A, 1999, FERTIL STERIL, V71, P354, DOI 10.1016/S0015-0282(98)00437-3; Kukita Y, 2005, GENOME RES, V15, P1511, DOI 10.1101/gr.4371105; Kyo S, 2003, AM J PATHOL, V163, P2259, DOI 10.1016/S0002-9440(10)63583-3; Lin PP, 2003, TOXICOL PATHOL, V31, P22, DOI 10.1080/01926230309746; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Long JR, 2006, PHARMACOGENET GENOM, V16, P237, DOI 10.1097/01.fpc.0000189803.34339.ed; Marconett CN, 2010, MOL BIOL CELL, V21, P1166, DOI 10.1091/mbc.E09-08-0689; Marlowe JL, 2005, J CELL BIOCHEM, V96, P1174, DOI 10.1002/jcb.20656; Moennikes O, 2004, CANCER RES, V64, P4707, DOI 10.1158/0008-5472.CAN-03-0875; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P4266, DOI 10.1073/pnas.80.14.4266; NEBL G, 1994, J BIOL CHEM, V269, P7371; Nilsson J, 2010, CANCER RES, V70, P2020, DOI 10.1158/0008-5472.CAN-09-1677; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; Opitz CA, 2011, NATURE, V478, P197, DOI 10.1038/nature10491; Rafty LA, 2002, EMBO J, V21, P334, DOI 10.1093/emboj/21.3.334; Rozen S, 2000, Methods Mol Biol, V132, P365; Schlezinger JJ, 2006, BIOL CHEM, V387, P1175, DOI 10.1515/BC.2006.145; Shehu A, 2011, MOL ENDOCRINOL, V25, P754, DOI 10.1210/me.2010-0261; Smart J, 2000, PHARMACOGENETICS, V10, P11, DOI 10.1097/00008571-200002000-00003; Tang TA, 2010, FREE RADICAL BIO MED, V49, P487, DOI 10.1016/j.freeradbiomed.2010.05.007; Ueoka Y, 2003, MOL CELL ENDOCRINOL, V202, P81, DOI 10.1016/S0303-7207(03)00067-4; Wong JMY, 2001, BIOCHEM BIOPH RES CO, V288, P990, DOI 10.1006/bbrc.2001.5861; Wormke M, 2000, J STEROID BIOCHEM, V72, P197, DOI 10.1016/S0960-0760(00)00030-3; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093	47	23	26	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4950	4959		10.1038/onc.2012.509	http://dx.doi.org/10.1038/onc.2012.509			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23208493				2022-12-17	WOS:000325717800011
J	Hagemann, N; Ackermann, N; Christmann, J; Brier, S; Yu, F; Erdmann, KS				Hagemann, N.; Ackermann, N.; Christmann, J.; Brier, S.; Yu, F.; Erdmann, K. S.			The serologically defined colon cancer antigen-3 interacts with the protein tyrosine phosphatase PTPN13 and is involved in the regulation of cytokinesis	ONCOGENE			English	Article						endosome; cytokinesis; Arf6; colon; vesicular trafficking; protein tyrosine phosphatase	FAS-MEDIATED APOPTOSIS; FERM DOMAIN; CELL-SURFACE; KINASE; FAP-1; TUMORIGENESIS; BL; AGGRESSIVENESS; TRAFFICKING; ANEUPLOIDY	Cytokinesis is the final step of cell division. Increasing evidence suggests failure of cytokinesis might contribute to the development of cancer. Here, we demonstrate that the serologically defined colon cancer antigen-3 (SDCCAG3) forms a complex with PTPN13, a protein tyrosine phosphatase known to be involved in the regulation of cytokinesis, carcinogenesis and tumor aggressiveness. We show that SDCCAG3 is a novel endosomal protein, primarily localized at the early/recycling endosomal compartment. SDCCAG3 undergoes dynamic localization during cell division with strong accumulation at the midbody during cytokinesis. Overexpression as well as downregulation correlates with the generation of multinucleate cells. Furthermore, we show interaction of SDCCAG3 with the Arf GTPase activating protein GIT1 (G protein-coupled receptor kinase interactor-1). Overexpression of an ArfGAP-negative version of GIT1 also results in an increased number of multinucleate cells suggesting regulation of Arf-mediated vesicular trafficking or signaling via SDCCAG3. Finally, we demonstrate that SDCCAG3 expression levels are elevated in colon cancers. In summary, we have established SDCCAG3 as a novel endosomal protein, which is involved in the regulation of cytokinesis.	[Hagemann, N.; Ackermann, N.; Christmann, J.; Brier, S.; Yu, F.; Erdmann, K. S.] Ruhr Univ Bochum, Dept Biochem 2, D-44780 Bochum, Germany	Ruhr University Bochum	Erdmann, KS (corresponding author), Univ Sheffield, Dept Biomed Sci, Ctr Membrane Interact & Dynam, Sheffield S10 2TN, S Yorkshire, England.	k.erdmann@sheffield.ac.uk	Brier, Sebastien/L-7787-2019	Brier, Sebastien/0000-0003-1758-8237; Christmann, Jens/0000-0002-8625-2991	German research foundation [SFB642]	German research foundation(German Research Foundation (DFG))	We would like to thank Rolf Heumann for longstanding support. This work was supported by a grant from the German research foundation (SFB642) to KSE.	Abaan OD, 2005, ONCOGENE, V24, P2715, DOI 10.1038/sj.onc.1208247; Ai Erkang, 2009, Communicative & Integrative Biology, V2, P444; Bompard G, 2003, J CELL SCI, V116, P2519, DOI 10.1242/jcs.00448; Chesneau L, 2012, CURR BIOL, V22, P147, DOI 10.1016/j.cub.2011.11.058; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; Cuppen E, 1999, J CELL SCI, V112, P3299; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Echard A, 2008, BIOCHEM SOC T, V36, P395, DOI 10.1042/BST0360395; Erdmann KS, 2003, EUR J BIOCHEM, V270, P4789, DOI 10.1046/j.1432-1033.2003.03895.x; Freiss G, 2011, ANTI-CANCER AGENT ME, V11, P78, DOI 10.2174/187152011794941262; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Glondu-Lassis M, 2010, CANCER RES, V70, P5116, DOI 10.1158/0008-5472.CAN-09-4368; Gross C, 2001, FEBS LETT, V496, P101, DOI 10.1016/S0014-5793(01)02401-2; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Hendriks W, 1995, J CELL BIOCHEM, V59, P418, DOI 10.1002/jcb.240590403; Herrmann L, 2003, MOL BIOL CELL, V14, P230, DOI 10.1091/mbc.E02-04-0191; Hoover AC, 2009, ONCOGENE, V28, P3960, DOI 10.1038/onc.2009.251; Ivanov VN, 2003, MOL CELL BIOL, V23, P3623, DOI 10.1128/MCB.23.10.3623-3635.2003; Kouranti I, 2006, CURR BIOL, V16, P1719, DOI 10.1016/j.cub.2006.07.020; Lahuna O, 2005, EMBO J, V24, P1364, DOI 10.1038/sj.emboj.7600616; Li Y, 2000, INT J CANCER, V87, P473, DOI 10.1002/1097-0215(20000815)87:4<473::AID-IJC3>3.0.CO;2-1; Montagnac G, 2008, CURR OPIN CELL BIOL, V20, P454, DOI 10.1016/j.ceb.2008.03.011; Montagnac G, 2009, CURR BIOL, V19, P184, DOI 10.1016/j.cub.2008.12.043; Neto H, 2011, BIOCHEM J, V437, P13, DOI 10.1042/BJ20110153; Neznanov N, 2005, DNA CELL BIOL, V24, P777, DOI 10.1089/dna.2005.24.777; Prekeris R, 2008, J CELL SCI, V121, P1569, DOI 10.1242/jcs.018770; Premont RT, 2000, J BIOL CHEM, V275, P22373, DOI 10.1074/jbc.275.29.22373; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Scanlan MJ, 1998, INT J CANCER, V76, P652, DOI 10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9; Schickel R, 2010, MOL CELL, V38, P908, DOI 10.1016/j.molcel.2010.05.018; Schmidt A, 2007, EMBO J, V26, P1624, DOI 10.1038/sj.emboj.7601637; Schweitzer JK, 2005, EXP CELL RES, V311, P74, DOI 10.1016/j.yexcr.2005.07.033; Scrima M, 2012, AM J PATHOL, V180, P1202, DOI 10.1016/j.ajpath.2011.11.038; Steigemann P, 2009, CELL, V136, P473, DOI 10.1016/j.cell.2008.12.020; Stelzl U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029; Ungefroren H, 2001, J CELL SCI, V114, P2735; Ungefroren H, 1998, CANCER RES, V58, P1741; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Weaver BAA, 2007, CANCER RES, V67, P10103, DOI 10.1158/0008-5472.CAN-07-2266; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035; Zhu JH, 2008, ONCOGENE, V27, P2525, DOI 10.1038/sj.onc.1210922	43	23	28	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2013	32	39					4602	4613		10.1038/onc.2012.485	http://dx.doi.org/10.1038/onc.2012.485			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23108400				2022-12-17	WOS:000325072200002
J	Schroeder, MC; Chen, CL; Gajewski, K; Halder, G				Schroeder, M. C.; Chen, C-L; Gajewski, K.; Halder, G.			A non-cell-autonomous tumor suppressor role for Stat in eliminating oncogenic scribble cells	ONCOGENE			English	Article						cell competition; JAK/STAT; scribble	TISSUE OVERGROWTH; GENETIC MOSAICS; DROSOPHILA; GROWTH; POLARITY; PATHWAY; COMPETITION; ACTIVATION; EXPRESSION; MUTANTS	Elucidating signaling events between tumor cells and their microenvironment is a major challenge in understanding cancer development. Drosophila melanogaster has emerged as an important tool for dissecting the genetic circuits tumors depend on because their imaginal discs, simple epithelia present in the larva, can be genetically manipulated to serve as models to study cancer mechanisms. Imaginal disc cells mutant for the tumor-suppressor gene scribble (scrib) lose apical-basal polarity and have the potential to form large neoplastic tumors. Interestingly, when scrib mutant (scrib(-)) cells are surrounded by normal cells the scrib(-) population is eliminated. However, the signals and mechanisms that cause the elimination of clones of scrib(-) cells are poorly understood. Here, we analyzed the role of Stat, a component of the JAK/STAT signaling pathway, in tissues with clones of scrib(-) cells. We found that Stat activity is required in normal cells for the elimination of neighboring scrib(-) cells. Importantly, these competitive defects of stat mutant cells are not simply due to defects in cell proliferation because even stat(-) cells manipulated to hyperproliferate are unable to eliminate scrib(-) cells. These data identify Stat activity as a critical determinant of whether or not a tissue can eliminate abnormal cells and provide an important step forward in understanding the complex network of signals operating in and around tumorigenic cells.	[Schroeder, M. C.; Halder, G.] Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; [Schroeder, M. C.; Chen, C-L; Halder, G.] Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Chen, C-L; Halder, G.] Univ Texas MD Anderson Canc Ctr, Program Genes & Dev, Houston, TX 77030 USA; [Gajewski, K.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Halder, G.] Univ Louvain, KU Leuven Ctr Human Genet, VIB Ctr Biol Dis, B-3000 Louvain, Belgium; [Chen, C-L] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Flanders Institute for Biotechnology (VIB); KU Leuven; Harvard University; Harvard Medical School	Halder, G (corresponding author), Univ Louvain, KU Leuven Ctr Human Genet, VIB Ctr Biol Dis, B-3000 Louvain, Belgium.	georg.halder@med.kuleuven.be	Halder, Georg/F-2966-2015	Halder, Georg/0000-0001-7580-3236	NIH; Baylor Research Advocates for Student Scientists scholarship	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Baylor Research Advocates for Student Scientists scholarship	We thank Erika Bach, Hugo Bellen, Andreas Bergmann, David Bilder, Michael Galko, Robert Holmgren, Kenneth Irvine, Jin Jiang, Ed Laufer, Graeme Mardon, Sang-Chul Nam, Duojia Pan, Hong Wen and the Developmental Studies Hybridoma Bank (University of Iowa) for fly stocks and antibodies. We thank Leisa McCord for artwork and the Halder lab for discussions. This work was supported by an NIH grant to GH and a Baylor Research Advocates for Student Scientists scholarship to MCS.	Bach EA, 2007, GENE EXPR PATTERNS, V7, P323, DOI 10.1016/j.modgep.2006.08.003; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Blair SS, 2003, DEVELOPMENT, V130, P5065, DOI 10.1242/dev.00774; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Chen CL, 2012, P NATL ACAD SCI USA, V109, P484, DOI 10.1073/pnas.1113882109; Cordero JB, 2010, DEV CELL, V18, P999, DOI 10.1016/j.devcel.2010.05.014; de la Cova C, 2004, CELL, V117, P107, DOI 10.1016/S0092-8674(04)00214-4; Doggett K, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-57; Ekas LA, 2006, DEVELOPMENT, V133, P4721, DOI 10.1242/dev.02675; Flaherty MS, 2009, DEV DYNAM, V238, P2235, DOI 10.1002/dvdy.21989; Grusche FA, 2011, DEV BIOL, V350, P255, DOI 10.1016/j.ydbio.2010.11.020; Halder G, 2011, DEVELOPMENT, V138, P9, DOI 10.1242/dev.045500; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Humbert PO, 2008, ONCOGENE, V27, P6888, DOI 10.1038/onc.2008.341; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Igaki T, 2009, APOPTOSIS, V14, P1021, DOI 10.1007/s10495-009-0361-7; Igaki T, 2009, DEV CELL, V16, P458, DOI 10.1016/j.devcel.2009.01.002; Johnston LA, 2009, SCIENCE, V324, P1679, DOI 10.1126/science.1163862; Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4; Leong GR, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-62; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; Moreno E, 2008, NAT REV CANCER, V8, P141, DOI 10.1038/nrc2252; Narisawa A, 2012, HUM MOL GENET, V21, P1496, DOI 10.1093/hmg/ddr585; Neto-Silva RM, 2010, DEV CELL, V19, P507, DOI 10.1016/j.devcel.2010.09.009; Newsome TP, 2000, DEVELOPMENT, V127, P851; Ohsawa S, 2011, DEV CELL, V20, P315, DOI 10.1016/j.devcel.2011.02.007; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Rogulja D, 2008, DEV CELL, V15, P309, DOI 10.1016/j.devcel.2008.06.003; Silver DL, 2001, CELL, V107, P831, DOI 10.1016/S0092-8674(01)00607-9; Tyler DM, 2007, GENETICS, V175, P643, DOI 10.1534/genetics.106.061929; Uhlirova M, 2005, P NATL ACAD SCI USA, V102, P13123, DOI 10.1073/pnas.0504170102; Willecke M, 2008, P NATL ACAD SCI USA, V105, P14897, DOI 10.1073/pnas.0805201105; Wu M, 2010, NATURE, V463, P545, DOI 10.1038/nature08702; XU T, 1993, DEVELOPMENT, V117, P1223; XU TA, 1995, DEVELOPMENT, V121, P1053; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yuan M, 2008, CELL DEATH DIFFER, V15, P1752, DOI 10.1038/cdd.2008.108; Zeidler MP, 2000, ONCOGENE, V19, P2598, DOI 10.1038/sj.onc.1203482; Ziosi M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001140	42	23	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2013	32	38					4471	4479		10.1038/onc.2012.476	http://dx.doi.org/10.1038/onc.2012.476			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23108407				2022-12-17	WOS:000324831300002
J	Ying, M; Liu, G; Shimada, H; Ding, W; May, WA; He, Q; Adams, GB; Wu, L				Ying, M.; Liu, G.; Shimada, H.; Ding, W.; May, W. A.; He, Q.; Adams, G. B.; Wu, L.			Human osteosarcoma CD49f(-) CD133(+) cells: impaired in osteogenic fate while gain of tumorigenicity	ONCOGENE			English	Article						osteosarcoma-initiating cells; self-renewal; tumorigenicity; lineage differentiation; osteosarcoma-forming cells; osteogenic differentiation	CANCER-STEM-CELLS; PROSPECTIVE IDENTIFICATION; INITIATING CELLS; TUMOR-GROWTH; EXPRESSION; DIFFERENTIATION; MARKERS; METASTASIS; EXPANSION; ANTIGEN	The biological relationships among self-renewal, tumorigenicity and lineage differentiation of human osteosarcoma-initiating cells (OSIC) remain elusive, making it difficult to identify and distinguish OSIC from osteosarcoma-forming cells (OSFC) for developing OSIC-targeted therapies. Using a new inverse-lineage tracking strategy coupled with serial human-to-mouse xenotransplantation, we identified a subpopulation of osteosarcoma cells with OSIC-like properties and sought to distinguish them from their progeny, OSFC. We found that serial transplantation of cells from different osteosarcoma cell lines and primary osteosarcoma tissues progressively increased the CD49f(+) subpopulation composing the bulk of the osteosarcoma mass. These CD49f(+) cells displayed characteristics of OSFC: limited in vivo tumorigenicity, weak lineage differentiation, more differentiated osteogenic feature and greater chemo-sensitivity. By contrast, their parental CD49f(-) CD133(+) cells had an inhibited osteogenic fate, together with OSIC-like properties of self-renewal, strong tumorigenicity and differentiation to CD49f(+) progeny. Hence, the CD49f(-)CD133(+) phenotype appears to identify OSIC-like cells that possess strong tumorigenicity correlated with an impaired osteogenic fate and the ability to initiate tumor growth through the generation of CD49f(+) progeny. These findings advance our understanding of OSIC-like properties and, for the first time, provide a much-needed distinction between OSIC and OSFC in this cancer.	[Ying, M.; Liu, G.; Shimada, H.; Ding, W.; Wu, L.] Childrens Hosp Los Angeles, Dept Pathol, Saban Res Inst, Los Angeles, CA 90027 USA; [Shimada, H.; May, W. A.; Adams, G. B.; Wu, L.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90027 USA; [May, W. A.] Childrens Hosp Los Angeles, Dept Pediat, Saban Res Inst, Los Angeles, CA 90027 USA; [He, Q.] Zhejiang Univ, Sch Pharmaceut Sci, Inst Pharmacol & Toxicol, Hangzhou 310003, Zhejiang, Peoples R China; [Adams, G. B.] Univ So Calif, Keck Sch Med, Ctr Stem Cell & Regenerat Med, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California; Children's Hospital Los Angeles; Zhejiang University; University of Southern California	Wu, L (corresponding author), Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Dept Pathol, MS 103,4650 Sunset Blvd, Los Angeles, CA 90027 USA.	lingtaow@usc.edu	Liu, Gang/B-7635-2012		National Institutes of Health [R01 CA120512, ARRA-R01CA120512]; NATIONAL CANCER INSTITUTE [R21CA137485, R01CA120512] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Institutes of Health (R01 CA120512 and ARRA-R01CA120512 to LW).	Adhikari AS, 2010, CANCER RES, V70, P4602, DOI 10.1158/0008-5472.CAN-09-3463; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bakhshi S, 2010, EXPERT REV ANTICANC, V10, P271, DOI 10.1586/ERA.09.186; Bomken S, 2010, BRIT J CANCER, V103, P439, DOI 10.1038/sj.bjc.6605821; Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630; Chou Alexander J, 2008, Paediatr Drugs, V10, P315, DOI 10.2165/00148581-200810050-00005; Cox CV, 2007, BLOOD, V109, P674, DOI 10.1182/blood-2006-06-030445; Cox CV, 2004, BLOOD, V104, P2919, DOI 10.1182/blood-2004-03-0901; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Dewan MZ, 2006, BIOMED PHARMACOTHER, V60, P273, DOI 10.1016/j.biopha.2006.06.004; Di Fiore R, 2009, J CELL PHYSIOL, V219, P301, DOI 10.1002/jcp.21667; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Dylla SJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002428; Ferrandina G, 2009, EXPERT OPIN THER TAR, V13, P823, DOI 10.1517/14728220903005616; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hong DL, 2008, SCIENCE, V319, P336, DOI 10.1126/science.1150648; Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008-5472.CAN-08-4418; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Joo KM, 2008, LAB INVEST, V88, P808, DOI 10.1038/labinvest.2008.57; Joo KM, 2009, METHODS MOL BIOL, V568, P57, DOI 10.1007/978-1-59745-280-9_5; Kang HG, 2007, CANCER RES, V67, P3094, DOI 10.1158/0008-5472.CAN-06-3259; Lathia JD, 2010, CELL STEM CELL, V6, P421, DOI 10.1016/j.stem.2010.02.018; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lee RH, 2009, BLOOD, V113, P816, DOI 10.1182/blood-2007-12-128702; Levings PP, 2009, CANCER RES, V69, P5648, DOI 10.1158/0008-5472.CAN-08-3580; Luo P, 2010, ONCOGENE, V29, P2772, DOI 10.1038/onc.2010.50; Luo PH, 2007, STEM CELLS, V25, P2628, DOI 10.1634/stemcells.2007-0264; Majetl R, 2009, P NATL ACAD SCI USA, V106, P3396, DOI 10.1073/pnas.0900089106; Maxson S, 2008, J TISSUE ENG REGEN M, V2, P147, DOI 10.1002/term.76; Mizrak D, 2008, J PATHOL, V214, P3, DOI 10.1002/path.2283; Noel AC, 1996, J CLIN INVEST, V97, P1924, DOI 10.1172/JCI118624; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; Oda Y, 2006, MODERN PATHOL, V19, P738, DOI 10.1038/modpathol.3800587; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Rountree CB, 2009, STEM CELLS, V27, P290, DOI 10.1634/stemcells.2008-0332; Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999-008-0335-z; Thomas D, 2006, J CELL BIOCHEM, V98, P757, DOI 10.1002/jcb.20850; Tirino V, 2011, FASEB J, V25, P2022, DOI 10.1096/fj.10-179036; Tirino V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003469; Wang L, 2011, INT J CANCER, V128, P294, DOI 10.1002/ijc.25331; Woodward WA, 2008, CANCER METAST REV, V27, P459, DOI 10.1007/s10555-008-9130-2; Wu Y, 2010, NATURE, V464, P1052, DOI 10.1038/nature08878; Wu YJ, 2009, STEM CELLS DEV, V18, P1127, DOI 10.1089/scd.2008.0338; Zhang WL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011917	47	23	25	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2013	32	36					4252	4263		10.1038/onc.2012.438	http://dx.doi.org/10.1038/onc.2012.438			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23045288	Green Accepted			2022-12-17	WOS:000324168000007
J	Dolfini, D; Mantovani, R				Dolfini, D.; Mantovani, R.			YB-1 (YBX1) does not bind to Y/CCAAT boxes in vivo	ONCOGENE			English	Letter									[Dolfini, D.; Mantovani, R.] Univ Milan, Dipartimento Biosci, Milan, Italy	University of Milan	Dolfini, D (corresponding author), Univ Milan, Dipartimento Biosci, Via Celoria 26, Milan, Italy.	mantor@unimi.it	DOLFINI, DILETTA/D-8286-2017	DOLFINI, DILETTA/0000-0002-5346-6096				Astanehe A, 2012, ONCOGENE, V31, P4434, DOI 10.1038/onc.2011.617; Dolfini D, 2012, CRIT REV BIOCHEM MOL, V47, P29, DOI 10.3109/10409238.2011.628970; Eliseeva IA, 2011, BIOCHEMISTRY-MOSCOW+, V76, P1402, DOI 10.1134/S0006297911130049; Goodarzi H, 2009, MOL CELL, V36, P900, DOI 10.1016/j.molcel.2009.11.016; Tiwari VK, 2012, NAT GENET, V44, P94, DOI 10.1038/ng.1036; Wang J, 2012, GENOME RES, V22, P1798, DOI 10.1101/gr.139105.112	6	23	23	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2013	32	35					4189	4190		10.1038/onc.2012.521	http://dx.doi.org/10.1038/onc.2012.521			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	23160378	Bronze			2022-12-17	WOS:000323748500014
J	Thuault, S; Hayashi, S; Lagirand-Cantaloube, J; Plutoni, C; Comunale, F; Delattre, O; Relaix, F; Gauthier-Rouviere, C				Thuault, S.; Hayashi, S.; Lagirand-Cantaloube, J.; Plutoni, C.; Comunale, F.; Delattre, O.; Relaix, F.; Gauthier-Rouviere, C.			P-cadherin is a direct PAX3-FOXO1A target involved in alveolar rhabdomyosarcoma aggressiveness	ONCOGENE			English	Article						P-cadherin; rhabdomyosarcoma; PAX3-FOXO1A; invasion; cadherin switch	TRANSCRIPTIONAL ACTIVATOR; SKELETAL MYOGENESIS; CELL-MIGRATION; GENE FUSIONS; PAX GENES; EXPRESSION; PAX3-FKHR; IDENTIFICATION; FAMILY; TRANSFORMATION	Alveolar rhabdomyosarcoma (ARMS) is an aggressive childhood cancer of striated muscle characterized by the presence of the PAX3-FOXO1A or PAX7-FOXO1A chimeric oncogenic transcription factor. Identification of their targets is essential for understanding ARMS pathogenesis. To this aim, we analyzed transcriptomic data from rhabdomyosarcoma samples and found that P-cadherin expression is correlated with PAX3/7-FOXO1A presence. We then show that expression of a PAX3 dominant negative variant inhibits P-cadherin expression in ARMS cells. Using mouse models carrying modified Pax3 alleles, we demonstrate that P-cadherin is expressed in the dermomyotome and lies genetically downstream from the myogenic factor Pax3. Moreover, in vitro gel shift analysis and chromatin immunoprecipitation indicate that the P-cadherin gene is a direct transcriptional target for PAX3/7-FOXO1A. Finally, P-cadherin expression in normal myoblasts inhibits myogenesis and induces myoblast transformation, migration and invasion. Conversely, P-cadherin downregulation by small hairpin RNA decreases the transformation, migration and invasive potential of ARMS cells. P-cadherin also favors cadherin switching, which is a hallmark of metastatic progression, by controlling N- and M-cadherin expression and/or localization. Our findings demonstrate that P-cadherin is a direct PAX3-FOXO1A transcriptional target involved in ARMS aggressiveness. Therefore, P-cadherin emerges as a new and attractive target for therapeutic intervention in ARMS. Oncogene (2013) 32, 1876-1887; doi:10.1038/onc.2012.217; published online 18 June 2012	[Thuault, S.; Lagirand-Cantaloube, J.; Plutoni, C.; Comunale, F.; Gauthier-Rouviere, C.] Univ Montpellier 2, CRBM, CNRS, UMR 5237, F-34293 Montpellier, France; [Thuault, S.; Lagirand-Cantaloube, J.; Plutoni, C.; Comunale, F.; Gauthier-Rouviere, C.] Univ Montpellier I, CRBM, CNRS, UMR 5237, F-34293 Montpellier, France; [Hayashi, S.; Relaix, F.] INSERM UPMC AIM, UMRS787, Paris, France; [Delattre, O.] Inst Curie, INSERM Unite 830, Unite Genet Somat, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite	Gauthier-Rouviere, C (corresponding author), Univ Montpellier 2, CRBM, CNRS, UMR 5237, 1919 Route Mende, F-34293 Montpellier, France.	cecile.gauthier@crbm.cnrs.fr		THUAULT, Sylvie/0000-0003-0133-3803; Relaix, Frederic/0000-0003-1270-1472; Comunale, Franck/0000-0001-8838-2151; Hayashi, Shinichiro/0000-0001-5553-7698; delattre, olivier/0000-0002-8730-2276; GAUTHIER-ROUVIERE, Cecile/0000-0002-8364-3882	"Cartes d'Identite des Tumeurs" program of the Ligue Nationale contre le Cancer; Ligue Nationale contre le Cancer (LNCC) ("Equipe labellisee"); Institut National du Cancer (INCa); INSERM; INCa; Association pour la Recherche contre le Cancer (ARC); INSERM Avenir Program; Association Francaise Contre les Myopathies; LNCC; ARC; Fondation pour la Recherche Medicale; European Union, project ENDOSTEM [241440]	"Cartes d'Identite des Tumeurs" program of the Ligue Nationale contre le Cancer; Ligue Nationale contre le Cancer (LNCC) ("Equipe labellisee"); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); INCa(Institut National du Cancer (INCA) France); Association pour la Recherche contre le Cancer (ARC)(Fondation ARC pour la Recherche sur le CancerFrench National Research Agency (ANR)); INSERM Avenir Program(Institut National de la Sante et de la Recherche Medicale (Inserm)); Association Francaise Contre les Myopathies(Association Francaise contre les Myopathies); LNCC; ARC(Australian Research Council); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); European Union, project ENDOSTEM	We thank Vincent Mouly for the LHCN-M2 myoblasts, Setsuo Hirohashi and Keith Johnson for the P-cadherin cDNA, Mickael Rudnicki for the pBRIT plasmid, Pete Zammit for the pMSCV-Pax3-En-IRES-eGFP plasmids. We thank the Montpellier Imaging Facility (http://www.mri.cnrs.fr/) and Lionel Larue, Sophie Charrasse and Stephane Bodin for discussion. This work was supported by the "Cartes d'Identite des Tumeurs" program (http://cit.ligue-cancer.net/) of the Ligue Nationale contre le Cancer, the Ligue Nationale contre le Cancer (LNCC) ("Equipe labellisee") and the Institut National du Cancer (INCa). CGR was supported by INSERM, ST by INCa and JLC by the Association pour la Recherche contre le Cancer (ARC). FR's team is supported by the INSERM Avenir Program, Association Francaise Contre les Myopathies, LNCC, ARC, Fondation pour la Recherche Medicale, INCa and from the European Union Seventh Framework Programme, project ENDOSTEM (number 241440).	Bach AS, 2010, MOL BIOL CELL, V21, P2412, DOI 10.1091/mbc.E09-12-1063; Bajard L, 2006, GENE DEV, V20, P2450, DOI 10.1101/gad.382806; Barr FG, 2001, ONCOGENE, V20, P5736, DOI 10.1038/sj.onc.1204599; Ben-Yair R, 2005, DEVELOPMENT, V132, P689, DOI 10.1242/dev.01617; Buckingham M, 2007, ANNU REV CELL DEV BI, V23, P645, DOI 10.1146/annurev.cellbio.23.090506.123438; Cao LA, 2010, CANCER RES, V70, P6497, DOI 10.1158/0008-5472.CAN-10-0582; Cavallaro U, 2002, CANCER LETT, V176, P123, DOI 10.1016/S0304-3835(01)00759-5; Charrasse S, 2004, ONCOGENE, V23, P2420, DOI 10.1038/sj.onc.1207382; Charrasse S, 2002, J CELL BIOL, V158, P953, DOI 10.1083/jcb.200202034; Cheung LWT, 2010, ONCOGENE, V29, P2427, DOI 10.1038/onc.2009.523; Christofori G, 2003, EMBO J, V22, P2318, DOI 10.1093/emboj/cdg228; Collins CA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004475; Davicioni E, 2006, CANCER RES, V66, P6936, DOI 10.1158/0008-5472.CAN-05-4578; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; Fortier M, 2008, CELL DEATH DIFFER, V15, P1221, DOI 10.1038/cdd.2008.34; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; Gadea G, 2007, J CELL BIOL, V178, P23, DOI 10.1083/jcb.200701120; Grass B, 2009, HISTOPATHOLOGY, V54, P873, DOI 10.1111/j.1365-2559.2009.03303.x; Hayashi S, 2011, MOL BIOL EVOL, V28, P2787, DOI 10.1093/molbev/msr114; Imai K, 2008, CLIN CANCER RES, V14, P6487, DOI 10.1158/1078-0432.CCR-08-1086; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Kjaer KW, 2005, J MED GENET, V42, P292, DOI 10.1136/jmg.2004.027821; Kucharczak J, 2008, CANCER RES, V68, P6559, DOI 10.1158/0008-5472.CAN-08-0196; Lae M, 2007, J PATHOL, V212, P143, DOI 10.1002/path.2170; Manceau M, 2008, GENE DEV, V22, P668, DOI 10.1101/gad.454408; McKinnell IW, 2008, NAT CELL BIOL, V10, P77, DOI 10.1038/ncb1671; Meriane M, 2000, MOL BIOL CELL, V11, P2513, DOI 10.1091/mbc.11.8.2513; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; NOSE A, 1987, EMBO J, V6, P3655, DOI 10.1002/j.1460-2075.1987.tb02698.x; Paredes J, 2005, CLIN CANCER RES, V11, P5869, DOI 10.1158/1078-0432.CCR-05-0059; Park J, 2011, INVEST NEW DRUGS, V11, P9710; Puskulluoglu M, 2010, FOLIA HISTOCHEM CYTO, V48, P671, DOI 10.2478/v10042-010-0046-7; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; Relaix F, 2006, J CELL BIOL, V172, P91, DOI 10.1083/jcb.200508044; Relaix F, 2003, GENE DEV, V17, P2950, DOI 10.1101/gad.281203; Robson EJD, 2006, NAT REV CANCER, V6, P52, DOI 10.1038/nrc1778; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; Tarnowski M, 2010, MOL CANCER RES, V8, P1, DOI 10.1158/1541-7786.MCR-09-0259; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Wachtel M, 2006, J CLIN ONCOL, V24, P816, DOI 10.1200/JCO.2005.03.4934; Wachtel M, 2004, CANCER RES, V64, P5539, DOI 10.1158/0008-5472.CAN-04-0844; Wheelock MJ, 2008, J CELL SCI, V121, P727, DOI 10.1242/jcs.000455; Wiercinska E, 2011, BREAST CANCER RES TR, V128, P657, DOI 10.1007/s10549-010-1147-x; Williamson D, 2010, J CLIN ONCOL, V28, P2151, DOI 10.1200/JCO.2009.26.3814; Zhang CC, 2010, CLIN CANCER RES, V16, P5177, DOI 10.1158/1078-0432.CCR-10-1343	46	23	23	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2013	32	15					1876	1887		10.1038/onc.2012.217	http://dx.doi.org/10.1038/onc.2012.217			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22710718				2022-12-17	WOS:000317599900002
J	Kashyap, A; Zimmerman, T; Ergul, N; Bosserhoff, A; Hartman, U; Alla, V; Bataille, F; Galle, PR; Strand, S; Strand, D				Kashyap, A.; Zimmerman, T.; Erguel, N.; Bosserhoff, A.; Hartman, U.; Alla, V.; Bataille, F.; Galle, P. R.; Strand, S.; Strand, D.			The human Lgl polarity gene, Hugl-2, induces MET and suppresses Snail tumorigenesis	ONCOGENE			English	Article						Lgl; Hugl-2; Snail; EMT; MET; tumour suppression	EPITHELIAL-MESENCHYMAL TRANSITIONS; TRANSCRIPTION FACTOR SNAIL; SQUAMOUS-CELL CARCINOMAS; E-CADHERIN EXPRESSION; TUMOR-SUPPRESSOR; HEPATOCELLULAR-CARCINOMA; DROSOPHILA-MELANOGASTER; PANCREATIC-CANCER; BREAST-CANCER; PRIMARY HEAD	Lethal giant larvae proteins have key roles in regulating polarity in a variety of cell types and function as tumour suppressors. A transcriptional programme initiated by aberrant Snail expression transforms epithelial cells to potentially aggressive cancer cells. Although progress in defining the molecular determinants of this programme has been made, we have little knowledge as to how the Snail-induced phenotype can be suppressed. In our studies we identified the human lethal giant larvae homologue 2, Hugl-2, (Llgl2/Lgl2) polarity gene as downregulated by Snail. Snail binds E-boxes in the Hugl-2 promoter and represses Hugl-2 expression, whereas removal of the E-boxes releases Hugl-2 from Snail repression. We demonstrate that inducing Hugl-2 in cells with constitutive Snail expression reverses the phenotype including changes in morphology, motility, tumour growth and dissemination in vivo, and expression of epithelial markers. Hugl-2 expression reduced the nuclear localization of Snail and thus binding of Snail to its target promoters. Our results placing Hugl-2 within the Snail network as well as its ability to suppress Snail carcinogenesis identifies Hugl-2 as a target molecule driving cascades, which may have preventative and therapeutic promise to minimize cancer progression. Oncogene (2013) 32, 1396-1407; doi:10.1038/onc.2012.162; published online 14 May 2012	[Kashyap, A.; Zimmerman, T.; Erguel, N.; Hartman, U.; Alla, V.; Galle, P. R.; Strand, S.; Strand, D.] Johannes Gutenberg Univ Mainz, Dept Internal Med 1, D-55101 Mainz, Germany; [Bosserhoff, A.; Bataille, F.] Univ Regensburg, Inst Pathol, D-93053 Regensburg, Germany	Johannes Gutenberg University of Mainz; University of Regensburg	Strand, D (corresponding author), Johannes Gutenberg Univ Mainz, Dept Internal Med 1, Obere Zahlbacherstr 63, D-55101 Mainz, Germany.	dstrand@uni-mainz.de	Galle, Peter R/T-5292-2018; Galle, Peter/ABE-2872-2021; Bosserhoff, Anja/GNH-4801-2022	Galle, Peter R/0000-0001-8294-0992; Galle, Peter/0000-0001-8294-0992; Bosserhoff, Anja/0000-0001-8147-394X	MAIFOR program	MAIFOR program	We thank A Garcia de Herreros for allowing us to use the Snail-HA expression plasmid and PH Krammer for providing anti-Apo-1 antibody. MDA-MB-231 cells were a gift of Thomas Efferth. We kindly thank Anil K Rustgi and Eric R Fearon for providing CyclinD1- and E-cadherin-luciferase constructs, respectively. The expert technical assistance of Mirjam Weisser, Daniela Gottfried, Henry Alizor, Shenchu Jin and Henning Janssen is gratefully acknowledged. Special thanks to the laser-scanning microscopy Core Facility of the Forschungszentrum Immunolgie Mainz. This work was supported by grants from the MAIFOR program to DS and SS. DS and SS should be considered as equal senior authors.	Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Aichberger KJ, 2009, BLOOD, V114, P5342, DOI 10.1182/blood-2008-08-175190; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Albertson R, 2003, NAT CELL BIOL, V5, P166, DOI 10.1038/ncb922; Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Brown CJ, 2009, NAT REV CANCER, V9, P862, DOI 10.1038/nrc2763; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Dahiya N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002436; Froldi F, 2008, CURR GENOMICS, V9, P147, DOI 10.2174/138920208784340786; Gaspar C, 2008, AM J PATHOL, V172, P1363, DOI 10.2353/ajpath.2008.070851; GATEFF E, 1967, AM ZOOL, V7, P760; Gavert N, 2008, TRENDS MOL MED, V14, P199, DOI 10.1016/j.molmed.2008.03.004; Grifoni D, 2007, ONCOGENE, V26, P5960, DOI 10.1038/sj.onc.1210389; Grifoni D, 2004, ONCOGENE, V23, P8688, DOI 10.1038/sj.onc.1208023; Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336; Harada T, 2009, PANCREATOLOGY, V9, P13, DOI 10.1159/000178871; Hensen EF, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-168; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Klezovitch O, 2004, GENE DEV, V18, P559, DOI 10.1101/gad.1178004; Kuphal S, 2006, ONCOGENE, V25, P103, DOI 10.1038/sj.onc.1209008; Lassmann S, 2007, J MOL MED-JMM, V85, P289, DOI 10.1007/s00109-006-0126-5; Lee MH, 2008, J CELL SCI, V121, P1141, DOI 10.1242/jcs.016634; Lisovsky M, 2010, HUM PATHOL, V41, P902, DOI 10.1016/j.humpath.2009.12.004; Lisovsky M, 2009, MODERN PATHOL, V22, P977, DOI 10.1038/modpathol.2009.68; Lu XF, 2009, CLIN CANCER RES, V15, P3287, DOI 10.1158/1078-0432.CCR-08-2078; Maas K, 2002, J IMMUNOL, V169, P5, DOI 10.4049/jimmunol.169.1.5; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; Miyoshi A, 2005, BRIT J CANCER, V92, P252, DOI 10.1038/sj.bjc.6602266; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Moreno-Bueno G, 2011, EMBO MOL MED, V3, P528, DOI 10.1002/emmm.201100156; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Ohali A, 2004, ONCOGENE, V23, P8997, DOI 10.1038/sj.onc.1208060; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pena C, 2009, ONCOGENE, V28, P4375, DOI 10.1038/onc.2009.285; Roepman P, 2005, NAT GENET, V37, P182, DOI 10.1038/ng1502; Schimanski CC, 2005, ONCOGENE, V24, P3100, DOI 10.1038/sj.onc.1208520; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Skotheim RI, 2002, CANCER RES, V62, P2359; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Taxman DJ, 2003, CANCER RES, V63, P5095; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tomioka H, 2006, J ORAL PATHOL MED, V35, P206, DOI 10.1111/j.1600-0714.2006.00410.x; Tsuruga T, 2007, ONCOL RES, V16, P431, DOI 10.3727/000000007783980855; Veekony H, 2007, CLIN CANCER RES, V13, P3133, DOI 10.1158/1078-0432.CCR-06-2555; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398	51	23	24	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2013	32	11					1396	1407		10.1038/onc.2012.162	http://dx.doi.org/10.1038/onc.2012.162			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22580609				2022-12-17	WOS:000316455600006
J	Liu, J; Cheng, X; Zhang, Y; Li, S; Cui, H; Zhang, L; Shi, R; Zhao, Z; He, C; Wang, C; Zhao, H; Zhang, C; Fisk, HA; Guadagno, TM; Cui, Y				Liu, J.; Cheng, X.; Zhang, Y.; Li, S.; Cui, H.; Zhang, L.; Shi, R.; Zhao, Z.; He, C.; Wang, C.; Zhao, H.; Zhang, C.; Fisk, H. A.; Guadagno, T. M.; Cui, Y.			Phosphorylation of Mps1 by BRAF(V600E) prevents Mps1 degradation and contributes to chromosome instability in melanoma	ONCOGENE			English	Article						BRAF(V600E); Mps1; centrosome amplification; chromosome instability; melanoma	SPINDLE-CHECKPOINT; CENTROSOME DUPLICATION; KINASE-ACTIVITY; CELL-CYCLE; ACTIVATION; BRAF; AMPLIFICATION; ACCUMULATION; KINETOCHORES; MUTATIONS	Activating BRAF mutations that deregulate the mitogen-activated protein kinase (MAPK) pathway commonly occur in cancer. BRAF(V600E) induces centrosome amplification and spindle abnormalities that result in aneuploidy. We find modification of Mps1 is critical for contributing to centrosome amplification and chromosome instability induced by BRAF(V600E). Phosphorylation of Mps1 at residue S281 induced by BRAF(V600E) stabilizes Mps1 protein by preventing its ubiquitination by APC/C and subsequent degradation, allowing the non-degraded protein to accumulate at centrosomes. Cells in which endogenous Mps1 was replaced with a phospho-mimetic Mps1 mutant are viable but amplify centrosomes and missegregate chromosomes frequently. Importantly, analysis of tumor micro arrays revealed that phospho-MAPK and 5281-phosphorylated Mps1 were highly correlated in human melanoma tissues, implying that MAPK contributes to defects in the degradation of Mps1 in situ. We propose that continuously activated BRAF(V600E) signaling may be a possible mechanism for the deregulation of Mps1 stability and kinase activity in human tumors, and that persistent phosphorylation of Mps1 through BRAFV600E signaling is a key event in disrupting the control of centrosonne duplication and chromosome stability that may contribute to tumorigenesis. Our findings raise the possibility that targeting the oncogenic BRAF and 5281-phosphorylated Mps1, especially when used in combination could potentially provide great therapeutic opportunities for cancer treatment. Oncogene (2013) 32, 713-723; doi:10.1038/onc.2012.94; published online 19 March 2012	[Liu, J.; Zhao, H.] Shanxi Med Univ, Dept Gen Surg, Hosp 1, Taiyuan 030001, Shanxi, Peoples R China; [Liu, J.; Cheng, X.; Zhang, Y.; Li, S.; Cui, H.; Zhang, L.; Zhao, Z.; He, C.; Zhang, C.; Cui, Y.] Shanxi Med Univ, Minist Educ, Key Lab Cellular Physiol, Taiyuan 030001, Shanxi, Peoples R China; [Cheng, X.; Zhang, Y.; Li, S.; Cui, H.; Zhang, L.; Shi, R.; Zhao, Z.; He, C.; Cui, Y.] Shanxi Med Univ, Dept Cell Biol & Genet, Taiyuan 030001, Shanxi, Peoples R China; [Wang, C.] E China Normal Univ, Sch Life Sci, Shanghai 200062, Peoples R China; [Fisk, H. A.] Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; [Guadagno, T. M.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA	Shanxi Medical University; Shanxi Medical University; Shanxi Medical University; East China Normal University; University System of Ohio; Ohio State University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Cui, Y (corresponding author), Shanxi Med Univ, Dept Cell Biol & Genet, Key Lab Cellular Physiol, Minist Educ, Taiyuan 030001, Shanxi, Peoples R China.	cuiy0922@yahoo.com			Program for New Century Excellent Talents University of China [NCET-10-0872]; National Nature Science Foundation of China [30872932, 30971518, 81071625]; Scientific Research Foundation for the Returned Overseas Chinese Scholars; State Education Ministry [2009-8]; Shanxi Province Foundation for Returness [2008-49]; Trainee Development Award from Bankhead Coley Program [30-15066-02-07]; Program for the Top Young Academic Leaders of Higher Learning Institutions of Shanxi	Program for New Century Excellent Talents University of China(Program for New Century Excellent Talents in University (NCET)); National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Scientific Research Foundation for the Returned Overseas Chinese Scholars(Scientific Research Foundation for the Returned Overseas Chinese Scholars); State Education Ministry; Shanxi Province Foundation for Returness(Scientific Research Foundation for the Returned Overseas Chinese Scholars); Trainee Development Award from Bankhead Coley Program; Program for the Top Young Academic Leaders of Higher Learning Institutions of Shanxi	We thank Kenji Fukasawa (H Lee Moffitt Cancer Center) for critical reading of this article. This work was supported by the Program for New Century Excellent Talents University of China (Grant NCET-10-0872), National Nature Science Foundation of China (Grant 30872932 & 30971518), Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry (Grant 2009-8), Shanxi Province Foundation for Returness (2008-49), Trainee Development Award from Bankhead Coley Program (Grant 30-15066-02-07) to YC and National Nature Science Foundation of China (Grant 81071625), Program for the Top Young Academic Leaders of Higher Learning Institutions of Shanxi to XC.	Acilan C, 2008, CELL, V134, P572, DOI 10.1016/j.cell.2008.08.007; Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Compton DA, 2011, CURR OPIN CELL BIOL, V23, P109, DOI 10.1016/j.ceb.2010.08.007; Cui Y, 2008, ONCOGENE, V27, P3122, DOI 10.1038/sj.onc.1210972; Cui YP, 2010, J BIOL CHEM, V285, P32988, DOI 10.1074/jbc.M110.140905; Cui YP, 2010, CANCER RES, V70, P675, DOI 10.1158/0008-5472.CAN-09-1491; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Fabunmi RP, 2000, J BIOL CHEM, V275, P409, DOI 10.1074/jbc.275.1.409; Fisk HA, 2003, P NATL ACAD SCI USA, V100, P14875, DOI 10.1073/pnas.2434156100; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Haering CH, 2008, NATURE, V454, P297, DOI 10.1038/nature07098; Hewitt L, 2010, J CELL BIOL, V190, P25, DOI 10.1083/jcb.201002133; Janssen A, 2009, P NATL ACAD SCI USA, V106, P19108, DOI 10.1073/pnas.0904343106; Jelluma N, 2008, CELL, V132, P233, DOI 10.1016/j.cell.2007.11.046; Kanai M, 2007, GENES CELLS, V12, P797, DOI 10.1111/j.1365-2443.2007.01091.x; Kang JS, 2007, P NATL ACAD SCI USA, V104, P20232, DOI 10.1073/pnas.0710519105; Karreth FA, 2009, CURR OPIN GENET DEV, V19, P4, DOI 10.1016/j.gde.2008.12.006; Kasbek C, 2007, MOL BIOL CELL, V18, P4457, DOI 10.1091/mbc.E07-03-0283; Kasbek C, 2010, MOL BIOL CELL, V21, P3878, DOI 10.1091/mbc.E10-04-0281; Kasbek C, 2009, ENVIRON MOL MUTAGEN, V50, P654, DOI 10.1002/em.20476; Liu ST, 2003, MOL BIOL CELL, V14, P1638, DOI 10.1091/mbc.02-05-0074; Mangold U, 2008, ONCOGENE, V27, P604, DOI 10.1038/sj.onc.1210685; Mattison CP, 2007, J BIOL CHEM, V282, P30553, DOI 10.1074/jbc.M707063200; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Palframan WJ, 2006, SCIENCE, V313, P680, DOI 10.1126/science.1127205; Pike AN, 2011, CELL DIV, V6, DOI 10.1186/1747-1028-6-9; Santaguida S, 2010, J CELL BIOL, V190, P73, DOI 10.1083/jcb.201001036; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; Tighe A, 2008, J CELL BIOL, V181, P893, DOI 10.1083/jcb.200712028; Tsou MFB, 2006, NATURE, V442, P947, DOI 10.1038/nature04985; Tyler RK, 2009, BIOCHEM J, V417, P173, DOI 10.1042/BJ20081310; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wojcik EJ, 2000, CURR BIOL, V10, P1131, DOI 10.1016/S0960-9822(00)00703-X; Yang CH, 2010, MOL BIOL CELL, V21, P4361, DOI 10.1091/mbc.E10-04-0298; Zhao Y, 2006, CURR BIOL, V16, P1764, DOI 10.1016/j.cub.2006.07.058	39	23	25	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2013	32	6					713	723		10.1038/onc.2012.94	http://dx.doi.org/10.1038/onc.2012.94			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22430208				2022-12-17	WOS:000315746700005
J	Barger, JF; Gallo, CA; Tandon, P; Liu, H; Sullivan, A; Grimes, HL; Plas, DR				Barger, J. F.; Gallo, C. A.; Tandon, P.; Liu, H.; Sullivan, A.; Grimes, H. L.; Plas, D. R.			S6K1 determines the metabolic requirements for BCR-ABL survival	ONCOGENE			English	Article						S6K1; glycolysis; fatty-acid oxidation; rapamycin; leukemia; Cpt1c	CHRONIC MYELOID-LEUKEMIA; FACTOR-INDEPENDENT SURVIVAL; GLUCOSE-METABOLISM; CELL-GROWTH; IMATINIB RESISTANCE; POSITIVE CELLS; RAG GTPASES; ACTIVATION; AKT; INHIBITION	In chronic myelogenous leukemia, the constitutive activation of the BCR-ABL kinase transforms cells to an addicted state that requires glucose metabolism for survival. We investigated S6K1, a protein kinase that drives glycolysis in leukemia cells, as a target for counteracting glucose-dependent survival induced by BCR-ABL. BCR-ABL potently activated S6K1-dependent signaling and glycolysis. Although S6K1 knockdown or rapamycin treatment suppressed glycolysis in BCR-ABL-transformed cells, these treatments did not induce cell death. Instead, loss of S6K1 triggered compensatory activation of fatty-acid oxidation, a metabolic program that can support glucose-independent cell survival. Fatty-acid oxidation in response to S6K1 inactivation required the expression of the fatty-acid transporter carnitine palmitoyl transferase 1c, which was recently linked to rapamycin resistance in cancer. Finally, addition of an inhibitor of fatty-acid oxidation significantly enhanced cytotoxicity in response to S6K1 inactivation. These data indicate that S6K1 dictates the metabolic requirements mediating BCR-ABL survival and provide a rationale for combining targeted inhibitors of signal transduction, with strategies to interrupt oncogene-induced metabolism. Oncogene (2013) 32, 453-461; doi:10.1038/onc.2012.70; published online 5 March 2012	[Barger, J. F.; Gallo, C. A.; Tandon, P.; Liu, H.; Sullivan, A.; Plas, D. R.] Univ Cincinnati, Dept Canc & Cell Biol, Cincinnati, OH 45208 USA; [Grimes, H. L.] Cincinnati Childrens Hosp, Div Immunobiol, Cincinnati, OH USA; [Grimes, H. L.] Cincinnati Childrens Hosp, Div Expt Hematol, Cincinnati, OH USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Plas, DR (corresponding author), Univ Cincinnati, Dept Canc & Cell Biol, 3125 Eden Ave, Cincinnati, OH 45208 USA.	plasd@uc.edu	Barger, Jennifer/N-1263-2015	Grimes, H. Leighton/0000-0001-8162-6758	IGERT [0333377]; NIH [CA133164]; American Cancer Society [RSG-08-293-01-CCG]; University of Cincinnati; NATIONAL CANCER INSTITUTE [T32CA117846, R01CA133164] Funding Source: NIH RePORTER	IGERT(National Science Foundation (NSF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); University of Cincinnati; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs George Thomas and Sara Kozma for their advice and access to S6K1 knockout mice. We thank Dr Shane Horman, Jim Phelan and Meghan Brundage for their help with CML models in mice, and Drs Czyzyk-Krzeska and Godar for critique of the manuscript. JFB was supported by an IGERT fellowship #0333377. This work was supported by NIH Grant CA133164, the American Cancer Society RSG-08-293-01-CCG and the University of Cincinnati's Millennium Scholars program.	Barnes K, 2005, ONCOGENE, V24, P3257, DOI 10.1038/sj.onc.1208461; Bonnefont Jean-Paul, 2004, Molecular Aspects of Medicine, V25, P495, DOI 10.1016/j.mam.2004.06.004; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Branford S, 2002, BLOOD, V99, P3472, DOI 10.1182/blood.V99.9.3472; Burchert A, 2005, LEUKEMIA, V19, P1774, DOI 10.1038/sj.leu.2403898; Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622; Chalhoub N, 2006, BRAIN RES, V1100, P32, DOI 10.1016/j.brainres.2006.05.013; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Choo AY, 2010, MOL CELL, V38, P487, DOI 10.1016/j.molcel.2010.05.007; Djouadi F, 2003, MOL GENET METAB, V78, P112, DOI 10.1016/S1096-7192(03)00017-9; Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Eaton S, 1996, BIOCH J 2, V320, P345; Gottschalk S, 2004, CLIN CANCER RES, V10, P6661, DOI 10.1158/1078-0432.CCR-04-0039; Hochhaus A, 2002, LEUKEMIA, V16, P2190, DOI 10.1038/sj.leu.2402741; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016; Kharas MG, 2008, J CLIN INVEST, V118, P3038, DOI 10.1172/JCI33337; Kim E, 2008, NAT CELL BIOL, V10, P935, DOI 10.1038/ncb1753; Klawitter J, 2009, BRIT J PHARMACOL, V158, P588, DOI 10.1111/j.1476-5381.2009.00345.x; Kominsky DJ, 2009, CLIN CANCER RES, V15, P3442, DOI 10.1158/1078-0432.CCR-08-3291; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Markova B, 2010, ONCOGENE, V29, P739, DOI 10.1038/onc.2009.374; Mason EF, 2010, CANCER RES, V70, P8066, DOI 10.1158/0008-5472.CAN-10-0608; McCubrey JA, 2008, LEUKEMIA, V22, P708, DOI 10.1038/leu.2008.27; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Nardella C, 2011, CANCER RES, V71, P3669, DOI 10.1158/0008-5472.CAN-10-3962; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Plas DR, 2009, CURR OPIN CELL BIOL, V21, P230, DOI 10.1016/j.ceb.2008.12.013; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Sengupta S, 2010, NATURE, V468, P1100, DOI 10.1038/nature09584; Serra V, 2011, ONCOGENE, V30, P2547, DOI 10.1038/onc.2010.626; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Tandon P, 2011, P NATL ACAD SCI USA, V108, P2361, DOI 10.1073/pnas.1013629108; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Um SH, 2006, CELL METAB, V3, P393, DOI 10.1016/j.cmet.2006.05.003; Vander Heiden MG, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001210; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Zaugg K, 2011, GENE DEV, V25, P1041, DOI 10.1101/gad.1987211	50	23	24	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2013	32	4					453	461		10.1038/onc.2012.70	http://dx.doi.org/10.1038/onc.2012.70			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22391570	Green Accepted			2022-12-17	WOS:000315551300006
J	Sos, ML; Thomas, RK				Sos, M. L.; Thomas, R. K.			Genetic insight and therapeutic targets in squamous-cell lung cancer	ONCOGENE			English	Review						squamous-cell lung cancer; FGFR1; DDR2	ACTIVATING MUTATIONS; NEVER-SMOKERS; PHASE-III; GEFITINIB; CARBOPLATIN; PACLITAXEL; INHIBITOR; ONCOGENE; SINGLE; GROWTH	Squamous-cell lung cancer is one of the most prevalent subtypes of lung cancer worldwide and its pathogenesis is closely linked with tobacco exposure. Unfortunately, squamous-cell lung cancer patients do not benefit from major advances in the development of targeted therapeutics such as epidermal growth factor receptor (EGFR) inhibitors or anaplastic lymphoma kinase (ALK) inhibitors that show exquisite activity in lung adenocarcinomas with EGFR mutations or echinoderm microtubule associated protein like-4 (EML4)-ALK fusions, respectively. Major efforts have been launched to characterize the genomes of squamous-cell lung cancers. Among the new results emanating from these efforts are amplifications of the fibroblast growth factor receptor 1 gene and mutations of the discoidin domain receptor 2 gene as potential novel targets for the treatment of squamous-cell lung cancer patients. Here, we provide a review on these discoveries and their implications for clinical trials in squamous-cell lung cancer assessing the value of novel therapeutics addressing these targets.	[Sos, M. L.; Thomas, R. K.] Univ Cologne, Max Planck Inst Neurol Res, Klaus Joachim Zulch Labs, Max Planck Soc, D-50931 Cologne, Germany; [Sos, M. L.; Thomas, R. K.] Univ Cologne, Fac Med, D-50931 Cologne, Germany; [Thomas, R. K.] Univ Cologne, Ctr Integrated Oncol Koln Bonn, Lab Translat Canc Genom, D-50931 Cologne, Germany; [Sos, M. L.; Thomas, R. K.] Univ Cologne, Dept Internal Med 1, D-50931 Cologne, Germany	Max Planck Society; University of Cologne; University of Cologne; University of Cologne; University of Cologne	Thomas, RK (corresponding author), Univ Cologne, Max Planck Inst Neurol Res, Dept Internal Med 1, Gleuelerstr 50, D-50931 Cologne Nrw, Germany.	nini@nf.mpg.de	Sos, Martin L/I-1852-2014		German Ministry of Science and Education (BMBF), NGFNplus program [01GS08100]; Max Planck Society [M.I.F. A.NEUR8061]; Deutsche Forschungsgemeinschaft (DFG) [SFB (TP6)]; Ministry for Innovation, Science, Research and Technology of the State of Nordrhein-Westfalen (MIWT) [4000- 12 09]; Fritz-Thyssen-Stiftung [10.08.2.175]; IASLC Lung Cancer Fellowship; Sanofi-Aventis; Merck; Roche; Boehringer Ingelheim; Astra-Zeneca; Atlas-Biolabs; JohnsonJohnson; AstraZeneca	German Ministry of Science and Education (BMBF), NGFNplus program(Federal Ministry of Education & Research (BMBF)); Max Planck Society(Max Planck SocietyFoundation CELLEX); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Ministry for Innovation, Science, Research and Technology of the State of Nordrhein-Westfalen (MIWT); Fritz-Thyssen-Stiftung; IASLC Lung Cancer Fellowship; Sanofi-Aventis(Sanofi-Aventis); Merck(Merck & Company); Roche(Roche Holding); Boehringer Ingelheim(Boehringer Ingelheim); Astra-Zeneca(AstraZeneca); Atlas-Biolabs; JohnsonJohnson(Johnson & JohnsonJohnson & Johnson USA); AstraZeneca(AstraZeneca)	RKT is supported by the German Ministry of Science and Education (BMBF) as part of the NGFNplus program (grant 01GS08100), by the Max Planck Society (M.I.F. A.NEUR8061 to RKT), by the Deutsche Forschungsgemeinschaft (DFG) through SFB (TP6), the Ministry for Innovation, Science, Research and Technology of the State of Nordrhein-Westfalen (MIWT, 4000- 12 09), by the Fritz-Thyssen-Stiftung (grant 10.08.2.175) and by an anonymous foundation. MLS is supported by an IASLC Lung Cancer Fellowship Award. RKT received consulting and lecture fees (Sanofi-Aventis, Merck, Roche, Boehringer Ingelheim, Astra-Zeneca, Atlas-Biolabs, Johnson&Johnson), as well as research support (AstraZeneca, Merck).	Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Dutt A, 2008, P NATL ACAD SCI USA, V105, P8713, DOI 10.1073/pnas.0803379105; Dutt A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020351; Hammerman PS, 2011, CANCER DISCOV, V1, P78, DOI 10.1158/2159-8274.CD-11-0005; Harris TD, 2008, SCIENCE, V320, P106, DOI 10.1126/science.1150427; Haura EB, 2010, J CLIN ONCOL, V28, P1387, DOI 10.1200/JCO.2009.25.4029; Hilberg F, 2008, CANCER RES, V68, P4774, DOI 10.1158/0008-5472.CAN-07-6307; Hussenet T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008960; Ikeda K, 2002, J BIOL CHEM, V277, P19206, DOI 10.1074/jbc.M201078200; Kunii K, 2008, CANCER RES, V68, P2340, DOI 10.1158/0008-5472.CAN-07-5229; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Lipson D, 2009, NAT BIOTECHNOL, V27, P652, DOI 10.1038/nbt.1551; Lu Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011022; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Marek L, 2009, MOL PHARMACOL, V75, P196, DOI 10.1124/mol.108.049544; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pirker R, 2009, LANCET, V373, P1525, DOI 10.1016/S0140-6736(09)60569-9; Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Sarker D, 2008, CLIN CANCER RES, V14, P2075, DOI 10.1158/1078-0432.CCR-07-1466; Scagliotti G, 2010, J CLIN ONCOL, V28, P1835, DOI 10.1200/JCO.2009.26.1321; Shendure J, 2005, SCIENCE, V309, P1728, DOI 10.1126/science.1117389; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Sos ML, 2009, P NATL ACAD SCI USA, V106, P18351, DOI 10.1073/pnas.0907325106; Sos ML, 2009, J CLIN INVEST, V119, P1727, DOI 10.1172/JCI37127; Sun YH, 2010, J CLIN ONCOL, V28, P4616, DOI 10.1200/JCO.2010.29.6038; Thomas RK, 2006, NAT MED, V12, P852, DOI 10.1038/nm1437; Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975; Turner N, 2010, CANCER RES, V70, P2085, DOI 10.1158/0008-5472.CAN-09-3746; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Turner NC, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001942; Weiss J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001451; Yuan P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009112	38	23	27	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	46					4811	4814		10.1038/onc.2011.640	http://dx.doi.org/10.1038/onc.2011.640			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	038YT	22266863				2022-12-17	WOS:000311210700001
J	Guijarro, MV; Vergel, M; Marin, JJ; Munoz-Galvan, S; Ferrer, I; Cajal, SRY; Roncador, G; Blanco-Aparicio, C; Carnero, A				Guijarro, M. V.; Vergel, M.; Marin, J. J.; Munoz-Galvan, S.; Ferrer, I.; Ramon y Cajal, S.; Roncador, G.; Blanco-Aparicio, C.; Carnero, A.			p38 alpha limits the contribution of MAP17 to cancer progression in breast tumors	ONCOGENE			English	Article						breast carcinoma; MAP17; ROS; p38	EPITHELIAL-CELL TRANSFORMATION; INDUCED GROWTH ARREST; OXIDATIVE STRESS; HYDROGEN-PEROXIDE; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; INDUCED SENESCENCE; HUMAN CARCINOMAS; KINASE; P38	MAP17 is a small, 17-kDa, non-glycosylated membrane protein that is overexpressed in a percentage of carcinomas. In the present work, we have analyzed the role of MAP17 expression during mammary cancer progression. We have found that MAP17 is expressed in 60% human mammary tumors while it is not expressed in normal or benign neoplasias. MAP17 levels increased with breast tumor stage and were strongly correlated with mammary tumoral progression. A significant increase in the levels of reactive oxygen species (ROS) was observed in MAP17-expressing cells, as compared with parental cells. This increase was further paralleled by an increase in the tumorigenic capacity of carcinoma cells but not in immortal non-tumoral breast epithelial cells, which provides a selective advantage once tumorigenesis has begun. Expression of specific MAP17 shRNA in protein-expressing tumor cells reduced their tumorigenic capabilities, which suggests that this effect is dependent upon MAP17 protein expression. Our data show that ROS functions as a second messenger that enhances tumoral properties, which are inhibited in non-tumoral cells. We have found that p38 alpha activation mediates this response. MAP17 triggers a ROS-dependent, senescence-like response that is abolished in the absence of p38a activation. Furthermore, in human breast tumors, MAP17 activation is correlated with a lack of phosphorylation of p38a. Therefore, MAP17 is overexpressed in late-stage breast tumors, in which oncogenic activity relies on p38 insensitivity to induce intracellular ROS. Oncogene (2012) 31, 4447-4459; doi: 10.1038/onc.2011.619; published online 23 January 2012	[Carnero, A.] Hosp Univ Virgen del Rocio, CSIC, Inst Biomed Sevilla IBIS HUVR, Seville 41013, Spain; [Guijarro, M. V.] NYU, Sch Med, Dept Pathol, New York, NY USA; [Marin, J. J.] Univ Seville, Dept Prevent Med & Publ Hlth, Seville, Spain; [Ferrer, I.] Inst Invest Biomed Bellvitge IDIBELL, Bellvitge, Spain; [Ramon y Cajal, S.] Recerca Hosp Vall Hebron, Fundacio Inst, Dept Pathol, Barcelona, Spain; [Roncador, G.] Spanish Natl Canc Ctr CNIO, Biotechnol Program, Madrid, Spain; [Carnero, A.] CSIC, Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital; New York University; University of Sevilla; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Universitari Vall d'Hebron; Centro Nacional de Investigaciones Oncologicas (CNIO); Consejo Superior de Investigaciones Cientificas (CSIC)	Carnero, A (corresponding author), Hosp Univ Virgen del Rocio, CSIC, Inst Biomed Sevilla IBIS HUVR, Avda Manuel Siurot S-N, Seville 41013, Spain.	acarnero@us.es	IBIS, CANCER/P-3323-2015; Ramon y Cajal, Santiago/H-4955-2016; Blanco-Aparicio, Carmen/I-3162-2015; Muñoz-Galván, Sandra/K-5827-2015; Roncador, Giovanna/L-1764-2014; Marín-López, Juan J./G-7123-2012; Ferrer, Irene/C-9418-2015	Ramon y Cajal, Santiago/0000-0002-3867-1390; Blanco-Aparicio, Carmen/0000-0002-3249-6595; Roncador, Giovanna/0000-0002-9807-2875; Marín-López, Juan J./0000-0001-6072-739X; Ferrer, Irene/0000-0002-2748-2607; Carnero, Amancio/0000-0003-4357-3979; Munoz-Galvan, Sandra/0000-0003-0579-325X	Spanish Ministry of Science and Innovation; FEDER [SAF2009-08605]; Consejeria de Ciencia e Innovacion; Consejeria de Salud of the Junta de Andalucia [CTS-6844, PI-0142]; Fundacion Oncologica FERO; Fundacio Josep Botet	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); FEDER(European Commission); Consejeria de Ciencia e Innovacion; Consejeria de Salud of the Junta de Andalucia(Junta de Andalucia); Fundacion Oncologica FERO; Fundacio Josep Botet	We thank Augusto Silva and Ricardo Sanchez Prieto for their critical reading of the manuscript and valuable suggestions. This work was supported by grants from the Spanish Ministry of Science and Innovation and FEDER (SAF2009-08605), Consejeria de Ciencia e Innovacion and Consejeria de Salud of the Junta de Andalucia (CTS-6844 and PI-0142). AC's laboratory is also funded by a fellowship from the Fundacion Oncologica FERO, supported by Fundacio Josep Botet.	Adams RH, 2000, MOL CELL, V6, P109, DOI 10.1016/S1097-2765(00)00012-5; Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; Apel K, 2004, ANNU REV PLANT BIOL, V55, P373, DOI 10.1146/annurev.arplant.55.031903.141701; Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; Bae GU, 1999, J BIOL CHEM, V274, P32596, DOI 10.1074/jbc.274.46.32596; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; Behrend L, 2003, BIOCHEM SOC T, V31, P1441; Blasco T, 2003, AM J PHYSIOL-RENAL, V285, pF799, DOI 10.1152/ajprenal.00149.2003; Bulavin DV, 2004, ADV CANCER RES, V92, P95, DOI 10.1016/S0065-230X(04)92005-2; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; Burdon RH, 1996, BIOCHEM SOC T, V24, P1028, DOI 10.1042/bst0241028; Carnero A, 2004, ONCOGENE, V23, P6006, DOI 10.1038/sj.onc.1207839; Carnero A, 2000, NUCLEIC ACIDS RES, V28, P2234, DOI 10.1093/nar/28.11.2234; Carnero A, 2010, CURR PHARM DESIGN, V16, P34, DOI 10.2174/138161210789941865; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323; Dimri G, 2005, BREAST CANCER RES, V7, P171, DOI 10.1186/bcr1275; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Dorion S, 2002, J BIOL CHEM, V277, P30792, DOI 10.1074/jbc.M203642200; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; England K, 2005, REDOX REP, V10, P237, DOI 10.1179/135100005X70224; FERNANDEZPOL JA, 1982, CANCER RES, V42, P609; Guijarro MV, 2007, J CELL BIOCHEM, V101, P112, DOI 10.1002/jcb.21163; Guijarro MV, 2007, CARCINOGENESIS, V28, P2443, DOI 10.1093/carcin/bgm154; Guijarro MV, 2007, CARCINOGENESIS, V28, P2096, DOI 10.1093/carcin/bgm124; Guijarro MV, 2007, CARCINOGENESIS, V28, P1646, DOI 10.1093/carcin/bgm083; Hancock JT, 2001, BIOFACTORS, V15, P99, DOI 10.1002/biof.5520150210; Herbert BS, 2002, ONCOGENE, V21, P7897, DOI 10.1038/sj.onc.1205902; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jaeger C, 2000, J INVEST DERMATOL, V115, P375, DOI 10.1046/j.1523-1747.2000.00071.x; Klaunig JE, 1998, ENVIRON HEALTH PERSP, V106, P289, DOI 10.2307/3433929; Kocher O, 1996, AM J PATHOL, V149, P493; Kocher O, 1995, CLIN CANCER RES, V1, P1209; Lanaspa MA, 2007, AM J PHYSIOL-RENAL, V292, pF230, DOI 10.1152/ajprenal.00075.2006; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Lewis CM, 2006, BREAST CANCER RES TR, V99, P103, DOI 10.1007/s10549-006-9189-9; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Matsukawa J, 2004, J BIOCHEM, V136, P261, DOI 10.1093/jb/mvh134; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Nicke B, 2005, MOL CELL, V20, P673, DOI 10.1016/j.molcel.2005.10.038; Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004; Pribanic S, 2003, AM J PHYSIOL-RENAL, V285, pF784, DOI 10.1152/ajprenal.00109.2003; Ruiz L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003230; Samanta AK, 2009, CANCER-AM CANCER SOC, V115, P3897, DOI 10.1002/cncr.24445; Stampfer MR, 2003, CANCER LETT, V194, P199, DOI 10.1016/S0304-3835(02)00707-3; Stampfer MR, 2000, J MAMMARY GLAND BIOL, V5, P365, DOI 10.1023/A:1009525827514; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Woo RA, 2004, GENE DEV, V18, P1317, DOI 10.1101/gad.1165204; Yan T, 1996, CANCER RES, V56, P2864; Yoon SO, 2002, MECH AGEING DEV, V123, P1597, DOI 10.1016/S0047-6374(02)00095-7; Zuluaga S, 2007, CELL SIGNAL, V19, P62, DOI 10.1016/j.cellsig.2006.05.032	59	23	24	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	41					4447	4459		10.1038/onc.2011.619	http://dx.doi.org/10.1038/onc.2011.619			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	018YR	22266858				2022-12-17	WOS:000309704500003
J	Huang, W; Fridman, Y; Bonfil, RD; Ustach, CV; Conley-LaComb, MK; Wiesner, C; Saliganan, A; Cher, ML; Kim, HRC				Huang, W.; Fridman, Y.; Bonfil, R. D.; Ustach, C. V.; Conley-LaComb, M. K.; Wiesner, C.; Saliganan, A.; Cher, M. L.; Kim, H-R C.			A novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growth	ONCOGENE			English	Article						prostate cancer; bone responses; osteoclastic differentiation; PDGF-D	PROSTATE-CANCER; PLASMINOGEN-ACTIVATOR; PDGF-D; BONE; RANKL; METALLOPROTEINASE; THERAPY	Although increasing evidence suggests a critical role for platelet-derived growth factor (PDGF) receptor beta (beta-PDGFR) signaling in prostate cancer (PCa) progression, the precise roles of beta-PDGFR and PDGF isoform-specific cell signaling have not been delineated. Recently, we identified the PDGF-D isoform as a ligand for beta-PDGFR in PCa and showed that PDGF-D is activated by serine protease-mediated proteolytic removal of the CUB domain in a two-step process, yielding first a hemidimer (HD) and then a growth factor domain dimer. Herein, we demonstrate that the expression of PDGF-D in human PCa LNCaP cells leads to enhanced bone tumor growth and bone responses in immunodeficient mice. Histopathological analyses of bone tumors generated by PDGF-D-expressing LNCaP cells (LNCaP-PDGF-D) revealed osteolytic and osteoblastic responses similar to those observed in human PCa bone metastases. Importantly, we discovered a novel function of PDGF-D in the regulation of osteoclast differentiation, independent of the RANKL/RANK signaling axis. Although both PDGF-B and -D were able to activate beta-PDGFR, only PDGF-D was able to induce osteoclastic differentiation in vitro, and upregulate the expression and nuclear translocation of nuclear factor of activated T cells 1, a master transcription factor for osteoclastogenesis. Taken together, these results reveal a new function of PDGF-D as a regulator of osteoclastic differentiation, an activity critical for the establishment of skeletal metastatic deposit in PCa patients.	[Huang, W.; Fridman, Y.; Bonfil, R. D.; Ustach, C. V.; Conley-LaComb, M. K.; Cher, M. L.; Kim, H-R C.] Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA; [Bonfil, R. D.; Wiesner, C.; Saliganan, A.; Cher, M. L.] Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dept Urol, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Kim, HRC (corresponding author), Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Dept Pathol, 540 E Canfield, Detroit, MI 48201 USA.	hrckim@med.wayne.edu	Huang, Wei/O-2346-2013	Bonfil, R. Daniel/0000-0002-1605-8317	NIH/NCI [CA64139, CA123362, R01CA137280]; Ruth L. Kirschstein National Research Service Award [T32-CA009531]; NATIONAL CANCER INSTITUTE [T32CA009531, R01CA137280, R01CA123362, R01CA064139, R29CA064139] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ruth L. Kirschstein National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH/NCI RO1 grants CA64139 and CA123362 (to H-RCK), R01CA137280 (to MLC) as well as the Ruth L. Kirschstein National Research Service Award T32-CA009531 (to MKC-L). We thank Dr. C-J Kim for his help with IHC analysis.	Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Berman E, 2006, NEW ENGL J MED, V354, P2006, DOI 10.1056/NEJMoa051140; Blair JM, 2006, NAT CLIN PRACT ONCOL, V3, P41, DOI 10.1038/ncponc0381; Bonfil RD, 2007, AM J PATHOL, V170, P2100, DOI 10.2353/ajpath.2007.060720; Breccia M, 2009, LEUKEMIA RES, V33, P871, DOI 10.1016/j.leukres.2009.01.040; Buijs JT, 2009, CANCER LETT, V273, P177, DOI 10.1016/j.canlet.2008.05.044; Chaudhary LR, 2004, BONE, V34, P402, DOI 10.1016/j.bone.2003.11.014; Chott A, 1999, AM J PATHOL, V155, P1271, DOI 10.1016/S0002-9440(10)65229-7; Deininger MWN, 2003, PHARMACOL REV, V55, P401, DOI 10.1124/pr.55.3.4; Ehnman M, 2009, ONCOGENE, V28, P534, DOI 10.1038/onc.2008.410; Fredriksson L, 2004, EMBO J, V23, P3793, DOI 10.1038/sj.emboj.7600397; Godwin SL, 1997, J BIOL CHEM, V272, P11307; Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564; Guilhot F, 2004, ONCOLOGIST, V9, P271, DOI 10.1634/theoncologist.9-3-271; Himeno M, 2002, J BONE MINER RES, V17, P1297, DOI 10.1359/jbmr.2002.17.7.1297; Kerkela R, 2006, NAT MED, V12, P908, DOI 10.1038/nm1446; Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050; Kubota K, 2003, PROTEOMICS, V3, P616, DOI 10.1002/pmic.200300410; Kubota K, 2002, J BONE MINER RES, V17, P257, DOI 10.1359/jbmr.2002.17.2.257; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Mathew P, 2007, CLIN CANCER RES, V13, P5816, DOI 10.1158/1078-0432.CCR-07-1269; Mehrotra M, 2004, J CELL BIOCHEM, V93, P741, DOI 10.1002/jcb.20138; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Ng SSW, 2004, CLIN CANCER RES, V10, P4192, DOI 10.1158/1078-0432.CCR-03-0700; Reigstad LJ, 2005, FEBS J, V272, P5723, DOI 10.1111/j.1742-4658.2005.04989.x; Robbins JR, 1999, DEV BIOL, V212, P255, DOI 10.1006/dbio.1999.9373; Roudier MP, 2008, J UROLOGY, V180, P1154, DOI 10.1016/j.juro.2008.04.140; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Taichman RS, 2007, J CLIN INVEST, V117, P2351, DOI 10.1172/JCI31791; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Ustach CV, 2010, CANCER RES, V70, P9631, DOI 10.1158/0008-5472.CAN-10-0511; Ustach CV, 2005, MOL CELL BIOL, V25, P6279, DOI 10.1128/MCB.25.14.6279-6288.2005; Ustach CV, 2004, CANCER RES, V64, P1722, DOI 10.1158/0008-5472.CAN-03-3047; Uutela M, 2004, BLOOD, V104, P3198, DOI 10.1182/blood-2004-04-1485; van der Poel HG, 2004, EUR UROL, V45, P1, DOI 10.1016/j.eururo.2003.08.011; Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007; Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685	37	23	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	42					4527	4535		10.1038/onc.2011.573	http://dx.doi.org/10.1038/onc.2011.573			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	022SH	22158043	Green Published, hybrid			2022-12-17	WOS:000309982100004
J	Sidler, D; Brockmann, A; Mueller, J; Nachbur, U; Corazza, N; Renzulli, P; Hemphill, A; Brunner, T				Sidler, D.; Brockmann, A.; Mueller, J.; Nachbur, U.; Corazza, N.; Renzulli, P.; Hemphill, A.; Brunner, T.			Thiazolide-induced apoptosis in colorectal cancer cells is mediated via the Jun kinase-Bim axis and reveals glutathione-S-transferase P1 as Achilles' heel	ONCOGENE			English	Article						apoptosis; colon cancer; glutathione S-transferase; Bim; TRAIL; chemotherapy	N-TERMINAL KINASE; BAX-DEPENDENT APOPTOSIS; ETHACRYNIC-ACID; FLOW-CYTOMETRY; LIVER-DAMAGE; JNK; TRAIL; DEATH; PI; PHOSPHORYLATION	Glutathione-S-transferase of the Pi class (GSTP1) is frequently overexpressed in a variety of solid tumors and has been identified as a potential therapeutic target for cancer therapy. GSTP1 is a phase II detoxification enzyme and conjugates the tripeptide glutathione to endogenous metabolites and xenobiotics, thereby limiting the efficacy of antitumor chemotherapeutic treatments. In addition, GSTP1 regulates cellular stress responses and apoptosis by sequestering and inactivating c-Jun N-terminal kinase (JNK). Thiazolides are a novel class of antibiotics for the treatment of intestinal pathogens with no apparent side effects on the host cells and tissue. Here we show that thiazolides induce a GSTP1-dependent and glutathione-enhanced cell death in colorectal tumor cell lines. Downregulation of GSTP1 reduced the apoptotic activity of thiazolides, whereas overexpression enhanced it. Thiazolide treatment caused strong Jun kinase activation and Jun kinase-dependent apoptosis. As a critical downstream target of Jun kinase we identified the proapoptotic Bcl-2 homolog Bim. Thiazolides induced Bim expression and activation in a JNK-dependent manner. Downregulation of Bim in turn significantly blocked thiazolide-induced apoptosis. Whereas low concentrations of thiazolides failed to induce apoptosis directly, they potently sensitized colon cancer cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic drug-induced cell death. Although GSTP1 overexpression generally limits chemotherapy and thus antitumor treatment, our study identifies GSTP1 as Achilles' heel and thiazolides as novel interesting apoptosis sensitizer for the treatment of colorectal tumors. Oncogene (2012) 31, 4095-4106; doi:10.1038/onc.2011.575; published online 12 December 2011	[Brockmann, A.; Brunner, T.] Univ Konstanz, Dept Biol, Div Biochem Pharmacol, D-78457 Constance, Germany; [Mueller, J.; Hemphill, A.] Univ Bern, Inst Parasitol, Vetsuisse Fac, Bern, Switzerland; [Nachbur, U.] Walter & Eliza Hall Inst Med Res, Div Cell Signalling & Cell Death, Parkville, Vic, Australia; [Renzulli, P.] Cantonal Hosp, Dept Surg, Munsterlingen, Switzerland; [Sidler, D.; Corazza, N.; Brunner, T.] Univ Bern, Inst Pathol Expt Pathol, Bern, Switzerland	University of Konstanz; University of Bern; Walter & Eliza Hall Institute; University of Bern	Brunner, T (corresponding author), Univ Konstanz, Dept Biol, Div Biochem Pharmacol, Box 660, D-78457 Constance, Germany.	thomas.brunner@uni-konstanz.de	Sidler, Daniel/G-2447-2019; Renzulli, Pietro/GQH-9366-2022	Renzulli, Pietro/0000-0001-5557-5512; Hemphill, Andrew/0000-0002-0622-2128; Nachbur, Ueli/0000-0001-5968-2235	Swiss National Science Foundation; Oncosuisse; AFF grant from the University of Konstanz; Graduate School Chemical Biology of the University of Konstanz	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Oncosuisse; AFF grant from the University of Konstanz; Graduate School Chemical Biology of the University of Konstanz	The authors thank the members of the Brunner and Corazza lab for their excellent technical help and scientific advice, Thomas Kaufmann from the Institute of Pharmacology, University of Berne for providing the antibodies, Philippe Bouillet from the Walter and Eliza Hall Institute, Melbourne, for the Bim promoter construct, Christian Leumann from the Department of Chemistry and Biochemistry, University of Bern for the synthesis of RM4819, and Vicky Hatzig and Thomas Herdegen, University of Kiel for expression plasmids. This work was supported by grants from the Swiss National Science Foundation, Oncosuisse and AFF grant from the University of Konstanz to Thomas Brunner. Daniel Sidler was supported by an MD-PhD fellowship from the Swiss National Science Foundation. Anette Brockmann was supported by a fellowship from the Graduate School Chemical Biology of the University of Konstanz.	Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Badmann A, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.55; Balendiran GK, 2004, CELL BIOCHEM FUNCT, V22, P343, DOI 10.1002/cbf.1149; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen YR, 2000, INT J ONCOL, V16, P651; Corazza N, 2006, J CLIN INVEST, V116, P2493, DOI 10.1172/JCI27726; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301; Elsby R, 2003, J BIOL CHEM, V278, P22243, DOI 10.1074/jbc.M301211200; Fox LM, 2005, CLIN INFECT DIS, V40, P1173, DOI 10.1086/428839; Garrett CR, 2011, EXPERT OPIN BIOL TH, V11, P937, DOI 10.1517/14712598.2011.582464; Goto S, 1999, FREE RADICAL RES, V31, P549, DOI 10.1080/10715769900301121; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; ISHIKAWA T, 1993, J BIOL CHEM, V268, P20116; Ishimoto TM, 2002, PHARMACOGENETICS, V12, P543, DOI 10.1097/00008571-200210000-00006; Jakob S, 2008, METHODS, V44, P255, DOI 10.1016/j.ymeth.2007.11.004; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kaufmann T, 2009, IMMUNITY, V30, P56, DOI 10.1016/j.immuni.2008.10.017; Kuo CT, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-43; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; McIlwain CC, 2006, ONCOGENE, V25, P1639, DOI 10.1038/sj.onc.1209373; Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958; Muller J, 2008, INT J CANCER, V123, P1797, DOI 10.1002/ijc.23755; Muller J, 2008, EXP PARASITOL, V118, P80, DOI 10.1016/j.exppara.2007.06.008; Mueller M, 2007, ENDOCRINOLOGY, V148, P1445, DOI 10.1210/en.2006-0591; Muller J, 2006, ANTIMICROB AGENTS CH, V50, P162, DOI 10.1128/AAC.50.1.162-170.2006; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; ODWYER PJ, 1991, CANCER RES, V51, P6059; Ozoren N, 2002, NEOPLASIA, V4, P551, DOI 10.1038/sj.neo.7900270; PETRINI M, 1993, BRIT J HAEMATOL, V85, P409, DOI 10.1111/j.1365-2141.1993.tb03187.x; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Ritchie KJ, 2009, P NATL ACAD SCI USA, V106, P20859, DOI 10.1073/pnas.0911351106; Ruzza P, 2009, ANTI-CANCER AGENT ME, V9, P763, DOI 10.2174/187152009789056895; Schneider-Jakob S, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.66; Steensma DP, 2010, HEMATOL ONCOL CLIN N, V24, P423, DOI 10.1016/j.hoc.2010.02.010; Strahl BD, 1997, ENDOCRINOLOGY, V138, P2621, DOI 10.1210/en.138.6.2621; Tew KD, 2005, EXPERT OPIN INV DRUG, V14, P1047, DOI 10.1517/13543784.14.8.1047; TEW KD, 1988, CANCER RES, V48, P3622; Townsend DM, 2003, ONCOGENE, V22, P7369, DOI 10.1038/sj.onc.1206940; Villafania A, 2000, ANN CLIN LAB SCI, V30, P57; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Watson MA, 1998, CARCINOGENESIS, V19, P275, DOI 10.1093/carcin/19.2.275; Webb C, 2006, VET IMMUNOL IMMUNOP, V112, P129, DOI 10.1016/j.vetimm.2006.02.009; Weitz J, 2005, LANCET, V365, P153, DOI 10.1016/S0140-6736(05)17706-X; Yang SY, 2009, TRENDS MOL MED, V15, P225, DOI 10.1016/j.molmed.2009.03.003; Yin ZM, 2000, CANCER RES, V60, P4053; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308	49	23	24	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	37					4095	4106		10.1038/onc.2011.575	http://dx.doi.org/10.1038/onc.2011.575			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NR	22158036	Green Submitted			2022-12-17	WOS:000308688900002
J	Villagrasa, P; Diaz, VM; Vinas-Castells, R; Peiro, S; Del Valle-Perez, B; Dave, N; Rodriguez-Asiain, A; Casal, JI; Lizcano, JM; Dunach, M; de Herreros, AG				Villagrasa, P.; Diaz, V. M.; Vinas-Castells, R.; Peiro, S.; Del Valle-Perez, B.; Dave, N.; Rodriguez-Asiain, A.; Casal, J. I.; Lizcano, J. M.; Dunach, M.; Garcia de Herreros, A.			Akt2 interacts with Snail1 in the E-cadherin promoter	ONCOGENE			English	Article						Snail1; EMT; Akt; E-cadherin	PROTEIN-KINASE-B; EPITHELIAL-MESENCHYMAL TRANSITIONS; TRANSCRIPTION FACTOR SNAIL; NF-KAPPA-B; COLORECTAL-CANCER; HISTONE H3; GENE-EXPRESSION; DISTINCT ROLES; UP-REGULATION; ACTIVATION	Snail1 is a transcriptional factor essential for triggering epithelial-to-mesenchymal transition. Moreover, Snail1 promotes resistance to apoptosis, an effect associated to PTEN gene repression and Akt stimulation. In this article we demonstrate that Snail1 activates Akt at an additional level, as it directly binds to and activates this protein kinase. The interaction is observed in the nucleus and increases the intrinsic Akt activity. We determined that Akt2 is the isoform interacting with Snail1, an association that requires the pleckstrin homology domain in Akt2 and the C-terminal half in Snail1. Snail1 enhances the binding of Akt2 to the E-cadherin (CDH1) promoter and Akt2 interference prevents Snail1 repression of CDH1 gene. We also show that Snail1 binding increases Akt2 intrinsic activity on histone H3 and have identified Thr45 as a residue modified on this protein. Phosphorylation of Thr45 in histone H3 is sensitive to Snail1 and Akt2 cellular levels; moreover, Snail1 upregulates the binding of phosphoThr45 histone H3 to the CDH1 promoter. These results uncover an unexpected role of Akt2 in transcriptional control and point out to phosphorylation of Thr45 in histone H3 as a new epigenetic mark related to Snail1 and Akt2 action. Oncogene (2012) 31, 4022-4033; doi:10.1038/onc.2011.562; published online 12 December 2011	[Villagrasa, P.; Del Valle-Perez, B.; Dunach, M.] Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Fac Med, Unitat Biofis CEB, E-08193 Bellaterra, Spain; [Villagrasa, P.; Diaz, V. M.; Vinas-Castells, R.; Peiro, S.; Dave, N.; Garcia de Herreros, A.] IMIM Hosp Mar, Programa Recerca Canc, Barcelona, Spain; [Diaz, V. M.; Garcia de Herreros, A.] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona, Spain; [Rodriguez-Asiain, A.; Lizcano, J. M.] Univ Autonoma Barcelona, Fac Med, Inst Neurociencia, Bellaterra, Spain; [Rodriguez-Asiain, A.; Lizcano, J. M.] Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Fac Med, Bellaterra, Spain; [Casal, J. I.] Ctr Invest Biol CSIC, Madrid, Spain	Autonomous University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Pompeu Fabra University; Autonomous University of Barcelona; Autonomous University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Dunach, M (corresponding author), Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Fac Med, Unitat Biofis CEB, E-08193 Bellaterra, Spain.	mireia.dunach@uab.cat; agarcia@imim.es	de Herreros, A Garcia/H-3104-2014; Casal, Ignacio/M-2312-2014; lizcano, jose m/AAK-3577-2020; Lizcano, Jose M/E-6080-2010; Viñas-Castells, Rosa/J-7722-2017; Dunach, Mireia/E-3604-2015; Díaz, Víctor Manuel/F-5013-2016	de Herreros, A Garcia/0000-0001-5270-0808; Casal, Ignacio/0000-0003-1085-2840; lizcano, jose m/0000-0002-3154-5383; Lizcano, Jose M/0000-0002-3154-5383; Viñas-Castells, Rosa/0000-0003-0610-4495; Dunach, Mireia/0000-0001-9844-5603; Díaz, Víctor Manuel/0000-0001-8561-7576; Peiro, Sandra/0000-0001-9519-3877; Villagrasa-Gonzalez, Patricia/0000-0002-8662-3641	Ministerio de Ciencia e Innovacion [BFU2006-03203, BFU2009-07578, SAF2006-00339, SAF2010-16089]; Fundacio La Marato de TV3; Instituto Carlos III-Fondos FEDER (RTICCC) [C03710, RD06/0020/0040]; Generalitat de Catalunya [2009SGR867]; predoctoral fellowship from the Ministerio de Ciencia y Tecnologia; predoctoral fellowship from the Instituto Carlos III	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Fundacio La Marato de TV3; Instituto Carlos III-Fondos FEDER (RTICCC); Generalitat de Catalunya(Generalitat de Catalunya); predoctoral fellowship from the Ministerio de Ciencia y Tecnologia; predoctoral fellowship from the Instituto Carlos III	We are grateful to Neus Ontiveros for technical help; Dr David Casagolda for assistance with confocal microscopy; and Drs Lionel Larue and Alberto Munoz for reagents. This study was supported by grants awarded by the Ministerio de Ciencia e Innovacion (BFU2006-03203 and BFU2009-07578 to MD and SAF2006-00339 and SAF2010-16089 to AGH) and Fundacio La Marato de TV3 (to AGH). The partial support from the Instituto Carlos III-Fondos FEDER (RTICCC, C03710, RD06/0020/0040) and the Generalitat de Catalunya (2009SGR867) is also appreciated. PV and RV-C were supported by predoctoral fellowships from the Ministerio de Ciencia y Tecnologia and Instituto Carlos III, respectively.	AHMED NN, 1993, ONCOGENE, V8, P1957; Ahn JY, 2006, EMBO J, V25, P2083, DOI 10.1038/sj.emboj.7601111; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Arboleda MJ, 2003, CANCER RES, V63, P196; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bellacosa A, 2004, CANCER BIOL THER, V3, P268, DOI 10.4161/cbt.3.3.703; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Calleja V, 2007, PLOS BIOL, V5, P780, DOI 10.1371/journal.pbio.0050095; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Cho HJ, 2007, BIOCHEM BIOPH RES CO, V353, P337, DOI 10.1016/j.bbrc.2006.12.035; De Craene B, 2005, CELL SIGNAL, V17, P535, DOI 10.1016/j.cellsig.2004.10.011; Dillon RL, 2009, CANCER RES, V69, P5057, DOI 10.1158/0008-5472.CAN-08-4287; Dominguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003; Du KY, 2005, ONCOGENE, V24, P7401, DOI 10.1038/sj.onc.1209099; Ericson K, 2010, P NATL ACAD SCI USA, V107, P2598, DOI 10.1073/pnas.0914018107; Escriva M, 2008, MOL CELL BIOL, V28, P1528, DOI 10.1128/MCB.02061-07; Franci C, 2006, ONCOGENE, V25, P5134, DOI 10.1038/sj.onc.1209519; Gan Y, 2010, ONCOGENE, V29, P4947, DOI 10.1038/onc.2010.240; Gao HD, 2007, MOL CELL BIOCHEM, V305, P35, DOI 10.1007/s11010-007-9525-3; de Herreros AG, 2010, J MAMMARY GLAND BIOL, V15, P135, DOI 10.1007/s10911-010-9179-8; Grille SJ, 2003, CANCER RES, V63, P2172; He ZW, 2003, J BIOL CHEM, V278, P10588, DOI 10.1074/jbc.M208581200; Herranz N, 2008, MOL CELL BIOL, V28, P3198; Hurd PJ, 2009, J BIOL CHEM, V284, P16575, DOI 10.1074/jbc.M109.005421; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Jahn T, 2002, MOL CELL BIOL, V22, P979, DOI 10.1128/MCB.22.4.979-991.2002; Jorda M, 2005, J CELL SCI, V118, P3371, DOI 10.1242/jcs.02465; Jorda M, 2007, EXP CELL RES, V313, P2389, DOI 10.1016/j.yexcr.2007.04.001; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Lee SB, 2008, P NATL ACAD SCI USA, V105, P16584, DOI 10.1073/pnas.0807668105; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; Ohkubo T, 2004, J CELL SCI, V117, P1675, DOI 10.1242/jcs.01004; Palmer HG, 2004, NAT MED, V10, P917, DOI 10.1038/nm1095; Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a; Peiro S, 2006, NUCLEIC ACIDS RES, V34, P2077, DOI 10.1093/nar/gkl141; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Raurell I, 2006, J BIOL CHEM, V281, P1401, DOI 10.1074/jbc.M508153200; Rychahou PG, 2008, P NATL ACAD SCI USA, V105, P20315, DOI 10.1073/pnas.0810715105; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Solanas G, 2008, J CELL SCI, V121, P2224, DOI 10.1242/jcs.021667; Stemmer V, 2008, ONCOGENE, V27, P5075, DOI 10.1038/onc.2008.140; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Woodgett JR, 2005, CURR OPIN CELL BIOL, V17, P150, DOI 10.1016/j.ceb.2005.02.010; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	50	23	24	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	36					4022	4033		10.1038/onc.2011.562	http://dx.doi.org/10.1038/onc.2011.562			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NQ	22158034				2022-12-17	WOS:000308688800003
J	Li, X; Gilkes, D; Li, B; Cheng, Q; Pernazza, D; Lawrence, H; Lawrence, N; Chen, J				Li, X.; Gilkes, D.; Li, B.; Cheng, Q.; Pernazza, D.; Lawrence, H.; Lawrence, N.; Chen, J.			Abnormal MDMX degradation in tumor cells due to ARF deficiency	ONCOGENE			English	Article						MDM2; MDMX; ARF; p53; ubiquitination; nutlin	AUTOREGULATORY FEEDBACK LOOP; SMALL-MOLECULE INHIBITORS; DNA-DAMAGE; EMBRYONIC LETHALITY; P53 ACTIVATION; IN-VIVO; MDM2-DEFICIENT MICE; ACIDIC DOMAIN; RING DOMAIN; UBIQUITINATION	MDMX is a heterodimeric partner of MDM2 and a critical regulator of p53. The MDMX level is generally elevated in tumors with wild-type p53 and contributes to p53 inactivation. MDMX degradation is controlled in part by MDM2-mediated ubiquitination. Here, we show that MDMX turnover is highly responsive to changes in MDM2 level in non-transformed cells, but not in tumor cells. We found that loss of alternate reading frame (ARF) expression, which occurs in most tumors with wild-type p53, significantly reduces MDMX sensitivity to MDM2. Restoration of ARF expression in tumor cells enables MDM2 to degrade MDMX in a dose-dependent manner. ARF binds to MDM2 and stimulates a second-site interaction between the central region of MDM2 and MDMX, and thus increases MDMX-MDM2 binding and MDMX ubiquitination. These results reveal an important abnormality in the p53-regulatory pathway as a consequence of ARF deficiency. Loss of ARF during tumor development not only prevents p53 stabilization by proliferative stress but also causes accumulation of MDMX that compromises p53 activity. This phenomenon may reduce the clinical efficacy of MDM2-specific inhibitors by preventing MDMX downregulation. Oncogene (2012) 31, 3721-3732; doi:10.1038/onc.2011.534; published online 28 November 2011	[Li, X.; Gilkes, D.; Li, B.; Cheng, Q.; Chen, J.] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA; [Li, X.] Tianjin Med Univ, Dept Head & Neck Tumor, Canc Inst & Hosp, Tianjin, Peoples R China; [Pernazza, D.; Lawrence, H.; Lawrence, N.] H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Dept, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; Tianjin Medical University; H Lee Moffitt Cancer Center & Research Institute	Chen, J (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, MRC3057A,12902 Magnolia Dr, Tampa, FL 33612 USA.	Jiandong.chen@moffitt.org	Li, Baozong/ABD-4742-2020; Gilkes, Daniele M/AAI-8133-2020; li, baozong/K-4176-2012	Gilkes, Daniele M/0000-0003-3984-9338; 	National Institutes of Health [CA141244, CA109636, CA118210]; NATIONAL CANCER INSTITUTE [R01CA109636, R01CA141244, P01CA118210] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Dawn Quelle for NARF6 cells and Dr Yanping Zhang for ARF-null MEF. This work was supported in part by grants from the National Institutes of Health (CA141244, CA109636 and CA118210).	Badciong JC, 2002, J BIOL CHEM, V277, P49668, DOI 10.1074/jbc.M208593200; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Chen DL, 2010, NATURE, V464, P624, DOI 10.1038/nature08820; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen LH, 2005, EMBO J, V24, P3411, DOI 10.1038/sj.emboj.7600812; Cheng Q, 2009, EMBO J, V28, P3857, DOI 10.1038/emboj.2009.294; Cross B, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M111.228981; Dang JJ, 2002, CANCER RES, V62, P1222; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; Ding K, 2006, J MED CHEM, V49, P3432, DOI 10.1021/jm051122a; Gilkes DM, 2006, EMBO J, V25, P5614, DOI 10.1038/sj.emboj.7601424; Grier JD, 2006, MOL CELL BIOL, V26, P192, DOI 10.1128/MCB.26.1.192-198.2006; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Hu BL, 2006, J BIOL CHEM, V281, P33030, DOI 10.1074/jbc.C600147200; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kawai H, 2003, MOL CELL BIOL, V23, P4939, DOI 10.1128/MCB.23.14.4939-4947.2003; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Li BZ, 2010, CELL CYCLE, V9, P1411, DOI 10.4161/cc.9.7.11255; Li CG, 2002, MOL CELL BIOL, V22, P7562, DOI 10.1128/MCB.22.21.7562-7571.2002; Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100; Linke K, 2008, CELL DEATH DIFFER, V15, P841, DOI 10.1038/sj.cdd.4402309; LUNA RMD, 1995, NATURE, V378, P203; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Maetens M, 2007, BLOOD, V109, P2630, DOI 10.1182/blood-2006-03-013656; Meulmeester E, 2003, MOL CELL BIOL, V23, P4929, DOI 10.1128/MCB.23.14.4929-4938.2003; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Millard M, 2011, CURR PHARM DESIGN, V17, P536, DOI 10.2174/138161211795222649; Okamoto K, 2005, MOL CELL BIOL, V25, P9608, DOI 10.1128/MCB.25.21.9608-9620.2005; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Patton JT, 2006, CANCER RES, V66, P3169, DOI 10.1158/0008-5472.CAN-05-3832; Pereg Y, 2005, P NATL ACAD SCI USA, V102, P5056, DOI 10.1073/pnas.0408595102; Phillips A, 2010, J BIOL CHEM, V285, P29111, DOI 10.1074/jbc.M110.129726; Ramos YFM, 2001, CANCER RES, V61, P1839; Sasaki M, 2007, J BIOL CHEM, V282, P14626, DOI 10.1074/jbc.M610514200; Shangary S, 2008, P NATL ACAD SCI USA, V105, P3933, DOI 10.1073/pnas.0708917105; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; Sivakolundu SG, 2008, J MOL BIOL, V384, P240, DOI 10.1016/j.jmb.2008.09.019; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Terzian T, 2007, MOL CELL BIOL, V27, P5479, DOI 10.1128/MCB.00555-06; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wade M, 2006, J BIOL CHEM, V281, P33036, DOI 10.1074/jbc.M605405200; Wang XQ, 2001, FEBS LETT, V490, P202, DOI 10.1016/S0014-5793(01)02124-X; Wang YYV, 2009, CANCER CELL, V16, P33, DOI 10.1016/j.ccr.2009.05.008; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xia MX, 2008, CELL CYCLE, V7, P1604, DOI 10.4161/cc.7.11.5929; Xiong SB, 2006, P NATL ACAD SCI USA, V103, P3226, DOI 10.1073/pnas.0508500103; Xiong SB, 2010, CANCER RES, V70, P7148, DOI 10.1158/0008-5472.CAN-10-1457; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024	54	23	24	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	32					3721	3732		10.1038/onc.2011.534	http://dx.doi.org/10.1038/onc.2011.534			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	990TF	22120712	Green Accepted			2022-12-17	WOS:000307653800006
J	Torchia, EC; Caulin, C; Acin, S; Terzian, T; Kubick, BJ; Box, NF; Roop, DR				Torchia, E. C.; Caulin, C.; Acin, S.; Terzian, T.; Kubick, B. J.; Box, N. F.; Roop, D. R.			Myc, Aurora Kinase A, and mutant p53(R172H) co-operate in a mouse model of metastatic skin carcinoma	ONCOGENE			English	Article						Aurora Kinase A; genomic instability; Myc; p53; SCC; tumor progression	LI-FRAUMENI-SYNDROME; PSORALEN-PLUS-ULTRAVIOLET; SQUAMOUS-CELL CARCINOMAS; C-MYC; CHROMOSOMAL INSTABILITY; GENE-EXPRESSION; PHARMACOLOGICAL ACTIVATION; PSORIASIS PATIENTS; COLORECTAL-CANCER; LUNG-CANCER	Clinical observations, as well as data obtained from the analysis of genetically engineered mouse models, firmly established the gain-of-function (GOF) properties of certain p53 mutations. However, little is known about the underlying mechanisms. We have used two independent microarray platforms to perform a comprehensive and global analysis of tumors arising in a model of metastatic skin cancer progression, which compares the consequences of a GOF p53R(172H) mutant vs p53 deficiency. DNA profiling revealed a higher level of genomic instability in GOF vs loss-of-function (LOF) p53 squamous cell carcinomas (SCCs). Moreover, GOF p53 SCCs showed preferential amplification of Myc with a corresponding increase in its expression and deregulation of Aurora Kinase A. Fluorescent in situ hybridization confirmed amplification of Myc in primary GOF p53 SCCs and its retention in metastatic tumors. We also identified by RNA profiling distinct gene expression profiles in GOF p53 tumors, which included enriched integrin and Rho signaling, independent of tumor stage. Thus, the progression of GOF p53 papillomas to carcinoma was marked by the acquisition of epithelial-to-mesenchymal transition and metastatic signatures. In contrast, LOF p53 tumors showed enrichment of genes associated with cancer proliferation and chromosomal instability. Collectively, these observations suggest that genomic instability has a prominent role in the early stages of GOF p53 tumor progression (that is, papillomas), whereas it is implicated at a later stage in LOF p53 tumors (that is, SCCs). This model will allow us to identify specific targets in mutant p53 SCCs, which may lead to the development of new therapeutic agents for the treatment of metastatic SCCs. Oncogene (2012) 31, 2680-2690; doi:10.1038/onc.2011.441; published online 3 October 2011	[Torchia, E. C.; Terzian, T.; Kubick, B. J.; Box, N. F.; Roop, D. R.] Univ Colorado, Dept Dermatol, Aurora, CO 80045 USA; [Torchia, E. C.; Terzian, T.; Kubick, B. J.; Box, N. F.; Roop, D. R.] Univ Colorado, Ctr Regenerat Med & Stem Cell Biol, Aurora, CO 80045 USA; [Caulin, C.; Acin, S.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Texas System; UTMD Anderson Cancer Center	Roop, DR (corresponding author), Univ Colorado, Dept Dermatol, Anschutz Med Campus,POB 6511, Aurora, CO 80045 USA.	Dennis.Roop@UCDenver.edu	Acin, Sergio/S-5185-2017; Box, Neil/F-3591-2010	Acin, Sergio/0000-0001-7335-2865; Box, Neil/0000-0002-3486-0346	NIH [DE015344, CA52607, CA105491]; National Institute of Cancer, USA; NATIONAL CANCER INSTITUTE [R01CA052607, U01CA105491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015344] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Cancer, USA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	Grant Support: NIH grants: DE015344 (CC), CA52607 and CA105491 (DRR). We acknowledge Dr Lisa White and Laura Liles for their assistance with microarray experiments; Dr Leila Garcia for her assistance with the FISH experiments and Dr Ariefdjohan for the reading of the manuscript. This work was funded by grants from the National Institute of Cancer, USA.	Bickers DR, 2006, J AM ACAD DERMATOL, V55, P490, DOI 10.1016/j.jaad.2006.05.048; Bin Cho K, 2010, CANCER LETT, V293, P230, DOI 10.1016/j.canlet.2010.01.013; Birkenfeld J, 2008, TRENDS CELL BIOL, V18, P210, DOI 10.1016/j.tcb.2008.02.006; Birkenfeld J, 2007, DEV CELL, V12, P699, DOI 10.1016/j.devcel.2007.03.014; Boelens MC, 2009, LUNG CANCER, V66, P372, DOI 10.1016/j.lungcan.2009.02.017; Bougeard G, 2008, J MED GENET, V45, P535, DOI 10.1136/jmg.2008.057570; Boukamp P, 2005, CARCINOGENESIS, V26, P1657, DOI 10.1093/carcin/bgi123; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Caulin C, 2007, J CLIN INVEST, V117, P1893, DOI 10.1172/JCI31721; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Cheok CF, 2010, CELL DEATH DIFFER, V17, P1486, DOI 10.1038/cdd.2010.18; Cheok CF, 2011, NAT REV CLIN ONCOL, V8, P25, DOI 10.1038/nrclinonc.2010.174; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Daya-Grosjean L, 2005, MUTAT RES-FUND MOL M, V571, P43, DOI 10.1016/j.mrfmmm.2004.11.013; den Hollander J, 2010, BLOOD, V116, P1498, DOI 10.1182/blood-2009-11-251074; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Denys H, 2009, CURR PHARM DESIGN, V15, P1373, DOI 10.2174/138161209787846711; Doyle B, 2010, J PATHOL, V222, P129, DOI 10.1002/path.2748; Euvrard S, 2003, NEW ENGL J MED, V348, P1681, DOI 10.1056/NEJMra022137; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; HAUGHEY BH, 1992, AM J OTOLARYNG, V13, P168, DOI 10.1016/0196-0709(92)90117-C; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jechlinger M, 2003, ONCOGENE, V22, P7155, DOI 10.1038/sj.onc.1206887; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Karlsson R, 2009, BBA-REV CANCER, V1796, P91, DOI 10.1016/j.bbcan.2009.03.003; Karthigeyan D, 2011, MED RES REV, V31, P757, DOI 10.1002/med.20203; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kim YH, 2006, ONCOGENE, V25, P130, DOI 10.1038/sj.onc.1208997; KOZMA L, 1994, CANCER LETT, V81, P165, DOI 10.1016/0304-3835(94)90198-8; Kreimer-Erlacher H, 2003, J INVEST DERMATOL, V120, P676, DOI 10.1046/j.1523-1747.2003.12085.x; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lee JS, 2004, NAT GENET, V36, P1306, DOI 10.1038/ng1481; Lim SK, 2007, BIOCHEM J, V403, P119, DOI 10.1042/BJ20061272; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; Lu SL, 2006, GENE DEV, V20, P1331, DOI 10.1101/gad.1413306; Mizuarai S, 2006, CANCER RES, V66, P6319, DOI 10.1158/0008-5472.CAN-05-4629; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Ozakyol A, 2006, HEPATO-GASTROENTEROL, V53, P192; Paterson IC, 1996, ORAL ONCOL, V32B, P150, DOI 10.1016/0964-1955(95)00065-8; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; Prochownik EV, 2007, CELL CYCLE, V6, P1024, DOI 10.4161/cc.6.9.4161; Ramos DM, 2002, MATRIX BIOL, V21, P297, DOI 10.1016/S0945-053X(02)00002-1; Rao CV, 2009, CARCINOGENESIS, V30, P1469, DOI 10.1093/carcin/bgp081; Rounbehler RJ, 2001, ONCOGENE, V20, P5341, DOI 10.1038/sj.onc.1204691; Saha MN, 2010, J CLIN PATHOL, V63, P204, DOI 10.1136/jcp.2009.070961; Salvatore G, 2007, CANCER RES, V67, P10148, DOI 10.1158/0008-5472.CAN-07-1887; Sauer L, 2010, ONCOGENE, V29, P2628, DOI 10.1038/onc.2010.24; Shen H, 2011, CURR PHARM DESIGN, V17, P560, DOI 10.2174/138161211795222603; Shi J, 2009, BIOORG MED CHEM LETT, V19, P6038, DOI 10.1016/j.bmcl.2009.09.044; SPENCER JM, 1995, ARCH DERMATOL, V131, P796, DOI 10.1001/archderm.131.7.796; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; Sur S, 2009, P NATL ACAD SCI USA, V106, P3964, DOI 10.1073/pnas.0813333106; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Torchia EC, 2009, CANCER RES, V69, P7207, DOI 10.1158/0008-5472.CAN-09-1059; van der Meel R, 2011, DRUG DISCOV TODAY, V16, P219, DOI 10.1016/j.drudis.2011.01.005; Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5; Wolf P, 2004, J INVEST DERMATOL, V122, P190, DOI 10.1046/j.0022-202X.2004.22118.x; Xu L, 2008, MOL CANCER RES, V6, P760, DOI 10.1158/1541-7786.MCR-07-0344; Yakut T, 2003, LUNG, V181, P245, DOI 10.1007/s00408-003-1026-x; Yang SB, 2010, EXP MOL MED, V42, P759, DOI 10.3858/emm.2010.42.11.077; Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538; Zhang B, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-16; Zheng S, 2007, ONCOGENE, V26, P6896, DOI 10.1038/sj.onc.1210493	71	23	24	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	21					2680	2690		10.1038/onc.2011.441	http://dx.doi.org/10.1038/onc.2011.441			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	948SS	21963848	Green Accepted			2022-12-17	WOS:000304523500007
J	Chow, C; Wong, N; Pagano, M; Lun, SWM; Nakayama, KI; Nakayama, K; Lo, KW				Chow, C.; Wong, N.; Pagano, M.; Lun, S. W-M; Nakayama, K-I; Nakayama, K.; Lo, K-W			Regulation of APC/C-Cdc20 activity by RASSF1A-APC/C-Cdc20 circuitry	ONCOGENE			English	Article						RASSF1A; APC/C-Cdc20; Aurora; ubiquitination; mitotic checkpoint	TUMOR-SUPPRESSOR RASSF1A; ANAPHASE-PROMOTING COMPLEX/CYCLOSOME; UBIQUITIN-MEDIATED DEGRADATION; SPINDLE ASSEMBLY CHECKPOINT; KINASE AURORA-A; CYCLIN-A; CELL-CYCLE; PSEUDOSUBSTRATE INHIBITOR; MITOTIC CHECKPOINT; D-BOX	RASSF1A is a key tumor-suppressor gene that is often inactivated in a wide variety of solid tumors. Studies have illustrated that RASSF1A plays vital roles in the regulation of cell-cycle progression and functions as a guardian of mitosis. Nevertheless, the precise mechanism of RASSF1A-dependent regulation of mitosis remains largely unclear. APC/C-Cdc20 is the master switch and regulator of mitosis. The activity of APC/C-Cdc20 is tightly controlled by phosphorylation and specific inhibitors to ensure the sequential ubiquitination of downstream targets. Here, we report on the novel finding of a regulated circuitry that controls the timely expression and hence activity of APC/C-Cdc20 during mitosis. Our study showed that RASSF1A and APC/C-Cdc20 form a molecular relay that regulates the APC/C-Cdc20 activity at early mitosis. We found that RASSF1A inhibits APC/C-Cdc20 function through its D-box motifs. Paradoxically, RASSF1A was also demonstrated to be ubiquitinated by APC/C-Cdc20 in vitro and degraded at prometaphase despite of active spindle checkpoint presence. The first two unique D-boxes at the N-terminal of RASSF1A served as specific degron recognized by APC/C-Cdc20. Importantly, we found that Aurora A and Aurora B directly phosphorylate RASSF1A, a critical step by which RASSF1A switches from being an inhibitor to a substrate of APC/C-Cdc20 during the course of mitotic progression. As a result of RASSF1A degradation, APC/C-Cdc20 can then partially activate the ubiquitination of Cyclin A in the presence of spindle checkpoint. This circuitry is essential for the timely degradation of Cyclin A. To conclude, our results propose a new model for RASSF1A-APC/C-Cdc20 interaction in ensuring the sequential progression of mitosis. Oncogene (2012) 31, 1975-1987; doi:10.1038/onc.2011.372; published online 29 August 2011	[Chow, C.; Wong, N.; Lun, S. W-M; Lo, K-W] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, State Key Lab Oncol S China, Shatin, Hong Kong, Peoples R China; [Wong, N.; Lo, K-W] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Pagano, M.] NYU, Sch Med, Dept Pathol, Inst Canc, New York, NY USA; [Nakayama, K-I] Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 812, Japan; [Nakayama, K.] Tohoku Univ, Grad Sch Med, Ctr Translat & Adv Anim Res, Dept Dev Genet,Aoba Ku, Sendai, Miyagi 980, Japan	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; New York University; Kyushu University; Tohoku University	Lo, KW (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, State Key Lab Oncol S China, Shatin, Hong Kong, Peoples R China.	kwlo@cuhk.edu.hk		pagano, michele/0000-0003-3210-2442	Michael and Betty Kadoorie Cancer Genetics Research Program II (MBKCGRPII); Li Ka Shing Institute of Health Science; Hong Kong Research Grant Council [440606]; NATIONAL CANCER INSTITUTE [R37CA076584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057587] Funding Source: NIH RePORTER	Michael and Betty Kadoorie Cancer Genetics Research Program II (MBKCGRPII); Li Ka Shing Institute of Health Science; Hong Kong Research Grant Council(Hong Kong Research Grants Council); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by Michael and Betty Kadoorie Cancer Genetics Research Program II (MBKCGRPII), Li Ka Shing Institute of Health Science and Hong Kong Research Grant Council (440606).	Amador V, 2007, MOL CELL, V27, P462, DOI 10.1016/j.molcel.2007.06.013; Braunstein I, 2007, P NATL ACAD SCI USA, V104, P4870, DOI 10.1073/pnas.0700523104; Burton JL, 2007, GENE DEV, V21, P655, DOI 10.1101/gad.1511107; Carmena M, 2009, CURR OPIN CELL BIOL, V21, P796, DOI 10.1016/j.ceb.2009.09.008; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Enquist-Newman M, 2008, MOL CELL, V30, P437, DOI 10.1016/j.molcel.2008.04.004; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; Hames RS, 2001, EMBO J, V20, P7117, DOI 10.1093/emboj/20.24.7117; Hayes MJ, 2006, NAT CELL BIOL, V8, P607, DOI 10.1038/ncb1410; Heron NM, 2006, BIOORG MED CHEM LETT, V16, P1320, DOI 10.1016/j.bmcl.2005.11.053; Izawa D, 2011, NAT CELL BIOL, V13, P223, DOI 10.1038/ncb2165; Jiang LY, 2011, J BIOL CHEM, V286, P6971, DOI 10.1074/jbc.M110.186494; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Liu L, 2008, ONCOGENE, V27, P6175, DOI 10.1038/onc.2008.220; Liu L, 2007, CELL CYCLE, V6, P1663, DOI 10.4161/cc.6.13.4435; Miller JJ, 2006, GENE DEV, V20, P2410, DOI 10.1101/gad.1454006; Mortlock A, 2005, CURR TOP MED CHEM, V5, P805, DOI 10.2174/1568026054637719; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Pfleger CM, 2000, GENE DEV, V14, P655; Pines J, 2006, TRENDS CELL BIOL, V16, P55, DOI 10.1016/j.tcb.2005.11.006; Reddy SK, 2007, NATURE, V446, P921, DOI 10.1038/nature05734; Rong R, 2007, ONCOGENE, V26, P7700, DOI 10.1038/sj.onc.1210575; Rong R, 2004, ONCOGENE, V23, P8216, DOI 10.1038/sj.onc.1207901; Song MS, 2008, ONCOGENE, V27, P3176, DOI 10.1038/sj.onc.1210971; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Song SJ, 2009, CANCER RES, V69, P8540, DOI 10.1158/0008-5472.CAN-09-1554; van Zon W, 2010, BIOCHEM SOC T, V38, P72, DOI 10.1042/BST0380072; Wang X, 2008, ONCOGENE, V27, P4456, DOI 10.1038/onc.2008.87; Wolthuis R, 2008, MOL CELL, V30, P290, DOI 10.1016/j.molcel.2008.02.027; Woodbury EL, 2007, NAT CELL BIOL, V9, P106, DOI 10.1038/ncb1523; Yamano H, 2004, MOL CELL, V13, P137, DOI 10.1016/S1097-2765(03)00480-5; Yu H, 2007, MOL CELL, V27, P3, DOI 10.1016/j.molcel.2007.06.009; Yudkovsky Y, 2000, BIOCHEM BIOPH RES CO, V271, P299, DOI 10.1006/bbrc.2000.2622; Zur A, 2001, EMBO J, V20, P792, DOI 10.1093/emboj/20.4.792	37	23	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	15					1975	1987		10.1038/onc.2011.372	http://dx.doi.org/10.1038/onc.2011.372			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	926CW	21874044	hybrid, Green Published			2022-12-17	WOS:000302809900009
J	Haapa-Paananen, S; Kiviluoto, S; Waltari, M; Puputti, M; Mpindi, JP; Kohonen, P; Tynninen, O; Haapasalo, H; Joensuu, H; Perala, M; Kallioniemi, O				Haapa-Paananen, S.; Kiviluoto, S.; Waltari, M.; Puputti, M.; Mpindi, J. P.; Kohonen, P.; Tynninen, O.; Haapasalo, H.; Joensuu, H.; Perala, M.; Kallioniemi, O.			HES6 gene is selectively overexpressed in glioma and represents an important transcriptional regulator of glioma proliferation	ONCOGENE			English	Article						HES6; glioma; astrocytoma; glioblastoma; TMA; RNAi	BINDING PROTEIN; NEURONAL DIFFERENTIATION; GLIOBLASTOMA-MULTIFORME; CELL-PROLIFERATION; PROMOTES; RECEPTOR; GROWTH; EXPRESSION; PATHWAYS; KIT	Malignant glioma is the most common brain tumor with 16 000 new cases diagnosed annually in the United States. We performed a systematic large-scale transcriptomics data mining study of 9783 tissue samples from the GeneSapiens database to systematically identify genes that are most glioma-specific. We searched for genes that were highly expressed in 322 glioblastoma multiforme tissue samples and 66 anaplastic astrocytomas as compared with 425 samples from histologically normal central nervous system. Transcription cofactor HES6 (hairy and enhancer of split 6) emerged as the most glioma-specific gene. Immunostaining of a tissue micro-array showed HES6 expression in 335 (98.8%) out of the 339 glioma samples. HES6 was expressed in endothelial cells of the normal brain and glioma tissue. Recurrent grade 2 astrocytomas and grade 2 or 3 oligodendrogliomas showed higher levels of HES6 immunoreactivity than the corresponding primary tumors. High HES6 mRNA expression correlated with the proneural subtype that generally has a favorable outcome but is prone to recur. Functional studies suggested an important role for HES6 in supporting survival of glioma cells, as evidenced by reduction of cancer cell proliferation and migration after HES6 silencing. The biological role and consequences of HES6 silencing and overexpression was explored with genome-wide analyses, which implicated a role for HES6 in p53, c-myc and nuclear factor-kappa B transcriptional networks. We conclude that HES6 is important for glioma cell proliferation and migration, and may have a role in angiogenesis. Oncogene (2012) 31, 1299-1310; doi:10.1038/onc.2011.316; published online 25 July 2011	[Haapa-Paananen, S.; Kiviluoto, S.; Mpindi, J. P.; Kohonen, P.; Perala, M.; Kallioniemi, O.] Univ Turku, Dept Med Biotechnol, VTT Tech Res Ctr Finland, FI-20521 Turku, Finland; [Haapa-Paananen, S.; Kiviluoto, S.; Mpindi, J. P.; Kohonen, P.; Perala, M.; Kallioniemi, O.] Univ Turku, Ctr Biotechnol, FI-20521 Turku, Finland; [Waltari, M.; Puputti, M.; Joensuu, H.] Univ Helsinki, Dept Oncol, Helsinki, Finland; [Tynninen, O.] Helsinki Univ Cent Hosp, Dept Pathol, Helsinki, Finland; [Mpindi, J. P.; Kallioniemi, O.] Univ Helsinki, FIMM Inst Mol Med Finland, Helsinki, Finland; [Tynninen, O.] Univ Helsinki, Haartman Inst, Helsinki, Finland; [Haapasalo, H.] Tampere Univ Hosp, Dept Pathol, Tampere, Finland	University of Turku; VTT Technical Research Center Finland; University of Turku; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Helsinki; Tampere University; Tampere University Hospital	Haapa-Paananen, S (corresponding author), Univ Turku, Dept Med Biotechnol, VTT Tech Res Ctr Finland, Itainen Pitkakatu 4C,POB 106, FI-20521 Turku, Finland.	saija.haapa-paananen@vtt.fi	Kohonen, Pekka/F-9596-2011; Kallioniemi, Olli P/H-5111-2011; Kiviluoto, Santeri/M-2743-2014; Haapa-Paananen, Saija/D-3075-2012	Kohonen, Pekka/0000-0002-7845-3611; Kallioniemi, Olli P/0000-0002-3231-0332; Kiviluoto, Santeri/0000-0001-5010-5327; Joensuu, Heikki/0000-0003-0281-2507	Academy of Finland Translational Genome-Scale Biology Center of Excellence; Sigrid Juselius foundation; EU [LSHB-CT-2004-005276]; Cancer Foundation Finland sr [120084, 110071] Funding Source: researchfish	Academy of Finland Translational Genome-Scale Biology Center of Excellence(Academy of Finland); Sigrid Juselius foundation(Sigrid Juselius Foundation); EU(European Commission); Cancer Foundation Finland sr	This work was supported by the Academy of Finland Translational Genome-Scale Biology Center of Excellence, the Sigrid Juselius foundation and EU-FP6 project RIGHT (LSHB-CT-2004-005276). We acknowledge Dr Bokkee Eun for the generous gift of the HES6 overexpression plasmid pEYFP-C1-Hes6 (Eun et al., 2008). We also acknowledge the Finnish DNA Microarray Centre for their excellent technical assistance.	Bae SK, 2000, DEVELOPMENT, V127, P2933; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cooper LAD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012548; Cossins J, 2002, DEVELOPMENT, V129, P2195; Eun B, 2008, J BIOL CHEM, V283, P5939, DOI 10.1074/jbc.M707683200; Eun B, 2010, BRAIN RES, V1313, P1, DOI 10.1016/j.brainres.2009.11.078; Gratton MO, 2003, MOL CELL BIOL, V23, P6922, DOI 10.1128/MCB.23.19.6922-6935.2003; Haapasalo JA, 2006, CLIN CANCER RES, V12, P473, DOI 10.1158/1078-0432.CCR-05-0848; Hartman J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2446; Hong FX, 2006, BIOINFORMATICS, V22, P2825, DOI 10.1093/bioinformatics/btl476; Illi B, 2000, CIRC RES, V86, pE110; Jennings BH, 1999, MOL CELL BIOL, V19, P4600; Jhas S, 2006, J NEUROSCI, V26, P11061, DOI 10.1523/JNEUROSCI.1358-06.2006; Joensuu H, 2005, J PATHOL, V207, P224, DOI 10.1002/path.1823; Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139; Koyano-Nakagawa N, 2000, DEVELOPMENT, V127, P4203; Kumar Hari R, 2008, Expert Rev Neurother, V8, P1497, DOI 10.1586/14737175.8.10.1497; Lassman AB, 2004, NEURON GLIA BIOL, V1, P157, DOI 10.1017/S1740925X04000249; Madhavan S, 2009, MOL CANCER RES, V7, P157, DOI 10.1158/1541-7786.MCR-08-0435; Margolin AA, 2009, P NATL ACAD SCI USA, V106, P244, DOI 10.1073/pnas.0806445106; Mpindi JP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017259; Naumann U, 2008, INT J ONCOL, V33, P759, DOI 10.3892/ijo_00000062; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Ohgaki H, 2009, CANCER SCI, V100, P2235, DOI 10.1111/j.1349-7006.2009.01308.x; Ovaska K, 2010, GENOME MED, V2, DOI 10.1186/gm186; Panicker SP, 2010, ONCOTARGET, V1, P289; Puputti M, 2006, MOL CANCER RES, V4, P927, DOI 10.1158/1541-7786.MCR-06-0085; Schiffer D, 2010, ANTICANCER RES, V30, P1977; Sihto H, 2009, HISTOPATHOLOGY, V55, P544, DOI 10.1111/j.1365-2559.2009.03418.x; Somasundaram K, 2005, ONCOGENE, V24, P7073, DOI 10.1038/sj.onc.1208865; Strojnik T, 2007, SURG NEUROL, V68, P133, DOI 10.1016/j.surneu.2006.10.050; Swearingen ML, 2003, CANCER LETT, V198, P229, DOI 10.1016/S0304-3835(03)00313-6; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vias M, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-17; Wang GK, 2006, J BIOL CHEM, V281, P14085, DOI 10.1074/jbc.M513686200; Watson PA, 2002, ENDOCRINOLOGY, V143, P2922, DOI 10.1210/en.143.8.2922; Wesolowska A, 2008, ONCOGENE, V27, P918, DOI 10.1038/sj.onc.1210683; Wu JM, 2009, NAT METHODS, V6, P75, DOI [10.1038/NMETH.1282, 10.1038/nmeth.1282]	39	23	23	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	10					1299	1310		10.1038/onc.2011.316	http://dx.doi.org/10.1038/onc.2011.316			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906KS	21785461				2022-12-17	WOS:000301344600009
J	Liu, XF; Xiang, L; Zhang, Y; Becker, KG; Bera, TK; Pastan, I				Liu, X-F; Xiang, L.; Zhang, Y.; Becker, K. G.; Bera, T. K.; Pastan, I.			CAPC negatively regulates NF-kappa B activation and suppresses tumor growth and metastasis	ONCOGENE			English	Article						CAPC; tumor growth; NF-kappa B; cytokines	BREAST-CANCER CELLS; COLORECTAL-CANCER; CYSTATIN SN; INFLAMMATION; PROTEIN; PATHWAY; GENES	CAPC, also known as LRRC26, is expressed in normal prostate and salivary gland. We developed a mAb to CAPC and used it to characterize the protein and study its function. CAPC protein was detected in normal prostate and salivary gland, in several human breast cancer cell lines and in the prostate cancer cell line LNCaP. Knockdown of CAPC by siRNA in LNCaP cells enhanced anchorage-independent growth in soft agar. Conversely, overexpression of CAPC in MDA-231 breast cancer cells and A431 epidermoid cancer cells inhibited growth in soft agar and tumorigenesis in nude mice, and suppressed the metastasis of MDA-231 cells to the lung. Overexpression of CAPC downregulated NF-kappa B activity and its target genes, including GM-CSF (CSF2), CXCL1, IL8 and LTB1. It also suppressed genes encoding the serine protease mesotrypsin (PRSS3) and cystatin SN (CST1). CAPC expressing tumors showed a decrease in the number of proliferating cells and a large increase in ECM. The role of CAPC in the suppression of tumor growth and metastasis may be through its alteration of the tumor microenvironment. Oncogene (2012) 31, 1673-1682; doi:10.1038/onc.2011.355; published online 8 August 2011	[Liu, X-F; Xiang, L.; Bera, T. K.; Pastan, I.] NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Zhang, Y.; Becker, K. G.] NIA, Gene Express & Genom Unit, Res Resources Branch, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Pastan, I (corresponding author), NCI, Mol Biol Lab, Ctr Canc Res, NIH, 37 Convent Dr,Room 5106, Bethesda, MD 20892 USA.	pastani@mail.nih.gov	pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270; Becker, Kevin/0000-0002-6794-6656	NIH, National Cancer Institute, Center for Cancer Research; National Institute on Aging; NATIONAL CANCER INSTITUTE [ZIABC010298] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZICAG000616] Funding Source: NIH RePORTER	NIH, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The CAPC antibody was provided by BD BioSciences Pharmingen as an outcome of Antibody Co-development Collaboration between the NCI and BD BioSciences. We thank William H Wood III (National Institute on Aging) and the Confocal Core Facility members (Center for Cancer Research, NIH) for technical assistance. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research, and in part by the National Institute on Aging.	American Cancer Society, 2009, CANC FACTS FIG 2009; Apte RN, 2006, CANCER METAST REV, V25, P387, DOI 10.1007/s10555-006-9004-4; Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; Chatterjee Sabarni K, 2005, Future Oncol, V1, P37, DOI 10.1517/14796694.1.1.37; Choi EH, 2009, CLIN CHIM ACTA, V406, P45, DOI 10.1016/j.cca.2009.05.008; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; Egland KA, 2006, P NATL ACAD SCI USA, V103, P5929, DOI 10.1073/pnas.0601296103; Egland KA, 2003, P NATL ACAD SCI USA, V100, P1099, DOI 10.1073/pnas.0337425100; Friedl P, 2008, CANCER RES, V68, P7247, DOI 10.1158/0008-5472.CAN-08-0784; Hockla A, 2010, BREAST CANCER RES TR, V124, P27, DOI 10.1007/s10549-009-0699-0; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Lee CH, 2007, BIOFACTORS, V29, P19, DOI 10.1002/biof.5520290103; Lee M, 2004, CHEM SOC REV, V33, P401, DOI 10.1039/b209224g; Li F, 2010, BBA-REV CANCER, V1805, P167, DOI 10.1016/j.bbcan.2010.01.002; Loza MJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001035; Nam JS, 2006, CANCER RES, V66, P7176, DOI 10.1158/0008-5472.CAN-06-0825; Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020; Pacifico F, 2006, BIOCHEM PHARMACOL, V72, P1142, DOI 10.1016/j.bcp.2006.07.032; Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519; Porta C, 2009, IMMUNOBIOLOGY, V214, P761, DOI 10.1016/j.imbio.2009.06.014; Raman D, 2007, CANCER LETT, V256, P137, DOI 10.1016/j.canlet.2007.05.013; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Wang SL, 2009, CELL MOL IMMUNOL, V6, P327, DOI 10.1038/cmi.2009.43; Wu Y, 2009, CELL CYCLE, V8, P3267, DOI 10.4161/cc.8.20.9699; Yan JS, 2010, NATURE, V466, P513, DOI 10.1038/nature09162; Yoneda K, 2009, INT J ONCOL, V35, P33, DOI 10.3892/ijo_00000310	27	23	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	13					1673	1682		10.1038/onc.2011.355	http://dx.doi.org/10.1038/onc.2011.355			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	918EF	21822313	Green Accepted			2022-12-17	WOS:000302231400006
J	Li, Y; Jaramillo-Lambert, AN; Yang, Y; Williams, R; Lee, NH; Zhu, W				Li, Y.; Jaramillo-Lambert, A. N.; Yang, Y.; Williams, R.; Lee, N. H.; Zhu, W.			And-1 is required for the stability of histone acetyltransferase Gcn5	ONCOGENE			English	Article						Ctf4/And-1; Gcn5; DNA replication; histone acetylation	DNA-POLYMERASE-ALPHA; BINDING PROTEIN; REPLICATION; ACETYLATION; COMPLEX; CTF4; YEAST; DOMAIN; H3; ACTIVATION	Histone acetyltransferases (HATs) have a central role in the modification of chromatin as well as in the pathogenesis of a broad set of diseases including cancers. Gcn5 is the first identified transcription-related HAT that has been implicated in the regulation of diverse cellular functions. However, how Gcn5 proteins are regulated remains largely unknown. Here we show that acidic nucleoplasmic DNA-binding protein (And-1, a high mobility group domain-containing protein) has remarkable capability to regulate the stability of Gcn5 proteins and thereby histone H3 acetylation. We find that And-1 forms a complex with both histone H3 and Gcn5. Downregulation of And-1 results in Gcn5 degradation, leading to the reduction of H3K9 and H3K56 acetylation. And-1 overexpression stabilizes Gcn5 through protein-protein interactions in vivo. Furthermore, And-1 expression is increased in cancer cells in a manner correlating with increased Gcn5 and H3K9Ac and H3K56Ac. Thus, our data reveal not only a functional link between Gcn5 and And-1 that is essential for Gcn5 protein stability and histone H3 acetylation, but also a potential role of And-1 in cancer. Oncogene (2012) 31, 643-652; doi:10.1038/onc.2011.261; published online 4 July 2011	[Li, Y.; Jaramillo-Lambert, A. N.; Yang, Y.; Zhu, W.] George Washington Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20037 USA; [Williams, R.; Lee, N. H.] George Washington Univ, Sch Med, Dept Pharmacol & Physiol, Washington, DC 20037 USA	George Washington University; George Washington University	Zhu, W (corresponding author), George Washington Univ, Sch Med, Dept Biochem & Mol Biol, 2300 Eye St NW, Washington, DC 20037 USA.	bcmwxz@gwumc.edu		Jaramillo-Lambert, Aimee/0000-0001-7697-8580	National Institutes of Health [4R00CA136555, CA120316]; NATIONAL CANCER INSTITUTE [R01CA120316, R00CA136555] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Anindya Dutta for And-1 plasmids and antibodies, Ezra Burstein for Gcn5 plasmids, Rakesh Kumar and Jeyanthy Eswaran for reading the manuscript. This work was supported by funding from the National Institutes of Health (4R00CA136555 awarded to WZ; CA120316 awarded to NHL).	Armas-Pineda C, 2007, J EXP CLIN CANC RES, V26, P269; Atanassov BS, 2009, MOL CELL, V35, P352, DOI 10.1016/j.molcel.2009.06.015; Bermudez VP, 2010, J BIOL CHEM, V285, P9493, DOI 10.1074/jbc.M109.093609; Brand M, 2001, EMBO J, V20, P3187, DOI 10.1093/emboj/20.12.3187; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Burgess RJ, 2010, CELL CYCLE, V9, P2979, DOI 10.4161/cc.9.15.12498; Burgess RJ, 2010, MOL CELL, V37, P469, DOI 10.1016/j.molcel.2010.01.020; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Cavusoglu N, 2003, PROTEOMICS, V3, P217, DOI 10.1002/pmic.200390030; Celic I, 2008, GENETICS, V179, P1769, DOI 10.1534/genetics.108.088914; Collins SR, 2007, NATURE, V446, P806, DOI 10.1038/nature05649; Das C, 2009, NATURE, V459, P113, DOI 10.1038/nature07861; Espinosa MC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008964; Gambus A, 2009, EMBO J, V28, P2992, DOI 10.1038/emboj.2009.226; Goren A, 2008, GENE DEV, V22, P1319, DOI 10.1101/gad.468308; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Hanna JS, 2001, MOL CELL BIOL, V21, P3144, DOI 10.1128/MCB.21.9.3144-3158.2001; Im JS, 2009, P NATL ACAD SCI USA, V106, P15628, DOI 10.1073/pnas.0908039106; Karnani N, 2007, GENOME RES, V17, P865, DOI 10.1101/gr.5427007; Kikuchi H, 2011, BIOCHEM BIOPH RES CO, V405, P657, DOI 10.1016/j.bbrc.2011.01.088; KOUPRINA N, 1992, MOL CELL BIOL, V12, P5736, DOI 10.1128/MCB.12.12.5736; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Lang SE, 2001, J BIOL CHEM, V276, P32627, DOI 10.1074/jbc.M102067200; Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145; Liu XH, 2003, J BIOL CHEM, V278, P20405, DOI 10.1074/jbc.M211795200; Lucas I, 2007, EMBO REP, V8, P770, DOI 10.1038/sj.embor.7401026; Masumoto H, 2005, NATURE, V436, P294, DOI 10.1038/nature03714; Mayer ML, 2004, MOL BIOL CELL, V15, P1736, DOI 10.1091/mbc.E03-08-0619; Nagy Z, 2007, ONCOGENE, V26, P5341, DOI 10.1038/sj.onc.1210604; Orpinell M, 2010, EMBO J, V29, P2381, DOI 10.1038/emboj.2010.125; Paolinelli R, 2009, NAT STRUCT MOL BIOL, V16, P412, DOI 10.1038/nsmb.1583; Petronczki M, 2004, J CELL SCI, V117, P3547, DOI 10.1242/jcs.01231; Shahbazian MD, 2007, ANNU REV BIOCHEM, V76, P75, DOI 10.1146/annurev.biochem.76.052705.162114; Shechter D, 2007, NAT PROTOC, V2, P1445, DOI 10.1038/nprot.2007.202; Tamburini BA, 2005, MOL CELL BIOL, V25, P4903, DOI 10.1128/MCB.25.12.4903-4913.2005; Tjeertes JV, 2009, EMBO J, V28, P1878, DOI 10.1038/emboj.2009.119; Tsutsui Y, 2005, CURR GENET, V48, P34, DOI 10.1007/s00294-005-0584-2; Vogelauer M, 2002, MOL CELL, V10, P1223, DOI 10.1016/S1097-2765(02)00702-5; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; Wang YL, 2008, J BIOL CHEM, V283, P33808, DOI 10.1074/jbc.M806936200; Williams DR, 2002, EUKARYOT CELL, V1, P758, DOI 10.1128/EC.1.5.758-773.2002; Yoshizawa-Sugata N, 2009, J BIOL CHEM, V284, P20718, DOI 10.1074/jbc.M806711200; Zhou J, 2005, CELL CYCLE, V4, P889, DOI 10.4161/cc.4.7.1823; Zhu WG, 2007, GENE DEV, V21, P2288, DOI 10.1101/gad.1585607; Zhu WG, 2004, MOL CELL BIOL, V24, P7140, DOI 10.1128/MCB.24.16.7140-7150.2004	46	23	23	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	5					643	652		10.1038/onc.2011.261	http://dx.doi.org/10.1038/onc.2011.261			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MS	21725360	Green Accepted			2022-12-17	WOS:000300221800010
J	Verhaegen, M; Checinska, A; Riblett, MB; Wang, S; Soengas, MS				Verhaegen, M.; Checinska, A.; Riblett, M. B.; Wang, S.; Soengas, M. S.			E2F1-dependent oncogenic addiction of melanoma cells to MDM2	ONCOGENE			English	Article						melanoma; senescence; oncogene dependency; MDM-2 inhibitors	TUMOR-SUPPRESSOR; P53 ACTIVATION; E3 LIGASE; APOPTOSIS; PROTEIN; DEGRADATION; INHIBITOR; EXPRESSION; UBIQUITINATION; INACTIVATION	One of the defining features of aggressive melanomas is their complexity. Hundreds of mutations and an ever increasing list of changes in the transcriptome and proteome distinguish normal from malignant melanocytic cells. Yet, despite this altered genetic background, a long-known attribute of melanomas is a relatively low rate of mutations in the p53 gene. However, it is unclear whether p53 is maintained in melanoma cells because it is required for their survival, or because it is functionally disabled. More pressing from a translational perspective, is to define whether there is a tumor cell-selective wiring of p53 that offers a window for therapeutic intervention. Here, we provide genetic and pharmacological evidence demonstrating that p53 represents a liability to melanoma cells, which they thwart by assuming an oncogenic dependency on the E3 ligase murine double minute-2 (MDM2). Specifically, we used a combination of RNA interference and two structurally independent small molecule inhibitors of the p53-MDM2 interaction to assess the relative requirement of both proteins for the viability of normal melanocytes and a broad panel of melanoma cell lines. We demonstrated in vitro and in vivo that MDM2 is selectively required to blunt latent pro-senescence signals in melanoma cells. Notably, the outcome of MDM2 inactivation depends not only on the mutational status of p53, but also on its ability to signal to the transcription factor E2F1. These data support MDM2 as a drug target in melanoma cells, and identify E2F1 as a biomarker to consider when stratifying putative candidates for clinical studies of p53-MDM2 inhibitors. Oncogene (2012) 31, 828-841; doi: 10.1038/onc.2011.277; published online 11 July 2011	[Checinska, A.; Soengas, M. S.] Spanish Natl Canc Res Ctr, Melanoma Lab, Mol Pathol Programme, CNIO, Madrid 28049, Spain; [Verhaegen, M.; Riblett, M. B.] Univ Michigan, Sch Med, Dept Dermatol, Ann Arbor, MI USA; [Verhaegen, M.; Riblett, M. B.; Wang, S.] Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI USA; [Wang, S.] Univ Michigan, Dept Internal Med & Pharmacol, Ann Arbor, MI 48109 USA	Centro Nacional de Investigaciones Oncologicas (CNIO); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Soengas, MS (corresponding author), Spanish Natl Canc Res Ctr, Melanoma Lab, Mol Pathol Programme, CNIO, Melchor Fernandez Almagro 3, Madrid 28049, Spain.	msoengas@cnio.es	Soengas, Maria S/H-6455-2015	Soengas, Maria S/0000-0003-0612-6299; Wang, Shaomeng/0000-0002-8782-6950	NIH [R01CA107237]; Spanish Ministry of Science and Innovation [SAF2008-01950]; Spanish Association Against Cancer (AECC); Dermatology Foundation;  [R01CA121279]; NATIONAL CANCER INSTITUTE [R01CA121279, R01CA107237] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Spanish Association Against Cancer (AECC); Dermatology Foundation; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Joshua A Bauer, J Chadwick Brenner and Thomas E Carey for shRNA constructs against p53 and MDM2, Andrzej Dlugosz for support and Mikhail Nikiforov for helpful suggestions at early stages of this study. MSS was supported by R01CA107237 from the NIH, SAF2008-01950 from the Spanish Ministry of Science and Innovation, and a development grant from the Spanish Association Against Cancer (AECC). SW was funded by R01CA121279 and MV is the recipient of a Career Development Award from the Dermatology Foundation.	Ambrosini G, 2007, ONCOGENE, V26, P3473, DOI 10.1038/sj.onc.1210136; Avery-Kiejda KA, 2008, CLIN CANCER RES, V14, P1659, DOI 10.1158/1078-0432.CCR-07-1422; Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bennett DC, 2008, PIGM CELL MELANOMA R, V21, P27, DOI 10.1111/j.1755-148X.2007.00433.x; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; Fu W, 2009, J BIOL CHEM, V284, P13987, DOI 10.1074/jbc.M901758200; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Ha L, 2007, P NATL ACAD SCI USA, V104, P10968, DOI 10.1073/pnas.0611638104; Hoek KS, 2007, PIGM CELL RES, V20, P466, DOI 10.1111/j.1600-0749.2007.00412.x; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Hu BL, 2006, J BIOL CHEM, V281, P33030, DOI 10.1074/jbc.C600147200; Huang BY, 2009, MOL CANCER RES, V7, P1497, DOI 10.1158/1541-7786.MCR-09-0144; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kass EM, 2009, CELL CYCLE, V8, P430, DOI 10.4161/cc.8.3.7624; Korotchkina LG, 2009, CELL CYCLE, V8, P3777, DOI 10.4161/cc.8.22.10121; Kumamoto K, 2008, CANCER RES, V68, P3193, DOI 10.1158/0008-5472.CAN-07-2780; Long JT, 2010, BLOOD, V116, P71, DOI 10.1182/blood-2010-01-261628; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Moran DM, 2010, MOL CANCER THER, V9, P895, DOI 10.1158/1535-7163.MCT-09-1220; Murga M, 2009, NAT GENET, V41, P891, DOI 10.1038/ng.420; Nikiforov MA, 2007, P NATL ACAD SCI USA, V104, P19488, DOI 10.1073/pnas.0708380104; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Polager S, 2009, NAT REV CANCER, V9, P738, DOI 10.1038/nrc2718; Polsky D, 2003, ONCOGENE, V22, P3087, DOI 10.1038/sj.onc.1206449; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Prieur A, 2008, CURR OPIN CELL BIOL, V20, P150, DOI 10.1016/j.ceb.2008.01.007; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Satyamoorthy K, 2000, CELL GROWTH DIFFER, V11, P467; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Shangary S, 2008, P NATL ACAD SCI USA, V105, P3933, DOI 10.1073/pnas.0708917105; Shangary S, 2009, ANNU REV PHARMACOL, V49, P223, DOI 10.1146/annurev.pharmtox.48.113006.094723; Shen H, 2008, CANCER RES, V68, P8260, DOI 10.1158/0008-5472.CAN-08-1901; Smalley KSM, 2007, CANCER RES, V67, P209, DOI 10.1158/0008-5472.CAN-06-1538; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Terzian T, 2010, PIGM CELL MELANOMA R, V23, P781, DOI 10.1111/j.1755-148X.2010.00773.x; Vassilev LT, 2007, TRENDS MOL MED, V13, P23, DOI 10.1016/j.molmed.2006.11.002; Vazquez A, 2008, NAT REV DRUG DISCOV, V7, P979, DOI 10.1038/nrd2656; Verhaegen M, 2006, CANCER RES, V66, P11348, DOI 10.1158/0008-5472.CAN-06-1748; Verma R, 2010, BIOCHEM PHARMACOL, V79, P565, DOI 10.1016/j.bcp.2009.09.020; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yang G, 2006, J INVEST DERMATOL, V126, P2490, DOI 10.1038/sj.jid.5700470; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; Zhu Y, 2009, MOL CELL, V35, P316, DOI 10.1016/j.molcel.2009.07.014	50	23	24	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	7					828	841		10.1038/onc.2011.277	http://dx.doi.org/10.1038/onc.2011.277			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	897BL	21743494	Green Accepted, Green Submitted			2022-12-17	WOS:000300615800003
J	Kuphal, S; Shaw-Hallgren, G; Eberl, M; Karrer, S; Aberger, F; Bosserhoff, AK; Massoumi, R				Kuphal, S.; Shaw-Hallgren, G.; Eberl, M.; Karrer, S.; Aberger, F.; Bosserhoff, A. K.; Massoumi, R.			GLI1-dependent transcriptional repression of CYLD in basal cell carcinoma	ONCOGENE			English	Article						CYLD; GLI1; Snail1; BCC; Bcl-3	CYCLE PROGRESSION; HEDGEHOG PATHWAY; EXPRESSION; TUMOR; GLI1; MICE; DIFFERENTIATION; TRANSFORMATION; MANIPULATION; INHIBITION	CYLD is a deubiquitination enzyme that regulates different cellular processes, such as cell proliferation and cell survival. Mutation and loss of heterozygosity of the CYLD gene causes development of cylindromatosis, a benign tumour originating from the skin. Our study shows that CYLD expression is dramatically downregulated in basal cell carcinoma (BCC), the most common cancer in humans. Reduced CYLD expression in basal cell carcinoma was mediated by GLI1-dependent activation of the transcriptional repressor Snail. Inhibition of GLI1 restored the CYLD expression-mediated Snail signaling pathway, and caused a significant delay in the G1 to S phase transition, as well as proliferation. Our data suggest that GLI1-mediated suppression of CYLD has a significant role in basal cell carcinoma progression. Oncogene (2011) 30, 4523-4530; doi: 10.1038/onc.2011.163; published online 16 May 2011	[Shaw-Hallgren, G.; Massoumi, R.] Lund Univ, UMAS, Dept Lab Med, S-20502 Malmo, Sweden; [Kuphal, S.; Bosserhoff, A. K.] Univ Regensburg, Inst Pathol, Regensburg, Germany; [Eberl, M.; Aberger, F.] Salzburg Univ, Dept Mol Biol, A-5020 Salzburg, Austria; [Karrer, S.] Univ Regensburg, Dept Dermatol, Regensburg, Germany	Lund University; Skane University Hospital; University of Regensburg; Salzburg University; University of Regensburg	Massoumi, R (corresponding author), Lund Univ, UMAS, Dept Lab Med, Entrance 78, S-20502 Malmo, Sweden.	Ramin.Massoumi@med.lu.se	Kuphal, Silke/AAW-2702-2020; Bosserhoff, Anja/GNH-4801-2022; Massoumi, Ramin/AAG-4786-2019; Aberger, Fritz/B-6357-2012	Aberger, Fritz/0000-0003-2009-6305; Bosserhoff, Anja/0000-0001-8147-394X	Swedish Society for Medical Research; Swedish Cancer Foundation; Swedish Medical Research Council; Crafoordska Foundation; Royal Physiographic Society in Lund; Gunnar Nilsson Cancer Foundation; U-MAS Research Foundations; ERC; Austrian Science Fund FWF [P20652]; University of Salzburg; Austrian Genome program Gen-AU	Swedish Society for Medical Research; Swedish Cancer Foundation; Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Crafoordska Foundation; Royal Physiographic Society in Lund; Gunnar Nilsson Cancer Foundation; U-MAS Research Foundations; ERC(European Research Council (ERC)European Commission); Austrian Science Fund FWF(Austrian Science Fund (FWF)); University of Salzburg; Austrian Genome program Gen-AU	We thank Rudolf Jung and Elise Nilsson for excellent technical assistance, Dr Anders Edsjo, for discussion, Dr Ervin H Epstein for the mouse BCC cell line ASZ001 and CSZ-1. This work was supported by the Swedish Society for Medical Research, Swedish Cancer Foundation, Swedish Medical Research Council, Crafoordska Foundation, Royal Physiographic Society in Lund, Gunnar Nilsson Cancer Foundation, U-MAS Research Foundations and ERC grant to RM and the Austrian Science Fund FWF (projects P20652), the priority program of the University of Salzburg and the Austrian Genome program Gen-AU to FA.	Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Buonamici S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001599; Epstein EH, 2008, NAT REV CANCER, V8, P743, DOI 10.1038/nrc2503; Fiaschi M, 2009, CANCER RES, V69, P4810, DOI 10.1158/0008-5472.CAN-08-3938; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Jeong JH, 2004, GENE DEV, V18, P937, DOI 10.1101/gad.1190304; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kasper M, 2006, EUR J CANCER, V42, P437, DOI 10.1016/j.ejca.2005.08.039; Kasper Maria, 2007, V397, P67; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; Li X, 2007, ONCOGENE, V26, P4489, DOI 10.1038/sj.onc.1210241; Li X, 2006, ONCOGENE, V25, P609, DOI 10.1038/sj.onc.1209077; Louro ID, 2002, CANCER RES, V62, P5867; Massoumi R, 2006, J INVEST DERMATOL, V126, P1182, DOI 10.1038/sj.jid.5700218; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Massoumi R, 2010, TRENDS BIOCHEM SCI, V35, P392, DOI 10.1016/j.tibs.2010.02.007; Massoumi R, 2009, J EXP MED, V206, P221, DOI 10.1084/jem.20082044; Moriwaki K, 2007, J INVEST DERMATOL, V127, pS107; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Nitzki F, 2010, CANCER RES, V70, P2739, DOI 10.1158/0008-5472.CAN-09-3743; Regl G, 2004, ONCOGENE, V23, P1263, DOI 10.1038/sj.onc.1207240; Regl G, 2002, ONCOGENE, V21, P5529, DOI 10.1038/sj.onc.1205748; So PL, 2006, EXP DERMATOL, V15, P742, DOI 10.1111/j.1600-0625.2006.00465.x; Von Hoff DD, 2009, NEW ENGL J MED, V361, P1164, DOI 10.1056/NEJMoa0905360; Wickstrom SA, 2010, EMBO J, V29, P131, DOI 10.1038/emboj.2009.317; Yang SH, 2008, NAT GENET, V40, P1130, DOI 10.1038/ng.192; Yauch RL, 2009, SCIENCE, V326, P572, DOI 10.1126/science.1179386	28	23	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2011	30	44					4523	4530		10.1038/onc.2011.163	http://dx.doi.org/10.1038/onc.2011.163			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	844FN	21577203				2022-12-17	WOS:000296733200007
J	Zhang, Q; Zhong, Q; Evans, AG; Levy, D; Zhong, S				Zhang, Q.; Zhong, Q.; Evans, A. G.; Levy, D.; Zhong, S.			Phosphorylation of histone H3 serine 28 modulates RNA polymerase III-dependent transcription	ONCOGENE			English	Article						phosphorylation; histone H3; EGFR; Pol III transcription; Brf1; cell transformation	B-INDUCED PHOSPHORYLATION; ONCOGENIC TRANSFORMATION; CHROMOSOME CONDENSATION; POL II; GROWTH; TFIIIB; GENES; TRICHOSTATIN; ACETYLATION; DEACETYLASE	Deregulation of RNA polymerase III (Pol III) transcription enhances cellular tRNAs and 5S rRNA production, leading to an increase in translational capacity to promote cell proliferation, transformation and tumor formation. Phosphorylation of histone H3 (H3ph) is induced by tumor promoters (EGF, UV and TPA) and immediate early genes, such as c-myc, c-jun and c-fos. However, it remains to be determined whether H3ph is involved in RNA Pol III transcription. Here, we report that EGF strongly induced H3ph at serine 28 (H3S28ph). EGF significantly increased transcription of RNA Pol III-dependent genes (Pol III genes), tRNA(Leu), tRNA(Tyr), 5S rRNA and 7SL RNA. Inhibition of EGFR, but not PI3K, reduced both H3S28ph and tRNA(Leu) and 5S rRNA transcription. EGF enhanced occupancy of H3S28ph in the promoters of tRNA(Leu) and 5S rRNA. Further analysis indicates that EGF augmented cellular levels of protein and mRNA of TFIIIB subunits, Brf1 and TATA box-binding protein (TBP). Brf1 is a specific transcription factor for RNA Pol III genes. EGF enhanced occupancy of H3S28ph in the Brf1 and TBP promoters. Inhibition of H3S28ph by mutant H3S28A repressed Brf1, TBP and tRNA(Leu) and 5S rRNA expression and decreased occupancy of H3S28ph in their promoters. Reduction of Brf1 significantly decreased tRNA(Leu) and 5S rRNA transcription and repressed EGF-induced anchorage-independent growth. Blocking H3S28ph signaling by using mutant H3S28A reduced EGF-induced cell transformation. Together, these results indicate that EGF activates EGFR signaling to induce H3S28ph, which, in turn, upregulates tRNA(Leu) and 5S rRNA transcription through Brf1 and TBP and promotes cell transformation. The studies demonstrate that epigenetic modification of H3S28ph has a critical role in the activity of Pol III genes. Oncogene (2011) 30, 3943-3952; doi:10.1038/onc.2011.105; published online 4 April 2011	[Zhang, Q.; Zhong, Q.; Evans, A. G.; Levy, D.; Zhong, S.] Univ So Calif, Dept Biochem & Mol Biol, Keck Sch Med, Los Angeles, CA 90033 USA; [Zhang, Q.] Jinling Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China	University of Southern California	Zhong, S (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, Keck Sch Med, 2011 Zonal Ave,HMR 605, Los Angeles, CA 90033 USA.	szhong@usc.edu			National Institutes of Health [AA017288, DK025836-26]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R21AA023247, R21AA017288] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	We want to thank DL, Johnson and MR Stallcup (University of Southern California) for scientific discussions. We would like to thank Z Dong (University of Minnesota) and C Huang (University of New York) who provided cell lines. This work was supported by National Institutes of Health grants AA017288 to SZ and DK025836-26 to DL.	Barski A, 2010, NAT STRUCT MOL BIOL, V17, P629, DOI 10.1038/nsmb.1806; Brunmeir R, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000927; Chen NY, 2001, J BIOL CHEM, V276, P46722, DOI 10.1074/jbc.M107156200; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Crighton D, 2003, EMBO J, V22, P2810, DOI 10.1093/emboj/cdg265; Dieci G, 2007, TRENDS GENET, V23, P614, DOI 10.1016/j.tig.2007.09.001; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Gehani SS, 2010, MOL CELL, V39, P886, DOI 10.1016/j.molcel.2010.08.020; Goodfellow SJ, 2006, EMBO J, V25, P1522, DOI 10.1038/sj.emboj.7601040; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnson DL, 2008, SCIENCE, V320, P461, DOI 10.1126/science.1158680; Johnson SAS, 2008, J BIOL CHEM, V283, P19184, DOI 10.1074/jbc.M802872200; Kenneth NS, 2007, P NATL ACAD SCI USA, V104, P14917, DOI 10.1073/pnas.0702909104; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; Kim HG, 2008, CANCER RES, V68, P2538, DOI 10.1158/0008-5472.CAN-07-6597; Marshall L, 2008, CELL, V133, P78, DOI 10.1016/j.cell.2008.02.035; Metzger E, 2010, NATURE, V464, P792, DOI 10.1038/nature08839; Moqtaderi Z, 2010, NAT STRUCT MOL BIOL, V17, P635, DOI 10.1038/nsmb.1794; Oler AJ, 2010, NAT STRUCT MOL BIOL, V17, P620, DOI 10.1038/nsmb.1801; Raha D, 2010, P NATL ACAD SCI USA, V107, P3639, DOI 10.1073/pnas.0911315106; Shimada M, 2010, J BIOL CHEM, V285, P9390, DOI 10.1074/jbc.M109.057745; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; ULLU E, 1984, NATURE, V312, P171, DOI 10.1038/312171a0; Wang FW, 2010, SCIENCE, V330, P231, DOI 10.1126/science.1189435; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; White RJ, 2004, ONCOGENE, V23, P3208, DOI 10.1038/sj.onc.1207547; Winter AG, 2000, P NATL ACAD SCI USA, V97, P12619, DOI 10.1073/pnas.230224097; Woiwode A, 2008, MOL CELL BIOL, V28, P4204, DOI 10.1128/MCB.01912-07; Yoshida M, 1999, ANN NY ACAD SCI, V886, P23, DOI 10.1111/j.1749-6632.1999.tb09397.x; Zhong SP, 2009, P NATL ACAD SCI USA, V106, P12682, DOI 10.1073/pnas.0904843106; Zhong SP, 2000, J BIOL CHEM, V275, P20980, DOI 10.1074/jbc.M909934199; Zhong SP, 2004, MOL CELL BIOL, V24, P5119, DOI 10.1128/MCB.24.12.5119-5129.2004; Zhong SP, 2003, ONCOGENE, V22, P5291, DOI 10.1038/sj.onc.1206507; Zhong SP, 2001, J BIOL CHEM, V276, P33213, DOI 10.1074/jbc.M103973200; Zhong SP, 2001, J BIOL CHEM, V276, P12932, DOI 10.1074/jbc.M010931200	37	23	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	37					3943	3952		10.1038/onc.2011.105	http://dx.doi.org/10.1038/onc.2011.105			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820FG	21460852	Green Accepted			2022-12-17	WOS:000294890400004
J	Walker, MP; Zhang, M; Le, TP; Wu, P; Laine, M; Greene, GL				Walker, M. P.; Zhang, M.; Le, T. P.; Wu, P.; Laine, M.; Greene, G. L.			RAC3 is a pro-migratory co-activator of ER alpha	ONCOGENE			English	Article						transcription; estrogen receptor; RAC3; breast cancer	ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER CELLS; RHO GTPASES; PROTEIN; TRANSCRIPTION; METASTASIS; PHOSPHORYLATION; PROLIFERATION; ACTIVATION; EXPRESSION	Estrogen receptor alpha (ER alpha) is a ligand-dependent nuclear receptor that is important in breast cancer genesis, behavior and response to hormone-based therapies. A T7 phage display screen against full-length human ER alpha, coupled with genome-wide exon arrays, was used to identify RAC3 as a putative ER alpha co-regulator. RAC3 is a Rho family small GTPase that is associated with cytoskeletal rearrangement. We demonstrate a novel role for nuclear RAC3 as an ER alpha transcriptional activator, with prognostic implications for metastatic disease. Through in vitro and cell-based studies, RAC3 was shown to exist in a GTP-bound state and act as a ligand specific ER alpha co-activator of E2-induced transcription. Overexpression of RAC3 induced pro-growth and pro-migratory genes that resulted in increased migration of ER alpha-positive breast cancer cells. Chemical inhibition and genetic knockdown of RAC3 antagonized E2-induced cell proliferation, cell migration and ER alpha mediated gene expression, indicating that RAC3 is necessary for full ER alpha transcriptional activity. In agreement with the molecular and cellular data, RAC3 overexpression in ER alpha-positive breast cancers correlated with a significant decrease in recurrence free survival and a significant increase in the odds ratio of metastasis. In conclusion, RAC3 is a novel ER alpha a co-activator that promotes cell migration and has prognostic value for ER alpha-positive breast cancer metastasis. RAC3 may also be a useful therapeutic target for ER alpha-positive breast cancers. Oncogene (2011) 30, 1984-1994; doi:10.1038/onc.2010.583; published online 10 January 2011	[Zhang, M.; Wu, P.; Laine, M.; Greene, G. L.] Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA; [Walker, M. P.] Univ Chicago, Comm Canc Biol, Chicago, IL 60637 USA; [Le, T. P.] Univ Chicago, Comm Pathol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Greene, GL (corresponding author), Univ Chicago, Ben May Dept Canc Res, 929 57th St GCIS, Chicago, IL 60637 USA.	ggreene@uchicago.edu		Wu, Patricia/0000-0003-3134-3789	NCI [2-RO1-CA089489]; Department of Defense [W81XWH-04-1-0791]; Ludwig Foundation; Cancer Center [5P30-CA01459935]; NIH [5T32GM007183-35]; NATIONAL CANCER INSTITUTE [R01CA089489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007183] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense(United States Department of Defense); Ludwig Foundation; Cancer Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NCI 2-RO1-CA089489 (GLG), Department of Defense W81XWH-04-1-0791 (GLG) and a gift from the Ludwig Foundation (GLG). Core services were supported in part by a 5P30-CA01459935 Cancer Center grant. MPW was partially supported by NIH grant 5T32GM007183-35.	Baugher PJ, 2005, BREAST CANCER RES, V7, pR965, DOI 10.1186/bcr1329; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Chan AY, 2005, ONCOGENE, V24, P7821, DOI 10.1038/sj.onc.1208909; Chang CY, 2003, METHOD ENZYMOL, V364, P118; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Gould CM, 2010, NUCLEIC ACIDS RES, V38, pD167, DOI 10.1093/nar/gkp1016; Gururaj AE, 2006, P NATL ACAD SCI USA, V103, P6670, DOI 10.1073/pnas.0601989103; Hajdo-Milasinovic A, 2007, J CELL SCI, V120, P555, DOI 10.1242/jcs.03364; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hall JM, 2005, MOL INTERV, V5, P343, DOI 10.1124/mi.5.6.7; Hampf M, 2006, ANAL BIOCHEM, V356, P94, DOI 10.1016/j.ab.2006.04.046; Harrell JC, 2006, CANCER RES, V66, P9308, DOI 10.1158/0008-5472.CAN-06-1769; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Johnston SRD, 2010, CLIN CANCER RES, V16, P1979, DOI 10.1158/1078-0432.CCR-09-1823; Kumar R, 2005, CLIN CANCER RES, V11, P2822, DOI 10.1158/1078-0432.CCR-04-1276; Lahusen T, 2009, BREAST CANCER RES TR, V116, P225, DOI 10.1007/s10549-009-0405-2; Leong HY, 2005, MOL ENDOCRINOL, V19, P2930, DOI 10.1210/me.2005-0178; Leung K, 2003, CELLS TISSUES ORGANS, V175, P72, DOI 10.1159/000073751; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Muramatsu M, 2000, BIOCHEM BIOPH RES CO, V270, P1, DOI 10.1006/bbrc.2000.2214; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Oesterreich S, 2001, CANCER RES, V61, P5771; Onesto C, 2008, METHOD ENZYMOL, V439, P111, DOI 10.1016/S0076-6879(07)00409-0; Pan YF, 2008, J BIOL CHEM, V283, P32977, DOI 10.1074/jbc.M802024200; Pike ACW, 2006, BEST PRACT RES CL EN, V20, P1, DOI 10.1016/j.beem.2005.09.002; Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892; Prest SJ, 2002, FASEB J, V16, P592, DOI 10.1096/fj.01-0498fje; Rayala SK, 2006, CANCER RES, V66, P1694, DOI 10.1158/0008-5472.CAN-05-2922; Saji S, 2005, ONCOGENE, V24, P4531, DOI 10.1038/sj.onc.1208646; Sanchez AM, 2010, MOL ENDOCRINOL, V24, P2114, DOI 10.1210/me.2010-0252; Sandrock K, 2010, TRAFFIC, V11, P198, DOI 10.1111/j.1600-0854.2009.01015.x; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Talukder AH, 2006, ONCOGENE, V25, P1311, DOI 10.1038/sj.onc.1209172; Weil RJ, 2005, AM J PATHOL, V167, P913, DOI 10.1016/S0002-9440(10)61180-7; Xie JW, 2008, BREAST CANCER RES TR, V110, P257, DOI 10.1007/s10549-007-9719-0	40	23	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2011	30	17					1984	1994		10.1038/onc.2010.583	http://dx.doi.org/10.1038/onc.2010.583			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755YL	21217774	Green Accepted			2022-12-17	WOS:000289977400002
J	He, Y; Northey, JJ; Primeau, M; Machado, RD; Trembath, R; Siegel, PM; Lamarche-Vane, N				He, Y.; Northey, J. J.; Primeau, M.; Machado, R. D.; Trembath, R.; Siegel, P. M.; Lamarche-Vane, N.			CdGAP is required for transforming growth factor beta- and Neu/ErbB-2-induced breast cancer cell motility and invasion	ONCOGENE			English	Article						Rho GTPases; RhoGAPs; TGF beta; breast cancer; cell migration and invasion	GTPASE-ACTIVATING PROTEIN; MAMMARY EPITHELIAL-CELLS; RHO-GTPASES; MESENCHYMAL TRANSITION; PHOSPHORYLATES CDGAP; TUMOR-SUPPRESSOR; FOCAL ADHESION; FAMILY; TUMORIGENESIS; INDUCTION	RhoA, Rac1 and Cdc42, the best-characterized members of the Rho family of small GTPases, are critical regulators of many cellular activities. Cdc42 GTPase-activating protein (CdGAP) is a serine-and proline-rich RhoGAP protein showing GAP activity against both Cdc42 and Rac1 but not RhoA. CdGAP is phosphorylated downstream of the MEK-ERK (extracellular signal-regulated kinase) pathway in response to serum and is required for normal cell spreading and polarized lamellipodia formation. In this study, we found that CdGAP protein and mRNA levels are highly increased in mammary tumor explants expressing an activated Neu/ErbB-2 (Neu-NT) receptor. In response to transforming growth factor-beta (TGF beta) stimulation, Neu-NT-expressing mammary tumor explants demonstrate a clear induction in cell motility and invasion. We show that downregulation of CdGAP expression by small interfering RNA abrogates the ability of TGF beta to induce cell motility and invasion of Neu-NT-expressing mammary tumor explants. However, it has no effect on TGF beta-mediated cell adhesion on type 1 collagen and fibronectin. Interestingly, protein expression of E-Cadherin is highly increased in Neu-NT-expressing mammary tumor explants depleted of CdGAP. In addition, complete loss of E-Cadherin expression is not observed in CdGAP-depleted cells during TGF beta-mediated epithelial to mesenchymal transition. Downregulation of the CdGAP expression also decreases cell proliferation of Neu-NT-expressing mammary tumor explants independently of TGF beta. Rescue analysis using re-expression of various CdGAP deletion-mutant proteins revealed that the proline-rich domain (PRD) but not the GAP domain of CdGAP is essential to mediate TGF beta-induced cell motility and invasion. Finally, we found that TGF beta induces the expression and phosphorylation of CdGAP in mammary epithelial NMuMG cells. Taken together, these studies identify CdGAP as a novel molecular target in TGF beta signaling and implicate CdGAP as an essential component in the synergistic interaction between TGF beta and Neu/ErbB-2 signaling pathways in breast cancer cells. Oncogene (2011) 30, 1032-1045; doi:10.1038/onc.2010.477; published online 1 November 2010	[He, Y.; Primeau, M.; Lamarche-Vane, N.] McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; [Northey, J. J.; Siegel, P. M.] McGill Univ, Dept Biochem, Montreal, PQ H3A 2B2, Canada; [Northey, J. J.; Siegel, P. M.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 2B2, Canada; [Machado, R. D.; Trembath, R.] Kings Coll London, Dept Med & Mol Genet, Sch Med, London WC2R 2LS, England; [Trembath, R.] Guys Hosp, Dept Clin Studies, London SE1 9RT, England	McGill University; McGill University; McGill University; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	Lamarche-Vane, N (corresponding author), McGill Univ, Dept Anat & Cell Biol, 3460 Univ St, Montreal, PQ H3A 2B2, Canada.	nathalie.lamarche@mcgill.ca	Machado, Rajiv D./AAD-7813-2019; Northey, Jason/AAX-6365-2021	Machado, Rajiv D./0000-0001-9247-0744; Northey, Jason/0000-0003-3115-2560; Trembath, Richard/0000-0003-0550-3400	Canadian Institute of Health Research (CIHR) [MOP-84449]; Cancer Research Society; Research Institute of the McGill University Health Centre; National Institute for Health Research [NF-SI-0507-10379] Funding Source: researchfish	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Cancer Research Society; Research Institute of the McGill University Health Centre; National Institute for Health Research(National Institute for Health Research (NIHR))	This research was supported by grants from Canadian Institute of Health Research (CIHR) MOP-84449 to NL-V and the Cancer Research Society to PMS. JJN is supported by a studentship from the Research Institute of the McGill University Health Centre. MP was a recipient of a CIHR Canada Graduate scholarship. NL-V is a recipient of a FRSQ chercheur-boursier senior. PMS is a research scientist of the Canadian Cancer Society. RDM is a British Heart Foundation Intermediate Research Fellow (BHF-FS/07/036).	Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Barrios-Rodiles M, 2005, SCIENCE, V307, P1621, DOI 10.1126/science.1105776; Broussard JA, 2008, CURR OPIN CELL BIOL, V20, P85, DOI 10.1016/j.ceb.2007.10.009; Bustelo XR, 2007, BIOESSAYS, V29, P356, DOI 10.1002/bies.20558; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Danek EI, 2007, J BIOL CHEM, V282, P3624, DOI 10.1074/jbc.M610073200; del Pulgar TG, 2005, BIOESSAYS, V27, P602, DOI 10.1002/bies.20238; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jenna S, 2002, J BIOL CHEM, V277, P6366, DOI 10.1074/jbc.M105516200; Jiang W, 2008, J BIOL CHEM, V283, P20978, DOI 10.1074/jbc.M802588200; Karlsson R, 2009, BBA-REV CANCER, V1796, P91, DOI 10.1016/j.bbcan.2009.03.003; Kim T, 2009, CANCER METAST REV, V28, P77, DOI 10.1007/s10555-008-9167-2; LALONDE D, 2006, CURR BIOL, V16, P1; Lamarche-Vane N, 1998, J BIOL CHEM, V273, P29172, DOI 10.1074/jbc.273.44.29172; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Muraoka RS, 2003, MOL CELL BIOL, V23, P8691, DOI 10.1128/MCB.23.23.8691-8703.2003; Muraoka-Cook RS, 2006, ONCOGENE, V25, P3408, DOI 10.1038/sj.onc.1208964; Muraoka-Cook RS, 2005, CLIN CANCER RES, V11, p937S; Nagaraj NS, 2010, EXPERT OPIN INV DRUG, V19, P77, DOI 10.1517/13543780903382609; Northey JJ, 2008, MOL CELL BIOL, V28, P3162, DOI 10.1128/MCB.01734-07; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Pardali E, 2009, FRONT BIOSCI-LANDMRK, V14, P4848, DOI 10.2741/3573; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOUTHGATE L, N ENGL J MED UNPUB; Tcherkezian J, 2005, MOL CELL BIOL, V25, P6314, DOI 10.1128/MCB.25.15.6314-6329.2005; Tcherkezian J, 2007, BIOL CELL, V99, P67, DOI 10.1042/BC20060086; Tcherkezian J, 2006, BIOL CELL, V98, P445, DOI 10.1042/BC20050101; Titus B, 2005, CRIT REV EUKAR GENE, V15, P103, DOI 10.1615/CritRevEukaryotGeneExpr.v15.i2.20; Tomar A, 2009, J CELL SCI, V122, P1852, DOI 10.1242/jcs.046870; Tybulewicz VLJ, 2009, NAT REV IMMUNOL, V9, P630, DOI 10.1038/nri2606; Ursini-Siegel J, 2007, NAT REV CANCER, V7, P389, DOI 10.1038/nrc2127; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Wang SE, 2005, MOL CELL BIOL, V25, P4703, DOI 10.1128/MCB.25.11.4703-4715.2005; Wong CM, 2005, CANCER RES, V65, P8861, DOI 10.1158/0008-5472.CAN-05-1318; Xue W, 2008, GENE DEV, V22, P1439, DOI 10.1101/gad.1672608; Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333	45	23	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	9					1032	1045		10.1038/onc.2010.477	http://dx.doi.org/10.1038/onc.2010.477			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729PX	21042277				2022-12-17	WOS:000287964100003
J	Kitajima, S; Miki, T; Takegami, Y; Kido, Y; Noda, M; Hara, E; Shamma, A; Takahashi, C				Kitajima, S.; Miki, T.; Takegami, Y.; Kido, Y.; Noda, M.; Hara, E.; Shamma, A.; Takahashi, C.			Reversion-inducing cysteine-rich protein with Kazal motifs interferes with epidermal growth factor receptor signaling	ONCOGENE			English	Article						senescence; negative feedback; RECK; EGFR; RAS; MMP	ONCOGENE-INDUCED SENESCENCE; METASTASIS SUPPRESSOR RECK; CELL LUNG-CANCER; DNA-DAMAGE RESPONSE; MATRIX-METALLOPROTEINASE; DOWN-REGULATION; PROGNOSTIC-SIGNIFICANCE; PROMOTER METHYLATION; NEGATIVE FEEDBACK; EXPRESSION	The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) gene had been isolated as an antagonist to RAS signaling; however, the mechanism of its action is not clear. In this study, the effect of loss of RECK function was assessed in various ways and cell systems. Successive cell cultivation of mouse embryonic fibroblasts (MEFs) according to 3T3 protocol revealed that the germline knockout of RECK confers accelerated cell proliferation and early escape from cellular senescence associated with downregulation of p19(Arf), Trp53 and p21(Cdkn1a). In contrast, short hairpin RNA-mediated depletion of RECK induced irreversible growth arrest along with several features of the Arf, Trp53 and Cdkn1a-dependent cellular senescence. Within 2 days of RECK depletion, we observed a transient increase in protein kinase B (AKT) and extracellular signal-regulated kinase (ERK) phosphorylation associated with an upregulated expression of cyclin D1, p19(Arf), Trp53, p21(Cdkn1a) and Sprouty 2. On further cultivation, RAS, AKT and ERK activities were then downregulated to a level lower than control, indicating that RECK depletion leads to a negative feedback to RAS signaling and subsequent cellular senescence. In addition, we observed that epidermal growth factor receptor (EGFR) activity was transiently upregulated by RECK depletion in MEFs, and continuously downregulated by RECK overexpression in colon cancer cells. These findings indicate that RECK is a novel modulator of EGFR signaling. Oncogene (2011) 30, 737-750; doi:10.1038/onc.2010.448; published online 4 October 2010	[Kitajima, S.; Kido, Y.; Shamma, A.; Takahashi, C.] Kanazawa Univ, Canc Res Inst, Canc & Stem Cell Res Program, Div Oncol & Mol Biol, Kanazawa, Ishikawa 9201192, Japan; [Kitajima, S.; Miki, T.; Takegami, Y.; Noda, M.; Shamma, A.; Takahashi, C.] Kyoto Univ, Grad Sch Med, Dept Mol Oncol, Sakyo Ku, Kyoto, Japan; [Miki, T.; Shamma, A.; Takahashi, C.] Kyoto Univ, Grad Sch Med, 21st Century Ctr Excellence Program, Sakyo Ku, Kyoto, Japan; [Miki, T.] Univ Texas Hlth Sci Ctr, Dept Biochem & Mol Biol, Houston, TX USA; [Hara, E.] Japanese Fdn Canc Res, Inst Canc, Div Canc Biol, Koto Ku, Tokyo 170, Japan	Kanazawa University; Kyoto University; Kyoto University; University of Texas System; University of Texas Health Science Center Houston; Japanese Foundation for Cancer Research	Takahashi, C (corresponding author), Kanazawa Univ, Canc Res Inst, Canc & Stem Cell Res Program, Div Oncol & Mol Biol, Kakuma Machi, Kanazawa, Ishikawa 9201192, Japan.	chtakaha@staff.kanazawa-u.ac.jp		Shamma, Awad/0000-0002-3037-616X	JASSO scholarship; Princess Takamatsu Cancer Research Fund; Astellas Foundation for Research on Metabolic Disorders; Takeda Science Foundation; Japanese Ministry of Education, Culture, Sports, Science and Technology; Grants-in-Aid for Scientific Research [22500998] Funding Source: KAKEN	JASSO scholarship; Princess Takamatsu Cancer Research Fund; Astellas Foundation for Research on Metabolic Disorders; Takeda Science Foundation(Takeda Science Foundation (TSF)); Japanese Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank H Sato and T Muraguchi for critical reading of the paper; T Kamijo, P Leder, N Sharpless, S Itohara, Y Okada and M Seiki for providing the mice; M Seiki, T Sakamoto and T Nakano for providing cells; S Yano and K Matsumoto and S Higashiyama for providing the reagents; C Sugita for supporting mouse transfer; W Hung, K Lee and J Oh for encouragement; H Gu and A Nishimoto for technical assistance; and A Miyazaki and M Suzuki for secretarial assistance. SK thanks the JASSO scholarship for support. This work was supported by a Research Grant from the Princess Takamatsu Cancer Research Fund, Astellas Foundation for Research on Metabolic Disorders, the Takeda Science Foundation and the Japanese Ministry of Education, Culture, Sports, Science and Technology.	Andratschke Nicolaus H, 2004, Clin Lung Cancer, V5, P340, DOI 10.3816/CLC.2004.n.012; ANKER P, 1994, CR ACAD SCI III-VIE, V317, P869; Bardeesy N, 2006, CANCER CELL, V10, P451, DOI 10.1016/j.ccr.2006.11.015; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Chang HC, 2004, CELL SIGNAL, V16, P675, DOI 10.1016/j.cellsig.2003.11.001; Chang HC, 2007, CANCER SCI, V98, P169, DOI 10.1111/j.1349-7006.2006.00367.x; Chang HC, 2006, CANCER RES, V66, P8413, DOI 10.1158/0008-5472.CAN-06-0685; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8; Clark JCM, 2007, CANCER METAST REV, V26, P675, DOI 10.1007/s10555-007-9093-8; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Courtois-Cox S, 2008, ONCOGENE, V27, P2801, DOI 10.1038/sj.onc.1210950; Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003; D'Souza B, 2008, ONCOGENE, V27, P5148, DOI 10.1038/onc.2008.229; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Hatta M, 2009, CELL SIGNAL, V21, P1885, DOI 10.1016/j.cellsig.2009.08.005; Hsu MC, 2006, J BIOL CHEM, V281, P4718, DOI 10.1074/jbc.M510937200; Hu SJ, 2008, J BIOL CHEM, V283, P23473, DOI 10.1074/jbc.M800406200; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Janne PA, 2005, SEMIN ONCOL, V32, pS9, DOI 10.1053/j.seminoncol.2005.10.004; Jodele S, 2006, CANCER METAST REV, V25, P35, DOI 10.1007/s10555-006-7887-8; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400; Liu LT, 2003, ONCOGENE, V22, P8263, DOI 10.1038/sj.onc.1207157; Loayza-Puch F, 2010, ONCOGENE, V29, P2638, DOI 10.1038/onc.2010.23; Long NK, 2008, ORAL ONCOL, V44, P1052, DOI 10.1016/j.oraloncology.2008.02.004; LYONS JG, 1993, J BIOL CHEM, V268, P19143; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Miki T, 2007, J BIOL CHEM, V282, P12341, DOI 10.1074/jbc.M610948200; Miki T, 2010, MOL CANCER RES, V8, P665, DOI 10.1158/1541-7786.MCR-09-0351; Morioka Y, 2009, ONCOGENE, V28, P1454, DOI 10.1038/onc.2008.486; Muraguchi T, 2007, NAT NEUROSCI, V10, P838, DOI 10.1038/nn1922; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Noda M, 2007, CANCER SCI, V98, P1659, DOI 10.1111/j.1349-7006.2007.00588.x; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Oh J, 2004, ONCOGENE, V23, P5041, DOI 10.1038/sj.onc.1207688; Omura A, 2009, J BIOL CHEM, V284, P3461, DOI 10.1074/jbc.M806212200; Rabien A, 2007, EUR UROL, V51, P1259, DOI 10.1016/j.eururo.2006.05.050; RAHMAH NN, 2009, NEUROSURG REV, V173, P167; Sasahara RM, 1999, BIOCHEM BIOPH RES CO, V264, P668, DOI 10.1006/bbrc.1999.1552; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shamma A, 2009, CANCER CELL, V15, P255, DOI 10.1016/j.ccr.2009.03.001; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Takagi S, 2009, CANCER RES, V69, P1502, DOI 10.1158/0008-5472.CAN-08-2635; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; Takemoto N, 2007, LUNG CANCER, V58, P376, DOI 10.1016/j.lungcan.2007.07.004; Takenaka K, 2005, ANN SURG ONCOL, V12, P817, DOI 10.1245/ASO.2005.09.018; Takenaka K, 2004, EUR J CANCER, V40, P1617, DOI 10.1016/j.ejca.2004.02.028; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TSUKADA T, 1993, ONCOGENE, V8, P3313; Young AP, 2008, NAT CELL BIOL, V10, P361, DOI 10.1038/ncb1699; Zhang ZY, 2008, LAB INVEST, V88, P1358, DOI 10.1038/labinvest.2008.94; Zolkiewska A, 2008, CELL MOL LIFE SCI, V65, P2056, DOI 10.1007/s00018-008-7586-4	57	23	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	6					737	750		10.1038/onc.2010.448	http://dx.doi.org/10.1038/onc.2010.448			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	719GY	20890302	Green Submitted			2022-12-17	WOS:000287192000010
J	von Bubnoff, N; Gorantla, SP; Engh, RA; Oliveira, TM; Thone, S; Aberg, E; Peschel, C; Duyster, J				von Bubnoff, N.; Gorantla, S. P.; Engh, R. A.; Oliveira, T. M.; Thoene, S.; Aberg, E.; Peschel, C.; Duyster, J.			The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro	ONCOGENE			English	Article						myeloid neoplasms; FIP1L1-PDGFRA; signaling therapies; drug resistance	GROWTH-FACTOR-RECEPTOR; GASTROINTESTINAL STROMAL TUMORS; BCR-ABL; HYPEREOSINOPHILIC SYNDROME; EOSINOPHILIC LEUKEMIA; MYELOPROLIFERATIVE DISEASE; NILOTINIB AMN107; T674I MUTATION; C-KIT; IMATINIB	Myeloproliferation with prominent eosinophilia is associated with rearrangements of PDGFR-A or -B. The most common rearrangement is FIP1L1-PDGFRA (FP). The majority of patients with PDGFR-rearranged myeloproliferation respond to treatment with imatinib. In contrast to BCR-ABL-positive chronic myelogenous leukemia, only few cases of imatinib resistance and mutations of the FP kinase domain have been described so far. We hypothesized that the number of critical residues mediating imatinib resistance in FP in contrast to BCR-ABL might be limited. We performed an established systematic and comprehensive in vitro resistance screen to determine the pattern and frequency of possible TKI resistance mutations in FP. We identified 27 different FP kinase domain mutations including 25 novel variants, which attenuated response to imatinib, nilotinib or sorafenib. However, the majority of these exchanges did not confer complete inhibitor resistance. At clinically achievable drug concentrations, FP/T674I predominated with imatinib, whereas with nilotinib and sorafenib, FP/D842V and the compound mutation T674I+T874I became prevalent. Our results suggest that the PDGFR kinase domain contains a limited number of residues where exchanges critically interfere with binding of and inhibition by available PDGFR kinase inhibitors at achievable concentrations, which might explain the low frequency of imatinib resistance in this patient population. In addition, these findings would help to select the appropriate second-line drug in cases of imatinib-resistant disease and may be translated to other neoplasms driven by activated forms of PDGFR-A or -B. Oncogene (2011) 30, 933-943; doi:10.1038/onc.2010.476; published online 25 October 2010	[von Bubnoff, N.; Gorantla, S. P.; Peschel, C.; Duyster, J.] Tech Univ Munich, Klinikum Rechts Isar, Med Klin & Poliklin 3, D-81675 Munich, Bavaria, Germany; [Engh, R. A.; Oliveira, T. M.; Aberg, E.] Univ Tromso, Dept Chem, Norwegian Struct Biol Ctr, Tromso, Norway; [Engh, R. A.; Oliveira, T. M.; Aberg, E.] Univ Tromso, Dept Pharm, Norwegian Struct Biol Ctr, Tromso, Norway; [Thoene, S.] Ctr Comprehens Canc, Inst Expt Canc Res, Ulm, Germany; [Thoene, S.] Univ Hosp Ulm, Ulm, Germany	Technical University of Munich; UiT The Arctic University of Tromso; UiT The Arctic University of Tromso; Ulm University; Ulm University	von Bubnoff, N (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Med Klin & Poliklin 3, Ismaningerstr 22, D-81675 Munich, Bavaria, Germany.	n.bubnoff@lrz.tum.de	Thoene, Silvia/P-2687-2018; von Bubnoff, Nikolas/AAG-1845-2021; von Bubnoff, Nikolas/F-2351-2017	Thoene, Silvia/0000-0003-3155-7293; von Bubnoff, Nikolas/0000-0001-9593-8947; Engh, Richard/0000-0002-6207-0560	Bundesministerium fur Bildung und Forschung (NGFNplus); Wilhelm-Sander Stiftung; Deutsche Forschungsgemeinschaft [SFB 684/A11]; Kommission fur Klinische Forschung (KKF), Technische Universitat Munchen	Bundesministerium fur Bildung und Forschung (NGFNplus)(Federal Ministry of Education & Research (BMBF)); Wilhelm-Sander Stiftung; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Kommission fur Klinische Forschung (KKF), Technische Universitat Munchen	This work was supported by a grant to JD and NvB from the Bundesministerium fur Bildung und Forschung (NGFNplus), and from the Wilhelm-Sander Stiftung, by a grant to JD from the Deutsche Forschungsgemeinschaft (SFB 684/A11), and by a grant to NvB by the Kommission fur Klinische Forschung (KKF), Technische Universitat Munchen.	Apperley JF, 2007, LANCET ONCOL, V8, P1018, DOI 10.1016/S1470-2045(07)70342-X; Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Baccarani M, 2009, J CLIN ONCOL, V27, P6041, DOI 10.1200/JCO.2009.25.0779; Bradeen HA, 2006, BLOOD, V108, P2332, DOI 10.1182/blood-2006-02-004580; Branford S, 2009, BLOOD, V114, P5426, DOI 10.1182/blood-2009-08-215939; Burgess MR, 2005, P NATL ACAD SCI USA, V102, P3395, DOI 10.1073/pnas.0409770102; CHUSID MJ, 1975, MEDICINE, V54, P1, DOI 10.1097/00005792-197501000-00001; Cools J, 2003, CANCER CELL, V3, P459, DOI 10.1016/S1535-6108(03)00108-9; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Corless CL, 2008, ANNU REV PATHOL-MECH, V3, P557, DOI 10.1146/annurev.pathmechdis.3.121806.151538; Corless CL, 2005, J CLIN ONCOL, V23, P5357, DOI 10.1200/JCO.2005.14.068; Cortes J, 2007, BLOOD, V110, P4005, DOI 10.1182/blood-2007-03-080838; Cross NCP, 2008, ACTA HAEMATOL-BASEL, V119, P199, DOI 10.1159/000140631; Debiec-Rychter M, 2005, GASTROENTEROLOGY, V128, P270, DOI 10.1053/j.gastro.2004.11.020; Dewaele B, 2008, CLIN CANCER RES, V14, P5749, DOI 10.1158/1078-0432.CCR-08-0533; Gleich GJ, 2002, LANCET, V359, P1577, DOI 10.1016/S0140-6736(02)08505-7; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gotlib J, 2008, LEUKEMIA, V22, P1999, DOI 10.1038/leu.2008.287; Guida T, 2007, CLIN CANCER RES, V13, P3363, DOI 10.1158/1078-0432.CCR-06-2667; Guo T, 2007, CLIN CANCER RES, V13, P4874, DOI 10.1158/1078-0432.CCR-07-0484; Heidel F, 2006, BLOOD, V107, P293, DOI 10.1182/blood-2005-06-2469; Heinrich MC, 2006, J CLIN ONCOL, V24, P4764, DOI 10.1200/JCO.2006.06.2265; Hirota S, 2003, GASTROENTEROLOGY, V125, P660, DOI 10.1016/S0016-5085(03)01046-1; Hughes T, 2009, J CLIN ONCOL, V27, P4204, DOI 10.1200/JCO.2009.21.8230; Kantarjian H, 2006, NEW ENGL J MED, V354, P2542, DOI 10.1056/NEJMoa055104; Kindler T, 2005, BLOOD, V105, P335, DOI 10.1182/blood-2004-02-0660; Lahaye T, 2005, CANCER-AM CANCER SOC, V103, P1659, DOI 10.1002/cncr.20922; Lierman E, 2009, LEUKEMIA, V23, P845, DOI 10.1038/leu.2009.2; Lierman E, 2006, BLOOD, V108, P1374, DOI 10.1182/blood-2006-02-004457; Ma YS, 2002, BLOOD, V99, P1741, DOI 10.1182/blood.V99.5.1741; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Nicolini FE, 2007, LEUKEMIA RES, V31, P865, DOI 10.1016/j.leukres.2006.12.003; O'Hare T, 2007, BLOOD, V110, P2242, DOI 10.1182/blood-2007-03-066936; Ohnishi H, 2006, BRIT J HAEMATOL, V134, P547, DOI 10.1111/j.1365-2141.2006.06221.x; Peng B, 2004, J CLIN ONCOL, V22, P935, DOI 10.1200/JCO.2004.03.050; Redaelli S, 2009, J CLIN ONCOL, V27, P469, DOI 10.1200/JCO.2008.19.8853; Score J, 2009, LEUKEMIA, V23, P332, DOI 10.1038/leu.2008.309; Simon D, 2008, J ALLERGY CLIN IMMUN, V121, P1054, DOI 10.1016/j.jaci.2007.11.027; Stover EH, 2005, BLOOD, V106, P3206, DOI 10.1182/blood-2005-05-1932; Strumberg D, 2005, J CLIN ONCOL, V23, P965, DOI 10.1200/JCO.2005.06.124; Tefferi A, 2008, LEUKEMIA, V22, P14, DOI 10.1038/sj.leu.2404955; von Bubnoff N, 2005, BLOOD, V105, P1652, DOI 10.1182/blood-2004-06-2445; von Bubnoff N, 2005, LEUKEMIA, V19, P286, DOI 10.1038/sj.leu.2403600; von Bubnoff N, 2006, BLOOD, V108, P1328, DOI 10.1182/blood-2005-12-010132; von Bubnoff N, 2006, BLOOD, V107, P4970, DOI 10.1182/blood-2006-01-0285; von Bubnoff N, 2009, CANCER RES, V69, P3032, DOI 10.1158/0008-5472.CAN-08-2923; Weisberg E, 2005, CANCER CELL, V7, P129, DOI 10.1016/j.ccr.2005.01.007; Weisberg E, 2006, GASTROENTEROLOGY, V131, P1734, DOI 10.1053/j.gastro.2006.09.017	48	23	24	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	8					933	943		10.1038/onc.2010.476	http://dx.doi.org/10.1038/onc.2010.476			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	726CJ	20972453				2022-12-17	WOS:000287695900005
J	Bralten, LBC; Gravendeel, AM; Kloosterhof, NK; Sacchetti, A; Vrijenhoek, T; Veltman, JA; van den Bent, MJ; Kros, JM; Hoogenraad, CC; Smitt, PAES; French, PJ				Bralten, L. B. C.; Gravendeel, A. M.; Kloosterhof, N. K.; Sacchetti, A.; Vrijenhoek, T.; Veltman, J. A.; van den Bent, M. J.; Kros, J. M.; Hoogenraad, C. C.; Smitt, P. A. E. Sillevis; French, P. J.			The CASPR2 cell adhesion molecule functions as a tumor suppressor gene in glioma	ONCOGENE			English	Article						CASPR2; CNTNAP2; glioma; tumor suppressor gene; NCOAI; translocation	FRAGILE SITE GENES; NEUREXIN SUPERFAMILY; MYELINATED AXONS; EXPRESSION; CNTNAP2; BRAIN; AUTISM; JUXTAPARANODES; CHANNELS; FUSION	Genomic translocations have been implicated in cancer. In this study, we performed a screen for genetic translocations in gliomas based on exon-level expression profiles. We identified a translocation in the contactin-associated protein-like 2 (CASPR2) gene, encoding a cell adhesion molecule. CASPR2 mRNA was fused to an expressed sequence tag that likely is part of the nuclear receptor coactivator 1 gene. Despite high mRNA expression levels, no CASPR2 fusion protein was detected. In a set of 25 glioblastomas and 22 oligodendrogliomas, mutation analysis identified two additional samples with genetic alterations in the CASPR2 gene and all three identified genetic alterations are likely to reduce CASPR2 protein expression levels. Methylation of the CASPR2 gene was also observed in gliomas and glioma cell lines. CASPR2-overexpressing cells showed decreased proliferation rates, likely because of an increase in apoptosis. Moreover, high CASPR2 mRNA expression level is positively correlated with survival and is an independent prognostic factor. These results indicate that CASPR2 acts as a tumor suppressor gene in glioma. Oncogene (2010) 29, 6138-6148; doi:10.1038/onc.2010.342; published online 16 August 2010	[Bralten, L. B. C.; Gravendeel, A. M.; Kloosterhof, N. K.; van den Bent, M. J.; Smitt, P. A. E. Sillevis; French, P. J.] Erasmus MC, Dept Neurol, NL-3000 CA Rotterdam, Netherlands; [Kloosterhof, N. K.] Erasmus MC, Dept Pediat Oncol & Hematol, NL-3000 CA Rotterdam, Netherlands; [Sacchetti, A.; Kros, J. M.] Erasmus MC, Dept Pathol, NL-3000 CA Rotterdam, Netherlands; [Vrijenhoek, T.; Veltman, J. A.] Radboud Univ Nijmegen, Dept Human Genet, Nijmegen Ctr Mol Life Sci, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Hoogenraad, C. C.] Erasmus MC, Dept Neurosci, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Radboud University Nijmegen; Erasmus University Rotterdam; Erasmus MC	French, PJ (corresponding author), Erasmus MC, Dept Neurol, Room Be 462A,POB 2040, NL-3000 CA Rotterdam, Netherlands.	p.french@erasmusmc.nl	Sacchetti, Andrea/H-8763-2019; Veltman, Joris A/F-5128-2010; Hoogenraad, Casper/B-8866-2011	Veltman, Joris A/0000-0002-3218-8250; Hoogenraad, Casper/0000-0002-2666-0758; French, Pim/0000-0002-0668-9529; van den Bent, Martin/0000-0001-5710-5127				Alarcon M, 2008, AM J HUM GENET, V82, P150, DOI 10.1016/j.ajhg.2007.09.005; Arking DE, 2008, AM J HUM GENET, V82, P160, DOI 10.1016/j.ajhg.2007.09.015; Bakkaloglu B, 2008, AM J HUM GENET, V82, P165, DOI 10.1016/j.ajhg.2007.09.017; Balss J, 2008, ACTA NEUROPATHOL, V116, P597, DOI 10.1007/s00401-008-0455-2; Bralten LBC, 2010, GENE CHROMOSOME CANC, V49, P509, DOI 10.1002/gcc.20760; Bredel M, 2005, CANCER RES, V65, P4088, DOI 10.1158/0008-5472.CAN-04-4229; Clark TA, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r64; Collier LS, 2005, NATURE, V436, P272, DOI 10.1038/nature03681; Denisenko-Nehrbass N, 2003, EUR J NEUROSCI, V17, P411, DOI 10.1046/j.1460-9568.2003.02441.x; Freire P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004076; French PJ, 2007, CANCER RES, V67, P5635, DOI 10.1158/0008-5472.CAN-06-2869; French PJ, 2005, CANCER RES, V65, P11335, DOI 10.1158/0008-5472.CAN-05-1886; Friedman JI, 2008, MOL PSYCHIATR, V13, P261, DOI 10.1038/sj.mp.4002049; Gerber MA, 2006, CANCER RES, V66, P5295, DOI 10.1158/0008-5472.CAN-05-1628; Gravendeel LAM, 2009, CANCER RES, V69, P9065, DOI 10.1158/0008-5472.CAN-09-2307; Gutmann DH, 2000, HUM MOL GENET, V9, P1495, DOI 10.1093/hmg/9.10.1495; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; Horresh I, 2008, J NEUROSCI, V28, P14213, DOI 10.1523/JNEUROSCI.3398-08.2008; Jackman C, 2009, PEDIATR NEUROL, V40, P310, DOI 10.1016/j.pediatrneurol.2008.10.013; Jaworski J, 2005, J NEUROSCI, V25, P11300, DOI 10.1523/JNEUROSCI.2270-05.2005; Kleihues, 2000, WHO CLASSIFICATION T; KRAUS JA, 1995, J NEUROPATH EXP NEUR, V54, P91, DOI 10.1097/00005072-199501000-00011; Lieberoth A, 2009, J NEUROSCI, V29, P6677, DOI 10.1523/JNEUROSCI.4361-08.2009; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Maher CA, 2009, NATURE, V458, P97, DOI 10.1038/nature07638; McAvoy S, 2007, CYTOGENET GENOME RES, V118, P260, DOI 10.1159/000108309; Ohgaki H, 2005, ACTA NEUROPATHOL, V109, P93, DOI 10.1007/s00401-005-0991-y; Omura N, 2008, CANCER BIOL THER, V7, P1146, DOI 10.4161/cbt.7.7.6208; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Poliak S, 2003, J CELL BIOL, V162, P1149, DOI 10.1083/jcb.200305018; Poliak S, 1999, NEURON, V24, P1037, DOI 10.1016/S0896-6273(00)81049-1; Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-3; Schutte M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003007; Smith DI, 2007, SEMIN CANCER BIOL, V17, P31, DOI 10.1016/j.semcancer.2006.10.003; Strauss KA, 2006, NEW ENGL J MED, V354, P1370, DOI 10.1056/NEJMoa052773; Thorell K, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-53; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tran Y, 1998, ONCOGENE, V17, P3499, DOI 10.1038/sj.onc.1202258; Verkerk AJMH, 2003, GENOMICS, V82, P1, DOI 10.1016/S0888-7543(03)00097-1; Vernes SC, 2008, NEW ENGL J MED, V359, P2337, DOI 10.1056/NEJMoa0802828; Wachtel M, 2004, CANCER RES, V64, P5539, DOI 10.1158/0008-5472.CAN-04-0844; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Zecchini S, 2010, ADV EXP MED BIOL, V663, P319, DOI 10.1007/978-1-4419-1170-4_20	43	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	46					6138	6148		10.1038/onc.2010.342	http://dx.doi.org/10.1038/onc.2010.342			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681XD	20711234				2022-12-17	WOS:000284356500006
J	Santonico, E; Belleudi, F; Panni, S; Torrisi, MR; Cesareni, G; Castagnoli, L				Santonico, E.; Belleudi, F.; Panni, S.; Torrisi, M. R.; Cesareni, G.; Castagnoli, L.			Multiple modification and protein interaction signals drive the Ring finger protein 11 (RNF11) E3 ligase to the endosomal compartment	ONCOGENE			English	Article						RING E3-ligase; acylation; endosome compartment; ubiquitination	LIPID RAFTS; BREAST-CANCER; WW DOMAIN; STABILITY; HRS; UBIQUITINATION; ENZYMOLOGY; EXPRESSION; PROTEOMICS; CAVEOLAE	Ring finger protein 11 (RNF11) is a small RING E3-ligase overexpressed in numerous human prostate, colon and invasive breast cancers. Although functional studies have implicated RNF11 in a variety of biological processes, including signal transduction and apoptosis, the molecular mechanisms underlying its function are still poorly understood. In this study we show that RNF11 is a membrane-associated E3 ligase co-localizing with markers of both the early and the recycling endosomes. Several modification and protein interaction signals in the RNF11 sequence are shown to affect its compartmentalization. Membrane binding requires two acylation motifs driving the myristoylation of Gly2 and the S-palmitoylation of Cys4. Accordingly, genetic removal of the myristoylating signal results in diffuse staining, whereas an RNF11 protein mutated in the palmitoylation signal is retained in compartments of the early secretory pathway. However, amino-terminal fusion to green fluorescent protein of a 10-residue peptide containing both acylation signals re-localizes the chimera to the plasma membrane, but it is not sufficient to direct it to the recycling compartment suggesting that additional signals contribute to the correct localization. In addition, we show that membrane anchoring through acylation is necessary for RNF11 to be post-translationally modified by the addition of several ubiquitin moieties and that loss of acylation severely impairs the in vivo ubiquitination mediated by the HECT E3-ligases Itch and Nedd4. Finally, in cells transfected with RNF11 we observe a correlation between high RNF11 expression, as in tumor cells, and a swelling of the endosomal compartment suggesting a possible role of the dysregulation of the endosome compartment in tumorigenesis. Oncogene (2010) 29, 5604-5618; doi:10.1038/onc.2010.294; published online 2 August 2010	[Santonico, E.; Cesareni, G.; Castagnoli, L.] Univ Roma Tor Vergata, Dept Mol Biol, I-00133 Rome, Italy; [Belleudi, F.; Torrisi, M. R.] Univ Roma La Sapienza, Dept Mol & Clin Med, Inst Pasteur, Fdn Cenci Bolognetti, Rome, Italy; [Panni, S.] Univ Calabria, Dept Cell Biol, Calabria, Italy; [Torrisi, M. R.] Azienda Osped S Andrea, Rome, Italy; [Cesareni, G.] IRCCS Fdn S Lucia, Rome, Italy	University of Rome Tor Vergata; Fondazione Cenci Bolognetti; Sapienza University Rome; University of Calabria; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; IRCCS Santa Lucia	Santonico, E (corresponding author), Univ Roma Tor Vergata, Dept Mol Biol, Via Ric Sci, I-00133 Rome, Italy.	Elena.Santonico@uniroma2.it; Cesareni@uniroma2.it; Castagnoli@uniroma2.it	Santonico, Elena/ABB-8919-2020; Cesareni, Gianni/AAW-1382-2020	Santonico, Elena/0000-0002-3897-8990; Castagnoli, Luisa/0000-0001-5283-8671; panni, simona/0000-0002-7500-4028	AIRC (Italian Association for Cancer Research)	AIRC (Italian Association for Cancer Research)(Fondazione AIRC per la ricerca sul cancro)	The work described in this study has been supported by AIRC (Italian Association for Cancer Research). We thank Dr Maurizio Mattei for RNF11 antibody production and Dr Palma Mattioli for helpful suggestions and support with microscopy.	Anderson LR, 2007, J NEUROPATH EXP NEUR, V66, P955, DOI 10.1097/nen.0b013e3181567f17; Azmi P, 2005, EUR J CANCER, V41, P2549, DOI 10.1016/j.ejca.2005.08.020; Azmi PB, 2009, ANTICANCER RES, V29, P2253; Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001; Burger A, 1998, ONCOGENE, V16, P327, DOI 10.1038/sj.onc.1201517; Burger AM, 1998, ONCOGENE, V16, P2459, DOI 10.1038/sj.onc.1201772; Chen C, 2008, ONCOGENE, V27, P6845, DOI 10.1038/onc.2008.288; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; Colland F, 2004, GENOME RES, V14, P1324, DOI 10.1101/gr.2334104; Doray B, 2002, J BIOL CHEM, V277, P18477, DOI 10.1074/jbc.M201879200; Farazi TA, 2001, J BIOL CHEM, V276, P39501, DOI 10.1074/jbc.R100042200; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Jacque E, 2009, EMBO J, V28, P455, DOI 10.1038/emboj.2009.18; Kim HT, 2007, J BIOL CHEM, V282, P17375, DOI 10.1074/jbc.M609659200; Kitching R, 2003, BBA-MOL BASIS DIS, V1639, P104, DOI 10.1016/j.bbadis.2003.07.001; Komada M, 1999, GENE DEV, V13, P1475, DOI 10.1101/gad.13.11.1475; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Li HX, 2004, ONCOGENE, V23, P1801, DOI 10.1038/sj.onc.1207319; Linder ME, 2007, NAT REV MOL CELL BIO, V8, P74, DOI 10.1038/nrm2084; Misra S, 2002, NATURE, V415, P933, DOI 10.1038/415933a; Mizuno E, 2004, J BIOCHEM, V135, P385, DOI 10.1093/jb/mvh046; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Parton RG, 2003, TRAFFIC, V4, P724, DOI 10.1034/j.1600-0854.2003.00128.x; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; RESH MD, 2006, SCI STKE, pRE14, DOI DOI 10.1126/STKE.3592006RE14; Santonico Elena, 2007, BMC Biochemistry, V8, P29, DOI 10.1186/1471-2091-8-29; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Scialpi F, 2008, BIOCHEM PHARMACOL, V76, P1515, DOI 10.1016/j.bcp.2008.07.028; Seki N, 1999, BBA-GENE STRUCT EXPR, V1489, P421, DOI 10.1016/S0167-4781(99)00190-6; Shembade N, 2009, EMBO J, V28, P513, DOI 10.1038/emboj.2008.285; Staub O, 2000, KIDNEY INT, V57, P809, DOI 10.1046/j.1523-1755.2000.00919.x; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Subramaniam V, 2003, BRIT J CANCER, V89, P1538, DOI 10.1038/sj.bjc.6601301; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; Wilkin MB, 2004, CURR BIOL, V14, P2237, DOI 10.1016/j.cub.2004.11.030; Xue Y, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-458	38	23	28	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	41					5604	5618		10.1038/onc.2010.294	http://dx.doi.org/10.1038/onc.2010.294			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FX	20676133				2022-12-17	WOS:000282946900007
J	Mitra, A; Radha, V				Mitra, A.; Radha, V.			F-actin-binding domain of c-Abl regulates localized phosphorylation of C3G: role of C3G in c-Abl-mediated cell death	ONCOGENE			English	Article						guanine nucleotide exchange factor; tyrosine kinase; apoptosis; c-Abl	NUCLEOTIDE EXCHANGE FACTOR; PROTEIN-TYROSINE-PHOSPHATASE; SRC HOMOLOGY-3 DOMAIN; FAMILY KINASES; INDUCED APOPTOSIS; BCR-ABL; ACTIVATION; RAP1; CRK; OVEREXPRESSION	The c-Abl tyrosine kinase maintains cellular homeostasis through its ability to regulate apoptosis and actin dynamics. In vivo, c-Abl activity is stringently regulated and mechanisms involved are not fully understood. Here, we identified the Rap1 guanine nucleotide exchange factor, C3G (RapGEF1), as a substrate and an effector of c-Abl-mediated functions. Ectopic expression of c-Abl in mammalian cell lines, known to induce apoptosis, resulted in phosphorylation of endogenous C3G on Y504 coincident with cell detachment and chromatin condensation. Phosphorylation of C3G coincided with restricted c-Abl activation in regions rich in actin, and was dependent on cellular F-actin dynamics. Unlike C3G or c-Abl, p-C3G was resistant to detergent extraction, suggesting its enhanced affinity for the cytoskeleton. Localized C3G phosphorylation and coincidence with cells undergoing cell death was dependent on F-actin-binding domain (FABD) of c-Abl. Activation of endogenous c-Abl by oxidative stress was associated with phosphorylation of cellular C3G on Y504. Inhibition of C3G expression and function using RNAi or dominant-negative approaches inhibited c-Abl-mediated cell death. These findings identify C3G as a novel target of c-Abl and also show that FABD of c-Abl is essential for regulation of its restricted activation to induce apoptosis. Oncogene (2010) 29, 4528-4542; doi: 10.1038/onc.2010.113; published online 28 June 2010	[Mitra, A.; Radha, V.] Ctr Cellular & Mol Biol, CSIR, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Radha, V (corresponding author), Ctr Cellular & Mol Biol, CSIR, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	vradha@ccmb.res.in			Council for Scientific and Industrial Research; Department of Science and Technology, Government of India	Council for Scientific and Industrial Research(Council of Scientific & Industrial Research (CSIR) - India); Department of Science and Technology, Government of India(Department of Science & Technology (India))	We thank Drs PJS Stork (Oregon Health and Science University), Richard Van Etten (Tufts University), Patrick Casey (Duke University), S Tanaka (Hokkaido University School of Medicine), Bruce Mayer (University of Connecticut Health Center) for gifts of various constructs. We thank Dr Ghanshyam Swarup for support extended and for critically reading the paper. Assistance received from Ms Nandini Rangaraj during use of confocal microscopes is gratefully acknowledged. AM was supported by a fellowship from the Council for Scientific and Industrial Research. This work was supported by the Department of Science and Technology, Government of India through a grant awarded to VR.	Agami R, 1999, NATURE, V399, P809; Alvarez AR, 2004, NEUROBIOL DIS, V17, P326, DOI 10.1016/j.nbd.2004.06.007; Ba XQ, 2005, J CELL BIOCHEM, V94, P365, DOI 10.1002/jcb.20213; Balzac F, 2005, J CELL SCI, V118, P4765, DOI 10.1242/jcs.02584; Bivona TG, 2004, J CELL BIOL, V164, P461, DOI 10.1083/jcb.200311093; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Chen CX, 2006, J BIOCHEM, V140, P229, DOI 10.1093/jb/mvj149; Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6; Chiang SH, 2006, METHOD ENZYMOL, V406, P701, DOI 10.1016/S0076-6879(06)06055-1; Cho YJ, 2005, BIOCHEM BIOPH RES CO, V333, P1276, DOI 10.1016/j.bbrc.2005.06.030; Cipres A, 2007, CELL SIGNAL, V19, P1662, DOI 10.1016/j.cellsig.2007.02.011; Cong F, 2000, MOL CELL, V6, P1413, DOI 10.1016/S1097-2765(00)00138-6; Cong F, 1999, P NATL ACAD SCI USA, V96, P13819, DOI 10.1073/pnas.96.24.13819; Franklin-Tong VE, 2008, BIOCHEM J, V413, P389, DOI 10.1042/BJ20080320; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Grevengoed EE, 2003, J CELL BIOL, V163, P1267, DOI 10.1083/jcb.200307026; Guerrero C, 2004, ONCOGENE, V23, P4885, DOI 10.1038/sj.onc.1207622; Gutierrez-Berzal J, 2006, EXP CELL RES, V312, P938, DOI 10.1016/j.yexcr.2005.12.007; Halle M, 2007, MOL CELL BIOL, V27, P1172, DOI 10.1128/MCB.02462-05; Hernandez SE, 2004, TRENDS CELL BIOL, V14, P36, DOI 10.1016/j.tcb.2003.11.003; Holcomb M, 2006, J BIOL CHEM, V281, P2430, DOI 10.1074/jbc.M508454200; Hu HL, 2005, CURR BIOL, V15, P815, DOI 10.1016/j.cub.2005.03.049; Huang XD, 2008, J CELL BIOL, V183, P711, DOI 10.1083/jcb.200801192; Huang YP, 2008, BLOOD, V112, P111, DOI 10.1182/blood-2007-10-118232; Huang YY, 1997, ONCOGENE, V15, P1947, DOI 10.1038/sj.onc.1201376; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Janji B, 2006, J CELL SCI, V119, P1947, DOI 10.1242/jcs.02874; Kain KH, 2003, ONCOGENE, V22, P6071, DOI 10.1038/sj.onc.1206930; Kirsch KH, 1998, J BIOL CHEM, V273, P25673, DOI 10.1074/jbc.273.40.25673; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Kobayashi Y, 2006, ONCOGENE, V25, P512, DOI 10.1038/sj.onc.1209072; Lawrenson ID, 2002, J CELL SCI, V115, P1059; Machuy N, 2004, CELL DEATH DIFFER, V11, P290, DOI 10.1038/sj.cdd.4401336; Maia V, 2009, CELL SIGNAL, V21, P1229, DOI 10.1016/j.cellsig.2009.03.015; Martin-Encabo S, 2007, EXP CELL RES, V313, P3881, DOI 10.1016/j.yexcr.2007.07.036; Mochizuki N, 2000, J BIOL CHEM, V275, P12667, DOI 10.1074/jbc.275.17.12667; Nolz JC, 2008, J CELL BIOL, V182, P1231, DOI 10.1083/jcb.200801121; Ohba Y, 2000, MOL CELL BIOL, V20, P6074, DOI 10.1128/MCB.20.16.6074-6083.2000; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Radha V, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-31; Radha V, 1999, FEBS LETT, V453, P308, DOI 10.1016/S0014-5793(99)00734-6; Radha V, 2007, EXP CELL RES, V313, P2476, DOI 10.1016/j.yexcr.2007.03.019; Radha V, 2008, J NEUROCHEM, V107, P1424, DOI 10.1111/j.1471-4159.2008.05710.x; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Shishido T, 2001, GENES CELLS, V6, P431, DOI 10.1046/j.1365-2443.2001.00431.x; Shivakrupa R, 2003, J BIOL CHEM, V278, P52188, DOI 10.1074/jbc.M310656200; Skourides PA, 1999, ONCOGENE, V18, P1165, DOI 10.1038/sj.onc.1202407; SMITH JM, 2002, FRONT BIOSCI, V7, P131; Stevens TL, 2008, MOL BIOL CELL, V19, P378, DOI 10.1091/mbc.E07-01-0008; SUBHASH T, 2006, FEBS J, V273, P2766; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Tamada M, 2004, DEV CELL, V7, P709, DOI 10.1016/j.devcel.2004.08.021; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Theis S, 1998, ONCOGENE, V17, P557, DOI 10.1038/sj.onc.1201973; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Wang JYJ, 2004, NAT CELL BIOL, V6, P3, DOI 10.1038/ncb0104-3; Woodring PJ, 2005, J BIOL CHEM, V280, P10318, DOI 10.1074/jbc.M410658200; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Woodring PJ, 2001, J BIOL CHEM, V276, P27104, DOI 10.1074/jbc.M100559200; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Zhu JY, 2004, CURR TOP DEV BIOL, V59, P165, DOI 10.1016/S0070-2153(04)59007-5	64	23	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2010	29	32					4528	4542		10.1038/onc.2010.113	http://dx.doi.org/10.1038/onc.2010.113			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	638AQ	20581864				2022-12-17	WOS:000280862300004
J	Xu, Y; Yan, W; Chen, X				Xu, Y.; Yan, W.; Chen, X.			SNF5, a core component of the SWI/SNF complex, is necessary for p53 expression and cell survival, in part through eIF4E	ONCOGENE			English	Article						p53; SNF5; chromatin remodeling; Mdm2; eIF4E; AMPK	CHROMATIN REMODELING COMPLEXES; MALIGNANT RHABDOID TUMORS; DNA-DAMAGE; CYCLE PROGRESSION; SUPPRESSOR; CANCER; MUTATIONS; FAMILY; TRANSCRIPTION; CHECKPOINT	SNF5, a core component of the SWI/SNF chromatin remodeling complex, is expressed as two isoforms, SNF5a and SNF5b. SNF5 is a tumor suppressor, as mutation of SNF5 leads to tumor formation and cooperates with p53 deficiency to enhance cancer susceptibility. Interestingly, lack of SNF5 inhibits cell survival and embryonic development, potentially through abnormal activation of p53. To further examine this, we generated cell lines in which SNF5a, SNF5b or both can be inducibly knocked down. We found that SNF5 knockdown leads to cell-cycle arrest in G1, and SNF5a and SNF5b are functionally redundant. We also showed that SNF5 knockdown impairs p53-dependent transcription of p21 and murine double minute 2. However, contrary to earlier reports that p53 is activated by SNF5 knockout in murine cells, SNF5 knockdown leads to decreased, but not increased, expression of both basal and stress-induced p53 in multiple human cell lines. In addition, we showed that SNF5 knockdown induces adenosine monophosphate-activated protein kinase activation and inhibits eIF4E expression. Finally, we showed that SNF5 knockdown inhibits p53 translation by eIF4E and replacement of eIF4E in SNF5 knockdown cells restores p53 expression and cell survival. Together, our study results suggest that the p53 pathway is regulated by, and mediates the activity of, SNF5 in tumor suppression and prosurvival. Oncogene (2010) 29, 4090-4100; doi:10.1038/onc.2010.159; published online 17 May 2010	[Xu, Y.; Yan, W.; Chen, X.] Univ Calif Davis, Ctr Comparat Oncol, VM Surg & Radiol Sci, Davis, CA 95616 USA; [Xu, Y.] Zhejiang Univ, Dept Hematol, Affiliated Hosp 2, Hangzhou 310003, Zhejiang, Peoples R China	University of California System; University of California Davis; Zhejiang University	Chen, X (corresponding author), Univ Calif Davis, Ctr Comparat Oncol, VM Surg & Radiol Sci, 2128 Tupper Hall, Davis, CA 95616 USA.	xbchen@ucdavis.edu			NIH [CA081237, CA076069, CA102188]; NATIONAL CANCER INSTITUTE [R29CA076069, R01CA121137, R01CA102188, R01CA076069, R01CA081237] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported in part by NIH Grants CA081237, CA076069 and CA102188.	Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Caramel J, 2008, ONCOGENE, V27, P2035, DOI 10.1038/sj.onc.1210847; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; Chai JJ, 2007, CANCER RES, V67, P3002, DOI 10.1158/0008-5472.CAN-06-4207; CHEN XB, 1995, CANCER RES, V55, P4257; Graff JR, 2008, CANCER RES, V68, P631, DOI 10.1158/0008-5472.CAN-07-5635; Gresh L, 2005, EMBO J, V24, P3313, DOI 10.1038/sj.emboj.7600802; Guidi CJ, 2004, J BIOL CHEM, V279, P4180, DOI 10.1074/jbc.M312043200; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Harms K, 2004, CELL MOL LIFE SCI, V61, P822, DOI 10.1007/s00018-003-3304-4; Harms KL, 2005, MOL CELL BIOL, V25, P2014, DOI 10.1128/MCB.25.5.2014-2030.2005; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Isakoff MS, 2005, P NATL ACAD SCI USA, V102, P17745, DOI 10.1073/pnas.0509014102; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Klochendler-Yeivin A, 2006, MOL CELL BIOL, V26, P2661, DOI 10.1128/MCB.26.7.2661-2674.2006; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; Liu G, 2006, MOL CELL BIOL, V26, P1398, DOI 10.1128/MCB.26.4.1398-1413.2006; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Martens JA, 2003, CURR OPIN GENET DEV, V13, P136, DOI 10.1016/S0959-437X(03)00022-4; McKenna ES, 2008, MOL CELL BIOL, V28, P6223, DOI 10.1128/MCB.00658-08; Oruetxebarria I, 2004, J BIOL CHEM, V279, P3807, DOI 10.1074/jbc.M309333200; Peters Charles R., 1996, Kaupia Darmstaedter Beitraege zur Naturgeschichte, V6, P175; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X; Scoumanne A, 2008, HISTOL HISTOPATHOL, V23, P1143, DOI 10.14670/HH-23.1143; Scoumanne A, 2009, NUCLEIC ACIDS RES, V37, P4965, DOI 10.1093/nar/gkp516; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vries RGJ, 2005, GENE DEV, V19, P665, DOI 10.1101/gad.335805; Xu Y, 2007, J BIOL CHEM, V282, P37429, DOI 10.1074/jbc.M706039200; Zhang ZK, 2002, MOL CELL BIOL, V22, P5975, DOI 10.1128/MCB.22.16.5975-5988.2002	41	23	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	2010	29	28					4090	4100		10.1038/onc.2010.159	http://dx.doi.org/10.1038/onc.2010.159			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	625JW	20473326	Green Accepted			2022-12-17	WOS:000279892400009
J	Li, YJ; Stark, JM; Chen, DJ; Ann, DK; Chen, Y				Li, Y-J; Stark, J. M.; Chen, D. J.; Ann, D. K.; Chen, Y.			Role of SUMO:SIM-mediated protein-protein interaction in non-homologous end joining	ONCOGENE			English	Article						SUMO; NHEJ; SUMO-interacting motif; SBM; inhibitor; DNA repair	STRAND BREAK REPAIR; UBIQUITIN-LIKE PROTEINS; DNA-DAMAGE; BINDING MOTIF; LIGASE; XRCC4; IDENTIFICATION; RECOMBINATION; LOCALIZATION; NUCLEUS	Although post-translational modi. cations by the small ubiquitin-like modifiers (SUMO) are known to be important in DNA damage response, it is unclear whether they have a role in double-strand break (DSB) repair by non-homologous end joining (NHEJ). Here, we analyzed various DSB repair pathways upon inhibition of SUMO-mediated protein-protein interactions using peptides that contain the SUMO-interaction motif (SIM) and discriminate between mono-and SUMO-chain modi. cations. The SIM peptides specifically inhibit NHEJ as shown by in vivo repair assays and radio-sensitivity of cell lines deficient in different DSB repair pathways. Furthermore, mono-SUMO, instead of SUMO-chain, modi. cations appear to be involved in NHEJ. Immunoprecipitation experiments also showed that the SIM peptide interacted with SUMOylated Ku70 after radiation. This study is the first to show an important role for SUMO: SIM-mediated protein-protein interactions in NHEJ, and provides a mechanistic basis for the role of SIM peptide in sensitizing genotoxic stress of cancer cells. Oncogene (2010) 29, 3509-3518; doi:10.1038/onc.2010.108; published online 19 April 2010	[Li, Y-J; Chen, Y.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Med, Duarte, CA 91010 USA; [Stark, J. M.] City Hope Natl Med Ctr, Beckman Res Inst, Div Radiat Biol, Duarte, CA 91010 USA; [Chen, D. J.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Ann, D. K.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Clin & Mol Pharmacol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; University of Texas System; University of Texas Southwestern Medical Center Dallas; City of Hope; Beckman Research Institute of City of Hope	Chen, Y (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Med, 1500 E Duarte Rd, Duarte, CA 91010 USA.	ychen@coh.org		Li, Yi-Jia/0000-0002-8791-8097	NIH [R01GM074748, R01GM-086171, RO1CA120954, R37CA050519-20, F32CA134180]; NATIONAL CANCER INSTITUTE [F32CA134180, R01CA120954, R37CA050519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014183] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM086171, R01GM074748] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work is funded by NIH Grants R01GM074748 and R01GM-086171 to Y Chen, RO1CA120954 to JM Stark, R37CA050519-20 to DJ Chen and R01DE14183 to DK Ann. Y-J Li is a recipient of the NIH National Research Service Award (F32CA134180).	Andrews EA, 2005, MOL CELL BIOL, V25, P185, DOI 10.1128/MCB.25.1.185-196.2005; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Carson JP, 2004, CANCER RES, V64, P2096, DOI 10.1158/0008-5472.CAN-03-2029; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Hardeland U, 2002, EMBO J, V21, P1456, DOI 10.1093/emboj/21.6.1456; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Krebber H, 2000, METHOD ENZYMOL, V327, P283, DOI 10.1016/S0076-6879(00)27284-4; Mari PO, 2006, P NATL ACAD SCI USA, V103, P18597, DOI 10.1073/pnas.0609061103; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Pastink A, 2001, MUTAT RES-FUND MOL M, V480, P37, DOI 10.1016/S0027-5107(01)00167-1; Pastwa E, 2003, ACTA BIOCHIM POL, V50, P891; Prudden J, 2007, EMBO J, V26, P4089, DOI 10.1038/sj.emboj.7601838; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sacher M, 2006, NAT CELL BIOL, V8, P1284, DOI 10.1038/ncb1488; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shayeghi M, 1997, NUCLEIC ACIDS RES, V25, P1162, DOI 10.1093/nar/25.6.1162; Song J, 2005, J BIOL CHEM, V280, P40122, DOI 10.1074/jbc.M507059200; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; Sonoda E, 2006, DNA REPAIR, V5, P1021, DOI 10.1016/j.dnarep.2006.05.022; Stucki M, 2006, DNA REPAIR, V5, P534, DOI 10.1016/j.dnarep.2006.01.012; Sun H, 2007, EMBO J, V26, P4102, DOI 10.1038/sj.emboj.7601839; TATHAM MH, 2001, J BIOL CHEM, V12, P12; Uzunova K, 2007, J BIOL CHEM, V282, P34167, DOI 10.1074/jbc.M706505200; Weinstock DM, 2006, METHOD ENZYMOL, V409, P524, DOI 10.1016/S0076-6879(05)09031-2; Weinstock DM, 2006, MOL CELL BIOL, V26, P131, DOI 10.1128/MCB.26.1.131-139.2006; Xie Y, 2007, J BIOL CHEM, V282, P34176, DOI 10.1074/jbc.M706025200; Yano K, 2008, CELL CYCLE, V7, P1321, DOI 10.4161/cc.7.10.5898; Yano KI, 2008, EMBO REP, V9, P91, DOI 10.1038/sj.embor.7401137; Yurchenko V, 2006, MOL CELL BIOL, V26, P1786, DOI 10.1128/MCB.26.5.1786-1794.2006; Yurchenko V, 2008, BIOCHEM BIOPH RES CO, V366, P263, DOI 10.1016/j.bbrc.2007.11.136; Zhao XL, 2005, P NATL ACAD SCI USA, V102, P4777, DOI 10.1073/pnas.0500537102	35	23	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	2010	29	24					3509	3518		10.1038/onc.2010.108	http://dx.doi.org/10.1038/onc.2010.108			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	611QN	20400978	Green Accepted			2022-12-17	WOS:000278835400006
J	Odvody, J; Vincent, T; Arrate, MP; Grieb, B; Wang, S; Garriga, J; Lozano, G; Iwakuma, T; Haines, DS; Eischen, CM				Odvody, J.; Vincent, T.; Arrate, M. P.; Grieb, B.; Wang, S.; Garriga, J.; Lozano, G.; Iwakuma, T.; Haines, D. S.; Eischen, C. M.			A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis	ONCOGENE			English	Article						MTBP; Myc; Mdm2; p53; lymphoma	C-MYC; APOPTOSIS; MTBP; P53; HAPLOINSUFFICIENCY; INSTABILITY; MICE	Mdm2 binding protein (MTBP) has been implicated in cell-cycle arrest and the Mdm2/p53 tumor suppressor pathway through its interaction with Mdm2. To determine the function of MTBP in tumorigenesis and its potential role in the Mdm2/p53 pathway, we crossed Mtbp-deficient mice to E mu-myc transgenic mice, in which overexpression of the oncogene c-Myc induces B-cell lymphomas primarily through inactivation of the Mdm2/p53 pathway. We report that Myc-induced B-cell lymphoma development in Mtbp heterozygous mice was profoundly delayed. Surprisingly, reduced levels of Mtbp did not lead to an increase in B-cell apoptosis or affect Mdm2. Instead, an Mtbp deficiency inhibited Myc-induced proliferation and the upregulation of Myc target genes necessary for cell growth. Consistent with a role in proliferation, Mtbp expression was induced by Myc and other factors that promote cell-cycle progression and was elevated in lymphomas from humans and mice. Therefore, Mtbp functioned independent of Mdm2 and was a limiting factor for the proliferative and transforming functions of Myc. Thus, Mtbp is a previously unrecognized regulator of Myc-induced tumorigenesis. Oncogene (2010) 29, 3287-3296; doi: 10.1038/onc.2010.82; published online 22 March 2010	[Eischen, C. M.] Vanderbilt Univ, Dept Pathol, Med Ctr, Sch Med, Nashville, TN 37232 USA; [Wang, S.; Haines, D. S.] Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19122 USA; [Garriga, J.; Haines, D. S.] Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA; [Lozano, G.] Univ Texas MD Anderson Canc Ctr, Dept Mol Genet, Sect Canc Genet, Houston, TX 77030 USA; [Iwakuma, T.] Louisiana State Univ, Dept Genet, Hlth Sci Ctr, New Orleans, LA USA	Vanderbilt University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Texas System; UTMD Anderson Cancer Center; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Eischen, CM (corresponding author), Vanderbilt Univ, Dept Pathol, Med Ctr, Sch Med, C3321 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	christine.eischen@vanderbilt.edu		Grieb, Brian/0000-0003-3980-8050	NCI [R01CA098139, R01CA117935, P30CA068485]; Leukemia & Lymphoma Society;  [P01CA095569]; NATIONAL CANCER INSTITUTE [R01CA098139, P01CA095569, R01CA117935, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Leukemia & Lymphoma Society(Leukemia and Lymphoma Society); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Silvia Plaza, Brandon Metge, Jane Kennedy, and Dr Chris Carbone for expert technical assistance, Dr Xavier Grana for assistance with the adenoviruses and the H1299 cell-cycle studies, and Dr William Dupont and Dale Plummer for Kaplan-Meier analysis. We also thank the following individuals for providing recombinant adenoviruses: Dr Joseph Nevins (Duke University) E2F1 and c-Myc, Dr Juan Fueyo (MD Anderson Cancer Center) p16, Dr Wafik El-Deiry (University of Pennsylvania) p21, and Dr Ruiz-Lozano (Burnham Institute) GFP. This work was supported by NCI Grants R01CA098139, R01CA117935 and P30CA068485 (CME); the Leukemia & Lymphoma Society (CME) and P01CA095569 (DH and JG).	Alt JR, 2003, EMBO J, V22, P1442, DOI 10.1093/emboj/cdg133; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; Boyd MT, 2000, J BIOL CHEM, V275, P31883, DOI 10.1074/jbc.M004252200; Brady M, 2005, MOL CELL BIOL, V25, P545, DOI 10.1128/MCB.25.2.545-553.2005; Carrasco DR, 2006, CANCER CELL, V9, P313, DOI 10.1016/j.ccr.2006.03.019; Eischen CM, 2004, ONCOGENE, V23, P8931, DOI 10.1038/sj.onc.1208052; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Iwakuma T, 2008, ONCOGENE, V27, P1813, DOI 10.1038/sj.onc.1210827; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Marine JC, 2010, CELL DEATH DIFFER, V17, P93, DOI 10.1038/cdd.2009.68; Martin ES, 2007, CANCER RES, V67, P10736, DOI 10.1158/0008-5472.CAN-07-2742; Nilsson JA, 2005, CANCER CELL, V7, P433, DOI 10.1016/j.ccr.2005.03.036; Ray S, 2006, CANCER RES, V66, P6598, DOI 10.1158/0008-5472.CAN-05-3115; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Wang P, 2008, ONCOGENE, V27, P1590, DOI 10.1038/sj.onc.1210788; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	19	23	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	2010	29	22					3287	3296		10.1038/onc.2010.82	http://dx.doi.org/10.1038/onc.2010.82			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20305689	Green Accepted			2022-12-17	WOS:000278321100011
J	Dudnakova, T; Spraggon, L; Slight, J; Hastie, N				Dudnakova, T.; Spraggon, L.; Slight, J.; Hastie, N.			Actin: a novel interaction partner of WT1 influencing its cell dynamic properties	ONCOGENE			English	Article						WT1; actin; nucleo-cytoplasmic shuttling	WILMS-TUMOR GENE; PROTEIN; TRANSCRIPTS; EXPRESSION; NUCLEUS; MYOSIN	The Wilms' tumour suppressor, WT1, is a zinc finger protein with key roles in normal development of the genitourinary system and tumourigenesis. Mutations or deletion of WT1 result in a spectrum of developmental disorders and susceptibility to Wilms' tumour in children. Ectopic expression of Wt1 associated with oncogenic functions has been observed in a large number of malignancies, including haematological and solid cancers. Although Wt1 is predominantly a nuclear protein in normal tissues, it is mostly cytoplasmic in the majority of Wt1-expressing tumours. Actin was identified in this study as a new WT1 interaction partner both in the nucleus and in the cytoplasm. We confirmed this interaction both in vitro and in vivo and started to explore its functional significance. Perturbation of the actin cytoskeleton moved Wt1 off the polysome fraction in the cytoplasm, cancelled its nucleo-cytoplasmic shuttling and altered Wt1 DNA- and RNA-binding abilities. These data have implications for Wt1 functions in relation to RNA metabolism and response to cytoskeletal alterations in cancer cells. Thus, our findings could shed more light on the functions of both these proteins and possibly pave way for the development of new cancer therapies. Oncogene (2010) 29, 1085-1092; doi:10.1038/onc.2009.444; published online 7 December 2009	[Dudnakova, T.; Spraggon, L.; Slight, J.; Hastie, N.] Western Gen Hosp, MRC Human Genet Unit, Inst Genet & Mol Med, Edinburgh EH4 2XU, Midlothian, Scotland; [Spraggon, L.] Univ Newcastle, Inst Human Genet, Int Ctr Life, Newcastle Upon Tyne, Tyne & Wear, England	University of Edinburgh; Newcastle University - UK	Hastie, N (corresponding author), Western Gen Hosp, MRC Human Genet Unit, Inst Genet & Mol Med, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	nick.hastie@hgu.mrc.ac.uk	Spraggon, Lee/E-5900-2012	Dudnakova, Tatyana/0000-0002-8388-8871	MRC; EU; MRC [MC_U127527180] Funding Source: UKRI; Medical Research Council [MC_U127527180] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); EU(European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Drs J Caceres and S Guil for their useful advice and GFP-hnRNP A1 and GFP-SF2 expressing constructs and anti-hnRNP A1 antibody. We also thank Mr Nick Tomczyk from the Chemistry Department at the University of Edinburgh for carrying out MALDI-TOF analysis. This study was funded by a core grant from the MRC and an EU Marie Curie Fellowship to TD.	Bing ZY, 2008, APPL IMMUNOHISTO M M, V16, P316, DOI 10.1097/PAI.0b013e31815c2e02; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; de Lanerolle P, 2005, NAT STRUCT MOL BIOL, V12, P742, DOI 10.1038/nsmb983; Discenza MT, 1997, NUCLEIC ACIDS RES, V25, P4314, DOI 10.1093/nar/25.21.4314; Gabert J, 2003, LEUKEMIA, V17, P2318, DOI 10.1038/sj.leu.2403135; Gimona M, 2008, SEMIN CANCER BIOL, V18, P23, DOI 10.1016/j.semcancer.2007.08.005; Hohenstein P, 2006, HUM MOL GENET, V15, pR196, DOI 10.1093/hmg/ddl196; Jansen RP, 1999, FASEB J, V13, P455, DOI 10.1096/fasebj.13.3.455; Jomgeow T, 2006, CANCER SCI, V97, P259, DOI 10.1111/j.1349-7006.2006.00169.x; Ladomery M, 2003, J CELL SCI, V116, P1539, DOI 10.1242/jcs.00324; Ladomery MR, 1999, J BIOL CHEM, V274, P36520, DOI 10.1074/jbc.274.51.36520; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Louvet E, 2009, INT REV CEL MOL BIO, V272, P107, DOI 10.1016/S1937-6448(08)01603-1; Nakatsuka S, 2006, MODERN PATHOL, V19, P804, DOI 10.1038/modpathol.3800588; Niksic M, 2004, HUM MOL GENET, V13, P463, DOI 10.1093/hmg/ddh040; Rao JY, 2004, CURR CANCER DRUG TAR, V4, P345, DOI 10.2174/1568009043332998; Sheikh S, 1997, BIOCHEM BIOPH RES CO, V238, P910, DOI 10.1006/bbrc.1997.7407; Spraggon L, 2007, ONCOGENE, V26, P1484, DOI 10.1038/sj.onc.1209922; TELLMANN G, 2006, BIOCHEMICA MANNHEIM, V4, P16; Vajjhala PR, 2003, FEBS LETT, V554, P143, DOI 10.1016/S0014-5793(03)01144-X; Viney RL, 2007, PROTEOMICS, V7, P804, DOI 10.1002/pmic.200600666	22	23	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					1085	1092		10.1038/onc.2009.444	http://dx.doi.org/10.1038/onc.2009.444			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19966868				2022-12-17	WOS:000274604400014
J	Solassol, J; Rouanet, P; Lamy, PJ; Allal, C; Favre, G; Maudelonde, T; Mange, A				Solassol, J.; Rouanet, P.; Lamy, P. J.; Allal, C.; Favre, G.; Maudelonde, T.; Mange, A.			Serum protein signature may improve detection of ductal carcinoma in situ of the breast	ONCOGENE			English	Article						breast; diagnosis; serum; profiling	PLATELET FACTOR-IV; SELDI-TOF-MS; PROTEOMIC ANALYSIS; MASS-SPECTROMETRY; OVARIAN-CANCER; ENDOTHELIAL-CELL; TUMOR-MARKERS; BIOMARKERS; IDENTIFICATION; GROWTH	Ductal carcinoma in situ (DCIS) of the breast is part of a spectrum of preinvasive lesions that originate within normal breast tissue and progress to invasive breast cancer. The detection of DCIS is important for the reduction of mortality from breast cancer, but the diagnosis of preinvasive breast tumors is hampered by the lack of an adequate detection method. To identify the changes in protein expression during the initial stage of tumorigenesis and to identify the presence of new DCIS markers, we analysed serum from 60 patients with breast cancer and 60 normal controls using mass spectrometry. A 23-protein index was generated that correctly distinguishes the DCIS and control groups with sensitivities and specificities in excess of 80% in two independent cohorts. Two candidate peptides were purified and identified as platelet factor 4 (PF-4) and complement C3a(desArg) anaphylatoxin (C3a(desArg)) using liquid chromatography-tandem mass spectrometry (LC-MS/MS). In an independent serum set of 165 patients, PF-4 and C3a(desArg) were significantly upregulated in DCIS compared with non-cancerous controls, as validated using western blot and enzyme-linked immunosorbent assay. We conclude that our serum protein-based test, used in conjunction with image-based screening practices, could improve the sensitivity and specificity of breast cancer detection. Oncogene (2010) 29, 550-560; doi: 10.1038/onc.2009.341; published online 26 October 2009	[Solassol, J.; Maudelonde, T.; Mange, A.] Univ Montpellier I, Montpellier, France; [Solassol, J.; Maudelonde, T.; Mange, A.] CHU Montpellier, Univ Hosp Montpellier, Dept Cellular Biol, Montpellier, France; [Solassol, J.; Maudelonde, T.; Mange, A.] CRLC, Dept Clin Oncoprote, Montpellier, France; [Rouanet, P.] CRLC, Dept Surg Oncol, Montpellier, France; [Lamy, P. J.] CRLC, Dept Biol, Montpellier, France; [Allal, C.; Favre, G.] CPTP, U563, INSERM, Toulouse, France	Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; Universite de Montpellier; Universite de Montpellier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Mange, A (corresponding author), Batiment Rech CRLC Val Aurelle,Parc Euromed,208, F-34298 Montpellier 5, France.	alain.mange@univ-montp1.fr	Solassol, Jerome/G-2320-2018; FAVRE, Gilles/K-9189-2014; ALLAL, Ben C/I-8146-2014; Mange, Alain/U-1157-2017; Lamy, Pierre-Jean/I-6077-2015; Lamy, Pierre-Jean/AAZ-1696-2020	Solassol, Jerome/0000-0002-0293-6158; FAVRE, Gilles/0000-0002-2344-1883; ALLAL, Ben C/0000-0002-4207-2219; Mange, Alain/0000-0002-1566-9407; Lamy, Pierre-Jean/0000-0002-5750-159X; Lamy, Pierre-Jean/0000-0002-5750-159X	Comite de l'Herault de la Ligue Contre le Cancer; INSERM [RBM 03-63]	Comite de l'Herault de la Ligue Contre le Cancer; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	This work was supported in part by grants from the Comite de l'Herault de la Ligue Contre le Cancer. Serum collection was supported by INSERM (RBM 03-63).	Albrethsen J, 2007, CLIN CHEM, V53, P852, DOI 10.1373/clinchem.2006.082644; Alexander H, 2004, CLIN CANCER RES, V10, P7500, DOI 10.1158/1078-0432.CCR-04-1002; Becker S, 2004, ANN SURG ONCOL, V11, P907, DOI 10.1245/ASO.2004.03.557; Belluco C, 2007, ANN SURG ONCOL, V14, P2470, DOI 10.1245/s10434-007-9354-3; Bijker N, 2006, J CLIN ONCOL, V24, P3381, DOI 10.1200/JCO.2006.06.1366; Bjorge L, 2005, BRIT J CANCER, V92, P895, DOI 10.1038/sj.bjc.6602334; Brozkova K, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2101; Carlevaro MF, 1997, J CELL BIOL, V136, P1375, DOI 10.1083/jcb.136.6.1375; Cavanaugh PG, 1998, J CELL PHYSIOL, V174, P48, DOI 10.1002/(SICI)1097-4652(199801)174:1<48::AID-JCP6>3.0.CO;2-G; Cavanaugh PG, 1999, BREAST CANCER RES TR, V56, P203; Cervi D, 2008, BLOOD, V111, P1201, DOI 10.1182/blood-2007-04-084798; Cho WCS, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-25; Elmore JG, 2005, JAMA-J AM MED ASSOC, V293, P1245, DOI 10.1001/jama.293.10.1245; Esserman LJ, 2007, EXPERT REV MOL DIAGN, V7, P533, DOI 10.1586/14737159.7.5.533; Gast M. C. W., 2006, Cancer Biomarkers, V2, P235; Gast MCW, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-389; GENGRINOVITCH S, 1995, J BIOL CHEM, V270, P15059, DOI 10.1074/jbc.270.25.15059; Goncalves A, 2006, ONCOGENE, V25, P981, DOI 10.1038/sj.onc.1209131; Greene FL, 2002, CANC STAGING MANUAL; GUPTA SK, 1994, J CELL BIOL, V127, P1121, DOI 10.1083/jcb.127.4.1121; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; Hagedorn M, 2001, FASEB J, V15, P550; Hanash S, 2003, NATURE, V422, P226, DOI 10.1038/nature01514; Hanash SM, 2008, NATURE, V452, P571, DOI 10.1038/nature06916; Harris L, 2007, J CLIN ONCOL, V25, P5287, DOI 10.1200/JCO.2007.14.2364; Hu Y, 2005, BREAST, V14, P250, DOI 10.1016/j.breast.2005.01.008; Jacot W, 2008, J THORAC ONCOL, V3, P840, DOI 10.1097/JTO.0b013e31817e464a; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kang XX, 2005, CLIN CHEM, V51, P56, DOI 10.1373/clinchem.2004.032458; Kopczynski Z, 1998, BRIT J CANCER, V78, P466, DOI 10.1038/bjc.1998.516; Kozak KR, 2005, PROTEOMICS, V5, P4589, DOI 10.1002/pmic.200500093; Kramar A, 2001, COMPUT METH PROG BIO, V66, P199, DOI 10.1016/S0169-2607(00)00129-2; Kuerer HM, 2009, J CLIN ONCOL, V27, P279, DOI 10.1200/JCO.2008.18.3103; Lee IN, 2006, PROTEOMICS, V6, P2865, DOI 10.1002/pmic.200500488; Levenson VV, 2007, BBA-GEN SUBJECTS, V1770, P847, DOI 10.1016/j.bbagen.2007.01.017; Li JN, 2005, CLIN CHEM, V51, P2229, DOI 10.1373/clinchem.2005.052878; Li JN, 2002, CLIN CHEM, V48, P1296; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; Mange A, 2008, J CHROMATOGR B, V876, P252, DOI 10.1016/j.jchromb.2008.11.003; Mathelin C, 2006, BREAST CANCER RES TR, V96, P83, DOI 10.1007/s10549-005-9046-2; Miguet L, 2006, J PROTEOME RES, V5, P2258, DOI 10.1021/pr060058y; NICOLSON GL, 1992, J NATL CANCER I MONO, V13, P153; Orel SG, 1999, RADIOLOGY, V211, P845, DOI 10.1148/radiology.211.3.r99jn31845; Pavlakis K, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-88; Perollet C, 1998, BLOOD, V91, P3289, DOI 10.1182/blood.V91.9.3289.3289_3289_3299; Petricoin EF, 2004, CURR OPIN BIOTECH, V15, P24, DOI 10.1016/j.copbio.2004.01.005; Pierce BL, 2009, J CLIN ONCOL, V27, P3437, DOI 10.1200/JCO.2008.18.9068; Rai AJ, 2002, ARCH PATHOL LAB MED, V126, P1518; Roesch-Ely M, 2007, ONCOGENE, V26, P54, DOI 10.1038/sj.onc.1209770; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Sahu A, 2001, IMMUNOL REV, V180, P35, DOI 10.1034/j.1600-065X.2001.1800103.x; Schagger H, 2006, NAT PROTOC, V1, P16, DOI 10.1038/nprot.2006.4; Semmes OJ, 2005, CLIN CHEM, V51, P102, DOI 10.1373/clinchem.2004.038950; SHARPE RJ, 1990, JNCI-J NATL CANCER I, V82, P848, DOI 10.1093/jnci/82.10.848; Solassol J, 2006, EXPERT REV PROTEOMIC, V3, P311, DOI 10.1586/14789450.3.3.311; Solassol K, 2005, ANAL BIOCHEM, V338, P26, DOI 10.1016/j.ab.2004.11.031; Song J, 2006, CLIN CHEM, V52, P1045, DOI 10.1373/clinchem.2005.065722; Timms JF, 2007, CLIN CHEM, V53, P645, DOI 10.1373/clinchem.2006.080101; van der Merwe DE, 2007, ADV CANCER RES, V96, P23, DOI 10.1016/S0065-230X(06)96002-3; Vlahou Antonia, 2003, Clin Breast Cancer, V4, P203, DOI 10.3816/CBC.2003.n.026; Ward DG, 2006, BRIT J CANCER, V94, P1898, DOI 10.1038/sj.bjc.6603188	61	23	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					550	560		10.1038/onc.2009.341	http://dx.doi.org/10.1038/onc.2009.341			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19855429				2022-12-17	WOS:000274084600008
J	Yang, L; Olsson, B; Pfeifer, D; Jonsson, JI; Zhou, ZG; Jiang, X; Fredriksson, BA; Zhang, H; Sun, XF				Yang, L.; Olsson, B.; Pfeifer, D.; Jonsson, J.-I.; Zhou, Z-G; Jiang, X.; Fredriksson, B-A; Zhang, H.; Sun, X-F			Knockdown of peroxisome proliferator-activated receptor-beta induces less differentiation and enhances cell-fibronectin adhesion of colon cancer cells	ONCOGENE			English	Article						peroxisome proliferator-activated receptor; colon neoplasm; pathogenesis; RNA interference; differentiation	INTEGRIN-LINKED KINASE; PPAR-DELTA; COLORECTAL-CANCER; EXTRACELLULAR-MATRIX; METABOLIC SYNDROME; SIGNALING PATHWAY; EXPRESSION; CARCINOGENESIS; PROTEIN; GROWTH	The role of peroxisome proliferator-activated receptor-beta/delta (PPAR-beta/delta) in the pathogenesis of colon cancer remains highly controversial. This study specifically silenced the PPAR-beta expression in three colon cancer cell lines with different metastatic potentials. Although PPAR-beta knockdown resulted in more malignant morphological changes, bigger colony sizes and lower carcinoembryonic antigen (CEA) secretion, and enhanced the cell-fibronectin adhesion, cell invasion and migration were unaffected. These effects were stronger in poorly metastatic cell lines compared with highly metastatic ones. Simultaneously, PPAR-beta knockdown decreased the mRNAs encoding adipocyte differentiation-related protein and liver fatty acid binding protein, and increased the mRNA of ILK, whereas the mRNAs encoding integrin-beta 1 and angiopoietin-like 4 were unchanged. Using immunohistochemistry, we determined that the intensity of PPAR-beta expression was stronger in rectal cancers with better differentiation than in those with poor differentiation, and was stronger in early-stage tumors than in advanced ones. Together, these findings consistently indicate that PPAR-beta may facilitate differentiation and inhibit the cell-fibronectin adhesion of colon cancer, having a role as an inhibitor in the carcinogenesis and progression of colorectal cancer. Interestingly, PPAR-beta seems to have a more important role in poorly metastatic cells than in highly metastatic ones. Oncogene (2010) 29, 516-526; doi: 10.1038/onc.2009.370; published online 23 November 2009	[Yang, L.; Olsson, B.; Pfeifer, D.; Sun, X-F] Linkoping Univ, Div Oncol, Dept Clin & Expt Med, S-58185 Linkoping, Sweden; [Jonsson, J.-I.] Linkoping Univ, Div Expt Hematol, Dept Clin & Expt Med, S-58185 Linkoping, Sweden; [Yang, L.; Zhou, Z-G; Jiang, X.] Sichuan Univ, W China Hosp, State Key Lab Biotherapy, Chengdu, Sichuan Prov, Peoples R China; [Yang, L.; Zhou, Z-G; Jiang, X.] Sichuan Univ, Inst Digest Surg, Chengdu, Sichuan Prov, Peoples R China; [Fredriksson, B-A] Linkoping Univ, Div Expt Pathol, Dept Clin & Expt Med, S-58185 Linkoping, Sweden; [Zhang, H.] Univ Skovde, Div Biomed, Skovde, Sweden	Linkoping University; Linkoping University; Sichuan University; Sichuan University; Linkoping University; University of Skovde	Sun, XF (corresponding author), Linkoping Univ, Div Oncol, Dept Clin & Expt Med, S-58185 Linkoping, Sweden.	xiao-feng.sun@liu.se		Jonsson, Jan-Ingvar/0000-0003-4814-978X; , Zongguang/0000-0002-7616-1199	Swedish Cancer Foundation; Swedish Research Council; Health Research Council in the South-East of Sweden; Natural Science Foundation of China [30801332]; National Science Foundation [20070421149]	Swedish Cancer Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); Health Research Council in the South-East of Sweden; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science Foundation(National Science Foundation (NSF))	We thank Petter Hammar (Linkoping University, Sweden) for his help in lentivirus construction, and thank Prof IJ Fidler (Anderson Cancer Center, Houston, TX) for offering KM12 cell lines. This study was financially supported by grants from the Swedish Cancer Foundation, Swedish Research Council and the Health Research Council in the South-East of Sweden, the Natural Science Foundation of China (Grant No. 30801332) and the National Science Foundation for post-doctoral Scientists of China (Grant No. 20070421149).	Alexandrova AY, 2008, BIOCHEMISTRY-MOSCOW+, V73, P733, DOI 10.1134/S0006297908070018; Aung CS, 2006, BIOCHEM BIOPH RES CO, V340, P656, DOI 10.1016/j.bbrc.2005.12.061; Barak Y, 2002, P NATL ACAD SCI USA, V99, P303, DOI 10.1073/pnas.012610299; Barish GD, 2006, J CLIN INVEST, V116, P590, DOI 10.1172/JCI27955; Bordonaro M, 2002, INT J CANCER, V97, P42, DOI 10.1002/ijc.1577; Burdick AD, 2006, CELL SIGNAL, V18, P9, DOI 10.1016/j.cellsig.2005.07.009; Camps J, 2004, INT J CANCER, V110, P869, DOI 10.1002/ijc.20195; Chen LC, 2004, CANCER RES, V64, P3694, DOI 10.1158/0008-5472.CAN-03-3264; Cheng LH, 2004, NAT MED, V10, P1245, DOI 10.1038/nm1116; Cordes N, 2003, BRIT J CANCER, V88, P1470, DOI 10.1038/sj.bjc.6600912; Di-Poi N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9; DOHERTY UO, 2000, J VIROL, V74, P10074; Galaup A, 2006, P NATL ACAD SCI USA, V103, P18721, DOI 10.1073/pnas.0609025103; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Harman FS, 2004, NAT MED, V10, P481, DOI 10.1038/nm1026; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hinnebusch BF, 2002, J NUTR, V132, P1012, DOI 10.1093/jn/132.5.1012; Hollingshead HE, 2008, CARCINOGENESIS, V29, P169, DOI 10.1093/carcin/bgm209; JEFFREY MP, 2008, CLIN SCI, V115, P107; Kim DJ, 2006, CELL DEATH DIFFER, V13, P53, DOI 10.1038/sj.cdd.4401713; Kim DJ, 2004, J BIOL CHEM, V279, P23719, DOI 10.1074/jbc.M312063200; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Lawrie LC, 2004, BRIT J CANCER, V90, P1955, DOI 10.1038/sj.bjc.6601828; MORIKAWA K, 1988, CANCER RES, V48, P6863; Orner GA, 2003, CARCINOGENESIS, V24, P263, DOI 10.1093/carcin/24.2.263; Ouyang N, 2006, CARCINOGENESIS, V27, P232, DOI 10.1093/carcin/bgi221; Park EY, 2005, CANCER RES, V65, P9923, DOI 10.1158/0008-5472.CAN-05-1604; Peraza MA, 2006, TOXICOL SCI, V90, P269, DOI 10.1093/toxsci/kfj062; Piqueras L, 2007, ARTERIOSCL THROM VAS, V27, P63, DOI 10.1161/01.ATV.0000250972.83623.61; Reddig PJ, 2005, CANCER METAST REV, V24, P425, DOI 10.1007/s10555-005-5134-3; Reed KR, 2004, ONCOGENE, V23, P8992, DOI 10.1038/sj.onc.1208143; Schmuth M, 2004, J INVEST DERMATOL, V122, P971, DOI 10.1111/j.0022-202X.2004.22412.x; Schroeder F, 2001, MOL CELL BIOCHEM, V219, P127, DOI 10.1023/A:1010851130136; Shao JY, 2002, CANCER RES, V62, P3282; Takahashi S, 2006, PHARMACOL RES, V53, P501, DOI 10.1016/j.phrs.2006.03.019; Targett-Adams P, 2005, BBA-GENE STRUCT EXPR, V1728, P95, DOI 10.1016/j.bbaexp.2005.01.017; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Worth DC, 2008, INT J BIOCHEM CELL B, V40, P2397, DOI 10.1016/j.biocel.2008.04.008; Wozniak MA, 2004, BBA-MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007; Yang L, 2008, DIS COLON RECTUM, V51, P318, DOI 10.1007/s10350-007-9145-8; Yang L, 2006, EJSO-EUR J SURG ONC, V32, P181, DOI 10.1016/j.ejso.2005.11.005; Yeatman TJ, 1996, CLIN EXP METASTAS, V14, P246	44	23	25	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					516	526		10.1038/onc.2009.370	http://dx.doi.org/10.1038/onc.2009.370			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19935699				2022-12-17	WOS:000274084600005
J	Perez-Soler, R				Perez-Soler, R.			Individualized therapy in non-small-cell lung cancer: future versus current clinical practice	ONCOGENE			English	Review						EGFR; biomarker; genomics; proteomics	GROWTH-FACTOR RECEPTOR; MESSENGER-RNA EXPRESSION; BETA-TUBULIN GENE; ACQUIRED-RESISTANCE; ACTIVATING MUTATIONS; PROLONGED SURVIVAL; ERCC1 EXPRESSION; PREDICTIVE-VALUE; PHASE-III; GEFITINIB	Despite advances in the management of non-small-cell lung cancer (NSCLC), including the introduction of targeted therapies such as epidermal growth factor receptor tyrosine kinase inhibitors, improvements in survival are marginal and the overall prognosis for patients remains poor. Tailoring therapy to the individual patient is a promising approach for selecting the most appropriate therapeutic regimens to maximize efficacy and minimize toxicity. The identification of predictive biomarkers that can guide treatment decisions is an important step for individualized therapy and in ultimately improving patient outcomes. Genomic and proteomic studies provide a means for the molecular profiling of tumor tissue from patients with NSCLC, and allow tailoring of therapy whereby the most appropriate treatment is administered to each individual patient. Although there are still significant challenges to implementing genomic and proteomic testing in clinical practice, the rapid development of newer technologies provides hope for overcoming these barriers. Oncogene (2009) 28, S38-S45; doi:10.1038/onc.2009.200	Albert Einstein Coll Med, Montefiore Med Ctr, Dept Oncol, Div Med Oncol, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Perez-Soler, R (corresponding author), Albert Einstein Coll Med, Montefiore Med Ctr, Dept Oncol, Div Med Oncol, 111 E 210th St,Hofheimer Room 100A, Bronx, NY 10467 USA.	rperezso@montefiore.org			Boehringer Ingelheim Pharmaceuticals Inc.	Boehringer Ingelheim Pharmaceuticals Inc.(Boehringer Ingelheim)	I thank Johnathan C Maher, PhD of BlueSpark Healthcare Communications for medical and editorial assistance with this article. Financial support for medical and editorial assistance was provided by Boehringer Ingelheim Pharmaceuticals Inc.	Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Atkins D, 2004, J HISTOCHEM CYTOCHEM, V52, P893, DOI 10.1369/jhc.3A6195.2004; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bonomi PD, 2007, CLIN CANCER RES, V13, p4606S, DOI 10.1158/1078-0432.CCR-07-0332; Chen GA, 2003, P NATL ACAD SCI USA, V100, P13537, DOI 10.1073/pnas.2233850100; Chiappori A, 2005, ONCOLOGY-BASEL, V68, P382, DOI 10.1159/000086979; CLARK GM, 2006, P AM SOC CLIN ONCO S, V24, P7166; Conrad DH, 2008, J GEN INTERN MED, V23, P78, DOI 10.1007/s11606-007-0411-1; Cortes-Funes H, 2005, ANN ONCOL, V16, P1081, DOI 10.1093/annonc/mdi221; de Reynies A, 2008, J CLIN ONCOL, V26, P228, DOI 10.1200/JCO.2007.15.9186; De Roock W, 2008, ANN ONCOL, V19, P508, DOI 10.1093/annonc/mdm496; Di Fiore F, 2007, BRIT J CANCER, V96, P1166, DOI 10.1038/sj.bjc.6603685; Douillard J, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.8001; Dowlati A, 2006, J CLIN ONCOL, V24, p370S; DZIADZIUSZKO R, 2007, J CLIN ONCOL, V25, pS403; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Eberhard DA, 2008, J CLIN ONCOL, V26, P983, DOI 10.1200/JCO.2007.12.9858; EISMANN U, 2006, J CLIN ONCOL S, V24, P13058; Engelman JA, 2008, CLIN CANCER RES, V14, P2895, DOI 10.1158/1078-0432.CCR-07-2248; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; GANDARA DR, 2007, J CLIN ONCOL S, V25; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Granville CA, 2005, AM J RESP CELL MOL, V32, P169, DOI 10.1165/rcmb.F290; Guney N, 2008, MED ONCOL, V25, P194, DOI 10.1007/s12032-007-9026-y; Han SW, 2005, J CLIN ONCOL, V23, P2493, DOI 10.1200/JCO.2005.01.388; Hasegawa S, 2002, INT J CANCER, V101, P46, DOI 10.1002/ijc.10575; Hirsch FR, 2009, ONCOGENE, V28, pS32, DOI 10.1038/onc.2009.199; Hirsch FR, 2006, J CLIN ONCOL, V24, P5034, DOI 10.1200/JCO.2006.06.3958; Hirsch J, 2004, AM J PHYSIOL-LUNG C, V287, pL1, DOI 10.1152/ajplung.00301.2003; Huang Cheng-Long, 2006, Future Oncol, V2, P289, DOI 10.2217/14796694.2.2.289; Huncharek M, 1999, CARCINOGENESIS, V20, P1507, DOI 10.1093/carcin/20.8.1507; Kikuchi T, 2007, RESPIROLOGY, V12, P22, DOI 10.1111/j.1440-1843.2006.00957.x; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Li D, 2008, ONCOGENE, V27, P4702, DOI 10.1038/onc.2008.109; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Lord RVN, 2002, CLIN CANCER RES, V8, P2286; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; MAHESWARAN S, 2008, NEW ENGL J MED, V359, P1; Marchetti A, 2006, NEW ENGL J MED, V354, P526; Mitsudomi T, 2005, J CLIN ONCOL, V23, P2513, DOI 10.1200/JCO.2005.00.992; Mok T, 2008, ANN ONCOL, V19, P1; Monzo M, 1999, J CLIN ONCOL, V17, P1786, DOI 10.1200/JCO.1999.17.6.1786; *NCCN, 2008, CLIN PRACT GUID NONS; Okano T, 2007, CLIN CANCER RES, V13, P799, DOI 10.1158/1078-0432.CCR-06-1654; Oldenhuis CNAM, 2008, EUR J CANCER, V44, P946, DOI 10.1016/j.ejca.2008.03.006; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Patterson SD, 2003, NAT BIOTECHNOL, V21, P221, DOI 10.1038/nbt0303-221; Pitterle DM, 1999, MAMM GENOME, V10, P916, DOI 10.1007/s003359901114; Potti A, 2006, NEW ENGL J MED, V355, P570, DOI 10.1056/NEJMoa060467; Reckamp KL, 2008, J THORAC ONCOL, V3, P117, DOI 10.1097/JTO.0b013e3181622bef; Rosell R, 2004, CLIN CANCER RES, V10, P1318, DOI 10.1158/1078-0432.CCR-03-0156; Rosell R, 2003, ONCOGENE, V22, P3548, DOI 10.1038/sj.onc.1206419; Sequist LV, 2008, J CLIN ONCOL, V26, P2442, DOI 10.1200/JCO.2007.14.8494; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shepherd FA, 2006, J CLIN ONCOL, V24, P1219, DOI 10.1200/JCO.2005.04.4420; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Simon G, 2007, J CLIN ONCOL, V25, P2741, DOI 10.1200/JCO.2006.08.2099; Simon GR, 2005, CHEST, V127, P978, DOI 10.1378/chest.127.3.978; Solan Merrill J, 2003, Semin Surg Oncol, V21, P64, DOI 10.1002/ssu.10023; Solomon BJ, 2007, J CLIN ONCOL, V25; Stinchcombe TE, 2008, ONCOLOGIST, V13, P28, DOI 10.1634/theoncologist.13-S1-28; Takano T, 2005, J CLIN ONCOL, V23, P6829, DOI 10.1200/JCO.2005.01.0793; Taron M, 2004, HUM MOL GENET, V13, P2443, DOI 10.1093/hmg/ddh260; Thatcher N, 2005, LANCET, V366, P1527, DOI 10.1016/S0140-6736(05)67625-8; Tsao MS, 2008, J CLIN ONCOL, V26; Van Cutsem E, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.2; Webster J, 2005, METH MOL B, V310, P227; Wong KK, 2007, CLIN CANCER RES, V13, p4593S, DOI 10.1158/1078-0432.CCR-07-0369; Yanagisawa K, 2003, LANCET, V362, P433, DOI 10.1016/S0140-6736(03)14068-8; Yun CH, 2008, P NATL ACAD SCI USA, V105, P2070, DOI 10.1073/pnas.0709662105; Zhu CQ, 2008, J CLIN ONCOL, V26, P4268, DOI 10.1200/JCO.2007.14.8924	72	23	28	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2009	28			1			S38	S45		10.1038/onc.2009.200	http://dx.doi.org/10.1038/onc.2009.200			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QF	19680295				2022-12-17	WOS:000269515400006
J	Liu, Y; Pixley, R; Fusaro, M; Godoy, G; Kim, E; Bromberg, ME; Colman, RW				Liu, Y.; Pixley, R.; Fusaro, M.; Godoy, G.; Kim, E.; Bromberg, M. E.; Colman, R. W.			Cleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathway	ONCOGENE			English	Article						Hka; prostate cancer; EGFR; uPAR	PLASMINOGEN-ACTIVATOR RECEPTOR; HUMAN ENDOTHELIAL-CELLS; UROKINASE RECEPTOR; HUMAN CARCINOMA; TUBE FORMATION; TUMOR-GROWTH; IN-VIVO; KALLIKREIN; DORMANCY; PLASMA	Upregulation and activation of epidermal growth factor receptor and/or urokinase-type plasminogen activator receptor in a variety of cancers have been shown to be associated with poor prognosis. High-molecular-weight kininogen can be hydrolysed by plasma kallikrein to bradykinin and cleaved high-molecular-weight kininogen (HKa). HKa and its domain 5 (D5) both have been shown to have potent anti-angiogenic activity. We now show that HKa blocks human prostate cancer cell (DU145) migration by 76.0 +/- 2.4% at 300 nM and invasion by 78.0 +/- 12.9% at 11.1 nM. D5 inhibits tumor migration and invasion in a concentration-dependent manner. Stimulation by basic fibroblast growth factor (bFGF) or vascular endothelial growth factor results in clustering of urokinase-type plasminogen activator receptor (uPAR) and epidermal growth factor receptor (EGFR) on the surface of DU145 cells. The co-localization of uPAR and EGFR is prevented by HKa. Immunoprecipitation suggests that uPAR, EGFR and alpha 5 beta 1 integrin formed a ternary complex. Immunoblotting shows that HKa significantly decreases the bFGF-transactivated phosphorylation of EGFR at Tyr 1173 between 30 min and 4 h. The phosphorylation of extracellular signal-regulated kinase (ERK) and AKT, which are downstream effectors of EGFR, is also inhibited by HKa. These novel data indicate that HKa and D5 inhibit migration and invasion of human prostate cancer cells through an EGFR/uPAR pathway, suggesting the therapeutic potential of HKa and D5 to decrease metastasis of human prostate cancer. Oncogene (2009) 28, 2756-2765; doi:10.1038/onc.2009.132; published online 1 June 2009	[Liu, Y.; Pixley, R.; Fusaro, M.; Godoy, G.; Kim, E.; Bromberg, M. E.; Colman, R. W.] Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Liu, Y (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St,Room 808 OMS, Philadelphia, PA 19140 USA.	yuchuan@temple.edu	fusaro, maria/R-3386-2016; Fusaro, Maria/AAA-5509-2019	fusaro, maria/0000-0001-9478-4851; Fusaro, Maria/0000-0001-9478-4851	National Institutes of Health [R01 CA83121, R01 AR051713, T32 HL07777]; NATIONAL CANCER INSTITUTE [R01CA083121] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051713] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This study was supported by National Institutes of Health Grants R01 CA83121, R01 AR051713 and T32 HL07777 to RW Colman.	Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Cao DJ, 2004, CIRC RES, V94, P1227, DOI 10.1161/01.RES.0000126567.75232.46; Chaurasia P, 2006, J BIOL CHEM, V281, P14852, DOI 10.1074/jbc.M512311200; Colman RW, 1998, CLIN REV ALLERG IMMU, V16, P365, DOI 10.1007/BF02737657; Colman RW, 2006, CURR PHARM DESIGN, V12, P2599, DOI 10.2174/138161206777698710; Colman RW, 1999, IMMUNOPHARMACOLOGY, V43, P103, DOI 10.1016/S0162-3109(99)00068-5; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Katkade V, 2005, THROMB HAEMOSTASIS, V94, P606, DOI 10.1160/TH04-12-0834; KIRCHHEIMER JC, 1985, INVAS METAST, V5, P344; Li Y, 2007, CANCER TREAT REV, V33, P521, DOI 10.1016/j.ctrv.2007.06.003; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Liu YC, 2004, J BIOL CHEM, V279, P36142, DOI 10.1074/jbc.M405039200; Liu YC, 2008, AM J PHYSIOL-CELL PH, V295, pC257, DOI 10.1152/ajpcell.00569.2007; Liu Y, 2008, EXP CELL RES, V314, P774, DOI 10.1016/j.yexcr.2007.10.008; Ma Z, 2001, J CELL SCI, V114, P3387; Mahdi F, 2004, J BIOL CHEM, V279, P16621, DOI 10.1074/jbc.M313850200; Mamoune A, 2004, EXP CELL RES, V299, P91, DOI 10.1016/j.yexcr.2004.05.008; Mazzieri R, 2006, MOL BIOL CELL, V17, P367, DOI 10.1091/mbc.E05-07-0635; Miyake H, 1999, INT J ONCOL, V14, P535; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; Nykjaer A, 1998, J CELL BIOL, V141, P815, DOI 10.1083/jcb.141.3.815; Pixley RA, 2003, J THROMB HAEMOST, V1, P1791, DOI 10.1046/j.1538-7836.2003.00291.x; Prager GW, 2004, BLOOD, V103, P955, DOI 10.1182/blood-2003-07-2214; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schlomm T, 2007, CLIN CANCER RES, V13, P6579, DOI 10.1158/1078-0432.CCR-07-1257; Schmaier AH, 2007, J THROMB HAEMOST, V5, P2323, DOI 10.1111/j.1538-7836.2007.02770.x; Wang XQ, 2005, J INVEST DERMATOL, V124, P839, DOI 10.1111/j.0022-202X.2005.23669.x; Yarden Y, 2001, EUR J CANCER, V37, pS3	31	23	25	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	30					2756	2765		10.1038/onc.2009.132	http://dx.doi.org/10.1038/onc.2009.132			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476OW	19483730	Green Accepted			2022-12-17	WOS:000268452900006
J	Ito, K; Inoue, K; Bae, SC; Ito, Y				Ito, K.; Inoue, K-i; Bae, S-C; Ito, Y.			Runx3 expression in gastrointestinal tract epithelium: resolving the controversy	ONCOGENE			English	Article						detection of Runx3; immunohistochemistry; gastrointestinal epithelial cells; monoclonal antibody	ROOT GANGLION NEURONS; GASTRIC-CANCER; GROWTH-FACTOR; TUMOR-SUPPRESSOR; REGULATES DEVELOPMENT; CELLS; GENE; ADENOCARCINOMA; METASTASIS; RUNX1/AML1	We reported earlier that RUNX3 is expressed in human and mouse gastrointestinal tract (GIT) epithelium and that it functions as a tumor suppressor in gastric and colorectal tissues. However, there have been conflicting reports describing the absence of Runx3 in GIT epithelial cells. A part of the controversy may be derived from the use of a specific antibody by other groups ( referred to as G-poly). Here, we show further evidence to support our earlier observations and provide a possible explanation for this apparent controversy. We generated multiple anti-RUNX3 monoclonal antibodies and found that RUNX3 antibodies recognizing the RUNX3 N-terminal region (residues 1-234) react with RUNX3 in gastric epithelial cells, whereas those recognizing the C-terminal region (beyond residue 234) did not. G-poly primarily recognizes the region beyond 234 and hence, is unable to detect Runx3 in this tissue.	[Ito, K.; Inoue, K-i; Ito, Y.] Inst Mol & Cell Biol, Singapore 138673, Singapore; [Ito, K.; Ito, Y.] Natl Univ Singapore, Oncol Res Inst, Singapore 117548, Singapore; [Bae, S-C] Chungbuk Natl Univ, Sch Med, Dept Biochem, Cheongju, South Korea; [Bae, S-C] Chungbuk Natl Univ, Inst Tumor Res, Cheongju, South Korea	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Chungbuk National University; Chungbuk National University	Ito, Y (corresponding author), Inst Mol & Cell Biol, 61 Biopolis Dr, Singapore 138673, Singapore.	itoy@imcb.a-star.edu.sg						Brenner O, 2004, P NATL ACAD SCI USA, V101, P16016, DOI 10.1073/pnas.0407180101; Carvalho R, 2005, ONCOGENE, V24, P8252, DOI 10.1038/sj.onc.1208963; Chen AI, 2006, NEURON, V49, P395, DOI 10.1016/j.neuron.2005.12.028; Chen CL, 2006, NEURON, V49, P365, DOI 10.1016/j.neuron.2005.10.036; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Inoue KI, 2007, J BIOL CHEM, V282, P24175, DOI 10.1074/jbc.M703746200; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito K, 2008, CANCER CELL, V14, P226, DOI 10.1016/j.ccr.2008.08.004; Ito Y, 2008, ADV CANCER RES, V99, P33, DOI 10.1016/S0065-230X(07)99002-8; Katuri V, 2006, ONCOGENE, V25, P1871, DOI 10.1038/sj.onc.1209211; Kramer I, 2006, NEURON, V49, P379, DOI 10.1016/j.neuron.2006.01.008; Le XF, 1999, J BIOL CHEM, V274, P21651, DOI 10.1074/jbc.274.31.21651; Levanon D, 2003, EMBO REP, V4, P560, DOI 10.1038/sj.embor.embor868; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Marmigere F, 2006, NAT NEUROSCI, V9, P180, DOI 10.1038/nn1631; Nakamura S, 2008, DEVELOPMENT, V135, P1703, DOI 10.1242/dev.015248; Osaki M, 2004, EUR J CLIN INVEST, V34, P605, DOI 10.1111/j.1365-2362.2004.01401.x; Oshimo Y, 2004, PATHOBIOLOGY, V71, P137, DOI 10.1159/000076468; Peng ZH, 2006, CLIN CANCER RES, V12, P6386, DOI 10.1158/1078-0432.CCR-05-2359; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Torquati A, 2004, SURGERY, V136, P310, DOI 10.1016/j.surg.2004.05.005; Usui T, 2006, INT J ONCOL, V29, P779; Wei DY, 2005, CANCER RES, V65, P4809, DOI 10.1158/0008-5472.CAN-04-3741; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Yano T, 2006, MOL CELL BIOL, V26, P4474, DOI 10.1128/MCB.01926-05; Zavros Y, 2005, ONCOGENE, V24, P2354, DOI 10.1038/sj.onc.1208407	29	23	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2009	28	10					1379	1384		10.1038/onc.2008.496	http://dx.doi.org/10.1038/onc.2008.496			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	417ZC	19169278				2022-12-17	WOS:000264116000010
J	Tchougounova, E; Jiang, Y; Brasater, D; Lindberg, N; Kastemar, M; Asplund, A; Westermark, B; Uhrbom, L				Tchougounova, E.; Jiang, Y.; Brasater, D.; Lindberg, Nanna; Kastemar, M.; Asplund, A.; Westermark, B.; Uhrbom, L.			Sox5 can suppress platelet-derived growth factor B-induced glioma development in Ink4a-deficient mice through induction of acute cellular senescence	ONCOGENE			English	Article						Sox5; glioma; PDGF; p27(Kip1); senescence	NEURAL PROGENITORS; IN-VIVO; INHIBITOR P27(KIP1); CYCLE PROGRESSION; BRAIN-TUMORS; PROTEIN; EXPRESSION; CANCER; GENES; CELLS	SOX5 is a member of the high-mobility group superfamily of architectural non-histone proteins involved in gene regulation and maintenance of chromatin structure in a wide variety of developmental processes. Sox5 was identified as a brain tumor locus in a retroviral insertional mutagenesis screen of platelet-derived growth factor B (PDGFB)-induced mouse gliomas. Here we have investigated the role of Sox5 in PDGFB-induced gliomagenesis in mice. We show that Sox5 can suppress PDGFB-induced glioma development predominantly upon Ink4a-loss. In human glioma cell lines and tissues, we found very low levels of SOX5 compared with normal brain. Overexpression of Sox5 in human glioma cells led to a reduction in clone formation and inhibition of proliferation. Combined expression of Sox5 and PDGFB in primary brain cell cultures caused decreased proliferation and an increased number of senescent cells in the Ink4a(-/-) cells only. Protein analyses showed a reduction in the amount and activation of Akt and increased levels of p27(Kip1) upon Sox5 expression that was dominant to PDGFB signaling and specific to Ink4a(-/-) cells. Upon inhibition of p27(Kip1), the effects of Sox5 on proliferation and senescence could be reversed. Our data suggest a novel pathway, where Sox5 may suppress the oncogenic effects of PDGFB signaling during glioma development by regulating p27(Kip1) in a p19(Arf)-dependent manner, leading to acute cellular senescence.	[Tchougounova, E.; Jiang, Y.; Brasater, D.; Lindberg, Nanna; Kastemar, M.; Asplund, A.; Westermark, B.; Uhrbom, L.] Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Sweden	Uppsala University	Uhrbom, L (corresponding author), Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Sweden.	lene.uhrbom@genpat.uu.se		Westermark, Bengt/0000-0001-7153-5545	Swedish Cancer Society; Swedish Research Council; Association for International Cancer Research; Swedish Society for Medical Research	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Association for International Cancer Research; Swedish Society for Medical Research	We thank Veronique Lefebvre for the Sox5 cDNA, Fredrik Ponten for supplying the normal and tumor tissue microarrays, and Umashankar Singh for advice on siRNA. This work has been supported by grants from the Swedish Cancer Society, the Swedish Research Council and Association for International Cancer Research, and by donations in the memory of Joacim Bonnevier. ET has been supported by postdoctoral grants from the Swedish Research Council, the Swedish Society for Medical Research and the Swedish Cancer Society.	Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; CONNER F, 1994, NUCLEIC ACIDS RES, V22, P3339, DOI 10.1093/nar/22.16.3339; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dong C, 2004, CYTOGENET GENOME RES, V105, P442, DOI 10.1159/000078217; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; Hagerstrand D, 2006, ONCOGENE, V25, P4913, DOI 10.1038/sj.onc.1209497; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Huang DY, 2008, J PATHOL, V214, P445, DOI 10.1002/path.2299; JEN J, 1994, CANCER RES, V54, P6353; Johansson FK, 2004, P NATL ACAD SCI USA, V101, P11334, DOI 10.1073/pnas.0402716101; KAMB A, 1994, SCIENCE, V264, P440; Lee BY, 2006, AGING CELL, V5, P187, DOI 10.1111/j.1474-9726.2006.00199.x; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Louis DN, 2007, WHO CLASSIFICATION T; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Rempel SA, 1998, J NEUROPATH EXP NEUR, V57, P1112, DOI 10.1097/00005072-199812000-00002; Schlierf B, 2007, NEUROPATH APPL NEURO, V33, P621, DOI 10.1111/j.1365-2990.2007.00881.x; Schultz C, 2002, CANCER RES, V62, P6270; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; Shih AH, 2004, CANCER RES, V64, P4783, DOI 10.1158/0008-5472.CAN-03-3831; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Stolt CC, 2006, DEV CELL, V11, P697, DOI 10.1016/j.devcel.2006.08.011; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Tchougounova E, 2007, ONCOGENE, V26, P6289, DOI 10.1038/sj.onc.1210455; Ueda R, 2007, INT J CANCER, V120, P1704, DOI 10.1002/ijc.22472; Uhlen M, 2005, MOL CELL PROTEOMICS, V4, P384, DOI 10.1074/mcp.R500009-MCP200; Uhrbom L, 2005, CANCER RES, V65, P2065, DOI 10.1158/0008-5472.CAN-04-3588; Uhrbom L, 2002, CANCER RES, V62, P5551; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wegner M, 2005, TRENDS NEUROSCI, V28, P583, DOI 10.1016/j.tins.2005.08.008; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wolf RM, 2003, GENE DEV, V17, P476, DOI 10.1101/gad.1040003; Xia Y, 2000, CANCER RES, V60, P6303; Zafarana G, 2002, CANCER RES, V62, P1822	42	23	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	12					1537	1548		10.1038/onc.2009.9	http://dx.doi.org/10.1038/onc.2009.9			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	424AH	19219070				2022-12-17	WOS:000264537400006
J	Koch, A; Scherr, M; Breyer, B; Mancini, A; Kardinal, C; Battmer, K; Eder, M; Tamura, T				Koch, A.; Scherr, M.; Breyer, B.; Mancini, A.; Kardinal, C.; Battmer, K.; Eder, M.; Tamura, T.			Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover	ONCOGENE			English	Article						TrkA and Bcr-Abl; CML; imatinib; receptor internalization; CD34+cells	CHRONIC MYELOID-LEUKEMIA; TRK NEUROTROPHIN RECEPTORS; HEMATOPOIETIC-CELLS; C-KIT; PHILADELPHIA-CHROMOSOME; 5-PHOSPHATASE SHIP2; IN-VITRO; STI 571; EXPRESSION; NGF	Receptor tyrosine kinase-mediated signaling is tightly regulated by a number of cytoplasmic signaling molecules. In this report, we show that Bcr-Abl transformed chronic myelogenous leukemia (CML) cell lines, K562 and Meg-01, express the receptor for nerve growth factor (NGF), TrkA, on the cell surface; however, the NGF-mediated signal is not particularly strong. Treatment with imatinib, a potent inhibitor of Bcr-Abl tyrosine kinase, downmodulates phosphorylation of downstream molecules. Upon stimulation with NGF, Erk and Akt are phosphorylated to a much greater degree in imatinib-treated cells than in untreated cells. Knockdown of expression of Bcr-Abl using small interfering RNA technique also enhanced NGF-mediated Akt phosphorylation, indicating that Bcr-Abl kinase modifies NGF signaling directly. Imatinib treatment also enhanced NGF signaling in rat adrenal pheochromocytoma cell line PC12 that expresses TrkA and c-Abl, suggesting that it is not only restoration of responsiveness to NGF after blocking oncoprotein activity, but also c-Abl tyrosine kinase per se may be a negative regulator of growth factor signaling. Furthermore, inhibition of Abl tyrosine kinase enhanced clearance of surface TrkA after NGF treatment and simultaneously enhanced NGF-mediated signaling, suggesting that as in neuronal cells 'signaling endosomes' are formed in hematopoietic cells. To examine the role of TrkA in CML cells, we studied cell growth or colony formation in the presence or absence of imatinib with or without NGF. We found that NGF treatment induces cell survival in imatinib-treated CML cell lines, as well as colony formation of primary CD34+ CML cells, strongly suggesting that NGF/TrkA signaling contributes to aberrant signaling in CML.	[Koch, A.; Breyer, B.; Mancini, A.; Tamura, T.] Hannover Med Sch, Inst Biochem, OE 4310, D-30623 Hannover, Germany; [Scherr, M.; Battmer, K.; Eder, M.] Hannover Med Sch, OE 6860, D-30623 Hannover, Germany; [Kardinal, C.] Hannover Med Sch, OE 6780, D-30623 Hannover, Germany	Hannover Medical School; Hannover Medical School; Hannover Medical School	Tamura, T (corresponding author), Hannover Med Sch, Inst Biochem, OE 4310, Carl Neuberg Str 1, D-30623 Hannover, Germany.	tamura.teruko@MH-Hannover.de						Blero D, 2001, BIOCHEM BIOPH RES CO, V282, P839, DOI 10.1006/bbrc.2001.4639; Bonati A, 2000, CANCER RES, V60, P728; Bracci-Laudiero L, 2003, J NEUROIMMUNOL, V136, P130, DOI 10.1016/S0165-5728(03)00007-9; Buchdunger E, 1996, CANCER RES, V56, P100; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Burton EA, 2003, EMBO J, V22, P5471, DOI 10.1093/emboj/cdg512; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Chen ZY, 2005, MOL BIOL CELL, V16, P5761, DOI 10.1091/mbc.E05-07-0651; CHEVALIER S, 1994, BLOOD, V83, P1479; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Giuriato S, 2002, BIOCHEM BIOPH RES CO, V296, P106, DOI 10.1016/S0006-291X(02)00787-8; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Howe CL, 2001, NEURON, V32, P801, DOI 10.1016/S0896-6273(01)00526-8; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Kaebisch A, 1996, BRIT J HAEMATOL, V95, P102, DOI 10.1046/j.1365-2141.1996.d01-1874.x; Koch A, 2005, ONCOGENE, V24, P3436, DOI 10.1038/sj.onc.1208558; Koch A, 2000, FEBS LETT, V469, P72, DOI 10.1016/S0014-5793(00)01242-4; Mancini A, 2002, J BIOL CHEM, V277, P14635, DOI 10.1074/jbc.M109214200; MATSUDA H, 1988, P NATL ACAD SCI USA, V85, P6508, DOI 10.1073/pnas.85.17.6508; Mulloy JC, 2005, P NATL ACAD SCI USA, V102, P4016, DOI 10.1073/pnas.0404701102; Muraille E, 1999, BIOCHEM J, V342, P697, DOI 10.1042/0264-6021:3420697; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; Rajagopal R, 2004, J NEUROSCI, V24, P6650, DOI 10.1523/JNEUROSCI.0010-04.2004; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Saxena S, 2005, MOL CELL NEUROSCI, V28, P571, DOI 10.1016/j.mcn.2004.11.011; Scheijen B, 2002, ONCOGENE, V21, P3314, DOI 10.1038/sj.onc.1205317; Scherr M, 2005, GENE THER, V12, P12, DOI 10.1038/sj.gt.3302328; Scherr M, 2003, BLOOD, V101, P1566, DOI 10.1182/blood-2002-06-1685; Scherr M, 2002, BLOOD, V99, P709, DOI 10.1182/blood.V99.2.709; Simone MD, 1999, HEMATOL ONCOL, V17, P1; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Tam SY, 1997, BLOOD, V90, P1807, DOI 10.1182/blood.V90.5.1807; Tanos B, 2006, J BIOL CHEM, V281, P32714, DOI 10.1074/jbc.M603126200; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; von Bubnoff N, 2003, LEUKEMIA, V17, P829, DOI 10.1038/sj.leu.2402889; Wang WL, 2000, ONCOGENE, V19, P3521, DOI 10.1038/sj.onc.1203698; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720; Yano H, 2000, J NEUROSCI RES, V59, P356, DOI 10.1002/(SICI)1097-4547(20000201)59:3<356::AID-JNR9>3.0.CO;2-G; Zhang YZ, 2000, J NEUROSCI, V20, P5671, DOI 10.1523/JNEUROSCI.20-15-05671.2000	46	23	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2008	27	34					4678	4689		10.1038/onc.2008.107	http://dx.doi.org/10.1038/onc.2008.107			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18427551				2022-12-17	WOS:000258236300006
J	Nittka, S; Bohm, C; Zentgraf, H; Neumaier, M				Nittka, S.; Boehm, C.; Zentgraf, H.; Neumaier, M.			The CEACAM1-mediated apoptosis pathway is activated by CEA and triggers dual cleavage of CEACAM1	ONCOGENE			English	Article						CEACAM1; apoptosis; CEA; caspases	CELL-ADHESION MOLECULE; CARCINOEMBRYONIC ANTIGEN FAMILY; BILIARY GLYCOPROTEIN CD66A; C-CAM; COLORECTAL CARCINOMAS; CYTOPLASMIC DOMAIN; EPITHELIAL-CELLS; HUMAN COLON; EXPRESSION; MEMBERS	Marked reduction in apoptosis is a hallmark of early colon tumour growth and the vast majority of these tumours exhibit a loss of expression of the glycoprotein carcinoembryonic-antigen-related cell adhesion molecule 1 (CEACAM1). We recently reported that the CEACAM1 functions as a mediator of apoptosis implicating this cell surface protein in early tumour development. However, the mechanistic involvement of CEACAM1 in cell death pathways is unclear. Here, we show that apoptosis triggers cleavage of the long form of CEACAM1 (CEACAM1-4L) at intracellular and extracellular sites in Jurkat cells and HEK293 cells. Signalling through CEACAM1 leads to caspase activation including caspase-1 and -3 and also involves non-caspase proteases. Moreover, we provide evidence that the naturally occurring CEACAM family member CEA is an inducer of CEACAM1-mediated apoptosis in HT29 colon cancer cells, an effect that depends on the abundance of CEACAM1 on the cell surface. Together, our results demonstrate that the CEACAM1-dependent cell death pathway involves dual cleavage of CEACAM1 and caspase activation and can be activated by CEA.	[Nittka, S.; Neumaier, M.] Univ Heidelberg, Inst Clin Chem, Univ Hosp Mannheim, D-68167 Mannheim, Germany; [Boehm, C.; Zentgraf, H.] German Canc Res Ctr, Dept Appl Tumor Virol, D-6900 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Neumaier, M (corresponding author), Univ Heidelberg, Inst Clin Chem, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	michael.neumaier@ikc.ma.uni-heidelberg.de						BARANOV V, 1994, CANCER RES, V54, P3305; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; BRUMMER J, 1995, ONCOGENE, V11, P1649; Charbonneau J, 1999, CELL ADHES COMMUN, V7, P233, DOI 10.3109/15419069909010805; Edlund M, 1998, FEBS LETT, V425, P166, DOI 10.1016/S0014-5793(98)00222-1; Edlund M, 1996, J BIOL CHEM, V271, P1393, DOI 10.1074/jbc.271.3.1393; Fournes B, 2001, ONCOGENE, V20, P219, DOI 10.1038/sj.onc.1204058; Frangsmyr L, 1999, TUMOR BIOL, V20, P277, DOI 10.1159/000030075; FRANGSMYR L, 1995, CANCER RES, V55, P2963; Hammarstrom S, 1999, SEMIN CANCER BIOL, V9, P67, DOI 10.1006/scbi.1998.0119; HEFTA SA, 1988, P NATL ACAD SCI USA, V85, P4648, DOI 10.1073/pnas.85.13.4648; Hilbi H, 1998, J BIOL CHEM, V273, P32895, DOI 10.1074/jbc.273.49.32895; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; Houde C, 2003, J BIOL CHEM, V278, P16929, DOI 10.1074/jbc.M301842200; Huang J, 1999, J CELL SCI, V112, P4193; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; Kirshner J, 2003, P NATL ACAD SCI USA, V100, P521, DOI 10.1073/pnas.232711199; Kunath T, 1995, ONCOGENE, V11, P2375; Liu KB, 2003, J IMMUNOL, V170, P6329, DOI 10.4049/jimmunol.170.12.6329; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nittka S, 2004, ONCOGENE, V23, P9306, DOI 10.1038/sj.onc.1208259; Nollau P, 1997, AM J PATHOL, V151, P521; Nollau P, 1997, CANCER RES, V57, P2354; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; PAXTON RJ, 1987, P NATL ACAD SCI USA, V84, P920, DOI 10.1073/pnas.84.4.920; RONCUCCI L, 1991, HUM PATHOL, V22, P287, DOI 10.1016/0046-8177(91)90163-J; Singer BB, 2000, CANCER RES, V60, P1236; Vancompernolle K, 1998, FEBS LETT, V438, P150, DOI 10.1016/S0014-5793(98)01275-7; Watt SM, 2001, BLOOD, V98, P1469, DOI 10.1182/blood.V98.5.1469	29	23	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2008	27	26					3721	3728		10.1038/sj.onc.1211033	http://dx.doi.org/10.1038/sj.onc.1211033			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18278069				2022-12-17	WOS:000256659300009
J	Helton, ES; Zhang, J; Chen, X				Helton, E. S.; Zhang, J.; Chen, X.			The proline-rich domain in p63 is necessary for the transcriptional and apoptosis-inducing activities of TAp63	ONCOGENE			English	Article						p53 family; p63; transcription; cell cycle; apoptosis	TARGET GENES; P53 FAMILY; MOUSE MODELS; TUMOR-CELLS; DELTA-NP63-ALPHA; IDENTIFICATION; HOMOLOG; ARREST; MUTANT; LIMB	p63 shares considerable sequence identity with p53, especially in its DNA-binding, activation and tetramerization domains. When the upstream promoter is used for p63 expression, three major transactivation p63 (TAp63) isoforms (alpha, beta and gamma) are produced. p63 is also expressed from an alternate promoter located in intron 3, producing three major Delta Np63 isoforms. Recent studies demonstrated that p63 has the potential to function as a tumor suppressor or an oncoprotein. To further address this, we generated cell lines that inducibly express each TAp63 isoform. We showed that TAp63 isoforms are capable of inducing p53-responsive genes, inhibiting cell proliferation and promoting apoptosis. Interestingly, we discovered that both the activation domain (residues 1-59) and the proline-rich domain (residues 67-127) are required for TAp63 transcriptional activity. Likewise, TAp63 beta(Delta PRD), deleted of residues 60-133, possessed a greatly attenuated ability to induce endogenous target genes and promote apoptosis, but retained the ability to inhibit cell proliferation when expressed in stable, inducible cell lines. TAp63 beta(Delta PRD) also functioned as a dominant negative to wild-type p63 beta in a dose-dependent manner. Furthermore, the loss of function seen with deletion of the proline-rich domain was not due to a DNA-binding defect, as TAp63 beta(Delta PRD) was found to strongly bind endogenous promoters using chromatin immunoprecipitation assay. Finally, mutational analysis revealed that a PXXP motif at residues 124-127 contributes to the transcriptional activity of TAp63. Altogether, our findings suggest that TAp63 transcriptional activity can be regulated by modification(s) of, or protein interactions with, the p63 proline-rich domain.	[Helton, E. S.; Zhang, J.; Chen, X.] Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Ctr Comparat Oncol, Davis, CA 95616 USA	University of California System; University of California Davis	Chen, X (corresponding author), Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Ctr Comparat Oncol, 2128 Tupper Hall, Davis, CA 95616 USA.	xbchen@ucdavis.edu			NATIONAL CANCER INSTITUTE [R01CA102188] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102188, R01 CA102188-07, CA102188] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attardi LD, 2005, MUTAT RES-FUND MOL M, V576, P4, DOI 10.1016/j.mrfmmm.2004.08.022; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Boyle JM, 1998, BRIT J CANCER, V77, P2181, DOI 10.1038/bjc.1998.364; Brunner HG, 2002, AM J MED GENET, V112, P284, DOI 10.1002/ajmg.10778; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Edwards SJ, 2003, ONCOGENE, V22, P4517, DOI 10.1038/sj.onc.1206726; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Ghioni P, 2002, MOL CELL BIOL, V22, P8659, DOI 10.1128/MCB.22.24.8659-8668.2002; Gressner O, 2005, EMBO J, V24, P2458, DOI 10.1038/sj.emboj.7600708; Harms KL, 2005, MOL CELL BIOL, V25, P2014, DOI 10.1128/MCB.25.5.2014-2030.2005; Helton ES, 2006, J BIOL CHEM, V281, P2533, DOI 10.1074/jbc.M507964200; King KE, 2003, ONCOGENE, V22, P3635, DOI 10.1038/sj.onc.1206536; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Phang BH, 2007, ONCOGENE, V26, P2964, DOI 10.1038/sj.onc.1210112; Senoo M, 2004, CANCER CELL, V6, P85, DOI 10.1016/j.ccr.2004.06.005; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Willis A, 2004, ONCOGENE, V23, P2330, DOI 10.1038/sj.onc.1207396; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	24	23	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2008	27	20					2843	2850		10.1038/sj.onc.1210948	http://dx.doi.org/10.1038/sj.onc.1210948			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18037962	Green Accepted			2022-12-17	WOS:000255502500005
J	Odgerel, T; Kikuchi, J; Wada, T; Shimizu, R; Futaki, K; Kano, Y; Furukawa, Y				Odgerel, T.; Kikuchi, J.; Wada, T.; Shimizu, R.; Futaki, K.; Kano, Y.; Furukawa, Y.			The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations	ONCOGENE			English	Article						FLT3 inhibitor; leukemia; cell cycle; CDC2; CDC25; bad	INTERNAL TANDEM DUPLICATION; TYROSINE KINASE INHIBITOR; ACUTE MYELOID-LEUKEMIA; SIGNAL-TRANSDUCTION; DEATH MACHINERY; BAD; PHOSPHORYLATION; PROTEIN; STAUROSPORINE; ACTIVATION	PKC412 is a staurosporine derivative that inhibits several protein kinases including FLT3, and is highly anticipated as a novel therapeutic agent for acute myeloblastic leukemia (AML) carrying FLT3 mutations. In this study, we show that PKC412 exerts differential cell cycle effects on AML cells depending on the presence of FLT3 mutations. PKC412 elicits massive apoptosis without markedly affecting cell cycle patterns in AML cell lines with FLT3 mutations (MV4-11 and MOLM13), whereas it induces G(2) arrest but not apoptosis in AML cell lines without FLT3 mutations (THP-1 and U937). In MV4-11 and MOLM13 cells, PKC412 inactivates Myt-1 and activates CDC25c, leading to the activation of CDC2. Activated CDC2 phosphorylates Bad at serine-128 and facilitates its translocation to the mitochondria, where Bad triggers apoptosis. In contrast, PKC412 inactivates CDC2 by inducing serine-216 phosphorylation and subsequent cytoplasmic sequestration of CDC25c in THP-1 and U937 cells. As a result, cells are arrested in the G2 phase of the cell cycle, but do not undergo apoptosis because Bad is not activated. The FLT3 mutation-dependent differential cell cycle effect of PKC412 is considered an important factor when PKC412 is combined with cell cycle-specific anticancer drugs in the treatment of cancer and leukemia.	[Odgerel, T.; Kikuchi, J.; Wada, T.; Shimizu, R.; Futaki, K.; Furukawa, Y.] Ctr Mol Med, Jichi Med Sch, Div Stem Cell Regulat, Shimotsuke, Tochigi 3290498, Japan	Jichi Medical University	Furukawa, Y (corresponding author), Ctr Mol Med, Jichi Med Sch, Div Stem Cell Regulat, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.	furuyu@jichi.ac.jp	Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418				Begemann M, 1998, ANTICANCER RES, V18, P2275; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; Furukawa Y, 2007, LEUKEMIA, V21, P1005, DOI 10.1038/sj.leu.2404593; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Galonek HL, 2006, NAT CELL BIOL, V8, P1317, DOI 10.1038/ncb1206-1317; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Green DR, 2006, CANCER CELL, V9, P328, DOI 10.1016/j.ccr.2006.05.004; Griffin JD, 2004, HEMATOL J, V5, pS188, DOI 10.1038/sj.thj.6200450; Ikegami Y, 1996, ARZNEIMITTEL-FORSCH, V46, P201; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; Kim KT, 2006, BRIT J HAEMATOL, V134, P500, DOI 10.1111/j.1365-2141.2006.06225.x; Kiyoi H, 1997, LEUKEMIA, V11, P1447, DOI 10.1038/sj.leu.2400756; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; Levis M, 2005, INT J HEMATOL, V82, P100, DOI 10.1532/IJH97.05079; Levis M, 2004, BLOOD, V104, P1145, DOI 10.1182/blood-2004-01-0388; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; Neben K, 2005, ONCOGENE, V24, P1580, DOI 10.1038/sj.onc.1208344; Propper DJ, 2001, J CLIN ONCOL, V19, P1485, DOI 10.1200/JCO.2001.19.5.1485; Quentmeier H, 2003, LEUKEMIA, V17, P120, DOI 10.1038/sj.leu.2402740; Schmitt E, 2007, ONCOGENE, V26, P5851, DOI 10.1038/sj.onc.1210396; SMALL D, 1994, P NATL ACAD SCI USA, V91, P459, DOI 10.1073/pnas.91.2.459; Stone RM, 2005, BLOOD, V105, P54, DOI 10.1182/blood-2004-03-0891; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Weisberg E, 2002, CANCER CELL, V1, P433, DOI 10.1016/S1535-6108(02)00069-7; Yang XP, 2005, CANCER RES, V65, P7338, DOI 10.1158/0008-5472.CAN-04-2263; Yao Q, 2003, CLIN CANCER RES, V9, P4483; Yee KWH, 2004, BLOOD, V104, P4202, DOI 10.1182/blood-2003-10-3381; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	29	23	24	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	22					3102	3110		10.1038/sj.onc.1210980	http://dx.doi.org/10.1038/sj.onc.1210980			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18071308				2022-12-17	WOS:000255897600003
J	Olshavsky, NA; Groh, EM; Comstock, CES; Morey, LM; Wang, Y; Revelo, MP; Burd, C; Meller, J; Knudsen, KE				Olshavsky, N. A.; Groh, E. M.; Comstock, C. E. S.; Morey, L. M.; Wang, Y.; Revelo, M. P.; Burd, C.; Meller, J.; Knudsen, K. E.			Cyclin D3 action in androgen receptor regulation and prostate cancer	ONCOGENE			English	Article						cell cycle; prostatic adenocarcinoma; CDK; PSA and G1	VITAMIN-D-RECEPTOR; D-DEPENDENT KINASE; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVITY; CELL-LINES; D1-DEPENDENT KINASE; BINDING DOMAIN; GROWTH-FACTOR; CO-REPRESSOR; G(1) PHASE	Prostate cancer (PCa) cell proliferation is dependent on activation of the androgen receptor (AR), a ligand-dependent transcription factor. AR activation controls G1-S phase progression through fostering enhanced translation of the D-type cyclins, which promote cell cycle progression through activation of CDK4/6. However, the D-type cyclins harbor additional, CDK4/6 kinase-independent, functions through manipulation of transcription factors, including AR. It was previously established that cyclins D1 and D3 have the potential to modulate AR, and with regard to cyclin D1, disruption of this function occurs in human tumors. Therefore, it was essential to interrogate cyclin D3 function in this tumor type. Here, we show that cyclin D3 is found in association with AR in PCa cells, as mediated through a conserved motif. Cyclin D3 functions to attenuate AR activity through defined mechanisms that include modulation of ligand-dependent conformational changes and modulation of chromatin binding activity. Accumulated cyclin D3 slows cell proliferation in AR-dependent cells, thus suggesting that androgen-induced D-type cyclin production serves to temper the mitogenic response to androgen. Supporting this hypothesis, it is shown that cyclin D3 expression is reduced in primary PCas as a function of tumor grade, and inversely correlates with the proliferative index. In total, these data identify cyclin D3 as a critical modulator of the androgen response, whose deregulation may foster unchecked AR activity in PCa.	[Olshavsky, N. A.; Groh, E. M.; Comstock, C. E. S.; Morey, L. M.; Wang, Y.; Knudsen, K. E.] Univ Cincinnati, Coll Med, Vontz Ctr Mol Studies, Dept Cell & Canc Biol, Cincinnati, OH 45267 USA; [Revelo, M. P.] Univ Utah, Dept Pathol & Lab Med, Salt Lake City, UT USA; [Burd, C.] NIEHS, Mol Carcinogenesis Lab, Res Triangle Pk, NC 27709 USA; [Meller, J.; Knudsen, K. E.] Univ Cincinnati, Coll Med, UC Canc Ctr, Cincinnati, OH USA; [Meller, J.] Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA; [Knudsen, K. E.] Univ Cincinnati, Coll Med, Ctr Environm Genet, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; Utah System of Higher Education; University of Utah; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Knudsen, KE (corresponding author), Univ Cincinnati, Coll Med, Vontz Ctr Mol Studies, Dept Cell & Canc Biol, 3125 Eden Ave,ML0521, Cincinnati, OH 45267 USA.	Karen.Knudsen@uc.edu	Meller, Jaroslaw/A-1971-2011; Duch, Wlodzislaw/A-2002-2011; Comstock, Clay/B-6122-2008	Meller, Jaroslaw/0000-0002-1162-8253; Duch, Wlodzislaw/0000-0001-7882-4729; Comstock, Clay/0000-0001-5867-1489; Knudsen, Karen/0000-0002-1301-890X; Burd, Craig/0000-0002-6899-6751	NCI NIH HHS [CA116777, T32 CA117846, T32-CA117846, CA099996] Funding Source: Medline; NIEHS NIH HHS [T32-ES07250] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA099996, R01CA116777, T32CA117846] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007250] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARAP W, 1995, CANCER RES, V55, P1351; Bienvenu F, 2001, J BIOL CHEM, V276, P16840, DOI 10.1074/jbc.M100795200; Braden WA, 2006, MOL CELL BIOL, V26, P7667, DOI 10.1128/MCB.00045-06; Burd CJ, 2006, P NATL ACAD SCI USA, V103, P2190, DOI 10.1073/pnas.0506281103; Burd CJ, 2005, MOL ENDOCRINOL, V19, P607, DOI 10.1210/me.2004-0266; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Comstock CES, 2007, BRIT J CANCER, V96, P970, DOI 10.1038/sj.bjc.6603615; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Ewen ME, 2004, TRENDS MOL MED, V10, P158, DOI 10.1016/j.molmed.2004.02.005; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fribourg AF, 2000, CELL GROWTH DIFFER, V11, P361; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Fu MF, 2005, J BIOL CHEM, V280, P16934, DOI 10.1074/jbc.M500403200; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; Hedberg Y, 2002, ACTA ONCOL, V41, P175, DOI 10.1080/028418602753669562; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Jian YZ, 2005, BIOCHEM BIOPH RES CO, V335, P739, DOI 10.1016/j.bbrc.2005.07.141; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kato A, 1998, BIOCHEM BIOPH RES CO, V245, P70, DOI 10.1006/bbrc.1998.8377; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KIESS M, 1995, ONCOGENE, V10, P159; Knudsen KE, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-15; Knudsen KE, 1999, CANCER RES, V59, P2297; Knudsen KE, 2006, ONCOGENE, V25, P1620, DOI 10.1038/sj.onc.1209371; Knudsen KE, 1998, J BIOL CHEM, V273, P20213, DOI 10.1074/jbc.273.32.20213; Lamb J, 2000, MOL CELL BIOL, V20, P8667, DOI 10.1128/MCB.20.23.8667-8675.2000; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; LI J, 2007, MOL ENDOCRINOL; Lim J, 2000, MOL ENDOCRINOL, V14, P1187, DOI 10.1210/me.14.8.1187; Lim JTE, 2005, P NATL ACAD SCI USA, V102, P5156, DOI 10.1073/pnas.0501203102; Lin HM, 2002, J BIOL CHEM, V277, P28733, DOI 10.1074/jbc.M203380200; Link KA, 2005, MOL CELL BIOL, V25, P2200, DOI 10.1128/MCB.25.6.2200-2215.2005; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Miehlke S, 2002, DIGEST DIS SCI, V47, P1248, DOI 10.1023/A:1015358127751; Miller GJ, 1995, CLIN CANCER RES, V1, P997; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Parry D, 1999, MOL CELL BIOL, V19, P1775; Perry JE, 1998, PROSTATE, V35, P117; Peterson LF, 2005, MOL CELL BIOL, V25, P10205, DOI 10.1128/MCB.25.23.10205-10219.2005; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; Petre-Draviam CE, 2005, ONCOGENE, V24, P431, DOI 10.1038/sj.onc.1208200; Petre-Draviam CE, 2003, CANCER RES, V63, P4903; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; RUNDLETT SE, 1990, MOL ENDOCRINOL, V4, P708, DOI 10.1210/mend-4-5-708; Sarruf DA, 2005, MOL CELL BIOL, V25, P9985, DOI 10.1128/MCB.25.22.9985-9995.2005; SCHWARTZ GG, 1994, ANTICANCER RES, V14, P1077; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SKOWRONSKI RJ, 1993, ENDOCRINOLOGY, V132, P1952, DOI 10.1210/en.132.5.1952; Timchenko LT, 2006, J BIOL CHEM, V281, P32806, DOI 10.1074/jbc.M605701200; Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159-6173.2003; Wang GL, 2006, MOL CELL BIOL, V26, P2570, DOI 10.1128/MCB.26.7.2570-2582.2006; Wang GL, 2007, J BIOL CHEM, V282, P1468, DOI 10.1074/jbc.M608226200; Wetherill YB, 2006, MOL CANCER THER, V5, P3181, DOI 10.1158/1535-7163.MCT-06-0272; Xu YY, 2006, CANCER RES, V66, P7783, DOI 10.1158/0008-5472.CAN-05-4472; Zhuang SH, 1997, MOL CELL ENDOCRINOL, V126, P83, DOI 10.1016/S0303-7207(96)03974-3; Zong HL, 2007, MOL CELL BIOL, V27, P7125, DOI 10.1128/MCB.01753-06; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	69	23	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	22					3111	3121		10.1038/sj.onc.1210981	http://dx.doi.org/10.1038/sj.onc.1210981			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18084330				2022-12-17	WOS:000255897600004
J	Pan, Q; Zhu, YJ; Gu, BW; Cai, X; Bai, XT; Yun, HY; Zhu, J; Chen, B; Weng, L; Chen, Z; Xue, YQ; Chen, SJ				Pan, Q.; Zhu, Y-J; Gu, B-W; Cai, X.; Bai, X-T; Yun, H-Y; Zhu, J.; Chen, B.; Weng, L.; Chen, Z.; Xue, Y-Q; Chen, S-J			New fusion gene NUP98-IQCG identified in an acute T-lymphoid/myeloid leukemia with a t(3;11)(q29q13;p15)del(3)(q29) translocation	ONCOGENE			English	Article						NUP98-IQCG; fusion gene; acute T-lymphoid/myeloid leukemia	ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; PARTNER GENE; NUCLEAR-PORE; FG REPEATS; NUP98-HOXA9; LEUKEMOGENESIS; ABNORMALITIES; PROLIFERATION; DYSREGULATION	NUP98 has been involved in multiple recurrent chromosome rearrangements in leukemia. We identified a novel fusion between NUP98 and IQ motif containing G (IQCG) gene from a de novo acute T-lymphoid/myeloid leukemia harboring t(3;11)(q29q13;p15)del(3)(q29). IQCG has two putative coiled-coil domains and one IQ domain. The FG repeat from NUP98 and the coiled-coil domain from IQCG were retained in the fusion protein. We demonstrated that NUP98-IQCG could form homodimer, heterodimerize with NUP98 or IQCG, bind coactivators and/or co-repressors, and show transcriptional activity in vitro. Expression of NUP98-IQCG inhibited 32Dcl3 cell apoptosis induced by Ara-C, and partially blocked granulocyte differentiation induced by G-CSF. Colony-forming assay and serial replating assays indicated that NUP98-IQCG was able to stimulate proliferation, partially block differentiation of hematopoietic stem/progenitor cells but was unable to confer transformation alone. Taken together, our data indicate that newly identified NUP98-IQCG fusion protein may play an essential role in leukemogenesis, but by itself may not be sufficient to induce leukemia.	[Pan, Q.; Gu, B-W; Cai, X.; Bai, X-T; Yun, H-Y; Zhu, J.; Chen, B.; Weng, L.; Chen, Z.; Chen, S-J] Shanghai Jiao Tong Univ, Sch Med, State Key Lab Med Genom, Shanghai Inst Hematol,Ruijin Hosp, Shanghai 200030, Peoples R China; [Zhu, Y-J; Xue, Y-Q] Soochow Univ, Affiliated Hosp 1, JiangSu Inst Hematol, Leukemia Res Unit, Suzhou, Peoples R China	Chinese Academy of Sciences; Shanghai Jiao Tong University; Soochow University - China	Chen, SJ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, State Key Lab Med Genom, Shanghai Inst Hematol,Ruijin Hosp, 197,Ruijin Rd 2, Shanghai 200030, Peoples R China.	uujihsmc@public1.sz.js.cn; sjchen@stn.sh.cn		Yun, Haiyang/0000-0001-8714-205X				Bai XT, 2006, CANCER RES, V66, P4584, DOI 10.1158/0008-5472.CAN-05-3101; Chung KY, 2006, CANCER RES, V66, P11781, DOI 10.1158/0008-5472.CAN-06-0706; Gervais C, 2005, LEUKEMIA, V19, P145, DOI 10.1038/sj.leu.2403565; Gu BW, 2003, LEUKEMIA, V17, P1858, DOI 10.1038/sj.leu.2403036; Gurevich RM, 2004, BLOOD, V104, P1127, DOI 10.1182/blood-2003-10-3550; Iwasaki M, 2005, BLOOD, V105, P784, DOI 10.1182/blood-2004-04-1508; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Kroon E, 2001, EMBO J, V20, P350, DOI 10.1093/emboj/20.3.350; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Lin YW, 2005, BLOOD, V106, P287, DOI 10.1182/blood-2004-12-4794; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Moore MAS, 2007, ANN NY ACAD SCI, V1106, P114, DOI 10.1196/annals.1392.019; Nakamura T, 2005, INT J HEMATOL, V82, P21, DOI 10.1532/IJH97.04160; Nebral K, 2005, CLIN CANCER RES, V11, P6489, DOI 10.1158/1078-0432.CCR-05-0150; Ohta H, 2007, EXP HEMATOL, V35, P817, DOI 10.1016/j.exphem.2007.02.012; Panagopoulos I, 2007, BRIT J HAEMATOL, V136, P294, DOI 10.1111/j.1365-2141.2006.06410.x; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; Reader JC, 2007, LEUKEMIA, V21, P842, DOI 10.1038/sj.leu.2404579; Shaffer LG., 2005, INT SYSTEM HUMAN CYT; Slape C, 2004, LEUKEMIA LYMPHOMA, V45, P1341, DOI 10.1080/10428190310001659325; Takeda A, 2006, CANCER RES, V66, P6628, DOI 10.1158/0008-5472.CAN-06-0458; Tosi S, 2005, GENE CHROMOSOME CANC, V44, P225, DOI 10.1002/gcc.20233; van Zutven LJCM, 2006, GENE CHROMOSOME CANC, V45, P437, DOI 10.1002/gcc.20308; Wang GG, 2007, NAT CELL BIOL, V9, P804, DOI 10.1038/ncb1608; Xu L, 2001, LEUKEMIA, V15, P1359, DOI 10.1038/sj.leu.2402205	25	23	25	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	24					3414	3423		10.1038/sj.onc.1210999	http://dx.doi.org/10.1038/sj.onc.1210999			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18084320				2022-12-17	WOS:000256309900006
J	Savio, MG; Rotondo, G; Maglie, S; Rossetti, G; Bender, JR; Pardi, R				Savio, M. G.; Rotondo, G.; Maglie, S.; Rossetti, G.; Bender, J. R.; Pardi, R.			COP1D, an alternatively spliced constitutive photomorphogenic-1 (COP1) product, stabilizes UV stress-induced c-Jun through inhibition of full-length COP1	ONCOGENE			English	Article						AP-1; transcription; ubiquitin ligase; alternative splicing; genotoxic stress	UBIQUITIN LIGASE COP1; TRANSCRIPTION FACTORS; NEGATIVE REGULATOR; P53; PROTEIN; KINASES; CELLS; TRANSACTIVATION; DEGRADATION; EXPRESSION	COP1 is an evolutionarily conserved RING-finger ubiquitin ligase acting within a Cullin- RING ligase ( CRL) complex that promotes polyubiquitination of c- Jun and p53. Stability of the above substrates is affected by post-translational changes priming the proteins for polyubiquitination and proteasome- dependent degradation. However, degradation of both substrates is controlled indirectly by signaling pathways affecting the E3 ligases involved in their polyubiquitination. Here, we report the identification of COP1D, a ubiquitously expressed splice variant of COP1 lacking a portion of a coiled- coil region involved in intermolecular associations. While being unable to associate with other components of the CRL complex, COP1D exerts a dominant- negative function over the full- length protein, due to its ability to heterodimerize with COP1 and sequester it from the enzymatically active complex. Ectopic expression of COP1D antagonizes the function of COP1, while its selective downregulation by RNA interference promotes more efficient degradation of c- Jun and p53 by the full- length protein. The COP1/ COP1D mRNA ratio is modulated by UV stress and a decreased COP1/ COP1D ratio correlates with elevated c- Jun, but not p53 protein levels in invasive ductal breast cancer. Thus, dynamic changes of the COP1/ COP1D ratio provide an additional level of regulation of the half-life of the substrates of this E3 ligase under homeostatic or pathological conditions.	[Savio, M. G.; Rotondo, G.; Maglie, S.; Rossetti, G.; Pardi, R.] Univ Vita Salute San Raffaele, Sch Med, DIBIT Sci Inst San Raffaele, Unit Leukocyte Biol, I-20132 Milan, Italy; [Bender, J. R.] Yale Univ, Sch Med, Sect Cardiovasc Med, Raymond & Beverly Sackler Fdn Cardiovasc Lab, New Haven, CT USA	Vita-Salute San Raffaele University; Yale University	Pardi, R (corresponding author), Univ Vita Salute San Raffaele, Sch Med, DIBIT Sci Inst San Raffaele, Unit Leukocyte Biol, I-20132 Milan, Italy.	pardi.ruggero@hsr.it	rossetti, grazisa/C-3722-2015	rossetti, grazisa/0000-0001-6361-311X; Rotondo, Giuseppe/0000-0001-7811-1753	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043331] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL43331] Funding Source: Medline	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bianchi E, 2003, J BIOL CHEM, V278, P19682, DOI 10.1074/jbc.M212681200; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Dornan D, 2004, CANCER RES, V64, P7226, DOI 10.1158/0008-5472.CAN-04-2601; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Dornan D, 2006, SCIENCE, V313, P1122, DOI 10.1126/science.1127335; Feng LJ, 2005, MOL CELL BIOL, V25, P5389, DOI 10.1128/MCB.25.13.5389-5395.2005; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Koivusalo R, 2006, CANCER RES, V66, P11817, DOI 10.1158/0008-5472.CAN-06-2185; Krummel KA, 2005, P NATL ACAD SCI USA, V102, P10188, DOI 10.1073/pnas.0503068102; Langer S, 2006, EUR J GYNAECOL ONCOL, V27, P345; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Reed SE, 2004, CANCER RES, V64, P795, DOI 10.1158/0008-5472.CAN-03-3417; Shin C, 2004, NAT REV MOL CELL BIO, V5, P727, DOI 10.1038/nrm1467; Subramanian C, 2004, P NATL ACAD SCI USA, V101, P6798, DOI 10.1073/pnas.0307964101; Torii KU, 1998, EMBO J, V17, P5577, DOI 10.1093/emboj/17.19.5577; Tsuge T, 2001, MOL GENET GENOMICS, V265, P43, DOI 10.1007/s004380000396; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Wertz IE, 2004, SCIENCE, V303, P1371, DOI 10.1126/science.1093549; Yanagawa Y, 2004, GENE DEV, V18, P2172, DOI 10.1101/gad.1229504; Yi CL, 2005, TRENDS CELL BIOL, V15, P618, DOI 10.1016/j.tcb.2005.09.007; Yi CL, 2005, CANCER RES, V65, P5835, DOI 10.1158/0008-5472.CAN-05-0423	28	23	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2401	2411		10.1038/sj.onc.1210892	http://dx.doi.org/10.1038/sj.onc.1210892			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17968316				2022-12-17	WOS:000254844900005
J	Ueki, N; Zhang, L; Haymann, MJ				Ueki, N.; Zhang, L.; Haymann, M. J.			Ski can negatively regulates macrophage differentiation through its interaction with PU.1	ONCOGENE			English	Article						ski oncoprotein; PU.1; HDAC3; hematopoiesis; leukemogenesis; transcriptional repression	TRANSFORMING-GROWTH-FACTOR; TRANSCRIPTION FACTOR PU.1; ACUTE MYELOID-LEUKEMIA; CO-REPRESSOR; ERYTHROID-DIFFERENTIATION; V-SKI; HEMATOPOIETIC-CELLS; LINEAGE COMMITMENT; DNA-BINDING; ONCOPROTEIN	In the hematopoietic cell system, the oncoprotein Ski dramatically affects growth and differentiation programs, in some cases leading to malignant leukemia. However, little is known about the interaction partners or signaling pathways involved in the Ski-mediated block of differentiation in hematopoietic cells. Here we show that Ski interacts with PU.1, a lineage-specific transcription factor essential for terminal myeloid differentiation, and thereby represses PU.1-dependent transcriptional activation. Consistent with this, Ski inhibits the biological function of PU.1 to promote myeloid cells to differentiate into macrophage colony-stimulating factor receptor (M-CSFR)positive macrophages. Using a Ski mutant deficient in PU.1 binding, we demonstrate that Ski-PU.1 interaction is critical for Ski's ability to repress PU.1-dependent transcription and block macrophage differentiation. Furthermore, we provide evidence that Ski-mediated repression of PU.1 is due to Ski's ability to recruit histone deacetylase 3 to PU.1 bound to DNA. Since inactivation of PU.1 is closely related to the development of myeloid leukemia and Ski strongly inhibits PU.1 function, we propose that aberrant Ski expression in certain types of myeloid cell lineages might contribute to leukemogenesis.	[Ueki, N.; Zhang, L.; Haymann, M. J.] SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Haymann, MJ (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.	mhayman@ms.cc.sunysb.edu			NATIONAL CANCER INSTITUTE [R01CA042573] Funding Source: NIH RePORTER; NCI NIH HHS [CA42573, R01 CA042573-20, R01 CA042573] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Ano S, 2004, J BIOL CHEM, V279, P2993, DOI 10.1074/jbc.M303816200; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; BEUG H, 1995, ONCOGENE, V11, P59; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; Dahl R, 2003, BLOOD CELL MOL DIS, V31, P229, DOI 10.1016/S1079-9796(03)00152-9; Dahl R, 2007, J BIOL CHEM, V282, P6473, DOI 10.1074/jbc.M607613200; Fukuchi M, 2004, INT J CANCER, V108, P818, DOI 10.1002/ijc.11651; Jepsen K, 2002, J CELL SCI, V115, P689; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kronenwett R, 2005, ONCOGENE, V24, P5313, DOI 10.1038/sj.onc.1208596; LARSEN J, 1992, ONCOGENE, V7, P1903; LARSEN J, 1993, ONCOGENE, V8, P3221; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Metcalf D, 2006, P NATL ACAD SCI USA, V103, P1486, DOI 10.1073/pnas.0510616103; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Ohneda K, 2002, ACTA HAEMATOL-BASEL, V108, P237, DOI 10.1159/000065660; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; Reed JA, 2001, CANCER RES, V61, P8074; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Ritter M, 2006, LEUKEMIA, V20, P437, DOI 10.1038/sj.leu.2404093; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Simon MC, 1996, CURR TOP MICROBIOL, V211, P113; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Suzuki M, 2003, ONCOGENE, V22, P8688, DOI 10.1038/sj.onc.1207182; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Ueki N, 2004, MOL CELL BIOL, V24, P10118, DOI 10.1128/MCB.24.23.10118-10125.2004; Ueki N, 2003, J BIOL CHEM, V278, P32489, DOI 10.1074/jbc.C300276200; Ueki N, 2003, J BIOL CHEM, V278, P24858, DOI 10.1074/jbc.M303447200; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	39	23	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2008	27	3					300	307		10.1038/sj.onc.1210654	http://dx.doi.org/10.1038/sj.onc.1210654			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249UR	17621263	Green Accepted			2022-12-17	WOS:000252256000005
J	Venkatachalam, P; de Toledo, S; Pandey, B; Tephly, L; Carter, A; Little, J; Spitz, D; Azzam, E				Venkatachalam, P.; de Toledo, Sm; Pandey, Bn; Tephly, La; Carter, Ab; Little, Jb; Spitz, Dr; Azzam, Ei			Regulation of normal cell cycle progression by flavin-containing oxidases	ONCOGENE			English	Article						flavin-containing oxidases; NAD(P)H oxidase/nitric oxide synthase; reactive oxygen species; cellular proliferation/G1 checkpoint/G2 checkpoint; ATM/p53/p21(Waf1)/p38(MAPK)/cyclin D1	NORMAL HUMAN FIBROBLASTS; DOSE IONIZING-RADIATION; SIGNAL-TRANSDUCTION; HYDROGEN-PEROXIDE; DIPHENYLENE IODONIUM; NADPH OXIDASE; FREE-RADICALS; DNA-SYNTHESIS; SUPEROXIDE; KINASE	Mechanisms underlying the role of reactive oxygen species (ROS) generated by flavin-containing oxidases in regulating cell cycle progression were examined in human and rodent fibroblasts. Incubation of confluent cell cultures with nontoxic/nonclastogenic concentrations of the flavoprotein inhibitor, diphenyleneiodonium (DPI), reduced nicotinamide adenine dinucleotide phosphate (NAD(P) H) oxidase activity and basal ROS levels, but increased proteolysis of cyclin D1, p21(Waf1) and phospho-p38(MAPK). When these cells were allowed to proliferate by subculture in DPI-free medium, an extensive G(1) delay was observed with concomitant activation of p53/p21(Waf1) signaling and reduced phosphorylation of mitogen-activated kinases. Compensation for decreased oxidant generation by simultaneous exposure to DPI and nontoxic doses of the ROS generators, gamma-radiation or t-butyl-hydroperoxide, attenuated the G(1) delay. Whereas the DPI-induced G(1) checkpoint was completely dependent on PHOX91, ATM and WAF1, it was only partially dependent on P53. Interestingly, G(1) to S progression was not affected when another flavin-containing enzyme, nitric oxide synthase, was inhibited nor was it associated with changes in mitochondrial membrane potential. Proliferating cells treated with DPI also experienced a significant but attenuated delay in G(2). We propose that ATM performs a critical function in mediating normal cellular proliferation that is regulated by nonphagocytic NAD(P)H oxidase enzymes activity, which may serve as a novel target for arresting cancer cells in G1.	[Venkatachalam, P.; de Toledo, Sm; Pandey, Bn; Azzam, Ei] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Radiol, Newark, NJ 07101 USA; [Tephly, La; Carter, Ab] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Med, Iowa City, IA USA; [Little, Jb] Harvard Univ, Sch Publ Hlth, Ctr Radiat Sci & Environm Hlth, Boston, MA 02115 USA; [Spitz, Dr] Univ Iowa, Holden Comprehens Canc Ctr, Free Rad & Radiat Biol Program, Dept Radiat Oncol, Iowa City, IA USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Iowa; Harvard University; Harvard T.H. Chan School of Public Health; University of Iowa	Azzam, E (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Radiol, 185 S Orange Ave,MSB F-451, Newark, NJ 07101 USA.	azzamei@umdnj.edu	Venkatachalam, Perumal/AAU-9320-2020	Venkatachalam, Perumal/0000-0003-2152-2003; Spitz, Douglas/0000-0002-1254-8765	NCI NIH HHS [CA92262] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092262] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 2002, CANCER LETT, V177, P111, DOI 10.1016/S0304-3835(01)00785-6; Ammendola R, 2002, ARCH BIOCHEM BIOPHYS, V397, P253, DOI 10.1006/abbi.2001.2641; Azzam EI, 1997, CELL GROWTH DIFFER, V8, P1161; Azzam EI, 2002, CANCER RES, V62, P5436; Azzam EI, 1996, RADIAT RES, V146, P369, DOI 10.2307/3579298; Azzam EI, 2000, CANCER RES, V60, P2623; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BEGG AC, 1985, CYTOMETRY, V6, P620, DOI 10.1002/cyto.990060618; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Cals-Grierson MM, 2004, NITRIC OXIDE-BIOL CH, V10, P179, DOI 10.1016/j.niox.2004.04.005; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CHO KR, 1992, CANCER, V70, P1727, DOI 10.1002/1097-0142(19920915)70:4+<1727::AID-CNCR2820701613>3.0.CO;2-P; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; de Toledo SM, 1998, CELL GROWTH DIFFER, V9, P887; de Toledo SM, 2000, ONCOGENE, V19, P6185, DOI 10.1038/sj.onc.1204020; de Toledo SM, 2006, RADIAT RES, V166, P849, DOI 10.1667/RR0640.1; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dietz S, 2002, FEBS LETT, V525, P93, DOI 10.1016/S0014-5793(02)03093-4; DOUSSIERE J, 1992, EUR J BIOCHEM, V208, P61, DOI 10.1111/j.1432-1033.1992.tb17159.x; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Esposito F, 2001, IUBMB LIFE, V52, P67, DOI 10.1080/15216540252774793; FENECH M, 1985, MUTAT RES, V147, P29, DOI 10.1016/0165-1161(85)90015-9; Frigo DE, 2006, MOL ENDOCRINOL, V20, P971, DOI 10.1210/me.2004-0075; Gordon DM, 2000, ESSAYS BIOCHEM, V36, P61, DOI 10.1042/bse0360061; Halliwell B, 1996, BIOCHEM SOC T, V24, P1023, DOI 10.1042/bst0241023; Hempel SL, 1999, FREE RADICAL BIO MED, V27, P146, DOI 10.1016/S0891-5849(99)00061-1; Irani K, 1998, BIOCHEM PHARMACOL, V55, P1339; Juretic N, 2001, J CELL BIOCHEM, V83, P92, DOI 10.1002/jcb.1211; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Lavin LF, 1999, INT J RADIAT BIOL, V75, P1201; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LI WG, 2001, J BIOL CHEM, V17, P17; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; LITTLE JB, 1968, NATURE, V218, P1064, DOI 10.1038/2181064a0; LITTLE JB, 1994, RADIAT RES, V140, P299, DOI 10.2307/3579106; Maki CG, 1996, CANCER RES, V56, P2649; Matsumoto H, 2007, J RADIAT RES, V48, P97, DOI 10.1269/jrr.06090; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Menon SG, 2003, CANCER RES, V63, P2109; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; NAGASAWA H, 1995, CANCER RES, V55, P1842; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pandey BN, 2006, ANTIOXID REDOX SIGN, V8, P1253, DOI 10.1089/ars.2006.8.1253; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schulze-Osthoff Klaus, 1997, P239; Spitz DR, 2004, CANCER METAST REV, V23, P311, DOI 10.1023/B:CANC.0000031769.14728.bc; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; SZATROWSKI TP, 1991, CANCER RES, V51, P794; TERASIMA T, 1963, SCIENCE, V140, P490, DOI 10.1126/science.140.3566.490; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218	56	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2008	27	1					20	31		10.1038/sj.onc.1210634	http://dx.doi.org/10.1038/sj.onc.1210634			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17637756				2022-12-17	WOS:000252118700003
J	Wells, V; Downward, J; Mallucci, L				Wells, V.; Downward, J.; Mallucci, L.			Functional inhibition of PI3K by the beta GBP molecule suppresses Ras-MAPK signalling to block cell proliferation	ONCOGENE			English	Article						beta GBP; beta-galactoside binding protein; PI3K; Ras; MAPK	GALACTOSIDE-BINDING-PROTEIN; NEGATIVE GROWTH-FACTOR; PHOSPHOINOSITIDE 3-KINASE; KINASE; CANCER; ACTIVATION; CHROMOSOME-22; ABNORMALITIES; EXPRESSION; SARCOMA	The mechanisms of signal transduction from cell surface receptors to the interior of the cell are fundamental to the understanding of the role that positive and negative growth factors play in cell physiology and in human diseases. Here, we show that a functional link between phosphatidylinositol-3-OH kinase (PI3K) and Ras is suppressed by the beta-galactoside binding protein (bGBP) molecule, a cytokine and a negative cell-cycle regulator. Ras-mitogen-activated protein kinase (MAPK) signalling is blocked by bGBP owing to its ability to inhibit the p110 catalytic subunit of PI3K, whose basal activity is required for Ras activation. Functional inhibition of p110 by bGBP results in downregulation of PI3K activity, suppression of Ras-GTP loading, consequent loss of MAPK activation and block of cell proliferation. This study sheds light on the molecular mechanisms whereby bGBP can control cell proliferation and, by extension, may potentially control tumorigenesis by controlling PI3K.	[Wells, V.; Mallucci, L.] Kings Coll London, Pharmaceut Sci Res Div, Cell Signalling & Growth Lab, London SE1 9NH, England; [Downward, J.] Canc Res UK, Lincolns Inn Fields Labs, London Res Inst, Signal Transduct Lab, London, England	University of London; King's College London; Cancer Research UK	Mallucci, L (corresponding author), Kings Coll London, Pharmaceut Sci Res Div, Cell Signalling & Growth Lab, Franklin Wilkins Bldg,150 Stamford St, London SE1 9NH, England.	livio.mallucci@kcl.ac.uk	Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				AURIAS A, 1984, CANCER GENET CYTOGEN, V12, P21, DOI 10.1016/0165-4608(84)90003-7; BALDINI A, 1993, GENOMICS, V15, P216, DOI 10.1006/geno.1993.1039; Blaser C, 1998, EUR J IMMUNOL, V28, P2311, DOI 10.1002/(SICI)1521-4141(199808)28:08<2311::AID-IMMU2311>3.0.CO;2-G; BRIDGE JA, 1990, AM J CLIN PATHOL, V93, P26, DOI 10.1093/ajcp/93.1.26; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CHIARIOTTI L, 1991, BIOCHIM BIOPHYS ACTA, V1089, P54, DOI 10.1016/0167-4781(91)90084-Y; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; Garcia Z, 2006, EMBO J, V25, P655, DOI 10.1038/sj.emboj.7600967; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; HIRABAYASHI J, 1989, FEBS LETT, V250, P161, DOI 10.1016/0014-5793(89)80711-2; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Mallucci L, 2003, BIOCHEM PHARMACOL, V66, P1563, DOI 10.1016/S0006-2952(03)00512-4; Mitin N, 2005, CURR BIOL, V15, pR563, DOI 10.1016/j.cub.2005.07.010; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; POWIS G, 1994, CANCER RES, V54, P2419; Ravatn R, 2005, CANCER RES, V65, P1631, DOI 10.1158/0008-5472.CAN-04-1970; REY JA, 1993, CANCER GENET CYTOGEN, V66, P1, DOI 10.1016/0165-4608(93)90140-H; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Suire S, 2005, CURR BIOL, V15, P566, DOI 10.1016/j.cub.2005.02.020; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V30, P145, DOI 10.1016/0165-4608(88)90103-3; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(00)00088-5; WELLS V, 1992, BIOCHIM BIOPHYS ACTA, V1121, P239, DOI 10.1016/0167-4838(92)90152-4; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279	33	23	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2007	26	55					7709	7714		10.1038/sj.onc.1210580	http://dx.doi.org/10.1038/sj.onc.1210580			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17603562				2022-12-17	WOS:000251537800013
J	Pecha, J; Ankrapp, D; Jiang, C; Tang, W; Hoshino, I; Bruck, K; Wagner, KU; Xiao, H				Pecha, J.; Ankrapp, D.; Jiang, C.; Tang, W.; Hoshino, I.; Bruck, K.; Wagner, K-U; Xiao, H.			Deletion of Tip30 leads to rapid immortalization of murine mammary epithelial cells and ductal hyperplasia in the mammary gland	ONCOGENE			English	Article						tip30; mammary epithelial cell; hyperplasia; proliferation	HUMAN BREAST-CANCER; EXPRESSION; ESTROGEN; MICE; SUSCEPTIBILITY; PROGRESSION; ALPHA; GENE	Transformation of mammary epithelial cells (MECs) from the normal to the neoplastic stage requires the dysregulation of tumor suppressor genes and proto-oncogenes. Tip30 is a tumor suppressor that can inhibit estrogen receptor-mediated transcription in MECs, but its role in MEC proliferation remains unknown. Here, we show that deleting the Tip30 gene leads to ductal hyperplasia in mouse mammary glands early in life and extensive mammary hyperplasia with age. Tip30 (-/-) mammary glands transplanted into wild-type mammary fat pads also display mammary trees with extensive ductal hyperplasia. Strikingly, Tip30 deletion promotes proliferation of primary MECs and results in rapid immortalization of MECs in vitro relative to wild-type cells. Gene array analysis identified significant increases in the expression of mammary epithelial growth factors Wisp2 and Igf-1 in Tip30(-/-) cells. Knockdown of either Wisp2 or Igf-1 using short interfering RNA dramatically inhibited proliferation of Tip30(-/-) cells. Together, these results suggest that Tip30 is an intrinsic and negative regulator of MEC proliferation partly through the inhibition of Wisp2 and Igf-1 expression, and its absence in the mammary gland may predispose MECs to neoplastic transformation.	Michigan State Univ, Dept Pathol Physiol, E Lansing, MI 48824 USA; Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE USA; Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA	Michigan State University; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Xiao, H (corresponding author), Michigan State Univ, Dept Pathol Physiol, 3193 Biomed & Phys Sci Bldg, E Lansing, MI 48824 USA.	xiaoh@msu.edu	Wagner, Kay-Uwe/B-6044-2009	Wagner, Kay-Uwe/0000-0002-5081-0226	NIDDK NIH HHS [DK066110-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK066110] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Banerjee S, 2003, NEOPLASIA, V5, P63, DOI 10.1016/S1476-5586(03)80018-0; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Dimri GP, 2002, CANCER RES, V62, P4736; Hewitt RE, 2000, J PATHOL, V192, P455; Ito M, 2003, CANCER RES, V63, P8763; Jiang C, 2004, J BIOL CHEM, V279, P27781, DOI 10.1074/jbc.M401809200; King FW, 2004, MOL CELL BIOL, V24, P7091, DOI 10.1128/MCB.24.16.7091-7101.2004; Lee H, 2002, AM J PATHOL, V161, P1357, DOI 10.1016/S0002-9440(10)64412-4; Lee L W, 2004, Ann Acad Med Singap, V33, pS30; Ma ZQ, 1999, ONCOGENE, V18, P4564, DOI 10.1038/sj.onc.1202809; MEDINA D, 1993, CARCINOGENESIS, V14, P25, DOI 10.1093/carcin/14.1.25; Medina D, 2002, BBA-REV CANCER, V1603, P1, DOI 10.1016/S0304-419X(02)00053-7; MEDINA D, 2000, METHODS MAMMARY GLAN, P137; Nonet GH, 2001, CANCER RES, V61, P1250; Oh A, 2004, CANCER RES, V64, P8299, DOI 10.1158/0008-5472.CAN-04-0354; Radice GL, 1997, J CELL BIOL, V139, P1025, DOI 10.1083/jcb.139.4.1025; Saxena N, 2001, MOL CELL BIOCHEM, V228, P99, DOI 10.1023/A:1013338912642; Shillingford JM, 2002, MOL ENDOCRINOL, V16, P1309, DOI 10.1210/me.16.6.1309; Shtivelman E, 1997, ONCOGENE, V14, P2167, DOI 10.1038/sj.onc.1201059; Ullrich RL, 1996, RADIAT RES, V146, P353, DOI 10.2307/3579468; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Xiao H, 1998, P NATL ACAD SCI USA, V95, P2146, DOI 10.1073/pnas.95.5.2146; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Zhang S, 2005, J MOL ENDOCRINOL, V35, P433, DOI 10.1677/jme.1.01858; Zhang Y, 2004, J BIOL CHEM, V279, P34353, DOI 10.1074/jbc.M401300200; Zhao J, 2007, HUM PATHOL, V38, P293, DOI 10.1016/j.humpath.2006.08.005	27	23	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2007	26	53					7423	7431		10.1038/sj.onc.1210548	http://dx.doi.org/10.1038/sj.onc.1210548			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17533366				2022-12-17	WOS:000251282000004
J	Yuli, C; Shao, N; Rao, R; Aysola, P; Reddy, V; Oprea-llies, G; Lee, L; Okoli, J; Partridge, E; Reddy, ESP; Rao, VN				Yuli, C.; Shao, N.; Rao, R.; Aysola, P.; Reddy, V.; Oprea-llies, G.; Lee, L.; Okoli, J.; Partridge, E.; Reddy, E. S. P.; Rao, V. N.			BRCA1a has antitumor activity in TN breast, ovarian and prostate cancers	ONCOGENE			English	Article						BRCA1a/1b; ovarian cancers; prostate cancer; tumor suppressor; estrogen receptor; triple-negative breast cancers	MAMMARY EPITHELIAL-CELLS; SPLICE VARIANTS; GENE BRCA1; EXPRESSION; P53; SUPPRESSION; INHIBITION; INTERACTS; DISTINCT; RNA	Breast cancer gene 1 ( BRCA1) mutations predispose women to breast and ovarian cancers and men to increased risks for prostate cancer. We have previously showed BRCA1 splice variant BRCA1a/p110 to induce apoptosis of human breast cancer cells. In the current study, stable expression of BRCA1a/p110 resulted in inhibition of growth of estrogen receptor ( ER)- positive and triple-negative ( TN) human breast, ovarian, prostate and colon cancer cells and mouse fibroblast cells. Similar to wildtype BRCA1, only those cells with wild- type Rb were sensitive to BRCA1a-induced growth suppression and the status of p53 did not affect the ability of BRCA1a to suppress growth of tumor cells. BRCA1a also significantly inhibited tumor mass in nude mice bearing human CAL- 51 TN breast cancer, ES- 2 ovarian cancer and PC- 3 prostate cancer xenografts. These results suggest that the majority of exon 11 sequences ( residues 263 - 1365) are not required for the tumor suppressor function of BRCA1 proteins. This is the first report demonstrating antitumor activity of BRCA1a in human ER- positive and TN breast, hormone-independent ovarian and prostate cancer cells. Currently, there are no effective treatments against TN breast cancers and results from these studies will provide new treatments for one of the biggest needs in breast cancer research.	Grady Hlth Syst, Georgia Canc Ctr Excellence, Morehouse Sch Med,RM 10C011, Dept Obstet & Gynecol,Canc Biol Program, Atlanta, GA 30303 USA; Drexel Univ, Dept Biochem, Program Canc Genet, Philadelphia, PA 19104 USA; Emory Univ, Dept Pathol, Atlanta, GA 30322 USA; Sci Applicat Int Corp, Frederick, MD USA; Grady Hlth Syst, Georgia Canc Ctr Excellence, Morehouse Sch Med, Dept Surg, Atlanta, GA USA; Univ Alabama Birmingham, Ctr Comprehens Canc, Dept Gynecol Oncol, Birmingham, AL USA	Morehouse School of Medicine; Drexel University; Emory University; Science Applications International Corporation (SAIC); Morehouse School of Medicine; University of Alabama System; University of Alabama Birmingham	Rao, VN (corresponding author), Grady Hlth Syst, Georgia Canc Ctr Excellence, Morehouse Sch Med,RM 10C011, Dept Obstet & Gynecol,Canc Biol Program, 80 Jesse Hill Jr Dr, Atlanta, GA 30303 USA.	vrao@msm.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011104, G12RR003034] Funding Source: NIH RePORTER; NCRR NIH HHS [SP20RR11104, G-12-RR03034] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Chai YL, 2001, ONCOGENE, V20, P1357, DOI 10.1038/sj.onc.1204256; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; Grunberg E, 2000, TUMOR BIOL, V21, P211, DOI 10.1159/000030127; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; Lu ML, 1996, CANCER RES, V56, P4578; Lu ML, 2000, ONCOGENE, V19, P6351, DOI 10.1038/sj.onc.1204025; Marot D, 2006, GENE THER, V13, P235, DOI 10.1038/sj.gt.3302637; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Orban TI, 2003, J CLIN PATHOL-MOL PA, V56, P191, DOI 10.1136/mp.56.4.191; Orban TI, 2001, BIOCHEM BIOPH RES CO, V280, P32, DOI 10.1006/bbrc.2000.4068; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Randrianarison V, 2001, CANCER GENE THER, V8, P759, DOI 10.1038/sj.cgt.7700366; Rao VN, 1996, ONCOGENE, V12, P523; Rosen ED, 2003, J THROMB HAEMOST, V1, P19, DOI 10.1046/j.1538-7836.2003.00030.x; SHAO Q, 1996, CARDIOVASC PATHOBIOL, V1, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Tait DL, 2000, GYNECOL ONCOL, V79, P471, DOI 10.1006/gyno.2000.5969; THEILE M, 1995, ONCOGENE, V10, P439; Tischkowitz MD, 2006, CELL CYCLE, V5, P963, DOI 10.4161/cc.5.9.2713; Wang G, 2002, INT J CAST METAL RES, V15, P143; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; You FL, 2004, ONCOGENE, V23, P5792, DOI 10.1038/sj.onc.1207739; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	28	23	27	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					6031	6037		10.1038/sj.onc.1210420	http://dx.doi.org/10.1038/sj.onc.1210420			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17384678				2022-12-17	WOS:000249277200006
J	Ohi, H; Mishima, Y; Kamimura, K; Maruyama, M; Sasai, K; Kominami, R				Ohi, H.; Mishima, Y.; Kamimura, K.; Maruyama, M.; Sasai, K.; Kominami, R.			Multi-step lymphomagenesis deduced from DNA changes in thymic lymphomas and atrophic thymuses at various times after gamma-irradiation	ONCOGENE			English	Article						multistep lymphomagenesis; gamma-ray; atrophic thymuses; clonal growth; Bcl11b	ACUTE LYMPHOBLASTIC-LEUKEMIA; T-CELL DEVELOPMENT; TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR; DEFICIENT MICE; HOMOZYGOUS DELETIONS; N-METHYLNITROSOUREA; NOTCH1 MUTATIONS; POINT MUTATIONS; TRANSGENIC MICE	Whole-body gamma-irradiation to mice causes thymic atrophy where a population of precancerous cells with mutation can be found. Thus, clonal growth and DNA changes at Bcl11b, Ikaros, Pten, Notch1 and Myc were examined in not only thymic lymphomas but also in atrophic thymuses at various times after irradiation. Clonal expansion was detected from the distinct patterns of rearrangements at the TCR beta receptor locus in a fraction of atrophic thymuses at as early as 30 days after irradiation. This expansion may be in part owing to the rearranged TCR beta signaling because the transfer of bone marrow cells with the rearrangement and the wild-type locus into severe-combined immunodeficiency mice showed preferential growth of the rearranged thymocytes in atrophic thymus. Loss of heterozygosity (LOH) at Bcl11b and trisomy of Myc were found at high frequencies in both lymphomas and atrophic thymuses, and in contrast, LOH at Ikaros and Pten were rare in atrophic thymuses but prevalent in lymphomas. Notch1 activation was detected in lymphomas and in atrophic thymuses only at a late stage. Similar patterns of DNA changes were found in atrophic thymuses induced in Bcl11b(+/-) mice. These results suggest the order of genetic changes during lymphomagenesis, Bcl11b and Myc being at the early stage; whereas Ikaros, Pten and Notch1 at the late stage.	Niigata Univ, Grad Sch Med & Dent Sci, Dept Mol Genet, Div Mol Biol, Niigata 9518510, Japan; Niigata Univ, Ctr Transdisciplinary Res, Niigata, Japan	Niigata University; Niigata University	Kominami, R (corresponding author), Niigata Univ, Grad Sch Med & Dent Sci, Dept Mol Genet, Div Mol Biol, Asahimachi Doori 1-757, Niigata 9518510, Japan.	rykomina@med.niigata-u.ac.jp	Kamimura, Kenya/U-6797-2019	Maruyama, Masaki/0000-0002-9534-4652				ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; Avram D, 2000, J BIOL CHEM, V275, P10315, DOI 10.1074/jbc.275.14.10315; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bernard OA, 2001, LEUKEMIA, V15, P1495, DOI 10.1038/sj.leu.2402249; Bezrookove V, 2004, CANCER GENET CYTOGEN, V149, P72, DOI 10.1016/S0165-4608(03)00302-9; BRATHWAITE O, 1992, CANCER RES, V52, P3791; Dumortier A, 2006, MOL CELL BIOL, V26, P209, DOI 10.1128/MCB.26.1.209-220.2006; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; GRAHAM M, 1985, NATURE, V314, P740, DOI 10.1038/314740a0; Gray DHD, 2005, CURR OPIN IMMUNOL, V17, P137, DOI 10.1016/j.coi.2005.02.001; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoemann CD, 2000, MOL CELL BIOL, V20, P3831, DOI 10.1128/MCB.20.11.3831-3842.2000; Inoue J, 2006, J IMMUNOL, V176, P5871, DOI 10.4049/jimmunol.176.10.5871; Itoyama A, 2001, BLOOD, V97, P3612, DOI 10.1182/blood.V97.11.3612; Kabra NH, 2001, P NATL ACAD SCI USA, V98, P6307, DOI 10.1073/pnas.111158698; Kakinuma S, 2002, RADIAT RES, V157, P331, DOI 10.1667/0033-7587(2002)157[0331:SOZIIA]2.0.CO;2; KAMIMURA K, IN PRESS BIOCH BIOPH; KAPLAN HENRY S., 1964, NAT CANCER INST MONOGR, V14, P207; Kawamoto H, 2003, EUR J IMMUNOL, V33, P606, DOI 10.1002/eji.200323461; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KLEIN G, 1979, P NATL ACAD SCI USA, V76, P2442, DOI 10.1073/pnas.76.5.2442; Kominami R, 2006, CANCER SCI, V97, P575, DOI 10.1111/j.1349-7006.2006.00218.x; Lin YW, 2006, BLOOD, V107, P2540, DOI 10.1182/blood-2005-07-3013; LUDWIG FC, 1968, LAB INVEST, V19, P240; MacLeod RAF, 2003, GENE CHROMOSOME CANC, V37, P84, DOI 10.1002/gcc.10194; Mao JH, 2003, ONCOGENE, V22, P8379, DOI 10.1038/sj.onc.1207083; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; McArthur GA, 2002, MOL CELL BIOL, V22, P3014, DOI 10.1128/MCB.22.9.3014-3023.2002; MCMORROW LE, 1988, LEUKEMIA, V2, P115; MOMBAERTS P, 1994, IMMUNITY, V1, P261, DOI 10.1016/1074-7613(94)90077-9; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; MUTO M, 1987, CANCER RES, V47, P3469; Nagel S, 2003, CANCER RES, V63, P5329; NEWCOMB EW, 1988, CANCER RES, V48, P5514; Newton K, 2000, EMBO J, V19, P931, DOI 10.1093/emboj/19.5.931; O'Neil J, 2006, BLOOD, V107, P781, DOI 10.1182/blood-2005-06-2553; Okano H, 1999, ONCOGENE, V18, P6677, DOI 10.1038/sj.onc.1203100; Przybylski GK, 2005, LEUKEMIA, V19, P201, DOI 10.1038/sj.leu.2403619; Ruiz A, 2004, BRIT J HAEMATOL, V125, P31, DOI 10.1111/j.1365-2141.2004.04854.x; SADO T, 1991, J RADIAT RES, V32, P168, DOI 10.1269/jrr.32.SUPPLEMENT2_168; Shinbo T, 1999, ONCOGENE, V18, P4131, DOI 10.1038/sj.onc.1202767; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; Tsuji H, 2004, CANCER RES, V64, P8882, DOI 10.1158/0008-5472.CAN-03-1163; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wakabayashi Y, 2003, NAT IMMUNOL, V4, P533, DOI 10.1038/ni927; Wakabayashi Y, 2003, BIOCHEM BIOPH RES CO, V301, P598, DOI 10.1016/S0006-291X(02)03069-3; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; Yagi T, 2002, BLOOD, V99, P1350, DOI 10.1182/blood.V99.4.1350	58	23	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2007	26	36					5280	5289		10.1038/sj.onc.1210325	http://dx.doi.org/10.1038/sj.onc.1210325			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17325664				2022-12-17	WOS:000248674200011
J	Kurabe, N; Katagiri, K; Komiya, Y; Ito, R; Sugiyama, A; Kawasaki, Y; Tashiro, F				Kurabe, N.; Katagiri, K.; Komiya, Y.; Ito, R.; Sugiyama, A.; Kawasaki, Y.; Tashiro, F.			Deregulated expression of a novel component of TFTC/STAGA histone acetyltransferase complexes, rat SGF29, in hepatocellular carcinoma: possible implication for the oncogenic potential of c-Myc	ONCOGENE			English	Article						c-Myc; metastasis; STAGA; transcription control; tumorigenicity	ACETYLASE COMPLEX; ORNITHINE-DECARBOXYLASE; NUCLEOSOME ACETYLATION; ESSENTIAL COFACTOR; IN-VIVO; IDENTIFICATION; MACHINERY; TRRAP; ONCOPROTEINS; INVOLVEMENT	c-Myc N-terminal conserved domains, MbI and MbII, are essential for c-Myc-mediated transformation and transactivation. These domains recruit the STAGA (SPT3-TAF9-GCN5-acetyltransferase) coactivator complex, but not TFTC (TATA-binding protein-free TAF-containing) to the target gene promoter. Although components of this complex are well conserved between yeast and mammals, four mammalian orthologs of yeast SPT8, SPT20, SGF11 and SGF29 remain to be identified. Here, we isolated a rat ortholog of yeast SGF29, a component of yeast SAGA (SPT-ADA-GCN5-acetyltransferase) complex. Both rat (r) SGF29 and c-myc mRNAs were overexpressed in five out of the eight tested rodent tumor cells. rSGF29 directly interacted with rADA3 and co-immunoprecipitated with two other TFTC/STAGA components, rGCN5 and rSPT3. rSGF29 was recruited to the c-Myc target gene promoters together with c-Myc, and it activated c-Myc target gene expressions. Downregulation of rSGF29 suppressed the expression of c-Myc target genes and inhibited anchorage-independent growth and tumorigenicity and lung metastasis of rat hepatoma K2 cells when injected into nude mice. These results show that rSGF29 is a novel component of TFTC/STAGA complexes and could be involved in the c-Myc-mediated malignant transformation.	Tokyo Univ Sci, Fac Ind Sci & Technol, Dept Biol Sci & Technol, Noda, Chiba 2788510, Japan	Tokyo University of Science	Tashiro, F (corresponding author), Tokyo Univ Sci, Fac Ind Sci & Technol, Dept Biol Sci & Technol, Yamazaki 2641, Noda, Chiba 2788510, Japan.	ftashir@rs.noda.tus.ac.jp						Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Liu XH, 2003, J BIOL CHEM, V278, P20405, DOI 10.1074/jbc.M211795200; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Nilsson JA, 2005, CANCER CELL, V7, P433, DOI 10.1016/j.ccr.2005.03.036; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; PENA A, 1993, J BIOL CHEM, V268, P27277; Rodriguez-Navarro S, 2004, CELL, V116, P75, DOI 10.1016/S0092-8674(03)01025-0; Saleh A, 1997, J BIOL CHEM, V272, P5571, DOI 10.1074/jbc.272.9.5571; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; Sanders SL, 2002, MOL CELL BIOL, V22, P4723, DOI 10.1128/MCB.22.13.4723-4738.2002; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Sugiyama A, 2003, CARCINOGENESIS, V24, P1549, DOI 10.1093/carcin/bgg113; Urano Y, 2006, J BIOL CHEM, V281, P7498, DOI 10.1074/jbc.M510881200; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Zhang XY, 2005, P NATL ACAD SCI USA, V102, P13968, DOI 10.1073/pnas.0502330102	24	23	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5626	5634		10.1038/sj.onc.1210349	http://dx.doi.org/10.1038/sj.onc.1210349			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17334388				2022-12-17	WOS:000248801900008
J	Haase, D; Meister, M; Muley, T; Hess, J; Teurich, S; Schnabel, P; Hartenstein, B; Angel, P				Haase, D.; Meister, M.; Muley, T.; Hess, J.; Teurich, S.; Schnabel, P.; Hartenstein, B.; Angel, P.			FRMD3, a novel putative tumour suppressor in NSCLC	ONCOGENE			English	Article						protein 4.1; lung cancer; ferm containing 3; apoptosis	PROTEIN 4.1B; EXPRESSION; GROWTH; CANCER; DAL-1; MENINGIOMA; GENE; DOMAIN; MEMBER; MERLIN	Lung cancer including non-small cell lung carcinoma (NSCLC) represents a leading cause of cancer death in Western countries. Yet, understanding its pathobiology to improve early diagnosis and therapeutic strategies is still a major challenge of today's biomedical research. We analyzed a set of differentially regulated genes that were identifi. ed in skin cancer by a comprehensive microarray study, for their expression in NSCLC. We found that ferm domain containing protein 3 (FRMD3), a member of the protein 4.1 superfamily, is expressed in normal lung tissue but silenced in 54 out of 58 independent primary NSCLC tumours compared to patient-matched normal lung tissue. FRMD3 overexpression in different epithelial cell lines resulted in a decreased clonogenicity as measured by colony formation assay. Although cell attachment capabilities and cell proliferation rate remained unchanged, this phenotype was most likely owing to induced apoptosis. Our data identify FRMD3 as a novel putative tumour suppressor gene suggesting an important role in the origin and progression of lung cancer.	Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control A100, D-69120 Heidelberg, Germany; Thoraxklin Heidelberg GmbH, Sekt Translat Forschung, Heidelberg, Germany; Univ Hosp, Dept Gen Pathol, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Hartenstein, B (corresponding author), Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control A100, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	b.hartenstein@dkfz.de	Hess, Jochen/ABE-1144-2021	Hess, Jochen/0000-0003-3493-1711				Breitenbach U, 2001, J INVEST DERMATOL, V117, P634, DOI 10.1046/j.0022-202x.2001.01437.x; Charboneau AL, 2002, INT J CANCER, V100, P181, DOI 10.1002/ijc.10470; Forgacs Eva, 2001, Pathology and Oncology Research, V7, P6; Gerber MA, 2006, CANCER RES, V66, P5295, DOI 10.1158/0008-5472.CAN-05-1628; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Gutmann DH, 2001, NEUROBIOL DIS, V8, P266, DOI 10.1006/nbdi.2000.0376; Gutmann DH, 2000, HUM MOL GENET, V9, P1495, DOI 10.1093/hmg/9.10.1495; Hanada T, 2003, J BIOL CHEM, V278, P34445, DOI 10.1074/jbc.M305209200; Huang S, 2001, EUR J CLIN INVEST, V31, P907, DOI 10.1046/j.1365-2362.2001.00892.x; Hummerich L, 2006, ONCOGENE, V25, P111, DOI 10.1038/sj.onc.1209016; Jiang W, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-4; Kuns R, 2005, ONCOGENE, V24, P6502, DOI 10.1038/sj.onc.1208813; Mao XL, 2003, CANCER RES, V63, P7979; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Ni XH, 2003, J HUM GENET, V48, P101, DOI 10.1007/s100380300015; Panani AD, 2006, CANCER LETT, V239, P1, DOI 10.1016/j.canlet.2005.06.030; Perry A, 2000, J NEUROPATH EXP NEUR, V59, P872, DOI 10.1093/jnen/59.10.872; Rapp UR, 2003, ADV ENZYME REGUL, V43, P183, DOI 10.1016/S0065-2571(03)00002-5; Robb VA, 2003, NEUROBIOL DIS, V13, P191, DOI 10.1016/S0969-9961(03)00071-8; Robb VA, 2005, ONCOGENE, V24, P1946, DOI 10.1038/sj.onc.1208335; Robb VA, 2004, ONCOGENE, V23, P3589, DOI 10.1038/sj.onc.1207445; Schlingemann J, 2003, INT J CANCER, V104, P699, DOI 10.1002/ijc.11008; Shaw AT, 2005, CLIN CANCER RES, V11, p4999S, DOI 10.1158/1078-0432.CCR-05-9005; Sherman LS, 2001, TRENDS CELL BIOL, V11, P442, DOI 10.1016/S0962-8924(01)02128-6; Singh V, 2004, ONCOGENE, V23, P7761, DOI 10.1038/sj.onc.1208057; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; Tran YK, 1999, CANCER RES, V59, P35; Yageta M, 2002, CANCER RES, V62, P5129	28	23	26	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4464	4468		10.1038/sj.onc.1210225	http://dx.doi.org/10.1038/sj.onc.1210225			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17260017				2022-12-17	WOS:000247620000014
J	Starczynowski, DT; Trautmann, H; Pott, C; Harder, L; Arnold, N; Africa, JA; Leeman, JR; Siebert, R; Gilmore, TD				Starczynowski, D. T.; Trautmann, H.; Pott, C.; Harder, L.; Arnold, N.; Africa, J. A.; Leeman, J. R.; Siebert, R.; Gilmore, T. D.			Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity	ONCOGENE			English	Article						c-Rel; Rel; NF-kB; malignant transformation; lymphoma; human mutation	NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTOR REL; CHICKEN SPLEEN-CELLS; FACTOR-KAPPA-B; C-REL; HODGKINS LYMPHOMA; ACTIVATION; KINASE; PROLIFERATION; ABERRATIONS	The human c-rel proto-oncogene (REL) encodes a subunit of the nuclear factor-kappaB(NF-kappa B) transcription factor. In this report, we have identified an identical point mutation in two human B-cell lymphomas (follicular (FL) and mediastinal) that changes serine (Ser) 525 (TCA) to proline (Pro) (CCA) within the REL transactivation domain. This mutation was not identified in a similarly sized cohort of healthy individuals. In the mediastinal B-cell lymphoma, the mutation in REL is of germ-line origin. In both tumors, the S525P mutant allele is over-represented. REL-S525P shows enhanced in vitro transforming activity in chicken spleen cells. REL-S525P has a reduced ability to activate the human manganese superoxide dismutase (MnSOD) promoter in A293 cells; however, the MnSOD protein shows increased expression in REL-S525P-transformed chicken spleen cells as compared to wild-type REL-transformed cells. Ser525 is a site for phosphorylation by I kappa B kinase (IKK) in vitro. The S525P mutation reduces IKK alpha- and tumor necrosis factor (TNF)alpha-stimulated transactivation by a GAL4-REL protein. Furthermore, REL-S525P-transformed chicken spleen cells are more resistant to TNF alpha-induced cell death than cells transformed by wild-type REL. These results suggest that the S525P mutation contributes to the development of human B-cell lymphomas by affecting an IKK alpha-regulated transactivation activity of REL.	Boston Univ, Dept Biol, Boston, MA 02215 USA; Univ Kiel, Hosp Schleswig Holstein, Dept Med Hematol & Oncol, Kiel, Germany; Univ Kiel, Hosp Schleswig Holstein, Inst Human Genet, Kiel, Germany; Univ Kiel, Hosp Schleswig Holstein, Dept Gynecol & Obstet, Kiel, Germany	Boston University; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu	Arnold, Norbert/E-3012-2010; Siebert, Reiner/A-8049-2010	Arnold, Norbert/0000-0003-4523-8808; 	NCI NIH HHS [CA47763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brown SL, 2002, ARTHRITIS RHEUM-US, V46, P3151, DOI 10.1002/art.10679; Bryder D, 2001, J EXP MED, V194, P941, DOI 10.1084/jem.194.7.941; Feuerhake F, 2005, BLOOD, V106, P1392, DOI 10.1182/blood-2004-12-4901; Fognani C, 2000, ONCOGENE, V19, P2224, DOI 10.1038/sj.onc.1203543; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Harris J, 2006, J IMMUNOL, V177, P2527, DOI 10.4049/jimmunol.177.4.2527; Harris NL, 1999, ANN ONCOL, V10, P1419, DOI 10.1023/A:1008375931236; Joos S, 2003, INT J CANCER, V103, P489, DOI 10.1002/ijc.10845; Kalaitzidis D, 2002, ONCOGENE, V21, P8759, DOI 10.1038/sj.onc.1206033; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kralova J, 2002, J VIROL, V76, P11960, DOI 10.1128/JVI.76.23.11960-11970.2002; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Liang MC, 2003, MOL PHARMACOL, V64, P123, DOI 10.1124/mol.64.1.123; Martin AG, 2000, J BIOL CHEM, V275, P24383, DOI 10.1074/jbc.M909396199; Martin AG, 2001, J BIOL CHEM, V276, P15840, DOI 10.1074/jbc.M011313200; Martin-Subero JI, 2003, LEUKEMIA, V17, P2214, DOI 10.1038/sj.leu.2403129; Martin-Subero JI, 2002, BLOOD, V99, P1474, DOI 10.1182/blood.V99.4.1474; MITTLEMANN F, 1995, INT SYSTEM HUMAN CYT; Neiman PE, 2003, ONCOGENE, V22, P1073, DOI 10.1038/sj.onc.1206070; Rhodes DR, 2005, NAT GENET, V37, P579, DOI 10.1038/ng1578; Sanchez-Valdepenas C, 2006, J IMMUNOL, V176, P4666, DOI 10.4049/jimmunol.176.8.4666; Sasaki CY, 2005, J BIOL CHEM, V280, P34538, DOI 10.1074/jbc.M504943200; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Schlegelberger B, 1999, DIAGNOSTIC CYTOGENET, P151, DOI DOI 10.1007/978-3-642-59918-7_9; Starczynowski DT, 2005, ONCOGENE, V24, P7355, DOI 10.1038/sj.onc.1208902; Starczynowski DT, 2003, ONCOGENE, V22, P6928, DOI 10.1038/sj.onc.1206801; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Yu SH, 2004, J MOL MED, V82, P621, DOI 10.1007/s00109-004-0559-7	29	23	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2007	26	19					2685	2694		10.1038/sj.onc.1210089	http://dx.doi.org/10.1038/sj.onc.1210089			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17072339				2022-12-17	WOS:000246210600003
J	Cotroneo, MS; Haag, JD; Zan, Y; Lopez, CC; Thuwajit, P; Petukhova, GV; Camerini-Otero, RD; Gendron-Fitzpatrick, A; Griep, AE; Murphy, CJ; Dubielzig, RR; Gould, MN				Cotroneo, M. S.; Haag, J. D.; Zan, Y.; Lopez, C. C.; Thuwajit, P.; Petukhova, G. V.; Camerini-Otero, R. D.; Gendron-Fitzpatrick, A.; Griep, A. E.; Murphy, C. J.; Dubielzig, R. R.; Gould, M. N.			Characterizing a rat Brca2 knockout model	ONCOGENE			English	Article						Brca2; knockout; rat; carcinogenesis; tumors	DOUBLE-STRAND BREAKS; DNA-REPAIR; SYNAPTONEMAL COMPLEX; MEIOTIC CHROMOSOMES; MICE; RECOMBINATION; LOCALIZATION; RADIATION; CANCER; SUSCEPTIBILITY	Evidence exists that BRCA2 carriers may have an elevated risk of breast, ovarian, colon, prostate, and pancreatic cancer. In general, carriers are defined as individuals with protein truncating mutations within the BRCA2 gene. Many Brca2 knockout lines have been produced and characterized in the mouse. We previously produced a rat Brca2 knockout strain in which there is a nonsense mutation in exon 11 between BRC repeats 2 and 3, and a truncated protein is produced. Interestingly, while such a mutation in homozygous mice would lead to limited survival of approximately 3 months, the Brca2(-/-) rats are 100% viable and the vast majority live to over 1 year of age. Brca2(-/-) rats show a phenotype of growth inhibition and sterility in both sexes. Aspermatogenesis in the Brca2(-/-) rats is due to a failure of homologous chromosome synapsis. Long-term phenotypes include underdeveloped mammary glands, cataract formation and lifespan shortening due to the development of tumors and cancers in multiple organs. The establishment of the rat Brca2 knockout model provides a means to study the role of Brca2 in increasing cancer susceptibility and inducing a novel ocular phenotype not previously associated with this gene.	Univ Wisconsin, Canc Res Lab, Madison, WI 53706 USA; NIDDK, Genet & Biochem Branch, NIH, Bethesda, MD USA; Univ Wisconsin, Res Anim Resource Ctr, Comparat Pathol Lab, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Anat, Madison, WI 53706 USA; Univ Wisconsin, Sch Vet Med, Dept Surg Sci, Madison, WI 53706 USA; Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Gould, MN (corresponding author), Univ Wisconsin, Canc Res Lab, 1400 Univ Ave, Madison, WI 53706 USA.	gould@oncology.wisc.edu	Griep, Anne/ABA-9636-2020; Thuwajit, Peti/AAD-1014-2021; Gould, Michael N/C-7414-2014	Thuwajit, Peti/0000-0003-0798-1510	NATIONAL CANCER INSTITUTE [R01CA106216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK052008, Z01DK052033, ZIADK052033] Funding Source: NIH RePORTER; NCI NIH HHS [CA106216] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allers T, 2001, CELL, V106, P47, DOI 10.1016/S0092-8674(01)00416-0; Barlow C, 1998, DEVELOPMENT, V125, P4007; Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Bigsby RM, 1999, P NATL ACAD SCI USA, V96, P9328, DOI 10.1073/pnas.96.16.9328; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; BRENNER S, 1981, J CELL BIOL, V91, P95, DOI 10.1083/jcb.91.1.95; BROWN NM, 1995, ENVIRON HEALTH PERSP, V103, P708, DOI 10.2307/3432863; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Cucinotta FA, 2001, RADIAT RES, V156, P460, DOI 10.1667/0033-7587(2001)156[0460:SRACIA]2.0.CO;2; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; DOBSON MJ, 1994, J CELL SCI, V107, P2749; Dynlacht JR, 2006, RADIAT RES, V165, P9, DOI 10.1667/RR3481.1; Eijpe M, 2000, CHROMOSOMA, V109, P123, DOI 10.1007/s004120050420; Elliott B, 2002, CELL MOL LIFE SCI, V59, P373, DOI 10.1007/s00018-002-8429-3; Friedman LS, 1998, CANCER RES, V58, P1338; Houghtaling S, 2003, GENE DEV, V17, P2021, DOI 10.1101/gad.1103403; Hunter N, 2001, CELL, V106, P59, DOI 10.1016/S0092-8674(01)00430-5; Keeney S, 2001, CURR TOP DEV BIOL, V52, P1, DOI 10.1016/S0070-2153(01)52008-6; Klein BEK, 1998, ARCH OPHTHALMOL-CHIC, V116, P219, DOI 10.1001/archopht.116.2.219; Liu JG, 1996, EXP CELL RES, V226, P11, DOI 10.1006/excr.1996.0197; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; McAllister KA, 2002, CANCER RES, V62, P990; McAllister KA, 2006, TOXICOL PATHOL, V34, P187, DOI 10.1080/01926230600611794; Moens PB, 1998, CURR TOP DEV BIOL, V37, P241; Mohr U., 1994, PATHOBIOLOGY AGING R, V2; Moynahan ME, 2002, ONCOGENE, V21, P8994, DOI 10.1038/sj.onc.1206177; Nakazawa M, 2001, EXP ANIM TOKYO, V50, P99, DOI 10.1538/expanim.50.99; Pellegrini L, 2004, TRENDS BIOCHEM SCI, V29, P310, DOI 10.1016/j.tibs.2004.04.009; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Samuelson DJ, 2003, CARCINOGENESIS, V24, P1455, DOI 10.1093/carcin/bgg112; Sarkisian CJ, 2001, J BIOL CHEM, V276, P37640, DOI 10.1074/jbc.M106281200; Schulze W, 1999, HUM REPROD, V14, P82, DOI 10.1093/humrep/14.suppl_1.82; Sharan SK, 2004, DEVELOPMENT, V131, P131, DOI 10.1242/dev.00888; Shivji MKK, 2004, DNA REPAIR, V3, P835, DOI 10.1016/j.dnarep.2004.03.008; Siaud N, 2004, EMBO J, V23, P1392, DOI 10.1038/sj.emboj.7600146; Villeneuve AM, 2001, CELL, V106, P647, DOI 10.1016/S0092-8674(01)00500-1; WORGUL BV, 1991, MUTAGENESIS, V6, P495, DOI 10.1093/mutage/6.6.495; Worgul BV, 2002, P NATL ACAD SCI USA, V99, P9836, DOI 10.1073/pnas.162349699; Yoshida K, 2004, CANCER SCI, V95, P866, DOI 10.1111/j.1349-7006.2004.tb02195.x; Zan YH, 2003, NAT BIOTECHNOL, V21, P645, DOI 10.1038/nbt830; Zhoucun A, 2006, EUR J OBSTET GYN R B, V124, P61, DOI 10.1016/j.ejogrb.2005.09.001; Zickler D, 1999, ANNU REV GENET, V33, P603, DOI 10.1146/annurev.genet.33.1.603; Zierhut D, 2000, INT J RADIAT ONCOL, V46, P131, DOI 10.1016/S0360-3016(99)00354-5	43	23	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1626	1635		10.1038/sj.onc.1209960	http://dx.doi.org/10.1038/sj.onc.1209960			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16964288				2022-12-17	WOS:000244782500012
J	Pecquet, C; Nyga, R; Penard-Lacronique, V; Smithgall, TE; Murakami, H; Regnier, A; Lassoued, K; Gouilleux, F				Pecquet, C.; Nyga, R.; Penard-Lacronique, V.; Smithgall, T. E.; Murakami, H.; Regnier, A.; Lassoued, K.; Gouilleux, F.			The Src tyrosine kinase Hck is required for Tel-Abl- but not for Tel-Jak2-induced cell transformation	ONCOGENE			English	Article						Tel-Abl; Tel-Jak2; Src kinases; Hck; signal transduction; oncogenes	KAPPA-B PATHWAY; BCR-ABL; FUSION PROTEINS; LEUKEMIA-CELLS; C-SRC; ACTIVATION; GENE; FAMILY; LYN; RECEPTOR	Tel-Abl and Tel-Jak2 are fusion proteins associated with human haematologic neoplasms. They possess constitutive tyrosine kinase activity and activate common downstream signalling pathways like Stat-5, PI3-K/Akt, Ras/MapK and NF-kappa B. In this study, we showed the specific requirement of Src family members for the Tel-Abl-mediated cell growth, activation of Stat5, PI3-K/Akt and Ras/MapK while dispensable for Tel-Jak2. Hck was found strongly phosphorylated in Tel-Abl-expressing Ba/F3 cells and sensitive to imatinib mesylate treatment, providing evidence that Hck is a target of Tel-Abl tyrosine kinase activity. Overexpression of a kinase dead form of Hck inhibits the proliferation of Ba/F3 cells expressing Tel-Abl as the phosphorylation of Akt and Erk1/2. These results argue for an important role of Hck in Tel-Abl oncogenic signalling.	Univ Picardie, INSERM, E351, F-80036 Amiens, France; Hop Necker Enfants Malad, INSERM, E210, Paris, France; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Okayama Univ, Dept Biotechnol, Okayama 7008530, Japan	Institut National de la Sante et de la Recherche Medicale (Inserm); Picardie Universites; Universite de Picardie Jules Verne (UPJV); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Okayama University	Gouilleux, F (corresponding author), Univ Picardie, INSERM, E351, 3 Rue Louvels, F-80036 Amiens, France.	fabrice.gouilleux@sa.u-picardie.fr	Penard-Lacronique, Virginie/E-5729-2016; Penard-Lacronique, Virginie/R-1938-2019	Penard-Lacronique, Virginie/0000-0001-9435-7331; Penard-Lacronique, Virginie/0000-0001-9435-7331; Gouilleux, Fabrice/0000-0001-6047-1718; Christian, Pecquet/0000-0002-8623-3483	NATIONAL CANCER INSTITUTE [R01CA101828] Funding Source: NIH RePORTER; NCI NIH HHS [CA101828] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; Carron C, 2000, BLOOD, V95, P3891; Cazzaniga G, 1999, BLOOD, V94, P4370, DOI 10.1182/blood.V94.12.4370.424k34_4370_4373; Chin H, 1998, BLOOD, V91, P3734; Dai Y, 2004, J BIOL CHEM, V279, P34227, DOI 10.1074/jbc.M402290200; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; dos Santos NR, 2006, LEUKEMIA, V20, P182, DOI 10.1038/sj.leu.2404026; ERNST TJ, 1994, J BIOL CHEM, V269, P5764; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Ho JMY, 2002, BLOOD, V100, P1438; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Keung YK, 2002, CANCER GENET CYTOGEN, V138, P139, DOI 10.1016/S0165-4608(02)00609-X; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Kuno Y, 2001, BLOOD, V97, P1050, DOI 10.1182/blood.V97.4.1050; Lacronique V, 2000, BLOOD, V95, P2076, DOI 10.1182/blood.V95.6.2076; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lionberger JM, 2000, J BIOL CHEM, V275, P18581, DOI 10.1074/jbc.C000126200; Malinge S, 2006, ONCOGENE, V25, P3589, DOI 10.1038/sj.onc.1209390; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Million RP, 2004, MOL CELL BIOL, V24, P4685, DOI 10.1128/MCB.24.11.4685-4695.2004; Million RP, 2002, BLOOD, V99, P4568, DOI 10.1182/blood-2001-12-0244; Omura T, 2002, EUR J BIOCHEM, V269, P381, DOI 10.1046/j.0014-2956.2001.02661.x; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Santos SCR, 2000, ONCOGENE, V19, P1164, DOI 10.1038/sj.onc.1203418; Santos SCR, 2001, FEBS LETT, V497, P148; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Spiekermann K, 2002, EXP HEMATOL, V30, P262, DOI 10.1016/S0301-472X(01)00787-1; Stanglmaier M, 2003, LEUKEMIA, V17, P283, DOI 10.1038/sj.leu.2402778; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Tatosyan AG, 2000, BIOCHEMISTRY-MOSCOW+, V65, P49; Tatton L, 2003, J BIOL CHEM, V278, P4847, DOI 10.1074/jbc.M209321200; Tilbrook PA, 2001, CANCER RES, V61, P2453; Van Limbergen H, 2001, GENE CHROMOSOME CANC, V30, P274, DOI 10.1002/1098-2264(2000)9999:9999<1::AID-GCC1089>3.3.CO;2-T; Voss J, 2000, ONCOGENE, V19, P1684, DOI 10.1038/sj.onc.1203467; Warmuth M, 2003, BLOOD, V101, P664, DOI 10.1182/blood-2002-01-0288; Warmuth M, 1997, J BIOL CHEM, V272, P33260, DOI 10.1074/jbc.272.52.33260; Wilson MB, 2002, ONCOGENE, V21, P8075, DOI 10.1038/sj.onc.1206008	46	23	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1577	1585		10.1038/sj.onc.1209949	http://dx.doi.org/10.1038/sj.onc.1209949			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16953222	Green Published			2022-12-17	WOS:000244782500007
J	Lebedeva, IV; Su, ZZ; Emdad, L; Kolomeyer, A; Sarkar, D; Kitada, S; Waxman, S; Reed, JC; Fisher, PB				Lebedeva, I. V.; Su, Z-Z; Emdad, L.; Kolomeyer, A.; Sarkar, D.; Kitada, S.; Waxman, S.; Reed, J. C.; Fisher, P. B.			Targeting inhibition of K-ras enhances Ad.mda-7-induced growth suppression and apoptosis in mutant K-ras colorectal cancer cells	ONCOGENE			English	Article						mda-7/IL-24; K-ras single-chain antibody; K-ras AS; bipartite adenovirus; colorectal carcinoma; Bcl-family of proteins	DIFFERENTIATION-ASSOCIATED GENE-7; MELANOMA-DIFFERENTIATION; BCL-2 EXPRESSION; IN-VITRO; BYSTANDER ACTIVITY; MDA-7/IL-24; MDA-7; PROTEIN; LINES; ADENOVIRUS	Melanoma differentiation-associated gene-7/interleukin-24 (mda-7/IL-24) is a cancer-specific, growth-suppressing and apoptosis-inducing gene with broad-spectrum antitumor activity. However, when administered by means of a replication-incompetent adenovirus, Ad.mda-7, several colorectal carcinoma cell lines are resistant to its antiproliferative and antisurvival effects. We have presently endeavored to determine if K-ras mutations, present in similar to 40-50% of colorectal cancers and which may mediate resistance to chemotherapy and radiotherapy, represent a predisposing genetic factor mitigating reduced sensitivity to Ad.mda-7. To suppress ras expression, three structurally different replication-incompetent adenoviral vectors were engineered that express (1) an intracellular, neutralizing single-chain antibody (scAb) to p21 ras (Ad.K-ras scAb), (2) an antisense (AS) K-ras gene (Ad.K-ras AS) or (3) both mda-7/IL-24 and a K-ras AS gene in a single bipartite virus (Ad.m7.KAS). Simultaneous inhibition of K-ras and expression of mda-7/IL-24 enhanced killing of colorectal carcinoma cells with mutated K-ras, but not with wild-type K-ras. The extent of killing depended on the degree of K-ras downregulation, with Ad.K-ras AS being generally more efficient than Ad.K-ras scAb in combination with Ad.mda-7. These findings support an effective dual-combinatorial approach for the therapy of colorectal cancers that employs a unique cancer-specific suppressor gene (mda-7/IL-24) with targeted inhibition of oncogene (ras) expression.	Columbia Univ, Herbert Irving Comprehens Canc Ctr, Dept Pathol, Coll Phys & Surg,Med Ctr, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Med Ctr, Herbert Irving Comprehens Canc Ctr,Dept Urol, New York, NY USA; Mt Sinai Sch Med, Div Hematol Oncol, Dept Med, New York, NY USA; Burnham Inst, La Jolla, CA USA; Columbia Univ, Herbert Irving Comprehens Canc Ctr, Dept Neurosurg, Coll Phys & Surg,Med Ctr, New York, NY 10032 USA	Columbia University; Columbia University; Icahn School of Medicine at Mount Sinai; Sanford Burnham Prebys Medical Discovery Institute; Columbia University	Fisher, PB (corresponding author), Columbia Univ, Herbert Irving Comprehens Canc Ctr, Dept Pathol, Coll Phys & Surg,Med Ctr, New York, NY 10032 USA.	pbf1@columbia.edu	Lebedeva, Irina V/A-3156-2008	Lebedeva, Irina V/0000-0002-1693-9392	NCI NIH HHS [R01 CA097318, R01 CA098712] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097318, R01CA098712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964; Aoki K, 1997, MOL CARCINOGEN, V20, P251, DOI 10.1002/(SICI)1098-2744(199710)20:2<251::AID-MC12>3.0.CO;2-9; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1989, CANCER RES, V49, P4682; Brand K, 1999, GENE THER, V6, P1054, DOI 10.1038/sj.gt.3300914; Canevari S, 2002, J NATL CANCER I, V94, P1031; Cardinale A, 1998, FEBS LETT, V439, P197, DOI 10.1016/S0014-5793(98)01369-6; Chada S, 2006, CANCER GENE THER, V13, P490, DOI 10.1038/sj.cgt.7700915; Chada S, 2004, MOL THER, V10, P1085, DOI 10.1016/j.ymthe.2004.08.020; Chada S, 2004, INT IMMUNOPHARMACOL, V4, P649, DOI 10.1016/j.intimp.2004.01.017; Cochet O, 1998, CANCER RES, V58, P1170; Cunningham CC, 2005, MOL THER, V11, P149, DOI 10.1016/j.ymthe.2004.09.019; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; Fisher PB, 2005, CANCER RES, V65, P10128, DOI 10.1158/0008-5472.CAN-05-3127; Fisher PB, 2003, CANCER BIOL THER, V2, pS23; GUPTA P, 2006, IN PRESS PHARM THER; HAGUE A, 1994, ONCOGENE, V9, P3367; Holmes Matthew, 2003, Methods Mol Biol, V234, P1; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Jiang HP, 1995, ONCOGENE, V11, P2477; KINOSHITA T, 1995, ONCOGENE, V10, P2207; Kita K, 1999, INT J CANCER, V80, P553, DOI 10.1002/(SICI)1097-0215(19990209)80:4<553::AID-IJC12>3.0.CO;2-6; Krajewska M, 1996, CANCER RES, V56, P2422; Krajewska M, 1996, AM J PATHOL, V148, P1567; Krajewski S, 1997, CLIN CANCER RES, V3, P199; Lebedeva IV, 2006, CANCER RES, V66, P2403, DOI 10.1158/0008-5472.CAN-05-3510; Lebedeva IV, 2005, ONCOGENE, V24, P585, DOI 10.1038/sj.onc.1208183; Lebedeva IV, 2003, ONCOGENE, V22, P8758, DOI 10.1038/sj.onc.1206891; Lebedeva IV, 2005, MOL THER, V11, P4, DOI 10.1016/j.ymthe.2004.08.012; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; MUKHOPADHYAY T, 1991, CANCER RES, V51, P1744; Oida Y, 2005, MOL CANCER THER, V4, P291; Ramesh R, 2003, CANCER RES, V63, P5105; Russell JS, 1999, CANCER RES, V59, P5239; Russo P, 2002, INT J CANCER, V100, P266, DOI 10.1002/ijc.10461; Sarkar D, 2005, P NATL ACAD SCI USA, V102, P14034, DOI 10.1073/pnas.0506837102; Sarkar D, 2005, CANCER RES, V65, P9056, DOI 10.1158/0008-5472.CAN-05-1261; SARKAR D, IN PRESS ANTIINFLAMM; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SKLAR MD, 1988, CANCER RES, V48, P793; Su ZZ, 2006, ONCOGENE, V25, P2339, DOI 10.1038/sj.onc.1209271; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 2001, P NATL ACAD SCI USA, V98, P10332, DOI 10.1073/pnas.171315198; Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062; Su ZZ, 2005, ONCOGENE, V24, P7552, DOI 10.1038/sj.onc.1208911; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Tong AW, 2005, MOL THER, V11, P160, DOI 10.1016/j.ymthe.2004.09.021; Viale Pamela Hallquist, 2005, Clin J Oncol Nurs, V9, P541, DOI 10.1188/05.CJON.541-552; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Ward RL, 1997, CANCER, V79, P1106, DOI 10.1002/(SICI)1097-0142(19970315)79:6<1106::AID-CNCR8>3.0.CO;2-D; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Yacoub A, 2004, CANCER BIOL THER, V3, P739, DOI 10.4161/cbt.3.8.968; Yacoub A, 2003, CANCER BIOL THER, V2, P347, DOI 10.4161/cbt.2.4.422; Yacoub A, 2003, CLIN CANCER RES, V9, P3272; YOUNG IT, 1977, J HISTOCHEM CYTOCHEM, V25, P935, DOI 10.1177/25.7.894009; Zhao LL, 2005, HUM GENE THER, V16, P845, DOI 10.1089/hum.2005.16.845	60	23	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					733	744		10.1038/sj.onc.1209813	http://dx.doi.org/10.1038/sj.onc.1209813			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16924242				2022-12-17	WOS:000243902200010
J	Rodrigues, S; Rodrigue, CM; Attoub, S; Flejou, JF; Bruyneel, E; Bracke, M; Emami, S; Gespach, C				Rodrigues, S.; Rodrigue, C. M.; Attoub, S.; Flejou, J. F.; Bruyneel, E.; Bracke, M.; Emami, S.; Gespach, C.			Induction of the adenoma-carcinoma progression and Cdc25A-B phosphatases by the trefoil factor TFF1 in human colon epithelial cells	ONCOGENE			English	Article						differential display; anchorage-independent growth; invasion; apoptosis; tumor growth; human colorectal tumors	HUMAN COLORECTAL-CARCINOMA; HUMAN BREAST-CANCER; IN-VIVO; SIGNALING PATHWAYS; CELLULAR INVASION; POOR-PROGNOSIS; EXPRESSION; PEPTIDES; MDM2; P53	TFF1 is overexpressed in inflammatory diseases and human cancers of the digestive and urogenital systems. To examine the transforming potential of TFF1 in human colon epithelial cells, premalignant PC/AA/C1 adenoma cells (PC) derived from a patient with familial adenomatous polyposis (FAP) were transformed by the TFF1 cDNA and used as a model of the adenoma-carcinoma transition. Constitutive expression of TFF1 increased anchorage-independent cell growth in soft agar, and induced or potentiated the growth of colon PC-TFF1 and kidney MDCKts.src-TFF1 tumor xenografts in athymic mice. This resulted in reduction of thapsigargin-induced apoptosis and promotion of collagen type I invasion through several oncogenic pathways. Using the differential display approach to identify TFF1 target genes, we found that the dual specific phosphatases Cdc25A and B implicated in cell cycle transitions are strongly upregulated under active forms in both PC-TFF1 and HCT8/S11-TFF1 colon cancer cells. Accordingly, TFF1 expression is absent in normal human colon crypts but is induced in correlation with Cdc25a and b transcript levels and tumor grade in familial and sporadic colon adenomas and carcinomas. We propose that TFF1 and Cdc25A-B cooperate with other dominant oncogenic pathways to induce the adenoma and adenocarcinoma transitions. Agents that target TFF1/Cdc25 signaling pathways may be useful for treating patients with TFF1-positive solid tumors.	Hop St Antoine, INSERM, U673, F-75571 Paris 12, France; Univ Paris 06, Paris 12, France; Hop St Antoine, Dept Pathol, F-75571 Paris 12, France; Ghent Univ Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital	Gespach, C (corresponding author), Hop St Antoine, INSERM, U673, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.	gespach@st-antoine.inserm.fr	Attoub, Samir/N-6852-2018					Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P489, DOI 10.1053/gast.1996.v110.pm8566596; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bossenmeyer-Pourie C, 2002, J CELL BIOL, V157, P761, DOI 10.1083/jcb200108056; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; BRACKE ME, 2001, METHODS MOL MED; Brezak MC, 2005, MOL CANCER THER, V4, P1378, DOI 10.1158/1535-7163.MCT-05-0168; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; Christine R, 2005, CANCER RES, V65, P195; Daga RR, 1999, J CELL SCI, V112, P3137; Dhar DK, 2005, CLIN CANCER RES, V11, P6472, DOI 10.1158/1078-0432.CCR-05-0671; Emami S, 2004, PEPTIDES, V25, P885, DOI 10.1016/j.peptides.2003.10.019; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; Empereur S, 1997, BRIT J CANCER, V75, P241, DOI 10.1038/bjc.1997.40; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Hernandez S, 2001, LAB INVEST, V81, P465, DOI 10.1038/labinvest.3780254; Hipfner DR, 2004, NAT REV MOL CELL BIO, V5, P805, DOI 10.1038/nrm1491; Jourdan F, 2003, VIRCHOWS ARCH, V443, P115, DOI 10.1007/s00428-003-0833-z; Kallstrom H, 2005, EXP CELL RES, V303, P89, DOI 10.1016/j.yexcr.2004.09.012; Kang CM, 2004, CARCINOGENESIS, V25, P123, DOI 10.1093/carcin/bgg187; KINDON H, 1995, GASTROENTEROLOGY, V109, P516, DOI 10.1016/0016-5085(95)90340-2; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Leisser C, 2004, CELL DEATH DIFFER, V11, P80, DOI 10.1038/sj.cdd.4401318; Loffler H, 2003, ONCOGENE, V22, P8063, DOI 10.1038/sj.onc.1206976; Mitra J, 2004, ONCOGENE, V23, P3361, DOI 10.1038/sj.onc.1207446; Moore L, 2003, ONCOGENE, V22, P7831, DOI 10.1038/sj.onc.1206985; Onel K, 2004, MOL CANCER RES, V2, P1; Ozen M, 2005, CLIN CANCER RES, V11, P4701, DOI 10.1158/1078-0432.CCR-04-2551; RIO MC, 1988, SCIENCE, V241, P705, DOI 10.1126/science.3041593; Rodrigue CM, 2005, ONCOGENE, V24, P3274, DOI 10.1038/sj.onc.1208485; Rodrigues S, 2003, FASEB J, V17, P7, DOI 10.1096/fj.02-0201com; Rodrigues S, 2003, ONCOGENE, V22, P4488, DOI 10.1038/sj.onc.1206685; Rodrigues S, 2001, FASEB J, V15, P1517, DOI 10.1096/fj.00-0802com; SHOUSHA S, 1993, MODERN PATHOL, V6, P446; Soufla G, 2005, INT J BIOL MARKER, V20, P18, DOI 10.1177/172460080502000104; Takemasa I, 2000, CANCER RES, V60, P3043; Taupin D, 2003, NAT REV MOL CELL BIO, V4, P721, DOI 10.1038/nrm1203; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; Tomasetto C, 2000, GASTROENTEROLOGY, V118, P70, DOI 10.1016/S0016-5085(00)70415-X; Torres LF, 2002, MOL MED, V8, P273, DOI 10.1007/BF03402153; Van de Bovenkamp JHB, 2005, DIGEST DIS SCI, V50, P1078, DOI 10.1007/s10620-005-2708-4; WILLIAMS AC, 1994, ONCOGENE, V9, P1479; Xu XD, 2003, CLIN CANCER RES, V9, P1764; Yio XY, 2005, CLIN EXP METASTAS, V22, P157, DOI 10.1007/s10585-005-6615-z; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200	44	23	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6628	6636		10.1038/sj.onc.1209665	http://dx.doi.org/10.1038/sj.onc.1209665			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16715141				2022-12-17	WOS:000241569700007
J	Baillat, D; Leprivier, G; Regnier, D; Vintonenko, N; Begue, A; Stehelin, D; Aumercier, M				Baillat, D.; Leprivier, G.; Regnier, D.; Vintonenko, N.; Begue, A.; Stehelin, D.; Aumercier, M.			Stromelysin-1 expression is activated in vivo by Ets-1 through palindromic head-to-head Ets binding sites present in the promoter	ONCOGENE			English	Article						Ets-1; MMP-3; gene regulation; synovial fibroblasts cell transcription	TRANSCRIPTION FACTOR EXPRESSION; MATRIX-METALLOPROTEINASE GENES; DNA-BINDING; RHEUMATOID-ARTHRITIS; ANGIOGENESIS; FUMAGILLIN; PROTEIN; ELEMENTS; RAS; INHIBITION	Regulation of the gene expression of Stromelysin-1 (matrix metalloproteinase-3), a member of the matrix metalloproteinase family, is critical for tissue homeostasis. The Stromelysin-1 promoter is known to be transactivated by Ets proteins through palindromic head-to-head Ets binding sites (EBS), an unusual configuration among metalloproteinase promoters. Patterns of increased co-expression of Stromelysin-1 and Ets-1 genes have been observed in pathological processes such as rheumatoid arthritis, glomerulonephritis and tumor invasion. In this context, we show in a synovial fibroblastic model cell line (HIG-82), which is able to co-express Stromelysin-1 and Ets-1, that the EBS palindrome is essential for the expression of Stromelysin-1. More precisely, using electrophoretic mobility shift assays, DNA affinity purification and chromatin immunoprecipitation, we demonstrate that endogenous Ets-1, but not Ets-2, is present on this palindrome. The use of a dominant-negative form of Ets-1 and the decrease of Ets-1 amount either by fumagillin, an antiangiogenic compound, or by short interfering RNA show that the activation rate of the promoter and the expression of Stromelysin-1 correlate with the level of endogenous Ets-1. Thus, it is the first demonstration, using this cellular model, that endogenously expressed Ets-1 is actually a main activator of the Stromelysin-1 promoter through its effective binding to the EBS palindrome.	Univ Lille 2, Inst Biol Lille, UMR 8526, Inst Pasteur Lille,CNRS, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Aumercier, M (corresponding author), Univ Lille 2, Inst Biol Lille, UMR 8526, Inst Pasteur Lille,CNRS, 1 Rue Prof Calmette,BP 447, F-59021 Lille, France.	marc.aumercier@ibl.fr		Aumercier, Marc/0000-0002-0370-3452				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baillat D, 2002, J BIOL CHEM, V277, P29386, DOI 10.1074/jbc.M200088200; Barrett JM, 2002, BREAST CANCER RES TR, V72, P227, DOI 10.1023/A:1014993006190; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; Bernier SG, 2004, P NATL ACAD SCI USA, V101, P10768, DOI 10.1073/pnas.0404105101; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Calmels TPG, 1995, BIOL CELL, V84, P53, DOI 10.1016/0248-4900(96)81318-9; Catalano A, 2001, AM J PATHOL, V159, P721, DOI 10.1016/S0002-9440(10)61743-9; CHEN JH, 1990, ONCOGENE RES, V5, P277; Chen YF, 2005, DNA CELL BIOL, V24, P126, DOI 10.1089/dna.2005.24.126; Constantin A, 2002, ARTHRITIS RHEUM, V46, P1754, DOI 10.1002/art.10336; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; Datta B, 2004, BIOCHEMISTRY-US, V43, P14821, DOI 10.1021/bi049172p; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, P1; FRISCH SM, 1987, P NATL ACAD SCI USA, V84, P2600, DOI 10.1073/pnas.84.9.2600; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gaire M, 1996, MOL CARCINOGEN, V15, P124, DOI 10.1002/(SICI)1098-2744(199602)15:2<124::AID-MC5>3.0.CO;2-J; GALANG CK, 1994, ONCOGENE, V9, P2913; GEORGESCU HI, 1988, IN VITRO CELL DEV B, V24, P1015; Ghilardi G, 2002, CLIN CANCER RES, V8, P3820; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Hodge DR, 1996, ONCOGENE, V12, P11; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Kirstein M, 1996, J BIOL CHEM, V271, P18231, DOI 10.1074/jbc.271.30.18231; Kria L, 1998, CURR EYE RES, V17, P986, DOI 10.1076/ceyr.17.10.986.5245; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin CW, 1996, EXP CELL RES, V223, P117, DOI 10.1006/excr.1996.0064; Lowther WT, 2000, BBA-PROTEIN STRUCT M, V1477, P157, DOI 10.1016/S0167-4838(99)00271-X; MAJERUS MA, 1992, NUCLEIC ACIDS RES, V20, P2699, DOI 10.1093/nar/20.11.2699; MALEMUD CJ, 1999, FRONT BIOSCI, V4, P762; Man AK, 2003, MOL CELL BIOL, V23, P8614, DOI 10.1128/MCB.23.23.8614-8625.2003; Maroulakou IG, 2000, ONCOGENE, V19, P6432, DOI 10.1038/sj.onc.1204039; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; Mukherjee T, 2003, J CANCER RES CLIN, V129, P430, DOI 10.1007/s00432-003-0457-3; Naito T, 2000, J AM SOC NEPHROL, V11, P2243, DOI 10.1681/ASN.V11122243; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Ozaki I, 2003, HEPATOL RES, V27, P288, DOI 10.1016/S1386-6346(03)00268-7; Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297; Pufall MA, 2005, SCIENCE, V309, P142, DOI 10.1126/science.1111915; Pufall MA, 2002, ANNU REV CELL DEV BI, V18, P421, DOI 10.1146/annurev.cellbio.18.031502.133614; QUINONES S, 1994, BIOCHEM J, V302, P471, DOI 10.1042/bj3020471; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Redlich K, 2001, ARTHRITIS RHEUM, V44, P266, DOI 10.1002/1529-0131(200102)44:2<266::AID-ANR43>3.3.CO;2-7; Rekdal C, 2000, J BIOL CHEM, V275, P40288, DOI 10.1074/jbc.M006978200; Rodriguez-Nieto S, 2001, ANTICANCER RES, V21, P3457; Rothhammer T, 2004, CELL MOL LIFE SCI, V61, P118, DOI 10.1007/s00018-003-3337-8; Sato Y, 2000, ADV EXP MED BIOL, V476, P109; Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099; Singh S, 2002, CURR DRUG TARGETS, V3, P359, DOI 10.2174/1389450023347489; Span PN, 2002, ONCOGENE, V21, P8506, DOI 10.1038/sj.onc.1206040; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Sternlicht MD, 1999, GUIDEBOOK EXTRACELLU, P505; Sun HB, 2001, BONE, V28, P303, DOI 10.1016/S8756-3282(00)00454-3; Terashima M, 1999, CIRCULATION, V99, P2717, DOI 10.1161/01.CIR.99.21.2717; Tokuhara K, 2003, INT SURG, V88, P25; Trojanowska M, 2000, ONCOGENE, V19, P6464, DOI 10.1038/sj.onc.1204043; Vetter M, 2005, ONCOGENE, V24, P650, DOI 10.1038/sj.onc.1208234; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; Wang JY, 2000, J CELL BIOCHEM, V77, P465, DOI 10.1002/(SICI)1097-4644(20000601)77:3<465::AID-JCB11>3.3.CO;2-D; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; Wernert N, 1999, ANGEW CHEM INT EDIT, V38, P3228, DOI 10.1002/(SICI)1521-3773(19991102)38:21<3228::AID-ANIE3228>3.0.CO;2-8; WERNERT N, 1994, CANCER RES, V54, P5683; Yamamoto H, 1998, GENE DEV, V12, P1315, DOI 10.1101/gad.12.9.1315; Yang BS, 1996, MOL CELL BIOL, V16, P538; Ye S, 1999, FEBS LETT, V450, P268, DOI 10.1016/S0014-5793(99)00509-8; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P6427, DOI 10.1073/pnas.97.12.6427; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	72	23	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5764	5776		10.1038/sj.onc.1209583	http://dx.doi.org/10.1038/sj.onc.1209583			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16652151				2022-12-17	WOS:000240765800007
J	Li, H; Watts, GS; Oshiro, MM; Futscher, BW; Domann, FE				Li, H.; Watts, G. S.; Oshiro, M. M.; Futscher, B. W.; Domann, F. E.			AP-2 alpha and AP-2 gamma are transcriptional targets of p53 in human breast carcinoma cells	ONCOGENE			English	Article						activator protein-2; p53; tumor suppressor gene; breast carcinoma	FACTOR AP-2; DOWN-REGULATION; EPIDERMAL MORPHOGENESIS; GENE-EXPRESSION; HUMAN-MELANOMA; DNA-BINDING; CANCER; DIFFERENTIATION; METASTASIS; APOPTOSIS	Activating enhancer-binding protein 2 alpha (AP-2 alpha) and activating enhancer-binding protein 2 gamma (AP-2 gamma) are transcription factors that bind GC-rich consensus sequences and regulate the expression of many downstream genes. AP-2 alpha and AP-2 gamma interact with p53 both physically and functionally. Expression microarray results in human breast carcinoma cells with forced p53 expression revealed AP-2 gamma as a putative transcriptional target of p53. To command extend these findings we measured the effects of forced p53 expression in human breast carcinoma cells by real-time reverse transcription-PCR, Western blotting, electrophoretic gel mobility shift assays, promoter reporter, chromatin immunoprecipitation and chromatin accessibility assays. Wild-type p53 expression rapidly induced not only AP-2 gamma but also AP-2 alpha mRNA. The subsequent increase in these proteins led to increased AP-2 DNA-binding and transactivating activity. Candidate p53-binding sites were identified in the AP-2 alpha and AP-2 gamma promoters. p53 binding to these cis-elements in vivo was also observed, together with a relaxation of chromatin structure in these regions. Finally, expression of either AP-2 alpha or gamma inhibited growth of human breast carcinoma cells in vitro. Taken together, our findings indicate that these AP-2 genes are targets for transcriptional activation by p53 and suggest that AP-2 proteins may mediate some of the downstream effects of p53 expression such as inhibition of proliferation.	Univ Iowa, Free Rad & Radiat Biol Program, Dept Radiat Oncol, Iowa City, IA 52242 USA; Univ Arizona, Bone Marrow Transplant Program, Arizona Canc Ctr, Tucson, AZ 85721 USA; Univ Arizona, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA	University of Iowa; Arizona Center Cancer Care; University of Arizona; University of Arizona	Domann, FE (corresponding author), Univ Iowa, Free Rad & Radiat Biol Program, Dept Radiat Oncol, Med Lab B180, Iowa City, IA 52242 USA.	Frederick-domann@uiowa.edu		Domann, Frederick/0000-0002-0489-2179	NCI NIH HHS [CA66081, CA65662, CA73612, P30 CA023074] Funding Source: Medline; NIEHS NIH HHS [P30 ES006694] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065662, R56CA073612, P01CA066081, P30CA023074, R29CA065662, R29CA073612, R01CA073612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; CHEN PH, 1993, CLIN CHEM, V39, P2186; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Douglas DB, 2004, CANCER RES, V64, P1611, DOI 10.1158/0008-5472.CAN-0318-2; Gee JMW, 1999, J PATHOL, V189, P514, DOI 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang Y, 1998, BIOCHEM BIOPH RES CO, V249, P307, DOI 10.1006/bbrc.1998.9139; HURSTING SD, 1994, P NATL ACAD SCI USA, V91, P7036, DOI 10.1073/pnas.91.15.7036; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Karjalainen JM, 2000, BRIT J CANCER, V82, P2015; Koster MI, 2006, DEV BIOL, V289, P253, DOI 10.1016/j.ydbio.2005.10.041; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Marreiros A, 2003, GENE, V302, P155, DOI 10.1016/S0378-1119(02)01101-0; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; McPherson LA, 2002, J BIOL CHEM, V277, P45028, DOI 10.1074/jbc.M208924200; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Modugno M, 2002, ONCOGENE, V21, P7478, DOI 10.1038/sj.onc.1205957; Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545; Paggi MG, 2001, ONCOGENE, V20, P2570, DOI 10.1038/sj.onc.1204356; Pellikainen J, 2002, CLIN CANCER RES, V8, P3487; PETSKO G, 2002, CURRENT PROTOCOLS BI; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Ruiz M, 2001, CLIN CANCER RES, V7, P4086; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; STABACH PR, 2005, ONCOGENE; Tellez C, 2003, J BIOL CHEM, V278, P46632, DOI 10.1074/jbc.M309159200; Tummala R, 2003, GENE, V321, P93, DOI 10.1016/S0378-1119(03)00840-0; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wajapeyee N, 2003, J BIOL CHEM, V278, P52093, DOI 10.1074/jbc.M305624200; Watts GS, 2004, NEOPLASIA, V6, P187, DOI 10.1593/neo.03292; West-Mays JA, 2003, DIFFERENTIATION, V71, P206, DOI 10.1046/j.1432-0436.2003.710302.x; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200; Zhu CH, 2001, J BIOL CHEM, V276, P14407, DOI 10.1074/jbc.M009708200	40	23	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2006	25	39					5405	5415		10.1038/sj.onc.1209534	http://dx.doi.org/10.1038/sj.onc.1209534			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16636674				2022-12-17	WOS:000240144900005
J	Malinge, S; Monni, R; Bernard, O; Penard-Lacronique, V				Malinge, S.; Monni, R.; Bernard, O.; Penard-Lacronique, V.			Activation of the NF-kappa B pathway by the leukemogenic TEL-Jak2 and TEL-Abl fusion proteins leads to the accumulation of antiapoptotic IAP proteins and involves IKK alpha	ONCOGENE			English	Article							BCR-ABL; TRANSCRIPTION FACTOR; MYELOPROLIFERATIVE DISEASE; TYROSINE PHOSPHORYLATION; LYMPHOBLASTIC-LEUKEMIA; CELL-RECEPTOR; BINDING-SITE; KINASE; EXPRESSION; INDUCE	Abnormal activation of tyrosine kinases and of signaling pathways they control plays a critical role in the neoplastic process of human hematopoietic malignancy. The nuclear factor-kappa B (NF-kappa B) pathway is one of the signalings activated by the TEL-Jak2 and TEL-Abl oncoproteins and required for their antiapoptotic activity. To define the signal relay responsible for this activation, we used mouse embryonic fibroblast (MEF) cells and observed that TEL-Jak2- and TEL-Abl-mediated NF-kappa B induction was abolished in cells lacking the I kappa B kinase (IKK)alpha but not in IKK beta(-/-) cells. Similar observations were performed with oncogenic forms of the FMS-like tyrosine kinase 3 (Flt-3) involved in the pathogenesis of one-third of acute myeloid leukemias. Rescue of TEL-Jak2-mediated NF-kappa B activation was obtained with a kinase-proficient form of IKK alpha in IKK alpha(-/-) MEF. Hematopoietic cells transformed by TEL-Jak2 and TEL-Abl showed sustained IKK alpha activity without promotion of NF-kappa B2/p100 processing, generally associated to IKK alpha functions. Furthermore, IAP1, IAP2 and XIAP, which are central regulators of the NF-kappa B-mediated survival pathway, were highly expressed in cells transformed by these oncoproteins. Our results indicate that these oncogenic tyrosine kinases preferentially use an IKK alpha-dependent mechanism to induce a persistent NF-kappa B activity and allow the production of antiapoptotic effectors that participate to their leukemogenic properties.	Hop Necker Enfants Malad, F-75743 Paris, France; INSERM, U528, Sect Rech, Inst Curie, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Penard-Lacronique, V (corresponding author), Hop Necker Enfants Malad, EMI 0210,Tour Pasteur,149 Rue Sevres, F-75743 Paris, France.	penard@necker.fr	Malinge, Sebastien/AAK-1158-2021; Penard-Lacronique, Virginie/R-1938-2019; Malinge, Sebastien/AAP-9452-2021; Penard-Lacronique, Virginie/E-5729-2016; Malinge, Sebastien/B-3507-2014; Bernard, Olivier A./E-5721-2016	Malinge, Sebastien/0000-0002-9533-7778; Penard-Lacronique, Virginie/0000-0001-9435-7331; Penard-Lacronique, Virginie/0000-0001-9435-7331; Malinge, Sebastien/0000-0002-9533-7778; Bernard, Olivier/0000-0002-0463-9747				Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Baumgartner B, 2002, LEUKEMIA, V16, P2062, DOI 10.1038/sj.leu.2402641; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Feinman R, 1999, BLOOD, V93, P3044; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Guasch G, 2001, MOL CELL BIOL, V21, P8129, DOI 10.1128/MCB.21.23.8129-8142.2001; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Hanson JL, 2003, J BIOL CHEM, V278, P34910, DOI 10.1074/jbc.M304189200; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang WC, 2003, J IMMUNOL, V170, P4767, DOI 10.4049/jimmunol.170.9.4767; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Kashkar H, 2003, J EXP MED, V198, P341, DOI 10.1084/jem.20021279; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; Kirchner D, 2003, EXP HEMATOL, V31, P504, DOI 10.1016/S0301-472X(03)00069-9; Kordes U, 2000, LEUKEMIA, V14, P399, DOI 10.1038/sj.leu.2401705; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luftig M, 2004, P NATL ACAD SCI USA, V101, P141, DOI 10.1073/pnas.2237183100; Matta H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI 10.1073/pnas.0308016101; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Million RP, 2004, MOL CELL BIOL, V24, P4685, DOI 10.1128/MCB.24.11.4685-4695.2004; Million RP, 2002, BLOOD, V99, P4568, DOI 10.1182/blood-2001-12-0244; Minami Y, 2003, BLOOD, V102, P2969, DOI 10.1182/blood-2002-12-3813; Monni R, 2001, ONCOGENE, V20, P849, DOI 10.1038/sj.onc.1204201; Mordmuller B, 2003, EMBO REP, V4, P82, DOI 10.1038/embor710; Nawata R, 2003, ONCOGENE, V22, P7774, DOI 10.1038/sj.onc.1206901; OMAHONY AM, 2004, J BIOL CHEM, V12, P12; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Perrotti D, 2004, ONCOGENE, V23, P3222, DOI 10.1038/sj.onc.1207543; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; Piccolella E, 2003, J IMMUNOL, V170, P2895, DOI 10.4049/jimmunol.170.6.2895; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Santos SCR, 2001, FEBS LETT, V497, P148; SAVAGE KJ, 2003, BLOOD, V106, P1392; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; Ten RM, 1999, J IMMUNOL, V163, P3851; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Voss J, 2000, ONCOGENE, V19, P1684, DOI 10.1038/sj.onc.1203467; Weil R, 2004, CURR OPIN IMMUNOL, V16, P374, DOI 10.1016/j.coi.2004.03.003; Xiao GT, 2004, J BIOL CHEM, V279, P30099, DOI 10.1074/jbc.M401428200; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805	67	23	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3589	3597		10.1038/sj.onc.1209390	http://dx.doi.org/10.1038/sj.onc.1209390			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16434962				2022-12-17	WOS:000238448200011
J	De Oliveira, F; Chauvin, C; Ronot, X; Mousseau, M; Leverve, X; Fontaine, E				De Oliveira, F; Chauvin, C; Ronot, X; Mousseau, M; Leverve, X; Fontaine, E			Effects of permeability transition inhibition and decrease in cytochrome c content on doxorubicin toxicity in K562 cells	ONCOGENE			English	Article						chemoresistance; PTP; mitochondria; cytochrome c	INDUCED MITOCHONDRIAL DYSFUNCTION; CYCLOPHILIN-D; P-GLYCOPROTEIN; INDUCED APOPTOSIS; TUMOR-CELLS; DEATH; BCL-2; PORE; ANTHRACYCLINES; CHEMORESISTANCE	As mitochondria play a key role in the commitment to cell death, we have investigated the mitochondrial consequences of resistance to doxorubicin ( DOX) in K562 cells. We found that the permeability transition pore ( PTP) inhibitor cyclosporine A ( CsA) failed to inhibit PTP opening in the resistant clone. Moreover, the Ca2+ loading capacity in the resistant clone was identical to that observed in the parent cells in the presence of CsA, suggesting that the PTP was already inhibited in a CsA-like manner in the resistant cells. In agreement with this proposal, the mitochondrial target of CsA cyclophilin D ( CyD) decreased by half in the resistant cells. The levels of adenine nucleotide translocator, voltage anion-dependent channel, Bax, Bcl-2, Bcl-x(L), AIF and Smac/Diablo, were similar in both cell lines, whereas cytochrome c content was divided by three in the resistant cells. Since P-glycoprotein inhibition did not restore DOX toxicity in the resistant cells, while DOX-induced cell death in the parent cells was prevented by either PTP inhibition or siRNA-induced decrease in cytochrome c content, we conclude that the inhibition of PTP opening and the decrease in cytochrome c content participate in the mechanism that makes K562 cells resistant to DOX.	Univ Grenoble 1, INSERM E0221, Lab Bioenerget Fontamentale & Appl, F-38041 Grenoble, France; EPHE, CNRS, UMR, Lab Dynam Cellulaire,Inst Albert Bonniot, La Tronche, France; Hop Albert Michallon, Dept Cancerol & Hematol, Grenoble, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); CHU Grenoble Alpes	Fontaine, E (corresponding author), Univ Grenoble 1, INSERM E0221, Lab Bioenerget Fontamentale & Appl, BP 53, F-38041 Grenoble, France.	eric.fontaine@ujf-grenoble.fr	Mousseau, Mireille/M-5942-2014; RONOT, Xavier/B-8412-2014; Fontaine, Eric/ABA-8853-2020	Fontaine, Eric/0000-0002-5204-9477				Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; Campone M, 2001, LEUKEMIA, V15, P1377, DOI 10.1038/sj.leu.2402222; Chauvin C, 2001, J BIOL CHEM, V276, P41394, DOI 10.1074/jbc.M106417200; Childs AC, 2002, CANCER RES, V62, P4592; Connern CP, 1996, BIOCHEMISTRY-US, V35, P8172, DOI 10.1021/bi9525177; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Crompton Martin, 1998, Biochemical Society Transactions, V26, pS330; Decaudin D, 1997, CANCER RES, V57, P62; Denis-Gay M, 1998, BIOCHEM PHARMACOL, V56, P451, DOI 10.1016/S0006-2952(98)00084-7; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Fukushima T, 2000, LEUKEMIA RES, V24, P249, DOI 10.1016/S0145-2126(99)00177-0; GALAT A, 1995, PROG BIOPHYS MOL BIO, V63, P67, DOI 10.1016/0079-6107(94)00009-X; Gamen S, 2000, EXP CELL RES, V258, P223, DOI 10.1006/excr.2000.4924; Gauchez AS, 2001, IN VIVO, V15, P101; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Grandjean F, 2002, BIOCHEM PHARMACOL, V63, P823, DOI 10.1016/S0006-2952(01)00865-6; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Green PS, 2002, BBA-MOL BASIS DIS, V1588, P94, DOI 10.1016/S0925-4439(02)00144-8; Huigsloot M, 2002, J BIOL CHEM, V277, P35869, DOI 10.1074/jbc.M200378200; Jung K, 2001, ADV DRUG DELIVER REV, V49, P87, DOI 10.1016/S0169-409X(01)00128-4; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Kowaltowski A, 2000, CELL DEATH DIFFER, V7, P903, DOI 10.1038/sj.cdd.4400722; Li YM, 2004, BIOCHEM J, V383, P101, DOI 10.1042/BJ20040669; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mankhetkorn S, 1998, EUR J PHARMACOL, V343, P313, DOI 10.1016/S0014-2999(97)01548-3; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Nielsen D, 1996, GEN PHARMACOL-VASC S, V27, P251, DOI 10.1016/0306-3623(95)02013-6; Nogueira V, 2005, J BIOENERG BIOMEMBR, V37, P25, DOI 10.1007/s10863-005-4120-3; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Seelig A, 1998, EUR J BIOCHEM, V251, P252, DOI 10.1046/j.1432-1327.1998.2510252.x; Serafino A, 2000, ANTICANCER RES, V20, P3383; Smyth MJ, 1998, P NATL ACAD SCI USA, V95, P7024, DOI 10.1073/pnas.95.12.7024; Solem LE, 1996, J MOL CELL CARDIOL, V28, P1023, DOI 10.1006/jmcc.1996.0095; Trindade GS, 1999, PHOTOCHEM PHOTOBIOL, V69, P694, DOI 10.1562/0031-8655(1999)069<0694:DISTUU>2.3.CO;2; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287	41	23	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2646	2655		10.1038/sj.onc.1209293	http://dx.doi.org/10.1038/sj.onc.1209293			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16331251				2022-12-17	WOS:000237099400008
J	Teal, HE; Ni, S; Xu, J; Finkelstein, LD; Cheng, AM; Paulson, RF; Feng, GS; Correll, PH				Teal, HE; Ni, S; Xu, J; Finkelstein, LD; Cheng, AM; Paulson, RF; Feng, GS; Correll, PH			GRB2-mediated recruitment of GAB2, but not GAB1, to SF-STK supports the expansion of Friend virus-infected erythroid progenitor cells	ONCOGENE			English	Article						Friend virus; erythroleukemia; Fv2; Sf-Stk	RECEPTOR TYROSINE KINASE; PLECKSTRIN HOMOLOGY DOMAIN; TERMINAL SH3 DOMAIN; EPITHELIAL MORPHOGENESIS DOWNSTREAM; GRB2 BINDING-SITE; C-MET RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTER PROTEIN; IN-VIVO	Friend virus induces the development of erythroleukemia in mice through the interaction of a viral glycoprotein, gp55, with a truncated form of the Stk receptor tyrosine kinase, short form-Stk (Sf-Stk), and the EpoR. We have shown previously that the ability of Sf-Stk to participate in the transformation of Friend virus-infected cells requires the kinase activity and Grb2-binding site of Sf-Stk. Here we show that Grb2 heterozygous mice exhibit decreased susceptibility to Friend erythroleukemia and that expansion of erythroid progenitors in response to infection requires the C-terminal SH3 domain of Grb2. A fusion protein in which the Grb2-binding site in Sf-Stk is replaced by Gab2, supports the growth of progenitors from mice lacking Sf-Stk, whereas a Sf-Stk/Gab1 fusion protein does not. Gab2 is expressed in spleens from Friend virus-infected mice, co-immunoprecipitates with Sf-Stk and is tyrosine phosphorylated in the presence of Sf-Stk. Mice with a targeted deletion in Gab2 are less susceptible to Friend erythroleukemia and the expansion of erythroid progenitor cells in response to infection can be rescued by expression of Gab2, but not Gab1. Taken together, these data indicate that a Sf-Stk/Grb2/Gab2 complex mediates the growth of primary erythroid progenitor cells in response to Friend virus.	Penn State Univ, Dept Vet & Biomed Sci, Ctr Mol Immunol & Infect Dis, University Pk, PA USA; NHGRI, NIH, Bethesda, MD USA; Washington Univ, St Louis, MO USA; Burnham Inst, San Diego, CA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Washington University (WUSTL)	Correll, PH (corresponding author), Dept Vet Sci, 115 Henning Bldg, University Pk, PA 16802 USA.	phc7@psu.edu			NHLBI NIH HHS [R01 HL066471, R01-HL66208] Funding Source: Medline; PHS HHS [R01-L66471] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066471, R01HL066208] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AXELRAD A, 1969, CAN CANC C, V8, P313; Bausenwein BS, 2000, MECH DEVELOP, V90, P205, DOI 10.1016/S0925-4773(99)00252-X; BEHRINGER RR, 1985, CELL, V40, P441, DOI 10.1016/0092-8674(85)90158-8; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; DANDREA AD, 1992, CANCER SURV, V15, P19; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Finkelstein LD, 2002, ONCOGENE, V21, P3562, DOI 10.1038/sj.onc.1205442; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Gong K, 2001, NAT IMMUNOL, V2, P29, DOI 10.1038/83134; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; Herbst R, 1999, EMBO J, V18, P6950, DOI 10.1093/emboj/18.24.6950; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; Hibi M, 2000, LEUKEMIA LYMPHOMA, V37, P299, DOI 10.3109/10428190009089430; HOROSZEWICZ JS, 1975, J NATL CANCER I, V54, P265, DOI 10.1093/jnci/54.1.265; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Ischenko I, 2003, ONCOGENE, V22, P6311, DOI 10.1038/sj.onc.1206742; KOHDA D, 1994, STRUCTURE, V2, P1029, DOI 10.1016/S0969-2126(94)00106-5; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Lewitzky M, 2001, ONCOGENE, V20, P1052, DOI 10.1038/sj.onc.1204202; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIAO SK, 1975, INT J CANCER, V15, P467, DOI 10.1002/ijc.2910150313; LILLY F, 1970, J NATL CANCER I, V45, P163; Liu Y, 2002, FEBS LETT, V515, P1, DOI 10.1016/S0014-5793(02)02425-0; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Maroun CR, 1999, J BIOL CHEM, V274, P31719, DOI 10.1074/jbc.274.44.31719; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; MIRAND EA, 1968, P SOC EXP BIOL MED, V128, P844; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Nishigaki K, 2001, J VIROL, V75, P7893, DOI 10.1128/JVI.75.17.7893-7903.2001; Nishigaki K, 2000, J VIROL, V74, P3037, DOI 10.1128/JVI.74.7.3037-3045.2000; Park CY, 1999, J BIOL CHEM, V274, P7583, DOI 10.1074/jbc.274.11.7583; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Saxton TM, 2001, CURR BIOL, V11, P662, DOI 10.1016/S0960-9822(01)00198-1; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Schutzman JL, 2001, MOL CELL BIOL, V21, P8104, DOI 10.1128/MCB.21.23.8104-8116.2001; Seiffert M, 2003, MOL CELL BIOL, V23, P2415, DOI 10.1128/MCB.23.7.2415-2424.2003; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; TAMBOURIN P, 1971, NATURE-NEW BIOL, V234, P230, DOI 10.1038/newbio234230a0; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; VANDERAKKER E, 2005, BLOOD, V103, P4457; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Wolf I, 2002, MOL CELL BIOL, V22, P231, DOI 10.1128/MCB.22.1.231-244.2002; Zhang SS, 2003, ARTERIOSCL THROM VAS, V23, P1788, DOI 10.1161/01.ATV.0000085015.49110.85; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	60	23	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2433	2443		10.1038/sj.onc.1209288	http://dx.doi.org/10.1038/sj.onc.1209288			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16314834	Bronze			2022-12-17	WOS:000236948000002
J	Jean, D; Rousselet, N; Frade, R				Jean, D; Rousselet, N; Frade, R			Expression of cathepsin L in human tumor cells is under the control of distinct regulatory mechanisms	ONCOGENE			English	Article						gene amplification; DNA methylation; transcription regulation; mRNA stability	HUMAN-MELANOMA CELLS; CHAIN VARIABLE FRAGMENT; CLEAVES HUMAN C3; 3RD COMPONENT; CYSTEINE PROTEINASE; PROCATHEPSIN-L; L GENE; METASTATIC PROPERTIES; COMPLEMENT; PROMOTER	Cathepsin L, a cysteine protease, is overexpressed in human tumor cells and plays a major role in melanoma progression. Our aim was herein to identify molecular mechanisms, which contribute to its overexpression. We found that cathepsin L protein expression correlated with mRNA level in tumor cells. Therefore, we focused on mechanisms involved in cathepsin L mRNA regulation. CpG island was localized in the 5' region of cathepsin L gene that encompassed regulatory regions identified as essential for promoter activity. CpG dinucleotides, not methylated in any melanoma cells analysed, were methylated in a B lymphoma cell line, which poorly express cathepsin L. Our data demonstrate that in lymphoma cells, cathepsin L silencing was methylation-dependent. Furthermore, gene amplification was involved in cathepsin L overexpression in one melanoma cell line, while transcriptional mechanisms but not mRNA stability are responsible of cathepsin L overexpression in others melanoma cells. In addition, NF-Y, Sp1, Sp2 and Sp3 transcription factors, essential to basal cathepsin L transcription, are not directly involved in overexpression. Thus, our data provides the first demonstration that cathepsin L expression in tumor cells is under the control of distinct molecular mechanisms.	INSERM, U 672, U 354, F-91030 Evry, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Jean, D (corresponding author), INSERM, U 672, U 354, Batiment G8,Campus 1,5 Rue Henri Desbrueres,Genop, F-91030 Evry, France.	jean354@genopole.evry.inserm.fr	Jean, Didier/A-1615-2009	Jean, Didier/0000-0001-5823-7404				Abdollahi A, 1999, J SOC GYNECOL INVEST, V6, P32, DOI 10.1016/S1071-5576(98)00048-3; Agirre X, 2003, ONCOGENE, V22, P1070, DOI 10.1038/sj.onc.1206236; Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910; BAREL M, 1989, P NATL ACAD SCI USA, V86, P10054, DOI 10.1073/pnas.86.24.10054; Charron M, 2003, BIOL REPROD, V68, P1649, DOI 10.1095/biolreprod.102.012328; CHAUHAN SS, 1993, J BIOL CHEM, V268, P1039; Frade R, 1999, IMMUNOPHARMACOLOGY, V42, P39, DOI 10.1016/S0162-3109(99)00028-4; Frade R, 2000, CANCER RES, V60, P6585; Frade R, 1998, CANCER RES, V58, P2733; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Grzybowska EA, 2001, BIOCHEM BIOPH RES CO, V288, P291, DOI 10.1006/bbrc.2001.5738; Guillaume-Rousselet N, 2002, BIOCHEM J, V367, P219, DOI 10.1042/BJ20020350; Huang SY, 2002, AM J PATHOL, V161, P125, DOI 10.1016/S0002-9440(10)64164-8; Hughes SJ, 1998, P NATL ACAD SCI USA, V95, P12410, DOI 10.1073/pnas.95.21.12410; Ishidoh K, 1997, BIOCHEM BIOPH RES CO, V238, P665, DOI 10.1006/bbrc.1997.7349; Jean D, 1996, CANCER RES, V56, P254; Jean D, 1997, IMMUNOL LETT, V58, P107, DOI 10.1016/S0165-2478(97)00030-8; Jean D, 2002, BIOCHEM J, V361, P173, DOI 10.1042/0264-6021:3610173; Jean D, 1995, BIOCHEM J, V312, P961, DOI 10.1042/bj3120961; KAMBOJ RC, 1993, BIOCHIMIE, V75, P873, DOI 10.1016/0300-9084(93)90042-Q; Kawada A, 1997, ARCH DERMATOL RES, V289, P87, DOI 10.1007/s004030050160; Kirschke H, 2000, EUR J CANCER, V36, P787, DOI 10.1016/S0959-8049(00)00014-9; Krueger S, 2001, CANCER GENE THER, V8, P522, DOI 10.1038/sj.cgt.7700341; Levicar N, 2003, CANCER GENE THER, V10, P141, DOI 10.1038/sj.cgt.7700546; Luca MR, 1998, HISTOL HISTOPATHOL, V13, P1225, DOI 10.14670/HH-13.1225; Malone CS, 2001, P NATL ACAD SCI USA, V98, P10404, DOI 10.1073/pnas.181206898; Mao X, 2000, CANCER GENET CYTOGEN, V122, P87, DOI 10.1016/S0165-4608(00)00278-8; Ohashi K, 2003, BBA-PROTEINS PROTEOM, V1649, P30, DOI 10.1016/S1570-9639(03)00152-3; Pesole G, 1999, TRENDS GENET, V15, P378, DOI 10.1016/S0168-9525(99)01795-3; Rousselet N, 2004, CANCER RES, V64, P146, DOI 10.1158/0008-5472.CAN-03-1717; Sriraman V, 2004, ENDOCRINOLOGY, V145, P582, DOI 10.1210/en.2003-0963; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Turk V, 2002, ADV ENZYME REGUL, V42, P285, DOI 10.1016/S0065-2571(01)00034-6	33	23	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2006	25	10					1474	1484		10.1038/sj.onc.1209196	http://dx.doi.org/10.1038/sj.onc.1209196			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16261157				2022-12-17	WOS:000235890400005
